304953	100736228	20992699629	@@##	----------	----------
304953	100736228	20992699630	@@100736228		FO
304953	100736228	20992699631	@4936228/		VV0_NN1
304953	100736228	20992699632	46989		MC
304953	100736228	20992699633	@qwx906989		FO
304953	100736228	20992699634	<p>		NULL
304953	100736228	20992699635	When	when	CS_RRQ
304953	100736228	20992699636	it	it	PPH1
304953	100736228	20992699637	comes	come	VVZ
304953	100736228	20992699638	to	to	II
304953	100736228	20992699639	prostate	prostate	NN1
304953	100736228	20992699640	trouble	trouble	NN1
304953	100736228	20992699641	,	,	,
304953	100736228	20992699642	the	the	AT
304953	100736228	20992699643	lions	lion	NN2
304953	100736228	20992699644	share	share	NN1_VV0
304953	100736228	20992699645	of	of	IO
304953	100736228	20992699646	attention	attention	NN1
304953	100736228	20992699647	goes	go	VVZ
304953	100736228	20992699648	to	to	II
304953	100736228	20992699649	prostate	prostate	NN1
304953	100736228	20992699650	cancer	cancer	NN1
304953	100736228	20992699651	and	and	CC
304953	100736228	20992699652	an	a	AT1
304953	100736228	20992699653	enlarged	enlarged	JJ
304953	100736228	20992699654	prostate	prostate	NN1
304953	100736228	20992699655	.	.	.
304953	100736228	20992699656	A	a	AT1
304953	100736228	20992699657	third	third	MD
304953	100736228	20992699658	condition	condition	NN1
304953	100736228	20992699659	,	,	,
304953	100736228	20992699660	prostatitis	prostatitis	NN1
304953	100736228	20992699661	,	,	,
304953	100736228	20992699662	flies	fly	VVZ_NN2
304953	100736228	20992699663	under	under	II
304953	100736228	20992699664	the	the	AT
304953	100736228	20992699665	radar	radar	NN1
304953	100736228	20992699666	even	even	CS21
304953	100736228	20992699667	though	though	CS22
304953	100736228	20992699668	it	it	PPH1
304953	100736228	20992699669	affects	affect	VVZ
304953	100736228	20992699670	up	up	RG21
304953	100736228	20992699671	to	to	RG22
304953	100736228	20992699672	one	one	MC1_PN1
304953	100736228	20992699673	in	in	II
304953	100736228	20992699674	six	six	MC
304953	100736228	20992699675	men	man	NN2
304953	100736228	20992699676	at	at	II
304953	100736228	20992699677	some	some	DD
304953	100736228	20992699678	point	point	NN1
304953	100736228	20992699679	in	in	II
304953	100736228	20992699680	their	their	APPGE
304953	100736228	20992699681	lifetimes	lifetime	NNT2
304953	100736228	20992699682	.	.	.
304953	100736228	20992699683	It	it	PPH1
304953	100736228	20992699684	triggers	trigger	VVZ
304953	100736228	20992699685	more	more	DAR
304953	100736228	20992699686	than	than	CSN
304953	100736228	20992699687	two	two	MC
304953	100736228	20992699688	million	million	NNO
304953	100736228	20992699689	visits	visit	NN2
304953	100736228	20992699690	to	to	II
304953	100736228	20992699691	doctors	doctor	NN2
304953	100736228	20992699692	and	and	CC
304953	100736228	20992699693	untold	untold	JJ
304953	100736228	20992699694	agony	agony	NN1
304953	100736228	20992699695	each	each	DD1
304953	100736228	20992699696	year	year	NNT1
304953	100736228	20992699697	.	.	.
304953	100736228	20992699698	<p>		NULL
304953	100736228	20992699699	Prostatitis	prostatitis	NN1_NP1@
304953	100736228	20992699700	,	,	,
304953	100736228	20992699701	which	which	DDQ
304953	100736228	20992699702	means	mean	VVZ
304953	100736228	20992699703	inflammation	inflammation	NN1
304953	100736228	20992699704	of	of	IO
304953	100736228	20992699705	the	the	AT
304953	100736228	20992699706	prostate	prostate	NN1
304953	100736228	20992699707	gland	gland	NN1
304953	100736228	20992699708	,	,	,
304953	100736228	20992699709	is	be	VBZ
304953	100736228	20992699710	an	a	AT1
304953	100736228	20992699711	equal	equal	JJ
304953	100736228	20992699712	opportunity	opportunity	NN1
304953	100736228	20992699713	disorder	disorder	NN1
304953	100736228	20992699714	.	.	.
304953	100736228	20992699715	Unlike	unlike	JJ
304953	100736228	20992699716	prostate	prostate	NN1
304953	100736228	20992699717	cancer	cancer	NN1
304953	100736228	20992699718	and	and	CC
304953	100736228	20992699719	benign	benign	JJ
304953	100736228	20992699720	prostatic	prostatic	JJ
304953	100736228	20992699721	hyperplasia	hyperplasia	NN1
304953	100736228	20992699722	(	(	(
304953	100736228	20992699723	BPH	bph	NP1
304953	100736228	20992699724	)	)	)
304953	100736228	20992699725	,	,	,
304953	100736228	20992699726	which	which	DDQ
304953	100736228	20992699727	predominantly	predominantly	RR
304953	100736228	20992699728	affect	affect	VV0
304953	100736228	20992699729	older	old	JJR
304953	100736228	20992699730	men	man	NN2
304953	100736228	20992699731	,	,	,
304953	100736228	20992699732	prostatitis	prostatitis	NN1
304953	100736228	20992699733	affects	affect	VVZ
304953	100736228	20992699734	men	man	NN2
304953	100736228	20992699735	of	of	IO
304953	100736228	20992699736	all	all	DB
304953	100736228	20992699737	ages	age	NN2
304953	100736228	20992699738	.	.	.
304953	100736228	20992699739	<p>		NULL
304953	100736228	20992699740	Prostatitis	prostatitis	NN1_NP1@
304953	100736228	20992699741	refers	refer	VVZ
304953	100736228	20992699742	to	to	II
304953	100736228	20992699743	a	a	AT1
304953	100736228	20992699744	loose	loose	JJ
304953	100736228	20992699745	assemblage	assemblage	NN1
304953	100736228	20992699746	of	of	IO
304953	100736228	20992699747	syndromes	syndrome	NN2
304953	100736228	20992699748	characterized	characterize	VVN
304953	100736228	20992699749	by	by	II
304953	100736228	20992699750	urinary	urinary	JJ_NN1
304953	100736228	20992699751	problems	problem	NN2
304953	100736228	20992699752	such	such	II21
304953	100736228	20992699753	as	as	II22
304953	100736228	20992699754	burning	burn	VVG_JJ
304953	100736228	20992699755	or	or	CC
304953	100736228	20992699756	painful	painful	JJ
304953	100736228	20992699757	urination	urination	NN1
304953	100736228	20992699758	,	,	,
304953	100736228	20992699759	the	the	AT
304953	100736228	20992699760	urgent	urgent	JJ
304953	100736228	20992699761	need	need	NN1
304953	100736228	20992699762	to	to	TO
304953	100736228	20992699763	urinate	urinate	VVI
304953	100736228	20992699764	,	,	,
304953	100736228	20992699765	trouble	trouble	NN1_VV0@
304953	100736228	20992699766	voiding	void	VVG_NN1@
304953	100736228	20992699767	,	,	,
304953	100736228	20992699768	difficult	difficult	JJ
304953	100736228	20992699769	or	or	CC
304953	100736228	20992699770	painful	painful	JJ
304953	100736228	20992699771	ejaculation	ejaculation	NN1
304953	100736228	20992699772	,	,	,
304953	100736228	20992699773	and	and	CC
304953	100736228	20992699774	pain	pain	NN1
304953	100736228	20992699775	in	in	II
304953	100736228	20992699776	the	the	AT
304953	100736228	20992699777	area	area	NN1
304953	100736228	20992699778	between	between	II
304953	100736228	20992699779	the	the	AT
304953	100736228	20992699780	scrotum	scrotum	NN1
304953	100736228	20992699781	and	and	CC
304953	100736228	20992699782	rectum	rectum	NN1
304953	100736228	20992699783	(	(	(
304953	100736228	20992699784	known	know	VVN
304953	100736228	20992699785	as	as	II
304953	100736228	20992699786	the	the	AT
304953	100736228	20992699787	perineum	perineum	NN1
304953	100736228	20992699788	)	)	)
304953	100736228	20992699789	or	or	CC
304953	100736228	20992699790	lower	low	JJR_VV0@
304953	100736228	20992699791	back	back	NN1_RP
304953	100736228	20992699792	.	.	.
304953	100736228	20992699793	Although	although	CS
304953	100736228	20992699794	it	it	PPH1
304953	100736228	20992699795	causes	cause	VVZ
304953	100736228	20992699796	some	some	DD
304953	100736228	20992699797	of	of	IO
304953	100736228	20992699798	the	the	AT
304953	100736228	20992699799	same	same	DA
304953	100736228	20992699800	symptoms	symptom	NN2
304953	100736228	20992699801	as	as	CSA
304953	100736228	20992699802	BPH	bph	NP1
304953	100736228	20992699803	and	and	CC
304953	100736228	20992699804	can	can	VM
304953	100736228	20992699805	occur	occur	VVI
304953	100736228	20992699806	at	at	II
304953	100736228	20992699807	the	the	AT
304953	100736228	20992699808	same	same	DA
304953	100736228	20992699809	time	time	NNT1
304953	100736228	20992699810	,	,	,
304953	100736228	20992699811	prostatitis	prostatitis	NN1
304953	100736228	20992699812	is	be	VBZ
304953	100736228	20992699813	a	a	AT1
304953	100736228	20992699814	separate	separate	JJ
304953	100736228	20992699815	condition	condition	NN1
304953	100736228	20992699816	.	.	.
304953	100736228	20992699817	<p>		NULL
304953	100736228	20992699818	Some	some	DD
304953	100736228	20992699819	types	type	NN2
304953	100736228	20992699820	of	of	IO
304953	100736228	20992699821	@		II
304953	100736228	20992699822	@		II
304953	100736228	20992699823	@		II
304953	100736228	20992699824	@		II
304953	100736228	20992699825	@		II
304953	100736228	20992699826	@		II
304953	100736228	20992699827	@		II
304953	100736228	20992699828	@		II
304953	100736228	20992699829	@		II
304953	100736228	20992699830	@		II
304953	100736228	20992699831	often	often	RR
304953	100736228	20992699832	accompanied	accompany	VVN
304953	100736228	20992699833	by	by	II
304953	100736228	20992699834	the	the	AT
304953	100736228	20992699835	classic	classic	JJ_NN1
304953	100736228	20992699836	symptoms	symptom	NN2
304953	100736228	20992699837	of	of	IO
304953	100736228	20992699838	infection	infection	NN1
304953	100736228	20992699839	,	,	,
304953	100736228	20992699840	such	such	II21
304953	100736228	20992699841	as	as	II22
304953	100736228	20992699842	fever	fever	NN1
304953	100736228	20992699843	,	,	,
304953	100736228	20992699844	chills	chill	NN2
304953	100736228	20992699845	,	,	,
304953	100736228	20992699846	and	and	CC
304953	100736228	20992699847	muscle	muscle	NN1
304953	100736228	20992699848	pain	pain	NN1
304953	100736228	20992699849	along	along	II21
304953	100736228	20992699850	with	with	II22
304953	100736228	20992699851	urinary	urinary	JJ_NN1
304953	100736228	20992699852	problems	problem	NN2
304953	100736228	20992699853	.	.	.
304953	100736228	20992699854	As	as	II
304953	100736228	20992699855	a	a	AT1
304953	100736228	20992699856	result	result	NN1
304953	100736228	20992699857	,	,	,
304953	100736228	20992699858	they	they	PPHS2
304953	100736228	20992699859	are	be	VBR
304953	100736228	20992699860	relatively	relatively	RR
304953	100736228	20992699861	easy	easy	JJ
304953	100736228	20992699862	to	to	TO
304953	100736228	20992699863	diagnose	diagnose	VVI
304953	100736228	20992699864	and	and	CC
304953	100736228	20992699865	treat	treat	NN1_VV0
304953	100736228	20992699866	,	,	,
304953	100736228	20992699867	and	and	CC
304953	100736228	20992699868	they	they	PPHS2
304953	100736228	20992699869	usually	usually	RR
304953	100736228	20992699870	respond	respond	VV0
304953	100736228	20992699871	well	well	RR
304953	100736228	20992699872	to	to	II
304953	100736228	20992699873	antibiotics	antibiotic	NN2
304953	100736228	20992699874	.	.	.
304953	100736228	20992699875	Unfortunately	unfortunately	RR
304953	100736228	20992699876	,	,	,
304953	100736228	20992699877	such	such	DA
304953	100736228	20992699878	straightforward	straightforward	JJ
304953	100736228	20992699879	forms	form	NN2
304953	100736228	20992699880	of	of	IO
304953	100736228	20992699881	prostatitis	prostatitis	NN1
304953	100736228	20992699882	are	be	VBR
304953	100736228	20992699883	the	the	AT
304953	100736228	20992699884	minority	minority	NN1
304953	100736228	20992699885	.	.	.
304953	100736228	20992699886	<p>		NULL
304953	100736228	20992699887	Physicians	physician	NN2
304953	100736228	20992699888	are	be	VB0
304953	100736228	20992699889	n't 	n't	XX
304953	100736228	20992699890	sure	sure	JJ_RR%
304953	100736228	20992699891	what	what	DDQ
304953	100736228	20992699892	causes	cause	VVZ
304953	100736228	20992699893	the	the	AT
304953	100736228	20992699894	rest	rest	NN1
304953	100736228	20992699895	.	.	.
304953	100736228	20992699896	Potential	potential	JJ_NN1
304953	100736228	20992699897	culprits	culprit	NN2
304953	100736228	20992699898	include	include	VV0
304953	100736228	20992699899	difficult-to-detect	difficult-to-detect	VV0
304953	100736228	20992699900	bacteria	bacteria	NN2
304953	100736228	20992699901	,	,	,
304953	100736228	20992699902	inflammation	inflammation	NN1
304953	100736228	20992699903	,	,	,
304953	100736228	20992699904	depression	depression	NN1
304953	100736228	20992699905	and	and	CC
304953	100736228	20992699906	stress	stress	NN1
304953	100736228	20992699907	,	,	,
304953	100736228	20992699908	and	and	CC
304953	100736228	20992699909	mechanical	mechanical	JJ
304953	100736228	20992699910	or	or	CC
304953	100736228	20992699911	neuromuscular	neuromuscular	JJ
304953	100736228	20992699912	problems	problem	NN2
304953	100736228	20992699913	in	in	II
304953	100736228	20992699914	the	the	AT
304953	100736228	20992699915	pelvic	pelvic	JJ
304953	100736228	20992699916	muscles	muscle	NN2
304953	100736228	20992699917	that	that	CST
304953	100736228	20992699918	irritate	irritate	VV0
304953	100736228	20992699919	the	the	AT
304953	100736228	20992699920	general	general	JJ_NN1
304953	100736228	20992699921	area	area	NN1
304953	100736228	20992699922	.	.	.
304953	100736228	20992699923	This	this	DD1
304953	100736228	20992699924	uncertainty	uncertainty	NN1
304953	100736228	20992699925	is	be	VBZ
304953	100736228	20992699926	what	what	DDQ
304953	100736228	20992699927	can	can	VM
304953	100736228	20992699928	make	make	VVI
304953	100736228	20992699929	the	the	AT
304953	100736228	20992699930	treatment	treatment	NN1
304953	100736228	20992699931	of	of	IO
304953	100736228	20992699932	prostatitis	prostatitis	NN1
304953	100736228	20992699933	so	so	RR_RG
304953	100736228	20992699934	maddening	madden	VVG_JJ@
304953	100736228	20992699935	.	.	.
304953	100736228	20992699936	<h>		NULL
304953	100736228	20992699937	Types	type	NN2
304953	100736228	20992699938	of	of	IO
304953	100736228	20992699939	prostatitis	prostatitis	NN1
304953	100736228	20992699940	<p>		NULL
304953	100736228	20992699941	Prostatitis	prostatitis	NN1_NP1@
304953	100736228	20992699942	is	be	VBZ
304953	100736228	20992699943	classified	classify	VVN
304953	100736228	20992699944	into	into	II
304953	100736228	20992699945	four	four	MC
304953	100736228	20992699946	categories	category	NN2
304953	100736228	20992699947	,	,	,
304953	100736228	20992699948	each	each	DD1
304953	100736228	20992699949	with	with	IW
304953	100736228	20992699950	its	its	APPGE
304953	100736228	20992699951	own	own	DA
304953	100736228	20992699952	treatment	treatment	NN1
304953	100736228	20992699953	approach	approach	NN1_VV0@
304953	100736228	20992699954	<h>		NULL
304953	100736228	20992699955	Acute	acute	JJ
304953	100736228	20992699956	infection	infection	NN1
304953	100736228	20992699957	of	of	IO
304953	100736228	20992699958	the	the	AT
304953	100736228	20992699959	prostate	prostate	NN1
304953	100736228	20992699960	<p>		NULL
304953	100736228	20992699961	This	this	DD1
304953	100736228	20992699962	sudden-onset	sudden-onset	JJ_NN1
304953	100736228	20992699963	infection	infection	NN1
304953	100736228	20992699964	is	be	VBZ
304953	100736228	20992699965	caused	cause	VVN
304953	100736228	20992699966	by	by	II
304953	100736228	20992699967	bacteria	bacteria	NN2
304953	100736228	20992699968	that	that	CST_DD1
304953	100736228	20992699969	travel	travel	VV0_NN1
304953	100736228	20992699970	from	from	II
304953	100736228	20992699971	the	the	AT
304953	100736228	20992699972	urethra	urethra	NN1
304953	100736228	20992699973	,	,	,
304953	100736228	20992699974	and	and	CC
304953	100736228	20992699975	perhaps	perhaps	RR
304953	100736228	20992699976	from	from	II
304953	100736228	20992699977	the	the	AT
304953	100736228	20992699978	rectum	rectum	NN1
304953	100736228	20992699979	,	,	,
304953	100736228	20992699980	to	to	II
304953	100736228	20992699981	the	the	AT
304953	100736228	20992699982	prostate	prostate	NN1
304953	100736228	20992699983	.	.	.
304953	100736228	20992699984	Its	its	APPGE
304953	100736228	20992699985	the	the	AT
304953	100736228	20992699986	least	least	RGT
304953	100736228	20992699987	common	common	JJ
304953	100736228	20992699988	but	but	CCB
304953	100736228	20992699989	most	most	RGT_DAT
304953	100736228	20992699990	dramatic	dramatic	JJ
304953	100736228	20992699991	form	form	NN1
304953	100736228	20992699992	of	of	IO
304953	100736228	20992699993	prostatitis	prostatitis	NN1
304953	100736228	20992699994	,	,	,
304953	100736228	20992699995	beginning	begin	VVG
304953	100736228	20992699996	abruptly	abruptly	RR
304953	100736228	20992699997	with	with	IW
304953	100736228	20992699998	high	high	JJ
304953	100736228	20992699999	fever	fever	NN1
304953	100736228	20992700000	,	,	,
304953	100736228	20992700001	chills	chill	NN2
304953	100736228	20992700002	,	,	,
304953	100736228	20992700003	joint	joint	JJ
304953	100736228	20992700004	and	and	CC
304953	100736228	20992700005	muscle	muscle	NN1
304953	100736228	20992700006	aches	ache	NN2_VVZ
304953	100736228	20992700007	,	,	,
304953	100736228	20992700008	and	and	CC
304953	100736228	20992700009	profound	profound	JJ
304953	100736228	20992700010	fatigue	fatigue	NN1
304953	100736228	20992700011	.	.	.
304953	100736228	20992700012	In	in	RR21
304953	100736228	20992700013	addition	addition	RR22
304953	100736228	20992700014	,	,	,
304953	100736228	20992700015	you	you	PPY
304953	100736228	20992700016	may	may	VM
304953	100736228	20992700017	have	have	VHI
304953	100736228	20992700018	pain	pain	NN1
304953	100736228	20992700019	around	around	II
304953	100736228	20992700020	the	the	AT
304953	100736228	20992700021	@		II
304953	100736228	20992700022	@		II
304953	100736228	20992700023	@		II
304953	100736228	20992700024	@		II
304953	100736228	20992700025	@		II
304953	100736228	20992700026	@		II
304953	100736228	20992700027	@		II
304953	100736228	20992700028	@		II
304953	100736228	20992700029	@		II
304953	100736228	20992700030	@		II
304953	100736228	20992700031	in	in	II
304953	100736228	20992700032	the	the	AT
304953	100736228	20992700033	lower	low	JJR
304953	100736228	20992700034	back	back	NN1
304953	100736228	20992700035	,	,	,
304953	100736228	20992700036	and	and	CC
304953	100736228	20992700037	the	the	AT
304953	100736228	20992700038	feeling	feeling	NN1
304953	100736228	20992700039	of	of	IO
304953	100736228	20992700040	a	a	AT1
304953	100736228	20992700041	full	full	JJ
304953	100736228	20992700042	rectum	rectum	NN1
304953	100736228	20992700043	.	.	.
304953	100736228	20992700044	As	as	II_CSA
304953	100736228	20992700045	the	the	AT
304953	100736228	20992700046	prostate	prostate	NN1
304953	100736228	20992700047	becomes	become	VVZ
304953	100736228	20992700048	more	more	RGR_RRR_DAR
304953	100736228	20992700049	swollen	swollen	JJ_VVN
304953	100736228	20992700050	,	,	,
304953	100736228	20992700051	you	you	PPY
304953	100736228	20992700052	may	may	VM
304953	100736228	20992700053	find	find	VVI
304953	100736228	20992700054	it	it	PPH1
304953	100736228	20992700055	more	more	RGR
304953	100736228	20992700056	difficult	difficult	JJ
304953	100736228	20992700057	to	to	TO
304953	100736228	20992700058	urinate	urinate	VVI
304953	100736228	20992700059	,	,	,
304953	100736228	20992700060	and	and	CC
304953	100736228	20992700061	the	the	AT
304953	100736228	20992700062	urine	urine	NN1
304953	100736228	20992700063	stream	stream	NN1
304953	100736228	20992700064	may	may	VM
304953	100736228	20992700065	become	become	VVI
304953	100736228	20992700066	weak	weak	JJ
304953	100736228	20992700067	.	.	.
304953	100736228	20992700068	(	(	(
304953	100736228	20992700069	If	if	CS_CSW@
304953	100736228	20992700070	you	you	PPY
304953	100736228	20992700071	ca n't		JJ
304953	100736228	20992700072	urinate	urinate	NN1_JJ
304953	100736228	20992700073	at	at	RR21_II
304953	100736228	20992700074	all	all	RR22_DB
304953	100736228	20992700075	,	,	,
304953	100736228	20992700076	its	its	APPGE
304953	100736228	20992700077	a	a	AT1
304953	100736228	20992700078	medical	medical	JJ
304953	100736228	20992700079	emergency	emergency	NN1
304953	100736228	20992700080	;	;	;
304953	100736228	20992700081	this	this	DD1
304953	100736228	20992700082	usually	usually	RR
304953	100736228	20992700083	means	mean	VVZ
304953	100736228	20992700084	the	the	AT
304953	100736228	20992700085	prostate	prostate	NN1
304953	100736228	20992700086	is	be	VBZ
304953	100736228	20992700087	so	so	RR_RG
304953	100736228	20992700088	swollen	swell	VVN_JJ
304953	100736228	20992700089	that	that	CST
304953	100736228	20992700090	its	its	APPGE
304953	100736228	20992700091	completely	completely	RR
304953	100736228	20992700092	blocking	blocking	JJ_VVG
304953	100736228	20992700093	urine	urine	NN1
304953	100736228	20992700094	flow	flow	NN1
304953	100736228	20992700095	.	.	.
304953	100736228	20992700096	Depending	depending	II21
304953	100736228	20992700097	on	on	II22
304953	100736228	20992700098	the	the	AT
304953	100736228	20992700099	severity	severity	NN1
304953	100736228	20992700100	of	of	IO
304953	100736228	20992700101	symptoms	symptom	NN2
304953	100736228	20992700102	,	,	,
304953	100736228	20992700103	hospitalization	hospitalization	NN1
304953	100736228	20992700104	may	may	VM
304953	100736228	20992700105	be	be	VBI
304953	100736228	20992700106	necessary	necessary	JJ
304953	100736228	20992700107	.	.	.
304953	100736228	20992700108	)	)	)
304953	100736228	20992700109	<p>		NULL
304953	100736228	20992700110	Antibiotics	antibiotic	NN2
304953	100736228	20992700111	are	be	VBR
304953	100736228	20992700112	the	the	AT
304953	100736228	20992700113	standard	standard	JJ_NN1
304953	100736228	20992700114	treatment	treatment	NN1
304953	100736228	20992700115	and	and	CC
304953	100736228	20992700116	are	be	VBR
304953	100736228	20992700117	highly	highly	RR
304953	100736228	20992700118	effective	effective	JJ
304953	100736228	20992700119	for	for	IF
304953	100736228	20992700120	this	this	DD1
304953	100736228	20992700121	form	form	NN1
304953	100736228	20992700122	of	of	IO
304953	100736228	20992700123	prostatitis	prostatitis	NN1
304953	100736228	20992700124	Typical	typical	JJ
304953	100736228	20992700125	choices	choice	NN2
304953	100736228	20992700126	include	include	VV0
304953	100736228	20992700127	fluoroquinolones	fluoroquinolone	NN2
304953	100736228	20992700128	"	"	"
304953	100736228	20992700129	such	such	II21
304953	100736228	20992700130	as	as	II22
304953	100736228	20992700131	ciprofloxacin	ciprofloxacin	NN1
304953	100736228	20992700132	(	(	(
304953	100736228	20992700133	Cipro	cipro	NP1
304953	100736228	20992700134	)	)	)
304953	100736228	20992700135	,	,	,
304953	100736228	20992700136	levofloxacin	levofloxacin	NN1
304953	100736228	20992700137	(	(	(
304953	100736228	20992700138	Levaquin		NP1
304953	100736228	20992700139	)	)	)
304953	100736228	20992700140	,	,	,
304953	100736228	20992700141	and	and	CC
304953	100736228	20992700142	ofloxacin	ofloxacin	NN1
304953	100736228	20992700143	(	(	(
304953	100736228	20992700144	Floxin		NP1
304953	100736228	20992700145	)	)	)
304953	100736228	20992700146	"	"	"
304953	100736228	20992700147	and	and	CC
304953	100736228	20992700148	**29;0;TOOLONG	**29;0;toolong	FO
304953	100736228	20992700149	(	(	(
304953	100736228	20992700150	Bactrim		NP1_VV0_NN1
304953	100736228	20992700151	,	,	,
304953	100736228	20992700152	Septra		NP1
304953	100736228	20992700153	,	,	,
304953	100736228	20992700154	Cotrim		NP1
304953	100736228	20992700155	)	)	)
304953	100736228	20992700156	.	.	.
304953	100736228	20992700157	Its	its	APPGE
304953	100736228	20992700158	important	important	JJ
304953	100736228	20992700159	to	to	TO
304953	100736228	20992700160	continue	continue	VVI
304953	100736228	20992700161	your	your	APPGE
304953	100736228	20992700162	medication	medication	NN1
304953	100736228	20992700163	for	for	IF
304953	100736228	20992700164	the	the	AT
304953	100736228	20992700165	entire	entire	JJ
304953	100736228	20992700166	prescribed	prescribed	JJ
304953	100736228	20992700167	course	course	NN1
304953	100736228	20992700168	,	,	,
304953	100736228	20992700169	even	even	CS21
304953	100736228	20992700170	if	if	CS22
304953	100736228	20992700171	you	you	PPY
304953	100736228	20992700172	are	be	VBR
304953	100736228	20992700173	feeling	feel	VVG
304953	100736228	20992700174	better	better	RRR_JJR
304953	100736228	20992700175	.	.	.
304953	100736228	20992700176	This	this	DD1
304953	100736228	20992700177	will	will	VM
304953	100736228	20992700178	help	help	VVI
304953	100736228	20992700179	prevent	prevent	VVI
304953	100736228	20992700180	your	your	APPGE
304953	100736228	20992700181	infection	infection	NN1
304953	100736228	20992700182	from	from	II
304953	100736228	20992700183	returning	return	VVG_NN1@
304953	100736228	20992700184	.	.	.
304953	100736228	20992700185	<p>		NULL
304953	100736228	20992700186	To	to	TO
304953	100736228	20992700187	help	help	VVI
304953	100736228	20992700188	ease	ease	VVI
304953	100736228	20992700189	any	any	DD
304953	100736228	20992700190	discomfort	discomfort	NN1
304953	100736228	20992700191	,	,	,
304953	100736228	20992700192	try	try	VV0
304953	100736228	20992700193	sitting	sit	VVG
304953	100736228	20992700194	in	in	II_RP@
304953	100736228	20992700195	a	a	AT1
304953	100736228	20992700196	hot	hot	JJ
304953	100736228	20992700197	bath	bath	NN1
304953	100736228	20992700198	,	,	,
304953	100736228	20992700199	take	take	VV0
304953	100736228	20992700200	stool	stool	NN1
304953	100736228	20992700201	softeners	softener	NN2
304953	100736228	20992700202	,	,	,
304953	100736228	20992700203	and	and	CC
304953	100736228	20992700204	use	use	VV0_NN1
304953	100736228	20992700205	over-the-counter	over-the-counter	JJ_NN1
304953	100736228	20992700206	pain	pain	NN1
304953	100736228	20992700207	relievers	reliever	VVZ
304953	100736228	20992700208	,	,	,
304953	100736228	20992700209	such	such	II21
304953	100736228	20992700210	as	as	II22
304953	100736228	20992700211	aspirin	aspirin	NN
304953	100736228	20992700212	or	or	CC
304953	100736228	20992700213	ibuprofen	ibuprofen	NN1_JJ
304953	100736228	20992700214	.	.	.
304953	100736228	20992700215	Drinking	drink	VVG
304953	100736228	20992700216	plenty	plenty	PN
304953	100736228	20992700217	of	of	IO
304953	100736228	20992700218	fluids	fluid	NN2
304953	100736228	20992700219	can	can	VM
304953	100736228	20992700220	help	help	VVI
304953	100736228	20992700221	@		II
304953	100736228	20992700222	@		II
304953	100736228	20992700223	@		II
304953	100736228	20992700224	@		II
304953	100736228	20992700225	@		II
304953	100736228	20992700226	@		II
304953	100736228	20992700227	@		II
304953	100736228	20992700228	@		II
304953	100736228	20992700229	@		II
304953	100736228	20992700230	@		II
304953	100736228	20992700231	Chronic	chronic	JJ
304953	100736228	20992700232	bacterial	bacterial	JJ
304953	100736228	20992700233	prostatitis	prostatitis	NN1
304953	100736228	20992700234	<p>		NULL
304953	100736228	20992700235	This	this	DD1
304953	100736228	20992700236	type	type	NN1
304953	100736228	20992700237	of	of	IO
304953	100736228	20992700238	prostatitis	prostatitis	NN1
304953	100736228	20992700239	is	be	VBZ
304953	100736228	20992700240	also	also	RR
304953	100736228	20992700241	caused	cause	VVN
304953	100736228	20992700242	by	by	II
304953	100736228	20992700243	bacteria	bacteria	NN2
304953	100736228	20992700244	.	.	.
304953	100736228	20992700245	Its	its	APPGE
304953	100736228	20992700246	more	more	RGR
304953	100736228	20992700247	common	common	JJ
304953	100736228	20992700248	in	in	II
304953	100736228	20992700249	older	old	JJR
304953	100736228	20992700250	men	man	NN2
304953	100736228	20992700251	who	who	PNQS
304953	100736228	20992700252	have	have	VH0
304953	100736228	20992700253	BPH	bph	NP1
304953	100736228	20992700254	.	.	.
304953	100736228	20992700255	It	it	PPH1
304953	100736228	20992700256	sometimes	sometimes	RT
304953	100736228	20992700257	follows	follow	VVZ
304953	100736228	20992700258	a	a	AT1
304953	100736228	20992700259	bout	bout	NN1
304953	100736228	20992700260	of	of	IO
304953	100736228	20992700261	acute	acute	JJ
304953	100736228	20992700262	bacterial	bacterial	JJ
304953	100736228	20992700263	prostatitis	prostatitis	NN1
304953	100736228	20992700264	.	.	.
304953	100736228	20992700265	Unlike	unlike	II@
304953	100736228	20992700266	the	the	AT
304953	100736228	20992700267	acute	acute	JJ
304953	100736228	20992700268	form	form	NN1
304953	100736228	20992700269	,	,	,
304953	100736228	20992700270	however	however	RR
304953	100736228	20992700271	,	,	,
304953	100736228	20992700272	chronic	chronic	JJ
304953	100736228	20992700273	bacterial	bacterial	JJ
304953	100736228	20992700274	prostatitis	prostatitis	NN1
304953	100736228	20992700275	is	be	VBZ
304953	100736228	20992700276	a	a	AT1
304953	100736228	20992700277	subtle	subtle	JJ
304953	100736228	20992700278	,	,	,
304953	100736228	20992700279	low-grade	low-grade	JJ_NN1
304953	100736228	20992700280	infection	infection	NN1
304953	100736228	20992700281	that	that	CST_DD1
304953	100736228	20992700282	can	can	VM
304953	100736228	20992700283	begin	begin	VVI
304953	100736228	20992700284	insidiously	insidiously	RR
304953	100736228	20992700285	and	and	CC
304953	100736228	20992700286	persist	persist	VVI
304953	100736228	20992700287	for	for	IF
304953	100736228	20992700288	weeks	week	NNT2
304953	100736228	20992700289	or	or	CC
304953	100736228	20992700290	even	even	RR_JJ%
304953	100736228	20992700291	months	month	NNT2
304953	100736228	20992700292	.	.	.
304953	100736228	20992700293	<p>		NULL
304953	100736228	20992700294	A	a	AT1
304953	100736228	20992700295	man	man	NN1
304953	100736228	20992700296	with	with	IW
304953	100736228	20992700297	chronic	chronic	JJ
304953	100736228	20992700298	bacterial	bacterial	JJ
304953	100736228	20992700299	prostatitis	prostatitis	NN1
304953	100736228	20992700300	usually	usually	RR
304953	100736228	20992700301	does	do	VDZ
304953	100736228	20992700302	n't 	n't	XX
304953	100736228	20992700303	have	have	VHI
304953	100736228	20992700304	a	a	AT1
304953	100736228	20992700305	fever	fever	NN1
304953	100736228	20992700306	,	,	,
304953	100736228	20992700307	but	but	CCB
304953	100736228	20992700308	is	be	VBZ
304953	100736228	20992700309	troubled	trouble	VVN
304953	100736228	20992700310	by	by	II
304953	100736228	20992700311	intermittent	intermittent	JJ
304953	100736228	20992700312	symptoms	symptom	NN2
304953	100736228	20992700313	such	such	II21
304953	100736228	20992700314	as	as	II22
304953	100736228	20992700315	a	a	AT1
304953	100736228	20992700316	sudden	sudden	JJ
304953	100736228	20992700317	urge	urge	NN1
304953	100736228	20992700318	to	to	TO
304953	100736228	20992700319	urinate	urinate	VVI
304953	100736228	20992700320	,	,	,
304953	100736228	20992700321	frequent	frequent	JJ
304953	100736228	20992700322	urination	urination	NN1
304953	100736228	20992700323	,	,	,
304953	100736228	20992700324	painful	painful	JJ
304953	100736228	20992700325	urination	urination	NN1
304953	100736228	20992700326	,	,	,
304953	100736228	20992700327	or	or	CC
304953	100736228	20992700328	the	the	AT
304953	100736228	20992700329	need	need	NN1
304953	100736228	20992700330	to	to	TO
304953	100736228	20992700331	get	get	VVI
304953	100736228	20992700332	up	up	RP
304953	100736228	20992700333	at	at	II
304953	100736228	20992700334	night	night	NNT1
304953	100736228	20992700335	to	to	TO
304953	100736228	20992700336	urinate	urinate	VVI
304953	100736228	20992700337	.	.	.
304953	100736228	20992700338	Some	some	DD
304953	100736228	20992700339	men	man	NN2
304953	100736228	20992700340	have	have	VH0
304953	100736228	20992700341	low	low	JJ_RR@
304953	100736228	20992700342	back	back	NN1_JJ@
304953	100736228	20992700343	pain	pain	NN1
304953	100736228	20992700344	,	,	,
304953	100736228	20992700345	pain	pain	NN1
304953	100736228	20992700346	in	in	II
304953	100736228	20992700347	the	the	AT
304953	100736228	20992700348	rectum	rectum	NN1
304953	100736228	20992700349	,	,	,
304953	100736228	20992700350	or	or	CC
304953	100736228	20992700351	a	a	AT1
304953	100736228	20992700352	feeling	feeling	NN1
304953	100736228	20992700353	of	of	IO
304953	100736228	20992700354	heaviness	heaviness	NN1
304953	100736228	20992700355	behind	behind	II
304953	100736228	20992700356	the	the	AT
304953	100736228	20992700357	scrotum	scrotum	NN1
304953	100736228	20992700358	.	.	.
304953	100736228	20992700359	Others	others	NN2
304953	100736228	20992700360	have	have	VH0
304953	100736228	20992700361	pain	pain	NN1
304953	100736228	20992700362	after	after	II_CS
304953	100736228	20992700363	ejaculation	ejaculation	NN1
304953	100736228	20992700364	,	,	,
304953	100736228	20992700365	and	and	CC
304953	100736228	20992700366	the	the	AT
304953	100736228	20992700367	semen	semen	NN1
304953	100736228	20992700368	may	may	VM
304953	100736228	20992700369	be	be	VBI
304953	100736228	20992700370	tinged	tinge	VVN
304953	100736228	20992700371	with	with	IW
304953	100736228	20992700372	blood	blood	NN1
304953	100736228	20992700373	.	.	.
304953	100736228	20992700374	These	these	DD2
304953	100736228	20992700375	symptoms	symptom	NN2
304953	100736228	20992700376	wax	wax	VV0_NN1
304953	100736228	20992700377	and	and	CC
304953	100736228	20992700378	wane	wane	NN1_VV0
304953	100736228	20992700379	,	,	,
304953	100736228	20992700380	and	and	CC
304953	100736228	20992700381	they	they	PPHS2
304953	100736228	20992700382	are	be	VBR
304953	100736228	20992700383	sometimes	sometimes	RT
304953	100736228	20992700384	so	so	RR
304953	100736228	20992700385	understated	understate	VVN_VVD
304953	100736228	20992700386	that	that	CST
304953	100736228	20992700387	they	they	PPHS2
304953	100736228	20992700388	are	be	VB0
304953	100736228	20992700389	n't 	n't	XX
304953	100736228	20992700390	noticeable	noticeable	JJ
304953	100736228	20992700391	.	.	.
304953	100736228	20992700392	<p>		NULL
304953	100736228	20992700393	Treatment	treatment	NN1
304953	100736228	20992700394	requires	require	VVZ
304953	100736228	20992700395	the	the	AT
304953	100736228	20992700396	same	same	DA
304953	100736228	20992700397	antibiotics	antibiotic	NN2
304953	100736228	20992700398	used	use	VVN_VVD
304953	100736228	20992700399	for	for	IF
304953	100736228	20992700400	the	the	AT
304953	100736228	20992700401	acute	acute	JJ
304953	100736228	20992700402	form	form	NN1
304953	100736228	20992700403	,	,	,
304953	100736228	20992700404	usually	usually	RR
304953	100736228	20992700405	for	for	IF
304953	100736228	20992700406	one	one	MC1
304953	100736228	20992700407	to	to	II
304953	100736228	20992700408	three	three	MC
304953	100736228	20992700409	months	month	NNT2
304953	100736228	20992700410	,	,	,
304953	100736228	20992700411	but	but	CCB
304953	100736228	20992700412	even	even	RR
304953	100736228	20992700413	with	with	IW
304953	100736228	20992700414	the	the	AT
304953	100736228	20992700415	prolonged	prolonged	JJ
304953	100736228	20992700416	treatment	treatment	NN1
304953	100736228	20992700417	,	,	,
304953	100736228	20992700418	the	the	AT
304953	100736228	20992700419	infection	infection	NN1
304953	100736228	20992700420	often	often	RR
304953	100736228	20992700421	@		II
304953	100736228	20992700422	@		II
304953	100736228	20992700423	@		II
304953	100736228	20992700424	@		II
304953	100736228	20992700425	@		II
304953	100736228	20992700426	@		II
304953	100736228	20992700427	@		II
304953	100736228	20992700428	@		II
304953	100736228	20992700429	@		II
304953	100736228	20992700430	@		II
304953	100736228	20992700431	be	be	VBI
304953	100736228	20992700432	controlled	control	VVN
304953	100736228	20992700433	with	with	IW
304953	100736228	20992700434	another	another	DD1
304953	100736228	20992700435	course	course	NN1
304953	100736228	20992700436	of	of	IO
304953	100736228	20992700437	antibiotics	antibiotic	NN2
304953	100736228	20992700438	.	.	.
304953	100736228	20992700439	<h>		NULL
304953	100736228	20992700440	Chronic	chronic	JJ
304953	100736228	20992700441	nonbacterial	nonbacterial	JJ
304953	100736228	20992700442	prostatitis	prostatitis	NN1
304953	100736228	20992700443	<p>		NULL
304953	100736228	20992700444	Chronic	chronic	JJ
304953	100736228	20992700445	nonbacterial	nonbacterial	JJ
304953	100736228	20992700446	prostatitis	prostatitis	NN1
304953	100736228	20992700447	,	,	,
304953	100736228	20992700448	also	also	RR
304953	100736228	20992700449	known	know	VVN
304953	100736228	20992700450	as	as	II
304953	100736228	20992700451	chronic	chronic	JJ
304953	100736228	20992700452	pelvic	pelvic	JJ
304953	100736228	20992700453	pain	pain	NN1
304953	100736228	20992700454	syndrome	syndrome	NN1
304953	100736228	20992700455	is	be	VBZ
304953	100736228	20992700456	the	the	AT
304953	100736228	20992700457	most	most	RGT
304953	100736228	20992700458	common	common	JJ
304953	100736228	20992700459	form	form	NN1
304953	100736228	20992700460	of	of	IO
304953	100736228	20992700461	prostatitis	prostatitis	NN1
304953	100736228	20992700462	.	.	.
304953	100736228	20992700463	Its	its	APPGE
304953	100736228	20992700464	symptoms	symptom	NN2
304953	100736228	20992700465	resemble	resemble	VV0
304953	100736228	20992700466	those	those	DD2
304953	100736228	20992700467	of	of	IO
304953	100736228	20992700468	chronic	chronic	JJ
304953	100736228	20992700469	bacterial	bacterial	JJ
304953	100736228	20992700470	prostatitis	prostatitis	NN1
304953	100736228	20992700471	.	.	.
304953	100736228	20992700472	Yet	yet	RR
304953	100736228	20992700473	no	no	AT
304953	100736228	20992700474	bacteria	bacteria	NN2
304953	100736228	20992700475	are	be	VBR
304953	100736228	20992700476	evident	evident	JJ
304953	100736228	20992700477	,	,	,
304953	100736228	20992700478	and	and	CC
304953	100736228	20992700479	pinpointing	pinpoint	VVG
304953	100736228	20992700480	a	a	AT1
304953	100736228	20992700481	cause	cause	NN1
304953	100736228	20992700482	or	or	CC
304953	100736228	20992700483	causes	cause	NN2
304953	100736228	20992700484	has	have	VHZ
304953	100736228	20992700485	been	be	VBN
304953	100736228	20992700486	difficult	difficult	JJ
304953	100736228	20992700487	.	.	.
304953	100736228	20992700488	<p>		NULL
304953	100736228	20992700489	Research	research	NN1
304953	100736228	20992700490	suggests	suggest	VVZ
304953	100736228	20992700491	that	that	CST_DD1
304953	100736228	20992700492	chronic	chronic	JJ
304953	100736228	20992700493	nonbacterial	nonbacterial	JJ
304953	100736228	20992700494	prostatitis	prostatitis	NN1
304953	100736228	20992700495	may	may	VM
304953	100736228	20992700496	result	result	VVI
304953	100736228	20992700497	from	from	II
304953	100736228	20992700498	a	a	AT1
304953	100736228	20992700499	cascade	cascade	NN1
304953	100736228	20992700500	of	of	IO
304953	100736228	20992700501	interconnected	interconnected	JJ@
304953	100736228	20992700502	events	event	NN2
304953	100736228	20992700503	.	.	.
304953	100736228	20992700504	The	the	AT
304953	100736228	20992700505	initiating	initiating	JJ%_VVG_NN1%
304953	100736228	20992700506	event	event	NN1
304953	100736228	20992700507	may	may	VM
304953	100736228	20992700508	be	be	VBI
304953	100736228	20992700509	stress	stress	NN1
304953	100736228	20992700510	,	,	,
304953	100736228	20992700511	an	a	AT1
304953	100736228	20992700512	undetectable	undetectable	JJ
304953	100736228	20992700513	infectious	infectious	JJ
304953	100736228	20992700514	agent	agent	NN1
304953	100736228	20992700515	,	,	,
304953	100736228	20992700516	or	or	CC
304953	100736228	20992700517	a	a	AT1
304953	100736228	20992700518	physical	physical	JJ
304953	100736228	20992700519	trauma	trauma	NN1
304953	100736228	20992700520	that	that	CST_DD1
304953	100736228	20992700521	causes	cause	VVZ
304953	100736228	20992700522	inflammation	inflammation	NN1
304953	100736228	20992700523	or	or	CC
304953	100736228	20992700524	nerve	nerve	NN1_VV0@
304953	100736228	20992700525	damage	damage	NN1_VV0
304953	100736228	20992700526	in	in	II
304953	100736228	20992700527	the	the	AT
304953	100736228	20992700528	genitourinary	genitourinary	JJ_NN1
304953	100736228	20992700529	area	area	NN1
304953	100736228	20992700530	.	.	.
304953	100736228	20992700531	Over	over	II
304953	100736228	20992700532	time	time	NNT1
304953	100736228	20992700533	,	,	,
304953	100736228	20992700534	this	this	DD1
304953	100736228	20992700535	may	may	VM
304953	100736228	20992700536	lead	lead	VVI
304953	100736228	20992700537	to	to	II
304953	100736228	20992700538	heightened	heightened	JJ
304953	100736228	20992700539	sensitivity	sensitivity	NN1
304953	100736228	20992700540	of	of	IO
304953	100736228	20992700541	the	the	AT
304953	100736228	20992700542	nervous	nervous	JJ
304953	100736228	20992700543	system	system	NN1
304953	100736228	20992700544	.	.	.
304953	100736228	20992700545	In	in	II
304953	100736228	20992700546	other	other	JJ
304953	100736228	20992700547	words	word	NN2
304953	100736228	20992700548	,	,	,
304953	100736228	20992700549	CP/CPPS		FU
304953	100736228	20992700550	may	may	VM
304953	100736228	20992700551	be	be	VBI
304953	100736228	20992700552	an	a	AT1
304953	100736228	20992700553	overactive	overactive	JJ
304953	100736228	20992700554	pain	pain	NN1
304953	100736228	20992700555	syndrome	syndrome	NN1
304953	100736228	20992700556	.	.	.
304953	100736228	20992700557	What 's		NN2
304953	100736228	20992700558	more	more	RRR
304953	100736228	20992700559	,	,	,
304953	100736228	20992700560	some	some	DD
304953	100736228	20992700561	physicians	physician	NN2
304953	100736228	20992700562	and	and	CC
304953	100736228	20992700563	researchers	researcher	NN2
304953	100736228	20992700564	are	be	VBR
304953	100736228	20992700565	beginning	begin	VVG
304953	100736228	20992700566	to	to	TO
304953	100736228	20992700567	think	think	VVI
304953	100736228	20992700568	that	that	CST
304953	100736228	20992700569	the	the	AT
304953	100736228	20992700570	condition	condition	NN1
304953	100736228	20992700571	may	may	VM
304953	100736228	20992700572	affect	affect	VVI
304953	100736228	20992700573	the	the	AT
304953	100736228	20992700574	entire	entire	JJ
304953	100736228	20992700575	pelvic	pelvic	JJ
304953	100736228	20992700576	floor	floor	NN1
304953	100736228	20992700577	"	"	"
304953	100736228	20992700578	all	all	DB
304953	100736228	20992700579	of	of	IO
304953	100736228	20992700580	the	the	AT
304953	100736228	20992700581	muscles	muscle	NN2
304953	100736228	20992700582	involved	involved	JJ
304953	100736228	20992700583	with	with	IW
304953	100736228	20992700584	bowel	bowel	NN1
304953	100736228	20992700585	,	,	,
304953	100736228	20992700586	bladder	bladder	NN1
304953	100736228	20992700587	,	,	,
304953	100736228	20992700588	and	and	CC
304953	100736228	20992700589	sexual	sexual	JJ
304953	100736228	20992700590	function	function	NN1
304953	100736228	20992700591	"	"	"
304953	100736228	20992700592	not	not	XX
304953	100736228	20992700593	just	just	RR
304953	100736228	20992700594	the	the	AT
304953	100736228	20992700595	prostate	prostate	NN1
304953	100736228	20992700596	gland	gland	NN1
304953	100736228	20992700597	.	.	.
304953	100736228	20992700598	<p>		NULL
304953	100736228	20992700599	Because	because	CS
304953	100736228	20992700600	men	man	NN2
304953	100736228	20992700601	often	often	RR
304953	100736228	20992700602	suffer	suffer	VV0
304953	100736228	20992700603	from	from	II
304953	100736228	20992700604	multiple	multiple	JJ_NN1
304953	100736228	20992700605	symptoms	symptom	NN2
304953	100736228	20992700606	simultaneously	simultaneously	RR
304953	100736228	20992700607	"	"	"
304953	100736228	20992700608	such	such	II21
304953	100736228	20992700609	as	as	II22
304953	100736228	20992700610	pain	pain	NN1
304953	100736228	20992700611	and	and	CC
304953	100736228	20992700612	difficulty	difficulty	NN1
304953	100736228	20992700613	urinating	urinate	VVG
304953	100736228	20992700614	"	"	"
304953	100736228	20992700615	they	they	PPHS2
304953	100736228	20992700616	may	may	VM
304953	100736228	20992700617	require	require	VVI
304953	100736228	20992700618	several	several	DA2
304953	100736228	20992700619	types	type	NN2
304953	100736228	20992700620	of	of	IO
304953	100736228	20992700621	@		II
304953	100736228	20992700622	@		II
304953	100736228	20992700623	@		II
304953	100736228	20992700624	@		II
304953	100736228	20992700625	@		II
304953	100736228	20992700626	@		II
304953	100736228	20992700627	@		II
304953	100736228	20992700628	@		II
304953	100736228	20992700629	@		II
304953	100736228	20992700630	@		II
304953	100736228	20992700631	symptoms	symptom	NN2
304953	100736228	20992700632	.	.	.
304953	100736228	20992700633	These	these	DD2
304953	100736228	20992700634	include	include	VV0
304953	100736228	20992700635	antibiotics	antibiotic	NN2
304953	100736228	20992700636	,	,	,
304953	100736228	20992700637	Pain	pain	NN1
304953	100736228	20992700638	relievers	reliever	VVZ
304953	100736228	20992700639	,	,	,
304953	100736228	20992700640	a	a	AT1
304953	100736228	20992700641	medication	medication	NN1
304953	100736228	20992700642	to	to	TO
304953	100736228	20992700643	reduce	reduce	VVI
304953	100736228	20992700644	the	the	AT
304953	100736228	20992700645	urge	urge	NN1
304953	100736228	20992700646	to	to	TO
304953	100736228	20992700647	urinate	urinate	VVI
304953	100736228	20992700648	,	,	,
304953	100736228	20992700649	a	a	AT1
304953	100736228	20992700650	medication	medication	NN1
304953	100736228	20992700651	to	to	TO
304953	100736228	20992700652	ease	ease	VVI
304953	100736228	20992700653	urine	urine	NN1
304953	100736228	20992700654	flow	flow	NN1
304953	100736228	20992700655	by	by	II
304953	100736228	20992700656	relaxing	relax	VVG
304953	100736228	20992700657	the	the	AT
304953	100736228	20992700658	muscles	muscle	NN2
304953	100736228	20992700659	at	at	II
304953	100736228	20992700660	the	the	AT
304953	100736228	20992700661	neck	neck	NN1
304953	100736228	20992700662	of	of	IO
304953	100736228	20992700663	the	the	AT
304953	100736228	20992700664	bladder	bladder	NN1
304953	100736228	20992700665	,	,	,
304953	100736228	20992700666	and	and	CC
304953	100736228	20992700667	even	even	RR
304953	100736228	20992700668	some	some	DD
304953	100736228	20992700669	alternative	alternative	JJ_NN1
304953	100736228	20992700670	therapies	therapy	NN2
304953	100736228	20992700671	such	such	II21
304953	100736228	20992700672	as	as	II22
304953	100736228	20992700673	myofascial	myofascial	JJ
304953	100736228	20992700674	release	release	NN1
304953	100736228	20992700675	.	.	.
304953	100736228	20992700676	(	(	(
304953	100736228	20992700677	**28;31;TOOLONG		NP1
304953	100736228	20992700678	will	will	VM
304953	100736228	20992700679	explore	explore	VVI
304953	100736228	20992700680	treatments	treatment	NN2
304953	100736228	20992700681	for	for	IF
304953	100736228	20992700682	chronic	chronic	JJ
304953	100736228	20992700683	nonbacterial	nonbacterial	JJ
304953	100736228	20992700684	prostatitis/chronic		FU
304953	100736228	20992700685	pelvic	pelvic	JJ
304953	100736228	20992700686	pain	pain	NN1
304953	100736228	20992700687	syndrome	syndrome	NN1
304953	100736228	20992700688	in	in	II
304953	100736228	20992700689	a	a	AT1
304953	100736228	20992700690	future	future	JJ_NN1
304953	100736228	20992700691	article	article	NN1
304953	100736228	20992700692	.	.	.
304953	100736228	20992700693	)	)	)
304953	100736228	20992700694	<h>		NULL
304953	100736228	20992700695	Asymptomatic	asymptomatic	JJ
304953	100736228	20992700696	inflammatory	inflammatory	JJ
304953	100736228	20992700697	prostatitis	prostatitis	NN1
304953	100736228	20992700698	<p>		NULL
304953	100736228	20992700699	This	this	DD1
304953	100736228	20992700700	is	be	VBZ
304953	100736228	20992700701	usually	usually	RR
304953	100736228	20992700702	discovered	discover	VVN
304953	100736228	20992700703	during	during	II
304953	100736228	20992700704	tests	test	NN2
304953	100736228	20992700705	for	for	IF
304953	100736228	20992700706	another	another	DD1
304953	100736228	20992700707	medical	medical	JJ
304953	100736228	20992700708	condition	condition	NN1
304953	100736228	20992700709	,	,	,
304953	100736228	20992700710	such	such	II21
304953	100736228	20992700711	as	as	II22
304953	100736228	20992700712	infertility	infertility	NN1
304953	100736228	20992700713	or	or	CC
304953	100736228	20992700714	other	other	JJ
304953	100736228	20992700715	prostate	prostate	NN1
304953	100736228	20992700716	disorders	disorder	NN2
304953	100736228	20992700717	.	.	.
304953	100736228	20992700718	White	white	JJ
304953	100736228	20992700719	blood	blood	NN1
304953	100736228	20992700720	cells	cell	NN2
304953	100736228	20992700721	are	be	VBR
304953	100736228	20992700722	present	present	JJ
304953	100736228	20992700723	in	in	II
304953	100736228	20992700724	the	the	AT
304953	100736228	20992700725	urine	urine	NN1
304953	100736228	20992700726	or	or	CC
304953	100736228	20992700727	prostate	prostate	NN1
304953	100736228	20992700728	secretions	secretion	NN2
304953	100736228	20992700729	,	,	,
304953	100736228	20992700730	but	but	CCB
304953	100736228	20992700731	there	there	EX
304953	100736228	20992700732	are	be	VBR
304953	100736228	20992700733	no	no	AT
304953	100736228	20992700734	symptoms	symptom	NN2
304953	100736228	20992700735	.	.	.
304953	100736228	20992700736	With	with	IW
304953	100736228	20992700737	no	no	AT
304953	100736228	20992700738	symptoms	symptom	NN2
304953	100736228	20992700739	and	and	CC
304953	100736228	20992700740	no	no	AT
304953	100736228	20992700741	known	known	JJ@
304953	100736228	20992700742	cause	cause	NN1
304953	100736228	20992700743	,	,	,
304953	100736228	20992700744	it	it	PPH1
304953	100736228	20992700745	is n't		NN1_VV0
304953	100736228	20992700746	treated	treat	VVN_VVD@
304953	100736228	20992700747	.	.	.
304953	100736229	20992700767	@@##	----------	----------
304953	100736229	20992700768	@@100736229		FO
304953	100736229	20992700769	@4936229/		VV0
304953	100736229	20992700770	<h>		NULL
304953	100736229	20992700771	How	how	RGQ@_RRQ
304953	100736229	20992700772	reliable	reliable	JJ
304953	100736229	20992700773	is	be	VBZ
304953	100736229	20992700774	the	the	AT
304953	100736229	20992700775	prostate-specific	prostate-specific	JJ
304953	100736229	20992700776	antigen	antigen	NN1
304953	100736229	20992700777	(	(	(
304953	100736229	20992700778	PSA	psa	NP1
304953	100736229	20992700779	)	)	)
304953	100736229	20992700780	test	test	VV0_NN1
304953	100736229	20992700781	when	when	RRQ_CS
304953	100736229	20992700782	it	it	PPH1
304953	100736229	20992700783	comes	come	VVZ
304953	100736229	20992700784	to	to	II
304953	100736229	20992700785	detecting	detect	VVG
304953	100736229	20992700786	prostate	prostate	NN1
304953	100736229	20992700787	cancer	cancer	NN1
304953	100736229	20992700788	?	?	?
304953	100736229	20992700789	<p>		NULL
304953	100736229	20992700790	Although	although	CS
304953	100736229	20992700791	PSA	psa	NP1
304953	100736229	20992700792	testing	testing	NN1
304953	100736229	20992700793	can	can	VM
304953	100736229	20992700794	help	help	VVI
304953	100736229	20992700795	catch	catch	NN1
304953	100736229	20992700796	prostate	prostate	NN1
304953	100736229	20992700797	cancer	cancer	NN1
304953	100736229	20992700798	at	at	II
304953	100736229	20992700799	an	a	AT1
304953	100736229	20992700800	early	early	JJ
304953	100736229	20992700801	stage	stage	NN1
304953	100736229	20992700802	,	,	,
304953	100736229	20992700803	having	have	VHG
304953	100736229	20992700804	an	a	AT1
304953	100736229	20992700805	elevated	elevated	JJ
304953	100736229	20992700806	PSA	psa	NP1
304953	100736229	20992700807	(	(	(
304953	100736229	20992700808	generally	generally	RR
304953	100736229	20992700809	considered	consider	VVN_VVD
304953	100736229	20992700810	more	more	DAR
304953	100736229	20992700811	than	than	CSN
304953	100736229	20992700812	4	4	MC
304953	100736229	20992700813	ng/ml	ng/ml	FU
304953	100736229	20992700814	)	)	)
304953	100736229	20992700815	does	do	VDZ
304953	100736229	20992700816	n't	n't	XX
304953	100736229	20992700817	necessarily	necessarily	RR
304953	100736229	20992700818	mean	mean	VVI
304953	100736229	20992700819	that	that	CST
304953	100736229	20992700820	a	a	AT1
304953	100736229	20992700821	man	man	NN1
304953	100736229	20992700822	has	have	VHZ
304953	100736229	20992700823	cancer	cancer	NN1
304953	100736229	20992700824	.	.	.
304953	100736229	20992700825	Noncancerous	non-cancerous	JJ
304953	100736229	20992700826	conditions	condition	NN2
304953	100736229	20992700827	,	,	,
304953	100736229	20992700828	including	including	II_VVG@
304953	100736229	20992700829	benign	benign	JJ
304953	100736229	20992700830	prostatic	prostatic	JJ
304953	100736229	20992700831	hyperplasia	hyperplasia	NN1
304953	100736229	20992700832	(	(	(
304953	100736229	20992700833	BPH	bph	NP1
304953	100736229	20992700834	)	)	)
304953	100736229	20992700835	,	,	,
304953	100736229	20992700836	or	or	CC
304953	100736229	20992700837	an	a	AT1
304953	100736229	20992700838	enlarged	enlarged	JJ
304953	100736229	20992700839	prostate	prostate	NN1
304953	100736229	20992700840	,	,	,
304953	100736229	20992700841	and	and	CC
304953	100736229	20992700842	prostatitis	prostatitis	NN1
304953	100736229	20992700843	,	,	,
304953	100736229	20992700844	can	can	VM
304953	100736229	20992700845	raise	raise	VVI
304953	100736229	20992700846	PSA	psa	NP1
304953	100736229	20992700847	levels	level	NN2
304953	100736229	20992700848	.	.	.
304953	100736229	20992700849	In	in	II
304953	100736229	20992700850	fact	fact	NN1
304953	100736229	20992700851	,	,	,
304953	100736229	20992700852	studies	study	NN2
304953	100736229	20992700853	have	have	VH0
304953	100736229	20992700854	shown	show	VVN
304953	100736229	20992700855	that	that	CST_DD1
304953	100736229	20992700856	about	about	RG
304953	100736229	20992700857	70%		NNU
304953	100736229	20992700858	to	to	II
304953	100736229	20992700859	80%		NNU
304953	100736229	20992700860	of	of	IO
304953	100736229	20992700861	men	man	NN2
304953	100736229	20992700862	with	with	IW
304953	100736229	20992700863	an	a	AT1
304953	100736229	20992700864	elevated	elevated	JJ
304953	100736229	20992700865	PSA	psa	NP1
304953	100736229	20992700866	who	who	PNQS
304953	100736229	20992700867	have	have	VH0
304953	100736229	20992700868	a	a	AT1
304953	100736229	20992700869	biopsy	biopsy	NN1
304953	100736229	20992700870	do	do	VD0
304953	100736229	20992700871	not	not	XX
304953	100736229	20992700872	have	have	VHI
304953	100736229	20992700873	cancer	cancer	NN1
304953	100736229	20992700874	.	.	.
304953	100736229	20992700875	However	however	RR
304953	100736229	20992700876	,	,	,
304953	100736229	20992700877	many	many	DA2
304953	100736229	20992700878	men	man	NN2
304953	100736229	20992700879	undergo	undergo	VV0
304953	100736229	20992700880	an	a	AT1
304953	100736229	20992700881	ultrasound	ultrasound	NN1
304953	100736229	20992700882	and	and	CC
304953	100736229	20992700883	prostate	prostate	NN1
304953	100736229	20992700884	biopsy	biopsy	NN1
304953	100736229	20992700885	,	,	,
304953	100736229	20992700886	to	to	TO
304953	100736229	20992700887	be	be	VBI
304953	100736229	20992700888	certain	certain	JJ
304953	100736229	20992700889	.	.	.
304953	100736229	20992700890	<p>		NULL
304953	100736229	20992700891	Conversely	conversely	RR
304953	100736229	20992700892	,	,	,
304953	100736229	20992700893	the	the	AT
304953	100736229	20992700894	PSA	psa	NP1
304953	100736229	20992700895	test	test	NN1_VV0
304953	100736229	20992700896	does	do	VDZ
304953	100736229	20992700897	n't	n't	XX
304953	100736229	20992700898	detect	detect	VVI
304953	100736229	20992700899	all	all	DB
304953	100736229	20992700900	cancers	cancer	NN2
304953	100736229	20992700901	.	.	.
304953	100736229	20992700902	About	about	RG
304953	100736229	20992700903	20%		NNU
304953	100736229	20992700904	of	of	IO
304953	100736229	20992700905	men	man	NN2
304953	100736229	20992700906	who	who	PNQS
304953	100736229	20992700907	have	have	VH0
304953	100736229	20992700908	cancer	cancer	NN1
304953	100736229	20992700909	also	also	RR
304953	100736229	20992700910	have	have	VH0
304953	100736229	20992700911	a	a	AT1
304953	100736229	20992700912	normal	normal	JJ
304953	100736229	20992700913	PSA	psa	NP1
304953	100736229	20992700914	(	(	(
304953	100736229	20992700915	less	less	DAR
304953	100736229	20992700916	than	than	CSN
304953	100736229	20992700917	4	4	MC
304953	100736229	20992700918	ng/ml	ng/ml	FU
304953	100736229	20992700919	)	)	)
304953	100736229	20992700920	,	,	,
304953	100736229	20992700921	so	so	CS@_RR
304953	100736229	20992700922	the	the	AT
304953	100736229	20992700923	test	test	NN1
304953	100736229	20992700924	may	may	VM
304953	100736229	20992700925	give	give	VVI
304953	100736229	20992700926	some	some	DD
304953	100736229	20992700927	men	man	NN2
304953	100736229	20992700928	a	a	AT1
304953	100736229	20992700929	false	false	JJ
304953	100736229	20992700930	sense	sense	NN1
304953	100736229	20992700931	of	of	IO
304953	100736229	20992700932	security	security	NN1
304953	100736229	20992700933	.	.	.
304953	100736229	20992700934	For	for	IF
304953	100736229	20992700935	this	this	DD1
304953	100736229	20992700936	reason	reason	NN1
304953	100736229	20992700937	,	,	,
304953	100736229	20992700938	some	some	DD
304953	100736229	20992700939	experts	expert	NN2
304953	100736229	20992700940	take	take	VV0
304953	100736229	20992700941	a	a	AT1
304953	100736229	20992700942	man	man	NN1
304953	100736229	20992700943	's	's	GE
304953	100736229	20992700944	age	age	NN1
304953	100736229	20992700945	into	into	II
304953	100736229	20992700946	account	account	NN1
304953	100736229	20992700947	when	when	CS
304953	100736229	20992700948	considering	consider	VVG_II_CS
304953	100736229	20992700949	a	a	AT1
304953	100736229	20992700950	PSA	psa	NP1
304953	100736229	20992700951	level	level	NN1_JJ
304953	100736229	20992700952	.	.	.
304953	100736229	20992700953	And	and	CC
304953	100736229	20992700954	most	most	DAT
304953	100736229	20992700955	doctors	doctor	NN2
304953	100736229	20992700956	observe	observe	VV0
304953	100736229	20992700957	how	how	RRQ
304953	100736229	20992700958	a	a	AT1
304953	100736229	20992700959	@		II
304953	100736229	20992700960	@		II
304953	100736229	20992700961	@		II
304953	100736229	20992700962	@		II
304953	100736229	20992700963	@		II
304953	100736229	20992700964	@		II
304953	100736229	20992700965	@		II
304953	100736229	20992700966	@		II
304953	100736229	20992700967	@		II
304953	100736229	20992700968	@		II
304953	100736229	20992700969	called	call	VVN
304953	100736229	20992700970	PSA	psa	NP1
304953	100736229	20992700971	velocity	velocity	NN1
304953	100736229	20992700972	,	,	,
304953	100736229	20992700973	rather	rather	II21
304953	100736229	20992700974	than	than	II22
304953	100736229	20992700975	using	use	VVG
304953	100736229	20992700976	it	it	PPH1
304953	100736229	20992700977	as	as	II_CSA
304953	100736229	20992700978	a	a	AT1
304953	100736229	20992700979	one-time	one-time	JJ
304953	100736229	20992700980	indicator	indicator	NN1
304953	100736229	20992700981	.	.	.
304953	100736229	20992700982	PSA	psa	NP1
304953	100736229	20992700983	scores	score	NN2
304953	100736229	20992700984	tend	tend	VV0
304953	100736229	20992700985	to	to	TO
304953	100736229	20992700986	rise	rise	VVI
304953	100736229	20992700987	more	more	RGR
304953	100736229	20992700988	rapidly	rapidly	RR
304953	100736229	20992700989	in	in	II
304953	100736229	20992700990	men	man	NN2
304953	100736229	20992700991	with	with	IW
304953	100736229	20992700992	cancer	cancer	NN1
304953	100736229	20992700993	than	than	CSN
304953	100736229	20992700994	in	in	II
304953	100736229	20992700995	those	those	DD2
304953	100736229	20992700996	with	with	IW
304953	100736229	20992700997	BPH	bph	NP1
304953	100736229	20992700998	,	,	,
304953	100736229	20992700999	for	for	REX21
304953	100736229	20992701000	example	example	REX22
304953	100736229	20992701001	.	.	.
304953	100736229	20992701002	<p>		NULL
304953	100736229	20992701003	Some	some	DD
304953	100736229	20992701004	doctors	doctor	NN2
304953	100736229	20992701005	also	also	RR
304953	100736229	20992701006	measure	measure	VV0
304953	100736229	20992701007	the	the	AT
304953	100736229	20992701008	level	level	NN1
304953	100736229	20992701009	of	of	IO
304953	100736229	20992701010	free	free	JJ
304953	100736229	20992701011	PSA	psa	NP1
304953	100736229	20992701012	.	.	.
304953	100736229	20992701013	The	the	AT
304953	100736229	20992701014	PSA	psa	NP1
304953	100736229	20992701015	protein	protein	NN1
304953	100736229	20992701016	circulates	circulate	VVZ
304953	100736229	20992701017	in	in	II
304953	100736229	20992701018	the	the	AT
304953	100736229	20992701019	blood	blood	NN1
304953	100736229	20992701020	in	in	II
304953	100736229	20992701021	two	two	MC
304953	100736229	20992701022	forms	form	NN2_VVZ
304953	100736229	20992701023	:	:	:
304953	100736229	20992701024	bound	bind	VVN_VV0@_VVD
304953	100736229	20992701025	to	to	II
304953	100736229	20992701026	other	other	JJ
304953	100736229	20992701027	proteins	protein	NN2
304953	100736229	20992701028	or	or	CC
304953	100736229	20992701029	unbound	unbound	JJ_VVN
304953	100736229	20992701030	(	(	(
304953	100736229	20992701031	free	free	JJ_VV0@
304953	100736229	20992701032	)	)	)
304953	100736229	20992701033	.	.	.
304953	100736229	20992701034	Several	several	DA2
304953	100736229	20992701035	studies	study	NN2
304953	100736229	20992701036	suggest	suggest	VV0
304953	100736229	20992701037	that	that	CST
304953	100736229	20992701038	men	man	NN2
304953	100736229	20992701039	with	with	IW
304953	100736229	20992701040	elevated	elevated	JJ
304953	100736229	20992701041	PSA	psa	NP1
304953	100736229	20992701042	levels	level	NN2
304953	100736229	20992701043	and	and	CC
304953	100736229	20992701044	a	a	AT1
304953	100736229	20992701045	very	very	RG
304953	100736229	20992701046	low	low	JJ
304953	100736229	20992701047	percentage	percentage	NN1
304953	100736229	20992701048	of	of	IO
304953	100736229	20992701049	free	free	JJ
304953	100736229	20992701050	PSA	psa	NP1
304953	100736229	20992701051	are	be	VBR
304953	100736229	20992701052	more	more	RGR
304953	100736229	20992701053	likely	likely	JJ
304953	100736229	20992701054	to	to	TO
304953	100736229	20992701055	have	have	VHI
304953	100736229	20992701056	prostate	prostate	NN1
304953	100736229	20992701057	cancer	cancer	NN1
304953	100736229	20992701058	than	than	CSN
304953	100736229	20992701059	a	a	AT1
304953	100736229	20992701060	benign	benign	JJ
304953	100736229	20992701061	condition	condition	NN1
304953	100736229	20992701062	.	.	.
304953	100736229	20992701063	Knowing	know	VVG
304953	100736229	20992701064	your	your	APPGE
304953	100736229	20992701065	free	free	JJ
304953	100736229	20992701066	PSA	psa	NP1
304953	100736229	20992701067	level	level	NN1
304953	100736229	20992701068	wo	will	VM
304953	100736229	20992701069	n't	n't	XX
304953	100736229	20992701070	give	give	VVI
304953	100736229	20992701071	you	you	PPY
304953	100736229	20992701072	a	a	AT1
304953	100736229	20992701073	definitive	definitive	JJ
304953	100736229	20992701074	answer	answer	NN1
304953	100736229	20992701075	about	about	II
304953	100736229	20992701076	cancer	cancer	NN1
304953	100736229	20992701077	,	,	,
304953	100736229	20992701078	but	but	CCB
304953	100736229	20992701079	it	it	PPH1
304953	100736229	20992701080	may	may	VM
304953	100736229	20992701081	be	be	VBI
304953	100736229	20992701082	useful	useful	JJ
304953	100736229	20992701083	when	when	CS
304953	100736229	20992701084	considering	consider	VVG
304953	100736229	20992701085	whether	whether	CSW
304953	100736229	20992701086	a	a	AT1
304953	100736229	20992701087	biopsy	biopsy	NN1
304953	100736229	20992701088	is	be	VBZ
304953	100736229	20992701089	an	a	AT1
304953	100736229	20992701090	appropriate	appropriate	JJ
304953	100736229	20992701091	next	next	MD
304953	100736229	20992701092	step	step	NN1
304953	100736229	20992701093	.	.	.
304953	100736229	20992701094	<p>		NULL
304953	100736229	20992701095	Researchers	researcher	NN2
304953	100736229	20992701096	are	be	VBR
304953	100736229	20992701097	developing	develop	VVG_JJ
304953	100736229	20992701098	new	new	JJ
304953	100736229	20992701099	screening	screening	NN1
304953	100736229	20992701100	tests	test	NN2_VVZ@
304953	100736229	20992701101	for	for	IF
304953	100736229	20992701102	prostate	prostate	NN1
304953	100736229	20992701103	cancer	cancer	NN1
304953	100736229	20992701104	.	.	.
304953	100736229	20992701105	Like	like	II
304953	100736229	20992701106	the	the	AT
304953	100736229	20992701107	PSA	psa	NP1
304953	100736229	20992701108	test	test	NN1_VV0
304953	100736229	20992701109	,	,	,
304953	100736229	20992701110	they	they	PPHS2
304953	100736229	20992701111	rely	rely	VV0
304953	100736229	20992701112	on	on	II_RP@
304953	100736229	20992701113	biomarkers	biomarker	NN2
304953	100736229	20992701114	,	,	,
304953	100736229	20992701115	such	such	II21
304953	100736229	20992701116	as	as	II22
304953	100736229	20992701117	antigens	antigen	NN2
304953	100736229	20992701118	or	or	CC
304953	100736229	20992701119	proteins	protein	NN2
304953	100736229	20992701120	,	,	,
304953	100736229	20992701121	which	which	DDQ
304953	100736229	20992701122	are	be	VBR
304953	100736229	20992701123	elevated	elevate	VVN_JJ
304953	100736229	20992701124	or	or	CC
304953	100736229	20992701125	may	may	VM
304953	100736229	20992701126	only	only	JJ
304953	100736229	20992701127	be	be-	VBI
304953	100736229	20992701128	present	present	NN1
304953	100736229	20992701129	in	in	II
304953	100736229	20992701130	men	man	NN2
304953	100736229	20992701131	who	who	PNQS
304953	100736229	20992701132	have	have	VH0
304953	100736229	20992701133	prostate	prostate	NN1
304953	100736229	20992701134	cancer	cancer	NN1
304953	100736229	20992701135	.	.	.
304953	100736229	20992701136	The	the	AT
304953	100736229	20992701137	hope	hope	NN1
304953	100736229	20992701138	is	be	VBZ
304953	100736229	20992701139	that	that	CST
304953	100736229	20992701140	these	these	DD2
304953	100736229	20992701141	tests	test	NN2
304953	100736229	20992701142	will	will	VM
304953	100736229	20992701143	better	better	RRR
304953	100736229	20992701144	detect	detect	VVI
304953	100736229	20992701145	existing	existing	JJ
304953	100736229	20992701146	cancers	cancer	NN2
304953	100736229	20992701147	without	without	IW
304953	100736229	20992701148	raising	raise	VVG
304953	100736229	20992701149	the	the	AT
304953	100736229	20992701150	alarm	alarm	NN1
304953	100736229	20992701151	for	for	IF
304953	100736229	20992701152	cancer	cancer	NN1
304953	100736229	20992701153	when	when	CS_RRQ
304953	100736229	20992701154	it	it	PPH1
304953	100736229	20992701155	is	be	VBZ
304953	100736229	20992701156	n't	n't	XX
304953	100736229	20992701157	there	there	RL
304953	100736229	20992701158	.	.	.
304953	100736229	20992701159	@		II
304953	100736229	20992701160	@		II
304953	100736229	20992701161	@		II
304953	100736229	20992701162	@		II
304953	100736229	20992701163	@		II
304953	100736229	20992701164	@		II
304953	100736229	20992701165	@		II
304953	100736229	20992701166	@		II
304953	100736229	20992701167	@		II
304953	100736229	20992701168	@		II
304953	100736229	20992701169	to	to	TO
304953	100736229	20992701170	correct	correct	VVI
304953	100736229	20992701171	any	any	DD
304953	100736229	20992701172	medical	medical	JJ
304953	100736229	20992701173	condition	condition	NN1
304953	100736229	20992701174	;	;	;
304953	100736229	20992701175	am	am	RA@
304953	100736229	20992701176	in	in	II
304953	100736229	20992701177	excellent	excellent	JJ
304953	100736229	20992701178	health	health	NN1
304953	100736229	20992701179	;	;	;
304953	100736229	20992701180	5	5	MC
304953	100736229	20992701181	'	'	GE
304953	100736229	20992701182	-10		MC
304953	100736229	20992701183	?	?	?
304953	100736229	20992701184	,	,	,
304953	100736229	20992701185	180	180	MC
304953	100736229	20992701186	lbs	lb	NNU2
304953	100736229	20992701187	;	;	;
304953	100736229	20992701188	workout	workout	VV0_NN1
304953	100736229	20992701189	in	in	II_RP@
304953	100736229	20992701190	a	a	AT1
304953	100736229	20992701191	gym	gym	NN1
304953	100736229	20992701192	regularly	regularly	RR
304953	100736229	20992701193	;	;	;
304953	100736229	20992701194	no	no	AT
304953	100736229	20992701195	noticeable	noticeable	JJ
304953	100736229	20992701196	urinary	urinary	NN1_JJ
304953	100736229	20992701197	or	or	CC
304953	100736229	20992701198	sexual	sexual	JJ
304953	100736229	20992701199	problems	problem	NN2
304953	100736229	20992701200	.	.	.
304953	100736229	20992701201	I	i	PPIS1
304953	100736229	20992701202	had	have	VHD
304953	100736229	20992701203	an	a	AT1
304953	100736229	20992701204	annual	annual	JJ
304953	100736229	20992701205	physical	physical	JJ
304953	100736229	20992701206	from	from	II
304953	100736229	20992701207	age	age	NN1
304953	100736229	20992701208	50	50	MC
304953	100736229	20992701209	;	;	;
304953	100736229	20992701210	never	never	RR
304953	100736229	20992701211	any	any	DD
304953	100736229	20992701212	issues	issue	NN2
304953	100736229	20992701213	;	;	;
304953	100736229	20992701214	perfect	perfect	JJ
304953	100736229	20992701215	health	health	NN1
304953	100736229	20992701216	.	.	.
304953	100736229	20992701217	I	i	PPIS1
304953	100736229	20992701218	live	live	VV0
304953	100736229	20992701219	much	much	DA1
304953	100736229	20992701220	of	of	IO
304953	100736229	20992701221	the	the	AT
304953	100736229	20992701222	year	year	NNT1
304953	100736229	20992701223	in	in	II
304953	100736229	20992701224	Mexico	mexico	NP1
304953	100736229	20992701225	and	and	CC
304953	100736229	20992701226	did	do	VDD
304953	100736229	20992701227	a	a	AT1
304953	100736229	20992701228	physical	physical	JJ
304953	100736229	20992701229	after	after	II_CS
304953	100736229	20992701230	a	a	AT1
304953	100736229	20992701231	7	7	MC
304953	100736229	20992701232	year	year	NNT1
304953	100736229	20992701233	hiatus	hiatus	NN1
304953	100736229	20992701234	,	,	,
304953	100736229	20992701235	which	which	DDQ
304953	100736229	20992701236	was	be	VBDZ
304953	100736229	20992701237	good	good	JJ
304953	100736229	20992701238	,	,	,
304953	100736229	20992701239	as	as	CSA_RG@
304953	100736229	20992701240	always	always	RR
304953	100736229	20992701241	;	;	;
304953	100736229	20992701242	however	however	RR
304953	100736229	20992701243	,	,	,
304953	100736229	20992701244	the	the	AT
304953	100736229	20992701245	PSA	psa	NP1
304953	100736229	20992701246	came	come	VVD
304953	100736229	20992701247	back	back	RP
304953	100736229	20992701248	at	at	II
304953	100736229	20992701249	8.3	8.3	MC
304953	100736229	20992701250	.	.	.
304953	100736229	20992701251	I	i	PPIS1
304953	100736229	20992701252	have	have	VH0
304953	100736229	20992701253	read	read	VVN
304953	100736229	20992701254	a	a	RR21@_AT1
304953	100736229	20992701255	lot	lot	RR22_NN1
304953	100736229	20992701256	about	about	II
304953	100736229	20992701257	prostate	prostate	NN1
304953	100736229	20992701258	and	and	CC
304953	100736229	20992701259	find	find	VV0
304953	100736229	20992701260	it	it	PPH1
304953	100736229	20992701261	to	to	TO
304953	100736229	20992701262	be	be	VBI
304953	100736229	20992701263	quite	quite	RG
304953	100736229	20992701264	a	a	AT1
304953	100736229	20992701265	difficult	difficult	JJ
304953	100736229	20992701266	thing	thing	NN1
304953	100736229	20992701267	to	to	II_TO
304953	100736229	20992701268	in	in	RP@_II
304953	100736229	20992701269	down	down	RP_NN1%
304953	100736229	20992701270	.	.	.
304953	100736229	20992701271	The	the	AT
304953	100736229	20992701272	Mexican	mexican	JJ
304953	100736229	20992701273	doctor	doctor	NN1
304953	100736229	20992701274	was	be	VBDZ
304953	100736229	20992701275	talking	talk	VVG
304953	100736229	20992701276	surgical	surgical	JJ
304953	100736229	20992701277	procedure	procedure	NN1
304953	100736229	20992701278	even	even	RR
304953	100736229	20992701279	before	before	CS_II
304953	100736229	20992701280	any	any	DD
304953	100736229	20992701281	discussion	discussion	NN1
304953	100736229	20992701282	or	or	CC
304953	100736229	20992701283	additional/retests		FU
304953	100736229	20992701284	.	.	.
304953	100736229	20992701285	I	i	PPIS1
304953	100736229	20992701286	have	have	VH0
304953	100736229	20992701287	excellent	excellent	JJ
304953	100736229	20992701288	US	us	NP1
304953	100736229	20992701289	health	health	NN1
304953	100736229	20992701290	insurance	insurance	NN1
304953	100736229	20992701291	,	,	,
304953	100736229	20992701292	which	which	DDQ
304953	100736229	20992701293	I	i	PPIS1
304953	100736229	20992701294	have	have	VH0
304953	100736229	20992701295	seldom	seldom	RR
304953	100736229	20992701296	used	use	VVN
304953	100736229	20992701297	for	for	IF
304953	100736229	20992701298	the	the	AT
304953	100736229	20992701299	past	past	JJ
304953	100736229	20992701300	50	50	MC
304953	100736229	20992701301	years	year	NNT2
304953	100736229	20992701302	.	.	.
304953	100736229	20992701303	I	i	PPIS1
304953	100736229	20992701304	am	be	VBM
304953	100736229	20992701305	looking	look	VVG
304953	100736229	20992701306	to	to	TO
304953	100736229	20992701307	set	set	VVI
304953	100736229	20992701308	up	up	RP
304953	100736229	20992701309	an	a	AT1
304953	100736229	20992701310	office	office	NN1
304953	100736229	20992701311	visit	visit	NN1_VV0
304953	100736229	20992701312	in	in	II
304953	100736229	20992701313	Boca	boca	NP1
304953	100736229	20992701314	when	when	RRQ
304953	100736229	20992701315	I	i	PPIS1
304953	100736229	20992701316	am	be	VBM
304953	100736229	20992701317	back	back	RP
304953	100736229	20992701318	in	in	II
304953	100736229	20992701319	the	the	AT
304953	100736229	20992701320	States	state	NP1
304953	100736229	20992701321	mid-June	mid-june	NP1@_NPM1
304953	100736229	20992701322	.	.	.
304953	100736229	20992701323	Some	some	DD
304953	100736229	20992701324	written	written	JJ@
304953	100736229	20992701325	material	material	NN1
304953	100736229	20992701326	suggest	suggest	VV0
304953	100736229	20992701327	at	at	II
304953	100736229	20992701328	my	my	APPGE
304953	100736229	20992701329	age	age	NN1
304953	100736229	20992701330	,	,	,
304953	100736229	20992701331	the	the	AT
304953	100736229	20992701332	problem	problem	NN1
304953	100736229	20992701333	is	be	VBZ
304953	100736229	20992701334	best	best	RRT
304953	100736229	20992701335	left	leave	VVN
304953	100736229	20992701336	as	as	CSA
304953	100736229	20992701337	is	be	VBZ
304953	100736229	20992701338	.	.	.
304953	100736229	20992701339	Any	any	DD
304953	100736229	20992701340	thoughts	thought	NN2
304953	100736229	20992701341	?	?	?
304953	100736229	20992701342	Jim	jim	NP1
304953	100736229	20992701343	<p>		NULL
304953	100736229	20992701344	You	you	PPY
304953	100736229	20992701345	are	be	VBR
304953	100736229	20992701346	70	70	MC
304953	100736229	20992701347	and	and	CC
304953	100736229	20992701348	in	in	II
304953	100736229	20992701349	good	good	JJ
304953	100736229	20992701350	health	health	NN1
304953	100736229	20992701351	.	.	.
304953	100736229	20992701352	your	your	APPGE
304953	100736229	20992701353	chances	chance	NN2
304953	100736229	20992701354	of	of	IO
304953	100736229	20992701355	dying	die	VVG_JJ
304953	100736229	20992701356	from	from	II
304953	100736229	20992701357	old	old	JJ
304953	100736229	20992701358	age	age	NN1
304953	100736229	20992701359	@		II
304953	100736229	20992701360	@		II
304953	100736229	20992701361	@		II
304953	100736229	20992701362	@		II
304953	100736229	20992701363	@		II
304953	100736229	20992701364	@		II
304953	100736229	20992701365	@		II
304953	100736229	20992701366	@		II
304953	100736229	20992701367	@		II
304953	100736229	20992701368	@		II
304953	100736229	20992701369	the	the	AT
304953	100736229	20992701370	PSA	psa	NP1
304953	100736229	20992701371	test	test	NN1
304953	100736229	20992701372	is	be	VBZ
304953	100736229	20992701373	a	a	AT1
304953	100736229	20992701374	bs	bs	FO
304953	100736229	20992701375	test	test	NN1_VV0
304953	100736229	20992701376	.	.	.
304953	100736229	20992701377	The	the	AT
304953	100736229	20992701378	person	person	NN1
304953	100736229	20992701379	who	who	PNQS
304953	100736229	20992701380	developed	develop	VVD
304953	100736229	20992701381	the	the	AT
304953	100736229	20992701382	test	test	NN1
304953	100736229	20992701383	no	no	RR21
304953	100736229	20992701384	longer	long	RR22
304953	100736229	20992701385	supports	support	VVZ
304953	100736229	20992701386	PSA	psa	NP1
304953	100736229	20992701387	testing	testing	NN1_VVG
304953	100736229	20992701388	.	.	.
304953	100736229	20992701389	what	what	DDQ
304953	100736229	20992701390	does	do	VDZ
304953	100736229	20992701391	that	that	DD1
304953	100736229	20992701392	tell	tell	VVI
304953	100736229	20992701393	you	you	PPY
304953	100736229	20992701394	?	?	?
304953	100736229	20992701395	<p>		NULL
304953	100736229	20992701396	1	1	MC1
304953	100736229	20992701397	.	.	.
304953	100736229	20992701398	A	a	AT1
304953	100736229	20992701399	psa		NN1
304953	100736229	20992701400	test	test	NN1
304953	100736229	20992701401	is	be	VBZ
304953	100736229	20992701402	only	only	JJ
304953	100736229	20992701403	one	one	MC1
304953	100736229	20992701404	test	test	NN1
304953	100736229	20992701405	and	and	CC
304953	100736229	20992701406	should	should	VM
304953	100736229	20992701407	be	be	VBI
304953	100736229	20992701408	seen	see	VVN
304953	100736229	20992701409	as	as	CSA_II@
304953	100736229	20992701410	one	one	MC1
304953	100736229	20992701411	step	step	NN1
304953	100736229	20992701412	towards	towards	II
304953	100736229	20992701413	a	a	AT1
304953	100736229	20992701414	diagnosis	diagnosis	NN1
304953	100736229	20992701415	.	.	.
304953	100736229	20992701416	A	a	ZZ1_AT1
304953	100736229	20992701417	PSA	psa	NP1
304953	100736229	20992701418	test	test	NN1
304953	100736229	20992701419	of	of	IO
304953	100736229	20992701420	and	and	CC
304953	100736229	20992701421	by	by	II
304953	100736229	20992701422	itself	itself	PPX1
304953	100736229	20992701423	is	be	VBZ
304953	100736229	20992701424	nothing	nothing	PN1
304953	100736229	20992701425	.	.	.
304953	100736229	20992701426	Anyone	anyone	PN1
304953	100736229	20992701427	who	who	PNQS
304953	100736229	20992701428	does	do	VDZ
304953	100736229	20992701429	not	not	XX
304953	100736229	20992701430	have	have	VHI
304953	100736229	20992701431	other	other	JJ
304953	100736229	20992701432	diagnostic	diagnostic	JJ
304953	100736229	20992701433	tests	test	NN2
304953	100736229	20992701434	and	and	CC
304953	100736229	20992701435	goes	go	VVZ
304953	100736229	20992701436	by	by	II
304953	100736229	20992701437	a	a	AT1
304953	100736229	20992701438	single	single	JJ
304953	100736229	20992701439	PSA	psa	NP1
304953	100736229	20992701440	test	test	NN1
304953	100736229	20992701441	seems	seem	VVZ
304953	100736229	20992701442	to	to	II
304953	100736229	20992701443	acting	act	VVG
304953	100736229	20992701444	from	from	II
304953	100736229	20992701445	a	a	AT1
304953	100736229	20992701446	place	place	NN1
304953	100736229	20992701447	of	of	IO
304953	100736229	20992701448	fear	fear	NN1
304953	100736229	20992701449	,	,	,
304953	100736229	20992701450	instead	instead	II21_CS21%
304953	100736229	20992701451	of	of	II22_CS22
304953	100736229	20992701452	a	a	AT1
304953	100736229	20992701453	place	place	NN1
304953	100736229	20992701454	of	of	IO
304953	100736229	20992701455	fact	fact	NN1
304953	100736229	20992701456	.	.	.
304953	100736229	20992701457	<p>		NULL
304953	100736229	20992701458	2.		MC
304953	100736229	20992701459	susanne		NN1
304953	100736229	20992701460	,	,	,
304953	100736229	20992701461	get	get	VV0
304953	100736229	20992701462	your	your	APPGE
304953	100736229	20992701463	boyfriend	boyfriend	NN1
304953	100736229	20992701464	into	into	II
304953	100736229	20992701465	a	a	AT1
304953	100736229	20992701466	doctor	doctor	NN1
304953	100736229	20992701467	as	as	RG
304953	100736229	20992701468	soon	soon	RR
304953	100736229	20992701469	as	as	CSA
304953	100736229	20992701470	possible	possible	JJ
304953	100736229	20992701471	.	.	.
304953	100736229	20992701472	These	these	DD2
304953	100736229	20992701473	are	be	VBR
304953	100736229	20992701474	not	not	XX
304953	100736229	20992701475	symptoms	symptom	NN2
304953	100736229	20992701476	that	that	CST_DD1
304953	100736229	20992701477	should	should	VM
304953	100736229	20992701478	be	be	VBI
304953	100736229	20992701479	taken	take	VVN
304953	100736229	20992701480	lightly	lightly	RR
304953	100736229	20992701481	.	.	.
304953	100736229	20992701482	While	while	CS
304953	100736229	20992701483	they	they	PPHS2
304953	100736229	20992701484	could	could	VM
304953	100736229	20992701485	be	be	VBI
304953	100736229	20992701486	signs	sign	NN2
304953	100736229	20992701487	of	of	IO
304953	100736229	20992701488	an	a	AT1
304953	100736229	20992701489	infection	infection	NN1
304953	100736229	20992701490	,	,	,
304953	100736229	20992701491	if	if	CS
304953	100736229	20992701492	the	the	AT
304953	100736229	20992701493	infection	infection	NN1
304953	100736229	20992701494	is	be	VBZ
304953	100736229	20992701495	left	left	JJ_VVN
304953	100736229	20992701496	untreated	untreated	JJ
304953	100736229	20992701497	it	it	PPH1
304953	100736229	20992701498	is	be	VBZ
304953	100736229	20992701499	not	not	XX
304953	100736229	20992701500	a	a	AT1
304953	100736229	20992701501	good	good	JJ
304953	100736229	20992701502	idea	idea	NN1
304953	100736229	20992701503	.	.	.
304953	100736229	20992701504	The	the	AT
304953	100736229	20992701505	sooner	soon	RRR
304953	100736229	20992701506	you	you	PPY
304953	100736229	20992701507	both	both	DB2_RR
304953	100736229	20992701508	get	get	VV0
304953	100736229	20992701509	information	information	NN1
304953	100736229	20992701510	the	the	AT
304953	100736229	20992701511	better	better	JJR_RRR
304953	100736229	20992701512	.	.	.
304953	100736229	20992701513	Just	just	RR21
304953	100736229	20992701514	about	about	RR22
304953	100736229	20992701515	any	any	DD
304953	100736229	20992701516	disease	disease	NN1
304953	100736229	20992701517	or	or	CC
304953	100736229	20992701518	infection	infection	NN1
304953	100736229	20992701519	that	that	CST_DD1
304953	100736229	20992701520	is	be	VBZ
304953	100736229	20992701521	left	left	JJ_VVN
304953	100736229	20992701522	untreated	untreated	JJ
304953	100736229	20992701523	can	can	VM
304953	100736229	20992701524	get	get	VVI
304953	100736229	20992701525	worse	bad	JJR_RRR@
304953	100736229	20992701526	.	.	.
304953	100736229	20992701527	Please	please	RR
304953	100736229	20992701528	do	do	VD0
304953	100736229	20992701529	n't 	n't	XX
304953	100736229	20992701530	let	let	VVI
304953	100736229	20992701531	your	your	APPGE
304953	100736229	20992701532	boyfriend	boyfriend	NN1
304953	100736229	20992701533	whimp		NN1_VV0
304953	100736229	20992701534	out	out	II21
304953	100736229	20992701535	of	of	II22
304953	100736229	20992701536	this	this	DD1
304953	100736229	20992701537	.	.	.
304953	100736229	20992701538	Men	man	NN2
304953	100736229	20992701539	are	be	VBR
304953	100736229	20992701540	terrible	terrible	JJ
304953	100736229	20992701541	when	when	CS
304953	100736229	20992701542	it	it	PPH1
304953	100736229	20992701543	comes	come	VVZ
304953	100736229	20992701544	to	to	II
304953	100736229	20992701545	dealing	deal	VVG
304953	100736229	20992701546	with	with	IW
304953	100736229	20992701547	"	"	"
304953	100736229	20992701548	male	male	JJ
304953	100736229	20992701549	"	"	"
304953	100736229	20992701550	problems	problem	NN2
304953	100736229	20992701551	.	.	.
304953	100736229	20992701552	<p>		NULL
304953	100736229	20992701553	Went	go	VVD
304953	100736229	20992701554	to	to	II
304953	100736229	20992701555	the	the	AT
304953	100736229	20992701556	urologist	urologist	NN1
304953	100736229	20992701557	due	due	II21
304953	100736229	20992701558	to	to	II22
304953	100736229	20992701559	@		II
304953	100736229	20992701560	@		II
304953	100736229	20992701561	@		II
304953	100736229	20992701562	@		II
304953	100736229	20992701563	@		II
304953	100736229	20992701564	@		II
304953	100736229	20992701565	@		II
304953	100736229	20992701566	@		II
304953	100736229	20992701567	@		II
304953	100736229	20992701568	@		II
304953	100736229	20992701569	it	it	PPH1
304953	100736229	20992701570	came	come	VVD
304953	100736229	20992701571	back	back	RP
304953	100736229	20992701572	5.5	5.5	MC
304953	100736229	20992701573	and	and	CC
304953	100736229	20992701574	the	the	AT
304953	100736229	20992701575	Percentage	percentage	NN1
304953	100736229	20992701576	Free	free	JJ_VV0@
304953	100736229	20992701577	PSA	psa	NP1
304953	100736229	20992701578	was	be	VBDZ
304953	100736229	20992701579	16%		NNU
304953	100736229	20992701580	.	.	.
304953	100736229	20992701581	He	he	PPHS1
304953	100736229	20992701582	recommended	recommend	VVD
304953	100736229	20992701583	an	a	AT1
304953	100736229	20992701584	ultrasound	ultrasound	NN1
304953	100736229	20992701585	and	and	CC
304953	100736229	20992701586	biopsy	biopsy	NN1
304953	100736229	20992701587	.	.	.
304953	100736229	20992701588	I	i	PPIS1
304953	100736229	20992701589	told	tell	VVD
304953	100736229	20992701590	him	him	PPHO1
304953	100736229	20992701591	I	i	PPIS1
304953	100736229	20992701592	would	would	VM
304953	100736229	20992701593	hold	hold	VVI
304953	100736229	20992701594	off	off	RP
304953	100736229	20992701595	and	and	CC
304953	100736229	20992701596	maybe	maybe	RR
304953	100736229	20992701597	consider	consider	VVI
304953	100736229	20992701598	it	it	PPH1
304953	100736229	20992701599	down	down	RP_II@
304953	100736229	20992701600	the	the	AT
304953	100736229	20992701601	line	line	NN1
304953	100736229	20992701602	.	.	.
304953	100736229	20992701603	Should	should	VM
304953	100736229	20992701604	I	i	PPIS1
304953	100736229	20992701605	have	have	VHI
304953	100736229	20992701606	the	the	AT
304953	100736229	20992701607	ultrasound/biopsy		NN1
304953	100736229	20992701608	done	do	VDN
304953	100736229	20992701609	sooner	soon	RRR
304953	100736229	20992701610	?	?	?
304953	100736229	20992701611	What	what	DDQ
304953	100736229	20992701612	are	be	VBR
304953	100736229	20992701613	my	my	APPGE
304953	100736229	20992701614	considerations	consideration	NN2
304953	100736229	20992701615	.	.	.
304953	100736229	20992701616	Thanks	thanks	NN2
304953	100736229	20992701617	.	.	.
304953	100736229	20992701618	<p>		NULL
304953	100736229	20992701619	I	i	PPIS1
304953	100736229	20992701620	have	have	VH0
304953	100736229	20992701621	been	be	VBN
304953	100736229	20992701622	suffering	suffer	VVG
304953	100736229	20992701623	from	from	II
304953	100736229	20992701624	pain	pain	NN1
304953	100736229	20992701625	in	in	II
304953	100736229	20992701626	my	my	APPGE
304953	100736229	20992701627	prostate	prostate	NN1
304953	100736229	20992701628	since	since	RR@_CS
304953	100736229	20992701629	april	april	VV0_NN1
304953	100736229	20992701630	this	this	DD1
304953	100736229	20992701631	year	year	NNT1
304953	100736229	20992701632	.	.	.
304953	100736229	20992701633	I	i	PPIS1
304953	100736229	20992701634	am	be	VBM
304953	100736229	20992701635	45	45	MC
304953	100736229	20992701636	years	year	NNT2
304953	100736229	20992701637	old.I		NNU
304953	100736229	20992701638	have	have	VH0
304953	100736229	20992701639	done	do	VDN
304953	100736229	20992701640	all	all	RR@
304953	100736229	20992701641	the	the	AT
304953	100736229	20992701642	tests	test	NN2
304953	100736229	20992701643	to	to	TO
304953	100736229	20992701644	find	find	VVI
304953	100736229	20992701645	out	out	RP
304953	100736229	20992701646	bacteria	bacteria	NN2
304953	100736229	20992701647	infection	infection	NN1
304953	100736229	20992701648	,	,	,
304953	100736229	20992701649	but	but	CCB
304953	100736229	20992701650	did	do	VDD
304953	100736229	20992701651	not	not	XX
304953	100736229	20992701652	found	find	VVN
304953	100736229	20992701653	bacteria	bacteria	NN2
304953	100736229	20992701654	in	in	II
304953	100736229	20992701655	the	the	AT
304953	100736229	20992701656	prostate.I		NNU
304953	100736229	20992701657	would	would	VM
304953	100736229	20992701658	like	like	VVI
304953	100736229	20992701659	to	to	TO
304953	100736229	20992701660	know	know	VVI
304953	100736229	20992701661	why	why	RRQ
304953	100736229	20992701662	my	my	APPGE
304953	100736229	20992701663	pain	pain	NN1
304953	100736229	20992701664	intensify	intensify	VV0
304953	100736229	20992701665	in	in	II_RP@
304953	100736229	20992701666	the	the	AT
304953	100736229	20992701667	night	night	NNT1
304953	100736229	20992701668	after	after	CS_RT%
304953	100736229	20992701669	eat	eat	VV0
304953	100736229	20992701670	high	high	JJ_RR@
304953	100736229	20992701671	carbohidrate		JJ_NN1
304953	100736229	20992701672	diat	diat	NN1
304953	100736229	20992701673	.	.	.
304953	100736229	20992701674	Plea	plea	NN1
304953	100736229	20992701675	give	give	VV0
304953	100736229	20992701676	me	me	PPIO1
304953	100736229	20992701677	answer	answer	NN1
304953	100736229	20992701678	becaus	becaus	NN2
304953	100736229	20992701679	i	i	MC1_ZZ1
304953	100736229	20992701680	am	am	RA@_VBM
304953	100736229	20992701681	suffering	suffer	VVG
304953	100736229	20992701682	too	too	RG
304953	100736229	20992701683	much	much	DA1_RR
304953	100736229	20992701684	.	.	.
304953	100736229	20992701685	<p>		NULL
304953	100736229	20992701686	I	i	PPIS1
304953	100736229	20992701687	have	have	VH0
304953	100736229	20992701688	been	be	VBN
304953	100736229	20992701689	on	on	II
304953	100736229	20992701690	hormone	hormone	NN1
304953	100736229	20992701691	therapyabout		NN1_VV0
304953	100736229	20992701692	18	18	MC
304953	100736229	20992701693	months	month	NNT2
304953	100736229	20992701694	I	i	PPIS1
304953	100736229	20992701695	get	get	VV0
304953	100736229	20992701696	a	a	AT1
304953	100736229	20992701697	check	check	NN1
304953	100736229	20992701698	up	up	RP
304953	100736229	20992701699	in	in	II
304953	100736229	20992701700	november	november	NN1
304953	100736229	20992701701	.	.	.
304953	100736229	20992701702	regardless	regardless	RR
304953	100736229	20992701703	of	of	IO
304953	100736229	20992701704	the	the	AT
304953	100736229	20992701705	outcome	outcome	NN1
304953	100736229	20992701706	they	they	PPHS2
304953	100736229	20992701707	told	tell	VVD
304953	100736229	20992701708	me	me	PPIO1
304953	100736229	20992701709	,	,	,
304953	100736229	20992701710	they	they	PPHS2
304953	100736229	20992701711	being	be	VBG
304953	100736229	20992701712	my	my	APPGE
304953	100736229	20992701713	oncologist	oncologist	NN1
304953	100736229	20992701714	that	that	CST
304953	100736229	20992701715	I	i	PPIS1
304953	100736229	20992701716	will	will	VM
304953	100736229	20992701717	get	get	VVI
304953	100736229	20992701718	another	another	DD1
304953	100736229	20992701719	six	six	MC
304953	100736229	20992701720	month	month	NNT1
304953	100736229	20992701721	injection	injection	NN1
304953	100736229	20992701722	.	.	.
304953	100736229	20992701723	I	i	PPIS1
304953	100736229	20992701724	take	take	VV0
304953	100736229	20992701725	cholesteral		JJ_NN1
304953	100736229	20992701726	and	and	CC
304953	100736229	20992701727	blood	blood	NN1
304953	100736229	20992701728	pressure	pressure	NN1
304953	100736229	20992701729	meds	med	NN2_VVZ
304953	100736229	20992701730	and	and	CC
304953	100736229	20992701731	antidepressents		NN2
304953	100736229	20992701732	.	.	.
304953	100736229	20992701733	My	my	APPGE
304953	100736229	20992701734	cancer	cancer	NN1
304953	100736229	20992701735	was	be	VBDZ
304953	100736229	20992701736	alledgedly		RR
304953	100736229	20992701737	in	in	II
304953	100736229	20992701738	my	my	APPGE
304953	100736229	20992701739	lower	low	JJR
304953	100736229	20992701740	lymph	lymph	NN1
304953	100736229	20992701741	node	node	NN1
304953	100736229	20992701742	based	base	VVN
304953	100736229	20992701743	in	in	II
304953	100736229	20992701744	its	its	APPGE
304953	100736229	20992701745	inflammation	inflammation	NN1
304953	100736229	20992701746	.	.	.
304953	100736229	20992701747	no	no	AT_UH
304953	100736229	20992701748	biopsy	biopsy	NN1
304953	100736229	20992701749	.	.	.
304953	100736229	20992701750	I	i	PPIS1
304953	100736229	20992701751	feel	feel	VV0
304953	100736229	20992701752	poorly	poorly	RR
304953	100736229	20992701753	most	most	DAT
304953	100736229	20992701754	of	of	IO
304953	100736229	20992701755	the	the	AT
304953	100736229	20992701756	time	time	NNT1
304953	100736229	20992701757	and	and	CC
304953	100736229	20992701758	am	be	VBM
304953	100736229	20992701759	@		II
304953	100736229	20992701760	@		II
304953	100736229	20992701761	@		II
304953	100736229	20992701762	@		II
304953	100736229	20992701763	@		II
304953	100736229	20992701764	@		II
304953	100736229	20992701765	@		II
304953	100736229	20992701766	@		II
304953	100736229	20992701767	@		II
304953	100736229	20992701768	@		II
304953	100736229	20992701769	do	do	VD0
304953	100736229	20992701770	n't 	n't	XX
304953	100736229	20992701771	know	know	VVI
304953	100736229	20992701772	if	if	CSW@_CS
304953	100736229	20992701773	its	its	APPGE
304953	100736229	20992701774	physical	physical	JJ
304953	100736229	20992701775	or	or	CC
304953	100736229	20992701776	mental	mental	JJ
304953	100736229	20992701777	Are	be	VBR
304953	100736229	20992701778	there	there	EX_RL
304953	100736229	20992701779	any	any	DD
304953	100736229	20992701780	drugs	drug	NN2
304953	100736229	20992701781	to	to	TO
304953	100736229	20992701782	offer	offer	VVI
304953	100736229	20992701783	energy	energy	NN1
304953	100736229	20992701784	<p>		NULL
304953	100736229	20992701785	ten	ten	MC
304953	100736229	20992701786	years	year	NNT2
304953	100736229	20992701787	ago	ago	RA
304953	100736229	20992701788	we	we	PPIS2
304953	100736229	20992701789	found	find	VVD
304953	100736229	20992701790	out	out	RP
304953	100736229	20992701791	my	my	APPGE
304953	100736229	20992701792	uncle	uncle	NN1
304953	100736229	20992701793	is	be	VBZ
304953	100736229	20992701794	having	have	VHG
304953	100736229	20992701795	4	4	MC
304953	100736229	20992701796	stones	stone	NN2
304953	100736229	20992701797	in	in	II
304953	100736229	20992701798	his	his	APPGE
304953	100736229	20992701799	pancreas	pancreas	NN1
304953	100736229	20992701800	,	,	,
304953	100736229	20992701801	&amp;		CC
304953	100736229	20992701802	went	go	VVD
304953	100736229	20992701803	with	with	IW
304953	100736229	20992701804	the	the	AT
304953	100736229	20992701805	medication	medication	NN1
304953	100736229	20992701806	available	available	JJ
304953	100736229	20992701807	at	at	II
304953	100736229	20992701808	that	that	DD1
304953	100736229	20992701809	time	time	NNT1
304953	100736229	20992701810	as	as	II_CSA
304953	100736229	20992701811	no	no	AT
304953	100736229	20992701812	surgery	surgery	NN1
304953	100736229	20992701813	was	be	VBDZ
304953	100736229	20992701814	developed	develop	VVN
304953	100736229	20992701815	at	at	II
304953	100736229	20992701816	that	that	DD1
304953	100736229	20992701817	time	time	NNT1
304953	100736229	20992701818	and	and	CC
304953	100736229	20992701819	there	there	EX
304953	100736229	20992701820	was	be	VBDZ
304953	100736229	20992701821	no	no	AT
304953	100736229	20992701822	pain	pain	NN1
304953	100736229	20992701823	as	as	CSA_II@
304953	100736229	20992701824	such	such	DA
304953	100736229	20992701825	but	but	CCB
304953	100736229	20992701826	four	four	MC
304953	100736229	20992701827	months	month	NNT2
304953	100736229	20992701828	earlier	early	RRR
304953	100736229	20992701829	he	he	PPHS1
304953	100736229	20992701830	started	start	VVD
304953	100736229	20992701831	having	have	VHG
304953	100736229	20992701832	chronic	chronic	JJ
304953	100736229	20992701833	pain	pain	NN1
304953	100736229	20992701834	in	in	II
304953	100736229	20992701835	his	his	APPGE
304953	100736229	20992701836	back	back	NN1
304953	100736229	20992701837	,	,	,
304953	100736229	20992701838	we	we	PPIS2
304953	100736229	20992701839	had	have	VHD
304953	100736229	20992701840	certain	certain	JJ
304953	100736229	20992701841	examinations	examination	NN2
304953	100736229	20992701842	done	do	VDN
304953	100736229	20992701843	to	to	II
304953	100736229	20992701844	that	that	DD1
304953	100736229	20992701845	and	and	CC
304953	100736229	20992701846	found	find	VVD_VVN
304953	100736229	20992701847	certain	certain	JJ
304953	100736229	20992701848	small	small	JJ
304953	100736229	20992701849	mass	mass	NN1
304953	100736229	20992701850	been	be	VBN
304953	100736229	20992701851	developed	develop	VVN
304953	100736229	20992701852	in	in	II
304953	100736229	20992701853	pancreas	pancreas	NN1
304953	100736229	20992701854	any	any	DD_RR%
304953	100736229	20992701855	went	go	VVD
304953	100736229	20992701856	for	for	IF
304953	100736229	20992701857	biopsy	biopsy	NN1
304953	100736229	20992701858	by	by	II
304953	100736229	20992701859	cutting	cut	VVG_NN1
304953	100736229	20992701860	open	open	VV0_RR@
304953	100736229	20992701861	the	the	AT
304953	100736229	20992701862	stomach	stomach	NN1
304953	100736229	20992701863	and	and	CC
304953	100736229	20992701864	after	after	II_CS
304953	100736229	20992701865	report	report	NN1
304953	100736229	20992701866	came	come	VVD
304953	100736229	20992701867	it	it	PPH1
304953	100736229	20992701868	is	be	VBZ
304953	100736229	20992701869	showing	show	VVG
304953	100736229	20992701870	highly	highly	RR
304953	100736229	20992701871	suspicious	suspicious	JJ
304953	100736229	20992701872	,	,	,
304953	100736229	20992701873	any	any	DD
304953	100736229	20992701874	chemotherapist		NN1
304953	100736229	20992701875	is	be	VBZ
304953	100736229	20992701876	not	not	XX
304953	100736229	20992701877	performing	perform	VVG_JJ@
304953	100736229	20992701878	chemo	chemo	NN1
304953	100736229	20992701879	as	as	CSA_II@
304953	100736229	20992701880	reports	report	NN2
304953	100736229	20992701881	are	be	VBR
304953	100736229	20992701882	not	not	XX
304953	100736229	20992701883	conclusive	conclusive	JJ
304953	100736229	20992701884	&amp;		CC
304953	100736229	20992701885	after	after	II_CS
304953	100736229	20992701886	4	4	MC
304953	100736229	20992701887	months	month	NNT2
304953	100736229	20992701888	also	also	RR
304953	100736229	20992701889	we	we	PPIS2
304953	100736229	20992701890	do	do	VD0
304953	100736229	20992701891	not	not	XX
304953	100736229	20992701892	have	have	VHI
304953	100736229	20992701893	any	any	DD
304953	100736229	20992701894	exact	exact	JJ
304953	100736229	20992701895	reason	reason	NN1
304953	100736229	20992701896	for	for	IF
304953	100736229	20992701897	the	the	AT
304953	100736229	20992701898	pain	pain	NN1
304953	100736229	20992701899	&amp;		CC
304953	100736229	20992701900	about	about	II
304953	100736229	20992701901	the	the	AT
304953	100736229	20992701902	tumor	tumor	NN1
304953	100736229	20992701903	,	,	,
304953	100736229	20992701904	He	he	PPHS1
304953	100736229	20992701905	is	be	VBZ
304953	100736229	20992701906	suffering	suffer	VVG_JJ
304953	100736229	20992701907	from	from	II
304953	100736229	20992701908	severe	severe	JJ
304953	100736229	20992701909	back	back	NN1_JJ@
304953	100736229	20992701910	pain	pain	NN1
304953	100736229	20992701911	,	,	,
304953	100736229	20992701912	can	can	VM
304953	100736229	20992701913	some	some	PN121
304953	100736229	20992701914	one	one	PN122
304953	100736229	20992701915	please	please	RR
304953	100736229	20992701916	suggest	suggest	VVI
304953	100736229	20992701917	something	something	PN1
304953	100736229	20992701918	<p>		NULL
304953	100736229	20992701919	I	i	PPIS1
304953	100736229	20992701920	had	have	VHD
304953	100736229	20992701921	a	a	AT1
304953	100736229	20992701922	radical	radical	JJ_NN1
304953	100736229	20992701923	prostectomy		NN1
304953	100736229	20992701924	4	4	MC
304953	100736229	20992701925	years	year	NNT2
304953	100736229	20992701926	ago	ago	RA
304953	100736229	20992701927	.	.	.
304953	100736229	20992701928	The	the	AT
304953	100736229	20992701929	surgeon	surgeon	NN1
304953	100736229	20992701930	told	tell	VVD
304953	100736229	20992701931	he	he	PPHS1
304953	100736229	20992701932	did	do	VDD
304953	100736229	20992701933	n't 	n't	XX
304953	100736229	20992701934	think	think	VVI
304953	100736229	20992701935	he	he	PPHS1
304953	100736229	20992701936	got	get	VVD
304953	100736229	20992701937	it	it	PPH1
304953	100736229	20992701938	all	all	DB_RR@
304953	100736229	20992701939	.	.	.
304953	100736229	20992701940	So	so	RR
304953	100736229	20992701941	,	,	,
304953	100736229	20992701942	I 've		NN1_NP1
304953	100736229	20992701943	been	be	VBN
304953	100736229	20992701944	watching	watch	VVG
304953	100736229	20992701945	my	my	APPGE
304953	100736229	20992701946	PSA	psa	NP1
304953	100736229	20992701947	results	result	NN2_VVZ@
304953	100736229	20992701948	as	as	II_CSA
304953	100736229	20992701949	an	a	AT1
304953	100736229	20992701950	indicator	indicator	NN1
304953	100736229	20992701951	.	.	.
304953	100736229	20992701952	PSA	psa	NP1
304953	100736229	20992701953	has	have	VHZ
304953	100736229	20992701954	been	be	VBN
304953	100736229	20992701955	steadily	steadily	RR
304953	100736229	20992701956	rising	rise	VVG
304953	100736229	20992701957	from	from	II
304953	100736229	20992701958	0	0	MC
304953	100736229	20992701959	@		II
304953	100736229	20992701960	@		II
304953	100736229	20992701961	@		II
304953	100736229	20992701962	@		II
304953	100736229	20992701963	@		II
304953	100736229	20992701964	@		II
304953	100736229	20992701965	@		II
304953	100736229	20992701966	@		II
304953	100736229	20992701967	@		II
304953	100736229	20992701968	@		II
304953	100736229	20992701969	to	to	II
304953	100736229	20992701970	2.3	2.3	MC
304953	100736229	20992701971	within	within	II
304953	100736229	20992701972	6	6	MC
304953	100736229	20992701973	months	month	NNT2
304953	100736229	20992701974	.	.	.
304953	100736229	20992701975	Is	be	VBZ
304953	100736229	20992701976	the	the	AT
304953	100736229	20992701977	cancer	cancer	NN1
304953	100736229	20992701978	gaining	gain	VVG_NN1@
304953	100736229	20992701979	momentum	momentum	NN1
304953	100736229	20992701980	?	?	?
304953	100736229	20992701981	Then	then	RT
304953	100736229	20992701982	I	i	PPIS1
304953	100736229	20992701983	wonder	wonder	VV0
304953	100736229	20992701984	how	how	RGQ@_RRQ
304953	100736229	20992701985	accurate	accurate	JJ
304953	100736229	20992701986	are	be	VBR
304953	100736229	20992701987	PSA	psa	NP1
304953	100736229	20992701988	tests	test	NN2_VVZ@
304953	100736229	20992701989	if	if	CS
304953	100736229	20992701990	I	i	PPIS1
304953	100736229	20992701991	do	do	VD0
304953	100736229	20992701992	n't 	n't	XX
304953	100736229	20992701993	have	have	VHI
304953	100736229	20992701994	a	a	AT1
304953	100736229	20992701995	prostate	prostate	NN1
304953	100736229	20992701996	?	?	?
304953	100736229	20992701997	<p>		NULL
304953	100736229	20992701998	10	10	MC
304953	100736229	20992701999	yrs	yr	NNU2
304953	100736229	20992702000	ago	ago	RA
304953	100736229	20992702001	my	my	APPGE
304953	100736229	20992702002	psa		NN1
304953	100736229	20992702003	was	be	VBDZ
304953	100736229	20992702004	3.7	3.7	MC
304953	100736229	20992702005	I 'm		NP1_NN1_VV0
304953	100736229	20992702006	67	67	MC
304953	100736229	20992702007	now	now	RT
304953	100736229	20992702008	doctor	doctor	NN1_VV0%
304953	100736229	20992702009	did	do	VDD
304953	100736229	20992702010	a	a	AT1
304953	100736229	20992702011	biop		NN1
304953	100736229	20992702012	and	and	CC
304953	100736229	20992702013	came	come	VVD
304953	100736229	20992702014	up	up	RP
304953	100736229	20992702015	neg.		NNU
304953	100736229	20992702016	now	now	RT_CS%
304953	100736229	20992702017	my	my	APPGE
304953	100736229	20992702018	psa		NN1
304953	100736229	20992702019	is	be	VBZ
304953	100736229	20992702020	4.0	4.0	MC
304953	100736229	20992702021	urinate		JJ_NN1_VV0
304953	100736229	20992702022	allot		NN1_VV0
304953	100736229	20992702023	up	up	RP_II@
304953	100736229	20992702024	a	a	AT1
304953	100736229	20992702025	few	few	DA2
304953	100736229	20992702026	times	time	NNT2
304953	100736229	20992702027	a	a	AT1
304953	100736229	20992702028	night	night	NNT1
304953	100736229	20992702029	,	,	,
304953	100736229	20992702030	no	no	AT
304953	100736229	20992702031	other	other	JJ
304953	100736229	20992702032	problems.If		NNU
304953	100736229	20992702033	I	i	PPIS1
304953	100736229	20992702034	do	do	VD0
304953	100736229	20992702035	n't 	n't	XX
304953	100736229	20992702036	drink	drink	VVI
304953	100736229	20992702037	coffee	coffee	NN1
304953	100736229	20992702038	in	in	II
304953	100736229	20992702039	the	the	AT
304953	100736229	20992702040	morning	morning	NNT1
304953	100736229	20992702041	I	i	PPIS1
304953	100736229	20992702042	go	go	VV0
304953	100736229	20992702043	for	for	IF
304953	100736229	20992702044	hours	hour	NNT2
304953	100736229	20992702045	.	.	.
304953	100736229	20992702046	the	the	AT
304953	100736229	20992702047	reason	reason	NN1
304953	100736229	20992702048	I	i	PPIS1_MC1%
304953	100736229	20992702049	have n't		VV0_NN1
304953	100736229	20992702050	been	be	VBN
304953	100736229	20992702051	to	to	II
304953	100736229	20992702052	a	a	AT1
304953	100736229	20992702053	doctor	doctor	NN1
304953	100736229	20992702054	for	for	IF
304953	100736229	20992702055	this	this	DD1
304953	100736229	20992702056	in	in	II
304953	100736229	20992702057	years	year	NNT2
304953	100736229	20992702058	is	be	VBZ
304953	100736229	20992702059	because	because	CS
304953	100736229	20992702060	the	the	AT
304953	100736229	20992702061	bio	bio	NN1
304953	100736229	20992702062	was	be	VBDZ
304953	100736229	20992702063	so	so	RG_RR
304953	100736229	20992702064	hard	hard	JJ
304953	100736229	20992702065	on	on	II
304953	100736229	20992702066	me	me	PPIO1
304953	100736229	20992702067	.	.	.
304953	100736229	20992702068	Ill	ill	JJ_NP1@
304953	100736229	20992702069	never	never	RR
304953	100736229	20992702070	do	do	VD0
304953	100736229	20992702071	it	it	PPH1
304953	100736229	20992702072	again	again	RT
304953	100736229	20992702073	.	.	.
304953	100736229	20992702074	<p>		NULL
304953	100736229	20992702075	I	i	PPIS1
304953	100736229	20992702076	had	have	VHD
304953	100736229	20992702077	a	a	AT1
304953	100736229	20992702078	radical	radical	JJ_NN1
304953	100736229	20992702079	prostectomy		NN1
304953	100736229	20992702080	done	do	VDN
304953	100736229	20992702081	3	3	MC
304953	100736229	20992702082	years	year	NNT2
304953	100736229	20992702083	ago	ago	RA
304953	100736229	20992702084	and	and	CC
304953	100736229	20992702085	Dr.		NNB
304953	100736229	20992702086	said	say	VVD
304953	100736229	20992702087	he	he	PPHS1
304953	100736229	20992702088	was	be	VBDZ
304953	100736229	20992702089	able	able	JK
304953	100736229	20992702090	to	to	TO
304953	100736229	20992702091	remove	remove	VVI
304953	100736229	20992702092	all	all	DB
304953	100736229	20992702093	cancerous	cancerous	JJ
304953	100736229	20992702094	cells	cell	NN2
304953	100736229	20992702095	and	and	CC
304953	100736229	20992702096	no	no	AT
304953	100736229	20992702097	margins	margin	NN2
304953	100736229	20992702098	left	leave	VVD_VVN
304953	100736229	20992702099	.	.	.
304953	100736229	20992702100	Since	since	II
304953	100736229	20992702101	then	then	RT
304953	100736229	20992702102	I	i	PPIS1
304953	100736229	20992702103	have	have	VH0
304953	100736229	20992702104	been	be	VBN
304953	100736229	20992702105	watching	watch	VVG
304953	100736229	20992702106	my	my	APPGE
304953	100736229	20992702107	PSA	psa	NP1
304953	100736229	20992702108	.	.	.
304953	100736229	20992702109	Lately	lately	RR
304953	100736229	20992702110	my	my	APPGE
304953	100736229	20992702111	psa		NN1
304953	100736229	20992702112	has	have	VHZ
304953	100736229	20992702113	been	be	VBN
304953	100736229	20992702114	little	little	DA1_RR_JJ
304953	100736229	20992702115	high	high	JJ_RR@
304953	100736229	20992702116	as	as	CSA_II@_RG@
304953	100736229	20992702117	0.06	0.06	MC
304953	100736229	20992702118	.	.	.
304953	100736229	20992702119	I	i	PPIS1
304953	100736229	20992702120	went	go	VVD
304953	100736229	20992702121	to	to	TO
304953	100736229	20992702122	see	see	VVI
304953	100736229	20992702123	my	my	APPGE
304953	100736229	20992702124	urologist	urologist	NN1
304953	100736229	20992702125	and	and	CC
304953	100736229	20992702126	he	he	PPHS1
304953	100736229	20992702127	refered		VVD
304953	100736229	20992702128	me	me	PPIO1
304953	100736229	20992702129	yo	yo	UH
304953	100736229	20992702130	a	a	AT1
304953	100736229	20992702131	an	a	AT1
304953	100736229	20992702132	oncologist	oncologist	NN1
304953	100736229	20992702133	.	.	.
304953	100736229	20992702134	Should	should	VM
304953	100736229	20992702135	I	i	PPIS1
304953	100736229	20992702136	worry	worry	VVI
304953	100736229	20992702137	or	or	CC
304953	100736229	20992702138	just	just	RR
304953	100736229	20992702139	ignore	ignore	VVI
304953	100736229	20992702140	the	the	AT
304953	100736229	20992702141	PSa		NP1
304953	100736229	20992702142	results	result	NN2_VVZ@
304953	100736229	20992702143	.	.	.
304953	100736229	20992702144	<p>		NULL
304953	100736229	20992702145	I	i	PPIS1
304953	100736229	20992702146	am	be	VBM
304953	100736229	20992702147	Dutch	dutch	JJ
304953	100736229	20992702148	and	and	CC
304953	100736229	20992702149	I	i	PPIS1_ZZ1%_MC1%
304953	100736229	20992702150	red	red	JJ_NN1
304953	100736229	20992702151	in	in	II
304953	100736229	20992702152	the	the	AT
304953	100736229	20992702153	book	book	NN1
304953	100736229	20992702154	of	of	IO
304953	100736229	20992702155	Dr.Greger		NP1
304953	100736229	20992702156	MD	md	NNA
304953	100736229	20992702157	:	:	:
304953	100736229	20992702158	HOW	how	RRQ
304953	100736229	20992702159	@		II
304953	100736229	20992702160	@		II
304953	100736229	20992702161	@		II
304953	100736229	20992702162	@		II
304953	100736229	20992702163	@		II
304953	100736229	20992702164	@		II
304953	100736229	20992702165	@		II
304953	100736229	20992702166	@		II
304953	100736229	20992702167	@		II
304953	100736229	20992702168	@		II
304953	100736229	20992702169	day	day	NNT1
304953	100736229	20992702170	double	double	VV0@_NN1_RR@
304953	100736229	20992702171	the	the	AT
304953	100736229	20992702172	risk	risk	NN1
304953	100736229	20992702173	of	of	IO
304953	100736229	20992702174	prostate	prostate	NN1
304953	100736229	20992702175	cancer	cancer	NN1
304953	100736229	20992702176	due	due	II21
304953	100736229	20992702177	to	to	II22
304953	100736229	20992702178	choline	choline	NN1
304953	100736229	20992702179	found	find	VVD_VVN
304953	100736229	20992702180	concentrated	concentrate	VVN
304953	100736229	20992702181	in	in	II
304953	100736229	20992702182	eggs	egg	NN2
304953	100736229	20992702183	.	.	.
304953	100736229	20992702184	He	he	PPHS1
304953	100736229	20992702185	writes	write	VVZ
304953	100736229	20992702186	:	:	:
304953	100736229	20992702187	higher	high	JJR
304953	100736229	20992702188	levels	level	NN2
304953	100736229	20992702189	of	of	IO
304953	100736229	20992702190	choline	choline	NN1
304953	100736229	20992702191	in	in	II
304953	100736229	20992702192	the	the	AT
304953	100736229	20992702193	blood	blood	NN1
304953	100736229	20992702194	has	have	VHZ
304953	100736229	20992702195	been	be	VBN
304953	100736229	20992702196	associated	associate	VVN
304953	100736229	20992702197	with	with	IW
304953	100736229	20992702198	increased	increased	JJ
304953	100736229	20992702199	risk	risk	NN1
304953	100736229	20992702200	of	of	IO
304953	100736229	20992702201	developing	developing	JJ_VVG
304953	100736229	20992702202	prostate	prostate	NN1
304953	100736229	20992702203	cancer	cancer	NN1
304953	100736229	20992702204	in	in	II
304953	100736229	20992702205	the	the	AT
304953	100736229	20992702206	first	first	MD
304953	100736229	20992702207	place	place	NN1
304953	100736229	20992702208	.	.	.
304953	100736229	20992702209	The	the	AT
304953	100736229	20992702210	choline	choline	NN1
304953	100736229	20992702211	in	in	II
304953	100736229	20992702212	eggs	egg	NN2
304953	100736229	20992702213	is	be	VBZ
304953	100736229	20992702214	converted	convert	VVN
304953	100736229	20992702215	into	into	II
304953	100736229	20992702216	a	a	AT1
304953	100736229	20992702217	toxin	toxin	NN1
304953	100736229	20992702218	called	call	VVN_VVD@
304953	100736229	20992702219	trimethylamine		NN1_VV0
304953	100736229	20992702220	by	by	II
304953	100736229	20992702221	bacteria	bacteria	NN2
304953	100736229	20992702222	that	that	CST
304953	100736229	20992702223	exist	exist	VV0
304953	100736229	20992702224	in	in	II_RP@
304953	100736229	20992702225	the	the	AT
304953	100736229	20992702226	guts	gut	NN2
304953	100736229	20992702227	of	of	IO
304953	100736229	20992702228	those	those	DD2
304953	100736229	20992702229	who	who	PNQS
304953	100736229	20992702230	eat	eat	VV0
304953	100736229	20992702231	meet	meet	VV0
304953	100736229	20992702232	.	.	.
304953	100736229	20992702233	<p>		NULL
304953	100736229	20992702234	Please	please	RR
304953	100736229	20992702235	comment	comment	VV0
304953	100736229	20992702236	to	to	II
304953	100736229	20992702237	this	this	DD1
304953	100736229	20992702238	info	info	NN1
304953	100736229	20992702239	from	from	II
304953	100736229	20992702240	the	the	AT
304953	100736229	20992702241	a/m		FU
304953	100736229	20992702242	book	book	NN1
304953	100736229	20992702243	.	.	.
304953	100736229	20992702244	Thank	thank	VV0
304953	100736229	20992702245	you	you	PPY
304953	100736229	20992702246	for	for	IF
304953	100736229	20992702247	your	your	APPGE
304953	100736229	20992702248	info	info	NN1
304953	100736229	20992702249	.	.	.
304953	100736229	20992702250	<p>		NULL
304953	100736229	20992702251	PSA	psa	NP1
304953	100736229	20992702252	is	be	VBZ
304953	100736229	20992702253	steady	steady	JJ_RR@
304953	100736229	20992702254	at	at	II
304953	100736229	20992702255	8	8	MC
304953	100736229	20992702256	.	.	.
304953	100736229	20992702257	Have	have	VH0
304953	100736229	20992702258	had	have	VHN
304953	100736229	20992702259	two	two	MC
304953	100736229	20992702260	biopsies	biopsy	NN2
304953	100736229	20992702261	.	.	.
304953	100736229	20992702262	Horrific	horrific	JJ
304953	100736229	20992702263	experiences	experience	NN2
304953	100736229	20992702264	.	.	.
304953	100736229	20992702265	Got	get	VVN_VVD
304953	100736229	20992702266	sepsis	sepsis	NN1
304953	100736229	20992702267	from	from	II
304953	100736229	20992702268	the	the	AT
304953	100736229	20992702269	first	first	MD
304953	100736229	20992702270	one	one	PN1
304953	100736229	20992702271	and	and	CC
304953	100736229	20992702272	nearly	nearly	RR
304953	100736229	20992702273	died	die	VVD_VVN@
304953	100736229	20992702274	.	.	.
304953	100736229	20992702275	No	no	AT
304953	100736229	20992702276	more	more	RRR_DAR
304953	100736229	20992702277	.	.	.
304953	100736229	20992702278	My	my	APPGE
304953	100736229	20992702279	PSA	psa	NP1
304953	100736229	20992702280	goes	go	VVZ
304953	100736229	20992702281	up	up	RP
304953	100736229	20992702282	slowly	slowly	RR
304953	100736229	20992702283	each	each	DD1
304953	100736229	20992702284	year	year	NNT1
304953	100736229	20992702285	.	.	.
304953	100736229	20992702286	I	i	PPIS1
304953	100736229	20992702287	am	be	VBM
304953	100736229	20992702288	60	60	MC
304953	100736229	20992702289	.	.	.
304953	100736229	20992702290	Now	now	RT
304953	100736229	20992702291	there	there	EX
304953	100736229	20992702292	is	be	VBZ
304953	100736229	20992702293	a	a	AT1
304953	100736229	20992702294	new	new	JJ
304953	100736229	20992702295	urine	urine	NN1
304953	100736229	20992702296	test	test	NN1_VV0
304953	100736229	20992702297	where	where	CS_RRQ
304953	100736229	20992702298	a	a	AT1
304953	100736229	20992702299	score	score	NN1
304953	100736229	20992702300	of	of	IO
304953	100736229	20992702301	under	under	RG
304953	100736229	20992702302	15	15	MC
304953	100736229	20992702303	says	say	VVZ
304953	100736229	20992702304	97%		NNU
304953	100736229	20992702305	chance	chance	NN1_VV0%
304953	100736229	20992702306	you	you	PPY
304953	100736229	20992702307	are	be	VBR
304953	100736229	20992702308	safe	safe	JJ
304953	100736229	20992702309	.	.	.
304953	100736229	20992702310	I	i	PPIS1
304953	100736229	20992702311	got	get	VVD
304953	100736229	20992702312	30	30	MC
304953	100736229	20992702313	.	.	.
304953	100736229	20992702314	Not	not	XX
304953	100736229	20992702315	sure	sure	JJ_RR%
304953	100736229	20992702316	what	what	DDQ
304953	100736229	20992702317	that	that	DD1
304953	100736229	20992702318	means	mean	VVZ_NN
304953	100736229	20992702319	.	.	.
304953	100736229	20992702320	This	this	DD1
304953	100736229	20992702321	whole	whole	JJ_NN1
304953	100736229	20992702322	area	area	NN1
304953	100736229	20992702323	is	be	VBZ
304953	100736229	20992702324	tough	tough	JJ
304953	100736229	20992702325	to	to	TO
304953	100736229	20992702326	figure	figure	VVI
304953	100736229	20992702327	out	out	RP
304953	100736229	20992702328	.	.	.
304953	100736229	20992702329	Seems	seem	VVZ
304953	100736229	20992702330	like	like	CS%_RR%
304953	100736229	20992702331	we	we	PPIS2
304953	100736229	20992702332	all	all	DB
304953	100736229	20992702333	have	have	VH0
304953	100736229	20992702334	it	it	PPH1
304953	100736229	20992702335	,	,	,
304953	100736229	20992702336	issue	issue	NN1_VV0
304953	100736229	20992702337	is	be	VBZ
304953	100736229	20992702338	how	how	RRQ_RGQ@
304953	100736229	20992702339	aggressive	aggressive	JJ
304953	100736229	20992702340	is	be	VBZ
304953	100736229	20992702341	it	it	PPH1
304953	100736229	20992702342	.	.	.
304953	100736229	20992702343	I	i	PPIS1
304953	100736229	20992702344	do	do	VD0
304953	100736229	20992702345	know	know	VVI
304953	100736229	20992702346	that	that	CST
304953	100736229	20992702347	if	if	CS
304953	100736229	20992702348	my	my	APPGE
304953	100736229	20992702349	Doc	doc	NN1
304953	100736229	20992702350	and	and	CC
304953	100736229	20992702351	I	i	PPIS1
304953	100736229	20992702352	conclude	conclude	VV0
304953	100736229	20992702353	that	that	CST
304953	100736229	20992702354	I	i	PPIS1
304953	100736229	20992702355	have	have	VH0
304953	100736229	20992702356	it	it	PPH1
304953	100736229	20992702357	or	or	CC
304953	100736229	20992702358	need	need	VV0
304953	100736229	20992702359	@		II
304953	100736229	20992702360	@		II
304953	100736229	20992702361	@		II
304953	100736229	20992702362	@		II
304953	100736229	20992702363	@		II
304953	100736229	20992702364	@		II
304953	100736229	20992702365	@		II
304953	100736229	20992702366	@		II
304953	100736229	20992702367	@		II
304953	100736229	20992702368	@		II
304953	100736229	20992702369	cutting	cut	VVG
304953	100736229	20992702370	it	it	PPH1
304953	100736229	20992702371	out	out	RP
304953	100736229	20992702372	and	and	CC
304953	100736229	20992702373	losing	lose	VVG_JJ@
304953	100736229	20992702374	sexual	sexual	JJ
304953	100736229	20992702375	function	function	NN1
304953	100736229	20992702376	and	and	CC
304953	100736229	20992702377	peeing	pee	VVG
304953	100736229	20992702378	my	my	APPGE
304953	100736229	20992702379	pants	pant	NN2
304953	100736229	20992702380	.	.	.
304953	100736229	20992702381	<p>		NULL
304953	100736229	20992702382	Initially	initially	RR
304953	100736229	20992702383	at	at	II
304953	100736229	20992702384	age	age	NN1
304953	100736229	20992702385	70	70	MC
304953	100736229	20992702386	had	have	VHD
304953	100736229	20992702387	a	a	AT1
304953	100736229	20992702388	PSA	psa	NP1
304953	100736229	20992702389	of	of	IO
304953	100736229	20992702390	6	6	MC
304953	100736229	20992702391	,	,	,
304953	100736229	20992702392	and	and	CC
304953	100736229	20992702393	over	over	RG
304953	100736229	20992702394	2	2	MC
304953	100736229	20992702395	years	year	NNT2
304953	100736229	20992702396	had	have	VHD
304953	100736229	20992702397	6	6	MC
304953	100736229	20992702398	monthly	monthly	JJ
304953	100736229	20992702399	checks	check	NN2
304953	100736229	20992702400	.	.	.
304953	100736229	20992702401	Spiked	spike	VVN_VVD
304953	100736229	20992702402	at	at	II
304953	100736229	20992702403	PSA	psa	NP1
304953	100736229	20992702404	of	of	IO
304953	100736229	20992702405	8	8	MC
304953	100736229	20992702406	at	at	II
304953	100736229	20992702407	which	which	DDQ
304953	100736229	20992702408	time	time	VV0%_NNT1
304953	100736229	20992702409	my	my	APPGE
304953	100736229	20992702410	UK	uk	NP1
304953	100736229	20992702411	doc	doc	NN1
304953	100736229	20992702412	sent	send	VVD_VVN
304953	100736229	20992702413	me	me	PPIO1
304953	100736229	20992702414	for	for	IF
304953	100736229	20992702415	ultrasound	ultrasound	NN1
304953	100736229	20992702416	followed	follow	VVN
304953	100736229	20992702417	by	by	II
304953	100736229	20992702418	a	a	AT1
304953	100736229	20992702419	prostate	prostate	NN1
304953	100736229	20992702420	biopsy	biopsy	NN1
304953	100736229	20992702421	(	(	(
304953	100736229	20992702422	bit	bit	NN1_VVD
304953	100736229	20992702423	uncomfortable	uncomfortable	JJ
304953	100736229	20992702424	but	but	CCB
304953	100736229	20992702425	bearable	bearable	JJ
304953	100736229	20992702426	)	)	)
304953	100736229	20992702427	which	which	DDQ
304953	100736229	20992702428	was	be	VBDZ
304953	100736229	20992702429	negative	negative	JJ
304953	100736229	20992702430	.	.	.
304953	100736229	20992702431	Subsequent	subsequent	JJ
304953	100736229	20992702432	PSA	psa	NP1
304953	100736229	20992702433	of	of	IO
304953	100736229	20992702434	6	6	MC
304953	100736229	20992702435	which	which	DDQ
304953	100736229	20992702436	although	although	CS
304953	100736229	20992702437	on	on	II
304953	100736229	20992702438	the	the	AT
304953	100736229	20992702439	high	high	JJ
304953	100736229	20992702440	side	side	NN1
304953	100736229	20992702441	my	my	APPGE
304953	100736229	20992702442	doctor	doctor	NN1
304953	100736229	20992702443	considered	consider	VVD
304953	100736229	20992702444	I	i	PPIS1
304953	100736229	20992702445	had	have	VHD
304953	100736229	20992702446	BPH	bph	NP1
304953	100736229	20992702447	(	(	(
304953	100736229	20992702448	urine	urine	NN1
304953	100736229	20992702449	flow	flow	NN1
304953	100736229	20992702450	&amp;		CC
304953	100736229	20992702451	ED	ed	NP1
304953	100736229	20992702452	)	)	)
304953	100736229	20992702453	and	and	CC
304953	100736229	20992702454	is	be	VBZ
304953	100736229	20992702455	treating	treat	VVG
304953	100736229	20992702456	me	me	PPIO1
304953	100736229	20992702457	with	with	IW
304953	100736229	20992702458	Tamulosin		NN1_NP1
304953	100736229	20992702459	which	which	DDQ
304953	100736229	20992702460	I	i	PPIS1
304953	100736229	20992702461	am	be	VBM
304953	100736229	20992702462	hoping	hope	VVG
304953	100736229	20992702463	will	will	VM
304953	100736229	20992702464	sort	sort	VVI
304953	100736229	20992702465	it	it	PPH1
304953	100736229	20992702466	.	.	.
304953	100736229	20992702467	<p>		NULL
304953	100736229	20992702468	I	i	PPIS1
304953	100736229	20992702469	am	be	VBM
304953	100736229	20992702470	69	69	MC
304953	100736229	20992702471	years	year	NNT2
304953	100736229	20992702472	old	old	JJ
304953	100736229	20992702473	and	and	CC
304953	100736229	20992702474	have	have	VH0
304953	100736229	20992702475	Benign	benign	JJ
304953	100736229	20992702476	Prostate	prostate	NN1
304953	100736229	20992702477	.	.	.
304953	100736229	20992702478	I	i	PPIS1
304953	100736229	20992702479	have	have	VH0
304953	100736229	20992702480	been	be	VBN
304953	100736229	20992702481	taking	take	VVG
304953	100736229	20992702482	medicines	medicine	NN2
304953	100736229	20992702483	for	for	IF
304953	100736229	20992702484	the	the	AT
304953	100736229	20992702485	last	last	MD
304953	100736229	20992702486	7	7	MC
304953	100736229	20992702487	years	year	NNT2
304953	100736229	20992702488	.	.	.
304953	100736229	20992702489	The	the	AT
304953	100736229	20992702490	result	result	NN1
304953	100736229	20992702491	is	be	VBZ
304953	100736229	20992702492	that	that	CST_DD1
304953	100736229	20992702493	now	now	RT
304953	100736229	20992702494	I	i	PPIS1
304953	100736229	20992702495	have	have	VH0
304953	100736229	20992702496	ED	ed	NP1_NN1@
304953	100736229	20992702497	&amp;		CC
304953	100736229	20992702498	also	also	RR
304953	100736229	20992702499	whenever	whenever	RRQV
304953	100736229	20992702500	I	i	PPIS1
304953	100736229	20992702501	try	try	VV0
304953	100736229	20992702502	to	to	TO
304953	100736229	20992702503	have	have	VHI
304953	100736229	20992702504	sex	sex	NN1
304953	100736229	20992702505	I	i	PPIS1
304953	100736229	20992702506	get	get	VV0
304953	100736229	20992702507	a	a	AT1
304953	100736229	20992702508	weird	weird	JJ
304953	100736229	20992702509	feeling	feeling	NN1
304953	100736229	20992702510	when	when	CS_RRQ
304953	100736229	20992702511	I	i	PPIS1
304953	100736229	20992702512	reach	reach	VV0
304953	100736229	20992702513	orgasm	orgasm	NN1
304953	100736229	20992702514	but	but	CCB
304953	100736229	20992702515	there	there	EX
304953	100736229	20992702516	is	be	VBZ
304953	100736229	20992702517	no	no	AT
304953	100736229	20992702518	Simon	simon	NP1
304953	100736229	20992702519	ejeculation		NN1
304953	100736229	20992702520	<p>		NULL
304953	100736229	20992702521	I	i	PPIS1
304953	100736229	20992702522	am	be	VBM
304953	100736229	20992702523	58	58	MC
304953	100736229	20992702524	.	.	.
304953	100736229	20992702525	At	at	II
304953	100736229	20992702526	my	my	APPGE
304953	100736229	20992702527	annual	annual	JJ
304953	100736229	20992702528	physical	physical	JJ
304953	100736229	20992702529	exam	exam	NN1
304953	100736229	20992702530	the	the	AT
304953	100736229	20992702531	doctor	doctor	NN1
304953	100736229	20992702532	did	do	VDD
304953	100736229	20992702533	a	a	AT1
304953	100736229	20992702534	prostate	prostate	NN1
304953	100736229	20992702535	exam	exam	NN1
304953	100736229	20992702536	and	and	CC
304953	100736229	20992702537	found	find	VVD_VVN
304953	100736229	20992702538	a	a	AT1
304953	100736229	20992702539	lump	lump	NN1
304953	100736229	20992702540	or	or	CC
304953	100736229	20992702541	nodule	nodule	VV0_NN1
304953	100736229	20992702542	on	on	II
304953	100736229	20992702543	the	the	AT
304953	100736229	20992702544	upper	upper	JJ
304953	100736229	20992702545	right	right	JJ
304953	100736229	20992702546	side	side	NN1
304953	100736229	20992702547	.	.	.
304953	100736229	20992702548	My	my	APPGE
304953	100736229	20992702549	PSA	psa	NP1
304953	100736229	20992702550	level	level	NN1
304953	100736229	20992702551	had	have	VHD
304953	100736229	20992702552	gone	go	VVN
304953	100736229	20992702553	from	from	II
304953	100736229	20992702554	0.7	0.7	MC
304953	100736229	20992702555	last	last	MD
304953	100736229	20992702556	year	year	NNT1
304953	100736229	20992702557	to	to	II
304953	100736229	20992702558	1.9	1.9	MC
304953	100736229	20992702559	@		II
304953	100736229	20992702560	@		II
304953	100736229	20992702561	@		II
304953	100736229	20992702562	@		II
304953	100736229	20992702563	@		II
304953	100736229	20992702564	@		II
304953	100736229	20992702565	@		II
304953	100736229	20992702566	@		II
304953	100736229	20992702567	@		II
304953	100736229	20992702568	@		II
304953	100736229	20992702569	that	that	CST
304953	100736229	20992702570	I	i	PPIS1
304953	100736229	20992702571	have	have	VH0
304953	100736229	20992702572	a	a	AT1
304953	100736229	20992702573	biopsy	biopsy	NN1
304953	100736229	20992702574	done	do	VDN
304953	100736229	20992702575	and	and	CC
304953	100736229	20992702576	I	i	PPIS1
304953	100736229	20992702577	did	do	VDD
304953	100736229	20992702578	.	.	.
304953	100736229	20992702579	Although	although	CS
304953	100736229	20992702580	mildly	mildly	RR
304953	100736229	20992702581	unpleasant	unpleasant	JJ
304953	100736229	20992702582	overall	overall	NN1_RR
304953	100736229	20992702583	the	the	AT
304953	100736229	20992702584	biopsy	biopsy	NN1
304953	100736229	20992702585	went	go	VVD
304953	100736229	20992702586	ok	ok	RR
304953	100736229	20992702587	with	with	IW
304953	100736229	20992702588	few	few	DA2
304953	100736229	20992702589	side	side	NN1
304953	100736229	20992702590	affects	affect	VVZ
304953	100736229	20992702591	and	and	CC
304953	100736229	20992702592	the	the	AT
304953	100736229	20992702593	results	result	NN2
304953	100736229	20992702594	for	for	IF
304953	100736229	20992702595	cancer	cancer	NN1
304953	100736229	20992702596	came	come	VVD
304953	100736229	20992702597	out	out	RP
304953	100736229	20992702598	negative	negative	JJ_NN1@
304953	100736229	20992702599	.	.	.
304953	100736229	20992702600	Although	although	CS
304953	100736229	20992702601	from	from	II
304953	100736229	20992702602	here	here	RL
304953	100736229	20992702603	on	on	II_RP@
304953	100736229	20992702604	out	out	RP
304953	100736229	20992702605	I	i	PPIS1
304953	100736229	20992702606	will	will	VM
304953	100736229	20992702607	always	always	RR
304953	100736229	20992702608	wonder	wonder	VVI
304953	100736229	20992702609	.	.	.
304953	100736229	20992702610	The	the	AT
304953	100736229	20992702611	plan	plan	NN1
304953	100736229	20992702612	of	of	IO
304953	100736229	20992702613	action	action	NN1
304953	100736229	20992702614	is	be	VBZ
304953	100736229	20992702615	to	to	TO
304953	100736229	20992702616	monitor	monitor	VVI
304953	100736229	20992702617	via	via	II
304953	100736229	20992702618	velocity	velocity	NN1
304953	100736229	20992702619	,	,	,
304953	100736229	20992702620	or	or	CC
304953	100736229	20992702621	routine	routine	NN1_JJ@
304953	100736229	20992702622	PSA	psa	NP1
304953	100736229	20992702623	tests	test	NN2_VVZ@
304953	100736229	20992702624	.	.	.
304953	100736229	20992702625	I	i	PPIS1
304953	100736229	20992702626	am	be	VBM
304953	100736229	20992702627	concerned	concerned	JJ
304953	100736229	20992702628	that	that	CST
304953	100736229	20992702629	the	the	AT
304953	100736229	20992702630	doctor	doctor	NN1
304953	100736229	20992702631	who	who	PNQS
304953	100736229	20992702632	invented	invent	VVD
304953	100736229	20992702633	the	the	AT
304953	100736229	20992702634	PSA	psa	NP1
304953	100736229	20992702635	test	test	NN1
304953	100736229	20992702636	has	have	VHZ
304953	100736229	20992702637	now	now	RT
304953	100736229	20992702638	come	come	VVN
304953	100736229	20992702639	out	out	RP
304953	100736229	20992702640	with	with	IW
304953	100736229	20992702641	a	a	AT1
304953	100736229	20992702642	book	book	NN1
304953	100736229	20992702643	called	call	VVN_VVD@
304953	100736229	20992702644	"	"	"
304953	100736229	20992702645	The	the	AT
304953	100736229	20992702646	PSA	psa	NP1
304953	100736229	20992702647	hoax	hoax	NN1_VV0
304953	100736229	20992702648	.	.	.
304953	100736229	20992702649	"	"	"
304953	100736229	20992702650	He	he	PPHS1
304953	100736229	20992702651	claims	claim	VVZ
304953	100736229	20992702652	the	the	AT
304953	100736229	20992702653	PSA	psa	NP1
304953	100736229	20992702654	test	test	NN1
304953	100736229	20992702655	is	be	VBZ
304953	100736229	20992702656	not	not	XX
304953	100736229	20992702657	reliable	reliable	JJ
304953	100736229	20992702658	.	.	.
304953	100736229	20992702659	Hope	hope	VV0
304953	100736229	20992702660	some	some	DD
304953	100736229	20992702661	more	more	DAR_RGR
304953	100736229	20992702662	reliable	reliable	JJ
304953	100736229	20992702663	tests	test	NN2
304953	100736229	20992702664	are	be	VBR
304953	100736229	20992702665	available	available	JJ
304953	100736229	20992702666	soon	soon	RR
304953	100736229	20992702667	.	.	.
304953	100736229	20992702668	<p>		NULL
304953	100736229	20992702669	Rajinderss		VV0_NN1
304953	100736229	20992702670	comment	comment	NN1
304953	100736229	20992702671	aplied		VVD_VVN@
304953	100736229	20992702672	to	to	II
304953	100736229	20992702673	me	me	PPIO1
304953	100736229	20992702674	6	6	MC
304953	100736229	20992702675	mnths		NNU
304953	100736229	20992702676	back	back	NN1_RP
304953	100736229	20992702677	,	,	,
304953	100736229	20992702678	but	but	CCB
304953	100736229	20992702679	now	now	RT
304953	100736229	20992702680	Siemens	siemens	NP1
304953	100736229	20992702681	at	at	II
304953	100736229	20992702682	slow	slow	JJ
304953	100736229	20992702683	rate	rate	NN1
304953	100736229	20992702684	is	be	VBZ
304953	100736229	20992702685	appearing	appear	VVG
304953	100736229	20992702686	and	and	CC
304953	100736229	20992702687	Jesss		NP1_VV0_NN1
304953	100736229	20992702688	comment	comment	NN1
304953	100736229	20992702689	applies	apply	VVZ
304953	100736229	20992702690	as	as	II21
304953	100736229	20992702691	to	to	II22
304953	100736229	20992702692	a	a	AT1
304953	100736229	20992702693	lump	lump	NN1
304953	100736229	20992702694	recently	recently	RR
304953	100736229	20992702695	found	find	VVN_VVD
304953	100736229	20992702696	,	,	,
304953	100736229	20992702697	Urin		NP1_NN1
304953	100736229	20992702698	test	test	NN1
304953	100736229	20992702699	showed	show	VVD
304953	100736229	20992702700	clear	clear	JJ_RR@
304953	100736229	20992702701	but	but	CCB
304953	100736229	20992702702	PSA	psa	NP1
304953	100736229	20992702703	registered	register	VVD
304953	100736229	20992702704	18	18	MC
304953	100736229	20992702705	.	.	.
304953	100736229	20992702706	Specialist	specialist	NN1
304953	100736229	20992702707	at	at	II
304953	100736229	20992702708	RMH		NP1
304953	100736229	20992702709	Melbourne	melbourne	NP1
304953	100736229	20992702710	AUS	aus	NP1
304953	100736229	20992702711	ready	ready	JJ
304953	100736229	20992702712	to	to	TO
304953	100736229	20992702713	do	do	VDI
304953	100736229	20992702714	a	a	AT1
304953	100736229	20992702715	Rectal	rectal	JJ
304953	100736229	20992702716	U/sound		JJ
304953	100736229	20992702717	Biopsy	biopsy	NN1
304953	100736229	20992702718	Nov.8th		FO
304953	100736229	20992702719	.	.	.
304953	100736229	20992702720	My	my	APPGE
304953	100736229	20992702721	concern	concern	NN1
304953	100736229	20992702722	for	for	IF
304953	100736229	20992702723	infection	infection	NN1
304953	100736229	20992702724	was	be	VBDZ
304953	100736229	20992702725	dis-quelled		JJ_NN1
304953	100736229	20992702726	by	by	II
304953	100736229	20992702727	surgeon	surgeon	NN1
304953	100736229	20992702728	stating	state	VVG
304953	100736229	20992702729	they	they	PPHS2
304953	100736229	20992702730	would	would	VM
304953	100736229	20992702731	use	use	VVI
304953	100736229	20992702732	a	a	AT1
304953	100736229	20992702733	stronger	strong	JJR
304953	100736229	20992702734	anti	anti	JJ
304953	100736229	20992702735	infection	infection	NN1
304953	100736229	20992702736	agent.I		NNU
304953	100736229	20992702737	think	think	VV0
304953	100736229	20992702738	I	i	PPIS1
304953	100736229	20992702739	should	should	VM
304953	100736229	20992702740	give	give	VVI
304953	100736229	20992702741	it	it	PPH1
304953	100736229	20992702742	a	a	AT1
304953	100736229	20992702743	miss	miss	NN1@
304953	100736229	20992702744	but	but	CCB
304953	100736229	20992702745	I	i	PPIS1
304953	100736229	20992702746	think	think	VV0
304953	100736229	20992702747	Biopsy	biopsy	NN1
304953	100736229	20992702748	tells	tell	VVZ
304953	100736229	20992702749	if	if	CS_CSW@
304953	100736229	20992702750	benign	benign	JJ
304953	100736229	20992702751	or	or	CC
304953	100736229	20992702752	not	not	XX
304953	100736229	20992702753	!	!	!
304953	100736229	20992702754	I	i	PPIS1
304953	100736229	20992702755	am	be	VBM
304953	100736229	20992702756	80	80	MC
304953	100736229	20992702757	yrs	yr	NNU2
304953	100736229	20992702758	old	old	JJ
304953	100736229	20992702759	@		II
304953	100736229	20992702760	@		II
304953	100736229	20992702761	@		II
304953	100736229	20992702762	@		II
304953	100736229	20992702763	@		II
304953	100736229	20992702764	@		II
304953	100736229	20992702765	@		II
304953	100736229	20992702766	@		II
304953	100736229	20992702767	@		II
304953	100736229	20992702768	@		II
304953	100736229	20992702769	<p>		NULL
304953	100736229	20992702770	Further	far	JJR
304953	100736229	20992702771	conversation	conversation	NN1
304953	100736229	20992702772	with	with	IW
304953	100736229	20992702773	Australian	australian	JJ
304953	100736229	20992702774	friend	friend	NN1
304953	100736229	20992702775	where	where	CS_RRQ
304953	100736229	20992702776	he	he	PPHS1
304953	100736229	20992702777	relates	relate	VVZ
304953	100736229	20992702778	to	to	II
304953	100736229	20992702779	another	another	DD1
304953	100736229	20992702780	Aust.		NP1
304953	100736229	20992702781	having	have	VHG
304953	100736229	20992702782	a	a	AT1
304953	100736229	20992702783	PSA	psa	NP1
304953	100736229	20992702784	count	count	NN1
304953	100736229	20992702785	of	of	IO
304953	100736229	20992702786	500	500	MC
304953	100736229	20992702787	after	after	II
304953	100736229	20992702788	getting	get	VVG
304953	100736229	20992702789	very	very	RG
304953	100736229	20992702790	short	short	JJ
304953	100736229	20992702791	survival	survival	NN1
304953	100736229	20992702792	time	time	NNT1
304953	100736229	20992702793	decided	decide	VVD_VVN
304953	100736229	20992702794	to	to	TO
304953	100736229	20992702795	start	start	VVI
304953	100736229	20992702796	taking	take	VVG
304953	100736229	20992702797	Metformin		NN1_NP1
304953	100736229	20992702798	100mg		NNU
304953	100736229	20992702799	.	.	.
304953	100736229	20992702800	HE	he	PPHS1
304953	100736229	20992702801	has	have	VHZ
304953	100736229	20992702802	survived	survive	VVN
304953	100736229	20992702803	6	6	MC
304953	100736229	20992702804	years	year	NNT2
304953	100736229	20992702805	to	to	II
304953	100736229	20992702806	date	date	NN1
304953	100736229	20992702807	and	and	CC
304953	100736229	20992702808	count	count	NN1_VV0
304953	100736229	20992702809	is	be	VBZ
304953	100736229	20992702810	in	in	II
304953	100736229	20992702811	low	low	JJ_RR@
304953	100736229	20992702812	figures.		NNU
304953	100736229	20992702813	?	?	?
304953	100736229	20992702814	?	?	?
304953	100736229	20992702815	Comments	comment	NN2_VVZ@
304953	100736229	20992702816	anyone	anyone	PN1
304953	100736229	20992702817	?	?	?
304953	100736229	20992702818	?	?	?
304953	100736229	20992702819	?	?	?
304953	100736229	20992702820	<p>		NULL
304953	100736229	20992702821	@Rajinder		FO
304953	100736229	20992702822	Sounds	sound	VVZ
304953	100736229	20992702823	like	like	II
304953	100736229	20992702824	retrograde	retrograde	NN1
304953	100736229	20992702825	ejaculation	ejaculation	NN1
304953	100736229	20992702826	.	.	.
304953	100736229	20992702827	Semen	semen	NN1
304953	100736229	20992702828	goes	go	VVZ
304953	100736229	20992702829	down	down	RP
304953	100736229	20992702830	into	into	II
304953	100736229	20992702831	bladder	bladder	NN1
304953	100736229	20992702832	rather	rather	II21
304953	100736229	20992702833	than	than	II22
304953	100736229	20992702834	coming	come	VVG
304953	100736229	20992702835	up	up	RP
304953	100736229	20992702836	and	and	CC
304953	100736229	20992702837	out	out	RP
304953	100736229	20992702838	.	.	.
304953	100736229	20992702839	Likely	likely	RR@
304953	100736229	20992702840	caused	cause	VVN
304953	100736229	20992702841	by	by	II
304953	100736229	20992702842	your	your	APPGE
304953	100736229	20992702843	meds	med	NN2
304953	100736229	20992702844	for	for	IF
304953	100736229	20992702845	BPH	bph	NP1
304953	100736229	20992702846	weakening	weaken	VVG
304953	100736229	20992702847	the	the	AT
304953	100736229	20992702848	bladder	bladder	NN1
304953	100736229	20992702849	sphincter	sphincter	JJR
304953	100736229	20992702850	muscle	muscle	NN1
304953	100736229	20992702851	so	so	CS@_RR
304953	100736229	20992702852	you	you	PPY
304953	100736229	20992702853	can	can	VM
304953	100736229	20992702854	pee	pee	VVI
304953	100736229	20992702855	better	better	RRR_JJR
304953	100736229	20992702856	.	.	.
304953	100736229	20992702857	Wikipedia	wikipedia	NN1_NP1@
304953	100736229	20992702858	has	have	VHZ
304953	100736229	20992702859	a	a	AT1
304953	100736229	20992702860	good	good	JJ
304953	100736229	20992702861	article	article	NN1
304953	100736229	20992702862	on	on	II
304953	100736229	20992702863	it	it	PPH1
304953	100736229	20992702864	.	.	.
304953	100736229	20992702865	<p>		NULL
304953	100736229	20992702866	Mike	mike	NP1
304953	100736229	20992702867	Z	z	ZZ1_NP1@
304953	100736229	20992702868	About	about	RG
304953	100736229	20992702869	2	2	MC
304953	100736229	20992702870	years	year	NNT2
304953	100736229	20992702871	ago	ago	RA
304953	100736229	20992702872	,	,	,
304953	100736229	20992702873	with	with	IW
304953	100736229	20992702874	a	a	AT1
304953	100736229	20992702875	PSA	psa	NP1
304953	100736229	20992702876	of	of	IO
304953	100736229	20992702877	about	about	RG
304953	100736229	20992702878	11	11	MC
304953	100736229	20992702879	or	or	CC
304953	100736229	20992702880	12	12	MC
304953	100736229	20992702881	,	,	,
304953	100736229	20992702882	my	my	APPGE
304953	100736229	20992702883	Doctor	doctor	NN1
304953	100736229	20992702884	arranged	arrange	VVD_VVN
304953	100736229	20992702885	an	a	AT1
304953	100736229	20992702886	appointment	appointment	NN1
304953	100736229	20992702887	with	with	IW
304953	100736229	20992702888	an	a	AT1
304953	100736229	20992702889	Urologist	urologist	NN1
304953	100736229	20992702890	who	who	PNQS
304953	100736229	20992702891	performed	perform	VVD
304953	100736229	20992702892	a	a	AT1
304953	100736229	20992702893	biopsy	biopsy	NN1
304953	100736229	20992702894	.	.	.
304953	100736229	20992702895	There	there	EX
304953	100736229	20992702896	was	be	VBDZ
304953	100736229	20992702897	no	no	AT
304953	100736229	20992702898	real	real	JJ
304953	100736229	20992702899	discomfort	discomfort	NN1
304953	100736229	20992702900	in	in	II
304953	100736229	20992702901	the	the	AT
304953	100736229	20992702902	procedure	procedure	NN1
304953	100736229	20992702903	which	which	DDQ
304953	100736229	20992702904	confirmed	confirm	VVD
304953	100736229	20992702905	cancer	cancer	NN1
304953	100736229	20992702906	on	on	II
304953	100736229	20992702907	one	one	MC1
304953	100736229	20992702908	side	side	NN1
304953	100736229	20992702909	.	.	.
304953	100736229	20992702910	He	he	PPHS1
304953	100736229	20992702911	recommended	recommend	VVD
304953	100736229	20992702912	X-Ray	x-ray	NN1
304953	100736229	20992702913	Radiation	radiation	NN1
304953	100736229	20992702914	treatments	treatment	NN2
304953	100736229	20992702915	combined	combine	VVN
304953	100736229	20992702916	with	with	IW
304953	100736229	20992702917	hormone	hormone	NN1
304953	100736229	20992702918	treatments	treatment	NN2
304953	100736229	20992702919	.	.	.
304953	100736229	20992702920	However	however	RR
304953	100736229	20992702921	,	,	,
304953	100736229	20992702922	only	only	JJ
304953	100736229	20992702923	radiation	radiation	NN1
304953	100736229	20992702924	treatments	treatment	NN2
304953	100736229	20992702925	(	(	(
304953	100736229	20992702926	35		VV0_NN1
304953	100736229	20992702927	@		II
304953	100736229	20992702928	5	5	MC
304953	100736229	20992702929	per	per	II
304953	100736229	20992702930	week	week	NNT1
304953	100736229	20992702931	)	)	)
304953	100736229	20992702932	were	be	VBDR
304953	100736229	20992702933	done	do	VDN
304953	100736229	20992702934	,	,	,
304953	100736229	20992702935	as	as	CSA
304953	100736229	20992702936	recommended	recommend	VVN
304953	100736229	20992702937	by	by	II
304953	100736229	20992702938	my	my	APPGE
304953	100736229	20992702939	Oncologist	oncologist	NN1
304953	100736229	20992702940	.	.	.
304953	100736229	20992702941	My	my	APPGE
304953	100736229	20992702942	PSA	psa	NP1
304953	100736229	20992702943	result	result	NN1_VV0
304953	100736229	20992702944	6	6	MC
304953	100736229	20992702945	months	month	NNT2
304953	100736229	20992702946	later	later	RRR
304953	100736229	20992702947	was	be	VBDZ
304953	100736229	20992702948	0.71	0.71	MC
304953	100736229	20992702949	and	and	CC
304953	100736229	20992702950	the	the	AT
304953	100736229	20992702951	one	one	MC1
304953	100736229	20992702952	year	year	NNT1
304953	100736229	20992702953	result	result	NN1
304953	100736229	20992702954	was	be	VBDZ
304953	100736229	20992702955	0.55	0.55	MC
304953	100736229	20992702956	.	.	.
304953	100736229	20992702957	Another	another	DD1
304953	100736229	20992702958	test	test	NN1
304953	100736229	20992702959	@		II
304953	100736229	20992702960	@		II
304953	100736229	20992702961	@		II
304953	100736229	20992702962	@		II
304953	100736229	20992702963	@		II
304953	100736229	20992702964	@		II
304953	100736229	20992702965	@		II
304953	100736229	20992702966	@		II
304953	100736229	20992702967	@		II
304953	100736229	20992702968	@		II
304953	100736229	20992702969	am	be	VBM
304953	100736229	20992702970	now	now	RT
304953	100736229	20992702971	77	77	MC
304953	100736229	20992702972	,	,	,
304953	100736229	20992702973	play	play	VV0_NN1
304953	100736229	20992702974	table	table	NN1
304953	100736229	20992702975	tennis	tennis	NN1
304953	100736229	20992702976	regularly	regularly	RR
304953	100736229	20992702977	,	,	,
304953	100736229	20992702978	look	look	VV0
304953	100736229	20992702979	after	after	II
304953	100736229	20992702980	a	a	AT1
304953	100736229	20992702981	large	large	JJ
304953	100736229	20992702982	garden	garden	NN1
304953	100736229	20992702983	with	with	IW
304953	100736229	20992702984	a	a	AT1
304953	100736229	20992702985	300	300	MC
304953	100736229	20992702986	foot	foot	NN1
304953	100736229	20992702987	hedge	hedge	NN1
304953	100736229	20992702988	half-way	halfway	RR
304953	100736229	20992702989	around	around	RP
304953	100736229	20992702990	,	,	,
304953	100736229	20992702991	shovel	shovel	NN1
304953	100736229	20992702992	snow	snow	NN1
304953	100736229	20992702993	etc.		RA
304953	100736229	20992702994	despite	despite	II
304953	100736229	20992702995	2	2	MC
304953	100736229	20992702996	hip	hip	NN1_JJ@
304953	100736229	20992702997	and	and	CC
304953	100736229	20992702998	one	one	MC1
304953	100736229	20992702999	knee	knee	NN1
304953	100736229	20992703000	replacements	replacement	NN2
304953	100736229	20992703001	.	.	.
304953	100736229	20992703002	I	i	PPIS1
304953	100736229	20992703003	feel	feel	VV0
304953	100736229	20992703004	fortunate	fortunate	JJ
304953	100736229	20992703005	especially	especially	RR
304953	100736229	20992703006	since	since	CS_II@
304953	100736229	20992703007	a	a	AT1
304953	100736229	20992703008	close	close	JJ
304953	100736229	20992703009	and	and	CC
304953	100736229	20992703010	much	much	RR_DA1
304953	100736229	20992703011	younger	young	JJR
304953	100736229	20992703012	friend	friend	NN1
304953	100736229	20992703013	(	(	(
304953	100736229	20992703014	61	61	MC
304953	100736229	20992703015	)	)	)
304953	100736229	20992703016	is	be	VBZ
304953	100736229	20992703017	on	on	II
304953	100736229	20992703018	heavy	heavy	JJ
304953	100736229	20992703019	chemotherapy	chemotherapy	NN1
304953	100736229	20992703020	for	for	IF
304953	100736229	20992703021	his	his	APPGE
304953	100736229	20992703022	much	much	RR
304953	100736229	20992703023	more	more	RGR
304953	100736229	20992703024	advanced	advanced	JJ
304953	100736229	20992703025	condition	condition	NN1
304953	100736229	20992703026	.	.	.
304953	100736229	20992703027	At	at	II
304953	100736229	20992703028	the	the	AT
304953	100736229	20992703029	"	"	"
304953	100736229	20992703030	prostrate	prostrate	JJ
304953	100736229	20992703031	cancer	cancer	NN1
304953	100736229	20992703032	support	support	NN1_VV0
304953	100736229	20992703033	group	group	NN1
304953	100736229	20992703034	"	"	"
304953	100736229	20992703035	we	we	PPIS2
304953	100736229	20992703036	all	all	DB
304953	100736229	20992703037	have	have	VH0
304953	100736229	20992703038	learned	learn	VVN
304953	100736229	20992703039	that	that	CST
304953	100736229	20992703040	PSA	psa	NP1
304953	100736229	20992703041	results	result	NN2
304953	100736229	20992703042	are	be	VBR
304953	100736229	20992703043	only	only	JJ
304953	100736229	20992703044	a	a-i	AT1
304953	100736229	20992703045	"	"	"
304953	100736229	20992703046	guideline	guideline	NN1
304953	100736229	20992703047	"	"	"
304953	100736229	20992703048	.	.	.
304953	100736229	20992703049	<p>		NULL
304953	100736229	20992703050	I	i	PPIS1
304953	100736229	20992703051	am	be	VBM
304953	100736229	20992703052	a	a	AT1
304953	100736229	20992703053	58-year-old	58-year-old	JJ
304953	100736229	20992703054	healthy	healthy	JJ
304953	100736229	20992703055	man	man	NN1
304953	100736229	20992703056	.	.	.
304953	100736229	20992703057	I	i	PPIS1
304953	100736229	20992703058	was	be	VBDZ
304953	100736229	20992703059	diagnosed	diagnose	VVN
304953	100736229	20992703060	with	with	IW
304953	100736229	20992703061	prostatitis	prostatitis	NN1
304953	100736229	20992703062	in	in	II
304953	100736229	20992703063	early	early	JJ
304953	100736229	20992703064	November	november	NPM1
304953	100736229	20992703065	2016	2016	MC
304953	100736229	20992703066	.	.	.
304953	100736229	20992703067	I	i	PPIS1
304953	100736229	20992703068	was	be	VBDZ
304953	100736229	20992703069	discharged	discharge	VVN
304953	100736229	20992703070	from	from	II
304953	100736229	20992703071	hospital	hospital	NN1
304953	100736229	20992703072	four	four	MC
304953	100736229	20992703073	days	day	NNT2
304953	100736229	20992703074	later	later	RRR
304953	100736229	20992703075	,	,	,
304953	100736229	20992703076	feeling	feel	VVG
304953	100736229	20992703077	good	good	JJ
304953	100736229	20992703078	.	.	.
304953	100736229	20992703079	Just	just	RR
304953	100736229	20992703080	prior	prior	II21
304953	100736229	20992703081	to	to	II22
304953	100736229	20992703082	prostatitis	prostatitis	NN1
304953	100736229	20992703083	my	my	APPGE
304953	100736229	20992703084	PSA	psa	NP1
304953	100736229	20992703085	was	be	VBDZ
304953	100736229	20992703086	0.8	0.8	MC
304953	100736229	20992703087	,	,	,
304953	100736229	20992703088	coincidentally	coincidentally	RR
304953	100736229	20992703089	I	i	PPIS1
304953	100736229	20992703090	had	have	VHD
304953	100736229	20992703091	had	have	VHN
304953	100736229	20992703092	my	my	APPGE
304953	100736229	20992703093	annual	annual	JJ
304953	100736229	20992703094	blood	blood	NN1
304953	100736229	20992703095	test	test	VV0_NN1
304953	100736229	20992703096	a	a	AT1
304953	100736229	20992703097	few	few	DA2
304953	100736229	20992703098	days	day	NNT2
304953	100736229	20992703099	before	before	II_CS
304953	100736229	20992703100	diagnosis	diagnosis	NN1
304953	100736229	20992703101	of	of	IO
304953	100736229	20992703102	prostatitis	prostatitis	NN1
304953	100736229	20992703103	.	.	.
304953	100736229	20992703104	One	one	MC1
304953	100736229	20992703105	month	month	NNT1
304953	100736229	20992703106	later	later	RRR
304953	100736229	20992703107	my	my	APPGE
304953	100736229	20992703108	PSA	psa	NP1
304953	100736229	20992703109	was	be	VBDZ
304953	100736229	20992703110	4.0	4.0	MC
304953	100736229	20992703111	(	(	(
304953	100736229	20992703112	is	be	VBZ
304953	100736229	20992703113	this	this	DD1_RG%
304953	100736229	20992703114	high	high	JJ
304953	100736229	20992703115	number	number	NN1
304953	100736229	20992703116	an	a	AT1
304953	100736229	20992703117	expected	expected	JJ
304953	100736229	20992703118	PSA	psa	NP1
304953	100736229	20992703119	level	level	NN1_JJ
304953	100736229	20992703120	following	follow	VVG_JJ@_II@_NN1@
304953	100736229	20992703121	prostatitis	prostatitis	NN1
304953	100736229	20992703122	?	?	?
304953	100736229	20992703123	)	)	)
304953	100736229	20992703124	At	at	II
304953	100736229	20992703125	this	this	DD1
304953	100736229	20992703126	time	time	NNT1
304953	100736229	20992703127	the	the	AT
304953	100736229	20992703128	GP	gp	NN1
304953	100736229	20992703129	conducted	conduct	VVD_VVN
304953	100736229	20992703130	a	a	AT1
304953	100736229	20992703131	DRE	dre	NN1
304953	100736229	20992703132	and	and	CC
304953	100736229	20992703133	no	no	AT
304953	100736229	20992703134	nodules	nodule	NN2
304953	100736229	20992703135	were	be	VBDR
304953	100736229	20992703136	detected	detect	VVN
304953	100736229	20992703137	,	,	,
304953	100736229	20992703138	but	but	CCB
304953	100736229	20992703139	a	a	AT1
304953	100736229	20992703140	larger	large	JJR
304953	100736229	20992703141	than	than	CSN
304953	100736229	20992703142	normal	normal	JJ
304953	100736229	20992703143	prostate	prostate	NN1
304953	100736229	20992703144	was	be	VBDZ
304953	100736229	20992703145	mentioned	mention	VVN
304953	100736229	20992703146	.	.	.
304953	100736229	20992703147	Following	follow	VVG_JJ@_II@
304953	100736229	20992703148	discharge	discharge	NN1
304953	100736229	20992703149	from	from	II
304953	100736229	20992703150	hospital	hospital	NN1
304953	100736229	20992703151	my	my	APPGE
304953	100736229	20992703152	thirst	thirst	NN1
304953	100736229	20992703153	was	be	VBDZ
304953	100736229	20992703154	higher	high	JJR_RRR@
304953	100736229	20992703155	than	than	CSN
304953	100736229	20992703156	normal	normal	JJ
304953	100736229	20992703157	and	and	CC
304953	100736229	20992703158	I	i	PPIS1
304953	100736229	20992703159	@		II
304953	100736229	20992703160	@		II
304953	100736229	20992703161	@		II
304953	100736229	20992703162	@		II
304953	100736229	20992703163	@		II
304953	100736229	20992703164	@		II
304953	100736229	20992703165	@		II
304953	100736229	20992703166	@		II
304953	100736229	20992703167	@		II
304953	100736229	20992703168	@		II
304953	100736229	20992703169	times	time	NNT2
304953	100736229	20992703170	.	.	.
304953	100736229	20992703171	This	this	DD1
304953	100736229	20992703172	has	have	VHZ
304953	100736229	20992703173	settled	settle	VVN
304953	100736229	20992703174	down	down	RP
304953	100736229	20992703175	(	(	(
304953	100736229	20992703176	thirst	thirst	VV0
304953	100736229	20992703177	normal	normal	JJ
304953	100736229	20992703178	and	and	CC
304953	100736229	20992703179	urination	urination	NN1
304953	100736229	20992703180	only	only	JJ
304953	100736229	20992703181	once	once-	NN1
304953	100736229	20992703182	per	per	II
304953	100736229	20992703183	night	night	NNT1
304953	100736229	20992703184	now	now	RT
304953	100736229	20992703185	)	)	)
304953	100736229	20992703186	.	.	.
304953	100736229	20992703187	Six	six	MC
304953	100736229	20992703188	weeks	week	NNT2
304953	100736229	20992703189	later	later	RRR
304953	100736229	20992703190	(	(	(
304953	100736229	20992703191	last	last	MD
304953	100736229	20992703192	week	week	NNT1
304953	100736229	20992703193	in	in	II
304953	100736229	20992703194	January	january	NPM1
304953	100736229	20992703195	2017	2017	MC
304953	100736229	20992703196	)	)	)
304953	100736229	20992703197	the	the	AT
304953	100736229	20992703198	PSA	psa	NP1
304953	100736229	20992703199	reading	reading	NN1
304953	100736229	20992703200	was	be	VBDZ
304953	100736229	20992703201	slightly	slightly	RR
304953	100736229	20992703202	higher	high	JJR
304953	100736229	20992703203	at	at	II
304953	100736229	20992703204	4.1	4.1	MC
304953	100736229	20992703205	.	.	.
304953	100736229	20992703206	Urine	urine	NN1
304953	100736229	20992703207	sample	sample	NN1
304953	100736229	20992703208	detected	detect	VVD_VVN
304953	100736229	20992703209	no	no	AT
304953	100736229	20992703210	infections	infection	NN2
304953	100736229	20992703211	.	.	.
304953	100736229	20992703212	I	i	PPIS1
304953	100736229	20992703213	am	be	VBM
304953	100736229	20992703214	waiting	wait	VVG
304953	100736229	20992703215	another	another	DD1
304953	100736229	20992703216	four	four	MC
304953	100736229	20992703217	weeks	week	NNT2
304953	100736229	20992703218	for	for	IF
304953	100736229	20992703219	the	the	AT
304953	100736229	20992703220	next	next	MD
304953	100736229	20992703221	PSA	psa	NP1
304953	100736229	20992703222	to	to	TO
304953	100736229	20992703223	see	see	VVI
304953	100736229	20992703224	if	if	CSW@_CS
304953	100736229	20992703225	the	the	AT
304953	100736229	20992703226	reading	reading	NN1
304953	100736229	20992703227	goes	go	VVZ
304953	100736229	20992703228	down	down	RP
304953	100736229	20992703229	.	.	.
304953	100736229	20992703230	Typically	typically	RR
304953	100736229	20992703231	,	,	,
304953	100736229	20992703232	would	would	VM
304953	100736229	20992703233	this	this	DD1
304953	100736229	20992703234	be	be	VBI
304953	100736229	20992703235	normal	normal	JJ
304953	100736229	20992703236	that	that	CST
304953	100736229	20992703237	the	the	AT
304953	100736229	20992703238	PSA	psa	NP1
304953	100736229	20992703239	level	level	NN1
304953	100736229	20992703240	is	be	VBZ
304953	100736229	20992703241	so	so	RG_RR
304953	100736229	20992703242	high	high	JJ_RR@
304953	100736229	20992703243	following	following	JJ@_NN1@_VVG
304953	100736229	20992703244	prostatitis	prostatitis	NN1
304953	100736229	20992703245	?	?	?
304953	100736229	20992703246	Could	could	VM
304953	100736229	20992703247	this	this	DD1
304953	100736229	20992703248	be	be	VBI
304953	100736229	20992703249	cancer	cancer	NN1
304953	100736229	20992703250	,	,	,
304953	100736229	20992703251	BPH	bph	NP1
304953	100736229	20992703252	or	or	CC
304953	100736229	20992703253	something	something	PN1
304953	100736229	20992703254	else	else	RR
304953	100736229	20992703255	?	?	?
304953	100736229	20992703256	Should	should	VM
304953	100736229	20992703257	I	i	PPIS1
304953	100736229	20992703258	go	go	VVI
304953	100736229	20992703259	for	for	IF
304953	100736229	20992703260	a	a	AT1
304953	100736229	20992703261	prostate	prostate	NN1
304953	100736229	20992703262	biopsy	biopsy	NN1
304953	100736229	20992703263	now	now	RT
304953	100736229	20992703264	or	or	CC
304953	100736229	20992703265	should	should	VM
304953	100736229	20992703266	I	i	PPIS1
304953	100736229	20992703267	wait	wait	VVI
304953	100736229	20992703268	until	until	II@_CS
304953	100736229	20992703269	March	march	NPM1_NP1@
304953	100736229	20992703270	to	to	TO
304953	100736229	20992703271	consult	consult	VVI
304953	100736229	20992703272	with	with	IW
304953	100736229	20992703273	a	a	AT1
304953	100736229	20992703274	Urologist	urologist	NN1
304953	100736229	20992703275	?	?	?
304953	100736229	20992703276	Thank	thank	VV0
304953	100736229	20992703277	you	you	PPY
304953	100736229	20992703278	.	.	.
304953	100736229	20992703279	<p>		NULL
304953	100736229	20992703280	The	the	AT
304953	100736229	20992703281	PSA	psa	NP1
304953	100736229	20992703282	is	be	VBZ
304953	100736229	20992703283	individually	individually	RR
304953	100736229	20992703284	based	base	VVN
304953	100736229	20992703285	.	.	.
304953	100736229	20992703286	I	i	PPIS1
304953	100736229	20992703287	had	have	VHD
304953	100736229	20992703288	my	my	APPGE
304953	100736229	20992703289	prostate	prostate	NN1
304953	100736229	20992703290	out	out	RP
304953	100736229	20992703291	late	late	JJ_RR
304953	100736229	20992703292	December	december	NPM1
304953	100736229	20992703293	2016	2016	MC
304953	100736229	20992703294	.	.	.
304953	100736229	20992703295	First	first	MD
304953	100736229	20992703296	biopsy	biopsy	NN1
304953	100736229	20992703297	in	in	II
304953	100736229	20992703298	February	february	NPM1
304953	100736229	20992703299	2016	2016	MC
304953	100736229	20992703300	showed	show	VVD
304953	100736229	20992703301	Gleason	gleason	NP1
304953	100736229	20992703302	6	6	MC
304953	100736229	20992703303	.	.	.
304953	100736229	20992703304	The	the	AT
304953	100736229	20992703305	PSA	psa	NP1
304953	100736229	20992703306	at	at	II
304953	100736229	20992703307	that	that	DD1
304953	100736229	20992703308	time	time	NNT1
304953	100736229	20992703309	was	be	VBDZ
304953	100736229	20992703310	a	a	AT1
304953	100736229	20992703311	2.1	2.1	MC
304953	100736229	20992703312	.	.	.
304953	100736229	20992703313	Second	second	MD
304953	100736229	20992703314	biopsy	biopsy	NN1
304953	100736229	20992703315	in	in	II
304953	100736229	20992703316	October	october	NPM1
304953	100736229	20992703317	2016	2016	MC
304953	100736229	20992703318	revealed	reveal	VVD_JJ@
304953	100736229	20992703319	Gleason	gleason	NP1
304953	100736229	20992703320	7	7	MC
304953	100736229	20992703321	BUT	but	CCB
304953	100736229	20992703322	my	my	APPGE
304953	100736229	20992703323	PSA	psa	NP1
304953	100736229	20992703324	DROPPED	drop	VVD
304953	100736229	20992703325	to	to	II
304953	100736229	20992703326	a	a	AT1
304953	100736229	20992703327	1.5	1.5	MC
304953	100736229	20992703328	.	.	.
304953	100736229	20992703329	PSA	psa	NP1
304953	100736229	20992703330	is	be	VBZ
304953	100736229	20992703331	not	not	XX
304953	100736229	20992703332	universal	universal	JJ
304953	100736229	20992703333	<p>		NULL
304953	100736229	20992703334	I	i	PPIS1
304953	100736229	20992703335	am	be	VBM
304953	100736229	20992703336	81and		FO
304953	100736229	20992703337	in	in	II
304953	100736229	20992703338	good	good	JJ
304953	100736229	20992703339	health.I		NNU
304953	100736229	20992703340	walk	walk	NN1_VV0
304953	100736229	20992703341	two	two	MC
304953	100736229	20992703342	to	to	II
304953	100736229	20992703343	three	three	MC
304953	100736229	20992703344	Km	km	NNU
304953	100736229	20992703345	.	.	.
304953	100736229	20992703346	Daily	daily	NP1_RR_JJ
304953	100736229	20992703347	and	and	CC
304953	100736229	20992703348	agile	agile	JJ
304953	100736229	20992703349	enough	enough	RR
304953	100736229	20992703350	to	to	TO
304953	100736229	20992703351	play	play	VVI
304953	100736229	20992703352	table	table	NN1
304953	100736229	20992703353	tennis	tennis	NN1
304953	100736229	20992703354	.	.	.
304953	100736229	20992703355	A	a	AT1
304953	100736229	20992703356	month	month	NNT1
304953	100736229	20992703357	back	back	RP_NN1
304953	100736229	20992703358	i	i	MC1_ZZ1
304953	100736229	20992703359	@		II
304953	100736229	20992703360	@		II
304953	100736229	20992703361	@		II
304953	100736229	20992703362	@		II
304953	100736229	20992703363	@		II
304953	100736229	20992703364	@		II
304953	100736229	20992703365	@		II
304953	100736229	20992703366	@		II
304953	100736229	20992703367	@		II
304953	100736229	20992703368	@		II
304953	100736229	20992703369	was	be	VBDZ
304953	100736229	20992703370	very	very	RG
304953	100736229	20992703371	hard	hard	JJ_RR
304953	100736229	20992703372	fall	fall	NN1_VV0
304953	100736229	20992703373	.	.	.
304953	100736229	20992703374	I	i	PPIS1
304953	100736229	20992703375	developed	develop	VVD
304953	100736229	20992703376	a	a	AT1
304953	100736229	20992703377	bad	bad	JJ
304953	100736229	20992703378	lower	low	JJR
304953	100736229	20992703379	back	back	NN1
304953	100736229	20992703380	ache	ache	NN1
304953	100736229	20992703381	.	.	.
304953	100736229	20992703382	As	as	II_CSA
304953	100736229	20992703383	the	the	AT
304953	100736229	20992703384	ache	ache	NN1
304953	100736229	20992703385	is	be	VBZ
304953	100736229	20992703386	persisting	persist	VVG
304953	100736229	20992703387	the	the	AT
304953	100736229	20992703388	Doc	doc	NN1
304953	100736229	20992703389	suggested	suggest	VVD_VVN
304953	100736229	20992703390	a	a	AT1
304953	100736229	20992703391	PSA	psa	NP1
304953	100736229	20992703392	test	test	NN1_VV0
304953	100736229	20992703393	which	which	DDQ
304953	100736229	20992703394	gave	give	VVD
304953	100736229	20992703395	an	a	AT1
304953	100736229	20992703396	alarming	alarming	JJ
304953	100736229	20992703397	reading	reading	NN1
304953	100736229	20992703398	of	of	IO
304953	100736229	20992703399	25	25	MC
304953	100736229	20992703400	.	.	.
304953	100736229	20992703401	The	the	AT
304953	100736229	20992703402	urologist	urologist	NN1
304953	100736229	20992703403	did	do	VDD
304953	100736229	20992703404	a	a	AT1
304953	100736229	20992703405	DRE	dre	NN1
304953	100736229	20992703406	and	and	CC
304953	100736229	20992703407	advised	advise	VVD_VVN
304953	100736229	20992703408	a	a	AT1
304953	100736229	20992703409	biopsy	biopsy	NN1
304953	100736229	20992703410	.	.	.
304953	100736229	20992703411	I	i	PPIS1
304953	100736229	20992703412	do	do	VD0
304953	100736229	20992703413	not	not	XX
304953	100736229	20992703414	have	have	VHI
304953	100736229	20992703415	any	any	DD
304953	100736229	20992703416	symptoms	symptom	NN2
304953	100736229	20992703417	of	of	IO
304953	100736229	20992703418	p	xx_p	ZZ1_NNU@_NN1@
304953	100736229	20992703419	.	.	.
304953	100736229	20992703420	Cancer	cancer	NN1
304953	100736229	20992703421	like	like	II
304953	100736229	20992703422	frequent	frequent	JJ
304953	100736229	20992703423	urination	urination	NN1
304953	100736229	20992703424	etc	etc	RA
304953	100736229	20992703425	.	.	.
304953	100736229	20992703426	Can	can	VV0%_VM
304953	100736229	20992703427	the	the	AT
304953	100736229	20992703428	high	high	JJ
304953	100736229	20992703429	psa		NN1
304953	100736229	20992703430	result	result	NN1
304953	100736229	20992703431	of	of	IO
304953	100736229	20992703432	the	the	AT
304953	100736229	20992703433	fall	fall	NN1
304953	100736229	20992703434	!	!	!
304953	100736229	20992703435	Should	should	VM
304953	100736229	20992703436	i	i	MC1_ZZ1
304953	100736229	20992703437	subject	subject	NN1
304953	100736229	20992703438	myself	myself	PPX1
304953	100736229	20992703439	to	to	II
304953	100736229	20992703440	biopsy.Are		NNU
304953	100736229	20992703441	there	there	RL
304953	100736229	20992703442	any	any	DD
304953	100736229	20992703443	non	non	FU
304953	100736229	20992703444	intrusive	intrusive	JJ
304953	100736229	20992703445	alternatives	alternative	NN2
304953	100736229	20992703446	.	.	.
304953	100736229	20992703447	<p>		NULL
304953	100736229	20992703448	My	my	APPGE
304953	100736229	20992703449	husband	husband	NN1
304953	100736229	20992703450	had	have	VHD
304953	100736229	20992703451	a	a	AT1
304953	100736229	20992703452	surgeon	surgeon	NN1
304953	100736229	20992703453	do	do	VD0
304953	100736229	20992703454	a	a	AT1
304953	100736229	20992703455	radical	radical	JJ
304953	100736229	20992703456	retropubic		JJ
304953	100736229	20992703457	prostectomy		NN1
304953	100736229	20992703458	with	with	IW
304953	100736229	20992703459	nerve	nerve	NN1
304953	100736229	20992703460	sparing	spare	VVG
304953	100736229	20992703461	in	in	II
304953	100736229	20992703462	2011	2011	MC
304953	100736229	20992703463	September	september	NPM1
304953	100736229	20992703464	He	he	PPHS1
304953	100736229	20992703465	was	be	VBDZ
304953	100736229	20992703466	put	put	VVN
304953	100736229	20992703467	on	on	II
304953	100736229	20992703468	high	high	JJ
304953	100736229	20992703469	dose	dose	NN1
304953	100736229	20992703470	of	of	IO
304953	100736229	20992703471	Cialis	cialis	NN1_NP1
304953	100736229	20992703472	to	to	TO
304953	100736229	20992703473	take	take	VVI
304953	100736229	20992703474	when	when	RRQ_CS
304953	100736229	20992703475	sexual	sexual	JJ
304953	100736229	20992703476	relations	relation	NN2
304953	100736229	20992703477	were	be	VBDR
304953	100736229	20992703478	to	to	TO
304953	100736229	20992703479	happen	happen	VVI
304953	100736229	20992703480	.	.	.
304953	100736229	20992703481	This	this	DD1
304953	100736229	20992703482	gave	give	VVD
304953	100736229	20992703483	him	him	PPHO1
304953	100736229	20992703484	headaches	headache	NN2_VVZ
304953	100736229	20992703485	and	and	CC
304953	100736229	20992703486	flushing	flush	VVG
304953	100736229	20992703487	so	so	RR_CS@
304953	100736229	20992703488	they	they	PPHS2
304953	100736229	20992703489	changed	change	VVD
304953	100736229	20992703490	his	his	APPGE
304953	100736229	20992703491	dose	dose	NN1
304953	100736229	20992703492	to	to	II
304953	100736229	20992703493	everyday	everyday	JJ
304953	100736229	20992703494	Cialis	cialis	NN1
304953	100736229	20992703495	.	.	.
304953	100736229	20992703496	Our	our	APPGE
304953	100736229	20992703497	question	question	NN1
304953	100736229	20992703498	is	be	VBZ
304953	100736229	20992703499	this	this	DD1
304953	100736229	20992703500	"	"	"
304953	100736229	20992703501	why	why	RRQ
304953	100736229	20992703502	is	be	VBZ
304953	100736229	20992703503	his	his	APPGE
304953	100736229	20992703504	erection	erection	NN1
304953	100736229	20992703505	now	now	RT
304953	100736229	20992703506	fleeting	fleet	VVG_JJ
304953	100736229	20992703507	,	,	,
304953	100736229	20992703508	it	it	PPH1
304953	100736229	20992703509	comes	come	VVZ
304953	100736229	20992703510	then	then	RT
304953	100736229	20992703511	it	it	PPH1
304953	100736229	20992703512	goes	go	VVZ
304953	100736229	20992703513	"	"	"
304953	100736229	20992703514	He	he	PPHS1
304953	100736229	20992703515	has	have	VHZ
304953	100736229	20992703516	admitted	admit	VVN
304953	100736229	20992703517	to	to	II
304953	100736229	20992703518	missing	miss	VVG
304953	100736229	20992703519	a	a	AT1
304953	100736229	20992703520	few	few	DA2
304953	100736229	20992703521	pills	pill	NN2
304953	100736229	20992703522	here	here	RL
304953	100736229	20992703523	and	and	CC
304953	100736229	20992703524	there	there	RL
304953	100736229	20992703525	,	,	,
304953	100736229	20992703526	would	would	VM
304953	100736229	20992703527	this	this	DD1
304953	100736229	20992703528	be	be	VBI
304953	100736229	20992703529	the	the	AT
304953	100736229	20992703530	reason	reason	NN1
304953	100736229	20992703531	?	?	?
304953	100736229	20992703532	<p>		NULL
304953	100736229	20992703533	Guys	guys	NP1_NN2
304953	100736229	20992703534	,	,	,
304953	100736229	20992703535	if	if	CS
304953	100736229	20992703536	you	you	PPY
304953	100736229	20992703537	care	care	VV0
304953	100736229	20992703538	at	at	II
304953	100736229	20992703539	all	all	DB
304953	100736229	20992703540	about	about	II
304953	100736229	20992703541	your	your	APPGE
304953	100736229	20992703542	health	health	NN1
304953	100736229	20992703543	and	and	CC
304953	100736229	20992703544	living	living	NN1_JJ_VVG
304953	100736229	20992703545	,	,	,
304953	100736229	20992703546	and	and	CC
304953	100736229	20992703547	your	your	APPGE
304953	100736229	20992703548	family	family	NN1
304953	100736229	20992703549	,	,	,
304953	100736229	20992703550	you	you	PPY
304953	100736229	20992703551	owe	owe	VV0
304953	100736229	20992703552	it	it	PPH1
304953	100736229	20992703553	to	to	II
304953	100736229	20992703554	yourself	yourself	PPX1
304953	100736229	20992703555	to	to	TO
304953	100736229	20992703556	spend	spend	VVI
304953	100736229	20992703557	a	a	AT1
304953	100736229	20992703558	minute	minute	NNT1
304953	100736229	20992703559	@		II
304953	100736229	20992703560	@		II
304953	100736229	20992703561	@		II
304953	100736229	20992703562	@		II
304953	100736229	20992703563	@		II
304953	100736229	20992703564	@		II
304953	100736229	20992703565	@		II
304953	100736229	20992703566	@		II
304953	100736229	20992703567	@		II
304953	100736229	20992703568	@		II
304953	100736229	20992703569	a	a	AT1
304953	100736229	20992703570	fairly	fairly	RR
304953	100736229	20992703571	complete	complete	JJ_VV0
304953	100736229	20992703572	physical	physical	JJ
304953	100736229	20992703573	exam	exam	NN1
304953	100736229	20992703574	each	each	DD1
304953	100736229	20992703575	year	year	NNT1
304953	100736229	20992703576	.	.	.
304953	100736229	20992703577	At	at	II
304953	100736229	20992703578	my	my	APPGE
304953	100736229	20992703579	last	last	MD
304953	100736229	20992703580	yearly	yearly	JJ_RR
304953	100736229	20992703581	physical	physical	JJ
304953	100736229	20992703582	,	,	,
304953	100736229	20992703583	for	for	IF
304953	100736229	20992703584	reasons	reason	NN2
304953	100736229	20992703585	completely	completely	RR
304953	100736229	20992703586	unknown	unknown	JJ
304953	100736229	20992703587	to	to	II
304953	100736229	20992703588	me	me	PPIO1
304953	100736229	20992703589	as	as	CSA
304953	100736229	20992703590	I	i	PPIS1
304953	100736229	20992703591	had	have	VHD
304953	100736229	20992703592	no	no	AT
304953	100736229	20992703593	symptoms	symptom	NN2
304953	100736229	20992703594	whatsoever	whatsoever	DDQV
304953	100736229	20992703595	,	,	,
304953	100736229	20992703596	no	no	AT
304953	100736229	20992703597	family	family	NN1
304953	100736229	20992703598	history	history	NN1
304953	100736229	20992703599	,	,	,
304953	100736229	20992703600	and	and	CC
304953	100736229	20992703601	no	no	AT
304953	100736229	20992703602	known	known	JJ@
304953	100736229	20992703603	risk	risk	NN1
304953	100736229	20992703604	factors	factor	NN2
304953	100736229	20992703605	,	,	,
304953	100736229	20992703606	I	i	PPIS1
304953	100736229	20992703607	asked	ask	VVD
304953	100736229	20992703608	(	(	(
304953	100736229	20992703609	almost	almost	RR
304953	100736229	20992703610	had	have	VHN@_VHD
304953	100736229	20992703611	to	to	TO
304953	100736229	20992703612	insist	insist	VVI
304953	100736229	20992703613	actually	actually	RR
304953	100736229	20992703614	)	)	)
304953	100736229	20992703615	,	,	,
304953	100736229	20992703616	to	to	TO
304953	100736229	20992703617	have	have	VHI
304953	100736229	20992703618	a	a	AT1
304953	100736229	20992703619	PSA	psa	NP1
304953	100736229	20992703620	test	test	NN1_VV0
304953	100736229	20992703621	for	for	IF
304953	100736229	20992703622	prostate	prostate	NN1
304953	100736229	20992703623	cancer	cancer	NN1
304953	100736229	20992703624	done	do	VDN
304953	100736229	20992703625	.	.	.
304953	100736229	20992703626	Its	its	APPGE
304953	100736229	20992703627	a	a	AT1
304953	100736229	20992703628	simple	simple	JJ
304953	100736229	20992703629	blood	blood	NN1
304953	100736229	20992703630	test	test	NN1
304953	100736229	20992703631	and	and	CC
304953	100736229	20992703632	can	can	VM
304953	100736229	20992703633	be	be	VBI
304953	100736229	20992703634	done	do	VDN
304953	100736229	20992703635	along	along	II21
304953	100736229	20992703636	with	with	II22
304953	100736229	20992703637	all	all	DB
304953	100736229	20992703638	the	the	AT
304953	100736229	20992703639	other	other	JJ
304953	100736229	20992703640	blood	blood	NN1
304953	100736229	20992703641	work	work	NN1_VV0
304953	100736229	20992703642	during	during	II
304953	100736229	20992703643	a	a	AT1
304953	100736229	20992703644	physical	physical	JJ
304953	100736229	20992703645	.	.	.
304953	100736229	20992703646	Sadly	sadly	RR
304953	100736229	20992703647	,	,	,
304953	100736229	20992703648	this	this	DD1
304953	100736229	20992703649	test	test	NN1
304953	100736229	20992703650	showed	show	VVD
304953	100736229	20992703651	my	my	APPGE
304953	100736229	20992703652	PSA	psa	NP1
304953	100736229	20992703653	number	number	NN1
304953	100736229	20992703654	had	have	VHD
304953	100736229	20992703655	gotten	get	VVN
304953	100736229	20992703656	very	very	RG
304953	100736229	20992703657	high	high	JJ_RR@
304953	100736229	20992703658	.	.	.
304953	100736229	20992703659	<p>		NULL
304953	100736229	20992703660	My	my	APPGE
304953	100736229	20992703661	last	last	MD
304953	100736229	20992703662	PSA	psa	NP1
304953	100736229	20992703663	test	test	NN1
304953	100736229	20992703664	had	have	VHD
304953	100736229	20992703665	been	be	VBN
304953	100736229	20992703666	done	do	VDN
304953	100736229	20992703667	8	8	MC
304953	100736229	20992703668	years	year	NNT2
304953	100736229	20992703669	previously	previously	RR
304953	100736229	20992703670	,	,	,
304953	100736229	20992703671	but	but	CCB
304953	100736229	20992703672	right	right	RR
304953	100736229	20992703673	about	about	II
304953	100736229	20992703674	that	that	DD1
304953	100736229	20992703675	time	time	NNT1
304953	100736229	20992703676	many	many	DA2
304953	100736229	20992703677	family	family	NN1
304953	100736229	20992703678	practice	practice	NN1
304953	100736229	20992703679	doctors	doctor	NN2
304953	100736229	20992703680	,	,	,
304953	100736229	20992703681	mine	mine	NN1_PPGE
304953	100736229	20992703682	included	include	VVD_VVN
304953	100736229	20992703683	,	,	,
304953	100736229	20992703684	stopped	stop	VVD_VVN
304953	100736229	20992703685	giving	give	VVG
304953	100736229	20992703686	this	this	DD1
304953	100736229	20992703687	test	test	NN1
304953	100736229	20992703688	.	.	.
304953	100736229	20992703689	Their	their	APPGE
304953	100736229	20992703690	reasoning	reasoning	NN1
304953	100736229	20992703691	is	be	VBZ
304953	100736229	20992703692	that	that	CST
304953	100736229	20992703693	the	the	AT
304953	100736229	20992703694	test	test	NN1
304953	100736229	20992703695	sometimes	sometimes	RT
304953	100736229	20992703696	gives	give	VVZ
304953	100736229	20992703697	a	a	AT1
304953	100736229	20992703698	false	false	JJ
304953	100736229	20992703699	positive	positive	JJ
304953	100736229	20992703700	,	,	,
304953	100736229	20992703701	and	and	CC
304953	100736229	20992703702	having	have	VHG
304953	100736229	20992703703	a	a	AT1
304953	100736229	20992703704	positive	positive	JJ
304953	100736229	20992703705	means	mean	NN_VVZ
304953	100736229	20992703706	that	that	CST
304953	100736229	20992703707	you	you	PPY
304953	100736229	20992703708	then	then	RT
304953	100736229	20992703709	need	need	VV0
304953	100736229	20992703710	to	to	TO
304953	100736229	20992703711	then	then	RT
304953	100736229	20992703712	have	have	VHI
304953	100736229	20992703713	a	a	AT1
304953	100736229	20992703714	biopsy	biopsy	NN1
304953	100736229	20992703715	done	do	VDN
304953	100736229	20992703716	by	by	II
304953	100736229	20992703717	a	a	AT1
304953	100736229	20992703718	urologist	urologist	NN1
304953	100736229	20992703719	to	to	TO
304953	100736229	20992703720	determine	determine	VVI
304953	100736229	20992703721	whether	whether	CSW
304953	100736229	20992703722	you	you	PPY
304953	100736229	20992703723	do	do	VD0
304953	100736229	20992703724	or	or	CC
304953	100736229	20992703725	do	do	VD0
304953	100736229	20992703726	not	not	XX
304953	100736229	20992703727	have	have	VHI
304953	100736229	20992703728	prostate	prostate	NN1
304953	100736229	20992703729	cancer	cancer	NN1
304953	100736229	20992703730	.	.	.
304953	100736229	20992703731	In	in	II
304953	100736229	20992703732	my	my	APPGE
304953	100736229	20992703733	opinion	opinion	NN1
304953	100736229	20992703734	their	their	APPGE
304953	100736229	20992703735	abandonment	abandonment	NN1
304953	100736229	20992703736	of	of	IO
304953	100736229	20992703737	the	the	AT
304953	100736229	20992703738	PSA	psa	NP1
304953	100736229	20992703739	test	test	NN1
304953	100736229	20992703740	is	be	VBZ
304953	100736229	20992703741	DEAD	dead	RG
304953	100736229	20992703742	wrong	wrong	JJ_RR@
304953	100736229	20992703743	,	,	,
304953	100736229	20992703744	and	and	CC
304953	100736229	20992703745	I	i	PPIS1
304953	100736229	20992703746	am	be	VBM
304953	100736229	20992703747	one	one	PN1
304953	100736229	20992703748	who	who	PNQS
304953	100736229	20992703749	almost	almost	RR
304953	100736229	20992703750	wound	wind	VVN_VVD
304953	100736229	20992703751	up	up	RP_II@
304953	100736229	20992703752	DEAD	dead	JJ
304953	100736229	20992703753	because	because	II21
304953	100736229	20992703754	of	of	II22
304953	100736229	20992703755	it	it	PPH1
304953	100736229	20992703756	.	.	.
304953	100736229	20992703757	Although	although	CS
304953	100736229	20992703758	any	any	DD
304953	100736229	20992703759	@		II
304953	100736229	20992703760	@		II
304953	100736229	20992703761	@		II
304953	100736229	20992703762	@		II
304953	100736229	20992703763	@		II
304953	100736229	20992703764	@		II
304953	100736229	20992703765	@		II
304953	100736229	20992703766	@		II
304953	100736229	20992703767	@		II
304953	100736229	20992703768	@		II
304953	100736229	20992703769	,	,	,
304953	100736229	20992703770	if	if	CS
304953	100736229	20992703771	needed	need	VVN
304953	100736229	20992703772	,	,	,
304953	100736229	20992703773	is	be	VBZ
304953	100736229	20992703774	a	a	AT1
304953	100736229	20992703775	simple	simple	JJ
304953	100736229	20992703776	routine	routine	NN1_JJ@
304953	100736229	20992703777	out-patient	outpatient	NN1
304953	100736229	20992703778	test	test	NN1
304953	100736229	20992703779	done	do	VDN
304953	100736229	20992703780	at	at	II
304953	100736229	20992703781	a	a	AT1
304953	100736229	20992703782	hospital	hospital	NN1
304953	100736229	20992703783	.	.	.
304953	100736229	20992703784	I	i	PPIS1
304953	100736229	20992703785	was	be	VBDZ
304953	100736229	20992703786	put	put	VVN
304953	100736229	20992703787	to	to	TO
304953	100736229	20992703788	sleep	sleep	VVI
304953	100736229	20992703789	for	for	IF
304953	100736229	20992703790	the	the	AT
304953	100736229	20992703791	procedure	procedure	NN1
304953	100736229	20992703792	,	,	,
304953	100736229	20992703793	total	total	JJ
304953	100736229	20992703794	time	time	NNT1
304953	100736229	20992703795	spent	spend	VVN
304953	100736229	20992703796	at	at	II
304953	100736229	20992703797	the	the	AT
304953	100736229	20992703798	hospital	hospital	NN1
304953	100736229	20992703799	was	be	VBDZ
304953	100736229	20992703800	less	less	DAR
304953	100736229	20992703801	than	than	CSN
304953	100736229	20992703802	4	4	MC
304953	100736229	20992703803	hours	hour	NNT2
304953	100736229	20992703804	,	,	,
304953	100736229	20992703805	and	and	CC
304953	100736229	20992703806	most	most	DAT
304953	100736229	20992703807	of	of	IO
304953	100736229	20992703808	that	that	DD1
304953	100736229	20992703809	time	time	NNT1
304953	100736229	20992703810	is	be	VBZ
304953	100736229	20992703811	spent	spend	VVN
304953	100736229	20992703812	being	be	VBG
304953	100736229	20992703813	put	put	VVN
304953	100736229	20992703814	under	under	RP@_II
304953	100736229	20992703815	and	and	CC
304953	100736229	20992703816	then	then	RT
304953	100736229	20992703817	slowly	slowly	RR
304953	100736229	20992703818	waking	wake	VVG
304953	100736229	20992703819	up	up	RP
304953	100736229	20992703820	again	again	RT
304953	100736229	20992703821	.	.	.
304953	100736229	20992703822	I	i	PPIS1
304953	100736229	20992703823	had	have	VHD
304953	100736229	20992703824	very	very	RG
304953	100736229	20992703825	little	little	DA1
304953	100736229	20992703826	pain	pain	NN1
304953	100736229	20992703827	afterwards	afterwards	RT
304953	100736229	20992703828	,	,	,
304953	100736229	20992703829	I	i	PPIS1
304953	100736229	20992703830	was	be	VBDZ
304953	100736229	20992703831	back	back	NN1_RP
304953	100736229	20992703832	doing	do	VDG
304953	100736229	20992703833	whatever	whatever	DDQV
304953	100736229	20992703834	I	i	PPIS1
304953	100736229	20992703835	wanted	want	VVD
304953	100736229	20992703836	the	the	AT
304953	100736229	20992703837	same	same	DA
304953	100736229	20992703838	day	day	NNT1
304953	100736229	20992703839	,	,	,
304953	100736229	20992703840	and	and	CC
304953	100736229	20992703841	was	be	VBDZ
304953	100736229	20992703842	given	give	VVN_JJ@
304953	100736229	20992703843	antibiotics	antibiotic	NN2
304953	100736229	20992703844	to	to	TO
304953	100736229	20992703845	take	take	VVI
304953	100736229	20992703846	for	for	IF
304953	100736229	20992703847	3	3	MC
304953	100736229	20992703848	weeks	week	NNT2
304953	100736229	20992703849	.	.	.
304953	100736229	20992703850	<p>		NULL
304953	100736229	20992703851	Another	another	DD1
304953	100736229	20992703852	reason	reason	NN1
304953	100736229	20992703853	I	i	PPIS1
304953	100736229	20992703854	have	have	VH0
304953	100736229	20992703855	heard	hear	VVN
304953	100736229	20992703856	for	for	IF
304953	100736229	20992703857	doctors	doctor	NN2
304953	100736229	20992703858	not	not	XX
304953	100736229	20992703859	giving	give	VVG
304953	100736229	20992703860	PSA	psa	NP1
304953	100736229	20992703861	tests	test	VVZ@_NN2
304953	100736229	20992703862	anymore	anymore	RR
304953	100736229	20992703863	is	be	VBZ
304953	100736229	20992703864	that	that	CST
304953	100736229	20992703865	they	they	PPHS2
304953	100736229	20992703866	feel	feel	VV0
304953	100736229	20992703867	patients	patient	NN2
304953	100736229	20992703868	who	who	PNQS
304953	100736229	20992703869	have	have	VH0
304953	100736229	20992703870	to	to	TO
304953	100736229	20992703871	have	have	VHI
304953	100736229	20992703872	a	a	AT1
304953	100736229	20992703873	biopsy	biopsy	NN1
304953	100736229	20992703874	,	,	,
304953	100736229	20992703875	and	and	CC
304953	100736229	20992703876	find	find	VV0
304953	100736229	20992703877	out	out	RP
304953	100736229	20992703878	from	from	II
304953	100736229	20992703879	it	it	PPH1
304953	100736229	20992703880	that	that	CST
304953	100736229	20992703881	they	they	PPHS2
304953	100736229	20992703882	do	do	VD0
304953	100736229	20992703883	not	not	XX
304953	100736229	20992703884	have	have	VHI
304953	100736229	20992703885	prostate	prostate	NN1
304953	100736229	20992703886	cancer	cancer	NN1
304953	100736229	20992703887	will	will	VM
304953	100736229	20992703888	be	be	VBI
304953	100736229	20992703889	angry	angry	JJ
304953	100736229	20992703890	.	.	.
304953	100736229	20992703891	This	this	DD1
304953	100736229	20992703892	is	be	VBZ
304953	100736229	20992703893	absurd	absurd	JJ
304953	100736229	20992703894	and	and	CC
304953	100736229	20992703895	defies	defy	VVZ
304953	100736229	20992703896	common	common	JJ
304953	100736229	20992703897	sense	sense	NN1
304953	100736229	20992703898	,	,	,
304953	100736229	20992703899	I	i	PPIS1
304953	100736229	20992703900	would	would	VM
304953	100736229	20992703901	have	have	VHI
304953	100736229	20992703902	been	be	VBN
304953	100736229	20992703903	elated	elated	JJ_VVN%
304953	100736229	20992703904	to	to	TO
304953	100736229	20992703905	have	have	VHI
304953	100736229	20992703906	the	the	AT
304953	100736229	20992703907	biopsy	biopsy	NN1
304953	100736229	20992703908	and	and	CC
304953	100736229	20992703909	find	find	VV0
304953	100736229	20992703910	out	out	RP
304953	100736229	20992703911	I	i	PPIS1
304953	100736229	20992703912	did	do	VDD
304953	100736229	20992703913	not	not	XX
304953	100736229	20992703914	have	have	VHI
304953	100736229	20992703915	cancer	cancer	NN1
304953	100736229	20992703916	,	,	,
304953	100736229	20992703917	just	just	RR
304953	100736229	20992703918	as	as	CSA
304953	100736229	20992703919	I	i	PPIS1
304953	100736229	20992703920	think	think	VV0
304953	100736229	20992703921	any	any	DD
304953	100736229	20992703922	guy	guy	NN1
304953	100736229	20992703923	would	would	VM
304953	100736229	20992703924	be	be	VBI
304953	100736229	20992703925	.	.	.
304953	100736229	20992703926	<p>		NULL
304953	100736229	20992703927	Anyway	anyway	RR
304953	100736229	20992703928	,	,	,
304953	100736229	20992703929	my	my	APPGE
304953	100736229	20992703930	biopsy	biopsy	NN1
304953	100736229	20992703931	showed	show	VVD
304953	100736229	20992703932	I	i	PPIS1
304953	100736229	20992703933	DID	do	VDD
304953	100736229	20992703934	have	have	VHI
304953	100736229	20992703935	advanced	advance	VVN
304953	100736229	20992703936	fast	fast	RR_JJ
304953	100736229	20992703937	growing	growing	JJ_VVG
304953	100736229	20992703938	prostate	prostate	NN1
304953	100736229	20992703939	cancer	cancer	NN1
304953	100736229	20992703940	.	.	.
304953	100736229	20992703941	My	my	APPGE
304953	100736229	20992703942	ONLY	only	JJ
304953	100736229	20992703943	option	option	NN1
304953	100736229	20992703944	was	be	VBDZ
304953	100736229	20992703945	to	to	TO
304953	100736229	20992703946	have	have	VHI
304953	100736229	20992703947	my	my	APPGE
304953	100736229	20992703948	prostate	prostate	NN1
304953	100736229	20992703949	completely	completely	RR
304953	100736229	20992703950	removed	remove	VVN_VVD
304953	100736229	20992703951	as	as	RG
304953	100736229	20992703952	soon	soon	RR
304953	100736229	20992703953	as	as	CSA
304953	100736229	20992703954	possible	possible	JJ
304953	100736229	20992703955	,	,	,
304953	100736229	20992703956	and	and	CC
304953	100736229	20992703957	it	it	PPH1
304953	100736229	20992703958	was	be	VBDZ
304953	100736229	20992703959	@		II
304953	100736229	20992703960	@		II
304953	100736229	20992703961	@		II
304953	100736229	20992703962	@		II
304953	100736229	20992703963	@		II
304953	100736229	20992703964	@		II
304953	100736229	20992703965	@		II
304953	100736229	20992703966	@		II
304953	100736229	20992703967	@		II
304953	100736229	20992703968	@		II
304953	100736229	20992703969	me	me	PPIO1
304953	100736229	20992703970	I	i	PPIS1
304953	100736229	20992703971	had	have	VHD
304953	100736229	20992703972	probably	probably	RR
304953	100736229	20992703973	had	have	VHN
304953	100736229	20992703974	this	this	DD1
304953	100736229	20992703975	cancer	cancer	NN1
304953	100736229	20992703976	for	for	IF
304953	100736229	20992703977	over	over	RG
304953	100736229	20992703978	4	4	MC
304953	100736229	20992703979	years	year	NNT2
304953	100736229	20992703980	,	,	,
304953	100736229	20992703981	and	and	CC
304953	100736229	20992703982	if	if	CS
304953	100736229	20992703983	I	i	PPIS1
304953	100736229	20992703984	had	have	VHD
304953	100736229	20992703985	been	be	VBN
304953	100736229	20992703986	having	have	VHG
304953	100736229	20992703987	yearly	yearly	JJ_RR
304953	100736229	20992703988	PSA	psa	NP1
304953	100736229	20992703989	tests	test	VVZ@
304953	100736229	20992703990	the	the	AT
304953	100736229	20992703991	test	test	NN1
304953	100736229	20992703992	would	would	VM
304953	100736229	20992703993	have	have	VHI
304953	100736229	20992703994	shown	show	VVN
304953	100736229	20992703995	a	a	AT1
304953	100736229	20992703996	large	large	JJ
304953	100736229	20992703997	spike	spike	NN1
304953	100736229	20992703998	4	4	MC
304953	100736229	20992703999	years	year	NNT2
304953	100736229	20992704000	ago	ago	RA
304953	100736229	20992704001	when	when	CS_RRQ
304953	100736229	20992704002	the	the	AT
304953	100736229	20992704003	cancer	cancer	NN1
304953	100736229	20992704004	started	start	VVD
304953	100736229	20992704005	.	.	.
304953	100736229	20992704006	I	i	PPIS1
304953	100736229	20992704007	could	could	VM
304953	100736229	20992704008	have	have	VHI
304953	100736229	20992704009	then	then	RT
304953	100736229	20992704010	been	be	VBN
304953	100736229	20992704011	treated	treat	VVN
304953	100736229	20992704012	AT	at	II
304953	100736229	20992704013	THAT	that	DD1
304953	100736229	20992704014	TIME	time	NNT1
304953	100736229	20992704015	with	with	IW
304953	100736229	20992704016	much	much	DA1_RR
304953	100736229	20992704017	simpler	simple	JJR
304953	100736229	20992704018	,	,	,
304953	100736229	20992704019	cheaper	cheap	JJR
304953	100736229	20992704020	,	,	,
304953	100736229	20992704021	less	less	RGR
304953	100736229	20992704022	invasive	invasive	JJ
304953	100736229	20992704023	procedures	procedure	NN2
304953	100736229	20992704024	,	,	,
304953	100736229	20992704025	and	and	CC
304953	100736229	20992704026	not	not	XX
304953	100736229	20992704027	needed	need	VVN
304953	100736229	20992704028	what	what	DDQ
304953	100736229	20992704029	turned	turn	VVD
304953	100736229	20992704030	out	out	RP
304953	100736229	20992704031	to	to	TO
304953	100736229	20992704032	be	be	VBI
304953	100736229	20992704033	a	a	AT1
304953	100736229	20992704034	$100,000		NNU
304953	100736229	20992704035	operation	operation	NN1
304953	100736229	20992704036	and	and	CC
304953	100736229	20992704037	its	its	APPGE
304953	100736229	20992704038	possible	possible	JJ
304953	100736229	20992704039	complications	complication	NN2
304953	100736229	20992704040	.	.	.
304953	100736229	20992704041	They	they	PPHS2
304953	100736229	20992704042	also	also	RR
304953	100736229	20992704043	told	tell	VVD
304953	100736229	20992704044	me	me	PPIO1
304953	100736229	20992704045	that	that	CST
304953	100736229	20992704046	I	i	PPIS1
304953	100736229	20992704047	had	have	VHD
304953	100736229	20992704048	saved	save	VVN
304953	100736229	20992704049	my	my	APPGE
304953	100736229	20992704050	own	own	DA
304953	100736229	20992704051	life	life	NN1
304953	100736229	20992704052	by	by	II
304953	100736229	20992704053	asking	ask	VVG
304953	100736229	20992704054	for	for	IF
304953	100736229	20992704055	a	a	AT1
304953	100736229	20992704056	PSA	psa	NP1
304953	100736229	20992704057	test	test	VV0_NN1
304953	100736229	20992704058	when	when	RRQ_CS
304953	100736229	20992704059	I	i	PPIS1
304953	100736229	20992704060	did	do	VDD
304953	100736229	20992704061	,	,	,
304953	100736229	20992704062	and	and	CC
304953	100736229	20992704063	if	if	CS
304953	100736229	20992704064	I	i	PPIS1
304953	100736229	20992704065	had	have	VHD
304953	100736229	20992704066	waited	wait	VVN
304953	100736229	20992704067	even	even	RR
304953	100736229	20992704068	one	one	MC1
304953	100736229	20992704069	more	more	DAR
304953	100736229	20992704070	year	year	NNT1
304953	100736229	20992704071	it	it	PPH1
304953	100736229	20992704072	would	would	VM
304953	100736229	20992704073	have	have	VHI
304953	100736229	20992704074	been	be	VBN
304953	100736229	20992704075	TOO	too	RG
304953	100736229	20992704076	LATE	late	JJ
304953	100736229	20992704077	.	.	.
304953	100736229	20992704078	One	one	MC1
304953	100736229	20992704079	urologist	urologist	NN1
304953	100736229	20992704080	even	even	RR
304953	100736229	20992704081	told	tell	VVD_VVN
304953	100736229	20992704082	me	me	PPIO1
304953	100736229	20992704083	that	that	CST_DD1_RG%
304953	100736229	20992704084	26,000	26,000	MC
304953	100736229	20992704085	guys	guy	NN2
304953	100736229	20992704086	are	be	VBR
304953	100736229	20992704087	dying	die	VVG
304953	100736229	20992704088	needlessly	needlessly	RR
304953	100736229	20992704089	each	each	DD1
304953	100736229	20992704090	year	year	NNT1
304953	100736229	20992704091	due	due	II21
304953	100736229	20992704092	to	to	II22
304953	100736229	20992704093	PSA	psa	NP1
304953	100736229	20992704094	testing	testing	NN1_VVG
304953	100736229	20992704095	not	not	XX
304953	100736229	20992704096	being	be	VBG
304953	100736229	20992704097	done	do	VDN
304953	100736229	20992704098	.	.	.
304953	100736229	20992704099	<p>		NULL
304953	100736229	20992704100	So	so	RR
304953	100736229	20992704101	please	please	VV0@_RR
304953	100736229	20992704102	guys	guy	NN2
304953	100736229	20992704103	,	,	,
304953	100736229	20992704104	despite	despite	II
304953	100736229	20992704105	what	what	DDQ
304953	100736229	20992704106	your	your	APPGE
304953	100736229	20992704107	doctor	doctor	NN1
304953	100736229	20992704108	may	may	VM
304953	100736229	20992704109	tell	tell	VVI
304953	100736229	20992704110	you	you	PPY
304953	100736229	20992704111	,	,	,
304953	100736229	20992704112	ask	ask	VV0
304953	100736229	20992704113	for	for	IF
304953	100736229	20992704114	a	a	AT1
304953	100736229	20992704115	yearly	yearly	JJ
304953	100736229	20992704116	PSA	psa	NP1
304953	100736229	20992704117	test	test	NN1_VV0
304953	100736229	20992704118	and	and	CC
304953	100736229	20992704119	watch	watch	VV0_NN1
304953	100736229	20992704120	for	for	IF
304953	100736229	20992704121	a	a	AT1
304953	100736229	20992704122	sudden	sudden	JJ
304953	100736229	20992704123	rise	rise	NN1
304953	100736229	20992704124	in	in	II
304953	100736229	20992704125	the	the	AT
304953	100736229	20992704126	number	number	NN1
304953	100736229	20992704127	each	each	DD1
304953	100736229	20992704128	year	year	NNT1
304953	100736229	20992704129	and	and	CC
304953	100736229	20992704130	if	if	CS_CSW@
304953	100736229	20992704131	that	that	DD1
304953	100736229	20992704132	occurs	occur	VVZ
304953	100736229	20992704133	get	get	VV0
304953	100736229	20992704134	to	to	II
304953	100736229	20992704135	a	a	AT1
304953	100736229	20992704136	urologist	urologist	NN1
304953	100736229	20992704137	quickly	quickly	RR
304953	100736229	20992704138	.	.	.
304953	100736229	20992704139	And	and	CC
304953	100736229	20992704140	if	if	CS_CSW@
304953	100736229	20992704141	your	your	APPGE
304953	100736229	20992704142	doctor	doctor	NN1
304953	100736229	20992704143	tries	try	VVZ_NN2
304953	100736229	20992704144	to	to	TO
304953	100736229	20992704145	talk	talk	VVI
304953	100736229	20992704146	you	you	PPY
304953	100736229	20992704147	out	out	II21
304953	100736229	20992704148	of	of	II22
304953	100736229	20992704149	a	a	AT1
304953	100736229	20992704150	yearly	yearly	JJ
304953	100736229	20992704151	PSA	psa	NP1
304953	100736229	20992704152	test	test	NN1_VV0
304953	100736229	20992704153	,	,	,
304953	100736229	20992704154	my	my	APPGE
304953	100736229	20992704155	advice	advice	NN1
304953	100736229	20992704156	is	be	VBZ
304953	100736229	20992704157	to	to	TO
304953	100736229	20992704158	absolutely	absolutely	RR
304953	100736229	20992704159	@		II
304953	100736229	20992704160	@		II
304953	100736229	20992704161	@		II
304953	100736229	20992704162	@		II
304953	100736229	20992704163	@		II
304953	100736229	20992704164	@		II
304953	100736229	20992704165	@		II
304953	100736229	20992704166	@		II
304953	100736229	20992704167	@		II
304953	100736229	20992704168	@		II
304953	100736229	20992704169	prior	prior	II21
304953	100736229	20992704170	to	to	II22
304953	100736229	20992704171	an	a	AT1
304953	100736229	20992704172	MRI	mri	NN1_JJ
304953	100736229	20992704173	,	,	,
304953	100736229	20992704174	its	its	APPGE
304953	100736229	20992704175	time	time	NNT1
304953	100736229	20992704176	to	to	TO
304953	100736229	20992704177	move	move	VVI
304953	100736229	20992704178	on	on	RP_II21
304953	100736229	20992704179	to	to	II_II22
304953	100736229	20992704180	another	another	DD1
304953	100736229	20992704181	urologist	urologist	NN1
304953	100736229	20992704182	.	.	.
304953	100736229	20992704183	<p>		NULL
304953	100736229	20992704184	Its	its	APPGE
304953	100736229	20992704185	as	as	RG
304953	100736229	20992704186	simple	simple	JJ
304953	100736229	20992704187	as	as	CSA
304953	100736229	20992704188	that	that	DD1
304953	100736229	20992704189	.	.	.
304953	100736229	20992704190	<p>		NULL
304953	100736229	20992704191	"	"	"
304953	100736229	20992704192	One	one	MC1
304953	100736229	20992704193	urologist	urologist	NN1
304953	100736229	20992704194	even	even	RR
304953	100736229	20992704195	told	tell	VVD_VVN
304953	100736229	20992704196	me	me	PPIO1
304953	100736229	20992704197	that	that	CST_DD1_RG%
304953	100736229	20992704198	26,000	26,000	MC
304953	100736229	20992704199	guys	guy	NN2
304953	100736229	20992704200	are	be	VBR
304953	100736229	20992704201	dying	die	VVG
304953	100736229	20992704202	needlessly	needlessly	RR
304953	100736229	20992704203	each	each	DD1
304953	100736229	20992704204	year	year	NNT1
304953	100736229	20992704205	due	due	II21
304953	100736229	20992704206	to	to	II22
304953	100736229	20992704207	PSA	psa	NP1
304953	100736229	20992704208	testing	testing	NN1_VVG
304953	100736229	20992704209	not	not	XX
304953	100736229	20992704210	being	be	VBG
304953	100736229	20992704211	done	do	VDN
304953	100736229	20992704212	.	.	.
304953	100736229	20992704213	"	"	"
304953	100736229	20992704214	<p>		NULL
304953	100736229	20992704215	But	but	CCB
304953	100736229	20992704216	they	they	PPHS2
304953	100736229	20992704217	do	do	VD0
304953	100736229	20992704218	n't 	n't	XX
304953	100736229	20992704219	tell	tell	VVI
304953	100736229	20992704220	how	how	RGQ@
304953	100736229	20992704221	much	much	DA1
304953	100736229	20992704222	damage	damage	NN1
304953	100736229	20992704223	was	be	VBDZ
304953	100736229	20992704224	done	do	VDN
304953	100736229	20992704225	by	by	II
304953	100736229	20992704226	a	a	AT1
304953	100736229	20992704227	needless	needless	JJ
304953	100736229	20992704228	biopsy	biopsy	NN1
304953	100736229	20992704229	.	.	.
304953	100736229	20992704230	<p>		NULL
304953	100736229	20992704231	I	i	PPIS1
304953	100736229	20992704232	went	go	VVD
304953	100736229	20992704233	to	to	II
304953	100736229	20992704234	two	two	MC
304953	100736229	20992704235	urologists	urologist	NN2
304953	100736229	20992704236	as	as	II
304953	100736229	20992704237	a	a	AT1
304953	100736229	20992704238	result	result	NN1
304953	100736229	20992704239	of	of	IO
304953	100736229	20992704240	an	a	AT1
304953	100736229	20992704241	increased	increased	JJ
304953	100736229	20992704242	PSA	psa	NP1
304953	100736229	20992704243	.	.	.
304953	100736229	20992704244	Both	both	DB2_RR
304953	100736229	20992704245	wanted	want	VVD_VVN
304953	100736229	20992704246	to	to	TO
304953	100736229	20992704247	perform	perform	VVI
304953	100736229	20992704248	a	a	AT1
304953	100736229	20992704249	biopsy	biopsy	NN1
304953	100736229	20992704250	.	.	.
304953	100736229	20992704251	Discussed	discuss	VVN_VVD
304953	100736229	20992704252	with	with	IW
304953	100736229	20992704253	my	my	APPGE
304953	100736229	20992704254	GP	gp	NN1
304953	100736229	20992704255	and	and	CC
304953	100736229	20992704256	she	she	PPHS1
304953	100736229	20992704257	suggested	suggest	VVD
304953	100736229	20992704258	that	that	CST
304953	100736229	20992704259	it	it	PPH1
304953	100736229	20992704260	just	just	RR
304953	100736229	20992704261	might	might	VM
304953	100736229	20992704262	be	be	VBI
304953	100736229	20992704263	an	a	AT1
304953	100736229	20992704264	infection	infection	NN1
304953	100736229	20992704265	and	and	CC
304953	100736229	20992704266	was	be	VBDZ
304953	100736229	20992704267	surprised	surprised	JJ_VVN%
304953	100736229	20992704268	that	that	CST
304953	100736229	20992704269	neither	neither	RR_DD1
304953	100736229	20992704270	urologists	urologist	NN2
304953	100736229	20992704271	considered	consider	VVD_VVN
304953	100736229	20992704272	that	that	DD1
304953	100736229	20992704273	possibility	possibility	NN1
304953	100736229	20992704274	.	.	.
304953	100736229	20992704275	In	in	RP@_II
304953	100736229	20992704276	about	about	RG
304953	100736229	20992704277	40	40	MC
304953	100736229	20992704278	days	day	NNT2
304953	100736229	20992704279	the	the	AT
304953	100736229	20992704280	PSA	psa	NP1
304953	100736229	20992704281	,	,	,
304953	100736229	20992704282	with	with	IW
304953	100736229	20992704283	meds	med	NN2
304953	100736229	20992704284	,	,	,
304953	100736229	20992704285	went	go	VVD
304953	100736229	20992704286	from	from	II
304953	100736229	20992704287	12	12	MC
304953	100736229	20992704288	to	to	II
304953	100736229	20992704289	5	5	MC
304953	100736229	20992704290	.	.	.
304953	100736229	20992704291	(	(	(
304953	100736229	20992704292	I	i	PPIS1
304953	100736229	20992704293	am	be	VBM
304953	100736229	20992704294	70	70	MC
304953	100736229	20992704295	)	)	)
304953	100736229	20992704296	.	.	.
304953	100736229	20992704297	<p>		NULL
304953	100736229	20992704298	Second	second	MD
304953	100736229	20992704299	time	time	NNT1
304953	100736229	20992704300	PSA	psa	NP1
304953	100736229	20992704301	climbed	climb	VVD
304953	100736229	20992704302	when	when	RRQ
304953	100736229	20992704303	to	to	II
304953	100736229	20992704304	another	another	DD1
304953	100736229	20992704305	Urologist	urologist	NN1
304953	100736229	20992704306	let 's		VVZ
304953	100736229	20992704307	do	do	VD0
304953	100736229	20992704308	a	a	AT1
304953	100736229	20992704309	biopsy	biopsy	NN1
304953	100736229	20992704310	My	my	APPGE
304953	100736229	20992704311	GP	gp	NN1
304953	100736229	20992704312	suggest	suggest	VV0
304953	100736229	20992704313	a	a	AT1
304953	100736229	20992704314	picture	picture	NN1
304953	100736229	20992704315	rather	rather	II21
304953	100736229	20992704316	than	than	II22
304953	100736229	20992704317	a	a	AT1
304953	100736229	20992704318	poke	poke	NN1
304953	100736229	20992704319	.	.	.
304953	100736229	20992704320	One	one	PN1
304953	100736229	20992704321	can	can	VM
304953	100736229	20992704322	always	always	RR
304953	100736229	20992704323	poke	poke	VVI
304953	100736229	20992704324	.	.	.
304953	100736229	20992704325	And	and	CC
304953	100736229	20992704326	if	if	CS_CSW@
304953	100736229	20992704327	there	there	EX
304953	100736229	20992704328	is	be	VBZ
304953	100736229	20992704329	an	a	AT1
304953	100736229	20992704330	issue	issue	NN1
304953	100736229	20992704331	,	,	,
304953	100736229	20992704332	the	the	AT
304953	100736229	20992704333	pokes	poke	NN2@
304953	100736229	20992704334	will	will	VM
304953	100736229	20992704335	be	be	VBI
304953	100736229	20992704336	fewer	fewer	DAR
304953	100736229	20992704337	(	(	(
304953	100736229	20992704338	less	less	DAR_RRR
304953	100736229	20992704339	damage	damage	NN1_VV0
304953	100736229	20992704340	)	)	)
304953	100736229	20992704341	because	because	CS
304953	100736229	20992704342	the	the	AT
304953	100736229	20992704343	image	image	NN1
304953	100736229	20992704344	indicates	indicate	VVZ
304953	100736229	20992704345	where	where	RRQ
304953	100736229	20992704346	to	to	TO
304953	100736229	20992704347	poke	poke	VVI
304953	100736229	20992704348	.	.	.
304953	100736229	20992704349	(	(	(
304953	100736229	20992704350	usually	usually	RR
304953	100736229	20992704351	,	,	,
304953	100736229	20992704352	3	3	MC
304953	100736229	20992704353	vs	vs	II
304953	100736229	20992704354	12	12	MC
304953	100736229	20992704355	)	)	)
304953	100736229	20992704356	<p>		NULL
304953	100736229	20992704357	Result	result	NN1_VV0
304953	100736229	20992704358	of	of	IO
304953	100736229	20992704359	@		II
304953	100736229	20992704360	@		II
304953	100736229	20992704361	@		II
304953	100736229	20992704362	@		II
304953	100736229	20992704363	@		II
304953	100736229	20992704364	@		II
304953	100736229	20992704365	@		II
304953	100736229	20992704366	@		II
304953	100736229	20992704367	@		II
304953	100736229	20992704368	@		II
304953	100736229	20992704369	Kong	kong	NP1
304953	100736229	20992704370	would	would	VM
304953	100736229	20992704371	be	be	VBI
304953	100736229	20992704372	proud	proud	JJ
304953	100736229	20992704373	of	of	IO
304953	100736229	20992704374	.	.	.
304953	100736229	20992704375	<p>		NULL
304953	100736229	20992704376	Sorry	sorry	JJ
304953	100736229	20992704377	guys	guy	NN2
304953	100736229	20992704378	who	who	PNQS
304953	100736229	20992704379	are	be	VBR
304953	100736229	20992704380	writing	write	VVG
304953	100736229	20992704381	that	that	CST
304953	100736229	20992704382	a	a	AT1
304953	100736229	20992704383	PSA	psa	NP1
304953	100736229	20992704384	test	test	NN1
304953	100736229	20992704385	caught	catch	VVD_VVN
304953	100736229	20992704386	their	their	APPGE
304953	100736229	20992704387	cancer	cancer	NN1
304953	100736229	20992704388	.	.	.
304953	100736229	20992704389	A	a	AT1_ZZ1
304953	100736229	20992704390	routine	routine	NN1_JJ@
304953	100736229	20992704391	prostate	prostate	NN1
304953	100736229	20992704392	exam	exam	NN1
304953	100736229	20992704393	will	will	VM
304953	100736229	20992704394	usually	usually	RR
304953	100736229	20992704395	indicate	indicate	VVI
304953	100736229	20992704396	whether	whether	CSW
304953	100736229	20992704397	a	a	AT1
304953	100736229	20992704398	ultrasound	ultrasound	NN1
304953	100736229	20992704399	of	of	IO
304953	100736229	20992704400	the	the	AT
304953	100736229	20992704401	prostate	prostate	NN1
304953	100736229	20992704402	is	be	VBZ
304953	100736229	20992704403	needed	need	VVN
304953	100736229	20992704404	.	.	.
304953	100736229	20992704405	This	this	DD1
304953	100736229	20992704406	should	should	VM
304953	100736229	20992704407	be	be	VBI
304953	100736229	20992704408	the	the	AT
304953	100736229	20992704409	first	first	MD
304953	100736229	20992704410	test	test	NN1_VV0
304953	100736229	20992704411	after	after	II_CS
304953	100736229	20992704412	an	a	AT1
304953	100736229	20992704413	abnormal	abnormal	JJ
304953	100736229	20992704414	prostate	prostate	NN1
304953	100736229	20992704415	exam	exam	NN1
304953	100736229	20992704416	,	,	,
304953	100736229	20992704417	NOT	not	XX
304953	100736229	20992704418	a	a	AT1
304953	100736229	20992704419	biopsy	biopsy	NN1
304953	100736229	20992704420	.	.	.
304953	100736229	20992704421	<p>		NULL
304953	100736229	20992704422	The	the	AT
304953	100736229	20992704423	PSA	psa	NP1
304953	100736229	20992704424	test	test	NN1
304953	100736229	20992704425	lacks	lack	VVZ
304953	100736229	20992704426	two	two	MC
304953	100736229	20992704427	important	important	JJ
304953	100736229	20992704428	measures	measure	NN2
304953	100736229	20992704429	of	of	IO
304953	100736229	20992704430	relevance	relevance	NN1
304953	100736229	20992704431	to	to	II
304953	100736229	20992704432	medical	medical	JJ
304953	100736229	20992704433	diagnostic	diagnostic	JJ
304953	100736229	20992704434	procedures	procedure	NN2
304953	100736229	20992704435	:	:	:
304953	100736229	20992704436	sensitivity	sensitivity	NN1
304953	100736229	20992704437	and	and	CC
304953	100736229	20992704438	specificity	specificity	NN1
304953	100736229	20992704439	.	.	.
304953	100736229	20992704440	Consider	consider	VV0
304953	100736229	20992704441	that	that	CST
304953	100736229	20992704442	the	the	AT
304953	100736229	20992704443	PSA	psa	NP1
304953	100736229	20992704444	level	level	NN1_JJ
304953	100736229	20992704445	in	in	II
304953	100736229	20992704446	your	your	APPGE
304953	100736229	20992704447	blood	blood	NN1
304953	100736229	20992704448	can	can	VM
304953	100736229	20992704449	vary	vary	VVI
304953	100736229	20992704450	widely	widely	RR
304953	100736229	20992704451	throughout	throughout	II
304953	100736229	20992704452	the	the	AT
304953	100736229	20992704453	day	day	NNT1
304953	100736229	20992704454	,	,	,
304953	100736229	20992704455	hence	hence	RR
304953	100736229	20992704456	its	its	APPGE
304953	100736229	20992704457	lack	lack	NN1
304953	100736229	20992704458	of	of	IO
304953	100736229	20992704459	sensitivity	sensitivity	NN1
304953	100736229	20992704460	.	.	.
304953	100736229	20992704461	And	and	CC
304953	100736229	20992704462	an	a	AT1
304953	100736229	20992704463	elevated	elevated	JJ
304953	100736229	20992704464	PSA	psa	NP1
304953	100736229	20992704465	can	can	VM
304953	100736229	20992704466	indicate	indicate	VVI
304953	100736229	20992704467	cancer	cancer	NN1
304953	100736229	20992704468	,	,	,
304953	100736229	20992704469	prostatitis	prostatitis	NN1
304953	100736229	20992704470	,	,	,
304953	100736229	20992704471	BPH	bph	NP1
304953	100736229	20992704472	,	,	,
304953	100736229	20992704473	that	that	CST
304953	100736229	20992704474	you	you	PPY
304953	100736229	20992704475	have	have	VH0
304953	100736229	20992704476	had	have	VHN
304953	100736229	20992704477	sex	sex	NN1
304953	100736229	20992704478	sometime	sometime	RT
304953	100736229	20992704479	in	in	II
304953	100736229	20992704480	the	the	AT
304953	100736229	20992704481	last	last	MD
304953	100736229	20992704482	12	12	MC
304953	100736229	20992704483	hours	hour	NNT2
304953	100736229	20992704484	or	or	CC
304953	100736229	20992704485	that	that	CST
304953	100736229	20992704486	you	you	PPY
304953	100736229	20992704487	havent		NN1_VV0
304953	100736229	20992704488	had	have	VHD_VHN@
304953	100736229	20992704489	sex	sex	NN1
304953	100736229	20992704490	in	in	II
304953	100736229	20992704491	several	several	DA2
304953	100736229	20992704492	days	day	NNT2
304953	100736229	20992704493	.	.	.
304953	100736229	20992704494	Hence	hence	RR
304953	100736229	20992704495	the	the	AT
304953	100736229	20992704496	lack	lack	NN1
304953	100736229	20992704497	of	of	IO
304953	100736229	20992704498	specificity	specificity	NN1
304953	100736229	20992704499	.	.	.
304953	100736229	20992704500	<p>		NULL
304953	100736229	20992704501	The	the	AT
304953	100736229	20992704502	PSA	psa	NP1
304953	100736229	20992704503	test	test	NN1
304953	100736229	20992704504	is	be	VBZ
304953	100736229	20992704505	not	not	XX
304953	100736229	20992704506	reliable	reliable	JJ
304953	100736229	20992704507	and	and	CC
304953	100736229	20992704508	too	too	RG
304953	100736229	20992704509	many	many	DA2
304953	100736229	20992704510	urologist	urologist	NN1
304953	100736229	20992704511	do	do	VD0
304953	100736229	20992704512	unnecessary	unnecessary	JJ
304953	100736229	20992704513	biopsies	biopsy	NN2
304953	100736229	20992704514	,	,	,
304953	100736229	20992704515	which	which	DDQ
304953	100736229	20992704516	are	be	VBR
304953	100736229	20992704517	extremely	extremely	RR
304953	100736229	20992704518	painful	painful	JJ
304953	100736229	20992704519	and	and	CC
304953	100736229	20992704520	potentially	potentially	RR
304953	100736229	20992704521	dangerous	dangerous	JJ
304953	100736229	20992704522	.	.	.
304953	100736229	20992704523	They	they	PPHS2
304953	100736229	20992704524	can	can	VM
304953	100736229	20992704525	cause	cause	VVI
304953	100736229	20992704526	serious	serious	JJ
304953	100736229	20992704527	infections	infection	NN2
304953	100736229	20992704528	and	and	CC
304953	100736229	20992704529	,	,	,
304953	100736229	20992704530	if	if	CS
304953	100736229	20992704531	you	you	PPY
304953	100736229	20992704532	have	have	VH0
304953	100736229	20992704533	a	a	AT1
304953	100736229	20992704534	slow-growing	slow-growing	JJ
304953	100736229	20992704535	cancer	cancer	NN1
304953	100736229	20992704536	that	that	CST_DD1
304953	100736229	20992704537	is	be	VBZ
304953	100736229	20992704538	well	well	RR
304953	100736229	20992704539	encapsulated	encapsulate	VVN_JJ
304953	100736229	20992704540	(	(	(
304953	100736229	20992704541	little	little	JJ
304953	100736229	20992704542	chance	chance	NN1
304953	100736229	20992704543	of	of	IO
304953	100736229	20992704544	metastasis	metastasis	NN1
304953	100736229	20992704545	)	)	)
304953	100736229	20992704546	,	,	,
304953	100736229	20992704547	the	the	AT
304953	100736229	20992704548	biopsy	biopsy	NN1
304953	100736229	20992704549	itself	itself	PPX1
304953	100736229	20992704550	can	can	VM
304953	100736229	20992704551	rupture	rupture	VVI
304953	100736229	20992704552	the	the	AT
304953	100736229	20992704553	capsule	capsule	NN1
304953	100736229	20992704554	making	make	VVG_NN1@
304953	100736229	20992704555	metastasis	metastasis	NN1
304953	100736229	20992704556	much	much	RR
304953	100736229	20992704557	more	more	RGR
304953	100736229	20992704558	likely	likely	JJ
304953	100736229	20992704559	@		II
304953	100736229	20992704560	@		II
304953	100736229	20992704561	@		II
304953	100736229	20992704562	@		II
304953	100736229	20992704563	@		II
304953	100736229	20992704564	@		II
304953	100736229	20992704565	@		II
304953	100736229	20992704566	@		II
304953	100736229	20992704567	@		II
304953	100736229	20992704568	@		II
304953	100736229	20992704569	.	.	.
304953	100736229	20992704570	The	the	AT
304953	100736229	20992704571	physician	physician	NN1
304953	100736229	20992704572	who	who	PNQS
304953	100736229	20992704573	developed	develop	VVD
304953	100736229	20992704574	it	it	PPH1
304953	100736229	20992704575	no	no	RR21
304953	100736229	20992704576	longer	long	RR22
304953	100736229	20992704577	recommends	recommend	VVZ
304953	100736229	20992704578	it	it	PPH1
304953	100736229	20992704579	.	.	.
304953	100736229	20992704580	<p>		NULL
304953	100736229	20992704581	In	in	II
304953	100736229	20992704582	2011	2011	MC
304953	100736229	20992704583	I	i	PPIS1
304953	100736229	20992704584	had	have	VHD
304953	100736229	20992704585	a	a	AT1
304953	100736229	20992704586	PSA	psa	NP1
304953	100736229	20992704587	test	test	VV0_NN1
304953	100736229	20992704588	that	that	CST_DD1
304953	100736229	20992704589	gave	give	VVD
304953	100736229	20992704590	a	a	AT1
304953	100736229	20992704591	reading	reading	NN1
304953	100736229	20992704592	of	of	IO
304953	100736229	20992704593	3100	3100	MC
304953	100736229	20992704594	I	i	PPIS1
304953	100736229	20992704595	have	have	VH0
304953	100736229	20992704596	never	never	RR
304953	100736229	20992704597	had	have	VHN
304953	100736229	20992704598	a	a	AT1
304953	100736229	20992704599	biopsy	biopsy	NN1
304953	100736229	20992704600	.	.	.
304953	100736229	20992704601	It	it	PPH1
304953	100736229	20992704602	is	be	VBZ
304953	100736229	20992704603	now	now	RT
304953	100736229	20992704604	2017	2017	MC
304953	100736229	20992704605	I	i	PPIS1
304953	100736229	20992704606	have	have	VH0
304953	100736229	20992704607	hormone	hormone	NN1
304953	100736229	20992704608	injections	injection	NN2
304953	100736229	20992704609	off	off	RP_II
304953	100736229	20992704610	and	and	CC
304953	100736229	20992704611	on	on	RP@_II
304953	100736229	20992704612	over	over	II
304953	100736229	20992704613	this	this	DD1
304953	100736229	20992704614	period	period	NN1
304953	100736229	20992704615	and	and	CC
304953	100736229	20992704616	some	some	DD
304953	100736229	20992704617	radio	radio	NN1
304953	100736229	20992704618	therapy	therapy	NN1
304953	100736229	20992704619	on	on	II
304953	100736229	20992704620	two	two	MC
304953	100736229	20992704621	occasions	occasion	NN2
304953	100736229	20992704622	.	.	.
304953	100736229	20992704623	I	i	PPIS1
304953	100736229	20992704624	now	now	RT
304953	100736229	20992704625	have	have	VH0
304953	100736229	20992704626	a	a	AT1
304953	100736229	20992704627	PSA	psa	NP1
304953	100736229	20992704628	reading	reading	NN1
304953	100736229	20992704629	of	of	IO
304953	100736229	20992704630	over	over	RG
304953	100736229	20992704631	1300	1300	MC
304953	100736229	20992704632	after	after	II
304953	100736229	20992704633	having	have	VHG
304953	100736229	20992704634	been	be	VBN
304953	100736229	20992704635	down	down	RP
304953	100736229	20992704636	as	as	RG
304953	100736229	20992704637	low	low	JJ_RR@
304953	100736229	20992704638	as	as	CSA
304953	100736229	20992704639	3	3	MC
304953	100736229	20992704640	.	.	.
304953	100736229	20992704641	I	i	PPIS1
304953	100736229	20992704642	have	have	VH0
304953	100736229	20992704643	no	no	AT
304953	100736229	20992704644	Idea	idea	NN1
304953	100736229	20992704645	what	what	DDQ
304953	100736229	20992704646	is	be	VBZ
304953	100736229	20992704647	going	go	VVG
304953	100736229	20992704648	on	on	RP@_II
304953	100736229	20992704649	and	and	CC
304953	100736229	20992704650	the	the	AT
304953	100736229	20992704651	oncologists	oncologist	NN2
304953	100736229	20992704652	can	can	VM
304953	100736229	20992704653	not	not	XX
304953	100736229	20992704654	understand	understand	VVI
304953	100736229	20992704655	how	how	RRQ
304953	100736229	20992704656	I	i	PPIS1
304953	100736229	20992704657	manage	manage	VV0
304953	100736229	20992704658	to	to	TO
304953	100736229	20992704659	survive	survive	VVI
304953	100736229	20992704660	such	such	DA
304953	100736229	20992704661	high	high	JJ
304953	100736229	20992704662	PSA	psa	NP1
304953	100736229	20992704663	readings	reading	NN2
304953	100736229	20992704664	Early	early	RR
304953	100736229	20992704665	in	in	II
304953	100736229	20992704666	2011	2011	MC
304953	100736229	20992704667	I	i	PPIS1
304953	100736229	20992704668	got	get	VVD
304953	100736229	20992704669	a	a	AT1
304953	100736229	20992704670	very	very	RG
304953	100736229	20992704671	bad	bad	JJ
304953	100736229	20992704672	mosquito	mosquito	NN1
304953	100736229	20992704673	bite	bite	NN1_VV0
304953	100736229	20992704674	in	in	II
304953	100736229	20992704675	Dili	dili	NP1
304953	100736229	20992704676	East	east	ND1
304953	100736229	20992704677	Timor	timor	NP1
304953	100736229	20992704678	that	that	CST_DD1
304953	100736229	20992704679	reduced	reduce	VVD_VVN
304953	100736229	20992704680	to	to	II
304953	100736229	20992704681	a	a	AT1
304953	100736229	20992704682	cripple	cripple	NN1
304953	100736229	20992704683	as	as	CSA
304953	100736229	20992704684	in	in	II
304953	100736229	20992704685	a	a	AT1
304953	100736229	20992704686	very	very	RG
304953	100736229	20992704687	bad	bad	JJ
304953	100736229	20992704688	case	case	NN1
304953	100736229	20992704689	of	of	IO
304953	100736229	20992704690	Dengi		NP1_NN1_JJ
304953	100736229	20992704691	or	or	CC
304953	100736229	20992704692	Ross	ross	NP1
304953	100736229	20992704693	River	river	NNL1
304953	100736229	20992704694	virus	virus	NN1
304953	100736229	20992704695	and	and	CC
304953	100736229	20992704696	every	every	AT1
304953	100736229	20992704697	thing	thing	NN1
304953	100736229	20992704698	progressed	progress	VVN_VVD
304953	100736229	20992704699	from	from	II
304953	100736229	20992704700	there	there	RL
304953	100736229	20992704701	.	.	.
304953	100736229	20992704702	<p>		NULL
304953	100736229	20992704703	I	i	PPIS1
304953	100736229	20992704704	do	do	VD0
304953	100736229	20992704705	n't 	n't	XX
304953	100736229	20992704706	know	know	VVI
304953	100736229	20992704707	what	what	DDQ
304953	100736229	20992704708	to	to	TO
304953	100736229	20992704709	make	make	VVI
304953	100736229	20992704710	of	of	IO
304953	100736229	20992704711	my	my	APPGE
304953	100736229	20992704712	situation	situation	NN1
304953	100736229	20992704713	and	and	CC
304953	100736229	20992704714	the	the	AT
304953	100736229	20992704715	oncologists	oncologist	NN2
304953	100736229	20992704716	want	want	VV0
304953	100736229	20992704717	me	me	PPIO1
304953	100736229	20992704718	to	to	TO
304953	100736229	20992704719	start	start	VVI
304953	100736229	20992704720	on	on	II
304953	100736229	20992704721	chemo	chemo	NN1
304953	100736229	20992704722	,	,	,
304953	100736229	20992704723	I	i	PPIS1
304953	100736229	20992704724	do	do	VD0
304953	100736229	20992704725	not	not	XX
304953	100736229	20992704726	want	want	VVI
304953	100736229	20992704727	to	to	TO
304953	100736229	20992704728	do	do	VDI
304953	100736229	20992704729	a	a	AT1
304953	100736229	20992704730	chemo	chemo	NN1
304953	100736229	20992704731	course	course	NN1
304953	100736229	20992704732	as	as	CSA
304953	100736229	20992704733	I	i	PPIS1
304953	100736229	20992704734	am	be	VBM
304953	100736229	20992704735	not	not	XX
304953	100736229	20992704736	100%		NNU
304953	100736229	20992704737	sure	sure	JJ
304953	100736229	20992704738	I	i	PPIS1
304953	100736229	20992704739	even	even	RR
304953	100736229	20992704740	have	have	VH0
304953	100736229	20992704741	cancer	cancer	NN1
304953	100736229	20992704742	.	.	.
304953	100736229	20992704743	46996		MC
304953	100736229	20992704744	@qwx906996		FO
304953	100736236	20992708695	@@##	----------	----------
304953	100736236	20992708696	@@100736236		FO
304953	100736236	20992708697	@4936236/		JJ_NN1_VV0
304953	100736236	20992708698	<h>		NULL
304953	100736236	20992708699	Prostate	prostate	NN1
304953	100736236	20992708700	Cancer	cancer	NN1
304953	100736236	20992708701	Survival	survival	NN1
304953	100736236	20992708702	Rates	rate	NN2_VVZ@
304953	100736236	20992708703	:	:	:
304953	100736236	20992708704	What	what	DDQ
304953	100736236	20992708705	They	they	PPHS2
304953	100736236	20992708706	Mean	mean	VV0
304953	100736236	20992708707	<h>		NULL
304953	100736236	20992708708	In	in	II_RP@
304953	100736236	20992708709	this	this	DD1
304953	100736236	20992708710	Article	article	NN1
304953	100736236	20992708711	<p>		NULL
304953	100736236	20992708712	As	as	CSA_II@
304953	100736236	20992708713	cancer	cancer	NN1
304953	100736236	20992708714	diagnoses	diagnosis	NN2
304953	100736236	20992708715	go	go	VV0
304953	100736236	20992708716	,	,	,
304953	100736236	20992708717	prostate	prostate	NN1
304953	100736236	20992708718	cancer	cancer	NN1
304953	100736236	20992708719	is	be	VBZ
304953	100736236	20992708720	often	often	RR
304953	100736236	20992708721	a	a	AT1
304953	100736236	20992708722	less	less	RGR
304953	100736236	20992708723	serious	serious	JJ
304953	100736236	20992708724	one	one	PN1
304953	100736236	20992708725	.	.	.
304953	100736236	20992708726	Prostate	prostate	NN1
304953	100736236	20992708727	cancer	cancer	NN1
304953	100736236	20992708728	is	be	VBZ
304953	100736236	20992708729	frequently	frequently	RR
304953	100736236	20992708730	slow-growing	slow-growing	JJ
304953	100736236	20992708731	and	and	CC
304953	100736236	20992708732	slow	slow	JJ_VV0@
304953	100736236	20992708733	to	to	TO
304953	100736236	20992708734	spread	spread	VVI
304953	100736236	20992708735	.	.	.
304953	100736236	20992708736	For	for	IF
304953	100736236	20992708737	many	many	DA2
304953	100736236	20992708738	men	man	NN2
304953	100736236	20992708739	,	,	,
304953	100736236	20992708740	prostate	prostate	NN1
304953	100736236	20992708741	cancer	cancer	NN1
304953	100736236	20992708742	is	be	VBZ
304953	100736236	20992708743	less	less	RGR
304953	100736236	20992708744	serious	serious	JJ
304953	100736236	20992708745	than	than	CSN
304953	100736236	20992708746	their	their	APPGE
304953	100736236	20992708747	other	other	JJ
304953	100736236	20992708748	medical	medical	JJ
304953	100736236	20992708749	conditions	condition	NN2
304953	100736236	20992708750	.	.	.
304953	100736236	20992708751	<p>		NULL
304953	100736236	20992708752	For	for	IF
304953	100736236	20992708753	these	these	DD2
304953	100736236	20992708754	reasons	reason	NN2
304953	100736236	20992708755	,	,	,
304953	100736236	20992708756	and	and	CC
304953	100736236	20992708757	possibly	possibly	RR
304953	100736236	20992708758	because	because	II21
304953	100736236	20992708759	of	of	II22
304953	100736236	20992708760	earlier	early	JJR
304953	100736236	20992708761	detection	detection	NN1
304953	100736236	20992708762	of	of	IO
304953	100736236	20992708763	low-grade	low-grade	JJ_NN1
304953	100736236	20992708764	prostate	prostate	NN1
304953	100736236	20992708765	cancers	cancer	NN2
304953	100736236	20992708766	,	,	,
304953	100736236	20992708767	prostate	prostate	NN1
304953	100736236	20992708768	cancer	cancer	NN1
304953	100736236	20992708769	has	have	VHZ
304953	100736236	20992708770	one	one	MC1
304953	100736236	20992708771	of	of	IO
304953	100736236	20992708772	the	the	AT
304953	100736236	20992708773	highest	high	JJT
304953	100736236	20992708774	survival	survival	NN1
304953	100736236	20992708775	rates	rate	NN2
304953	100736236	20992708776	of	of	IO
304953	100736236	20992708777	any	any	DD
304953	100736236	20992708778	type	type	NN1
304953	100736236	20992708779	of	of	IO
304953	100736236	20992708780	cancer	cancer	NN1
304953	100736236	20992708781	.	.	.
304953	100736236	20992708782	WebMD		NN1_NP1@
304953	100736236	20992708783	takes	take	VVZ
304953	100736236	20992708784	a	a	AT1
304953	100736236	20992708785	look	look	NN1
304953	100736236	20992708786	at	at	II
304953	100736236	20992708787	prostate	prostate	NN1
304953	100736236	20992708788	cancer	cancer	NN1
304953	100736236	20992708789	survival	survival	NN1
304953	100736236	20992708790	rates	rate	NN2
304953	100736236	20992708791	and	and	CC
304953	100736236	20992708792	what	what	DDQ
304953	100736236	20992708793	they	they	PPHS2
304953	100736236	20992708794	mean	mean	VV0
304953	100736236	20992708795	to	to	II
304953	100736236	20992708796	you	you	PPY
304953	100736236	20992708797	.	.	.
304953	100736236	20992708798	<h>		NULL
304953	100736236	20992708799	Prostate	prostate	NN1
304953	100736236	20992708800	Cancer	cancer	NN1
304953	100736236	20992708801	Is	be	VBZ
304953	100736236	20992708802	Common	common	JJ
304953	100736236	20992708803	With	with	IW
304953	100736236	20992708804	Aging	aging	NN1_JJ_VVG
304953	100736236	20992708805	<p>		NULL
304953	100736236	20992708806	After	after	CS_II
304953	100736236	20992708807	skin	skin	NN1
304953	100736236	20992708808	cancer	cancer	NN1
304953	100736236	20992708809	,	,	,
304953	100736236	20992708810	prostate	prostate	NN1
304953	100736236	20992708811	cancer	cancer	NN1
304953	100736236	20992708812	is	be	VBZ
304953	100736236	20992708813	the	the	AT
304953	100736236	20992708814	most	most	RGT
304953	100736236	20992708815	common	common	JJ
304953	100736236	20992708816	cancer	cancer	NN1
304953	100736236	20992708817	in	in	II
304953	100736236	20992708818	men	man	NN2
304953	100736236	20992708819	.	.	.
304953	100736236	20992708820	About	about	II
304953	100736236	20992708821	1	1	MC1
304953	100736236	20992708822	in	in	II
304953	100736236	20992708823	7	7	MC
304953	100736236	20992708824	men	man	NN2
304953	100736236	20992708825	will	will	VM
304953	100736236	20992708826	be	be	VBI
304953	100736236	20992708827	diagnosed	diagnose	VVN
304953	100736236	20992708828	with	with	IW
304953	100736236	20992708829	prostate	prostate	NN1
304953	100736236	20992708830	cancer	cancer	NN1
304953	100736236	20992708831	in	in	II
304953	100736236	20992708832	his	his	APPGE
304953	100736236	20992708833	lifetime	lifetime	NNT1
304953	100736236	20992708834	.	.	.
304953	100736236	20992708835	And	and	CC
304953	100736236	20992708836	these	these	DD2
304953	100736236	20992708837	are	be	VBR
304953	100736236	20992708838	just	just	RR
304953	100736236	20992708839	the	the	AT
304953	100736236	20992708840	men	man	NN2
304953	100736236	20992708841	who	who	PNQS
304953	100736236	20992708842	are	be	VBR
304953	100736236	20992708843	diagnosed	diagnose	VVN
304953	100736236	20992708844	.	.	.
304953	100736236	20992708845	Among	among	II
304953	100736236	20992708846	very	very	RG
304953	100736236	20992708847	elderly	elderly	JJ
304953	100736236	20992708848	men	man	NN2
304953	100736236	20992708849	dying	die	VVG_JJ
304953	100736236	20992708850	of	of	IO
304953	100736236	20992708851	other	other	JJ
304953	100736236	20992708852	causes	cause	NN2
304953	100736236	20992708853	,	,	,
304953	100736236	20992708854	a	a	AT1
304953	100736236	20992708855	surprising	surprising	JJ
304953	100736236	20992708856	two-thirds	two-thirds	MF
304953	100736236	20992708857	may	may	VM
304953	100736236	20992708858	have	have	VHI
304953	100736236	20992708859	prostate	prostate	NN1
304953	100736236	20992708860	cancer	cancer	NN1
304953	100736236	20992708861	that	that	CST_DD1
304953	100736236	20992708862	was	be	VBDZ
304953	100736236	20992708863	never	never	RR
304953	100736236	20992708864	diagnosed	diagnose	VVN_VVD
304953	100736236	20992708865	.	.	.
304953	100736236	20992708866	<p>		NULL
304953	100736236	20992708867	Only	only	JJ
304953	100736236	20992708868	1		NN1
304953	100736236	20992708869	in	in	II
304953	100736236	20992708870	36	36	MC
304953	100736236	20992708871	men	man	NN2
304953	100736236	20992708872	,	,	,
304953	100736236	20992708873	though	though	CS_RR@
304953	100736236	20992708874	,	,	,
304953	100736236	20992708875	actually	actually	RR
304953	100736236	20992708876	dies	die	VVZ
304953	100736236	20992708877	from	from	II
304953	100736236	20992708878	prostate	prostate	NN1
304953	100736236	20992708879	cancer	cancer	NN1
304953	100736236	20992708880	.	.	.
304953	100736236	20992708881	That	that	DD1
304953	100736236	20992708882	's	be	VBZ
304953	100736236	20992708883	because	because	CS
304953	100736236	20992708884	most	most	DAT
304953	100736236	20992708885	prostate	prostate	NN1
304953	100736236	20992708886	cancers	cancer	NN2
304953	100736236	20992708887	@		II
304953	100736236	20992708888	@		II
304953	100736236	20992708889	@		II
304953	100736236	20992708890	@		II
304953	100736236	20992708891	@		II
304953	100736236	20992708892	@		II
304953	100736236	20992708893	@		II
304953	100736236	20992708894	@		II
304953	100736236	20992708895	@		II
304953	100736236	20992708896	@		II
304953	100736236	20992708897	more	more	RGR
304953	100736236	20992708898	likely	likely	JJ
304953	100736236	20992708899	to	to	TO
304953	100736236	20992708900	be	be	VBI
304953	100736236	20992708901	slow-growing	slow-growing	JJ
304953	100736236	20992708902	and	and	CC
304953	100736236	20992708903	non-aggressive	nonaggressive	JJ
304953	100736236	20992708904	.	.	.
304953	100736236	20992708905	The	the	AT
304953	100736236	20992708906	majority	majority	NN1
304953	100736236	20992708907	of	of	IO
304953	100736236	20992708908	these	these	DD2
304953	100736236	20992708909	men	man	NN2
304953	100736236	20992708910	eventually	eventually	RR
304953	100736236	20992708911	pass	pass	VV0
304953	100736236	20992708912	away	away	II21_RL
304953	100736236	20992708913	from	from	II22_II
304953	100736236	20992708914	heart	heart	NN1
304953	100736236	20992708915	disease	disease	NN1
304953	100736236	20992708916	,	,	,
304953	100736236	20992708917	stroke	stroke	VV0_NN1
304953	100736236	20992708918	,	,	,
304953	100736236	20992708919	or	or	CC
304953	100736236	20992708920	other	other	JJ_NN1@
304953	100736236	20992708921	causes	cause	NN2_VVZ
304953	100736236	20992708922	--		NN1_JJ
304953	100736236	20992708923	not	not	XX
304953	100736236	20992708924	their	their	APPGE
304953	100736236	20992708925	prostate	prostate	NN1
304953	100736236	20992708926	cancer	cancer	NN1
304953	100736236	20992708927	.	.	.
304953	100736236	20992708928	<h>		NULL
304953	100736236	20992708929	Prostate	prostate	NN1
304953	100736236	20992708930	Cancer	cancer	NN1
304953	100736236	20992708931	Survival	survival	NN1
304953	100736236	20992708932	Rates	rate	NN2
304953	100736236	20992708933	Are	be	VBR
304953	100736236	20992708934	Favorable	favorable	JJ
304953	100736236	20992708935	Overall	overall	NN1
304953	100736236	20992708936	<p>		NULL
304953	100736236	20992708937	Thinking	think	VVG_NN1
304953	100736236	20992708938	about	about	II
304953	100736236	20992708939	survival	survival	NN1
304953	100736236	20992708940	rates	rate	NN2
304953	100736236	20992708941	for	for	IF
304953	100736236	20992708942	prostate	prostate	NN1
304953	100736236	20992708943	cancer	cancer	NN1
304953	100736236	20992708944	takes	take	VVZ
304953	100736236	20992708945	a	a	RR21_AT1
304953	100736236	20992708946	little	little	RR22_JJ
304953	100736236	20992708947	mental	mental	JJ
304953	100736236	20992708948	stretching	stretching	NN1@
304953	100736236	20992708949	.	.	.
304953	100736236	20992708950	Keep	keep	VV0
304953	100736236	20992708951	in	in	II_RP@
304953	100736236	20992708952	mind	mind	NN1
304953	100736236	20992708953	that	that	CST
304953	100736236	20992708954	most	most	DAT
304953	100736236	20992708955	men	man	NN2
304953	100736236	20992708956	are	be	VBR
304953	100736236	20992708957	around	around	RG
304953	100736236	20992708958	70	70	MC
304953	100736236	20992708959	when	when	CS_RRQ
304953	100736236	20992708960	diagnosed	diagnose	VVN
304953	100736236	20992708961	with	with	IW
304953	100736236	20992708962	prostate	prostate	NN1
304953	100736236	20992708963	cancer	cancer	NN1
304953	100736236	20992708964	.	.	.
304953	100736236	20992708965	Over	over	RP_II
304953	100736236	20992708966	,	,	,
304953	100736236	20992708967	say	say	VV0
304953	100736236	20992708968	,	,	,
304953	100736236	20992708969	five	five	MC
304953	100736236	20992708970	years	year	NNT2
304953	100736236	20992708971	,	,	,
304953	100736236	20992708972	many	many	DA2
304953	100736236	20992708973	of	of	IO
304953	100736236	20992708974	these	these	DD2
304953	100736236	20992708975	men	man	NN2
304953	100736236	20992708976	will	will	VM
304953	100736236	20992708977	die	die	VVI
304953	100736236	20992708978	from	from	II
304953	100736236	20992708979	other	other	JJ
304953	100736236	20992708980	medical	medical	JJ
304953	100736236	20992708981	problems	problem	NN2
304953	100736236	20992708982	unrelated	unrelated	JJ
304953	100736236	20992708983	to	to	II
304953	100736236	20992708984	prostate	prostate	NN1
304953	100736236	20992708985	cancer	cancer	NN1
304953	100736236	20992708986	.	.	.
304953	100736236	20992708987	<p>		NULL
304953	100736236	20992708988	To	to	TO
304953	100736236	20992708989	determine	determine	VVI
304953	100736236	20992708990	the	the	AT
304953	100736236	20992708991	prostate	prostate	NN1
304953	100736236	20992708992	cancer	cancer	NN1
304953	100736236	20992708993	survival	survival	NN1
304953	100736236	20992708994	rate	rate	NN1
304953	100736236	20992708995	,	,	,
304953	100736236	20992708996	these	these	DD2
304953	100736236	20992708997	men	man	NN2
304953	100736236	20992708998	are	be	VBR
304953	100736236	20992708999	subtracted	subtract	VVN
304953	100736236	20992709000	out	out	II21
304953	100736236	20992709001	of	of	II22
304953	100736236	20992709002	the	the	AT
304953	100736236	20992709003	calculations	calculation	NN2
304953	100736236	20992709004	.	.	.
304953	100736236	20992709005	Counting	count	VVG
304953	100736236	20992709006	only	only	JJ
304953	100736236	20992709007	the	the-	AT
304953	100736236	20992709008	men	man	NN2
304953	100736236	20992709009	who	who	PNQS
304953	100736236	20992709010	are	be	VBR
304953	100736236	20992709011	left	leave	VVN_JJ
304953	100736236	20992709012	provides	provide	VVZ
304953	100736236	20992709013	what	what	DDQ
304953	100736236	20992709014	's	be	VBZ
304953	100736236	20992709015	called	call	VVN
304953	100736236	20992709016	the	the	AT
304953	100736236	20992709017	relative	relative	JJ_NN1
304953	100736236	20992709018	survival	survival	NN1
304953	100736236	20992709019	rate	rate	NN1
304953	100736236	20992709020	for	for	IF
304953	100736236	20992709021	prostate	prostate	NN1
304953	100736236	20992709022	cancer	cancer	NN1
304953	100736236	20992709023	.	.	.
304953	100736236	20992709024	<p>		NULL
304953	100736236	20992709025	Taking	take	VVG
304953	100736236	20992709026	that	that	DD1
304953	100736236	20992709027	into	into	II
304953	100736236	20992709028	consideration	consideration	NN1
304953	100736236	20992709029	,	,	,
304953	100736236	20992709030	the	the	AT
304953	100736236	20992709031	relative	relative	JJ_NN1
304953	100736236	20992709032	survival	survival	NN1
304953	100736236	20992709033	rates	rate	NN2
304953	100736236	20992709034	for	for	IF
304953	100736236	20992709035	most	most	DAT
304953	100736236	20992709036	kinds	kind	NN2
304953	100736236	20992709037	of	of	IO
304953	100736236	20992709038	prostate	prostate	NN1
304953	100736236	20992709039	cancer	cancer	NN1
304953	100736236	20992709040	are	be	VBR
304953	100736236	20992709041	actually	actually	RR
304953	100736236	20992709042	pretty	pretty	RG
304953	100736236	20992709043	good	good	JJ
304953	100736236	20992709044	.	.	.
304953	100736236	20992709045	Remember	remember	VV0
304953	100736236	20992709046	,	,	,
304953	100736236	20992709047	we	we	PPIS2
304953	100736236	20992709048	're	be	VBR
304953	100736236	20992709049	not	not	XX
304953	100736236	20992709050	counting	count	VVG
304953	100736236	20992709051	men	man	NN2
304953	100736236	20992709052	with	with	IW
304953	100736236	20992709053	prostate	prostate	NN1
304953	100736236	20992709054	cancer	cancer	NN1
304953	100736236	20992709055	who	who	PNQS
304953	100736236	20992709056	die	die	VV0
304953	100736236	20992709057	of	of	IO
304953	100736236	20992709058	other	other	JJ
304953	100736236	20992709059	causes	cause	NN2
304953	100736236	20992709060	:	:	:
304953	100736236	20992709061	<p>		NULL
304953	100736236	20992709062	For	for	IF
304953	100736236	20992709063	the	the	AT
304953	100736236	20992709064	more	more	DAR_RRR
304953	100736236	20992709065	than	than	CSN
304953	100736236	20992709066	90%		NNU
304953	100736236	20992709067	of	of	IO
304953	100736236	20992709068	men	man	NN2
304953	100736236	20992709069	whose	whose	DDQGE
304953	100736236	20992709070	prostate	prostate	NN1
304953	100736236	20992709071	cancer	cancer	NN1
304953	100736236	20992709072	is	be	VBZ
304953	100736236	20992709073	localized	localize	VVN@_JJ
304953	100736236	20992709074	to	to	II
304953	100736236	20992709075	the	the	AT
304953	100736236	20992709076	prostate	prostate	NN1
304953	100736236	20992709077	or	or	CC
304953	100736236	20992709078	just	just	RR
304953	100736236	20992709079	nearby	nearby	RL_JJ
304953	100736236	20992709080	,	,	,
304953	100736236	20992709081	the	the	AT
304953	100736236	20992709082	prognosis	prognosis	NN1
304953	100736236	20992709083	is	be	VBZ
304953	100736236	20992709084	even	even	RR
304953	100736236	20992709085	better	better	JJR
304953	100736236	20992709086	.	.	.
304953	100736236	20992709087	@		II
304953	100736236	20992709088	@		II
304953	100736236	20992709089	@		II
304953	100736236	20992709090	@		II
304953	100736236	20992709091	@		II
304953	100736236	20992709092	@		II
304953	100736236	20992709093	@		II
304953	100736236	20992709094	@		II
304953	100736236	20992709095	@		II
304953	100736236	20992709096	@		II
304953	100736236	20992709097	years	year	NNT2
304953	100736236	20992709098	.	.	.
304953	100736236	20992709099	<h>		NULL
304953	100736236	20992709100	Continued	continued	JJ_VVN
304953	100736236	20992709101	<p>		NULL
304953	100736236	20992709102	Another	another	DD1
304953	100736236	20992709103	way	way	NN1
304953	100736236	20992709104	to	to	TO
304953	100736236	20992709105	put	put	VVI
304953	100736236	20992709106	this	this	DD1
304953	100736236	20992709107	last	last	MD
304953	100736236	20992709108	point	point	NN1
304953	100736236	20992709109	is	be	VBZ
304953	100736236	20992709110	nine	nine	MC
304953	100736236	20992709111	out	out	II21
304953	100736236	20992709112	of	of	II22
304953	100736236	20992709113	10	10	MC
304953	100736236	20992709114	men	man	NN2
304953	100736236	20992709115	with	with	IW
304953	100736236	20992709116	prostate	prostate	NN1
304953	100736236	20992709117	cancer	cancer	NN1
304953	100736236	20992709118	have	have	VH0
304953	100736236	20992709119	localized	localize	VVN
304953	100736236	20992709120	cancer	cancer	NN1
304953	100736236	20992709121	.	.	.
304953	100736236	20992709122	Almost	almost	RR
304953	100736236	20992709123	none	none	PN
304953	100736236	20992709124	of	of	IO
304953	100736236	20992709125	these	these	DD2
304953	100736236	20992709126	men	man	NN2
304953	100736236	20992709127	will	will	VM
304953	100736236	20992709128	die	die	VVI
304953	100736236	20992709129	from	from	II
304953	100736236	20992709130	their	their	APPGE
304953	100736236	20992709131	prostate	prostate	NN1
304953	100736236	20992709132	cancer	cancer	NN1
304953	100736236	20992709133	over	over	RG
304953	100736236	20992709134	five	five	MC
304953	100736236	20992709135	years	year	NNT2
304953	100736236	20992709136	.	.	.
304953	100736236	20992709137	<p>		NULL
304953	100736236	20992709138	Fewer	fewer	DAR
304953	100736236	20992709139	men	man	NN2
304953	100736236	20992709140	(	(	(
304953	100736236	20992709141	about	about	RG
304953	100736236	20992709142	5%		NNU
304953	100736236	20992709143	)	)	)
304953	100736236	20992709144	have	have	VH0
304953	100736236	20992709145	more	more	RRR_DAR
304953	100736236	20992709146	advanced	advance	VVN
304953	100736236	20992709147	prostate	prostate	NN1
304953	100736236	20992709148	cancer	cancer	NN1
304953	100736236	20992709149	at	at	II
304953	100736236	20992709150	the	the	AT
304953	100736236	20992709151	time	time	NNT1
304953	100736236	20992709152	of	of	IO
304953	100736236	20992709153	diagnosis	diagnosis	NN1
304953	100736236	20992709154	.	.	.
304953	100736236	20992709155	Once	once	RR_CS@
304953	100736236	20992709156	prostate	prostate	NN1
304953	100736236	20992709157	cancer	cancer	NN1
304953	100736236	20992709158	has	have	VHZ
304953	100736236	20992709159	spread	spread	VVN
304953	100736236	20992709160	beyond	beyond	II
304953	100736236	20992709161	the	the	AT
304953	100736236	20992709162	prostate	prostate	NN1
304953	100736236	20992709163	,	,	,
304953	100736236	20992709164	survival	survival	NN1
304953	100736236	20992709165	rates	rate	NN2
304953	100736236	20992709166	fall	fall	VV0_NN1
304953	100736236	20992709167	.	.	.
304953	100736236	20992709168	For	for	IF
304953	100736236	20992709169	men	man	NN2
304953	100736236	20992709170	with	with	IW
304953	100736236	20992709171	distant	distant	JJ
304953	100736236	20992709172	spread	spread	NN1
304953	100736236	20992709173	(	(	(
304953	100736236	20992709174	metastasis	metastasis	NN1
304953	100736236	20992709175	)	)	)
304953	100736236	20992709176	of	of	IO
304953	100736236	20992709177	prostate	prostate	NN1
304953	100736236	20992709178	cancer	cancer	NN1
304953	100736236	20992709179	,	,	,
304953	100736236	20992709180	about	about	II
304953	100736236	20992709181	one-third	one-third	MF
304953	100736236	20992709182	will	will	VM
304953	100736236	20992709183	survive	survive	VVI
304953	100736236	20992709184	for	for	IF
304953	100736236	20992709185	five	five	MC
304953	100736236	20992709186	years	year	NNT2
304953	100736236	20992709187	after	after	II_CS
304953	100736236	20992709188	diagnosis	diagnosis	NN1
304953	100736236	20992709189	.	.	.
304953	100736236	20992709190	<p>		NULL
304953	100736236	20992709191	Many	many	DA2
304953	100736236	20992709192	men	man	NN2
304953	100736236	20992709193	with	with	IW
304953	100736236	20992709194	prostate	prostate	NN1
304953	100736236	20992709195	cancer	cancer	NN1
304953	100736236	20992709196	actually	actually	RR
304953	100736236	20992709197	will	will	VM
304953	100736236	20992709198	live	live	VVI
304953	100736236	20992709199	much	much	RR_DA1
304953	100736236	20992709200	longer	long	RRR_JJR
304953	100736236	20992709201	than	than	CSN
304953	100736236	20992709202	five	five	MC
304953	100736236	20992709203	years	year	NNT2
304953	100736236	20992709204	after	after	II_CS
304953	100736236	20992709205	diagnosis	diagnosis	NN1
304953	100736236	20992709206	.	.	.
304953	100736236	20992709207	What	what	DDQ
304953	100736236	20992709208	about	about	II_RG%
304953	100736236	20992709209	longer-term	longer-term	JJ
304953	100736236	20992709210	survival	survival	NN1
304953	100736236	20992709211	rates	rate	NN2
304953	100736236	20992709212	?	?	?
304953	100736236	20992709213	According	according	II21
304953	100736236	20992709214	to	to	II22
304953	100736236	20992709215	the	the	AT
304953	100736236	20992709216	American	american	JJ
304953	100736236	20992709217	Cancer	cancer	NN1
304953	100736236	20992709218	Society	society	NN1
304953	100736236	20992709219	:	:	:
304953	100736236	20992709220	<p>		NULL
304953	100736236	20992709221	The	the	AT
304953	100736236	20992709222	relative	relative	JJ_NN1
304953	100736236	20992709223	10-year	10-year	JJ_NNT1
304953	100736236	20992709224	survival	survival	NN1
304953	100736236	20992709225	rate	rate	NN1
304953	100736236	20992709226	is	be	VBZ
304953	100736236	20992709227	91%		NNU
304953	100736236	20992709228	.	.	.
304953	100736236	20992709229	<p>		NULL
304953	100736236	20992709230	The	the	AT
304953	100736236	20992709231	relative	relative	JJ_NN1
304953	100736236	20992709232	15-year	15-year	JJ_NNT1
304953	100736236	20992709233	survival	survival	NN1
304953	100736236	20992709234	rate	rate	NN1
304953	100736236	20992709235	is	be	VBZ
304953	100736236	20992709236	76%		NNU
304953	100736236	20992709237	.	.	.
304953	100736236	20992709238	<h>		NULL
304953	100736236	20992709239	Staging	staging	NN1_VVG
304953	100736236	20992709240	,	,	,
304953	100736236	20992709241	Spread	spread	VVD_VV0_NN1_VVN
304953	100736236	20992709242	,	,	,
304953	100736236	20992709243	and	and	CC
304953	100736236	20992709244	Survival	survival	NN1
304953	100736236	20992709245	Rates	rate	NN2
304953	100736236	20992709246	<p>		NULL
304953	100736236	20992709247	As	as	CSA
304953	100736236	20992709248	with	with	IW
304953	100736236	20992709249	all	all	DB
304953	100736236	20992709250	cancers	cancer	NN2
304953	100736236	20992709251	,	,	,
304953	100736236	20992709252	doctors	doctor	NN2
304953	100736236	20992709253	use	use	VV0
304953	100736236	20992709254	the	the	AT
304953	100736236	20992709255	term	term	NN1
304953	100736236	20992709256	stage	stage	NN1
304953	100736236	20992709257	to	to	TO
304953	100736236	20992709258	describe	describe	VVI
304953	100736236	20992709259	the	the	AT
304953	100736236	20992709260	characteristics	characteristic	NN2
304953	100736236	20992709261	of	of	IO
304953	100736236	20992709262	the	the	AT
304953	100736236	20992709263	primary	primary	JJ_NN1
304953	100736236	20992709264	tumor	tumor	NN1
304953	100736236	20992709265	itself	itself	PPX1
304953	100736236	20992709266	,	,	,
304953	100736236	20992709267	such	such	II21
304953	100736236	20992709268	as	as	II22
304953	100736236	20992709269	its	its	APPGE
304953	100736236	20992709270	size	size	NN1
304953	100736236	20992709271	and	and	CC
304953	100736236	20992709272	how	how	RGQ@_RRQ
304953	100736236	20992709273	far	far	JJ
304953	100736236	20992709274	prostate	prostate	NN1
304953	100736236	20992709275	cancer	cancer	NN1
304953	100736236	20992709276	has	have	VHZ
304953	100736236	20992709277	spread	spread	VVN
304953	100736236	20992709278	when	when	CS_RRQ
304953	100736236	20992709279	it	it	PPH1
304953	100736236	20992709280	is	be	VBZ
304953	100736236	20992709281	found	find	VVN
304953	100736236	20992709282	.	.	.
304953	100736236	20992709283	<p>		NULL
304953	100736236	20992709284	Staging	stage	VVG_NN1
304953	100736236	20992709285	systems	system	NN2
304953	100736236	20992709286	are	be	VBR
304953	100736236	20992709287	@		II
304953	100736236	20992709288	@		II
304953	100736236	20992709289	@		II
304953	100736236	20992709290	@		II
304953	100736236	20992709291	@		II
304953	100736236	20992709292	@		II
304953	100736236	20992709293	@		II
304953	100736236	20992709294	@		II
304953	100736236	20992709295	@		II
304953	100736236	20992709296	@		II
304953	100736236	20992709297	prostate	prostate	NN1
304953	100736236	20992709298	cancer	cancer	NN1
304953	100736236	20992709299	,	,	,
304953	100736236	20992709300	uses	use	VVZ
304953	100736236	20992709301	three	three	MC
304953	100736236	20992709302	different	different	JJ
304953	100736236	20992709303	aspects	aspect	NN2
304953	100736236	20992709304	of	of	IO
304953	100736236	20992709305	tumor	tumor	NN1
304953	100736236	20992709306	growth	growth	NN1
304953	100736236	20992709307	and	and	CC
304953	100736236	20992709308	spread	spread	NN1_VVD_VV0_VVN
304953	100736236	20992709309	.	.	.
304953	100736236	20992709310	It	it	PPH1
304953	100736236	20992709311	's	be	VBZ
304953	100736236	20992709312	called	call	VVN
304953	100736236	20992709313	the	the	AT
304953	100736236	20992709314	TNM	tnm	NP1
304953	100736236	20992709315	system	system	NN1
304953	100736236	20992709316	,	,	,
304953	100736236	20992709317	for	for	IF
304953	100736236	20992709318	tumor	tumor	NN1
304953	100736236	20992709319	,	,	,
304953	100736236	20992709320	nodes	node	NN2
304953	100736236	20992709321	,	,	,
304953	100736236	20992709322	and	and	CC
304953	100736236	20992709323	metastasis	metastasis	NN1
304953	100736236	20992709324	:	:	:
304953	100736236	20992709325	<p>		NULL
304953	100736236	20992709326	T	t	ZZ1_NP1@
304953	100736236	20992709327	,	,	,
304953	100736236	20992709328	for	for	IF
304953	100736236	20992709329	tumor	tumor	NN1
304953	100736236	20992709330	(	(	(
304953	100736236	20992709331	which	which	DDQ
304953	100736236	20992709332	means	mean	VVZ
304953	100736236	20992709333	a	a	AT1
304953	100736236	20992709334	swelling	swelling	JJ
304953	100736236	20992709335	,	,	,
304953	100736236	20992709336	a	a	AT1
304953	100736236	20992709337	growth	growth	NN1
304953	100736236	20992709338	or	or	CC
304953	100736236	20992709339	mass	mass	NN1_JJ
304953	100736236	20992709340	,	,	,
304953	100736236	20992709341	and	and	CC
304953	100736236	20992709342	describes	describe	VVZ
304953	100736236	20992709343	the	the	AT
304953	100736236	20992709344	cancer	cancer	NN1
304953	100736236	20992709345	as	as	II
304953	100736236	20992709346	found	find	VVD_VVN
304953	100736236	20992709347	in	in	II_RP@
304953	100736236	20992709348	its	its	APPGE
304953	100736236	20992709349	place	place	NN1
304953	100736236	20992709350	of	of	IO
304953	100736236	20992709351	origin	origin	NN1
304953	100736236	20992709352	)	)	)
304953	100736236	20992709353	describes	describe	VVZ
304953	100736236	20992709354	the	the	AT
304953	100736236	20992709355	size	size	NN1
304953	100736236	20992709356	of	of	IO
304953	100736236	20992709357	the	the	AT
304953	100736236	20992709358	main	main	JJ
304953	100736236	20992709359	area	area	NN1
304953	100736236	20992709360	of	of	IO
304953	100736236	20992709361	prostate	prostate	NN1
304953	100736236	20992709362	cancer	cancer	NN1
304953	100736236	20992709363	.	.	.
304953	100736236	20992709364	<p>		NULL
304953	100736236	20992709365	N	xx_n	ZZ1_NP1@
304953	100736236	20992709366	,	,	,
304953	100736236	20992709367	for	for	IF
304953	100736236	20992709368	nodes	node	NN2
304953	100736236	20992709369	,	,	,
304953	100736236	20992709370	describes	describe	VVZ
304953	100736236	20992709371	whether	whether	CSW
304953	100736236	20992709372	prostate	prostate	NN1
304953	100736236	20992709373	cancer	cancer	NN1
304953	100736236	20992709374	has	have	VHZ
304953	100736236	20992709375	spread	spread	VVN
304953	100736236	20992709376	to	to	II
304953	100736236	20992709377	any	any	DD
304953	100736236	20992709378	lymph	lymph	NN1
304953	100736236	20992709379	nodes	node	NN2
304953	100736236	20992709380	,	,	,
304953	100736236	20992709381	and	and	CC
304953	100736236	20992709382	how	how	RGQ@
304953	100736236	20992709383	many	many	DA2
304953	100736236	20992709384	and	and	CC
304953	100736236	20992709385	in	in	II
304953	100736236	20992709386	what	what	DDQ
304953	100736236	20992709387	locations	location	NN2
304953	100736236	20992709388	.	.	.
304953	100736236	20992709389	<p>		NULL
304953	100736236	20992709390	M	m	ZZ1
304953	100736236	20992709391	,	,	,
304953	100736236	20992709392	for	for	IF
304953	100736236	20992709393	metastasis	metastasis	NN1
304953	100736236	20992709394	,	,	,
304953	100736236	20992709395	means	mean	VVZ_NN
304953	100736236	20992709396	distant	distant	JJ
304953	100736236	20992709397	spread	spread	NN1
304953	100736236	20992709398	of	of	IO
304953	100736236	20992709399	prostate	prostate	NN1
304953	100736236	20992709400	cancer	cancer	NN1
304953	100736236	20992709401	,	,	,
304953	100736236	20992709402	for	for	REX21
304953	100736236	20992709403	example	example	REX22
304953	100736236	20992709404	,	,	,
304953	100736236	20992709405	to	to	II
304953	100736236	20992709406	the	the	AT
304953	100736236	20992709407	bones	bone	NN2
304953	100736236	20992709408	or	or	CC
304953	100736236	20992709409	liver	liver	NN1
304953	100736236	20992709410	.	.	.
304953	100736236	20992709411	<p>		NULL
304953	100736236	20992709412	Using	use	VVG
304953	100736236	20992709413	the	the	AT
304953	100736236	20992709414	TNM	tnm	NP1
304953	100736236	20992709415	system	system	NN1
304953	100736236	20992709416	,	,	,
304953	100736236	20992709417	each	each	DD1
304953	100736236	20992709418	man	man	NN1
304953	100736236	20992709419	's	's	GE
304953	100736236	20992709420	prostate	prostate	NN1
304953	100736236	20992709421	cancer	cancer	NN1
304953	100736236	20992709422	can	can	VM
304953	100736236	20992709423	be	be	VBI
304953	100736236	20992709424	described	describe	VVN
304953	100736236	20992709425	in	in	II
304953	100736236	20992709426	detail	detail	NN1
304953	100736236	20992709427	and	and	CC
304953	100736236	20992709428	compared	compare	VVN
304953	100736236	20992709429	to	to	II
304953	100736236	20992709430	other	other	JJ
304953	100736236	20992709431	men	man	NN2
304953	100736236	20992709432	's	's	GE
304953	100736236	20992709433	prostate	prostate	NN1
304953	100736236	20992709434	cancer	cancer	NN1
304953	100736236	20992709435	.	.	.
304953	100736236	20992709436	Doctors	doctor	NN2
304953	100736236	20992709437	use	use	VV0
304953	100736236	20992709438	this	this	DD1
304953	100736236	20992709439	information	information	NN1
304953	100736236	20992709440	for	for	IF
304953	100736236	20992709441	studies	study	NN2
304953	100736236	20992709442	and	and	CC
304953	100736236	20992709443	to	to	TO
304953	100736236	20992709444	decide	decide	VVI
304953	100736236	20992709445	on	on	II_RP@
304953	100736236	20992709446	treatments	treatment	NN2
304953	100736236	20992709447	.	.	.
304953	100736236	20992709448	<p>		NULL
304953	100736236	20992709449	As	as	CS31
304953	100736236	20992709450	far	far	CS32
304953	100736236	20992709451	as	as	CS33
304953	100736236	20992709452	survival	survival	NN1
304953	100736236	20992709453	rates	rate	NN2
304953	100736236	20992709454	for	for	IF
304953	100736236	20992709455	prostate	prostate	NN1
304953	100736236	20992709456	cancer	cancer	NN1
304953	100736236	20992709457	go	go	VV0
304953	100736236	20992709458	,	,	,
304953	100736236	20992709459	however	however	RR
304953	100736236	20992709460	,	,	,
304953	100736236	20992709461	the	the	AT
304953	100736236	20992709462	staging	staging	NN1
304953	100736236	20992709463	system	system	NN1
304953	100736236	20992709464	is	be	VBZ
304953	100736236	20992709465	pretty	pretty	RG
304953	100736236	20992709466	simple	simple	JJ
304953	100736236	20992709467	.	.	.
304953	100736236	20992709468	As	as	CSA
304953	100736236	20992709469	we	we	PPIS2
304953	100736236	20992709470	've	have	VH0
304953	100736236	20992709471	mentioned	mention	VVN
304953	100736236	20992709472	,	,	,
304953	100736236	20992709473	in	in	II31
304953	100736236	20992709474	terms	terms	II32
304953	100736236	20992709475	of	of	II33
304953	100736236	20992709476	survival	survival	NN1
304953	100736236	20992709477	rates	rate	NN2
304953	100736236	20992709478	,	,	,
304953	100736236	20992709479	men	man	NN2
304953	100736236	20992709480	with	with	IW
304953	100736236	20992709481	prostate	prostate	NN1
304953	100736236	20992709482	cancer	cancer	NN1
304953	100736236	20992709483	can	can	VM
304953	100736236	20992709484	be	be	VBI
304953	100736236	20992709485	divided	divide	VVN
304953	100736236	20992709486	into	into	II
304953	100736236	20992709487	@		II
304953	100736236	20992709488	@		II
304953	100736236	20992709489	@		II
304953	100736236	20992709490	@		II
304953	100736236	20992709491	@		II
304953	100736236	20992709492	@		II
304953	100736236	20992709493	@		II
304953	100736236	20992709494	@		II
304953	100736236	20992709495	@		II
304953	100736236	20992709496	@		II
304953	100736236	20992709497	localized	localize	VVN@_JJ
304953	100736236	20992709498	to	to	II
304953	100736236	20992709499	the	the	AT
304953	100736236	20992709500	prostate	prostate	NN1
304953	100736236	20992709501	or	or	CC
304953	100736236	20992709502	just	just	RR
304953	100736236	20992709503	nearby	nearby	RL_JJ
304953	100736236	20992709504	.	.	.
304953	100736236	20992709505	These	these	DD2
304953	100736236	20992709506	men	man	NN2
304953	100736236	20992709507	have	have	VH0
304953	100736236	20992709508	a	a	AT1
304953	100736236	20992709509	high	high	JJ
304953	100736236	20992709510	long-term	long-term	JJ
304953	100736236	20992709511	survival	survival	NN1
304953	100736236	20992709512	rate	rate	NN1
304953	100736236	20992709513	for	for	IF
304953	100736236	20992709514	their	their	APPGE
304953	100736236	20992709515	prostate	prostate	NN1
304953	100736236	20992709516	cancer	cancer	NN1
304953	100736236	20992709517	.	.	.
304953	100736236	20992709518	Almost	almost	RR
304953	100736236	20992709519	all	all	DB
304953	100736236	20992709520	will	will	VM
304953	100736236	20992709521	survive	survive	VVI
304953	100736236	20992709522	their	their	APPGE
304953	100736236	20992709523	prostate	prostate	NN1
304953	100736236	20992709524	cancer	cancer	NN1
304953	100736236	20992709525	for	for	IF
304953	100736236	20992709526	longer	long	JJR_RRR
304953	100736236	20992709527	than	than	CSN
304953	100736236	20992709528	five	five	MC
304953	100736236	20992709529	years	year	NNT2
304953	100736236	20992709530	--	--	JJ_NN1
304953	100736236	20992709531	and	and	CC
304953	100736236	20992709532	well	well	RR
304953	100736236	20992709533	beyond	beyond	RL@
304953	100736236	20992709534	for	for	IF
304953	100736236	20992709535	many	many	DA2
304953	100736236	20992709536	men	man	NN2
304953	100736236	20992709537	.	.	.
304953	100736236	20992709538	<p>		NULL
304953	100736236	20992709539	Men	man	NN2
304953	100736236	20992709540	whose	whose	DDQGE
304953	100736236	20992709541	prostate	prostate	NN1
304953	100736236	20992709542	cancer	cancer	NN1
304953	100736236	20992709543	has	have	VHZ
304953	100736236	20992709544	spread	spread	VVN
304953	100736236	20992709545	to	to	II
304953	100736236	20992709546	distant	distant	JJ
304953	100736236	20992709547	areas	area	NN2
304953	100736236	20992709548	,	,	,
304953	100736236	20992709549	like	like	II
304953	100736236	20992709550	their	their	APPGE
304953	100736236	20992709551	bones	bone	NN2
304953	100736236	20992709552	.	.	.
304953	100736236	20992709553	These	these	DD2
304953	100736236	20992709554	men	man	NN2
304953	100736236	20992709555	may	may	VM
304953	100736236	20992709556	need	need	VVI
304953	100736236	20992709557	more	more	RGR_DAR
304953	100736236	20992709558	aggressive	aggressive	JJ
304953	100736236	20992709559	treatment	treatment	NN1
304953	100736236	20992709560	for	for	IF
304953	100736236	20992709561	their	their	APPGE
304953	100736236	20992709562	prostate	prostate	NN1
304953	100736236	20992709563	cancer	cancer	NN1
304953	100736236	20992709564	.	.	.
304953	100736236	20992709565	Fewer	fewer	DAR
304953	100736236	20992709566	of	of	IO
304953	100736236	20992709567	these	these	DD2
304953	100736236	20992709568	men	man	NN2
304953	100736236	20992709569	--		NN1_JJ
304953	100736236	20992709570	about	about	II
304953	100736236	20992709571	one-third	one-third	MF
304953	100736236	20992709572	--		NN1
304953	100736236	20992709573	will	will	VM
304953	100736236	20992709574	survive	survive	VVI
304953	100736236	20992709575	their	their	APPGE
304953	100736236	20992709576	prostate	prostate	NN1
304953	100736236	20992709577	cancer	cancer	NN1
304953	100736236	20992709578	for	for	IF
304953	100736236	20992709579	more	more	DAR
304953	100736236	20992709580	than	than	CSN
304953	100736236	20992709581	five	five	MC
304953	100736236	20992709582	years	year	NNT2
304953	100736236	20992709583	.	.	.
304953	100736236	20992709584	<p>		NULL
304953	100736236	20992709585	In	in	II
304953	100736236	20992709586	a	a	AT1
304953	100736236	20992709587	good	good	JJ
304953	100736236	20992709588	way	way	NN1
304953	100736236	20992709589	,	,	,
304953	100736236	20992709590	these	these	DD2
304953	100736236	20992709591	figures	figure	NN2
304953	100736236	20992709592	are	be	VBR
304953	100736236	20992709593	already	already	RR
304953	100736236	20992709594	outdated	outdated	JJ_VVN@
304953	100736236	20992709595	.	.	.
304953	100736236	20992709596	Prostate	prostate	NN1
304953	100736236	20992709597	cancer	cancer	NN1
304953	100736236	20992709598	treatments	treatment	NN2
304953	100736236	20992709599	are	be	VBR
304953	100736236	20992709600	improving	improve	VVG_JJ
304953	100736236	20992709601	,	,	,
304953	100736236	20992709602	and	and	CC
304953	100736236	20992709603	men	man	NN2
304953	100736236	20992709604	are	be	VBR
304953	100736236	20992709605	being	be	VBG
304953	100736236	20992709606	diagnosed	diagnose	VVN
304953	100736236	20992709607	earlier	early	RRR
304953	100736236	20992709608	than	than	CSN
304953	100736236	20992709609	in	in	II
304953	100736236	20992709610	previous	previous	JJ
304953	100736236	20992709611	years	year	NNT2
304953	100736236	20992709612	.	.	.
304953	100736236	20992709613	Men	man	NN2
304953	100736236	20992709614	diagnosed	diagnose	VVN_VVD
304953	100736236	20992709615	with	with	IW
304953	100736236	20992709616	prostate	prostate	NN1
304953	100736236	20992709617	cancer	cancer	NN1
304953	100736236	20992709618	today	today	RT
304953	100736236	20992709619	might	might	VM
304953	100736236	20992709620	have	have	VHI
304953	100736236	20992709621	even	even	RR
304953	100736236	20992709622	better	better	JJR
304953	100736236	20992709623	survival	survival	NN1
304953	100736236	20992709624	rates	rate	NN2
304953	100736236	20992709625	than	than	CSN
304953	100736236	20992709626	these	these	DD2
304953	100736236	20992709627	.	.	.
304953	100736236	20992709628	For	for	REX21
304953	100736236	20992709629	example	example	REX22
304953	100736236	20992709630	,	,	,
304953	100736236	20992709631	the	the	AT
304953	100736236	20992709632	five-year	five-year	JJ
304953	100736236	20992709633	relative	relative	JJ_NN1
304953	100736236	20992709634	survival	survival	NN1
304953	100736236	20992709635	rate	rate	NN1
304953	100736236	20992709636	for	for	IF
304953	100736236	20992709637	men	man	NN2
304953	100736236	20992709638	diagnosed	diagnose	VVN_VVD
304953	100736236	20992709639	with	with	IW
304953	100736236	20992709640	prostate	prostate	NN1
304953	100736236	20992709641	cancer	cancer	NN1
304953	100736236	20992709642	in	in	II
304953	100736236	20992709643	1990	1990	MC
304953	100736236	20992709644	was	be	VBDZ
304953	100736236	20992709645	92.9%	92.9%	FO
304953	100736236	20992709646	,	,	,
304953	100736236	20992709647	and	and	CC
304953	100736236	20992709648	now	now	RT
304953	100736236	20992709649	it	it	PPH1
304953	100736236	20992709650	's	be	VBZ
304953	100736236	20992709651	99%.		FO
304953	100736244	20992709671	@@##	----------	----------
304953	100736244	20992709672	@@100736244		FO
304953	100736244	20992709673	@4936244/		VV0_NN1
304953	100736244	20992709674	46989		MC
304953	100736244	20992709675	@qwx906989		FO
304953	100736244	20992709676	<p>		NULL
304953	100736244	20992709677	Men	man	NN2
304953	100736244	20992709678	worry	worry	VV0
304953	100736244	20992709679	about	about	II_RP@
304953	100736244	20992709680	erectile	erectile	JJ
304953	100736244	20992709681	dysfunction	dysfunction	NN1
304953	100736244	20992709682	after	after	II_CS
304953	100736244	20992709683	radical	radical	JJ_NN1
304953	100736244	20992709684	prostatectomy	prostatectomy	NN1
304953	100736244	20992709685	,	,	,
304953	100736244	20992709686	the	the	AT
304953	100736244	20992709687	operation	operation	NN1
304953	100736244	20992709688	that	that	CST_DD1
304953	100736244	20992709689	involves	involve	VVZ
304953	100736244	20992709690	removing	remove	VVG
304953	100736244	20992709691	the	the	AT
304953	100736244	20992709692	prostate	prostate	NN1
304953	100736244	20992709693	gland	gland	NN1
304953	100736244	20992709694	as	as	II_CSA
304953	100736244	20992709695	a	a	AT1
304953	100736244	20992709696	way	way	NN1
304953	100736244	20992709697	to	to	TO
304953	100736244	20992709698	treat	treat	VVI
304953	100736244	20992709699	prostate	prostate	NN1
304953	100736244	20992709700	cancer.		NNU
304953	100736244	20992709701	-	-	-
304953	100736244	20992709702	Its	its	APPGE
304953	100736244	20992709703	a	a	AT1
304953	100736244	20992709704	legitimate	legitimate	JJ
304953	100736244	20992709705	concern	concern	NN1
304953	100736244	20992709706	.	.	.
304953	100736244	20992709707	Men	man	NN2
304953	100736244	20992709708	,	,	,
304953	100736244	20992709709	their	their	APPGE
304953	100736244	20992709710	spouses	spouse	NN2
304953	100736244	20992709711	and	and	CC
304953	100736244	20992709712	partners	partner	NN2
304953	100736244	20992709713	,	,	,
304953	100736244	20992709714	and	and	CC
304953	100736244	20992709715	their	their	APPGE
304953	100736244	20992709716	surgeons	surgeon	NN2
304953	100736244	20992709717	should	should	VM
304953	100736244	20992709718	talk	talk	VVI
304953	100736244	20992709719	about	about	II
304953	100736244	20992709720	erectile	erectile	JJ
304953	100736244	20992709721	dysfunction	dysfunction	NN1
304953	100736244	20992709722	before	before	II_CS_RT@
304953	100736244	20992709723	and	and	CC
304953	100736244	20992709724	after	after	CS_II
304953	100736244	20992709725	the	the	AT
304953	100736244	20992709726	surgery	surgery	NN1
304953	100736244	20992709727	.	.	.
304953	100736244	20992709728	Almost	almost	RR
304953	100736244	20992709729	all	all	DB
304953	100736244	20992709730	men	man	NN2
304953	100736244	20992709731	will	will	VM
304953	100736244	20992709732	experience	experience	VVI
304953	100736244	20992709733	erectile	erectile	JJ
304953	100736244	20992709734	dysfunction	dysfunction	NN1
304953	100736244	20992709735	for	for	IF
304953	100736244	20992709736	several	several	DA2
304953	100736244	20992709737	months	month	NNT2
304953	100736244	20992709738	to	to	II
304953	100736244	20992709739	a	a	AT1
304953	100736244	20992709740	year	year	NNT1
304953	100736244	20992709741	after	after	II_CS
304953	100736244	20992709742	a	a	AT1
304953	100736244	20992709743	radical	radical	JJ_NN1
304953	100736244	20992709744	prostatectomy	prostatectomy	NN1
304953	100736244	20992709745	,	,	,
304953	100736244	20992709746	although	although	CS
304953	100736244	20992709747	todays	todays	NN2
304953	100736244	20992709748	nerve-sparing	nerve-sparing	JJ_NN1
304953	100736244	20992709749	operation	operation	NN1
304953	100736244	20992709750	has	have	VHZ
304953	100736244	20992709751	decreased	decrease	VVN
304953	100736244	20992709752	the	the	AT
304953	100736244	20992709753	number	number	NN1
304953	100736244	20992709754	of	of	IO
304953	100736244	20992709755	cases	case	NN2
304953	100736244	20992709756	when	when	CS_RRQ
304953	100736244	20992709757	its	its	APPGE
304953	100736244	20992709758	permanent	permanent	JJ
304953	100736244	20992709759	.	.	.
304953	100736244	20992709760	<p>		NULL
304953	100736244	20992709761	But	but	CCB
304953	100736244	20992709762	orgasm	orgasm	VV0_NN1
304953	100736244	20992709763	after	after	II_CS
304953	100736244	20992709764	radical	radical	JJ_NN1
304953	100736244	20992709765	prostatectomy	prostatectomy	NN1
304953	100736244	20992709766	?	?	?
304953	100736244	20992709767	Its	its	APPGE
304953	100736244	20992709768	often	often	RR
304953	100736244	20992709769	even	even	RR
304953	100736244	20992709770	not	not	XX
304953	100736244	20992709771	on	on	II
304953	100736244	20992709772	the	the	AT
304953	100736244	20992709773	radar	radar	NN1
304953	100736244	20992709774	screen	screen	NN1
304953	100736244	20992709775	.	.	.
304953	100736244	20992709776	Dr.		NNB
304953	100736244	20992709777	Ravi	ravi	NP1
304953	100736244	20992709778	Kacker		NP1
304953	100736244	20992709779	thinks	think	VVZ
304953	100736244	20992709780	that	that	DD1
304953	100736244	20992709781	should	should	VM
304953	100736244	20992709782	change	change	VVI
304953	100736244	20992709783	.	.	.
304953	100736244	20992709784	<p>		NULL
304953	100736244	20992709785	"	"	"
304953	100736244	20992709786	Sometimes	sometimes	RT
304953	100736244	20992709787	orgasm	orgasm	NN1_VV0
304953	100736244	20992709788	gets	get	VVZ
304953	100736244	20992709789	forgotten	forget	VVN
304953	100736244	20992709790	because	because	CS
304953	100736244	20992709791	everyone	everyone	PN1
304953	100736244	20992709792	is	be	VBZ
304953	100736244	20992709793	so	so	RR
304953	100736244	20992709794	focused	focus	VVN_VVD
304953	100736244	20992709795	on	on	II
304953	100736244	20992709796	erectile	erectile	JJ
304953	100736244	20992709797	dysfunction	dysfunction	NN1
304953	100736244	20992709798	,	,	,
304953	100736244	20992709799	"	"	"
304953	100736244	20992709800	says	say	VVZ
304953	100736244	20992709801	Dr.		NNB
304953	100736244	20992709802	Kacker		NP1
304953	100736244	20992709803	,	,	,
304953	100736244	20992709804	a	a	AT1
304953	100736244	20992709805	urologist	urologist	NN1
304953	100736244	20992709806	and	and	CC
304953	100736244	20992709807	fellow	fellow	NN1_JJ
304953	100736244	20992709808	in	in	II
304953	100736244	20992709809	male	male	JJ
304953	100736244	20992709810	sexual	sexual	JJ
304953	100736244	20992709811	medicine	medicine	NN1
304953	100736244	20992709812	at	at	II
304953	100736244	20992709813	Harvard-affiliated	harvard-affiliated	JJ_NN1
304953	100736244	20992709814	**26;61;TOOLONG		JJ
304953	100736244	20992709815	Center	center	NN1
304953	100736244	20992709816	.	.	.
304953	100736244	20992709817	"	"	"
304953	100736244	20992709818	But	but	II21_CCB
304953	100736244	20992709819	for	for	II22_IF
304953	100736244	20992709820	some	some	DD
304953	100736244	20992709821	"	"	"
304953	100736244	20992709822	maybe	maybe	RR
304953	100736244	20992709823	most	most	DAT
304953	100736244	20992709824	"	"	"
304953	100736244	20992709825	men	man	NN2
304953	100736244	20992709826	and	and	CC
304953	100736244	20992709827	their	their	APPGE
304953	100736244	20992709828	partners	partner	NN2
304953	100736244	20992709829	,	,	,
304953	100736244	20992709830	achieving	achieve	VVG
304953	100736244	20992709831	orgasm	orgasm	NN1
304953	100736244	20992709832	can	can	VM
304953	100736244	20992709833	be	be	VBI
304953	100736244	20992709834	as	as	RG
304953	100736244	20992709835	important	important	JJ
304953	100736244	20992709836	as	as	CSA
304953	100736244	20992709837	erections	erection	NN2
304953	100736244	20992709838	"	"	"
304953	100736244	20992709839	or	or	CC
304953	100736244	20992709840	even	even	RR
304953	100736244	20992709841	more	more	RGR
304953	100736244	20992709842	so	so	RR
304953	100736244	20992709843	"	"	"
304953	100736244	20992709844	for	for	IF
304953	100736244	20992709845	having	have	VHG
304953	100736244	20992709846	a	a	AT1
304953	100736244	20992709847	healthy	healthy	JJ
304953	100736244	20992709848	sex	sex	NN1
304953	100736244	20992709849	life	life	NN1
304953	100736244	20992709850	.	.	.
304953	100736244	20992709851	"	"	"
304953	100736244	20992709852	<p>		NULL
304953	100736244	20992709853	And	and	CC
304953	100736244	20992709854	,	,	,
304953	100736244	20992709855	says	say	VVZ
304953	100736244	20992709856	Dr.		NNB
304953	100736244	20992709857	Kacker		NP1
304953	100736244	20992709858	,	,	,
304953	100736244	20992709859	there 's		NN2
304953	100736244	20992709860	good	good	JJ_RR%
304953	100736244	20992709861	news.		NNU
304953	100736244	20992709862	-	-	-
304953	100736244	20992709863	@		II
304953	100736244	20992709864	@		II
304953	100736244	20992709865	@		II
304953	100736244	20992709866	@		II
304953	100736244	20992709867	@		II
304953	100736244	20992709868	@		II
304953	100736244	20992709869	@		II
304953	100736244	20992709870	@		II
304953	100736244	20992709871	@		II
304953	100736244	20992709872	@		II
304953	100736244	20992709873	most	most	DAT
304953	100736244	20992709874	men	man	NN2
304953	100736244	20992709875	,	,	,
304953	100736244	20992709876	but	but	CCB
304953	100736244	20992709877	they	they	PPHS2
304953	100736244	20992709878	do	do	VD0
304953	100736244	20992709879	n't 	n't	XX
304953	100736244	20992709880	need	need	VVI
304953	100736244	20992709881	to	to	TO
304953	100736244	20992709882	be	be	VBI
304953	100736244	20992709883	any	any	DD
304953	100736244	20992709884	less	less	DAR_RGR
304953	100736244	20992709885	pleasurable	pleasurable	JJ
304953	100736244	20992709886	or	or	CC
304953	100736244	20992709887	satisfying	satisfying	JJ
304953	100736244	20992709888	.	.	.
304953	100736244	20992709889	"	"	"
304953	100736244	20992709890	<h>		NULL
304953	100736244	20992709891	The	the	AT
304953	100736244	20992709892	three	three	MC
304953	100736244	20992709893	parts	part	NN2
304953	100736244	20992709894	of	of	IO
304953	100736244	20992709895	male	male	JJ_NN1
304953	100736244	20992709896	orgasm	orgasm	NN1
304953	100736244	20992709897	<p>		NULL
304953	100736244	20992709898	Kacker		NN1_NP1@
304953	100736244	20992709899	starts	start	VVZ
304953	100736244	20992709900	by	by	II
304953	100736244	20992709901	pointing	point	VVG
304953	100736244	20992709902	out	out	RP
304953	100736244	20992709903	a	a	AT1
304953	100736244	20992709904	common	common	JJ
304953	100736244	20992709905	misconception	misconception	NN1
304953	100736244	20992709906	that	that	CST
304953	100736244	20992709907	erections	erection	NN2
304953	100736244	20992709908	are	be	VBR
304953	100736244	20992709909	necessary	necessary	JJ
304953	100736244	20992709910	for	for	IF
304953	100736244	20992709911	male	male	JJ_NN1
304953	100736244	20992709912	orgasm	orgasm	NN1
304953	100736244	20992709913	.	.	.
304953	100736244	20992709914	They	they	PPHS2
304953	100736244	20992709915	are	be	VB0
304953	100736244	20992709916	n't 	n't	XX
304953	100736244	20992709917	.	.	.
304953	100736244	20992709918	Men	man	NN2
304953	100736244	20992709919	can	can	VM
304953	100736244	20992709920	have	have	VHI
304953	100736244	20992709921	experience	experience	NN1
304953	100736244	20992709922	orgasm	orgasm	NN1_VV0
304953	100736244	20992709923	without	without	IW
304953	100736244	20992709924	an	a	AT1
304953	100736244	20992709925	erection	erection	NN1
304953	100736244	20992709926	.	.	.
304953	100736244	20992709927	The	the	AT
304953	100736244	20992709928	converse	converse	NN1
304953	100736244	20992709929	is	be	VBZ
304953	100736244	20992709930	also	also	RR
304953	100736244	20992709931	true	true	JJ
304953	100736244	20992709932	,	,	,
304953	100736244	20992709933	of	of	RR21
304953	100736244	20992709934	course	course	RR22
304953	100736244	20992709935	:	:	:
304953	100736244	20992709936	men	man	NN2
304953	100736244	20992709937	can	can	VM
304953	100736244	20992709938	have	have	VHI
304953	100736244	20992709939	an	a	AT1
304953	100736244	20992709940	erection	erection	NN1
304953	100736244	20992709941	without	without	IW
304953	100736244	20992709942	having	have	VHG
304953	100736244	20992709943	an	a	AT1
304953	100736244	20992709944	orgasm	orgasm	NN1
304953	100736244	20992709945	.	.	.
304953	100736244	20992709946	<p>		NULL
304953	100736244	20992709947	When	when	CS
304953	100736244	20992709948	discussing	discuss	VVG
304953	100736244	20992709949	orgasm	orgasm	NN1
304953	100736244	20992709950	and	and	CC
304953	100736244	20992709951	radical	radical	JJ_NN1
304953	100736244	20992709952	prostatectomy	prostatectomy	NN1
304953	100736244	20992709953	,	,	,
304953	100736244	20992709954	its	its	APPGE
304953	100736244	20992709955	useful	useful	JJ
304953	100736244	20992709956	to	to	TO
304953	100736244	20992709957	think	think	VVI
304953	100736244	20992709958	of	of	IO
304953	100736244	20992709959	the	the	AT
304953	100736244	20992709960	male	male	JJ_NN1
304953	100736244	20992709961	orgasm	orgasm	NN1
304953	100736244	20992709962	as	as	CSA
304953	100736244	20992709963	having	have	VHG
304953	100736244	20992709964	three	three	MC
304953	100736244	20992709965	separate	separate	JJ
304953	100736244	20992709966	parts	part	NN2
304953	100736244	20992709967	,	,	,
304953	100736244	20992709968	says	say	VVZ
304953	100736244	20992709969	Dr.		NNB
304953	100736244	20992709970	Kacker		NP1
304953	100736244	20992709971	.	.	.
304953	100736244	20992709972	<p>		NULL
304953	100736244	20992709973	First	first	MD
304953	100736244	20992709974	,	,	,
304953	100736244	20992709975	secretions	secretion	NN2
304953	100736244	20992709976	from	from	II
304953	100736244	20992709977	the	the	AT
304953	100736244	20992709978	testicles	testicle	NN2
304953	100736244	20992709979	,	,	,
304953	100736244	20992709980	the	the	AT
304953	100736244	20992709981	prostate	prostate	NN1
304953	100736244	20992709982	,	,	,
304953	100736244	20992709983	and	and	CC
304953	100736244	20992709984	the	the	AT
304953	100736244	20992709985	seminal	seminal	JJ
304953	100736244	20992709986	vesicles	vesicle	NN2
304953	100736244	20992709987	"	"	"
304953	100736244	20992709988	small	small	JJ_RR%
304953	100736244	20992709989	,	,	,
304953	100736244	20992709990	slender	slender	JJ
304953	100736244	20992709991	glands	gland	NN2
304953	100736244	20992709992	near	near	II
304953	100736244	20992709993	the	the	AT
304953	100736244	20992709994	prostate	prostate	NN1
304953	100736244	20992709995	"	"	"
304953	100736244	20992709996	flow	flow	NN1
304953	100736244	20992709997	into	into	II
304953	100736244	20992709998	the	the	AT
304953	100736244	20992709999	urethra	urethra	NN1
304953	100736244	20992710000	,	,	,
304953	100736244	20992710001	the	the	AT
304953	100736244	20992710002	tube-like	tube-like	JJ
304953	100736244	20992710003	structure	structure	NN1
304953	100736244	20992710004	that	that	CST_DD1
304953	100736244	20992710005	carries	carry	VVZ
304953	100736244	20992710006	semen	semen	NN1
304953	100736244	20992710007	through	through	II
304953	100736244	20992710008	the	the	AT
304953	100736244	20992710009	penis	penis	NN1
304953	100736244	20992710010	and	and	CC
304953	100736244	20992710011	out	out	RP
304953	100736244	20992710012	the	the	AT
304953	100736244	20992710013	body	body	NN1
304953	100736244	20992710014	.	.	.
304953	100736244	20992710015	The	the	AT
304953	100736244	20992710016	emission	emission	NN1
304953	100736244	20992710017	of	of	IO
304953	100736244	20992710018	those	those	DD2
304953	100736244	20992710019	fluids	fluid	NN2
304953	100736244	20992710020	creates	create	VVZ
304953	100736244	20992710021	a	a	AT1
304953	100736244	20992710022	feeling	feeling	NN1
304953	100736244	20992710023	of	of	IO
304953	100736244	20992710024	fullness	fullness	NN1
304953	100736244	20992710025	and	and	CC
304953	100736244	20992710026	a	a	AT1
304953	100736244	20992710027	sensation	sensation	NN1
304953	100736244	20992710028	of	of	IO
304953	100736244	20992710029	inevitability	inevitability	NN1
304953	100736244	20992710030	.	.	.
304953	100736244	20992710031	<p>		NULL
304953	100736244	20992710032	Second	second	MD
304953	100736244	20992710033	,	,	,
304953	100736244	20992710034	there 's		NN2
304953	100736244	20992710035	ejaculation	ejaculation	NN1
304953	100736244	20992710036	,	,	,
304953	100736244	20992710037	which	which	DDQ
304953	100736244	20992710038	is	be	VBZ
304953	100736244	20992710039	accompanied	accompany	VVN
304953	100736244	20992710040	by	by	II
304953	100736244	20992710041	contractions	contraction	NN2
304953	100736244	20992710042	of	of	IO
304953	100736244	20992710043	the	the	AT
304953	100736244	20992710044	pelvic	pelvic	JJ
304953	100736244	20992710045	floor	floor	NN1
304953	100736244	20992710046	muscles	muscle	NN2
304953	100736244	20992710047	,	,	,
304953	100736244	20992710048	the	the	AT
304953	100736244	20992710049	group	group	NN1
304953	100736244	20992710050	of	of	IO
304953	100736244	20992710051	muscles	muscle	NN2
304953	100736244	20992710052	used	use	VMK
304953	100736244	20992710053	to	to	TO
304953	100736244	20992710054	hold	hold	VVI
304953	100736244	20992710055	in	in	II_RP@
304953	100736244	20992710056	intestinal	intestinal	JJ
304953	100736244	20992710057	gas	gas	NN1
304953	100736244	20992710058	and	and	CC
304953	100736244	20992710059	urine	urine	NN1
304953	100736244	20992710060	.	.	.
304953	100736244	20992710061	<p>		NULL
304953	100736244	20992710062	And	and	CC
304953	100736244	20992710063	@		II
304953	100736244	20992710064	@		II
304953	100736244	20992710065	@		II
304953	100736244	20992710066	@		II
304953	100736244	20992710067	@		II
304953	100736244	20992710068	@		II
304953	100736244	20992710069	@		II
304953	100736244	20992710070	@		II
304953	100736244	20992710071	@		II
304953	100736244	20992710072	@		II
304953	100736244	20992710073	the	the	AT
304953	100736244	20992710074	brain	brain	NN1
304953	100736244	20992710075	does	do	VDZ
304953	100736244	20992710076	of	of	IO
304953	100736244	20992710077	incoming	incoming	JJ
304953	100736244	20992710078	sensory	sensory	JJ
304953	100736244	20992710079	signals	signal	NN2
304953	100736244	20992710080	from	from	II
304953	100736244	20992710081	penis	penis	NN1
304953	100736244	20992710082	and	and	CC
304953	100736244	20992710083	pelvis	pelvis	NN1
304953	100736244	20992710084	that	that	CST
304953	100736244	20992710085	contribute	contribute	VV0
304953	100736244	20992710086	to	to	II
304953	100736244	20992710087	the	the	AT
304953	100736244	20992710088	mental	mental	JJ
304953	100736244	20992710089	experience	experience	NN1
304953	100736244	20992710090	of	of	IO
304953	100736244	20992710091	"	"	"
304953	100736244	20992710092	build	build	VV0_NN1@
304953	100736244	20992710093	up	up	RP
304953	100736244	20992710094	and	and	CC
304953	100736244	20992710095	release	release	NN1_VV0
304953	100736244	20992710096	.	.	.
304953	100736244	20992710097	"	"	"
304953	100736244	20992710098	<h>		NULL
304953	100736244	20992710099	How	how	RGQ@_RRQ
304953	100736244	20992710100	radical	radical	JJ
304953	100736244	20992710101	prostatectomy	prostatectomy	NN1
304953	100736244	20992710102	affects	affect	VVZ
304953	100736244	20992710103	orgasm	orgasm	NN1
304953	100736244	20992710104	<p>		NULL
304953	100736244	20992710105	The	the	AT
304953	100736244	20992710106	first	first	MD
304953	100736244	20992710107	two	two	MC
304953	100736244	20992710108	parts	part	NN2
304953	100736244	20992710109	of	of	IO
304953	100736244	20992710110	orgasm	orgasm	NN1
304953	100736244	20992710111	are	be	VBR
304953	100736244	20992710112	affected	affect	VVN
304953	100736244	20992710113	by	by	II
304953	100736244	20992710114	radical	radical	JJ_NN1
304953	100736244	20992710115	prostatectomy	prostatectomy	NN1
304953	100736244	20992710116	,	,	,
304953	100736244	20992710117	explains	explain	VVZ
304953	100736244	20992710118	Dr.		NNB
304953	100736244	20992710119	Kacker		NP1
304953	100736244	20992710120	.	.	.
304953	100736244	20992710121	Removal	removal	NN1
304953	100736244	20992710122	of	of	IO
304953	100736244	20992710123	the	the	AT
304953	100736244	20992710124	seminal	seminal	JJ
304953	100736244	20992710125	vesicles	vesicle	NN2
304953	100736244	20992710126	and	and	CC
304953	100736244	20992710127	prostate	prostate	NN1
304953	100736244	20992710128	gland	gland	NN1
304953	100736244	20992710129	during	during	II
304953	100736244	20992710130	the	the	AT
304953	100736244	20992710131	operation	operation	NN1
304953	100736244	20992710132	means	mean	VVZ
304953	100736244	20992710133	no	no	AT
304953	100736244	20992710134	fluid	fluid	NN1
304953	100736244	20992710135	can	can	VM
304953	100736244	20992710136	come	come	VVI
304953	100736244	20992710137	in	in	RP@
304953	100736244	20992710138	from	from	II
304953	100736244	20992710139	the	the	AT
304953	100736244	20992710140	testicles	testicle	NN2
304953	100736244	20992710141	or	or	CC
304953	100736244	20992710142	the	the	AT
304953	100736244	20992710143	prostate	prostate	NN1
304953	100736244	20992710144	.	.	.
304953	100736244	20992710145	With	with	IW
304953	100736244	20992710146	the	the	AT
304953	100736244	20992710147	gland	gland	NN1
304953	100736244	20992710148	or	or	CC
304953	100736244	20992710149	the	the	AT
304953	100736244	20992710150	vesicles	vesicle	NN2
304953	100736244	20992710151	gone	go	VVN
304953	100736244	20992710152	,	,	,
304953	100736244	20992710153	there 's		NN2
304953	100736244	20992710154	no	no	AT
304953	100736244	20992710155	fluid	fluid	NN1_JJ@
304953	100736244	20992710156	buildup	buildup	NN1_VV0
304953	100736244	20992710157	in	in	II
304953	100736244	20992710158	the	the	AT
304953	100736244	20992710159	urethra	urethra	NN1
304953	100736244	20992710160	and	and	CC
304953	100736244	20992710161	the	the	AT
304953	100736244	20992710162	sense	sense	NN1
304953	100736244	20992710163	of	of	IO
304953	100736244	20992710164	fullness	fullness	NN1
304953	100736244	20992710165	and	and	CC
304953	100736244	20992710166	inevitability	inevitability	NN1
304953	100736244	20992710167	,	,	,
304953	100736244	20992710168	which	which	DDQ
304953	100736244	20992710169	may	may	VM
304953	100736244	20992710170	have	have	VHI
304953	100736244	20992710171	been	be	VBN
304953	100736244	20992710172	a	a	AT1
304953	100736244	20992710173	familiar	familiar	JJ
304953	100736244	20992710174	part	part	NN1
304953	100736244	20992710175	of	of	IO
304953	100736244	20992710176	your	your	APPGE
304953	100736244	20992710177	orgasm	orgasm	NN1
304953	100736244	20992710178	prior	prior	II21
304953	100736244	20992710179	to	to	II22
304953	100736244	20992710180	surgery	surgery	NN1
304953	100736244	20992710181	,	,	,
304953	100736244	20992710182	is	be	VBZ
304953	100736244	20992710183	now	now	RT
304953	100736244	20992710184	missing	miss	VVG_JJ
304953	100736244	20992710185	.	.	.
304953	100736244	20992710186	<p>		NULL
304953	100736244	20992710187	And	and	CC
304953	100736244	20992710188	there 's		NN2
304953	100736244	20992710189	no	no	AT
304953	100736244	20992710190	ejaculate	ejaculate	NN1
304953	100736244	20992710191	after	after	II_CS
304953	100736244	20992710192	radical	radical	JJ_NN1
304953	100736244	20992710193	prostatectomy	prostatectomy	NN1
304953	100736244	20992710194	.	.	.
304953	100736244	20992710195	Some	some	DD
304953	100736244	20992710196	men	man	NN2
304953	100736244	20992710197	also	also	RR
304953	100736244	20992710198	report	report	VV0@
304953	100736244	20992710199	that	that	CST
304953	100736244	20992710200	the	the	AT
304953	100736244	20992710201	operation	operation	NN1
304953	100736244	20992710202	affects	affect	VVZ
304953	100736244	20992710203	their	their	APPGE
304953	100736244	20992710204	pelvic	pelvic	JJ
304953	100736244	20992710205	floor	floor	NN1
304953	100736244	20992710206	and	and	CC
304953	100736244	20992710207	its	its	APPGE
304953	100736244	20992710208	contractions	contraction	NN2
304953	100736244	20992710209	.	.	.
304953	100736244	20992710210	<p>		NULL
304953	100736244	20992710211	But	but	CCB
304953	100736244	20992710212	the	the	AT
304953	100736244	20992710213	third	third	MD
304953	100736244	20992710214	part	part	NN1
304953	100736244	20992710215	of	of	IO
304953	100736244	20992710216	orgasm	orgasm	NN1
304953	100736244	20992710217	occurs	occur	VVZ
304953	100736244	20992710218	in	in	II
304953	100736244	20992710219	the	the	AT
304953	100736244	20992710220	brain	brain	NN1
304953	100736244	20992710221	and	and	CC
304953	100736244	20992710222	can	can	VM
304953	100736244	20992710223	be	be	VBI
304953	100736244	20992710224	just	just	RR
304953	100736244	20992710225	as	as	RG
304953	100736244	20992710226	intense	intense	JJ
304953	100736244	20992710227	as	as	CSA
304953	100736244	20992710228	before	before	II_CS
304953	100736244	20992710229	surgery	surgery	NN1
304953	100736244	20992710230	.	.	.
304953	100736244	20992710231	<h>		NULL
304953	100736244	20992710232	Steps	step	NN2_VVZ@
304953	100736244	20992710233	men	man	NN2
304953	100736244	20992710234	can	can	VM
304953	100736244	20992710235	take	take	VVI
304953	100736244	20992710236	to	to	TO
304953	100736244	20992710237	improve	improve	VVI
304953	100736244	20992710238	or	or	CC
304953	100736244	20992710239	recover	recover	VVI
304953	100736244	20992710240	orgasms	orgasm	NN2
304953	100736244	20992710241	<p>		NULL
304953	100736244	20992710242	This	this	DD1
304953	100736244	20992710243	does	do	VDZ
304953	100736244	20992710244	n't 	n't	XX
304953	100736244	20992710245	mean	mean	VVI
304953	100736244	20992710246	that	that	CST
304953	100736244	20992710247	some	some	DD
304953	100736244	20992710248	men	man	NN2
304953	100736244	20992710249	do	do	VD0
304953	100736244	20992710250	n't 	n't	XX
304953	100736244	20992710251	have	have	VHI
304953	100736244	20992710252	difficulty	difficulty	NN1
304953	100736244	20992710253	experiencing	experience	VVG
304953	100736244	20992710254	orgasm	orgasm	NN1_VV0
304953	100736244	20992710255	after	after	II_CS
304953	100736244	20992710256	radical	radical	JJ_NN1
304953	100736244	20992710257	prostatectomy	prostatectomy	NN1
304953	100736244	20992710258	.	.	.
304953	100736244	20992710259	The	the	AT
304953	100736244	20992710260	missing	missing	JJ
304953	100736244	20992710261	sensation	sensation	NN1
304953	100736244	20992710262	of	of	IO
304953	100736244	20992710263	@		II
304953	100736244	20992710264	@		II
304953	100736244	20992710265	@		II
304953	100736244	20992710266	@		II
304953	100736244	20992710267	@		II
304953	100736244	20992710268	@		II
304953	100736244	20992710269	@		II
304953	100736244	20992710270	@		II
304953	100736244	20992710271	@		II
304953	100736244	20992710272	@		II
304953	100736244	20992710273	But	but	CCB
304953	100736244	20992710274	there	there	EX
304953	100736244	20992710275	are	be	VBR
304953	100736244	20992710276	some	some	DD
304953	100736244	20992710277	things	thing	NN2
304953	100736244	20992710278	you	you	PPY
304953	100736244	20992710279	can	can	VM
304953	100736244	20992710280	do	do	VDI
304953	100736244	20992710281	to	to	TO
304953	100736244	20992710282	correct	correct	VVI
304953	100736244	20992710283	the	the	AT
304953	100736244	20992710284	problem	problem	NN1
304953	100736244	20992710285	,	,	,
304953	100736244	20992710286	according	according	II21
304953	100736244	20992710287	to	to	II22
304953	100736244	20992710288	Dr.		NNB
304953	100736244	20992710289	Kacker		NP1
304953	100736244	20992710290	.	.	.
304953	100736244	20992710291	<p>		NULL
304953	100736244	20992710292	Men	man	NN2
304953	100736244	20992710293	can	can	VM
304953	100736244	20992710294	achieve	achieve	VVI
304953	100736244	20992710295	an	a	AT1
304953	100736244	20992710296	orgasm	orgasm	NN1
304953	100736244	20992710297	on	on	II
304953	100736244	20992710298	their	their	APPGE
304953	100736244	20992710299	own	own	DA
304953	100736244	20992710300	with	with	IW
304953	100736244	20992710301	manual	manual	JJ
304953	100736244	20992710302	stimulation	stimulation	NN1
304953	100736244	20992710303	or	or	CC
304953	100736244	20992710304	with	with	IW
304953	100736244	20992710305	a	a	AT1
304953	100736244	20992710306	partner	partner	NN1
304953	100736244	20992710307	through	through	II
304953	100736244	20992710308	manual	manual	NN1_JJ
304953	100736244	20992710309	or	or	CC
304953	100736244	20992710310	oral	oral	JJ_NN1
304953	100736244	20992710311	stimulation	stimulation	NN1
304953	100736244	20992710312	.	.	.
304953	100736244	20992710313	Just	just	RR
304953	100736244	20992710314	remember	remember	VV0
304953	100736244	20992710315	that	that	CST
304953	100736244	20992710316	an	a	AT1
304953	100736244	20992710317	erection	erection	NN1
304953	100736244	20992710318	is	be	VBZ
304953	100736244	20992710319	not	not	XX
304953	100736244	20992710320	needed	need	VVN
304953	100736244	20992710321	.	.	.
304953	100736244	20992710322	Using	use	VVG
304953	100736244	20992710323	a	a	AT1
304953	100736244	20992710324	vibrator	vibrator	NN1
304953	100736244	20992710325	on	on	II
304953	100736244	20992710326	the	the	AT
304953	100736244	20992710327	head	head	NN1
304953	100736244	20992710328	of	of	IO
304953	100736244	20992710329	penis	penis	NN1
304953	100736244	20992710330	is	be	VBZ
304953	100736244	20992710331	often	often	RR
304953	100736244	20992710332	helpful	helpful	JJ
304953	100736244	20992710333	.	.	.
304953	100736244	20992710334	Vibration	vibration	NN1
304953	100736244	20992710335	can	can	VM
304953	100736244	20992710336	stimulate	stimulate	VVI
304953	100736244	20992710337	the	the	AT
304953	100736244	20992710338	nerves	nerve	NN2
304953	100736244	20992710339	in	in	II
304953	100736244	20992710340	the	the	AT
304953	100736244	20992710341	penis	penis	NN1
304953	100736244	20992710342	and	and	CC
304953	100736244	20992710343	increase	increase	VV0
304953	100736244	20992710344	the	the	AT
304953	100736244	20992710345	signals	signal	NN2
304953	100736244	20992710346	being	be	VBG
304953	100736244	20992710347	sent	send	VVN
304953	100736244	20992710348	to	to	II
304953	100736244	20992710349	the	the	AT
304953	100736244	20992710350	brain	brain	NN1
304953	100736244	20992710351	.	.	.
304953	100736244	20992710352	<h>		NULL
304953	100736244	20992710353	Hormone	hormone	NN1
304953	100736244	20992710354	adjustments	adjustment	NN2
304953	100736244	20992710355	can	can	VM
304953	100736244	20992710356	help	help	VVI
304953	100736244	20992710357	with	with	IW
304953	100736244	20992710358	orgasm	orgasm	NN1
304953	100736244	20992710359	<p>		NULL
304953	100736244	20992710360	Sometimes	sometimes	RT
304953	100736244	20992710361	hormone	hormone	NN1
304953	100736244	20992710362	levels	level	NN2
304953	100736244	20992710363	contribute	contribute	VV0
304953	100736244	20992710364	to	to	II
304953	100736244	20992710365	orgasmic	orgasmic	JJ
304953	100736244	20992710366	problem	problem	NN1
304953	100736244	20992710367	.	.	.
304953	100736244	20992710368	Many	many	DA2
304953	100736244	20992710369	men	man	NN2
304953	100736244	20992710370	with	with	IW
304953	100736244	20992710371	low	low	JJ
304953	100736244	20992710372	testosterone	testosterone	NN1
304953	100736244	20992710373	have	have	VH0
304953	100736244	20992710374	problems	problem	NN2
304953	100736244	20992710375	with	with	IW
304953	100736244	20992710376	orgasm	orgasm	NN1
304953	100736244	20992710377	,	,	,
304953	100736244	20992710378	but	but	CCB
304953	100736244	20992710379	treating	treat	VVG
304953	100736244	20992710380	prostate	prostate	NN1
304953	100736244	20992710381	cancer	cancer	NN1
304953	100736244	20992710382	patients	patient	NN2
304953	100736244	20992710383	with	with	IW
304953	100736244	20992710384	testosterone	testosterone	NN1
304953	100736244	20992710385	is	be	VBZ
304953	100736244	20992710386	still	still	RR
304953	100736244	20992710387	very	very	RG
304953	100736244	20992710388	controversial	controversial	JJ
304953	100736244	20992710389	.	.	.
304953	100736244	20992710390	Other	other	JJ
304953	100736244	20992710391	hormones	hormone	NN2
304953	100736244	20992710392	can	can	VM
304953	100736244	20992710393	also	also	RR
304953	100736244	20992710394	play	play	VVI
304953	100736244	20992710395	a	a	AT1
304953	100736244	20992710396	role	role	NN1
304953	100736244	20992710397	.	.	.
304953	100736244	20992710398	For	for	REX21
304953	100736244	20992710399	example	example	REX22
304953	100736244	20992710400	,	,	,
304953	100736244	20992710401	a	a	AT1
304953	100736244	20992710402	low	low	JJ
304953	100736244	20992710403	thyroid	thyroid	JJ_NN1
304953	100736244	20992710404	hormone	hormone	NN1
304953	100736244	20992710405	level	level	NN1
304953	100736244	20992710406	or	or	CC
304953	100736244	20992710407	a	a	AT1
304953	100736244	20992710408	high	high	JJ
304953	100736244	20992710409	prolactin	prolactin	NN1
304953	100736244	20992710410	level	level	NN1
304953	100736244	20992710411	can	can	VM
304953	100736244	20992710412	make	make	VVI
304953	100736244	20992710413	it	it	PPH1
304953	100736244	20992710414	more	more	RGR
304953	100736244	20992710415	difficult	difficult	JJ
304953	100736244	20992710416	to	to	TO
304953	100736244	20992710417	reach	reach	VVI
304953	100736244	20992710418	orgasm	orgasm	NN1
304953	100736244	20992710419	.	.	.
304953	100736244	20992710420	Even	even	CS21
304953	100736244	20992710421	if	if	CS22
304953	100736244	20992710422	you	you	PPY
304953	100736244	20992710423	have	have	VH0
304953	100736244	20992710424	a	a	AT1
304953	100736244	20992710425	normal	normal	JJ
304953	100736244	20992710426	hormone	hormone	NN1
304953	100736244	20992710427	levels	level	NN2
304953	100736244	20992710428	,	,	,
304953	100736244	20992710429	there	there	EX
304953	100736244	20992710430	are	be	VBR
304953	100736244	20992710431	a	a	AT1
304953	100736244	20992710432	few	few	DA2
304953	100736244	20992710433	hormonal	hormonal	JJ
304953	100736244	20992710434	medications	medication	NN2
304953	100736244	20992710435	that	that	CST_DD1
304953	100736244	20992710436	may	may	VM
304953	100736244	20992710437	be	be	VBI
304953	100736244	20992710438	able	able	JK
304953	100736244	20992710439	to	to	TO
304953	100736244	20992710440	help	help	VVI
304953	100736244	20992710441	.	.	.
304953	100736244	20992710442	<p>		NULL
304953	100736244	20992710443	Another	another	DD1
304953	100736244	20992710444	hormone	hormone	NN1
304953	100736244	20992710445	that	that	CST_DD1
304953	100736244	20992710446	plays	play	VVZ
304953	100736244	20992710447	a	a	AT1
304953	100736244	20992710448	role	role	NN1
304953	100736244	20992710449	in	in	II
304953	100736244	20992710450	orgasm	orgasm	NN1
304953	100736244	20992710451	is	be	VBZ
304953	100736244	20992710452	oxytocin	oxytocin	NN1
304953	100736244	20992710453	.	.	.
304953	100736244	20992710454	(	(	(
304953	100736244	20992710455	Do	do	VD0
304953	100736244	20992710456	n't 	n't	XX
304953	100736244	20992710457	confuse	confuse	VVI
304953	100736244	20992710458	it	it	PPH1
304953	100736244	20992710459	with	with	IW
304953	100736244	20992710460	OxyContin	oxycontin	NP1
304953	100736244	20992710461	,	,	,
304953	100736244	20992710462	the	the	AT
304953	100736244	20992710463	@		II
304953	100736244	20992710464	@		II
304953	100736244	20992710465	@		II
304953	100736244	20992710466	@		II
304953	100736244	20992710467	@		II
304953	100736244	20992710468	@		II
304953	100736244	20992710469	@		II
304953	100736244	20992710470	@		II
304953	100736244	20992710471	@		II
304953	100736244	20992710472	@		II
304953	100736244	20992710473	in	in	RP@_II
304953	100736244	20992710474	both	both	RR
304953	100736244	20992710475	men	man	NN2
304953	100736244	20992710476	and	and	CC
304953	100736244	20992710477	women	woman	NN2
304953	100736244	20992710478	during	during	II
304953	100736244	20992710479	sexual	sexual	JJ
304953	100736244	20992710480	arousal	arousal	NN1
304953	100736244	20992710481	.	.	.
304953	100736244	20992710482	Taking	take	VVG
304953	100736244	20992710483	an	a	AT1
304953	100736244	20992710484	under-the-tongue		NN1_JJ
304953	100736244	20992710485	(	(	(
304953	100736244	20992710486	sublingual	sublingual	JJ
304953	100736244	20992710487	)	)	)
304953	100736244	20992710488	formulation	formulation	NN1
304953	100736244	20992710489	of	of	IO
304953	100736244	20992710490	oxytocin	oxytocin	NN1
304953	100736244	20992710491	five	five	MC
304953	100736244	20992710492	to	to	II
304953	100736244	20992710493	10	10	MC
304953	100736244	20992710494	minutes	minute	NNT2
304953	100736244	20992710495	before	before	II_CS
304953	100736244	20992710496	sexual	sexual	JJ
304953	100736244	20992710497	activity	activity	NN1
304953	100736244	20992710498	can	can	VM
304953	100736244	20992710499	help	help	VVI
304953	100736244	20992710500	some	some	DD
304953	100736244	20992710501	men	man	NN2
304953	100736244	20992710502	achieve	achieve	VV0
304953	100736244	20992710503	orgasm	orgasm	NN1_VV0
304953	100736244	20992710504	.	.	.
304953	100736244	20992710505	Its	its	APPGE
304953	100736244	20992710506	safe	safe	JJ_NN1@
304953	100736244	20992710507	and	and	CC
304953	100736244	20992710508	no	no	AT
304953	100736244	20992710509	side	side	NN1
304953	100736244	20992710510	effects	effect	NN2
304953	100736244	20992710511	have	have	VH0
304953	100736244	20992710512	been	be	VBN
304953	100736244	20992710513	reported	report	VVN
304953	100736244	20992710514	,	,	,
304953	100736244	20992710515	says	say	VVZ
304953	100736244	20992710516	Dr.		NNB
304953	100736244	20992710517	Kacker		NP1
304953	100736244	20992710518	.	.	.
304953	100736244	20992710519	You	you	PPY
304953	100736244	20992710520	need	need	VV0
304953	100736244	20992710521	a	a	AT1
304953	100736244	20992710522	prescription	prescription	NN1
304953	100736244	20992710523	for	for	IF
304953	100736244	20992710524	oxytocin	oxytocin	NN1
304953	100736244	20992710525	,	,	,
304953	100736244	20992710526	and	and	CC
304953	100736244	20992710527	its	its	APPGE
304953	100736244	20992710528	available	available	JJ
304953	100736244	20992710529	only	only	JJ
304953	100736244	20992710530	through	through-	II
304953	100736244	20992710531	special	special	JJ
304953	100736244	20992710532	compounding		JJ@_NN1@_VVG
304953	100736244	20992710533	pharmacies	pharmacy	NN2
304953	100736244	20992710534	,	,	,
304953	100736244	20992710535	not	not	XX
304953	100736244	20992710536	through	through	II
304953	100736244	20992710537	retail	retail	JJ
304953	100736244	20992710538	pharmacies	pharmacy	NN2
304953	100736244	20992710539	.	.	.
304953	100736244	20992710540	<p>		NULL
304953	100736244	20992710541	Cabergoline		NN1_VV0_NP1@
304953	100736244	20992710542	is	be	VBZ
304953	100736244	20992710543	another	another	DD1
304953	100736244	20992710544	medication	medication	NN1
304953	100736244	20992710545	that	that	CST_DD1
304953	100736244	20992710546	can	can	VM
304953	100736244	20992710547	help	help	VVI
304953	100736244	20992710548	with	with	IW
304953	100736244	20992710549	orgasm	orgasm	NN1
304953	100736244	20992710550	problems	problem	NN2
304953	100736244	20992710551	.	.	.
304953	100736244	20992710552	It	it	PPH1
304953	100736244	20992710553	blocks	block	VVZ@
304953	100736244	20992710554	the	the	AT
304953	100736244	20992710555	release	release	NN1
304953	100736244	20992710556	of	of	IO
304953	100736244	20992710557	prolactin	prolactin	NN1
304953	100736244	20992710558	,	,	,
304953	100736244	20992710559	a	a	AT1
304953	100736244	20992710560	hormone	hormone	NN1
304953	100736244	20992710561	that	that	CST_DD1
304953	100736244	20992710562	appears	appear	VVZ
304953	100736244	20992710563	to	to	TO
304953	100736244	20992710564	play	play	VVI
304953	100736244	20992710565	an	a	AT1
304953	100736244	20992710566	important	important	JJ
304953	100736244	20992710567	role	role	NN1
304953	100736244	20992710568	in	in	II
304953	100736244	20992710569	the	the	AT
304953	100736244	20992710570	refractory	refractory	JJ
304953	100736244	20992710571	period	period	NN1
304953	100736244	20992710572	after	after	II_CS
304953	100736244	20992710573	orgasm	orgasm	NN1
304953	100736244	20992710574	when	when	RRQ_CS
304953	100736244	20992710575	men	man	NN2
304953	100736244	20992710576	cant	cant	NN1_JJ
304953	100736244	20992710577	have	have	VH0
304953	100736244	20992710578	another	another	DD1
304953	100736244	20992710579	orgasm	orgasm	NN1
304953	100736244	20992710580	for	for	IF
304953	100736244	20992710581	a	a	AT1
304953	100736244	20992710582	while	while	NNT1@
304953	100736244	20992710583	.	.	.
304953	100736244	20992710584	<h>		NULL
304953	100736244	20992710585	Cut	cut	VV0
304953	100736244	20992710586	back	back	RP
304953	100736244	20992710587	or	or	CC
304953	100736244	20992710588	change	change	VV0_NN1
304953	100736244	20992710589	antidepressants	anti-depressant	NN2
304953	100736244	20992710590	<p>		NULL
304953	100736244	20992710591	Another	another	DD1
304953	100736244	20992710592	thing	thing	NN1
304953	100736244	20992710593	to	to	TO
304953	100736244	20992710594	think	think	VVI
304953	100736244	20992710595	about	about	II
304953	100736244	20992710596	is	be	VBZ
304953	100736244	20992710597	any	any	DD
304953	100736244	20992710598	other	other	JJ
304953	100736244	20992710599	medications	medication	NN2
304953	100736244	20992710600	you 're		VV0
304953	100736244	20992710601	taking	take	VVG
304953	100736244	20992710602	,	,	,
304953	100736244	20992710603	notes	note	VVZ
304953	100736244	20992710604	Dr.		NNB
304953	100736244	20992710605	Kacker		NP1
304953	100736244	20992710606	.	.	.
304953	100736244	20992710607	Many	many	DA2
304953	100736244	20992710608	men	man	NN2
304953	100736244	20992710609	are	be	VBR
304953	100736244	20992710610	,	,	,
304953	100736244	20992710611	unknowingly	unknowingly	RR
304953	100736244	20992710612	,	,	,
304953	100736244	20992710613	taking	take	VVG
304953	100736244	20992710614	medications	medication	NN2
304953	100736244	20992710615	that	that	CST
304953	100736244	20992710616	suppress	suppress	VV0
304953	100736244	20992710617	orgasm	orgasm	NN1_VV0
304953	100736244	20992710618	.	.	.
304953	100736244	20992710619	By	by	RR21
304953	100736244	20992710620	far	far	RR22
304953	100736244	20992710621	the	the	AT
304953	100736244	20992710622	number	number	NN1
304953	100736244	20992710623	one	one	MC1
304953	100736244	20992710624	offender	offender	NN1
304953	100736244	20992710625	is	be	VBZ
304953	100736244	20992710626	the	the	AT
304953	100736244	20992710627	SSRI	ssri	JJ_NN1
304953	100736244	20992710628	class	class	NN1
304953	100736244	20992710629	of	of	IO
304953	100736244	20992710630	antidepressants	anti-depressant	NN2
304953	100736244	20992710631	,	,	,
304953	100736244	20992710632	which	which	DDQ
304953	100736244	20992710633	include	include	VV0
304953	100736244	20992710634	fluoxetine	fluoxetine	NN1_JJ
304953	100736244	20992710635	(	(	(
304953	100736244	20992710636	Prozac	prozac	NP1
304953	100736244	20992710637	)	)	)
304953	100736244	20992710638	and	and	CC
304953	100736244	20992710639	Paxil	paxil	NP1
304953	100736244	20992710640	(	(	(
304953	100736244	20992710641	paroxetine	paroxetine	NN1_JJ
304953	100736244	20992710642	)	)	)
304953	100736244	20992710643	.	.	.
304953	100736244	20992710644	By	by	II
304953	100736244	20992710645	reducing	reduce	VVG
304953	100736244	20992710646	the	the	AT
304953	100736244	20992710647	dose	dose	NN1
304953	100736244	20992710648	of	of	IO
304953	100736244	20992710649	these	these	DD2
304953	100736244	20992710650	drugs	drug	NN2
304953	100736244	20992710651	or	or	CC
304953	100736244	20992710652	eliminating	eliminate	VVG
304953	100736244	20992710653	them	them	PPHO2
304953	100736244	20992710654	entirely	entirely	RR
304953	100736244	20992710655	,	,	,
304953	100736244	20992710656	or	or	CC
304953	100736244	20992710657	switching	switch	VVG_NN1_JJ
304953	100736244	20992710658	to	to	II
304953	100736244	20992710659	a	a	AT1
304953	100736244	20992710660	non-SSRI		NN1_JJ
304953	100736244	20992710661	like	like	II_JJ@
304953	100736244	20992710662	bupropion	bupropion	NN1
304953	100736244	20992710663	@		II
304953	100736244	20992710664	@		II
304953	100736244	20992710665	@		II
304953	100736244	20992710666	@		II
304953	100736244	20992710667	@		II
304953	100736244	20992710668	@		II
304953	100736244	20992710669	@		II
304953	100736244	20992710670	@		II
304953	100736244	20992710671	@		II
304953	100736244	20992710672	@		II
304953	100736244	20992710673	their	their	APPGE
304953	100736244	20992710674	ability	ability	NN1
304953	100736244	20992710675	to	to	TO
304953	100736244	20992710676	orgasm	orgasm	VVI
304953	100736244	20992710677	.	.	.
304953	100736244	20992710678	<h>		NULL
304953	100736244	20992710679	Talking	talk	VVG
304953	100736244	20992710680	about	about	II
304953	100736244	20992710681	orgasm	orgasm	NN1
304953	100736244	20992710682	problems	problem	NN2
304953	100736244	20992710683	is	be	VBZ
304953	100736244	20992710684	important	important	JJ
304953	100736244	20992710685	<p>		NULL
304953	100736244	20992710686	Men	man	NN2
304953	100736244	20992710687	and	and	CC
304953	100736244	20992710688	their	their	APPGE
304953	100736244	20992710689	partners	partner	NN2
304953	100736244	20992710690	have	have	VH0
304953	100736244	20992710691	become	become	VVN@
304953	100736244	20992710692	much	much	RR_DA1
304953	100736244	20992710693	more	more	RGR_DAR
304953	100736244	20992710694	open	open	JJ
304953	100736244	20992710695	about	about	II
304953	100736244	20992710696	talking	talk	VVG
304953	100736244	20992710697	erectile	erectile	JJ
304953	100736244	20992710698	dysfunction	dysfunction	NN1
304953	100736244	20992710699	,	,	,
304953	100736244	20992710700	in	in	RR21
304953	100736244	20992710701	general	general	RR22
304953	100736244	20992710702	and	and	CC
304953	100736244	20992710703	as	as	II
304953	100736244	20992710704	a	a	AT1
304953	100736244	20992710705	consequence	consequence	NN1
304953	100736244	20992710706	of	of	IO
304953	100736244	20992710707	prostate	prostate	NN1
304953	100736244	20992710708	cancer	cancer	NN1
304953	100736244	20992710709	treatment	treatment	NN1
304953	100736244	20992710710	,	,	,
304953	100736244	20992710711	notes	note	VVZ
304953	100736244	20992710712	Dr.		NNB
304953	100736244	20992710713	Kacker		NP1
304953	100736244	20992710714	.	.	.
304953	100736244	20992710715	<p>		NULL
304953	100736244	20992710716	Whatever	whatever	DDQV
304953	100736244	20992710717	you	you	PPY
304953	100736244	20992710718	think	think	VV0
304953	100736244	20992710719	about	about	II
304953	100736244	20992710720	all	all	DB
304953	100736244	20992710721	those	those	DD2
304953	100736244	20992710722	ads	ad	NN2
304953	100736244	20992710723	for	for	IF
304953	100736244	20992710724	Viagra	viagra	NP1
304953	100736244	20992710725	and	and	CC
304953	100736244	20992710726	Cialis	cialis	NP1_NN1
304953	100736244	20992710727	,	,	,
304953	100736244	20992710728	they	they	PPHS2
304953	100736244	20992710729	have	have	VH0
304953	100736244	20992710730	made	make	VVN
304953	100736244	20992710731	it	it	PPH1
304953	100736244	20992710732	easier	easy	JJR_RRR
304953	100736244	20992710733	to	to	TO
304953	100736244	20992710734	talk	talk	VVI
304953	100736244	20992710735	about	about	II
304953	100736244	20992710736	ED	ed	NP1
304953	100736244	20992710737	and	and	CC
304953	100736244	20992710738	helped	help	VVN_VVD
304953	100736244	20992710739	remove	remove	VVI
304953	100736244	20992710740	some	some	DD
304953	100736244	20992710741	of	of	IO
304953	100736244	20992710742	the	the	AT
304953	100736244	20992710743	stigma	stigma	NN1
304953	100736244	20992710744	around	around	II
304953	100736244	20992710745	the	the	AT
304953	100736244	20992710746	condition	condition	NN1
304953	100736244	20992710747	.	.	.
304953	100736244	20992710748	<p>		NULL
304953	100736244	20992710749	"	"	"
304953	100736244	20992710750	We	we	PPIS2
304953	100736244	20992710751	should	should	VM
304953	100736244	20992710752	be	be	VBI
304953	100736244	20992710753	having	have	VHG
304953	100736244	20992710754	the	the	AT
304953	100736244	20992710755	same	same	DA
304953	100736244	20992710756	frank	frank	JJ
304953	100736244	20992710757	,	,	,
304953	100736244	20992710758	open	open	JJ_VV0
304953	100736244	20992710759	discussions	discussion	NN2
304953	100736244	20992710760	about	about	II
304953	100736244	20992710761	orgasm	orgasm	NN1
304953	100736244	20992710762	,	,	,
304953	100736244	20992710763	"	"	"
304953	100736244	20992710764	says	say	VVZ
304953	100736244	20992710765	Dr.		NNB
304953	100736244	20992710766	Kacker		NP1
304953	100736244	20992710767	.	.	.
304953	100736244	20992710768	"	"	"
304953	100736244	20992710769	Orgasms	orgasm	NN2
304953	100736244	20992710770	can	can	VM
304953	100736244	20992710771	bring	bring	VVI
304953	100736244	20992710772	a	a	AT1
304953	100736244	20992710773	couple	couple	NN1
304953	100736244	20992710774	together	together	RL
304953	100736244	20992710775	and	and	CC
304953	100736244	20992710776	allow	allow	VVI
304953	100736244	20992710777	them	them	PPHO2
304953	100736244	20992710778	to	to	TO
304953	100736244	20992710779	maintain	maintain	VVI
304953	100736244	20992710780	sexual	sexual	JJ
304953	100736244	20992710781	intimacy	intimacy	NN1
304953	100736244	20992710782	in	in	II
304953	100736244	20992710783	the	the	AT
304953	100736244	20992710784	difficult	difficult	JJ
304953	100736244	20992710785	period	period	NN1
304953	100736244	20992710786	around	around	II
304953	100736244	20992710787	diagnosis	diagnosis	NN1
304953	100736244	20992710788	and	and	CC
304953	100736244	20992710789	treatment	treatment	NN1
304953	100736244	20992710790	of	of	IO
304953	100736244	20992710791	prostate	prostate	NN1
304953	100736244	20992710792	cancer	cancer	NN1
304953	100736244	20992710793	.	.	.
304953	100736244	20992710794	"	"	"
304953	100736245	20992710814	@@##	----------	----------
304953	100736245	20992710815	@@100736245		FO
304953	100736245	20992710816	@4936245/		VV0_NN1
304953	100736245	20992710817	46989		MC
304953	100736245	20992710818	@qwx906989		FO
304953	100736245	20992710819	<h>		NULL
304953	100736245	20992710820	I	i	PPIS1_MC1%
304953	100736245	20992710821	am	be	VBM_RA@
304953	100736245	20992710822	59	59	MC
304953	100736245	20992710823	years	year	NNT2
304953	100736245	20992710824	old	old	JJ
304953	100736245	20992710825	and	and	CC
304953	100736245	20992710826	have	have	VH0
304953	100736245	20992710827	a	a	AT1
304953	100736245	20992710828	fluctuating	fluctuating	JJ
304953	100736245	20992710829	PSA	psa	NP1
304953	100736245	20992710830	.	.	.
304953	100736245	20992710831	In	in	II
304953	100736245	20992710832	2005	2005	MC
304953	100736245	20992710833	,	,	,
304953	100736245	20992710834	it	it	PPH1
304953	100736245	20992710835	was	be	VBDZ
304953	100736245	20992710836	2.5	2.5	MC
304953	100736245	20992710837	ng/ml	ng/ml	FU
304953	100736245	20992710838	.	.	.
304953	100736245	20992710839	A	a	AT1_ZZ1
304953	100736245	20992710840	12-core		JJ_NN1
304953	100736245	20992710841	biopsy	biopsy	NN1
304953	100736245	20992710842	was	be	VBDZ
304953	100736245	20992710843	negative	negative	JJ
304953	100736245	20992710844	.	.	.
304953	100736245	20992710845	In	in	II
304953	100736245	20992710846	2006	2006	MC
304953	100736245	20992710847	,	,	,
304953	100736245	20992710848	my	my	APPGE
304953	100736245	20992710849	PSA	psa	NP1
304953	100736245	20992710850	dropped	drop	VVD
304953	100736245	20992710851	to	to	II
304953	100736245	20992710852	0.97	0.97	MC
304953	100736245	20992710853	ng/ml	ng/ml	FU
304953	100736245	20992710854	.	.	.
304953	100736245	20992710855	In	in	II
304953	100736245	20992710856	2007	2007	MC
304953	100736245	20992710857	,	,	,
304953	100736245	20992710858	it	it	PPH1
304953	100736245	20992710859	went	go	VVD
304953	100736245	20992710860	up	up	RG21
304953	100736245	20992710861	to	to	RG22
304953	100736245	20992710862	2.54	2.54	MC
304953	100736245	20992710863	,	,	,
304953	100736245	20992710864	and	and	CC
304953	100736245	20992710865	I	i	PPIS1
304953	100736245	20992710866	had	have	VHD
304953	100736245	20992710867	another	another	DD1
304953	100736245	20992710868	biopsy	biopsy	NN1
304953	100736245	20992710869	.	.	.
304953	100736245	20992710870	All	all	DB
304953	100736245	20992710871	14	14	MC
304953	100736245	20992710872	cores	core	NN2
304953	100736245	20992710873	were	be	VBDR
304953	100736245	20992710874	negative	negative	JJ
304953	100736245	20992710875	for	for	IF
304953	100736245	20992710876	cancer	cancer	NN1
304953	100736245	20992710877	.	.	.
304953	100736245	20992710878	What	what	DDQ
304953	100736245	20992710879	does	do	VDZ
304953	100736245	20992710880	this	this	DD1
304953	100736245	20992710881	mean	mean	VVI
304953	100736245	20992710882	for	for	IF
304953	100736245	20992710883	my	my	APPGE
304953	100736245	20992710884	prostate	prostate	NN1
304953	100736245	20992710885	health	health	NN1
304953	100736245	20992710886	?	?	?
304953	100736245	20992710887	<p>		NULL
304953	100736245	20992710888	Variations	variation	NN2
304953	100736245	20992710889	in	in	II
304953	100736245	20992710890	PSA	psa	NP1
304953	100736245	20992710891	like	like	II
304953	100736245	20992710892	yours	yours	PPGE
304953	100736245	20992710893	are	be	VBR
304953	100736245	20992710894	n't	n't	XX
304953	100736245	20992710895	particularly	particularly	RR
304953	100736245	20992710896	remarkable	remarkable	JJ
304953	100736245	20992710897	.	.	.
304953	100736245	20992710898	In	in	II
304953	100736245	20992710899	fact	fact	NN1
304953	100736245	20992710900	,	,	,
304953	100736245	20992710901	fluctuations	fluctuation	NN2
304953	100736245	20992710902	in	in	II
304953	100736245	20992710903	PSA	psa	NP1
304953	100736245	20992710904	of	of	IO
304953	100736245	20992710905	up	up	RG21
304953	100736245	20992710906	to	to	RG22
304953	100736245	20992710907	36%		NNU
304953	100736245	20992710908	from	from	II
304953	100736245	20992710909	one	one	MC1
304953	100736245	20992710910	day	day	NNT1
304953	100736245	20992710911	to	to	II
304953	100736245	20992710912	the	the	AT
304953	100736245	20992710913	next	next	MD
304953	100736245	20992710914	may	may	VM
304953	100736245	20992710915	have	have	VHI
304953	100736245	20992710916	nothing	nothing	PN1
304953	100736245	20992710917	to	to	TO
304953	100736245	20992710918	do	do	VDI
304953	100736245	20992710919	with	with	IW
304953	100736245	20992710920	cancer	cancer	NN1
304953	100736245	20992710921	.	.	.
304953	100736245	20992710922	Prostate	prostate	NN1
304953	100736245	20992710923	infections	infection	NN2
304953	100736245	20992710924	and	and	CC
304953	100736245	20992710925	inflammation	inflammation	NN1
304953	100736245	20992710926	may	may	VM
304953	100736245	20992710927	account	account	VVI
304953	100736245	20992710928	for	for	IF
304953	100736245	20992710929	some	some	DD
304953	100736245	20992710930	of	of	IO
304953	100736245	20992710931	the	the	AT
304953	100736245	20992710932	variation	variation	NN1
304953	100736245	20992710933	,	,	,
304953	100736245	20992710934	as	as	CSA
304953	100736245	20992710935	can	can	VM
304953	100736245	20992710936	an	a	AT1
304953	100736245	20992710937	enlarged	enlarged	JJ
304953	100736245	20992710938	prostate	prostate	NN1
304953	100736245	20992710939	and	and	CC
304953	100736245	20992710940	advancing	advancing	JJ
304953	100736245	20992710941	age	age	NN1
304953	100736245	20992710942	.	.	.
304953	100736245	20992710943	However	however	RR
304953	100736245	20992710944	,	,	,
304953	100736245	20992710945	the	the	AT
304953	100736245	20992710946	Prostate	prostate	NN1
304953	100736245	20992710947	Cancer	cancer	NN1
304953	100736245	20992710948	Prevention	prevention	NN1
304953	100736245	20992710949	Trial	trial	NN1
304953	100736245	20992710950	found	find	VVD_VVN
304953	100736245	20992710951	that	that	DD1_CST
304953	100736245	20992710952	prostate	prostate	NN1
304953	100736245	20992710953	cancer	cancer	NN1
304953	100736245	20992710954	might	might	VM
304953	100736245	20992710955	be	be	VBI
304953	100736245	20992710956	detected	detect	VVN
304953	100736245	20992710957	in	in	II
304953	100736245	20992710958	23.9%	23.9%	FO
304953	100736245	20992710959	of	of	IO
304953	100736245	20992710960	patients	patient	NN2
304953	100736245	20992710961	with	with	IW
304953	100736245	20992710962	a	a	AT1
304953	100736245	20992710963	PSA	psa	NP1
304953	100736245	20992710964	of	of	IO
304953	100736245	20992710965	2.1	2.1	MC
304953	100736245	20992710966	to	to	II
304953	100736245	20992710967	3	3	MC
304953	100736245	20992710968	ng/ml	ng/ml	FU
304953	100736245	20992710969	,	,	,
304953	100736245	20992710970	so	so	CS@_RR
304953	100736245	20992710971	you	you	PPY
304953	100736245	20992710972	do	do	VD0
304953	100736245	20992710973	n't	n't	XX
304953	100736245	20992710974	want	want	VVI
304953	100736245	20992710975	to	to	TO
304953	100736245	20992710976	ignore	ignore	VVI
304953	100736245	20992710977	an	a	AT1
304953	100736245	20992710978	elevated	elevated	JJ
304953	100736245	20992710979	PSA	psa	NP1
304953	100736245	20992710980	either	either	RR_DD1
304953	100736245	20992710981	.	.	.
304953	100736245	20992710982	<p>		NULL
304953	100736245	20992710983	Before	before	CS
304953	100736245	20992710984	you	you	PPY
304953	100736245	20992710985	have	have	VH0
304953	100736245	20992710986	a	a	AT1
304953	100736245	20992710987	third	third	MD
304953	100736245	20992710988	biopsy	biopsy	NN1
304953	100736245	20992710989	,	,	,
304953	100736245	20992710990	consider	consider	VV0
304953	100736245	20992710991	having	have	VHG
304953	100736245	20992710992	your	your	APPGE
304953	100736245	20992710993	free	free	JJ
304953	100736245	20992710994	PSA	psa	NP1
304953	100736245	20992710995	measured.		NNU
304953	100736245	20992710996	-	-	-
304953	100736245	20992710997	A	a	ZZ1
304953	100736245	20992710998	2008	2008	MC
304953	100736245	20992710999	study	study	NN1
304953	100736245	20992711000	of	of	IO
304953	100736245	20992711001	125	125	MC
304953	100736245	20992711002	men	man	NN2
304953	100736245	20992711003	who	who	PNQS
304953	100736245	20992711004	had	have	VHD
304953	100736245	20992711005	a	a	AT1
304953	100736245	20992711006	@		II
304953	100736245	20992711007	@		II
304953	100736245	20992711008	@		II
304953	100736245	20992711009	@		II
304953	100736245	20992711010	@		II
304953	100736245	20992711011	@		II
304953	100736245	20992711012	@		II
304953	100736245	20992711013	@		II
304953	100736245	20992711014	@		II
304953	100736245	20992711015	@		II
304953	100736245	20992711016	men	man	NN2
304953	100736245	20992711017	with	with	IW
304953	100736245	20992711018	a	a	AT1
304953	100736245	20992711019	total	total	JJ_NN1
304953	100736245	20992711020	PSA	psa	NP1
304953	100736245	20992711021	of	of	IO
304953	100736245	20992711022	2.5	2.5	MC
304953	100736245	20992711023	ng/ml	ng/ml	FU
304953	100736245	20992711024	or	or	CC
304953	100736245	20992711025	less	less	DAR_RRR
304953	100736245	20992711026	could	could	VM
304953	100736245	20992711027	indicate	indicate	VVI
304953	100736245	20992711028	who	who	PNQS
304953	100736245	20992711029	was	be	VBDZ
304953	100736245	20992711030	most	most	RGT
304953	100736245	20992711031	likely	likely	JJ
304953	100736245	20992711032	to	to	TO
304953	100736245	20992711033	have	have	VHI
304953	100736245	20992711034	prostate	prostate	NN1
304953	100736245	20992711035	cancer	cancer	NN1
304953	100736245	20992711036	:	:	:
304953	100736245	20992711037	59%		NNU
304953	100736245	20992711038	of	of	IO
304953	100736245	20992711039	the	the	AT
304953	100736245	20992711040	men	man	NN2
304953	100736245	20992711041	with	with	IW
304953	100736245	20992711042	a	a	AT1
304953	100736245	20992711043	free	free	JJ
304953	100736245	20992711044	PSA	psa	NP1
304953	100736245	20992711045	of	of	IO
304953	100736245	20992711046	14%		NNU
304953	100736245	20992711047	or	or	CC
304953	100736245	20992711048	less	less	RRR
304953	100736245	20992711049	had	have	VHD
304953	100736245	20992711050	prostate	prostate	NN1
304953	100736245	20992711051	cancer	cancer	NN1
304953	100736245	20992711052	versus	versus	II
304953	100736245	20992711053	just	just	RR
304953	100736245	20992711054	13%		NNU
304953	100736245	20992711055	of	of	IO
304953	100736245	20992711056	the	the	AT
304953	100736245	20992711057	men	man	NN2
304953	100736245	20992711058	with	with	IW
304953	100736245	20992711059	a	a	AT1
304953	100736245	20992711060	free	free	JJ
304953	100736245	20992711061	PSA	psa	NP1
304953	100736245	20992711062	of	of	IO
304953	100736245	20992711063	28%		NNU
304953	100736245	20992711064	or	or	CC
304953	100736245	20992711065	more	more	RRR_DAR
304953	100736245	20992711066	.	.	.
304953	100736245	20992711067	So	so	RR
304953	100736245	20992711068	the	the	AT
304953	100736245	20992711069	lower	low	RRR@_VV0@
304953	100736245	20992711070	your	your	APPGE
304953	100736245	20992711071	percentage	percentage	NN1
304953	100736245	20992711072	of	of	IO
304953	100736245	20992711073	free	free	JJ
304953	100736245	20992711074	PSA	psa	NP1
304953	100736245	20992711075	,	,	,
304953	100736245	20992711076	the	the	AT
304953	100736245	20992711077	more	more	RGR_DAR_RRR
304953	100736245	20992711078	you	you	PPY
304953	100736245	20992711079	might	might	VM
304953	100736245	20992711080	want	want	VVI
304953	100736245	20992711081	to	to	TO
304953	100736245	20992711082	think	think	VVI
304953	100736245	20992711083	about	about	II
304953	100736245	20992711084	having	have	VHG
304953	100736245	20992711085	another	another	DD1
304953	100736245	20992711086	biopsy	biopsy	NN1
304953	100736245	20992711087	.	.	.
304953	100736245	20992711088	<p>		NULL
304953	100736245	20992711089	You	you	PPY
304953	100736245	20992711090	could	could	VM
304953	100736245	20992711091	also	also	RR
304953	100736245	20992711092	ask	ask	VVI
304953	100736245	20992711093	about	about	II
304953	100736245	20992711094	having	have	VHG
304953	100736245	20992711095	an	a	AT1
304953	100736245	20992711096	endorectal		JJ
304953	100736245	20992711097	MRI	mri	NN2_NN1
304953	100736245	20992711098	.	.	.
304953	100736245	20992711099	This	this	DD1
304953	100736245	20992711100	imaging	imaging	NN1_JJ@
304953	100736245	20992711101	test	test	NN1
304953	100736245	20992711102	can	can	VM
304953	100736245	20992711103	help	help	VVI
304953	100736245	20992711104	physicians	physician	NN2
304953	100736245	20992711105	spot	spot	VVI
304953	100736245	20992711106	abnormalities	abnormality	NN2
304953	100736245	20992711107	in	in	II
304953	100736245	20992711108	regions	region	NN2
304953	100736245	20992711109	of	of	IO
304953	100736245	20992711110	the	the	AT
304953	100736245	20992711111	prostate	prostate	NN1
304953	100736245	20992711112	not	not	XX
304953	100736245	20992711113	typically	typically	RR
304953	100736245	20992711114	sampled	sample	VVN_VVD
304953	100736245	20992711115	during	during	II
304953	100736245	20992711116	a	a	AT1
304953	100736245	20992711117	biopsy	biopsy	NN1
304953	100736245	20992711118	.	.	.
304953	100736245	20992711119	Any	any	DD
304953	100736245	20992711120	follow-up	follow-up	JJ_NN1
304953	100736245	20992711121	biopsies	biopsy	NN2
304953	100736245	20992711122	could	could	VM
304953	100736245	20992711123	then	then	RT
304953	100736245	20992711124	target	target	VVI
304953	100736245	20992711125	those	those	DD2
304953	100736245	20992711126	suspicious	suspicious	JJ
304953	100736245	20992711127	areas	area	NN2
304953	100736245	20992711128	.	.	.
304953	100736245	20992711129	<p>		NULL
304953	100736245	20992711130	Assuming	assume	VVG
304953	100736245	20992711131	the	the	AT
304953	100736245	20992711132	endorectal		JJ
304953	100736245	20992711133	MRI	mri	NN2_NN1
304953	100736245	20992711134	and	and	CC
304953	100736245	20992711135	your	your	APPGE
304953	100736245	20992711136	digital	digital	JJ
304953	100736245	20992711137	rectal	rectal	JJ
304953	100736245	20992711138	examination	examination	NN1
304953	100736245	20992711139	(	(	(
304953	100736245	20992711140	DRE	dre	NP1
304953	100736245	20992711141	)	)	)
304953	100736245	20992711142	are	be	VBR
304953	100736245	20992711143	normal	normal	JJ
304953	100736245	20992711144	,	,	,
304953	100736245	20992711145	and	and	CC
304953	100736245	20992711146	depending	depending	II21
304953	100736245	20992711147	on	on	II22
304953	100736245	20992711148	your	your	APPGE
304953	100736245	20992711149	general	general	JJ_NN1
304953	100736245	20992711150	health	health	NN1
304953	100736245	20992711151	and	and	CC
304953	100736245	20992711152	any	any	DD
304953	100736245	20992711153	medications	medication	NN2
304953	100736245	20992711154	you	you	PPY
304953	100736245	20992711155	take	take	VV0
304953	100736245	20992711156	,	,	,
304953	100736245	20992711157	you	you	PPY
304953	100736245	20992711158	and	and	CC
304953	100736245	20992711159	your	your	APPGE
304953	100736245	20992711160	doctor	doctor	NN1
304953	100736245	20992711161	might	might	VM
304953	100736245	20992711162	simply	simply	RR
304953	100736245	20992711163	want	want	VVI
304953	100736245	20992711164	to	to	TO
304953	100736245	20992711165	track	track	VVI
304953	100736245	20992711166	your	your	APPGE
304953	100736245	20992711167	PSA	psa	NP1
304953	100736245	20992711168	over	over	II
304953	100736245	20992711169	time	time	NNT1
304953	100736245	20992711170	.	.	.
304953	100736245	20992711171	If	if	CS
304953	100736245	20992711172	it	it	PPH1
304953	100736245	20992711173	jumps	jump	VVZ
304953	100736245	20992711174	much	much	RR_DA1
304953	100736245	20992711175	above	above	II
304953	100736245	20992711176	its	its	APPGE
304953	100736245	20992711177	current	current	JJ
304953	100736245	20992711178	level	level	NN1_JJ
304953	100736245	20992711179	,	,	,
304953	100736245	20992711180	you	you	PPY
304953	100736245	20992711181	could	could	VM
304953	100736245	20992711182	opt	opt	VVI
304953	100736245	20992711183	for	for	IF
304953	100736245	20992711184	a	a	AT1
304953	100736245	20992711185	biopsy	biopsy	NN1
304953	100736245	20992711186	then	then	RT
304953	100736245	20992711187	.	.	.
304953	100736245	20992711188	<p>		NULL
304953	100736245	20992711189	Unfortunately	unfortunately	RR
304953	100736245	20992711190	,	,	,
304953	100736245	20992711191	there	there	EX
304953	100736245	20992711192	is	be	VBZ
304953	100736245	20992711193	no	no	RR
304953	100736245	20992711194	one	one	MC1
304953	100736245	20992711195	right	right	JJ_NN1
304953	100736245	20992711196	answer	answer	NN1_VV0
304953	100736245	20992711197	to	to	II
304953	100736245	20992711198	your	your	APPGE
304953	100736245	20992711199	question	question	NN1
304953	100736245	20992711200	.	.	.
304953	100736245	20992711201	In	in	II
304953	100736245	20992711202	the	the	AT
304953	100736245	20992711203	end	end	NN1
304953	100736245	20992711204	,	,	,
304953	100736245	20992711205	it	it	PPH1
304953	100736245	20992711206	@		II
304953	100736245	20992711207	@		II
304953	100736245	20992711208	@		II
304953	100736245	20992711209	@		II
304953	100736245	20992711210	@		II
304953	100736245	20992711211	@		II
304953	100736245	20992711212	@		II
304953	100736245	20992711213	@		II
304953	100736245	20992711214	@		II
304953	100736245	20992711215	@		II
304953	100736245	20992711216	,	,	,
304953	100736245	20992711217	talking	talk	VVG
304953	100736245	20992711218	with	with	IW
304953	100736245	20992711219	your	your	APPGE
304953	100736245	20992711220	doctor	doctor	NN1
304953	100736245	20992711221	,	,	,
304953	100736245	20992711222	and	and	CC
304953	100736245	20992711223	making	make	VVG
304953	100736245	20992711224	an	a	AT1
304953	100736245	20992711225	educated	educated	JJ
304953	100736245	20992711226	decision	decision	NN1
304953	100736245	20992711227	about	about	II
304953	100736245	20992711228	what	what	DDQ
304953	100736245	20992711229	to	to	TO
304953	100736245	20992711230	do	do	VDI
304953	100736245	20992711231	next	next	MD
304953	100736245	20992711232	.	.	.
304953	100736245	20992711233	<p>		NULL
304953	100736245	20992711234	men	man	NN2
304953	100736245	20992711235	,	,	,
304953	100736245	20992711236	PSA	psa	NP1
304953	100736245	20992711237	levels	level	NN2
304953	100736245	20992711238	fluctuate	fluctuate	VV0
304953	100736245	20992711239	on	on	II_RP@
304953	100736245	20992711240	a	a	AT1
304953	100736245	20992711241	regular	regular	JJ
304953	100736245	20992711242	basis	basis	NN1
304953	100736245	20992711243	.	.	.
304953	100736245	20992711244	Some	some	DD
304953	100736245	20992711245	days	day	NNT2
304953	100736245	20992711246	the	the	AT
304953	100736245	20992711247	readings	reading	NN2
304953	100736245	20992711248	can	can	VM
304953	100736245	20992711249	be	be	VBI
304953	100736245	20992711250	higher	high	JJR
304953	100736245	20992711251	than	than	CSN
304953	100736245	20992711252	others	others	NN2
304953	100736245	20992711253	"	"	"
304953	100736245	20992711254	up	up	RG21
304953	100736245	20992711255	to	to	RG22
304953	100736245	20992711256	36	36	MC
304953	100736245	20992711257	percent	percent	NNU
304953	100736245	20992711258	different	different	JJ
304953	100736245	20992711259	,	,	,
304953	100736245	20992711260	according	according	II21
304953	100736245	20992711261	to	to	II22
304953	100736245	20992711262	Harvard	harvard	NP1
304953	100736245	20992711263	research	research	NN1_VV0@
304953	100736245	20992711264	"	"	"
304953	100736245	20992711265	usually	usually	RR
304953	100736245	20992711266	without	without	IW
304953	100736245	20992711267	explanation	explanation	NN1
304953	100736245	20992711268	.	.	.
304953	100736245	20992711269	Doctors	doctor	NN2
304953	100736245	20992711270	suspect	suspect	VV0
304953	100736245	20992711271	that	that	CST
304953	100736245	20992711272	the	the	AT
304953	100736245	20992711273	inconsistent	inconsistent	JJ
304953	100736245	20992711274	readings	reading	NN2
304953	100736245	20992711275	might	might	VM
304953	100736245	20992711276	be	be	VBI
304953	100736245	20992711277	caused	cause	VVN
304953	100736245	20992711278	by	by	II_RP%
304953	100736245	20992711279	<p>		NULL
304953	100736245	20992711280	A	a	AT1
304953	100736245	20992711281	friend	friend	NN1
304953	100736245	20992711282	was	be	VBDZ
304953	100736245	20992711283	treated	treat	VVN
304953	100736245	20992711284	with	with	IW
304953	100736245	20992711285	testosterone	testosterone	NN1
304953	100736245	20992711286	therapywhether		VV0
304953	100736245	20992711287	or	or	CC
304953	100736245	20992711288	not	not	XX
304953	100736245	20992711289	he	he	PPHS1
304953	100736245	20992711290	had	have	VHD
304953	100736245	20992711291	an	a	AT1
304953	100736245	20992711292	enlarged	enlarged	JJ
304953	100736245	20992711293	prostate	prostate	NN1
304953	100736245	20992711294	prior		RR_NN1%_JJ
304953	100736245	20992711295	is	be	VBZ
304953	100736245	20992711296	unknown	unknown	JJ
304953	100736245	20992711297	.	.	.
304953	100736245	20992711298	Nevertheless	nevertheless	RR
304953	100736245	20992711299	,	,	,
304953	100736245	20992711300	he	he	PPHS1
304953	100736245	20992711301	had	have	VHD
304953	100736245	20992711302	prostate	prostate	NN1
304953	100736245	20992711303	surgery	surgery	NN1
304953	100736245	20992711304	March	march	NN1%_NPM1
304953	100736245	20992711305	of	of	IO
304953	100736245	20992711306	13	13	MC
304953	100736245	20992711307	,	,	,
304953	100736245	20992711308	with	with	IW
304953	100736245	20992711309	a	a	AT1
304953	100736245	20992711310	very	very	RG
304953	100736245	20992711311	long	long	JJ
304953	100736245	20992711312	healing	healing	NN1
304953	100736245	20992711313	process	process	NN1
304953	100736245	20992711314	.	.	.
304953	100736245	20992711315	This	this	DD1
304953	100736245	20992711316	is	be	VBZ
304953	100736245	20992711317	a	a	AT1
304953	100736245	20992711318	59	59	MC
304953	100736245	20992711319	year	year	NNT1
304953	100736245	20992711320	old	old	JJ
304953	100736245	20992711321	very	very	RG
304953	100736245	20992711322	active	active	JJ
304953	100736245	20992711323	,	,	,
304953	100736245	20992711324	very	very	RG
304953	100736245	20992711325	athletic	athletic	JJ
304953	100736245	20992711326	male	male	NN1
304953	100736245	20992711327	.	.	.
304953	100736245	20992711328	He	he	PPHS1
304953	100736245	20992711329	continues	continue	VVZ
304953	100736245	20992711330	to	to	TO
304953	100736245	20992711331	take	take	VVI
304953	100736245	20992711332	1/2	1/2	MF
304953	100736245	20992711333	cc	cc	NNU
304953	100736245	20992711334	of	of	IO
304953	100736245	20992711335	testosterone	testosterone	NN1
304953	100736245	20992711336	a	a	AT1
304953	100736245	20992711337	week	week	NNT1
304953	100736245	20992711338	(	(	(
304953	100736245	20992711339	injection	injection	NN1
304953	100736245	20992711340	)	)	)
304953	100736245	20992711341	.	.	.
304953	100736245	20992711342	In	in	II
304953	100736245	20992711343	Feb.		NPM1
304953	100736245	20992711344	2014	2014	MC
304953	100736245	20992711345	his	his	APPGE
304953	100736245	20992711346	PSA	psa	NP1
304953	100736245	20992711347	level	level	NN1
304953	100736245	20992711348	was	be	VBDZ
304953	100736245	20992711349	5.5	5.5	MC
304953	100736245	20992711350	ng/ml	ng/ml	FU
304953	100736245	20992711351	..	...	...
304953	100736245	20992711352	On	on	II
304953	100736245	20992711353	5/12	5/12	MF
304953	100736245	20992711354	a	a	AT1
304953	100736245	20992711355	PSA	psa	NP1
304953	100736245	20992711356	was	be	VBDZ
304953	100736245	20992711357	performed	perform	VVN
304953	100736245	20992711358	with	with	IW
304953	100736245	20992711359	a	a	AT1
304953	100736245	20992711360	result	result	NN1
304953	100736245	20992711361	of	of	IO
304953	100736245	20992711362	5.7ng/ml		NNU
304953	100736245	20992711363	..	...	...
304953	100736245	20992711364	On	on	II
304953	100736245	20992711365	5/22	5/22	MF
304953	100736245	20992711366	his	his	APPGE
304953	100736245	20992711367	urologist	urologist	NN1
304953	100736245	20992711368	ordered	order	VVD_VVN
304953	100736245	20992711369	another	another	DD1
304953	100736245	20992711370	PSA	psa	NP1
304953	100736245	20992711371	with	with	IW
304953	100736245	20992711372	a	a	AT1
304953	100736245	20992711373	free	free	JJ
304953	100736245	20992711374	PSAresults		NN2_NP1
304953	100736245	20992711375	8.5	-8.5	MC
304953	100736245	20992711376	ng/mg		FU
304953	100736245	20992711377	and	and	CC
304953	100736245	20992711378	a	a	AT1
304953	100736245	20992711379	free	free	JJ
304953	100736245	20992711380	PSA	psa	NP1
304953	100736245	20992711381	of	of	IO
304953	100736245	20992711382	.77	.77	MC
304953	100736245	20992711383	ng/ml	ng/ml	FU
304953	100736245	20992711384	or	or	CC
304953	100736245	20992711385	9.1%	9.1%	FO
304953	100736245	20992711386	in	in	II
304953	100736245	20992711387	10	10	MC
304953	100736245	20992711388	daysThe		NN1_VV0
304953	100736245	20992711389	methodology	methodology	NN1
304953	100736245	20992711390	used	use	VVD_VVN
304953	100736245	20992711391	Was	be	VBDZ
304953	100736245	20992711392	ECLIA		NP1_NN1
304953	100736245	20992711393	.	.	.
304953	100736245	20992711394	The	the	AT
304953	100736245	20992711395	Urologist		NN1_NP1
304953	100736245	20992711396	is	be	VBZ
304953	100736245	20992711397	insisting	insist	VVG
304953	100736245	20992711398	on	on	II_RP@
304953	100736245	20992711399	a	a	AT1
304953	100736245	20992711400	biopsy	biopsy	NN1
304953	100736245	20992711401	.	.	.
304953	100736245	20992711402	What	what	DDQ
304953	100736245	20992711403	are	be	VBR
304953	100736245	20992711404	the	the	AT
304953	100736245	20992711405	other	other	JJ
304953	100736245	20992711406	@		II
304953	100736245	20992711407	@		II
304953	100736245	20992711408	@		II
304953	100736245	20992711409	@		II
304953	100736245	20992711410	@		II
304953	100736245	20992711411	@		II
304953	100736245	20992711412	@		II
304953	100736245	20992711413	@		II
304953	100736245	20992711414	@		II
304953	100736245	20992711415	@		II
304953	100736245	20992711416	What	what	DDQ
304953	100736245	20992711417	would	would	VM
304953	100736245	20992711418	be	be	VBI
304953	100736245	20992711419	your	your	APPGE
304953	100736245	20992711420	recommendation	recommendation	NN1
304953	100736245	20992711421	?	?	?
304953	100736245	20992711422	a	a	AT1
304953	100736245	20992711423	repeat	repeat	NN1%_VV0
304953	100736245	20992711424	,	,	,
304953	100736245	20992711425	perhaps	perhaps	RR
304953	100736245	20992711426	?	?	?
304953	100736245	20992711427	<p>		NULL
304953	100736245	20992711428	It	it	PPH1
304953	100736245	20992711429	is	be	VBZ
304953	100736245	20992711430	hard	hard	JJ
304953	100736245	20992711431	to	to	TO
304953	100736245	20992711432	believe	believe	VVI
304953	100736245	20992711433	that	that	CST_DD1
304953	100736245	20992711434	with	with	IW
304953	100736245	20992711435	all	all	DB
304953	100736245	20992711436	the	the	AT
304953	100736245	20992711437	billions	billion	NNO2
304953	100736245	20992711438	spent	spend	VVD
304953	100736245	20992711439	on	on	II_RP@
304953	100736245	20992711440	medical	medical	JJ
304953	100736245	20992711441	research	research	NN1
304953	100736245	20992711442	no	no	PN121
304953	100736245	20992711443	one	one	PN122
304953	100736245	20992711444	has	have	VHZ
304953	100736245	20992711445	done	do	VDN
304953	100736245	20992711446	any	any	DD
304953	100736245	20992711447	research	research	NN1
304953	100736245	20992711448	on	on	II
304953	100736245	20992711449	patterns	pattern	NN2
304953	100736245	20992711450	over	over	RG
304953	100736245	20992711451	five	five	MC
304953	100736245	20992711452	years	year	NNT2
304953	100736245	20992711453	of	of	IO
304953	100736245	20992711454	psa		NN1
304953	100736245	20992711455	and	and	CC
304953	100736245	20992711456	free	free	JJ
304953	100736245	20992711457	psa		NN1
304953	100736245	20992711458	in	in	II
304953	100736245	20992711459	people	people	NN
304953	100736245	20992711460	with	with	IW
304953	100736245	20992711461	prostate	prostate	NN1
304953	100736245	20992711462	cancer	cancer	NN1
304953	100736245	20992711463	.	.	.
304953	100736245	20992711464	This	this	DD1
304953	100736245	20992711465	is	be	VBZ
304953	100736245	20992711466	beyond	beyond	II
304953	100736245	20992711467	belief	belief	NN1
304953	100736245	20992711468	.	.	.
304953	100736245	20992711469	<p>		NULL
304953	100736245	20992711470	Insist	insist	VV0
304953	100736245	20992711471	on	on	II_RP@
304953	100736245	20992711472	a	a	AT1
304953	100736245	20992711473	multi-parametric		JJ
304953	100736245	20992711474	MRI	mri	NN2_JJ_NN1
304953	100736245	20992711475	scan	scan	VV0_NN1
304953	100736245	20992711476	which	which	DDQ
304953	100736245	20992711477	concentrates	concentrate	VVZ
304953	100736245	20992711478	specifically	specifically	RR
304953	100736245	20992711479	on	on	II
304953	100736245	20992711480	the	the	AT
304953	100736245	20992711481	prostate	prostate	NN1
304953	100736245	20992711482	gland	gland	NN1
304953	100736245	20992711483	and	and	CC
304953	100736245	20992711484	close	close	JJ_VV0
304953	100736245	20992711485	organs	organ	NN2
304953	100736245	20992711486	..	...	...
304953	100736245	20992711487	My	my	APPGE
304953	100736245	20992711488	partner	partner	NN1
304953	100736245	20992711489	had	have	VHD
304953	100736245	20992711490	an	a	AT1
304953	100736245	20992711491	exam	exam	NN1
304953	100736245	20992711492	done	do	VDN
304953	100736245	20992711493	by	by	II
304953	100736245	20992711494	his	his	APPGE
304953	100736245	20992711495	GPgland		NN1@_NP1
304953	100736245	20992711496	normal	normal	JJ
304953	100736245	20992711497	size	size	NN1
304953	100736245	20992711498	although	although	CS
304953	100736245	20992711499	slightly	slightly	RR
304953	100736245	20992711500	firm	firm	JJ
304953	100736245	20992711501	..	...	...
304953	100736245	20992711502	psa		NN1
304953	100736245	20992711503	4.5	-4.5	MC
304953	100736245	20992711504	.	.	.
304953	100736245	20992711505	GP	gp	NN1
304953	100736245	20992711506	recommended	recommend	VVD_VVN
304953	100736245	20992711507	a	a	AT1
304953	100736245	20992711508	biopsy	biopsy	NN1
304953	100736245	20992711509	via	via	II
304953	100736245	20992711510	NHS	nhs	NP1
304953	100736245	20992711511	but	but	CCB
304953	100736245	20992711512	as	as	CSA
304953	100736245	20992711513	this	this	DD1
304953	100736245	20992711514	procedure	procedure	NN1
304953	100736245	20992711515	would	would	VM
304953	100736245	20992711516	distort	distort	VVI
304953	100736245	20992711517	a	a	AT1
304953	100736245	20992711518	future	future	JJ_NN1
304953	100736245	20992711519	image	image	NN1
304953	100736245	20992711520	of	of	IO
304953	100736245	20992711521	the	the	AT
304953	100736245	20992711522	gland	gland	NN1
304953	100736245	20992711523	for	for	IF
304953	100736245	20992711524	scan	scan	NN1
304953	100736245	20992711525	purposes	purpose	NN2
304953	100736245	20992711526	we	we	PPIS2
304953	100736245	20992711527	declined	decline	VVD
304953	100736245	20992711528	.	.	.
304953	100736245	20992711529	Decided	decide	VVN_VVD
304953	100736245	20992711530	on	on	II
304953	100736245	20992711531	a	a	AT1
304953	100736245	20992711532	private	private	JJ
304953	100736245	20992711533	consultancymuch		NN1
304953	100736245	20992711534	more	more	RGR
304953	100736245	20992711535	thorough	thorough	JJ
304953	100736245	20992711536	exam	exam	NN1
304953	100736245	20992711537	of	of	IO
304953	100736245	20992711538	the	the	AT
304953	100736245	20992711539	prostate	prostate	NN1
304953	100736245	20992711540	done	do	VDN
304953	100736245	20992711541	by	by	II
304953	100736245	20992711542	the	the	AT
304953	100736245	20992711543	consultantprostate		NN1
304953	100736245	20992711544	enlarged	enlarge	VVN_VVD_JJ
304953	100736245	20992711545	and	and	CC
304953	100736245	20992711546	two	two	MC
304953	100736245	20992711547	bumps	bump	NN2
304953	100736245	20992711548	found	find	VVN_VVD
304953	100736245	20992711549	!	!	!
304953	100736245	20992711550	Recommended	recommend	VVD_VVN
304953	100736245	20992711551	m.p		NNU
304953	100736245	20992711552	.	.	.
304953	100736245	20992711553	MRI	mri	NN2_NP1_JJ_NN1
304953	100736245	20992711554	as	as	CSA
304953	100736245	20992711555	above	above	RL
304953	100736245	20992711556	(	(	(
304953	100736245	20992711557	cost	cost	NN1_VV0
304953	100736245	20992711558	-700		MC
304953	100736245	20992711559	)	)	)
304953	100736245	20992711560	.	.	.
304953	100736245	20992711561	Result	result	VV0_NN1
304953	100736245	20992711562	within	within	II
304953	100736245	20992711563	3	3	MC
304953	100736245	20992711564	days	day	NNT2
304953	100736245	20992711565	..	...	...
304953	100736245	20992711566	benign	benign	JJ
304953	100736245	20992711567	hyperplasia	hyperplasia	NN1
304953	100736245	20992711568	..	...	...
304953	100736245	20992711569	continue	continue	VV0
304953	100736245	20992711570	to	to	TO
304953	100736245	20992711571	monitor	monitor	VVI
304953	100736245	20992711572	psa		NN1
304953	100736245	20992711573	every	every	AT1
304953	100736245	20992711574	3	3	MC
304953	100736245	20992711575	months	month	NNT2
304953	100736245	20992711576	..	...	...
304953	100736245	20992711577	further	further	VV0%_RRR
304953	100736245	20992711578	checks	check	NN2_VVZ
304953	100736245	20992711579	if	if	CS
304953	100736245	20992711580	psa		NN1
304953	100736245	20992711581	rises	rise	VVZ_NN2
304953	100736245	20992711582	by	by	II
304953	100736245	20992711583	more	more	DAR
304953	100736245	20992711584	than	than	CSN
304953	100736245	20992711585	1.0	1.0	MC
304953	100736245	20992711586	over	over	II
304953	100736245	20992711587	a	a	AT1
304953	100736245	20992711588	12	12	MC
304953	100736245	20992711589	month	month	NNT1
304953	100736245	20992711590	period	period	NN1
304953	100736245	20992711591	.	.	.
304953	100736245	20992711592	My	my	APPGE
304953	100736245	20992711593	partner	partner	NN1
304953	100736245	20992711594	is	be	VBZ
304953	100736245	20992711595	54	54	MC
304953	100736245	20992711596	and	and	CC
304953	100736245	20992711597	his	his	APPGE
304953	100736245	20992711598	father	father	NN1
304953	100736245	20992711599	had	have	VHD
304953	100736245	20992711600	prostate	prostate	NN1
304953	100736245	20992711601	cancer	cancer	NN1
304953	100736245	20992711602	so	so	CS@_RR
304953	100736245	20992711603	he	he	PPHS1
304953	100736245	20992711604	was	be	VBDZ
304953	100736245	20992711605	under	under	RG@
304953	100736245	20992711606	@		II
304953	100736245	20992711607	@		II
304953	100736245	20992711608	@		II
304953	100736245	20992711609	@		II
304953	100736245	20992711610	@		II
304953	100736245	20992711611	@		II
304953	100736245	20992711612	@		II
304953	100736245	20992711613	@		II
304953	100736245	20992711614	@		II
304953	100736245	20992711615	@		II
304953	100736245	20992711616	in	in	II
304953	100736245	20992711617	my	my	APPGE
304953	100736245	20992711618	opinion	opinion	NN1
304953	100736245	20992711619	,	,	,
304953	100736245	20992711620	it	it	PPH1
304953	100736245	20992711621	would	would	VM
304953	100736245	20992711622	be	be	VBI
304953	100736245	20992711623	looking	look	VVG
304953	100736245	20992711624	for	for	IF
304953	100736245	20992711625	a	a	AT1
304953	100736245	20992711626	needle	needle	NN1
304953	100736245	20992711627	in	in	II
304953	100736245	20992711628	a	a	AT1
304953	100736245	20992711629	hay	hay	NN1
304953	100736245	20992711630	stack	stack	NN1
304953	100736245	20992711631	.	.	.
304953	100736245	20992711632	<p>		NULL
304953	100736245	20992711633	I	i	PPIS1
304953	100736245	20992711634	understand	understand	VV0
304953	100736245	20992711635	there	there	RL_EX
304953	100736245	20992711636	has	have	VHZ
304953	100736245	20992711637	recently	recently	RR
304953	100736245	20992711638	been	be	VBN
304953	100736245	20992711639	a	a	AT1
304953	100736245	20992711640	change	change	NN1
304953	100736245	20992711641	of	of	IO
304953	100736245	20992711642	thinking	think	VVG_NN1
304953	100736245	20992711643	in	in	II
304953	100736245	20992711644	the	the	AT
304953	100736245	20992711645	NHS	nhs	NP1
304953	100736245	20992711646	in	in	CS21%_II
304953	100736245	20992711647	that	that	CS22@_DD1
304953	100736245	20992711648	they	they	PPHS2
304953	100736245	20992711649	no	no	RR21
304953	100736245	20992711650	longer	long	RR22
304953	100736245	20992711651	just	just	RR
304953	100736245	20992711652	go	go	VV0
304953	100736245	20992711653	for	for	IF
304953	100736245	20992711654	a	a	AT1
304953	100736245	20992711655	biopsy	biopsy	NN1
304953	100736245	20992711656	but	but	CCB
304953	100736245	20992711657	think	think	VV0
304953	100736245	20992711658	more	more	RRR_DAR
304953	100736245	20992711659	about	about	II
304953	100736245	20992711660	MRI	mri	NP1_NN2_NN1_JJ
304953	100736245	20992711661	and	and	CC
304953	100736245	20992711662	f	f	ZZ1
304953	100736245	20992711663	necessary	necessary	JJ
304953	100736245	20992711664	any	any	RR%_DD
304953	100736245	20992711665	identified	identify	VVN_VVD@_JJ%
304953	100736245	20992711666	possible	possible	JJ
304953	100736245	20992711667	tumour	tumor	NN1
304953	100736245	20992711668	areas	area	NN2
304953	100736245	20992711669	can	can	VM
304953	100736245	20992711670	be	be	VBI
304953	100736245	20992711671	targeted	target	VVN
304953	100736245	20992711672	for	for	IF
304953	100736245	20992711673	biopsy	biopsy	NN1
304953	100736245	20992711674	.	.	.
304953	100736245	20992711675	Wish	wish	VV0
304953	100736245	20992711676	this	this	DD1
304953	100736245	20992711677	policy	policy	NN1
304953	100736245	20992711678	had	have	VHD
304953	100736245	20992711679	been	be	VBN
304953	100736245	20992711680	adopted	adopt	VVN
304953	100736245	20992711681	much	much	RR_DA1
304953	100736245	20992711682	earlier	early	RRR_JJR
304953	100736245	20992711683	.	.	.
304953	100736245	20992711684	Hope	hope	VV0
304953	100736245	20992711685	this	this	DD1
304953	100736245	20992711686	helps	help	VVZ
304953	100736245	20992711687	someoneCarol		NN1
304953	100736245	20992711688	46996		MC
304953	100736245	20992711689	@qwx906996		FO
304953	100736247	20992711709	@@##	----------	----------
304953	100736247	20992711710	@@100736247		FO
304953	100736247	20992711711	@4936247/		NN1_VV0
304953	100736247	20992711712	<p>		NULL
304953	100736247	20992711713	Concern	concern	VV0@_NN1
304953	100736247	20992711714	that	that	CST_DD1
304953	100736247	20992711715	getting	get	VVG
304953	100736247	20992711716	a	a	AT1
304953	100736247	20992711717	vasectomy	vasectomy	NN1
304953	100736247	20992711718	could	could	VM
304953	100736247	20992711719	lead	lead	VVI
304953	100736247	20992711720	to	to	II
304953	100736247	20992711721	prostate	prostate	NN1
304953	100736247	20992711722	cancer	cancer	NN1
304953	100736247	20992711723	flared	flare	VVD_VVN@
304953	100736247	20992711724	in	in	II
304953	100736247	20992711725	1993	1993	MC
304953	100736247	20992711726	when	when	RRQ
304953	100736247	20992711727	the	the	AT
304953	100736247	20992711728	Harvard	harvard	NP1
304953	100736247	20992711729	Health	health	NN1
304953	100736247	20992711730	Professionals	professional	NN2
304953	100736247	20992711731	Follow-up	follow-up	JJ_NN1
304953	100736247	20992711732	Study	study	NN1
304953	100736247	20992711733	reported	report	VVD_VVN
304953	100736247	20992711734	that	that	CST
304953	100736247	20992711735	men	man	NN2
304953	100736247	20992711736	who	who	PNQS
304953	100736247	20992711737	had	have	VHD
304953	100736247	20992711738	undergone	undergo	VVN
304953	100736247	20992711739	vasectomies	vasectomy	NN2
304953	100736247	20992711740	were	be	VBDR
304953	100736247	20992711741	about	about	RG%_II
304953	100736247	20992711742	one-and-a-half	one-and-a-half	MF
304953	100736247	20992711743	times	time	NNT2
304953	100736247	20992711744	more	more	RRR_RGR
304953	100736247	20992711745	likely	likely	JJ
304953	100736247	20992711746	to	to	TO
304953	100736247	20992711747	develop	develop	VVI
304953	100736247	20992711748	prostate	prostate	NN1
304953	100736247	20992711749	cancer	cancer	NN1
304953	100736247	20992711750	than	than	CSN
304953	100736247	20992711751	men	man	NN2
304953	100736247	20992711752	who	who	PNQS
304953	100736247	20992711753	had	have	VHD
304953	100736247	20992711754	not	not	XX
304953	100736247	20992711755	had	have	VHN
304953	100736247	20992711756	the	the	AT
304953	100736247	20992711757	operation	operation	NN1
304953	100736247	20992711758	.	.	.
304953	100736247	20992711759	The	the	AT
304953	100736247	20992711760	study	study	NN1
304953	100736247	20992711761	was	be	VBDZ
304953	100736247	20992711762	careful	careful	JJ
304953	100736247	20992711763	and	and	CC
304953	100736247	20992711764	large	large	JJ
304953	100736247	20992711765	,	,	,
304953	100736247	20992711766	including	including	II
304953	100736247	20992711767	10,055		MC
304953	100736247	20992711768	men	man	NN2
304953	100736247	20992711769	who	who	PNQS
304953	100736247	20992711770	'd	have	VHD
304953	100736247	20992711771	had	have	VHN
304953	100736247	20992711772	vasectomies	vasectomy	NN2
304953	100736247	20992711773	and	and	CC
304953	100736247	20992711774	37,800		MC
304953	100736247	20992711775	who	who	PNQS
304953	100736247	20992711776	had	have	VHD
304953	100736247	20992711777	not	not	XX
304953	100736247	20992711778	.	.	.
304953	100736247	20992711779	Still	still	RR
304953	100736247	20992711780	,	,	,
304953	100736247	20992711781	many	many	DA2
304953	100736247	20992711782	experts	expert	NN2
304953	100736247	20992711783	were	be	VBDR
304953	100736247	20992711784	skeptical	skeptical	JJ
304953	100736247	20992711785	,	,	,
304953	100736247	20992711786	pointing	point	VVG
304953	100736247	20992711787	out	out	RP
304953	100736247	20992711788	that	that	CST
304953	100736247	20992711789	there	there	EX
304953	100736247	20992711790	were	be	VBDR
304953	100736247	20992711791	only	only	JJ
304953	100736247	20992711792	300		NN1
304953	100736247	20992711793	newly	newly	RR
304953	100736247	20992711794	diagnosed	diagnose	VVN_VVD
304953	100736247	20992711795	cases	case	NN2
304953	100736247	20992711796	of	of	IO
304953	100736247	20992711797	prostate	prostate	NN1
304953	100736247	20992711798	cancer	cancer	NN1
304953	100736247	20992711799	in	in	II
304953	100736247	20992711800	the	the	AT
304953	100736247	20992711801	entire	entire	JJ
304953	100736247	20992711802	group	group	NN1
304953	100736247	20992711803	.	.	.
304953	100736247	20992711804	Some	some	DD
304953	100736247	20992711805	also	also	RR
304953	100736247	20992711806	noted	note	VVN_VVD
304953	100736247	20992711807	that	that	CST
304953	100736247	20992711808	men	man	NN2
304953	100736247	20992711809	who	who	PNQS
304953	100736247	20992711810	had	have	VHD
304953	100736247	20992711811	undergone	undergo	VVN
304953	100736247	20992711812	vasectomy	vasectomy	NN1
304953	100736247	20992711813	were	be	VBDR
304953	100736247	20992711814	more	more	RGR
304953	100736247	20992711815	likely	likely	JJ
304953	100736247	20992711816	to	to	TO
304953	100736247	20992711817	be	be	VBI
304953	100736247	20992711818	under	under	II
304953	100736247	20992711819	the	the	AT
304953	100736247	20992711820	care	care	NN1
304953	100736247	20992711821	of	of	IO
304953	100736247	20992711822	a	a	AT1
304953	100736247	20992711823	urologist	urologist	NN1
304953	100736247	20992711824	and	and	CC
304953	100736247	20992711825	undergo	undergo	VV0
304953	100736247	20992711826	tests	test	NN2
304953	100736247	20992711827	leading	lead	VVG
304953	100736247	20992711828	to	to	II
304953	100736247	20992711829	the	the	AT
304953	100736247	20992711830	diagnosis	diagnosis	NN1
304953	100736247	20992711831	of	of	IO
304953	100736247	20992711832	early	early	JJ_RR
304953	100736247	20992711833	,	,	,
304953	100736247	20992711834	clinically	clinically	RR
304953	100736247	20992711835	silent	silent	JJ
304953	100736247	20992711836	prostate	prostate	NN1
304953	100736247	20992711837	cancer	cancer	NN1
304953	100736247	20992711838	.	.	.
304953	100736247	20992711839	<p>		NULL
304953	100736247	20992711840	Indeed	indeed	RR
304953	100736247	20992711841	,	,	,
304953	100736247	20992711842	many	many	DA2
304953	100736247	20992711843	studies	study	NN2
304953	100736247	20992711844	since	since	II
304953	100736247	20992711845	1993	1993	MC
304953	100736247	20992711846	have	have	VH0
304953	100736247	20992711847	failed	fail	VVN
304953	100736247	20992711848	to	to	TO
304953	100736247	20992711849	find	find	VVI
304953	100736247	20992711850	a	a	AT1
304953	100736247	20992711851	link	link	NN1
304953	100736247	20992711852	between	between	II
304953	100736247	20992711853	a	a	AT1
304953	100736247	20992711854	vasectomy	vasectomy	NN1
304953	100736247	20992711855	and	and	CC
304953	100736247	20992711856	prostate	prostate	NN1
304953	100736247	20992711857	cancer	cancer	NN1
304953	100736247	20992711858	,	,	,
304953	100736247	20992711859	and	and	CC
304953	100736247	20992711860	scientists	scientist	NN2
304953	100736247	20992711861	have	have	VH0
304953	100736247	20992711862	been	be	VBN
304953	100736247	20992711863	unable	unable	JK
304953	100736247	20992711864	to	to	TO
304953	100736247	20992711865	identify	identify	VVI
304953	100736247	20992711866	a	a	AT1
304953	100736247	20992711867	biologically	biologically	RR
304953	100736247	20992711868	plausible	plausible	JJ
304953	100736247	20992711869	reason	reason	NN1
304953	100736247	20992711870	why	why	RRQ
304953	100736247	20992711871	vasectomy	vasectomy	NN1
304953	100736247	20992711872	might	might	VM
304953	100736247	20992711873	increase	increase	VVI
304953	100736247	20992711874	a	a	AT1
304953	100736247	20992711875	man	man	NN1
304953	100736247	20992711876	's	's	GE
304953	100736247	20992711877	cancer	cancer	NN1
304953	100736247	20992711878	risk	risk	NN1
304953	100736247	20992711879	.	.	.
304953	100736247	20992711880	At	at	RR21
304953	100736247	20992711881	present	present	RR22
304953	100736247	20992711882	,	,	,
304953	100736247	20992711883	most	most	DAT
304953	100736247	20992711884	authorities	authority	NN2
304953	100736247	20992711885	,	,	,
304953	100736247	20992711886	including	including	II_VVG@
304953	100736247	20992711887	the	the	AT
304953	100736247	20992711888	National	national	JJ
304953	100736247	20992711889	Cancer	cancer	NN1
304953	100736247	20992711890	Institute	institute	NN1
304953	100736247	20992711891	and	and	CC
304953	100736247	20992711892	the	the	AT
304953	100736247	20992711893	American	american	JJ
304953	100736247	20992711894	Urological	urological	JJ
304953	100736247	20992711895	Association	association	NN1
304953	100736247	20992711896	,	,	,
304953	100736247	20992711897	agree	agree	VV0
304953	100736247	20992711898	that	that	DD1_CST
304953	100736247	20992711899	vasectomy	vasectomy	NN1
304953	100736247	20992711900	does	do	VDZ
304953	100736247	20992711901	@		II
304953	100736247	20992711902	@		II
304953	100736247	20992711903	@		II
304953	100736247	20992711904	@		II
304953	100736247	20992711905	@		II
304953	100736247	20992711906	@		II
304953	100736247	20992711907	@		II
304953	100736247	20992711908	@		II
304953	100736247	20992711909	@		II
304953	100736247	20992711910	@		II
304953	100736247	20992711911	should	should	VM
304953	100736247	20992711912	still	still	RR
304953	100736247	20992711913	consider	consider	VVI
304953	100736247	20992711914	your	your	APPGE
304953	100736247	20992711915	options	option	NN2
304953	100736247	20992711916	carefully	carefully	RR
304953	100736247	20992711917	.	.	.
304953	100736247	20992711918	A	a	AT1
304953	100736247	20992711919	vasectomy	vasectomy	NN1
304953	100736247	20992711920	will	will	VM
304953	100736247	20992711921	make	make	VVI
304953	100736247	20992711922	you	you	PPY
304953	100736247	20992711923	unable	unable	JK
304953	100736247	20992711924	to	to	TO
304953	100736247	20992711925	father	father	NN1
304953	100736247	20992711926	children	child	NN2
304953	100736247	20992711927	(	(	(
304953	100736247	20992711928	see	see	VV0
304953	100736247	20992711929	illustration	illustration	NN1
304953	100736247	20992711930	below	below	RL
304953	100736247	20992711931	)	)	)
304953	100736247	20992711932	.	.	.
304953	100736247	20992711933	Although	although	CS
304953	100736247	20992711934	a	a	AT1
304953	100736247	20992711935	vasectomy	vasectomy	NN1
304953	100736247	20992711936	can	can	VM
304953	100736247	20992711937	be	be	VBI
304953	100736247	20992711938	reversed	reverse	VVN
304953	100736247	20992711939	,	,	,
304953	100736247	20992711940	the	the	AT
304953	100736247	20992711941	procedure	procedure	NN1
304953	100736247	20992711942	is	be	VBZ
304953	100736247	20992711943	expensive	expensive	JJ
304953	100736247	20992711944	and	and	CC
304953	100736247	20992711945	not	not	XX
304953	100736247	20992711946	always	always	RR
304953	100736247	20992711947	successful	successful	JJ
304953	100736247	20992711948	at	at	II
304953	100736247	20992711949	restoring	restoring	JJ_VVG
304953	100736247	20992711950	fertility	fertility	NN1
304953	100736247	20992711951	.	.	.
304953	100736247	20992711952	If	if	CS
304953	100736247	20992711953	you	you	PPY
304953	100736247	20992711954	have	have	VH0
304953	100736247	20992711955	even	even	RR
304953	100736247	20992711956	the	the	AT
304953	100736247	20992711957	slightest	slight	JJT
304953	100736247	20992711958	doubt	doubt	NN1
304953	100736247	20992711959	about	about	II
304953	100736247	20992711960	ending	end	VVG
304953	100736247	20992711961	your	your	APPGE
304953	100736247	20992711962	chances	chance	NN2
304953	100736247	20992711963	for	for	IF
304953	100736247	20992711964	future	future	JJ_NN1
304953	100736247	20992711965	fatherhood	fatherhood	NN1
304953	100736247	20992711966	,	,	,
304953	100736247	20992711967	I	i	PPIS1
304953	100736247	20992711968	'd	have	VM
304953	100736247	20992711969	encourage	encourage	VVI
304953	100736247	20992711970	you	you	PPY
304953	100736247	20992711971	to	to	TO
304953	100736247	20992711972	hold	hold	VVI
304953	100736247	20992711973	off	off	RP
304953	100736247	20992711974	on	on	II
304953	100736247	20992711975	the	the	AT
304953	100736247	20992711976	vasectomy	vasectomy	NN1
304953	100736247	20992711977	and	and	CC
304953	100736247	20992711978	use	use	VVI
304953	100736247	20992711979	another	another	DD1
304953	100736247	20992711980	form	form	NN1
304953	100736247	20992711981	of	of	IO
304953	100736247	20992711982	birth	birth	NN1
304953	100736247	20992711983	control	control	NN1
304953	100736247	20992711984	.	.	.
304953	100736247	20992711985	<h>		NULL
304953	100736247	20992711986	A	a	AT1
304953	100736247	20992711987	vasectomy	vasectomy	NN1
304953	100736247	20992711988	<p>		NULL
304953	100736247	20992711989	During	during	II
304953	100736247	20992711990	a	a	AT1
304953	100736247	20992711991	vasectomy	vasectomy	NN1
304953	100736247	20992711992	,	,	,
304953	100736247	20992711993	a	a	AT1
304953	100736247	20992711994	doctor	doctor	NN1
304953	100736247	20992711995	will	will	VM
304953	100736247	20992711996	cut	cut	VVI
304953	100736247	20992711997	the	the	AT
304953	100736247	20992711998	vas	vas	NN2
304953	100736247	20992711999	deferens	deferens	NN2
304953	100736247	20992712000	,	,	,
304953	100736247	20992712001	the	the	AT
304953	100736247	20992712002	tube	tube	NN1
304953	100736247	20992712003	that	that	CST_DD1
304953	100736247	20992712004	transports	transport	VVZ
304953	100736247	20992712005	sperm	sperm	NN
304953	100736247	20992712006	from	from	II
304953	100736247	20992712007	the	the	AT
304953	100736247	20992712008	epididymis	epididymis	NN1
304953	100736247	20992712009	to	to	II
304953	100736247	20992712010	the	the	AT
304953	100736247	20992712011	seminal	seminal	JJ
304953	100736247	20992712012	vesicles	vesicle	NN2
304953	100736247	20992712013	,	,	,
304953	100736247	20992712014	through	through	II
304953	100736247	20992712015	small	small	JJ
304953	100736247	20992712016	incisions	incision	NN2
304953	100736247	20992712017	in	in	II
304953	100736247	20992712018	the	the	AT
304953	100736247	20992712019	scrotum	scrotum	NN1
304953	100736247	20992712020	.	.	.
304953	100736247	20992712021	This	this	DD1
304953	100736247	20992712022	keeps	keep	VVZ
304953	100736247	20992712023	sperm	sperm	NN
304953	100736247	20992712024	from	from	II
304953	100736247	20992712025	entering	enter	VVG
304953	100736247	20992712026	semen	semen	NN1
304953	100736247	20992712027	and	and	CC
304953	100736247	20992712028	prevents	prevent	VVZ
304953	100736247	20992712029	conception	conception	NN1
304953	100736247	20992712030	.	.	.
304953	100736247	20992712031	The	the	AT
304953	100736247	20992712032	testicles	testicle	NN2
304953	100736247	20992712033	continue	continue	VV0
304953	100736247	20992712034	to	to	TO
304953	100736247	20992712035	produce	produce	VVI
304953	100736247	20992712036	sperm	sperm	NN
304953	100736247	20992712037	,	,	,
304953	100736247	20992712038	but	but	CCB
304953	100736247	20992712039	the	the	AT
304953	100736247	20992712040	sperm	sperm	NN
304953	100736247	20992712041	are	be	VBR
304953	100736247	20992712042	absorbed	absorb	VVN
304953	100736247	20992712043	by	by	II
304953	100736247	20992712044	the	the	AT
304953	100736247	20992712045	body	body	NN1
304953	100736247	20992712046	.	.	.
304953	100736247	20992712047	Semen	semen	NN1
304953	100736247	20992712048	is	be	VBZ
304953	100736247	20992712049	still	still	RR
304953	100736247	20992712050	ejaculated	ejaculate	VVN
304953	100736247	20992712051	,	,	,
304953	100736247	20992712052	but	but	CCB
304953	100736247	20992712053	it	it	PPH1
304953	100736247	20992712054	contains	contain	VVZ
304953	100736247	20992712055	no	no	AT
304953	100736247	20992712056	sperm	sperm	NN
304953	100736247	20992712057	.	.	.
304953	100736247	20992712058	<p>		NULL
304953	100736247	20992712059	Prostate	prostate	NN1
304953	100736247	20992712060	cancer	cancer	NN1
304953	100736247	20992712061	is	be	VBZ
304953	100736247	20992712062	the	the	AT
304953	100736247	20992712063	least	least	DAT_RRT
304953	100736247	20992712064	of	of	IO
304953	100736247	20992712065	your	your	APPGE
304953	100736247	20992712066	worries	worry	NN2
304953	100736247	20992712067	.	.	.
304953	100736247	20992712068	I	i	PPIS1
304953	100736247	20992712069	had	have	VHD
304953	100736247	20992712070	a	a	AT1
304953	100736247	20992712071	vas	vas	NN2
304953	100736247	20992712072	when	when	RRQ_CS
304953	100736247	20992712073	i	i	ZZ1_MC1
304953	100736247	20992712074	was	be	VBDZ
304953	100736247	20992712075	27	27	MC
304953	100736247	20992712076	,	,	,
304953	100736247	20992712077	at	at	II
304953	100736247	20992712078	age	age	NN1
304953	100736247	20992712079	48	48	MC
304953	100736247	20992712080	my	my	APPGE
304953	100736247	20992712081	testosterone	testosterone	NN1
304953	100736247	20992712082	levels	level	NN2
304953	100736247	20992712083	were	be	VBDR
304953	100736247	20992712084	in	in	II
304953	100736247	20992712085	rhe	rhe	NN1
304953	100736247	20992712086	celler		NN1
304953	100736247	20992712087	.	.	.
304953	100736247	20992712088	Reasearch		VV0_NN1_NP1@
304953	100736247	20992712089	shows	show	NN2_VVZ
304953	100736247	20992712090	there	there	EX_RL
304953	100736247	20992712091	is	be	VBZ
304953	100736247	20992712092	a	a	AT1
304953	100736247	20992712093	coorlation		NN1
304953	100736247	20992712094	between	between	II
304953	100736247	20992712095	a	a	AT1
304953	100736247	20992712096	vasectomy	vasectomy	NN1
304953	100736247	20992712097	and	and	CC
304953	100736247	20992712098	later	later	RRR_JJR
304953	100736247	20992712099	low	low	JJ
304953	100736247	20992712100	testosterone	testosterone	NN1
304953	100736247	20992712101	@		II
304953	100736247	20992712102	@		II
304953	100736247	20992712103	@		II
304953	100736247	20992712104	@		II
304953	100736247	20992712105	@		II
304953	100736247	20992712106	@		II
304953	100736247	20992712107	@		II
304953	100736247	20992712108	@		II
304953	100736247	20992712109	@		II
304953	100736247	20992712110	@		II
304953	100736247	20992712111	testosterone	testosterone	NN1
304953	100736247	20992712112	gell		NN1
304953	100736247	20992712113	and	and	CC
304953	100736247	20992712114	am	be	VBM
304953	100736247	20992712115	watching	watch	VVG
304953	100736247	20992712116	my	my	APPGE
304953	100736247	20992712117	balls	ball	NN2
304953	100736247	20992712118	simply	simply	RR
304953	100736247	20992712119	shrivel	shrivel	VV0
304953	100736247	20992712120	up	up	RP
304953	100736247	20992712121	.	.	.
304953	100736247	20992712122	<p>		NULL
304953	100736247	20992712123	about	about	II
304953	100736247	20992712124	vasectomies	vasectomy	NN2
304953	100736247	20992712125	causing	cause	VVG
304953	100736247	20992712126	prostate	prostate	NN1
304953	100736247	20992712127	cancer	cancer	NN1
304953	100736247	20992712128	were	be	VBDR
304953	100736247	20992712129	first	first	MD
304953	100736247	20992712130	raised	raise	VVN_VVD
304953	100736247	20992712131	after	after	II_CS
304953	100736247	20992712132	the	the	AT
304953	100736247	20992712133	publication	publication	NN1
304953	100736247	20992712134	of	of	IO
304953	100736247	20992712135	a	a	AT1
304953	100736247	20992712136	1993	1993	MC
304953	100736247	20992712137	Harvard	harvard	NP1
304953	100736247	20992712138	study	study	NN1
304953	100736247	20992712139	,	,	,
304953	100736247	20992712140	which	which	DDQ
304953	100736247	20992712141	analyzed	analyze	VVD
304953	100736247	20992712142	a	a	AT1
304953	100736247	20992712143	group	group	NN1
304953	100736247	20992712144	of	of	IO
304953	100736247	20992712145	over	over	RG
304953	100736247	20992712146	10,000	10,000	MC
304953	100736247	20992712147	men	man	NN2
304953	100736247	20992712148	who	who	PNQS
304953	100736247	20992712149	had	have	VHD
304953	100736247	20992712150	vasectomies	vasectomy	NN2
304953	100736247	20992712151	and	and	CC
304953	100736247	20992712152	roughly	roughly	RR
304953	100736247	20992712153	37,800		MC
304953	100736247	20992712154	who	who	PNQS
304953	100736247	20992712155	had	have	VHD
304953	100736247	20992712156	not	not	XX
304953	100736247	20992712157	<p>		NULL
304953	100736247	20992712158	Ltg		NP1
304953	100736247	20992712159	Curious	curious	JJ
304953	100736247	20992712160	as	as	II21
304953	100736247	20992712161	to	to	II22
304953	100736247	20992712162	this	this	DD1
304953	100736247	20992712163	study	study	NN1
304953	100736247	20992712164	.	.	.
304953	100736247	20992712165	I	i	PPIS1
304953	100736247	20992712166	had	have	VHD
304953	100736247	20992712167	a	a	AT1
304953	100736247	20992712168	vasectomy	vasectomy	NN1
304953	100736247	20992712169	in	in	II
304953	100736247	20992712170	96	96	MC
304953	100736247	20992712171	and	and	CC
304953	100736247	20992712172	am	be	VBM_RA@
304953	100736247	20992712173	now	now	RT
304953	100736247	20992712174	52	52	MC
304953	100736247	20992712175	.	.	.
304953	100736247	20992712176	Just	just	RR
304953	100736247	20992712177	had	have	VHN@_VHD
304953	100736247	20992712178	my	my	APPGE
304953	100736247	20992712179	testosterone	testosterone	NN1
304953	100736247	20992712180	tested	test	VVN
304953	100736247	20992712181	just	just	RR
304953	100736247	20992712182	to	to	TO
304953	100736247	20992712183	see	see	VVI
304953	100736247	20992712184	.	.	.
304953	100736247	20992712185	I	i	PPIS1
304953	100736247	20992712186	work	work	VV0
304953	100736247	20992712187	out	out	RP
304953	100736247	20992712188	lifting	lift	VVG_NN1
304953	100736247	20992712189	and	and	CC
304953	100736247	20992712190	have	have	VH0
304953	100736247	20992712191	a	a	AT1
304953	100736247	20992712192	diet	diet	NN1
304953	100736247	20992712193	that	that	CST_DD1
304953	100736247	20992712194	is	be	VBZ
304953	100736247	20992712195	supposed	supposed	JJ
304953	100736247	20992712196	to	to	TO
304953	100736247	20992712197	promote	promote	VVI
304953	100736247	20992712198	testosterone	testosterone	NN1
304953	100736247	20992712199	.	.	.
304953	100736247	20992712200	Well	well	RR
304953	100736247	20992712201	results	result	VVZ@_NN2
304953	100736247	20992712202	from	from	II
304953	100736247	20992712203	the	the	AT
304953	100736247	20992712204	Mayo	mayo	NP1
304953	100736247	20992712205	CLinic		NN1
304953	100736247	20992712206	had	have	VHD
304953	100736247	20992712207	a	a	AT1
304953	100736247	20992712208	range	range	NN1
304953	100736247	20992712209	of	of	IO
304953	100736247	20992712210	240	240	MC
304953	100736247	20992712211	950	950	MC
304953	100736247	20992712212	which	which	DDQ
304953	100736247	20992712213	means	mean	VVZ
304953	100736247	20992712214	that	that	CST
304953	100736247	20992712215	so	so	RG
304953	100736247	20992712216	far	far	RR
304953	100736247	20992712217	is	be	VBZ
304953	100736247	20992712218	what	what	DDQ
304953	100736247	20992712219	they	they	PPHS2
304953	100736247	20992712220	have	have	VH0
304953	100736247	20992712221	tested	test	VVN
304953	100736247	20992712222	.	.	.
304953	100736247	20992712223	I	i	PPIS1
304953	100736247	20992712224	was	be	VBDZ
304953	100736247	20992712225	983	983	MC
304953	100736247	20992712226	.	.	.
304953	100736247	20992712227	I	i	PPIS1
304953	100736247	20992712228	have	have	VH0
304953	100736247	20992712229	found	find	VVN
304953	100736247	20992712230	that	that	CST
304953	100736247	20992712231	my	my	APPGE
304953	100736247	20992712232	numbers	number	NN2
304953	100736247	20992712233	are	be	VBR
304953	100736247	20992712234	in	in	II
304953	100736247	20992712235	the	the	AT
304953	100736247	20992712236	upper	upper	JJ
304953	100736247	20992712237	end	end	NN1
304953	100736247	20992712238	for	for	IF
304953	100736247	20992712239	all	all	DB
304953	100736247	20992712240	ages	age	NN2
304953	100736247	20992712241	and	and	CC
304953	100736247	20992712242	from	from	II
304953	100736247	20992712243	variety	variety	NN1
304953	100736247	20992712244	of	of	IO
304953	100736247	20992712245	test	test	NN1
304953	100736247	20992712246	ages	age	VVZ@_NN2
304953	100736247	20992712247	only	only	JJ
304953	100736247	20992712248	those	those-	DD2
304953	100736247	20992712249	around	around	RG
304953	100736247	20992712250	19	19	MC
304953	100736247	20992712251	years	year	NNT2
304953	100736247	20992712252	old	old	JJ
304953	100736247	20992712253	had	have	VHD
304953	100736247	20992712254	higher	high	RRR@_JJR
304953	100736247	20992712255	.	.	.
304953	100736247	20992712256	NO	no	UH
304953	100736247	20992712257	I	i	PPIS1
304953	100736247	20992712258	do	do	VD0
304953	100736247	20992712259	not	not	XX
304953	100736247	20992712260	take	take	VVI
304953	100736247	20992712261	any	any	DD
304953	100736247	20992712262	hormones	hormone	NN2
304953	100736247	20992712263	or	or	CC
304953	100736247	20992712264	steroids	steroids	NN2
304953	100736247	20992712265	at	at	RR21
304953	100736247	20992712266	all	all	RR22
304953	100736247	20992712267	.	.	.
304953	100736247	20992712268	<p>		NULL
304953	100736247	20992712269	I	i	PPIS1
304953	100736247	20992712270	wonder	wonder	VV0
304953	100736247	20992712271	if	if	CS
304953	100736247	20992712272	having	have	VHG
304953	100736247	20992712273	a	a	AT1
304953	100736247	20992712274	reversal	reversal	NN1
304953	100736247	20992712275	would	would	VM
304953	100736247	20992712276	impact	impact	VVI
304953	100736247	20992712277	the	the	AT
304953	100736247	20992712278	results	result	NN2
304953	100736247	20992712279	(	(	(
304953	100736247	20992712280	AKA	aka	NP1_NN1
304953	100736247	20992712281	clearing	clear	VVG
304953	100736247	20992712282	out	out	RP
304953	100736247	20992712283	the	the	AT
304953	100736247	20992712284	pipes	pipe	NN2
304953	100736247	20992712285	is	be	VBZ
304953	100736247	20992712286	good	good	JJ
304953	100736247	20992712287	health	health	NN1
304953	100736247	20992712288	)	)	)
304953	100736247	20992712289	,	,	,
304953	100736247	20992712290	the	the	AT
304953	100736247	20992712291	type	type	NN1
304953	100736247	20992712292	of	of	IO
304953	100736247	20992712293	vas	vas	NN2
304953	100736247	20992712294	(	(	(
304953	100736247	20992712295	what	what	DDQ
304953	100736247	20992712296	type	type	NN1
304953	100736247	20992712297	metal	metal	NN1
304953	100736247	20992712298	clip	clip	NN1_VV0
304953	100736247	20992712299	etc	etc	RA
304953	100736247	20992712300	used	used	JJ_VVD
304953	100736247	20992712301	@		II
304953	100736247	20992712302	@		II
304953	100736247	20992712303	@		II
304953	100736247	20992712304	@		II
304953	100736247	20992712305	@		II
304953	100736247	20992712306	@		II
304953	100736247	20992712307	@		II
304953	100736247	20992712308	@		II
304953	100736247	20992712309	@		II
304953	100736247	20992712310	@		II
304953	100736247	20992712311	)	)	)
304953	100736247	20992712312	.	.	.
304953	100736247	20992712313	So	so	RG
304953	100736247	20992712314	many	many	DA2
304953	100736247	20992712315	questions	question	NN2
304953	100736247	20992712316	that	that	CST_DD1
304953	100736247	20992712317	may	may	VM
304953	100736247	20992712318	answer	answer	VVI
304953	100736247	20992712319	this	this	DD1
304953	100736247	20992712320	issue	issue	NN1
304953	100736247	20992712321	.	.	.
304953	100736247	20992712322	Ive		NN1_NP1@
304953	100736247	20992712323	notices	notice	VVZ
304953	100736247	20992712324	the	the	AT
304953	100736247	20992712325	T	t	ZZ1_NP1@
304953	100736247	20992712326	drop	drop	VV0_NN1
304953	100736247	20992712327	in	in	II_RP@
304953	100736247	20992712328	my	my	APPGE
304953	100736247	20992712329	hubs	hub	NN2
304953	100736247	20992712330	and	and	CC
304953	100736247	20992712331	its	its	APPGE
304953	100736247	20992712332	sad	sad	JJ
304953	100736247	20992712333	,	,	,
304953	100736247	20992712334	but	but	CCB
304953	100736247	20992712335	cancer	cancer	NN1
304953	100736247	20992712336	is	be	VBZ
304953	100736247	20992712337	WAY	way	NN1
304953	100736247	20992712338	worse	bad	JJR_RRR@
304953	100736247	20992712339	and	and	CC
304953	100736247	20992712340	it	it	PPH1
304953	100736247	20992712341	seems	seem	VVZ
304953	100736247	20992712342	to	to	TO
304953	100736247	20992712343	be	be	VBI
304953	100736247	20992712344	pretty	pretty	RG
304953	100736247	20992712345	common	common	JJ
304953	100736247	20992712346	now	now	RT
304953	100736247	20992712347	.	.	.
304953	100736247	20992712348	<p>		NULL
304953	100736247	20992712349	I	i	PPIS1
304953	100736247	20992712350	had	have	VHD
304953	100736247	20992712351	a	a	AT1
304953	100736247	20992712352	V	xx_v	ZZ1
304953	100736247	20992712353	when	when	RRQ_CS
304953	100736247	20992712354	I	i	PPIS1
304953	100736247	20992712355	was	be	VBDZ
304953	100736247	20992712356	28	28	MC
304953	100736247	20992712357	,	,	,
304953	100736247	20992712358	my	my	APPGE
304953	100736247	20992712359	testosterone	testosterone	NN1
304953	100736247	20992712360	level	level	NN1
304953	100736247	20992712361	were	be	VBDR
304953	100736247	20992712362	also	also	RR
304953	100736247	20992712363	in	in	II
304953	100736247	20992712364	the	the	AT
304953	100736247	20992712365	cellar	cellar	NN1
304953	100736247	20992712366	!	!	!
304953	100736247	20992712367	I	i	PPIS1
304953	100736247	20992712368	had	have	VHD
304953	100736247	20992712369	to	to	TO
304953	100736247	20992712370	take	take	VVI
304953	100736247	20992712371	T	t	ZZ1_NP1@
304953	100736247	20992712372	jel		VV0_NN1
304953	100736247	20992712373	however	however	RR_RRQV
304953	100736247	20992712374	after	after	II
304953	100736247	20992712375	changing	change	VVG
304953	100736247	20992712376	my	my	APPGE
304953	100736247	20992712377	diet	diet	NN1
304953	100736247	20992712378	and	and	CC
304953	100736247	20992712379	started	start	VVD
304953	100736247	20992712380	to	to	TO
304953	100736247	20992712381	eat	eat	VVI
304953	100736247	20992712382	clean	clean	JJ
304953	100736247	20992712383	,	,	,
304953	100736247	20992712384	my	my	APPGE
304953	100736247	20992712385	T	t	ZZ1_NP1@
304953	100736247	20992712386	levels	level	NN2
304953	100736247	20992712387	went	go	VVD
304953	100736247	20992712388	up	up	RP
304953	100736247	20992712389	over	over	RG
304953	100736247	20992712390	600	600	MC
304953	100736247	20992712391	no	no	AT
304953	100736247	20992712392	gel	gel	NN1
304953	100736247	20992712393	for	for	IF
304953	100736247	20992712394	over	over	RG
304953	100736247	20992712395	a	a	AT1
304953	100736247	20992712396	year	year	NNT1
304953	100736247	20992712397	!	!	!
304953	100736247	20992712398	!	!	!
304953	100736247	20992712399	I	i	PPIS1
304953	100736247	20992712400	am	be	VBM
304953	100736247	20992712401	57	57	MC
304953	100736247	20992712402	,	,	,
304953	100736247	20992712403	diagnosed	diagnose	VVN_VVD
304953	100736247	20992712404	with	with	IW
304953	100736247	20992712405	LOW	low	JJ_NP1@
304953	100736247	20992712406	t	t	ZZ1
304953	100736247	20992712407	at	at	II
304953	100736247	20992712408	around	around	RG
304953	100736247	20992712409	50.		MC
304953	100736247	20992712410	took	take	VVD
304953	100736247	20992712411	jell		NN1_VV0
304953	100736247	20992712412	for	for	IF
304953	100736247	20992712413	over	over	RG
304953	100736247	20992712414	5	5	MC
304953	100736247	20992712415	years	year	NNT2
304953	100736247	20992712416	,	,	,
304953	100736247	20992712417	not	not	XX
304953	100736247	20992712418	good	good	RR%_JJ
304953	100736247	20992712419	EAT	eat	VV0
304953	100736247	20992712420	CLEAN	clean	JJ
304953	100736247	20992712421	IS	be	VBZ
304953	100736247	20992712422	THE	the	AT
304953	100736247	20992712423	KEY	key	NN1_JJ
304953	100736247	20992712424	AND	and	CC
304953	100736247	20992712425	EXERCISE	exercise	VV0_NN1
304953	100736247	20992712426	WALKING	walk	VVG_NN1_JJ@
304953	100736247	20992712427	TESTAMENT	testament	NN1
304953	100736247	20992712428	!	!	!
304953	100736247	20992712429	CHOLESTEROL	cholesterol	NN1
304953	100736247	20992712430	WENT	go	VVD
304953	100736247	20992712431	FROM	from	II
304953	100736247	20992712432	250-170		MCMC
304953	100736247	20992712433	IN	in	II
304953	100736247	20992712434	ONE	one	MC1
304953	100736247	20992712435	MONTH	month	NNT1
304953	100736247	20992712436	NO	no	AT
304953	100736247	20992712437	GIMMIC		JJ
304953	100736247	20992712438	FOOD	food	NN1
304953	100736247	20992712439	IS	be	VBZ
304953	100736247	20992712440	MEDICINE	medicine	NN1
304953	100736247	20992712441	!	!	!
304953	100736247	20992712442	!	!	!
304953	100736247	20992712443	<p>		NULL
304953	100736247	20992712444	My	my	APPGE
304953	100736247	20992712445	husband	husband	NN1
304953	100736247	20992712446	had	have	VHD
304953	100736247	20992712447	a	a	AT1
304953	100736247	20992712448	vasectomy	vasectomy	NN1
304953	100736247	20992712449	and	and	CC
304953	100736247	20992712450	got	get	VVD
304953	100736247	20992712451	the	the	AT
304953	100736247	20992712452	all	all	DB_RR@
304953	100736247	20992712453	clear	clear	JJ_VV0@
304953	100736247	20992712454	from	from	II
304953	100736247	20992712455	the	the	AT
304953	100736247	20992712456	dr	dr	NNU
304953	100736247	20992712457	a	a	AT1
304953	100736247	20992712458	few	few	DA2
304953	100736247	20992712459	months	month	NNT2
304953	100736247	20992712460	ago	ago	RA
304953	100736247	20992712461	.	.	.
304953	100736247	20992712462	Now	now	RT
304953	100736247	20992712463	I	i	PPIS1
304953	100736247	20992712464	am	be	VBM
304953	100736247	20992712465	6	6	MC
304953	100736247	20992712466	weeks	week	NNT2
304953	100736247	20992712467	pregnant	pregnant	JJ
304953	100736247	20992712468	.	.	.
304953	100736247	20992712469	My	my	APPGE
304953	100736247	20992712470	husband	husband	NN1
304953	100736247	20992712471	had	have	VHD
304953	100736247	20992712472	testicular	testicular	JJ
304953	100736247	20992712473	cancer	cancer	NN1
304953	100736247	20992712474	15	15	MC
304953	100736247	20992712475	years	year	NNT2
304953	100736247	20992712476	ago	ago	RA
304953	100736247	20992712477	and	and	CC
304953	100736247	20992712478	had	have	VHD_VHN@
304953	100736247	20992712479	part	part	NN1
304953	100736247	20992712480	of	of	IO
304953	100736247	20992712481	his	his	APPGE
304953	100736247	20992712482	testicle	testicle	NN1
304953	100736247	20992712483	removed	remove	VVD_VVN
304953	100736247	20992712484	.	.	.
304953	100736247	20992712485	This	this	DD1
304953	100736247	20992712486	vasectomy	vasectomy	NN1
304953	100736247	20992712487	was	be	VBDZ
304953	100736247	20992712488	performed	perform	VVN
304953	100736247	20992712489	with	with	IW
304953	100736247	20992712490	1/2	1/2	MF
304953	100736247	20992712491	of	of	IO
304953	100736247	20992712492	1	1	MC1
304953	100736247	20992712493	testicle	testicle	NN1
304953	100736247	20992712494	removed	remove	VVD_VVN
304953	100736247	20992712495	.	.	.
304953	100736247	20992712496	Could	could	VM
304953	100736247	20992712497	this	this	DD1
304953	100736247	20992712498	be	be	VBI
304953	100736247	20992712499	the	the	AT
304953	100736247	20992712500	cause	cause	NN1
304953	100736247	20992712501	@		II
304953	100736247	20992712502	@		II
304953	100736247	20992712503	@		II
304953	100736247	20992712504	@		II
304953	100736247	20992712505	@		II
304953	100736247	20992712506	@		II
304953	100736247	20992712507	@		II
304953	100736247	20992712508	@		II
304953	100736247	20992712509	@		II
304953	100736247	20992712510	@		II
304953	100736247	20992712511	scheduled	scheduled	JJ
304953	100736247	20992712512	Vasectomy	vasectomy	NN1
304953	100736247	20992712513	in	in	II
304953	100736247	20992712514	a	a	AT1
304953	100736247	20992712515	few	few	DA2
304953	100736247	20992712516	weeks	week	NNT2
304953	100736247	20992712517	.	.	.
304953	100736247	20992712518	I 'm		VV0
304953	100736247	20992712519	a	a	AT1
304953	100736247	20992712520	healthy	healthy	JJ
304953	100736247	20992712521	male	male	JJ_NN1
304953	100736247	20992712522	meaning	meaning	NN1
304953	100736247	20992712523	I	i	PPIS1
304953	100736247	20992712524	eat	eat	VV0
304953	100736247	20992712525	mainly	mainly	RR
304953	100736247	20992712526	organic	organic	JJ
304953	100736247	20992712527	whole	whole	JJ_NN1
304953	100736247	20992712528	foods	food	NN2
304953	100736247	20992712529	and	and	CC
304953	100736247	20992712530	have	have	VH0
304953	100736247	20992712531	never	never	RR
304953	100736247	20992712532	been	be	VBN
304953	100736247	20992712533	out	out	II21
304953	100736247	20992712534	of	of	II22
304953	100736247	20992712535	shape	shape	NN1
304953	100736247	20992712536	or	or	CC
304953	100736247	20992712537	overweight	overweight	JJ
304953	100736247	20992712538	.	.	.
304953	100736247	20992712539	I	i	PPIS1
304953	100736247	20992712540	workout	workout	VV0
304953	100736247	20992712541	4	4	MC
304953	100736247	20992712542	days	day	NNT2
304953	100736247	20992712543	a	a	AT1
304953	100736247	20992712544	week	week	NNT1
304953	100736247	20992712545	and	and	CC
304953	100736247	20992712546	still	still	RR_JJ@
304953	100736247	20992712547	play	play	VV0_NN1
304953	100736247	20992712548	basketball	basketball	NN1
304953	100736247	20992712549	with	with	IW
304953	100736247	20992712550	college	college	NN1
304953	100736247	20992712551	student	student	NN1
304953	100736247	20992712552	.	.	.
304953	100736247	20992712553	I	i	PPIS1
304953	100736247	20992712554	have	have	VH0
304953	100736247	20992712555	great	great	JJ
304953	100736247	20992712556	numbers	number	NN2
304953	100736247	20992712557	across	across	II
304953	100736247	20992712558	the	the	AT
304953	100736247	20992712559	board	board	NN1
304953	100736247	20992712560	(	(	(
304953	100736247	20992712561	I.e.	ie	REX
304953	100736247	20992712562	BP	bp	NP1
304953	100736247	20992712563	,	,	,
304953	100736247	20992712564	cholesterol	cholesterol	NN1
304953	100736247	20992712565	,	,	,
304953	100736247	20992712566	etc.		RA
304953	100736247	20992712567	)	)	)
304953	100736247	20992712568	and	and	CC
304953	100736247	20992712569	have	have	VH0
304953	100736247	20992712570	always	always	RR
304953	100736247	20992712571	been	be	VBN
304953	100736247	20992712572	in	in	II
304953	100736247	20992712573	the	the	AT
304953	100736247	20992712574	very	very	JJ
304953	100736247	20992712575	top	top	JJ_NN1
304953	100736247	20992712576	percentile	percentile	NN1
304953	100736247	20992712577	of	of	IO
304953	100736247	20992712578	healthy	healthy	JJ
304953	100736247	20992712579	adult	adult	NN1_JJ@
304953	100736247	20992712580	men	man	NN2
304953	100736247	20992712581	.	.	.
304953	100736247	20992712582	I 'm		VV0_NN1
304953	100736247	20992712583	62	62	MC
304953	100736247	20992712584	?	?	?
304953	100736247	20992712585	and	and	CC
304953	100736247	20992712586	185	185	MC
304953	100736247	20992712587	lbs	lb	NNU2
304953	100736247	20992712588	.	.	.
304953	100736247	20992712589	But	but	CCB
304953	100736247	20992712590	I	i	PPIS1
304953	100736247	20992712591	am	be	VBM
304953	100736247	20992712592	a	a	RR21
304953	100736247	20992712593	little	little	RR22
304953	100736247	20992712594	skeptical	skeptical	JJ
304953	100736247	20992712595	and	and	CC
304953	100736247	20992712596	afraid	afraid	JJ
304953	100736247	20992712597	of	of	IO
304953	100736247	20992712598	this	this	DD1
304953	100736247	20992712599	research	research	NN1
304953	100736247	20992712600	.	.	.
304953	100736247	20992712601	It	it	PPH1
304953	100736247	20992712602	is	be	VBZ
304953	100736247	20992712603	the	the	AT
304953	100736247	20992712604	only	only	JJ
304953	100736247	20992712605	thing	thing	NN1
304953	100736247	20992712606	that 's		NN2_VVZ
304953	100736247	20992712607	holding	hold	VVG
304953	100736247	20992712608	me	me	PPIO1
304953	100736247	20992712609	back	back	RP
304953	100736247	20992712610	.	.	.
304953	100736247	20992712611	If	if	CS
304953	100736247	20992712612	anyone	anyone	PN1
304953	100736247	20992712613	have	have	VH0
304953	100736247	20992712614	any	any	DD
304953	100736247	20992712615	info	info	NN1
304953	100736247	20992712616	out	out	RP
304953	100736247	20992712617	there	there	RL
304953	100736247	20992712618	that	that	CST_DD1
304953	100736247	20992712619	could	could	VM
304953	100736247	20992712620	help	help	VVI
304953	100736247	20992712621	shed		VVN_NN1_VV0
304953	100736247	20992712622	more	more	RGR_DAR
304953	100736247	20992712623	light	light	JJ_NN1
304953	100736247	20992712624	,	,	,
304953	100736247	20992712625	please	please	RR
304953	100736247	20992712626	advise	advise	VV0
304953	100736247	20992712627	.	.	.
304953	100736247	20992712628	Thank	thank	VV0
304953	100736247	20992712629	you	you	PPY
304953	100736247	20992712630	.	.	.
304953	100736247	20992712631	<p>		NULL
304953	100736247	20992712632	I	i	PPIS1
304953	100736247	20992712633	had	have	VHD
304953	100736247	20992712634	a	a	AT1
304953	100736247	20992712635	vasectomy	vasectomy	NN1
304953	100736247	20992712636	when	when	CS_RRQ
304953	100736247	20992712637	I	i	PPIS1
304953	100736247	20992712638	was	be	VBDZ
304953	100736247	20992712639	25	25	MC
304953	100736247	20992712640	I	i	PPIS1
304953	100736247	20992712641	am	be	VBM
304953	100736247	20992712642	still	still	RR
304953	100736247	20992712643	as	as	CSA_RG@
304953	100736247	20992712644	rampant	rampant	JJ
304953	100736247	20992712645	now	now	RT
304953	100736247	20992712646	at	at	II
304953	100736247	20992712647	68	68	MC
304953	100736247	20992712648	as	as	CSA
304953	100736247	20992712649	I	i	PPIS1
304953	100736247	20992712650	was	be	VBDZ
304953	100736247	20992712651	befor	befor	NN1
304953	100736247	20992712652	and	and	CC
304953	100736247	20992712653	have	have	VH0
304953	100736247	20992712654	no	no	AT
304953	100736247	20992712655	troubles	trouble	NN2
304953	100736247	20992712656	ejaculating	ejaculate	VVG
304953	100736247	20992712657	my	my	APPGE
304953	100736247	20992712658	only	only	JJ
304953	100736247	20992712659	problem	problem	NN1
304953	100736247	20992712660	is	be	VBZ
304953	100736247	20992712661	not	not	XX
304953	100736247	20992712662	maintaining	maintain	VVG
304953	100736247	20992712663	an	a	AT1
304953	100736247	20992712664	erection.l		NNU
304953	100736247	20992712665	put	put	VVD_VV0_VVN
304953	100736247	20992712666	that	that	DD1
304953	100736247	20992712667	down	down	RP
304953	100736247	20992712668	to	to	II
304953	100736247	20992712669	heavy	heavy	JJ
304953	100736247	20992712670	smoking	smoking	NN1
304953	100736247	20992712671	in	in	II
304953	100736247	20992712672	my	my	APPGE
304953	100736247	20992712673	younger	young	JJR
304953	100736247	20992712674	years	year	NNT2
304953	100736247	20992712675	.	.	.
304953	100736247	20992712676	<p>		NULL
304953	100736247	20992712677	Now	now	RT
304953	100736247	20992712678	where	where	CS_RRQ
304953	100736247	20992712679	I	i	PPIS1
304953	100736247	20992712680	work	work	VV0
304953	100736247	20992712681	it	it	PPH1
304953	100736247	20992712682	is	be	VBZ
304953	100736247	20992712683	the	the	AT
304953	100736247	20992712684	exact	exact	JJ
304953	100736247	20992712685	opposite	opposite	JJ_NN1@
304953	100736247	20992712686	.	.	.
304953	100736247	20992712687	All	all	DB
304953	100736247	20992712688	the	the	AT
304953	100736247	20992712689	men	man	NN2
304953	100736247	20992712690	who	who	PNQS
304953	100736247	20992712691	have	have	VH0
304953	100736247	20992712692	had	have	VHN
304953	100736247	20992712693	or	or	CC
304953	100736247	20992712694	have	have	VH0
304953	100736247	20992712695	prostrate	prostrate	JJ
304953	100736247	20992712696	Cancer	cancer	NN1
304953	100736247	20992712697	were	be	VBDR
304953	100736247	20992712698	all	all	DB
304953	100736247	20992712699	men	man	NN2
304953	100736247	20992712700	who	who	PNQS
304953	100736247	20992712701	@		II
304953	100736247	20992712702	@		II
304953	100736247	20992712703	@		II
304953	100736247	20992712704	@		II
304953	100736247	20992712705	@		II
304953	100736247	20992712706	@		II
304953	100736247	20992712707	@		II
304953	100736247	20992712708	@		II
304953	100736247	20992712709	@		II
304953	100736247	20992712710	@		II
304953	100736247	20992712711	had	have	VHD
304953	100736247	20992712712	Vasectomies	vasectomy	NN2
304953	100736247	20992712713	have	have	VH0
304953	100736247	20992712714	now	now	RT
304953	100736247	20992712715	or	or	CC
304953	100736247	20992712716	have	have	VH0
304953	100736247	20992712717	ever	ever	RR
304953	100736247	20992712718	had	have	VHN
304953	100736247	20992712719	Prostrate	prostrate	JJ
304953	100736247	20992712720	Cancer	cancer	NN1
304953	100736247	20992712721	so	so	RR_RG
304953	100736247	20992712722	what	what	DDQ
304953	100736247	20992712723	can	can	VM_VV0%
304953	100736247	20992712724	on	on	II_RP@
304953	100736247	20992712725	believe	believe	VVI
304953	100736247	20992712726	?	?	?
304953	100736247	20992712727	So	so	RR
304953	100736247	20992712728	when	when	CS_RRQ
304953	100736247	20992712729	the	the	AT
304953	100736247	20992712730	Doctors	doctor	NN2
304953	100736247	20992712731	run	run	VV0_VVN
304953	100736247	20992712732	surveys	survey	NN2
304953	100736247	20992712733	and	and	CC
304953	100736247	20992712734	test	test	VV0
304953	100736247	20992712735	it	it	PPH1
304953	100736247	20992712736	shows	show	VVZ
304953	100736247	20992712737	Vasectomies		NP1_NN2
304953	100736247	20992712738	men	man	NN2
304953	100736247	20992712739	prostrate	prostrate	JJ
304953	100736247	20992712740	Cancer	cancer	NN1
304953	100736247	20992712741	but	but	CCB
304953	100736247	20992712742	when	when	CS_RRQ
304953	100736247	20992712743	you	you	PPY
304953	100736247	20992712744	ask	ask	VV0
304953	100736247	20992712745	the	the	AT
304953	100736247	20992712746	people	people	NN
304953	100736247	20992712747	you	you	PPY
304953	100736247	20992712748	work	work	VV0
304953	100736247	20992712749	with	with	IW
304953	100736247	20992712750	you	you	PPY
304953	100736247	20992712751	find	find	VV0
304953	100736247	20992712752	the	the	AT
304953	100736247	20992712753	opposite	opposite	NN1@_JJ
304953	100736247	20992712754	is	be	VBZ
304953	100736247	20992712755	true	true	JJ
304953	100736247	20992712756	,	,	,
304953	100736247	20992712757	Geeeeeeees		NP1_NN2
304953	100736247	20992712758	<p>		NULL
304953	100736247	20992712759	I	i	PPIS1
304953	100736247	20992712760	had	have	VHD
304953	100736247	20992712761	vasectomy	vasectomy	NN1
304953	100736247	20992712762	when	when	CS_RRQ
304953	100736247	20992712763	I	i	PPIS1
304953	100736247	20992712764	was	be	VBDZ
304953	100736247	20992712765	32	32	MC
304953	100736247	20992712766	and	and	CC
304953	100736247	20992712767	I	i	PPIS1
304953	100736247	20992712768	am	be	VBM
304953	100736247	20992712769	now	now	RT
304953	100736247	20992712770	75	75	MC
304953	100736247	20992712771	.	.	.
304953	100736247	20992712772	About	about	RG
304953	100736247	20992712773	20	20	MC
304953	100736247	20992712774	years	year	NNT2
304953	100736247	20992712775	ago	ago	RA
304953	100736247	20992712776	I	i	PPIS1
304953	100736247	20992712777	had	have	VHD
304953	100736247	20992712778	a	a	AT1
304953	100736247	20992712779	brief	brief	JJ
304953	100736247	20992712780	episode	episode	NN1
304953	100736247	20992712781	of	of	IO
304953	100736247	20992712782	low	low	JJ
304953	100736247	20992712783	T	t	ZZ1
304953	100736247	20992712784	,	,	,
304953	100736247	20992712785	which	which	DDQ
304953	100736247	20992712786	cleared	clear	VVD
304953	100736247	20992712787	up	up	RP
304953	100736247	20992712788	by	by	II
304953	100736247	20992712789	itself	itself	PPX1
304953	100736247	20992712790	in	in	II
304953	100736247	20992712791	a	a	AT1
304953	100736247	20992712792	few	few	DA2
304953	100736247	20992712793	months	month	NNT2
304953	100736247	20992712794	with	with	IW
304953	100736247	20992712795	no	no	AT
304953	100736247	20992712796	treatment	treatment	NN1
304953	100736247	20992712797	.	.	.
304953	100736247	20992712798	my	my	APPGE
304953	100736247	20992712799	sex	sex	NN1
304953	100736247	20992712800	life	life	NN1
304953	100736247	20992712801	remains	remain	VVZ
304953	100736247	20992712802	very	very	RG
304953	100736247	20992712803	active	active	JJ
304953	100736247	20992712804	at	at	RR21
304953	100736247	20992712805	least	least	RR22
304953	100736247	20992712806	twice	twice	RR
304953	100736247	20992712807	a	a	AT1
304953	100736247	20992712808	week	week	NNT1
304953	100736247	20992712809	with	with	IW
304953	100736247	20992712810	no	no	AT
304953	100736247	20992712811	difficulties	difficulty	NN2
304953	100736247	20992712812	obtaining	obtain	VVG
304953	100736247	20992712813	an	a	AT1
304953	100736247	20992712814	erection	erection	NN1
304953	100736247	20992712815	but	but	CCB
304953	100736247	20992712816	my	my	APPGE
304953	100736247	20992712817	semen	semen	NN1
304953	100736247	20992712818	production	production	NN1
304953	100736247	20992712819	is	be	VBZ
304953	100736247	20992712820	reduced	reduce	VVN
304953	100736247	20992712821	.	.	.
304953	100736247	20992712822	I	i	PPIS1
304953	100736247	20992712823	run	run	VV0
304953	100736247	20992712824	,	,	,
304953	100736247	20992712825	lift	lift	VV0_NN1
304953	100736247	20992712826	weights	weight	NN2
304953	100736247	20992712827	,	,	,
304953	100736247	20992712828	do	do	VD0
304953	100736247	20992712829	yoga	yoga	NN1
304953	100736247	20992712830	and	and	CC
304953	100736247	20992712831	pilates	pilates	VVZ
304953	100736247	20992712832	several	several	DA2
304953	100736247	20992712833	times	time	NNT2
304953	100736247	20992712834	a	a	AT1
304953	100736247	20992712835	week	week	NNT1
304953	100736247	20992712836	.	.	.
304953	100736247	20992712837	I	i	PPIS1
304953	100736247	20992712838	get	get	VV0
304953	100736247	20992712839	PSA	psa	NP1
304953	100736247	20992712840	once	once	RR
304953	100736247	20992712841	per	per	II
304953	100736247	20992712842	year	year	NNT1
304953	100736247	20992712843	and	and	CC
304953	100736247	20992712844	see	see	VV0
304953	100736247	20992712845	a	a	AT1
304953	100736247	20992712846	urologist	urologist	NN1
304953	100736247	20992712847	for	for	IF
304953	100736247	20992712848	checkup	checkup	NN1
304953	100736247	20992712849	once	once	RR_CS@
304953	100736247	20992712850	a	a	AT1
304953	100736247	20992712851	year	year	NNT1
304953	100736247	20992712852	.	.	.
304953	100736247	20992712853	I	i	PPIS1
304953	100736247	20992712854	do	do	VD0
304953	100736247	20992712855	take	take	VVI
304953	100736247	20992712856	herbal	herbal	JJ_NN1
304953	100736247	20992712857	extracts	extract	NN2
304953	100736247	20992712858	Nettle	nettle	NN1
304953	100736247	20992712859	Root	root	NN1
304953	100736247	20992712860	,	,	,
304953	100736247	20992712861	Saw	see	VVD
304953	100736247	20992712862	Palmetto	palmetto	NP1_NN1
304953	100736247	20992712863	and	and	CC
304953	100736247	20992712864	Tribulus		NP1
304953	100736247	20992712865	Terrestris	terrestris	NP1
304953	100736247	20992712866	,	,	,
304953	100736247	20992712867	which	which	DDQ
304953	100736247	20992712868	may	may	VM
304953	100736247	20992712869	or	or	CC
304953	100736247	20992712870	may	may	VM
304953	100736247	20992712871	not	not	XX
304953	100736247	20992712872	help	help	VVI
304953	100736247	20992712873	.	.	.
304953	100736247	20992712874	<p>		NULL
304953	100736247	20992712875	I	i	PPIS1
304953	100736247	20992712876	am	be	VBM
304953	100736247	20992712877	contemplating	contemplate	VVG
304953	100736247	20992712878	The	the	AT
304953	100736247	20992712879	above-noted	above-noted	JJ_NN1
304953	100736247	20992712880	procedure	procedure	NN1
304953	100736247	20992712881	,	,	,
304953	100736247	20992712882	however	however	RRQV
304953	100736247	20992712883	I	i	PPIS1
304953	100736247	20992712884	am	be	VBM
304953	100736247	20992712885	hesitant	hesitant	JJ
304953	100736247	20992712886	,	,	,
304953	100736247	20992712887	due	due	II21
304953	100736247	20992712888	to	to	II22
304953	100736247	20992712889	the	the	AT
304953	100736247	20992712890	fact	fact	NN1
304953	100736247	20992712891	that	that	CST_DD1
304953	100736247	20992712892	prostrate	prostrate	JJ
304953	100736247	20992712893	cancer	cancer	NN1
304953	100736247	20992712894	runs	run	VVZ_NN2
304953	100736247	20992712895	in	in	II_RP@
304953	100736247	20992712896	my	my	APPGE
304953	100736247	20992712897	family	family	NN1
304953	100736247	20992712898	.	.	.
304953	100736247	20992712899	He	he	PPHS1
304953	100736247	20992712900	even	even	CS21
304953	100736247	20992712901	@		II
304953	100736247	20992712902	@		II
304953	100736247	20992712903	@		II
304953	100736247	20992712904	@		II
304953	100736247	20992712905	@		II
304953	100736247	20992712906	@		II
304953	100736247	20992712907	@		II
304953	100736247	20992712908	@		II
304953	100736247	20992712909	@		II
304953	100736247	20992712910	@		II
304953	100736247	20992712911	has	have	VHZ
304953	100736247	20992712912	not	not	XX
304953	100736247	20992712913	dispel	dispel	VV0
304953	100736247	20992712914	the	the	AT
304953	100736247	20992712915	fear	fear	NN1
304953	100736247	20992712916	that	that	CST
304953	100736247	20992712917	the	the	AT
304953	100736247	20992712918	research	research	NN1
304953	100736247	20992712919	is	be	VBZ
304953	100736247	20992712920	wrong	wrong	JJ_RR@
304953	100736247	20992712921	.	.	.
304953	100736247	20992712922	<p>		NULL
304953	100736247	20992712923	I	i	PPIS1
304953	100736247	20992712924	had	have	VHD
304953	100736247	20992712925	a	a	AT1
304953	100736247	20992712926	vasectomy	vasectomy	NN1
304953	100736247	20992712927	at	at	II
304953	100736247	20992712928	age	age	NN1
304953	100736247	20992712929	22	22	MC
304953	100736247	20992712930	,	,	,
304953	100736247	20992712931	now	now	RT
304953	100736247	20992712932	47	47	MC
304953	100736247	20992712933	,	,	,
304953	100736247	20992712934	healthy	healthy	JJ
304953	100736247	20992712935	and	and	CC
304953	100736247	20992712936	active	active	JJ
304953	100736247	20992712937	.	.	.
304953	100736247	20992712938	The	the	AT
304953	100736247	20992712939	key	key	NN1_JJ
304953	100736247	20992712940	to	to	II
304953	100736247	20992712941	no	no	AT
304953	100736247	20992712942	cancer	cancer	NN1
304953	100736247	20992712943	is	be	VBZ
304953	100736247	20992712944	a	a	AT1
304953	100736247	20992712945	vegetarian	vegetarian	NN1
304953	100736247	20992712946	based	base	VVN
304953	100736247	20992712947	diet	diet	NN1
304953	100736247	20992712948	.	.	.
304953	100736247	20992712949	You	you	PPY
304953	100736247	20992712950	are	be	VBR
304953	100736247	20992712951	3	3	MC
304953	100736247	20992712952	times	time	NNT2
304953	100736247	20992712953	less	less	RRR_RGR
304953	100736247	20992712954	likely	likely	JJ
304953	100736247	20992712955	to	to	TO
304953	100736247	20992712956	get	get	VVI
304953	100736247	20992712957	cancer	cancer	NN1
304953	100736247	20992712958	if	if	CS
304953	100736247	20992712959	you	you	PPY
304953	100736247	20992712960	eat	eat	VV0
304953	100736247	20992712961	a	a	AT1
304953	100736247	20992712962	plant	plant	NN1
304953	100736247	20992712963	rich	rich	JJ
304953	100736247	20992712964	diet	diet	NN1
304953	100736247	20992712965	with	with	IW
304953	100736247	20992712966	little	little	JJ_DA1
304953	100736247	20992712967	or	or	CC
304953	100736247	20992712968	no	no	AT
304953	100736247	20992712969	meat	meat	NN1
304953	100736247	20992712970	.	.	.
304953	100736247	20992712971	And	and	CC
304953	100736247	20992712972	,	,	,
304953	100736247	20992712973	cut	cut	VV0_VVN_VVD@
304953	100736247	20992712974	out	out	RP
304953	100736247	20992712975	all	all	DB_RR@
304953	100736247	20992712976	deep	deep	JJ_RR
304953	100736247	20992712977	fried	fried	JJ_VVN@
304953	100736247	20992712978	,	,	,
304953	100736247	20992712979	sugary	sugary	JJ_NN1
304953	100736247	20992712980	&amp;		CC
304953	100736247	20992712981	processed	processed	JJ
304953	100736247	20992712982	foods	food	NN2
304953	100736247	20992712983	.	.	.
304953	100736247	20992712984	Combine	combine	VV0
304953	100736247	20992712985	that	that	CST_DD1
304953	100736247	20992712986	with	with	IW
304953	100736247	20992712987	exercise	exercise	NN1
304953	100736247	20992712988	or	or	CC
304953	100736247	20992712989	better	better	RRR_JJR
304953	100736247	20992712990	yet	yet	RR
304953	100736247	20992712991	,	,	,
304953	100736247	20992712992	sexercise		VV0_NN1
304953	100736247	20992712993	,	,	,
304953	100736247	20992712994	and	and	CC
304953	100736247	20992712995	your	your	APPGE
304953	100736247	20992712996	golden	golden	JJ
304953	100736247	20992712997	.	.	.
304953	100736247	20992712998	:	:	:
304953	100736247	20992712999	)	)	)
304953	100736247	20992713000	Wonder	wonder	VV0
304953	100736247	20992713001	how	how	RGQ@
304953	100736247	20992713002	many	many	DA2
304953	100736247	20992713003	of	of	IO
304953	100736247	20992713004	those	those	DD2
304953	100736247	20992713005	men	man	NN2
304953	100736247	20992713006	in	in	II
304953	100736247	20992713007	the	the	AT
304953	100736247	20992713008	study	study	NN1
304953	100736247	20992713009	with	with	IW
304953	100736247	20992713010	prostate	prostate	NN1
304953	100736247	20992713011	cancer	cancer	NN1
304953	100736247	20992713012	were	be	VBDR
304953	100736247	20992713013	vegetarian	vegetarian	JJ
304953	100736247	20992713014	?	?	?
304953	100736247	20992713015	Not	not	XX
304953	100736247	20992713016	many	many	DA2
304953	100736247	20992713017	,	,	,
304953	100736247	20992713018	I	i	PPIS1
304953	100736247	20992713019	bet	bet	VV0_VVD@
304953	100736247	20992713020	.	.	.
304953	100736247	20992713021	Save	save	VV0
304953	100736247	20992713022	nature	nature	NN1
304953	100736247	20992713023	,	,	,
304953	100736247	20992713024	go	go	VV0
304953	100736247	20992713025	veg	veg	NN1
304953	100736247	20992713026	!	!	!
304953	100736247	20992713027	<p>		NULL
304953	100736247	20992713028	I	i	PPIS1
304953	100736247	20992713029	just	just	RR
304953	100736247	20992713030	had	have	VHD
304953	100736247	20992713031	a	a	AT1
304953	100736247	20992713032	vasectomy	vasectomy	NN1
304953	100736247	20992713033	last	last	MD
304953	100736247	20992713034	month	month	NNT1
304953	100736247	20992713035	and	and	CC
304953	100736247	20992713036	the	the	AT
304953	100736247	20992713037	mild	mild	JJ
304953	100736247	20992713038	chronic	chronic	JJ
304953	100736247	20992713039	constant	constant	JJ
304953	100736247	20992713040	pressure	pressure	NN1
304953	100736247	20992713041	is	be	VBZ
304953	100736247	20992713042	not	not	XX
304953	100736247	20992713043	worth	worth	II
304953	100736247	20992713044	it	it	PPH1
304953	100736247	20992713045	.	.	.
304953	100736247	20992713046	The	the	AT
304953	100736247	20992713047	pain	pain	NN1
304953	100736247	20992713048	after	after	II_CS
304953	100736247	20992713049	ejaculation	ejaculation	NN1
304953	100736247	20992713050	makes	make	VVZ
304953	100736247	20992713051	me	me	PPIO1
304953	100736247	20992713052	want	want	VVI
304953	100736247	20992713053	to	to	TO
304953	100736247	20992713054	avoid	avoid	VVI
304953	100736247	20992713055	it	it	PPH1
304953	100736247	20992713056	completely	completely	RR
304953	100736247	20992713057	.	.	.
304953	100736247	20992713058	I 'm		VV0_NN1
304953	100736247	20992713059	37	37	MC
304953	100736247	20992713060	and	and	CC
304953	100736247	20992713061	this	this	DD1
304953	100736247	20992713062	surgery	surgery	NN1
304953	100736247	20992713063	is	be	VBZ
304953	100736247	20992713064	a	a	AT1
304953	100736247	20992713065	major	major	JJ
304953	100736247	20992713066	regret	regret	NN1
304953	100736247	20992713067	of	of	IO
304953	100736247	20992713068	mine	mine	PPGE
304953	100736247	20992713069	.	.	.
304953	100736247	20992713070	If	if	CS
304953	100736247	20992713071	I	i	PPIS1
304953	100736247	20992713072	could	could	VM
304953	100736247	20992713073	undo	undo	VVI
304953	100736247	20992713074	it	it	PPH1
304953	100736247	20992713075	and	and	CC
304953	100736247	20992713076	make	make	VVI
304953	100736247	20992713077	the	the	AT
304953	100736247	20992713078	symptoms	symptom	NN2
304953	100736247	20992713079	go	go	VV0
304953	100736247	20992713080	away	away	RL
304953	100736247	20992713081	for	for	IF
304953	100736247	20992713082	10k	10k	FO
304953	100736247	20992713083	,	,	,
304953	100736247	20992713084	I 'd		NN1
304953	100736247	20992713085	do	do	VD0
304953	100736247	20992713086	it	it	PPH1
304953	100736247	20992713087	.	.	.
304953	100736247	20992713088	The	the	AT
304953	100736247	20992713089	feeling	feeling	NN1
304953	100736247	20992713090	Im		NN1_NP1
304953	100736247	20992713091	left	leave	VVN_VVD
304953	100736247	20992713092	with	with	IW
304953	100736247	20992713093	where	where	RRQ_CS
304953	100736247	20992713094	my	my	APPGE
304953	100736247	20992713095	belt	belt	NN1
304953	100736247	20992713096	would	would	VM
304953	100736247	20992713097	normally	normally	RR
304953	100736247	20992713098	sit	sit	VVI
304953	100736247	20992713099	is	be	VBZ
304953	100736247	20992713100	enough	enough	DD
304953	100736247	20992713101	@		II
304953	100736247	20992713102	@		II
304953	100736247	20992713103	@		II
304953	100736247	20992713104	@		II
304953	100736247	20992713105	@		II
304953	100736247	20992713106	@		II
304953	100736247	20992713107	@		II
304953	100736247	20992713108	@		II
304953	100736247	20992713109	@		II
304953	100736247	20992713110	@		II
304953	100736247	20992713111	.	.	.
304953	100736247	20992713112	This	this	DD1
304953	100736247	20992713113	is	be	VBZ
304953	100736247	20992713114	the	the	AT
304953	100736247	20992713115	worst	bad	JJT
304953	100736247	20992713116	.	.	.
304953	100736247	20992713117	<p>		NULL
304953	100736247	20992713118	Hopefully	hopefully	RR
304953	100736247	20992713119	you 're		VV0
304953	100736247	20992713120	feeling	feel	VVG_NN1
304953	100736247	20992713121	better	better	RRR_JJR
304953	100736247	20992713122	now	now	RT
304953	100736247	20992713123	.	.	.
304953	100736247	20992713124	I	i	PPIS1
304953	100736247	20992713125	too	too	RR@
304953	100736247	20992713126	had	have	VHD
304953	100736247	20992713127	the	the	AT
304953	100736247	20992713128	pressure	pressure	NN1
304953	100736247	20992713129	and	and	CC
304953	100736247	20992713130	discomfort	discomfort	NN1
304953	100736247	20992713131	you	you	PPY
304953	100736247	20992713132	describe	describe	VV0
304953	100736247	20992713133	,	,	,
304953	100736247	20992713134	but	but	CCB
304953	100736247	20992713135	it	it	PPH1
304953	100736247	20992713136	eventually	eventually	RR
304953	100736247	20992713137	went	go	VVD
304953	100736247	20992713138	away	away	RL
304953	100736247	20992713139	.	.	.
304953	100736247	20992713140	I	i	PPIS1
304953	100736247	20992713141	think	think	VV0
304953	100736247	20992713142	it	it	PPH1
304953	100736247	20992713143	was	be	VBDZ
304953	100736247	20992713144	at	at	RR21
304953	100736247	20992713145	least	least	RR22
304953	100736247	20992713146	4	4	MC
304953	100736247	20992713147	months	month	NNT2
304953	100736247	20992713148	before	before	CS_II
304953	100736247	20992713149	all	all	DB
304953	100736247	20992713150	of	of	IO
304953	100736247	20992713151	my	my	APPGE
304953	100736247	20992713152	discomfort	discomfort	NN1
304953	100736247	20992713153	went	go	VVD
304953	100736247	20992713154	away	away	RL
304953	100736247	20992713155	.	.	.
304953	100736247	20992713156	I	i	PPIS1
304953	100736247	20992713157	have	have	VH0
304953	100736247	20992713158	friends	friend	NN2
304953	100736247	20992713159	with	with	IW
304953	100736247	20992713160	similar	similar	JJ
304953	100736247	20992713161	experiences	experience	NN2
304953	100736247	20992713162	also	also	RR
304953	100736247	20992713163	.	.	.
304953	100736247	20992713164	<p>		NULL
304953	100736247	20992713165	I	i	PPIS1
304953	100736247	20992713166	considered	consider	VVD
304953	100736247	20992713167	having	have	VHG
304953	100736247	20992713168	a	a	AT1
304953	100736247	20992713169	vasectomy	vasectomy	NN1
304953	100736247	20992713170	recently	recently	RR
304953	100736247	20992713171	however	however	RR_RGQV_RRQV
304953	100736247	20992713172	decided	decide	VVN
304953	100736247	20992713173	against	against	II
304953	100736247	20992713174	it	it	PPH1
304953	100736247	20992713175	mostly	mostly	RR
304953	100736247	20992713176	because	because	II21
304953	100736247	20992713177	of	of	II22
304953	100736247	20992713178	the	the	AT
304953	100736247	20992713179	small	small	JJ
304953	100736247	20992713180	risk	risk	NN1
304953	100736247	20992713181	of	of	IO
304953	100736247	20992713182	chronic	chronic	JJ
304953	100736247	20992713183	pain	pain	NN1
304953	100736247	20992713184	.	.	.
304953	100736247	20992713185	If	if	CS
304953	100736247	20992713186	you	you	PPY
304953	100736247	20992713187	read	read	VV0_VVD
304953	100736247	20992713188	the	the	AT
304953	100736247	20992713189	literature	literature	NN1
304953	100736247	20992713190	you 'll		NN1_VV0
304953	100736247	20992713191	find	find	VV0
304953	100736247	20992713192	chronic	chronic	JJ
304953	100736247	20992713193	pain	pain	NN1
304953	100736247	20992713194	in	in	II
304953	100736247	20992713195	a	a	AT1
304953	100736247	20992713196	small	small	JJ
304953	100736247	20992713197	but	but	CCB
304953	100736247	20992713198	considerable	considerable	JJ
304953	100736247	20992713199	percent	percent	NNU
304953	100736247	20992713200	of	of	IO
304953	100736247	20992713201	men	man	NN2
304953	100736247	20992713202	after	after	II_CS
304953	100736247	20992713203	the	the	AT
304953	100736247	20992713204	procedure	procedure	NN1
304953	100736247	20992713205	that	that	CST_DD1
304953	100736247	20992713206	may	may	VM
304953	100736247	20992713207	persist	persist	VVI
304953	100736247	20992713208	for	for	IF
304953	100736247	20992713209	years	year	NNT2
304953	100736247	20992713210	.	.	.
304953	100736247	20992713211	The	the	AT
304953	100736247	20992713212	risk	risk	NN1
304953	100736247	20992713213	of	of	IO
304953	100736247	20992713214	prostate	prostate	NN1
304953	100736247	20992713215	cancer	cancer	NN1
304953	100736247	20992713216	may	may	VM
304953	100736247	20992713217	exist	exist	VVI
304953	100736247	20992713218	,	,	,
304953	100736247	20992713219	the	the	AT
304953	100736247	20992713220	literature	literature	NN1
304953	100736247	20992713221	is	be	VBZ
304953	100736247	20992713222	not	not	XX
304953	100736247	20992713223	clear	clear	JJ_RR@
304953	100736247	20992713224	on	on	II
304953	100736247	20992713225	that	that	DD1
304953	100736247	20992713226	based	base	VVN
304953	100736247	20992713227	on	on	II
304953	100736247	20992713228	what	what	DDQ
304953	100736247	20992713229	I	i	PPIS1
304953	100736247	20992713230	read	read	VV0_VVD
304953	100736247	20992713231	,	,	,
304953	100736247	20992713232	but	but	CCB
304953	100736247	20992713233	in	in	II
304953	100736247	20992713234	my	my	APPGE
304953	100736247	20992713235	mind	mind	NN1
304953	100736247	20992713236	better	better	RRR_JJR
304953	100736247	20992713237	safe	safe	JJ_NN1@
304953	100736247	20992713238	than	than	CSN
304953	100736247	20992713239	sorry	sorry	JJ
304953	100736247	20992713240	.	.	.
304953	100736247	20992713241	I 'm		VV0
304953	100736247	20992713242	not	not	XX
304953	100736247	20992713243	going	go	VVG
304953	100736247	20992713244	to	to	TO
304953	100736247	20992713245	have	have	VHI
304953	100736247	20992713246	a	a	AT1
304953	100736247	20992713247	vasectomy	vasectomy	NN1
304953	100736247	20992713248	now	now	RT
304953	100736247	20992713249	.	.	.
304953	100736247	20992713250	<p>		NULL
304953	100736247	20992713251	I	i	PPIS1
304953	100736247	20992713252	had	have	VHD
304953	100736247	20992713253	a	a	AT1
304953	100736247	20992713254	vasectomy	vasectomy	NN1
304953	100736247	20992713255	in	in	II
304953	100736247	20992713256	2001	2001	MC
304953	100736247	20992713257	.	.	.
304953	100736247	20992713258	In	in	II
304953	100736247	20992713259	2005	2005	MC
304953	100736247	20992713260	i	i	MC1_ZZ1
304953	100736247	20992713261	was	be	VBDZ
304953	100736247	20992713262	found	find	VVN
304953	100736247	20992713263	to	to	TO
304953	100736247	20992713264	have	have	VHI
304953	100736247	20992713265	a	a	AT1
304953	100736247	20992713266	very	very	RG
304953	100736247	20992713267	high	high	JJ
304953	100736247	20992713268	grade	grade	NN1
304953	100736247	20992713269	of	of	IO
304953	100736247	20992713270	prostrate	prostrate	JJ
304953	100736247	20992713271	cancer.So		NNU
304953	100736247	20992713272	the	the	AT
304953	100736247	20992713273	prostrate	prostrate	JJ
304953	100736247	20992713274	was	be	VBDZ
304953	100736247	20992713275	removed.There		NNU
304953	100736247	20992713276	is	be	VBZ
304953	100736247	20992713277	no	no	AT
304953	100736247	20992713278	history	history	NN1
304953	100736247	20992713279	in	in	II
304953	100736247	20992713280	my	my	APPGE
304953	100736247	20992713281	family	family	NN1
304953	100736247	20992713282	of	of	IO
304953	100736247	20992713283	prostrate	prostrate	JJ
304953	100736247	20992713284	cancer	cancer	NN1
304953	100736247	20992713285	.	.	.
304953	100736247	20992713286	Yet	yet	RR
304953	100736247	20992713287	a	a	AT1
304953	100736247	20992713288	friend	friend	NN1
304953	100736247	20992713289	,	,	,
304953	100736247	20992713290	who 's		NN2
304953	100736247	20992713291	father	father	NN1
304953	100736247	20992713292	had	have	VHD
304953	100736247	20992713293	prostrate	prostrate	JJ
304953	100736247	20992713294	cancer	cancer	NN1
304953	100736247	20992713295	,	,	,
304953	100736247	20992713296	has	have	VHZ
304953	100736247	20992713297	been	be	VBN
304953	100736247	20992713298	tested	test	VVN
304953	100736247	20992713299	every	every	AT1
304953	100736247	20992713300	year	year	NNT1
304953	100736247	20992713301	@		II
304953	100736247	20992713302	@		II
304953	100736247	20992713303	@		II
304953	100736247	20992713304	@		II
304953	100736247	20992713305	@		II
304953	100736247	20992713306	@		II
304953	100736247	20992713307	@		II
304953	100736247	20992713308	@		II
304953	100736247	20992713309	@		II
304953	100736247	20992713310	@		II
304953	100736247	20992713311	healthy	healthy	JJ
304953	100736247	20992713312	sex	sex	NN1
304953	100736247	20992713313	life	life	NN1
304953	100736247	20992713314	,	,	,
304953	100736247	20992713315	like	like	II
304953	100736247	20992713316	every	every	AT1
304953	100736247	20992713317	day.Its		NNU
304953	100736247	20992713318	like	like	II
304953	100736247	20992713319	the	the	AT
304953	100736247	20992713320	saying	saying	NN1@_VVG
304953	100736247	20992713321	use	use	VV0_NN1
304953	100736247	20992713322	it	it	PPH1
304953	100736247	20992713323	or	or	CC
304953	100736247	20992713324	lose	lose	VV0
304953	100736247	20992713325	it	it	PPH1
304953	100736247	20992713326	may	may	VM
304953	100736247	20992713327	have	have	VHI
304953	100736247	20992713328	something	something	PN1
304953	100736247	20992713329	to	to	II
304953	100736247	20992713330	it	it	PPH1
304953	100736247	20992713331	.	.	.
304953	100736247	20992713332	I	i	PPIS1
304953	100736247	20992713333	would	would	VM
304953	100736247	20992713334	not	not	XX
304953	100736247	20992713335	knowing	know	VVG
304953	100736247	20992713336	what	what	DDQ
304953	100736247	20992713337	i	i	ZZ1_MC1
304953	100736247	20992713338	know	know	VV0
304953	100736247	20992713339	now	now	RT
304953	100736247	20992713340	have	have	VH0
304953	100736247	20992713341	a	a	AT1
304953	100736247	20992713342	vasectomy	vasectomy	NN1
304953	100736247	20992713343	.	.	.
304953	100736247	20992713344	<p>		NULL
304953	100736247	20992713345	Folks	folk	NN2
304953	100736247	20992713346	:	:	:
304953	100736247	20992713347	I	i	PPIS1
304953	100736247	20992713348	have	have	VH0
304953	100736247	20992713349	done	do	VDN
304953	100736247	20992713350	an	a	AT1
304953	100736247	20992713351	extensive	extensive	JJ
304953	100736247	20992713352	amount	amount	NN1
304953	100736247	20992713353	of	of	IO
304953	100736247	20992713354	research	research	NN1
304953	100736247	20992713355	of	of	IO
304953	100736247	20992713356	all	all	DB
304953	100736247	20992713357	studies	study	NN2
304953	100736247	20992713358	related	relate	VVN_VVD
304953	100736247	20992713359	to	to	II
304953	100736247	20992713360	Vasectomy		NP1_NN1
304953	100736247	20992713361	and	and	CC
304953	100736247	20992713362	Prostate	prostate	NN1
304953	100736247	20992713363	Cancer	cancer	NN1
304953	100736247	20992713364	utilizing	utilize	VVG_NN1@
304953	100736247	20992713365	google	google	NN1
304953	100736247	20992713366	scholar	scholar	NN1
304953	100736247	20992713367	.	.	.
304953	100736247	20992713368	Bottom	bottom	JJ_NN1
304953	100736247	20992713369	lineolder		NN1
304953	100736247	20992713370	studies	study	NN2
304953	100736247	20992713371	(	(	(
304953	100736247	20992713372	pre-2000		JJ
304953	100736247	20992713373	)	)	)
304953	100736247	20992713374	contended	contend	VVD
304953	100736247	20992713375	there	there	EX_RL
304953	100736247	20992713376	might	might	VM
304953	100736247	20992713377	be	be	VBI
304953	100736247	20992713378	a	a	AT1
304953	100736247	20992713379	causal	causal	JJ
304953	100736247	20992713380	relationship	relationship	NN1
304953	100736247	20992713381	,	,	,
304953	100736247	20992713382	but	but	CCB
304953	100736247	20992713383	all	all	DB
304953	100736247	20992713384	of	of	IO
304953	100736247	20992713385	the	the	AT
304953	100736247	20992713386	recent	recent	JJ
304953	100736247	20992713387	studies	study	NN2
304953	100736247	20992713388	with	with	IW
304953	100736247	20992713389	VERY	very	RG
304953	100736247	20992713390	large	large	JJ
304953	100736247	20992713391	populations	population	NN2
304953	100736247	20992713392	almost	almost	RR
304953	100736247	20992713393	unanimously	unanimously	RR
304953	100736247	20992713394	agree	agree	VV0
304953	100736247	20992713395	that	that	CST
304953	100736247	20992713396	there	there	EX
304953	100736247	20992713397	is	be	VBZ
304953	100736247	20992713398	NO	no	AT
304953	100736247	20992713399	causal	causal	JJ
304953	100736247	20992713400	relationship	relationship	NN1
304953	100736247	20992713401	.	.	.
304953	100736247	20992713402	Folks	folk	NN2
304953	100736247	20992713403	who	who	PNQS
304953	100736247	20992713404	will	will	VM
304953	100736247	20992713405	get	get	VVI
304953	100736247	20992713406	prostate	prostate	NN1
304953	100736247	20992713407	cancer	cancer	NN1
304953	100736247	20992713408	will	will	VM
304953	100736247	20992713409	get	get	VVI
304953	100736247	20992713410	prostate	prostate	NN1
304953	100736247	20992713411	cancer	cancer	NN1
304953	100736247	20992713412	regardless	regardless	RR
304953	100736247	20992713413	of	of	IO
304953	100736247	20992713414	whether	whether	CSW
304953	100736247	20992713415	they	they	PPHS2
304953	100736247	20992713416	have	have	VH0
304953	100736247	20992713417	a	a	AT1
304953	100736247	20992713418	vasectomy	vasectomy	NN1
304953	100736247	20992713419	or	or	CC
304953	100736247	20992713420	not	not	XX
304953	100736247	20992713421	.	.	.
304953	100736247	20992713422	I	i	PPIS1
304953	100736247	20992713423	did	do	VDD
304953	100736247	20992713424	the	the	AT
304953	100736247	20992713425	research	research	NN1
304953	100736247	20992713426	because	because	CS
304953	100736247	20992713427	I	i	PPIS1
304953	100736247	20992713428	am	be	VBM
304953	100736247	20992713429	looking	look	VVG
304953	100736247	20992713430	into	into	II
304953	100736247	20992713431	getting	get	VVG
304953	100736247	20992713432	the	the	AT
304953	100736247	20992713433	procedure	procedure	NN1
304953	100736247	20992713434	and	and	CC
304953	100736247	20992713435	I	i	PPIS1
304953	100736247	20992713436	am	be	VBM
304953	100736247	20992713437	confident	confident	JJ
304953	100736247	20992713438	there	there	EX_RL
304953	100736247	20992713439	is	be	VBZ
304953	100736247	20992713440	no	no	AT
304953	100736247	20992713441	relationship	relationship	NN1
304953	100736247	20992713442	.	.	.
304953	100736247	20992713443	With	with	IW
304953	100736247	20992713444	that	that	DD1
304953	100736247	20992713445	said	say	VVD
304953	100736247	20992713446	,	,	,
304953	100736247	20992713447	I	i	PPIS1
304953	100736247	20992713448	am	be	VBM
304953	100736247	20992713449	likely	likely	JJ
304953	100736247	20992713450	to	to	TO
304953	100736247	20992713451	get	get	VVI
304953	100736247	20992713452	prostate	prostate	NN1
304953	100736247	20992713453	cancer	cancer	NN1
304953	100736247	20992713454	since	since	CS
304953	100736247	20992713455	it	it	PPH1
304953	100736247	20992713456	runs	run	VVZ
304953	100736247	20992713457	in	in	II_RP@
304953	100736247	20992713458	my	my	APPGE
304953	100736247	20992713459	family	family	NN1
304953	100736247	20992713460	,	,	,
304953	100736247	20992713461	but	but	CCB
304953	100736247	20992713462	I	i	PPIS1
304953	100736247	20992713463	will	will	VM
304953	100736247	20992713464	just	just	RR
304953	100736247	20992713465	be	be	VBI
304953	100736247	20992713466	diligent	diligent	JJ
304953	100736247	20992713467	with	with	IW
304953	100736247	20992713468	the	the	AT
304953	100736247	20992713469	check-ups	checkup	NN2
304953	100736247	20992713470	.	.	.
304953	100736247	20992713471	I	i	PPIS1
304953	100736247	20992713472	recommend	recommend	VV0
304953	100736247	20992713473	getting	get	VVG
304953	100736247	20992713474	the	the	AT
304953	100736247	20992713475	surgery	surgery	NN1
304953	100736247	20992713476	if	if	CS
304953	100736247	20992713477	it	it	PPH1
304953	100736247	20992713478	is	be	VBZ
304953	100736247	20992713479	the	the	AT
304953	100736247	20992713480	right	right	JJ_NN1
304953	100736247	20992713481	choice	choice	NN1
304953	100736247	20992713482	for	for	IF
304953	100736247	20992713483	you	you	PPY
304953	100736247	20992713484	and	and	CC
304953	100736247	20992713485	just	just	RR
304953	100736247	20992713486	being	be	VBG
304953	100736247	20992713487	diligent	diligent	JJ
304953	100736247	20992713488	in	in	II
304953	100736247	20992713489	your	your	APPGE
304953	100736247	20992713490	annual	annual	JJ
304953	100736247	20992713491	checks	check	NN2
304953	100736247	20992713492	,	,	,
304953	100736247	20992713493	coupled	couple	VVN_VVD
304953	100736247	20992713494	with	with	IW
304953	100736247	20992713495	proper	proper	JJ
304953	100736247	20992713496	nutrition	nutrition	NN1
304953	100736247	20992713497	as	as	CSA
304953	100736247	20992713498	relayed	relay	VVN@
304953	100736247	20992713499	above	above	RL
304953	100736247	20992713500	.	.	.
304953	100736247	20992713501	@		II
304953	100736247	20992713502	@		II
304953	100736247	20992713503	@		II
304953	100736247	20992713504	@		II
304953	100736247	20992713505	@		II
304953	100736247	20992713506	@		II
304953	100736247	20992713507	@		II
304953	100736247	20992713508	@		II
304953	100736247	20992713509	@		II
304953	100736247	20992713510	@		II
304953	100736247	20992713511	suffering	suffer	VVG_JJ
304953	100736247	20992713512	from	from	II
304953	100736247	20992713513	a	a	AT1
304953	100736247	20992713514	hemotoma		NN1
304953	100736247	20992713515	.	.	.
304953	100736247	20992713516	A	a	AT1
304953	100736247	20992713517	very	very	RG
304953	100736247	20992713518	real	real	JJ
304953	100736247	20992713519	side	side	NN1
304953	100736247	20992713520	affect	affect	NN1_VV0
304953	100736247	20992713521	if	if	CS_CSW@
304953	100736247	20992713522	you	you	PPY
304953	100736247	20992713523	look	look	VV0
304953	100736247	20992713524	it	it	PPH1
304953	100736247	20992713525	up	up	RP
304953	100736247	20992713526	.	.	.
304953	100736247	20992713527	They	they	PPHS2
304953	100736247	20992713528	say	say	VV0
304953	100736247	20992713529	it	it	PPH1
304953	100736247	20992713530	happens	happen	VVZ
304953	100736247	20992713531	to	to	II@
304953	100736247	20992713532	1	1	MC1
304953	100736247	20992713533	in	in	II
304953	100736247	20992713534	1000	1000	MC
304953	100736247	20992713535	but	but	CCB
304953	100736247	20992713536	it	it	PPH1
304953	100736247	20992713537	seems	seem	VVZ
304953	100736247	20992713538	more	more	RGR_DAR
304953	100736247	20992713539	common	common	JJ
304953	100736247	20992713540	than	than	CSN
304953	100736247	20992713541	that	that	DD1
304953	100736247	20992713542	.	.	.
304953	100736247	20992713543	He	he	PPHS1
304953	100736247	20992713544	is	be	VBZ
304953	100736247	20992713545	in	in	II
304953	100736247	20992713546	constant	constant	JJ
304953	100736247	20992713547	pain	pain	NN1
304953	100736247	20992713548	,	,	,
304953	100736247	20992713549	feels	feel	VVZ
304953	100736247	20992713550	nausea	nausea	NN1
304953	100736247	20992713551	and	and	CC
304953	100736247	20992713552	helpless	helpless	JJ
304953	100736247	20992713553	most	most	DAT
304953	100736247	20992713554	days	day	NNT2
304953	100736247	20992713555	.	.	.
304953	100736247	20992713556	Its	its	APPGE
304953	100736247	20992713557	been	be	VBN
304953	100736247	20992713558	over	over	II_RP
304953	100736247	20992713559	a	a	AT1
304953	100736247	20992713560	month	month	NNT1
304953	100736247	20992713561	.	.	.
304953	100736247	20992713562	They	they	PPHS2
304953	100736247	20992713563	say	say	VV0
304953	100736247	20992713564	time	time	NNT1
304953	100736247	20992713565	will	will	VM
304953	100736247	20992713566	heal	heal	VVI
304953	100736247	20992713567	but	but	CCB
304953	100736247	20992713568	Ive		NP1_VV0
304953	100736247	20992713569	read	read	VVD_VV0
304953	100736247	20992713570	cases	case	NN2
304953	100736247	20992713571	that	that	CST
304953	100736247	20992713572	go	go	VV0
304953	100736247	20992713573	on	on	RP@
304953	100736247	20992713574	for	for	IF
304953	100736247	20992713575	years	year	NNT2
304953	100736247	20992713576	.	.	.
304953	100736247	20992713577	Think	think	VV0
304953	100736247	20992713578	twice	twice	RR
304953	100736247	20992713579	guys	guy	NN2
304953	100736247	20992713580	and	and	CC
304953	100736247	20992713581	use	use	VV0
304953	100736247	20992713582	a	a	AT1
304953	100736247	20992713583	condom	condom	NN1
304953	100736247	20992713584	.	.	.
304953	100736247	20992713585	<p>		NULL
304953	100736247	20992713586	I	i	PPIS1
304953	100736247	20992713587	agree	agree	VV0
304953	100736247	20992713588	with	with	IW
304953	100736247	20992713589	Laura	laura	NP1
304953	100736247	20992713590	.	.	.
304953	100736247	20992713591	I	i	PPIS1
304953	100736247	20992713592	regret	regret	VV0
304953	100736247	20992713593	getting	get	VVG
304953	100736247	20992713594	a	a	AT1
304953	100736247	20992713595	vasectomy	vasectomy	NN1
304953	100736247	20992713596	in	in	II
304953	100736247	20992713597	2003	2003	MC
304953	100736247	20992713598	.	.	.
304953	100736247	20992713599	I	i	PPIS1
304953	100736247	20992713600	have	have	VH0
304953	100736247	20992713601	had	have	VHN
304953	100736247	20992713602	a	a	AT1
304953	100736247	20992713603	constant	constant	JJ
304953	100736247	20992713604	dull	dull	JJ
304953	100736247	20992713605	ache	ache	NN1
304953	100736247	20992713606	since	since	II
304953	100736247	20992713607	then	then	RT
304953	100736247	20992713608	.	.	.
304953	100736247	20992713609	Now	now	RT
304953	100736247	20992713610	I	i	PPIS1
304953	100736247	20992713611	have	have	VH0
304953	100736247	20992713612	granuloma	granuloma	NN1
304953	100736247	20992713613	and	and	CC
304953	100736247	20992713614	cyst	cyst	VV0_NN1
304953	100736247	20992713615	pain	pain	NN1
304953	100736247	20992713616	also	also	RR
304953	100736247	20992713617	.	.	.
304953	100736247	20992713618	I	i	PPIS1
304953	100736247	20992713619	can	can	VM
304953	100736247	20992713620	not	not	XX
304953	100736247	20992713621	get	get	VVI
304953	100736247	20992713622	a	a	AT1
304953	100736247	20992713623	reversal	reversal	NN1
304953	100736247	20992713624	because	because	CS
304953	100736247	20992713625	the	the	AT
304953	100736247	20992713626	surgeon	surgeon	NN1
304953	100736247	20992713627	took	take	VVD
304953	100736247	20992713628	a	a	AT1
304953	100736247	20992713629	large	large	JJ
304953	100736247	20992713630	chunk	chunk	NN1
304953	100736247	20992713631	of	of	IO
304953	100736247	20992713632	the	the	AT
304953	100736247	20992713633	vas	vas	NN2
304953	100736247	20992713634	out	out	RP
304953	100736247	20992713635	.	.	.
304953	100736247	20992713636	A	a	AT1_ZZ1
304953	100736247	20992713637	difficult	difficult	JJ
304953	100736247	20992713638	way	way	NN1
304953	100736247	20992713639	to	to	TO
304953	100736247	20992713640	learn	learn	VVI
304953	100736247	20992713641	that	that	DD1_CST
304953	100736247	20992713642	elective	elective	JJ
304953	100736247	20992713643	surgery	surgery	NN1
304953	100736247	20992713644	is	be	VBZ
304953	100736247	20992713645	not	not	XX
304953	100736247	20992713646	worth	worth	II
304953	100736247	20992713647	the	the	AT
304953	100736247	20992713648	risk	risk	NN1
304953	100736247	20992713649	.	.	.
304953	100736247	20992713650	One	one	MC1
304953	100736247	20992713651	urologist	urologist	NN1
304953	100736247	20992713652	offered	offer	VVD_VVN
304953	100736247	20992713653	to	to	TO
304953	100736247	20992713654	remove	remove	VVI
304953	100736247	20992713655	my	my	APPGE
304953	100736247	20992713656	testicles	testicle	NN2
304953	100736247	20992713657	.	.	.
304953	100736247	20992713658	I	i	MC1@
304953	100736247	20992713659	cant	cant	NN1_JJ
304953	100736247	20992713660	believe	believe	VV0
304953	100736247	20992713661	I	i	PPIS1
304953	100736247	20992713662	did	do	VDD
304953	100736247	20992713663	this	this	DD1
304953	100736247	20992713664	to	to	II
304953	100736247	20992713665	myself	myself	PPX1
304953	100736247	20992713666	!	!	!
304953	100736247	20992713667	<p>		NULL
304953	100736247	20992713668	I	i	PPIS1
304953	100736247	20992713669	had	have	VHD
304953	100736247	20992713670	a	a	AT1
304953	100736247	20992713671	vasectomy	vasectomy	NN1
304953	100736247	20992713672	and	and	CC
304953	100736247	20992713673	after	after	CS_RT%
304953	100736247	20992713674	,	,	,
304953	100736247	20992713675	my	my	APPGE
304953	100736247	20992713676	wife	wife	NN1
304953	100736247	20992713677	no	no	RR21
304953	100736247	20992713678	longer	long	RR22
304953	100736247	20992713679	wanted	want	VVD_VVN_JJ@
304953	100736247	20992713680	sex	sex	NN1
304953	100736247	20992713681	.	.	.
304953	100736247	20992713682	I	i	PPIS1
304953	100736247	20992713683	too	too	RR@
304953	100736247	20992713684	had	have	VHD
304953	100736247	20992713685	a	a	AT1
304953	100736247	20992713686	lot	lot	NN1
304953	100736247	20992713687	of	of	IO
304953	100736247	20992713688	pain	pain	NN1
304953	100736247	20992713689	and	and	CC
304953	100736247	20992713690	bruised	bruise	VVN_JJ
304953	100736247	20992713691	like	like	II
304953	100736247	20992713692	purple	purple	JJ
304953	100736247	20992713693	cabbage	cabbage	NN1
304953	100736247	20992713694	.	.	.
304953	100736247	20992713695	I	i	PPIS1
304953	100736247	20992713696	still	still	RR
304953	100736247	20992713697	have	have	VH0
304953	100736247	20992713698	mild	mild	JJ
304953	100736247	20992713699	discomfort	discomfort	NN1
304953	100736247	20992713700	after	after	II_CS
304953	100736247	20992713701	@		II
304953	100736247	20992713702	@		II
304953	100736247	20992713703	@		II
304953	100736247	20992713704	@		II
304953	100736247	20992713705	@		II
304953	100736247	20992713706	@		II
304953	100736247	20992713707	@		II
304953	100736247	20992713708	@		II
304953	100736247	20992713709	@		II
304953	100736247	20992713710	@		II
304953	100736247	20992713711	donor	donor	NN1
304953	100736247	20992713712	.	.	.
304953	100736247	20992713713	Sad	sad	JJ
304953	100736247	20992713714	.	.	.
304953	100736247	20992713715	Life	life	NN1
304953	100736247	20992713716	goes	go	VVZ
304953	100736247	20992713717	on	on	RP@
304953	100736247	20992713718	!	!	!
304953	100736247	20992713719	My	my	APPGE
304953	100736247	20992713720	psa		NN1
304953	100736247	20992713721	is	be	VBZ
304953	100736247	20992713722	1	1	MC1
304953	100736247	20992713723	.	.	.
304953	100736247	20992713724	something	something	PN1
304953	100736247	20992713725	.	.	.
304953	100736247	20992713726	I	i	PPIS1
304953	100736247	20992713727	do	do	VD0
304953	100736247	20992713728	have	have	VHI
304953	100736247	20992713729	an	a	AT1
304953	100736247	20992713730	enlarged	enlarged	JJ
304953	100736247	20992713731	prostate	prostate	NN1
304953	100736247	20992713732	but	but	CCB
304953	100736247	20992713733	no	no	AT
304953	100736247	20992713734	cancer	cancer	NN1
304953	100736247	20992713735	,	,	,
304953	100736247	20992713736	do	do	VD0
304953	100736247	20992713737	n't 	n't	XX
304953	100736247	20992713738	know	know	VVI
304953	100736247	20992713739	about	about	II
304953	100736247	20992713740	any	any	DD
304953	100736247	20992713741	of	of	IO
304953	100736247	20992713742	these	these	DD2
304953	100736247	20992713743	studies	study	NN2
304953	100736247	20992713744	.	.	.
304953	100736247	20992713745	Drs	drs	NP1
304953	100736247	20992713746	are	be	VB0
304953	100736247	20992713747	n't 	n't	XX
304953	100736247	20992713748	GOD	god	NP1_NN1
304953	100736247	20992713749	!	!	!
304953	100736247	20992713750	<p>		NULL
304953	100736247	20992713751	I	i	PPIS1
304953	100736247	20992713752	had	have	VHD
304953	100736247	20992713753	the	the	AT
304953	100736247	20992713754	traditional	traditional	JJ
304953	100736247	20992713755	bilateral	bilateral	JJ
304953	100736247	20992713756	vasectomy	vasectomy	NN1
304953	100736247	20992713757	when	when	CS_RRQ
304953	100736247	20992713758	I	i	PPIS1
304953	100736247	20992713759	was	be	VBDZ
304953	100736247	20992713760	27	27	MC
304953	100736247	20992713761	.	.	.
304953	100736247	20992713762	I	i	PPIS1
304953	100736247	20992713763	am	be	VBM
304953	100736247	20992713764	now	now	RT
304953	100736247	20992713765	63	63	MC
304953	100736247	20992713766	years	year	NNT2
304953	100736247	20992713767	of	of	IO
304953	100736247	20992713768	age	age	NN1
304953	100736247	20992713769	and	and	CC
304953	100736247	20992713770	have	have	VH0
304953	100736247	20992713771	had	have	VHN
304953	100736247	20992713772	no	no	AT
304953	100736247	20992713773	related	related	JJ
304953	100736247	20992713774	health	health	NN1
304953	100736247	20992713775	problems	problem	NN2
304953	100736247	20992713776	from	from	II
304953	100736247	20992713777	the	the	AT
304953	100736247	20992713778	vasectomy	vasectomy	NN1
304953	100736247	20992713779	other	other	II21
304953	100736247	20992713780	than	than	II22
304953	100736247	20992713781	now	now	RT
304953	100736247	20992713782	having	have	VHG
304953	100736247	20992713783	an	a	AT1
304953	100736247	20992713784	enlarged	enlarged	JJ
304953	100736247	20992713785	prostate	prostate	NN1
304953	100736247	20992713786	.	.	.
304953	100736247	20992713787	From	from	II
304953	100736247	20992713788	reading	read	VVG
304953	100736247	20992713789	various	various	JJ
304953	100736247	20992713790	articles	article	NN2
304953	100736247	20992713791	,	,	,
304953	100736247	20992713792	the	the	AT
304953	100736247	20992713793	enlarged	enlarged	JJ
304953	100736247	20992713794	prostate	prostate	NN1
304953	100736247	20992713795	is	be	VBZ
304953	100736247	20992713796	most	most	RGT
304953	100736247	20992713797	likely	likely	RR@_JJ
304953	100736247	20992713798	caused	cause	VVN
304953	100736247	20992713799	by	by	II
304953	100736247	20992713800	age	age	NN1
304953	100736247	20992713801	and	and	CC
304953	100736247	20992713802	has	have	VHZ
304953	100736247	20992713803	no	no	AT
304953	100736247	20992713804	relationship	relationship	NN1
304953	100736247	20992713805	to	to	II
304953	100736247	20992713806	having	have	VHG
304953	100736247	20992713807	had	have	VHN
304953	100736247	20992713808	a	a	AT1
304953	100736247	20992713809	vasectomy	vasectomy	NN1
304953	100736247	20992713810	.	.	.
304953	100736247	20992713811	I	i	PPIS1
304953	100736247	20992713812	would	would	VM
304953	100736247	20992713813	suspect	suspect	VVI
304953	100736247	20992713814	it	it	PPH1
304953	100736247	20992713815	will	will	VM
304953	100736247	20992713816	take	take	VVI
304953	100736247	20992713817	yet	yet	RR
304953	100736247	20992713818	another	another	DD1
304953	100736247	20992713819	50	50	MC
304953	100736247	20992713820	years	year	NNT2
304953	100736247	20992713821	of	of	IO
304953	100736247	20992713822	research	research	NN1
304953	100736247	20992713823	and	and	CC
304953	100736247	20992713824	studies	study	NN2
304953	100736247	20992713825	for	for	IF
304953	100736247	20992713826	doctors	doctor	NN2
304953	100736247	20992713827	to	to	TO
304953	100736247	20992713828	determine	determine	VVI
304953	100736247	20992713829	if	if	CSW@_CS
304953	100736247	20992713830	there	there	EX
304953	100736247	20992713831	are	be	VBR
304953	100736247	20992713832	any	any	DD
304953	100736247	20992713833	long	long	JJ
304953	100736247	20992713834	term	term	NN1
304953	100736247	20992713835	side	side	NN1
304953	100736247	20992713836	effects	effect	NN2
304953	100736247	20992713837	of	of	IO
304953	100736247	20992713838	having	have	VHG
304953	100736247	20992713839	a	a	AT1
304953	100736247	20992713840	vasectomy.		NNU
304953	100736247	20992713841	46996		MC
304953	100736247	20992713842	@qwx906996		FO
304953	100736251	20992713862	@@##	----------	----------
304953	100736251	20992713863	@@100736251		FO
304953	100736251	20992713864	@4936251/		VV0_NN1
304953	100736251	20992713865	46989		MC
304953	100736251	20992713866	@qwx906989		FO
304953	100736251	20992713867	<p>		NULL
304953	100736251	20992713868	The	the	AT
304953	100736251	20992713869	omega-3	omega-3	MC
304953	100736251	20992713870	fats	fat	NN2
304953	100736251	20992713871	in	in	II
304953	100736251	20992713872	fish	fish	NN
304953	100736251	20992713873	have	have	VH0
304953	100736251	20992713874	been	be	VBN
304953	100736251	20992713875	linked	link	VVN
304953	100736251	20992713876	to	to	II
304953	100736251	20992713877	all	all	DB
304953	100736251	20992713878	sorts	sort	NN2
304953	100736251	20992713879	of	of	IO
304953	100736251	20992713880	health	health	NN1
304953	100736251	20992713881	benefits	benefit	NN2
304953	100736251	20992713882	,	,	,
304953	100736251	20992713883	including	including	II_VVG@
304953	100736251	20992713884	protection	protection	NN1
304953	100736251	20992713885	against	against	II
304953	100736251	20992713886	prostate	prostate	NN1
304953	100736251	20992713887	cancer.		NNU
304953	100736251	20992713888	-	-	-
304953	100736251	20992713889	But	but	II21_CCB
304953	100736251	20992713890	for	for	II22_IF
304953	100736251	20992713891	the	the	AT
304953	100736251	20992713892	second	second	MD
304953	100736251	20992713893	time	time	NNT1
304953	100736251	20992713894	in	in	II
304953	100736251	20992713895	two	two	MC
304953	100736251	20992713896	years	year	NNT2
304953	100736251	20992713897	,	,	,
304953	100736251	20992713898	researchers	researcher	NN2
304953	100736251	20992713899	have	have	VH0
304953	100736251	20992713900	found	find	VVN
304953	100736251	20992713901	a	a	AT1
304953	100736251	20992713902	link	link	NN1
304953	100736251	20992713903	between	between	II
304953	100736251	20992713904	high	high	JJ
304953	100736251	20992713905	levels	level	NN2
304953	100736251	20992713906	of	of	IO
304953	100736251	20992713907	omega-3	omega-3	MC
304953	100736251	20992713908	fats	fat	NN2
304953	100736251	20992713909	in	in	II
304953	100736251	20992713910	the	the	AT
304953	100736251	20992713911	blood	blood	NN1
304953	100736251	20992713912	and	and	CC
304953	100736251	20992713913	prostate	prostate	NN1
304953	100736251	20992713914	cancer	cancer	NN1
304953	100736251	20992713915	.	.	.
304953	100736251	20992713916	<p>		NULL
304953	100736251	20992713917	The	the	AT
304953	100736251	20992713918	latest	late	JJT
304953	100736251	20992713919	report	report	NN1
304953	100736251	20992713920	comes	come	VVZ
304953	100736251	20992713921	from	from	II
304953	100736251	20992713922	researchers	researcher	NN2
304953	100736251	20992713923	at	at	II
304953	100736251	20992713924	the	the	AT
304953	100736251	20992713925	Fred	fred	NP1
304953	100736251	20992713926	Hutchinson	hutchinson	NP1
304953	100736251	20992713927	Cancer	cancer	NN1
304953	100736251	20992713928	Center	center	NN1
304953	100736251	20992713929	in	in	II
304953	100736251	20992713930	Seattle	seattle	NP1
304953	100736251	20992713931	.	.	.
304953	100736251	20992713932	Their	their	APPGE
304953	100736251	20992713933	case-control	case-control	JJ_NN1
304953	100736251	20992713934	study	study	NN1
304953	100736251	20992713935	compared	compare	VVD_VVN
304953	100736251	20992713936	blood	blood	NN1
304953	100736251	20992713937	samples	sample	NN2_VVZ@
304953	100736251	20992713938	from	from	II
304953	100736251	20992713939	834	834	MC
304953	100736251	20992713940	men	man	NN2
304953	100736251	20992713941	diagnosed	diagnose	VVN_VVD
304953	100736251	20992713942	with	with	IW
304953	100736251	20992713943	prostate	prostate	NN1
304953	100736251	20992713944	cancer	cancer	NN1
304953	100736251	20992713945	with	with	IW
304953	100736251	20992713946	samples	sample	NN2
304953	100736251	20992713947	from	from	II
304953	100736251	20992713948	1,393	1,393	MC
304953	100736251	20992713949	men	man	NN2
304953	100736251	20992713950	who	who	PNQS
304953	100736251	20992713951	did	do	VDD
304953	100736251	20992713952	n't 	n't	XX
304953	100736251	20992713953	have	have	VHI
304953	100736251	20992713954	the	the	AT
304953	100736251	20992713955	disease	disease	NN1
304953	100736251	20992713956	.	.	.
304953	100736251	20992713957	The	the	AT
304953	100736251	20992713958	blood	blood	NN1
304953	100736251	20992713959	samples	sample	NN2
304953	100736251	20992713960	had	have	VHD
304953	100736251	20992713961	been	be	VBN
304953	100736251	20992713962	collected	collect	VVN
304953	100736251	20992713963	as	as	II
304953	100736251	20992713964	part	part	NN1
304953	100736251	20992713965	of	of	IO
304953	100736251	20992713966	the	the	AT
304953	100736251	20992713967	SELECT	select	JJ
304953	100736251	20992713968	trial	trial	NN1
304953	100736251	20992713969	designed	design	VVN_VVD
304953	100736251	20992713970	to	to	TO
304953	100736251	20992713971	find	find	VVI
304953	100736251	20992713972	out	out	RP
304953	100736251	20992713973	if	if	CS
304953	100736251	20992713974	taking	take	VVG
304953	100736251	20992713975	selenium	selenium	NN1
304953	100736251	20992713976	or	or	CC
304953	100736251	20992713977	vitamin	vitamin	NN1
304953	100736251	20992713978	E	e	ZZ1
304953	100736251	20992713979	could	could	VM
304953	100736251	20992713980	prevent	prevent	VVI
304953	100736251	20992713981	men	man	NN2
304953	100736251	20992713982	from	from	II
304953	100736251	20992713983	developing	developing	JJ_VVG
304953	100736251	20992713984	prostate	prostate	NN1
304953	100736251	20992713985	cancer	cancer	NN1
304953	100736251	20992713986	.	.	.
304953	100736251	20992713987	(	(	(
304953	100736251	20992713988	Selenium		NP1@_NN1
304953	100736251	20992713989	had	have	VHD
304953	100736251	20992713990	no	no	AT
304953	100736251	20992713991	effect	effect	NN1
304953	100736251	20992713992	and	and	CC
304953	100736251	20992713993	vitamin	vitamin	NN1
304953	100736251	20992713994	E	e	ZZ1_NP1@
304953	100736251	20992713995	was	be	VBDZ
304953	100736251	20992713996	associated	associate	VVN
304953	100736251	20992713997	with	with	IW
304953	100736251	20992713998	an	a	AT1
304953	100736251	20992713999	increase	increase	NN1
304953	100736251	20992714000	in	in	II
304953	100736251	20992714001	risk	risk	NN1
304953	100736251	20992714002	.	.	.
304953	100736251	20992714003	)	)	)
304953	100736251	20992714004	<p>		NULL
304953	100736251	20992714005	The	the	AT
304953	100736251	20992714006	researchers	researcher	NN2
304953	100736251	20992714007	tested	test	VVD_VVN
304953	100736251	20992714008	the	the	AT
304953	100736251	20992714009	samples	sample	NN2
304953	100736251	20992714010	for	for	IF
304953	100736251	20992714011	their	their	APPGE
304953	100736251	20992714012	omega-3	omega-3	MC
304953	100736251	20992714013	content	content	JJ_NN1
304953	100736251	20992714014	.	.	.
304953	100736251	20992714015	Men	man	NN2
304953	100736251	20992714016	whose	whose	DDQGE
304953	100736251	20992714017	blood	blood	NN1
304953	100736251	20992714018	samples	sample	NN2
304953	100736251	20992714019	were	be	VBDR
304953	100736251	20992714020	in	in	II
304953	100736251	20992714021	the	the	AT
304953	100736251	20992714022	top	top	JJ_NN1
304953	100736251	20992714023	25%		NNU
304953	100736251	20992714024	of	of	IO
304953	100736251	20992714025	omega-3	omega-3	MC
304953	100736251	20992714026	fat	fat	JJ
304953	100736251	20992714027	content	content	NN1
304953	100736251	20992714028	were	be	VBDR
304953	100736251	20992714029	43%		NNU
304953	100736251	20992714030	more	more	DAR_RRR
304953	100736251	20992714031	likely	likely	JJ
304953	100736251	20992714032	to	to	TO
304953	100736251	20992714033	have	have	VHI
304953	100736251	20992714034	been	be	VBN
304953	100736251	20992714035	diagnosed	diagnose	VVN
304953	100736251	20992714036	with	with	IW
304953	100736251	20992714037	prostate	prostate	NN1
304953	100736251	20992714038	cancer	cancer	NN1
304953	100736251	20992714039	than	than	CSN
304953	100736251	20992714040	men	man	NN2
304953	100736251	20992714041	whose	whose	DDQGE
304953	100736251	20992714042	blood	blood	NN1
304953	100736251	20992714043	samples	sample	NN2
304953	100736251	20992714044	were	be	VBDR
304953	100736251	20992714045	in	in	II
304953	100736251	20992714046	the	the	AT
304953	100736251	20992714047	lowest	low	JJT_RRT
304953	100736251	20992714048	25%		NNU
304953	100736251	20992714049	of	of	IO
304953	100736251	20992714050	omega-3	omega-3	MC
304953	100736251	20992714051	content	content	JJ_NN1
304953	100736251	20992714052	.	.	.
304953	100736251	20992714053	The	the	AT
304953	100736251	20992714054	@		II
304953	100736251	20992714055	@		II
304953	100736251	20992714056	@		II
304953	100736251	20992714057	@		II
304953	100736251	20992714058	@		II
304953	100736251	20992714059	@		II
304953	100736251	20992714060	@		II
304953	100736251	20992714061	@		II
304953	100736251	20992714062	@		II
304953	100736251	20992714063	@		II
304953	100736251	20992714064	Cancer	cancer	NN1
304953	100736251	20992714065	Institute	institute	NN1
304953	100736251	20992714066	.	.	.
304953	100736251	20992714067	<p>		NULL
304953	100736251	20992714068	The	the	AT
304953	100736251	20992714069	results	result	NN2
304953	100736251	20992714070	did	do	VDD
304953	100736251	20992714071	n't 	n't	XX
304953	100736251	20992714072	differ	differ	VVI
304953	100736251	20992714073	much	much	RR_DA1
304953	100736251	20992714074	when	when	CS_RRQ
304953	100736251	20992714075	the	the	AT
304953	100736251	20992714076	three	three	MC
304953	100736251	20992714077	different	different	JJ
304953	100736251	20992714078	types	type	NN2
304953	100736251	20992714079	of	of	IO
304953	100736251	20992714080	omega-3	omega-3	MC
304953	100736251	20992714081	fats	fat	NN2
304953	100736251	20992714082	found	find	VVN_VVD
304953	100736251	20992714083	in	in	II
304953	100736251	20992714084	fish	fish	NN
304953	100736251	20992714085	and	and	CC
304953	100736251	20992714086	fish	fish	NN
304953	100736251	20992714087	oil	oil	NN1_VV0%
304953	100736251	20992714088	"	"	"
304953	100736251	20992714089	eicosapentaenoic	eicosapentaenoic	JJ
304953	100736251	20992714090	acid	acid	NN1
304953	100736251	20992714091	(	(	(
304953	100736251	20992714092	EPA	epa	NP1
304953	100736251	20992714093	)	)	)
304953	100736251	20992714094	,	,	,
304953	100736251	20992714095	docosahexaenoic	docosahexaenoic	JJ
304953	100736251	20992714096	acid	acid	NN1
304953	100736251	20992714097	(	(	(
304953	100736251	20992714098	DHA		NP1
304953	100736251	20992714099	)	)	)
304953	100736251	20992714100	and	and	CC
304953	100736251	20992714101	docosapentaenoic		JJ
304953	100736251	20992714102	acid	acid	NN1
304953	100736251	20992714103	(	(	(
304953	100736251	20992714104	DPA	dpa	NP1
304953	100736251	20992714105	)	)	)
304953	100736251	20992714106	"	"	"
304953	100736251	20992714107	were	be	VBDR
304953	100736251	20992714108	analyzed	analyze	VVN@
304953	100736251	20992714109	separately	separately	RR
304953	100736251	20992714110	.	.	.
304953	100736251	20992714111	<p>		NULL
304953	100736251	20992714112	A	a	AT1_ZZ1
304953	100736251	20992714113	similar	similar	JJ
304953	100736251	20992714114	study	study	NN1
304953	100736251	20992714115	published	publish	VVD_VVN
304953	100736251	20992714116	two	two	MC
304953	100736251	20992714117	years	year	NNT2
304953	100736251	20992714118	in	in	II
304953	100736251	20992714119	the	the	AT
304953	100736251	20992714120	American	american	JJ
304953	100736251	20992714121	Journal	journal	NN1
304953	100736251	20992714122	of	of	IO
304953	100736251	20992714123	Epidemiology	epidemiology	NP1_NN1
304953	100736251	20992714124	used	used	JJ_VVD
304953	100736251	20992714125	blood	blood	NN1
304953	100736251	20992714126	samples	sample	NN2_VVZ@
304953	100736251	20992714127	from	from	II
304953	100736251	20992714128	a	a	AT1
304953	100736251	20992714129	different	different	JJ
304953	100736251	20992714130	prostate	prostate	NN1
304953	100736251	20992714131	prevention	prevention	NN1
304953	100736251	20992714132	study	study	NN1
304953	100736251	20992714133	.	.	.
304953	100736251	20992714134	The	the	AT
304953	100736251	20992714135	results	result	NN2
304953	100736251	20992714136	of	of	IO
304953	100736251	20992714137	that	that	DD1
304953	100736251	20992714138	study	study	NN1
304953	100736251	20992714139	did	do	VDD
304953	100736251	20992714140	n't 	n't	XX
304953	100736251	20992714141	show	show	VVI
304953	100736251	20992714142	any	any	DD
304953	100736251	20992714143	correlation	correlation	NN1
304953	100736251	20992714144	between	between	II
304953	100736251	20992714145	omega-fat		JJ_NN1
304953	100736251	20992714146	levels	level	NN2
304953	100736251	20992714147	in	in	II
304953	100736251	20992714148	the	the	AT
304953	100736251	20992714149	blood	blood	NN1
304953	100736251	20992714150	and	and	CC
304953	100736251	20992714151	low-risk	low-risk	JJ_NN1
304953	100736251	20992714152	prostate	prostate	NN1
304953	100736251	20992714153	cancer	cancer	NN1
304953	100736251	20992714154	.	.	.
304953	100736251	20992714155	<p>		NULL
304953	100736251	20992714156	But	but	CCB
304953	100736251	20992714157	there	there	EX
304953	100736251	20992714158	was	be	VBDZ
304953	100736251	20992714159	a	a	AT1
304953	100736251	20992714160	catch	catch	NN1
304953	100736251	20992714161	,	,	,
304953	100736251	20992714162	because	because	CS
304953	100736251	20992714163	men	man	NN2
304953	100736251	20992714164	with	with	IW
304953	100736251	20992714165	the	the	AT
304953	100736251	20992714166	highest	high	JJT
304953	100736251	20992714167	DHA	dha	NN1
304953	100736251	20992714168	levels	level	NN2
304953	100736251	20992714169	were	be	VBDR
304953	100736251	20992714170	found	find	VVN
304953	100736251	20992714171	to	to	TO
304953	100736251	20992714172	be	be	VBI
304953	100736251	20992714173	2.5	2.5	MC
304953	100736251	20992714174	times	time	NNT2
304953	100736251	20992714175	more	more	RRR_RGR
304953	100736251	20992714176	likely	likely	JJ
304953	100736251	20992714177	to	to	TO
304953	100736251	20992714178	have	have	VHI
304953	100736251	20992714179	developed	develop	VVN
304953	100736251	20992714180	high-risk	high-risk	JJ
304953	100736251	20992714181	prostate	prostate	NN1
304953	100736251	20992714182	cancer	cancer	NN1
304953	100736251	20992714183	than	than	CSN
304953	100736251	20992714184	men	man	NN2
304953	100736251	20992714185	with	with	IW
304953	100736251	20992714186	the	the	AT
304953	100736251	20992714187	lowest	low	JJT
304953	100736251	20992714188	levels	level	NN2
304953	100736251	20992714189	.	.	.
304953	100736251	20992714190	<h>		NULL
304953	100736251	20992714191	Doubt	doubt	NN1_VV0
304953	100736251	20992714192	cast	cast	VVN_VV0
304953	100736251	20992714193	on	on	II
304953	100736251	20992714194	omega-3s	omega-3s	MC2
304953	100736251	20992714195	and	and	CC
304953	100736251	20992714196	heart	heart	NN1
304953	100736251	20992714197	disease	disease	NN1
304953	100736251	20992714198	protection	protection	NN1
304953	100736251	20992714199	<p>		NULL
304953	100736251	20992714200	Recent	recent	JJ
304953	100736251	20992714201	research	research	NN1
304953	100736251	20992714202	has	have	VHZ
304953	100736251	20992714203	also	also	RR
304953	100736251	20992714204	dented	dent	VVN
304953	100736251	20992714205	the	the	AT
304953	100736251	20992714206	reputation	reputation	NN1
304953	100736251	20992714207	that	that	CST
304953	100736251	20992714208	omega-3	omega-3	MC
304953	100736251	20992714209	fats	fat	NN2
304953	100736251	20992714210	have	have	VH0
304953	100736251	20992714211	for	for	IF
304953	100736251	20992714212	protecting	protect	VVG_JJ@
304953	100736251	20992714213	folks	folk	NN2
304953	100736251	20992714214	against	against	II
304953	100736251	20992714215	heart	heart	NN1
304953	100736251	20992714216	disease	disease	NN1
304953	100736251	20992714217	.	.	.
304953	100736251	20992714218	<p>		NULL
304953	100736251	20992714219	In	in	II
304953	100736251	20992714220	May	may	NPM1
304953	100736251	20992714221	of	of	IO
304953	100736251	20992714222	this	this	DD1
304953	100736251	20992714223	year	year	NNT1
304953	100736251	20992714224	,	,	,
304953	100736251	20992714225	Italian	italian	JJ_NN1
304953	100736251	20992714226	researchers	researcher	NN2
304953	100736251	20992714227	reported	report	VVN_VVD
304953	100736251	20992714228	in	in	II
304953	100736251	20992714229	the	the	AT
304953	100736251	20992714230	New	new	NP1
304953	100736251	20992714231	England	england	NP1
304953	100736251	20992714232	Journal	journal	NN1
304953	100736251	20992714233	of	of	IO
304953	100736251	20992714234	Medicine	medicine	NN1
304953	100736251	20992714235	that	that	CST
304953	100736251	20992714236	omega-3	omega-3	MC
304953	100736251	20992714237	fatty	fatty	JJ
304953	100736251	20992714238	acid	acid	NN1
304953	100736251	20992714239	supplements	supplement	NN2
304953	100736251	20992714240	did	do	VDD
304953	100736251	20992714241	nothing	nothing	PN1
304953	100736251	20992714242	to	to	TO
304953	100736251	20992714243	reduce	reduce	VVI
304953	100736251	20992714244	heart	heart	NN1
304953	100736251	20992714245	attacks	attack	NN2
304953	100736251	20992714246	,	,	,
304953	100736251	20992714247	strokes	stroke	NN2_VVZ
304953	100736251	20992714248	,	,	,
304953	100736251	20992714249	or	or	CC
304953	100736251	20992714250	deaths	death	NN2
304953	100736251	20992714251	from	from	II
304953	100736251	20992714252	heart	heart	NN1
304953	100736251	20992714253	disease	disease	NN1
304953	100736251	20992714254	@		II
304953	100736251	20992714255	@		II
304953	100736251	20992714256	@		II
304953	100736251	20992714257	@		II
304953	100736251	20992714258	@		II
304953	100736251	20992714259	@		II
304953	100736251	20992714260	@		II
304953	100736251	20992714261	@		II
304953	100736251	20992714262	@		II
304953	100736251	20992714263	@		II
304953	100736251	20992714264	Late	late	RR_JJ
304953	100736251	20992714265	last	last	MD
304953	100736251	20992714266	year	year	NNT1
304953	100736251	20992714267	,	,	,
304953	100736251	20992714268	a	a	AT1
304953	100736251	20992714269	Harvard	harvard	NP1
304953	100736251	20992714270	study	study	NN1
304953	100736251	20992714271	published	publish	VVN
304953	100736251	20992714272	in	in	II
304953	100736251	20992714273	JAMAfound		NN1_NP1
304953	100736251	20992714274	that	that	CST_DD1
304953	100736251	20992714275	fish	fish	NN_VV0@
304953	100736251	20992714276	oil	oil	NN1
304953	100736251	20992714277	supplements	supplement	NN2
304953	100736251	20992714278	immediately	immediately	RR
304953	100736251	20992714279	before	before	CS_II_RT@
304953	100736251	20992714280	and	and	CC
304953	100736251	20992714281	after	after	II_CS
304953	100736251	20992714282	surgery	surgery	NN1
304953	100736251	20992714283	did	do	VDD
304953	100736251	20992714284	n't 	n't	XX
304953	100736251	20992714285	prevent	prevent	VVI
304953	100736251	20992714286	postoperative	postoperative	JJ
304953	100736251	20992714287	atrial	atrial	JJ
304953	100736251	20992714288	fibrillation	fibrillation	NN1
304953	100736251	20992714289	among	among	II
304953	100736251	20992714290	cardiac	cardiac	JJ
304953	100736251	20992714291	surgery	surgery	NN1
304953	100736251	20992714292	patients	patient	NN2
304953	100736251	20992714293	.	.	.
304953	100736251	20992714294	<p>		NULL
304953	100736251	20992714295	And	and	CC
304953	100736251	20992714296	a	a	AT1
304953	100736251	20992714297	few	few	DA2
304953	100736251	20992714298	months	month	NNT2
304953	100736251	20992714299	before	before	CS_II
304953	100736251	20992714300	that	that	DD1
304953	100736251	20992714301	study	study	NN1
304953	100736251	20992714302	,	,	,
304953	100736251	20992714303	Greek	greek	JJ_NN1
304953	100736251	20992714304	researchers	researcher	NN2
304953	100736251	20992714305	weighed	weigh	VVD_VVN
304953	100736251	20992714306	in	in	RP@
304953	100736251	20992714307	with	with	IW
304953	100736251	20992714308	a	a	AT1
304953	100736251	20992714309	meta-analysis	meta-analysis	NN1
304953	100736251	20992714310	that	that	CST
304953	100736251	20992714311	came	come	VVD
304953	100736251	20992714312	to	to	II
304953	100736251	20992714313	the	the	AT
304953	100736251	20992714314	conclusion	conclusion	NN1
304953	100736251	20992714315	that	that	CST
304953	100736251	20992714316	fish	fish	NN_VV0@
304953	100736251	20992714317	oil	oil	NN1
304953	100736251	20992714318	supplements	supplement	NN2
304953	100736251	20992714319	are	be	VBR
304953	100736251	20992714320	useless	useless	JJ
304953	100736251	20992714321	if	if	CS_CSW@
304953	100736251	20992714322	you 're		NN1_VV0
304953	100736251	20992714323	looking	look	VVG
304953	100736251	20992714324	for	for	IF
304953	100736251	20992714325	protection	protection	NN1
304953	100736251	20992714326	from	from	II
304953	100736251	20992714327	heart	heart	NN1
304953	100736251	20992714328	disease	disease	NN1
304953	100736251	20992714329	"	"	"
304953	100736251	20992714330	related	related	JJ_VVD_VVN
304953	100736251	20992714331	death	death	NN1
304953	100736251	20992714332	,	,	,
304953	100736251	20992714333	heart	heart	NN1
304953	100736251	20992714334	attacks	attack	NN2
304953	100736251	20992714335	,	,	,
304953	100736251	20992714336	or	or	CC
304953	100736251	20992714337	stroke	stroke	NN1_VV0
304953	100736251	20992714338	.	.	.
304953	100736251	20992714339	<h>		NULL
304953	100736251	20992714340	Could	could	VM
304953	100736251	20992714341	it	it	PPH1
304953	100736251	20992714342	be	be	VBI
304953	100736251	20992714343	fish	fish	NN
304953	100736251	20992714344	oil	oil	NN1
304953	100736251	20992714345	and	and	CC
304953	100736251	20992714346	not	not	XX
304953	100736251	20992714347	fish	fish	NN
304953	100736251	20992714348	that 's		VVZ_NN2
304953	100736251	20992714349	to	to	TO
304953	100736251	20992714350	blame	blame	VVI
304953	100736251	20992714351	?	?	?
304953	100736251	20992714352	<p>		NULL
304953	100736251	20992714353	Omega-3s	omega-3s	MC2
304953	100736251	20992714354	have	have	VH0
304953	100736251	20992714355	anti-inflammatory	anti-inflammatory	JJ
304953	100736251	20992714356	effects	effect	NN2
304953	100736251	20992714357	,	,	,
304953	100736251	20992714358	and	and	CC
304953	100736251	20992714359	that 's		VVZ_NN2
304953	100736251	20992714360	part	part	NN1
304953	100736251	20992714361	of	of	IO
304953	100736251	20992714362	the	the	AT
304953	100736251	20992714363	reason	reason	NN1
304953	100736251	20992714364	they	they	PPHS2
304953	100736251	20992714365	have	have	VH0
304953	100736251	20992714366	been	be	VBN
304953	100736251	20992714367	seen	see	VVN
304953	100736251	20992714368	as	as	CSA_RG@_II@
304953	100736251	20992714369	dietary	dietary	JJ
304953	100736251	20992714370	good	good	JJ
304953	100736251	20992714371	guys	guy	NN2
304953	100736251	20992714372	and	and	CC
304953	100736251	20992714373	possibly	possibly	RR
304953	100736251	20992714374	having	have	VHG
304953	100736251	20992714375	an	a	AT1
304953	100736251	20992714376	anticancer	anticancer	NN1
304953	100736251	20992714377	effect	effect	NN1
304953	100736251	20992714378	.	.	.
304953	100736251	20992714379	Why	why	RRQ
304953	100736251	20992714380	they	they	PPHS2
304953	100736251	20992714381	might	might	VM
304953	100736251	20992714382	have	have	VHI
304953	100736251	20992714383	a	a	AT1
304953	100736251	20992714384	dark	dark	JJ_NN1
304953	100736251	20992714385	side	side	NN1
304953	100736251	20992714386	that	that	CST_DD1
304953	100736251	20992714387	increases	increase	VVZ
304953	100736251	20992714388	prostate	prostate	NN1
304953	100736251	20992714389	cancer	cancer	NN1
304953	100736251	20992714390	risk	risk	NN1
304953	100736251	20992714391	is	be	VBZ
304953	100736251	20992714392	anybodys	anybody	NN2
304953	100736251	20992714393	guess	guess	VV0
304953	100736251	20992714394	.	.	.
304953	100736251	20992714395	<p>		NULL
304953	100736251	20992714396	One	one	MC1
304953	100736251	20992714397	important	important	JJ
304953	100736251	20992714398	point	point	NN1
304953	100736251	20992714399	to	to	TO
304953	100736251	20992714400	keep	keep	VVI
304953	100736251	20992714401	in	in	II
304953	100736251	20992714402	mind	mind	NN1
304953	100736251	20992714403	,	,	,
304953	100736251	20992714404	though	though	CS_RR@
304953	100736251	20992714405	,	,	,
304953	100736251	20992714406	is	be	VBZ
304953	100736251	20992714407	that	that	DD1
304953	100736251	20992714408	there	there	EX
304953	100736251	20992714409	may	may	VM
304953	100736251	20992714410	be	be	VBI
304953	100736251	20992714411	a	a	AT1
304953	100736251	20992714412	difference	difference	NN1
304953	100736251	20992714413	between	between	II
304953	100736251	20992714414	eating	eat	VVG_NN1
304953	100736251	20992714415	fish	fish	NN
304953	100736251	20992714416	and	and	CC
304953	100736251	20992714417	taking	take	VVG
304953	100736251	20992714418	fish-oil	fish-oil	JJ_NN1
304953	100736251	20992714419	supplements	supplement	NN2
304953	100736251	20992714420	.	.	.
304953	100736251	20992714421	Over	over	RP_II
304953	100736251	20992714422	and	and	CC
304953	100736251	20992714423	over	over	RP_II
304953	100736251	20992714424	again	again	RT
304953	100736251	20992714425	,	,	,
304953	100736251	20992714426	nutrition	nutrition	NN1
304953	100736251	20992714427	research	research	NN1
304953	100736251	20992714428	has	have	VHZ
304953	100736251	20992714429	shown	show	VVN
304953	100736251	20992714430	that	that	CST_DD1
304953	100736251	20992714431	diets	diet	VVZ@_NN2
304953	100736251	20992714432	full	full	JJ
304953	100736251	20992714433	of	of	IO
304953	100736251	20992714434	food	food	NN1
304953	100736251	20992714435	and	and	CC
304953	100736251	20992714436	drink	drink	VV0
304953	100736251	20992714437	that	that	CST_DD1
304953	100736251	20992714438	supply	supply	VV0_NN1
304953	100736251	20992714439	vitamins	vitamin	NN2
304953	100736251	20992714440	,	,	,
304953	100736251	20992714441	minerals	mineral	NN2
304953	100736251	20992714442	,	,	,
304953	100736251	20992714443	and	and	CC
304953	100736251	20992714444	healthful	healthful	JJ
304953	100736251	20992714445	fats	fat	NN2
304953	100736251	20992714446	are	be	VBR
304953	100736251	20992714447	correlated	correlate	VVN
304953	100736251	20992714448	with	with	IW
304953	100736251	20992714449	good	good	JJ
304953	100736251	20992714450	health	health	NN1
304953	100736251	20992714451	,	,	,
304953	100736251	20992714452	whereas	whereas	CS
304953	100736251	20992714453	studies	study	NN2
304953	100736251	20992714454	@		II
304953	100736251	20992714455	@		II
304953	100736251	20992714456	@		II
304953	100736251	20992714457	@		II
304953	100736251	20992714458	@		II
304953	100736251	20992714459	@		II
304953	100736251	20992714460	@		II
304953	100736251	20992714461	@		II
304953	100736251	20992714462	@		II
304953	100736251	20992714463	@		II
304953	100736251	20992714464	be	be	VBI
304953	100736251	20992714465	the	the	AT
304953	100736251	20992714466	healthful	healthful	JJ
304953	100736251	20992714467	constituents	constituent	NN2
304953	100736251	20992714468	of	of	IO
304953	100736251	20992714469	the	the	AT
304953	100736251	20992714470	food	food	NN1
304953	100736251	20992714471	have	have	VH0
304953	100736251	20992714472	consistently	consistently	RR
304953	100736251	20992714473	been	be	VBN
304953	100736251	20992714474	disappointing	disappointing	JJ_VVG@
304953	100736251	20992714475	.	.	.
304953	100736251	20992714476	<p>		NULL
304953	100736251	20992714477	Just	just	RR
304953	100736251	20992714478	to	to	TO
304953	100736251	20992714479	be	be	VBI
304953	100736251	20992714480	clear	clear	JJ
304953	100736251	20992714481	:	:	:
304953	100736251	20992714482	this	this	DD1
304953	100736251	20992714483	latest	late	JJT
304953	100736251	20992714484	study	study	NN1
304953	100736251	20992714485	correlated	correlate	VVD_VVN_JJ@
304953	100736251	20992714486	blood	blood	NN1
304953	100736251	20992714487	levels	level	NN2
304953	100736251	20992714488	of	of	IO
304953	100736251	20992714489	omega-3	omega-3	MC
304953	100736251	20992714490	fats	fat	NN2
304953	100736251	20992714491	to	to	II
304953	100736251	20992714492	prostate	prostate	NN1
304953	100736251	20992714493	cancer	cancer	NN1
304953	100736251	20992714494	.	.	.
304953	100736251	20992714495	It	it	PPH1
304953	100736251	20992714496	was n't		VV0
304953	100736251	20992714497	able	able	JK
304953	100736251	20992714498	to	to	TO
304953	100736251	20992714499	prove	prove	VVI
304953	100736251	20992714500	that	that	CST_DD1
304953	100736251	20992714501	omega-3	omega-3	MC
304953	100736251	20992714502	fats	fat	NN2
304953	100736251	20992714503	cause	cause	VV0
304953	100736251	20992714504	prostate	prostate	NN1
304953	100736251	20992714505	cancer	cancer	NN1
304953	100736251	20992714506	,	,	,
304953	100736251	20992714507	nor	nor	CC
304953	100736251	20992714508	did	do	VDD
304953	100736251	20992714509	it	it	PPH1
304953	100736251	20992714510	go	go	VVI
304953	100736251	20992714511	into	into	II
304953	100736251	20992714512	how	how	RRQ
304953	100736251	20992714513	those	those	DD2
304953	100736251	20992714514	blood	blood	NN1
304953	100736251	20992714515	levels	level	NN2
304953	100736251	20992714516	came	come	VVD
304953	100736251	20992714517	about	about	RP@
304953	100736251	20992714518	and	and	CC
304953	100736251	20992714519	whether	whether	CSW
304953	100736251	20992714520	men	man	NN2
304953	100736251	20992714521	with	with	IW
304953	100736251	20992714522	high	high	JJ
304953	100736251	20992714523	blood	blood	NN1
304953	100736251	20992714524	levels	level	NN2
304953	100736251	20992714525	were	be	VBDR
304953	100736251	20992714526	big	big	JJ
304953	100736251	20992714527	fish	fish	NN
304953	100736251	20992714528	eaters	eater	NN2
304953	100736251	20992714529	,	,	,
304953	100736251	20992714530	took	take	VVD
304953	100736251	20992714531	fish-oil	fish-oil	JJ
304953	100736251	20992714532	supplements	supplement	NN2
304953	100736251	20992714533	,	,	,
304953	100736251	20992714534	or	or	CC
304953	100736251	20992714535	both	both	DB2
304953	100736251	20992714536	.	.	.
304953	100736251	20992714537	<p>		NULL
304953	100736251	20992714538	Despite	despite	II
304953	100736251	20992714539	this	this	DD1
304953	100736251	20992714540	one	one	MC1
304953	100736251	20992714541	study	study	NN1_VV0@
304953	100736251	20992714542	,	,	,
304953	100736251	20992714543	you	you	PPY
304953	100736251	20992714544	should	should	VM
304953	100736251	20992714545	still	still	RR
304953	100736251	20992714546	consider	consider	VVI
304953	100736251	20992714547	eating	eat	VVG_NN1
304953	100736251	20992714548	fish	fish	NN
304953	100736251	20992714549	and	and	CC
304953	100736251	20992714550	other	other	JJ
304953	100736251	20992714551	seafood	seafood	NN1
304953	100736251	20992714552	as	as	II_CSA
304953	100736251	20992714553	a	a	AT1
304953	100736251	20992714554	healthy	healthy	JJ
304953	100736251	20992714555	strategy	strategy	NN1
304953	100736251	20992714556	.	.	.
304953	100736251	20992714557	If	if	CS
304953	100736251	20992714558	we	we	PPIS2
304953	100736251	20992714559	could	could	VM
304953	100736251	20992714560	absolutely	absolutely	RR
304953	100736251	20992714561	,	,	,
304953	100736251	20992714562	positively	positively	RR
304953	100736251	20992714563	say	say	VV0
304953	100736251	20992714564	that	that	CST
304953	100736251	20992714565	the	the	AT
304953	100736251	20992714566	benefits	benefit	NN2
304953	100736251	20992714567	of	of	IO
304953	100736251	20992714568	eating	eat	VVG_NN1
304953	100736251	20992714569	seafood	seafood	NN1
304953	100736251	20992714570	comes	come	VVZ
304953	100736251	20992714571	entirely	entirely	RR
304953	100736251	20992714572	from	from	II
304953	100736251	20992714573	omega-3	omega-3	MC
304953	100736251	20992714574	fats	fat	NN2
304953	100736251	20992714575	,	,	,
304953	100736251	20992714576	then	then	RT
304953	100736251	20992714577	downing	down	VVG
304953	100736251	20992714578	fish	fish	NN
304953	100736251	20992714579	oil	oil	NN1
304953	100736251	20992714580	pills	pill	NN2
304953	100736251	20992714581	would	would	VM
304953	100736251	20992714582	be	be	VBI
304953	100736251	20992714583	an	a	AT1
304953	100736251	20992714584	alternative	alternative	NN1_JJ
304953	100736251	20992714585	to	to	II
304953	100736251	20992714586	eating	eat	VVG_NN1
304953	100736251	20992714587	fish	fish	NN
304953	100736251	20992714588	.	.	.
304953	100736251	20992714589	But	but	CCB
304953	100736251	20992714590	its	its	APPGE
304953	100736251	20992714591	more	more	DAR_RRR
304953	100736251	20992714592	than	than	CSN
304953	100736251	20992714593	likely	likely	JJ
304953	100736251	20992714594	that	that	CST
304953	100736251	20992714595	you	you	PPY
304953	100736251	20992714596	need	need	VV0
304953	100736251	20992714597	the	the	AT
304953	100736251	20992714598	entire	entire	JJ
304953	100736251	20992714599	orchestra	orchestra	NN1
304953	100736251	20992714600	of	of	IO
304953	100736251	20992714601	fish	fish	NN
304953	100736251	20992714602	fats	fat	NN2
304953	100736251	20992714603	,	,	,
304953	100736251	20992714604	vitamins	vitamin	NN2
304953	100736251	20992714605	,	,	,
304953	100736251	20992714606	minerals	mineral	NN2
304953	100736251	20992714607	,	,	,
304953	100736251	20992714608	and	and	CC
304953	100736251	20992714609	supporting	supporting	JJ_VVG
304953	100736251	20992714610	molecules	molecule	NN2
304953	100736251	20992714611	,	,	,
304953	100736251	20992714612	rather	rather	II21_CS21@
304953	100736251	20992714613	than	than	II22_CS22@
304953	100736251	20992714614	the	the	AT
304953	100736251	20992714615	lone	lone	JJ
304953	100736251	20992714616	notes	note	NN2
304953	100736251	20992714617	of	of	IO
304953	100736251	20992714618	EPA	epa	NP1
304953	100736251	20992714619	and	and	CC
304953	100736251	20992714620	DHA.		NP1
304953	100736259	20992714640	@@##	----------	----------
304953	100736259	20992714641	@@100736259		FO
304953	100736259	20992714642	@4936259/		VV0_NN1
304953	100736259	20992714643	46989		MC
304953	100736259	20992714644	@qwx906989		FO
304953	100736259	20992714645	<p>		NULL
304953	100736259	20992714646	Metformin	metformin	NN1_NP1@
304953	100736259	20992714647	"	"	"
304953	100736259	20992714648	the	the	AT
304953	100736259	20992714649	drug	drug	NN1
304953	100736259	20992714650	that	that	CST
304953	100736259	20992714651	millions	million	NNO2
304953	100736259	20992714652	of	of	IO
304953	100736259	20992714653	people	people	NN
304953	100736259	20992714654	with	with	IW
304953	100736259	20992714655	diabetes	diabetes	NN1
304953	100736259	20992714656	take	take	VV0
304953	100736259	20992714657	to	to	TO
304953	100736259	20992714658	control	control	VVI
304953	100736259	20992714659	their	their	APPGE
304953	100736259	20992714660	blood	blood	NN1
304953	100736259	20992714661	sugar	sugar	NN1
304953	100736259	20992714662	"	"	"
304953	100736259	20992714663	may	may	VM
304953	100736259	20992714664	be	be	VBI
304953	100736259	20992714665	on	on	II
304953	100736259	20992714666	the	the	AT
304953	100736259	20992714667	brink	brink	NN1
304953	100736259	20992714668	of	of	IO
304953	100736259	20992714669	a	a	AT1
304953	100736259	20992714670	second	second	MD_NNT1
304953	100736259	20992714671	career	career	NN1
304953	100736259	20992714672	.	.	.
304953	100736259	20992714673	Evidence	evidence	NN1
304953	100736259	20992714674	from	from	II
304953	100736259	20992714675	a	a	AT1
304953	100736259	20992714676	variety	variety	NN1
304953	100736259	20992714677	of	of	IO
304953	100736259	20992714678	studies	study	NN2
304953	100736259	20992714679	suggests	suggest	VVZ
304953	100736259	20992714680	that	that	DD1_CST
304953	100736259	20992714681	metformin	metformin	NN1
304953	100736259	20992714682	may	may	VM
304953	100736259	20992714683	delay	delay	VVI
304953	100736259	20992714684	or	or	CC
304953	100736259	20992714685	slow	slow	VVI
304953	100736259	20992714686	the	the	AT
304953	100736259	20992714687	progression	progression	NN1
304953	100736259	20992714688	of	of	IO
304953	100736259	20992714689	prostate	prostate	NN1
304953	100736259	20992714690	cancer	cancer	NN1
304953	100736259	20992714691	.	.	.
304953	100736259	20992714692	<p>		NULL
304953	100736259	20992714693	At	at	II
304953	100736259	20992714694	same	same	DA
304953	100736259	20992714695	time	time	NNT1
304953	100736259	20992714696	,	,	,
304953	100736259	20992714697	researchers	researcher	NN2
304953	100736259	20992714698	are	be	VBR
304953	100736259	20992714699	finding	find	VVG
304953	100736259	20992714700	that	that	DD1_CST
304953	100736259	20992714701	metformin	metformin	NN1
304953	100736259	20992714702	does	do	VDZ
304953	100736259	20992714703	not	not	XX
304953	100736259	20992714704	seem	seem	VVI
304953	100736259	20992714705	to	to	TO
304953	100736259	20992714706	prevent	prevent	VVI
304953	100736259	20992714707	the	the	AT
304953	100736259	20992714708	development	development	NN1
304953	100736259	20992714709	of	of	IO
304953	100736259	20992714710	prostate	prostate	NN1
304953	100736259	20992714711	cancer	cancer	NN1
304953	100736259	20992714712	in	in	II
304953	100736259	20992714713	the	the	AT
304953	100736259	20992714714	first	first	MD
304953	100736259	20992714715	place	place	NN1
304953	100736259	20992714716	.	.	.
304953	100736259	20992714717	One	one	MC1
304953	100736259	20992714718	possible	possible	JJ
304953	100736259	20992714719	explanation	explanation	NN1
304953	100736259	20992714720	for	for	IF
304953	100736259	20992714721	the	the	AT
304953	100736259	20992714722	discrepancy	discrepancy	NN1
304953	100736259	20992714723	is	be	VBZ
304953	100736259	20992714724	that	that	CST_DD1
304953	100736259	20992714725	while	while	CS_NNT1@
304953	100736259	20992714726	metformin	metformin	NN1
304953	100736259	20992714727	may	may	VM
304953	100736259	20992714728	curtail	curtail	VVI
304953	100736259	20992714729	the	the	AT
304953	100736259	20992714730	survival	survival	NN1
304953	100736259	20992714731	of	of	IO
304953	100736259	20992714732	cancer	cancer	NN1
304953	100736259	20992714733	cells	cell	NN2
304953	100736259	20992714734	,	,	,
304953	100736259	20992714735	and	and	CC
304953	100736259	20992714736	so	so	RR
304953	100736259	20992714737	be	be	VBI
304953	100736259	20992714738	helpful	helpful	JJ
304953	100736259	20992714739	in	in	II
304953	100736259	20992714740	treatment	treatment	NN1
304953	100736259	20992714741	,	,	,
304953	100736259	20992714742	it	it	PPH1
304953	100736259	20992714743	may	may	VM
304953	100736259	20992714744	not	not	XX
304953	100736259	20992714745	have	have	VHI
304953	100736259	20992714746	much	much	DA1
304953	100736259	20992714747	influence	influence	NN1
304953	100736259	20992714748	on	on	II
304953	100736259	20992714749	the	the	AT
304953	100736259	20992714750	events	event	NN2
304953	100736259	20992714751	that	that	CST
304953	100736259	20992714752	initiate	initiate	VV0
304953	100736259	20992714753	cancer	cancer	NN1
304953	100736259	20992714754	and	and	CC
304953	100736259	20992714755	transform	transform	VV0
304953	100736259	20992714756	normal	normal	JJ
304953	100736259	20992714757	cells	cell	NN2
304953	100736259	20992714758	into	into	II
304953	100736259	20992714759	cancerous	cancerous	JJ
304953	100736259	20992714760	<p>		NULL
304953	100736259	20992714761	The	the	AT
304953	100736259	20992714762	interest	interest	NN1
304953	100736259	20992714763	in	in	II
304953	100736259	20992714764	metformins		NN2
304953	100736259	20992714765	anticancer	anticancer	NN1
304953	100736259	20992714766	potential	potential	NN1
304953	100736259	20992714767	is	be	VBZ
304953	100736259	20992714768	not	not	XX
304953	100736259	20992714769	limited	limit	VVN
304953	100736259	20992714770	to	to	II
304953	100736259	20992714771	prostate	prostate	NN1
304953	100736259	20992714772	cancer	cancer	NN1
304953	100736259	20992714773	.	.	.
304953	100736259	20992714774	On	on	II
304953	100736259	20992714775	www.clinicaltrials.gov	www.clinicaltrials.gov	NNU
304953	100736259	20992714776	,	,	,
304953	100736259	20992714777	maintained	maintain	VVN
304953	100736259	20992714778	by	by	II
304953	100736259	20992714779	the	the	AT
304953	100736259	20992714780	National	national	JJ
304953	100736259	20992714781	Institutes	institute	NN2
304953	100736259	20992714782	of	of	IO
304953	100736259	20992714783	Health	health	NN1
304953	100736259	20992714784	,	,	,
304953	100736259	20992714785	you 'll		VV0_NN1
304953	100736259	20992714786	find	find	VV0
304953	100736259	20992714787	more	more	DAR
304953	100736259	20992714788	than	than	CSN
304953	100736259	20992714789	60	60	MC
304953	100736259	20992714790	clinical	clinical	JJ
304953	100736259	20992714791	trials	trial	NN2
304953	100736259	20992714792	of	of	IO
304953	100736259	20992714793	metformin	metformin	NN1
304953	100736259	20992714794	being	be	VBG
304953	100736259	20992714795	tested	test	VVN
304953	100736259	20992714796	as	as	II
304953	100736259	20992714797	a	a	AT1
304953	100736259	20992714798	treatment	treatment	NN1
304953	100736259	20992714799	for	for	IF
304953	100736259	20992714800	many	many	DA2
304953	100736259	20992714801	different	different	JJ
304953	100736259	20992714802	cancers	cancer	NN2
304953	100736259	20992714803	,	,	,
304953	100736259	20992714804	including	including	II_VVG@
304953	100736259	20992714805	breast	breast	NN1
304953	100736259	20992714806	,	,	,
304953	100736259	20992714807	colon	colon	NN1
304953	100736259	20992714808	,	,	,
304953	100736259	20992714809	endometrial	endometrial	JJ
304953	100736259	20992714810	,	,	,
304953	100736259	20992714811	and	and	CC
304953	100736259	20992714812	pancreatic	pancreatic	JJ
304953	100736259	20992714813	cancer	cancer	NN1
304953	100736259	20992714814	.	.	.
304953	100736259	20992714815	A	a	AT1
304953	100736259	20992714816	dozen	dozen	NNO
304953	100736259	20992714817	different	different	JJ
304953	100736259	20992714818	prostate	prostate	NN1
304953	100736259	20992714819	cancer	cancer	NN1
304953	100736259	20992714820	trials	trial	NN2
304953	100736259	20992714821	are	be	VBR
304953	100736259	20992714822	listed	list	VVN_JJ
304953	100736259	20992714823	,	,	,
304953	100736259	20992714824	four	four	MC
304953	100736259	20992714825	of	of	IO
304953	100736259	20992714826	which	which	DDQ
304953	100736259	20992714827	are	be	VBR
304953	100736259	20992714828	still	still	RR
304953	100736259	20992714829	recruiting	recruit	VVG_NN1
304953	100736259	20992714830	volunteers	volunteer	NN2
304953	100736259	20992714831	.	.	.
304953	100736259	20992714832	@		II
304953	100736259	20992714833	@		II
304953	100736259	20992714834	@		II
304953	100736259	20992714835	@		II
304953	100736259	20992714836	@		II
304953	100736259	20992714837	@		II
304953	100736259	20992714838	@		II
304953	100736259	20992714839	@		II
304953	100736259	20992714840	@		II
304953	100736259	20992714841	@		II
304953	100736259	20992714842	inexpensive	inexpensive	JJ
304953	100736259	20992714843	.	.	.
304953	100736259	20992714844	Metformin	metformin	NN1_NP1@
304953	100736259	20992714845	is	be	VBZ
304953	100736259	20992714846	sold	sell	VVN
304953	100736259	20992714847	under	under	II
304953	100736259	20992714848	brand	brand	NN1
304953	100736259	20992714849	names	name	NN2_VVZ@
304953	100736259	20992714850	like	like	II
304953	100736259	20992714851	Glucophage	glucophage	NP1
304953	100736259	20992714852	and	and	CC
304953	100736259	20992714853	Fortamet		NN1_NP1
304953	100736259	20992714854	but	but	CCB
304953	100736259	20992714855	is	be	VBZ
304953	100736259	20992714856	readily	readily	RR
304953	100736259	20992714857	available	available	JJ
304953	100736259	20992714858	as	as	II_CSA
304953	100736259	20992714859	a	a	AT1
304953	100736259	20992714860	generic	generic	JJ
304953	100736259	20992714861	.	.	.
304953	100736259	20992714862	For	for	IF
304953	100736259	20992714863	someone	someone	PN1
304953	100736259	20992714864	taking	take	VVG
304953	100736259	20992714865	metformin	metformin	NN1
304953	100736259	20992714866	for	for	IF
304953	100736259	20992714867	diabetes	diabetes	NN1
304953	100736259	20992714868	,	,	,
304953	100736259	20992714869	a	a	AT1
304953	100736259	20992714870	months	month	NNT2
304953	100736259	20992714871	supply	supply	NN1
304953	100736259	20992714872	of	of	IO
304953	100736259	20992714873	the	the	AT
304953	100736259	20992714874	generic	generic	JJ
304953	100736259	20992714875	can	can	VM
304953	100736259	20992714876	cost	cost	VVI
304953	100736259	20992714877	as	as	RG
304953	100736259	20992714878	little	little	DA1
304953	100736259	20992714879	as	as	CSA
304953	100736259	20992714880	$5		NNU
304953	100736259	20992714881	.	.	.
304953	100736259	20992714882	<h>		NULL
304953	100736259	20992714883	Study	study	NN1_VV0@
304953	100736259	20992714884	finding	finding	NN1_VVG
304953	100736259	20992714885	:	:	:
304953	100736259	20992714886	Metformin	metformin	NP1_NN1
304953	100736259	20992714887	use	use	NN1_VV0
304953	100736259	20992714888	after	after	II_CS
304953	100736259	20992714889	diagnosis	diagnosis	NN1
304953	100736259	20992714890	lowers	lower	VVZ
304953	100736259	20992714891	risk	risk	NN1
304953	100736259	20992714892	of	of	IO
304953	100736259	20992714893	dying	die	VVG_JJ
304953	100736259	20992714894	from	from	II
304953	100736259	20992714895	prostate	prostate	NN1
304953	100736259	20992714896	cancer	cancer	NN1
304953	100736259	20992714897	<p>		NULL
304953	100736259	20992714898	The	the	AT
304953	100736259	20992714899	latest	late	JJT
304953	100736259	20992714900	findings	finding	NN2
304953	100736259	20992714901	regarding	regarding	II_VVG
304953	100736259	20992714902	metformin	metformin	NN1
304953	100736259	20992714903	and	and	CC
304953	100736259	20992714904	prostate	prostate	NN1
304953	100736259	20992714905	cancer	cancer	NN1
304953	100736259	20992714906	come	come	VVN@_VV0
304953	100736259	20992714907	from	from	II
304953	100736259	20992714908	a	a	AT1
304953	100736259	20992714909	research	research	NN1
304953	100736259	20992714910	group	group	NN1
304953	100736259	20992714911	at	at	II
304953	100736259	20992714912	the	the	AT
304953	100736259	20992714913	University	university	NN1
304953	100736259	20992714914	of	of	IO
304953	100736259	20992714915	Toronto	toronto	NP1
304953	100736259	20992714916	.	.	.
304953	100736259	20992714917	Because	because	II21
304953	100736259	20992714918	of	of	II22
304953	100736259	20992714919	universal	universal	JJ
304953	100736259	20992714920	health	health	NN1
304953	100736259	20992714921	insurance	insurance	NN1
304953	100736259	20992714922	,	,	,
304953	100736259	20992714923	Canada	canada	NP1
304953	100736259	20992714924	is	be	VBZ
304953	100736259	20992714925	a	a	AT1
304953	100736259	20992714926	treasure	treasure	NN1
304953	100736259	20992714927	trove	trove	NN1
304953	100736259	20992714928	of	of	IO
304953	100736259	20992714929	patient	patient	JJ_NN1
304953	100736259	20992714930	databases	database	NN2
304953	100736259	20992714931	,	,	,
304953	100736259	20992714932	and	and	CC
304953	100736259	20992714933	the	the	AT
304953	100736259	20992714934	Toronto	toronto	NP1
304953	100736259	20992714935	researchers	researcher	NN2
304953	100736259	20992714936	did	do	VDD
304953	100736259	20992714937	this	this	DD1
304953	100736259	20992714938	study	study	VVI
304953	100736259	20992714939	by	by	II
304953	100736259	20992714940	cross-referencing	cross-reference	VVG_NN1
304953	100736259	20992714941	diabetes	diabetes	NN1
304953	100736259	20992714942	,	,	,
304953	100736259	20992714943	cancer	cancer	NN1
304953	100736259	20992714944	,	,	,
304953	100736259	20992714945	and	and	CC
304953	100736259	20992714946	drug	drug	NN1
304953	100736259	20992714947	benefit	benefit	NN1_VV0
304953	100736259	20992714948	databases	database	NN2
304953	100736259	20992714949	for	for	IF
304953	100736259	20992714950	the	the	AT
304953	100736259	20992714951	province	province	NN1
304953	100736259	20992714952	of	of	IO
304953	100736259	20992714953	Ontario	ontario	NP1
304953	100736259	20992714954	.	.	.
304953	100736259	20992714955	They	they	PPHS2
304953	100736259	20992714956	study	study	VV0@
304953	100736259	20992714957	included	include	VVN_VVD
304953	100736259	20992714958	3,837	3,837	MC
304953	100736259	20992714959	men	man	NN2
304953	100736259	20992714960	with	with	IW
304953	100736259	20992714961	diabetes	diabetes	NN1
304953	100736259	20992714962	and	and	CC
304953	100736259	20992714963	median	median	JJ_NN1
304953	100736259	20992714964	age	age	NN1
304953	100736259	20992714965	of	of	IO
304953	100736259	20992714966	diagnosis	diagnosis	NN1
304953	100736259	20992714967	was	be	VBDZ
304953	100736259	20992714968	75	75	MC
304953	100736259	20992714969	.	.	.
304953	100736259	20992714970	<p>		NULL
304953	100736259	20992714971	Writing	write	VVG_NN1
304953	100736259	20992714972	in	in	II
304953	100736259	20992714973	the	the	AT
304953	100736259	20992714974	Journal	journal	NN1
304953	100736259	20992714975	of	of	IO
304953	100736259	20992714976	Clinical	clinical	JJ
304953	100736259	20992714977	Oncology	oncology	NN1_NP1
304953	100736259	20992714978	,	,	,
304953	100736259	20992714979	the	the	AT
304953	100736259	20992714980	researchers	researcher	NN2
304953	100736259	20992714981	showed	show	VVD
304953	100736259	20992714982	a	a	AT1
304953	100736259	20992714983	correlation	correlation	NN1
304953	100736259	20992714984	between	between	II
304953	100736259	20992714985	taking	take	VVG
304953	100736259	20992714986	metformin	metformin	NN1
304953	100736259	20992714987	after	after	II_CS
304953	100736259	20992714988	prostate	prostate	NN1
304953	100736259	20992714989	cancer	cancer	NN1
304953	100736259	20992714990	diagnosis	diagnosis	NN1
304953	100736259	20992714991	and	and	CC
304953	100736259	20992714992	a	a	AT1
304953	100736259	20992714993	decreased	decreased	JJ@
304953	100736259	20992714994	risk	risk	NN1
304953	100736259	20992714995	of	of	IO
304953	100736259	20992714996	dying	die	VVG_JJ
304953	100736259	20992714997	from	from	II
304953	100736259	20992714998	the	the	AT
304953	100736259	20992714999	disease	disease	NN1
304953	100736259	20992715000	.	.	.
304953	100736259	20992715001	More	more	RGR_RRR
304953	100736259	20992715002	specifically	specifically	RR
304953	100736259	20992715003	,	,	,
304953	100736259	20992715004	the	the	AT
304953	100736259	20992715005	researchers	researcher	NN2
304953	100736259	20992715006	found	find	VVD_VVN
304953	100736259	20992715007	that	that	CST
304953	100736259	20992715008	each	each	DD1
304953	100736259	20992715009	additional	additional	JJ
304953	100736259	20992715010	six	six	MC
304953	100736259	20992715011	months	month	NNT2
304953	100736259	20992715012	of	of	IO
304953	100736259	20992715013	metformin	metformin	NN1
304953	100736259	20992715014	use	use	NN1_VV0
304953	100736259	20992715015	after	after	II_CS
304953	100736259	20992715016	diagnosis	diagnosis	NN1
304953	100736259	20992715017	was	be	VBDZ
304953	100736259	20992715018	associated	associate	VVN
304953	100736259	20992715019	with	with	IW
304953	100736259	20992715020	a	a	AT1
304953	100736259	20992715021	24%		NNU
304953	100736259	20992715022	decrease	decrease	NN1_VV0
304953	100736259	20992715023	in	in	II
304953	100736259	20992715024	the	the	AT
304953	100736259	20992715025	risk	risk	NN1
304953	100736259	20992715026	of	of	IO
304953	100736259	20992715027	dying	die	VVG_JJ
304953	100736259	20992715028	from	from	II
304953	100736259	20992715029	prostate	prostate	NN1
304953	100736259	20992715030	cancer	cancer	NN1
304953	100736259	20992715031	.	.	.
304953	100736259	20992715032	@		II
304953	100736259	20992715033	@		II
304953	100736259	20992715034	@		II
304953	100736259	20992715035	@		II
304953	100736259	20992715036	@		II
304953	100736259	20992715037	@		II
304953	100736259	20992715038	@		II
304953	100736259	20992715039	@		II
304953	100736259	20992715040	@		II
304953	100736259	20992715041	@		II
304953	100736259	20992715042	post-diagnosis		JJ
304953	100736259	20992715043	metformin	metformin	NN1
304953	100736259	20992715044	use	use	NN1
304953	100736259	20992715045	but	but	CCB
304953	100736259	20992715046	that	that	DD1
304953	100736259	20992715047	association	association	NN1
304953	100736259	20992715048	weakened	weaken	VVN_VVD
304953	100736259	20992715049	as	as	CSA_II@
304953	100736259	20992715050	time	time	NNT1
304953	100736259	20992715051	went	go	VVD
304953	100736259	20992715052	on	on	RP@
304953	100736259	20992715053	.	.	.
304953	100736259	20992715054	<p>		NULL
304953	100736259	20992715055	Toronto	toronto	NP1
304953	100736259	20992715056	researchers	researcher	NN2
304953	100736259	20992715057	conducted	conduct	VVD_VVN
304953	100736259	20992715058	several	several	DA2
304953	100736259	20992715059	studies-within-the-study		NN2
304953	100736259	20992715060	,	,	,
304953	100736259	20992715061	looking	look	VVG
304953	100736259	20992715062	at	at	II
304953	100736259	20992715063	various	various	JJ
304953	100736259	20992715064	subgroups	subgroup	NN2
304953	100736259	20992715065	,	,	,
304953	100736259	20992715066	partly	partly	RR
304953	100736259	20992715067	to	to	TO
304953	100736259	20992715068	guard	guard	VVI
304953	100736259	20992715069	against	against	II
304953	100736259	20992715070	the	the	AT
304953	100736259	20992715071	misleading	misleading	JJ
304953	100736259	20992715072	"	"	"
304953	100736259	20992715073	healthy-user		JJ_NN1
304953	100736259	20992715074	effect	effect	NN1
304953	100736259	20992715075	"	"	"
304953	100736259	20992715076	:	:	:
304953	100736259	20992715077	metformin	metformin	NN1
304953	100736259	20992715078	users	user	NN2
304953	100736259	20992715079	might	might	VM
304953	100736259	20992715080	have	have	VHI
304953	100736259	20992715081	lower	low	JJR
304953	100736259	20992715082	risk	risk	NN1
304953	100736259	20992715083	of	of	IO
304953	100736259	20992715084	deadly	deadly	JJ
304953	100736259	20992715085	prostate	prostate	NN1
304953	100736259	20992715086	cancer	cancer	NN1
304953	100736259	20992715087	because	because	CS
304953	100736259	20992715088	they	they	PPHS2
304953	100736259	20992715089	are	be	VBR
304953	100736259	20992715090	healthier	healthy	JJR
304953	100736259	20992715091	to	to	TO
304953	100736259	20992715092	begin	begin	VVI
304953	100736259	20992715093	with	with	IW
304953	100736259	20992715094	,	,	,
304953	100736259	20992715095	not	not	XX
304953	100736259	20992715096	because	because	II21
304953	100736259	20992715097	of	of	II22
304953	100736259	20992715098	anything	anything	PN1
304953	100736259	20992715099	to	to	TO
304953	100736259	20992715100	do	do	VDI
304953	100736259	20992715101	with	with	IW
304953	100736259	20992715102	metformin	metformin	NN1
304953	100736259	20992715103	.	.	.
304953	100736259	20992715104	But	but	CCB
304953	100736259	20992715105	when	when	CS
304953	100736259	20992715106	they	they	PPHS2
304953	100736259	20992715107	compared	compare	VVD
304953	100736259	20992715108	men	man	NN2
304953	100736259	20992715109	who	who	PNQS
304953	100736259	20992715110	took	take	VVD
304953	100736259	20992715111	metformin	metformin	NN1
304953	100736259	20992715112	to	to	II
304953	100736259	20992715113	those	those	DD2
304953	100736259	20992715114	who	who	PNQS
304953	100736259	20992715115	managed	manage	VVD
304953	100736259	20992715116	"	"	"
304953	100736259	20992715117	or	or	CC
304953	100736259	20992715118	tried	try	VVD
304953	100736259	20992715119	to	to	TO
304953	100736259	20992715120	manage	manage	VVI
304953	100736259	20992715121	"	"	"
304953	100736259	20992715122	their	their	APPGE
304953	100736259	20992715123	diabetes	diabetes	NN1
304953	100736259	20992715124	with	with	IW
304953	100736259	20992715125	diet	diet	NN1
304953	100736259	20992715126	,	,	,
304953	100736259	20992715127	metformin	metformin	NN1
304953	100736259	20992715128	again	again	RT
304953	100736259	20992715129	came	come	VVD
304953	100736259	20992715130	out	out	RP
304953	100736259	20992715131	looking	look	VVG
304953	100736259	20992715132	like	like	II_CS@
304953	100736259	20992715133	it	it	PPH1
304953	100736259	20992715134	was	be	VBDZ
304953	100736259	20992715135	protective	protective	JJ
304953	100736259	20992715136	;	;	;
304953	100736259	20992715137	the	the	AT
304953	100736259	20992715138	metformin	metformin	NN1
304953	100736259	20992715139	takers	taker	NN2
304953	100736259	20992715140	were	be	VBDR
304953	100736259	20992715141	46%		NNU
304953	100736259	20992715142	less	less	DAR_RRR
304953	100736259	20992715143	likely	likely	JJ
304953	100736259	20992715144	to	to	TO
304953	100736259	20992715145	have	have	VHI
304953	100736259	20992715146	died	die	VVN@
304953	100736259	20992715147	from	from	II
304953	100736259	20992715148	prostate	prostate	NN1
304953	100736259	20992715149	cancer	cancer	NN1
304953	100736259	20992715150	than	than	CSN
304953	100736259	20992715151	the	the	AT
304953	100736259	20992715152	dieters	dieter	NN2
304953	100736259	20992715153	.	.	.
304953	100736259	20992715154	<p>		NULL
304953	100736259	20992715155	All	all	DB
304953	100736259	20992715156	the	the	AT
304953	100736259	20992715157	usual	usual	JJ
304953	100736259	20992715158	warnings	warning	NN2
304953	100736259	20992715159	about	about	II
304953	100736259	20992715160	correlation	correlation	NN1
304953	100736259	20992715161	not	not	XX
304953	100736259	20992715162	equaling	equal	VVG_JJ@
304953	100736259	20992715163	correlation	correlation	NN1
304953	100736259	20992715164	apply	apply	VV0
304953	100736259	20992715165	.	.	.
304953	100736259	20992715166	And	and	CC
304953	100736259	20992715167	keep	keep	VV0
304953	100736259	20992715168	this	this	DD1
304953	100736259	20992715169	mind	mind	NN1
304953	100736259	20992715170	:	:	:
304953	100736259	20992715171	only	only	JJ
304953	100736259	20992715172	men	men-	NN1
304953	100736259	20992715173	with	with	IW
304953	100736259	20992715174	diabetes	diabetes	NN1
304953	100736259	20992715175	were	be	VBDR
304953	100736259	20992715176	included	include	VVN
304953	100736259	20992715177	in	in	II
304953	100736259	20992715178	this	this	DD1
304953	100736259	20992715179	study	study	NN1
304953	100736259	20992715180	.	.	.
304953	100736259	20992715181	It	it	PPH1
304953	100736259	20992715182	is	be	VBZ
304953	100736259	20992715183	an	a	AT1
304953	100736259	20992715184	open	open	JJ
304953	100736259	20992715185	question	question	NN1
304953	100736259	20992715186	whether	whether	CSW
304953	100736259	20992715187	men	man	NN2
304953	100736259	20992715188	with	with	IW
304953	100736259	20992715189	prostate	prostate	NN1
304953	100736259	20992715190	cancer	cancer	NN1
304953	100736259	20992715191	who	who	PNQS
304953	100736259	20992715192	do	do	VD0
304953	100736259	20992715193	n't 	n't	XX
304953	100736259	20992715194	have	have	VHI
304953	100736259	20992715195	diabetes	diabetes	NN1
304953	100736259	20992715196	might	might	VM
304953	100736259	20992715197	benefit	benefit	VVI
304953	100736259	20992715198	from	from	II
304953	100736259	20992715199	metformin	metformin	NN1
304953	100736259	20992715200	.	.	.
304953	100736259	20992715201	That	that	DD1
304953	100736259	20992715202	is	be	VBZ
304953	100736259	20992715203	one	one	MC1
304953	100736259	20992715204	of	of	IO
304953	100736259	20992715205	the	the	AT
304953	100736259	20992715206	questions	question	NN2
304953	100736259	20992715207	the	the	AT
304953	100736259	20992715208	current	current	JJ
304953	100736259	20992715209	crop	crop	NN1
304953	100736259	20992715210	of	of	IO
304953	100736259	20992715211	clinical	clinical	JJ
304953	100736259	20992715212	trials	trial	NN2
304953	100736259	20992715213	may	may	VM
304953	100736259	20992715214	answer	answer	VVI
304953	100736259	20992715215	.	.	.
304953	100736259	20992715216	<h>		NULL
304953	100736259	20992715217	Metformin	metformin	NN1_NP1@
304953	100736259	20992715218	does	do	VDZ
304953	100736259	20992715219	not	not	XX
304953	100736259	20992715220	prevent	prevent	VVI
304953	100736259	20992715221	prostate	prostate	NN1
304953	100736259	20992715222	cancer	cancer	NN1
304953	100736259	20992715223	<p>		NULL
304953	100736259	20992715224	The	the	AT
304953	100736259	20992715225	same	same	DA
304953	100736259	20992715226	group	group	NN1
304953	100736259	20992715227	of	of	IO
304953	100736259	20992715228	researchers	researcher	NN2
304953	100736259	20992715229	published	publish	VVD_VVN
304953	100736259	20992715230	the	the	AT
304953	100736259	20992715231	results	result	NN2
304953	100736259	20992715232	@		II
304953	100736259	20992715233	@		II
304953	100736259	20992715234	@		II
304953	100736259	20992715235	@		II
304953	100736259	20992715236	@		II
304953	100736259	20992715237	@		II
304953	100736259	20992715238	@		II
304953	100736259	20992715239	@		II
304953	100736259	20992715240	@		II
304953	100736259	20992715241	@		II
304953	100736259	20992715242	Cancer	cancer	NN1
304953	100736259	20992715243	Institute	institute	NN1
304953	100736259	20992715244	.	.	.
304953	100736259	20992715245	This	this	DD1
304953	100736259	20992715246	time	time	NNT1
304953	100736259	20992715247	they	they	PPHS2
304953	100736259	20992715248	looked	look	VVD
304953	100736259	20992715249	at	at	II
304953	100736259	20992715250	metformin	metformin	NN1
304953	100736259	20992715251	use	use	NN1_VV0
304953	100736259	20992715252	before	before	II_CS
304953	100736259	20992715253	diagnosis	diagnosis	NN1
304953	100736259	20992715254	.	.	.
304953	100736259	20992715255	Crunching	crunch	VVG_JJ@
304953	100736259	20992715256	numbers	number	NN2
304953	100736259	20992715257	from	from	II
304953	100736259	20992715258	some	some	DD
304953	100736259	20992715259	of	of	IO
304953	100736259	20992715260	the	the	AT
304953	100736259	20992715261	same	same	DA
304953	100736259	20992715262	databases	database	NN2
304953	100736259	20992715263	used	use	VVN_VVD
304953	100736259	20992715264	in	in	II
304953	100736259	20992715265	the	the	AT
304953	100736259	20992715266	other	other	JJ
304953	100736259	20992715267	study	study	NN1
304953	100736259	20992715268	,	,	,
304953	100736259	20992715269	the	the	AT
304953	100736259	20992715270	researchers	researcher	NN2
304953	100736259	20992715271	found	find	VVD_VVN
304953	100736259	20992715272	no	no	AT
304953	100736259	20992715273	correlation	correlation	NN1
304953	100736259	20992715274	between	between	II
304953	100736259	20992715275	metformin	metformin	NN1
304953	100736259	20992715276	use	use	NN1
304953	100736259	20992715277	and	and	CC
304953	100736259	20992715278	the	the	AT
304953	100736259	20992715279	risk	risk	NN1
304953	100736259	20992715280	of	of	IO
304953	100736259	20992715281	being	be	VBG
304953	100736259	20992715282	diagnosed	diagnose	VVN
304953	100736259	20992715283	with	with	IW
304953	100736259	20992715284	prostate	prostate	NN1
304953	100736259	20992715285	cancer	cancer	NN1
304953	100736259	20992715286	among	among	II
304953	100736259	20992715287	older	old	JJR
304953	100736259	20992715288	men	man	NN2
304953	100736259	20992715289	(	(	(
304953	100736259	20992715290	ages	age	VVZ@_NN2
304953	100736259	20992715291	66	66	MC
304953	100736259	20992715292	and	and	CC
304953	100736259	20992715293	older	old	JJR
304953	100736259	20992715294	)	)	)
304953	100736259	20992715295	with	with	IW
304953	100736259	20992715296	newly	newly	RR
304953	100736259	20992715297	diagnosed	diagnose	VVN_VVD
304953	100736259	20992715298	diabetes	diabetes	NN1
304953	100736259	20992715299	.	.	.
304953	100736259	20992715300	<p>		NULL
304953	100736259	20992715301	Other	other	JJ
304953	100736259	20992715302	prostate	prostate	NN1
304953	100736259	20992715303	cancer	cancer	NN1
304953	100736259	20992715304	prevention	prevention	NN1
304953	100736259	20992715305	studies	study	NN2
304953	100736259	20992715306	have	have	VH0
304953	100736259	20992715307	found	find	VVN
304953	100736259	20992715308	that	that	CST
304953	100736259	20992715309	an	a	AT1
304953	100736259	20992715310	agent	agent	NN1
304953	100736259	20992715311	or	or	CC
304953	100736259	20992715312	risk	risk	NN1_VV0
304953	100736259	20992715313	factor	factor	NN1
304953	100736259	20992715314	appears	appear	VVZ
304953	100736259	20992715315	to	to	TO_II
304953	100736259	20992715316	protects	protect	VVZ
304953	100736259	20992715317	against	against	II
304953	100736259	20992715318	low-grade	low-grade	JJ_NN1
304953	100736259	20992715319	prostate	prostate	NN1
304953	100736259	20992715320	cancer	cancer	NN1
304953	100736259	20992715321	"	"	"
304953	100736259	20992715322	which	which	DDQ
304953	100736259	20992715323	may	may	VM
304953	100736259	20992715324	be	be	VBI
304953	100736259	20992715325	so	so	RG
304953	100736259	20992715326	slow	slow	RR
304953	100736259	20992715327	growing	growing	JJ_VVG
304953	100736259	20992715328	(	(	(
304953	100736259	20992715329	"	"	"
304953	100736259	20992715330	indolent	indolent	JJ
304953	100736259	20992715331	"	"	"
304953	100736259	20992715332	)	)	)
304953	100736259	20992715333	that	that	CST
304953	100736259	20992715334	it	it	PPH1
304953	100736259	20992715335	does	do	VDZ
304953	100736259	20992715336	n't 	n't	XX
304953	100736259	20992715337	pose	pose	VVI
304953	100736259	20992715338	much	much	DA1
304953	100736259	20992715339	of	of	IO
304953	100736259	20992715340	a	a	AT1
304953	100736259	20992715341	health	health	NN1
304953	100736259	20992715342	risk	risk	NN1
304953	100736259	20992715343	"	"	"
304953	100736259	20992715344	but	but	CCB
304953	100736259	20992715345	not	not	XX
304953	100736259	20992715346	against	against	II
304953	100736259	20992715347	advanced	advanced	JJ
304953	100736259	20992715348	disease	disease	NN1
304953	100736259	20992715349	,	,	,
304953	100736259	20992715350	which	which	DDQ
304953	100736259	20992715351	certainly	certainly	RR
304953	100736259	20992715352	can	can	VM
304953	100736259	20992715353	be	be	VBI
304953	100736259	20992715354	lethal	lethal	JJ
304953	100736259	20992715355	and	and	CC
304953	100736259	20992715356	is	be	VBZ
304953	100736259	20992715357	what	what	DDQ
304953	100736259	20992715358	you	you	PPY
304953	100736259	20992715359	really	really	RR
304953	100736259	20992715360	want	want	VV0
304953	100736259	20992715361	the	the	AT
304953	100736259	20992715362	most	most	DAT_RGT
304953	100736259	20992715363	protection	protection	NN1
304953	100736259	20992715364	against	against	II
304953	100736259	20992715365	.	.	.
304953	100736259	20992715366	<p>		NULL
304953	100736259	20992715367	But	but	CCB
304953	100736259	20992715368	this	this	DD1
304953	100736259	20992715369	study	study	NN1
304953	100736259	20992715370	did	do	VDD
304953	100736259	20992715371	n't 	n't	XX
304953	100736259	20992715372	find	find	VVI
304953	100736259	20992715373	any	any	DD
304953	100736259	20992715374	such	such	DA
304953	100736259	20992715375	difference	difference	NN1
304953	100736259	20992715376	.	.	.
304953	100736259	20992715377	Metformin		NP1@_NN1
304953	100736259	20992715378	had	have	VHD
304953	100736259	20992715379	no	no	AT
304953	100736259	20992715380	effect	effect	NN1
304953	100736259	20992715381	on	on	II
304953	100736259	20992715382	the	the	AT
304953	100736259	20992715383	diagnosis	diagnosis	NN1
304953	100736259	20992715384	of	of	IO
304953	100736259	20992715385	low-grade	low-grade	JJ_NN1
304953	100736259	20992715386	prostate	prostate	NN1
304953	100736259	20992715387	or	or	CC
304953	100736259	20992715388	high-grade	high-grade	JJ_NN1
304953	100736259	20992715389	prostate	prostate	NN1
304953	100736259	20992715390	cancer	cancer	NN1
304953	100736259	20992715391	.	.	.
304953	100736259	20992715392	The	the	AT
304953	100736259	20992715393	negative	negative	JJ
304953	100736259	20992715394	result	result	NN1
304953	100736259	20992715395	is	be	VBZ
304953	100736259	20992715396	not	not	XX
304953	100736259	20992715397	a	a	AT1
304953	100736259	20992715398	huge	huge	JJ
304953	100736259	20992715399	surprise	surprise	NN1
304953	100736259	20992715400	.	.	.
304953	100736259	20992715401	Similar	similar	JJ
304953	100736259	20992715402	studies	study	NN2
304953	100736259	20992715403	have	have	VH0
304953	100736259	20992715404	also	also	RR
304953	100736259	20992715405	come	come	VVN
304953	100736259	20992715406	up	up	RP
304953	100736259	20992715407	empty	empty	JJ_NN1%
304953	100736259	20992715408	handed	hand	VVD_VVN
304953	100736259	20992715409	,	,	,
304953	100736259	20992715410	and	and	CC
304953	100736259	20992715411	the	the	AT
304953	100736259	20992715412	ones	one	NN2
304953	100736259	20992715413	that	that	CST_DD1
304953	100736259	20992715414	havent		NN1_VV0
304953	100736259	20992715415	have	have	VH0
304953	100736259	20992715416	had	have	VHN
304953	100736259	20992715417	some	some	DD
304953	100736259	20992715418	flaws	flaw	NN2
304953	100736259	20992715419	that	that	CST
304953	100736259	20992715420	make	make	VV0
304953	100736259	20992715421	the	the	AT
304953	100736259	20992715422	results	result	NN2
304953	100736259	20992715423	unreliable	unreliable	JJ
304953	100736259	20992715424	.	.	.
304953	100736259	20992715425	<h>		NULL
304953	100736259	20992715426	Why	why	RRQ
304953	100736259	20992715427	would	would	VM
304953	100736259	20992715428	metformin	metformin	NN1
304953	100736259	20992715429	have	have	VHI
304953	100736259	20992715430	anti	anti	JJ
304953	100736259	20992715431	"	"	"
304953	100736259	20992715432	@		II
304953	100736259	20992715433	@		II
304953	100736259	20992715434	@		II
304953	100736259	20992715435	@		II
304953	100736259	20992715436	@		II
304953	100736259	20992715437	@		II
304953	100736259	20992715438	@		II
304953	100736259	20992715439	@		II
304953	100736259	20992715440	@		II
304953	100736259	20992715441	@		II
304953	100736259	20992715442	will	will	VM
304953	100736259	20992715443	be	be	VBI
304953	100736259	20992715444	useful	useful	JJ
304953	100736259	20992715445	in	in	II
304953	100736259	20992715446	prostate	prostate	NN1
304953	100736259	20992715447	cancer	cancer	NN1
304953	100736259	20992715448	treatment	treatment	NN1
304953	100736259	20992715449	are	be	VBR
304953	100736259	20992715450	very	very	RG
304953	100736259	20992715451	much	much	DA1_RR
304953	100736259	20992715452	alive	alive	JJ
304953	100736259	20992715453	and	and	CC
304953	100736259	20992715454	kicking	kick	VVG_NN1@
304953	100736259	20992715455	.	.	.
304953	100736259	20992715456	And	and	CC
304953	100736259	20992715457	even	even	CS21
304953	100736259	20992715458	if	if	CS22
304953	100736259	20992715459	you	you	PPY
304953	100736259	20992715460	were	be	VBDR
304953	100736259	20992715461	to	to	TO
304953	100736259	20992715462	ignore	ignore	VVI
304953	100736259	20992715463	the	the	AT
304953	100736259	20992715464	epidemiological	epidemiological	JJ
304953	100736259	20992715465	evidence	evidence	NN1
304953	100736259	20992715466	,	,	,
304953	100736259	20992715467	there	there	EX
304953	100736259	20992715468	are	be	VBR
304953	100736259	20992715469	reasons	reason	NN2
304953	100736259	20992715470	to	to	TO
304953	100736259	20992715471	believe	believe	VVI
304953	100736259	20992715472	that	that	DD1_CST
304953	100736259	20992715473	metformin	metformin	NN1
304953	100736259	20992715474	might	might	VM
304953	100736259	20992715475	have	have	VHI
304953	100736259	20992715476	some	some	DD
304953	100736259	20992715477	treatment	treatment	NN1
304953	100736259	20992715478	benefit	benefit	NN1
304953	100736259	20992715479	.	.	.
304953	100736259	20992715480	<p>		NULL
304953	100736259	20992715481	The	the	AT
304953	100736259	20992715482	effect	effect	NN1
304953	100736259	20992715483	may	may	VM
304953	100736259	20992715484	be	be	VBI
304953	100736259	20992715485	indirect	indirect	JJ
304953	100736259	20992715486	.	.	.
304953	100736259	20992715487	Metformin	metformin	NN1_NP1@
304953	100736259	20992715488	lowers	lower	VVZ
304953	100736259	20992715489	the	the	AT
304953	100736259	20992715490	amount	amount	NN1
304953	100736259	20992715491	of	of	IO
304953	100736259	20992715492	insulin	insulin	NN1
304953	100736259	20992715493	circulating	circulate	VVG
304953	100736259	20992715494	in	in	II
304953	100736259	20992715495	the	the	AT
304953	100736259	20992715496	blood	blood	NN1
304953	100736259	20992715497	by	by	II
304953	100736259	20992715498	lowering	lower	VVG_NN1
304953	100736259	20992715499	blood	blood	NN1
304953	100736259	20992715500	sugar	sugar	NN1
304953	100736259	20992715501	levels	level	NN2
304953	100736259	20992715502	and	and	CC
304953	100736259	20992715503	by	by	II
304953	100736259	20992715504	making	make	VVG
304953	100736259	20992715505	tissue	tissue	NN1
304953	100736259	20992715506	more	more	RGR
304953	100736259	20992715507	sensitive	sensitive	JJ
304953	100736259	20992715508	to	to	II
304953	100736259	20992715509	insulin	insulin	NN1
304953	100736259	20992715510	,	,	,
304953	100736259	20992715511	which	which	DDQ
304953	100736259	20992715512	is	be	VBZ
304953	100736259	20992715513	a	a	AT1
304953	100736259	20992715514	hormone	hormone	NN1
304953	100736259	20992715515	that	that	CST_DD1
304953	100736259	20992715516	pulls	pull	VVZ
304953	100736259	20992715517	blood	blood	NN1
304953	100736259	20992715518	sugar	sugar	NN1
304953	100736259	20992715519	out	out	II21
304953	100736259	20992715520	of	of	II22
304953	100736259	20992715521	the	the	AT
304953	100736259	20992715522	blood	blood	NN1
304953	100736259	20992715523	and	and	CC
304953	100736259	20992715524	into	into	II
304953	100736259	20992715525	cells	cell	NN2
304953	100736259	20992715526	.	.	.
304953	100736259	20992715527	Insulin	insulin	NN1_NP1@
304953	100736259	20992715528	and	and	CC
304953	100736259	20992715529	related	related	JJ
304953	100736259	20992715530	factors	factor	NN2
304953	100736259	20992715531	tend	tend	VV0
304953	100736259	20992715532	to	to	II
304953	100736259	20992715533	rev	rev	NNU
304953	100736259	20992715534	up	up	II@_RP
304953	100736259	20992715535	some	some	DD
304953	100736259	20992715536	cancers	cancer	NN2
304953	100736259	20992715537	,	,	,
304953	100736259	20992715538	including	including	II_VVG@
304953	100736259	20992715539	prostate	prostate	NN1
304953	100736259	20992715540	cancer	cancer	NN1
304953	100736259	20992715541	,	,	,
304953	100736259	20992715542	making	make	VVG
304953	100736259	20992715543	them	them	PPHO2
304953	100736259	20992715544	more	more	RGR
304953	100736259	20992715545	likely	likely	JJ
304953	100736259	20992715546	to	to	TO
304953	100736259	20992715547	proliferate	proliferate	VVI
304953	100736259	20992715548	and	and	CC
304953	100736259	20992715549	spread	spread	NN1_VVD_VV0_VVN
304953	100736259	20992715550	.	.	.
304953	100736259	20992715551	So	so	RR
304953	100736259	20992715552	by	by	II
304953	100736259	20992715553	lowering	lower	VVG_NN1
304953	100736259	20992715554	circulating	circulating	JJ@_VVG_NN1@
304953	100736259	20992715555	insulin	insulin	NN1
304953	100736259	20992715556	levels	level	NN2
304953	100736259	20992715557	,	,	,
304953	100736259	20992715558	metformin	metformin	NN1
304953	100736259	20992715559	may	may	VM
304953	100736259	20992715560	be	be	VBI
304953	100736259	20992715561	taking	take	VVG
304953	100736259	20992715562	away	away	RL
304953	100736259	20992715563	some	some	DD
304953	100736259	20992715564	of	of	IO
304953	100736259	20992715565	the	the	AT
304953	100736259	20992715566	stimulus	stimulus	NN1
304953	100736259	20992715567	for	for	IF
304953	100736259	20992715568	prostate	prostate	NN1
304953	100736259	20992715569	cancer	cancer	NN1
304953	100736259	20992715570	cell	cell	NN1
304953	100736259	20992715571	growth	growth	NN1
304953	100736259	20992715572	.	.	.
304953	100736259	20992715573	<p>		NULL
304953	100736259	20992715574	Metformin	metformin	NN1_NP1@
304953	100736259	20992715575	may	may	VM
304953	100736259	20992715576	also	also	RR
304953	100736259	20992715577	have	have	VHI
304953	100736259	20992715578	more	more	DAR
304953	100736259	20992715579	direct	direct	JJ
304953	100736259	20992715580	effects	effect	NN2
304953	100736259	20992715581	.	.	.
304953	100736259	20992715582	Metformin	metformin	NN1_NP1@
304953	100736259	20992715583	lowers	lower	VVZ
304953	100736259	20992715584	the	the	AT
304953	100736259	20992715585	blood	blood	NN1
304953	100736259	20992715586	sugar	sugar	NN1
304953	100736259	20992715587	output	output	NN1
304953	100736259	20992715588	of	of	IO
304953	100736259	20992715589	liver	liver	NN1
304953	100736259	20992715590	cells	cell	NN2
304953	100736259	20992715591	by	by	II
304953	100736259	20992715592	hampering	hamper	VVG
304953	100736259	20992715593	energy-generating	energy-generating	JJ_NN1
304953	100736259	20992715594	processes	process	NN2
304953	100736259	20992715595	within	within	II
304953	100736259	20992715596	their	their	APPGE
304953	100736259	20992715597	mitochondria	mitochondria	NN1
304953	100736259	20992715598	.	.	.
304953	100736259	20992715599	It	it	PPH1
304953	100736259	20992715600	may	may	VM
304953	100736259	20992715601	do	do	VDI
304953	100736259	20992715602	the	the	AT
304953	100736259	20992715603	same	same	DA
304953	100736259	20992715604	to	to	II
304953	100736259	20992715605	cancer	cancer	NN1
304953	100736259	20992715606	cells	cell	NN2
304953	100736259	20992715607	and	and	CC
304953	100736259	20992715608	their	their	APPGE
304953	100736259	20992715609	mitochondria	mitochondria	NN1
304953	100736259	20992715610	"	"	"
304953	100736259	20992715611	and	and	CC
304953	100736259	20992715612	cancer	cancer	NN1
304953	100736259	20992715613	cells	cell	NN2
304953	100736259	20992715614	,	,	,
304953	100736259	20992715615	which	which	DDQ
304953	100736259	20992715616	are	be	VBR
304953	100736259	20992715617	growing	grow	VVG_JJ
304953	100736259	20992715618	and	and	CC
304953	100736259	20992715619	dividing	divide	VVG
304953	100736259	20992715620	with	with	IW
304953	100736259	20992715621	the	the	AT
304953	100736259	20992715622	brakes	brake	NN2
304953	100736259	20992715623	off	off	RP
304953	100736259	20992715624	,	,	,
304953	100736259	20992715625	need	need	VV0
304953	100736259	20992715626	those	those	DD2
304953	100736259	20992715627	energy-generating		JJ
304953	100736259	20992715628	processes	process	NN2
304953	100736259	20992715629	going	go	VVG
304953	100736259	20992715630	full	full	JJ
304953	100736259	20992715631	tilt	tilt	NN1
304953	100736259	20992715632	@		II
304953	100736259	20992715633	@		II
304953	100736259	20992715634	@		II
304953	100736259	20992715635	@		II
304953	100736259	20992715636	@		II
304953	100736259	20992715637	@		II
304953	100736259	20992715638	@		II
304953	100736259	20992715639	@		II
304953	100736259	20992715640	@		II
304953	100736259	20992715641	@		II
304953	100736259	20992715642	be	be	VBI
304953	100736259	20992715643	the	the	AT
304953	100736259	20992715644	result	result	NN1
304953	100736259	20992715645	of	of	IO
304953	100736259	20992715646	its	its	APPGE
304953	100736259	20992715647	interactions	interaction	NN2
304953	100736259	20992715648	with	with	IW
304953	100736259	20992715649	complicated	complicated	JJ
304953	100736259	20992715650	chains	chain	NN2
304953	100736259	20992715651	of	of	IO
304953	100736259	20992715652	chemical	chemical	JJ_NN1
304953	100736259	20992715653	reactions	reaction	NN2
304953	100736259	20992715654	called	call	VVN_VVD@
304953	100736259	20992715655	signaling	signal	VVG_JJ@
304953	100736259	20992715656	pathways	pathway	NN2
304953	100736259	20992715657	that	that	CST_DD1
304953	100736259	20992715658	can	can	VM
304953	100736259	20992715659	nudge	nudge	VVI
304953	100736259	20992715660	dangerous	dangerous	JJ
304953	100736259	20992715661	cancer	cancer	NN1
304953	100736259	20992715662	cells	cell	NN2
304953	100736259	20992715663	into	into	II
304953	100736259	20992715664	programmed	programmed	JJ@
304953	100736259	20992715665	cell	cell	NN1
304953	100736259	20992715666	death	death	NN1
304953	100736259	20992715667	(	(	(
304953	100736259	20992715668	apoptosis	apoptosis	NN1
304953	100736259	20992715669	)	)	)
304953	100736259	20992715670	.	.	.
304953	100736259	20992715671	<p>		NULL
304953	100736259	20992715672	University	university	NN1
304953	100736259	20992715673	of	of	IO
304953	100736259	20992715674	Toronto	toronto	NP1
304953	100736259	20992715675	researchers	researcher	NN2
304953	100736259	20992715676	are	be	VBR
304953	100736259	20992715677	conducting	conduct	VVG
304953	100736259	20992715678	the	the	AT
304953	100736259	20992715679	Metformin		NN1_NP1
304953	100736259	20992715680	Active	active	JJ
304953	100736259	20992715681	Surveillance	surveillance	NN1
304953	100736259	20992715682	Trial	trial	NN1
304953	100736259	20992715683	(	(	(
304953	100736259	20992715684	MAST	mast	NN1
304953	100736259	20992715685	)	)	)
304953	100736259	20992715686	study	study	NN1_VV0@
304953	100736259	20992715687	.	.	.
304953	100736259	20992715688	Men	man	NN2
304953	100736259	20992715689	in	in	II
304953	100736259	20992715690	active	active	JJ
304953	100736259	20992715691	surveillance	surveillance	NN1
304953	100736259	20992715692	have	have	VH0
304953	100736259	20992715693	elected	elect	VVN
304953	100736259	20992715694	to	to	TO
304953	100736259	20992715695	have	have	VHI
304953	100736259	20992715696	their	their	APPGE
304953	100736259	20992715697	low-risk	low-risk	JJ_NN1
304953	100736259	20992715698	prostate	prostate	NN1
304953	100736259	20992715699	cancer	cancer	NN1
304953	100736259	20992715700	closely	closely	RR
304953	100736259	20992715701	monitored	monitor	VVN_VVD
304953	100736259	20992715702	rather	rather	II21_CS21@
304953	100736259	20992715703	than	than	II22_CS22@
304953	100736259	20992715704	treated	treated	JJ@_VVN
304953	100736259	20992715705	right	right	NN1_RR
304953	100736259	20992715706	away	away	RL
304953	100736259	20992715707	.	.	.
304953	100736259	20992715708	The	the	AT
304953	100736259	20992715709	study	study	NN1
304953	100736259	20992715710	randomizes		VVZ
304953	100736259	20992715711	men	man	NN2
304953	100736259	20992715712	on	on	II
304953	100736259	20992715713	active	active	JJ
304953	100736259	20992715714	surveillance	surveillance	NN1
304953	100736259	20992715715	to	to	TO
304953	100736259	20992715716	receive	receive	VVI
304953	100736259	20992715717	metformin	metformin	NN1
304953	100736259	20992715718	(	(	(
304953	100736259	20992715719	850	850	MC
304953	100736259	20992715720	mg	mg	NNU
304953	100736259	20992715721	,	,	,
304953	100736259	20992715722	twice	twice	RR
304953	100736259	20992715723	a	a	AT1
304953	100736259	20992715724	day	day	NNT1
304953	100736259	20992715725	)	)	)
304953	100736259	20992715726	or	or	CC
304953	100736259	20992715727	a	a	AT1
304953	100736259	20992715728	placebo	placebo	NN1
304953	100736259	20992715729	for	for	IF
304953	100736259	20992715730	three	three	MC
304953	100736259	20992715731	years	year	NNT2
304953	100736259	20992715732	.	.	.
304953	100736259	20992715733	The	the	AT
304953	100736259	20992715734	study	study	NN1
304953	100736259	20992715735	is	be	VBZ
304953	100736259	20992715736	designed	design	VVN
304953	100736259	20992715737	to	to	TO
304953	100736259	20992715738	see	see	VVI
304953	100736259	20992715739	whether	whether	CSW
304953	100736259	20992715740	metformin	metformin	NN1
304953	100736259	20992715741	will	will	VM
304953	100736259	20992715742	delay	delay	VVI
304953	100736259	20992715743	the	the	AT
304953	100736259	20992715744	need	need	NN1
304953	100736259	20992715745	for	for	IF
304953	100736259	20992715746	primary	primary	JJ_NN1
304953	100736259	20992715747	prostate	prostate	NN1
304953	100736259	20992715748	cancer	cancer	NN1
304953	100736259	20992715749	treatment	treatment	NN1
304953	100736259	20992715750	(	(	(
304953	100736259	20992715751	prostatectomy	prostatectomy	NN1
304953	100736259	20992715752	,	,	,
304953	100736259	20992715753	radiation	radiation	NN1
304953	100736259	20992715754	,	,	,
304953	100736259	20992715755	hormone	hormone	NN1
304953	100736259	20992715756	therapy	therapy	NN1
304953	100736259	20992715757	)	)	)
304953	100736259	20992715758	.	.	.
304953	100736259	20992715759	<p>		NULL
304953	100736259	20992715760	Other	other	JJ
304953	100736259	20992715761	studies	study	NN2
304953	100736259	20992715762	are	be	VBR
304953	100736259	20992715763	focusing	focus	VVG
304953	100736259	20992715764	on	on	II_RP@
304953	100736259	20992715765	men	man	NN2
304953	100736259	20992715766	starting	start	VVG
304953	100736259	20992715767	hormone	hormone	NN1
304953	100736259	20992715768	therapy	therapy	NN1
304953	100736259	20992715769	,	,	,
304953	100736259	20992715770	also	also	RR
304953	100736259	20992715771	known	know	VVN
304953	100736259	20992715772	as	as	II
304953	100736259	20992715773	androgen	androgen	NN1
304953	100736259	20992715774	deprivation	deprivation	NN1
304953	100736259	20992715775	therapy	therapy	NN1
304953	100736259	20992715776	.	.	.
304953	100736259	20992715777	Hormone	hormone	NN1
304953	100736259	20992715778	therapy	therapy	NN1
304953	100736259	20992715779	lowers	lower	VVZ
304953	100736259	20992715780	testosterone	testosterone	NN1
304953	100736259	20992715781	levels	level	NN2
304953	100736259	20992715782	.	.	.
304953	100736259	20992715783	When	when	CS
304953	100736259	20992715784	that	that	DD1
304953	100736259	20992715785	happens	happen	VVZ
304953	100736259	20992715786	,	,	,
304953	100736259	20992715787	insulin	insulin	NN1
304953	100736259	20992715788	levels	level	NN2
304953	100736259	20992715789	often	often	RR
304953	100736259	20992715790	increase	increase	VV0
304953	100736259	20992715791	,	,	,
304953	100736259	20992715792	which	which	DDQ
304953	100736259	20992715793	metformin	metformin	NN1
304953	100736259	20992715794	could	could	VM
304953	100736259	20992715795	presumably	presumably	RR
304953	100736259	20992715796	counteract	counteract	VVI
304953	100736259	20992715797	.	.	.
304953	100736259	20992715798	High	high	JJ
304953	100736259	20992715799	insulin	insulin	NN1
304953	100736259	20992715800	levels	level	NN2
304953	100736259	20992715801	are	be	VBR
304953	100736259	20992715802	unhealthy	unhealthy	JJ
304953	100736259	20992715803	for	for	IF
304953	100736259	20992715804	a	a	AT1
304953	100736259	20992715805	variety	variety	NN1
304953	100736259	20992715806	of	of	IO
304953	100736259	20992715807	metabolic	metabolic	JJ
304953	100736259	20992715808	reasons	reason	NN2
304953	100736259	20992715809	,	,	,
304953	100736259	20992715810	but	but	CCB
304953	100736259	20992715811	they	they	PPHS2
304953	100736259	20992715812	may	may	VM
304953	100736259	20992715813	also	also	RR
304953	100736259	20992715814	contribute	contribute	VVI
304953	100736259	20992715815	to	to	II
304953	100736259	20992715816	the	the	AT
304953	100736259	20992715817	return	return	NN1
304953	100736259	20992715818	of	of	IO
304953	100736259	20992715819	prostate	prostate	NN1
304953	100736259	20992715820	cancer	cancer	NN1
304953	100736259	20992715821	despite	despite	II
304953	100736259	20992715822	hormone	hormone	NN1
304953	100736259	20992715823	therapy	therapy	NN1
304953	100736259	20992715824	and	and	CC
304953	100736259	20992715825	the	the	AT
304953	100736259	20992715826	suppression	suppression	NN1
304953	100736259	20992715827	of	of	IO
304953	100736259	20992715828	testosterone	testosterone	NN1
304953	100736259	20992715829	levels	level	NN2
304953	100736259	20992715830	.	.	.
304953	100736259	20992715831	So	so	RR
304953	100736259	20992715832	@		II
304953	100736259	20992715833	@		II
304953	100736259	20992715834	@		II
304953	100736259	20992715835	@		II
304953	100736259	20992715836	@		II
304953	100736259	20992715837	@		II
304953	100736259	20992715838	@		II
304953	100736259	20992715839	@		II
304953	100736259	20992715840	@		II
304953	100736259	20992715841	@		II
304953	100736259	20992715842	hormone	hormone	NN1
304953	100736259	20992715843	therapy	therapy	NN1
304953	100736259	20992715844	.	.	.
304953	100736259	20992715845	<p>		NULL
304953	100736259	20992715846	Researchers	researcher	NN2
304953	100736259	20992715847	are	be	VBR
304953	100736259	20992715848	also	also	RR
304953	100736259	20992715849	conducting	conduct	VVG
304953	100736259	20992715850	trials	trial	NN2
304953	100736259	20992715851	in	in	II
304953	100736259	20992715852	men	man	NN2
304953	100736259	20992715853	after	after	II_CS
304953	100736259	20992715854	hormone	hormone	NN1
304953	100736259	20992715855	therapy	therapy	NN1
304953	100736259	20992715856	has	have	VHZ
304953	100736259	20992715857	failed	fail	VVN
304953	100736259	20992715858	to	to	TO
304953	100736259	20992715859	control	control	VVI
304953	100736259	20992715860	their	their	APPGE
304953	100736259	20992715861	cancer	cancer	NN1
304953	100736259	20992715862	.	.	.
304953	100736259	20992715863	For	for	REX21
304953	100736259	20992715864	example	example	REX22
304953	100736259	20992715865	,	,	,
304953	100736259	20992715866	French	french	JJ_NN1
304953	100736259	20992715867	investigators	investigator	NN2
304953	100736259	20992715868	are	be	VBR
304953	100736259	20992715869	conducting	conduct	VVG
304953	100736259	20992715870	a	a	AT1
304953	100736259	20992715871	trial	trial	NN1
304953	100736259	20992715872	called	call	VVN
304953	100736259	20992715873	TAXOMET		NN1_NP1
304953	100736259	20992715874	which	which	DDQ
304953	100736259	20992715875	is	be	VBZ
304953	100736259	20992715876	comparing	compare	VVG
304953	100736259	20992715877	the	the	AT
304953	100736259	20992715878	chemotherapy	chemotherapy	NN1
304953	100736259	20992715879	drug	drug	NN1
304953	100736259	20992715880	docetaxel	docetaxel	NN1
304953	100736259	20992715881	(	(	(
304953	100736259	20992715882	sold	sell	VVN
304953	100736259	20992715883	under	under	II
304953	100736259	20992715884	the	the	AT
304953	100736259	20992715885	brand	brand	NN1
304953	100736259	20992715886	name	name	NN1
304953	100736259	20992715887	Taxotere		NN1_NP1
304953	100736259	20992715888	)	)	)
304953	100736259	20992715889	alone	alone	JJ_RR
304953	100736259	20992715890	or	or	CC
304953	100736259	20992715891	with	with	IW
304953	100736259	20992715892	metformin	metformin	NN1
304953	100736259	20992715893	.	.	.
304953	100736259	20992715894	Prostate	prostate	NN1
304953	100736259	20992715895	cancer	cancer	NN1
304953	100736259	20992715896	that	that	CST_DD1
304953	100736259	20992715897	comes	come	VVZ
304953	100736259	20992715898	back	back	RP
304953	100736259	20992715899	after	after	II_CS
304953	100736259	20992715900	hormone	hormone	NN1
304953	100736259	20992715901	therapy	therapy	NN1
304953	100736259	20992715902	is	be	VBZ
304953	100736259	20992715903	often	often	RR
304953	100736259	20992715904	lethal	lethal	JJ
304953	100736259	20992715905	,	,	,
304953	100736259	20992715906	but	but	CCB
304953	100736259	20992715907	a	a	AT1
304953	100736259	20992715908	number	number	NN1
304953	100736259	20992715909	of	of	IO
304953	100736259	20992715910	new	new	JJ
304953	100736259	20992715911	treatments	treatment	NN2
304953	100736259	20992715912	have	have	VH0
304953	100736259	20992715913	become	become	VVN@
304953	100736259	20992715914	available	available	JJ
304953	100736259	20992715915	lately	lately	RR
304953	100736259	20992715916	,	,	,
304953	100736259	20992715917	and	and	CC
304953	100736259	20992715918	there 's		NN2
304953	100736259	20992715919	a	a	AT1
304953	100736259	20992715920	lot	lot	NN1
304953	100736259	20992715921	of	of	IO
304953	100736259	20992715922	interest	interest	NN1
304953	100736259	20992715923	in	in	II
304953	100736259	20992715924	any	any	DD
304953	100736259	20992715925	modifications	modification	NN2
304953	100736259	20992715926	that	that	CST_DD1
304953	100736259	20992715927	might	might	VM
304953	100736259	20992715928	make	make	VVI
304953	100736259	20992715929	them	them	PPHO2
304953	100736259	20992715930	more	more	RGR
304953	100736259	20992715931	effective	effective	JJ
304953	100736259	20992715932	.	.	.
304953	100736260	20992715952	@@##	----------	----------
304953	100736260	20992715953	@@100736260		FO
304953	100736260	20992715954	@4936260/		VV0_NN1
304953	100736260	20992715955	46989		MC
304953	100736260	20992715956	@qwx906989		FO
304953	100736260	20992715957	<p>		NULL
304953	100736260	20992715958	Chronic	chronic	JJ
304953	100736260	20992715959	nonbacterial	nonbacterial	JJ
304953	100736260	20992715960	prostatitis	prostatitis	NN1
304953	100736260	20992715961	(	(	(
304953	100736260	20992715962	also	also	RR
304953	100736260	20992715963	known	know	VVN
304953	100736260	20992715964	as	as	II
304953	100736260	20992715965	chronic	chronic	JJ
304953	100736260	20992715966	pelvic	pelvic	JJ
304953	100736260	20992715967	pain	pain	NN1
304953	100736260	20992715968	syndrome	syndrome	NN1
304953	100736260	20992715969	)	)	)
304953	100736260	20992715970	is	be	VBZ
304953	100736260	20992715971	the	the	AT
304953	100736260	20992715972	most	most	RGT
304953	100736260	20992715973	common	common	JJ
304953	100736260	20992715974	form	form	NN1
304953	100736260	20992715975	of	of	IO
304953	100736260	20992715976	prostatitis	prostatitis	NN1
304953	100736260	20992715977	,	,	,
304953	100736260	20992715978	an	a	AT1
304953	100736260	20992715979	all-too-common	all-too-common	JJ
304953	100736260	20992715980	genitourinary	genitourinary	JJ_NN1
304953	100736260	20992715981	condition	condition	NN1
304953	100736260	20992715982	in	in	II
304953	100736260	20992715983	men	man	NN2
304953	100736260	20992715984	.	.	.
304953	100736260	20992715985	It	it	PPH1
304953	100736260	20992715986	's	be	VBZ
304953	100736260	20992715987	characterized	characterize	VVN
304953	100736260	20992715988	by	by	II
304953	100736260	20992715989	episodes	episode	NN2
304953	100736260	20992715990	of	of	IO
304953	100736260	20992715991	pain	pain	NN1
304953	100736260	20992715992	and	and	CC
304953	100736260	20992715993	discomfort	discomfort	NN1
304953	100736260	20992715994	that	that	CST
304953	100736260	20992715995	come	come	VV0
304953	100736260	20992715996	and	and	CC
304953	100736260	20992715997	go	go	VV0
304953	100736260	20992715998	unpredictably	unpredictably	RR
304953	100736260	20992715999	,	,	,
304953	100736260	20992716000	trouble	trouble	NN1_VV0@
304953	100736260	20992716001	urinating	urinate	VVG
304953	100736260	20992716002	,	,	,
304953	100736260	20992716003	and	and	CC
304953	100736260	20992716004	sexual	sexual	JJ
304953	100736260	20992716005	dysfunction	dysfunction	NN1
304953	100736260	20992716006	.	.	.
304953	100736260	20992716007	Although	although	CS
304953	100736260	20992716008	chronic	chronic	JJ
304953	100736260	20992716009	nonbacterial	nonbacterial	JJ
304953	100736260	20992716010	prostatitis	prostatitis	NN1
304953	100736260	20992716011	is	be	VBZ
304953	100736260	20992716012	n't	n't	XX
304953	100736260	20992716013	life-threatening	life-threatening	JJ_NN1
304953	100736260	20992716014	,	,	,
304953	100736260	20992716015	it	it	PPH1
304953	100736260	20992716016	can	can	VM
304953	100736260	20992716017	certainly	certainly	RR
304953	100736260	20992716018	degrade	degrade	VVI
304953	100736260	20992716019	a	a	AT1
304953	100736260	20992716020	man	man	NN1
304953	100736260	20992716021	's	's	GE
304953	100736260	20992716022	quality	quality	NN1
304953	100736260	20992716023	of	of	IO
304953	100736260	20992716024	life	life	NN1
304953	100736260	20992716025	and	and	CC
304953	100736260	20992716026	lead	lead	VV0_NN1
304953	100736260	20992716027	to	to	II
304953	100736260	20992716028	depression	depression	NN1
304953	100736260	20992716029	.	.	.
304953	100736260	20992716030	Particularly	particularly	RR
304953	100736260	20992716031	troubling	trouble	VVG_JJ
304953	100736260	20992716032	for	for	IF
304953	100736260	20992716033	doctors	doctor	NN2
304953	100736260	20992716034	and	and	CC
304953	100736260	20992716035	patients	patient	NN2
304953	100736260	20992716036	alike	alike	RR_JJ
304953	100736260	20992716037	is	be	VBZ
304953	100736260	20992716038	the	the	AT
304953	100736260	20992716039	lack	lack	NN1
304953	100736260	20992716040	of	of	IO
304953	100736260	20992716041	clear	clear	JJ
304953	100736260	20992716042	diagnostic	diagnostic	JJ
304953	100736260	20992716043	criteria	criteria	NN2
304953	100736260	20992716044	and	and	CC
304953	100736260	20992716045	effective	effective	JJ
304953	100736260	20992716046	treatments	treatment	NN2
304953	100736260	20992716047	.	.	.
304953	100736260	20992716048	<p>		NULL
304953	100736260	20992716049	To	to	TO
304953	100736260	20992716050	better	better	RRR
304953	100736260	20992716051	understand	understand	VVI
304953	100736260	20992716052	risk	risk	NN1_VV0
304953	100736260	20992716053	factors	factor	NN2
304953	100736260	20992716054	for	for	IF
304953	100736260	20992716055	chronic	chronic	JJ
304953	100736260	20992716056	nonbacterial	nonbacterial	JJ
304953	100736260	20992716057	prostatitis	prostatitis	NN1
304953	100736260	20992716058	,	,	,
304953	100736260	20992716059	Michigan	michigan	NP1
304953	100736260	20992716060	researchers	researcher	NN2
304953	100736260	20992716061	collected	collect	VVD_VVN
304953	100736260	20992716062	data	data	NN
304953	100736260	20992716063	from	from	II
304953	100736260	20992716064	703	703	MC
304953	100736260	20992716065	men	man	NN2
304953	100736260	20992716066	enrolled	enroll	VVN_VVD
304953	100736260	20992716067	in	in	II
304953	100736260	20992716068	the	the	AT
304953	100736260	20992716069	Flint	flint	NP1_NN1@
304953	100736260	20992716070	Men	man	NN2
304953	100736260	20992716071	's	's	GE
304953	100736260	20992716072	Health	health	NN1
304953	100736260	20992716073	Study	study	NN1
304953	100736260	20992716074	,	,	,
304953	100736260	20992716075	a	a	AT1
304953	100736260	20992716076	population-based	population-based	JJ_NN1
304953	100736260	20992716077	health	health	NN1
304953	100736260	20992716078	study	study	NN1
304953	100736260	20992716079	of	of	IO
304953	100736260	20992716080	African	african	JJ
304953	100736260	20992716081	American	american	JJ
304953	100736260	20992716082	men	man	NN2
304953	100736260	20992716083	.	.	.
304953	100736260	20992716084	Participants	participant	NN2
304953	100736260	20992716085	were	be	VBDR
304953	100736260	20992716086	interviewed	interview	VVN
304953	100736260	20992716087	about	about	II
304953	100736260	20992716088	their	their	APPGE
304953	100736260	20992716089	health	health	NN1
304953	100736260	20992716090	history	history	NN1
304953	100736260	20992716091	and	and	CC
304953	100736260	20992716092	lifestyle	lifestyle	NN1
304953	100736260	20992716093	factors	factor	NN2
304953	100736260	20992716094	,	,	,
304953	100736260	20992716095	such	such	II21
304953	100736260	20992716096	as	as	II22
304953	100736260	20992716097	physical	physical	JJ
304953	100736260	20992716098	activity	activity	NN1
304953	100736260	20992716099	.	.	.
304953	100736260	20992716100	They	they	PPHS2
304953	100736260	20992716101	also	also	RR
304953	100736260	20992716102	answered	answer	VVD
304953	100736260	20992716103	questions	question	NN2
304953	100736260	20992716104	about	about	II
304953	100736260	20992716105	stress	stress	NN1
304953	100736260	20992716106	and	and	CC
304953	100736260	20992716107	emotional	emotional	JJ
304953	100736260	20992716108	health	health	NN1
304953	100736260	20992716109	.	.	.
304953	100736260	20992716110	<p>		NULL
304953	100736260	20992716111	The	the	AT
304953	100736260	20992716112	researchers	researcher	NN2
304953	100736260	20992716113	reported	report	VVN_VVD
304953	100736260	20992716114	in	in	II
304953	100736260	20992716115	2009	2009	MC
304953	100736260	20992716116	that	that	DD1_CST
304953	100736260	20992716117	poor	poor	JJ
304953	100736260	20992716118	emotional	emotional	JJ
304953	100736260	20992716119	health	health	NN1
304953	100736260	20992716120	,	,	,
304953	100736260	20992716121	high	high	JJ
304953	100736260	20992716122	levels	level	NN2
304953	100736260	20992716123	of	of	IO
304953	100736260	20992716124	stress	stress	NN1
304953	100736260	20992716125	(	(	(
304953	100736260	20992716126	as	as	CSA
304953	100736260	20992716127	perceived	perceive	VVN
304953	100736260	20992716128	by	by	II
304953	100736260	20992716129	study	study	NN1
304953	100736260	20992716130	participants	participant	NN2
304953	100736260	20992716131	)	)	)
304953	100736260	20992716132	,	,	,
304953	100736260	20992716133	and	and	CC
304953	100736260	20992716134	a	a	AT1
304953	100736260	20992716135	lack	lack	NN1
304953	100736260	20992716136	of	of	IO
304953	100736260	20992716137	social	social	JJ
304953	100736260	20992716138	support	support	NN1
304953	100736260	20992716139	were	be	VBDR
304953	100736260	20992716140	associated	associate	VVN
304953	100736260	20992716141	with	with	IW
304953	100736260	20992716142	a	a	AT1
304953	100736260	20992716143	history	history	NN1
304953	100736260	20992716144	@		II
304953	100736260	20992716145	@		II
304953	100736260	20992716146	@		II
304953	100736260	20992716147	@		II
304953	100736260	20992716148	@		II
304953	100736260	20992716149	@		II
304953	100736260	20992716150	@		II
304953	100736260	20992716151	@		II
304953	100736260	20992716152	@		II
304953	100736260	20992716153	@		II
304953	100736260	20992716154	a	a	AT1
304953	100736260	20992716155	2002	2002	MC
304953	100736260	20992716156	Harvard	harvard	NP1
304953	100736260	20992716157	study	study	NN1
304953	100736260	20992716158	which	which	DDQ
304953	100736260	20992716159	observed	observe	VVD
304953	100736260	20992716160	that	that	CST
304953	100736260	20992716161	men	man	NN2
304953	100736260	20992716162	who	who	PNQS
304953	100736260	20992716163	reported	report	VVD
304953	100736260	20992716164	severe	severe	JJ
304953	100736260	20992716165	stress	stress	NN1
304953	100736260	20992716166	at	at	II
304953	100736260	20992716167	work	work	NN1
304953	100736260	20992716168	or	or	CC
304953	100736260	20992716169	home	home	RL_NN1
304953	100736260	20992716170	were	be	VBDR
304953	100736260	20992716171	1.2	1.2	MC
304953	100736260	20992716172	and	and	CC
304953	100736260	20992716173	1.5	1.5	MC
304953	100736260	20992716174	times	time	NNT2
304953	100736260	20992716175	more	more	RRR_RGR
304953	100736260	20992716176	likely	likely	JJ
304953	100736260	20992716177	to	to	TO
304953	100736260	20992716178	report	report	VVI
304953	100736260	20992716179	prostatitis	prostatitis	NN1
304953	100736260	20992716180	,	,	,
304953	100736260	20992716181	respectively	respectively	RR
304953	100736260	20992716182	,	,	,
304953	100736260	20992716183	than	than	CSN
304953	100736260	20992716184	those	those	DD2
304953	100736260	20992716185	whose	whose	DDQGE
304953	100736260	20992716186	lives	life	NN2
304953	100736260	20992716187	were	be	VBDR
304953	100736260	20992716188	relatively	relatively	RR
304953	100736260	20992716189	stress-free	stress-free	JJ
304953	100736260	20992716190	.	.	.
304953	100736260	20992716191	<p>		NULL
304953	100736260	20992716192	Stress	stress	VV0@_NN1
304953	100736260	20992716193	also	also	RR
304953	100736260	20992716194	seems	seem	VVZ
304953	100736260	20992716195	to	to	TO
304953	100736260	20992716196	heighten	heighten	VVI
304953	100736260	20992716197	prostatitis	prostatitis	NN1
304953	100736260	20992716198	pain	pain	NN1
304953	100736260	20992716199	,	,	,
304953	100736260	20992716200	according	according	II21
304953	100736260	20992716201	to	to	II22
304953	100736260	20992716202	researchers	researcher	NN2
304953	100736260	20992716203	in	in	II
304953	100736260	20992716204	Seattle	seattle	NP1
304953	100736260	20992716205	.	.	.
304953	100736260	20992716206	They	they	PPHS2
304953	100736260	20992716207	interviewed	interview	VVD
304953	100736260	20992716208	men	man	NN2
304953	100736260	20992716209	about	about	II
304953	100736260	20992716210	stress	stress	NN1
304953	100736260	20992716211	and	and	CC
304953	100736260	20992716212	pain	pain	NN1
304953	100736260	20992716213	intensity	intensity	NN1
304953	100736260	20992716214	by	by	II
304953	100736260	20992716215	telephone	telephone	NN1_VV0
304953	100736260	20992716216	a	a	AT1
304953	100736260	20992716217	month	month	NNT1
304953	100736260	20992716218	after	after	II_CS
304953	100736260	20992716219	the	the	AT
304953	100736260	20992716220	men	man	NN2
304953	100736260	20992716221	were	be	VBDR
304953	100736260	20992716222	diagnosed	diagnose	VVN
304953	100736260	20992716223	with	with	IW
304953	100736260	20992716224	prostatitis	prostatitis	NN1
304953	100736260	20992716225	and	and	CC
304953	100736260	20992716226	then	then	RT
304953	100736260	20992716227	again	again	RT
304953	100736260	20992716228	three	three	MC
304953	100736260	20992716229	,	,	,
304953	100736260	20992716230	six	six	MC
304953	100736260	20992716231	,	,	,
304953	100736260	20992716232	and	and	CC
304953	100736260	20992716233	12	12	MC
304953	100736260	20992716234	months	month	NNT2
304953	100736260	20992716235	later	later	RRR
304953	100736260	20992716236	.	.	.
304953	100736260	20992716237	They	they	PPHS2
304953	100736260	20992716238	concluded	conclude	VVD
304953	100736260	20992716239	that	that	CST
304953	100736260	20992716240	the	the	AT
304953	100736260	20992716241	men	man	NN2
304953	100736260	20992716242	with	with	IW
304953	100736260	20992716243	more	more	RGR_DAR
304953	100736260	20992716244	perceived	perceived	JJ@_VVN
304953	100736260	20992716245	stress	stress	NN1
304953	100736260	20992716246	during	during	II
304953	100736260	20992716247	the	the	AT
304953	100736260	20992716248	six	six	MC
304953	100736260	20992716249	months	month	NNT2
304953	100736260	20992716250	following	following	RA@_VVG_II@
304953	100736260	20992716251	diagnosis	diagnosis	NN1
304953	100736260	20992716252	were	be	VBDR
304953	100736260	20992716253	in	in	II_RP@
304953	100736260	20992716254	more	more	DAR
304953	100736260	20992716255	pain	pain	NN1
304953	100736260	20992716256	after	after	II_CS
304953	100736260	20992716257	a	a	AT1
304953	100736260	20992716258	year	year	NNT1
304953	100736260	20992716259	than	than	CSN
304953	100736260	20992716260	those	those	DD2
304953	100736260	20992716261	who	who	PNQS
304953	100736260	20992716262	experienced	experience	VVD
304953	100736260	20992716263	less	less	DAR
304953	100736260	20992716264	stress	stress	NN1
304953	100736260	20992716265	.	.	.
304953	100736260	20992716266	Despite	despite	II
304953	100736260	20992716267	the	the	AT
304953	100736260	20992716268	limitations	limitation	NN2
304953	100736260	20992716269	of	of	IO
304953	100736260	20992716270	the	the	AT
304953	100736260	20992716271	study	study	NN1
304953	100736260	20992716272	,	,	,
304953	100736260	20992716273	such	such	II21
304953	100736260	20992716274	as	as	II22
304953	100736260	20992716275	the	the	AT
304953	100736260	20992716276	lack	lack	NN1
304953	100736260	20992716277	of	of	IO
304953	100736260	20992716278	health	health	NN1
304953	100736260	20992716279	data	data	NN
304953	100736260	20992716280	on	on	II
304953	100736260	20992716281	participants	participant	NN2
304953	100736260	20992716282	prior	prior	II21
304953	100736260	20992716283	to	to	II22
304953	100736260	20992716284	diagnosis	diagnosis	NN1
304953	100736260	20992716285	,	,	,
304953	100736260	20992716286	the	the	AT
304953	100736260	20992716287	researchers	researcher	NN2
304953	100736260	20992716288	wrote	write	VVD
304953	100736260	20992716289	that	that	DD1_CST
304953	100736260	20992716290	treatment	treatment	NN1
304953	100736260	20992716291	should	should	VM
304953	100736260	20992716292	include	include	VVI
304953	100736260	20992716293	stress	stress	NN1
304953	100736260	20992716294	management	management	NN1
304953	100736260	20992716295	techniques	technique	NN2
304953	100736260	20992716296	.	.	.
304953	100736260	20992716297	<p>		NULL
304953	100736260	20992716298	Prostatitis	prostatitis	NN1_NP1@
304953	100736260	20992716299	is	be	VBZ
304953	100736260	20992716300	classified	classify	VVN
304953	100736260	20992716301	into	into	II
304953	100736260	20992716302	acute	acute	JJ
304953	100736260	20992716303	barcetial		JJ
304953	100736260	20992716304	,	,	,
304953	100736260	20992716305	chronic	chronic	JJ
304953	100736260	20992716306	barcetial		JJ
304953	100736260	20992716307	and	and	CC
304953	100736260	20992716308	abarcetial		JJ
304953	100736260	20992716309	prostatitis	prostatitis	NN1
304953	100736260	20992716310	.	.	.
304953	100736260	20992716311	Acute	acute	JJ
304953	100736260	20992716312	prostatitis	prostatitis	NN1
304953	100736260	20992716313	is	be	VBZ
304953	100736260	20992716314	caused	cause	VVN
304953	100736260	20992716315	by	by	II
304953	100736260	20992716316	urinary	urinary	JJ_NN1
304953	100736260	20992716317	tract	tract	NN1
304953	100736260	20992716318	pathogens	pathogen	NN2
304953	100736260	20992716319	,	,	,
304953	100736260	20992716320	adequate	adequate	JJ
304953	100736260	20992716321	hydration	hydration	NN1
304953	100736260	20992716322	should	should	VM
304953	100736260	20992716323	be	be	VBI
304953	100736260	20992716324	maintained	maintain	VVN
304953	100736260	20992716325	,	,	,
304953	100736260	20992716326	rest	rest	NN1_VV0
304953	100736260	20992716327	encouraged	encourage	VVN_VVD
304953	100736260	20992716328	and	and	CC
304953	100736260	20992716329	analgesics	analgesic	NN2
304953	100736260	20992716330	such	such	II21
304953	100736260	20992716331	as	as	II22
304953	100736260	20992716332	non-steroidal	nonsteroidal	JJ
304953	100736260	20992716333	anti-inflammatory	anti-inflammatory	JJ
304953	100736260	20992716334	drugs	drug	NN2
304953	100736260	20992716335	if	if	CS
304953	100736260	20992716336	required	require	VVN_JJ
304953	100736260	20992716337	.	.	.
304953	100736260	20992716338	As	as	CSA_RG@
304953	100736260	20992716339	acute	acute	JJ
304953	100736260	20992716340	prostatitis	prostatitis	NN1
304953	100736260	20992716341	is	be	VBZ
304953	100736260	20992716342	a	a	AT1
304953	100736260	20992716343	serious	serious	JJ
304953	100736260	20992716344	@		II
304953	100736260	20992716345	@		II
304953	100736260	20992716346	@		II
304953	100736260	20992716347	@		II
304953	100736260	20992716348	@		II
304953	100736260	20992716349	@		II
304953	100736260	20992716350	@		II
304953	100736260	20992716351	@		II
304953	100736260	20992716352	@		II
304953	100736260	20992716353	@		II
304953	100736260	20992716354	blood	blood	NN1
304953	100736260	20992716355	and	and	CC
304953	100736260	20992716356	urine	urine	NN1
304953	100736260	20992716357	cultures	culture	NN2
304953	100736260	20992716358	have	have	VH0
304953	100736260	20992716359	been	be	VBN
304953	100736260	20992716360	obtained	obtain	VVN
304953	100736260	20992716361	.	.	.
304953	100736260	20992716362	Parenteral		NN1_JJ_NP1@
304953	100736260	20992716363	or	or	CC
304953	100736260	20992716364	oral	oral	JJ_NN1
304953	100736260	20992716365	treatment	treatment	NN1
304953	100736260	20992716366	should	should	VM
304953	100736260	20992716367	be	be	VBI
304953	100736260	20992716368	selected	select	VVN
304953	100736260	20992716369	according	according	II21
304953	100736260	20992716370	to	to	II22
304953	100736260	20992716371	the	the	AT
304953	100736260	20992716372	clinical	clinical	JJ
304953	100736260	20992716373	condition	condition	NN1
304953	100736260	20992716374	of	of	IO
304953	100736260	20992716375	the	the	AT
304953	100736260	20992716376	patient	patient	NN1_JJ
304953	100736260	20992716377	.	.	.
304953	100736260	20992716378	If	if	CS
304953	100736260	20992716379	there	there	EX
304953	100736260	20992716380	is	be	VBZ
304953	100736260	20992716381	deterioration	deterioration	NN1
304953	100736260	20992716382	or	or	CC
304953	100736260	20992716383	failure	failure	NN1
304953	100736260	20992716384	to	to	TO
304953	100736260	20992716385	respond	respond	VVI
304953	100736260	20992716386	to	to	II
304953	100736260	20992716387	oral	oral	JJ_NN1
304953	100736260	20992716388	therapy	therapy	NN1
304953	100736260	20992716389	urgent	urgent	JJ
304953	100736260	20992716390	admission	admission	NN1
304953	100736260	20992716391	and	and	CC
304953	100736260	20992716392	parenteral	parenteral	JJ_NN1
304953	100736260	20992716393	therapy	therapy	NN1
304953	100736260	20992716394	should	should	VM
304953	100736260	20992716395	be	be	VBI
304953	100736260	20992716396	arranged	arrange	VVN
304953	100736260	20992716397	.	.	.
304953	100736260	20992716398	For	for	IF
304953	100736260	20992716399	patients	patient	NN2
304953	100736260	20992716400	requiring	require	VVG
304953	100736260	20992716401	parenteral	parenteral	JJ_NN1
304953	100736260	20992716402	therapy	therapy	NN1
304953	100736260	20992716403	antibiotics	antibiotic	NN2
304953	100736260	20992716404	covering	cover	VVG
304953	100736260	20992716405	the	the	AT
304953	100736260	20992716406	likely	likely	JJ
304953	100736260	20992716407	organisms	organism	NN2
304953	100736260	20992716408	should	should	VM
304953	100736260	20992716409	be	be	VBI
304953	100736260	20992716410	used	use	VVN
304953	100736260	20992716411	.	.	.
304953	100736260	20992716412	A	a	AT1_ZZ1
304953	100736260	20992716413	high	high	JJ
304953	100736260	20992716414	dose	dose	NN1
304953	100736260	20992716415	broad	broad	JJ
304953	100736260	20992716416	spectrum	spectrum	NN1
304953	100736260	20992716417	cephalosporin	cephalosporin	NN1
304953	100736260	20992716418	(	(	(
304953	100736260	20992716419	for	for	REX21
304953	100736260	20992716420	example	example	REX22
304953	100736260	20992716421	,	,	,
304953	100736260	20992716422	cefuroxime	cefuroxime	NN1
304953	100736260	20992716423	,	,	,
304953	100736260	20992716424	cefotaxime	cefotaxime	NN1
304953	100736260	20992716425	or	or	CC
304953	100736260	20992716426	Ceftriaxone		NP1_NN1
304953	100736260	20992716427	)	)	)
304953	100736260	20992716428	plus	plus	II
304953	100736260	20992716429	gentamicin.When		NNU
304953	100736260	20992716430	clinically	clinically	RR
304953	100736260	20992716431	improved	improve	VVD_VVN
304953	100736260	20992716432	the	the	AT
304953	100736260	20992716433	therapy	therapy	NN1
304953	100736260	20992716434	can	can	VM
304953	100736260	20992716435	be	be	VBI
304953	100736260	20992716436	switched	switch	VVN
304953	100736260	20992716437	to	to	II
304953	100736260	20992716438	oral	oral	JJ_NN1
304953	100736260	20992716439	treatment	treatment	NN1
304953	100736260	20992716440	according	according	II21
304953	100736260	20992716441	to	to	II22
304953	100736260	20992716442	sensitivities.For		NNU
304953	100736260	20992716443	patients	patient	NN2
304953	100736260	20992716444	suitable	suitable	JJ
304953	100736260	20992716445	for	for	IF
304953	100736260	20992716446	oral	oral	JJ_NN1
304953	100736260	20992716447	therapy	therapy	NN1
304953	100736260	20992716448	,	,	,
304953	100736260	20992716449	quinolones	quinolone	NN2_VVZ
304953	100736260	20992716450	can	can	VM
304953	100736260	20992716451	be	be	VBI
304953	100736260	20992716452	used	use	VVN
304953	100736260	20992716453	,	,	,
304953	100736260	20992716454	Ciprofloxacin	ciprofloxacin	NP1_NN1
304953	100736260	20992716455	500mg		NNU
304953	100736260	20992716456	twice	twice	RR
304953	100736260	20992716457	daily	daily	JJ_RR
304953	100736260	20992716458	for	for	IF
304953	100736260	20992716459	28	28	MC
304953	100736260	20992716460	days	day	NNT2
304953	100736260	20992716461	or	or	CC
304953	100736260	20992716462	Ofloxacin		NN1_NP1
304953	100736260	20992716463	200mg		NNU
304953	100736260	20992716464	twice	twice	RR
304953	100736260	20992716465	daily	daily	JJ_RR
304953	100736260	20992716466	for	for	IF
304953	100736260	20992716467	28	28	MC
304953	100736260	20992716468	days.Chronic		NNU
304953	100736260	20992716469	barcetial		JJ
304953	100736260	20992716470	infection	infection	NN1
304953	100736260	20992716471	of	of	IO
304953	100736260	20992716472	the	the	AT
304953	100736260	20992716473	prostate	prostate	NN1
304953	100736260	20992716474	with	with	IW
304953	100736260	20992716475	or	or	CC
304953	100736260	20992716476	without	without	IW
304953	100736260	20992716477	symptoms	symptom	NN2
304953	100736260	20992716478	of	of	IO
304953	100736260	20992716479	prostatitis	prostatitis	NN1
304953	100736260	20992716480	,	,	,
304953	100736260	20992716481	and	and	CC
304953	100736260	20992716482	with	with	IW
304953	100736260	20992716483	a	a	AT1
304953	100736260	20992716484	history	history	NN1
304953	100736260	20992716485	of	of	IO
304953	100736260	20992716486	recurrent	recurrent	JJ_NN1
304953	100736260	20992716487	urinary	urinary	JJ_NN1
304953	100736260	20992716488	tract	tract	NN1
304953	100736260	20992716489	infections	infection	NN2
304953	100736260	20992716490	caused	cause	VVN
304953	100736260	20992716491	by	by	II
304953	100736260	20992716492	the	the	AT
304953	100736260	20992716493	same	same	DA
304953	100736260	20992716494	barcetial		JJ
304953	100736260	20992716495	strain	strain	NN1
304953	100736260	20992716496	without	without	IW
304953	100736260	20992716497	any	any	DD
304953	100736260	20992716498	structural	structural	JJ
304953	100736260	20992716499	abnormalities	abnormality	NN2
304953	100736260	20992716500	,	,	,
304953	100736260	20992716501	Antibiotic	antibiotic	NN1
304953	100736260	20992716502	treatment	treatment	NN1
304953	100736260	20992716503	should	should	VM
304953	100736260	20992716504	be	be	VBI
304953	100736260	20992716505	chosen	choose	VVN
304953	100736260	20992716506	according	according	II21
304953	100736260	20992716507	to	to	II22
304953	100736260	20992716508	barcetial		JJ
304953	100736260	20992716509	cultures	culture	NN2
304953	100736260	20992716510	and	and	CC
304953	100736260	20992716511	**30;89;TOOLONG		NN2
304953	100736260	20992716512	have	have	VH0
304953	100736260	20992716513	become	become	VVN@
304953	100736260	20992716514	standard	standard	NN1_JJ
304953	100736260	20992716515	of	of	IO
304953	100736260	20992716516	care	care	NN1
304953	100736260	20992716517	in	in	II
304953	100736260	20992716518	CBP	cbp	NP1
304953	100736260	20992716519	they	they	PPHS2
304953	100736260	20992716520	have	have	VH0
304953	100736260	20992716521	good	good	JJ
304953	100736260	20992716522	penetration	penetration	NN1
304953	100736260	20992716523	of	of	IO
304953	100736260	20992716524	the	the	AT
304953	100736260	20992716525	prostate	prostate	NN1
304953	100736260	20992716526	gland	gland	NN1
304953	100736260	20992716527	and	and	CC
304953	100736260	20992716528	broad	broad	JJ
304953	100736260	20992716529	spectrum	spectrum	NN1
304953	100736260	20992716530	activity	activity	NN1
304953	100736260	20992716531	against	against	II
304953	100736260	20992716532	both	both	DB2_RR
304953	100736260	20992716533	gram-negative	gram-negative	JJ
304953	100736260	20992716534	and	and	CC
304953	100736260	20992716535	gram-positive	gram-positive	JJ
304953	100736260	20992716536	organisms	organism	NN2
304953	100736260	20992716537	.	.	.
304953	100736260	20992716538	Most	most	DAT_RGT
304953	100736260	20992716539	comparative	comparative	JJ
304953	100736260	20992716540	studies	study	NN2
304953	100736260	20992716541	have	have	VH0
304953	100736260	20992716542	shown	show	VVN
304953	100736260	20992716543	similar	similar	JJ
304953	100736260	20992716544	@		II
304953	100736260	20992716545	@		II
304953	100736260	20992716546	@		II
304953	100736260	20992716547	@		II
304953	100736260	20992716548	@		II
304953	100736260	20992716549	@		II
304953	100736260	20992716550	@		II
304953	100736260	20992716551	@		II
304953	100736260	20992716552	@		II
304953	100736260	20992716553	@		II
304953	100736260	20992716554	.	.	.
304953	100736260	20992716555	The	the	AT
304953	100736260	20992716556	recommendations	recommendation	NN2
304953	100736260	20992716557	for	for	IF
304953	100736260	20992716558	other	other	JJ
304953	100736260	20992716559	antibiotics	antibiotic	NN2
304953	100736260	20992716560	are	be	VBR
304953	100736260	20992716561	based	base	VVN
304953	100736260	20992716562	on	on	II
304953	100736260	20992716563	small	small	JJ
304953	100736260	20992716564	studies	study	NN2
304953	100736260	20992716565	plus	plus	II
304953	100736260	20992716566	expert	expert	NN1_JJ@
304953	100736260	20992716567	opinion.For		NNU
304953	100736260	20992716568	patients	patient	NN2
304953	100736260	20992716569	with	with	IW
304953	100736260	20992716570	CBP	cbp	NP1
304953	100736260	20992716571	first-line	first-line	JJ_NN1
304953	100736260	20992716572	treatment	treatment	NN1
304953	100736260	20992716573	is	be	VBZ
304953	100736260	20992716574	with	with	IW
304953	100736260	20992716575	a	a	AT1
304953	100736260	20992716576	quinolone	quinolone	NN1
304953	100736260	20992716577	such	such	II21
304953	100736260	20992716578	as	as	II22
304953	100736260	20992716579	Ciprofloxacin	ciprofloxacin	NP1_NN1
304953	100736260	20992716580	500mg		NNU
304953	100736260	20992716581	twice	twice	RR
304953	100736260	20992716582	daily	daily	JJ_RR
304953	100736260	20992716583	for	for	IF
304953	100736260	20992716584	28	28	MC
304953	100736260	20992716585	days	day	NNT2
304953	100736260	20992716586	or	or	CC
304953	100736260	20992716587	Levofloxacin		NN1_NP1
304953	100736260	20992716588	500mg		NNU
304953	100736260	20992716589	od	od	NN1_VV0
304953	100736260	20992716590	for	for	IF
304953	100736260	20992716591	28	28	MC
304953	100736260	20992716592	days	day	NNT2
304953	100736260	20992716593	or	or	CC
304953	100736260	20992716594	Ofloxacin		NN1_NP1
304953	100736260	20992716595	200mg		NNU
304953	100736260	20992716596	twice	twice	RR
304953	100736260	20992716597	daily	daily	JJ_RR
304953	100736260	20992716598	for	for	IF
304953	100736260	20992716599	28	28	MC
304953	100736260	20992716600	days	day	NNT2
304953	100736260	20992716601	or	or	CC
304953	100736260	20992716602	Norfloxacin		NN1_NP1
304953	100736260	20992716603	400mg		NNU
304953	100736260	20992716604	twice	twice	RR
304953	100736260	20992716605	daily	daily	JJ_RR
304953	100736260	20992716606	for	for	IF
304953	100736260	20992716607	28	28	MC
304953	100736260	20992716608	days	day	NNT2
304953	100736260	20992716609	.	.	.
304953	100736260	20992716610	<p>		NULL
304953	100736260	20992716611	Many	many	DA2
304953	100736260	20992716612	people	people	NN
304953	100736260	20992716613	confuse	confuse	VV0
304953	100736260	20992716614	bph		NNU
304953	100736260	20992716615	with	with	IW
304953	100736260	20992716616	prostatitis	prostatitis	NN1
304953	100736260	20992716617	,	,	,
304953	100736260	20992716618	I	i	PPIS1
304953	100736260	20992716619	was	be	VBDZ
304953	100736260	20992716620	confused	confuse	VVN
304953	100736260	20992716621	about	about	II
304953	100736260	20992716622	it	it	PPH1
304953	100736260	20992716623	as	as	RR21_RG
304953	100736260	20992716624	well	well	RR22_RR
304953	100736260	20992716625	until	until	CS_II@
304953	100736260	20992716626	the	the	AT
304953	100736260	20992716627	doctor	doctor	NN1
304953	100736260	20992716628	explained	explain	VVD
304953	100736260	20992716629	me	me	PPIO1
304953	100736260	20992716630	the	the	AT
304953	100736260	20992716631	difference	difference	NN1
304953	100736260	20992716632	between	between	II
304953	100736260	20992716633	those	those	DD2
304953	100736260	20992716634	,	,	,
304953	100736260	20992716635	I	i	PPIS1
304953	100736260	20992716636	had	have	VHD
304953	100736260	20992716637	strong	strong	JJ
304953	100736260	20992716638	prostate	prostate	NN1
304953	100736260	20992716639	symptoms	symptom	NN2
304953	100736260	20992716640	and	and	CC
304953	100736260	20992716641	they	they	PPHS2
304953	100736260	20992716642	were	be	VBDR
304953	100736260	20992716643	getting	get	VVG
304953	100736260	20992716644	worse	bad	JJR
304953	100736260	20992716645	and	and	CC
304953	100736260	20992716646	stronger	strong	JJR
304953	100736260	20992716647	because	because	CS
304953	100736260	20992716648	I	i	PPIS1
304953	100736260	20992716649	had	have	VHD
304953	100736260	20992716650	a	a	AT1
304953	100736260	20992716651	stressful	stressful	JJ
304953	100736260	20992716652	lifestyle	lifestyle	NN1
304953	100736260	20992716653	,	,	,
304953	100736260	20992716654	He	he	PPHS1
304953	100736260	20992716655	prescribed	prescribe	VVD@
304953	100736260	20992716656	me	me	PPIO1
304953	100736260	20992716657	a	a	AT1
304953	100736260	20992716658	treatment	treatment	NN1
304953	100736260	20992716659	based	base	VVN
304953	100736260	20992716660	on	on	II
304953	100736260	20992716661	a	a	AT1
304953	100736260	20992716662	supplement	supplement	NN1
304953	100736260	20992716663	named	name	VVD_VVN_JJ@
304953	100736260	20992716664	alpharise		NN1_VV0
304953	100736260	20992716665	..	...	...
304953	100736260	20992716666	I	i	PPIS1
304953	100736260	20992716667	am	be	VBM
304953	100736260	20992716668	so	so	RG
304953	100736260	20992716669	happy	happy	JJ
304953	100736260	20992716670	!	!	!
304953	100736260	20992716671	46996		MC
304953	100736260	20992716672	@qwx906996		FO
304953	100736266	20992716692	@@##	----------	----------
304953	100736266	20992716693	@@100736266		FO
304953	100736266	20992716694	@4936266/		VV0_NN1
304953	100736266	20992716695	46989		MC
304953	100736266	20992716696	@qwx906989		FO
304953	100736266	20992716697	<p>		NULL
304953	100736266	20992716698	With	with	IW
304953	100736266	20992716699	their	their	APPGE
304953	100736266	20992716700	ability	ability	NN1
304953	100736266	20992716701	to	to	TO
304953	100736266	20992716702	smell	smell	VVI
304953	100736266	20992716703	tiny	tiny	JJ
304953	100736266	20992716704	amounts	amount	NN2
304953	100736266	20992716705	of	of	IO
304953	100736266	20992716706	chemicals	chemical	NN2
304953	100736266	20992716707	,	,	,
304953	100736266	20992716708	trained	trained	JJ@_VVN_VVD@
304953	100736266	20992716709	dogs	dog	NN2
304953	100736266	20992716710	can	can	VM
304953	100736266	20992716711	easily	easily	RR
304953	100736266	20992716712	find	find	VVI
304953	100736266	20992716713	explosives	explosives	NN2
304953	100736266	20992716714	or	or	CC
304953	100736266	20992716715	illegal	illegal	JJ
304953	100736266	20992716716	drugs	drug	NN2
304953	100736266	20992716717	hidden	hide	VVN
304953	100736266	20992716718	in	in	II
304953	100736266	20992716719	a	a	AT1
304953	100736266	20992716720	suitcase	suitcase	NN1
304953	100736266	20992716721	.	.	.
304953	100736266	20992716722	But	but	CCB
304953	100736266	20992716723	mounting	mount	VVG_JJ@
304953	100736266	20992716724	evidence	evidence	NN1
304953	100736266	20992716725	points	point	VVZ_NN2
304953	100736266	20992716726	to	to	II
304953	100736266	20992716727	another	another	DD1
304953	100736266	20992716728	helpful	helpful	JJ
304953	100736266	20992716729	job	job	NN1
304953	100736266	20992716730	for	for	IF
304953	100736266	20992716731	mans	man	NN2
304953	100736266	20992716732	best	best	VV0%_JJT
304953	100736266	20992716733	friend	friend	NN1
304953	100736266	20992716734	:	:	:
304953	100736266	20992716735	finding	find	VVG_JJ@_NN1
304953	100736266	20992716736	cancers	cancer	NN2
304953	100736266	20992716737	before	before	CS
304953	100736266	20992716738	they	they	PPHS2
304953	100736266	20992716739	cause	cause	VV0
304953	100736266	20992716740	any	any	DD
304953	100736266	20992716741	symptoms	symptom	NN2
304953	100736266	20992716742	.	.	.
304953	100736266	20992716743	A	a	AT1
304953	100736266	20992716744	study	study	NN1
304953	100736266	20992716745	presented	present	VVN_VVD
304953	100736266	20992716746	at	at	II
304953	100736266	20992716747	the	the	AT
304953	100736266	20992716748	annual	annual	JJ
304953	100736266	20992716749	meeting	meeting	NN1
304953	100736266	20992716750	of	of	IO
304953	100736266	20992716751	the	the	AT
304953	100736266	20992716752	American	american	JJ
304953	100736266	20992716753	Urological	urological	JJ
304953	100736266	20992716754	Association	association	NN1
304953	100736266	20992716755	in	in	II
304953	100736266	20992716756	Orlando	orlando	NP1
304953	100736266	20992716757	showed	show	VVD
304953	100736266	20992716758	that	that	CST
304953	100736266	20992716759	dogs	dog	NN2
304953	100736266	20992716760	can	can	VM
304953	100736266	20992716761	almost	almost	RR
304953	100736266	20992716762	unerringly	unerringly	RR
304953	100736266	20992716763	detect	detect	VVI
304953	100736266	20992716764	prostate	prostate	NN1
304953	100736266	20992716765	cancer	cancer	NN1
304953	100736266	20992716766	in	in	II
304953	100736266	20992716767	urine	urine	NN1
304953	100736266	20992716768	samples	sample	NN2
304953	100736266	20992716769	.	.	.
304953	100736266	20992716770	<p>		NULL
304953	100736266	20992716771	Doctors	doctor	NN2
304953	100736266	20992716772	currently	currently	RR
304953	100736266	20992716773	check	check	VV0
304953	100736266	20992716774	for	for	IF
304953	100736266	20992716775	hidden	hidden	JJ@
304953	100736266	20992716776	prostate	prostate	NN1
304953	100736266	20992716777	cancer	cancer	NN1
304953	100736266	20992716778	by	by	II
304953	100736266	20992716779	measuring	measure	VVG_JJ@
304953	100736266	20992716780	levels	level	NN2
304953	100736266	20992716781	of	of	IO
304953	100736266	20992716782	a	a	AT1
304953	100736266	20992716783	protein	protein	NN1
304953	100736266	20992716784	called	call	VVN_VVD@
304953	100736266	20992716785	prostate-specific	prostate-specific	JJ
304953	100736266	20992716786	antigen	antigen	NN1
304953	100736266	20992716787	(	(	(
304953	100736266	20992716788	PSA	psa	NP1
304953	100736266	20992716789	)	)	)
304953	100736266	20992716790	in	in	II
304953	100736266	20992716791	blood	blood	NN1
304953	100736266	20992716792	.	.	.
304953	100736266	20992716793	Men	man	NN2
304953	100736266	20992716794	without	without	IW
304953	100736266	20992716795	prostate	prostate	NN1
304953	100736266	20992716796	cancer	cancer	NN1
304953	100736266	20992716797	have	have	VH0
304953	100736266	20992716798	little	little	DA1_RR_JJ
304953	100736266	20992716799	or	or	CC
304953	100736266	20992716800	no	no	AT
304953	100736266	20992716801	PSA	psa	NP1
304953	100736266	20992716802	in	in	II
304953	100736266	20992716803	their	their	APPGE
304953	100736266	20992716804	blood	blood	NN1
304953	100736266	20992716805	.	.	.
304953	100736266	20992716806	An	a	AT1
304953	100736266	20992716807	above-normal	above-normal	JJ
304953	100736266	20992716808	PSA	psa	NP1
304953	100736266	20992716809	can	can	VM
304953	100736266	20992716810	be	be	VBI
304953	100736266	20992716811	an	a	AT1
304953	100736266	20992716812	early	early	JJ
304953	100736266	20992716813	warning	warning	NN1
304953	100736266	20992716814	sign	sign	NN1
304953	100736266	20992716815	of	of	IO
304953	100736266	20992716816	prostate	prostate	NN1
304953	100736266	20992716817	cancer	cancer	NN1
304953	100736266	20992716818	.	.	.
304953	100736266	20992716819	Yet	yet	RR
304953	100736266	20992716820	a	a	AT1
304953	100736266	20992716821	spike	spike	NN1
304953	100736266	20992716822	in	in	II
304953	100736266	20992716823	PSA	psa	NP1
304953	100736266	20992716824	can	can	VM
304953	100736266	20992716825	also	also	RR
304953	100736266	20992716826	result	result	VVI
304953	100736266	20992716827	from	from	II
304953	100736266	20992716828	other	other	JJ
304953	100736266	20992716829	illnesses	illness	NN2
304953	100736266	20992716830	,	,	,
304953	100736266	20992716831	such	such	II21
304953	100736266	20992716832	as	as	II22
304953	100736266	20992716833	prostatitis	prostatitis	NN1
304953	100736266	20992716834	.	.	.
304953	100736266	20992716835	The	the	AT
304953	100736266	20992716836	only	only	JJ
304953	100736266	20992716837	way	way	NN1
304953	100736266	20992716838	to	to	TO
304953	100736266	20992716839	confirm	confirm	VVI
304953	100736266	20992716840	the	the	AT
304953	100736266	20992716841	presence	presence	NN1
304953	100736266	20992716842	of	of	IO
304953	100736266	20992716843	prostate	prostate	NN1
304953	100736266	20992716844	cancer	cancer	NN1
304953	100736266	20992716845	is	be	VBZ
304953	100736266	20992716846	with	with	IW
304953	100736266	20992716847	a	a	AT1
304953	100736266	20992716848	biopsy	biopsy	NN1
304953	100736266	20992716849	.	.	.
304953	100736266	20992716850	<p>		NULL
304953	100736266	20992716851	That	that	DD1
304953	100736266	20992716852	shortcoming	shortcoming	NN1
304953	100736266	20992716853	reflects	reflect	VVZ
304953	100736266	20992716854	a	a	AT1
304953	100736266	20992716855	need	need	NN1
304953	100736266	20992716856	for	for	IF
304953	100736266	20992716857	better	better	JJR
304953	100736266	20992716858	screening	screening	NN1
304953	100736266	20992716859	tools	tool	NN2
304953	100736266	20992716860	,	,	,
304953	100736266	20992716861	according	according	II21
304953	100736266	20992716862	to	to	II22
304953	100736266	20992716863	the	the	AT
304953	100736266	20992716864	studys		NN2
304953	100736266	20992716865	lead	lead	VV0
304953	100736266	20992716866	author	author	NN1
304953	100736266	20992716867	,	,	,
304953	100736266	20992716868	Dr.		NNB
304953	100736266	20992716869	Gianluigi		NP1
304953	100736266	20992716870	Taverna	taverna	NP1
304953	100736266	20992716871	,	,	,
304953	100736266	20992716872	a	a	AT1
304953	100736266	20992716873	urologist	urologist	NN1
304953	100736266	20992716874	at	at	II
304953	100736266	20992716875	the	the	AT
304953	100736266	20992716876	Huminatas		NP2
304953	100736266	20992716877	Research	research	NN1_VV0@
304953	100736266	20992716878	Center	center	NN1
304953	100736266	20992716879	in	in	II
304953	100736266	20992716880	Milan	milan	NP1
304953	100736266	20992716881	,	,	,
304953	100736266	20992716882	Italy	italy	NP1
304953	100736266	20992716883	.	.	.
304953	100736266	20992716884	@		II
304953	100736266	20992716885	@		II
304953	100736266	20992716886	@		II
304953	100736266	20992716887	@		II
304953	100736266	20992716888	@		II
304953	100736266	20992716889	@		II
304953	100736266	20992716890	@		II
304953	100736266	20992716891	@		II
304953	100736266	20992716892	@		II
304953	100736266	20992716893	@		II
304953	100736266	20992716894	more	more	DAR
304953	100736266	20992716895	studies	study	NN2
304953	100736266	20992716896	are	be	VBR
304953	100736266	20992716897	needed	need	VVN
304953	100736266	20992716898	to	to	TO
304953	100736266	20992716899	determine	determine	VVI
304953	100736266	20992716900	how	how	RRQ
304953	100736266	20992716901	they	they	PPHS2
304953	100736266	20992716902	could	could	VM
304953	100736266	20992716903	be	be	VBI
304953	100736266	20992716904	introduced	introduce	VVN
304953	100736266	20992716905	into	into	II
304953	100736266	20992716906	healthcare	health-care	NN1
304953	100736266	20992716907	systems	system	NN2
304953	100736266	20992716908	,	,	,
304953	100736266	20992716909	"	"	"
304953	100736266	20992716910	Taverna	taverna	NP1
304953	100736266	20992716911	says	say	VVZ
304953	100736266	20992716912	.	.	.
304953	100736266	20992716913	<p>		NULL
304953	100736266	20992716914	Dog	dog	NN1
304953	100736266	20992716915	handlers	handler	NN2
304953	100736266	20992716916	from	from	II
304953	100736266	20992716917	the	the	AT
304953	100736266	20992716918	Italian	italian	JJ_NN1
304953	100736266	20992716919	Ministry	ministry	NN1
304953	100736266	20992716920	of	of	IO
304953	100736266	20992716921	Defense	defense	NN1
304953	100736266	20992716922	trained	train	VVN_VVD@
304953	100736266	20992716923	a	a	AT1
304953	100736266	20992716924	pair	pair	NN
304953	100736266	20992716925	of	of	IO
304953	100736266	20992716926	German	german	JJ_NN1
304953	100736266	20992716927	Shepherds	shepherd	NN2
304953	100736266	20992716928	to	to	TO
304953	100736266	20992716929	detect	detect	VVI
304953	100736266	20992716930	the	the	AT
304953	100736266	20992716931	smell	smell	NN1
304953	100736266	20992716932	of	of	IO
304953	100736266	20992716933	prostate	prostate	NN1
304953	100736266	20992716934	cancer	cancer	NN1
304953	100736266	20992716935	by	by	II
304953	100736266	20992716936	sniffing	sniff	VVG
304953	100736266	20992716937	urine	urine	NN1
304953	100736266	20992716938	samples	sample	NN2_VVZ@
304953	100736266	20992716939	from	from	II
304953	100736266	20992716940	men	man	NN2
304953	100736266	20992716941	with	with	IW
304953	100736266	20992716942	prostate	prostate	NN1
304953	100736266	20992716943	cancer	cancer	NN1
304953	100736266	20992716944	.	.	.
304953	100736266	20992716945	Taverna		NN1_NP1@
304953	100736266	20992716946	and	and	CC
304953	100736266	20992716947	his	his	APPGE
304953	100736266	20992716948	colleagues	colleague	NN2
304953	100736266	20992716949	then	then	RT
304953	100736266	20992716950	presented	present	VVD_VVN
304953	100736266	20992716951	the	the	AT
304953	100736266	20992716952	animals	animal	NN2
304953	100736266	20992716953	with	with	IW
304953	100736266	20992716954	677	677	MC
304953	100736266	20992716955	urine	urine	NN1
304953	100736266	20992716956	samples	sample	NN2_VVZ@
304953	100736266	20992716957	"	"	"
304953	100736266	20992716958	320	320	MC
304953	100736266	20992716959	of	of	IO
304953	100736266	20992716960	them	them	PPHO2
304953	100736266	20992716961	collected	collect	VVD_VVN
304953	100736266	20992716962	from	from	II
304953	100736266	20992716963	men	man	NN2
304953	100736266	20992716964	with	with	IW
304953	100736266	20992716965	prostate	prostate	NN1
304953	100736266	20992716966	cancer	cancer	NN1
304953	100736266	20992716967	and	and	CC
304953	100736266	20992716968	357	357	MC
304953	100736266	20992716969	from	from	II
304953	100736266	20992716970	men	man	NN2
304953	100736266	20992716971	without	without	IW
304953	100736266	20992716972	cancer	cancer	NN1
304953	100736266	20992716973	.	.	.
304953	100736266	20992716974	The	the	AT
304953	100736266	20992716975	dogs	dog	NN2
304953	100736266	20992716976	undoubtedly	undoubtedly	RR
304953	100736266	20992716977	earned	earn	VVD_VVN
304953	100736266	20992716978	their	their	APPGE
304953	100736266	20992716979	rewards	reward	NN2
304953	100736266	20992716980	:	:	:
304953	100736266	20992716981	they	they	PPHS2
304953	100736266	20992716982	correctly	correctly	RR
304953	100736266	20992716983	identified	identify	VVN_VVD@
304953	100736266	20992716984	the	the	AT
304953	100736266	20992716985	urine	urine	NN1
304953	100736266	20992716986	samples	sample	NN2_VVZ@
304953	100736266	20992716987	with	with	IW
304953	100736266	20992716988	prostate	prostate	NN1
304953	100736266	20992716989	cancer	cancer	NN1
304953	100736266	20992716990	99%		NNU
304953	100736266	20992716991	of	of	IO
304953	100736266	20992716992	the	the	AT
304953	100736266	20992716993	time	time	NNT1
304953	100736266	20992716994	and	and	CC
304953	100736266	20992716995	those	those	DD2
304953	100736266	20992716996	without	without	IW
304953	100736266	20992716997	cancer	cancer	NN1
304953	100736266	20992716998	97%		NNU
304953	100736266	20992716999	of	of	IO
304953	100736266	20992717000	the	the	AT
304953	100736266	20992717001	time	time	NNT1
304953	100736266	20992717002	.	.	.
304953	100736266	20992717003	<p>		NULL
304953	100736266	20992717004	"	"	"
304953	100736266	20992717005	If	if	CS
304953	100736266	20992717006	true	true	JJ
304953	100736266	20992717007	,	,	,
304953	100736266	20992717008	these	these	DD2
304953	100736266	20992717009	accuracy	accuracy	NN1
304953	100736266	20992717010	figures	figure	NN2
304953	100736266	20992717011	are	be	VBR
304953	100736266	20992717012	far	far	RG
304953	100736266	20992717013	better	better	RRR_JJR
304953	100736266	20992717014	than	than	CSN
304953	100736266	20992717015	any	any	DD
304953	100736266	20992717016	tests	test	NN2
304953	100736266	20992717017	currently	currently	RR
304953	100736266	20992717018	available	available	JJ
304953	100736266	20992717019	short	short	JJ_NN1%
304953	100736266	20992717020	of	of	IO
304953	100736266	20992717021	a	a	AT1
304953	100736266	20992717022	prostate	prostate	NN1
304953	100736266	20992717023	biopsy	biopsy	NN1
304953	100736266	20992717024	in	in	II
304953	100736266	20992717025	detecting	detect	VVG
304953	100736266	20992717026	the	the	AT
304953	100736266	20992717027	presence	presence	NN1
304953	100736266	20992717028	of	of	IO
304953	100736266	20992717029	prostate	prostate	NN1
304953	100736266	20992717030	cancer	cancer	NN1
304953	100736266	20992717031	,	,	,
304953	100736266	20992717032	"	"	"
304953	100736266	20992717033	comments	comment	NN2_VVZ@
304953	100736266	20992717034	prostate	prostate	NN1
304953	100736266	20992717035	cancer	cancer	NN1
304953	100736266	20992717036	specialist	specialist	NN1
304953	100736266	20992717037	Dr.		NNB
304953	100736266	20992717038	Marc	marc	NP1
304953	100736266	20992717039	B.		NP1
304953	100736266	20992717040	Garnick		NP1
304953	100736266	20992717041	,	,	,
304953	100736266	20992717042	the	the	AT
304953	100736266	20992717043	Gorman	gorman	NN1_NP1
304953	100736266	20992717044	Brothers	brother	NN2
304953	100736266	20992717045	Professor	professor	NN1
304953	100736266	20992717046	of	of	IO
304953	100736266	20992717047	Medicine	medicine	NN1
304953	100736266	20992717048	at	at	II
304953	100736266	20992717049	Harvard	harvard	NP1
304953	100736266	20992717050	Medical	medical	JJ
304953	100736266	20992717051	School	school	NN1
304953	100736266	20992717052	and	and	CC
304953	100736266	20992717053	Beth	beth	NP1
304953	100736266	20992717054	Israel	israel	NP1
304953	100736266	20992717055	Deaconess	deaconess	NN1
304953	100736266	20992717056	Medical	medical	JJ
304953	100736266	20992717057	Center	center	NN1
304953	100736266	20992717058	.	.	.
304953	100736266	20992717059	"	"	"
304953	100736266	20992717060	But	but	CCB
304953	100736266	20992717061	while	while	CS
304953	100736266	20992717062	provocative	provocative	JJ
304953	100736266	20992717063	,	,	,
304953	100736266	20992717064	they	they	PPHS2
304953	100736266	20992717065	must	must	VM
304953	100736266	20992717066	also	also	RR
304953	100736266	20992717067	be	be	VBI
304953	100736266	20992717068	viewed	view	VVN
304953	100736266	20992717069	cautiously	cautiously	RR
304953	100736266	20992717070	.	.	.
304953	100736266	20992717071	"	"	"
304953	100736266	20992717072	<p>		NULL
304953	100736266	20992717073	Tavernas		NN2_NP1@
304953	100736266	20992717074	study	study	VV0@_NN1
304953	100736266	20992717075	was n't		VV0
304953	100736266	20992717076	the	the	AT
304953	100736266	20992717077	first	first	MD
304953	100736266	20992717078	to	to	TO
304953	100736266	20992717079	show	show	VVI
304953	100736266	20992717080	that	that	CST
304953	100736266	20992717081	dogs	dog	NN2
304953	100736266	20992717082	can	can	VM
304953	100736266	20992717083	detect	detect	VVI
304953	100736266	20992717084	@		II
304953	100736266	20992717085	@		II
304953	100736266	20992717086	@		II
304953	100736266	20992717087	@		II
304953	100736266	20992717088	@		II
304953	100736266	20992717089	@		II
304953	100736266	20992717090	@		II
304953	100736266	20992717091	@		II
304953	100736266	20992717092	@		II
304953	100736266	20992717093	@		II
304953	100736266	20992717094	France	france	NP1
304953	100736266	20992717095	,	,	,
304953	100736266	20992717096	reported	report	VVN_VVD
304953	100736266	20992717097	in	in	II
304953	100736266	20992717098	2011	2011	MC
304953	100736266	20992717099	that	that	CST
304953	100736266	20992717100	a	a	AT1
304953	100736266	20992717101	single	single	JJ
304953	100736266	20992717102	trained	trained	JJ@
304953	100736266	20992717103	dog	dog	NN1
304953	100736266	20992717104	detected	detect	VVD_VVN
304953	100736266	20992717105	prostate	prostate	NN1
304953	100736266	20992717106	cancer	cancer	NN1
304953	100736266	20992717107	with	with	IW
304953	100736266	20992717108	better	better	JJR_RRR
304953	100736266	20992717109	than	than	CSN
304953	100736266	20992717110	90%		NNU
304953	100736266	20992717111	accuracy	accuracy	NN1
304953	100736266	20992717112	in	in	II
304953	100736266	20992717113	66	66	MC
304953	100736266	20992717114	urine	urine	NN1
304953	100736266	20992717115	samples	sample	NN2
304953	100736266	20992717116	split	split	VV0_VVD_VVN
304953	100736266	20992717117	evenly	evenly	RR
304953	100736266	20992717118	from	from	II
304953	100736266	20992717119	men	man	NN2
304953	100736266	20992717120	with	with	IW
304953	100736266	20992717121	and	and	CC
304953	100736266	20992717122	without	without	IW
304953	100736266	20992717123	prostate	prostate	NN1
304953	100736266	20992717124	cancer	cancer	NN1
304953	100736266	20992717125	.	.	.
304953	100736266	20992717126	Taverna		NN1_NP1@
304953	100736266	20992717127	and	and	CC
304953	100736266	20992717128	his	his	APPGE
304953	100736266	20992717129	colleagues	colleague	NN2
304953	100736266	20992717130	wanted	want	VVD_VVN
304953	100736266	20992717131	to	to	TO
304953	100736266	20992717132	confirm	confirm	VVI
304953	100736266	20992717133	those	those	DD2
304953	100736266	20992717134	findings	finding	NN2
304953	100736266	20992717135	with	with	IW
304953	100736266	20992717136	two	two	MC
304953	100736266	20992717137	dogs	dog	NN2
304953	100736266	20992717138	instead	instead	II21
304953	100736266	20992717139	of	of	II22
304953	100736266	20992717140	one	one	MC1_PN1
304953	100736266	20992717141	,	,	,
304953	100736266	20992717142	and	and	CC
304953	100736266	20992717143	with	with	IW
304953	100736266	20992717144	a	a	AT1
304953	100736266	20992717145	much	much	RR
304953	100736266	20992717146	bigger	big	JJR
304953	100736266	20992717147	sample	sample	NN1
304953	100736266	20992717148	size	size	NN1
304953	100736266	20992717149	.	.	.
304953	100736266	20992717150	<p>		NULL
304953	100736266	20992717151	Evidence	evidence	NN1
304953	100736266	20992717152	dating	date	VVG
304953	100736266	20992717153	back	back	RP
304953	100736266	20992717154	more	more	DAR
304953	100736266	20992717155	than	than	CSN
304953	100736266	20992717156	two	two	MC
304953	100736266	20992717157	decades	decade	NNT2
304953	100736266	20992717158	reveals	reveal	VVZ
304953	100736266	20992717159	dogs	dog	NN2
304953	100736266	20992717160	abilities	ability	NN2
304953	100736266	20992717161	to	to	TO
304953	100736266	20992717162	sniff	sniff	VVI
304953	100736266	20992717163	out	out	RP
304953	100736266	20992717164	other	other	JJ
304953	100736266	20992717165	malignancies	malignancy	NN2
304953	100736266	20992717166	,	,	,
304953	100736266	20992717167	including	including	II_VVG@
304953	100736266	20992717168	melanoma	melanoma	NN1
304953	100736266	20992717169	,	,	,
304953	100736266	20992717170	and	and	CC
304953	100736266	20992717171	cancers	cancer	NN2
304953	100736266	20992717172	of	of	IO
304953	100736266	20992717173	the	the	AT
304953	100736266	20992717174	lung	lung	NN1
304953	100736266	20992717175	and	and	CC
304953	100736266	20992717176	breast	breast	NN1
304953	100736266	20992717177	.	.	.
304953	100736266	20992717178	In	in	II
304953	100736266	20992717179	the	the	AT
304953	100736266	20992717180	first	first	MD
304953	100736266	20992717181	reported	reported	JJ@_VVD_VVN
304953	100736266	20992717182	case	case	NN1
304953	100736266	20992717183	,	,	,
304953	100736266	20992717184	published	publish	VVN
304953	100736266	20992717185	in	in	II
304953	100736266	20992717186	The	the	AT
304953	100736266	20992717187	Lancet	lancet	NP1
304953	100736266	20992717188	in	in	II
304953	100736266	20992717189	1989	1989	MC
304953	100736266	20992717190	,	,	,
304953	100736266	20992717191	a	a	AT1
304953	100736266	20992717192	Border	border	NN1
304953	100736266	20992717193	Collie/Doberman		NN1
304953	100736266	20992717194	Pinscher	pinscher	NN1_NP1
304953	100736266	20992717195	mix	mix	NN1_VV0
304953	100736266	20992717196	relentlessly	relentlessly	RR
304953	100736266	20992717197	sniffed	sniff	VVD_VVN@
304953	100736266	20992717198	and	and	CC
304953	100736266	20992717199	nipped	nip	VVD
304953	100736266	20992717200	at	at	II
304953	100736266	20992717201	a	a	AT1
304953	100736266	20992717202	single	single	JJ
304953	100736266	20992717203	mole	mole	NN1
304953	100736266	20992717204	on	on	II
304953	100736266	20992717205	her	her	APPGE
304953	100736266	20992717206	owners	owner	NN2
304953	100736266	20992717207	leg	leg	NN1
304953	100736266	20992717208	(	(	(
304953	100736266	20992717209	but	but	CCB
304953	100736266	20992717210	not	not	XX
304953	100736266	20992717211	other	other	JJ
304953	100736266	20992717212	moles	mole	NN2
304953	100736266	20992717213	)	)	)
304953	100736266	20992717214	.	.	.
304953	100736266	20992717215	The	the	AT
304953	100736266	20992717216	one	one	PN1
304953	100736266	20992717217	that	that	CST
304953	100736266	20992717218	attracted	attract	VVD
304953	100736266	20992717219	the	the	AT
304953	100736266	20992717220	dogs	dog	NN2
304953	100736266	20992717221	attention	attention	NN1
304953	100736266	20992717222	turned	turn	VVD_VVN
304953	100736266	20992717223	out	out	RP
304953	100736266	20992717224	to	to	TO
304953	100736266	20992717225	be	be	VBI
304953	100736266	20992717226	malignant	malignant	JJ_NN1
304953	100736266	20992717227	.	.	.
304953	100736266	20992717228	<p>		NULL
304953	100736266	20992717229	Taverna		NN1_NP1@
304953	100736266	20992717230	speculates	speculate	VVZ
304953	100736266	20992717231	that	that	CST
304953	100736266	20992717232	cancers	cancer	NN2
304953	100736266	20992717233	emit	emit	VV0
304953	100736266	20992717234	chemical	chemical	JJ_NN1
304953	100736266	20992717235	odors	odor	NN2
304953	100736266	20992717236	with	with	IW
304953	100736266	20992717237	tumor-specific	tumor-specific	JJ
304953	100736266	20992717238	"	"	"
304953	100736266	20992717239	signatures	signature	NN2
304953	100736266	20992717240	.	.	.
304953	100736266	20992717241	"	"	"
304953	100736266	20992717242	That	that	DD1
304953	100736266	20992717243	means	mean	VVZ
304953	100736266	20992717244	the	the	AT
304953	100736266	20992717245	odor	odor	NN1
304953	100736266	20992717246	emitted	emit	VVD_VVN@
304953	100736266	20992717247	by	by	II
304953	100736266	20992717248	prostate	prostate	NN1
304953	100736266	20992717249	tumors	tumor	NN2
304953	100736266	20992717250	differs	differ	VVZ
304953	100736266	20992717251	from	from	II
304953	100736266	20992717252	that	that	DD1
304953	100736266	20992717253	given	give	VVN
304953	100736266	20992717254	off	off	RP
304953	100736266	20992717255	by	by	II
304953	100736266	20992717256	other	other	JJ
304953	100736266	20992717257	types	type	NN2
304953	100736266	20992717258	of	of	IO
304953	100736266	20992717259	cancer	cancer	NN1
304953	100736266	20992717260	.	.	.
304953	100736266	20992717261	Determining	determine	VVG
304953	100736266	20992717262	the	the	AT
304953	100736266	20992717263	specific	specific	JJ
304953	100736266	20992717264	compounds	compound	NN2
304953	100736266	20992717265	given	give	VVN
304953	100736266	20992717266	off	off	RP
304953	100736266	20992717267	by	by	II
304953	100736266	20992717268	prostate	prostate	NN1
304953	100736266	20992717269	cancer	cancer	NN1
304953	100736266	20992717270	that	that	CST
304953	100736266	20992717271	dogs	dog	NN2
304953	100736266	20992717272	detect	detect	VV0
304953	100736266	20992717273	is	be	VBZ
304953	100736266	20992717274	the	the	AT
304953	100736266	20992717275	next	next	MD
304953	100736266	20992717276	phase	phase	NN1
304953	100736266	20992717277	in	in	II
304953	100736266	20992717278	his	his	APPGE
304953	100736266	20992717279	research	research	NN1
304953	100736266	20992717280	.	.	.
304953	100736266	20992717281	<p>		NULL
304953	100736266	20992717282	"	"	"
304953	100736266	20992717283	This	this	DD1
304953	100736266	20992717284	@		II
304953	100736266	20992717285	@		II
304953	100736266	20992717286	@		II
304953	100736266	20992717287	@		II
304953	100736266	20992717288	@		II
304953	100736266	20992717289	@		II
304953	100736266	20992717290	@		II
304953	100736266	20992717291	@		II
304953	100736266	20992717292	@		II
304953	100736266	20992717293	@		II
304953	100736266	20992717294	health	health	NN1
304953	100736266	20992717295	delivery	delivery	NN1
304953	100736266	20992717296	implications	implication	NN2
304953	100736266	20992717297	,	,	,
304953	100736266	20992717298	"	"	"
304953	100736266	20992717299	Garnick		NP1_NN1
304953	100736266	20992717300	says	say	VVZ
304953	100736266	20992717301	.	.	.
304953	100736266	20992717302	"	"	"
304953	100736266	20992717303	They	they	PPHS2
304953	100736266	20992717304	should	should	VM
304953	100736266	20992717305	be	be	VBI
304953	100736266	20992717306	viewed	view	VVN
304953	100736266	20992717307	cautiously	cautiously	RR
304953	100736266	20992717308	,	,	,
304953	100736266	20992717309	but	but	CCB
304953	100736266	20992717310	I	i	PPIS1
304953	100736266	20992717311	look	look	VV0
304953	100736266	20992717312	forward	forward	RL
304953	100736266	20992717313	to	to	II
304953	100736266	20992717314	the	the	AT
304953	100736266	20992717315	maturing	maturing	JJ
304953	100736266	20992717316	of	of	IO
304953	100736266	20992717317	these	these	DD2
304953	100736266	20992717318	data	data	NN
304953	100736266	20992717319	and	and	CC
304953	100736266	20992717320	hopefully	hopefully	RR
304953	100736266	20992717321	confirmation	confirmation	NN1
304953	100736266	20992717322	of	of	IO
304953	100736266	20992717323	the	the	AT
304953	100736266	20992717324	findings	finding	NN2
304953	100736266	20992717325	by	by	II
304953	100736266	20992717326	other	other	JJ
304953	100736266	20992717327	researchers	researcher	NN2
304953	100736266	20992717328	.	.	.
304953	100736266	20992717329	"	"	"
304953	100736268	20992717349	@@##	----------	----------
304953	100736268	20992717350	@@100736268		FO
304953	100736268	20992717351	@4936268/		VV0_NN1
304953	100736268	20992717352	46989		MC
304953	100736268	20992717353	@qwx906989		FO
304953	100736268	20992717354	<p>		NULL
304953	100736268	20992717355	Two	two	MC
304953	100736268	20992717356	early	early	JJ
304953	100736268	20992717357	warning	warning	NN1
304953	100736268	20992717358	signs	sign	NN2
304953	100736268	20992717359	of	of	IO
304953	100736268	20992717360	possible	possible	JJ
304953	100736268	20992717361	prostate	prostate	NN1
304953	100736268	20992717362	cancer	cancer	NN1
304953	100736268	20992717363	are	be	VBR
304953	100736268	20992717364	a	a	AT1
304953	100736268	20992717365	high	high	JJ
304953	100736268	20992717366	level	level	NN1
304953	100736268	20992717367	of	of	IO
304953	100736268	20992717368	prostate-specific	prostate-specific	JJ
304953	100736268	20992717369	antigen	antigen	NN1
304953	100736268	20992717370	(	(	(
304953	100736268	20992717371	PSA	psa	NP1
304953	100736268	20992717372	)	)	)
304953	100736268	20992717373	in	in	II
304953	100736268	20992717374	the	the	AT
304953	100736268	20992717375	bloodstream	bloodstream	NN1
304953	100736268	20992717376	and	and	CC
304953	100736268	20992717377	an	a	AT1
304953	100736268	20992717378	abnormal	abnormal	JJ
304953	100736268	20992717379	digital	digital	JJ
304953	100736268	20992717380	rectal	rectal	JJ
304953	100736268	20992717381	exam	exam	NN1
304953	100736268	20992717382	.	.	.
304953	100736268	20992717383	When	when	CS
304953	100736268	20992717384	either	either	DD1_RR
304953	100736268	20992717385	occurs	occur	VVZ
304953	100736268	20992717386	,	,	,
304953	100736268	20992717387	a	a	AT1
304953	100736268	20992717388	prostate	prostate	NN1
304953	100736268	20992717389	biopsy	biopsy	NN1
304953	100736268	20992717390	is	be	VBZ
304953	100736268	20992717391	usually	usually	RR
304953	100736268	20992717392	done	do	VDN
304953	100736268	20992717393	to	to	TO
304953	100736268	20992717394	see	see	VVI
304953	100736268	20992717395	if	if	CSW@_CS
304953	100736268	20992717396	that	that	DD1
304953	100736268	20992717397	warning	warning	NN1
304953	100736268	20992717398	sign	sign	NN1
304953	100736268	20992717399	is	be	VBZ
304953	100736268	20992717400	being	be	VBG
304953	100736268	20992717401	caused	cause	VVN
304953	100736268	20992717402	by	by	II
304953	100736268	20992717403	prostate	prostate	NN1
304953	100736268	20992717404	cancer	cancer	NN1
304953	100736268	20992717405	.	.	.
304953	100736268	20992717406	A	a	AT1_ZZ1
304953	100736268	20992717407	new	new	JJ
304953	100736268	20992717408	study	study	NN1
304953	100736268	20992717409	indicates	indicate	VVZ
304953	100736268	20992717410	that	that	CST
304953	100736268	20992717411	images	image	NN2
304953	100736268	20992717412	from	from	II
304953	100736268	20992717413	an	a	AT1
304953	100736268	20992717414	MRI	mri	JJ_NN1
304953	100736268	20992717415	scan	scan	NN1
304953	100736268	20992717416	can	can	VM
304953	100736268	20992717417	help	help	VVI
304953	100736268	20992717418	improve	improve	VVI
304953	100736268	20992717419	biopsy	biopsy	NN1
304953	100736268	20992717420	results	result	NN2
304953	100736268	20992717421	.	.	.
304953	100736268	20992717422	<p>		NULL
304953	100736268	20992717423	A	a	AT1_ZZ1
304953	100736268	20992717424	standard	standard	JJ
304953	100736268	20992717425	biopsy	biopsy	NN1
304953	100736268	20992717426	is	be	VBZ
304953	100736268	20992717427	done	do	VDN
304953	100736268	20992717428	like	like	II
304953	100736268	20992717429	this	this	DD1
304953	100736268	20992717430	:	:	:
304953	100736268	20992717431	A	a	AT1@_ZZ1
304953	100736268	20992717432	doctor	doctor	NN1
304953	100736268	20992717433	inserts	insert	VVZ
304953	100736268	20992717434	an	a	AT1
304953	100736268	20992717435	ultrasound	ultrasound	NN1
304953	100736268	20992717436	probe	probe	NN1_VV0
304953	100736268	20992717437	into	into	II
304953	100736268	20992717438	a	a	AT1
304953	100736268	20992717439	mans	man	NN2
304953	100736268	20992717440	rectum	rectum	NN1
304953	100736268	20992717441	.	.	.
304953	100736268	20992717442	The	the	AT
304953	100736268	20992717443	probe	probe	NN1
304953	100736268	20992717444	uses	use	VVZ
304953	100736268	20992717445	high-frequency	high-frequency	JJ
304953	100736268	20992717446	sound	sound	NN1
304953	100736268	20992717447	waves	wave	NN2_VVZ@
304953	100736268	20992717448	to	to	TO
304953	100736268	20992717449	create	create	VVI
304953	100736268	20992717450	images	image	NN2
304953	100736268	20992717451	of	of	IO
304953	100736268	20992717452	the	the	AT
304953	100736268	20992717453	prostate	prostate	NN1
304953	100736268	20992717454	gland	gland	NN1
304953	100736268	20992717455	.	.	.
304953	100736268	20992717456	These	these	DD2
304953	100736268	20992717457	images	image	NN2
304953	100736268	20992717458	help	help	VV0
304953	100736268	20992717459	the	the	AT
304953	100736268	20992717460	doctor	doctor	NN1
304953	100736268	20992717461	guide	guide	VVI
304953	100736268	20992717462	several	several	DA2
304953	100736268	20992717463	small	small	JJ
304953	100736268	20992717464	,	,	,
304953	100736268	20992717465	hollow	hollow	JJ_NN1
304953	100736268	20992717466	needles	needle	NN2
304953	100736268	20992717467	into	into	II
304953	100736268	20992717468	the	the	AT
304953	100736268	20992717469	gland	gland	NN1
304953	100736268	20992717470	.	.	.
304953	100736268	20992717471	These	these	DD2
304953	100736268	20992717472	needles	needle	NN2
304953	100736268	20992717473	grab	grab	VV0
304953	100736268	20992717474	samples	sample	NN2
304953	100736268	20992717475	of	of	IO
304953	100736268	20992717476	prostate	prostate	NN1
304953	100736268	20992717477	tissue	tissue	NN1
304953	100736268	20992717478	that	that	CST
304953	100736268	20992717479	are	be	VBR
304953	100736268	20992717480	later	later	RRR
304953	100736268	20992717481	analyzed	analyze	VVN
304953	100736268	20992717482	to	to	TO
304953	100736268	20992717483	determine	determine	VVI
304953	100736268	20992717484	if	if	CSW@_CS
304953	100736268	20992717485	prostate	prostate	NN1
304953	100736268	20992717486	cancer	cancer	NN1
304953	100736268	20992717487	cells	cell	NN2
304953	100736268	20992717488	are	be	VBR
304953	100736268	20992717489	present	present	JJ
304953	100736268	20992717490	.	.	.
304953	100736268	20992717491	<p>		NULL
304953	100736268	20992717492	One	one	MC1
304953	100736268	20992717493	drawback	drawback	NN1
304953	100736268	20992717494	with	with	IW
304953	100736268	20992717495	this	this	DD1
304953	100736268	20992717496	method	method	NN1
304953	100736268	20992717497	is	be	VBZ
304953	100736268	20992717498	that	that	DD1_CST
304953	100736268	20992717499	ultrasound	ultrasound	NN1_VV0
304953	100736268	20992717500	cant	cant	NN1_JJ
304953	100736268	20992717501	readily	readily	RR
304953	100736268	20992717502	distinguish	distinguish	VV0
304953	100736268	20992717503	cancerous	cancerous	JJ
304953	100736268	20992717504	tissue	tissue	NN1
304953	100736268	20992717505	from	from	II
304953	100736268	20992717506	healthy	healthy	JJ
304953	100736268	20992717507	tissue	tissue	NN1
304953	100736268	20992717508	.	.	.
304953	100736268	20992717509	That	that	DD1
304953	100736268	20992717510	means	mean	VVZ
304953	100736268	20992717511	the	the	AT
304953	100736268	20992717512	needles	needle	NN2
304953	100736268	20992717513	could	could	VM
304953	100736268	20992717514	miss	miss	VVI
304953	100736268	20992717515	a	a	AT1
304953	100736268	20992717516	section	section	NN1
304953	100736268	20992717517	of	of	IO
304953	100736268	20992717518	prostate	prostate	NN1
304953	100736268	20992717519	tissue	tissue	NN1
304953	100736268	20992717520	harboring	harbor	VVG
304953	100736268	20992717521	potentially	potentially	RR
304953	100736268	20992717522	aggressive	aggressive	JJ
304953	100736268	20992717523	cancer	cancer	NN1
304953	100736268	20992717524	cells	cell	NN2
304953	100736268	20992717525	.	.	.
304953	100736268	20992717526	In	in	II
304953	100736268	20992717527	fact	fact	NN1
304953	100736268	20992717528	,	,	,
304953	100736268	20992717529	ultrasound-guided		JJ_NN1
304953	100736268	20992717530	biopsies	biopsy	NN2
304953	100736268	20992717531	miss	miss	VV0
304953	100736268	20992717532	such	such	DA
304953	100736268	20992717533	high-grade	high-grade	JJ_NN1
304953	100736268	20992717534	tumors	tumor	NN2
304953	100736268	20992717535	about	about	RG
304953	100736268	20992717536	40%		NNU
304953	100736268	20992717537	of	of	IO
304953	100736268	20992717538	the	the	AT
304953	100736268	20992717539	time	time	NNT1
304953	100736268	20992717540	.	.	.
304953	100736268	20992717541	@		II
304953	100736268	20992717542	@		II
304953	100736268	20992717543	@		II
304953	100736268	20992717544	@		II
304953	100736268	20992717545	@		II
304953	100736268	20992717546	@		II
304953	100736268	20992717547	@		II
304953	100736268	20992717548	@		II
304953	100736268	20992717549	@		II
304953	100736268	20992717550	@		II
304953	100736268	20992717551	reports	report	VVZ_NN2
304953	100736268	20992717552	promising	promising	JJ
304953	100736268	20992717553	results	result	NN2
304953	100736268	20992717554	from	from	II
304953	100736268	20992717555	a	a	AT1
304953	100736268	20992717556	more	more	RGR
304953	100736268	20992717557	targeted	targeted	JJ%
304953	100736268	20992717558	way	way	NN1
304953	100736268	20992717559	to	to	II
304953	100736268	20992717560	biopsy	biopsy	NN1
304953	100736268	20992717561	the	the	AT
304953	100736268	20992717562	prostate	prostate	NN1
304953	100736268	20992717563	.	.	.
304953	100736268	20992717564	Researchers	researcher	NN2
304953	100736268	20992717565	call	call	VV0
304953	100736268	20992717566	it	it	PPH1
304953	100736268	20992717567	"	"	"
304953	100736268	20992717568	fusion-guided		JJ
304953	100736268	20992717569	biopsy	biopsy	NN1
304953	100736268	20992717570	"	"	"
304953	100736268	20992717571	because	because	CS
304953	100736268	20992717572	it	it	PPH1
304953	100736268	20992717573	fuses	fuse	VVZ
304953	100736268	20992717574	ultrasound	ultrasound	NN1
304953	100736268	20992717575	images	image	NN2
304953	100736268	20992717576	with	with	IW
304953	100736268	20992717577	high-resolution	high-resolution	JJ
304953	100736268	20992717578	pictures	picture	NN2
304953	100736268	20992717579	of	of	IO
304953	100736268	20992717580	the	the	AT
304953	100736268	20992717581	prostate	prostate	NN1
304953	100736268	20992717582	made	make	VVN
304953	100736268	20992717583	by	by	II
304953	100736268	20992717584	a	a	AT1
304953	100736268	20992717585	newer	new	JJR
304953	100736268	20992717586	technology	technology	NN1
304953	100736268	20992717587	called	call	VVN_VVD@
304953	100736268	20992717588	multi-parametric		JJ
304953	100736268	20992717589	magnetic	magnetic	JJ
304953	100736268	20992717590	resonance	resonance	NN1
304953	100736268	20992717591	imaging	imaging	NN1_VVG
304953	100736268	20992717592	(	(	(
304953	100736268	20992717593	MP-MRI		NN1_JJ
304953	100736268	20992717594	)	)	)
304953	100736268	20992717595	.	.	.
304953	100736268	20992717596	Prostate	prostate	NN1
304953	100736268	20992717597	tumors	tumor	NN2
304953	100736268	20992717598	show	show	VV0
304953	100736268	20992717599	up	up	RP
304953	100736268	20992717600	on	on	II
304953	100736268	20992717601	MP-MRI		JJ_NN1
304953	100736268	20992717602	as	as	CSA
304953	100736268	20992717603	dark	dark	JJ
304953	100736268	20992717604	spots	spot	NN2
304953	100736268	20992717605	.	.	.
304953	100736268	20992717606	By	by	II
304953	100736268	20992717607	adding	add	VVG
304953	100736268	20992717608	MP-MRI		JJ_NN1
304953	100736268	20992717609	images	image	NN2
304953	100736268	20992717610	taken	take	VVN
304953	100736268	20992717611	beforehand	beforehand	RR
304953	100736268	20992717612	to	to	II
304953	100736268	20992717613	the	the	AT
304953	100736268	20992717614	real-time	real-time	JJ_NN1
304953	100736268	20992717615	ultrasound	ultrasound	NN1
304953	100736268	20992717616	images	image	NN2
304953	100736268	20992717617	,	,	,
304953	100736268	20992717618	doctors	doctor	NN2
304953	100736268	20992717619	can	can	VM
304953	100736268	20992717620	target	target	VVI
304953	100736268	20992717621	suspicious	suspicious	JJ
304953	100736268	20992717622	regions	region	NN2
304953	100736268	20992717623	of	of	IO
304953	100736268	20992717624	the	the	AT
304953	100736268	20992717625	gland	gland	NN1
304953	100736268	20992717626	while	while	CS
304953	100736268	20992717627	steering	steer	VVG
304953	100736268	20992717628	clear	clear	JJ
304953	100736268	20992717629	of	of	IO
304953	100736268	20992717630	healthy	healthy	JJ
304953	100736268	20992717631	tissue	tissue	NN1
304953	100736268	20992717632	.	.	.
304953	100736268	20992717633	<p>		NULL
304953	100736268	20992717634	The	the	AT
304953	100736268	20992717635	JAMA	jama	NP1
304953	100736268	20992717636	study	study	NN1
304953	100736268	20992717637	set	set	VVD_VVN_VV0
304953	100736268	20992717638	out	out	RP
304953	100736268	20992717639	to	to	TO
304953	100736268	20992717640	compare	compare	VVI
304953	100736268	20992717641	the	the	AT
304953	100736268	20992717642	two	two	MC
304953	100736268	20992717643	approaches	approach	NN2_VVZ
304953	100736268	20992717644	independently	independently	RR
304953	100736268	20992717645	.	.	.
304953	100736268	20992717646	Mohammad	mohammad	NP1
304953	100736268	20992717647	Minhaj		NP1
304953	100736268	20992717648	Siddiqui	siddiqui	NP1
304953	100736268	20992717649	,	,	,
304953	100736268	20992717650	an	a	AT1
304953	100736268	20992717651	assistant	assistant	JJ_NN1
304953	100736268	20992717652	professor	professor	NN1
304953	100736268	20992717653	of	of	IO
304953	100736268	20992717654	urologic	urologic	JJ
304953	100736268	20992717655	surgery	surgery	NN1
304953	100736268	20992717656	at	at	II
304953	100736268	20992717657	the	the	AT
304953	100736268	20992717658	University	university	NN1
304953	100736268	20992717659	of	of	IO
304953	100736268	20992717660	Maryland	maryland	NP1
304953	100736268	20992717661	,	,	,
304953	100736268	20992717662	and	and	CC
304953	100736268	20992717663	his	his	APPGE
304953	100736268	20992717664	colleagues	colleague	NN2
304953	100736268	20992717665	recruited	recruit	VVN_VVD@
304953	100736268	20992717666	1,003	1,003	MC
304953	100736268	20992717667	men	man	NN2
304953	100736268	20992717668	with	with	IW
304953	100736268	20992717669	either	either	RR
304953	100736268	20992717670	a	a	AT1
304953	100736268	20992717671	high	high	JJ
304953	100736268	20992717672	PSA	psa	NP1
304953	100736268	20992717673	level	level	NN1_JJ
304953	100736268	20992717674	or	or	CC
304953	100736268	20992717675	an	a	AT1
304953	100736268	20992717676	abnormal	abnormal	JJ
304953	100736268	20992717677	digital	digital	JJ
304953	100736268	20992717678	rectal	rectal	JJ
304953	100736268	20992717679	exam	exam	NN1
304953	100736268	20992717680	and	and	CC
304953	100736268	20992717681	at	at	RR21
304953	100736268	20992717682	least	least	RR22
304953	100736268	20992717683	one	one	MC1
304953	100736268	20992717684	suspicious	suspicious	JJ
304953	100736268	20992717685	spot	spot	NN1
304953	100736268	20992717686	identified	identify	VVN
304953	100736268	20992717687	by	by	II
304953	100736268	20992717688	MP-MRI		NN1_JJ
304953	100736268	20992717689	.	.	.
304953	100736268	20992717690	All	all	DB
304953	100736268	20992717691	the	the	AT
304953	100736268	20992717692	men	man	NN2
304953	100736268	20992717693	had	have	VHD
304953	100736268	20992717694	two	two	MC
304953	100736268	20992717695	biopsies	biopsy	NN2
304953	100736268	20992717696	during	during	II
304953	100736268	20992717697	a	a	AT1
304953	100736268	20992717698	single	single	JJ
304953	100736268	20992717699	session	session	NNT1
304953	100736268	20992717700	:	:	:
304953	100736268	20992717701	a	a	AT1
304953	100736268	20992717702	fusion-guided		JJ_NN1
304953	100736268	20992717703	biopsy	biopsy	NN1
304953	100736268	20992717704	by	by	II
304953	100736268	20992717705	one	one	MC1
304953	100736268	20992717706	doctor	doctor	NN1
304953	100736268	20992717707	,	,	,
304953	100736268	20992717708	followed	follow	VVN
304953	100736268	20992717709	by	by	II
304953	100736268	20992717710	a	a	AT1
304953	100736268	20992717711	standard	standard	JJ_NN1
304953	100736268	20992717712	biopsy	biopsy	NN1
304953	100736268	20992717713	by	by	II
304953	100736268	20992717714	a	a	AT1
304953	100736268	20992717715	different	different	JJ
304953	100736268	20992717716	doctor	doctor	NN1
304953	100736268	20992717717	who	who	PNQS
304953	100736268	20992717718	was n't		VV0
304953	100736268	20992717719	shown	show	VVN
304953	100736268	20992717720	the	the	AT
304953	100736268	20992717721	MP-MRI		JJ_NN1
304953	100736268	20992717722	images	image	NN2
304953	100736268	20992717723	.	.	.
304953	100736268	20992717724	<p>		NULL
304953	100736268	20992717725	Prostate	prostate	NN1
304953	100736268	20992717726	cancer	cancer	NN1
304953	100736268	20992717727	diagnoses	diagnosis	NN2
304953	100736268	20992717728	were	be	VBDR
304953	100736268	20992717729	almost	almost	RR
304953	100736268	20992717730	identical	identical	JJ
304953	100736268	20992717731	in	in	II
304953	100736268	20992717732	both	both	DB2
304953	100736268	20992717733	methods	method	NN2
304953	100736268	20992717734	:	:	:
304953	100736268	20992717735	fusion-guided		JJ
304953	100736268	20992717736	biopsy	biopsy	NN1
304953	100736268	20992717737	detected	detect	VVD_VVN
304953	100736268	20992717738	461	461	MC
304953	100736268	20992717739	cases	case	NN2
304953	100736268	20992717740	,	,	,
304953	100736268	20992717741	@		II
304953	100736268	20992717742	@		II
304953	100736268	20992717743	@		II
304953	100736268	20992717744	@		II
304953	100736268	20992717745	@		II
304953	100736268	20992717746	@		II
304953	100736268	20992717747	@		II
304953	100736268	20992717748	@		II
304953	100736268	20992717749	@		II
304953	100736268	20992717750	@		II
304953	100736268	20992717751	However	however	RR
304953	100736268	20992717752	,	,	,
304953	100736268	20992717753	fusion-guided		JJ_NN1
304953	100736268	20992717754	biopsy	biopsy	NN1
304953	100736268	20992717755	detected	detect	VVD_VVN
304953	100736268	20992717756	30%		NNU
304953	100736268	20992717757	more	more	DAR
304953	100736268	20992717758	high-grade	high-grade	JJ_NN1
304953	100736268	20992717759	cancers	cancer	NN2
304953	100736268	20992717760	,	,	,
304953	100736268	20992717761	which	which	DDQ
304953	100736268	20992717762	are	be	VBR
304953	100736268	20992717763	potentially	potentially	RR
304953	100736268	20992717764	more	more	RGR
304953	100736268	20992717765	dangerous	dangerous	JJ
304953	100736268	20992717766	,	,	,
304953	100736268	20992717767	and	and	CC
304953	100736268	20992717768	17%		NNU
304953	100736268	20992717769	fewer	fewer	DAR
304953	100736268	20992717770	slow-growing	slow-growing	JJ
304953	100736268	20992717771	,	,	,
304953	100736268	20992717772	low-risk	low-risk	JJ_NN1
304953	100736268	20992717773	cancers	cancer	NN2
304953	100736268	20992717774	than	than	CSN
304953	100736268	20992717775	standard	standard	JJ
304953	100736268	20992717776	biopsy	biopsy	NN1
304953	100736268	20992717777	.	.	.
304953	100736268	20992717778	<p>		NULL
304953	100736268	20992717779	"	"	"
304953	100736268	20992717780	The	the	AT
304953	100736268	20992717781	fusion-guided		JJ_NN1
304953	100736268	20992717782	method	method	NN1
304953	100736268	20992717783	allowed	allow	VVD_VVN
304953	100736268	20992717784	us	us	PPIO2
304953	100736268	20992717785	to	to	TO
304953	100736268	20992717786	reliably	reliably	RR
304953	100736268	20992717787	find	find	VVI
304953	100736268	20992717788	more	more	RGR_DAR
304953	100736268	20992717789	high-grade	high-grade	JJ_NN1
304953	100736268	20992717790	prostate	prostate	NN1
304953	100736268	20992717791	tumors	tumor	NN2
304953	100736268	20992717792	,	,	,
304953	100736268	20992717793	"	"	"
304953	100736268	20992717794	said	say	VVD
304953	100736268	20992717795	Siddiqui		NP1_NN1_JJ
304953	100736268	20992717796	,	,	,
304953	100736268	20992717797	who	who	PNQS
304953	100736268	20992717798	did	do	VDD
304953	100736268	20992717799	the	the	AT
304953	100736268	20992717800	study	study	NN1
304953	100736268	20992717801	while	while	CS
304953	100736268	20992717802	he	he	PPHS1
304953	100736268	20992717803	was	be	VBDZ
304953	100736268	20992717804	a	a	AT1
304953	100736268	20992717805	fellow	fellow	NN1_JJ
304953	100736268	20992717806	at	at	II
304953	100736268	20992717807	the	the	AT
304953	100736268	20992717808	National	national	JJ
304953	100736268	20992717809	Institutes	institute	NN2
304953	100736268	20992717810	of	of	IO
304953	100736268	20992717811	Health	health	NN1
304953	100736268	20992717812	.	.	.
304953	100736268	20992717813	"	"	"
304953	100736268	20992717814	And	and	CC
304953	100736268	20992717815	it	it	PPH1
304953	100736268	20992717816	also	also	RR
304953	100736268	20992717817	reduced	reduce	VVD_VVN
304953	100736268	20992717818	the	the	AT
304953	100736268	20992717819	diagnoses	diagnosis	NN2
304953	100736268	20992717820	of	of	IO
304953	100736268	20992717821	indolent	indolent	JJ
304953	100736268	20992717822	tumors	tumor	NN2
304953	100736268	20992717823	that	that	DD1
304953	100736268	20992717824	are	be	VB0
304953	100736268	20992717825	n't 	n't	XX
304953	100736268	20992717826	likely	likely	JJ_RR@
304953	100736268	20992717827	to	to	TO
304953	100736268	20992717828	harm	harm	VVI
304953	100736268	20992717829	the	the	AT
304953	100736268	20992717830	patient	patient	NN1_JJ
304953	100736268	20992717831	.	.	.
304953	100736268	20992717832	"	"	"
304953	100736268	20992717833	<p>		NULL
304953	100736268	20992717834	The	the	AT
304953	100736268	20992717835	combination	combination	NN1
304953	100736268	20992717836	of	of	IO
304953	100736268	20992717837	fusion-guided		NN1_JJ
304953	100736268	20992717838	and	and	CC
304953	100736268	20992717839	standard	standard	JJ_NN1
304953	100736268	20992717840	biopsies	biopsy	NN2
304953	100736268	20992717841	detected	detect	VVD_VVN
304953	100736268	20992717842	an	a	AT1
304953	100736268	20992717843	extra	extra	JJ
304953	100736268	20992717844	103	103	MC
304953	100736268	20992717845	cancers	cancer	NN2
304953	100736268	20992717846	,	,	,
304953	100736268	20992717847	or	or	CC
304953	100736268	20992717848	22%		NNU
304953	100736268	20992717849	more	more	DAR_RRR
304953	100736268	20992717850	than	than	CSN
304953	100736268	20992717851	either	either	DD1
304953	100736268	20992717852	method	method	NN1
304953	100736268	20992717853	alone	alone	RR_JJ
304953	100736268	20992717854	.	.	.
304953	100736268	20992717855	But	but	CCB
304953	100736268	20992717856	the	the	AT
304953	100736268	20992717857	vast	vast	JJ
304953	100736268	20992717858	majority	majority	NN1
304953	100736268	20992717859	of	of	IO
304953	100736268	20992717860	these	these	DD2
304953	100736268	20992717861	additional	additional	JJ
304953	100736268	20992717862	cancers	cancer	NN2
304953	100736268	20992717863	were	be	VBDR
304953	100736268	20992717864	slow-growing	slow-growing	JJ
304953	100736268	20992717865	,	,	,
304953	100736268	20992717866	low-risk	low-risk	JJ_NN1
304953	100736268	20992717867	tumors	tumor	NN2
304953	100736268	20992717868	.	.	.
304953	100736268	20992717869	"	"	"
304953	100736268	20992717870	This	this	DD1
304953	100736268	20992717871	suggests	suggest	VVZ
304953	100736268	20992717872	that	that	CST_DD1
304953	100736268	20992717873	fusion-guided		JJ_NN1
304953	100736268	20992717874	biopsy	biopsy	NN1
304953	100736268	20992717875	by	by	II
304953	100736268	20992717876	itself	itself	PPX1
304953	100736268	20992717877	is	be	VBZ
304953	100736268	20992717878	sufficient	sufficient	JJ
304953	100736268	20992717879	,	,	,
304953	100736268	20992717880	"	"	"
304953	100736268	20992717881	Siddiqui	siddiqui	NP1
304953	100736268	20992717882	said	say	VVD
304953	100736268	20992717883	.	.	.
304953	100736268	20992717884	"	"	"
304953	100736268	20992717885	Combining	combine	VVG
304953	100736268	20992717886	the	the	AT
304953	100736268	20992717887	two	two	MC
304953	100736268	20992717888	biopsies	biopsy	NN2
304953	100736268	20992717889	likely	likely	RR@_JJ
304953	100736268	20992717890	exposes	expose	VVZ
304953	100736268	20992717891	the	the	AT
304953	100736268	20992717892	patient	patient	NN1_JJ
304953	100736268	20992717893	to	to	II
304953	100736268	20992717894	more	more	DAR
304953	100736268	20992717895	discomfort	discomfort	NN1
304953	100736268	20992717896	and	and	CC
304953	100736268	20992717897	even	even	RR
304953	100736268	20992717898	a	a	AT1
304953	100736268	20992717899	higher	high	JJR
304953	100736268	20992717900	risk	risk	NN1
304953	100736268	20992717901	of	of	IO
304953	100736268	20992717902	complications	complication	NN2
304953	100736268	20992717903	such	such	II21
304953	100736268	20992717904	as	as	II22
304953	100736268	20992717905	infection	infection	NN1
304953	100736268	20992717906	and	and	CC
304953	100736268	20992717907	bleeding	bleeding	JJ_VVG
304953	100736268	20992717908	,	,	,
304953	100736268	20992717909	with	with	IW
304953	100736268	20992717910	limited	limited	JJ
304953	100736268	20992717911	clinical	clinical	JJ
304953	100736268	20992717912	benefit	benefit	NN1
304953	100736268	20992717913	.	.	.
304953	100736268	20992717914	"	"	"
304953	100736268	20992717915	<p>		NULL
304953	100736268	20992717916	In	in	II
304953	100736268	20992717917	an	a	AT1
304953	100736268	20992717918	accompanying	accompanying	JJ
304953	100736268	20992717919	editorial	editorial	NN1_JJ
304953	100736268	20992717920	,	,	,
304953	100736268	20992717921	Lawrence	lawrence	NP1
304953	100736268	20992717922	H.		NP1
304953	100736268	20992717923	Schwartz	schwartz	NP1
304953	100736268	20992717924	,	,	,
304953	100736268	20992717925	of	of	IO
304953	100736268	20992717926	the	the	AT
304953	100736268	20992717927	Columbia	columbia	NP1
304953	100736268	20992717928	University	university	NN1
304953	100736268	20992717929	College	college	NN1
304953	100736268	20992717930	of	of	IO
304953	100736268	20992717931	Physicians	physician	NN2
304953	100736268	20992717932	and	and	CC
304953	100736268	20992717933	Surgeons	surgeon	NN2
304953	100736268	20992717934	,	,	,
304953	100736268	20992717935	and	and	CC
304953	100736268	20992717936	Ethan	ethan	NP1
304953	100736268	20992717937	Basch	basch	NP1
304953	100736268	20992717938	,	,	,
304953	100736268	20992717939	a	a	AT1
304953	100736268	20992717940	medical	medical	JJ
304953	100736268	20992717941	@		II
304953	100736268	20992717942	@		II
304953	100736268	20992717943	@		II
304953	100736268	20992717944	@		II
304953	100736268	20992717945	@		II
304953	100736268	20992717946	@		II
304953	100736268	20992717947	@		II
304953	100736268	20992717948	@		II
304953	100736268	20992717949	@		II
304953	100736268	20992717950	@		II
304953	100736268	20992717951	editor	editor	NN1
304953	100736268	20992717952	of	of	IO
304953	100736268	20992717953	JAMA	jama	NP1
304953	100736268	20992717954	,	,	,
304953	100736268	20992717955	wrote	write	VVD
304953	100736268	20992717956	that	that	CST_DD1
304953	100736268	20992717957	fusion-guided		JJ_NN1
304953	100736268	20992717958	biopsy	biopsy	NN1
304953	100736268	20992717959	promises	promise	VVZ
304953	100736268	20992717960	"	"	"
304953	100736268	20992717961	more	more	RGR
304953	100736268	20992717962	appropriate	appropriate	JJ
304953	100736268	20992717963	treatment	treatment	NN1
304953	100736268	20992717964	recommendations	recommendation	NN2
304953	100736268	20992717965	,	,	,
304953	100736268	20992717966	such	such	II21
304953	100736268	20992717967	as	as	II22
304953	100736268	20992717968	higher-intensity	higher-intensity	JJ_NN1
304953	100736268	20992717969	treatment	treatment	NN1
304953	100736268	20992717970	for	for	IF
304953	100736268	20992717971	high-risk	high-risk	JJ
304953	100736268	20992717972	disease	disease	NN1
304953	100736268	20992717973	and	and	CC
304953	100736268	20992717974	active	active	JJ
304953	100736268	20992717975	surveillance	surveillance	NN1
304953	100736268	20992717976	for	for	IF
304953	100736268	20992717977	men	man	NN2
304953	100736268	20992717978	with	with	IW
304953	100736268	20992717979	low-grade	low-grade	JJ
304953	100736268	20992717980	tumors	tumor	NN2
304953	100736268	20992717981	.	.	.
304953	100736268	20992717982	"	"	"
304953	100736268	20992717983	<p>		NULL
304953	100736268	20992717984	Yet	yet	RR
304953	100736268	20992717985	Schwartz	schwartz	NP1_VV0@
304953	100736268	20992717986	and	and	CC
304953	100736268	20992717987	Basch	basch	NP1_NN1
304953	100736268	20992717988	emphasize	emphasize	VV0
304953	100736268	20992717989	that	that	CST_DD1
304953	100736268	20992717990	additional	additional	JJ
304953	100736268	20992717991	studies	study	NN2
304953	100736268	20992717992	are	be	VBR
304953	100736268	20992717993	needed	need	VVN
304953	100736268	20992717994	to	to	TO
304953	100736268	20992717995	determine	determine	VVI
304953	100736268	20992717996	whether	whether	CSW
304953	100736268	20992717997	the	the	AT
304953	100736268	20992717998	fusion-guided		JJ_NN1
304953	100736268	20992717999	biopsy	biopsy	NN1
304953	100736268	20992718000	has	have	VHZ
304953	100736268	20992718001	any	any	DD
304953	100736268	20992718002	influence	influence	NN1_VV0
304953	100736268	20992718003	on	on	II
304953	100736268	20992718004	long-term	long-term	JJ
304953	100736268	20992718005	survival	survival	NN1
304953	100736268	20992718006	,	,	,
304953	100736268	20992718007	a	a	AT1
304953	100736268	20992718008	point	point	NN1
304953	100736268	20992718009	with	with	IW
304953	100736268	20992718010	which	which	DDQ
304953	100736268	20992718011	Siddiqui	siddiqui	NP1_NN1
304953	100736268	20992718012	agrees	agree	VVZ
304953	100736268	20992718013	.	.	.
304953	100736268	20992718014	<p>		NULL
304953	100736268	20992718015	Marc	marc	NP1
304953	100736268	20992718016	Garnick		NP1
304953	100736268	20992718017	,	,	,
304953	100736268	20992718018	the	the	AT
304953	100736268	20992718019	Gorman	gorman	NN1_NP1
304953	100736268	20992718020	Brothers	brother	NN2
304953	100736268	20992718021	Professor	professor	NN1
304953	100736268	20992718022	of	of	IO
304953	100736268	20992718023	Medicine	medicine	NN1
304953	100736268	20992718024	at	at	II
304953	100736268	20992718025	Harvard	harvard	NP1
304953	100736268	20992718026	Medical	medical	JJ
304953	100736268	20992718027	School	school	NN1
304953	100736268	20992718028	and	and	CC
304953	100736268	20992718029	Beth	beth	NP1
304953	100736268	20992718030	Israel	israel	NP1
304953	100736268	20992718031	Deaconess	deaconess	NN1
304953	100736268	20992718032	Medical	medical	JJ
304953	100736268	20992718033	Center	center	NN1
304953	100736268	20992718034	and	and	CC
304953	100736268	20992718035	Editor	editor	NN1
304953	100736268	20992718036	in	in	II
304953	100736268	20992718037	Chief	chief	NN1
304953	100736268	20992718038	of	of	IO
304953	100736268	20992718039	**28;121;TOOLONG		NP1
304953	100736268	20992718040	,	,	,
304953	100736268	20992718041	said	say	VVD
304953	100736268	20992718042	results	result	NN2
304953	100736268	20992718043	from	from	II
304953	100736268	20992718044	the	the	AT
304953	100736268	20992718045	study	study	NN1
304953	100736268	20992718046	suggest	suggest	VV0
304953	100736268	20992718047	that	that	CST_DD1
304953	100736268	20992718048	fusion-guided		JJ_NN1
304953	100736268	20992718049	biopsy	biopsy	NN1
304953	100736268	20992718050	"	"	"
304953	100736268	20992718051	along	along	II21
304953	100736268	20992718052	with	with	II22
304953	100736268	20992718053	newer	new	JJR
304953	100736268	20992718054	molecular	molecular	JJ
304953	100736268	20992718055	tools	tool	NN2
304953	100736268	20992718056	for	for	IF
304953	100736268	20992718057	characterizing	characterize	VVG_JJ@
304953	100736268	20992718058	prostate	prostate	NN1
304953	100736268	20992718059	cancer	cancer	NN1
304953	100736268	20992718060	"	"	"
304953	100736268	20992718061	could	could	VM
304953	100736268	20992718062	help	help	VVI
304953	100736268	20992718063	patients	patient	NN2
304953	100736268	20992718064	make	make	VVI
304953	100736268	20992718065	more	more	RGR_DAR
304953	100736268	20992718066	rational	rational	JJ
304953	100736268	20992718067	treatment	treatment	NN1
304953	100736268	20992718068	choices	choice	NN2
304953	100736268	20992718069	.	.	.
304953	100736268	20992718070	But	but	CCB
304953	100736268	20992718071	he	he	PPHS1
304953	100736268	20992718072	emphasized	emphasize	VVD
304953	100736268	20992718073	that	that	CST_DD1
304953	100736268	20992718074	data	data	NN
304953	100736268	20992718075	about	about	II
304953	100736268	20992718076	the	the	AT
304953	100736268	20992718077	final	final	JJ_NN1
304953	100736268	20992718078	outcomes	outcome	NN2
304953	100736268	20992718079	of	of	IO
304953	100736268	20992718080	patients	patient	NN2
304953	100736268	20992718081	who	who	PNQS
304953	100736268	20992718082	undergo	undergo	VV0
304953	100736268	20992718083	fusion-guided		JJ_NN1
304953	100736268	20992718084	biopsy	biopsy	NN1
304953	100736268	20992718085	are	be	VBR
304953	100736268	20992718086	desperately	desperately	RR
304953	100736268	20992718087	needed	need	VVN_VVD
304953	100736268	20992718088	.	.	.
304953	100736268	20992718089	"	"	"
304953	100736268	20992718090	We	we	PPIS2
304953	100736268	20992718091	need	need	VV0
304953	100736268	20992718092	to	to	TO
304953	100736268	20992718093	know	know	VVI
304953	100736268	20992718094	if	if	CS
304953	100736268	20992718095	these	these	DD2
304953	100736268	20992718096	diagnostic	diagnostic	JJ
304953	100736268	20992718097	aids	aids	NN2
304953	100736268	20992718098	will	will	VM
304953	100736268	20992718099	lead	lead	VVI
304953	100736268	20992718100	to	to	II
304953	100736268	20992718101	both	both	DB2_RR
304953	100736268	20992718102	short-term	short-term	JJ
304953	100736268	20992718103	and	and	CC
304953	100736268	20992718104	long-term	long-term	JJ
304953	100736268	20992718105	clinical	clinical	JJ
304953	100736268	20992718106	benefits	benefit	NN2
304953	100736268	20992718107	,	,	,
304953	100736268	20992718108	"	"	"
304953	100736268	20992718109	he	he	PPHS1
304953	100736268	20992718110	said	say	VVD
304953	100736268	20992718111	.	.	.
304953	100736269	20992718131	@@##	----------	----------
304953	100736269	20992718132	@@100736269		FO
304953	100736269	20992718133	@4936269/		VV0_NN1
304953	100736269	20992718134	46989		MC
304953	100736269	20992718135	@qwx906989		FO
304953	100736269	20992718136	<p>		NULL
304953	100736269	20992718137	I	i	PPIS1
304953	100736269	20992718138	had	have	VHD
304953	100736269	20992718139	a	a	AT1
304953	100736269	20992718140	nerve-sparing	nerve-sparing	JJ_NN1
304953	100736269	20992718141	prostatectomy	prostatectomy	NN1
304953	100736269	20992718142	a	a	AT1
304953	100736269	20992718143	year	year	NNT1
304953	100736269	20992718144	ago	ago	RA
304953	100736269	20992718145	and	and	CC
304953	100736269	20992718146	can	can	VM
304953	100736269	20992718147	usually	usually	RR
304953	100736269	20992718148	get	get	VVI
304953	100736269	20992718149	an	a	AT1
304953	100736269	20992718150	erection	erection	NN1
304953	100736269	20992718151	.	.	.
304953	100736269	20992718152	Do	do	VD0
304953	100736269	20992718153	my	my	APPGE
304953	100736269	20992718154	girlfriend	girlfriend	NN1
304953	100736269	20992718155	and	and	CC
304953	100736269	20992718156	I	i	PPIS1
304953	100736269	20992718157	still	still	RR
304953	100736269	20992718158	need	need	VV0
304953	100736269	20992718159	to	to	TO
304953	100736269	20992718160	use	use	VVI
304953	100736269	20992718161	condoms	condom	NN2
304953	100736269	20992718162	to	to	TO
304953	100736269	20992718163	protect	protect	VVI
304953	100736269	20992718164	against	against	II
304953	100736269	20992718165	sexually	sexually	RR
304953	100736269	20992718166	transmitted	transmitted	JJ_VVN
304953	100736269	20992718167	diseases	disease	NN2
304953	100736269	20992718168	even	even	CS21
304953	100736269	20992718169	though	though	CS22
304953	100736269	20992718170	I	i	PPIS1
304953	100736269	20992718171	no	no	RR21
304953	100736269	20992718172	longer	long	RR22
304953	100736269	20992718173	ejaculate	ejaculate	VV0
304953	100736269	20992718174	when	when	RRQ_CS
304953	100736269	20992718175	I	i	PPIS1
304953	100736269	20992718176	reach	reach	VV0
304953	100736269	20992718177	orgasm	orgasm	NN1_VV0
304953	100736269	20992718178	?	?	?
304953	100736269	20992718179	<p>		NULL
304953	100736269	20992718180	In	in	II
304953	100736269	20992718181	a	a	AT1
304953	100736269	20992718182	word	word	NN1
304953	100736269	20992718183	,	,	,
304953	100736269	20992718184	yes	yes	UH
304953	100736269	20992718185	.	.	.
304953	100736269	20992718186	Even	even	CS21
304953	100736269	20992718187	if	if	CS22
304953	100736269	20992718188	a	a	AT1
304953	100736269	20992718189	man	man	NN1
304953	100736269	20992718190	does	do	VDZ
304953	100736269	20992718191	n't	n't	XX
304953	100736269	20992718192	ejaculate	ejaculate	VVI
304953	100736269	20992718193	,	,	,
304953	100736269	20992718194	sexually	sexually	RR
304953	100736269	20992718195	transmitted	transmitted	JJ_VVN
304953	100736269	20992718196	diseases	disease	NN2
304953	100736269	20992718197	(	(	(
304953	100736269	20992718198	STDs	std	NN2
304953	100736269	20992718199	)	)	)
304953	100736269	20992718200	can	can	VM
304953	100736269	20992718201	still	still	RR
304953	100736269	20992718202	be	be	VBI
304953	100736269	20992718203	passed	pass	VVN
304953	100736269	20992718204	from	from	II
304953	100736269	20992718205	one	one	MC1
304953	100736269	20992718206	partner	partner	NN1
304953	100736269	20992718207	to	to	II
304953	100736269	20992718208	another	another	DD1
304953	100736269	20992718209	during	during	II
304953	100736269	20992718210	sexual	sexual	JJ
304953	100736269	20992718211	activity	activity	NN1
304953	100736269	20992718212	.	.	.
304953	100736269	20992718213	Some	some	DD
304953	100736269	20992718214	diseases	disease	NN2
304953	100736269	20992718215	,	,	,
304953	100736269	20992718216	such	such	II21
304953	100736269	20992718217	as	as	II22
304953	100736269	20992718218	HIV/AIDS	hiv/aids	FU
304953	100736269	20992718219	,	,	,
304953	100736269	20992718220	gonorrhea	gonorrhea	NN1
304953	100736269	20992718221	,	,	,
304953	100736269	20992718222	chlamydia	chlamydia	NN1
304953	100736269	20992718223	,	,	,
304953	100736269	20992718224	and	and	CC
304953	100736269	20992718225	trichomoniasis	trichomoniasis	NN1
304953	100736269	20992718226	,	,	,
304953	100736269	20992718227	are	be	VBR
304953	100736269	20992718228	transmitted	transmit	VVN
304953	100736269	20992718229	when	when	CS_RRQ
304953	100736269	20992718230	infected	infected	JJ_VVN
304953	100736269	20992718231	vaginal	vaginal	JJ
304953	100736269	20992718232	or	or	CC
304953	100736269	20992718233	urethral	urethral	JJ_NN1
304953	100736269	20992718234	secretions	secretion	NN2
304953	100736269	20992718235	come	come	VV0_VVN@
304953	100736269	20992718236	into	into	II
304953	100736269	20992718237	contact	contact	NN1
304953	100736269	20992718238	with	with	IW
304953	100736269	20992718239	surfaces	surface	NN2
304953	100736269	20992718240	that	that	CST
304953	100736269	20992718241	secrete	secrete	VV0
304953	100736269	20992718242	or	or	CC
304953	100736269	20992718243	contain	contain	VV0
304953	100736269	20992718244	mucus	mucus	NN1
304953	100736269	20992718245	"	"	"
304953	100736269	20992718246	the	the	AT
304953	100736269	20992718247	vagina	vagina	NN1
304953	100736269	20992718248	and	and	CC
304953	100736269	20992718249	cervix	cervix	VV0_NN1
304953	100736269	20992718250	in	in	II_RP@
304953	100736269	20992718251	women	woman	NN2
304953	100736269	20992718252	and	and	CC
304953	100736269	20992718253	the	the	AT
304953	100736269	20992718254	urethra	urethra	NN1
304953	100736269	20992718255	in	in	II
304953	100736269	20992718256	men	man	NN2
304953	100736269	20992718257	.	.	.
304953	100736269	20992718258	That	that	DD1
304953	100736269	20992718259	means	mean	VVZ
304953	100736269	20992718260	a	a	AT1
304953	100736269	20992718261	man	man	NN1
304953	100736269	20992718262	who	who	PNQS
304953	100736269	20992718263	has	have	VHZ
304953	100736269	20992718264	had	have	VHN
304953	100736269	20992718265	a	a	AT1
304953	100736269	20992718266	prostatectomy	prostatectomy	NN1
304953	100736269	20992718267	can	can	VM
304953	100736269	20992718268	become	become	VVI
304953	100736269	20992718269	infected	infected	JJ_VVN
304953	100736269	20992718270	if	if	CS_CSW@
304953	100736269	20992718271	,	,	,
304953	100736269	20992718272	for	for	REX21
304953	100736269	20992718273	example	example	REX22
304953	100736269	20992718274	,	,	,
304953	100736269	20992718275	vaginal	vaginal	JJ
304953	100736269	20992718276	secretions	secretion	NN2
304953	100736269	20992718277	from	from	II
304953	100736269	20992718278	a	a	AT1
304953	100736269	20992718279	woman	woman	NN1
304953	100736269	20992718280	with	with	IW
304953	100736269	20992718281	chlamydia	chlamydia	NN1
304953	100736269	20992718282	enter	enter	VV0
304953	100736269	20992718283	his	his	APPGE
304953	100736269	20992718284	urethra	urethra	NN1
304953	100736269	20992718285	.	.	.
304953	100736269	20992718286	<p>		NULL
304953	100736269	20992718287	Other	other	JJ
304953	100736269	20992718288	STDs	std	NN2
304953	100736269	20992718289	can	can	VM
304953	100736269	20992718290	be	be	VBI
304953	100736269	20992718291	transmitted	transmit	VVN
304953	100736269	20992718292	through	through	II
304953	100736269	20992718293	skin-to-skin	skin-to-skin	JJ_NN1
304953	100736269	20992718294	contact	contact	NN1
304953	100736269	20992718295	from	from	II
304953	100736269	20992718296	sores	sore	NN2
304953	100736269	20992718297	,	,	,
304953	100736269	20992718298	ulcers	ulcer	NN2
304953	100736269	20992718299	,	,	,
304953	100736269	20992718300	or	or	CC
304953	100736269	20992718301	infected	infected	JJ
304953	100736269	20992718302	skin	skin	NN1
304953	100736269	20992718303	that	that	CST_DD1
304953	100736269	20992718304	looks	look	VVZ
304953	100736269	20992718305	normal	normal	JJ
304953	100736269	20992718306	,	,	,
304953	100736269	20992718307	including	including	II_VVG@
304953	100736269	20992718308	genital	genital	JJ
304953	100736269	20992718309	skin	skin	NN1
304953	100736269	20992718310	.	.	.
304953	100736269	20992718311	These	these	DD2
304953	100736269	20992718312	STDs	std	NN2
304953	100736269	20992718313	include	include	VV0
304953	100736269	20992718314	syphilis	syphilis	NN1
304953	100736269	20992718315	,	,	,
304953	100736269	20992718316	genital	genital	JJ
304953	100736269	20992718317	herpes	herpes	NN2
304953	100736269	20992718318	,	,	,
304953	100736269	20992718319	and	and	CC
304953	100736269	20992718320	human	human	JJ_NN1
304953	100736269	20992718321	papillomavirus	papillomavirus	NN1
304953	100736269	20992718322	(	(	(
304953	100736269	20992718323	@		II
304953	100736269	20992718324	@		II
304953	100736269	20992718325	@		II
304953	100736269	20992718326	@		II
304953	100736269	20992718327	@		II
304953	100736269	20992718328	@		II
304953	100736269	20992718329	@		II
304953	100736269	20992718330	@		II
304953	100736269	20992718331	@		II
304953	100736269	20992718332	@		II
304953	100736269	20992718333	men	man	NN2
304953	100736269	20992718334	and	and	CC
304953	100736269	20992718335	women	woman	NN2
304953	100736269	20992718336	and	and	CC
304953	100736269	20992718337	cervical	cervical	JJ
304953	100736269	20992718338	cancer	cancer	NN1
304953	100736269	20992718339	in	in	II
304953	100736269	20992718340	women	woman	NN2
304953	100736269	20992718341	.	.	.
304953	100736269	20992718342	Proper	proper	JJ
304953	100736269	20992718343	use	use	NN1
304953	100736269	20992718344	of	of	IO
304953	100736269	20992718345	condoms	condom	NN2
304953	100736269	20992718346	helps	help	VVZ
304953	100736269	20992718347	lower	low	JJR_RRR@
304953	100736269	20992718348	the	the	AT
304953	100736269	20992718349	risk	risk	NN1
304953	100736269	20992718350	of	of	IO
304953	100736269	20992718351	these	these	DD2
304953	100736269	20992718352	diseases	disease	NN2
304953	100736269	20992718353	,	,	,
304953	100736269	20992718354	though	though	CS
304953	100736269	20992718355	HPV	hpv	NP1
304953	100736269	20992718356	can	can	VM
304953	100736269	20992718357	infect	infect	VVI
304953	100736269	20992718358	skin	skin	NN1_VV0@
304953	100736269	20992718359	not	not	XX
304953	100736269	20992718360	covered	cover	VVN
304953	100736269	20992718361	by	by	II
304953	100736269	20992718362	a	a	AT1
304953	100736269	20992718363	condom	condom	NN1
304953	100736269	20992718364	.	.	.
304953	100736269	20992718365	Latex	latex	VV0_NN1
304953	100736269	20992718366	condoms	condom	NN2
304953	100736269	20992718367	are	be	VBR
304953	100736269	20992718368	best	best	JJT
304953	100736269	20992718369	;	;	;
304953	100736269	20992718370	condoms	condom	NN2
304953	100736269	20992718371	made	make	VVN_VVD
304953	100736269	20992718372	from	from	II
304953	100736269	20992718373	animal	animal	NN1
304953	100736269	20992718374	tissues	tissue	NN2
304953	100736269	20992718375	do	do	VD0
304953	100736269	20992718376	not	not	XX
304953	100736269	20992718377	prevent	prevent	VVI
304953	100736269	20992718378	STDs	std	NN2
304953	100736269	20992718379	,	,	,
304953	100736269	20992718380	so	so	RR_CS@
304953	100736269	20992718381	if	if	CS
304953	100736269	20992718382	either	either	DD1
304953	100736269	20992718383	partner	partner	NN1
304953	100736269	20992718384	is	be	VBZ
304953	100736269	20992718385	allergic	allergic	JJ
304953	100736269	20992718386	to	to	TO
304953	100736269	20992718387	latex	latex	VVI
304953	100736269	20992718388	,	,	,
304953	100736269	20992718389	use	use	VV0_NN1
304953	100736269	20992718390	polyurethane	polyurethane	NN1
304953	100736269	20992718391	condoms	condom	NN2
304953	100736269	20992718392	.	.	.
304953	100736269	20992718393	<p>		NULL
304953	100736269	20992718394	Many	many	DA2
304953	100736269	20992718395	people	people	NN
304953	100736269	20992718396	infected	infect	VVN_VVD
304953	100736269	20992718397	with	with	IW
304953	100736269	20992718398	STDs	std	NN2
304953	100736269	20992718399	do	do	VD0
304953	100736269	20992718400	not	not	XX
304953	100736269	20992718401	have	have	VHI
304953	100736269	20992718402	any	any	DD
304953	100736269	20992718403	signs	sign	NN2
304953	100736269	20992718404	or	or	CC
304953	100736269	20992718405	symptoms	symptom	NN2
304953	100736269	20992718406	of	of	IO
304953	100736269	20992718407	disease	disease	NN1
304953	100736269	20992718408	and	and	CC
304953	100736269	20992718409	are	be	VBR
304953	100736269	20992718410	n't	n't	XX
304953	100736269	20992718411	aware	aware	JJ
304953	100736269	20992718412	that	that	CST
304953	100736269	20992718413	they	they	PPHS2
304953	100736269	20992718414	are	be	VBR
304953	100736269	20992718415	passing	pass	VVG
304953	100736269	20992718416	an	a	AT1
304953	100736269	20992718417	infection	infection	NN1
304953	100736269	20992718418	to	to	II
304953	100736269	20992718419	their	their	APPGE
304953	100736269	20992718420	partner	partner	NN1
304953	100736269	20992718421	.	.	.
304953	100736269	20992718422	Some	some	DD
304953	100736269	20992718423	people	people	NN
304953	100736269	20992718424	can	can	VM
304953	100736269	20992718425	harbor	harbor	VVI
304953	100736269	20992718426	a	a	AT1
304953	100736269	20992718427	virus	virus	NN1
304953	100736269	20992718428	like	like	II
304953	100736269	20992718429	herpes	herpes	NN2
304953	100736269	20992718430	and	and	CC
304953	100736269	20992718431	transmit	transmit	VVI
304953	100736269	20992718432	it	it	PPH1
304953	100736269	20992718433	to	to	II
304953	100736269	20992718434	their	their	APPGE
304953	100736269	20992718435	partners	partner	NN2
304953	100736269	20992718436	even	even	CS21
304953	100736269	20992718437	if	if	CS22
304953	100736269	20992718438	years	year	NNT2
304953	100736269	20992718439	have	have	VH0
304953	100736269	20992718440	passed	pass	VVN
304953	100736269	20992718441	since	since	CS_II@
304953	100736269	20992718442	the	the	AT
304953	100736269	20992718443	infection	infection	NN1
304953	100736269	20992718444	was	be	VBDZ
304953	100736269	20992718445	contracted	contract	VVN
304953	100736269	20992718446	.	.	.
304953	100736269	20992718447	And	and	CC
304953	100736269	20992718448	although	although	CS
304953	100736269	20992718449	STDs	std	NN2
304953	100736269	20992718450	can	can	VM
304953	100736269	20992718451	be	be	VBI
304953	100736269	20992718452	treated	treat	VVN
304953	100736269	20992718453	,	,	,
304953	100736269	20992718454	some	some	DD
304953	100736269	20992718455	,	,	,
304953	100736269	20992718456	including	including	II
304953	100736269	20992718457	HIV	hiv	NP1
304953	100736269	20992718458	infection	infection	NN1
304953	100736269	20992718459	and	and	CC
304953	100736269	20992718460	genital	genital	JJ
304953	100736269	20992718461	herpes	herpes	NN2
304953	100736269	20992718462	,	,	,
304953	100736269	20992718463	can	can	VM
304953	100736269	20992718464	not	not	XX
304953	100736269	20992718465	be	be	VBI
304953	100736269	20992718466	cured	cure	VVN
304953	100736269	20992718467	.	.	.
304953	100736269	20992718468	<p>		NULL
304953	100736269	20992718469	The	the	AT
304953	100736269	20992718470	bottom	bottom	JJ_NN1
304953	100736269	20992718471	line	line	NN1
304953	100736269	20992718472	:	:	:
304953	100736269	20992718473	it	it	PPH1
304953	100736269	20992718474	does	do	VDZ
304953	100736269	20992718475	n't	n't	XX
304953	100736269	20992718476	matter	matter	VVI
304953	100736269	20992718477	whether	whether	CSW
304953	100736269	20992718478	the	the	AT
304953	100736269	20992718479	man	man	NN1
304953	100736269	20992718480	ejaculates	ejaculate	NN2_VVZ
304953	100736269	20992718481	.	.	.
304953	100736269	20992718482	Until	until	CS
304953	100736269	20992718483	you	you	PPY
304953	100736269	20992718484	are	be	VBR
304953	100736269	20992718485	in	in	II
304953	100736269	20992718486	a	a	AT1
304953	100736269	20992718487	long-term	long-term	JJ
304953	100736269	20992718488	,	,	,
304953	100736269	20992718489	mutually	mutually	RR
304953	100736269	20992718490	monogamous	monogamous	JJ
304953	100736269	20992718491	relationship	relationship	NN1
304953	100736269	20992718492	with	with	IW
304953	100736269	20992718493	a	a	AT1
304953	100736269	20992718494	partner	partner	NN1
304953	100736269	20992718495	who	who	PNQS
304953	100736269	20992718496	has	have	VHZ
304953	100736269	20992718497	been	be	VBN
304953	100736269	20992718498	tested	test	VVN
304953	100736269	20992718499	for	for	IF
304953	100736269	20992718500	STDs	std	NN2
304953	100736269	20992718501	and	and	CC
304953	100736269	20992718502	is	be	VBZ
304953	100736269	20992718503	not	not	XX
304953	100736269	20992718504	infected	infect	VVN_JJ
304953	100736269	20992718505	,	,	,
304953	100736269	20992718506	always	always	RR
304953	100736269	20992718507	use	use	VV0
304953	100736269	20992718508	a	a	AT1
304953	100736269	20992718509	condom	condom	NN1
304953	100736269	20992718510	during	during	II
304953	100736269	20992718511	sexual	sexual	JJ
304953	100736269	20992718512	activity	activity	NN1
304953	100736269	20992718513	"	"	"
304953	100736269	20992718514	and	and	CC
304953	100736269	20992718515	use	use	VV0
304953	100736269	20992718516	it	it	PPH1
304953	100736269	20992718517	correctly	correctly	RR
304953	100736269	20992718518	.	.	.
304953	100736269	20992718519	You	you	PPY
304953	100736269	20992718520	should	should	VM
304953	100736269	20992718521	be	be	VBI
304953	100736269	20992718522	tested	test	VVN
304953	100736269	20992718523	@		II
304953	100736269	20992718524	@		II
304953	100736269	20992718525	@		II
304953	100736269	20992718526	@		II
304953	100736269	20992718527	@		II
304953	100736269	20992718528	@		II
304953	100736269	20992718529	@		II
304953	100736269	20992718530	@		II
304953	100736269	20992718531	@		II
304953	100736269	20992718532	@		II
304953	100736269	20992718533	n't	n't	XX
304953	100736269	20992718534	infected	infect	VVN_JJ
304953	100736269	20992718535	.	.	.
304953	100736269	20992718536	For	for	IF
304953	100736269	20992718537	more	more	DAR
304953	100736269	20992718538	information	information	NN1
304953	100736269	20992718539	,	,	,
304953	100736269	20992718540	log	log	NN1_VV0@
304953	100736269	20992718541	on	on	II21_RP
304953	100736269	20992718542	to	to	II22_II
304953	100736269	20992718543	the	the	AT
304953	100736269	20992718544	Centers	center	NN2
304953	100736269	20992718545	for	for	IF
304953	100736269	20992718546	Disease	disease	NN1
304953	100736269	20992718547	Control	control	NN1
304953	100736269	20992718548	and	and	CC
304953	100736269	20992718549	Prevention	prevention	NN1
304953	100736269	20992718550	's	's	GE
304953	100736269	20992718551	Web	web	NN1
304953	100736269	20992718552	site	site	NN1
304953	100736269	20992718553	on	on	II
304953	100736269	20992718554	STD	std	NN1
304953	100736269	20992718555	prevention	prevention	NN1
304953	100736269	20992718556	,	,	,
304953	100736269	20992718557	www.cdc.gov/std		FU
304953	100736269	20992718558	.	.	.
304953	100736269	20992718559	<p>		NULL
304953	100736269	20992718560	do	do	VD0
304953	100736269	20992718561	you	you	PPY
304953	100736269	20992718562	know	know	VVI
304953	100736269	20992718563	that	that	CST
304953	100736269	20992718564	there	there	EX
304953	100736269	20992718565	is	be	VBZ
304953	100736269	20992718566	a	a	AT1
304953	100736269	20992718567	great	great	JJ
304953	100736269	20992718568	spell	spell	NN1
304953	100736269	20992718569	caster	caster	NN1
304953	100736269	20992718570	who	who	PNQS
304953	100736269	20992718571	can	can	VM
304953	100736269	20992718572	cure	cure	VVI
304953	100736269	20992718573	any	any	DD
304953	100736269	20992718574	deadly	deadly	JJ
304953	100736269	20992718575	disease	disease	NN1
304953	100736269	20992718576	.	.	.
304953	100736269	20992718577	Like	like	II_JJ@
304953	100736269	20992718578	Cancer	cancer	NN1
304953	100736269	20992718579	,	,	,
304953	100736269	20992718580	Hiv	hiv	NP1
304953	100736269	20992718581	,	,	,
304953	100736269	20992718582	syphilis	syphilis	NN1
304953	100736269	20992718583	,	,	,
304953	100736269	20992718584	e.t.c	e.t.c	RA
304953	100736269	20992718585	.	.	.
304953	100736269	20992718586	Well	well	RR
304953	100736269	20992718587	my	my	APPGE
304953	100736269	20992718588	main	main	JJ
304953	100736269	20992718589	reason	reason	NN1
304953	100736269	20992718590	why	why	RRQ
304953	100736269	20992718591	i	i	ZZ1_MC1
304953	100736269	20992718592	am	be	VBM_RA@
304953	100736269	20992718593	writing	write	VVG
304953	100736269	20992718594	this	this	DD1
304953	100736269	20992718595	right	right	NN1_RR_JJ
304953	100736269	20992718596	now	now	RT
304953	100736269	20992718597	is	be	VBZ
304953	100736269	20992718598	to	to	TO
304953	100736269	20992718599	inform	inform	VVI
304953	100736269	20992718600	the	the	AT
304953	100736269	20992718601	whole	whole	JJ
304953	100736269	20992718602	world	world	NN1
304953	100736269	20992718603	about	about	II
304953	100736269	20992718604	the	the	AT
304953	100736269	20992718605	great	great	JJ
304953	100736269	20992718606	deeds	deed	NN2
304953	100736269	20992718607	,	,	,
304953	100736269	20992718608	Dr.		NNB
304953	100736269	20992718609	Jerry	jerry	NP1
304953	100736269	20992718610	did	do	VDD
304953	100736269	20992718611	for	for	IF
304953	100736269	20992718612	me	me	PPIO1
304953	100736269	20992718613	.	.	.
304953	100736269	20992718614	I	i	PPIS1
304953	100736269	20992718615	was	be	VBDZ
304953	100736269	20992718616	diagnosed	diagnose	VVN
304953	100736269	20992718617	of	of	IO
304953	100736269	20992718618	this	this	DD1
304953	100736269	20992718619	deadly	deadly	JJ
304953	100736269	20992718620	disease	disease	NN1
304953	100736269	20992718621	in	in	II
304953	100736269	20992718622	the	the	AT
304953	100736269	20992718623	year	year	NNT1
304953	100736269	20992718624	2010	2010	MC
304953	100736269	20992718625	ever	ever	RR
304953	100736269	20992718626	since	since	II
304953	100736269	20992718627	then	then	RT
304953	100736269	20992718628	i	i	MC1_ZZ1
304953	100736269	20992718629	was	be	VBDZ
304953	100736269	20992718630	taking	take	VVG
304953	100736269	20992718631	my	my	APPGE
304953	100736269	20992718632	medications	medication	NN2
304953	100736269	20992718633	,	,	,
304953	100736269	20992718634	until	until	CS
304953	100736269	20992718635	i	i	ZZ1_MC1
304953	100736269	20992718636	met	meet	VVD_VVN
304953	100736269	20992718637	the	the	AT
304953	100736269	20992718638	great	great	JJ
304953	100736269	20992718639	spell	spell	NN1
304953	100736269	20992718640	caster	caster	NN1
304953	100736269	20992718641	,	,	,
304953	100736269	20992718642	though	though	CS
304953	100736269	20992718643	i	i	ZZ1
304953	100736269	20992718644	never	never	RR
304953	100736269	20992718645	believed	believe	VVN_VVD
304953	100736269	20992718646	in	in	II
304953	100736269	20992718647	spell	spell	NN1
304953	100736269	20992718648	.	.	.
304953	100736269	20992718649	I	i	PPIS1
304953	100736269	20992718650	saw	see	VVD
304953	100736269	20992718651	many	many	DA2
304953	100736269	20992718652	testimonies	testimony	NN2
304953	100736269	20992718653	on	on	II
304953	100736269	20992718654	how	how	RRQ
304953	100736269	20992718655	a	a	AT1
304953	100736269	20992718656	great	great	JJ
304953	100736269	20992718657	spell	spell	NN1
304953	100736269	20992718658	caster	caster	NN1
304953	100736269	20992718659	cured	cure	VVD_VVN
304953	100736269	20992718660	their	their	APPGE
304953	100736269	20992718661	deadly	deadly	JJ
304953	100736269	20992718662	diseases	disease	NN2
304953	100736269	20992718663	.	.	.
304953	100736269	20992718664	I	i	PPIS1
304953	100736269	20992718665	contacted	contact	VVD
304953	100736269	20992718666	him	him	PPHO1
304953	100736269	20992718667	through	through	II_RP@
304953	100736269	20992718668	his	his	APPGE
304953	100736269	20992718669	phone	phone	NN1
304953	100736269	20992718670	number	number	NN1
304953	100736269	20992718671	.	.	.
304953	100736269	20992718672	I	i	PPIS1
304953	100736269	20992718673	called	call	VVD
304953	100736269	20992718674	him	him	PPHO1
304953	100736269	20992718675	,	,	,
304953	100736269	20992718676	he	he	PPHS1
304953	100736269	20992718677	asked	ask	VVD
304953	100736269	20992718678	me	me	PPIO1
304953	100736269	20992718679	to	to	TO
304953	100736269	20992718680	send	send	VVI
304953	100736269	20992718681	him	him	PPHO1
304953	100736269	20992718682	my	my	APPGE
304953	100736269	20992718683	email	email	NN1
304953	100736269	20992718684	,	,	,
304953	100736269	20992718685	which	which	DDQ
304953	100736269	20992718686	i	i	MC1_ZZ1
304953	100736269	20992718687	did	do	VDD
304953	100736269	20992718688	.	.	.
304953	100736269	20992718689	He	he	PPHS1
304953	100736269	20992718690	gave	give	VVD
304953	100736269	20992718691	me	me	PPIO1
304953	100736269	20992718692	a	a	AT1
304953	100736269	20992718693	form	form	NN1
304953	100736269	20992718694	to	to	TO
304953	100736269	20992718695	fill	fill	VVI
304953	100736269	20992718696	,	,	,
304953	100736269	20992718697	I	i	PPIS1
304953	100736269	20992718698	filled	fill	VVD
304953	100736269	20992718699	it	it	PPH1
304953	100736269	20992718700	and	and	CC
304953	100736269	20992718701	send	send	VV0
304953	100736269	20992718702	it	it	PPH1
304953	100736269	20992718703	back	back	RP
304953	100736269	20992718704	to	to	II
304953	100736269	20992718705	him	him	PPHO1
304953	100736269	20992718706	.	.	.
304953	100736269	20992718707	He	he	PPHS1
304953	100736269	20992718708	told	tell	VVD
304953	100736269	20992718709	me	me	PPIO1
304953	100736269	20992718710	that	that	CST
304953	100736269	20992718711	his	his	APPGE
304953	100736269	20992718712	gods	god	NN2
304953	100736269	20992718713	required	require	VVN_VVD@
304953	100736269	20992718714	some	some	DD
304953	100736269	20992718715	items	item	NN2
304953	100736269	20992718716	in	in	II
304953	100736269	20992718717	which	which	DDQ
304953	100736269	20992718718	he	he	PPHS1
304953	100736269	20992718719	will	will	VM
304953	100736269	20992718720	use	use	VVI
304953	100736269	20992718721	in	in	II_RP@
304953	100736269	20992718722	casting	cast	VVG
304953	100736269	20992718723	@		II
304953	100736269	20992718724	@		II
304953	100736269	20992718725	@		II
304953	100736269	20992718726	@		II
304953	100736269	20992718727	@		II
304953	100736269	20992718728	@		II
304953	100736269	20992718729	@		II
304953	100736269	20992718730	@		II
304953	100736269	20992718731	@		II
304953	100736269	20992718732	@		II
304953	100736269	20992718733	to	to	TO
304953	100736269	20992718734	find	find	VVI
304953	100736269	20992718735	the	the	AT
304953	100736269	20992718736	items	item	NN2
304953	100736269	20992718737	he	he	PPHS1
304953	100736269	20992718738	required	require	VVD@
304953	100736269	20992718739	.	.	.
304953	100736269	20992718740	He	he	PPHS1
304953	100736269	20992718741	told	tell	VVD
304953	100736269	20992718742	me	me	PPIO1
304953	100736269	20992718743	that	that	CST
304953	100736269	20992718744	the	the	AT
304953	100736269	20992718745	only	only	JJ
304953	100736269	20992718746	alternative	alternative	NN1
304953	100736269	20992718747	is	be	VBZ
304953	100736269	20992718748	for	for	CS%_IF
304953	100736269	20992718749	of	of	IO
304953	100736269	20992718750	to	to	TO
304953	100736269	20992718751	send	send	VVI
304953	100736269	20992718752	him	him	PPHO1
304953	100736269	20992718753	the	the	AT
304953	100736269	20992718754	money	money	NN1
304953	100736269	20992718755	,	,	,
304953	100736269	20992718756	then	then	RT
304953	100736269	20992718757	he	he	PPHS1
304953	100736269	20992718758	can	can	VM
304953	100736269	20992718759	help	help	VVI
304953	100736269	20992718760	me	me	PPIO1
304953	100736269	20992718761	to	to	TO
304953	100736269	20992718762	purchase	purchase	VVI
304953	100736269	20992718763	the	the	AT
304953	100736269	20992718764	items	item	NN2
304953	100736269	20992718765	from	from	II
304953	100736269	20992718766	the	the	AT
304953	100736269	20992718767	items	item	NN2
304953	100736269	20992718768	sellers	seller	NN2
304953	100736269	20992718769	.	.	.
304953	100736269	20992718770	I	i	PPIS1
304953	100736269	20992718771	promised	promise	VVD
304953	100736269	20992718772	myself	myself	PPX1
304953	100736269	20992718773	to	to	TO
304953	100736269	20992718774	do	do	VDI
304953	100736269	20992718775	anything	anything	PN1
304953	100736269	20992718776	to	to	TO
304953	100736269	20992718777	get	get	VVI
304953	100736269	20992718778	cured	cure	VVN
304953	100736269	20992718779	.	.	.
304953	100736269	20992718780	I	i	PPIS1
304953	100736269	20992718781	sent	send	VVD
304953	100736269	20992718782	him	him	PPHO1
304953	100736269	20992718783	the	the	AT
304953	100736269	20992718784	money	money	NN1
304953	100736269	20992718785	.	.	.
304953	100736269	20992718786	He	he	PPHS1
304953	100736269	20992718787	bought	buy	VVD
304953	100736269	20992718788	the	the	AT
304953	100736269	20992718789	items	item	NN2
304953	100736269	20992718790	and	and	CC
304953	100736269	20992718791	casted	cast	VVD
304953	100736269	20992718792	a	a	AT1
304953	100736269	20992718793	curing	cure	VVG
304953	100736269	20992718794	spell	spell	NN1_VV0
304953	100736269	20992718795	on	on	II
304953	100736269	20992718796	me	me	PPIO1
304953	100736269	20992718797	.	.	.
304953	100736269	20992718798	Two	two	MC
304953	100736269	20992718799	day	day	NNT1
304953	100736269	20992718800	later	later	RRR
304953	100736269	20992718801	he	he	PPHS1
304953	100736269	20992718802	asked	ask	VVD
304953	100736269	20992718803	me	me	PPIO1
304953	100736269	20992718804	to	to	TO
304953	100736269	20992718805	go	go	VVI
304953	100736269	20992718806	for	for	IF
304953	100736269	20992718807	check-up	checkup	NN1
304953	100736269	20992718808	,	,	,
304953	100736269	20992718809	when	when	CS_RRQ
304953	100736269	20992718810	i	i	ZZ1_MC1
304953	100736269	20992718811	did	do	VDD
304953	100736269	20992718812	the	the	AT
304953	100736269	20992718813	check-up	checkup	NN1
304953	100736269	20992718814	i	i	MC1_ZZ1
304953	100736269	20992718815	was	be	VBDZ
304953	100736269	20992718816	tested	test	VVN
304953	100736269	20992718817	HIV	hiv	NP1
304953	100736269	20992718818	Negative	negative	JJ_NN1@
304953	100736269	20992718819	.	.	.
304953	100736269	20992718820	If	if	CS
304953	100736269	20992718821	you	you	PPY
304953	100736269	20992718822	passing	pass	VVG
304953	100736269	20992718823	through	through	II
304953	100736269	20992718824	hardship	hardship	NN1
304953	100736269	20992718825	and	and	CC
304953	100736269	20992718826	you	you	PPY
304953	100736269	20992718827	need	need	VV0
304953	100736269	20992718828	a	a	AT1
304953	100736269	20992718829	way	way	NN1
304953	100736269	20992718830	out	out	RP
304953	100736269	20992718831	,	,	,
304953	100736269	20992718832	kindly	kindly	RR
304953	100736269	20992718833	contact	contact	VV0
304953	100736269	20992718834	him	him	PPHO1
304953	100736269	20992718835	via	via	II
304953	100736269	20992718836	his	his	APPGE
304953	100736269	20992718837	email	email	NN1
304953	100736269	20992718838	on	on	II
304953	100736269	20992718839	(	(	(
304953	100736269	20992718840	**29;151;TOOLONG		FO
304953	100736269	20992718841	)	)	)
304953	100736269	20992718842	+2348142559061		MC
304953	100736269	20992718843	<p>		NULL
304953	100736269	20992718844	ALL	all	DB
304953	100736269	20992718845	THE	the	AT
304953	100736269	20992718846	VIEWERS	viewer	NN2
304953	100736269	20992718847	AND	and	CC
304953	100736269	20992718848	READERS	reader	NN2
304953	100736269	20992718849	PLEASE	please	RR
304953	100736269	20992718850	FIND	find	VV0
304953	100736269	20992718851	IT	it	NN1_PPH1@
304953	100736269	20992718852	IN	in	II
304953	100736269	20992718853	YOUR	your	APPGE
304953	100736269	20992718854	HEART	heart	NN1
304953	100736269	20992718855	TO	to	TO
304953	100736269	20992718856	FORGIVE	forgive	VVI
304953	100736269	20992718857	ME	me	PPIO1
304953	100736269	20992718858	,	,	,
304953	100736269	20992718859	I	i	PPIS1
304953	100736269	20992718860	KNOW	know	VV0
304953	100736269	20992718861	I	i	PPIS1
304953	100736269	20992718862	HAD	have	VHD
304953	100736269	20992718863	DONE	do	VDN
304953	100736269	20992718864	SO	so	RG
304953	100736269	20992718865	MANY	many	DA2
304953	100736269	20992718866	WRONG	wrong	JJ
304953	100736269	20992718867	THINGS	thing	NN2
304953	100736269	20992718868	AT	at	II
304953	100736269	20992718869	PAST	past	JJ
304953	100736269	20992718870	TIMES	time	NNT2
304953	100736269	20992718871	,	,	,
304953	100736269	20992718872	I	i	PPIS1
304953	100736269	20992718873	DO	do	VD0
304953	100736269	20992718874	NT		XX
304953	100736269	20992718875	KNOW	know	VVI
304953	100736269	20992718876	WHERE	where	RRQ
304953	100736269	20992718877	TO	to	TO
304953	100736269	20992718878	START	start	VVI
304953	100736269	20992718879	WITH	with	IW
304953	100736269	20992718880	MY	my	APPGE
304953	100736269	20992718881	TESTIMONY	testimony	NN1
304953	100736269	20992718882	..	...	...
304953	100736269	20992718883	I	i	PPIS1
304953	100736269	20992718884	AM	be	VBM
304953	100736269	20992718885	VANESSA	vanessa	NP1
304953	100736269	20992718886	,	,	,
304953	100736269	20992718887	i	i	ZZ1_MC1
304953	100736269	20992718888	got	get	VVD_VVN
304953	100736269	20992718889	married	marry	VVN
304953	100736269	20992718890	to	to	II
304953	100736269	20992718891	a	a	AT1
304953	100736269	20992718892	man	man	NN1
304953	100736269	20992718893	JEROME	jerome	NP1
304953	100736269	20992718894	,	,	,
304953	100736269	20992718895	who	who	PNQS
304953	100736269	20992718896	had	have	VHD
304953	100736269	20992718897	a	a	AT1
304953	100736269	20992718898	wife	wife	NN1
304953	100736269	20992718899	JOSEPHINE	josephine	NP1
304953	100736269	20992718900	already	already	RR
304953	100736269	20992718901	,	,	,
304953	100736269	20992718902	then	then	RT
304953	100736269	20992718903	i	i	MC1_ZZ1
304953	100736269	20992718904	was	be	VBDZ
304953	100736269	20992718905	made	make	VVN
304953	100736269	20992718906	the	the	AT
304953	100736269	20992718907	second	second	MD
304953	100736269	20992718908	wife	wife	NN1
304953	100736269	20992718909	,	,	,
304953	100736269	20992718910	and	and	CC
304953	100736269	20992718911	this	this	DD1
304953	100736269	20992718912	JOSEPHINE	josephine	NP1
304953	100736269	20992718913	has	have	VHZ
304953	100736269	20992718914	a	a	AT1
304953	100736269	20992718915	daughter	daughter	NN1
304953	100736269	20992718916	for	for	IF
304953	100736269	20992718917	my	my	APPGE
304953	100736269	20992718918	husband	husband	NN1
304953	100736269	20992718919	,	,	,
304953	100736269	20992718920	called	call	VVN
304953	100736269	20992718921	CHRISTABEL	christabel	NP1
304953	100736269	20992718922	,	,	,
304953	100736269	20992718923	@		II
304953	100736269	20992718924	@		II
304953	100736269	20992718925	@		II
304953	100736269	20992718926	@		II
304953	100736269	20992718927	@		II
304953	100736269	20992718928	@		II
304953	100736269	20992718929	@		II
304953	100736269	20992718930	@		II
304953	100736269	20992718931	@		II
304953	100736269	20992718932	@		II
304953	100736269	20992718933	her	her	APPGE
304953	100736269	20992718934	life	life	NN1
304953	100736269	20992718935	.	.	.
304953	100736269	20992718936	so	so	RR
304953	100736269	20992718937	Christabel	christabel	NP1
304953	100736269	20992718938	was	be	VBDZ
304953	100736269	20992718939	left	leave	VVN
304953	100736269	20992718940	to	to	TO
304953	100736269	20992718941	live	live	VVI
304953	100736269	20992718942	with	with	IW
304953	100736269	20992718943	me	me	PPIO1
304953	100736269	20992718944	,	,	,
304953	100736269	20992718945	and	and	CC
304953	100736269	20992718946	my	my	APPGE
304953	100736269	20992718947	two	two	MC
304953	100736269	20992718948	kids	kid	NN2
304953	100736269	20992718949	,	,	,
304953	100736269	20992718950	PATIENCE	patience	NN1
304953	100736269	20992718951	AND	and	CC
304953	100736269	20992718952	GLORY	glory	NN1
304953	100736269	20992718953	,	,	,
304953	100736269	20992718954	Christabel	christabel	NP1
304953	100736269	20992718955	was	be	VBDZ
304953	100736269	20992718956	the	the	AT
304953	100736269	20992718957	eldest	eldest	JJT
304953	100736269	20992718958	of	of	IO
304953	100736269	20992718959	them	them	PPHO2
304953	100736269	20992718960	,	,	,
304953	100736269	20992718961	so	so	RR_RG_CS@
304953	100736269	20992718962	i	i	MC1_ZZ1
304953	100736269	20992718963	was	be	VBDZ
304953	100736269	20992718964	misusing	misuse	VVG
304953	100736269	20992718965	CHRISTABEL	christabel	NP1
304953	100736269	20992718966	,	,	,
304953	100736269	20992718967	SHE	she	PPHS1
304953	100736269	20992718968	is	be	VBZ
304953	100736269	20992718969	the	the	AT
304953	100736269	20992718970	only	only	JJ
304953	100736269	20992718971	one	one	PN1
304953	100736269	20992718972	doing	do	VDG
304953	100736269	20992718973	all	all	DB
304953	100736269	20992718974	the	the	AT
304953	100736269	20992718975	house	house	NN1
304953	100736269	20992718976	work	work	NN1_VV0
304953	100736269	20992718977	,	,	,
304953	100736269	20992718978	anytime	anytime	NNT1
304953	100736269	20992718979	she	she	PPHS1
304953	100736269	20992718980	dose	dose	NN1
304953	100736269	20992718981	some	some	DD
304953	100736269	20992718982	thing	thing	NN1
304953	100736269	20992718983	wrong	wrong	JJ_NN1@_RR@
304953	100736269	20992718984	,	,	,
304953	100736269	20992718985	i	i	MC1_ZZ1
304953	100736269	20992718986	would n't		NN1_VV0
304953	100736269	20992718987	give	give	VV0
304953	100736269	20992718988	her	her	APPGE
304953	100736269	20992718989	food	food	NN1
304953	100736269	20992718990	to	to	TO
304953	100736269	20992718991	eat	eat	VVI
304953	100736269	20992718992	all	all	DB_RR@
304953	100736269	20992718993	through	through	II
304953	100736269	20992718994	the	the	AT
304953	100736269	20992718995	day	day	NNT1
304953	100736269	20992718996	,	,	,
304953	100736269	20992718997	and	and	CC
304953	100736269	20992718998	beat	beat	VVD_VV0
304953	100736269	20992718999	her	her	PPHO1
304953	100736269	20992719000	up	up	RP
304953	100736269	20992719001	with	with	IW
304953	100736269	20992719002	anything	anything	PN1
304953	100736269	20992719003	close	close	RR_JJ
304953	100736269	20992719004	to	to	II
304953	100736269	20992719005	me	me	PPIO1
304953	100736269	20992719006	,	,	,
304953	100736269	20992719007	but	but	CCB
304953	100736269	20992719008	she	she	PPHS1
304953	100736269	20992719009	never	never	RR
304953	100736269	20992719010	worry	worry	VV0
304953	100736269	20992719011	,	,	,
304953	100736269	20992719012	or	or	CC
304953	100736269	20992719013	insult	insult	VV0
304953	100736269	20992719014	me.or		NNU
304953	100736269	20992719015	report	report	NN1
304953	100736269	20992719016	to	to	II
304953	100736269	20992719017	my	my	APPGE
304953	100736269	20992719018	husband.because		NNU
304953	100736269	20992719019	i	i	ZZ1
304953	100736269	20992719020	told	tell	VVD_VVN
304953	100736269	20992719021	her	her	PPHO1
304953	100736269	20992719022	if	if	CS_CSW@
304953	100736269	20992719023	she	she	PPHS1
304953	100736269	20992719024	did	do	VDD
304953	100736269	20992719025	i	i	ZZ1_MC1
304953	100736269	20992719026	will	will	VM
304953	100736269	20992719027	kill	kill	VVI
304953	100736269	20992719028	her	her	PPHO1
304953	100736269	20992719029	,	,	,
304953	100736269	20992719030	i	i	ZZ1_MC1
304953	100736269	20992719031	did	do	VDD
304953	100736269	20992719032	this	this	DD1
304953	100736269	20992719033	to	to	II
304953	100736269	20992719034	some	some	DD
304953	100736269	20992719035	extent	extent	NN1
304953	100736269	20992719036	that	that	CST_DD1
304953	100736269	20992719037	,	,	,
304953	100736269	20992719038	one	one	MC1
304953	100736269	20992719039	day	day	NNT1
304953	100736269	20992719040	,	,	,
304953	100736269	20992719041	she	she	PPHS1
304953	100736269	20992719042	was	be	VBDZ
304953	100736269	20992719043	on	on	II
304953	100736269	20992719044	her	her	APPGE
304953	100736269	20992719045	menstruation	menstruation	NN1
304953	100736269	20992719046	period	period	NN1
304953	100736269	20992719047	,	,	,
304953	100736269	20992719048	she	she	PPHS1
304953	100736269	20992719049	was	be	VBDZ
304953	100736269	20992719050	afraid	afraid	JJ
304953	100736269	20992719051	to	to	TO
304953	100736269	20992719052	tell	tell	VVI
304953	100736269	20992719053	me	me	PPIO1
304953	100736269	20992719054	,	,	,
304953	100736269	20992719055	she	she	PPHS1
304953	100736269	20992719056	was	be	VBDZ
304953	100736269	20992719057	not	not	XX
304953	100736269	20992719058	having	have	VHG
304953	100736269	20992719059	enough	enough	DD
304953	100736269	20992719060	cloth	cloth	NN1
304953	100736269	20992719061	,	,	,
304953	100736269	20992719062	so	so	CS@_RR
304953	100736269	20992719063	the	the	AT
304953	100736269	20992719064	only	only	JJ
304953	100736269	20992719065	cloth	cloth	NN1
304953	100736269	20992719066	she	she	PPHS1
304953	100736269	20992719067	had	have	VHD
304953	100736269	20992719068	she	she	PPHS1
304953	100736269	20992719069	put	put	VVN
304953	100736269	20992719070	it	it	PPH1
304953	100736269	20992719071	into	into	II
304953	100736269	20992719072	her	her	APPGE
304953	100736269	20992719073	pant	pant	NN1
304953	100736269	20992719074	,	,	,
304953	100736269	20992719075	so	so	CS21
304953	100736269	20992719076	that	that	CS22
304953	100736269	20992719077	,	,	,
304953	100736269	20992719078	the	the	AT
304953	100736269	20992719079	cloth	cloth	NN1
304953	100736269	20992719080	would	would	VM
304953	100736269	20992719081	soak	soak	VVI
304953	100736269	20992719082	the	the	AT
304953	100736269	20992719083	bleeding	bleeding	JJ
304953	100736269	20992719084	,	,	,
304953	100736269	20992719085	and	and	CC
304953	100736269	20992719086	the	the	AT
304953	100736269	20992719087	cloth	cloth	NN1
304953	100736269	20992719088	,	,	,
304953	100736269	20992719089	i	i	MC1_ZZ1
304953	100736269	20992719090	was	be	VBDZ
304953	100736269	20992719091	the	the	AT
304953	100736269	20992719092	one	one	PN1
304953	100736269	20992719093	that	that	CST
304953	100736269	20992719094	brought	bring	VVD
304953	100736269	20992719095	it	it	PPH1
304953	100736269	20992719096	for	for	IF
304953	100736269	20992719097	her	her	PPHO1
304953	100736269	20992719098	,	,	,
304953	100736269	20992719099	that	that	CST
304953	100736269	20992719100	the	the	AT
304953	100736269	20992719101	only	only	JJ
304953	100736269	20992719102	cloth	cloth	NN1
304953	100736269	20992719103	i	i	ZZ1_MC1
304953	100736269	20992719104	ever	ever	RR
304953	100736269	20992719105	brought	bring	VVN_VVD
304953	100736269	20992719106	for	for	IF
304953	100736269	20992719107	her	her	PPHO1
304953	100736269	20992719108	,	,	,
304953	100736269	20992719109	then	then	RT
304953	100736269	20992719110	the	the	AT
304953	100736269	20992719111	following	following	JJ
304953	100736269	20992719112	morning	morning	NNT1
304953	100736269	20992719113	i	i	ZZ1_MC1
304953	100736269	20992719114	saw	see	VVD
304953	100736269	20992719115	her	her	APPGE
304953	100736269	20992719116	cloth	cloth	NN1
304953	100736269	20992719117	on	on	II
304953	100736269	20992719118	the	the	AT
304953	100736269	20992719119	ground	ground	NN1
304953	100736269	20992719120	,	,	,
304953	100736269	20992719121	with	with	IW
304953	100736269	20992719122	blood	blood	NN1
304953	100736269	20992719123	@		II
304953	100736269	20992719124	@		II
304953	100736269	20992719125	@		II
304953	100736269	20992719126	@		II
304953	100736269	20992719127	@		II
304953	100736269	20992719128	@		II
304953	100736269	20992719129	@		II
304953	100736269	20992719130	@		II
304953	100736269	20992719131	@		II
304953	100736269	20992719132	@		II
304953	100736269	20992719133	is	be	VBZ
304953	100736269	20992719134	this	this	DD1
304953	100736269	20992719135	,	,	,
304953	100736269	20992719136	she	she	PPHS1
304953	100736269	20992719137	told	tell	VVD
304953	100736269	20992719138	me	me	PPIO1
304953	100736269	20992719139	every	every	AT1
304953	100736269	20992719140	thing	thing	NN1
304953	100736269	20992719141	,	,	,
304953	100736269	20992719142	but	but	CCB
304953	100736269	20992719143	i	i	MC1_ZZ1
304953	100736269	20992719144	beat	beat	VVD_VV0
304953	100736269	20992719145	her	her	PPHO1
304953	100736269	20992719146	up	up	RP
304953	100736269	20992719147	,	,	,
304953	100736269	20992719148	and	and	CC
304953	100736269	20992719149	force	force	VV0@_NN1
304953	100736269	20992719150	the	the	AT
304953	100736269	20992719151	blood	blood	NN1
304953	100736269	20992719152	in	in	II
304953	100736269	20992719153	the	the	AT
304953	100736269	20992719154	cloth	cloth	NN1
304953	100736269	20992719155	into	into	II
304953	100736269	20992719156	her	her	APPGE
304953	100736269	20992719157	mouth	mouth	NN1
304953	100736269	20992719158	,	,	,
304953	100736269	20992719159	i	i	MC1_ZZ1
304953	100736269	20992719160	over	over	NN1%_II
304953	100736269	20992719161	heard	hear	VVD_VVN
304953	100736269	20992719162	her	her	PPHO1
304953	100736269	20992719163	,	,	,
304953	100736269	20992719164	as	as	CSA
304953	100736269	20992719165	she	she	PPHS1
304953	100736269	20992719166	was	be	VBDZ
304953	100736269	20992719167	crying	cry	VVG
304953	100736269	20992719168	,	,	,
304953	100736269	20992719169	cursing	curse	VVG
304953	100736269	20992719170	me	me	PPIO1
304953	100736269	20992719171	,	,	,
304953	100736269	20992719172	but	but	CCB
304953	100736269	20992719173	never	never	RR
304953	100736269	20992719174	bother	bother	VV0
304953	100736269	20992719175	to	to	TO
304953	100736269	20992719176	listen	listen	VVI
304953	100736269	20992719177	to	to	II
304953	100736269	20992719178	the	the	AT
304953	100736269	20992719179	word	word	NN1
304953	100736269	20992719180	she	she	PPHS1
304953	100736269	20992719181	was	be	VBDZ
304953	100736269	20992719182	using	use	VVG
304953	100736269	20992719183	,	,	,
304953	100736269	20992719184	but	but	CCB
304953	100736269	20992719185	now	now	RT
304953	100736269	20992719186	my	my	APPGE
304953	100736269	20992719187	two	two	MC
304953	100736269	20992719188	daughters	daughter	NN2
304953	100736269	20992719189	and	and	CC
304953	100736269	20992719190	my	my	APPGE
304953	100736269	20992719191	son	son	NN1
304953	100736269	20992719192	are	be	VBR
304953	100736269	20992719193	yet	yet	RR
304953	100736269	20992719194	to	to	TO
304953	100736269	20992719195	give	give	VVI
304953	100736269	20992719196	birth	birth	NN1
304953	100736269	20992719197	,	,	,
304953	100736269	20992719198	PATIENCE	patience	NN1
304953	100736269	20992719199	,	,	,
304953	100736269	20992719200	GLORY	glory	NN1
304953	100736269	20992719201	AND	and	CC
304953	100736269	20992719202	EXCEL	excel	VV0
304953	100736269	20992719203	,	,	,
304953	100736269	20992719204	AT	at	II
304953	100736269	20992719205	their	their	APPGE
304953	100736269	20992719206	age37,34		FO
304953	100736269	20992719207	and	and	CC
304953	100736269	20992719208	31but		FO
304953	100736269	20992719209	they	they	PPHS2
304953	100736269	20992719210	are	be	VBR
304953	100736269	20992719211	married	married	JJ_VVN%
304953	100736269	20992719212	no	no	AT_NN1%
304953	100736269	20992719213	children	child	NN2
304953	100736269	20992719214	,	,	,
304953	100736269	20992719215	i	i	ZZ1
304953	100736269	20992719216	had	have	VHD
304953	100736269	20992719217	gone	go	VVN
304953	100736269	20992719218	to	to	II
304953	100736269	20992719219	many	many	DA2
304953	100736269	20992719220	places	place	NN2
304953	100736269	20992719221	to	to	TO
304953	100736269	20992719222	know	know	VVI
304953	100736269	20992719223	the	the	AT
304953	100736269	20992719224	cause	cause	NN1
304953	100736269	20992719225	of	of	IO
304953	100736269	20992719226	the	the	AT
304953	100736269	20992719227	problem	problem	NN1
304953	100736269	20992719228	,	,	,
304953	100736269	20992719229	and	and	CC
304953	100736269	20992719230	CHRISTABEL	christabel	NP1
304953	100736269	20992719231	WAS	be	VBDZ
304953	100736269	20992719232	LIVING	live	VVG
304953	100736269	20992719233	HAPPILY	happily	RR
304953	100736269	20992719234	with	with	IW
304953	100736269	20992719235	her	her	APPGE
304953	100736269	20992719236	husband	husband	NN1
304953	100736269	20992719237	and	and	CC
304953	100736269	20992719238	four	four	MC
304953	100736269	20992719239	kids	kid	NN2
304953	100736269	20992719240	,	,	,
304953	100736269	20992719241	three	three	MC
304953	100736269	20992719242	boys	boy	NN2
304953	100736269	20992719243	and	and	CC
304953	100736269	20992719244	a	a	AT1
304953	100736269	20992719245	girl.i		NNU
304953	100736269	20992719246	do	do	VD0
304953	100736269	20992719247	n't 	n't	XX
304953	100736269	20992719248	know	know	VVI
304953	100736269	20992719249	how	how	RRQ
304953	100736269	20992719250	my	my	APPGE
304953	100736269	20992719251	children	child	NN2
304953	100736269	20992719252	,	,	,
304953	100736269	20992719253	came	come	VVD
304953	100736269	20992719254	to	to	TO
304953	100736269	20992719255	know	know	VVI
304953	100736269	20992719256	about	about	II
304953	100736269	20992719257	this	this	DD1
304953	100736269	20992719258	HIOYA		NN1_NP1
304953	100736269	20992719259	TEMPLE	temple	NN1_NP1
304953	100736269	20992719260	,	,	,
304953	100736269	20992719261	when	when	CS_RRQ
304953	100736269	20992719262	they	they	PPHS2
304953	100736269	20992719263	got	get	VVD
304953	100736269	20992719264	there	there	RL
304953	100736269	20992719265	,	,	,
304953	100736269	20992719266	they	they	PPHS2
304953	100736269	20992719267	told	tell	VVD
304953	100736269	20992719268	them	them	PPHO2
304953	100736269	20992719269	i	i	MC1_ZZ1
304953	100736269	20992719270	was	be	VBDZ
304953	100736269	20992719271	the	the	AT
304953	100736269	20992719272	curse	curse	NN1
304953	100736269	20992719273	of	of	IO
304953	100736269	20992719274	their	their	APPGE
304953	100736269	20992719275	,	,	,
304953	100736269	20992719276	problem	problem	NN1
304953	100736269	20992719277	,	,	,
304953	100736269	20992719278	so	so	RR_RG
304953	100736269	20992719279	one	one	MC1
304953	100736269	20992719280	morning	morning	NNT1
304953	100736269	20992719281	they	they	PPHS2
304953	100736269	20992719282	all	all	DB_RR@
304953	100736269	20992719283	came	come	VVD
304953	100736269	20992719284	home	home	RL
304953	100736269	20992719285	,	,	,
304953	100736269	20992719286	and	and	CC
304953	100736269	20992719287	ask	ask	VV0
304953	100736269	20992719288	me	me	PPIO1
304953	100736269	20992719289	what	what	DDQ
304953	100736269	20992719290	have	have	VH0
304953	100736269	20992719291	i	i	MC1
304953	100736269	20992719292	done	do	VDN
304953	100736269	20992719293	to	to	TO
304953	100736269	20992719294	disturb	disturb	VVI
304953	100736269	20992719295	their	their	APPGE
304953	100736269	20992719296	lives	life	NN2
304953	100736269	20992719297	,	,	,
304953	100736269	20992719298	the	the	AT
304953	100736269	20992719299	question	question	NN1
304953	100736269	20992719300	sound	sound	NN1
304953	100736269	20992719301	,	,	,
304953	100736269	20992719302	funny.i		NNU
304953	100736269	20992719303	told	tell	VVD_VVN
304953	100736269	20992719304	them	them	PPHO2
304953	100736269	20992719305	i	i	ZZ1
304953	100736269	20992719306	had	have	VHD
304953	100736269	20992719307	done	do	VDN
304953	100736269	20992719308	nothing	nothing	PN1
304953	100736269	20992719309	to	to	TO
304953	100736269	20992719310	hold	hold	VVI
304953	100736269	20992719311	their	their	APPGE
304953	100736269	20992719312	lives	life	NN2
304953	100736269	20992719313	back	back	RP_NN1
304953	100736269	20992719314	,	,	,
304953	100736269	20992719315	they	they	PPHS2
304953	100736269	20992719316	cried	cry	VVD
304953	100736269	20992719317	me	me	PPIO1
304953	100736269	20992719318	,	,	,
304953	100736269	20992719319	down	down	RP
304953	100736269	20992719320	to	to	II
304953	100736269	20992719321	this	this	DD1
304953	100736269	20992719322	Hioya		NN1@_NP1
304953	100736269	20992719323	@		II
304953	100736269	20992719324	@		II
304953	100736269	20992719325	@		II
304953	100736269	20992719326	@		II
304953	100736269	20992719327	@		II
304953	100736269	20992719328	@		II
304953	100736269	20992719329	@		II
304953	100736269	20992719330	@		II
304953	100736269	20992719331	@		II
304953	100736269	20992719332	@		II
304953	100736269	20992719333	did	do	VDD
304953	100736269	20992719334	i	i	ZZ1_MC1
304953	100736269	20992719335	do	do	VD0
304953	100736269	20992719336	to	to	II
304953	100736269	20992719337	some	some	PN121
304953	100736269	20992719338	one	one	PN122
304953	100736269	20992719339	,	,	,
304953	100736269	20992719340	over	over	RG
304953	100736269	20992719341	19	19	MC
304953	100736269	20992719342	year	year	NNT1
304953	100736269	20992719343	ago	ago	RA
304953	100736269	20992719344	,	,	,
304953	100736269	20992719345	i	i	ZZ1_MC1
304953	100736269	20992719346	forgot	forget	VVD
304953	100736269	20992719347	everything.i		NNU
304953	100736269	20992719348	said	say	VVD
304953	100736269	20992719349	nothing	nothing	PN1
304953	100736269	20992719350	,	,	,
304953	100736269	20992719351	HE	he	PPHS1
304953	100736269	20992719352	EXPLAIN	explain	VV0
304953	100736269	20992719353	WHAT	what	DDQ
304953	100736269	20992719354	I	i	PPIS1
304953	100736269	20992719355	DID	do	VDD
304953	100736269	20992719356	TO	to	II
304953	100736269	20992719357	ME	me	PPIO1_NN1
304953	100736269	20992719358	,	,	,
304953	100736269	20992719359	and	and	CC
304953	100736269	20992719360	this	this	DD1
304953	100736269	20992719361	CHRISTABEL	christabel	NP1
304953	100736269	20992719362	was	be	VBDZ
304953	100736269	20992719363	helping	help	VVG
304953	100736269	20992719364	my	my	APPGE
304953	100736269	20992719365	children	child	NN2
304953	100736269	20992719366	with	with	IW
304953	100736269	20992719367	their	their	APPGE
304953	100736269	20992719368	needs	need	NN2
304953	100736269	20992719369	and	and	CC
304953	100736269	20992719370	always	always	RR
304953	100736269	20992719371	come	come	VV0
304953	100736269	20992719372	and	and	CC
304953	100736269	20992719373	pay	pay	VV0
304953	100736269	20992719374	me	me	PPIO1
304953	100736269	20992719375	a	a	AT1
304953	100736269	20992719376	visit	visit	NN1
304953	100736269	20992719377	and	and	CC
304953	100736269	20992719378	she	she	PPHS1
304953	100736269	20992719379	always	always	RR
304953	100736269	20992719380	called	call	VVN_VVD@
304953	100736269	20992719381	me	me	PPIO1
304953	100736269	20992719382	mummy	mummy	NN1
304953	100736269	20992719383	,	,	,
304953	100736269	20992719384	so	so	CS@_RR
304953	100736269	20992719385	this	this	DD1
304953	100736269	20992719386	MAN	man	NN1
304953	100736269	20992719387	HIOYA		NN1_NP1
304953	100736269	20992719388	told	tell	VVD
304953	100736269	20992719389	me	me	PPIO1
304953	100736269	20992719390	to	to	TO
304953	100736269	20992719391	go	go	VVI
304953	100736269	20992719392	and	and	CC
304953	100736269	20992719393	apologize	apologize	VVI
304953	100736269	20992719394	to	to	II
304953	100736269	20992719395	her	her	PPHO1
304953	100736269	20992719396	,	,	,
304953	100736269	20992719397	once	once	CS@_RR
304953	100736269	20992719398	she	she	PPHS1
304953	100736269	20992719399	accept	accept	VV0
304953	100736269	20992719400	the	the	AT
304953	100736269	20992719401	apology	apology	NN1
304953	100736269	20992719402	,	,	,
304953	100736269	20992719403	then	then	RT
304953	100736269	20992719404	he	he	PPHS1
304953	100736269	20992719405	will	will	VM
304953	100736269	20992719406	cast	cast	VVI
304953	100736269	20992719407	a	a	AT1
304953	100736269	20992719408	pregnancy	pregnancy	NN1
304953	100736269	20992719409	spell	spell	NN1_VV0
304953	100736269	20992719410	on	on	II
304953	100736269	20992719411	my	my	APPGE
304953	100736269	20992719412	children	child	NN2
304953	100736269	20992719413	,	,	,
304953	100736269	20992719414	we	we	PPIS2
304953	100736269	20992719415	all	all	DB
304953	100736269	20992719416	went	go	VVD
304953	100736269	20992719417	to	to	II
304953	100736269	20992719418	CHRISTABELS		NP2
304953	100736269	20992719419	house	house	NN1_VV0@
304953	100736269	20992719420	and	and	CC
304953	100736269	20992719421	apologize	apologize	VV0
304953	100736269	20992719422	,	,	,
304953	100736269	20992719423	she	she	PPHS1
304953	100736269	20992719424	forgives	forgive	VVZ
304953	100736269	20992719425	me	me	PPIO1
304953	100736269	20992719426	,	,	,
304953	100736269	20992719427	so	so	CS@_RR
304953	100736269	20992719428	they	they	PPHS2
304953	100736269	20992719429	went	go	VVD
304953	100736269	20992719430	back	back	RP
304953	100736269	20992719431	to	to	II
304953	100736269	20992719432	the	the	AT
304953	100736269	20992719433	spell	spell	NN1
304953	100736269	20992719434	caster	caster	NN1
304953	100736269	20992719435	,	,	,
304953	100736269	20992719436	for	for	IF
304953	100736269	20992719437	the	the	AT
304953	100736269	20992719438	pregnancy	pregnancy	NN1
304953	100736269	20992719439	spell	spell	NN1_VV0
304953	100736269	20992719440	,	,	,
304953	100736269	20992719441	TODAY	today	RT
304953	100736269	20992719442	PATIENCE	patience	NN1
304953	100736269	20992719443	CALL	call	VV0_NN1
304953	100736269	20992719444	ME	me	PPIO1_NN1
304953	100736269	20992719445	AND	and	CC
304953	100736269	20992719446	TOLD	tell	VVD
304953	100736269	20992719447	ME	me	PPIO1
304953	100736269	20992719448	SHE	she	PPHS1
304953	100736269	20992719449	IS	be	VBZ
304953	100736269	20992719450	PREGNANT	pregnant	JJ
304953	100736269	20992719451	,	,	,
304953	100736269	20992719452	but	but	CCB
304953	100736269	20992719453	I	i	PPIS1
304953	100736269	20992719454	have n't		VV0
304953	100736269	20992719455	heard	hear	VVN_VVD
304953	100736269	20992719456	anything	anything	PN1
304953	100736269	20992719457	from	from	II
304953	100736269	20992719458	the	the	AT
304953	100736269	20992719459	others	others	NN2
304953	100736269	20992719460	,	,	,
304953	100736269	20992719461	maybe	maybe	RR
304953	100736269	20992719462	they	they	PPHS2
304953	100736269	20992719463	are	be	VBR
304953	100736269	20992719464	still	still	RR
304953	100736269	20992719465	angry.with		NNU
304953	100736269	20992719466	me	me	PPIO1
304953	100736269	20992719467	that 's		VVZ
304953	100736269	20992719468	why	why	RRQ
304953	100736269	20992719469	they	they	PPHS2
304953	100736269	20992719470	have n't		VV0
304953	100736269	20992719471	called	call	VVN
304953	100736269	20992719472	me	me	PPIO1
304953	100736269	20992719473	,	,	,
304953	100736269	20992719474	..	...	...
304953	100736269	20992719475	THANKS	thanks	II21
304953	100736269	20992719476	TO	to	II22
304953	100736269	20992719477	DOCTOR	doctor	NN1
304953	100736269	20992719478	HIOYA		NN1
304953	100736269	20992719479	FOR	for	IF
304953	100736269	20992719480	EVERY	every	AT1
304953	100736269	20992719481	THING	thing	NN1
304953	100736269	20992719482	,	,	,
304953	100736269	20992719483	IF	if	CS
304953	100736269	20992719484	YOU	you	PPY
304953	100736269	20992719485	ARE	be	VBR
304953	100736269	20992719486	FACINGS		NN2
304953	100736269	20992719487	ANY	any	DD
304953	100736269	20992719488	PROBLEM	problem	NN1
304953	100736269	20992719489	,	,	,
304953	100736269	20992719490	VISIT	visit	VV0
304953	100736269	20992719491	THIS	this	DD1
304953	100736269	20992719492	GREAT	great	JJ
304953	100736269	20992719493	HIOYA		NN1
304953	100736269	20992719494	VIA	via	II
304953	100736269	20992719495	**26;182;TOOLONG		FO
304953	100736269	20992719496	<p>		NULL
304953	100736269	20992719497	Hello	hello	UH
304953	100736269	20992719498	am	be	VBM_RA@
304953	100736269	20992719499	GOLDINA		NP1_NN1
304953	100736269	20992719500	from	from	II
304953	100736269	20992719501	the	the	AT
304953	100736269	20992719502	united	united	JJ
304953	100736269	20992719503	state	state	NN1
304953	100736269	20992719504	,	,	,
304953	100736269	20992719505	i	i	ZZ1_MC1
304953	100736269	20992719506	read	read	VV0_VVD_VVN
304953	100736269	20992719507	some	some	DD
304953	100736269	20992719508	testimony	testimony	NN1
304953	100736269	20992719509	about	about	II
304953	100736269	20992719510	Dr	dr	NNB
304953	100736269	20992719511	LOLA	lola	NP1
304953	100736269	20992719512	on	on	II
304953	100736269	20992719513	how	how	RRQ
304953	100736269	20992719514	he	he	PPHS1
304953	100736269	20992719515	has	have	VHZ
304953	100736269	20992719516	helped	help	VVN
304953	100736269	20992719517	people	people	NN
304953	100736269	20992719518	in	in	II
304953	100736269	20992719519	bringing	bring	VVG
304953	100736269	20992719520	back	back	RP
304953	100736269	20992719521	there	there	RL
304953	100736269	20992719522	ex	ex	II
304953	100736269	20992719523	@		II
304953	100736269	20992719524	@		II
304953	100736269	20992719525	@		II
304953	100736269	20992719526	@		II
304953	100736269	20992719527	@		II
304953	100736269	20992719528	@		II
304953	100736269	20992719529	@		II
304953	100736269	20992719530	@		II
304953	100736269	20992719531	@		II
304953	100736269	20992719532	@		II
304953	100736269	20992719533	,	,	,
304953	100736269	20992719534	And	and	CC
304953	100736269	20992719535	decided	decide	VVD_VVN
304953	100736269	20992719536	to	to	TO
304953	100736269	20992719537	call	call	VVI
304953	100736269	20992719538	a	a	AT1
304953	100736269	20992719539	lady	lady	NN1
304953	100736269	20992719540	who	who	PNQS
304953	100736269	20992719541	made	make	VVD
304953	100736269	20992719542	a	a	AT1
304953	100736269	20992719543	testimony	testimony	NN1
304953	100736269	20992719544	and	and	CC
304953	100736269	20992719545	also	also	RR
304953	100736269	20992719546	dropped	drop	VVD_VVN
304953	100736269	20992719547	her	her	APPGE
304953	100736269	20992719548	number	number	NN1
304953	100736269	20992719549	,	,	,
304953	100736269	20992719550	So	-so	RR_CS@_RG
304953	100736269	20992719551	i	i	MC1_ZZ1
304953	100736269	20992719552	called	call	VVN_VVD@
304953	100736269	20992719553	her	her	PPHO1
304953	100736269	20992719554	and	and	CC
304953	100736269	20992719555	ask	ask	VV0
304953	100736269	20992719556	her	her	PPHO1
304953	100736269	20992719557	about	about	II
304953	100736269	20992719558	Dr	dr	NNB
304953	100736269	20992719559	LOLA	lola	NP1
304953	100736269	20992719560	she	she	PPHS1
304953	100736269	20992719561	said	say	VVD
304953	100736269	20992719562	Dr	dr	NNB
304953	100736269	20992719563	LOLA	lola	NP1
304953	100736269	20992719564	is	be	VBZ
304953	100736269	20992719565	a	a	AT1
304953	100736269	20992719566	trustworthy	trustworthy	JJ
304953	100736269	20992719567	man	man	NN1
304953	100736269	20992719568	and	and	CC
304953	100736269	20992719569	he	he	PPHS1
304953	100736269	20992719570	his	his	APPGE
304953	100736269	20992719571	ready	ready	JJ
304953	100736269	20992719572	to	to	TO
304953	100736269	20992719573	bring	bring	VVI
304953	100736269	20992719574	back	back	RP
304953	100736269	20992719575	my	my	APPGE
304953	100736269	20992719576	lover	lover	NN1
304953	100736269	20992719577	for	for	IF
304953	100736269	20992719578	me	me	PPIO1
304953	100736269	20992719579	,	,	,
304953	100736269	20992719580	i	i	MC1_ZZ1
304953	100736269	20992719581	was	be	VBDZ
304953	100736269	20992719582	just	just	RR
304953	100736269	20992719583	so	so	RG
304953	100736269	20992719584	happy	happy	JJ
304953	100736269	20992719585	and	and	CC
304953	100736269	20992719586	a	a	AT1
304953	100736269	20992719587	little	little	JJ
304953	100736269	20992719588	bit	bit	NN1
304953	100736269	20992719589	relief	relief	NN1
304953	100736269	20992719590	that	that	CST
304953	100736269	20992719591	my	my	APPGE
304953	100736269	20992719592	lover	lover	NN1
304953	100736269	20992719593	will	will	VM
304953	100736269	20992719594	be	be	VBI
304953	100736269	20992719595	back	back	RP
304953	100736269	20992719596	to	to	II
304953	100736269	20992719597	me	me	PPIO1
304953	100736269	20992719598	soon	soon	RR
304953	100736269	20992719599	,	,	,
304953	100736269	20992719600	Then	then	RT
304953	100736269	20992719601	i	i	MC1_ZZ1
304953	100736269	20992719602	decided	decide	VVD_VVN
304953	100736269	20992719603	in	in	II_RP@
304953	100736269	20992719604	contacting	contact	VVG
304953	100736269	20992719605	Dr	dr	NNB
304953	100736269	20992719606	LOLA	lola	NP1
304953	100736269	20992719607	which	which	DDQ
304953	100736269	20992719608	i	i	MC1_ZZ1
304953	100736269	20992719609	did	do	VDD
304953	100736269	20992719610	,	,	,
304953	100736269	20992719611	And	and	CC
304953	100736269	20992719612	before	before	CS_II
304953	100736269	20992719613	i	i	ZZ1_MC1
304953	100736269	20992719614	could	could	VM
304953	100736269	20992719615	share	share	VVI
304953	100736269	20992719616	him	him	PPHO1
304953	100736269	20992719617	my	my	APPGE
304953	100736269	20992719618	problem	problem	NN1
304953	100736269	20992719619	he	he	PPHS1
304953	100736269	20992719620	has	have	VHZ
304953	100736269	20992719621	already	already	RR
304953	100736269	20992719622	told	tell	VVN
304953	100736269	20992719623	me	me	PPIO1
304953	100736269	20992719624	what	what	DDQ
304953	100736269	20992719625	i	i	MC1_ZZ1
304953	100736269	20992719626	came	come	VVD
304953	100736269	20992719627	for	for	IF
304953	100736269	20992719628	,	,	,
304953	100736269	20992719629	And	and	CC
304953	100736269	20992719630	he	he	PPHS1
304953	100736269	20992719631	said	say	VVD
304953	100736269	20992719632	everything	everything	PN1
304953	100736269	20992719633	will	will	VM
304953	100736269	20992719634	be	be	VBI
304953	100736269	20992719635	okay	okay	JJ
304953	100736269	20992719636	within	within	II
304953	100736269	20992719637	48hours		FO
304953	100736269	20992719638	that	that	CST
304953	100736269	20992719639	my	my	APPGE
304953	100736269	20992719640	lover	lover	NN1
304953	100736269	20992719641	will	will	VM
304953	100736269	20992719642	be	be	VBI
304953	100736269	20992719643	back	back	RP
304953	100736269	20992719644	to	to	II
304953	100736269	20992719645	my	my	APPGE
304953	100736269	20992719646	arms	arm	NN2
304953	100736269	20992719647	,	,	,
304953	100736269	20992719648	So	so	CS@_RR
304953	100736269	20992719649	he	he	PPHS1
304953	100736269	20992719650	said	say	VVD
304953	100736269	20992719651	he	he	PPHS1
304953	100736269	20992719652	would	would	VM
304953	100736269	20992719653	be	be	VBI
304953	100736269	20992719654	casting	cast	VVG
304953	100736269	20992719655	the	the	AT
304953	100736269	20992719656	spell	spell	NN1
304953	100736269	20992719657	and	and	CC
304953	100736269	20992719658	that	that	CST_DD1
304953	100736269	20992719659	within	within	II
304953	100736269	20992719660	48hours		FO
304953	100736269	20992719661	my	my	APPGE
304953	100736269	20992719662	lover	lover	NN1
304953	100736269	20992719663	would	would	VM
304953	100736269	20992719664	call	call	VVI
304953	100736269	20992719665	me	me	PPIO1
304953	100736269	20992719666	,	,	,
304953	100736269	20992719667	So	-so	RR_CS@_RG
304953	100736269	20992719668	i	i	MC1_ZZ1
304953	100736269	20992719669	hoped	hope	VVD_VVN
304953	100736269	20992719670	so	so	RG
304953	100736269	20992719671	truly	truly	RR
304953	100736269	20992719672	before	before	II_CS
304953	100736269	20992719673	the	the	AT
304953	100736269	20992719674	48hours		FO
304953	100736269	20992719675	i	i	ZZ1_MC1
304953	100736269	20992719676	got	get	VVD_VVN
304953	100736269	20992719677	a	a	AT1
304953	100736269	20992719678	call	call	NN1
304953	100736269	20992719679	from	from	II
304953	100736269	20992719680	a	a	AT1
304953	100736269	20992719681	man	man	NN1
304953	100736269	20992719682	who	who	PNQS
304953	100736269	20992719683	has	have	VHZ
304953	100736269	20992719684	left	leave	VVN
304953	100736269	20992719685	me	me	PPIO1
304953	100736269	20992719686	for	for	IF
304953	100736269	20992719687	the	the	AT
304953	100736269	20992719688	past	past	NN1_JJ
304953	100736269	20992719689	6years		FO
304953	100736269	20992719690	saying	say	VVG
304953	100736269	20992719691	he	he	PPHS1
304953	100736269	20992719692	is	be	VBZ
304953	100736269	20992719693	sorry	sorry	JJ
304953	100736269	20992719694	and	and	CC
304953	100736269	20992719695	he	he	PPHS1
304953	100736269	20992719696	wants	want	VVZ
304953	100736269	20992719697	me	me	PPIO1
304953	100736269	20992719698	back	back	RP
304953	100736269	20992719699	,	,	,
304953	100736269	20992719700	i	i	MC1_ZZ1
304953	100736269	20992719701	was	be	VBDZ
304953	100736269	20992719702	happy	happy	JJ
304953	100736269	20992719703	and	and	CC
304953	100736269	20992719704	i	i	ZZ1_MC1
304953	100736269	20992719705	said	say	VVD
304953	100736269	20992719706	i	i	MC1_ZZ1
304953	100736269	20992719707	also	also	RR
304953	100736269	20992719708	want	want	VV0
304953	100736269	20992719709	him	him	PPHO1
304953	100736269	20992719710	back	back	RP
304953	100736269	20992719711	,	,	,
304953	100736269	20992719712	Then	then	RT
304953	100736269	20992719713	i	i	MC1_ZZ1
304953	100736269	20992719714	traveled	travel	VVD_JJ@_VVN@
304953	100736269	20992719715	to	to	II
304953	100736269	20992719716	Canada	canada	NP1
304953	100736269	20992719717	to	to	TO
304953	100736269	20992719718	meet	meet	VVI
304953	100736269	20992719719	him	him	PPHO1
304953	100736269	20992719720	up	up	RP
304953	100736269	20992719721	,	,	,
304953	100736269	20992719722	And	and	CC
304953	100736269	20992719723	@		II
304953	100736269	20992719724	@		II
304953	100736269	20992719725	@		II
304953	100736269	20992719726	@		II
304953	100736269	20992719727	@		II
304953	100736269	20992719728	@		II
304953	100736269	20992719729	@		II
304953	100736269	20992719730	@		II
304953	100736269	20992719731	@		II
304953	100736269	20992719732	@		II
304953	100736269	20992719733	he	he	PPHS1
304953	100736269	20992719734	proposed	propose	VVD
304953	100736269	20992719735	to	to	TO
304953	100736269	20992719736	marry	marry	VVI
304953	100736269	20992719737	me	me	PPIO1
304953	100736269	20992719738	and	and	CC
304953	100736269	20992719739	we	we	PPIS2
304953	100736269	20992719740	are	be	VBR
304953	100736269	20992719741	both	both	RR_DB2
304953	100736269	20992719742	preparing	prepare	VVG
304953	100736269	20992719743	for	for	IF
304953	100736269	20992719744	our	our	APPGE
304953	100736269	20992719745	wedding	wedding	NN1
304953	100736269	20992719746	soon	soon	RR
304953	100736269	20992719747	,	,	,
304953	100736269	20992719748	All	all	DB
304953	100736269	20992719749	thanks	thanks	NN2
304953	100736269	20992719750	to	to	II
304953	100736269	20992719751	the	the	AT
304953	100736269	20992719752	great	great	JJ
304953	100736269	20992719753	and	and	CC
304953	100736269	20992719754	World	world	NN1
304953	100736269	20992719755	best	best	RRT
304953	100736269	20992719756	spell	spell	VV0
304953	100736269	20992719757	caster	caster	NN1
304953	100736269	20992719758	,	,	,
304953	100736269	20992719759	Dr	dr	NNB
304953	100736269	20992719760	LOLA	lola	NP1
304953	100736269	20992719761	His	his	APPGE
304953	100736269	20992719762	private	private	JJ
304953	100736269	20992719763	mail	mail	NN1
304953	100736269	20992719764	(	(	(
304953	100736269	20992719765	**25;210;TOOLONG		FO
304953	100736269	20992719766	)	)	)
304953	100736269	20992719767	<p>		NULL
304953	100736269	20992719768	Am	be	VBM
304953	100736269	20992719769	Judymay		NP1
304953	100736269	20992719770	Bourbon	bourbon	NP1_NN1
304953	100736269	20992719771	.	.	.
304953	100736269	20992719772	I	i	PPIS1
304953	100736269	20992719773	have	have	VH0
304953	100736269	20992719774	been	be	VBN
304953	100736269	20992719775	suffering	suffer	VVG
304953	100736269	20992719776	from	from	II
304953	100736269	20992719777	(	(	(
304953	100736269	20992719778	HERPES		NP2_NN2
304953	100736269	20992720007	all	all	RR22_DB
304953	100736269	20992720008	you	you	PPY
304953	100736269	20992720009	can	can	VM
304953	100736269	20992720010	email	email	VVI
304953	100736269	20992720011	Dr	dr	NNB
304953	100736269	20992720012	IDEMUDIAN		NP1
304953	100736269	20992720013	on	on	RP@_II
304953	100736269	20992720014	;	;	;
304953	100736269	20992720015	(	(	(
304953	100736269	20992720016	dridemudian@gmail.com		FO
304953	100736269	20992720017	)	)	)
304953	100736269	20992720018	or	or	CC
304953	100736269	20992720019	call	call	VV0_NN1
304953	100736269	20992720020	+2348068540264		MC
304953	100736269	20992720021	for	for	IF
304953	100736269	20992720022	assistance	assistance	NN1
304953	100736269	20992720023	.	.	.
304953	100736269	20992720024	sir	sir	NN1
304953	100736269	20992720025	i	i	MC1_ZZ1
304953	100736269	20992720026	am	am	RA@_VBM
304953	100736269	20992720027	indeed	indeed	RR
304953	100736269	20992720028	grateful	grateful	JJ
304953	100736269	20992720029	for	for	IF
304953	100736269	20992720030	the	the	AT
304953	100736269	20992720031	help	help	NN1
304953	100736269	20992720032	i	i	ZZ1_MC1
304953	100736269	20992720033	will	will	VM
304953	100736269	20992720034	forever	forever	RT
304953	100736269	20992720035	recommend	recommend	VVI
304953	100736269	20992720036	you	you	PPY
304953	100736269	20992720037	to	to	II
304953	100736269	20992720038	my	my	APPGE
304953	100736269	20992720039	friends	friend	NN2
304953	100736269	20992720040	!	!	!
304953	100736269	20992720041	!	!	!
304953	100736269	20992720042	<p>		NULL
304953	100736269	20992720043	I	i	PPIS1
304953	100736269	20992720044	had	have	VHD
304953	100736269	20992720045	a	a	AT1
304953	100736269	20992720046	nerve-sparing	nerve-sparing	JJ_NN1
304953	100736269	20992720047	prostatectomy	prostatectomy	NN1
304953	100736269	20992720048	14	14	MC
304953	100736269	20992720049	years	year	NNT2
304953	100736269	20992720050	ago	ago	RA
304953	100736269	20992720051	.	.	.
304953	100736269	20992720052	A	a	AT1
304953	100736269	20992720053	year	year	NNT1
304953	100736269	20992720054	later	later	RRR
304953	100736269	20992720055	a	a	AT1
304953	100736269	20992720056	was	be	VBDZ
304953	100736269	20992720057	divorce	divorce	NN1
304953	100736269	20992720058	and	and	CC
304953	100736269	20992720059	single	single	JJ_NN1@
304953	100736269	20992720060	for	for	IF
304953	100736269	20992720061	the	the	AT
304953	100736269	20992720062	first	first	MD
304953	100736269	20992720063	time	time	NNT1
304953	100736269	20992720064	in	in	II
304953	100736269	20992720065	20	20	MC
304953	100736269	20992720066	years	year	NNT2
304953	100736269	20992720067	.	.	.
304953	100736269	20992720068	I	i	PPIS1
304953	100736269	20992720069	found	find	VVD
304953	100736269	20992720070	most	most	DAT
304953	100736269	20992720071	women	woman	NN2
304953	100736269	20992720072	hate	hate	VV0
304953	100736269	20992720073	condoms	condom	NN2
304953	100736269	20992720074	and	and	CC
304953	100736269	20992720075	for	for	IF
304953	100736269	20992720076	me	me	PPIO1
304953	100736269	20992720077	Viagra	viagra	NP1
304953	100736269	20992720078	had	have	VHD
304953	100736269	20992720079	side	side	NN1
304953	100736269	20992720080	effects	effect	NN2
304953	100736269	20992720081	.	.	.
304953	100736269	20992720082	The	the	AT
304953	100736269	20992720083	less	less	DAR
304953	100736269	20992720084	sensation	sensation	NN1
304953	100736269	20992720085	of	of	IO
304953	100736269	20992720086	condoms	condom	NN2
304953	100736269	20992720087	was	be	VBDZ
304953	100736269	20992720088	often	often	RR
304953	100736269	20992720089	a	a	AT1
304953	100736269	20992720090	boner	boner	NN1
304953	100736269	20992720091	killer	killer	NN1
304953	100736269	20992720092	.	.	.
304953	100736269	20992720093	I	i	PPIS1
304953	100736269	20992720094	got	get	VVD
304953	100736269	20992720095	an	a	AT1
304953	100736269	20992720096	std	std	NNU
304953	100736269	20992720097	right	right	NN1_RR
304953	100736269	20992720098	away	away	RL
304953	100736269	20992720099	.	.	.
304953	100736269	20992720100	I	i	PPIS1
304953	100736269	20992720101	started	start	VVD
304953	100736269	20992720102	long	long	JJ
304953	100736269	20992720103	term	term	NN1_VV0@
304953	100736269	20992720104	relationship	relationship	NN1
304953	100736269	20992720105	but	but	CCB
304953	100736269	20992720106	a	a	AT1
304953	100736269	20992720107	few	few	DA2
304953	100736269	20992720108	years	year	NNT2
304953	100736269	20992720109	later	later	RRR
304953	100736269	20992720110	she	she	PPHS1
304953	100736269	20992720111	cheated	cheat	VVD
304953	100736269	20992720112	and	and	CC
304953	100736269	20992720113	I	i	PPIS1
304953	100736269	20992720114	got	get	VVD
304953	100736269	20992720115	another	another	DD1
304953	100736269	20992720116	.	.	.
304953	100736269	20992720117	I	i	PPIS1
304953	100736269	20992720118	have	have	VH0
304953	100736269	20992720119	been	be	VBN
304953	100736269	20992720120	in	in	II
304953	100736269	20992720121	a	a	AT1
304953	100736269	20992720122	10	10	MC
304953	100736269	20992720123	@		II
304953	100736269	20992720124	@		II
304953	100736269	20992720125	@		II
304953	100736269	20992720126	@		II
304953	100736269	20992720127	@		II
304953	100736269	20992720128	@		II
304953	100736269	20992720129	@		II
304953	100736269	20992720130	@		II
304953	100736269	20992720131	@		II
304953	100736269	20992720132	@		II
304953	100736269	20992720133	I	i	PPIS1
304953	100736269	20992720134	attended	attend	VVD
304953	100736269	20992720135	a	a	AT1
304953	100736269	20992720136	drinking	drinking	NN1
304953	100736269	20992720137	pool	pool	NN1
304953	100736269	20992720138	party	party	NN1
304953	100736269	20992720139	.	.	.
304953	100736269	20992720140	Some	some	DD
304953	100736269	20992720141	attractive	attractive	JJ
304953	100736269	20992720142	woman	woman	NN1
304953	100736269	20992720143	20	20	MC
304953	100736269	20992720144	years	year	NNT2
304953	100736269	20992720145	younger	young	JJR
304953	100736269	20992720146	offer	offer	NN1
304953	100736269	20992720147	to	to	TO
304953	100736269	20992720148	suck	suck	VVI
304953	100736269	20992720149	my	my	APPGE
304953	100736269	20992720150	penis	penis	NN1
304953	100736269	20992720151	.	.	.
304953	100736269	20992720152	Guess	guess	VV0
304953	100736269	20992720153	what	what	DDQ
304953	100736269	20992720154	?	?	?
304953	100736269	20992720155	A	a	AT1
304953	100736269	20992720156	few	few	DA2
304953	100736269	20992720157	minutes	minute	NNT2
304953	100736269	20992720158	of	of	IO
304953	100736269	20992720159	oral	oral	JJ_NN1
304953	100736269	20992720160	sex	sex	NN1
304953	100736269	20992720161	turned	turn	VVD_VVN
304953	100736269	20992720162	into	into	II
304953	100736269	20992720163	much	much	DA1
304953	100736269	20992720164	pain	pain	NN1
304953	100736269	20992720165	.	.	.
304953	100736269	20992720166	So	so	RG
304953	100736269	20992720167	far	far	RR
304953	100736269	20992720168	its	its	APPGE
304953	100736269	20992720169	just	just	RR
304953	100736269	20992720170	the	the	AT
304953	100736269	20992720171	clap	clap	NN1
304953	100736269	20992720172	but	but	CCB
304953	100736269	20992720173	its	its	APPGE
304953	100736269	20992720174	only	only	JJ
304953	100736269	20992720175	been	been-	VBN
304953	100736269	20992720176	a	a	AT1
304953	100736269	20992720177	week	week	NNT1
304953	100736269	20992720178	could	could	VM
304953	100736269	20992720179	get	get	VVI
304953	100736269	20992720180	worse	bad	JJR_RRR@
304953	100736269	20992720181	like	like	II_JJ@
304953	100736269	20992720182	herpes	herpes	NN2
304953	100736269	20992720183	hiv	hiv	NN1
304953	100736269	20992720184	.	.	.
304953	100736269	20992720185	<p>		NULL
304953	100736269	20992720186	Hello	hello	UH
304953	100736269	20992720187	,	,	,
304953	100736269	20992720188	is	be	VBZ
304953	100736269	20992720189	good	good	JJ_RR%
304953	100736269	20992720190	I	i	PPIS1
304953	100736269	20992720191	inform	inform	VV0
304953	100736269	20992720192	all	all	DB
304953	100736269	20992720193	the	the	AT
304953	100736269	20992720194	men	man	NN2
304953	100736269	20992720195	and	and	CC
304953	100736269	20992720196	guys	guy	NN2
304953	100736269	20992720197	out	out	RP
304953	100736269	20992720198	there	there	RL
304953	100736269	20992720199	,	,	,
304953	100736269	20992720200	that	that	DD1_CST
304953	100736269	20992720201	sometime	sometime	RT
304953	100736269	20992720202	we	we	PPIS2
304953	100736269	20992720203	all	all	DB
304953	100736269	20992720204	make	make	VV0
304953	100736269	20992720205	mistakes	mistake	NN2
304953	100736269	20992720206	in	in	II
304953	100736269	20992720207	our	our	APPGE
304953	100736269	20992720208	relationship	relationship	NN1
304953	100736269	20992720209	and	and	CC
304953	100736269	20992720210	made	make	VVD
304953	100736269	20992720211	our	our	APPGE
304953	100736269	20992720212	relationship	relationship	NN1
304953	100736269	20992720213	to	to	TO
304953	100736269	20992720214	be	be	VBI
304953	100736269	20992720215	broken	break	VVN_JJ
304953	100736269	20992720216	and	and	CC
304953	100736269	20992720217	is	be	VBZ
304953	100736269	20992720218	also	also	RR
304953	100736269	20992720219	our	our	APPGE
304953	100736269	20992720220	responsibility	responsibility	NN1
304953	100736269	20992720221	to	to	TO
304953	100736269	20992720222	make	make	VVI
304953	100736269	20992720223	it	it	PPH1
304953	100736269	20992720224	work	work	VVI
304953	100736269	20992720225	by	by	II
304953	100736269	20992720226	seeking	seek	VVG
304953	100736269	20992720227	for	for	IF
304953	100736269	20992720228	solution	solution	NN1
304953	100736269	20992720229	to	to	II
304953	100736269	20992720230	it	it	PPH1
304953	100736269	20992720231	,	,	,
304953	100736269	20992720232	I 'm		VV0
304953	100736269	20992720233	very	very	RG
304953	100736269	20992720234	happy	happy	JJ
304953	100736269	20992720235	today	today	RT
304953	100736269	20992720236	to	to	TO
304953	100736269	20992720237	tell	tell	VVI
304953	100736269	20992720238	you	you	PPY
304953	100736269	20992720239	little	little	RR_JJ
304953	100736269	20992720240	of	of	IO
304953	100736269	20992720241	my	my	APPGE
304953	100736269	20992720242	relationship	relationship	NN1
304953	100736269	20992720243	problem	problem	NN1
304953	100736269	20992720244	,	,	,
304953	100736269	20992720245	i	i	ZZ1_MC1
304953	100736269	20992720246	cheated	cheat	VVD_JJ_VVN
304953	100736269	20992720247	once	once	RR
304953	100736269	20992720248	on	on	II
304953	100736269	20992720249	my	my	APPGE
304953	100736269	20992720250	wife	wife	NN1
304953	100736269	20992720251	and	and	CC
304953	100736269	20992720252	she	she	PPHS1
304953	100736269	20992720253	caught	catch	VVD
304953	100736269	20992720254	me	me	PPIO1
304953	100736269	20992720255	and	and	CC
304953	100736269	20992720256	she	she	PPHS1
304953	100736269	20992720257	was	be	VBDZ
304953	100736269	20992720258	ready	ready	JJ_RR@
304953	100736269	20992720259	to	to	TO
304953	100736269	20992720260	end	end	VVI
304953	100736269	20992720261	our	our	APPGE
304953	100736269	20992720262	marriage	marriage	NN1
304953	100736269	20992720263	because	because	CS
304953	100736269	20992720264	i	i	ZZ1
304953	100736269	20992720265	truly	truly	RR
304953	100736269	20992720266	love	love	VV0
304953	100736269	20992720267	her	her	PPHO1_APPGE
304953	100736269	20992720268	i	i	MC1_ZZ1
304953	100736269	20992720269	quickly	quickly	RR
304953	100736269	20992720270	seek	seek	VV0
304953	100736269	20992720271	for	for	IF
304953	100736269	20992720272	solution	solution	NN1
304953	100736269	20992720273	to	to	TO
304953	100736269	20992720274	stop	stop	VVI
304953	100736269	20992720275	her	her	PPHO1
304953	100736269	20992720276	that	that	CST_DD1
304953	100736269	20992720277	is	be	VBZ
304953	100736269	20992720278	when	when	RRQ_CS
304953	100736269	20992720279	i	i	ZZ1
304953	100736269	20992720280	came	come	VVD
304953	100736269	20992720281	across	across	II
304953	100736269	20992720282	Dr.Ekpen		NP1
304953	100736269	20992720283	temple	temple	NN1
304953	100736269	20992720284	who	who	PNQS
304953	100736269	20992720285	has	have	VHZ
304953	100736269	20992720286	help	help	NN1
304953	100736269	20992720287	so	so	RG
304953	100736269	20992720288	many	many	DA2
304953	100736269	20992720289	people	people	NN
304953	100736269	20992720290	restore	restore	VV0
304953	100736269	20992720291	their	their	APPGE
304953	100736269	20992720292	broken	broken	JJ
304953	100736269	20992720293	marriage	marriage	NN1
304953	100736269	20992720294	and	and	CC
304953	100736269	20992720295	relationship	relationship	NN1
304953	100736269	20992720296	i	i	ZZ1_MC1
304953	100736269	20992720297	also	also	RR
304953	100736269	20992720298	contact	contact	VV0
304953	100736269	20992720299	him	him	PPHO1
304953	100736269	20992720300	today	today	RT
304953	100736269	20992720301	my	my	APPGE
304953	100736269	20992720302	marriage	marriage	NN1
304953	100736269	20992720303	is	be	VBZ
304953	100736269	20992720304	restored	restore	VVN_JJ
304953	100736269	20992720305	,	,	,
304953	100736269	20992720306	I 'm		VV0_NP1_NN1
304953	100736269	20992720307	going	go	VVGK
304953	100736269	20992720308	to	to	TO
304953	100736269	20992720309	drop	drop	VVI
304953	100736269	20992720310	his	his	APPGE
304953	100736269	20992720311	contact	contact	NN1
304953	100736269	20992720312	so	so	CS@_RR
304953	100736269	20992720313	that	that	DD1_CST
304953	100736269	20992720314	does	do	VDZ
304953	100736269	20992720315	having	have	VHG
304953	100736269	20992720316	the	the	AT
304953	100736269	20992720317	same	same	DA
304953	100736269	20992720318	issues	issue	NN2
304953	100736269	20992720319	can	can	VM
304953	100736269	20992720320	contact	contact	VVI
304953	100736269	20992720321	him	him	PPHO1
304953	100736269	20992720322	for	for	IF
304953	100736269	20992720323	@		II
304953	100736269	20992720324	@		II
304953	100736269	20992720325	@		II
304953	100736269	20992720326	@		II
304953	100736269	20992720327	@		II
304953	100736269	20992720328	@		II
304953	100736269	20992720329	@		II
304953	100736269	20992720330	@		II
304953	100736269	20992720331	@		II
304953	100736269	20992720332	@		II
304953	100736269	20992720333	i	i	ZZ1_MC1
304953	100736269	20992720334	seriously	seriously	RR
304953	100736269	20992720335	can	can	VM
304953	100736269	20992720336	not	not	XX
304953	100736269	20992720337	hide	hide	VVI
304953	100736269	20992720338	the	the	AT
304953	100736269	20992720339	joy	joy	NN1
304953	100736269	20992720340	and	and	CC
304953	100736269	20992720341	happiness	happiness	NN1
304953	100736269	20992720342	i	i	ZZ1_MC1
304953	100736269	20992720343	feel	feel	VV0
304953	100736269	20992720344	inside	inside	RL_NN1@
304953	100736269	20992720345	of	of	IO
304953	100736269	20992720346	me	me	PPIO1
304953	100736269	20992720347	right	right	RR
304953	100736269	20992720348	now	now	RT
304953	100736269	20992720349	have	have	VH0
304953	100736269	20992720350	been	be	VBN
304953	100736269	20992720351	having	have	VHG
304953	100736269	20992720352	issues	issue	NN2
304953	100736269	20992720353	with	with	IW
304953	100736269	20992720354	my	my	APPGE
304953	100736269	20992720355	relationship	relationship	NN1
304953	100736269	20992720356	for	for	IF
304953	100736269	20992720357	some	some	DD
304953	100736269	20992720358	time	time	NNT1
304953	100736269	20992720359	now	now	RT
304953	100736269	20992720360	and	and	CC
304953	100736269	20992720361	after	after	CS_II
304953	100736269	20992720362	i	i	ZZ1_MC1
304953	100736269	20992720363	came	come	VVD
304953	100736269	20992720364	in	in	II31
304953	100736269	20992720365	contact	contact	II32
304953	100736269	20992720366	with	with	II33
304953	100736269	20992720367	this	this	DD1
304953	100736269	20992720368	great	great	JJ
304953	100736269	20992720369	man	man	NN1
304953	100736269	20992720370	all	all	DB
304953	100736269	20992720371	my	my	APPGE
304953	100736269	20992720372	problems	problem	NN2
304953	100736269	20992720373	in	in	II
304953	100736269	20992720374	my	my	APPGE
304953	100736269	20992720375	relationship	relationship	NN1
304953	100736269	20992720376	were	be	VBDR
304953	100736269	20992720377	gone	go	VVN
304953	100736269	20992720378	after	after	II_CS
304953	100736269	20992720379	i	i	MC1_ZZ1
304953	100736269	20992720380	did	do	VDD
304953	100736269	20992720381	what	what	DDQ
304953	100736269	20992720382	he	he	PPHS1
304953	100736269	20992720383	told	tell	VVD
304953	100736269	20992720384	me	me	PPIO1
304953	100736269	20992720385	to	to	TO
304953	100736269	20992720386	do	do	VDI
304953	100736269	20992720387	incase	incase	NN1
304953	100736269	20992720388	you	you	PPY
304953	100736269	20992720389	are	be	VBR
304953	100736269	20992720390	out	out	RP
304953	100736269	20992720391	there	there	RL
304953	100736269	20992720392	having	have	VHG
304953	100736269	20992720393	any	any	DD
304953	100736269	20992720394	problem	problem	NN1
304953	100736269	20992720395	with	with	IW
304953	100736269	20992720396	your	your	APPGE
304953	100736269	20992720397	relationship	relationship	NN1
304953	100736269	20992720398	or	or	CC
304953	100736269	20992720399	any	any	DD
304953	100736269	20992720400	problem	problem	NN1
304953	100736269	20992720401	at	at	RR21_II
304953	100736269	20992720402	all	all	RR22_DB
304953	100736269	20992720403	you	you	PPY
304953	100736269	20992720404	can	can	VM
304953	100736269	20992720405	contact	contact	VVI
304953	100736269	20992720406	this	this	DD1
304953	100736269	20992720407	great	great	JJ
304953	100736269	20992720408	man	man	NN1
304953	100736269	20992720409	for	for	IF
304953	100736269	20992720410	help	help	NN1
304953	100736269	20992720411	through	through	II
304953	100736269	20992720412	his	his	APPGE
304953	100736269	20992720413	email	email	NN1
304953	100736269	20992720414	@prophetkalito@gmail		FO
304953	100736269	20992720415	,	,	,
304953	100736269	20992720416	com	com/	VV0_NN1
304953	100736269	20992720417	Thanks	thanks	NN2
304953	100736269	20992720418	prophetkalito		NN1
304953	100736269	20992720419	you	you	PPY
304953	100736269	20992720420	are	be	VBR
304953	100736269	20992720421	really	really	RR
304953	100736269	20992720422	God	god	NP1
304953	100736269	20992720423	sent	send	VVD
304953	100736269	20992720424	<p>		NULL
304953	100736269	20992720425	I	i	PPIS1
304953	100736269	20992720426	am	be	VBM
304953	100736269	20992720427	almost	almost	RR
304953	100736269	20992720428	speechless	speechless	JJ
304953	100736269	20992720429	,	,	,
304953	100736269	20992720430	I	i	PPIS1
304953	100736269	20992720431	have	have	VH0
304953	100736269	20992720432	been	be	VBN
304953	100736269	20992720433	suffering	suffer	VVG
304953	100736269	20992720434	with	with	IW
304953	100736269	20992720435	HSV2		FO
304953	100736269	20992720436	positive	positive	JJ
304953	100736269	20992720437	now	now	RT
304953	100736269	20992720438	for	for	IF
304953	100736269	20992720439	about	about	RG
304953	100736269	20992720440	a	a	AT1
304953	100736269	20992720441	year	year	NNT1
304953	100736269	20992720442	,	,	,
304953	100736269	20992720443	and	and	CC
304953	100736269	20992720444	I	i	PPIS1
304953	100736269	20992720445	tried	try	VVD
304953	100736269	20992720446	everything	everything	PN1
304953	100736269	20992720447	to	to	TO
304953	100736269	20992720448	get	get	VVI
304953	100736269	20992720449	it	it	PPH1
304953	100736269	20992720450	to	to	TO
304953	100736269	20992720451	go	go	VVI
304953	100736269	20992720452	away	away	RL
304953	100736269	20992720453	.	.	.
304953	100736269	20992720454	I	i	PPIS1
304953	100736269	20992720455	was	be	VBDZ
304953	100736269	20992720456	diagnosed	diagnose	VVN
304953	100736269	20992720457	with	with	IW
304953	100736269	20992720458	it	it	PPH1
304953	100736269	20992720459	about	about	RG
304953	100736269	20992720460	a	a	AT1
304953	100736269	20992720461	year	year	NNT1
304953	100736269	20992720462	ago	ago	RA
304953	100736269	20992720463	.	.	.
304953	100736269	20992720464	Some	some	DD
304953	100736269	20992720465	guy	guy	NN1
304953	100736269	20992720466	I	i	PPIS1
304953	100736269	20992720467	was	be	VBDZ
304953	100736269	20992720468	with	with	IW
304953	100736269	20992720469	gave	give	VVD
304953	100736269	20992720470	it	it	PPH1
304953	100736269	20992720471	to	to	II
304953	100736269	20992720472	me	me	PPIO1
304953	100736269	20992720473	,	,	,
304953	100736269	20992720474	but	but	CCB
304953	100736269	20992720475	the	the	AT
304953	100736269	20992720476	doctor	doctor	NN1
304953	100736269	20992720477	said	say	VVD
304953	100736269	20992720478	,	,	,
304953	100736269	20992720479	lucky	lucky	JJ
304953	100736269	20992720480	I	i	PPIS1
304953	100736269	20992720481	did	do	VDD
304953	100736269	20992720482	n't 	n't	XX
304953	100736269	20992720483	have	have	VHI
304953	100736269	20992720484	a	a	AT1
304953	100736269	20992720485	bad	bad	JJ
304953	100736269	20992720486	case	case	NN1
304953	100736269	20992720487	of	of	IO
304953	100736269	20992720488	it	it	PPH1
304953	100736269	20992720489	.	.	.
304953	100736269	20992720490	The	the	AT
304953	100736269	20992720491	doctor	doctor	NN1
304953	100736269	20992720492	told	tell	VVD
304953	100736269	20992720493	me	me	PPIO1
304953	100736269	20992720494	my	my	APPGE
304953	100736269	20992720495	levels	level	NN2
304953	100736269	20992720496	were	be	VBDR
304953	100736269	20992720497	very	very	RG
304953	100736269	20992720498	low	low	JJ_RR@
304953	100736269	20992720499	.	.	.
304953	100736269	20992720500	I	i	PPIS1
304953	100736269	20992720501	am	be	VBM
304953	100736269	20992720502	so	so	RR
304953	100736269	20992720503	saddened	sadden	VVN
304953	100736269	20992720504	by	by	II
304953	100736269	20992720505	our	our	APPGE
304953	100736269	20992720506	government	government	NN1
304953	100736269	20992720507	that	that	CST
304953	100736269	20992720508	they	they	PPHS2
304953	100736269	20992720509	do	do	VD0
304953	100736269	20992720510	n't 	n't	XX
304953	100736269	20992720511	take	take	VVI
304953	100736269	20992720512	this	this	DD1
304953	100736269	20992720513	disease	disease	NN1
304953	100736269	20992720514	more	more	RGR_RRR
304953	100736269	20992720515	seriously	seriously	RR
304953	100736269	20992720516	.	.	.
304953	100736269	20992720517	I	i	PPIS1
304953	100736269	20992720518	am	be	VBM
304953	100736269	20992720519	so	so	RG
304953	100736269	20992720520	depressed	depressed	JJ
304953	100736269	20992720521	everyday	everyday	JJ
304953	100736269	20992720522	,	,	,
304953	100736269	20992720523	@		II
304953	100736269	20992720524	@		II
304953	100736269	20992720525	@		II
304953	100736269	20992720526	@		II
304953	100736269	20992720527	@		II
304953	100736269	20992720528	@		II
304953	100736269	20992720529	@		II
304953	100736269	20992720530	@		II
304953	100736269	20992720531	@		II
304953	100736269	20992720532	@		II
304953	100736269	20992720533	especially	especially	RR
304953	100736269	20992720534	ever	ever	RR
304953	100736269	20992720535	finding	find	VVG_JJ@
304953	100736269	20992720536	love	love	NN1
304953	100736269	20992720537	.	.	.
304953	100736269	20992720538	This	this	DD1
304953	100736269	20992720539	disease	disease	NN1
304953	100736269	20992720540	is	be	VBZ
304953	100736269	20992720541	almost	almost	RR
304953	100736269	20992720542	worse	bad	JJR_RRR@
304953	100736269	20992720543	then	then	RT_JJ%
304953	100736269	20992720544	Aids	aids	NN2
304953	100736269	20992720545	,	,	,
304953	100736269	20992720546	because	because	CS
304953	100736269	20992720547	it	it	PPH1
304953	100736269	20992720548	spreads	spread	VVZ
304953	100736269	20992720549	so	so	RG
304953	100736269	20992720550	quickly	quickly	RR
304953	100736269	20992720551	.	.	.
304953	100736269	20992720552	I	i	PPIS1
304953	100736269	20992720553	feel	feel	VV0
304953	100736269	20992720554	so	so	RG_RR
304953	100736269	20992720555	bad	bad	JJ
304953	100736269	20992720556	for	for	IF
304953	100736269	20992720557	everyone	everyone	PN1
304953	100736269	20992720558	the	the	AT
304953	100736269	20992720559	suffers	suffer	VVZ
304953	100736269	20992720560	with	with	IW
304953	100736269	20992720561	this	this	DD1
304953	100736269	20992720562	nightmare	nightmare	NN1
304953	100736269	20992720563	,	,	,
304953	100736269	20992720564	and	and	CC
304953	100736269	20992720565	my	my	APPGE
304953	100736269	20992720566	only	only	JJ
304953	100736269	20992720567	wish	wish	NN1
304953	100736269	20992720568	is	be	VBZ
304953	100736269	20992720569	that	that	CST
304953	100736269	20992720570	our	our	APPGE
304953	100736269	20992720571	government	government	NN1
304953	100736269	20992720572	will	will	VM
304953	100736269	20992720573	support	support	VVI
304953	100736269	20992720574	finding	find	VVG
304953	100736269	20992720575	a	a	AT1
304953	100736269	20992720576	cure	cure	NN1
304953	100736269	20992720577	quickly	quickly	RR
304953	100736269	20992720578	.	.	.
304953	100736269	20992720579	My	my	APPGE
304953	100736269	20992720580	heart	heart	NN1
304953	100736269	20992720581	goes	go	VVZ
304953	100736269	20992720582	out	out	RP
304953	100736269	20992720583	to	to	II
304953	100736269	20992720584	you	you	PPY
304953	100736269	20992720585	all	all	DB_RR@
304953	100736269	20992720586	.	.	.
304953	100736269	20992720587	I	i	PPIS1
304953	100736269	20992720588	cry	cry	VV0
304953	100736269	20992720589	almost	almost	RR
304953	100736269	20992720590	everyday	everyday	JJ
304953	100736269	20992720591	,	,	,
304953	100736269	20992720592	because	because	CS
304953	100736269	20992720593	I	i	PPIS1
304953	100736269	20992720594	was	be	VBDZ
304953	100736269	20992720595	healthy	healthy	JJ
304953	100736269	20992720596	and	and	CC
304953	100736269	20992720597	someone	someone	PN1
304953	100736269	20992720598	gave	give	VVD
304953	100736269	20992720599	me	me	PPIO1
304953	100736269	20992720600	this	this	DD1
304953	100736269	20992720601	terrible	terrible	JJ
304953	100736269	20992720602	disease	disease	NN1
304953	100736269	20992720603	,	,	,
304953	100736269	20992720604	and	and	CC
304953	100736269	20992720605	I	i	PPIS1
304953	100736269	20992720606	have	have	VH0
304953	100736269	20992720607	two	two	MC
304953	100736269	20992720608	children	child	NN2
304953	100736269	20992720609	to	to	TO
304953	100736269	20992720610	look	look	VVI
304953	100736269	20992720611	after	after	II
304953	100736269	20992720612	.	.	.
304953	100736269	20992720613	I	i	PPIS1
304953	100736269	20992720614	have	have	VH0
304953	100736269	20992720615	never	never	RR
304953	100736269	20992720616	told	tell	VVN
304953	100736269	20992720617	anyone	anyone	PN1
304953	100736269	20992720618	about	about	II
304953	100736269	20992720619	my	my	APPGE
304953	100736269	20992720620	diagnosis	diagnosis	NN1
304953	100736269	20992720621	,	,	,
304953	100736269	20992720622	because	because	CS
304953	100736269	20992720623	people	people	NN
304953	100736269	20992720624	really	really	RR
304953	100736269	20992720625	make	make	VV0
304953	100736269	20992720626	fun	fun	NN1
304953	100736269	20992720627	of	of	IO
304953	100736269	20992720628	it	it	PPH1
304953	100736269	20992720629	and	and	CC
304953	100736269	20992720630	its	its	APPGE
304953	100736269	20992720631	no	no	NN1%
304953	100736269	20992720632	joke	joke	NN1
304953	100736269	20992720633	!	!	!
304953	100736269	20992720634	!	!	!
304953	100736269	20992720635	till	till	CS_II
304953	100736269	20992720636	last	last	MD
304953	100736269	20992720637	month	month	NNT1
304953	100736269	20992720638	i	i	ZZ1_MC1
304953	100736269	20992720639	found	find	VVD_VVN
304953	100736269	20992720640	a	a	AT1
304953	100736269	20992720641	contact	contact	NN1
304953	100736269	20992720642	of	of	IO
304953	100736269	20992720643	DR	dr	NNB
304953	100736269	20992720644	AJAGUNA		NP1
304953	100736269	20992720645	who	who	PNQS
304953	100736269	20992720646	help	help	VV0
304953	100736269	20992720647	me	me	PPIO1
304953	100736269	20992720648	with	with	IW
304953	100736269	20992720649	his	his	APPGE
304953	100736269	20992720650	herpes	herpes	NN2
304953	100736269	20992720651	now	now	RT
304953	100736269	20992720652	am	be	VBM
304953	100736269	20992720653	cured	cure	VVN_JJ@
304953	100736269	20992720654	you	you	PPY
304953	100736269	20992720655	can	can	VM
304953	100736269	20992720656	as	as	RR21
304953	100736269	20992720657	well	well	RR22
304953	100736269	20992720658	contact	contact	VVI
304953	100736269	20992720659	him	him	PPHO1
304953	100736269	20992720660	Email	email	NN1_VV0@
304953	100736269	20992720661	:	:	:
304953	100736269	20992720662	(	(	(
304953	100736269	20992720663	ajaguna7demons@gmail.com		FO
304953	100736269	20992720664	)	)	)
304953	100736269	20992720665	<p>		NULL
304953	100736269	20992720666	Am	be	VBM
304953	100736269	20992720667	James	james	NP1
304953	100736269	20992720668	Pedro	pedro	NP1
304953	100736269	20992720669	am	am	RA@
304953	100736269	20992720670	from	from	II
304953	100736269	20992720671	USA	usa	NP1
304953	100736269	20992720672	,	,	,
304953	100736269	20992720673	there	there	EX
304953	100736269	20992720674	is	be	VBZ
304953	100736269	20992720675	this	this	DD1
304953	100736269	20992720676	spell	spell	NN1
304953	100736269	20992720677	caster	caster	NN1
304953	100736269	20992720678	from	from	II
304953	100736269	20992720679	africa	africa	NN1
304953	100736269	20992720680	his	his	APPGE
304953	100736269	20992720681	name	name	NN1
304953	100736269	20992720682	is	be	VBZ
304953	100736269	20992720683	DR	dr	NNB
304953	100736269	20992720684	LAGI		NP1
304953	100736269	20992720685	he	he	PPHS1
304953	100736269	20992720686	help	help	VV0
304953	100736269	20992720687	me	me	PPIO1
304953	100736269	20992720688	get	get	VVI
304953	100736269	20992720689	back	back	RP
304953	100736269	20992720690	my	my	APPGE
304953	100736269	20992720691	ex	ex	NN1@
304953	100736269	20992720692	with	with	IW
304953	100736269	20992720693	in	in	II
304953	100736269	20992720694	24hrs		NNU
304953	100736269	20992720695	I	i	PPIS1_ZZ1%
304953	100736269	20992720696	got	get	VVD
304953	100736269	20992720697	his	his	APPGE
304953	100736269	20992720698	email	email	NN1
304953	100736269	20992720699	online	online	RR_JJ
304953	100736269	20992720700	and	and	CC
304953	100736269	20992720701	I	i	PPIS1
304953	100736269	20992720702	email	email	VV0@
304953	100736269	20992720703	him	him	PPHO1
304953	100736269	20992720704	and	and	CC
304953	100736269	20992720705	he	he	PPHS1
304953	100736269	20992720706	said	say	VVD
304953	100736269	20992720707	if	if	CS_CSW@
304953	100736269	20992720708	I	i	PPIS1
304953	100736269	20992720709	trust	trust	VV0
304953	100736269	20992720710	him	him	PPHO1
304953	100736269	20992720711	that	that	CST
304953	100736269	20992720712	my	my	APPGE
304953	100736269	20992720713	ex	ex	NN1@
304953	100736269	20992720714	will	will	VM
304953	100736269	20992720715	come	come	VVI
304953	100736269	20992720716	back	back	RP
304953	100736269	20992720717	so	so	CS@_RR
304953	100736269	20992720718	I	i	PPIS1
304953	100736269	20992720719	told	tell	VVD
304953	100736269	20992720720	him	him	PPHO1
304953	100736269	20992720721	that	that	CST
304953	100736269	20992720722	I	i	PPIS1
304953	100736269	20992720723	@		II
304953	100736269	20992720724	@		II
304953	100736269	20992720725	@		II
304953	100736269	20992720726	@		II
304953	100736269	20992720727	@		II
304953	100736269	20992720728	@		II
304953	100736269	20992720729	@		II
304953	100736269	20992720730	@		II
304953	100736269	20992720731	@		II
304953	100736269	20992720732	@		II
304953	100736269	20992720733	on	on	II
304953	100736269	20992720734	my	my	APPGE
304953	100736269	20992720735	door	door	NN1
304953	100736269	20992720736	to	to	II
304953	100736269	20992720737	my	my	APPGE
304953	100736269	20992720738	greatest	greatest	JJT
304953	100736269	20992720739	surprise	surprise	NN1
304953	100736269	20992720740	it	it	PPH1
304953	100736269	20992720741	was	be	VBDZ
304953	100736269	20992720742	Sonia	sonia	NP1
304953	100736269	20992720743	my	my	APPGE
304953	100736269	20992720744	ex	ex	NN1@
304953	100736269	20992720745	so	so	RR_RG_CS@
304953	100736269	20992720746	all	all	DB
304953	100736269	20992720747	thanks	thanks	NN2
304953	100736269	20992720748	to	to	II
304953	100736269	20992720749	DR	dr	NNB
304953	100736269	20992720750	LAGI		NP1
304953	100736269	20992720751	here	here	RL
304953	100736269	20992720752	are	be	VBR
304953	100736269	20992720753	many	many	DA2
304953	100736269	20992720754	other	other	JJ
304953	100736269	20992720755	spell	spell	NN1
304953	100736269	20992720756	he	he	PPHS1
304953	100736269	20992720757	can	can	VM
304953	100736269	20992720758	cast	cast	VVI
304953	100736269	20992720759	<p>		NULL
304953	100736269	20992720760	SPELL	spell	VV0
304953	100736269	20992720761	TO	to	TO
304953	100736269	20992720762	STOP	stop	VVI
304953	100736269	20992720763	YOUR	your	APPGE
304953	100736269	20992720764	EX	ex	NN1@
304953	100736269	20992720765	FROM	from	II
304953	100736269	20992720766	CHEATING	cheat	VVG_JJ@
304953	100736269	20992720767	SPELL	spell	NN1_VV0
304953	100736269	20992720768	TO	to	TO
304953	100736269	20992720769	GET	get	VVI
304953	100736269	20992720770	BACK	back	RP
304953	100736269	20992720771	YOUR	your	APPGE
304953	100736269	20992720772	EX	ex	NN1@
304953	100736269	20992720773	Spell	spell	NN1_VV0
304953	100736269	20992720774	for	for	IF
304953	100736269	20992720775	magic	magic	JJ_NN1
304953	100736269	20992720776	Spell	spell	NN1
304953	100736269	20992720777	for	for	IF
304953	100736269	20992720778	exam	exam	NN1
304953	100736269	20992720779	success	success	NN1
304953	100736269	20992720780	Spell	spell	NN1_VV0
304953	100736269	20992720781	for	for	IF
304953	100736269	20992720782	kidney	kidney	NN1
304953	100736269	20992720783	problem	problem	NN1
304953	100736269	20992720784	Spell	spell	NN1_VV0
304953	100736269	20992720785	for	for	IF
304953	100736269	20992720786	H.I.V	hiv	NP1
304953	100736269	20992720787	and	and	CC
304953	100736269	20992720788	AIDS	aids	NN1_NN2@
304953	100736269	20992720789	Spell	spell	NN1_VV0
304953	100736269	20992720790	for	for	IF
304953	100736269	20992720791	cancer	cancer	NN1
304953	100736269	20992720792	Spell	spell	NN1_VV0
304953	100736269	20992720793	to	to	TO
304953	100736269	20992720794	keep	keep	VVI
304953	100736269	20992720795	your	your	APPGE
304953	100736269	20992720796	job	job	NN1
304953	100736269	20992720797	secure	secure	JJ_VV0
304953	100736269	20992720798	Spell	spell	NN1_VV0
304953	100736269	20992720799	to	to	TO
304953	100736269	20992720800	get	get	VVI
304953	100736269	20992720801	a	a	AT1
304953	100736269	20992720802	job	job	NN1
304953	100736269	20992720803	Spell	spell	NN1_VV0
304953	100736269	20992720804	to	to	TO
304953	100736269	20992720805	get	get	VVI
304953	100736269	20992720806	a	a	AT1
304953	100736269	20992720807	husband	husband	NN1
304953	100736269	20992720808	Spell	spell	NN1_VV0
304953	100736269	20992720809	to	to	TO
304953	100736269	20992720810	get	get	VVI
304953	100736269	20992720811	your	your	APPGE
304953	100736269	20992720812	child	child	NN1
304953	100736269	20992720813	from	from	II
304953	100736269	20992720814	your	your	APPGE
304953	100736269	20992720815	ex	ex	NN1@
304953	100736269	20992720816	Spell	spell	NN1_VV0
304953	100736269	20992720817	for	for	IF
304953	100736269	20992720818	stroke	stroke	NN1
304953	100736269	20992720819	Spell	spell	NN1_VV0
304953	100736269	20992720820	for	for	IF
304953	100736269	20992720821	your	your	APPGE
304953	100736269	20992720822	ex	ex	NN1@
304953	100736269	20992720823	to	to	TO
304953	100736269	20992720824	be	be	VBI
304953	100736269	20992720825	submissive	submissive	JJ
304953	100736269	20992720826	to	to	II
304953	100736269	20992720827	you	you	PPY
304953	100736269	20992720828	Spell	spell	VV0
304953	100736269	20992720829	for	for	IF
304953	100736269	20992720830	you	you	PPY
304953	100736269	20992720831	to	to	TO
304953	100736269	20992720832	get	get	VVI
304953	100736269	20992720833	back	back	RP
304953	100736269	20992720834	your	your	APPGE
304953	100736269	20992720835	ex	ex	NN1@
304953	100736269	20992720836	Spell	spell	NN1_VV0
304953	100736269	20992720837	to	to	TO
304953	100736269	20992720838	stop	stop	VVI
304953	100736269	20992720839	your	your	APPGE
304953	100736269	20992720840	ex	ex	NN1@
304953	100736269	20992720841	from	from	II
304953	100736269	20992720842	drunkenness	drunkenness	NN1
304953	100736269	20992720843	Spell	spell	NN1_VV0
304953	100736269	20992720844	for	for	IF
304953	100736269	20992720845	asthma	asthma	NN1
304953	100736269	20992720846	Spell	spell	NN1_VV0
304953	100736269	20992720847	for	for	IF
304953	100736269	20992720848	weak	weak	JJ
304953	100736269	20992720849	ejaculation	ejaculation	NN1
304953	100736269	20992720850	Spell	spell	NN1_VV0
304953	100736269	20992720851	for	for	IF
304953	100736269	20992720852	pile	pile	NN1
304953	100736269	20992720853	Spell	spell	NN1_VV0
304953	100736269	20992720854	for	for	IF
304953	100736269	20992720855	fibrous	fibrous	JJ
304953	100736269	20992720856	<p>		NULL
304953	100736269	20992720857	Hello	hello	UH
304953	100736269	20992720858	my	my	APPGE
304953	100736269	20992720859	dear	dear	NN1_JJ
304953	100736269	20992720860	I	i	PPIS1
304953	100736269	20992720861	want	want	VV0
304953	100736269	20992720862	to	to	TO
304953	100736269	20992720863	let	let	VVI
304953	100736269	20992720864	you	you	PPY
304953	100736269	20992720865	know	know	VVI
304953	100736269	20992720866	that	that	CST
304953	100736269	20992720867	you	you	PPY
304953	100736269	20992720868	already	already	RR
304953	100736269	20992720869	own	own	DA_VV0@
304953	100736269	20992720870	a	a	AT1
304953	100736269	20992720871	better	better	JJR
304953	100736269	20992720872	half	half	NN1@
304953	100736269	20992720873	in	in	II
304953	100736269	20992720874	me	me	PPIO1
304953	100736269	20992720875	..	...	...
304953	100736269	20992720876	you	you	PPY
304953	100736269	20992720877	have	have	VH0
304953	100736269	20992720878	aroused	arouse	VVN
304953	100736269	20992720879	the	the	AT
304953	100736269	20992720880	feeling	feeling	NN1
304953	100736269	20992720881	that	that	CST_DD1
304953	100736269	20992720882	has	have	VHZ
304953	100736269	20992720883	been	be	VBN
304953	100736269	20992720884	lying	lie	VVG
304953	100736269	20992720885	there	there	RL
304953	100736269	20992720886	for	for	IF
304953	100736269	20992720887	so	so	RG
304953	100736269	20992720888	long	long	RR_JJ
304953	100736269	20992720889	,	,	,
304953	100736269	20992720890	i	i	ZZ1_MC1
304953	100736269	20992720891	just	just	RR
304953	100736269	20992720892	wished	wish	VVD
304953	100736269	20992720893	you	you	PPY
304953	100736269	20992720894	could	could	VM
304953	100736269	20992720895	see	see	VVI
304953	100736269	20992720896	that	that	RG
304953	100736269	20992720897	much	much	DA1
304953	100736269	20992720898	difference	difference	NN1
304953	100736269	20992720899	you	you	PPY
304953	100736269	20992720900	make	make	VV0
304953	100736269	20992720901	in	in	II_RP@
304953	100736269	20992720902	my	my	APPGE
304953	100736269	20992720903	life	life	NN1
304953	100736269	20992720904	at	at	II
304953	100736269	20992720905	this	this	DD1
304953	100736269	20992720906	point	point	NN1
304953	100736269	20992720907	in	in	II
304953	100736269	20992720908	time	time	NNT1
304953	100736269	20992720909	..	...	...
304953	100736269	20992720910	i	i	ZZ1_MC1
304953	100736269	20992720911	slept	sleep	VVD_VVN@
304953	100736269	20992720912	like	like	II
304953	100736269	20992720913	a	a	AT1
304953	100736269	20992720914	baby	baby	NN1
304953	100736269	20992720915	knowing	know	VVG
304953	100736269	20992720916	i	i	ZZ1_MC1
304953	100736269	20992720917	would	would	VM
304953	100736269	20992720918	read	read	VVI
304953	100736269	20992720919	from	from	II
304953	100736269	20992720920	you	you	PPY
304953	100736269	20992720921	in	in	II
304953	100736269	20992720922	the	the	AT
304953	100736269	20992720923	@		II
304953	100736269	20992720924	@		II
304953	100736269	20992720925	@		II
304953	100736269	20992720926	@		II
304953	100736269	20992720927	@		II
304953	100736269	20992720928	@		II
304953	100736269	20992720929	@		II
304953	100736269	20992720930	@		II
304953	100736269	20992720931	@		II
304953	100736269	20992720932	@		II
304953	100736269	20992720933	start	start	VVI
304953	100736269	20992720934	my	my	APPGE
304953	100736269	20992720935	day	day	NNT1
304953	100736269	20992720936	,	,	,
304953	100736269	20992720937	i	i	ZZ1_MC1
304953	100736269	20992720938	know	know	VV0
304953	100736269	20992720939	you	you	PPY
304953	100736269	20992720940	would	would	VM
304953	100736269	20992720941	be	be	VBI
304953	100736269	20992720942	sleeping	sleep	VVG_JJ
304953	100736269	20992720943	right	right	RR_NN1_JJ
304953	100736269	20992720944	now	now	RT
304953	100736269	20992720945	and	and	CC
304953	100736269	20992720946	am	be	VBM
304953	100736269	20992720947	sending	send	VVG
304953	100736269	20992720948	you	you	PPY
304953	100736269	20992720949	the	the	AT
304953	100736269	20992720950	angels	angel	NN2
304953	100736269	20992720951	to	to	TO
304953	100736269	20992720952	watch	watch	VVI
304953	100736269	20992720953	over	over	RP_II
304953	100736269	20992720954	you	you	PPY
304953	100736269	20992720955	..	...	...
304953	100736269	20992720956	well	well	RR
304953	100736269	20992720957	i	i	MC1_ZZ1
304953	100736269	20992720958	would	would	VM
304953	100736269	20992720959	let	let	VVI
304953	100736269	20992720960	you	you	PPY
304953	100736269	20992720961	know	know	VVI
304953	100736269	20992720962	that	that	CST_DD1
304953	100736269	20992720963	In	in	II
304953	100736269	20992720964	a	a	AT1
304953	100736269	20992720965	relationship	relationship	NN1
304953	100736269	20992720966	,	,	,
304953	100736269	20992720967	each	each	DD1
304953	100736269	20992720968	body	body	NN1
304953	100736269	20992720969	has	have	VHZ
304953	100736269	20992720970	its	its	APPGE
304953	100736269	20992720971	own	own	DA
304953	100736269	20992720972	mind	mind	NN1
304953	100736269	20992720973	,	,	,
304953	100736269	20992720974	but	but	CCB
304953	100736269	20992720975	share	share	VV0
304953	100736269	20992720976	the	the	AT
304953	100736269	20992720977	same	same	DA
304953	100736269	20992720978	heart	heart	NN1
304953	100736269	20992720979	.	.	.
304953	100736269	20992720980	your	your	APPGE
304953	100736269	20992720981	life	life	NN1
304953	100736269	20992720982	is	be	VBZ
304953	100736269	20992720983	gods	god	NN2
304953	100736269	20992720984	gift	gift	NN1
304953	100736269	20992720985	to	to	II
304953	100736269	20992720986	you	you	PPY
304953	100736269	20992720987	,	,	,
304953	100736269	20992720988	your	your	APPGE
304953	100736269	20992720989	heart	heart	NN1
304953	100736269	20992720990	is	be	VBZ
304953	100736269	20992720991	your	your	APPGE
304953	100736269	20992720992	gift	gift	NN1
304953	100736269	20992720993	to	to	II
304953	100736269	20992720994	the	the	AT
304953	100736269	20992720995	world	world	NN1
304953	100736269	20992720996	.	.	.
304953	100736269	20992720997	46996		MC
304953	100736269	20992720998	@qwx906996		FO
304953	100736273	20992721018	@@##	----------	----------
304953	100736273	20992721019	@@100736273		FO
304953	100736273	20992721020	@4936273/		VV0_NN1
304953	100736273	20992721021	46989		MC
304953	100736273	20992721022	@qwx906989		FO
304953	100736273	20992721023	<p>		NULL
304953	100736273	20992721024	Testosterone	testosterone	NN1
304953	100736273	20992721025	is	be	VBZ
304953	100736273	20992721026	often	often	RR
304953	100736273	20992721027	called	call	VVN_VVD@
304953	100736273	20992721028	the	the	AT
304953	100736273	20992721029	male	male	JJ_NN1
304953	100736273	20992721030	hormone	hormone	NN1
304953	100736273	20992721031	.	.	.
304953	100736273	20992721032	But	but	CCB
304953	100736273	20992721033	womens	womens	VVZ
304953	100736273	20992721034	bodies	body	NN2
304953	100736273	20992721035	make	make	VV0
304953	100736273	20992721036	it	it	PPH1
304953	100736273	20992721037	,	,	,
304953	100736273	20992721038	too	too	RR@_RG
304953	100736273	20992721039	,	,	,
304953	100736273	20992721040	though	though	CS_RR@
304953	100736273	20992721041	in	in	II
304953	100736273	20992721042	lesser	lesser	JJ
304953	100736273	20992721043	amounts	amount	NN2
304953	100736273	20992721044	than	than	CSN
304953	100736273	20992721045	men	man	NN2
304953	100736273	20992721046	make	make	VV0
304953	100736273	20992721047	.	.	.
304953	100736273	20992721048	In	in	II
304953	100736273	20992721049	both	both	RR
304953	100736273	20992721050	women	woman	NN2
304953	100736273	20992721051	and	and	CC
304953	100736273	20992721052	men	man	NN2
304953	100736273	20992721053	,	,	,
304953	100736273	20992721054	testosterone	testosterone	NN1
304953	100736273	20992721055	levels	level	NN2
304953	100736273	20992721056	naturally	naturally	RR
304953	100736273	20992721057	decline	decline	VV0
304953	100736273	20992721058	with	with	IW
304953	100736273	20992721059	age	age	NN1
304953	100736273	20992721060	.	.	.
304953	100736273	20992721061	This	this	DD1
304953	100736273	20992721062	can	can	VM
304953	100736273	20992721063	diminish	diminish	VVI
304953	100736273	20992721064	a	a	AT1
304953	100736273	20992721065	womans	woman	NN2
304953	100736273	20992721066	sex	sex	NN1_VV0%
304953	100736273	20992721067	drive	drive	NN1_VV0
304953	100736273	20992721068	,	,	,
304953	100736273	20992721069	just	just	RR
304953	100736273	20992721070	as	as	CSA
304953	100736273	20992721071	it	it	PPH1
304953	100736273	20992721072	can	can	VM
304953	100736273	20992721073	a	a	AT1
304953	100736273	20992721074	mans	man	NN2
304953	100736273	20992721075	.	.	.
304953	100736273	20992721076	Some	some	DD
304953	100736273	20992721077	women	woman	NN2
304953	100736273	20992721078	try	try	VV0
304953	100736273	20992721079	to	to	TO
304953	100736273	20992721080	boost	boost	VVI
304953	100736273	20992721081	a	a	AT1
304953	100736273	20992721082	waning	waning	JJ@
304953	100736273	20992721083	sex	sex	NN1
304953	100736273	20992721084	drive	drive	NN1_VV0
304953	100736273	20992721085	with	with	IW
304953	100736273	20992721086	a	a	AT1
304953	100736273	20992721087	testosterone-based		JJ
304953	100736273	20992721088	vaginal	vaginal	JJ
304953	100736273	20992721089	cream	cream	NN1
304953	100736273	20992721090	,	,	,
304953	100736273	20992721091	which	which	DDQ
304953	100736273	20992721092	can	can	VM
304953	100736273	20992721093	be	be	VBI
304953	100736273	20992721094	mixed	mix	VVN
304953	100736273	20992721095	to	to	TO
304953	100736273	20992721096	order	order	VVI
304953	100736273	20992721097	by	by	II
304953	100736273	20992721098	a	a	AT1
304953	100736273	20992721099	compounding	compounding	JJ@_NN1@
304953	100736273	20992721100	pharmacy	pharmacy	NN1
304953	100736273	20992721101	with	with	IW
304953	100736273	20992721102	a	a	AT1
304953	100736273	20992721103	doctors	doctor	NN2
304953	100736273	20992721104	prescription	prescription	NN1
304953	100736273	20992721105	.	.	.
304953	100736273	20992721106	<p>		NULL
304953	100736273	20992721107	That	that	DD1
304953	100736273	20992721108	could	could	VM
304953	100736273	20992721109	have	have	VHI
304953	100736273	20992721110	a	a	AT1
304953	100736273	20992721111	downside	downside	NN1
304953	100736273	20992721112	for	for	IF
304953	100736273	20992721113	their	their	APPGE
304953	100736273	20992721114	male	male	JJ_NN1
304953	100736273	20992721115	sex	sex	NN1
304953	100736273	20992721116	partners	partner	NN2
304953	100736273	20992721117	with	with	IW
304953	100736273	20992721118	prostate	prostate	NN1
304953	100736273	20992721119	cancer	cancer	NN1
304953	100736273	20992721120	.	.	.
304953	100736273	20992721121	<p>		NULL
304953	100736273	20992721122	In	in	II
304953	100736273	20992721123	the	the	AT
304953	100736273	20992721124	Journal	journal	NN1
304953	100736273	20992721125	of	of	IO
304953	100736273	20992721126	Clinical	clinical	JJ
304953	100736273	20992721127	Oncology	oncology	NN1_NP1
304953	100736273	20992721128	,	,	,
304953	100736273	20992721129	doctors	doctor	NN2
304953	100736273	20992721130	from	from	II
304953	100736273	20992721131	the	the	AT
304953	100736273	20992721132	Penn	penn	NP1
304953	100736273	20992721133	State	state	NN1
304953	100736273	20992721134	Hershey	hershey	NP1_NN1@
304953	100736273	20992721135	Cancer	cancer	NN1
304953	100736273	20992721136	Institute	institute	NN1
304953	100736273	20992721137	reported	report	VVN_VVD
304953	100736273	20992721138	on	on	II
304953	100736273	20992721139	the	the	AT
304953	100736273	20992721140	unusual	unusual	JJ
304953	100736273	20992721141	case	case	NN1
304953	100736273	20992721142	of	of	IO
304953	100736273	20992721143	a	a	AT1
304953	100736273	20992721144	68-year-old	68-year-old	JJ
304953	100736273	20992721145	man	man	NN1
304953	100736273	20992721146	who	who	PNQS
304953	100736273	20992721147	had	have	VHD
304953	100736273	20992721148	been	be	VBN
304953	100736273	20992721149	diagnosed	diagnose	VVN
304953	100736273	20992721150	with	with	IW
304953	100736273	20992721151	advanced	advanced	JJ
304953	100736273	20992721152	prostate	prostate	NN1
304953	100736273	20992721153	cancer	cancer	NN1
304953	100736273	20992721154	and	and	CC
304953	100736273	20992721155	had	have	VHD_VHN@
304953	100736273	20992721156	his	his	APPGE
304953	100736273	20992721157	prostate	prostate	NN1
304953	100736273	20992721158	removed	remove	VVN
304953	100736273	20992721159	.	.	.
304953	100736273	20992721160	The	the	AT
304953	100736273	20992721161	mans	man	NN2
304953	100736273	20992721162	PSA	psa	NP1
304953	100736273	20992721163	level	level	NN1
304953	100736273	20992721164	fell	fall	VVD
304953	100736273	20992721165	dramatically	dramatically	RR
304953	100736273	20992721166	after	after	II_CS
304953	100736273	20992721167	the	the	AT
304953	100736273	20992721168	surgery	surgery	NN1
304953	100736273	20992721169	,	,	,
304953	100736273	20992721170	a	a	AT1
304953	100736273	20992721171	sign	sign	NN1
304953	100736273	20992721172	that	that	CST
304953	100736273	20992721173	the	the	AT
304953	100736273	20992721174	treatment	treatment	NN1
304953	100736273	20992721175	had	have	VHD
304953	100736273	20992721176	worked	work	VVN
304953	100736273	20992721177	.	.	.
304953	100736273	20992721178	After	after	CS_II
304953	100736273	20992721179	his	his	APPGE
304953	100736273	20992721180	recovery	recovery	NN1
304953	100736273	20992721181	,	,	,
304953	100736273	20992721182	he	he	PPHS1
304953	100736273	20992721183	"	"	"
304953	100736273	20992721184	continued	continue	VVD
304953	100736273	20992721185	having	have	VHG
304953	100736273	20992721186	sex	sex	NN1
304953	100736273	20992721187	with	with	IW
304953	100736273	20992721188	his	his	APPGE
304953	100736273	20992721189	wife	wife	NN1
304953	100736273	20992721190	three	three	MC
304953	100736273	20992721191	or	or	CC
304953	100736273	20992721192	four	four	MC
304953	100736273	20992721193	times	time	NNT2
304953	100736273	20992721194	a	a	AT1
304953	100736273	20992721195	week	week	NNT1
304953	100736273	20992721196	,	,	,
304953	100736273	20992721197	"	"	"
304953	100736273	20992721198	said	say	VVD
304953	100736273	20992721199	his	his	APPGE
304953	100736273	20992721200	oncologist	oncologist	NN1
304953	100736273	20992721201	,	,	,
304953	100736273	20992721202	Dr.		NNB
304953	100736273	20992721203	Joseph	joseph	NP1
304953	100736273	20992721204	Drabick		NP1_NN1
304953	100736273	20992721205	.	.	.
304953	100736273	20992721206	<p>		NULL
304953	100736273	20992721207	A	a	AT1
304953	100736273	20992721208	year	year	NNT1
304953	100736273	20992721209	later	later	RRR
304953	100736273	20992721210	@		II
304953	100736273	20992721211	@		II
304953	100736273	20992721212	@		II
304953	100736273	20992721213	@		II
304953	100736273	20992721214	@		II
304953	100736273	20992721215	@		II
304953	100736273	20992721216	@		II
304953	100736273	20992721217	@		II
304953	100736273	20992721218	@		II
304953	100736273	20992721219	@		II
304953	100736273	20992721220	even	even	RR
304953	100736273	20992721221	after	after	CS
304953	100736273	20992721222	he	he	PPHS1
304953	100736273	20992721223	underwent	undergo	VVD
304953	100736273	20992721224	radiation	radiation	NN1
304953	100736273	20992721225	therapy	therapy	NN1
304953	100736273	20992721226	,	,	,
304953	100736273	20992721227	which	which	DDQ
304953	100736273	20992721228	is	be	VBZ
304953	100736273	20992721229	often	often	RR
304953	100736273	20992721230	used	use	VVN
304953	100736273	20992721231	to	to	TO
304953	100736273	20992721232	treat	treat	VVI
304953	100736273	20992721233	prostate	prostate	NN1
304953	100736273	20992721234	cancer	cancer	NN1
304953	100736273	20992721235	that	that	CST_DD1
304953	100736273	20992721236	recurs	recur	VVZ
304953	100736273	20992721237	after	after	II_CS
304953	100736273	20992721238	surgery	surgery	NN1
304953	100736273	20992721239	.	.	.
304953	100736273	20992721240	Meanwhile	meanwhile	RR
304953	100736273	20992721241	,	,	,
304953	100736273	20992721242	his	his	APPGE
304953	100736273	20992721243	doctors	doctor	NN2
304953	100736273	20992721244	could	could	VM
304953	100736273	20992721245	find	find	VVI
304953	100736273	20992721246	no	no	AT
304953	100736273	20992721247	physical	physical	JJ
304953	100736273	20992721248	evidence	evidence	NN1
304953	100736273	20992721249	that	that	CST
304953	100736273	20992721250	his	his	APPGE
304953	100736273	20992721251	prostate	prostate	NN1
304953	100736273	20992721252	cancer	cancer	NN1
304953	100736273	20992721253	had	have	VHD
304953	100736273	20992721254	returned	return	VVN
304953	100736273	20992721255	.	.	.
304953	100736273	20992721256	<p>		NULL
304953	100736273	20992721257	They	they	PPHS2
304953	100736273	20992721258	did	do	VDD
304953	100736273	20992721259	notice	notice	VVI
304953	100736273	20992721260	that	that	CST
304953	100736273	20992721261	the	the	AT
304953	100736273	20992721262	mans	man	NN2
304953	100736273	20992721263	testosterone	testosterone	NN1
304953	100736273	20992721264	level	level	NN1
304953	100736273	20992721265	was	be	VBDZ
304953	100736273	20992721266	unusually	unusually	RR
304953	100736273	20992721267	high	high	JJ_RR@
304953	100736273	20992721268	"	"	"
304953	100736273	20992721269	780	780	MC
304953	100736273	20992721270	nanograms	nanogram	NN2_VVZ
304953	100736273	20992721271	per	per	II
304953	100736273	20992721272	deciliter	deciliter	NN1
304953	100736273	20992721273	(	(	(
304953	100736273	20992721274	ng/dL		NN1_VV0
304953	100736273	20992721275	)	)	)
304953	100736273	20992721276	at	at	RR21
304953	100736273	20992721277	first	first	RR22
304953	100736273	20992721278	,	,	,
304953	100736273	20992721279	increasing	increase	VVG
304953	100736273	20992721280	to	to	II
304953	100736273	20992721281	908	908	MC
304953	100736273	20992721282	ng/dL		VV0_NN1
304953	100736273	20992721283	nearly	nearly	RR
304953	100736273	20992721284	a	a	AT1
304953	100736273	20992721285	year	year	NNT1
304953	100736273	20992721286	later	later	RRR
304953	100736273	20992721287	.	.	.
304953	100736273	20992721288	The	the	AT
304953	100736273	20992721289	normal	normal	JJ
304953	100736273	20992721290	testosterone	testosterone	NN1
304953	100736273	20992721291	level	level	NN1
304953	100736273	20992721292	for	for	IF
304953	100736273	20992721293	a	a	AT1
304953	100736273	20992721294	nearly	nearly	RR
304953	100736273	20992721295	70-year-old	70-year-old	JJ
304953	100736273	20992721296	man	man	NN1
304953	100736273	20992721297	is	be	VBZ
304953	100736273	20992721298	in	in	II
304953	100736273	20992721299	the	the	AT
304953	100736273	20992721300	500	500	MC
304953	100736273	20992721301	ng/dL		NN1_VV0
304953	100736273	20992721302	range	range	NN1
304953	100736273	20992721303	.	.	.
304953	100736273	20992721304	Extra	extra	JJ
304953	100736273	20992721305	testosterone	testosterone	NN1
304953	100736273	20992721306	can	can	VM_NN1%
304953	100736273	20992721307	fuel	fuel	VVI
304953	100736273	20992721308	the	the	AT
304953	100736273	20992721309	growth	growth	NN1
304953	100736273	20992721310	of	of	IO
304953	100736273	20992721311	cancer	cancer	NN1
304953	100736273	20992721312	cells	cell	NN2
304953	100736273	20992721313	lurking	lurk	VVG
304953	100736273	20992721314	in	in	II
304953	100736273	20992721315	the	the	AT
304953	100736273	20992721316	body	body	NN1
304953	100736273	20992721317	.	.	.
304953	100736273	20992721318	<p>		NULL
304953	100736273	20992721319	The	the	AT
304953	100736273	20992721320	man	man	NN1
304953	100736273	20992721321	told	tell	VVD_VVN
304953	100736273	20992721322	his	his	APPGE
304953	100736273	20992721323	doctors	doctor	NN2
304953	100736273	20992721324	that	that	CST
304953	100736273	20992721325	he	he	PPHS1
304953	100736273	20992721326	did	do	VDD
304953	100736273	20992721327	not	not	XX
304953	100736273	20992721328	take	take	VVI
304953	100736273	20992721329	testosterone	testosterone	NN1
304953	100736273	20992721330	supplements	supplement	NN2
304953	100736273	20992721331	.	.	.
304953	100736273	20992721332	His	his	APPGE
304953	100736273	20992721333	wife	wife	NN1
304953	100736273	20992721334	,	,	,
304953	100736273	20992721335	however	however	RR
304953	100736273	20992721336	,	,	,
304953	100736273	20992721337	said	say	VVD
304953	100736273	20992721338	she	she	PPHS1
304953	100736273	20992721339	had	have	VHD
304953	100736273	20992721340	been	be	VBN
304953	100736273	20992721341	using	use	VVG
304953	100736273	20992721342	a	a	AT1
304953	100736273	20992721343	testosterone-based		JJ
304953	100736273	20992721344	vaginal	vaginal	JJ
304953	100736273	20992721345	cream	cream	NN1
304953	100736273	20992721346	as	as	II_CSA
304953	100736273	20992721347	a	a	AT1
304953	100736273	20992721348	sexual	sexual	JJ
304953	100736273	20992721349	lubricant	lubricant	NN1
304953	100736273	20992721350	for	for	IF
304953	100736273	20992721351	more	more	DAR
304953	100736273	20992721352	than	than	CSN
304953	100736273	20992721353	a	a	AT1
304953	100736273	20992721354	year	year	NNT1
304953	100736273	20992721355	.	.	.
304953	100736273	20992721356	After	after	CS
304953	100736273	20992721357	she	she	PPHS1
304953	100736273	20992721358	stopped	stop	VVD
304953	100736273	20992721359	using	use	VVG
304953	100736273	20992721360	the	the	AT
304953	100736273	20992721361	cream	cream	NN1
304953	100736273	20992721362	,	,	,
304953	100736273	20992721363	her	her	APPGE
304953	100736273	20992721364	husbands	husband	NN2
304953	100736273	20992721365	testosterone	testosterone	NN1
304953	100736273	20992721366	level	level	NN1
304953	100736273	20992721367	plummeted	plummet	VVD
304953	100736273	20992721368	,	,	,
304953	100736273	20992721369	though	though	CS
304953	100736273	20992721370	his	his	APPGE
304953	100736273	20992721371	PSA	psa	NP1
304953	100736273	20992721372	level	level	NN1
304953	100736273	20992721373	continued	continue	VVD_VVN
304953	100736273	20992721374	to	to	TO
304953	100736273	20992721375	rise	rise	VVI
304953	100736273	20992721376	.	.	.
304953	100736273	20992721377	He	he	PPHS1
304953	100736273	20992721378	was	be	VBDZ
304953	100736273	20992721379	eventually	eventually	RR
304953	100736273	20992721380	treated	treat	VVN
304953	100736273	20992721381	with	with	IW
304953	100736273	20992721382	androgen-deprivation		JJ
304953	100736273	20992721383	therapy	therapy	NN1
304953	100736273	20992721384	,	,	,
304953	100736273	20992721385	a	a	AT1
304953	100736273	20992721386	hormonal	hormonal	JJ
304953	100736273	20992721387	approach	approach	NN1
304953	100736273	20992721388	to	to	II
304953	100736273	20992721389	treating	treat	VVG
304953	100736273	20992721390	recurrent	recurrent	JJ_NN1
304953	100736273	20992721391	prostate	prostate	NN1
304953	100736273	20992721392	cancer	cancer	NN1
304953	100736273	20992721393	.	.	.
304953	100736273	20992721394	<p>		NULL
304953	100736273	20992721395	Dr.		NNB
304953	100736273	20992721396	Drabick		NP1
304953	100736273	20992721397	speculates	speculate	VVZ
304953	100736273	20992721398	that	that	CST
304953	100736273	20992721399	the	the	AT
304953	100736273	20992721400	man	man	NN1
304953	100736273	20992721401	absorbed	absorbed	JJ_VVD_VVN
304953	100736273	20992721402	testosterone	testosterone	NN1
304953	100736273	20992721403	into	into	II
304953	100736273	20992721404	his	his	APPGE
304953	100736273	20992721405	penis	penis	NN1
304953	100736273	20992721406	during	during	II
304953	100736273	20992721407	intercourse	intercourse	NN1
304953	100736273	20992721408	.	.	.
304953	100736273	20992721409	Could	could	VM
304953	100736273	20992721410	@		II
304953	100736273	20992721411	@		II
304953	100736273	20992721412	@		II
304953	100736273	20992721413	@		II
304953	100736273	20992721414	@		II
304953	100736273	20992721415	@		II
304953	100736273	20992721416	@		II
304953	100736273	20992721417	@		II
304953	100736273	20992721418	@		II
304953	100736273	20992721419	@		II
304953	100736273	20992721420	He	he	PPHS1
304953	100736273	20992721421	was	be	VBDZ
304953	100736273	20992721422	headed	head	VVN
304953	100736273	20992721423	down	down	RP_II@
304953	100736273	20992721424	that	that	DD1_CST
304953	100736273	20992721425	path	path	NN1
304953	100736273	20992721426	anyway	anyway	RR
304953	100736273	20992721427	,	,	,
304953	100736273	20992721428	but	but	CCB
304953	100736273	20992721429	it	it	PPH1
304953	100736273	20992721430	might	might	VM
304953	100736273	20992721431	have	have	VHI
304953	100736273	20992721432	sped	speed	VVN@
304953	100736273	20992721433	it	it	PPH1
304953	100736273	20992721434	along.the		NNU
304953	100736273	20992721435	blood	blood	NN1
304953	100736273	20992721436	levels	level	NN2
304953	100736273	20992721437	of	of	IO
304953	100736273	20992721438	testosterone	testosterone	NN1
304953	100736273	20992721439	were	be	VBDR
304953	100736273	20992721440	far	far	RG
304953	100736273	20992721441	higher	high	JJR_RRR@
304953	100736273	20992721442	than	than	CSN
304953	100736273	20992721443	what	what	DDQ
304953	100736273	20992721444	his	his	APPGE
304953	100736273	20992721445	testicles	testicle	NN2
304953	100736273	20992721446	could	could	VM
304953	100736273	20992721447	produce	produce	VVI
304953	100736273	20992721448	,	,	,
304953	100736273	20992721449	"	"	"
304953	100736273	20992721450	said	say	VVD
304953	100736273	20992721451	Dr.		NNB
304953	100736273	20992721452	Drabick		NP1
304953	100736273	20992721453	.	.	.
304953	100736273	20992721454	<p>		NULL
304953	100736273	20992721455	The	the	AT
304953	100736273	20992721456	FDA	fda	NN1_NP1
304953	100736273	20992721457	has	have	VHZ
304953	100736273	20992721458	never	never	RR
304953	100736273	20992721459	approved	approve	VVN
304953	100736273	20992721460	any	any	DD
304953	100736273	20992721461	testosterone-containing		JJ_NN1
304953	100736273	20992721462	products	product	NN2
304953	100736273	20992721463	,	,	,
304953	100736273	20992721464	including	including	II_VVG@
304953	100736273	20992721465	topical	topical	JJ
304953	100736273	20992721466	testosterone	testosterone	NN1
304953	100736273	20992721467	formulations	formulation	NN2
304953	100736273	20992721468	,	,	,
304953	100736273	20992721469	for	for	IF
304953	100736273	20992721470	non-cancer	non-cancer	JJ_NN1
304953	100736273	20992721471	uses	use	NN2_VVZ
304953	100736273	20992721472	in	in	II
304953	100736273	20992721473	women	woman	NN2
304953	100736273	20992721474	.	.	.
304953	100736273	20992721475	At	at	II
304953	100736273	20992721476	the	the	AT
304953	100736273	20992721477	same	same	DA
304953	100736273	20992721478	time	time	NNT1
304953	100736273	20992721479	,	,	,
304953	100736273	20992721480	the	the	AT
304953	100736273	20992721481	FDA	fda	NN1_NP1
304953	100736273	20992721482	does	do	VDZ
304953	100736273	20992721483	n't 	n't	XX
304953	100736273	20992721484	regulate	regulate	VVI
304953	100736273	20992721485	off-label	off-label	JJ_NN1
304953	100736273	20992721486	uses	use	NN2_VVZ
304953	100736273	20992721487	for	for	IF
304953	100736273	20992721488	lawfully	lawfully	RR
304953	100736273	20992721489	marketed	market	VVN_VVD
304953	100736273	20992721490	medications	medication	NN2
304953	100736273	20992721491	,	,	,
304953	100736273	20992721492	like	like	II_JJ@
304953	100736273	20992721493	testosterone	testosterone	NN1
304953	100736273	20992721494	.	.	.
304953	100736273	20992721495	So	so	RR
304953	100736273	20992721496	women	woman	NN2
304953	100736273	20992721497	can	can	VM
304953	100736273	20992721498	,	,	,
304953	100736273	20992721499	and	and	CC
304953	100736273	20992721500	do	do	VD0
304953	100736273	20992721501	,	,	,
304953	100736273	20992721502	easily	easily	RR
304953	100736273	20992721503	and	and	CC
304953	100736273	20992721504	legally	legally	RR
304953	100736273	20992721505	obtain	obtain	VV0
304953	100736273	20992721506	testosterone-based	testosterone-based	JJ_NN1
304953	100736273	20992721507	creams	cream	NN2
304953	100736273	20992721508	.	.	.
304953	100736273	20992721509	<p>		NULL
304953	100736273	20992721510	Dr.		NNB
304953	100736273	20992721511	Marc	marc	NP1
304953	100736273	20992721512	Garnick		NP1
304953	100736273	20992721513	,	,	,
304953	100736273	20992721514	the	the	AT
304953	100736273	20992721515	Gorman	gorman	NN1_NP1
304953	100736273	20992721516	Brothers	brother	NN2
304953	100736273	20992721517	Professor	professor	NN1
304953	100736273	20992721518	of	of	IO
304953	100736273	20992721519	Medicine	medicine	NN1
304953	100736273	20992721520	at	at	II
304953	100736273	20992721521	Harvard	harvard	NP1
304953	100736273	20992721522	Medical	medical	JJ
304953	100736273	20992721523	School	school	NN1
304953	100736273	20992721524	and	and	CC
304953	100736273	20992721525	Beth	beth	NP1
304953	100736273	20992721526	Israel	israel	NP1
304953	100736273	20992721527	Deaconess	deaconess	NN1
304953	100736273	20992721528	Medical	medical	JJ
304953	100736273	20992721529	Center	center	NN1
304953	100736273	20992721530	,	,	,
304953	100736273	20992721531	says	say	VVZ
304953	100736273	20992721532	the	the	AT
304953	100736273	20992721533	case	case	NN1
304953	100736273	20992721534	report	report	NN1
304953	100736273	20992721535	underscores	underscore	VVZ
304953	100736273	20992721536	the	the	AT
304953	100736273	20992721537	need	need	NN1
304953	100736273	20992721538	not	not	XX
304953	100736273	20992721539	just	just	RR
304953	100736273	20992721540	for	for	IF
304953	100736273	20992721541	a	a	AT1
304953	100736273	20992721542	mans	man	NN2
304953	100736273	20992721543	detailed	detailed	JJ_VVD@_VVN@
304953	100736273	20992721544	medical	medical	JJ
304953	100736273	20992721545	history	history	NN1
304953	100736273	20992721546	,	,	,
304953	100736273	20992721547	but	but	CCB
304953	100736273	20992721548	also	also	RR
304953	100736273	20992721549	for	for	IF
304953	100736273	20992721550	a	a	AT1
304953	100736273	20992721551	review	review	NN1
304953	100736273	20992721552	of	of	IO
304953	100736273	20992721553	medications	medication	NN2
304953	100736273	20992721554	used	use	VVN
304953	100736273	20992721555	by	by	II
304953	100736273	20992721556	a	a	AT1
304953	100736273	20992721557	spouse	spouse	NN1
304953	100736273	20992721558	or	or	CC
304953	100736273	20992721559	partner	partner	NN1
304953	100736273	20992721560	,	,	,
304953	100736273	20992721561	including	including	II_VVG@
304953	100736273	20992721562	those	those	DD2
304953	100736273	20992721563	that	that	CST
304953	100736273	20992721564	can	can	VM
304953	100736273	20992721565	be	be	VBI
304953	100736273	20992721566	applied	apply	VVN
304953	100736273	20992721567	topically	topically	RR
304953	100736273	20992721568	or	or	CC
304953	100736273	20992721569	transvaginally		RR
304953	100736273	20992721570	.	.	.
304953	100736273	20992721571	<p>		NULL
304953	100736273	20992721572	"	"	"
304953	100736273	20992721573	Whether	whether	CSW
304953	100736273	20992721574	this	this	DD1
304953	100736273	20992721575	exposure	exposure	NN1
304953	100736273	20992721576	was	be	VBDZ
304953	100736273	20992721577	in	in	II_RP@
304953	100736273	20992721578	any	any	DD
304953	100736273	20992721579	way	way	NN1
304953	100736273	20992721580	contributing	contribute	VVG
304953	100736273	20992721581	to	to	II
304953	100736273	20992721582	the	the	AT
304953	100736273	20992721583	patients	patient	NN2
304953	100736273	20992721584	clinical	clinical	JJ
304953	100736273	20992721585	course	course	NN1
304953	100736273	20992721586	,	,	,
304953	100736273	20992721587	is	be	VBZ
304953	100736273	20992721588	,	,	,
304953	100736273	20992721589	of	of	RR21
304953	100736273	20992721590	course	course	RR22
304953	100736273	20992721591	,	,	,
304953	100736273	20992721592	speculative	speculative	JJ
304953	100736273	20992721593	,	,	,
304953	100736273	20992721594	"	"	"
304953	100736273	20992721595	Garnick		NP1
304953	100736273	20992721596	said	say	VVD
304953	100736273	20992721597	.	.	.
304953	100736273	20992721598	"	"	"
304953	100736273	20992721599	But	but	CCB
304953	100736273	20992721600	it	it	PPH1
304953	100736273	20992721601	may	may	VM
304953	100736273	20992721602	have	have	VHI
304953	100736273	20992721603	indeed	indeed	RR
304953	100736273	20992721604	contributed	contribute	VVN_VVD
304953	100736273	20992721605	to	to	II
304953	100736273	20992721606	the	the	AT
304953	100736273	20992721607	elevated	elevated	JJ
304953	100736273	20992721608	testosterone	testosterone	NN1
304953	100736273	20992721609	value	value	NN1
304953	100736273	20992721610	that	that	CST
304953	100736273	20992721611	Dr.		NNB
304953	100736273	20992721612	Drabick		NP1
304953	100736273	20992721613	measured	measure	VVD
304953	100736273	20992721614	.	.	.
304953	100736273	20992721615	"	"	"
304953	100736274	20992721635	@@##	----------	----------
304953	100736274	20992721636	@@100736274		FO
304953	100736274	20992721637	@4936274/		VV0_NN1
304953	100736274	20992721638	46989		MC
304953	100736274	20992721639	@qwx906989		FO
304953	100736274	20992721640	<p>		NULL
304953	100736274	20992721641	As	as	II_CSA
304953	100736274	20992721642	a	a	AT1
304953	100736274	20992721643	nutrient	nutrient	NN1
304953	100736274	20992721644	,	,	,
304953	100736274	20992721645	vitamin	vitamin	NN1
304953	100736274	20992721646	D	d	ZZ1
304953	100736274	20992721647	is	be	VBZ
304953	100736274	20992721648	surely	surely	RR
304953	100736274	20992721649	essential	essential	JJ
304953	100736274	20992721650	"	"	"
304953	100736274	20992721651	without	without	IW
304953	100736274	20992721652	it	it	PPH1
304953	100736274	20992721653	,	,	,
304953	100736274	20992721654	we	we	PPIS2
304953	100736274	20992721655	could n't		VV0
304953	100736274	20992721656	absorb	absorb	VV0
304953	100736274	20992721657	the	the	AT
304953	100736274	20992721658	calcium	calcium	NN1
304953	100736274	20992721659	and	and	CC
304953	100736274	20992721660	phosphorus	phosphorus	NN1
304953	100736274	20992721661	we	we	PPIS2
304953	100736274	20992721662	need	need	VV0
304953	100736274	20992721663	for	for	IF
304953	100736274	20992721664	healthy	healthy	JJ
304953	100736274	20992721665	bones	bone	NN2
304953	100736274	20992721666	.	.	.
304953	100736274	20992721667	But	but	CCB
304953	100736274	20992721668	research	research	VV0@_NN1
304953	100736274	20992721669	increasingly	increasingly	RR
304953	100736274	20992721670	points	point	VVZ
304953	100736274	20992721671	to	to	II
304953	100736274	20992721672	other	other	JJ
304953	100736274	20992721673	benefits	benefit	NN2
304953	100736274	20992721674	from	from	II
304953	100736274	20992721675	vitamin	vitamin	NN1
304953	100736274	20992721676	D.		NP1
304953	100736274	20992721677	One	one	MC1
304953	100736274	20992721678	of	of	IO
304953	100736274	20992721679	these	these	DD2
304953	100736274	20992721680	is	be	VBZ
304953	100736274	20992721681	possible	possible	JJ
304953	100736274	20992721682	protection	protection	NN1
304953	100736274	20992721683	against	against	II
304953	100736274	20992721684	cancer	cancer	NN1
304953	100736274	20992721685	.	.	.
304953	100736274	20992721686	Scientists	scientist	NN2
304953	100736274	20992721687	are	be	VBR
304953	100736274	20992721688	finding	find	VVG
304953	100736274	20992721689	that	that	DD1_CST
304953	100736274	20992721690	vitamin	vitamin	NN1
304953	100736274	20992721691	D	d	ZZ1
304953	100736274	20992721692	can	can	VM
304953	100736274	20992721693	slow	slow	VVI
304953	100736274	20992721694	the	the	AT
304953	100736274	20992721695	growth	growth	NN1
304953	100736274	20992721696	of	of	IO
304953	100736274	20992721697	abnormal	abnormal	JJ
304953	100736274	20992721698	cells	cell	NN2
304953	100736274	20992721699	.	.	.
304953	100736274	20992721700	It	it	PPH1
304953	100736274	20992721701	might	might	VM
304953	100736274	20992721702	also	also	RR
304953	100736274	20992721703	starve	starve	VVI
304953	100736274	20992721704	tumors	tumor	NN2
304953	100736274	20992721705	by	by	II
304953	100736274	20992721706	making	make	VVG
304953	100736274	20992721707	it	it	PPH1
304953	100736274	20992721708	difficult	difficult	JJ
304953	100736274	20992721709	for	for	IF
304953	100736274	20992721710	them	them	PPHO2
304953	100736274	20992721711	to	to	TO
304953	100736274	20992721712	sprout	sprout	VVI
304953	100736274	20992721713	new	new	JJ
304953	100736274	20992721714	blood	blood	NN1
304953	100736274	20992721715	vessels	vessel	NN2
304953	100736274	20992721716	.	.	.
304953	100736274	20992721717	<p>		NULL
304953	100736274	20992721718	"	"	"
304953	100736274	20992721719	This	this	DD1
304953	100736274	20992721720	study	study	NN1
304953	100736274	20992721721	adds	add	VVZ
304953	100736274	20992721722	to	to	II
304953	100736274	20992721723	the	the	AT
304953	100736274	20992721724	growing	growing	JJ
304953	100736274	20992721725	body	body	NN1
304953	100736274	20992721726	of	of	IO
304953	100736274	20992721727	sound	sound	NN1_JJ@
304953	100736274	20992721728	information	information	NN1
304953	100736274	20992721729	that	that	CST_DD1
304953	100736274	20992721730	vitamin	vitamin	NN1
304953	100736274	20992721731	D	d	ZZ1
304953	100736274	20992721732	may	may	VM
304953	100736274	20992721733	be	be	VBI
304953	100736274	20992721734	important	important	JJ
304953	100736274	20992721735	to	to	II
304953	100736274	20992721736	several	several	DA2
304953	100736274	20992721737	areas	area	NN2
304953	100736274	20992721738	of	of	IO
304953	100736274	20992721739	health	health	NN1
304953	100736274	20992721740	,	,	,
304953	100736274	20992721741	cancer	cancer	NN1
304953	100736274	20992721742	being	be	VBG
304953	100736274	20992721743	one	one	MC1
304953	100736274	20992721744	of	of	IO
304953	100736274	20992721745	them	them	PPHO2
304953	100736274	20992721746	,	,	,
304953	100736274	20992721747	"	"	"
304953	100736274	20992721748	says	say	VVZ
304953	100736274	20992721749	prostate	prostate	NN1
304953	100736274	20992721750	cancer	cancer	NN1
304953	100736274	20992721751	expert	expert	NN1
304953	100736274	20992721752	Dr.		NNB
304953	100736274	20992721753	Marc	marc	NP1
304953	100736274	20992721754	Garnick		NP1
304953	100736274	20992721755	,	,	,
304953	100736274	20992721756	the	the	AT
304953	100736274	20992721757	Gorman	gorman	NN1_NP1
304953	100736274	20992721758	Brothers	brother	NN2
304953	100736274	20992721759	Professor	professor	NN1
304953	100736274	20992721760	of	of	IO
304953	100736274	20992721761	Medicine	medicine	NN1
304953	100736274	20992721762	at	at	II
304953	100736274	20992721763	Harvard-affiliated	harvard-affiliated	JJ_NN1
304953	100736274	20992721764	Beth	beth	NP1
304953	100736274	20992721765	Israel	israel	NP1
304953	100736274	20992721766	Deaconess	deaconess	NN1
304953	100736274	20992721767	Medical	medical	JJ
304953	100736274	20992721768	Center	center	NN1
304953	100736274	20992721769	and	and	CC
304953	100736274	20992721770	editor	editor	NN1
304953	100736274	20992721771	in	in	II
304953	100736274	20992721772	chief	chief	NN1
304953	100736274	20992721773	of	of	IO
304953	100736274	20992721774	Harvards	harvard	NP2
304953	100736274	20992721775	Annual	annual	JJ
304953	100736274	20992721776	Report	report	NN1
304953	100736274	20992721777	on	on	II
304953	100736274	20992721778	Prostate	prostate	NN1
304953	100736274	20992721779	Diseases	disease	NN2
304953	100736274	20992721780	.	.	.
304953	100736274	20992721781	"	"	"
304953	100736274	20992721782	In	in	II
304953	100736274	20992721783	my	my	APPGE
304953	100736274	20992721784	practice	practice	NN1
304953	100736274	20992721785	,	,	,
304953	100736274	20992721786	vitamin	vitamin	NN1
304953	100736274	20992721787	D	d	ZZ1
304953	100736274	20992721788	,	,	,
304953	100736274	20992721789	and	and	CC
304953	100736274	20992721790	if	if	CS_CSW@
304953	100736274	20992721791	necessary	necessary	JJ
304953	100736274	20992721792	,	,	,
304953	100736274	20992721793	supplemental	supplemental	JJ
304953	100736274	20992721794	calcium	calcium	NN1
304953	100736274	20992721795	in	in	II
304953	100736274	20992721796	appropriate	appropriate	JJ
304953	100736274	20992721797	doses	dose	NN2
304953	100736274	20992721798	is	be	VBZ
304953	100736274	20992721799	generally	generally	RR
304953	100736274	20992721800	a	a	AT1
304953	100736274	20992721801	sound	sound	NN1_JJ@
304953	100736274	20992721802	recommendation	recommendation	NN1
304953	100736274	20992721803	to	to	TO
304953	100736274	20992721804	consider	consider	VVI
304953	100736274	20992721805	.	.	.
304953	100736274	20992721806	"	"	"
304953	100736274	20992721807	<p>		NULL
304953	100736274	20992721808	During	during	II
304953	100736274	20992721809	the	the	AT
304953	100736274	20992721810	study	study	NN1
304953	100736274	20992721811	,	,	,
304953	100736274	20992721812	investigators	investigator	NN2
304953	100736274	20992721813	measured	measure	VVD_VVN
304953	100736274	20992721814	blood	blood	NN1
304953	100736274	20992721815	levels	level	NN2
304953	100736274	20992721816	of	of	IO
304953	100736274	20992721817	vitamin	vitamin	NN1
304953	100736274	20992721818	D	d	ZZ1
304953	100736274	20992721819	in	in	II
304953	100736274	20992721820	nearly	nearly	RR
304953	100736274	20992721821	700	700	MC
304953	100736274	20992721822	men	man	NN2
304953	100736274	20992721823	who	who	PNQS
304953	100736274	20992721824	had	have	VHD
304953	100736274	20992721825	first	first	MD
304953	100736274	20992721826	prostate	prostate	NN1
304953	100736274	20992721827	@		II
304953	100736274	20992721828	@		II
304953	100736274	20992721829	@		II
304953	100736274	20992721830	@		II
304953	100736274	20992721831	@		II
304953	100736274	20992721832	@		II
304953	100736274	20992721833	@		II
304953	100736274	20992721834	@		II
304953	100736274	20992721835	@		II
304953	100736274	20992721836	@		II
304953	100736274	20992721837	the	the	AT
304953	100736274	20992721838	men	man	NN2
304953	100736274	20992721839	were	be	VBDR
304953	100736274	20992721840	of	of	IO
304953	100736274	20992721841	European	european	JJ
304953	100736274	20992721842	descent	descent	NN1
304953	100736274	20992721843	,	,	,
304953	100736274	20992721844	while	while	CS
304953	100736274	20992721845	the	the	AT
304953	100736274	20992721846	other	other	JJ
304953	100736274	20992721847	half	half	NN1@_DB
304953	100736274	20992721848	were	be	VBDR
304953	100736274	20992721849	of	of	IO
304953	100736274	20992721850	African	african	JJ
304953	100736274	20992721851	American	american	JJ
304953	100736274	20992721852	descent	descent	NN1
304953	100736274	20992721853	.	.	.
304953	100736274	20992721854	<p>		NULL
304953	100736274	20992721855	Low	low	JJ
304953	100736274	20992721856	vitamin	vitamin	NN1
304953	100736274	20992721857	D	d	ZZ1
304953	100736274	20992721858	levels	level	NN2
304953	100736274	20992721859	were	be	VBDR
304953	100736274	20992721860	associated	associate	VVN
304953	100736274	20992721861	with	with	IW
304953	100736274	20992721862	high-grade	high-grade	NN1_JJ
304953	100736274	20992721863	,	,	,
304953	100736274	20992721864	more	more	RGR
304953	100736274	20992721865	advanced	advanced	JJ
304953	100736274	20992721866	tumors	tumor	NN2
304953	100736274	20992721867	in	in	II
304953	100736274	20992721868	both	both	DB2
304953	100736274	20992721869	groups	group	NN2
304953	100736274	20992721870	.	.	.
304953	100736274	20992721871	In	in	RR21
304953	100736274	20992721872	addition	addition	RR22
304953	100736274	20992721873	,	,	,
304953	100736274	20992721874	among	among	II
304953	100736274	20992721875	African	african	JJ
304953	100736274	20992721876	American	american	JJ
304953	100736274	20992721877	men	man	NN2
304953	100736274	20992721878	low	low	JJ
304953	100736274	20992721879	vitamin	vitamin	NN1
304953	100736274	20992721880	D	d	ZZ1_NP1@
304953	100736274	20992721881	was	be	VBDZ
304953	100736274	20992721882	also	also	RR
304953	100736274	20992721883	linked	link	VVN
304953	100736274	20992721884	to	to	II
304953	100736274	20992721885	a	a	AT1
304953	100736274	20992721886	higher	high	JJR
304953	100736274	20992721887	risk	risk	NN1
304953	100736274	20992721888	of	of	IO
304953	100736274	20992721889	developing	developing	JJ_VVG
304953	100736274	20992721890	prostate	prostate	NN1
304953	100736274	20992721891	cancer	cancer	NN1
304953	100736274	20992721892	.	.	.
304953	100736274	20992721893	That	that	DD1_CST
304953	100736274	20992721894	was n't		NN1_VV0
304953	100736274	20992721895	true	true	JJ_NN1%
304953	100736274	20992721896	among	among	II
304953	100736274	20992721897	European	european	JJ
304953	100736274	20992721898	American	american	JJ
304953	100736274	20992721899	men	man	NN2
304953	100736274	20992721900	,	,	,
304953	100736274	20992721901	for	for	IF
304953	100736274	20992721902	whom	whom	PNQO
304953	100736274	20992721903	low	low	JJ
304953	100736274	20992721904	vitamin	vitamin	NN1
304953	100736274	20992721905	D	d	ZZ1_NP1@
304953	100736274	20992721906	was	be	VBDZ
304953	100736274	20992721907	linked	link	VVN_JJ
304953	100736274	20992721908	only	only	JJ
304953	100736274	20992721909	to	-to	II
304953	100736274	20992721910	more	more	RGR
304953	100736274	20992721911	aggressive	aggressive	JJ
304953	100736274	20992721912	tumors	tumor	NN2
304953	100736274	20992721913	.	.	.
304953	100736274	20992721914	<p>		NULL
304953	100736274	20992721915	A	a	AT1
304953	100736274	20992721916	few	few	DA2
304953	100736274	20992721917	foods	food	NN2
304953	100736274	20992721918	contain	contain	VV0
304953	100736274	20992721919	vitamin	vitamin	NN1
304953	100736274	20992721920	D	d	ZZ1
304953	100736274	20992721921	,	,	,
304953	100736274	20992721922	especially	especially	RR
304953	100736274	20992721923	some	some	DD
304953	100736274	20992721924	types	type	NN2
304953	100736274	20992721925	of	of	IO
304953	100736274	20992721926	fatty	fatty	JJ_NN1
304953	100736274	20992721927	fish	fish	NN
304953	100736274	20992721928	,	,	,
304953	100736274	20992721929	eggs	egg	NN2
304953	100736274	20992721930	,	,	,
304953	100736274	20992721931	some	some	DD
304953	100736274	20992721932	types	type	NN2
304953	100736274	20992721933	of	of	IO
304953	100736274	20992721934	mushroom	mushroom	NN1
304953	100736274	20992721935	,	,	,
304953	100736274	20992721936	and	and	CC
304953	100736274	20992721937	foods	food	NN2
304953	100736274	20992721938	fortified	fortify	VVN
304953	100736274	20992721939	with	with	IW
304953	100736274	20992721940	the	the	AT
304953	100736274	20992721941	vitamin	vitamin	NN1
304953	100736274	20992721942	,	,	,
304953	100736274	20992721943	like	like	II_JJ@
304953	100736274	20992721944	milk	milk	NN1
304953	100736274	20992721945	and	and	CC
304953	100736274	20992721946	other	other	JJ
304953	100736274	20992721947	dairy	dairy	NN1
304953	100736274	20992721948	foods	food	NN2
304953	100736274	20992721949	.	.	.
304953	100736274	20992721950	Another	another	DD1
304953	100736274	20992721951	way	way	NN1
304953	100736274	20992721952	to	to	TO
304953	100736274	20992721953	get	get	VVI
304953	100736274	20992721954	vitamin	vitamin	NN1
304953	100736274	20992721955	D	d	ZZ1
304953	100736274	20992721956	is	be	VBZ
304953	100736274	20992721957	to	to	TO
304953	100736274	20992721958	make	make	VVI
304953	100736274	20992721959	it	it	PPH1
304953	100736274	20992721960	yourself	yourself	PPX1
304953	100736274	20992721961	by	by	II
304953	100736274	20992721962	getting	get	VVG
304953	100736274	20992721963	some	some	DD
304953	100736274	20992721964	sunlight	sunlight	NN1
304953	100736274	20992721965	.	.	.
304953	100736274	20992721966	<p>		NULL
304953	100736274	20992721967	Men	man	NN2
304953	100736274	20992721968	with	with	IW
304953	100736274	20992721969	dark	dark	JJ
304953	100736274	20992721970	skin	skin	NN1
304953	100736274	20992721971	absorb	absorb	VV0
304953	100736274	20992721972	less	less	RGR_DAR
304953	100736274	20992721973	ultraviolet	ultraviolet	JJ
304953	100736274	20992721974	light	light	NN1
304953	100736274	20992721975	from	from	II
304953	100736274	20992721976	the	the	AT
304953	100736274	20992721977	sun	sun	NN1
304953	100736274	20992721978	than	than	CSN
304953	100736274	20992721979	men	man	NN2
304953	100736274	20992721980	of	of	IO
304953	100736274	20992721981	a	a	AT1
304953	100736274	20992721982	lighter	light	JJR_NN1
304953	100736274	20992721983	complexion	complexion	NN1
304953	100736274	20992721984	,	,	,
304953	100736274	20992721985	and	and	CC
304953	100736274	20992721986	so	so	RR
304953	100736274	20992721987	tend	tend	VV0
304953	100736274	20992721988	to	to	TO
304953	100736274	20992721989	make	make	VVI
304953	100736274	20992721990	less	less	DAR
304953	100736274	20992721991	vitamin	vitamin	NN1
304953	100736274	20992721992	D.		NP1
304953	100736274	20992721993	This	this	DD1
304953	100736274	20992721994	could	could	VM
304953	100736274	20992721995	explain	explain	VVI
304953	100736274	20992721996	why	why	RRQ
304953	100736274	20992721997	they 're		NN1
304953	100736274	20992721998	also	also	RR
304953	100736274	20992721999	at	at	II
304953	100736274	20992722000	greater	great	JJR
304953	100736274	20992722001	risk	risk	NN1
304953	100736274	20992722002	of	of	IO
304953	100736274	20992722003	prostate	prostate	NN1
304953	100736274	20992722004	cancer	cancer	NN1
304953	100736274	20992722005	,	,	,
304953	100736274	20992722006	the	the	AT
304953	100736274	20992722007	investigators	investigator	NN2
304953	100736274	20992722008	speculated	speculate	VVD
304953	100736274	20992722009	.	.	.
304953	100736274	20992722010	Indeed	indeed	RR
304953	100736274	20992722011	,	,	,
304953	100736274	20992722012	prostate	prostate	NN1
304953	100736274	20992722013	cancer	cancer	NN1
304953	100736274	20992722014	is	be	VBZ
304953	100736274	20992722015	more	more	RGR
304953	100736274	20992722016	common	common	JJ
304953	100736274	20992722017	among	among	II
304953	100736274	20992722018	African	african	JJ
304953	100736274	20992722019	American	american	JJ
304953	100736274	20992722020	men	man	NN2
304953	100736274	20992722021	,	,	,
304953	100736274	20992722022	and	and	CC
304953	100736274	20992722023	their	their	APPGE
304953	100736274	20992722024	death	death	NN1
304953	100736274	20992722025	rates	rate	NN2_VVZ@
304953	100736274	20992722026	from	from	II
304953	100736274	20992722027	@		II
304953	100736274	20992722028	@		II
304953	100736274	20992722029	@		II
304953	100736274	20992722030	@		II
304953	100736274	20992722031	@		II
304953	100736274	20992722032	@		II
304953	100736274	20992722033	@		II
304953	100736274	20992722034	@		II
304953	100736274	20992722035	@		II
304953	100736274	20992722036	@		II
304953	100736274	20992722037	has	have	VHZ
304953	100736274	20992722038	some	some	DD
304953	100736274	20992722039	shortcomings	shortcoming	NN2
304953	100736274	20992722040	,	,	,
304953	100736274	20992722041	including	include	VVG@
304953	100736274	20992722042	that	that	CST
304953	100736274	20992722043	a	a	AT1
304953	100736274	20992722044	one-time	one-time	JJ
304953	100736274	20992722045	vitamin	vitamin	NN1
304953	100736274	20992722046	D	d	ZZ1
304953	100736274	20992722047	measure	measure	NN1_VV0
304953	100736274	20992722048	may	may	VM
304953	100736274	20992722049	not	not	XX
304953	100736274	20992722050	reflect	reflect	VVI
304953	100736274	20992722051	a	a	AT1
304953	100736274	20992722052	chronic	chronic	JJ
304953	100736274	20992722053	deficiency	deficiency	NN1
304953	100736274	20992722054	of	of	IO
304953	100736274	20992722055	the	the	AT
304953	100736274	20992722056	vitamin	vitamin	NN1
304953	100736274	20992722057	.	.	.
304953	100736274	20992722058	But	but	CCB
304953	100736274	20992722059	the	the	AT
304953	100736274	20992722060	findings	finding	NN2
304953	100736274	20992722061	add	add	VV0
304953	100736274	20992722062	to	to	II
304953	100736274	20992722063	mounting	mount	VVG_JJ@
304953	100736274	20992722064	evidence	evidence	NN1
304953	100736274	20992722065	that	that	CST_DD1
304953	100736274	20992722066	vitamin	vitamin	NN1
304953	100736274	20992722067	D	d	ZZ1
304953	100736274	20992722068	helps	help	NN2@_VVZ
304953	100736274	20992722069	protect	protect	VVI
304953	100736274	20992722070	against	against	II
304953	100736274	20992722071	prostate	prostate	NN1
304953	100736274	20992722072	cancer	cancer	NN1
304953	100736274	20992722073	,	,	,
304953	100736274	20992722074	and	and	CC
304953	100736274	20992722075	that	that	CST
304953	100736274	20992722076	a	a	AT1
304953	100736274	20992722077	healthy	healthy	JJ
304953	100736274	20992722078	lifestyle	lifestyle	NN1
304953	100736274	20992722079	that	that	CST_DD1
304953	100736274	20992722080	includes	include	VVZ
304953	100736274	20992722081	safe	safe	JJ
304953	100736274	20992722082	sun	sun	NN1
304953	100736274	20992722083	exposure	exposure	NN1
304953	100736274	20992722084	is	be	VBZ
304953	100736274	20992722085	a	a	AT1
304953	100736274	20992722086	good	good	JJ
304953	100736274	20992722087	way	way	NN1
304953	100736274	20992722088	to	to	TO
304953	100736274	20992722089	lower	lower	VVI
304953	100736274	20992722090	the	the	AT
304953	100736274	20992722091	chance	chance	NN1
304953	100736274	20992722092	of	of	IO
304953	100736274	20992722093	developing	develop	VVG
304953	100736274	20992722094	it	it	PPH1
304953	100736274	20992722095	.	.	.
304953	100736274	20992722096	<p>		NULL
304953	100736274	20992722097	National	national	JJ
304953	100736274	20992722098	guidelines	guideline	NN2
304953	100736274	20992722099	recommend	recommend	VV0
304953	100736274	20992722100	a	a	AT1
304953	100736274	20992722101	daily	daily	JJ
304953	100736274	20992722102	vitamin	vitamin	NN1
304953	100736274	20992722103	D	d	ZZ1
304953	100736274	20992722104	intake	intake	NN1
304953	100736274	20992722105	of	of	IO
304953	100736274	20992722106	600	600	MC
304953	100736274	20992722107	international	international	JJ
304953	100736274	20992722108	units	unit	NN2
304953	100736274	20992722109	for	for	IF
304953	100736274	20992722110	men	man	NN2
304953	100736274	20992722111	up	up	RP
304953	100736274	20992722112	to	to	TO
304953	100736274	20992722113	age	age	VVI
304953	100736274	20992722114	70	70	MC
304953	100736274	20992722115	,	,	,
304953	100736274	20992722116	and	and	CC
304953	100736274	20992722117	800	800	MC
304953	100736274	20992722118	international	international	JJ
304953	100736274	20992722119	units	unit	NN2
304953	100736274	20992722120	thereafter	thereafter	RT
304953	100736274	20992722121	.	.	.
304953	100736275	20992722141	@@##	----------	----------
304953	100736275	20992722142	@@100736275		FO
304953	100736275	20992722143	@4936275/		VV0_NN1
304953	100736275	20992722144	46989		MC
304953	100736275	20992722145	@qwx906989		FO
304953	100736275	20992722146	<p>		NULL
304953	100736275	20992722147	Its	its	APPGE
304953	100736275	20992722148	normal	normal	JJ
304953	100736275	20992722149	for	for	IF
304953	100736275	20992722150	men	man	NN2
304953	100736275	20992722151	to	to	TO
304953	100736275	20992722152	lose	lose	VVI
304953	100736275	20992722153	some	some	DD
304953	100736275	20992722154	physical	physical	JJ
304953	100736275	20992722155	vitality	vitality	NN1
304953	100736275	20992722156	as	as	CSA
304953	100736275	20992722157	they	they	PPHS2
304953	100736275	20992722158	age	age	VV0@
304953	100736275	20992722159	.	.	.
304953	100736275	20992722160	But	but	CCB
304953	100736275	20992722161	a	a	AT1
304953	100736275	20992722162	growing	growing	JJ
304953	100736275	20992722163	number	number	NN1
304953	100736275	20992722164	of	of	IO
304953	100736275	20992722165	men	man	NN2
304953	100736275	20992722166	are	be	VBR
304953	100736275	20992722167	trying	try	VVG
304953	100736275	20992722168	to	to	TO
304953	100736275	20992722169	hold	hold	VVI
304953	100736275	20992722170	on	on	RP_II21
304953	100736275	20992722171	to	to	II_II22
304953	100736275	20992722172	their	their	APPGE
304953	100736275	20992722173	youthful	youthful	JJ
304953	100736275	20992722174	vigor	vigor	NN1
304953	100736275	20992722175	by	by	II
304953	100736275	20992722176	taking	take	VVG
304953	100736275	20992722177	testosterone	testosterone	NN1
304953	100736275	20992722178	.	.	.
304953	100736275	20992722179	Marketers	marketer	NN2
304953	100736275	20992722180	hawk	hawk	VV0@_NN1
304953	100736275	20992722181	testosterone	testosterone	NN1
304953	100736275	20992722182	with	with	IW
304953	100736275	20992722183	the	the	AT
304953	100736275	20992722184	promise	promise	NN1
304953	100736275	20992722185	of	of	IO
304953	100736275	20992722186	a	a	AT1
304953	100736275	20992722187	better	better	JJR
304953	100736275	20992722188	sex	sex	NN1
304953	100736275	20992722189	drive	drive	NN1_VV0
304953	100736275	20992722190	,	,	,
304953	100736275	20992722191	increased	increased	JJ_VVD
304953	100736275	20992722192	energy	energy	NN1
304953	100736275	20992722193	,	,	,
304953	100736275	20992722194	more	more	DAR
304953	100736275	20992722195	muscle	muscle	NN1
304953	100736275	20992722196	mass	mass	NN1
304953	100736275	20992722197	and	and	CC
304953	100736275	20992722198	other	other	JJ
304953	100736275	20992722199	age-defying	age-defying	JJ_NN1
304953	100736275	20992722200	benefits	benefit	NN2
304953	100736275	20992722201	.	.	.
304953	100736275	20992722202	That 's		NN2
304953	100736275	20992722203	been	be	VBN
304953	100736275	20992722204	a	a	AT1
304953	100736275	20992722205	successful	successful	JJ
304953	100736275	20992722206	strategy	strategy	NN1
304953	100736275	20992722207	.	.	.
304953	100736275	20992722208	Fueled	fuel	VVN
304953	100736275	20992722209	by	by	II
304953	100736275	20992722210	direct-to-consumer	direct-to-consumer	JJ_NN1
304953	100736275	20992722211	advertising	advertising	NN1
304953	100736275	20992722212	,	,	,
304953	100736275	20992722213	the	the	AT
304953	100736275	20992722214	number	number	NN1
304953	100736275	20992722215	of	of	IO
304953	100736275	20992722216	American	american	JJ
304953	100736275	20992722217	men	man	NN2
304953	100736275	20992722218	with	with	IW
304953	100736275	20992722219	prescriptions	prescription	NN2
304953	100736275	20992722220	for	for	IF
304953	100736275	20992722221	testosterone	testosterone	NN1
304953	100736275	20992722222	surged	surge	VVD_VVN@
304953	100736275	20992722223	from	from	II
304953	100736275	20992722224	1.3	-1.3	MC
304953	100736275	20992722225	million	million	NNO
304953	100736275	20992722226	in	in	II
304953	100736275	20992722227	2011	2011	MC
304953	100736275	20992722228	to	to	II
304953	100736275	20992722229	2.3	2.3	MC
304953	100736275	20992722230	million	million	NNO
304953	100736275	20992722231	in	in	II
304953	100736275	20992722232	2013	2013	MC
304953	100736275	20992722233	,	,	,
304953	100736275	20992722234	mostly	mostly	RR
304953	100736275	20992722235	in	in	II
304953	100736275	20992722236	the	the	AT
304953	100736275	20992722237	40-64	40-64	MCMC
304953	100736275	20992722238	year	year	NNT1
304953	100736275	20992722239	age	age	NN1
304953	100736275	20992722240	group	group	NN1
304953	100736275	20992722241	.	.	.
304953	100736275	20992722242	<p>		NULL
304953	100736275	20992722243	The	the	AT
304953	100736275	20992722244	Food	food	NN1
304953	100736275	20992722245	and	and	CC
304953	100736275	20992722246	Drug	drug	NN1
304953	100736275	20992722247	Administration	administration	NN1
304953	100736275	20992722248	(	(	(
304953	100736275	20992722249	FDA	fda	NP1
304953	100736275	20992722250	)	)	)
304953	100736275	20992722251	has	have	VHZ
304953	100736275	20992722252	approved	approve	VVN
304953	100736275	20992722253	testosterone	testosterone	NN1
304953	100736275	20992722254	products	product	NN2
304953	100736275	20992722255	only	only	JJ
304953	100736275	20992722256	for	-for	IF
304953	100736275	20992722257	men	man	NN2
304953	100736275	20992722258	who	who	PNQS
304953	100736275	20992722259	do	do	VD0
304953	100736275	20992722260	n't 	n't	XX
304953	100736275	20992722261	make	make	VVI
304953	100736275	20992722262	enough	enough	DD
304953	100736275	20992722263	of	of	IO
304953	100736275	20992722264	the	the	AT
304953	100736275	20992722265	hormone	hormone	NN1
304953	100736275	20992722266	.	.	.
304953	100736275	20992722267	These	these	DD2
304953	100736275	20992722268	men	man	NN2
304953	100736275	20992722269	have	have	VH0
304953	100736275	20992722270	a	a	AT1
304953	100736275	20992722271	clinically	clinically	RR
304953	100736275	20992722272	diagnosable	diagnosable	JJ
304953	100736275	20992722273	condition	condition	NN1
304953	100736275	20992722274	called	call	VVN_VVD@
304953	100736275	20992722275	hypogonadism	hypogonadism	NN1
304953	100736275	20992722276	,	,	,
304953	100736275	20992722277	characterized	characterize	VVN
304953	100736275	20992722278	by	by	II
304953	100736275	20992722279	testosterone	testosterone	NN1
304953	100736275	20992722280	levels	level	NN2_VVZ%
304953	100736275	20992722281	that	that	CST
304953	100736275	20992722282	are	be	VBR
304953	100736275	20992722283	below	below	RG
304953	100736275	20992722284	normal	normal	JJ
304953	100736275	20992722285	,	,	,
304953	100736275	20992722286	usually	usually	RR
304953	100736275	20992722287	meaning	mean	VVG
304953	100736275	20992722288	less	less	DAR
304953	100736275	20992722289	than	than	CSN
304953	100736275	20992722290	300	300	MC
304953	100736275	20992722291	nanograms	nanogram	NN2
304953	100736275	20992722292	of	of	IO
304953	100736275	20992722293	testosterone	testosterone	NN1
304953	100736275	20992722294	per	per	II
304953	100736275	20992722295	deciliter	deciliter	NN1
304953	100736275	20992722296	of	of	IO
304953	100736275	20992722297	blood	blood	NN1
304953	100736275	20992722298	.	.	.
304953	100736275	20992722299	Testosterone	testosterone	NN1
304953	100736275	20992722300	supplements	supplement	NN2
304953	100736275	20992722301	can	can	VM
304953	100736275	20992722302	relieve	relieve	VVI
304953	100736275	20992722303	symptoms	symptom	NN2
304953	100736275	20992722304	in	in	II
304953	100736275	20992722305	these	these	DD2
304953	100736275	20992722306	men	man	NN2
304953	100736275	20992722307	,	,	,
304953	100736275	20992722308	such	such	II21
304953	100736275	20992722309	as	as	II22
304953	100736275	20992722310	erectile	erectile	JJ
304953	100736275	20992722311	dysfunction	dysfunction	NN1
304953	100736275	20992722312	,	,	,
304953	100736275	20992722313	low	low	JJ
304953	100736275	20992722314	energy	energy	NN1
304953	100736275	20992722315	levels	level	NN2
304953	100736275	20992722316	,	,	,
304953	100736275	20992722317	decreased	decrease	VVD_JJ@_VVN
304953	100736275	20992722318	muscle	muscle	NN1
304953	100736275	20992722319	mass	mass	NN1
304953	100736275	20992722320	,	,	,
304953	100736275	20992722321	and	and	CC
304953	100736275	20992722322	poor	poor	JJ
304953	100736275	20992722323	bone	bone	NN1
304953	100736275	20992722324	strength	strength	NN1
304953	100736275	20992722325	.	.	.
304953	100736275	20992722326	<p>		NULL
304953	100736275	20992722327	But	but	CCB
304953	100736275	20992722328	mounting	mount	VVG_JJ@
304953	100736275	20992722329	evidence	evidence	NN1
304953	100736275	20992722330	suggests	suggest	VVZ
304953	100736275	20992722331	that	that	DD1_CST
304953	100736275	20992722332	testosterone	testosterone	NN1
304953	100736275	20992722333	@		II
304953	100736275	20992722334	@		II
304953	100736275	20992722335	@		II
304953	100736275	20992722336	@		II
304953	100736275	20992722337	@		II
304953	100736275	20992722338	@		II
304953	100736275	20992722339	@		II
304953	100736275	20992722340	@		II
304953	100736275	20992722341	@		II
304953	100736275	20992722342	@		II
304953	100736275	20992722343	and	and	CC
304953	100736275	20992722344	strokes	stroke	NN2_VVZ
304953	100736275	20992722345	,	,	,
304953	100736275	20992722346	especially	especially	RR
304953	100736275	20992722347	in	in	II
304953	100736275	20992722348	men	man	NN2
304953	100736275	20992722349	with	with	IW
304953	100736275	20992722350	pre-existing	pre-existing	JJ
304953	100736275	20992722351	heart	heart	NN1
304953	100736275	20992722352	disease	disease	NN1
304953	100736275	20992722353	.	.	.
304953	100736275	20992722354	The	the	AT
304953	100736275	20992722355	evidence	evidence	NN1
304953	100736275	20992722356	is	be	VBZ
304953	100736275	20992722357	by	by	RR31
304953	100736275	20992722358	no	no	RR32
304953	100736275	20992722359	means	means	RR33
304953	100736275	20992722360	certain	certain	JJ
304953	100736275	20992722361	"	"	"
304953	100736275	20992722362	some	some	DD
304953	100736275	20992722363	studies	study	NN2
304953	100736275	20992722364	have	have	VH0
304953	100736275	20992722365	found	find	VVN
304953	100736275	20992722366	these	these	DD2
304953	100736275	20992722367	risks	risk	NN2
304953	100736275	20992722368	,	,	,
304953	100736275	20992722369	others	others	NN2
304953	100736275	20992722370	have n't		VV0_NN1
304953	100736275	20992722371	.	.	.
304953	100736275	20992722372	<p>		NULL
304953	100736275	20992722373	While	while	CS
304953	100736275	20992722374	the	the	AT
304953	100736275	20992722375	benefits	benefit	NN2
304953	100736275	20992722376	of	of	IO
304953	100736275	20992722377	taking	take	VVG
304953	100736275	20992722378	testosterone	testosterone	NN1
304953	100736275	20992722379	likely	likely	RR@_JJ
304953	100736275	20992722380	outweigh	outweigh	VV0_NN1
304953	100736275	20992722381	the	the	AT
304953	100736275	20992722382	risks	risk	NN2
304953	100736275	20992722383	for	for	IF
304953	100736275	20992722384	hypogonadal	hypogonadal	JJ
304953	100736275	20992722385	men	man	NN2
304953	100736275	20992722386	,	,	,
304953	100736275	20992722387	the	the	AT
304953	100736275	20992722388	same	same	DA
304953	100736275	20992722389	may	may	VM
304953	100736275	20992722390	not	not	XX
304953	100736275	20992722391	be	be	VBI
304953	100736275	20992722392	true	true	JJ
304953	100736275	20992722393	for	for	IF
304953	100736275	20992722394	aging	aging	JJ_VVG_NN1
304953	100736275	20992722395	men	man	NN2
304953	100736275	20992722396	who	who	PNQS
304953	100736275	20992722397	take	take	VV0
304953	100736275	20992722398	testosterone	testosterone	NN1
304953	100736275	20992722399	because	because	CS
304953	100736275	20992722400	they	they	PPHS2
304953	100736275	20992722401	think	think	VV0
304953	100736275	20992722402	it	it	PPH1
304953	100736275	20992722403	will	will	VM
304953	100736275	20992722404	make	make	VVI
304953	100736275	20992722405	them	them	PPHO2
304953	100736275	20992722406	look	look	VVI
304953	100736275	20992722407	and	and	CC
304953	100736275	20992722408	feel	feel	VVI
304953	100736275	20992722409	younger	young	JJR
304953	100736275	20992722410	.	.	.
304953	100736275	20992722411	Indeed	indeed	RR
304953	100736275	20992722412	,	,	,
304953	100736275	20992722413	recent	recent	JJ
304953	100736275	20992722414	evidence	evidence	NN1
304953	100736275	20992722415	shows	show	VVZ
304953	100736275	20992722416	that	that	CST
304953	100736275	20992722417	nearly	nearly	RR
304953	100736275	20992722418	a	a	AT1
304953	100736275	20992722419	quarter	quarter	NN1
304953	100736275	20992722420	of	of	IO
304953	100736275	20992722421	men	man	NN2
304953	100736275	20992722422	with	with	IW
304953	100736275	20992722423	a	a	AT1
304953	100736275	20992722424	prescription	prescription	NN1
304953	100736275	20992722425	for	for	IF
304953	100736275	20992722426	testosterone	testosterone	NN1
304953	100736275	20992722427	have	have	VH0
304953	100736275	20992722428	never	never	RR
304953	100736275	20992722429	even	even	RR
304953	100736275	20992722430	had	have	VHN
304953	100736275	20992722431	their	their	APPGE
304953	100736275	20992722432	hormone	hormone	NN1
304953	100736275	20992722433	levels	level	NN2
304953	100736275	20992722434	checked	check	VVD_VVN
304953	100736275	20992722435	.	.	.
304953	100736275	20992722436	Whether	whether	CSW
304953	100736275	20992722437	aging	aging	JJ_VVG
304953	100736275	20992722438	men	man	NN2
304953	100736275	20992722439	in	in	II
304953	100736275	20992722440	this	this	DD1
304953	100736275	20992722441	so-called	so-called	JJ
304953	100736275	20992722442	"	"	"
304953	100736275	20992722443	low-T		NP1
304953	100736275	20992722444	"	"	"
304953	100736275	20992722445	population	population	NN1
304953	100736275	20992722446	benefit	benefit	NN1_VV0
304953	100736275	20992722447	from	from	II
304953	100736275	20992722448	taking	take	VVG
304953	100736275	20992722449	testosterone	testosterone	NN1
304953	100736275	20992722450	is	be	VBZ
304953	100736275	20992722451	an	a	AT1
304953	100736275	20992722452	open	open	JJ
304953	100736275	20992722453	question	question	NN1
304953	100736275	20992722454	.	.	.
304953	100736275	20992722455	<p>		NULL
304953	100736275	20992722456	Concerns	concern	NN2_VVZ
304953	100736275	20992722457	over	over	II_RP
304953	100736275	20992722458	possible	possible	JJ
304953	100736275	20992722459	health	health	NN1
304953	100736275	20992722460	hazards	hazard	NN2
304953	100736275	20992722461	have	have	VH0
304953	100736275	20992722462	prompted	prompt	VVN
304953	100736275	20992722463	the	the	AT
304953	100736275	20992722464	FDA	fda	NN1_NP1
304953	100736275	20992722465	to	to	TO
304953	100736275	20992722466	investigate	investigate	VVI
304953	100736275	20992722467	the	the	AT
304953	100736275	20992722468	risk	risk	NN1
304953	100736275	20992722469	of	of	IO
304953	100736275	20992722470	heart	heart	NN1
304953	100736275	20992722471	attack	attack	NN1
304953	100736275	20992722472	,	,	,
304953	100736275	20992722473	stroke	stroke	VV0_NN1
304953	100736275	20992722474	,	,	,
304953	100736275	20992722475	and	and	CC
304953	100736275	20992722476	death	death	NN1
304953	100736275	20992722477	in	in	II
304953	100736275	20992722478	men	man	NN2
304953	100736275	20992722479	taking	take	VVG
304953	100736275	20992722480	FDA-approved	fda-approved	JJ_NN1
304953	100736275	20992722481	testosterone	testosterone	NN1
304953	100736275	20992722482	products	product	NN2
304953	100736275	20992722483	.	.	.
304953	100736275	20992722484	<h>		NULL
304953	100736275	20992722485	The	the	AT
304953	100736275	20992722486	evidence	evidence	NN1
304953	100736275	20992722487	<p>		NULL
304953	100736275	20992722488	Two	two	MC
304953	100736275	20992722489	recent	recent	JJ
304953	100736275	20992722490	studies	study	NN2
304953	100736275	20992722491	raised	raise	VVD_VVN_JJ@
304953	100736275	20992722492	health	health	NN1
304953	100736275	20992722493	concerns	concern	VVZ_NN2
304953	100736275	20992722494	over	over	II_RP
304953	100736275	20992722495	testosterone	testosterone	NN1
304953	100736275	20992722496	.	.	.
304953	100736275	20992722497	The	the	AT
304953	100736275	20992722498	first	first	MD
304953	100736275	20992722499	,	,	,
304953	100736275	20992722500	published	publish	VVD_VVN
304953	100736275	20992722501	last	last	MD
304953	100736275	20992722502	year	year	NNT1
304953	100736275	20992722503	in	in	II
304953	100736275	20992722504	JAMA	jama	NP1
304953	100736275	20992722505	,	,	,
304953	100736275	20992722506	linked	link	VVN_VVD@
304953	100736275	20992722507	the	the	AT
304953	100736275	20992722508	use	use	NN1
304953	100736275	20992722509	of	of	IO
304953	100736275	20992722510	testosterone	testosterone	NN1
304953	100736275	20992722511	supplements	supplement	NN2
304953	100736275	20992722512	to	to	II
304953	100736275	20992722513	a	a	AT1
304953	100736275	20992722514	nearly	nearly	RR
304953	100736275	20992722515	30%		NNU
304953	100736275	20992722516	increase	increase	NN1_VV0
304953	100736275	20992722517	in	in	II
304953	100736275	20992722518	the	the	AT
304953	100736275	20992722519	risk	risk	NN1
304953	100736275	20992722520	of	of	IO
304953	100736275	20992722521	death	death	NN1
304953	100736275	20992722522	from	from	II
304953	100736275	20992722523	heart	heart	NN1
304953	100736275	20992722524	attack	attack	NN1
304953	100736275	20992722525	,	,	,
304953	100736275	20992722526	stroke	stroke	VV0_NN1
304953	100736275	20992722527	,	,	,
304953	100736275	20992722528	or	or	CC
304953	100736275	20992722529	any	any	DD
304953	100736275	20992722530	other	other	JJ
304953	100736275	20992722531	cause	cause	NN1
304953	100736275	20992722532	among	among	II
304953	100736275	20992722533	@		II
304953	100736275	20992722534	@		II
304953	100736275	20992722535	@		II
304953	100736275	20992722536	@		II
304953	100736275	20992722537	@		II
304953	100736275	20992722538	@		II
304953	100736275	20992722539	@		II
304953	100736275	20992722540	@		II
304953	100736275	20992722541	@		II
304953	100736275	20992722542	@		II
304953	100736275	20992722543	the	the	AT
304953	100736275	20992722544	Veterans	veteran	NN2
304953	100736275	20992722545	Affairs	affair	NN2
304953	100736275	20992722546	Health	health	NN1
304953	100736275	20992722547	System	system	NN1
304953	100736275	20992722548	between	between	II
304953	100736275	20992722549	2005	2005	MC
304953	100736275	20992722550	and	and	CC
304953	100736275	20992722551	2011	2011	MC
304953	100736275	20992722552	.	.	.
304953	100736275	20992722553	It	it	PPH1
304953	100736275	20992722554	is	be	VBZ
304953	100736275	20992722555	possible	possible	JJ
304953	100736275	20992722556	that	that	CST_DD1
304953	100736275	20992722557	pre-existing	pre-existing	JJ_NN1
304953	100736275	20992722558	heart	heart	NN1
304953	100736275	20992722559	disease	disease	NN1
304953	100736275	20992722560	may	may	VM
304953	100736275	20992722561	have	have	VHI
304953	100736275	20992722562	contributed	contribute	VVN
304953	100736275	20992722563	to	to	II
304953	100736275	20992722564	worse	bad	JJR
304953	100736275	20992722565	outcomes	outcome	NN2
304953	100736275	20992722566	with	with	IW
304953	100736275	20992722567	testosterone	testosterone	NN1
304953	100736275	20992722568	treatment	treatment	NN1
304953	100736275	20992722569	.	.	.
304953	100736275	20992722570	<p>		NULL
304953	100736275	20992722571	The	the	AT
304953	100736275	20992722572	second	second	MD
304953	100736275	20992722573	study	study	NN1
304953	100736275	20992722574	detected	detect	VVD_VVN
304953	100736275	20992722575	a	a	AT1
304953	100736275	20992722576	two-fold	two-fold	JJ
304953	100736275	20992722577	increased	increased	JJ
304953	100736275	20992722578	risk	risk	NN1
304953	100736275	20992722579	of	of	IO
304953	100736275	20992722580	heart	heart	NN1
304953	100736275	20992722581	attack	attack	NN1
304953	100736275	20992722582	among	among	II
304953	100736275	20992722583	men	man	NN2
304953	100736275	20992722584	older	old	JJR
304953	100736275	20992722585	than	than	CSN
304953	100736275	20992722586	65	65	MC
304953	100736275	20992722587	within	within	II
304953	100736275	20992722588	90	90	MC
304953	100736275	20992722589	days	day	NNT2
304953	100736275	20992722590	of	of	IO
304953	100736275	20992722591	their	their	APPGE
304953	100736275	20992722592	obtaining	obtain	VVG
304953	100736275	20992722593	a	a	AT1
304953	100736275	20992722594	testosterone	testosterone	NN1
304953	100736275	20992722595	prescription	prescription	NN1
304953	100736275	20992722596	.	.	.
304953	100736275	20992722597	This	this	DD1
304953	100736275	20992722598	study	study	NN1
304953	100736275	20992722599	,	,	,
304953	100736275	20992722600	published	publish	VVD_VVN
304953	100736275	20992722601	last	last	MD
304953	100736275	20992722602	year	year	NNT1
304953	100736275	20992722603	in	in	II
304953	100736275	20992722604	PLoS	plo	NP2
304953	100736275	20992722605	One	one	PN1_MC1
304953	100736275	20992722606	,	,	,
304953	100736275	20992722607	found	find	VVD_VVN
304953	100736275	20992722608	that	that	CST_DD1
304953	100736275	20992722609	younger	young	JJR
304953	100736275	20992722610	men	man	NN2
304953	100736275	20992722611	with	with	IW
304953	100736275	20992722612	a	a	AT1
304953	100736275	20992722613	history	history	NN1
304953	100736275	20992722614	of	of	IO
304953	100736275	20992722615	heart	heart	NN1
304953	100736275	20992722616	disease	disease	NN1
304953	100736275	20992722617	had	have	VHD
304953	100736275	20992722618	an	a	AT1
304953	100736275	20992722619	even	even	RR
304953	100736275	20992722620	greater	great	JJR
304953	100736275	20992722621	three-fold	three-fold	JJ
304953	100736275	20992722622	risk	risk	NN1
304953	100736275	20992722623	of	of	IO
304953	100736275	20992722624	heart	heart	NN1
304953	100736275	20992722625	attack	attack	NN1
304953	100736275	20992722626	within	within	II
304953	100736275	20992722627	90	90	MC
304953	100736275	20992722628	days	day	NNT2
304953	100736275	20992722629	of	of	IO
304953	100736275	20992722630	going	go	VVG
304953	100736275	20992722631	on	on	II
304953	100736275	20992722632	testosterone	testosterone	NN1
304953	100736275	20992722633	supplements	supplement	NN2
304953	100736275	20992722634	.	.	.
304953	100736275	20992722635	No	no	AT
304953	100736275	20992722636	such	such	DA
304953	100736275	20992722637	increase	increase	NN1
304953	100736275	20992722638	was	be	VBDZ
304953	100736275	20992722639	seen	see	VVN
304953	100736275	20992722640	in	in	II
304953	100736275	20992722641	younger	young	JJR
304953	100736275	20992722642	men	man	NN2
304953	100736275	20992722643	without	without	IW
304953	100736275	20992722644	pre-existing	pre-existing	JJ
304953	100736275	20992722645	heart	heart	NN1
304953	100736275	20992722646	disease	disease	NN1
304953	100736275	20992722647	.	.	.
304953	100736275	20992722648	<p>		NULL
304953	100736275	20992722649	As	as	II
304953	100736275	20992722650	part	part	NN1
304953	100736275	20992722651	of	of	IO
304953	100736275	20992722652	its	its	APPGE
304953	100736275	20992722653	review	review	NN1
304953	100736275	20992722654	process	process	NN1_VV0
304953	100736275	20992722655	,	,	,
304953	100736275	20992722656	the	the	AT
304953	100736275	20992722657	FDA	fda	NP1_NN1
304953	100736275	20992722658	convened	convene	VVD_VVN
304953	100736275	20992722659	an	a	AT1
304953	100736275	20992722660	expert	expert	NN1_JJ@
304953	100736275	20992722661	panel	panel	NN1
304953	100736275	20992722662	and	and	CC
304953	100736275	20992722663	gave	give	VVD
304953	100736275	20992722664	it	it	PPH1
304953	100736275	20992722665	the	the	AT
304953	100736275	20992722666	task	task	NN1
304953	100736275	20992722667	of	of	IO
304953	100736275	20992722668	reviewing	review	VVG
304953	100736275	20992722669	key	key	JJ_NN1
304953	100736275	20992722670	studies	study	NN2
304953	100736275	20992722671	.	.	.
304953	100736275	20992722672	After	after	II
304953	100736275	20992722673	completing	complete	VVG
304953	100736275	20992722674	its	its	APPGE
304953	100736275	20992722675	review	review	NN1
304953	100736275	20992722676	,	,	,
304953	100736275	20992722677	the	the	AT
304953	100736275	20992722678	panel	panel	NN1
304953	100736275	20992722679	made	make	VVD_VVN
304953	100736275	20992722680	a	a	AT1
304953	100736275	20992722681	number	number	NN1
304953	100736275	20992722682	of	of	IO
304953	100736275	20992722683	recommendations	recommendation	NN2
304953	100736275	20992722684	:	:	:
304953	100736275	20992722685	<p>		NULL
304953	100736275	20992722686	Doctors	doctor	NN2
304953	100736275	20992722687	should	should	VM
304953	100736275	20992722688	be	be	VBI
304953	100736275	20992722689	required	require	VVN
304953	100736275	20992722690	to	to	TO
304953	100736275	20992722691	document	document	VVI
304953	100736275	20992722692	signs	sign	NN2
304953	100736275	20992722693	and	and	CC
304953	100736275	20992722694	symptoms	symptom	NN2
304953	100736275	20992722695	of	of	IO
304953	100736275	20992722696	low	low	JJ
304953	100736275	20992722697	testosterone	testosterone	NN1
304953	100736275	20992722698	in	in	II
304953	100736275	20992722699	a	a	AT1
304953	100736275	20992722700	man	man	NN1
304953	100736275	20992722701	before	before	II
304953	100736275	20992722702	prescribing	prescribe	VVG
304953	100736275	20992722703	the	the	AT
304953	100736275	20992722704	hormone	hormone	NN1
304953	100736275	20992722705	<p>		NULL
304953	100736275	20992722706	The	the	AT
304953	100736275	20992722707	label	label	NN1
304953	100736275	20992722708	on	on	II
304953	100736275	20992722709	testosterone	testosterone	NN1
304953	100736275	20992722710	products	product	NN2
304953	100736275	20992722711	should	should	VM
304953	100736275	20992722712	specify	specify	VVI
304953	100736275	20992722713	the	the	AT
304953	100736275	20992722714	potential	potential	NN1_JJ
304953	100736275	20992722715	for	for	IF
304953	100736275	20992722716	cardiovascular	cardiovascular	JJ
304953	100736275	20992722717	risk	risk	NN1
304953	100736275	20992722718	<p>		NULL
304953	100736275	20992722719	Before	before	CS_II
304953	100736275	20992722720	a	a	AT1
304953	100736275	20992722721	man	man	NN1
304953	100736275	20992722722	starts	start	VVZ
304953	100736275	20992722723	taking	take	VVG
304953	100736275	20992722724	testosterone	testosterone	NN1
304953	100736275	20992722725	,	,	,
304953	100736275	20992722726	his	his	APPGE
304953	100736275	20992722727	doctor	doctor	NN1
304953	100736275	20992722728	should	should	VM
304953	100736275	20992722729	check	check	VVI
304953	100736275	20992722730	his	his	APPGE
304953	100736275	20992722731	cardiovascular	cardiovascular	JJ
304953	100736275	20992722732	history	history	NN1
304953	100736275	20992722733	@		II
304953	100736275	20992722734	@		II
304953	100736275	20992722735	@		II
304953	100736275	20992722736	@		II
304953	100736275	20992722737	@		II
304953	100736275	20992722738	@		II
304953	100736275	20992722739	@		II
304953	100736275	20992722740	@		II
304953	100736275	20992722741	@		II
304953	100736275	20992722742	@		II
304953	100736275	20992722743	treatment	treatment	NN1
304953	100736275	20992722744	should	should	VM
304953	100736275	20992722745	be	be	VBI
304953	100736275	20992722746	halted	halt	VVN
304953	100736275	20992722747	.	.	.
304953	100736275	20992722748	<p>		NULL
304953	100736275	20992722749	FDAs	fdas	NP2_NN2
304953	100736275	20992722750	review	review	NN1_VV0
304953	100736275	20992722751	of	of	IO
304953	100736275	20992722752	testosterone	testosterone	NN1
304953	100736275	20992722753	health	health	NN1
304953	100736275	20992722754	risks	risk	NN2
304953	100736275	20992722755	is	be	VBZ
304953	100736275	20992722756	still	still	RR
304953	100736275	20992722757	ongoing	ongoing	JJ
304953	100736275	20992722758	,	,	,
304953	100736275	20992722759	and	and	CC
304953	100736275	20992722760	officials	official	NN2
304953	100736275	20992722761	emphasize	emphasize	VV0
304953	100736275	20992722762	that	that	CST_DD1
304953	100736275	20992722763	approved	approved	JJ_VVD
304953	100736275	20992722764	testosterone	testosterone	NN1
304953	100736275	20992722765	products	product	NN2
304953	100736275	20992722766	have	have	VH0
304953	100736275	20992722767	not	not	XX
304953	100736275	20992722768	been	be	VBN
304953	100736275	20992722769	conclusively	conclusively	RR
304953	100736275	20992722770	shown	show	VVN
304953	100736275	20992722771	to	to	TO
304953	100736275	20992722772	increase	increase	VVI
304953	100736275	20992722773	the	the	AT
304953	100736275	20992722774	risk	risk	NN1
304953	100736275	20992722775	of	of	IO
304953	100736275	20992722776	heart	heart	NN1
304953	100736275	20992722777	attack	attack	NN1
304953	100736275	20992722778	,	,	,
304953	100736275	20992722779	stroke	stroke	VV0_NN1
304953	100736275	20992722780	,	,	,
304953	100736275	20992722781	or	or	CC
304953	100736275	20992722782	death	death	NN1
304953	100736275	20992722783	.	.	.
304953	100736275	20992722784	A	a	AT1_ZZ1
304953	100736275	20992722785	final	final	JJ
304953	100736275	20992722786	determination	determination	NN1
304953	100736275	20992722787	will	will	VM
304953	100736275	20992722788	be	be	VBI
304953	100736275	20992722789	rendered	render	VVN
304953	100736275	20992722790	once	once	RR_CS@
304953	100736275	20992722791	the	the	AT
304953	100736275	20992722792	FDAs	fdas	NP2_NN2
304953	100736275	20992722793	review	review	NN1_VV0
304953	100736275	20992722794	is	be	VBZ
304953	100736275	20992722795	complete	complete	JJ
304953	100736275	20992722796	.	.	.
304953	100736275	20992722797	<p>		NULL
304953	100736275	20992722798	"	"	"
304953	100736275	20992722799	We	we	PPIS2
304953	100736275	20992722800	await	await	VV0
304953	100736275	20992722801	the	the	AT
304953	100736275	20992722802	results	result	NN2
304953	100736275	20992722803	of	of	IO
304953	100736275	20992722804	ongoing	ongoing	JJ
304953	100736275	20992722805	randomized	randomized	JJ@
304953	100736275	20992722806	studies	study	NN2
304953	100736275	20992722807	and	and	CC
304953	100736275	20992722808	the	the	AT
304953	100736275	20992722809	final	final	JJ_NN1
304953	100736275	20992722810	deliberations	deliberation	NN2
304953	100736275	20992722811	of	of	IO
304953	100736275	20992722812	the	the	AT
304953	100736275	20992722813	FDA	fda	NN1_NP1
304953	100736275	20992722814	,	,	,
304953	100736275	20992722815	"	"	"
304953	100736275	20992722816	said	say	VVD
304953	100736275	20992722817	Dr.		NNB
304953	100736275	20992722818	Marc	marc	NP1
304953	100736275	20992722819	B.		NP1
304953	100736275	20992722820	Garnick		NP1
304953	100736275	20992722821	,	,	,
304953	100736275	20992722822	the	the	AT
304953	100736275	20992722823	Gorman	gorman	NN1_NP1
304953	100736275	20992722824	Brothers	brother	NN2
304953	100736275	20992722825	Professor	professor	NN1
304953	100736275	20992722826	of	of	IO
304953	100736275	20992722827	Medicine	medicine	NN1
304953	100736275	20992722828	at	at	II
304953	100736275	20992722829	Harvard	harvard	NP1
304953	100736275	20992722830	Medical	medical	JJ
304953	100736275	20992722831	School	school	NN1
304953	100736275	20992722832	and	and	CC
304953	100736275	20992722833	Beth	beth	NP1
304953	100736275	20992722834	Israel	israel	NP1
304953	100736275	20992722835	Deaconess	deaconess	NN1
304953	100736275	20992722836	Medical	medical	JJ
304953	100736275	20992722837	Center	center	NN1
304953	100736275	20992722838	,	,	,
304953	100736275	20992722839	who	who	PNQS
304953	100736275	20992722840	served	serve	VVD
304953	100736275	20992722841	on	on	II
304953	100736275	20992722842	the	the	AT
304953	100736275	20992722843	FDA	fda	NN1_NP1
304953	100736275	20992722844	panel	panel	NN1
304953	100736275	20992722845	.	.	.
304953	100736275	20992722846	"	"	"
304953	100736275	20992722847	In	in	II
304953	100736275	20992722848	the	the	AT
304953	100736275	20992722849	meantime	meantime	NNT1
304953	100736275	20992722850	,	,	,
304953	100736275	20992722851	men	man	NN2
304953	100736275	20992722852	should	should	VM
304953	100736275	20992722853	be	be	VBI
304953	100736275	20992722854	cautious	cautious	JJ
304953	100736275	20992722855	about	about	II
304953	100736275	20992722856	these	these	DD2
304953	100736275	20992722857	new	new	JJ
304953	100736275	20992722858	issues	issue	NN2
304953	100736275	20992722859	that	that	CST
304953	100736275	20992722860	have	have	VH0
304953	100736275	20992722861	been	be	VBN
304953	100736275	20992722862	raised	raise	VVN
304953	100736275	20992722863	.	.	.
304953	100736275	20992722864	"	"	"
304953	100736279	20992722884	@@##	----------	----------
304953	100736279	20992722885	@@100736279		FO
304953	100736279	20992722886	@4936279/		VV0_NN1
304953	100736279	20992722887	46989		MC
304953	100736279	20992722888	@qwx906989		FO
304953	100736279	20992722889	<p>		NULL
304953	100736279	20992722890	For	for	IF
304953	100736279	20992722891	the	the	AT
304953	100736279	20992722892	past	past	JJ_NN1
304953	100736279	20992722893	several	several	DA2
304953	100736279	20992722894	years	year	NNT2
304953	100736279	20992722895	,	,	,
304953	100736279	20992722896	I	i	PPIS1
304953	100736279	20992722897	used	use	VVD
304953	100736279	20992722898	finasteride	finasteride	NN1
304953	100736279	20992722899	(	(	(
304953	100736279	20992722900	Proscar	proscar	NP1
304953	100736279	20992722901	)	)	)
304953	100736279	20992722902	to	to	TO
304953	100736279	20992722903	treat	treat	VVI
304953	100736279	20992722904	my	my	APPGE
304953	100736279	20992722905	BPH	bph	NP1
304953	100736279	20992722906	.	.	.
304953	100736279	20992722907	Although	although	CS
304953	100736279	20992722908	the	the	AT
304953	100736279	20992722909	drug	drug	NN1
304953	100736279	20992722910	reduced	reduce	VVD_VVN
304953	100736279	20992722911	the	the	AT
304953	100736279	20992722912	size	size	NN1
304953	100736279	20992722913	of	of	IO
304953	100736279	20992722914	my	my	APPGE
304953	100736279	20992722915	prostate	prostate	NN1
304953	100736279	20992722916	,	,	,
304953	100736279	20992722917	my	my	APPGE
304953	100736279	20992722918	body	body	NN1
304953	100736279	20992722919	's	's	GE
304953	100736279	20992722920	production	production	NN1
304953	100736279	20992722921	of	of	IO
304953	100736279	20992722922	semen	semen	NN1
304953	100736279	20992722923	has	have	VHZ
304953	100736279	20992722924	diminished	diminish	VVN
304953	100736279	20992722925	considerably	considerably	RR
304953	100736279	20992722926	.	.	.
304953	100736279	20992722927	After	after	II
304953	100736279	20992722928	talking	talk	VVG
304953	100736279	20992722929	with	with	IW
304953	100736279	20992722930	my	my	APPGE
304953	100736279	20992722931	urologist	urologist	NN1
304953	100736279	20992722932	,	,	,
304953	100736279	20992722933	I	i	PPIS1
304953	100736279	20992722934	recently	recently	RR
304953	100736279	20992722935	started	start	VVD
304953	100736279	20992722936	taking	take	VVG
304953	100736279	20992722937	dutasteride		NN1
304953	100736279	20992722938	(	(	(
304953	100736279	20992722939	Avodart		NP1
304953	100736279	20992722940	)	)	)
304953	100736279	20992722941	instead	instead	RR
304953	100736279	20992722942	.	.	.
304953	100736279	20992722943	Will	will	VM
304953	100736279	20992722944	the	the	AT
304953	100736279	20992722945	switch	switch	NN1
304953	100736279	20992722946	help	help	VVI
304953	100736279	20992722947	?	?	?
304953	100736279	20992722948	<p>		NULL
304953	100736279	20992722949	What	what	DDQ
304953	100736279	20992722950	you	you	PPY
304953	100736279	20992722951	are	be	VBR
304953	100736279	20992722952	experiencing	experience	VVG
304953	100736279	20992722953	is	be	VBZ
304953	100736279	20992722954	,	,	,
304953	100736279	20992722955	I	i	PPIS1
304953	100736279	20992722956	think	think	VV0
304953	100736279	20992722957	,	,	,
304953	100736279	20992722958	relatively	relatively	RR
304953	100736279	20992722959	common	common	JJ
304953	100736279	20992722960	with	with	IW
304953	100736279	20992722961	both	both	RR
304953	100736279	20992722962	finasteride		VV0
304953	100736279	20992722963	and	and	CC
304953	100736279	20992722964	dutasteride		NN1_VV0
304953	100736279	20992722965	,	,	,
304953	100736279	20992722966	although	although	CS
304953	100736279	20992722967	the	the	AT
304953	100736279	20992722968	drug	drug	NN1
304953	100736279	20992722969	manufacturers	manufacturer	NN2
304953	100736279	20992722970	report	report	VV0@_NN1
304953	100736279	20992722971	that	that	CST
304953	100736279	20992722972	this	this	DD1
304953	100736279	20992722973	side	side	NN1
304953	100736279	20992722974	effect	effect	NN1
304953	100736279	20992722975	is	be	VBZ
304953	100736279	20992722976	uncommon	uncommon	JJ
304953	100736279	20992722977	.	.	.
304953	100736279	20992722978	Following	follow	VVG_II@
304953	100736279	20992722979	a	a	AT1
304953	100736279	20992722980	four-year	four-year	JJ
304953	100736279	20992722981	,	,	,
304953	100736279	20992722982	placebo-controlled	placebo-controlled	JJ_NN1
304953	100736279	20992722983	study	study	NN1
304953	100736279	20992722984	of	of	IO
304953	100736279	20992722985	finasteride	finasteride	NN1
304953	100736279	20992722986	,	,	,
304953	100736279	20992722987	the	the	AT
304953	100736279	20992722988	makers	maker	NN2
304953	100736279	20992722989	of	of	IO
304953	100736279	20992722990	Proscar	proscar	NP1
304953	100736279	20992722991	noted	note	VVD
304953	100736279	20992722992	that	that	CST_DD1
304953	100736279	20992722993	3.7%	3.7%	FO
304953	100736279	20992722994	of	of	IO
304953	100736279	20992722995	the	the	AT
304953	100736279	20992722996	1,524	1,524	MC
304953	100736279	20992722997	patients	patient	NN2
304953	100736279	20992722998	taking	take	VVG
304953	100736279	20992722999	the	the	AT
304953	100736279	20992723000	drug	drug	NN1
304953	100736279	20992723001	reported	report	VVD_VVN
304953	100736279	20992723002	decreased	decreased	JJ@
304953	100736279	20992723003	ejaculate	ejaculate	NN1
304953	100736279	20992723004	volume	volume	NN1
304953	100736279	20992723005	in	in	II
304953	100736279	20992723006	the	the	AT
304953	100736279	20992723007	first	first	MD
304953	100736279	20992723008	year	year	NNT1
304953	100736279	20992723009	;	;	;
304953	100736279	20992723010	fewer	fewer	DAR
304953	100736279	20992723011	patients	patient	NN2
304953	100736279	20992723012	reported	report	VVD_VVN
304953	100736279	20992723013	this	this	DD1
304953	100736279	20992723014	problem	problem	NN1
304953	100736279	20992723015	in	in	II
304953	100736279	20992723016	subsequent	subsequent	JJ
304953	100736279	20992723017	years	year	NNT2
304953	100736279	20992723018	.	.	.
304953	100736279	20992723019	Other	other	JJ
304953	100736279	20992723020	tests	test	NN2
304953	100736279	20992723021	to	to	TO
304953	100736279	20992723022	evaluate	evaluate	VVI
304953	100736279	20992723023	semen	semen	NN1
304953	100736279	20992723024	in	in	II
304953	100736279	20992723025	healthy	healthy	JJ
304953	100736279	20992723026	male	male	JJ_NN1
304953	100736279	20992723027	volunteers	volunteer	NN2
304953	100736279	20992723028	found	find	VVD_VVN
304953	100736279	20992723029	a	a	AT1
304953	100736279	20992723030	22.1%	22.1%	FO
304953	100736279	20992723031	median	median	JJ_NN1
304953	100736279	20992723032	decrease	decrease	NN1
304953	100736279	20992723033	in	in	II
304953	100736279	20992723034	ejaculate	ejaculate	NN1
304953	100736279	20992723035	volume	volume	NN1
304953	100736279	20992723036	.	.	.
304953	100736279	20992723037	Avodart		NP1@_NN1
304953	100736279	20992723038	's	's	GE
304953	100736279	20992723039	manufacturer	manufacturer	NN1
304953	100736279	20992723040	also	also	RR
304953	100736279	20992723041	evaluated	evaluate	VVN_VVD
304953	100736279	20992723042	semen	semen	NN1
304953	100736279	20992723043	from	from	II
304953	100736279	20992723044	27	27	MC
304953	100736279	20992723045	healthy	healthy	JJ
304953	100736279	20992723046	volunteers	volunteer	NN2
304953	100736279	20992723047	who	who	PNQS
304953	100736279	20992723048	took	take	VVD
304953	100736279	20992723049	that	that	DD1
304953	100736279	20992723050	drug	drug	NN1
304953	100736279	20992723051	for	for	IF
304953	100736279	20992723052	a	a	AT1
304953	100736279	20992723053	year	year	NNT1
304953	100736279	20992723054	.	.	.
304953	100736279	20992723055	On	on	II
304953	100736279	20992723056	average	average	NN1_JJ
304953	100736279	20992723057	,	,	,
304953	100736279	20992723058	their	their	APPGE
304953	100736279	20992723059	ejaculate	ejaculate	NN1
304953	100736279	20992723060	volume	volume	NN1
304953	100736279	20992723061	decreased	decrease	VVN
304953	100736279	20992723062	by	by	II
304953	100736279	20992723063	26%		NNU
304953	100736279	20992723064	.	.	.
304953	100736279	20992723065	<p>		NULL
304953	100736279	20992723066	Because	because	CS
304953	100736279	20992723067	pharmaceutical	pharmaceutical	JJ
304953	100736279	20992723068	companies	company	NN2
304953	100736279	20992723069	conduct	conduct	VV0
304953	100736279	20992723070	clinical	clinical	JJ
304953	100736279	20992723071	trials	trial	NN2
304953	100736279	20992723072	under	under	II_RG@
304953	100736279	20992723073	different	different	JJ
304953	100736279	20992723074	conditions	condition	NN2
304953	100736279	20992723075	,	,	,
304953	100736279	20992723076	@		II
304953	100736279	20992723077	@		II
304953	100736279	20992723078	@		II
304953	100736279	20992723079	@		II
304953	100736279	20992723080	@		II
304953	100736279	20992723081	@		II
304953	100736279	20992723082	@		II
304953	100736279	20992723083	@		II
304953	100736279	20992723084	@		II
304953	100736279	20992723085	@		II
304953	100736279	20992723086	,	,	,
304953	100736279	20992723087	placebo-controlled	placebo-controlled	NN1_JJ
304953	100736279	20992723088	,	,	,
304953	100736279	20992723089	head-to-head	head-to-head	JJ
304953	100736279	20992723090	study	study	NN1
304953	100736279	20992723091	of	of	IO
304953	100736279	20992723092	both	both	DB2
304953	100736279	20992723093	drugs	drug	NN2
304953	100736279	20992723094	published	publish	VVN
304953	100736279	20992723095	in	in	II
304953	100736279	20992723096	the	the	AT
304953	100736279	20992723097	Journal	journal	NN1
304953	100736279	20992723098	of	of	IO
304953	100736279	20992723099	Clinical	clinical	JJ
304953	100736279	20992723100	Endocrinology	endocrinology	NN1
304953	100736279	20992723101	and	and	CC
304953	100736279	20992723102	Metabolism	metabolism	NN1
304953	100736279	20992723103	in	in	II
304953	100736279	20992723104	May	may	NPM1
304953	100736279	20992723105	2007	2007	MC
304953	100736279	20992723106	yielded	yield	VVD_VVN
304953	100736279	20992723107	similar	similar	JJ
304953	100736279	20992723108	data	data	NN
304953	100736279	20992723109	.	.	.
304953	100736279	20992723110	Among	among	II
304953	100736279	20992723111	the	the	AT
304953	100736279	20992723112	73	73	MC
304953	100736279	20992723113	participants	participant	NN2
304953	100736279	20992723114	who	who	PNQS
304953	100736279	20992723115	completed	complete	VVD
304953	100736279	20992723116	the	the	AT
304953	100736279	20992723117	trial	trial	NN1
304953	100736279	20992723118	,	,	,
304953	100736279	20992723119	average	average	JJ_NN1
304953	100736279	20992723120	semen	semen	NN1
304953	100736279	20992723121	volume	volume	NN1
304953	100736279	20992723122	dropped	drop	VVN
304953	100736279	20992723123	by	by	II
304953	100736279	20992723124	21.1%	21.1%	FO
304953	100736279	20992723125	in	in	II
304953	100736279	20992723126	men	man	NN2
304953	100736279	20992723127	taking	take	VVG
304953	100736279	20992723128	finasteride	finasteride	NN1
304953	100736279	20992723129	,	,	,
304953	100736279	20992723130	and	and	CC
304953	100736279	20992723131	by	by	II
304953	100736279	20992723132	24%		NNU
304953	100736279	20992723133	in	in	II
304953	100736279	20992723134	those	those	DD2
304953	100736279	20992723135	taking	take	VVG
304953	100736279	20992723136	dutasteride		NN1_VV0
304953	100736279	20992723137	over	over	RG
304953	100736279	20992723138	six	six	MC
304953	100736279	20992723139	months	month	NNT2
304953	100736279	20992723140	.	.	.
304953	100736279	20992723141	Keep	keep	VV0
304953	100736279	20992723142	in	in	II_RP@
304953	100736279	20992723143	mind	mind	NN1
304953	100736279	20992723144	that	that	CST
304953	100736279	20992723145	these	these	DD2
304953	100736279	20992723146	numbers	number	NN2
304953	100736279	20992723147	are	be	VBR
304953	100736279	20992723148	averages	average	NN2
304953	100736279	20992723149	and	and	CC
304953	100736279	20992723150	not	not	XX
304953	100736279	20992723151	necessarily	necessarily	RR
304953	100736279	20992723152	what	what	DDQ
304953	100736279	20992723153	one	one	MC1
304953	100736279	20992723154	particular	particular	JJ
304953	100736279	20992723155	person	person	NN1
304953	100736279	20992723156	will	will	VM
304953	100736279	20992723157	experience	experience	VVI
304953	100736279	20992723158	.	.	.
304953	100736279	20992723159	<p>		NULL
304953	100736279	20992723160	Keep	keep	VV0
304953	100736279	20992723161	in	in	II_RP@
304953	100736279	20992723162	mind	mind	NN1
304953	100736279	20992723163	,	,	,
304953	100736279	20992723164	too	too	RR@_RG
304953	100736279	20992723165	,	,	,
304953	100736279	20992723166	that	that	CST_DD1
304953	100736279	20992723167	even	even	CS21
304953	100736279	20992723168	though	though	CS22
304953	100736279	20992723169	these	these	DD2
304953	100736279	20992723170	drugs	drug	NN2
304953	100736279	20992723171	are	be	VBR
304953	100736279	20992723172	prescribed	prescribe	VVN
304953	100736279	20992723173	for	for	IF
304953	100736279	20992723174	the	the	AT
304953	100736279	20992723175	same	same	DA
304953	100736279	20992723176	condition	condition	NN1
304953	100736279	20992723177	,	,	,
304953	100736279	20992723178	they	they	PPHS2
304953	100736279	20992723179	work	work	VV0
304953	100736279	20992723180	a	a	RR21
304953	100736279	20992723181	bit	bit	RR22
304953	100736279	20992723182	differently	differently	RR
304953	100736279	20992723183	.	.	.
304953	100736279	20992723184	You	you	PPY
304953	100736279	20992723185	might	might	VM
304953	100736279	20992723186	experience	experience	VVI
304953	100736279	20992723187	a	a	AT1
304953	100736279	20992723188	more	more	RGR
304953	100736279	20992723189	noticeable	noticeable	JJ
304953	100736279	20992723190	drop	drop	NN1
304953	100736279	20992723191	in	in	II
304953	100736279	20992723192	semen	semen	NN1
304953	100736279	20992723193	volume	volume	NN1
304953	100736279	20992723194	with	with	IW
304953	100736279	20992723195	one	one	MC1
304953	100736279	20992723196	drug	drug	NN1
304953	100736279	20992723197	than	than	CSN
304953	100736279	20992723198	another	another	DD1
304953	100736279	20992723199	.	.	.
304953	100736279	20992723200	Try	try	VV0
304953	100736279	20992723201	dutasteride		NN1_VV0
304953	100736279	20992723202	and	and	CC
304953	100736279	20992723203	see	see	VV0
304953	100736279	20992723204	what	what	DDQ
304953	100736279	20992723205	happens	happen	VVZ
304953	100736279	20992723206	.	.	.
304953	100736279	20992723207	You	you	PPY
304953	100736279	20992723208	can	can	VM
304953	100736279	20992723209	always	always	RR
304953	100736279	20992723210	switch	switch	VVI
304953	100736279	20992723211	back	back	RP
304953	100736279	20992723212	to	to	TO
304953	100736279	20992723213	finasteride		VVI
304953	100736279	20992723214	.	.	.
304953	100736279	20992723215	<p>		NULL
304953	100736279	20992723216	I	i	PPIS1
304953	100736279	20992723217	can	can	VM
304953	100736279	20992723218	attest	attest	VVI
304953	100736279	20992723219	that	that	CST_DD1
304953	100736279	20992723220	stopping	stop	VVG
304953	100736279	20992723221	the	the	AT
304953	100736279	20992723222	drug	drug	NN1
304953	100736279	20992723223	,	,	,
304953	100736279	20992723224	even	even	RR
304953	100736279	20992723225	for	for	IF
304953	100736279	20992723226	just	just	RR
304953	100736279	20992723227	a	a	AT1
304953	100736279	20992723228	few	few	DA2
304953	100736279	20992723229	days	day	NNT2
304953	100736279	20992723230	,	,	,
304953	100736279	20992723231	will	will	VM
304953	100736279	20992723232	cause	cause	VVI
304953	100736279	20992723233	your	your	APPGE
304953	100736279	20992723234	volume	volume	NN1
304953	100736279	20992723235	to	to	TO
304953	100736279	20992723236	return	return	VVI
304953	100736279	20992723237	to	to	II
304953	100736279	20992723238	normal	normal	JJ
304953	100736279	20992723239	.	.	.
304953	100736279	20992723240	Mine	mine	NN1
304953	100736279	20992723241	has	have	VHZ
304953	100736279	20992723242	every	every	AT1
304953	100736279	20992723243	time	time	NNT1
304953	100736279	20992723244	Ive	ive	NN1
304953	100736279	20992723245	done	do	VDN
304953	100736279	20992723246	this	this	DD1
304953	100736279	20992723247	and	and	CC
304953	100736279	20992723248	so	so	RG
304953	100736279	20992723249	far	far	RR
304953	100736279	20992723250	my	my	APPGE
304953	100736279	20992723251	blood	blood	NN1
304953	100736279	20992723252	test	test	NN1_VV0
304953	100736279	20992723253	results	result	NN2
304953	100736279	20992723254	are	be	VBR
304953	100736279	20992723255	still	still	RR
304953	100736279	20992723256	fine	fine	JJ
304953	100736279	20992723257	,	,	,
304953	100736279	20992723258	probably	probably	RR
304953	100736279	20992723259	because	because	CS
304953	100736279	20992723260	I	i	PPIS1
304953	100736279	20992723261	return	return	VV0
304953	100736279	20992723262	to	to	II
304953	100736279	20992723263	taking	take	VVG
304953	100736279	20992723264	it	it	PPH1
304953	100736279	20992723265	.	.	.
304953	100736279	20992723266	Low	low	JJ
304953	100736279	20992723267	sperm	sperm	NN
304953	100736279	20992723268	volume	volume	NN1
304953	100736279	20992723269	is	be	VBZ
304953	100736279	20992723270	hard	hard	JJ
304953	100736279	20992723271	to	to	TO
304953	100736279	20992723272	accept	accept	VVI
304953	100736279	20992723273	for	for	IF
304953	100736279	20992723274	me	me	PPIO1
304953	100736279	20992723275	anyway	anyway	RR
304953	100736279	20992723276	@		II
304953	100736279	20992723277	@		II
304953	100736279	20992723278	@		II
304953	100736279	20992723279	@		II
304953	100736279	20992723280	@		II
304953	100736279	20992723281	@		II
304953	100736279	20992723282	@		II
304953	100736279	20992723283	@		II
304953	100736279	20992723284	@		II
304953	100736279	20992723285	@		II
304953	100736279	20992723286	volume	volume	NN1
304953	100736279	20992723287	.	.	.
304953	100736279	20992723288	I	i	PPIS1
304953	100736279	20992723289	was	be	VBDZ
304953	100736279	20992723290	on	on	II
304953	100736279	20992723291	Tamsulosin		NP1_NN1
304953	100736279	20992723292	and	and	CC
304953	100736279	20992723293	Finasteride		VV0
304953	100736279	20992723294	together	together	RL
304953	100736279	20992723295	for	for	IF
304953	100736279	20992723296	around	around	RG
304953	100736279	20992723297	8	8	MC
304953	100736279	20992723298	Months	month	NNT2
304953	100736279	20992723299	and	and	CC
304953	100736279	20992723300	it	it	PPH1
304953	100736279	20992723301	really	really	RR
304953	100736279	20992723302	affected	affect	VVN_VVD@
304953	100736279	20992723303	my	my	APPGE
304953	100736279	20992723304	.	.	.
304953	100736279	20992723305	Ability	ability	NN1
304953	100736279	20992723306	to	to	TO
304953	100736279	20992723307	get	get	VVI
304953	100736279	20992723308	erect	erect	JJ
304953	100736279	20992723309	or	or	CC
304953	100736279	20992723310	feel	feel	VV0
304953	100736279	20992723311	like	like	CS%_II_VV0@_RR%
304953	100736279	20992723312	I	i	PPIS1
304953	100736279	20992723313	wanted	want	VVD
304953	100736279	20992723314	sex	sex	NN1
304953	100736279	20992723315	.	.	.
304953	100736279	20992723316	I	i	PPIS1
304953	100736279	20992723317	am	be	VBM
304953	100736279	20992723318	now	now	RT
304953	100736279	20992723319	only	only	JJ
304953	100736279	20992723320	on	on-	II
304953	100736279	20992723321	Finasteride	finasteride	NN1_VV0
304953	100736279	20992723322	due	due	II21
304953	100736279	20992723323	to	to	II22
304953	100736279	20992723324	not	not	XX
304953	100736279	20992723325	tolerating	tolerate	VVG
304953	100736279	20992723326	the	the	AT
304953	100736279	20992723327	side	side	NN1
304953	100736279	20992723328	effect	effect	NN1
304953	100736279	20992723329	of	of	IO
304953	100736279	20992723330	Tamsulosin		NN1_NP1
304953	100736279	20992723331	.	.	.
304953	100736279	20992723332	Too	too	RG
304953	100736279	20992723333	much	much	DA1
304953	100736279	20992723334	to	to	TO
304953	100736279	20992723335	bare	bare	VVI
304953	100736279	20992723336	!	!	!
304953	100736279	20992723337	.	.	.
304953	100736279	20992723338	<p>		NULL
304953	100736279	20992723339	I	i	PPIS1
304953	100736279	20992723340	started	start	VVD
304953	100736279	20992723341	on	on	II
304953	100736279	20992723342	5	5	MC
304953	100736279	20992723343	mg	mg	NNU
304953	100736279	20992723344	of	of	IO
304953	100736279	20992723345	finasteride	finasteride	NN1
304953	100736279	20992723346	.	.	.
304953	100736279	20992723347	Within	within	II
304953	100736279	20992723348	a	a	AT1
304953	100736279	20992723349	week	week	NNT1
304953	100736279	20992723350	of	of	IO
304953	100736279	20992723351	taking	take	VVG
304953	100736279	20992723352	it	it	PPH1
304953	100736279	20992723353	consistently	consistently	RR
304953	100736279	20992723354	my	my	APPGE
304953	100736279	20992723355	volume	volume	NN1
304953	100736279	20992723356	was	be	VBDZ
304953	100736279	20992723357	gone	go	VVN
304953	100736279	20992723358	!	!	!
304953	100736279	20992723359	Gone	go	VVN
304953	100736279	20992723360	!	!	!
304953	100736279	20992723361	Nothing	nothing	PN1
304953	100736279	20992723362	.	.	.
304953	100736279	20992723363	Nada	nada	NN1_NP1@
304953	100736279	20992723364	!	!	!
304953	100736279	20992723365	Scared	scare	VVD@_JJ
304953	100736279	20992723366	the	the	AT
304953	100736279	20992723367	xxxx	xxxx	NNU
304953	100736279	20992723368	out	out	II21
304953	100736279	20992723369	of	of	II22
304953	100736279	20992723370	me	me	PPIO1
304953	100736279	20992723371	.	.	.
304953	100736279	20992723372	Going	go	VVGK
304953	100736279	20992723373	to	to	TO
304953	100736279	20992723374	talk	talk	VVI
304953	100736279	20992723375	to	to	II
304953	100736279	20992723376	my	my	APPGE
304953	100736279	20992723377	doctor	doctor	NN1
304953	100736279	20992723378	.	.	.
304953	100736279	20992723379	This	this	DD1
304953	100736279	20992723380	just	just	RR
304953	100736279	20992723381	freaked	freak	VVD_VVN
304953	100736279	20992723382	me	me	PPIO1
304953	100736279	20992723383	out	out	RP
304953	100736279	20992723384	.	.	.
304953	100736279	20992723385	Hard	hard	RR_JJ
304953	100736279	20992723386	to	to	TO
304953	100736279	20992723387	think	think	VVI
304953	100736279	20992723388	about	about	II
304953	100736279	20992723389	not	not	XX
304953	100736279	20992723390	having	have	VHG
304953	100736279	20992723391	a	a	AT1
304953	100736279	20992723392	normal	normal	JJ
304953	100736279	20992723393	orgasm	orgasm	NN1
304953	100736279	20992723394	thinking	think	VVG_NN1
304953	100736279	20992723395	about	about	II
304953	100736279	20992723396	this	this	DD1
304953	100736279	20992723397	side	side	NN1
304953	100736279	20992723398	effect	effect	NN1
304953	100736279	20992723399	.	.	.
304953	100736279	20992723400	I	i	PPIS1
304953	100736279	20992723401	thought	think	VVD
304953	100736279	20992723402	that	that	CST
304953	100736279	20992723403	if	if	CS
304953	100736279	20992723404	had	have	VHN@_VHD
304953	100736279	20992723405	a	a	AT1
304953	100736279	20992723406	reduction	reduction	NN1
304953	100736279	20992723407	in	in	II
304953	100736279	20992723408	volume	volume	NN1
304953	100736279	20992723409	I	i	PPIS1
304953	100736279	20992723410	was	be	VBDZ
304953	100736279	20992723411	sure	sure	JJ
304953	100736279	20992723412	I	i	PPIS1
304953	100736279	20992723413	could	could	VM
304953	100736279	20992723414	live	live	VVI
304953	100736279	20992723415	with	with	IW
304953	100736279	20992723416	it	it	PPH1
304953	100736279	20992723417	,	,	,
304953	100736279	20992723418	but	but	CCB
304953	100736279	20992723419	given	give	VVN
304953	100736279	20992723420	this	this	DD1
304953	100736279	20992723421	,	,	,
304953	100736279	20992723422	I	i	PPIS1_ZZ1%
304953	100736279	20992723423	,	,	,
304953	100736279	20992723424	just	just	RR
304953	100736279	20992723425	might	might	VM
304953	100736279	20992723426	be	be	VBI
304953	100736279	20992723427	the	the	AT
304953	100736279	20992723428	one	one	PN1
304953	100736279	20992723429	that	that	CST
304953	100736279	20992723430	contracts	contract	VVZ@
304953	100736279	20992723431	the	the	AT
304953	100736279	20992723432	more	more	RGR
304953	100736279	20992723433	aggressive	aggressive	JJ
304953	100736279	20992723434	form	form	NN1
304953	100736279	20992723435	of	of	IO
304953	100736279	20992723436	prostate	prostate	NN1
304953	100736279	20992723437	cancer	cancer	NN1
304953	100736279	20992723438	this	this	DD1
304953	100736279	20992723439	medication	medication	NN1
304953	100736279	20992723440	can	can	VM
304953	100736279	20992723441	cause	cause	VVI
304953	100736279	20992723442	.	.	.
304953	100736279	20992723443	No	no	UH
304953	100736279	20992723444	thanks	thanks	NN2
304953	100736279	20992723445	!	!	!
304953	100736279	20992723446	<p>		NULL
304953	100736279	20992723447	This	this	DD1
304953	100736279	20992723448	is	be	VBZ
304953	100736279	20992723449	an	a	AT1
304953	100736279	20992723450	update	update	NN1
304953	100736279	20992723451	to	to	II
304953	100736279	20992723452	my	my	APPGE
304953	100736279	20992723453	post	post	NN1
304953	100736279	20992723454	of	of	IO
304953	100736279	20992723455	March	march	NPM1
304953	100736279	20992723456	23	23	MC
304953	100736279	20992723457	,	,	,
304953	100736279	20992723458	2017	2017	MC
304953	100736279	20992723459	.	.	.
304953	100736279	20992723460	Since	since	II
304953	100736279	20992723461	stopping	stop	VVG
304953	100736279	20992723462	the	the	AT
304953	100736279	20992723463	finasteride	finasteride	NN1
304953	100736279	20992723464	,	,	,
304953	100736279	20992723465	my	my	APPGE
304953	100736279	20992723466	volume	volume	NN1
304953	100736279	20992723467	has	have	VHZ
304953	100736279	20992723468	returned	return	VVN
304953	100736279	20992723469	but	but	CCB
304953	100736279	20992723470	not	not	XX
304953	100736279	20992723471	like	like	II_RR%_JJ@
304953	100736279	20992723472	before	before	RT
304953	100736279	20992723473	.	.	.
304953	100736279	20992723474	Volume	volume	NN1
304953	100736279	20992723475	is	be	VBZ
304953	100736279	20992723476	@		II
304953	100736279	20992723477	@		II
304953	100736279	20992723478	@		II
304953	100736279	20992723479	@		II
304953	100736279	20992723480	@		II
304953	100736279	20992723481	@		II
304953	100736279	20992723482	@		II
304953	100736279	20992723483	@		II
304953	100736279	20992723484	@		II
304953	100736279	20992723485	@		II
304953	100736279	20992723486	read	read	VV0_VVD
304953	100736279	20992723487	somewhere	somewhere	RL
304953	100736279	20992723488	that	that	CST
304953	100736279	20992723489	even	even	CS21
304953	100736279	20992723490	if	if	CS22
304953	100736279	20992723491	you	you	PPY
304953	100736279	20992723492	stop	stop	VV0
304953	100736279	20992723493	taking	take	VVG
304953	100736279	20992723494	it	it	PPH1
304953	100736279	20992723495	,	,	,
304953	100736279	20992723496	you	you	PPY
304953	100736279	20992723497	do	do	VD0
304953	100736279	20992723498	not	not	XX
304953	100736279	20992723499	return	return	VVI
304953	100736279	20992723500	to	to	II
304953	100736279	20992723501	normal	normal	JJ
304953	100736279	20992723502	.	.	.
304953	100736279	20992723503	Anyway	anyway	RR
304953	100736279	20992723504	,	,	,
304953	100736279	20992723505	I	i	PPIS1
304953	100736279	20992723506	thought	think	VVD
304953	100736279	20992723507	I	i	PPIS1
304953	100736279	20992723508	would	would	VM
304953	100736279	20992723509	update	update	VVI
304953	100736279	20992723510	this	this	DD1
304953	100736279	20992723511	.	.	.
304953	100736279	20992723512	Good	good	JJ
304953	100736279	20992723513	luck	luck	NN1
304953	100736279	20992723514	.	.	.
304953	100736279	20992723515	46996		MC
304953	100736279	20992723516	@qwx906996		FO
304953	100736285	20992723536	@@##	----------	----------
304953	100736285	20992723537	@@100736285		FO
304953	100736285	20992723538	@4936285/		VV0_NN1
304953	100736285	20992723539	46989		MC
304953	100736285	20992723540	@qwx906989		FO
304953	100736285	20992723541	<p>		NULL
304953	100736285	20992723542	Repeat	repeat	VV0
304953	100736285	20992723543	prostate	prostate	NN1
304953	100736285	20992723544	biopsies	biopsy	NN2
304953	100736285	20992723545	can	can	VM
304953	100736285	20992723546	help	help	VVI
304953	100736285	20992723547	detect	detect	VVI
304953	100736285	20992723548	disease	disease	NN1
304953	100736285	20992723549	progression	progression	NN1
304953	100736285	20992723550	in	in	II
304953	100736285	20992723551	men	man	NN2
304953	100736285	20992723552	diagnosed	diagnose	VVN_VVD
304953	100736285	20992723553	with	with	IW
304953	100736285	20992723554	early-stage	early-stage	JJ
304953	100736285	20992723555	prostate	prostate	NN1
304953	100736285	20992723556	cancer	cancer	NN1
304953	100736285	20992723557	pursuing	pursue	VVG
304953	100736285	20992723558	active	active	JJ
304953	100736285	20992723559	surveillance	surveillance	NN1
304953	100736285	20992723560	.	.	.
304953	100736285	20992723561	But	but	CCB
304953	100736285	20992723562	whether	whether	CSW
304953	100736285	20992723563	repeat	repeat	NN1%
304953	100736285	20992723564	biopsies	biopsy	NN2
304953	100736285	20992723565	are	be	VBR
304953	100736285	20992723566	really	really	RR
304953	100736285	20992723567	needed	need	VVN_VVD
304953	100736285	20992723568	"	"	"
304953	100736285	20992723569	and	and	CC
304953	100736285	20992723570	if	if	CS
304953	100736285	20992723571	so	so	RR
304953	100736285	20992723572	,	,	,
304953	100736285	20992723573	when	when	CS_RRQ
304953	100736285	20992723574	they	they	PPHS2
304953	100736285	20992723575	should	should	VM
304953	100736285	20992723576	be	be	VBI
304953	100736285	20992723577	done	do	VDN
304953	100736285	20992723578	"	"	"
304953	100736285	20992723579	are	be	VBR
304953	100736285	20992723580	unanswered	unanswered	JJ
304953	100736285	20992723581	questions	question	NN2
304953	100736285	20992723582	.	.	.
304953	100736285	20992723583	To	to	TO
304953	100736285	20992723584	add	add	VVI
304953	100736285	20992723585	to	to	II
304953	100736285	20992723586	the	the	AT
304953	100736285	20992723587	debate	debate	NN1
304953	100736285	20992723588	,	,	,
304953	100736285	20992723589	British	british	JJ
304953	100736285	20992723590	researchers	researcher	NN2
304953	100736285	20992723591	studied	study	VVD_VVN
304953	100736285	20992723592	119	119	MC
304953	100736285	20992723593	men	man	NN2
304953	100736285	20992723594	with	with	IW
304953	100736285	20992723595	untreated	untreated	JJ
304953	100736285	20992723596	disease	disease	NN1
304953	100736285	20992723597	who	who	PNQS
304953	100736285	20992723598	had	have	VHD
304953	100736285	20992723599	a	a	AT1
304953	100736285	20992723600	biopsy	biopsy	NN1
304953	100736285	20992723601	to	to	TO
304953	100736285	20992723602	diagnose	diagnose	VVI
304953	100736285	20992723603	the	the	AT
304953	100736285	20992723604	condition	condition	NN1
304953	100736285	20992723605	and	and	CC
304953	100736285	20992723606	a	a	AT1
304953	100736285	20992723607	follow-up	follow-up	JJ_NN1
304953	100736285	20992723608	biopsy	biopsy	NN1
304953	100736285	20992723609	18	18	MC
304953	100736285	20992723610	to	to	II
304953	100736285	20992723611	24	24	MC
304953	100736285	20992723612	months	month	NNT2
304953	100736285	20992723613	later	later	RRR
304953	100736285	20992723614	.	.	.
304953	100736285	20992723615	Among	among	II
304953	100736285	20992723616	the	the	AT
304953	100736285	20992723617	28%		NNU
304953	100736285	20992723618	of	of	IO
304953	100736285	20992723619	patients	patient	NN2
304953	100736285	20992723620	whose	whose	DDQGE
304953	100736285	20992723621	disease	disease	NN1
304953	100736285	20992723622	advanced	advance	VVD_VVN
304953	100736285	20992723623	,	,	,
304953	100736285	20992723624	two	two	MC
304953	100736285	20992723625	histological	histological	JJ
304953	100736285	20992723626	factors	factor	NN2
304953	100736285	20992723627	proved	prove	VVD_VVN
304953	100736285	20992723628	key	key	JJ
304953	100736285	20992723629	predictors	predictor	NN2
304953	100736285	20992723630	of	of	IO
304953	100736285	20992723631	cancer	cancer	NN1
304953	100736285	20992723632	progression	progression	NN1
304953	100736285	20992723633	:	:	:
304953	100736285	20992723634	PSA	psa	NP1
304953	100736285	20992723635	density	density	NN1
304953	100736285	20992723636	of	of	IO
304953	100736285	20992723637	0.2	0.2	MC
304953	100736285	20992723638	ng/ml/ml		FU
304953	100736285	20992723639	or	or	CC
304953	100736285	20992723640	greater	great	JJR
304953	100736285	20992723641	(	(	(
304953	100736285	20992723642	PSA	psa	NP1
304953	100736285	20992723643	density	density	NN1
304953	100736285	20992723644	is	be	VBZ
304953	100736285	20992723645	the	the	AT
304953	100736285	20992723646	PSA	psa	NP1
304953	100736285	20992723647	level	level	NN1_JJ
304953	100736285	20992723648	in	in	II
304953	100736285	20992723649	the	the	AT
304953	100736285	20992723650	blood	blood	NN1
304953	100736285	20992723651	divided	divide	VVN
304953	100736285	20992723652	by	by	II
304953	100736285	20992723653	the	the	AT
304953	100736285	20992723654	volume	volume	NN1
304953	100736285	20992723655	of	of	IO
304953	100736285	20992723656	the	the	AT
304953	100736285	20992723657	prostate	prostate	NN1
304953	100736285	20992723658	)	)	)
304953	100736285	20992723659	,	,	,
304953	100736285	20992723660	and	and	CC
304953	100736285	20992723661	any	any	DD
304953	100736285	20992723662	tissue	tissue	NN1
304953	100736285	20992723663	sample	sample	NN1
304953	100736285	20992723664	considered	consider	VVD_VVN
304953	100736285	20992723665	15%		NNU
304953	100736285	20992723666	cancerous	cancerous	JJ
304953	100736285	20992723667	or	or	CC
304953	100736285	20992723668	more	more	RRR_DAR
304953	100736285	20992723669	.	.	.
304953	100736285	20992723670	As	as	II
304953	100736285	20992723671	a	a	AT1
304953	100736285	20992723672	result	result	NN1
304953	100736285	20992723673	,	,	,
304953	100736285	20992723674	the	the	AT
304953	100736285	20992723675	researchers	researcher	NN2
304953	100736285	20992723676	conclude	conclude	VV0
304953	100736285	20992723677	that	that	CST
304953	100736285	20992723678	a	a	AT1
304953	100736285	20992723679	repeat	repeat	NN1%_VV0
304953	100736285	20992723680	biopsy	biopsy	NN1
304953	100736285	20992723681	should	should	VM
304953	100736285	20992723682	be	be	VBI
304953	100736285	20992723683	an	a	AT1
304953	100736285	20992723684	integral	integral	JJ
304953	100736285	20992723685	part	part	NN1
304953	100736285	20992723686	of	of	IO
304953	100736285	20992723687	active	active	JJ
304953	100736285	20992723688	surveillance	surveillance	NN1
304953	100736285	20992723689	for	for	IF
304953	100736285	20992723690	untreated	untreated	JJ
304953	100736285	20992723691	,	,	,
304953	100736285	20992723692	localized	localized	JJ_VVD
304953	100736285	20992723693	prostate	prostate	NN1
304953	100736285	20992723694	cancer	cancer	NN1
304953	100736285	20992723695	.	.	.
304953	100736285	20992723696	They	they	PPHS2
304953	100736285	20992723697	also	also	RR
304953	100736285	20992723698	recommend	recommend	VV0
304953	100736285	20992723699	considering	considering	II_VVG
304953	100736285	20992723700	an	a	AT1
304953	100736285	20992723701	immediate	immediate	JJ
304953	100736285	20992723702	repeat	repeat	NN1%_VV0
304953	100736285	20992723703	biopsy	biopsy	NN1
304953	100736285	20992723704	for	for	IF
304953	100736285	20992723705	patients	patient	NN2
304953	100736285	20992723706	with	with	IW
304953	100736285	20992723707	a	a	AT1
304953	100736285	20992723708	PSA	psa	NP1
304953	100736285	20992723709	density	density	NN1
304953	100736285	20992723710	greater	great	JJR
304953	100736285	20992723711	than	than	CSN
304953	100736285	20992723712	0.2	0.2	MC
304953	100736285	20992723713	ng/ml/ml		FU
304953	100736285	20992723714	.	.	.
304953	100736285	20992723715	<p>		NULL
304953	100736285	20992723716	Just	just	RR
304953	100736285	20992723717	yesterday	yesterday	RT
304953	100736285	20992723718	,	,	,
304953	100736285	20992723719	I	i	PPIS1
304953	100736285	20992723720	leanred		VVD
304953	100736285	20992723721	of	of	IO
304953	100736285	20992723722	the	the	AT
304953	100736285	20992723723	passing	passing	NN1
304953	100736285	20992723724	of	of	IO
304953	100736285	20992723725	an	a	AT1
304953	100736285	20992723726	old	old	JJ
304953	100736285	20992723727	high	high	JJ
304953	100736285	20992723728	@		II
304953	100736285	20992723729	@		II
304953	100736285	20992723730	@		II
304953	100736285	20992723731	@		II
304953	100736285	20992723732	@		II
304953	100736285	20992723733	@		II
304953	100736285	20992723734	@		II
304953	100736285	20992723735	@		II
304953	100736285	20992723736	@		II
304953	100736285	20992723737	@		II
304953	100736285	20992723738	of	of	II22
304953	100736285	20992723739	me	me	PPIO1
304953	100736285	20992723740	.	.	.
304953	100736285	20992723741	But	but	CCB
304953	100736285	20992723742	we	we	PPIS2
304953	100736285	20992723743	lived	live	VVD
304953	100736285	20992723744	about	about	II
304953	100736285	20992723745	7	7	MC
304953	100736285	20992723746	houses	house	NN2
304953	100736285	20992723747	from	from	II
304953	100736285	20992723748	each	each	PPX221
304953	100736285	20992723749	other	other	PPX222
304953	100736285	20992723750	for	for	IF
304953	100736285	20992723751	about	about	RG
304953	100736285	20992723752	15	15	MC
304953	100736285	20992723753	years	year	NNT2
304953	100736285	20992723754	.	.	.
304953	100736285	20992723755	Unfortunately	unfortunately	RR
304953	100736285	20992723756	,	,	,
304953	100736285	20992723757	he	he	PPHS1
304953	100736285	20992723758	died	die	VVD
304953	100736285	20992723759	from	from	II
304953	100736285	20992723760	prostate	prostate	NN1
304953	100736285	20992723761	cancer	cancer	NN1
304953	100736285	20992723762	.	.	.
304953	100736285	20992723763	Is	be	VBZ
304953	100736285	20992723764	this	this	DD1
304953	100736285	20992723765	the	the	AT
304953	100736285	20992723766	devils	devil	NN2
304953	100736285	20992723767	way	way	NN1
304953	100736285	20992723768	of	of	IO
304953	100736285	20992723769	sewing	sew	VVG_NN1
304953	100736285	20992723770	seeds	seed	NN2
304953	100736285	20992723771	of	of	IO
304953	100736285	20992723772	doubt	doubt	NN1
304953	100736285	20992723773	and	and	CC
304953	100736285	20992723774	fear	fear	VV0_NN1
304953	100736285	20992723775	in	in	II_RP@
304953	100736285	20992723776	my	my	APPGE
304953	100736285	20992723777	mind	mind	NN1
304953	100736285	20992723778	?	?	?
304953	100736285	20992723779	I	i	PPIS1
304953	100736285	20992723780	believe	believe	VV0
304953	100736285	20992723781	so	so	RR
304953	100736285	20992723782	.	.	.
304953	100736285	20992723783	Shook	shake	VVD
304953	100736285	20992723784	me	me	PPIO1
304953	100736285	20992723785	up	up	RP
304953	100736285	20992723786	quite	quite	RG
304953	100736285	20992723787	a	a	RR21
304953	100736285	20992723788	bit	bit	RR22
304953	100736285	20992723789	last	last	MD
304953	100736285	20992723790	night	night	NNT1
304953	100736285	20992723791	.	.	.
304953	100736285	20992723792	But	but	CCB
304953	100736285	20992723793	today	today	RT
304953	100736285	20992723794	is	be	VBZ
304953	100736285	20992723795	a	a	AT1
304953	100736285	20992723796	new	new	JJ
304953	100736285	20992723797	day	day	NNT1
304953	100736285	20992723798	.	.	.
304953	100736285	20992723799	A	a	AT1_ZZ1
304953	100736285	20992723800	new	new	JJ
304953	100736285	20992723801	opportunity	opportunity	NN1
304953	100736285	20992723802	to	to	TO
304953	100736285	20992723803	be	be	VBI
304953	100736285	20992723804	thankful	thankful	JJ
304953	100736285	20992723805	.	.	.
304953	100736285	20992723806	Maybe	maybe	RR
304953	100736285	20992723807	even	even	RR
304953	100736285	20992723808	pause	pause	VV0@_NN1
304953	100736285	20992723809	to	to	TO
304953	100736285	20992723810	think	think	VVI
304953	100736285	20992723811	and	and	CC
304953	100736285	20992723812	smile	smile	NN1_VV0
304953	100736285	20992723813	.	.	.
304953	100736285	20992723814	46996		MC
304953	100736285	20992723815	@qwx906996		FO
304953	100736290	20992723835	@@##	----------	----------
304953	100736290	20992723836	@@100736290		FO
304953	100736290	20992723837	@4936290/		VV0_NN1
304953	100736290	20992723838	46989		MC
304953	100736290	20992723839	@qwx906989		FO
304953	100736290	20992723840	<p>		NULL
304953	100736290	20992723841	Is	be	VBZ
304953	100736290	20992723842	it	it	PPH1
304953	100736290	20992723843	possible	possible	JJ
304953	100736290	20992723844	for	for	IF
304953	100736290	20992723845	a	a	AT1
304953	100736290	20992723846	gene	gene	NN1
304953	100736290	20992723847	test	test	NN1_VV0
304953	100736290	20992723848	to	to	TO
304953	100736290	20992723849	identify	identify	VVI
304953	100736290	20992723850	whether	whether	CSW
304953	100736290	20992723851	a	a	AT1
304953	100736290	20992723852	prostate	prostate	NN1
304953	100736290	20992723853	that 's		VVZ
304953	100736290	20992723854	healthy	healthy	JJ
304953	100736290	20992723855	today	today	RT
304953	100736290	20992723856	is	be	VBZ
304953	100736290	20992723857	sure	sure	JJ
304953	100736290	20992723858	to	to	TO
304953	100736290	20992723859	develop	develop	VVI
304953	100736290	20992723860	cancer	cancer	NN1
304953	100736290	20992723861	down	down	II
304953	100736290	20992723862	the	the	AT
304953	100736290	20992723863	road	road	NN1
304953	100736290	20992723864	?	?	?
304953	100736290	20992723865	And	and	CC
304953	100736290	20992723866	should	should	VM
304953	100736290	20992723867	results	result	NN2
304953	100736290	20992723868	of	of	IO
304953	100736290	20992723869	such	such	DA
304953	100736290	20992723870	a	a	AT1
304953	100736290	20992723871	test	test	NN1
304953	100736290	20992723872	be	be	VBI
304953	100736290	20992723873	the	the	AT
304953	100736290	20992723874	basis	basis	NN1
304953	100736290	20992723875	for	for	IF
304953	100736290	20992723876	removing	remove	VVG
304953	100736290	20992723877	a	a	AT1
304953	100736290	20992723878	seemingly	seemingly	RR
304953	100736290	20992723879	healthy	healthy	JJ
304953	100736290	20992723880	prostate	prostate	NN1
304953	100736290	20992723881	gland	gland	NN1
304953	100736290	20992723882	?	?	?
304953	100736290	20992723883	Those	those	DD2
304953	100736290	20992723884	are	be	VBR
304953	100736290	20992723885	questions	question	NN2
304953	100736290	20992723886	raised	raise	VVN
304953	100736290	20992723887	by	by	II
304953	100736290	20992723888	recent	recent	JJ
304953	100736290	20992723889	press	press	NN1
304953	100736290	20992723890	reports	report	NN2
304953	100736290	20992723891	of	of	IO
304953	100736290	20992723892	a	a	AT1
304953	100736290	20992723893	British	british	JJ
304953	100736290	20992723894	man	man	NN1
304953	100736290	20992723895	who	who	PNQS
304953	100736290	20992723896	had	have	VHD
304953	100736290	20992723897	his	his	APPGE
304953	100736290	20992723898	prostate	prostate	NN1
304953	100736290	20992723899	gland	gland	NN1
304953	100736290	20992723900	removed	remove	VVN_VVD
304953	100736290	20992723901	because	because	CS
304953	100736290	20992723902	he	he	PPHS1
304953	100736290	20992723903	carried	carry	VVD
304953	100736290	20992723904	a	a	AT1
304953	100736290	20992723905	faulty	faulty	JJ
304953	100736290	20992723906	gene	gene	NN1
304953	100736290	20992723907	called	call	VVN
304953	100736290	20992723908	BRCA2	brca2	FO
304953	100736290	20992723909	.	.	.
304953	100736290	20992723910	The	the	AT
304953	100736290	20992723911	53-year-old	53-year-old	JJ
304953	100736290	20992723912	man	man	NN1
304953	100736290	20992723913	was	be	VBDZ
304953	100736290	20992723914	taking	take	VVG
304953	100736290	20992723915	part	part	NN1
304953	100736290	20992723916	in	in	II
304953	100736290	20992723917	a	a	AT1
304953	100736290	20992723918	prostate	prostate	NN1
304953	100736290	20992723919	cancer	cancer	NN1
304953	100736290	20992723920	trial	trial	NN1
304953	100736290	20992723921	conducted	conduct	VVN
304953	100736290	20992723922	by	by	II
304953	100736290	20992723923	the	the	AT
304953	100736290	20992723924	Institute	institute	NN1
304953	100736290	20992723925	of	of	IO
304953	100736290	20992723926	Cancer	cancer	NN1
304953	100736290	20992723927	Research	research	NN1
304953	100736290	20992723928	.	.	.
304953	100736290	20992723929	<p>		NULL
304953	100736290	20992723930	Genetic	genetic	JJ
304953	100736290	20992723931	testing	testing	NN1
304953	100736290	20992723932	has	have	VHZ
304953	100736290	20992723933	been	be	VBN
304953	100736290	20992723934	used	use	VVN
304953	100736290	20992723935	to	to	TO
304953	100736290	20992723936	guide	guide	VVI
304953	100736290	20992723937	cancer	cancer	NN1
304953	100736290	20992723938	treatment	treatment	NN1
304953	100736290	20992723939	for	for	IF
304953	100736290	20992723940	several	several	DA2
304953	100736290	20992723941	years	year	NNT2
304953	100736290	20992723942	.	.	.
304953	100736290	20992723943	But	but	CCB
304953	100736290	20992723944	it	it	PPH1
304953	100736290	20992723945	reached	reach	VVD
304953	100736290	20992723946	a	a	AT1
304953	100736290	20992723947	new	new	JJ
304953	100736290	20992723948	height	height	NN1
304953	100736290	20992723949	when	when	CS_RRQ
304953	100736290	20992723950	actress	actress	NN1
304953	100736290	20992723951	Angelina	angelina	NP1
304953	100736290	20992723952	Jolie	jolie	NP1
304953	100736290	20992723953	revealed	reveal	VVD
304953	100736290	20992723954	in	in	II
304953	100736290	20992723955	The	the	AT
304953	100736290	20992723956	New	new	NP1
304953	100736290	20992723957	York	york	NP1
304953	100736290	20992723958	Times	time	NNT2
304953	100736290	20992723959	that	that	CST
304953	100736290	20992723960	she	she	PPHS1
304953	100736290	20992723961	had	have	VHD
304953	100736290	20992723962	both	both	DB2
304953	100736290	20992723963	of	of	IO
304953	100736290	20992723964	her	her	APPGE
304953	100736290	20992723965	breasts	breast	NN2
304953	100736290	20992723966	removed	remove	VVD_VVN
304953	100736290	20992723967	.	.	.
304953	100736290	20992723968	She	she	PPHS1
304953	100736290	20992723969	did	do	VDD
304953	100736290	20992723970	this	this	DD1
304953	100736290	20992723971	not	not	XX
304953	100736290	20992723972	because	because	CS
304953	100736290	20992723973	she	she	PPHS1
304953	100736290	20992723974	had	have	VHD
304953	100736290	20992723975	breast	breast	NN1
304953	100736290	20992723976	cancer	cancer	NN1
304953	100736290	20992723977	,	,	,
304953	100736290	20992723978	but	but	CCB
304953	100736290	20992723979	because	because	CS
304953	100736290	20992723980	she	she	PPHS1
304953	100736290	20992723981	carried	carry	VVD
304953	100736290	20992723982	a	a	AT1
304953	100736290	20992723983	gene	gene	NN1
304953	100736290	20992723984	called	call	VVN
304953	100736290	20992723985	BRCA1	brca1	FO
304953	100736290	20992723986	that	that	DD1_CST
304953	100736290	20992723987	put	put	VVD_VV0
304953	100736290	20992723988	her	her	PPHO1
304953	100736290	20992723989	at	at	II
304953	100736290	20992723990	high	high	JJ
304953	100736290	20992723991	risk	risk	NN1
304953	100736290	20992723992	of	of	IO
304953	100736290	20992723993	developing	developing	JJ_VVG
304953	100736290	20992723994	breast	breast	NN1
304953	100736290	20992723995	cancer	cancer	NN1
304953	100736290	20992723996	in	in	II
304953	100736290	20992723997	her	her	APPGE_PPHO1
304953	100736290	20992723998	lifetime	lifetime	NNT1
304953	100736290	20992723999	.	.	.
304953	100736290	20992724000	Jolie	jolie	NN1_NP1@
304953	100736290	20992724001	was n't		VV0
304953	100736290	20992724002	the	the	AT
304953	100736290	20992724003	first	first	MD
304953	100736290	20992724004	woman	woman	NN1
304953	100736290	20992724005	to	to	TO
304953	100736290	20992724006	do	do	VDI
304953	100736290	20992724007	this	this	DD1
304953	100736290	20992724008	,	,	,
304953	100736290	20992724009	but	but	CCB
304953	100736290	20992724010	was	be	VBDZ
304953	100736290	20992724011	certainly	certainly	RR
304953	100736290	20992724012	the	the	AT
304953	100736290	20992724013	most	most	RGT
304953	100736290	20992724014	famous	famous	JJ
304953	100736290	20992724015	one	one	PN1
304953	100736290	20992724016	so	so	RG
304953	100736290	20992724017	far	far	RR
304953	100736290	20992724018	.	.	.
304953	100736290	20992724019	<p>		NULL
304953	100736290	20992724020	Although	although	CS
304953	100736290	20992724021	press	press	NN1
304953	100736290	20992724022	reports	report	NN2
304953	100736290	20992724023	likened	liken	VVD_VVN
304953	100736290	20992724024	the	the	AT
304953	100736290	20992724025	British	british	JJ
304953	100736290	20992724026	mans	man	NN2
304953	100736290	20992724027	@		II
304953	100736290	20992724028	@		II
304953	100736290	20992724029	@		II
304953	100736290	20992724030	@		II
304953	100736290	20992724031	@		II
304953	100736290	20992724032	@		II
304953	100736290	20992724033	@		II
304953	100736290	20992724034	@		II
304953	100736290	20992724035	@		II
304953	100736290	20992724036	@		II
304953	100736290	20992724037	the	the	AT
304953	100736290	20992724038	comparison	comparison	NN1
304953	100736290	20992724039	is	be	VBZ
304953	100736290	20992724040	not	not	XX
304953	100736290	20992724041	entirely	entirely	RR
304953	100736290	20992724042	valid	valid	JJ
304953	100736290	20992724043	.	.	.
304953	100736290	20992724044	<p>		NULL
304953	100736290	20992724045	For	for	IF
304953	100736290	20992724046	one	one	MC1
304953	100736290	20992724047	thing	thing	NN1
304953	100736290	20992724048	,	,	,
304953	100736290	20992724049	removal	removal	NN1
304953	100736290	20992724050	of	of	IO
304953	100736290	20992724051	the	the	AT
304953	100736290	20992724052	mans	man	NN2
304953	100736290	20992724053	prostate	prostate	NN1
304953	100736290	20992724054	was	be	VBDZ
304953	100736290	20992724055	not	not	XX
304953	100736290	20992724056	purely	purely	RR
304953	100736290	20992724057	preventive	preventive	JJ
304953	100736290	20992724058	,	,	,
304953	100736290	20992724059	because	because	CS
304953	100736290	20992724060	a	a	AT1
304953	100736290	20992724061	biopsy	biopsy	NN1
304953	100736290	20992724062	had	have	VHD
304953	100736290	20992724063	already	already	RR
304953	100736290	20992724064	shown	show	VVN
304953	100736290	20992724065	the	the	AT
304953	100736290	20992724066	presence	presence	NN1
304953	100736290	20992724067	of	of	IO
304953	100736290	20992724068	very	very	RG
304953	100736290	20992724069	early	early	JJ
304953	100736290	20992724070	prostate	prostate	NN1
304953	100736290	20992724071	cancer	cancer	NN1
304953	100736290	20992724072	.	.	.
304953	100736290	20992724073	He	he	PPHS1
304953	100736290	20992724074	also	also	RR
304953	100736290	20992724075	had	have	VHD
304953	100736290	20992724076	a	a	AT1
304953	100736290	20992724077	family	family	NN1
304953	100736290	20992724078	history	history	NN1
304953	100736290	20992724079	of	of	IO
304953	100736290	20992724080	prostate	prostate	NN1
304953	100736290	20992724081	and	and	CC
304953	100736290	20992724082	breast	breast	NN1
304953	100736290	20992724083	cancer	cancer	NN1
304953	100736290	20992724084	,	,	,
304953	100736290	20992724085	further	far	RRR
304953	100736290	20992724086	raising	raise	VVG
304953	100736290	20992724087	his	his	APPGE
304953	100736290	20992724088	risk	risk	NN1
304953	100736290	20992724089	above	above	II
304953	100736290	20992724090	that	that	DD1
304953	100736290	20992724091	of	of	IO
304953	100736290	20992724092	the	the	AT
304953	100736290	20992724093	average	average	JJ_NN1
304953	100736290	20992724094	man	man	NN1
304953	100736290	20992724095	.	.	.
304953	100736290	20992724096	Under	under	II
304953	100736290	20992724097	these	these	DD2
304953	100736290	20992724098	circumstances	circumstance	NN2
304953	100736290	20992724099	,	,	,
304953	100736290	20992724100	many	many	DA2
304953	100736290	20992724101	men	man	NN2
304953	100736290	20992724102	in	in	II
304953	100736290	20992724103	the	the	AT
304953	100736290	20992724104	United	united	NP1
304953	100736290	20992724105	States	state	NP1
304953	100736290	20992724106	"	"	"
304953	100736290	20992724107	and	and	CC
304953	100736290	20992724108	their	their	APPGE
304953	100736290	20992724109	doctors	doctor	NN2
304953	100736290	20992724110	"	"	"
304953	100736290	20992724111	might	might	VM
304953	100736290	20992724112	have	have	VHI
304953	100736290	20992724113	considered	consider	VVN
304953	100736290	20992724114	treatment	treatment	NN1
304953	100736290	20992724115	,	,	,
304953	100736290	20992724116	whether	whether	CSW31
304953	100736290	20992724117	or	or	CSW32
304953	100736290	20992724118	not	not	CSW33
304953	100736290	20992724119	they	they	PPHS2
304953	100736290	20992724120	had	have	VHD
304953	100736290	20992724121	the	the	AT
304953	100736290	20992724122	BRCA	brca	NN1_NP1
304953	100736290	20992724123	mutations	mutation	NN2
304953	100736290	20992724124	or	or	CC
304953	100736290	20992724125	not	not	XX
304953	100736290	20992724126	.	.	.
304953	100736290	20992724127	<p>		NULL
304953	100736290	20992724128	Jolie	jolie	NN1_NP1@
304953	100736290	20992724129	,	,	,
304953	100736290	20992724130	in	in	II
304953	100736290	20992724131	contrast	contrast	NN1
304953	100736290	20992724132	,	,	,
304953	100736290	20992724133	made	make	VVD_VVN
304953	100736290	20992724134	her	her	APPGE
304953	100736290	20992724135	decision	decision	NN1
304953	100736290	20992724136	to	to	TO
304953	100736290	20992724137	have	have	VHI
304953	100736290	20992724138	both	both	DB2
304953	100736290	20992724139	breasts	breast	NN2
304953	100736290	20992724140	removed	remove	VVN
304953	100736290	20992724141	based	base	VVN
304953	100736290	20992724142	solely	solely	RR
304953	100736290	20992724143	on	on	II
304953	100736290	20992724144	her	her	APPGE
304953	100736290	20992724145	BRCA	brca	NN1
304953	100736290	20992724146	gene	gene	NN1
304953	100736290	20992724147	status	status	NN1
304953	100736290	20992724148	.	.	.
304953	100736290	20992724149	No	no	AT_UH
304953	100736290	20992724150	biopsy	biopsy	NN1
304953	100736290	20992724151	had	have	VHD
304953	100736290	20992724152	shown	show	VVN
304953	100736290	20992724153	the	the	AT
304953	100736290	20992724154	presence	presence	NN1
304953	100736290	20992724155	of	of	IO
304953	100736290	20992724156	early	early	JJ
304953	100736290	20992724157	stage	stage	NN1
304953	100736290	20992724158	breast	breast	NN1
304953	100736290	20992724159	cancer	cancer	NN1
304953	100736290	20992724160	.	.	.
304953	100736290	20992724161	<h>		NULL
304953	100736290	20992724162	BRCA1	brca1	FO
304953	100736290	20992724163	and	and	CC
304953	100736290	20992724164	BRCA2	brca2	FO
304953	100736290	20992724165	<p>		NULL
304953	100736290	20992724166	BRCA1	brca1	FO
304953	100736290	20992724167	and	and	CC
304953	100736290	20992724168	BRCA2	brca2	FO
304953	100736290	20992724169	belong	belong	VV0
304953	100736290	20992724170	to	to	II
304953	100736290	20992724171	a	a	AT1
304953	100736290	20992724172	class	class	NN1
304953	100736290	20992724173	of	of	IO
304953	100736290	20992724174	genes	gene	NN2
304953	100736290	20992724175	known	know	VVN
304953	100736290	20992724176	as	as	II
304953	100736290	20992724177	tumor	tumor	NN1
304953	100736290	20992724178	suppressors	suppressor	NN2
304953	100736290	20992724179	.	.	.
304953	100736290	20992724180	They	they	PPHS2
304953	100736290	20992724181	make	make	VV0
304953	100736290	20992724182	proteins	protein	NN2
304953	100736290	20992724183	that	that	CST
304953	100736290	20992724184	somehow	somehow	RR
304953	100736290	20992724185	suppress	suppress	VV0
304953	100736290	20992724186	the	the	AT
304953	100736290	20992724187	birth	birth	NN1
304953	100736290	20992724188	or	or	CC
304953	100736290	20992724189	survival	survival	NN1
304953	100736290	20992724190	of	of	IO
304953	100736290	20992724191	cancer	cancer	NN1
304953	100736290	20992724192	cells	cell	NN2
304953	100736290	20992724193	.	.	.
304953	100736290	20992724194	These	these	DD2
304953	100736290	20992724195	genes	gene	NN2
304953	100736290	20992724196	were	be	VBDR
304953	100736290	20992724197	discovered	discover	VVN@
304953	100736290	20992724198	in	in	II
304953	100736290	20992724199	hereditary	hereditary	JJ
304953	100736290	20992724200	BReast	breast	NN1
304953	100736290	20992724201	CAncer	cancer	NN1
304953	100736290	20992724202	cells	cell	NN2
304953	100736290	20992724203	,	,	,
304953	100736290	20992724204	which	which	DDQ
304953	100736290	20992724205	is	be	VBZ
304953	100736290	20992724206	how	how	RRQ
304953	100736290	20992724207	they	they	PPHS2
304953	100736290	20992724208	got	get	VVD
304953	100736290	20992724209	their	their	APPGE
304953	100736290	20992724210	names	name	NN2
304953	100736290	20992724211	.	.	.
304953	100736290	20992724212	Since	since	II
304953	100736290	20992724213	then	then	RT
304953	100736290	20992724214	,	,	,
304953	100736290	20992724215	mutations	mutation	NN2
304953	100736290	20992724216	in	in	II
304953	100736290	20992724217	the	the	AT
304953	100736290	20992724218	BRCA1	brca1	FO
304953	100736290	20992724219	and	and	CC
304953	100736290	20992724220	BRCA2	brca2	FO
304953	100736290	20992724221	genes	gene	NN2
304953	100736290	20992724222	have	have	VH0
304953	100736290	20992724223	also	also	RR
304953	100736290	20992724224	been	be	VBN
304953	100736290	20992724225	linked	link	VVN
304953	100736290	20992724226	to	to	II
304953	100736290	20992724227	@		II
304953	100736290	20992724228	@		II
304953	100736290	20992724229	@		II
304953	100736290	20992724230	@		II
304953	100736290	20992724231	@		II
304953	100736290	20992724232	@		II
304953	100736290	20992724233	@		II
304953	100736290	20992724234	@		II
304953	100736290	20992724235	@		II
304953	100736290	20992724236	@		II
304953	100736290	20992724237	,	,	,
304953	100736290	20992724238	uterine	uterine	JJ
304953	100736290	20992724239	,	,	,
304953	100736290	20992724240	pancreatic	pancreatic	JJ
304953	100736290	20992724241	,	,	,
304953	100736290	20992724242	testicular	testicular	JJ
304953	100736290	20992724243	,	,	,
304953	100736290	20992724244	and	and	CC
304953	100736290	20992724245	prostate	prostate	NN1
304953	100736290	20992724246	cancers	cancer	NN2
304953	100736290	20992724247	.	.	.
304953	100736290	20992724248	(	(	(
304953	100736290	20992724249	You	you	PPY
304953	100736290	20992724250	can	can	VM
304953	100736290	20992724251	learn	learn	VVI
304953	100736290	20992724252	more	more	RRR_DAR
304953	100736290	20992724253	about	about	II
304953	100736290	20992724254	BRCA1	brca1	FO
304953	100736290	20992724255	and	and	CC
304953	100736290	20992724256	BRAC2		FO
304953	100736290	20992724257	at	at	II
304953	100736290	20992724258	the	the	AT
304953	100736290	20992724259	National	national	JJ
304953	100736290	20992724260	Cancer	cancer	NN1
304953	100736290	20992724261	Institutes	institute	NN2
304953	100736290	20992724262	website	website	NN1
304953	100736290	20992724263	.	.	.
304953	100736290	20992724264	)	)	)
304953	100736290	20992724265	<p>		NULL
304953	100736290	20992724266	Results	result	NN2
304953	100736290	20992724267	from	from	II
304953	100736290	20992724268	an	a	AT1
304953	100736290	20992724269	international	international	JJ
304953	100736290	20992724270	clinical	clinical	JJ
304953	100736290	20992724271	trial	trial	NN1
304953	100736290	20992724272	published	publish	VVD_VVN
304953	100736290	20992724273	earlier	early	RRR
304953	100736290	20992724274	this	this	DD1
304953	100736290	20992724275	year	year	NNT1
304953	100736290	20992724276	in	in	II
304953	100736290	20992724277	the	the	AT
304953	100736290	20992724278	Journal	journal	NN1
304953	100736290	20992724279	of	of	IO
304953	100736290	20992724280	Clinical	clinical	JJ
304953	100736290	20992724281	Oncology	oncology	NN1_NP1
304953	100736290	20992724282	found	find	VVD_VVN
304953	100736290	20992724283	that	that	CST
304953	100736290	20992724284	men	man	NN2
304953	100736290	20992724285	with	with	IW
304953	100736290	20992724286	the	the	AT
304953	100736290	20992724287	BRCA2	brca2	FO
304953	100736290	20992724288	gene	gene	NN1
304953	100736290	20992724289	mutation	mutation	NN1
304953	100736290	20992724290	are	be	VBR
304953	100736290	20992724291	more	more	RGR
304953	100736290	20992724292	likely	likely	JJ
304953	100736290	20992724293	to	to	TO
304953	100736290	20992724294	develop	develop	VVI
304953	100736290	20992724295	aggressive	aggressive	JJ
304953	100736290	20992724296	and	and	CC
304953	100736290	20992724297	fatal	fatal	JJ
304953	100736290	20992724298	prostate	prostate	NN1
304953	100736290	20992724299	cancers	cancer	NN2
304953	100736290	20992724300	.	.	.
304953	100736290	20992724301	<p>		NULL
304953	100736290	20992724302	Should	should	VM
304953	100736290	20992724303	testing	testing	NN1
304953	100736290	20992724304	for	for	IF
304953	100736290	20992724305	BRCA2	brca2	FO
304953	100736290	20992724306	guide	guide	VV0
304953	100736290	20992724307	whether	whether	CSW
304953	100736290	20992724308	a	a	AT1
304953	100736290	20992724309	man	man	NN1
304953	100736290	20992724310	have	have	VH0
304953	100736290	20992724311	his	his	APPGE
304953	100736290	20992724312	prostate	prostate	NN1
304953	100736290	20992724313	removed	remove	VVN
304953	100736290	20992724314	?	?	?
304953	100736290	20992724315	Although	although	CS
304953	100736290	20992724316	it	it	PPH1
304953	100736290	20992724317	is n't		VV0
304953	100736290	20992724318	currently	currently	RR
304953	100736290	20992724319	the	the	AT
304953	100736290	20992724320	sole	sole	JJ
304953	100736290	20992724321	piece	piece	NN1
304953	100736290	20992724322	of	of	IO
304953	100736290	20992724323	evidence	evidence	NN1
304953	100736290	20992724324	,	,	,
304953	100736290	20992724325	it	it	PPH1
304953	100736290	20992724326	may	may	VM
304953	100736290	20992724327	contribute	contribute	VVI
304953	100736290	20992724328	to	to	II
304953	100736290	20992724329	the	the	AT
304953	100736290	20992724330	decision	decision	NN1
304953	100736290	20992724331	making	make	VVG_NN1@
304953	100736290	20992724332	process	process	NN1
304953	100736290	20992724333	.	.	.
304953	100736290	20992724334	"	"	"
304953	100736290	20992724335	In	in	II
304953	100736290	20992724336	the	the	AT
304953	100736290	20992724337	setting	setting	NN1
304953	100736290	20992724338	of	of	IO
304953	100736290	20992724339	a	a	AT1
304953	100736290	20992724340	strong	strong	JJ
304953	100736290	20992724341	family	family	NN1
304953	100736290	20992724342	history	history	NN1
304953	100736290	20992724343	,	,	,
304953	100736290	20992724344	this	this	DD1
304953	100736290	20992724345	could	could	VM
304953	100736290	20992724346	be	be	VBI
304953	100736290	20992724347	one	one	MC1
304953	100736290	20992724348	additional	additional	JJ
304953	100736290	20992724349	data	data	NN
304953	100736290	20992724350	point	point	NN1
304953	100736290	20992724351	used	use	VMK
304953	100736290	20992724352	to	to	TO
304953	100736290	20992724353	arrive	arrive	VVI
304953	100736290	20992724354	at	at	II
304953	100736290	20992724355	a	a	AT1
304953	100736290	20992724356	decision	decision	NN1
304953	100736290	20992724357	,	,	,
304953	100736290	20992724358	"	"	"
304953	100736290	20992724359	says	say	VVZ
304953	100736290	20992724360	Dr.		NNB
304953	100736290	20992724361	Marc	marc	NP1
304953	100736290	20992724362	B.		NP1
304953	100736290	20992724363	Garnick		NP1
304953	100736290	20992724364	,	,	,
304953	100736290	20992724365	clinical	clinical	JJ
304953	100736290	20992724366	professor	professor	NN1
304953	100736290	20992724367	of	of	IO
304953	100736290	20992724368	medicine	medicine	NN1
304953	100736290	20992724369	at	at	II
304953	100736290	20992724370	Harvard-affiliated	harvard-affiliated	JJ_NN1
304953	100736290	20992724371	Beth	beth	NP1
304953	100736290	20992724372	Israel	israel	NP1
304953	100736290	20992724373	Deaconess	deaconess	NN1
304953	100736290	20992724374	Medical	medical	JJ
304953	100736290	20992724375	Center	center	NN1
304953	100736290	20992724376	in	in	II
304953	100736290	20992724377	Boston	boston	NP1
304953	100736290	20992724378	,	,	,
304953	100736290	20992724379	and	and	CC
304953	100736290	20992724380	editor	editor	NN1
304953	100736290	20992724381	of	of	IO
304953	100736290	20992724382	the	the	AT
304953	100736290	20992724383	Harvard	harvard	NP1
304953	100736290	20992724384	Medical	medical	JJ
304953	100736290	20992724385	School	school	NN1
304953	100736290	20992724386	Annual	annual	JJ_NN1@
304953	100736290	20992724387	Report	report	NN1
304953	100736290	20992724388	on	on	II
304953	100736290	20992724389	Prostate	prostate	NN1
304953	100736290	20992724390	Diseases	disease	NN2
304953	100736290	20992724391	.	.	.
304953	100736290	20992724392	"	"	"
304953	100736290	20992724393	But	but	CCB
304953	100736290	20992724394	we	we	PPIS2
304953	100736290	20992724395	are	be	VBR
304953	100736290	20992724396	nowhere	nowhere	RL
304953	100736290	20992724397	near	near	II_RL
304953	100736290	20992724398	providing	provide	VVG
304953	100736290	20992724399	any	any	DD
304953	100736290	20992724400	definitive	definitive	JJ
304953	100736290	20992724401	answers	answer	NN2
304953	100736290	20992724402	on	on	II
304953	100736290	20992724403	this	this	DD1
304953	100736290	20992724404	question	question	NN1
304953	100736290	20992724405	in	in	II
304953	100736290	20992724406	2013	2013	MC
304953	100736290	20992724407	.	.	.
304953	100736290	20992724408	"	"	"
304953	100736290	20992724409	<p>		NULL
304953	100736290	20992724410	Trying	try	VVG
304953	100736290	20992724411	to	to	TO
304953	100736290	20992724412	predict	predict	VVI
304953	100736290	20992724413	the	the	AT
304953	100736290	20992724414	development	development	NN1
304953	100736290	20992724415	of	of	IO
304953	100736290	20992724416	cancer	cancer	NN1
304953	100736290	20992724417	before	before	CS
304953	100736290	20992724418	it	it	PPH1
304953	100736290	20992724419	happens	happen	VVZ
304953	100736290	20992724420	is	be	VBZ
304953	100736290	20992724421	still	still	RR
304953	100736290	20992724422	in	in	II
304953	100736290	20992724423	its	its	APPGE
304953	100736290	20992724424	infancy	infancy	NN1
304953	100736290	20992724425	.	.	.
304953	100736290	20992724426	No	no	PN121
304953	100736290	20992724427	@		II
304953	100736290	20992724428	@		II
304953	100736290	20992724429	@		II
304953	100736290	20992724430	@		II
304953	100736290	20992724431	@		II
304953	100736290	20992724432	@		II
304953	100736290	20992724433	@		II
304953	100736290	20992724434	@		II
304953	100736290	20992724435	@		II
304953	100736290	20992724436	@		II
304953	100736290	20992724437	prostate	prostate	NN1
304953	100736290	20992724438	removal	removal	NN1
304953	100736290	20992724439	prevents	prevent	VVZ
304953	100736290	20992724440	death	death	NN1
304953	100736290	20992724441	and	and	CC
304953	100736290	20992724442	disability	disability	NN1
304953	100736290	20992724443	.	.	.
304953	100736290	20992724444	"	"	"
304953	100736290	20992724445	If	if	CS
304953	100736290	20992724446	a	a	AT1
304953	100736290	20992724447	man	man	NN1
304953	100736290	20992724448	decides	decide	VVZ
304953	100736290	20992724449	to	to	TO
304953	100736290	20992724450	undergo	undergo	VVI
304953	100736290	20992724451	prostatectomy	prostatectomy	NN1
304953	100736290	20992724452	or	or	CC
304953	100736290	20992724453	other	other	JJ
304953	100736290	20992724454	treatment	treatment	NN1
304953	100736290	20992724455	due	due	II21
304953	100736290	20992724456	to	to	II22
304953	100736290	20992724457	the	the	AT
304953	100736290	20992724458	possibility	possibility	NN1
304953	100736290	20992724459	of	of	IO
304953	100736290	20992724460	developing	developing	JJ_VVG
304953	100736290	20992724461	prostate	prostate	NN1
304953	100736290	20992724462	cancer	cancer	NN1
304953	100736290	20992724463	suggested	suggest	VVN
304953	100736290	20992724464	by	by	II
304953	100736290	20992724465	a	a	AT1
304953	100736290	20992724466	BRCA	brca	NN1
304953	100736290	20992724467	test	test	NN1_VV0
304953	100736290	20992724468	,	,	,
304953	100736290	20992724469	there	there	EX
304953	100736290	20992724470	are	be	VBR
304953	100736290	20992724471	absolutely	absolutely	RR
304953	100736290	20992724472	no	no	AT
304953	100736290	20992724473	viable	viable	JJ
304953	100736290	20992724474	data	data	NN
304953	100736290	20992724475	to	to	TO
304953	100736290	20992724476	support	support	VVI
304953	100736290	20992724477	such	such	DA
304953	100736290	20992724478	a	a	AT1
304953	100736290	20992724479	decision	decision	NN1
304953	100736290	20992724480	,	,	,
304953	100736290	20992724481	"	"	"
304953	100736290	20992724482	Dr.		NNB
304953	100736290	20992724483	Garnick		NP1
304953	100736290	20992724484	says	say	VVZ
304953	100736290	20992724485	.	.	.
304953	100736290	20992724486	"	"	"
304953	100736290	20992724487	We	we	PPIS2
304953	100736290	20992724488	need	need	VV0
304953	100736290	20992724489	to	to	TO
304953	100736290	20992724490	study	study	VVI
304953	100736290	20992724491	this	this	DD1
304953	100736290	20992724492	in	in	II
304953	100736290	20992724493	greater	great	JJR
304953	100736290	20992724494	depth	depth	NN1
304953	100736290	20992724495	to	to	TO
304953	100736290	20992724496	understand	understand	VVI
304953	100736290	20992724497	the	the	AT
304953	100736290	20992724498	risks	risk	NN2
304953	100736290	20992724499	and	and	CC
304953	100736290	20992724500	benefits	benefit	NN2
304953	100736290	20992724501	of	of	IO
304953	100736290	20992724502	such	such	DA
304953	100736290	20992724503	an	a	AT1
304953	100736290	20992724504	approach	approach	NN1
304953	100736290	20992724505	.	.	.
304953	100736290	20992724506	"	"	"
304953	100736290	20992724507	<p>		NULL
304953	100736290	20992724508	Such	such	DA
304953	100736290	20992724509	early	early	JJ
304953	100736290	20992724510	detection	detection	NN1
304953	100736290	20992724511	is	be	VBZ
304953	100736290	20992724512	especially	especially	RR
304953	100736290	20992724513	problematic	problematic	JJ
304953	100736290	20992724514	for	for	IF
304953	100736290	20992724515	prostate	prostate	NN1
304953	100736290	20992724516	cancer	cancer	NN1
304953	100736290	20992724517	.	.	.
304953	100736290	20992724518	Many	many	DA2
304953	100736290	20992724519	older	old	JJR
304953	100736290	20992724520	men	man	NN2
304953	100736290	20992724521	"	"	"
304953	100736290	20992724522	perhaps	perhaps	RR
304953	100736290	20992724523	the	the	AT
304953	100736290	20992724524	majority	majority	NN1
304953	100736290	20992724525	of	of	IO
304953	100736290	20992724526	them	them	PPHO2
304953	100736290	20992724527	"	"	"
304953	100736290	20992724528	have	have	VH0
304953	100736290	20992724529	some	some	DD
304953	100736290	20992724530	cancer	cancer	NN1
304953	100736290	20992724531	cells	cell	NN2
304953	100736290	20992724532	in	in	II
304953	100736290	20992724533	their	their	APPGE
304953	100736290	20992724534	prostate	prostate	NN1
304953	100736290	20992724535	glands	gland	NN2
304953	100736290	20992724536	.	.	.
304953	100736290	20992724537	But	but	CCB
304953	100736290	20992724538	these	these	DD2
304953	100736290	20992724539	cells	cell	NN2
304953	100736290	20992724540	tend	tend	VV0
304953	100736290	20992724541	to	to	TO
304953	100736290	20992724542	grow	grow	VVI
304953	100736290	20992724543	so	so	RG
304953	100736290	20992724544	slowly	slowly	RR
304953	100736290	20992724545	that	that	CST
304953	100736290	20992724546	they	they	PPHS2
304953	100736290	20992724547	never	never	RR
304953	100736290	20992724548	threaten	threaten	VV0
304953	100736290	20992724549	health	health	NN1
304953	100736290	20992724550	or	or	CC
304953	100736290	20992724551	longevity	longevity	NN1
304953	100736290	20992724552	.	.	.
304953	100736290	20992724553	If	if	CS
304953	100736290	20992724554	methods	method	NN2
304953	100736290	20992724555	to	to	TO
304953	100736290	20992724556	eliminate	eliminate	VVI
304953	100736290	20992724557	cancer	cancer	NN1
304953	100736290	20992724558	cells	cell	NN2
304953	100736290	20992724559	,	,	,
304953	100736290	20992724560	such	such	II21
304953	100736290	20992724561	as	as	II22
304953	100736290	20992724562	removing	remove	VVG
304953	100736290	20992724563	the	the	AT
304953	100736290	20992724564	prostate	prostate	NN1
304953	100736290	20992724565	or	or	CC
304953	100736290	20992724566	killing	kill	VVG_NN1
304953	100736290	20992724567	cancer	cancer	NN1
304953	100736290	20992724568	cells	cell	NN2
304953	100736290	20992724569	with	with	IW
304953	100736290	20992724570	radiation	radiation	NN1
304953	100736290	20992724571	,	,	,
304953	100736290	20992724572	were	be	VBDR
304953	100736290	20992724573	completely	completely	RR
304953	100736290	20992724574	safe	safe	JJ
304953	100736290	20992724575	and	and	CC
304953	100736290	20992724576	effective	effective	JJ
304953	100736290	20992724577	,	,	,
304953	100736290	20992724578	then	then	RT
304953	100736290	20992724579	early	early	JJ
304953	100736290	20992724580	warning	warning	NN1
304953	100736290	20992724581	would	would	VM
304953	100736290	20992724582	make	make	VVI
304953	100736290	20992724583	sense	sense	NN1
304953	100736290	20992724584	.	.	.
304953	100736290	20992724585	But	but	CCB
304953	100736290	20992724586	they	they	PPHS2
304953	100736290	20992724587	arent.		NNU
304953	100736290	20992724588	-	-	-
304953	100736290	20992724589	Treatment	treatment	NN1
304953	100736290	20992724590	can	can	VM
304953	100736290	20992724591	cause	cause	VVI
304953	100736290	20992724592	erectile	erectile	JJ
304953	100736290	20992724593	dysfunction	dysfunction	NN1
304953	100736290	20992724594	,	,	,
304953	100736290	20992724595	incontinence	incontinence	NN1
304953	100736290	20992724596	,	,	,
304953	100736290	20992724597	and	and	CC
304953	100736290	20992724598	others	others	NN2
304953	100736290	20992724599	problems	problem	NN2
304953	100736290	20992724600	.	.	.
304953	100736290	20992724601	These	these	DD2
304953	100736290	20992724602	must	must	VM
304953	100736290	20992724603	be	be	VBI
304953	100736290	20992724604	weighed	weigh	VVN
304953	100736290	20992724605	against	against	II
304953	100736290	20992724606	the	the	AT
304953	100736290	20992724607	hypothetical	hypothetical	JJ
304953	100736290	20992724608	benefit	benefit	NN1
304953	100736290	20992724609	of	of	IO
304953	100736290	20992724610	"	"	"
304953	100736290	20992724611	preventive	preventive	JJ
304953	100736290	20992724612	"	"	"
304953	100736290	20992724613	treatment	treatment	NN1
304953	100736290	20992724614	.	.	.
304953	100736290	20992724615	<p>		NULL
304953	100736290	20992724616	Someday	someday	RT
304953	100736290	20992724617	,	,	,
304953	100736290	20992724618	a	a	AT1
304953	100736290	20992724619	simple	simple	JJ
304953	100736290	20992724620	blood	blood	NN1
304953	100736290	20992724621	test	test	NN1
304953	100736290	20992724622	may	may	VM
304953	100736290	20992724623	identify	identify	VVI
304953	100736290	20992724624	men	man	NN2
304953	100736290	20992724625	who	who	PNQS
304953	100736290	20992724626	almost	almost	RR
304953	100736290	20992724627	@		II
304953	100736290	20992724628	@		II
304953	100736290	20992724629	@		II
304953	100736290	20992724630	@		II
304953	100736290	20992724631	@		II
304953	100736290	20992724632	@		II
304953	100736290	20992724633	@		II
304953	100736290	20992724634	@		II
304953	100736290	20992724635	@		II
304953	100736290	20992724636	@		II
304953	100736290	20992724637	turn	turn	VVI
304953	100736290	20992724638	deadly	deadly	JJ
304953	100736290	20992724639	.	.	.
304953	100736290	20992724640	Until	until	II
304953	100736290	20992724641	then	then	RT
304953	100736290	20992724642	,	,	,
304953	100736290	20992724643	BRCA	brca	NP1_NN1
304953	100736290	20992724644	testing	testing	NN1
304953	100736290	20992724645	should	should	VM
304953	100736290	20992724646	be	be	VBI
304953	100736290	20992724647	just	just	RR
304953	100736290	20992724648	one	one	MC1
304953	100736290	20992724649	piece	piece	NN1
304953	100736290	20992724650	of	of	IO
304953	100736290	20992724651	evidence	evidence	NN1
304953	100736290	20992724652	used	use	VMK
304953	100736290	20992724653	to	to	TO
304953	100736290	20992724654	guide	guide	VVI
304953	100736290	20992724655	treatment	treatment	NN1
304953	100736290	20992724656	.	.	.
304953	100736291	20992724676	@@##	----------	----------
304953	100736291	20992724677	@@100736291		FO
304953	100736291	20992724678	@4936291/		VV0_NN1
304953	100736291	20992724679	46989		MC
304953	100736291	20992724680	@qwx906989		FO
304953	100736291	20992724681	<p>		NULL
304953	100736291	20992724682	When	when	CS_RRQ
304953	100736291	20992724683	prostate	prostate	NN1
304953	100736291	20992724684	cancer	cancer	NN1
304953	100736291	20992724685	spreads	spread	VVZ
304953	100736291	20992724686	from	from	II
304953	100736291	20992724687	the	the	AT
304953	100736291	20992724688	prostate	prostate	NN1
304953	100736291	20992724689	gland	gland	NN1
304953	100736291	20992724690	into	into	II
304953	100736291	20992724691	nearby	nearby	JJ
304953	100736291	20992724692	lymph	lymph	NN1
304953	100736291	20992724693	nodes	node	NN2
304953	100736291	20992724694	or	or	CC
304953	100736291	20992724695	bladder	bladder	NN1
304953	100736291	20992724696	tissue	tissue	NN1
304953	100736291	20992724697	,	,	,
304953	100736291	20992724698	it	it	PPH1
304953	100736291	20992724699	is	be	VBZ
304953	100736291	20992724700	called	call	VVN
304953	100736291	20992724701	locally	locally	RR
304953	100736291	20992724702	advanced	advanced	JJ_VVN
304953	100736291	20992724703	prostate	prostate	NN1
304953	100736291	20992724704	cancer	cancer	NN1
304953	100736291	20992724705	.	.	.
304953	100736291	20992724706	The	the	AT
304953	100736291	20992724707	standard	standard	JJ_NN1
304953	100736291	20992724708	treatment	treatment	NN1
304953	100736291	20992724709	for	for	IF
304953	100736291	20992724710	it	it	PPH1
304953	100736291	20992724711	is	be	VBZ
304953	100736291	20992724712	a	a	AT1
304953	100736291	20992724713	combination	combination	NN1
304953	100736291	20992724714	of	of	IO
304953	100736291	20992724715	radiation	radiation	NN1
304953	100736291	20992724716	therapy	therapy	NN1
304953	100736291	20992724717	and	and	CC
304953	100736291	20992724718	hormone	hormone	NN1
304953	100736291	20992724719	therapy	therapy	NN1
304953	100736291	20992724720	.	.	.
304953	100736291	20992724721	Radiation	radiation	NN1
304953	100736291	20992724722	kills	kill	VVZ
304953	100736291	20992724723	prostate	prostate	NN1
304953	100736291	20992724724	cancer	cancer	NN1
304953	100736291	20992724725	cells	cell	NN2
304953	100736291	20992724726	.	.	.
304953	100736291	20992724727	Hormone	hormone	NN1
304953	100736291	20992724728	therapy	therapy	NN1
304953	100736291	20992724729	,	,	,
304953	100736291	20992724730	formally	formally	RR
304953	100736291	20992724731	known	know	VVN
304953	100736291	20992724732	as	as	II
304953	100736291	20992724733	androgen	androgen	NN1
304953	100736291	20992724734	deprivation	deprivation	NN1
304953	100736291	20992724735	therapy	therapy	NN1
304953	100736291	20992724736	(	(	(
304953	100736291	20992724737	ADT	adt	NP1
304953	100736291	20992724738	)	)	)
304953	100736291	20992724739	,	,	,
304953	100736291	20992724740	deprives	deprive	VVZ
304953	100736291	20992724741	prostate	prostate	NN1
304953	100736291	20992724742	cancer	cancer	NN1
304953	100736291	20992724743	cells	cell	NN2
304953	100736291	20992724744	of	of	IO
304953	100736291	20992724745	testosterone	testosterone	NN1
304953	100736291	20992724746	,	,	,
304953	100736291	20992724747	which	which	DDQ
304953	100736291	20992724748	they	they	PPHS2
304953	100736291	20992724749	need	need	VV0
304953	100736291	20992724750	in	in	RP@_II
304953	100736291	20992724751	order	order	VVI
304953	100736291	20992724752	to	to	TO
304953	100736291	20992724753	grow	grow	VVI
304953	100736291	20992724754	and	and	CC
304953	100736291	20992724755	spread	spread	NN1_VVD_VV0_VVN
304953	100736291	20992724756	.	.	.
304953	100736291	20992724757	<p>		NULL
304953	100736291	20992724758	But	but	CCB
304953	100736291	20992724759	both	both	RR
304953	100736291	20992724760	types	type	NN2
304953	100736291	20992724761	of	of	IO
304953	100736291	20992724762	therapy	therapy	NN1
304953	100736291	20992724763	have	have	VH0
304953	100736291	20992724764	their	their	APPGE
304953	100736291	20992724765	own	own	DA
304953	100736291	20992724766	sets	set	NN2
304953	100736291	20992724767	of	of	IO
304953	100736291	20992724768	side	side	NN1
304953	100736291	20992724769	effects	effect	NN2
304953	100736291	20992724770	.	.	.
304953	100736291	20992724771	So	so	RR
304953	100736291	20992724772	is	be	VBZ
304953	100736291	20992724773	such	such	DA
304953	100736291	20992724774	a	a	AT1
304953	100736291	20992724775	one-two	one-two	MC
304953	100736291	20992724776	punch	punch	VV0_NN1
304953	100736291	20992724777	really	really	RR
304953	100736291	20992724778	needed	need	VVN_VVD
304953	100736291	20992724779	?	?	?
304953	100736291	20992724780	It	it	PPH1
304953	100736291	20992724781	is	be	VBZ
304953	100736291	20992724782	.	.	.
304953	100736291	20992724783	That 's		VVZ_NN2
304953	100736291	20992724784	the	the	AT
304953	100736291	20992724785	conclusion	conclusion	NN1
304953	100736291	20992724786	drawn	draw	VVN
304953	100736291	20992724787	from	from	II
304953	100736291	20992724788	the	the	AT
304953	100736291	20992724789	largest	large	JJT
304953	100736291	20992724790	clinical	clinical	JJ
304953	100736291	20992724791	trial	trial	NN1
304953	100736291	20992724792	of	of	IO
304953	100736291	20992724793	the	the	AT
304953	100736291	20992724794	combination	combination	NN1
304953	100736291	20992724795	to	to	II
304953	100736291	20992724796	date	date	NN1
304953	100736291	20992724797	.	.	.
304953	100736291	20992724798	<p>		NULL
304953	100736291	20992724799	Using	use	VVG
304953	100736291	20992724800	radiation	radiation	NN1
304953	100736291	20992724801	therapy	therapy	NN1
304953	100736291	20992724802	plus	plus	II
304953	100736291	20992724803	ADT	adt	NP1
304953	100736291	20992724804	against	against	II
304953	100736291	20992724805	locally	locally	RR
304953	100736291	20992724806	advanced	advanced	JJ_VVN
304953	100736291	20992724807	prostate	prostate	NN1
304953	100736291	20992724808	cancer	cancer	NN1
304953	100736291	20992724809	came	come	VVD
304953	100736291	20992724810	into	into	II
304953	100736291	20992724811	favor	favor	NN1
304953	100736291	20992724812	after	after	II_CS
304953	100736291	20992724813	studies	study	NN2
304953	100736291	20992724814	began	begin	VVD
304953	100736291	20992724815	showing	show	VVG
304953	100736291	20992724816	that	that	CST
304953	100736291	20992724817	men	man	NN2
304953	100736291	20992724818	treated	treat	VVN
304953	100736291	20992724819	with	with	IW
304953	100736291	20992724820	both	both	RR
304953	100736291	20992724821	radiation	radiation	NN1
304953	100736291	20992724822	and	and	CC
304953	100736291	20992724823	ADT	adt	NP1
304953	100736291	20992724824	lived	live	VVD
304953	100736291	20992724825	longer	long	RRR_JJR
304953	100736291	20992724826	than	than	CSN
304953	100736291	20992724827	men	man	NN2
304953	100736291	20992724828	treated	treat	VVN
304953	100736291	20992724829	with	with	IW
304953	100736291	20992724830	radiation	radiation	NN1
304953	100736291	20992724831	alone	alone	RR_JJ
304953	100736291	20992724832	.	.	.
304953	100736291	20992724833	In	in	II
304953	100736291	20992724834	one	one	MC1
304953	100736291	20992724835	such	such	DA
304953	100736291	20992724836	study	study	NN1
304953	100736291	20992724837	,	,	,
304953	100736291	20992724838	French	french	JJ_NN1
304953	100736291	20992724839	researchers	researcher	NN2
304953	100736291	20992724840	divided	divide	VVD_VVN
304953	100736291	20992724841	415	415	MC
304953	100736291	20992724842	men	man	NN2
304953	100736291	20992724843	with	with	IW
304953	100736291	20992724844	locally	locally	RR
304953	100736291	20992724845	advanced	advanced	JJ_VVN
304953	100736291	20992724846	prostate	prostate	NN1
304953	100736291	20992724847	cancer	cancer	NN1
304953	100736291	20992724848	into	into	II
304953	100736291	20992724849	two	two	MC
304953	100736291	20992724850	groups	group	NN2
304953	100736291	20992724851	:	:	:
304953	100736291	20992724852	one	one	MC1
304953	100736291	20992724853	group	group	NN1
304953	100736291	20992724854	was	be	VBDZ
304953	100736291	20992724855	treated	treat	VVN
304953	100736291	20992724856	with	with	IW
304953	100736291	20992724857	radiation	radiation	NN1
304953	100736291	20992724858	only	only	JJ
304953	100736291	20992724859	,		Y
304953	100736291	20992724860	while	while	CS
304953	100736291	20992724861	the	the	AT
304953	100736291	20992724862	other	other	JJ
304953	100736291	20992724863	group	group	NN1
304953	100736291	20992724864	was	be	VBDZ
304953	100736291	20992724865	treated	treat	VVN
304953	100736291	20992724866	with	with	IW
304953	100736291	20992724867	radiation	radiation	NN1
304953	100736291	20992724868	@		II
304953	100736291	20992724869	@		II
304953	100736291	20992724870	@		II
304953	100736291	20992724871	@		II
304953	100736291	20992724872	@		II
304953	100736291	20992724873	@		II
304953	100736291	20992724874	@		II
304953	100736291	20992724875	@		II
304953	100736291	20992724876	@		II
304953	100736291	20992724877	@		II
304953	100736291	20992724878	60%		NNU
304953	100736291	20992724879	of	of	IO
304953	100736291	20992724880	the	the	AT
304953	100736291	20992724881	men	man	NN2
304953	100736291	20992724882	on	on	II
304953	100736291	20992724883	the	the	AT
304953	100736291	20992724884	combination	combination	NN1
304953	100736291	20992724885	treatment	treatment	NN1
304953	100736291	20992724886	were	be	VBDR
304953	100736291	20992724887	still	still	RR
304953	100736291	20992724888	alive	alive	JJ
304953	100736291	20992724889	,	,	,
304953	100736291	20992724890	compared	compare	VVN
304953	100736291	20992724891	with	with	IW
304953	100736291	20992724892	40%		NNU
304953	100736291	20992724893	of	of	IO
304953	100736291	20992724894	those	those	DD2
304953	100736291	20992724895	who	who	PNQS
304953	100736291	20992724896	had	have	VHD
304953	100736291	20992724897	been	be	VBN
304953	100736291	20992724898	treated	treat	VVN
304953	100736291	20992724899	with	with	IW
304953	100736291	20992724900	radiation	radiation	NN1
304953	100736291	20992724901	only	only	JJ
304953	100736291	20992724902	.		Y
304953	100736291	20992724903	<p>		NULL
304953	100736291	20992724904	What	what	DDQ
304953	100736291	20992724905	that	that	DD1
304953	100736291	20992724906	and	and	CC
304953	100736291	20992724907	other	other	JJ
304953	100736291	20992724908	studies	study	NN2
304953	100736291	20992724909	did	do	VDD
304953	100736291	20992724910	not	not	XX
304953	100736291	20992724911	investigate	investigate	VVI
304953	100736291	20992724912	was	be	VBDZ
304953	100736291	20992724913	how	how	RRQ
304953	100736291	20992724914	combination	combination	NN1
304953	100736291	20992724915	therapy	therapy	NN1
304953	100736291	20992724916	stacks	stack	VVZ@_NN2
304953	100736291	20992724917	up	up	RP
304953	100736291	20992724918	against	against	II
304953	100736291	20992724919	ADT	adt	NP1
304953	100736291	20992724920	alone	alone	RR_JJ
304953	100736291	20992724921	.	.	.
304953	100736291	20992724922	An	a	AT1
304953	100736291	20992724923	international	international	JJ
304953	100736291	20992724924	research	research	NN1
304953	100736291	20992724925	team	team	NN1
304953	100736291	20992724926	has	have	VHZ
304953	100736291	20992724927	addressed	address	VVN
304953	100736291	20992724928	this	this	DD1
304953	100736291	20992724929	question	question	NN1
304953	100736291	20992724930	,	,	,
304953	100736291	20992724931	and	and	CC
304953	100736291	20992724932	the	the	AT
304953	100736291	20992724933	results	result	NN2
304953	100736291	20992724934	strongly	strongly	RR
304953	100736291	20992724935	favor	favor	VV0
304953	100736291	20992724936	combination	combination	NN1
304953	100736291	20992724937	therapy	therapy	NN1
304953	100736291	20992724938	.	.	.
304953	100736291	20992724939	<p>		NULL
304953	100736291	20992724940	"	"	"
304953	100736291	20992724941	Adding	add	VVG_JJ@
304953	100736291	20992724942	radiation	radiation	NN1
304953	100736291	20992724943	to	to	II
304953	100736291	20992724944	ADT	adt	NP1
304953	100736291	20992724945	more	more	RRR
304953	100736291	20992724946	than	than	CSN
304953	100736291	20992724947	halved	halve	VVN
304953	100736291	20992724948	the	the	AT
304953	100736291	20992724949	risk	risk	NN1
304953	100736291	20992724950	of	of	IO
304953	100736291	20992724951	dying	die	VVG_JJ
304953	100736291	20992724952	from	from	II
304953	100736291	20992724953	locally	locally	RR
304953	100736291	20992724954	advanced	advanced	JJ_VVN
304953	100736291	20992724955	prostate	prostate	NN1
304953	100736291	20992724956	cancer	cancer	NN1
304953	100736291	20992724957	,	,	,
304953	100736291	20992724958	"	"	"
304953	100736291	20992724959	said	say	VVD
304953	100736291	20992724960	Malcolm	malcolm	NP1
304953	100736291	20992724961	Mason	mason	NP1
304953	100736291	20992724962	,	,	,
304953	100736291	20992724963	a	a	AT1
304953	100736291	20992724964	professor	professor	NN1
304953	100736291	20992724965	at	at	II
304953	100736291	20992724966	Cardiff	cardiff	NP1
304953	100736291	20992724967	University	university	NN1
304953	100736291	20992724968	in	in	II
304953	100736291	20992724969	Wales	wales	NP1
304953	100736291	20992724970	and	and	CC
304953	100736291	20992724971	lead	lead	VV0_NN1
304953	100736291	20992724972	author	author	NN1
304953	100736291	20992724973	of	of	IO
304953	100736291	20992724974	the	the	AT
304953	100736291	20992724975	study	study	NN1
304953	100736291	20992724976	.	.	.
304953	100736291	20992724977	<p>		NULL
304953	100736291	20992724978	Mason	mason	NP1_NN1
304953	100736291	20992724979	and	and	CC
304953	100736291	20992724980	his	his	APPGE
304953	100736291	20992724981	colleagues	colleague	NN2
304953	100736291	20992724982	enrolled	enroll	VVD_VVN
304953	100736291	20992724983	1,205	1,205	MC
304953	100736291	20992724984	men	man	NN2
304953	100736291	20992724985	between	between	II
304953	100736291	20992724986	the	the	AT
304953	100736291	20992724987	ages	age	NN2
304953	100736291	20992724988	of	of	IO
304953	100736291	20992724989	50	50	MC
304953	100736291	20992724990	and	and	CC
304953	100736291	20992724991	80	80	MC
304953	100736291	20992724992	who	who	PNQS
304953	100736291	20992724993	were	be	VBDR
304953	100736291	20992724994	diagnosed	diagnose	VVN
304953	100736291	20992724995	with	with	IW
304953	100736291	20992724996	locally	locally	RR
304953	100736291	20992724997	advanced	advanced	JJ_VVN
304953	100736291	20992724998	prostate	prostate	NN1
304953	100736291	20992724999	cancer	cancer	NN1
304953	100736291	20992725000	between	between	II
304953	100736291	20992725001	1995	1995	MC
304953	100736291	20992725002	and	and	CC
304953	100736291	20992725003	2005	2005	MC
304953	100736291	20992725004	.	.	.
304953	100736291	20992725005	Half	half	DB
304953	100736291	20992725006	of	of	IO
304953	100736291	20992725007	the	the	AT
304953	100736291	20992725008	men	man	NN2
304953	100736291	20992725009	were	be	VBDR
304953	100736291	20992725010	treated	treat	VVN
304953	100736291	20992725011	with	with	IW
304953	100736291	20992725012	lifelong	lifelong	JJ
304953	100736291	20992725013	ADT	adt	NP1
304953	100736291	20992725014	;	;	;
304953	100736291	20992725015	the	the	AT
304953	100736291	20992725016	other	other	JJ
304953	100736291	20992725017	half	half	NN1@_DB
304953	100736291	20992725018	were	be	VBDR
304953	100736291	20992725019	treated	treat	VVN
304953	100736291	20992725020	with	with	IW
304953	100736291	20992725021	ADT	adt	NP1
304953	100736291	20992725022	plus	plus	II
304953	100736291	20992725023	a	a	AT1
304953	100736291	20992725024	seven-week	seven-week	JJ_NNT1
304953	100736291	20992725025	course	course	NN1
304953	100736291	20992725026	of	of	IO
304953	100736291	20992725027	radiation	radiation	NN1
304953	100736291	20992725028	.	.	.
304953	100736291	20992725029	<p>		NULL
304953	100736291	20992725030	After	after	II_CS
304953	100736291	20992725031	10	10	MC
304953	100736291	20992725032	years	year	NNT2
304953	100736291	20992725033	,	,	,
304953	100736291	20992725034	43%		NNU
304953	100736291	20992725035	of	of	IO
304953	100736291	20992725036	the	the	AT
304953	100736291	20992725037	men	man	NN2
304953	100736291	20992725038	treated	treat	VVN
304953	100736291	20992725039	with	with	IW
304953	100736291	20992725040	ADT	adt	NP1
304953	100736291	20992725041	alone	alone	RR
304953	100736291	20992725042	had	have	VHD
304953	100736291	20992725043	died	die	VVN
304953	100736291	20992725044	,	,	,
304953	100736291	20992725045	compared	compare	VVN
304953	100736291	20992725046	to	to	II
304953	100736291	20992725047	34%		NNU
304953	100736291	20992725048	of	of	IO
304953	100736291	20992725049	the	the	AT
304953	100736291	20992725050	men	man	NN2
304953	100736291	20992725051	treated	treat	VVN
304953	100736291	20992725052	with	with	IW
304953	100736291	20992725053	ADT	adt	NP1
304953	100736291	20992725054	plus	plus	II
304953	100736291	20992725055	radiation	radiation	NN1
304953	100736291	20992725056	.	.	.
304953	100736291	20992725057	That	that	DD1
304953	100736291	20992725058	translates	translate	VVZ
304953	100736291	20992725059	into	into	II
304953	100736291	20992725060	a	a	AT1
304953	100736291	20992725061	30%		NNU
304953	100736291	20992725062	lower	low	JJR
304953	100736291	20992725063	risk	risk	NN1
304953	100736291	20992725064	of	of	IO
304953	100736291	20992725065	death	death	NN1
304953	100736291	20992725066	from	from	II
304953	100736291	20992725067	any	any	DD
304953	100736291	20992725068	@		II
304953	100736291	20992725069	@		II
304953	100736291	20992725070	@		II
304953	100736291	20992725071	@		II
304953	100736291	20992725072	@		II
304953	100736291	20992725073	@		II
304953	100736291	20992725074	@		II
304953	100736291	20992725075	@		II
304953	100736291	20992725076	@		II
304953	100736291	20992725077	@		II
304953	100736291	20992725078	prostate	prostate	NN1
304953	100736291	20992725079	cancer	cancer	NN1
304953	100736291	20992725080	were	be	VBDR
304953	100736291	20992725081	nearly	nearly	RR
304953	100736291	20992725082	50%		NNU
304953	100736291	20992725083	lower	low	JJR_RRR@
304953	100736291	20992725084	among	among	II
304953	100736291	20992725085	men	man	NN2
304953	100736291	20992725086	who	who	PNQS
304953	100736291	20992725087	got	get	VVD
304953	100736291	20992725088	ADT	adt	NP1
304953	100736291	20992725089	plus	plus	II
304953	100736291	20992725090	radiation	radiation	NN1
304953	100736291	20992725091	.	.	.
304953	100736291	20992725092	Mason	mason	NP1_NN1
304953	100736291	20992725093	cites	cite	VVZ
304953	100736291	20992725094	that	that	CST
304953	100736291	20992725095	as	as	II_CSA
304953	100736291	20992725096	the	the	AT
304953	100736291	20992725097	studys		NN2
304953	100736291	20992725098	take-away	takeaway	NN1
304953	100736291	20992725099	conclusion	conclusion	NN1
304953	100736291	20992725100	.	.	.
304953	100736291	20992725101	The	the	AT
304953	100736291	20992725102	results	result	NN2
304953	100736291	20992725103	were	be	VBDR
304953	100736291	20992725104	published	publish	VVN
304953	100736291	20992725105	in	in	II
304953	100736291	20992725106	the	the	AT
304953	100736291	20992725107	Journal	journal	NN1
304953	100736291	20992725108	of	of	IO
304953	100736291	20992725109	Clinical	clinical	JJ
304953	100736291	20992725110	Oncology	oncology	NN1
304953	100736291	20992725111	.	.	.
304953	100736291	20992725112	<p>		NULL
304953	100736291	20992725113	Side	side	NN1
304953	100736291	20992725114	effects	effect	NN2
304953	100736291	20992725115	were	be	VBDR
304953	100736291	20992725116	roughly	roughly	RR
304953	100736291	20992725117	comparable	comparable	JJ
304953	100736291	20992725118	in	in	II
304953	100736291	20992725119	the	the	AT
304953	100736291	20992725120	two	two	MC
304953	100736291	20992725121	treatment	treatment	NN1
304953	100736291	20992725122	groups	group	NN2
304953	100736291	20992725123	,	,	,
304953	100736291	20992725124	with	with	IW
304953	100736291	20992725125	about	about	II_RG%
304953	100736291	20992725126	one	one	MC1
304953	100736291	20992725127	in	in	II
304953	100736291	20992725128	three	three	MC
304953	100736291	20992725129	men	man	NN2
304953	100736291	20992725130	reporting	report	VVG
304953	100736291	20992725131	a	a	AT1
304953	100736291	20992725132	low	low	JJ
304953	100736291	20992725133	sex	sex	NN1
304953	100736291	20992725134	drive	drive	NN1
304953	100736291	20992725135	and	and	CC
304953	100736291	20992725136	difficulty	difficulty	NN1
304953	100736291	20992725137	getting	get	VVG
304953	100736291	20992725138	or	or	CC
304953	100736291	20992725139	keeping	keep	VVG
304953	100736291	20992725140	an	a	AT1
304953	100736291	20992725141	erection	erection	NN1
304953	100736291	20992725142	.	.	.
304953	100736291	20992725143	Other	other	JJ
304953	100736291	20992725144	side	side	NN1
304953	100736291	20992725145	effects	effect	NN2
304953	100736291	20992725146	included	include	VVD_VVN
304953	100736291	20992725147	bowel	bowel	NN1
304953	100736291	20992725148	problems	problem	NN2
304953	100736291	20992725149	,	,	,
304953	100736291	20992725150	hot	hot	JJ
304953	100736291	20992725151	flashes	flash	NN2
304953	100736291	20992725152	,	,	,
304953	100736291	20992725153	and	and	CC
304953	100736291	20992725154	a	a	AT1
304953	100736291	20992725155	frequent	frequent	JJ
304953	100736291	20992725156	urge	urge	NN1
304953	100736291	20992725157	to	to	TO
304953	100736291	20992725158	urinate	urinate	VVI
304953	100736291	20992725159	,	,	,
304953	100736291	20992725160	which	which	DDQ
304953	100736291	20992725161	were	be	VBDR
304953	100736291	20992725162	all	all	DB_RR@
304953	100736291	20992725163	slightly	slightly	RR
304953	100736291	20992725164	more	more	RGR
304953	100736291	20992725165	common	common	JJ
304953	100736291	20992725166	in	in	II
304953	100736291	20992725167	the	the	AT
304953	100736291	20992725168	combined	combined	JJ
304953	100736291	20992725169	treatment	treatment	NN1
304953	100736291	20992725170	arm	arm	NN1
304953	100736291	20992725171	.	.	.
304953	100736291	20992725172	<p>		NULL
304953	100736291	20992725173	"	"	"
304953	100736291	20992725174	This	this	DD1
304953	100736291	20992725175	paper	paper	NN1
304953	100736291	20992725176	is	be	VBZ
304953	100736291	20992725177	significant	significant	JJ
304953	100736291	20992725178	because	because	CS
304953	100736291	20992725179	it	it	PPH1
304953	100736291	20992725180	shows	show	VVZ
304953	100736291	20992725181	that	that	CST
304953	100736291	20992725182	ADT	adt	NP1
304953	100736291	20992725183	by	by	II
304953	100736291	20992725184	itself	itself	PPX1
304953	100736291	20992725185	is	be	VBZ
304953	100736291	20992725186	not	not	XX
304953	100736291	20992725187	enough	enough	RR_DD
304953	100736291	20992725188	for	for	IF
304953	100736291	20992725189	men	man	NN2
304953	100736291	20992725190	with	with	IW
304953	100736291	20992725191	locally	locally	RR
304953	100736291	20992725192	advanced	advanced	JJ_VVN
304953	100736291	20992725193	prostate	prostate	NN1
304953	100736291	20992725194	cancer	cancer	NN1
304953	100736291	20992725195	,	,	,
304953	100736291	20992725196	"	"	"
304953	100736291	20992725197	said	say	VVD
304953	100736291	20992725198	Dr.		NNB
304953	100736291	20992725199	Marc	marc	NP1
304953	100736291	20992725200	Garnick		NP1
304953	100736291	20992725201	,	,	,
304953	100736291	20992725202	the	the	AT
304953	100736291	20992725203	Gorman	gorman	NN1_NP1
304953	100736291	20992725204	Brothers	brother	NN2
304953	100736291	20992725205	Professor	professor	NN1
304953	100736291	20992725206	of	of	IO
304953	100736291	20992725207	Medicine	medicine	NN1
304953	100736291	20992725208	at	at	II
304953	100736291	20992725209	Harvard	harvard	NP1
304953	100736291	20992725210	Medical	medical	JJ
304953	100736291	20992725211	School	school	NN1
304953	100736291	20992725212	and	and	CC
304953	100736291	20992725213	Beth	beth	NP1
304953	100736291	20992725214	Israel	israel	NP1
304953	100736291	20992725215	Deaconess	deaconess	NN1
304953	100736291	20992725216	Medical	medical	JJ
304953	100736291	20992725217	Center	center	NN1
304953	100736291	20992725218	,	,	,
304953	100736291	20992725219	and	and	CC
304953	100736291	20992725220	Editor	editor	NN1
304953	100736291	20992725221	in	in	II
304953	100736291	20992725222	Chief	chief	NN1
304953	100736291	20992725223	of	of	IO
304953	100736291	20992725224	**28;237;TOOLONG		NP1
304953	100736291	20992725225	.	.	.
304953	100736291	20992725226	"	"	"
304953	100736291	20992725227	They	they	PPHS2
304953	100736291	20992725228	also	also	RR
304953	100736291	20992725229	need	need	VV0
304953	100736291	20992725230	radiation	radiation	NN1
304953	100736291	20992725231	therapy	therapy	NN1
304953	100736291	20992725232	.	.	.
304953	100736291	20992725233	"	"	"
304953	100736291	20992725234	<p>		NULL
304953	100736291	20992725235	But	but	CCB
304953	100736291	20992725236	Garnick		NP1_NN1
304953	100736291	20992725237	points	point	VVZ
304953	100736291	20992725238	out	out	RP
304953	100736291	20992725239	that	that	CST
304953	100736291	20992725240	a	a	AT1
304953	100736291	20992725241	critical	critical	JJ
304953	100736291	20992725242	question	question	NN1
304953	100736291	20992725243	remains	remain	VVZ
304953	100736291	20992725244	:	:	:
304953	100736291	20992725245	as	as	II
304953	100736291	20992725246	part	part	NN1
304953	100736291	20992725247	of	of	IO
304953	100736291	20992725248	combination	combination	NN1
304953	100736291	20992725249	therapy	therapy	NN1
304953	100736291	20992725250	,	,	,
304953	100736291	20992725251	how	how	RRQ_RGQ@
304953	100736291	20992725252	long	long	RR
304953	100736291	20992725253	should	should	VM
304953	100736291	20992725254	ADT	adt	NP1
304953	100736291	20992725255	last	last	VVI
304953	100736291	20992725256	?	?	?
304953	100736291	20992725257	In	in	II
304953	100736291	20992725258	a	a	AT1
304953	100736291	20992725259	separate	separate	JJ
304953	100736291	20992725260	study	study	NN1
304953	100736291	20992725261	,	,	,
304953	100736291	20992725262	the	the	AT
304953	100736291	20992725263	French	french	JJ_NN1
304953	100736291	20992725264	researchers	researcher	NN2
304953	100736291	20992725265	showed	show	VVD
304953	100736291	20992725266	that	that	CST_DD1
304953	100736291	20992725267	three	three	MC
304953	100736291	20992725268	@		II
304953	100736291	20992725269	@		II
304953	100736291	20992725270	@		II
304953	100736291	20992725271	@		II
304953	100736291	20992725272	@		II
304953	100736291	20992725273	@		II
304953	100736291	20992725274	@		II
304953	100736291	20992725275	@		II
304953	100736291	20992725276	@		II
304953	100736291	20992725277	@		II
304953	100736291	20992725278	But	but	CCB
304953	100736291	20992725279	ADT	adt	NP1
304953	100736291	20992725280	can	can	VM
304953	100736291	20992725281	be	be	VBI
304953	100736291	20992725282	difficult	difficult	JJ
304953	100736291	20992725283	to	to	TO
304953	100736291	20992725284	tolerate	tolerate	VVI
304953	100736291	20992725285	,	,	,
304953	100736291	20992725286	and	and	CC
304953	100736291	20992725287	some	some	DD
304953	100736291	20992725288	men	man	NN2
304953	100736291	20992725289	in	in	II
304953	100736291	20992725290	the	the	AT
304953	100736291	20992725291	trials	trial	NN2
304953	100736291	20992725292	three-year	three-year	JJ
304953	100736291	20992725293	treatment	treatment	NN1
304953	100736291	20992725294	arm	arm	NN1
304953	100736291	20992725295	werent		NN1
304953	100736291	20992725296	able	able	JK
304953	100736291	20992725297	to	to	TO
304953	100736291	20992725298	complete	complete	VVI
304953	100736291	20992725299	it	it	PPH1
304953	100736291	20992725300	.	.	.
304953	100736291	20992725301	<p>		NULL
304953	100736291	20992725302	"	"	"
304953	100736291	20992725303	We	we	PPIS2
304953	100736291	20992725304	try	try	VV0
304953	100736291	20992725305	to	to	TO
304953	100736291	20992725306	give	give	VVI
304953	100736291	20992725307	at	at	RR21
304953	100736291	20992725308	least	least	RR22
304953	100736291	20992725309	two	two	MC
304953	100736291	20992725310	years	year	NNT2
304953	100736291	20992725311	of	of	IO
304953	100736291	20992725312	ADT	adt	NP1
304953	100736291	20992725313	to	to	II
304953	100736291	20992725314	men	man	NN2
304953	100736291	20992725315	with	with	IW
304953	100736291	20992725316	high-risk	high-risk	JJ
304953	100736291	20992725317	disease	disease	NN1
304953	100736291	20992725318	,	,	,
304953	100736291	20992725319	but	but	CCB
304953	100736291	20992725320	it	it	PPH1
304953	100736291	20992725321	depends	depend	VVZ
304953	100736291	20992725322	on	on	II
304953	100736291	20992725323	what	what	DDQ
304953	100736291	20992725324	they	they	PPHS2
304953	100736291	20992725325	can	can	VM
304953	100736291	20992725326	tolerate	tolerate	VVI
304953	100736291	20992725327	,	,	,
304953	100736291	20992725328	"	"	"
304953	100736291	20992725329	Garnick		NP1
304953	100736291	20992725330	said	say	VVD
304953	100736291	20992725331	.	.	.
304953	100736291	20992725332	"	"	"
304953	100736291	20992725333	And	and	CC
304953	100736291	20992725334	as	as	II_CSA
304953	100736291	20992725335	the	the	AT
304953	100736291	20992725336	optimal	optimal	JJ
304953	100736291	20992725337	duration	duration	NN1
304953	100736291	20992725338	is n't		NN1
304953	100736291	20992725339	known	know	VVN
304953	100736291	20992725340	,	,	,
304953	100736291	20992725341	this	this	DD1
304953	100736291	20992725342	will	will	VM
304953	100736291	20992725343	require	require	VVI
304953	100736291	20992725344	further	far	JJR@_RRR
304953	100736291	20992725345	study	study	NN1
304953	100736291	20992725346	.	.	.
304953	100736291	20992725347	"	"	"
304953	100736293	20992725367	@@##	----------	----------
304953	100736293	20992725368	@@100736293		FO
304953	100736293	20992725369	@4936293/		VV0_NN1
304953	100736293	20992725370	46989		MC
304953	100736293	20992725371	@qwx906989		FO
304953	100736293	20992725372	<p>		NULL
304953	100736293	20992725373	I	i	PPIS1
304953	100736293	20992725374	am	be	VBM
304953	100736293	20992725375	an	a	AT1
304953	100736293	20992725376	avid	avid	JJ
304953	100736293	20992725377	bicyclist	bicyclist	NN1
304953	100736293	20992725378	,	,	,
304953	100736293	20992725379	and	and	CC
304953	100736293	20992725380	I	i	PPIS1
304953	100736293	20992725381	am	be	VBM
304953	100736293	20992725382	having	have	VHG
304953	100736293	20992725383	a	a	AT1
304953	100736293	20992725384	prostate	prostate	NN1
304953	100736293	20992725385	biopsy	biopsy	NN1
304953	100736293	20992725386	in	in	II
304953	100736293	20992725387	a	a	AT1
304953	100736293	20992725388	few	few	DA2
304953	100736293	20992725389	weeks	week	NNT2
304953	100736293	20992725390	.	.	.
304953	100736293	20992725391	How	how	RGQ@_RRQ
304953	100736293	20992725392	long	long	RR
304953	100736293	20992725393	do	do	VD0
304953	100736293	20992725394	I	i	PPIS1
304953	100736293	20992725395	need	need	VVI
304953	100736293	20992725396	to	to	TO
304953	100736293	20992725397	wait	wait	VVI
304953	100736293	20992725398	after	after	II_CS
304953	100736293	20992725399	the	the	AT
304953	100736293	20992725400	biopsy	biopsy	NN1
304953	100736293	20992725401	before	before	CS
304953	100736293	20992725402	I	i	PPIS1
304953	100736293	20992725403	can	can	VM
304953	100736293	20992725404	start	start	VVI
304953	100736293	20992725405	biking	bike	VVG
304953	100736293	20992725406	again	again	RT
304953	100736293	20992725407	?	?	?
304953	100736293	20992725408	<p>		NULL
304953	100736293	20992725409	William	william	NP1
304953	100736293	20992725410	DeWolf	dewolf	NP1
304953	100736293	20992725411	,	,	,
304953	100736293	20992725412	M.D.	m.d	NNA
304953	100736293	20992725413	,	,	,
304953	100736293	20992725414	Chief	chief	NN1
304953	100736293	20992725415	of	of	IO
304953	100736293	20992725416	the	the	AT
304953	100736293	20992725417	Division	division	NN1
304953	100736293	20992725418	of	of	IO
304953	100736293	20992725419	Urology	urology	NN1_NP1
304953	100736293	20992725420	at	at	II
304953	100736293	20992725421	Beth	beth	NP1
304953	100736293	20992725422	Israel	israel	NP1
304953	100736293	20992725423	Deaconess	deaconess	NN1
304953	100736293	20992725424	Medical	medical	JJ
304953	100736293	20992725425	Center	center	NN1
304953	100736293	20992725426	,	,	,
304953	100736293	20992725427	says	say	VVZ
304953	100736293	20992725428	:	:	:
304953	100736293	20992725429	<p>		NULL
304953	100736293	20992725430	Although	although	CS
304953	100736293	20992725431	most	most	DAT
304953	100736293	20992725432	men	man	NN2
304953	100736293	20992725433	can	can	VM
304953	100736293	20992725434	return	return	VVI
304953	100736293	20992725435	to	to	II
304953	100736293	20992725436	work	work	NN1
304953	100736293	20992725437	and	and	CC
304953	100736293	20992725438	resume	resume	VVI
304953	100736293	20992725439	most	most	RGT_DAT
304953	100736293	20992725440	normal	normal	JJ
304953	100736293	20992725441	activities	activity	NN2
304953	100736293	20992725442	the	the	AT
304953	100736293	20992725443	same	same	DA
304953	100736293	20992725444	day	day	NNT1
304953	100736293	20992725445	,	,	,
304953	100736293	20992725446	I	i	PPIS1
304953	100736293	20992725447	recommend	recommend	VV0
304953	100736293	20992725448	that	that	CST
304953	100736293	20992725449	patients	patient	NN2
304953	100736293	20992725450	avoid	avoid	VV0
304953	100736293	20992725451	vigorous	vigorous	JJ
304953	100736293	20992725452	exercise	exercise	NN1
304953	100736293	20992725453	and	and	CC
304953	100736293	20992725454	weight	weight	NN1
304953	100736293	20992725455	lifting	lift	VVG_NN1
304953	100736293	20992725456	for	for	IF
304953	100736293	20992725457	several	several	DA2
304953	100736293	20992725458	days	day	NNT2
304953	100736293	20992725459	to	to	TO
304953	100736293	20992725460	be	be	VBI
304953	100736293	20992725461	sure	sure	JJ
304953	100736293	20992725462	that	that	CST
304953	100736293	20992725463	any	any	DD
304953	100736293	20992725464	rectal	rectal	JJ
304953	100736293	20992725465	or	or	CC
304953	100736293	20992725466	urinary	urinary	JJ_NN1
304953	100736293	20992725467	bleeding	bleeding	JJ_NN1%
304953	100736293	20992725468	has	have	VHZ
304953	100736293	20992725469	stopped	stop	VVN
304953	100736293	20992725470	.	.	.
304953	100736293	20992725471	As	as	II21_CSA
304953	100736293	20992725472	for	for	II22_IF
304953	100736293	20992725473	activities	activity	NN2
304953	100736293	20992725474	that	that	CST
304953	100736293	20992725475	put	put	VV0_VVD
304953	100736293	20992725476	pressure	pressure	NN1
304953	100736293	20992725477	on	on	II
304953	100736293	20992725478	the	the	AT
304953	100736293	20992725479	prostate	prostate	NN1
304953	100736293	20992725480	,	,	,
304953	100736293	20992725481	such	such	II21
304953	100736293	20992725482	as	as	II22
304953	100736293	20992725483	riding	ride	VVG
304953	100736293	20992725484	a	a	AT1
304953	100736293	20992725485	horse	horse	NN1
304953	100736293	20992725486	,	,	,
304953	100736293	20992725487	motorcycle	motorcycle	NN1_VV0@
304953	100736293	20992725488	,	,	,
304953	100736293	20992725489	or	or	CC
304953	100736293	20992725490	bicycle	bicycle	NN1
304953	100736293	20992725491	,	,	,
304953	100736293	20992725492	I	i	PPIS1
304953	100736293	20992725493	'd	have	VM
304953	100736293	20992725494	hold	hold	VVI
304953	100736293	20992725495	off	off	RP
304953	100736293	20992725496	for	for	IF
304953	100736293	20992725497	about	about	II_RG%
304953	100736293	20992725498	one	one	MC1
304953	100736293	20992725499	to	to	II
304953	100736293	20992725500	four	four	MC
304953	100736293	20992725501	weeks	week	NNT2
304953	100736293	20992725502	,	,	,
304953	100736293	20992725503	depending	depending	II21
304953	100736293	20992725504	on	on	II22
304953	100736293	20992725505	any	any	DD
304953	100736293	20992725506	history	history	NN1
304953	100736293	20992725507	of	of	IO
304953	100736293	20992725508	prostatitis	prostatitis	NN1
304953	100736293	20992725509	and	and	CC
304953	100736293	20992725510	the	the	AT
304953	100736293	20992725511	amount	amount	NN1
304953	100736293	20992725512	of	of	IO
304953	100736293	20992725513	exercise	exercise	NN1_VV0
304953	100736293	20992725514	you	you	PPY
304953	100736293	20992725515	want	want	VV0
304953	100736293	20992725516	to	to	TO
304953	100736293	20992725517	do	do	VDI
304953	100736293	20992725518	.	.	.
304953	100736293	20992725519	<p>		NULL
304953	100736293	20992725520	My	my	APPGE
304953	100736293	20992725521	recommendation	recommendation	NN1
304953	100736293	20992725522	may	may	VM
304953	100736293	20992725523	be	be	VBI
304953	100736293	20992725524	overly	overly	RR
304953	100736293	20992725525	cautious	cautious	JJ
304953	100736293	20992725526	.	.	.
304953	100736293	20992725527	A	a	RR21@_AT1
304953	100736293	20992725528	lot	lot	RR22_NN1
304953	100736293	20992725529	depends	depend	VVZ
304953	100736293	20992725530	on	on	II
304953	100736293	20992725531	what	what	DDQ
304953	100736293	20992725532	kind	kind	NN1
304953	100736293	20992725533	of	of	IO
304953	100736293	20992725534	riding	ride	VVG
304953	100736293	20992725535	you	you	PPY
304953	100736293	20992725536	do	do	VD0
304953	100736293	20992725537	.	.	.
304953	100736293	20992725538	Do	do	VD0
304953	100736293	20992725539	you	you	PPY
304953	100736293	20992725540	ride	ride	VVI
304953	100736293	20992725541	a	a	AT1
304953	100736293	20992725542	bike	bike	NN1
304953	100736293	20992725543	with	with	IW
304953	100736293	20992725544	a	a	AT1
304953	100736293	20992725545	hard	hard	JJ_RR
304953	100736293	20992725546	,	,	,
304953	100736293	20992725547	narrow	narrow	JJ
304953	100736293	20992725548	seat	seat	NN1
304953	100736293	20992725549	or	or	CC
304953	100736293	20992725550	a	a	AT1
304953	100736293	20992725551	large	large	JJ
304953	100736293	20992725552	,	,	,
304953	100736293	20992725553	padded	padded	JJ_VVN@
304953	100736293	20992725554	one	one	PN1
304953	100736293	20992725555	?	?	?
304953	100736293	20992725556	Will	will	VM_VV0%
304953	100736293	20992725557	you	you	PPY
304953	100736293	20992725558	travel	travel	VVI
304953	100736293	20992725559	@		II
304953	100736293	20992725560	@		II
304953	100736293	20992725561	@		II
304953	100736293	20992725562	@		II
304953	100736293	20992725563	@		II
304953	100736293	20992725564	@		II
304953	100736293	20992725565	@		II
304953	100736293	20992725566	@		II
304953	100736293	20992725567	@		II
304953	100736293	20992725568	@		II
304953	100736293	20992725569	pedaling	pedal	VVG
304953	100736293	20992725570	across	across	II
304953	100736293	20992725571	flat	flat	NN1_JJ
304953	100736293	20992725572	,	,	,
304953	100736293	20992725573	even	even	RR_JJ%
304953	100736293	20992725574	pavement	pavement	NN1
304953	100736293	20992725575	?	?	?
304953	100736293	20992725576	How	how	RGQ@_RRQ
304953	100736293	20992725577	long	long	RR_JJ
304953	100736293	20992725578	will	will	VM_VV0%
304953	100736293	20992725579	you	you	PPY
304953	100736293	20992725580	be	be	VBI
304953	100736293	20992725581	on	on	II
304953	100736293	20992725582	the	the	AT
304953	100736293	20992725583	bike	bike	NN1
304953	100736293	20992725584	?	?	?
304953	100736293	20992725585	It	it	PPH1
304953	100736293	20992725586	also	also	RR
304953	100736293	20992725587	depends	depend	VVZ
304953	100736293	20992725588	a	a	RR21_AT1
304953	100736293	20992725589	bit	bit	RR22_NN1
304953	100736293	20992725590	on	on	II
304953	100736293	20992725591	how	how	RRQ
304953	100736293	20992725592	you	you	PPY
304953	100736293	20992725593	are	be	VBR
304953	100736293	20992725594	feeling	feel	VVG
304953	100736293	20992725595	.	.	.
304953	100736293	20992725596	If	if	CS
304953	100736293	20992725597	you	you	PPY
304953	100736293	20992725598	have	have	VH0
304953	100736293	20992725599	any	any	DD
304953	100736293	20992725600	trouble	trouble	NN1
304953	100736293	20992725601	urinating	urinate	VVG
304953	100736293	20992725602	or	or	CC
304953	100736293	20992725603	develop	develop	VV0
304953	100736293	20992725604	an	a	AT1
304953	100736293	20992725605	infection	infection	NN1
304953	100736293	20992725606	,	,	,
304953	100736293	20992725607	you	you	PPY
304953	100736293	20992725608	should	should	VM
304953	100736293	20992725609	wait	wait	VVI
304953	100736293	20992725610	until	until	CS
304953	100736293	20992725611	after	after	CS_II
304953	100736293	20992725612	those	those	DD2
304953	100736293	20992725613	problems	problem	NN2
304953	100736293	20992725614	are	be	VBR
304953	100736293	20992725615	resolved	resolve	VVN
304953	100736293	20992725616	before	before	II
304953	100736293	20992725617	riding	ride	VVG
304953	100736293	20992725618	.	.	.
304953	100736293	20992725619	<p>		NULL
304953	100736293	20992725620	When	when	CS_RRQ
304953	100736293	20992725621	you	you	PPY
304953	100736293	20992725622	feel	feel	VV0
304953	100736293	20992725623	up	up	RP
304953	100736293	20992725624	to	to	II
304953	100736293	20992725625	biking	bike	VVG
304953	100736293	20992725626	again	again	RT
304953	100736293	20992725627	,	,	,
304953	100736293	20992725628	start	start	VV0
304953	100736293	20992725629	slowly	slowly	RR
304953	100736293	20992725630	.	.	.
304953	100736293	20992725631	Limit	limit	VV0
304953	100736293	20992725632	the	the	AT
304953	100736293	20992725633	amount	amount	NN1
304953	100736293	20992725634	of	of	IO
304953	100736293	20992725635	time	time	NNT1
304953	100736293	20992725636	you	you	PPY
304953	100736293	20992725637	spend	spend	VV0
304953	100736293	20992725638	on	on	II_RP@
304953	100736293	20992725639	the	the	AT
304953	100736293	20992725640	bike	bike	NN1
304953	100736293	20992725641	and	and	CC
304953	100736293	20992725642	stick	stick	VV0_NN1
304953	100736293	20992725643	to	to	II
304953	100736293	20992725644	an	a	AT1
304953	100736293	20992725645	easy	easy	JJ
304953	100736293	20992725646	route	route	NN1
304953	100736293	20992725647	.	.	.
304953	100736293	20992725648	In	in	II
304953	100736293	20992725649	the	the	AT
304953	100736293	20992725650	meantime	meantime	NNT1
304953	100736293	20992725651	,	,	,
304953	100736293	20992725652	pedaling	pedal	VVG
304953	100736293	20992725653	a	a	AT1
304953	100736293	20992725654	recumbent	recumbent	JJ
304953	100736293	20992725655	bicycle	bicycle	NN1
304953	100736293	20992725656	at	at	II
304953	100736293	20992725657	your	your	APPGE
304953	100736293	20992725658	local	local	JJ
304953	100736293	20992725659	gym	gym	NN1
304953	100736293	20992725660	can	can	VM
304953	100736293	20992725661	help	help	VVI
304953	100736293	20992725662	keep	keep	VVI
304953	100736293	20992725663	you	you	PPY
304953	100736293	20992725664	fit	fit	VV0
304953	100736293	20992725665	.	.	.
304953	100736293	20992725666	And	and	CC
304953	100736293	20992725667	if	if	CS_CSW@
304953	100736293	20992725668	you	you	PPY
304953	100736293	20992725669	experience	experience	VV0
304953	100736293	20992725670	any	any	DD
304953	100736293	20992725671	pain	pain	NN1
304953	100736293	20992725672	or	or	CC
304953	100736293	20992725673	bleeding	bleeding	JJ_VVG
304953	100736293	20992725674	after	after	CS_II
304953	100736293	20992725675	you	you	PPY
304953	100736293	20992725676	resume	resume	VV0
304953	100736293	20992725677	your	your	APPGE
304953	100736293	20992725678	riding	riding	NN1@_VVG
304953	100736293	20992725679	regimen	regimen	NN1
304953	100736293	20992725680	,	,	,
304953	100736293	20992725681	contact	contact	VV0
304953	100736293	20992725682	your	your	APPGE
304953	100736293	20992725683	doctor	doctor	NN1
304953	100736293	20992725684	.	.	.
304953	100736293	20992725685	46996		MC
304953	100736293	20992725686	@qwx906996		FO
304953	100736294	20992725706	@@##	----------	----------
304953	100736294	20992725707	@@100736294		FO
304953	100736294	20992725708	@4936294/		VV0_NN1
304953	100736294	20992725709	46989		MC
304953	100736294	20992725710	@qwx906989		FO
304953	100736294	20992725711	<p>		NULL
304953	100736294	20992725712	Treating	treat	VVG
304953	100736294	20992725713	prostate	prostate	NN1
304953	100736294	20992725714	cancer	cancer	NN1
304953	100736294	20992725715	patients	patient	NN2
304953	100736294	20992725716	with	with	IW
304953	100736294	20992725717	drugs	drug	NN2
304953	100736294	20992725718	that	that	CST
304953	100736294	20992725719	block	block	VV0@
304953	100736294	20992725720	the	the	AT
304953	100736294	20992725721	activity	activity	NN1
304953	100736294	20992725722	of	of	IO
304953	100736294	20992725723	hormones	hormone	NN2
304953	100736294	20992725724	has	have	VHZ
304953	100736294	20992725725	been	be	VBN
304953	100736294	20992725726	linked	link	VVN
304953	100736294	20992725727	to	to	II
304953	100736294	20992725728	an	a	AT1
304953	100736294	20992725729	increased	increased	JJ
304953	100736294	20992725730	risk	risk	NN1
304953	100736294	20992725731	of	of	IO
304953	100736294	20992725732	coronary	coronary	JJ
304953	100736294	20992725733	artery	artery	NN1
304953	100736294	20992725734	disease	disease	NN1
304953	100736294	20992725735	and	and	CC
304953	100736294	20992725736	heart	heart	NN1
304953	100736294	20992725737	attack	attack	NN1
304953	100736294	20992725738	.	.	.
304953	100736294	20992725739	But	but	CCB
304953	100736294	20992725740	whether	whether	CSW
304953	100736294	20992725741	the	the	AT
304953	100736294	20992725742	drugs	drug	NN2
304953	100736294	20992725743	"	"	"
304953	100736294	20992725744	called	call	VVN_VVD@
304953	100736294	20992725745	gonadotropin-releasing	gonadotropin-releasing	JJ_NN1
304953	100736294	20992725746	hormone	hormone	NN1
304953	100736294	20992725747	(	(	(
304953	100736294	20992725748	GnRH	gnrh	NP1
304953	100736294	20992725749	)	)	)
304953	100736294	20992725750	agonists	agonist	NN2
304953	100736294	20992725751	and	and	CC
304953	100736294	20992725752	luteinizing	luteinizing	VVG_JJ@
304953	100736294	20992725753	hormone	hormone	NN1
304953	100736294	20992725754	"	"	"
304953	100736294	20992725755	releasing	release	VVG
304953	100736294	20992725756	hormone	hormone	NN1
304953	100736294	20992725757	(	(	(
304953	100736294	20992725758	LHRH	lhrh	NP1
304953	100736294	20992725759	)	)	)
304953	100736294	20992725760	agonists	agonist	NN2
304953	100736294	20992725761	"	"	"
304953	100736294	20992725762	raise	raise	VV0
304953	100736294	20992725763	the	the	AT
304953	100736294	20992725764	risk	risk	NN1
304953	100736294	20992725765	of	of	IO
304953	100736294	20992725766	death	death	NN1
304953	100736294	20992725767	from	from	II
304953	100736294	20992725768	cardiovascular	cardiovascular	JJ
304953	100736294	20992725769	disease	disease	NN1
304953	100736294	20992725770	has	have	VHZ
304953	100736294	20992725771	been	be	VBN
304953	100736294	20992725772	the	the	AT
304953	100736294	20992725773	subject	subject	NN1
304953	100736294	20992725774	of	of	IO
304953	100736294	20992725775	debate	debate	NN1
304953	100736294	20992725776	.	.	.
304953	100736294	20992725777	In	in	II
304953	100736294	20992725778	2006	2006	MC
304953	100736294	20992725779	,	,	,
304953	100736294	20992725780	a	a	AT1
304953	100736294	20992725781	team	team	NN1
304953	100736294	20992725782	of	of	IO
304953	100736294	20992725783	researchers	researcher	NN2
304953	100736294	20992725784	reported	report	VVD_VVN
304953	100736294	20992725785	that	that	CST
304953	100736294	20992725786	GnRH	gnrh	NP1
304953	100736294	20992725787	agonists	agonist	NN2
304953	100736294	20992725788	increase	increase	VV0
304953	100736294	20992725789	the	the	AT
304953	100736294	20992725790	risk	risk	NN1
304953	100736294	20992725791	of	of	IO
304953	100736294	20992725792	sudden	sudden	JJ
304953	100736294	20992725793	cardiac	cardiac	JJ
304953	100736294	20992725794	death	death	NN1
304953	100736294	20992725795	.	.	.
304953	100736294	20992725796	<p>		NULL
304953	100736294	20992725797	More	more	RGR_RRR
304953	100736294	20992725798	recently	recently	RR
304953	100736294	20992725799	,	,	,
304953	100736294	20992725800	researchers	researcher	NN2
304953	100736294	20992725801	from	from	II
304953	100736294	20992725802	Massachusetts	massachusetts	NP1
304953	100736294	20992725803	General	general	JJ_NN1
304953	100736294	20992725804	Hospital	hospital	NN1
304953	100736294	20992725805	randomly	randomly	RR
304953	100736294	20992725806	assigned	assign	VVN
304953	100736294	20992725807	945	945	MC
304953	100736294	20992725808	men	man	NN2
304953	100736294	20992725809	with	with	IW
304953	100736294	20992725810	locally	locally	RR
304953	100736294	20992725811	advanced	advanced	JJ_VVN
304953	100736294	20992725812	prostate	prostate	NN1
304953	100736294	20992725813	cancer	cancer	NN1
304953	100736294	20992725814	to	to	TO
304953	100736294	20992725815	receive	receive	VVI
304953	100736294	20992725816	radiation	radiation	NN1
304953	100736294	20992725817	therapy	therapy	NN1
304953	100736294	20992725818	either	either	RR
304953	100736294	20992725819	alone	alone	JJ_RR
304953	100736294	20992725820	or	or	CC
304953	100736294	20992725821	followed	follow	VVN
304953	100736294	20992725822	by	by	II
304953	100736294	20992725823	hormone	hormone	NN1
304953	100736294	20992725824	therapy	therapy	NN1
304953	100736294	20992725825	with	with	IW
304953	100736294	20992725826	the	the	AT
304953	100736294	20992725827	drug	drug	NN1
304953	100736294	20992725828	goserelin		NN1
304953	100736294	20992725829	(	(	(
304953	100736294	20992725830	Zoladex		NP1
304953	100736294	20992725831	)	)	)
304953	100736294	20992725832	.	.	.
304953	100736294	20992725833	After	after	CS_II
304953	100736294	20992725834	a	a	AT1
304953	100736294	20992725835	median	median	JJ
304953	100736294	20992725836	follow-up	follow-up	JJ_NN1
304953	100736294	20992725837	time	time	NNT1
304953	100736294	20992725838	of	of	IO
304953	100736294	20992725839	8.1	8.1	MC
304953	100736294	20992725840	years	year	NNT2
304953	100736294	20992725841	,	,	,
304953	100736294	20992725842	117	117	MC
304953	100736294	20992725843	participants	participant	NN2
304953	100736294	20992725844	had	have	VHD
304953	100736294	20992725845	died	die	VVN
304953	100736294	20992725846	of	of	IO
304953	100736294	20992725847	cardiovascular	cardiovascular	JJ
304953	100736294	20992725848	problems	problem	NN2
304953	100736294	20992725849	.	.	.
304953	100736294	20992725850	But	but	CCB
304953	100736294	20992725851	there	there	EX
304953	100736294	20992725852	was	be	VBDZ
304953	100736294	20992725853	no	no	AT
304953	100736294	20992725854	significant	significant	JJ
304953	100736294	20992725855	difference	difference	NN1
304953	100736294	20992725856	in	in	II
304953	100736294	20992725857	the	the	AT
304953	100736294	20992725858	number	number	NN1
304953	100736294	20992725859	of	of	IO
304953	100736294	20992725860	cardiovascular	cardiovascular	JJ
304953	100736294	20992725861	deaths	death	NN2
304953	100736294	20992725862	between	between	II
304953	100736294	20992725863	the	the	AT
304953	100736294	20992725864	two	two	MC
304953	100736294	20992725865	groups	group	NN2
304953	100736294	20992725866	.	.	.
304953	100736294	20992725867	<p>		NULL
304953	100736294	20992725868	However	however	RR
304953	100736294	20992725869	,	,	,
304953	100736294	20992725870	the	the	AT
304953	100736294	20992725871	finding	finding	NN1
304953	100736294	20992725872	does	do	VDZ
304953	100736294	20992725873	not	not	XX
304953	100736294	20992725874	exclude	exclude	VVI
304953	100736294	20992725875	the	the	AT
304953	100736294	20992725876	possibility	possibility	NN1
304953	100736294	20992725877	that	that	CST
304953	100736294	20992725878	LHRH	lhrh	NP1
304953	100736294	20992725879	agonists	agonist	NN2
304953	100736294	20992725880	increase	increase	VV0
304953	100736294	20992725881	the	the	AT
304953	100736294	20992725882	risk	risk	NN1
304953	100736294	20992725883	of	of	IO
304953	100736294	20992725884	death	death	NN1
304953	100736294	20992725885	from	from	II
304953	100736294	20992725886	other	other	JJ
304953	100736294	20992725887	causes	cause	NN2
304953	100736294	20992725888	.	.	.
304953	100736294	20992725889	The	the	AT
304953	100736294	20992725890	drugs	drug	NN2
304953	100736294	20992725891	can	can	VM
304953	100736294	20992725892	raise	raise	VVI
304953	100736294	20992725893	the	the	AT
304953	100736294	20992725894	chances	chance	NN2
304953	100736294	20992725895	of	of	IO
304953	100736294	20992725896	diabetes	diabetes	NN1
304953	100736294	20992725897	and	and	CC
304953	100736294	20992725898	@		II
304953	100736294	20992725899	@		II
304953	100736294	20992725900	@		II
304953	100736294	20992725901	@		II
304953	100736294	20992725902	@		II
304953	100736294	20992725903	@		II
304953	100736294	20992725904	@		II
304953	100736294	20992725905	@		II
304953	100736294	20992725906	@		II
304953	100736294	20992725907	@		II
304953	100736294	20992725908	can	can	VM
304953	100736294	20992725909	also	also	RR
304953	100736294	20992725910	cause	cause	VVI
304953	100736294	20992725911	weight	weight	NN1
304953	100736294	20992725912	gain	gain	NN1
304953	100736294	20992725913	and	and	CC
304953	100736294	20992725914	adversely	adversely	RR
304953	100736294	20992725915	affect	affect	VV0
304953	100736294	20992725916	cholesterol	cholesterol	NN1
304953	100736294	20992725917	levels	level	NN2
304953	100736294	20992725918	,	,	,
304953	100736294	20992725919	mood	mood	NN1
304953	100736294	20992725920	,	,	,
304953	100736294	20992725921	and	and	CC
304953	100736294	20992725922	sexual	sexual	JJ
304953	100736294	20992725923	function	function	NN1
304953	100736294	20992725924	.	.	.
304953	100736294	20992725925	As	as	II
304953	100736294	20992725926	a	a	AT1
304953	100736294	20992725927	result	result	NN1
304953	100736294	20992725928	,	,	,
304953	100736294	20992725929	physicians	physician	NN2
304953	100736294	20992725930	should	should	VM
304953	100736294	20992725931	carefully	carefully	RR
304953	100736294	20992725932	weigh	weigh	VVI
304953	100736294	20992725933	the	the	AT
304953	100736294	20992725934	potential	potential	JJ_NN1
304953	100736294	20992725935	risks	risk	NN2
304953	100736294	20992725936	and	and	CC
304953	100736294	20992725937	benefits	benefit	NN2
304953	100736294	20992725938	of	of	IO
304953	100736294	20992725939	LHRH	lhrh	NP1
304953	100736294	20992725940	agonists	agonist	NN2
304953	100736294	20992725941	before	before	II
304953	100736294	20992725942	prescribing	prescribe	VVG
304953	100736294	20992725943	them	them	PPHO2
304953	100736294	20992725944	.	.	.
304953	100736294	20992725945	46996		MC
304953	100736294	20992725946	@qwx906996		FO
304953	100736297	20992725966	@@##	----------	----------
304953	100736297	20992725967	@@100736297		FO
304953	100736297	20992725968	@4936297/		VV0_NN1
304953	100736297	20992725969	46989		MC
304953	100736297	20992725970	@qwx906989		FO
304953	100736297	20992725971	<p>		NULL
304953	100736297	20992725972	According	according	II21
304953	100736297	20992725973	to	to	II22
304953	100736297	20992725974	a	a	AT1
304953	100736297	20992725975	study	study	NN1
304953	100736297	20992725976	in	in	II
304953	100736297	20992725977	the	the	AT
304953	100736297	20992725978	Archives	archive	NN2
304953	100736297	20992725979	of	of	IO
304953	100736297	20992725980	Internal	internal	JJ
304953	100736297	20992725981	Medicine	medicine	NN1
304953	100736297	20992725982	,	,	,
304953	100736297	20992725983	a	a	AT1
304953	100736297	20992725984	prostate	prostate	NN1
304953	100736297	20992725985	cancer	cancer	NN1
304953	100736297	20992725986	diagnosis	diagnosis	NN1
304953	100736297	20992725987	may	may	VM
304953	100736297	20992725988	send	send	VVI
304953	100736297	20992725989	a	a	AT1
304953	100736297	20992725990	man	man	NN1
304953	100736297	20992725991	to	to	II
304953	100736297	20992725992	the	the	AT
304953	100736297	20992725993	operating	operating	NN1
304953	100736297	20992725994	room	room	NN1
304953	100736297	20992725995	or	or	CC
304953	100736297	20992725996	drive	drive	VV0
304953	100736297	20992725997	him	him	PPHO1
304953	100736297	20992725998	to	to	TO
304953	100736297	20992725999	get	get	VVI
304953	100736297	20992726000	radiation	radiation	NN1
304953	100736297	20992726001	therapy	therapy	NN1
304953	100736297	20992726002	"	"	"
304953	100736297	20992726003	even	even	CS21
304953	100736297	20992726004	when	when	CS22
304953	100736297	20992726005	the	the	AT
304953	100736297	20992726006	cancer	cancer	NN1
304953	100736297	20992726007	is	be	VBZ
304953	100736297	20992726008	unlikely	unlikely	JJ
304953	100736297	20992726009	to	to	TO
304953	100736297	20992726010	spread	spread	VVI
304953	100736297	20992726011	or	or	CC
304953	100736297	20992726012	cause	cause	NN1_VV0
304953	100736297	20992726013	harm	harm	NN1
304953	100736297	20992726014	.	.	.
304953	100736297	20992726015	<p>		NULL
304953	100736297	20992726016	Using	use	VVG
304953	100736297	20992726017	data	data	NN
304953	100736297	20992726018	from	from	II
304953	100736297	20992726019	a	a	AT1
304953	100736297	20992726020	large	large	JJ
304953	100736297	20992726021	national	national	JJ
304953	100736297	20992726022	cancer	cancer	NN1
304953	100736297	20992726023	registry	registry	NN1
304953	100736297	20992726024	,	,	,
304953	100736297	20992726025	researchers	researcher	NN2
304953	100736297	20992726026	looked	look	VVN_VVD
304953	100736297	20992726027	at	at	II
304953	100736297	20992726028	treatment	treatment	NN1
304953	100736297	20992726029	choices	choice	NN2
304953	100736297	20992726030	of	of	IO
304953	100736297	20992726031	more	more	DAR
304953	100736297	20992726032	than	than	CSN
304953	100736297	20992726033	123,900		MC
304953	100736297	20992726034	men	man	NN2
304953	100736297	20992726035	diagnosed	diagnose	VVN_VVD
304953	100736297	20992726036	with	with	IW
304953	100736297	20992726037	prostate	prostate	NN1
304953	100736297	20992726038	cancer	cancer	NN1
304953	100736297	20992726039	between	between	II
304953	100736297	20992726040	2004	2004	MC
304953	100736297	20992726041	and	and	CC
304953	100736297	20992726042	2006	2006	MC
304953	100736297	20992726043	.	.	.
304953	100736297	20992726044	Of	of	IO
304953	100736297	20992726045	these	these	DD2
304953	100736297	20992726046	patients	patient	NN2
304953	100736297	20992726047	,	,	,
304953	100736297	20992726048	14%		NNU
304953	100736297	20992726049	had	have	VHD
304953	100736297	20992726050	prostate-specific	prostate-specific	JJ
304953	100736297	20992726051	antigen	antigen	NN1
304953	100736297	20992726052	(	(	(
304953	100736297	20992726053	PSA	psa	NP1
304953	100736297	20992726054	)	)	)
304953	100736297	20992726055	levels	level	NN2_VVZ%
304953	100736297	20992726056	below	below	RG
304953	100736297	20992726057	4	4	MC
304953	100736297	20992726058	ng/mL	ng/ml	FU
304953	100736297	20992726059	,	,	,
304953	100736297	20992726060	and	and	CC
304953	100736297	20992726061	more	more	DAR
304953	100736297	20992726062	than	than	CSN
304953	100736297	20992726063	half	half	DB
304953	100736297	20992726064	of	of	IO
304953	100736297	20992726065	those	those	DD2
304953	100736297	20992726066	patients	patient	NN2
304953	100736297	20992726067	had	have	VHD
304953	100736297	20992726068	low-risk	low-risk	JJ
304953	100736297	20992726069	disease	disease	NN1
304953	100736297	20992726070	.	.	.
304953	100736297	20992726071	Despite	despite	II
304953	100736297	20992726072	being	be	VBG
304953	100736297	20992726073	less	less	RGR
304953	100736297	20992726074	likely	likely	JJ
304953	100736297	20992726075	to	to	TO
304953	100736297	20992726076	develop	develop	VVI
304953	100736297	20992726077	aggressive	aggressive	JJ
304953	100736297	20992726078	tumors	tumor	NN2
304953	100736297	20992726079	,	,	,
304953	100736297	20992726080	they	they	PPHS2
304953	100736297	20992726081	were	be	VBDR
304953	100736297	20992726082	just	just	RR
304953	100736297	20992726083	as	as	RG
304953	100736297	20992726084	likely	likely	JJ
304953	100736297	20992726085	to	to	TO
304953	100736297	20992726086	undergo	undergo	VVI
304953	100736297	20992726087	radiation	radiation	NN1
304953	100736297	20992726088	or	or	CC
304953	100736297	20992726089	surgery	surgery	NN1
304953	100736297	20992726090	as	as	CSA_II@
304953	100736297	20992726091	men	man	NN2
304953	100736297	20992726092	with	with	IW
304953	100736297	20992726093	more	more	RGR_DAR
304953	100736297	20992726094	active	active	JJ
304953	100736297	20992726095	tumors	tumor	NN2
304953	100736297	20992726096	and	and	CC
304953	100736297	20992726097	PSA	psa	NP1
304953	100736297	20992726098	levels	level	NN2
304953	100736297	20992726099	between	between	II
304953	100736297	20992726100	4	4	MC
304953	100736297	20992726101	and	and	CC
304953	100736297	20992726102	20	20	MC
304953	100736297	20992726103	ng/mL	ng/ml	FU
304953	100736297	20992726104	.	.	.
304953	100736297	20992726105	<p>		NULL
304953	100736297	20992726106	Although	although	CS
304953	100736297	20992726107	effective	effective	JJ
304953	100736297	20992726108	,	,	,
304953	100736297	20992726109	surgery	surgery	NN1
304953	100736297	20992726110	and	and	CC
304953	100736297	20992726111	radiation	radiation	NN1
304953	100736297	20992726112	therapy	therapy	NN1
304953	100736297	20992726113	are	be	VBR
304953	100736297	20992726114	costly	costly	JJ
304953	100736297	20992726115	procedures	procedure	NN2
304953	100736297	20992726116	that	that	CST_DD1
304953	100736297	20992726117	can	can	VM
304953	100736297	20992726118	lead	lead	VVI
304953	100736297	20992726119	to	to	II
304953	100736297	20992726120	serious	serious	JJ
304953	100736297	20992726121	side	side	NN1
304953	100736297	20992726122	effects	effect	NN2
304953	100736297	20992726123	,	,	,
304953	100736297	20992726124	including	including	II_VVG@
304953	100736297	20992726125	incontinence	incontinence	NN1
304953	100736297	20992726126	and	and	CC
304953	100736297	20992726127	erectile	erectile	JJ
304953	100736297	20992726128	dysfunction	dysfunction	NN1
304953	100736297	20992726129	.	.	.
304953	100736297	20992726130	Such	such	DA
304953	100736297	20992726131	complications	complication	NN2
304953	100736297	20992726132	may	may	VM
304953	100736297	20992726133	offset	offset	VVI
304953	100736297	20992726134	the	the	AT
304953	100736297	20992726135	intended	intended	JJ@
304953	100736297	20992726136	benefit	benefit	NN1
304953	100736297	20992726137	of	of	IO
304953	100736297	20992726138	treating	treat	VVG
304953	100736297	20992726139	the	the	AT
304953	100736297	20992726140	cancer	cancer	NN1
304953	100736297	20992726141	,	,	,
304953	100736297	20992726142	which	which	DDQ
304953	100736297	20992726143	might	might	VM
304953	100736297	20992726144	never	never	RR
304953	100736297	20992726145	have	have	VHI
304953	100736297	20992726146	caused	cause	VVN
304953	100736297	20992726147	harm	harm	NN1_VV0
304953	100736297	20992726148	.	.	.
304953	100736297	20992726149	<p>		NULL
304953	100736297	20992726150	The	the	AT
304953	100736297	20992726151	researchers	researcher	NN2
304953	100736297	20992726152	conclude	conclude	VV0
304953	100736297	20992726153	that	that	CST_DD1
304953	100736297	20992726154	conservative	conservative	JJ_NN1
304953	100736297	20992726155	treatment	treatment	NN1
304953	100736297	20992726156	may	may	VM
304953	100736297	20992726157	be	be	VBI
304953	100736297	20992726158	@		II
304953	100736297	20992726159	@		II
304953	100736297	20992726160	@		II
304953	100736297	20992726161	@		II
304953	100736297	20992726162	@		II
304953	100736297	20992726163	@		II
304953	100736297	20992726164	@		II
304953	100736297	20992726165	@		II
304953	100736297	20992726166	@		II
304953	100736297	20992726167	@		II
304953	100736297	20992726168	also	also	RR
304953	100736297	20992726169	note	note	VV0
304953	100736297	20992726170	that	that	DD1_CST
304953	100736297	20992726171	performing	performing	NN1_JJ@_VVG
304953	100736297	20992726172	biopsies	biopsy	NN2
304953	100736297	20992726173	on	on	II
304953	100736297	20992726174	men	man	NN2
304953	100736297	20992726175	with	with	IW
304953	100736297	20992726176	a	a	AT1
304953	100736297	20992726177	PSA	psa	NP1
304953	100736297	20992726178	below	below	RG
304953	100736297	20992726179	2.5	2.5	MC
304953	100736297	20992726180	ng/mL	ng/ml	FU
304953	100736297	20992726181	may	may	VM
304953	100736297	20992726182	increase	increase	VVI
304953	100736297	20992726183	the	the	AT
304953	100736297	20992726184	risk	risk	NN1
304953	100736297	20992726185	of	of	IO
304953	100736297	20992726186	being	be	VBG
304953	100736297	20992726187	diagnosed	diagnose	VVN
304953	100736297	20992726188	with	with	IW
304953	100736297	20992726189	prostate	prostate	NN1
304953	100736297	20992726190	cancer	cancer	NN1
304953	100736297	20992726191	and	and	CC
304953	100736297	20992726192	needlessly	needlessly	RR
304953	100736297	20992726193	receiving	receive	VVG_JJ@
304953	100736297	20992726194	treatment	treatment	NN1
304953	100736297	20992726195	.	.	.
304953	100736297	20992726196	<p>		NULL
304953	100736297	20992726197	"	"	"
304953	100736297	20992726198	Copy	copy	VV0_NN1
304953	100736297	20992726199	Paste	paste	NN1
304953	100736297	20992726200	"	"	"
304953	100736297	20992726201	response	response	NN1
304953	100736297	20992726202	is	be	VBZ
304953	100736297	20992726203	biallirnt		NN1
304953	100736297	20992726204	but	but	CCB
304953	100736297	20992726205	he	he	PPHS1
304953	100736297	20992726206	would	would	VM
304953	100736297	20992726207	do	do	VDI
304953	100736297	20992726208	well	well	RR
304953	100736297	20992726209	not	not	XX
304953	100736297	20992726210	to	to	TO
304953	100736297	20992726211	plagiarise		VVI
304953	100736297	20992726212	other	other	JJ
304953	100736297	20992726213	peoples	people	NN2
304953	100736297	20992726214	responses	response	NN2
304953	100736297	20992726215	!	!	!
304953	100736297	20992726216	!	!	!
304953	100736297	20992726217	!	!	!
304953	100736297	20992726218	!	!	!
304953	100736297	20992726219	!	!	!
304953	100736297	20992726220	!	!	!
304953	100736297	20992726221	!	!	!
304953	100736297	20992726222	!	!	!
304953	100736297	20992726223	The	the	AT
304953	100736297	20992726224	fact	fact	NN1
304953	100736297	20992726225	is	be	VBZ
304953	100736297	20992726226	that	that	DD1_CST
304953	100736297	20992726227	exposure	exposure	NN1
304953	100736297	20992726228	to	to	II
304953	100736297	20992726229	microwave	microwave	NN1
304953	100736297	20992726230	radiation	radiation	NN1
304953	100736297	20992726231	for	for	IF
304953	100736297	20992726232	extended	extended	JJ@
304953	100736297	20992726233	periods	period	NN2
304953	100736297	20992726234	may	may	VM
304953	100736297	20992726235	well	well	RR
304953	100736297	20992726236	cause	cause	VVI
304953	100736297	20992726237	certain	certain	JJ
304953	100736297	20992726238	cancers	cancer	NN2
304953	100736297	20992726239	to	to	TO
304953	100736297	20992726240	occur	occur	VVI
304953	100736297	20992726241	.	.	.
304953	100736297	20992726242	They	they	PPHS2
304953	100736297	20992726243	may	may	VM
304953	100736297	20992726244	also	also	RR
304953	100736297	20992726245	cause	cause	VVI
304953	100736297	20992726246	cataracts	cataract	NN2
304953	100736297	20992726247	,	,	,
304953	100736297	20992726248	birth	birth	NN1
304953	100736297	20992726249	defects	defect	NN2
304953	100736297	20992726250	and	and	CC
304953	100736297	20992726251	other	other	JJ
304953	100736297	20992726252	serious	serious	JJ
304953	100736297	20992726253	health	health	NN1
304953	100736297	20992726254	problems	problem	NN2
304953	100736297	20992726255	including	including	II
304953	100736297	20992726256	nervous	nervous	JJ
304953	100736297	20992726257	system	system	NN1
304953	100736297	20992726258	damage	damage	NN1
304953	100736297	20992726259	,	,	,
304953	100736297	20992726260	headaches	headache	NN2_VVZ
304953	100736297	20992726261	,	,	,
304953	100736297	20992726262	and	and	CC
304953	100736297	20992726263	pacemaker	pacemaker	NN1
304953	100736297	20992726264	interference.However		NNU
304953	100736297	20992726265	,	,	,
304953	100736297	20992726266	new	new	JJ
304953	100736297	20992726267	ovens	oven	NN2
304953	100736297	20992726268	are	be	VBR
304953	100736297	20992726269	typically	typically	RR
304953	100736297	20992726270	designed	design	VVN_VVD
304953	100736297	20992726271	so	so	RR
304953	100736297	20992726272	as	as	CSA
304953	100736297	20992726273	not	not	XX
304953	100736297	20992726274	to	to	TO
304953	100736297	20992726275	exceed	exceed	VVI
304953	100736297	20992726276	1mW/cm2		NN1
304953	100736297	20992726277	of	of	IO
304953	100736297	20992726278	radiated	radiated	JJ@
304953	100736297	20992726279	power	power	NN1
304953	100736297	20992726280	.	.	.
304953	100736297	20992726281	In	in	RR21
304953	100736297	20992726282	addition	addition	RR22
304953	100736297	20992726283	,	,	,
304953	100736297	20992726284	any	any	DD
304953	100736297	20992726285	leak	leak	NN1_VV0
304953	100736297	20992726286	that	that	CST_DD1
304953	100736297	20992726287	exceeds	exceed	VVZ
304953	100736297	20992726288	5mW/cm2		NN1
304953	100736297	20992726289	at	at	II
304953	100736297	20992726290	a	a	AT1
304953	100736297	20992726291	distance	distance	NN1
304953	100736297	20992726292	of	of	IO
304953	100736297	20992726293	2	2	MC
304953	100736297	20992726294	inches	inch	NNU2
304953	100736297	20992726295	from	from	II
304953	100736297	20992726296	a	a	AT1
304953	100736297	20992726297	microwave	microwave	NN1
304953	100736297	20992726298	oven	oven	NN1
304953	100736297	20992726299	is	be	VBZ
304953	100736297	20992726300	considered	consider	VVN
304953	100736297	20992726301	to	to	TO
304953	100736297	20992726302	be	be	VBI
304953	100736297	20992726303	dangerous	dangerous	JJ
304953	100736297	20992726304	and	and	CC
304953	100736297	20992726305	the	the	AT
304953	100736297	20992726306	oven	oven	NN1
304953	100736297	20992726307	should	should	VM
304953	100736297	20992726308	not	not	XX
304953	100736297	20992726309	be	be	VBI
304953	100736297	20992726310	used	use	VVN
304953	100736297	20992726311	.	.	.
304953	100736297	20992726312	Ovens	oven	NN2
304953	100736297	20992726313	can	can	VM
304953	100736297	20992726314	deteriorate	deteriorate	VVI
304953	100736297	20992726315	over	over	II_RP
304953	100736297	20992726316	time	time	NNT1
304953	100736297	20992726317	and	and	CC
304953	100736297	20992726318	should	should	VM
304953	100736297	20992726319	be	be	VBI
304953	100736297	20992726320	checked	check	VVN
304953	100736297	20992726321	to	to	TO
304953	100736297	20992726322	ensure	ensure	VVI
304953	100736297	20992726323	that	that	CST
304953	100736297	20992726324	these	these	DD2
304953	100736297	20992726325	limits	limit	NN2
304953	100736297	20992726326	are	be	VBR
304953	100736297	20992726327	not	not	XX
304953	100736297	20992726328	exceeded.This		NNU
304953	100736297	20992726329	can	can	VM
304953	100736297	20992726330	be	be	VBI
304953	100736297	20992726331	done	do	VDN
304953	100736297	20992726332	by	by	II
304953	100736297	20992726333	your	your	APPGE
304953	100736297	20992726334	local	local	JJ
304953	100736297	20992726335	service	service	NN1
304953	100736297	20992726336	centre	centre	NN1
304953	100736297	20992726337	or	or	CC
304953	100736297	20992726338	you	you	PPY
304953	100736297	20992726339	can	can	VM
304953	100736297	20992726340	purchase	purchase	VVI
304953	100736297	20992726341	an	a	AT1
304953	100736297	20992726342	earth	earth	NN1
304953	100736297	20992726343	leakage	leakage	NN1
304953	100736297	20992726344	detector	detector	NN1
304953	100736297	20992726345	and	and	CC
304953	100736297	20992726346	have	have	VH0
304953	100736297	20992726347	it	it	PPH1
304953	100736297	20992726348	on	on	II
304953	100736297	20992726349	hand	hand	NN1
304953	100736297	20992726350	to	to	TO
304953	100736297	20992726351	keep	keep	VVI
304953	100736297	20992726352	a	a	AT1
304953	100736297	20992726353	regular	regular	JJ
304953	100736297	20992726354	maintenance	maintenance	NN1
304953	100736297	20992726355	check	check	NN1
304953	100736297	20992726356	of	of	IO
304953	100736297	20992726357	your	your	APPGE
304953	100736297	20992726358	@		II
304953	100736297	20992726359	@		II
304953	100736297	20992726360	@		II
304953	100736297	20992726361	@		II
304953	100736297	20992726362	@		II
304953	100736297	20992726363	@		II
304953	100736297	20992726364	@		II
304953	100736297	20992726365	@		II
304953	100736297	20992726366	@		II
304953	100736297	20992726367	@		II
304953	100736297	20992726368	it	it	PPH1
304953	100736297	20992726369	would	would	VM
304953	100736297	20992726370	present	present	VVI
304953	100736297	20992726371	no	no	AT
304953	100736297	20992726372	more	more	DAR
304953	100736297	20992726373	risk	risk	NN1_VV0
304953	100736297	20992726374	then	then	RT
304953	100736297	20992726375	anything	anything	PN1
304953	100736297	20992726376	else	else	RR
304953	100736297	20992726377	around	around	II_RP
304953	100736297	20992726378	your	your	APPGE
304953	100736297	20992726379	home	home	NN1
304953	100736297	20992726380	such	such	II21
304953	100736297	20992726381	as	as	II22
304953	100736297	20992726382	eating	eat	VVG
304953	100736297	20992726383	processed	processed	JJ
304953	100736297	20992726384	food	food	NN1
304953	100736297	20992726385	,	,	,
304953	100736297	20992726386	using	use	VVG
304953	100736297	20992726387	mobile	mobile	JJ_NN1
304953	100736297	20992726388	phones	phone	NN2
304953	100736297	20992726389	,	,	,
304953	100736297	20992726390	living	live	VVG
304953	100736297	20992726391	near	near	II
304953	100736297	20992726392	HV	hv	NP1
304953	100736297	20992726393	power	power	NN1
304953	100736297	20992726394	lines	line	NN2
304953	100736297	20992726395	,	,	,
304953	100736297	20992726396	or	or	CC
304953	100736297	20992726397	living	live	VVG_NN1_JJ
304953	100736297	20992726398	in	in	II_RP@
304953	100736297	20992726399	your	your	APPGE
304953	100736297	20992726400	house	house	NN1
304953	100736297	20992726401	which	which	DDQ
304953	100736297	20992726402	exposes	expose	VVZ
304953	100736297	20992726403	you	you	PPY
304953	100736297	20992726404	to	to	II
304953	100736297	20992726405	electromagnetic	electromagnetic	JJ
304953	100736297	20992726406	radiation	radiation	NN1
304953	100736297	20992726407	from	from	II
304953	100736297	20992726408	the	the	AT
304953	100736297	20992726409	electrical	electrical	JJ
304953	100736297	20992726410	wiring	wiring	NN1
304953	100736297	20992726411	.	.	.
304953	100736297	20992726412	Also	also	RR
304953	100736297	20992726413	,	,	,
304953	100736297	20992726414	as	as	CSA
304953	100736297	20992726415	I	i	PPIS1
304953	100736297	20992726416	had	have	VHD
304953	100736297	20992726417	indicated	indicate	VVN
304953	100736297	20992726418	in	in	II
304953	100736297	20992726419	an	a	AT1
304953	100736297	20992726420	earlier	early	JJR
304953	100736297	20992726421	posting	posting	NN1
304953	100736297	20992726422	;	;	;
304953	100736297	20992726423	the	the	AT
304953	100736297	20992726424	other	other	JJ
304953	100736297	20992726425	aspect	aspect	NN1
304953	100736297	20992726426	and	and	CC
304953	100736297	20992726427	some	some	DD
304953	100736297	20992726428	area	area	NN1
304953	100736297	20992726429	of	of	IO
304953	100736297	20992726430	concern	concern	NN1
304953	100736297	20992726431	is	be	VBZ
304953	100736297	20992726432	the	the	AT
304953	100736297	20992726433	safety	safety	NN1
304953	100736297	20992726434	of	of	IO
304953	100736297	20992726435	eating	eat	VVG_NN1
304953	100736297	20992726436	foods	food	NN2
304953	100736297	20992726437	from	from	II
304953	100736297	20992726438	a	a	AT1
304953	100736297	20992726439	microwave	microwave	NN1
304953	100736297	20992726440	.	.	.
304953	100736297	20992726441	This	this	DD1
304953	100736297	20992726442	really	really	RR
304953	100736297	20992726443	depends	depend	VVZ
304953	100736297	20992726444	on	on	II
304953	100736297	20992726445	the	the	AT
304953	100736297	20992726446	containers	container	NN2
304953	100736297	20992726447	used	use	VMK
304953	100736297	20992726448	to	to	TO
304953	100736297	20992726449	heat	heat	VVI
304953	100736297	20992726450	the	the	AT
304953	100736297	20992726451	food	food	NN1
304953	100736297	20992726452	in	in	RP@_II
304953	100736297	20992726453	.	.	.
304953	100736297	20992726454	Some	some	DD
304953	100736297	20992726455	plastics	plastic	NN2
304953	100736297	20992726456	,	,	,
304953	100736297	20992726457	for	for	REX21
304953	100736297	20992726458	instance	instance	REX22
304953	100736297	20992726459	,	,	,
304953	100736297	20992726460	are	be	VBR
304953	100736297	20992726461	more	more	RGR
304953	100736297	20992726462	prone	prone	JJ
304953	100736297	20992726463	to	to	II
304953	100736297	20992726464	the	the	AT
304953	100736297	20992726465	effect	effect	NN1
304953	100736297	20992726466	of	of	IO
304953	100736297	20992726467	"	"	"
304953	100736297	20992726468	migration	migration	NN1
304953	100736297	20992726469	"	"	"
304953	100736297	20992726470	.	.	.
304953	100736297	20992726471	whereby	whereby	RRQ
304953	100736297	20992726472	some	some	DD
304953	100736297	20992726473	additives	additive	NN2
304953	100736297	20992726474	used	use	VVN_VVD
304953	100736297	20992726475	in	in	II
304953	100736297	20992726476	plastics	plastic	NN2
304953	100736297	20992726477	are	be	VBR
304953	100736297	20992726478	more	more	RGR
304953	100736297	20992726479	likely	likely	JJ
304953	100736297	20992726480	to	to	TO
304953	100736297	20992726481	migrate	migrate	VVI
304953	100736297	20992726482	to	to	II
304953	100736297	20992726483	foods	food	NN2
304953	100736297	20992726484	more	more	RRR
304953	100736297	20992726485	than	than	CSN
304953	100736297	20992726486	others	others	NN2
304953	100736297	20992726487	.	.	.
304953	100736297	20992726488	The	the	AT
304953	100736297	20992726489	main	main	JJ
304953	100736297	20992726490	concern	concern	NN1
304953	100736297	20992726491	in	in	II
304953	100736297	20992726492	the	the	AT
304953	100736297	20992726493	past	past	NN1
304953	100736297	20992726494	has	have	VHZ
304953	100736297	20992726495	been	be	VBN
304953	100736297	20992726496	in	in	II31
304953	100736297	20992726497	connection	connection	II32
304953	100736297	20992726498	with	with	II33
304953	100736297	20992726499	plasticisers		NN2
304953	100736297	20992726500	which	which	DDQ
304953	100736297	20992726501	are	be	VBR
304953	100736297	20992726502	used	use	VVN
304953	100736297	20992726503	to	to	TO
304953	100736297	20992726504	improve	improve	VVI
304953	100736297	20992726505	the	the	AT
304953	100736297	20992726506	flexibility	flexibility	NN1
304953	100736297	20992726507	of	of	IO
304953	100736297	20992726508	some	some	DD
304953	100736297	20992726509	packaging	packaging	NN1
304953	100736297	20992726510	materials	material	NN2
304953	100736297	20992726511	.	.	.
304953	100736297	20992726512	As	as	II_CSA
304953	100736297	20992726513	the	the	AT
304953	100736297	20992726514	tendency	tendency	NN1
304953	100736297	20992726515	for	for	IF
304953	100736297	20992726516	plasticisers		NN2
304953	100736297	20992726517	to	to	TO
304953	100736297	20992726518	migrate	migrate	VVI
304953	100736297	20992726519	increases	increase	NN2
304953	100736297	20992726520	at	at	II
304953	100736297	20992726521	higher	high	JJR
304953	100736297	20992726522	temperatures	temperature	NN2
304953	100736297	20992726523	,	,	,
304953	100736297	20992726524	only	only	JJ
304953	100736297	20992726525	those	those-	DD2
304953	100736297	20992726526	plastics	plastic	NN2
304953	100736297	20992726527	specifically	specifically	RR
304953	100736297	20992726528	designed	design	VVN
304953	100736297	20992726529	for	for	IF
304953	100736297	20992726530	oven	oven	NN1
304953	100736297	20992726531	use	use	NN1
304953	100736297	20992726532	are	be	VBR
304953	100736297	20992726533	suitable	suitable	JJ
304953	100736297	20992726534	for	for	IF
304953	100736297	20992726535	cooking	cooking	NN1_VVG
304953	100736297	20992726536	.	.	.
304953	100736297	20992726537	To	to	TO
304953	100736297	20992726538	reduce	reduce	VVI
304953	100736297	20992726539	any	any	DD
304953	100736297	20992726540	possible	possible	JJ
304953	100736297	20992726541	risk	risk	NN1_VV0
304953	100736297	20992726542	one	one	PN1_MC1
304953	100736297	20992726543	should	should	VM
304953	100736297	20992726544	;	;	;
304953	100736297	20992726545	*	*	FU
304953	100736297	20992726546	Use	use	NN1
304953	100736297	20992726547	only	only	JJ
304953	100736297	20992726548	microwave-safe		NN1
304953	100736297	20992726549	utensils.		NNU
304953	100736297	20992726550	*	*	FU
304953	100736297	20992726551	While	while	CS
304953	100736297	20992726552	some	some	DD
304953	100736297	20992726553	packaging	packaging	NN1
304953	100736297	20992726554	films	film	NN2
304953	100736297	20992726555	may	may	VM
304953	100736297	20992726556	be	be	VBI
304953	100736297	20992726557	labelled	label	VVN
304953	100736297	20992726558	@		II
304953	100736297	20992726559	@		II
304953	100736297	20992726560	@		II
304953	100736297	20992726561	@		II
304953	100736297	20992726562	@		II
304953	100736297	20992726563	@		II
304953	100736297	20992726564	@		II
304953	100736297	20992726565	@		II
304953	100736297	20992726566	@		II
304953	100736297	20992726567	@		II
304953	100736297	20992726568	the	the	AT
304953	100736297	20992726569	food	food	NN1
304953	100736297	20992726570	when	when	CS
304953	100736297	20992726571	using	use	VVG
304953	100736297	20992726572	them	them	PPHO2
304953	100736297	20992726573	to	to	TO
304953	100736297	20992726574	cover	cover	VVI
304953	100736297	20992726575	containers	container	NN2
304953	100736297	20992726576	or	or	CC
304953	100736297	20992726577	to	to	TO
304953	100736297	20992726578	reheat	reheat	VVI
304953	100736297	20992726579	dinners	dinner	NN2
304953	100736297	20992726580	on	on	II
304953	100736297	20992726581	plates.		NNU
304953	100736297	20992726582	*	*	FU
304953	100736297	20992726583	As	as	II@
304953	100736297	20992726584	migration	migration	NN1
304953	100736297	20992726585	is	be	VBZ
304953	100736297	20992726586	more	more	RGR
304953	100736297	20992726587	likely	likely	JJ
304953	100736297	20992726588	to	to	TO
304953	100736297	20992726589	occur	occur	VVI
304953	100736297	20992726590	into	into	II
304953	100736297	20992726591	hot	hot	JJ
304953	100736297	20992726592	fatty	fatty	JJ_NN1
304953	100736297	20992726593	foods	food	NN2
304953	100736297	20992726594	,	,	,
304953	100736297	20992726595	glass	glass	NN1
304953	100736297	20992726596	containers	container	NN2
304953	100736297	20992726597	are	be	VBR
304953	100736297	20992726598	a	a	AT1
304953	100736297	20992726599	suitable	suitable	JJ
304953	100736297	20992726600	choice	choice	NN1
304953	100736297	20992726601	for	for	IF
304953	100736297	20992726602	heating	heat	VVG@
304953	100736297	20992726603	these	these	DD2
304953	100736297	20992726604	products	product	NN2
304953	100736297	20992726605	.	.	.
304953	100736297	20992726606	As	as	RR21
304953	100736297	20992726607	yet	yet	RR22
304953	100736297	20992726608	there	there	EX
304953	100736297	20992726609	are	be	VBR
304953	100736297	20992726610	no	no	AT
304953	100736297	20992726611	standards	standard	NN2
304953	100736297	20992726612	for	for	IF
304953	100736297	20992726613	claims	claim	NN2
304953	100736297	20992726614	such	such	II21
304953	100736297	20992726615	as	as	II22
304953	100736297	20992726616	"	"	"
304953	100736297	20992726617	microwave	microwave	NN1
304953	100736297	20992726618	safe	safe	NN1@_JJ
304953	100736297	20992726619	"	"	"
304953	100736297	20992726620	;	;	;
304953	100736297	20992726621	if	if	CS
304953	100736297	20992726622	you	you	PPY
304953	100736297	20992726623	are	be	VBR
304953	100736297	20992726624	in	in	II
304953	100736297	20992726625	doubt	doubt	NN1
304953	100736297	20992726626	as	as	II21
304953	100736297	20992726627	to	to	II22
304953	100736297	20992726628	the	the	AT
304953	100736297	20992726629	safety	safety	NN1
304953	100736297	20992726630	of	of	IO
304953	100736297	20992726631	such	such	DA
304953	100736297	20992726632	materials	material	NN2
304953	100736297	20992726633	contact	contact	VV0
304953	100736297	20992726634	the	the	AT
304953	100736297	20992726635	manufacturer	manufacturer	NN1
304953	100736297	20992726636	or	or	CC
304953	100736297	20992726637	use	use	VV0
304953	100736297	20992726638	a	a	AT1
304953	100736297	20992726639	ceramic/glass		NN1
304953	100736297	20992726640	alternative.In		NNU
304953	100736297	20992726641	the	the	AT
304953	100736297	20992726642	end	end	NN1
304953	100736297	20992726643	,	,	,
304953	100736297	20992726644	I	i	PPIS1
304953	100736297	20992726645	guess	guess	VV0
304953	100736297	20992726646	time	time	NNT1
304953	100736297	20992726647	will	will	VM
304953	100736297	20992726648	tell	tell	VVI
304953	100736297	20992726649	as	as	II21
304953	100736297	20992726650	to	to	II22
304953	100736297	20992726651	what	what	DDQ
304953	100736297	20992726652	other	other	JJ
304953	100736297	20992726653	possible	possible	JJ
304953	100736297	20992726654	adverse	adverse	JJ
304953	100736297	20992726655	effects	effect	NN2
304953	100736297	20992726656	,	,	,
304953	100736297	20992726657	microwave	microwave	NN1
304953	100736297	20992726658	ovens	oven	NN2
304953	100736297	20992726659	may	may	VM
304953	100736297	20992726660	have	have	VHI
304953	100736297	20992726661	on	on	II
304953	100736297	20992726662	our	our	APPGE
304953	100736297	20992726663	lifes	life	NN2
304953	100736297	20992726664	!	!	!
304953	100736297	20992726665	46996		MC
304953	100736297	20992726666	@qwx906996		FO
304953	100736299	20992726686	@@##	----------	----------
304953	100736299	20992726687	@@100736299		FO
304953	100736299	20992726688	@4936299/		VV0_NN1
304953	100736299	20992726689	46989		MC
304953	100736299	20992726690	@qwx906989		FO
304953	100736299	20992726691	<p>		NULL
304953	100736299	20992726692	Men	man	NN2
304953	100736299	20992726693	whose	whose	DDQGE
304953	100736299	20992726694	blood	blood	NN1
304953	100736299	20992726695	calcium	calcium	NN1
304953	100736299	20992726696	levels	level	NN2
304953	100736299	20992726697	fall	fall	VV0
304953	100736299	20992726698	at	at	II
304953	100736299	20992726699	the	the	AT
304953	100736299	20992726700	high	high	JJ
304953	100736299	20992726701	end	end	NN1
304953	100736299	20992726702	of	of	IO
304953	100736299	20992726703	the	the	AT
304953	100736299	20992726704	normal	normal	JJ
304953	100736299	20992726705	range	range	NN1
304953	100736299	20992726706	are	be	VBR
304953	100736299	20992726707	more	more	DAR_RRR
304953	100736299	20992726708	than	than	CSN
304953	100736299	20992726709	two-and-a-half	two-and-a-half	MF
304953	100736299	20992726710	times	time	NNT2
304953	100736299	20992726711	as	as	RG
304953	100736299	20992726712	likely	likely	JJ
304953	100736299	20992726713	to	to	TO
304953	100736299	20992726714	develop	develop	VVI
304953	100736299	20992726715	fatal	fatal	JJ
304953	100736299	20992726716	prostate	prostate	NN1
304953	100736299	20992726717	cancer	cancer	NN1
304953	100736299	20992726718	as	as	CSA_II@
304953	100736299	20992726719	men	man	NN2
304953	100736299	20992726720	with	with	IW
304953	100736299	20992726721	lower	low	JJR
304953	100736299	20992726722	blood	blood	NN1
304953	100736299	20992726723	calcium	calcium	NN1
304953	100736299	20992726724	levels	level	NN2
304953	100736299	20992726725	,	,	,
304953	100736299	20992726726	according	according	II21
304953	100736299	20992726727	to	to	II22
304953	100736299	20992726728	a	a	AT1
304953	100736299	20992726729	recent	recent	JJ
304953	100736299	20992726730	study	study	NN1
304953	100736299	20992726731	.	.	.
304953	100736299	20992726732	If	if	CS
304953	100736299	20992726733	confirmed	confirm	VVN
304953	100736299	20992726734	in	in	II
304953	100736299	20992726735	other	other	JJ
304953	100736299	20992726736	studies	study	NN2
304953	100736299	20992726737	,	,	,
304953	100736299	20992726738	the	the	AT
304953	100736299	20992726739	findings	finding	NN2
304953	100736299	20992726740	could	could	VM
304953	100736299	20992726741	have	have	VHI
304953	100736299	20992726742	important	important	JJ
304953	100736299	20992726743	implications	implication	NN2
304953	100736299	20992726744	for	for	IF
304953	100736299	20992726745	prostate	prostate	NN1
304953	100736299	20992726746	cancer	cancer	NN1
304953	100736299	20992726747	prevention	prevention	NN1
304953	100736299	20992726748	and	and	CC
304953	100736299	20992726749	treatment	treatment	NN1
304953	100736299	20992726750	.	.	.
304953	100736299	20992726751	<p>		NULL
304953	100736299	20992726752	Researchers	researcher	NN2
304953	100736299	20992726753	analyzed	analyze	VVD_JJ@
304953	100736299	20992726754	health	health	NN1
304953	100736299	20992726755	records	record	NN2
304953	100736299	20992726756	of	of	IO
304953	100736299	20992726757	2,814		MC
304953	100736299	20992726758	men	man	NN2
304953	100736299	20992726759	in	in	II
304953	100736299	20992726760	the	the	AT
304953	100736299	20992726761	National	national	JJ
304953	100736299	20992726762	Health	health	NN1
304953	100736299	20992726763	and	and	CC
304953	100736299	20992726764	Nutrition	nutrition	NN1
304953	100736299	20992726765	Examination	examination	NN1
304953	100736299	20992726766	Survey	survey	NN1
304953	100736299	20992726767	(	(	(
304953	100736299	20992726768	NHANES	nhanes	NP2_NN2
304953	100736299	20992726769	)	)	)
304953	100736299	20992726770	and	and	CC
304953	100736299	20992726771	the	the	AT
304953	100736299	20992726772	NHANES	nhanes	NP2_NN2
304953	100736299	20992726773	Epidemiologic	epidemiologic	JJ
304953	100736299	20992726774	Follow-up	follow-up	JJ_NN1
304953	100736299	20992726775	Study	study	NN1
304953	100736299	20992726776	for	for	IF
304953	100736299	20992726777	whom	whom	PNQO
304953	100736299	20992726778	baseline	baseline	NN1
304953	100736299	20992726779	blood	blood	NN1
304953	100736299	20992726780	calcium	calcium	NN1
304953	100736299	20992726781	measurements	measurement	NN2
304953	100736299	20992726782	were	be	VBDR
304953	100736299	20992726783	available	available	JJ
304953	100736299	20992726784	.	.	.
304953	100736299	20992726785	At	at	II
304953	100736299	20992726786	the	the	AT
304953	100736299	20992726787	time	time	NNT1
304953	100736299	20992726788	of	of	IO
304953	100736299	20992726789	the	the	AT
304953	100736299	20992726790	initial	initial	JJ_NN1
304953	100736299	20992726791	blood	blood	NN1
304953	100736299	20992726792	collection	collection	NN1
304953	100736299	20992726793	,	,	,
304953	100736299	20992726794	between	between	II
304953	100736299	20992726795	1971	1971	MC
304953	100736299	20992726796	and	and	CC
304953	100736299	20992726797	1975	1975	MC
304953	100736299	20992726798	,	,	,
304953	100736299	20992726799	the	the	AT
304953	100736299	20992726800	men	man	NN2
304953	100736299	20992726801	ranged	range	VVN_VVD
304953	100736299	20992726802	in	in	II
304953	100736299	20992726803	age	age	NN1
304953	100736299	20992726804	from	from	II
304953	100736299	20992726805	24	24	MC
304953	100736299	20992726806	to	to	II
304953	100736299	20992726807	77	77	MC
304953	100736299	20992726808	.	.	.
304953	100736299	20992726809	After	after	CS_II
304953	100736299	20992726810	an	a	AT1
304953	100736299	20992726811	average	average	NN1
304953	100736299	20992726812	of	of	IO
304953	100736299	20992726813	nearly	nearly	RR
304953	100736299	20992726814	10	10	MC
304953	100736299	20992726815	years	year	NNT2
304953	100736299	20992726816	of	of	IO
304953	100736299	20992726817	follow-up	follow-up	NN1_JJ
304953	100736299	20992726818	,	,	,
304953	100736299	20992726819	there	there	EX
304953	100736299	20992726820	were	be	VBDR
304953	100736299	20992726821	85	85	MC
304953	100736299	20992726822	total	total	JJ
304953	100736299	20992726823	cases	case	NN2
304953	100736299	20992726824	of	of	IO
304953	100736299	20992726825	prostate	prostate	NN1
304953	100736299	20992726826	cancer	cancer	NN1
304953	100736299	20992726827	,	,	,
304953	100736299	20992726828	including	including	II
304953	100736299	20992726829	25	25	MC
304953	100736299	20992726830	fatal	fatal	JJ
304953	100736299	20992726831	cases	case	NN2
304953	100736299	20992726832	.	.	.
304953	100736299	20992726833	<p>		NULL
304953	100736299	20992726834	When	when	RRQ_CS
304953	100736299	20992726835	researchers	researcher	NN2
304953	100736299	20992726836	correlated	correlate	VVD_VVN
304953	100736299	20992726837	these	these	DD2
304953	100736299	20992726838	cases	case	NN2
304953	100736299	20992726839	according	according	II21
304953	100736299	20992726840	to	to	II22
304953	100736299	20992726841	blood	blood	NN1
304953	100736299	20992726842	calcium	calcium	NN1
304953	100736299	20992726843	levels	level	NN2
304953	100736299	20992726844	,	,	,
304953	100736299	20992726845	they	they	PPHS2
304953	100736299	20992726846	found	find	VVD
304953	100736299	20992726847	that	that	CST
304953	100736299	20992726848	the	the	AT
304953	100736299	20992726849	men	man	NN2
304953	100736299	20992726850	with	with	IW
304953	100736299	20992726851	a	a	AT1
304953	100736299	20992726852	blood	blood	NN1
304953	100736299	20992726853	calcium	calcium	NN1
304953	100736299	20992726854	level	level	NN1
304953	100736299	20992726855	in	in	II
304953	100736299	20992726856	the	the	AT
304953	100736299	20992726857	highest	high	JJT
304953	100736299	20992726858	third	third	MD
304953	100736299	20992726859	were	be	VBDR
304953	100736299	20992726860	about	about	RG
304953	100736299	20992726861	2.7	2.7	MC
304953	100736299	20992726862	times	time	NNT2
304953	100736299	20992726863	more	more	RRR_RGR
304953	100736299	20992726864	likely	likely	JJ
304953	100736299	20992726865	to	to	TO
304953	100736299	20992726866	die	die	VVI
304953	100736299	20992726867	of	of	IO
304953	100736299	20992726868	prostate	prostate	NN1
304953	100736299	20992726869	cancer	cancer	NN1
304953	100736299	20992726870	than	than	CSN
304953	100736299	20992726871	those	those	DD2
304953	100736299	20992726872	with	with	IW
304953	100736299	20992726873	blood	blood	NN1
304953	100736299	20992726874	calcium	calcium	NN1
304953	100736299	20992726875	levels	level	NN2
304953	100736299	20992726876	in	in	II
304953	100736299	20992726877	the	the	AT
304953	100736299	20992726878	@		II
304953	100736299	20992726879	@		II
304953	100736299	20992726880	@		II
304953	100736299	20992726881	@		II
304953	100736299	20992726882	@		II
304953	100736299	20992726883	@		II
304953	100736299	20992726884	@		II
304953	100736299	20992726885	@		II
304953	100736299	20992726886	@		II
304953	100736299	20992726887	@		II
304953	100736299	20992726888	after	after	II_CS
304953	100736299	20992726889	the	the	AT
304953	100736299	20992726890	researchers	researcher	NN2
304953	100736299	20992726891	took	take	VVD
304953	100736299	20992726892	family	family	NN1
304953	100736299	20992726893	history	history	NN1
304953	100736299	20992726894	,	,	,
304953	100736299	20992726895	age	age	NN1_VV0@
304953	100736299	20992726896	,	,	,
304953	100736299	20992726897	weight	weight	NN1
304953	100736299	20992726898	,	,	,
304953	100736299	20992726899	and	and	CC
304953	100736299	20992726900	race	race	NN1_VV0@
304953	100736299	20992726901	into	into	II
304953	100736299	20992726902	account	account	NN1
304953	100736299	20992726903	.	.	.
304953	100736299	20992726904	There	there	EX
304953	100736299	20992726905	was	be	VBDZ
304953	100736299	20992726906	no	no	AT
304953	100736299	20992726907	connection	connection	NN1
304953	100736299	20992726908	between	between	II
304953	100736299	20992726909	blood	blood	NN1
304953	100736299	20992726910	calcium	calcium	NN1
304953	100736299	20992726911	levels	level	NN2
304953	100736299	20992726912	and	and	CC
304953	100736299	20992726913	prostate	prostate	NN1
304953	100736299	20992726914	cancer	cancer	NN1
304953	100736299	20992726915	in	in	RR21
304953	100736299	20992726916	general	general	RR22
304953	100736299	20992726917	.	.	.
304953	100736299	20992726918	<p>		NULL
304953	100736299	20992726919	Blood	blood	NN1
304953	100736299	20992726920	calcium	calcium	NN1
304953	100736299	20992726921	levels	level	NN2
304953	100736299	20992726922	have	have	VH0
304953	100736299	20992726923	little	little	DA1_RR
304953	100736299	20992726924	to	to	TO
304953	100736299	20992726925	do	do	VDI
304953	100736299	20992726926	with	with	IW
304953	100736299	20992726927	dietary	dietary	JJ
304953	100736299	20992726928	calcium	calcium	NN1
304953	100736299	20992726929	,	,	,
304953	100736299	20992726930	the	the	AT
304953	100736299	20992726931	amount	amount	NN1
304953	100736299	20992726932	consumed	consume	VVN_VVD
304953	100736299	20992726933	through	through	II
304953	100736299	20992726934	food	food	NN1
304953	100736299	20992726935	.	.	.
304953	100736299	20992726936	A	a	AT1
304953	100736299	20992726937	person	person	NN1
304953	100736299	20992726938	's	's	GE
304953	100736299	20992726939	genetics	genetics	NN1
304953	100736299	20992726940	,	,	,
304953	100736299	20992726941	not	not	XX
304953	100736299	20992726942	how	how	RGQ@
304953	100736299	20992726943	much	much	DA1
304953	100736299	20992726944	milk	milk	NN1
304953	100736299	20992726945	and	and	CC
304953	100736299	20992726946	cheese	cheese	NN1
304953	100736299	20992726947	he	he	PPHS1
304953	100736299	20992726948	eats	eat	VVZ
304953	100736299	20992726949	,	,	,
304953	100736299	20992726950	mainly	mainly	RR
304953	100736299	20992726951	determines	determine	VVZ
304953	100736299	20992726952	blood	blood	NN1
304953	100736299	20992726953	calcium	calcium	NN1
304953	100736299	20992726954	levels	level	NN2
304953	100736299	20992726955	.	.	.
304953	100736299	20992726956	If	if	CS
304953	100736299	20992726957	the	the	AT
304953	100736299	20992726958	findings	finding	NN2
304953	100736299	20992726959	can	can	VM
304953	100736299	20992726960	be	be	VBI
304953	100736299	20992726961	validated	validate	VVN@
304953	100736299	20992726962	in	in	II
304953	100736299	20992726963	other	other	JJ
304953	100736299	20992726964	studies	study	NN2
304953	100736299	20992726965	,	,	,
304953	100736299	20992726966	physicians	physician	NN2
304953	100736299	20992726967	might	might	VM
304953	100736299	20992726968	one	one	MC1
304953	100736299	20992726969	day	day	NNT1
304953	100736299	20992726970	look	look	VVI
304953	100736299	20992726971	at	at	II
304953	100736299	20992726972	blood	blood	NN1
304953	100736299	20992726973	calcium	calcium	NN1
304953	100736299	20992726974	to	to	TO
304953	100736299	20992726975	determine	determine	VVI
304953	100736299	20992726976	which	which	DDQ
304953	100736299	20992726977	patients	patient	NN2
304953	100736299	20992726978	need	need	VV0
304953	100736299	20992726979	more	more	RRR
304953	100736299	20992726980	frequent	frequent	VVI
304953	100736299	20992726981	screening	screening	NN1_VVG
304953	100736299	20992726982	or	or	CC
304953	100736299	20992726983	aggressive	aggressive	JJ
304953	100736299	20992726984	therapy	therapy	NN1
304953	100736299	20992726985	.	.	.
304953	100736299	20992726986	<p>		NULL
304953	100736299	20992726987	this	this	DD1
304953	100736299	20992726988	"	"	"
304953	100736299	20992726989	desire	desire	NN1
304953	100736299	20992726990	"	"	"
304953	100736299	20992726991	from	from	II
304953	100736299	20992726992	when	when	RRQ
304953	100736299	20992726993	you	you	PPY
304953	100736299	20992726994	were	be	VBDR
304953	100736299	20992726995	little	little	RR_JJ
304953	100736299	20992726996	(	(	(
304953	100736299	20992726997	your	your	APPGE
304953	100736299	20992726998	little	little	JJ
304953	100736299	20992726999	fingers	finger	NN2
304953	100736299	20992727000	)	)	)
304953	100736299	20992727001	why	why	RRQ
304953	100736299	20992727002	does	do	VDZ
304953	100736299	20992727003	n't 	n't	XX
304953	100736299	20992727004	it	it	PPH1
304953	100736299	20992727005	surprise	surprise	VVI
304953	100736299	20992727006	me	me	PPIO1
304953	100736299	20992727007	one	one	MC1
304953	100736299	20992727008	bit	bit	NN1_VVD
304953	100736299	20992727009	?	?	?
304953	100736299	20992727010	its	its	APPGE
304953	100736299	20992727011	great	great	JJ
304953	100736299	20992727012	that	that	CST
304953	100736299	20992727013	you	you	PPY
304953	100736299	20992727014	have	have	VH0
304953	100736299	20992727015	the	the	AT
304953	100736299	20992727016	old	old	JJ
304953	100736299	20992727017	literature	literature	NN1
304953	100736299	20992727018	with	with	IW
304953	100736299	20992727019	it	it	PPH1
304953	100736299	20992727020	,	,	,
304953	100736299	20992727021	too	too	RR@
304953	100736299	20992727022	.	.	.
304953	100736299	20992727023	I	i	PPIS1
304953	100736299	20992727024	have	have	VH0
304953	100736299	20992727025	an	a	AT1
304953	100736299	20992727026	old	old	JJ
304953	100736299	20992727027	old	old	JJ
304953	100736299	20992727028	Re.o.gtinnm.		NP1
304953	100736299	20992727029	its	its	APPGE
304953	100736299	20992727030	like	like	II_JJ@_NN1%
304953	100736299	20992727031	a	a	AT1
304953	100736299	20992727032	black	black	JJ
304953	100736299	20992727033	train	train	NN1
304953	100736299	20992727034	.	.	.
304953	100736299	20992727035	46996		MC
304953	100736299	20992727036	@qwx906996		FO
304953	100736300	20992727056	@@##	----------	----------
304953	100736300	20992727057	@@100736300		FO
304953	100736300	20992727058	@4936300/		VV0_NN1
304953	100736300	20992727059	46989		MC
304953	100736300	20992727060	@qwx906989		FO
304953	100736300	20992727061	<p>		NULL
304953	100736300	20992727062	Swedish	swedish	JJ
304953	100736300	20992727063	researchers	researcher	NN2
304953	100736300	20992727064	report	report	VV0@_NN1
304953	100736300	20992727065	that	that	CST
304953	100736300	20992727066	PSA	psa	NP1
304953	100736300	20992727067	levels	level	NN2
304953	100736300	20992727068	measured	measure	VVN_VVD
304953	100736300	20992727069	at	at	II
304953	100736300	20992727070	ages	age	NN2
304953	100736300	20992727071	44	44	MC
304953	100736300	20992727072	to	to	II
304953	100736300	20992727073	50	50	MC
304953	100736300	20992727074	may	may	VM
304953	100736300	20992727075	accurately	accurately	RR
304953	100736300	20992727076	predict	predict	VVI
304953	100736300	20992727077	which	which	DDQ
304953	100736300	20992727078	men	man	NN2
304953	100736300	20992727079	will	will	VM
304953	100736300	20992727080	develop	develop	VVI
304953	100736300	20992727081	cancer	cancer	NN1
304953	100736300	20992727082	up	up	RG21
304953	100736300	20992727083	to	to	RG22
304953	100736300	20992727084	25	25	MC
304953	100736300	20992727085	years	year	NNT2
304953	100736300	20992727086	later	later	RRR
304953	100736300	20992727087	.	.	.
304953	100736300	20992727088	Researchers	researcher	NN2
304953	100736300	20992727089	at	at	II
304953	100736300	20992727090	Lund	lund	NP1
304953	100736300	20992727091	University	university	NN1
304953	100736300	20992727092	in	in	II
304953	100736300	20992727093	Malm+		FO
304953	100736300	20992727094	,	,	,
304953	100736300	20992727095	Sweden	sweden	NP1
304953	100736300	20992727096	,	,	,
304953	100736300	20992727097	analyzed	analyze	VVD_JJ@
304953	100736300	20992727098	blood	blood	NN1
304953	100736300	20992727099	samples	sample	NN2_VVZ@
304953	100736300	20992727100	originally	originally	RR
304953	100736300	20992727101	collected	collect	VVN_VVD
304953	100736300	20992727102	from	from	II
304953	100736300	20992727103	1974	1974	MC
304953	100736300	20992727104	to	to	II
304953	100736300	20992727105	1986	1986	MC
304953	100736300	20992727106	as	as	II
304953	100736300	20992727107	part	part	NN1
304953	100736300	20992727108	of	of	IO
304953	100736300	20992727109	a	a	AT1
304953	100736300	20992727110	heart	heart	NN1
304953	100736300	20992727111	disease	disease	NN1
304953	100736300	20992727112	study	study	NN1
304953	100736300	20992727113	,	,	,
304953	100736300	20992727114	and	and	CC
304953	100736300	20992727115	at	at	II
304953	100736300	20992727116	a	a	AT1
304953	100736300	20992727117	time	time	NNT1
304953	100736300	20992727118	when	when	RRQ
304953	100736300	20992727119	most	most	DAT
304953	100736300	20992727120	men	man	NN2
304953	100736300	20992727121	were	be	VBDR
304953	100736300	20992727122	not	not	XX
304953	100736300	20992727123	routinely	routinely	RR
304953	100736300	20992727124	screened	screen	VVN_VVD
304953	100736300	20992727125	with	with	IW
304953	100736300	20992727126	PSA	psa	NP1
304953	100736300	20992727127	tests	test	NN2_VVZ@
304953	100736300	20992727128	.	.	.
304953	100736300	20992727129	The	the	AT
304953	100736300	20992727130	researchers	researcher	NN2
304953	100736300	20992727131	thawed	thaw	VVD
304953	100736300	20992727132	462	462	MC
304953	100736300	20992727133	blood	blood	NN1
304953	100736300	20992727134	samples	sample	NN2
304953	100736300	20992727135	taken	take	VVN
304953	100736300	20992727136	from	from	II
304953	100736300	20992727137	men	man	NN2
304953	100736300	20992727138	later	later	RRR
304953	100736300	20992727139	diagnosed	diagnose	VVN_VVD
304953	100736300	20992727140	with	with	IW
304953	100736300	20992727141	prostate	prostate	NN1
304953	100736300	20992727142	cancer	cancer	NN1
304953	100736300	20992727143	,	,	,
304953	100736300	20992727144	measured	measure	VVD
304953	100736300	20992727145	PSA	psa	NP1
304953	100736300	20992727146	,	,	,
304953	100736300	20992727147	and	and	CC
304953	100736300	20992727148	then	then	RT
304953	100736300	20992727149	compared	compare	VVD_VVN
304953	100736300	20992727150	them	them	PPHO2
304953	100736300	20992727151	with	with	IW
304953	100736300	20992727152	1,222	1,222	MC
304953	100736300	20992727153	thawed	thawed	JJ@_VVD
304953	100736300	20992727154	blood	blood	NN1
304953	100736300	20992727155	samples	sample	NN2_VVZ@
304953	100736300	20992727156	from	from	II
304953	100736300	20992727157	controls	control	NN2
304953	100736300	20992727158	without	without	IW
304953	100736300	20992727159	cancer	cancer	NN1
304953	100736300	20992727160	.	.	.
304953	100736300	20992727161	They	they	PPHS2
304953	100736300	20992727162	found	find	VVD
304953	100736300	20992727163	that	that	DD1_CST
304953	100736300	20992727164	prostate	prostate	NN1
304953	100736300	20992727165	cancer	cancer	NN1
304953	100736300	20992727166	risk	risk	NN1
304953	100736300	20992727167	increased	increase	VVN_VVD
304953	100736300	20992727168	about	about	RG
304953	100736300	20992727169	3.7	3.7	MC
304953	100736300	20992727170	times	time	NNT2
304953	100736300	20992727171	for	for	IF
304953	100736300	20992727172	each	each	DD1
304953	100736300	20992727173	1	1	MC1
304953	100736300	20992727174	ng/ml	ng/ml	FU
304953	100736300	20992727175	increase	increase	NN1
304953	100736300	20992727176	in	in	II
304953	100736300	20992727177	PSA	psa	NP1
304953	100736300	20992727178	level	level	NN1_JJ
304953	100736300	20992727179	.	.	.
304953	100736300	20992727180	<p>		NULL
304953	100736300	20992727181	Although	although	CS
304953	100736300	20992727182	PSA	psa	NP1
304953	100736300	20992727183	screening	screening	NN1
304953	100736300	20992727184	remains	remain	VVZ
304953	100736300	20992727185	a	a	AT1
304953	100736300	20992727186	controversial	controversial	JJ
304953	100736300	20992727187	issue	issue	NN1
304953	100736300	20992727188	,	,	,
304953	100736300	20992727189	this	this	DD1
304953	100736300	20992727190	study	study	NN1
304953	100736300	20992727191	suggests	suggest	VVZ
304953	100736300	20992727192	that	that	CST
304953	100736300	20992727193	all	all	DB
304953	100736300	20992727194	men	man	NN2
304953	100736300	20992727195	may	may	VM
304953	100736300	20992727196	want	want	VVI
304953	100736300	20992727197	to	to	TO
304953	100736300	20992727198	consider	consider	VVI
304953	100736300	20992727199	an	a	AT1
304953	100736300	20992727200	initial	initial	JJ_NN1
304953	100736300	20992727201	PSA	psa	NP1
304953	100736300	20992727202	test	test	NN1_VV0
304953	100736300	20992727203	between	between	II
304953	100736300	20992727204	ages	age	NN2
304953	100736300	20992727205	45	45	MC
304953	100736300	20992727206	and	and	CC
304953	100736300	20992727207	50	50	MC
304953	100736300	20992727208	,	,	,
304953	100736300	20992727209	to	to	TO
304953	100736300	20992727210	assess	assess	VVI
304953	100736300	20992727211	long-term	long-term	JJ
304953	100736300	20992727212	risk	risk	NN1
304953	100736300	20992727213	of	of	IO
304953	100736300	20992727214	developing	developing	JJ_VVG
304953	100736300	20992727215	prostate	prostate	NN1
304953	100736300	20992727216	cancer	cancer	NN1
304953	100736300	20992727217	.	.	.
304953	100736300	20992727218	Men	man	NN2
304953	100736300	20992727219	whose	whose	DDQGE
304953	100736300	20992727220	tests	test	NN2
304953	100736300	20992727221	indicate	indicate	VV0
304953	100736300	20992727222	they	they	PPHS2
304953	100736300	20992727223	are	be	VBR
304953	100736300	20992727224	at	at	II
304953	100736300	20992727225	low	low	JJ
304953	100736300	20992727226	risk	risk	NN1
304953	100736300	20992727227	could	could	VM
304953	100736300	20992727228	then	then	RT
304953	100736300	20992727229	undergo	undergo	VVI
304953	100736300	20992727230	only	only	JJ
304953	100736300	20992727231	periodic		NN1
304953	100736300	20992727232	follow-up	follow-up	NN1_JJ
304953	100736300	20992727233	PSA	psa	NP1
304953	100736300	20992727234	tests	test	NN2_VVZ@
304953	100736300	20992727235	,	,	,
304953	100736300	20992727236	while	while	CS
304953	100736300	20992727237	those	those	DD2
304953	100736300	20992727238	at	at	II
304953	100736300	20992727239	higher	high	JJR
304953	100736300	20992727240	risk	risk	NN1
304953	100736300	20992727241	could	could	VM
304953	100736300	20992727242	undergo	undergo	VVI
304953	100736300	20992727243	more	more	RGR_DAR
304953	100736300	20992727244	frequent	frequent	JJ
304953	100736300	20992727245	testing	testing	NN1
304953	100736300	20992727246	.	.	.
304953	100736300	20992727247	But	but	CCB
304953	100736300	20992727248	@		II
304953	100736300	20992727249	@		II
304953	100736300	20992727250	@		II
304953	100736300	20992727251	@		II
304953	100736300	20992727252	@		II
304953	100736300	20992727253	@		II
304953	100736300	20992727254	@		II
304953	100736300	20992727255	@		II
304953	100736300	20992727256	@		II
304953	100736300	20992727257	@		II
304953	100736300	20992727258	conduct	conduct	VVI
304953	100736300	20992727259	follow-up	follow-up	JJ_NN1
304953	100736300	20992727260	studies	study	NN2
304953	100736300	20992727261	,	,	,
304953	100736300	20992727262	to	to	TO
304953	100736300	20992727263	determine	determine	VVI
304953	100736300	20992727264	how	how	RRQ
304953	100736300	20992727265	best	best	RRT
304953	100736300	20992727266	to	to	TO
304953	100736300	20992727267	target	target	VVI
304953	100736300	20992727268	screening	screen	VVG_NN1
304953	100736300	20992727269	efforts	effort	NN2
304953	100736300	20992727270	.	.	.
304953	100736300	20992727271	46996		MC
304953	100736300	20992727272	@qwx906996		FO
304953	100736302	20992727292	@@##	----------	----------
304953	100736302	20992727293	@@100736302		FO
304953	100736302	20992727294	@4936302/		VV0_NN1
304953	100736302	20992727295	46989		MC
304953	100736302	20992727296	@qwx906989		FO
304953	100736302	20992727297	<p>		NULL
304953	100736302	20992727298	I	i	PPIS1
304953	100736302	20992727299	take	take	VV0
304953	100736302	20992727300	Flomax		NP1_NN1
304953	100736302	20992727301	(	(	(
304953	100736302	20992727302	tamsulosin		NN1
304953	100736302	20992727303	)	)	)
304953	100736302	20992727304	to	to	TO
304953	100736302	20992727305	manage	manage	VVI
304953	100736302	20992727306	my	my	APPGE
304953	100736302	20992727307	BPH	bph	NP1
304953	100736302	20992727308	.	.	.
304953	100736302	20992727309	The	the	AT
304953	100736302	20992727310	commercials	commercial	NN2
304953	100736302	20992727311	say	say	VV0
304953	100736302	20992727312	something	something	PN1
304953	100736302	20992727313	about	about	II
304953	100736302	20992727314	having	have	VHG
304953	100736302	20992727315	cataract	cataract	NN1
304953	100736302	20992727316	surgery	surgery	NN1
304953	100736302	20992727317	.	.	.
304953	100736302	20992727318	What	what	DDQ
304953	100736302	20992727319	's	be	VBZ
304953	100736302	20992727320	the	the	AT
304953	100736302	20992727321	connection	connection	NN1
304953	100736302	20992727322	between	between	II
304953	100736302	20992727323	the	the	AT
304953	100736302	20992727324	drug	drug	NN1
304953	100736302	20992727325	and	and	CC
304953	100736302	20992727326	cataracts	cataract	NN2_VVZ
304953	100736302	20992727327	?	?	?
304953	100736302	20992727328	If	if	CS
304953	100736302	20992727329	I	i	PPIS1
304953	100736302	20992727330	'm	be	VBM
304953	100736302	20992727331	taking-		JJ
304953	100736302	20992727332	Flomax		NN1_NP1
304953	100736302	20992727333	,	,	,
304953	100736302	20992727334	do	do	VD0
304953	100736302	20992727335	I	i	PPIS1
304953	100736302	20992727336	have	have	VHI
304953	100736302	20992727337	to	to	TO
304953	100736302	20992727338	forgo	forgo	VVI
304953	100736302	20992727339	having	have	VHG
304953	100736302	20992727340	my	my	APPGE
304953	100736302	20992727341	cataracts	cataract	NN2
304953	100736302	20992727342	removed	remove	VVN
304953	100736302	20992727343	?	?	?
304953	100736302	20992727344	<p>		NULL
304953	100736302	20992727345	Flomax		VV0_NN1_NP1@
304953	100736302	20992727346	works	works	NN_VVZ
304953	100736302	20992727347	by	by	II
304953	100736302	20992727348	blocking	block	VVG_JJ
304953	100736302	20992727349	certain	certain	JJ
304953	100736302	20992727350	cellular	cellular	JJ
304953	100736302	20992727351	receptors	receptor	NN2
304953	100736302	20992727352	,	,	,
304953	100736302	20992727353	causing	cause	VVG
304953	100736302	20992727354	the	the	AT
304953	100736302	20992727355	smooth	smooth	JJ
304953	100736302	20992727356	muscle	muscle	NN1
304953	100736302	20992727357	in	in	II
304953	100736302	20992727358	the	the	AT
304953	100736302	20992727359	neck	neck	NN1
304953	100736302	20992727360	of	of	IO
304953	100736302	20992727361	the	the	AT
304953	100736302	20992727362	bladder	bladder	NN1
304953	100736302	20992727363	and	and	CC
304953	100736302	20992727364	the	the	AT
304953	100736302	20992727365	urethra	urethra	NN1
304953	100736302	20992727366	to	to	TO
304953	100736302	20992727367	relax	relax	VVI
304953	100736302	20992727368	.	.	.
304953	100736302	20992727369	As	as	II
304953	100736302	20992727370	a	a	AT1
304953	100736302	20992727371	result	result	NN1
304953	100736302	20992727372	,	,	,
304953	100736302	20992727373	urine	urine	NN1
304953	100736302	20992727374	flow	flow	NN1
304953	100736302	20992727375	improves	improve	VVZ
304953	100736302	20992727376	.	.	.
304953	100736302	20992727377	Although	although	CS
304953	100736302	20992727378	they	they	PPHS2
304953	100736302	20992727379	are	be	VBR
304953	100736302	20992727380	n't	n't	XX
304953	100736302	20992727381	particularly	particularly	RR
304953	100736302	20992727382	abundant	abundant	JJ
304953	100736302	20992727383	,	,	,
304953	100736302	20992727384	these	these	DD2
304953	100736302	20992727385	same	same	DA
304953	100736302	20992727386	receptors	receptor	NN2
304953	100736302	20992727387	exist	exist	VV0
304953	100736302	20992727388	elsewhere	elsewhere	RL
304953	100736302	20992727389	in	in	II
304953	100736302	20992727390	the	the	AT
304953	100736302	20992727391	body	body	NN1
304953	100736302	20992727392	,	,	,
304953	100736302	20992727393	including	including	II_VVG@
304953	100736302	20992727394	the	the	AT
304953	100736302	20992727395	iris	iris	NN1
304953	100736302	20992727396	in	in	II
304953	100736302	20992727397	your	your	APPGE
304953	100736302	20992727398	eye	eye	NN1
304953	100736302	20992727399	.	.	.
304953	100736302	20992727400	The	the	AT
304953	100736302	20992727401	iris	iris	NN1
304953	100736302	20992727402	opens	open	VVZ
304953	100736302	20992727403	and	and	CC
304953	100736302	20992727404	closes	close	VVZ
304953	100736302	20992727405	to	to	TO
304953	100736302	20992727406	adjust	adjust	VVI
304953	100736302	20992727407	the	the	AT
304953	100736302	20992727408	amount	amount	NN1
304953	100736302	20992727409	of	of	IO
304953	100736302	20992727410	light	light	NN1_JJ
304953	100736302	20992727411	entering	enter	VVG
304953	100736302	20992727412	the	the	AT
304953	100736302	20992727413	pupil	pupil	NN1
304953	100736302	20992727414	.	.	.
304953	100736302	20992727415	When	when	CS
304953	100736302	20992727416	the	the	AT
304953	100736302	20992727417	receptors	receptor	NN2
304953	100736302	20992727418	that	that	CST
304953	100736302	20992727419	control	control	VV0
304953	100736302	20992727420	the	the	AT
304953	100736302	20992727421	iris	iris	NN1
304953	100736302	20992727422	are	be	VBR
304953	100736302	20992727423	blocked	block	VVN
304953	100736302	20992727424	,	,	,
304953	100736302	20992727425	the	the	AT
304953	100736302	20992727426	pupil	pupil	NN1
304953	100736302	20992727427	constricts	constrict	NN2_VVZ
304953	100736302	20992727428	.	.	.
304953	100736302	20992727429	<p>		NULL
304953	100736302	20992727430	During	during	II
304953	100736302	20992727431	cataract	cataract	NN1
304953	100736302	20992727432	surgery	surgery	NN1
304953	100736302	20992727433	,	,	,
304953	100736302	20992727434	the	the	AT
304953	100736302	20992727435	ophthalmologist	ophthalmologist	NN1
304953	100736302	20992727436	removes	remove	VVZ
304953	100736302	20992727437	the	the	AT
304953	100736302	20992727438	clouded	clouded	JJ%
304953	100736302	20992727439	lens	lens	NN1
304953	100736302	20992727440	,	,	,
304953	100736302	20992727441	which	which	DDQ
304953	100736302	20992727442	sits	sit	VVZ
304953	100736302	20992727443	beneath	beneath	II
304953	100736302	20992727444	the	the	AT
304953	100736302	20992727445	iris	iris	NN1
304953	100736302	20992727446	inside	inside	II
304953	100736302	20992727447	the	the	AT
304953	100736302	20992727448	lens	lens	NN1
304953	100736302	20992727449	capsule	capsule	NN1
304953	100736302	20992727450	(	(	(
304953	100736302	20992727451	see	see	VV0
304953	100736302	20992727452	illustration	illustration	NN1
304953	100736302	20992727453	)	)	)
304953	100736302	20992727454	.	.	.
304953	100736302	20992727455	When	when	CS
304953	100736302	20992727456	the	the	AT
304953	100736302	20992727457	pupil	pupil	NN1
304953	100736302	20992727458	is	be	VBZ
304953	100736302	20992727459	small	small	JJ
304953	100736302	20992727460	,	,	,
304953	100736302	20992727461	the	the	AT
304953	100736302	20992727462	relatively	relatively	RR
304953	100736302	20992727463	large	large	JJ
304953	100736302	20992727464	iris	iris	NN1
304953	100736302	20992727465	obscures	obscure	VVZ
304953	100736302	20992727466	the	the	AT
304953	100736302	20992727467	cataract	cataract	NN1
304953	100736302	20992727468	.	.	.
304953	100736302	20992727469	The	the	AT
304953	100736302	20992727470	iris	iris	NN1
304953	100736302	20992727471	can	can	VM
304953	100736302	20992727472	also	also	RR
304953	100736302	20992727473	slip	slip	VVI
304953	100736302	20992727474	out	out	II21
304953	100736302	20992727475	of	of	II22
304953	100736302	20992727476	its	its	APPGE
304953	100736302	20992727477	normal	normal	JJ
304953	100736302	20992727478	position	position	NN1
304953	100736302	20992727479	during	during	II
304953	100736302	20992727480	surgery	surgery	NN1
304953	100736302	20992727481	,	,	,
304953	100736302	20992727482	making	make	VVG
304953	100736302	20992727483	it	it	PPH1
304953	100736302	20992727484	@		II
304953	100736302	20992727485	@		II
304953	100736302	20992727486	@		II
304953	100736302	20992727487	@		II
304953	100736302	20992727488	@		II
304953	100736302	20992727489	@		II
304953	100736302	20992727490	@		II
304953	100736302	20992727491	@		II
304953	100736302	20992727492	@		II
304953	100736302	20992727493	@		II
304953	100736302	20992727494	and	and	CC
304953	100736302	20992727495	insert	insert	VVI
304953	100736302	20992727496	a	a	AT1
304953	100736302	20992727497	new	new	JJ
304953	100736302	20992727498	one	one	PN1
304953	100736302	20992727499	.	.	.
304953	100736302	20992727500	This	this	DD1
304953	100736302	20992727501	condition	condition	NN1
304953	100736302	20992727502	,	,	,
304953	100736302	20992727503	dubbed	dub	VVN_VVD@
304953	100736302	20992727504	floppy	floppy	JJ
304953	100736302	20992727505	iris	iris	NN1
304953	100736302	20992727506	syndrome	syndrome	NN1
304953	100736302	20992727507	,	,	,
304953	100736302	20992727508	increases	increase	VVZ
304953	100736302	20992727509	the	the	AT
304953	100736302	20992727510	chance	chance	NN1
304953	100736302	20992727511	of	of	IO
304953	100736302	20992727512	complications	complication	NN2
304953	100736302	20992727513	,	,	,
304953	100736302	20992727514	including	including	II_VVG@
304953	100736302	20992727515	vision	vision	NN1
304953	100736302	20992727516	loss	loss	NN1
304953	100736302	20992727517	.	.	.
304953	100736302	20992727518	<p>		NULL
304953	100736302	20992727519	Some	some	DD
304953	100736302	20992727520	researchers	researcher	NN2
304953	100736302	20992727521	have	have	VH0
304953	100736302	20992727522	suggested	suggest	VVN
304953	100736302	20992727523	that	that	CST
304953	100736302	20992727524	patients	patient	NN2
304953	100736302	20992727525	on	on	II
304953	100736302	20992727526	Flomax		NP1_NN1
304953	100736302	20992727527	should	should	VM
304953	100736302	20992727528	temporarily	temporarily	RR
304953	100736302	20992727529	stop	stop	VVI
304953	100736302	20992727530	taking	take	VVG
304953	100736302	20992727531	it	it	PPH1
304953	100736302	20992727532	several	several	DA2
304953	100736302	20992727533	days	day	NNT2
304953	100736302	20992727534	before	before	II_CS_RT@
304953	100736302	20992727535	cataract	cataract	NN1_VV0
304953	100736302	20992727536	surgery	surgery	NN1
304953	100736302	20992727537	.	.	.
304953	100736302	20992727538	However	however	RR
304953	100736302	20992727539	,	,	,
304953	100736302	20992727540	the	the	AT
304953	100736302	20992727541	benefit	benefit	NN1
304953	100736302	20992727542	of	of	IO
304953	100736302	20992727543	discontinuing	discontinue	VVG
304953	100736302	20992727544	the	the	AT
304953	100736302	20992727545	drug	drug	NN1
304953	100736302	20992727546	has	have	VHZ
304953	100736302	20992727547	not	not	XX
304953	100736302	20992727548	been	be	VBN
304953	100736302	20992727549	proven	prove	VVN
304953	100736302	20992727550	.	.	.
304953	100736302	20992727551	Instead	instead	RR
304953	100736302	20992727552	,	,	,
304953	100736302	20992727553	tell	tell	VV0
304953	100736302	20992727554	your	your	APPGE
304953	100736302	20992727555	eye	eye	NN1
304953	100736302	20992727556	surgeon	surgeon	NN1
304953	100736302	20992727557	that	that	CST
304953	100736302	20992727558	you	you	PPY
304953	100736302	20992727559	take	take	VV0
304953	100736302	20992727560	this	this	DD1
304953	100736302	20992727561	drug	drug	NN1
304953	100736302	20992727562	.	.	.
304953	100736302	20992727563	He	he	PPHS1
304953	100736302	20992727564	or	or	CC
304953	100736302	20992727565	she	she	PPHS1
304953	100736302	20992727566	can	can	VM
304953	100736302	20992727567	modify	modify	VVI
304953	100736302	20992727568	the	the	AT
304953	100736302	20992727569	surgery	surgery	NN1
304953	100736302	20992727570	to	to	TO
304953	100736302	20992727571	minimize	minimize	VVI
304953	100736302	20992727572	the	the	AT
304953	100736302	20992727573	risk	risk	NN1
304953	100736302	20992727574	of	of	IO
304953	100736302	20992727575	any	any	DD
304953	100736302	20992727576	problems	problem	NN2
304953	100736302	20992727577	.	.	.
304953	100736302	20992727578	<h>		NULL
304953	100736302	20992727579	Cataracts	cataract	NN2_NP1@
304953	100736302	20992727580	and	and	CC
304953	100736302	20992727581	Flomax		NP1_NN1_VV0
304953	100736302	20992727582	<p>		NULL
304953	100736302	20992727583	Flomax		NP1@_VV0_NN1
304953	100736302	20992727584	(	(	(
304953	100736302	20992727585	tamsulosin		NN1
304953	100736302	20992727586	)	)	)
304953	100736302	20992727587	can	can	VM
304953	100736302	20992727588	affect	affect	VVI
304953	100736302	20992727589	the	the	AT
304953	100736302	20992727590	opening	opening	NN1
304953	100736302	20992727591	and	and	CC
304953	100736302	20992727592	closing	closing	NN1
304953	100736302	20992727593	of	of	IO
304953	100736302	20992727594	the	the	AT
304953	100736302	20992727595	iris	iris	NN1
304953	100736302	20992727596	,	,	,
304953	100736302	20992727597	causing	cause	VVG
304953	100736302	20992727598	the	the	AT
304953	100736302	20992727599	pupil	pupil	NN1
304953	100736302	20992727600	to	to	TO
304953	100736302	20992727601	constrict	constrict	VVI
304953	100736302	20992727602	.	.	.
304953	100736302	20992727603	If	if	CS
304953	100736302	20992727604	this	this	DD1
304953	100736302	20992727605	occurs	occur	VVZ
304953	100736302	20992727606	during	during	II
304953	100736302	20992727607	surgery	surgery	NN1
304953	100736302	20992727608	,	,	,
304953	100736302	20992727609	or	or	CC
304953	100736302	20992727610	if	if	CS_CSW@
304953	100736302	20992727611	the	the	AT
304953	100736302	20992727612	iris	iris	NN1
304953	100736302	20992727613	slips	slip	VVZ_NN2
304953	100736302	20992727614	out	out	II21
304953	100736302	20992727615	of	of	II22
304953	100736302	20992727616	position	position	NN1
304953	100736302	20992727617	,	,	,
304953	100736302	20992727618	the	the	AT
304953	100736302	20992727619	surgeon	surgeon	NN1
304953	100736302	20992727620	may	may	VM
304953	100736302	20992727621	have	have	VHI
304953	100736302	20992727622	a	a	AT1
304953	100736302	20992727623	harder	hard	JJR
304953	100736302	20992727624	time	time	NNT1
304953	100736302	20992727625	removing	remove	VVG
304953	100736302	20992727626	and	and	CC
304953	100736302	20992727627	replacing	replace	VVG
304953	100736302	20992727628	the	the	AT
304953	100736302	20992727629	lens	lens	NN1
304953	100736302	20992727630	,	,	,
304953	100736302	20992727631	which	which	DDQ
304953	100736302	20992727632	sits	sit	VVZ
304953	100736302	20992727633	beneath	beneath	II
304953	100736302	20992727634	it	it	PPH1
304953	100736302	20992727635	.	.	.
304953	100736302	20992727636	<p>		NULL
304953	100736302	20992727637	Jose	jose	NP1
304953	100736302	20992727638	Olvera	olvera	NP1
304953	100736302	20992727639	,	,	,
304953	100736302	20992727640	age	age	NN1_VV0@
304953	100736302	20992727641	79	79	MC
304953	100736302	20992727642	;	;	;
304953	100736302	20992727643	first	first	MD
304953	100736302	20992727644	diagnosed	diagnose	VVN_VVD
304953	100736302	20992727645	in	in	II
304953	100736302	20992727646	October	october	NPM1
304953	100736302	20992727647	1993	1993	MC
304953	100736302	20992727648	and	and	CC
304953	100736302	20992727649	had	have	VHD
304953	100736302	20992727650	metastasized	metastasize	VVN
304953	100736302	20992727651	to	to	II
304953	100736302	20992727652	the	the	AT
304953	100736302	20992727653	bones	bone	NN2
304953	100736302	20992727654	resulting	result	VVG
304953	100736302	20992727655	in	in	II
304953	100736302	20992727656	8	8	MC
304953	100736302	20992727657	tumors	tumor	NN2
304953	100736302	20992727658	after	after	II_CS
304953	100736302	20992727659	an	a	AT1
304953	100736302	20992727660	MRI	mri	NN1_JJ
304953	100736302	20992727661	in	in	II
304953	100736302	20992727662	2012	2012	MC
304953	100736302	20992727663	.	.	.
304953	100736302	20992727664	An	a	AT1
304953	100736302	20992727665	MRI	mri	NN1_JJ
304953	100736302	20992727666	taken	take	VVN
304953	100736302	20992727667	one	one	MC1
304953	100736302	20992727668	year	year	NNT1
304953	100736302	20992727669	ago	ago	RA
304953	100736302	20992727670	showed	show	VVD
304953	100736302	20992727671	no	no	AT
304953	100736302	20992727672	metastatic	metastatic	JJ
304953	100736302	20992727673	tumors	tumor	NN2
304953	100736302	20992727674	evident	evident	JJ
304953	100736302	20992727675	.	.	.
304953	100736302	20992727676	I	i	PPIS1
304953	100736302	20992727677	have	have	VH0
304953	100736302	20992727678	been	be	VBN
304953	100736302	20992727679	on	on	II
304953	100736302	20992727680	elegard		NN1
304953	100736302	20992727681	(	(	(
304953	100736302	20992727682	a	a	AT1
304953	100736302	20992727683	shot	shot	NN1
304953	100736302	20992727684	@		II
304953	100736302	20992727685	@		II
304953	100736302	20992727686	@		II
304953	100736302	20992727687	@		II
304953	100736302	20992727688	@		II
304953	100736302	20992727689	@		II
304953	100736302	20992727690	@		II
304953	100736302	20992727691	@		II
304953	100736302	20992727692	@		II
304953	100736302	20992727693	@		II
304953	100736302	20992727694	who	who	PNQS
304953	100736302	20992727695	died	die	VVD
304953	100736302	20992727696	in	in	II
304953	100736302	20992727697	1976	1976	MC
304953	100736302	20992727698	at	at	II
304953	100736302	20992727699	age	age	NN1
304953	100736302	20992727700	64	64	MC
304953	100736302	20992727701	had	have	VHD
304953	100736302	20992727702	cancer	cancer	NN1
304953	100736302	20992727703	of	of	IO
304953	100736302	20992727704	the	the	AT
304953	100736302	20992727705	bladder	bladder	NN1
304953	100736302	20992727706	that	that	CST
304953	100736302	20992727707	had	have	VHD
304953	100736302	20992727708	metastasized	metastasize	VVN
304953	100736302	20992727709	to	to	II
304953	100736302	20992727710	his	his	APPGE
304953	100736302	20992727711	colon	colon	NN1
304953	100736302	20992727712	.	.	.
304953	100736302	20992727713	<p>		NULL
304953	100736302	20992727714	The	the	AT
304953	100736302	20992727715	fact	fact	NN1
304953	100736302	20992727716	that	that	CST_DD1
304953	100736302	20992727717	cancer	cancer	NN1
304953	100736302	20992727718	of	of	IO
304953	100736302	20992727719	the	the	AT
304953	100736302	20992727720	prostate	prostate	NN1
304953	100736302	20992727721	was	be	VBDZ
304953	100736302	20992727722	not	not	XX
304953	100736302	20992727723	evident	evident	JJ
304953	100736302	20992727724	during	during	II
304953	100736302	20992727725	his	his	APPGE
304953	100736302	20992727726	lifetime	lifetime	NNT1
304953	100736302	20992727727	,	,	,
304953	100736302	20992727728	what	what	DDQ
304953	100736302	20992727729	are	be	VBR
304953	100736302	20992727730	my	my	APPGE
304953	100736302	20992727731	risks	risk	NN2
304953	100736302	20992727732	?	?	?
304953	100736302	20992727733	46996		MC
304953	100736302	20992727734	@qwx906996		FO
304953	100736305	20992727754	@@##	----------	----------
304953	100736305	20992727755	@@100736305		FO
304953	100736305	20992727756	@4936305/		VV0_NN1
304953	100736305	20992727757	46989		MC
304953	100736305	20992727758	@qwx906989		FO
304953	100736305	20992727759	<p>		NULL
304953	100736305	20992727760	Researchers	researcher	NN2
304953	100736305	20992727761	have	have	VH0
304953	100736305	20992727762	long	long	RR
304953	100736305	20992727763	believed	believe	VVN
304953	100736305	20992727764	that	that	CST_DD1
304953	100736305	20992727765	male	male	JJ_NN1
304953	100736305	20992727766	sex	sex	NN1
304953	100736305	20992727767	hormones	hormone	NN2
304953	100736305	20992727768	,	,	,
304953	100736305	20992727769	including	including	II_VVG@
304953	100736305	20992727770	testosterone	testosterone	NN1
304953	100736305	20992727771	,	,	,
304953	100736305	20992727772	influence	influence	VV0
304953	100736305	20992727773	the	the	AT
304953	100736305	20992727774	risk	risk	NN1
304953	100736305	20992727775	of	of	IO
304953	100736305	20992727776	prostate	prostate	NN1
304953	100736305	20992727777	cancer	cancer	NN1
304953	100736305	20992727778	.	.	.
304953	100736305	20992727779	However	however	RR
304953	100736305	20992727780	,	,	,
304953	100736305	20992727781	a	a	AT1
304953	100736305	20992727782	collaborative	collaborative	JJ
304953	100736305	20992727783	analysis	analysis	NN1
304953	100736305	20992727784	of	of	IO
304953	100736305	20992727785	18	18	MC
304953	100736305	20992727786	prospective	prospective	JJ
304953	100736305	20992727787	studies	study	NN2
304953	100736305	20992727788	,	,	,
304953	100736305	20992727789	published	publish	VVN
304953	100736305	20992727790	in	in	II
304953	100736305	20992727791	February	february	NPM1
304953	100736305	20992727792	2008	2008	MC
304953	100736305	20992727793	,	,	,
304953	100736305	20992727794	determined	determine	VVN_VVD@_JJ
304953	100736305	20992727795	that	that	CST
304953	100736305	20992727796	they	they	PPHS2
304953	100736305	20992727797	are	be	VBR
304953	100736305	20992727798	not	not	XX
304953	100736305	20992727799	associated	associate	VVN
304953	100736305	20992727800	with	with	IW
304953	100736305	20992727801	prostate	prostate	NN1
304953	100736305	20992727802	cancer	cancer	NN1
304953	100736305	20992727803	risk	risk	NN1
304953	100736305	20992727804	.	.	.
304953	100736305	20992727805	<p>		NULL
304953	100736305	20992727806	Launched	launch	VVN
304953	100736305	20992727807	by	by	II
304953	100736305	20992727808	the	the	AT
304953	100736305	20992727809	Endogenous	endogenous	JJ
304953	100736305	20992727810	Hormones	hormone	NN2
304953	100736305	20992727811	and	and	CC
304953	100736305	20992727812	Prostate	prostate	NN1
304953	100736305	20992727813	Cancer	cancer	NN1
304953	100736305	20992727814	Collaborative	collaborative	JJ
304953	100736305	20992727815	Group	group	NN1
304953	100736305	20992727816	,	,	,
304953	100736305	20992727817	this	this	DD1
304953	100736305	20992727818	study	study	NN1
304953	100736305	20992727819	pooled	pool	VVD_VVN
304953	100736305	20992727820	data	data	NN
304953	100736305	20992727821	from	from	II
304953	100736305	20992727822	18	18	MC
304953	100736305	20992727823	previous	previous	JJ
304953	100736305	20992727824	trials	trial	NN2
304953	100736305	20992727825	,	,	,
304953	100736305	20992727826	the	the	AT
304953	100736305	20992727827	results	result	NN2
304953	100736305	20992727828	of	of	IO
304953	100736305	20992727829	which	which	DDQ
304953	100736305	20992727830	had	have	VHD
304953	100736305	20992727831	been	be	VBN
304953	100736305	20992727832	inconsistent	inconsistent	JJ
304953	100736305	20992727833	.	.	.
304953	100736305	20992727834	Some	some	DD
304953	100736305	20992727835	found	find	VVD
304953	100736305	20992727836	minor	minor	JJ
304953	100736305	20992727837	associations	association	NN2
304953	100736305	20992727838	between	between	II
304953	100736305	20992727839	some	some	DD
304953	100736305	20992727840	hormones	hormone	NN2
304953	100736305	20992727841	and	and	CC
304953	100736305	20992727842	cancer	cancer	NN1
304953	100736305	20992727843	,	,	,
304953	100736305	20992727844	while	while	CS
304953	100736305	20992727845	others	others	NN2
304953	100736305	20992727846	did	do	VDD
304953	100736305	20992727847	not	not	XX
304953	100736305	20992727848	.	.	.
304953	100736305	20992727849	Individually	individually	RR
304953	100736305	20992727850	,	,	,
304953	100736305	20992727851	however	however	RR
304953	100736305	20992727852	,	,	,
304953	100736305	20992727853	those	those	DD2
304953	100736305	20992727854	studies	study	NN2
304953	100736305	20992727855	had	have	VHD
304953	100736305	20992727856	limited	limit	VVN
304953	100736305	20992727857	power	power	NN1
304953	100736305	20992727858	to	to	TO
304953	100736305	20992727859	determine	determine	VVI
304953	100736305	20992727860	a	a	AT1
304953	100736305	20992727861	link	link	NN1
304953	100736305	20992727862	.	.	.
304953	100736305	20992727863	<p>		NULL
304953	100736305	20992727864	In	in	II
304953	100736305	20992727865	this	this	DD1
304953	100736305	20992727866	new	new	JJ
304953	100736305	20992727867	study	study	NN1
304953	100736305	20992727868	,	,	,
304953	100736305	20992727869	researchers	researcher	NN2
304953	100736305	20992727870	examined	examine	VVD_VVN
304953	100736305	20992727871	data	data	NN
304953	100736305	20992727872	on	on	II
304953	100736305	20992727873	testosterone	testosterone	NN1
304953	100736305	20992727874	levels	level	NN2
304953	100736305	20992727875	in	in	II
304953	100736305	20992727876	a	a	AT1
304953	100736305	20992727877	total	total	NN1_JJ
304953	100736305	20992727878	of	of	IO
304953	100736305	20992727879	3,886	3,886	MC
304953	100736305	20992727880	patients	patient	NN2
304953	100736305	20992727881	with	with	IW
304953	100736305	20992727882	prostate	prostate	NN1
304953	100736305	20992727883	cancer	cancer	NN1
304953	100736305	20992727884	and	and	CC
304953	100736305	20992727885	6,438		MC
304953	100736305	20992727886	healthy	healthy	JJ
304953	100736305	20992727887	men	man	NN2
304953	100736305	20992727888	.	.	.
304953	100736305	20992727889	They	they	PPHS2
304953	100736305	20992727890	found	find	VVD
304953	100736305	20992727891	that	that	CST
304953	100736305	20992727892	men	man	NN2
304953	100736305	20992727893	with	with	IW
304953	100736305	20992727894	the	the	AT
304953	100736305	20992727895	highest	high	JJT
304953	100736305	20992727896	testosterone	testosterone	NN1
304953	100736305	20992727897	levels	level	NN2
304953	100736305	20992727898	were	be	VBDR
304953	100736305	20992727899	just	just	RR
304953	100736305	20992727900	as	as	RG
304953	100736305	20992727901	likely	likely	JJ
304953	100736305	20992727902	to	to	TO
304953	100736305	20992727903	develop	develop	VVI
304953	100736305	20992727904	prostate	prostate	NN1
304953	100736305	20992727905	cancer	cancer	NN1
304953	100736305	20992727906	as	as	CSA_II@
304953	100736305	20992727907	men	man	NN2
304953	100736305	20992727908	with	with	IW
304953	100736305	20992727909	the	the	AT
304953	100736305	20992727910	lowest	low	JJT_RRT
304953	100736305	20992727911	.	.	.
304953	100736305	20992727912	The	the	AT
304953	100736305	20992727913	same	same	DA
304953	100736305	20992727914	held	hold	VVD_VVN_JJ%
304953	100736305	20992727915	true	true	JJ
304953	100736305	20992727916	for	for	IF
304953	100736305	20992727917	concentrations	concentration	NN2
304953	100736305	20992727918	of	of	IO
304953	100736305	20992727919	other	other	JJ
304953	100736305	20992727920	sex	sex	NN1
304953	100736305	20992727921	hormones	hormone	NN2
304953	100736305	20992727922	,	,	,
304953	100736305	20992727923	including	including	II
304953	100736305	20992727924	DHT	dht	NP1
304953	100736305	20992727925	,	,	,
304953	100736305	20992727926	estradiol	estradiol	VV0_NN1
304953	100736305	20992727927	,	,	,
304953	100736305	20992727928	and	and	CC
304953	100736305	20992727929	androstenedione	androstenedione	NN1_VV0
304953	100736305	20992727930	.	.	.
304953	100736305	20992727931	<p>		NULL
304953	100736305	20992727932	The	the	AT
304953	100736305	20992727933	role	role	NN1
304953	100736305	20992727934	of	of	IO
304953	100736305	20992727935	testosterone	testosterone	NN1
304953	100736305	20992727936	in	in	II
304953	100736305	20992727937	prostate	prostate	NN1
304953	100736305	20992727938	cancer	cancer	NN1
304953	100736305	20992727939	has	have	VHZ
304953	100736305	20992727940	not	not	XX
304953	100736305	20992727941	been	be	VBN
304953	100736305	20992727942	well	well	RR
304953	100736305	20992727943	understood	understand	VVN_VVD
304953	100736305	20992727944	.	.	.
304953	100736305	20992727945	Many	many	DA2
304953	100736305	20992727946	@		II
304953	100736305	20992727947	@		II
304953	100736305	20992727948	@		II
304953	100736305	20992727949	@		II
304953	100736305	20992727950	@		II
304953	100736305	20992727951	@		II
304953	100736305	20992727952	@		II
304953	100736305	20992727953	@		II
304953	100736305	20992727954	@		II
304953	100736305	20992727955	@		II
304953	100736305	20992727956	block	block	VV0@
304953	100736305	20992727957	the	the	AT
304953	100736305	20992727958	hormone	hormone	NN1
304953	100736305	20992727959	cause	cause	NN1_VV0
304953	100736305	20992727960	tumors	tumor	NN2
304953	100736305	20992727961	to	to	TO
304953	100736305	20992727962	shrink	shrink	VVI
304953	100736305	20992727963	.	.	.
304953	100736305	20992727964	Over	over	II
304953	100736305	20992727965	time	time	NNT1
304953	100736305	20992727966	,	,	,
304953	100736305	20992727967	however	however	RR
304953	100736305	20992727968	,	,	,
304953	100736305	20992727969	cancers	cancer	NN2
304953	100736305	20992727970	deprived	deprive	VVN_VVD
304953	100736305	20992727971	of	of	IO
304953	100736305	20992727972	testosterone	testosterone	NN1
304953	100736305	20992727973	resume	resume	VV0
304953	100736305	20992727974	their	their	APPGE
304953	100736305	20992727975	growth	growth	NN1
304953	100736305	20992727976	.	.	.
304953	100736305	20992727977	That	that	DD1
304953	100736305	20992727978	knowledge	knowledge	NN1
304953	100736305	20992727979	,	,	,
304953	100736305	20992727980	combined	combine	VVN
304953	100736305	20992727981	with	with	IW
304953	100736305	20992727982	the	the	AT
304953	100736305	20992727983	latest	late	JJT
304953	100736305	20992727984	findings	finding	NN2
304953	100736305	20992727985	,	,	,
304953	100736305	20992727986	may	may	VM
304953	100736305	20992727987	spur	spur	VVI
304953	100736305	20992727988	scientists	scientist	NN2
304953	100736305	20992727989	to	to	TO
304953	100736305	20992727990	shift	shift	VVI
304953	100736305	20992727991	their	their	APPGE
304953	100736305	20992727992	focus	focus	NN1
304953	100736305	20992727993	to	to	II
304953	100736305	20992727994	other	other	JJ
304953	100736305	20992727995	risk	risk	NN1
304953	100736305	20992727996	factors	factor	NN2
304953	100736305	20992727997	.	.	.
304953	100736305	20992727998	46996		MC
304953	100736305	20992727999	@qwx906996		FO
304953	100736306	20992728019	@@##	----------	----------
304953	100736306	20992728020	@@100736306		FO
304953	100736306	20992728021	@4936306/		NN1_VV0
304953	100736306	20992728022	<p>		NULL
304953	100736306	20992728023	For	for	IF
304953	100736306	20992728024	men	man	NN2
304953	100736306	20992728025	everywhere	everywhere	RL
304953	100736306	20992728026	,	,	,
304953	100736306	20992728027	the	the	AT
304953	100736306	20992728028	news	news	NN1
304953	100736306	20992728029	was	be	VBDZ
304953	100736306	20992728030	disappointing	disappointing	JJ_VVG@
304953	100736306	20992728031	.	.	.
304953	100736306	20992728032	At	at	II
304953	100736306	20992728033	the	the	AT
304953	100736306	20992728034	end	end	NN1
304953	100736306	20992728035	of	of	IO
304953	100736306	20992728036	October	october	NPM1
304953	100736306	20992728037	2008	2008	MC
304953	100736306	20992728038	,	,	,
304953	100736306	20992728039	the	the	AT
304953	100736306	20992728040	National	national	JJ
304953	100736306	20992728041	Cancer	cancer	NN1
304953	100736306	20992728042	Institute	institute	NN1
304953	100736306	20992728043	(	(	(
304953	100736306	20992728044	NCI	nci	NP1
304953	100736306	20992728045	)	)	)
304953	100736306	20992728046	announced	announce	VVD
304953	100736306	20992728047	that	that	CST
304953	100736306	20992728048	a	a	AT1
304953	100736306	20992728049	study	study	NN1
304953	100736306	20992728050	designed	design	VVN_VVD
304953	100736306	20992728051	to	to	TO
304953	100736306	20992728052	test	test	VVI
304953	100736306	20992728053	whether	whether	CSW
304953	100736306	20992728054	selenium	selenium	NN1
304953	100736306	20992728055	and	and	CC
304953	100736306	20992728056	vitamin	vitamin	NN1
304953	100736306	20992728057	E	e	ZZ1
304953	100736306	20992728058	,	,	,
304953	100736306	20992728059	taken	take	VVN
304953	100736306	20992728060	alone	alone	RR_JJ
304953	100736306	20992728061	or	or	CC
304953	100736306	20992728062	in	in	II
304953	100736306	20992728063	combination	combination	NN1
304953	100736306	20992728064	,	,	,
304953	100736306	20992728065	could	could	VM
304953	100736306	20992728066	lower	lower	VVI
304953	100736306	20992728067	the	the	AT
304953	100736306	20992728068	risk	risk	NN1
304953	100736306	20992728069	of	of	IO
304953	100736306	20992728070	prostate	prostate	NN1
304953	100736306	20992728071	cancer	cancer	NN1
304953	100736306	20992728072	was	be	VBDZ
304953	100736306	20992728073	ending	end	VVG
304953	100736306	20992728074	early	early	RR_JJ
304953	100736306	20992728075	;	;	;
304953	100736306	20992728076	researchers	researcher	NN2
304953	100736306	20992728077	had	have	VHD
304953	100736306	20992728078	grown	grow	VVN
304953	100736306	20992728079	concerned	concerned	JJ
304953	100736306	20992728080	that	that	CST
304953	100736306	20992728081	taking	take	VVG
304953	100736306	20992728082	the	the	AT
304953	100736306	20992728083	supplements	supplement	NN2
304953	100736306	20992728084	might	might	VM
304953	100736306	20992728085	do	do	VDI
304953	100736306	20992728086	more	more	DAR
304953	100736306	20992728087	harm	harm	NN1
304953	100736306	20992728088	than	than	CSN
304953	100736306	20992728089	good	good	JJ
304953	100736306	20992728090	.	.	.
304953	100736306	20992728091	It	it	PPH1
304953	100736306	20992728092	was	be	VBDZ
304953	100736306	20992728093	n't	n't	XX
304953	100736306	20992728094	the	the	AT
304953	100736306	20992728095	conclusion	conclusion	NN1
304953	100736306	20992728096	we	we	PPIS2
304953	100736306	20992728097	were	be	VBDR
304953	100736306	20992728098	expecting	expect	VVG
304953	100736306	20992728099	.	.	.
304953	100736306	20992728100	<p>		NULL
304953	100736306	20992728101	Based	base	VVN
304953	100736306	20992728102	on	on	II
304953	100736306	20992728103	earlier	early	JJR
304953	100736306	20992728104	data	data	NN
304953	100736306	20992728105	,	,	,
304953	100736306	20992728106	researchers	researcher	NN2
304953	100736306	20992728107	had	have	VHD
304953	100736306	20992728108	had	have	VHN
304953	100736306	20992728109	high	high	JJ
304953	100736306	20992728110	hopes	hope	NN2
304953	100736306	20992728111	for	for	IF
304953	100736306	20992728112	selenium	selenium	NN1
304953	100736306	20992728113	and	and	CC
304953	100736306	20992728114	vitamin	vitamin	NN1
304953	100736306	20992728115	E	e	ZZ1
304953	100736306	20992728116	as	as	CSA_II@
304953	100736306	20992728117	cancer	cancer	NN1
304953	100736306	20992728118	fighters	fighter	NN2
304953	100736306	20992728119	.	.	.
304953	100736306	20992728120	Though	though	CS
304953	100736306	20992728121	a	a	AT1
304953	100736306	20992728122	study	study	NN1
304953	100736306	20992728123	of	of	IO
304953	100736306	20992728124	selenium	selenium	NN1
304953	100736306	20992728125	and	and	CC
304953	100736306	20992728126	skin	skin	NN1_VV0@
304953	100736306	20992728127	cancer	cancer	NN1
304953	100736306	20992728128	first	first	MD
304953	100736306	20992728129	reported	report	VVN_VVD
304953	100736306	20992728130	in	in	II
304953	100736306	20992728131	1996	1996	MC
304953	100736306	20992728132	found	find	VVD_VVN
304953	100736306	20992728133	that	that	CST
304953	100736306	20992728134	the	the	AT
304953	100736306	20992728135	supplement	supplement	NN1
304953	100736306	20992728136	offered	offer	VVD_VVN
304953	100736306	20992728137	no	no	AT
304953	100736306	20992728138	protection	protection	NN1
304953	100736306	20992728139	against	against	II
304953	100736306	20992728140	skin	skin	NN1
304953	100736306	20992728141	cancer	cancer	NN1
304953	100736306	20992728142	,	,	,
304953	100736306	20992728143	researchers	researcher	NN2
304953	100736306	20992728144	discovered	discover	VVD
304953	100736306	20992728145	that	that	CST
304953	100736306	20992728146	the	the	AT
304953	100736306	20992728147	incidence	incidence	NN1
304953	100736306	20992728148	of	of	IO
304953	100736306	20992728149	prostate	prostate	NN1
304953	100736306	20992728150	cancer	cancer	NN1
304953	100736306	20992728151	was	be	VBDZ
304953	100736306	20992728152	63%		NNU
304953	100736306	20992728153	lower	low	JJR_RRR@
304953	100736306	20992728154	among	among	II
304953	100736306	20992728155	men	man	NN2
304953	100736306	20992728156	who	who	PNQS
304953	100736306	20992728157	had	have	VHD
304953	100736306	20992728158	taken	take	VVN
304953	100736306	20992728159	selenium	selenium	NN1
304953	100736306	20992728160	for	for	IF
304953	100736306	20992728161	about	about	RG%_II
304953	100736306	20992728162	six-and-a-half	six-and-a-half	MF
304953	100736306	20992728163	years	year	NNT2
304953	100736306	20992728164	than	than	CSN
304953	100736306	20992728165	among	among	II
304953	100736306	20992728166	men	man	NN2
304953	100736306	20992728167	who	who	PNQS
304953	100736306	20992728168	had	have	VHD
304953	100736306	20992728169	taken	take	VVN
304953	100736306	20992728170	a	a	AT1
304953	100736306	20992728171	placebo	placebo	NN1
304953	100736306	20992728172	.	.	.
304953	100736306	20992728173	A	a	ZZ1_AT1
304953	100736306	20992728174	2002	2002	MC
304953	100736306	20992728175	follow-up	follow-up	JJ
304953	100736306	20992728176	report	report	NN1
304953	100736306	20992728177	showed	show	VVD
304953	100736306	20992728178	that	that	CST_DD1
304953	100736306	20992728179	among	among	II
304953	100736306	20992728180	men	man	NN2
304953	100736306	20992728181	who	who	PNQS
304953	100736306	20992728182	took	take	VVD
304953	100736306	20992728183	selenium	selenium	NN1
304953	100736306	20992728184	for	for	IF
304953	100736306	20992728185	more	more	DAR
304953	100736306	20992728186	than	than	CSN
304953	100736306	20992728187	seven-and-a-half	seven-and-a-half	MF
304953	100736306	20992728188	years	year	NNT2
304953	100736306	20992728189	,	,	,
304953	100736306	20992728190	the	the	AT
304953	100736306	20992728191	incidence	incidence	NN1
304953	100736306	20992728192	was	be	VBDZ
304953	100736306	20992728193	52%		NNU
304953	100736306	20992728194	lower	low	JJR_RRR@
304953	100736306	20992728195	.	.	.
304953	100736306	20992728196	<p>		NULL
304953	100736306	20992728197	In	in	II_CS21%
304953	100736306	20992728198	that	that	DD1_CS22@
304953	100736306	20992728199	same	same	DA
304953	100736306	20992728200	vein	vein	NN1
304953	100736306	20992728201	,	,	,
304953	100736306	20992728202	a	a	AT1
304953	100736306	20992728203	1998	1998	MC
304953	100736306	20992728204	study	study	NN1
304953	100736306	20992728205	of	of	IO
304953	100736306	20992728206	supplements	supplement	NN2
304953	100736306	20992728207	and	and	CC
304953	100736306	20992728208	lung	lung	NN1
304953	100736306	20992728209	cancer	cancer	NN1
304953	100736306	20992728210	in	in	II
304953	100736306	20992728211	@		II
304953	100736306	20992728212	@		II
304953	100736306	20992728213	@		II
304953	100736306	20992728214	@		II
304953	100736306	20992728215	@		II
304953	100736306	20992728216	@		II
304953	100736306	20992728217	@		II
304953	100736306	20992728218	@		II
304953	100736306	20992728219	@		II
304953	100736306	20992728220	@		II
304953	100736306	20992728221	prostate	prostate	NN1
304953	100736306	20992728222	cancer	cancer	NN1
304953	100736306	20992728223	and	and	CC
304953	100736306	20992728224	40%		NNU
304953	100736306	20992728225	fewer	fewer	DAR
304953	100736306	20992728226	prostate	prostate	NN1
304953	100736306	20992728227	cancer	cancer	NN1
304953	100736306	20992728228	"	"	"
304953	100736306	20992728229	related	related	JJ_VVD_VVN
304953	100736306	20992728230	deaths	death	NN2
304953	100736306	20992728231	among	among	II
304953	100736306	20992728232	men	man	NN2
304953	100736306	20992728233	who	who	PNQS
304953	100736306	20992728234	took	take	VVD
304953	100736306	20992728235	vitamin	vitamin	NN1
304953	100736306	20992728236	E	e	NP1@_ND1%
304953	100736306	20992728237	than	than	CSN
304953	100736306	20992728238	among	among	II
304953	100736306	20992728239	men	man	NN2
304953	100736306	20992728240	who	who	PNQS
304953	100736306	20992728241	took	take	VVD
304953	100736306	20992728242	a	a	AT1
304953	100736306	20992728243	placebo	placebo	NN1
304953	100736306	20992728244	.	.	.
304953	100736306	20992728245	Some	some	DD
304953	100736306	20992728246	men	man	NN2
304953	100736306	20992728247	in	in	II
304953	100736306	20992728248	that	that	DD1
304953	100736306	20992728249	trial	trial	NN1
304953	100736306	20992728250	also	also	RR
304953	100736306	20992728251	took	take	VVD
304953	100736306	20992728252	beta	beta	NN1
304953	100736306	20992728253	carotene	carotene	NN1
304953	100736306	20992728254	supplements	supplement	NN2
304953	100736306	20992728255	,	,	,
304953	100736306	20992728256	but	but	CCB
304953	100736306	20992728257	neither	neither	DD1
304953	100736306	20992728258	substance	substance	NN1
304953	100736306	20992728259	did	do	VDD
304953	100736306	20992728260	anything	anything	PN1
304953	100736306	20992728261	to	to	TO
304953	100736306	20992728262	prevent	prevent	VVI
304953	100736306	20992728263	lung	lung	NN1
304953	100736306	20992728264	cancer	cancer	NN1
304953	100736306	20992728265	,	,	,
304953	100736306	20992728266	and	and	CC
304953	100736306	20992728267	beta	beta	NN1
304953	100736306	20992728268	carotene	carotene	NN1
304953	100736306	20992728269	did	do	VDD
304953	100736306	20992728270	not	not	XX
304953	100736306	20992728271	affect	affect	VVI
304953	100736306	20992728272	prostate	prostate	NN1
304953	100736306	20992728273	cancer	cancer	NN1
304953	100736306	20992728274	rates	rate	NN2
304953	100736306	20992728275	.	.	.
304953	100736306	20992728276	(	(	(
304953	100736306	20992728277	To	to	TO
304953	100736306	20992728278	read	read	VVI
304953	100736306	20992728279	these	these	DD2
304953	100736306	20992728280	studies	study	NN2
304953	100736306	20992728281	on	on	II
304953	100736306	20992728282	your	your	APPGE
304953	100736306	20992728283	own	own	DA
304953	100736306	20992728284	,	,	,
304953	100736306	20992728285	see	see	VV0
304953	100736306	20992728286	Early	early	JJ
304953	100736306	20992728287	selenium	selenium	NN1
304953	100736306	20992728288	and	and	CC
304953	100736306	20992728289	vitamin	vitamin	NN1
304953	100736306	20992728290	E	e	ZZ1
304953	100736306	20992728291	studies	study	NN2
304953	100736306	20992728292	.	.	.
304953	100736306	20992728293	"	"	"
304953	100736306	20992728294	)	)	)
304953	100736306	20992728295	<p>		NULL
304953	100736306	20992728296	Neither	neither	DD1
304953	100736306	20992728297	of	of	IO
304953	100736306	20992728298	those	those	DD2
304953	100736306	20992728299	studies	study	NN2
304953	100736306	20992728300	,	,	,
304953	100736306	20992728301	however	however	RR
304953	100736306	20992728302	,	,	,
304953	100736306	20992728303	was	be	VBDZ
304953	100736306	20992728304	specifically	specifically	RR
304953	100736306	20992728305	designed	design	VVN
304953	100736306	20992728306	to	to	II
304953	100736306	20992728307	measure	measure	NN1
304953	100736306	20992728308	changes	change	NN2_VVZ@
304953	100736306	20992728309	in	in	II
304953	100736306	20992728310	prostate	prostate	NN1
304953	100736306	20992728311	cancer	cancer	NN1
304953	100736306	20992728312	risk	risk	NN1
304953	100736306	20992728313	.	.	.
304953	100736306	20992728314	Many	many	DA2
304953	100736306	20992728315	variables	variable	NN2
304953	100736306	20992728316	,	,	,
304953	100736306	20992728317	such	such	II21
304953	100736306	20992728318	as	as	II22
304953	100736306	20992728319	the	the	AT
304953	100736306	20992728320	age	age	NN1
304953	100736306	20992728321	of	of	IO
304953	100736306	20992728322	participants	participant	NN2
304953	100736306	20992728323	and	and	CC
304953	100736306	20992728324	their	their	APPGE
304953	100736306	20992728325	family	family	NN1
304953	100736306	20992728326	history	history	NN1
304953	100736306	20992728327	,	,	,
304953	100736306	20992728328	could	could	VM
304953	100736306	20992728329	have	have	VHI
304953	100736306	20992728330	skewed	skew	VVN
304953	100736306	20992728331	the	the	AT
304953	100736306	20992728332	results	result	NN2
304953	100736306	20992728333	.	.	.
304953	100736306	20992728334	So	so	RR
304953	100736306	20992728335	in	in	II
304953	100736306	20992728336	2001	2001	MC
304953	100736306	20992728337	,	,	,
304953	100736306	20992728338	researchers	researcher	NN2
304953	100736306	20992728339	launched	launch	VVD_VVN
304953	100736306	20992728340	SELECT	select	JJ_VV0
304953	100736306	20992728341	,	,	,
304953	100736306	20992728342	short	short	JJ_RR@
304953	100736306	20992728343	for	for	IF
304953	100736306	20992728344	the	the	AT
304953	100736306	20992728345	Selenium	selenium	NN1_NP1
304953	100736306	20992728346	and	and	CC
304953	100736306	20992728347	Vitamin	vitamin	NN1
304953	100736306	20992728348	E	e	ZZ1
304953	100736306	20992728349	Cancer	cancer	NN1
304953	100736306	20992728350	Prevention	prevention	NN1
304953	100736306	20992728351	Trial	trial	NN1
304953	100736306	20992728352	,	,	,
304953	100736306	20992728353	enrolling	enroll	VVG
304953	100736306	20992728354	more	more	DAR
304953	100736306	20992728355	than	than	CSN
304953	100736306	20992728356	35,000	35,000	MC
304953	100736306	20992728357	male	male	JJ
304953	100736306	20992728358	volunteers	volunteer	NN2
304953	100736306	20992728359	.	.	.
304953	100736306	20992728360	Participants	participant	NN2
304953	100736306	20992728361	were	be	VBDR
304953	100736306	20992728362	randomly	randomly	RR
304953	100736306	20992728363	assigned	assign	VVN
304953	100736306	20992728364	to	to	TO
304953	100736306	20992728365	take	take	VVI
304953	100736306	20992728366	one	one	MC1
304953	100736306	20992728367	of	of	IO
304953	100736306	20992728368	these	these	DD2
304953	100736306	20992728369	combinations	combination	NN2
304953	100736306	20992728370	daily	daily	RR_JJ
304953	100736306	20992728371	:	:	:
304953	100736306	20992728372	<p>		NULL
304953	100736306	20992728373	200	200	MC
304953	100736306	20992728374	micrograms	microgram	NN2
304953	100736306	20992728375	(	(	(
304953	100736306	20992728376	mcg	mcg	NNU
304953	100736306	20992728377	)	)	)
304953	100736306	20992728378	of	of	IO
304953	100736306	20992728379	selenium	selenium	NN1
304953	100736306	20992728380	and	and	CC
304953	100736306	20992728381	400	400	MC
304953	100736306	20992728382	international	international	JJ
304953	100736306	20992728383	units	unit	NN2
304953	100736306	20992728384	(	(	(
304953	100736306	20992728385	IU	iu	NP1
304953	100736306	20992728386	)	)	)
304953	100736306	20992728387	of	of	IO
304953	100736306	20992728388	vitamin	vitamin	NN1
304953	100736306	20992728389	E	e	ZZ1
304953	100736306	20992728390	<p>		NULL
304953	100736306	20992728391	200	200	MC
304953	100736306	20992728392	mcg	mcg	NNU
304953	100736306	20992728393	of	of	IO
304953	100736306	20992728394	selenium	selenium	NN1
304953	100736306	20992728395	and	and	CC
304953	100736306	20992728396	a	a	AT1
304953	100736306	20992728397	placebo	placebo	NN1
304953	100736306	20992728398	<p>		NULL
304953	100736306	20992728399	400	400	MC
304953	100736306	20992728400	IU	iu	NP1
304953	100736306	20992728401	of	of	IO
304953	100736306	20992728402	vitamin	vitamin	NN1
304953	100736306	20992728403	E	e	ZZ1
304953	100736306	20992728404	and	and	CC
304953	100736306	20992728405	a	a	AT1
304953	100736306	20992728406	placebo	placebo	NN1
304953	100736306	20992728407	<p>		NULL
304953	100736306	20992728408	Two	two	MC
304953	100736306	20992728409	placebos	placebo	NN2
304953	100736306	20992728410	<p>		NULL
304953	100736306	20992728411	@		II
304953	100736306	20992728412	@		II
304953	100736306	20992728413	@		II
304953	100736306	20992728414	@		II
304953	100736306	20992728415	@		II
304953	100736306	20992728416	@		II
304953	100736306	20992728417	@		II
304953	100736306	20992728418	@		II
304953	100736306	20992728419	@		II
304953	100736306	20992728420	@		II
304953	100736306	20992728421	participants	participant	NN2
304953	100736306	20992728422	nor	nor	CC
304953	100736306	20992728423	the	the	AT
304953	100736306	20992728424	researchers	researcher	NN2
304953	100736306	20992728425	knew	know	VVD
304953	100736306	20992728426	who	who	PNQS
304953	100736306	20992728427	received	receive	VVD
304953	100736306	20992728428	which	which	DDQ
304953	100736306	20992728429	combination	combination	NN1
304953	100736306	20992728430	.	.	.
304953	100736306	20992728431	<p>		NULL
304953	100736306	20992728432	The	the	AT
304953	100736306	20992728433	trial	trial	NN1
304953	100736306	20992728434	had	have	VHD
304953	100736306	20992728435	been	be	VBN
304953	100736306	20992728436	expected	expect	VVN
304953	100736306	20992728437	to	to	TO
304953	100736306	20992728438	run	run	VVI
304953	100736306	20992728439	until	until	II
304953	100736306	20992728440	2011	2011	MC
304953	100736306	20992728441	.	.	.
304953	100736306	20992728442	But	but	CCB
304953	100736306	20992728443	in	in	II
304953	100736306	20992728444	reviewing	review	VVG
304953	100736306	20992728445	an	a	AT1
304953	100736306	20992728446	average	average	NN1
304953	100736306	20992728447	of	of	IO
304953	100736306	20992728448	five	five	MC
304953	100736306	20992728449	years	year	NNT2
304953	100736306	20992728450	'	'	GE
304953	100736306	20992728451	worth	worth	NN1@
304953	100736306	20992728452	of	of	IO
304953	100736306	20992728453	data	data	NN
304953	100736306	20992728454	,	,	,
304953	100736306	20992728455	the	the	AT
304953	100736306	20992728456	independent	independent	JJ
304953	100736306	20992728457	Data	data	NN
304953	100736306	20992728458	and	and	CC
304953	100736306	20992728459	Safety	safety	NN1
304953	100736306	20992728460	Monitoring	monitoring	NN1
304953	100736306	20992728461	Committee	committee	NN1
304953	100736306	20992728462	found	find	VVD_VVN
304953	100736306	20992728463	that	that	CST
304953	100736306	20992728464	the	the	AT
304953	100736306	20992728465	supplements	supplement	NN2
304953	100736306	20992728466	,	,	,
304953	100736306	20992728467	taken	take	VVN
304953	100736306	20992728468	alone	alone	RR_JJ
304953	100736306	20992728469	or	or	CC
304953	100736306	20992728470	together	together	RL
304953	100736306	20992728471	,	,	,
304953	100736306	20992728472	did	do	VDD
304953	100736306	20992728473	not	not	XX
304953	100736306	20992728474	prevent	prevent	VVI
304953	100736306	20992728475	prostate	prostate	NN1
304953	100736306	20992728476	cancer	cancer	NN1
304953	100736306	20992728477	.	.	.
304953	100736306	20992728478	<p>		NULL
304953	100736306	20992728479	Two	two	MC
304953	100736306	20992728480	worrisome	worrisome	JJ
304953	100736306	20992728481	"	"	"
304953	100736306	20992728482	though	though	CS
304953	100736306	20992728483	not	not	XX
304953	100736306	20992728484	statistically	statistically	RR
304953	100736306	20992728485	significant	significant	JJ
304953	100736306	20992728486	"	"	"
304953	100736306	20992728487	trends	trend	NN2
304953	100736306	20992728488	also	also	RR
304953	100736306	20992728489	emerged	emerge	VVD
304953	100736306	20992728490	:	:	:
304953	100736306	20992728491	there	there	EX
304953	100736306	20992728492	were	be	VBDR
304953	100736306	20992728493	slightly	slightly	RR
304953	100736306	20992728494	more	more	DAR
304953	100736306	20992728495	cases	case	NN2
304953	100736306	20992728496	of	of	IO
304953	100736306	20992728497	prostate	prostate	NN1
304953	100736306	20992728498	cancer	cancer	NN1
304953	100736306	20992728499	in	in	II
304953	100736306	20992728500	men	man	NN2
304953	100736306	20992728501	taking	take	VVG
304953	100736306	20992728502	only	only	JJ
304953	100736306	20992728503	vitamin	vitamin	NN1
304953	100736306	20992728504	E	e	ZZ1
304953	100736306	20992728505	and	and	CC
304953	100736306	20992728506	slightly	slightly	RR
304953	100736306	20992728507	more	more	DAR
304953	100736306	20992728508	cases	case	NN2
304953	100736306	20992728509	of	of	IO
304953	100736306	20992728510	diabetes	diabetes	NN1
304953	100736306	20992728511	in	in	II
304953	100736306	20992728512	men	man	NN2
304953	100736306	20992728513	taking	take	VVG
304953	100736306	20992728514	only	only	JJ
304953	100736306	20992728515	selenium	selenium	NN1
304953	100736306	20992728516	.	.	.
304953	100736306	20992728517	True	true	JJ
304953	100736306	20992728518	,	,	,
304953	100736306	20992728519	these	these	DD2
304953	100736306	20992728520	findings	finding	NN2
304953	100736306	20992728521	could	could	VM
304953	100736306	20992728522	be	be	VBI
304953	100736306	20992728523	due	due	JJ
304953	100736306	20992728524	purely	purely	RR
304953	100736306	20992728525	to	to	II
304953	100736306	20992728526	chance	chance	NN1
304953	100736306	20992728527	.	.	.
304953	100736306	20992728528	But	but	CCB
304953	100736306	20992728529	noting	note	VVG
304953	100736306	20992728530	the	the	AT
304953	100736306	20992728531	lack	lack	NN1
304953	100736306	20992728532	of	of	IO
304953	100736306	20992728533	any	any	DD
304953	100736306	20992728534	benefit	benefit	NN1
304953	100736306	20992728535	and	and	CC
304953	100736306	20992728536	the	the	AT
304953	100736306	20992728537	potential	potential	JJ_NN1
304953	100736306	20992728538	risks	risk	NN2
304953	100736306	20992728539	associated	associate	VVN
304953	100736306	20992728540	with	with	IW
304953	100736306	20992728541	the	the	AT
304953	100736306	20992728542	supplements	supplement	NN2
304953	100736306	20992728543	in	in	II
304953	100736306	20992728544	this	this	DD1
304953	100736306	20992728545	trial	trial	NN1
304953	100736306	20992728546	,	,	,
304953	100736306	20992728547	researchers	researcher	NN2
304953	100736306	20992728548	appropriately	appropriately	RR
304953	100736306	20992728549	brought	bring	VVN_VVD
304953	100736306	20992728550	SELECT	select	JJ_VV0
304953	100736306	20992728551	to	to	II
304953	100736306	20992728552	a	a	AT1
304953	100736306	20992728553	close	close	JJ_NN1@
304953	100736306	20992728554	.	.	.
304953	100736306	20992728555	<p>		NULL
304953	100736306	20992728556	Patients	patient	NN2
304953	100736306	20992728557	have	have	VH0
304953	100736306	20992728558	asked	ask	VVN
304953	100736306	20992728559	me	me	PPIO1
304953	100736306	20992728560	if	if	CS_CSW@
304953	100736306	20992728561	they	they	PPHS2
304953	100736306	20992728562	should	should	VM
304953	100736306	20992728563	stop	stop	VVI
304953	100736306	20992728564	taking	take	VVG
304953	100736306	20992728565	multivitamins	multivitamin	NN2
304953	100736306	20992728566	because	because	CS
304953	100736306	20992728567	they	they	PPHS2
304953	100736306	20992728568	contain	contain	VV0
304953	100736306	20992728569	selenium	selenium	NN1
304953	100736306	20992728570	and	and	CC
304953	100736306	20992728571	vitamin	vitamin	NN1
304953	100736306	20992728572	E.		NP1
304953	100736306	20992728573	A	a	ZZ1
304953	100736306	20992728574	typical	typical	JJ
304953	100736306	20992728575	multivitamin	multivitamin	NN1
304953	100736306	20992728576	contains	contain	VVZ
304953	100736306	20992728577	about	about	RG
304953	100736306	20992728578	50	50	MC
304953	100736306	20992728579	mcg	mcg	NNU
304953	100736306	20992728580	of	of	IO
304953	100736306	20992728581	selenium	selenium	NN1
304953	100736306	20992728582	and	and	CC
304953	100736306	20992728583	200	200	MC
304953	100736306	20992728584	IU	iu	NP1
304953	100736306	20992728585	(	(	(
304953	100736306	20992728586	or	or	CC
304953	100736306	20992728587	less	less	RRR_DAR
304953	100736306	20992728588	)	)	)
304953	100736306	20992728589	of	of	IO
304953	100736306	20992728590	vitamin	vitamin	NN1
304953	100736306	20992728591	E	e	ZZ1
304953	100736306	20992728592	,	,	,
304953	100736306	20992728593	much	much	DA1_RR
304953	100736306	20992728594	less	less	DAR_RRR
304953	100736306	20992728595	than	than	CSN
304953	100736306	20992728596	was	be	VBDZ
304953	100736306	20992728597	prescribed	prescribe	VVN
304953	100736306	20992728598	for	for	IF
304953	100736306	20992728599	SELECT	select	JJ
304953	100736306	20992728600	participants	participant	NN2
304953	100736306	20992728601	.	.	.
304953	100736306	20992728602	Still	still	RR
304953	100736306	20992728603	,	,	,
304953	100736306	20992728604	there	there	EX
304953	100736306	20992728605	is	be	VBZ
304953	100736306	20992728606	no	no	AT
304953	100736306	20992728607	evidence	evidence	NN1
304953	100736306	20992728608	that	that	CST
304953	100736306	20992728609	multivitamins	multivitamin	NN2
304953	100736306	20992728610	prevent	prevent	VV0
304953	100736306	20992728611	@		II
304953	100736306	20992728612	@		II
304953	100736306	20992728613	@		II
304953	100736306	20992728614	@		II
304953	100736306	20992728615	@		II
304953	100736306	20992728616	@		II
304953	100736306	20992728617	@		II
304953	100736306	20992728618	@		II
304953	100736306	20992728619	@		II
304953	100736306	20992728620	@		II
304953	100736306	20992728621	you	you	PPY
304953	100736306	20992728622	are	be	VBR
304953	100736306	20992728623	taking	take	VVG
304953	100736306	20992728624	a	a	AT1
304953	100736306	20992728625	multivitamin	multivitamin	NN1
304953	100736306	20992728626	,	,	,
304953	100736306	20992728627	you	you	PPY
304953	100736306	20992728628	might	might	VM
304953	100736306	20992728629	drop	drop	VVI
304953	100736306	20992728630	it	it	PPH1
304953	100736306	20992728631	in	in	II31
304953	100736306	20992728632	favor	favor	II32
304953	100736306	20992728633	of	of	II33
304953	100736306	20992728634	simply	simply	RR
304953	100736306	20992728635	taking	take	VVG
304953	100736306	20992728636	vitamin	vitamin	NN1
304953	100736306	20992728637	D	d	ZZ1
304953	100736306	20992728638	,	,	,
304953	100736306	20992728639	the	the	AT
304953	100736306	20992728640	only	only	JJ
304953	100736306	20992728641	component	component	NN1
304953	100736306	20992728642	that	that	CST
304953	100736306	20992728643	you	you	PPY
304953	100736306	20992728644	're	be	VBR
304953	100736306	20992728645	not	not	XX
304953	100736306	20992728646	likely	likely	JJ_RR@
304953	100736306	20992728647	to	to	TO
304953	100736306	20992728648	get	get	VVI
304953	100736306	20992728649	enough	enough	DD
304953	100736306	20992728650	of	of	IO
304953	100736306	20992728651	from	from	II
304953	100736306	20992728652	foods	food	NN2
304953	100736306	20992728653	.	.	.
304953	100736306	20992728654	<p>		NULL
304953	100736306	20992728655	The	the	AT
304953	100736306	20992728656	results	result	NN2
304953	100736306	20992728657	of	of	IO
304953	100736306	20992728658	SELECT	select	JJ
304953	100736306	20992728659	serve	serve	VV0_NN1%
304953	100736306	20992728660	as	as	II_CSA
304953	100736306	20992728661	a	a	AT1
304953	100736306	20992728662	reminder	reminder	NN1
304953	100736306	20992728663	that	that	CST
304953	100736306	20992728664	vitamins	vitamin	NN2
304953	100736306	20992728665	,	,	,
304953	100736306	20992728666	nutritional	nutritional	JJ
304953	100736306	20992728667	supplements	supplement	NN2
304953	100736306	20992728668	,	,	,
304953	100736306	20992728669	and	and	CC
304953	100736306	20992728670	so-called	so-called	JJ
304953	100736306	20992728671	natural	natural	JJ
304953	100736306	20992728672	remedies	remedy	NN2
304953	100736306	20992728673	need	need	VV0
304953	100736306	20992728674	to	to	TO
304953	100736306	20992728675	be	be	VBI
304953	100736306	20992728676	thoroughly	thoroughly	RR
304953	100736306	20992728677	studied	study	VVN_VVD
304953	100736306	20992728678	before	before	II_CS
304953	100736306	20992728679	people	people	NN
304953	100736306	20992728680	use	use	VV0
304953	100736306	20992728681	them	them	PPHO2
304953	100736306	20992728682	to	to	TO
304953	100736306	20992728683	prevent	prevent	VVI
304953	100736306	20992728684	disease	disease	NN1
304953	100736306	20992728685	.	.	.
304953	100736306	20992728686	Some	some	DD
304953	100736306	20992728687	may	may	VM
304953	100736306	20992728688	indeed	indeed	RR
304953	100736306	20992728689	prove	prove	VVI
304953	100736306	20992728690	efficacious	efficacious	JJ
304953	100736306	20992728691	in	in	II
304953	100736306	20992728692	time	time	NNT1
304953	100736306	20992728693	,	,	,
304953	100736306	20992728694	but	but	CCB
304953	100736306	20992728695	until	until	II
304953	100736306	20992728696	then	then	RT
304953	100736306	20992728697	,	,	,
304953	100736306	20992728698	savvy	savvy	JJ_NN1
304953	100736306	20992728699	consumers	consumer	NN2
304953	100736306	20992728700	should	should	VM
304953	100736306	20992728701	save	save	VVI
304953	100736306	20992728702	their	their	APPGE
304953	100736306	20992728703	money	money	NN1
304953	100736306	20992728704	and	and	CC
304953	100736306	20992728705	work	work	VVI
304953	100736306	20992728706	to	to	TO
304953	100736306	20992728707	lower	lower	VVI
304953	100736306	20992728708	their	their	APPGE
304953	100736306	20992728709	cancer	cancer	NN1
304953	100736306	20992728710	risk	risk	NN1_VV0
304953	100736306	20992728711	by	by	II
304953	100736306	20992728712	making	make	VVG
304953	100736306	20992728713	some	some	DD
304953	100736306	20992728714	tried-and-true	tried-and-true	JJ
304953	100736306	20992728715	lifestyle	lifestyle	NN1
304953	100736306	20992728716	changes	change	NN2
304953	100736306	20992728717	.	.	.
304953	100736306	20992728718	<p>		NULL
304953	100736306	20992728719	First	first	MD
304953	100736306	20992728720	,	,	,
304953	100736306	20992728721	lose	lose	VV0
304953	100736306	20992728722	weight	weight	NN1
304953	100736306	20992728723	if	if	CS
304953	100736306	20992728724	you	you	PPY
304953	100736306	20992728725	are	be	VBR
304953	100736306	20992728726	overweight	overweight	JJ
304953	100736306	20992728727	.	.	.
304953	100736306	20992728728	Men	man	NN2
304953	100736306	20992728729	who	who	PNQS
304953	100736306	20992728730	are	be	VBR
304953	100736306	20992728731	obese	obese	JJ
304953	100736306	20992728732	have	have	VH0
304953	100736306	20992728733	a	a	AT1
304953	100736306	20992728734	higher	high	JJR
304953	100736306	20992728735	risk	risk	NN1
304953	100736306	20992728736	of	of	IO
304953	100736306	20992728737	developing	developing	JJ_VVG
304953	100736306	20992728738	prostate	prostate	NN1
304953	100736306	20992728739	cancer	cancer	NN1
304953	100736306	20992728740	,	,	,
304953	100736306	20992728741	especially	especially	RR
304953	100736306	20992728742	the	the	AT
304953	100736306	20992728743	more	more	RGR
304953	100736306	20992728744	aggressive	aggressive	JJ
304953	100736306	20992728745	type	type	NN1
304953	100736306	20992728746	.	.	.
304953	100736306	20992728747	Losing	lose	VVG_JJ@
304953	100736306	20992728748	weight	weight	NN1
304953	100736306	20992728749	can	can	VM
304953	100736306	20992728750	bring	bring	VVI
304953	100736306	20992728751	that	that	DD1
304953	100736306	20992728752	risk	risk	NN1
304953	100736306	20992728753	way	way	NN1
304953	100736306	20992728754	down	down	RP
304953	100736306	20992728755	.	.	.
304953	100736306	20992728756	One	one	MC1
304953	100736306	20992728757	study	study	NN1
304953	100736306	20992728758	showed	show	VVD
304953	100736306	20992728759	that	that	CST_DD1
304953	100736306	20992728760	,	,	,
304953	100736306	20992728761	compared	compare	VVN
304953	100736306	20992728762	with	with	IW
304953	100736306	20992728763	men	man	NN2
304953	100736306	20992728764	who	who	PNQS
304953	100736306	20992728765	held	hold	VVD
304953	100736306	20992728766	their	their	APPGE
304953	100736306	20992728767	weight	weight	NN1
304953	100736306	20992728768	steady	steady	JJ_RR@
304953	100736306	20992728769	,	,	,
304953	100736306	20992728770	men	man	NN2
304953	100736306	20992728771	who	who	PNQS
304953	100736306	20992728772	lost	lose	VVD
304953	100736306	20992728773	more	more	DAR
304953	100736306	20992728774	than	than	CSN
304953	100736306	20992728775	11	11	MC
304953	100736306	20992728776	pounds	pound	NN2
304953	100736306	20992728777	enjoyed	enjoy	VVD_VVN
304953	100736306	20992728778	a	a	AT1
304953	100736306	20992728779	42%		NNU
304953	100736306	20992728780	lower	low	JJR
304953	100736306	20992728781	risk	risk	NN1
304953	100736306	20992728782	of	of	IO
304953	100736306	20992728783	being	be	VBG
304953	100736306	20992728784	diagnosed	diagnose	VVN
304953	100736306	20992728785	with	with	IW
304953	100736306	20992728786	high-grade	high-grade	JJ
304953	100736306	20992728787	prostate	prostate	NN1
304953	100736306	20992728788	cancer	cancer	NN1
304953	100736306	20992728789	.	.	.
304953	100736306	20992728790	<p>		NULL
304953	100736306	20992728791	Next	next	MD
304953	100736306	20992728792	,	,	,
304953	100736306	20992728793	look	look	VV0_NN1
304953	100736306	20992728794	at	at	II
304953	100736306	20992728795	your	your	APPGE
304953	100736306	20992728796	diet	diet	NN1
304953	100736306	20992728797	.	.	.
304953	100736306	20992728798	Consuming	consume	VVG_JJ@
304953	100736306	20992728799	certain	certain	JJ
304953	100736306	20992728800	foods	food	NN2
304953	100736306	20992728801	,	,	,
304953	100736306	20992728802	such	such	II21
304953	100736306	20992728803	as	as	II22
304953	100736306	20992728804	red	red	NN1_JJ
304953	100736306	20992728805	,	,	,
304953	100736306	20992728806	fatty	fatty	NN1_JJ
304953	100736306	20992728807	,	,	,
304953	100736306	20992728808	and	and	CC
304953	100736306	20992728809	processed	processed	JJ
304953	100736306	20992728810	meats	meat	NN2
304953	100736306	20992728811	@		II
304953	100736306	20992728812	@		II
304953	100736306	20992728813	@		II
304953	100736306	20992728814	@		II
304953	100736306	20992728815	@		II
304953	100736306	20992728816	@		II
304953	100736306	20992728817	@		II
304953	100736306	20992728818	@		II
304953	100736306	20992728819	@		II
304953	100736306	20992728820	@		II
304953	100736306	20992728821	your	your	APPGE
304953	100736306	20992728822	risk	risk	NN1
304953	100736306	20992728823	of	of	IO
304953	100736306	20992728824	prostate	prostate	NN1
304953	100736306	20992728825	cancer	cancer	NN1
304953	100736306	20992728826	.	.	.
304953	100736306	20992728827	Foods	food	NN2
304953	100736306	20992728828	that	that	CST_DD1
304953	100736306	20992728829	may	may	VM
304953	100736306	20992728830	decrease	decrease	VVI
304953	100736306	20992728831	risk	risk	NN1
304953	100736306	20992728832	include	include	VV0
304953	100736306	20992728833	fish	fish	NN
304953	100736306	20992728834	,	,	,
304953	100736306	20992728835	especially	especially	RR
304953	100736306	20992728836	fatty	fatty	JJ
304953	100736306	20992728837	fish	fish	NN
304953	100736306	20992728838	like	like	II_JJ@_VV0@
304953	100736306	20992728839	salmon	salmon	NN
304953	100736306	20992728840	and	and	CC
304953	100736306	20992728841	sardines	sardine	NN2
304953	100736306	20992728842	,	,	,
304953	100736306	20992728843	leafy	leafy	JJ
304953	100736306	20992728844	green	green	JJ_NN1
304953	100736306	20992728845	vegetables	vegetable	NN2
304953	100736306	20992728846	,	,	,
304953	100736306	20992728847	broccoli	broccoli	NN1
304953	100736306	20992728848	,	,	,
304953	100736306	20992728849	and	and	CC
304953	100736306	20992728850	tomatoes	tomato	NN2
304953	100736306	20992728851	.	.	.
304953	100736306	20992728852	Why	why	RRQ
304953	100736306	20992728853	tomatoes	tomato	NN2
304953	100736306	20992728854	?	?	?
304953	100736306	20992728855	Some	some	DD
304953	100736306	20992728856	evidence	evidence	NN1
304953	100736306	20992728857	suggests	suggest	VVZ
304953	100736306	20992728858	that	that	CST
304953	100736306	20992728859	men	man	NN2
304953	100736306	20992728860	who	who	PNQS
304953	100736306	20992728861	eat	eat	VV0
304953	100736306	20992728862	more	more	DAR
304953	100736306	20992728863	tomatoes	tomato	NN2
304953	100736306	20992728864	,	,	,
304953	100736306	20992728865	which	which	DDQ
304953	100736306	20992728866	are	be	VBR
304953	100736306	20992728867	rich	rich	JJ
304953	100736306	20992728868	in	in	II
304953	100736306	20992728869	lycopene	lycopene	NN1
304953	100736306	20992728870	along	along	II21
304953	100736306	20992728871	with	with	II22
304953	100736306	20992728872	oils	oil	NN2
304953	100736306	20992728873	to	to	TO
304953	100736306	20992728874	aid	aid	VVI
304953	100736306	20992728875	absorption	absorption	NN1
304953	100736306	20992728876	,	,	,
304953	100736306	20992728877	have	have	VH0
304953	100736306	20992728878	a	a	AT1
304953	100736306	20992728879	lower	low	JJR
304953	100736306	20992728880	risk	risk	NN1
304953	100736306	20992728881	of	of	IO
304953	100736306	20992728882	prostate	prostate	NN1
304953	100736306	20992728883	cancer	cancer	NN1
304953	100736306	20992728884	.	.	.
304953	100736306	20992728885	It	it	PPH1
304953	100736306	20992728886	remains	remain	VVZ
304953	100736306	20992728887	unclear	unclear	JJ
304953	100736306	20992728888	whether	whether	CSW
304953	100736306	20992728889	lycopene	lycopene	NN1
304953	100736306	20992728890	,	,	,
304953	100736306	20992728891	some	some	DD
304953	100736306	20992728892	other	other	JJ
304953	100736306	20992728893	nutrient	nutrient	NN1
304953	100736306	20992728894	,	,	,
304953	100736306	20992728895	or	or	CC
304953	100736306	20992728896	a	a	AT1
304953	100736306	20992728897	combination	combination	NN1
304953	100736306	20992728898	of	of	IO
304953	100736306	20992728899	nutrients	nutrient	NN2
304953	100736306	20992728900	underlies	underly	VVZ
304953	100736306	20992728901	the	the	AT
304953	100736306	20992728902	protective	protective	JJ
304953	100736306	20992728903	effect	effect	NN1
304953	100736306	20992728904	of	of	IO
304953	100736306	20992728905	tomatoes	tomato	NN2
304953	100736306	20992728906	.	.	.
304953	100736306	20992728907	Clinical	clinical	JJ
304953	100736306	20992728908	trials	trial	NN2
304953	100736306	20992728909	sponsored	sponsor	VVN
304953	100736306	20992728910	by	by	II
304953	100736306	20992728911	the	the	AT
304953	100736306	20992728912	NCI	nci	NN1_NN2
304953	100736306	20992728913	will	will	VM
304953	100736306	20992728914	assess	assess	VVI
304953	100736306	20992728915	the	the	AT
304953	100736306	20992728916	value	value	NN1
304953	100736306	20992728917	of	of	IO
304953	100736306	20992728918	lycopene	lycopene	NN1
304953	100736306	20992728919	and	and	CC
304953	100736306	20992728920	other	other	JJ
304953	100736306	20992728921	agents	agent	NN2
304953	100736306	20992728922	,	,	,
304953	100736306	20992728923	such	such	II21
304953	100736306	20992728924	as	as	II22
304953	100736306	20992728925	soy	soy	JJ
304953	100736306	20992728926	and	and	CC
304953	100736306	20992728927	green	green	JJ
304953	100736306	20992728928	tea	tea	NN1
304953	100736306	20992728929	extract	extract	NN1
304953	100736306	20992728930	.	.	.
304953	100736306	20992728931	<p>		NULL
304953	100736306	20992728932	Even	even	CS21
304953	100736306	20992728933	if	if	CS22
304953	100736306	20992728934	these	these	DD2
304953	100736306	20992728935	steps	step	NN2
304953	100736306	20992728936	do	do	VD0
304953	100736306	20992728937	little	little	RR_JJ
304953	100736306	20992728938	to	to	TO
304953	100736306	20992728939	influence	influence	VVI
304953	100736306	20992728940	your	your	APPGE
304953	100736306	20992728941	prostate	prostate	NN1
304953	100736306	20992728942	cancer	cancer	NN1
304953	100736306	20992728943	risk	risk	NN1
304953	100736306	20992728944	,	,	,
304953	100736306	20992728945	they	they	PPHS2
304953	100736306	20992728946	'll	will	VM
304953	100736306	20992728947	likely	likely	RR@
304953	100736306	20992728948	improve	improve	VVI
304953	100736306	20992728949	your	your	APPGE
304953	100736306	20992728950	health	health	NN1
304953	100736306	20992728951	in	in	II
304953	100736306	20992728952	other	other	JJ
304953	100736306	20992728953	ways	way	NN2
304953	100736306	20992728954	.	.	.
304953	100736306	20992728955	And	and	CC
304953	100736306	20992728956	given	given	CS21
304953	100736306	20992728957	that	that	CS22
304953	100736306	20992728958	most	most	DAT
304953	100736306	20992728959	men	man	NN2
304953	100736306	20992728960	with	with	IW
304953	100736306	20992728961	prostate	prostate	NN1
304953	100736306	20992728962	cancer	cancer	NN1
304953	100736306	20992728963	now	now	RT
304953	100736306	20992728964	die	die	VV0
304953	100736306	20992728965	with	with	IW
304953	100736306	20992728966	their	their	APPGE
304953	100736306	20992728967	disease	disease	NN1
304953	100736306	20992728968	,	,	,
304953	100736306	20992728969	not	not	XX
304953	100736306	20992728970	from	from	II
304953	100736306	20992728971	it	it	PPH1
304953	100736306	20992728972	,	,	,
304953	100736306	20992728973	watching	watch	VVG
304953	100736306	20992728974	your	your	APPGE
304953	100736306	20992728975	weight	weight	NN1
304953	100736306	20992728976	,	,	,
304953	100736306	20992728977	sticking	stick	VVG
304953	100736306	20992728978	with	with	IW
304953	100736306	20992728979	a	a	AT1
304953	100736306	20992728980	heart-healthy	heart-healthy	JJ
304953	100736306	20992728981	diet	diet	NN1
304953	100736306	20992728982	,	,	,
304953	100736306	20992728983	and	and	CC
304953	100736306	20992728984	exercising	exercise	VVG
304953	100736306	20992728985	regularly	regularly	RR
304953	100736306	20992728986	are	be	VBR
304953	100736306	20992728987	your	your	APPGE
304953	100736306	20992728988	best	best	JJT
304953	100736306	20992728989	bets	bet	NN2
304953	100736306	20992728990	.	.	.
304953	100736306	20992728991	<p>		NULL
304953	100736306	20992728992	"	"	"
304953	100736306	20992728993	Still	still	RR
304953	100736306	20992728994	,	,	,
304953	100736306	20992728995	there	there	EX
304953	100736306	20992728996	is	be	VBZ
304953	100736306	20992728997	no	no	AT
304953	100736306	20992728998	evidence	evidence	NN1
304953	100736306	20992728999	that	that	CST
304953	100736306	20992729000	multivitamins	multivitamin	NN2
304953	100736306	20992729001	prevent	prevent	VV0
304953	100736306	20992729002	heart	heart	NN1
304953	100736306	20992729003	disease	disease	NN1
304953	100736306	20992729004	,	,	,
304953	100736306	20992729005	cancer	cancer	NN1
304953	100736306	20992729006	,	,	,
304953	100736306	20992729007	or	or	CC
304953	100736306	20992729008	other	other	JJ
304953	100736306	20992729009	illnesses	illness	NN2
304953	100736306	20992729010	.	.	.
304953	100736306	20992729011	@		II
304953	100736306	20992729012	@		II
304953	100736306	20992729013	@		II
304953	100736306	20992729014	@		II
304953	100736306	20992729015	@		II
304953	100736306	20992729016	@		II
304953	100736306	20992729017	@		II
304953	100736306	20992729018	@		II
304953	100736306	20992729019	@		II
304953	100736306	20992729020	@		II
304953	100736306	20992729021	it	it	PPH1
304953	100736306	20992729022	in	in	II31
304953	100736306	20992729023	favor	favor	II32
304953	100736306	20992729024	of	of	II33
304953	100736306	20992729025	simply	simply	RR
304953	100736306	20992729026	taking	take	VVG
304953	100736306	20992729027	vitamin	vitamin	NN1
304953	100736306	20992729028	D	d	ZZ1
304953	100736306	20992729029	,	,	,
304953	100736306	20992729030	the	the	AT
304953	100736306	20992729031	only	only	JJ
304953	100736306	20992729032	component	component	NN1
304953	100736306	20992729033	that	that	CST
304953	100736306	20992729034	you	you	PPY
304953	100736306	20992729035	're	be	VBR
304953	100736306	20992729036	not	not	XX
304953	100736306	20992729037	likely	likely	JJ_RR@
304953	100736306	20992729038	to	to	TO
304953	100736306	20992729039	get	get	VVI
304953	100736306	20992729040	enough	enough	DD
304953	100736306	20992729041	of	of	IO
304953	100736306	20992729042	from	from	II
304953	100736306	20992729043	foods	food	NN2
304953	100736306	20992729044	.	.	.
304953	100736306	20992729045	"	"	"
304953	100736306	20992729046	<p>		NULL
304953	100736306	20992729047	That 's		VVZ_NN2
304953	100736306	20992729048	very	very	RG
304953	100736306	20992729049	debatable	debatable	JJ
304953	100736306	20992729050	,	,	,
304953	100736306	20992729051	for	for	REX21
304953	100736306	20992729052	example	example	REX22
304953	100736306	20992729053	,	,	,
304953	100736306	20992729054	see	see	VV0
304953	100736306	20992729055	the	the	AT
304953	100736306	20992729056	EPIC	epic	JJ_NN1
304953	100736306	20992729057	Heidelberg	heidelberg	NP1
304953	100736306	20992729058	studies	study	NN2
304953	100736306	20992729059	.	.	.
304953	100736306	20992729060	Moreover	moreover	RR
304953	100736306	20992729061	,	,	,
304953	100736306	20992729062	anyone	anyone	PN1
304953	100736306	20992729063	with	with	IW
304953	100736306	20992729064	only	only	JJ
304953	100736306	20992729065	a	a-i	AT1
304953	100736306	20992729066	little	little	JJ
304953	100736306	20992729067	knowledge	knowledge	NN1
304953	100736306	20992729068	about	about	II
304953	100736306	20992729069	nutrition	nutrition	NN1
304953	100736306	20992729070	knows	know	VVZ
304953	100736306	20992729071	that	that	CST
304953	100736306	20992729072	many	many	DA2
304953	100736306	20992729073	people	people	NN
304953	100736306	20992729074	are	be	VBR
304953	100736306	20992729075	deficient	-deficient	JJ
304953	100736306	20992729076	in	in	II
304953	100736306	20992729077	several	several	DA2
304953	100736306	20992729078	vitamins/minerals		NN2
304953	100736306	20992729079	.	.	.
304953	100736306	20992729080	The	the	AT
304953	100736306	20992729081	data	data	NN
304953	100736306	20992729082	of	of	IO
304953	100736306	20992729083	the	the	AT
304953	100736306	20992729084	statistiscal		JJ
304953	100736306	20992729085	office	office	NN1
304953	100736306	20992729086	in	in	II
304953	100736306	20992729087	the	the	AT
304953	100736306	20992729088	Netherlands	netherlands	NP1
304953	100736306	20992729089	clearly	clearly	RR
304953	100736306	20992729090	demonstrates	demonstrate	VVZ
304953	100736306	20992729091	this	this	DD1
304953	100736306	20992729092	.	.	.
304953	100736306	20992729093	I	i	PPIS1
304953	100736306	20992729094	am	be	VBM
304953	100736306	20992729095	sure	sure	JJ
304953	100736306	20992729096	in	in	II
304953	100736306	20992729097	the	the	AT
304953	100736306	20992729098	US	us	NP1
304953	100736306	20992729099	such	such	DA
304953	100736306	20992729100	data	data	NN
304953	100736306	20992729101	exists	exist	VVZ
304953	100736306	20992729102	,	,	,
304953	100736306	20992729103	too	too	RR@
304953	100736306	20992729104	.	.	.
304953	100736306	20992729105	<p>		NULL
304953	100736306	20992729106	It	it	PPH1
304953	100736306	20992729107	would	would	VM
304953	100736306	20992729108	be	be	VBI
304953	100736306	20992729109	nice	nice	JJ_RR@
304953	100736306	20992729110	if	if	CS_CSW@
304953	100736306	20992729111	doctors	doctor	NN2
304953	100736306	20992729112	had	have	VHD
304953	100736306	20992729113	a	a	RR21
304953	100736306	20992729114	little	little	RR22
304953	100736306	20992729115	more	more	DAR
304953	100736306	20992729116	knowledge	knowledge	NN1
304953	100736306	20992729117	about	about	II
304953	100736306	20992729118	nutrients	nutrient	NN2
304953	100736306	20992729119	before	before	II
304953	100736306	20992729120	making	make	VVG
304953	100736306	20992729121	such	such	DA
304953	100736306	20992729122	obviously	obviously	RR
304953	100736306	20992729123	faulty	faulty	JJ
304953	100736306	20992729124	statements	statement	NN2
304953	100736306	20992729125	.	.	.
304953	100736306	20992729126	46996		MC
304953	100736306	20992729127	@qwx906996		FO
304953	100736307	20992729147	@@##	----------	----------
304953	100736307	20992729148	@@100736307		FO
304953	100736307	20992729149	@4936307/		VV0_NN1
304953	100736307	20992729150	46989		MC
304953	100736307	20992729151	@qwx906989		FO
304953	100736307	20992729152	<p>		NULL
304953	100736307	20992729153	When	when	CS_RRQ
304953	100736307	20992729154	prostate	prostate	NN1
304953	100736307	20992729155	cells	cell	NN2
304953	100736307	20992729156	that	that	CST_DD1
304953	100736307	20992729157	line	line	VV0@_NN1
304953	100736307	20992729158	tiny	tiny	JJ
304953	100736307	20992729159	sacs	sac	NN2
304953	100736307	20992729160	in	in	II
304953	100736307	20992729161	the	the	AT
304953	100736307	20992729162	prostate	prostate	NN1
304953	100736307	20992729163	and	and	CC
304953	100736307	20992729164	the	the	AT
304953	100736307	20992729165	ducts	duct	NN2
304953	100736307	20992729166	that	that	CST
304953	100736307	20992729167	carry	carry	VV0
304953	100736307	20992729168	fluid	fluid	NN1
304953	100736307	20992729169	to	to	II
304953	100736307	20992729170	the	the	AT
304953	100736307	20992729171	ejaculatory	ejaculatory	JJ
304953	100736307	20992729172	duct	duct	NN1
304953	100736307	20992729173	begin	begin	VV0
304953	100736307	20992729174	to	to	TO
304953	100736307	20992729175	look	look	VVI
304953	100736307	20992729176	abnormal	abnormal	JJ
304953	100736307	20992729177	,	,	,
304953	100736307	20992729178	pathologists	pathologist	NN2
304953	100736307	20992729179	render	render	VV0
304953	100736307	20992729180	a	a	AT1
304953	100736307	20992729181	diagnosis	diagnosis	NN1
304953	100736307	20992729182	of	of	IO
304953	100736307	20992729183	prostatic	prostatic	JJ
304953	100736307	20992729184	intraepithelial	intraepithelial	JJ
304953	100736307	20992729185	neoplasia	neoplasia	NN1
304953	100736307	20992729186	(	(	(
304953	100736307	20992729187	PIN	pin	NN1
304953	100736307	20992729188	)	)	)
304953	100736307	20992729189	,	,	,
304953	100736307	20992729190	classifying	classify	VVG
304953	100736307	20992729191	it	it	PPH1
304953	100736307	20992729192	as	as	RG@_CSA
304953	100736307	20992729193	either	either	RR
304953	100736307	20992729194	high-grade	high-grade	JJ
304953	100736307	20992729195	or	or	CC
304953	100736307	20992729196	low-grade	low-grade	JJ_NN1
304953	100736307	20992729197	PIN	pin	NN1
304953	100736307	20992729198	.	.	.
304953	100736307	20992729199	In	in	II
304953	100736307	20992729200	high-grade	high-grade	JJ_NN1
304953	100736307	20992729201	PIN	pin	NN1
304953	100736307	20992729202	,	,	,
304953	100736307	20992729203	the	the	AT
304953	100736307	20992729204	degree	degree	NN1
304953	100736307	20992729205	of	of	IO
304953	100736307	20992729206	cellular	cellular	JJ
304953	100736307	20992729207	abnormality	abnormality	NN1
304953	100736307	20992729208	is	be	VBZ
304953	100736307	20992729209	more	more	RGR
304953	100736307	20992729210	pronounced	pronounced	JJ
304953	100736307	20992729211	than	than	CSN
304953	100736307	20992729212	in	in	II
304953	100736307	20992729213	low-grade	low-grade	JJ_NN1
304953	100736307	20992729214	PIN	pin	NN1
304953	100736307	20992729215	,	,	,
304953	100736307	20992729216	and	and	CC
304953	100736307	20992729217	studies	study	NN2
304953	100736307	20992729218	have	have	VH0
304953	100736307	20992729219	shown	show	VVN
304953	100736307	20992729220	that	that	CST_DD1
304953	100736307	20992729221	high-grade	high-grade	JJ_NN1
304953	100736307	20992729222	PIN	pin	NN1
304953	100736307	20992729223	is	be	VBZ
304953	100736307	20992729224	more	more	RGR
304953	100736307	20992729225	likely	likely	JJ
304953	100736307	20992729226	to	to	TO
304953	100736307	20992729227	progress	progress	VVI
304953	100736307	20992729228	to	to	II
304953	100736307	20992729229	cancer	cancer	NN1
304953	100736307	20992729230	.	.	.
304953	100736307	20992729231	<p>		NULL
304953	100736307	20992729232	In	in	II
304953	100736307	20992729233	men	man	NN2
304953	100736307	20992729234	with	with	IW
304953	100736307	20992729235	both	both	DB2
304953	100736307	20992729236	prostate	prostate	NN1
304953	100736307	20992729237	cancer	cancer	NN1
304953	100736307	20992729238	and	and	CC
304953	100736307	20992729239	high-grade	high-grade	JJ_NN1
304953	100736307	20992729240	PIN	pin	NN1
304953	100736307	20992729241	,	,	,
304953	100736307	20992729242	hormone	hormone	NN1
304953	100736307	20992729243	therapy	therapy	NN1
304953	100736307	20992729244	has	have	VHZ
304953	100736307	20992729245	markedly	markedly	RR
304953	100736307	20992729246	decreased	decrease	VVN
304953	100736307	20992729247	the	the	AT
304953	100736307	20992729248	prevalence	prevalence	NN1
304953	100736307	20992729249	and	and	CC
304953	100736307	20992729250	extent	extent	NN1
304953	100736307	20992729251	of	of	IO
304953	100736307	20992729252	PIN	pin	NN1
304953	100736307	20992729253	.	.	.
304953	100736307	20992729254	That	that	DD1
304953	100736307	20992729255	got	get	VVD_VVN
304953	100736307	20992729256	two	two	MC
304953	100736307	20992729257	Chinese	chinese	JJ
304953	100736307	20992729258	researchers	researcher	NN2
304953	100736307	20992729259	wondering	wonder	VVG
304953	100736307	20992729260	:	:	:
304953	100736307	20992729261	could	could	VM
304953	100736307	20992729262	a	a	AT1
304953	100736307	20992729263	drug	drug	NN1
304953	100736307	20992729264	used	use	VVN_VVD
304953	100736307	20992729265	for	for	IF
304953	100736307	20992729266	hormone	hormone	NN1
304953	100736307	20992729267	therapy	therapy	NN1
304953	100736307	20992729268	prevent	prevent	VV0
304953	100736307	20992729269	the	the	AT
304953	100736307	20992729270	progression	progression	NN1
304953	100736307	20992729271	of	of	IO
304953	100736307	20992729272	high-grade	high-grade	JJ_NN1
304953	100736307	20992729273	PIN	pin	NN1
304953	100736307	20992729274	to	to	II
304953	100736307	20992729275	cancer	cancer	NN1
304953	100736307	20992729276	?	?	?
304953	100736307	20992729277	<p>		NULL
304953	100736307	20992729278	To	to	TO
304953	100736307	20992729279	find	find	VVI
304953	100736307	20992729280	out	out	RP
304953	100736307	20992729281	,	,	,
304953	100736307	20992729282	they	they	PPHS2
304953	100736307	20992729283	followed	follow	VVD
304953	100736307	20992729284	172	172	MC
304953	100736307	20992729285	patients	patient	NN2
304953	100736307	20992729286	diagnosed	diagnose	VVN_VVD
304953	100736307	20992729287	with	with	IW
304953	100736307	20992729288	high-grade	high-grade	JJ
304953	100736307	20992729289	PIN	pin	NN1
304953	100736307	20992729290	but	but	CCB
304953	100736307	20992729291	no	no	AT
304953	100736307	20992729292	evidence	evidence	NN1
304953	100736307	20992729293	of	of	IO
304953	100736307	20992729294	prostate	prostate	NN1
304953	100736307	20992729295	cancer	cancer	NN1
304953	100736307	20992729296	for	for	IF
304953	100736307	20992729297	five	five	MC
304953	100736307	20992729298	years	year	NNT2
304953	100736307	20992729299	.	.	.
304953	100736307	20992729300	Half	half	DB_RR@
304953	100736307	20992729301	took	take	VVD
304953	100736307	20992729302	a	a	AT1
304953	100736307	20992729303	small	small	JJ
304953	100736307	20992729304	daily	daily	JJ
304953	100736307	20992729305	dose	dose	NN1
304953	100736307	20992729306	of	of	IO
304953	100736307	20992729307	flutamide		NN1
304953	100736307	20992729308	for	for	IF
304953	100736307	20992729309	12	12	MC
304953	100736307	20992729310	months	month	NNT2
304953	100736307	20992729311	;	;	;
304953	100736307	20992729312	the	the	AT
304953	100736307	20992729313	rest	rest	NN1
304953	100736307	20992729314	took	take	VVD
304953	100736307	20992729315	a	a	AT1
304953	100736307	20992729316	placebo	placebo	NN1
304953	100736307	20992729317	.	.	.
304953	100736307	20992729318	At	at	II
304953	100736307	20992729319	the	the	AT
304953	100736307	20992729320	end	end	NN1
304953	100736307	20992729321	of	of	IO
304953	100736307	20992729322	the	the	AT
304953	100736307	20992729323	study	study	NN1
304953	100736307	20992729324	,	,	,
304953	100736307	20992729325	11.6%	-11.6%	FO
304953	100736307	20992729326	of	of	IO
304953	100736307	20992729327	the	the	AT
304953	100736307	20992729328	patients	patient	NN2
304953	100736307	20992729329	taking	take	VVG
304953	100736307	20992729330	flutamide		NN1
304953	100736307	20992729331	had	have	VHD
304953	100736307	20992729332	developed	develop	VVN
304953	100736307	20992729333	prostate	prostate	NN1
304953	100736307	20992729334	cancer	cancer	NN1
304953	100736307	20992729335	compared	compare	VVN
304953	100736307	20992729336	with	with	IW
304953	100736307	20992729337	30.2%	30.2%	FO
304953	100736307	20992729338	of	of	IO
304953	100736307	20992729339	@		II
304953	100736307	20992729340	@		II
304953	100736307	20992729341	@		II
304953	100736307	20992729342	@		II
304953	100736307	20992729343	@		II
304953	100736307	20992729344	@		II
304953	100736307	20992729345	@		II
304953	100736307	20992729346	@		II
304953	100736307	20992729347	@		II
304953	100736307	20992729348	@		II
304953	100736307	20992729349	of	of	IO
304953	100736307	20992729350	flutamide		NN1
304953	100736307	20992729351	can	can	VM
304953	100736307	20992729352	keep	keep	VVI
304953	100736307	20992729353	high-grade	high-grade	JJ_NN1
304953	100736307	20992729354	PIN	pin	NN1
304953	100736307	20992729355	in	in	II
304953	100736307	20992729356	check	check	NN1
304953	100736307	20992729357	.	.	.
304953	100736307	20992729358	<p>		NULL
304953	100736307	20992729359	12	12	MC
304953	100736307	20992729360	years	year	NNT2
304953	100736307	20992729361	ago	ago	RA
304953	100736307	20992729362	a	a	AT1
304953	100736307	20992729363	biopsy	biopsy	NN1
304953	100736307	20992729364	of	of	IO
304953	100736307	20992729365	my	my	APPGE
304953	100736307	20992729366	prostate	prostate	NN1
304953	100736307	20992729367	showed	show	VVD
304953	100736307	20992729368	PIN	pin	NN1
304953	100736307	20992729369	.	.	.
304953	100736307	20992729370	6	6	MC
304953	100736307	20992729371	weeks	week	NNT2
304953	100736307	20992729372	later	later	RRR
304953	100736307	20992729373	a	a	AT1
304953	100736307	20992729374	repeat	repeat	NN1%_VV0
304953	100736307	20992729375	biopsy	biopsy	NN1
304953	100736307	20992729376	was	be	VBDZ
304953	100736307	20992729377	normal	normal	JJ
304953	100736307	20992729378	.	.	.
304953	100736307	20992729379	I	i	PPIS1
304953	100736307	20992729380	have	have	VH0
304953	100736307	20992729381	take	take	NN1%
304953	100736307	20992729382	Proscar		NN1@_NP1
304953	100736307	20992729383	for	for	IF
304953	100736307	20992729384	the	the	AT
304953	100736307	20992729385	last	last	MD
304953	100736307	20992729386	12	12	MC
304953	100736307	20992729387	years	year	NNT2
304953	100736307	20992729388	.	.	.
304953	100736307	20992729389	My	my	APPGE
304953	100736307	20992729390	PSA	psa	NP1
304953	100736307	20992729391	has	have	VHZ
304953	100736307	20992729392	stayed	stay	VVN
304953	100736307	20992729393	around	around	RG
304953	100736307	20992729394	2.17	-2.17	MC
304953	100736307	20992729395	.	.	.
304953	100736307	20992729396	The	the	AT
304953	100736307	20992729397	Urologist		NN1_NP1
304953	100736307	20992729398	now	now	RT
304953	100736307	20992729399	12	12	MC
304953	100736307	20992729400	years	year	NNT2
304953	100736307	20992729401	later	later	RRR
304953	100736307	20992729402	wants	want	VVZ
304953	100736307	20992729403	to	to	TO
304953	100736307	20992729404	do	do	VDI
304953	100736307	20992729405	another	another	DD1
304953	100736307	20992729406	biopsy	biopsy	NN1
304953	100736307	20992729407	.	.	.
304953	100736307	20992729408	My	my	APPGE
304953	100736307	20992729409	prostate	prostate	NN1
304953	100736307	20992729410	exam	exam	NN1
304953	100736307	20992729411	is	be	VBZ
304953	100736307	20992729412	normal	normal	JJ
304953	100736307	20992729413	.	.	.
304953	100736307	20992729414	I	i	PPIS1
304953	100736307	20992729415	am	be	VBM
304953	100736307	20992729416	70	70	MC
304953	100736307	20992729417	years	year	NNT2
304953	100736307	20992729418	old	old	JJ
304953	100736307	20992729419	and	and	CC
304953	100736307	20992729420	possibly	possibly	RR
304953	100736307	20992729421	have	have	VH0
304953	100736307	20992729422	had	have	VHN
304953	100736307	20992729423	two	two	MC
304953	100736307	20992729424	heart	heart	NN1
304953	100736307	20992729425	attacks	attack	NN2
304953	100736307	20992729426	.	.	.
304953	100736307	20992729427	I	i	PPIS1
304953	100736307	20992729428	feel	feel	VV0
304953	100736307	20992729429	a	a	AT1
304953	100736307	20992729430	biopsy	biopsy	NN1
304953	100736307	20992729431	at	at	II
304953	100736307	20992729432	this	this	DD1
304953	100736307	20992729433	time	time	NNT1
304953	100736307	20992729434	is	be	VBZ
304953	100736307	20992729435	too	too	RG
304953	100736307	20992729436	aggressive	aggressive	JJ
304953	100736307	20992729437	.	.	.
304953	100736307	20992729438	What	what	DDQ
304953	100736307	20992729439	is	be	VBZ
304953	100736307	20992729440	the	the	AT
304953	100736307	20992729441	latest	late	JJT
304953	100736307	20992729442	thinking	thinking	NN1_VVG
304953	100736307	20992729443	about	about	II
304953	100736307	20992729444	how	how	RRQ
304953	100736307	20992729445	to	to	TO
304953	100736307	20992729446	proceed	proceed	VVI
304953	100736307	20992729447	.	.	.
304953	100736307	20992729448	46996		MC
304953	100736307	20992729449	@qwx906996		FO
304953	100736308	20992729469	@@##	----------	----------
304953	100736308	20992729470	@@100736308		FO
304953	100736308	20992729471	@4936308/		VV0_NN1
304953	100736308	20992729472	46989		MC
304953	100736308	20992729473	@qwx906989		FO
304953	100736308	20992729474	<p>		NULL
304953	100736308	20992729475	As	as	CSA
304953	100736308	20992729476	is	be	VBZ
304953	100736308	20992729477	true	true	JJ
304953	100736308	20992729478	for	for	IF
304953	100736308	20992729479	so	so	RG
304953	100736308	20992729480	many	many	DA2
304953	100736308	20992729481	types	type	NN2
304953	100736308	20992729482	of	of	IO
304953	100736308	20992729483	cancer	cancer	NN1
304953	100736308	20992729484	,	,	,
304953	100736308	20992729485	prostate	prostate	NN1
304953	100736308	20992729486	cancer	cancer	NN1
304953	100736308	20992729487	is	be	VBZ
304953	100736308	20992729488	caused	cause	VVN
304953	100736308	20992729489	partly	partly	RR
304953	100736308	20992729490	by	by	II
304953	100736308	20992729491	environmental	environmental	JJ
304953	100736308	20992729492	factors	factor	NN2
304953	100736308	20992729493	and	and	CC
304953	100736308	20992729494	partly	partly	RR
304953	100736308	20992729495	by	by	II
304953	100736308	20992729496	genetic	genetic	JJ
304953	100736308	20992729497	factors	factor	NN2
304953	100736308	20992729498	.	.	.
304953	100736308	20992729499	Men	man	NN2
304953	100736308	20992729500	are	be	VBR
304953	100736308	20992729501	at	at	II
304953	100736308	20992729502	greater	great	JJR
304953	100736308	20992729503	risk	risk	NN1
304953	100736308	20992729504	for	for	IF
304953	100736308	20992729505	developing	developing	JJ_VVG
304953	100736308	20992729506	prostate	prostate	NN1
304953	100736308	20992729507	cancer	cancer	NN1
304953	100736308	20992729508	if	if	CS
304953	100736308	20992729509	their	their	APPGE
304953	100736308	20992729510	fathers	father	NN2
304953	100736308	20992729511	or	or	CC
304953	100736308	20992729512	brothers	brother	NN2
304953	100736308	20992729513	also	also	RR
304953	100736308	20992729514	developed	develop	VVN_VVD
304953	100736308	20992729515	the	the	AT
304953	100736308	20992729516	disease	disease	NN1
304953	100736308	20992729517	.	.	.
304953	100736308	20992729518	But	but	CCB
304953	100736308	20992729519	does	do	VDZ
304953	100736308	20992729520	the	the	AT
304953	100736308	20992729521	risk	risk	NN1
304953	100736308	20992729522	also	also	RR
304953	100736308	20992729523	increase	increase	VVI
304953	100736308	20992729524	if	if	CSW@_CS
304953	100736308	20992729525	a	a	AT1
304953	100736308	20992729526	mans	man	NN2
304953	100736308	20992729527	more	more	RGR
304953	100736308	20992729528	distant	distant	JJ
304953	100736308	20992729529	relatives	relative	NN2
304953	100736308	20992729530	had	have	VHD
304953	100736308	20992729531	prostate	prostate	NN1
304953	100736308	20992729532	cancer	cancer	NN1
304953	100736308	20992729533	?	?	?
304953	100736308	20992729534	<p>		NULL
304953	100736308	20992729535	A	a	AT1
304953	100736308	20992729536	study	study	NN1
304953	100736308	20992729537	published	publish	VVN
304953	100736308	20992729538	in	in	II
304953	100736308	20992729539	The	the	AT
304953	100736308	20992729540	Prostate	prostate	NN1
304953	100736308	20992729541	provides	provide	VVZ
304953	100736308	20992729542	an	a	AT1
304953	100736308	20992729543	answer	answer	NN1
304953	100736308	20992729544	.	.	.
304953	100736308	20992729545	Using	use	VVG
304953	100736308	20992729546	a	a	AT1
304953	100736308	20992729547	database	database	NN1
304953	100736308	20992729548	covering	cover	VVG
304953	100736308	20992729549	more	more	DAR
304953	100736308	20992729550	than	than	CSN
304953	100736308	20992729551	100	100	MC
304953	100736308	20992729552	years	year	NNT2
304953	100736308	20992729553	,	,	,
304953	100736308	20992729554	Utah	utah	NP1
304953	100736308	20992729555	investigators	investigator	NN2
304953	100736308	20992729556	quantified	quantify	VVN_JJ@_VVD@
304953	100736308	20992729557	prostate	prostate	NN1
304953	100736308	20992729558	cancer	cancer	NN1
304953	100736308	20992729559	risk	risk	NN1_VV0
304953	100736308	20992729560	according	according	II21
304953	100736308	20992729561	to	to	II22
304953	100736308	20992729562	three	three	MC
304953	100736308	20992729563	levels	level	NN2
304953	100736308	20992729564	of	of	IO
304953	100736308	20992729565	relatedness	relatedness	NN1
304953	100736308	20992729566	:	:	:
304953	100736308	20992729567	<p>		NULL
304953	100736308	20992729568	first	first	MD
304953	100736308	20992729569	degree	degree	NN1
304953	100736308	20992729570	relatives	relative	NN2
304953	100736308	20992729571	,	,	,
304953	100736308	20992729572	such	such	II21
304953	100736308	20992729573	as	as	II22
304953	100736308	20992729574	parents	parent	NN2
304953	100736308	20992729575	,	,	,
304953	100736308	20992729576	full	full	JJ
304953	100736308	20992729577	siblings	sibling	NN2
304953	100736308	20992729578	,	,	,
304953	100736308	20992729579	and	and	CC
304953	100736308	20992729580	children	child	NN2
304953	100736308	20992729581	<p>		NULL
304953	100736308	20992729582	second	second	MD
304953	100736308	20992729583	degree	degree	NN1
304953	100736308	20992729584	relatives	relative	NN2
304953	100736308	20992729585	,	,	,
304953	100736308	20992729586	such	such	II21
304953	100736308	20992729587	as	as	II22
304953	100736308	20992729588	grandparents	grandparent	NN2
304953	100736308	20992729589	,	,	,
304953	100736308	20992729590	grandchildren	grandchild	NN2
304953	100736308	20992729591	,	,	,
304953	100736308	20992729592	uncles	uncle	NN2
304953	100736308	20992729593	,	,	,
304953	100736308	20992729594	nephews	nephew	NN2
304953	100736308	20992729595	,	,	,
304953	100736308	20992729596	or	or	CC
304953	100736308	20992729597	half-siblings	half-siblings	NN2
304953	100736308	20992729598	,	,	,
304953	100736308	20992729599	and	and	CC
304953	100736308	20992729600	<p>		NULL
304953	100736308	20992729601	third-degree	third-degree	JJ_NN1
304953	100736308	20992729602	relatives	relative	NN2
304953	100736308	20992729603	,	,	,
304953	100736308	20992729604	such	such	DA
304953	100736308	20992729605	great	great	JJ
304953	100736308	20992729606	grandparents	grandparent	NN2
304953	100736308	20992729607	,	,	,
304953	100736308	20992729608	great	great	JJ
304953	100736308	20992729609	grandchildren	grandchild	NN2
304953	100736308	20992729610	,	,	,
304953	100736308	20992729611	and	and	CC
304953	100736308	20992729612	first	first	MD
304953	100736308	20992729613	cousins	cousin	NN2
304953	100736308	20992729614	.	.	.
304953	100736308	20992729615	<p>		NULL
304953	100736308	20992729616	As	as	CSA
304953	100736308	20992729617	expected	expect	VVN_JJ
304953	100736308	20992729618	,	,	,
304953	100736308	20992729619	men	man	NN2
304953	100736308	20992729620	who	who	PNQS
304953	100736308	20992729621	had	have	VHD
304953	100736308	20992729622	first-degree	first-degree	JJ
304953	100736308	20992729623	family	family	NN1
304953	100736308	20992729624	members	member	NN2
304953	100736308	20992729625	with	with	IW
304953	100736308	20992729626	prostate	prostate	NN1
304953	100736308	20992729627	cancer	cancer	NN1
304953	100736308	20992729628	faced	face	VVD_VVN
304953	100736308	20992729629	the	the	AT
304953	100736308	20992729630	highest	high	JJT
304953	100736308	20992729631	relative	relative	JJ_NN1
304953	100736308	20992729632	risk	risk	NN1
304953	100736308	20992729633	:	:	:
304953	100736308	20992729634	estimates	estimate	NN2
304953	100736308	20992729635	ranged	range	VVN_VVD
304953	100736308	20992729636	from	from	II
304953	100736308	20992729637	2.5	2.5	MC
304953	100736308	20992729638	times	time	NNT2
304953	100736308	20992729639	higher	high	RRR@_JJR
304953	100736308	20992729640	if	if	CS
304953	100736308	20992729641	one	one	MC1
304953	100736308	20992729642	first-degree	first-degree	JJ_NN1
304953	100736308	20992729643	relative	relative	NN1
304953	100736308	20992729644	was	be	VBDZ
304953	100736308	20992729645	affected	affect	VVN
304953	100736308	20992729646	to	to	II_TO
304953	100736308	20992729647	nearly	nearly	RR
304953	100736308	20992729648	8	8	MC
304953	100736308	20992729649	times	time	NNT2
304953	100736308	20992729650	higher	high	RRR@_JJR
304953	100736308	20992729651	if	if	CS
304953	100736308	20992729652	four	four	MC
304953	100736308	20992729653	first-degree	first-degree	JJ
304953	100736308	20992729654	relatives	relative	NN2
304953	100736308	20992729655	had	have	VHD
304953	100736308	20992729656	prostate	prostate	NN1
304953	100736308	20992729657	cancer	cancer	NN1
304953	100736308	20992729658	.	.	.
304953	100736308	20992729659	But	but	CCB
304953	100736308	20992729660	prostate	prostate	NN1
304953	100736308	20992729661	@		II
304953	100736308	20992729662	@		II
304953	100736308	20992729663	@		II
304953	100736308	20992729664	@		II
304953	100736308	20992729665	@		II
304953	100736308	20992729666	@		II
304953	100736308	20992729667	@		II
304953	100736308	20992729668	@		II
304953	100736308	20992729669	@		II
304953	100736308	20992729670	@		II
304953	100736308	20992729671	.	.	.
304953	100736308	20992729672	<p>		NULL
304953	100736308	20992729673	A	a	AT1
304953	100736308	20992729674	diagnosis	diagnosis	NN1
304953	100736308	20992729675	in	in	II
304953	100736308	20992729676	a	a	AT1
304953	100736308	20992729677	mans	man	NN2
304953	100736308	20992729678	uncles	uncle	NN2
304953	100736308	20992729679	(	(	(
304953	100736308	20992729680	second-degree	second-degree	JJ_NN1
304953	100736308	20992729681	relatives	relative	NN2
304953	100736308	20992729682	)	)	)
304953	100736308	20992729683	,	,	,
304953	100736308	20992729684	for	for	REX21
304953	100736308	20992729685	instance	instance	REX22
304953	100736308	20992729686	,	,	,
304953	100736308	20992729687	roughly	roughly	RR
304953	100736308	20992729688	doubled	double	VVD_VVN
304953	100736308	20992729689	his	his	APPGE
304953	100736308	20992729690	risk	risk	NN1
304953	100736308	20992729691	.	.	.
304953	100736308	20992729692	Having	have	VHG
304953	100736308	20992729693	third-degree	third-degree	JJ_NN1
304953	100736308	20992729694	relatives	relative	NN2
304953	100736308	20992729695	with	with	IW
304953	100736308	20992729696	prostate	prostate	NN1
304953	100736308	20992729697	cancer	cancer	NN1
304953	100736308	20992729698	also	also	RR
304953	100736308	20992729699	increases	increase	VVZ
304953	100736308	20992729700	a	a	AT1
304953	100736308	20992729701	mans	man	NN2
304953	100736308	20992729702	risk	risk	NN1_VV0
304953	100736308	20992729703	of	of	IO
304953	100736308	20992729704	developing	develop	VVG
304953	100736308	20992729705	the	the	AT
304953	100736308	20992729706	disease	disease	NN1
304953	100736308	20992729707	.	.	.
304953	100736308	20992729708	No	no	AT
304953	100736308	20992729709	added	added	JJ
304953	100736308	20992729710	risks	risk	NN2
304953	100736308	20992729711	were	be	VBDR
304953	100736308	20992729712	noted	note	VVN
304953	100736308	20992729713	for	for	IF
304953	100736308	20992729714	men	man	NN2
304953	100736308	20992729715	who	who	PNQS
304953	100736308	20992729716	had	have	VHD
304953	100736308	20992729717	a	a	AT1
304953	100736308	20992729718	fourth-degree	fourth-degree	JJ_NN1
304953	100736308	20992729719	relative	relative	NN1_JJ
304953	100736308	20992729720	with	with	IW
304953	100736308	20992729721	prostate	prostate	NN1
304953	100736308	20992729722	cancer	cancer	NN1
304953	100736308	20992729723	.	.	.
304953	100736308	20992729724	<p>		NULL
304953	100736308	20992729725	Lisa	lisa	NP1
304953	100736308	20992729726	Albright	albright	NP1
304953	100736308	20992729727	,	,	,
304953	100736308	20992729728	a	a	AT1
304953	100736308	20992729729	statistical	statistical	JJ
304953	100736308	20992729730	geneticist	geneticist	NN1
304953	100736308	20992729731	at	at	II
304953	100736308	20992729732	the	the	AT
304953	100736308	20992729733	University	university	NN1
304953	100736308	20992729734	of	of	IO
304953	100736308	20992729735	Utah	utah	NP1
304953	100736308	20992729736	School	school	NN1
304953	100736308	20992729737	of	of	IO
304953	100736308	20992729738	Medicine	medicine	NN1
304953	100736308	20992729739	who	who	PNQS
304953	100736308	20992729740	led	lead	VVD
304953	100736308	20992729741	the	the	AT
304953	100736308	20992729742	study	study	NN1
304953	100736308	20992729743	,	,	,
304953	100736308	20992729744	said	say	VVD
304953	100736308	20992729745	the	the	AT
304953	100736308	20992729746	risks	risk	NN2
304953	100736308	20992729747	were	be	VBDR
304953	100736308	20992729748	similar	similar	JJ
304953	100736308	20992729749	regardless	regardless	RR
304953	100736308	20992729750	of	of	IO
304953	100736308	20992729751	whether	whether	CSW
304953	100736308	20992729752	the	the	AT
304953	100736308	20992729753	genes	gene	NN2
304953	100736308	20992729754	were	be	VBDR
304953	100736308	20992729755	passed	pass	VVN
304953	100736308	20992729756	through	through	II
304953	100736308	20992729757	the	the	AT
304953	100736308	20992729758	mother	mother	NN1
304953	100736308	20992729759	or	or	CC
304953	100736308	20992729760	the	the	AT
304953	100736308	20992729761	father	father	NN1
304953	100736308	20992729762	.	.	.
304953	100736308	20992729763	"	"	"
304953	100736308	20992729764	This	this	DD1
304953	100736308	20992729765	is n't		NN1_VV0
304953	100736308	20992729766	something	something	PN1
304953	100736308	20992729767	people	people	NN
304953	100736308	20992729768	normally	normally	RR
304953	100736308	20992729769	think	think	VV0
304953	100736308	20992729770	about	about	II
304953	100736308	20992729771	,	,	,
304953	100736308	20992729772	"	"	"
304953	100736308	20992729773	she	she	PPHS1
304953	100736308	20992729774	said	say	VVD
304953	100736308	20992729775	.	.	.
304953	100736308	20992729776	"	"	"
304953	100736308	20992729777	But	but	CCB
304953	100736308	20992729778	if	if	CS
304953	100736308	20992729779	the	the	AT
304953	100736308	20992729780	mothers	mother	NN2
304953	100736308	20992729781	brother	brother	NN1
304953	100736308	20992729782	had	have	VHD
304953	100736308	20992729783	prostate	prostate	NN1
304953	100736308	20992729784	cancer	cancer	NN1
304953	100736308	20992729785	,	,	,
304953	100736308	20992729786	then	then	RT
304953	100736308	20992729787	the	the	AT
304953	100736308	20992729788	nephew	nephew	NN1
304953	100736308	20992729789	is	be	VBZ
304953	100736308	20992729790	also	also	RR
304953	100736308	20992729791	at	at	II
304953	100736308	20992729792	greater	great	JJR
304953	100736308	20992729793	risk	risk	NN1
304953	100736308	20992729794	.	.	.
304953	100736308	20992729795	"	"	"
304953	100736308	20992729796	<p>		NULL
304953	100736308	20992729797	To	to	TO
304953	100736308	20992729798	generate	generate	VVI
304953	100736308	20992729799	the	the	AT
304953	100736308	20992729800	results	result	NN2
304953	100736308	20992729801	,	,	,
304953	100736308	20992729802	Albrights		NP1
304953	100736308	20992729803	team	team	NN1
304953	100736308	20992729804	scoured	scour	VVD_VVN
304953	100736308	20992729805	two	two	MC
304953	100736308	20992729806	data	data	NN
304953	100736308	20992729807	repositories	repository	NN2
304953	100736308	20992729808	"	"	"
304953	100736308	20992729809	a	a	AT1
304953	100736308	20992729810	genealogy	genealogy	NN1
304953	100736308	20992729811	database	database	NN1
304953	100736308	20992729812	for	for	IF
304953	100736308	20992729813	Utah	utah	NP1
304953	100736308	20992729814	residents	resident	NN2
304953	100736308	20992729815	dating	date	VVG
304953	100736308	20992729816	back	back	RP
304953	100736308	20992729817	to	to	II
304953	100736308	20992729818	the	the	AT
304953	100736308	20992729819	1880s	1880s	MC2
304953	100736308	20992729820	,	,	,
304953	100736308	20992729821	and	and	CC
304953	100736308	20992729822	a	a	AT1
304953	100736308	20992729823	cancer	cancer	NN1
304953	100736308	20992729824	registry	registry	NN1
304953	100736308	20992729825	for	for	IF
304953	100736308	20992729826	the	the	AT
304953	100736308	20992729827	state	state	NN1
304953	100736308	20992729828	that	that	CST_DD1
304953	100736308	20992729829	dates	date	VVZ
304953	100736308	20992729830	back	back	RP
304953	100736308	20992729831	to	to	II
304953	100736308	20992729832	1966	1966	MC
304953	100736308	20992729833	.	.	.
304953	100736308	20992729834	The	the	AT
304953	100736308	20992729835	two	two	MC
304953	100736308	20992729836	databases	database	NN2
304953	100736308	20992729837	were	be	VBDR
304953	100736308	20992729838	linked	link	VVN_JJ
304953	100736308	20992729839	,	,	,
304953	100736308	20992729840	allowing	allow	VVG
304953	100736308	20992729841	the	the	AT
304953	100736308	20992729842	investigators	investigator	NN2
304953	100736308	20992729843	to	to	TO
304953	100736308	20992729844	assess	assess	VVI
304953	100736308	20992729845	family	family	NN1
304953	100736308	20992729846	history	history	NN1
304953	100736308	20992729847	of	of	IO
304953	100736308	20992729848	prostate	prostate	NN1
304953	100736308	20992729849	cancer	cancer	NN1
304953	100736308	20992729850	over	over	II
304953	100736308	20992729851	multiple	multiple	JJ_NN1
304953	100736308	20992729852	generations	generation	NN2
304953	100736308	20992729853	.	.	.
304953	100736308	20992729854	<p>		NULL
304953	100736308	20992729855	Risks	risk	NN2
304953	100736308	20992729856	for	for	IF
304953	100736308	20992729857	dozens	dozen	NNO2
304953	100736308	20992729858	of	of	IO
304953	100736308	20992729859	familial	familial	JJ
304953	100736308	20992729860	combinations	combination	NN2
304953	100736308	20992729861	@		II
304953	100736308	20992729862	@		II
304953	100736308	20992729863	@		II
304953	100736308	20992729864	@		II
304953	100736308	20992729865	@		II
304953	100736308	20992729866	@		II
304953	100736308	20992729867	@		II
304953	100736308	20992729868	@		II
304953	100736308	20992729869	@		II
304953	100736308	20992729870	@		II
304953	100736308	20992729871	a	a	AT1
304953	100736308	20992729872	single	single	JJ
304953	100736308	20992729873	table	table	NN1
304953	100736308	20992729874	"	"	"
304953	100736308	20992729875	that	that	CST
304953	100736308	20992729876	we	we	PPIS2
304953	100736308	20992729877	hope	hope	VV0
304953	100736308	20992729878	clinicians	clinician	NN2
304953	100736308	20992729879	will	will	VM
304953	100736308	20992729880	laminate	laminate	VVI
304953	100736308	20992729881	and	and	CC
304953	100736308	20992729882	keep	keep	VVI
304953	100736308	20992729883	in	in	II_RP@
304953	100736308	20992729884	a	a	AT1
304953	100736308	20992729885	back	back	NN1_JJ@
304953	100736308	20992729886	pocket	pocket	NN1
304953	100736308	20992729887	,	,	,
304953	100736308	20992729888	"	"	"
304953	100736308	20992729889	Albright	albright	NP1
304953	100736308	20992729890	said	say	VVD
304953	100736308	20992729891	.	.	.
304953	100736308	20992729892	Presented	present	VVN_VVD
304953	100736308	20992729893	here	here	RL
304953	100736308	20992729894	,	,	,
304953	100736308	20992729895	the	the	AT
304953	100736308	20992729896	table	table	NN1
304953	100736308	20992729897	describes	describe	VVZ
304953	100736308	20992729898	the	the	AT
304953	100736308	20992729899	kinds	kind	NN2
304953	100736308	20992729900	of	of	IO
304953	100736308	20992729901	family	family	NN1
304953	100736308	20992729902	histories	history	NN2
304953	100736308	20992729903	that	that	CST
304953	100736308	20992729904	either	either	RR
304953	100736308	20992729905	double	double	JJ
304953	100736308	20992729906	or	or	CC
304953	100736308	20992729907	triple	triple	VV0
304953	100736308	20992729908	the	the	AT
304953	100736308	20992729909	relative	relative	JJ_NN1
304953	100736308	20992729910	risk	risk	NN1
304953	100736308	20992729911	of	of	IO
304953	100736308	20992729912	prostate	prostate	NN1
304953	100736308	20992729913	cancer	cancer	NN1
304953	100736308	20992729914	.	.	.
304953	100736308	20992729915	<h>		NULL
304953	100736308	20992729916	Family	family	NN1
304953	100736308	20992729917	history	history	NN1
304953	100736308	20992729918	constellations	constellation	NN2
304953	100736308	20992729919	that	that	CST_DD1
304953	100736308	20992729920	double	double	JJ_NN1
304953	100736308	20992729921	or	or	CC
304953	100736308	20992729922	triple	triple	JJ_VV0_NN1
304953	100736308	20992729923	prostate	prostate	NN1
304953	100736308	20992729924	cancer	cancer	NN1
304953	100736308	20992729925	risk	risk	NN1
304953	100736308	20992729926	<p>		NULL
304953	100736308	20992729927	Relative	relative	JJ_NN1
304953	100736308	20992729928	risk	risk	NN1_VV0
304953	100736308	20992729929	greater	great	JJR
304953	100736308	20992729930	than	than	CSN
304953	100736308	20992729931	2	2	MC
304953	100736308	20992729932	(	(	(
304953	100736308	20992729933	26%		NNU
304953	100736308	20992729934	of	of	IO
304953	100736308	20992729935	males	male	NN2
304953	100736308	20992729936	)	)	)
304953	100736308	20992729937	<p>		NULL
304953	100736308	20992729938	Relative	relative	JJ_NN1
304953	100736308	20992729939	riskgreater		NN1
304953	100736308	20992729940	than3		FO
304953	100736308	20992729941	(	(	(
304953	100736308	20992729942	10%		NNU
304953	100736308	20992729943	of	of	IO
304953	100736308	20992729944	males	male	NN2
304953	100736308	20992729945	)	)	)
304953	100736308	20992729946	<p>		NULL
304953	100736308	20992729947	1	1	MC1
304953	100736308	20992729948	affected	affect	VVN_JJ@_VVD@
304953	100736308	20992729949	first	first	MD
304953	100736308	20992729950	degree	degree	NN1
304953	100736308	20992729951	relative	relative	NN1
304953	100736308	20992729952	<p>		NULL
304953	100736308	20992729953	2	2	MC
304953	100736308	20992729954	or	or	CC
304953	100736308	20992729955	more	more	RGR_RRR_DAR
304953	100736308	20992729956	affected	affected	JJ@_VVN
304953	100736308	20992729957	first-degree	first-degree	JJ_NN1
304953	100736308	20992729958	relatives	relative	NN2
304953	100736308	20992729959	<p>		NULL
304953	100736308	20992729960	3	3	MC
304953	100736308	20992729961	or	or	CC
304953	100736308	20992729962	more	more	RGR_RRR_DAR
304953	100736308	20992729963	affected	affected	JJ@_VVN
304953	100736308	20992729964	second-degree	second-degree	JJ_NN1
304953	100736308	20992729965	relatives	relative	NN2
304953	100736308	20992729966	<p>		NULL
304953	100736308	20992729967	5	5	MC
304953	100736308	20992729968	or	or	CC
304953	100736308	20992729969	more	more	RGR_RRR_DAR
304953	100736308	20992729970	affected	affected	JJ@_VVN
304953	100736308	20992729971	second-degree	second-degree	JJ_NN1
304953	100736308	20992729972	relatives	relative	NN2
304953	100736308	20992729973	<p>		NULL
304953	100736308	20992729974	Mothers	mother	NN2
304953	100736308	20992729975	father	father	NN1
304953	100736308	20992729976	affected	affect	VVN
304953	100736308	20992729977	<p>		NULL
304953	100736308	20992729978	Both	both	DB2
304953	100736308	20992729979	grandfathers	grandfather	NN2
304953	100736308	20992729980	affected	affect	VVN
304953	100736308	20992729981	<p>		NULL
304953	100736308	20992729982	Nephew	nephew	NN1
304953	100736308	20992729983	affected	affect	VVN
304953	100736308	20992729984	<p>		NULL
304953	100736308	20992729985	1	1	MC1
304953	100736308	20992729986	or	or	CC
304953	100736308	20992729987	more	more	RGR_RRR_DAR
304953	100736308	20992729988	affected	affected	JJ@_VVN
304953	100736308	20992729989	first-degree	first-degree	JJ_NN1
304953	100736308	20992729990	relatives	relative	NN2
304953	100736308	20992729991	and	and	CC
304953	100736308	20992729992	2	2	MC
304953	100736308	20992729993	or	or	CC
304953	100736308	20992729994	more	more	RGR_RRR_DAR
304953	100736308	20992729995	affected	affected	JJ@_VVN
304953	100736308	20992729996	second-degree	second-degree	JJ_NN1
304953	100736308	20992729997	relatives	relative	NN2
304953	100736308	20992729998	<p>		NULL
304953	100736308	20992729999	Because	because	CS
304953	100736308	20992730000	the	the	AT
304953	100736308	20992730001	analysis	analysis	NN1
304953	100736308	20992730002	is	be	VBZ
304953	100736308	20992730003	limited	limit	VVN
304953	100736308	20992730004	to	to	II
304953	100736308	20992730005	Utah	utah	NP1
304953	100736308	20992730006	residents	resident	NN2
304953	100736308	20992730007	"	"	"
304953	100736308	20992730008	mostly	mostly	RR
304953	100736308	20992730009	of	of	IO
304953	100736308	20992730010	Northern	northern	JJ
304953	100736308	20992730011	European	european	JJ
304953	100736308	20992730012	descent	descent	NN1
304953	100736308	20992730013	"	"	"
304953	100736308	20992730014	it	it	PPH1
304953	100736308	20992730015	may	may	VM
304953	100736308	20992730016	not	not	XX
304953	100736308	20992730017	account	account	VVI
304953	100736308	20992730018	for	for	IF
304953	100736308	20992730019	the	the	AT
304953	100736308	20992730020	effect	effect	NN1
304953	100736308	20992730021	of	of	IO
304953	100736308	20992730022	family	family	NN1
304953	100736308	20992730023	history	history	NN1
304953	100736308	20992730024	in	in	II
304953	100736308	20992730025	other	other	JJ
304953	100736308	20992730026	races	race	NN2
304953	100736308	20992730027	or	or	CC
304953	100736308	20992730028	ethnicities	ethnicity	NN2
304953	100736308	20992730029	,	,	,
304953	100736308	20992730030	Albright	albright	NP1
304953	100736308	20992730031	acknowledged	acknowledge	VVD
304953	100736308	20992730032	.	.	.
304953	100736308	20992730033	"	"	"
304953	100736308	20992730034	We	we	PPIS2
304953	100736308	20992730035	hope	hope	VV0
304953	100736308	20992730036	to	to	TO
304953	100736308	20992730037	collaborate	collaborate	VVI
304953	100736308	20992730038	with	with	IW
304953	100736308	20992730039	others	others	NN2
304953	100736308	20992730040	elsewhere	elsewhere	RL
304953	100736308	20992730041	who	who	PNQS
304953	100736308	20992730042	have	have	VH0
304953	100736308	20992730043	similar	similar	JJ
304953	100736308	20992730044	resources	resource	NN2
304953	100736308	20992730045	to	to	TO@_II
304953	100736308	20992730046	work	work	VVI_NN1
304953	100736308	20992730047	with	with	IW
304953	100736308	20992730048	,	,	,
304953	100736308	20992730049	"	"	"
304953	100736308	20992730050	he	he	PPHS1
304953	100736308	20992730051	said	say	VVD
304953	100736308	20992730052	.	.	.
304953	100736308	20992730053	<p>		NULL
304953	100736308	20992730054	Still	still	RR
304953	100736308	20992730055	,	,	,
304953	100736308	20992730056	the	the	AT
304953	100736308	20992730057	results	result	NN2
304953	100736308	20992730058	indicate	indicate	VV0
304953	100736308	20992730059	that	that	CST
304953	100736308	20992730060	"	"	"
304953	100736308	20992730061	@		II
304953	100736308	20992730062	@		II
304953	100736308	20992730063	@		II
304953	100736308	20992730064	@		II
304953	100736308	20992730065	@		II
304953	100736308	20992730066	@		II
304953	100736308	20992730067	@		II
304953	100736308	20992730068	@		II
304953	100736308	20992730069	@		II
304953	100736308	20992730070	@		II
304953	100736308	20992730071	careful	careful	JJ
304953	100736308	20992730072	scrutiny	scrutiny	NN1
304953	100736308	20992730073	with	with	II31
304953	100736308	20992730074	respect	respect	II32
304953	100736308	20992730075	to	to	II33
304953	100736308	20992730076	screening	screening	NN1_VVG
304953	100736308	20992730077	,	,	,
304953	100736308	20992730078	"	"	"
304953	100736308	20992730079	said	say	VVD
304953	100736308	20992730080	co-author	co-author	NN1
304953	100736308	20992730081	Robert	robert	NP1
304953	100736308	20992730082	Stevenson	stevenson	NP1
304953	100736308	20992730083	,	,	,
304953	100736308	20992730084	a	a	AT1
304953	100736308	20992730085	urological	urological	JJ
304953	100736308	20992730086	surgeon	surgeon	NN1
304953	100736308	20992730087	at	at	II
304953	100736308	20992730088	the	the	AT
304953	100736308	20992730089	University	university	NN1
304953	100736308	20992730090	of	of	IO
304953	100736308	20992730091	Utah	utah	NP1
304953	100736308	20992730092	School	school	NN1
304953	100736308	20992730093	of	of	IO
304953	100736308	20992730094	Medicine	medicine	NN1
304953	100736308	20992730095	.	.	.
304953	100736308	20992730096	Screening	screen	VVG_NN1
304953	100736308	20992730097	means	mean	NN_VVZ
304953	100736308	20992730098	checking	check	VVG
304953	100736308	20992730099	apparently	apparently	RR
304953	100736308	20992730100	healthy	healthy	JJ
304953	100736308	20992730101	individuals	individual	NN2
304953	100736308	20992730102	for	for	IF
304953	100736308	20992730103	signs	sign	NN2
304953	100736308	20992730104	of	of	IO
304953	100736308	20992730105	hidden	hidden	JJ@
304953	100736308	20992730106	disease	disease	NN1
304953	100736308	20992730107	.	.	.
304953	100736308	20992730108	For	for	IF
304953	100736308	20992730109	prostate	prostate	NN1
304953	100736308	20992730110	cancer	cancer	NN1
304953	100736308	20992730111	,	,	,
304953	100736308	20992730112	this	this	DD1
304953	100736308	20992730113	is	be	VBZ
304953	100736308	20992730114	usually	usually	RR
304953	100736308	20992730115	done	do	VDN
304953	100736308	20992730116	with	with	IW
304953	100736308	20992730117	the	the	AT
304953	100736308	20992730118	prostate-specific	prostate-specific	JJ
304953	100736308	20992730119	antigen	antigen	NN1
304953	100736308	20992730120	(	(	(
304953	100736308	20992730121	PSA	psa	NP1
304953	100736308	20992730122	)	)	)
304953	100736308	20992730123	blood	blood	NN1
304953	100736308	20992730124	test	test	NN1
304953	100736308	20992730125	.	.	.
304953	100736308	20992730126	<p>		NULL
304953	100736308	20992730127	The	the	AT
304953	100736308	20992730128	US	us	NP1
304953	100736308	20992730129	Preventive	preventive	JJ
304953	100736308	20992730130	Services	service	NN2
304953	100736308	20992730131	Task	task	NN1
304953	100736308	20992730132	Force	force	NN1
304953	100736308	20992730133	recommends	recommend	VVZ
304953	100736308	20992730134	against	against	II
304953	100736308	20992730135	routine	routine	NN1_JJ@
304953	100736308	20992730136	PSA	psa	NP1
304953	100736308	20992730137	testing	testing	NN1_VVG
304953	100736308	20992730138	.	.	.
304953	100736308	20992730139	But	but	CCB
304953	100736308	20992730140	it	it	PPH1
304953	100736308	20992730141	has	have	VHZ
304953	100736308	20992730142	said	say	VVN
304953	100736308	20992730143	that	that	CST_DD1
304953	100736308	20992730144	additional	additional	JJ
304953	100736308	20992730145	research	research	NN1
304953	100736308	20992730146	is	be	VBZ
304953	100736308	20992730147	needed	need	VVN
304953	100736308	20992730148	to	to	TO
304953	100736308	20992730149	determine	determine	VVI
304953	100736308	20992730150	whether	whether	CSW
304953	100736308	20992730151	the	the	AT
304953	100736308	20992730152	balance	balance	NN1
304953	100736308	20992730153	of	of	IO
304953	100736308	20992730154	benefits	benefit	NN2
304953	100736308	20992730155	and	and	CC
304953	100736308	20992730156	harms	harm	NN2
304953	100736308	20992730157	of	of	IO
304953	100736308	20992730158	prostate	prostate	NN1
304953	100736308	20992730159	cancer	cancer	NN1
304953	100736308	20992730160	screening	screening	NN1
304953	100736308	20992730161	differs	differ	VVZ
304953	100736308	20992730162	in	in	II_RP@
304953	100736308	20992730163	men	man	NN2
304953	100736308	20992730164	at	at	II
304953	100736308	20992730165	higher	high	JJR
304953	100736308	20992730166	risk	risk	NN1
304953	100736308	20992730167	of	of	IO
304953	100736308	20992730168	developing	developing	JJ_VVG
304953	100736308	20992730169	or	or	CC
304953	100736308	20992730170	dying	dying	JJ_VVG
304953	100736308	20992730171	of	of	IO
304953	100736308	20992730172	prostate	prostate	NN1
304953	100736308	20992730173	cancer	cancer	NN1
304953	100736308	20992730174	.	.	.
304953	100736308	20992730175	<p>		NULL
304953	100736308	20992730176	"	"	"
304953	100736308	20992730177	This	this	DD1
304953	100736308	20992730178	is	be	VBZ
304953	100736308	20992730179	a	a	AT1
304953	100736308	20992730180	unique	unique	JJ
304953	100736308	20992730181	data	data	NN
304953	100736308	20992730182	set	set	VV0_VVD
304953	100736308	20992730183	that	that	CST_DD1
304953	100736308	20992730184	provides	provide	VVZ
304953	100736308	20992730185	a	a	AT1
304953	100736308	20992730186	greater	great	JJR
304953	100736308	20992730187	degree	degree	NN1
304953	100736308	20992730188	of	of	IO
304953	100736308	20992730189	precision	precision	NN1
304953	100736308	20992730190	of	of	IO
304953	100736308	20992730191	prostate	prostate	NN1
304953	100736308	20992730192	cancer	cancer	NN1
304953	100736308	20992730193	risk	risk	NN1
304953	100736308	20992730194	,	,	,
304953	100736308	20992730195	"	"	"
304953	100736308	20992730196	said	say	VVD
304953	100736308	20992730197	Dr.		NNB
304953	100736308	20992730198	Marc	marc	NP1
304953	100736308	20992730199	Garnick		NP1
304953	100736308	20992730200	,	,	,
304953	100736308	20992730201	the	the	AT
304953	100736308	20992730202	Gorman	gorman	NN1_NP1
304953	100736308	20992730203	Brothers	brother	NN2
304953	100736308	20992730204	Professor	professor	NN1
304953	100736308	20992730205	of	of	IO
304953	100736308	20992730206	Medicine	medicine	NN1
304953	100736308	20992730207	at	at	II
304953	100736308	20992730208	Harvard	harvard	NP1
304953	100736308	20992730209	Medical	medical	JJ
304953	100736308	20992730210	School	school	NN1
304953	100736308	20992730211	and	and	CC
304953	100736308	20992730212	Beth	beth	NP1
304953	100736308	20992730213	Israel	israel	NP1
304953	100736308	20992730214	Deaconess	deaconess	NN1
304953	100736308	20992730215	Medical	medical	JJ
304953	100736308	20992730216	Center	center	NN1
304953	100736308	20992730217	.	.	.
304953	100736308	20992730218	"	"	"
304953	100736308	20992730219	The	the	AT
304953	100736308	20992730220	real	real	JJ
304953	100736308	20992730221	dilemma	dilemma	NN1
304953	100736308	20992730222	,	,	,
304953	100736308	20992730223	which	which	DDQ
304953	100736308	20992730224	this	this	DD1
304953	100736308	20992730225	study	study	NN1
304953	100736308	20992730226	does	do	VDZ
304953	100736308	20992730227	not	not	XX
304953	100736308	20992730228	address	address	VVI
304953	100736308	20992730229	,	,	,
304953	100736308	20992730230	is	be	VBZ
304953	100736308	20992730231	whether	whether	CSW
304953	100736308	20992730232	there	there	EX
304953	100736308	20992730233	are	be	VBR
304953	100736308	20992730234	any	any	DD_RR%
304953	100736308	20992730235	meaningfully	meaningfully	RR
304953	100736308	20992730236	beneficial	beneficial	JJ
304953	100736308	20992730237	outcomes	outcome	NN2
304953	100736308	20992730238	to	to	II
304953	100736308	20992730239	those	those	DD2
304953	100736308	20992730240	individuals	individual	NN2
304953	100736308	20992730241	who	who	PNQS
304953	100736308	20992730242	are	be	VBR
304953	100736308	20992730243	diagnosed	diagnose	VVN
304953	100736308	20992730244	(	(	(
304953	100736308	20992730245	after	after	II
304953	100736308	20992730246	being	be	VBG
304953	100736308	20992730247	identified	identify	VVN
304953	100736308	20992730248	as	as	CSA
304953	100736308	20992730249	being	be	VBG
304953	100736308	20992730250	at	at	II
304953	100736308	20992730251	high	high	JJ
304953	100736308	20992730252	risk	risk	NN1
304953	100736308	20992730253	of	of	IO
304953	100736308	20992730254	having	have	VHG
304953	100736308	20992730255	the	the	AT
304953	100736308	20992730256	disease	disease	NN1
304953	100736308	20992730257	)	)	)
304953	100736308	20992730258	and	and	CC
304953	100736308	20992730259	treated	treat	VVN_VVD@
304953	100736308	20992730260	.	.	.
304953	100736308	20992730261	@		II
304953	100736308	20992730262	@		II
304953	100736308	20992730263	@		II
304953	100736308	20992730264	@		II
304953	100736308	20992730265	@		II
304953	100736308	20992730266	@		II
304953	100736308	20992730267	@		II
304953	100736308	20992730268	@		II
304953	100736308	20992730269	@		II
304953	100736308	20992730270	@		II
304953	100736308	20992730271	elucidate	elucidate	VVI
304953	100736308	20992730272	the	the	AT
304953	100736308	20992730273	genes	gene	NN2
304953	100736308	20992730274	that	that	CST_DD1
304953	100736308	20992730275	may	may	VM
304953	100736308	20992730276	be	be	VBI
304953	100736308	20992730277	responsible	responsible	JJ
304953	100736308	20992730278	for	for	IF
304953	100736308	20992730279	the	the	AT
304953	100736308	20992730280	development	development	NN1
304953	100736308	20992730281	of	of	IO
304953	100736308	20992730282	prostate	prostate	NN1
304953	100736308	20992730283	cancer	cancer	NN1
304953	100736308	20992730284	.	.	.
304953	100736308	20992730285	"	"	"
304953	100736309	20992730305	@@##	----------	----------
304953	100736309	20992730306	@@100736309		FO
304953	100736309	20992730307	@4936309/		VV0_NN1
304953	100736309	20992730308	46989		MC
304953	100736309	20992730309	@qwx906989		FO
304953	100736309	20992730310	<p>		NULL
304953	100736309	20992730311	There	there	EX
304953	100736309	20992730312	are	be	VBR
304953	100736309	20992730313	many	many	DA2
304953	100736309	20992730314	ways	way	NN2
304953	100736309	20992730315	to	to	TO
304953	100736309	20992730316	kill	kill	VVI
304953	100736309	20992730317	prostate	prostate	NN1
304953	100736309	20992730318	cancer	cancer	NN1
304953	100736309	20992730319	cells	cell	NN2
304953	100736309	20992730320	.	.	.
304953	100736309	20992730321	Radiation	radiation	NN1
304953	100736309	20992730322	and	and	CC
304953	100736309	20992730323	chemotherapy	chemotherapy	NN1
304953	100736309	20992730324	are	be	VBR
304953	100736309	20992730325	the	the	AT
304953	100736309	20992730326	most	most	RGT
304953	100736309	20992730327	widely	widely	RR
304953	100736309	20992730328	used	use	VVN_VVD_JJ
304953	100736309	20992730329	.	.	.
304953	100736309	20992730330	Freezing	freezing	JJ
304953	100736309	20992730331	(	(	(
304953	100736309	20992730332	cryotherapy	cryotherapy	NN1
304953	100736309	20992730333	)	)	)
304953	100736309	20992730334	is	be	VBZ
304953	100736309	20992730335	another	another	DD1
304953	100736309	20992730336	.	.	.
304953	100736309	20992730337	A	a	AT1_ZZ1
304953	100736309	20992730338	French	french	JJ_NN1
304953	100736309	20992730339	company	company	NN1
304953	100736309	20992730340	wanted	want	VVD_VVN
304953	100736309	20992730341	to	to	TO
304953	100736309	20992730342	add	add	VVI
304953	100736309	20992730343	heat	heat	NN1
304953	100736309	20992730344	generated	generate	VVN
304953	100736309	20992730345	by	by	II
304953	100736309	20992730346	ultrasound	ultrasound	NN1
304953	100736309	20992730347	waves	wave	NN2_VVZ@
304953	100736309	20992730348	to	to	II
304953	100736309	20992730349	the	the	AT
304953	100736309	20992730350	armamentarium	armamentarium	NN1
304953	100736309	20992730351	,	,	,
304953	100736309	20992730352	but	but	CCB
304953	100736309	20992730353	an	a	AT1
304953	100736309	20992730354	FDA	fda	NN1_NP1
304953	100736309	20992730355	advisory	advisory	JJ
304953	100736309	20992730356	panel	panel	NN1
304953	100736309	20992730357	has	have	VHZ
304953	100736309	20992730358	said	say	VVN
304953	100736309	20992730359	"	"	"
304953	100736309	20992730360	no	no	UH
304953	100736309	20992730361	.	.	.
304953	100736309	20992730362	"	"	"
304953	100736309	20992730363	<p>		NULL
304953	100736309	20992730364	The	the	AT
304953	100736309	20992730365	heat	heat	NN1
304953	100736309	20992730366	technique	technique	NN1
304953	100736309	20992730367	,	,	,
304953	100736309	20992730368	known	know	VVN
304953	100736309	20992730369	as	as	II
304953	100736309	20992730370	high-intensity	high-intensity	JJ
304953	100736309	20992730371	focused-		JJ_NN1
304953	100736309	20992730372	ultrasound	ultrasound	NN1
304953	100736309	20992730373	(	(	(
304953	100736309	20992730374	HIFU		NP1
304953	100736309	20992730375	)	)	)
304953	100736309	20992730376	,	,	,
304953	100736309	20992730377	is	be	VBZ
304953	100736309	20992730378	being	be	VBG
304953	100736309	20992730379	used	use	VVN
304953	100736309	20992730380	in	in	II
304953	100736309	20992730381	several	several	DA2
304953	100736309	20992730382	countries	country	NN2
304953	100736309	20992730383	for	for	IF
304953	100736309	20992730384	treating	treat	VVG
304953	100736309	20992730385	localized	localized	JJ
304953	100736309	20992730386	prostate	prostate	NN1
304953	100736309	20992730387	cancer	cancer	NN1
304953	100736309	20992730388	.	.	.
304953	100736309	20992730389	To	to	TO
304953	100736309	20992730390	administer	administer	VVI
304953	100736309	20992730391	high-intensity	high-intensity	JJ
304953	100736309	20992730392	focused-		JJ_NN1
304953	100736309	20992730393	ultrasound	ultrasound	NN1
304953	100736309	20992730394	,	,	,
304953	100736309	20992730395	a	a	AT1
304953	100736309	20992730396	doctor	doctor	NN1
304953	100736309	20992730397	inserts	insert	VVZ
304953	100736309	20992730398	an	a	AT1
304953	100736309	20992730399	ultrasound	ultrasound	NN1
304953	100736309	20992730400	probe	probe	NN1_VV0
304953	100736309	20992730401	into	into	II
304953	100736309	20992730402	the	the	AT
304953	100736309	20992730403	rectum	rectum	NN1
304953	100736309	20992730404	,	,	,
304953	100736309	20992730405	then	then	RT
304953	100736309	20992730406	focuses	focus	VVZ
304953	100736309	20992730407	beams	beam	NN2
304953	100736309	20992730408	of	of	IO
304953	100736309	20992730409	sound	sound	NN1_JJ@
304953	100736309	20992730410	waves	wave	NN2_VVZ@
304953	100736309	20992730411	on	on	II
304953	100736309	20992730412	cancerous	cancerous	JJ
304953	100736309	20992730413	portions	portion	NN2
304953	100736309	20992730414	of	of	IO
304953	100736309	20992730415	the	the	AT
304953	100736309	20992730416	gland	gland	NN1
304953	100736309	20992730417	.	.	.
304953	100736309	20992730418	Supporters	supporter	NN2
304953	100736309	20992730419	say	say	VV0
304953	100736309	20992730420	that	that	CST_DD1
304953	100736309	20992730421	high-intensity	high-intensity	JJ_NN1
304953	100736309	20992730422	focused-		JJ_NN1
304953	100736309	20992730423	ultrasound	ultrasound	NN1
304953	100736309	20992730424	offers	offer	VVZ@_NN2
304953	100736309	20992730425	a	a	AT1
304953	100736309	20992730426	noninvasive	noninvasive	JJ
304953	100736309	20992730427	(	(	(
304953	100736309	20992730428	meaning	mean	VVG_NN1
304953	100736309	20992730429	nonsurgical	nonsurgical	JJ
304953	100736309	20992730430	)	)	)
304953	100736309	20992730431	way	way	NN1
304953	100736309	20992730432	to	to	TO
304953	100736309	20992730433	target	target	VVI
304953	100736309	20992730434	cancer	cancer	NN1
304953	100736309	20992730435	cells	cell	NN2
304953	100736309	20992730436	that	that	CST_DD1
304953	100736309	20992730437	wo n't		JJ_NN1
304953	100736309	20992730438	damage	damage	NN1_VV0
304953	100736309	20992730439	the	the	AT
304953	100736309	20992730440	nerves	nerve	NN2
304953	100736309	20992730441	that	that	CST
304953	100736309	20992730442	control	control	VV0
304953	100736309	20992730443	a	a	AT1
304953	100736309	20992730444	mans	man	NN2
304953	100736309	20992730445	ability	ability	NN1
304953	100736309	20992730446	to	to	TO
304953	100736309	20992730447	have	have	VHI
304953	100736309	20992730448	an	a	AT1
304953	100736309	20992730449	erection	erection	NN1
304953	100736309	20992730450	.	.	.
304953	100736309	20992730451	<p>		NULL
304953	100736309	20992730452	As	as	II
304953	100736309	20992730453	part	part	NN1
304953	100736309	20992730454	of	of	IO
304953	100736309	20992730455	its	its	APPGE
304953	100736309	20992730456	standard	standard	JJ_NN1
304953	100736309	20992730457	review	review	NN1
304953	100736309	20992730458	process	process	NN1_VV0
304953	100736309	20992730459	for	for	IF
304953	100736309	20992730460	all	all	DB
304953	100736309	20992730461	new	new	JJ
304953	100736309	20992730462	devices	device	NN2
304953	100736309	20992730463	,	,	,
304953	100736309	20992730464	the	the	AT
304953	100736309	20992730465	FDA	fda	NP1_NN1
304953	100736309	20992730466	convened	convene	VVD_VVN
304953	100736309	20992730467	a	a	AT1
304953	100736309	20992730468	panel	panel	NN1
304953	100736309	20992730469	of	of	IO
304953	100736309	20992730470	experts	expert	NN2
304953	100736309	20992730471	whose	whose	DDQGE
304953	100736309	20992730472	job	job	NN1
304953	100736309	20992730473	was	be	VBDZ
304953	100736309	20992730474	to	to	TO
304953	100736309	20992730475	assess	assess	VVI
304953	100736309	20992730476	the	the	AT
304953	100736309	20992730477	available	available	JJ
304953	100736309	20992730478	data	data	NN
304953	100736309	20992730479	on	on	II
304953	100736309	20992730480	the	the	AT
304953	100736309	20992730481	safety	safety	NN1
304953	100736309	20992730482	and	and	CC
304953	100736309	20992730483	effectiveness	effectiveness	NN1
304953	100736309	20992730484	of	of	IO
304953	100736309	20992730485	HIFU		NN1_NP1
304953	100736309	20992730486	for	for	IF
304953	100736309	20992730487	localized	localized	JJ
304953	100736309	20992730488	prostate	prostate	NN1
304953	100736309	20992730489	cancer	cancer	NN1
304953	100736309	20992730490	.	.	.
304953	100736309	20992730491	<p>		NULL
304953	100736309	20992730492	The	the	AT
304953	100736309	20992730493	panel	panel	NN1
304953	100736309	20992730494	looked	look	VVN_VVD
304953	100736309	20992730495	at	at	II
304953	100736309	20992730496	publications	publication	NN2
304953	100736309	20992730497	@		II
304953	100736309	20992730498	@		II
304953	100736309	20992730499	@		II
304953	100736309	20992730500	@		II
304953	100736309	20992730501	@		II
304953	100736309	20992730502	@		II
304953	100736309	20992730503	@		II
304953	100736309	20992730504	@		II
304953	100736309	20992730505	@		II
304953	100736309	20992730506	@		II
304953	100736309	20992730507	results	result	NN2
304953	100736309	20992730508	from	from	II
304953	100736309	20992730509	an	a	AT1
304953	100736309	20992730510	unfinished	unfinished	JJ
304953	100736309	20992730511	clinical	clinical	JJ
304953	100736309	20992730512	trial	trial	NN1
304953	100736309	20992730513	comparing	compare	VVG
304953	100736309	20992730514	high-intensity	high-intensity	JJ
304953	100736309	20992730515	focused-		JJ_NN1
304953	100736309	20992730516	ultrasound	ultrasound	NN1
304953	100736309	20992730517	treatment	treatment	NN1
304953	100736309	20992730518	for	for	IF
304953	100736309	20992730519	early	early	JJ
304953	100736309	20992730520	prostate	prostate	NN1
304953	100736309	20992730521	cancer	cancer	NN1
304953	100736309	20992730522	with	with	IW
304953	100736309	20992730523	cryotherapy	cryotherapy	NN1
304953	100736309	20992730524	.	.	.
304953	100736309	20992730525	(	(	(
304953	100736309	20992730526	Like	like	II
304953	100736309	20992730527	HIFU		NP1_NN1
304953	100736309	20992730528	,	,	,
304953	100736309	20992730529	cryotherapy	cryotherapy	NN1
304953	100736309	20992730530	is	be	VBZ
304953	100736309	20992730531	also	also	RR
304953	100736309	20992730532	a	a	AT1
304953	100736309	20992730533	noninvasive	noninvasive	JJ
304953	100736309	20992730534	treatment	treatment	NN1
304953	100736309	20992730535	.	.	.
304953	100736309	20992730536	)	)	)
304953	100736309	20992730537	Known	know	VVN
304953	100736309	20992730538	as	as	II
304953	100736309	20992730539	the	the	AT
304953	100736309	20992730540	U.S.	us	NP1
304953	100736309	20992730541	Pivotal	pivotal	JJ
304953	100736309	20992730542	Study	study	NN1
304953	100736309	20992730543	,	,	,
304953	100736309	20992730544	this	this	DD1
304953	100736309	20992730545	trial	trial	NN1
304953	100736309	20992730546	was	be	VBDZ
304953	100736309	20992730547	launched	launch	VVN
304953	100736309	20992730548	in	in	II
304953	100736309	20992730549	2012	2012	MC
304953	100736309	20992730550	but	but	CCB
304953	100736309	20992730551	never	never	RR
304953	100736309	20992730552	met	meet	VVD_VVN
304953	100736309	20992730553	its	its	APPGE
304953	100736309	20992730554	goal	goal	NN1
304953	100736309	20992730555	to	to	TO
304953	100736309	20992730556	recruit	recruit	VVI
304953	100736309	20992730557	205	205	MC
304953	100736309	20992730558	men	man	NN2
304953	100736309	20992730559	for	for	IF
304953	100736309	20992730560	each	each	DD1
304953	100736309	20992730561	treatment	treatment	NN1
304953	100736309	20992730562	arm	arm	NN1
304953	100736309	20992730563	.	.	.
304953	100736309	20992730564	When	when	CS
304953	100736309	20992730565	the	the	AT
304953	100736309	20992730566	trial	trial	NN1
304953	100736309	20992730567	was	be	VBDZ
304953	100736309	20992730568	cancelled	cancel	VVN
304953	100736309	20992730569	earlier	early	RRR
304953	100736309	20992730570	this	this	DD1
304953	100736309	20992730571	year	year	NNT1
304953	100736309	20992730572	,	,	,
304953	100736309	20992730573	only	only	JJ
304953	100736309	20992730574	135		NN1
304953	100736309	20992730575	men	man	NN2
304953	100736309	20992730576	had	have	VHD
304953	100736309	20992730577	been	be	VBN
304953	100736309	20992730578	treated	treat	VVN
304953	100736309	20992730579	with	with	IW
304953	100736309	20992730580	high-intensity	high-intensity	JJ
304953	100736309	20992730581	focused-		JJ_NN1
304953	100736309	20992730582	ultrasound	ultrasound	NN1
304953	100736309	20992730583	and	and	CC
304953	100736309	20992730584	just	just	RR
304953	100736309	20992730585	5	5	MC
304953	100736309	20992730586	men	man	NN2
304953	100736309	20992730587	had	have	VHD
304953	100736309	20992730588	been	be	VBN
304953	100736309	20992730589	treated	treat	VVN
304953	100736309	20992730590	with	with	IW
304953	100736309	20992730591	cryotherapy	cryotherapy	NN1
304953	100736309	20992730592	.	.	.
304953	100736309	20992730593	<p>		NULL
304953	100736309	20992730594	Unpublished	unpublished	JJ
304953	100736309	20992730595	results	result	NN2
304953	100736309	20992730596	showed	show	VVD
304953	100736309	20992730597	that	that	CST_DD1
304953	100736309	20992730598	high-intensity	high-intensity	JJ_NN1
304953	100736309	20992730599	focused-		JJ_NN1
304953	100736309	20992730600	ultrasound	ultrasound	NN1
304953	100736309	20992730601	was	be	VBDZ
304953	100736309	20992730602	not	not	XX
304953	100736309	20992730603	highly	highly	RR
304953	100736309	20992730604	effective	effective	JJ
304953	100736309	20992730605	.	.	.
304953	100736309	20992730606	Nearly	nearly	RR
304953	100736309	20992730607	one	one	MC1
304953	100736309	20992730608	in	in	II
304953	100736309	20992730609	three	three	MC
304953	100736309	20992730610	prostates	prostate	NN2
304953	100736309	20992730611	treated	treat	VVN
304953	100736309	20992730612	with	with	IW
304953	100736309	20992730613	HIFU		NP1_NN1
304953	100736309	20992730614	tested	test	VVD
304953	100736309	20992730615	positive	positive	JJ
304953	100736309	20992730616	for	for	IF
304953	100736309	20992730617	cancer	cancer	NN1
304953	100736309	20992730618	in	in	II
304953	100736309	20992730619	biopsies	biopsy	NN2
304953	100736309	20992730620	taken	take	VVN
304953	100736309	20992730621	two	two	MC
304953	100736309	20992730622	years	year	NNT2
304953	100736309	20992730623	after	after	II_CS
304953	100736309	20992730624	treatment	treatment	NN1
304953	100736309	20992730625	.	.	.
304953	100736309	20992730626	It	it	PPH1
304953	100736309	20992730627	also	also	RR
304953	100736309	20992730628	posed	pose	VVD
304953	100736309	20992730629	a	a	AT1
304953	100736309	20992730630	high	high	JJ
304953	100736309	20992730631	risk	risk	NN1
304953	100736309	20992730632	of	of	IO
304953	100736309	20992730633	side	side	NN1
304953	100736309	20992730634	effects	effect	NN2
304953	100736309	20992730635	,	,	,
304953	100736309	20992730636	with	with	IW
304953	100736309	20992730637	more	more	DAR
304953	100736309	20992730638	than	than	CSN
304953	100736309	20992730639	half	half	DB
304953	100736309	20992730640	of	of	IO
304953	100736309	20992730641	the	the	AT
304953	100736309	20992730642	men	man	NN2
304953	100736309	20992730643	treated	treat	VVN
304953	100736309	20992730644	with	with	IW
304953	100736309	20992730645	high-intensity	high-intensity	JJ
304953	100736309	20992730646	focused-		JJ_NN1
304953	100736309	20992730647	ultrasound	ultrasound	NN1_VV0
304953	100736309	20992730648	experiencing	experience	VVG
304953	100736309	20992730649	erectile	erectile	JJ
304953	100736309	20992730650	dysfunction	dysfunction	NN1
304953	100736309	20992730651	,	,	,
304953	100736309	20992730652	urinary	urinary	JJ_NN1
304953	100736309	20992730653	retention	retention	NN1
304953	100736309	20992730654	,	,	,
304953	100736309	20992730655	incontinence	incontinence	NN1
304953	100736309	20992730656	,	,	,
304953	100736309	20992730657	or	or	CC
304953	100736309	20992730658	other	other	JJ
304953	100736309	20992730659	health	health	NN1
304953	100736309	20992730660	problems	problem	NN2
304953	100736309	20992730661	.	.	.
304953	100736309	20992730662	<p>		NULL
304953	100736309	20992730663	The	the	AT
304953	100736309	20992730664	FDA	fda	NN1_NP1
304953	100736309	20992730665	generally	generally	RR
304953	100736309	20992730666	heeds	heed	VVZ
304953	100736309	20992730667	recommendations	recommendation	NN2
304953	100736309	20992730668	from	from	II
304953	100736309	20992730669	its	its	APPGE
304953	100736309	20992730670	advisory	advisory	JJ
304953	100736309	20992730671	panels	panel	NN2
304953	100736309	20992730672	"	"	"
304953	100736309	20992730673	a	a	AT1
304953	100736309	20992730674	strong	strong	JJ
304953	100736309	20992730675	indication	indication	NN1
304953	100736309	20992730676	that	that	CST_DD1
304953	100736309	20992730677	high-intensity	high-intensity	JJ_NN1
304953	100736309	20992730678	focused-		JJ_NN1
304953	100736309	20992730679	ultrasound	ultrasound	NN1
304953	100736309	20992730680	will	will	VM
304953	100736309	20992730681	not	not	XX
304953	100736309	20992730682	be	be	VBI
304953	100736309	20992730683	approved	approve	VVN
304953	100736309	20992730684	here	here	RL
304953	100736309	20992730685	any	any	DD
304953	100736309	20992730686	time	time	NNT1
304953	100736309	20992730687	soon	soon	RR
304953	100736309	20992730688	.	.	.
304953	100736309	20992730689	"	"	"
304953	100736309	20992730690	In	in	II
304953	100736309	20992730691	our	our	APPGE
304953	100736309	20992730692	view	view	NN1
304953	100736309	20992730693	,	,	,
304953	100736309	20992730694	HIFU		NP1_NN1
304953	100736309	20992730695	in	in	II
304953	100736309	20992730696	this	this	DD1
304953	100736309	20992730697	@		II
304953	100736309	20992730698	@		II
304953	100736309	20992730699	@		II
304953	100736309	20992730700	@		II
304953	100736309	20992730701	@		II
304953	100736309	20992730702	@		II
304953	100736309	20992730703	@		II
304953	100736309	20992730704	@		II
304953	100736309	20992730705	@		II
304953	100736309	20992730706	@		II
304953	100736309	20992730707	says	say	VVZ
304953	100736309	20992730708	Eric	eric	NP1
304953	100736309	20992730709	Klein	klein	NP1
304953	100736309	20992730710	,	,	,
304953	100736309	20992730711	a	a	AT1
304953	100736309	20992730712	panelist	panelist	NN1
304953	100736309	20992730713	and	and	CC
304953	100736309	20992730714	chairman	chairman	NN1
304953	100736309	20992730715	of	of	IO
304953	100736309	20992730716	the	the	AT
304953	100736309	20992730717	Glickman	glickman	NP1_NN1
304953	100736309	20992730718	Urological		NP1
304953	100736309	20992730719	and	and	CC
304953	100736309	20992730720	Kidney	kidney	NN1
304953	100736309	20992730721	Institute	institute	NN1
304953	100736309	20992730722	at	at	II
304953	100736309	20992730723	the	the	AT
304953	100736309	20992730724	Cleveland	cleveland	NP1
304953	100736309	20992730725	Clinic	clinic	NN1
304953	100736309	20992730726	.	.	.
304953	100736309	20992730727	The	the	AT
304953	100736309	20992730728	French	french	JJ_NN1
304953	100736309	20992730729	company	company	NN1
304953	100736309	20992730730	that	that	CST_DD1
304953	100736309	20992730731	was	be	VBDZ
304953	100736309	20992730732	seeking	seek	VVG
304953	100736309	20992730733	the	the	AT
304953	100736309	20992730734	FDAs	fdas	NP2_NN2
304953	100736309	20992730735	okay	okay	JJ
304953	100736309	20992730736	,	,	,
304953	100736309	20992730737	or	or	CC
304953	100736309	20992730738	another	another	DD1
304953	100736309	20992730739	company	company	NN1
304953	100736309	20992730740	,	,	,
304953	100736309	20992730741	could	could	VM
304953	100736309	20992730742	apply	apply	VVI
304953	100736309	20992730743	again	again	RT
304953	100736309	20992730744	with	with	IW
304953	100736309	20992730745	more	more	RGR_DAR
304953	100736309	20992730746	complete	complete	JJ
304953	100736309	20992730747	or	or	CC
304953	100736309	20992730748	persuasive	persuasive	JJ
304953	100736309	20992730749	data	data	NN
304953	100736309	20992730750	.	.	.
304953	100736309	20992730751	<p>		NULL
304953	100736309	20992730752	Since	since	CS
304953	100736309	20992730753	men	man	NN2
304953	100736309	20992730754	with	with	IW
304953	100736309	20992730755	localized	localized	JJ
304953	100736309	20992730756	prostate	prostate	NN1
304953	100736309	20992730757	cancer	cancer	NN1
304953	100736309	20992730758	might	might	VM
304953	100736309	20992730759	also	also	RR
304953	100736309	20992730760	be	be	VBI
304953	100736309	20992730761	candidates	candidate	NN2
304953	100736309	20992730762	for	for	IF
304953	100736309	20992730763	active	active	JJ
304953	100736309	20992730764	surveillance	surveillance	NN1
304953	100736309	20992730765	,	,	,
304953	100736309	20992730766	which	which	DDQ
304953	100736309	20992730767	spares	spare	VVZ@
304953	100736309	20992730768	them	them	PPHO2
304953	100736309	20992730769	from	from	II
304953	100736309	20992730770	side	side	NN1
304953	100736309	20992730771	effects	effect	NN2
304953	100736309	20992730772	like	like	II
304953	100736309	20992730773	erectile	erectile	JJ
304953	100736309	20992730774	dysfunction	dysfunction	NN1
304953	100736309	20992730775	and	and	CC
304953	100736309	20992730776	incontinence	incontinence	NN1
304953	100736309	20992730777	,	,	,
304953	100736309	20992730778	"	"	"
304953	100736309	20992730779	it	it	PPH1
304953	100736309	20992730780	would	would	VM
304953	100736309	20992730781	be	be	VBI
304953	100736309	20992730782	difficult	difficult	JJ
304953	100736309	20992730783	for	for	IF
304953	100736309	20992730784	me	me	PPIO1
304953	100736309	20992730785	as	as	II
304953	100736309	20992730786	a	a	AT1
304953	100736309	20992730787	practicing	practicing	JJ@_NN1@
304953	100736309	20992730788	physician	physician	NN1
304953	100736309	20992730789	to	to	TO
304953	100736309	20992730790	recommend	recommend	VVI
304953	100736309	20992730791	that	that	CST
304953	100736309	20992730792	they	they	PPHS2
304953	100736309	20992730793	be	be	VBI
304953	100736309	20992730794	treated	treat	VVN
304953	100736309	20992730795	with	with	IW
304953	100736309	20992730796	HIFU		NP1_NN1
304953	100736309	20992730797	,	,	,
304953	100736309	20992730798	"	"	"
304953	100736309	20992730799	says	say	VVZ
304953	100736309	20992730800	FDA	fda	NN1_NP1
304953	100736309	20992730801	panelist	panelist	NN1
304953	100736309	20992730802	and	and	CC
304953	100736309	20992730803	prostate	prostate	NN1
304953	100736309	20992730804	cancer	cancer	NN1
304953	100736309	20992730805	specialist	specialist	NN1
304953	100736309	20992730806	Dr.		NNB
304953	100736309	20992730807	Marc	marc	NP1
304953	100736309	20992730808	B.		NP1
304953	100736309	20992730809	Garnick		NP1
304953	100736309	20992730810	,	,	,
304953	100736309	20992730811	the	the	AT
304953	100736309	20992730812	Gorman	gorman	NN1_NP1
304953	100736309	20992730813	Brothers	brother	NN2
304953	100736309	20992730814	Professor	professor	NN1
304953	100736309	20992730815	of	of	IO
304953	100736309	20992730816	Medicine	medicine	NN1
304953	100736309	20992730817	at	at	II
304953	100736309	20992730818	Harvard	harvard	NP1
304953	100736309	20992730819	Medical	medical	JJ
304953	100736309	20992730820	School	school	NN1
304953	100736309	20992730821	and	and	CC
304953	100736309	20992730822	Beth	beth	NP1
304953	100736309	20992730823	Israel	israel	NP1
304953	100736309	20992730824	Deaconess	deaconess	NN1
304953	100736309	20992730825	Medical	medical	JJ
304953	100736309	20992730826	Center	center	NN1
304953	100736309	20992730827	,	,	,
304953	100736309	20992730828	and	and	CC
304953	100736309	20992730829	Editor	editor	NN1
304953	100736309	20992730830	in	in	II
304953	100736309	20992730831	Chief	chief	NN1
304953	100736309	20992730832	of	of	IO
304953	100736309	20992730833	Harvard	harvard	NP1
304953	100736309	20992730834	Medical	medical	JJ
304953	100736309	20992730835	Schools	school	NN2
304953	100736309	20992730836	2014	2014	MC
304953	100736309	20992730837	Annual	annual	JJ
304953	100736309	20992730838	Report	report	NN1
304953	100736309	20992730839	on	on	II
304953	100736309	20992730840	Prostate	prostate	NN1
304953	100736309	20992730841	Diseases	disease	NN2
304953	100736309	20992730842	.	.	.
304953	100736309	20992730843	<p>		NULL
304953	100736309	20992730844	Whether	whether	CSW
304953	100736309	20992730845	the	the	AT
304953	100736309	20992730846	FDA	fda	NN1_NP1
304953	100736309	20992730847	panels	panel	NN2
304953	100736309	20992730848	denial	denial	NN1
304953	100736309	20992730849	will	will	VM
304953	100736309	20992730850	affect	affect	VVI
304953	100736309	20992730851	the	the	AT
304953	100736309	20992730852	availability	availability	NN1
304953	100736309	20992730853	of	of	IO
304953	100736309	20992730854	high-intensity	high-intensity	JJ_NN1
304953	100736309	20992730855	focused-		JJ_NN1
304953	100736309	20992730856	ultrasound	ultrasound	NN1_VV0
304953	100736309	20992730857	outside	outside	II
304953	100736309	20992730858	the	the	AT
304953	100736309	20992730859	U.S.	us	NP1
304953	100736309	20992730860	is	be	VBZ
304953	100736309	20992730861	unknown	unknown	JJ
304953	100736309	20992730862	,	,	,
304953	100736309	20992730863	says	say	VVZ
304953	100736309	20992730864	Garnick		NP1_NN1
304953	100736309	20992730865	,	,	,
304953	100736309	20992730866	given	given	CS21
304953	100736309	20992730867	that	that	CS22
304953	100736309	20992730868	other	other	JJ
304953	100736309	20992730869	countries	country	NN2
304953	100736309	20992730870	base	base	VV0@
304953	100736309	20992730871	the	the	AT
304953	100736309	20992730872	approval	approval	NN1
304953	100736309	20992730873	of	of	IO
304953	100736309	20992730874	medical	medical	JJ
304953	100736309	20992730875	treatments	treatment	NN2
304953	100736309	20992730876	,	,	,
304953	100736309	20992730877	and	and	CC
304953	100736309	20992730878	in	in	II
304953	100736309	20992730879	some	some	DD
304953	100736309	20992730880	cases	case	NN2
304953	100736309	20992730881	the	the	AT
304953	100736309	20992730882	availability	availability	NN1
304953	100736309	20992730883	,	,	,
304953	100736309	20992730884	on	on	II
304953	100736309	20992730885	their	their	APPGE
304953	100736309	20992730886	own	own	DA
304953	100736309	20992730887	criteria	criteria	NN2
304953	100736309	20992730888	.	.	.
304953	100736309	20992730889	"	"	"
304953	100736309	20992730890	And	and	CC
304953	100736309	20992730891	other	other	JJ
304953	100736309	20992730892	potential	potential	JJ_NN1
304953	100736309	20992730893	indications	indication	NN2
304953	100736309	20992730894	for	for	IF
304953	100736309	20992730895	HIFU		NN1_NP1
304953	100736309	20992730896	in	in	II
304953	100736309	20992730897	@		II
304953	100736309	20992730898	@		II
304953	100736309	20992730899	@		II
304953	100736309	20992730900	@		II
304953	100736309	20992730901	@		II
304953	100736309	20992730902	@		II
304953	100736309	20992730903	@		II
304953	100736309	20992730904	@		II
304953	100736309	20992730905	@		II
304953	100736309	20992730906	@		II
304953	100736309	20992730907	says	say	VVZ
304953	100736309	20992730908	.	.	.
304953	100736310	20992730928	@@##	----------	----------
304953	100736310	20992730929	@@100736310		FO
304953	100736310	20992730930	@4936310/		VV0_NN1
304953	100736310	20992730931	46989		MC
304953	100736310	20992730932	@qwx906989		FO
304953	100736310	20992730933	<p>		NULL
304953	100736310	20992730934	Men	man	NN2
304953	100736310	20992730935	whose	whose	DDQGE
304953	100736310	20992730936	mothers	mother	NN2
304953	100736310	20992730937	,	,	,
304953	100736310	20992730938	daughters	daughter	NN2
304953	100736310	20992730939	,	,	,
304953	100736310	20992730940	or	or	CC
304953	100736310	20992730941	sisters	sister	NN2
304953	100736310	20992730942	have	have	VH0
304953	100736310	20992730943	tested	test	VVN
304953	100736310	20992730944	positive	positive	JJ
304953	100736310	20992730945	for	for	IF
304953	100736310	20992730946	the	the	AT
304953	100736310	20992730947	breast	breast	NN1
304953	100736310	20992730948	cancer	cancer	NN1
304953	100736310	20992730949	genes	gene	NN2
304953	100736310	20992730950	BRCA1	brca1	FO
304953	100736310	20992730951	and	and	CC
304953	100736310	20992730952	BRCA2	brca2	FO
304953	100736310	20992730953	may	may	VM
304953	100736310	20992730954	want	want	VVI
304953	100736310	20992730955	to	to	TO
304953	100736310	20992730956	find	find	VVI
304953	100736310	20992730957	out	out	RP
304953	100736310	20992730958	if	if	CS
304953	100736310	20992730959	they	they	PPHS2
304953	100736310	20992730960	carry	carry	VV0
304953	100736310	20992730961	the	the	AT
304953	100736310	20992730962	genes	gene	NN2
304953	100736310	20992730963	.	.	.
304953	100736310	20992730964	Studies	study	NN2
304953	100736310	20992730965	have	have	VH0
304953	100736310	20992730966	shown	show	VVN
304953	100736310	20992730967	that	that	CST_DD1
304953	100736310	20992730968	BRCA1	brca1	FO
304953	100736310	20992730969	and	and	CC
304953	100736310	20992730970	BRCA2	brca2	FO
304953	100736310	20992730971	carriers	carrier	NN2
304953	100736310	20992730972	are	be	VBR
304953	100736310	20992730973	more	more	RGR
304953	100736310	20992730974	likely	likely	JJ
304953	100736310	20992730975	to	to	TO
304953	100736310	20992730976	develop	develop	VVI
304953	100736310	20992730977	prostate	prostate	NN1
304953	100736310	20992730978	cancer	cancer	NN1
304953	100736310	20992730979	than	than	CSN
304953	100736310	20992730980	men	man	NN2
304953	100736310	20992730981	without	without	IW
304953	100736310	20992730982	them	them	PPHO2
304953	100736310	20992730983	.	.	.
304953	100736310	20992730984	Now	now	RT
304953	100736310	20992730985	a	a	AT1
304953	100736310	20992730986	British	british	JJ
304953	100736310	20992730987	study	study	NN1
304953	100736310	20992730988	suggests	suggest	VVZ
304953	100736310	20992730989	that	that	CST
304953	100736310	20992730990	these	these	DD2
304953	100736310	20992730991	men	man	NN2
304953	100736310	20992730992	are	be	VBR
304953	100736310	20992730993	also	also	RR
304953	100736310	20992730994	more	more	RGR
304953	100736310	20992730995	likely	likely	JJ
304953	100736310	20992730996	to	to	TO
304953	100736310	20992730997	suffer	suffer	VVI
304953	100736310	20992730998	from	from	II
304953	100736310	20992730999	more	more	RGR
304953	100736310	20992731000	aggressive	aggressive	JJ
304953	100736310	20992731001	forms	form	NN2
304953	100736310	20992731002	of	of	IO
304953	100736310	20992731003	the	the	AT
304953	100736310	20992731004	disease	disease	NN1
304953	100736310	20992731005	.	.	.
304953	100736310	20992731006	<p>		NULL
304953	100736310	20992731007	The	the	AT
304953	100736310	20992731008	researchers	researcher	NN2
304953	100736310	20992731009	collected	collect	VVD_VVN
304953	100736310	20992731010	20	20	MC
304953	100736310	20992731011	tissue	tissue	NN1
304953	100736310	20992731012	samples	sample	NN2_VVZ@
304953	100736310	20992731013	from	from	II
304953	100736310	20992731014	men	man	NN2
304953	100736310	20992731015	with	with	IW
304953	100736310	20992731016	the	the	AT
304953	100736310	20992731017	BRCA1	brca1	FO
304953	100736310	20992731018	or	or	CC
304953	100736310	20992731019	BRCA2	brca2	FO
304953	100736310	20992731020	genes	gene	NN2
304953	100736310	20992731021	and	and	CC
304953	100736310	20992731022	compared	compare	VVD
304953	100736310	20992731023	them	them	PPHO2
304953	100736310	20992731024	with	with	IW
304953	100736310	20992731025	samples	sample	NN2
304953	100736310	20992731026	from	from	II
304953	100736310	20992731027	patients	patient	NN2
304953	100736310	20992731028	with	with	IW
304953	100736310	20992731029	similar	similar	JJ
304953	100736310	20992731030	characteristics	characteristic	NN2
304953	100736310	20992731031	"	"	"
304953	100736310	20992731032	age	age	NN1_VV0@
304953	100736310	20992731033	,	,	,
304953	100736310	20992731034	prostate	prostate	NN1
304953	100736310	20992731035	disease	disease	NN1
304953	100736310	20992731036	stage	stage	NN1
304953	100736310	20992731037	,	,	,
304953	100736310	20992731038	and	and	CC
304953	100736310	20992731039	PSA	psa	NP1
304953	100736310	20992731040	level	level	NN1_JJ
304953	100736310	20992731041	"	"	"
304953	100736310	20992731042	but	but	CCB
304953	100736310	20992731043	not	not	XX
304953	100736310	20992731044	the	the	AT
304953	100736310	20992731045	genes	gene	NN2
304953	100736310	20992731046	.	.	.
304953	100736310	20992731047	Men	man	NN2
304953	100736310	20992731048	with	with	IW
304953	100736310	20992731049	the	the	AT
304953	100736310	20992731050	genes	gene	NN2
304953	100736310	20992731051	had	have	VHD
304953	100736310	20992731052	significantly	significantly	RR
304953	100736310	20992731053	higher	high	JJR
304953	100736310	20992731054	Gleason	gleason	NN1@_NP1
304953	100736310	20992731055	scores	score	NN2
304953	100736310	20992731056	than	than	CSN
304953	100736310	20992731057	those	those	DD2
304953	100736310	20992731058	in	in	II
304953	100736310	20992731059	the	the	AT
304953	100736310	20992731060	control	control	NN1
304953	100736310	20992731061	group	group	NN1
304953	100736310	20992731062	.	.	.
304953	100736310	20992731063	Higher	high	JJR
304953	100736310	20992731064	Gleason	gleason	NN1@_NP1
304953	100736310	20992731065	scores	score	NN2
304953	100736310	20992731066	are	be	VBR
304953	100736310	20992731067	associated	associate	VVN
304953	100736310	20992731068	with	with	IW
304953	100736310	20992731069	more	more	RGR_DAR
304953	100736310	20992731070	aggressive	aggressive	JJ
304953	100736310	20992731071	cancer	cancer	NN1
304953	100736310	20992731072	and	and	CC
304953	100736310	20992731073	poorer	poor	JJR
304953	100736310	20992731074	outcome	outcome	NN1
304953	100736310	20992731075	.	.	.
304953	100736310	20992731076	<p>		NULL
304953	100736310	20992731077	Targeted	target	VVN_JJ%_VVD
304953	100736310	20992731078	screening	screening	NN1
304953	100736310	20992731079	of	of	IO
304953	100736310	20992731080	male	male	NN1_JJ
304953	100736310	20992731081	BRCA1	brca1	FO
304953	100736310	20992731082	and	and	CC
304953	100736310	20992731083	BRCA2	brca2	FO
304953	100736310	20992731084	carriers	carrier	NN2
304953	100736310	20992731085	,	,	,
304953	100736310	20992731086	the	the	AT
304953	100736310	20992731087	researchers	researcher	NN2
304953	100736310	20992731088	say	say	VV0
304953	100736310	20992731089	,	,	,
304953	100736310	20992731090	could	could	VM
304953	100736310	20992731091	detect	detect	VVI
304953	100736310	20992731092	prostate	prostate	NN1
304953	100736310	20992731093	disease	disease	NN1
304953	100736310	20992731094	at	at	II
304953	100736310	20992731095	an	a	AT1
304953	100736310	20992731096	earlier	early	JJR
304953	100736310	20992731097	stage	stage	NN1
304953	100736310	20992731098	,	,	,
304953	100736310	20992731099	possibly	possibly	RR
304953	100736310	20992731100	improving	improve	VVG
304953	100736310	20992731101	a	a	AT1
304953	100736310	20992731102	patient	patient	NN1
304953	100736310	20992731103	's	's	GE
304953	100736310	20992731104	chances	chance	NN2
304953	100736310	20992731105	of	of	IO
304953	100736310	20992731106	a	a	AT1
304953	100736310	20992731107	successful	successful	JJ
304953	100736310	20992731108	treatment	treatment	NN1
304953	100736310	20992731109	.	.	.
304953	100736310	20992731110	46996		MC
304953	100736310	20992731111	@qwx906996		FO
304953	100736313	20992731131	@@##	----------	----------
304953	100736313	20992731132	@@100736313		FO
304953	100736313	20992731133	@4936313/		VV0_NN1
304953	100736313	20992731134	46989		MC
304953	100736313	20992731135	@qwx906989		FO
304953	100736313	20992731136	<p>		NULL
304953	100736313	20992731137	Screening	screen	VVG_NN1
304953	100736313	20992731138	for	for	IF
304953	100736313	20992731139	prostate	prostate	NN1
304953	100736313	20992731140	cancer	cancer	NN1
304953	100736313	20992731141	leads	lead	VVZ
304953	100736313	20992731142	to	to	II
304953	100736313	20992731143	so	so	RG
304953	100736313	20992731144	much	much	DA1
304953	100736313	20992731145	anxiety	anxiety	NN1
304953	100736313	20992731146	"	"	"
304953	100736313	20992731147	and	and	CC
304953	100736313	20992731148	so	so	RG
304953	100736313	20992731149	many	many	DA2
304953	100736313	20992731150	unnecessary	unnecessary	JJ
304953	100736313	20992731151	biopsies	biopsy	NN2
304953	100736313	20992731152	,	,	,
304953	100736313	20992731153	surgeries	surgery	NN2
304953	100736313	20992731154	,	,	,
304953	100736313	20992731155	and	and	CC
304953	100736313	20992731156	complications	complication	NN2
304953	100736313	20992731157	"	"	"
304953	100736313	20992731158	that	that	CST
304953	100736313	20992731159	doctors	doctor	NN2
304953	100736313	20992731160	should	should	VM
304953	100736313	20992731161	stop	stop	VVI
304953	100736313	20992731162	testing	test	VVG_NN1_JJ@
304953	100736313	20992731163	men	man	NN2
304953	100736313	20992731164	who	who	PNQS
304953	100736313	20992731165	are	be	VBR
304953	100736313	20992731166	75	75	MC
304953	100736313	20992731167	or	or	CC
304953	100736313	20992731168	older	old	JJR
304953	100736313	20992731169	,	,	,
304953	100736313	20992731170	according	according	II21
304953	100736313	20992731171	to	to	II22
304953	100736313	20992731172	a	a	AT1
304953	100736313	20992731173	new	new	JJ
304953	100736313	20992731174	recommendation	recommendation	NN1
304953	100736313	20992731175	from	from	II
304953	100736313	20992731176	the	the	AT
304953	100736313	20992731177	U.S.	us	NP1
304953	100736313	20992731178	Preventive	preventive	JJ
304953	100736313	20992731179	Services	service	NN2
304953	100736313	20992731180	Task	task	NN1
304953	100736313	20992731181	Force	force	NN1
304953	100736313	20992731182	announced	announce	VVN_VVD
304953	100736313	20992731183	in	in	II
304953	100736313	20992731184	August	august	NPM1
304953	100736313	20992731185	2008	2008	MC
304953	100736313	20992731186	.	.	.
304953	100736313	20992731187	The	the	AT
304953	100736313	20992731188	panel	panel	NN1
304953	100736313	20992731189	also	also	RR
304953	100736313	20992731190	concluded	conclude	VVN_VVD
304953	100736313	20992731191	that	that	CST
304953	100736313	20992731192	the	the	AT
304953	100736313	20992731193	benefit	benefit	NN1
304953	100736313	20992731194	of	of	IO
304953	100736313	20992731195	screening	screen	VVG_NN1
304953	100736313	20992731196	in	in	II
304953	100736313	20992731197	younger	young	JJR
304953	100736313	20992731198	men	man	NN2
304953	100736313	20992731199	is	be	VBZ
304953	100736313	20992731200	uncertain	uncertain	JJ
304953	100736313	20992731201	.	.	.
304953	100736313	20992731202	<p>		NULL
304953	100736313	20992731203	In	in	II
304953	100736313	20992731204	the	the	AT
304953	100736313	20992731205	United	united	NP1
304953	100736313	20992731206	States	state	NP1
304953	100736313	20992731207	,	,	,
304953	100736313	20992731208	more	more	DAR
304953	100736313	20992731209	than	than	CSN
304953	100736313	20992731210	218,000	218,000	MC
304953	100736313	20992731211	men	man	NN2
304953	100736313	20992731212	are	be	VBR
304953	100736313	20992731213	diagnosed	diagnose	VVN
304953	100736313	20992731214	with	with	IW
304953	100736313	20992731215	prostate	prostate	NN1
304953	100736313	20992731216	cancer	cancer	NN1
304953	100736313	20992731217	and	and	CC
304953	100736313	20992731218	about	about	RG
304953	100736313	20992731219	28,000	28,000	MC
304953	100736313	20992731220	die	die	VV0_NN1%
304953	100736313	20992731221	of	of	IO
304953	100736313	20992731222	it	it	PPH1
304953	100736313	20992731223	each	each	DD1
304953	100736313	20992731224	year	year	NNT1
304953	100736313	20992731225	.	.	.
304953	100736313	20992731226	Physicians	physician	NN2
304953	100736313	20992731227	most	most	RGT
304953	100736313	20992731228	often	often	RR
304953	100736313	20992731229	screen	screen	VV0@_NN1
304953	100736313	20992731230	for	for	IF
304953	100736313	20992731231	the	the	AT
304953	100736313	20992731232	disease	disease	NN1
304953	100736313	20992731233	with	with	IW
304953	100736313	20992731234	blood	blood	NN1
304953	100736313	20992731235	tests	test	NN2_VVZ@
304953	100736313	20992731236	to	to	TO
304953	100736313	20992731237	check	check	VVI
304953	100736313	20992731238	for	for	IF
304953	100736313	20992731239	prostate-specific	prostate-specific	JJ
304953	100736313	20992731240	antigen	antigen	NN1
304953	100736313	20992731241	(	(	(
304953	100736313	20992731242	PSA	psa	NP1
304953	100736313	20992731243	)	)	)
304953	100736313	20992731244	and	and	CC
304953	100736313	20992731245	digital	digital	JJ
304953	100736313	20992731246	rectal	rectal	JJ
304953	100736313	20992731247	exams	exam	NN2
304953	100736313	20992731248	;	;	;
304953	100736313	20992731249	of	of	IO
304953	100736313	20992731250	the	the	AT
304953	100736313	20992731251	two	two	MC
304953	100736313	20992731252	,	,	,
304953	100736313	20992731253	the	the	AT
304953	100736313	20992731254	PSA	psa	NP1
304953	100736313	20992731255	test	test	NN1
304953	100736313	20992731256	is	be	VBZ
304953	100736313	20992731257	more	more	RGR
304953	100736313	20992731258	likely	likely	JJ
304953	100736313	20992731259	to	to	TO
304953	100736313	20992731260	detect	detect	VVI
304953	100736313	20992731261	prostate	prostate	NN1
304953	100736313	20992731262	cancer	cancer	NN1
304953	100736313	20992731263	,	,	,
304953	100736313	20992731264	especially	especially	RR
304953	100736313	20992731265	during	during	II
304953	100736313	20992731266	early	early	JJ
304953	100736313	20992731267	stages	stage	NN2
304953	100736313	20992731268	of	of	IO
304953	100736313	20992731269	development	development	NN1
304953	100736313	20992731270	.	.	.
304953	100736313	20992731271	Men	man	NN2
304953	100736313	20992731272	with	with	IW
304953	100736313	20992731273	an	a	AT1
304953	100736313	20992731274	elevated	elevated	JJ
304953	100736313	20992731275	PSA	psa	NP1
304953	100736313	20992731276	may	may	VM
304953	100736313	20992731277	then	then	RT
304953	100736313	20992731278	have	have	VHI
304953	100736313	20992731279	a	a	AT1
304953	100736313	20992731280	biopsy	biopsy	NN1
304953	100736313	20992731281	and	and	CC
304953	100736313	20992731282	,	,	,
304953	100736313	20992731283	depending	depending	II21
304953	100736313	20992731284	on	on	II22
304953	100736313	20992731285	the	the	AT
304953	100736313	20992731286	results	result	NN2
304953	100736313	20992731287	,	,	,
304953	100736313	20992731288	undergo	undergo	VV0
304953	100736313	20992731289	treatment	treatment	NN1
304953	100736313	20992731290	.	.	.
304953	100736313	20992731291	Complications	complication	NN2
304953	100736313	20992731292	often	often	RR
304953	100736313	20992731293	result	result	VV0
304953	100736313	20992731294	,	,	,
304953	100736313	20992731295	including	including	II_VVG@
304953	100736313	20992731296	urinary	urinary	JJ_NN1
304953	100736313	20992731297	incontinence	incontinence	NN1
304953	100736313	20992731298	and	and	CC
304953	100736313	20992731299	impotence	impotence	NN1
304953	100736313	20992731300	.	.	.
304953	100736313	20992731301	<p>		NULL
304953	100736313	20992731302	However	however	RR
304953	100736313	20992731303	,	,	,
304953	100736313	20992731304	cancers	cancer	NN2
304953	100736313	20992731305	discovered	discover	VVD_VVN@
304953	100736313	20992731306	through	through	II
304953	100736313	20992731307	PSA	psa	NP1
304953	100736313	20992731308	testing	testing	NN1_VVG_JJ@
304953	100736313	20992731309	take	take	NN1%
304953	100736313	20992731310	years	year	NNT2
304953	100736313	20992731311	to	to	TO
304953	100736313	20992731312	affect	affect	VVI
304953	100736313	20992731313	health	health	NN1
304953	100736313	20992731314	,	,	,
304953	100736313	20992731315	and	and	CC
304953	100736313	20992731316	those	those	DD2
304953	100736313	20992731317	that	that	CST
304953	100736313	20992731318	are	be	VBR
304953	100736313	20992731319	serious	serious	JJ
304953	100736313	20992731320	enough	enough	RR
304953	100736313	20992731321	to	to	TO
304953	100736313	20992731322	kill	kill	VVI
304953	100736313	20992731323	@		II
304953	100736313	20992731324	@		II
304953	100736313	20992731325	@		II
304953	100736313	20992731326	@		II
304953	100736313	20992731327	@		II
304953	100736313	20992731328	@		II
304953	100736313	20992731329	@		II
304953	100736313	20992731330	@		II
304953	100736313	20992731331	@		II
304953	100736313	20992731332	@		II
304953	100736313	20992731333	a	a	AT1
304953	100736313	20992731334	75-year-old	75-year-old	JJ
304953	100736313	20992731335	man	man	NN1
304953	100736313	20992731336	has	have	VHZ
304953	100736313	20992731337	an	a	AT1
304953	100736313	20992731338	average	average	JJ_NN1
304953	100736313	20992731339	life	life	NN1
304953	100736313	20992731340	expectancy	expectancy	NN1
304953	100736313	20992731341	of	of	IO
304953	100736313	20992731342	about	about	RG
304953	100736313	20992731343	10	10	MC
304953	100736313	20992731344	years	year	NNT2
304953	100736313	20992731345	and	and	CC
304953	100736313	20992731346	is	be	VBZ
304953	100736313	20992731347	more	more	RGR
304953	100736313	20992731348	likely	likely	JJ
304953	100736313	20992731349	to	to	TO
304953	100736313	20992731350	die	die	VVI
304953	100736313	20992731351	from	from	II
304953	100736313	20992731352	other	other	JJ
304953	100736313	20992731353	causes	cause	NN2
304953	100736313	20992731354	,	,	,
304953	100736313	20992731355	such	such	II21
304953	100736313	20992731356	as	as	II22
304953	100736313	20992731357	heart	heart	NN1
304953	100736313	20992731358	disease	disease	NN1
304953	100736313	20992731359	or	or	CC
304953	100736313	20992731360	stroke	stroke	NN1_VV0
304953	100736313	20992731361	,	,	,
304953	100736313	20992731362	prostate	prostate	NN1
304953	100736313	20992731363	screening	screening	NN1
304953	100736313	20992731364	is	be	VBZ
304953	100736313	20992731365	unlikely	unlikely	JJ
304953	100736313	20992731366	to	to	TO
304953	100736313	20992731367	help	help	VVI
304953	100736313	20992731368	men	man	NN2
304953	100736313	20992731369	who	who	PNQS
304953	100736313	20992731370	are	be	VBR
304953	100736313	20992731371	75	75	MC
304953	100736313	20992731372	or	or	CC
304953	100736313	20992731373	older	old	JJR
304953	100736313	20992731374	to	to	TO
304953	100736313	20992731375	live	live	VVI
304953	100736313	20992731376	longer	long	RRR_JJR
304953	100736313	20992731377	,	,	,
304953	100736313	20992731378	the	the	AT
304953	100736313	20992731379	panel	panel	NN1
304953	100736313	20992731380	determined	determine	VVN_VVD@_JJ
304953	100736313	20992731381	.	.	.
304953	100736313	20992731382	Men	man	NN2
304953	100736313	20992731383	younger	young	JJR
304953	100736313	20992731384	than	than	CSN
304953	100736313	20992731385	75	75	MC
304953	100736313	20992731386	with	with	IW
304953	100736313	20992731387	chronic	chronic	JJ
304953	100736313	20992731388	medical	medical	JJ
304953	100736313	20992731389	problems	problem	NN2
304953	100736313	20992731390	and	and	CC
304953	100736313	20992731391	a	a	AT1
304953	100736313	20992731392	life	life	NN1
304953	100736313	20992731393	expectancy	expectancy	NN1
304953	100736313	20992731394	of	of	IO
304953	100736313	20992731395	less	less	DAR
304953	100736313	20992731396	than	than	CSN
304953	100736313	20992731397	10	10	MC
304953	100736313	20992731398	years	year	NNT2
304953	100736313	20992731399	are	be	VBR
304953	100736313	20992731400	also	also	RR
304953	100736313	20992731401	unlikely	unlikely	JJ
304953	100736313	20992731402	to	to	TO
304953	100736313	20992731403	benefit	benefit	VVI
304953	100736313	20992731404	from	from	II
304953	100736313	20992731405	screening	screening	NN1_VVG
304953	100736313	20992731406	,	,	,
304953	100736313	20992731407	according	according	II21
304953	100736313	20992731408	to	to	II22
304953	100736313	20992731409	the	the	AT
304953	100736313	20992731410	task	task	NN1
304953	100736313	20992731411	force	force	NN1
304953	100736313	20992731412	.	.	.
304953	100736313	20992731413	<p>		NULL
304953	100736313	20992731414	The	the	AT
304953	100736313	20992731415	panel	panel	NN1
304953	100736313	20992731416	did	do	VDD
304953	100736313	20992731417	not	not	XX
304953	100736313	20992731418	find	find	VVI
304953	100736313	20992731419	enough	enough	DD
304953	100736313	20992731420	evidence	evidence	NN1
304953	100736313	20992731421	to	to	TO
304953	100736313	20992731422	assess	assess	VVI
304953	100736313	20992731423	whether	whether	CSW
304953	100736313	20992731424	the	the	AT
304953	100736313	20992731425	benefits	benefit	NN2
304953	100736313	20992731426	of	of	IO
304953	100736313	20992731427	PSA	psa	NP1
304953	100736313	20992731428	testing	testing	NN1_VVG
304953	100736313	20992731429	outweigh	outweigh	VV0_NN1
304953	100736313	20992731430	the	the	AT
304953	100736313	20992731431	risks	risk	NN2
304953	100736313	20992731432	in	in	II
304953	100736313	20992731433	younger	young	JJR
304953	100736313	20992731434	,	,	,
304953	100736313	20992731435	healthy	healthy	JJ
304953	100736313	20992731436	men	man	NN2
304953	100736313	20992731437	.	.	.
304953	100736313	20992731438	Instead	instead	RR
304953	100736313	20992731439	,	,	,
304953	100736313	20992731440	the	the	AT
304953	100736313	20992731441	panel	panel	NN1
304953	100736313	20992731442	encouraged	encourage	VVD_VVN
304953	100736313	20992731443	men	man	NN2
304953	100736313	20992731444	to	to	TO
304953	100736313	20992731445	talk	talk	VVI
304953	100736313	20992731446	with	with	IW
304953	100736313	20992731447	their	their	APPGE
304953	100736313	20992731448	doctor	doctor	NN1
304953	100736313	20992731449	about	about	II
304953	100736313	20992731450	the	the	AT
304953	100736313	20992731451	potential	potential	JJ_NN1
304953	100736313	20992731452	benefits	benefit	NN2
304953	100736313	20992731453	and	and	CC
304953	100736313	20992731454	possible	possible	JJ
304953	100736313	20992731455	harms	harm	NN2
304953	100736313	20992731456	of	of	IO
304953	100736313	20992731457	getting	get	VVG
304953	100736313	20992731458	the	the	AT
304953	100736313	20992731459	PSA	psa	NP1
304953	100736313	20992731460	test	test	NN1_VV0
304953	100736313	20992731461	before	before	CS
304953	100736313	20992731462	they	they	PPHS2
304953	100736313	20992731463	opt	opt	VV0
304953	100736313	20992731464	for	for	IF
304953	100736313	20992731465	screening	screening	NN1_VVG
304953	100736313	20992731466	.	.	.
304953	100736313	20992731467	<p>		NULL
304953	100736313	20992731468	The	the	AT
304953	100736313	20992731469	U.S.	us	NP1
304953	100736313	20992731470	Preventive	preventive	JJ
304953	100736313	20992731471	Services	service	NN2
304953	100736313	20992731472	Task	task	NN1
304953	100736313	20992731473	Force	force	NN1
304953	100736313	20992731474	is	be	VBZ
304953	100736313	20992731475	the	the	AT
304953	100736313	20992731476	first	first	MD
304953	100736313	20992731477	group	group	NN1
304953	100736313	20992731478	to	to	TO
304953	100736313	20992731479	define	define	VVI
304953	100736313	20992731480	an	a	AT1
304953	100736313	20992731481	explicit	explicit	JJ
304953	100736313	20992731482	age	age	NN1
304953	100736313	20992731483	above	above	II
304953	100736313	20992731484	which	which	DDQ
304953	100736313	20992731485	screening	screening	NN1
304953	100736313	20992731486	is	be	VBZ
304953	100736313	20992731487	likely	likely	JJ
304953	100736313	20992731488	to	to	TO
304953	100736313	20992731489	be	be	VBI
304953	100736313	20992731490	ineffective	ineffective	JJ
304953	100736313	20992731491	or	or	CC
304953	100736313	20992731492	harmful	harmful	JJ
304953	100736313	20992731493	.	.	.
304953	100736313	20992731494	The	the	AT
304953	100736313	20992731495	results	result	NN2
304953	100736313	20992731496	of	of	IO
304953	100736313	20992731497	two	two	MC
304953	100736313	20992731498	ongoing	ongoing	JJ
304953	100736313	20992731499	trials	trial	NN2
304953	100736313	20992731500	"	"	"
304953	100736313	20992731501	the	the	AT
304953	100736313	20992731502	National	national	JJ
304953	100736313	20992731503	Cancer	cancer	NN1
304953	100736313	20992731504	Institute	institute	NN1
304953	100736313	20992731505	's	's	GE
304953	100736313	20992731506	Prostate	prostate	NN1
304953	100736313	20992731507	,	,	,
304953	100736313	20992731508	Lung	lung	NN1
304953	100736313	20992731509	,	,	,
304953	100736313	20992731510	Colorectal		NP1_JJ
304953	100736313	20992731511	,	,	,
304953	100736313	20992731512	and	and	CC
304953	100736313	20992731513	Ovarian	ovarian	JJ
304953	100736313	20992731514	Cancer	cancer	NN1
304953	100736313	20992731515	Screening	screening	NN1_VVG
304953	100736313	20992731516	Trial	trial	NN1
304953	100736313	20992731517	and	and	CC
304953	100736313	20992731518	the	the	AT
304953	100736313	20992731519	European	european	JJ_NN1
304953	100736313	20992731520	Randomized	randomized	JJ
304953	100736313	20992731521	Study	study	NN1
304953	100736313	20992731522	of	of	IO
304953	100736313	20992731523	@		II
304953	100736313	20992731524	@		II
304953	100736313	20992731525	@		II
304953	100736313	20992731526	@		II
304953	100736313	20992731527	@		II
304953	100736313	20992731528	@		II
304953	100736313	20992731529	@		II
304953	100736313	20992731530	@		II
304953	100736313	20992731531	@		II
304953	100736313	20992731532	@		II
304953	100736313	20992731533	potential	potential	JJ_NN1
304953	100736313	20992731534	benefits	benefit	NN2
304953	100736313	20992731535	of	of	IO
304953	100736313	20992731536	screening	screen	VVG_NN1
304953	100736313	20992731537	in	in	II_RP@
304953	100736313	20992731538	men	man	NN2
304953	100736313	20992731539	under	under	II
304953	100736313	20992731540	the	the	AT
304953	100736313	20992731541	age	age	NN1
304953	100736313	20992731542	of	of	IO
304953	100736313	20992731543	75.		MC
304953	100736313	20992731544	*	*	FU
304953	100736313	20992731545	<p>		NULL
304953	100736313	20992731546	Hi	hi	UH
304953	100736313	20992731547	,	,	,
304953	100736313	20992731548	I 'm		VV0
304953	100736313	20992731549	an	a	AT1
304953	100736313	20992731550	fresh	fresh	JJ
304953	100736313	20992731551	MBA	mba	NN1
304953	100736313	20992731552	graduate	graduate	NN1
304953	100736313	20992731553	who	who	PNQS
304953	100736313	20992731554	is	be	VBZ
304953	100736313	20992731555	prareping		VVG
304953	100736313	20992731556	for	for	IF
304953	100736313	20992731557	2nd	2nd	MD
304953	100736313	20992731558	round	round	II_JJ
304953	100736313	20992731559	BCG	bcg	NP1
304953	100736313	20992731560	interview	interview	NN1
304953	100736313	20992731561	.	.	.
304953	100736313	20992731562	Ive	ive	NN1
304953	100736313	20992731563	been	be	VBN
304953	100736313	20992731564	practicing	practice	VVG
304953	100736313	20992731565	interviews	interview	NN2
304953	100736313	20992731566	for	for	IF
304953	100736313	20992731567	a	a	AT1
304953	100736313	20992731568	few	few	DA2
304953	100736313	20992731569	months	month	NNT2
304953	100736313	20992731570	and	and	CC
304953	100736313	20992731571	have	have	VH0
304953	100736313	20992731572	a	a	AT1
304953	100736313	20992731573	good	good	JJ
304953	100736313	20992731574	collection	collection	NN1
304953	100736313	20992731575	of	of	IO
304953	100736313	20992731576	case	case	NN1
304953	100736313	20992731577	books	book	NN2
304953	100736313	20992731578	.	.	.
304953	100736313	20992731579	Previously	previously	RR
304953	100736313	20992731580	I	i	PPIS1
304953	100736313	20992731581	had	have	VHD
304953	100736313	20992731582	interviews	interview	NN2
304953	100736313	20992731583	with	with	IW
304953	100736313	20992731584	Bain	bain	FW
304953	100736313	20992731585	,	,	,
304953	100736313	20992731586	Roland	roland	NP1
304953	100736313	20992731587	Berger	berger	NP1
304953	100736313	20992731588	and	and	CC
304953	100736313	20992731589	Siemens	siemens	NP1
304953	100736313	20992731590	Internal	internal	JJ
304953	100736313	20992731591	Cougnltins		NP2_NN2@
304953	100736313	20992731592	.	.	.
304953	100736313	20992731593	I 'm		VV0_NN1
304953	100736313	20992731594	looking	look	VVG
304953	100736313	20992731595	for	for	IF
304953	100736313	20992731596	a	a	AT1
304953	100736313	20992731597	partner	partner	NN1
304953	100736313	20992731598	who	who	PNQS
304953	100736313	20992731599	preferably	preferably	RR
304953	100736313	20992731600	also	also	RR
304953	100736313	20992731601	have	have	VH0
304953	100736313	20992731602	some	some	DD
304953	100736313	20992731603	live	live	JJ
304953	100736313	20992731604	experience	experience	NN1
304953	100736313	20992731605	with	with	IW
304953	100736313	20992731606	case	case	NN1
304953	100736313	20992731607	interviews	interview	NN2
304953	100736313	20992731608	.	.	.
304953	100736313	20992731609	I 'm		VV0
304953	100736313	20992731610	currently	currently	RR
304953	100736313	20992731611	in	in	II
304953	100736313	20992731612	Shanghai	shanghai	NP1
304953	100736313	20992731613	.	.	.
304953	100736313	20992731614	Can	can	VM
304953	100736313	20992731615	do	do	VDI
304953	100736313	20992731616	practice	practice	NN1
304953	100736313	20992731617	in	in	II
304953	100736313	20992731618	the	the	AT
304953	100736313	20992731619	next	next	MD
304953	100736313	20992731620	2	2	MC
304953	100736313	20992731621	weeks	week	NNT2
304953	100736313	20992731622	after	after	II
304953	100736313	20992731623	7pm	7pm	RA
304953	100736313	20992731624	during	during	II
304953	100736313	20992731625	the	the	AT
304953	100736313	20992731626	weekdays	weekday	NNT2
304953	100736313	20992731627	and	and	CC
304953	100736313	20992731628	flexible	flexible	JJ
304953	100736313	20992731629	on	on	II
304953	100736313	20992731630	weekends	weekend	NNT2
304953	100736313	20992731631	.	.	.
304953	100736313	20992731632	If	if	CS
304953	100736313	20992731633	anyone	anyone	PN1
304953	100736313	20992731634	is	be	VBZ
304953	100736313	20992731635	interested	interested	JJ
304953	100736313	20992731636	in	in	II
304953	100736313	20992731637	talking	talk	VVG
304953	100736313	20992731638	with	with	IW
304953	100736313	20992731639	me	me	PPIO1
304953	100736313	20992731640	,	,	,
304953	100736313	20992731641	please	please	RR
304953	100736313	20992731642	drop	drop	VV0
304953	100736313	20992731643	me	me	PPIO1
304953	100736313	20992731644	a	a	AT1
304953	100736313	20992731645	note	note	NN1
304953	100736313	20992731646	at	at	II
304953	100736313	20992731647	.	.	.
304953	100736313	20992731648	46996		MC
304953	100736313	20992731649	@qwx906996		FO
304953	100736314	20992731669	@@##	----------	----------
304953	100736314	20992731670	@@100736314		FO
304953	100736314	20992731671	@4936314/		VV0_NN1
304953	100736314	20992731672	46989		MC
304953	100736314	20992731673	@qwx906989		FO
304953	100736314	20992731674	<p>		NULL
304953	100736314	20992731675	Following	follow	VVG_II@_JJ@
304953	100736314	20992731676	radical	radical	JJ_NN1
304953	100736314	20992731677	prostatectomy	prostatectomy	NN1
304953	100736314	20992731678	,	,	,
304953	100736314	20992731679	a	a	AT1
304953	100736314	20992731680	significant	significant	JJ
304953	100736314	20992731681	number	number	NN1
304953	100736314	20992731682	of	of	IO
304953	100736314	20992731683	patients	patient	NN2
304953	100736314	20992731684	notice	notice	VV0
304953	100736314	20992731685	a	a	AT1
304953	100736314	20992731686	progressive	progressive	JJ
304953	100736314	20992731687	shortening	shortening	NN1@
304953	100736314	20992731688	of	of	IO
304953	100736314	20992731689	the	the	AT
304953	100736314	20992731690	penis	penis	NN1
304953	100736314	20992731691	,	,	,
304953	100736314	20992731692	a	a	AT1
304953	100736314	20992731693	fact	fact	NN1
304953	100736314	20992731694	confirmed	confirm	VVN_VVD
304953	100736314	20992731695	in	in	II
304953	100736314	20992731696	recent	recent	JJ
304953	100736314	20992731697	studies	study	NN2
304953	100736314	20992731698	.	.	.
304953	100736314	20992731699	To	to	TO
304953	100736314	20992731700	better	better	RRR
304953	100736314	20992731701	understand	understand	VVI
304953	100736314	20992731702	why	why	RRQ
304953	100736314	20992731703	,	,	,
304953	100736314	20992731704	Italian	italian	JJ_NN1
304953	100736314	20992731705	researchers	researcher	NN2
304953	100736314	20992731706	measured	measure	VVD_VVN
304953	100736314	20992731707	the	the	AT
304953	100736314	20992731708	length	length	NN1
304953	100736314	20992731709	of	of	IO
304953	100736314	20992731710	the	the	AT
304953	100736314	20992731711	flaccid	flaccid	JJ
304953	100736314	20992731712	and	and	CC
304953	100736314	20992731713	stretched	stretched	JJ@_VVD_VVN
304953	100736314	20992731714	penis	penis	NN1
304953	100736314	20992731715	in	in	II
304953	100736314	20992731716	126	126	MC
304953	100736314	20992731717	patients	patient	NN2
304953	100736314	20992731718	at	at	II
304953	100736314	20992731719	five	five	MC
304953	100736314	20992731720	time	time	NNT1
304953	100736314	20992731721	points	point	VVZ_NN2
304953	100736314	20992731722	:	:	:
304953	100736314	20992731723	just	just	RR
304953	100736314	20992731724	before	before	II_CS
304953	100736314	20992731725	surgery	surgery	NN1
304953	100736314	20992731726	,	,	,
304953	100736314	20992731727	when	when	CS_RRQ
304953	100736314	20992731728	the	the	AT
304953	100736314	20992731729	catheter	catheter	NN1
304953	100736314	20992731730	was	be	VBDZ
304953	100736314	20992731731	removed	remove	VVN
304953	100736314	20992731732	7	7	MC
304953	100736314	20992731733	to	to	II
304953	100736314	20992731734	10	10	MC
304953	100736314	20992731735	days	day	NNT2
304953	100736314	20992731736	later	later	RRR
304953	100736314	20992731737	,	,	,
304953	100736314	20992731738	and	and	CC
304953	100736314	20992731739	at	at	II
304953	100736314	20992731740	3	3	MC
304953	100736314	20992731741	,	,	,
304953	100736314	20992731742	6	6	MC
304953	100736314	20992731743	,	,	,
304953	100736314	20992731744	and	and	CC
304953	100736314	20992731745	12	12	MC
304953	100736314	20992731746	months	month	NNT2
304953	100736314	20992731747	postoperatively	postoperatively	RR
304953	100736314	20992731748	.	.	.
304953	100736314	20992731749	They	they	PPHS2
304953	100736314	20992731750	reported	report	VVD
304953	100736314	20992731751	that	that	DD1_CST
304953	100736314	20992731752	shortening	shortening	NN1@_VVG
304953	100736314	20992731753	peaked	peak	VVN_VVD
304953	100736314	20992731754	at	at	II
304953	100736314	20992731755	the	the	AT
304953	100736314	20992731756	time	time	NNT1
304953	100736314	20992731757	the	the	AT
304953	100736314	20992731758	catheter	catheter	NN1
304953	100736314	20992731759	was	be	VBDZ
304953	100736314	20992731760	removed	remove	VVN
304953	100736314	20992731761	and	and	CC
304953	100736314	20992731762	continued	continue	VVN
304953	100736314	20992731763	,	,	,
304953	100736314	20992731764	though	though	CS_RR@
304953	100736314	20992731765	to	to	II
304953	100736314	20992731766	a	a	AT1
304953	100736314	20992731767	lesser	lesser	JJ
304953	100736314	20992731768	extent	extent	NN1
304953	100736314	20992731769	,	,	,
304953	100736314	20992731770	for	for	IF_CS%
304953	100736314	20992731771	at	at	RR21
304953	100736314	20992731772	least	least	RR22
304953	100736314	20992731773	a	a	AT1
304953	100736314	20992731774	year	year	NNT1
304953	100736314	20992731775	.	.	.
304953	100736314	20992731776	(	(	(
304953	100736314	20992731777	The	the	AT
304953	100736314	20992731778	average	average	JJ_NN1
304953	100736314	20992731779	reduction	reduction	NN1
304953	100736314	20992731780	in	in	II
304953	100736314	20992731781	length	length	NN1
304953	100736314	20992731782	after	after	II_CS
304953	100736314	20992731783	one	one	MC1
304953	100736314	20992731784	year	year	NNT1
304953	100736314	20992731785	was	be	VBDZ
304953	100736314	20992731786	just	just	RR
304953	100736314	20992731787	over	over	II_RP
304953	100736314	20992731788	a	a	AT1
304953	100736314	20992731789	half	half	DB_RR@
304953	100736314	20992731790	inch	inch	VV0%
304953	100736314	20992731791	when	when	RRQ_CS
304953	100736314	20992731792	flaccid	flaccid	JJ
304953	100736314	20992731793	and	and	CC
304953	100736314	20992731794	nearly	nearly	RR
304953	100736314	20992731795	an	a	AT1
304953	100736314	20992731796	inch	inch	NNU1
304953	100736314	20992731797	when	when	CS
304953	100736314	20992731798	stretched	stretch	VVN_VVD
304953	100736314	20992731799	.	.	.
304953	100736314	20992731800	)	)	)
304953	100736314	20992731801	Interestingly	interestingly	RR
304953	100736314	20992731802	,	,	,
304953	100736314	20992731803	men	man	NN2
304953	100736314	20992731804	who	who	PNQS
304953	100736314	20992731805	had	have	VHD
304953	100736314	20992731806	nerve-sparing		JJ
304953	100736314	20992731807	surgery	surgery	NN1
304953	100736314	20992731808	,	,	,
304953	100736314	20992731809	as	as	II31_RG
304953	100736314	20992731810	well	well	II32_RR
304953	100736314	20992731811	as	as	II33_CSA
304953	100736314	20992731812	those	those	DD2
304953	100736314	20992731813	who	who	PNQS
304953	100736314	20992731814	recovered	recover	VVD
304953	100736314	20992731815	some	some	DD
304953	100736314	20992731816	erectile	erectile	JJ
304953	100736314	20992731817	function	function	NN1
304953	100736314	20992731818	during	during	II
304953	100736314	20992731819	the	the	AT
304953	100736314	20992731820	year	year	NNT1
304953	100736314	20992731821	of	of	IO
304953	100736314	20992731822	follow-up	follow-up	NN1_JJ
304953	100736314	20992731823	,	,	,
304953	100736314	20992731824	lost	lose	VVD_VVN
304953	100736314	20992731825	less	less	DAR
304953	100736314	20992731826	length	length	NN1
304953	100736314	20992731827	than	than	CSN
304953	100736314	20992731828	other	other	JJ
304953	100736314	20992731829	study	study	NN1
304953	100736314	20992731830	participants	participant	NN2
304953	100736314	20992731831	.	.	.
304953	100736314	20992731832	<p>		NULL
304953	100736314	20992731833	The	the	AT
304953	100736314	20992731834	researchers	researcher	NN2
304953	100736314	20992731835	theorize	theorize	VV0
304953	100736314	20992731836	that	that	CST
304953	100736314	20992731837	the	the	AT
304953	100736314	20992731838	death	death	NN1
304953	100736314	20992731839	of	of	IO
304953	100736314	20992731840	nerve	nerve	NN1
304953	100736314	20992731841	cells	cell	NN2
304953	100736314	20992731842	and	and	CC
304953	100736314	20992731843	reduced	reduced	JJ@_VVD_VVN
304953	100736314	20992731844	blood	blood	NN1
304953	100736314	20992731845	flow	flow	NN1
304953	100736314	20992731846	(	(	(
304953	100736314	20992731847	and	and	CC
304953	100736314	20992731848	thus	thus	RR
304953	100736314	20992731849	a	a	AT1
304953	100736314	20992731850	loss	loss	NN1
304953	100736314	20992731851	of	of	IO
304953	100736314	20992731852	oxygen	oxygen	NN1
304953	100736314	20992731853	)	)	)
304953	100736314	20992731854	to	to	II
304953	100736314	20992731855	the	the	AT
304953	100736314	20992731856	penis	penis	NN1
304953	100736314	20992731857	during	during	II
304953	100736314	20992731858	surgery	surgery	NN1
304953	100736314	20992731859	and	and	CC
304953	100736314	20992731860	recovery	recovery	NN1
304953	100736314	20992731861	@		II
304953	100736314	20992731862	@		II
304953	100736314	20992731863	@		II
304953	100736314	20992731864	@		II
304953	100736314	20992731865	@		II
304953	100736314	20992731866	@		II
304953	100736314	20992731867	@		II
304953	100736314	20992731868	@		II
304953	100736314	20992731869	@		II
304953	100736314	20992731870	@		II
304953	100736314	20992731871	,	,	,
304953	100736314	20992731872	they	they	PPHS2
304953	100736314	20992731873	suggest	suggest	VV0
304953	100736314	20992731874	that	that	CST
304953	100736314	20992731875	it	it	PPH1
304953	100736314	20992731876	might	might	VM
304953	100736314	20992731877	help	help	VVI
304953	100736314	20992731878	temper	temper	NN1
304953	100736314	20992731879	shortening	shorten	VVG_NN1@
304953	100736314	20992731880	,	,	,
304953	100736314	20992731881	a	a	AT1
304953	100736314	20992731882	conclusion	conclusion	NN1
304953	100736314	20992731883	supported	support	VVN
304953	100736314	20992731884	by	by	II
304953	100736314	20992731885	a	a	AT1
304953	100736314	20992731886	study	study	NN1
304953	100736314	20992731887	from	from	II
304953	100736314	20992731888	a	a	AT1
304953	100736314	20992731889	team	team	NN1
304953	100736314	20992731890	of	of	IO
304953	100736314	20992731891	researchers	researcher	NN2
304953	100736314	20992731892	in	in	II
304953	100736314	20992731893	Minnesota	minnesota	NP1
304953	100736314	20992731894	.	.	.
304953	100736314	20992731895	They	they	PPHS2
304953	100736314	20992731896	found	find	VVD
304953	100736314	20992731897	that	that	CST_DD1
304953	100736314	20992731898	starting	start	VVG
304953	100736314	20992731899	the	the	AT
304953	100736314	20992731900	use	use	NN1
304953	100736314	20992731901	of	of	IO
304953	100736314	20992731902	a	a	AT1
304953	100736314	20992731903	vacuum	vacuum	NN1
304953	100736314	20992731904	erection	erection	NN1
304953	100736314	20992731905	device	device	NN1
304953	100736314	20992731906	one	one	MC1
304953	100736314	20992731907	month	month	NNT1
304953	100736314	20992731908	after	after	II_CS
304953	100736314	20992731909	surgery	surgery	NN1
304953	100736314	20992731910	improves	improve	VVZ
304953	100736314	20992731911	sexual	sexual	JJ
304953	100736314	20992731912	function	function	NN1
304953	100736314	20992731913	and	and	CC
304953	100736314	20992731914	helps	help	VVZ
304953	100736314	20992731915	to	to	TO
304953	100736314	20992731916	preserve	preserve	VVI
304953	100736314	20992731917	penile	penile	JJ_NN1
304953	100736314	20992731918	length	length	NN1
304953	100736314	20992731919	.	.	.
304953	100736314	20992731920	<p>		NULL
304953	100736314	20992731921	Twenty	twenty	MC
304953	100736314	20992731922	years	year	NNT2
304953	100736314	20992731923	post	post	II@_NN1
304953	100736314	20992731924	radical	radical	NN1_JJ
304953	100736314	20992731925	(	(	(
304953	100736314	20992731926	not	not	XX
304953	100736314	20992731927	nerve	nerve	NN1_VV0@
304953	100736314	20992731928	sparing	spare	VVG
304953	100736314	20992731929	)	)	)
304953	100736314	20992731930	and	and	CC
304953	100736314	20992731931	I	i	PPIS1
304953	100736314	20992731932	can	can	VM
304953	100736314	20992731933	maintain	maintain	VVI
304953	100736314	20992731934	good	good	JJ
304953	100736314	20992731935	blood	blood	NN1
304953	100736314	20992731936	flow	flow	NN1
304953	100736314	20992731937	by	by	II
304953	100736314	20992731938	wearing	wear	VVG
304953	100736314	20992731939	my	my	APPGE
304953	100736314	20992731940	soft	soft	JJ
304953	100736314	20992731941	penile	penile	JJ_NN1
304953	100736314	20992731942	wrap	wrap	NN1_VV0
304953	100736314	20992731943	during	during	II
304953	100736314	20992731944	the	the	AT
304953	100736314	20992731945	night	night	NNT1
304953	100736314	20992731946	.	.	.
304953	100736314	20992731947	If	if	CS
304953	100736314	20992731948	I	i	PPIS1
304953	100736314	20992731949	wear	wear	VV0
304953	100736314	20992731950	it	it	PPH1
304953	100736314	20992731951	slightly	slightly	RR
304953	100736314	20992731952	tighter	tighter	RRR@_JJR
304953	100736314	20992731953	I	i	PPIS1
304953	100736314	20992731954	can	can	VM
304953	100736314	20992731955	get	get	VVI
304953	100736314	20992731956	an	a	AT1
304953	100736314	20992731957	erection	erection	NN1
304953	100736314	20992731958	every	every	AT1
304953	100736314	20992731959	time	time	NNT1
304953	100736314	20992731960	.	.	.
304953	100736314	20992731961	Look	look	VV0
304953	100736314	20992731962	up	up	RP_II@
304953	100736314	20992731963	Johnson	johnson	NP1
304953	100736314	20992731964	Soft	soft	JJ
304953	100736314	20992731965	Penile	penile	JJ_NN1
304953	100736314	20992731966	Clamp	clamp	NN1_VV0
304953	100736314	20992731967	on	on	II
304953	100736314	20992731968	Google	google	NP1_NN1
304953	100736314	20992731969	.	.	.
304953	100736314	20992731970	<p>		NULL
304953	100736314	20992731971	This	this	DD1
304953	100736314	20992731972	discussion	discussion	NN1
304953	100736314	20992731973	may	may	VM
304953	100736314	20992731974	be	be	VBI
304953	100736314	20992731975	missing	miss	VVG
304953	100736314	20992731976	the	the	AT
304953	100736314	20992731977	obvious	obvious	JJ
304953	100736314	20992731978	.	.	.
304953	100736314	20992731979	The	the	AT
304953	100736314	20992731980	problem	problem	NN1
304953	100736314	20992731981	may	may	VM
304953	100736314	20992731982	be	be	VBI
304953	100736314	20992731983	that	that	CST
304953	100736314	20992731984	the	the	AT
304953	100736314	20992731985	prostate	prostate	NN1
304953	100736314	20992731986	is	be	VBZ
304953	100736314	20992731987	approximately	approximately	RR
304953	100736314	20992731988	1.5-2	1.5-2	MCMC
304953	100736314	20992731989	?	?	?
304953	100736314	20992731990	long	long	RR
304953	100736314	20992731991	.	.	.
304953	100736314	20992731992	When	when	CS
304953	100736314	20992731993	removed	remove	VVN
304953	100736314	20992731994	,	,	,
304953	100736314	20992731995	where	where	RRQ
304953	100736314	20992731996	is	be	VBZ
304953	100736314	20992731997	this	this	DD1
304953	100736314	20992731998	replacement	replacement	NN1
304953	100736314	20992731999	length	length	NN1
304953	100736314	20992732000	of	of	IO
304953	100736314	20992732001	urethra	urethra	NN1
304953	100736314	20992732002	to	to	TO
304953	100736314	20992732003	come	come	VVI
304953	100736314	20992732004	from	from	II
304953	100736314	20992732005	?	?	?
304953	100736314	20992732006	Most	most	RGT
304953	100736314	20992732007	obviously	obviously	RR
304953	100736314	20992732008	,	,	,
304953	100736314	20992732009	it	it	PPH1
304953	100736314	20992732010	comes	come	VVZ
304953	100736314	20992732011	from	from	II
304953	100736314	20992732012	pulling	pull	VVG
304953	100736314	20992732013	up	up	RP_II@
304953	100736314	20992732014	the	the	AT
304953	100736314	20992732015	penis	penis	NN1
304953	100736314	20992732016	,	,	,
304953	100736314	20992732017	thus	thus	RR
304953	100736314	20992732018	shortening	shorten	VVG
304953	100736314	20992732019	it	it	PPH1
304953	100736314	20992732020	.	.	.
304953	100736314	20992732021	One	one	MC1
304953	100736314	20992732022	solution	solution	NN1
304953	100736314	20992732023	,	,	,
304953	100736314	20992732024	not	not	XX
304953	100736314	20992732025	yet	yet	RR
304953	100736314	20992732026	considered	consider	VVN_VVD
304953	100736314	20992732027	,	,	,
304953	100736314	20992732028	is	be	VBZ
304953	100736314	20992732029	rather	rather	II21
304953	100736314	20992732030	than	than	II22
304953	100736314	20992732031	shortening	shorten	VVG
304953	100736314	20992732032	the	the	AT
304953	100736314	20992732033	penis	penis	NN1
304953	100736314	20992732034	,	,	,
304953	100736314	20992732035	to	to	TO
304953	100736314	20992732036	replace	replace	VVI
304953	100736314	20992732037	the	the	AT
304953	100736314	20992732038	piece	piece	NN1
304953	100736314	20992732039	of	of	IO
304953	100736314	20992732040	urethra	urethra	NN1
304953	100736314	20992732041	within	within	II
304953	100736314	20992732042	the	the	AT
304953	100736314	20992732043	prostate	prostate	NN1
304953	100736314	20992732044	with	with	IW
304953	100736314	20992732045	a	a	AT1
304953	100736314	20992732046	substitute	substitute	JJ_NN1
304953	100736314	20992732047	piece	piece	NN1
304953	100736314	20992732048	of	of	IO
304953	100736314	20992732049	"	"	"
304953	100736314	20992732050	tubing	tubing	NN1
304953	100736314	20992732051	"	"	"
304953	100736314	20992732052	from	from	II
304953	100736314	20992732053	another	another	DD1
304953	100736314	20992732054	source	source	NN1
304953	100736314	20992732055	.	.	.
304953	100736314	20992732056	<p>		NULL
304953	100736314	20992732057	Yes	yes	UH
304953	100736314	20992732058	why	why	RRQ
304953	100736314	20992732059	has	have	VHZ
304953	100736314	20992732060	no	no	AT
304953	100736314	20992732061	@		II
304953	100736314	20992732062	@		II
304953	100736314	20992732063	@		II
304953	100736314	20992732064	@		II
304953	100736314	20992732065	@		II
304953	100736314	20992732066	@		II
304953	100736314	20992732067	@		II
304953	100736314	20992732068	@		II
304953	100736314	20992732069	@		II
304953	100736314	20992732070	@		II
304953	100736314	20992732071	a	a	AT1
304953	100736314	20992732072	prostectamy		NN1_JJ
304953	100736314	20992732073	its	its	APPGE
304953	100736314	20992732074	a	a	AT1
304953	100736314	20992732075	worrying	worrying	JJ
304953	100736314	20992732076	enough	enough	DD_RR
304953	100736314	20992732077	time	time	NNT1
304953	100736314	20992732078	having	have	VHG
304953	100736314	20992732079	to	to	TO
304953	100736314	20992732080	think	think	VVI
304953	100736314	20992732081	about	about	II
304953	100736314	20992732082	surgery	surgery	NN1
304953	100736314	20992732083	,	,	,
304953	100736314	20992732084	then	then	RT
304953	100736314	20992732085	to	to	TO
304953	100736314	20992732086	be	be	VBI
304953	100736314	20992732087	told	tell	VVN
304953	100736314	20992732088	apart	apart	II21
304953	100736314	20992732089	from	from	II22
304953	100736314	20992732090	being	be	VBG
304953	100736314	20992732091	important	important	JJ
304953	100736314	20992732092	your	your	APPGE
304953	100736314	20992732093	also	also	RR
304953	100736314	20992732094	going	go	VVGK
304953	100736314	20992732095	to	to	TO
304953	100736314	20992732096	lose	lose	VVI
304953	100736314	20992732097	an	a	AT1
304953	100736314	20992732098	inch	inch	NNU1
304953	100736314	20992732099	of	of	IO
304953	100736314	20992732100	your	your	APPGE
304953	100736314	20992732101	willy	willy	NN1
304953	100736314	20992732102	.	.	.
304953	100736314	20992732103	Wouldnt		VV0
304953	100736314	20992732104	it	it	PPH1
304953	100736314	20992732105	be	be	VBI
304953	100736314	20992732106	just	just	RR
304953	100736314	20992732107	as	as	RG
304953	100736314	20992732108	easy	easy	JJ
304953	100736314	20992732109	to	to	TO
304953	100736314	20992732110	put	put	VVI
304953	100736314	20992732111	an	a	AT1
304953	100736314	20992732112	extention	extention	NN1
304953	100736314	20992732113	tube	tube	NN1
304953	100736314	20992732114	in	in	RP@_II
304953	100736314	20992732115	to	to	TO
304953	100736314	20992732116	replace	replace	VVI
304953	100736314	20992732117	the	the	AT
304953	100736314	20992732118	prostate	prostate	NN1
304953	100736314	20992732119	<p>		NULL
304953	100736314	20992732120	I	i	MC1@_ZZ1@_PPIS1
304953	100736314	20992732121	just	just	JJ
304953	100736314	20992732122	wish	wish	NN1_VV0
304953	100736314	20992732123	my	my	APPGE
304953	100736314	20992732124	urologist	urologist	NN1
304953	100736314	20992732125	had	have	VHD
304953	100736314	20992732126	discussed	discuss	VVN
304953	100736314	20992732127	this	this	DD1
304953	100736314	20992732128	with	with	IW
304953	100736314	20992732129	me	me	PPIO1
304953	100736314	20992732130	pre	pre	II
304953	100736314	20992732131	surgery	surgery	NN1
304953	100736314	20992732132	rather	rather	CS21
304953	100736314	20992732133	than	than	CS22
304953	100736314	20992732134	convince	convince	VVI
304953	100736314	20992732135	me	me	PPIO1
304953	100736314	20992732136	that	that	DD1_CST
304953	100736314	20992732137	,	,	,
304953	100736314	20992732138	because	because	CS
304953	100736314	20992732139	I 'd		NN1
304953	100736314	20992732140	had	have	VHD
304953	100736314	20992732141	laparoscopic	laparoscopic	JJ
304953	100736314	20992732142	nerve	nerve	NN1
304953	100736314	20992732143	sparing	spare	VVG_JJ@
304953	100736314	20992732144	surgery	surgery	NN1
304953	100736314	20992732145	,	,	,
304953	100736314	20992732146	I	i	PPIS1
304953	100736314	20992732147	had	have	VHD
304953	100736314	20992732148	a	a	AT1
304953	100736314	20992732149	good	good	JJ
304953	100736314	20992732150	chance	chance	NN1
304953	100736314	20992732151	of	of	IO
304953	100736314	20992732152	having	have	VHG
304953	100736314	20992732153	normal	normal	JJ
304953	100736314	20992732154	erections	erection	NN2
304953	100736314	20992732155	down	down	II
304953	100736314	20992732156	the	the	AT
304953	100736314	20992732157	track	track	NN1
304953	100736314	20992732158	.	.	.
304953	100736314	20992732159	After	after	II_CS
304953	100736314	20992732160	8	8	MC
304953	100736314	20992732161	years	year	NNT2
304953	100736314	20992732162	and	and	CC
304953	100736314	20992732163	the	the	AT
304953	100736314	20992732164	loss	loss	NN1
304953	100736314	20992732165	of	of	IO
304953	100736314	20992732166	my	my	APPGE
304953	100736314	20992732167	partner	partner	NN1
304953	100736314	20992732168	due	due	II%_JJ
304953	100736314	20992732169	this	this	DD1
304953	100736314	20992732170	my	my	APPGE
304953	100736314	20992732171	erectile	erectile	JJ
304953	100736314	20992732172	disfunction	disfunction	NN1
304953	100736314	20992732173	I	i	PPIS1
304953	100736314	20992732174	had	have	VHD
304953	100736314	20992732175	a	a	AT1
304953	100736314	20992732176	saline	saline	JJ
304953	100736314	20992732177	pump	pump	NN1
304953	100736314	20992732178	implant	implant	NN1
304953	100736314	20992732179	which	which	DDQ
304953	100736314	20992732180	works	work	VVZ
304953	100736314	20992732181	amazingly	amazingly	RR
304953	100736314	20992732182	well	well	RR_JJ@
304953	100736314	20992732183	but	but	CCB
304953	100736314	20992732184	discovered	discover	VVD
304953	100736314	20992732185	I 'd		NN1
304953	100736314	20992732186	lost	lose	VVD_VVN
304953	100736314	20992732187	2	2	MC
304953	100736314	20992732188	inches	inch	NNU2
304953	100736314	20992732189	from	from	II
304953	100736314	20992732190	my	my	APPGE
304953	100736314	20992732191	erection	erection	NN1
304953	100736314	20992732192	.	.	.
304953	100736314	20992732193	I	i	PPIS1
304953	100736314	20992732194	had	have	VHD
304953	100736314	20992732195	no	no	AT
304953	100736314	20992732196	knowledge	knowledge	NN1
304953	100736314	20992732197	of	of	IO
304953	100736314	20992732198	the	the	AT
304953	100736314	20992732199	reason	reason	NN1
304953	100736314	20992732200	for	for	IF
304953	100736314	20992732201	this	this	DD1
304953	100736314	20992732202	until	until	CS
304953	100736314	20992732203	I	i	PPIS1
304953	100736314	20992732204	Googled	googled	VVD@
304953	100736314	20992732205	it	it	PPH1
304953	100736314	20992732206	.	.	.
304953	100736314	20992732207	Borders	borders	NP1_NN2
304953	100736314	20992732208	on	on	II
304953	100736314	20992732209	neglect	neglect	NN1
304953	100736314	20992732210	!	!	!
304953	100736314	20992732211	<p>		NULL
304953	100736314	20992732212	Rod	rod	NN1
304953	100736314	20992732213	,	,	,
304953	100736314	20992732214	welcome	welcome	VV0_NN1_JJ
304953	100736314	20992732215	to	to	II
304953	100736314	20992732216	the	the	AT
304953	100736314	20992732217	medical	medical	JJ
304953	100736314	20992732218	profession	profession	NN1
304953	100736314	20992732219	,	,	,
304953	100736314	20992732220	where	where	CS_RRQ
304953	100736314	20992732221	95%+		FO
304953	100736314	20992732222	of	of	IO
304953	100736314	20992732223	practitioners	practitioner	NN2
304953	100736314	20992732224	are	be	VBR
304953	100736314	20992732225	bone-headed		JJ
304953	100736314	20992732226	Neanderthal	neanderthal	JJ
304953	100736314	20992732227	morons.		NNU
304953	100736314	20992732228	5cm		NNU
304953	100736314	20992732229	loss	loss	NN1
304953	100736314	20992732230	must	must	VM
304953	100736314	20992732231	be	be	VBI
304953	100736314	20992732232	devastating	devastating	JJ_VVG@
304953	100736314	20992732233	.	.	.
304953	100736314	20992732234	No	no	PN121
304953	100736314	20992732235	one	one	PN122
304953	100736314	20992732236	gives	give	VVZ
304953	100736314	20992732237	a	a	AT1
304953	100736314	20992732238	flying	flying	JJ_NN1
304953	100736314	20992732239	fluck		NN1
304953	100736314	20992732240	about	about	II
304953	100736314	20992732241	you	you	PPY
304953	100736314	20992732242	,	,	,
304953	100736314	20992732243	except	except	CS
304953	100736314	20992732244	you	you	PPY
304953	100736314	20992732245	.	.	.
304953	100736314	20992732246	EVERYONE	everyone	PN1
304953	100736314	20992732247	is	be	VBZ
304953	100736314	20992732248	incompetent	incompetent	JJ
304953	100736314	20992732249	until	until	CS
304953	100736314	20992732250	proven	prove	VVN_JJ
304953	100736314	20992732251	otherwise	otherwise	RR
304953	100736314	20992732252	.	.	.
304953	100736314	20992732253	It	it	PPH1
304953	100736314	20992732254	does	do	VDZ
304953	100736314	20992732255	not	not	XX
304953	100736314	20992732256	matter	matter	VVI
304953	100736314	20992732257	how	how	RGQ@_RRQ
304953	100736314	20992732258	qualified	qualified	JJ
304953	100736314	20992732259	they	they	PPHS2
304953	100736314	20992732260	are	be	VBR
304953	100736314	20992732261	@		II
304953	100736314	20992732262	@		II
304953	100736314	20992732263	@		II
304953	100736314	20992732264	@		II
304953	100736314	20992732265	@		II
304953	100736314	20992732266	@		II
304953	100736314	20992732267	@		II
304953	100736314	20992732268	@		II
304953	100736314	20992732269	@		II
304953	100736314	20992732270	@		II
304953	100736314	20992732271	wank	wank	NN1_VV0
304953	100736314	20992732272	.	.	.
304953	100736314	20992732273	EVERYONE	everyone	PN1
304953	100736314	20992732274	!	!	!
304953	100736314	20992732275	!	!	!
304953	100736314	20992732276	If	if	CS
304953	100736314	20992732277	you	you	PPY
304953	100736314	20992732278	deal	deal	VV0
304953	100736314	20992732279	with	with	IW
304953	100736314	20992732280	everyone	everyone	PN1
304953	100736314	20992732281	on	on	II
304953	100736314	20992732282	that	that	DD1
304953	100736314	20992732283	basis	basis	NN1
304953	100736314	20992732284	,	,	,
304953	100736314	20992732285	you 'll		VV0
304953	100736314	20992732286	often	often	RR
304953	100736314	20992732287	avoid	avoid	VV0
304953	100736314	20992732288	paying	pay	VVG_JJ@
304953	100736314	20992732289	money	money	NN1
304953	100736314	20992732290	to	to	II
304953	100736314	20992732291	some	some	DD
304953	100736314	20992732292	jackass	jackass	VV0_NN1
304953	100736314	20992732293	low-life	low-life	JJ_NN1
304953	100736314	20992732294	scumbag	scumbag	NN1
304953	100736314	20992732295	filth	filth	NN1
304953	100736314	20992732296	as	as	II31
304953	100736314	20992732297	well	well	II32
304953	100736314	20992732298	as	as	II33
304953	100736314	20992732299	paying	pay	VVG
304953	100736314	20992732300	the	the	AT
304953	100736314	20992732301	extra	extra	JJ
304953	100736314	20992732302	price	price	NN1
304953	100736314	20992732303	later	later	RRR_JJR
304953	100736314	20992732304	of	of	IO
304953	100736314	20992732305	a	a	AT1
304953	100736314	20992732306	poor	poor	JJ
304953	100736314	20992732307	health	health	NN1
304953	100736314	20992732308	outcome	outcome	NN1
304953	100736314	20992732309	.	.	.
304953	100736314	20992732310	I	i	PPIS1
304953	100736314	20992732311	hope	hope	VV0
304953	100736314	20992732312	your	your	APPGE
304953	100736314	20992732313	stupid	stupid	JJ
304953	100736314	20992732314	reedy	reedy	JJ
304953	100736314	20992732315	Urologist		NN1_NP1
304953	100736314	20992732316	dies	die	VVZ
304953	100736314	20992732317	a	a	AT1
304953	100736314	20992732318	slow	slow	JJ
304953	100736314	20992732319	painful	painful	JJ
304953	100736314	20992732320	death	death	NN1
304953	100736314	20992732321	from	from	II
304953	100736314	20992732322	bone	bone	NN1
304953	100736314	20992732323	cancer	cancer	NN1
304953	100736314	20992732324	!	!	!
304953	100736314	20992732325	!	!	!
304953	100736314	20992732326	He	he	PPHS1
304953	100736314	20992732327	deserves	deserve	VVZ
304953	100736314	20992732328	it	it	PPH1
304953	100736314	20992732329	.	.	.
304953	100736314	20992732330	It	it	PPH1
304953	100736314	20992732331	does	do	VDZ
304953	100736314	20992732332	not	not	XX
304953	100736314	20992732333	just	just	RR
304953	100736314	20992732334	border	border	VVI
304953	100736314	20992732335	on	on	II
304953	100736314	20992732336	neglect	neglect	NN1
304953	100736314	20992732337	.	.	.
304953	100736314	20992732338	Its	its	APPGE
304953	100736314	20992732339	your	your	APPGE
304953	100736314	20992732340	health	health	NN1
304953	100736314	20992732341	.	.	.
304953	100736314	20992732342	You	you	PPY
304953	100736314	20992732343	must	must	VM
304953	100736314	20992732344	take	take	VVI
304953	100736314	20992732345	it	it	PPH1
304953	100736314	20992732346	into	into	II
304953	100736314	20992732347	your	your	APPGE
304953	100736314	20992732348	own	own	DA
304953	100736314	20992732349	hands	hand	NN2
304953	100736314	20992732350	.	.	.
304953	100736314	20992732351	Trust	trust	VV0
304953	100736314	20992732352	no	no	PN121
304953	100736314	20992732353	one	one	PN122
304953	100736314	20992732354	.	.	.
304953	100736314	20992732355	Theyre		NP1@_NN1
304953	100736314	20992732356	only	only	JJ
304953	100736314	20992732357	interested		NN1
304953	100736314	20992732358	in	in	II
304953	100736314	20992732359	your	your	APPGE
304953	100736314	20992732360	money	money	NN1
304953	100736314	20992732361	,	,	,
304953	100736314	20992732362	not	not	XX
304953	100736314	20992732363	you	you	PPY
304953	100736314	20992732364	.	.	.
304953	100736314	20992732365	<p>		NULL
304953	100736314	20992732366	Hi	hi	UH
304953	100736314	20992732367	.	.	.
304953	100736314	20992732368	I	i	PPIS1
304953	100736314	20992732369	am	be	VBM
304953	100736314	20992732370	from	from	II
304953	100736314	20992732371	South	south	NP1
304953	100736314	20992732372	Africa	africa	NP1
304953	100736314	20992732373	.	.	.
304953	100736314	20992732374	I	i	PPIS1
304953	100736314	20992732375	am	be	VBM
304953	100736314	20992732376	going	go	VVG
304953	100736314	20992732377	into	into	II
304953	100736314	20992732378	surgery	surgery	NN1
304953	100736314	20992732379	the	the	AT
304953	100736314	20992732380	13th	13th	MD
304953	100736314	20992732381	of	of	IO
304953	100736314	20992732382	Jan	jan	NPM1
304953	100736314	20992732383	2017	2017	MC
304953	100736314	20992732384	for	for	IF
304953	100736314	20992732385	a	a	AT1
304953	100736314	20992732386	sling	sling	NN1
304953	100736314	20992732387	.	.	.
304953	100736314	20992732388	Two	two	MC
304953	100736314	20992732389	years	year	NNT2
304953	100736314	20992732390	and	and	CC
304953	100736314	20992732391	4	4	MC
304953	100736314	20992732392	months	month	NNT2
304953	100736314	20992732393	down	down	II@_RP
304953	100736314	20992732394	the	the	AT
304953	100736314	20992732395	line	line	NN1
304953	100736314	20992732396	and	and	CC
304953	100736314	20992732397	no	no	AT
304953	100736314	20992732398	erection	erection	NN1
304953	100736314	20992732399	yet	yet	RR
304953	100736314	20992732400	.	.	.
304953	100736314	20992732401	Caverject		VV0_NN1_NP1@
304953	100736314	20992732402	and	and	CC
304953	100736314	20992732403	the	the	AT
304953	100736314	20992732404	other	other	JJ
304953	100736314	20992732405	injections	injection	NN2
304953	100736314	20992732406	does	do	VDZ
304953	100736314	20992732407	not	not	XX
304953	100736314	20992732408	work	work	VVI
304953	100736314	20992732409	.	.	.
304953	100736314	20992732410	a	a	AT1
304953	100736314	20992732411	Big	big	JJ
304953	100736314	20992732412	loss	loss	NN1
304953	100736314	20992732413	of	of	IO
304953	100736314	20992732414	about	about	RG
304953	100736314	20992732415	50mm		NNU
304953	100736314	20992732416	penis	penis	NN1
304953	100736314	20992732417	length	length	NN1
304953	100736314	20992732418	What	what	DDQ
304953	100736314	20992732419	is	be	VBZ
304953	100736314	20992732420	the	the	AT
304953	100736314	20992732421	best	best	JJT
304953	100736314	20992732422	we	we	PPIS2
304953	100736314	20992732423	can	can	VM
304953	100736314	20992732424	do	do	VDI
304953	100736314	20992732425	to	to	TO
304953	100736314	20992732426	rectify	rectify	VVI
304953	100736314	20992732427	this	this	DD1
304953	100736314	20992732428	.	.	.
304953	100736314	20992732429	We	we	PPIS2
304953	100736314	20992732430	are	be	VBR
304953	100736314	20992732431	planning	plan	VVG
304953	100736314	20992732432	an	a	AT1
304953	100736314	20992732433	Penile	penile	JJ_NN1
304953	100736314	20992732434	Implant	implant	NN1
304953	100736314	20992732435	in	in	II
304953	100736314	20992732436	June	june	NPM1
304953	100736314	20992732437	,	,	,
304953	100736314	20992732438	but	but	CCB
304953	100736314	20992732439	if	if	CS
304953	100736314	20992732440	the	the	AT
304953	100736314	20992732441	Penis	penis	NN1
304953	100736314	20992732442	is	be	VBZ
304953	100736314	20992732443	short	short	JJ_RR@
304953	100736314	20992732444	,	,	,
304953	100736314	20992732445	the	the	AT
304953	100736314	20992732446	will	will	NN1@
304953	100736314	20992732447	only	only	RR
304953	100736314	20992732448	implant	implant	VVI
304953	100736314	20992732449	the	the	AT
304953	100736314	20992732450	short	short	JJ
304953	100736314	20992732451	tube	tube	NN1
304953	100736314	20992732452	What	what	DDQ
304953	100736314	20992732453	can	can	VM
304953	100736314	20992732454	I	i	PPIS1
304953	100736314	20992732455	do	do	VDI
304953	100736314	20992732456	?	?	?
304953	100736314	20992732457	?	?	?
304953	100736314	20992732458	<p>		NULL
304953	100736314	20992732459	My	my	APPGE
304953	100736314	20992732460	surgeon	surgeon	NN1
304953	100736314	20992732461	@		II
304953	100736314	20992732462	@		II
304953	100736314	20992732463	@		II
304953	100736314	20992732464	@		II
304953	100736314	20992732465	@		II
304953	100736314	20992732466	@		II
304953	100736314	20992732467	@		II
304953	100736314	20992732468	@		II
304953	100736314	20992732469	@		II
304953	100736314	20992732470	@		II
304953	100736314	20992732471	my	my	APPGE
304953	100736314	20992732472	laparoscopic	laparoscopic	JJ
304953	100736314	20992732473	prostate	prostate	NN1
304953	100736314	20992732474	surgery	surgery	NN1
304953	100736314	20992732475	two	two	MC
304953	100736314	20992732476	years	year	NNT2
304953	100736314	20992732477	ago	ago	RA
304953	100736314	20992732478	.	.	.
304953	100736314	20992732479	I	i	PPIS1
304953	100736314	20992732480	immediately	immediately	RR
304953	100736314	20992732481	noticed	notice	VVD
304953	100736314	20992732482	a	a	AT1
304953	100736314	20992732483	huge	huge	JJ
304953	100736314	20992732484	difference	difference	NN1
304953	100736314	20992732485	in	in	II
304953	100736314	20992732486	penis	penis	NN1
304953	100736314	20992732487	length	length	NN1
304953	100736314	20992732488	,	,	,
304953	100736314	20992732489	so	so	RR
304953	100736314	20992732490	tried	try	VVD
304953	100736314	20992732491	the	the	AT
304953	100736314	20992732492	vacuum	vacuum	NN1
304953	100736314	20992732493	pump	pump	NN1
304953	100736314	20992732494	method	method	NN1
304953	100736314	20992732495	and	and	CC
304953	100736314	20992732496	low	low	JJ
304953	100736314	20992732497	dose	dose	NN1
304953	100736314	20992732498	Cialis	cialis	NN1_NP1
304953	100736314	20992732499	suggested	suggest	VVN
304953	100736314	20992732500	by	by	II
304953	100736314	20992732501	my	my	APPGE
304953	100736314	20992732502	GP	gp	NN1
304953	100736314	20992732503	.	.	.
304953	100736314	20992732504	I	i	PPIS1
304953	100736314	20992732505	have	have	VH0
304953	100736314	20992732506	to	to	II%_TO
304953	100736314	20992732507	this	this	DD1
304953	100736314	20992732508	day	day	NNT1
304953	100736314	20992732509	,	,	,
304953	100736314	20992732510	not	not	XX
304953	100736314	20992732511	regained	regain	VVN
304953	100736314	20992732512	the	the	AT
304953	100736314	20992732513	50	50	MC
304953	100736314	20992732514	mm	mm	NNU
304953	100736314	20992732515	lost	lose	VVN_VVD
304953	100736314	20992732516	after	after	II
304953	100736314	20992732517	surgery	surgery	NN1
304953	100736314	20992732518	.	.	.
304953	100736314	20992732519	My	my	APPGE
304953	100736314	20992732520	pride	pride	NN1
304953	100736314	20992732521	gets	get	VVZ
304953	100736314	20992732522	in	in	II
304953	100736314	20992732523	the	the	AT
304953	100736314	20992732524	way	way	NN1
304953	100736314	20992732525	sometimes	sometimes	RT
304953	100736314	20992732526	.	.	.
304953	100736314	20992732527	I 've		NP1@_NN1_VV0
304953	100736314	20992732528	stopped	stop	VVD
304953	100736314	20992732529	going	go	VVG
304953	100736314	20992732530	to	to	II
304953	100736314	20992732531	the	the	AT
304953	100736314	20992732532	gym	gym	NN1
304953	100736314	20992732533	and	and	CC
304953	100736314	20992732534	swimming	swimming	NN1
304953	100736314	20992732535	pool	pool	NN1
304953	100736314	20992732536	etc	etc	RA
304953	100736314	20992732537	.	.	.
304953	100736314	20992732538	Fortunately	fortunately	RR
304953	100736314	20992732539	I	i	PPIS1
304953	100736314	20992732540	have	have	VH0
304953	100736314	20992732541	a	a	AT1
304953	100736314	20992732542	very	very	RG
304953	100736314	20992732543	understanding	understanding	JJ@
304953	100736314	20992732544	partner	partner	NN1
304953	100736314	20992732545	,	,	,
304953	100736314	20992732546	however	however	RGQV
304953	100736314	20992732547	intimate	intimate	JJ
304953	100736314	20992732548	encounters	encounter	NN2
304953	100736314	20992732549	have	have	VH0
304953	100736314	20992732550	become	become	VVN@
304953	100736314	20992732551	much	much	RR_DA1
304953	100736314	20992732552	less	less	RGR_DAR
304953	100736314	20992732553	frequent	frequent	JJ
304953	100736314	20992732554	.	.	.
304953	100736314	20992732555	<p>		NULL
304953	100736314	20992732556	Hi	hi	UH
304953	100736314	20992732557	guys	guy	NN2
304953	100736314	20992732558	.	.	.
304953	100736314	20992732559	In	in	II
304953	100736314	20992732560	July	july	NPM1
304953	100736314	20992732561	2015	2015	MC
304953	100736314	20992732562	I	i	PPIS1
304953	100736314	20992732563	was	be	VBDZ
304953	100736314	20992732564	diagnosed	diagnose	VVN
304953	100736314	20992732565	as	as	CSA
304953	100736314	20992732566	having	have	VHG
304953	100736314	20992732567	an	a	AT1
304953	100736314	20992732568	aggressive	aggressive	JJ
304953	100736314	20992732569	cancer	cancer	NN1
304953	100736314	20992732570	in	in	II
304953	100736314	20992732571	my	my	APPGE
304953	100736314	20992732572	prostate	prostate	NN1
304953	100736314	20992732573	.	.	.
304953	100736314	20992732574	There	there	EX
304953	100736314	20992732575	was	be	VBDZ
304953	100736314	20992732576	a	a	AT1
304953	100736314	20992732577	slight	slight	JJ
304953	100736314	20992732578	break/tear		NN1
304953	100736314	20992732579	of	of	IO
304953	100736314	20992732580	the	the	AT
304953	100736314	20992732581	covering	covering	NN1@
304953	100736314	20992732582	membrane	membrane	NN1
304953	100736314	20992732583	&amp;		CC
304953	100736314	20992732584	at	at	II
304953	100736314	20992732585	that	that	DD1
304953	100736314	20992732586	time	time	NNT1
304953	100736314	20992732587	,	,	,
304953	100736314	20992732588	no	no	AT
304953	100736314	20992732589	protruding	protruding	JJ
304953	100736314	20992732590	tumour	tumor	NN1
304953	100736314	20992732591	.	.	.
304953	100736314	20992732592	My	my	APPGE
304953	100736314	20992732593	wife	wife	NN1
304953	100736314	20992732594	&amp;		CC
304953	100736314	20992732595	I	i	PPIS1
304953	100736314	20992732596	were	be	VBDR
304953	100736314	20992732597	both	both	DB2_RR
304953	100736314	20992732598	devastated	devastate	VVD_VVN
304953	100736314	20992732599	.	.	.
304953	100736314	20992732600	My	my	APPGE
304953	100736314	20992732601	urologist	urologist	NN1
304953	100736314	20992732602	advised	advise	VVD
304953	100736314	20992732603	I	i	PPIS1
304953	100736314	20992732604	speak	speak	VV0
304953	100736314	20992732605	to	to	II
304953	100736314	20992732606	specialists	specialist	NN2
304953	100736314	20992732607	with	with	II41
304953	100736314	20992732608	a	a	II42
304953	100736314	20992732609	view	view	II43
304953	100736314	20992732610	to	to	II44
304953	100736314	20992732611	treat	treat	NN1
304953	100736314	20992732612	by	by	II
304953	100736314	20992732613	radiotherapy	radiotherapy	NN1
304953	100736314	20992732614	,	,	,
304953	100736314	20992732615	hormone	hormone	NN1
304953	100736314	20992732616	therapy	therapy	NN1
304953	100736314	20992732617	and	and	CC
304953	100736314	20992732618	chemotherapy	chemotherapy	NN1
304953	100736314	20992732619	or	or	CC
304953	100736314	20992732620	a	a	AT1
304953	100736314	20992732621	mixture	mixture	NN1
304953	100736314	20992732622	of	of	IO
304953	100736314	20992732623	all	all	DB
304953	100736314	20992732624	.	.	.
304953	100736314	20992732625	She	she	PPHS1
304953	100736314	20992732626	also	also	RR
304953	100736314	20992732627	suggested	suggest	VVD
304953	100736314	20992732628	I	i	PPIS1
304953	100736314	20992732629	speak	speak	VV0
304953	100736314	20992732630	to	to	II
304953	100736314	20992732631	a	a	AT1
304953	100736314	20992732632	professor	professor	NN1
304953	100736314	20992732633	of	of	IO
304953	100736314	20992732634	urology	urology	NN1
304953	100736314	20992732635	for	for	IF
304953	100736314	20992732636	surgery	surgery	NN1
304953	100736314	20992732637	.	.	.
304953	100736314	20992732638	After	after	CS_II
304953	100736314	20992732639	discussions	discussion	NN2
304953	100736314	20992732640	&amp;		CC
304953	100736314	20992732641	some	some	DD
304953	100736314	20992732642	soul	soul	NN1
304953	100736314	20992732643	searching	search	VVG
304953	100736314	20992732644	,	,	,
304953	100736314	20992732645	I	i	ZZ1%_MC1%
304953	100736314	20992732646	(	(	(
304953	100736314	20992732647	&amp;		CC
304953	100736314	20992732648	my	my	APPGE
304953	100736314	20992732649	loving	loving	JJ
304953	100736314	20992732650	wife	wife	NN1
304953	100736314	20992732651	)	)	)
304953	100736314	20992732652	was	be	VBDZ
304953	100736314	20992732653	emphatic	emphatic	JJ
304953	100736314	20992732654	that	that	CST
304953	100736314	20992732655	a	a	AT1
304953	100736314	20992732656	prostatectomy	prostatectomy	NN1
304953	100736314	20992732657	was	be	VBDZ
304953	100736314	20992732658	the	the	AT
304953	100736314	20992732659	way	way	NN1
304953	100736314	20992732660	forward	forward	RL
304953	100736314	20992732661	@		II
304953	100736314	20992732662	@		II
304953	100736314	20992732663	@		II
304953	100736314	20992732664	@		II
304953	100736314	20992732665	@		II
304953	100736314	20992732666	@		II
304953	100736314	20992732667	@		II
304953	100736314	20992732668	@		II
304953	100736314	20992732669	@		II
304953	100736314	20992732670	@		II
304953	100736314	20992732671	to	to	II
304953	100736314	20992732672	me	me	PPIO1
304953	100736314	20992732673	by	by	II
304953	100736314	20992732674	Professor	professor	NNB
304953	100736314	20992732675	Leung	leung	NP1
304953	100736314	20992732676	Queen	queen	NNB
304953	100736314	20992732677	Elizabeth	elizabeth	NP1
304953	100736314	20992732678	University	university	NN1
304953	100736314	20992732679	Hospital	hospital	NN1
304953	100736314	20992732680	,	,	,
304953	100736314	20992732681	Glasgow	glasgow	NP1
304953	100736314	20992732682	,	,	,
304953	100736314	20992732683	UK	uk	NP1
304953	100736314	20992732684	.	.	.
304953	100736314	20992732685	At	at	II
304953	100736314	20992732686	this	this	DD1
304953	100736314	20992732687	point	point	NN1
304953	100736314	20992732688	it	it	PPH1
304953	100736314	20992732689	is	be	VBZ
304953	100736314	20992732690	important	important	JJ
304953	100736314	20992732691	to	to	TO
304953	100736314	20992732692	say	say	VVI
304953	100736314	20992732693	that	that	CST_DD1
304953	100736314	20992732694	at	at	II
304953	100736314	20992732695	that	that	DD1
304953	100736314	20992732696	time	time	NNT1
304953	100736314	20992732697	I	i	PPIS1
304953	100736314	20992732698	was	be	VBDZ
304953	100736314	20992732699	age	age	NN1
304953	100736314	20992732700	63	63	MC
304953	100736314	20992732701	and	and	CC
304953	100736314	20992732702	our	our	APPGE
304953	100736314	20992732703	one	one	MC1
304953	100736314	20992732704	child	child	NN1
304953	100736314	20992732705	was	be	VBDZ
304953	100736314	20992732706	a	a	AT1
304953	100736314	20992732707	married	married	JJ
304953	100736314	20992732708	Mother	mother	NN1
304953	100736314	20992732709	with	with	IW
304953	100736314	20992732710	two	two	MC
304953	100736314	20992732711	lovely	lovely	JJ
304953	100736314	20992732712	children	child	NN2
304953	100736314	20992732713	.	.	.
304953	100736314	20992732714	Surgery	surgery	NN1
304953	100736314	20992732715	took	take	VVD
304953	100736314	20992732716	place	place	NN1
304953	100736314	20992732717	in	in	II
304953	100736314	20992732718	November	november	NPM1
304953	100736314	20992732719	2015	2015	MC
304953	100736314	20992732720	and	and	CC
304953	100736314	20992732721	post-op	post-op	JJ_NN1
304953	100736314	20992732722	results	result	NN2
304953	100736314	20992732723	showed	show	VVD
304953	100736314	20992732724	no	no	AT
304953	100736314	20992732725	cancer	cancer	NN1
304953	100736314	20992732726	cells	cell	NN2
304953	100736314	20992732727	remained	remain	VVD_VVN
304953	100736314	20992732728	.	.	.
304953	100736314	20992732729	Good	good	JJ
304953	100736314	20992732730	job	job	NN1
304953	100736314	20992732731	well	well	RR
304953	100736314	20992732732	done	do	VDN
304953	100736314	20992732733	and	and	CC
304953	100736314	20992732734	my	my	APPGE
304953	100736314	20992732735	grateful	grateful	JJ
304953	100736314	20992732736	thanks	thanks	NN2
304953	100736314	20992732737	to	to	II
304953	100736314	20992732738	Prof	professor	NNB
304953	100736314	20992732739	Leung	leung	NP1
304953	100736314	20992732740	&amp;		CC
304953	100736314	20992732741	his	his	APPGE
304953	100736314	20992732742	excellent	excellent	JJ
304953	100736314	20992732743	team	team	NN1
304953	100736314	20992732744	.	.	.
304953	100736314	20992732745	Here	here	RL
304953	100736314	20992732746	I	i	PPIS1
304953	100736314	20992732747	am	be	VBM
304953	100736314	20992732748	15	15	MC
304953	100736314	20992732749	months	month	NNT2
304953	100736314	20992732750	later	later	RRR
304953	100736314	20992732751	and	and	CC
304953	100736314	20992732752	my	my	APPGE
304953	100736314	20992732753	most	most	RGT
304953	100736314	20992732754	recent	recent	JJ
304953	100736314	20992732755	PSA	psa	NP1
304953	100736314	20992732756	results	result	NN2
304953	100736314	20992732757	are	be	VBR
304953	100736314	20992732758	still	still	RR
304953	100736314	20992732759	0.01	0.01	MC
304953	100736314	20992732760	non-detectable	non-detectable	JJ
304953	100736314	20992732761	.	.	.
304953	100736314	20992732762	I	i	MC1@_ZZ1@
304953	100736314	20992732763	for	for	IF
304953	100736314	20992732764	one	one	PN1_MC1
304953	100736314	20992732765	,	,	,
304953	100736314	20992732766	hope	hope	VV0
304953	100736314	20992732767	that	that	CST
304953	100736314	20992732768	those	those	DD2
304953	100736314	20992732769	of	of	IO
304953	100736314	20992732770	you	you	PPY
304953	100736314	20992732771	who	who	PNQS
304953	100736314	20992732772	are	be	VBR
304953	100736314	20992732773	much	much	RR
304953	100736314	20992732774	younger	young	JJR
304953	100736314	20992732775	than	than	CSN
304953	100736314	20992732776	me	me	PPIO1
304953	100736314	20992732777	can	can	VM
304953	100736314	20992732778	get	get	VVI
304953	100736314	20992732779	some	some	DD
304953	100736314	20992732780	medical	medical	JJ
304953	100736314	20992732781	help	help	NN1
304953	100736314	20992732782	or	or	CC
304953	100736314	20992732783	therapy	therapy	NN1
304953	100736314	20992732784	to	to	TO
304953	100736314	20992732785	overcome	overcome	VVI
304953	100736314	20992732786	the	the	AT
304953	100736314	20992732787	problems	problem	NN2
304953	100736314	20992732788	associated	associate	VVN
304953	100736314	20992732789	with	with	IW
304953	100736314	20992732790	your	your	APPGE
304953	100736314	20992732791	shortened	shortened	JJ@
304953	100736314	20992732792	penis	penis	NN1
304953	100736314	20992732793	(	(	(
304953	100736314	20992732794	I	i	PPIS1
304953	100736314	20992732795	have	have	VH0
304953	100736314	20992732796	little	little	DA1
304953	100736314	20992732797	comprehension	comprehension	NN1
304953	100736314	20992732798	of	of	IO
304953	100736314	20992732799	how	how	RRQ
304953	100736314	20992732800	I	i	PPIS1
304953	100736314	20992732801	would	would	VM
304953	100736314	20992732802	feel	feel	VVI
304953	100736314	20992732803	if	if	CS_CSW@
304953	100736314	20992732804	I	i	PPIS1
304953	100736314	20992732805	were	be	VBDR
304953	100736314	20992732806	20	20	MC
304953	100736314	20992732807	or	or	CC
304953	100736314	20992732808	30	30	MC
304953	100736314	20992732809	years	year	NNT2
304953	100736314	20992732810	younger	young	JJR
304953	100736314	20992732811	)	)	)
304953	100736314	20992732812	but	but	CCB
304953	100736314	20992732813	I	i	PPIS1
304953	100736314	20992732814	can	can	VM
304953	100736314	20992732815	assure	assure	VVI
304953	100736314	20992732816	you	you	PPY
304953	100736314	20992732817	and	and	CC
304953	100736314	20992732818	all	all	DB_RR@
304953	100736314	20992732819	other	other	JJ
304953	100736314	20992732820	readers	reader	NN2
304953	100736314	20992732821	of	of	IO
304953	100736314	20992732822	this	this	DD1
304953	100736314	20992732823	rather	rather	RG
304953	100736314	20992732824	lengthy	lengthy	JJ
304953	100736314	20992732825	post	post	NN1
304953	100736314	20992732826	,	,	,
304953	100736314	20992732827	I	i	PPIS1
304953	100736314	20992732828	am	be	VBM
304953	100736314	20992732829	totally	totally	RR
304953	100736314	20992732830	accepting	accept	VVG
304953	100736314	20992732831	of	of	IO
304953	100736314	20992732832	my	my	APPGE
304953	100736314	20992732833	shortened	shortened	JJ@
304953	100736314	20992732834	penis	penis	NN1
304953	100736314	20992732835	&amp;		CC
304953	100736314	20992732836	inability	inability	NN1
304953	100736314	20992732837	to	to	TO
304953	100736314	20992732838	achieve	achieve	VVI
304953	100736314	20992732839	an	a	AT1
304953	100736314	20992732840	erection	erection	NN1
304953	100736314	20992732841	.	.	.
304953	100736314	20992732842	At	at	RR21
304953	100736314	20992732843	least	least	RR22
304953	100736314	20992732844	I	i	PPIS1
304953	100736314	20992732845	am	be	VBM
304953	100736314	20992732846	still	still	RR
304953	100736314	20992732847	alive	alive	JJ
304953	100736314	20992732848	.	.	.
304953	100736314	20992732849	Good	good	JJ
304953	100736314	20992732850	luck	luck	NN1
304953	100736314	20992732851	to	to	II
304953	100736314	20992732852	all	all	DB
304953	100736314	20992732853	.	.	.
304953	100736314	20992732854	<p>		NULL
304953	100736314	20992732855	In	in	II
304953	100736314	20992732856	2014	2014	MC
304953	100736314	20992732857	I	i	PPIS1
304953	100736314	20992732858	underwent	undergo	VVD
304953	100736314	20992732859	nerve	nerve	NN1
304953	100736314	20992732860	sparing	spare	VVG
304953	100736314	20992732861	@		II
304953	100736314	20992732862	@		II
304953	100736314	20992732863	@		II
304953	100736314	20992732864	@		II
304953	100736314	20992732865	@		II
304953	100736314	20992732866	@		II
304953	100736314	20992732867	@		II
304953	100736314	20992732868	@		II
304953	100736314	20992732869	@		II
304953	100736314	20992732870	@		II
304953	100736314	20992732871	Score	score	NN1
304953	100736314	20992732872	was	be	VBDZ
304953	100736314	20992732873	8	8	MC
304953	100736314	20992732874	with	with	IW
304953	100736314	20992732875	a	a	AT1
304953	100736314	20992732876	PSA	psa	NP1
304953	100736314	20992732877	of	of	IO
304953	100736314	20992732878	only	only	JJ
304953	100736314	20992732879	4.7		NN1
304953	100736314	20992732880	.	.	.
304953	100736314	20992732881	During	during	II
304953	100736314	20992732882	the	the	AT
304953	100736314	20992732883	surgery	surgery	NN1
304953	100736314	20992732884	the	the	AT
304953	100736314	20992732885	surgeon	surgeon	NN1
304953	100736314	20992732886	removed	remove	VVD_VVN
304953	100736314	20992732887	26	26	MC
304953	100736314	20992732888	lymph	lymph	NN1
304953	100736314	20992732889	nodes	node	NN2
304953	100736314	20992732890	,	,	,
304953	100736314	20992732891	all	all	DB_RR@
304953	100736314	20992732892	tested	test	VVD_VVN_JJ@
304953	100736314	20992732893	clear	clear	JJ
304953	100736314	20992732894	and	and	CC
304953	100736314	20992732895	it	it	PPH1
304953	100736314	20992732896	was	be	VBDZ
304953	100736314	20992732897	felt	feel	VVN
304953	100736314	20992732898	the	the	AT
304953	100736314	20992732899	cancer	cancer	NN1
304953	100736314	20992732900	was	be	VBDZ
304953	100736314	20992732901	confined	confine	VVN
304953	100736314	20992732902	to	to	II
304953	100736314	20992732903	the	the	AT
304953	100736314	20992732904	prostate	prostate	NN1
304953	100736314	20992732905	.	.	.
304953	100736314	20992732906	I	i	PPIS1
304953	100736314	20992732907	am	be	VBM
304953	100736314	20992732908	not	not	XX
304953	100736314	20992732909	sure	sure	JJ_RR%
304953	100736314	20992732910	what	what	DDQ
304953	100736314	20992732911	there	there	EX
304953	100736314	20992732912	was	be	VBDZ
304953	100736314	20992732913	a	a	AT1
304953	100736314	20992732914	need	need	NN1
304953	100736314	20992732915	to	to	TO
304953	100736314	20992732916	remove	remove	VVI
304953	100736314	20992732917	so	so	RG
304953	100736314	20992732918	many	many	DA2
304953	100736314	20992732919	.	.	.
304953	100736314	20992732920	I	i	PPIS1
304953	100736314	20992732921	began	begin	VVD
304953	100736314	20992732922	a	a	AT1
304953	100736314	20992732923	very	very	RG
304953	100736314	20992732924	good	good	JJ
304953	100736314	20992732925	recovery	recovery	NN1
304953	100736314	20992732926	and	and	CC
304953	100736314	20992732927	even	even	RR
304953	100736314	20992732928	had	have	VHN@_VHD
304953	100736314	20992732929	erection	erection	NN1
304953	100736314	20992732930	.	.	.
304953	100736314	20992732931	Within	within	II
304953	100736314	20992732932	6	6	MC
304953	100736314	20992732933	weeks	week	NNT2
304953	100736314	20992732934	I	i	PPIS1
304953	100736314	20992732935	started	start	VVD
304953	100736314	20992732936	having	have	VHG
304953	100736314	20992732937	pain	pain	NN1
304953	100736314	20992732938	in	in	II
304953	100736314	20992732939	my	my	APPGE
304953	100736314	20992732940	lower	low	JJR
304953	100736314	20992732941	abdomen	abdomen	NN1
304953	100736314	20992732942	and	and	CC
304953	100736314	20992732943	low	low	JJ
304953	100736314	20992732944	grade	grade	NN1
304953	100736314	20992732945	fever	fever	NN1
304953	100736314	20992732946	.	.	.
304953	100736314	20992732947	I	i	PPIS1
304953	100736314	20992732948	discussed	discuss	VVD
304953	100736314	20992732949	with	with	IW
304953	100736314	20992732950	the	the	AT
304953	100736314	20992732951	surgical	surgical	JJ
304953	100736314	20992732952	oncologist-urologist		NN1
304953	100736314	20992732953	.	.	.
304953	100736314	20992732954	He	he	PPHS1
304953	100736314	20992732955	said	say	VVD
304953	100736314	20992732956	it	it	PPH1
304953	100736314	20992732957	would	would	VM
304953	100736314	20992732958	clear	clear	VVI
304953	100736314	20992732959	up	up	RP
304953	100736314	20992732960	.	.	.
304953	100736314	20992732961	The	the	AT
304953	100736314	20992732962	pain	pain	NN1
304953	100736314	20992732963	increased	increase	VVD_VVN_JJ
304953	100736314	20992732964	daily	daily	JJ_RR
304953	100736314	20992732965	and	and	CC
304953	100736314	20992732966	the	the	AT
304953	100736314	20992732967	night	night	NNT1
304953	100736314	20992732968	sweats	sweat	NN2_VVZ
304953	100736314	20992732969	and	and	CC
304953	100736314	20992732970	testicular	testicular	JJ
304953	100736314	20992732971	swelling	swelling	JJ
304953	100736314	20992732972	became	become	VVD
304953	100736314	20992732973	unbearable	unbearable	JJ
304953	100736314	20992732974	.	.	.
304953	100736314	20992732975	I	i	PPIS1
304953	100736314	20992732976	went	go	VVD
304953	100736314	20992732977	to	to	II
304953	100736314	20992732978	the	the	AT
304953	100736314	20992732979	surgeons	surgeon	NN2
304953	100736314	20992732980	office	office	NN1
304953	100736314	20992732981	for	for	IF
304953	100736314	20992732982	a	a	AT1
304953	100736314	20992732983	3	3	MC
304953	100736314	20992732984	month	month	NNT1
304953	100736314	20992732985	follow	follow	VV0_NN121@
304953	100736314	20992732986	up	up	RP_NN122
304953	100736314	20992732987	and	and	CC
304953	100736314	20992732988	discussed	discuss	VVD
304953	100736314	20992732989	the	the	AT
304953	100736314	20992732990	issues	issue	NN2
304953	100736314	20992732991	and	and	CC
304953	100736314	20992732992	the	the	AT
304953	100736314	20992732993	intense	intense	JJ
304953	100736314	20992732994	pain	pain	NN1
304953	100736314	20992732995	.	.	.
304953	100736314	20992732996	He	he	PPHS1
304953	100736314	20992732997	had	have	VHD
304953	100736314	20992732998	a	a	AT1
304953	100736314	20992732999	CT	ct	NN1
304953	100736314	20992733000	scan	scan	NN1
304953	100736314	20992733001	performed	perform	VVN_VVD
304953	100736314	20992733002	in	in	II_RP@
304953	100736314	20992733003	his	his	APPGE
304953	100736314	20992733004	office	office	NN1
304953	100736314	20992733005	.	.	.
304953	100736314	20992733006	He	he	PPHS1
304953	100736314	20992733007	found	find	VVD
304953	100736314	20992733008	a	a	AT1
304953	100736314	20992733009	large	large	JJ
304953	100736314	20992733010	pocket	pocket	NN1
304953	100736314	20992733011	of	of	IO
304953	100736314	20992733012	fluid	fluid	NN1
304953	100736314	20992733013	in	in	II
304953	100736314	20992733014	the	the	AT
304953	100736314	20992733015	prostate	prostate	NN1
304953	100736314	20992733016	bed	bed	NN1
304953	100736314	20992733017	due	due	II21
304953	100736314	20992733018	to	to	II22
304953	100736314	20992733019	the	the	AT
304953	100736314	20992733020	removal	removal	NN1
304953	100736314	20992733021	of	of	IO
304953	100736314	20992733022	the	the	AT
304953	100736314	20992733023	prostate	prostate	NN1
304953	100736314	20992733024	and	and	CC
304953	100736314	20992733025	lymph	lymph	NN1
304953	100736314	20992733026	nod	nod	NN1_VV0
304953	100736314	20992733027	removal	removal	NN1
304953	100736314	20992733028	.	.	.
304953	100736314	20992733029	He	he	PPHS1
304953	100736314	20992733030	informed	inform	VVD
304953	100736314	20992733031	me	me	PPIO1
304953	100736314	20992733032	he	he	PPHS1
304953	100736314	20992733033	could	could	VM
304953	100736314	20992733034	open	open	VVI
304953	100736314	20992733035	me	me	PPIO1
304953	100736314	20992733036	up	up	RP
304953	100736314	20992733037	with	with	IW
304953	100736314	20992733038	a	a	AT1
304953	100736314	20992733039	surgical	surgical	JJ
304953	100736314	20992733040	procedure	procedure	NN1
304953	100736314	20992733041	and	and	CC
304953	100736314	20992733042	remove	remove	VV0
304953	100736314	20992733043	it	it	PPH1
304953	100736314	20992733044	or	or	CC
304953	100736314	20992733045	just	just	RR
304953	100736314	20992733046	let	let	VV0_VVD@
304953	100736314	20992733047	my	my	APPGE
304953	100736314	20992733048	body	body	NN1
304953	100736314	20992733049	absorb	absorb	VVI
304953	100736314	20992733050	the	the	AT
304953	100736314	20992733051	fluid	fluid	NN1
304953	100736314	20992733052	and	and	CC
304953	100736314	20992733053	I	i	PPIS1
304953	100736314	20992733054	will	will	VM
304953	100736314	20992733055	be	be	VBI
304953	100736314	20992733056	fine	fine	JJ
304953	100736314	20992733057	.	.	.
304953	100736314	20992733058	He	he	PPHS1
304953	100736314	20992733059	did	do	VDD
304953	100736314	20992733060	n't 	n't	XX
304953	100736314	20992733061	@		II
304953	100736314	20992733062	@		II
304953	100736314	20992733063	@		II
304953	100736314	20992733064	@		II
304953	100736314	20992733065	@		II
304953	100736314	20992733066	@		II
304953	100736314	20992733067	@		II
304953	100736314	20992733068	@		II
304953	100736314	20992733069	@		II
304953	100736314	20992733070	@		II
304953	100736314	20992733071	an	a	AT1
304953	100736314	20992733072	appointment	appointment	NN1
304953	100736314	20992733073	with	with	IW
304953	100736314	20992733074	my	my	APPGE
304953	100736314	20992733075	regular	regular	JJ
304953	100736314	20992733076	medical	medical	JJ
304953	100736314	20992733077	doctor	doctor	NN1
304953	100736314	20992733078	within	within	II
304953	100736314	20992733079	an	a	AT1
304953	100736314	20992733080	hour	hour	NNT1
304953	100736314	20992733081	of	of	IO
304953	100736314	20992733082	the	the	AT
304953	100736314	20992733083	previous	previous	JJ
304953	100736314	20992733084	visit	visit	NN1
304953	100736314	20992733085	.	.	.
304953	100736314	20992733086	As	as	CS31
304953	100736314	20992733087	soon	soon	CS32
304953	100736314	20992733088	as	as	CS33
304953	100736314	20992733089	he	he	PPHS1
304953	100736314	20992733090	walked	walk	VVD
304953	100736314	20992733091	into	into	II
304953	100736314	20992733092	the	the	AT
304953	100736314	20992733093	room	room	NN1
304953	100736314	20992733094	he	he	PPHS1
304953	100736314	20992733095	said	say	VVD
304953	100736314	20992733096	something	something	PN1
304953	100736314	20992733097	was	be	VBDZ
304953	100736314	20992733098	wrong	wrong	JJ_RR@
304953	100736314	20992733099	.	.	.
304953	100736314	20992733100	He	he	PPHS1
304953	100736314	20992733101	examined	examine	VVD
304953	100736314	20992733102	me	me	PPIO1
304953	100736314	20992733103	,	,	,
304953	100736314	20992733104	took	take	VVD
304953	100736314	20992733105	a	a	AT1
304953	100736314	20992733106	look	look	NN1
304953	100736314	20992733107	at	at	II
304953	100736314	20992733108	the	the	AT
304953	100736314	20992733109	swelling	swelling	JJ
304953	100736314	20992733110	of	of	IO
304953	100736314	20992733111	my	my	APPGE
304953	100736314	20992733112	lower	low	JJR
304953	100736314	20992733113	extremities	extremity	NN2
304953	100736314	20992733114	.	.	.
304953	100736314	20992733115	He	he	PPHS1
304953	100736314	20992733116	had	have	VHD
304953	100736314	20992733117	me	me	PPIO1
304953	100736314	20992733118	go	go	NN1%_VV0
304953	100736314	20992733119	directly	directly	RR
304953	100736314	20992733120	to	to	II
304953	100736314	20992733121	the	the	AT
304953	100736314	20992733122	hospital	hospital	NN1
304953	100736314	20992733123	lab	lab	NN1
304953	100736314	20992733124	"	"	"
304953	100736314	20992733125	STAT	stat	NN1_NP1
304953	100736314	20992733126	"	"	"
304953	100736314	20992733127	and	and	CC
304953	100736314	20992733128	have	have	VH0
304953	100736314	20992733129	blood	blood	NN1
304953	100736314	20992733130	cultures	culture	NN2
304953	100736314	20992733131	along	along	II21
304953	100736314	20992733132	with	with	II22
304953	100736314	20992733133	other	other	JJ
304953	100736314	20992733134	lab	lab	NN1
304953	100736314	20992733135	work	work	NN1
304953	100736314	20992733136	.	.	.
304953	100736314	20992733137	My	my	APPGE
304953	100736314	20992733138	CRP	crp	NP1
304953	100736314	20992733139	(	(	(
304953	100736314	20992733140	normally	normally	RR
304953	100736314	20992733141	0-5	0-5	MCMC
304953	100736314	20992733142	)	)	)
304953	100736314	20992733143	was	be	VBDZ
304953	100736314	20992733144	hit	hit	VVN
304953	100736314	20992733145	192	192	MC
304953	100736314	20992733146	.	.	.
304953	100736314	20992733147	The	the	AT
304953	100736314	20992733148	following	following	JJ
304953	100736314	20992733149	morning	morning	NNT1
304953	100736314	20992733150	my	my	APPGE
304953	100736314	20992733151	doctor	doctor	NN1
304953	100736314	20992733152	called	call	VVN
304953	100736314	20992733153	and	and	CC
304953	100736314	20992733154	woke	wake	VVN
304953	100736314	20992733155	me	me	PPIO1
304953	100736314	20992733156	up	up	RP
304953	100736314	20992733157	and	and	CC
304953	100736314	20992733158	had	have	VHD
304953	100736314	20992733159	me	me	PPIO1
304953	100736314	20992733160	report	report	NN1
304953	100736314	20992733161	to	to	II
304953	100736314	20992733162	the	the	AT
304953	100736314	20992733163	hospital	hospital	NN1
304953	100736314	20992733164	as	as	RG
304953	100736314	20992733165	soon	soon	RR
304953	100736314	20992733166	as	as	CSA
304953	100736314	20992733167	possible	possible	JJ
304953	100736314	20992733168	.	.	.
304953	100736314	20992733169	After	after	II_CS
304953	100736314	20992733170	9	9	MC
304953	100736314	20992733171	days	day	NNT2
304953	100736314	20992733172	of	of	IO
304953	100736314	20992733173	IV	iv	MC
304953	100736314	20992733174	antibiotics	antibiotic	NN2
304953	100736314	20992733175	and	and	CC
304953	100736314	20992733176	the	the	AT
304953	100736314	20992733177	placement	placement	NN1
304953	100736314	20992733178	of	of	IO
304953	100736314	20992733179	2	2	MC
304953	100736314	20992733180	drain	drain	NN1_VV0
304953	100736314	20992733181	tubes	tube	NN2
304953	100736314	20992733182	I	i	PPIS1
304953	100736314	20992733183	was	be	VBDZ
304953	100736314	20992733184	able	able	JK
304953	100736314	20992733185	to	to	TO
304953	100736314	20992733186	return	return	VVI
304953	100736314	20992733187	home	home	RL_NN1
304953	100736314	20992733188	and	and	CC
304953	100736314	20992733189	take	take	VVI
304953	100736314	20992733190	oral	oral	JJ_NN1
304953	100736314	20992733191	antibiotics	antibiotic	NN2
304953	100736314	20992733192	for	for	IF
304953	100736314	20992733193	another	another	DD1
304953	100736314	20992733194	month	month	NNT1
304953	100736314	20992733195	.	.	.
304953	100736314	20992733196	From	from	II
304953	100736314	20992733197	that	that	DD1
304953	100736314	20992733198	time	time	NNT1
304953	100736314	20992733199	I	i	PPIS1
304953	100736314	20992733200	had	have	VHD
304953	100736314	20992733201	loss	loss	NN1
304953	100736314	20992733202	of	of	IO
304953	100736314	20992733203	bladder	bladder	NN1
304953	100736314	20992733204	control	control	NN1_VV0
304953	100736314	20992733205	that	that	CST
304953	100736314	20992733206	I	i	PPIS1
304953	100736314	20992733207	had	have	VHD
304953	100736314	20992733208	regained	regain	VVN
304953	100736314	20992733209	within	within	II
304953	100736314	20992733210	the	the	AT
304953	100736314	20992733211	first	first	MD
304953	100736314	20992733212	6	6	MC
304953	100736314	20992733213	weeks	week	NNT2
304953	100736314	20992733214	of	of	IO
304953	100736314	20992733215	surgery	surgery	NN1
304953	100736314	20992733216	and	and	CC
304953	100736314	20992733217	not	not	XX
304953	100736314	20992733218	able	able	JK
304953	100736314	20992733219	to	to	TO
304953	100736314	20992733220	have	have	VHI
304953	100736314	20992733221	an	a	AT1
304953	100736314	20992733222	erection	erection	NN1
304953	100736314	20992733223	.	.	.
304953	100736314	20992733224	The	the	AT
304953	100736314	20992733225	infection	infection	NN1
304953	100736314	20992733226	and	and	CC
304953	100736314	20992733227	the	the	AT
304953	100736314	20992733228	drain	drain	NN1
304953	100736314	20992733229	tubes	tube	NN2
304953	100736314	20992733230	damaged	damage	VVN_VVD@
304953	100736314	20992733231	the	the	AT
304953	100736314	20992733232	nerves	nerve	NN2
304953	100736314	20992733233	.	.	.
304953	100736314	20992733234	A	a	AT1
304953	100736314	20992733235	few	few	DA2
304953	100736314	20992733236	months	month	NNT2
304953	100736314	20992733237	later	later	RRR
304953	100736314	20992733238	my	my	APPGE
304953	100736314	20992733239	PSA	psa	NP1
304953	100736314	20992733240	began	begin	VVD
304953	100736314	20992733241	to	to	TO
304953	100736314	20992733242	rise	rise	VVI
304953	100736314	20992733243	and	and	CC
304953	100736314	20992733244	I	i	PPIS1
304953	100736314	20992733245	had	have	VHD
304953	100736314	20992733246	7	7	MC
304953	100736314	20992733247	weeks	week	NNT2
304953	100736314	20992733248	of	of	IO
304953	100736314	20992733249	radiation	radiation	NN1
304953	100736314	20992733250	treatment	treatment	NN1
304953	100736314	20992733251	.	.	.
304953	100736314	20992733252	The	the	AT
304953	100736314	20992733253	side	side	NN1
304953	100736314	20992733254	effects	effect	NN2
304953	100736314	20992733255	from	from	II
304953	100736314	20992733256	the	the	AT
304953	100736314	20992733257	surgery	surgery	NN1
304953	100736314	20992733258	and	and	CC
304953	100736314	20992733259	complications	complication	NN2
304953	100736314	20992733260	and	and	CC
304953	100736314	20992733261	@		II
304953	100736314	20992733262	@		II
304953	100736314	20992733263	@		II
304953	100736314	20992733264	@		II
304953	100736314	20992733265	@		II
304953	100736314	20992733266	@		II
304953	100736314	20992733267	@		II
304953	100736314	20992733268	@		II
304953	100736314	20992733269	@		II
304953	100736314	20992733270	@		II
304953	100736314	20992733271	this	this	DD1
304953	100736314	20992733272	and	and	CC
304953	100736314	20992733273	If	if	CS
304953	100736314	20992733274	I	i	PPIS1
304953	100736314	20992733275	can	can	VM
304953	100736314	20992733276	share	share	VVI
304953	100736314	20992733277	one	one	MC1
304953	100736314	20992733278	thing	thing	NN1
304953	100736314	20992733279	if	if	CS
304953	100736314	20992733280	you	you	PPY
304953	100736314	20992733281	are	be	VBR
304953	100736314	20992733282	confronted	confront	VVN
304953	100736314	20992733283	with	with	IW
304953	100736314	20992733284	prostate	prostate	NN1
304953	100736314	20992733285	cancer	cancer	NN1
304953	100736314	20992733286	seek	seek	VV0
304953	100736314	20992733287	treatment	treatment	NN1
304953	100736314	20992733288	early	early	RR_JJ
304953	100736314	20992733289	and	and	CC
304953	100736314	20992733290	go	go	VV0
304953	100736314	20992733291	to	to	II
304953	100736314	20992733292	a	a	AT1
304953	100736314	20992733293	major	major	JJ
304953	100736314	20992733294	cancer	cancer	NN1
304953	100736314	20992733295	hospital	hospital	NN1
304953	100736314	20992733296	like	like	II
304953	100736314	20992733297	M	m	ZZ1
304953	100736314	20992733298	D	d	ZZ1
304953	100736314	20992733299	Anderson	anderson	NP1
304953	100736314	20992733300	or	or	CC
304953	100736314	20992733301	John	john	NP1
304953	100736314	20992733302	Hopkins	hopkins	NP1
304953	100736314	20992733303	.	.	.
304953	100736314	20992733304	I	i	PPIS1
304953	100736314	20992733305	would	would	VM
304953	100736314	20992733306	never	never	RR
304953	100736314	20992733307	use	use	VVI
304953	100736314	20992733308	a	a	AT1
304953	100736314	20992733309	local	local	JJ
304953	100736314	20992733310	surgeon-urologist		NN1_JJ
304953	100736314	20992733311	that	that	CST_DD1
304953	100736314	20992733312	may	may	VM
304953	100736314	20992733313	have	have	VHI
304953	100736314	20992733314	done	do	VDN
304953	100736314	20992733315	many	many	DA2
304953	100736314	20992733316	surgeries	surgery	NN2
304953	100736314	20992733317	but	but	CCB
304953	100736314	20992733318	is	be	VBZ
304953	100736314	20992733319	one	one	MC1
304953	100736314	20992733320	person	person	NN1
304953	100736314	20992733321	with	with	IW
304953	100736314	20992733322	one	one	MC1
304953	100736314	20992733323	view	view	NN1
304953	100736314	20992733324	point	point	NN1
304953	100736314	20992733325	.	.	.
304953	100736314	20992733326	Remember	remember	VV0
304953	100736314	20992733327	a	a	AT1
304953	100736314	20992733328	surgeon	surgeon	NN1
304953	100736314	20992733329	recommends	recommend	VVZ
304953	100736314	20992733330	surgical	surgical	JJ
304953	100736314	20992733331	solutions	solution	NN2
304953	100736314	20992733332	,	,	,
304953	100736314	20992733333	a	a	AT1
304953	100736314	20992733334	radiation	radiation	NN1
304953	100736314	20992733335	oncologist	oncologist	NN1
304953	100736314	20992733336	recommends	recommend	VVZ
304953	100736314	20992733337	radiation	radiation	NN1
304953	100736314	20992733338	and	and	CC
304953	100736314	20992733339	a	a	AT1
304953	100736314	20992733340	chemical	chemical	JJ_NN1
304953	100736314	20992733341	oncologist	oncologist	NN1
304953	100736314	20992733342	recommends	recommend	VVZ
304953	100736314	20992733343	chemicals	chemical	NN2
304953	100736314	20992733344	.	.	.
304953	100736314	20992733345	A	a	AT1
304953	100736314	20992733346	hospital	hospital	NN1
304953	100736314	20992733347	like	like	II
304953	100736314	20992733348	M	m	ZZ1
304953	100736314	20992733349	D	d	ZZ1
304953	100736314	20992733350	Anderson	anderson	NP1
304953	100736314	20992733351	has	have	VHZ
304953	100736314	20992733352	treatment	treatment	NN1
304953	100736314	20992733353	teams	team	NN2
304953	100736314	20992733354	that	that	CST_DD1
304953	100736314	20992733355	look	look	VV0_NN1
304953	100736314	20992733356	and	and	CC
304953	100736314	20992733357	agree	agree	VV0
304953	100736314	20992733358	on	on	II_RP@
304953	100736314	20992733359	the	the	AT
304953	100736314	20992733360	best	best	JJT_RRT
304953	100736314	20992733361	plan	plan	NN1_VV0
304953	100736314	20992733362	for	for	IF
304953	100736314	20992733363	you	you	PPY
304953	100736314	20992733364	.	.	.
304953	100736314	20992733365	<p>		NULL
304953	100736314	20992733366	The	the	AT
304953	100736314	20992733367	first	first	MD
304953	100736314	20992733368	time	time	NNT1
304953	100736314	20992733369	I	i	PPIS1
304953	100736314	20992733370	heard	hear	VVD
304953	100736314	20992733371	about	about	II
304953	100736314	20992733372	"	"	"
304953	100736314	20992733373	penile	penile	JJ_NN1
304953	100736314	20992733374	shortening	shortening	NN1@
304953	100736314	20992733375	"	"	"
304953	100736314	20992733376	was	be	VBDZ
304953	100736314	20992733377	when	when	RRQ_CS
304953	100736314	20992733378	I	i	PPIS1
304953	100736314	20992733379	saw	see	VVD
304953	100736314	20992733380	it	it	PPH1
304953	100736314	20992733381	on	on	II
304953	100736314	20992733382	the	the	AT
304953	100736314	20992733383	consent	consent	NN1
304953	100736314	20992733384	forms	form	VVZ_NN2
304953	100736314	20992733385	about	about	RG
304953	100736314	20992733386	an	a	AT1
304953	100736314	20992733387	hour	hour	NNT1
304953	100736314	20992733388	before	before	CS
304953	100736314	20992733389	I	i	PPIS1
304953	100736314	20992733390	was	be	VBDZ
304953	100736314	20992733391	scheduled	schedule	VVN
304953	100736314	20992733392	for	for	IF
304953	100736314	20992733393	my	my	APPGE
304953	100736314	20992733394	radical	radical	JJ_NN1
304953	100736314	20992733395	prostatectomy	prostatectomy	NN1
304953	100736314	20992733396	at	at	II
304953	100736314	20992733397	Johns	john	NP1
304953	100736314	20992733398	Hopkins	hopkins	NP1
304953	100736314	20992733399	in	in	II
304953	100736314	20992733400	2008	2008	MC
304953	100736314	20992733401	.	.	.
304953	100736314	20992733402	As	as	CS31
304953	100736314	20992733403	soon	soon	CS32
304953	100736314	20992733404	as	as	CS33
304953	100736314	20992733405	the	the	AT
304953	100736314	20992733406	abdominal/groin		NN1
304953	100736314	20992733407	swelling	swell	VVG
304953	100736314	20992733408	from	from	II
304953	100736314	20992733409	the	the	AT
304953	100736314	20992733410	operation	operation	NN1
304953	100736314	20992733411	went	go	VVD
304953	100736314	20992733412	down	down	RP
304953	100736314	20992733413	I	i	PPIS1
304953	100736314	20992733414	know	know	VV0
304953	100736314	20992733415	that	that	CST_DD1
304953	100736314	20992733416	something	something	PN1
304953	100736314	20992733417	was	be	VBDZ
304953	100736314	20992733418	not	not	XX
304953	100736314	20992733419	as	as	CSA
304953	100736314	20992733420	it	it	PPH1
304953	100736314	20992733421	had	have	VHD
304953	100736314	20992733422	been	be	VBN
304953	100736314	20992733423	.	.	.
304953	100736314	20992733424	The	the	AT
304953	100736314	20992733425	surgeons	surgeon	NN2
304953	100736314	20992733426	assistant	assistant	NN1
304953	100736314	20992733427	said	say	VVD
304953	100736314	20992733428	that	that	CST
304953	100736314	20992733429	it	it	PPH1
304953	100736314	20992733430	would	would	VM
304953	100736314	20992733431	affect	affect	VVI
304953	100736314	20992733432	me	me	PPIO1
304953	100736314	20992733433	only	only	JJ
304953	100736314	20992733434	in	-in	II
304953	100736314	20992733435	the	the	AT
304953	100736314	20992733436	non-erect		JJ
304953	100736314	20992733437	state	state	NN1
304953	100736314	20992733438	which	which	DDQ
304953	100736314	20992733439	was	be	VBDZ
304953	100736314	20992733440	a	a	AT1
304953	100736314	20992733441	lie	lie	NN1@
304953	100736314	20992733442	.	.	.
304953	100736314	20992733443	Finally	finally	RR
304953	100736314	20992733444	,	,	,
304953	100736314	20992733445	during	during	II
304953	100736314	20992733446	a	a	AT1
304953	100736314	20992733447	visit	visit	NN1
304953	100736314	20992733448	to	to	II
304953	100736314	20992733449	a	a	AT1
304953	100736314	20992733450	new	new	JJ
304953	100736314	20992733451	urologist	urologist	NN1
304953	100736314	20992733452	a	a	AT1
304953	100736314	20992733453	couple	couple	NN1
304953	100736314	20992733454	of	of	IO
304953	100736314	20992733455	months	month	NNT2
304953	100736314	20992733456	ago	ago	RA
304953	100736314	20992733457	,	,	,
304953	100736314	20992733458	he	he	PPHS1
304953	100736314	20992733459	stated	state	VVD
304953	100736314	20992733460	that	that	CST_DD1
304953	100736314	20992733461	@		II
304953	100736314	20992733462	@		II
304953	100736314	20992733463	@		II
304953	100736314	20992733464	@		II
304953	100736314	20992733465	@		II
304953	100736314	20992733466	@		II
304953	100736314	20992733467	@		II
304953	100736314	20992733468	@		II
304953	100736314	20992733469	@		II
304953	100736314	20992733470	@		II
304953	100736314	20992733471	to	to	II
304953	100736314	20992733472	3cm		NNU
304953	100736314	20992733473	in	in	II
304953	100736314	20992733474	lenth		MD
304953	100736314	20992733475	.	.	.
304953	100736314	20992733476	With	with	IW
304953	100736314	20992733477	ED	ed	NP1
304953	100736314	20992733478	meds	meds	VVZ_NN2
304953	100736314	20992733479	I	i	PPIS1
304953	100736314	20992733480	can	can	VM
304953	100736314	20992733481	get	get	VVI
304953	100736314	20992733482	an	a	AT1
304953	100736314	20992733483	erection	erection	NN1
304953	100736314	20992733484	,	,	,
304953	100736314	20992733485	so	so	CS@_RR
304953	100736314	20992733486	I	i	PPIS1
304953	100736314	20992733487	do	do	VD0
304953	100736314	20992733488	have	have	VHI
304953	100736314	20992733489	nerve	nerve	NN1
304953	100736314	20992733490	function	function	NN1
304953	100736314	20992733491	,	,	,
304953	100736314	20992733492	but	but	CCB
304953	100736314	20992733493	there	there	EX
304953	100736314	20992733494	is	be	VBZ
304953	100736314	20992733495	1.25	1.25	MC
304953	100736314	20992733496	inches	inch	NNU2
304953	100736314	20992733497	less	less	RRR
304953	100736314	20992733498	of	of	IO
304953	100736314	20992733499	me	me	PPIO1
304953	100736314	20992733500	flaccid	flaccid	JJ
304953	100736314	20992733501	or	or	CC
304953	100736314	20992733502	erect	erect	VV0_JJ
304953	100736314	20992733503	.	.	.
304953	100736314	20992733504	Obviously	obviously	RR
304953	100736314	20992733505	,	,	,
304953	100736314	20992733506	the	the	AT
304953	100736314	20992733507	cause	cause	NN1
304953	100736314	20992733508	was	be	VBDZ
304953	100736314	20992733509	removing	remove	VVG
304953	100736314	20992733510	the	the	AT
304953	100736314	20992733511	prostate	prostate	NN1
304953	100736314	20992733512	and	and	CC
304953	100736314	20992733513	pulling	pull	VVG
304953	100736314	20992733514	in	in	II
304953	100736314	20992733515	the	the	AT
304953	100736314	20992733516	penis	penis	NN1
304953	100736314	20992733517	to	to	TO
304953	100736314	20992733518	reconnect	reconnect	VVI
304953	100736314	20992733519	the	the	AT
304953	100736314	20992733520	urethra	urethra	NN1
304953	100736314	20992733521	.	.	.
304953	100736314	20992733522	<p>		NULL
304953	100736314	20992733523	My	my	APPGE
304953	100736314	20992733524	husband	husband	NN1
304953	100736314	20992733525	had	have	VHD
304953	100736314	20992733526	his	his	APPGE
304953	100736314	20992733527	surgery	surgery	NN1
304953	100736314	20992733528	in	in	II_RP@
304953	100736314	20992733529	july	july	RR
304953	100736314	20992733530	2015	2015	MC
304953	100736314	20992733531	and	and	CC
304953	100736314	20992733532	at	at	II
304953	100736314	20992733533	no	no	AT
304953	100736314	20992733534	point	point	NN1
304953	100736314	20992733535	was	be	VBDZ
304953	100736314	20992733536	he	he	PPHS1
304953	100736314	20992733537	warned	warn	VVN
304953	100736314	20992733538	that	that	CST
304953	100736314	20992733539	his	his	APPGE
304953	100736314	20992733540	penis	penis	NN1
304953	100736314	20992733541	would	would	VM
304953	100736314	20992733542	become	become	VVI
304953	100736314	20992733543	shorter	short	JJR
304953	100736314	20992733544	.	.	.
304953	100736314	20992733545	He	he	PPHS1
304953	100736314	20992733546	was	be	VBDZ
304953	100736314	20992733547	also	also	RR
304953	100736314	20992733548	not	not	XX
304953	100736314	20992733549	prepared	prepare	VVN
304953	100736314	20992733550	for	for	IF
304953	100736314	20992733551	the	the	AT
304953	100736314	20992733552	lack	lack	NN1
304953	100736314	20992733553	of	of	IO
304953	100736314	20992733554	bladder	bladder	NN1
304953	100736314	20992733555	control	control	NN1_VV0
304953	100736314	20992733556	after	after	II_CS
304953	100736314	20992733557	the	the	AT
304953	100736314	20992733558	operation	operation	NN1
304953	100736314	20992733559	as	as	CSA
304953	100736314	20992733560	again	again	RT
304953	100736314	20992733561	,	,	,
304953	100736314	20992733562	his	his	APPGE
304953	100736314	20992733563	doctor	doctor	NN1
304953	100736314	20992733564	failed	fail	VVD_VVN
304953	100736314	20992733565	to	to	TO
304953	100736314	20992733566	discuss	discuss	VVI
304953	100736314	20992733567	this	this	DD1
304953	100736314	20992733568	side	side	NN1
304953	100736314	20992733569	effect	effect	NN1
304953	100736314	20992733570	.	.	.
304953	100736314	20992733571	He	he	PPHS1
304953	100736314	20992733572	is	be	VBZ
304953	100736314	20992733573	extremely	extremely	RR
304953	100736314	20992733574	self	self	JJ%_NN1
304953	100736314	20992733575	conscious	conscious	JJ
304953	100736314	20992733576	about	about	II
304953	100736314	20992733577	the	the	AT
304953	100736314	20992733578	size	size	NN1
304953	100736314	20992733579	of	of	IO
304953	100736314	20992733580	his	his	APPGE
304953	100736314	20992733581	penis	penis	NN1
304953	100736314	20992733582	now	now	RT
304953	100736314	20992733583	,	,	,
304953	100736314	20992733584	even	even	CS21
304953	100736314	20992733585	though	though	CS22
304953	100736314	20992733586	I	i	PPIS1
304953	100736314	20992733587	constantly	constantly	RR
304953	100736314	20992733588	tell	tell	VV0
304953	100736314	20992733589	him	him	PPHO1
304953	100736314	20992733590	that	that	CST
304953	100736314	20992733591	to	to	II
304953	100736314	20992733592	me	me	PPIO1
304953	100736314	20992733593	it	it	PPH1
304953	100736314	20992733594	does	do	VDZ
304953	100736314	20992733595	n't 	n't	XX
304953	100736314	20992733596	make	make	VVI
304953	100736314	20992733597	a	a	AT1
304953	100736314	20992733598	difference	difference	NN1
304953	100736314	20992733599	.	.	.
304953	100736314	20992733600	I 'm		VV0
304953	100736314	20992733601	struggling	struggle	VVG_JJ
304953	100736314	20992733602	to	to	TO
304953	100736314	20992733603	find	find	VVI
304953	100736314	20992733604	a	a	AT1
304953	100736314	20992733605	way	way	NN1
304953	100736314	20992733606	to	to	TO
304953	100736314	20992733607	help	help	VVI
304953	100736314	20992733608	him	him	PPHO1
304953	100736314	20992733609	come	come	VVI
304953	100736314	20992733610	to	to	II
304953	100736314	20992733611	terms	term	NN2
304953	100736314	20992733612	with	with	IW
304953	100736314	20992733613	this	this	DD1
304953	100736314	20992733614	new	new	JJ
304953	100736314	20992733615	reality	reality	NN1
304953	100736314	20992733616	.	.	.
304953	100736314	20992733617	<p>		NULL
304953	100736314	20992733618	It	it	PPH1
304953	100736314	20992733619	is	be	VBZ
304953	100736314	20992733620	so	so	RG_RR
304953	100736314	20992733621	nice	nice	JJ
304953	100736314	20992733622	to	to	TO
304953	100736314	20992733623	know	know	VVI
304953	100736314	20992733624	I	i	PPIS1
304953	100736314	20992733625	am	be	VBM
304953	100736314	20992733626	not	not	XX
304953	100736314	20992733627	alonethis		NN1
304953	100736314	20992733628	is n't		VV0_NN1
304953	100736314	20992733629	the	the	AT
304953	100736314	20992733630	kind	kind	NN1
304953	100736314	20992733631	of	of	IO
304953	100736314	20992733632	thing	thing	NN1
304953	100736314	20992733633	you	you	PPY
304953	100736314	20992733634	discuss	discuss	VV0
304953	100736314	20992733635	with	with	IW
304953	100736314	20992733636	anyone	anyone	PN1
304953	100736314	20992733637	.	.	.
304953	100736314	20992733638	All	all	DB
304953	100736314	20992733639	the	the	AT
304953	100736314	20992733640	articles	article	NN2
304953	100736314	20992733641	mention	mention	VV0
304953	100736314	20992733642	a	a	AT1
304953	100736314	20992733643	sight	sight	NN1
304953	100736314	20992733644	reduction	reduction	NN1
304953	100736314	20992733645	of	of	IO
304953	100736314	20992733646	1	1	MC1
304953	100736314	20992733647	to	to	II
304953	100736314	20992733648	2	2	MC
304953	100736314	20992733649	centimeterswell		VV0_NN1
304953	100736314	20992733650	if	if	CSW@_CS
304953	100736314	20992733651	a	a	AT1
304953	100736314	20992733652	centimeter	centimeter	NN1
304953	100736314	20992733653	equals	equal	VVZ_NN2
304953	100736314	20992733654	an	a	AT1
304953	100736314	20992733655	inch	inch	NNU1
304953	100736314	20992733656	,	,	,
304953	100736314	20992733657	then	then	RT
304953	100736314	20992733658	they	they	PPHS2
304953	100736314	20992733659	are	be	VBR
304953	100736314	20992733660	correct	correct	JJ
304953	100736314	20992733661	@		II
304953	100736314	20992733662	@		II
304953	100736314	20992733663	@		II
304953	100736314	20992733664	@		II
304953	100736314	20992733665	@		II
304953	100736314	20992733666	@		II
304953	100736314	20992733667	@		II
304953	100736314	20992733668	@		II
304953	100736314	20992733669	@		II
304953	100736314	20992733670	@		II
304953	100736314	20992733671	before	before	II_CS
304953	100736314	20992733672	surgery	surgery	NN1
304953	100736314	20992733673	but	but	CCB
304953	100736314	20992733674	the	the	AT
304953	100736314	20992733675	loss	loss	NN1
304953	100736314	20992733676	of	of	IO
304953	100736314	20992733677	3	3	MC
304953	100736314	20992733678	inches	inch	NNU2
304953	100736314	20992733679	erect	erect	JJ_VV0
304953	100736314	20992733680	is	be	VBZ
304953	100736314	20992733681	a	a	AT1
304953	100736314	20992733682	major	major	JJ
304953	100736314	20992733683	blow	blow	NN1
304953	100736314	20992733684	to	to	II
304953	100736314	20992733685	my	my	APPGE
304953	100736314	20992733686	self	self	NN1
304953	100736314	20992733687	confidenceyes		VVZ
304953	100736314	20992733688	sorry	sorry	JJ
304953	100736314	20992733689	I	i	PPIS1
304953	100736314	20992733690	am	be	VBM
304953	100736314	20992733691	vain	vain	JJ
304953	100736314	20992733692	.	.	.
304953	100736314	20992733693	<p>		NULL
304953	100736314	20992733694	My	my	APPGE
304953	100736314	20992733695	surgeon	surgeon	NN1
304953	100736314	20992733696	said	say	VVD
304953	100736314	20992733697	that	that	CST
304953	100736314	20992733698	my	my	APPGE
304953	100736314	20992733699	erections	erection	NN2
304953	100736314	20992733700	would	would	VM
304953	100736314	20992733701	not	not	XX
304953	100736314	20992733702	be	be	VBI
304953	100736314	20992733703	the	the	AT
304953	100736314	20992733704	sameI		NN2
304953	100736314	20992733705	guess	guess	VV0
304953	100736314	20992733706	I	i	PPIS1
304953	100736314	20992733707	should	should	VM
304953	100736314	20992733708	have	have	VHI
304953	100736314	20992733709	pressed	press	VVN
304953	100736314	20992733710	him	him	PPHO1
304953	100736314	20992733711	to	to	TO
304953	100736314	20992733712	tell	tell	VVI
304953	100736314	20992733713	me	me	PPIO1
304953	100736314	20992733714	what	what	DDQ
304953	100736314	20992733715	exactly	exactly	RR
304953	100736314	20992733716	he	he	PPHS1
304953	100736314	20992733717	meant	mean	VVD
304953	100736314	20992733718	by	by	II
304953	100736314	20992733719	that	that	DD1
304953	100736314	20992733720	.	.	.
304953	100736314	20992733721	After	after	CS_II
304953	100736314	20992733722	the	the	AT
304953	100736314	20992733723	catheter	catheter	NN1
304953	100736314	20992733724	was	be	VBDZ
304953	100736314	20992733725	removed	remove	VVN
304953	100736314	20992733726	(	(	(
304953	100736314	20992733727	ouch	ouch	UH
304953	100736314	20992733728	)	)	)
304953	100736314	20992733729	the	the	AT
304953	100736314	20992733730	nurse	nurse	NN1
304953	100736314	20992733731	said	say	VVD
304953	100736314	20992733732	that	that	CST
304953	100736314	20992733733	she	she	PPHS1
304953	100736314	20992733734	wanted	want	VVD
304953	100736314	20992733735	to	to	TO
304953	100736314	20992733736	schedule	schedule	VVI
304953	100736314	20992733737	me	me	PPIO1
304953	100736314	20992733738	to	to	TO
304953	100736314	20992733739	meet	meet	VVI
304953	100736314	20992733740	with	with	IW
304953	100736314	20992733741	the	the	AT
304953	100736314	20992733742	penis	penis	NN1
304953	100736314	20992733743	pump	pump	NN1
304953	100736314	20992733744	sales	sales	NN
304953	100736314	20992733745	repsilly		JJ@_RR
304953	100736314	20992733746	me	me	PPIO1
304953	100736314	20992733747	I	i	PPIS1
304953	100736314	20992733748	did	do	VDD
304953	100736314	20992733749	n't 	n't	XX
304953	100736314	20992733750	follow	follow	VVI
304953	100736314	20992733751	thru	thru	RP@
304953	100736314	20992733752	with	with	IW
304953	100736314	20992733753	that	that	DD1
304953	100736314	20992733754	.	.	.
304953	100736314	20992733755	<p>		NULL
304953	100736314	20992733756	2	2	MC
304953	100736314	20992733757	years	year	NNT2
304953	100736314	20992733758	later	later	RRR
304953	100736314	20992733759	,	,	,
304953	100736314	20992733760	I	i	PPIS1
304953	100736314	20992733761	ordered	order	VVD
304953	100736314	20992733762	a	a	AT1
304953	100736314	20992733763	penis	penis	NN1
304953	100736314	20992733764	pump	pump	NN1
304953	100736314	20992733765	and	and	CC
304953	100736314	20992733766	use	use	VV0
304953	100736314	20992733767	it	it	PPH1
304953	100736314	20992733768	several	several	DA2
304953	100736314	20992733769	times	time	NNT2
304953	100736314	20992733770	a	a	AT1
304953	100736314	20992733771	day	day	NNT1
304953	100736314	20992733772	.	.	.
304953	100736314	20992733773	IDK		NP1
304953	100736314	20992733774	this	this	DD1
304953	100736314	20992733775	late	late	JJ_RR
304953	100736314	20992733776	in	in	II
304953	100736314	20992733777	the	the	AT
304953	100736314	20992733778	game	game	NN1
304953	100736314	20992733779	,	,	,
304953	100736314	20992733780	if	if	CS
304953	100736314	20992733781	it	it	PPH1
304953	100736314	20992733782	will	will	VM
304953	100736314	20992733783	reverse	reverse	VVI
304953	100736314	20992733784	the	the	AT
304953	100736314	20992733785	loss	loss	NN1
304953	100736314	20992733786	of	of	IO
304953	100736314	20992733787	length	length	NN1
304953	100736314	20992733788	.	.	.
304953	100736314	20992733789	<p>		NULL
304953	100736314	20992733790	My	my	APPGE
304953	100736314	20992733791	only	only	JJ
304953	100736314	20992733792	advice	advice	NN1
304953	100736314	20992733793	is	be	VBZ
304953	100736314	20992733794	to	to	TO
304953	100736314	20992733795	start	start	VVI
304953	100736314	20992733796	using	use	VVG
304953	100736314	20992733797	the	the	AT
304953	100736314	20992733798	pump	pump	NN1
304953	100736314	20992733799	as	as	CS31
304953	100736314	20992733800	soon	soon	CS32
304953	100736314	20992733801	as	as	CS33
304953	100736314	20992733802	you	you	PPY
304953	100736314	20992733803	are	be	VBR
304953	100736314	20992733804	cleared	clear	VVN
304953	100736314	20992733805	by	by	II
304953	100736314	20992733806	your	your	APPGE
304953	100736314	20992733807	Doctor	doctor	NN1
304953	100736314	20992733808	.	.	.
304953	100736314	20992733809	hind	hind	JJ
304953	100736314	20992733810	sight	sight	NN1
304953	100736314	20992733811	is	be	VBZ
304953	100736314	20992733812	20/20	20/20	MF
304953	100736314	20992733813	but	but	CCB
304953	100736314	20992733814	I	i	PPIS1
304953	100736314	20992733815	bet	bet	VV0
304953	100736314	20992733816	if	if	CS_CSW@
304953	100736314	20992733817	I	i	PPIS1
304953	100736314	20992733818	had	have	VHD
304953	100736314	20992733819	used	use	VVN
304953	100736314	20992733820	it	it	PPH1
304953	100736314	20992733821	within	within	II
304953	100736314	20992733822	a	a	AT1
304953	100736314	20992733823	few	few	DA2
304953	100736314	20992733824	weeks	week	NNT2
304953	100736314	20992733825	post	post	II@_NN1
304953	100736314	20992733826	surgery	surgery	NN1
304953	100736314	20992733827	,	,	,
304953	100736314	20992733828	I	i	PPIS1_MC1%
304953	100736314	20992733829	would n't		VV0_NN1
304953	100736314	20992733830	be	be	VBI
304953	100736314	20992733831	hon	hon	JJ
304953	100736314	20992733832	this	this	DD1
304953	100736314	20992733833	blog	blog	NN1
304953	100736314	20992733834	.	.	.
304953	100736314	20992733835	<p>		NULL
304953	100736314	20992733836	It	it	PPH1
304953	100736314	20992733837	is	be	VBZ
304953	100736314	20992733838	amazing	amazing	JJ_VVG%
304953	100736314	20992733839	how	how	RGQ@
304953	100736314	20992733840	much	much	DA1
304953	100736314	20992733841	more	more	DAR
304953	100736314	20992733842	discussion	discussion	NN1
304953	100736314	20992733843	of	of	IO
304953	100736314	20992733844	this	this	DD1
304953	100736314	20992733845	issue	issue	NN1
304953	100736314	20992733846	is	be	VBZ
304953	100736314	20992733847	occurring	occur	VVG
304953	100736314	20992733848	now	now	RT
304953	100736314	20992733849	.	.	.
304953	100736314	20992733850	My	my	APPGE
304953	100736314	20992733851	surgery	surgery	NN1
304953	100736314	20992733852	was	be	VBDZ
304953	100736314	20992733853	in	in	II
304953	100736314	20992733854	2001	2001	MC
304953	100736314	20992733855	and	and	CC
304953	100736314	20992733856	my	my	APPGE
304953	100736314	20992733857	urologist	urologist	NN1
304953	100736314	20992733858	basically	basically	RR
304953	100736314	20992733859	called	call	VVN_VVD@
304953	100736314	20992733860	me	me	PPIO1
304953	100736314	20992733861	@		II
304953	100736314	20992733862	@		II
304953	100736314	20992733863	@		II
304953	100736314	20992733864	@		II
304953	100736314	20992733865	@		II
304953	100736314	20992733866	@		II
304953	100736314	20992733867	@		II
304953	100736314	20992733868	@		II
304953	100736314	20992733869	@		II
304953	100736314	20992733870	@		II
304953	100736314	20992733871	?	?	?
304953	100736314	20992733872	shorter	short	JJR
304953	100736314	20992733873	in	in	II
304953	100736314	20992733874	length	length	NN1
304953	100736314	20992733875	.	.	.
304953	100736314	20992733876	Tried	try	VVD_VVN@_JJ@
304953	100736314	20992733877	to	to	TO
304953	100736314	20992733878	blame	blame	VVI
304953	100736314	20992733879	it	it	PPH1
304953	100736314	20992733880	on	on	II
304953	100736314	20992733881	scar	scar	NN1
304953	100736314	20992733882	tissue	tissue	NN1
304953	100736314	20992733883	and	and	CC
304953	100736314	20992733884	blood	blood	NN1
304953	100736314	20992733885	flow	flow	NN1
304953	100736314	20992733886	but	but	CCB
304953	100736314	20992733887	unless	unless	CS
304953	100736314	20992733888	the	the	AT
304953	100736314	20992733889	scar	scar	NN1
304953	100736314	20992733890	tissue	tissue	NN1
304953	100736314	20992733891	occurred	occur	VVD_VVN@
304953	100736314	20992733892	over	over	II_RP
304953	100736314	20992733893	night	night	NNT1
304953	100736314	20992733894	that	that	CST_DD1
304953	100736314	20992733895	was	be	VBDZ
304953	100736314	20992733896	simply	simply	RR
304953	100736314	20992733897	a	a	AT1
304953	100736314	20992733898	lie	lie	NN1@
304953	100736314	20992733899	on	on	II
304953	100736314	20992733900	his	his	APPGE
304953	100736314	20992733901	part	part	NN1
304953	100736314	20992733902	.	.	.
304953	100736314	20992733903	Would	would	VM
304953	100736314	20992733904	I	i	PPIS1
304953	100736314	20992733905	have	have	VHI
304953	100736314	20992733906	had	have	VHN@
304953	100736314	20992733907	the	the	AT
304953	100736314	20992733908	RP	rp	NP1
304953	100736314	20992733909	surgery	surgery	NN1
304953	100736314	20992733910	anyway	anyway	RR
304953	100736314	20992733911	,	,	,
304953	100736314	20992733912	you	you	PPY
304953	100736314	20992733913	bet	bet	VV0
304953	100736314	20992733914	but	but	CCB
304953	100736314	20992733915	could	could	VM
304953	100736314	20992733916	something	something	PN1
304953	100736314	20992733917	more	more	RRR
304953	100736314	20992733918	have	have	VHI
304953	100736314	20992733919	been	be	VBN
304953	100736314	20992733920	done	do	VDN
304953	100736314	20992733921	to	to	TO
304953	100736314	20992733922	preserve	preserve	VVI
304953	100736314	20992733923	my	my	APPGE
304953	100736314	20992733924	rather	rather	RG
304953	100736314	20992733925	average	average	JJ
304953	100736314	20992733926	length	length	NN1
304953	100736314	20992733927	,	,	,
304953	100736314	20992733928	I	i	PPIS1
304953	100736314	20992733929	wish	wish	VV0
304953	100736314	20992733930	I	i	PPIS1
304953	100736314	20992733931	knew	know	VVD
304953	100736314	20992733932	.	.	.
304953	100736314	20992733933	Since	since	CS
304953	100736314	20992733934	the	the	AT
304953	100736314	20992733935	medical	medical	JJ
304953	100736314	20992733936	community	community	NN1
304953	100736314	20992733937	does	do	VDZ
304953	100736314	20992733938	not	not	XX
304953	100736314	20992733939	like	like	VVI
304953	100736314	20992733940	to	to	TO
304953	100736314	20992733941	discuss	discuss	VVI
304953	100736314	20992733942	this	this	DD1
304953	100736314	20992733943	with	with	IW
304953	100736314	20992733944	the	the	AT
304953	100736314	20992733945	public	public	NN1
304953	100736314	20992733946	what	what	DDQ
304953	100736314	20992733947	the	the	AT
304953	100736314	20992733948	art	art	NN1
304953	100736314	20992733949	of	of	IO
304953	100736314	20992733950	the	the	AT
304953	100736314	20992733951	possible	possible	JJ
304953	100736314	20992733952	is	be	VBZ
304953	100736314	20992733953	,	,	,
304953	100736314	20992733954	with	with	IW
304953	100736314	20992733955	what	what	DDQ
304953	100736314	20992733956	risk	risk	VV0_NN1
304953	100736314	20992733957	and	and	CC
304953	100736314	20992733958	cost	cost	NN1
304953	100736314	20992733959	is	be	VBZ
304953	100736314	20992733960	unknown	unknown	JJ
304953	100736314	20992733961	to	to	II
304953	100736314	20992733962	the	the	AT
304953	100736314	20992733963	public	public	NN1_JJ
304953	100736314	20992733964	but	but	CCB
304953	100736314	20992733965	maybe	maybe	RR
304953	100736314	20992733966	with	with	IW
304953	100736314	20992733967	more	more	DAR
304953	100736314	20992733968	blogs	blog	NN2
304953	100736314	20992733969	like	like	II
304953	100736314	20992733970	this	this	DD1
304953	100736314	20992733971	more	more	DAR
304953	100736314	20992733972	will	will	NN1@
304953	100736314	20992733973	surface	surface	NN1
304953	100736314	20992733974	.	.	.
304953	100736314	20992733975	<p>		NULL
304953	100736314	20992733976	Hello	hello	UH
304953	100736314	20992733977	everyone	everyone	PN1
304953	100736314	20992733978	here	here	RL
304953	100736314	20992733979	,	,	,
304953	100736314	20992733980	my	my	APPGE
304953	100736314	20992733981	name	name	NN1
304953	100736314	20992733982	is	be	VBZ
304953	100736314	20992733983	barry		NN1
304953	100736314	20992733984	white	white	NN1@_JJ
304953	100736314	20992733985	,	,	,
304953	100736314	20992733986	i	i	ZZ1_MC1
304953	100736314	20992733987	want	want	VV0
304953	100736314	20992733988	to	to	TO
304953	100736314	20992733989	share	share	VVI
304953	100736314	20992733990	a	a	AT1
304953	100736314	20992733991	testimony	testimony	NN1
304953	100736314	20992733992	on	on	II
304953	100736314	20992733993	how	how	RRQ
304953	100736314	20992733994	Dr	dr	NNB
304953	100736314	20992733995	Sebi		NP1
304953	100736314	20992733996	herbal	herbal	JJ_NN1
304953	100736314	20992733997	mixture	mixture	NN1
304953	100736314	20992733998	saves	save	VVZ
304953	100736314	20992733999	me	me	PPIO1
304953	100736314	20992734000	from	from	II
304953	100736314	20992734001	shame	shame	NN1
304953	100736314	20992734002	and	and	CC
304953	100736314	20992734003	disgrace	disgrace	NN1
304953	100736314	20992734004	,	,	,
304953	100736314	20992734005	my	my	APPGE
304953	100736314	20992734006	penis	penis	NN1
304953	100736314	20992734007	was	be	VBDZ
304953	100736314	20992734008	a	a	AT1
304953	100736314	20992734009	big	big	JJ
304953	100736314	20992734010	problem	problem	NN1
304953	100736314	20992734011	to	to	II
304953	100736314	20992734012	me	me	PPIO1
304953	100736314	20992734013	as	as	II
304953	100736314	20992734014	the	the	AT
304953	100736314	20992734015	size	size	NN1
304953	100736314	20992734016	was	be	VBDZ
304953	100736314	20992734017	really	really	RR
304953	100736314	20992734018	so	so	RG
304953	100736314	20992734019	embarrassing	embarrassing	JJ
304953	100736314	20992734020	,	,	,
304953	100736314	20992734021	a	a	AT1
304953	100736314	20992734022	full	full	JJ_RR%
304953	100736314	20992734023	grown	grow	VVN
304953	100736314	20992734024	man	man	NN1
304953	100736314	20992734025	like	like	II
304953	100736314	20992734026	me	me	PPIO1
304953	100736314	20992734027	having	have	VHG
304953	100736314	20992734028	4	4	MC
304953	100736314	20992734029	inches	inch	NNU2
304953	100736314	20992734030	penis	penis	NN1
304953	100736314	20992734031	and	and	CC
304953	100736314	20992734032	to	to	TO
304953	100736314	20992734033	worsen	worsen	VVI
304953	100736314	20992734034	it	it	PPH1
304953	100736314	20992734035	i	i	MC1
304953	100736314	20992734036	do	do	VD0
304953	100736314	20992734037	n't 	n't	XX
304953	100736314	20992734038	last	last	VVI
304953	100736314	20992734039	in	in	II
304953	100736314	20992734040	sex	sex	NN1
304953	100736314	20992734041	i	i	MC1_ZZ1
304953	100736314	20992734042	cant	cant	NN1_JJ
304953	100736314	20992734043	even	even	RR
304953	100736314	20992734044	last	last	MD_VV0@
304953	100736314	20992734045	two	two	MC
304953	100736314	20992734046	minutes	minute	NNT2
304953	100736314	20992734047	it	it	PPH1
304953	100736314	20992734048	was	be	VBDZ
304953	100736314	20992734049	really	really	RR
304953	100736314	20992734050	a	a	AT1
304953	100736314	20992734051	thing	thing	NN1
304953	100736314	20992734052	of	of	IO
304953	100736314	20992734053	shame	shame	NN1
304953	100736314	20992734054	my	my	APPGE
304953	100736314	20992734055	wife	wife	NN1
304953	100736314	20992734056	was	be	VBDZ
304953	100736314	20992734057	really	really	RR
304953	100736314	20992734058	tired	tired	JJ
304953	100736314	20992734059	of	of	IO
304953	100736314	20992734060	me	me	PPIO1
304953	100736314	20992734061	@		II
304953	100736314	20992734062	@		II
304953	100736314	20992734063	@		II
304953	100736314	20992734064	@		II
304953	100736314	20992734065	@		II
304953	100736314	20992734066	@		II
304953	100736314	20992734067	@		II
304953	100736314	20992734068	@		II
304953	100736314	20992734069	@		II
304953	100736314	20992734070	@		II
304953	100736314	20992734071	enjoyed	enjoy	VVN_VVD
304953	100736314	20992734072	sex	sex	NN1
304953	100736314	20992734073	,	,	,
304953	100736314	20992734074	i	i	MC1_ZZ1
304953	100736314	20992734075	was	be	VBDZ
304953	100736314	20992734076	always	always	RR
304953	100736314	20992734077	thinking	think	VVG
304953	100736314	20992734078	and	and	CC
304953	100736314	20992734079	searching	search	VVG
304953	100736314	20992734080	for	for	IF
304953	100736314	20992734081	solutions	solution	NN2
304953	100736314	20992734082	everywhere	everywhere	RL
304953	100736314	20992734083	until	until	CS
304953	100736314	20992734084	i	i	ZZ1_MC1
304953	100736314	20992734085	saw	see	VVD
304953	100736314	20992734086	a	a	AT1
304953	100736314	20992734087	testimony	testimony	NN1
304953	100736314	20992734088	of	of	IO
304953	100736314	20992734089	how	how	RRQ
304953	100736314	20992734090	Dr	dr	NNB
304953	100736314	20992734091	Sebi		NP1
304953	100736314	20992734092	herbal	herbal	JJ_NN1
304953	100736314	20992734093	mixture	mixture	NN1
304953	100736314	20992734094	have	have	VH0
304953	100736314	20992734095	been	be	VBN
304953	100736314	20992734096	helping	help	VVG
304953	100736314	20992734097	people	people	NN
304953	100736314	20992734098	so	so	RR_RG_CS@
304953	100736314	20992734099	i	i	MC1_ZZ1
304953	100736314	20992734100	decided	decide	VVD_VVN
304953	100736314	20992734101	to	to	TO
304953	100736314	20992734102	give	give	VVI
304953	100736314	20992734103	him	him	PPHO1
304953	100736314	20992734104	a	a	AT1
304953	100736314	20992734105	try	try	NN1@
304953	100736314	20992734106	and	and	CC
304953	100736314	20992734107	to	to	II
304953	100736314	20992734108	my	my	APPGE
304953	100736314	20992734109	greatest	greatest	JJT
304953	100736314	20992734110	surprise	surprise	NN1
304953	100736314	20992734111	in	in	II
304953	100736314	20992734112	less	less	DAR
304953	100736314	20992734113	than	than	CSN
304953	100736314	20992734114	one	one	MC1
304953	100736314	20992734115	weeks	week	NNT2
304953	100736314	20992734116	of	of	IO
304953	100736314	20992734117	taking	take	VVG
304953	100736314	20992734118	the	the	AT
304953	100736314	20992734119	herbs	herb	NN2
304953	100736314	20992734120	my	my	APPGE
304953	100736314	20992734121	penis	penis	NN1
304953	100736314	20992734122	grow	grow	VV0
304953	100736314	20992734123	to	to	II
304953	100736314	20992734124	8	8	MC
304953	100736314	20992734125	inches	inch	NNU2_VVZ%
304953	100736314	20992734126	i	i	MC1_ZZ1
304953	100736314	20992734127	couldnt		NN1_VV0
304953	100736314	20992734128	believe	believe	VV0
304953	100736314	20992734129	my	my	APPGE
304953	100736314	20992734130	eyes	eye	NN2
304953	100736314	20992734131	all	all	DB
304953	100736314	20992734132	thanks	thanks	NN2
304953	100736314	20992734133	to	to	II
304953	100736314	20992734134	Dr	dr	NNB
304953	100736314	20992734135	Sebi		NP1
304953	100736314	20992734136	herbal	herbal	JJ_NN1
304953	100736314	20992734137	mixture	mixture	NN1
304953	100736314	20992734138	you	you	PPY
304953	100736314	20992734139	can	can	VM
304953	100736314	20992734140	contact	contact	VVI
304953	100736314	20992734141	him	him	PPHO1
304953	100736314	20992734142	on	on	RP@_II
304953	100736314	20992734143	<p>		NULL
304953	100736314	20992734144	I	i	PPIS1
304953	100736314	20992734145	did	do	VDD
304953	100736314	20992734146	n't 	n't	XX
304953	100736314	20992734147	think	think	VVI
304953	100736314	20992734148	I	i	PPIS1
304953	100736314	20992734149	would	would	VM
304953	100736314	20992734150	find	find	VVI
304953	100736314	20992734151	a	a	AT1
304953	100736314	20992734152	thread	thread	NN1
304953	100736314	20992734153	about	about	II
304953	100736314	20992734154	this	this	DD1
304953	100736314	20992734155	subject	subject	NN1
304953	100736314	20992734156	but	but	CCB
304953	100736314	20992734157	it	it	PPH1
304953	100736314	20992734158	is	be	VBZ
304953	100736314	20992734159	comforting	comforting	JJ
304953	100736314	20992734160	,	,	,
304953	100736314	20992734161	having	have	VHG
304953	100736314	20992734162	read	read	VVN
304953	100736314	20992734163	the	the	AT
304953	100736314	20992734164	other	other	JJ
304953	100736314	20992734165	comments	comment	NN2
304953	100736314	20992734166	that	that	CST
304953	100736314	20992734167	my	my	APPGE
304953	100736314	20992734168	total	total	JJ_NN1
304953	100736314	20992734169	loss	loss	NN1
304953	100736314	20992734170	of	of	IO
304953	100736314	20992734171	length	length	NN1
304953	100736314	20992734172	is	be	VBZ
304953	100736314	20992734173	not	not	XX
304953	100736314	20992734174	an	a	AT1
304953	100736314	20992734175	uncommon	uncommon	JJ
304953	100736314	20992734176	problem	problem	NN1
304953	100736314	20992734177	.	.	.
304953	100736314	20992734178	I	i	PPIS1
304953	100736314	20992734179	have	have	VH0
304953	100736314	20992734180	recently	recently	RR
304953	100736314	20992734181	had	have	VHN
304953	100736314	20992734182	surgery	surgery	NN1
304953	100736314	20992734183	and	and	CC
304953	100736314	20992734184	everything	everything	PN1
304953	100736314	20992734185	is	be	VBZ
304953	100736314	20992734186	progressing	progress	VVG
304953	100736314	20992734187	very	very	RG
304953	100736314	20992734188	well	well	RR
304953	100736314	20992734189	apart	apart	II21
304953	100736314	20992734190	from	from	II22
304953	100736314	20992734191	the	the	AT
304953	100736314	20992734192	penile	penile	JJ_NN1
304953	100736314	20992734193	area	area	NN1
304953	100736314	20992734194	which	which	DDQ
304953	100736314	20992734195	has	have	VHZ
304953	100736314	20992734196	appeared	appear	VVN
304953	100736314	20992734197	to	to	TO
304953	100736314	20992734198	have	have	VHI
304953	100736314	20992734199	completely	completely	RR
304953	100736314	20992734200	disappeared	disappear	VVN
304953	100736314	20992734201	.	.	.
304953	100736314	20992734202	That	that	DD1
304953	100736314	20992734203	area	area	NN1
304953	100736314	20992734204	has	have	VHZ
304953	100736314	20992734205	been	be	VBN
304953	100736314	20992734206	an	a	AT1
304953	100736314	20992734207	area	area	NN1
304953	100736314	20992734208	of	of	IO
304953	100736314	20992734209	concern	concern	NN1
304953	100736314	20992734210	anyway	anyway	RR
304953	100736314	20992734211	having	have	VHG
304953	100736314	20992734212	been	be	VBN
304953	100736314	20992734213	diagnosed	diagnose	VVN
304953	100736314	20992734214	with	with	IW
304953	100736314	20992734215	Peyronies		NP1_NN2
304953	100736314	20992734216	disease	disease	NN1
304953	100736314	20992734217	some	some	DD
304953	100736314	20992734218	five	five	MC
304953	100736314	20992734219	years	year	NNT2
304953	100736314	20992734220	ago	ago	RA
304953	100736314	20992734221	so	so	CS@
304953	100736314	20992734222	life	life	NN1
304953	100736314	20992734223	in	in	II
304953	100736314	20992734224	the	the	AT
304953	100736314	20992734225	sex	sex	NN1
304953	100736314	20992734226	department	department	NN1
304953	100736314	20992734227	had	have	VHD
304953	100736314	20992734228	been	be	VBN
304953	100736314	20992734229	challenging	challenge	VVG
304953	100736314	20992734230	anyway	anyway	RR
304953	100736314	20992734231	.	.	.
304953	100736314	20992734232	What	what	DDQ
304953	100736314	20992734233	the	the	AT
304953	100736314	20992734234	thread	thread	NN1
304953	100736314	20992734235	has	have	VHZ
304953	100736314	20992734236	given	give	VVN
304953	100736314	20992734237	me	me	PPIO1
304953	100736314	20992734238	is	be	VBZ
304953	100736314	20992734239	a	a	AT1
304953	100736314	20992734240	comfort	comfort	NN1
304953	100736314	20992734241	that	that	CST
304953	100736314	20992734242	I	i	PPIS1
304953	100736314	20992734243	am	be	VBM
304953	100736314	20992734244	not	not	XX
304953	100736314	20992734245	alone	alone	JJ
304953	100736314	20992734246	.	.	.
304953	100736314	20992734247	Having	have	VHG
304953	100736314	20992734248	been	be	VBN
304953	100736314	20992734249	married	marry	VVN%_JJ
304953	100736314	20992734250	to	to	II
304953	100736314	20992734251	the	the	AT
304953	100736314	20992734252	same	same	DA
304953	100736314	20992734253	loving	loving	JJ
304953	100736314	20992734254	and	and	CC
304953	100736314	20992734255	understanding	understanding	NN1_VVG_JJ@
304953	100736314	20992734256	lady	lady	NN1
304953	100736314	20992734257	for	for	IF
304953	100736314	20992734258	42	42	MC
304953	100736314	20992734259	years	year	NNT2
304953	100736314	20992734260	,	,	,
304953	100736314	20992734261	@		II
304953	100736314	20992734262	@		II
304953	100736314	20992734263	@		II
304953	100736314	20992734264	@		II
304953	100736314	20992734265	@		II
304953	100736314	20992734266	@		II
304953	100736314	20992734267	@		II
304953	100736314	20992734268	@		II
304953	100736314	20992734269	@		II
304953	100736314	20992734270	@		II
304953	100736314	20992734271	,	,	,
304953	100736314	20992734272	it	it	PPH1
304953	100736314	20992734273	is	be	VBZ
304953	100736314	20992734274	just	just	RR
304953	100736314	20992734275	making	make	VVG
304953	100736314	20992734276	us	us	PPIO2
304953	100736314	20992734277	more	more	DAR
304953	100736314	20992734278	inventive	inventive	JJ
304953	100736314	20992734279	.	.	.
304953	100736314	20992734280	I	i	PPIS1
304953	100736314	20992734281	wish	wish	VV0
304953	100736314	20992734282	all	all	DB
304953	100736314	20992734283	other	other	JJ
304953	100736314	20992734284	contributors	contributor	NN2
304953	100736314	20992734285	a	a	AT1
304953	100736314	20992734286	safe	safe	JJ
304953	100736314	20992734287	and	and	CC
304953	100736314	20992734288	prolonged	prolonged	JJ
304953	100736314	20992734289	health	health	NN1
304953	100736314	20992734290	have	have	VH0
304953	100736314	20992734291	taken	take	VVN
304953	100736314	20992734292	this	this	DD1
304953	100736314	20992734293	course	course	NN1
304953	100736314	20992734294	of	of	IO
304953	100736314	20992734295	action	action	NN1
304953	100736314	20992734296	.	.	.
304953	100736314	20992734297	<p>		NULL
304953	100736314	20992734298	I	i	PPIS1
304953	100736314	20992734299	am	be	VBM
304953	100736314	20992734300	going	go	VVG
304953	100736314	20992734301	in	in	RP@
304953	100736314	20992734302	for	for	IF
304953	100736314	20992734303	a	a	AT1
304953	100736314	20992734304	RP	rp	NP1
304953	100736314	20992734305	this	this	DD1
304953	100736314	20992734306	August	august	NPM1
304953	100736314	20992734307	8	8	MC
304953	100736314	20992734308	.	.	.
304953	100736314	20992734309	I	i	PPIS1
304953	100736314	20992734310	heard	hear	VVD
304953	100736314	20992734311	about	about	II
304953	100736314	20992734312	penis	penis	NN1
304953	100736314	20992734313	shrinkage	shrinkage	NN1
304953	100736314	20992734314	from	from	II
304953	100736314	20992734315	a	a	AT1
304953	100736314	20992734316	friend	friend	NN1
304953	100736314	20992734317	who	who	PNQS
304953	100736314	20992734318	had	have	VHD
304953	100736314	20992734319	the	the	AT
304953	100736314	20992734320	same	same	DA
304953	100736314	20992734321	surgery	surgery	NN1
304953	100736314	20992734322	last	last	MD
304953	100736314	20992734323	week	week	NNT1
304953	100736314	20992734324	,	,	,
304953	100736314	20992734325	and	and	CC
304953	100736314	20992734326	in	in	II
304953	100736314	20992734327	his	his	APPGE
304953	100736314	20992734328	exploration	exploration	NN1
304953	100736314	20992734329	of	of	IO
304953	100736314	20992734330	his	his	APPGE
304953	100736314	20992734331	options	option	NN2
304953	100736314	20992734332	,	,	,
304953	100736314	20992734333	was	be	VBDZ
304953	100736314	20992734334	told	tell	VVN
304953	100736314	20992734335	by	by	II
304953	100736314	20992734336	someone	someone	PN1
304953	100736314	20992734337	that	that	CST
304953	100736314	20992734338	his	his	APPGE
304953	100736314	20992734339	penis	penis	NN1
304953	100736314	20992734340	lost	lose	VVD_VVN_JJ@
304953	100736314	20992734341	length	length	NN1
304953	100736314	20992734342	.	.	.
304953	100736314	20992734343	<p>		NULL
304953	100736314	20992734344	This	this	DD1
304953	100736314	20992734345	whole	whole	JJ_NN1
304953	100736314	20992734346	situation	situation	NN1
304953	100736314	20992734347	is	be	VBZ
304953	100736314	20992734348	upsetting	upset	VVG_JJ
304953	100736314	20992734349	:	:	:
304953	100736314	20992734350	I 'm		VV0
304953	100736314	20992734351	a	a	AT1
304953	100736314	20992734352	cyclist	cyclist	NN1
304953	100736314	20992734353	,	,	,
304953	100736314	20992734354	eat	eat	VV0
304953	100736314	20992734355	healthy	healthy	JJ
304953	100736314	20992734356	food	food	NN1
304953	100736314	20992734357	,	,	,
304953	100736314	20992734358	never	never	RR
304953	100736314	20992734359	been	be	VBN
304953	100736314	20992734360	a	a	AT1
304953	100736314	20992734361	smoker	smoker	NN1
304953	100736314	20992734362	,	,	,
304953	100736314	20992734363	not	not	XX
304953	100736314	20992734364	a	a	AT1
304953	100736314	20992734365	heavy	heavy	JJ
304953	100736314	20992734366	drinker	drinker	NN1
304953	100736314	20992734367	,	,	,
304953	100736314	20992734368	but	but	CCB
304953	100736314	20992734369	I	i	PPIS1
304953	100736314	20992734370	have	have	VH0
304953	100736314	20992734371	a	a	AT1
304953	100736314	20992734372	Gleason	gleason	NN1@_NP1
304953	100736314	20992734373	8	8	MC
304953	100736314	20992734374	and	and	CC
304953	100736314	20992734375	two	two	MC
304953	100736314	20992734376	Gleason	gleason	NP1
304953	100736314	20992734377	7s	7s	MC2
304953	100736314	20992734378	(	(	(
304953	100736314	20992734379	a	a	AT1
304953	100736314	20992734380	3+4		FO
304953	100736314	20992734381	and	and	CC
304953	100736314	20992734382	a	a	AT1
304953	100736314	20992734383	4+3		FO
304953	100736314	20992734384	)	)	)
304953	100736314	20992734385	.	.	.
304953	100736314	20992734386	I	i	PPIS1
304953	100736314	20992734387	am	be	VBM
304953	100736314	20992734388	nervous	nervous	JJ
304953	100736314	20992734389	,	,	,
304953	100736314	20992734390	despite	despite	II
304953	100736314	20992734391	the	the	AT
304953	100736314	20992734392	fact	fact	NN1
304953	100736314	20992734393	that	that	CST
304953	100736314	20992734394	a	a	AT1
304953	100736314	20992734395	bone	bone	NN1
304953	100736314	20992734396	scan	scan	NN1
304953	100736314	20992734397	was	be	VBDZ
304953	100736314	20992734398	negative	negative	JJ
304953	100736314	20992734399	and	and	CC
304953	100736314	20992734400	its	its	APPGE
304953	100736314	20992734401	not	not	XX
304953	100736314	20992734402	in	in	II
304953	100736314	20992734403	my	my	APPGE
304953	100736314	20992734404	surrounding	surrounding	JJ
304953	100736314	20992734405	lymph	lymph	NN1
304953	100736314	20992734406	tissue	tissue	NN1
304953	100736314	20992734407	.	.	.
304953	100736314	20992734408	<p>		NULL
304953	100736314	20992734409	The	the	AT
304953	100736314	20992734410	penis	penis	NN1
304953	100736314	20992734411	shrinkage	shrinkage	NN1
304953	100736314	20992734412	is	be	VBZ
304953	100736314	20992734413	very	very	RG
304953	100736314	20992734414	disappointing	disappointing	JJ
304953	100736314	20992734415	.	.	.
304953	100736314	20992734416	My	my	APPGE
304953	100736314	20992734417	doctor	doctor	NN1
304953	100736314	20992734418	was	be	VBDZ
304953	100736314	20992734419	not	not	XX
304953	100736314	20992734420	upfront	up-front	RR
304953	100736314	20992734421	about	about	II
304953	100736314	20992734422	this	this	DD1
304953	100736314	20992734423	.	.	.
304953	100736314	20992734424	Ive		VV0_NN1_NP1@
304953	100736314	20992734425	overcome	overcome	VV0_VVN
304953	100736314	20992734426	my	my	APPGE
304953	100736314	20992734427	concern	concern	NN1
304953	100736314	20992734428	about	about	II
304953	100736314	20992734429	the	the	AT
304953	100736314	20992734430	catheter	catheter	NN1_JJR
304953	100736314	20992734431	,	,	,
304953	100736314	20992734432	but	but	CCB
304953	100736314	20992734433	shrinkage	shrinkage	NN1
304953	100736314	20992734434	is	be	VBZ
304953	100736314	20992734435	a	a	AT1
304953	100736314	20992734436	bummer	bummer	NN1
304953	100736314	20992734437	.	.	.
304953	100736314	20992734438	But	but	CCB
304953	100736314	20992734439	thanks	thanks	NN2
304953	100736314	20992734440	for	for	IF
304953	100736314	20992734441	your	your	APPGE
304953	100736314	20992734442	frank	frank	JJ
304953	100736314	20992734443	discussion	discussion	NN1
304953	100736314	20992734444	.	.	.
304953	100736314	20992734445	<p>		NULL
304953	100736314	20992734446	I	i	PPIS1
304953	100736314	20992734447	had	have	VHD
304953	100736314	20992734448	a	a	AT1
304953	100736314	20992734449	radical	radical	JJ_NN1
304953	100736314	20992734450	prostatectomy	prostatectomy	NN1
304953	100736314	20992734451	in	in	II
304953	100736314	20992734452	2003	2003	MC
304953	100736314	20992734453	.	.	.
304953	100736314	20992734454	Slightly	slightly	RR
304953	100736314	20992734455	elevated	elevate	VVD_VVN_JJ
304953	100736314	20992734456	PSA	psa	NP1
304953	100736314	20992734457	year	year	NNT1
304953	100736314	20992734458	and	and	CC
304953	100736314	20992734459	a	a	AT1
304953	100736314	20992734460	half	half	RR@_NN1@_DB
304953	100736314	20992734461	@		II
304953	100736314	20992734462	@		II
304953	100736314	20992734463	@		II
304953	100736314	20992734464	@		II
304953	100736314	20992734465	@		II
304953	100736314	20992734466	@		II
304953	100736314	20992734467	@		II
304953	100736314	20992734468	@		II
304953	100736314	20992734469	@		II
304953	100736314	20992734470	@		II
304953	100736314	20992734471	non	non	FU
304953	100736314	20992734472	detectable	detectable	JJ
304953	100736314	20992734473	PSAs	psas	NP2
304953	100736314	20992734474	.	.	.
304953	100736314	20992734475	However	however	RR
304953	100736314	20992734476	,	,	,
304953	100736314	20992734477	penis	penis	NN1
304953	100736314	20992734478	when	when	CS_RRQ
304953	100736314	20992734479	erect	erect	JJ_VV0
304953	100736314	20992734480	is	be	VBZ
304953	100736314	20992734481	now	now	RT
304953	100736314	20992734482	only	only	JJ
304953	100736314	20992734483	4		NN1
304953	100736314	20992734484	1/2	1/2	MF
304953	100736314	20992734485	inches	inch	NNU2
304953	100736314	20992734486	long	long	JJ_RR
304953	100736314	20992734487	,	,	,
304953	100736314	20992734488	before	before	CS_II
304953	100736314	20992734489	surgery	surgery	NN1
304953	100736314	20992734490	6	6	MC
304953	100736314	20992734491	1/4	1/4	MF
304953	100736314	20992734492	inches	inch	NNU2
304953	100736314	20992734493	long	long	JJ_RR
304953	100736314	20992734494	.	.	.
304953	100736314	20992734495	Girth	girth	NN1_NP1@
304953	100736314	20992734496	now	now	RT
304953	100736314	20992734497	4.75	4.75	MC
304953	100736314	20992734498	inches	inch	NNU2
304953	100736314	20992734499	,	,	,
304953	100736314	20992734500	before	before	CS
304953	100736314	20992734501	it	it	PPH1
304953	100736314	20992734502	was	be	VBDZ
304953	100736314	20992734503	over	over	RG
304953	100736314	20992734504	5	5	MC
304953	100736314	20992734505	inches	inch	NNU2
304953	100736314	20992734506	around	around	RP
304953	100736314	20992734507	.	.	.
304953	100736314	20992734508	No	no	PN121
304953	100736314	20992734509	one	one	PN122
304953	100736314	20992734510	told	tell	VVD
304953	100736314	20992734511	me	me	PPIO1
304953	100736314	20992734512	this	this	DD1
304953	100736314	20992734513	would	would	VM
304953	100736314	20992734514	happen	happen	VVI
304953	100736314	20992734515	.	.	.
304953	100736314	20992734516	Nerves	nerve	NN2
304953	100736314	20992734517	saved	save	VVN_VVD
304953	100736314	20992734518	but	but	CCB
304953	100736314	20992734519	drugs	drug	NN2
304953	100736314	20992734520	like	like	II
304953	100736314	20992734521	Viagara		NP1
304953	100736314	20992734522	,	,	,
304953	100736314	20992734523	etc.		RA
304953	100736314	20992734524	do	do	VD0
304953	100736314	20992734525	very	very	RG
304953	100736314	20992734526	little	little	DA1
304953	100736314	20992734527	for	for	IF
304953	100736314	20992734528	me	me	PPIO1
304953	100736314	20992734529	.	.	.
304953	100736314	20992734530	Used	used	JJ
304953	100736314	20992734531	needle	needle	NN1
304953	100736314	20992734532	for	for	IF
304953	100736314	20992734533	bout	bout	NN1
304953	100736314	20992734534	year	year	NNT1
304953	100736314	20992734535	and	and	CC
304953	100736314	20992734536	a	a	AT1
304953	100736314	20992734537	half	half	NN1@_DB
304953	100736314	20992734538	.	.	.
304953	100736314	20992734539	Worked	work	VVN_VVD
304953	100736314	20992734540	fine	fine	JJ
304953	100736314	20992734541	but	but	CCB
304953	100736314	20992734542	left	leave	VVD
304953	100736314	20992734543	my	my	APPGE
304953	100736314	20992734544	penis	penis	NN1
304953	100736314	20992734545	with	with	IW
304953	100736314	20992734546	much	much	DA1
304953	100736314	20992734547	scar	scar	NN1
304953	100736314	20992734548	tissue	tissue	NN1
304953	100736314	20992734549	.	.	.
304953	100736314	20992734550	(	(	(
304953	100736314	20992734551	Used	used	JJ
304953	100736314	20992734552	needle	needle	NN1
304953	100736314	20992734553	a	a	RR21@_AT1
304953	100736314	20992734554	lot	lot	RR22_NN1
304953	100736314	20992734555	,	,	,
304953	100736314	20992734556	about	about	RG
304953	100736314	20992734557	5	5	MC
304953	100736314	20992734558	or	or	CC
304953	100736314	20992734559	6	6	MC
304953	100736314	20992734560	times	time	NNT2
304953	100736314	20992734561	per	per	II
304953	100736314	20992734562	week	week	NNT1
304953	100736314	20992734563	.	.	.
304953	100736314	20992734564	)	)	)
304953	100736314	20992734565	Now	now	RT
304953	100736314	20992734566	have	have	VH0
304953	100736314	20992734567	a	a	AT1
304953	100736314	20992734568	penile	penile	JJ_NN1
304953	100736314	20992734569	implant	implant	NN1
304953	100736314	20992734570	which	which	DDQ
304953	100736314	20992734571	works	work	VVZ
304953	100736314	20992734572	fantastic	fantastic	JJ
304953	100736314	20992734573	and	and	CC
304953	100736314	20992734574	my	my	APPGE
304953	100736314	20992734575	penis	penis	NN1
304953	100736314	20992734576	is	be	VBZ
304953	100736314	20992734577	hard	hard	JJ
304953	100736314	20992734578	like	like	II
304953	100736314	20992734579	a	a	AT1
304953	100736314	20992734580	rock	rock	NN1
304953	100736314	20992734581	but	but	CCB
304953	100736314	20992734582	the	the	AT
304953	100736314	20992734583	size	size	NN1
304953	100736314	20992734584	of	of	IO
304953	100736314	20992734585	a	a	AT1
304953	100736314	20992734586	boys	boy	NN2
304953	100736314	20992734587	pecker	pecker	NN1
304953	100736314	20992734588	.	.	.
304953	100736314	20992734589	I 've		NP1@_NN1
304953	100736314	20992734590	got	get	VVD
304953	100736314	20992734591	a	a	AT1
304953	100736314	20992734592	super	super	JJ
304953	100736314	20992734593	wife	wife	NN1
304953	100736314	20992734594	who	who	PNQS
304953	100736314	20992734595	says	say	VVZ
304953	100736314	20992734596	it	it	PPH1
304953	100736314	20992734597	does	do	VDZ
304953	100736314	20992734598	n't 	n't	XX
304953	100736314	20992734599	matter	matter	VVI
304953	100736314	20992734600	but	but	CCB
304953	100736314	20992734601	I	i	PPIS1
304953	100736314	20992734602	really	really	RR
304953	100736314	20992734603	think	think	VV0
304953	100736314	20992734604	it	it	PPH1
304953	100736314	20992734605	does	do	VDZ
304953	100736314	20992734606	.	.	.
304953	100736314	20992734607	I 'm		VV0
304953	100736314	20992734608	sure	sure	JJ_RR%
304953	100736314	20992734609	shed		NN1_VVN
304953	100736314	20992734610	like	like	II
304953	100736314	20992734611	it	it	PPH1
304953	100736314	20992734612	bigger	big	JJR
304953	100736314	20992734613	but	but	CCB
304953	100736314	20992734614	shed		VV0_VVD
304953	100736314	20992734615	never	never	RR
304953	100736314	20992734616	say	say	VV0
304953	100736314	20992734617	that	that	CST
304953	100736314	20992734618	because	because	CS
304953	100736314	20992734619	she	she	PPHS1
304953	100736314	20992734620	loves	love	VVZ
304953	100736314	20992734621	me	me	PPIO1
304953	100736314	20992734622	and	and	CC
304953	100736314	20992734623	knows	know	VVZ
304953	100736314	20992734624	how	how	RRQ
304953	100736314	20992734625	devastated	devastate	VVD_JJ@
304953	100736314	20992734626	I	i	PPIS1
304953	100736314	20992734627	really	really	RR
304953	100736314	20992734628	am	am	RA@_VBM
304953	100736314	20992734629	.	.	.
304953	100736314	20992734630	I	i	PPIS1
304953	100736314	20992734631	wish	wish	VV0
304953	100736314	20992734632	they	they	PPHS2
304953	100736314	20992734633	could	could	VM
304953	100736314	20992734634	put	put	VVI
304953	100736314	20992734635	bigger	big	JJR
304953	100736314	20992734636	implants	implant	NN2
304953	100736314	20992734637	in	in	RP@_II
304953	100736314	20992734638	but	but	CCB
304953	100736314	20992734639	I	i	PPIS1
304953	100736314	20992734640	do	do	VD0
304953	100736314	20992734641	n't 	n't	XX
304953	100736314	20992734642	think	think	VVI
304953	100736314	20992734643	they	they	PPHS2
304953	100736314	20992734644	would	would	VM
304953	100736314	20992734645	.	.	.
304953	100736314	20992734646	Yeah	yeah	UH
304953	100736314	20992734647	I 'm		VV0_NP1
304953	100736314	20992734648	still	still	RR
304953	100736314	20992734649	alive	alive	JJ
304953	100736314	20992734650	but	but	CCB
304953	100736314	20992734651	I	i	PPIS1
304953	100736314	20992734652	think	think	VV0
304953	100736314	20992734653	about	about	II
304953	100736314	20992734654	my	my	APPGE
304953	100736314	20992734655	dick	dick	NN1
304953	100736314	20992734656	every	every	AT1
304953	100736314	20992734657	single	single	JJ
304953	100736314	20992734658	day	day	NNT1
304953	100736314	20992734659	.	.	.
304953	100736314	20992734660	46996		MC
304953	100736314	20992734661	@qwx906996		FO
304953	100736315	20992734681	@@##	----------	----------
304953	100736315	20992734682	@@100736315		FO
304953	100736315	20992734683	@4936315/		VV0_NN1
304953	100736315	20992734684	46989		MC
304953	100736315	20992734685	@qwx906989		FO
304953	100736315	20992734686	<p>		NULL
304953	100736315	20992734687	Although	although	CS
304953	100736315	20992734688	the	the	AT
304953	100736315	20992734689	reason	reason	NN1
304953	100736315	20992734690	why	why	RRQ
304953	100736315	20992734691	is	be	VBZ
304953	100736315	20992734692	n't	n't	XX
304953	100736315	20992734693	clear	clear	JJ_RR@
304953	100736315	20992734694	,	,	,
304953	100736315	20992734695	studies	study	NN2
304953	100736315	20992734696	have	have	VH0
304953	100736315	20992734697	shown	show	VVN
304953	100736315	20992734698	that	that	CST
304953	100736315	20992734699	among	among	II
304953	100736315	20992734700	men	man	NN2
304953	100736315	20992734701	of	of	IO
304953	100736315	20992734702	European	european	JJ
304953	100736315	20992734703	ancestry	ancestry	NN1
304953	100736315	20992734704	,	,	,
304953	100736315	20992734705	those	those	DD2
304953	100736315	20992734706	with	with	IW
304953	100736315	20992734707	diabetes	diabetes	NN1
304953	100736315	20992734708	have	have	VH0
304953	100736315	20992734709	a	a	AT1
304953	100736315	20992734710	lower	low	JJR
304953	100736315	20992734711	risk	risk	NN1
304953	100736315	20992734712	of	of	IO
304953	100736315	20992734713	developing	developing	JJ_VVG
304953	100736315	20992734714	prostate	prostate	NN1
304953	100736315	20992734715	cancer	cancer	NN1
304953	100736315	20992734716	than	than	CSN
304953	100736315	20992734717	those	those	DD2
304953	100736315	20992734718	without	without	IW
304953	100736315	20992734719	the	the	AT
304953	100736315	20992734720	condition	condition	NN1
304953	100736315	20992734721	.	.	.
304953	100736315	20992734722	That	that	DD1
304953	100736315	20992734723	got	get	VVD
304953	100736315	20992734724	California	california	NP1
304953	100736315	20992734725	researchers	researcher	NN2
304953	100736315	20992734726	wondering	wonder	VVG
304953	100736315	20992734727	whether	whether	CSW
304953	100736315	20992734728	that	that	DD1
304953	100736315	20992734729	inverse	inverse	JJ_NN1
304953	100736315	20992734730	relationship	relationship	NN1
304953	100736315	20992734731	existed	exist	VVD_VVN@
304953	100736315	20992734732	across	across	II
304953	100736315	20992734733	other	other	JJ
304953	100736315	20992734734	racial	racial	JJ
304953	100736315	20992734735	and	and	CC
304953	100736315	20992734736	ethnic	ethnic	JJ
304953	100736315	20992734737	groups	group	NN2
304953	100736315	20992734738	.	.	.
304953	100736315	20992734739	<p>		NULL
304953	100736315	20992734740	To	to	TO
304953	100736315	20992734741	find	find	VVI
304953	100736315	20992734742	out	out	RP
304953	100736315	20992734743	,	,	,
304953	100736315	20992734744	they	they	PPHS2
304953	100736315	20992734745	analyzed	analyze	VVD
304953	100736315	20992734746	5,941		MC
304953	100736315	20992734747	cases	case	NN2
304953	100736315	20992734748	of	of	IO
304953	100736315	20992734749	prostate	prostate	NN1
304953	100736315	20992734750	cancer	cancer	NN1
304953	100736315	20992734751	identified	identify	VVN
304953	100736315	20992734752	over	over	RG
304953	100736315	20992734753	12	12	MC
304953	100736315	20992734754	years	year	NNT2
304953	100736315	20992734755	in	in	II
304953	100736315	20992734756	86,303		MC
304953	100736315	20992734757	European	european	JJ
304953	100736315	20992734758	American	american	JJ_NN1@
304953	100736315	20992734759	,	,	,
304953	100736315	20992734760	African	african	JJ
304953	100736315	20992734761	American	american	JJ_NN1@
304953	100736315	20992734762	,	,	,
304953	100736315	20992734763	Latino	latino	NP1_NN1
304953	100736315	20992734764	,	,	,
304953	100736315	20992734765	Japanese	japanese	JJ
304953	100736315	20992734766	American	american	JJ_NN1@
304953	100736315	20992734767	,	,	,
304953	100736315	20992734768	and	and	CC
304953	100736315	20992734769	Native	native	JJ
304953	100736315	20992734770	Hawaiian	hawaiian	JJ
304953	100736315	20992734771	men	man	NN2
304953	100736315	20992734772	in	in	II
304953	100736315	20992734773	the	the	AT
304953	100736315	20992734774	Multiethnic	multi-ethnic	JJ_NN1
304953	100736315	20992734775	Cohort	cohort	NN1
304953	100736315	20992734776	Study	study	NN1
304953	100736315	20992734777	,	,	,
304953	100736315	20992734778	a	a	AT1
304953	100736315	20992734779	prospective	prospective	JJ
304953	100736315	20992734780	cohort	cohort	NN1
304953	100736315	20992734781	study	study	NN1
304953	100736315	20992734782	under	under	RR21
304953	100736315	20992734783	way	way	RR22
304953	100736315	20992734784	in	in	II
304953	100736315	20992734785	Hawaii	hawaii	NP1
304953	100736315	20992734786	and	and	CC
304953	100736315	20992734787	Los	los	NP1
304953	100736315	20992734788	Angeles	angeles	NP1
304953	100736315	20992734789	.	.	.
304953	100736315	20992734790	Participants	participant	NN2
304953	100736315	20992734791	completed	complete	VVD_VVN
304953	100736315	20992734792	an	a	AT1
304953	100736315	20992734793	initial	initial	JJ_NN1
304953	100736315	20992734794	questionnaire	questionnaire	NN1
304953	100736315	20992734795	about	about	II
304953	100736315	20992734796	lifestyle	lifestyle	NN1
304953	100736315	20992734797	factors	factor	NN2
304953	100736315	20992734798	,	,	,
304953	100736315	20992734799	such	such	II21
304953	100736315	20992734800	as	as	II22
304953	100736315	20992734801	diet	diet	NN1
304953	100736315	20992734802	and	and	CC
304953	100736315	20992734803	physical	physical	JJ
304953	100736315	20992734804	activity	activity	NN1
304953	100736315	20992734805	,	,	,
304953	100736315	20992734806	any	any	DD
304953	100736315	20992734807	medical	medical	JJ
304953	100736315	20992734808	conditions	condition	NN2
304953	100736315	20992734809	,	,	,
304953	100736315	20992734810	and	and	CC
304953	100736315	20992734811	family	family	NN1
304953	100736315	20992734812	history	history	NN1
304953	100736315	20992734813	of	of	IO
304953	100736315	20992734814	common	common	JJ
304953	100736315	20992734815	cancers	cancer	NN2
304953	100736315	20992734816	.	.	.
304953	100736315	20992734817	A	a	AT1_ZZ1
304953	100736315	20992734818	short	short	JJ
304953	100736315	20992734819	follow-up	follow-up	JJ_NN1
304953	100736315	20992734820	questionnaire	questionnaire	NN1
304953	100736315	20992734821	sent	send	VVN_VVD
304953	100736315	20992734822	in	in	II
304953	100736315	20992734823	2001	2001	MC
304953	100736315	20992734824	also	also	RR
304953	100736315	20992734825	asked	ask	VVD_VVN@
304953	100736315	20992734826	about	about	II
304953	100736315	20992734827	history	history	NN1
304953	100736315	20992734828	of	of	IO
304953	100736315	20992734829	prostate-specific	prostate-specific	JJ
304953	100736315	20992734830	antigen	antigen	NN1
304953	100736315	20992734831	(	(	(
304953	100736315	20992734832	PSA	psa	NP1
304953	100736315	20992734833	)	)	)
304953	100736315	20992734834	screening	screening	NN1_VVG
304953	100736315	20992734835	.	.	.
304953	100736315	20992734836	<p>		NULL
304953	100736315	20992734837	Researchers	researcher	NN2
304953	100736315	20992734838	discovered	discover	VVD
304953	100736315	20992734839	that	that	CST
304953	100736315	20992734840	men	man	NN2
304953	100736315	20992734841	with	with	IW
304953	100736315	20992734842	diabetes	diabetes	NN1
304953	100736315	20992734843	had	have	VHD
304953	100736315	20992734844	a	a	AT1
304953	100736315	20992734845	significantly	significantly	RR
304953	100736315	20992734846	lower	low	JJR
304953	100736315	20992734847	risk	risk	NN1
304953	100736315	20992734848	of	of	IO
304953	100736315	20992734849	prostate	prostate	NN1
304953	100736315	20992734850	cancer	cancer	NN1
304953	100736315	20992734851	than	than	CSN
304953	100736315	20992734852	nondiabetics		NN2_NN1
304953	100736315	20992734853	across	across	II
304953	100736315	20992734854	all	all	DB
304953	100736315	20992734855	populations	population	NN2
304953	100736315	20992734856	,	,	,
304953	100736315	20992734857	though	though	CS
304953	100736315	20992734858	the	the	AT
304953	100736315	20992734859	risk	risk	NN1
304953	100736315	20992734860	varied	vary	VVD_VVN
304953	100736315	20992734861	somewhat	somewhat	RR
304953	100736315	20992734862	among	among	II
304953	100736315	20992734863	the	the	AT
304953	100736315	20992734864	groups	group	NN2
304953	100736315	20992734865	.	.	.
304953	100736315	20992734866	They	they	PPHS2
304953	100736315	20992734867	also	also	RR
304953	100736315	20992734868	found	find	VVD
304953	100736315	20992734869	that	that	CST_DD1
304953	100736315	20992734870	average	average	JJ_NN1_VV0@
304953	100736315	20992734871	PSA	psa	NP1
304953	100736315	20992734872	levels	level	NN2
304953	100736315	20992734873	@		II
304953	100736315	20992734874	@		II
304953	100736315	20992734875	@		II
304953	100736315	20992734876	@		II
304953	100736315	20992734877	@		II
304953	100736315	20992734878	@		II
304953	100736315	20992734879	@		II
304953	100736315	20992734880	@		II
304953	100736315	20992734881	@		II
304953	100736315	20992734882	@		II
304953	100736315	20992734883	These	these	DD2
304953	100736315	20992734884	conclusions	conclusion	NN2
304953	100736315	20992734885	suggest	suggest	VV0
304953	100736315	20992734886	a	a	AT1
304953	100736315	20992734887	biological	biological	JJ
304953	100736315	20992734888	link	link	NN1
304953	100736315	20992734889	between	between	II
304953	100736315	20992734890	the	the	AT
304953	100736315	20992734891	two	two	MC
304953	100736315	20992734892	conditions	condition	NN2
304953	100736315	20992734893	.	.	.
304953	100736315	20992734894	Similarly	similarly	RR
304953	100736315	20992734895	,	,	,
304953	100736315	20992734896	a	a	AT1
304953	100736315	20992734897	Harvard	harvard	NP1
304953	100736315	20992734898	study	study	NN1
304953	100736315	20992734899	of	of	IO
304953	100736315	20992734900	51,529		MC
304953	100736315	20992734901	men	man	NN2
304953	100736315	20992734902	published	publish	VVN
304953	100736315	20992734903	in	in	II
304953	100736315	20992734904	March	march	NPM1_NP1@
304953	100736315	20992734905	found	find	VVD
304953	100736315	20992734906	that	that	CST_DD1
304953	100736315	20992734907	,	,	,
304953	100736315	20992734908	for	for	IF
304953	100736315	20992734909	a	a	AT1
304953	100736315	20992734910	man	man	NN1
304953	100736315	20992734911	with	with	IW
304953	100736315	20992734912	diabetes	diabetes	NN1
304953	100736315	20992734913	,	,	,
304953	100736315	20992734914	the	the	AT
304953	100736315	20992734915	risk	risk	NN1
304953	100736315	20992734916	of	of	IO
304953	100736315	20992734917	prostate	prostate	NN1
304953	100736315	20992734918	cancer	cancer	NN1
304953	100736315	20992734919	decreased	decrease	VVN_VVD
304953	100736315	20992734920	over	over	II
304953	100736315	20992734921	time	time	NNT1
304953	100736315	20992734922	.	.	.
304953	100736315	20992734923	Men	man	NN2
304953	100736315	20992734924	in	in	II
304953	100736315	20992734925	that	that	DD1
304953	100736315	20992734926	study	study	NN1
304953	100736315	20992734927	were	be	VBDR
304953	100736315	20992734928	followed	follow	VVN
304953	100736315	20992734929	from	from	II
304953	100736315	20992734930	1986	1986	MC
304953	100736315	20992734931	to	to	II
304953	100736315	20992734932	2004	2004	MC
304953	100736315	20992734933	.	.	.
304953	100736315	20992734934	But	but	CCB
304953	100736315	20992734935	a	a	AT1
304953	100736315	20992734936	Swedish	swedish	JJ
304953	100736315	20992734937	study	study	NN1
304953	100736315	20992734938	that	that	CST
304953	100736315	20992734939	followed	follow	VVD
304953	100736315	20992734940	10,564		MC
304953	100736315	20992734941	men	man	NN2
304953	100736315	20992734942	for	for	IF
304953	100736315	20992734943	11	11	MC
304953	100736315	20992734944	years	year	NNT2
304953	100736315	20992734945	on	on	II
304953	100736315	20992734946	average	average	NN1
304953	100736315	20992734947	concluded	conclude	VVD_VVN
304953	100736315	20992734948	that	that	CST
304953	100736315	20992734949	there	there	EX
304953	100736315	20992734950	was	be	VBDZ
304953	100736315	20992734951	no	no	AT
304953	100736315	20992734952	significant	significant	JJ
304953	100736315	20992734953	association	association	NN1
304953	100736315	20992734954	between	between	II
304953	100736315	20992734955	diabetes	diabetes	NN1
304953	100736315	20992734956	and	and	CC
304953	100736315	20992734957	prostate	prostate	NN1
304953	100736315	20992734958	cancer	cancer	NN1
304953	100736315	20992734959	risk	risk	NN1
304953	100736315	20992734960	.	.	.
304953	100736315	20992734961	However	however	RR
304953	100736315	20992734962	,	,	,
304953	100736315	20992734963	researchers	researcher	NN2
304953	100736315	20992734964	noted	note	VVD_VVN
304953	100736315	20992734965	that	that	CST
304953	100736315	20992734966	the	the	AT
304953	100736315	20992734967	relatively	relatively	RR
304953	100736315	20992734968	small	small	JJ
304953	100736315	20992734969	number	number	NN1
304953	100736315	20992734970	of	of	IO
304953	100736315	20992734971	diabetics	diabetic	NN2
304953	100736315	20992734972	in	in	II
304953	100736315	20992734973	the	the	AT
304953	100736315	20992734974	study	study	NN1
304953	100736315	20992734975	may	may	VM
304953	100736315	20992734976	have	have	VHI
304953	100736315	20992734977	skewed	skew	VVN
304953	100736315	20992734978	the	the	AT
304953	100736315	20992734979	results	result	NN2
304953	100736315	20992734980	.	.	.
304953	100736315	20992734981	46996		MC
304953	100736315	20992734982	@qwx906996		FO
304953	100736321	20992735002	@@##	----------	----------
304953	100736321	20992735003	@@100736321		FO
304953	100736321	20992735004	@4936321/		VV0_NN1
304953	100736321	20992735005	46989		MC
304953	100736321	20992735006	@qwx906989		FO
304953	100736321	20992735007	<p>		NULL
304953	100736321	20992735008	According	according	II21
304953	100736321	20992735009	to	to	II22
304953	100736321	20992735010	a	a	AT1
304953	100736321	20992735011	study	study	NN1
304953	100736321	20992735012	presented	present	VVN_VVD
304953	100736321	20992735013	at	at	II
304953	100736321	20992735014	the	the	AT
304953	100736321	20992735015	American	american	JJ
304953	100736321	20992735016	Urological	urological	JJ
304953	100736321	20992735017	Association	association	NN1
304953	100736321	20992735018	's	's	GE
304953	100736321	20992735019	annual	annual	JJ
304953	100736321	20992735020	meeting	meeting	NN1
304953	100736321	20992735021	in	in	II
304953	100736321	20992735022	2009	2009	MC
304953	100736321	20992735023	,	,	,
304953	100736321	20992735024	drinking	drink	VVG_NN1
304953	100736321	20992735025	8	8	MC
304953	100736321	20992735026	ounces	ounce	NNU2
304953	100736321	20992735027	of	of	IO
304953	100736321	20992735028	pomegranate	pomegranate	NN1
304953	100736321	20992735029	juice	juice	NN1
304953	100736321	20992735030	a	a	AT1
304953	100736321	20992735031	day	day	NNT1
304953	100736321	20992735032	may	may	VM
304953	100736321	20992735033	slow	slow	VVI
304953	100736321	20992735034	the	the	AT
304953	100736321	20992735035	progression	progression	NN1
304953	100736321	20992735036	of	of	IO
304953	100736321	20992735037	prostate	prostate	NN1
304953	100736321	20992735038	cancer	cancer	NN1
304953	100736321	20992735039	.	.	.
304953	100736321	20992735040	<p>		NULL
304953	100736321	20992735041	The	the	AT
304953	100736321	20992735042	study	study	NN1
304953	100736321	20992735043	included	include	VVD_VVN
304953	100736321	20992735044	48	48	MC
304953	100736321	20992735045	men	man	NN2
304953	100736321	20992735046	who	who	PNQS
304953	100736321	20992735047	had	have	VHD
304953	100736321	20992735048	a	a	AT1
304953	100736321	20992735049	rising	rising	JJ@
304953	100736321	20992735050	prostate-specific	prostate-specific	JJ
304953	100736321	20992735051	antigen	antigen	NN1
304953	100736321	20992735052	(	(	(
304953	100736321	20992735053	PSA	psa	NP1
304953	100736321	20992735054	)	)	)
304953	100736321	20992735055	level	level	JJ_NN1_VV0@
304953	100736321	20992735056	following	following	JJ@_VVG_NN1@_II@
304953	100736321	20992735057	radiation	radiation	NN1
304953	100736321	20992735058	therapy	therapy	NN1
304953	100736321	20992735059	or	or	CC
304953	100736321	20992735060	surgery	surgery	NN1
304953	100736321	20992735061	to	to	TO
304953	100736321	20992735062	treat	treat	VVI
304953	100736321	20992735063	localized	localized	JJ
304953	100736321	20992735064	prostate	prostate	NN1
304953	100736321	20992735065	cancer	cancer	NN1
304953	100736321	20992735066	.	.	.
304953	100736321	20992735067	At	at	II
304953	100736321	20992735068	the	the	AT
304953	100736321	20992735069	start	start	NN1
304953	100736321	20992735070	of	of	IO
304953	100736321	20992735071	the	the	AT
304953	100736321	20992735072	study	study	NN1
304953	100736321	20992735073	in	in	II
304953	100736321	20992735074	2003	2003	MC
304953	100736321	20992735075	,	,	,
304953	100736321	20992735076	the	the	AT
304953	100736321	20992735077	men	man	NN2
304953	100736321	20992735078	had	have	VHD
304953	100736321	20992735079	PSA	psa	NP1
304953	100736321	20992735080	levels	level	NN2_VVZ%
304953	100736321	20992735081	greater	great	JJR
304953	100736321	20992735082	than	than	CSN
304953	100736321	20992735083	0.2	0.2	MC
304953	100736321	20992735084	and	and	CC
304953	100736321	20992735085	less	less	DAR
304953	100736321	20992735086	than	than	CSN
304953	100736321	20992735087	5.0	5.0	MC
304953	100736321	20992735088	ng/ml	ng/ml	FU
304953	100736321	20992735089	,	,	,
304953	100736321	20992735090	and	and	CC
304953	100736321	20992735091	an	a	AT1
304953	100736321	20992735092	average	average	JJ_NN1
304953	100736321	20992735093	PSA	psa	NP1
304953	100736321	20992735094	doubling	doubling	NN1_VVG
304953	100736321	20992735095	time	time	NNT1
304953	100736321	20992735096	of	of	IO
304953	100736321	20992735097	15.4	15.4	MC
304953	100736321	20992735098	months	month	NNT2
304953	100736321	20992735099	.	.	.
304953	100736321	20992735100	(	(	(
304953	100736321	20992735101	PSA	psa	NP1
304953	100736321	20992735102	doubling	doubling	NN1_VVG
304953	100736321	20992735103	time	time	NNT1
304953	100736321	20992735104	is	be	VBZ
304953	100736321	20992735105	a	a	AT1
304953	100736321	20992735106	measure	measure	NN1
304953	100736321	20992735107	of	of	IO
304953	100736321	20992735108	cancer	cancer	NN1
304953	100736321	20992735109	's	's	GE
304953	100736321	20992735110	activity	activity	NN1
304953	100736321	20992735111	,	,	,
304953	100736321	20992735112	with	with	IW
304953	100736321	20992735113	shorter	short	JJR
304953	100736321	20992735114	times	time	NNT2
304953	100736321	20992735115	indicating	indicate	VVG
304953	100736321	20992735116	more	more	RGR
304953	100736321	20992735117	aggressive	aggressive	JJ
304953	100736321	20992735118	behavior	behavior	NN1
304953	100736321	20992735119	.	.	.
304953	100736321	20992735120	)	)	)
304953	100736321	20992735121	In	in	II
304953	100736321	20992735122	2006	2006	MC
304953	100736321	20992735123	,	,	,
304953	100736321	20992735124	researchers	researcher	NN2
304953	100736321	20992735125	reported	report	VVD_VVN
304953	100736321	20992735126	that	that	CST
304953	100736321	20992735127	the	the	AT
304953	100736321	20992735128	men	man	NN2
304953	100736321	20992735129	who	who	PNQS
304953	100736321	20992735130	drank	drink	VVD
304953	100736321	20992735131	8	8	MC
304953	100736321	20992735132	ounces	ounce	NNU2
304953	100736321	20992735133	of	of	IO
304953	100736321	20992735134	pomegranate	pomegranate	NN1
304953	100736321	20992735135	juice	juice	NN1
304953	100736321	20992735136	daily	daily	RR_NN1@
304953	100736321	20992735137	had	have	VHD_VHN@
304953	100736321	20992735138	slower	slow	RRR_JJR
304953	100736321	20992735139	PSA	psa	NP1
304953	100736321	20992735140	doubling	doubling	NN1_VVG
304953	100736321	20992735141	times	time	NNT2
304953	100736321	20992735142	.	.	.
304953	100736321	20992735143	<p>		NULL
304953	100736321	20992735144	Since	since	II
304953	100736321	20992735145	then	then	RT
304953	100736321	20992735146	,	,	,
304953	100736321	20992735147	researchers	researcher	NN2
304953	100736321	20992735148	continued	continue	VVD_VVN
304953	100736321	20992735149	to	to	TO
304953	100736321	20992735150	follow	follow	VVI
304953	100736321	20992735151	the	the	AT
304953	100736321	20992735152	participants	participant	NN2
304953	100736321	20992735153	,	,	,
304953	100736321	20992735154	15	15	MC
304953	100736321	20992735155	of	of	IO
304953	100736321	20992735156	whom	whom	PNQO
304953	100736321	20992735157	stuck	stick	VVD
304953	100736321	20992735158	with	with	IW
304953	100736321	20992735159	the	the	AT
304953	100736321	20992735160	study	study	NN1
304953	100736321	20992735161	for	for	IF
304953	100736321	20992735162	as	as	CS31_RG
304953	100736321	20992735163	long	long	CS32_RR
304953	100736321	20992735164	as	as	CS33_CSA
304953	100736321	20992735165	64	64	MC
304953	100736321	20992735166	months	month	NNT2
304953	100736321	20992735167	.	.	.
304953	100736321	20992735168	They	they	PPHS2
304953	100736321	20992735169	found	find	VVD
304953	100736321	20992735170	that	that	CST
304953	100736321	20992735171	the	the	AT
304953	100736321	20992735172	PSA	psa	NP1
304953	100736321	20992735173	doubling	doubling	NN1_VVG
304953	100736321	20992735174	times	time	NNT2
304953	100736321	20992735175	of	of	IO
304953	100736321	20992735176	the	the	AT
304953	100736321	20992735177	men	man	NN2
304953	100736321	20992735178	who	who	PNQS
304953	100736321	20992735179	kept	keep	VVD
304953	100736321	20992735180	drinking	drink	VVG_NN1
304953	100736321	20992735181	pomegranate	pomegranate	NN1
304953	100736321	20992735182	juice	juice	NN1
304953	100736321	20992735183	were	be	VBDR
304953	100736321	20992735184	about	about	RG
304953	100736321	20992735185	four	four	MC
304953	100736321	20992735186	times	time	NNT2
304953	100736321	20992735187	longer	long	RRR
304953	100736321	20992735188	than	than	CSN
304953	100736321	20992735189	the	the	AT
304953	100736321	20992735190	PSA	psa	NP1
304953	100736321	20992735191	doubling	doubling	NN1_VVG
304953	100736321	20992735192	times	time	NNT2
304953	100736321	20992735193	at	at	II
304953	100736321	20992735194	@		II
304953	100736321	20992735195	@		II
304953	100736321	20992735196	@		II
304953	100736321	20992735197	@		II
304953	100736321	20992735198	@		II
304953	100736321	20992735199	@		II
304953	100736321	20992735200	@		II
304953	100736321	20992735201	@		II
304953	100736321	20992735202	@		II
304953	100736321	20992735203	@		II
304953	100736321	20992735204	doubling	doubling	NN1_VVG
304953	100736321	20992735205	times	time	NNT2
304953	100736321	20992735206	of	of	IO
304953	100736321	20992735207	the	the	AT
304953	100736321	20992735208	men	man	NN2
304953	100736321	20992735209	who	who	PNQS
304953	100736321	20992735210	stopped	stop	VVD
304953	100736321	20992735211	drinking	drink	VVG
304953	100736321	20992735212	the	the	AT
304953	100736321	20992735213	juice	juice	NN1
304953	100736321	20992735214	.	.	.
304953	100736321	20992735215	<p>		NULL
304953	100736321	20992735216	For	for	IF
304953	100736321	20992735217	those	those	DD2
304953	100736321	20992735218	who	who	PNQS
304953	100736321	20992735219	want	want	VV0
304953	100736321	20992735220	to	to	TO
304953	100736321	20992735221	try	try	VVI
304953	100736321	20992735222	pomegranate	pomegranate	NN1
304953	100736321	20992735223	juice	juice	NN1
304953	100736321	20992735224	,	,	,
304953	100736321	20992735225	one	one	MC1
304953	100736321	20992735226	note	note	NN1
304953	100736321	20992735227	of	of	IO
304953	100736321	20992735228	caution	caution	NN1
304953	100736321	20992735229	:	:	:
304953	100736321	20992735230	it	it	PPH1
304953	100736321	20992735231	's	be	VBZ
304953	100736321	20992735232	high	high	JJ_RR@
304953	100736321	20992735233	in	in	II
304953	100736321	20992735234	calories	calorie	NNU2
304953	100736321	20992735235	.	.	.
304953	100736321	20992735236	An	a	AT1
304953	100736321	20992735237	8-ounce		NNU1_JJ
304953	100736321	20992735238	glass	glass	NN1
304953	100736321	20992735239	of	of	IO
304953	100736321	20992735240	POM	pom	NP1_NN1
304953	100736321	20992735241	Wonderful	wonderful	JJ
304953	100736321	20992735242	,	,	,
304953	100736321	20992735243	the	the	AT
304953	100736321	20992735244	juice	juice	NN1
304953	100736321	20992735245	used	use	VVN_VVD
304953	100736321	20992735246	in	in	II
304953	100736321	20992735247	the	the	AT
304953	100736321	20992735248	study	study	NN1
304953	100736321	20992735249	,	,	,
304953	100736321	20992735250	contains	contain	VVZ
304953	100736321	20992735251	160	160	MC
304953	100736321	20992735252	calories	calorie	NNU2
304953	100736321	20992735253	,	,	,
304953	100736321	20992735254	50	50	MC
304953	100736321	20992735255	calories	calorie	NNU2
304953	100736321	20992735256	more	more	RRR
304953	100736321	20992735257	than	than	CSN
304953	100736321	20992735258	a	a	AT1
304953	100736321	20992735259	typical	typical	JJ
304953	100736321	20992735260	glass	glass	NN1
304953	100736321	20992735261	of	of	IO
304953	100736321	20992735262	orange	orange	NN1
304953	100736321	20992735263	juice	juice	NN1
304953	100736321	20992735264	.	.	.
304953	100736321	20992735265	<p>		NULL
304953	100736321	20992735266	My	my	APPGE
304953	100736321	20992735267	husband	husband	NN1
304953	100736321	20992735268	was	be	VBDZ
304953	100736321	20992735269	recently	recently	RR
304953	100736321	20992735270	diagnosed	diagnose	VVN_VVD
304953	100736321	20992735271	with	with	IW
304953	100736321	20992735272	prostate	prostate	NN1
304953	100736321	20992735273	CA	ca	NP1@_VM
304953	100736321	20992735274	recoring		VVG_NN1@
304953	100736321	20992735275	after	after	II
304953	100736321	20992735276	cryo	cryo	NN1
304953	100736321	20992735277	about	about	RG
304953	100736321	20992735278	8	8	MC
304953	100736321	20992735279	years	year	NNT2
304953	100736321	20992735280	ago	ago	RA
304953	100736321	20992735281	.	.	.
304953	100736321	20992735282	His	his	APPGE
304953	100736321	20992735283	most	most	RGT
304953	100736321	20992735284	recent	recent	JJ
304953	100736321	20992735285	PSA	psa	NP1
304953	100736321	20992735286	was	be	VBDZ
304953	100736321	20992735287	12.9	12.9	MC
304953	100736321	20992735288	.	.	.
304953	100736321	20992735289	Now	now	RT
304953	100736321	20992735290	,	,	,
304953	100736321	20992735291	his	his	APPGE
304953	100736321	20992735292	L	l	ZZ1_NP1@
304953	100736321	20992735293	groin	groin	NN1
304953	100736321	20992735294	lymph	lymph	NN1
304953	100736321	20992735295	node	node	NN1
304953	100736321	20992735296	was	be	VBDZ
304953	100736321	20992735297	biopsed		VVN
304953	100736321	20992735298	.	.	.
304953	100736321	20992735299	The	the	AT
304953	100736321	20992735300	result	result	NN1
304953	100736321	20992735301	was	be	VBDZ
304953	100736321	20992735302	lymphoma	lymphoma	NN1
304953	100736321	20992735303	and	and	CC
304953	100736321	20992735304	negative	negative	JJ_NN1@
304953	100736321	20992735305	for	for	IF
304953	100736321	20992735306	carcinoma	carcinoma	NN1
304953	100736321	20992735307	.	.	.
304953	100736321	20992735308	Would	would	VM
304953	100736321	20992735309	you	you	PPY
304953	100736321	20992735310	recommend	recommend	VVI
304953	100736321	20992735311	Proton	proton	NP1
304953	100736321	20992735312	x	x	ZZ1
304953	100736321	20992735313	regular	regular	JJ
304953	100736321	20992735314	radion		NN1
304953	100736321	20992735315	Therapy	therapy	NN1
304953	100736321	20992735316	?	?	?
304953	100736321	20992735317	What	what	DDQ
304953	100736321	20992735318	is	be	VBZ
304953	100736321	20992735319	your	your	APPGE
304953	100736321	20992735320	taken	taken	JJ%_VVN
304953	100736321	20992735321	on	on	RP_II%
304953	100736321	20992735322	these	these	DD2
304953	100736321	20992735323	treatments	treatment	NN2
304953	100736321	20992735324	?	?	?
304953	100736321	20992735325	Should	should	VM
304953	100736321	20992735326	we	we	PPIS2
304953	100736321	20992735327	try	try	VVI
304953	100736321	20992735328	something	something	PN1
304953	100736321	20992735329	else	else	RR
304953	100736321	20992735330	?	?	?
304953	100736321	20992735331	<p>		NULL
304953	100736321	20992735332	Due	due	II21
304953	100736321	20992735333	to	to	II22
304953	100736321	20992735334	symptoms	symptom	NN2
304953	100736321	20992735335	seen	see	VVN
304953	100736321	20992735336	as	as	CSA
304953	100736321	20992735337	presented	present	VVN
304953	100736321	20992735338	above	above	RL
304953	100736321	20992735339	in	in	II
304953	100736321	20992735340	the	the	AT
304953	100736321	20992735341	area	area	NN1
304953	100736321	20992735342	of	of	IO
304953	100736321	20992735343	chief	chief	JJ_NN1
304953	100736321	20992735344	complaint	complaint	NN1
304953	100736321	20992735345	an	a	AT1
304953	100736321	20992735346	ultrasound	ultrasound	NN1
304953	100736321	20992735347	study	study	NN1
304953	100736321	20992735348	was	be	VBDZ
304953	100736321	20992735349	performed	perform	VVN
304953	100736321	20992735350	.	.	.
304953	100736321	20992735351	Area/s		FU
304953	100736321	20992735352	scanned		JJ@_VVN@
304953	100736321	20992735353	:	:	:
304953	100736321	20992735354	The	the	AT
304953	100736321	20992735355	area	area	NN1
304953	100736321	20992735356	of	of	IO
304953	100736321	20992735357	chief	chief	JJ_NN1
304953	100736321	20992735358	complaint	complaint	NN1
304953	100736321	20992735359	was	be	VBDZ
304953	100736321	20992735360	scanned	scan	VVN@
304953	100736321	20992735361	using	use	VVG
304953	100736321	20992735362	an	a	AT1
304953	100736321	20992735363	15	15	MC
304953	100736321	20992735364	MHz	mhz	NNU
304953	100736321	20992735365	probe	probe	NN1
304953	100736321	20992735366	.	.	.
304953	100736321	20992735367	Views	view	NN2
304953	100736321	20992735368	were	be	VBDR
304953	100736321	20992735369	taken	take	VVN
304953	100736321	20992735370	in	in	II
304953	100736321	20992735371	both	both	DB2
304953	100736321	20992735372	the	the	AT
304953	100736321	20992735373	longitudinal	longitudinal	JJ
304953	100736321	20992735374	and	and	CC
304953	100736321	20992735375	transverse	transverse	JJ_NN1
304953	100736321	20992735376	planes	plane	NN2
304953	100736321	20992735377	.	.	.
304953	100736321	20992735378	The	the	AT
304953	100736321	20992735379	plantar	plantar	NN1
304953	100736321	20992735380	aspect	aspect	NN1
304953	100736321	20992735381	of	of	IO
304953	100736321	20992735382	the	the	AT
304953	100736321	20992735383	foot	foot	NN1
304953	100736321	20992735384	was	be	VBDZ
304953	100736321	20992735385	scanned	scan	VVN@
304953	100736321	20992735386	concentrating	concentrate	VVG
304953	100736321	20992735387	on	on	II
304953	100736321	20992735388	the	the	AT
304953	100736321	20992735389	plantar	plantar	NN1
304953	100736321	20992735390	fascia	fascia	NN1
304953	100736321	20992735391	.	.	.
304953	100736321	20992735392	A	a	AT1_ZZ1
304953	100736321	20992735393	series	series	NN
304953	100736321	20992735394	@		II
304953	100736321	20992735395	@		II
304953	100736321	20992735396	@		II
304953	100736321	20992735397	@		II
304953	100736321	20992735398	@		II
304953	100736321	20992735399	@		II
304953	100736321	20992735400	@		II
304953	100736321	20992735401	@		II
304953	100736321	20992735402	@		II
304953	100736321	20992735403	@		II
304953	100736321	20992735404	Ultrasound		VV0_NP1_NN1
304953	100736321	20992735405	examination	examination	NN1
304953	100736321	20992735406	reveals	reveal	VVZ
304953	100736321	20992735407	inflammation	inflammation	NN1
304953	100736321	20992735408	of	of	IO
304953	100736321	20992735409	the	the	AT
304953	100736321	20992735410	proximal	proximal	JJ
304953	100736321	20992735411	plantar	plantar	NN1
304953	100736321	20992735412	fascia	fascia	NN1
304953	100736321	20992735413	.	.	.
304953	100736321	20992735414	This	this	DD1
304953	100736321	20992735415	was	be	VBDZ
304953	100736321	20992735416	easily	easily	RR
304953	100736321	20992735417	seen	see	VVN
304953	100736321	20992735418	in	in	II
304953	100736321	20992735419	both	both	DB2
304953	100736321	20992735420	the	the	AT
304953	100736321	20992735421	longitudinal	longitudinal	JJ
304953	100736321	20992735422	and	and	CC
304953	100736321	20992735423	transverse	transverse	JJ_NN1
304953	100736321	20992735424	scans	scan	NN2
304953	100736321	20992735425	.	.	.
304953	100736321	20992735426	A	a	AT1_ZZ1
304953	100736321	20992735427	linear	linear	JJ
304953	100736321	20992735428	hypoechoic	hypoechoic	JJ
304953	100736321	20992735429	band	band	NN1
304953	100736321	20992735430	of	of	IO
304953	100736321	20992735431	tissue	tissue	NN1
304953	100736321	20992735432	with	with	IW
304953	100736321	20992735433	its	its	APPGE
304953	100736321	20992735434	origin	origin	NN1
304953	100736321	20992735435	at	at	II
304953	100736321	20992735436	the	the	AT
304953	100736321	20992735437	medial	medial	JJ
304953	100736321	20992735438	plantar	plantar	NN1
304953	100736321	20992735439	tuberosity	tuberosity	NN1
304953	100736321	20992735440	of	of	IO
304953	100736321	20992735441	the	the	AT
304953	100736321	20992735442	calcaneus	calcaneus	NN
304953	100736321	20992735443	is	be	VBZ
304953	100736321	20992735444	noted	note	VVN
304953	100736321	20992735445	.	.	.
304953	100736321	20992735446	This	this	DD1
304953	100736321	20992735447	same	same	DA
304953	100736321	20992735448	area	area	NN1
304953	100736321	20992735449	extends	extend	VVZ
304953	100736321	20992735450	distal	distal	JJ
304953	100736321	20992735451	to	to	TO_II
304953	100736321	20992735452	just	just	RR
304953	100736321	20992735453	to	to	II
304953	100736321	20992735454	the	the	AT
304953	100736321	20992735455	end	end	NN1
304953	100736321	20992735456	of	of	IO
304953	100736321	20992735457	the	the	AT
304953	100736321	20992735458	calcaneus	calcaneus	NN
304953	100736321	20992735459	on	on	II
304953	100736321	20992735460	the	the	AT
304953	100736321	20992735461	plantar	plantar	NN1
304953	100736321	20992735462	aspect	aspect	NN1
304953	100736321	20992735463	.	.	.
304953	100736321	20992735464	This	this	DD1
304953	100736321	20992735465	area	area	NN1
304953	100736321	20992735466	of	of	IO
304953	100736321	20992735467	inflammation	inflammation	NN1
304953	100736321	20992735468	measures	measure	VVZ@_NN2
304953	100736321	20992735469	mm	mm	NNU@
304953	100736321	20992735470	at	at	II
304953	100736321	20992735471	its	its	APPGE
304953	100736321	20992735472	greatest	greatest	JJT
304953	100736321	20992735473	thickness	thickness	NN1
304953	100736321	20992735474	(	(	(
304953	100736321	20992735475	normal	normal	JJ
304953	100736321	20992735476	thickness	thickness	NN1
304953	100736321	20992735477	is	be	VBZ
304953	100736321	20992735478	approximately	approximately	RR
304953	100736321	20992735479	3mm		NNU
304953	100736321	20992735480	)	)	)
304953	100736321	20992735481	.	.	.
304953	100736321	20992735482	There	there	EX
304953	100736321	20992735483	is	be	VBZ
304953	100736321	20992735484	no	no	AT
304953	100736321	20992735485	indication	indication	NN1
304953	100736321	20992735486	of	of	IO
304953	100736321	20992735487	a	a	AT1
304953	100736321	20992735488	tear	tear	NN1
304953	100736321	20992735489	or	or	CC
304953	100736321	20992735490	rupture	rupture	NN1
304953	100736321	20992735491	of	of	IO
304953	100736321	20992735492	the	the	AT
304953	100736321	20992735493	plantar	plantar	NN1
304953	100736321	20992735494	fascia	fascia	NN1
304953	100736321	20992735495	.	.	.
304953	100736321	20992735496	An	a	AT1
304953	100736321	20992735497	Ultrasound	ultrasound	NN1_NP1
304953	100736321	20992735498	guided	guided	JJ_VVD_VVN
304953	100736321	20992735499	injection	injection	NN1
304953	100736321	20992735500	war	war	NN1
304953	100736321	20992735501	performed	perform	VVN_VVD
304953	100736321	20992735502	into	into	II
304953	100736321	20992735503	the	the	AT
304953	100736321	20992735504	hypoechoic	hypoechoic	JJ
304953	100736321	20992735505	area	area	NN1
304953	100736321	20992735506	utilizing	utilize	VVG_NN1@
304953	100736321	20992735507	<p>		NULL
304953	100736321	20992735508	Apparently	apparently	RR
304953	100736321	20992735509	,	,	,
304953	100736321	20992735510	no	no	PN121
304953	100736321	20992735511	one	one	PN122
304953	100736321	20992735512	is	be	VBZ
304953	100736321	20992735513	monitoring	monitor	VVG
304953	100736321	20992735514	this	this	DD1
304953	100736321	20992735515	web	web	NN1
304953	100736321	20992735516	blog	blog	NN1
304953	100736321	20992735517	or	or	CC
304953	100736321	20992735518	answering	answering	JJ_VVG_NN1
304953	100736321	20992735519	questions	question	NN2
304953	100736321	20992735520	.	.	.
304953	100736321	20992735521	My	my	APPGE
304953	100736321	20992735522	own	own	DA
304953	100736321	20992735523	research	research	NN1
304953	100736321	20992735524	suggests	suggest	VVZ
304953	100736321	20992735525	that	that	CST
304953	100736321	20992735526	there	there	EX
304953	100736321	20992735527	is	be	VBZ
304953	100736321	20992735528	much	much	DA1
304953	100736321	20992735529	more	more	DAR
304953	100736321	20992735530	evidence	evidence	NN1
304953	100736321	20992735531	that	that	CST_DD1
304953	100736321	20992735532	Vitamin	vitamin	NN1
304953	100736321	20992735533	D3	d3	FO
304953	100736321	20992735534	slows	slow	VVZ
304953	100736321	20992735535	the	the	AT
304953	100736321	20992735536	progression	progression	NN1
304953	100736321	20992735537	of	of	IO
304953	100736321	20992735538	prostate	prostate	NN1
304953	100736321	20992735539	cancer	cancer	NN1
304953	100736321	20992735540	.	.	.
304953	100736321	20992735541	Every	every	AT1
304953	100736321	20992735542	male	male	NN1
304953	100736321	20992735543	should	should	VM
304953	100736321	20992735544	be	be	VBI
304953	100736321	20992735545	taking	take	VVG
304953	100736321	20992735546	at	at	RR21
304953	100736321	20992735547	least	least	RR22
304953	100736321	20992735548	4000	4000	MC
304953	100736321	20992735549	IU	iu	NP1
304953	100736321	20992735550	daily	daily	RR_JJ_NN1@
304953	100736321	20992735551	.	.	.
304953	100736321	20992735552	Ignore	ignore	VV0
304953	100736321	20992735553	the	the	AT
304953	100736321	20992735554	government	government	NN1
304953	100736321	20992735555	nonsensical	nonsensical	JJ
304953	100736321	20992735556	recommendation	recommendation	NN1
304953	100736321	20992735557	to	to	TO
304953	100736321	20992735558	take	take	VVI
304953	100736321	20992735559	only	only	JJ
304953	100736321	20992735560	400		NN1
304953	100736321	20992735561	IU	iu	NP1
304953	100736321	20992735562	.	.	.
304953	100736321	20992735563	(	(	(
304953	100736321	20992735564	Just	just	RR
304953	100736321	20992735565	for	for	IF
304953	100736321	20992735566	referencea		NN1
304953	100736321	20992735567	day	day	NNT1
304953	100736321	20992735568	in	in	II
304953	100736321	20992735569	the	the	AT
304953	100736321	20992735570	sun	sun	NN1
304953	100736321	20992735571	is	be	VBZ
304953	100736321	20992735572	equivalent	equivalent	JJ
304953	100736321	20992735573	to	to	II
304953	100736321	20992735574	10,000	10,000	MC
304953	100736321	20992735575	to	to	II
304953	100736321	20992735576	20,000	20,000	MC
304953	100736321	20992735577	IU	iu	NP1
304953	100736321	20992735578	of	of	IO
304953	100736321	20992735579	D3	d3	FO
304953	100736321	20992735580	.	.	.
304953	100736321	20992735581	)	)	)
304953	100736321	20992735582	I	i	PPIS1
304953	100736321	20992735583	have	have	VH0
304953	100736321	20992735584	prostate	prostate	NN1
304953	100736321	20992735585	cancer	cancer	NN1
304953	100736321	20992735586	,	,	,
304953	100736321	20992735587	am	am	RA@_VBM
304953	100736321	20992735588	in	in	II
304953	100736321	20992735589	Active	active	JJ
304953	100736321	20992735590	Surveillance	surveillance	NN1
304953	100736321	20992735591	,	,	,
304953	100736321	20992735592	and	and	CC
304953	100736321	20992735593	take	take	VV0
304953	100736321	20992735594	@		II
304953	100736321	20992735595	@		II
304953	100736321	20992735596	@		II
304953	100736321	20992735597	@		II
304953	100736321	20992735598	@		II
304953	100736321	20992735599	@		II
304953	100736321	20992735600	@		II
304953	100736321	20992735601	@		II
304953	100736321	20992735602	@		II
304953	100736321	20992735603	@		II
304953	100736321	20992735604	needs	need	VVZ
304953	100736321	20992735605	fat	fat	JJ_NN1
304953	100736321	20992735606	)	)	)
304953	100736321	20992735607	Perhaps	perhaps	RR
304953	100736321	20992735608	not	not	XX
304953	100736321	20992735609	coincidentally	coincidentally	RR
304953	100736321	20992735610	,	,	,
304953	100736321	20992735611	my	my	APPGE
304953	100736321	20992735612	PSA	psa	NP1
304953	100736321	20992735613	has	have	VHZ
304953	100736321	20992735614	gove		NN1
304953	100736321	20992735615	from	from	II
304953	100736321	20992735616	6.3	-6.3	MC
304953	100736321	20992735617	at	at	II
304953	100736321	20992735618	time	time	NNT1
304953	100736321	20992735619	of	of	IO
304953	100736321	20992735620	biopsy	biopsy	NN1
304953	100736321	20992735621	to	to	II
304953	100736321	20992735622	5.0	5.0	MC
304953	100736321	20992735623	to	to	II
304953	100736321	20992735624	4.2	4.2	MC
304953	100736321	20992735625	to	to	II
304953	100736321	20992735626	3.8	3.8	MC
304953	100736321	20992735627	over	over	II
304953	100736321	20992735628	the	the	AT
304953	100736321	20992735629	past	past	JJ
304953	100736321	20992735630	20	20	MC
304953	100736321	20992735631	months	month	NNT2
304953	100736321	20992735632	.	.	.
304953	100736321	20992735633	<p>		NULL
304953	100736321	20992735634	Stan	stan	NP1
304953	100736321	20992735635	:	:	:
304953	100736321	20992735636	I	i	PPIS1
304953	100736321	20992735637	understand	understand	VV0
304953	100736321	20992735638	there 's		NN2
304953	100736321	20992735639	quite	quite	RG_RR@
304953	100736321	20992735640	a	a	AT1
304953	100736321	20992735641	range	range	NN1
304953	100736321	20992735642	between	between	II
304953	100736321	20992735643	the	the	AT
304953	100736321	20992735644	strength/concentration		NN1
304953	100736321	20992735645	among	among	II
304953	100736321	20992735646	brands	brand	NN2
304953	100736321	20992735647	of	of	IO
304953	100736321	20992735648	D3	d3	FO
304953	100736321	20992735649	supplements	supplement	NN2
304953	100736321	20992735650	.	.	.
304953	100736321	20992735651	How	how	RRQ
304953	100736321	20992735652	did	do	VDD
304953	100736321	20992735653	you	you	PPY
304953	100736321	20992735654	settle	settle	VVI
304953	100736321	20992735655	on	on	II
304953	100736321	20992735656	the	the	AT
304953	100736321	20992735657	one	one	PN1
304953	100736321	20992735658	you	you	PPY
304953	100736321	20992735659	are	be	VBR
304953	100736321	20992735660	taking	take	VVG
304953	100736321	20992735661	?	?	?
304953	100736321	20992735662	Your	your	APPGE
304953	100736321	20992735663	PSA	psa	NP1
304953	100736321	20992735664	numbers	number	NN2
304953	100736321	20992735665	are	be	VBR
304953	100736321	20992735666	quite	quite	RG
304953	100736321	20992735667	a	a	AT1
304953	100736321	20992735668	significant	significant	JJ
304953	100736321	20992735669	drop	drop	NN1
304953	100736321	20992735670	.	.	.
304953	100736321	20992735671	Have	have	VH0
304953	100736321	20992735672	you	you	PPY
304953	100736321	20992735673	located	locate	VVN
304953	100736321	20992735674	any	any	DD
304953	100736321	20992735675	other	other	JJ
304953	100736321	20992735676	studies	study	NN2
304953	100736321	20992735677	of	of	IO
304953	100736321	20992735678	D3s		FO
304953	100736321	20992735679	effectiveness	effectiveness	NN1
304953	100736321	20992735680	?	?	?
304953	100736321	20992735681	46996		MC
304953	100736321	20992735682	@qwx906996		FO
304953	100736322	20992735702	@@##	----------	----------
304953	100736322	20992735703	@@100736322		FO
304953	100736322	20992735704	@4936322/		VV0_NN1
304953	100736322	20992735705	46989		MC
304953	100736322	20992735706	@qwx906989		FO
304953	100736322	20992735707	<p>		NULL
304953	100736322	20992735708	Does	do	VDZ
304953	100736322	20992735709	size	size	NN1
304953	100736322	20992735710	matter	matter	NN1_VV0
304953	100736322	20992735711	?	?	?
304953	100736322	20992735712	When	when	CS
304953	100736322	20992735713	the	the	AT
304953	100736322	20992735714	issue	issue	NN1
304953	100736322	20992735715	is	be	VBZ
304953	100736322	20992735716	penis	penis	NN1
304953	100736322	20992735717	size	size	NN1
304953	100736322	20992735718	,	,	,
304953	100736322	20992735719	many	many	DA2
304953	100736322	20992735720	men	man	NN2
304953	100736322	20992735721	would	would	VM
304953	100736322	20992735722	answer	answer	VVI
304953	100736322	20992735723	yes	yes	UH
304953	100736322	20992735724	.	.	.
304953	100736322	20992735725	So	so	RR
304953	100736322	20992735726	even	even	RR
304953	100736322	20992735727	the	the	AT
304953	100736322	20992735728	possibility	possibility	NN1
304953	100736322	20992735729	that	that	CST_DD1
304953	100736322	20992735730	radical	radical	JJ_NN1
304953	100736322	20992735731	prostatectomy	prostatectomy	NN1
304953	100736322	20992735732	(	(	(
304953	100736322	20992735733	an	a	AT1
304953	100736322	20992735734	operation	operation	NN1
304953	100736322	20992735735	to	to	TO
304953	100736322	20992735736	remove	remove	VVI
304953	100736322	20992735737	a	a	AT1
304953	100736322	20992735738	cancerous	cancerous	JJ
304953	100736322	20992735739	prostate	prostate	NN1
304953	100736322	20992735740	gland	gland	NN1
304953	100736322	20992735741	)	)	)
304953	100736322	20992735742	could	could	VM
304953	100736322	20992735743	shorten	shorten	VVI
304953	100736322	20992735744	the	the	AT
304953	100736322	20992735745	penis	penis	NN1
304953	100736322	20992735746	is	be	VBZ
304953	100736322	20992735747	understandably	understandably	RR
304953	100736322	20992735748	troubling	trouble	VVG_JJ
304953	100736322	20992735749	to	to	II
304953	100736322	20992735750	men	man	NN2
304953	100736322	20992735751	who	who	PNQS
304953	100736322	20992735752	face	face	VV0
304953	100736322	20992735753	that	that	DD1
304953	100736322	20992735754	operation	operation	NN1
304953	100736322	20992735755	.	.	.
304953	100736322	20992735756	The	the	AT
304953	100736322	20992735757	true	true	JJ
304953	100736322	20992735758	effect	effect	NN1
304953	100736322	20992735759	is n't		NN1
304953	100736322	20992735760	known	know	VVN
304953	100736322	20992735761	:	:	:
304953	100736322	20992735762	some	some	DD
304953	100736322	20992735763	studies	study	NN2
304953	100736322	20992735764	have	have	VH0
304953	100736322	20992735765	reported	report	VVN
304953	100736322	20992735766	a	a	AT1
304953	100736322	20992735767	temporary	temporary	JJ
304953	100736322	20992735768	shortening	shortening	NN1@
304953	100736322	20992735769	of	of	IO
304953	100736322	20992735770	the	the	AT
304953	100736322	20992735771	penis	penis	NN1
304953	100736322	20992735772	averaging	average	VVG_NN1
304953	100736322	20992735773	at	at	RR21
304953	100736322	20992735774	most	most	RR22
304953	100736322	20992735775	a	a	AT1
304953	100736322	20992735776	half-inch	half-inch	NNU1_JJ
304953	100736322	20992735777	or	or	CC
304953	100736322	20992735778	so	so	RR
304953	100736322	20992735779	after	after	II_CS
304953	100736322	20992735780	prostate	prostate	NN1
304953	100736322	20992735781	removal	removal	NN1
304953	100736322	20992735782	surgery	surgery	NN1
304953	100736322	20992735783	,	,	,
304953	100736322	20992735784	while	while	CS
304953	100736322	20992735785	others	others	NN2
304953	100736322	20992735786	have	have	VH0
304953	100736322	20992735787	reported	report	VVN
304953	100736322	20992735788	no	no	AT
304953	100736322	20992735789	change	change	NN1
304953	100736322	20992735790	in	in	II
304953	100736322	20992735791	penis	penis	NN1
304953	100736322	20992735792	size	size	NN1
304953	100736322	20992735793	.	.	.
304953	100736322	20992735794	<p>		NULL
304953	100736322	20992735795	Now	now	RT
304953	100736322	20992735796	one	one	MC1
304953	100736322	20992735797	of	of	IO
304953	100736322	20992735798	the	the	AT
304953	100736322	20992735799	largest	large	JJT
304953	100736322	20992735800	investigations	investigation	NN2
304953	100736322	20992735801	to	to	II
304953	100736322	20992735802	date	date	NN1
304953	100736322	20992735803	,	,	,
304953	100736322	20992735804	published	publish	VVN
304953	100736322	20992735805	in	in	II
304953	100736322	20992735806	a	a	AT1
304953	100736322	20992735807	May	may	NPM1
304953	100736322	20992735808	2014	2014	MC
304953	100736322	20992735809	supplement	supplement	VV0_NN1
304953	100736322	20992735810	to	to	II
304953	100736322	20992735811	BJU		NP1_NN1
304953	100736322	20992735812	International	international	JJ
304953	100736322	20992735813	,	,	,
304953	100736322	20992735814	has	have	VHZ
304953	100736322	20992735815	found	find	VVN
304953	100736322	20992735816	that	that	CST
304953	100736322	20992735817	while	while	CS
304953	100736322	20992735818	some	some	DD
304953	100736322	20992735819	men	man	NN2
304953	100736322	20992735820	do	do	VD0
304953	100736322	20992735821	end	end	VVI
304953	100736322	20992735822	up	up	RP
304953	100736322	20992735823	with	with	IW
304953	100736322	20992735824	a	a	AT1
304953	100736322	20992735825	slightly	slightly	RR
304953	100736322	20992735826	shorter	short	JJR
304953	100736322	20992735827	penis	penis	NN1
304953	100736322	20992735828	after	after	II_CS
304953	100736322	20992735829	radical	radical	JJ_NN1
304953	100736322	20992735830	prostatectomy	prostatectomy	NN1
304953	100736322	20992735831	,	,	,
304953	100736322	20992735832	taking	take	VVG
304953	100736322	20992735833	a	a	AT1
304953	100736322	20992735834	low	low	JJ
304953	100736322	20992735835	dose	dose	NN1
304953	100736322	20992735836	of	of	IO
304953	100736322	20992735837	an	a	AT1
304953	100736322	20992735838	erectile	erectile	JJ
304953	100736322	20992735839	dysfunction	dysfunction	NN1
304953	100736322	20992735840	drug	drug	NN1
304953	100736322	20992735841	like	like	II
304953	100736322	20992735842	sildenafil	sildenafil	NN1
304953	100736322	20992735843	(	(	(
304953	100736322	20992735844	Viagra	viagra	NP1
304953	100736322	20992735845	)	)	)
304953	100736322	20992735846	or	or	CC
304953	100736322	20992735847	tadalafil		NN1_VV0
304953	100736322	20992735848	(	(	(
304953	100736322	20992735849	Cialis		NP1
304953	100736322	20992735850	)	)	)
304953	100736322	20992735851	every	every	AT1
304953	100736322	20992735852	day	day	NNT1
304953	100736322	20992735853	or	or	CC
304953	100736322	20992735854	a	a	AT1
304953	100736322	20992735855	higher	high	JJR
304953	100736322	20992735856	dose	dose	NN1
304953	100736322	20992735857	twice	twice	RR
304953	100736322	20992735858	a	a	AT1
304953	100736322	20992735859	week	week	NNT1
304953	100736322	20992735860	might	might	VM
304953	100736322	20992735861	prevent	prevent	VVI
304953	100736322	20992735862	that	that	CST_DD1
304953	100736322	20992735863	from	from	II
304953	100736322	20992735864	happening	happening	NN1_VVG
304953	100736322	20992735865	.	.	.
304953	100736322	20992735866	The	the	AT
304953	100736322	20992735867	take-away	takeaway	NN1
304953	100736322	20992735868	point	point	NN1
304953	100736322	20992735869	?	?	?
304953	100736322	20992735870	Having	have	VHG
304953	100736322	20992735871	erections	erection	NN2
304953	100736322	20992735872	after	after	II_CS
304953	100736322	20992735873	surgery	surgery	NN1
304953	100736322	20992735874	may	may	VM
304953	100736322	20992735875	preserve	preserve	VVI
304953	100736322	20992735876	penis	penis	NN1
304953	100736322	20992735877	size	size	NN1
304953	100736322	20992735878	,	,	,
304953	100736322	20992735879	possibly	possibly	RR
304953	100736322	20992735880	by	by	II
304953	100736322	20992735881	increasing	increasing	JJ_VVG
304953	100736322	20992735882	blood	blood	NN1
304953	100736322	20992735883	flow	flow	NN1
304953	100736322	20992735884	.	.	.
304953	100736322	20992735885	<p>		NULL
304953	100736322	20992735886	"	"	"
304953	100736322	20992735887	Its	its	APPGE
304953	100736322	20992735888	becoming	become	VVG_JJ@
304953	100736322	20992735889	increasingly	increasingly	RR
304953	100736322	20992735890	clear	clear	VV0@_JJ
304953	100736322	20992735891	that	that	CST_DD1
304953	100736322	20992735892	having	have	VHG
304953	100736322	20992735893	erections	erection	NN2
304953	100736322	20992735894	@		II
304953	100736322	20992735895	@		II
304953	100736322	20992735896	@		II
304953	100736322	20992735897	@		II
304953	100736322	20992735898	@		II
304953	100736322	20992735899	@		II
304953	100736322	20992735900	@		II
304953	100736322	20992735901	@		II
304953	100736322	20992735902	@		II
304953	100736322	20992735903	@		II
304953	100736322	20992735904	tissues	tissue	NN2
304953	100736322	20992735905	"	"	"
304953	100736322	20992735906	helps	help	NN2@_VVZ
304953	100736322	20992735907	improve	improve	VVI
304953	100736322	20992735908	sexual	sexual	JJ
304953	100736322	20992735909	rehabilitation	rehabilitation	NN1
304953	100736322	20992735910	after	after	II_CS
304953	100736322	20992735911	prostate	prostate	NN1
304953	100736322	20992735912	cancer	cancer	NN1
304953	100736322	20992735913	surgery	surgery	NN1
304953	100736322	20992735914	,	,	,
304953	100736322	20992735915	"	"	"
304953	100736322	20992735916	says	say	VVZ
304953	100736322	20992735917	Dr.		NNB
304953	100736322	20992735918	Marc	marc	NP1
304953	100736322	20992735919	B.		NP1
304953	100736322	20992735920	Garnick		NP1
304953	100736322	20992735921	,	,	,
304953	100736322	20992735922	a	a	AT1
304953	100736322	20992735923	clinical	clinical	JJ
304953	100736322	20992735924	professor	professor	NN1
304953	100736322	20992735925	of	of	IO
304953	100736322	20992735926	medicine	medicine	NN1
304953	100736322	20992735927	at	at	II
304953	100736322	20992735928	Harvard	harvard	NP1
304953	100736322	20992735929	Medical	medical	JJ
304953	100736322	20992735930	School	school	NN1
304953	100736322	20992735931	,	,	,
304953	100736322	20992735932	an	a	AT1
304953	100736322	20992735933	oncologist	oncologist	NN1
304953	100736322	20992735934	at	at	II
304953	100736322	20992735935	Beth	beth	NP1
304953	100736322	20992735936	Israel	israel	NP1
304953	100736322	20992735937	Deaconess	deaconess	NN1
304953	100736322	20992735938	Medical	medical	JJ
304953	100736322	20992735939	Center	center	NN1
304953	100736322	20992735940	,	,	,
304953	100736322	20992735941	and	and	CC
304953	100736322	20992735942	editor	editor	NN1
304953	100736322	20992735943	in	in	II
304953	100736322	20992735944	chief	chief	NN1
304953	100736322	20992735945	of	of	IO
304953	100736322	20992735946	Harvard	harvard	NP1
304953	100736322	20992735947	Medical	medical	JJ
304953	100736322	20992735948	Schools	school	NN2
304953	100736322	20992735949	Annual	annual	JJ
304953	100736322	20992735950	Report	report	NN1
304953	100736322	20992735951	on	on	II
304953	100736322	20992735952	Prostate	prostate	NN1
304953	100736322	20992735953	Diseases	disease	NN2
304953	100736322	20992735954	.	.	.
304953	100736322	20992735955	"	"	"
304953	100736322	20992735956	The	the	AT
304953	100736322	20992735957	current	current	JJ
304953	100736322	20992735958	study	study	NN1
304953	100736322	20992735959	shows	show	VVZ
304953	100736322	20992735960	that	that	DD1_CST
304953	100736322	20992735961	routine	routine	NN1_JJ@
304953	100736322	20992735962	use	use	NN1
304953	100736322	20992735963	of	of	IO
304953	100736322	20992735964	an	a	AT1
304953	100736322	20992735965	erectile	erectile	JJ
304953	100736322	20992735966	dysfunction	dysfunction	NN1
304953	100736322	20992735967	drug	drug	NN1
304953	100736322	20992735968	is	be	VBZ
304953	100736322	20992735969	helpful	helpful	JJ
304953	100736322	20992735970	in	in	II
304953	100736322	20992735971	this	this	DD1
304953	100736322	20992735972	respect	respect	NN1
304953	100736322	20992735973	.	.	.
304953	100736322	20992735974	"	"	"
304953	100736322	20992735975	<p>		NULL
304953	100736322	20992735976	Investigators	investigator	NN2
304953	100736322	20992735977	from	from	II
304953	100736322	20992735978	the	the	AT
304953	100736322	20992735979	Memorial	memorial	NN1
304953	100736322	20992735980	Sloan	sloan	NP1_NN1
304953	100736322	20992735981	Kettering	kettering	NP1
304953	100736322	20992735982	Cancer	cancer	NN1
304953	100736322	20992735983	Center	center	NN1
304953	100736322	20992735984	in	in	II
304953	100736322	20992735985	New	new	NP1
304953	100736322	20992735986	York	york	NP1
304953	100736322	20992735987	City	city	NN1
304953	100736322	20992735988	recruited	recruit	VVN_VVD@
304953	100736322	20992735989	-	-	-
304953	100736322	20992735990	118	118	MC
304953	100736322	20992735991	volunteers	volunteer	NN2
304953	100736322	20992735992	to	to	TO
304953	100736322	20992735993	participate	participate	VVI
304953	100736322	20992735994	in	in	II
304953	100736322	20992735995	the	the	AT
304953	100736322	20992735996	study	study	NN1
304953	100736322	20992735997	.	.	.
304953	100736322	20992735998	All	all	DB
304953	100736322	20992735999	were	be	VBDR
304953	100736322	20992736000	getting	get	VVG
304953	100736322	20992736001	ready	ready	JJ
304953	100736322	20992736002	to	to	TO
304953	100736322	20992736003	undergo	undergo	VVI
304953	100736322	20992736004	prostate	prostate	NN1
304953	100736322	20992736005	removal	removal	NN1
304953	100736322	20992736006	surgery	surgery	NN1
304953	100736322	20992736007	.	.	.
304953	100736322	20992736008	A	a	AT1_ZZ1
304953	100736322	20992736009	male	male	JJ_NN1
304953	100736322	20992736010	nurse	nurse	NN1
304953	100736322	20992736011	measured	measure	VVD_VVN
304953	100736322	20992736012	each	each	DD1
304953	100736322	20992736013	mans	man	VVZ%
304953	100736322	20992736014	flaccid	flaccid	JJ
304953	100736322	20992736015	penis	penis	NN1
304953	100736322	20992736016	before	before	II_CS
304953	100736322	20992736017	the	the	AT
304953	100736322	20992736018	operation	operation	NN1
304953	100736322	20992736019	,	,	,
304953	100736322	20992736020	and	and	CC
304953	100736322	20992736021	then	then	RT
304953	100736322	20992736022	again	again	RT
304953	100736322	20992736023	at	at	II
304953	100736322	20992736024	two	two	MC
304953	100736322	20992736025	and	and	CC
304953	100736322	20992736026	six	six	MC
304953	100736322	20992736027	months	month	NNT2
304953	100736322	20992736028	after	after	II_CS
304953	100736322	20992736029	the	the	AT
304953	100736322	20992736030	operation	operation	NN1
304953	100736322	20992736031	.	.	.
304953	100736322	20992736032	<p>		NULL
304953	100736322	20992736033	Roughly	roughly	RR
304953	100736322	20992736034	half	half	DB
304953	100736322	20992736035	of	of	IO
304953	100736322	20992736036	the	the	AT
304953	100736322	20992736037	men	man	NN2
304953	100736322	20992736038	experienced	experience	VVD_VVN
304953	100736322	20992736039	no	no	AT
304953	100736322	20992736040	change	change	NN1
304953	100736322	20992736041	in	in	II
304953	100736322	20992736042	penis	penis	NN1
304953	100736322	20992736043	length	length	NN1
304953	100736322	20992736044	.	.	.
304953	100736322	20992736045	Most	most	DAT
304953	100736322	20992736046	of	of	IO
304953	100736322	20992736047	the	the	AT
304953	100736322	20992736048	rest	rest	NN1
304953	100736322	20992736049	lost	lose	VVN_VVD
304953	100736322	20992736050	about	about	II_RP@
304953	100736322	20992736051	one-tenth	one-tenth	MF
304953	100736322	20992736052	of	of	IO
304953	100736322	20992736053	an	a	AT1
304953	100736322	20992736054	inch	inch	NNU1
304953	100736322	20992736055	(	(	(
304953	100736322	20992736056	2.5	2.5	MC
304953	100736322	20992736057	millimeters	millimeter	NN2
304953	100736322	20992736058	)	)	)
304953	100736322	20992736059	in	in	II
304953	100736322	20992736060	length	length	NN1
304953	100736322	20992736061	,	,	,
304953	100736322	20992736062	but	but	CCB
304953	100736322	20992736063	had	have	VHD
304953	100736322	20992736064	recovered	recover	VVN
304953	100736322	20992736065	to	to	II
304953	100736322	20992736066	their	their	APPGE
304953	100736322	20992736067	pre-surgery	pre-surgery	JJ_NN1
304953	100736322	20992736068	size	size	NN1
304953	100736322	20992736069	by	by	II
304953	100736322	20992736070	six	six	MC
304953	100736322	20992736071	months	month	NNT2
304953	100736322	20992736072	.	.	.
304953	100736322	20992736073	A	a	AT1_ZZ1
304953	100736322	20992736074	small	small	JJ
304953	100736322	20992736075	group	group	NN1
304953	100736322	20992736076	of	of	IO
304953	100736322	20992736077	men	man	NN2
304953	100736322	20992736078	"	"	"
304953	100736322	20992736079	roughly	roughly	RR
304953	100736322	20992736080	5%		NNU
304953	100736322	20992736081	"	"	"
304953	100736322	20992736082	had	have	VHD
304953	100736322	20992736083	a	a	AT1
304953	100736322	20992736084	persistent	persistent	JJ
304953	100736322	20992736085	loss	loss	NN1
304953	100736322	20992736086	of	of	IO
304953	100736322	20992736087	at	at	RR21
304953	100736322	20992736088	least	least	RR22
304953	100736322	20992736089	one-third	one-third	MF
304953	100736322	20992736090	of	of	IO
304953	100736322	20992736091	an	a	AT1
304953	100736322	20992736092	inch	inch	NNU1
304953	100736322	20992736093	(	(	(
304953	100736322	20992736094	@		II
304953	100736322	20992736095	@		II
304953	100736322	20992736096	@		II
304953	100736322	20992736097	@		II
304953	100736322	20992736098	@		II
304953	100736322	20992736099	@		II
304953	100736322	20992736100	@		II
304953	100736322	20992736101	@		II
304953	100736322	20992736102	@		II
304953	100736322	20992736103	@		II
304953	100736322	20992736104	took	take	VVD
304953	100736322	20992736105	an	a	AT1
304953	100736322	20992736106	erectile	erectile	JJ
304953	100736322	20992736107	dysfunction	dysfunction	NN1
304953	100736322	20992736108	drug	drug	NN1
304953	100736322	20992736109	every	every	AT1
304953	100736322	20992736110	day	day	NNT1
304953	100736322	20992736111	(	(	(
304953	100736322	20992736112	which	which	DDQ
304953	100736322	20992736113	is	be	VBZ
304953	100736322	20992736114	increasingly	increasingly	RR
304953	100736322	20992736115	recommended	recommend	VVN_VVD
304953	100736322	20992736116	as	as	II
304953	100736322	20992736117	part	part	NN1
304953	100736322	20992736118	of	of	IO
304953	100736322	20992736119	post-prostatectomy		JJ_NN1
304953	100736322	20992736120	care	care	NN1
304953	100736322	20992736121	)	)	)
304953	100736322	20992736122	were	be	VBDR
304953	100736322	20992736123	back	back	RP
304953	100736322	20992736124	to	to	II
304953	100736322	20992736125	their	their	APPGE
304953	100736322	20992736126	pre-surgery	pre-surgery	JJ_NN1
304953	100736322	20992736127	sizes	size	NN2
304953	100736322	20992736128	within	within	II
304953	100736322	20992736129	six	six	MC
304953	100736322	20992736130	months	month	NNT2
304953	100736322	20992736131	,	,	,
304953	100736322	20992736132	while	while	CS
304953	100736322	20992736133	those	those	DD2
304953	100736322	20992736134	who	who	PNQS
304953	100736322	20992736135	did	do	VDD
304953	100736322	20992736136	n't 	n't	XX
304953	100736322	20992736137	take	take	VVI
304953	100736322	20992736138	an	a	AT1
304953	100736322	20992736139	erectile	erectile	JJ
304953	100736322	20992736140	dysfunction	dysfunction	NN1
304953	100736322	20992736141	drug	drug	NN1
304953	100736322	20992736142	continued	continue	VVD_VVN
304953	100736322	20992736143	to	to	TO
304953	100736322	20992736144	have	have	VHI
304953	100736322	20992736145	slightly	slightly	RR
304953	100736322	20992736146	smaller	small	JJR
304953	100736322	20992736147	penises	penis	NN2
304953	100736322	20992736148	than	than	CSN
304953	100736322	20992736149	before	before	II_CS
304953	100736322	20992736150	the	the	AT
304953	100736322	20992736151	surgery	surgery	NN1
304953	100736322	20992736152	.	.	.
304953	100736322	20992736153	<p>		NULL
304953	100736322	20992736154	According	according	II21
304953	100736322	20992736155	to	to	II22
304953	100736322	20992736156	the	the	AT
304953	100736322	20992736157	researchers	researcher	NN2
304953	100736322	20992736158	,	,	,
304953	100736322	20992736159	the	the	AT
304953	100736322	20992736160	shortening	shortening	NN1@
304953	100736322	20992736161	was	be	VBDZ
304953	100736322	20992736162	minimal	minimal	JJ
304953	100736322	20992736163	"	"	"
304953	100736322	20992736164	and	and	CC
304953	100736322	20992736165	almost	almost	RR
304953	100736322	20992736166	certainty	certainty	NN1
304953	100736322	20992736167	not	not	XX
304953	100736322	20992736168	clinically	clinically	RR
304953	100736322	20992736169	meaningful	meaningful	JJ
304953	100736322	20992736170	,	,	,
304953	100736322	20992736171	"	"	"
304953	100736322	20992736172	meaning	mean	VVG
304953	100736322	20992736173	that	that	CST
304953	100736322	20992736174	it	it	PPH1
304953	100736322	20992736175	probably	probably	RR
304953	100736322	20992736176	had	have	VHD_VHN@
304953	100736322	20992736177	no	no	AT
304953	100736322	20992736178	effect	effect	NN1
304953	100736322	20992736179	on	on	II
304953	100736322	20992736180	sexual	sexual	JJ
304953	100736322	20992736181	intercourse	intercourse	NN1
304953	100736322	20992736182	or	or	CC
304953	100736322	20992736183	a	a	AT1
304953	100736322	20992736184	partners	partner	NN2
304953	100736322	20992736185	satisfaction	satisfaction	NN1
304953	100736322	20992736186	.	.	.
304953	100736322	20992736187	<h>		NULL
304953	100736322	20992736188	Causes	cause	VVZ_NN2
304953	100736322	20992736189	unclear	unclear	JJ
304953	100736322	20992736190	<p>		NULL
304953	100736322	20992736191	It	it	PPH1
304953	100736322	20992736192	is n't		VV0
304953	100736322	20992736193	clear	clear	JJ
304953	100736322	20992736194	how	how	RRQ
304953	100736322	20992736195	prostate	prostate	NN1
304953	100736322	20992736196	removal	removal	NN1
304953	100736322	20992736197	surgery	surgery	NN1
304953	100736322	20992736198	might	might	VM
304953	100736322	20992736199	shorten	shorten	VVI
304953	100736322	20992736200	the	the	AT
304953	100736322	20992736201	penis	penis	NN1
304953	100736322	20992736202	.	.	.
304953	100736322	20992736203	One	one	MC1
304953	100736322	20992736204	possible	possible	JJ
304953	100736322	20992736205	explanation	explanation	NN1
304953	100736322	20992736206	is	be	VBZ
304953	100736322	20992736207	that	that	DD1_CST
304953	100736322	20992736208	nerve	nerve	NN1
304953	100736322	20992736209	injury	injury	NN1
304953	100736322	20992736210	during	during	II
304953	100736322	20992736211	the	the	AT
304953	100736322	20992736212	operation	operation	NN1
304953	100736322	20992736213	causes	cause	VVZ
304953	100736322	20992736214	muscles	muscle	NN2
304953	100736322	20992736215	in	in	II_RP@
304953	100736322	20992736216	and	and	CC
304953	100736322	20992736217	around	around	II_RP
304953	100736322	20992736218	the	the	AT
304953	100736322	20992736219	penis	penis	NN1
304953	100736322	20992736220	to	to	TO
304953	100736322	20992736221	contract	contract	VVI
304953	100736322	20992736222	.	.	.
304953	100736322	20992736223	That	that	DD1
304953	100736322	20992736224	idea	idea	NN1
304953	100736322	20992736225	is	be	VBZ
304953	100736322	20992736226	supported	support	VVN
304953	100736322	20992736227	by	by	II
304953	100736322	20992736228	earlier	early	JJR
304953	100736322	20992736229	studies	study	NN2
304953	100736322	20992736230	showing	show	VVG
304953	100736322	20992736231	that	that	CST
304953	100736322	20992736232	efforts	effort	NN2
304953	100736322	20992736233	to	to	TO
304953	100736322	20992736234	spare	spare	VVI
304953	100736322	20992736235	nerves	nerve	NN2
304953	100736322	20992736236	during	during	II
304953	100736322	20992736237	surgery	surgery	NN1
304953	100736322	20992736238	can	can	VM
304953	100736322	20992736239	protect	protect	VVI
304953	100736322	20992736240	against	against	II
304953	100736322	20992736241	penis	penis	NN1
304953	100736322	20992736242	shrinkage	shrinkage	NN1
304953	100736322	20992736243	.	.	.
304953	100736322	20992736244	<p>		NULL
304953	100736322	20992736245	The	the	AT
304953	100736322	20992736246	new	new	JJ
304953	100736322	20992736247	study	study	NN1
304953	100736322	20992736248	has	have	VHZ
304953	100736322	20992736249	some	some	DD
304953	100736322	20992736250	advantages	advantage	NN2
304953	100736322	20992736251	over	over	II
304953	100736322	20992736252	earlier	early	JJR
304953	100736322	20992736253	ones	one	NN2
304953	100736322	20992736254	.	.	.
304953	100736322	20992736255	It	it	PPH1
304953	100736322	20992736256	followed	follow	VVD
304953	100736322	20992736257	the	the	AT
304953	100736322	20992736258	volunteers	volunteer	NN2
304953	100736322	20992736259	for	for	IF
304953	100736322	20992736260	longer	long	JJR_RRR
304953	100736322	20992736261	than	than	CSN
304953	100736322	20992736262	most	most	DAT
304953	100736322	20992736263	earlier	early	JJR
304953	100736322	20992736264	studies	study	NN2
304953	100736322	20992736265	.	.	.
304953	100736322	20992736266	In	in	RR21
304953	100736322	20992736267	addition	addition	RR22
304953	100736322	20992736268	,	,	,
304953	100736322	20992736269	all	all	DB
304953	100736322	20992736270	of	of	IO
304953	100736322	20992736271	the	the	AT
304953	100736322	20992736272	measurements	measurement	NN2
304953	100736322	20992736273	were	be	VBDR
304953	100736322	20992736274	made	make	VVN
304953	100736322	20992736275	by	by	II
304953	100736322	20992736276	just	just	RR
304953	100736322	20992736277	one	one	MC1
304953	100736322	20992736278	nurse	nurse	NN1
304953	100736322	20992736279	,	,	,
304953	100736322	20992736280	while	while	CS
304953	100736322	20992736281	earlier	early	JJR
304953	100736322	20992736282	studies	study	NN2
304953	100736322	20992736283	often	often	RR
304953	100736322	20992736284	used	use	VVN_VVD
304953	100736322	20992736285	several	several	DA2
304953	100736322	20992736286	nurses	nurse	NN2
304953	100736322	20992736287	.	.	.
304953	100736322	20992736288	That	that	DD1
304953	100736322	20992736289	helped	help	VVN_VVD_JJ@
304953	100736322	20992736290	minimize	minimize	VVI
304953	100736322	20992736291	the	the	AT
304953	100736322	20992736292	possibility	possibility	NN1
304953	100736322	20992736293	of	of	IO
304953	100736322	20992736294	@		II
304953	100736322	20992736295	@		II
304953	100736322	20992736296	@		II
304953	100736322	20992736297	@		II
304953	100736322	20992736298	@		II
304953	100736322	20992736299	@		II
304953	100736322	20992736300	@		II
304953	100736322	20992736301	@		II
304953	100736322	20992736302	@		II
304953	100736322	20992736303	@		II
304953	100736322	20992736304	study	study	NN1
304953	100736322	20992736305	,	,	,
304953	100736322	20992736306	especially	especially	RR
304953	100736322	20992736307	that	that	CST_DD1
304953	100736322	20992736308	half	half	DB_NN1@
304953	100736322	20992736309	of	of	IO
304953	100736322	20992736310	the	the	AT
304953	100736322	20992736311	men	man	NN2
304953	100736322	20992736312	who	who	PNQS
304953	100736322	20992736313	volunteered	volunteer	VVD
304953	100736322	20992736314	did	do	VDD
304953	100736322	20992736315	n't 	n't	XX
304953	100736322	20992736316	follow	follow	VVI
304953	100736322	20992736317	through	through	RP@
304953	100736322	20992736318	and	and	CC
304953	100736322	20992736319	have	have	VHI
304953	100736322	20992736320	all	all	DB
304953	100736322	20992736321	of	of	IO
304953	100736322	20992736322	the	the	AT
304953	100736322	20992736323	post-prostatectomy		JJ_NN1
304953	100736322	20992736324	measurements	measurement	NN2
304953	100736322	20992736325	.	.	.
304953	100736322	20992736326	<p>		NULL
304953	100736322	20992736327	Shortening		NN1@_VVG_NP1@
304953	100736322	20992736328	of	of	IO
304953	100736322	20992736329	the	the	AT
304953	100736322	20992736330	penis	penis	NN1
304953	100736322	20992736331	can	can	VM
304953	100736322	20992736332	happen	happen	VVI
304953	100736322	20992736333	with	with	IW
304953	100736322	20992736334	other	other	JJ
304953	100736322	20992736335	prostate	prostate	NN1
304953	100736322	20992736336	cancer	cancer	NN1
304953	100736322	20992736337	treatments	treatment	NN2
304953	100736322	20992736338	beside	beside	II
304953	100736322	20992736339	prostatectomy	prostatectomy	NN1
304953	100736322	20992736340	.	.	.
304953	100736322	20992736341	Some	some	DD
304953	100736322	20992736342	men	man	NN2
304953	100736322	20992736343	who	who	PNQS
304953	100736322	20992736344	have	have	VH0
304953	100736322	20992736345	radiation	radiation	NN1
304953	100736322	20992736346	therapy	therapy	NN1
304953	100736322	20992736347	or	or	CC
304953	100736322	20992736348	hormone	hormone	NN1
304953	100736322	20992736349	therapy	therapy	NN1
304953	100736322	20992736350	notice	notice	VV0_NN1
304953	100736322	20992736351	it	it	PPH1
304953	100736322	20992736352	,	,	,
304953	100736322	20992736353	too	too	RR@
304953	100736322	20992736354	.	.	.
304953	100736322	20992736355	The	the	AT
304953	100736322	20992736356	results	result	NN2
304953	100736322	20992736357	of	of	IO
304953	100736322	20992736358	the	the	AT
304953	100736322	20992736359	Memorial	memorial	NN1
304953	100736322	20992736360	Sloan	sloan	NP1_NN1
304953	100736322	20992736361	Kettering	kettering	NP1
304953	100736322	20992736362	study	study	NN1
304953	100736322	20992736363	support	support	VV0_NN1
304953	100736322	20992736364	the	the	AT
304953	100736322	20992736365	idea	idea	NN1
304953	100736322	20992736366	that	that	CST
304953	100736322	20992736367	men	man	NN2
304953	100736322	20992736368	should	should	VM
304953	100736322	20992736369	counseled	counsel	VVD
304953	100736322	20992736370	about	about	II_RP@
304953	100736322	20992736371	potential	potential	JJ_NN1
304953	100736322	20992736372	losses	loss	NN2
304953	100736322	20992736373	in	in	II
304953	100736322	20992736374	penis	penis	NN1
304953	100736322	20992736375	size	size	NN1
304953	100736322	20992736376	from	from	II
304953	100736322	20992736377	prostate	prostate	NN1
304953	100736322	20992736378	cancer	cancer	NN1
304953	100736322	20992736379	treatment	treatment	NN1
304953	100736322	20992736380	and	and	CC
304953	100736322	20992736381	be	be	VBI
304953	100736322	20992736382	encouraged	encourage	VVN
304953	100736322	20992736383	to	to	TO
304953	100736322	20992736384	take	take	VVI
304953	100736322	20992736385	an	a	AT1
304953	100736322	20992736386	erectile	erectile	JJ
304953	100736322	20992736387	dysfunction	dysfunction	NN1
304953	100736322	20992736388	drug	drug	NN1
304953	100736322	20992736389	to	to	TO
304953	100736322	20992736390	keep	keep	VVI
304953	100736322	20992736391	it	it	PPH1
304953	100736322	20992736392	from	from	II
304953	100736322	20992736393	happening	happening	NN1_VVG
304953	100736322	20992736394	.	.	.
304953	100736322	20992736395	<p>		NULL
304953	100736322	20992736396	"	"	"
304953	100736322	20992736397	The	the	AT
304953	100736322	20992736398	current	current	JJ
304953	100736322	20992736399	study	study	NN1
304953	100736322	20992736400	should	should	VM
304953	100736322	20992736401	focus	focus	VVI
304953	100736322	20992736402	more	more	DAR
304953	100736322	20992736403	attention	attention	NN1
304953	100736322	20992736404	on	on	II
304953	100736322	20992736405	this	this	DD1
304953	100736322	20992736406	important	important	JJ
304953	100736322	20992736407	topic	topic	NN1
304953	100736322	20992736408	,	,	,
304953	100736322	20992736409	"	"	"
304953	100736322	20992736410	says	say	VVZ
304953	100736322	20992736411	Dr.		NNB
304953	100736322	20992736412	Garnick.		NP1
304953	100736323	20992736432	@@##	----------	----------
304953	100736323	20992736433	@@100736323		FO
304953	100736323	20992736434	@4936323/		NN1_VV0
304953	100736323	20992736435	<p>		NULL
304953	100736323	20992736436	"	"	"
304953	100736323	20992736437	What	what	DDQ
304953	100736323	20992736438	can	can	VM
304953	100736323	20992736439	I	i	PPIS1
304953	100736323	20992736440	eat	eat	VVI
304953	100736323	20992736441	to	to	TO
304953	100736323	20992736442	reduce	reduce	VVI
304953	100736323	20992736443	my	my	APPGE
304953	100736323	20992736444	risk	risk	NN1
304953	100736323	20992736445	of	of	IO
304953	100736323	20992736446	developing	developing	JJ_VVG
304953	100736323	20992736447	prostate	prostate	NN1
304953	100736323	20992736448	cancer	cancer	NN1
304953	100736323	20992736449	?	?	?
304953	100736323	20992736450	"	"	"
304953	100736323	20992736451	That 's		VVZ_NN2_NP1@
304953	100736323	20992736452	one	one	MC1
304953	100736323	20992736453	of	of	IO
304953	100736323	20992736454	the	the	AT
304953	100736323	20992736455	most	most	RGT
304953	100736323	20992736456	common	common	JJ
304953	100736323	20992736457	questions	question	NN2
304953	100736323	20992736458	physicians	physician	NN2
304953	100736323	20992736459	hear	hear	VV0
304953	100736323	20992736460	from	from	II
304953	100736323	20992736461	men	man	NN2
304953	100736323	20992736462	concerned	concerned	JJ
304953	100736323	20992736463	about	about	II
304953	100736323	20992736464	prostate	prostate	NN1
304953	100736323	20992736465	health	health	NN1
304953	100736323	20992736466	.	.	.
304953	100736323	20992736467	Undoubtedly	undoubtedly	RR
304953	100736323	20992736468	,	,	,
304953	100736323	20992736469	many	many	DA2
304953	100736323	20992736470	hope	hope	VV0_NN1
304953	100736323	20992736471	to	to	TO
304953	100736323	20992736472	hear	hear	VVI
304953	100736323	20992736473	their	their	APPGE
304953	100736323	20992736474	doctor	doctor	NN1
304953	100736323	20992736475	rattle	rattle	NN1_VV0
304953	100736323	20992736476	off	off	II_RP
304953	100736323	20992736477	a	a	AT1
304953	100736323	20992736478	few	few	DA2
304953	100736323	20992736479	foods	food	NN2
304953	100736323	20992736480	guaranteed	guarantee	VVD_VVN
304953	100736323	20992736481	to	to	TO
304953	100736323	20992736482	shield	shield	VVI
304953	100736323	20992736483	them	them	PPHO2
304953	100736323	20992736484	from	from	II
304953	100736323	20992736485	disease	disease	NN1
304953	100736323	20992736486	.	.	.
304953	100736323	20992736487	Although	although	CS
304953	100736323	20992736488	some	some	DD
304953	100736323	20992736489	foods	food	NN2
304953	100736323	20992736490	have	have	VH0
304953	100736323	20992736491	been	be	VBN
304953	100736323	20992736492	linked	link	VVN
304953	100736323	20992736493	with	with	IW
304953	100736323	20992736494	reduced	reduced	JJ@
304953	100736323	20992736495	risk	risk	NN1
304953	100736323	20992736496	of	of	IO
304953	100736323	20992736497	prostate	prostate	NN1
304953	100736323	20992736498	cancer	cancer	NN1
304953	100736323	20992736499	,	,	,
304953	100736323	20992736500	the	the	AT
304953	100736323	20992736501	proof	proof	NN1
304953	100736323	20992736502	is	be	VBZ
304953	100736323	20992736503	lacking	lack	VVG
304953	100736323	20992736504	,	,	,
304953	100736323	20992736505	at	at	RR21
304953	100736323	20992736506	least	least	RR22
304953	100736323	20992736507	for	for	IF
304953	100736323	20992736508	now	now	RT
304953	100736323	20992736509	.	.	.
304953	100736323	20992736510	<p>		NULL
304953	100736323	20992736511	What	what	DDQ
304953	100736323	20992736512	dietitians	dietitian	NN2
304953	100736323	20992736513	,	,	,
304953	100736323	20992736514	physicians	physician	NN2
304953	100736323	20992736515	,	,	,
304953	100736323	20992736516	and	and	CC
304953	100736323	20992736517	researchers	researcher	NN2
304953	100736323	20992736518	can	can	VM
304953	100736323	20992736519	say	say	VVI
304953	100736323	20992736520	and	and	CC
304953	100736323	20992736521	there 's		NN2
304953	100736323	20992736522	plenty	plenty	PN
304953	100736323	20992736523	of	of	IO
304953	100736323	20992736524	evidence	evidence	NN1
304953	100736323	20992736525	to	to	TO
304953	100736323	20992736526	support	support	VVI
304953	100736323	20992736527	this	this	DD1
304953	100736323	20992736528	statement	statement	NN1
304953	100736323	20992736529	is	be	VBZ
304953	100736323	20992736530	that	that	CST
304953	100736323	20992736531	a	a	AT1
304953	100736323	20992736532	balanced	balanced	JJ
304953	100736323	20992736533	,	,	,
304953	100736323	20992736534	healthy	healthy	JJ
304953	100736323	20992736535	diet	diet	NN1
304953	100736323	20992736536	rich	rich	JJ
304953	100736323	20992736537	in	in	II
304953	100736323	20992736538	fruits	fruit	NN2
304953	100736323	20992736539	,	,	,
304953	100736323	20992736540	vegetables	vegetable	NN2
304953	100736323	20992736541	,	,	,
304953	100736323	20992736542	and	and	CC
304953	100736323	20992736543	whole	whole	JJ_NN1
304953	100736323	20992736544	grains	grain	NN2
304953	100736323	20992736545	remains	remain	VVZ
304953	100736323	20992736546	your	your	APPGE
304953	100736323	20992736547	best	best	JJT
304953	100736323	20992736548	bet	bet	NN1
304953	100736323	20992736549	.	.	.
304953	100736323	20992736550	In	in	II
304953	100736323	20992736551	fact	fact	NN1
304953	100736323	20992736552	,	,	,
304953	100736323	20992736553	given	given	CS21
304953	100736323	20992736554	that	that	CS22
304953	100736323	20992736555	most	most	DAT
304953	100736323	20992736556	men	man	NN2
304953	100736323	20992736557	with	with	IW
304953	100736323	20992736558	prostate	prostate	NN1
304953	100736323	20992736559	cancer	cancer	NN1
304953	100736323	20992736560	now	now	RT
304953	100736323	20992736561	die	die	VV0
304953	100736323	20992736562	with	with	IW
304953	100736323	20992736563	their	their	APPGE
304953	100736323	20992736564	disease	disease	NN1
304953	100736323	20992736565	,	,	,
304953	100736323	20992736566	not	not	XX
304953	100736323	20992736567	from	from	II
304953	100736323	20992736568	it	it	PPH1
304953	100736323	20992736569	,	,	,
304953	100736323	20992736570	and	and	CC
304953	100736323	20992736571	that	that	DD1
304953	100736323	20992736572	heart	heart	NN1
304953	100736323	20992736573	disease	disease	NN1
304953	100736323	20992736574	ranks	rank	NN2_VVZ@
304953	100736323	20992736575	as	as	II_CSA
304953	100736323	20992736576	the	the	AT
304953	100736323	20992736577	nations	nation	NN2
304953	100736323	20992736578	No.		NN1
304953	100736323	20992736579	1	1	MC1
304953	100736323	20992736580	killer	killer	NN1
304953	100736323	20992736581	,	,	,
304953	100736323	20992736582	sticking	stick	VVG
304953	100736323	20992736583	to	to	II
304953	100736323	20992736584	a	a	AT1
304953	100736323	20992736585	heart-healthy	heart-healthy	JJ
304953	100736323	20992736586	diet	diet	NN1
304953	100736323	20992736587	can	can	VM
304953	100736323	20992736588	help	help	VVI
304953	100736323	20992736589	increase	increase	NN1
304953	100736323	20992736590	survival	survival	NN1
304953	100736323	20992736591	.	.	.
304953	100736323	20992736592	Admittedly	admittedly	RR
304953	100736323	20992736593	,	,	,
304953	100736323	20992736594	you	you	PPY
304953	100736323	20992736595	might	might	VM
304953	100736323	20992736596	want	want	VVI
304953	100736323	20992736597	to	to	TO
304953	100736323	20992736598	tweak	tweak	VVI
304953	100736323	20992736599	your	your	APPGE
304953	100736323	20992736600	eating	eating	NN1
304953	100736323	20992736601	plan	plan	NN1_VV0
304953	100736323	20992736602	to	to	TO
304953	100736323	20992736603	suit	suit	VVI
304953	100736323	20992736604	your	your	APPGE
304953	100736323	20992736605	particular	particular	JJ
304953	100736323	20992736606	tastes	taste	NN2
304953	100736323	20992736607	and	and	CC
304953	100736323	20992736608	medical	medical	JJ
304953	100736323	20992736609	concerns	concern	NN2
304953	100736323	20992736610	(	(	(
304953	100736323	20992736611	allergies	allergy	NN2
304953	100736323	20992736612	,	,	,
304953	100736323	20992736613	for	for	REX21
304953	100736323	20992736614	example	example	REX22
304953	100736323	20992736615	)	)	)
304953	100736323	20992736616	,	,	,
304953	100736323	20992736617	but	but	CCB
304953	100736323	20992736618	Mom	mom	NN1
304953	100736323	20992736619	was	be	VBDZ
304953	100736323	20992736620	right	right	JJ
304953	100736323	20992736621	:	:	:
304953	100736323	20992736622	fruits	fruit	NN2
304953	100736323	20992736623	,	,	,
304953	100736323	20992736624	@		II
304953	100736323	20992736625	@		II
304953	100736323	20992736626	@		II
304953	100736323	20992736627	@		II
304953	100736323	20992736628	@		II
304953	100736323	20992736629	@		II
304953	100736323	20992736630	@		II
304953	100736323	20992736631	@		II
304953	100736323	20992736632	@		II
304953	100736323	20992736633	@		II
304953	100736323	20992736634	for	for	IF
304953	100736323	20992736635	you	you	PPY
304953	100736323	20992736636	.	.	.
304953	100736323	20992736637	<p>		NULL
304953	100736323	20992736638	But	but	CCB
304953	100736323	20992736639	just	just	RR
304953	100736323	20992736640	how	how	RGQ@
304953	100736323	20992736641	much	much	DA1
304953	100736323	20992736642	broccoli	broccoli	NN1
304953	100736323	20992736643	do	do	VD0
304953	100736323	20992736644	you	you	PPY
304953	100736323	20992736645	need	need	VVI
304953	100736323	20992736646	to	to	TO
304953	100736323	20992736647	put	put	VVI
304953	100736323	20992736648	on	on	II_RP@
304953	100736323	20992736649	your	your	APPGE
304953	100736323	20992736650	plate	plate	NN1
304953	100736323	20992736651	?	?	?
304953	100736323	20992736652	Do	do	VD0
304953	100736323	20992736653	you	you	PPY
304953	100736323	20992736654	have	have	VHI
304953	100736323	20992736655	to	to	TO
304953	100736323	20992736656	buy	buy	VVI
304953	100736323	20992736657	organic	organic	JJ
304953	100736323	20992736658	fruits	fruit	NN2
304953	100736323	20992736659	?	?	?
304953	100736323	20992736660	What 's		NN2
304953	100736323	20992736661	wrong	wrong	JJ_RR@_VV0%
304953	100736323	20992736662	with	with	IW
304953	100736323	20992736663	white	white	JJ
304953	100736323	20992736664	bread	bread	NN1
304953	100736323	20992736665	?	?	?
304953	100736323	20992736666	And	and	CC
304953	100736323	20992736667	why	why	RRQ
304953	100736323	20992736668	cant	cant	JJ_NN1
304953	100736323	20992736669	you	you	PPY
304953	100736323	20992736670	simply	simply	RR
304953	100736323	20992736671	take	take	VV0
304953	100736323	20992736672	a	a	AT1
304953	100736323	20992736673	supplement	supplement	NN1
304953	100736323	20992736674	to	to	TO
304953	100736323	20992736675	get	get	VVI
304953	100736323	20992736676	the	the	AT
304953	100736323	20992736677	vitamins	vitamin	NN2
304953	100736323	20992736678	and	and	CC
304953	100736323	20992736679	minerals	mineral	NN2
304953	100736323	20992736680	your	your	APPGE
304953	100736323	20992736681	body	body	NN1
304953	100736323	20992736682	needs	need	VVZ_NN2
304953	100736323	20992736683	?	?	?
304953	100736323	20992736684	To	to	TO
304953	100736323	20992736685	find	find	VVI
304953	100736323	20992736686	out	out	RP
304953	100736323	20992736687	,	,	,
304953	100736323	20992736688	Harvard	harvard	NP1
304953	100736323	20992736689	editors	editor	NN2
304953	100736323	20992736690	invited	invite	VVD_VVN
304953	100736323	20992736691	two	two	MC
304953	100736323	20992736692	registered	registered	JJ
304953	100736323	20992736693	dietitians	dietitian	NN2
304953	100736323	20992736694	from	from	II
304953	100736323	20992736695	Harvard-affiliated	harvard-affiliated	JJ_NN1
304953	100736323	20992736696	hospitals	hospital	NN2
304953	100736323	20992736697	to	to	TO
304953	100736323	20992736698	share	share	VVI
304953	100736323	20992736699	their	their	APPGE
304953	100736323	20992736700	expertise	expertise	NN1
304953	100736323	20992736701	:	:	:
304953	100736323	20992736702	<p>		NULL
304953	100736323	20992736703	Kathy	kathy	NP1
304953	100736323	20992736704	McManus	mcmanus	NP1
304953	100736323	20992736705	,	,	,
304953	100736323	20992736706	M.S.	ms	NN1
304953	100736323	20992736707	,	,	,
304953	100736323	20992736708	R.D.	r.d	NN1
304953	100736323	20992736709	,	,	,
304953	100736323	20992736710	L.D.N.		NP1
304953	100736323	20992736711	,	,	,
304953	100736323	20992736712	director	director	NN1
304953	100736323	20992736713	of	of	IO
304953	100736323	20992736714	the	the	AT
304953	100736323	20992736715	Department	department	NN1
304953	100736323	20992736716	of	of	IO
304953	100736323	20992736717	Nutrition	nutrition	NN1
304953	100736323	20992736718	at	at	II
304953	100736323	20992736719	Brigham	brigham	NP1
304953	100736323	20992736720	and	and	CC
304953	100736323	20992736721	Womens	womens	NP1
304953	100736323	20992736722	Hospital	hospital	NN1
304953	100736323	20992736723	.	.	.
304953	100736323	20992736724	During	during	II
304953	100736323	20992736725	her	her	APPGE
304953	100736323	20992736726	career	career	NN1
304953	100736323	20992736727	,	,	,
304953	100736323	20992736728	she	she	PPHS1
304953	100736323	20992736729	has	have	VHZ
304953	100736323	20992736730	been	be	VBN
304953	100736323	20992736731	a	a	AT1
304953	100736323	20992736732	co-investigator	co-investigator	NN1
304953	100736323	20992736733	on	on	II
304953	100736323	20992736734	a	a	AT1
304953	100736323	20992736735	number	number	NN1
304953	100736323	20992736736	of	of	IO
304953	100736323	20992736737	obesity	obesity	NN1
304953	100736323	20992736738	research	research	NN1
304953	100736323	20992736739	trials	trial	NN2
304953	100736323	20992736740	,	,	,
304953	100736323	20992736741	presented	present	VVD_VVN
304953	100736323	20992736742	her	her	APPGE
304953	100736323	20992736743	research	research	NN1
304953	100736323	20992736744	in	in	II
304953	100736323	20992736745	national	national	JJ
304953	100736323	20992736746	and	and	CC
304953	100736323	20992736747	international	international	JJ
304953	100736323	20992736748	forums	forum	NN2
304953	100736323	20992736749	,	,	,
304953	100736323	20992736750	and	and	CC
304953	100736323	20992736751	written	write	VVN_JJ@
304953	100736323	20992736752	numerous	numerous	JJ
304953	100736323	20992736753	publications	publication	NN2
304953	100736323	20992736754	and	and	CC
304953	100736323	20992736755	book	book	NN1
304953	100736323	20992736756	chapters	chapter	NN2
304953	100736323	20992736757	.	.	.
304953	100736323	20992736758	<p>		NULL
304953	100736323	20992736759	When	when	RRQ_CS
304953	100736323	20992736760	people	people	NN
304953	100736323	20992736761	talk	talk	VV0_NN1
304953	100736323	20992736762	about	about	II
304953	100736323	20992736763	eating	eat	VVG_NN1
304953	100736323	20992736764	for	for	IF
304953	100736323	20992736765	prostate	prostate	NN1
304953	100736323	20992736766	health	health	NN1
304953	100736323	20992736767	,	,	,
304953	100736323	20992736768	what	what	DDQ
304953	100736323	20992736769	do	do	VD0
304953	100736323	20992736770	they	they	PPHS2
304953	100736323	20992736771	mean	mean	VVI
304953	100736323	20992736772	?	?	?
304953	100736323	20992736773	Is	be	VBZ
304953	100736323	20992736774	there	there	EX
304953	100736323	20992736775	a	a	AT1
304953	100736323	20992736776	specific	specific	JJ
304953	100736323	20992736777	"	"	"
304953	100736323	20992736778	prostate	prostate	NN1
304953	100736323	20992736779	diet	diet	NN1
304953	100736323	20992736780	,	,	,
304953	100736323	20992736781	"	"	"
304953	100736323	20992736782	or	or	CC
304953	100736323	20992736783	should	should	VM
304953	100736323	20992736784	people	people	NN
304953	100736323	20992736785	simply	simply	RR
304953	100736323	20992736786	stick	stick	VV0
304953	100736323	20992736787	to	to	II
304953	100736323	20992736788	a	a	AT1
304953	100736323	20992736789	healthy	healthy	JJ
304953	100736323	20992736790	diet	diet	NN1
304953	100736323	20992736791	in	in	RR21
304953	100736323	20992736792	general	general	RR22
304953	100736323	20992736793	?	?	?
304953	100736323	20992736794	<p>		NULL
304953	100736323	20992736795	KENNEDY	kennedy	NP1
304953	100736323	20992736796	:	:	:
304953	100736323	20992736797	There	there	EX
304953	100736323	20992736798	is	be	VBZ
304953	100736323	20992736799	not	not	XX
304953	100736323	20992736800	a	a	AT1
304953	100736323	20992736801	prostate	prostate	NN1
304953	100736323	20992736802	diet	diet	NN1
304953	100736323	20992736803	per	per	RR21
304953	100736323	20992736804	se	se	RR22
304953	100736323	20992736805	.	.	.
304953	100736323	20992736806	But	but	CCB
304953	100736323	20992736807	there	there	EX
304953	100736323	20992736808	is	be	VBZ
304953	100736323	20992736809	a	a	AT1
304953	100736323	20992736810	healthy	healthy	JJ
304953	100736323	20992736811	diet	diet	NN1
304953	100736323	20992736812	.	.	.
304953	100736323	20992736813	We	we	PPIS2
304953	100736323	20992736814	can	can	VM
304953	100736323	20992736815	talk	talk	VVI
304953	100736323	20992736816	about	about	II
304953	100736323	20992736817	diet	diet	NN1
304953	100736323	20992736818	for	for	IF
304953	100736323	20992736819	a	a	AT1
304953	100736323	20992736820	whole	whole	JJ
304953	100736323	20992736821	host	host	NN1
304953	100736323	20992736822	of	of	IO
304953	100736323	20992736823	diseases	disease	NN2
304953	100736323	20992736824	@		II
304953	100736323	20992736825	@		II
304953	100736323	20992736826	@		II
304953	100736323	20992736827	@		II
304953	100736323	20992736828	@		II
304953	100736323	20992736829	@		II
304953	100736323	20992736830	@		II
304953	100736323	20992736831	@		II
304953	100736323	20992736832	@		II
304953	100736323	20992736833	@		II
304953	100736323	20992736834	high	high	JJ
304953	100736323	20992736835	blood	blood	NN1
304953	100736323	20992736836	pressure	pressure	NN1
304953	100736323	20992736837	,	,	,
304953	100736323	20992736838	and	and	CC
304953	100736323	20992736839	other	other	JJ
304953	100736323	20992736840	chronic	chronic	JJ
304953	100736323	20992736841	diseases	disease	NN2
304953	100736323	20992736842	but	but	CCB
304953	100736323	20992736843	there	there	EX
304953	100736323	20992736844	is	be	VBZ
304953	100736323	20992736845	a	a	AT1
304953	100736323	20992736846	general	general	JJ
304953	100736323	20992736847	healthy	healthy	JJ
304953	100736323	20992736848	way	way	NN1
304953	100736323	20992736849	of	of	IO
304953	100736323	20992736850	eating	eating	NN1_VVG
304953	100736323	20992736851	.	.	.
304953	100736323	20992736852	That 's		NN2
304953	100736323	20992736853	what	what	DDQ
304953	100736323	20992736854	were	be	VBDR
304953	100736323	20992736855	trying	try	VVG
304953	100736323	20992736856	to	to	TO
304953	100736323	20992736857	promote	promote	VVI
304953	100736323	20992736858	.	.	.
304953	100736323	20992736859	There	there	EX
304953	100736323	20992736860	can	can	VM
304953	100736323	20992736861	be	be	VBI
304953	100736323	20992736862	some	some	DD
304953	100736323	20992736863	nuances	nuance	NN2
304953	100736323	20992736864	.	.	.
304953	100736323	20992736865	Evidence	evidence	NN1
304953	100736323	20992736866	might	might	VM
304953	100736323	20992736867	show	show	VVI
304953	100736323	20992736868	this	this	DD1
304953	100736323	20992736869	,	,	,
304953	100736323	20992736870	that	that	DD1_CST
304953	100736323	20992736871	,	,	,
304953	100736323	20992736872	or	or	CC
304953	100736323	20992736873	the	the	AT
304953	100736323	20992736874	other	others	NN1@_JJ
304953	100736323	20992736875	may	may	VM
304953	100736323	20992736876	help	help	VVI
304953	100736323	20992736877	decrease	decrease	VVI
304953	100736323	20992736878	the	the	AT
304953	100736323	20992736879	risk	risk	NN1
304953	100736323	20992736880	of	of	IO
304953	100736323	20992736881	prostate	prostate	NN1
304953	100736323	20992736882	cancer	cancer	NN1
304953	100736323	20992736883	and	and	CC
304953	100736323	20992736884	other	other	JJ
304953	100736323	20992736885	prostate	prostate	NN1
304953	100736323	20992736886	disorders	disorder	NN2
304953	100736323	20992736887	,	,	,
304953	100736323	20992736888	but	but	CCB
304953	100736323	20992736889	there	there	EX_RL
304953	100736323	20992736890	really	really	RR
304953	100736323	20992736891	is n't		VV0
304953	100736323	20992736892	one	one	MC1
304953	100736323	20992736893	thing	thing	NN1
304953	100736323	20992736894	or	or	CC
304953	100736323	20992736895	one	one	MC1
304953	100736323	20992736896	prescribed	prescribed	JJ
304953	100736323	20992736897	diet	diet	NN1
304953	100736323	20992736898	.	.	.
304953	100736323	20992736899	Patients	patient	NN2
304953	100736323	20992736900	should	should	VM
304953	100736323	20992736901	pay	pay	VVI
304953	100736323	20992736902	attention	attention	NN1
304953	100736323	20992736903	to	to	II
304953	100736323	20992736904	their	their	APPGE
304953	100736323	20992736905	overall	overall	JJ_NN1
304953	100736323	20992736906	eating	eating	NN1_VVG
304953	100736323	20992736907	pattern	pattern	NN1
304953	100736323	20992736908	,	,	,
304953	100736323	20992736909	not	not	XX
304953	100736323	20992736910	a	a	AT1
304953	100736323	20992736911	few	few	DA2
304953	100736323	20992736912	particular	particular	JJ
304953	100736323	20992736913	foods	food	NN2
304953	100736323	20992736914	.	.	.
304953	100736323	20992736915	<p>		NULL
304953	100736323	20992736916	Do	do	VD0
304953	100736323	20992736917	n't 	n't	XX
304953	100736323	20992736918	fruits	fruit	NN2
304953	100736323	20992736919	and	and	CC
304953	100736323	20992736920	vegetables	vegetable	NN2
304953	100736323	20992736921	help	help	VV0
304953	100736323	20992736922	protect	protect	VVI
304953	100736323	20992736923	against	against	II
304953	100736323	20992736924	disease	disease	NN1
304953	100736323	20992736925	?	?	?
304953	100736323	20992736926	<p>		NULL
304953	100736323	20992736927	KENNEDY	kennedy	NP1
304953	100736323	20992736928	:	:	:
304953	100736323	20992736929	A	a	ZZ1_AT1@
304953	100736323	20992736930	plant-based		JJ
304953	100736323	20992736931	diet	diet	NN1
304953	100736323	20992736932	,	,	,
304953	100736323	20992736933	which	which	DDQ
304953	100736323	20992736934	includes	include	VVZ
304953	100736323	20992736935	not	not	XX
304953	100736323	20992736936	only	only	JJ
304953	100736323	20992736937	fruits		NN1
304953	100736323	20992736938	and	and	CC
304953	100736323	20992736939	vegetables	vegetable	NN2
304953	100736323	20992736940	,	,	,
304953	100736323	20992736941	but	but	CCB
304953	100736323	20992736942	also	also	RR
304953	100736323	20992736943	other	other	JJ
304953	100736323	20992736944	things	thing	NN2
304953	100736323	20992736945	like	like	II
304953	100736323	20992736946	nuts	nut	NN2
304953	100736323	20992736947	and	and	CC
304953	100736323	20992736948	seeds	seed	NN2
304953	100736323	20992736949	,	,	,
304953	100736323	20992736950	whole	whole	JJ_NN1
304953	100736323	20992736951	grains	grain	NN2
304953	100736323	20992736952	,	,	,
304953	100736323	20992736953	spices	spice	NN2
304953	100736323	20992736954	,	,	,
304953	100736323	20992736955	and	and	CC
304953	100736323	20992736956	seasonings	seasoning	NN2
304953	100736323	20992736957	,	,	,
304953	100736323	20992736958	has	have	VHZ
304953	100736323	20992736959	been	be	VBN
304953	100736323	20992736960	shown	show	VVN
304953	100736323	20992736961	to	to	TO
304953	100736323	20992736962	help	help	VVI
304953	100736323	20992736963	decrease	decrease	VVI
304953	100736323	20992736964	the	the	AT
304953	100736323	20992736965	risk	risk	NN1
304953	100736323	20992736966	of	of	IO
304953	100736323	20992736967	developing	developing	JJ_VVG
304953	100736323	20992736968	cancer	cancer	NN1
304953	100736323	20992736969	when	when	CS_RRQ
304953	100736323	20992736970	consumed	consume	VVN
304953	100736323	20992736971	consistently	consistently	RR
304953	100736323	20992736972	.	.	.
304953	100736323	20992736973	Can	can	VM_VV0%
304953	100736323	20992736974	we	we	PPIS2
304953	100736323	20992736975	say	say	VVI
304953	100736323	20992736976	that	that	DD1_CST
304953	100736323	20992736977	eating	eating	NN1_VVG
304953	100736323	20992736978	fruits	fruit	NN2
304953	100736323	20992736979	and	and	CC
304953	100736323	20992736980	vegetables	vegetable	NN2
304953	100736323	20992736981	is	be	VBZ
304953	100736323	20992736982	certainly	certainly	RR
304953	100736323	20992736983	going	go	VVGK
304953	100736323	20992736984	to	to	TO
304953	100736323	20992736985	prevent	prevent	VVI
304953	100736323	20992736986	an	a	AT1
304953	100736323	20992736987	individual	individual	NN1_JJ
304953	100736323	20992736988	from	from	II
304953	100736323	20992736989	getting	get	VVG
304953	100736323	20992736990	prostate	prostate	NN1
304953	100736323	20992736991	cancer	cancer	NN1
304953	100736323	20992736992	?	?	?
304953	100736323	20992736993	No	no	UH
304953	100736323	20992736994	.	.	.
304953	100736323	20992736995	But	but	CCB
304953	100736323	20992736996	it	it	PPH1
304953	100736323	20992736997	is	be	VBZ
304953	100736323	20992736998	one	one	MC1
304953	100736323	20992736999	way	way	NN1
304953	100736323	20992737000	of	of	IO
304953	100736323	20992737001	helping	help	VVG_NN1
304953	100736323	20992737002	to	to	TO
304953	100736323	20992737003	reduce	reduce	VVI
304953	100736323	20992737004	the	the	AT
304953	100736323	20992737005	risk	risk	NN1
304953	100736323	20992737006	.	.	.
304953	100736323	20992737007	Fruits	fruit	NN2
304953	100736323	20992737008	and	and	CC
304953	100736323	20992737009	vegetables	vegetable	NN2
304953	100736323	20992737010	are	be	VBR
304953	100736323	20992737011	also	also	RR
304953	100736323	20992737012	beneficial	beneficial	JJ
304953	100736323	20992737013	because	because	CS
304953	100736323	20992737014	they	they	PPHS2
304953	100736323	20992737015	contain	contain	VV0
304953	100736323	20992737016	lots	lots	PN
304953	100736323	20992737017	of	of	IO
304953	100736323	20992737018	nutrients	nutrient	NN2
304953	100736323	20992737019	that	that	CST
304953	100736323	20992737020	are	be	VBR
304953	100736323	20992737021	important	important	JJ
304953	100736323	20992737022	for	for	IF
304953	100736323	20992737023	overall	overall	JJ_NN1
304953	100736323	20992737024	@		II
304953	100736323	20992737025	@		II
304953	100736323	20992737026	@		II
304953	100736323	20992737027	@		II
304953	100736323	20992737028	@		II
304953	100736323	20992737029	@		II
304953	100736323	20992737030	@		II
304953	100736323	20992737031	@		II
304953	100736323	20992737032	@		II
304953	100736323	20992737033	@		II
304953	100736323	20992737034	and	and	CC
304953	100736323	20992737035	vegetables	vegetable	NN2
304953	100736323	20992737036	should	should	VM
304953	100736323	20992737037	someone	someone	PN1
304953	100736323	20992737038	eat	eat	VVI
304953	100736323	20992737039	in	in	II_RP@
304953	100736323	20992737040	a	a	AT1
304953	100736323	20992737041	day	day	NNT1
304953	100736323	20992737042	?	?	?
304953	100736323	20992737043	<p>		NULL
304953	100736323	20992737044	KENNEDY	kennedy	NP1
304953	100736323	20992737045	:	:	:
304953	100736323	20992737046	Our	our	APPGE
304953	100736323	20992737047	recommendation	recommendation	NN1
304953	100736323	20992737048	is	be	VBZ
304953	100736323	20992737049	five	five	MC
304953	100736323	20992737050	to	to	II
304953	100736323	20992737051	10	10	MC
304953	100736323	20992737052	servings	serving	NN2
304953	100736323	20992737053	a	a	AT1
304953	100736323	20992737054	day	day	NNT1
304953	100736323	20992737055	.	.	.
304953	100736323	20992737056	See	see	VV0
304953	100736323	20992737057	"	"	"
304953	100736323	20992737058	What	what	DDQ
304953	100736323	20992737059	counts	count	VVZ
304953	100736323	20992737060	as	as	II
304953	100736323	20992737061	a	a	AT1
304953	100736323	20992737062	serving	serving	NN1@
304953	100736323	20992737063	?	?	?
304953	100736323	20992737064	"	"	"
304953	100736323	20992737065	<p>		NULL
304953	100736323	20992737066	Ten	ten	MC
304953	100736323	20992737067	servings	serving	NN2
304953	100736323	20992737068	?	?	?
304953	100736323	20992737069	That	that	DD1
304953	100736323	20992737070	sounds	sound	VVZ
304953	100736323	20992737071	like	like	II
304953	100736323	20992737072	a	a	AT1
304953	100736323	20992737073	tremendous	tremendous	JJ
304953	100736323	20992737074	amount	amount	NN1
304953	100736323	20992737075	.	.	.
304953	100736323	20992737076	<p>		NULL
304953	100736323	20992737077	KENNEDY	kennedy	NP1
304953	100736323	20992737078	:	:	:
304953	100736323	20992737079	It	it	PPH1
304953	100736323	20992737080	does	do	VDZ
304953	100736323	20992737081	.	.	.
304953	100736323	20992737082	It	it	PPH1
304953	100736323	20992737083	really	really	RR
304953	100736323	20992737084	does	do	VDZ
304953	100736323	20992737085	.	.	.
304953	100736323	20992737086	<p>		NULL
304953	100736323	20992737087	McMANUS	mcmanus	NP1
304953	100736323	20992737088	:	:	:
304953	100736323	20992737089	Well	well	RR
304953	100736323	20992737090	,	,	,
304953	100736323	20992737091	let 's		VVZ
304953	100736323	20992737092	explain	explain	VVI
304953	100736323	20992737093	what	what	DDQ
304953	100736323	20992737094	we	we	PPIS2
304953	100736323	20992737095	mean	mean	VV0
304953	100736323	20992737096	by	by	II
304953	100736323	20992737097	a	a	AT1
304953	100736323	20992737098	"	"	"
304953	100736323	20992737099	serving	serving	NN1@
304953	100736323	20992737100	.	.	.
304953	100736323	20992737101	"	"	"
304953	100736323	20992737102	A	a	AT1_ZZ1
304953	100736323	20992737103	serving	serving	NN1@
304953	100736323	20992737104	is	be	VBZ
304953	100736323	20992737105	a	a	AT1
304953	100736323	20992737106	cup	cup	NN1
304953	100736323	20992737107	of	of	IO
304953	100736323	20992737108	leafy	leafy	JJ
304953	100736323	20992737109	greens	green	NN2
304953	100736323	20992737110	.	.	.
304953	100736323	20992737111	So	so	RR
304953	100736323	20992737112	if	if	CS
304953	100736323	20992737113	you	you	PPY
304953	100736323	20992737114	have	have	VH0
304953	100736323	20992737115	a	a	AT1
304953	100736323	20992737116	salad	salad	NN1
304953	100736323	20992737117	,	,	,
304953	100736323	20992737118	you	you	PPY
304953	100736323	20992737119	might	might	VM
304953	100736323	20992737120	have	have	VHI
304953	100736323	20992737121	three	three	MC
304953	100736323	20992737122	cups	cup	NN2
304953	100736323	20992737123	,	,	,
304953	100736323	20992737124	or	or	CC
304953	100736323	20992737125	three	three	MC
304953	100736323	20992737126	servings	serving	NN2
304953	100736323	20992737127	,	,	,
304953	100736323	20992737128	of	of	IO
304953	100736323	20992737129	vegetables	vegetable	NN2
304953	100736323	20992737130	right	right	RR_VV0%
304953	100736323	20992737131	there	there	RL
304953	100736323	20992737132	.	.	.
304953	100736323	20992737133	A	a	AT1_ZZ1
304953	100736323	20992737134	serving	serving	NN1@
304953	100736323	20992737135	is	be	VBZ
304953	100736323	20992737136	also	also	RR
304953	100736323	20992737137	a	a	AT1
304953	100736323	20992737138	half-cup	half-cup	NN1
304953	100736323	20992737139	of	of	IO
304953	100736323	20992737140	cooked	cooked	JJ
304953	100736323	20992737141	vegetables	vegetable	NN2
304953	100736323	20992737142	or	or	CC
304953	100736323	20992737143	a	a	AT1
304953	100736323	20992737144	medium-sized	medium-sized	JJ
304953	100736323	20992737145	piece	piece	NN1
304953	100736323	20992737146	of	of	IO
304953	100736323	20992737147	fruit	fruit	NN
304953	100736323	20992737148	or	or	CC
304953	100736323	20992737149	a	a	AT1
304953	100736323	20992737150	cup	cup	NN1
304953	100736323	20992737151	of	of	IO
304953	100736323	20992737152	berries	berry	NN2
304953	100736323	20992737153	.	.	.
304953	100736323	20992737154	<p>		NULL
304953	100736323	20992737155	KENNEDY	kennedy	NP1
304953	100736323	20992737156	:	:	:
304953	100736323	20992737157	A	a	ZZ1_AT1@
304953	100736323	20992737158	medium-sized	medium-sized	JJ
304953	100736323	20992737159	banana	banana	NN1
304953	100736323	20992737160	is	be	VBZ
304953	100736323	20992737161	actually	actually	RR
304953	100736323	20992737162	a	a	AT1
304953	100736323	20992737163	serving	serving	NN1@
304953	100736323	20992737164	,	,	,
304953	100736323	20992737165	too	too	RR@
304953	100736323	20992737166	.	.	.
304953	100736323	20992737167	So	so	RR
304953	100736323	20992737168	if	if	CS
304953	100736323	20992737169	you	you	PPY
304953	100736323	20992737170	make	make	VV0
304953	100736323	20992737171	a	a	AT1
304953	100736323	20992737172	smoothie	smoothie	NN1
304953	100736323	20992737173	in	in	II
304953	100736323	20992737174	the	the	AT
304953	100736323	20992737175	blender	blender	NN1
304953	100736323	20992737176	and	and	CC
304953	100736323	20992737177	put	put	VVN_VVD_VV0
304953	100736323	20992737178	in	in	II_RP@
304953	100736323	20992737179	a	a	AT1
304953	100736323	20992737180	banana	banana	NN1
304953	100736323	20992737181	and	and	CC
304953	100736323	20992737182	a	a	AT1
304953	100736323	20992737183	cup	cup	NN1
304953	100736323	20992737184	of	of	IO
304953	100736323	20992737185	blueberries	blueberry	NN2
304953	100736323	20992737186	,	,	,
304953	100736323	20992737187	you 've		NN1_VV0
304953	100736323	20992737188	got	get	VVD_VVN
304953	100736323	20992737189	two	two	MC
304953	100736323	20992737190	servings	serving	NN2
304953	100736323	20992737191	right	right	RR_VV0%
304953	100736323	20992737192	there	there	RL
304953	100736323	20992737193	.	.	.
304953	100736323	20992737194	Then	then	RT
304953	100736323	20992737195	you	you	PPY
304953	100736323	20992737196	make	make	VV0
304953	100736323	20992737197	a	a	AT1
304953	100736323	20992737198	salad	salad	NN1
304953	100736323	20992737199	with	with	IW
304953	100736323	20992737200	two	two	MC
304953	100736323	20992737201	cups	cup	NN2
304953	100736323	20992737202	of	of	IO
304953	100736323	20992737203	greens	green	NN2
304953	100736323	20992737204	,	,	,
304953	100736323	20992737205	throw	throw	VV0_NN1
304953	100736323	20992737206	on	on	II_RP@
304953	100736323	20992737207	a	a	AT1
304953	100736323	20992737208	half-cup	half-cup	NN1
304953	100736323	20992737209	of	of	IO
304953	100736323	20992737210	carrots	carrot	NN2
304953	100736323	20992737211	and	and	CC
304953	100736323	20992737212	a	a	AT1
304953	100736323	20992737213	half-cup	half-cup	NN1
304953	100736323	20992737214	of	of	IO
304953	100736323	20992737215	peppers	pepper	NN2
304953	100736323	20992737216	,	,	,
304953	100736323	20992737217	and	and	CC
304953	100736323	20992737218	the	the	AT
304953	100736323	20992737219	number	number	NN1
304953	100736323	20992737220	of	of	IO
304953	100736323	20992737221	servings	serving	NN2
304953	100736323	20992737222	is	be	VBZ
304953	100736323	20992737223	quickly	quickly	RR
304953	100736323	20992737224	@		II
304953	100736323	20992737225	@		II
304953	100736323	20992737226	@		II
304953	100736323	20992737227	@		II
304953	100736323	20992737228	@		II
304953	100736323	20992737229	@		II
304953	100736323	20992737230	@		II
304953	100736323	20992737231	@		II
304953	100736323	20992737232	@		II
304953	100736323	20992737233	@		II
304953	100736323	20992737234	here	here	RL
304953	100736323	20992737235	is	be	VBZ
304953	100736323	20992737236	that	that	DD1_CST
304953	100736323	20992737237	color	color	NN1
304953	100736323	20992737238	is	be	VBZ
304953	100736323	20992737239	an	a	AT1
304953	100736323	20992737240	indicator	indicator	NN1
304953	100736323	20992737241	of	of	IO
304953	100736323	20992737242	phytonutrient	phytonutrient	JJ_NN1
304953	100736323	20992737243	content	content	NN1
304953	100736323	20992737244	.	.	.
304953	100736323	20992737245	<p>		NULL
304953	100736323	20992737246	What	what	DDQ
304953	100736323	20992737247	are	be	VBR
304953	100736323	20992737248	phytonutrients	phytonutrient	NN2
304953	100736323	20992737249	?	?	?
304953	100736323	20992737250	<p>		NULL
304953	100736323	20992737251	KENNEDY	kennedy	NP1
304953	100736323	20992737252	:	:	:
304953	100736323	20992737253	Phytonutrients		NN2_NP1
304953	100736323	20992737254	are	be	VBR
304953	100736323	20992737255	plant-based		JJ
304953	100736323	20992737256	nutrients	nutrient	NN2
304953	100736323	20992737257	.	.	.
304953	100736323	20992737258	Its	its	APPGE
304953	100736323	20992737259	really	really	RR
304953	100736323	20992737260	an	a	AT1
304953	100736323	20992737261	umbrella	umbrella	NN1
304953	100736323	20992737262	term	term	NN1
304953	100736323	20992737263	for	for	IF
304953	100736323	20992737264	all	all	DB
304953	100736323	20992737265	of	of	IO
304953	100736323	20992737266	the	the	AT
304953	100736323	20992737267	good	good	JJ
304953	100736323	20992737268	things	thing	NN2
304953	100736323	20992737269	that	that	CST
304953	100736323	20992737270	are	be	VBR
304953	100736323	20992737271	found	find	VVN
304953	100736323	20992737272	in	in	II
304953	100736323	20992737273	plant	plant	NN1
304953	100736323	20992737274	foods	food	NN2
304953	100736323	20992737275	.	.	.
304953	100736323	20992737276	<p>		NULL
304953	100736323	20992737277	McMANUS	mcmanus	NP1
304953	100736323	20992737278	:	:	:
304953	100736323	20992737279	The	the	AT
304953	100736323	20992737280	deeper	deep	JJR_RRR
304953	100736323	20992737281	the	the	AT
304953	100736323	20992737282	color	color	NN1
304953	100736323	20992737283	,	,	,
304953	100736323	20992737284	the	the	AT
304953	100736323	20992737285	more	more	RGR
304953	100736323	20992737286	vibrant	vibrant	JJ
304953	100736323	20992737287	the	the	AT
304953	100736323	20992737288	color	color	NN1
304953	100736323	20992737289	,	,	,
304953	100736323	20992737290	supposedly	supposedly	RR
304953	100736323	20992737291	,	,	,
304953	100736323	20992737292	the	the	AT
304953	100736323	20992737293	higher	high	JJR
304953	100736323	20992737294	the	the	AT
304953	100736323	20992737295	phytonutrient	phytonutrient	JJ_NN1
304953	100736323	20992737296	content	content	NN1
304953	100736323	20992737297	.	.	.
304953	100736323	20992737298	For	for	REX21
304953	100736323	20992737299	example	example	REX22
304953	100736323	20992737300	,	,	,
304953	100736323	20992737301	lettuce	lettuce	NN1
304953	100736323	20992737302	that 's		VVZ
304953	100736323	20992737303	deep	deep	JJ
304953	100736323	20992737304	green	green	NN1
304953	100736323	20992737305	has	have	VHZ
304953	100736323	20992737306	more	more	DAR
304953	100736323	20992737307	nutrients	nutrient	NN2
304953	100736323	20992737308	than	than	CSN
304953	100736323	20992737309	iceberg	iceberg	NN1
304953	100736323	20992737310	lettuce	lettuce	NN1
304953	100736323	20992737311	.	.	.
304953	100736323	20992737312	<p>		NULL
304953	100736323	20992737313	KENNEDY	kennedy	NP1
304953	100736323	20992737314	:	:	:
304953	100736323	20992737315	People	people	NN
304953	100736323	20992737316	have	have	VH0
304953	100736323	20992737317	probably	probably	RR
304953	100736323	20992737318	seen	see	VVN
304953	100736323	20992737319	fancy	fancy	JJ_NN1
304953	100736323	20992737320	words	word	NN2
304953	100736323	20992737321	like	like	II
304953	100736323	20992737322	"	"	"
304953	100736323	20992737323	flavonoids	flavonoid	NN2
304953	100736323	20992737324	"	"	"
304953	100736323	20992737325	and	and	CC
304953	100736323	20992737326	"	"	"
304953	100736323	20992737327	lycopene	lycopene	NN1
304953	100736323	20992737328	"	"	"
304953	100736323	20992737329	when	when	CS_RRQ
304953	100736323	20992737330	they	they	PPHS2
304953	100736323	20992737331	read	read	VV0_VVD
304953	100736323	20992737332	about	about	II_RP@
304953	100736323	20992737333	fruits	fruit	NN2
304953	100736323	20992737334	and	and	CC
304953	100736323	20992737335	vegetables	vegetable	NN2
304953	100736323	20992737336	.	.	.
304953	100736323	20992737337	These	these	DD2
304953	100736323	20992737338	are	be	VBR
304953	100736323	20992737339	considered	consider	VVN
304953	100736323	20992737340	phytonutrients	phytonutrient	NN2
304953	100736323	20992737341	.	.	.
304953	100736323	20992737342	<h>		NULL
304953	100736323	20992737343	What	what	DDQ
304953	100736323	20992737344	counts	count	VVZ
304953	100736323	20992737345	as	as	II
304953	100736323	20992737346	a	a	AT1
304953	100736323	20992737347	serving	serving	NN1@
304953	100736323	20992737348	?	?	?
304953	100736323	20992737349	<p>		NULL
304953	100736323	20992737350	Many	many	DA2
304953	100736323	20992737351	organizations	organization	NN2
304953	100736323	20992737352	and	and	CC
304953	100736323	20992737353	government	government	NN1
304953	100736323	20992737354	agencies	agency	NN2
304953	100736323	20992737355	publish	publish	VV0
304953	100736323	20992737356	guidelines	guideline	NN2
304953	100736323	20992737357	on	on	II
304953	100736323	20992737358	what	what	DDQ
304953	100736323	20992737359	constitutes	constitute	VVZ
304953	100736323	20992737360	a	a	AT1
304953	100736323	20992737361	serving	serving	NN1@
304953	100736323	20992737362	.	.	.
304953	100736323	20992737363	The	the	AT
304953	100736323	20992737364	USDA	usda	NN1_NP1
304953	100736323	20992737365	guidelines	guideline	NN2
304953	100736323	20992737366	are	be	VBR
304953	100736323	20992737367	the	the	AT
304953	100736323	20992737368	most	most	RGT
304953	100736323	20992737369	widely	widely	RR
304953	100736323	20992737370	accepted	accept	VVN_VVD
304953	100736323	20992737371	.	.	.
304953	100736323	20992737372	here 's		NN2_NP1@
304953	100736323	20992737373	how	how	RRQ
304953	100736323	20992737374	they	they	PPHS2
304953	100736323	20992737375	define	define	VV0
304953	100736323	20992737376	serving	serve	VVG
304953	100736323	20992737377	sizes	size	NN2
304953	100736323	20992737378	for	for	IF
304953	100736323	20992737379	the	the	AT
304953	100736323	20992737380	food	food	NN1
304953	100736323	20992737381	groups	group	NN2
304953	100736323	20992737382	in	in	II
304953	100736323	20992737383	this	this	DD1
304953	100736323	20992737384	article	article	NN1
304953	100736323	20992737385	:	:	:
304953	100736323	20992737386	<p>		NULL
304953	100736323	20992737387	Grains	grain	NN2
304953	100736323	20992737388	<p>		NULL
304953	100736323	20992737389	1	1	MC1
304953	100736323	20992737390	slice	slice	NN1
304953	100736323	20992737391	of	of	IO
304953	100736323	20992737392	bread	bread	NN1
304953	100736323	20992737393	<p>		NULL
304953	100736323	20992737394	1	1	MC1
304953	100736323	20992737395	cup	cup	NN1
304953	100736323	20992737396	of	of	IO
304953	100736323	20992737397	ready-to-eat	ready-to-eat	JJ
304953	100736323	20992737398	cereal	cereal	NN1
304953	100736323	20992737399	<p>		NULL
304953	100736323	20992737400	+	+	FO
304953	100736323	20992737401	cup	cup	NN1
304953	100736323	20992737402	of	of	IO
304953	100736323	20992737403	cooked	cooked	JJ
304953	100736323	20992737404	cereal	cereal	NN1
304953	100736323	20992737405	,	,	,
304953	100736323	20992737406	rice	rice	NN1
304953	100736323	20992737407	,	,	,
304953	100736323	20992737408	or	or	CC
304953	100736323	20992737409	pasta	pasta	NN1
304953	100736323	20992737410	<p>		NULL
304953	100736323	20992737411	Vegetables	vegetable	NN2
304953	100736323	20992737412	<p>		NULL
304953	100736323	20992737413	1	1	MC1
304953	100736323	20992737414	cup	cup	NN1
304953	100736323	20992737415	of	of	IO
304953	100736323	20992737416	raw	raw	JJ
304953	100736323	20992737417	leafy	leafy	JJ
304953	100736323	20992737418	vegetables	vegetable	NN2
304953	100736323	20992737419	<p>		NULL
304953	100736323	20992737420	+	+	FO
304953	100736323	20992737421	cup	cup	NN1
304953	100736323	20992737422	of	of	IO
304953	100736323	20992737423	other	other	JJ
304953	100736323	20992737424	@		II
304953	100736323	20992737425	@		II
304953	100736323	20992737426	@		II
304953	100736323	20992737427	@		II
304953	100736323	20992737428	@		II
304953	100736323	20992737429	@		II
304953	100736323	20992737430	@		II
304953	100736323	20992737431	@		II
304953	100736323	20992737432	@		II
304953	100736323	20992737433	@		II
304953	100736323	20992737434	juice	juice	NN1
304953	100736323	20992737435	<p>		NULL
304953	100736323	20992737436	Fruits	fruit	NN2
304953	100736323	20992737437	<p>		NULL
304953	100736323	20992737438	1	1	MC1
304953	100736323	20992737439	medium	medium	JJ_NN1
304953	100736323	20992737440	apple	apple	NN1
304953	100736323	20992737441	,	,	,
304953	100736323	20992737442	orange	orange	NN1_JJ
304953	100736323	20992737443	,	,	,
304953	100736323	20992737444	or	or	CC
304953	100736323	20992737445	banana	banana	NN1
304953	100736323	20992737446	<p>		NULL
304953	100736323	20992737447	+	+	FO
304953	100736323	20992737448	cup	cup	NN1
304953	100736323	20992737449	of	of	IO
304953	100736323	20992737450	chopped	chopped	JJ
304953	100736323	20992737451	,	,	,
304953	100736323	20992737452	cooked	cook	VVD_VVN_JJ
304953	100736323	20992737453	,	,	,
304953	100736323	20992737454	or	or	CC
304953	100736323	20992737455	canned	canned	JJ
304953	100736323	20992737456	fruit	fruit	NN
304953	100736323	20992737457	<p>		NULL
304953	100736323	20992737458	+	+	FO
304953	100736323	20992737459	cup	cup	NN1
304953	100736323	20992737460	of	of	IO
304953	100736323	20992737461	fruit	fruit	NN
304953	100736323	20992737462	juice	juice	NN1
304953	100736323	20992737463	.	.	.
304953	100736323	20992737464	<p>		NULL
304953	100736323	20992737465	Should	should	VM
304953	100736323	20992737466	people	people	NN
304953	100736323	20992737467	eat	eat	VV0
304953	100736323	20992737468	specific	specific	JJ
304953	100736323	20992737469	types	type	NN2
304953	100736323	20992737470	of	of	IO
304953	100736323	20992737471	fruits	fruit	NN2
304953	100736323	20992737472	and	and	CC
304953	100736323	20992737473	vegetables	vegetable	NN2
304953	100736323	20992737474	?	?	?
304953	100736323	20992737475	Or	or	CC
304953	100736323	20992737476	does	do	VDZ
304953	100736323	20992737477	that	that	DD1
304953	100736323	20992737478	not	not	XX
304953	100736323	20992737479	matter	matter	VVI
304953	100736323	20992737480	much	much	RR_DA1
304953	100736323	20992737481	beyond	beyond	II
304953	100736323	20992737482	substituting	substitute	VVG
304953	100736323	20992737483	a	a	AT1
304953	100736323	20992737484	darker	dark	JJR
304953	100736323	20992737485	lettuce	lettuce	NN1
304953	100736323	20992737486	for	for	IF
304953	100736323	20992737487	iceberg	iceberg	NN1
304953	100736323	20992737488	lettuce	lettuce	NN1
304953	100736323	20992737489	?	?	?
304953	100736323	20992737490	<p>		NULL
304953	100736323	20992737491	KENNEDY	kennedy	NP1
304953	100736323	20992737492	:	:	:
304953	100736323	20992737493	I	i	PPIS1
304953	100736323	20992737494	think	think	VV0
304953	100736323	20992737495	there	there	EX_RL
304953	100736323	20992737496	are	be	VBR
304953	100736323	20992737497	two	two	MC
304953	100736323	20992737498	key	key	JJ_NN1
304953	100736323	20992737499	points	point	NN2
304953	100736323	20992737500	here	here	RL
304953	100736323	20992737501	.	.	.
304953	100736323	20992737502	One	one	PN1_MC1
304953	100736323	20992737503	is	be	VBZ
304953	100736323	20992737504	quantity	quantity	NN1
304953	100736323	20992737505	.	.	.
304953	100736323	20992737506	We	we	PPIS2
304953	100736323	20992737507	definitely	definitely	RR
304953	100736323	20992737508	want	want	VV0
304953	100736323	20992737509	fruits	fruit	NN2
304953	100736323	20992737510	and	and	CC
304953	100736323	20992737511	vegetables	vegetable	NN2
304953	100736323	20992737512	to	to	TO
304953	100736323	20992737513	be	be	VBI
304953	100736323	20992737514	more	more	RGR
304953	100736323	20992737515	prominent	prominent	JJ
304953	100736323	20992737516	in	in	II
304953	100736323	20992737517	our	our	APPGE
304953	100736323	20992737518	diet	diet	NN1
304953	100736323	20992737519	in	in	II
304953	100736323	20992737520	our	our	APPGE
304953	100736323	20992737521	meals	meal	NN2
304953	100736323	20992737522	and	and	CC
304953	100736323	20992737523	in	in	II
304953	100736323	20992737524	our	our	APPGE
304953	100736323	20992737525	snacks	snack	NN2
304953	100736323	20992737526	.	.	.
304953	100736323	20992737527	In	in	RR21
304953	100736323	20992737528	addition	addition	RR22
304953	100736323	20992737529	,	,	,
304953	100736323	20992737530	eat	eat	VV0
304953	100736323	20992737531	"	"	"
304953	100736323	20992737532	by	by	II
304953	100736323	20992737533	the	the	AT
304953	100736323	20992737534	rainbow	rainbow	NN1
304953	100736323	20992737535	.	.	.
304953	100736323	20992737536	"	"	"
304953	100736323	20992737537	That	that	DD1
304953	100736323	20992737538	means	mean	VVZ_NN
304953	100736323	20992737539	choosing	choose	VVG_NN1
304953	100736323	20992737540	things	thing	NN2
304953	100736323	20992737541	that	that	CST
304953	100736323	20992737542	are	be	VBR
304953	100736323	20992737543	red	red	JJ
304953	100736323	20992737544	,	,	,
304953	100736323	20992737545	orange	orange	NN1_JJ
304953	100736323	20992737546	,	,	,
304953	100736323	20992737547	yellow	yellow	JJ_NN1@
304953	100736323	20992737548	,	,	,
304953	100736323	20992737549	dark	dark	JJ
304953	100736323	20992737550	green	green	NN1_JJ
304953	100736323	20992737551	,	,	,
304953	100736323	20992737552	blue	blue	JJ_NN1@
304953	100736323	20992737553	,	,	,
304953	100736323	20992737554	and	and	CC
304953	100736323	20992737555	purple	purple	JJ_NN1@
304953	100736323	20992737556	,	,	,
304953	100736323	20992737557	as	as	II31
304953	100736323	20992737558	well	well	II32
304953	100736323	20992737559	as	as	II33
304953	100736323	20992737560	things	thing	NN2
304953	100736323	20992737561	that	that	CST
304953	100736323	20992737562	are	be	VBR
304953	100736323	20992737563	white	white	JJ
304953	100736323	20992737564	such	such	II21
304953	100736323	20992737565	as	as	II22
304953	100736323	20992737566	garlic	garlic	NN1
304953	100736323	20992737567	,	,	,
304953	100736323	20992737568	onions	onion	NN2
304953	100736323	20992737569	,	,	,
304953	100736323	20992737570	and	and	CC
304953	100736323	20992737571	cauliflower	cauliflower	NN1_VV0
304953	100736323	20992737572	.	.	.
304953	100736323	20992737573	You	you	PPY
304953	100736323	20992737574	want	want	VV0
304953	100736323	20992737575	to	to	TO
304953	100736323	20992737576	have	have	VHI
304953	100736323	20992737577	the	the	AT
304953	100736323	20992737578	entire	entire	JJ
304953	100736323	20992737579	color	color	NN1
304953	100736323	20992737580	spectrum	spectrum	NN1
304953	100736323	20992737581	because	because	CS
304953	100736323	20992737582	each	each	DD1
304953	100736323	20992737583	color	color	NN1
304953	100736323	20992737584	represents	represent	VVZ
304953	100736323	20992737585	different	different	JJ
304953	100736323	20992737586	and	and	CC
304953	100736323	20992737587	important	important	JJ
304953	100736323	20992737588	nutrients	nutrient	NN2
304953	100736323	20992737589	for	for	IF
304953	100736323	20992737590	reducing	reduce	VVG_JJ@
304953	100736323	20992737591	disease	disease	NN1
304953	100736323	20992737592	risk	risk	NN1
304953	100736323	20992737593	.	.	.
304953	100736323	20992737594	There	there	EX
304953	100736323	20992737595	are	be	VBR
304953	100736323	20992737596	other	other	JJ
304953	100736323	20992737597	groups	group	NN2
304953	100736323	20992737598	of	of	IO
304953	100736323	20992737599	vegetables	vegetable	NN2
304953	100736323	20992737600	that	that	DD1
304953	100736323	20992737601	are	be	VB0
304953	100736323	20992737602	n't 	n't	XX
304953	100736323	20992737603	sorted	sort	VVN
304953	100736323	20992737604	according	according	II21
304953	100736323	20992737605	to	to	II22
304953	100736323	20992737606	color	color	NN1
304953	100736323	20992737607	.	.	.
304953	100736323	20992737608	For	for	REX21
304953	100736323	20992737609	example	example	REX22
304953	100736323	20992737610	,	,	,
304953	100736323	20992737611	there 's		NN2
304953	100736323	20992737612	some	some	DD
304953	100736323	20992737613	preliminary	preliminary	JJ
304953	100736323	20992737614	research	research	NN1
304953	100736323	20992737615	showing	show	VVG
304953	100736323	20992737616	that	that	DD1_CST
304953	100736323	20992737617	cruciferous	cruciferous	JJ
304953	100736323	20992737618	vegetables	vegetable	NN2
304953	100736323	20992737619	broccoli	broccoli	NN1
304953	100736323	20992737620	,	,	,
304953	100736323	20992737621	cabbage	cabbage	NN1
304953	100736323	20992737622	,	,	,
304953	100736323	20992737623	cauliflower	cauliflower	VV0_NN1
304953	100736323	20992737624	@		II
304953	100736323	20992737625	@		II
304953	100736323	20992737626	@		II
304953	100736323	20992737627	@		II
304953	100736323	20992737628	@		II
304953	100736323	20992737629	@		II
304953	100736323	20992737630	@		II
304953	100736323	20992737631	@		II
304953	100736323	20992737632	@		II
304953	100736323	20992737633	@		II
304953	100736323	20992737634	kale	kale	NN1
304953	100736323	20992737635	may	may	VM
304953	100736323	20992737636	help	help	VVI
304953	100736323	20992737637	to	to	TO
304953	100736323	20992737638	decrease	decrease	VVI
304953	100736323	20992737639	the	the	AT
304953	100736323	20992737640	risk	risk	NN1
304953	100736323	20992737641	of	of	IO
304953	100736323	20992737642	aggressive	aggressive	JJ
304953	100736323	20992737643	prostate	prostate	NN1
304953	100736323	20992737644	cancer	cancer	NN1
304953	100736323	20992737645	.	.	.
304953	100736323	20992737646	<p>		NULL
304953	100736323	20992737647	What	what	DDQ
304953	100736323	20992737648	about	about	II
304953	100736323	20992737649	tomatoes	tomato	NN2
304953	100736323	20992737650	?	?	?
304953	100736323	20992737651	Some	some	DD
304953	100736323	20992737652	studies	study	NN2
304953	100736323	20992737653	have	have	VH0
304953	100736323	20992737654	shown	show	VVN
304953	100736323	20992737655	that	that	CST
304953	100736323	20992737656	tomatoes	tomato	NN2
304953	100736323	20992737657	,	,	,
304953	100736323	20992737658	which	which	DDQ
304953	100736323	20992737659	contain	contain	VV0
304953	100736323	20992737660	the	the	AT
304953	100736323	20992737661	nutrient	nutrient	NN1_JJ@
304953	100736323	20992737662	lycopene	lycopene	NN1
304953	100736323	20992737663	,	,	,
304953	100736323	20992737664	might	might	VM
304953	100736323	20992737665	help	help	VVI
304953	100736323	20992737666	prevent	prevent	VVI
304953	100736323	20992737667	cancer	cancer	NN1
304953	100736323	20992737668	;	;	;
304953	100736323	20992737669	others	others	NN2
304953	100736323	20992737670	have	have	VH0
304953	100736323	20992737671	come	come	VVN
304953	100736323	20992737672	to	to	II
304953	100736323	20992737673	the	the	AT
304953	100736323	20992737674	opposite	opposite	JJ
304953	100736323	20992737675	conclusion	conclusion	NN1
304953	100736323	20992737676	.	.	.
304953	100736323	20992737677	What	what	DDQ
304953	100736323	20992737678	do	do	VD0
304953	100736323	20992737679	you	you	PPY
304953	100736323	20992737680	recommend	recommend	VVI
304953	100736323	20992737681	to	to	II
304953	100736323	20992737682	patients	patient	NN2
304953	100736323	20992737683	?	?	?
304953	100736323	20992737684	<p>		NULL
304953	100736323	20992737685	KENNEDY	kennedy	NP1
304953	100736323	20992737686	:	:	:
304953	100736323	20992737687	Lycopene		NP1
304953	100736323	20992737688	may	may	VM
304953	100736323	20992737689	or	or	CC
304953	100736323	20992737690	may	may	VM
304953	100736323	20992737691	not	not	XX
304953	100736323	20992737692	turn	turn	VVI
304953	100736323	20992737693	out	out	RP
304953	100736323	20992737694	to	to	TO
304953	100736323	20992737695	be	be	VBI
304953	100736323	20992737696	a	a	AT1
304953	100736323	20992737697	nutrient	nutrient	NN1
304953	100736323	20992737698	that	that	CST_DD1
304953	100736323	20992737699	is	be	VBZ
304953	100736323	20992737700	particularly	particularly	RR
304953	100736323	20992737701	important	important	JJ
304953	100736323	20992737702	when	when	CS
304953	100736323	20992737703	it	it	PPH1
304953	100736323	20992737704	comes	come	VVZ
304953	100736323	20992737705	to	to	II
304953	100736323	20992737706	prostate	prostate	NN1
304953	100736323	20992737707	cancer	cancer	NN1
304953	100736323	20992737708	.	.	.
304953	100736323	20992737709	But	but	CCB
304953	100736323	20992737710	there	there	EX
304953	100736323	20992737711	are	be	VBR
304953	100736323	20992737712	many	many	DA2
304953	100736323	20992737713	beneficial	beneficial	JJ
304953	100736323	20992737714	nutrients	nutrient	NN2
304953	100736323	20992737715	in	in	II
304953	100736323	20992737716	tomatoes	tomato	NN2
304953	100736323	20992737717	besides	besides	II
304953	100736323	20992737718	lycopene	lycopene	NN1
304953	100736323	20992737719	.	.	.
304953	100736323	20992737720	You	you	PPY
304953	100736323	20992737721	can	can	VM
304953	100736323	20992737722	get	get	VVI
304953	100736323	20992737723	folic	folic	JJ
304953	100736323	20992737724	acid	acid	NN1
304953	100736323	20992737725	,	,	,
304953	100736323	20992737726	you	you	PPY
304953	100736323	20992737727	can	can	VM
304953	100736323	20992737728	get	get	VVI
304953	100736323	20992737729	vitamin	vitamin	NN1
304953	100736323	20992737730	C.		NP1_ZZ1@
304953	100736323	20992737731	There	there	EX
304953	100736323	20992737732	are	be	VBR
304953	100736323	20992737733	lots	lots	PN
304953	100736323	20992737734	of	of	IO
304953	100736323	20992737735	good	good	JJ
304953	100736323	20992737736	things	thing	NN2
304953	100736323	20992737737	in	in	II
304953	100736323	20992737738	tomatoes	tomato	NN2
304953	100736323	20992737739	.	.	.
304953	100736323	20992737740	Because	because	CS
304953	100736323	20992737741	we	we	PPIS2
304953	100736323	20992737742	know	know	VV0
304953	100736323	20992737743	tomatoes	tomato	NN2
304953	100736323	20992737744	are	be	VBR
304953	100736323	20992737745	a	a	AT1
304953	100736323	20992737746	healthy	healthy	JJ
304953	100736323	20992737747	food	food	NN1
304953	100736323	20992737748	for	for	IF
304953	100736323	20992737749	several	several	DA2
304953	100736323	20992737750	reasons	reason	NN2
304953	100736323	20992737751	,	,	,
304953	100736323	20992737752	I	i	PPIS1
304953	100736323	20992737753	think	think	VV0
304953	100736323	20992737754	it	it	PPH1
304953	100736323	20992737755	would	would	VM
304953	100736323	20992737756	make	make	VVI
304953	100736323	20992737757	sense	sense	NN1
304953	100736323	20992737758	to	to	TO
304953	100736323	20992737759	try	try	VVI
304953	100736323	20992737760	to	to	TO
304953	100736323	20992737761	include	include	VVI
304953	100736323	20992737762	some	some	DD
304953	100736323	20992737763	cooked	cooked	JJ
304953	100736323	20992737764	tomatoes	tomato	NN2
304953	100736323	20992737765	and	and	CC
304953	100736323	20992737766	tomato	tomato	NN1
304953	100736323	20992737767	sauce	sauce	NN1
304953	100736323	20992737768	in	in	II
304953	100736323	20992737769	your	your	APPGE
304953	100736323	20992737770	diet	diet	NN1
304953	100736323	20992737771	if	if	CS
304953	100736323	20992737772	you 're		NN1_VV0
304953	100736323	20992737773	at	at	II
304953	100736323	20992737774	risk	risk	NN1
304953	100736323	20992737775	for	for	IF
304953	100736323	20992737776	prostate	prostate	NN1
304953	100736323	20992737777	cancer	cancer	NN1
304953	100736323	20992737778	or	or	CC
304953	100736323	20992737779	if	if	CS
304953	100736323	20992737780	you 're		VV0_NN1
304953	100736323	20992737781	a	a	AT1
304953	100736323	20992737782	prostate	prostate	NN1
304953	100736323	20992737783	cancer	cancer	NN1
304953	100736323	20992737784	survivor	survivor	NN1
304953	100736323	20992737785	.	.	.
304953	100736323	20992737786	I	i	PPIS1
304953	100736323	20992737787	do	do	VD0
304953	100736323	20992737788	n't 	n't	XX
304953	100736323	20992737789	think	think	VVI
304953	100736323	20992737790	we	we	PPIS2
304953	100736323	20992737791	can	can	VM
304953	100736323	20992737792	conclusively	conclusively	RR
304953	100736323	20992737793	say	say	VVI
304953	100736323	20992737794	,	,	,
304953	100736323	20992737795	"	"	"
304953	100736323	20992737796	Youre		VV0_NP1
304953	100736323	20992737797	definitely	definitely	RR
304953	100736323	20992737798	going	go	VVGK
304953	100736323	20992737799	to	to	TO
304953	100736323	20992737800	benefit	benefit	VVI
304953	100736323	20992737801	from	from	II
304953	100736323	20992737802	eating	eat	VVG_NN1
304953	100736323	20992737803	tomatoes	tomato	NN2
304953	100736323	20992737804	,	,	,
304953	100736323	20992737805	"	"	"
304953	100736323	20992737806	but	but	CCB
304953	100736323	20992737807	we	we	PPIS2
304953	100736323	20992737808	can	can	VM
304953	100736323	20992737809	say	say	VVI
304953	100736323	20992737810	that	that	CST_DD1
304953	100736323	20992737811	eating	eat	VVG_NN1
304953	100736323	20992737812	more	more	DAR
304953	100736323	20992737813	tomatoes	tomato	NN2
304953	100736323	20992737814	is n't		VV0
304953	100736323	20992737815	going	go	VVG
304953	100736323	20992737816	to	to	TO
304953	100736323	20992737817	be	be	VBI
304953	100736323	20992737818	harmful	harmful	JJ
304953	100736323	20992737819	.	.	.
304953	100736323	20992737820	<p>		NULL
304953	100736323	20992737821	Should	should	VM
304953	100736323	20992737822	the	the	AT
304953	100736323	20992737823	tomatoes	tomato	NN2
304953	100736323	20992737824	@		II
304953	100736323	20992737825	@		II
304953	100736323	20992737826	@		II
304953	100736323	20992737827	@		II
304953	100736323	20992737828	@		II
304953	100736323	20992737829	@		II
304953	100736323	20992737830	@		II
304953	100736323	20992737831	@		II
304953	100736323	20992737832	@		II
304953	100736323	20992737833	@		II
304953	100736323	20992737834	eat	eat	VVI
304953	100736323	20992737835	cooked	cooked	JJ
304953	100736323	20992737836	or	or	CC
304953	100736323	20992737837	raw	raw	JJ
304953	100736323	20992737838	fruits	fruit	NN2
304953	100736323	20992737839	and	and	CC
304953	100736323	20992737840	vegetables	vegetable	NN2
304953	100736323	20992737841	?	?	?
304953	100736323	20992737842	<p>		NULL
304953	100736323	20992737843	KENNEDY	kennedy	NP1
304953	100736323	20992737844	:	:	:
304953	100736323	20992737845	That 's		VVZ
304953	100736323	20992737846	a	a	AT1
304953	100736323	20992737847	great	great	JJ
304953	100736323	20992737848	question	question	NN1
304953	100736323	20992737849	.	.	.
304953	100736323	20992737850	With	with	IW
304953	100736323	20992737851	tomatoes	tomato	NN2
304953	100736323	20992737852	,	,	,
304953	100736323	20992737853	the	the	AT
304953	100736323	20992737854	body	body	NN1
304953	100736323	20992737855	absorbs	absorb	VVZ
304953	100736323	20992737856	more	more	DAR
304953	100736323	20992737857	lycopene	lycopene	NN1
304953	100736323	20992737858	if	if	CS
304953	100736323	20992737859	they	they	PPHS2
304953	100736323	20992737860	are	be	VBR
304953	100736323	20992737861	cooked	cook	VVN
304953	100736323	20992737862	in	in	II
304953	100736323	20992737863	the	the	AT
304953	100736323	20992737864	presence	presence	NN1
304953	100736323	20992737865	of	of	IO
304953	100736323	20992737866	a	a	AT1
304953	100736323	20992737867	healthy	healthy	JJ
304953	100736323	20992737868	fat	fat	NN1
304953	100736323	20992737869	.	.	.
304953	100736323	20992737870	But	but	CCB
304953	100736323	20992737871	in	in	RR21
304953	100736323	20992737872	general	general	RR22
304953	100736323	20992737873	,	,	,
304953	100736323	20992737874	you 'll		VV0_NN1
304953	100736323	20992737875	absorb	absorb	VV0
304953	100736323	20992737876	or	or	CC
304953	100736323	20992737877	get	get	VV0
304953	100736323	20992737878	different	different	JJ
304953	100736323	20992737879	nutrients	nutrient	NN2
304953	100736323	20992737880	depending	depending	II21
304953	100736323	20992737881	on	on	II22
304953	100736323	20992737882	whether	whether	CSW
304953	100736323	20992737883	a	a	AT1
304953	100736323	20992737884	vegetable	vegetable	NN1
304953	100736323	20992737885	is	be	VBZ
304953	100736323	20992737886	cooked	cook	VVN_JJ
304953	100736323	20992737887	or	or	CC
304953	100736323	20992737888	eaten	eat	VVN
304953	100736323	20992737889	raw	raw	JJ
304953	100736323	20992737890	.	.	.
304953	100736323	20992737891	We	we	PPIS2
304953	100736323	20992737892	certainly	certainly	RR
304953	100736323	20992737893	do	do	VD0
304953	100736323	20992737894	n't 	n't	XX
304953	100736323	20992737895	want	want	VVI
304953	100736323	20992737896	people	people	NN
304953	100736323	20992737897	overcooking		VVG_JJ@
304953	100736323	20992737898	vegetables	vegetable	NN2
304953	100736323	20992737899	,	,	,
304953	100736323	20992737900	or	or	CC
304953	100736323	20992737901	fruits	fruit	NN2
304953	100736323	20992737902	for	for	IF
304953	100736323	20992737903	that	that	DD1
304953	100736323	20992737904	matter	matter	NN1
304953	100736323	20992737905	,	,	,
304953	100736323	20992737906	because	because	CS
304953	100736323	20992737907	that	that	DD1
304953	100736323	20992737908	degrades	degrade	VVZ
304953	100736323	20992737909	the	the	AT
304953	100736323	20992737910	nutrients	nutrient	NN2
304953	100736323	20992737911	.	.	.
304953	100736323	20992737912	Eating	eat	VVG_NN1
304953	100736323	20992737913	fruits	fruit	NN2
304953	100736323	20992737914	and	and	CC
304953	100736323	20992737915	vegetables	vegetable	NN2
304953	100736323	20992737916	lightly	lightly	RR
304953	100736323	20992737917	cooked	cook	VVN_JJ_VVD
304953	100736323	20992737918	or	or	CC
304953	100736323	20992737919	eating	eat	VVG
304953	100736323	20992737920	them	them	PPHO2
304953	100736323	20992737921	raw	raw	JJ
304953	100736323	20992737922	are	be	VBR
304953	100736323	20992737923	both	both	RR_DB2
304953	100736323	20992737924	good	good	JJ
304953	100736323	20992737925	choices	choice	NN2
304953	100736323	20992737926	,	,	,
304953	100736323	20992737927	but	but	II21_CCB
304953	100736323	20992737928	for	for	II22_IF
304953	100736323	20992737929	different	different	JJ
304953	100736323	20992737930	reasons	reason	NN2
304953	100736323	20992737931	.	.	.
304953	100736323	20992737932	<p>		NULL
304953	100736323	20992737933	McMANUS	mcmanus	NP1
304953	100736323	20992737934	:	:	:
304953	100736323	20992737935	I	i	PPIS1
304953	100736323	20992737936	do	do	VD0
304953	100736323	20992737937	n't 	n't	XX
304953	100736323	20992737938	think	think	VVI
304953	100736323	20992737939	we	we	PPIS2
304953	100736323	20992737940	want	want	VV0
304953	100736323	20992737941	people	people	NN
304953	100736323	20992737942	to	to	TO
304953	100736323	20992737943	get	get	VVI
304953	100736323	20992737944	too	too	RR@_RG
304953	100736323	20992737945	hung	hang	VVN_VVD
304953	100736323	20992737946	up	up	RP
304953	100736323	20992737947	on	on	II
304953	100736323	20992737948	whether	whether	CSW
304953	100736323	20992737949	vegetables	vegetable	NN2
304953	100736323	20992737950	should	should	VM
304953	100736323	20992737951	be	be	VBI
304953	100736323	20992737952	eaten	eat	VVN
304953	100736323	20992737953	raw	raw	JJ
304953	100736323	20992737954	or	or	CC
304953	100736323	20992737955	cooked	cook	VVD_JJ_VVN
304953	100736323	20992737956	.	.	.
304953	100736323	20992737957	Our	our	APPGE
304953	100736323	20992737958	main	main	JJ
304953	100736323	20992737959	goal	goal	NN1
304953	100736323	20992737960	is	be	VBZ
304953	100736323	20992737961	to	to	TO
304953	100736323	20992737962	get	get	VVI
304953	100736323	20992737963	people	people	NN
304953	100736323	20992737964	to	to	TO
304953	100736323	20992737965	eat	eat	VVI
304953	100736323	20992737966	more	more	DAR
304953	100736323	20992737967	fruits	fruit	NN2
304953	100736323	20992737968	and	and	CC
304953	100736323	20992737969	vegetables	vegetable	NN2
304953	100736323	20992737970	.	.	.
304953	100736323	20992737971	How	how	RRQ
304953	100736323	20992737972	they 're		NN1
304953	100736323	20992737973	prepared	prepare	VVN
304953	100736323	20992737974	is	be	VBZ
304953	100736323	20992737975	less	less	RGR
304953	100736323	20992737976	important	important	JJ
304953	100736323	20992737977	.	.	.
304953	100736323	20992737978	Mix	mix	VV0
304953	100736323	20992737979	it	it	PPH1
304953	100736323	20992737980	up	up	RP
304953	100736323	20992737981	.	.	.
304953	100736323	20992737982	Salad	salad	NN1
304953	100736323	20992737983	is	be	VBZ
304953	100736323	20992737984	obviously	obviously	RR
304953	100736323	20992737985	raw	raw	JJ
304953	100736323	20992737986	vegetables	vegetable	NN2
304953	100736323	20992737987	,	,	,
304953	100736323	20992737988	but	but	CCB
304953	100736323	20992737989	you	you	PPY
304953	100736323	20992737990	could	could	VM
304953	100736323	20992737991	have	have	VHI
304953	100736323	20992737992	some	some	DD
304953	100736323	20992737993	roasted	roasted	JJ
304953	100736323	20992737994	vegetables	vegetable	NN2
304953	100736323	20992737995	,	,	,
304953	100736323	20992737996	or	or	CC
304953	100736323	20992737997	you	you	PPY
304953	100736323	20992737998	could	could	VM
304953	100736323	20992737999	stir-fry	stir-fry	JJ
304953	100736323	20992738000	them	them	PPHO2
304953	100736323	20992738001	in	in	II_RP@
304953	100736323	20992738002	a	a	AT1
304953	100736323	20992738003	little	little	JJ
304953	100736323	20992738004	bit	bit	NN1
304953	100736323	20992738005	of	of	IO
304953	100736323	20992738006	olive	olive	JJ_NN1
304953	100736323	20992738007	oil	oil	NN1
304953	100736323	20992738008	and	and	CC
304953	100736323	20992738009	garlic	garlic	NN1
304953	100736323	20992738010	.	.	.
304953	100736323	20992738011	Make	make	VV0
304953	100736323	20992738012	them	them	PPHO2
304953	100736323	20992738013	appealing	appeal	VVG_JJ
304953	100736323	20992738014	.	.	.
304953	100736323	20992738015	Make	make	VV0
304953	100736323	20992738016	them	them	PPHO2
304953	100736323	20992738017	taste	taste	VVI
304953	100736323	20992738018	good	good	JJ
304953	100736323	20992738019	.	.	.
304953	100736323	20992738020	That	that	DD1
304953	100736323	20992738021	will	will	VM
304953	100736323	20992738022	really	really	RR
304953	100736323	20992738023	help	help	VVI
304953	100736323	20992738024	@		II
304953	100736323	20992738025	@		II
304953	100736323	20992738026	@		II
304953	100736323	20992738027	@		II
304953	100736323	20992738028	@		II
304953	100736323	20992738029	@		II
304953	100736323	20992738030	@		II
304953	100736323	20992738031	@		II
304953	100736323	20992738032	@		II
304953	100736323	20992738033	@		II
304953	100736323	20992738034	.	.	.
304953	100736323	20992738035	<p>		NULL
304953	100736323	20992738036	What	what	DDQ
304953	100736323	20992738037	strategies	strategy	NN2
304953	100736323	20992738038	can	can	VM_VV0%
304953	100736323	20992738039	our	our	APPGE
304953	100736323	20992738040	readers	reader	NN2
304953	100736323	20992738041	use	use	VVI
304953	100736323	20992738042	to	to	TO@
304953	100736323	20992738043	work	work	VVI
304953	100736323	20992738044	more	more	DAR
304953	100736323	20992738045	fruits	fruit	NN2
304953	100736323	20992738046	and	and	CC
304953	100736323	20992738047	vegetables	vegetable	NN2
304953	100736323	20992738048	into	into	II
304953	100736323	20992738049	their	their	APPGE
304953	100736323	20992738050	diet	diet	NN1
304953	100736323	20992738051	?	?	?
304953	100736323	20992738052	<p>		NULL
304953	100736323	20992738053	McMANUS	mcmanus	NP1
304953	100736323	20992738054	:	:	:
304953	100736323	20992738055	Well	well	RR
304953	100736323	20992738056	,	,	,
304953	100736323	20992738057	part	part	NN1
304953	100736323	20992738058	of	of	IO
304953	100736323	20992738059	it	it	PPH1
304953	100736323	20992738060	is	be	VBZ
304953	100736323	20992738061	taking	take	VVG
304953	100736323	20992738062	small	small	JJ
304953	100736323	20992738063	steps	step	NN2
304953	100736323	20992738064	.	.	.
304953	100736323	20992738065	When	when	CS_RRQ
304953	100736323	20992738066	you	you	PPY
304953	100736323	20992738067	tell	tell	VV0
304953	100736323	20992738068	people	people	NN
304953	100736323	20992738069	to	to	TO
304953	100736323	20992738070	get	get	VVI
304953	100736323	20992738071	five	five	MC
304953	100736323	20992738072	to	to	II
304953	100736323	20992738073	10	10	MC
304953	100736323	20992738074	servings	serving	NN2
304953	100736323	20992738075	a	a	AT1
304953	100736323	20992738076	day	day	NNT1
304953	100736323	20992738077	,	,	,
304953	100736323	20992738078	they	they	PPHS2
304953	100736323	20992738079	can	can	VM
304953	100736323	20992738080	feel	feel	VVI
304953	100736323	20992738081	overwhelmed	overwhelmed	JJ_VVN
304953	100736323	20992738082	.	.	.
304953	100736323	20992738083	So	so	RR
304953	100736323	20992738084	you	you	PPY
304953	100736323	20992738085	have	have	VH0
304953	100736323	20992738086	to	to	TO
304953	100736323	20992738087	think	think	VVI
304953	100736323	20992738088	about	about	II
304953	100736323	20992738089	it	it	PPH1
304953	100736323	20992738090	in	in	II_RP@
304953	100736323	20992738091	simple	simple	JJ
304953	100736323	20992738092	ways	way	NN2
304953	100736323	20992738093	.	.	.
304953	100736323	20992738094	Add	add	VV0
304953	100736323	20992738095	extra	extra	JJ_RR@
304953	100736323	20992738096	diced	diced	JJ@_VVD
304953	100736323	20992738097	vegetables	vegetable	NN2
304953	100736323	20992738098	into	into	II
304953	100736323	20992738099	soups	soup	NN2
304953	100736323	20992738100	,	,	,
304953	100736323	20992738101	casseroles	casserole	NN2
304953	100736323	20992738102	,	,	,
304953	100736323	20992738103	and	and	CC
304953	100736323	20992738104	spaghetti	spaghetti	NN1
304953	100736323	20992738105	sauce	sauce	NN1
304953	100736323	20992738106	.	.	.
304953	100736323	20992738107	That 's		VVZ
304953	100736323	20992738108	an	a	AT1
304953	100736323	20992738109	easy	easy	JJ
304953	100736323	20992738110	way	way	NN1
304953	100736323	20992738111	to	to	TO
304953	100736323	20992738112	do	do	VDI
304953	100736323	20992738113	it	it	PPH1
304953	100736323	20992738114	.	.	.
304953	100736323	20992738115	If	if	CS
304953	100736323	20992738116	you 've		NN1
304953	100736323	20992738117	got	get	VVD_VVN
304953	100736323	20992738118	something	something	PN1
304953	100736323	20992738119	cooking	cook	VVG
304953	100736323	20992738120	in	in	II
304953	100736323	20992738121	the	the	AT
304953	100736323	20992738122	oven	oven	NN1
304953	100736323	20992738123	,	,	,
304953	100736323	20992738124	throw	throw	VV0_NN1
304953	100736323	20992738125	in	in	II_RP@
304953	100736323	20992738126	some	some	DD
304953	100736323	20992738127	vegetables	vegetable	NN2
304953	100736323	20992738128	.	.	.
304953	100736323	20992738129	If	if	CS
304953	100736323	20992738130	you 're		NN1_VV0
304953	100736323	20992738131	roasting	roast	VVG
304953	100736323	20992738132	a	a	AT1
304953	100736323	20992738133	chicken	chicken	NN1
304953	100736323	20992738134	,	,	,
304953	100736323	20992738135	throw	throw	VV0_NN1
304953	100736323	20992738136	in	in	II_RP@
304953	100736323	20992738137	some	some	DD
304953	100736323	20992738138	carrots	carrot	NN2
304953	100736323	20992738139	,	,	,
304953	100736323	20992738140	sweet	sweet	JJ
304953	100736323	20992738141	potatoes	potato	NN2
304953	100736323	20992738142	,	,	,
304953	100736323	20992738143	peppers	pepper	NN2
304953	100736323	20992738144	,	,	,
304953	100736323	20992738145	and	and	CC
304953	100736323	20992738146	onions	onion	NN2
304953	100736323	20992738147	.	.	.
304953	100736323	20992738148	That 's		VVZ_NN2_NP1@
304953	100736323	20992738149	quick	quick	JJ
304953	100736323	20992738150	and	and	CC
304953	100736323	20992738151	easy	easy	JJ_RR@
304953	100736323	20992738152	.	.	.
304953	100736323	20992738153	Try	try	VV0
304953	100736323	20992738154	a	a	AT1
304953	100736323	20992738155	stir-fry	stir-fry	JJ
304953	100736323	20992738156	.	.	.
304953	100736323	20992738157	Make	make	VV0
304953	100736323	20992738158	vegetable	vegetable	NN1
304953	100736323	20992738159	stews	stew	NN2
304953	100736323	20992738160	and	and	CC
304953	100736323	20992738161	veggie	veggie	NN1
304953	100736323	20992738162	wraps	wrap	NN2_VVZ
304953	100736323	20992738163	.	.	.
304953	100736323	20992738164	Those	those	DD2
304953	100736323	20992738165	are	be	VBR
304953	100736323	20992738166	great	great	JJ
304953	100736323	20992738167	ways	way	NN2
304953	100736323	20992738168	to	to	TO
304953	100736323	20992738169	really	really	RR
304953	100736323	20992738170	pack	pack	VVI
304953	100736323	20992738171	in	in	II_RP@
304953	100736323	20992738172	extra	extra	JJ
304953	100736323	20992738173	vegetables	vegetable	NN2
304953	100736323	20992738174	without	without	IW
304953	100736323	20992738175	a	a	AT1
304953	100736323	20992738176	whole	whole	JJ
304953	100736323	20992738177	lot	lot	NN1
304953	100736323	20992738178	of	of	IO
304953	100736323	20992738179	extra	extra	JJ
304953	100736323	20992738180	effort	effort	NN1
304953	100736323	20992738181	.	.	.
304953	100736323	20992738182	<p>		NULL
304953	100736323	20992738183	People	people	NN
304953	100736323	20992738184	always	always	RR
304953	100736323	20992738185	talk	talk	VV0
304953	100736323	20992738186	about	about	II
304953	100736323	20992738187	having	have	VHG
304953	100736323	20992738188	something	something	PN1
304953	100736323	20992738189	sweet	sweet	JJ
304953	100736323	20992738190	for	for	IF
304953	100736323	20992738191	dessert	dessert	NN1
304953	100736323	20992738192	.	.	.
304953	100736323	20992738193	A	a	AT1_ZZ1
304953	100736323	20992738194	great	great	JJ
304953	100736323	20992738195	way	way	NN1
304953	100736323	20992738196	to	to	TO
304953	100736323	20992738197	do	do	VDI
304953	100736323	20992738198	that	that	DD1
304953	100736323	20992738199	is	be	VBZ
304953	100736323	20992738200	to	to	TO
304953	100736323	20992738201	choose	choose	VVI
304953	100736323	20992738202	fruit	fruit	NN
304953	100736323	20992738203	berries	berry	NN2
304953	100736323	20992738204	,	,	,
304953	100736323	20992738205	melon	melon	NN1
304953	100736323	20992738206	,	,	,
304953	100736323	20992738207	or	or	CC
304953	100736323	20992738208	clementines	clementine	NN2
304953	100736323	20992738209	.	.	.
304953	100736323	20992738210	Think	think	VV0
304953	100736323	20992738211	about	about	II
304953	100736323	20992738212	fruit	fruit	NN
304953	100736323	20992738213	as	as	II_CSA
304953	100736323	20992738214	a	a	AT1
304953	100736323	20992738215	great	great	JJ
304953	100736323	20992738216	way	way	NN1
304953	100736323	20992738217	to	to	TO
304953	100736323	20992738218	end	end	VVI
304953	100736323	20992738219	a	a	AT1
304953	100736323	20992738220	meal	meal	NN1
304953	100736323	20992738221	.	.	.
304953	100736323	20992738222	<p>		NULL
304953	100736323	20992738223	In	in	JJ21_RL21_II21
304953	100736323	20992738224	@		II
304953	100736323	20992738225	@		II
304953	100736323	20992738226	@		II
304953	100736323	20992738227	@		II
304953	100736323	20992738228	@		II
304953	100736323	20992738229	@		II
304953	100736323	20992738230	@		II
304953	100736323	20992738231	@		II
304953	100736323	20992738232	@		II
304953	100736323	20992738233	@		II
304953	100736323	20992738234	with	with	IW
304953	100736323	20992738235	hummus	hummus	NN1
304953	100736323	20992738236	,	,	,
304953	100736323	20992738237	black	black	JJ
304953	100736323	20992738238	bean	bean	NN1
304953	100736323	20992738239	dip	dip	VV0_NN1@
304953	100736323	20992738240	,	,	,
304953	100736323	20992738241	salsa	salsa	NN1
304953	100736323	20992738242	,	,	,
304953	100736323	20992738243	or	or	CC
304953	100736323	20992738244	light	light	JJ_NN1
304953	100736323	20992738245	dressing	dressing	NN1@_VVG
304953	100736323	20992738246	.	.	.
304953	100736323	20992738247	That	that	DD1
304953	100736323	20992738248	can	can	VM
304953	100736323	20992738249	be	be	VBI
304953	100736323	20992738250	a	a	AT1
304953	100736323	20992738251	good	good	JJ
304953	100736323	20992738252	way	way	NN1
304953	100736323	20992738253	to	to	TO
304953	100736323	20992738254	get	get	VVI
304953	100736323	20992738255	in	in	II_RP@
304953	100736323	20992738256	some	some	DD
304953	100736323	20992738257	extra	extra	JJ
304953	100736323	20992738258	vegetables	vegetable	NN2
304953	100736323	20992738259	.	.	.
304953	100736323	20992738260	Try	try	VV0
304953	100736323	20992738261	the	the	AT
304953	100736323	20992738262	same	same	DA
304953	100736323	20992738263	thing	thing	NN1
304953	100736323	20992738264	with	with	IW
304953	100736323	20992738265	fruit	fruit	NN
304953	100736323	20992738266	.	.	.
304953	100736323	20992738267	Slice	slice	VV0
304953	100736323	20992738268	up	up	RP
304953	100736323	20992738269	some	some	DD
304953	100736323	20992738270	fruit	fruit	NN
304953	100736323	20992738271	and	and	CC
304953	100736323	20992738272	dunk	dunk	VV0
304953	100736323	20992738273	it	it	PPH1
304953	100736323	20992738274	in	in	II
304953	100736323	20992738275	yogurt	yogurt	NN1
304953	100736323	20992738276	or	or	CC
304953	100736323	20992738277	put	put	VVD_VV0
304953	100736323	20992738278	a	a	AT1
304953	100736323	20992738279	little	little	JJ
304953	100736323	20992738280	bit	bit	NN1
304953	100736323	20992738281	of	of	IO
304953	100736323	20992738282	peanut	peanut	NN1
304953	100736323	20992738283	butter	butter	NN1
304953	100736323	20992738284	or	or	CC
304953	100736323	20992738285	almond	almond	NN1
304953	100736323	20992738286	butter	butter	NN1
304953	100736323	20992738287	on	on	II
304953	100736323	20992738288	it	it	PPH1
304953	100736323	20992738289	.	.	.
304953	100736323	20992738290	Smoothies	smoothy	NN2
304953	100736323	20992738291	are	be	VBR
304953	100736323	20992738292	a	a	AT1
304953	100736323	20992738293	great	great	JJ
304953	100736323	20992738294	way	way	NN1
304953	100736323	20992738295	to	to	TO
304953	100736323	20992738296	eat	eat	VVI
304953	100736323	20992738297	on	on	II
304953	100736323	20992738298	the	the	AT
304953	100736323	20992738299	run	run	NN1
304953	100736323	20992738300	.	.	.
304953	100736323	20992738301	If	if	CS
304953	100736323	20992738302	you	you	PPY
304953	100736323	20992738303	want	want	VV0
304953	100736323	20992738304	to	to	TO
304953	100736323	20992738305	have	have	VHI
304953	100736323	20992738306	a	a	AT1
304953	100736323	20992738307	quick	quick	JJ
304953	100736323	20992738308	and	and	CC
304953	100736323	20992738309	healthy	healthy	JJ
304953	100736323	20992738310	breakfast	breakfast	NN1
304953	100736323	20992738311	,	,	,
304953	100736323	20992738312	you	you	PPY
304953	100736323	20992738313	could	could	VM
304953	100736323	20992738314	blend	blend	VVI
304953	100736323	20992738315	some	some	DD
304953	100736323	20992738316	yogurt	yogurt	NN1
304953	100736323	20992738317	and	and	CC
304953	100736323	20992738318	fruit	fruit	NN
304953	100736323	20992738319	.	.	.
304953	100736323	20992738320	<p>		NULL
304953	100736323	20992738321	Is	be	VBZ
304953	100736323	20992738322	there	there	EX
304953	100736323	20992738323	any	any	DD
304953	100736323	20992738324	difference	difference	NN1
304953	100736323	20992738325	between	between	II
304953	100736323	20992738326	organic	organic	JJ
304953	100736323	20992738327	and	and	CC
304953	100736323	20992738328	conventional	conventional	JJ
304953	100736323	20992738329	produce	produce	NN1@_VV0
304953	100736323	20992738330	?	?	?
304953	100736323	20992738331	Is	be	VBZ
304953	100736323	20992738332	there	there	EX
304953	100736323	20992738333	any	any	DD
304953	100736323	20992738334	benefit	benefit	NN1_VV0
304953	100736323	20992738335	to	to	II
304953	100736323	20992738336	eating	eat	VVG
304953	100736323	20992738337	organic	organic	JJ
304953	100736323	20992738338	produce	produce	NN1@_VV0
304953	100736323	20992738339	?	?	?
304953	100736323	20992738340	<p>		NULL
304953	100736323	20992738341	KENNEDY	kennedy	NP1
304953	100736323	20992738342	:	:	:
304953	100736323	20992738343	Well	well	RR
304953	100736323	20992738344	,	,	,
304953	100736323	20992738345	the	the	AT
304953	100736323	20992738346	research	research	NN1
304953	100736323	20992738347	on	on	II
304953	100736323	20992738348	that	that	DD1
304953	100736323	20992738349	is	be	VBZ
304953	100736323	20992738350	still	still	RR
304953	100736323	20992738351	very	very	RG
304953	100736323	20992738352	new	new	JJ
304953	100736323	20992738353	.	.	.
304953	100736323	20992738354	We	we	PPIS2
304953	100736323	20992738355	can	can	VM
304953	100736323	20992738356	not	not	XX
304953	100736323	20992738357	say	say	VVI
304953	100736323	20992738358	conclusively	conclusively	RR
304953	100736323	20992738359	that	that	DD1_CST
304953	100736323	20992738360	choosing	choosing	NN1_VVG
304953	100736323	20992738361	organic	organic	JJ
304953	100736323	20992738362	necessarily	necessarily	RR
304953	100736323	20992738363	translates	translate	VVZ
304953	100736323	20992738364	into	into	II
304953	100736323	20992738365	any	any	DD
304953	100736323	20992738366	health	health	NN1
304953	100736323	20992738367	benefit	benefit	NN1
304953	100736323	20992738368	.	.	.
304953	100736323	20992738369	The	the	AT
304953	100736323	20992738370	evidence	evidence	NN1
304953	100736323	20992738371	certainly	certainly	RR
304953	100736323	20992738372	supports	support	VVZ
304953	100736323	20992738373	eating	eat	VVG
304953	100736323	20992738374	more	more	DAR
304953	100736323	20992738375	fruits	fruit	NN2
304953	100736323	20992738376	and	and	CC
304953	100736323	20992738377	vegetables	vegetable	NN2
304953	100736323	20992738378	the	the	AT
304953	100736323	20992738379	average	average	JJ_NN1
304953	100736323	20992738380	American	american	NN1@_JJ
304953	100736323	20992738381	eats	eat	VVZ
304953	100736323	20992738382	two	two	MC
304953	100736323	20992738383	to	to	II
304953	100736323	20992738384	two-and-a-half	two-and-a-half	MF
304953	100736323	20992738385	servings	serving	NN2
304953	100736323	20992738386	a	a	AT1
304953	100736323	20992738387	day	day	NNT1
304953	100736323	20992738388	;	;	;
304953	100736323	20992738389	were	be	VBDR
304953	100736323	20992738390	recommending	recommend	VVG
304953	100736323	20992738391	five	five	MC
304953	100736323	20992738392	to	to	II
304953	100736323	20992738393	10	10	MC
304953	100736323	20992738394	.	.	.
304953	100736323	20992738395	The	the	AT
304953	100736323	20992738396	studies	study	NN2
304953	100736323	20992738397	that	that	CST
304953	100736323	20992738398	have	have	VH0
304953	100736323	20992738399	been	be	VBN
304953	100736323	20992738400	done	do	VDN
304953	100736323	20992738401	havent		NN1
304953	100736323	20992738402	really	really	RR
304953	100736323	20992738403	looked	look	VVN_VVD
304953	100736323	20992738404	at	at	II
304953	100736323	20992738405	organic	organic	JJ
304953	100736323	20992738406	versus	versus	II
304953	100736323	20992738407	conventional	conventional	JJ
304953	100736323	20992738408	produce	produce	NN1@
304953	100736323	20992738409	;	;	;
304953	100736323	20992738410	theyve		VV0_NN1
304953	100736323	20992738411	looked	look	VVN_VVD
304953	100736323	20992738412	at	at	II
304953	100736323	20992738413	fruits	fruit	NN2
304953	100736323	20992738414	and	and	CC
304953	100736323	20992738415	vegetables	vegetable	NN2
304953	100736323	20992738416	over	over	II_RP
304953	100736323	20992738417	all	all	DB
304953	100736323	20992738418	.	.	.
304953	100736323	20992738419	Certainly	certainly	RR
304953	100736323	20992738420	if	if	CS
304953	100736323	20992738421	you	you	PPY
304953	100736323	20992738422	have	have	VH0
304953	100736323	20992738423	access	access	NN1
304953	100736323	20992738424	@		II
304953	100736323	20992738425	@		II
304953	100736323	20992738426	@		II
304953	100736323	20992738427	@		II
304953	100736323	20992738428	@		II
304953	100736323	20992738429	@		II
304953	100736323	20992738430	@		II
304953	100736323	20992738431	@		II
304953	100736323	20992738432	@		II
304953	100736323	20992738433	@		II
304953	100736323	20992738434	that	that	CST
304953	100736323	20992738435	they	they	PPHS2
304953	100736323	20992738436	have	have	VH0
304953	100736323	20992738437	some	some	DD
304953	100736323	20992738438	benefit	benefit	NN1_VV0
304953	100736323	20992738439	,	,	,
304953	100736323	20992738440	we	we	PPIS2
304953	100736323	20992738441	would	would	VM
304953	100736323	20992738442	be	be	VBI
304953	100736323	20992738443	supportive	supportive	JJ
304953	100736323	20992738444	of	of	IO
304953	100736323	20992738445	that	that	DD1
304953	100736323	20992738446	choice	choice	NN1
304953	100736323	20992738447	.	.	.
304953	100736323	20992738448	Its	its	APPGE
304953	100736323	20992738449	really	really	RR
304953	100736323	20992738450	a	a	AT1
304953	100736323	20992738451	personal	personal	JJ
304953	100736323	20992738452	decision	decision	NN1
304953	100736323	20992738453	.	.	.
304953	100736323	20992738454	<h>		NULL
304953	100736323	20992738455	The	the	AT
304953	100736323	20992738456	"	"	"
304953	100736323	20992738457	dirty	dirty	JJ
304953	100736323	20992738458	dozen	dozen	NNO
304953	100736323	20992738459	"	"	"
304953	100736323	20992738460	<p>		NULL
304953	100736323	20992738461	If	if	CS
304953	100736323	20992738462	you 're		NN1_VV0
304953	100736323	20992738463	worried	worry	VVN@_VVD@_JJ
304953	100736323	20992738464	about	about	II
304953	100736323	20992738465	pesticide	pesticide	NN1
304953	100736323	20992738466	residue	residue	NN1
304953	100736323	20992738467	on	on	II
304953	100736323	20992738468	produce	produce	NN1@
304953	100736323	20992738469	but	but	CCB
304953	100736323	20992738470	cant	cant	NN1_JJ
304953	100736323	20992738471	afford	afford	VV0
304953	100736323	20992738472	to	to	TO
304953	100736323	20992738473	purchase	purchase	VVI
304953	100736323	20992738474	every	every	AT1
304953	100736323	20992738475	organically	organically	RR
304953	100736323	20992738476	grown	grow	VVN
304953	100736323	20992738477	food	food	NN1
304953	100736323	20992738478	,	,	,
304953	100736323	20992738479	limit	limit	VV0
304953	100736323	20992738480	your	your	APPGE
304953	100736323	20992738481	organic	organic	JJ
304953	100736323	20992738482	buying	buying	NN1
304953	100736323	20992738483	to	to	II
304953	100736323	20992738484	these	these	DD2
304953	100736323	20992738485	12	12	MC
304953	100736323	20992738486	fruits	fruit	NN2
304953	100736323	20992738487	and	and	CC
304953	100736323	20992738488	vegetables	vegetable	NN2
304953	100736323	20992738489	.	.	.
304953	100736323	20992738490	When	when	CS
304953	100736323	20992738491	grown	grow	VVN
304953	100736323	20992738492	conventionally	conventionally	RR
304953	100736323	20992738493	,	,	,
304953	100736323	20992738494	these	these	DD2
304953	100736323	20992738495	items	item	NN2
304953	100736323	20992738496	tend	tend	VV0
304953	100736323	20992738497	to	to	TO
304953	100736323	20992738498	have	have	VHI
304953	100736323	20992738499	the	the	AT
304953	100736323	20992738500	highest	high	JJT
304953	100736323	20992738501	levels	level	NN2
304953	100736323	20992738502	of	of	IO
304953	100736323	20992738503	pesticides	pesticide	NN2
304953	100736323	20992738504	on	on	II
304953	100736323	20992738505	them	them	PPHO2
304953	100736323	20992738506	:	:	:
304953	100736323	20992738507	<p>		NULL
304953	100736323	20992738508	peaches	peach	NN2
304953	100736323	20992738509	<p>		NULL
304953	100736323	20992738510	apples	apple	NN2
304953	100736323	20992738511	<p>		NULL
304953	100736323	20992738512	bell	bell	NN1
304953	100736323	20992738513	peppers	pepper	NN2
304953	100736323	20992738514	(	(	(
304953	100736323	20992738515	red	red	NN1_JJ
304953	100736323	20992738516	and	and	CC
304953	100736323	20992738517	green	green	JJ_NN1
304953	100736323	20992738518	)	)	)
304953	100736323	20992738519	<p>		NULL
304953	100736323	20992738520	celery	celery	NN1
304953	100736323	20992738521	<p>		NULL
304953	100736323	20992738522	nectarines	nectarines	NN2
304953	100736323	20992738523	<p>		NULL
304953	100736323	20992738524	strawberries	strawberry	NN2
304953	100736323	20992738525	<p>		NULL
304953	100736323	20992738526	cherries	cherry	NN2
304953	100736323	20992738527	<p>		NULL
304953	100736323	20992738528	lettuce	lettuce	NN1
304953	100736323	20992738529	<p>		NULL
304953	100736323	20992738530	grapes	grape	NN2
304953	100736323	20992738531	(	(	(
304953	100736323	20992738532	imported	imported	JJ_VVN
304953	100736323	20992738533	)	)	)
304953	100736323	20992738534	<p>		NULL
304953	100736323	20992738535	pears	pear	NN2
304953	100736323	20992738536	<p>		NULL
304953	100736323	20992738537	spinach	spinach	NN1
304953	100736323	20992738538	<p>		NULL
304953	100736323	20992738539	potatoes	potato	NN2
304953	100736323	20992738540	.	.	.
304953	100736323	20992738541	<p>		NULL
304953	100736323	20992738542	What	what	DDQ
304953	100736323	20992738543	about	about	II
304953	100736323	20992738544	the	the	AT
304953	100736323	20992738545	pesticides	pesticide	NN2
304953	100736323	20992738546	used	use	VMK
304953	100736323	20992738547	to	to	TO
304953	100736323	20992738548	grow	grow	VVI
304953	100736323	20992738549	conventional	conventional	JJ
304953	100736323	20992738550	produce	produce	NN1@_VV0
304953	100736323	20992738551	?	?	?
304953	100736323	20992738552	<p>		NULL
304953	100736323	20992738553	KENNEDY	kennedy	NP1
304953	100736323	20992738554	:	:	:
304953	100736323	20992738555	Theres		NP1_NN2
304953	100736323	20992738556	a	a	AT1
304953	100736323	20992738557	list	list	NN1
304953	100736323	20992738558	that 's		NN2
304953	100736323	20992738559	referred	refer	VVN_VVD
304953	100736323	20992738560	to	to	II
304953	100736323	20992738561	as	as	II_CSA
304953	100736323	20992738562	the	the	AT
304953	100736323	20992738563	dirty	dirty	JJ
304953	100736323	20992738564	dozen	dozen	NNO
304953	100736323	20992738565	,	,	,
304953	100736323	20992738566	the	the	AT
304953	100736323	20992738567	12	12	MC
304953	100736323	20992738568	fruits	fruit	NN2
304953	100736323	20992738569	and	and	CC
304953	100736323	20992738570	vegetables	vegetable	NN2
304953	100736323	20992738571	that	that	CST
304953	100736323	20992738572	tend	tend	VV0
304953	100736323	20992738573	to	to	TO
304953	100736323	20992738574	carry	carry	VVI
304953	100736323	20992738575	the	the	AT
304953	100736323	20992738576	most	most	DAT
304953	100736323	20992738577	pesticides	pesticide	NN2
304953	100736323	20992738578	.	.	.
304953	100736323	20992738579	See	see	VV0
304953	100736323	20992738580	"	"	"
304953	100736323	20992738581	The	the	AT
304953	100736323	20992738582	dirty	dirty	JJ
304953	100736323	20992738583	dozen	dozen	NNO
304953	100736323	20992738584	.	.	.
304953	100736323	20992738585	"	"	"
304953	100736323	20992738586	If	if	CS
304953	100736323	20992738587	you	you	PPY
304953	100736323	20992738588	eat	eat	VV0
304953	100736323	20992738589	some	some	DD
304953	100736323	20992738590	of	of	IO
304953	100736323	20992738591	the	the	AT
304953	100736323	20992738592	fruits	fruit	NN2
304953	100736323	20992738593	and	and	CC
304953	100736323	20992738594	vegetables	vegetable	NN2
304953	100736323	20992738595	every	every	AT1
304953	100736323	20992738596	day	day	NNT1
304953	100736323	20992738597	that	that	CST
304953	100736323	20992738598	are	be	VBR
304953	100736323	20992738599	on	on	II
304953	100736323	20992738600	the	the	AT
304953	100736323	20992738601	list	list	NN1
304953	100736323	20992738602	,	,	,
304953	100736323	20992738603	you	you	PPY
304953	100736323	20992738604	might	might	VM
304953	100736323	20992738605	want	want	VVI
304953	100736323	20992738606	to	to	TO
304953	100736323	20992738607	look	look	VVI
304953	100736323	20992738608	at	at	II
304953	100736323	20992738609	organic	organic	JJ
304953	100736323	20992738610	options	option	NN2
304953	100736323	20992738611	.	.	.
304953	100736323	20992738612	So	so	RR
304953	100736323	20992738613	if	if	CS
304953	100736323	20992738614	you 're		NN1_VV0
304953	100736323	20992738615	eating	eat	VVG_NN1
304953	100736323	20992738616	conventional	conventional	JJ
304953	100736323	20992738617	spinach	spinach	NN1
304953	100736323	20992738618	and	and	CC
304953	100736323	20992738619	strawberries	strawberry	NN2
304953	100736323	20992738620	all	all	DB
304953	100736323	20992738621	the	the	AT
304953	100736323	20992738622	time	time	NNT1
304953	100736323	20992738623	and	and	CC
304953	100736323	20992738624	@		II
304953	100736323	20992738625	@		II
304953	100736323	20992738626	@		II
304953	100736323	20992738627	@		II
304953	100736323	20992738628	@		II
304953	100736323	20992738629	@		II
304953	100736323	20992738630	@		II
304953	100736323	20992738631	@		II
304953	100736323	20992738632	@		II
304953	100736323	20992738633	@		II
304953	100736323	20992738634	,	,	,
304953	100736323	20992738635	you	you	PPY
304953	100736323	20992738636	can	can	VM
304953	100736323	20992738637	try	try	VVI
304953	100736323	20992738638	frozen	frozen	JJ
304953	100736323	20992738639	varieties	variety	NN2
304953	100736323	20992738640	.	.	.
304953	100736323	20992738641	<p>		NULL
304953	100736323	20992738642	That	that	DD1
304953	100736323	20992738643	having	have	VHG
304953	100736323	20992738644	been	be	VBN
304953	100736323	20992738645	said	say	VVN@
304953	100736323	20992738646	,	,	,
304953	100736323	20992738647	there 's		NN2
304953	100736323	20992738648	certainly	certainly	RR
304953	100736323	20992738649	no	no	AT
304953	100736323	20992738650	evidence	evidence	NN1
304953	100736323	20992738651	that	that	CST
304953	100736323	20992738652	we	we	PPIS2
304953	100736323	20992738653	need	need	VV0
304953	100736323	20992738654	to	to	TO
304953	100736323	20992738655	choose	choose	VVI
304953	100736323	20992738656	organic	organic	JJ
304953	100736323	20992738657	.	.	.
304953	100736323	20992738658	When	when	CS_RRQ
304953	100736323	20992738659	you	you	PPY
304953	100736323	20992738660	look	look	VV0
304953	100736323	20992738661	at	at	II
304953	100736323	20992738662	the	the	AT
304953	100736323	20992738663	evidence	evidence	NN1
304953	100736323	20992738664	,	,	,
304953	100736323	20992738665	maintaining	maintain	VVG
304953	100736323	20992738666	a	a	AT1
304953	100736323	20992738667	healthy	healthy	JJ
304953	100736323	20992738668	weight	weight	NN1
304953	100736323	20992738669	,	,	,
304953	100736323	20992738670	engaging	engage	VVG
304953	100736323	20992738671	in	in	II_RP@
304953	100736323	20992738672	physical	physical	JJ
304953	100736323	20992738673	activity	activity	NN1
304953	100736323	20992738674	,	,	,
304953	100736323	20992738675	and	and	CC
304953	100736323	20992738676	eating	eat	VVG
304953	100736323	20992738677	a	a	AT1
304953	100736323	20992738678	plant-based		JJ
304953	100736323	20992738679	diet	diet	NN1
304953	100736323	20992738680	far	far	RR
304953	100736323	20992738681	outweigh	outweigh	VV0
304953	100736323	20992738682	the	the	AT
304953	100736323	20992738683	theoretical	theoretical	JJ
304953	100736323	20992738684	concerns	concern	NN2
304953	100736323	20992738685	about	about	II
304953	100736323	20992738686	organic	organic	JJ
304953	100736323	20992738687	versus	versus	II
304953	100736323	20992738688	conventional	conventional	JJ
304953	100736323	20992738689	foods	food	NN2
304953	100736323	20992738690	.	.	.
304953	100736323	20992738691	<p>		NULL
304953	100736323	20992738692	Ca n't		NP1
304953	100736323	20992738693	people	people	NN
304953	100736323	20992738694	just	just	RR
304953	100736323	20992738695	take	take	VV0
304953	100736323	20992738696	supplements	supplement	NN2
304953	100736323	20992738697	to	to	TO
304953	100736323	20992738698	get	get	VVI
304953	100736323	20992738699	the	the	AT
304953	100736323	20992738700	nutrients	nutrient	NN2
304953	100736323	20992738701	they	they	PPHS2
304953	100736323	20992738702	need	need	VV0
304953	100736323	20992738703	?	?	?
304953	100736323	20992738704	<p>		NULL
304953	100736323	20992738705	KENNEDY	kennedy	NP1
304953	100736323	20992738706	:	:	:
304953	100736323	20992738707	Research	research	NN1_VV0@
304953	100736323	20992738708	from	from	II
304953	100736323	20992738709	the	the	AT
304953	100736323	20992738710	World	world	NN1
304953	100736323	20992738711	Cancer	cancer	NN1
304953	100736323	20992738712	Research	research	NN1
304953	100736323	20992738713	Fund	fund	NN1
304953	100736323	20992738714	and	and	CC
304953	100736323	20992738715	the	the	AT
304953	100736323	20992738716	American	american	JJ
304953	100736323	20992738717	Institute	institute	NN1
304953	100736323	20992738718	for	for	IF
304953	100736323	20992738719	Cancer	cancer	NN1
304953	100736323	20992738720	Research	research	NN1
304953	100736323	20992738721	supports	support	VVZ_NN2
304953	100736323	20992738722	getting	get	VVG
304953	100736323	20992738723	nutrients	nutrient	NN2
304953	100736323	20992738724	primarily	primarily	RR
304953	100736323	20992738725	from	from	II
304953	100736323	20992738726	foods	food	NN2
304953	100736323	20992738727	,	,	,
304953	100736323	20992738728	rather	rather	II21
304953	100736323	20992738729	than	than	II22
304953	100736323	20992738730	looking	look	VVG
304953	100736323	20992738731	to	to	II
304953	100736323	20992738732	supplements	supplement	NN2
304953	100736323	20992738733	to	to	TO
304953	100736323	20992738734	prevent	prevent	VVI
304953	100736323	20992738735	cancer	cancer	NN1
304953	100736323	20992738736	.	.	.
304953	100736323	20992738737	Of	of	RR21
304953	100736323	20992738738	course	course	RR22
304953	100736323	20992738739	,	,	,
304953	100736323	20992738740	there	there	EX
304953	100736323	20992738741	are	be	VBR
304953	100736323	20992738742	reasons	reason	NN2
304953	100736323	20992738743	why	why	RRQ
304953	100736323	20992738744	an	a	AT1
304953	100736323	20992738745	individual	individual	NN1
304953	100736323	20992738746	might	might	VM
304953	100736323	20992738747	want	want	VVI
304953	100736323	20992738748	to	to	TO
304953	100736323	20992738749	take	take	VVI
304953	100736323	20992738750	a	a	AT1
304953	100736323	20992738751	supplement	supplement	NN1
304953	100736323	20992738752	.	.	.
304953	100736323	20992738753	For	for	REX21
304953	100736323	20992738754	example	example	REX22
304953	100736323	20992738755	,	,	,
304953	100736323	20992738756	a	a	AT1
304953	100736323	20992738757	person	person	NN1
304953	100736323	20992738758	with	with	IW
304953	100736323	20992738759	a	a	AT1
304953	100736323	20992738760	low	low	JJ
304953	100736323	20992738761	blood	blood	NN1
304953	100736323	20992738762	level	level	NN1
304953	100736323	20992738763	of	of	IO
304953	100736323	20992738764	vitamin	vitamin	NN1
304953	100736323	20992738765	D	d	ZZ1
304953	100736323	20992738766	might	might	VM
304953	100736323	20992738767	want	want	VVI
304953	100736323	20992738768	to	to	TO
304953	100736323	20992738769	take	take	VVI
304953	100736323	20992738770	vitamin	vitamin	NN1
304953	100736323	20992738771	D	d	ZZ1
304953	100736323	20992738772	to	to	TO
304953	100736323	20992738773	help	help	VVI
304953	100736323	20992738774	correct	correct	JJ_VV0@
304953	100736323	20992738775	the	the	AT
304953	100736323	20992738776	deficiency	deficiency	NN1
304953	100736323	20992738777	.	.	.
304953	100736323	20992738778	That 's		VVZ_NN2_NP1@
304953	100736323	20992738779	different	different	JJ
304953	100736323	20992738780	than	than	CSN
304953	100736323	20992738781	grabbing	grab	VVG
304953	100736323	20992738782	supplements	supplement	NN2
304953	100736323	20992738783	as	as	II_CSA
304953	100736323	20992738784	a	a	AT1
304953	100736323	20992738785	panacea	panacea	NN1
304953	100736323	20992738786	and	and	CC
304953	100736323	20992738787	taking	take	VVG
304953	100736323	20992738788	them	them	PPHO2
304953	100736323	20992738789	in	in	II31
304953	100736323	20992738790	place	place	II32
304953	100736323	20992738791	of	of	II33
304953	100736323	20992738792	eating	eat	VVG
304953	100736323	20992738793	a	a	AT1
304953	100736323	20992738794	healthy	healthy	JJ
304953	100736323	20992738795	diet	diet	NN1
304953	100736323	20992738796	.	.	.
304953	100736323	20992738797	<h>		NULL
304953	100736323	20992738798	Eat	eat	VV0
304953	100736323	20992738799	the	the	AT
304953	100736323	20992738800	W-H-O-L-E		JJ_NN1
304953	100736323	20992738801	grain	grain	NN1
304953	100736323	20992738802	<p>		NULL
304953	100736323	20992738803	What 's		NN2
304953	100736323	20992738804	the	the	AT
304953	100736323	20992738805	difference	difference	NN1
304953	100736323	20992738806	between	between	II
304953	100736323	20992738807	refined	refined	JJ
304953	100736323	20992738808	and	and	CC
304953	100736323	20992738809	whole	whole	JJ_NN1
304953	100736323	20992738810	grains	grain	NN2
304953	100736323	20992738811	?	?	?
304953	100736323	20992738812	<p>		NULL
304953	100736323	20992738813	McMANUS	mcmanus	NP1
304953	100736323	20992738814	:	:	:
304953	100736323	20992738815	Refined	refined	JJ
304953	100736323	20992738816	grains	grain	NN2
304953	100736323	20992738817	and	and	CC
304953	100736323	20992738818	carbohydrates	carbohydrate	NN2
304953	100736323	20992738819	are	be	VBR
304953	100736323	20992738820	easily	easily	RR
304953	100736323	20992738821	and	and	CC
304953	100736323	20992738822	rapidly	rapidly	RR
304953	100736323	20992738823	absorbed	absorb	VVN_VVD
304953	100736323	20992738824	@		II
304953	100736323	20992738825	@		II
304953	100736323	20992738826	@		II
304953	100736323	20992738827	@		II
304953	100736323	20992738828	@		II
304953	100736323	20992738829	@		II
304953	100736323	20992738830	@		II
304953	100736323	20992738831	@		II
304953	100736323	20992738832	@		II
304953	100736323	20992738833	@		II
304953	100736323	20992738834	in	in	II
304953	100736323	20992738835	blood	blood	NN1
304953	100736323	20992738836	sugar	sugar	NN1
304953	100736323	20992738837	.	.	.
304953	100736323	20992738838	At	at	II
304953	100736323	20992738839	the	the	AT
304953	100736323	20992738840	same	same	DA
304953	100736323	20992738841	time	time	NNT1
304953	100736323	20992738842	,	,	,
304953	100736323	20992738843	there 's		NN2
304953	100736323	20992738844	a	a	AT1
304953	100736323	20992738845	rise	rise	NN1
304953	100736323	20992738846	in	in	II
304953	100736323	20992738847	insulin	insulin	NN1
304953	100736323	20992738848	,	,	,
304953	100736323	20992738849	which	which	DDQ
304953	100736323	20992738850	can	can	VM
304953	100736323	20992738851	actually	actually	RR
304953	100736323	20992738852	drive	drive	VVI
304953	100736323	20992738853	the	the	AT
304953	100736323	20992738854	blood	blood	NN1
304953	100736323	20992738855	sugar	sugar	NN1
304953	100736323	20992738856	,	,	,
304953	100736323	20992738857	or	or	CC
304953	100736323	20992738858	blood	blood	NN1
304953	100736323	20992738859	glucose	glucose	NN1
304953	100736323	20992738860	,	,	,
304953	100736323	20992738861	too	too	RG
304953	100736323	20992738862	low	low	JJ_RR@
304953	100736323	20992738863	.	.	.
304953	100736323	20992738864	When	when	CS
304953	100736323	20992738865	that	that	DD1
304953	100736323	20992738866	happens	happen	VVZ
304953	100736323	20992738867	,	,	,
304953	100736323	20992738868	the	the	AT
304953	100736323	20992738869	gut	gut	NN1
304953	100736323	20992738870	and	and	CC
304953	100736323	20992738871	brain	brain	NN1
304953	100736323	20992738872	start	start	NN1_VV0
304953	100736323	20992738873	sending	send	VVG
304953	100736323	20992738874	out	out	RP
304953	100736323	20992738875	hunger	hunger	NN1
304953	100736323	20992738876	signals	signal	NN2
304953	100736323	20992738877	,	,	,
304953	100736323	20992738878	and	and	CC
304953	100736323	20992738879	the	the	AT
304953	100736323	20992738880	inclination	inclination	NN1
304953	100736323	20992738881	is	be	VBZ
304953	100736323	20992738882	to	to	TO
304953	100736323	20992738883	grab	grab	VVI
304953	100736323	20992738884	more	more	DAR
304953	100736323	20992738885	food	food	NN1
304953	100736323	20992738886	and	and	CC
304953	100736323	20992738887	potentially	potentially	RR
304953	100736323	20992738888	overeat	overeat	VV0
304953	100736323	20992738889	.	.	.
304953	100736323	20992738890	In	in	II
304953	100736323	20992738891	the	the	AT
304953	100736323	20992738892	long	long	JJ
304953	100736323	20992738893	run	run	NN1
304953	100736323	20992738894	,	,	,
304953	100736323	20992738895	we	we	PPIS2
304953	100736323	20992738896	think	think	VV0
304953	100736323	20992738897	this	this	DD1
304953	100736323	20992738898	constant	constant	JJ
304953	100736323	20992738899	barrage	barrage	NN1
304953	100736323	20992738900	of	of	IO
304953	100736323	20992738901	spikes	spike	NN2
304953	100736323	20992738902	in	in	II
304953	100736323	20992738903	blood	blood	NN1
304953	100736323	20992738904	sugar	sugar	NN1
304953	100736323	20992738905	and	and	CC
304953	100736323	20992738906	insulin	insulin	NN1
304953	100736323	20992738907	production	production	NN1
304953	100736323	20992738908	can	can	VM
304953	100736323	20992738909	lead	lead	VVI
304953	100736323	20992738910	to	to	II
304953	100736323	20992738911	type	type	NN1
304953	100736323	20992738912	2	2	MC
304953	100736323	20992738913	diabetes	diabetes	NN1
304953	100736323	20992738914	.	.	.
304953	100736323	20992738915	Whole	whole	JJ_NN1
304953	100736323	20992738916	grains	grain	NN2
304953	100736323	20992738917	help	help	VV0
304953	100736323	20992738918	limit	limit	VVI
304953	100736323	20992738919	the	the	AT
304953	100736323	20992738920	dramatic	dramatic	JJ
304953	100736323	20992738921	peaks	peak	NN2
304953	100736323	20992738922	and	and	CC
304953	100736323	20992738923	valleys	valley	NN2
304953	100736323	20992738924	in	in	II
304953	100736323	20992738925	blood	blood	NN1
304953	100736323	20992738926	sugar	sugar	NN1
304953	100736323	20992738927	,	,	,
304953	100736323	20992738928	so	so	RR_CS@
304953	100736323	20992738929	insulin	insulin	NN1
304953	100736323	20992738930	production	production	NN1
304953	100736323	20992738931	is	be	VBZ
304953	100736323	20992738932	steadier	steadier	NN1@_JJR
304953	100736323	20992738933	see	see	VV0
304953	100736323	20992738934	Figure	figure	NN1
304953	100736323	20992738935	1	1	MC1
304953	100736323	20992738936	.	.	.
304953	100736323	20992738937	<p>		NULL
304953	100736323	20992738938	Fiber	fiber	NN1_NP1@
304953	100736323	20992738939	is	be	VBZ
304953	100736323	20992738940	another	another	DD1
304953	100736323	20992738941	benefit	benefit	NN1
304953	100736323	20992738942	of	of	IO
304953	100736323	20992738943	whole	whole	JJ_NN1
304953	100736323	20992738944	grains	grain	NN2
304953	100736323	20992738945	.	.	.
304953	100736323	20992738946	There	there	EX
304953	100736323	20992738947	are	be	VBR
304953	100736323	20992738948	good	good	JJ
304953	100736323	20992738949	data	data	NN
304953	100736323	20992738950	from	from	II
304953	100736323	20992738951	both	both	DB2
304953	100736323	20992738952	the	the	AT
304953	100736323	20992738953	Nurses	nurse	NN2
304953	100736323	20992738954	Health	health	NN1
304953	100736323	20992738955	Study	study	NN1
304953	100736323	20992738956	and	and	CC
304953	100736323	20992738957	the	the	AT
304953	100736323	20992738958	Health	health	NN1
304953	100736323	20992738959	Professionals	professional	NN2
304953	100736323	20992738960	Follow-up	follow-up	JJ_NN1
304953	100736323	20992738961	Study	study	NN1
304953	100736323	20992738962	showing	show	VVG
304953	100736323	20992738963	that	that	CST
304953	100736323	20992738964	men	man	NN2
304953	100736323	20992738965	and	and	CC
304953	100736323	20992738966	women	woman	NN2
304953	100736323	20992738967	who	who	PNQS
304953	100736323	20992738968	ate	eat	VVD
304953	100736323	20992738969	the	the	AT
304953	100736323	20992738970	most	most	DAT_RGT
304953	100736323	20992738971	cereal	cereal	NN1
304953	100736323	20992738972	fiber	fiber	NN1
304953	100736323	20992738973	from	from	II
304953	100736323	20992738974	grains	grain	NN2
304953	100736323	20992738975	about	about	RG
304953	100736323	20992738976	7.5	7.5	MC
304953	100736323	20992738977	grams	gram	NNU2
304953	100736323	20992738978	a	a	AT1
304953	100736323	20992738979	day	day	NNT1
304953	100736323	20992738980	,	,	,
304953	100736323	20992738981	which	which	DDQ
304953	100736323	20992738982	is	be	VBZ
304953	100736323	20992738983	equivalent	equivalent	JJ
304953	100736323	20992738984	to	to	II
304953	100736323	20992738985	a	a	AT1
304953	100736323	20992738986	bowl	bowl	NN1
304953	100736323	20992738987	of	of	IO
304953	100736323	20992738988	oatmeal	oatmeal	NN1
304953	100736323	20992738989	and	and	CC
304953	100736323	20992738990	a	a	AT1
304953	100736323	20992738991	couple	couple	NN1
304953	100736323	20992738992	of	of	IO
304953	100736323	20992738993	pieces	piece	NN2
304953	100736323	20992738994	of	of	IO
304953	100736323	20992738995	whole-grain	whole-grain	JJ_NN1
304953	100736323	20992738996	bread	bread	NN1
304953	100736323	20992738997	were	be	VBDR
304953	100736323	20992738998	30%		NNU
304953	100736323	20992738999	less	less	DAR_RRR
304953	100736323	20992739000	likely	likely	JJ
304953	100736323	20992739001	to	to	TO
304953	100736323	20992739002	develop	develop	VVI
304953	100736323	20992739003	type	type	NN1
304953	100736323	20992739004	2	2	MC
304953	100736323	20992739005	diabetes	diabetes	NN1
304953	100736323	20992739006	than	than	CSN
304953	100736323	20992739007	those	those	DD2
304953	100736323	20992739008	who	who	PNQS
304953	100736323	20992739009	did	do	VDD
304953	100736323	20992739010	n't 	n't	XX
304953	100736323	20992739011	eat	eat	VVI
304953	100736323	20992739012	much	much	DA1
304953	100736323	20992739013	fiber	fiber	NN1
304953	100736323	20992739014	.	.	.
304953	100736323	20992739015	Other	other	JJ
304953	100736323	20992739016	data	data	NN
304953	100736323	20992739017	show	show	VV0
304953	100736323	20992739018	that	that	CST
304953	100736323	20992739019	those	those	DD2
304953	100736323	20992739020	who	who	PNQS
304953	100736323	20992739021	eat	eat	VV0
304953	100736323	20992739022	the	the	AT
304953	100736323	20992739023	most	most	RGT
304953	100736323	20992739024	@		II
304953	100736323	20992739025	@		II
304953	100736323	20992739026	@		II
304953	100736323	20992739027	@		II
304953	100736323	20992739028	@		II
304953	100736323	20992739029	@		II
304953	100736323	20992739030	@		II
304953	100736323	20992739031	@		II
304953	100736323	20992739032	@		II
304953	100736323	20992739033	@		II
304953	100736323	20992739034	day	day	NNT1
304953	100736323	20992739035	,	,	,
304953	100736323	20992739036	are	be	VBR
304953	100736323	20992739037	30%		NNU
304953	100736323	20992739038	less	less	DAR_RRR
304953	100736323	20992739039	likely	likely	JJ
304953	100736323	20992739040	to	to	TO
304953	100736323	20992739041	develop	develop	VVI
304953	100736323	20992739042	heart	heart	NN1
304953	100736323	20992739043	disease	disease	NN1
304953	100736323	20992739044	than	than	CSN
304953	100736323	20992739045	those	those	DD2
304953	100736323	20992739046	who	who	PNQS
304953	100736323	20992739047	eat	eat	VV0
304953	100736323	20992739048	few	few	DA2
304953	100736323	20992739049	whole-grain	whole-grain	JJ
304953	100736323	20992739050	foods	food	NN2
304953	100736323	20992739051	.	.	.
304953	100736323	20992739052	So	so	RR
304953	100736323	20992739053	you	you	PPY
304953	100736323	20992739054	can	can	VM
304953	100736323	20992739055	see	see	VVI
304953	100736323	20992739056	that	that	DD1_CST
304953	100736323	20992739057	whole	whole	JJ_NN1
304953	100736323	20992739058	grains	grain	NN2
304953	100736323	20992739059	are	be	VBR
304953	100736323	20992739060	beneficial	beneficial	JJ
304953	100736323	20992739061	.	.	.
304953	100736323	20992739062	We	we	PPIS2
304953	100736323	20992739063	also	also	RR
304953	100736323	20992739064	know	know	VV0
304953	100736323	20992739065	that	that	CST_DD1
304953	100736323	20992739066	whole	whole	JJ_NN1
304953	100736323	20992739067	grains	grain	NN2
304953	100736323	20992739068	and	and	CC
304953	100736323	20992739069	high-fiber	high-fiber	JJ_NN1
304953	100736323	20992739070	foods	food	NN2
304953	100736323	20992739071	can	can	VM
304953	100736323	20992739072	help	help	VVI
304953	100736323	20992739073	improve	improve	VVI
304953	100736323	20992739074	gastrointestinal	gastrointestinal	JJ
304953	100736323	20992739075	health	health	NN1
304953	100736323	20992739076	and	and	CC
304953	100736323	20992739077	help	help	VV0_NN1
304953	100736323	20992739078	prevent	prevent	VVI
304953	100736323	20992739079	constipation	constipation	NN1
304953	100736323	20992739080	.	.	.
304953	100736323	20992739081	Data	data	NN
304953	100736323	20992739082	linking	link	VVG
304953	100736323	20992739083	whole	whole	JJ_NN1
304953	100736323	20992739084	grains	grain	NN2
304953	100736323	20992739085	and	and	CC
304953	100736323	20992739086	cancer	cancer	NN1
304953	100736323	20992739087	prevention	prevention	NN1
304953	100736323	20992739088	are	be	VB0
304953	100736323	20992739089	n't 	n't	XX
304953	100736323	20992739090	really	really	RR
304953	100736323	20992739091	there	there	RL
304953	100736323	20992739092	,	,	,
304953	100736323	20992739093	but	but	CCB
304953	100736323	20992739094	were	be	VBDR
304953	100736323	20992739095	looking	look	VVG
304953	100736323	20992739096	at	at	II
304953	100736323	20992739097	the	the	AT
304953	100736323	20992739098	entire	entire	JJ
304953	100736323	20992739099	diet	diet	NN1
304953	100736323	20992739100	and	and	CC
304953	100736323	20992739101	how	how	RRQ
304953	100736323	20992739102	it	it	PPH1
304953	100736323	20992739103	can	can	VM
304953	100736323	20992739104	help	help	VVI
304953	100736323	20992739105	prevent	prevent	VVI
304953	100736323	20992739106	chronic	chronic	JJ
304953	100736323	20992739107	disease	disease	NN1
304953	100736323	20992739108	in	in	RR21
304953	100736323	20992739109	general	general	RR22
304953	100736323	20992739110	.	.	.
304953	100736323	20992739111	That 's		NN2_VVZ_NP1@
304953	100736323	20992739112	extremely	extremely	RR
304953	100736323	20992739113	important	important	JJ
304953	100736323	20992739114	.	.	.
304953	100736323	20992739115	<p>		NULL
304953	100736323	20992739116	Carbohydrates	carbohydrate	NN2
304953	100736323	20992739117	in	in	II
304953	100736323	20992739118	food	food	NN1
304953	100736323	20992739119	are	be	VBR
304953	100736323	20992739120	converted	convert	VVN
304953	100736323	20992739121	to	to	II
304953	100736323	20992739122	simple	simple	JJ
304953	100736323	20992739123	sugars	sugar	NN2
304953	100736323	20992739124	,	,	,
304953	100736323	20992739125	such	such	II21
304953	100736323	20992739126	as	as	II22
304953	100736323	20992739127	glucose	glucose	NN1
304953	100736323	20992739128	,	,	,
304953	100736323	20992739129	in	in	II
304953	100736323	20992739130	the	the	AT
304953	100736323	20992739131	intestines	intestine	NN2
304953	100736323	20992739132	.	.	.
304953	100736323	20992739133	<p>		NULL
304953	100736323	20992739134	Glucose	glucose	NN1
304953	100736323	20992739135	is	be	VBZ
304953	100736323	20992739136	absorbed	absorb	VVN
304953	100736323	20992739137	into	into	II
304953	100736323	20992739138	the	the	AT
304953	100736323	20992739139	bloodstream	bloodstream	NN1
304953	100736323	20992739140	and	and	CC
304953	100736323	20992739141	carried	carry	VVN_VVD
304953	100736323	20992739142	to	to	II
304953	100736323	20992739143	cells	cell	NN2
304953	100736323	20992739144	to	to	TO
304953	100736323	20992739145	provide	provide	VVI
304953	100736323	20992739146	energy	energy	NN1
304953	100736323	20992739147	.	.	.
304953	100736323	20992739148	<p>		NULL
304953	100736323	20992739149	The	the	AT
304953	100736323	20992739150	pancreas	pancreas	NN1
304953	100736323	20992739151	produces	produce	VVZ
304953	100736323	20992739152	insulin	insulin	NN1
304953	100736323	20992739153	,	,	,
304953	100736323	20992739154	which	which	DDQ
304953	100736323	20992739155	helps	help	VVZ
304953	100736323	20992739156	cells	cell	NN2
304953	100736323	20992739157	use	use	VVI
304953	100736323	20992739158	glucose	glucose	NN1
304953	100736323	20992739159	.	.	.
304953	100736323	20992739160	<p>		NULL
304953	100736323	20992739161	Normal	normal	JJ
304953	100736323	20992739162	glucose	glucose	NN1
304953	100736323	20992739163	absorption	absorption	NN1
304953	100736323	20992739164	<p>		NULL
304953	100736323	20992739165	Insulin	insulin	NN1_NP1@
304953	100736323	20992739166	binds	bind	VVZ
304953	100736323	20992739167	to	to	II
304953	100736323	20992739168	receptors	receptor	NN2
304953	100736323	20992739169	on	on	II
304953	100736323	20992739170	the	the	AT
304953	100736323	20992739171	cell	cell	NN1
304953	100736323	20992739172	membrane	membrane	NN1
304953	100736323	20992739173	,	,	,
304953	100736323	20992739174	much	much	DA1_RR
304953	100736323	20992739175	as	as	CSA_II
304953	100736323	20992739176	a	a	AT1
304953	100736323	20992739177	key	key	JJ_NN1
304953	100736323	20992739178	fits	fit	NN2_VVZ
304953	100736323	20992739179	into	into	II
304953	100736323	20992739180	a	a	AT1
304953	100736323	20992739181	lock	lock	NN1
304953	100736323	20992739182	,	,	,
304953	100736323	20992739183	signaling	signal	VVG_JJ@
304953	100736323	20992739184	glucose	glucose	NN1
304953	100736323	20992739185	transporters	transporter	NN2
304953	100736323	20992739186	.	.	.
304953	100736323	20992739187	<p>		NULL
304953	100736323	20992739188	Glucose	glucose	NN1
304953	100736323	20992739189	transporters	transporter	NN2
304953	100736323	20992739190	move	move	VV0
304953	100736323	20992739191	to	to	II
304953	100736323	20992739192	the	the	AT
304953	100736323	20992739193	cell	cell	NN1
304953	100736323	20992739194	membrane	membrane	NN1
304953	100736323	20992739195	and	and	CC
304953	100736323	20992739196	bind	bind	VV0
304953	100736323	20992739197	to	to	II
304953	100736323	20992739198	glucose	glucose	NN1
304953	100736323	20992739199	.	.	.
304953	100736323	20992739200	<p>		NULL
304953	100736323	20992739201	Glucose	glucose	NN1
304953	100736323	20992739202	enters	enter	VVZ
304953	100736323	20992739203	the	the	AT
304953	100736323	20992739204	cell	cell	NN1
304953	100736323	20992739205	.	.	.
304953	100736323	20992739206	<p>		NULL
304953	100736323	20992739207	Type	type	NN1
304953	100736323	20992739208	2	2	MC
304953	100736323	20992739209	diabetes	diabetes	NN1
304953	100736323	20992739210	<p>		NULL
304953	100736323	20992739211	Cells	cell	NN2
304953	100736323	20992739212	develop	develop	VV0
304953	100736323	20992739213	a	a	AT1
304953	100736323	20992739214	resistance	resistance	NN1
304953	100736323	20992739215	to	to	II
304953	100736323	20992739216	insulin	insulin	NN1
304953	100736323	20992739217	(	(	(
304953	100736323	20992739218	some	some	DD
304953	100736323	20992739219	insulin	insulin	NN1
304953	100736323	20992739220	"	"	"
304953	100736323	20992739221	locks	lock	NN2_VVZ@
304953	100736323	20992739222	"	"	"
304953	100736323	20992739223	on	on	II
304953	100736323	20992739224	@		II
304953	100736323	20992739225	@		II
304953	100736323	20992739226	@		II
304953	100736323	20992739227	@		II
304953	100736323	20992739228	@		II
304953	100736323	20992739229	@		II
304953	100736323	20992739230	@		II
304953	100736323	20992739231	@		II
304953	100736323	20992739232	@		II
304953	100736323	20992739233	@		II
304953	100736323	20992739234	.	.	.
304953	100736323	20992739235	Glucose	glucose	NN1
304953	100736323	20992739236	builds	build	VVZ
304953	100736323	20992739237	up	up	RP
304953	100736323	20992739238	in	in	II
304953	100736323	20992739239	the	the	AT
304953	100736323	20992739240	bloodstream	bloodstream	NN1
304953	100736323	20992739241	.	.	.
304953	100736323	20992739242	<p>		NULL
304953	100736323	20992739243	What	what	DDQ
304953	100736323	20992739244	makes	make	VVZ
304953	100736323	20992739245	whole	whole	JJ
304953	100736323	20992739246	grains	grain	NN2
304953	100736323	20992739247	so	so	RG_RR
304953	100736323	20992739248	effective	effective	JJ
304953	100736323	20992739249	at	at	II
304953	100736323	20992739250	controlling	control	VVG_JJ@
304953	100736323	20992739251	blood	blood	NN1
304953	100736323	20992739252	sugar	sugar	NN1
304953	100736323	20992739253	?	?	?
304953	100736323	20992739254	<p>		NULL
304953	100736323	20992739255	McMANUS	mcmanus	NP1
304953	100736323	20992739256	:	:	:
304953	100736323	20992739257	They	they	PPHS2
304953	100736323	20992739258	have n't		VV0
304953	100736323	20992739259	been	be	VBN
304953	100736323	20992739260	stripped	strip	VVN
304953	100736323	20992739261	of	of	IO
304953	100736323	20992739262	the	the	AT
304953	100736323	20992739263	intact	intact	JJ
304953	100736323	20992739264	bran	bran	NN1
304953	100736323	20992739265	.	.	.
304953	100736323	20992739266	When	when	CS_RRQ
304953	100736323	20992739267	grain	grain	NN1
304953	100736323	20992739268	gets	get	VVZ
304953	100736323	20992739269	refined	refined	JJ
304953	100736323	20992739270	,	,	,
304953	100736323	20992739271	that	that	DD1_CST
304953	100736323	20992739272	gets	get	VVZ
304953	100736323	20992739273	stripped	strip	VVN
304953	100736323	20992739274	away	away	RL
304953	100736323	20992739275	.	.	.
304953	100736323	20992739276	With	with	IW
304953	100736323	20992739277	the	the	AT
304953	100736323	20992739278	intact	intact	JJ
304953	100736323	20992739279	bran	bran	NN1
304953	100736323	20992739280	,	,	,
304953	100736323	20992739281	whole	whole	JJ_NN1
304953	100736323	20992739282	grains	grain	NN2
304953	100736323	20992739283	take	take	VV0
304953	100736323	20992739284	longer	long	RRR_JJR
304953	100736323	20992739285	to	to	TO
304953	100736323	20992739286	digest	digest	VVI
304953	100736323	20992739287	,	,	,
304953	100736323	20992739288	keep	keep	VV0
304953	100736323	20992739289	you	you	PPY
304953	100736323	20992739290	feeling	feel	VVG
304953	100736323	20992739291	full	full	RR%_JJ
304953	100736323	20992739292	longer	long	RRR_JJR
304953	100736323	20992739293	,	,	,
304953	100736323	20992739294	and	and	CC
304953	100736323	20992739295	control	control	NN1_VV0
304953	100736323	20992739296	spikes	spike	NN2_VVZ@
304953	100736323	20992739297	in	in	II
304953	100736323	20992739298	blood	blood	NN1
304953	100736323	20992739299	sugar	sugar	NN1
304953	100736323	20992739300	.	.	.
304953	100736323	20992739301	<p>		NULL
304953	100736323	20992739302	What	what	DDQ
304953	100736323	20992739303	should	should	VM
304953	100736323	20992739304	people	people	NN
304953	100736323	20992739305	look	look	VV0_NN1
304953	100736323	20992739306	for	for	IF
304953	100736323	20992739307	on	on	II
304953	100736323	20992739308	the	the	AT
304953	100736323	20992739309	label	label	NN1
304953	100736323	20992739310	?	?	?
304953	100736323	20992739311	<p>		NULL
304953	100736323	20992739312	McMANUS	mcmanus	NP1
304953	100736323	20992739313	:	:	:
304953	100736323	20992739314	The	the	AT
304953	100736323	20992739315	one	one	MC1
304953	100736323	20992739316	thing	thing	NN1
304953	100736323	20992739317	that	that	CST
304953	100736323	20992739318	you	you	PPY
304953	100736323	20992739319	want	want	VV0
304953	100736323	20992739320	to	to	TO
304953	100736323	20992739321	look	look	VVI
304953	100736323	20992739322	for	for	IF
304953	100736323	20992739323	is	be	VBZ
304953	100736323	20992739324	actually	actually	RR
304953	100736323	20992739325	the	the	AT
304953	100736323	20992739326	word	word	NN1
304953	100736323	20992739327	whole	whole	NN1
304953	100736323	20992739328	,	,	,
304953	100736323	20992739329	W-H-O-L-E		NN1_JJ
304953	100736323	20992739330	,	,	,
304953	100736323	20992739331	with	with	IW
304953	100736323	20992739332	the	the	AT
304953	100736323	20992739333	first	first	MD
304953	100736323	20992739334	ingredient	ingredient	NN1
304953	100736323	20992739335	.	.	.
304953	100736323	20992739336	Men	man	NN2
304953	100736323	20992739337	should	should	VM
304953	100736323	20992739338	also	also	RR
304953	100736323	20992739339	know	know	VVI
304953	100736323	20992739340	how	how	RGQ@
304953	100736323	20992739341	much	much	DA1
304953	100736323	20992739342	fiber	fiber	NN1
304953	100736323	20992739343	they	they	PPHS2
304953	100736323	20992739344	need	need	VV0
304953	100736323	20992739345	.	.	.
304953	100736323	20992739346	The	the	AT
304953	100736323	20992739347	fiber	fiber	NN1
304953	100736323	20992739348	goal	goal	NN1
304953	100736323	20992739349	for	for	IF
304953	100736323	20992739350	men	man	NN2
304953	100736323	20992739351	50	50	MC
304953	100736323	20992739352	years	year	NNT2
304953	100736323	20992739353	or	or	CC
304953	100736323	20992739354	younger	young	JJR
304953	100736323	20992739355	is	be	VBZ
304953	100736323	20992739356	38	38	MC
304953	100736323	20992739357	grams	gram	NNU2
304953	100736323	20992739358	a	a	AT1
304953	100736323	20992739359	day	day	NNT1
304953	100736323	20992739360	.	.	.
304953	100736323	20992739361	For	for	IF
304953	100736323	20992739362	men	man	NN2
304953	100736323	20992739363	older	old	JJR
304953	100736323	20992739364	than	than	CSN
304953	100736323	20992739365	50	50	MC
304953	100736323	20992739366	,	,	,
304953	100736323	20992739367	its	its	APPGE
304953	100736323	20992739368	30	30	MC
304953	100736323	20992739369	grams	gram	NNU2
304953	100736323	20992739370	a	a	AT1
304953	100736323	20992739371	day	day	NNT1
304953	100736323	20992739372	.	.	.
304953	100736323	20992739373	The	the	AT
304953	100736323	20992739374	key	key	NN1
304953	100736323	20992739375	is	be	VBZ
304953	100736323	20992739376	for	for	IF
304953	100736323	20992739377	people	people	NN
304953	100736323	20992739378	to	to	TO
304953	100736323	20992739379	not	not	XX
304953	100736323	20992739380	fall	fall	VVI
304953	100736323	20992739381	for	for	IF
304953	100736323	20992739382	the	the	AT
304953	100736323	20992739383	"	"	"
304953	100736323	20992739384	come-ons	come-on	NN2
304953	100736323	20992739385	"	"	"
304953	100736323	20992739386	on	on	II
304953	100736323	20992739387	the	the	AT
304953	100736323	20992739388	packages	package	NN2
304953	100736323	20992739389	,	,	,
304953	100736323	20992739390	even	even	CS21
304953	100736323	20992739391	though	though	CS22
304953	100736323	20992739392	they	they	PPHS2
304953	100736323	20992739393	may	may	VM
304953	100736323	20992739394	sound	sound	VVI
304953	100736323	20992739395	enticing	enticing	JJ_VVG
304953	100736323	20992739396	,	,	,
304953	100736323	20992739397	because	because	CS
304953	100736323	20992739398	the	the	AT
304953	100736323	20992739399	fiber	fiber	NN1
304953	100736323	20992739400	content	content	NN1
304953	100736323	20992739401	may	may	VM
304953	100736323	20992739402	not	not	XX
304953	100736323	20992739403	be	be	VBI
304953	100736323	20992739404	high	high	JJ_RR@
304953	100736323	20992739405	enough	enough	RR
304953	100736323	20992739406	.	.	.
304953	100736323	20992739407	The	the	AT
304953	100736323	20992739408	FDA	fda	NN1_NP1
304953	100736323	20992739409	has	have	VHZ
304953	100736323	20992739410	some	some	DD
304953	100736323	20992739411	specific	specific	JJ
304953	100736323	20992739412	guidelines	guideline	NN2
304953	100736323	20992739413	for	for	IF
304953	100736323	20992739414	what	what	DDQ
304953	100736323	20992739415	labels	label	NN2
304953	100736323	20992739416	can	can	VM
304953	100736323	20992739417	claim	claim	VVI
304953	100736323	20992739418	,	,	,
304953	100736323	20992739419	based	base	VVN
304953	100736323	20992739420	on	on	II
304953	100736323	20992739421	nutrient	nutrient	NN1_JJ@
304953	100736323	20992739422	content	content	NN1
304953	100736323	20992739423	.	.	.
304953	100736323	20992739424	@		II
304953	100736323	20992739425	@		II
304953	100736323	20992739426	@		II
304953	100736323	20992739427	@		II
304953	100736323	20992739428	@		II
304953	100736323	20992739429	@		II
304953	100736323	20992739430	@		II
304953	100736323	20992739431	@		II
304953	100736323	20992739432	@		II
304953	100736323	20992739433	@		II
304953	100736323	20992739434	good	good	JJ
304953	100736323	20992739435	source	source	NN1
304953	100736323	20992739436	of	of	IO
304953	100736323	20992739437	fiber	fiber	NN1
304953	100736323	20992739438	"	"	"
304953	100736323	20992739439	must	must	VM
304953	100736323	20992739440	contribute	contribute	VVI
304953	100736323	20992739441	10%		NNU
304953	100736323	20992739442	of	of	IO
304953	100736323	20992739443	what	what	DDQ
304953	100736323	20992739444	they	they	PPHS2
304953	100736323	20992739445	call	call	VV0
304953	100736323	20992739446	the	the	AT
304953	100736323	20992739447	daily	daily	JJ
304953	100736323	20992739448	value	value	NN1
304953	100736323	20992739449	,	,	,
304953	100736323	20992739450	the	the	AT
304953	100736323	20992739451	amount	amount	NN1
304953	100736323	20992739452	that	that	CST
304953	100736323	20992739453	one	one	PN1
304953	100736323	20992739454	should	should	VM
304953	100736323	20992739455	consume	consume	VVI
304953	100736323	20992739456	daily	daily	RR_JJ
304953	100736323	20992739457	.	.	.
304953	100736323	20992739458	<h>		NULL
304953	100736323	20992739459	Figure	figure	NN1
304953	100736323	20992739460	2	2	MC
304953	100736323	20992739461	:	:	:
304953	100736323	20992739462	Its	its	APPGE
304953	100736323	20992739463	all	all	DB_RR@
304953	100736323	20992739464	in	in	II
304953	100736323	20992739465	the	the	AT
304953	100736323	20992739466	label	label	NN1
304953	100736323	20992739467	<p>		NULL
304953	100736323	20992739468	That	that	DD1
304953	100736323	20992739469	does	do	VDZ
304953	100736323	20992739470	n't 	n't	XX
304953	100736323	20992739471	seem	seem	VVI
304953	100736323	20992739472	like	like	II
304953	100736323	20992739473	very	very	RG
304953	100736323	20992739474	much	much	DA1_RR
304953	100736323	20992739475	.	.	.
304953	100736323	20992739476	<p>		NULL
304953	100736323	20992739477	McMANUS	mcmanus	NP1
304953	100736323	20992739478	:	:	:
304953	100736323	20992739479	Exactly	exactly	RR
304953	100736323	20992739480	.	.	.
304953	100736323	20992739481	If	if	CS
304953	100736323	20992739482	you	you	PPY
304953	100736323	20992739483	consume	consume	VV0
304953	100736323	20992739484	2,000	2,000	MC
304953	100736323	20992739485	calories	calorie	NNU2
304953	100736323	20992739486	a	a	AT1
304953	100736323	20992739487	day	day	NNT1
304953	100736323	20992739488	,	,	,
304953	100736323	20992739489	the	the	AT
304953	100736323	20992739490	daily	daily	JJ
304953	100736323	20992739491	value	value	NN1
304953	100736323	20992739492	for	for	IF
304953	100736323	20992739493	fiber	fiber	NN1
304953	100736323	20992739494	is	be	VBZ
304953	100736323	20992739495	25	25	MC
304953	100736323	20992739496	grams	gram	NNU2
304953	100736323	20992739497	.	.	.
304953	100736323	20992739498	If	if	CS
304953	100736323	20992739499	a	a	AT1
304953	100736323	20992739500	food	food	NN1
304953	100736323	20992739501	has	have	VHZ
304953	100736323	20992739502	5	5	MC
304953	100736323	20992739503	grams	gram	NNU2
304953	100736323	20992739504	of	of	IO
304953	100736323	20992739505	fiber	fiber	NN1
304953	100736323	20992739506	per	per	II
304953	100736323	20992739507	serving	serve	VVG_NN1@
304953	100736323	20992739508	,	,	,
304953	100736323	20992739509	it	it	PPH1
304953	100736323	20992739510	contains	contain	VVZ
304953	100736323	20992739511	20%		NNU
304953	100736323	20992739512	of	of	IO
304953	100736323	20992739513	the	the	AT
304953	100736323	20992739514	daily	daily	JJ
304953	100736323	20992739515	value	value	NN1
304953	100736323	20992739516	for	for	IF
304953	100736323	20992739517	fiber	fiber	NN1
304953	100736323	20992739518	.	.	.
304953	100736323	20992739519	At	at	II
304953	100736323	20992739520	20%		NNU
304953	100736323	20992739521	,	,	,
304953	100736323	20992739522	the	the	AT
304953	100736323	20992739523	manufacturer	manufacturer	NN1
304953	100736323	20992739524	can	can	VM
304953	100736323	20992739525	claim	claim	VVI
304953	100736323	20992739526	that	that	CST
304953	100736323	20992739527	the	the	AT
304953	100736323	20992739528	food	food	NN1
304953	100736323	20992739529	is	be	VBZ
304953	100736323	20992739530	"	"	"
304953	100736323	20992739531	high	high	JJ_RR@
304953	100736323	20992739532	in	in	II
304953	100736323	20992739533	fiber	fiber	NN1
304953	100736323	20992739534	,	,	,
304953	100736323	20992739535	"	"	"
304953	100736323	20992739536	"	"	"
304953	100736323	20992739537	rich	rich	JJ
304953	100736323	20992739538	in	in	II
304953	100736323	20992739539	fiber	fiber	NN1
304953	100736323	20992739540	,	,	,
304953	100736323	20992739541	"	"	"
304953	100736323	20992739542	or	or	CC
304953	100736323	20992739543	"	"	"
304953	100736323	20992739544	an	a	AT1
304953	100736323	20992739545	excellent	excellent	JJ
304953	100736323	20992739546	source	source	NN1
304953	100736323	20992739547	of	of	IO
304953	100736323	20992739548	fiber	fiber	NN1
304953	100736323	20992739549	,	,	,
304953	100736323	20992739550	"	"	"
304953	100736323	20992739551	and	and	CC
304953	100736323	20992739552	yet	yet	RR
304953	100736323	20992739553	you 're		VV0
304953	100736323	20992739554	only	only	JJ
304953	100736323	20992739555	getting	getting	NN1
304953	100736323	20992739556	5	5	MC
304953	100736323	20992739557	grams	gram	NNU2
304953	100736323	20992739558	.	.	.
304953	100736323	20992739559	<p>		NULL
304953	100736323	20992739560	If	if	CS
304953	100736323	20992739561	you 're		NN1_VV0
304953	100736323	20992739562	trying	try	VVG
304953	100736323	20992739563	to	to	TO
304953	100736323	20992739564	get	get	VVI
304953	100736323	20992739565	35	35	MC
304953	100736323	20992739566	grams	gram	NNU2
304953	100736323	20992739567	of	of	IO
304953	100736323	20992739568	fiber	fiber	NN1
304953	100736323	20992739569	a	a	AT1
304953	100736323	20992739570	day	day	NNT1
304953	100736323	20992739571	,	,	,
304953	100736323	20992739572	eating	eat	VVG_NN1
304953	100736323	20992739573	foods	food	NN2
304953	100736323	20992739574	like	like	II
304953	100736323	20992739575	fruits	fruit	NN2
304953	100736323	20992739576	and	and	CC
304953	100736323	20992739577	vegetables	vegetable	NN2
304953	100736323	20992739578	foods	food	NN2
304953	100736323	20992739579	that	that	CST
304953	100736323	20992739580	do	do	VD0
304953	100736323	20992739581	n't 	n't	XX
304953	100736323	20992739582	have	have	VHI
304953	100736323	20992739583	labels	label	NN2
304953	100736323	20992739584	can	can	VM
304953	100736323	20992739585	be	be	VBI
304953	100736323	20992739586	very	very	RG
304953	100736323	20992739587	helpful	helpful	JJ
304953	100736323	20992739588	.	.	.
304953	100736323	20992739589	A	a	AT1_ZZ1
304953	100736323	20992739590	plant-based		JJ
304953	100736323	20992739591	diet	diet	NN1
304953	100736323	20992739592	is	be	VBZ
304953	100736323	20992739593	going	go	VVGK
304953	100736323	20992739594	to	to	TO
304953	100736323	20992739595	get	get	VVI
304953	100736323	20992739596	you	you	PPY
304953	100736323	20992739597	to	to	II
304953	100736323	20992739598	your	your	APPGE
304953	100736323	20992739599	35-gram		JJ
304953	100736323	20992739600	goal	goal	NN1
304953	100736323	20992739601	faster	fast	RRR_JJR
304953	100736323	20992739602	than	than	CSN
304953	100736323	20992739603	the	the	AT
304953	100736323	20992739604	traditional	traditional	JJ
304953	100736323	20992739605	Western	western	JJ
304953	100736323	20992739606	diet	diet	NN1
304953	100736323	20992739607	,	,	,
304953	100736323	20992739608	which	which	DDQ
304953	100736323	20992739609	is	be	VBZ
304953	100736323	20992739610	loaded	load	VVN
304953	100736323	20992739611	with	with	IW
304953	100736323	20992739612	red	red	JJ
304953	100736323	20992739613	meat	meat	NN1
304953	100736323	20992739614	and	and	CC
304953	100736323	20992739615	dairy	dairy	NN1
304953	100736323	20992739616	,	,	,
304953	100736323	20992739617	foods	food	NN2
304953	100736323	20992739618	that	that	CST
304953	100736323	20992739619	are	be	VBR
304953	100736323	20992739620	very	very	RG
304953	100736323	20992739621	low	low	JJ_RR@
304953	100736323	20992739622	in	in	II
304953	100736323	20992739623	fiber	fiber	NN1
304953	100736323	20992739624	@		II
304953	100736323	20992739625	@		II
304953	100736323	20992739626	@		II
304953	100736323	20992739627	@		II
304953	100736323	20992739628	@		II
304953	100736323	20992739629	@		II
304953	100736323	20992739630	@		II
304953	100736323	20992739631	@		II
304953	100736323	20992739632	@		II
304953	100736323	20992739633	@		II
304953	100736323	20992739634	and	and	CC
304953	100736323	20992739635	work	work	VVI
304953	100736323	20992739636	at	at	II
304953	100736323	20992739637	it	it	PPH1
304953	100736323	20992739638	slowly	slowly	RR
304953	100736323	20992739639	over	over	II
304953	100736323	20992739640	time	time	NNT1
304953	100736323	20992739641	.	.	.
304953	100736323	20992739642	And	and	CC
304953	100736323	20992739643	when	when	RRQ_CS
304953	100736323	20992739644	you 're		VV0_NN1
304953	100736323	20992739645	looking	look	VVG
304953	100736323	20992739646	at	at	II
304953	100736323	20992739647	the	the	AT
304953	100736323	20992739648	Nutrition	nutrition	NN1
304953	100736323	20992739649	Facts	fact	NN2
304953	100736323	20992739650	label	label	VV0
304953	100736323	20992739651	,	,	,
304953	100736323	20992739652	look	look	VV0_NN1
304953	100736323	20992739653	at	at	II
304953	100736323	20992739654	the	the	AT
304953	100736323	20992739655	number	number	NN1
304953	100736323	20992739656	of	of	IO
304953	100736323	20992739657	grams	gram	NNU2
304953	100736323	20992739658	of	of	IO
304953	100736323	20992739659	fiber	fiber	NN1
304953	100736323	20992739660	per	per	II
304953	100736323	20992739661	serving	serve	VVG
304953	100736323	20992739662	see	see	VV0
304953	100736323	20992739663	Figure	figure	NN1
304953	100736323	20992739664	2	2	MC
304953	100736323	20992739665	.	.	.
304953	100736323	20992739666	<p>		NULL
304953	100736323	20992739667	When	when	CS_RRQ
304953	100736323	20992739668	it	it	PPH1
304953	100736323	20992739669	comes	come	VVZ
304953	100736323	20992739670	to	to	II
304953	100736323	20992739671	making	make	VVG
304953	100736323	20992739672	all	all	DB
304953	100736323	20992739673	of	of	IO
304953	100736323	20992739674	these	these	DD2
304953	100736323	20992739675	healthy	healthy	JJ
304953	100736323	20992739676	changes	change	NN2
304953	100736323	20992739677	,	,	,
304953	100736323	20992739678	how	how	RRQ
304953	100736323	20992739679	can	can	VM
304953	100736323	20992739680	our	our	APPGE
304953	100736323	20992739681	readers	reader	NN2
304953	100736323	20992739682	up	up	II@_RP
304953	100736323	20992739683	their	their	APPGE
304953	100736323	20992739684	chances	chance	NN2
304953	100736323	20992739685	of	of	IO
304953	100736323	20992739686	success	success	NN1
304953	100736323	20992739687	?	?	?
304953	100736323	20992739688	<p>		NULL
304953	100736323	20992739689	McMANUS	mcmanus	NP1
304953	100736323	20992739690	:	:	:
304953	100736323	20992739691	Start	start	VV0_NN1
304953	100736323	20992739692	with	with	IW
304953	100736323	20992739693	small	small	JJ
304953	100736323	20992739694	steps	step	NN2
304953	100736323	20992739695	.	.	.
304953	100736323	20992739696	Making	make	VVG
304953	100736323	20992739697	too	too	RG
304953	100736323	20992739698	many	many	DA2
304953	100736323	20992739699	changes	change	NN2
304953	100736323	20992739700	at	at	RR21
304953	100736323	20992739701	once	once	RR22
304953	100736323	20992739702	can	can	VM
304953	100736323	20992739703	be	be	VBI
304953	100736323	20992739704	difficult	difficult	JJ
304953	100736323	20992739705	.	.	.
304953	100736323	20992739706	Make	make	VV0
304953	100736323	20992739707	one	one	MC1
304953	100736323	20992739708	change	change	NN1
304953	100736323	20992739709	and	and	CC
304953	100736323	20992739710	stick	stick	VV0_NN1
304953	100736323	20992739711	with	with	IW
304953	100736323	20992739712	it	it	PPH1
304953	100736323	20992739713	for	for	IF
304953	100736323	20992739714	a	a	AT1
304953	100736323	20992739715	while	while	NNT1@
304953	100736323	20992739716	.	.	.
304953	100736323	20992739717	Then	then	RT
304953	100736323	20992739718	take	take	VV0
304953	100736323	20992739719	another	another	DD1
304953	100736323	20992739720	step	step	NN1
304953	100736323	20992739721	.	.	.
304953	100736323	20992739722	Youll		NN1_NP1@
304953	100736323	20992739723	be	be	VBI
304953	100736323	20992739724	more	more	RGR
304953	100736323	20992739725	likely	likely	JJ
304953	100736323	20992739726	to	to	TO
304953	100736323	20992739727	succeed	succeed	VVI
304953	100736323	20992739728	.	.	.
304953	100736323	20992739729	46996		MC
304953	100736323	20992739730	@qwx906996		FO
304953	100736326	20992739750	@@##	----------	----------
304953	100736326	20992739751	@@100736326		FO
304953	100736326	20992739752	@4936326/		VV0_NN1
304953	100736326	20992739753	46989		MC
304953	100736326	20992739754	@qwx906989		FO
304953	100736326	20992739755	<p>		NULL
304953	100736326	20992739756	A	a	AT1_ZZ1
304953	100736326	20992739757	new	new	JJ
304953	100736326	20992739758	study	study	NN1
304953	100736326	20992739759	published	publish	VVN
304953	100736326	20992739760	in	in	II
304953	100736326	20992739761	The	the	AT
304953	100736326	20992739762	Journal	journal	NN1
304953	100736326	20992739763	of	of	IO
304953	100736326	20992739764	the	the	AT
304953	100736326	20992739765	American	american	JJ
304953	100736326	20992739766	Medical	medical	JJ
304953	100736326	20992739767	Association	association	NN1
304953	100736326	20992739768	finds	find	VVZ
304953	100736326	20992739769	that	that	CST_DD1
304953	100736326	20992739770	saw	see	VVD_NN1@
304953	100736326	20992739771	palmetto	palmetto	NN1
304953	100736326	20992739772	,	,	,
304953	100736326	20992739773	a	a	AT1
304953	100736326	20992739774	fruit	fruit	NN
304953	100736326	20992739775	extract	extract	VV0
304953	100736326	20992739776	commonly	commonly	RR
304953	100736326	20992739777	taken	take	VVN
304953	100736326	20992739778	to	to	TO
304953	100736326	20992739779	treat	treat	VVI
304953	100736326	20992739780	urinary	urinary	JJ_NN1
304953	100736326	20992739781	tract	tract	NN1
304953	100736326	20992739782	symptoms	symptom	NN2
304953	100736326	20992739783	caused	cause	VVN
304953	100736326	20992739784	by	by	II
304953	100736326	20992739785	an	a	AT1
304953	100736326	20992739786	enlarged	enlarged	JJ
304953	100736326	20992739787	prostate	prostate	NN1
304953	100736326	20992739788	(	(	(
304953	100736326	20992739789	technically	technically	RR
304953	100736326	20992739790	termed	term	VVN_VVD
304953	100736326	20992739791	benign	benign	JJ
304953	100736326	20992739792	prostatic	prostatic	JJ
304953	100736326	20992739793	hyperplasia	hyperplasia	NN1
304953	100736326	20992739794	,	,	,
304953	100736326	20992739795	or	or	CC
304953	100736326	20992739796	BPH	bph	NP1
304953	100736326	20992739797	)	)	)
304953	100736326	20992739798	,	,	,
304953	100736326	20992739799	is	be	VBZ
304953	100736326	20992739800	no	no	AT_RR%
304953	100736326	20992739801	more	more	RGR
304953	100736326	20992739802	effective	effective	JJ
304953	100736326	20992739803	in	in	II
304953	100736326	20992739804	relieving	relieving	JJ_VVG
304953	100736326	20992739805	symptoms	symptom	NN2
304953	100736326	20992739806	than	than	CSN
304953	100736326	20992739807	placebo	placebo	NN1
304953	100736326	20992739808	,	,	,
304953	100736326	20992739809	even	even	RR
304953	100736326	20992739810	at	at	II
304953	100736326	20992739811	high	high	JJ
304953	100736326	20992739812	doses	dose	NN2
304953	100736326	20992739813	.	.	.
304953	100736326	20992739814	<p>		NULL
304953	100736326	20992739815	The	the	AT
304953	100736326	20992739816	federally	federally	RR
304953	100736326	20992739817	funded	funded	JJ_VVN
304953	100736326	20992739818	study	study	NN1
304953	100736326	20992739819	included	include	VVD_VVN
304953	100736326	20992739820	nearly	nearly	RR
304953	100736326	20992739821	370	370	MC
304953	100736326	20992739822	moderately	moderately	RR
304953	100736326	20992739823	symptomatic	symptomatic	JJ
304953	100736326	20992739824	men	man	NN2
304953	100736326	20992739825	over	over	II
304953	100736326	20992739826	age	age	NN1
304953	100736326	20992739827	45	45	MC
304953	100736326	20992739828	from	from	II
304953	100736326	20992739829	11	11	MC
304953	100736326	20992739830	North	north	NP1
304953	100736326	20992739831	American	american	JJ
304953	100736326	20992739832	hospitals	hospital	NN2
304953	100736326	20992739833	.	.	.
304953	100736326	20992739834	Over	over	RG
304953	100736326	20992739835	72	72	MC
304953	100736326	20992739836	weeks	week	NNT2
304953	100736326	20992739837	,	,	,
304953	100736326	20992739838	the	the	AT
304953	100736326	20992739839	participants	participant	NN2
304953	100736326	20992739840	took	take	VVD
304953	100736326	20992739841	a	a	AT1
304953	100736326	20992739842	daily	daily	JJ
304953	100736326	20992739843	dose	dose	NN1
304953	100736326	20992739844	of	of	IO
304953	100736326	20992739845	either	either	RR
304953	100736326	20992739846	saw	see	VVD
304953	100736326	20992739847	palmetto	palmetto	NN1
304953	100736326	20992739848	or	or	CC
304953	100736326	20992739849	a	a	AT1
304953	100736326	20992739850	placebo	placebo	NN1
304953	100736326	20992739851	.	.	.
304953	100736326	20992739852	The	the	AT
304953	100736326	20992739853	standard	standard	JJ_NN1
304953	100736326	20992739854	dose	dose	NN1
304953	100736326	20992739855	of	of	IO
304953	100736326	20992739856	320mg/day		FU
304953	100736326	20992739857	of	of	IO
304953	100736326	20992739858	saw	saw	NN1@
304953	100736326	20992739859	palmetto	palmetto	NN1
304953	100736326	20992739860	was	be	VBDZ
304953	100736326	20992739861	tripled	triple	VVN@
304953	100736326	20992739862	over	over	II_RP
304953	100736326	20992739863	the	the	AT
304953	100736326	20992739864	course	course	NN1
304953	100736326	20992739865	of	of	IO
304953	100736326	20992739866	the	the	AT
304953	100736326	20992739867	study	study	NN1
304953	100736326	20992739868	.	.	.
304953	100736326	20992739869	Despite	despite	II
304953	100736326	20992739870	this	this	DD1
304953	100736326	20992739871	increase	increase	NN1
304953	100736326	20992739872	,	,	,
304953	100736326	20992739873	at	at	II
304953	100736326	20992739874	the	the	AT
304953	100736326	20992739875	end	end	NN1
304953	100736326	20992739876	of	of	IO
304953	100736326	20992739877	the	the	AT
304953	100736326	20992739878	study	study	NN1
304953	100736326	20992739879	period	period	NN1
304953	100736326	20992739880	,	,	,
304953	100736326	20992739881	saw	see	VVD
304953	100736326	20992739882	palmetto	palmetto	NN1
304953	100736326	20992739883	did	do	VDD
304953	100736326	20992739884	not	not	XX
304953	100736326	20992739885	relieve	relieve	VVI
304953	100736326	20992739886	urinary	urinary	JJ_NN1
304953	100736326	20992739887	tract	tract	NN1
304953	100736326	20992739888	symptoms	symptom	NN2
304953	100736326	20992739889	any	any	DD
304953	100736326	20992739890	more	more	DAR
304953	100736326	20992739891	than	than	CSN
304953	100736326	20992739892	the	the	AT
304953	100736326	20992739893	placebo	placebo	NN1
304953	100736326	20992739894	.	.	.
304953	100736326	20992739895	These	these	DD2
304953	100736326	20992739896	findings	finding	NN2
304953	100736326	20992739897	are	be	VBR
304953	100736326	20992739898	consistent	consistent	JJ
304953	100736326	20992739899	with	with	IW
304953	100736326	20992739900	findings	finding	NN2
304953	100736326	20992739901	from	from	II
304953	100736326	20992739902	a	a	AT1
304953	100736326	20992739903	one	one	MC1
304953	100736326	20992739904	year	year	NNT1
304953	100736326	20992739905	trial	trial	NN1
304953	100736326	20992739906	in	in	II
304953	100736326	20992739907	2006	2006	MC
304953	100736326	20992739908	that	that	CST_DD1
304953	100736326	20992739909	also	also	RR
304953	100736326	20992739910	found	find	VVD_VVN
304953	100736326	20992739911	no	no	AT
304953	100736326	20992739912	benefit	benefit	NN1
304953	100736326	20992739913	of	of	IO
304953	100736326	20992739914	saw	saw	NN1@
304953	100736326	20992739915	palmetto	palmetto	NN1
304953	100736326	20992739916	to	to	II
304953	100736326	20992739917	patients	patient	NN2
304953	100736326	20992739918	with	with	IW
304953	100736326	20992739919	BPH	bph	NP1
304953	100736326	20992739920	symptoms	symptom	NN2
304953	100736326	20992739921	.	.	.
304953	100736326	20992739922	<p>		NULL
304953	100736326	20992739923	A	a	AT1_ZZ1
304953	100736326	20992739924	large	large	JJ
304953	100736326	20992739925	majority	majority	NN1
304953	100736326	20992739926	of	of	IO
304953	100736326	20992739927	men	man	NN2
304953	100736326	20992739928	have	have	VH0
304953	100736326	20992739929	symptoms	symptom	NN2
304953	100736326	20992739930	of	of	IO
304953	100736326	20992739931	an	a	AT1
304953	100736326	20992739932	enlarged	enlarged	JJ
304953	100736326	20992739933	prostate	prostate	NN1
304953	100736326	20992739934	at	at	II
304953	100736326	20992739935	some	some	DD
304953	100736326	20992739936	point	point	NN1
304953	100736326	20992739937	after	after	II_CS
304953	100736326	20992739938	age	age	NN1
304953	100736326	20992739939	50	50	MC
304953	100736326	20992739940	,	,	,
304953	100736326	20992739941	which	which	DDQ
304953	100736326	20992739942	@		II
304953	100736326	20992739943	@		II
304953	100736326	20992739944	@		II
304953	100736326	20992739945	@		II
304953	100736326	20992739946	@		II
304953	100736326	20992739947	@		II
304953	100736326	20992739948	@		II
304953	100736326	20992739949	@		II
304953	100736326	20992739950	@		II
304953	100736326	20992739951	@		II
304953	100736326	20992739952	bathroom	bathroom	NN1
304953	100736326	20992739953	several	several	DA2
304953	100736326	20992739954	times	time	NNT2
304953	100736326	20992739955	at	at	II
304953	100736326	20992739956	night	night	NNT1
304953	100736326	20992739957	"	"	"
304953	100736326	20992739958	difficulty	difficulty	NN1
304953	100736326	20992739959	urinating	urinate	VVG
304953	100736326	20992739960	,	,	,
304953	100736326	20992739961	and	and	CC
304953	100736326	20992739962	weak	weak	JJ
304953	100736326	20992739963	or	or	CC
304953	100736326	20992739964	intermittent	intermittent	JJ
304953	100736326	20992739965	urinary	urinary	JJ_NN1
304953	100736326	20992739966	flow	flow	NN1
304953	100736326	20992739967	.	.	.
304953	100736326	20992739968	While	while	CS
304953	100736326	20992739969	these	these	DD2
304953	100736326	20992739970	symptoms	symptom	NN2
304953	100736326	20992739971	are	be	VBR
304953	100736326	20992739972	mild	mild	JJ
304953	100736326	20992739973	in	in	II
304953	100736326	20992739974	some	some	DD
304953	100736326	20992739975	men	man	NN2
304953	100736326	20992739976	,	,	,
304953	100736326	20992739977	they	they	PPHS2
304953	100736326	20992739978	are	be	VBR
304953	100736326	20992739979	severe	severe	JJ
304953	100736326	20992739980	enough	enough	RR
304953	100736326	20992739981	to	to	TO
304953	100736326	20992739982	interfere	interfere	VVI
304953	100736326	20992739983	with	with	IW
304953	100736326	20992739984	quality	quality	NN1
304953	100736326	20992739985	of	of	IO
304953	100736326	20992739986	life	life	NN1
304953	100736326	20992739987	in	in	II
304953	100736326	20992739988	others	others	NN2
304953	100736326	20992739989	.	.	.
304953	100736326	20992739990	Medications	medication	NN2
304953	100736326	20992739991	to	to	TO
304953	100736326	20992739992	treat	treat	VVI
304953	100736326	20992739993	BPH	bph	NP1
304953	100736326	20992739994	are	be	VBR
304953	100736326	20992739995	available	available	JJ
304953	100736326	20992739996	but	but	CCB
304953	100736326	20992739997	many	many	DA2
304953	100736326	20992739998	can	can	VM
304953	100736326	20992739999	produce	produce	VVI
304953	100736326	20992740000	unpleasant	unpleasant	JJ
304953	100736326	20992740001	side	side	NN1
304953	100736326	20992740002	effects	effect	NN2
304953	100736326	20992740003	.	.	.
304953	100736326	20992740004	Prior	prior	II21
304953	100736326	20992740005	to	to	II22
304953	100736326	20992740006	this	this	DD1
304953	100736326	20992740007	study	study	NN1
304953	100736326	20992740008	,	,	,
304953	100736326	20992740009	saw	see	VVD
304953	100736326	20992740010	palmetto	palmetto	NN1
304953	100736326	20992740011	was	be	VBDZ
304953	100736326	20992740012	thought	think	VVN
304953	100736326	20992740013	to	to	TO
304953	100736326	20992740014	be	be	VBI
304953	100736326	20992740015	a	a	AT1
304953	100736326	20992740016	low-cost	low-cost	JJ
304953	100736326	20992740017	,	,	,
304953	100736326	20992740018	safer	safe	JJR_RRR
304953	100736326	20992740019	alternative	alternative	NN1_JJ
304953	100736326	20992740020	.	.	.
304953	100736326	20992740021	<p>		NULL
304953	100736326	20992740022	Study	study	NN1_VV0@
304953	100736326	20992740023	author	author	NN1
304953	100736326	20992740024	and	and	CC
304953	100736326	20992740025	clinical	clinical	JJ
304953	100736326	20992740026	professor	professor	NN1
304953	100736326	20992740027	of	of	IO
304953	100736326	20992740028	Medicine	medicine	NN1
304953	100736326	20992740029	at	at	II
304953	100736326	20992740030	Harvard	harvard	NP1
304953	100736326	20992740031	Medical	medical	JJ
304953	100736326	20992740032	School	school	NN1
304953	100736326	20992740033	,	,	,
304953	100736326	20992740034	Michael	michael	NP1
304953	100736326	20992740035	Barry	barry	NP1
304953	100736326	20992740036	,	,	,
304953	100736326	20992740037	MD	md	NNA
304953	100736326	20992740038	,	,	,
304953	100736326	20992740039	concludes	conclude	VVZ
304953	100736326	20992740040	"	"	"
304953	100736326	20992740041	Saw	saw	NN1@
304953	100736326	20992740042	palmetto	palmetto	NN1
304953	100736326	20992740043	extracts	extract	NN2
304953	100736326	20992740044	are	be	VBR
304953	100736326	20992740045	commonly	commonly	RR
304953	100736326	20992740046	used	use	VVN
304953	100736326	20992740047	by	by	II
304953	100736326	20992740048	men	man	NN2
304953	100736326	20992740049	with	with	IW
304953	100736326	20992740050	bothersome	bothersome	JJ
304953	100736326	20992740051	lower	low	JJR
304953	100736326	20992740052	urinary	urinary	JJ_NN1
304953	100736326	20992740053	tract	tract	NN1
304953	100736326	20992740054	symptoms	symptom	NN2
304953	100736326	20992740055	,	,	,
304953	100736326	20992740056	but	but	CCB
304953	100736326	20992740057	our	our	APPGE
304953	100736326	20992740058	results	result	NN2
304953	100736326	20992740059	indicate	indicate	VV0
304953	100736326	20992740060	that	that	CST
304953	100736326	20992740061	the	the	AT
304953	100736326	20992740062	particular	particular	JJ
304953	100736326	20992740063	extract	extract	NN1_VV0
304953	100736326	20992740064	we	we	PPIS2
304953	100736326	20992740065	tested	test	VVD
304953	100736326	20992740066	was	be	VBDZ
304953	100736326	20992740067	no	no	AT_RR%
304953	100736326	20992740068	better	better	JJR_RRR
304953	100736326	20992740069	than	than	CSN
304953	100736326	20992740070	a	a	AT1
304953	100736326	20992740071	placebo	placebo	NN1
304953	100736326	20992740072	at	at	II
304953	100736326	20992740073	relieving	relieve	VVG
304953	100736326	20992740074	those	those	DD2
304953	100736326	20992740075	symptoms	symptom	NN2
304953	100736326	20992740076	.	.	.
304953	100736326	20992740077	It	it	PPH1
304953	100736326	20992740078	is	be	VBZ
304953	100736326	20992740079	possible	possible	JJ
304953	100736326	20992740080	that	that	CST_DD1
304953	100736326	20992740081	other	other	JJ
304953	100736326	20992740082	formulations	formulation	NN2
304953	100736326	20992740083	could	could	VM
304953	100736326	20992740084	be	be	VBI
304953	100736326	20992740085	helpful	helpful	JJ
304953	100736326	20992740086	,	,	,
304953	100736326	20992740087	but	but	CCB
304953	100736326	20992740088	a	a	AT1
304953	100736326	20992740089	number	number	NN1
304953	100736326	20992740090	of	of	IO
304953	100736326	20992740091	recent	recent	JJ
304953	100736326	20992740092	studies	study	NN2
304953	100736326	20992740093	with	with	IW
304953	100736326	20992740094	negative	negative	JJ
304953	100736326	20992740095	results	result	NN2
304953	100736326	20992740096	suggest	suggest	VV0
304953	100736326	20992740097	it	it	PPH1
304953	100736326	20992740098	may	may	VM
304953	100736326	20992740099	be	be	VBI
304953	100736326	20992740100	difficult	difficult	JJ
304953	100736326	20992740101	to	to	TO
304953	100736326	20992740102	find	find	VVI
304953	100736326	20992740103	a	a	AT1
304953	100736326	20992740104	saw	saw	NN1@
304953	100736326	20992740105	palmetto	palmetto	NN1
304953	100736326	20992740106	extract	extract	VVI
304953	100736326	20992740107	that	that	DD1_CST
304953	100736326	20992740108	is	be	VBZ
304953	100736326	20992740109	better	better	JJR_RRR
304953	100736326	20992740110	than	than	CSN
304953	100736326	20992740111	placebo.		NNU
304953	100736326	20992740112	"	"	"
304953	100736326	20992740113	46996		MC
304953	100736326	20992740114	@qwx906996		FO
304953	100736327	20992740134	@@##	----------	----------
304953	100736327	20992740135	@@100736327		FO
304953	100736327	20992740136	@4936327/		VV0_NN1
304953	100736327	20992740137	46989		MC
304953	100736327	20992740138	@qwx906989		FO
304953	100736327	20992740139	<h>		NULL
304953	100736327	20992740140	Understanding	understand	VVG_NN1
304953	100736327	20992740141	PSA	psa	NP1
304953	100736327	20992740142	Introduction	introduction	NN1
304953	100736327	20992740143	<p>		NULL
304953	100736327	20992740144	Welcome	welcome	VV0_NN1
304953	100736327	20992740145	to	to	II
304953	100736327	20992740146	this	this	DD1
304953	100736327	20992740147	Decision	decision	NN1
304953	100736327	20992740148	Guide	guide	NN1_VV0
304953	100736327	20992740149	about	about	II
304953	100736327	20992740150	PSA	psa	NP1
304953	100736327	20992740151	testing	testing	NN1_VVG
304953	100736327	20992740152	.	.	.
304953	100736327	20992740153	<p>		NULL
304953	100736327	20992740154	Prostate-specific	prostate-specific	JJ
304953	100736327	20992740155	antigen	antigen	NN1
304953	100736327	20992740156	,	,	,
304953	100736327	20992740157	or	or	CC
304953	100736327	20992740158	PSA	psa	NP1
304953	100736327	20992740159	,	,	,
304953	100736327	20992740160	is	be	VBZ
304953	100736327	20992740161	a	a	AT1
304953	100736327	20992740162	blood	blood	NN1
304953	100736327	20992740163	test	test	NN1
304953	100736327	20992740164	used	use	VVN
304953	100736327	20992740165	by	by	II
304953	100736327	20992740166	many	many	DA2
304953	100736327	20992740167	doctors	doctor	NN2
304953	100736327	20992740168	to	to	TO
304953	100736327	20992740169	screen	screen	VVI
304953	100736327	20992740170	for	for	IF
304953	100736327	20992740171	prostate	prostate	NN1
304953	100736327	20992740172	cancer	cancer	NN1
304953	100736327	20992740173	.	.	.
304953	100736327	20992740174	If	if	CS
304953	100736327	20992740175	you 've		NN1
304953	100736327	20992740176	had	have	VHD
304953	100736327	20992740177	your	your	APPGE
304953	100736327	20992740178	PSA	psa	NP1
304953	100736327	20992740179	level	level	NN1
304953	100736327	20992740180	checked	check	VVD_VVN
304953	100736327	20992740181	,	,	,
304953	100736327	20992740182	you	you	PPY
304953	100736327	20992740183	may	may	VM
304953	100736327	20992740184	have	have	VHI
304953	100736327	20992740185	been	be	VBN
304953	100736327	20992740186	told	tell	VVN
304953	100736327	20992740187	that	that	CST
304953	100736327	20992740188	your	your	APPGE
304953	100736327	20992740189	results	result	NN2
304953	100736327	20992740190	were	be	VBDR
304953	100736327	20992740191	"	"	"
304953	100736327	20992740192	normal	normal	JJ
304953	100736327	20992740193	"	"	"
304953	100736327	20992740194	or	or	CC
304953	100736327	20992740195	"	"	"
304953	100736327	20992740196	abnormal	abnormal	JJ
304953	100736327	20992740197	.	.	.
304953	100736327	20992740198	"	"	"
304953	100736327	20992740199	However	however	RR
304953	100736327	20992740200	,	,	,
304953	100736327	20992740201	some	some	DD
304953	100736327	20992740202	men	man	NN2
304953	100736327	20992740203	would	would	VM
304953	100736327	20992740204	like	like	VVI
304953	100736327	20992740205	to	to	TO
304953	100736327	20992740206	know	know	VVI
304953	100736327	20992740207	more	more	RRR_DAR
304953	100736327	20992740208	about	about	II
304953	100736327	20992740209	what	what	DDQ
304953	100736327	20992740210	their	their	APPGE
304953	100736327	20992740211	PSA	psa	NP1
304953	100736327	20992740212	level	level	JJ_NN1
304953	100736327	20992740213	means	mean	NN_VVZ
304953	100736327	20992740214	.	.	.
304953	100736327	20992740215	<p>		NULL
304953	100736327	20992740216	This	this	DD1
304953	100736327	20992740217	tool	tool	NN1
304953	100736327	20992740218	provides	provide	VVZ
304953	100736327	20992740219	more	more	DAR
304953	100736327	20992740220	information	information	NN1
304953	100736327	20992740221	about	about	II
304953	100736327	20992740222	PSA	psa	NP1
304953	100736327	20992740223	levels	level	NN2
304953	100736327	20992740224	,	,	,
304953	100736327	20992740225	and	and	CC
304953	100736327	20992740226	what 's		NN2
304953	100736327	20992740227	considered	consider	VVN_VVD
304953	100736327	20992740228	to	to	TO
304953	100736327	20992740229	be	be	VBI
304953	100736327	20992740230	reassuring	reassuring	JJ_VVG
304953	100736327	20992740231	or	or	CC
304953	100736327	20992740232	worrisome	worrisome	JJ
304953	100736327	20992740233	for	for	IF
304953	100736327	20992740234	men	man	NN2
304953	100736327	20992740235	of	of	IO
304953	100736327	20992740236	different	different	JJ
304953	100736327	20992740237	ages	age	NN2
304953	100736327	20992740238	.	.	.
304953	100736327	20992740239	<p>		NULL
304953	100736327	20992740240	Keep	keep	VV0
304953	100736327	20992740241	in	in	II_RP@
304953	100736327	20992740242	mind	mind	NN1
304953	100736327	20992740243	that	that	CST
304953	100736327	20992740244	PSA	psa	NP1
304953	100736327	20992740245	is	be	VBZ
304953	100736327	20992740246	simply	simply	RR
304953	100736327	20992740247	a	a	AT1
304953	100736327	20992740248	screening	screening	NN1
304953	100736327	20992740249	tool	tool	NN1
304953	100736327	20992740250	used	use	VVD_VVN
304953	100736327	20992740251	alone	alone	RR_JJ
304953	100736327	20992740252	,	,	,
304953	100736327	20992740253	it	it	PPH1
304953	100736327	20992740254	can	can	VM
304953	100736327	20992740255	not	not	XX
304953	100736327	20992740256	answer	answer	VVI
304953	100736327	20992740257	the	the	AT
304953	100736327	20992740258	question	question	NN1
304953	100736327	20992740259	of	of	IO
304953	100736327	20992740260	whether	whether	CSW31
304953	100736327	20992740261	or	or	CSW32
304953	100736327	20992740262	not	not	CSW33
304953	100736327	20992740263	you	you	PPY
304953	100736327	20992740264	have	have	VH0
304953	100736327	20992740265	prostate	prostate	NN1
304953	100736327	20992740266	cancer	cancer	NN1
304953	100736327	20992740267	.	.	.
304953	100736327	20992740268	However	however	RR
304953	100736327	20992740269	,	,	,
304953	100736327	20992740270	PSA	psa	NP1
304953	100736327	20992740271	levels	level	NN2
304953	100736327	20992740272	are	be	VBR
304953	100736327	20992740273	often	often	RR
304953	100736327	20992740274	helpful	helpful	JJ
304953	100736327	20992740275	for	for	IF
304953	100736327	20992740276	deciding	decide	VVG
304953	100736327	20992740277	which	which	DDQ
304953	100736327	20992740278	men	man	NN2
304953	100736327	20992740279	need	need	VV0
304953	100736327	20992740280	further	far	JJR@_RRR
304953	100736327	20992740281	testing	testing	NN1_VVG
304953	100736327	20992740282	or	or	CC
304953	100736327	20992740283	evaluation	evaluation	NN1
304953	100736327	20992740284	.	.	.
304953	100736327	20992740285	High	high	JJ_RR@
304953	100736327	20992740286	PSA	psa	NP1
304953	100736327	20992740287	levels	level	NN2
304953	100736327	20992740288	can	can	VM
304953	100736327	20992740289	signal	signal	VVI
304953	100736327	20992740290	prostate	prostate	NN1
304953	100736327	20992740291	cancer	cancer	NN1
304953	100736327	20992740292	,	,	,
304953	100736327	20992740293	but	but	CCB
304953	100736327	20992740294	they	they	PPHS2
304953	100736327	20992740295	can	can	VM
304953	100736327	20992740296	also	also	RR
304953	100736327	20992740297	reflect	reflect	VVI
304953	100736327	20992740298	benign	benign	JJ
304953	100736327	20992740299	(	(	(
304953	100736327	20992740300	non-cancerous	non-cancerous	JJ
304953	100736327	20992740301	)	)	)
304953	100736327	20992740302	growth	growth	NN1
304953	100736327	20992740303	of	of	IO
304953	100736327	20992740304	the	the	AT
304953	100736327	20992740305	prostate	prostate	NN1
304953	100736327	20992740306	,	,	,
304953	100736327	20992740307	as	as	II31
304953	100736327	20992740308	well	well	II32
304953	100736327	20992740309	as	as	II33
304953	100736327	20992740310	prostate	prostate	NN1
304953	100736327	20992740311	infections	infection	NN2
304953	100736327	20992740312	.	.	.
304953	100736327	20992740313	Only	only	JJ
304953	100736327	20992740314	a	a-i	AT1
304953	100736327	20992740315	biopsy	biopsy	NN1
304953	100736327	20992740316	can	can	VM
304953	100736327	20992740317	tell	tell	VVI
304953	100736327	20992740318	whether	whether	CSW31
304953	100736327	20992740319	or	or	CSW32
304953	100736327	20992740320	not	not	CSW33
304953	100736327	20992740321	you	you	PPY
304953	100736327	20992740322	have	have	VH0
304953	100736327	20992740323	prostate	prostate	NN1
304953	100736327	20992740324	cancer	cancer	NN1
304953	100736327	20992740325	or	or	CC
304953	100736327	20992740326	@		II
304953	100736327	20992740327	@		II
304953	100736327	20992740328	@		II
304953	100736327	20992740329	@		II
304953	100736327	20992740330	@		II
304953	100736327	20992740331	@		II
304953	100736327	20992740332	@		II
304953	100736327	20992740333	@		II
304953	100736327	20992740334	@		II
304953	100736327	20992740335	@		II
304953	100736327	20992740336	also	also	RR
304953	100736327	20992740337	important	important	JJ
304953	100736327	20992740338	to	to	TO
304953	100736327	20992740339	know	know	VVI
304953	100736327	20992740340	that	that	CST
304953	100736327	20992740341	many	many	DA2
304953	100736327	20992740342	doctors	doctor	NN2
304953	100736327	20992740343	consider	consider	VV0
304953	100736327	20992740344	PSA	psa	NP1
304953	100736327	20992740345	testing	test	VVG_NN1
304953	100736327	20992740346	to	to	TO
304953	100736327	20992740347	be	be	VBI
304953	100736327	20992740348	controversial	controversial	JJ
304953	100736327	20992740349	.	.	.
304953	100736327	20992740350	That 's		NN2_VVZ_NP1@
304953	100736327	20992740351	because	because	CS
304953	100736327	20992740352	PSA	psa	NP1
304953	100736327	20992740353	results	result	NN2
304953	100736327	20992740354	can	can	VM
304953	100736327	20992740355	be	be	VBI
304953	100736327	20992740356	misleading	misleading	JJ
304953	100736327	20992740357	,	,	,
304953	100736327	20992740358	but	but	CCB
304953	100736327	20992740359	also	also	RR
304953	100736327	20992740360	because	because	CS
304953	100736327	20992740361	there	there	EX
304953	100736327	20992740362	is	be	VBZ
304953	100736327	20992740363	uncertainty	uncertainty	NN1
304953	100736327	20992740364	about	about	II
304953	100736327	20992740365	whether	whether	CSW
304953	100736327	20992740366	aggressive	aggressive	JJ
304953	100736327	20992740367	treatment	treatment	NN1
304953	100736327	20992740368	of	of	IO
304953	100736327	20992740369	prostate	prostate	NN1
304953	100736327	20992740370	cancer	cancer	NN1
304953	100736327	20992740371	makes	make	VVZ
304953	100736327	20992740372	sense	sense	NN1
304953	100736327	20992740373	for	for	IF
304953	100736327	20992740374	many	many	DA2
304953	100736327	20992740375	older	old	JJR
304953	100736327	20992740376	men	man	NN2
304953	100736327	20992740377	.	.	.
304953	100736327	20992740378	While	while	CS
304953	100736327	20992740379	this	this	DD1
304953	100736327	20992740380	tool	tool	NN1
304953	100736327	20992740381	is	be	VBZ
304953	100736327	20992740382	designed	design	VVN
304953	100736327	20992740383	for	for	IF
304953	100736327	20992740384	men	man	NN2
304953	100736327	20992740385	who	who	PNQS
304953	100736327	20992740386	have	have	VH0
304953	100736327	20992740387	had	have	VHN
304953	100736327	20992740388	their	their	APPGE
304953	100736327	20992740389	PSA	psa	NP1
304953	100736327	20992740390	checked	check	VVN
304953	100736327	20992740391	,	,	,
304953	100736327	20992740392	keep	keep	VV0
304953	100736327	20992740393	in	in	II_RP@
304953	100736327	20992740394	mind	mind	NN1
304953	100736327	20992740395	that	that	CST
304953	100736327	20992740396	PSA	psa	NP1
304953	100736327	20992740397	testing	testing	NN1
304953	100736327	20992740398	may	may	VM
304953	100736327	20992740399	not	not	XX
304953	100736327	20992740400	make	make	VVI
304953	100736327	20992740401	sense	sense	NN1
304953	100736327	20992740402	for	for	IF
304953	100736327	20992740403	everybody	everybody	PN1
304953	100736327	20992740404	.	.	.
304953	100736327	20992740405	If	if	CS
304953	100736327	20992740406	you	you	PPY
304953	100736327	20992740407	have	have	VH0
304953	100736327	20992740408	questions	question	NN2
304953	100736327	20992740409	about	about	II
304953	100736327	20992740410	PSA	psa	NP1
304953	100736327	20992740411	testing	testing	NN1_VVG
304953	100736327	20992740412	,	,	,
304953	100736327	20992740413	be	be	VBI
304953	100736327	20992740414	sure	sure	JJ
304953	100736327	20992740415	to	to	TO
304953	100736327	20992740416	speak	speak	VVI
304953	100736327	20992740417	with	with	IW
304953	100736327	20992740418	your	your	APPGE
304953	100736327	20992740419	health	health	NN1
304953	100736327	20992740420	care	care	NN1
304953	100736327	20992740421	provider	provider	NN1
304953	100736327	20992740422	.	.	.
304953	100736327	20992740423	<p>		NULL
304953	100736327	20992740424	In	in	BCL21
304953	100736327	20992740425	order	order	BCL22
304953	100736327	20992740426	to	to	TO
304953	100736327	20992740427	understand	understand	VVI
304953	100736327	20992740428	your	your	APPGE
304953	100736327	20992740429	PSA	psa	NP1
304953	100736327	20992740430	results	result	NN2_VVZ@
304953	100736327	20992740431	,	,	,
304953	100736327	20992740432	well	well	RR
304953	100736327	20992740433	ask	ask	VV0
304953	100736327	20992740434	you	you	PPY
304953	100736327	20992740435	a	a	AT1
304953	100736327	20992740436	series	series	NN
304953	100736327	20992740437	of	of	IO
304953	100736327	20992740438	questions	question	NN2
304953	100736327	20992740439	about	about	II
304953	100736327	20992740440	you	you	PPY
304953	100736327	20992740441	and	and	CC
304953	100736327	20992740442	your	your	APPGE
304953	100736327	20992740443	medical	medical	JJ
304953	100736327	20992740444	history	history	NN1
304953	100736327	20992740445	.	.	.
304953	100736327	20992740446	Before	before	CS
304953	100736327	20992740447	you	you	PPY
304953	100736327	20992740448	begin	begin	VV0
304953	100736327	20992740449	,	,	,
304953	100736327	20992740450	it	it	PPH1
304953	100736327	20992740451	may	may	VM
304953	100736327	20992740452	be	be	VBI
304953	100736327	20992740453	helpful	helpful	JJ
304953	100736327	20992740454	to	to	TO
304953	100736327	20992740455	have	have	VHI
304953	100736327	20992740456	your	your	APPGE
304953	100736327	20992740457	most	most	RGT
304953	100736327	20992740458	recent	recent	JJ
304953	100736327	20992740459	PSA	psa	NP1
304953	100736327	20992740460	result	result	NN1_VV0
304953	100736327	20992740461	in	in	II31
304953	100736327	20992740462	front	front	II32
304953	100736327	20992740463	of	of	II33
304953	100736327	20992740464	you	you	PPY
304953	100736327	20992740465	,	,	,
304953	100736327	20992740466	as	as	II31
304953	100736327	20992740467	well	well	II32
304953	100736327	20992740468	as	as	II33
304953	100736327	20992740469	results	result	NN2
304953	100736327	20992740470	from	from	II
304953	100736327	20992740471	any	any	DD
304953	100736327	20992740472	prior	prior	JJ
304953	100736327	20992740473	PSA	psa	NP1
304953	100736327	20992740474	tests	test	NN2_VVZ@
304953	100736327	20992740475	.	.	.
304953	100736327	20992740476	<p>		NULL
304953	100736327	20992740477	Well	well	RR
304953	100736327	20992740478	start	start	VV0
304953	100736327	20992740479	by	by	II
304953	100736327	20992740480	finding	find	VVG
304953	100736327	20992740481	out	out	RP
304953	100736327	20992740482	your	your	APPGE
304953	100736327	20992740483	age	age	NN1
304953	100736327	20992740484	.	.	.
304953	100736327	20992740485	That 's		NN2_VVZ_NP1@
304953	100736327	20992740486	because	because	CS
304953	100736327	20992740487	PSA	psa	NP1
304953	100736327	20992740488	levels	level	NN2
304953	100736327	20992740489	tend	tend	VV0
304953	100736327	20992740490	to	to	TO
304953	100736327	20992740491	increase	increase	VVI
304953	100736327	20992740492	with	with	IW
304953	100736327	20992740493	age	age	NN1
304953	100736327	20992740494	,	,	,
304953	100736327	20992740495	and	and	CC
304953	100736327	20992740496	the	the	AT
304953	100736327	20992740497	cut-off	cut-off	NN1
304953	100736327	20992740498	for	for	IF
304953	100736327	20992740499	"	"	"
304953	100736327	20992740500	normal	normal	JJ
304953	100736327	20992740501	"	"	"
304953	100736327	20992740502	PSA	psa	NP1
304953	100736327	20992740503	levels	level	NN2
304953	100736327	20992740504	goes	go	VVZ
304953	100736327	20992740505	up	up	RP
304953	100736327	20992740506	as	as	RR21_RG
304953	100736327	20992740507	well	well	RR22_RR
304953	100736327	20992740508	.	.	.
304953	100736327	20992740509	46996		MC
304953	100736327	20992740510	@qwx906996		FO
304953	100736332	20992740530	@@##	----------	----------
304953	100736332	20992740531	@@100736332		FO
304953	100736332	20992740532	@4936332/		VV0_NN1
304953	100736332	20992740533	46989		MC
304953	100736332	20992740534	@qwx906989		FO
304953	100736332	20992740535	<p>		NULL
304953	100736332	20992740536	Physicians	physician	NN2
304953	100736332	20992740537	and	and	CC
304953	100736332	20992740538	researchers	researcher	NN2
304953	100736332	20992740539	have	have	VH0
304953	100736332	20992740540	long	long	RR
304953	100736332	20992740541	believed	believe	VVN
304953	100736332	20992740542	that	that	CST_DD1
304953	100736332	20992740543	consuming	consume	VVG_JJ@
304953	100736332	20992740544	high	high	JJ
304953	100736332	20992740545	amounts	amount	NN2
304953	100736332	20992740546	of	of	IO
304953	100736332	20992740547	calcium	calcium	NN1
304953	100736332	20992740548	and	and	CC
304953	100736332	20992740549	dairy	dairy	NN1
304953	100736332	20992740550	products	product	NN2
304953	100736332	20992740551	increases	increase	VVZ
304953	100736332	20992740552	the	the	AT
304953	100736332	20992740553	risk	risk	NN1
304953	100736332	20992740554	of	of	IO
304953	100736332	20992740555	prostate	prostate	NN1
304953	100736332	20992740556	cancer	cancer	NN1
304953	100736332	20992740557	,	,	,
304953	100736332	20992740558	although	although	CS
304953	100736332	20992740559	study	study	NN1
304953	100736332	20992740560	results	result	NN2
304953	100736332	20992740561	have	have	VH0
304953	100736332	20992740562	been	be	VBN
304953	100736332	20992740563	inconsistent	inconsistent	JJ
304953	100736332	20992740564	.	.	.
304953	100736332	20992740565	Two	two	MC
304953	100736332	20992740566	recent	recent	JJ
304953	100736332	20992740567	studies	study	NN2
304953	100736332	20992740568	make	make	VV0
304953	100736332	20992740569	clear	clear	JJ
304953	100736332	20992740570	that	that	CST
304953	100736332	20992740571	the	the	AT
304953	100736332	20992740572	jury	jury	NN1
304953	100736332	20992740573	is	be	VBZ
304953	100736332	20992740574	still	still	RR
304953	100736332	20992740575	out	out	RP
304953	100736332	20992740576	.	.	.
304953	100736332	20992740577	<p>		NULL
304953	100736332	20992740578	A	a	AT1
304953	100736332	20992740579	study	study	NN1
304953	100736332	20992740580	of	of	IO
304953	100736332	20992740581	29,133		MC
304953	100736332	20992740582	men	man	NN2
304953	100736332	20992740583	in	in	II
304953	100736332	20992740584	Finland	finland	NP1
304953	100736332	20992740585	found	find	VVD
304953	100736332	20992740586	that	that	CST
304953	100736332	20992740587	those	those	DD2
304953	100736332	20992740588	who	who	PNQS
304953	100736332	20992740589	consumed	consume	VVD
304953	100736332	20992740590	2,000	2,000	MC
304953	100736332	20992740591	mg	mg	NNU
304953	100736332	20992740592	of	of	IO
304953	100736332	20992740593	calcium	calcium	NN1
304953	100736332	20992740594	or	or	CC
304953	100736332	20992740595	more	more	RGR
304953	100736332	20992740596	daily	daily	RR
304953	100736332	20992740597	had	have	VHN@_VHD
304953	100736332	20992740598	a	a	AT1
304953	100736332	20992740599	marked	marked	JJ
304953	100736332	20992740600	increase	increase	NN1
304953	100736332	20992740601	in	in	II
304953	100736332	20992740602	prostate	prostate	NN1
304953	100736332	20992740603	cancer	cancer	NN1
304953	100736332	20992740604	risk	risk	NN1
304953	100736332	20992740605	.	.	.
304953	100736332	20992740606	High	high	JJ
304953	100736332	20992740607	consumption	consumption	NN1
304953	100736332	20992740608	of	of	IO
304953	100736332	20992740609	dairy	dairy	NN1
304953	100736332	20992740610	foods	food	NN2
304953	100736332	20992740611	was	be	VBDZ
304953	100736332	20992740612	also	also	RR
304953	100736332	20992740613	associated	associate	VVN
304953	100736332	20992740614	with	with	IW
304953	100736332	20992740615	an	a	AT1
304953	100736332	20992740616	increased	increased	JJ
304953	100736332	20992740617	risk	risk	NN1
304953	100736332	20992740618	of	of	IO
304953	100736332	20992740619	the	the	AT
304953	100736332	20992740620	disease	disease	NN1
304953	100736332	20992740621	,	,	,
304953	100736332	20992740622	which	which	DDQ
304953	100736332	20992740623	the	the	AT
304953	100736332	20992740624	researchers	researcher	NN2
304953	100736332	20992740625	attributed	attribute	VVN_VVD
304953	100736332	20992740626	to	to	II
304953	100736332	20992740627	the	the	AT
304953	100736332	20992740628	calcium	calcium	NN1
304953	100736332	20992740629	(	(	(
304953	100736332	20992740630	or	or	CC
304953	100736332	20992740631	a	a	AT1
304953	100736332	20992740632	closely	closely	RR
304953	100736332	20992740633	related	related	JJ_VVN
304953	100736332	20992740634	component	component	NN1
304953	100736332	20992740635	)	)	)
304953	100736332	20992740636	in	in	II
304953	100736332	20992740637	those	those	DD2
304953	100736332	20992740638	foods	food	NN2
304953	100736332	20992740639	.	.	.
304953	100736332	20992740640	<p>		NULL
304953	100736332	20992740641	The	the	AT
304953	100736332	20992740642	National	national	JJ
304953	100736332	20992740643	Institutes	institute	NN2
304953	100736332	20992740644	of	of	IO
304953	100736332	20992740645	Health	health	NN1
304953	100736332	20992740646	"	"	"
304953	100736332	20992740647	AARP	aarp	NN1_NP1_VV0
304953	100736332	20992740648	Diet	diet	NN1_NP1@
304953	100736332	20992740649	and	and	CC
304953	100736332	20992740650	Health	health	NN1
304953	100736332	20992740651	Study	study	NN1
304953	100736332	20992740652	came	come	VVD
304953	100736332	20992740653	to	to	II
304953	100736332	20992740654	a	a	AT1
304953	100736332	20992740655	somewhat	somewhat	RR
304953	100736332	20992740656	different	different	JJ
304953	100736332	20992740657	conclusion	conclusion	NN1
304953	100736332	20992740658	.	.	.
304953	100736332	20992740659	Researchers	researcher	NN2
304953	100736332	20992740660	reported	report	VVN_VVD
304953	100736332	20992740661	in	in	II
304953	100736332	20992740662	December	december	NPM1
304953	100736332	20992740663	2007	2007	MC
304953	100736332	20992740664	that	that	CST
304953	100736332	20992740665	a	a	AT1
304953	100736332	20992740666	total	total	JJ
304953	100736332	20992740667	calcium	calcium	NN1
304953	100736332	20992740668	intake	intake	NN1
304953	100736332	20992740669	of	of	IO
304953	100736332	20992740670	2,000	2,000	MC
304953	100736332	20992740671	mg	mg	NNU
304953	100736332	20992740672	or	or	CC
304953	100736332	20992740673	more	more	RRR
304953	100736332	20992740674	was	be	VBDZ
304953	100736332	20992740675	associated	associate	VVN
304953	100736332	20992740676	with	with	IW
304953	100736332	20992740677	advanced	advanced	JJ
304953	100736332	20992740678	prostate	prostate	NN1
304953	100736332	20992740679	cancer	cancer	NN1
304953	100736332	20992740680	,	,	,
304953	100736332	20992740681	although	although	CS
304953	100736332	20992740682	the	the	AT
304953	100736332	20992740683	link	link	NN1
304953	100736332	20992740684	was	be	VBDZ
304953	100736332	20992740685	not	not	XX
304953	100736332	20992740686	considered	consider	VVN
304953	100736332	20992740687	statistically	statistically	RR
304953	100736332	20992740688	significant	significant	JJ
304953	100736332	20992740689	.	.	.
304953	100736332	20992740690	In	in	II
304953	100736332	20992740691	contrast	contrast	NN1
304953	100736332	20992740692	,	,	,
304953	100736332	20992740693	they	they	PPHS2
304953	100736332	20992740694	found	find	VVD
304953	100736332	20992740695	that	that	DD1_CST
304953	100736332	20992740696	calcium	calcium	NN1
304953	100736332	20992740697	from	from	II
304953	100736332	20992740698	nondairy	nondairy	JJ_NN1
304953	100736332	20992740699	foods	food	NN2
304953	100736332	20992740700	actually	actually	RR
304953	100736332	20992740701	seemed	seem	VVD_VVN@
304953	100736332	20992740702	to	to	TO
304953	100736332	20992740703	lower	lower	VVI
304953	100736332	20992740704	prostate	prostate	NN1
304953	100736332	20992740705	cancer	cancer	NN1
304953	100736332	20992740706	risk	risk	NN1
304953	100736332	20992740707	.	.	.
304953	100736332	20992740708	<p>		NULL
304953	100736332	20992740709	Although	although	CS
304953	100736332	20992740710	the	the	AT
304953	100736332	20992740711	debate	debate	NN1
304953	100736332	20992740712	continues	continue	VVZ
304953	100736332	20992740713	,	,	,
304953	100736332	20992740714	men	man	NN2
304953	100736332	20992740715	might	might	VM
304953	100736332	20992740716	want	want	VVI
304953	100736332	20992740717	to	to	TO
304953	100736332	20992740718	keep	keep	VVI
304953	100736332	20992740719	calcium	calcium	NN1
304953	100736332	20992740720	consumption	consumption	NN1
304953	100736332	20992740721	well	well	RR
304953	100736332	20992740722	@		II
304953	100736332	20992740723	@		II
304953	100736332	20992740724	@		II
304953	100736332	20992740725	@		II
304953	100736332	20992740726	@		II
304953	100736332	20992740727	@		II
304953	100736332	20992740728	@		II
304953	100736332	20992740729	@		II
304953	100736332	20992740730	@		II
304953	100736332	20992740731	@		II
304953	100736332	20992740732	both	both	DB2
304953	100736332	20992740733	studies	study	NN2
304953	100736332	20992740734	found	find	VVD_VVN
304953	100736332	20992740735	an	a	AT1
304953	100736332	20992740736	increased	increased	JJ
304953	100736332	20992740737	incidence	incidence	NN1
304953	100736332	20992740738	of	of	IO
304953	100736332	20992740739	prostate	prostate	NN1
304953	100736332	20992740740	cancer	cancer	NN1
304953	100736332	20992740741	.	.	.
304953	100736332	20992740742	46996		MC
304953	100736332	20992740743	@qwx906996		FO
304953	100736333	20992740763	@@##	----------	----------
304953	100736333	20992740764	@@100736333		FO
304953	100736333	20992740765	@4936333/		VV0_NN1
304953	100736333	20992740766	46989		MC
304953	100736333	20992740767	@qwx906989		FO
304953	100736333	20992740768	<p>		NULL
304953	100736333	20992740769	Prostate	prostate	NN1
304953	100736333	20992740770	cancer	cancer	NN1
304953	100736333	20992740771	cells	cell	NN2
304953	100736333	20992740772	need	need	VV0
304953	100736333	20992740773	testosterone	testosterone	NN1
304953	100736333	20992740774	to	to	TO
304953	100736333	20992740775	grow	grow	VVI
304953	100736333	20992740776	and	and	CC
304953	100736333	20992740777	flourish	flourish	NN1_VV0
304953	100736333	20992740778	.	.	.
304953	100736333	20992740779	Interfering	interfere	VVG
304953	100736333	20992740780	with	with	IW
304953	100736333	20992740781	the	the	AT
304953	100736333	20992740782	bodys	bodys	NN2
304953	100736333	20992740783	ability	ability	NN1
304953	100736333	20992740784	to	to	TO
304953	100736333	20992740785	make	make	VVI
304953	100736333	20992740786	and	and	CC
304953	100736333	20992740787	use	use	VVI
304953	100736333	20992740788	this	this	DD1
304953	100736333	20992740789	hormone	hormone	NN1
304953	100736333	20992740790	,	,	,
304953	100736333	20992740791	also	also	RR
304953	100736333	20992740792	known	know	VVN
304953	100736333	20992740793	as	as	II
304953	100736333	20992740794	an	a	AT1
304953	100736333	20992740795	androgen	androgen	NN1
304953	100736333	20992740796	,	,	,
304953	100736333	20992740797	has	have	VHZ
304953	100736333	20992740798	been	be	VBN
304953	100736333	20992740799	a	a	AT1
304953	100736333	20992740800	mainstay	mainstay	NN1
304953	100736333	20992740801	of	of	IO
304953	100736333	20992740802	treating	treat	VVG
304953	100736333	20992740803	advanced	advanced	JJ
304953	100736333	20992740804	prostate	prostate	NN1
304953	100736333	20992740805	cancer	cancer	NN1
304953	100736333	20992740806	since	since	CS_II@
304953	100736333	20992740807	the	the	AT
304953	100736333	20992740808	1970s	1970s	MC2
304953	100736333	20992740809	.	.	.
304953	100736333	20992740810	This	this	DD1
304953	100736333	20992740811	approach	approach	NN1
304953	100736333	20992740812	is	be	VBZ
304953	100736333	20992740813	called	call	VVN
304953	100736333	20992740814	androgen-deprivation		JJ_NN1
304953	100736333	20992740815	therapy	therapy	NN1
304953	100736333	20992740816	(	(	(
304953	100736333	20992740817	ADT	adt	NP1
304953	100736333	20992740818	)	)	)
304953	100736333	20992740819	because	because	CS
304953	100736333	20992740820	it	it	PPH1
304953	100736333	20992740821	cuts	cut	VVZ
304953	100736333	20992740822	off	off	II_RP
304953	100736333	20992740823	the	the	AT
304953	100736333	20992740824	supply	supply	NN1
304953	100736333	20992740825	of	of	IO
304953	100736333	20992740826	testosterone	testosterone	NN1
304953	100736333	20992740827	to	to	II
304953	100736333	20992740828	prostate	prostate	NN1
304953	100736333	20992740829	cancer	cancer	NN1
304953	100736333	20992740830	cells	cell	NN2
304953	100736333	20992740831	and	and	CC
304953	100736333	20992740832	the	the	AT
304953	100736333	20992740833	rest	rest	NN1
304953	100736333	20992740834	of	of	IO
304953	100736333	20992740835	the	the	AT
304953	100736333	20992740836	body	body	NN1
304953	100736333	20992740837	.	.	.
304953	100736333	20992740838	<p>		NULL
304953	100736333	20992740839	In	in	II
304953	100736333	20992740840	men	man	NN2
304953	100736333	20992740841	with	with	IW
304953	100736333	20992740842	cancer	cancer	NN1
304953	100736333	20992740843	that	that	CST_DD1
304953	100736333	20992740844	has	have	VHZ
304953	100736333	20992740845	spread	spread	VVN
304953	100736333	20992740846	beyond	beyond	II
304953	100736333	20992740847	the	the	AT
304953	100736333	20992740848	prostate	prostate	NN1
304953	100736333	20992740849	gland	gland	NN1
304953	100736333	20992740850	,	,	,
304953	100736333	20992740851	radiation	radiation	NN1
304953	100736333	20992740852	therapy	therapy	NN1
304953	100736333	20992740853	plus	plus	II
304953	100736333	20992740854	ADT	adt	NP1
304953	100736333	20992740855	can	can	VM
304953	100736333	20992740856	ease	ease	VVI
304953	100736333	20992740857	symptoms	symptom	NN2
304953	100736333	20992740858	and	and	CC
304953	100736333	20992740859	improve	improve	VVI
304953	100736333	20992740860	survival	survival	NN1
304953	100736333	20992740861	.	.	.
304953	100736333	20992740862	But	but	CCB
304953	100736333	20992740863	some	some	DD
304953	100736333	20992740864	doctors	doctor	NN2
304953	100736333	20992740865	give	give	VV0
304953	100736333	20992740866	ADT	adt	NP1
304953	100736333	20992740867	by	by	II
304953	100736333	20992740868	itself	itself	PPX1
304953	100736333	20992740869	to	to	II
304953	100736333	20992740870	millions	million	NNO2
304953	100736333	20992740871	of	of	IO
304953	100736333	20992740872	men	man	NN2
304953	100736333	20992740873	with	with	IW
304953	100736333	20992740874	localized	localized	JJ
304953	100736333	20992740875	tumors	tumor	NN2
304953	100736333	20992740876	that	that	CST_DD1
304953	100736333	20992740877	have n't		VV0_NN1
304953	100736333	20992740878	spread	spread	NN1_VVN_VVD_VV0
304953	100736333	20992740879	beyond	beyond	II
304953	100736333	20992740880	the	the	AT
304953	100736333	20992740881	prostate	prostate	NN1
304953	100736333	20992740882	.	.	.
304953	100736333	20992740883	Some	some	DD
304953	100736333	20992740884	experts	expert	NN2
304953	100736333	20992740885	see	see	VV0
304953	100736333	20992740886	this	this	DD1
304953	100736333	20992740887	as	as	II_CSA
304953	100736333	20992740888	an	a	AT1
304953	100736333	20992740889	alarming	alarming	JJ
304953	100736333	20992740890	trend	trend	NN1
304953	100736333	20992740891	because	because	CS
304953	100736333	20992740892	ADTs		NP2
304953	100736333	20992740893	side	side	NN1
304953	100736333	20992740894	effects	effect	NN2
304953	100736333	20992740895	can	can	VM
304953	100736333	20992740896	include	include	VVI
304953	100736333	20992740897	impotence	impotence	NN1
304953	100736333	20992740898	,	,	,
304953	100736333	20992740899	bone	bone	NN1
304953	100736333	20992740900	fractures	fracture	NN2
304953	100736333	20992740901	,	,	,
304953	100736333	20992740902	weight	weight	NN1
304953	100736333	20992740903	gain	gain	NN1_VV0
304953	100736333	20992740904	,	,	,
304953	100736333	20992740905	diabetes	diabetes	NN1
304953	100736333	20992740906	,	,	,
304953	100736333	20992740907	and	and	CC
304953	100736333	20992740908	heart	heart	NN1
304953	100736333	20992740909	disease	disease	NN1
304953	100736333	20992740910	.	.	.
304953	100736333	20992740911	Guidelines	guideline	NN2
304953	100736333	20992740912	for	for	IF
304953	100736333	20992740913	treating	treat	VVG
304953	100736333	20992740914	prostate	prostate	NN1
304953	100736333	20992740915	cancer	cancer	NN1
304953	100736333	20992740916	have	have	VH0
304953	100736333	20992740917	never	never	RR
304953	100736333	20992740918	supported	support	VVN
304953	100736333	20992740919	the	the	AT
304953	100736333	20992740920	use	use	NN1
304953	100736333	20992740921	of	of	IO
304953	100736333	20992740922	ADT	adt	NP1
304953	100736333	20992740923	for	for	IF
304953	100736333	20992740924	early-stage	early-stage	NN1_JJ
304953	100736333	20992740925	(	(	(
304953	100736333	20992740926	localized	localized	JJ
304953	100736333	20992740927	)	)	)
304953	100736333	20992740928	prostate	prostate	NN1
304953	100736333	20992740929	cancer	cancer	NN1
304953	100736333	20992740930	.	.	.
304953	100736333	20992740931	<p>		NULL
304953	100736333	20992740932	A	a	AT1_ZZ1
304953	100736333	20992740933	new	new	JJ
304953	100736333	20992740934	study	study	NN1
304953	100736333	20992740935	out	out	II21
304953	100736333	20992740936	of	of	II22
304953	100736333	20992740937	Rutgers	rutgers	NP1
304953	100736333	20992740938	University	university	NN1
304953	100736333	20992740939	shows	show	VVZ
304953	100736333	20992740940	that	that	CST
304953	100736333	20992740941	men	man	NN2
304953	100736333	20992740942	with	with	IW
304953	100736333	20992740943	localized	localized	JJ
304953	100736333	20992740944	prostate	prostate	NN1
304953	100736333	20992740945	cancer	cancer	NN1
304953	100736333	20992740946	do	do	VD0
304953	100736333	20992740947	n't 	n't	XX
304953	100736333	20992740948	live	live	VVI
304953	100736333	20992740949	longer	long	RRR_JJR
304953	100736333	20992740950	if	if	CS
304953	100736333	20992740951	they 're		NN1
304953	100736333	20992740952	treated	treat	VVN
304953	100736333	20992740953	with	with	IW
304953	100736333	20992740954	ADT	adt	NP1
304953	100736333	20992740955	@		II
304953	100736333	20992740956	@		II
304953	100736333	20992740957	@		II
304953	100736333	20992740958	@		II
304953	100736333	20992740959	@		II
304953	100736333	20992740960	@		II
304953	100736333	20992740961	@		II
304953	100736333	20992740962	@		II
304953	100736333	20992740963	@		II
304953	100736333	20992740964	@		II
304953	100736333	20992740965	Rutgers	rutgers	NP1
304953	100736333	20992740966	Cancer	cancer	NN1
304953	100736333	20992740967	Institute	institute	NN1
304953	100736333	20992740968	of	of	IO
304953	100736333	20992740969	New	new	NP1
304953	100736333	20992740970	Jersey	jersey	NP1
304953	100736333	20992740971	,	,	,
304953	100736333	20992740972	told	tell	VVD
304953	100736333	20992740973	me	me	PPIO1
304953	100736333	20992740974	that	that	DD1_CST
304953	100736333	20992740975	for	for	IF
304953	100736333	20992740976	these	these	DD2
304953	100736333	20992740977	men	man	NN2
304953	100736333	20992740978	,	,	,
304953	100736333	20992740979	"	"	"
304953	100736333	20992740980	ADT	adt	NP1
304953	100736333	20992740981	will	will	VM
304953	100736333	20992740982	not	not	XX
304953	100736333	20992740983	be	be	VBI
304953	100736333	20992740984	beneficial	beneficial	JJ
304953	100736333	20992740985	"	"	"
304953	100736333	20992740986	with	with	II31
304953	100736333	20992740987	respect	respect	II32
304953	100736333	20992740988	to	to	II33
304953	100736333	20992740989	survival	survival	NN1
304953	100736333	20992740990	benefits	benefit	NN2
304953	100736333	20992740991	.	.	.
304953	100736333	20992740992	The	the	AT
304953	100736333	20992740993	study	study	NN1
304953	100736333	20992740994	was	be	VBDZ
304953	100736333	20992740995	published	publish	VVN
304953	100736333	20992740996	online	online	RR_JJ
304953	100736333	20992740997	in	in	II
304953	100736333	20992740998	JAMA	jama	NP1
304953	100736333	20992740999	Internal	internal	JJ
304953	100736333	20992741000	Medicine	medicine	NN1
304953	100736333	20992741001	.	.	.
304953	100736333	20992741002	<p>		NULL
304953	100736333	20992741003	Lu-Yao		NP1_JJ
304953	100736333	20992741004	and	and	CC
304953	100736333	20992741005	her	her	APPGE
304953	100736333	20992741006	colleagues	colleague	NN2
304953	100736333	20992741007	studied	study	VVD_VVN
304953	100736333	20992741008	more	more	DAR
304953	100736333	20992741009	than	than	CSN
304953	100736333	20992741010	66,000	66,000	MC
304953	100736333	20992741011	men	man	NN2
304953	100736333	20992741012	aged	aged	II
304953	100736333	20992741013	66	66	MC
304953	100736333	20992741014	years	year	NNT2
304953	100736333	20992741015	or	or	CC
304953	100736333	20992741016	older	old	JJR
304953	100736333	20992741017	who	who	PNQS
304953	100736333	20992741018	were	be	VBDR
304953	100736333	20992741019	diagnosed	diagnose	VVN
304953	100736333	20992741020	with	with	IW
304953	100736333	20992741021	localized	localized	JJ
304953	100736333	20992741022	prostate	prostate	NN1
304953	100736333	20992741023	cancer	cancer	NN1
304953	100736333	20992741024	between	between	II
304953	100736333	20992741025	1992	1992	MC
304953	100736333	20992741026	and	and	CC
304953	100736333	20992741027	2009	2009	MC
304953	100736333	20992741028	.	.	.
304953	100736333	20992741029	The	the	AT
304953	100736333	20992741030	researchers	researcher	NN2
304953	100736333	20992741031	followed	follow	VVD_VVN
304953	100736333	20992741032	the	the	AT
304953	100736333	20992741033	mens	mens	NN2
304953	100736333	20992741034	health	health	NN1
304953	100736333	20992741035	and	and	CC
304953	100736333	20992741036	survival	survival	NN1
304953	100736333	20992741037	using	use	VVG
304953	100736333	20992741038	records	record	NN2
304953	100736333	20992741039	maintained	maintain	VVN
304953	100736333	20992741040	by	by	II
304953	100736333	20992741041	the	the	AT
304953	100736333	20992741042	National	national	JJ
304953	100736333	20992741043	Cancer	cancer	NN1
304953	100736333	20992741044	Institute	institute	NN1
304953	100736333	20992741045	and	and	CC
304953	100736333	20992741046	the	the	AT
304953	100736333	20992741047	Center	center	NN1
304953	100736333	20992741048	for	for	IF
304953	100736333	20992741049	Medicare	medicare	NP1
304953	100736333	20992741050	and	and	CC
304953	100736333	20992741051	Medicaid	medicaid	NP1_VVD_JJ@
304953	100736333	20992741052	Services	service	NN2
304953	100736333	20992741053	.	.	.
304953	100736333	20992741054	Men	man	NN2
304953	100736333	20992741055	who	who	PNQS
304953	100736333	20992741056	got	get	VVD
304953	100736333	20992741057	ADT	adt	NP1
304953	100736333	20992741058	did	do	VDD
304953	100736333	20992741059	not	not	XX
304953	100736333	20992741060	live	live	VVI
304953	100736333	20992741061	any	any	RR21
304953	100736333	20992741062	longer	long	RR22
304953	100736333	20992741063	than	than	CSN
304953	100736333	20992741064	men	man	NN2
304953	100736333	20992741065	who	who	PNQS
304953	100736333	20992741066	did	do	VDD
304953	100736333	20992741067	not	not	XX
304953	100736333	20992741068	get	get	VVI
304953	100736333	20992741069	hormone	hormone	NN1
304953	100736333	20992741070	therapy	therapy	NN1
304953	100736333	20992741071	.	.	.
304953	100736333	20992741072	<p>		NULL
304953	100736333	20992741073	At	at	II
304953	100736333	20992741074	110	110	MC
304953	100736333	20992741075	months	month	NNT2
304953	100736333	20992741076	,	,	,
304953	100736333	20992741077	the	the	AT
304953	100736333	20992741078	new	new	JJ
304953	100736333	20992741079	studys		NN2
304953	100736333	20992741080	average	average	VV0@_JJ
304953	100736333	20992741081	follow-up	follow-up	JJ_NN1
304953	100736333	20992741082	time	time	NNT1
304953	100736333	20992741083	was	be	VBDZ
304953	100736333	20992741084	significantly	significantly	RR
304953	100736333	20992741085	longer	long	RRR_JJR
304953	100736333	20992741086	than	than	CSN
304953	100736333	20992741087	previous	previous	JJ
304953	100736333	20992741088	investigations	investigation	NN2
304953	100736333	20992741089	that	that	CST
304953	100736333	20992741090	reached	reach	VVD
304953	100736333	20992741091	the	the	AT
304953	100736333	20992741092	same	same	DA
304953	100736333	20992741093	conclusion	conclusion	NN1
304953	100736333	20992741094	.	.	.
304953	100736333	20992741095	For	for	REX21
304953	100736333	20992741096	instance	instance	REX22
304953	100736333	20992741097	,	,	,
304953	100736333	20992741098	after	after	II
304953	100736333	20992741099	reviewing	review	VVG
304953	100736333	20992741100	records	record	NN2
304953	100736333	20992741101	from	from	II
304953	100736333	20992741102	15,170		MC
304953	100736333	20992741103	men	man	NN2
304953	100736333	20992741104	diagnosed	diagnose	VVN_VVD
304953	100736333	20992741105	with	with	IW
304953	100736333	20992741106	localized	localized	JJ
304953	100736333	20992741107	prostate	prostate	NN1
304953	100736333	20992741108	cancer	cancer	NN1
304953	100736333	20992741109	between	between	II
304953	100736333	20992741110	1995	1995	MC
304953	100736333	20992741111	and	and	CC
304953	100736333	20992741112	2008	2008	MC
304953	100736333	20992741113	,	,	,
304953	100736333	20992741114	investigators	investigator	NN2
304953	100736333	20992741115	from	from	II
304953	100736333	20992741116	Georgetown	georgetown	NP1
304953	100736333	20992741117	University	university	NN1
304953	100736333	20992741118	Medical	medical	JJ
304953	100736333	20992741119	Center	center	NN1
304953	100736333	20992741120	in	in	II
304953	100736333	20992741121	Washington	washington	NP1
304953	100736333	20992741122	,	,	,
304953	100736333	20992741123	DC	dc	NP1
304953	100736333	20992741124	,	,	,
304953	100736333	20992741125	saw	see	VVD
304953	100736333	20992741126	no	no	AT
304953	100736333	20992741127	survival	survival	NN1
304953	100736333	20992741128	advantage	advantage	NN1
304953	100736333	20992741129	among	among	II
304953	100736333	20992741130	men	man	NN2
304953	100736333	20992741131	treated	treat	VVN
304953	100736333	20992741132	with	with	IW
304953	100736333	20992741133	ADT	adt	NP1
304953	100736333	20992741134	.	.	.
304953	100736333	20992741135	Writing	write	VVG_NN1
304953	100736333	20992741136	in	in	II
304953	100736333	20992741137	the	the	AT
304953	100736333	20992741138	Journal	journal	NN1
304953	100736333	20992741139	of	of	IO
304953	100736333	20992741140	Clinical	clinical	JJ
304953	100736333	20992741141	Oncology	oncology	NN1_NP1
304953	100736333	20992741142	,	,	,
304953	100736333	20992741143	the	the	AT
304953	100736333	20992741144	researchers	researcher	NN2
304953	100736333	20992741145	did	do	VDD
304953	100736333	20992741146	suggest	suggest	VVI
304953	100736333	20992741147	that	that	CST
304953	100736333	20992741148	men	man	NN2
304953	100736333	20992741149	with	with	IW
304953	100736333	20992741150	more	more	RGR_DAR
304953	100736333	20992741151	aggressive	aggressive	JJ
304953	100736333	20992741152	tumors	tumor	NN2
304953	100736333	20992741153	might	might	VM
304953	100736333	20992741154	benefit	benefit	VVI
304953	100736333	20992741155	@		II
304953	100736333	20992741156	@		II
304953	100736333	20992741157	@		II
304953	100736333	20992741158	@		II
304953	100736333	20992741159	@		II
304953	100736333	20992741160	@		II
304953	100736333	20992741161	@		II
304953	100736333	20992741162	@		II
304953	100736333	20992741163	@		II
304953	100736333	20992741164	@		II
304953	100736333	20992741165	.	.	.
304953	100736333	20992741166	<p>		NULL
304953	100736333	20992741167	Why	why	RRQ
304953	100736333	20992741168	might	might	VM
304953	100736333	20992741169	a	a	AT1
304953	100736333	20992741170	doctor	doctor	NN1
304953	100736333	20992741171	prescribe	prescribe	VVI
304953	100736333	20992741172	ADT	adt	NP1
304953	100736333	20992741173	for	for	IF
304953	100736333	20992741174	a	a	AT1
304953	100736333	20992741175	man	man	NN1
304953	100736333	20992741176	with	with	IW
304953	100736333	20992741177	localized	localized	JJ
304953	100736333	20992741178	prostate	prostate	NN1
304953	100736333	20992741179	cancer	cancer	NN1
304953	100736333	20992741180	even	even	CS21
304953	100736333	20992741181	though	though	CS22
304953	100736333	20992741182	there 's		NN2
304953	100736333	20992741183	little	little	JJ
304953	100736333	20992741184	evidence	evidence	NN1
304953	100736333	20992741185	to	to	TO
304953	100736333	20992741186	support	support	VVI
304953	100736333	20992741187	this	this	DD1
304953	100736333	20992741188	approach	approach	NN1
304953	100736333	20992741189	?	?	?
304953	100736333	20992741190	ADT	adt	NP1
304953	100736333	20992741191	might	might	VM
304953	100736333	20992741192	look	look	VVI
304953	100736333	20992741193	like	like	II_CS
304953	100736333	20992741194	a	a	AT1
304953	100736333	20992741195	proactive	proactive	JJ
304953	100736333	20992741196	step	step	NN1
304953	100736333	20992741197	for	for	IF
304953	100736333	20992741198	a	a	AT1
304953	100736333	20992741199	man	man	NN1
304953	100736333	20992741200	who	who	PNQS
304953	100736333	20992741201	wants	want	VVZ
304953	100736333	20992741202	to	to	TO
304953	100736333	20992741203	pursue	pursue	VVI
304953	100736333	20992741204	all	all	DB
304953	100736333	20992741205	available	available	JJ
304953	100736333	20992741206	options	option	NN2
304953	100736333	20992741207	.	.	.
304953	100736333	20992741208	And	and	CC
304953	100736333	20992741209	even	even	CS21
304953	100736333	20992741210	though	though	CS22
304953	100736333	20992741211	survival	survival	NN1
304953	100736333	20992741212	may	may	VM
304953	100736333	20992741213	not	not	XX
304953	100736333	20992741214	be	be	VBI
304953	100736333	20992741215	affected	affect	VVN
304953	100736333	20992741216	,	,	,
304953	100736333	20992741217	doctors	doctor	NN2
304953	100736333	20992741218	may	may	VM
304953	100736333	20992741219	have	have	VHI
304953	100736333	20992741220	other	other	JJ
304953	100736333	20992741221	reasons	reason	NN2
304953	100736333	20992741222	for	for	IF
304953	100736333	20992741223	considering	consider	VVG_II
304953	100736333	20992741224	ADT	adt	NP1
304953	100736333	20992741225	,	,	,
304953	100736333	20992741226	especially	especially	RR
304953	100736333	20992741227	for	for	IF
304953	100736333	20992741228	older	old	JJR
304953	100736333	20992741229	men	man	NN2
304953	100736333	20992741230	who	who	PNQS
304953	100736333	20992741231	may	may	VM
304953	100736333	20992741232	be	be	VBI
304953	100736333	20992741233	too	too	RG
304953	100736333	20992741234	i 'll		JJ
304953	100736333	20992741235	to	to	TO
304953	100736333	20992741236	undergo	undergo	VVI
304953	100736333	20992741237	surgery	surgery	NN1
304953	100736333	20992741238	to	to	TO
304953	100736333	20992741239	remove	remove	VVI
304953	100736333	20992741240	the	the	AT
304953	100736333	20992741241	prostate	prostate	NN1
304953	100736333	20992741242	,	,	,
304953	100736333	20992741243	or	or	CC
304953	100736333	20992741244	who	who	PNQS
304953	100736333	20992741245	may	may	VM
304953	100736333	20992741246	have	have	VHI
304953	100736333	20992741247	other	other	JJ
304953	100736333	20992741248	reasons	reason	NN2
304953	100736333	20992741249	for	for	IF
304953	100736333	20992741250	not	not	XX
304953	100736333	20992741251	undergoing	undergo	VVG
304953	100736333	20992741252	radiation	radiation	NN1
304953	100736333	20992741253	therapy	therapy	NN1
304953	100736333	20992741254	.	.	.
304953	100736333	20992741255	<p>		NULL
304953	100736333	20992741256	"	"	"
304953	100736333	20992741257	In	in	II
304953	100736333	20992741258	these	these	DD2
304953	100736333	20992741259	instances	instance	NN2
304953	100736333	20992741260	,	,	,
304953	100736333	20992741261	ADT	adt	NP1
304953	100736333	20992741262	can	can	VM
304953	100736333	20992741263	help	help	VVI
304953	100736333	20992741264	with	with	IW
304953	100736333	20992741265	urinary	urinary	JJ
304953	100736333	20992741266	difficulties	difficulty	NN2
304953	100736333	20992741267	or	or	CC
304953	100736333	20992741268	to	to	TO
304953	100736333	20992741269	shrink	shrink	VVI
304953	100736333	20992741270	the	the	AT
304953	100736333	20992741271	prostate	prostate	NN1
304953	100736333	20992741272	before	before	II_CS
304953	100736333	20992741273	other	other	JJ
304953	100736333	20992741274	therapies	therapy	NN2
304953	100736333	20992741275	,	,	,
304953	100736333	20992741276	"	"	"
304953	100736333	20992741277	says	say	VVZ
304953	100736333	20992741278	prostate	prostate	NN1
304953	100736333	20992741279	cancer	cancer	NN1
304953	100736333	20992741280	specialist	specialist	NN1
304953	100736333	20992741281	Dr.		NNB
304953	100736333	20992741282	Marc	marc	NP1
304953	100736333	20992741283	B.		NP1
304953	100736333	20992741284	Garnick		NP1
304953	100736333	20992741285	,	,	,
304953	100736333	20992741286	the	the	AT
304953	100736333	20992741287	Gorman	gorman	NN1_NP1
304953	100736333	20992741288	Brothers	brother	NN2
304953	100736333	20992741289	Professor	professor	NN1
304953	100736333	20992741290	of	of	IO
304953	100736333	20992741291	Medicine	medicine	NN1
304953	100736333	20992741292	at	at	II
304953	100736333	20992741293	Harvard	harvard	NP1
304953	100736333	20992741294	Medical	medical	JJ
304953	100736333	20992741295	School	school	NN1
304953	100736333	20992741296	and	and	CC
304953	100736333	20992741297	Beth	beth	NP1
304953	100736333	20992741298	Israel	israel	NP1
304953	100736333	20992741299	Deaconess	deaconess	NN1
304953	100736333	20992741300	Medical	medical	JJ
304953	100736333	20992741301	Center	center	NN1
304953	100736333	20992741302	,	,	,
304953	100736333	20992741303	and	and	CC
304953	100736333	20992741304	Editor	editor	NN1
304953	100736333	20992741305	in	in	II
304953	100736333	20992741306	Chief	chief	NN1
304953	100736333	20992741307	of	of	IO
304953	100736333	20992741308	Harvard	harvard	NP1
304953	100736333	20992741309	Medical	medical	JJ
304953	100736333	20992741310	Schools	school	NN2
304953	100736333	20992741311	2014	2014	MC
304953	100736333	20992741312	Annual	annual	JJ
304953	100736333	20992741313	Report	report	NN1
304953	100736333	20992741314	on	on	II
304953	100736333	20992741315	Prostate	prostate	NN1
304953	100736333	20992741316	Diseases	disease	NN2
304953	100736333	20992741317	.	.	.
304953	100736338	20992741337	@@##	----------	----------
304953	100736338	20992741338	@@100736338		FO
304953	100736338	20992741339	@4936338/		VV0_NN1
304953	100736338	20992741340	46989		MC
304953	100736338	20992741341	@qwx906989		FO
304953	100736338	20992741342	<p>		NULL
304953	100736338	20992741343	Health	health	NN1
304953	100736338	20992741344	myths	myth	NN2
304953	100736338	20992741345	die	die	VV0
304953	100736338	20992741346	hard	hard	RR_JJ
304953	100736338	20992741347	.	.	.
304953	100736338	20992741348	A	a	AT1_ZZ1
304953	100736338	20992741349	recent	recent	JJ
304953	100736338	20992741350	article	article	NN1
304953	100736338	20992741351	on	on	II
304953	100736338	20992741352	healthy	healthy	JJ
304953	100736338	20992741353	aging	aging	NN1
304953	100736338	20992741354	in	in	II
304953	100736338	20992741355	the	the	AT
304953	100736338	20992741356	Washington	washington	NP1
304953	100736338	20992741357	Post	post	NN1
304953	100736338	20992741358	suggested	suggest	VVD_VVN
304953	100736338	20992741359	that	that	CST_DD1
304953	100736338	20992741360	taking	take	VVG_JJ%
304953	100736338	20992741361	vitamin	vitamin	NN1
304953	100736338	20992741362	E	e	ZZ1
304953	100736338	20992741363	can	can	VM
304953	100736338	20992741364	help	help	VVI
304953	100736338	20992741365	men	man	NN2
304953	100736338	20992741366	prevent	prevent	VVI
304953	100736338	20992741367	prostate	prostate	NN1
304953	100736338	20992741368	and	and	CC
304953	100736338	20992741369	other	other	JJ
304953	100736338	20992741370	cancers	cancer	NN2
304953	100736338	20992741371	.	.	.
304953	100736338	20992741372	That	that	DD1
304953	100736338	20992741373	certainly	certainly	RR
304953	100736338	20992741374	is n't		VV0
304953	100736338	20992741375	what	what	DDQ
304953	100736338	20992741376	the	the	AT
304953	100736338	20992741377	evidence	evidence	NN1
304953	100736338	20992741378	shows	show	NN2_VVZ
304953	100736338	20992741379	.	.	.
304953	100736338	20992741380	In	in	II
304953	100736338	20992741381	fact	fact	NN1
304953	100736338	20992741382	,	,	,
304953	100736338	20992741383	a	a	AT1
304953	100736338	20992741384	key	key	JJ
304953	100736338	20992741385	clinical	clinical	JJ
304953	100736338	20992741386	trial	trial	NN1
304953	100736338	20992741387	of	of	IO
304953	100736338	20992741388	vitamin	vitamin	NN1
304953	100736338	20992741389	E	e	ZZ1_NP1@
304953	100736338	20992741390	was	be	VBDZ
304953	100736338	20992741391	stopped	stop	VVN
304953	100736338	20992741392	early	early	RR
304953	100736338	20992741393	because	because	CS
304953	100736338	20992741394	it	it	PPH1
304953	100736338	20992741395	showed	show	VVD
304953	100736338	20992741396	that	that	CST_DD1
304953	100736338	20992741397	taking	take	VVG
304953	100736338	20992741398	a	a	AT1
304953	100736338	20992741399	vitamin	vitamin	NN1
304953	100736338	20992741400	E	e	ZZ1
304953	100736338	20992741401	supplement	supplement	NN1_VV0
304953	100736338	20992741402	failed	fail	VVD_VVN
304953	100736338	20992741403	to	to	TO
304953	100736338	20992741404	prevent	prevent	VVI
304953	100736338	20992741405	prostate	prostate	NN1
304953	100736338	20992741406	cancer	cancer	NN1
304953	100736338	20992741407	and	and	CC
304953	100736338	20992741408	could	could	VM
304953	100736338	20992741409	"	"	"
304953	100736338	20992741410	emphasis	emphasis	NN1
304953	100736338	20992741411	on	on	II_RP@
304953	100736338	20992741412	could	could	VM
304953	100736338	20992741413	"	"	"
304953	100736338	20992741414	promote	promote	VV0
304953	100736338	20992741415	prostate	prostate	NN1
304953	100736338	20992741416	cancer	cancer	NN1
304953	100736338	20992741417	.	.	.
304953	100736338	20992741418	<p>		NULL
304953	100736338	20992741419	Early	early	JJ
304953	100736338	20992741420	cell	cell	NN1
304953	100736338	20992741421	culture	culture	NN1
304953	100736338	20992741422	and	and	CC
304953	100736338	20992741423	animal	animal	NN1
304953	100736338	20992741424	studies	study	NN2
304953	100736338	20992741425	put	put	VV0_VVD_VVN
304953	100736338	20992741426	a	a	AT1
304953	100736338	20992741427	spotlight	spotlight	NN1
304953	100736338	20992741428	on	on	II
304953	100736338	20992741429	vitamin	vitamin	NN1
304953	100736338	20992741430	E.		NP1_ND1@
304953	100736338	20992741431	Under	under	II_RG@
304953	100736338	20992741432	controlled	controlled	JJ@
304953	100736338	20992741433	conditions	condition	NN2
304953	100736338	20992741434	,	,	,
304953	100736338	20992741435	it	it	PPH1
304953	100736338	20992741436	was	be	VBDZ
304953	100736338	20992741437	shown	show	VVN
304953	100736338	20992741438	to	to	TO
304953	100736338	20992741439	slow	slow	VVI
304953	100736338	20992741440	prostate	prostate	NN1
304953	100736338	20992741441	cancer	cancer	NN1
304953	100736338	20992741442	growth	growth	NN1
304953	100736338	20992741443	.	.	.
304953	100736338	20992741444	But	but	CCB
304953	100736338	20992741445	as	as	CSA
304953	100736338	20992741446	is	be	VBZ
304953	100736338	20992741447	so	so	RG
304953	100736338	20992741448	often	often	RR
304953	100736338	20992741449	the	the	AT
304953	100736338	20992741450	case	case	NN1
304953	100736338	20992741451	in	in	II
304953	100736338	20992741452	medical	medical	JJ
304953	100736338	20992741453	research	research	NN1
304953	100736338	20992741454	,	,	,
304953	100736338	20992741455	these	these	DD2
304953	100736338	20992741456	results	result	NN2
304953	100736338	20992741457	have n't		VV0_NN1
304953	100736338	20992741458	held	hold	VVN_VVD
304953	100736338	20992741459	up	up	RP
304953	100736338	20992741460	in	in	II
304953	100736338	20992741461	humans	human	NN2
304953	100736338	20992741462	.	.	.
304953	100736338	20992741463	<p>		NULL
304953	100736338	20992741464	Back	back	NN1_RP
304953	100736338	20992741465	in	in	II
304953	100736338	20992741466	1998	1998	MC
304953	100736338	20992741467	,	,	,
304953	100736338	20992741468	the	the	AT
304953	100736338	20992741469	Alpha-Tocopherol		NP1
304953	100736338	20992741470	,	,	,
304953	100736338	20992741471	Beta-Carotene		NP1
304953	100736338	20992741472	(	(	(
304953	100736338	20992741473	ATBC		NP1
304953	100736338	20992741474	)	)	)
304953	100736338	20992741475	Cancer	cancer	NN1
304953	100736338	20992741476	Prevention	prevention	NN1
304953	100736338	20992741477	Trial	trial	NN1
304953	100736338	20992741478	raised	raise	VVD_VVN_JJ@
304953	100736338	20992741479	hopes	hope	NN2_VVZ
304953	100736338	20992741480	that	that	CST
304953	100736338	20992741481	taking	take	VVG_JJ%
304953	100736338	20992741482	vitamin	vitamin	NN1
304953	100736338	20992741483	E	e	ZZ1
304953	100736338	20992741484	supplements	supplement	NN2
304953	100736338	20992741485	could	could	VM
304953	100736338	20992741486	lower	lower	VVI
304953	100736338	20992741487	prostate	prostate	NN1
304953	100736338	20992741488	cancer	cancer	NN1
304953	100736338	20992741489	risk	risk	NN1
304953	100736338	20992741490	.	.	.
304953	100736338	20992741491	(	(	(
304953	100736338	20992741492	Alpha-tocopherol		NN1
304953	100736338	20992741493	is	be	VBZ
304953	100736338	20992741494	the	the	AT
304953	100736338	20992741495	most	most	RGT
304953	100736338	20992741496	active	active	JJ
304953	100736338	20992741497	of	of	IO
304953	100736338	20992741498	the	the	AT
304953	100736338	20992741499	eight	eight	MC
304953	100736338	20992741500	naturally	naturally	RR
304953	100736338	20992741501	occurring	occur	VVG_JJ@
304953	100736338	20992741502	forms	form	NN2
304953	100736338	20992741503	of	of	IO
304953	100736338	20992741504	vitamin	vitamin	NN1
304953	100736338	20992741505	E.		NP1
304953	100736338	20992741506	)	)	)
304953	100736338	20992741507	The	the	AT
304953	100736338	20992741508	trial	trial	NN1
304953	100736338	20992741509	found	find	VVD_VVN
304953	100736338	20992741510	that	that	CST
304953	100736338	20992741511	men	man	NN2
304953	100736338	20992741512	who	who	PNQS
304953	100736338	20992741513	took	take	VVD
304953	100736338	20992741514	daily	daily	RR_JJ
304953	100736338	20992741515	alpha-tocopherol		JJ_NN1
304953	100736338	20992741516	supplements	supplement	NN2
304953	100736338	20992741517	experienced	experience	VVD_VVN
304953	100736338	20992741518	32%		NNU
304953	100736338	20992741519	fewer	fewer	DAR
304953	100736338	20992741520	prostate	prostate	NN1
304953	100736338	20992741521	cancer	cancer	NN1
304953	100736338	20992741522	diagnoses	diagnosis	NN2_VVZ
304953	100736338	20992741523	and	and	CC
304953	100736338	20992741524	41%		NNU
304953	100736338	20992741525	fewer	fewer	DAR
304953	100736338	20992741526	prostate	prostate	NN1
304953	100736338	20992741527	cancer	cancer	NN1
304953	100736338	20992741528	deaths	death	NN2
304953	100736338	20992741529	@		II
304953	100736338	20992741530	@		II
304953	100736338	20992741531	@		II
304953	100736338	20992741532	@		II
304953	100736338	20992741533	@		II
304953	100736338	20992741534	@		II
304953	100736338	20992741535	@		II
304953	100736338	20992741536	@		II
304953	100736338	20992741537	@		II
304953	100736338	20992741538	@		II
304953	100736338	20992741539	these	these	DD2
304953	100736338	20992741540	results	result	NN2
304953	100736338	20992741541	were	be	VBDR
304953	100736338	20992741542	n't	n't	XX
304953	100736338	20992741543	considered	consider	VVN
304953	100736338	20992741544	conclusive	conclusive	JJ
304953	100736338	20992741545	.	.	.
304953	100736338	20992741546	That 's		NN2_VVZ_NP1@
304953	100736338	20992741547	because	because	CS
304953	100736338	20992741548	the	the	AT
304953	100736338	20992741549	ATBC		NN1_NP1
304953	100736338	20992741550	trial	trial	NN1
304953	100736338	20992741551	was	be	VBDZ
304953	100736338	20992741552	n't	n't	XX
304953	100736338	20992741553	specifically	specifically	RR
304953	100736338	20992741554	designed	design	VVN_VVD
304953	100736338	20992741555	to	to	TO
304953	100736338	20992741556	evaluate	evaluate	VVI
304953	100736338	20992741557	prostate	prostate	NN1
304953	100736338	20992741558	cancer	cancer	NN1
304953	100736338	20992741559	risk	risk	NN1
304953	100736338	20992741560	,	,	,
304953	100736338	20992741561	and	and	CC
304953	100736338	20992741562	almost	almost	RR
304953	100736338	20992741563	all	all	DB
304953	100736338	20992741564	of	of	IO
304953	100736338	20992741565	the	the	AT
304953	100736338	20992741566	participants	participant	NN2
304953	100736338	20992741567	were	be	VBDR
304953	100736338	20992741568	Caucasian	caucasian	JJ
304953	100736338	20992741569	smokers	smoker	NN2
304953	100736338	20992741570	.	.	.
304953	100736338	20992741571	<p>		NULL
304953	100736338	20992741572	To	to	TO
304953	100736338	20992741573	clarify	clarify	VVI
304953	100736338	20992741574	the	the	AT
304953	100736338	20992741575	ATBC		NN1_NP1
304953	100736338	20992741576	results	result	NN2
304953	100736338	20992741577	,	,	,
304953	100736338	20992741578	the	the	AT
304953	100736338	20992741579	Selenium	selenium	NN1_NP1
304953	100736338	20992741580	and	and	CC
304953	100736338	20992741581	Vitamin	vitamin	NN1
304953	100736338	20992741582	E	e	ZZ1
304953	100736338	20992741583	Cancer	cancer	NN1
304953	100736338	20992741584	Prevention	prevention	NN1
304953	100736338	20992741585	Trial	trial	NN1
304953	100736338	20992741586	(	(	(
304953	100736338	20992741587	SELECT	select	VV0_JJ
304953	100736338	20992741588	)	)	)
304953	100736338	20992741589	was	be	VBDZ
304953	100736338	20992741590	specifically	specifically	RR
304953	100736338	20992741591	designed	design	VVN_VVD
304953	100736338	20992741592	to	to	TO
304953	100736338	20992741593	assess	assess	VVI
304953	100736338	20992741594	the	the	AT
304953	100736338	20992741595	effect	effect	NN1
304953	100736338	20992741596	of	of	IO
304953	100736338	20992741597	supplemental	supplemental	JJ
304953	100736338	20992741598	vitamin	vitamin	NN1
304953	100736338	20992741599	E	e	ZZ1
304953	100736338	20992741600	on	on	II
304953	100736338	20992741601	prostate	prostate	NN1
304953	100736338	20992741602	cancer	cancer	NN1
304953	100736338	20992741603	risk	risk	NN1
304953	100736338	20992741604	.	.	.
304953	100736338	20992741605	As	as	CSA_II@
304953	100736338	20992741606	its	its	APPGE
304953	100736338	20992741607	name	name	NN1
304953	100736338	20992741608	suggests	suggest	VVZ
304953	100736338	20992741609	,	,	,
304953	100736338	20992741610	SELECT	select	VV0
304953	100736338	20992741611	also	also	RR
304953	100736338	20992741612	looked	look	VVN_VVD
304953	100736338	20992741613	at	at	II
304953	100736338	20992741614	whether	whether	CSW
304953	100736338	20992741615	another	another	DD1
304953	100736338	20992741616	antioxidant	antioxidant	JJ_NN1
304953	100736338	20992741617	nutrient	nutrient	NN1
304953	100736338	20992741618	,	,	,
304953	100736338	20992741619	selenium	selenium	NN1
304953	100736338	20992741620	,	,	,
304953	100736338	20992741621	affects	affect	VVZ
304953	100736338	20992741622	cancer	cancer	NN1
304953	100736338	20992741623	risk	risk	NN1
304953	100736338	20992741624	.	.	.
304953	100736338	20992741625	All	all	DB
304953	100736338	20992741626	of	of	IO
304953	100736338	20992741627	the	the	AT
304953	100736338	20992741628	35,533		MC
304953	100736338	20992741629	participants	participant	NN2
304953	100736338	20992741630	were	be	VBDR
304953	100736338	20992741631	men	man	NN2
304953	100736338	20992741632	aged	aged	II
304953	100736338	20992741633	50	50	MC
304953	100736338	20992741634	who	who	PNQS
304953	100736338	20992741635	did	do	VDD
304953	100736338	20992741636	not	not	XX
304953	100736338	20992741637	have	have	VHI
304953	100736338	20992741638	prostate	prostate	NN1
304953	100736338	20992741639	cancer	cancer	NN1
304953	100736338	20992741640	,	,	,
304953	100736338	20992741641	and	and	CC
304953	100736338	20992741642	nearly	nearly	RR
304953	100736338	20992741643	one	one	MC1
304953	100736338	20992741644	quarter	quarter	NN1
304953	100736338	20992741645	were	be	VBDR
304953	100736338	20992741646	minorities	minority	NN2_NNU
304953	100736338	20992741647	.	.	.
304953	100736338	20992741648	Participants	participant	NN2
304953	100736338	20992741649	were	be	VBDR
304953	100736338	20992741650	randomly	randomly	RR
304953	100736338	20992741651	assigned	assign	VVN
304953	100736338	20992741652	to	to	TO
304953	100736338	20992741653	take	take	VVI
304953	100736338	20992741654	daily	daily	JJ
304953	100736338	20992741655	pills	pill	NN2
304953	100736338	20992741656	that	that	CST
304953	100736338	20992741657	contained	contain	VVD_JJ@
304953	100736338	20992741658	alpha-tocopherol		NN1_JJ
304953	100736338	20992741659	,	,	,
304953	100736338	20992741660	selenium	selenium	NN1
304953	100736338	20992741661	,	,	,
304953	100736338	20992741662	both	both	RR_DB2
304953	100736338	20992741663	,	,	,
304953	100736338	20992741664	or	or	CC
304953	100736338	20992741665	neither	neither	RR_DD1
304953	100736338	20992741666	.	.	.
304953	100736338	20992741667	The	the	AT
304953	100736338	20992741668	trial	trial	NN1
304953	100736338	20992741669	was	be	VBDZ
304953	100736338	20992741670	initially	initially	RR
304953	100736338	20992741671	planned	plan	VVN_VVD
304953	100736338	20992741672	to	to	TO
304953	100736338	20992741673	continue	continue	VVI
304953	100736338	20992741674	for	for	IF
304953	100736338	20992741675	12	12	MC
304953	100736338	20992741676	years	year	NNT2
304953	100736338	20992741677	,	,	,
304953	100736338	20992741678	with	with	IW
304953	100736338	20992741679	five	five	MC
304953	100736338	20992741680	scheduled	scheduled	JJ
304953	100736338	20992741681	interim	interim	JJ_NN1
304953	100736338	20992741682	analyses	analysis	NN2_VVZ
304953	100736338	20992741683	.	.	.
304953	100736338	20992741684	<p>		NULL
304953	100736338	20992741685	At	at	II
304953	100736338	20992741686	the	the	AT
304953	100736338	20992741687	second	second	MD
304953	100736338	20992741688	interim	interim	JJ_NN1
304953	100736338	20992741689	analysis	analysis	NN1
304953	100736338	20992741690	in	in	II
304953	100736338	20992741691	September	september	NPM1
304953	100736338	20992741692	2008	2008	MC
304953	100736338	20992741693	,	,	,
304953	100736338	20992741694	the	the	AT
304953	100736338	20992741695	trial	trial	NN1
304953	100736338	20992741696	's	's	GE
304953	100736338	20992741697	Data	data	NN
304953	100736338	20992741698	and	and	CC
304953	100736338	20992741699	Safety	safety	NN1
304953	100736338	20992741700	Monitoring	monitoring	NN1
304953	100736338	20992741701	Committee	committee	NN1
304953	100736338	20992741702	concluded	conclude	VVD_VVN
304953	100736338	20992741703	that	that	CST_DD1
304953	100736338	20992741704	neither	neither	RR
304953	100736338	20992741705	vitamin	vitamin	NN1
304953	100736338	20992741706	E	e	ZZ1
304953	100736338	20992741707	nor	nor	CC
304953	100736338	20992741708	selenium	selenium	NN1
304953	100736338	20992741709	"	"	"
304953	100736338	20992741710	alone	alone	RR_JJ
304953	100736338	20992741711	or	or	CC
304953	100736338	20992741712	in	in	II
304953	100736338	20992741713	combination	combination	NN1
304953	100736338	20992741714	"	"	"
304953	100736338	20992741715	offered	offer	VVD_VVN_JJ@
304953	100736338	20992741716	protection	protection	NN1
304953	100736338	20992741717	against	against	II
304953	100736338	20992741718	prostate	prostate	NN1
304953	100736338	20992741719	cancer	cancer	NN1
304953	100736338	20992741720	.	.	.
304953	100736338	20992741721	In	in	II
304953	100736338	20992741722	fact	fact	NN1
304953	100736338	20992741723	,	,	,
304953	100736338	20992741724	the	the	AT
304953	100736338	20992741725	monitoring	monitoring	NN1
304953	100736338	20992741726	committee	committee	NN1
304953	100736338	20992741727	noted	note	VVD_VVN
304953	100736338	20992741728	that	that	CST
304953	100736338	20992741729	@		II
304953	100736338	20992741730	@		II
304953	100736338	20992741731	@		II
304953	100736338	20992741732	@		II
304953	100736338	20992741733	@		II
304953	100736338	20992741734	@		II
304953	100736338	20992741735	@		II
304953	100736338	20992741736	@		II
304953	100736338	20992741737	@		II
304953	100736338	20992741738	@		II
304953	100736338	20992741739	was	be	VBDZ
304953	100736338	20992741740	slightly	slightly	RR
304953	100736338	20992741741	higher	high	JJR
304953	100736338	20992741742	than	than	CSN
304953	100736338	20992741743	the	the	AT
304953	100736338	20992741744	rates	rate	NN2
304953	100736338	20992741745	in	in	II
304953	100736338	20992741746	the	the	AT
304953	100736338	20992741747	other	other	JJ_NN1@
304953	100736338	20992741748	three	three	MC
304953	100736338	20992741749	groups	group	NN2
304953	100736338	20992741750	.	.	.
304953	100736338	20992741751	The	the	AT
304953	100736338	20992741752	difference	difference	NN1
304953	100736338	20992741753	was	be	VBDZ
304953	100736338	20992741754	not	not	XX
304953	100736338	20992741755	statistically	statistically	RR
304953	100736338	20992741756	significant	significant	JJ
304953	100736338	20992741757	,	,	,
304953	100736338	20992741758	meaning	mean	VVG
304953	100736338	20992741759	it	it	PPH1
304953	100736338	20992741760	might	might	VM
304953	100736338	20992741761	have	have	VHI
304953	100736338	20992741762	been	be	VBN
304953	100736338	20992741763	due	due	II21
304953	100736338	20992741764	to	to	II22
304953	100736338	20992741765	chance	chance	NN1
304953	100736338	20992741766	,	,	,
304953	100736338	20992741767	but	but	CCB
304953	100736338	20992741768	the	the	AT
304953	100736338	20992741769	trend	trend	NN1
304953	100736338	20992741770	was	be	VBDZ
304953	100736338	20992741771	worrisome	worrisome	JJ
304953	100736338	20992741772	.	.	.
304953	100736338	20992741773	The	the	AT
304953	100736338	20992741774	committee	committee	NN1
304953	100736338	20992741775	decided	decide	VVD_VVN
304953	100736338	20992741776	to	to	TO
304953	100736338	20992741777	stop	stop	VVI
304953	100736338	20992741778	the	the	AT
304953	100736338	20992741779	trial	trial	NN1
304953	100736338	20992741780	early	early	RR_JJ
304953	100736338	20992741781	,	,	,
304953	100736338	20992741782	and	and	CC
304953	100736338	20992741783	participants	participant	NN2
304953	100736338	20992741784	were	be	VBDR
304953	100736338	20992741785	told	tell	VVN
304953	100736338	20992741786	to	to	TO
304953	100736338	20992741787	stop	stop	VVI
304953	100736338	20992741788	taking	take	VVG
304953	100736338	20992741789	their	their	APPGE
304953	100736338	20992741790	supplements	supplement	NN2
304953	100736338	20992741791	in	in	II
304953	100736338	20992741792	October	october	NPM1
304953	100736338	20992741793	2008	2008	MC
304953	100736338	20992741794	.	.	.
304953	100736338	20992741795	<p>		NULL
304953	100736338	20992741796	SELECT	select	JJ_VV0
304953	100736338	20992741797	had	have	VHD_VHN@
304953	100736338	20992741798	some	some	DD
304953	100736338	20992741799	limitations	limitation	NN2
304953	100736338	20992741800	.	.	.
304953	100736338	20992741801	For	for	REX21
304953	100736338	20992741802	example	example	REX22
304953	100736338	20992741803	,	,	,
304953	100736338	20992741804	the	the	AT
304953	100736338	20992741805	researchers	researcher	NN2
304953	100736338	20992741806	did	do	VDD
304953	100736338	20992741807	not	not	XX
304953	100736338	20992741808	test	test	VVI
304953	100736338	20992741809	different	different	JJ
304953	100736338	20992741810	doses	dose	NN2
304953	100736338	20992741811	or	or	CC
304953	100736338	20992741812	formulations	formulation	NN2
304953	100736338	20992741813	of	of	IO
304953	100736338	20992741814	vitamin	vitamin	NN1
304953	100736338	20992741815	E.-		NN1_JJ
304953	100736338	20992741816	But	but	CCB
304953	100736338	20992741817	SELECT	select	VV0_JJ
304953	100736338	20992741818	's	be	VBZ_GE
304953	100736338	20992741819	robust	robust	JJ
304953	100736338	20992741820	design	design	NN1
304953	100736338	20992741821	and	and	CC
304953	100736338	20992741822	large	large	JJ
304953	100736338	20992741823	number	number	NN1
304953	100736338	20992741824	of	of	IO
304953	100736338	20992741825	participants	participant	NN2
304953	100736338	20992741826	make	make	VV0
304953	100736338	20992741827	its	its	APPGE
304953	100736338	20992741828	results	result	NN2
304953	100736338	20992741829	trustworthy.		NNU
304953	100736338	20992741830	-	-	-
304953	100736338	20992741831	The	the	AT
304953	100736338	20992741832	results	result	NN2
304953	100736338	20992741833	are	be	VBR
304953	100736338	20992741834	also	also	RR
304953	100736338	20992741835	likely	likely	JJ
304953	100736338	20992741836	to	to	TO
304953	100736338	20992741837	be	be	VBI
304953	100736338	20992741838	widely	widely	RR
304953	100736338	20992741839	applicable	applicable	JJ
304953	100736338	20992741840	,	,	,
304953	100736338	20992741841	due	due	II21
304953	100736338	20992741842	to	to	II22
304953	100736338	20992741843	the	the	AT
304953	100736338	20992741844	trial	trial	NN1
304953	100736338	20992741845	's	's	GE
304953	100736338	20992741846	substantial	substantial	JJ
304953	100736338	20992741847	proportion	proportion	NN1
304953	100736338	20992741848	of	of	IO
304953	100736338	20992741849	non-white	non-white	JJ
304953	100736338	20992741850	men	man	NN2
304953	100736338	20992741851	and	and	CC
304953	100736338	20992741852	equal	equal	JJ
304953	100736338	20992741853	distribution	distribution	NN1
304953	100736338	20992741854	of	of	IO
304953	100736338	20992741855	prostate	prostate	NN1
304953	100736338	20992741856	cancer	cancer	NN1
304953	100736338	20992741857	risk	risk	NN1
304953	100736338	20992741858	factors	factor	NN2
304953	100736338	20992741859	across	across	II
304953	100736338	20992741860	all	all	DB
304953	100736338	20992741861	four	four	MC
304953	100736338	20992741862	study	study	NN1
304953	100736338	20992741863	groups	group	NN2
304953	100736338	20992741864	.	.	.
304953	100736338	20992741865	<p>		NULL
304953	100736338	20992741866	We	we	PPIS2
304953	100736338	20992741867	know	know	VV0
304953	100736338	20992741868	that	that	CST_DD1
304953	100736338	20992741869	eating	eat	VVG
304953	100736338	20992741870	a	a	AT1
304953	100736338	20992741871	healthy	healthy	JJ
304953	100736338	20992741872	,	,	,
304953	100736338	20992741873	balanced	balanced	JJ
304953	100736338	20992741874	diet	diet	NN1
304953	100736338	20992741875	can	can	VM
304953	100736338	20992741876	help	help	VVI
304953	100736338	20992741877	prevent	prevent	VVI
304953	100736338	20992741878	prostate	prostate	NN1
304953	100736338	20992741879	cancer	cancer	NN1
304953	100736338	20992741880	.	.	.
304953	100736338	20992741881	Based	base	VVN
304953	100736338	20992741882	on	on	II
304953	100736338	20992741883	the	the	AT
304953	100736338	20992741884	results	result	NN2
304953	100736338	20992741885	of	of	IO
304953	100736338	20992741886	the	the	AT
304953	100736338	20992741887	SELECT	select	JJ
304953	100736338	20992741888	trial	trial	NN1
304953	100736338	20992741889	,	,	,
304953	100736338	20992741890	I	i	PPIS1
304953	100736338	20992741891	strongly	strongly	RR
304953	100736338	20992741892	discourage	discourage	VV0
304953	100736338	20992741893	my	my	APPGE
304953	100736338	20992741894	patients	patient	NN2
304953	100736338	20992741895	from	from	II
304953	100736338	20992741896	taking	take	VVG
304953	100736338	20992741897	supplemental	supplemental	JJ
304953	100736338	20992741898	vitamin	vitamin	NN1
304953	100736338	20992741899	E	e	ZZ1
304953	100736338	20992741900	or	or	CC
304953	100736338	20992741901	selenium	selenium	NN1
304953	100736338	20992741902	.	.	.
304953	100736338	20992741903	Though	though	CS_RR@
304953	100736338	20992741904	surprised	surprised	JJ
304953	100736338	20992741905	,	,	,
304953	100736338	20992741906	nearly	nearly	RR
304953	100736338	20992741907	all	all	DB_RR@
304953	100736338	20992741908	heed	heed	VV0
304953	100736338	20992741909	this	this	DD1
304953	100736338	20992741910	advice	advice	NN1
304953	100736338	20992741911	and	and	CC
304953	100736338	20992741912	,	,	,
304953	100736338	20992741913	in	in	II
304953	100736338	20992741914	the	the	AT
304953	100736338	20992741915	process	process	NN1
304953	100736338	20992741916	,	,	,
304953	100736338	20992741917	many	many	DA2
304953	100736338	20992741918	become	become	VV0
304953	100736338	20992741919	more	more	RGR_DAR_RRR
304953	100736338	20992741920	educated	educated	JJ
304953	100736338	20992741921	consumers	consumer	NN2
304953	100736338	20992741922	of	of	IO
304953	100736338	20992741923	supplements	supplement	NN2
304953	100736338	20992741924	and	and	CC
304953	100736338	20992741925	neutraceuticals.		NNU
304953	100736338	20992741926	46996		MC
304953	100736338	20992741927	@qwx906996		FO
304953	100736339	20992741947	@@##	----------	----------
304953	100736339	20992741948	@@100736339		FO
304953	100736339	20992741949	@4936339/		VV0_NN1
304953	100736339	20992741950	46989		MC
304953	100736339	20992741951	@qwx906989		FO
304953	100736339	20992741952	<p>		NULL
304953	100736339	20992741953	After	after	CS_II
304953	100736339	20992741954	surgery	surgery	NN1
304953	100736339	20992741955	or	or	CC
304953	100736339	20992741956	radiation	radiation	NN1
304953	100736339	20992741957	therapy	therapy	NN1
304953	100736339	20992741958	for	for	IF
304953	100736339	20992741959	prostate	prostate	NN1
304953	100736339	20992741960	cancer	cancer	NN1
304953	100736339	20992741961	,	,	,
304953	100736339	20992741962	some	some	DD
304953	100736339	20992741963	men	man	NN2
304953	100736339	20992741964	get	get	VV0
304953	100736339	20992741965	an	a	AT1
304953	100736339	20992741966	unwelcome	unwelcome	JJ
304953	100736339	20992741967	surprise	surprise	NN1
304953	100736339	20992741968	"	"	"
304953	100736339	20992741969	a	a	AT1
304953	100736339	20992741970	sudden	sudden	JJ
304953	100736339	20992741971	spike	spike	NN1
304953	100736339	20992741972	in	in	II
304953	100736339	20992741973	the	the	AT
304953	100736339	20992741974	level	level	NN1
304953	100736339	20992741975	of	of	IO
304953	100736339	20992741976	prostate-specific	prostate-specific	JJ
304953	100736339	20992741977	antigen	antigen	NN1
304953	100736339	20992741978	(	(	(
304953	100736339	20992741979	PSA	psa	NP1
304953	100736339	20992741980	)	)	)
304953	100736339	20992741981	,	,	,
304953	100736339	20992741982	a	a	AT1
304953	100736339	20992741983	protein	protein	NN1
304953	100736339	20992741984	made	make	VVD_VVN
304953	100736339	20992741985	only	only	RR_JJ
304953	100736339	20992741986	by	by	II
304953	100736339	20992741987	prostate	prostate	NN1
304953	100736339	20992741988	cells	cell	NN2
304953	100736339	20992741989	.	.	.
304953	100736339	20992741990	It	it	PPH1
304953	100736339	20992741991	may	may	VM
304953	100736339	20992741992	be	be	VBI
304953	100736339	20992741993	an	a	AT1
304953	100736339	20992741994	entirely	entirely	RR
304953	100736339	20992741995	harmless	harmless	JJ
304953	100736339	20992741996	signal	signal	NN1
304953	100736339	20992741997	,	,	,
304953	100736339	20992741998	or	or	CC
304953	100736339	20992741999	it	it	PPH1
304953	100736339	20992742000	may	may	VM
304953	100736339	20992742001	mean	mean	VVI
304953	100736339	20992742002	the	the	AT
304953	100736339	20992742003	cancer	cancer	NN1
304953	100736339	20992742004	has	have	VHZ
304953	100736339	20992742005	n't 	n't	XX
304953	100736339	20992742006	been	be	VBN
304953	100736339	20992742007	entirely	entirely	RR
304953	100736339	20992742008	eradicated	eradicate	VVN_VVD
304953	100736339	20992742009	and	and	CC
304953	100736339	20992742010	is	be	VBZ
304953	100736339	20992742011	beginning	begin	VVG
304953	100736339	20992742012	to	to	TO
304953	100736339	20992742013	regrow	regrow	VVI
304953	100736339	20992742014	.	.	.
304953	100736339	20992742015	Some	some	DD
304953	100736339	20992742016	men	man	NN2
304953	100736339	20992742017	want	want	VV0
304953	100736339	20992742018	to	to	TO
304953	100736339	20992742019	start	start	VVI
304953	100736339	20992742020	hormone	hormone	NN1
304953	100736339	20992742021	treatment	treatment	NN1
304953	100736339	20992742022	immediately	immediately	RR
304953	100736339	20992742023	,	,	,
304953	100736339	20992742024	others	others	NN2
304953	100736339	20992742025	are	be	VBR
304953	100736339	20992742026	okay	okay	JJ
304953	100736339	20992742027	waiting	waiting	NN1@_VVG
304953	100736339	20992742028	for	for	IF
304953	100736339	20992742029	other	other	JJ
304953	100736339	20992742030	signs	sign	NN2
304953	100736339	20992742031	like	like	II
304953	100736339	20992742032	the	the	AT
304953	100736339	20992742033	appearance	appearance	NN1
304953	100736339	20992742034	of	of	IO
304953	100736339	20992742035	prostate	prostate	NN1
304953	100736339	20992742036	cancer	cancer	NN1
304953	100736339	20992742037	symptoms	symptom	NN2
304953	100736339	20992742038	.	.	.
304953	100736339	20992742039	A	a	AT1
304953	100736339	20992742040	study	study	NN1
304953	100736339	20992742041	presented	present	VVD_VVN
304953	100736339	20992742042	this	this	DD1
304953	100736339	20992742043	week	week	NNT1
304953	100736339	20992742044	at	at	II
304953	100736339	20992742045	the	the	AT
304953	100736339	20992742046	American	american	JJ
304953	100736339	20992742047	Society	society	NN1
304953	100736339	20992742048	of	of	IO
304953	100736339	20992742049	Clinical	clinical	JJ
304953	100736339	20992742050	Oncologys		NN2_NP1
304953	100736339	20992742051	(	(	(
304953	100736339	20992742052	ASCO	asco	NP1
304953	100736339	20992742053	)	)	)
304953	100736339	20992742054	annual	annual	JJ
304953	100736339	20992742055	meeting	meeting	NN1
304953	100736339	20992742056	in	in	II
304953	100736339	20992742057	Chicago	chicago	NP1
304953	100736339	20992742058	indicates	indicate	VVZ
304953	100736339	20992742059	that	that	CST_DD1
304953	100736339	20992742060	waiting	wait	VVG_NN1@
304953	100736339	20992742061	for	for	IF
304953	100736339	20992742062	up	up	RG21
304953	100736339	20992742063	to	to	RG22
304953	100736339	20992742064	two	two	MC
304953	100736339	20992742065	years	year	NNT2
304953	100736339	20992742066	poses	pose	VVZ
304953	100736339	20992742067	little	little	DA1_JJ_RR
304953	100736339	20992742068	risk	risk	NN1_VV0
304953	100736339	20992742069	to	to	II
304953	100736339	20992742070	survival	survival	NN1
304953	100736339	20992742071	.	.	.
304953	100736339	20992742072	<p>		NULL
304953	100736339	20992742073	Since	since	CS
304953	100736339	20992742074	PSA	psa	NP1
304953	100736339	20992742075	is	be	VBZ
304953	100736339	20992742076	made	make	VVN
304953	100736339	20992742077	only	only	RR_JJ
304953	100736339	20992742078	by	by	II
304953	100736339	20992742079	prostate	prostate	NN1
304953	100736339	20992742080	cells	cell	NN2
304953	100736339	20992742081	,	,	,
304953	100736339	20992742082	there	there	RL_EX
304953	100736339	20992742083	should n't		NN1
304953	100736339	20992742084	be	be	VBI
304953	100736339	20992742085	any	any	DD_RR%
304953	100736339	20992742086	in	in	II
304953	100736339	20992742087	the	the	AT
304953	100736339	20992742088	bloodstream	bloodstream	NN1
304953	100736339	20992742089	after	after	II_CS
304953	100736339	20992742090	a	a	AT1
304953	100736339	20992742091	radical	radical	JJ_NN1
304953	100736339	20992742092	prostatectomy	prostatectomy	NN1
304953	100736339	20992742093	,	,	,
304953	100736339	20992742094	the	the	AT
304953	100736339	20992742095	operation	operation	NN1
304953	100736339	20992742096	done	do	VDN
304953	100736339	20992742097	to	to	TO
304953	100736339	20992742098	remove	remove	VVI
304953	100736339	20992742099	a	a	AT1
304953	100736339	20992742100	cancerous	cancerous	JJ
304953	100736339	20992742101	prostate	prostate	NN1
304953	100736339	20992742102	gland	gland	NN1
304953	100736339	20992742103	.	.	.
304953	100736339	20992742104	There	there	EX
304953	100736339	20992742105	may	may	VM
304953	100736339	20992742106	be	be	VBI
304953	100736339	20992742107	a	a	AT1
304953	100736339	20992742108	small	small	JJ
304953	100736339	20992742109	amount	amount	NN1
304953	100736339	20992742110	in	in	II
304953	100736339	20992742111	the	the	AT
304953	100736339	20992742112	bloodstream	bloodstream	NN1
304953	100736339	20992742113	after	after	II_CS
304953	100736339	20992742114	radiation	radiation	NN1
304953	100736339	20992742115	treatment	treatment	NN1
304953	100736339	20992742116	,	,	,
304953	100736339	20992742117	which	which	DDQ
304953	100736339	20992742118	can	can	VM
304953	100736339	20992742119	leave	leave	VVI
304953	100736339	20992742120	small	small	JJ
304953	100736339	20992742121	amounts	amount	NN2
304953	100736339	20992742122	of	of	IO
304953	100736339	20992742123	the	the	AT
304953	100736339	20992742124	prostate	prostate	NN1
304953	100736339	20992742125	intact	intact	JJ
304953	100736339	20992742126	.	.	.
304953	100736339	20992742127	When	when	CS
304953	100736339	20992742128	a	a	AT1
304953	100736339	20992742129	mans	man	NN2
304953	100736339	20992742130	PSA	psa	NP1
304953	100736339	20992742131	level	level	NN1_JJ
304953	100736339	20992742132	rises	rise	VVZ_NN2
304953	100736339	20992742133	above	above	II
304953	100736339	20992742134	a	a	AT1
304953	100736339	20992742135	predefined	predefined	JJ@
304953	100736339	20992742136	threshold	threshold	NN1
304953	100736339	20992742137	but	but	CCB
304953	100736339	20992742138	he	he	PPHS1
304953	100736339	20992742139	@		II
304953	100736339	20992742140	@		II
304953	100736339	20992742141	@		II
304953	100736339	20992742142	@		II
304953	100736339	20992742143	@		II
304953	100736339	20992742144	@		II
304953	100736339	20992742145	@		II
304953	100736339	20992742146	@		II
304953	100736339	20992742147	@		II
304953	100736339	20992742148	@		II
304953	100736339	20992742149	cancer	cancer	NN1
304953	100736339	20992742150	,	,	,
304953	100736339	20992742151	he	he	PPHS1
304953	100736339	20992742152	is	be	VBZ
304953	100736339	20992742153	said	say	VVN@
304953	100736339	20992742154	to	to	TO
304953	100736339	20992742155	be	be	VBI
304953	100736339	20992742156	experiencing	experience	VVG
304953	100736339	20992742157	a	a	AT1
304953	100736339	20992742158	PSA-only		JJ
304953	100736339	20992742159	relapse	relapse	NN1
304953	100736339	20992742160	,	,	,
304953	100736339	20992742161	sometimes	sometimes	RT
304953	100736339	20992742162	called	call	VVN_VVD@
304953	100736339	20992742163	a	a	AT1
304953	100736339	20992742164	biochemical	biochemical	JJ
304953	100736339	20992742165	relapse	relapse	NN1
304953	100736339	20992742166	.	.	.
304953	100736339	20992742167	Doctors	doctor	NN2
304953	100736339	20992742168	have	have	VH0
304953	100736339	20992742169	traditionally	traditionally	RR
304953	100736339	20992742170	treated	treat	VVN
304953	100736339	20992742171	these	these	DD2
304953	100736339	20992742172	men	man	NN2
304953	100736339	20992742173	with	with	IW
304953	100736339	20992742174	hormone	hormone	NN1
304953	100736339	20992742175	therapy	therapy	NN1
304953	100736339	20992742176	to	to	TO
304953	100736339	20992742177	deprive	deprive	VVI
304953	100736339	20992742178	prostate	prostate	NN1
304953	100736339	20992742179	cancer	cancer	NN1
304953	100736339	20992742180	cells	cell	NN2
304953	100736339	20992742181	of	of	IO
304953	100736339	20992742182	growth-fueling		JJ_NN1
304953	100736339	20992742183	testosterone	testosterone	NN1
304953	100736339	20992742184	.	.	.
304953	100736339	20992742185	The	the	AT
304953	100736339	20992742186	downside	downside	NN1
304953	100736339	20992742187	is	be	VBZ
304953	100736339	20992742188	that	that	DD1_CST
304953	100736339	20992742189	hormone	hormone	NN1
304953	100736339	20992742190	therapy	therapy	NN1
304953	100736339	20992742191	has	have	VHZ
304953	100736339	20992742192	significant	significant	JJ
304953	100736339	20992742193	side	side	NN1
304953	100736339	20992742194	effects	effect	NN2
304953	100736339	20992742195	,	,	,
304953	100736339	20992742196	including	including	II_VVG@
304953	100736339	20992742197	difficulty	difficulty	NN1
304953	100736339	20992742198	getting	get	VVG
304953	100736339	20992742199	or	or	CC
304953	100736339	20992742200	keeping	keep	VVG
304953	100736339	20992742201	an	a	AT1
304953	100736339	20992742202	erection	erection	NN1
304953	100736339	20992742203	,	,	,
304953	100736339	20992742204	hot	hot	JJ
304953	100736339	20992742205	flashes	flash	NN2
304953	100736339	20992742206	,	,	,
304953	100736339	20992742207	fatigue	fatigue	NN1
304953	100736339	20992742208	,	,	,
304953	100736339	20992742209	or	or	CC
304953	100736339	20992742210	breast	breast	NN1
304953	100736339	20992742211	tenderness	tenderness	NN1
304953	100736339	20992742212	or	or	CC
304953	100736339	20992742213	pain	pain	NN1
304953	100736339	20992742214	.	.	.
304953	100736339	20992742215	<p>		NULL
304953	100736339	20992742216	Since	since	CS
304953	100736339	20992742217	the	the	AT
304953	100736339	20992742218	reason	reason	NN1
304953	100736339	20992742219	for	for	IF
304953	100736339	20992742220	a	a	AT1
304953	100736339	20992742221	post-treatment	post-treatment	JJ_NN1
304953	100736339	20992742222	PSA	psa	NP1
304953	100736339	20992742223	spike	spike	NN1_VV0
304953	100736339	20992742224	is n't		NN1_VV0
304953	100736339	20992742225	always	always	RR
304953	100736339	20992742226	known	know	VVN
304953	100736339	20992742227	,	,	,
304953	100736339	20992742228	and	and	CC
304953	100736339	20992742229	since	since	CS_II@
304953	100736339	20992742230	hormone	hormone	NN1
304953	100736339	20992742231	therapy	therapy	NN1
304953	100736339	20992742232	has	have	VHZ
304953	100736339	20992742233	unwanted	unwanted	JJ
304953	100736339	20992742234	side	side	NN1
304953	100736339	20992742235	effects	effect	NN2
304953	100736339	20992742236	,	,	,
304953	100736339	20992742237	waiting	wait	VVG
304953	100736339	20992742238	before	before	II
304953	100736339	20992742239	starting	starting	NN1_VVG
304953	100736339	20992742240	may	may	VM
304953	100736339	20992742241	make	make	VVI
304953	100736339	20992742242	sense	sense	NN1
304953	100736339	20992742243	for	for	IF
304953	100736339	20992742244	some	some	DD
304953	100736339	20992742245	men	man	NN2
304953	100736339	20992742246	.	.	.
304953	100736339	20992742247	There	there	RL_EX
304953	100736339	20992742248	currently	currently	RR
304953	100736339	20992742249	are	be	VB0
304953	100736339	20992742250	n't 	n't	XX
304953	100736339	20992742251	any	any	DD
304953	100736339	20992742252	widely	widely	RR
304953	100736339	20992742253	accepted	accepted	JJ_VVN
304953	100736339	20992742254	guidelines	guideline	NN2
304953	100736339	20992742255	for	for	IF
304953	100736339	20992742256	when	when	RRQ
304953	100736339	20992742257	to	to	TO
304953	100736339	20992742258	start	start	VVI
304953	100736339	20992742259	hormone	hormone	NN1
304953	100736339	20992742260	therapy	therapy	NN1
304953	100736339	20992742261	among	among	II
304953	100736339	20992742262	the	the	AT
304953	100736339	20992742263	60,000	60,000	MC
304953	100736339	20992742264	U.S.	us	NP1
304953	100736339	20992742265	men	man	NN2
304953	100736339	20992742266	who	who	PNQS
304953	100736339	20992742267	have	have	VH0
304953	100736339	20992742268	PSA-only		JJ
304953	100736339	20992742269	relapses	relapse	NN2_VVZ
304953	100736339	20992742270	each	each	DD1
304953	100736339	20992742271	year	year	NNT1
304953	100736339	20992742272	.	.	.
304953	100736339	20992742273	<p>		NULL
304953	100736339	20992742274	Researchers	researcher	NN2
304953	100736339	20992742275	from	from	II
304953	100736339	20992742276	the	the	AT
304953	100736339	20992742277	Harvard	harvard	NP1
304953	100736339	20992742278	School	school	NN1
304953	100736339	20992742279	of	of	IO
304953	100736339	20992742280	Public	public	JJ_NN1
304953	100736339	20992742281	Health	health	NN1
304953	100736339	20992742282	and	and	CC
304953	100736339	20992742283	the	the	AT
304953	100736339	20992742284	University	university	NN1
304953	100736339	20992742285	of	of	IO
304953	100736339	20992742286	California	california	NP1
304953	100736339	20992742287	,	,	,
304953	100736339	20992742288	San	san	NP1
304953	100736339	20992742289	Francisco	francisco	NP1
304953	100736339	20992742290	studied	study	VVD
304953	100736339	20992742291	data	data	NN
304953	100736339	20992742292	from	from	II
304953	100736339	20992742293	about	about	RG
304953	100736339	20992742294	2,000	2,000	MC
304953	100736339	20992742295	men	man	NN2
304953	100736339	20992742296	with	with	IW
304953	100736339	20992742297	PSA-only		JJ
304953	100736339	20992742298	relapse	relapse	NN1
304953	100736339	20992742299	who	who	PNQS
304953	100736339	20992742300	were	be	VBDR
304953	100736339	20992742301	tracked	track	VVN@
304953	100736339	20992742302	in	in	II
304953	100736339	20992742303	a	a	AT1
304953	100736339	20992742304	national	national	JJ
304953	100736339	20992742305	prostate	prostate	NN1
304953	100736339	20992742306	cancer	cancer	NN1
304953	100736339	20992742307	registry	registry	NN1
304953	100736339	20992742308	.	.	.
304953	100736339	20992742309	Some	some	DD
304953	100736339	20992742310	of	of	IO
304953	100736339	20992742311	the	the	AT
304953	100736339	20992742312	men	man	NN2
304953	100736339	20992742313	chose	choose	VVD
304953	100736339	20992742314	to	to	TO
304953	100736339	20992742315	start	start	VVI
304953	100736339	20992742316	hormone	hormone	NN1
304953	100736339	20992742317	therapy	therapy	NN1
304953	100736339	20992742318	within	within	II
304953	100736339	20992742319	three	three	MC
304953	100736339	20992742320	months	month	NNT2
304953	100736339	20992742321	of	of	IO
304953	100736339	20992742322	learning	learn	VVG_NN1
304953	100736339	20992742323	about	about	II_RP@
304953	100736339	20992742324	a	a	AT1
304953	100736339	20992742325	PSA-only		JJ
304953	100736339	20992742326	relapse	relapse	NN1
304953	100736339	20992742327	,	,	,
304953	100736339	20992742328	while	while	CS
304953	100736339	20992742329	others	others	NN2
304953	100736339	20992742330	started	start	VVD
304953	100736339	20992742331	at	at	RR21
304953	100736339	20992742332	least	least	RR22
304953	100736339	20992742333	two	two	MC
304953	100736339	20992742334	years	year	NNT2
304953	100736339	20992742335	later	later	RRR
304953	100736339	20992742336	or	or	CC
304953	100736339	20992742337	when	when	RRQ_CS
304953	100736339	20992742338	evidence	evidence	NN1
304953	100736339	20992742339	@		II
304953	100736339	20992742340	@		II
304953	100736339	20992742341	@		II
304953	100736339	20992742342	@		II
304953	100736339	20992742343	@		II
304953	100736339	20992742344	@		II
304953	100736339	20992742345	@		II
304953	100736339	20992742346	@		II
304953	100736339	20992742347	@		II
304953	100736339	20992742348	@		II
304953	100736339	20992742349	,	,	,
304953	100736339	20992742350	principal	principal	JJ_NN1
304953	100736339	20992742351	investigator	investigator	NN1
304953	100736339	20992742352	Xabier		NP1_NN1
304953	100736339	20992742353	Garcia-De-Albeniz		NP1
304953	100736339	20992742354	,	,	,
304953	100736339	20992742355	a	a	AT1
304953	100736339	20992742356	research	research	NN1
304953	100736339	20992742357	associate	associate	NN1_VV0
304953	100736339	20992742358	at	at	II
304953	100736339	20992742359	the	the	AT
304953	100736339	20992742360	Harvard	harvard	NP1
304953	100736339	20992742361	School	school	NN1
304953	100736339	20992742362	of	of	IO
304953	100736339	20992742363	Public	public	JJ_NN1
304953	100736339	20992742364	Health	health	NN1
304953	100736339	20992742365	,	,	,
304953	100736339	20992742366	reported	report	VVD_VVN
304953	100736339	20992742367	no	no	AT
304953	100736339	20992742368	difference	difference	NN1
304953	100736339	20992742369	in	in	II
304953	100736339	20992742370	five-year	five-year	JJ
304953	100736339	20992742371	and	and	CC
304953	100736339	20992742372	10-year	10-year	JJ
304953	100736339	20992742373	overall	overall	JJ_NN1
304953	100736339	20992742374	survival	survival	NN1
304953	100736339	20992742375	rates	rate	NN2_VVZ@
304953	100736339	20992742376	between	between	II
304953	100736339	20992742377	men	man	NN2
304953	100736339	20992742378	waited	wait	VVD_VVN@
304953	100736339	20992742379	and	and	CC
304953	100736339	20992742380	those	those	DD2
304953	100736339	20992742381	who	who	PNQS
304953	100736339	20992742382	began	begin	VVD
304953	100736339	20992742383	hormone	hormone	NN1
304953	100736339	20992742384	therapy	therapy	NN1
304953	100736339	20992742385	immediately	immediately	RR
304953	100736339	20992742386	.	.	.
304953	100736339	20992742387	<p>		NULL
304953	100736339	20992742388	The	the	AT
304953	100736339	20992742389	main	main	JJ
304953	100736339	20992742390	shortcoming	shortcoming	NN1
304953	100736339	20992742391	of	of	IO
304953	100736339	20992742392	the	the	AT
304953	100736339	20992742393	study	study	NN1
304953	100736339	20992742394	is	be	VBZ
304953	100736339	20992742395	that	that	CST
304953	100736339	20992742396	men	man	NN2
304953	100736339	20992742397	werent		NN1
304953	100736339	20992742398	randomized	randomize	VVD_VVN@
304953	100736339	20992742399	to	to	II
304953	100736339	20992742400	either	either	DD1
304953	100736339	20992742401	approach	approach	NN1
304953	100736339	20992742402	.	.	.
304953	100736339	20992742403	That	that	DD1
304953	100736339	20992742404	means	mean	VVZ_NN
304953	100736339	20992742405	differences	difference	NN2
304953	100736339	20992742406	between	between	II
304953	100736339	20992742407	the	the	AT
304953	100736339	20992742408	two	two	MC
304953	100736339	20992742409	groups	group	NN2
304953	100736339	20992742410	could	could	VM
304953	100736339	20992742411	have	have	VHI
304953	100736339	20992742412	influenced	influence	VVN
304953	100736339	20992742413	the	the	AT
304953	100736339	20992742414	study	study	NN1
304953	100736339	20992742415	results	result	NN2
304953	100736339	20992742416	,	,	,
304953	100736339	20992742417	although	although	CS
304953	100736339	20992742418	Garcia-Albinez		NP1
304953	100736339	20992742419	said	say	VVD
304953	100736339	20992742420	efforts	effort	NN2
304953	100736339	20992742421	were	be	VBDR
304953	100736339	20992742422	made	make	VVN
304953	100736339	20992742423	to	to	TO
304953	100736339	20992742424	control	control	VVI
304953	100736339	20992742425	for	for	IF
304953	100736339	20992742426	that	that	DD1
304953	100736339	20992742427	possibility	possibility	NN1
304953	100736339	20992742428	.	.	.
304953	100736339	20992742429	<p>		NULL
304953	100736339	20992742430	Dr.		NNB
304953	100736339	20992742431	Clifford	clifford	NP1
304953	100736339	20992742432	Hudis	hudis	NP1
304953	100736339	20992742433	,	,	,
304953	100736339	20992742434	the	the	AT
304953	100736339	20992742435	president	president	NN1
304953	100736339	20992742436	of	of	IO
304953	100736339	20992742437	ASCO	asco	NP1_NN1
304953	100736339	20992742438	and	and	CC
304953	100736339	20992742439	chief	chief	NN1
304953	100736339	20992742440	of	of	IO
304953	100736339	20992742441	the	the	AT
304953	100736339	20992742442	breast	breast	NN1
304953	100736339	20992742443	cancer	cancer	NN1
304953	100736339	20992742444	service	service	NN1
304953	100736339	20992742445	at	at	II
304953	100736339	20992742446	Memorial	memorial	NN1
304953	100736339	20992742447	Sloan	sloan	NP1_NN1
304953	100736339	20992742448	Kettering	kettering	NP1
304953	100736339	20992742449	Cancer	cancer	NN1
304953	100736339	20992742450	Center	center	NN1
304953	100736339	20992742451	in	in	II
304953	100736339	20992742452	New	new	NP1
304953	100736339	20992742453	York	york	NP1
304953	100736339	20992742454	,	,	,
304953	100736339	20992742455	said	say	VVD
304953	100736339	20992742456	the	the	AT
304953	100736339	20992742457	study	study	NN1
304953	100736339	20992742458	provides	provide	VVZ
304953	100736339	20992742459	much-needed	much-needed	JJ
304953	100736339	20992742460	evidence	evidence	NN1
304953	100736339	20992742461	that	that	CST_DD1
304953	100736339	20992742462	delaying	delaying	NN1_VVG
304953	100736339	20992742463	treatment	treatment	NN1
304953	100736339	20992742464	can	can	VM
304953	100736339	20992742465	be	be	VBI
304953	100736339	20992742466	safe	safe	JJ
304953	100736339	20992742467	.	.	.
304953	100736339	20992742468	He	he	PPHS1
304953	100736339	20992742469	said	say	VVD
304953	100736339	20992742470	that	that	CST
304953	100736339	20992742471	men	man	NN2
304953	100736339	20992742472	with	with	IW
304953	100736339	20992742473	PSA-only		JJ
304953	100736339	20992742474	relapse	relapse	NN1
304953	100736339	20992742475	and	and	CC
304953	100736339	20992742476	their	their	APPGE
304953	100736339	20992742477	doctors	doctor	NN2
304953	100736339	20992742478	should	should	VM
304953	100736339	20992742479	take	take	VVI
304953	100736339	20992742480	these	these	DD2
304953	100736339	20992742481	results	result	NN2
304953	100736339	20992742482	into	into	II
304953	100736339	20992742483	consideration	consideration	NN1
304953	100736339	20992742484	when	when	CS
304953	100736339	20992742485	deciding	decide	VVG
304953	100736339	20992742486	whether	whether	CSW
304953	100736339	20992742487	,	,	,
304953	100736339	20992742488	or	or	CC
304953	100736339	20992742489	when	when	RRQ_CS
304953	100736339	20992742490	,	,	,
304953	100736339	20992742491	to	to	TO
304953	100736339	20992742492	begin	begin	VVI
304953	100736339	20992742493	hormone	hormone	NN1
304953	100736339	20992742494	therapy	therapy	NN1
304953	100736339	20992742495	.	.	.
304953	100736339	20992742496	<p>		NULL
304953	100736339	20992742497	The	the	AT
304953	100736339	20992742498	results	result	NN2
304953	100736339	20992742499	may	may	VM
304953	100736339	20992742500	not	not	XX
304953	100736339	20992742501	apply	apply	VVI
304953	100736339	20992742502	to	to	II
304953	100736339	20992742503	all	all	DB
304953	100736339	20992742504	men	man	NN2
304953	100736339	20992742505	with	with	IW
304953	100736339	20992742506	PSA-only		JJ
304953	100736339	20992742507	relapse	relapse	NN1
304953	100736339	20992742508	,	,	,
304953	100736339	20992742509	but	but	CCB
304953	100736339	20992742510	"	"	"
304953	100736339	20992742511	they	they	PPHS2
304953	100736339	20992742512	do	do	VD0
304953	100736339	20992742513	offer	offer	VVI
304953	100736339	20992742514	some	some	DD
304953	100736339	20992742515	encouraging	encouraging	JJ
304953	100736339	20992742516	news	news	NN1
304953	100736339	20992742517	to	to	II
304953	100736339	20992742518	the	the	AT
304953	100736339	20992742519	majority	majority	NN1
304953	100736339	20992742520	of	of	IO
304953	100736339	20992742521	men	man	NN2
304953	100736339	20992742522	who	who	PNQS
304953	100736339	20992742523	experience	experience	VV0
304953	100736339	20992742524	it	it	PPH1
304953	100736339	20992742525	,	,	,
304953	100736339	20992742526	"	"	"
304953	100736339	20992742527	added	add	VVD
304953	100736339	20992742528	Dr.		NNB
304953	100736339	20992742529	Marc	marc	NP1
304953	100736339	20992742530	B.		NP1
304953	100736339	20992742531	Garnick		NP1
304953	100736339	20992742532	,	,	,
304953	100736339	20992742533	a	a	AT1
304953	100736339	20992742534	clinical	clinical	JJ
304953	100736339	20992742535	professor	professor	NN1
304953	100736339	20992742536	of	of	IO
304953	100736339	20992742537	medicine	medicine	NN1
304953	100736339	20992742538	at	at	II
304953	100736339	20992742539	@		II
304953	100736339	20992742540	@		II
304953	100736339	20992742541	@		II
304953	100736339	20992742542	@		II
304953	100736339	20992742543	@		II
304953	100736339	20992742544	@		II
304953	100736339	20992742545	@		II
304953	100736339	20992742546	@		II
304953	100736339	20992742547	@		II
304953	100736339	20992742548	@		II
304953	100736339	20992742549	Medical	medical	JJ
304953	100736339	20992742550	Center	center	NN1
304953	100736339	20992742551	,	,	,
304953	100736339	20992742552	and	and	CC
304953	100736339	20992742553	editor	editor	NN1
304953	100736339	20992742554	in	in	II
304953	100736339	20992742555	chief	chief	NN1
304953	100736339	20992742556	of	of	IO
304953	100736339	20992742557	Harvard	harvard	NP1
304953	100736339	20992742558	Medical	medical	JJ
304953	100736339	20992742559	Schools	school	NN2
304953	100736339	20992742560	Annual	annual	JJ
304953	100736339	20992742561	Report	report	NN1
304953	100736339	20992742562	on	on	II
304953	100736339	20992742563	Prostate	prostate	NN1
304953	100736339	20992742564	Diseases	disease	NN2
304953	100736339	20992742565	.	.	.
304953	100736339	20992742566	In	in	II
304953	100736339	20992742567	many	many	DA2
304953	100736339	20992742568	cases	case	NN2
304953	100736339	20992742569	,	,	,
304953	100736339	20992742570	Garnick		NP1
304953	100736339	20992742571	pointed	point	VVD
304953	100736339	20992742572	out	out	RP
304953	100736339	20992742573	,	,	,
304953	100736339	20992742574	years	year	NNT2
304953	100736339	20992742575	will	will	VM
304953	100736339	20992742576	pass	pass	VVI
304953	100736339	20992742577	before	before	II_CS
304953	100736339	20992742578	any	any	DD
304953	100736339	20992742579	cancer	cancer	NN1
304953	100736339	20992742580	cells	cell	NN2
304953	100736339	20992742581	that	that	CST_DD1
304953	100736339	20992742582	might	might	VM
304953	100736339	20992742583	be	be	VBI
304953	100736339	20992742584	circulating	circulate	VVG
304953	100736339	20992742585	in	in	II
304953	100736339	20992742586	the	the	AT
304953	100736339	20992742587	body	body	NN1
304953	100736339	20992742588	form	form	NN1_VV0
304953	100736339	20992742589	tumors	tumor	NN2
304953	100736339	20992742590	that	that	CST_DD1
304953	100736339	20992742591	can	can	VM
304953	100736339	20992742592	damage	damage	VVI
304953	100736339	20992742593	health	health	NN1
304953	100736339	20992742594	.	.	.
304953	100736339	20992742595	<p>		NULL
304953	100736339	20992742596	But	but	CCB
304953	100736339	20992742597	Garnick		NP1_NN1
304953	100736339	20992742598	cautioned	caution	VVD
304953	100736339	20992742599	against	against	II
304953	100736339	20992742600	a	a	AT1
304953	100736339	20992742601	one-size-fits-all	one-size-fits-all	DB
304953	100736339	20992742602	approach	approach	NN1_VV0@
304953	100736339	20992742603	.	.	.
304953	100736339	20992742604	Immediate	immediate	JJ
304953	100736339	20992742605	hormone	hormone	NN1
304953	100736339	20992742606	therapy	therapy	NN1
304953	100736339	20992742607	is	be	VBZ
304953	100736339	20992742608	warranted	warrant	VVN
304953	100736339	20992742609	if	if	CS_CSW@
304953	100736339	20992742610	the	the	AT
304953	100736339	20992742611	relapse	relapse	NN1
304953	100736339	20992742612	occurs	occur	VVZ
304953	100736339	20992742613	soon	soon	RR
304953	100736339	20992742614	after	after	II_CS
304953	100736339	20992742615	primary	primary	JJ_NN1
304953	100736339	20992742616	treatment	treatment	NN1
304953	100736339	20992742617	,	,	,
304953	100736339	20992742618	if	if	CS
304953	100736339	20992742619	the	the	AT
304953	100736339	20992742620	PSA	psa	NP1
304953	100736339	20992742621	level	level	NN1
304953	100736339	20992742622	begins	begin	VVZ
304953	100736339	20992742623	doubling	double	VVG
304953	100736339	20992742624	quickly	quickly	RR
304953	100736339	20992742625	,	,	,
304953	100736339	20992742626	or	or	CC
304953	100736339	20992742627	if	if	CS_CSW@
304953	100736339	20992742628	the	the	AT
304953	100736339	20992742629	man	man	NN1
304953	100736339	20992742630	had	have	VHD
304953	100736339	20992742631	initially	initially	RR
304953	100736339	20992742632	been	be	VBN
304953	100736339	20992742633	treated	treat	VVN
304953	100736339	20992742634	for	for	IF
304953	100736339	20992742635	a	a	AT1
304953	100736339	20992742636	high-grade	high-grade	NN1_JJ
304953	100736339	20992742637	,	,	,
304953	100736339	20992742638	advanced	advanced	JJ_VVD
304953	100736339	20992742639	prostate	prostate	NN1
304953	100736339	20992742640	cancer	cancer	NN1
304953	100736339	20992742641	and	and	CC
304953	100736339	20992742642	PSA	psa	NP1
304953	100736339	20992742643	either	either	RR
304953	100736339	20992742644	never	never	RR
304953	100736339	20992742645	became	become	VVD
304953	100736339	20992742646	undetectable	undetectable	JJ
304953	100736339	20992742647	or	or	CC
304953	100736339	20992742648	started	start	VVD
304953	100736339	20992742649	to	to	TO
304953	100736339	20992742650	rise	rise	VVI
304953	100736339	20992742651	a	a	AT1
304953	100736339	20992742652	short	short	JJ
304953	100736339	20992742653	time	time	NNT1
304953	100736339	20992742654	after	after	II_CS
304953	100736339	20992742655	surgery	surgery	NN1
304953	100736339	20992742656	.	.	.
304953	100736339	20992742657	"	"	"
304953	100736339	20992742658	In	in	II
304953	100736339	20992742659	these	these	DD2
304953	100736339	20992742660	cases	case	NN2
304953	100736339	20992742661	,	,	,
304953	100736339	20992742662	I	i	PPIS1
304953	100736339	20992742663	prefer	prefer	VV0
304953	100736339	20992742664	to	to	TO
304953	100736339	20992742665	begin	begin	VVI
304953	100736339	20992742666	hormone	hormone	NN1
304953	100736339	20992742667	treatment	treatment	NN1
304953	100736339	20992742668	early	early	RR
304953	100736339	20992742669	on	on	RP@_II
304953	100736339	20992742670	,	,	,
304953	100736339	20992742671	"	"	"
304953	100736339	20992742672	Garnick		NP1
304953	100736339	20992742673	said	say	VVD
304953	100736339	20992742674	.	.	.
304953	100736342	20992742694	@@##	----------	----------
304953	100736342	20992742695	@@100736342		FO
304953	100736342	20992742696	@4936342/		VV0_NN1
304953	100736342	20992742697	46989		MC
304953	100736342	20992742698	@qwx906989		FO
304953	100736342	20992742699	<p>		NULL
304953	100736342	20992742700	In	in	II
304953	100736342	20992742701	the	the	AT
304953	100736342	20992742702	United	united	NP1
304953	100736342	20992742703	States	state	NP1
304953	100736342	20992742704	,	,	,
304953	100736342	20992742705	about	about	II
304953	100736342	20992742706	one	one	MC1
304953	100736342	20992742707	in	in	II
304953	100736342	20992742708	every	every	AT1
304953	100736342	20992742709	seven	seven	MC
304953	100736342	20992742710	men	man	NN2
304953	100736342	20992742711	chooses	choose	VVZ
304953	100736342	20992742712	to	to	TO
304953	100736342	20992742713	have	have	VHI
304953	100736342	20992742714	a	a	AT1
304953	100736342	20992742715	vasectomy	vasectomy	NN1
304953	100736342	20992742716	.	.	.
304953	100736342	20992742717	This	this	DD1
304953	100736342	20992742718	surgical	surgical	JJ
304953	100736342	20992742719	procedure	procedure	NN1
304953	100736342	20992742720	cuts	cut	NN2_VVZ
304953	100736342	20992742721	and	and	CC
304953	100736342	20992742722	seals	seal	VVZ_NN2
304953	100736342	20992742723	off	off	II_RP
304953	100736342	20992742724	the	the	AT
304953	100736342	20992742725	tubes	tube	NN2
304953	100736342	20992742726	that	that	CST
304953	100736342	20992742727	carry	carry	VV0
304953	100736342	20992742728	sperm	sperm	NN
304953	100736342	20992742729	from	from	II
304953	100736342	20992742730	the	the	AT
304953	100736342	20992742731	testes	teste	NN2
304953	100736342	20992742732	to	to	II
304953	100736342	20992742733	the	the	AT
304953	100736342	20992742734	penis	penis	NN1
304953	100736342	20992742735	.	.	.
304953	100736342	20992742736	Although	although	CS
304953	100736342	20992742737	vasectomy	vasectomy	NN1
304953	100736342	20992742738	is	be	VBZ
304953	100736342	20992742739	a	a	AT1
304953	100736342	20992742740	safe	safe	JJ
304953	100736342	20992742741	and	and	CC
304953	100736342	20992742742	effective	effective	JJ
304953	100736342	20992742743	form	form	NN1
304953	100736342	20992742744	of	of	IO
304953	100736342	20992742745	contraception	contraception	NN1
304953	100736342	20992742746	,	,	,
304953	100736342	20992742747	it	it	PPH1
304953	100736342	20992742748	now	now	RT
304953	100736342	20992742749	has	have	VHZ
304953	100736342	20992742750	some	some	DD
304953	100736342	20992742751	men	man	NN2
304953	100736342	20992742752	and	and	CC
304953	100736342	20992742753	their	their	APPGE
304953	100736342	20992742754	doctors	doctor	NN2
304953	100736342	20992742755	worried	worry	VVD@_VVN@_JJ
304953	100736342	20992742756	.	.	.
304953	100736342	20992742757	<p>		NULL
304953	100736342	20992742758	In	in	II
304953	100736342	20992742759	a	a	AT1
304953	100736342	20992742760	report	report	NN1
304953	100736342	20992742761	in	in	II
304953	100736342	20992742762	the	the	AT
304953	100736342	20992742763	Journal	journal	NN1
304953	100736342	20992742764	of	of	IO
304953	100736342	20992742765	Clinical	clinical	JJ
304953	100736342	20992742766	Oncology	oncology	NN1_NP1
304953	100736342	20992742767	,	,	,
304953	100736342	20992742768	a	a	AT1
304953	100736342	20992742769	team	team	NN1
304953	100736342	20992742770	of	of	IO
304953	100736342	20992742771	Harvard	harvard	NP1
304953	100736342	20992742772	School	school	NN1
304953	100736342	20992742773	of	of	IO
304953	100736342	20992742774	Public	public	JJ_NN1
304953	100736342	20992742775	Health	health	NN1
304953	100736342	20992742776	researchers	researcher	NN2
304953	100736342	20992742777	linked	linked	JJ_VVN
304953	100736342	20992742778	vasectomy	vasectomy	NN1
304953	100736342	20992742779	with	with	IW
304953	100736342	20992742780	a	a	AT1
304953	100736342	20992742781	slightly	slightly	RR
304953	100736342	20992742782	elevated	elevated	JJ_VVN
304953	100736342	20992742783	risk	risk	NN1
304953	100736342	20992742784	for	for	IF
304953	100736342	20992742785	high-grade	high-grade	NN1_JJ
304953	100736342	20992742786	,	,	,
304953	100736342	20992742787	lethal	lethal	JJ
304953	100736342	20992742788	prostate	prostate	NN1
304953	100736342	20992742789	cancer	cancer	NN1
304953	100736342	20992742790	.	.	.
304953	100736342	20992742791	They	they	PPHS2
304953	100736342	20992742792	reviewed	review	VVD
304953	100736342	20992742793	24	24	MC
304953	100736342	20992742794	years	year	NNT2
304953	100736342	20992742795	of	of	IO
304953	100736342	20992742796	data	data	NN
304953	100736342	20992742797	from	from	II
304953	100736342	20992742798	nearly	nearly	RR
304953	100736342	20992742799	50,000	50,000	MC
304953	100736342	20992742800	men	man	NN2
304953	100736342	20992742801	,	,	,
304953	100736342	20992742802	12,321		MC
304953	100736342	20992742803	of	of	IO
304953	100736342	20992742804	whom	whom	PNQO
304953	100736342	20992742805	had	have	VHD
304953	100736342	20992742806	had	have	VHN
304953	100736342	20992742807	a	a	AT1
304953	100736342	20992742808	vasectomy	vasectomy	NN1
304953	100736342	20992742809	.	.	.
304953	100736342	20992742810	Over	over	II
304953	100736342	20992742811	the	the	AT
304953	100736342	20992742812	24-year	24-year	JJ_NNT1
304953	100736342	20992742813	study	study	NN1
304953	100736342	20992742814	,	,	,
304953	100736342	20992742815	12.37%		FO
304953	100736342	20992742816	of	of	IO
304953	100736342	20992742817	the	the	AT
304953	100736342	20992742818	men	man	NN2
304953	100736342	20992742819	who	who	PNQS
304953	100736342	20992742820	had	have	VHD
304953	100736342	20992742821	a	a	AT1
304953	100736342	20992742822	vasectomy	vasectomy	NN1
304953	100736342	20992742823	developed	develop	VVN
304953	100736342	20992742824	prostate	prostate	NN1
304953	100736342	20992742825	cancer	cancer	NN1
304953	100736342	20992742826	,	,	,
304953	100736342	20992742827	compared	compare	VVN
304953	100736342	20992742828	to	to	II
304953	100736342	20992742829	12.13%		FO
304953	100736342	20992742830	of	of	IO
304953	100736342	20992742831	the	the	AT
304953	100736342	20992742832	men	man	NN2
304953	100736342	20992742833	who	who	PNQS
304953	100736342	20992742834	did	do	VDD
304953	100736342	20992742835	n't 	n't	XX
304953	100736342	20992742836	.	.	.
304953	100736342	20992742837	When	when	CS
304953	100736342	20992742838	the	the	AT
304953	100736342	20992742839	researchers	researcher	NN2
304953	100736342	20992742840	looked	look	VVN_VVD
304953	100736342	20992742841	at	at	II
304953	100736342	20992742842	prostate	prostate	NN1
304953	100736342	20992742843	cancer	cancer	NN1
304953	100736342	20992742844	types	type	NN2
304953	100736342	20992742845	,	,	,
304953	100736342	20992742846	only	only	JJ
304953	100736342	20992742847	high-grade	high-grade	NN1
304953	100736342	20992742848	tumors	tumor	NN2
304953	100736342	20992742849	were	be	VBDR
304953	100736342	20992742850	different	different	JJ
304953	100736342	20992742851	across	across	II
304953	100736342	20992742852	the	the	AT
304953	100736342	20992742853	two	two	MC
304953	100736342	20992742854	groups	group	NN2
304953	100736342	20992742855	:	:	:
304953	100736342	20992742856	1.52%		FO
304953	100736342	20992742857	of	of	IO
304953	100736342	20992742858	cases	case	NN2
304953	100736342	20992742859	in	in	II
304953	100736342	20992742860	the	the	AT
304953	100736342	20992742861	vasectomy	vasectomy	NN1
304953	100736342	20992742862	group	group	NN1
304953	100736342	20992742863	and	and	CC
304953	100736342	20992742864	1.47%		FO
304953	100736342	20992742865	in	in	II
304953	100736342	20992742866	the	the	AT
304953	100736342	20992742867	non-vasectomy		JJ_NN1
304953	100736342	20992742868	group	group	NN1
304953	100736342	20992742869	.	.	.
304953	100736342	20992742870	The	the	AT
304953	100736342	20992742871	differences	difference	NN2
304953	100736342	20992742872	were	be	VBDR
304953	100736342	20992742873	statistically	statistically	RR
304953	100736342	20992742874	significant	significant	JJ
304953	100736342	20992742875	,	,	,
304953	100736342	20992742876	but	but	CCB
304953	100736342	20992742877	very	very	RG
304953	100736342	20992742878	small	small	JJ
304953	100736342	20992742879	.	.	.
304953	100736342	20992742880	<p>		NULL
304953	100736342	20992742881	The	the	AT
304953	100736342	20992742882	Harvard	harvard	NP1
304953	100736342	20992742883	authors	author	NN2
304953	100736342	20992742884	said	say	VVD
304953	100736342	20992742885	that	that	CST
304953	100736342	20992742886	@		II
304953	100736342	20992742887	@		II
304953	100736342	20992742888	@		II
304953	100736342	20992742889	@		II
304953	100736342	20992742890	@		II
304953	100736342	20992742891	@		II
304953	100736342	20992742892	@		II
304953	100736342	20992742893	@		II
304953	100736342	20992742894	@		II
304953	100736342	20992742895	@		II
304953	100736342	20992742896	prostate	prostate	NN1
304953	100736342	20992742897	cancer	cancer	NN1
304953	100736342	20992742898	risk	risk	NN1
304953	100736342	20992742899	,	,	,
304953	100736342	20992742900	but	but	CCB
304953	100736342	20992742901	shouldnt		VV0_NN1
304953	100736342	20992742902	let	let	VV0
304953	100736342	20992742903	it	it	PPH1
304953	100736342	20992742904	deter	deter	VVI
304953	100736342	20992742905	them	them	PPHO2
304953	100736342	20992742906	from	from	II
304953	100736342	20992742907	having	have	VHG
304953	100736342	20992742908	a	a	AT1
304953	100736342	20992742909	vasectomy	vasectomy	NN1
304953	100736342	20992742910	.	.	.
304953	100736342	20992742911	Media	media	NN
304953	100736342	20992742912	reports	report	NN2_VVZ
304953	100736342	20992742913	covering	cover	VVG
304953	100736342	20992742914	the	the	AT
304953	100736342	20992742915	finding	finding	NN1
304953	100736342	20992742916	,	,	,
304953	100736342	20992742917	however	however	RR
304953	100736342	20992742918	,	,	,
304953	100736342	20992742919	triggered	trigger	VVD
304953	100736342	20992742920	widespread	widespread	JJ
304953	100736342	20992742921	anxiety	anxiety	NN1
304953	100736342	20992742922	among	among	II
304953	100736342	20992742923	men	man	NN2
304953	100736342	20992742924	who	who	PNQS
304953	100736342	20992742925	either	either	RR
304953	100736342	20992742926	had	have	VHD
304953	100736342	20992742927	had	have	VHN@
304953	100736342	20992742928	a	a	AT1
304953	100736342	20992742929	vasectomy	vasectomy	NN1
304953	100736342	20992742930	or	or	CC
304953	100736342	20992742931	were	be	VBDR
304953	100736342	20992742932	thinking	think	VVG
304953	100736342	20992742933	about	about	II
304953	100736342	20992742934	having	have	VHG
304953	100736342	20992742935	one	one	PN1
304953	100736342	20992742936	.	.	.
304953	100736342	20992742937	<p>		NULL
304953	100736342	20992742938	Scientists	scientist	NN2
304953	100736342	20992742939	do	do	VD0
304953	100736342	20992742940	n't 	n't	XX
304953	100736342	20992742941	know	know	VVI
304953	100736342	20992742942	why	why	RRQ
304953	100736342	20992742943	vasectomy	vasectomy	NN1
304953	100736342	20992742944	might	might	VM
304953	100736342	20992742945	increase	increase	VVI
304953	100736342	20992742946	the	the	AT
304953	100736342	20992742947	risk	risk	NN1
304953	100736342	20992742948	of	of	IO
304953	100736342	20992742949	developing	developing	JJ_VVG
304953	100736342	20992742950	prostate	prostate	NN1
304953	100736342	20992742951	cancer	cancer	NN1
304953	100736342	20992742952	.	.	.
304953	100736342	20992742953	Some	some	DD
304953	100736342	20992742954	say	say	VV0
304953	100736342	20992742955	it	it	PPH1
304953	100736342	20992742956	could	could	VM
304953	100736342	20992742957	lead	lead	VVI
304953	100736342	20992742958	to	to	II
304953	100736342	20992742959	hormonal	hormonal	JJ
304953	100736342	20992742960	imbalances	imbalance	NN2
304953	100736342	20992742961	or	or	CC
304953	100736342	20992742962	changes	change	NN2_VVZ@
304953	100736342	20992742963	in	in	II
304953	100736342	20992742964	the	the	AT
304953	100736342	20992742965	immune	immune	JJ
304953	100736342	20992742966	system	system	NN1
304953	100736342	20992742967	that	that	CST_DD1
304953	100736342	20992742968	could	could	VM
304953	100736342	20992742969	make	make	VVI
304953	100736342	20992742970	cancer	cancer	NN1
304953	100736342	20992742971	more	more	RGR
304953	100736342	20992742972	likely	likely	JJ
304953	100736342	20992742973	.	.	.
304953	100736342	20992742974	Experts	expert	NN2
304953	100736342	20992742975	who	who	PNQS
304953	100736342	20992742976	doubt	doubt	VV0
304953	100736342	20992742977	the	the	AT
304953	100736342	20992742978	connection	connection	NN1
304953	100736342	20992742979	suggest	suggest	VV0
304953	100736342	20992742980	that	that	CST
304953	100736342	20992742981	men	man	NN2
304953	100736342	20992742982	who	who	PNQS
304953	100736342	20992742983	get	get	VV0
304953	100736342	20992742984	a	a	AT1
304953	100736342	20992742985	vasectomy	vasectomy	NN1
304953	100736342	20992742986	may	may	VM
304953	100736342	20992742987	also	also	RR
304953	100736342	20992742988	get	get	VVI
304953	100736342	20992742989	more	more	RGR_DAR
304953	100736342	20992742990	routine	routine	JJ@_NN1
304953	100736342	20992742991	medical	medical	JJ
304953	100736342	20992742992	attention	attention	NN1
304953	100736342	20992742993	,	,	,
304953	100736342	20992742994	and	and	CC
304953	100736342	20992742995	are	be	VBR
304953	100736342	20992742996	therefore	therefore	RR
304953	100736342	20992742997	more	more	RGR
304953	100736342	20992742998	likely	likely	JJ
304953	100736342	20992742999	to	to	TO
304953	100736342	20992743000	be	be	VBI
304953	100736342	20992743001	diagnosed	diagnose	VVN
304953	100736342	20992743002	with	with	IW
304953	100736342	20992743003	prostate	prostate	NN1
304953	100736342	20992743004	cancer	cancer	NN1
304953	100736342	20992743005	and	and	CC
304953	100736342	20992743006	other	other	JJ
304953	100736342	20992743007	conditions	condition	NN2
304953	100736342	20992743008	.	.	.
304953	100736342	20992743009	<p>		NULL
304953	100736342	20992743010	The	the	AT
304953	100736342	20992743011	American	american	JJ
304953	100736342	20992743012	Urological	urological	JJ
304953	100736342	20992743013	Association	association	NN1
304953	100736342	20992743014	(	(	(
304953	100736342	20992743015	AUA	aua	NP1
304953	100736342	20992743016	)	)	)
304953	100736342	20992743017	has	have	VHZ
304953	100736342	20992743018	downplayed	downplay	VVN
304953	100736342	20992743019	any	any	DD
304953	100736342	20992743020	link	link	NN1_VV0
304953	100736342	20992743021	between	between	II
304953	100736342	20992743022	vasectomy	vasectomy	NN1
304953	100736342	20992743023	and	and	CC
304953	100736342	20992743024	prostate	prostate	NN1
304953	100736342	20992743025	cancer	cancer	NN1
304953	100736342	20992743026	or	or	CC
304953	100736342	20992743027	other	other	JJ
304953	100736342	20992743028	conditions	condition	NN2
304953	100736342	20992743029	.	.	.
304953	100736342	20992743030	After	after	II
304953	100736342	20992743031	reviewing	review	VVG
304953	100736342	20992743032	all	all	DB
304953	100736342	20992743033	the	the	AT
304953	100736342	20992743034	vasectomy	vasectomy	NN1
304953	100736342	20992743035	literature	literature	NN1
304953	100736342	20992743036	since	since	II
304953	100736342	20992743037	1949	1949	MC
304953	100736342	20992743038	,	,	,
304953	100736342	20992743039	including	including	II_VVG@
304953	100736342	20992743040	the	the	AT
304953	100736342	20992743041	recent	recent	JJ
304953	100736342	20992743042	Harvard	harvard	NP1
304953	100736342	20992743043	study	study	NN1
304953	100736342	20992743044	,	,	,
304953	100736342	20992743045	the	the	AT
304953	100736342	20992743046	AUA	aua	NP1
304953	100736342	20992743047	concluded	conclude	VVD
304953	100736342	20992743048	that	that	CST
304953	100736342	20992743049	a	a	AT1
304953	100736342	20992743050	link	link	NN1
304953	100736342	20992743051	between	between	II
304953	100736342	20992743052	vasectomy	vasectomy	NN1
304953	100736342	20992743053	and	and	CC
304953	100736342	20992743054	prostate	prostate	NN1
304953	100736342	20992743055	cancer	cancer	NN1
304953	100736342	20992743056	is	be	VBZ
304953	100736342	20992743057	neither	neither	RR
304953	100736342	20992743058	clinically	clinically	RR
304953	100736342	20992743059	nor	nor	CC
304953	100736342	20992743060	statistically	statistically	RR
304953	100736342	20992743061	significant	significant	JJ
304953	100736342	20992743062	.	.	.
304953	100736342	20992743063	According	according	II21
304953	100736342	20992743064	to	to	II22
304953	100736342	20992743065	the	the	AT
304953	100736342	20992743066	AUA	aua	NP1
304953	100736342	20992743067	,	,	,
304953	100736342	20992743068	"	"	"
304953	100736342	20992743069	there	there	EX
304953	100736342	20992743070	is	be	VBZ
304953	100736342	20992743071	no	no	AT
304953	100736342	20992743072	need	need	NN1
304953	100736342	20992743073	for	for	IF
304953	100736342	20992743074	physicians	physician	NN2
304953	100736342	20992743075	to	to	TO
304953	100736342	20992743076	routinely	routinely	RR
304953	100736342	20992743077	discuss	discuss	VVI
304953	100736342	20992743078	prostate	prostate	NN1
304953	100736342	20992743079	cancer	cancer	NN1
304953	100736342	20992743080	in	in	II
304953	100736342	20992743081	their	their	APPGE
304953	100736342	20992743082	preoperative	preoperative	JJ
304953	100736342	20992743083	counseling	counseling	NN1
304953	100736342	20992743084	of	of	IO
304953	100736342	20992743085	vasectomy	vasectomy	NN1
304953	100736342	20992743086	@		II
304953	100736342	20992743087	@		II
304953	100736342	20992743088	@		II
304953	100736342	20992743089	@		II
304953	100736342	20992743090	@		II
304953	100736342	20992743091	@		II
304953	100736342	20992743092	@		II
304953	100736342	20992743093	@		II
304953	100736342	20992743094	@		II
304953	100736342	20992743095	@		II
304953	100736342	20992743096	Brothers	brother	NN2
304953	100736342	20992743097	Professor	professor	NN1
304953	100736342	20992743098	of	of	IO
304953	100736342	20992743099	Medicine	medicine	NN1
304953	100736342	20992743100	at	at	II
304953	100736342	20992743101	Harvard	harvard	NP1
304953	100736342	20992743102	Medical	medical	JJ
304953	100736342	20992743103	School	school	NN1
304953	100736342	20992743104	and	and	CC
304953	100736342	20992743105	Beth	beth	NP1
304953	100736342	20992743106	Israel	israel	NP1
304953	100736342	20992743107	Deaconess	deaconess	NN1
304953	100736342	20992743108	Medical	medical	JJ
304953	100736342	20992743109	Center	center	NN1
304953	100736342	20992743110	,	,	,
304953	100736342	20992743111	disagrees	disagree	VVZ
304953	100736342	20992743112	.	.	.
304953	100736342	20992743113	"	"	"
304953	100736342	20992743114	The	the	AT
304953	100736342	20992743115	association	association	NN1
304953	100736342	20992743116	between	between	II
304953	100736342	20992743117	prostate	prostate	NN1
304953	100736342	20992743118	cancer	cancer	NN1
304953	100736342	20992743119	and	and	CC
304953	100736342	20992743120	vasectomy	vasectomy	NN1
304953	100736342	20992743121	could	could	VM
304953	100736342	20992743122	be	be	VBI
304953	100736342	20992743123	due	due	II21
304953	100736342	20992743124	to	to	II22
304953	100736342	20992743125	chance	chance	NN1
304953	100736342	20992743126	,	,	,
304953	100736342	20992743127	but	but	CCB
304953	100736342	20992743128	the	the	AT
304953	100736342	20992743129	final	final	JJ_NN1
304953	100736342	20992743130	word	word	NN1
304953	100736342	20992743131	is	be	VBZ
304953	100736342	20992743132	not	not	XX
304953	100736342	20992743133	in	in	II_RP@
304953	100736342	20992743134	yet	yet	RR
304953	100736342	20992743135	,	,	,
304953	100736342	20992743136	"	"	"
304953	100736342	20992743137	he	he	PPHS1
304953	100736342	20992743138	says	say	VVZ
304953	100736342	20992743139	.	.	.
304953	100736342	20992743140	"	"	"
304953	100736342	20992743141	At	at	II
304953	100736342	20992743142	a	a	AT1
304953	100736342	20992743143	minimum	minimum	NN1_JJ
304953	100736342	20992743144	,	,	,
304953	100736342	20992743145	the	the	AT
304953	100736342	20992743146	data	data	NN
304953	100736342	20992743147	should	should	VM
304953	100736342	20992743148	be	be	VBI
304953	100736342	20992743149	placed	place	VVN
304953	100736342	20992743150	into	into	II
304953	100736342	20992743151	the	the	AT
304953	100736342	20992743152	conversation	conversation	NN1
304953	100736342	20992743153	so	so	CS21
304953	100736342	20992743154	that	that	CS22
304953	100736342	20992743155	men	man	NN2
304953	100736342	20992743156	can	can	VM
304953	100736342	20992743157	be	be	VBI
304953	100736342	20992743158	allowed	allow	VVN
304953	100736342	20992743159	to	to	TO
304953	100736342	20992743160	make	make	VVI
304953	100736342	20992743161	an	a	AT1
304953	100736342	20992743162	informed	informed	JJ@
304953	100736342	20992743163	choice	choice	NN1
304953	100736342	20992743164	in	in	II31
304953	100736342	20992743165	light	light	II32
304953	100736342	20992743166	of	of	II33
304953	100736342	20992743167	these	these	DD2
304953	100736342	20992743168	conflicting	conflicting	JJ
304953	100736342	20992743169	data	data	NN
304953	100736342	20992743170	.	.	.
304953	100736342	20992743171	"	"	"
304953	100736343	20992743191	@@##	----------	----------
304953	100736343	20992743192	@@100736343		FO
304953	100736343	20992743193	@4936343/		NN1_VV0
304953	100736343	20992743194	<p>		NULL
304953	100736343	20992743195	On	on	II
304953	100736343	20992743196	Friday	friday	NPD1
304953	100736343	20992743197	,	,	,
304953	100736343	20992743198	May	may	NPM1
304953	100736343	20992743199	20	20	MC
304953	100736343	20992743200	,	,	,
304953	100736343	20992743201	the	the	AT
304953	100736343	20992743202	Massachusetts	massachusetts	NP1
304953	100736343	20992743203	Prostate	prostate	NN1
304953	100736343	20992743204	Cancer	cancer	NN1
304953	100736343	20992743205	Coalition	coalition	NN1
304953	100736343	20992743206	hosts	host	NN2
304953	100736343	20992743207	its	its	APPGE
304953	100736343	20992743208	14th	14th	MD
304953	100736343	20992743209	annual	annual	JJ
304953	100736343	20992743210	prostate	prostate	NN1
304953	100736343	20992743211	cancer	cancer	NN1
304953	100736343	20992743212	symposium	symposium	NN1
304953	100736343	20992743213	.	.	.
304953	100736343	20992743214	Specialists	specialist	NN2
304953	100736343	20992743215	from	from	II
304953	100736343	20992743216	the	the	AT
304953	100736343	20992743217	Boston	boston	NP1
304953	100736343	20992743218	area	area	NN1
304953	100736343	20992743219	will	will	VM
304953	100736343	20992743220	cover	cover	VVI
304953	100736343	20992743221	a	a	AT1
304953	100736343	20992743222	variety	variety	NN1
304953	100736343	20992743223	of	of	IO
304953	100736343	20992743224	topics	topic	NN2
304953	100736343	20992743225	including	including	II_VVG@
304953	100736343	20992743226	:	:	:
304953	100736343	20992743227	<p>		NULL
304953	100736343	20992743228	new	new	JJ
304953	100736343	20992743229	molecular	molecular	JJ
304953	100736343	20992743230	tests	test	NN2
304953	100736343	20992743231	that	that	CST_DD1
304953	100736343	20992743232	might	might	VM
304953	100736343	20992743233	help	help	VVI
304953	100736343	20992743234	doctors	doctor	NN2
304953	100736343	20992743235	better	better	RRR
304953	100736343	20992743236	assess	assess	VVI
304953	100736343	20992743237	whether	whether	CSW
304953	100736343	20992743238	a	a	AT1
304953	100736343	20992743239	man	man	NN1
304953	100736343	20992743240	has	have	VHZ
304953	100736343	20992743241	prostate	prostate	NN1
304953	100736343	20992743242	cancer	cancer	NN1
304953	100736343	20992743243	and	and	CC
304953	100736343	20992743244	,	,	,
304953	100736343	20992743245	if	if	CS
304953	100736343	20992743246	so	so	RR
304953	100736343	20992743247	,	,	,
304953	100736343	20992743248	what	what	DDQ
304953	100736343	20992743249	to	to	TO
304953	100736343	20992743250	do	do	VDI
304953	100736343	20992743251	about	about	II
304953	100736343	20992743252	it	it	PPH1
304953	100736343	20992743253	<p>		NULL
304953	100736343	20992743254	concerns	concern	NN2
304953	100736343	20992743255	of	of	IO
304953	100736343	20992743256	men	man	NN2
304953	100736343	20992743257	who	who	PNQS
304953	100736343	20992743258	are	be	VBR
304953	100736343	20992743259	diagnosed	diagnose	VVN
304953	100736343	20992743260	with	with	IW
304953	100736343	20992743261	cancer	cancer	NN1
304953	100736343	20992743262	that	that	CST_DD1
304953	100736343	20992743263	's	be	VBZ
304953	100736343	20992743264	already	already	RR
304953	100736343	20992743265	fairly	fairly	RR
304953	100736343	20992743266	advanced	advance	VVN_VVD_JJ
304953	100736343	20992743267	<p>		NULL
304953	100736343	20992743268	active	active	JJ
304953	100736343	20992743269	surveillance	surveillance	NN1
304953	100736343	20992743270	vs.		II
304953	100736343	20992743271	treatment	treatment	NN1
304953	100736343	20992743272	for	for	IF
304953	100736343	20992743273	low-risk	low-risk	JJ_NN1
304953	100736343	20992743274	prostate	prostate	NN1
304953	100736343	20992743275	cancer	cancer	NN1
304953	100736343	20992743276	<p>		NULL
304953	100736343	20992743277	how	how	RGQ@_RRQ
304953	100736343	20992743278	radical	radical	JJ
304953	100736343	20992743279	prostatectomy	prostatectomy	NN1
304953	100736343	20992743280	stacks	stack	VVZ@_NN2
304953	100736343	20992743281	up	up	RP
304953	100736343	20992743282	against	against	II
304953	100736343	20992743283	other	other	JJ
304953	100736343	20992743284	treatments	treatment	NN2
304953	100736343	20992743285	<p>		NULL
304953	100736343	20992743286	the	the	AT
304953	100736343	20992743287	latest	late	JJT
304953	100736343	20992743288	information	information	NN1
304953	100736343	20992743289	on	on	II
304953	100736343	20992743290	brachytherapy	brachytherapy	NN1
304953	100736343	20992743291	(	(	(
304953	100736343	20992743292	seed	seed	NN1_VV0@
304953	100736343	20992743293	therapy	therapy	NN1
304953	100736343	20992743294	)	)	)
304953	100736343	20992743295	,	,	,
304953	100736343	20992743296	a	a	AT1
304953	100736343	20992743297	type	type	NN1
304953	100736343	20992743298	of	of	IO
304953	100736343	20992743299	radiation	radiation	NN1
304953	100736343	20992743300	<p>		NULL
304953	100736343	20992743301	what	what	DDQ
304953	100736343	20992743302	to	to	TO
304953	100736343	20992743303	do	do	VDI
304953	100736343	20992743304	about	about	II
304953	100736343	20992743305	urinary	urinary	JJ_NN1
304953	100736343	20992743306	incontinence	incontinence	NN1
304953	100736343	20992743307	after	after	II_CS
304953	100736343	20992743308	prostate	prostate	NN1
304953	100736343	20992743309	cancer	cancer	NN1
304953	100736343	20992743310	treatment	treatment	NN1
304953	100736343	20992743311	<p>		NULL
304953	100736343	20992743312	monitoring	monitor	VVG
304953	100736343	20992743313	your	your	APPGE
304953	100736343	20992743314	condition	condition	NN1
304953	100736343	20992743315	after	after	II_CS
304953	100736343	20992743316	treatment	treatment	NN1
304953	100736343	20992743317	"	"	"
304953	100736343	20992743318	is	be	VBZ
304953	100736343	20992743319	the	the	AT
304953	100736343	20992743320	cancer	cancer	NN1
304953	100736343	20992743321	in	in	II
304953	100736343	20992743322	remission	remission	NN1
304953	100736343	20992743323	?	?	?
304953	100736343	20992743324	<p>		NULL
304953	100736343	20992743325	the	the	AT
304953	100736343	20992743326	best	best	JJT
304953	100736343	20992743327	foods	food	NN2
304953	100736343	20992743328	to	to	TO
304953	100736343	20992743329	eat	eat	VVI
304953	100736343	20992743330	to	to	TO
304953	100736343	20992743331	promote	promote	VVI
304953	100736343	20992743332	healing	healing	JJ_NN1
304953	100736343	20992743333	and	and	CC
304953	100736343	20992743334	boost	boost	VVI
304953	100736343	20992743335	energy	energy	NN1
304953	100736343	20992743336	<p>		NULL
304953	100736343	20992743337	enrolling	enroll	VVG
304953	100736343	20992743338	in	in	II_RP@
304953	100736343	20992743339	a	a	AT1
304953	100736343	20992743340	clinical	clinical	JJ
304953	100736343	20992743341	trial	trial	NN1
304953	100736343	20992743342	.	.	.
304953	100736343	20992743343	<p>		NULL
304953	100736343	20992743344	Seemingly	seemingly	RR
304953	100736343	20992743345	everyone	everyone	PN1
304953	100736343	20992743346	turns	turn	VVZ
304953	100736343	20992743347	to	to	II
304953	100736343	20992743348	the	the	AT
304953	100736343	20992743349	Internet	internet	NN1_NP1
304953	100736343	20992743350	when	when	CS_RRQ
304953	100736343	20992743351	they	they	PPHS2
304953	100736343	20992743352	receive	receive	VV0
304953	100736343	20992743353	a	a	AT1
304953	100736343	20992743354	diagnosis	diagnosis	NN1
304953	100736343	20992743355	of	of	IO
304953	100736343	20992743356	prostate	prostate	NN1
304953	100736343	20992743357	cancer	cancer	NN1
304953	100736343	20992743358	,	,	,
304953	100736343	20992743359	but	but	CCB
304953	100736343	20992743360	finding	find	VVG
304953	100736343	20992743361	reputable	reputable	JJ
304953	100736343	20992743362	sites	site	NN2
304953	100736343	20992743363	with	with	IW
304953	100736343	20992743364	accurate	accurate	JJ
304953	100736343	20992743365	and	and	CC
304953	100736343	20992743366	unbiased	unbiased	JJ
304953	100736343	20992743367	information	information	NN1
304953	100736343	20992743368	can	can	VM
304953	100736343	20992743369	sometimes	sometimes	RT
304953	100736343	20992743370	be	be	VBI
304953	100736343	20992743371	challenging	challenge	VVG_JJ
304953	100736343	20992743372	.	.	.
304953	100736343	20992743373	I	i	PPIS1
304953	100736343	20992743374	will	will	VM
304953	100736343	20992743375	be	be	VBI
304953	100736343	20992743376	talking	talk	VVG
304953	100736343	20992743377	about	about	II
304953	100736343	20992743378	a	a	AT1
304953	100736343	20992743379	few	few	DA2
304953	100736343	20992743380	Web	web	NN1
304953	100736343	20992743381	sites	site	NN2
304953	100736343	20992743382	,	,	,
304953	100736343	20992743383	@		II
304953	100736343	20992743384	@		II
304953	100736343	20992743385	@		II
304953	100736343	20992743386	@		II
304953	100736343	20992743387	@		II
304953	100736343	20992743388	@		II
304953	100736343	20992743389	@		II
304953	100736343	20992743390	@		II
304953	100736343	20992743391	@		II
304953	100736343	20992743392	@		II
304953	100736343	20992743393	better	better	RRR
304953	100736343	20992743394	understand	understand	VVI
304953	100736343	20992743395	the	the	AT
304953	100736343	20992743396	controversies	controversy	NN2
304953	100736343	20992743397	surrounding	surround	VVG_JJ
304953	100736343	20992743398	prostate	prostate	NN1
304953	100736343	20992743399	cancer	cancer	NN1
304953	100736343	20992743400	screening	screening	NN1_VVG
304953	100736343	20992743401	and	and	CC
304953	100736343	20992743402	make	make	VV0
304953	100736343	20992743403	well-informed	well-informed	JJ_NN1
304953	100736343	20992743404	decisions	decision	NN2
304953	100736343	20992743405	about	about	II
304953	100736343	20992743406	treatment	treatment	NN1
304953	100736343	20992743407	.	.	.
304953	100736343	20992743408	I	i	PPIS1
304953	100736343	20992743409	will	will	VM
304953	100736343	20992743410	remind	remind	VVI
304953	100736343	20992743411	attendees	attendee	NN2
304953	100736343	20992743412	to	to	TO
304953	100736343	20992743413	check	check	VVI
304953	100736343	20992743414	the	the	AT
304953	100736343	20992743415	source	source	NN1
304953	100736343	20992743416	of	of	IO
304953	100736343	20992743417	information	information	NN1
304953	100736343	20992743418	they	they	PPHS2
304953	100736343	20992743419	find	find	VV0
304953	100736343	20992743420	online	online	RR_JJ
304953	100736343	20992743421	.	.	.
304953	100736343	20992743422	<p>		NULL
304953	100736343	20992743423	Suzanne	suzanne	NP1
304953	100736343	20992743424	Rose	rose	NP1_VVD
304953	100736343	20992743425	,	,	,
304953	100736343	20992743426	editor	editor	NN1
304953	100736343	20992743427	of	of	IO
304953	100736343	20992743428	the	the	AT
304953	100736343	20992743429	2011	2011	MC
304953	100736343	20992743430	Annual	annual	JJ
304953	100736343	20992743431	Report	report	NN1
304953	100736343	20992743432	on	on	II
304953	100736343	20992743433	Prostate	prostate	NN1
304953	100736343	20992743434	Diseases	disease	NN2
304953	100736343	20992743435	from	from	II
304953	100736343	20992743436	Harvard	harvard	NP1
304953	100736343	20992743437	Health	health	NN1
304953	100736343	20992743438	Publications	publication	NN2
304953	100736343	20992743439	(	(	(
304953	100736343	20992743440	HHP		NP1
304953	100736343	20992743441	)	)	)
304953	100736343	20992743442	,	,	,
304953	100736343	20992743443	will	will	VM
304953	100736343	20992743444	report	report	VVI
304953	100736343	20992743445	live	live	JJ_RR@_VV0
304953	100736343	20992743446	from	from	II
304953	100736343	20992743447	the	the	AT
304953	100736343	20992743448	symposium	symposium	NN1
304953	100736343	20992743449	via	via	II
304953	100736343	20992743450	Twitter	twitter	NN1
304953	100736343	20992743451	,	,	,
304953	100736343	20992743452	and	and	CC
304953	100736343	20992743453	post	post	NN1
304953	100736343	20992743454	updates	update	VVZ_NN2
304953	100736343	20992743455	to	to	II
304953	100736343	20992743456	the	the	AT
304953	100736343	20992743457	HHP		NP1
304953	100736343	20992743458	Facebook	facebook	NP1_NN1
304953	100736343	20992743459	page	page	NN1
304953	100736343	20992743460	.	.	.
304953	100736343	20992743461	Additional	additional	JJ
304953	100736343	20992743462	reports	report	NN2
304953	100736343	20992743463	and	and	CC
304953	100736343	20992743464	blog	blog	VV0_NN1
304953	100736343	20992743465	posts	post	NN2
304953	100736343	20992743466	will	will	VM
304953	100736343	20992743467	be	be	VBI
304953	100736343	20992743468	added	add	VVN
304953	100736343	20992743469	to	to	II
304953	100736343	20992743470	the	the	AT
304953	100736343	20992743471	HarvardProstateKnowledge		NN1_NP1
304953	100736343	20992743472	site	site	NN1
304953	100736343	20992743473	in	in	II
304953	100736343	20992743474	the	the	AT
304953	100736343	20992743475	coming	coming	JJ@
304953	100736343	20992743476	days	day	NNT2
304953	100736343	20992743477	,	,	,
304953	100736343	20992743478	so	so	RR
304953	100736343	20992743479	be	be	VBI
304953	100736343	20992743480	sure	sure	JJ
304953	100736343	20992743525	your	your	APPGE
304953	100736343	20992743526	post	post	NN1
304953	100736343	20992743527	.	.	.
304953	100736343	20992743528	Thanks	thanks	NN2
304953	100736343	20992743529	!	!	!
304953	100736343	20992743530	<p>		NULL
304953	100736343	20992743531	I	i	PPIS1_MC1@
304953	100736343	20992743532	not	not	XX
304953	100736343	20992743533	to	to	TO
304953	100736343	20992743534	mention	mention	VVI
304953	100736343	20992743535	my	my	APPGE
304953	100736343	20992743536	buedids		NN2
304953	100736343	20992743537	ended	end	VVD_VVN
304953	100736343	20992743538	up	up	RP
304953	100736343	20992743539	checking	check	VVG
304953	100736343	20992743540	out	out	RP
304953	100736343	20992743541	the	the	AT
304953	100736343	20992743542	best	best	JJT
304953	100736343	20992743543	recommendations	recommendation	NN2
304953	100736343	20992743544	found	find	VVN_VVD
304953	100736343	20992743545	on	on	II
304953	100736343	20992743546	the	the	AT
304953	100736343	20992743547	blog	blog	NN1
304953	100736343	20992743548	and	and	CC
304953	100736343	20992743549	so	so	RG_RR
304953	100736343	20992743550	quickly	quickly	RR
304953	100736343	20992743551	developed	develop	VVN_VVD
304953	100736343	20992743552	a	a	AT1
304953	100736343	20992743553	horrible	horrible	JJ
304953	100736343	20992743554	suspicion	suspicion	NN1
304953	100736343	20992743555	I	i	PPIS1
304953	100736343	20992743556	never	never	RR
304953	100736343	20992743557	expressed	express	VVN_JJ@_VVD
304953	100736343	20992743558	respect	respect	NN1
304953	100736343	20992743559	to	to	II
304953	100736343	20992743560	you	you	PPY
304953	100736343	20992743561	for	for	IF
304953	100736343	20992743562	those	those	DD2
304953	100736343	20992743563	tips	tip	NN2
304953	100736343	20992743564	.	.	.
304953	100736343	20992743565	The	the	AT
304953	100736343	20992743566	men	man	NN2
304953	100736343	20992743567	were	be	VBDR
304953	100736343	20992743568	as	as	II
304953	100736343	20992743569	a	a	AT1
304953	100736343	20992743570	result	result	NN1
304953	100736343	20992743571	warmed	warm	VVD_VVN
304953	100736343	20992743572	to	to	TO
304953	100736343	20992743573	see	see	VVI
304953	100736343	20992743574	all	all	DB
304953	100736343	20992743575	of	of	IO
304953	100736343	20992743576	them	them	PPHO2
304953	100736343	20992743577	and	and	CC
304953	100736343	20992743578	already	already	RR
304953	100736343	20992743579	have	have	VH0
304953	100736343	20992743580	actually	actually	RR
304953	100736343	20992743581	been	be	VBN
304953	100736343	20992743582	loving	love	VVG
304953	100736343	20992743583	@		II
304953	100736343	20992743584	@		II
304953	100736343	20992743585	@		II
304953	100736343	20992743586	@		II
304953	100736343	20992743587	@		II
304953	100736343	20992743588	@		II
304953	100736343	20992743589	@		II
304953	100736343	20992743590	@		II
304953	100736343	20992743591	@		II
304953	100736343	20992743592	@		II
304953	100736343	20992743593	then	then	RT
304953	100736343	20992743594	for	for	IF
304953	100736343	20992743595	making	make	VVG
304953	100736343	20992743596	a	a	AT1
304953	100736343	20992743597	choice	choice	NN1
304953	100736343	20992743598	on	on	II
304953	100736343	20992743599	varieties	variety	NN2
304953	100736343	20992743600	of	of	IO
304953	100736343	20992743601	marvelous	marvelous	JJ
304953	100736343	20992743602	guides	guide	NN2
304953	100736343	20992743603	most	most	DAT
304953	100736343	20992743604	people	people	NN
304953	100736343	20992743605	are	be	VBR
304953	100736343	20992743606	really	really	RR
304953	100736343	20992743607	needing	need	VVG
304953	100736343	20992743608	to	to	TO
304953	100736343	20992743609	be	be	VBI
304953	100736343	20992743610	aware	aware	JJ
304953	100736343	20992743611	of	of	IO
304953	100736343	20992743612	.	.	.
304953	100736343	20992743613	Our	our	APPGE
304953	100736343	20992743614	sincere	sincere	JJ
304953	100736343	20992743615	apologies	apology	NN2
304953	100736343	20992743616	for	for	IF
304953	100736343	20992743617	not	not	XX
304953	100736343	20992743618	saying	say	VVG
304953	100736343	20992743619	thanks	thanks	NN2
304953	100736343	20992743620	to	to	II_TO
304953	100736343	20992743621	earlier	early	JJR_RRR
304953	100736343	20992743622	.	.	.
304953	100736343	20992743623	<p>		NULL
304953	100736343	20992743624	NO	no	UH
304953	100736343	20992743625	!	!	!
304953	100736343	20992743626	It	it	PPH1
304953	100736343	20992743627	is	be	VBZ
304953	100736343	20992743628	just	just	RR
304953	100736343	20992743629	a	a	AT1
304953	100736343	20992743630	guess	guess	NN1@
304953	100736343	20992743631	based	base	VVN
304953	100736343	20992743632	on	on	II
304953	100736343	20992743633	the	the	AT
304953	100736343	20992743634	most	most	RGT
304953	100736343	20992743635	popular	popular	JJ
304953	100736343	20992743636	rrtuens		NN2
304953	100736343	20992743637	on	on	II
304953	100736343	20992743638	the	the	AT
304953	100736343	20992743639	search	search	NN1
304953	100736343	20992743640	engine.The		NNU
304953	100736343	20992743641	best	best	VV0%_JJT
304953	100736343	20992743642	and	and	CC
304953	100736343	20992743643	ONLY	only	JJ
304953	100736343	20992743644	way	way	NN1
304953	100736343	20992743645	to	to	TO
304953	100736343	20992743646	know	know	VVI
304953	100736343	20992743647	what 's		NN2
304953	100736343	20992743648	wrong	wrong	JJ_RR@_VV0%
304953	100736343	20992743649	with	with	IW
304953	100736343	20992743650	you	you	PPY
304953	100736343	20992743651	is	be	VBZ
304953	100736343	20992743652	to	to	TO
304953	100736343	20992743653	see	see	VVI
304953	100736343	20992743654	your	your	APPGE
304953	100736343	20992743655	doctor.Thats		NNU
304953	100736343	20992743656	what	what	DDQ
304953	100736343	20992743657	they	they	PPHS2
304953	100736343	20992743658	went	go	VVD
304953	100736343	20992743659	to	to	II
304953	100736343	20992743660	school	school	NN1
304953	100736343	20992743661	for	for	IF
304953	100736343	20992743662	.	.	.
304953	100736343	20992743663	They	they	PPHS2
304953	100736343	20992743664	studied	study	VVD
304953	100736343	20992743665	at	at	RR21
304953	100736343	20992743666	least	least	RR22
304953	100736343	20992743667	8	8	MC
304953	100736343	20992743668	years	year	NNT2
304953	100736343	20992743669	and	and	CC
304953	100736343	20992743670	did	do	VDD
304953	100736343	20992743671	their	their	APPGE
304953	100736343	20992743672	internship.Google		NNU
304953	100736343	20992743673	did	do	VDD
304953	100736343	20992743674	n't 	n't	XX
304953	100736343	20992743675	do	do	VDI
304953	100736343	20992743676	anything	anything	RR21
304953	100736343	20992743677	but	but	RR22
304953	100736343	20992743678	return	return	VVI
304953	100736343	20992743679	the	the	AT
304953	100736343	20992743680	most	most	RGT
304953	100736343	20992743681	common	common	JJ
304953	100736343	20992743682	hits.You		NNU
304953	100736343	20992743683	could	could	VM
304953	100736343	20992743684	have	have	VHI
304953	100736343	20992743685	nothing	nothing	PN1
304953	100736343	20992743686	wrong	wrong	JJ_RR@
304953	100736343	20992743687	with	with	IW
304953	100736343	20992743688	you	you	PPY
304953	100736343	20992743689	or	or	CC
304953	100736343	20992743690	you	you	PPY
304953	100736343	20992743691	could	could	VM
304953	100736343	20992743692	have	have	VHI
304953	100736343	20992743693	something	something	PN1
304953	100736343	20992743694	totally	totally	RR
304953	100736343	20992743695	unrelated	unrelated	JJ
304953	100736343	20992743696	to	to	II
304953	100736343	20992743697	your	your	APPGE
304953	100736343	20992743698	symptoms	symptom	NN2
304953	100736343	20992743699	.	.	.
304953	100736343	20992743700	46996		MC
304953	100736343	20992743701	@qwx906996		FO
304953	100736344	20992743721	@@##	----------	----------
304953	100736344	20992743722	@@100736344		FO
304953	100736344	20992743723	@4936344/		VV0_NN1
304953	100736344	20992743724	46989		MC
304953	100736344	20992743725	@qwx906989		FO
304953	100736344	20992743726	<p>		NULL
304953	100736344	20992743727	Testing	test	VVG_NN1_JJ@_NP1@
304953	100736344	20992743728	prostate	prostate	NN1
304953	100736344	20992743729	cancer	cancer	NN1
304953	100736344	20992743730	patients	patient	NN2
304953	100736344	20992743731	for	for	IF
304953	100736344	20992743732	a	a	AT1
304953	100736344	20992743733	protein	protein	NN1
304953	100736344	20992743734	called	call	VVN_VVD@
304953	100736344	20992743735	endoglin		NN1
304953	100736344	20992743736	in	in	II
304953	100736344	20992743737	their	their	APPGE
304953	100736344	20992743738	blood	blood	NN1
304953	100736344	20992743739	might	might	VM
304953	100736344	20992743740	help	help	VVI
304953	100736344	20992743741	doctors	doctor	NN2
304953	100736344	20992743742	better	better	RRR
304953	100736344	20992743743	determine	determine	VVI
304953	100736344	20992743744	whether	whether	CSW
304953	100736344	20992743745	the	the	AT
304953	100736344	20992743746	cancer	cancer	NN1
304953	100736344	20992743747	has	have	VHZ
304953	100736344	20992743748	spread	spread	VVN
304953	100736344	20992743749	beyond	beyond	II
304953	100736344	20992743750	the	the	AT
304953	100736344	20992743751	prostate	prostate	NN1
304953	100736344	20992743752	to	to	II
304953	100736344	20992743753	nearby	nearby	JJ
304953	100736344	20992743754	lymph	lymph	NN1
304953	100736344	20992743755	nodes	node	NN2
304953	100736344	20992743756	,	,	,
304953	100736344	20992743757	according	according	II21
304953	100736344	20992743758	to	to	II22
304953	100736344	20992743759	a	a	AT1
304953	100736344	20992743760	study	study	NN1
304953	100736344	20992743761	by	by	II
304953	100736344	20992743762	Texas	texas	NP1
304953	100736344	20992743763	researchers	researcher	NN2
304953	100736344	20992743764	.	.	.
304953	100736344	20992743765	Other	other	JJ
304953	100736344	20992743766	researchers	researcher	NN2
304953	100736344	20992743767	have	have	VH0
304953	100736344	20992743768	previously	previously	RR
304953	100736344	20992743769	shown	show	VVN
304953	100736344	20992743770	that	that	DD1_CST
304953	100736344	20992743771	endoglin		NN1
304953	100736344	20992743772	could	could	VM
304953	100736344	20992743773	predict	predict	VVI
304953	100736344	20992743774	the	the	AT
304953	100736344	20992743775	spread	spread	NN1
304953	100736344	20992743776	of	of	IO
304953	100736344	20992743777	colon	colon	NN1
304953	100736344	20992743778	and	and	CC
304953	100736344	20992743779	breast	breast	NN1
304953	100736344	20992743780	cancers	cancer	NN2
304953	100736344	20992743781	.	.	.
304953	100736344	20992743782	<p>		NULL
304953	100736344	20992743783	Investigators	investigator	NN2
304953	100736344	20992743784	studied	study	VVD_VVN
304953	100736344	20992743785	425	425	MC
304953	100736344	20992743786	men	man	NN2
304953	100736344	20992743787	who	who	PNQS
304953	100736344	20992743788	underwent	undergo	VVD
304953	100736344	20992743789	surgery	surgery	NN1
304953	100736344	20992743790	to	to	TO
304953	100736344	20992743791	remove	remove	VVI
304953	100736344	20992743792	the	the	AT
304953	100736344	20992743793	prostate	prostate	NN1
304953	100736344	20992743794	and	and	CC
304953	100736344	20992743795	pelvic	pelvic	JJ
304953	100736344	20992743796	lymph	lymph	NN1
304953	100736344	20992743797	nodes	node	NN2
304953	100736344	20992743798	.	.	.
304953	100736344	20992743799	They	they	PPHS2
304953	100736344	20992743800	found	find	VVD
304953	100736344	20992743801	that	that	CST
304953	100736344	20992743802	men	man	NN2
304953	100736344	20992743803	with	with	IW
304953	100736344	20992743804	an	a	AT1
304953	100736344	20992743805	elevated	elevated	JJ
304953	100736344	20992743806	level	level	NN1
304953	100736344	20992743807	of	of	IO
304953	100736344	20992743808	endoglin		NN1
304953	100736344	20992743809	were	be	VBDR
304953	100736344	20992743810	more	more	RGR
304953	100736344	20992743811	likely	likely	JJ
304953	100736344	20992743812	to	to	TO
304953	100736344	20992743813	have	have	VHI
304953	100736344	20992743814	cancer	cancer	NN1
304953	100736344	20992743815	that	that	CST
304953	100736344	20992743816	had	have	VHD
304953	100736344	20992743817	spread	spread	VVN
304953	100736344	20992743818	to	to	II
304953	100736344	20992743819	the	the	AT
304953	100736344	20992743820	lymph	lymph	NN1
304953	100736344	20992743821	nodes	node	NN2
304953	100736344	20992743822	and	and	CC
304953	100736344	20992743823	other	other	JJ
304953	100736344	20992743824	signs	sign	NN2
304953	100736344	20992743825	of	of	IO
304953	100736344	20992743826	more	more	RGR
304953	100736344	20992743827	aggressive	aggressive	JJ
304953	100736344	20992743828	cancer	cancer	NN1
304953	100736344	20992743829	.	.	.
304953	100736344	20992743830	<p>		NULL
304953	100736344	20992743831	Using	use	VVG
304953	100736344	20992743832	current	current	JJ
304953	100736344	20992743833	methods	method	NN2
304953	100736344	20992743834	,	,	,
304953	100736344	20992743835	the	the	AT
304953	100736344	20992743836	researchers	researcher	NN2
304953	100736344	20992743837	could	could	VM
304953	100736344	20992743838	predict	predict	VVI
304953	100736344	20992743839	with	with	IW
304953	100736344	20992743840	89%		NNU
304953	100736344	20992743841	accuracy	accuracy	NN1
304953	100736344	20992743842	whether	whether	CSW
304953	100736344	20992743843	the	the	AT
304953	100736344	20992743844	cancer	cancer	NN1
304953	100736344	20992743845	had	have	VHD
304953	100736344	20992743846	spread	spread	VVN
304953	100736344	20992743847	to	to	II
304953	100736344	20992743848	the	the	AT
304953	100736344	20992743849	lymph	lymph	NN1
304953	100736344	20992743850	nodes	node	NN2
304953	100736344	20992743851	.	.	.
304953	100736344	20992743852	When	when	CS_RRQ
304953	100736344	20992743853	they	they	PPHS2
304953	100736344	20992743854	factored	factor	VVD
304953	100736344	20992743855	endoglin		NN1
304953	100736344	20992743856	levels	level	NN2
304953	100736344	20992743857	into	into	II
304953	100736344	20992743858	the	the	AT
304953	100736344	20992743859	equation	equation	NN1
304953	100736344	20992743860	,	,	,
304953	100736344	20992743861	their	their	APPGE
304953	100736344	20992743862	predictions	prediction	NN2
304953	100736344	20992743863	were	be	VBDR
304953	100736344	20992743864	98%		NNU
304953	100736344	20992743865	accurate	accurate	JJ
304953	100736344	20992743866	.	.	.
304953	100736344	20992743867	If	if	CS
304953	100736344	20992743868	other	other	JJ
304953	100736344	20992743869	researchers	researcher	NN2
304953	100736344	20992743870	can	can	VM
304953	100736344	20992743871	confirm	confirm	VVI
304953	100736344	20992743872	these	these	DD2
304953	100736344	20992743873	findings	finding	NN2
304953	100736344	20992743874	,	,	,
304953	100736344	20992743875	doctors	doctor	NN2
304953	100736344	20992743876	might	might	VM
304953	100736344	20992743877	better	better	RRR
304953	100736344	20992743878	determine	determine	VVI
304953	100736344	20992743879	whether	whether	CSW
304953	100736344	20992743880	a	a	AT1
304953	100736344	20992743881	cancer	cancer	NN1
304953	100736344	20992743882	is	be	VBZ
304953	100736344	20992743883	likely	likely	JJ
304953	100736344	20992743884	to	to	TO
304953	100736344	20992743885	have	have	VHI
304953	100736344	20992743886	spread	spread	VVN
304953	100736344	20992743887	and	and	CC
304953	100736344	20992743888	spare	spare	VV0
304953	100736344	20992743889	some	some	DD
304953	100736344	20992743890	men	man	NN2
304953	100736344	20992743891	from	from	II
304953	100736344	20992743892	having	have	VHG
304953	100736344	20992743893	their	their	APPGE
304953	100736344	20992743894	lymph	lymph	NN1
304953	100736344	20992743895	nodes	node	NN2
304953	100736344	20992743896	removed	remove	VVD_VVN
304953	100736344	20992743897	.	.	.
304953	100736344	20992743898	<p>		NULL
304953	100736344	20992743899	had	have	VHD
304953	100736344	20992743900	particle	particle	NN1
304953	100736344	20992743901	beam	beam	NN1_VV0
304953	100736344	20992743902	radiation	radiation	NN1
304953	100736344	20992743903	for	for	IF
304953	100736344	20992743904	prostate	prostate	NN1
304953	100736344	20992743905	cancer	cancer	NN1
304953	100736344	20992743906	17	17	MC
304953	100736344	20992743907	years	year	NNT2
304953	100736344	20992743908	ago	ago	RA
304953	100736344	20992743909	,	,	,
304953	100736344	20992743910	and	and	CC
304953	100736344	20992743911	resulting	resulting	JJ_VVG
304953	100736344	20992743912	psa		NN1
304953	100736344	20992743913	@		II
304953	100736344	20992743914	@		II
304953	100736344	20992743915	@		II
304953	100736344	20992743916	@		II
304953	100736344	20992743917	@		II
304953	100736344	20992743918	@		II
304953	100736344	20992743919	@		II
304953	100736344	20992743920	@		II
304953	100736344	20992743921	@		II
304953	100736344	20992743922	@		II
304953	100736344	20992743923	psa		NN1
304953	100736344	20992743924	tests	test	NN2
304953	100736344	20992743925	.	.	.
304953	100736344	20992743926	I 'm		VV0
304953	100736344	20992743927	very	very	RG
304953	100736344	20992743928	strong	strong	JJ
304953	100736344	20992743929	and	and	CC
304953	100736344	20992743930	active	active	JJ
304953	100736344	20992743931	at	at	II
304953	100736344	20992743932	93	93	MC
304953	100736344	20992743933	years	year	NNT2
304953	100736344	20992743934	old	old	JJ
304953	100736344	20992743935	and	and	CC
304953	100736344	20992743936	plan	plan	VV0_NN1
304953	100736344	20992743937	to	to	TO
304953	100736344	20992743938	live	live	VVI
304953	100736344	20992743939	to	to	II
304953	100736344	20992743940	99.		MC
304953	100736344	20992743941	what 's		NN2
304953	100736344	20992743942	my	my	APPGE
304953	100736344	20992743943	chances	chance	NN2
304953	100736344	20992743944	of	of	IO
304953	100736344	20992743945	it	it	PPH1
304953	100736344	20992743946	breaking	break	VVG
304953	100736344	20992743947	out	out	RP
304953	100736344	20992743948	to	to	II
304953	100736344	20992743949	other	other	JJ
304953	100736344	20992743950	parts	part	NN2
304953	100736344	20992743951	of	of	IO
304953	100736344	20992743952	my	my	APPGE
304953	100736344	20992743953	body	body	NN1
304953	100736344	20992743954	46996		MC
304953	100736344	20992743955	@qwx906996		FO
304953	100736347	20992743975	@@##	----------	----------
304953	100736347	20992743976	@@100736347		FO
304953	100736347	20992743977	@4936347/		VV0_NN1
304953	100736347	20992743978	46989		MC
304953	100736347	20992743979	@qwx906989		FO
304953	100736347	20992743980	<p>		NULL
304953	100736347	20992743981	Magnetic	magnetic	JJ
304953	100736347	20992743982	resonance	resonance	NN1
304953	100736347	20992743983	imaging	imaging	NN1_VVG
304953	100736347	20992743984	(	(	(
304953	100736347	20992743985	MRI	mri	NP1
304953	100736347	20992743986	)	)	)
304953	100736347	20992743987	is	be	VBZ
304953	100736347	20992743988	a	a	AT1
304953	100736347	20992743989	diagnostic	diagnostic	JJ
304953	100736347	20992743990	technique	technique	NN1
304953	100736347	20992743991	that	that	CST_DD1
304953	100736347	20992743992	uses	use	VVZ
304953	100736347	20992743993	the	the	AT
304953	100736347	20992743994	electromagnetic	electromagnetic	JJ
304953	100736347	20992743995	properties	property	NN2
304953	100736347	20992743996	of	of	IO
304953	100736347	20992743997	hydrogen	hydrogen	NN1
304953	100736347	20992743998	molecules	molecule	NN2
304953	100736347	20992743999	to	to	TO
304953	100736347	20992744000	collect	collect	VVI
304953	100736347	20992744001	information	information	NN1
304953	100736347	20992744002	about	about	II
304953	100736347	20992744003	organs	organ	NN2
304953	100736347	20992744004	and	and	CC
304953	100736347	20992744005	other	other	JJ
304953	100736347	20992744006	tissues	tissue	NN2
304953	100736347	20992744007	.	.	.
304953	100736347	20992744008	A	a	AT1
304953	100736347	20992744009	computer	computer	NN1
304953	100736347	20992744010	then	then	RT
304953	100736347	20992744011	converts	convert	VVZ
304953	100736347	20992744012	this	this	DD1
304953	100736347	20992744013	information	information	NN1
304953	100736347	20992744014	into	into	II
304953	100736347	20992744015	an	a	AT1
304953	100736347	20992744016	image	image	NN1
304953	100736347	20992744017	.	.	.
304953	100736347	20992744018	MRI	mri	JJ_NP1_NN1
304953	100736347	20992744019	signals	signal	NN2
304953	100736347	20992744020	can	can	VM
304953	100736347	20992744021	give	give	VVI
304953	100736347	20992744022	an	a	AT1
304953	100736347	20992744023	image	image	NN1
304953	100736347	20992744024	of	of	IO
304953	100736347	20992744025	a	a	AT1
304953	100736347	20992744026	single	single	JJ
304953	100736347	20992744027	slice	slice	NN1
304953	100736347	20992744028	of	of	IO
304953	100736347	20992744029	any	any	DD
304953	100736347	20992744030	part	part	NN1
304953	100736347	20992744031	of	of	IO
304953	100736347	20992744032	the	the	AT
304953	100736347	20992744033	body	body	NN1
304953	100736347	20992744034	,	,	,
304953	100736347	20992744035	much	much	RR
304953	100736347	20992744036	like	like	II_VV0@
304953	100736347	20992744037	a	a	AT1
304953	100736347	20992744038	slice	slice	NN1
304953	100736347	20992744039	of	of	IO
304953	100736347	20992744040	bread	bread	NN1
304953	100736347	20992744041	in	in	II
304953	100736347	20992744042	a	a	AT1
304953	100736347	20992744043	loaf	loaf	NN1
304953	100736347	20992744044	.	.	.
304953	100736347	20992744045	Usually	usually	RR
304953	100736347	20992744046	,	,	,
304953	100736347	20992744047	images	image	NN2
304953	100736347	20992744048	are	be	VBR
304953	100736347	20992744049	created	create	VVN
304953	100736347	20992744050	of	of	IO
304953	100736347	20992744051	several	several	DA2
304953	100736347	20992744052	"	"	"
304953	100736347	20992744053	slices	slice	NN2
304953	100736347	20992744054	"	"	"
304953	100736347	20992744055	of	of	IO
304953	100736347	20992744056	an	a	AT1
304953	100736347	20992744057	organ	organ	NN1
304953	100736347	20992744058	or	or	CC
304953	100736347	20992744059	part	part	NN1
304953	100736347	20992744060	of	of	IO
304953	100736347	20992744061	the	the	AT
304953	100736347	20992744062	body	body	NN1
304953	100736347	20992744063	.	.	.
304953	100736347	20992744064	The	the	AT
304953	100736347	20992744065	computer	computer	NN1
304953	100736347	20992744066	also	also	RR
304953	100736347	20992744067	can	can	VM
304953	100736347	20992744068	combine	combine	VVI
304953	100736347	20992744069	these	these	DD2
304953	100736347	20992744070	slices	slice	NN2
304953	100736347	20992744071	into	into	II
304953	100736347	20992744072	three-dimensional	three-dimensional	JJ
304953	100736347	20992744073	(	(	(
304953	100736347	20992744074	3-D	3-d	JJ
304953	100736347	20992744075	)	)	)
304953	100736347	20992744076	images	image	NN2
304953	100736347	20992744077	.	.	.
304953	100736347	20992744078	<p>		NULL
304953	100736347	20992744079	Because	because	CS
304953	100736347	20992744080	water	water	NN1
304953	100736347	20992744081	molecules	molecule	NN2
304953	100736347	20992744082	are	be	VBR
304953	100736347	20992744083	especially	especially	RR
304953	100736347	20992744084	sensitive	sensitive	JJ
304953	100736347	20992744085	to	to	II
304953	100736347	20992744086	the	the	AT
304953	100736347	20992744087	forces	force	NN2
304953	100736347	20992744088	used	use	VVN_VVD
304953	100736347	20992744089	in	in	II
304953	100736347	20992744090	this	this	DD1
304953	100736347	20992744091	technique	technique	NN1
304953	100736347	20992744092	,	,	,
304953	100736347	20992744093	MRI	mri	JJ_NP1
304953	100736347	20992744094	scans	scan	NN2
304953	100736347	20992744095	are	be	VBR
304953	100736347	20992744096	very	very	RG
304953	100736347	20992744097	good	good	JJ
304953	100736347	20992744098	at	at	II
304953	100736347	20992744099	showing	show	VVG
304953	100736347	20992744100	differences	difference	NN2
304953	100736347	20992744101	in	in	II
304953	100736347	20992744102	water	water	NN1
304953	100736347	20992744103	content	content	NN1
304953	100736347	20992744104	between	between	II
304953	100736347	20992744105	different	different	JJ
304953	100736347	20992744106	body	body	NN1
304953	100736347	20992744107	tissues	tissue	NN2
304953	100736347	20992744108	.	.	.
304953	100736347	20992744109	This	this	DD1
304953	100736347	20992744110	is	be	VBZ
304953	100736347	20992744111	particularly	particularly	RR
304953	100736347	20992744112	helpful	helpful	JJ
304953	100736347	20992744113	in	in	II
304953	100736347	20992744114	distinguishing	distinguish	VVG_JJ
304953	100736347	20992744115	healthy	healthy	JJ
304953	100736347	20992744116	tissue	tissue	NN1
304953	100736347	20992744117	from	from	II
304953	100736347	20992744118	cancer	cancer	NN1
304953	100736347	20992744119	.	.	.
304953	100736347	20992744120	<p>		NULL
304953	100736347	20992744121	Before	before	II
304953	100736347	20992744122	undergoing	undergo	VVG
304953	100736347	20992744123	an	a	AT1
304953	100736347	20992744124	MRI	mri	NN1_JJ
304953	100736347	20992744125	,	,	,
304953	100736347	20992744126	your	your	APPGE
304953	100736347	20992744127	doctor	doctor	NN1
304953	100736347	20992744128	will	will	VM
304953	100736347	20992744129	ask	ask	VVI
304953	100736347	20992744130	whether	whether	CSW
304953	100736347	20992744131	you	you	PPY
304953	100736347	20992744132	have	have	VH0
304953	100736347	20992744133	any	any	DD
304953	100736347	20992744134	electronic	electronic	JJ
304953	100736347	20992744135	or	or	CC
304953	100736347	20992744136	metal	metal	NN1_VV0%
304953	100736347	20992744137	medical	medical	JJ
304953	100736347	20992744138	devices	device	NN2
304953	100736347	20992744139	in	in	II
304953	100736347	20992744140	your	your	APPGE
304953	100736347	20992744141	body	body	NN1
304953	100736347	20992744142	,	,	,
304953	100736347	20992744143	such	such	II21
304953	100736347	20992744144	as	as	II22
304953	100736347	20992744145	a	a	AT1
304953	100736347	20992744146	heart	heart	NN1
304953	100736347	20992744147	pacemaker	pacemaker	NN1
304953	100736347	20992744148	or	or	CC
304953	100736347	20992744149	any	any	DD
304953	100736347	20992744150	metallic	metallic	JJ
304953	100736347	20992744151	clips	clip	NN2
304953	100736347	20992744152	,	,	,
304953	100736347	20992744153	pins	pin	NN2
304953	100736347	20992744154	,	,	,
304953	100736347	20992744155	or	or	CC
304953	100736347	20992744156	screws	screw	NN2_VVZ
304953	100736347	20992744157	.	.	.
304953	100736347	20992744158	These	these	DD2
304953	100736347	20992744159	precautions	precaution	NN2
304953	100736347	20992744160	are	be	VBR
304953	100736347	20992744161	necessary	necessary	JJ
304953	100736347	20992744162	because	because	CS
304953	100736347	20992744163	the	the	AT
304953	100736347	20992744164	MRI	mri	JJ_NN1
304953	100736347	20992744165	magnet	magnet	NN1
304953	100736347	20992744166	is	be	VBZ
304953	100736347	20992744167	@		II
304953	100736347	20992744168	@		II
304953	100736347	20992744169	@		II
304953	100736347	20992744170	@		II
304953	100736347	20992744171	@		II
304953	100736347	20992744172	@		II
304953	100736347	20992744173	@		II
304953	100736347	20992744174	@		II
304953	100736347	20992744175	@		II
304953	100736347	20992744176	@		II
304953	100736347	20992744177	displace	displace	VV0
304953	100736347	20992744178	some	some	DD
304953	100736347	20992744179	implanted	implanted	JJ@
304953	100736347	20992744180	clips	clip	NN2
304953	100736347	20992744181	.	.	.
304953	100736347	20992744182	<p>		NULL
304953	100736347	20992744183	MRI	mri	NP1_NN1
304953	100736347	20992744184	is	be	VBZ
304953	100736347	20992744185	a	a	AT1
304953	100736347	20992744186	painless	painless	JJ
304953	100736347	20992744187	technique	technique	NN1
304953	100736347	20992744188	that	that	CST
304953	100736347	20992744189	usually	usually	RR
304953	100736347	20992744190	takes	take	VVZ
304953	100736347	20992744191	about	about	RG
304953	100736347	20992744192	45	45	MC
304953	100736347	20992744193	minutes	minute	NNT2
304953	100736347	20992744194	to	to	II_TO
304953	100736347	20992744195	a	a	RR21_AT1
304953	100736347	20992744196	little	little	RR22_JJ
304953	100736347	20992744197	over	over	II_RP
304953	100736347	20992744198	an	a	AT1
304953	100736347	20992744199	hour	hour	NNT1
304953	100736347	20992744200	.	.	.
304953	100736347	20992744201	Most	most	DAT_RGT
304953	100736347	20992744202	MRI	mri	JJ
304953	100736347	20992744203	scanners	scanner	NN2
304953	100736347	20992744204	require	require	VV0
304953	100736347	20992744205	you	you	PPY
304953	100736347	20992744206	to	to	TO
304953	100736347	20992744207	lie	lie	VVI
304953	100736347	20992744208	inside	inside	II_RL
304953	100736347	20992744209	a	a	AT1
304953	100736347	20992744210	narrow	narrow	JJ
304953	100736347	20992744211	cylinder	cylinder	NN1
304953	100736347	20992744212	.	.	.
304953	100736347	20992744213	This	this	DD1
304953	100736347	20992744214	can	can	VM
304953	100736347	20992744215	make	make	VVI
304953	100736347	20992744216	some	some	DD
304953	100736347	20992744217	people	people	NN
304953	100736347	20992744218	feel	feel	VVI
304953	100736347	20992744219	anxious	anxious	JJ
304953	100736347	20992744220	and	and	CC
304953	100736347	20992744221	claustrophobic	claustrophobic	JJ
304953	100736347	20992744222	.	.	.
304953	100736347	20992744223	If	if	CS
304953	100736347	20992744224	you	you	PPY
304953	100736347	20992744225	tend	tend	VV0
304953	100736347	20992744226	to	to	TO
304953	100736347	20992744227	feel	feel	VVI
304953	100736347	20992744228	anxious	anxious	JJ
304953	100736347	20992744229	in	in	II
304953	100736347	20992744230	tight	tight	JJ
304953	100736347	20992744231	places	place	NN2
304953	100736347	20992744232	,	,	,
304953	100736347	20992744233	ask	ask	VV0
304953	100736347	20992744234	your	your	APPGE
304953	100736347	20992744235	doctor	doctor	NN1
304953	100736347	20992744236	for	for	IF
304953	100736347	20992744237	medication	medication	NN1
304953	100736347	20992744238	to	to	TO
304953	100736347	20992744239	help	help	VVI
304953	100736347	20992744240	you	you	PPY
304953	100736347	20992744241	relax	relax	VVI
304953	100736347	20992744242	during	during	II
304953	100736347	20992744243	the	the	AT
304953	100736347	20992744244	procedure	procedure	NN1
304953	100736347	20992744245	.	.	.
304953	100736347	20992744246	A	a	AT1_ZZ1
304953	100736347	20992744247	new	new	JJ
304953	100736347	20992744248	type	type	NN1
304953	100736347	20992744249	of	of	IO
304953	100736347	20992744250	MRI	mri	JJ_NP1_NN1
304953	100736347	20992744251	scanner	scanner	NN1
304953	100736347	20992744252	,	,	,
304953	100736347	20992744253	called	call	VVN_VVD@
304953	100736347	20992744254	an	a	AT1
304953	100736347	20992744255	open	open	JJ
304953	100736347	20992744256	MRI	mri	NN2_NN1
304953	100736347	20992744257	,	,	,
304953	100736347	20992744258	is	be	VBZ
304953	100736347	20992744259	more	more	RGR
304953	100736347	20992744260	comfortable	comfortable	JJ
304953	100736347	20992744261	for	for	IF
304953	100736347	20992744262	some	some	DD
304953	100736347	20992744263	people	people	NN
304953	100736347	20992744264	because	because	CS
304953	100736347	20992744265	it	it	PPH1
304953	100736347	20992744266	is	be	VBZ
304953	100736347	20992744267	open	open	JJ
304953	100736347	20992744268	on	on	II
304953	100736347	20992744269	all	all	DB
304953	100736347	20992744270	sides	side	NN2
304953	100736347	20992744271	.	.	.
304953	100736347	20992744272	<p>		NULL
304953	100736347	20992744273	The	the	AT
304953	100736347	20992744274	procedure	procedure	NN1
304953	100736347	20992744275	itself	itself	PPX1
304953	100736347	20992744276	is	be	VBZ
304953	100736347	20992744277	very	very	RG
304953	100736347	20992744278	low-risk	low-risk	JJ
304953	100736347	20992744279	.	.	.
304953	100736347	20992744280	Ionizing	ionize	VVG_JJ@_NP1@
304953	100736347	20992744281	radiation	radiation	NN1
304953	100736347	20992744282	,	,	,
304953	100736347	20992744283	which	which	DDQ
304953	100736347	20992744284	is	be	VBZ
304953	100736347	20992744285	the	the	AT
304953	100736347	20992744286	type	type	NN1
304953	100736347	20992744287	used	use	VMK
304953	100736347	20992744288	to	to	TO
304953	100736347	20992744289	generate	generate	VVI
304953	100736347	20992744290	an	a	AT1
304953	100736347	20992744291	x-ray	x-ray	NN1_JJ
304953	100736347	20992744292	or	or	CC
304953	100736347	20992744293	CT	ct	NN1_NP1@
304953	100736347	20992744294	scan	scan	NN1_VV0
304953	100736347	20992744295	,	,	,
304953	100736347	20992744296	carries	carry	VVZ
304953	100736347	20992744297	some	some	DD
304953	100736347	20992744298	risk	risk	NN1
304953	100736347	20992744299	because	because	CS
304953	100736347	20992744300	too	too	RG
304953	100736347	20992744301	much	much	DA1
304953	100736347	20992744302	exposure	exposure	NN1
304953	100736347	20992744303	to	to	II
304953	100736347	20992744304	this	this	DD1
304953	100736347	20992744305	form	form	NN1
304953	100736347	20992744306	of	of	IO
304953	100736347	20992744307	radiation	radiation	NN1
304953	100736347	20992744308	can	can	VM
304953	100736347	20992744309	potentially	potentially	RR
304953	100736347	20992744310	damage	damage	VVI
304953	100736347	20992744311	a	a	AT1
304953	100736347	20992744312	person	person	NN1
304953	100736347	20992744313	's	's	GE
304953	100736347	20992744314	genetic	genetic	JJ
304953	100736347	20992744315	material	material	NN1
304953	100736347	20992744316	.	.	.
304953	100736347	20992744317	MRI	mri	NP1_NN1
304953	100736347	20992744318	does	do	VDZ
304953	100736347	20992744319	not	not	XX
304953	100736347	20992744320	involve	involve	VVI
304953	100736347	20992744321	ionizing	ionize	VVG_JJ@
304953	100736347	20992744322	radiation	radiation	NN1
304953	100736347	20992744323	,	,	,
304953	100736347	20992744324	so	so	CS@_RR
304953	100736347	20992744325	there	there	EX
304953	100736347	20992744326	is	be	VBZ
304953	100736347	20992744327	no	no	AT
304953	100736347	20992744328	danger	danger	NN1
304953	100736347	20992744329	with	with	IW
304953	100736347	20992744330	single	single	JJ
304953	100736347	20992744331	or	or	CC
304953	100736347	20992744332	repeat	repeat	VV0
304953	100736347	20992744333	exposures	exposure	NN2
304953	100736347	20992744334	.	.	.
304953	100736347	20992744335	<p>		NULL
304953	100736347	20992744336	MRI	mri	NP1_NN1
304953	100736347	20992744337	is	be	VBZ
304953	100736347	20992744338	usually	usually	RR
304953	100736347	20992744339	done	do	VDN
304953	100736347	20992744340	as	as	II
304953	100736347	20992744341	an	a	AT1
304953	100736347	20992744342	outpatient	outpatient	NN1
304953	100736347	20992744343	test	test	NN1_VV0
304953	100736347	20992744344	in	in	II
304953	100736347	20992744345	a	a	AT1
304953	100736347	20992744346	hospital	hospital	NN1
304953	100736347	20992744347	or	or	CC
304953	100736347	20992744348	in	in	II
304953	100736347	20992744349	a	a	AT1
304953	100736347	20992744350	scanning	scanning	NN1@_JJ%
304953	100736347	20992744351	facility	facility	NN1
304953	100736347	20992744352	.	.	.
304953	100736347	20992744353	If	if	CS
304953	100736347	20992744354	a	a	AT1
304953	100736347	20992744355	cylindrical	cylindrical	JJ
304953	100736347	20992744356	scanner	scanner	NN1
304953	100736347	20992744357	is	be	VBZ
304953	100736347	20992744358	being	be	VBG
304953	100736347	20992744359	used	use	VVN
304953	100736347	20992744360	,	,	,
304953	100736347	20992744361	the	the	AT
304953	100736347	20992744362	table	table	NN1
304953	100736347	20992744363	will	will	VM
304953	100736347	20992744364	slide	slide	VVI
304953	100736347	20992744365	into	into	II
304953	100736347	20992744366	the	the	AT
304953	100736347	20992744367	@		II
304953	100736347	20992744368	@		II
304953	100736347	20992744369	@		II
304953	100736347	20992744370	@		II
304953	100736347	20992744371	@		II
304953	100736347	20992744372	@		II
304953	100736347	20992744373	@		II
304953	100736347	20992744374	@		II
304953	100736347	20992744375	@		II
304953	100736347	20992744376	@		II
304953	100736347	20992744377	the	the	AT
304953	100736347	20992744378	table	table	NN1
304953	100736347	20992744379	will	will	VM
304953	100736347	20992744380	slide	slide	VVI
304953	100736347	20992744381	so	so	CS21
304953	100736347	20992744382	that	that	CS22
304953	100736347	20992744383	the	the	AT
304953	100736347	20992744384	part	part	NN1
304953	100736347	20992744385	of	of	IO
304953	100736347	20992744386	your	your	APPGE
304953	100736347	20992744387	body	body	NN1
304953	100736347	20992744388	being	be	VBG
304953	100736347	20992744389	scanned	scan	VVN@
304953	100736347	20992744390	is	be	VBZ
304953	100736347	20992744391	surrounded	surround	VVN
304953	100736347	20992744392	by	by	II
304953	100736347	20992744393	the	the	AT
304953	100736347	20992744394	scanning	scanning	NN1@_JJ%
304953	100736347	20992744395	element	element	NN1
304953	100736347	20992744396	,	,	,
304953	100736347	20992744397	or	or	CC
304953	100736347	20992744398	the	the	AT
304953	100736347	20992744399	machine	machine	NN1
304953	100736347	20992744400	will	will	VM
304953	100736347	20992744401	move	move	VVI
304953	100736347	20992744402	over	over	RP_II
304953	100736347	20992744403	you	you	PPY
304953	100736347	20992744404	as	as	CSA
304953	100736347	20992744405	you	you	PPY
304953	100736347	20992744406	lie	lie	VV0
304953	100736347	20992744407	on	on	II_RP@
304953	100736347	20992744408	the	the	AT
304953	100736347	20992744409	table	table	NN1
304953	100736347	20992744410	.	.	.
304953	100736347	20992744411	You	you	PPY
304953	100736347	20992744412	will	will	VM
304953	100736347	20992744413	need	need	VVI
304953	100736347	20992744414	to	to	TO
304953	100736347	20992744415	lie	lie	VVI
304953	100736347	20992744416	very	very	RG
304953	100736347	20992744417	still	still	RR
304953	100736347	20992744418	during	during	II
304953	100736347	20992744419	the	the	AT
304953	100736347	20992744420	procedure	procedure	NN1
304953	100736347	20992744421	,	,	,
304953	100736347	20992744422	and	and	CC
304953	100736347	20992744423	you	you	PPY
304953	100736347	20992744424	will	will	VM
304953	100736347	20992744425	periodically	periodically	RR
304953	100736347	20992744426	hear	hear	VVI
304953	100736347	20992744427	loud	loud	JJ_RR
304953	100736347	20992744428	knocking	knocking	NN1_VVG
304953	100736347	20992744429	noises	noise	NN2
304953	100736347	20992744430	as	as	II_CSA
304953	100736347	20992744431	the	the	AT
304953	100736347	20992744432	scanner	scanner	NN1
304953	100736347	20992744433	works	work	VVZ_NN
304953	100736347	20992744434	.	.	.
304953	100736347	20992744435	The	the	AT
304953	100736347	20992744436	technologist	technologist	NN1
304953	100736347	20992744437	operating	operate	VVG
304953	100736347	20992744438	the	the	AT
304953	100736347	20992744439	machine	machine	NN1
304953	100736347	20992744440	will	will	VM
304953	100736347	20992744441	be	be	VBI
304953	100736347	20992744442	in	in	II
304953	100736347	20992744443	another	another	DD1
304953	100736347	20992744444	room	room	NN1
304953	100736347	20992744445	,	,	,
304953	100736347	20992744446	but	but	CCB
304953	100736347	20992744447	you	you	PPY
304953	100736347	20992744448	will	will	VM
304953	100736347	20992744449	be	be	VBI
304953	100736347	20992744450	able	able	JK
304953	100736347	20992744451	to	to	TO
304953	100736347	20992744452	talk	talk	VVI
304953	100736347	20992744453	to	to	II
304953	100736347	20992744454	him	him	PPHO1
304953	100736347	20992744455	or	or	CC
304953	100736347	20992744456	her	her	APPGE
304953	100736347	20992744457	thoughout		NN1_VV0
304953	100736347	20992744458	the	the	AT
304953	100736347	20992744459	procedure	procedure	NN1
304953	100736347	20992744460	.	.	.
304953	100736347	20992744461	<p>		NULL
304953	100736347	20992744462	If	if	CS
304953	100736347	20992744463	your	your	APPGE
304953	100736347	20992744464	doctor	doctor	NN1
304953	100736347	20992744465	gave	give	VVD
304953	100736347	20992744466	you	you	PPY
304953	100736347	20992744467	a	a	AT1
304953	100736347	20992744468	sedative	sedative	NN1_JJ
304953	100736347	20992744469	or	or	CC
304953	100736347	20992744470	tranquilizer	tranquilizer	NN1
304953	100736347	20992744471	beforehand	beforehand	RR
304953	100736347	20992744472	,	,	,
304953	100736347	20992744473	you	you	PPY
304953	100736347	20992744474	may	may	VM
304953	100736347	20992744475	be	be	VBI
304953	100736347	20992744476	drowsy	drowsy	JJ
304953	100736347	20992744477	after	after	II_CS
304953	100736347	20992744478	your	your	APPGE
304953	100736347	20992744479	MRI	mri	JJ_NN1
304953	100736347	20992744480	procedure	procedure	NN1
304953	100736347	20992744481	and	and	CC
304953	100736347	20992744482	unable	unable	JK
304953	100736347	20992744483	to	to	TO
304953	100736347	20992744484	drive	drive	VVI
304953	100736347	20992744485	safely	safely	RR
304953	100736347	20992744486	.	.	.
304953	100736347	20992744487	Have	have	VH0
304953	100736347	20992744488	a	a	AT1
304953	100736347	20992744489	friend	friend	NN1
304953	100736347	20992744490	or	or	CC
304953	100736347	20992744491	family	family	NN1
304953	100736347	20992744492	member	member	NN1
304953	100736347	20992744493	take	take	VV0
304953	100736347	20992744494	you	you	PPY
304953	100736347	20992744495	home	home	RL
304953	100736347	20992744496	.	.	.
304953	100736347	20992744497	<p>		NULL
304953	100736347	20992744498	Your	your	APPGE
304953	100736347	20992744499	MRI	mri	JJ_NN1_NN2
304953	100736347	20992744500	scan	scan	NN1
304953	100736347	20992744501	will	will	VM
304953	100736347	20992744502	be	be	VBI
304953	100736347	20992744503	read	read	VVN
304953	100736347	20992744504	by	by	II
304953	100736347	20992744505	a	a	AT1
304953	100736347	20992744506	specialist	specialist	NN1
304953	100736347	20992744507	who	who	PNQS
304953	100736347	20992744508	will	will	VM
304953	100736347	20992744509	tell	tell	VVI
304953	100736347	20992744510	your	your	APPGE
304953	100736347	20992744511	doctor	doctor	NN1
304953	100736347	20992744512	the	the	AT
304953	100736347	20992744513	results	result	NN2
304953	100736347	20992744514	.	.	.
304953	100736347	20992744515	Ask	ask	VV0
304953	100736347	20992744516	when	when	RRQ_CS
304953	100736347	20992744517	you	you	PPY
304953	100736347	20992744518	should	should	VM
304953	100736347	20992744519	call	call	VVI
304953	100736347	20992744520	your	your	APPGE
304953	100736347	20992744521	doctor	doctor	NN1
304953	100736347	20992744522	for	for	IF
304953	100736347	20992744523	the	the	AT
304953	100736347	20992744524	official	official	JJ_NN1
304953	100736347	20992744525	report	report	NN1
304953	100736347	20992744526	.	.	.
304953	100736347	20992744527	46996		MC
304953	100736347	20992744528	@qwx906996		FO
304953	100736349	20992744548	@@##	----------	----------
304953	100736349	20992744549	@@100736349		FO
304953	100736349	20992744550	@4936349/		NN1_VV0
304953	100736349	20992744551	<p>		NULL
304953	100736349	20992744552	Sipuleucel-T		NP1
304953	100736349	20992744553	(	(	(
304953	100736349	20992744554	Provenge		NP1
304953	100736349	20992744555	)	)	)
304953	100736349	20992744556	,	,	,
304953	100736349	20992744557	a	a	AT1
304953	100736349	20992744558	"	"	"
304953	100736349	20992744559	vaccine	vaccine	NN1
304953	100736349	20992744560	"	"	"
304953	100736349	20992744561	that	that	CST_DD1
304953	100736349	20992744562	uses	use	VVZ
304953	100736349	20992744563	a	a	AT1
304953	100736349	20992744564	patients	patient	NN2
304953	100736349	20992744565	immune	immune	JJ
304953	100736349	20992744566	system	system	NN1
304953	100736349	20992744567	to	to	TO
304953	100736349	20992744568	fight	fight	VVI
304953	100736349	20992744569	advanced	advanced	JJ
304953	100736349	20992744570	stage	stage	NN1
304953	100736349	20992744571	disease	disease	NN1
304953	100736349	20992744572	,	,	,
304953	100736349	20992744573	was	be	VBDZ
304953	100736349	20992744574	approved	approve	VVN
304953	100736349	20992744575	by	by	II
304953	100736349	20992744576	the	the	AT
304953	100736349	20992744577	FDA	fda	NN1_NP1
304953	100736349	20992744578	in	in	II
304953	100736349	20992744579	April	april	NPM1
304953	100736349	20992744580	2010	2010	MC
304953	100736349	20992744581	.	.	.
304953	100736349	20992744582	The	the	AT
304953	100736349	20992744583	vaccine	vaccine	NN1
304953	100736349	20992744584	does	do	VDZ
304953	100736349	20992744585	not	not	XX
304953	100736349	20992744586	prevent	prevent	VVI
304953	100736349	20992744587	cancer	cancer	NN1
304953	100736349	20992744588	;	;	;
304953	100736349	20992744589	rather	rather	RR@_RG
304953	100736349	20992744590	,	,	,
304953	100736349	20992744591	it	it	PPH1
304953	100736349	20992744592	helps	help	VVZ
304953	100736349	20992744593	men	man	NN2
304953	100736349	20992744594	with	with	IW
304953	100736349	20992744595	advanced	advanced	JJ
304953	100736349	20992744596	stage	stage	NN1
304953	100736349	20992744597	,	,	,
304953	100736349	20992744598	hormone-resistant		JJ
304953	100736349	20992744599	disease	disease	NN1
304953	100736349	20992744600	live	live	VV0_RR@
304953	100736349	20992744601	longer	long	RRR_JJR
304953	100736349	20992744602	.	.	.
304953	100736349	20992744603	<p>		NULL
304953	100736349	20992744604	A	a	AT1
304953	100736349	20992744605	prostate	prostate	NN1
304953	100736349	20992744606	cancer	cancer	NN1
304953	100736349	20992744607	diagnosis	diagnosis	NN1
304953	100736349	20992744608	may	may	VM
304953	100736349	20992744609	send	send	VVI
304953	100736349	20992744610	a	a	AT1
304953	100736349	20992744611	man	man	NN1
304953	100736349	20992744612	to	to	II
304953	100736349	20992744613	the	the	AT
304953	100736349	20992744614	operating	operating	NN1
304953	100736349	20992744615	room	room	NN1
304953	100736349	20992744616	or	or	CC
304953	100736349	20992744617	drive	drive	VV0
304953	100736349	20992744618	him	him	PPHO1
304953	100736349	20992744619	to	to	TO
304953	100736349	20992744620	get	get	VVI
304953	100736349	20992744621	radiation	radiation	NN1
304953	100736349	20992744622	therapy	therapy	NN1
304953	100736349	20992744623	"	"	"
304953	100736349	20992744624	even	even	CS21
304953	100736349	20992744625	when	when	CS22
304953	100736349	20992744626	the	the	AT
304953	100736349	20992744627	cancer	cancer	NN1
304953	100736349	20992744628	is	be	VBZ
304953	100736349	20992744629	unlikely	unlikely	JJ
304953	100736349	20992744630	to	to	TO
304953	100736349	20992744631	spread	spread	VVI
304953	100736349	20992744632	or	or	CC
304953	100736349	20992744633	cause	cause	NN1_VV0
304953	100736349	20992744634	harm	harm	NN1
304953	100736349	20992744635	.	.	.
304953	100736349	20992744636	That 's		NN2
304953	100736349	20992744637	causing	cause	VVG
304953	100736349	20992744638	some	some	DD
304953	100736349	20992744639	to	to	TO
304953	100736349	20992744640	wonder	wonder	VVI
304953	100736349	20992744641	when	when	RRQ
304953	100736349	20992744642	a	a	AT1
304953	100736349	20992744643	biopsy	biopsy	NN1
304953	100736349	20992744644	should	should	VM
304953	100736349	20992744645	really	really	RR
304953	100736349	20992744646	be	be	VBI
304953	100736349	20992744647	done	do	VDN
304953	100736349	20992744648	.	.	.
304953	100736349	20992744649	<p>		NULL
304953	100736349	20992744650	Prostate	prostate	NN1
304953	100736349	20992744651	cancer	cancer	NN1
304953	100736349	20992744652	drug	drug	NN1
304953	100736349	20992744653	treatments	treatment	NN2
304953	100736349	20992744654	that	that	CST
304953	100736349	20992744655	block	block	VV0@
304953	100736349	20992744656	the	the	AT
304953	100736349	20992744657	activity	activity	NN1
304953	100736349	20992744658	of	of	IO
304953	100736349	20992744659	hormones	hormone	NN2
304953	100736349	20992744660	have	have	VH0
304953	100736349	20992744661	been	be	VBN
304953	100736349	20992744662	associated	associate	VVN
304953	100736349	20992744663	with	with	IW
304953	100736349	20992744664	a	a	AT1
304953	100736349	20992744665	higher	high	JJR
304953	100736349	20992744666	risk	risk	NN1
304953	100736349	20992744667	of	of	IO
304953	100736349	20992744668	heart	heart	NN1
304953	100736349	20992744669	attack	attack	NN1
304953	100736349	20992744670	and	and	CC
304953	100736349	20992744671	heart	heart	NN1
304953	100736349	20992744672	disease	disease	NN1
304953	100736349	20992744673	.	.	.
304953	100736349	20992744674	But	but	CCB
304953	100736349	20992744675	a	a	AT1
304953	100736349	20992744676	2009	2009	MC
304953	100736349	20992744677	study	study	NN1
304953	100736349	20992744678	suggests	suggest	VVZ
304953	100736349	20992744679	that	that	CST
304953	100736349	20992744680	these	these	DD2
304953	100736349	20992744681	drugs	drug	NN2
304953	100736349	20992744682	may	may	VM
304953	100736349	20992744683	not	not	XX
304953	100736349	20992744684	cause	cause	VVI
304953	100736349	20992744685	cardiovascular	cardiovascular	JJ
304953	100736349	20992744686	problems	problem	NN2
304953	100736349	20992744687	after	after	II
304953	100736349	20992744688	all	all	DB
304953	100736349	20992744689	.	.	.
304953	100736349	20992744690	<p>		NULL
304953	100736349	20992744691	Ever	ever	RR
304953	100736349	20992744692	since	since	CS_II@
304953	100736349	20992744693	the	the	AT
304953	100736349	20992744694	FDA	fda	NP1_NN1
304953	100736349	20992744695	approved	approve	VVD_VVN
304953	100736349	20992744696	the	the	AT
304953	100736349	20992744697	first	first	MD
304953	100736349	20992744698	cholesterol-lowering	cholesterol-lowering	JJ_NN1
304953	100736349	20992744699	statin	statin	NN1
304953	100736349	20992744700	in	in	II
304953	100736349	20992744701	1987	1987	MC
304953	100736349	20992744702	,	,	,
304953	100736349	20992744703	use	use	NN1
304953	100736349	20992744704	of	of	IO
304953	100736349	20992744705	the	the	AT
304953	100736349	20992744706	drugs	drug	NN2
304953	100736349	20992744707	has	have	VHZ
304953	100736349	20992744708	steadily	steadily	RR
304953	100736349	20992744709	increased	increase	VVN
304953	100736349	20992744710	,	,	,
304953	100736349	20992744711	with	with	IW
304953	100736349	20992744712	an	a	AT1
304953	100736349	20992744713	estimated	estimated	JJ@
304953	100736349	20992744714	13	13	MC
304953	100736349	20992744715	million	million	NNO
304953	100736349	20992744716	Americans	american	NN2
304953	100736349	20992744717	taking	take	VVG
304953	100736349	20992744718	them	them	PPHO2
304953	100736349	20992744719	to	to	II
304953	100736349	20992744720	ward	ward	NN1
304953	100736349	20992744721	off	off	II
304953	100736349	20992744722	heart	heart	NN1
304953	100736349	20992744723	and	and	CC
304953	100736349	20992744724	vascular	vascular	JJ
304953	100736349	20992744725	disease	disease	NN1
304953	100736349	20992744726	.	.	.
304953	100736349	20992744727	Recently	recently	RR
304953	100736349	20992744728	,	,	,
304953	100736349	20992744729	statins	statin	NN2
304953	100736349	20992744730	have	have	VH0
304953	100736349	20992744731	gained	gain	VVN
304953	100736349	20992744732	additional	additional	JJ
304953	100736349	20992744733	attention	attention	NN1
304953	100736349	20992744734	,	,	,
304953	100736349	20992744735	thanks	thanks	NN2
304953	100736349	20992744736	to	to	II
304953	100736349	20992744737	studies	study	NN2
304953	100736349	20992744738	showing	show	VVG
304953	100736349	20992744739	the	the	AT
304953	100736349	20992744740	@		II
304953	100736349	20992744741	@		II
304953	100736349	20992744742	@		II
304953	100736349	20992744743	@		II
304953	100736349	20992744744	@		II
304953	100736349	20992744745	@		II
304953	100736349	20992744746	@		II
304953	100736349	20992744747	@		II
304953	100736349	20992744748	@		II
304953	100736349	20992744749	@		II
304953	100736349	20992744750	answers	answer	NN2
304953	100736349	20992744751	to	to	II
304953	100736350	20992744771	@@##	----------	----------
304953	100736350	20992744772	@@100736350		FO
304953	100736350	20992744773	@4936350/		VV0_NN1
304953	100736350	20992744774	46989		MC
304953	100736350	20992744775	@qwx906989		FO
304953	100736350	20992744776	<p>		NULL
304953	100736350	20992744777	Its	its	APPGE
304953	100736350	20992744778	been	be	VBN
304953	100736350	20992744779	just	just	RR
304953	100736350	20992744780	over	over	RG
304953	100736350	20992744781	ten	ten	MC
304953	100736350	20992744782	years	year	NNT2
304953	100736350	20992744783	since	since	CS_II@
304953	100736350	20992744784	robot-assisted		JJ
304953	100736350	20992744785	radical	radical	JJ_NN1
304953	100736350	20992744786	prostatectomy	prostatectomy	NN1
304953	100736350	20992744787	came	come	VVD
304953	100736350	20992744788	on	on	II
304953	100736350	20992744789	the	the	AT
304953	100736350	20992744790	scene	scene	NN1
304953	100736350	20992744791	for	for	IF
304953	100736350	20992744792	the	the	AT
304953	100736350	20992744793	treatment	treatment	NN1
304953	100736350	20992744794	of	of	IO
304953	100736350	20992744795	localized	localized	JJ
304953	100736350	20992744796	prostate	prostate	NN1
304953	100736350	20992744797	cancer	cancer	NN1
304953	100736350	20992744798	.	.	.
304953	100736350	20992744799	Its	its	APPGE
304953	100736350	20992744800	use	use	NN1
304953	100736350	20992744801	has	have	VHZ
304953	100736350	20992744802	skyrocketed	skyrocket	VVN
304953	100736350	20992744803	,	,	,
304953	100736350	20992744804	driven	drive	VVN_JJ
304953	100736350	20992744805	in	in	RR21
304953	100736350	20992744806	part	part	RR22
304953	100736350	20992744807	by	by	II
304953	100736350	20992744808	direct-to-consumer	direct-to-consumer	JJ_NN1
304953	100736350	20992744809	advertising	advertising	NN1
304953	100736350	20992744810	and	and	CC
304953	100736350	20992744811	competition	competition	NN1
304953	100736350	20992744812	between	between	II
304953	100736350	20992744813	hospitals	hospital	NN2
304953	100736350	20992744814	.	.	.
304953	100736350	20992744815	Nearly	nearly	RR
304953	100736350	20992744816	two-thirds	two-thirds	MF
304953	100736350	20992744817	of	of	IO
304953	100736350	20992744818	all	all	DB
304953	100736350	20992744819	radical	radical	JJ
304953	100736350	20992744820	prostatectomies	prostatectomy	NN2
304953	100736350	20992744821	now	now	RT
304953	100736350	20992744822	performed	perform	VVN_VVD
304953	100736350	20992744823	in	in	II
304953	100736350	20992744824	the	the	AT
304953	100736350	20992744825	United	united	NP1
304953	100736350	20992744826	States	state	NP1
304953	100736350	20992744827	are	be	VBR
304953	100736350	20992744828	done	do	VDN
304953	100736350	20992744829	with	with	IW
304953	100736350	20992744830	the	the	AT
304953	100736350	20992744831	help	help	NN1
304953	100736350	20992744832	of	of	IO
304953	100736350	20992744833	a	a	AT1
304953	100736350	20992744834	robot	robot	NN1
304953	100736350	20992744835	.	.	.
304953	100736350	20992744836	Thanks	thanks	NN2
304953	100736350	20992744837	in	in	RR21
304953	100736350	20992744838	part	part	RR22
304953	100736350	20992744839	to	to	II
304953	100736350	20992744840	advertising	advertising	NN1
304953	100736350	20992744841	,	,	,
304953	100736350	20992744842	many	many	DA2
304953	100736350	20992744843	men	man	NN2
304953	100736350	20992744844	with	with	IW
304953	100736350	20992744845	prostate	prostate	NN1
304953	100736350	20992744846	cancer	cancer	NN1
304953	100736350	20992744847	believe	believe	VV0
304953	100736350	20992744848	that	that	CST_DD1
304953	100736350	20992744849	theyll		VV0_NN1
304953	100736350	20992744850	get	get	VV0
304953	100736350	20992744851	better	better	JJR
304953	100736350	20992744852	results	result	NN2
304953	100736350	20992744853	with	with	IW
304953	100736350	20992744854	robot-assisted		JJ
304953	100736350	20992744855	prostate	prostate	NN1
304953	100736350	20992744856	surgery	surgery	NN1
304953	100736350	20992744857	than	than	CSN
304953	100736350	20992744858	with	with	IW
304953	100736350	20992744859	more	more	RGR_DAR
304953	100736350	20992744860	traditional	traditional	JJ
304953	100736350	20992744861	open	open	JJ
304953	100736350	20992744862	surgery	surgery	NN1
304953	100736350	20992744863	.	.	.
304953	100736350	20992744864	But	but	CCB
304953	100736350	20992744865	so	so	RG
304953	100736350	20992744866	far	far	RR
304953	100736350	20992744867	,	,	,
304953	100736350	20992744868	studies	study	NN2
304953	100736350	20992744869	comparing	compare	VVG
304953	100736350	20992744870	the	the	AT
304953	100736350	20992744871	two	two	MC
304953	100736350	20992744872	approaches	approach	VVZ_NN2
304953	100736350	20992744873	havent		NN1_VV0
304953	100736350	20992744874	backed	back	VVD_VVN
304953	100736350	20992744875	that	that	DD1
304953	100736350	20992744876	up	up	RP
304953	100736350	20992744877	.	.	.
304953	100736350	20992744878	<p>		NULL
304953	100736350	20992744879	Robot-assisted	robot-assisted	JJ_NN1
304953	100736350	20992744880	surgery	surgery	NN1
304953	100736350	20992744881	was	be	VBDZ
304953	100736350	20992744882	designed	design	VVN
304953	100736350	20992744883	to	to	TO
304953	100736350	20992744884	help	help	VVI
304953	100736350	20992744885	surgeons	surgeon	NN2
304953	100736350	20992744886	do	do	VDI
304953	100736350	20992744887	a	a	AT1
304953	100736350	20992744888	variety	variety	NN1
304953	100736350	20992744889	of	of	IO
304953	100736350	20992744890	operations	operation	NN2
304953	100736350	20992744891	.	.	.
304953	100736350	20992744892	Instead	instead	CS21%_II21
304953	100736350	20992744893	of	of	CS22_II22
304953	100736350	20992744894	directly	directly	RR
304953	100736350	20992744895	moving	move	VVG
304953	100736350	20992744896	an	a	AT1
304953	100736350	20992744897	instrument	instrument	NN1
304953	100736350	20992744898	,	,	,
304953	100736350	20992744899	the	the	AT
304953	100736350	20992744900	surgeon	surgeon	NN1
304953	100736350	20992744901	manipulates	manipulate	VVZ
304953	100736350	20992744902	controls	control	NN2_VVZ
304953	100736350	20992744903	that	that	CST
304953	100736350	20992744904	guide	guide	VV0
304953	100736350	20992744905	a	a	AT1
304953	100736350	20992744906	robot	robot	NN1
304953	100736350	20992744907	to	to	TO
304953	100736350	20992744908	move	move	VVI
304953	100736350	20992744909	it	it	PPH1
304953	100736350	20992744910	.	.	.
304953	100736350	20992744911	In	in	II
304953	100736350	20992744912	theory	theory	NN1
304953	100736350	20992744913	,	,	,
304953	100736350	20992744914	the	the	AT
304953	100736350	20992744915	robot	robot	NN1
304953	100736350	20992744916	can	can	VM
304953	100736350	20992744917	perform	perform	VVI
304953	100736350	20992744918	some	some	DD
304953	100736350	20992744919	actions	action	NN2
304953	100736350	20992744920	more	more	RGR
304953	100736350	20992744921	smoothly	smoothly	RR
304953	100736350	20992744922	and	and	CC
304953	100736350	20992744923	accurately	accurately	RR
304953	100736350	20992744924	than	than	CSN
304953	100736350	20992744925	a	a	AT1
304953	100736350	20992744926	surgeon	surgeon	NN1
304953	100736350	20992744927	.	.	.
304953	100736350	20992744928	<p>		NULL
304953	100736350	20992744929	The	the	AT
304953	100736350	20992744930	latest	late	JJT
304953	100736350	20992744931	comparative	comparative	JJ
304953	100736350	20992744932	study	study	NN1
304953	100736350	20992744933	has	have	VHZ
304953	100736350	20992744934	generated	generate	VVN
304953	100736350	20992744935	similarly	similarly	RR
304953	100736350	20992744936	ambiguous	ambiguous	JJ
304953	100736350	20992744937	findings	finding	NN2
304953	100736350	20992744938	.	.	.
304953	100736350	20992744939	Its	its	APPGE
304953	100736350	20992744940	take-away	takeaway	NN1
304953	100736350	20992744941	point	point	NN1
304953	100736350	20992744942	is	be	VBZ
304953	100736350	20992744943	that	that	DD1_CST_RG%
304953	100736350	20992744944	good	good	JJ
304953	100736350	20992744945	results	result	NN2
304953	100736350	20992744946	depend	depend	VV0
304953	100736350	20992744947	far	far	RG
304953	100736350	20992744948	more	more	RRR_DAR
304953	100736350	20992744949	on	on	II
304953	100736350	20992744950	a	a	AT1
304953	100736350	20992744951	surgeons	surgeon	NN2
304953	100736350	20992744952	experience	experience	NN1
304953	100736350	20992744953	than	than	CSN
304953	100736350	20992744954	on	on	II
304953	100736350	20992744955	the	the	AT
304953	100736350	20992744956	specific	specific	JJ
304953	100736350	20992744957	method	method	NN1
304953	100736350	20992744958	he	he	PPHS1
304953	100736350	20992744959	or	or	CC
304953	100736350	20992744960	she	she	PPHS1
304953	100736350	20992744961	uses	use	VVZ
304953	100736350	20992744962	to	to	TO
304953	100736350	20992744963	@		II
304953	100736350	20992744964	@		II
304953	100736350	20992744965	@		II
304953	100736350	20992744966	@		II
304953	100736350	20992744967	@		II
304953	100736350	20992744968	@		II
304953	100736350	20992744969	@		II
304953	100736350	20992744970	@		II
304953	100736350	20992744971	@		II
304953	100736350	20992744972	@		II
304953	100736350	20992744973	experienced	experienced	JJ
304953	100736350	20992744974	surgeon	surgeon	NN1
304953	100736350	20992744975	,	,	,
304953	100736350	20992744976	at	at	II
304953	100736350	20992744977	an	a	AT1
304953	100736350	20992744978	institution	institution	NN1
304953	100736350	20992744979	with	with	IW
304953	100736350	20992744980	a	a	AT1
304953	100736350	20992744981	robust	robust	JJ
304953	100736350	20992744982	program	program	NN1
304953	100736350	20992744983	is	be	VBZ
304953	100736350	20992744984	by	by	RR21
304953	100736350	20992744985	far	far	RR22
304953	100736350	20992744986	the	the	AT
304953	100736350	20992744987	most	most	RGT
304953	100736350	20992744988	important	important	JJ
304953	100736350	20992744989	consideration	consideration	NN1
304953	100736350	20992744990	,	,	,
304953	100736350	20992744991	"	"	"
304953	100736350	20992744992	says	say	VVZ
304953	100736350	20992744993	prostate	prostate	NN1
304953	100736350	20992744994	cancer	cancer	NN1
304953	100736350	20992744995	expert	expert	NN1
304953	100736350	20992744996	Dr.		NNB
304953	100736350	20992744997	Marc	marc	NP1
304953	100736350	20992744998	Garnick		NP1
304953	100736350	20992744999	,	,	,
304953	100736350	20992745000	a	a	AT1
304953	100736350	20992745001	clinical	clinical	JJ
304953	100736350	20992745002	professor	professor	NN1
304953	100736350	20992745003	of	of	IO
304953	100736350	20992745004	medicine	medicine	NN1
304953	100736350	20992745005	at	at	II
304953	100736350	20992745006	Harvard	harvard	NP1
304953	100736350	20992745007	Medical	medical	JJ
304953	100736350	20992745008	School	school	NN1
304953	100736350	20992745009	,	,	,
304953	100736350	20992745010	an	a	AT1
304953	100736350	20992745011	oncologist	oncologist	NN1
304953	100736350	20992745012	at	at	II
304953	100736350	20992745013	Beth	beth	NP1
304953	100736350	20992745014	Israel	israel	NP1
304953	100736350	20992745015	Deaconess	deaconess	NN1
304953	100736350	20992745016	Medical	medical	JJ
304953	100736350	20992745017	Center	center	NN1
304953	100736350	20992745018	,	,	,
304953	100736350	20992745019	and	and	CC
304953	100736350	20992745020	editor	editor	NN1
304953	100736350	20992745021	in	in	II
304953	100736350	20992745022	chief	chief	NN1
304953	100736350	20992745023	of	of	IO
304953	100736350	20992745024	Harvard	harvard	NP1
304953	100736350	20992745025	's	's	GE
304953	100736350	20992745026	Annual	annual	JJ
304953	100736350	20992745027	Report	report	NN1
304953	100736350	20992745028	on	on	II
304953	100736350	20992745029	Prostate	prostate	NN1
304953	100736350	20992745030	Diseases	disease	NN2
304953	100736350	20992745031	.	.	.
304953	100736350	20992745032	<h>		NULL
304953	100736350	20992745033	Consistent	consistent	JJ
304953	100736350	20992745034	findings	finding	NN2
304953	100736350	20992745035	<p>		NULL
304953	100736350	20992745036	An	a	AT1
304953	100736350	20992745037	international	international	JJ
304953	100736350	20992745038	team	team	NN1
304953	100736350	20992745039	of	of	IO
304953	100736350	20992745040	researchers	researcher	NN2
304953	100736350	20992745041	analyzed	analyze	VVD
304953	100736350	20992745042	data	data	NN
304953	100736350	20992745043	from	from	II
304953	100736350	20992745044	the	the	AT
304953	100736350	20992745045	U.S.	us	NP1
304953	100736350	20992745046	Surveillance	surveillance	NN1
304953	100736350	20992745047	,	,	,
304953	100736350	20992745048	Epidemiology	epidemiology	NP1_NN1
304953	100736350	20992745049	and	and	CC
304953	100736350	20992745050	End	end	VV0_NN1
304953	100736350	20992745051	Results	result	NN2_VVZ@
304953	100736350	20992745052	database	database	NN1
304953	100736350	20992745053	for	for	IF
304953	100736350	20992745054	nearly	nearly	RR
304953	100736350	20992745055	6,000	6,000	MC
304953	100736350	20992745056	men	man	NN2
304953	100736350	20992745057	who	who	PNQS
304953	100736350	20992745058	were	be	VBDR
304953	100736350	20992745059	treated	treat	VVN
304953	100736350	20992745060	with	with	IW
304953	100736350	20992745061	robotic	robotic	JJ
304953	100736350	20992745062	or	or	CC
304953	100736350	20992745063	open	open	JJ_VV0
304953	100736350	20992745064	surgery	surgery	NN1
304953	100736350	20992745065	between	between	II
304953	100736350	20992745066	October	october	NPM1
304953	100736350	20992745067	2008	2008	MC
304953	100736350	20992745068	and	and	CC
304953	100736350	20992745069	December	december	NPM1
304953	100736350	20992745070	2009	2009	MC
304953	100736350	20992745071	.	.	.
304953	100736350	20992745072	This	this	DD1
304953	100736350	20992745073	database	database	NN1
304953	100736350	20992745074	offers	offer	VVZ@_NN2
304953	100736350	20992745075	the	the	AT
304953	100736350	20992745076	most	most	RGT
304953	100736350	20992745077	comprehensive	comprehensive	JJ
304953	100736350	20992745078	statistics	statistics	NN
304953	100736350	20992745079	available	available	JJ
304953	100736350	20992745080	on	on	II
304953	100736350	20992745081	cancer	cancer	NN1
304953	100736350	20992745082	incidence	incidence	NN1
304953	100736350	20992745083	,	,	,
304953	100736350	20992745084	stage	stage	NN1
304953	100736350	20992745085	at	at	II
304953	100736350	20992745086	diagnosis	diagnosis	NN1
304953	100736350	20992745087	,	,	,
304953	100736350	20992745088	first	first	MD
304953	100736350	20992745089	course	course	NN1
304953	100736350	20992745090	of	of	IO
304953	100736350	20992745091	treatment	treatment	NN1
304953	100736350	20992745092	,	,	,
304953	100736350	20992745093	demographics	demographics	NN2_NN1
304953	100736350	20992745094	,	,	,
304953	100736350	20992745095	treatment	treatment	NN1
304953	100736350	20992745096	follow-up	follow-up	NN1
304953	100736350	20992745097	,	,	,
304953	100736350	20992745098	and	and	CC
304953	100736350	20992745099	more	more	RRR_DAR
304953	100736350	20992745100	.	.	.
304953	100736350	20992745101	<p>		NULL
304953	100736350	20992745102	The	the	AT
304953	100736350	20992745103	researchers	researcher	NN2
304953	100736350	20992745104	compared	compare	VVD_VVN
304953	100736350	20992745105	how	how	RRQ
304953	100736350	20992745106	men	man	NN2
304953	100736350	20992745107	differed	differ	VVD_VVN
304953	100736350	20992745108	30	30	MC
304953	100736350	20992745109	and	and	CC
304953	100736350	20992745110	90	90	MC
304953	100736350	20992745111	days	day	NNT2
304953	100736350	20992745112	after	after	II_CS
304953	100736350	20992745113	surgery	surgery	NN1
304953	100736350	20992745114	with	with	II31
304953	100736350	20992745115	respect	respect	II32
304953	100736350	20992745116	to	to	II33
304953	100736350	20992745117	a	a	AT1
304953	100736350	20992745118	host	host	NN1
304953	100736350	20992745119	of	of	IO
304953	100736350	20992745120	complications	complication	NN2
304953	100736350	20992745121	.	.	.
304953	100736350	20992745122	After	after	II
304953	100736350	20992745123	adjusting	adjust	VVG
304953	100736350	20992745124	for	for	IF
304953	100736350	20992745125	socioeconomic	socioeconomic	JJ
304953	100736350	20992745126	status	status	NN1
304953	100736350	20992745127	,	,	,
304953	100736350	20992745128	tumor	tumor	NN1
304953	100736350	20992745129	grade	grade	NN1_VV0
304953	100736350	20992745130	,	,	,
304953	100736350	20992745131	stage	stage	NN1
304953	100736350	20992745132	,	,	,
304953	100736350	20992745133	and	and	CC
304953	100736350	20992745134	other	other	JJ
304953	100736350	20992745135	factors	factor	NN2
304953	100736350	20992745136	,	,	,
304953	100736350	20992745137	the	the	AT
304953	100736350	20992745138	study	study	NN1
304953	100736350	20992745139	authors	author	NN2
304953	100736350	20992745140	found	find	VVD_VVN
304953	100736350	20992745141	that	that	CST
304953	100736350	20992745142	:	:	:
304953	100736350	20992745143	<p>		NULL
304953	100736350	20992745144	Overall	overall	RR_JJ
304953	100736350	20992745145	postoperative	postoperative	JJ
304953	100736350	20992745146	complications	complication	NN2
304953	100736350	20992745147	and	and	CC
304953	100736350	20992745148	readmission	readmission	NN1
304953	100736350	20992745149	rates	rate	NN2
304953	100736350	20992745150	were	be	VBDR
304953	100736350	20992745151	similar	similar	JJ
304953	100736350	20992745152	at	at	II
304953	100736350	20992745153	both	both	DB2_RR
304953	100736350	20992745154	30	30	MC
304953	100736350	20992745155	and	and	CC
304953	100736350	20992745156	90	90	MC
304953	100736350	20992745157	days	day	NNT2
304953	100736350	20992745158	for	for	IF
304953	100736350	20992745159	men	man	NN2
304953	100736350	20992745160	treated	treat	VVN
304953	100736350	20992745161	with	with	IW
304953	100736350	20992745162	either	either	DD1
304953	100736350	20992745163	@		II
304953	100736350	20992745164	@		II
304953	100736350	20992745165	@		II
304953	100736350	20992745166	@		II
304953	100736350	20992745167	@		II
304953	100736350	20992745168	@		II
304953	100736350	20992745169	@		II
304953	100736350	20992745170	@		II
304953	100736350	20992745171	@		II
304953	100736350	20992745172	@		II
304953	100736350	20992745173	higher	high	JJR
304953	100736350	20992745174	risks	risk	NN2
304953	100736350	20992745175	of	of	IO
304953	100736350	20992745176	genitourinary	genitourinary	NN1_JJ
304953	100736350	20992745177	and	and	CC
304953	100736350	20992745178	miscellaneous	miscellaneous	JJ
304953	100736350	20992745179	medical	medical	JJ
304953	100736350	20992745180	complications	complication	NN2
304953	100736350	20992745181	both	both	RR
304953	100736350	20992745182	30	30	MC
304953	100736350	20992745183	and	and	CC
304953	100736350	20992745184	90	90	MC
304953	100736350	20992745185	days	day	NNT2
304953	100736350	20992745186	after	after	II_CS
304953	100736350	20992745187	surgery	surgery	NN1
304953	100736350	20992745188	.	.	.
304953	100736350	20992745189	<p>		NULL
304953	100736350	20992745190	Based	base	VVN
304953	100736350	20992745191	on	on	II
304953	100736350	20992745192	their	their	APPGE
304953	100736350	20992745193	findings	finding	NN2
304953	100736350	20992745194	,	,	,
304953	100736350	20992745195	published	publish	VVN
304953	100736350	20992745196	in	in	II
304953	100736350	20992745197	the	the	AT
304953	100736350	20992745198	Journal	journal	NN1
304953	100736350	20992745199	of	of	IO
304953	100736350	20992745200	Clinical	clinical	JJ
304953	100736350	20992745201	Oncology	oncology	NN1_NP1
304953	100736350	20992745202	,	,	,
304953	100736350	20992745203	the	the	AT
304953	100736350	20992745204	authors	author	NN2
304953	100736350	20992745205	concluded	conclude	VVD_VVN
304953	100736350	20992745206	that	that	CST_DD1
304953	100736350	20992745207	robot-assisted	robot-assisted	JJ_NN1
304953	100736350	20992745208	prostate	prostate	NN1
304953	100736350	20992745209	surgery	surgery	NN1
304953	100736350	20992745210	can	can	VM
304953	100736350	20992745211	not	not	XX
304953	100736350	20992745212	be	be	VBI
304953	100736350	20992745213	described	describe	VVN
304953	100736350	20992745214	as	as	II
304953	100736350	20992745215	the	the	AT
304953	100736350	20992745216	safer	safe	JJR
304953	100736350	20992745217	procedure	procedure	NN1
304953	100736350	20992745218	,	,	,
304953	100736350	20992745219	but	but	CCB
304953	100736350	20992745220	they	they	PPHS2
304953	100736350	20992745221	also	also	RR
304953	100736350	20992745222	emphasized	emphasize	VVN_VVD
304953	100736350	20992745223	that	that	CST
304953	100736350	20992745224	it	it	PPH1
304953	100736350	20992745225	is	be	VBZ
304953	100736350	20992745226	safe	safe	JJ
304953	100736350	20992745227	based	base	VVN
304953	100736350	20992745228	on	on	II
304953	100736350	20992745229	the	the	AT
304953	100736350	20992745230	weight-of-the-evidence		NN1_JJ
304953	100736350	20992745231	so	so	RG
304953	100736350	20992745232	far	far	RR
304953	100736350	20992745233	.	.	.
304953	100736350	20992745234	<p>		NULL
304953	100736350	20992745235	The	the	AT
304953	100736350	20992745236	new	new	JJ
304953	100736350	20992745237	findings	finding	NN2
304953	100736350	20992745238	are	be	VBR
304953	100736350	20992745239	consistent	consistent	JJ
304953	100736350	20992745240	with	with	IW
304953	100736350	20992745241	a	a	AT1
304953	100736350	20992745242	landmark	landmark	NN1
304953	100736350	20992745243	study	study	NN1
304953	100736350	20992745244	published	publish	VVN
304953	100736350	20992745245	in	in	II
304953	100736350	20992745246	the	the	AT
304953	100736350	20992745247	Journal	journal	NN1
304953	100736350	20992745248	of	of	IO
304953	100736350	20992745249	the	the	AT
304953	100736350	20992745250	American	american	JJ
304953	100736350	20992745251	Medical	medical	JJ
304953	100736350	20992745252	Associationin		NN1
304953	100736350	20992745253	2009	2009	MC
304953	100736350	20992745254	.	.	.
304953	100736350	20992745255	For	for	IF
304953	100736350	20992745256	that	that	DD1
304953	100736350	20992745257	effort	effort	NN1
304953	100736350	20992745258	,	,	,
304953	100736350	20992745259	researchers	researcher	NN2
304953	100736350	20992745260	reported	report	VVD_VVN
304953	100736350	20992745261	that	that	CST
304953	100736350	20992745262	men	man	NN2
304953	100736350	20992745263	treated	treat	VVN
304953	100736350	20992745264	with	with	IW
304953	100736350	20992745265	the	the	AT
304953	100736350	20992745266	robotic	robotic	JJ
304953	100736350	20992745267	method	method	NN1
304953	100736350	20992745268	had	have	VHD
304953	100736350	20992745269	shorter	short	JJR
304953	100736350	20992745270	hospital	hospital	NN1
304953	100736350	20992745271	stays	stay	NN2_VVZ
304953	100736350	20992745272	and	and	CC
304953	100736350	20992745273	also	also	RR
304953	100736350	20992745274	fewer	fewer	DAR
304953	100736350	20992745275	respiratory	respiratory	JJ
304953	100736350	20992745276	and	and	CC
304953	100736350	20992745277	miscellaneous	miscellaneous	JJ
304953	100736350	20992745278	surgical	surgical	JJ
304953	100736350	20992745279	complications	complication	NN2
304953	100736350	20992745280	than	than	CSN
304953	100736350	20992745281	men	man	NN2
304953	100736350	20992745282	treated	treat	VVN
304953	100736350	20992745283	with	with	IW
304953	100736350	20992745284	open	open	JJ
304953	100736350	20992745285	surgery	surgery	NN1
304953	100736350	20992745286	.	.	.
304953	100736350	20992745287	But	but	CCB
304953	100736350	20992745288	the	the	AT
304953	100736350	20992745289	men	man	NN2
304953	100736350	20992745290	who	who	PNQS
304953	100736350	20992745291	underwent	undergo	VVD
304953	100736350	20992745292	robot-assisted		JJ
304953	100736350	20992745293	surgery	surgery	NN1
304953	100736350	20992745294	also	also	RR
304953	100736350	20992745295	had	have	VHD_VHN@
304953	100736350	20992745296	more	more	DAR_RRR
304953	100736350	20992745297	genitourinary	genitourinary	JJ_NN1
304953	100736350	20992745298	complications	complication	NN2
304953	100736350	20992745299	and	and	CC
304953	100736350	20992745300	higher	high	JJR
304953	100736350	20992745301	rates	rate	NN2
304953	100736350	20992745302	of	of	IO
304953	100736350	20992745303	incontinence	incontinence	NN1
304953	100736350	20992745304	and	and	CC
304953	100736350	20992745305	erectile	erectile	JJ
304953	100736350	20992745306	dysfunction	dysfunction	NN1
304953	100736350	20992745307	.	.	.
304953	100736350	20992745308	<p>		NULL
304953	100736350	20992745309	The	the	AT
304953	100736350	20992745310	new	new	JJ
304953	100736350	20992745311	Journal	journal	NN1
304953	100736350	20992745312	of	of	IO
304953	100736350	20992745313	Clinical	clinical	JJ
304953	100736350	20992745314	Oncology	oncology	NN1
304953	100736350	20992745315	study	study	NN1
304953	100736350	20992745316	updates	update	VVZ
304953	100736350	20992745317	the	the	AT
304953	100736350	20992745318	2009	2009	MC
304953	100736350	20992745319	comparison	comparison	NN1
304953	100736350	20992745320	with	with	IW
304953	100736350	20992745321	newer	new	JJR
304953	100736350	20992745322	data	data	NN
304953	100736350	20992745323	gathered	gather	VVN_VVD
304953	100736350	20992745324	after	after	II_CS
304953	100736350	20992745325	robot-assisted	robot-assisted	JJ_NN1
304953	100736350	20992745326	prostatectomy	prostatectomy	NN1
304953	100736350	20992745327	became	become	VVD
304953	100736350	20992745328	more	more	RGR_RRR
304953	100736350	20992745329	widely	widely	RR
304953	100736350	20992745330	used	use	VVN_VVD_JJ
304953	100736350	20992745331	.	.	.
304953	100736350	20992745332	But	but	CCB
304953	100736350	20992745333	it	it	PPH1
304953	100736350	20992745334	also	also	RR
304953	100736350	20992745335	has	have	VHZ
304953	100736350	20992745336	some	some	DD
304953	100736350	20992745337	shortcomings	shortcoming	NN2
304953	100736350	20992745338	.	.	.
304953	100736350	20992745339	The	the	AT
304953	100736350	20992745340	men	man	NN2
304953	100736350	20992745341	in	in	II
304953	100736350	20992745342	the	the	AT
304953	100736350	20992745343	study	study	NN1
304953	100736350	20992745344	had	have	VHD
304953	100736350	20992745345	a	a	AT1
304953	100736350	20992745346	mean	mean	JJ
304953	100736350	20992745347	age	age	NN1
304953	100736350	20992745348	of	of	IO
304953	100736350	20992745349	69	69	MC
304953	100736350	20992745350	years	year	NNT2
304953	100736350	20992745351	at	at	II
304953	100736350	20992745352	diagnosis	diagnosis	NN1
304953	100736350	20992745353	,	,	,
304953	100736350	20992745354	when	when	CS_RRQ
304953	100736350	20992745355	surgical	surgical	JJ
304953	100736350	20992745356	risks	risk	NN2
304953	100736350	20992745357	are	be	VBR
304953	100736350	20992745358	high	high	RR@_JJ
304953	100736350	20992745359	regardless	regardless	RR
304953	100736350	20992745360	of	of	IO
304953	100736350	20992745361	technique	technique	NN1
304953	100736350	20992745362	.	.	.
304953	100736350	20992745363	@		II
304953	100736350	20992745364	@		II
304953	100736350	20992745365	@		II
304953	100736350	20992745366	@		II
304953	100736350	20992745367	@		II
304953	100736350	20992745368	@		II
304953	100736350	20992745369	@		II
304953	100736350	20992745370	@		II
304953	100736350	20992745371	@		II
304953	100736350	20992745372	@		II
304953	100736350	20992745373	younger	young	JJR
304953	100736350	20992745374	men	man	NN2
304953	100736350	20992745375	with	with	IW
304953	100736350	20992745376	prostate	prostate	NN1
304953	100736350	20992745377	cancer	cancer	NN1
304953	100736350	20992745378	,	,	,
304953	100736350	20992745379	cautioned	caution	VVD_VVN
304953	100736350	20992745380	the	the	AT
304953	100736350	20992745381	authors	author	NN2
304953	100736350	20992745382	of	of	IO
304953	100736350	20992745383	an	a	AT1
304953	100736350	20992745384	accompanying	accompanying	JJ
304953	100736350	20992745385	editorial	editorial	NN1
304953	100736350	20992745386	.	.	.
304953	100736350	20992745387	And	and	CC
304953	100736350	20992745388	given	give	VVN
304953	100736350	20992745389	the	the	AT
304953	100736350	20992745390	limited	limited	JJ
304953	100736350	20992745391	follow-up	follow-up	NN1_JJ
304953	100736350	20992745392	,	,	,
304953	100736350	20992745393	the	the	AT
304953	100736350	20992745394	study	study	NN1
304953	100736350	20992745395	couldnt		NN1_VV0
304953	100736350	20992745396	tell	tell	VV0
304953	100736350	20992745397	if	if	CS
304953	100736350	20992745398	one	one	MC1
304953	100736350	20992745399	approach	approach	NN1
304953	100736350	20992745400	was	be	VBDZ
304953	100736350	20992745401	better	better	RRR_JJR
304953	100736350	20992745402	than	than	CSN
304953	100736350	20992745403	the	the	AT
304953	100736350	20992745404	other	other	JJ_NN1@
304953	100736350	20992745405	at	at	II
304953	100736350	20992745406	controlling	control	VVG_JJ@
304953	100736350	20992745407	cancer	cancer	NN1
304953	100736350	20992745408	over	over	II
304953	100736350	20992745409	time	time	NNT1
304953	100736350	20992745410	.	.	.
304953	100736350	20992745411	<p>		NULL
304953	100736350	20992745412	"	"	"
304953	100736350	20992745413	Buyer	buyer	NN1
304953	100736350	20992745414	beware	beware	VV0
304953	100736350	20992745415	"	"	"
304953	100736350	20992745416	is	be	VBZ
304953	100736350	20992745417	the	the	AT
304953	100736350	20992745418	message	message	NN1
304953	100736350	20992745419	for	for	IF
304953	100736350	20992745420	men	man	NN2
304953	100736350	20992745421	who	who	PNQS
304953	100736350	20992745422	choose	choose	VV0
304953	100736350	20992745423	to	to	TO
304953	100736350	20992745424	have	have	VHI
304953	100736350	20992745425	surgery	surgery	NN1
304953	100736350	20992745426	after	after	II
304953	100736350	20992745427	being	be	VBG
304953	100736350	20992745428	diagnosed	diagnose	VVN
304953	100736350	20992745429	with	with	IW
304953	100736350	20992745430	localized	localized	JJ
304953	100736350	20992745431	prostate	prostate	NN1
304953	100736350	20992745432	cancer	cancer	NN1
304953	100736350	20992745433	,	,	,
304953	100736350	20992745434	the	the	AT
304953	100736350	20992745435	message	message	NN1
304953	100736350	20992745436	is	be	VBZ
304953	100736350	20992745437	buyer	buyer	NN1
304953	100736350	20992745438	beware	beware	VV0
304953	100736350	20992745439	.	.	.
304953	100736350	20992745440	"	"	"
304953	100736350	20992745441	Robotic	robotic	JJ
304953	100736350	20992745442	techniques	technique	NN2
304953	100736350	20992745443	are	be	VBR
304953	100736350	20992745444	too	too	RG
304953	100736350	20992745445	young	young	JJ
304953	100736350	20992745446	to	to	TO
304953	100736350	20992745447	make	make	VVI
304953	100736350	20992745448	any	any	DD
304953	100736350	20992745449	sweeping	sweeping	JJ
304953	100736350	20992745450	conclusions	conclusion	NN2
304953	100736350	20992745451	regarding	regarding	II_VVG
304953	100736350	20992745452	their	their	APPGE
304953	100736350	20992745453	overall	overall	JJ_NN1
304953	100736350	20992745454	effectiveness	effectiveness	NN1
304953	100736350	20992745455	in	in	II31
304953	100736350	20992745456	terms	terms	II32
304953	100736350	20992745457	of	of	II33
304953	100736350	20992745458	cancer	cancer	NN1
304953	100736350	20992745459	control	control	NN1
304953	100736350	20992745460	,	,	,
304953	100736350	20992745461	"	"	"
304953	100736350	20992745462	says	say	VVZ
304953	100736350	20992745463	Dr.		NNB
304953	100736350	20992745464	Garnick		NP1
304953	100736350	20992745465	.	.	.
304953	100736350	20992745466	"	"	"
304953	100736350	20992745467	I	i	PPIS1
304953	100736350	20992745468	find	find	VV0
304953	100736350	20992745469	that	that	CST_DD1
304953	100736350	20992745470	patient	patient	JJ_NN1
304953	100736350	20992745471	satisfaction	satisfaction	NN1
304953	100736350	20992745472	is	be	VBZ
304953	100736350	20992745473	comparable	comparable	JJ
304953	100736350	20992745474	for	for	IF
304953	100736350	20992745475	both	both	DB2
304953	100736350	20992745476	choices	choice	NN2
304953	100736350	20992745477	,	,	,
304953	100736350	20992745478	as	as	CS31
304953	100736350	20992745479	long	long	CS32
304953	100736350	20992745480	as	as	CS33
304953	100736350	20992745481	there	there	EX
304953	100736350	20992745482	has	have	VHZ
304953	100736350	20992745483	been	be	VBN
304953	100736350	20992745484	an	a	AT1
304953	100736350	20992745485	adequate	adequate	JJ
304953	100736350	20992745486	discussion	discussion	NN1
304953	100736350	20992745487	ahead	ahead	II21
304953	100736350	20992745488	of	of	II22
304953	100736350	20992745489	time	time	NNT1
304953	100736350	20992745490	about	about	II
304953	100736350	20992745491	the	the	AT
304953	100736350	20992745492	associated	associated	JJ
304953	100736350	20992745493	pros	pro	NN2
304953	100736350	20992745494	and	and	CC
304953	100736350	20992745495	cons	con	NN2_VVZ
304953	100736350	20992745496	.	.	.
304953	100736350	20992745497	A	a	AT1
304953	100736350	20992745498	man	man	NN1
304953	100736350	20992745499	selecting	select	VVG
304953	100736350	20992745500	one	one	MC1
304953	100736350	20992745501	approach	approach	NN1
304953	100736350	20992745502	over	over	II
304953	100736350	20992745503	another	another	DD1
304953	100736350	20992745504	should	should	VM
304953	100736350	20992745505	do	do	VDI
304953	100736350	20992745506	so	so	RR
304953	100736350	20992745507	with	with	IW
304953	100736350	20992745508	his	his	APPGE
304953	100736350	20992745509	eyes	eye	NN2
304953	100736350	20992745510	wide	wide	RR
304953	100736350	20992745511	open	open	JJ
304953	100736350	20992745512	.	.	.
304953	100736350	20992745513	"	"	"
304953	100736351	20992745533	@@##	----------	----------
304953	100736351	20992745534	@@100736351		FO
304953	100736351	20992745535	@4936351/		NN1_VV0
304953	100736351	20992745536	<p>		NULL
304953	100736351	20992745537	Muscle	muscle	NN1
304953	100736351	20992745538	loss	loss	NN1
304953	100736351	20992745539	(	(	(
304953	100736351	20992745540	and	and	CC
304953	100736351	20992745541	an	a	AT1
304953	100736351	20992745542	increase	increase	NN1
304953	100736351	20992745543	in	in	II
304953	100736351	20992745544	body	body	NN1
304953	100736351	20992745545	fat	fat	NN1
304953	100736351	20992745546	)	)	)
304953	100736351	20992745547	is	be	VBZ
304953	100736351	20992745548	a	a	AT1
304953	100736351	20992745549	common	common	JJ
304953	100736351	20992745550	side	side	NN1
304953	100736351	20992745551	effect	effect	NN1
304953	100736351	20992745552	of	of	IO
304953	100736351	20992745553	hormone	hormone	NN1
304953	100736351	20992745554	therapy	therapy	NN1
304953	100736351	20992745555	.	.	.
304953	100736351	20992745556	Hormones	hormone	NN2
304953	100736351	20992745557	tamp	tamp	VV0
304953	100736351	20992745558	down	down	RP
304953	100736351	20992745559	the	the	AT
304953	100736351	20992745560	production	production	NN1
304953	100736351	20992745561	of	of	IO
304953	100736351	20992745562	testosterone	testosterone	NN1
304953	100736351	20992745563	,	,	,
304953	100736351	20992745564	a	a	AT1
304953	100736351	20992745565	male	male	JJ_NN1
304953	100736351	20992745566	hormone	hormone	NN1
304953	100736351	20992745567	that	that	CST_DD1
304953	100736351	20992745568	plays	play	VVZ
304953	100736351	20992745569	a	a	AT1
304953	100736351	20992745570	role	role	NN1
304953	100736351	20992745571	in	in	II
304953	100736351	20992745572	developing	develop	VVG_JJ
304953	100736351	20992745573	and	and	CC
304953	100736351	20992745574	maintaining	maintain	VVG
304953	100736351	20992745575	muscle	muscle	NN1
304953	100736351	20992745576	mass	mass	NN1
304953	100736351	20992745577	.	.	.
304953	100736351	20992745578	(	(	(
304953	100736351	20992745579	Hormone	hormone	NN1
304953	100736351	20992745580	therapy	therapy	NN1
304953	100736351	20992745581	can	can	VM
304953	100736351	20992745582	also	also	RR
304953	100736351	20992745583	lead	lead	VVI
304953	100736351	20992745584	to	to	II
304953	100736351	20992745585	bone	bone	NN1
304953	100736351	20992745586	loss	loss	NN1
304953	100736351	20992745587	,	,	,
304953	100736351	20992745588	so	so	RR
304953	100736351	20992745589	be	be	VBI
304953	100736351	20992745590	sure	sure	JJ_RR%
304953	100736351	20992745591	your	your	APPGE
304953	100736351	20992745592	doctor	doctor	NN1
304953	100736351	20992745593	is	be	VBZ
304953	100736351	20992745594	on	on	II
304953	100736351	20992745595	the	the	AT
304953	100736351	20992745596	lookout	lookout	NN1
304953	100736351	20992745597	for	for	IF
304953	100736351	20992745598	osteoporosis	osteoporosis	NN1
304953	100736351	20992745599	.	.	.
304953	100736351	20992745600	)	)	)
304953	100736351	20992745601	I	i	PPIS1
304953	100736351	20992745602	recommend	recommend	VV0
304953	100736351	20992745603	regular	regular	JJ
304953	100736351	20992745604	exercise	exercise	NN1
304953	100736351	20992745605	to	to	II
304953	100736351	20992745606	my	my	APPGE
304953	100736351	20992745607	patients	patient	NN2
304953	100736351	20992745608	,	,	,
304953	100736351	20992745609	as	as	CSA
304953	100736351	20992745610	it	it	PPH1
304953	100736351	20992745611	may	may	VM
304953	100736351	20992745612	help	help	VVI
304953	100736351	20992745613	stave	stave	NN1_VV0
304953	100736351	20992745614	off	off	II_RP
304953	100736351	20992745615	muscle	muscle	NN1
304953	100736351	20992745616	and	and	CC
304953	100736351	20992745617	bone	bone	NN1
304953	100736351	20992745618	loss	loss	NN1
304953	100736351	20992745619	and	and	CC
304953	100736351	20992745620	limit	limit	VV0_NN1
304953	100736351	20992745621	changes	change	NN2
304953	100736351	20992745622	in	in	II
304953	100736351	20992745623	body	body	NN1
304953	100736351	20992745624	composition	composition	NN1
304953	100736351	20992745625	.	.	.
304953	100736351	20992745626	One	one	MC1
304953	100736351	20992745627	thing	thing	NN1
304953	100736351	20992745628	to	to	TO
304953	100736351	20992745629	look	look	VVI
304953	100736351	20992745630	forward	forward	RL
304953	100736351	20992745631	to	to	II_TO
304953	100736351	20992745632	:	:	:
304953	100736351	20992745633	these	these	DD2
304953	100736351	20992745634	side	side	NN1
304953	100736351	20992745635	effects	effect	NN2
304953	100736351	20992745636	will	will	VM
304953	100736351	20992745637	gradually	gradually	RR
304953	100736351	20992745638	diminish	diminish	VVI
304953	100736351	20992745639	when	when	RRQ_CS
304953	100736351	20992745640	you	you	PPY
304953	100736351	20992745641	stop	stop	VV0
304953	100736351	20992745642	hormone	hormone	NN1
304953	100736351	20992745643	therapy	therapy	NN1
304953	100736351	20992745644	.	.	.
304953	100736351	20992745645	<p>		NULL
304953	100736351	20992745646	I	i	PPIS1
304953	100736351	20992745647	started	start	VVD
304953	100736351	20992745648	taking	take	VVG
304953	100736351	20992745649	zoladex		NN1_VV0
304953	100736351	20992745650	as	as	II
304953	100736351	20992745651	part	part	NN1
304953	100736351	20992745652	of	of	IO
304953	100736351	20992745653	my	my	APPGE
304953	100736351	20992745654	prostrate	prostrate	JJ
304953	100736351	20992745655	cancer	cancer	NN1
304953	100736351	20992745656	therapy	therapy	NN1
304953	100736351	20992745657	in	in	II
304953	100736351	20992745658	2015	2015	MC
304953	100736351	20992745659	.	.	.
304953	100736351	20992745660	I	i	PPIS1
304953	100736351	20992745661	keep	keep	VV0
304953	100736351	20992745662	good	good	JJ
304953	100736351	20992745663	health	health	NN1
304953	100736351	20992745664	and	and	CC
304953	100736351	20992745665	I	i	PPIS1
304953	100736351	20992745666	have	have	VH0
304953	100736351	20992745667	now	now	RT
304953	100736351	20992745668	returned	return	VVN_VVD
304953	100736351	20992745669	to	to	II
304953	100736351	20992745670	the	the	AT
304953	100736351	20992745671	gym	gym	NN1
304953	100736351	20992745672	.	.	.
304953	100736351	20992745673	After	after	II
304953	100736351	20992745674	easing	ease	VVG
304953	100736351	20992745675	myself	myself	PPX1
304953	100736351	20992745676	into	into	II
304953	100736351	20992745677	training	training	NN1_VVG@
304953	100736351	20992745678	for	for	IF
304953	100736351	20992745679	4	4	MC
304953	100736351	20992745680	weeks	week	NNT2
304953	100736351	20992745681	I	i	PPIS1
304953	100736351	20992745682	started	start	VVD
304953	100736351	20992745683	doing	do	VDG
304953	100736351	20992745684	some	some	DD
304953	100736351	20992745685	hard	hard	JJ
304953	100736351	20992745686	workouts	workout	NN2
304953	100736351	20992745687	(	(	(
304953	100736351	20992745688	lifting	lift	VVG_NN1_JJ@
304953	100736351	20992745689	weights	weight	NN2
304953	100736351	20992745690	to	to	II
304953	100736351	20992745691	exhaustion	exhaustion	NN1
304953	100736351	20992745692	)	)	)
304953	100736351	20992745693	.	.	.
304953	100736351	20992745694	The	the	AT
304953	100736351	20992745695	following	following	JJ
304953	100736351	20992745696	day	day	NNT1
304953	100736351	20992745697	I	i	PPIS1
304953	100736351	20992745698	experience	experience	VV0
304953	100736351	20992745699	no	no	AT
304953	100736351	20992745700	muscle	muscle	NN1
304953	100736351	20992745701	soreness	soreness	NN1
304953	100736351	20992745702	which	which	DDQ
304953	100736351	20992745703	is	be	VBZ
304953	100736351	20992745704	an	a	AT1
304953	100736351	20992745705	unexpected	unexpected	JJ
304953	100736351	20992745706	surprise	surprise	NN1
304953	100736351	20992745707	.	.	.
304953	100736351	20992745708	Is	be	VBZ
304953	100736351	20992745709	that	that	DD1
304953	100736351	20992745710	the	the	AT
304953	100736351	20992745711	zoladex		NN1
304953	100736351	20992745712	inhabiting		VVG_NN1@_JJ@
304953	100736351	20992745713	muscle	muscle	NN1
304953	100736351	20992745714	growth	growth	NN1
304953	100736351	20992745715	?	?	?
304953	100736351	20992745716	46996		MC
304953	100736351	20992745717	@qwx906996		FO
304953	100736352	20992745737	@@##	----------	----------
304953	100736352	20992745738	@@100736352		FO
304953	100736352	20992745739	@4936352/		VV0_NN1
304953	100736352	20992745740	46989		MC
304953	100736352	20992745741	@qwx906989		FO
304953	100736352	20992745742	<p>		NULL
304953	100736352	20992745743	When	when	CS
304953	100736352	20992745744	a	a	AT1
304953	100736352	20992745745	young	young	JJ
304953	100736352	20992745746	man	man	NN1
304953	100736352	20992745747	joins	join	VVZ
304953	100736352	20992745748	the	the	AT
304953	100736352	20992745749	United	united	NP1
304953	100736352	20992745750	States	state	NP1
304953	100736352	20992745751	military	military	JJ_NN1@
304953	100736352	20992745752	,	,	,
304953	100736352	20992745753	a	a	AT1
304953	100736352	20992745754	possible	possible	JJ
304953	100736352	20992745755	future	future	JJ_NN1
304953	100736352	20992745756	battle	battle	NN1
304953	100736352	20992745757	with	with	IW
304953	100736352	20992745758	prostate	prostate	NN1
304953	100736352	20992745759	cancer	cancer	NN1
304953	100736352	20992745760	is	be	VBZ
304953	100736352	20992745761	probably	probably	RR
304953	100736352	20992745762	the	the	AT
304953	100736352	20992745763	last	last	MD
304953	100736352	20992745764	thing	thing	NN1
304953	100736352	20992745765	on	on	II
304953	100736352	20992745766	his	his	APPGE
304953	100736352	20992745767	mind	mind	NN1
304953	100736352	20992745768	.	.	.
304953	100736352	20992745769	But	but	CCB
304953	100736352	20992745770	he	he	PPHS1
304953	100736352	20992745771	has	have	VHZ
304953	100736352	20992745772	one	one	MC1
304953	100736352	20992745773	less	less	DAR
304953	100736352	20992745774	reason	reason	NN1
304953	100736352	20992745775	to	to	TO
304953	100736352	20992745776	worry	worry	VVI
304953	100736352	20992745777	about	about	II
304953	100736352	20992745778	it	it	PPH1
304953	100736352	20992745779	than	than	CSN
304953	100736352	20992745780	a	a	AT1
304953	100736352	20992745781	civilian	civilian	NN1
304953	100736352	20992745782	does	do	VDZ
304953	100736352	20992745783	:	:	:
304953	100736352	20992745784	servicemen	serviceman	NN2
304953	100736352	20992745785	with	with	IW
304953	100736352	20992745786	prostate	prostate	NN1
304953	100736352	20992745787	cancer	cancer	NN1
304953	100736352	20992745788	have	have	VH0
304953	100736352	20992745789	a	a	AT1
304953	100736352	20992745790	fighting	fighting	NN1_JJ%
304953	100736352	20992745791	advantage	advantage	NN1
304953	100736352	20992745792	when	when	CS_RRQ
304953	100736352	20992745793	it	it	PPH1
304953	100736352	20992745794	comes	come	VVZ
304953	100736352	20992745795	to	to	II
304953	100736352	20992745796	their	their	APPGE
304953	100736352	20992745797	treatment	treatment	NN1
304953	100736352	20992745798	.	.	.
304953	100736352	20992745799	That 's		NN2_VVZ_NP1@
304953	100736352	20992745800	because	because	CS
304953	100736352	20992745801	the	the	AT
304953	100736352	20992745802	Department	department	NN1
304953	100736352	20992745803	of	of	IO
304953	100736352	20992745804	Defense	defense	NN1
304953	100736352	20992745805	(	(	(
304953	100736352	20992745806	DOD	dod	NP1
304953	100736352	20992745807	)	)	)
304953	100736352	20992745808	offers	offer	NN2_VVZ@
304953	100736352	20992745809	access	access	VV0@_NN1
304953	100736352	20992745810	to	to	II
304953	100736352	20992745811	clinical	clinical	JJ
304953	100736352	20992745812	trials	trial	NN2
304953	100736352	20992745813	,	,	,
304953	100736352	20992745814	experimental	experimental	JJ
304953	100736352	20992745815	therapies	therapy	NN2
304953	100736352	20992745816	,	,	,
304953	100736352	20992745817	and	and	CC
304953	100736352	20992745818	state-of-the-art	state-of-the-art	JJ_NN1
304953	100736352	20992745819	care	care	NN1
304953	100736352	20992745820	through	through	II
304953	100736352	20992745821	its	its	APPGE
304953	100736352	20992745822	Center	center	NN1
304953	100736352	20992745823	for	for	IF
304953	100736352	20992745824	Prostate	prostate	NN1
304953	100736352	20992745825	Disease	disease	NN1
304953	100736352	20992745826	Research	research	NN1
304953	100736352	20992745827	(	(	(
304953	100736352	20992745828	CPDR		NP1
304953	100736352	20992745829	)	)	)
304953	100736352	20992745830	.	.	.
304953	100736352	20992745831	<p>		NULL
304953	100736352	20992745832	Established	establish	VVN_VVD
304953	100736352	20992745833	in	in	II
304953	100736352	20992745834	1992	1992	MC
304953	100736352	20992745835	,	,	,
304953	100736352	20992745836	and	and	CC
304953	100736352	20992745837	recognized	recognize	VVN_VVD
304953	100736352	20992745838	as	as	II
304953	100736352	20992745839	a	a	AT1
304953	100736352	20992745840	DOD	dod	NN1
304953	100736352	20992745841	Prostate	prostate	NN1
304953	100736352	20992745842	Center	center	NN1
304953	100736352	20992745843	of	of	IO
304953	100736352	20992745844	Excellence	excellence	NN1
304953	100736352	20992745845	,	,	,
304953	100736352	20992745846	the	the	AT
304953	100736352	20992745847	CPDR		NP1
304953	100736352	20992745848	"	"	"
304953	100736352	20992745849	supplies	supply	VVZ
304953	100736352	20992745850	those	those	DD2
304953	100736352	20992745851	services	service	NN2
304953	100736352	20992745852	equally	equally	RR
304953	100736352	20992745853	to	to	II
304953	100736352	20992745854	all	all	DB
304953	100736352	20992745855	active	active	JJ
304953	100736352	20992745856	and	and	CC
304953	100736352	20992745857	retired	retired	JJ
304953	100736352	20992745858	servicemen	serviceman	NN2
304953	100736352	20992745859	regardless	regardless	RR
304953	100736352	20992745860	of	of	IO
304953	100736352	20992745861	rank	rank	NN1
304953	100736352	20992745862	,	,	,
304953	100736352	20992745863	"	"	"
304953	100736352	20992745864	says	say	VVZ
304953	100736352	20992745865	its	its	APPGE
304953	100736352	20992745866	director	director	NN1
304953	100736352	20992745867	,	,	,
304953	100736352	20992745868	Dr.		NNB
304953	100736352	20992745869	David	david	NP1
304953	100736352	20992745870	G.		NP1
304953	100736352	20992745871	McLeod	mcleod	NP1
304953	100736352	20992745872	.	.	.
304953	100736352	20992745873	Spouses	spouse	NN2
304953	100736352	20992745874	and	and	CC
304953	100736352	20992745875	children	child	NN2
304953	100736352	20992745876	of	of	IO
304953	100736352	20992745877	those	those	DD2
304953	100736352	20992745878	who	who	PNQS
304953	100736352	20992745879	serve	serve	VV0
304953	100736352	20992745880	in	in	II_RP@
304953	100736352	20992745881	the	the	AT
304953	100736352	20992745882	military	military	JJ_NN1@
304953	100736352	20992745883	are	be	VBR
304953	100736352	20992745884	also	also	RR
304953	100736352	20992745885	eligible	eligible	JJ
304953	100736352	20992745886	for	for	IF
304953	100736352	20992745887	CPDR		NP1
304953	100736352	20992745888	services	service	NN2
304953	100736352	20992745889	.	.	.
304953	100736352	20992745890	<p>		NULL
304953	100736352	20992745891	Apart	apart	II21
304953	100736352	20992745892	from	from	II22
304953	100736352	20992745893	conducting	conduct	VVG
304953	100736352	20992745894	trials	trial	NN2
304953	100736352	20992745895	aimed	aim	VVN_VVD
304953	100736352	20992745896	at	at	II
304953	100736352	20992745897	treating	treat	VVG
304953	100736352	20992745898	prostate	prostate	NN1
304953	100736352	20992745899	cancer	cancer	NN1
304953	100736352	20992745900	,	,	,
304953	100736352	20992745901	the	the	AT
304953	100736352	20992745902	CPDR		NP1
304953	100736352	20992745903	also	also	RR
304953	100736352	20992745904	helps	help	VVZ
304953	100736352	20992745905	with	with	IW
304953	100736352	20992745906	quality	quality	NN1
304953	100736352	20992745907	of	of	IO
304953	100736352	20992745908	life	life	NN1
304953	100736352	20992745909	issues	issue	NN2
304953	100736352	20992745910	.	.	.
304953	100736352	20992745911	Servicemen	serviceman	NN2
304953	100736352	20992745912	who	who	PNQS
304953	100736352	20992745913	take	take	VV0
304953	100736352	20992745914	part	part	NN1
304953	100736352	20992745915	in	in	II
304953	100736352	20992745916	CPDR		NP1
304953	100736352	20992745917	programs	program	NN2
304953	100736352	20992745918	have	have	VH0
304953	100736352	20992745919	access	access	NN1
304953	100736352	20992745920	to	to	II
304953	100736352	20992745921	psychological	psychological	JJ
304953	100736352	20992745922	counseling	counseling	NN1
304953	100736352	20992745923	,	,	,
304953	100736352	20992745924	nutrition	nutrition	NN1
304953	100736352	20992745925	classes	class	NN2
304953	100736352	20992745926	,	,	,
304953	100736352	20992745927	help	help	VV0_NN1
304953	100736352	20992745928	with	with	IW
304953	100736352	20992745929	@		II
304953	100736352	20992745930	@		II
304953	100736352	20992745931	@		II
304953	100736352	20992745932	@		II
304953	100736352	20992745933	@		II
304953	100736352	20992745934	@		II
304953	100736352	20992745935	@		II
304953	100736352	20992745936	@		II
304953	100736352	20992745937	@		II
304953	100736352	20992745938	@		II
304953	100736352	20992745939	since	since	CS
304953	100736352	20992745940	their	their	APPGE
304953	100736352	20992745941	care	care	NN1
304953	100736352	20992745942	does	do	VDZ
304953	100736352	20992745943	n't 	n't	XX
304953	100736352	20992745944	incur	incur	VVI
304953	100736352	20992745945	out-of-pocket	out-of-pocket	JJ_NN1
304953	100736352	20992745946	expenses	expense	NN2
304953	100736352	20992745947	,	,	,
304953	100736352	20992745948	servicemen	serviceman	NN2
304953	100736352	20992745949	tend	tend	VV0
304953	100736352	20992745950	to	to	TO
304953	100736352	20992745951	go	go	VVI
304953	100736352	20992745952	for	for	IF
304953	100736352	20992745953	more	more	DAR
304953	100736352	20992745954	doctors	doctor	NN2
304953	100736352	20992745955	office	office	NN1
304953	100736352	20992745956	visits	visit	NN2
304953	100736352	20992745957	,	,	,
304953	100736352	20992745958	and	and	CC
304953	100736352	20992745959	they	they	PPHS2
304953	100736352	20992745960	have	have	VH0
304953	100736352	20992745961	longer-term	longer-term	JJ
304953	100736352	20992745962	follow-up	follow-up	NN1_JJ
304953	100736352	20992745963	,	,	,
304953	100736352	20992745964	than	than	CSN
304953	100736352	20992745965	men	man	NN2
304953	100736352	20992745966	treated	treat	VVN
304953	100736352	20992745967	for	for	IF
304953	100736352	20992745968	prostate	prostate	NN1
304953	100736352	20992745969	cancer	cancer	NN1
304953	100736352	20992745970	in	in	II
304953	100736352	20992745971	civilian	civilian	JJ_NN1
304953	100736352	20992745972	hospitals	hospital	NN2
304953	100736352	20992745973	.	.	.
304953	100736352	20992745974	That	that	DD1_CST
304953	100736352	20992745975	benefits	benefit	NN2
304953	100736352	20992745976	their	their	APPGE
304953	100736352	20992745977	own	own	DA
304953	100736352	20992745978	health	health	NN1
304953	100736352	20992745979	,	,	,
304953	100736352	20992745980	but	but	CCB
304953	100736352	20992745981	it	it	PPH1
304953	100736352	20992745982	also	also	RR
304953	100736352	20992745983	benefits	benefit	NN2
304953	100736352	20992745984	the	the	AT
304953	100736352	20992745985	CPDRs		NP1
304953	100736352	20992745986	broader	broad	JJR
304953	100736352	20992745987	mission	mission	NN1
304953	100736352	20992745988	to	to	TO
304953	100736352	20992745989	understand	understand	VVI
304953	100736352	20992745990	what	what	DDQ
304953	100736352	20992745991	causes	cause	VVZ
304953	100736352	20992745992	cancer	cancer	NN1
304953	100736352	20992745993	,	,	,
304953	100736352	20992745994	and	and	CC
304953	100736352	20992745995	how	how	RRQ
304953	100736352	20992745996	best	best	RRT
304953	100736352	20992745997	to	to	TO
304953	100736352	20992745998	treat	treat	VVI
304953	100736352	20992745999	it	it	PPH1
304953	100736352	20992746000	.	.	.
304953	100736352	20992746001	<p>		NULL
304953	100736352	20992746002	And	and	CC
304953	100736352	20992746003	those	those	DD2
304953	100736352	20992746004	data	data	NN
304953	100736352	20992746005	are	be	VBR
304953	100736352	20992746006	linked	link	VVN
304953	100736352	20992746007	with	with	IW
304953	100736352	20992746008	blood	blood	NN1
304953	100736352	20992746009	and	and	CC
304953	100736352	20992746010	tissue	tissue	NN1
304953	100736352	20992746011	samples	sample	NN2
304953	100736352	20992746012	housed	house	VVN_VVD
304953	100736352	20992746013	at	at	II
304953	100736352	20992746014	the	the	AT
304953	100736352	20992746015	CPDRs		NP1
304953	100736352	20992746016	biospecimen		NN2
304953	100736352	20992746017	repository	repository	NN1
304953	100736352	20992746018	at	at	II
304953	100736352	20992746019	Walter	walter	NP1
304953	100736352	20992746020	Reed	reed	NP1
304953	100736352	20992746021	.	.	.
304953	100736352	20992746022	The	the	AT
304953	100736352	20992746023	CPDRs		NP1
304953	100736352	20992746024	prostate	prostate	NN1
304953	100736352	20992746025	cancer	cancer	NN1
304953	100736352	20992746026	database	database	NN1
304953	100736352	20992746027	is	be	VBZ
304953	100736352	20992746028	now	now	RT
304953	100736352	20992746029	the	the	AT
304953	100736352	20992746030	largest	large	JJT
304953	100736352	20992746031	in	in	II
304953	100736352	20992746032	the	the	AT
304953	100736352	20992746033	country	country	NN1
304953	100736352	20992746034	,	,	,
304953	100736352	20992746035	"	"	"
304953	100736352	20992746036	which	which	DDQ
304953	100736352	20992746037	puts	put	VVZ
304953	100736352	20992746038	us	us	PPIO2
304953	100736352	20992746039	in	in	II
304953	100736352	20992746040	an	a	AT1
304953	100736352	20992746041	enviable	enviable	JJ
304953	100736352	20992746042	position	position	NN1
304953	100736352	20992746043	,	,	,
304953	100736352	20992746044	"	"	"
304953	100736352	20992746045	says	say	VVZ
304953	100736352	20992746046	McLeod	mcleod	NP1
304953	100736352	20992746047	.	.	.
304953	100736352	20992746048	"	"	"
304953	100736352	20992746049	Scientists	scientist	NN2
304953	100736352	20992746050	from	from	II
304953	100736352	20992746051	around	around	II
304953	100736352	20992746052	the	the	AT
304953	100736352	20992746053	world	world	NN1
304953	100736352	20992746054	are	be	VBR
304953	100736352	20992746055	always	always	RR
304953	100736352	20992746056	knocking	knock	VVG
304953	100736352	20992746057	on	on	II_RP@
304953	100736352	20992746058	our	our	APPGE
304953	100736352	20992746059	doors	door	NN2
304953	100736352	20992746060	.	.	.
304953	100736352	20992746061	"	"	"
304953	100736352	20992746062	Importantly	importantly	RR
304953	100736352	20992746063	,	,	,
304953	100736352	20992746064	the	the	AT
304953	100736352	20992746065	database	database	NN1
304953	100736352	20992746066	and	and	CC
304953	100736352	20992746067	specimens	specimen	NN2
304953	100736352	20992746068	collection	collection	NN1
304953	100736352	20992746069	are	be	VBR
304953	100736352	20992746070	heavily	heavily	RR
304953	100736352	20992746071	weighted	weight	VVN_VVD
304953	100736352	20992746072	towards	towards	II
304953	100736352	20992746073	African	african	JJ
304953	100736352	20992746074	American	american	JJ
304953	100736352	20992746075	men	man	NN2
304953	100736352	20992746076	,	,	,
304953	100736352	20992746077	who	who	PNQS
304953	100736352	20992746078	face	face	VV0
304953	100736352	20992746079	a	a	AT1
304953	100736352	20992746080	higher	high	JJR
304953	100736352	20992746081	than	than	CSN
304953	100736352	20992746082	average	average	JJ
304953	100736352	20992746083	risk	risk	NN1
304953	100736352	20992746084	of	of	IO
304953	100736352	20992746085	prostate	prostate	NN1
304953	100736352	20992746086	cancer	cancer	NN1
304953	100736352	20992746087	.	.	.
304953	100736352	20992746088	<p>		NULL
304953	100736352	20992746089	CPDR		NP1
304953	100736352	20992746090	scientists	scientist	NN2
304953	100736352	20992746091	using	use	VVG
304953	100736352	20992746092	these	these	DD2
304953	100736352	20992746093	resources	resource	NN2
304953	100736352	20992746094	have	have	VH0
304953	100736352	20992746095	made	make	VVN
304953	100736352	20992746096	important	important	JJ
304953	100736352	20992746097	discoveries	discovery	NN2
304953	100736352	20992746098	.	.	.
304953	100736352	20992746099	They	they	PPHS2
304953	100736352	20992746100	were	be	VBDR
304953	100736352	20992746101	among	among	II
304953	100736352	20992746102	the	the	AT
304953	100736352	20992746103	first	first	MD
304953	100736352	20992746104	to	to	TO
304953	100736352	20992746105	connect	connect	VVI
304953	100736352	20992746106	prostate	prostate	NN1
304953	100736352	20992746107	cancer	cancer	NN1
304953	100736352	20992746108	with	with	IW
304953	100736352	20992746109	defects	defect	NN2
304953	100736352	20992746110	in	in	II
304953	100736352	20992746111	a	a	AT1
304953	100736352	20992746112	gene	gene	NN1
304953	100736352	20992746113	called	call	VVN
304953	100736352	20992746114	p53	p53	FO
304953	100736352	20992746115	that	that	DD1_CST
304953	100736352	20992746116	ordinarily	ordinarily	RR
304953	100736352	20992746117	slows	slow	VVZ
304953	100736352	20992746118	or	or	CC
304953	100736352	20992746119	prevents	prevent	VVZ
304953	100736352	20992746120	tumors	tumor	NN2
304953	100736352	20992746121	from	from	II
304953	100736352	20992746122	growing	grow	VVG_JJ
304953	100736352	20992746123	.	.	.
304953	100736352	20992746124	And	and	CC
304953	100736352	20992746125	they	they	PPHS2
304953	100736352	20992746126	also	also	RR
304953	100736352	20992746127	found	find	VVD
304953	100736352	20992746128	many	many	DA2
304953	100736352	20992746129	@		II
304953	100736352	20992746130	@		II
304953	100736352	20992746131	@		II
304953	100736352	20992746132	@		II
304953	100736352	20992746133	@		II
304953	100736352	20992746134	@		II
304953	100736352	20992746135	@		II
304953	100736352	20992746136	@		II
304953	100736352	20992746137	@		II
304953	100736352	20992746138	@		II
304953	100736352	20992746139	ERG		NN1_NP1
304953	100736352	20992746140	.	.	.
304953	100736352	20992746141	Dr.		NNB
304953	100736352	20992746142	Matthew	matthew	NP1
304953	100736352	20992746143	Freedman	freedman	NP1
304953	100736352	20992746144	,	,	,
304953	100736352	20992746145	an	a	AT1
304953	100736352	20992746146	associate	associate	JJ_NN1
304953	100736352	20992746147	professor	professor	NN1
304953	100736352	20992746148	of	of	IO
304953	100736352	20992746149	medicine	medicine	NN1
304953	100736352	20992746150	at	at	II
304953	100736352	20992746151	Harvard	harvard	NP1
304953	100736352	20992746152	Medical	medical	JJ
304953	100736352	20992746153	School	school	NN1
304953	100736352	20992746154	and	and	CC
304953	100736352	20992746155	the	the	AT
304953	100736352	20992746156	Dana-Farber	dana-farber	NP1
304953	100736352	20992746157	Cancer	cancer	NN1
304953	100736352	20992746158	Institute	institute	NN1
304953	100736352	20992746159	,	,	,
304953	100736352	20992746160	is	be	VBZ
304953	100736352	20992746161	now	now	RT
304953	100736352	20992746162	working	work	VVG
304953	100736352	20992746163	with	with	IW
304953	100736352	20992746164	CPDR		NP1
304953	100736352	20992746165	scientists	scientist	NN2
304953	100736352	20992746166	to	to	TO
304953	100736352	20992746167	understand	understand	VVI
304953	100736352	20992746168	how	how	RRQ
304953	100736352	20992746169	ERG		NP1_NN1_VV0
304953	100736352	20992746170	activity	activity	NN1
304953	100736352	20992746171	differs	differ	VVZ
304953	100736352	20992746172	in	in	II
304953	100736352	20992746173	African	african	JJ
304953	100736352	20992746174	American	american	JJ_NN1@
304953	100736352	20992746175	and	and	CC
304953	100736352	20992746176	Caucasian	caucasian	JJ_NN1
304953	100736352	20992746177	men	man	NN2
304953	100736352	20992746178	with	with	IW
304953	100736352	20992746179	prostate	prostate	NN1
304953	100736352	20992746180	cancer	cancer	NN1
304953	100736352	20992746181	.	.	.
304953	100736352	20992746182	<p>		NULL
304953	100736352	20992746183	"	"	"
304953	100736352	20992746184	The	the	AT
304953	100736352	20992746185	DOD	dod	NP1_NN1
304953	100736352	20992746186	CPDR		NP1
304953	100736352	20992746187	is	be	VBZ
304953	100736352	20992746188	an	a	AT1
304953	100736352	20992746189	invaluable	invaluable	JJ
304953	100736352	20992746190	resource	resource	NN1
304953	100736352	20992746191	and	and	CC
304953	100736352	20992746192	the	the	AT
304953	100736352	20992746193	work	work	NN1
304953	100736352	20992746194	that	that	CST
304953	100736352	20992746195	Dr.		NNB
304953	100736352	20992746196	McLeod	mcleod	NP1
304953	100736352	20992746197	and	and	CC
304953	100736352	20992746198	his	his	APPGE
304953	100736352	20992746199	colleagues	colleague	NN2
304953	100736352	20992746200	have	have	VH0
304953	100736352	20992746201	performed	perform	VVN
304953	100736352	20992746202	has	have	VHZ
304953	100736352	20992746203	placed	place	VVN
304953	100736352	20992746204	this	this	DD1
304953	100736352	20992746205	program	program	NN1
304953	100736352	20992746206	at	at	II
304953	100736352	20992746207	the	the	AT
304953	100736352	20992746208	forefront	forefront	NN1
304953	100736352	20992746209	of	of	IO
304953	100736352	20992746210	prostate	prostate	NN1
304953	100736352	20992746211	cancer	cancer	NN1
304953	100736352	20992746212	research	research	NN1
304953	100736352	20992746213	,	,	,
304953	100736352	20992746214	"	"	"
304953	100736352	20992746215	said	say	VVD
304953	100736352	20992746216	Dr.		NNB
304953	100736352	20992746217	Marc	marc	NP1
304953	100736352	20992746218	Garnick		NP1
304953	100736352	20992746219	,	,	,
304953	100736352	20992746220	the	the	AT
304953	100736352	20992746221	Gorman	gorman	NN1_NP1
304953	100736352	20992746222	Brothers	brother	NN2
304953	100736352	20992746223	Professor	professor	NN1
304953	100736352	20992746224	of	of	IO
304953	100736352	20992746225	Medicine	medicine	NN1
304953	100736352	20992746226	at	at	II
304953	100736352	20992746227	Harvard	harvard	NP1
304953	100736352	20992746228	Medical	medical	JJ
304953	100736352	20992746229	School	school	NN1
304953	100736352	20992746230	and	and	CC
304953	100736352	20992746231	Beth	beth	NP1
304953	100736352	20992746232	Israel	israel	NP1
304953	100736352	20992746233	Deaconess	deaconess	NN1
304953	100736352	20992746234	Medical	medical	JJ
304953	100736352	20992746235	Center	center	NN1
304953	100736352	20992746236	,	,	,
304953	100736352	20992746237	and	and	CC
304953	100736352	20992746238	Editor	editor	NN1
304953	100736352	20992746239	in	in	II
304953	100736352	20992746240	Chief	chief	NN1
304953	100736352	20992746241	of	of	IO
304953	100736352	20992746242	**28;301;TOOLONG		NP1
304953	100736352	20992746243	.	.	.
304953	100736352	20992746244	"	"	"
304953	100736352	20992746245	In	in	RR21
304953	100736352	20992746246	addition	addition	RR22
304953	100736352	20992746247	,	,	,
304953	100736352	20992746248	the	the	AT
304953	100736352	20992746249	DOD	dod	NN1_NP1
304953	100736352	20992746250	graciously	graciously	RR
304953	100736352	20992746251	and	and	CC
304953	100736352	20992746252	generously	generously	RR
304953	100736352	20992746253	supports	support	VVZ
304953	100736352	20992746254	additional	additional	JJ
304953	100736352	20992746255	extramural	extramural	JJ_NN1
304953	100736352	20992746256	research	research	NN1
304953	100736352	20992746257	involving	involve	VVG
304953	100736352	20992746258	prostate	prostate	NN1
304953	100736352	20992746259	health	health	NN1
304953	100736352	20992746260	.	.	.
304953	100736352	20992746261	It	it	PPH1
304953	100736352	20992746262	is	be	VBZ
304953	100736352	20992746263	encouraging	encouraging	JJ_VVG@
304953	100736352	20992746264	that	that	CST_DD1
304953	100736352	20992746265	such	such	DA
304953	100736352	20992746266	facilities	facility	NN2
304953	100736352	20992746267	are	be	VBR
304953	100736352	20992746268	available	available	JJ
304953	100736352	20992746269	for	for	IF
304953	100736352	20992746270	our	our	APPGE
304953	100736352	20992746271	servicemen	serviceman	NN2
304953	100736352	20992746272	and	and	CC
304953	100736352	20992746273	their	their	APPGE
304953	100736352	20992746274	families	family	NN2
304953	100736352	20992746275	.	.	.
304953	100736352	20992746276	"	"	"
304953	100736353	20992746296	@@##	----------	----------
304953	100736353	20992746297	@@100736353		FO
304953	100736353	20992746298	@4936353/		VV0_NN1
304953	100736353	20992746299	46989		MC
304953	100736353	20992746300	@qwx906989		FO
304953	100736353	20992746301	<p>		NULL
304953	100736353	20992746302	Testosterone	testosterone	NN1
304953	100736353	20992746303	promotes	promote	VVZ
304953	100736353	20992746304	the	the	AT
304953	100736353	20992746305	growth	growth	NN1
304953	100736353	20992746306	and	and	CC
304953	100736353	20992746307	spread	spread	NN1
304953	100736353	20992746308	of	of	IO
304953	100736353	20992746309	prostate	prostate	NN1
304953	100736353	20992746310	cancer	cancer	NN1
304953	100736353	20992746311	cells	cell	NN2
304953	100736353	20992746312	.	.	.
304953	100736353	20992746313	That 's		NN2_VVZ
304953	100736353	20992746314	why	why	RRQ
304953	100736353	20992746315	advanced	advanced	JJ
304953	100736353	20992746316	prostate	prostate	NN1
304953	100736353	20992746317	cancer	cancer	NN1
304953	100736353	20992746318	can	can	VM
304953	100736353	20992746319	be	be	VBI
304953	100736353	20992746320	managed	manage	VVN
304953	100736353	20992746321	with	with	IW
304953	100736353	20992746322	hormonal	hormonal	JJ
304953	100736353	20992746323	therapy	therapy	NN1
304953	100736353	20992746324	that	that	CST_DD1
304953	100736353	20992746325	drives	drive	VVZ
304953	100736353	20992746326	down	down	RP_II@
304953	100736353	20992746327	production	production	NN1
304953	100736353	20992746328	of	of	IO
304953	100736353	20992746329	testosterone	testosterone	NN1
304953	100736353	20992746330	in	in	II
304953	100736353	20992746331	the	the	AT
304953	100736353	20992746332	testicles	testicle	NN2
304953	100736353	20992746333	.	.	.
304953	100736353	20992746334	But	but	CCB
304953	100736353	20992746335	almost	almost	RR
304953	100736353	20992746336	invariably	invariably	RR
304953	100736353	20992746337	,	,	,
304953	100736353	20992746338	the	the	AT
304953	100736353	20992746339	cancer	cancer	NN1
304953	100736353	20992746340	eventually	eventually	RR
304953	100736353	20992746341	breaks	break	VVZ
304953	100736353	20992746342	through	through	RP@_II
304953	100736353	20992746343	and	and	CC
304953	100736353	20992746344	starts	start	VVZ
304953	100736353	20992746345	growing	grow	VVG_JJ
304953	100736353	20992746346	again	again	RT
304953	100736353	20992746347	.	.	.
304953	100736353	20992746348	Such	such	DA
304953	100736353	20992746349	breakthrough	breakthrough	NN1
304953	100736353	20992746350	disease	disease	NN1
304953	100736353	20992746351	is	be	VBZ
304953	100736353	20992746352	called	call	VVN
304953	100736353	20992746353	castration-resistant		JJ
304953	100736353	20992746354	prostate	prostate	NN1
304953	100736353	20992746355	cancer	cancer	NN1
304953	100736353	20992746356	.	.	.
304953	100736353	20992746357	<p>		NULL
304953	100736353	20992746358	A	a	AT1
304953	100736353	20992746359	research	research	NN1
304953	100736353	20992746360	group	group	NN1
304953	100736353	20992746361	led	lead	VVN
304953	100736353	20992746362	by	by	II
304953	100736353	20992746363	the	the	AT
304953	100736353	20992746364	Cleveland	cleveland	NP1
304953	100736353	20992746365	Clinics	clinic	NN2
304953	100736353	20992746366	Nima	nima	NP1
304953	100736353	20992746367	Sharifi		NP1_NN1
304953	100736353	20992746368	has	have	VHZ
304953	100736353	20992746369	identified	identify	VVN
304953	100736353	20992746370	an	a	AT1
304953	100736353	20992746371	enzyme	enzyme	NN1
304953	100736353	20992746372	that	that	CST_DD1
304953	100736353	20992746373	may	may	VM
304953	100736353	20992746374	be	be	VBI
304953	100736353	20992746375	the	the	AT
304953	100736353	20992746376	escape	escape	NN1
304953	100736353	20992746377	hatch	hatch	VV0_NN1
304953	100736353	20992746378	that	that	CST_DD1
304953	100736353	20992746379	advanced	advanced	JJ_VVD
304953	100736353	20992746380	prostate	prostate	NN1
304953	100736353	20992746381	cancer	cancer	NN1
304953	100736353	20992746382	uses	use	VVZ
304953	100736353	20992746383	to	to	TO
304953	100736353	20992746384	evade	evade	VVI
304953	100736353	20992746385	hormone	hormone	NN1
304953	100736353	20992746386	therapy	therapy	NN1
304953	100736353	20992746387	.	.	.
304953	100736353	20992746388	If	if	CS
304953	100736353	20992746389	the	the	AT
304953	100736353	20992746390	findings	finding	NN2
304953	100736353	20992746391	hold	hold	VV0
304953	100736353	20992746392	up	up	RP
304953	100736353	20992746393	,	,	,
304953	100736353	20992746394	the	the	AT
304953	100736353	20992746395	enzyme	enzyme	NN1
304953	100736353	20992746396	might	might	VM
304953	100736353	20992746397	be	be	VBI
304953	100736353	20992746398	a	a	AT1
304953	100736353	20992746399	prime	prime	JJ
304953	100736353	20992746400	target	target	NN1
304953	100736353	20992746401	for	for	IF
304953	100736353	20992746402	a	a	AT1
304953	100736353	20992746403	drug	drug	NN1
304953	100736353	20992746404	that	that	CST_DD1
304953	100736353	20992746405	would	would	VM
304953	100736353	20992746406	treat	treat	VVI
304953	100736353	20992746407	castration-resistant		JJ
304953	100736353	20992746408	prostate	prostate	NN1
304953	100736353	20992746409	cancer	cancer	NN1
304953	100736353	20992746410	.	.	.
304953	100736353	20992746411	<h>		NULL
304953	100736353	20992746412	A	a	AT1_ZZ1
304953	100736353	20992746413	male	male	JJ_NN1
304953	100736353	20992746414	hormone	hormone	NN1
304953	100736353	20992746415	more	more	RGR
304953	100736353	20992746416	potent	potent	JJ
304953	100736353	20992746417	than	than	CSN
304953	100736353	20992746418	testosterone	testosterone	NN1
304953	100736353	20992746419	<p>		NULL
304953	100736353	20992746420	The	the	AT
304953	100736353	20992746421	enzyme	enzyme	NN1
304953	100736353	20992746422	that	that	CST_DD1
304953	100736353	20992746423	Sharifi	sharifi	NP1_NN1_JJ
304953	100736353	20992746424	and	and	CC
304953	100736353	20992746425	his	his	APPGE
304953	100736353	20992746426	colleagues	colleague	NN2
304953	100736353	20992746427	identified	identify	VVN
304953	100736353	20992746428	has	have	VHZ
304953	100736353	20992746429	one	one	MC1
304953	100736353	20992746430	of	of	IO
304953	100736353	20992746431	those	those	DD2
304953	100736353	20992746432	more-than-a-mouthful		JJ
304953	100736353	20992746433	names	name	NN2
304953	100736353	20992746434	"	"	"
304953	100736353	20992746435	3+-hydroxysteroid		FO
304953	100736353	20992746436	dehydrogenase	dehydrogenase	NN1_VV0
304953	100736353	20992746437	type	type	NN1
304953	100736353	20992746438	1	1	MC1
304953	100736353	20992746439	.	.	.
304953	100736353	20992746440	Its	its	APPGE
304953	100736353	20992746441	usually	usually	RR
304953	100736353	20992746442	referred	refer	VVN_VVD
304953	100736353	20992746443	to	to	II
304953	100736353	20992746444	by	by	II
304953	100736353	20992746445	the	the	AT
304953	100736353	20992746446	slightly	slightly	RR
304953	100736353	20992746447	less	less	RGR
304953	100736353	20992746448	intimidating	intimidating	JJ
304953	100736353	20992746449	soup	soup	NN1
304953	100736353	20992746450	of	of	IO
304953	100736353	20992746451	initials	initial	NN2
304953	100736353	20992746452	,	,	,
304953	100736353	20992746453	3+HSD1		FO
304953	100736353	20992746454	.	.	.
304953	100736353	20992746455	<p>		NULL
304953	100736353	20992746456	Using	use	VVG
304953	100736353	20992746457	cell	cell	NN1
304953	100736353	20992746458	lines	line	NN2
304953	100736353	20992746459	,	,	,
304953	100736353	20992746460	mice	mouse	NN2
304953	100736353	20992746461	,	,	,
304953	100736353	20992746462	and	and	CC
304953	100736353	20992746463	DNA	dna	NN1
304953	100736353	20992746464	from	from	II
304953	100736353	20992746465	the	the	AT
304953	100736353	20992746466	tumors	tumor	NN2
304953	100736353	20992746467	of	of	IO
304953	100736353	20992746468	men	man	NN2
304953	100736353	20992746469	with	with	IW
304953	100736353	20992746470	castration-resistant		JJ
304953	100736353	20992746471	prostate	prostate	NN1
304953	100736353	20992746472	cancer	cancer	NN1
304953	100736353	20992746473	,	,	,
304953	100736353	20992746474	they	they	PPHS2
304953	100736353	20992746475	laid	lay	VVD
304953	100736353	20992746476	out	out	RP
304953	100736353	20992746477	several	several	DA2
304953	100736353	20992746478	,	,	,
304953	100736353	20992746479	interlocking	interlock	VVG_JJ
304953	100736353	20992746480	lines	line	NN2
304953	100736353	20992746481	of	of	IO
304953	100736353	20992746482	evidence	evidence	NN1
304953	100736353	20992746483	to	to	TO
304953	100736353	20992746484	make	make	VVI
304953	100736353	20992746485	case	case	NN1
304953	100736353	20992746486	for	for	IF
304953	100736353	20992746487	an	a	AT1
304953	100736353	20992746488	@		II
304953	100736353	20992746489	@		II
304953	100736353	20992746490	@		II
304953	100736353	20992746491	@		II
304953	100736353	20992746492	@		II
304953	100736353	20992746493	@		II
304953	100736353	20992746494	@		II
304953	100736353	20992746495	@		II
304953	100736353	20992746496	@		II
304953	100736353	20992746497	@		II
304953	100736353	20992746498	castration-resistant		JJ
304953	100736353	20992746499	prostate	prostate	NN1
304953	100736353	20992746500	cancer	cancer	NN1
304953	100736353	20992746501	.	.	.
304953	100736353	20992746502	<p>		NULL
304953	100736353	20992746503	3+HSD1		FO
304953	100736353	20992746504	is	be	VBZ
304953	100736353	20992746505	crucial	crucial	JJ
304953	100736353	20992746506	to	to	II
304953	100736353	20992746507	a	a	AT1
304953	100736353	20992746508	complicated	complicated	JJ
304953	100736353	20992746509	process	process	NN1
304953	100736353	20992746510	that	that	CST_DD1
304953	100736353	20992746511	converts	convert	VVZ_NN2
304953	100736353	20992746512	dehydroepiandrosterone	dehydroepiandrosterone	NN1_VV0
304953	100736353	20992746513	(	(	(
304953	100736353	20992746514	DHEA	dhea	NP1
304953	100736353	20992746515	)	)	)
304953	100736353	20992746516	,	,	,
304953	100736353	20992746517	a	a	AT1
304953	100736353	20992746518	hormone	hormone	NN1
304953	100736353	20992746519	produced	produce	VVN
304953	100736353	20992746520	by	by	II
304953	100736353	20992746521	the	the	AT
304953	100736353	20992746522	adrenal	adrenal	JJ
304953	100736353	20992746523	glands	gland	NN2
304953	100736353	20992746524	,	,	,
304953	100736353	20992746525	into	into	II
304953	100736353	20992746526	dihydrotestosterone	dihydrotestosterone	NN1
304953	100736353	20992746527	(	(	(
304953	100736353	20992746528	DHT	dht	NP1
304953	100736353	20992746529	)	)	)
304953	100736353	20992746530	.	.	.
304953	100736353	20992746531	Like	like	II_JJ@
304953	100736353	20992746532	testosterone	testosterone	NN1
304953	100736353	20992746533	,	,	,
304953	100736353	20992746534	DHT	dht	NP1
304953	100736353	20992746535	is	be	VBZ
304953	100736353	20992746536	a	a	AT1
304953	100736353	20992746537	male	male	JJ_NN1
304953	100736353	20992746538	hormone	hormone	NN1
304953	100736353	20992746539	.	.	.
304953	100736353	20992746540	It	it	PPH1
304953	100736353	20992746541	is	be	VBZ
304953	100736353	20992746542	more	more	RGR
304953	100736353	20992746543	potent	potent	JJ
304953	100736353	20992746544	in	in	II
304953	100736353	20992746545	many	many	DA2
304953	100736353	20992746546	respects	respect	NN2
304953	100736353	20992746547	than	than	CSN
304953	100736353	20992746548	testosterone	testosterone	NN1
304953	100736353	20992746549	,	,	,
304953	100736353	20992746550	especially	especially	RR
304953	100736353	20992746551	as	as	II_CSA
304953	100736353	20992746552	a	a	AT1
304953	100736353	20992746553	hormonal	hormonal	JJ
304953	100736353	20992746554	provocateur	provocateur	NN1
304953	100736353	20992746555	of	of	IO
304953	100736353	20992746556	prostate	prostate	NN1
304953	100736353	20992746557	cancer	cancer	NN1
304953	100736353	20992746558	cell	cell	NN1
304953	100736353	20992746559	proliferation	proliferation	NN1
304953	100736353	20992746560	.	.	.
304953	100736353	20992746561	<p>		NULL
304953	100736353	20992746562	Normally	normally	RR
304953	100736353	20992746563	,	,	,
304953	100736353	20992746564	smaller	small	JJR
304953	100736353	20992746565	proteins	protein	NN2
304953	100736353	20992746566	glom	glom	VV0
304953	100736353	20992746567	on	on	RP_II21
304953	100736353	20992746568	to	to	II_II22
304953	100736353	20992746569	3+HSD1		FO
304953	100736353	20992746570	,	,	,
304953	100736353	20992746571	altering	alter	VVG
304953	100736353	20992746572	its	its	APPGE
304953	100736353	20992746573	shape	shape	NN1
304953	100736353	20992746574	and	and	CC
304953	100736353	20992746575	function	function	NN1
304953	100736353	20992746576	.	.	.
304953	100736353	20992746577	Sharifi		NN2_NP1@
304953	100736353	20992746578	and	and	CC
304953	100736353	20992746579	his	his	APPGE
304953	100736353	20992746580	group	group	NN1
304953	100736353	20992746581	identified	identify	VVN_VVD@
304953	100736353	20992746582	an	a	AT1
304953	100736353	20992746583	altered	altered	JJ
304953	100736353	20992746584	form	form	NN1
304953	100736353	20992746585	that	that	CST_DD1
304953	100736353	20992746586	resists	resist	VVZ
304953	100736353	20992746587	those	those	DD2
304953	100736353	20992746588	changes	change	NN2
304953	100736353	20992746589	.	.	.
304953	100736353	20992746590	More	more	RGR_DAR
304953	100736353	20992746591	intact	intact	JJ
304953	100736353	20992746592	3+HSD1		FO
304953	100736353	20992746593	in	in	II
304953	100736353	20992746594	circulation	circulation	NN1
304953	100736353	20992746595	means	mean	VVZ
304953	100736353	20992746596	more	more	DAR_RRR
304953	100736353	20992746597	DHEA	dhea	NN1_NP1
304953	100736353	20992746598	gets	get	VVZ
304953	100736353	20992746599	converted	convert	VVN
304953	100736353	20992746600	into	into	II
304953	100736353	20992746601	DHT	dht	NP1
304953	100736353	20992746602	,	,	,
304953	100736353	20992746603	which	which	DDQ
304953	100736353	20992746604	prods	prod	VVZ%_NN2
304953	100736353	20992746605	prostate	prostate	NN1
304953	100736353	20992746606	cancer	cancer	NN1
304953	100736353	20992746607	cells	cell	NN2
304953	100736353	20992746608	to	to	TO
304953	100736353	20992746609	proliferate	proliferate	VVI
304953	100736353	20992746610	"	"	"
304953	100736353	20992746611	even	even	CS21
304953	100736353	20992746612	if	if	CS22
304953	100736353	20992746613	hormone	hormone	NN1
304953	100736353	20992746614	therapy	therapy	NN1
304953	100736353	20992746615	has	have	VHZ
304953	100736353	20992746616	ratcheted	ratchete	VVN
304953	100736353	20992746617	down	down	RP_II@
304953	100736353	20992746618	testosterone	testosterone	NN1
304953	100736353	20992746619	levels	level	NN2
304953	100736353	20992746620	so	so	RG_RR
304953	100736353	20992746621	other	other	JJ
304953	100736353	20992746622	go-forth-and-multiply		VV0
304953	100736353	20992746623	signals	signal	NN2
304953	100736353	20992746624	are	be	VBR
304953	100736353	20992746625	lacking	lack	VVG
304953	100736353	20992746626	.	.	.
304953	100736353	20992746627	The	the	AT
304953	100736353	20992746628	result	result	NN1
304953	100736353	20992746629	:	:	:
304953	100736353	20992746630	castration-resistant		JJ
304953	100736353	20992746631	prostate	prostate	NN1
304953	100736353	20992746632	cancer	cancer	NN1
304953	100736353	20992746633	.	.	.
304953	100736353	20992746634	<h>		NULL
304953	100736353	20992746635	Could	could	VM
304953	100736353	20992746636	this	this	DD1
304953	100736353	20992746637	lead	lead	VVI
304953	100736353	20992746638	to	to	II
304953	100736353	20992746639	targeted	targeted	JJ%
304953	100736353	20992746640	treatment	treatment	NN1
304953	100736353	20992746641	for	for	IF
304953	100736353	20992746642	prostate	prostate	NN1
304953	100736353	20992746643	cancer	cancer	NN1
304953	100736353	20992746644	?	?	?
304953	100736353	20992746645	<p>		NULL
304953	100736353	20992746646	Several	several	DA2
304953	100736353	20992746647	new	new	JJ
304953	100736353	20992746648	treatments	treatment	NN2
304953	100736353	20992746649	for	for	IF
304953	100736353	20992746650	castration-resistant		JJ
304953	100736353	20992746651	prostate	prostate	NN1
304953	100736353	20992746652	cancer	cancer	NN1
304953	100736353	20992746653	have	have	VH0
304953	100736353	20992746654	been	be	VBN
304953	100736353	20992746655	developed	develop	VVN
304953	100736353	20992746656	recently	recently	RR
304953	100736353	20992746657	,	,	,
304953	100736353	20992746658	so	so	CS@_RR
304953	100736353	20992746659	its	its	APPGE
304953	100736353	20992746660	far	far	RG21
304953	100736353	20992746661	from	from	RG22
304953	100736353	20992746662	hopeless	hopeless	JJ
304953	100736353	20992746663	,	,	,
304953	100736353	20992746664	but	but	CCB
304953	100736353	20992746665	castration-resistant		JJ
304953	100736353	20992746666	prostate	prostate	NN1
304953	100736353	20992746667	cancer	cancer	NN1
304953	100736353	20992746668	is	be	VBZ
304953	100736353	20992746669	a	a	AT1
304953	100736353	20992746670	late-stage	late-stage	JJ_NN1
304953	100736353	20992746671	cancer	cancer	NN1
304953	100736353	20992746672	that	that	CST_DD1
304953	100736353	20992746673	remains	remain	VVZ
304953	100736353	20992746674	very	very	RG
304953	100736353	20992746675	difficult	difficult	JJ
304953	100736353	20992746676	to	to	TO
304953	100736353	20992746677	treat	treat	VVI
304953	100736353	20992746678	.	.	.
304953	100736353	20992746679	<p>		NULL
304953	100736353	20992746680	Where	where	CS_RRQ
304953	100736353	20992746681	exactly	exactly	RR
304953	100736353	20992746682	the	the	AT
304953	100736353	20992746683	research	research	NN1
304953	100736353	20992746684	on	on	II
304953	100736353	20992746685	3+HSD1		FO
304953	100736353	20992746686	might	might	VM
304953	100736353	20992746687	go	go	VVI
304953	100736353	20992746688	@		II
304953	100736353	20992746689	@		II
304953	100736353	20992746690	@		II
304953	100736353	20992746691	@		II
304953	100736353	20992746692	@		II
304953	100736353	20992746693	@		II
304953	100736353	20992746694	@		II
304953	100736353	20992746695	@		II
304953	100736353	20992746696	@		II
304953	100736353	20992746697	@		II
304953	100736353	20992746698	the	the	AT
304953	100736353	20992746699	researchers	researcher	NN2
304953	100736353	20992746700	pointed	point	VVN_VVD
304953	100736353	20992746701	to	to	II
304953	100736353	20992746702	other	other	JJ
304953	100736353	20992746703	cancer	cancer	NN1
304953	100736353	20992746704	drugs	drug	NN2
304953	100736353	20992746705	that	that	CST
304953	100736353	20992746706	are	be	VBR
304953	100736353	20992746707	tailored	tailor	VVN
304953	100736353	20992746708	to	to	II
304953	100736353	20992746709	certain	certain	JJ
304953	100736353	20992746710	mutations	mutation	NN2
304953	100736353	20992746711	,	,	,
304953	100736353	20992746712	which	which	DDQ
304953	100736353	20992746713	may	may	VM
304953	100736353	20992746714	set	set	VVI
304953	100736353	20992746715	a	a	AT1
304953	100736353	20992746716	precedent	precedent	NN1
304953	100736353	20992746717	for	for	IF
304953	100736353	20992746718	3+HSD1-targeted		FO
304953	100736353	20992746719	drugs	drug	NN2
304953	100736353	20992746720	for	for	IF
304953	100736353	20992746721	castration-resistant		JJ
304953	100736353	20992746722	prostate	prostate	NN1
304953	100736353	20992746723	cancer	cancer	NN1
304953	100736353	20992746724	.	.	.
304953	100736353	20992746725	No	no	AT
304953	100736353	20992746726	such	such	DA
304953	100736353	20992746727	drugs	drug	NN2
304953	100736353	20992746728	exist	exist	VV0
304953	100736353	20992746729	now	now	RT
304953	100736353	20992746730	.	.	.
304953	100736353	20992746731	And	and	CC
304953	100736353	20992746732	it	it	PPH1
304953	100736353	20992746733	is	be	VBZ
304953	100736353	20992746734	long	long	RR
304953	100736353	20992746735	shot	shoot	VVN_VVD
304953	100736353	20992746736	to	to	TO
304953	100736353	20992746737	go	go	VVI
304953	100736353	20992746738	from	from	II
304953	100736353	20992746739	identifying	identify	VVG
304953	100736353	20992746740	what	what	DDQ
304953	100736353	20992746741	might	might	VM
304953	100736353	20992746742	be	be	VBI
304953	100736353	20992746743	a	a	AT1
304953	100736353	20992746744	cancers	cancer	NN2
304953	100736353	20992746745	Achilles	achilles	NP1
304953	100736353	20992746746	heel	heel	NN1
304953	100736353	20992746747	to	to	II
304953	100736353	20992746748	developing	develop	VVG
304953	100736353	20992746749	a	a	AT1
304953	100736353	20992746750	medication	medication	NN1
304953	100736353	20992746751	that	that	CST_DD1
304953	100736353	20992746752	can	can	VM
304953	100736353	20992746753	reliably	reliably	RR
304953	100736353	20992746754	hit	hit	VVI
304953	100736353	20992746755	it	it	PPH1
304953	100736353	20992746756	.	.	.
304953	100736353	20992746757	<p>		NULL
304953	100736353	20992746758	Still	still	RR
304953	100736353	20992746759	,	,	,
304953	100736353	20992746760	we	we	PPIS2
304953	100736353	20992746761	are	be	VBR
304953	100736353	20992746762	in	in	II
304953	100736353	20992746763	the	the	AT
304953	100736353	20992746764	age	age	NN1
304953	100736353	20992746765	of	of	IO
304953	100736353	20992746766	targeted	targeted	JJ%
304953	100736353	20992746767	cancer	cancer	NN1
304953	100736353	20992746768	treatment	treatment	NN1
304953	100736353	20992746769	,	,	,
304953	100736353	20992746770	and	and	CC
304953	100736353	20992746771	to	to	TO
304953	100736353	20992746772	have	have	VHI
304953	100736353	20992746773	one	one	PN1_MC1
304953	100736353	20992746774	for	for	IF
304953	100736353	20992746775	prostate	prostate	NN1
304953	100736353	20992746776	cancer	cancer	NN1
304953	100736353	20992746777	would	would	VM
304953	100736353	20992746778	be	be	VBI
304953	100736353	20992746779	a	a	AT1
304953	100736353	20992746780	big	big	JJ
304953	100736353	20992746781	advance	advance	NN1
304953	100736353	20992746782	.	.	.
304953	100736355	20992746802	@@##	----------	----------
304953	100736355	20992746803	@@100736355		FO
304953	100736355	20992746804	@4936355/		VV0_NN1
304953	100736355	20992746805	46989		MC
304953	100736355	20992746806	@qwx906989		FO
304953	100736355	20992746807	<p>		NULL
304953	100736355	20992746808	This	this	DD1
304953	100736355	20992746809	year	year	NNT1
304953	100736355	20992746810	,	,	,
304953	100736355	20992746811	more	more	DAR
304953	100736355	20992746812	than	than	CSN
304953	100736355	20992746813	238,000	238,000	MC
304953	100736355	20992746814	American	american	JJ
304953	100736355	20992746815	men	man	NN2
304953	100736355	20992746816	will	will	VM
304953	100736355	20992746817	be	be	VBI
304953	100736355	20992746818	diagnosed	diagnose	VVN
304953	100736355	20992746819	with	with	IW
304953	100736355	20992746820	prostate	prostate	NN1
304953	100736355	20992746821	cancer	cancer	NN1
304953	100736355	20992746822	.	.	.
304953	100736355	20992746823	In	in	II
304953	100736355	20992746824	most	most	DAT
304953	100736355	20992746825	cases	case	NN2
304953	100736355	20992746826	,	,	,
304953	100736355	20992746827	the	the	AT
304953	100736355	20992746828	cancer	cancer	NN1
304953	100736355	20992746829	consists	consist	VVZ
304953	100736355	20992746830	of	of	IO
304953	100736355	20992746831	small	small	JJ
304953	100736355	20992746832	knots	knot	NN2
304953	100736355	20992746833	of	of	IO
304953	100736355	20992746834	abnormal	abnormal	JJ
304953	100736355	20992746835	cells	cell	NN2
304953	100736355	20992746836	growing	grow	VVG
304953	100736355	20992746837	slowly	slowly	RR
304953	100736355	20992746838	in	in	II
304953	100736355	20992746839	the	the	AT
304953	100736355	20992746840	walnut-sized	walnut-sized	JJ
304953	100736355	20992746841	prostate	prostate	NN1
304953	100736355	20992746842	gland	gland	NN1
304953	100736355	20992746843	.	.	.
304953	100736355	20992746844	In	in	II
304953	100736355	20992746845	many	many	DA2
304953	100736355	20992746846	men	man	NN2
304953	100736355	20992746847	,	,	,
304953	100736355	20992746848	the	the	AT
304953	100736355	20992746849	cancer	cancer	NN1
304953	100736355	20992746850	cells	cell	NN2
304953	100736355	20992746851	grow	grow	VV0
304953	100736355	20992746852	so	so	RG
304953	100736355	20992746853	slowly	slowly	RR
304953	100736355	20992746854	that	that	CST
304953	100736355	20992746855	they	they	PPHS2
304953	100736355	20992746856	never	never	RR
304953	100736355	20992746857	break	break	VV0
304953	100736355	20992746858	free	free	JJ
304953	100736355	20992746859	of	of	IO
304953	100736355	20992746860	the	the	AT
304953	100736355	20992746861	gland	gland	NN1
304953	100736355	20992746862	,	,	,
304953	100736355	20992746863	spread	spread	VVN_VVD_VV0
304953	100736355	20992746864	to	to	II
304953	100736355	20992746865	distant	distant	JJ
304953	100736355	20992746866	sites	site	NN2
304953	100736355	20992746867	,	,	,
304953	100736355	20992746868	and	and	CC
304953	100736355	20992746869	pose	pose	VV0
304953	100736355	20992746870	a	a	AT1
304953	100736355	20992746871	serious	serious	JJ
304953	100736355	20992746872	risk	risk	NN1
304953	100736355	20992746873	to	to	II
304953	100736355	20992746874	health	health	NN1
304953	100736355	20992746875	and	and	CC
304953	100736355	20992746876	longevity	longevity	NN1
304953	100736355	20992746877	.	.	.
304953	100736355	20992746878	<p>		NULL
304953	100736355	20992746879	Evidence	evidence	NN1
304953	100736355	20992746880	is	be	VBZ
304953	100736355	20992746881	growing	grow	VVG
304953	100736355	20992746882	that	that	RG
304953	100736355	20992746883	early	early	RR
304953	100736355	20992746884	treatment	treatment	NN1
304953	100736355	20992746885	with	with	IW
304953	100736355	20992746886	surgery	surgery	NN1
304953	100736355	20992746887	or	or	CC
304953	100736355	20992746888	radiation	radiation	NN1
304953	100736355	20992746889	prevents	prevent	VVZ
304953	100736355	20992746890	relatively	relatively	RR
304953	100736355	20992746891	few	few	DA2
304953	100736355	20992746892	men	man	NN2
304953	100736355	20992746893	from	from	II
304953	100736355	20992746894	ultimately	ultimately	RR
304953	100736355	20992746895	dying	die	VVG_JJ
304953	100736355	20992746896	from	from	II
304953	100736355	20992746897	prostate	prostate	NN1
304953	100736355	20992746898	cancer	cancer	NN1
304953	100736355	20992746899	,	,	,
304953	100736355	20992746900	while	while	CS
304953	100736355	20992746901	leaving	leave	VVG
304953	100736355	20992746902	many	many	DA2
304953	100736355	20992746903	with	with	IW
304953	100736355	20992746904	urinary	urinary	JJ_NN1
304953	100736355	20992746905	or	or	CC
304953	100736355	20992746906	erectile	erectile	JJ
304953	100736355	20992746907	problems	problem	NN2
304953	100736355	20992746908	and	and	CC
304953	100736355	20992746909	other	other	JJ
304953	100736355	20992746910	side	side	NN1
304953	100736355	20992746911	effects	effect	NN2
304953	100736355	20992746912	.	.	.
304953	100736355	20992746913	As	as	II
304953	100736355	20992746914	a	a	AT1
304953	100736355	20992746915	result	result	NN1
304953	100736355	20992746916	,	,	,
304953	100736355	20992746917	more	more	DAR
304953	100736355	20992746918	men	man	NN2
304953	100736355	20992746919	may	may	VM
304953	100736355	20992746920	be	be	VBI
304953	100736355	20992746921	willing	willing	JJ
304953	100736355	20992746922	to	to	TO
304953	100736355	20992746923	consider	consider	VVI
304953	100736355	20992746924	a	a	AT1
304953	100736355	20992746925	strategy	strategy	NN1
304953	100736355	20992746926	called	call	VVN_VVD@
304953	100736355	20992746927	active	active	JJ
304953	100736355	20992746928	surveillance	surveillance	NN1
304953	100736355	20992746929	,	,	,
304953	100736355	20992746930	in	in	II
304953	100736355	20992746931	which	which	DDQ
304953	100736355	20992746932	doctors	doctor	NN2
304953	100736355	20992746933	monitor	monitor	VV0
304953	100736355	20992746934	low-risk	low-risk	JJ_NN1
304953	100736355	20992746935	cancers	cancer	NN2
304953	100736355	20992746936	closely	closely	RR
304953	100736355	20992746937	and	and	CC
304953	100736355	20992746938	consider	consider	VV0
304953	100736355	20992746939	treatment	treatment	NN1
304953	100736355	20992746940	only	only	JJ
304953	100736355	20992746941	when	when-	CS
304953	100736355	20992746942	the	the	AT
304953	100736355	20992746943	disease	disease	NN1
304953	100736355	20992746944	appears	appear	VVZ
304953	100736355	20992746945	to	to	TO
304953	100736355	20992746946	make	make	VVI
304953	100736355	20992746947	threatening	threaten	VVG_JJ@
304953	100736355	20992746948	moves	move	NN2
304953	100736355	20992746949	toward	toward	II
304953	100736355	20992746950	growing	grow	VVG_JJ
304953	100736355	20992746951	and	and	CC
304953	100736355	20992746952	spreading	spreading	NN1_JJ_VVG
304953	100736355	20992746953	.	.	.
304953	100736355	20992746954	<p>		NULL
304953	100736355	20992746955	This	this	DD1
304953	100736355	20992746956	week	week	NNT1
304953	100736355	20992746957	,	,	,
304953	100736355	20992746958	a	a	AT1
304953	100736355	20992746959	study	study	NN1
304953	100736355	20992746960	by	by	II
304953	100736355	20992746961	Harvard	harvard	NP1
304953	100736355	20992746962	researchers	researcher	NN2
304953	100736355	20992746963	found	find	VVD_VVN
304953	100736355	20992746964	that	that	CST
304953	100736355	20992746965	the	the	AT
304953	100736355	20992746966	aggressiveness	aggressiveness	NN1
304953	100736355	20992746967	of	of	IO
304953	100736355	20992746968	prostate	prostate	NN1
304953	100736355	20992746969	cancer	cancer	NN1
304953	100736355	20992746970	at	at	II
304953	100736355	20992746971	diagnosis	diagnosis	NN1
304953	100736355	20992746972	appears	appear	VVZ
304953	100736355	20992746973	to	to	TO
304953	100736355	20992746974	remain	remain	VVI
304953	100736355	20992746975	stable	stable	JJ_NN1@
304953	100736355	20992746976	over	over	II
304953	100736355	20992746977	time	time	NNT1
304953	100736355	20992746978	for	for	IF
304953	100736355	20992746979	most	most	DAT
304953	100736355	20992746980	men	man	NN2
304953	100736355	20992746981	.	.	.
304953	100736355	20992746982	If	if	CS
304953	100736355	20992746983	that 's		NN2
304953	100736355	20992746984	true	true	JJ_VV0%
304953	100736355	20992746985	,	,	,
304953	100736355	20992746986	then	then	RT
304953	100736355	20992746987	prompt	prompt	VV0_JJ
304953	100736355	20992746988	treatment	treatment	NN1
304953	100736355	20992746989	can	can	VM
304953	100736355	20992746990	be	be	VBI
304953	100736355	20992746991	reserved	reserve	VVN
304953	100736355	20992746992	for	for	IF
304953	100736355	20992746993	the	the	AT
304953	100736355	20992746994	@		II
304953	100736355	20992746995	@		II
304953	100736355	20992746996	@		II
304953	100736355	20992746997	@		II
304953	100736355	20992746998	@		II
304953	100736355	20992746999	@		II
304953	100736355	20992747000	@		II
304953	100736355	20992747001	@		II
304953	100736355	20992747002	@		II
304953	100736355	20992747003	@		II
304953	100736355	20992747004	can	can	VM
304953	100736355	20992747005	reasonably	reasonably	RR
304953	100736355	20992747006	choose	choose	VVI
304953	100736355	20992747007	to	to	TO
304953	100736355	20992747008	watch	watch	VVI
304953	100736355	20992747009	and	and	CC
304953	100736355	20992747010	wait	wait	VVI
304953	100736355	20992747011	in	in	II_RP@
304953	100736355	20992747012	other	other	JJ
304953	100736355	20992747013	cases	case	NN2
304953	100736355	20992747014	.	.	.
304953	100736355	20992747015	<p>		NULL
304953	100736355	20992747016	"	"	"
304953	100736355	20992747017	If	if	CS
304953	100736355	20992747018	you	you	PPY
304953	100736355	20992747019	have	have	VH0
304953	100736355	20992747020	chosen	choose	VVN
304953	100736355	20992747021	active	active	JJ
304953	100736355	20992747022	surveillance	surveillance	NN1
304953	100736355	20992747023	,	,	,
304953	100736355	20992747024	then	then	RT
304953	100736355	20992747025	this	this	DD1
304953	100736355	20992747026	could	could	VM
304953	100736355	20992747027	possibly	possibly	RR
304953	100736355	20992747028	make	make	VVI
304953	100736355	20992747029	you	you	PPY
304953	100736355	20992747030	feel	feel	VVI
304953	100736355	20992747031	more	more	RGR_DAR
304953	100736355	20992747032	confident	confident	JJ
304953	100736355	20992747033	in	in	II
304953	100736355	20992747034	your	your	APPGE
304953	100736355	20992747035	decision	decision	NN1
304953	100736355	20992747036	,	,	,
304953	100736355	20992747037	"	"	"
304953	100736355	20992747038	says	say	VVZ
304953	100736355	20992747039	Kathryn	kathryn	NP1
304953	100736355	20992747040	L.		NP1
304953	100736355	20992747041	Penney	penney	NP1
304953	100736355	20992747042	,	,	,
304953	100736355	20992747043	Sc.D.		NP1
304953	100736355	20992747044	,	,	,
304953	100736355	20992747045	instructor	instructor	NN1
304953	100736355	20992747046	in	in	II
304953	100736355	20992747047	medicine	medicine	NN1
304953	100736355	20992747048	at	at	II
304953	100736355	20992747049	Harvard	harvard	NP1
304953	100736355	20992747050	Medical	medical	JJ
304953	100736355	20992747051	School	school	NN1
304953	100736355	20992747052	and	and	CC
304953	100736355	20992747053	the	the	AT
304953	100736355	20992747054	lead	lead	NN1
304953	100736355	20992747055	author	author	NN1
304953	100736355	20992747056	of	of	IO
304953	100736355	20992747057	a	a	AT1
304953	100736355	20992747058	report-		NN1
304953	100736355	20992747059	published	publish	VVD_VVN
304953	100736355	20992747060	today	today	RT
304953	100736355	20992747061	in	in	II
304953	100736355	20992747062	the	the	AT
304953	100736355	20992747063	journal-		JJ_NN1
304953	100736355	20992747064	Cancer	cancer	NN1
304953	100736355	20992747065	Research	research	NN1
304953	100736355	20992747066	.	.	.
304953	100736355	20992747067	<h>		NULL
304953	100736355	20992747068	Cancer	cancer	NN1
304953	100736355	20992747069	lethality	lethality	NN1
304953	100736355	20992747070	set	set	VVD_VVN_VV0_NN1
304953	100736355	20992747071	early	early	RR_JJ
304953	100736355	20992747072	<p>		NULL
304953	100736355	20992747073	The	the	AT
304953	100736355	20992747074	study	study	NN1
304953	100736355	20992747075	looked	look	VVN_VVD
304953	100736355	20992747076	for	for	IF
304953	100736355	20992747077	changes	change	NN2
304953	100736355	20992747078	in	in	II
304953	100736355	20992747079	cancer	cancer	NN1
304953	100736355	20992747080	aggressiveness	aggressiveness	NN1
304953	100736355	20992747081	in	in	II
304953	100736355	20992747082	men	man	NN2
304953	100736355	20992747083	diagnosed	diagnose	VVN_VVD
304953	100736355	20992747084	with	with	IW
304953	100736355	20992747085	prostate	prostate	NN1
304953	100736355	20992747086	cancer	cancer	NN1
304953	100736355	20992747087	from	from	II
304953	100736355	20992747088	1982	1982	MC
304953	100736355	20992747089	to	to	II
304953	100736355	20992747090	2004	2004	MC
304953	100736355	20992747091	.	.	.
304953	100736355	20992747092	All	all	DB
304953	100736355	20992747093	of	of	IO
304953	100736355	20992747094	the	the	AT
304953	100736355	20992747095	men	man	NN2
304953	100736355	20992747096	had	have	VHD
304953	100736355	20992747097	their	their	APPGE
304953	100736355	20992747098	prostates	prostate	NN2
304953	100736355	20992747099	removed	remove	VVN
304953	100736355	20992747100	after	after	II
304953	100736355	20992747101	diagnosis	diagnosis	NN1
304953	100736355	20992747102	,	,	,
304953	100736355	20992747103	and	and	CC
304953	100736355	20992747104	biopsy	biopsy	NN1
304953	100736355	20992747105	samples	sample	NN2
304953	100736355	20992747106	were	be	VBDR
304953	100736355	20992747107	taken	take	VVN
304953	100736355	20992747108	from	from	II
304953	100736355	20992747109	the	the	AT
304953	100736355	20992747110	glands	gland	NN2
304953	100736355	20992747111	.	.	.
304953	100736355	20992747112	The	the	AT
304953	100736355	20992747113	Harvard	harvard	NP1
304953	100736355	20992747114	team	team	NN1
304953	100736355	20992747115	reexamined	re-examine	VVD
304953	100736355	20992747116	the	the	AT
304953	100736355	20992747117	samples	sample	NN2
304953	100736355	20992747118	and	and	CC
304953	100736355	20992747119	graded	grade	VVD
304953	100736355	20992747120	them	them	PPHO2
304953	100736355	20992747121	using	use	VVG
304953	100736355	20992747122	a	a	AT1
304953	100736355	20992747123	tool	tool	NN1
304953	100736355	20992747124	called	call	VVN_VVD@
304953	100736355	20992747125	the	the	AT
304953	100736355	20992747126	Gleason	gleason	NP1_NN1@
304953	100736355	20992747127	score	score	NN1_VV0
304953	100736355	20992747128	,	,	,
304953	100736355	20992747129	which	which	DDQ
304953	100736355	20992747130	assigns	assign	VVZ
304953	100736355	20992747131	a	a	AT1
304953	100736355	20992747132	number	number	NN1
304953	100736355	20992747133	from	from	II
304953	100736355	20992747134	2	2	MC
304953	100736355	20992747135	to	to	II
304953	100736355	20992747136	10	10	MC
304953	100736355	20992747137	based	base	VVN
304953	100736355	20992747138	on	on	II
304953	100736355	20992747139	how	how	RGQ@_RRQ
304953	100736355	20992747140	abnormal	abnormal	JJ
304953	100736355	20992747141	the	the	AT
304953	100736355	20992747142	cells	cell	NN2
304953	100736355	20992747143	look	look	VV0
304953	100736355	20992747144	under	under	II_RP@
304953	100736355	20992747145	a	a	AT1
304953	100736355	20992747146	microscope	microscope	NN1
304953	100736355	20992747147	.	.	.
304953	100736355	20992747148	High-scoring	high-scoring	JJ
304953	100736355	20992747149	or	or	CC
304953	100736355	20992747150	"	"	"
304953	100736355	20992747151	high-grade	high-grade	JJ_NN1
304953	100736355	20992747152	cancers	cancer	NN2
304953	100736355	20992747153	"	"	"
304953	100736355	20992747154	tend	tend	VV0
304953	100736355	20992747155	to	to	TO
304953	100736355	20992747156	be	be	VBI
304953	100736355	20992747157	the	the	AT
304953	100736355	20992747158	most	most	RGT
304953	100736355	20992747159	lethal	lethal	JJ
304953	100736355	20992747160	.	.	.
304953	100736355	20992747161	<p>		NULL
304953	100736355	20992747162	Over	over	II
304953	100736355	20992747163	the	the	AT
304953	100736355	20992747164	study	study	NN1
304953	100736355	20992747165	period	period	NN1
304953	100736355	20992747166	,	,	,
304953	100736355	20992747167	fewer	fewer	DAR
304953	100736355	20992747168	and	and	CC
304953	100736355	20992747169	fewer	fewer	DAR
304953	100736355	20992747170	men	man	NN2
304953	100736355	20992747171	were	be	VBDR
304953	100736355	20992747172	diagnosed	diagnose	VVN
304953	100736355	20992747173	with	with	IW
304953	100736355	20992747174	advanced	advanced	JJ
304953	100736355	20992747175	,	,	,
304953	100736355	20992747176	late-stage	late-stage	JJ_NN1
304953	100736355	20992747177	prostate	prostate	NN1
304953	100736355	20992747178	cancers	cancer	NN2
304953	100736355	20992747179	that	that	CST
304953	100736355	20992747180	had	have	VHD
304953	100736355	20992747181	spread	spread	VVN
304953	100736355	20992747182	beyond	beyond	II
304953	100736355	20992747183	the	the	AT
304953	100736355	20992747184	prostate	prostate	NN1
304953	100736355	20992747185	gland	gland	NN1
304953	100736355	20992747186	.	.	.
304953	100736355	20992747187	This	this	DD1
304953	100736355	20992747188	reflected	reflect	VVD
304953	100736355	20992747189	the	the	AT
304953	100736355	20992747190	growing	growing	JJ
304953	100736355	20992747191	use	use	NN1
304953	100736355	20992747192	of	of	IO
304953	100736355	20992747193	prostate-specific	prostate-specific	JJ
304953	100736355	20992747194	@		II
304953	100736355	20992747195	@		II
304953	100736355	20992747196	@		II
304953	100736355	20992747197	@		II
304953	100736355	20992747198	@		II
304953	100736355	20992747199	@		II
304953	100736355	20992747200	@		II
304953	100736355	20992747201	@		II
304953	100736355	20992747202	@		II
304953	100736355	20992747203	@		II
304953	100736355	20992747204	and	and	CC
304953	100736355	20992747205	earlier	early	RRR_JJR
304953	100736355	20992747206	.	.	.
304953	100736355	20992747207	In	in	II
304953	100736355	20992747208	contrast	contrast	NN1
304953	100736355	20992747209	,	,	,
304953	100736355	20992747210	the	the	AT
304953	100736355	20992747211	proportion	proportion	NN1
304953	100736355	20992747212	of	of	IO
304953	100736355	20992747213	high-grade	high-grade	JJ_NN1
304953	100736355	20992747214	cancers	cancer	NN2
304953	100736355	20992747215	,	,	,
304953	100736355	20992747216	as	as	CSA
304953	100736355	20992747217	measured	measure	VVN
304953	100736355	20992747218	by	by	II
304953	100736355	20992747219	the	the	AT
304953	100736355	20992747220	Gleason	gleason	NP1_NN1@
304953	100736355	20992747221	score	score	NN1_VV0
304953	100736355	20992747222	,	,	,
304953	100736355	20992747223	remained	remain	VVD_VVN
304953	100736355	20992747224	relatively	relatively	RR
304953	100736355	20992747225	stable	stable	JJ
304953	100736355	20992747226	rather	rather	II21_CS21@
304953	100736355	20992747227	than	than	II22_CS22@
304953	100736355	20992747228	gradually	gradually	RR
304953	100736355	20992747229	becoming	become	VVG
304953	100736355	20992747230	more	more	RGR
304953	100736355	20992747231	aggressive	aggressive	JJ
304953	100736355	20992747232	.	.	.
304953	100736355	20992747233	Previous	previous	JJ
304953	100736355	20992747234	studies	study	NN2
304953	100736355	20992747235	have	have	VH0
304953	100736355	20992747236	seen	see	VVN
304953	100736355	20992747237	a	a	AT1
304953	100736355	20992747238	similar	similar	JJ
304953	100736355	20992747239	pattern	pattern	NN1
304953	100736355	20992747240	.	.	.
304953	100736355	20992747241	<p>		NULL
304953	100736355	20992747242	"	"	"
304953	100736355	20992747243	Its	its	APPGE
304953	100736355	20992747244	a	a	AT1
304953	100736355	20992747245	very	very	RG
304953	100736355	20992747246	interesting	interesting	JJ
304953	100736355	20992747247	study	study	NN1
304953	100736355	20992747248	that	that	CST_DD1
304953	100736355	20992747249	confirms	confirm	VVZ
304953	100736355	20992747250	what	what	DDQ
304953	100736355	20992747251	previous	previous	JJ
304953	100736355	20992747252	studies	study	NN2
304953	100736355	20992747253	have	have	VH0
304953	100736355	20992747254	found	find	VVN
304953	100736355	20992747255	,	,	,
304953	100736355	20992747256	"	"	"
304953	100736355	20992747257	says	say	VVZ
304953	100736355	20992747258	Dr.		NNB
304953	100736355	20992747259	Marc	marc	NP1
304953	100736355	20992747260	B.		NP1
304953	100736355	20992747261	Garnick		NP1
304953	100736355	20992747262	,	,	,
304953	100736355	20992747263	a	a	AT1
304953	100736355	20992747264	prostate	prostate	NN1
304953	100736355	20992747265	cancer	cancer	NN1
304953	100736355	20992747266	specialist	specialist	NN1
304953	100736355	20992747267	at	at	II
304953	100736355	20992747268	Harvard-affiliated	harvard-affiliated	JJ_NN1
304953	100736355	20992747269	Beth	beth	NP1
304953	100736355	20992747270	Israel	israel	NP1
304953	100736355	20992747271	Deaconess	deaconess	NN1
304953	100736355	20992747272	Medical	medical	JJ
304953	100736355	20992747273	Center	center	NN1
304953	100736355	20992747274	who	who	PNQS
304953	100736355	20992747275	was	be	VBDZ
304953	100736355	20992747276	not	not	XX
304953	100736355	20992747277	involved	involved	JJ
304953	100736355	20992747278	in	in	II
304953	100736355	20992747279	the	the	AT
304953	100736355	20992747280	study	study	NN1
304953	100736355	20992747281	.	.	.
304953	100736355	20992747282	"	"	"
304953	100736355	20992747283	There	there	EX
304953	100736355	20992747284	may	may	VM
304953	100736355	20992747285	be	be	VBI
304953	100736355	20992747286	rare	rare	JJ
304953	100736355	20992747287	exceptions	exception	NN2
304953	100736355	20992747288	,	,	,
304953	100736355	20992747289	but	but	CCB
304953	100736355	20992747290	in	in	II
304953	100736355	20992747291	the	the	AT
304953	100736355	20992747292	vast	vast	JJ
304953	100736355	20992747293	majority	majority	NN1
304953	100736355	20992747294	the	the	AT
304953	100736355	20992747295	cancer	cancer	NN1
304953	100736355	20992747296	is	be	VBZ
304953	100736355	20992747297	born	born	VVN
304953	100736355	20992747298	with	with	IW
304953	100736355	20992747299	a	a	AT1
304953	100736355	20992747300	particular	particular	JJ
304953	100736355	20992747301	Gleason	gleason	NN1@_NP1
304953	100736355	20992747302	score	score	NN1_VV0
304953	100736355	20992747303	.	.	.
304953	100736355	20992747304	"	"	"
304953	100736355	20992747305	<p>		NULL
304953	100736355	20992747306	That	that	DD1
304953	100736355	20992747307	means	mean	VVZ
304953	100736355	20992747308	most	most	DAT
304953	100736355	20992747309	prostate	prostate	NN1
304953	100736355	20992747310	cancers	cancer	NN2
304953	100736355	20992747311	that	that	CST
304953	100736355	20992747312	look	look	VV0
304953	100736355	20992747313	to	to	TO
304953	100736355	20992747314	be	be	VBI
304953	100736355	20992747315	slow	slow	JJ_RR@
304953	100736355	20992747316	growing	growing	NN1@_VVG_JJ
304953	100736355	20992747317	at	at	II
304953	100736355	20992747318	diagnosis	diagnosis	NN1
304953	100736355	20992747319	could	could	VM
304953	100736355	20992747320	stay	stay	VVI
304953	100736355	20992747321	that	that	DD1
304953	100736355	20992747322	way	way	NN1
304953	100736355	20992747323	long	long	RR
304953	100736355	20992747324	enough	enough	RR_DD
304953	100736355	20992747325	that	that	CST
304953	100736355	20992747326	the	the	AT
304953	100736355	20992747327	man	man	NN1
304953	100736355	20992747328	is	be	VBZ
304953	100736355	20992747329	likely	likely	JJ
304953	100736355	20992747330	to	to	TO
304953	100736355	20992747331	die	die	VVI
304953	100736355	20992747332	from	from	II
304953	100736355	20992747333	another	another	DD1
304953	100736355	20992747334	cause	cause	NN1
304953	100736355	20992747335	before	before	II_CS
304953	100736355	20992747336	the	the	AT
304953	100736355	20992747337	cancer	cancer	NN1
304953	100736355	20992747338	spreads	spread	VVZ
304953	100736355	20992747339	beyond	beyond	II
304953	100736355	20992747340	the	the	AT
304953	100736355	20992747341	prostate	prostate	NN1
304953	100736355	20992747342	.	.	.
304953	100736355	20992747343	"	"	"
304953	100736355	20992747344	The	the	AT
304953	100736355	20992747345	ones	one	NN2
304953	100736355	20992747346	that	that	CST
304953	100736355	20992747347	are	be	VBR
304953	100736355	20992747348	low-grade	low-grade	JJ
304953	100736355	20992747349	and	and	CC
304953	100736355	20992747350	indolent	indolent	JJ
304953	100736355	20992747351	are	be	VBR
304953	100736355	20992747352	unlikely	unlikely	JJ
304953	100736355	20992747353	to	to	TO
304953	100736355	20992747354	cause	cause	VVI
304953	100736355	20992747355	problems	problem	NN2
304953	100736355	20992747356	in	in	II
304953	100736355	20992747357	a	a	AT1
304953	100736355	20992747358	mans	man	NN2
304953	100736355	20992747359	lifetime	lifetime	NNT1
304953	100736355	20992747360	,	,	,
304953	100736355	20992747361	"	"	"
304953	100736355	20992747362	says	say	VVZ
304953	100736355	20992747363	Dr.		NNB
304953	100736355	20992747364	Garnick		NP1
304953	100736355	20992747365	,	,	,
304953	100736355	20992747366	editor	editor	NN1
304953	100736355	20992747367	of	of	IO
304953	100736355	20992747368	the-		JJ
304953	100736355	20992747369	Annual	annual	JJ
304953	100736355	20992747370	Report	report	NN1
304953	100736355	20992747371	on	on	II
304953	100736355	20992747372	Prostate	prostate	NN1
304953	100736355	20992747373	Diseases	disease	NN2
304953	100736355	20992747374	,	,	,
304953	100736355	20992747375	from	from	II
304953	100736355	20992747376	Harvard	harvard	NP1
304953	100736355	20992747377	Medical	medical	JJ
304953	100736355	20992747378	School	school	NN1
304953	100736355	20992747379	.	.	.
304953	100736355	20992747380	On	on	II
304953	100736355	20992747381	the	the	AT
304953	100736355	20992747382	other	other	JJ
304953	100736355	20992747383	hand	hand	NN1
304953	100736355	20992747384	,	,	,
304953	100736355	20992747385	he	he	PPHS1
304953	100736355	20992747386	adds	add	VVZ
304953	100736355	20992747387	,	,	,
304953	100736355	20992747388	most	most	RGT_DAT
304953	100736355	20992747389	high-grade	high-grade	JJ
304953	100736355	20992747390	prostate	prostate	NN1
304953	100736355	20992747391	cancers	cancer	NN2
304953	100736355	20992747392	are	be	VBR
304953	100736355	20992747393	also	also	RR
304953	100736355	20992747394	@		II
304953	100736355	20992747395	@		II
304953	100736355	20992747396	@		II
304953	100736355	20992747397	@		II
304953	100736355	20992747398	@		II
304953	100736355	20992747399	@		II
304953	100736355	20992747400	@		II
304953	100736355	20992747401	@		II
304953	100736355	20992747402	@		II
304953	100736355	20992747403	@		II
304953	100736355	20992747404	grade	grade	NN1
304953	100736355	20992747405	is	be	VBZ
304953	100736355	20992747406	one	one	MC1
304953	100736355	20992747407	of	of	IO
304953	100736355	20992747408	the	the	AT
304953	100736355	20992747409	best	best	JJT
304953	100736355	20992747410	predictors	predictor	NN2
304953	100736355	20992747411	of	of	IO
304953	100736355	20992747412	prostate	prostate	NN1
304953	100736355	20992747413	cancer	cancer	NN1
304953	100736355	20992747414	death	death	NN1
304953	100736355	20992747415	.	.	.
304953	100736355	20992747416	"	"	"
304953	100736355	20992747417	Men	man	NN2
304953	100736355	20992747418	with	with	IW
304953	100736355	20992747419	low-grade	low-grade	JJ
304953	100736355	20992747420	disease	disease	NN1
304953	100736355	20992747421	are	be	VBR
304953	100736355	20992747422	much	much	RR
304953	100736355	20992747423	less	less	RGR
304953	100736355	20992747424	likely	likely	JJ
304953	100736355	20992747425	to	to	TO
304953	100736355	20992747426	die	die	VVI
304953	100736355	20992747427	from	from	II
304953	100736355	20992747428	prostate	prostate	NN1
304953	100736355	20992747429	cancer	cancer	NN1
304953	100736355	20992747430	than	than	CSN
304953	100736355	20992747431	men	man	NN2
304953	100736355	20992747432	with	with	IW
304953	100736355	20992747433	high-grade	high-grade	JJ
304953	100736355	20992747434	cancers	cancer	NN2
304953	100736355	20992747435	,	,	,
304953	100736355	20992747436	"	"	"
304953	100736355	20992747437	says	say	VVZ
304953	100736355	20992747438	Penney	penney	NP1_NN1@
304953	100736355	20992747439	.	.	.
304953	100736355	20992747440	She	she	PPHS1
304953	100736355	20992747441	cautions	caution	VVZ
304953	100736355	20992747442	,	,	,
304953	100736355	20992747443	though	though	CS_RR@
304953	100736355	20992747444	,	,	,
304953	100736355	20992747445	that	that	CST
304953	100736355	20992747446	the	the	AT
304953	100736355	20992747447	study	study	NN1
304953	100736355	20992747448	looked	look	VVN_VVD
304953	100736355	20992747449	at	at	II
304953	100736355	20992747450	men	man	NN2
304953	100736355	20992747451	as	as	II_CSA
304953	100736355	20992747452	a	a	AT1
304953	100736355	20992747453	group	group	NN1
304953	100736355	20992747454	,	,	,
304953	100736355	20992747455	and	and	CC
304953	100736355	20992747456	in	in	II
304953	100736355	20992747457	this	this	DD1
304953	100736355	20992747458	population	population	NN1
304953	100736355	20992747459	the	the	AT
304953	100736355	20992747460	Gleason	gleason	NP1_NN1@
304953	100736355	20992747461	grade	grade	NN1
304953	100736355	20992747462	appeared	appear	VVD
304953	100736355	20992747463	to	to	TO
304953	100736355	20992747464	be	be	VBI
304953	100736355	20992747465	fairly	fairly	RR
304953	100736355	20992747466	stable	stable	JJ
304953	100736355	20992747467	.	.	.
304953	100736355	20992747468	"	"	"
304953	100736355	20992747469	You	you	PPY
304953	100736355	20992747470	might	might	VM
304953	100736355	20992747471	see	see	VVI
304953	100736355	20992747472	progression	progression	NN1
304953	100736355	20992747473	in	in	II
304953	100736355	20992747474	an	a	AT1
304953	100736355	20992747475	individual	individual	JJ_NN1
304953	100736355	20992747476	,	,	,
304953	100736355	20992747477	but	but	CCB
304953	100736355	20992747478	we	we	PPIS2
304953	100736355	20992747479	think	think	VV0
304953	100736355	20992747480	that	that	CST
304953	100736355	20992747481	its	its	APPGE
304953	100736355	20992747482	uncommon	uncommon	JJ
304953	100736355	20992747483	,	,	,
304953	100736355	20992747484	"	"	"
304953	100736355	20992747485	she	she	PPHS1
304953	100736355	20992747486	says	say	VVZ
304953	100736355	20992747487	.	.	.
304953	100736355	20992747488	"	"	"
304953	100736355	20992747489	We	we	PPIS2
304953	100736355	20992747490	just	just	RR
304953	100736355	20992747491	ca n't		JJ
304953	100736355	20992747492	rule	rule	NN1
304953	100736355	20992747493	out	out	RP_II%
304953	100736355	20992747494	this	this	DD1
304953	100736355	20992747495	possibility	possibility	NN1
304953	100736355	20992747496	in	in	II
304953	100736355	20992747497	our	our	APPGE
304953	100736355	20992747498	study	study	NN1
304953	100736355	20992747499	.	.	.
304953	100736355	20992747500	"	"	"
304953	100736355	20992747501	<h>		NULL
304953	100736355	20992747502	How	how	RGQ@_RRQ
304953	100736355	20992747503	active	active	JJ
304953	100736355	20992747504	surveillance	surveillance	NN1
304953	100736355	20992747505	works	work	VVZ_NN
304953	100736355	20992747506	<p>		NULL
304953	100736355	20992747507	The	the	AT
304953	100736355	20992747508	Gleason	gleason	NP1_NN1@
304953	100736355	20992747509	score	score	NN1
304953	100736355	20992747510	is	be	VBZ
304953	100736355	20992747511	just	just	RR
304953	100736355	20992747512	one	one	MC1
304953	100736355	20992747513	way	way	NN1
304953	100736355	20992747514	that	that	CST
304953	100736355	20992747515	doctors	doctor	NN2
304953	100736355	20992747516	monitor	monitor	VV0
304953	100736355	20992747517	prostate	prostate	NN1
304953	100736355	20992747518	cancer	cancer	NN1
304953	100736355	20992747519	during	during	II
304953	100736355	20992747520	active	active	JJ
304953	100736355	20992747521	surveillance	surveillance	NN1
304953	100736355	20992747522	.	.	.
304953	100736355	20992747523	They	they	PPHS2
304953	100736355	20992747524	also	also	RR
304953	100736355	20992747525	do	do	VD0
304953	100736355	20992747526	periodic	periodic	JJ
304953	100736355	20992747527	follow-up	follow-up	JJ_NN1
304953	100736355	20992747528	biopsies	biopsy	NN2
304953	100736355	20992747529	and	and	CC
304953	100736355	20992747530	measure	measure	VV0_NN1
304953	100736355	20992747531	PSA	psa	NP1
304953	100736355	20992747532	levels	level	NN2
304953	100736355	20992747533	,	,	,
304953	100736355	20992747534	which	which	DDQ
304953	100736355	20992747535	may	may	VM
304953	100736355	20992747536	rise	rise	VVI
304953	100736355	20992747537	if	if	CSW@_CS
304953	100736355	20992747538	cancer	cancer	NN1
304953	100736355	20992747539	starts	start	VVZ
304953	100736355	20992747540	to	to	TO
304953	100736355	20992747541	spread	spread	VVI
304953	100736355	20992747542	in	in	II
304953	100736355	20992747543	the	the	AT
304953	100736355	20992747544	prostate	prostate	NN1
304953	100736355	20992747545	.	.	.
304953	100736355	20992747546	Doctors	doctor	NN2
304953	100736355	20992747547	may	may	VM
304953	100736355	20992747548	recommend	recommend	VVI
304953	100736355	20992747549	treatment	treatment	NN1
304953	100736355	20992747550	sooner	soon	RRR
304953	100736355	20992747551	if	if	CS
304953	100736355	20992747552	PSA	psa	NP1
304953	100736355	20992747553	begins	begin	VVZ
304953	100736355	20992747554	to	to	TO
304953	100736355	20992747555	rise	rise	VVI
304953	100736355	20992747556	quickly	quickly	RR
304953	100736355	20992747557	or	or	CC
304953	100736355	20992747558	if	if	CS_CSW@
304953	100736355	20992747559	a	a	AT1
304953	100736355	20992747560	follow	follow	NN121@
304953	100736355	20992747561	up	up	NN122
304953	100736355	20992747562	biopsy	biopsy	NN1
304953	100736355	20992747563	reveals	reveal	VVZ
304953	100736355	20992747564	a	a	AT1
304953	100736355	20992747565	higher	high	JJR
304953	100736355	20992747566	Gleason	gleason	NN1@_NP1
304953	100736355	20992747567	score	score	NN1_VV0
304953	100736355	20992747568	or	or	CC
304953	100736355	20992747569	more	more	RGR
304953	100736355	20992747570	widespread	widespread	JJ
304953	100736355	20992747571	-	-	-
304953	100736355	20992747572	cancer	cancer	NN1
304953	100736355	20992747573	within	within	II
304953	100736355	20992747574	the	the	AT
304953	100736355	20992747575	prostate	prostate	NN1
304953	100736355	20992747576	.	.	.
304953	100736355	20992747577	Its	its	APPGE
304953	100736355	20992747578	an	a	AT1
304953	100736355	20992747579	inexact	inexact	JJ
304953	100736355	20992747580	science	science	NN1
304953	100736355	20992747581	that	that	CST_DD1
304953	100736355	20992747582	depends	depend	VVZ
304953	100736355	20992747583	on	on	II
304953	100736355	20992747584	a	a	AT1
304953	100736355	20992747585	doctors	doctor	NN2
304953	100736355	20992747586	skill	skill	NN1
304953	100736355	20992747587	and	and	CC
304953	100736355	20992747588	experience	experience	NN1_VV0
304953	100736355	20992747589	and	and	CC
304953	100736355	20992747590	a	a	AT1
304953	100736355	20992747591	mans	man	NN2
304953	100736355	20992747592	willingness	willingness	NN1
304953	100736355	20992747593	to	to	TO
304953	100736355	20992747594	@		II
304953	100736355	20992747595	@		II
304953	100736355	20992747596	@		II
304953	100736355	20992747597	@		II
304953	100736355	20992747598	@		II
304953	100736355	20992747599	@		II
304953	100736355	20992747600	@		II
304953	100736355	20992747601	@		II
304953	100736355	20992747602	@		II
304953	100736355	20992747603	@		II
304953	100736355	20992747604	before	before	II
304953	100736355	20992747605	opting	opt	VVG
304953	100736355	20992747606	for	for	IF
304953	100736355	20992747607	treatment	treatment	NN1
304953	100736355	20992747608	and	and	CC
304953	100736355	20992747609	its	its	APPGE
304953	100736355	20992747610	potential	potential	NN1_JJ
304953	100736355	20992747611	for	for	IF
304953	100736355	20992747612	side	side	NN1
304953	100736355	20992747613	effects	effect	NN2
304953	100736355	20992747614	.	.	.
304953	100736355	20992747615	<p>		NULL
304953	100736355	20992747616	Penney	penney	NN1_NP1@
304953	100736355	20992747617	says	say	VVZ
304953	100736355	20992747618	she	she	PPHS1
304953	100736355	20992747619	and	and	CC
304953	100736355	20992747620	her	her	APPGE
304953	100736355	20992747621	Harvard	harvard	NP1
304953	100736355	20992747622	colleagues	colleague	NN2
304953	100736355	20992747623	are	be	VBR
304953	100736355	20992747624	among	among	II
304953	100736355	20992747625	the	the	AT
304953	100736355	20992747626	many	many	DA2
304953	100736355	20992747627	scientists	scientist	NN2
304953	100736355	20992747628	now	now	RT
304953	100736355	20992747629	searching	search	VVG
304953	100736355	20992747630	for	for	IF
304953	100736355	20992747631	better	better	JJR
304953	100736355	20992747632	ways	way	NN2
304953	100736355	20992747633	to	to	TO
304953	100736355	20992747634	predict	predict	VVI
304953	100736355	20992747635	which	which	DDQ
304953	100736355	20992747636	prostate	prostate	NN1
304953	100736355	20992747637	cancers	cancer	NN2
304953	100736355	20992747638	are	be	VBR
304953	100736355	20992747639	likely	likely	JJ
304953	100736355	20992747640	to	to	TO
304953	100736355	20992747641	be	be	VBI
304953	100736355	20992747642	lethal	lethal	JJ
304953	100736355	20992747643	and	and	CC
304953	100736355	20992747644	which	which	DDQ
304953	100736355	20992747645	can	can	VM
304953	100736355	20992747646	be	be	VBI
304953	100736355	20992747647	monitored	monitor	VVN
304953	100736355	20992747648	and	and	CC
304953	100736355	20992747649	not	not	XX
304953	100736355	20992747650	treated	treat	VVN
304953	100736355	20992747651	.	.	.
304953	100736355	20992747652	The	the	AT
304953	100736355	20992747653	answer	answer	NN1
304953	100736355	20992747654	may	may	VM
304953	100736355	20992747655	be	be	VBI
304953	100736355	20992747656	found	find	VVN
304953	100736355	20992747657	in	in	II
304953	100736355	20992747658	genetic	genetic	JJ
304953	100736355	20992747659	changes	change	NN2
304953	100736355	20992747660	in	in	II
304953	100736355	20992747661	prostate	prostate	NN1
304953	100736355	20992747662	cancer	cancer	NN1
304953	100736355	20992747663	cells	cell	NN2
304953	100736355	20992747664	that	that	CST
304953	100736355	20992747665	signal	signal	VV0@
304953	100736355	20992747666	a	a	AT1
304953	100736355	20992747667	higher	high	JJR
304953	100736355	20992747668	threat	threat	NN1
304953	100736355	20992747669	.	.	.
304953	100736355	20992747670	But	but	CCB
304953	100736355	20992747671	finding	find	VVG
304953	100736355	20992747672	a	a	AT1
304953	100736355	20992747673	better	better	JJR
304953	100736355	20992747674	way	way	NN1
304953	100736355	20992747675	to	to	TO
304953	100736355	20992747676	predict	predict	VVI
304953	100736355	20992747677	which	which	DDQ
304953	100736355	20992747678	prostate	prostate	NN1
304953	100736355	20992747679	cancers	cancer	NN2
304953	100736355	20992747680	are	be	VBR
304953	100736355	20992747681	likely	likely	JJ
304953	100736355	20992747682	to	to	TO
304953	100736355	20992747683	turn	turn	VVI
304953	100736355	20992747684	lethal	lethal	JJ
304953	100736355	20992747685	is	be	VBZ
304953	100736355	20992747686	far	far	RG21
304953	100736355	20992747687	from	from	RG22
304953	100736355	20992747688	guaranteed	guaranteed	JJ
304953	100736355	20992747689	.	.	.
304953	100736355	20992747690	<p>		NULL
304953	100736355	20992747691	"	"	"
304953	100736355	20992747692	Some	some	DD
304953	100736355	20992747693	researchers	researcher	NN2
304953	100736355	20992747694	believe	believe	VV0
304953	100736355	20992747695	its	its	APPGE
304953	100736355	20992747696	not	not	XX
304953	100736355	20992747697	possible	possible	JJ
304953	100736355	20992747698	,	,	,
304953	100736355	20992747699	"	"	"
304953	100736355	20992747700	Penney	penney	NP1
304953	100736355	20992747701	says	say	VVZ
304953	100736355	20992747702	.	.	.
304953	100736355	20992747703	"	"	"
304953	100736355	20992747704	After	after	CS_II
304953	100736355	20992747705	the	the	AT
304953	100736355	20992747706	cancer	cancer	NN1
304953	100736355	20992747707	is	be	VBZ
304953	100736355	20992747708	diagnosed	diagnose	VVN
304953	100736355	20992747709	,	,	,
304953	100736355	20992747710	so	so	RG
304953	100736355	20992747711	many	many	DA2
304953	100736355	20992747712	things	thing	NN2
304953	100736355	20992747713	can	can	VM
304953	100736355	20992747714	change	change	VVI
304953	100736355	20992747715	in	in	II_RP@
304953	100736355	20992747716	unknown	unknown	JJ
304953	100736355	20992747717	ways	way	NN2
304953	100736355	20992747718	.	.	.
304953	100736355	20992747719	"	"	"
304953	100736355	20992747720	Diet	diet	NN1_VV0@
304953	100736355	20992747721	,	,	,
304953	100736355	20992747722	exercise	exercise	VV0_NN1
304953	100736355	20992747723	,	,	,
304953	100736355	20992747724	and	and	CC
304953	100736355	20992747725	other	other	JJ
304953	100736355	20992747726	lifestyle	lifestyle	NN1
304953	100736355	20992747727	factors	factor	NN2
304953	100736355	20992747728	,	,	,
304953	100736355	20992747729	for	for	REX21
304953	100736355	20992747730	example	example	REX22
304953	100736355	20992747731	,	,	,
304953	100736355	20992747732	could	could	VM
304953	100736355	20992747733	affect	affect	VVI
304953	100736355	20992747734	whether	whether	CSW
304953	100736355	20992747735	low-risk	low-risk	JJ
304953	100736355	20992747736	prostate	prostate	NN1
304953	100736355	20992747737	cancers	cancer	NN2
304953	100736355	20992747738	become	become	VV0
304953	100736355	20992747739	more	more	RGR_DAR
304953	100736355	20992747740	aggressive	aggressive	JJ
304953	100736355	20992747741	or	or	CC
304953	100736355	20992747742	threatening	threaten	VVG
304953	100736355	20992747743	over	over	II
304953	100736355	20992747744	time	time	NNT1
304953	100736355	20992747745	.	.	.
304953	100736356	20992747765	@@##	----------	----------
304953	100736356	20992747766	@@100736356		FO
304953	100736356	20992747767	@4936356/		VV0_NN1
304953	100736356	20992747768	46989		MC
304953	100736356	20992747769	@qwx906989		FO
304953	100736356	20992747770	<p>		NULL
304953	100736356	20992747771	A	a	AT1
304953	100736356	20992747772	team	team	NN1
304953	100736356	20992747773	of	of	IO
304953	100736356	20992747774	Harvard-affiliated	harvard-affiliated	JJ_NN1
304953	100736356	20992747775	investigators	investigator	NN2
304953	100736356	20992747776	made	make	VVD_VVN
304953	100736356	20992747777	headlines	headline	NN2
304953	100736356	20992747778	recently	recently	RR
304953	100736356	20992747779	when	when	CS_RRQ
304953	100736356	20992747780	they	they	PPHS2
304953	100736356	20992747781	reported	report	VVD
304953	100736356	20992747782	that	that	CST_DD1
304953	100736356	20992747783	treating	treat	VVG
304953	100736356	20992747784	men	man	NN2
304953	100736356	20992747785	with	with	IW
304953	100736356	20992747786	advanced	advanced	JJ
304953	100736356	20992747787	prostate	prostate	NN1
304953	100736356	20992747788	cancer	cancer	NN1
304953	100736356	20992747789	using	use	VVG
304953	100736356	20992747790	a	a	AT1
304953	100736356	20992747791	two-drug	two-drug	JJ_NN1
304953	100736356	20992747792	combination	combination	NN1
304953	100736356	20992747793	significantly	significantly	RR
304953	100736356	20992747794	increased	increased	JJ_VVN
304953	100736356	20992747795	survival	survival	NN1
304953	100736356	20992747796	.	.	.
304953	100736356	20992747797	One	one	MC1
304953	100736356	20992747798	expert	expert	NN1
304953	100736356	20992747799	called	call	VVN_VVD@
304953	100736356	20992747800	the	the	AT
304953	100736356	20992747801	results	result	NN2
304953	100736356	20992747802	potentially	potentially	RR
304953	100736356	20992747803	"	"	"
304953	100736356	20992747804	transformative	transformative	JJ
304953	100736356	20992747805	.	.	.
304953	100736356	20992747806	"	"	"
304953	100736356	20992747807	<p>		NULL
304953	100736356	20992747808	When	when	CS_RRQ
304953	100736356	20992747809	prostate	prostate	NN1
304953	100736356	20992747810	cancer	cancer	NN1
304953	100736356	20992747811	spreads	spread	VVZ
304953	100736356	20992747812	beyond	beyond	II
304953	100736356	20992747813	the	the	AT
304953	100736356	20992747814	prostate	prostate	NN1
304953	100736356	20992747815	gland	gland	NN1
304953	100736356	20992747816	,	,	,
304953	100736356	20992747817	the	the	AT
304953	100736356	20992747818	standard	standard	JJ_NN1
304953	100736356	20992747819	treatment	treatment	NN1
304953	100736356	20992747820	is	be	VBZ
304953	100736356	20992747821	androgen-deprivation		JJ
304953	100736356	20992747822	therapy	therapy	NN1
304953	100736356	20992747823	(	(	(
304953	100736356	20992747824	ADT	adt	NP1
304953	100736356	20992747825	)	)	)
304953	100736356	20992747826	.	.	.
304953	100736356	20992747827	This	this	DD1
304953	100736356	20992747828	treatment	treatment	NN1
304953	100736356	20992747829	cuts	cut	VVZ_NN2
304953	100736356	20992747830	off	off	II_RP
304953	100736356	20992747831	the	the	AT
304953	100736356	20992747832	bodys	bodys	NN2
304953	100736356	20992747833	production	production	NN1
304953	100736356	20992747834	of	of	IO
304953	100736356	20992747835	testosterone	testosterone	NN1
304953	100736356	20992747836	.	.	.
304953	100736356	20992747837	Prostate	prostate	NN1
304953	100736356	20992747838	cancer	cancer	NN1
304953	100736356	20992747839	cells	cell	NN2
304953	100736356	20992747840	need	need	VV0
304953	100736356	20992747841	testosterone	testosterone	NN1
304953	100736356	20992747842	(	(	(
304953	100736356	20992747843	a	a	AT1
304953	100736356	20992747844	type	type	NN1
304953	100736356	20992747845	of	of	IO
304953	100736356	20992747846	hormone	hormone	NN1
304953	100736356	20992747847	known	know	VVN
304953	100736356	20992747848	as	as	II
304953	100736356	20992747849	an	a	AT1
304953	100736356	20992747850	androgen	androgen	NN1
304953	100736356	20992747851	)	)	)
304953	100736356	20992747852	to	to	TO
304953	100736356	20992747853	grow	grow	VVI
304953	100736356	20992747854	.	.	.
304953	100736356	20992747855	ADT	adt	NP1
304953	100736356	20992747856	works	work	VVZ_NN
304953	100736356	20992747857	for	for	IF
304953	100736356	20992747858	a	a	AT1
304953	100736356	20992747859	time	time	NNT1
304953	100736356	20992747860	,	,	,
304953	100736356	20992747861	but	but	CCB
304953	100736356	20992747862	eventually	eventually	RR
304953	100736356	20992747863	cancer	cancer	NN1
304953	100736356	20992747864	cells	cell	NN2
304953	100736356	20992747865	become	become	VV0
304953	100736356	20992747866	resistant	resistant	JJ
304953	100736356	20992747867	to	to	II
304953	100736356	20992747868	it	it	PPH1
304953	100736356	20992747869	and	and	CC
304953	100736356	20992747870	begin	begin	VV0
304953	100736356	20992747871	to	to	TO
304953	100736356	20992747872	grow	grow	VVI
304953	100736356	20992747873	and	and	CC
304953	100736356	20992747874	spread	spread	VVD_VV0_NN1_VVN
304953	100736356	20992747875	again	again	RT
304953	100736356	20992747876	.	.	.
304953	100736356	20992747877	At	at	II
304953	100736356	20992747878	that	that	DD1
304953	100736356	20992747879	point	point	NN1
304953	100736356	20992747880	,	,	,
304953	100736356	20992747881	doctors	doctor	NN2
304953	100736356	20992747882	typically	typically	RR
304953	100736356	20992747883	add	add	VV0
304953	100736356	20992747884	a	a	AT1
304953	100736356	20992747885	chemotherapy	chemotherapy	NN1
304953	100736356	20992747886	drug	drug	NN1
304953	100736356	20992747887	called	call	VVN_VVD@
304953	100736356	20992747888	docetaxel		NN1_VV0
304953	100736356	20992747889	to	to	II
304953	100736356	20992747890	ADT	adt	NP1
304953	100736356	20992747891	.	.	.
304953	100736356	20992747892	<p>		NULL
304953	100736356	20992747893	Dr.		NNB
304953	100736356	20992747894	Christopher	christopher	NP1
304953	100736356	20992747895	Sweeney	sweeney	NP1
304953	100736356	20992747896	and	and	CC
304953	100736356	20992747897	his	his	APPGE
304953	100736356	20992747898	colleagues	colleague	NN2
304953	100736356	20992747899	at	at	II
304953	100736356	20992747900	the	the	AT
304953	100736356	20992747901	Dana-Farber	dana-farber	NP1
304953	100736356	20992747902	Cancer	cancer	NN1
304953	100736356	20992747903	Institutes	institute	NN2
304953	100736356	20992747904	Lank		VV0
304953	100736356	20992747905	Center	center	NN1
304953	100736356	20992747906	for	for	IF
304953	100736356	20992747907	Genitourinary		NP1_JJ
304953	100736356	20992747908	Oncology	oncology	NP1_NN1
304953	100736356	20992747909	recruited	recruit	VVD@_VVN
304953	100736356	20992747910	790	790	MC
304953	100736356	20992747911	men	man	NN2
304953	100736356	20992747912	with	with	IW
304953	100736356	20992747913	advanced	advanced	JJ
304953	100736356	20992747914	prostate	prostate	NN1
304953	100736356	20992747915	cancer	cancer	NN1
304953	100736356	20992747916	and	and	CC
304953	100736356	20992747917	randomly	randomly	RR
304953	100736356	20992747918	divided	divide	VVN_VVD
304953	100736356	20992747919	them	them	PPHO2
304953	100736356	20992747920	into	into	II
304953	100736356	20992747921	two	two	MC
304953	100736356	20992747922	groups	group	NN2
304953	100736356	20992747923	.	.	.
304953	100736356	20992747924	One	one	MC1
304953	100736356	20992747925	group	group	NN1
304953	100736356	20992747926	was	be	VBDZ
304953	100736356	20992747927	given	give	VVN
304953	100736356	20992747928	ADT	adt	NP1
304953	100736356	20992747929	and	and	CC
304953	100736356	20992747930	six	six	MC
304953	100736356	20992747931	cycles	cycle	NN2
304953	100736356	20992747932	of	of	IO
304953	100736356	20992747933	docetaxel	docetaxel	NN1
304953	100736356	20992747934	over	over	RG
304953	100736356	20992747935	18	18	MC
304953	100736356	20992747936	weeks	week	NNT2
304953	100736356	20992747937	,	,	,
304953	100736356	20992747938	then	then	RT
304953	100736356	20992747939	ADT	adt	NP1
304953	100736356	20992747940	alone	alone	RR_JJ
304953	100736356	20992747941	.	.	.
304953	100736356	20992747942	The	the	AT
304953	100736356	20992747943	other	other	JJ
304953	100736356	20992747944	group	group	NN1
304953	100736356	20992747945	was	be	VBDZ
304953	100736356	20992747946	initially	initially	RR
304953	100736356	20992747947	treated	treat	VVN
304953	100736356	20992747948	only	only	JJ
304953	100736356	20992747949	with	with-	IW
304953	100736356	20992747950	ADT	adt	NP1
304953	100736356	20992747951	,	,	,
304953	100736356	20992747952	and	and	CC
304953	100736356	20992747953	then	then	RT
304953	100736356	20992747954	started	start	VVD_VVN@
304953	100736356	20992747955	on	on	II_RP@
304953	100736356	20992747956	docetaxel	docetaxel	NN1
304953	100736356	20992747957	@		II
304953	100736356	20992747958	@		II
304953	100736356	20992747959	@		II
304953	100736356	20992747960	@		II
304953	100736356	20992747961	@		II
304953	100736356	20992747962	@		II
304953	100736356	20992747963	@		II
304953	100736356	20992747964	@		II
304953	100736356	20992747965	@		II
304953	100736356	20992747966	@		II
304953	100736356	20992747967	emphasized	emphasize	VVD
304953	100736356	20992747968	that	that	CST
304953	100736356	20992747969	the	the	AT
304953	100736356	20992747970	combined	combined	JJ
304953	100736356	20992747971	treatment	treatment	NN1
304953	100736356	20992747972	is	be	VBZ
304953	100736356	20992747973	suitable	suitable	JJ
304953	100736356	20992747974	only	only	JJ
304953	100736356	20992747975	for	-for	IF
304953	100736356	20992747976	men	man	NN2
304953	100736356	20992747977	who	who	PNQS
304953	100736356	20992747978	are	be	VBR
304953	100736356	20992747979	"	"	"
304953	100736356	20992747980	fit	fit	JJ
304953	100736356	20992747981	for	for	IF
304953	100736356	20992747982	chemotherapy	chemotherapy	NN1
304953	100736356	20992747983	,	,	,
304953	100736356	20992747984	"	"	"
304953	100736356	20992747985	meaning	mean	VVG
304953	100736356	20992747986	that	that	CST
304953	100736356	20992747987	they	they	PPHS2
304953	100736356	20992747988	are	be	VB0
304953	100736356	20992747989	n't 	n't	XX
304953	100736356	20992747990	old	old	JJ
304953	100736356	20992747991	,	,	,
304953	100736356	20992747992	or	or	CC
304953	100736356	20992747993	frail	frail	JJ
304953	100736356	20992747994	,	,	,
304953	100736356	20992747995	or	or	CC
304953	100736356	20992747996	sick	sick	JJ_NN1@
304953	100736356	20992747997	with	with	IW
304953	100736356	20992747998	other	other	JJ
304953	100736356	20992747999	potentially	potentially	RR
304953	100736356	20992748000	life-threatening	life-threatening	JJ
304953	100736356	20992748001	conditions	condition	NN2
304953	100736356	20992748002	.	.	.
304953	100736356	20992748003	<p>		NULL
304953	100736356	20992748004	Keep	keep	VV0
304953	100736356	20992748005	in	in	II_RP@
304953	100736356	20992748006	mind	mind	NN1
304953	100736356	20992748007	that	that	CST
304953	100736356	20992748008	these	these	DD2
304953	100736356	20992748009	results	result	NN2
304953	100736356	20992748010	have	have	VH0
304953	100736356	20992748011	yet	yet	RR
304953	100736356	20992748012	to	to	TO
304953	100736356	20992748013	be	be	VBI
304953	100736356	20992748014	published	publish	VVN
304953	100736356	20992748015	in	in	II
304953	100736356	20992748016	a	a	AT1
304953	100736356	20992748017	peer-reviewed	peer-reviewed	JJ
304953	100736356	20992748018	medical	medical	JJ
304953	100736356	20992748019	journal	journal	NN1
304953	100736356	20992748020	.	.	.
304953	100736356	20992748021	Other	other	JJ
304953	100736356	20992748022	scientists	scientist	NN2
304953	100736356	20992748023	will	will	VM
304953	100736356	20992748024	need	need	VVI
304953	100736356	20992748025	to	to	TO
304953	100736356	20992748026	evaluate	evaluate	VVI
304953	100736356	20992748027	the	the	AT
304953	100736356	20992748028	findings	finding	NN2
304953	100736356	20992748029	before	before	CS
304953	100736356	20992748030	they	they	PPHS2
304953	100736356	20992748031	can	can	VM
304953	100736356	20992748032	be	be	VBI
304953	100736356	20992748033	widely	widely	RR
304953	100736356	20992748034	accepted	accept	VVN_VVD
304953	100736356	20992748035	.	.	.
304953	100736356	20992748036	This	this	DD1
304953	100736356	20992748037	is	be	VBZ
304953	100736356	20992748038	especially	especially	RR
304953	100736356	20992748039	important	important	JJ
304953	100736356	20992748040	because	because	CS
304953	100736356	20992748041	some	some	DD
304953	100736356	20992748042	men	man	NN2
304953	100736356	20992748043	have	have	VH0
304953	100736356	20992748044	difficulty	difficulty	NN1
304953	100736356	20992748045	tolerating	tolerate	VVG_NN1@
304953	100736356	20992748046	docetaxel	docetaxel	NN1
304953	100736356	20992748047	.	.	.
304953	100736356	20992748048	<p>		NULL
304953	100736356	20992748049	Clifford	clifford	NP1
304953	100736356	20992748050	Hudis	hudis	NP1
304953	100736356	20992748051	,	,	,
304953	100736356	20992748052	M.D.	m.d	NNA
304953	100736356	20992748053	,	,	,
304953	100736356	20992748054	president	president	NN1
304953	100736356	20992748055	of	of	IO
304953	100736356	20992748056	the	the	AT
304953	100736356	20992748057	American	american	JJ
304953	100736356	20992748058	Society	society	NN1
304953	100736356	20992748059	of	of	IO
304953	100736356	20992748060	Clinical	clinical	JJ
304953	100736356	20992748061	Oncology	oncology	NN1
304953	100736356	20992748062	and	and	CC
304953	100736356	20992748063	chief	chief	NN1
304953	100736356	20992748064	of	of	IO
304953	100736356	20992748065	the	the	AT
304953	100736356	20992748066	Breast	breast	NN1
304953	100736356	20992748067	Cancer	cancer	NN1
304953	100736356	20992748068	Medical	medical	JJ
304953	100736356	20992748069	Service	service	NN1
304953	100736356	20992748070	at	at	II
304953	100736356	20992748071	Memorial	memorial	NN1
304953	100736356	20992748072	Sloan	sloan	NP1_NN1
304953	100736356	20992748073	Kettering	kettering	NP1
304953	100736356	20992748074	Cancer	cancer	NN1
304953	100736356	20992748075	Center	center	NN1
304953	100736356	20992748076	in	in	II
304953	100736356	20992748077	New	new	NP1
304953	100736356	20992748078	York	york	NP1
304953	100736356	20992748079	,	,	,
304953	100736356	20992748080	said	say	VVD
304953	100736356	20992748081	the	the	AT
304953	100736356	20992748082	results	result	NN2
304953	100736356	20992748083	revealed	reveal	VVD_VVN
304953	100736356	20992748084	an	a	AT1
304953	100736356	20992748085	"	"	"
304953	100736356	20992748086	almost	almost	RR
304953	100736356	20992748087	unprecedented	unprecedented	JJ
304953	100736356	20992748088	improvement	improvement	NN1
304953	100736356	20992748089	in	in	II
304953	100736356	20992748090	survival	survival	NN1
304953	100736356	20992748091	"	"	"
304953	100736356	20992748092	that	that	CST_DD1
304953	100736356	20992748093	could	could	VM
304953	100736356	20992748094	be	be	VBI
304953	100736356	20992748095	"	"	"
304953	100736356	20992748096	transformative	transformative	JJ
304953	100736356	20992748097	"	"	"
304953	100736356	20992748098	in	in	II
304953	100736356	20992748099	prostate	prostate	NN1
304953	100736356	20992748100	cancer	cancer	NN1
304953	100736356	20992748101	care	care	NN1
304953	100736356	20992748102	.	.	.
304953	100736356	20992748103	<p>		NULL
304953	100736356	20992748104	Doctors	doctor	NN2
304953	100736356	20992748105	might	might	VM
304953	100736356	20992748106	also	also	RR
304953	100736356	20992748107	consider	consider	VVI
304953	100736356	20992748108	a	a	AT1
304953	100736356	20992748109	multitude	multitude	NN1
304953	100736356	20992748110	of	of	IO
304953	100736356	20992748111	other	other	JJ_NN1@
304953	100736356	20992748112	,	,	,
304953	100736356	20992748113	potentially	potentially	RR
304953	100736356	20992748114	less	less	RGR
304953	100736356	20992748115	toxic	toxic	JJ
304953	100736356	20992748116	therapies	therapy	NN2
304953	100736356	20992748117	that	that	CST_DD1
304953	100736356	20992748118	may	may	VM
304953	100736356	20992748119	not	not	XX
304953	100736356	20992748120	have	have	VHI
304953	100736356	20992748121	been	be	VBN
304953	100736356	20992748122	available	available	JJ
304953	100736356	20992748123	when	when	CS
304953	100736356	20992748124	the	the	AT
304953	100736356	20992748125	study	study	NN1
304953	100736356	20992748126	was	be	VBDZ
304953	100736356	20992748127	launched	launch	VVN
304953	100736356	20992748128	,	,	,
304953	100736356	20992748129	recommended	recommend	VVD_JJ@_VVN
304953	100736356	20992748130	prostate	prostate	NN1
304953	100736356	20992748131	cancer	cancer	NN1
304953	100736356	20992748132	specialist	specialist	NN1
304953	100736356	20992748133	Dr.		NNB
304953	100736356	20992748134	Marc	marc	NP1
304953	100736356	20992748135	B.		NP1
304953	100736356	20992748136	Garnick		NP1
304953	100736356	20992748137	,	,	,
304953	100736356	20992748138	the	the	AT
304953	100736356	20992748139	Gorman	gorman	NN1_NP1
304953	100736356	20992748140	Brothers	brother	NN2
304953	100736356	20992748141	Professor	professor	NN1
304953	100736356	20992748142	of	of	IO
304953	100736356	20992748143	Medicine	medicine	NN1
304953	100736356	20992748144	at	at	II
304953	100736356	20992748145	Harvard	harvard	NP1
304953	100736356	20992748146	Medical	medical	JJ
304953	100736356	20992748147	School	school	NN1
304953	100736356	20992748148	and	and	CC
304953	100736356	20992748149	Beth	beth	NP1
304953	100736356	20992748150	Israel	israel	NP1
304953	100736356	20992748151	Deaconess	deaconess	NN1
304953	100736356	20992748152	Medical	medical	JJ
304953	100736356	20992748153	Center	center	NN1
304953	100736356	20992748154	.	.	.
304953	100736356	20992748155	"	"	"
304953	100736356	20992748156	We	we	PPIS2
304953	100736356	20992748157	@		II
304953	100736356	20992748158	@		II
304953	100736356	20992748159	@		II
304953	100736356	20992748160	@		II
304953	100736356	20992748161	@		II
304953	100736356	20992748162	@		II
304953	100736356	20992748163	@		II
304953	100736356	20992748164	@		II
304953	100736356	20992748165	@		II
304953	100736356	20992748166	@		II
304953	100736356	20992748167	a	a	AT1
304953	100736356	20992748168	peer-reviewed	peer-reviewed	JJ_NN1
304953	100736356	20992748169	publication	publication	NN1
304953	100736356	20992748170	,	,	,
304953	100736356	20992748171	"	"	"
304953	100736356	20992748172	Garnick		NP1
304953	100736356	20992748173	said	say	VVD
304953	100736356	20992748174	.	.	.
304953	100736359	20992748194	@@##	----------	----------
304953	100736359	20992748195	@@100736359		FO
304953	100736359	20992748196	@4936359/		VV0_NN1
304953	100736359	20992748197	46989		MC
304953	100736359	20992748198	@qwx906989		FO
304953	100736359	20992748199	<p>		NULL
304953	100736359	20992748200	After	after	II
304953	100736359	20992748201	receiving	receive	VVG
304953	100736359	20992748202	reports	report	NN2
304953	100736359	20992748203	of	of	IO
304953	100736359	20992748204	adverse	adverse	JJ
304953	100736359	20992748205	effects	effect	NN2
304953	100736359	20992748206	in	in	II
304953	100736359	20992748207	children	child	NN2
304953	100736359	20992748208	who	who	PNQS
304953	100736359	20992748209	were	be	VBDR
304953	100736359	20992748210	inadvertently	inadvertently	RR
304953	100736359	20992748211	exposed	expose	VVN_VVD
304953	100736359	20992748212	to	to	II
304953	100736359	20992748213	two	two	MC
304953	100736359	20992748214	testosterone	testosterone	NN1
304953	100736359	20992748215	gels	gel	NN2
304953	100736359	20992748216	,	,	,
304953	100736359	20992748217	the	the	AT
304953	100736359	20992748218	FDA	fda	NN1_NP1
304953	100736359	20992748219	announced	announce	VVN_VVD
304953	100736359	20992748220	in	in	II
304953	100736359	20992748221	May	may	NPM1
304953	100736359	20992748222	2009	2009	MC
304953	100736359	20992748223	that	that	CST
304953	100736359	20992748224	manufacturers	manufacturer	NN2
304953	100736359	20992748225	need	need	VV0
304953	100736359	20992748226	to	to	TO
304953	100736359	20992748227	add	add	VVI
304953	100736359	20992748228	a	a	AT1
304953	100736359	20992748229	boxed	boxed	JJ
304953	100736359	20992748230	warning	warning	NN1
304953	100736359	20992748231	on	on	II
304953	100736359	20992748232	the	the	AT
304953	100736359	20992748233	products	product	NN2
304953	100736359	20992748234	'	'	GE
304953	100736359	20992748235	labels	label	NN2
304953	100736359	20992748236	.	.	.
304953	100736359	20992748237	AndroGel		VV0_NN1_NP1@
304953	100736359	20992748238	and	and	CC
304953	100736359	20992748239	Testim		NP1_NN1_VV0
304953	100736359	20992748240	are	be	VBR
304953	100736359	20992748241	prescribed	prescribe	VVN
304953	100736359	20992748242	for	for	IF
304953	100736359	20992748243	men	man	NN2
304953	100736359	20992748244	who	who	PNQS
304953	100736359	20992748245	produce	produce	VV0
304953	100736359	20992748246	little	little	JJ_RR_DA1
304953	100736359	20992748247	or	or	CC
304953	100736359	20992748248	no	no	AT
304953	100736359	20992748249	testosterone	testosterone	NN1
304953	100736359	20992748250	.	.	.
304953	100736359	20992748251	Users	user	NN2
304953	100736359	20992748252	rub	rub	VV0
304953	100736359	20992748253	the	the	AT
304953	100736359	20992748254	gels	gel	NN2
304953	100736359	20992748255	into	into	II
304953	100736359	20992748256	the	the	AT
304953	100736359	20992748257	shoulders	shoulder	NN2
304953	100736359	20992748258	or	or	CC
304953	100736359	20992748259	upper	upper	JJ
304953	100736359	20992748260	arms	arm	NN2
304953	100736359	20992748261	.	.	.
304953	100736359	20992748262	<p>		NULL
304953	100736359	20992748263	Unfortunately	unfortunately	RR
304953	100736359	20992748264	,	,	,
304953	100736359	20992748265	eight	eight	MC
304953	100736359	20992748266	children	child	NN2
304953	100736359	20992748267	developed	developed	JJ_VVN_VVD
304953	100736359	20992748268	side	side	NN1
304953	100736359	20992748269	effects	effect	NN2
304953	100736359	20992748270	including	including	II
304953	100736359	20992748271	enlarged	enlarged	JJ
304953	100736359	20992748272	genitalia	genitalia	NN1
304953	100736359	20992748273	,	,	,
304953	100736359	20992748274	premature	premature	JJ
304953	100736359	20992748275	development	development	NN1
304953	100736359	20992748276	of	of	IO
304953	100736359	20992748277	pubic	pubic	JJ
304953	100736359	20992748278	hair	hair	NN1
304953	100736359	20992748279	,	,	,
304953	100736359	20992748280	increased	increased	JJ_VVD
304953	100736359	20992748281	libido	libido	NN1
304953	100736359	20992748282	,	,	,
304953	100736359	20992748283	and	and	CC
304953	100736359	20992748284	aggressive	aggressive	JJ
304953	100736359	20992748285	behavior	behavior	NN1
304953	100736359	20992748286	after	after	II_CS
304953	100736359	20992748287	exposure	exposure	NN1
304953	100736359	20992748288	to	to	II
304953	100736359	20992748289	the	the	AT
304953	100736359	20992748290	gels	gel	NN2
304953	100736359	20992748291	.	.	.
304953	100736359	20992748292	The	the	AT
304953	100736359	20992748293	children	child	NN2
304953	100736359	20992748294	ranged	range	VVN_VVD
304953	100736359	20992748295	in	in	II
304953	100736359	20992748296	age	age	NN1
304953	100736359	20992748297	from	from	II
304953	100736359	20992748298	9	9	MC
304953	100736359	20992748299	months	month	NNT2
304953	100736359	20992748300	to	to	II
304953	100736359	20992748301	5	5	MC
304953	100736359	20992748302	years	year	NNT2
304953	100736359	20992748303	old	old	JJ
304953	100736359	20992748304	.	.	.
304953	100736359	20992748305	In	in	II
304953	100736359	20992748306	most	most	DAT
304953	100736359	20992748307	cases	case	NN2
304953	100736359	20992748308	,	,	,
304953	100736359	20992748309	the	the	AT
304953	100736359	20992748310	signs	sign	NN2
304953	100736359	20992748311	and	and	CC
304953	100736359	20992748312	symptoms	symptom	NN2
304953	100736359	20992748313	went	go	VVD
304953	100736359	20992748314	away	away	RL
304953	100736359	20992748315	after	after	II_CS
304953	100736359	20992748316	their	their	APPGE
304953	100736359	20992748317	exposure	exposure	NN1
304953	100736359	20992748318	to	to	II
304953	100736359	20992748319	the	the	AT
304953	100736359	20992748320	gels	gel	NN2
304953	100736359	20992748321	ended	end	VVD_VVN
304953	100736359	20992748322	.	.	.
304953	100736359	20992748323	<p>		NULL
304953	100736359	20992748324	After	after	CS_II
304953	100736359	20992748325	a	a	AT1
304953	100736359	20992748326	man	man	NN1
304953	100736359	20992748327	applies	apply	VVZ
304953	100736359	20992748328	the	the	AT
304953	100736359	20992748329	gel	gel	NN1
304953	100736359	20992748330	,	,	,
304953	100736359	20992748331	he	he	PPHS1
304953	100736359	20992748332	should	should	VM
304953	100736359	20992748333	wash	wash	VVI
304953	100736359	20992748334	his	his	APPGE
304953	100736359	20992748335	hands	hand	NN2
304953	100736359	20992748336	with	with	IW
304953	100736359	20992748337	soap	soap	NN1
304953	100736359	20992748338	and	and	CC
304953	100736359	20992748339	warm	warm	JJ
304953	100736359	20992748340	water	water	NN1
304953	100736359	20992748341	and	and	CC
304953	100736359	20992748342	cover	cover	VV0
304953	100736359	20992748343	the	the	AT
304953	100736359	20992748344	treated	treated	JJ@
304953	100736359	20992748345	skin	skin	NN1
304953	100736359	20992748346	with	with	IW
304953	100736359	20992748347	clothing	clothing	NN1
304953	100736359	20992748348	.	.	.
304953	100736359	20992748349	He	he	PPHS1
304953	100736359	20992748350	should	should	VM
304953	100736359	20992748351	also	also	RR
304953	100736359	20992748352	wash	wash	VVI
304953	100736359	20992748353	the	the	AT
304953	100736359	20992748354	treated	treated	JJ@
304953	100736359	20992748355	skin	skin	NN1
304953	100736359	20992748356	if	if	CS
304953	100736359	20992748357	he	he	PPHS1
304953	100736359	20992748358	anticipates	anticipate	VVZ
304953	100736359	20992748359	skin-to-skin	skin-to-skin	JJ
304953	100736359	20992748360	contact	contact	NN1
304953	100736359	20992748361	with	with	IW
304953	100736359	20992748362	another	another	DD1
304953	100736359	20992748363	person	person	NN1
304953	100736359	20992748364	.	.	.
304953	100736359	20992748365	46996		MC
304953	100736359	20992748366	@qwx906996		FO
304953	100736361	20992748386	@@##	----------	----------
304953	100736361	20992748387	@@100736361		FO
304953	100736361	20992748388	@4936361/		VV0_NN1
304953	100736361	20992748389	46988		MC
304953	100736361	20992748390	@qwx906988		FO
304953	100736361	20992748391	46994		MC
304953	100736361	20992748392	@qwx906994		FO
304953	100736361	20992748393	46995		MC
304953	100736361	20992748394	@qwx906995		FO
304953	100736361	20992748395	46992		MC
304953	100736361	20992748396	@qwx906992		FO
304953	100736361	20992748397	46991		MC
304953	100736361	20992748398	@qwx906991		FO
304953	100736361	20992748399	46990		MC
304953	100736361	20992748400	@qwx906990		FO
304953	100736361	20992748401	46989		MC
304953	100736361	20992748402	@qwx906989		FO
304953	100736361	20992748403	46993		MC
304953	100736361	20992748404	@qwx906993		FO
304953	100736361	20992748405	<h>		NULL
304953	100736361	20992748406	Prostate	prostate	NN1
304953	100736361	20992748407	Health	health	NN1
304953	100736361	20992748408	Publications	publication	NN2
304953	100736361	20992748409	<p>		NULL
304953	100736361	20992748410	Harvard	harvard	NP1
304953	100736361	20992748411	Mens	mens	NP1
304953	100736361	20992748412	Health	health	NN1
304953	100736361	20992748413	Watch	watch	NN1
304953	100736361	20992748414	Written	write	VVN
304953	100736361	20992748415	specifically	specifically	RR
304953	100736361	20992748416	for	for	IF
304953	100736361	20992748417	men	man	NN2
304953	100736361	20992748418	,	,	,
304953	100736361	20992748419	to	to	TO
304953	100736361	20992748420	help	help	VVI
304953	100736361	20992748421	them	them	PPHO2
304953	100736361	20992748422	lead	lead	VVI
304953	100736361	20992748423	healthier	healthy	JJR
304953	100736361	20992748424	,	,	,
304953	100736361	20992748425	longer	long	JJR_RRR
304953	100736361	20992748426	lives	life	NN2
304953	100736361	20992748427	.	.	.
304953	100736361	20992748428	With	with	IW
304953	100736361	20992748429	mens	mens	NN2
304953	100736361	20992748430	health	health	NN1
304953	100736361	20992748431	news	news	NN1
304953	100736361	20992748432	covering	cover	VVG
304953	100736361	20992748433	everything	everything	PN1
304953	100736361	20992748434	from	from	II
304953	100736361	20992748435	prostate	prostate	NN1
304953	100736361	20992748436	disease	disease	NN1
304953	100736361	20992748437	and	and	CC
304953	100736361	20992748438	nutrition	nutrition	NN1
304953	100736361	20992748439	and	and	CC
304953	100736361	20992748440	exercise	exercise	NN1_VV0
304953	100736361	20992748441	,	,	,
304953	100736361	20992748442	to	to	II
304953	100736361	20992748443	erectile	erectile	JJ
304953	100736361	20992748444	dysfunction	dysfunction	NN1
304953	100736361	20992748445	(	(	(
304953	100736361	20992748446	ED	ed	NP1
304953	100736361	20992748447	)	)	)
304953	100736361	20992748448	and	and	CC
304953	100736361	20992748449	hair	hair	NN1
304953	100736361	20992748450	loss	loss	NN1
304953	100736361	20992748451	,	,	,
304953	100736361	20992748452	Harvard	harvard	NP1
304953	100736361	20992748453	Mens	mens	NP1
304953	100736361	20992748454	Health	health	NN1
304953	100736361	20992748455	Watch	watch	NN1
304953	100736361	20992748456	delivers	deliver	VVZ
304953	100736361	20992748457	on	on	II_RP@
304953	100736361	20992748458	its	its	APPGE
304953	100736361	20992748459	promise	promise	NN1
304953	100736361	20992748460	that	that	CST_DD1
304953	100736361	20992748461	"	"	"
304953	100736361	20992748462	Knowledge	knowledge	NN1
304953	100736361	20992748463	is	be	VBZ
304953	100736361	20992748464	Power	power	NN1_NP1@
304953	100736361	20992748465	.	.	.
304953	100736361	20992748466	"	"	"
304953	100736361	20992748467	Learn	learn	VV0
304953	100736361	20992748468	more	more	RRR_DAR
304953	100736361	20992748469	<p>		NULL
304953	100736361	20992748470	Erectile	erectile	JJ
304953	100736361	20992748471	Dysfunction	dysfunction	NN1
304953	100736361	20992748472	This	this	DD1
304953	100736361	20992748473	report	report	NN1
304953	100736361	20992748474	offers	offer	VVZ@_NN2
304953	100736361	20992748475	a	a	AT1
304953	100736361	20992748476	comprehensive	comprehensive	JJ
304953	100736361	20992748477	review	review	NN1
304953	100736361	20992748478	of	of	IO
304953	100736361	20992748479	the	the	AT
304953	100736361	20992748480	many	many	DA2
304953	100736361	20992748481	causes	cause	NN2
304953	100736361	20992748482	of	of	IO
304953	100736361	20992748483	erectile	erectile	JJ
304953	100736361	20992748484	dysfunction	dysfunction	NN1
304953	100736361	20992748485	and	and	CC
304953	100736361	20992748486	the	the	AT
304953	100736361	20992748487	most	most	RGT
304953	100736361	20992748488	effective	effective	JJ
304953	100736361	20992748489	male	male	JJ_NN1
304953	100736361	20992748490	impotence	impotence	NN1
304953	100736361	20992748491	treatment	treatment	NN1
304953	100736361	20992748492	options	option	NN2
304953	100736361	20992748493	.	.	.
304953	100736361	20992748494	It	it	PPH1
304953	100736361	20992748495	also	also	RR
304953	100736361	20992748496	includes	include	VVZ
304953	100736361	20992748497	information	information	NN1
304953	100736361	20992748498	on	on	II
304953	100736361	20992748499	sex	sex	NN1
304953	100736361	20992748500	therapy	therapy	NN1
304953	100736361	20992748501	and	and	CC
304953	100736361	20992748502	involving	involve	VVG
304953	100736361	20992748503	your	your	APPGE
304953	100736361	20992748504	partner	partner	NN1
304953	100736361	20992748505	in	in	II
304953	100736361	20992748506	treatment	treatment	NN1
304953	100736361	20992748507	.	.	.
304953	100736361	20992748508	Learn	learn	VV0
304953	100736361	20992748509	more	more	RRR_DAR
304953	100736361	20992748510	<p>		NULL
304953	100736361	20992748511	Sexuality	sexuality	NN1
304953	100736361	20992748512	in	in	II
304953	100736361	20992748513	Midlife		NP1
304953	100736361	20992748514	and	and	CC
304953	100736361	20992748515	Beyond	beyond	II
304953	100736361	20992748516	Advancing	advancing	JJ
304953	100736361	20992748517	years	year	NNT2
304953	100736361	20992748518	leave	leave	VV0
304953	100736361	20992748519	their	their	APPGE
304953	100736361	20992748520	mark	mark	NN1
304953	100736361	20992748521	on	on	II
304953	100736361	20992748522	the	the	AT
304953	100736361	20992748523	body	body	NN1
304953	100736361	20992748524	,	,	,
304953	100736361	20992748525	mind	mind	NN1_VV0
304953	100736361	20992748526	,	,	,
304953	100736361	20992748527	and	and	CC
304953	100736361	20992748528	emotions	emotion	NN2
304953	100736361	20992748529	.	.	.
304953	100736361	20992748530	Some	some	DD
304953	100736361	20992748531	of	of	IO
304953	100736361	20992748532	these	these	DD2
304953	100736361	20992748533	changes	change	NN2
304953	100736361	20992748534	are	be	VBR
304953	100736361	20992748535	for	for	IF
304953	100736361	20992748536	the	the	AT
304953	100736361	20992748537	better	better	JJR_RRR
304953	100736361	20992748538	,	,	,
304953	100736361	20992748539	while	while	CS
304953	100736361	20992748540	others	others	NN2
304953	100736361	20992748541	are	be	VBR
304953	100736361	20992748542	less	less	RGR
304953	100736361	20992748543	desirable	desirable	JJ
304953	100736361	20992748544	.	.	.
304953	100736361	20992748545	Sex	sex	NN1
304953	100736361	20992748546	is	be	VBZ
304953	100736361	20992748547	no	no	AT
304953	100736361	20992748548	exception	exception	NN1
304953	100736361	20992748549	.	.	.
304953	100736361	20992748550	But	but	CCB
304953	100736361	20992748551	you	you	PPY
304953	100736361	20992748552	can	can	VM
304953	100736361	20992748553	overcome	overcome	VVI
304953	100736361	20992748554	these	these	DD2
304953	100736361	20992748555	challenges	challenge	NN2
304953	100736361	20992748556	and	and	CC
304953	100736361	20992748557	enjoy	enjoy	VVI
304953	100736361	20992748558	a	a	AT1
304953	100736361	20992748559	better	better	JJR
304953	100736361	20992748560	sex	sex	NN1
304953	100736361	20992748561	life	life	NN1
304953	100736361	20992748562	.	.	.
304953	100736361	20992748563	This	this	DD1
304953	100736361	20992748564	report	report	NN1
304953	100736361	20992748565	details	detail	NN2_VVZ%
304953	100736361	20992748566	the	the	AT
304953	100736361	20992748567	treatments	treatment	NN2
304953	100736361	20992748568	,	,	,
304953	100736361	20992748569	medications	medication	NN2
304953	100736361	20992748570	,	,	,
304953	100736361	20992748571	and	and	CC
304953	100736361	20992748572	self-help	self-help	JJ_NN1
304953	100736361	20992748573	techniques	technique	NN2
304953	100736361	20992748574	that	that	CST_DD1
304953	100736361	20992748575	can	can	VM
304953	100736361	20992748576	resolve	resolve	VVI
304953	100736361	20992748577	common	common	JJ
304953	100736361	20992748578	@		II
304953	100736361	20992748579	@		II
304953	100736361	20992748580	@		II
304953	100736361	20992748581	@		II
304953	100736361	20992748582	@		II
304953	100736361	20992748583	@		II
304953	100736361	20992748584	@		II
304953	100736361	20992748585	@		II
304953	100736361	20992748586	@		II
304953	100736361	20992748587	@		II
304953	100736361	20992748588	report	report	NN1
304953	100736361	20992748589	answers	answer	VVZ
304953	100736361	20992748590	many	many	DA2
304953	100736361	20992748591	important	important	JJ
304953	100736361	20992748592	questions	question	NN2
304953	100736361	20992748593	about	about	II
304953	100736361	20992748594	physical	physical	JJ
304953	100736361	20992748595	activity	activity	NN1
304953	100736361	20992748596	,	,	,
304953	100736361	20992748597	from	from	II
304953	100736361	20992748598	how	how	RRQ
304953	100736361	20992748599	your	your	APPGE
304953	100736361	20992748600	body	body	NN1
304953	100736361	20992748601	changes	change	NN2_VVZ@
304953	100736361	20992748602	through	through	II
304953	100736361	20992748603	exercise	exercise	NN1
304953	100736361	20992748604	to	to	II
304953	100736361	20992748605	what	what	DDQ
304953	100736361	20992748606	diseases	disease	NN2
304953	100736361	20992748607	it	it	PPH1
304953	100736361	20992748608	helps	help	VVZ
304953	100736361	20992748609	prevent	prevent	VVI
304953	100736361	20992748610	.	.	.
304953	100736361	20992748611	It	it	PPH1
304953	100736361	20992748612	will	will	VM
304953	100736361	20992748613	also	also	RR
304953	100736361	20992748614	help	help	VVI
304953	100736361	20992748615	guide	guide	VVI
304953	100736361	20992748616	you	you	PPY
304953	100736361	20992748617	through	through	II
304953	100736361	20992748618	starting	start	VVG_NN1
304953	100736361	20992748619	and	and	CC
304953	100736361	20992748620	maintaining	maintain	VVG
304953	100736361	20992748621	an	a	AT1
304953	100736361	20992748622	exercise	exercise	NN1
304953	100736361	20992748623	program	program	NN1_VV0@
304953	100736361	20992748624	that	that	CST_DD1
304953	100736361	20992748625	suits	suit	VVZ
304953	100736361	20992748626	your	your	APPGE
304953	100736361	20992748627	abilities	ability	NN2
304953	100736361	20992748628	and	and	CC
304953	100736361	20992748629	lifestyle	lifestyle	NN1
304953	100736361	20992748630	.	.	.
304953	100736361	20992748631	Throughout	throughout	RL@
304953	100736361	20992748632	,	,	,
304953	100736361	20992748633	you 'll		VV0_NN1
304953	100736361	20992748634	find	find	VV0
304953	100736361	20992748635	advice	advice	NN1
304953	100736361	20992748636	on	on	II
304953	100736361	20992748637	being	be	VBG
304953	100736361	20992748638	a	a	AT1
304953	100736361	20992748639	savvy	savvy	JJ_NN1
304953	100736361	20992748640	consumer	consumer	NN1
304953	100736361	20992748641	when	when	CS_RRQ
304953	100736361	20992748642	it	it	PPH1
304953	100736361	20992748643	comes	come	VVZ
304953	100736361	20992748644	to	to	II
304953	100736361	20992748645	fitness	fitness	NN1
304953	100736361	20992748646	products	product	NN2
304953	100736361	20992748647	,	,	,
304953	100736361	20992748648	as	as	II31_RG
304953	100736361	20992748649	well	well	II32_RR
304953	100736361	20992748650	as	as	II33_CSA
304953	100736361	20992748651	useful	useful	JJ
304953	100736361	20992748652	tools	tool	NN2
304953	100736361	20992748653	and	and	CC
304953	100736361	20992748654	tips	tip	NN2
304953	100736361	20992748655	designed	design	VVN_VVD
304953	100736361	20992748656	to	to	TO
304953	100736361	20992748657	help	help	VVI
304953	100736361	20992748658	make	make	VVI
304953	100736361	20992748659	exercise	exercise	NN1_VV0
304953	100736361	20992748660	work	work	NN1_VV0
304953	100736361	20992748661	for	for	IF
304953	100736361	20992748662	you	you	PPY
304953	100736361	20992748663	.	.	.
304953	100736361	20992748664	Learn	learn	VV0
304953	100736361	20992748665	more	more	RRR_DAR
304953	100736361	20992748666	<p>		NULL
304953	100736361	20992748667	Workout	workout	VV0_NN1
304953	100736361	20992748668	Workbook	workbook	NN1
304953	100736361	20992748669	:	:	:
304953	100736361	20992748670	9	9	MC
304953	100736361	20992748671	complete	complete	JJ
304953	100736361	20992748672	workouts	workout	NN2
304953	100736361	20992748673	to	to	TO
304953	100736361	20992748674	help	help	VVI
304953	100736361	20992748675	you	you	PPY
304953	100736361	20992748676	get	get	VVI
304953	100736361	20992748677	fit	fit	JJ
304953	100736361	20992748678	and	and	CC
304953	100736361	20992748679	healthy	healthy	JJ
304953	100736361	20992748680	This	this	DD1
304953	100736361	20992748681	report	report	NN1
304953	100736361	20992748682	provides	provide	VVZ
304953	100736361	20992748683	nine	nine	MC
304953	100736361	20992748684	excellent	excellent	JJ
304953	100736361	20992748685	workouts	workout	NN2
304953	100736361	20992748686	inside	inside	RL
304953	100736361	20992748687	will	will	VM
304953	100736361	20992748688	challenge	challenge	VVI
304953	100736361	20992748689	your	your	APPGE
304953	100736361	20992748690	body	body	NN1
304953	100736361	20992748691	and	and	CC
304953	100736361	20992748692	spirit	spirit	NN1
304953	100736361	20992748693	in	in	II
304953	100736361	20992748694	a	a	AT1
304953	100736361	20992748695	variety	variety	NN1
304953	100736361	20992748696	of	of	IO
304953	100736361	20992748697	ways	way	NN2
304953	100736361	20992748698	while	while	CS
304953	100736361	20992748699	warding	ward	VVG
304953	100736361	20992748700	off	off	II_RP
304953	100736361	20992748701	boredom	boredom	NN1
304953	100736361	20992748702	.	.	.
304953	100736361	20992748703	Each	each	DD1
304953	100736361	20992748704	workout	workout	NN1
304953	100736361	20992748705	includes	include	VVZ
304953	100736361	20992748706	step-by-step	step-by-step	JJ
304953	100736361	20992748707	instructions	instruction	NN2
304953	100736361	20992748708	and	and	CC
304953	100736361	20992748709	photographs	photograph	NN2
304953	100736361	20992748710	for	for	IF
304953	100736361	20992748711	every	every	AT1
304953	100736361	20992748712	exercise	exercise	NN1
304953	100736361	20992748713	.	.	.
304953	100736361	20992748714	And	and	CC
304953	100736361	20992748715	we 've		NN1
304953	100736361	20992748716	designed	design	VVD_VVN
304953	100736361	20992748717	the	the	AT
304953	100736361	20992748718	exercises	exercise	NN2
304953	100736361	20992748719	so	so	CS21
304953	100736361	20992748720	that	that	CS22
304953	100736361	20992748721	you	you	PPY
304953	100736361	20992748722	can	can	VM
304953	100736361	20992748723	tailor	tailor	VVI
304953	100736361	20992748724	each	each	DD1
304953	100736361	20992748725	one	one	PN1
304953	100736361	20992748726	to	to	II
304953	100736361	20992748727	your	your	APPGE
304953	100736361	20992748728	fitness	fitness	NN1
304953	100736361	20992748729	level	level	NN1
304953	100736361	20992748730	using	use	VVG
304953	100736361	20992748731	variations	variation	NN2
304953	100736361	20992748732	to	to	TO
304953	100736361	20992748733	make	make	VVI
304953	100736361	20992748734	it	it	PPH1
304953	100736361	20992748735	easier	easy	JJR_RRR
304953	100736361	20992748736	or	or	CC
304953	100736361	20992748737	harder	hard	RRR_JJR
304953	100736361	20992748738	.	.	.
304953	100736361	20992748739	Learn	learn	VV0
304953	100736361	20992748740	more	more	RRR_DAR
304953	100736361	20992748741	<p>		NULL
304953	100736361	20992748742	Managing	managing	JJ_VVG
304953	100736361	20992748743	Your-		JJ_NN1
304953	100736361	20992748744	Cholesterol	cholesterol	NN1
304953	100736361	20992748745	This	this	DD1
304953	100736361	20992748746	report	report	NN1
304953	100736361	20992748747	includes	include	VVZ
304953	100736361	20992748748	guidelines	guideline	NN2
304953	100736361	20992748749	that	that	CST
304953	100736361	20992748750	give	give	VV0
304953	100736361	20992748751	you	you	PPY
304953	100736361	20992748752	an	a	AT1
304953	100736361	20992748753	easy	easy	JJ
304953	100736361	20992748754	,	,	,
304953	100736361	20992748755	step-by-step	step-by-step	JJ_NN1
304953	100736361	20992748756	method	method	NN1
304953	100736361	20992748757	to	to	TO
304953	100736361	20992748758	evaluate	evaluate	VVI
304953	100736361	20992748759	your	your	APPGE
304953	100736361	20992748760	risk	risk	NN1
304953	100736361	20992748761	of	of	IO
304953	100736361	20992748762	heart	heart	NN1
304953	100736361	20992748763	disease	disease	NN1
304953	100736361	20992748764	,	,	,
304953	100736361	20992748765	set	set	VVD_VV0
304953	100736361	20992748766	your	your	APPGE
304953	100736361	20992748767	cholesterol	cholesterol	NN1
304953	100736361	20992748768	goal	goal	NN1
304953	100736361	20992748769	,	,	,
304953	100736361	20992748770	and	and	CC
304953	100736361	20992748771	take	take	VV0
304953	100736361	20992748772	the	the	AT
304953	100736361	20992748773	steps	step	NN2
304953	100736361	20992748774	you	you	PPY
304953	100736361	20992748775	need	need	VV0
304953	100736361	20992748776	to	to	TO
304953	100736361	20992748777	reach	reach	VVI
304953	100736361	20992748778	@		II
304953	100736361	20992748779	@		II
304953	100736361	20992748780	@		II
304953	100736361	20992748781	@		II
304953	100736361	20992748782	@		II
304953	100736361	20992748783	@		II
304953	100736361	20992748784	@		II
304953	100736361	20992748785	@		II
304953	100736361	20992748786	@		II
304953	100736361	20992748787	@		II
304953	100736361	20992748788	and	and	CC
304953	100736361	20992748789	trans	trans	NN2
304953	100736361	20992748790	fats	fat	NN2
304953	100736361	20992748791	can	can	VM
304953	100736361	20992748792	help	help	VVI
304953	100736361	20992748793	you	you	PPY
304953	100736361	20992748794	go	go	VVI
304953	100736361	20992748795	a	a	AT1
304953	100736361	20992748796	long	long	JJ
304953	100736361	20992748797	way	way	NN1
304953	100736361	20992748798	toward	toward	II
304953	100736361	20992748799	that	that	DD1
304953	100736361	20992748800	goal	goal	NN1
304953	100736361	20992748801	.	.	.
304953	100736361	20992748802	If	if	CS
304953	100736361	20992748803	you	you	PPY
304953	100736361	20992748804	need	need	VV0
304953	100736361	20992748805	more	more	RRR
304953	100736361	20992748806	help	help	VVI
304953	100736361	20992748807	,	,	,
304953	100736361	20992748808	effective	effective	JJ
304953	100736361	20992748809	medications	medication	NN2
304953	100736361	20992748810	can	can	VM
304953	100736361	20992748811	take	take	VVI
304953	100736361	20992748812	you	you	PPY
304953	100736361	20992748813	the	the	AT
304953	100736361	20992748814	rest	rest	NN1
304953	100736361	20992748815	of	of	IO
304953	100736361	20992748816	the	the	AT
304953	100736361	20992748817	way	way	NN1
304953	100736361	20992748818	.	.	.
304953	100736361	20992748819	And	and	CC
304953	100736361	20992748820	this	this	DD1
304953	100736361	20992748821	report	report	NN1
304953	100736361	20992748822	should	should	VM
304953	100736361	20992748823	provide	provide	VVI
304953	100736361	20992748824	the	the	AT
304953	100736361	20992748825	further	far	JJR@
304953	100736361	20992748826	encouragement	encouragement	NN1
304953	100736361	20992748827	you	you	PPY
304953	100736361	20992748828	need	need	VV0
304953	100736361	20992748829	to	to	TO
304953	100736361	20992748830	get	get	VVI
304953	100736361	20992748831	your	your	APPGE
304953	100736361	20992748832	cholesterol	cholesterol	NN1
304953	100736361	20992748833	under	under	II
304953	100736361	20992748834	control	control	NN1
304953	100736361	20992748835	and	and	CC
304953	100736361	20992748836	keep	keep	VVI
304953	100736361	20992748837	it	it	PPH1
304953	100736361	20992748838	there	there	RL
304953	100736361	20992748839	.	.	.
304953	100736361	20992748840	Learn	learn	VV0
304953	100736361	20992748841	more	more	RRR_DAR
304953	100736361	20992748842	<p>		NULL
304953	100736361	20992748843	Healthy	healthy	JJ
304953	100736361	20992748844	Eating	eating	NN1
304953	100736361	20992748845	:	:	:
304953	100736361	20992748846	A	a	AT1@_ZZ1
304953	100736361	20992748847	guide	guide	NN1_VV0
304953	100736361	20992748848	to	to	II
304953	100736361	20992748849	the	the	AT
304953	100736361	20992748850	new	new	JJ
304953	100736361	20992748851	nutrition	nutrition	NN1
304953	100736361	20992748852	While	while	CS
304953	100736361	20992748853	some	some	DD
304953	100736361	20992748854	age-old	age-old	JJ
304953	100736361	20992748855	advice	advice	NN1
304953	100736361	20992748856	like	like	II_RR%_VV0@
304953	100736361	20992748857	"	"	"
304953	100736361	20992748858	eat	eat	VV0
304953	100736361	20992748859	your	your	APPGE
304953	100736361	20992748860	vegetables	vegetable	NN2
304953	100736361	20992748861	"	"	"
304953	100736361	20992748862	still	still	RR
304953	100736361	20992748863	holds	hold	VVZ
304953	100736361	20992748864	true	true	JJ
304953	100736361	20992748865	,	,	,
304953	100736361	20992748866	many	many	DA2
304953	100736361	20992748867	early	early	JJ
304953	100736361	20992748868	assumptions	assumption	NN2
304953	100736361	20992748869	have	have	VH0
304953	100736361	20992748870	turned	turn	VVN
304953	100736361	20992748871	out	out	RP
304953	100736361	20992748872	to	to	TO
304953	100736361	20992748873	be	be	VBI
304953	100736361	20992748874	wrong	wrong	JJ_RR@
304953	100736361	20992748875	.	.	.
304953	100736361	20992748876	Scientists	scientist	NN2
304953	100736361	20992748877	have	have	VH0
304953	100736361	20992748878	learned	learn	VVN
304953	100736361	20992748879	much	much	DA1_RR
304953	100736361	20992748880	more	more	DAR_RRR
304953	100736361	20992748881	about	about	II
304953	100736361	20992748882	why	why	RRQ
304953	100736361	20992748883	some	some	DD
304953	100736361	20992748884	foods	food	NN2
304953	100736361	20992748885	help	help	VV0
304953	100736361	20992748886	prevent	prevent	VVI
304953	100736361	20992748887	disease	disease	NN1
304953	100736361	20992748888	and	and	CC
304953	100736361	20992748889	why	why	RRQ
304953	100736361	20992748890	others	others	NN2
304953	100736361	20992748891	promote	promote	VV0
304953	100736361	20992748892	it	it	PPH1
304953	100736361	20992748893	.	.	.
304953	100736361	20992748894	The	the	AT
304953	100736361	20992748895	Healthy	healthy	JJ
304953	100736361	20992748896	Eating	eating	NN1
304953	100736361	20992748897	report	report	NN1
304953	100736361	20992748898	describes	describe	VVZ
304953	100736361	20992748899	the	the	AT
304953	100736361	20992748900	food-health		JJ_NN1
304953	100736361	20992748901	connection	connection	NN1
304953	100736361	20992748902	and	and	CC
304953	100736361	20992748903	takes	take	VVZ
304953	100736361	20992748904	on	on	RP
304953	100736361	20992748905	controversial	controversial	JJ
304953	100736361	20992748906	topics	topic	NN2
304953	100736361	20992748907	like	like	II
304953	100736361	20992748908	food	food	NN1
304953	100736361	20992748909	additives	additive	NN2
304953	100736361	20992748910	,	,	,
304953	100736361	20992748911	cooking	cook	VVG_NN1
304953	100736361	20992748912	methods	method	NN2
304953	100736361	20992748913	,	,	,
304953	100736361	20992748914	the	the	AT
304953	100736361	20992748915	role	role	NN1
304953	100736361	20992748916	of	of	IO
304953	100736361	20992748917	carbohydrates	carbohydrate	NN2
304953	100736361	20992748918	and	and	CC
304953	100736361	20992748919	more	more	RRR_DAR
304953	100736361	20992748920	.	.	.
304953	100736361	20992748921	Learn	learn	VV0
304953	100736361	20992748922	more	more	RRR_DAR
304953	100736361	20992748923	<p>		NULL
304953	100736361	20992748924	Testosterone	testosterone	NN1
304953	100736361	20992748925	for	for	IF
304953	100736361	20992748926	Life	life	NN1
304953	100736361	20992748927	Better	better	JJR_RRR
304953	100736361	20992748928	sex	sex	NN1
304953	100736361	20992748929	.	.	.
304953	100736361	20992748930	Increased	increased	JJ
304953	100736361	20992748931	vitality	vitality	NN1
304953	100736361	20992748932	.	.	.
304953	100736361	20992748933	More	more	DAR
304953	100736361	20992748934	muscle	muscle	NN1
304953	100736361	20992748935	.	.	.
304953	100736361	20992748936	Improved	improved	JJ
304953	100736361	20992748937	health	health	NN1
304953	100736361	20992748938	.	.	.
304953	100736361	20992748939	Greater	great	JJR_NP1@
304953	100736361	20992748940	mental	mental	JJ
304953	100736361	20992748941	agility	agility	NN1
304953	100736361	20992748942	.	.	.
304953	100736361	20992748943	These	these	DD2
304953	100736361	20992748944	are	be	VBR
304953	100736361	20992748945	just	just	RR
304953	100736361	20992748946	a	a	AT1
304953	100736361	20992748947	few	few	DA2
304953	100736361	20992748948	of	of	IO
304953	100736361	20992748949	the	the	AT
304953	100736361	20992748950	life-enhancing	life-enhancing	JJ
304953	100736361	20992748951	benefits	benefit	NN2
304953	100736361	20992748952	that	that	CST
304953	100736361	20992748953	men	man	NN2
304953	100736361	20992748954	with	with	IW
304953	100736361	20992748955	low	low	JJ
304953	100736361	20992748956	levels	level	NN2
304953	100736361	20992748957	of	of	IO
304953	100736361	20992748958	testosterone	testosterone	NN1
304953	100736361	20992748959	can	can	VM
304953	100736361	20992748960	experience	experience	VVI
304953	100736361	20992748961	when	when	RRQ_CS
304953	100736361	20992748962	they	they	PPHS2
304953	100736361	20992748963	increase	increase	VV0
304953	100736361	20992748964	their	their	APPGE
304953	100736361	20992748965	testosterone	testosterone	NN1
304953	100736361	20992748966	level	level	NN1
304953	100736361	20992748967	.	.	.
304953	100736361	20992748968	If	if	CS
304953	100736361	20992748969	you 've		NN1
304953	100736361	20992748970	noticed	notice	VVD_VVN
304953	100736361	20992748971	a	a	AT1
304953	100736361	20992748972	decrease	decrease	NN1
304953	100736361	20992748973	in	in	II
304953	100736361	20992748974	your	your	APPGE
304953	100736361	20992748975	sex	sex	NN1
304953	100736361	20992748976	drive	drive	NN1_VV0
304953	100736361	20992748977	;	;	;
304953	100736361	20992748978	@		II
304953	100736361	20992748979	@		II
304953	100736361	20992748980	@		II
304953	100736361	20992748981	@		II
304953	100736361	20992748982	@		II
304953	100736361	20992748983	@		II
304953	100736361	20992748984	@		II
304953	100736361	20992748985	@		II
304953	100736361	20992748986	@		II
304953	100736361	20992748987	@		II
304953	100736361	20992748988	and	and	CC
304953	100736361	20992748989	unmotivated	unmotivated	JJ
304953	100736361	20992748990	,	,	,
304953	100736361	20992748991	this	this	DD1
304953	100736361	20992748992	authoritative	authoritative	JJ
304953	100736361	20992748993	,	,	,
304953	100736361	20992748994	up-to-date	up-to-date	JJ
304953	100736361	20992748995	guide	guide	NN1
304953	100736361	20992748996	from	from	II
304953	100736361	20992748997	an	a	AT1
304953	100736361	20992748998	expert	expert	NN1
304953	100736361	20992748999	at	at	II
304953	100736361	20992749000	Harvard	harvard	NP1
304953	100736361	20992749001	Medical	medical	JJ
304953	100736361	20992749002	School	school	NN1
304953	100736361	20992749003	will	will	VM
304953	100736361	20992749004	help	help	VVI
304953	100736361	20992749005	you	you	PPY
304953	100736361	20992749006	.	.	.
304953	100736361	20992749007	Learn	learn	VV0
304953	100736361	20992749008	more	more	DAR_RRR_RGR
304953	100736364	20992749028	@@##	----------	----------
304953	100736364	20992749029	@@100736364		FO
304953	100736364	20992749030	@4936364/		VV0_NN1
304953	100736364	20992749031	46989		MC
304953	100736364	20992749032	@qwx906989		FO
304953	100736364	20992749033	<p>		NULL
304953	100736364	20992749034	A	a	AT1_ZZ1
304953	100736364	20992749035	new	new	JJ
304953	100736364	20992749036	prostate	prostate	NN1
304953	100736364	20992749037	cancer	cancer	NN1
304953	100736364	20992749038	vaccine	vaccine	NN1
304953	100736364	20992749039	may	may	VM
304953	100736364	20992749040	give	give	VVI
304953	100736364	20992749041	hope	hope	NN1_VV0
304953	100736364	20992749042	to	to	II
304953	100736364	20992749043	men	man	NN2
304953	100736364	20992749044	with	with	IW
304953	100736364	20992749045	metastatic	metastatic	JJ
304953	100736364	20992749046	prostate	prostate	NN1
304953	100736364	20992749047	cancer	cancer	NN1
304953	100736364	20992749048	by	by	II
304953	100736364	20992749049	spurring	spur	VVG
304953	100736364	20992749050	their	their	APPGE
304953	100736364	20992749051	immune	immune	JJ
304953	100736364	20992749052	systems	system	NN2
304953	100736364	20992749053	to	to	TO
304953	100736364	20992749054	fight	fight	VVI
304953	100736364	20992749055	the	the	AT
304953	100736364	20992749056	disease	disease	NN1
304953	100736364	20992749057	,	,	,
304953	100736364	20992749058	according	according	II21
304953	100736364	20992749059	to	to	II22
304953	100736364	20992749060	a	a	AT1
304953	100736364	20992749061	presentation	presentation	NN1
304953	100736364	20992749062	by	by	II
304953	100736364	20992749063	Iowa	iowa	NP1
304953	100736364	20992749064	researchers	researcher	NN2
304953	100736364	20992749065	at	at	II
304953	100736364	20992749066	the	the	AT
304953	100736364	20992749067	American	american	JJ
304953	100736364	20992749068	Urological	urological	JJ
304953	100736364	20992749069	Association	association	NN1
304953	100736364	20992749070	's	's	GE
304953	100736364	20992749071	annual	annual	JJ
304953	100736364	20992749072	meeting	meeting	NN1
304953	100736364	20992749073	in	in	II
304953	100736364	20992749074	May	may	NPM1
304953	100736364	20992749075	2008	2008	MC
304953	100736364	20992749076	.	.	.
304953	100736364	20992749077	Enabling	enable	VVG
304953	100736364	20992749078	a	a	AT1
304953	100736364	20992749079	patient	patient	NN1
304953	100736364	20992749080	's	's	GE
304953	100736364	20992749081	immune	immune	JJ
304953	100736364	20992749082	system	system	NN1
304953	100736364	20992749083	to	to	TO
304953	100736364	20992749084	attack	attack	VVI
304953	100736364	20992749085	cancer	cancer	NN1
304953	100736364	20992749086	cells	cell	NN2
304953	100736364	20992749087	can	can	VM
304953	100736364	20992749088	improve	improve	VVI
304953	100736364	20992749089	quality	quality	NN1
304953	100736364	20992749090	of	of	IO
304953	100736364	20992749091	life	life	NN1
304953	100736364	20992749092	and	and	CC
304953	100736364	20992749093	extend	extend	VVI
304953	100736364	20992749094	survival	survival	NN1
304953	100736364	20992749095	.	.	.
304953	100736364	20992749096	<p>		NULL
304953	100736364	20992749097	Their	their	APPGE
304953	100736364	20992749098	phase	phase	NN1
304953	100736364	20992749099	I	i	ZZ1%_MC1%_PPIS1
304953	100736364	20992749100	clinical	clinical	JJ
304953	100736364	20992749101	trial	trial	NN1
304953	100736364	20992749102	of	of	IO
304953	100736364	20992749103	the	the	AT
304953	100736364	20992749104	adenovirus/PSA		FU
304953	100736364	20992749105	vaccine	vaccine	NN1
304953	100736364	20992749106	included	include	VVD_VVN
304953	100736364	20992749107	32	32	MC
304953	100736364	20992749108	men	man	NN2
304953	100736364	20992749109	with	with	IW
304953	100736364	20992749110	metastatic	metastatic	JJ
304953	100736364	20992749111	prostate	prostate	NN1
304953	100736364	20992749112	cancer	cancer	NN1
304953	100736364	20992749113	who	who	PNQS
304953	100736364	20992749114	received	receive	VVD
304953	100736364	20992749115	a	a	AT1
304953	100736364	20992749116	single	single	JJ
304953	100736364	20992749117	injection	injection	NN1
304953	100736364	20992749118	of	of	IO
304953	100736364	20992749119	the	the	AT
304953	100736364	20992749120	vaccine	vaccine	NN1
304953	100736364	20992749121	.	.	.
304953	100736364	20992749122	At	at	RR21
304953	100736364	20992749123	least	least	RR22
304953	100736364	20992749124	40%		NNU
304953	100736364	20992749125	of	of	IO
304953	100736364	20992749126	the	the	AT
304953	100736364	20992749127	men	man	NN2
304953	100736364	20992749128	developed	develop	VVD_VVN
304953	100736364	20992749129	an	a	AT1
304953	100736364	20992749130	immune	immune	JJ
304953	100736364	20992749131	response	response	NN1
304953	100736364	20992749132	to	to	II
304953	100736364	20992749133	PSA	psa	NP1
304953	100736364	20992749134	.	.	.
304953	100736364	20992749135	PSA	psa	NP1
304953	100736364	20992749136	doubling	doubling	NN1_VVG
304953	100736364	20992749137	time	time	NNT1
304953	100736364	20992749138	,	,	,
304953	100736364	20992749139	a	a	AT1
304953	100736364	20992749140	measure	measure	NN1
304953	100736364	20992749141	of	of	IO
304953	100736364	20992749142	the	the	AT
304953	100736364	20992749143	aggressiveness	aggressiveness	NN1
304953	100736364	20992749144	of	of	IO
304953	100736364	20992749145	the	the	AT
304953	100736364	20992749146	disease	disease	NN1
304953	100736364	20992749147	,	,	,
304953	100736364	20992749148	increased	increase	VVN_VVD
304953	100736364	20992749149	in	in	II_RP@
304953	100736364	20992749150	48%		NNU
304953	100736364	20992749151	of	of	IO
304953	100736364	20992749152	participants	participant	NN2
304953	100736364	20992749153	.	.	.
304953	100736364	20992749154	And	and	CC
304953	100736364	20992749155	57%		NNU
304953	100736364	20992749156	of	of	IO
304953	100736364	20992749157	the	the	AT
304953	100736364	20992749158	participants	participant	NN2
304953	100736364	20992749159	lived	live	VVD_VVN
304953	100736364	20992749160	longer	long	RRR_JJR
304953	100736364	20992749161	than	than	CSN
304953	100736364	20992749162	predicted	predict	VVN
304953	100736364	20992749163	by	by	II
304953	100736364	20992749164	standard	standard	JJ_NN1
304953	100736364	20992749165	nomograms		NN2
304953	100736364	20992749166	.	.	.
304953	100736364	20992749167	The	the	AT
304953	100736364	20992749168	longest	long	JJT_RRT
304953	100736364	20992749169	surviving	surviving	JJ
304953	100736364	20992749170	patient	patient	NN1
304953	100736364	20992749171	lived	live	VVD_VVN
304953	100736364	20992749172	almost	almost	RR
304953	100736364	20992749173	six	six	MC
304953	100736364	20992749174	years	year	NNT2
304953	100736364	20992749175	after	after	II
304953	100736364	20992749176	receiving	receive	VVG
304953	100736364	20992749177	the	the	AT
304953	100736364	20992749178	vaccine	vaccine	NN1
304953	100736364	20992749179	.	.	.
304953	100736364	20992749180	<p>		NULL
304953	100736364	20992749181	Encouraged	encourage	VVN
304953	100736364	20992749182	by	by	II
304953	100736364	20992749183	the	the	AT
304953	100736364	20992749184	findings	finding	NN2
304953	100736364	20992749185	,	,	,
304953	100736364	20992749186	researchers	researcher	NN2
304953	100736364	20992749187	received	receive	VVD_VVN
304953	100736364	20992749188	FDA	fda	NP1_NN1
304953	100736364	20992749189	approval	approval	NN1
304953	100736364	20992749190	to	to	TO
304953	100736364	20992749191	conduct	conduct	VVI
304953	100736364	20992749192	a	a	AT1
304953	100736364	20992749193	larger	large	JJR
304953	100736364	20992749194	phase	phase	NN1
304953	100736364	20992749195	II	ii	MC
304953	100736364	20992749196	clinical	clinical	JJ
304953	100736364	20992749197	trial	trial	NN1
304953	100736364	20992749198	to	to	TO
304953	100736364	20992749199	collect	collect	VVI
304953	100736364	20992749200	more	more	DAR
304953	100736364	20992749201	data	data	NN
304953	100736364	20992749202	.	.	.
304953	100736364	20992749203	This	this	DD1
304953	100736364	20992749204	is	be	VBZ
304953	100736364	20992749205	just	just	RR
304953	100736364	20992749206	one	one	MC1
304953	100736364	20992749207	of	of	IO
304953	100736364	20992749208	several	several	DA2
304953	100736364	20992749209	studies	study	NN2
304953	100736364	20992749210	indicating	indicate	VVG
304953	100736364	20992749211	that	that	DD1_CST
304953	100736364	20992749212	modulation	modulation	NN1
304953	100736364	20992749213	of	of	IO
304953	100736364	20992749214	the	the	AT
304953	100736364	20992749215	immune	immune	JJ
304953	100736364	20992749216	system	system	NN1
304953	100736364	20992749217	may	may	VM
304953	100736364	20992749218	hold	hold	VVI
304953	100736364	20992749219	promise	promise	NN1_VV0
304953	100736364	20992749220	in	in	II
304953	100736364	20992749221	the	the	AT
304953	100736364	20992749222	treatment	treatment	NN1
304953	100736364	20992749223	of	of	IO
304953	100736364	20992749224	prostate	prostate	NN1
304953	100736364	20992749225	cancer	cancer	NN1
304953	100736364	20992749226	.	.	.
304953	100736364	20992749227	46996		MC
304953	100736364	20992749228	@qwx906996		FO
304953	100736365	20992749248	@@##	----------	----------
304953	100736365	20992749249	@@100736365		FO
304953	100736365	20992749250	@4936365/		VV0_NN1
304953	100736365	20992749251	46989		MC
304953	100736365	20992749252	@qwx906989		FO
304953	100736365	20992749253	<p>		NULL
304953	100736365	20992749254	The	the	AT
304953	100736365	20992749255	prostate-specific	prostate-specific	JJ
304953	100736365	20992749256	antigen	antigen	NN1
304953	100736365	20992749257	(	(	(
304953	100736365	20992749258	PSA	psa	NP1
304953	100736365	20992749259	)	)	)
304953	100736365	20992749260	test	test	VV0
304953	100736365	20992749261	to	to	TO
304953	100736365	20992749262	screen	screen	VVI
304953	100736365	20992749263	for	for	IF
304953	100736365	20992749264	prostate	prostate	NN1
304953	100736365	20992749265	cancer	cancer	NN1
304953	100736365	20992749266	is	be	VBZ
304953	100736365	20992749267	the	the	AT
304953	100736365	20992749268	most	most	RGT
304953	100736365	20992749269	important	important	JJ
304953	100736365	20992749270	issue	issue	NN1
304953	100736365	20992749271	in	in	II
304953	100736365	20992749272	mens	mens	NN2
304953	100736365	20992749273	health	health	NN1
304953	100736365	20992749274	.	.	.
304953	100736365	20992749275	It	it	PPH1
304953	100736365	20992749276	is	be	VBZ
304953	100736365	20992749277	also	also	RR
304953	100736365	20992749278	the	the	AT
304953	100736365	20992749279	most	most	RGT
304953	100736365	20992749280	controversial	controversial	JJ
304953	100736365	20992749281	.	.	.
304953	100736365	20992749282	That 's		NN2_VVZ_NP1@
304953	100736365	20992749283	because	because	CS
304953	100736365	20992749284	many	many	DA2
304953	100736365	20992749285	experts	expert	NN2
304953	100736365	20992749286	believe	believe	VV0
304953	100736365	20992749287	prostate	prostate	NN1
304953	100736365	20992749288	cancer	cancer	NN1
304953	100736365	20992749289	is	be	VBZ
304953	100736365	20992749290	the	the	AT
304953	100736365	20992749291	exception	exception	NN1
304953	100736365	20992749292	to	to	II
304953	100736365	20992749293	the	the	AT
304953	100736365	20992749294	rule	rule	NN1
304953	100736365	20992749295	that	that	RG
304953	100736365	20992749296	early	early	RR
304953	100736365	20992749297	detection	detection	NN1
304953	100736365	20992749298	of	of	IO
304953	100736365	20992749299	cancer	cancer	NN1
304953	100736365	20992749300	saves	save	VVZ_NN2
304953	100736365	20992749301	lives	life	NN2
304953	100736365	20992749302	.	.	.
304953	100736365	20992749303	In	in	II
304953	100736365	20992749304	fact	fact	NN1
304953	100736365	20992749305	,	,	,
304953	100736365	20992749306	the	the	AT
304953	100736365	20992749307	PSA	psa	NP1
304953	100736365	20992749308	screening	screening	NN1
304953	100736365	20992749309	may	may	VM
304953	100736365	20992749310	actually	actually	RR
304953	100736365	20992749311	do	do	VDI
304953	100736365	20992749312	more	more	DAR
304953	100736365	20992749313	harm	harm	NN1
304953	100736365	20992749314	than	than	CSN
304953	100736365	20992749315	good	good	JJ
304953	100736365	20992749316	.	.	.
304953	100736365	20992749317	<p>		NULL
304953	100736365	20992749318	Two	two	MC
304953	100736365	20992749319	much-anticipated	much-anticipated	JJ
304953	100736365	20992749320	studies	study	NN2
304953	100736365	20992749321	,	,	,
304953	100736365	20992749322	the	the	AT
304953	100736365	20992749323	results	result	NN2
304953	100736365	20992749324	of	of	IO
304953	100736365	20992749325	which	which	DDQ
304953	100736365	20992749326	were	be	VBDR
304953	100736365	20992749327	released	release	VVN
304953	100736365	20992749328	last	last	MD
304953	100736365	20992749329	month	month	NNT1
304953	100736365	20992749330	,	,	,
304953	100736365	20992749331	were	be	VBDR
304953	100736365	20992749332	hopefully	hopefully	RR
304953	100736365	20992749333	going	go	VVGK
304953	100736365	20992749334	to	to	TO
304953	100736365	20992749335	settle	settle	VVI
304953	100736365	20992749336	the	the	AT
304953	100736365	20992749337	debate	debate	NN1
304953	100736365	20992749338	over	over	II
304953	100736365	20992749339	the	the	AT
304953	100736365	20992749340	value	value	NN1
304953	100736365	20992749341	of	of	IO
304953	100736365	20992749342	the	the	AT
304953	100736365	20992749343	PSA	psa	NP1
304953	100736365	20992749344	.	.	.
304953	100736365	20992749345	While	while	CS
304953	100736365	20992749346	they	they	PPHS2
304953	100736365	20992749347	give	give	VV0
304953	100736365	20992749348	us	us	PPIO2
304953	100736365	20992749349	some	some	DD
304953	100736365	20992749350	much-needed	much-needed	JJ
304953	100736365	20992749351	answers	answer	NN2
304953	100736365	20992749352	,	,	,
304953	100736365	20992749353	we	we	PPIS2
304953	100736365	20992749354	are	be	VBR
304953	100736365	20992749355	still	still	RR
304953	100736365	20992749356	a	a	AT1
304953	100736365	20992749357	long	long	JJ
304953	100736365	20992749358	way	way	NN1
304953	100736365	20992749359	from	from	II
304953	100736365	20992749360	settling	settle	VVG
304953	100736365	20992749361	the	the	AT
304953	100736365	20992749362	debate	debate	NN1
304953	100736365	20992749363	:	:	:
304953	100736365	20992749364	Does	do	VDZ
304953	100736365	20992749365	PSA	psa	NP1
304953	100736365	20992749366	screening	screening	NN1_VVG
304953	100736365	20992749367	save	save	II@_VV0
304953	100736365	20992749368	lives	life	NN2
304953	100736365	20992749369	by	by	II
304953	100736365	20992749370	allowing	allow	VVG
304953	100736365	20992749371	doctors	doctor	NN2
304953	100736365	20992749372	to	to	TO
304953	100736365	20992749373	treat	treat	VVI
304953	100736365	20992749374	aggressive	aggressive	JJ
304953	100736365	20992749375	cancers	cancer	NN2
304953	100736365	20992749376	early	early	RR
304953	100736365	20992749377	,	,	,
304953	100736365	20992749378	or	or	CC
304953	100736365	20992749379	does	do	VDZ
304953	100736365	20992749380	it	it	PPH1
304953	100736365	20992749381	harm	harm	VVI
304953	100736365	20992749382	men	man	NN2
304953	100736365	20992749383	who	who	PNQS
304953	100736365	20992749384	would	would	VM
304953	100736365	20992749385	never	never	RR
304953	100736365	20992749386	die	die	VVI
304953	100736365	20992749387	from	from	II
304953	100736365	20992749388	the	the	AT
304953	100736365	20992749389	disease	disease	NN1
304953	100736365	20992749390	by	by	II
304953	100736365	20992749391	subjecting	subject	VVG
304953	100736365	20992749392	them	them	PPHO2
304953	100736365	20992749393	to	to	II
304953	100736365	20992749394	the	the	AT
304953	100736365	20992749395	side	side	NN1
304953	100736365	20992749396	effects	effect	NN2
304953	100736365	20992749397	of	of	IO
304953	100736365	20992749398	surgery	surgery	NN1
304953	100736365	20992749399	,	,	,
304953	100736365	20992749400	radiation	radiation	NN1
304953	100736365	20992749401	,	,	,
304953	100736365	20992749402	and/or	and/or	CC
304953	100736365	20992749403	hormone	hormone	NN1
304953	100736365	20992749404	therapy	therapy	NN1
304953	100736365	20992749405	?	?	?
304953	100736365	20992749406	<h>		NULL
304953	100736365	20992749407	The	the	AT
304953	100736365	20992749408	upside	upside	NN1
304953	100736365	20992749409	and	and	CC
304953	100736365	20992749410	downside	downside	NN1
304953	100736365	20992749411	of	of	IO
304953	100736365	20992749412	the	the	AT
304953	100736365	20992749413	PSA	psa	NP1
304953	100736365	20992749414	test	test	NN1_VV0
304953	100736365	20992749415	<p>		NULL
304953	100736365	20992749416	Most	most	DAT
304953	100736365	20992749417	men	man	NN2
304953	100736365	20992749418	in	in	II
304953	100736365	20992749419	the	the	AT
304953	100736365	20992749420	United	united	NP1
304953	100736365	20992749421	States	state	NP1
304953	100736365	20992749422	over	over	II
304953	100736365	20992749423	age	age	NN1
304953	100736365	20992749424	50	50	MC
304953	100736365	20992749425	get	get	VV0
304953	100736365	20992749426	the	the	AT
304953	100736365	20992749427	test	test	NN1
304953	100736365	20992749428	,	,	,
304953	100736365	20992749429	which	which	DDQ
304953	100736365	20992749430	was	be	VBDZ
304953	100736365	20992749431	approved	approve	VVN
304953	100736365	20992749432	by	by	II
304953	100736365	20992749433	the	the	AT
304953	100736365	20992749434	F.D.A.		NP1
304953	100736365	20992749435	in	in	II
304953	100736365	20992749436	1994	1994	MC
304953	100736365	20992749437	.	.	.
304953	100736365	20992749438	Many	many	DA2
304953	100736365	20992749439	men	man	NN2
304953	100736365	20992749440	@		II
304953	100736365	20992749441	@		II
304953	100736365	20992749442	@		II
304953	100736365	20992749443	@		II
304953	100736365	20992749444	@		II
304953	100736365	20992749445	@		II
304953	100736365	20992749446	@		II
304953	100736365	20992749447	@		II
304953	100736365	20992749448	@		II
304953	100736365	20992749449	@		II
304953	100736365	20992749450	we	we	PPIS2
304953	100736365	20992749451	value	value	VV0%
304953	100736365	20992749452	the	the	AT
304953	100736365	20992749453	early	early	JJ
304953	100736365	20992749454	diagnosis	diagnosis	NN1
304953	100736365	20992749455	of	of	IO
304953	100736365	20992749456	cancer	cancer	NN1
304953	100736365	20992749457	along	along	II21
304953	100736365	20992749458	with	with	II22
304953	100736365	20992749459	the	the	AT
304953	100736365	20992749460	prompt	prompt	NN1_JJ
304953	100736365	20992749461	and	and	CC
304953	100736365	20992749462	often	often	RR
304953	100736365	20992749463	aggressive	aggressive	JJ
304953	100736365	20992749464	treatments	treatment	NN2
304953	100736365	20992749465	that	that	CST
304953	100736365	20992749466	follow	follow	VV0
304953	100736365	20992749467	.	.	.
304953	100736365	20992749468	<h>		NULL
304953	100736365	20992749469	The	the	AT
304953	100736365	20992749470	big	big	JJ
304953	100736365	20992749471	picture	picture	NN1
304953	100736365	20992749472	<p>		NULL
304953	100736365	20992749473	Prostate	prostate	NN1
304953	100736365	20992749474	cancer	cancer	NN1
304953	100736365	20992749475	is	be	VBZ
304953	100736365	20992749476	extremely	extremely	RR
304953	100736365	20992749477	common	common	JJ
304953	100736365	20992749478	.	.	.
304953	100736365	20992749479	here 's		NN2_NP1@
304953	100736365	20992749480	a	a	AT1
304953	100736365	20992749481	look	look	NN1
304953	100736365	20992749482	at	at	II
304953	100736365	20992749483	the	the	AT
304953	100736365	20992749484	numbers	number	NN2
304953	100736365	20992749485	:	:	:
304953	100736365	20992749486	<p>		NULL
304953	100736365	20992749487	About	about	RG
304953	100736365	20992749488	17%		NNU
304953	100736365	20992749489	of	of	IO
304953	100736365	20992749490	American	american	JJ
304953	100736365	20992749491	men	man	NN2
304953	100736365	20992749492	will	will	VM
304953	100736365	20992749493	be	be	VBI
304953	100736365	20992749494	diagnosed	diagnose	VVN
304953	100736365	20992749495	with	with	IW
304953	100736365	20992749496	prostate	prostate	NN1
304953	100736365	20992749497	cancer	cancer	NN1
304953	100736365	20992749498	during	during	II
304953	100736365	20992749499	the	the	AT
304953	100736365	20992749500	course	course	NN1
304953	100736365	20992749501	of	of	IO
304953	100736365	20992749502	their	their	APPGE
304953	100736365	20992749503	lifetimes	lifetime	NNT2
304953	100736365	20992749504	.	.	.
304953	100736365	20992749505	<p>		NULL
304953	100736365	20992749506	The	the	AT
304953	100736365	20992749507	typical	typical	JJ
304953	100736365	20992749508	American	american	JJ
304953	100736365	20992749509	man	man	NN1
304953	100736365	20992749510	has	have	VHZ
304953	100736365	20992749511	just	just	RR
304953	100736365	20992749512	a	a	AT1
304953	100736365	20992749513	3%		NNU
304953	100736365	20992749514	chance	chance	NN1
304953	100736365	20992749515	of	of	IO
304953	100736365	20992749516	dying	die	VVG_JJ
304953	100736365	20992749517	from	from	II
304953	100736365	20992749518	prostate	prostate	NN1
304953	100736365	20992749519	cancer	cancer	NN1
304953	100736365	20992749520	.	.	.
304953	100736365	20992749521	In	in	II
304953	100736365	20992749522	other	other	JJ
304953	100736365	20992749523	words	word	NN2
304953	100736365	20992749524	,	,	,
304953	100736365	20992749525	only	only	JJ
304953	100736365	20992749526	about	about-	RG
304953	100736365	20992749527	one	one	MC1
304953	100736365	20992749528	of	of	IO
304953	100736365	20992749529	every	every	AT1
304953	100736365	20992749530	six	six	MC
304953	100736365	20992749531	clinically	clinically	RR
304953	100736365	20992749532	diagnosed	diagnose	VVN_VVD
304953	100736365	20992749533	prostate	prostate	NN1
304953	100736365	20992749534	cancers	cancer	NN2
304953	100736365	20992749535	will	will	VM
304953	100736365	20992749536	be	be	VBI
304953	100736365	20992749537	fatal	fatal	JJ
304953	100736365	20992749538	.	.	.
304953	100736365	20992749539	<p>		NULL
304953	100736365	20992749540	Many	many	DA2
304953	100736365	20992749541	prostate	prostate	NN1
304953	100736365	20992749542	cancers	cancer	NN2
304953	100736365	20992749543	never	never	RR
304953	100736365	20992749544	even	even	RR
304953	100736365	20992749545	become	become	VV0
304953	100736365	20992749546	large	large	JJ
304953	100736365	20992749547	enough	enough	RR
304953	100736365	20992749548	or	or	CC
304953	100736365	20992749549	troublesome	troublesome	JJ
304953	100736365	20992749550	enough	enough	RR
304953	100736365	20992749551	to	to	TO
304953	100736365	20992749552	be	be	VBI
304953	100736365	20992749553	diagnosed	diagnose	VVN
304953	100736365	20992749554	clinically	clinically	RR
304953	100736365	20992749555	.	.	.
304953	100736365	20992749556	<p>		NULL
304953	100736365	20992749557	The	the	AT
304953	100736365	20992749558	PSA	psa	NP1
304953	100736365	20992749559	ca n't		NN1
304953	100736365	20992749560	tell	tell	VV0
304953	100736365	20992749561	the	the	AT
304953	100736365	20992749562	difference	difference	NN1
304953	100736365	20992749563	between	between	II
304953	100736365	20992749564	the	the	AT
304953	100736365	20992749565	slow	slow	JJ
304953	100736365	20992749566	growing	growing	JJ_NN1@
304953	100736365	20992749567	,	,	,
304953	100736365	20992749568	harmless	harmless	JJ
304953	100736365	20992749569	prostate	prostate	NN1
304953	100736365	20992749570	cancers	cancer	NN2
304953	100736365	20992749571	and	and	CC
304953	100736365	20992749572	the	the	AT
304953	100736365	20992749573	less	less	RGR
304953	100736365	20992749574	common	common	JJ
304953	100736365	20992749575	,	,	,
304953	100736365	20992749576	aggressive	aggressive	JJ
304953	100736365	20992749577	,	,	,
304953	100736365	20992749578	potentially	potentially	RR
304953	100736365	20992749579	deadly	deadly	JJ
304953	100736365	20992749580	tumors	tumor	NN2
304953	100736365	20992749581	.	.	.
304953	100736365	20992749582	In	in	II
304953	100736365	20992749583	fact	fact	NN1
304953	100736365	20992749584	,	,	,
304953	100736365	20992749585	the	the	AT
304953	100736365	20992749586	PSA	psa	NP1
304953	100736365	20992749587	cant	cant	NN1_JJ
304953	100736365	20992749588	even	even	RR
304953	100736365	20992749589	diagnose	diagnose	VV0
304953	100736365	20992749590	cancer	cancer	NN1
304953	100736365	20992749591	.	.	.
304953	100736365	20992749592	Instead	instead	RR
304953	100736365	20992749593	,	,	,
304953	100736365	20992749594	depending	depending	II21
304953	100736365	20992749595	on	on	II22
304953	100736365	20992749596	the	the	AT
304953	100736365	20992749597	score	score	NN1
304953	100736365	20992749598	,	,	,
304953	100736365	20992749599	it	it	PPH1
304953	100736365	20992749600	can	can	VM
304953	100736365	20992749601	lead	lead	VVI
304953	100736365	20992749602	to	to	II
304953	100736365	20992749603	a	a	AT1
304953	100736365	20992749604	prostate	prostate	NN1
304953	100736365	20992749605	biopsy	biopsy	NN1
304953	100736365	20992749606	,	,	,
304953	100736365	20992749607	which	which	DDQ
304953	100736365	20992749608	is	be	VBZ
304953	100736365	20992749609	the	the	AT
304953	100736365	20992749610	only	only	JJ
304953	100736365	20992749611	way	way	NN1
304953	100736365	20992749612	to	to	TO
304953	100736365	20992749613	detect	detect	VVI
304953	100736365	20992749614	the	the	AT
304953	100736365	20992749615	cancer	cancer	NN1
304953	100736365	20992749616	.	.	.
304953	100736365	20992749617	If	if	CS
304953	100736365	20992749618	doctors	doctor	NN2
304953	100736365	20992749619	see	see	VV0
304953	100736365	20992749620	cancer	cancer	NN1
304953	100736365	20992749621	cells	cell	NN2
304953	100736365	20992749622	in	in	II
304953	100736365	20992749623	the	the	AT
304953	100736365	20992749624	tissue	tissue	NN1
304953	100736365	20992749625	sample	sample	NN1
304953	100736365	20992749626	,	,	,
304953	100736365	20992749627	they	they	PPHS2
304953	100736365	20992749628	try	try	VV0
304953	100736365	20992749629	to	to	TO
304953	100736365	20992749630	estimate	estimate	VVI
304953	100736365	20992749631	how	how	RGQ@_RRQ
304953	100736365	20992749632	aggressive	aggressive	JJ
304953	100736365	20992749633	the	the	AT
304953	100736365	20992749634	cancer	cancer	NN1
304953	100736365	20992749635	is	be	VBZ
304953	100736365	20992749636	based	base	VVN
304953	100736365	20992749637	on	on	II
304953	100736365	20992749638	its	its	APPGE
304953	100736365	20992749639	appearance	appearance	NN1
304953	100736365	20992749640	@		II
304953	100736365	20992749641	@		II
304953	100736365	20992749642	@		II
304953	100736365	20992749643	@		II
304953	100736365	20992749644	@		II
304953	100736365	20992749645	@		II
304953	100736365	20992749646	@		II
304953	100736365	20992749647	@		II
304953	100736365	20992749648	@		II
304953	100736365	20992749649	@		II
304953	100736365	20992749650	diagnosis	diagnosis	NN1
304953	100736365	20992749651	of	of	IO
304953	100736365	20992749652	aggressive	aggressive	JJ
304953	100736365	20992749653	prostate	prostate	NN1
304953	100736365	20992749654	cancers	cancer	NN2
304953	100736365	20992749655	can	can	VM
304953	100736365	20992749656	improve	improve	VVI
304953	100736365	20992749657	survival	survival	NN1
304953	100736365	20992749658	.	.	.
304953	100736365	20992749659	But	but	CCB
304953	100736365	20992749660	when	when	CS
304953	100736365	20992749661	screening	screening	NN1_VVG
304953	100736365	20992749662	finds	find	VVZ
304953	100736365	20992749663	cancers	cancer	NN2
304953	100736365	20992749664	that	that	CST_DD1
304953	100736365	20992749665	would	would	VM
304953	100736365	20992749666	never	never	RR
304953	100736365	20992749667	cause	cause	VVI
304953	100736365	20992749668	symptoms	symptom	NN2
304953	100736365	20992749669	or	or	CC
304953	100736365	20992749670	harm	harm	VV0_NN1
304953	100736365	20992749671	during	during	II
304953	100736365	20992749672	the	the	AT
304953	100736365	20992749673	patients	patient	NN2
304953	100736365	20992749674	lifetime	lifetime	NNT1
304953	100736365	20992749675	,	,	,
304953	100736365	20992749676	it	it	PPH1
304953	100736365	20992749677	results	result	VVZ@
304953	100736365	20992749678	in	in	II
304953	100736365	20992749679	the	the	AT
304953	100736365	20992749680	major	major	JJ
304953	100736365	20992749681	downside	downside	NN1
304953	100736365	20992749682	of	of	IO
304953	100736365	20992749683	PSA	psa	NP1
304953	100736365	20992749684	screening	screening	NN1_VVG
304953	100736365	20992749685	"	"	"
304953	100736365	20992749686	over-diagnosis		NN1
304953	100736365	20992749687	.	.	.
304953	100736365	20992749688	<p>		NULL
304953	100736365	20992749689	A	a	AT1
304953	100736365	20992749690	cancer	cancer	NN1
304953	100736365	20992749691	diagnosis	diagnosis	NN1
304953	100736365	20992749692	usually	usually	RR
304953	100736365	20992749693	leads	lead	VVZ
304953	100736365	20992749694	to	to	II
304953	100736365	20992749695	treatment	treatment	NN1
304953	100736365	20992749696	,	,	,
304953	100736365	20992749697	and	and	CC
304953	100736365	20992749698	all	all	DB
304953	100736365	20992749699	prostate	prostate	NN1
304953	100736365	20992749700	cancer	cancer	NN1
304953	100736365	20992749701	treatments	treatment	NN2
304953	100736365	20992749702	carry	carry	VV0
304953	100736365	20992749703	a	a	AT1
304953	100736365	20992749704	substantial	substantial	JJ
304953	100736365	20992749705	risk	risk	NN1
304953	100736365	20992749706	of	of	IO
304953	100736365	20992749707	side	side	NN1
304953	100736365	20992749708	effects	effect	NN2
304953	100736365	20992749709	.	.	.
304953	100736365	20992749710	These	these	DD2
304953	100736365	20992749711	may	may	VM
304953	100736365	20992749712	include	include	VVI
304953	100736365	20992749713	sexual	sexual	JJ
304953	100736365	20992749714	problems	problem	NN2
304953	100736365	20992749715	and	and	CC
304953	100736365	20992749716	urinary	urinary	JJ_NN1
304953	100736365	20992749717	incontinence	incontinence	NN1
304953	100736365	20992749718	.	.	.
304953	100736365	20992749719	As	as	II
304953	100736365	20992749720	a	a	AT1
304953	100736365	20992749721	result	result	NN1
304953	100736365	20992749722	,	,	,
304953	100736365	20992749723	diagnosing	diagnose	VVG
304953	100736365	20992749724	aggressive	aggressive	JJ
304953	100736365	20992749725	cancers	cancer	NN2
304953	100736365	20992749726	can	can	VM
304953	100736365	20992749727	be	be	VBI
304953	100736365	20992749728	lifesaving	lifesaving	VVG
304953	100736365	20992749729	,	,	,
304953	100736365	20992749730	but	but	CCB
304953	100736365	20992749731	diagnosing	diagnose	VVG
304953	100736365	20992749732	harmless	harmless	JJ
304953	100736365	20992749733	cancers	cancer	NN2
304953	100736365	20992749734	does	do	VDZ
304953	100736365	20992749735	more	more	RRR_DAR
304953	100736365	20992749736	damage	damage	VVI
304953	100736365	20992749737	than	than	CSN
304953	100736365	20992749738	good	good	JJ
304953	100736365	20992749739	.	.	.
304953	100736365	20992749740	<h>		NULL
304953	100736365	20992749741	The	the	AT
304953	100736365	20992749742	American	american	JJ
304953	100736365	20992749743	study	study	NN1
304953	100736365	20992749744	<p>		NULL
304953	100736365	20992749745	The	the	AT
304953	100736365	20992749746	Prostate	prostate	NN1
304953	100736365	20992749747	,	,	,
304953	100736365	20992749748	Lung	lung	NN1
304953	100736365	20992749749	,	,	,
304953	100736365	20992749750	Colorectal		NP1_JJ
304953	100736365	20992749751	,	,	,
304953	100736365	20992749752	and	and	CC
304953	100736365	20992749753	Ovarian	ovarian	JJ_NN1@
304953	100736365	20992749754	(	(	(
304953	100736365	20992749755	PLCO		NP1
304953	100736365	20992749756	)	)	)
304953	100736365	20992749757	Cancer	cancer	NN1
304953	100736365	20992749758	Screening	screening	NN1_VVG
304953	100736365	20992749759	Trial	trial	NN1
304953	100736365	20992749760	began	begin	VVD
304953	100736365	20992749761	in	in	II
304953	100736365	20992749762	1993	1993	MC
304953	100736365	20992749763	.	.	.
304953	100736365	20992749764	Over	over	II
304953	100736365	20992749765	the	the	AT
304953	100736365	20992749766	next	next	MD
304953	100736365	20992749767	eight	eight	MC
304953	100736365	20992749768	years	year	NNT2
304953	100736365	20992749769	,	,	,
304953	100736365	20992749770	76,693		MC
304953	100736365	20992749771	men	man	NN2
304953	100736365	20992749772	between	between	II
304953	100736365	20992749773	the	the	AT
304953	100736365	20992749774	ages	age	NN2
304953	100736365	20992749775	of	of	IO
304953	100736365	20992749776	55	55	MC
304953	100736365	20992749777	and	and	CC
304953	100736365	20992749778	74	74	MC
304953	100736365	20992749779	volunteered	volunteer	VVD_VVN
304953	100736365	20992749780	for	for	IF
304953	100736365	20992749781	the	the	AT
304953	100736365	20992749782	study	study	NN1
304953	100736365	20992749783	,	,	,
304953	100736365	20992749784	which	which	DDQ
304953	100736365	20992749785	took	take	VVD
304953	100736365	20992749786	place	place	NN1
304953	100736365	20992749787	at	at	II
304953	100736365	20992749788	10	10	MC
304953	100736365	20992749789	U.S.	us	NP1
304953	100736365	20992749790	medical	medical	JJ
304953	100736365	20992749791	centers	center	NN2
304953	100736365	20992749792	.	.	.
304953	100736365	20992749793	Scientists	scientist	NN2
304953	100736365	20992749794	randomly	randomly	RR
304953	100736365	20992749795	assigned	assign	VVN
304953	100736365	20992749796	half	half	DB
304953	100736365	20992749797	of	of	IO
304953	100736365	20992749798	the	the	AT
304953	100736365	20992749799	men	man	NN2
304953	100736365	20992749800	to	to	II
304953	100736365	20992749801	annual	annual	JJ
304953	100736365	20992749802	PSA	psa	NP1
304953	100736365	20992749803	testing	testing	NN1_VVG
304953	100736365	20992749804	for	for	IF
304953	100736365	20992749805	six	six	MC
304953	100736365	20992749806	years	year	NNT2
304953	100736365	20992749807	,	,	,
304953	100736365	20992749808	along	along	II21
304953	100736365	20992749809	with	with	II22
304953	100736365	20992749810	annual	annual	JJ
304953	100736365	20992749811	digital	digital	JJ
304953	100736365	20992749812	rectal	rectal	JJ
304953	100736365	20992749813	exams	exam	NN2
304953	100736365	20992749814	(	(	(
304953	100736365	20992749815	DRE	dre	NP1
304953	100736365	20992749816	)	)	)
304953	100736365	20992749817	for	for	IF
304953	100736365	20992749818	four	four	MC
304953	100736365	20992749819	years	year	NNT2
304953	100736365	20992749820	.	.	.
304953	100736365	20992749821	Men	man	NN2
304953	100736365	20992749822	with	with	IW
304953	100736365	20992749823	PSA-test		JJ
304953	100736365	20992749824	levels	level	NN2
304953	100736365	20992749825	above	above	II
304953	100736365	20992749826	4.0	4.0	MC
304953	100736365	20992749827	ng/ml	ng/ml	FU
304953	100736365	20992749828	or	or	CC
304953	100736365	20992749829	with	with	IW
304953	100736365	20992749830	abnormal	abnormal	JJ
304953	100736365	20992749831	DREs	dres	NN2_NP2
304953	100736365	20992749832	were	be	VBDR
304953	100736365	20992749833	advised	advise	VVN
304953	100736365	20992749834	to	to	TO
304953	100736365	20992749835	get	get	VVI
304953	100736365	20992749836	further	far	JJR@_RRR
304953	100736365	20992749837	evaluation	evaluation	NN1
304953	100736365	20992749838	.	.	.
304953	100736365	20992749839	This	this	DD1
304953	100736365	20992749840	@		II
304953	100736365	20992749841	@		II
304953	100736365	20992749842	@		II
304953	100736365	20992749843	@		II
304953	100736365	20992749844	@		II
304953	100736365	20992749845	@		II
304953	100736365	20992749846	@		II
304953	100736365	20992749847	@		II
304953	100736365	20992749848	@		II
304953	100736365	20992749849	@		II
304953	100736365	20992749850	group	group	NN1
304953	100736365	20992749851	continued	continue	VVD_VVN
304953	100736365	20992749852	to	to	TO
304953	100736365	20992749853	receive	receive	VVI
304953	100736365	20992749854	their	their	APPGE
304953	100736365	20992749855	usual	usual	JJ
304953	100736365	20992749856	medical	medical	JJ
304953	100736365	20992749857	care	care	NN1
304953	100736365	20992749858	.	.	.
304953	100736365	20992749859	Men	man	NN2
304953	100736365	20992749860	in	in	II
304953	100736365	20992749861	both	both	DB2
304953	100736365	20992749862	groups	group	NN2
304953	100736365	20992749863	who	who	PNQS
304953	100736365	20992749864	were	be	VBDR
304953	100736365	20992749865	diagnosed	diagnose	VVN
304953	100736365	20992749866	with	with	IW
304953	100736365	20992749867	prostate	prostate	NN1
304953	100736365	20992749868	cancer	cancer	NN1
304953	100736365	20992749869	were	be	VBDR
304953	100736365	20992749870	treated	treat	VVN
304953	100736365	20992749871	by	by	II
304953	100736365	20992749872	their	their	APPGE
304953	100736365	20992749873	personal	personal	JJ
304953	100736365	20992749874	physicians	physician	NN2
304953	100736365	20992749875	.	.	.
304953	100736365	20992749876	PLCO		NP1_NN1
304953	100736365	20992749877	researchers	researcher	NN2
304953	100736365	20992749878	found	find	VVD_VVN
304953	100736365	20992749879	that	that	CST
304953	100736365	20992749880	both	both	DB2
304953	100736365	20992749881	groups	group	NN2
304953	100736365	20992749882	had	have	VHD
304953	100736365	20992749883	similar	similar	JJ
304953	100736365	20992749884	treatments	treatment	NN2
304953	100736365	20992749885	.	.	.
304953	100736365	20992749886	<p>		NULL
304953	100736365	20992749887	After	after	II_CS
304953	100736365	20992749888	seven	seven	MC
304953	100736365	20992749889	years	year	NNT2
304953	100736365	20992749890	,	,	,
304953	100736365	20992749891	the	the	AT
304953	100736365	20992749892	researchers	researcher	NN2
304953	100736365	20992749893	found	find	VVD_VVN
304953	100736365	20992749894	22%		NNU
304953	100736365	20992749895	more	more	DAR
304953	100736365	20992749896	cases	case	NN2
304953	100736365	20992749897	of	of	IO
304953	100736365	20992749898	prostate	prostate	NN1
304953	100736365	20992749899	cancer	cancer	NN1
304953	100736365	20992749900	in	in	II
304953	100736365	20992749901	the	the	AT
304953	100736365	20992749902	men	man	NN2
304953	100736365	20992749903	who	who	PNQS
304953	100736365	20992749904	had	have	VHD
304953	100736365	20992749905	regular	regular	JJ
304953	100736365	20992749906	PSA	psa	NP1
304953	100736365	20992749907	screening	screening	NN1_VVG
304953	100736365	20992749908	.	.	.
304953	100736365	20992749909	Even	even	CS21
304953	100736365	20992749910	though	though	CS22
304953	100736365	20992749911	PSA	psa	NP1
304953	100736365	20992749912	screening	screening	NN1
304953	100736365	20992749913	increased	increase	VVD_VVN
304953	100736365	20992749914	the	the	AT
304953	100736365	20992749915	diagnosis	diagnosis	NN1
304953	100736365	20992749916	of	of	IO
304953	100736365	20992749917	prostate	prostate	NN1
304953	100736365	20992749918	cancer	cancer	NN1
304953	100736365	20992749919	,	,	,
304953	100736365	20992749920	it	it	PPH1
304953	100736365	20992749921	did	do	VDD
304953	100736365	20992749922	not	not	XX
304953	100736365	20992749923	improve	improve	VVI
304953	100736365	20992749924	survival	survival	NN1
304953	100736365	20992749925	.	.	.
304953	100736365	20992749926	There	there	EX
304953	100736365	20992749927	were	be	VBDR
304953	100736365	20992749928	no	no	AT
304953	100736365	20992749929	real	real	JJ
304953	100736365	20992749930	differences	difference	NN2
304953	100736365	20992749931	in	in	II
304953	100736365	20992749932	the	the	AT
304953	100736365	20992749933	numbers	number	NN2
304953	100736365	20992749934	of	of	IO
304953	100736365	20992749935	deaths	death	NN2
304953	100736365	20992749936	in	in	II
304953	100736365	20992749937	the	the	AT
304953	100736365	20992749938	two	two	MC
304953	100736365	20992749939	groups	group	NN2
304953	100736365	20992749940	.	.	.
304953	100736365	20992749941	About	about	II
304953	100736365	20992749942	two-thirds	two-thirds	MF
304953	100736365	20992749943	of	of	IO
304953	100736365	20992749944	the	the	AT
304953	100736365	20992749945	men	man	NN2
304953	100736365	20992749946	have	have	VH0
304953	100736365	20992749947	completed	complete	VVN
304953	100736365	20992749948	another	another	DD1
304953	100736365	20992749949	three	three	MC
304953	100736365	20992749950	years	year	NNT2
304953	100736365	20992749951	of	of	IO
304953	100736365	20992749952	follow-up	follow-up	NN1_JJ
304953	100736365	20992749953	in	in	II
304953	100736365	20992749954	this	this	DD1
304953	100736365	20992749955	ongoing	ongoing	JJ
304953	100736365	20992749956	study	study	NN1
304953	100736365	20992749957	.	.	.
304953	100736365	20992749958	The	the	AT
304953	100736365	20992749959	results	result	NN2
304953	100736365	20992749960	at	at	II
304953	100736365	20992749961	10	10	MC
304953	100736365	20992749962	years	year	NNT2
304953	100736365	20992749963	are	be	VBR
304953	100736365	20992749964	similar	similar	JJ
304953	100736365	20992749965	to	to	II
304953	100736365	20992749966	the	the	AT
304953	100736365	20992749967	previous	previous	JJ
304953	100736365	20992749968	findings	finding	NN2
304953	100736365	20992749969	.	.	.
304953	100736365	20992749970	<p>		NULL
304953	100736365	20992749971	The	the	AT
304953	100736365	20992749972	PLCO		NN1_NP1
304953	100736365	20992749973	study	study	NN1
304953	100736365	20992749974	will	will	VM
304953	100736365	20992749975	continue	continue	VVI
304953	100736365	20992749976	until	until	CS_II@
304953	100736365	20992749977	all	all	DB
304953	100736365	20992749978	the	the	AT
304953	100736365	20992749979	volunteers	volunteer	NN2
304953	100736365	20992749980	have	have	VH0
304953	100736365	20992749981	been	be	VBN
304953	100736365	20992749982	evaluated	evaluate	VVN
304953	100736365	20992749983	for	for	IF
304953	100736365	20992749984	13	13	MC
304953	100736365	20992749985	years	year	NNT2
304953	100736365	20992749986	.	.	.
304953	100736365	20992749987	Researchers	researcher	NN2
304953	100736365	20992749988	are	be	VBR
304953	100736365	20992749989	compiling	compile	VVG
304953	100736365	20992749990	information	information	NN1
304953	100736365	20992749991	on	on	II
304953	100736365	20992749992	treatment	treatment	NN1
304953	100736365	20992749993	side	side	NN1
304953	100736365	20992749994	effects	effect	NN2
304953	100736365	20992749995	and	and	CC
304953	100736365	20992749996	quality	quality	NN1
304953	100736365	20992749997	of	of	IO
304953	100736365	20992749998	life	life	NN1
304953	100736365	20992749999	along	along	II21
304953	100736365	20992750000	with	with	II22
304953	100736365	20992750001	additional	additional	JJ
304953	100736365	20992750002	deaths	death	NN2
304953	100736365	20992750003	.	.	.
304953	100736365	20992750004	<h>		NULL
304953	100736365	20992750005	The	the	AT
304953	100736365	20992750006	European	european	JJ
304953	100736365	20992750007	study	study	NN1
304953	100736365	20992750008	<p>		NULL
304953	100736365	20992750009	Like	like	II
304953	100736365	20992750010	the	the	AT
304953	100736365	20992750011	American	american	JJ
304953	100736365	20992750012	study	study	NN1
304953	100736365	20992750013	,	,	,
304953	100736365	20992750014	the	the	AT
304953	100736365	20992750015	European	european	JJ_NN1
304953	100736365	20992750016	Randomized	randomized	JJ
304953	100736365	20992750017	Study	study	NN1
304953	100736365	20992750018	of	of	IO
304953	100736365	20992750019	Screening	screen	VVG_NN1
304953	100736365	20992750020	for	for	IF
304953	100736365	20992750021	Prostate	prostate	NN1
304953	100736365	20992750022	Cancer	cancer	NN1
304953	100736365	20992750023	(	(	(
304953	100736365	20992750024	ERSPC		NP1
304953	100736365	20992750025	)	)	)
304953	100736365	20992750026	began	begin	VVD
304953	100736365	20992750027	in	in	II
304953	100736365	20992750028	the	the	AT
304953	100736365	20992750029	early	early	JJ
304953	100736365	20992750030	1990s	1990s	MC2
304953	100736365	20992750031	.	.	.
304953	100736365	20992750032	The	the	AT
304953	100736365	20992750033	study	study	NN1
304953	100736365	20992750034	enrolled	enroll	VVD_VVN
304953	100736365	20992750035	162,243		MC
304953	100736365	20992750036	men	man	NN2
304953	100736365	20992750037	between	between	II
304953	100736365	20992750038	the	the	AT
304953	100736365	20992750039	ages	age	NN2
304953	100736365	20992750040	@		II
304953	100736365	20992750041	@		II
304953	100736365	20992750042	@		II
304953	100736365	20992750043	@		II
304953	100736365	20992750044	@		II
304953	100736365	20992750045	@		II
304953	100736365	20992750046	@		II
304953	100736365	20992750047	@		II
304953	100736365	20992750048	@		II
304953	100736365	20992750049	@		II
304953	100736365	20992750050	the	the	AT
304953	100736365	20992750051	men	man	NN2
304953	100736365	20992750052	to	to	TO
304953	100736365	20992750053	receive	receive	VVI
304953	100736365	20992750054	PSA	psa	NP1
304953	100736365	20992750055	screening	screening	NN1_VVG
304953	100736365	20992750056	.	.	.
304953	100736365	20992750057	The	the	AT
304953	100736365	20992750058	other	other	JJ
304953	100736365	20992750059	half	half	NN1@_DB_RR@
304953	100736365	20992750060	had	have	VHD_VHN@
304953	100736365	20992750061	their	their	APPGE
304953	100736365	20992750062	usual	usual	JJ
304953	100736365	20992750063	medical	medical	JJ
304953	100736365	20992750064	care	care	NN1
304953	100736365	20992750065	.	.	.
304953	100736365	20992750066	The	the	AT
304953	100736365	20992750067	study	study	NN1
304953	100736365	20992750068	took	take	VVD
304953	100736365	20992750069	place	place	NN1
304953	100736365	20992750070	at	at	II
304953	100736365	20992750071	medical	medical	JJ
304953	100736365	20992750072	centers	center	NN2
304953	100736365	20992750073	in	in	II
304953	100736365	20992750074	seven	seven	MC
304953	100736365	20992750075	countries	country	NN2
304953	100736365	20992750076	.	.	.
304953	100736365	20992750077	PSA	psa	NP1
304953	100736365	20992750078	screening	screening	NN1
304953	100736365	20992750079	was	be	VBDZ
304953	100736365	20992750080	performed	perform	VVN
304953	100736365	20992750081	an	a	AT1
304953	100736365	20992750082	average	average	NN1
304953	100736365	20992750083	of	of	IO
304953	100736365	20992750084	once	once	RR
304953	100736365	20992750085	every	every	AT1
304953	100736365	20992750086	four	four	MC
304953	100736365	20992750087	years	year	NNT2
304953	100736365	20992750088	.	.	.
304953	100736365	20992750089	Men	man	NN2
304953	100736365	20992750090	with	with	IW
304953	100736365	20992750091	values	value	NN2
304953	100736365	20992750092	of	of	IO
304953	100736365	20992750093	3.0	3.0	MC
304953	100736365	20992750094	ng/ml	ng/ml	FU
304953	100736365	20992750095	or	or	CC
304953	100736365	20992750096	above	above	II_RL_JJ@
304953	100736365	20992750097	received	received	JJ@_VVD_VVN
304953	100736365	20992750098	prostate	prostate	NN1
304953	100736365	20992750099	biopsies	biopsy	NN2
304953	100736365	20992750100	.	.	.
304953	100736365	20992750101	Men	man	NN2
304953	100736365	20992750102	who	who	PNQS
304953	100736365	20992750103	were	be	VBDR
304953	100736365	20992750104	diagnosed	diagnose	VVN
304953	100736365	20992750105	with	with	IW
304953	100736365	20992750106	prostate	prostate	NN1
304953	100736365	20992750107	cancer	cancer	NN1
304953	100736365	20992750108	were	be	VBDR
304953	100736365	20992750109	treated	treat	VVN
304953	100736365	20992750110	by	by	II
304953	100736365	20992750111	their	their	APPGE
304953	100736365	20992750112	own	own	DA
304953	100736365	20992750113	physicians	physician	NN2
304953	100736365	20992750114	according	according	II21
304953	100736365	20992750115	to	to	II22
304953	100736365	20992750116	local	local	JJ
304953	100736365	20992750117	guidelines	guideline	NN2
304953	100736365	20992750118	.	.	.
304953	100736365	20992750119	<p>		NULL
304953	100736365	20992750120	After	after	CS
304953	100736365	20992750121	about	about	RG
304953	100736365	20992750122	9	9	MC
304953	100736365	20992750123	years	year	NNT2
304953	100736365	20992750124	of	of	IO
304953	100736365	20992750125	observation	observation	NN1
304953	100736365	20992750126	,	,	,
304953	100736365	20992750127	214	214	MC
304953	100736365	20992750128	men	man	NN2
304953	100736365	20992750129	in	in	II
304953	100736365	20992750130	the	the	AT
304953	100736365	20992750131	PSA	psa	NP1
304953	100736365	20992750132	screening	screening	NN1_VVG
304953	100736365	20992750133	group	group	NN1
304953	100736365	20992750134	and	and	CC
304953	100736365	20992750135	326	326	MC
304953	100736365	20992750136	men	man	NN2
304953	100736365	20992750137	in	in	II
304953	100736365	20992750138	the	the	AT
304953	100736365	20992750139	comparison	comparison	NN1
304953	100736365	20992750140	group	group	NN1
304953	100736365	20992750141	had	have	VHD
304953	100736365	20992750142	died	die	VVN
304953	100736365	20992750143	from	from	II
304953	100736365	20992750144	prostate	prostate	NN1
304953	100736365	20992750145	cancer	cancer	NN1
304953	100736365	20992750146	.	.	.
304953	100736365	20992750147	This	this	DD1
304953	100736365	20992750148	means	mean	VVZ
304953	100736365	20992750149	that	that	DD1_CST
304953	100736365	20992750150	screening	screening	NN1
304953	100736365	20992750151	reduced	reduce	VVD_VVN
304953	100736365	20992750152	the	the	AT
304953	100736365	20992750153	relative	relative	JJ_NN1
304953	100736365	20992750154	risk	risk	NN1
304953	100736365	20992750155	of	of	IO
304953	100736365	20992750156	dying	die	VVG_JJ
304953	100736365	20992750157	from	from	II
304953	100736365	20992750158	prostate	prostate	NN1
304953	100736365	20992750159	cancer	cancer	NN1
304953	100736365	20992750160	by	by	II
304953	100736365	20992750161	20%		NNU
304953	100736365	20992750162	.	.	.
304953	100736365	20992750163	Heres		NN2
304953	100736365	20992750164	what	what	DDQ
304953	100736365	20992750165	this	this	DD1
304953	100736365	20992750166	means	mean	VVZ
304953	100736365	20992750167	to	to	II
304953	100736365	20992750168	you	you	PPY
304953	100736365	20992750169	in	in	II
304953	100736365	20992750170	actual	actual	JJ
304953	100736365	20992750171	numbers	number	NN2
304953	100736365	20992750172	.	.	.
304953	100736365	20992750173	The	the	AT
304953	100736365	20992750174	risk	risk	NN1
304953	100736365	20992750175	of	of	IO
304953	100736365	20992750176	dying	die	VVG_JJ
304953	100736365	20992750177	from	from	II
304953	100736365	20992750178	prostate	prostate	NN1
304953	100736365	20992750179	cancer	cancer	NN1
304953	100736365	20992750180	is	be	VBZ
304953	100736365	20992750181	3	3	MC
304953	100736365	20992750182	in	in	II
304953	100736365	20992750183	100	100	MC
304953	100736365	20992750184	(	(	(
304953	100736365	20992750185	3%		NNU
304953	100736365	20992750186	)	)	)
304953	100736365	20992750187	for	for	IF
304953	100736365	20992750188	the	the	AT
304953	100736365	20992750189	typical	typical	JJ
304953	100736365	20992750190	American	american	JJ
304953	100736365	20992750191	man	man	NN1
304953	100736365	20992750192	.	.	.
304953	100736365	20992750193	A	a	ZZ1_AT1
304953	100736365	20992750194	20%		NNU
304953	100736365	20992750195	reduction	reduction	NN1
304953	100736365	20992750196	means	mean	VVZ
304953	100736365	20992750197	that	that	CST_DD1
304953	100736365	20992750198	with	with	IW
304953	100736365	20992750199	screening	screening	NN1_VVG
304953	100736365	20992750200	,	,	,
304953	100736365	20992750201	the	the	AT
304953	100736365	20992750202	risk	risk	NN1
304953	100736365	20992750203	drops	drop	VVZ_NN2
304953	100736365	20992750204	to	to	II
304953	100736365	20992750205	2.4	2.4	MC
304953	100736365	20992750206	in	in	II
304953	100736365	20992750207	100	100	MC
304953	100736365	20992750208	(	(	(
304953	100736365	20992750209	2.4%	2.4%	FO
304953	100736365	20992750210	)	)	)
304953	100736365	20992750211	.	.	.
304953	100736365	20992750212	<p>		NULL
304953	100736365	20992750213	This	this	DD1
304953	100736365	20992750214	very	very	RG
304953	100736365	20992750215	modest	modest	JJ
304953	100736365	20992750216	benefit	benefit	NN1
304953	100736365	20992750217	came	come	VVD
304953	100736365	20992750218	at	at	II
304953	100736365	20992750219	a	a	AT1
304953	100736365	20992750220	steep	steep	JJ
304953	100736365	20992750221	price	price	NN1
304953	100736365	20992750222	:	:	:
304953	100736365	20992750223	An	a	AT1
304953	100736365	20992750224	additional	additional	JJ
304953	100736365	20992750225	48	48	MC
304953	100736365	20992750226	men	man	NN2
304953	100736365	20992750227	who	who	PNQS
304953	100736365	20992750228	were	be	VBDR
304953	100736365	20992750229	not	not	XX
304953	100736365	20992750230	at	at	II
304953	100736365	20992750231	risk	risk	NN1
304953	100736365	20992750232	of	of	IO
304953	100736365	20992750233	dying	die	VVG_JJ
304953	100736365	20992750234	from	from	II
304953	100736365	20992750235	prostate	prostate	NN1
304953	100736365	20992750236	cancer	cancer	NN1
304953	100736365	20992750237	had	have	VHD
304953	100736365	20992750238	to	to	TO
304953	100736365	20992750239	be	be	VBI
304953	100736365	20992750240	@		II
304953	100736365	20992750241	@		II
304953	100736365	20992750242	@		II
304953	100736365	20992750243	@		II
304953	100736365	20992750244	@		II
304953	100736365	20992750245	@		II
304953	100736365	20992750246	@		II
304953	100736365	20992750247	@		II
304953	100736365	20992750248	@		II
304953	100736365	20992750249	@		II
304953	100736365	20992750250	The	the	AT
304953	100736365	20992750251	ERSCP		NN1_NP1
304953	100736365	20992750252	scientists	scientist	NN2
304953	100736365	20992750253	will	will	VM
304953	100736365	20992750254	continue	continue	VVI
304953	100736365	20992750255	to	to	TO
304953	100736365	20992750256	monitor	monitor	VVI
304953	100736365	20992750257	the	the	AT
304953	100736365	20992750258	deaths	death	NN2
304953	100736365	20992750259	from	from	II
304953	100736365	20992750260	prostate	prostate	NN1
304953	100736365	20992750261	cancer	cancer	NN1
304953	100736365	20992750262	,	,	,
304953	100736365	20992750263	treatment	treatment	NN1
304953	100736365	20992750264	side	side	NN1
304953	100736365	20992750265	effects	effect	NN2
304953	100736365	20992750266	and	and	CC
304953	100736365	20992750267	quality	quality	NN1
304953	100736365	20992750268	of	of	IO
304953	100736365	20992750269	life	life	NN1
304953	100736365	20992750270	for	for	IF
304953	100736365	20992750271	the	the	AT
304953	100736365	20992750272	men	man	NN2
304953	100736365	20992750273	.	.	.
304953	100736365	20992750274	<h>		NULL
304953	100736365	20992750275	Should	should	VM
304953	100736365	20992750276	I	i	PPIS1
304953	100736365	20992750277	have	have	VHI
304953	100736365	20992750278	a	a	AT1
304953	100736365	20992750279	PSA	psa	NP1
304953	100736365	20992750280	test	test	NN1_VV0
304953	100736365	20992750281	?	?	?
304953	100736365	20992750282	<p>		NULL
304953	100736365	20992750283	Despite	despite	II
304953	100736365	20992750284	these	these	DD2
304953	100736365	20992750285	major	major	JJ
304953	100736365	20992750286	new	new	JJ
304953	100736365	20992750287	studies	study	NN2
304953	100736365	20992750288	,	,	,
304953	100736365	20992750289	PSA	psa	NP1
304953	100736365	20992750290	testing	testing	NN1
304953	100736365	20992750291	remains	remain	VVZ
304953	100736365	20992750292	a	a	AT1
304953	100736365	20992750293	personal	personal	JJ
304953	100736365	20992750294	decision	decision	NN1
304953	100736365	20992750295	.	.	.
304953	100736365	20992750296	But	but	CCB
304953	100736365	20992750297	things	thing	NN2
304953	100736365	20992750298	have	have	VH0
304953	100736365	20992750299	changed	change	VVN
304953	100736365	20992750300	.	.	.
304953	100736365	20992750301	<p>		NULL
304953	100736365	20992750302	Before	before	CS_II
304953	100736365	20992750303	"	"	"
304953	100736365	20992750304	Theres		NP1_NN2
304953	100736365	20992750305	no	no	AT
304953	100736365	20992750306	evidence	evidence	NN1
304953	100736365	20992750307	that	that	CST
304953	100736365	20992750308	PSA	psa	NP1
304953	100736365	20992750309	screening	screening	NN1
304953	100736365	20992750310	saves	save	VVZ_NN2
304953	100736365	20992750311	lives	life	NN2_VVZ
304953	100736365	20992750312	.	.	.
304953	100736365	20992750313	<p>		NULL
304953	100736365	20992750314	Now	now	RT
304953	100736365	20992750315	"	"	"
304953	100736365	20992750316	Theres		NP1_NN2
304953	100736365	20992750317	good	good	JJ
304953	100736365	20992750318	evidence	evidence	NN1
304953	100736365	20992750319	that	that	CST_DD1
304953	100736365	20992750320	screening	screening	NN1
304953	100736365	20992750321	does	do	VDZ
304953	100736365	20992750322	not	not	XX
304953	100736365	20992750323	save	save	VVI
304953	100736365	20992750324	lives	life	NN2
304953	100736365	20992750325	.	.	.
304953	100736365	20992750326	<p>		NULL
304953	100736365	20992750327	Before	before	CS_RT@
304953	100736365	20992750328	"	"	"
304953	100736365	20992750329	If	if	CS
304953	100736365	20992750330	a	a	AT1
304953	100736365	20992750331	man	man	NN1
304953	100736365	20992750332	was	be	VBDZ
304953	100736365	20992750333	undecided	undecided	JJ
304953	100736365	20992750334	about	about	II
304953	100736365	20992750335	having	have	VHG
304953	100736365	20992750336	a	a	AT1
304953	100736365	20992750337	PSA	psa	NP1
304953	100736365	20992750338	test	test	NN1_VV0
304953	100736365	20992750339	,	,	,
304953	100736365	20992750340	the	the	AT
304953	100736365	20992750341	best	best	JJT
304953	100736365	20992750342	recommendation	recommendation	NN1
304953	100736365	20992750343	is	be	VBZ
304953	100736365	20992750344	to	to	TO
304953	100736365	20992750345	have	have	VHI
304953	100736365	20992750346	the	the	AT
304953	100736365	20992750347	test	test	NN1
304953	100736365	20992750348	.	.	.
304953	100736365	20992750349	<p>		NULL
304953	100736365	20992750350	Now	now	RT
304953	100736365	20992750351	"	"	"
304953	100736365	20992750352	Unless	unless	CS
304953	100736365	20992750353	a	a	AT1
304953	100736365	20992750354	man	man	NN1
304953	100736365	20992750355	has	have	VHZ
304953	100736365	20992750356	a	a	AT1
304953	100736365	20992750357	particular	particular	JJ
304953	100736365	20992750358	reason	reason	NN1
304953	100736365	20992750359	to	to	TO
304953	100736365	20992750360	ask	ask	VVI
304953	100736365	20992750361	for	for	IF
304953	100736365	20992750362	the	the	AT
304953	100736365	20992750363	test	test	NN1
304953	100736365	20992750364	,	,	,
304953	100736365	20992750365	the	the	AT
304953	100736365	20992750366	best	best	JJT
304953	100736365	20992750367	recommendation	recommendation	NN1
304953	100736365	20992750368	might	might	VM
304953	100736365	20992750369	be	be	VBI
304953	100736365	20992750370	to	to	TO
304953	100736365	20992750371	skip	skip	VVI
304953	100736365	20992750372	the	the	AT
304953	100736365	20992750373	test	test	NN1
304953	100736365	20992750374	.	.	.
304953	100736365	20992750375	<p>		NULL
304953	100736365	20992750376	The	the	AT
304953	100736365	20992750377	debate	debate	NN1
304953	100736365	20992750378	will	will	VM
304953	100736365	20992750379	continue	continue	VVI
304953	100736365	20992750380	,	,	,
304953	100736365	20992750381	but	but	CCB
304953	100736365	20992750382	the	the	AT
304953	100736365	20992750383	playing	playing	JJ%_VVG_NN1%
304953	100736365	20992750384	field	field	NN1
304953	100736365	20992750385	has	have	VHZ
304953	100736365	20992750386	shifted	shift	VVN
304953	100736365	20992750387	.	.	.
304953	100736365	20992750388	<h>		NULL
304953	100736365	20992750389	One	one	MC1
304953	100736365	20992750390	test	test	NN1
304953	100736365	20992750391	,	,	,
304953	100736365	20992750392	several	several	DA2
304953	100736365	20992750393	roles	role	NN2
304953	100736365	20992750394	<p>		NULL
304953	100736365	20992750395	Doctors	doctor	NN2
304953	100736365	20992750396	use	use	VV0
304953	100736365	20992750397	blood	blood	NN1
304953	100736365	20992750398	PSA	psa	NP1
304953	100736365	20992750399	levels	level	NN2
304953	100736365	20992750400	for	for	IF
304953	100736365	20992750401	several	several	DA2
304953	100736365	20992750402	very	very	RG
304953	100736365	20992750403	different	different	JJ
304953	100736365	20992750404	purposes	purpose	NN2
304953	100736365	20992750405	.	.	.
304953	100736365	20992750406	<p>		NULL
304953	100736365	20992750407	To	to	TO
304953	100736365	20992750408	diagnose	diagnose	VVI
304953	100736365	20992750409	prostate	prostate	NN1
304953	100736365	20992750410	cancer	cancer	NN1
304953	100736365	20992750411	in	in	II
304953	100736365	20992750412	men	man	NN2
304953	100736365	20992750413	who	who	PNQS
304953	100736365	20992750414	have	have	VH0
304953	100736365	20992750415	symptoms	symptom	NN2
304953	100736365	20992750416	or	or	CC
304953	100736365	20992750417	laboratory	laboratory	NN1
304953	100736365	20992750418	abnormalities	abnormality	NN2
304953	100736365	20992750419	that	that	CST
304953	100736365	20992750420	raise	raise	VV0
304953	100736365	20992750421	suspicion	suspicion	NN1
304953	100736365	20992750422	of	of	IO
304953	100736365	20992750423	the	the	AT
304953	100736365	20992750424	disease	disease	NN1
304953	100736365	20992750425	<p>		NULL
304953	100736365	20992750426	To	to	TO
304953	100736365	20992750427	evaluate	evaluate	VVI
304953	100736365	20992750428	the	the	AT
304953	100736365	20992750429	results	result	NN2
304953	100736365	20992750430	of	of	IO
304953	100736365	20992750431	prostate	prostate	NN1
304953	100736365	20992750432	cancer	cancer	NN1
304953	100736365	20992750433	treatment	treatment	NN1
304953	100736365	20992750434	<p>		NULL
304953	100736365	20992750435	To	to	TO
304953	100736365	20992750436	estimate	estimate	VVI
304953	100736365	20992750437	the	the	AT
304953	100736365	20992750438	severity	severity	NN1
304953	100736365	20992750439	of	of	IO
304953	100736365	20992750440	@		II
304953	100736365	20992750441	@		II
304953	100736365	20992750442	@		II
304953	100736365	20992750443	@		II
304953	100736365	20992750444	@		II
304953	100736365	20992750445	@		II
304953	100736365	20992750446	@		II
304953	100736365	20992750447	@		II
304953	100736365	20992750448	@		II
304953	100736365	20992750449	@		II
304953	100736365	20992750450	the	the	AT
304953	100736365	20992750451	gland	gland	NN1
304953	100736365	20992750452	<p>		NULL
304953	100736365	20992750453	There	there	EX
304953	100736365	20992750454	is	be	VBZ
304953	100736365	20992750455	no	no	AT
304953	100736365	20992750456	controversy	controversy	NN1
304953	100736365	20992750457	about	about	II
304953	100736365	20992750458	these	these	DD2
304953	100736365	20992750459	uses	use	NN2
304953	100736365	20992750460	of	of	IO
304953	100736365	20992750461	the	the	AT
304953	100736365	20992750462	PSA	psa	NP1
304953	100736365	20992750463	test	test	NN1_VV0
304953	100736365	20992750464	.	.	.
304953	100736365	20992750465	The	the	AT
304953	100736365	20992750466	huge	huge	JJ
304953	100736365	20992750467	controversy	controversy	NN1
304953	100736365	20992750468	is	be	VBZ
304953	100736365	20992750469	about	about	II
304953	100736365	20992750470	the	the	AT
304953	100736365	20992750471	widespread	widespread	JJ
304953	100736365	20992750472	use	use	NN1
304953	100736365	20992750473	of	of	IO
304953	100736365	20992750474	the	the	AT
304953	100736365	20992750475	PSA	psa	NP1
304953	100736365	20992750476	to	to	TO
304953	100736365	20992750477	screen	screen	VVI
304953	100736365	20992750478	for	for	IF
304953	100736365	20992750479	prostate	prostate	NN1
304953	100736365	20992750480	cancer	cancer	NN1
304953	100736365	20992750481	in	in	II
304953	100736365	20992750482	men	man	NN2
304953	100736365	20992750483	who	who	PNQS
304953	100736365	20992750484	are	be	VBR
304953	100736365	20992750485	free	free	JJ
304953	100736365	20992750486	of	of	IO
304953	100736365	20992750487	signs	sign	NN2
304953	100736365	20992750488	and	and	CC
304953	100736365	20992750489	symptoms	symptom	NN2
304953	100736365	20992750490	of	of	IO
304953	100736365	20992750491	the	the	AT
304953	100736365	20992750492	disease	disease	NN1
304953	100736365	20992750493	.	.	.
304953	100736365	20992750494	46996		MC
304953	100736365	20992750495	@qwx906996		FO
304953	100736366	20992750515	@@##	----------	----------
304953	100736366	20992750516	@@100736366		FO
304953	100736366	20992750517	@4936366/		VV0_NN1
304953	100736366	20992750518	46989		MC
304953	100736366	20992750519	@qwx906989		FO
304953	100736366	20992750520	<p>		NULL
304953	100736366	20992750521	In	in	II
304953	100736366	20992750522	this	this	DD1
304953	100736366	20992750523	test	test	NN1
304953	100736366	20992750524	,	,	,
304953	100736366	20992750525	commonly	commonly	RR
304953	100736366	20992750526	performed	perform	VVN_VVD
304953	100736366	20992750527	as	as	II
304953	100736366	20992750528	part	part	NN1
304953	100736366	20992750529	of	of	IO
304953	100736366	20992750530	prostate	prostate	NN1
304953	100736366	20992750531	cancer	cancer	NN1
304953	100736366	20992750532	screening	screening	NN1_VVG
304953	100736366	20992750533	,	,	,
304953	100736366	20992750534	a	a	AT1
304953	100736366	20992750535	doctor	doctor	NN1
304953	100736366	20992750536	inserts	insert	VVZ
304953	100736366	20992750537	a	a	AT1
304953	100736366	20992750538	lubricated	lubricated	JJ
304953	100736366	20992750539	,	,	,
304953	100736366	20992750540	gloved	gloved	JJ
304953	100736366	20992750541	finger	finger	NN1
304953	100736366	20992750542	into	into	II
304953	100736366	20992750543	the	the	AT
304953	100736366	20992750544	rectum	rectum	NN1
304953	100736366	20992750545	and	and	CC
304953	100736366	20992750546	feels	feel	VVZ
304953	100736366	20992750547	the	the	AT
304953	100736366	20992750548	surface	surface	NN1
304953	100736366	20992750549	of	of	IO
304953	100736366	20992750550	the	the	AT
304953	100736366	20992750551	prostate	prostate	NN1
304953	100736366	20992750552	to	to	TO
304953	100736366	20992750553	determine	determine	VVI
304953	100736366	20992750554	whether	whether	CSW
304953	100736366	20992750555	it	it	PPH1
304953	100736366	20992750556	is	be	VBZ
304953	100736366	20992750557	swollen	swell	VVN_JJ
304953	100736366	20992750558	or	or	CC
304953	100736366	20992750559	has	have	VHZ
304953	100736366	20992750560	any	any	DD
304953	100736366	20992750561	lumps	lump	NN2
304953	100736366	20992750562	or	or	CC
304953	100736366	20992750563	abnormally	abnormally	RR
304953	100736366	20992750564	textured	textured	JJ
304953	100736366	20992750565	areas	area	NN2
304953	100736366	20992750566	(	(	(
304953	100736366	20992750567	see	see	VV0
304953	100736366	20992750568	illustration	illustration	NN1
304953	100736366	20992750569	below	below	RL
304953	100736366	20992750570	)	)	)
304953	100736366	20992750571	.	.	.
304953	100736366	20992750572	<p>		NULL
304953	100736366	20992750573	Although	although	CS
304953	100736366	20992750574	this	this	DD1
304953	100736366	20992750575	exam	exam	NN1
304953	100736366	20992750576	generally	generally	RR
304953	100736366	20992750577	takes	take	VVZ
304953	100736366	20992750578	less	less	DAR_RRR
304953	100736366	20992750579	than	than	CSN
304953	100736366	20992750580	a	a	AT1
304953	100736366	20992750581	minute	minute	NNT1
304953	100736366	20992750582	,	,	,
304953	100736366	20992750583	some	some	DD
304953	100736366	20992750584	men	man	NN2
304953	100736366	20992750585	find	find	VV0
304953	100736366	20992750586	it	it	PPH1
304953	100736366	20992750587	uncomfortable	uncomfortable	JJ
304953	100736366	20992750588	and	and	CC
304953	100736366	20992750589	,	,	,
304953	100736366	20992750590	most	most	DAT
304953	100736366	20992750591	of	of	IO
304953	100736366	20992750592	all	all	DB
304953	100736366	20992750593	,	,	,
304953	100736366	20992750594	embarrassing	embarrassing	JJ
304953	100736366	20992750595	,	,	,
304953	100736366	20992750596	so	so	CS@_RR
304953	100736366	20992750597	they	they	PPHS2
304953	100736366	20992750598	postpone	postpone	VV0
304953	100736366	20992750599	it	it	PPH1
304953	100736366	20992750600	or	or	CC
304953	100736366	20992750601	avoid	avoid	VV0
304953	100736366	20992750602	going	go	VVG
304953	100736366	20992750603	to	to	II
304953	100736366	20992750604	a	a	AT1
304953	100736366	20992750605	physician	physician	NN1
304953	100736366	20992750606	altogether	altogether	RR
304953	100736366	20992750607	.	.	.
304953	100736366	20992750608	But	but	CCB
304953	100736366	20992750609	the	the	AT
304953	100736366	20992750610	discomfort	discomfort	NN1
304953	100736366	20992750611	is	be	VBZ
304953	100736366	20992750612	mild	mild	JJ
304953	100736366	20992750613	and	and	CC
304953	100736366	20992750614	lasts	last	VVZ
304953	100736366	20992750615	only	only	JJ
304953	100736366	20992750616	a	a-i	AT1
304953	100736366	20992750617	few	few	DA2
304953	100736366	20992750618	moments	moment	NN2
304953	100736366	20992750619	,	,	,
304953	100736366	20992750620	and	and	CC
304953	100736366	20992750621	the	the	AT
304953	100736366	20992750622	procedure	procedure	NN1
304953	100736366	20992750623	causes	cause	VVZ
304953	100736366	20992750624	no	no	AT
304953	100736366	20992750625	physical	physical	JJ
304953	100736366	20992750626	injury	injury	NN1
304953	100736366	20992750627	.	.	.
304953	100736366	20992750628	<p>		NULL
304953	100736366	20992750629	The	the	AT
304953	100736366	20992750630	DRE	dre	NN1_NP1
304953	100736366	20992750631	is	be	VBZ
304953	100736366	20992750632	a	a	AT1
304953	100736366	20992750633	useful	useful	JJ
304953	100736366	20992750634	screening	screening	NN1
304953	100736366	20992750635	test	test	NN1_VV0
304953	100736366	20992750636	,	,	,
304953	100736366	20992750637	but	but	CCB
304953	100736366	20992750638	it	it	PPH1
304953	100736366	20992750639	is	be	VBZ
304953	100736366	20992750640	n't	n't	XX
304953	100736366	20992750641	foolproof	foolproof	JJ_VV0
304953	100736366	20992750642	.	.	.
304953	100736366	20992750643	Its	its	APPGE
304953	100736366	20992750644	accuracy	accuracy	NN1
304953	100736366	20992750645	depends	depend	VVZ
304953	100736366	20992750646	on	on	II
304953	100736366	20992750647	the	the	AT
304953	100736366	20992750648	skill	skill	NN1
304953	100736366	20992750649	of	of	IO
304953	100736366	20992750650	the	the	AT
304953	100736366	20992750651	physician	physician	NN1
304953	100736366	20992750652	conducting	conduct	VVG_NN1@
304953	100736366	20992750653	and	and	CC
304953	100736366	20992750654	interpreting	interpret	VVG
304953	100736366	20992750655	the	the	AT
304953	100736366	20992750656	test	test	NN1
304953	100736366	20992750657	.	.	.
304953	100736366	20992750658	Moreover	moreover	RR
304953	100736366	20992750659	,	,	,
304953	100736366	20992750660	early	early	RR_JJ
304953	100736366	20992750661	cancerous	cancerous	JJ
304953	100736366	20992750662	tumors	tumor	NN2
304953	100736366	20992750663	are	be	VBR
304953	100736366	20992750664	often	often	RR
304953	100736366	20992750665	too	too	RG
304953	100736366	20992750666	small	small	JJ
304953	100736366	20992750667	to	to	TO
304953	100736366	20992750668	detect	detect	VVI
304953	100736366	20992750669	during	during	II
304953	100736366	20992750670	a	a	AT1
304953	100736366	20992750671	DRE	dre	NN1
304953	100736366	20992750672	,	,	,
304953	100736366	20992750673	and	and	CC
304953	100736366	20992750674	some	some	DD
304953	100736366	20992750675	are	be	VBR
304953	100736366	20992750676	located	locate	VVN
304953	100736366	20992750677	in	in	II
304953	100736366	20992750678	areas	area	NN2
304953	100736366	20992750679	a	a	AT1
304953	100736366	20992750680	doctor	doctor	NN1
304953	100736366	20992750681	's	's	GE
304953	100736366	20992750682	finger	finger	NN1
304953	100736366	20992750683	ca	can	VM
304953	100736366	20992750684	n't	n't	XX
304953	100736366	20992750685	reach	reach	VVI
304953	100736366	20992750686	.	.	.
304953	100736366	20992750687	For	for	IF
304953	100736366	20992750688	these	these	DD2
304953	100736366	20992750689	reasons	reason	NN2
304953	100736366	20992750690	,	,	,
304953	100736366	20992750691	clinicians	clinician	NN2
304953	100736366	20992750692	who	who	PNQS
304953	100736366	20992750693	use	use	VV0
304953	100736366	20992750694	DRE	dre	NN1_NP1
304953	100736366	20992750695	alone	alone	RR_JJ
304953	100736366	20992750696	to	to	TO
304953	100736366	20992750697	screen	screen	VVI
304953	100736366	20992750698	for	for	IF
304953	100736366	20992750699	prostate	prostate	NN1
304953	100736366	20992750700	cancer	cancer	NN1
304953	100736366	20992750701	sometimes	sometimes	RT
304953	100736366	20992750702	miss	miss	VV0
304953	100736366	20992750703	the	the	AT
304953	100736366	20992750704	smallest	small	JJT
304953	100736366	20992750705	and	and	CC
304953	100736366	20992750706	most	most	RGT_DAT
304953	100736366	20992750707	@		II
304953	100736366	20992750708	@		II
304953	100736366	20992750709	@		II
304953	100736366	20992750710	@		II
304953	100736366	20992750711	@		II
304953	100736366	20992750712	@		II
304953	100736366	20992750713	@		II
304953	100736366	20992750714	@		II
304953	100736366	20992750715	@		II
304953	100736366	20992750716	@		II
304953	100736366	20992750717	that	that	CST_DD1
304953	100736366	20992750718	ca	can	VM
304953	100736366	20992750719	n't	n't	XX
304953	100736366	20992750720	be	be	VBI
304953	100736366	20992750721	felt	feel	VVN
304953	100736366	20992750722	by	by	II
304953	100736366	20992750723	the	the	AT
304953	100736366	20992750724	physician	physician	NN1
304953	100736366	20992750725	may	may	VM
304953	100736366	20992750726	be	be	VBI
304953	100736366	20992750727	less	less	RGR
304953	100736366	20992750728	likely	likely	JJ
304953	100736366	20992750729	to	to	TO
304953	100736366	20992750730	cause	cause	VVI
304953	100736366	20992750731	future	future	JJ_NN1
304953	100736366	20992750732	problems	problem	NN2
304953	100736366	20992750733	.	.	.
304953	100736366	20992750734	<h>		NULL
304953	100736366	20992750735	Digital	digital	JJ
304953	100736366	20992750736	rectal	rectal	JJ
304953	100736366	20992750737	exam	exam	NN1
304953	100736366	20992750738	<p>		NULL
304953	100736366	20992750739	To	to	TO
304953	100736366	20992750740	perform	perform	VVI
304953	100736366	20992750741	a	a	AT1
304953	100736366	20992750742	digital	digital	JJ
304953	100736366	20992750743	rectal	rectal	JJ
304953	100736366	20992750744	examination	examination	NN1
304953	100736366	20992750745	(	(	(
304953	100736366	20992750746	DRE	dre	NP1
304953	100736366	20992750747	)	)	)
304953	100736366	20992750748	,	,	,
304953	100736366	20992750749	the	the	AT
304953	100736366	20992750750	doctor	doctor	NN1
304953	100736366	20992750751	inserts	insert	VVZ
304953	100736366	20992750752	a	a	AT1
304953	100736366	20992750753	lubricated	lubricated	JJ
304953	100736366	20992750754	,	,	,
304953	100736366	20992750755	gloved	gloved	JJ
304953	100736366	20992750756	finger	finger	NN1
304953	100736366	20992750757	into	into	II
304953	100736366	20992750758	the	the	AT
304953	100736366	20992750759	rectum	rectum	NN1
304953	100736366	20992750760	and	and	CC
304953	100736366	20992750761	presses	press	NN2_VVZ@
304953	100736366	20992750762	against	against	II
304953	100736366	20992750763	the	the	AT
304953	100736366	20992750764	rectal	rectal	JJ
304953	100736366	20992750765	wall	wall	NN1
304953	100736366	20992750766	to	to	TO
304953	100736366	20992750767	determine	determine	VVI
304953	100736366	20992750768	the	the	AT
304953	100736366	20992750769	size	size	NN1
304953	100736366	20992750770	of	of	IO
304953	100736366	20992750771	the	the	AT
304953	100736366	20992750772	prostate	prostate	NN1
304953	100736366	20992750773	and	and	CC
304953	100736366	20992750774	feel	feel	VV0
304953	100736366	20992750775	for	for	IF
304953	100736366	20992750776	irregularities	irregularity	NN2
304953	100736366	20992750777	.	.	.
304953	100736366	20992750778	Early-stage	early-stage	JJ_NN1
304953	100736366	20992750779	cancer	cancer	NN1
304953	100736366	20992750780	may	may	VM
304953	100736366	20992750781	be	be	VBI
304953	100736366	20992750782	felt	feel	VVN
304953	100736366	20992750783	as	as	II
304953	100736366	20992750784	a	a	AT1
304953	100736366	20992750785	small	small	JJ
304953	100736366	20992750786	lump	lump	NN1
304953	100736366	20992750787	on	on	II
304953	100736366	20992750788	the	the	AT
304953	100736366	20992750789	surface	surface	NN1
304953	100736366	20992750790	of	of	IO
304953	100736366	20992750791	the	the	AT
304953	100736366	20992750792	prostate	prostate	NN1
304953	100736366	20992750793	.	.	.
304953	100736366	20992750794	46996		MC
304953	100736366	20992750795	@qwx906996		FO
304953	100736368	20992750815	@@##	----------	----------
304953	100736368	20992750816	@@100736368		FO
304953	100736368	20992750817	@4936368/		VV0_NN1
304953	100736368	20992750818	46989		MC
304953	100736368	20992750819	@qwx906989		FO
304953	100736368	20992750820	<h>		NULL
304953	100736368	20992750821	Posts	post	NN2
304953	100736368	20992750822	Tagged	tag	VVD_VVN
304953	100736368	20992750823	news	news	NN1
304953	100736368	20992750824	<p>		NULL
304953	100736368	20992750825	Men	man	NN2
304953	100736368	20992750826	who	who	PNQS
304953	100736368	20992750827	experience	experience	VV0
304953	100736368	20992750828	a	a	AT1
304953	100736368	20992750829	spike	spike	NN1
304953	100736368	20992750830	in	in	II
304953	100736368	20992750831	PSA	psa	NP1
304953	100736368	20992750832	but	but	CCB
304953	100736368	20992750833	who	who	PNQS
304953	100736368	20992750834	have	have	VH0
304953	100736368	20992750835	no	no	AT
304953	100736368	20992750836	symptoms	symptom	NN2
304953	100736368	20992750837	after	after	II_CS
304953	100736368	20992750838	surgery	surgery	NN1
304953	100736368	20992750839	or	or	CC
304953	100736368	20992750840	radiation	radiation	NN1
304953	100736368	20992750841	therapy	therapy	NN1
304953	100736368	20992750842	for	for	IF
304953	100736368	20992750843	prostate	prostate	NN1
304953	100736368	20992750844	cancer	cancer	NN1
304953	100736368	20992750845	can	can	VM
304953	100736368	20992750846	wait	wait	VVI
304953	100736368	20992750847	for	for	IF
304953	100736368	20992750848	up	up	RG21
304953	100736368	20992750849	to	to	RG22
304953	100736368	20992750850	two	two	MC
304953	100736368	20992750851	years	year	NNT2
304953	100736368	20992750852	before	before	II
304953	100736368	20992750853	starting	start	VVG
304953	100736368	20992750854	hormone	hormone	NN1
304953	100736368	20992750855	therapy	therapy	NN1
304953	100736368	20992750856	,	,	,
304953	100736368	20992750857	according	according	II21
304953	100736368	20992750858	to	to	II22
304953	100736368	20992750859	a	a	AT1
304953	100736368	20992750860	new	new	JJ
304953	100736368	20992750861	study	study	NN1
304953	100736368	20992750862	.	.	.
304953	100736368	20992750863	<p>		NULL
304953	100736368	20992750864	Some	some	DD
304953	100736368	20992750865	men	man	NN2
304953	100736368	20992750866	have	have	VH0
304953	100736368	20992750867	a	a	AT1
304953	100736368	20992750868	slightly	slightly	RR
304953	100736368	20992750869	shorter	short	JJR
304953	100736368	20992750870	penis	penis	NN1
304953	100736368	20992750871	after	after	II
304953	100736368	20992750872	undergoing	undergo	VVG
304953	100736368	20992750873	surgery	surgery	NN1
304953	100736368	20992750874	to	to	TO
304953	100736368	20992750875	remove	remove	VVI
304953	100736368	20992750876	a	a	AT1
304953	100736368	20992750877	cancerous	cancerous	JJ
304953	100736368	20992750878	prostate	prostate	NN1
304953	100736368	20992750879	gland	gland	NN1
304953	100736368	20992750880	.	.	.
304953	100736368	20992750881	A	a	AT1_ZZ1
304953	100736368	20992750882	new	new	JJ
304953	100736368	20992750883	study	study	NN1
304953	100736368	20992750884	shows	show	VVZ
304953	100736368	20992750885	that	that	CST
304953	100736368	20992750886	taking	take	VVG
304953	100736368	20992750887	an	a	AT1
304953	100736368	20992750888	erectile	erectile	JJ
304953	100736368	20992750889	dysfunction	dysfunction	NN1
304953	100736368	20992750890	drug	drug	NN1
304953	100736368	20992750891	like	like	II
304953	100736368	20992750892	Viagra	viagra	NP1
304953	100736368	20992750893	or	or	CC
304953	100736368	20992750894	Cialis	cialis	NN1_NP1
304953	100736368	20992750895	after	after	II_CS
304953	100736368	20992750896	surgery	surgery	NN1
304953	100736368	20992750897	can	can	VM
304953	100736368	20992750898	prevent	prevent	VVI
304953	100736368	20992750899	that	that	CST_DD1
304953	100736368	20992750900	from	from	II
304953	100736368	20992750901	happening	happening	NN1_VVG
304953	100736368	20992750902	.	.	.
304953	100736368	20992750903	<p>		NULL
304953	100736368	20992750904	Thanks	thanks	NN2
304953	100736368	20992750905	in	in	RR21
304953	100736368	20992750906	part	part	RR22
304953	100736368	20992750907	to	to	II
304953	100736368	20992750908	advertising	advertising	NN1
304953	100736368	20992750909	,	,	,
304953	100736368	20992750910	many	many	DA2
304953	100736368	20992750911	men	man	NN2
304953	100736368	20992750912	with	with	IW
304953	100736368	20992750913	prostate	prostate	NN1
304953	100736368	20992750914	cancer	cancer	NN1
304953	100736368	20992750915	believe	believe	VV0
304953	100736368	20992750916	that	that	CST_DD1
304953	100736368	20992750917	theyll		VV0_NN1
304953	100736368	20992750918	get	get	VV0
304953	100736368	20992750919	better	better	JJR
304953	100736368	20992750920	results	result	NN2
304953	100736368	20992750921	with	with	IW
304953	100736368	20992750922	robot-assisted		JJ
304953	100736368	20992750923	prostate	prostate	NN1
304953	100736368	20992750924	surgery	surgery	NN1
304953	100736368	20992750925	than	than	CSN
304953	100736368	20992750926	with	with	IW
304953	100736368	20992750927	more	more	RGR_DAR
304953	100736368	20992750928	traditional	traditional	JJ
304953	100736368	20992750929	open	open	JJ
304953	100736368	20992750930	surgery	surgery	NN1
304953	100736368	20992750931	.	.	.
304953	100736368	20992750932	The	the	AT
304953	100736368	20992750933	latest	late	JJT
304953	100736368	20992750934	study	study	NN1
304953	100736368	20992750935	does	do	VDZ
304953	100736368	20992750936	n't 	n't	XX
304953	100736368	20992750937	bear	bear	VVI
304953	100736368	20992750938	that	that	DD1
304953	100736368	20992750939	out	out	RP
304953	100736368	20992750940	.	.	.
304953	100736368	20992750941	<p>		NULL
304953	100736368	20992750942	New	new	JJ
304953	100736368	20992750943	results	result	NN2
304953	100736368	20992750944	from	from	II
304953	100736368	20992750945	a	a	AT1
304953	100736368	20992750946	major	major	JJ
304953	100736368	20992750947	clinical	clinical	JJ
304953	100736368	20992750948	trial	trial	NN1
304953	100736368	20992750949	called	call	VVN_VVD@
304953	100736368	20992750950	SELECT	select	JJ
304953	100736368	20992750951	show	show	NN1_VV0
304953	100736368	20992750952	that	that	CST_DD1
304953	100736368	20992750953	taking	take	VVG_JJ%
304953	100736368	20992750954	selenium	selenium	NN1
304953	100736368	20992750955	or	or	CC
304953	100736368	20992750956	vitamin	vitamin	NN1
304953	100736368	20992750957	E	e	ZZ1
304953	100736368	20992750958	can	can	VM
304953	100736368	20992750959	increase	increase	VVI
304953	100736368	20992750960	the	the	AT
304953	100736368	20992750961	odds	odds	NN2
304953	100736368	20992750962	of	of	IO
304953	100736368	20992750963	developing	developing	JJ_VVG
304953	100736368	20992750964	prostate	prostate	NN1
304953	100736368	20992750965	cancer	cancer	NN1
304953	100736368	20992750966	.	.	.
304953	100736368	20992750967	Bottom	bottom	JJ_NN1
304953	100736368	20992750968	line	line	NN1
304953	100736368	20992750969	:	:	:
304953	100736368	20992750970	men	man	NN2
304953	100736368	20992750971	should n't		VV0
304953	100736368	20992750972	take	take	VV0
304953	100736368	20992750973	selenium	selenium	NN1
304953	100736368	20992750974	or	or	CC
304953	100736368	20992750975	vitamin	vitamin	NN1
304953	100736368	20992750976	E	e	ZZ1
304953	100736368	20992750977	as	as	II_CSA
304953	100736368	20992750978	a	a	AT1
304953	100736368	20992750979	way	way	NN1
304953	100736368	20992750980	to	to	TO
304953	100736368	20992750981	prevent	prevent	VVI
304953	100736368	20992750982	prostate	prostate	NN1
304953	100736368	20992750983	cancer	cancer	NN1
304953	100736368	20992750984	,	,	,
304953	100736368	20992750985	or	or	CC
304953	100736368	20992750986	anything	anything	PN1
304953	100736368	20992750987	else	else	RR
304953	100736368	20992750988	for	for	IF
304953	100736368	20992750989	that	that	DD1
304953	100736368	20992750990	matter	matter	NN1
304953	100736368	20992750991	.	.	.
304953	100736368	20992750992	<p>		NULL
304953	100736368	20992750993	Prostatitis		NP1@_NN1
304953	100736368	20992750994	(	(	(
304953	100736368	20992750995	infection	infection	NN1
304953	100736368	20992750996	or	or	CC
304953	100736368	20992750997	inflammation	inflammation	NN1
304953	100736368	20992750998	of	of	IO
304953	100736368	20992750999	the	the	AT
304953	100736368	20992751000	prostate	prostate	NN1
304953	100736368	20992751001	gland	gland	NN1
304953	100736368	20992751002	)	)	)
304953	100736368	20992751003	flies	fly	VVZ_NN2
304953	100736368	20992751004	under	under	II
304953	100736368	20992751005	the	the	AT
304953	100736368	20992751006	radar	radar	NN1
304953	100736368	20992751007	@		II
304953	100736368	20992751008	@		II
304953	100736368	20992751009	@		II
304953	100736368	20992751010	@		II
304953	100736368	20992751011	@		II
304953	100736368	20992751012	@		II
304953	100736368	20992751013	@		II
304953	100736368	20992751014	@		II
304953	100736368	20992751015	@		II
304953	100736368	20992751016	@		II
304953	100736368	20992751017	at	at	II
304953	100736368	20992751018	some	some	DD
304953	100736368	20992751019	point	point	NN1
304953	100736368	20992751020	in	in	II
304953	100736368	20992751021	their	their	APPGE
304953	100736368	20992751022	lifetimes	lifetime	NNT2
304953	100736368	20992751023	.	.	.
304953	100736368	20992751024	It	it	PPH1
304953	100736368	20992751025	triggers	trigger	VVZ
304953	100736368	20992751026	more	more	DAR
304953	100736368	20992751027	than	than	CSN
304953	100736368	20992751028	two	two	MC
304953	100736368	20992751029	million	million	NNO
304953	100736368	20992751030	visits	visit	NN2
304953	100736368	20992751031	to	to	II
304953	100736368	20992751032	doctors	doctor	NN2
304953	100736368	20992751033	and	and	CC
304953	100736368	20992751034	untold	untold	JJ
304953	100736368	20992751035	agony	agony	NN1
304953	100736368	20992751036	each	each	DD1
304953	100736368	20992751037	year	year	NNT1
304953	100736368	20992751038	.	.	.
304953	100736368	20992751039	<p>		NULL
304953	100736368	20992751040	Radical	radical	JJ_NN1
304953	100736368	20992751041	prostatectomy	prostatectomy	NN1
304953	100736368	20992751042	changes	change	VVZ@_NN2
304953	100736368	20992751043	the	the	AT
304953	100736368	20992751044	experience	experience	NN1
304953	100736368	20992751045	of	of	IO
304953	100736368	20992751046	orgasm	orgasm	NN1
304953	100736368	20992751047	.	.	.
304953	100736368	20992751048	But	but	CCB
304953	100736368	20992751049	it	it	PPH1
304953	100736368	20992751050	does	do	VDZ
304953	100736368	20992751051	n't 	n't	XX
304953	100736368	20992751052	need	need	VVI
304953	100736368	20992751053	to	to	TO
304953	100736368	20992751054	be	be	VBI
304953	100736368	20992751055	any	any	DD
304953	100736368	20992751056	less	less	DAR_RGR
304953	100736368	20992751057	pleasurable	pleasurable	JJ
304953	100736368	20992751058	or	or	CC
304953	100736368	20992751059	satisfying	satisfying	JJ
304953	100736368	20992751060	,	,	,
304953	100736368	20992751061	says	say	VVZ
304953	100736368	20992751062	Dr.		NNB
304953	100736368	20992751063	Ravi	ravi	NP1
304953	100736368	20992751064	Kacker		NP1
304953	100736368	20992751065	,	,	,
304953	100736368	20992751066	a	a	AT1
304953	100736368	20992751067	urologist	urologist	NN1
304953	100736368	20992751068	and	and	CC
304953	100736368	20992751069	fellow	fellow	NN1_JJ
304953	100736368	20992751070	in	in	II
304953	100736368	20992751071	male	male	JJ
304953	100736368	20992751072	sexual	sexual	JJ
304953	100736368	20992751073	medicine	medicine	NN1
304953	100736368	20992751074	at	at	II
304953	100736368	20992751075	Harvard-affiliated	harvard-affiliated	JJ_NN1
304953	100736368	20992751076	Beth	beth	NP1
304953	100736368	20992751077	Israel	israel	NP1
304953	100736368	20992751078	Deaconess	deaconess	NN1
304953	100736368	20992751079	Medical	medical	JJ
304953	100736368	20992751080	Center	center	NN1
304953	100736368	20992751081	.	.	.
304953	100736368	20992751082	<p>		NULL
304953	100736368	20992751083	New	new	JJ
304953	100736368	20992751084	research	research	NN1
304953	100736368	20992751085	has	have	VHZ
304953	100736368	20992751086	has	have	VHZ
304953	100736368	20992751087	identified	identify	VVN
304953	100736368	20992751088	an	a	AT1
304953	100736368	20992751089	enzyme	enzyme	NN1
304953	100736368	20992751090	that	that	CST_DD1
304953	100736368	20992751091	may	may	VM
304953	100736368	20992751092	be	be	VBI
304953	100736368	20992751093	the	the	AT
304953	100736368	20992751094	escape	escape	NN1
304953	100736368	20992751095	hatch	hatch	VV0_NN1
304953	100736368	20992751096	that	that	CST_DD1
304953	100736368	20992751097	advanced	advanced	JJ_VVD
304953	100736368	20992751098	prostate	prostate	NN1
304953	100736368	20992751099	cancer	cancer	NN1
304953	100736368	20992751100	uses	use	VVZ
304953	100736368	20992751101	to	to	TO
304953	100736368	20992751102	evade	evade	VVI
304953	100736368	20992751103	hormone	hormone	NN1
304953	100736368	20992751104	therapy	therapy	NN1
304953	100736368	20992751105	.	.	.
304953	100736368	20992751106	If	if	CS
304953	100736368	20992751107	the	the	AT
304953	100736368	20992751108	findings	finding	NN2
304953	100736368	20992751109	hold	hold	VV0
304953	100736368	20992751110	up	up	RP
304953	100736368	20992751111	,	,	,
304953	100736368	20992751112	the	the	AT
304953	100736368	20992751113	enzyme	enzyme	NN1
304953	100736368	20992751114	might	might	VM
304953	100736368	20992751115	be	be	VBI
304953	100736368	20992751116	a	a	AT1
304953	100736368	20992751117	prime	prime	JJ
304953	100736368	20992751118	target	target	NN1
304953	100736368	20992751119	for	for	IF
304953	100736368	20992751120	a	a	AT1
304953	100736368	20992751121	drug	drug	NN1
304953	100736368	20992751122	that	that	CST_DD1
304953	100736368	20992751123	would	would	VM
304953	100736368	20992751124	treat	treat	VVI
304953	100736368	20992751125	castration-resistant		JJ
304953	100736368	20992751126	prostate	prostate	NN1
304953	100736368	20992751127	cancer	cancer	NN1
304953	100736368	20992751128	.	.	.
304953	100736368	20992751129	<p>		NULL
304953	100736368	20992751130	Metformin	metformin	NN1_NP1@
304953	100736368	20992751131	"	"	"
304953	100736368	20992751132	the	the	AT
304953	100736368	20992751133	drug	drug	NN1
304953	100736368	20992751134	that	that	CST
304953	100736368	20992751135	millions	million	NNO2
304953	100736368	20992751136	of	of	IO
304953	100736368	20992751137	people	people	NN
304953	100736368	20992751138	with	with	IW
304953	100736368	20992751139	diabetes	diabetes	NN1
304953	100736368	20992751140	take	take	VV0
304953	100736368	20992751141	to	to	TO
304953	100736368	20992751142	control	control	VVI
304953	100736368	20992751143	their	their	APPGE
304953	100736368	20992751144	blood	blood	NN1
304953	100736368	20992751145	sugar	sugar	NN1
304953	100736368	20992751146	"	"	"
304953	100736368	20992751147	may	may	VM
304953	100736368	20992751148	be	be	VBI
304953	100736368	20992751149	on	on	II
304953	100736368	20992751150	the	the	AT
304953	100736368	20992751151	brink	brink	NN1
304953	100736368	20992751152	of	of	IO
304953	100736368	20992751153	a	a	AT1
304953	100736368	20992751154	second	second	MD_NNT1
304953	100736368	20992751155	career	career	NN1
304953	100736368	20992751156	.	.	.
304953	100736368	20992751157	Evidence	evidence	NN1
304953	100736368	20992751158	from	from	II
304953	100736368	20992751159	a	a	AT1
304953	100736368	20992751160	variety	variety	NN1
304953	100736368	20992751161	of	of	IO
304953	100736368	20992751162	studies	study	NN2
304953	100736368	20992751163	suggests	suggest	VVZ
304953	100736368	20992751164	that	that	DD1_CST
304953	100736368	20992751165	metformin	metformin	NN1
304953	100736368	20992751166	may	may	VM
304953	100736368	20992751167	delay	delay	VVI
304953	100736368	20992751168	or	or	CC
304953	100736368	20992751169	slow	slow	VVI
304953	100736368	20992751170	the	the	AT
304953	100736368	20992751171	progression	progression	NN1
304953	100736368	20992751172	of	of	IO
304953	100736368	20992751173	prostate	prostate	NN1
304953	100736368	20992751174	cancer	cancer	NN1
304953	100736368	20992751175	.	.	.
304953	100736368	20992751176	Metformin	metformin	NN1_NP1@
304953	100736368	20992751177	does	do	VDZ
304953	100736368	20992751178	not	not	XX
304953	100736368	20992751179	,	,	,
304953	100736368	20992751180	however	however	RR
304953	100736368	20992751181	,	,	,
304953	100736368	20992751182	appear	appear	VV0
304953	100736368	20992751183	to	to	TO
304953	100736368	20992751184	prevent	prevent	VVI
304953	100736368	20992751185	the	the	AT
304953	100736368	20992751186	development	development	NN1
304953	100736368	20992751187	of	of	IO
304953	100736368	20992751188	prostate	prostate	NN1
304953	100736368	20992751189	cancer	cancer	NN1
304953	100736368	20992751190	in	in	II
304953	100736368	20992751191	the	the	AT
304953	100736368	20992751192	first	first	MD
304953	100736368	20992751193	place	place	NN1
304953	100736368	20992751194	.	.	.
304953	100736368	20992751195	<p>		NULL
304953	100736368	20992751196	In	in	II
304953	100736368	20992751197	many	many	DA2
304953	100736368	20992751198	men	man	NN2
304953	100736368	20992751199	diagnosed	diagnose	VVN_VVD
304953	100736368	20992751200	with	with	IW
304953	100736368	20992751201	prostate	prostate	NN1
304953	100736368	20992751202	cancer	cancer	NN1
304953	100736368	20992751203	,	,	,
304953	100736368	20992751204	the	the	AT
304953	100736368	20992751205	cancer	cancer	NN1
304953	100736368	20992751206	cells	cell	NN2
304953	100736368	20992751207	@		II
304953	100736368	20992751208	@		II
304953	100736368	20992751209	@		II
304953	100736368	20992751210	@		II
304953	100736368	20992751211	@		II
304953	100736368	20992751212	@		II
304953	100736368	20992751213	@		II
304953	100736368	20992751214	@		II
304953	100736368	20992751215	@		II
304953	100736368	20992751216	@		II
304953	100736368	20992751217	gland	gland	NN1
304953	100736368	20992751218	,	,	,
304953	100736368	20992751219	spread	spread	VVN_VVD_VV0
304953	100736368	20992751220	to	to	II
304953	100736368	20992751221	distant	distant	JJ
304953	100736368	20992751222	sites	site	NN2
304953	100736368	20992751223	,	,	,
304953	100736368	20992751224	and	and	CC
304953	100736368	20992751225	pose	pose	VV0
304953	100736368	20992751226	a	a	AT1
304953	100736368	20992751227	serious	serious	JJ
304953	100736368	20992751228	risk	risk	NN1
304953	100736368	20992751229	to	to	II
304953	100736368	20992751230	health	health	NN1
304953	100736368	20992751231	and	and	CC
304953	100736368	20992751232	longevity	longevity	NN1
304953	100736368	20992751233	.	.	.
304953	100736368	20992751234	In	in	II
304953	100736368	20992751235	others	others	NN2
304953	100736368	20992751236	,	,	,
304953	100736368	20992751237	cancer	cancer	NN1
304953	100736368	20992751238	is	be	VBZ
304953	100736368	20992751239	fast	fast	RR
304953	100736368	20992751240	growing	growing	JJ_VVG
304953	100736368	20992751241	and	and	CC
304953	100736368	20992751242	aggressive	aggressive	JJ
304953	100736368	20992751243	from	from	II
304953	100736368	20992751244	the	the	AT
304953	100736368	20992751245	beginning	beginning	NN1
304953	100736368	20992751246	.	.	.
304953	100736368	20992751247	A	a	AT1_ZZ1
304953	100736368	20992751248	new	new	JJ
304953	100736368	20992751249	Harvard	harvard	NP1
304953	100736368	20992751250	study	study	NN1
304953	100736368	20992751251	shows	show	VVZ
304953	100736368	20992751252	that	that	CST
304953	100736368	20992751253	the	the	AT
304953	100736368	20992751254	aggressiveness	aggressiveness	NN1
304953	100736368	20992751255	of	of	IO
304953	100736368	20992751256	prostate	prostate	NN1
304953	100736368	20992751257	cancer	cancer	NN1
304953	100736368	20992751258	at	at	II
304953	100736368	20992751259	diagnosis	diagnosis	NN1
304953	100736368	20992751260	remains	remain	VVZ
304953	100736368	20992751261	stable	stable	JJ_NN1@
304953	100736368	20992751262	over	over	II
304953	100736368	20992751263	time	time	NNT1
304953	100736368	20992751264	for	for	IF
304953	100736368	20992751265	most	most	DAT
304953	100736368	20992751266	men	man	NN2
304953	100736368	20992751267	.	.	.
304953	100736368	20992751268	<p>		NULL
304953	100736368	20992751269	The	the	AT
304953	100736368	20992751270	omega-3	omega-3	MC
304953	100736368	20992751271	fats	fat	NN2
304953	100736368	20992751272	in	in	II
304953	100736368	20992751273	fish	fish	NN
304953	100736368	20992751274	have	have	VH0
304953	100736368	20992751275	been	be	VBN
304953	100736368	20992751276	linked	link	VVN
304953	100736368	20992751277	to	to	II
304953	100736368	20992751278	all	all	DB
304953	100736368	20992751279	sorts	sort	NN2
304953	100736368	20992751280	of	of	IO
304953	100736368	20992751281	health	health	NN1
304953	100736368	20992751282	benefits	benefit	NN2
304953	100736368	20992751283	,	,	,
304953	100736368	20992751284	including	including	II_VVG@
304953	100736368	20992751285	protection	protection	NN1
304953	100736368	20992751286	against	against	II
304953	100736368	20992751287	prostate	prostate	NN1
304953	100736368	20992751288	cancer	cancer	NN1
304953	100736368	20992751289	.	.	.
304953	100736368	20992751290	But	but	II21_CCB
304953	100736368	20992751291	for	for	II22_IF
304953	100736368	20992751292	the	the	AT
304953	100736368	20992751293	second	second	MD
304953	100736368	20992751294	time	time	NNT1
304953	100736368	20992751295	in	in	II
304953	100736368	20992751296	two	two	MC
304953	100736368	20992751297	years	year	NNT2
304953	100736368	20992751298	,	,	,
304953	100736368	20992751299	researchers	researcher	NN2
304953	100736368	20992751300	have	have	VH0
304953	100736368	20992751301	found	find	VVN
304953	100736368	20992751302	a	a	AT1
304953	100736368	20992751303	link	link	NN1
304953	100736368	20992751304	between	between	II
304953	100736368	20992751305	high	high	JJ
304953	100736368	20992751306	levels	level	NN2
304953	100736368	20992751307	of	of	IO
304953	100736368	20992751308	omega-3	omega-3	MC
304953	100736368	20992751309	fats	fat	NN2
304953	100736368	20992751310	in	in	II
304953	100736368	20992751311	the	the	AT
304953	100736368	20992751312	blood	blood	NN1
304953	100736368	20992751313	and	and	CC
304953	100736368	20992751314	prostate	prostate	NN1
304953	100736368	20992751315	cancer	cancer	NN1
304953	100736368	20992751316	.	.	.
304953	100736368	20992751317	Researchers	researcher	NN2
304953	100736368	20992751318	at	at	II
304953	100736368	20992751319	the	the	AT
304953	100736368	20992751320	Fred	fred	NP1
304953	100736368	20992751321	Hutchinson	hutchinson	NP1
304953	100736368	20992751322	Cancer	cancer	NN1
304953	100736368	20992751323	Center	center	NN1
304953	100736368	20992751324	in	in	II
304953	100736368	20992751325	Seattle	seattle	NP1
304953	100736368	20992751326	men	man	NN2
304953	100736368	20992751327	with	with	IW
304953	100736368	20992751328	high	high	JJ
304953	100736368	20992751329	levels	level	NN2
304953	100736368	20992751330	of	of	IO
304953	100736368	20992751331	omega-3	omega-3	MC
304953	100736368	20992751332	fats	fat	NN2
304953	100736368	20992751333	were	be	VBDR
304953	100736368	20992751334	43%		NNU
304953	100736368	20992751335	more	more	DAR_RRR
304953	100736368	20992751336	likely	likely	JJ
304953	100736368	20992751337	to	to	TO
304953	100736368	20992751338	have	have	VHI
304953	100736368	20992751339	been	be	VBN
304953	100736368	20992751340	diagnosed	diagnose	VVN
304953	100736368	20992751341	with	with	IW
304953	100736368	20992751342	prostate	prostate	NN1
304953	100736368	20992751343	cancer	cancer	NN1
304953	100736368	20992751344	than	than	CSN
304953	100736368	20992751345	men	man	NN2
304953	100736368	20992751346	with	with	IW
304953	100736368	20992751347	low	low	JJ
304953	100736368	20992751348	levels	level	NN2
304953	100736368	20992751349	.	.	.
304953	100736368	20992751350	The	the	AT
304953	100736368	20992751351	finding	finding	NN1
304953	100736368	20992751352	were	be	VBDR
304953	100736368	20992751353	published	publish	VVN
304953	100736368	20992751354	online	online	RR_JJ
304953	100736368	20992751355	in	in	II
304953	100736368	20992751356	the	the	AT
304953	100736368	20992751357	Journal	journal	NN1
304953	100736368	20992751358	of	of	IO
304953	100736368	20992751359	the	the	AT
304953	100736368	20992751360	National	national	JJ
304953	100736368	20992751361	Cancer	cancer	NN1
304953	100736368	20992751362	Institute	institute	NN1
304953	100736368	20992751363	.	.	.
304953	100736370	20992751383	@@##	----------	----------
304953	100736370	20992751384	@@100736370		FO
304953	100736370	20992751385	@4936370/		VV0_NN1
304953	100736370	20992751386	46989		MC
304953	100736370	20992751387	@qwx906989		FO
304953	100736370	20992751388	<p>		NULL
304953	100736370	20992751389	To	to	TO
304953	100736370	20992751390	explore	explore	VVI
304953	100736370	20992751391	the	the	AT
304953	100736370	20992751392	link	link	NN1
304953	100736370	20992751393	between	between	II
304953	100736370	20992751394	multivitamins	multivitamin	NN2
304953	100736370	20992751395	and	and	CC
304953	100736370	20992751396	prostate	prostate	NN1
304953	100736370	20992751397	cancer	cancer	NN1
304953	100736370	20992751398	,	,	,
304953	100736370	20992751399	scientists	scientist	NN2
304953	100736370	20992751400	at	at	II
304953	100736370	20992751401	the	the	AT
304953	100736370	20992751402	National	national	JJ
304953	100736370	20992751403	Cancer	cancer	NN1
304953	100736370	20992751404	Institute	institute	NN1
304953	100736370	20992751405	studied	study	VVD_VVN
304953	100736370	20992751406	295,344		MC
304953	100736370	20992751407	men	man	NN2
304953	100736370	20992751408	who	who	PNQS
304953	100736370	20992751409	participated	participate	VVD
304953	100736370	20992751410	in	in	II
304953	100736370	20992751411	the	the	AT
304953	100736370	20992751412	National	national	JJ
304953	100736370	20992751413	Institutes	institute	NN2
304953	100736370	20992751414	of	of	IO
304953	100736370	20992751415	Health	health	NN1
304953	100736370	20992751416	"	"	"
304953	100736370	20992751417	AARP	aarp	NN1_NP1_VV0
304953	100736370	20992751418	Diet	diet	NN1_NP1@
304953	100736370	20992751419	and	and	CC
304953	100736370	20992751420	Health	health	NN1
304953	100736370	20992751421	Study	study	NN1
304953	100736370	20992751422	.	.	.
304953	100736370	20992751423	At	at	II
304953	100736370	20992751424	the	the	AT
304953	100736370	20992751425	start	start	NN1
304953	100736370	20992751426	of	of	IO
304953	100736370	20992751427	the	the	AT
304953	100736370	20992751428	study	study	NN1
304953	100736370	20992751429	,	,	,
304953	100736370	20992751430	the	the	AT
304953	100736370	20992751431	men	man	NN2
304953	100736370	20992751432	were	be	VBDR
304953	100736370	20992751433	between	between	II
304953	100736370	20992751434	the	the	AT
304953	100736370	20992751435	ages	age	NN2
304953	100736370	20992751436	of	of	IO
304953	100736370	20992751437	50	50	MC
304953	100736370	20992751438	and	and	CC
304953	100736370	20992751439	71	71	MC
304953	100736370	20992751440	and	and	CC
304953	100736370	20992751441	free	free	JJ
304953	100736370	20992751442	of	of	IO
304953	100736370	20992751443	cancer	cancer	NN1
304953	100736370	20992751444	.	.	.
304953	100736370	20992751445	After	after	II_CS
304953	100736370	20992751446	five	five	MC
304953	100736370	20992751447	years	year	NNT2
304953	100736370	20992751448	of	of	IO
304953	100736370	20992751449	follow-up	follow-up	NN1_JJ
304953	100736370	20992751450	,	,	,
304953	100736370	20992751451	scientists	scientist	NN2
304953	100736370	20992751452	found	find	VVD_VVN
304953	100736370	20992751453	no	no	AT
304953	100736370	20992751454	link	link	NN1
304953	100736370	20992751455	between	between	II
304953	100736370	20992751456	multivitamin	multivitamin	NN1
304953	100736370	20992751457	use	use	NN1
304953	100736370	20992751458	and	and	CC
304953	100736370	20992751459	the	the	AT
304953	100736370	20992751460	risk	risk	NN1
304953	100736370	20992751461	of	of	IO
304953	100736370	20992751462	developing	developing	JJ_VVG
304953	100736370	20992751463	localized	localized	JJ
304953	100736370	20992751464	prostate	prostate	NN1
304953	100736370	20992751465	cancer	cancer	NN1
304953	100736370	20992751466	.	.	.
304953	100736370	20992751467	But	but	CCB
304953	100736370	20992751468	compared	compare	VVN_VVD@
304953	100736370	20992751469	with	with	IW
304953	100736370	20992751470	men	man	NN2
304953	100736370	20992751471	who	who	PNQS
304953	100736370	20992751472	did	do	VDD
304953	100736370	20992751473	not	not	XX
304953	100736370	20992751474	take	take	VVI
304953	100736370	20992751475	multivitamins	multivitamin	NN2
304953	100736370	20992751476	,	,	,
304953	100736370	20992751477	men	man	NN2
304953	100736370	20992751478	who	who	PNQS
304953	100736370	20992751479	took	take	VVD
304953	100736370	20992751480	them	them	PPHO2
304953	100736370	20992751481	more	more	DAR
304953	100736370	20992751482	than	than	CSN
304953	100736370	20992751483	seven	seven	MC
304953	100736370	20992751484	times	time	NNT2
304953	100736370	20992751485	a	a	AT1
304953	100736370	20992751486	week	week	NNT1
304953	100736370	20992751487	were	be	VBDR
304953	100736370	20992751488	32%		NNU
304953	100736370	20992751489	more	more	DAR_RRR
304953	100736370	20992751490	likely	likely	JJ
304953	100736370	20992751491	to	to	TO
304953	100736370	20992751492	develop	develop	VVI
304953	100736370	20992751493	advanced	advanced	JJ
304953	100736370	20992751494	prostate	prostate	NN1
304953	100736370	20992751495	cancer	cancer	NN1
304953	100736370	20992751496	and	and	CC
304953	100736370	20992751497	98%		NNU
304953	100736370	20992751498	more	more	DAR_RRR
304953	100736370	20992751499	likely	likely	JJ
304953	100736370	20992751500	to	to	TO
304953	100736370	20992751501	die	die	VVI
304953	100736370	20992751502	from	from	II
304953	100736370	20992751503	the	the	AT
304953	100736370	20992751504	disease	disease	NN1
304953	100736370	20992751505	.	.	.
304953	100736370	20992751506	<p>		NULL
304953	100736370	20992751507	The	the	AT
304953	100736370	20992751508	results	result	NN2
304953	100736370	20992751509	are	be	VBR
304953	100736370	20992751510	cause	cause	NN1_VV0
304953	100736370	20992751511	for	for	IF
304953	100736370	20992751512	concern	concern	NN1
304953	100736370	20992751513	,	,	,
304953	100736370	20992751514	but	but	CCB
304953	100736370	20992751515	not	not	XX
304953	100736370	20992751516	alarm	alarm	NN1_VV0
304953	100736370	20992751517	.	.	.
304953	100736370	20992751518	The	the	AT
304953	100736370	20992751519	apparent	apparent	JJ
304953	100736370	20992751520	link	link	NN1
304953	100736370	20992751521	between	between	II
304953	100736370	20992751522	heavy	heavy	JJ
304953	100736370	20992751523	multivitamin	multivitamin	NN1
304953	100736370	20992751524	use	use	NN1
304953	100736370	20992751525	and	and	CC
304953	100736370	20992751526	advanced	advanced	JJ_VVD_VVN
304953	100736370	20992751527	or	or	CC
304953	100736370	20992751528	fatal	fatal	JJ
304953	100736370	20992751529	prostate	prostate	NN1
304953	100736370	20992751530	cancer	cancer	NN1
304953	100736370	20992751531	was	be	VBDZ
304953	100736370	20992751532	strongest	strong	JJT
304953	100736370	20992751533	in	in	II
304953	100736370	20992751534	men	man	NN2
304953	100736370	20992751535	with	with	IW
304953	100736370	20992751536	a	a	AT1
304953	100736370	20992751537	family	family	NN1
304953	100736370	20992751538	history	history	NN1
304953	100736370	20992751539	of	of	IO
304953	100736370	20992751540	the	the	AT
304953	100736370	20992751541	disease	disease	NN1
304953	100736370	20992751542	(	(	(
304953	100736370	20992751543	who	who	PNQS
304953	100736370	20992751544	have	have	VH0
304953	100736370	20992751545	an	a	AT1
304953	100736370	20992751546	increased	increased	JJ
304953	100736370	20992751547	risk	risk	NN1
304953	100736370	20992751548	already	already	RR
304953	100736370	20992751549	)	)	)
304953	100736370	20992751550	and	and	CC
304953	100736370	20992751551	those	those	DD2
304953	100736370	20992751552	who	who	PNQS
304953	100736370	20992751553	took	take	VVD
304953	100736370	20992751554	one	one	MC1
304953	100736370	20992751555	or	or	CC
304953	100736370	20992751556	more	more	DAR
304953	100736370	20992751557	additional	additional	JJ
304953	100736370	20992751558	supplements	supplement	NN2
304953	100736370	20992751559	.	.	.
304953	100736370	20992751560	Men	man	NN2
304953	100736370	20992751561	who	who	PNQS
304953	100736370	20992751562	take	take	VV0
304953	100736370	20992751563	lots	lots	PN
304953	100736370	20992751564	of	of	IO
304953	100736370	20992751565	supplements	supplement	NN2
304953	100736370	20992751566	may	may	VM
304953	100736370	20992751567	have	have	VHI
304953	100736370	20992751568	premonitory	premonitory	JJ
304953	100736370	20992751569	symptoms	symptom	NN2
304953	100736370	20992751570	or	or	CC
304953	100736370	20992751571	other	other	JJ
304953	100736370	20992751572	reasons	reason	NN2
304953	100736370	20992751573	to	to	TO
304953	100736370	20992751574	worry	worry	VVI
304953	100736370	20992751575	@		II
304953	100736370	20992751576	@		II
304953	100736370	20992751577	@		II
304953	100736370	20992751578	@		II
304953	100736370	20992751579	@		II
304953	100736370	20992751580	@		II
304953	100736370	20992751581	@		II
304953	100736370	20992751582	@		II
304953	100736370	20992751583	@		II
304953	100736370	20992751584	@		II
304953	100736370	20992751585	determine	determine	VVI
304953	100736370	20992751586	whether	whether	CSW
304953	100736370	20992751587	the	the	AT
304953	100736370	20992751588	vitamins	vitamin	NN2
304953	100736370	20992751589	caused	cause	VVD_VVN
304953	100736370	20992751590	the	the	AT
304953	100736370	20992751591	cancers	cancer	NN2
304953	100736370	20992751592	.	.	.
304953	100736370	20992751593	Nor	nor	CC
304953	100736370	20992751594	did	do	VDD
304953	100736370	20992751595	it	it	PPH1
304953	100736370	20992751596	learn	learn	VVI
304953	100736370	20992751597	which	which	DDQ
304953	100736370	20992751598	multivitamins	multivitamin	NN2
304953	100736370	20992751599	the	the	AT
304953	100736370	20992751600	men	man	NN2
304953	100736370	20992751601	took	take	VVD
304953	100736370	20992751602	,	,	,
304953	100736370	20992751603	how	how	RRQ_RGQ@
304953	100736370	20992751604	long	long	RR
304953	100736370	20992751605	they	they	PPHS2
304953	100736370	20992751606	had	have	VHD
304953	100736370	20992751607	been	be	VBN
304953	100736370	20992751608	taking	take	VVG
304953	100736370	20992751609	them	them	PPHO2
304953	100736370	20992751610	,	,	,
304953	100736370	20992751611	or	or	CC
304953	100736370	20992751612	whether	whether	CSW
304953	100736370	20992751613	they	they	PPHS2
304953	100736370	20992751614	continued	continue	VVD
304953	100736370	20992751615	to	to	TO
304953	100736370	20992751616	use	use	VVI
304953	100736370	20992751617	them	them	PPHO2
304953	100736370	20992751618	during	during	II
304953	100736370	20992751619	the	the	AT
304953	100736370	20992751620	follow-up	follow-up	JJ_NN1
304953	100736370	20992751621	period	period	NN1
304953	100736370	20992751622	.	.	.
304953	100736370	20992751623	46996		MC
304953	100736370	20992751624	@qwx906996		FO
304953	100736371	20992751644	@@##	----------	----------
304953	100736371	20992751645	@@100736371		FO
304953	100736371	20992751646	@4936371/		VV0_NN1
304953	100736371	20992751647	46989		MC
304953	100736371	20992751648	@qwx906989		FO
304953	100736371	20992751649	<p>		NULL
304953	100736371	20992751650	External	external	JJ
304953	100736371	20992751651	beam	beam	NN1
304953	100736371	20992751652	radiation	radiation	NN1
304953	100736371	20992751653	does	do	VDZ
304953	100736371	20992751654	n't	n't	XX
304953	100736371	20992751655	always	always	RR
304953	100736371	20992751656	eradicate	eradicate	VVI
304953	100736371	20992751657	prostate	prostate	NN1
304953	100736371	20992751658	cancer	cancer	NN1
304953	100736371	20992751659	.	.	.
304953	100736371	20992751660	Researchers	researcher	NN2
304953	100736371	20992751661	estimate	estimate	VV0
304953	100736371	20992751662	that	that	CST_DD1
304953	100736371	20992751663	about	about	RG
304953	100736371	20992751664	20%		NNU
304953	100736371	20992751665	to	to	II
304953	100736371	20992751666	30%		NNU
304953	100736371	20992751667	of	of	IO
304953	100736371	20992751668	patients	patient	NN2
304953	100736371	20992751669	experience	experience	VV0
304953	100736371	20992751670	a	a	AT1
304953	100736371	20992751671	rising	rising	JJ@
304953	100736371	20992751672	prostate-specific	prostate-specific	JJ
304953	100736371	20992751673	antigen	antigen	NN1
304953	100736371	20992751674	(	(	(
304953	100736371	20992751675	PSA	psa	NP1
304953	100736371	20992751676	)	)	)
304953	100736371	20992751677	,	,	,
304953	100736371	20992751678	or	or	CC
304953	100736371	20992751679	biochemical	biochemical	JJ
304953	100736371	20992751680	recurrence	recurrence	NN1
304953	100736371	20992751681	of	of	IO
304953	100736371	20992751682	their	their	APPGE
304953	100736371	20992751683	disease	disease	NN1
304953	100736371	20992751684	,	,	,
304953	100736371	20992751685	following	follow	VVG_JJ@
304953	100736371	20992751686	treatment	treatment	NN1
304953	100736371	20992751687	.	.	.
304953	100736371	20992751688	Debate	debate	NN1_VV0@
304953	100736371	20992751689	about	about	II
304953	100736371	20992751690	what	what	DDQ
304953	100736371	20992751691	secondary	secondary	NN1
304953	100736371	20992751692	,	,	,
304953	100736371	20992751693	or	or	CC
304953	100736371	20992751694	salvage	salvage	NN1_VV0
304953	100736371	20992751695	,	,	,
304953	100736371	20992751696	treatment	treatment	NN1
304953	100736371	20992751697	to	to	TO
304953	100736371	20992751698	try	try	VVI
304953	100736371	20992751699	next	next	MD
304953	100736371	20992751700	has	have	VHZ
304953	100736371	20992751701	blossomed	blossom	VVN
304953	100736371	20992751702	.	.	.
304953	100736371	20992751703	<p>		NULL
304953	100736371	20992751704	High-intensity	high-intensity	JJ_NN1
304953	100736371	20992751705	focused	focused	JJ@_VVD_VVN
304953	100736371	20992751706	ultrasound	ultrasound	NN1
304953	100736371	20992751707	(	(	(
304953	100736371	20992751708	HIFU		NP1
304953	100736371	20992751709	)	)	)
304953	100736371	20992751710	,	,	,
304953	100736371	20992751711	which	which	DDQ
304953	100736371	20992751712	uses	use	VVZ
304953	100736371	20992751713	sound	sound	NN1_JJ@
304953	100736371	20992751714	waves	wave	NN2_VVZ@
304953	100736371	20992751715	to	to	TO
304953	100736371	20992751716	destroy	destroy	VVI
304953	100736371	20992751717	cancerous	cancerous	JJ
304953	100736371	20992751718	tissue	tissue	NN1
304953	100736371	20992751719	,	,	,
304953	100736371	20992751720	is	be	VBZ
304953	100736371	20992751721	one	one	MC1
304953	100736371	20992751722	option	option	NN1
304953	100736371	20992751723	for	for	IF
304953	100736371	20992751724	treating	treat	VVG
304953	100736371	20992751725	a	a	AT1
304953	100736371	20992751726	localized	localized	JJ
304953	100736371	20992751727	recurrence	recurrence	NN1
304953	100736371	20992751728	(	(	(
304953	100736371	20992751729	see	see	VV0
304953	100736371	20992751730	Figure	figure	NN1
304953	100736371	20992751731	1	1	MC1
304953	100736371	20992751732	below	below	RL
304953	100736371	20992751733	)	)	)
304953	100736371	20992751734	.	.	.
304953	100736371	20992751735	Because	because	CS
304953	100736371	20992751736	each	each	DD1
304953	100736371	20992751737	pulse	pulse	NN1
304953	100736371	20992751738	of	of	IO
304953	100736371	20992751739	energy	energy	NN1
304953	100736371	20992751740	ablates		VVZ
304953	100736371	20992751741	only	only	JJ
304953	100736371	20992751742	a	a-i	AT1
304953	100736371	20992751743	small	small	JJ
304953	100736371	20992751744	amount	amount	NN1
304953	100736371	20992751745	of	of	IO
304953	100736371	20992751746	tissue	tissue	NN1
304953	100736371	20992751747	,	,	,
304953	100736371	20992751748	doctors	doctor	NN2
304953	100736371	20992751749	can	can	VM
304953	100736371	20992751750	target	target	VVI
304953	100736371	20992751751	certain	certain	JJ
304953	100736371	20992751752	areas	area	NN2
304953	100736371	20992751753	and	and	CC
304953	100736371	20992751754	spare	spare	JJ_VV0
304953	100736371	20992751755	others	others	NN2
304953	100736371	20992751756	,	,	,
304953	100736371	20992751757	theoretically	theoretically	RR
304953	100736371	20992751758	minimizing	minimize	VVG
304953	100736371	20992751759	the	the	AT
304953	100736371	20992751760	chances	chance	NN2
304953	100736371	20992751761	of	of	IO
304953	100736371	20992751762	side	side	NN1
304953	100736371	20992751763	effects	effect	NN2
304953	100736371	20992751764	.	.	.
304953	100736371	20992751765	<h>		NULL
304953	100736371	20992751766	Figure	figure	VV0@_NN1
304953	100736371	20992751767	1	1	MC1
304953	100736371	20992751768	:	:	:
304953	100736371	20992751769	High-intensity	high-intensity	JJ_NN1
304953	100736371	20992751770	focused	focused	JJ@_VVD
304953	100736371	20992751771	ultrasound	ultrasound	NN1
304953	100736371	20992751772	(	(	(
304953	100736371	20992751773	HIFU		NP1
304953	100736371	20992751774	)	)	)
304953	100736371	20992751775	<p>		NULL
304953	100736371	20992751776	During	during	II
304953	100736371	20992751777	HIFU		NP1_NN1
304953	100736371	20992751778	,	,	,
304953	100736371	20992751779	pulses	pulse	NN2
304953	100736371	20992751780	of	of	IO
304953	100736371	20992751781	energy	energy	NN1
304953	100736371	20992751782	produced	produce	VVN
304953	100736371	20992751783	by	by	II
304953	100736371	20992751784	a	a	AT1
304953	100736371	20992751785	rectal	rectal	JJ
304953	100736371	20992751786	probe	probe	NN1
304953	100736371	20992751787	destroy	destroy	VV0
304953	100736371	20992751788	tissue	tissue	NN1
304953	100736371	20992751789	at	at	II
304953	100736371	20992751790	the	the	AT
304953	100736371	20992751791	point	point	NN1
304953	100736371	20992751792	where	where	RRQ
304953	100736371	20992751793	sound	sound	NN1_JJ@
304953	100736371	20992751794	waves	wave	NN2
304953	100736371	20992751795	converge	converge	VV0
304953	100736371	20992751796	.	.	.
304953	100736371	20992751797	Because	because	CS
304953	100736371	20992751798	the	the	AT
304953	100736371	20992751799	technology	technology	NN1
304953	100736371	20992751800	can	can	VM
304953	100736371	20992751801	target	target	VVI
304953	100736371	20992751802	certain	certain	JJ
304953	100736371	20992751803	areas	area	NN2
304953	100736371	20992751804	and	and	CC
304953	100736371	20992751805	spare	spare	JJ_VV0
304953	100736371	20992751806	others	others	NN2
304953	100736371	20992751807	,	,	,
304953	100736371	20992751808	side	side	NN1
304953	100736371	20992751809	effects	effect	NN2
304953	100736371	20992751810	may	may	VM
304953	100736371	20992751811	be	be	VBI
304953	100736371	20992751812	minimized	minimize	VVN@
304953	100736371	20992751813	.	.	.
304953	100736371	20992751814	<p>		NULL
304953	100736371	20992751815	British	british	JJ
304953	100736371	20992751816	researchers	researcher	NN2
304953	100736371	20992751817	recently	recently	RR
304953	100736371	20992751818	examined	examine	VVD_VVN
304953	100736371	20992751819	the	the	AT
304953	100736371	20992751820	effectiveness	effectiveness	NN1
304953	100736371	20992751821	of	of	IO
304953	100736371	20992751822	HIFU		NN1_NP1
304953	100736371	20992751823	in	in	II
304953	100736371	20992751824	31	31	MC
304953	100736371	20992751825	men	man	NN2
304953	100736371	20992751826	who	who	PNQS
304953	100736371	20992751827	experienced	experience	VVD
304953	100736371	20992751828	a	a	AT1
304953	100736371	20992751829	biochemical	biochemical	JJ
304953	100736371	20992751830	recurrence	recurrence	NN1
304953	100736371	20992751831	of	of	IO
304953	100736371	20992751832	prostate	prostate	NN1
304953	100736371	20992751833	cancer	cancer	NN1
304953	100736371	20992751834	following	follow	VVG_II@
304953	100736371	20992751835	external	external	JJ
304953	100736371	20992751836	@		II
304953	100736371	20992751837	@		II
304953	100736371	20992751838	@		II
304953	100736371	20992751839	@		II
304953	100736371	20992751840	@		II
304953	100736371	20992751841	@		II
304953	100736371	20992751842	@		II
304953	100736371	20992751843	@		II
304953	100736371	20992751844	@		II
304953	100736371	20992751845	@		II
304953	100736371	20992751846	among	among	II
304953	100736371	20992751847	the	the	AT
304953	100736371	20992751848	men	man	NN2
304953	100736371	20992751849	was	be	VBDZ
304953	100736371	20992751850	7.7	7.7	MC
304953	100736371	20992751851	ng/ml	ng/ml	FU
304953	100736371	20992751852	.	.	.
304953	100736371	20992751853	Three	three	MC
304953	100736371	20992751854	months	month	NNT2
304953	100736371	20992751855	after	after	II_CS
304953	100736371	20992751856	HIFU		NP1_NN1
304953	100736371	20992751857	,	,	,
304953	100736371	20992751858	about	about	RG
304953	100736371	20992751859	65%		NNU
304953	100736371	20992751860	had	have	VHD
304953	100736371	20992751861	a	a	AT1
304953	100736371	20992751862	PSA	psa	NP1
304953	100736371	20992751863	of	of	IO
304953	100736371	20992751864	0.2	0.2	MC
304953	100736371	20992751865	ng/ml	ng/ml	FU
304953	100736371	20992751866	or	or	CC
304953	100736371	20992751867	less	less	RRR_DAR
304953	100736371	20992751868	.	.	.
304953	100736371	20992751869	Of	of	IO
304953	100736371	20992751870	those	those	DD2
304953	100736371	20992751871	who	who	PNQS
304953	100736371	20992751872	reached	reach	VVD
304953	100736371	20992751873	the	the	AT
304953	100736371	20992751874	six-		NN1_JJ
304953	100736371	20992751875	and	and	CC
304953	100736371	20992751876	nine-month	nine-month	JJ
304953	100736371	20992751877	check-ups	checkup	NN2
304953	100736371	20992751878	,	,	,
304953	100736371	20992751879	about	about	RG
304953	100736371	20992751880	half	half	DB
304953	100736371	20992751881	maintained	maintain	VVD_VVN
304953	100736371	20992751882	a	a	AT1
304953	100736371	20992751883	PSA	psa	NP1
304953	100736371	20992751884	at	at	II
304953	100736371	20992751885	that	that	DD1
304953	100736371	20992751886	level	level	NN1
304953	100736371	20992751887	.	.	.
304953	100736371	20992751888	<p>		NULL
304953	100736371	20992751889	Side	side	NN1
304953	100736371	20992751890	effects	effect	NN2
304953	100736371	20992751891	of	of	IO
304953	100736371	20992751892	HIFU		NP1_NN1
304953	100736371	20992751893	included	include	VVD
304953	100736371	20992751894	narrowing	narrow	VVG_NN1@
304953	100736371	20992751895	of	of	IO
304953	100736371	20992751896	the	the	AT
304953	100736371	20992751897	urethra	urethra	NN1
304953	100736371	20992751898	and	and	CC
304953	100736371	20992751899	the	the	AT
304953	100736371	20992751900	need	need	NN1
304953	100736371	20992751901	for	for	IF
304953	100736371	20992751902	a	a	AT1
304953	100736371	20992751903	procedure	procedure	NN1
304953	100736371	20992751904	to	to	TO
304953	100736371	20992751905	remove	remove	VVI
304953	100736371	20992751906	dead	dead	JJ
304953	100736371	20992751907	tissue	tissue	NN1
304953	100736371	20992751908	,	,	,
304953	100736371	20992751909	urinary	urinary	JJ_NN1
304953	100736371	20992751910	tract	tract	NN1
304953	100736371	20992751911	infections	infection	NN2
304953	100736371	20992751912	,	,	,
304953	100736371	20992751913	painful	painful	JJ
304953	100736371	20992751914	urination	urination	NN1
304953	100736371	20992751915	,	,	,
304953	100736371	20992751916	urinary	urinary	JJ_NN1
304953	100736371	20992751917	incontinence	incontinence	NN1
304953	100736371	20992751918	,	,	,
304953	100736371	20992751919	and	and	CC
304953	100736371	20992751920	,	,	,
304953	100736371	20992751921	rarely	rarely	RR
304953	100736371	20992751922	,	,	,
304953	100736371	20992751923	the	the	AT
304953	100736371	20992751924	formation	formation	NN1
304953	100736371	20992751925	of	of	IO
304953	100736371	20992751926	a	a	AT1
304953	100736371	20992751927	hole	hole	NN1
304953	100736371	20992751928	between	between	II
304953	100736371	20992751929	the	the	AT
304953	100736371	20992751930	rectum	rectum	NN1
304953	100736371	20992751931	and	and	CC
304953	100736371	20992751932	urethra	urethra	NN1
304953	100736371	20992751933	.	.	.
304953	100736371	20992751934	The	the	AT
304953	100736371	20992751935	chance	chance	NN1
304953	100736371	20992751936	of	of	IO
304953	100736371	20992751937	side	side	NN1
304953	100736371	20992751938	effects	effect	NN2
304953	100736371	20992751939	was	be	VBDZ
304953	100736371	20992751940	on	on	II
304953	100736371	20992751941	a	a	AT1
304953	100736371	20992751942	par	par	NN1
304953	100736371	20992751943	with	with	IW
304953	100736371	20992751944	that	that	DD1
304953	100736371	20992751945	of	of	IO
304953	100736371	20992751946	other	other	JJ
304953	100736371	20992751947	salvage	salvage	NN1
304953	100736371	20992751948	treatments	treatment	NN2
304953	100736371	20992751949	,	,	,
304953	100736371	20992751950	making	make	VVG
304953	100736371	20992751951	HIFU		NN1_NP1
304953	100736371	20992751952	a	a	AT1
304953	100736371	20992751953	seemingly	seemingly	RR
304953	100736371	20992751954	feasible	feasible	JJ
304953	100736371	20992751955	option	option	NN1
304953	100736371	20992751956	.	.	.
304953	100736371	20992751957	<p>		NULL
304953	100736371	20992751958	Choosing	choose	VVG
304953	100736371	20992751959	appropriate	appropriate	JJ
304953	100736371	20992751960	patients	patient	NN2
304953	100736371	20992751961	for	for	IF
304953	100736371	20992751962	salvage	salvage	NN1
304953	100736371	20992751963	HIFU		NN1_NP1
304953	100736371	20992751964	remains	remain	VVZ
304953	100736371	20992751965	the	the	AT
304953	100736371	20992751966	biggest	big	JJT
304953	100736371	20992751967	challenge	challenge	NN1
304953	100736371	20992751968	,	,	,
304953	100736371	20992751969	the	the	AT
304953	100736371	20992751970	researchers	researcher	NN2
304953	100736371	20992751971	noted	note	VVN_VVD
304953	100736371	20992751972	.	.	.
304953	100736371	20992751973	HIFU		NP1_NN1
304953	100736371	20992751974	will	will	VM
304953	100736371	20992751975	not	not	XX
304953	100736371	20992751976	effectively	effectively	RR
304953	100736371	20992751977	treat	treat	VVI
304953	100736371	20992751978	metastatic	metastatic	JJ
304953	100736371	20992751979	cancer	cancer	NN1
304953	100736371	20992751980	,	,	,
304953	100736371	20992751981	but	but	CCB
304953	100736371	20992751982	some	some	DD
304953	100736371	20992751983	patients	patient	NN2
304953	100736371	20992751984	harbor	harbor	VV0@_NN1
304953	100736371	20992751985	cancer	cancer	NN1
304953	100736371	20992751986	that	that	CST_DD1
304953	100736371	20992751987	has	have	VHZ
304953	100736371	20992751988	spread	spread	VVN
304953	100736371	20992751989	elsewhere	elsewhere	RL
304953	100736371	20992751990	in	in	II
304953	100736371	20992751991	the	the	AT
304953	100736371	20992751992	body	body	NN1
304953	100736371	20992751993	and	and	CC
304953	100736371	20992751994	evades	evade	VVZ
304953	100736371	20992751995	detection	detection	NN1
304953	100736371	20992751996	prior	prior	II21
304953	100736371	20992751997	to	to	II22
304953	100736371	20992751998	HIFU		NP1_NN1
304953	100736371	20992751999	.	.	.
304953	100736371	20992752000	<p>		NULL
304953	100736371	20992752001	Hi	hi	UH
304953	100736371	20992752002	I	i	PPIS1
304953	100736371	20992752003	have	have	VH0
304953	100736371	20992752004	been	be	VBN
304953	100736371	20992752005	in	in	II
304953	100736371	20992752006	hormone	hormone	NN1
304953	100736371	20992752007	treatment	treatment	NN1
304953	100736371	20992752008	for	for	IF
304953	100736371	20992752009	3	3	MC
304953	100736371	20992752010	years	year	NNT2
304953	100736371	20992752011	and	and	CC
304953	100736371	20992752012	the	the	AT
304953	100736371	20992752013	psa		NN1
304953	100736371	20992752014	is	be	VBZ
304953	100736371	20992752015	always	always	RR
304953	100736371	20992752016	been	be	VBN
304953	100736371	20992752017	low	low	JJ_RR@
304953	100736371	20992752018	(	(	(
304953	100736371	20992752019	0.9	0.9	MC
304953	100736371	20992752020	or	or	CC
304953	100736371	20992752021	lower	low	JJR_RRR@
304953	100736371	20992752022	)	)	)
304953	100736371	20992752023	but	but	CCB
304953	100736371	20992752024	at	at	II
304953	100736371	20992752025	the	the	AT
304953	100736371	20992752026	same	same	DA
304953	100736371	20992752027	time	time	NNT1
304953	100736371	20992752028	the	the	AT
304953	100736371	20992752029	side	side	NN1
304953	100736371	20992752030	effects	effect	NN2
304953	100736371	20992752031	are	be	VBR
304953	100736371	20992752032	taking	take	VVG
304953	100736371	20992752033	a	a	AT1
304953	100736371	20992752034	toll	toll	NN1
304953	100736371	20992752035	on	on	II
304953	100736371	20992752036	@		II
304953	100736371	20992752037	@		II
304953	100736371	20992752038	@		II
304953	100736371	20992752039	@		II
304953	100736371	20992752040	@		II
304953	100736371	20992752041	@		II
304953	100736371	20992752042	@		II
304953	100736371	20992752043	@		II
304953	100736371	20992752044	@		II
304953	100736371	20992752045	@		II
304953	100736371	20992752046	flashes	flash	NN2_VVZ
304953	100736371	20992752047	46996		MC
304953	100736371	20992752048	@qwx906996		FO
304953	100736373	20992752068	@@##	----------	----------
304953	100736373	20992752069	@@100736373		FO
304953	100736373	20992752070	@4936373/		VV0_NN1
304953	100736373	20992752071	46989		MC
304953	100736373	20992752072	@qwx906989		FO
304953	100736373	20992752073	<p>		NULL
304953	100736373	20992752074	There	there	EX
304953	100736373	20992752075	's	be	VBZ
304953	100736373	20992752076	good	good	JJ
304953	100736373	20992752077	news	news	NN1
304953	100736373	20992752078	for	for	IF
304953	100736373	20992752079	patients	patient	NN2
304953	100736373	20992752080	with	with	IW
304953	100736373	20992752081	metastatic	metastatic	JJ
304953	100736373	20992752082	prostate	prostate	NN1
304953	100736373	20992752083	cancer	cancer	NN1
304953	100736373	20992752084	who	who	PNQS
304953	100736373	20992752085	have	have	VH0
304953	100736373	20992752086	been	be	VBN
304953	100736373	20992752087	eagerly	eagerly	RR
304953	100736373	20992752088	awaiting	await	VVG
304953	100736373	20992752089	a	a	AT1
304953	100736373	20992752090	new	new	JJ
304953	100736373	20992752091	treatment	treatment	NN1
304953	100736373	20992752092	option	option	NN1
304953	100736373	20992752093	.	.	.
304953	100736373	20992752094	In	in	II
304953	100736373	20992752095	April	april	NPM1
304953	100736373	20992752096	2010	2010	MC
304953	100736373	20992752097	,	,	,
304953	100736373	20992752098	the	the	AT
304953	100736373	20992752099	FDA	fda	NP1_NN1
304953	100736373	20992752100	approved	approve	VVD
304953	100736373	20992752101	sipuleucel-T		NP1
304953	100736373	20992752102	(	(	(
304953	100736373	20992752103	Provenge		NP1
304953	100736373	20992752104	)	)	)
304953	100736373	20992752105	,	,	,
304953	100736373	20992752106	a	a	AT1
304953	100736373	20992752107	vaccine	vaccine	NN1
304953	100736373	20992752108	that	that	CST_DD1
304953	100736373	20992752109	uses	use	VVZ
304953	100736373	20992752110	the	the	AT
304953	100736373	20992752111	immune	immune	JJ
304953	100736373	20992752112	system	system	NN1
304953	100736373	20992752113	to	to	TO
304953	100736373	20992752114	fight	fight	VVI
304953	100736373	20992752115	advanced	advanced	JJ
304953	100736373	20992752116	stage	stage	NN1
304953	100736373	20992752117	disease	disease	NN1
304953	100736373	20992752118	.	.	.
304953	100736373	20992752119	<p>		NULL
304953	100736373	20992752120	Unlike	unlike	II@
304953	100736373	20992752121	a	a	AT1
304953	100736373	20992752122	preventive	preventive	JJ
304953	100736373	20992752123	vaccine	vaccine	NN1
304953	100736373	20992752124	,	,	,
304953	100736373	20992752125	which	which	DDQ
304953	100736373	20992752126	boosts	boost	VVZ
304953	100736373	20992752127	the	the	AT
304953	100736373	20992752128	immune	immune	JJ
304953	100736373	20992752129	system	system	NN1
304953	100736373	20992752130	to	to	TO
304953	100736373	20992752131	protect	protect	VVI
304953	100736373	20992752132	people	people	NN
304953	100736373	20992752133	from	from	II
304953	100736373	20992752134	illness	illness	NN1
304953	100736373	20992752135	,	,	,
304953	100736373	20992752136	sipuleucel-T		NP1
304953	100736373	20992752137	is	be	VBZ
304953	100736373	20992752138	a	a	AT1
304953	100736373	20992752139	therapeutic	therapeutic	JJ
304953	100736373	20992752140	vaccine	vaccine	NN1
304953	100736373	20992752141	.	.	.
304953	100736373	20992752142	It	it	PPH1
304953	100736373	20992752143	shows	show	VVZ
304953	100736373	20992752144	the	the	AT
304953	100736373	20992752145	immune	immune	JJ
304953	100736373	20992752146	system	system	NN1
304953	100736373	20992752147	what	what	DDQ
304953	100736373	20992752148	the	the	AT
304953	100736373	20992752149	tumor	tumor	NN1
304953	100736373	20992752150	cells	cell	NN2
304953	100736373	20992752151	look	look	VV0
304953	100736373	20992752152	like	like	II
304953	100736373	20992752153	and	and	CC
304953	100736373	20992752154	primes	prime	VVZ_NN2
304953	100736373	20992752155	immune	immune	JJ
304953	100736373	20992752156	cells	cell	NN2
304953	100736373	20992752157	to	to	TO
304953	100736373	20992752158	attack	attack	VVI
304953	100736373	20992752159	when	when	RRQ_CS
304953	100736373	20992752160	they	they	PPHS2
304953	100736373	20992752161	encounter	encounter	VV0
304953	100736373	20992752162	lingering	lingering	JJ
304953	100736373	20992752163	tumor	tumor	NN1
304953	100736373	20992752164	cells	cell	NN2
304953	100736373	20992752165	.	.	.
304953	100736373	20992752166	<p>		NULL
304953	100736373	20992752167	The	the	AT
304953	100736373	20992752168	approval	approval	NN1
304953	100736373	20992752169	of	of	IO
304953	100736373	20992752170	the	the	AT
304953	100736373	20992752171	vaccine	vaccine	NN1
304953	100736373	20992752172	follows	follow	VVZ
304953	100736373	20992752173	the	the	AT
304953	100736373	20992752174	release	release	NN1
304953	100736373	20992752175	of	of	IO
304953	100736373	20992752176	data	data	NN
304953	100736373	20992752177	in	in	II
304953	100736373	20992752178	2009	2009	MC
304953	100736373	20992752179	from	from	II
304953	100736373	20992752180	the	the	AT
304953	100736373	20992752181	phase	phase	NN1
304953	100736373	20992752182	III	iii	MC
304953	100736373	20992752183	Immunotherapy		NN1_NP1
304953	100736373	20992752184	for	for	IF
304953	100736373	20992752185	Prostate	prostate	NN1
304953	100736373	20992752186	Adenocarcinoma		NP1_NN1@
304953	100736373	20992752187	Treatment	treatment	NN1
304953	100736373	20992752188	(	(	(
304953	100736373	20992752189	IMPACT	impact	NN1
304953	100736373	20992752190	)	)	)
304953	100736373	20992752191	study.		NNU
304953	100736373	20992752192	*	*	FU
304953	100736373	20992752193	The	the	AT
304953	100736373	20992752194	study	study	NN1
304953	100736373	20992752195	followed	follow	VVD_VVN
304953	100736373	20992752196	more	more	DAR
304953	100736373	20992752197	than	than	CSN
304953	100736373	20992752198	500	500	MC
304953	100736373	20992752199	men	man	NN2
304953	100736373	20992752200	with	with	IW
304953	100736373	20992752201	advanced	advanced	JJ
304953	100736373	20992752202	stage	stage	NN1
304953	100736373	20992752203	prostate	prostate	NN1
304953	100736373	20992752204	cancer	cancer	NN1
304953	100736373	20992752205	who	who	PNQS
304953	100736373	20992752206	no	no	RR21
304953	100736373	20992752207	longer	long	RR22
304953	100736373	20992752208	responded	respond	VVN_VVD
304953	100736373	20992752209	to	to	II
304953	100736373	20992752210	hormone	hormone	NN1
304953	100736373	20992752211	therapy	therapy	NN1
304953	100736373	20992752212	.	.	.
304953	100736373	20992752213	The	the	AT
304953	100736373	20992752214	participants	participant	NN2
304953	100736373	20992752215	were	be	VBDR
304953	100736373	20992752216	randomly	randomly	RR
304953	100736373	20992752217	assigned	assign	VVN
304953	100736373	20992752218	to	to	TO
304953	100736373	20992752219	receive	receive	VVI
304953	100736373	20992752220	the	the	AT
304953	100736373	20992752221	vaccine	vaccine	NN1
304953	100736373	20992752222	or	or	CC
304953	100736373	20992752223	an	a	AT1
304953	100736373	20992752224	inactive	inactive	JJ
304953	100736373	20992752225	placebo	placebo	NN1
304953	100736373	20992752226	.	.	.
304953	100736373	20992752227	Among	among	II
304953	100736373	20992752228	those	those	DD2
304953	100736373	20992752229	treated	treat	VVN
304953	100736373	20992752230	with	with	IW
304953	100736373	20992752231	sipuleucel-T		NP1
304953	100736373	20992752232	,	,	,
304953	100736373	20992752233	the	the	AT
304953	100736373	20992752234	median	median	JJ_NN1
304953	100736373	20992752235	survival	survival	NN1
304953	100736373	20992752236	time	time	NNT1
304953	100736373	20992752237	increased	increase	VVD_VVN
304953	100736373	20992752238	by	by	RP%_II
304953	100736373	20992752239	over	over	RG
304953	100736373	20992752240	four	four	MC
304953	100736373	20992752241	months	month	NNT2
304953	100736373	20992752242	and	and	CC
304953	100736373	20992752243	the	the	AT
304953	100736373	20992752244	chance	chance	NN1
304953	100736373	20992752245	of	of	IO
304953	100736373	20992752246	living	live	VVG_NN1
304953	100736373	20992752247	at	at	RR21
304953	100736373	20992752248	least	least	RR22
304953	100736373	20992752249	three	three	MC
304953	100736373	20992752250	years	year	NNT2
304953	100736373	20992752251	after	after	II_CS
304953	100736373	20992752252	treatment	treatment	NN1
304953	100736373	20992752253	improved	improve	VVN
304953	100736373	20992752254	by	by	II
304953	100736373	20992752255	38%		NNU
304953	100736373	20992752256	.	.	.
304953	100736373	20992752257	<p>		NULL
304953	100736373	20992752258	Patients	patient	NN2
304953	100736373	20992752259	receive	receive	VV0
304953	100736373	20992752260	@		II
304953	100736373	20992752261	@		II
304953	100736373	20992752262	@		II
304953	100736373	20992752263	@		II
304953	100736373	20992752264	@		II
304953	100736373	20992752265	@		II
304953	100736373	20992752266	@		II
304953	100736373	20992752267	@		II
304953	100736373	20992752268	@		II
304953	100736373	20992752269	@		II
304953	100736373	20992752270	the	the	AT
304953	100736373	20992752271	course	course	NN1
304953	100736373	20992752272	of	of	IO
304953	100736373	20992752273	a	a	AT1
304953	100736373	20992752274	month	month	NNT1
304953	100736373	20992752275	.	.	.
304953	100736373	20992752276	Common	common	JJ
304953	100736373	20992752277	side	side	NN1
304953	100736373	20992752278	effects	effect	NN2
304953	100736373	20992752279	reported	report	VVN
304953	100736373	20992752280	by	by	II
304953	100736373	20992752281	study	study	NN1
304953	100736373	20992752282	participants	participant	NN2
304953	100736373	20992752283	included	include	VVD_VVN
304953	100736373	20992752284	chills	chill	NN2
304953	100736373	20992752285	,	,	,
304953	100736373	20992752286	fever	fever	NN1
304953	100736373	20992752287	,	,	,
304953	100736373	20992752288	back	back	NN1_JJ@
304953	100736373	20992752289	pain	pain	NN1
304953	100736373	20992752290	,	,	,
304953	100736373	20992752291	nausea	nausea	NN1
304953	100736373	20992752292	,	,	,
304953	100736373	20992752293	headache	headache	NN1
304953	100736373	20992752294	,	,	,
304953	100736373	20992752295	and	and	CC
304953	100736373	20992752296	fatigue	fatigue	NN1
304953	100736373	20992752297	.	.	.
304953	100736373	20992752298	Approximately	approximately	RR
304953	100736373	20992752299	one	one	MC1
304953	100736373	20992752300	quarter	quarter	NN1
304953	100736373	20992752301	of	of	IO
304953	100736373	20992752302	patients	patient	NN2
304953	100736373	20992752303	treated	treat	VVN
304953	100736373	20992752304	with	with	IW
304953	100736373	20992752305	the	the	AT
304953	100736373	20992752306	vaccine	vaccine	NN1
304953	100736373	20992752307	experienced	experience	VVD_VVN_JJ
304953	100736373	20992752308	severe	severe	JJ
304953	100736373	20992752309	adverse	adverse	JJ
304953	100736373	20992752310	events	event	NN2
304953	100736373	20992752311	,	,	,
304953	100736373	20992752312	including	including	II_VVG@
304953	100736373	20992752313	infusion	infusion	NN1
304953	100736373	20992752314	reactions	reaction	NN2
304953	100736373	20992752315	and	and	CC
304953	100736373	20992752316	stroke	stroke	NN1_VV0
304953	100736373	20992752317	.	.	.
304953	100736373	20992752318	<p>		NULL
304953	100736373	20992752319	Sipuleucel-T		NP1
304953	100736373	20992752320	is	be	VBZ
304953	100736373	20992752321	currently	currently	RR
304953	100736373	20992752322	available	available	JJ
304953	100736373	20992752323	to	to	II
304953	100736373	20992752324	a	a	AT1
304953	100736373	20992752325	limited	limited	JJ
304953	100736373	20992752326	number	number	NN1
304953	100736373	20992752327	of	of	IO
304953	100736373	20992752328	patients	patient	NN2
304953	100736373	20992752329	with	with	IW
304953	100736373	20992752330	advanced	advanced	JJ
304953	100736373	20992752331	stage	stage	NN1
304953	100736373	20992752332	,	,	,
304953	100736373	20992752333	hormone-resistant		JJ
304953	100736373	20992752334	prostate	prostate	NN1
304953	100736373	20992752335	cancer	cancer	NN1
304953	100736373	20992752336	at	at	II
304953	100736373	20992752337	a	a	AT1
304953	100736373	20992752338	few	few	DA2
304953	100736373	20992752339	dozen	dozen	NNO
304953	100736373	20992752340	medical	medical	JJ
304953	100736373	20992752341	centers	center	NN2
304953	100736373	20992752342	in	in	II
304953	100736373	20992752343	the	the	AT
304953	100736373	20992752344	United	united	NP1
304953	100736373	20992752345	States	state	NP1
304953	100736373	20992752346	.	.	.
304953	100736373	20992752347	It	it	PPH1
304953	100736373	20992752348	is	be	VBZ
304953	100736373	20992752349	likely	likely	JJ
304953	100736373	20992752350	to	to	TO
304953	100736373	20992752351	be	be	VBI
304953	100736373	20992752352	more	more	RGR
304953	100736373	20992752353	widely	widely	RR
304953	100736373	20992752354	available	available	JJ
304953	100736373	20992752355	within	within	II
304953	100736373	20992752356	a	a	AT1
304953	100736373	20992752357	year	year	NNT1
304953	100736373	20992752358	.	.	.
304953	100736373	20992752359	Medicare	medicare	NP1
304953	100736373	20992752360	seems	seem	VVZ
304953	100736373	20992752361	to	to	TO
304953	100736373	20992752362	be	be	VBI
304953	100736373	20992752363	covering	cover	VVG
304953	100736373	20992752364	the	the	AT
304953	100736373	20992752365	cost	cost	NN1
304953	100736373	20992752366	of	of	IO
304953	100736373	20992752367	a	a	AT1
304953	100736373	20992752368	full	full	JJ
304953	100736373	20992752369	course	course	NN1
304953	100736373	20992752370	of	of	IO
304953	100736373	20992752371	sipuleucel-T		NP1
304953	100736373	20992752372	,	,	,
304953	100736373	20992752373	but	but	CCB
304953	100736373	20992752374	some	some	DD
304953	100736373	20992752375	private	private	JJ
304953	100736373	20992752376	insurance	insurance	NN1
304953	100736373	20992752377	companies	company	NN2
304953	100736373	20992752378	may	may	VM
304953	100736373	20992752379	not	not	XX
304953	100736373	20992752380	pay	pay	VVI
304953	100736373	20992752381	for	for	IF
304953	100736373	20992752382	the	the	AT
304953	100736373	20992752383	treatment	treatment	NN1
304953	100736373	20992752384	,	,	,
304953	100736373	20992752385	which	which	DDQ
304953	100736373	20992752386	runs	run	VVZ
304953	100736373	20992752387	over	over	RG
304953	100736373	20992752388	$90,000.		NNU
304953	100736373	20992752389	46996		MC
304953	100736373	20992752390	@qwx906996		FO
304953	100736374	20992752410	@@##	----------	----------
304953	100736374	20992752411	@@100736374		FO
304953	100736374	20992752412	@4936374/		VV0_JJ
304953	100736374	20992752413	<h>		NULL
304953	100736374	20992752414	Other	other	JJ
304953	100736374	20992752415	Conditions	condition	NN2
304953	100736374	20992752416	46988		MC
304953	100736374	20992752417	@qwx906988		FO
304953	100736374	20992752418	46994		MC
304953	100736374	20992752419	@qwx906994		FO
304953	100736374	20992752420	46995		MC
304953	100736374	20992752421	@qwx906995		FO
304953	100736374	20992752422	46992		MC
304953	100736374	20992752423	@qwx906992		FO
304953	100736374	20992752424	46991		MC
304953	100736374	20992752425	@qwx906991		FO
304953	100736374	20992752426	46990		MC
304953	100736374	20992752427	@qwx906990		FO
304953	100736374	20992752428	46989		MC
304953	100736374	20992752429	@qwx906989		FO
304953	100736374	20992752430	46993		MC
304953	100736374	20992752431	@qwx906993		FO
304953	100736374	20992752432	<h>		NULL
304953	100736374	20992752433	Prostatic	prostatic	JJ
304953	100736374	20992752434	Intraepithelial		NP1_JJ
304953	100736374	20992752435	Neoplasia		NP1
304953	100736374	20992752436	(	(	(
304953	100736374	20992752437	PIN	pin	NN1
304953	100736374	20992752438	)	)	)
304953	100736374	20992752439	<p>		NULL
304953	100736374	20992752440	Prostatic	prostatic	JJ
304953	100736374	20992752441	intraepithelial	intraepithelial	JJ
304953	100736374	20992752442	neoplasia	neoplasia	NN1
304953	100736374	20992752443	(	(	(
304953	100736374	20992752444	PIN	pin	NN1
304953	100736374	20992752445	)	)	)
304953	100736374	20992752446	is	be	VBZ
304953	100736374	20992752447	a	a	AT1
304953	100736374	20992752448	condition	condition	NN1
304953	100736374	20992752449	in	in	II
304953	100736374	20992752450	which	which	DDQ
304953	100736374	20992752451	some	some	DD
304953	100736374	20992752452	of	of	IO
304953	100736374	20992752453	the	the	AT
304953	100736374	20992752454	prostate	prostate	NN1
304953	100736374	20992752455	's	's	GE
304953	100736374	20992752456	epithelial	epithelial	JJ
304953	100736374	20992752457	cells	cell	NN2
304953	100736374	20992752458	look	look	VV0
304953	100736374	20992752459	abnormal	abnormal	JJ
304953	100736374	20992752460	under	under	II
304953	100736374	20992752461	the	the	AT
304953	100736374	20992752462	microscope	microscope	NN1
304953	100736374	20992752463	.	.	.
304953	100736374	20992752464	Epithelial	epithelial	JJ
304953	100736374	20992752465	cells	cell	NN2
304953	100736374	20992752466	are	be	VBR
304953	100736374	20992752467	the	the	AT
304953	100736374	20992752468	cells	cell	NN2
304953	100736374	20992752469	that	that	CST
304953	100736374	20992752470	line	line	VV0@_NN1
304953	100736374	20992752471	the	the	AT
304953	100736374	20992752472	tiny	tiny	JJ
304953	100736374	20992752473	sacs	sac	NN2
304953	100736374	20992752474	in	in	II
304953	100736374	20992752475	the	the	AT
304953	100736374	20992752476	prostate	prostate	NN1
304953	100736374	20992752477	and	and	CC
304953	100736374	20992752478	the	the	AT
304953	100736374	20992752479	ducts	duct	NN2
304953	100736374	20992752480	that	that	CST
304953	100736374	20992752481	carry	carry	VV0
304953	100736374	20992752482	fluid	fluid	NN1
304953	100736374	20992752483	in	in	II
304953	100736374	20992752484	the	the	AT
304953	100736374	20992752485	prostate	prostate	NN1
304953	100736374	20992752486	.	.	.
304953	100736374	20992752487	Sometimes	sometimes	RT
304953	100736374	20992752488	the	the	AT
304953	100736374	20992752489	abnormalities	abnormality	NN2
304953	100736374	20992752490	are	be	VBR
304953	100736374	20992752491	minor	minor	JJ
304953	100736374	20992752492	,	,	,
304953	100736374	20992752493	but	but	CCB
304953	100736374	20992752494	sometimes	sometimes	RT
304953	100736374	20992752495	they	they	PPHS2
304953	100736374	20992752496	start	start	VV0
304953	100736374	20992752497	to	to	TO
304953	100736374	20992752498	look	look	VVI
304953	100736374	20992752499	like	like	II_CS
304953	100736374	20992752500	the	the	AT
304953	100736374	20992752501	cellular	cellular	JJ
304953	100736374	20992752502	changes	change	NN2
304953	100736374	20992752503	characteristic	characteristic	NN1
304953	100736374	20992752504	of	of	IO
304953	100736374	20992752505	cancer	cancer	NN1
304953	100736374	20992752506	cells	cell	NN2
304953	100736374	20992752507	.	.	.
304953	100736374	20992752508	Whether	whether	CSW
304953	100736374	20992752509	PIN	pin	NN1
304953	100736374	20992752510	will	will	VM
304953	100736374	20992752511	progress	progress	VVI
304953	100736374	20992752512	to	to	II
304953	100736374	20992752513	cancer	cancer	NN1
304953	100736374	20992752514	and	and	CC
304953	100736374	20992752515	what	what	DDQ
304953	100736374	20992752516	,	,	,
304953	100736374	20992752517	if	if	CS
304953	100736374	20992752518	anything	anything	PN1
304953	100736374	20992752519	,	,	,
304953	100736374	20992752520	should	should	VM
304953	100736374	20992752521	be	be	VBI
304953	100736374	20992752522	done	do	VDN
304953	100736374	20992752523	to	to	TO
304953	100736374	20992752524	treat	treat	VVI
304953	100736374	20992752525	it	it	PPH1
304953	100736374	20992752526	remains	remain	VVZ
304953	100736374	20992752527	unclear	unclear	JJ
304953	100736374	20992752528	.	.	.
304953	100736375	20992752548	@@##	----------	----------
304953	100736375	20992752549	@@100736375		FO
304953	100736375	20992752550	@4936375/		VV0_NN1
304953	100736375	20992752551	46989		MC
304953	100736375	20992752552	@qwx906989		FO
304953	100736375	20992752553	<p>		NULL
304953	100736375	20992752554	A	a	AT1_ZZ1
304953	100736375	20992752555	recent	recent	JJ
304953	100736375	20992752556	clinical	clinical	JJ
304953	100736375	20992752557	trial	trial	NN1
304953	100736375	20992752558	concluded	conclude	VVD_VVN
304953	100736375	20992752559	that	that	CST
304953	100736375	20992752560	the	the	AT
304953	100736375	20992752561	targeted	targeted	JJ%
304953	100736375	20992752562	therapy	therapy	NN1
304953	100736375	20992752563	MDV3100		FO
304953	100736375	20992752564	is	be	VBZ
304953	100736375	20992752565	both	both	RR
304953	100736375	20992752566	safe	safe	JJ
304953	100736375	20992752567	and	and	CC
304953	100736375	20992752568	effective	effective	JJ
304953	100736375	20992752569	for	for	IF
304953	100736375	20992752570	patients	patient	NN2
304953	100736375	20992752571	with	with	IW
304953	100736375	20992752572	castration-resistant		JJ
304953	100736375	20992752573	prostate	prostate	NN1
304953	100736375	20992752574	cancer	cancer	NN1
304953	100736375	20992752575	"	"	"
304953	100736375	20992752576	disease	disease	NN1
304953	100736375	20992752577	that	that	CST
304953	100736375	20992752578	no	no	RR21
304953	100736375	20992752579	longer	long	RR22
304953	100736375	20992752580	responds	respond	VVZ
304953	100736375	20992752581	to	to	II
304953	100736375	20992752582	hormone	hormone	NN1
304953	100736375	20992752583	therapy	therapy	NN1
304953	100736375	20992752584	.	.	.
304953	100736375	20992752585	(	(	(
304953	100736375	20992752586	Castration-resistant		JJ
304953	100736375	20992752587	prostate	prostate	NN1
304953	100736375	20992752588	cancer	cancer	NN1
304953	100736375	20992752589	may	may	VM
304953	100736375	20992752590	also	also	RR
304953	100736375	20992752591	be	be	VBI
304953	100736375	20992752592	called	call	VVN
304953	100736375	20992752593	androgen	androgen	NN1
304953	100736375	20992752594	independent	independent	JJ_NN1@
304953	100736375	20992752595	or	or	CC
304953	100736375	20992752596	hormone	hormone	NN1
304953	100736375	20992752597	refractory	refractory	JJ
304953	100736375	20992752598	prostate	prostate	NN1
304953	100736375	20992752599	cancer	cancer	NN1
304953	100736375	20992752600	.	.	.
304953	100736375	20992752601	)	)	)
304953	100736375	20992752602	<p>		NULL
304953	100736375	20992752603	In	in	II
304953	100736375	20992752604	the	the	AT
304953	100736375	20992752605	trial	trial	NN1
304953	100736375	20992752606	,	,	,
304953	100736375	20992752607	140	140	MC
304953	100736375	20992752608	men	man	NN2
304953	100736375	20992752609	with	with	IW
304953	100736375	20992752610	castration-resistant		JJ
304953	100736375	20992752611	prostate	prostate	NN1
304953	100736375	20992752612	cancer	cancer	NN1
304953	100736375	20992752613	received	receive	VVD_VVN
304953	100736375	20992752614	doses	dose	NN2
304953	100736375	20992752615	of	of	IO
304953	100736375	20992752616	MDV3100		FO
304953	100736375	20992752617	ranging	range	VVG
304953	100736375	20992752618	from	from	II
304953	100736375	20992752619	30	30	MC
304953	100736375	20992752620	to	to	II
304953	100736375	20992752621	600	600	MC
304953	100736375	20992752622	milligrams	milligram	NNU2
304953	100736375	20992752623	(	(	(
304953	100736375	20992752624	mg	mg	NNU
304953	100736375	20992752625	)	)	)
304953	100736375	20992752626	daily	daily	RR_JJ
304953	100736375	20992752627	.	.	.
304953	100736375	20992752628	Researchers	researcher	NN2
304953	100736375	20992752629	used	used	JJ_VVD_VVN
304953	100736375	20992752630	bone	bone	NN1
304953	100736375	20992752631	scans	scan	NN2
304953	100736375	20992752632	,	,	,
304953	100736375	20992752633	PET	pet	NN1_JJ@_VV0@
304953	100736375	20992752634	imaging	imaging	NN1_VVG
304953	100736375	20992752635	,	,	,
304953	100736375	20992752636	and	and	CC
304953	100736375	20992752637	blood	blood	NN1
304953	100736375	20992752638	tests	test	NN2_VVZ@
304953	100736375	20992752639	to	to	TO
304953	100736375	20992752640	assess	assess	VVI
304953	100736375	20992752641	the	the	AT
304953	100736375	20992752642	drug	drug	NN1
304953	100736375	20992752643	's	's	GE
304953	100736375	20992752644	antitumor	antitumor	NN1
304953	100736375	20992752645	effects	effect	NN2
304953	100736375	20992752646	.	.	.
304953	100736375	20992752647	Overall	overall	RR_NN1
304953	100736375	20992752648	,	,	,
304953	100736375	20992752649	more	more	DAR
304953	100736375	20992752650	than	than	CSN
304953	100736375	20992752651	half	half	DB
304953	100736375	20992752652	of	of	IO
304953	100736375	20992752653	the	the	AT
304953	100736375	20992752654	patients	patient	NN2
304953	100736375	20992752655	experienced	experience	VVD_VVN
304953	100736375	20992752656	a	a	AT1
304953	100736375	20992752657	decline	decline	NN1
304953	100736375	20992752658	in	in	II
304953	100736375	20992752659	prostate-specific	prostate-specific	JJ
304953	100736375	20992752660	antigen	antigen	NN1
304953	100736375	20992752661	(	(	(
304953	100736375	20992752662	PSA	psa	NP1
304953	100736375	20992752663	)	)	)
304953	100736375	20992752664	levels	level	NN2
304953	100736375	20992752665	of	of	IO
304953	100736375	20992752666	at	at	RR21
304953	100736375	20992752667	least	least	RR22
304953	100736375	20992752668	50%		NNU
304953	100736375	20992752669	,	,	,
304953	100736375	20992752670	while	while	CS
304953	100736375	20992752671	22%		NNU
304953	100736375	20992752672	saw	see	VVD
304953	100736375	20992752673	their	their	APPGE
304953	100736375	20992752674	tumors	tumor	NN2
304953	100736375	20992752675	shrink	shrink	VVI
304953	100736375	20992752676	.	.	.
304953	100736375	20992752677	Over	over	II_RP
304953	100736375	20992752678	two-thirds	two-thirds	MF
304953	100736375	20992752679	of	of	IO
304953	100736375	20992752680	patients	patient	NN2
304953	100736375	20992752681	had	have	VHD
304953	100736375	20992752682	partial	partial	JJ
304953	100736375	20992752683	remission	remission	NN1
304953	100736375	20992752684	or	or	CC
304953	100736375	20992752685	learned	learn	VVD_VVN
304953	100736375	20992752686	that	that	DD1_CST
304953	100736375	20992752687	disease	disease	NN1
304953	100736375	20992752688	that	that	CST
304953	100736375	20992752689	had	have	VHD
304953	100736375	20992752690	spread	spread	VVN
304953	100736375	20992752691	to	to	II
304953	100736375	20992752692	bone	bone	NN1
304953	100736375	20992752693	or	or	CC
304953	100736375	20992752694	soft	soft	JJ
304953	100736375	20992752695	tissue	tissue	NN1
304953	100736375	20992752696	was	be	VBDZ
304953	100736375	20992752697	no	no	RR21
304953	100736375	20992752698	longer	long	RR22
304953	100736375	20992752699	progressing	progress	VVG
304953	100736375	20992752700	.	.	.
304953	100736375	20992752701	<p>		NULL
304953	100736375	20992752702	Circulating	circulate	VVG_JJ@
304953	100736375	20992752703	tumor	tumor	NN1
304953	100736375	20992752704	cells	cell	NN2
304953	100736375	20992752705	,	,	,
304953	100736375	20992752706	cells	cell	NN2
304953	100736375	20992752707	that	that	CST
304953	100736375	20992752708	break	break	VV0_NN1
304953	100736375	20992752709	away	away	II21_RL
304953	100736375	20992752710	from	from	II22_II
304953	100736375	20992752711	the	the	AT
304953	100736375	20992752712	tumor	tumor	NN1
304953	100736375	20992752713	and	and	CC
304953	100736375	20992752714	travel	travel	VV0_NN1
304953	100736375	20992752715	in	in	II
304953	100736375	20992752716	the	the	AT
304953	100736375	20992752717	bloodstream	bloodstream	NN1
304953	100736375	20992752718	,	,	,
304953	100736375	20992752719	also	also	RR
304953	100736375	20992752720	decreased	decrease	VVN_VVD
304953	100736375	20992752721	in	in	II_RP@
304953	100736375	20992752722	49%		NNU
304953	100736375	20992752723	of	of	IO
304953	100736375	20992752724	patients	patient	NN2
304953	100736375	20992752725	,	,	,
304953	100736375	20992752726	and	and	CC
304953	100736375	20992752727	more	more	DAR_RRR
304953	100736375	20992752728	than	than	CSN
304953	100736375	20992752729	90%		NNU
304953	100736375	20992752730	of	of	IO
304953	100736375	20992752731	patients	patient	NN2
304953	100736375	20992752732	who	who	PNQS
304953	100736375	20992752733	started	start	VVD
304953	100736375	20992752734	therapy	therapy	NN1
304953	100736375	20992752735	with	with	IW
304953	100736375	20992752736	favorable	favorable	JJ
304953	100736375	20992752737	cell	cell	NN1
304953	100736375	20992752738	counts	count	NN2
304953	100736375	20992752739	retained	retain	VVD_VVN
304953	100736375	20992752740	@		II
304953	100736375	20992752741	@		II
304953	100736375	20992752742	@		II
304953	100736375	20992752743	@		II
304953	100736375	20992752744	@		II
304953	100736375	20992752745	@		II
304953	100736375	20992752746	@		II
304953	100736375	20992752747	@		II
304953	100736375	20992752748	@		II
304953	100736375	20992752749	@		II
304953	100736375	20992752750	,	,	,
304953	100736375	20992752751	given	given	CS21
304953	100736375	20992752752	that	that	CS22
304953	100736375	20992752753	post-treatment	post-treatment	JJ_NN1
304953	100736375	20992752754	changes	change	NN2
304953	100736375	20992752755	in	in	II
304953	100736375	20992752756	tumor	tumor	NN1
304953	100736375	20992752757	cell	cell	NN1
304953	100736375	20992752758	counts	count	NN2
304953	100736375	20992752759	are	be	VBR
304953	100736375	20992752760	often	often	RR
304953	100736375	20992752761	more	more	RGR
304953	100736375	20992752762	predictive	predictive	JJ
304953	100736375	20992752763	of	of	IO
304953	100736375	20992752764	survival	survival	NN1
304953	100736375	20992752765	than	than	CSN
304953	100736375	20992752766	changes	change	NN2
304953	100736375	20992752767	in	in	II
304953	100736375	20992752768	PSA	psa	NP1
304953	100736375	20992752769	.	.	.
304953	100736375	20992752770	<p>		NULL
304953	100736375	20992752771	MDV3100		FO
304953	100736375	20992752772	works	work	VVZ
304953	100736375	20992752773	by	by	II
304953	100736375	20992752774	blocking	blocking	JJ_VVG_NN1
304953	100736375	20992752775	testosterone	testosterone	NN1
304953	100736375	20992752776	from	from	II
304953	100736375	20992752777	binding	bind	VVG
304953	100736375	20992752778	to	to	II
304953	100736375	20992752779	the	the	AT
304953	100736375	20992752780	androgen	androgen	NN1
304953	100736375	20992752781	receptor	receptor	NN1
304953	100736375	20992752782	,	,	,
304953	100736375	20992752783	which	which	DDQ
304953	100736375	20992752784	,	,	,
304953	100736375	20992752785	in	in	II
304953	100736375	20992752786	turn	turn	NN1
304953	100736375	20992752787	,	,	,
304953	100736375	20992752788	prevents	prevent	VVZ
304953	100736375	20992752789	the	the	AT
304953	100736375	20992752790	receptor	receptor	NN1
304953	100736375	20992752791	from	from	II
304953	100736375	20992752792	entering	enter	VVG
304953	100736375	20992752793	a	a	AT1
304953	100736375	20992752794	cell	cell	NN1
304953	100736375	20992752795	,	,	,
304953	100736375	20992752796	binding	bind	VVG
304953	100736375	20992752797	to	to	II
304953	100736375	20992752798	its	its	APPGE
304953	100736375	20992752799	DNA	dna	NN1
304953	100736375	20992752800	,	,	,
304953	100736375	20992752801	turning	turn	VVG
304953	100736375	20992752802	on	on	II_RP@
304953	100736375	20992752803	specific	specific	JJ
304953	100736375	20992752804	genes	gene	NN2
304953	100736375	20992752805	,	,	,
304953	100736375	20992752806	and	and	CC
304953	100736375	20992752807	allowing	allow	VVG
304953	100736375	20992752808	the	the	AT
304953	100736375	20992752809	cell	cell	NN1
304953	100736375	20992752810	to	to	TO
304953	100736375	20992752811	grow	grow	VVI
304953	100736375	20992752812	.	.	.
304953	100736375	20992752813	Ultimately	ultimately	RR
304953	100736375	20992752814	,	,	,
304953	100736375	20992752815	this	this	DD1
304953	100736375	20992752816	process	process	NN1
304953	100736375	20992752817	leads	lead	VVZ
304953	100736375	20992752818	to	to	II
304953	100736375	20992752819	cancer	cancer	NN1
304953	100736375	20992752820	cell	cell	NN1
304953	100736375	20992752821	death	death	NN1
304953	100736375	20992752822	,	,	,
304953	100736375	20992752823	research	research	NN1_VV0@
304953	100736375	20992752824	shows	show	NN2_VVZ
304953	100736375	20992752825	.	.	.
304953	100736375	20992752826	<p>		NULL
304953	100736375	20992752827	Investigators	investigator	NN2
304953	100736375	20992752828	established	establish	VVD_VVN
304953	100736375	20992752829	240	240	MC
304953	100736375	20992752830	mg	mg	NNU
304953	100736375	20992752831	as	as	II
304953	100736375	20992752832	the	the	AT
304953	100736375	20992752833	maximum	maximum	JJ_NN1
304953	100736375	20992752834	daily	daily	JJ
304953	100736375	20992752835	dose	dose	NN1
304953	100736375	20992752836	.	.	.
304953	100736375	20992752837	Fatigue	fatigue	NN1
304953	100736375	20992752838	was	be	VBDZ
304953	100736375	20992752839	the	the	AT
304953	100736375	20992752840	most	most	RGT
304953	100736375	20992752841	common	common	JJ
304953	100736375	20992752842	side	side	NN1
304953	100736375	20992752843	effect	effect	NN1
304953	100736375	20992752844	,	,	,
304953	100736375	20992752845	though	though	CS
304953	100736375	20992752846	some	some	DD
304953	100736375	20992752847	patients	patient	NN2
304953	100736375	20992752848	experienced	experienced	JJ_VVD_VVN
304953	100736375	20992752849	nausea	nausea	NN1
304953	100736375	20992752850	,	,	,
304953	100736375	20992752851	constipation	constipation	NN1
304953	100736375	20992752852	,	,	,
304953	100736375	20992752853	diarrhea	diarrhea	NN1
304953	100736375	20992752854	,	,	,
304953	100736375	20992752855	and	and	CC
304953	100736375	20992752856	anorexia	anorexia	NN1
304953	100736375	20992752857	.	.	.
304953	100736375	20992752858	<p>		NULL
304953	100736375	20992752859	An	a	AT1
304953	100736375	20992752860	international	international	JJ
304953	100736375	20992752861	phase	phase	NN1
304953	100736375	20992752862	III	iii	MC
304953	100736375	20992752863	clinical	clinical	JJ
304953	100736375	20992752864	trial	trial	NN1
304953	100736375	20992752865	now	now	RT
304953	100736375	20992752866	under	under	RR21
304953	100736375	20992752867	way	way	RR22
304953	100736375	20992752868	will	will	VM
304953	100736375	20992752869	compare	compare	VVI
304953	100736375	20992752870	MDV3100		FO
304953	100736375	20992752871	with	with	IW
304953	100736375	20992752872	a	a	AT1
304953	100736375	20992752873	placebo	placebo	NN1
304953	100736375	20992752874	in	in	II
304953	100736375	20992752875	prostate	prostate	NN1
304953	100736375	20992752876	cancer	cancer	NN1
304953	100736375	20992752877	patients	patient	NN2
304953	100736375	20992752878	previously	previously	RR
304953	100736375	20992752879	treated	treat	VVN
304953	100736375	20992752880	with	with	IW
304953	100736375	20992752881	chemotherapy	chemotherapy	NN1
304953	100736375	20992752882	.	.	.
304953	100736375	20992752883	For	for	IF
304953	100736375	20992752884	more	more	DAR
304953	100736375	20992752885	information	information	NN1
304953	100736375	20992752886	about	about	II
304953	100736375	20992752887	the	the	AT
304953	100736375	20992752888	trial	trial	NN1
304953	100736375	20992752889	and	and	CC
304953	100736375	20992752890	a	a	AT1
304953	100736375	20992752891	list	list	NN1
304953	100736375	20992752892	of	of	IO
304953	100736375	20992752893	participating	participating	JJ_VVG
304953	100736375	20992752894	medical	medical	JJ
304953	100736375	20992752895	centers	center	NN2
304953	100736375	20992752896	,	,	,
304953	100736375	20992752897	log	log	NN1_VV0@
304953	100736375	20992752898	on	on	II21_RP
304953	100736375	20992752899	to	to	II22_II
304953	100736375	20992752900	www.clinicaltrials.gov	www.clinicaltrials.gov	NNU
304953	100736375	20992752901	and	and	CC
304953	100736375	20992752902	search	search	NN1_VV0@
304953	100736375	20992752903	for	for	IF
304953	100736375	20992752904	MDV3100		FO
304953	100736375	20992752905	.	.	.
304953	100736375	20992752906	<p>		NULL
304953	100736375	20992752907	Editor	editor	NN1
304953	100736375	20992752908	's	's	GE
304953	100736375	20992752909	note	note	NN1
304953	100736375	20992752910	:	:	:
304953	100736375	20992752911	Several	several	DA2
304953	100736375	20992752912	of	of	IO
304953	100736375	20992752913	the	the	AT
304953	100736375	20992752914	authors	author	NN2
304953	100736375	20992752915	of	of	IO
304953	100736375	20992752916	this	this	DD1
304953	100736375	20992752917	study	study	NN1
304953	100736375	20992752918	are	be	VBR
304953	100736375	20992752919	employed	employ	VVN
304953	100736375	20992752920	by	by	II_RP%
304953	100736375	20992752921	,	,	,
304953	100736375	20992752922	have	have	VH0
304953	100736375	20992752923	stock	stock	NN1
304953	100736375	20992752924	in	in	RP@_II
304953	100736375	20992752925	,	,	,
304953	100736375	20992752926	or	or	CC
304953	100736375	20992752927	have	have	VH0
304953	100736375	20992752928	received	receive	VVN
304953	100736375	20992752929	funding	funding	NN1_VVG@
304953	100736375	20992752930	from	from	II
304953	100736375	20992752931	Medivation		NN1
304953	100736375	20992752932	,	,	,
304953	100736375	20992752933	the	the	AT
304953	100736375	20992752934	maker	maker	NN1
304953	100736375	20992752935	of	of	IO
304953	100736375	20992752936	MDV3100		FO
304953	100736375	20992752937	.	.	.
304953	100736375	20992752938	<p>		NULL
304953	100736375	20992752939	I	i	PPIS1
304953	100736375	20992752940	@		II
304953	100736375	20992752941	@		II
304953	100736375	20992752942	@		II
304953	100736375	20992752943	@		II
304953	100736375	20992752944	@		II
304953	100736375	20992752945	@		II
304953	100736375	20992752946	@		II
304953	100736375	20992752947	@		II
304953	100736375	20992752948	@		II
304953	100736375	20992752949	@		II
304953	100736375	20992752950	therapy	therapy	NN1
304953	100736375	20992752951	in	in	II
304953	100736375	20992752952	preparation	preparation	NN1
304953	100736375	20992752953	for	for	IF
304953	100736375	20992752954	a	a	AT1
304953	100736375	20992752955	prostatectomy	prostatectomy	NN1
304953	100736375	20992752956	.	.	.
304953	100736375	20992752957	My	my	APPGE
304953	100736375	20992752958	PSA	psa	NP1
304953	100736375	20992752959	is	be	VBZ
304953	100736375	20992752960	now	now	RT
304953	100736375	20992752961	extremely	extremely	RR
304953	100736375	20992752962	low	low	JJ
304953	100736375	20992752963	and	and	CC
304953	100736375	20992752964	the	the	AT
304953	100736375	20992752965	surgeon	surgeon	NN1
304953	100736375	20992752966	has	have	VHZ
304953	100736375	20992752967	reported	report	VVN
304953	100736375	20992752968	that	that	CST
304953	100736375	20992752969	the	the	AT
304953	100736375	20992752970	tumour	tumor	NN1
304953	100736375	20992752971	feels	feel	VVZ
304953	100736375	20992752972	shrunken	shrunken	JJ_NN1
304953	100736375	20992752973	and	and	CC
304953	100736375	20992752974	pliable	pliable	JJ
304953	100736375	20992752975	.	.	.
304953	100736375	20992752976	I	i	PPIS1
304953	100736375	20992752977	am	be	VBM
304953	100736375	20992752978	wondering	wonder	VVG
304953	100736375	20992752979	why	why	RRQ
304953	100736375	20992752980	I	i	PPIS1
304953	100736375	20992752981	can	can	VM
304953	100736375	20992752982	not	not	XX
304953	100736375	20992752983	just	just	RR
304953	100736375	20992752984	keep	keep	VVI
304953	100736375	20992752985	on	on	II
304953	100736375	20992752986	MCV3100		FO
304953	100736375	20992752987	and	and	CC
304953	100736375	20992752988	employ	employ	VVI
304953	100736375	20992752989	watchful	watchful	JJ
304953	100736375	20992752990	waiting	waiting	NN1@_VVG
304953	100736375	20992752991	rather	rather	II21
304953	100736375	20992752992	than	than	II22
304953	100736375	20992752993	have	have	VH0
304953	100736375	20992752994	the	the	AT
304953	100736375	20992752995	operation	operation	NN1
304953	100736375	20992752996	.	.	.
304953	100736375	20992752997	46996		MC
304953	100736375	20992752998	@qwx906996		FO
304953	100736378	20992753018	@@##	----------	----------
304953	100736378	20992753019	@@100736378		FO
304953	100736378	20992753020	@4936378/		VV0_JJ
304953	100736378	20992753021	<h>		NULL
304953	100736378	20992753022	Other	other	JJ
304953	100736378	20992753023	Conditions	condition	NN2
304953	100736378	20992753024	46988		MC
304953	100736378	20992753025	@qwx906988		FO
304953	100736378	20992753026	46994		MC
304953	100736378	20992753027	@qwx906994		FO
304953	100736378	20992753028	46995		MC
304953	100736378	20992753029	@qwx906995		FO
304953	100736378	20992753030	46992		MC
304953	100736378	20992753031	@qwx906992		FO
304953	100736378	20992753032	46991		MC
304953	100736378	20992753033	@qwx906991		FO
304953	100736378	20992753034	46990		MC
304953	100736378	20992753035	@qwx906990		FO
304953	100736378	20992753036	46989		MC
304953	100736378	20992753037	@qwx906989		FO
304953	100736378	20992753038	46993		MC
304953	100736378	20992753039	@qwx906993		FO
304953	100736378	20992753040	<h>		NULL
304953	100736378	20992753041	Benign	benign	JJ
304953	100736378	20992753042	Prostatic	prostatic	JJ
304953	100736378	20992753043	Hyperplasia		NP1_NN1@
304953	100736378	20992753044	(	(	(
304953	100736378	20992753045	BPH	bph	NP1
304953	100736378	20992753046	)	)	)
304953	100736378	20992753047	<p>		NULL
304953	100736378	20992753048	Benign	benign	JJ
304953	100736378	20992753049	prostate	prostate	NN1
304953	100736378	20992753050	hyperplasia	hyperplasia	NN1
304953	100736378	20992753051	(	(	(
304953	100736378	20992753052	BPH	bph	NP1
304953	100736378	20992753053	)	)	)
304953	100736378	20992753054	is	be	VBZ
304953	100736378	20992753055	an	a	AT1
304953	100736378	20992753056	enlargement	enlargement	NN1
304953	100736378	20992753057	of	of	IO
304953	100736378	20992753058	the	the	AT
304953	100736378	20992753059	prostate	prostate	NN1
304953	100736378	20992753060	that	that	CST_DD1
304953	100736378	20992753061	is	be	VBZ
304953	100736378	20992753062	not	not	XX
304953	100736378	20992753063	due	due	II21
304953	100736378	20992753064	to	to	II22
304953	100736378	20992753065	cancer	cancer	NN1
304953	100736378	20992753066	.	.	.
304953	100736378	20992753067	BPH	bph	NP1
304953	100736378	20992753068	can	can	VM
304953	100736378	20992753069	cause	cause	VVI
304953	100736378	20992753070	problems	problem	NN2
304953	100736378	20992753071	with	with	IW
304953	100736378	20992753072	urination	urination	NN1
304953	100736378	20992753073	because	because	CS
304953	100736378	20992753074	as	as	II_CSA
304953	100736378	20992753075	the	the	AT
304953	100736378	20992753076	prostate	prostate	NN1
304953	100736378	20992753077	gets	get	VVZ
304953	100736378	20992753078	bigger	big	JJR
304953	100736378	20992753079	,	,	,
304953	100736378	20992753080	it	it	PPH1
304953	100736378	20992753081	compresses	compress	VVZ
304953	100736378	20992753082	the	the	AT
304953	100736378	20992753083	urethra	urethra	NN1
304953	100736378	20992753084	,	,	,
304953	100736378	20992753085	the	the	AT
304953	100736378	20992753086	tube	tube	NN1
304953	100736378	20992753087	that	that	CST_DD1
304953	100736378	20992753088	carries	carry	VVZ
304953	100736378	20992753089	urine	urine	NN1
304953	100736378	20992753090	from	from	II
304953	100736378	20992753091	the	the	AT
304953	100736378	20992753092	bladder	bladder	NN1
304953	100736378	20992753093	out	out	II21
304953	100736378	20992753094	of	of	II22
304953	100736378	20992753095	the	the	AT
304953	100736378	20992753096	body	body	NN1
304953	100736378	20992753097	.	.	.
304953	100736378	20992753098	Thankfully	thankfully	RR
304953	100736378	20992753099	,	,	,
304953	100736378	20992753100	medications	medication	NN2
304953	100736378	20992753101	and	and	CC
304953	100736378	20992753102	procedures	procedure	NN2
304953	100736378	20992753103	can	can	VM
304953	100736378	20992753104	ease	ease	VVI
304953	100736378	20992753105	the	the	AT
304953	100736378	20992753106	symptoms	symptom	NN2
304953	100736378	20992753107	of	of	IO
304953	100736378	20992753108	BPH	bph	NP1
304953	100736378	20992753109	.	.	.
304953	100736378	20992753110	<p>		NULL
304953	100736378	20992753111	If	if	CS
304953	100736378	20992753112	you	you	PPY
304953	100736378	20992753113	are	be	VBR
304953	100736378	20992753114	like	like	II
304953	100736378	20992753115	many	many	DA2
304953	100736378	20992753116	of	of	IO
304953	100736378	20992753117	the	the	AT
304953	100736378	20992753118	14	14	MC
304953	100736378	20992753119	million	million	NNO
304953	100736378	20992753120	men	man	NN2
304953	100736378	20992753121	in	in	II
304953	100736378	20992753122	the	the	AT
304953	100736378	20992753123	United	united	NP1
304953	100736378	20992753124	States	state	NP1
304953	100736378	20992753125	who	who	PNQS
304953	100736378	20992753126	have	have	VH0
304953	100736378	20992753127	been	be	VBN
304953	100736378	20992753128	diagnosed	diagnose	VVN
304953	100736378	20992753129	with	with	IW
304953	100736378	20992753130	benign	benign	JJ
304953	100736378	20992753131	prostatic	prostatic	JJ
304953	100736378	20992753132	hyperplasia	hyperplasia	NN1
304953	100736378	20992753133	(	(	(
304953	100736378	20992753134	BPH	bph	NP1
304953	100736378	20992753135	)	)	)
304953	100736378	20992753136	,	,	,
304953	100736378	20992753137	youve		VV0
304953	100736378	20992753138	probably	probably	RR
304953	100736378	20992753139	been	be	VBN
304953	100736378	20992753140	taking	take	VVG
304953	100736378	20992753141	the	the	AT
304953	100736378	20992753142	same	same	DA
304953	100736378	20992753143	medication	medication	NN1
304953	100736378	20992753144	,	,	,
304953	100736378	20992753145	at	at	II
304953	100736378	20992753146	the	the	AT
304953	100736378	20992753147	same	same	DA
304953	100736378	20992753148	dose	dose	NN1
304953	100736378	20992753149	,	,	,
304953	100736378	20992753150	for	for	IF
304953	100736378	20992753151	years	year	NNT2
304953	100736378	20992753152	.	.	.
304953	100736378	20992753153	If	if	CS
304953	100736378	20992753154	so	so	RR
304953	100736378	20992753155	,	,	,
304953	100736378	20992753156	consider	consider	VV0
304953	100736378	20992753157	the	the	AT
304953	100736378	20992753158	experiences	experience	NN2
304953	100736378	20992753159	of	of	IO
304953	100736378	20992753160	two	two	MC
304953	100736378	20992753161	patients	patient	NN2
304953	100736378	20992753162	,	,	,
304953	100736378	20992753163	both	both	DB2
304953	100736378	20992753164	of	of	IO
304953	100736378	20992753165	whom	whom	PNQO
304953	100736378	20992753166	were	be	VBDR
304953	100736378	20992753167	taking	take	VVG
304953	100736378	20992753168	some	some	DD
304953	100736378	20992753169	type	type	NN1
304953	100736378	20992753170	of	of	IO
304953	100736378	20992753171	medication	medication	NN1
304953	100736378	20992753172	for	for	IF
304953	100736378	20992753173	BPH	bph	NP1
304953	100736378	20992753174	.	.	.
304953	100736378	20992753175	Their	their	APPGE
304953	100736378	20992753176	names	name	NN2
304953	100736378	20992753177	have	have	VH0
304953	100736378	20992753178	been	be	VBN
304953	100736378	20992753179	changed	change	VVN
304953	100736378	20992753180	,	,	,
304953	100736378	20992753181	but	but	CCB
304953	100736378	20992753182	all	all	DB_RR@
304953	100736378	20992753183	other	other	JJ
304953	100736378	20992753184	details	detail	NN2
304953	100736378	20992753185	are	be	VBR
304953	100736378	20992753186	accurate	accurate	JJ
304953	100736378	20992753187	(	(	(
304953	100736378	20992753188	see	see	VV0
304953	100736378	20992753189	"	"	"
304953	100736378	20992753190	Jack	jack	NP1
304953	100736378	20992753191	Muriel	muriel	NP1
304953	100736378	20992753192	"	"	"
304953	100736378	20992753193	and	and	CC
304953	100736378	20992753194	"	"	"
304953	100736378	20992753195	Henry	henry	NP1
304953	100736378	20992753196	Banks	banks	NP1@_NN2
304953	100736378	20992753197	"	"	"
304953	100736378	20992753198	)	)	)
304953	100736378	20992753199	.	.	.
304953	100736380	20992753219	@@##	----------	----------
304953	100736380	20992753220	@@100736380		FO
304953	100736380	20992753221	@4936380/		VV0_NN1
304953	100736380	20992753222	46989		MC
304953	100736380	20992753223	@qwx906989		FO
304953	100736380	20992753224	<p>		NULL
304953	100736380	20992753225	When	when	CS
304953	100736380	20992753226	the	the	AT
304953	100736380	20992753227	SELECT	select	JJ
304953	100736380	20992753228	trial	trial	NN1
304953	100736380	20992753229	started	start	VVD_VVN@
304953	100736380	20992753230	in	in	II
304953	100736380	20992753231	2001	2001	MC
304953	100736380	20992753232	,	,	,
304953	100736380	20992753233	there	there	EX
304953	100736380	20992753234	were	be	VBDR
304953	100736380	20992753235	high	high	RR@_JJ
304953	100736380	20992753236	hopes	hope	VVZ_NN2
304953	100736380	20992753237	it	it	PPH1
304953	100736380	20992753238	would	would	VM
304953	100736380	20992753239	prove	prove	VVI
304953	100736380	20992753240	that	that	CST_DD1
304953	100736380	20992753241	taking	take	VVG_JJ%
304953	100736380	20992753242	vitamin	vitamin	NN1
304953	100736380	20992753243	E	e	ZZ1
304953	100736380	20992753244	or	or	CC
304953	100736380	20992753245	selenium	selenium	NN1
304953	100736380	20992753246	could	could	VM
304953	100736380	20992753247	help	help	VVI
304953	100736380	20992753248	prevent	prevent	VVI
304953	100736380	20992753249	prostate	prostate	NN1
304953	100736380	20992753250	cancer	cancer	NN1
304953	100736380	20992753251	.	.	.
304953	100736380	20992753252	The	the	AT
304953	100736380	20992753253	newest	new	JJT
304953	100736380	20992753254	results	result	NN2
304953	100736380	20992753255	from	from	II
304953	100736380	20992753256	the	the	AT
304953	100736380	20992753257	trial	trial	NN1
304953	100736380	20992753258	show	show	NN1_VV0
304953	100736380	20992753259	just	just	RR
304953	100736380	20992753260	the	the	AT
304953	100736380	20992753261	opposite	opposite	JJ_NN1@
304953	100736380	20992753262	"	"	"
304953	100736380	20992753263	that	that	CST
304953	100736380	20992753264	taking	take	VVG_JJ%
304953	100736380	20992753265	selenium	selenium	NN1
304953	100736380	20992753266	or	or	CC
304953	100736380	20992753267	vitamin	vitamin	NN1
304953	100736380	20992753268	E	e	ZZ1
304953	100736380	20992753269	can	can	VM
304953	100736380	20992753270	actually	actually	RR
304953	100736380	20992753271	increase	increase	VVI
304953	100736380	20992753272	the	the	AT
304953	100736380	20992753273	odds	odds	NN2
304953	100736380	20992753274	of	of	IO
304953	100736380	20992753275	developing	developing	JJ_VVG
304953	100736380	20992753276	prostate	prostate	NN1
304953	100736380	20992753277	cancer	cancer	NN1
304953	100736380	20992753278	.	.	.
304953	100736380	20992753279	<p>		NULL
304953	100736380	20992753280	Bottom	bottom	JJ_NN1
304953	100736380	20992753281	line	line	NN1
304953	100736380	20992753282	:	:	:
304953	100736380	20992753283	men	man	NN2
304953	100736380	20992753284	should n't		VV0
304953	100736380	20992753285	take	take	VV0
304953	100736380	20992753286	selenium	selenium	NN1
304953	100736380	20992753287	or	or	CC
304953	100736380	20992753288	vitamin	vitamin	NN1
304953	100736380	20992753289	E	e	ZZ1
304953	100736380	20992753290	as	as	II_CSA
304953	100736380	20992753291	a	a	AT1
304953	100736380	20992753292	way	way	NN1
304953	100736380	20992753293	to	to	TO
304953	100736380	20992753294	prevent	prevent	VVI
304953	100736380	20992753295	prostate	prostate	NN1
304953	100736380	20992753296	cancer	cancer	NN1
304953	100736380	20992753297	,	,	,
304953	100736380	20992753298	or	or	CC
304953	100736380	20992753299	anything	anything	PN1
304953	100736380	20992753300	else	else	RR
304953	100736380	20992753301	for	for	IF
304953	100736380	20992753302	that	that	DD1
304953	100736380	20992753303	matter	matter	NN1
304953	100736380	20992753304	.	.	.
304953	100736380	20992753305	<h>		NULL
304953	100736380	20992753306	The	the	AT
304953	100736380	20992753307	case	case	NN1
304953	100736380	20992753308	against	against	II
304953	100736380	20992753309	selenium	selenium	NN1
304953	100736380	20992753310	and	and	CC
304953	100736380	20992753311	vitamin	vitamin	NN1
304953	100736380	20992753312	E	e	ZZ1
304953	100736380	20992753313	<p>		NULL
304953	100736380	20992753314	Studies	study	NN2
304953	100736380	20992753315	done	do	VDN
304953	100736380	20992753316	in	in	II
304953	100736380	20992753317	the	the	AT
304953	100736380	20992753318	1980s	1980s	MC2
304953	100736380	20992753319	and	and	CC
304953	100736380	20992753320	1990s	1990s	MC2
304953	100736380	20992753321	suggested	suggest	VVD
304953	100736380	20992753322	that	that	DD1_CST
304953	100736380	20992753323	vitamin	vitamin	NN1
304953	100736380	20992753324	E	e	ZZ1
304953	100736380	20992753325	and	and	CC
304953	100736380	20992753326	selenium	selenium	NN1
304953	100736380	20992753327	each	each	DD1
304953	100736380	20992753328	somehow	somehow	RR
304953	100736380	20992753329	provided	provide	VVN_VVD_CS
304953	100736380	20992753330	protection	protection	NN1
304953	100736380	20992753331	against	against	II
304953	100736380	20992753332	prostate	prostate	NN1
304953	100736380	20992753333	cancer	cancer	NN1
304953	100736380	20992753334	.	.	.
304953	100736380	20992753335	The	the	AT
304953	100736380	20992753336	Selenium	selenium	NN1_NP1
304953	100736380	20992753337	and	and	CC
304953	100736380	20992753338	Vitamin	vitamin	NN1
304953	100736380	20992753339	E	e	ZZ1
304953	100736380	20992753340	Cancer	cancer	NN1
304953	100736380	20992753341	Prevention	prevention	NN1
304953	100736380	20992753342	Trial	trial	NN1
304953	100736380	20992753343	(	(	(
304953	100736380	20992753344	SELECT	select	VV0_JJ
304953	100736380	20992753345	)	)	)
304953	100736380	20992753346	was	be	VBDZ
304953	100736380	20992753347	started	start	VVN@
304953	100736380	20992753348	in	in	II
304953	100736380	20992753349	2001	2001	MC
304953	100736380	20992753350	to	to	TO
304953	100736380	20992753351	see	see	VVI
304953	100736380	20992753352	if	if	CSW@_CS
304953	100736380	20992753353	that	that	DD1
304953	100736380	20992753354	was	be	VBDZ
304953	100736380	20992753355	true	true	JJ
304953	100736380	20992753356	.	.	.
304953	100736380	20992753357	The	the	AT
304953	100736380	20992753358	36,000	36,000	MC
304953	100736380	20992753359	healthy	healthy	JJ
304953	100736380	20992753360	,	,	,
304953	100736380	20992753361	middle-aged	middle-aged	JJ
304953	100736380	20992753362	volunteers	volunteer	NN2
304953	100736380	20992753363	were	be	VBDR
304953	100736380	20992753364	divided	divide	VVN
304953	100736380	20992753365	into	into	II
304953	100736380	20992753366	four	four	MC
304953	100736380	20992753367	groups	group	NN2
304953	100736380	20992753368	.	.	.
304953	100736380	20992753369	Each	each	DD1
304953	100736380	20992753370	man	man	NN1
304953	100736380	20992753371	took	take	VVD
304953	100736380	20992753372	two	two	MC
304953	100736380	20992753373	pills	pill	NN2
304953	100736380	20992753374	a	a	AT1
304953	100736380	20992753375	day	day	NNT1
304953	100736380	20992753376	:	:	:
304953	100736380	20992753377	400	400	MC
304953	100736380	20992753378	international	international	JJ
304953	100736380	20992753379	units	unit	NN2
304953	100736380	20992753380	(	(	(
304953	100736380	20992753381	IU	iu	NP1
304953	100736380	20992753382	)	)	)
304953	100736380	20992753383	of	of	IO
304953	100736380	20992753384	vitamin	vitamin	NN1
304953	100736380	20992753385	E	e	ZZ1
304953	100736380	20992753386	plus	plus	II
304953	100736380	20992753387	200	200	MC
304953	100736380	20992753388	micrograms	microgram	NN2
304953	100736380	20992753389	of	of	IO
304953	100736380	20992753390	selenium	selenium	NN1
304953	100736380	20992753391	;	;	;
304953	100736380	20992753392	vitamin	vitamin	NN1
304953	100736380	20992753393	E	e	ZZ1
304953	100736380	20992753394	plus	plus	II
304953	100736380	20992753395	a	a	AT1
304953	100736380	20992753396	placebo	placebo	NN1
304953	100736380	20992753397	;	;	;
304953	100736380	20992753398	selenium	selenium	NN1
304953	100736380	20992753399	plus	plus	II
304953	100736380	20992753400	a	a	AT1
304953	100736380	20992753401	placebo	placebo	NN1
304953	100736380	20992753402	;	;	;
304953	100736380	20992753403	or	or	CC
304953	100736380	20992753404	two	two	MC
304953	100736380	20992753405	placebos	placebo	NN2
304953	100736380	20992753406	.	.	.
304953	100736380	20992753407	Neither	neither	RR
304953	100736380	20992753408	the	the	AT
304953	100736380	20992753409	men	man	NN2
304953	100736380	20992753410	nor	nor	CC
304953	100736380	20992753411	@		II
304953	100736380	20992753412	@		II
304953	100736380	20992753413	@		II
304953	100736380	20992753414	@		II
304953	100736380	20992753415	@		II
304953	100736380	20992753416	@		II
304953	100736380	20992753417	@		II
304953	100736380	20992753418	@		II
304953	100736380	20992753419	@		II
304953	100736380	20992753420	@		II
304953	100736380	20992753421	SELECT	select	JJ
304953	100736380	20992753422	was	be	VBDZ
304953	100736380	20992753423	supposed	supposed	JJ
304953	100736380	20992753424	to	to	TO
304953	100736380	20992753425	last	last	VVI
304953	100736380	20992753426	until	until	II@_CS
304953	100736380	20992753427	2011	2011	MC
304953	100736380	20992753428	,	,	,
304953	100736380	20992753429	it	it	PPH1
304953	100736380	20992753430	was	be	VBDZ
304953	100736380	20992753431	stopped	stop	VVN
304953	100736380	20992753432	three	three	MC
304953	100736380	20992753433	years	year	NNT2
304953	100736380	20992753434	early	early	RR_JJ
304953	100736380	20992753435	because	because	CS
304953	100736380	20992753436	neither	neither	RR
304953	100736380	20992753437	vitamin	vitamin	NN1
304953	100736380	20992753438	E	e	ZZ1
304953	100736380	20992753439	nor	nor	CC
304953	100736380	20992753440	selenium	selenium	NN1
304953	100736380	20992753441	were	be	VBDR
304953	100736380	20992753442	showing	show	VVG
304953	100736380	20992753443	any	any	DD
304953	100736380	20992753444	benefit	benefit	NN1
304953	100736380	20992753445	"	"	"
304953	100736380	20992753446	and	and	CC
304953	100736380	20992753447	there	there	EX
304953	100736380	20992753448	were	be	VBDR
304953	100736380	20992753449	hazy	hazy	JJ
304953	100736380	20992753450	warning	warning	NN1
304953	100736380	20992753451	signs	sign	NN2_VVZ@
304953	100736380	20992753452	they	they	PPHS2
304953	100736380	20992753453	might	might	VM
304953	100736380	20992753454	be	be	VBI
304953	100736380	20992753455	doing	do	VDG
304953	100736380	20992753456	some	some	DD
304953	100736380	20992753457	harm	harm	NN1
304953	100736380	20992753458	.	.	.
304953	100736380	20992753459	<p>		NULL
304953	100736380	20992753460	A	a	AT1_ZZ1
304953	100736380	20992753461	new	new	JJ
304953	100736380	20992753462	report	report	NN1
304953	100736380	20992753463	in	in	II
304953	100736380	20992753464	the	the	AT
304953	100736380	20992753465	Journal	journal	NN1
304953	100736380	20992753466	of	of	IO
304953	100736380	20992753467	the	the	AT
304953	100736380	20992753468	National	national	JJ
304953	100736380	20992753469	Cancer	cancer	NN1
304953	100736380	20992753470	Institute	institute	NN1
304953	100736380	20992753471	clarifies	clarify	VVZ
304953	100736380	20992753472	the	the	AT
304953	100736380	20992753473	picture	picture	NN1
304953	100736380	20992753474	.	.	.
304953	100736380	20992753475	A	a	AT1
304953	100736380	20992753476	team	team	NN1
304953	100736380	20992753477	of	of	IO
304953	100736380	20992753478	researchers	researcher	NN2
304953	100736380	20992753479	from	from	II
304953	100736380	20992753480	across	across	II_RL@
304953	100736380	20992753481	the	the	AT
304953	100736380	20992753482	U.S.	us	NP1
304953	100736380	20992753483	looked	look	VVD
304953	100736380	20992753484	specifically	specifically	RR
304953	100736380	20992753485	at	at	II
304953	100736380	20992753486	almost	almost	RR
304953	100736380	20992753487	5,000	5,000	MC
304953	100736380	20992753488	of	of	IO
304953	100736380	20992753489	the	the	AT
304953	100736380	20992753490	SELECT	select	JJ
304953	100736380	20992753491	volunteers	volunteer	NN2
304953	100736380	20992753492	who	who	PNQS
304953	100736380	20992753493	sent	send	VVD
304953	100736380	20992753494	in	in	II_RP@
304953	100736380	20992753495	toenail	toenail	NN1
304953	100736380	20992753496	clippings	clipping	NN2
304953	100736380	20992753497	when	when	CS_RRQ
304953	100736380	20992753498	they	they	PPHS2
304953	100736380	20992753499	joined	join	VVD
304953	100736380	20992753500	the	the	AT
304953	100736380	20992753501	trial	trial	NN1
304953	100736380	20992753502	.	.	.
304953	100736380	20992753503	Toenail	toenail	VV0_NN1
304953	100736380	20992753504	clippings	clipping	NN2
304953	100736380	20992753505	are	be	VBR
304953	100736380	20992753506	a	a	AT1
304953	100736380	20992753507	great	great	JJ
304953	100736380	20992753508	way	way	NN1
304953	100736380	20992753509	to	to	TO
304953	100736380	20992753510	measure	measure	VVI
304953	100736380	20992753511	how	how	RGQ@
304953	100736380	20992753512	much	much	DA1
304953	100736380	20992753513	selenium	selenium	NN1
304953	100736380	20992753514	is	be	VBZ
304953	100736380	20992753515	in	in	II
304953	100736380	20992753516	a	a	AT1
304953	100736380	20992753517	mans	man	NN2
304953	100736380	20992753518	(	(	(
304953	100736380	20992753519	or	or	CC
304953	100736380	20992753520	womans	woman	NN2
304953	100736380	20992753521	)	)	)
304953	100736380	20992753522	body	body	NN1
304953	100736380	20992753523	.	.	.
304953	100736380	20992753524	The	the	AT
304953	100736380	20992753525	new	new	JJ
304953	100736380	20992753526	study	study	NN1
304953	100736380	20992753527	showed	show	VVD
304953	100736380	20992753528	that	that	CST
304953	100736380	20992753529	:	:	:
304953	100736380	20992753530	<p>		NULL
304953	100736380	20992753531	Taking	take	VVG
304953	100736380	20992753532	vitamin	vitamin	NN1
304953	100736380	20992753533	E	e	ZZ1
304953	100736380	20992753534	alone	alone	RR
304953	100736380	20992753535	boosted	boost	VVD_VVN
304953	100736380	20992753536	the	the	AT
304953	100736380	20992753537	risk	risk	NN1
304953	100736380	20992753538	of	of	IO
304953	100736380	20992753539	developing	developing	JJ_VVG
304953	100736380	20992753540	high-grade	high-grade	JJ_NN1
304953	100736380	20992753541	prostate	prostate	NN1
304953	100736380	20992753542	cancer	cancer	NN1
304953	100736380	20992753543	,	,	,
304953	100736380	20992753544	but	but	CCB
304953	100736380	20992753545	only	only	JJ
304953	100736380	20992753546	in	-in	II
304953	100736380	20992753547	men	man	NN2
304953	100736380	20992753548	who	who	PNQS
304953	100736380	20992753549	started	start	VVD
304953	100736380	20992753550	the	the	AT
304953	100736380	20992753551	study	study	NN1
304953	100736380	20992753552	with	with	IW
304953	100736380	20992753553	low	low	JJ
304953	100736380	20992753554	selenium	selenium	NN1
304953	100736380	20992753555	levels	level	NN2
304953	100736380	20992753556	.	.	.
304953	100736380	20992753557	<p>		NULL
304953	100736380	20992753558	Taking	take	VVG
304953	100736380	20992753559	selenium	selenium	NN1
304953	100736380	20992753560	,	,	,
304953	100736380	20992753561	either	either	RR
304953	100736380	20992753562	alone	alone	JJ_RR
304953	100736380	20992753563	or	or	CC
304953	100736380	20992753564	in	in	II
304953	100736380	20992753565	combination	combination	NN1
304953	100736380	20992753566	with	with	IW
304953	100736380	20992753567	vitamin	vitamin	NN1
304953	100736380	20992753568	E	e	ZZ1
304953	100736380	20992753569	,	,	,
304953	100736380	20992753570	increased	increase	VVD_VVN
304953	100736380	20992753571	the	the	AT
304953	100736380	20992753572	risk	risk	NN1
304953	100736380	20992753573	of	of	IO
304953	100736380	20992753574	high-grade	high-grade	JJ_NN1
304953	100736380	20992753575	prostate	prostate	NN1
304953	100736380	20992753576	cancer	cancer	NN1
304953	100736380	20992753577	in	in	II
304953	100736380	20992753578	men	man	NN2
304953	100736380	20992753579	who	who	PNQS
304953	100736380	20992753580	started	start	VVD
304953	100736380	20992753581	the	the	AT
304953	100736380	20992753582	study	study	NN1
304953	100736380	20992753583	with	with	IW
304953	100736380	20992753584	high	high	JJ
304953	100736380	20992753585	selenium	selenium	NN1
304953	100736380	20992753586	levels	level	NN2
304953	100736380	20992753587	,	,	,
304953	100736380	20992753588	but	but	CCB
304953	100736380	20992753589	not	not	XX
304953	100736380	20992753590	in	in	II
304953	100736380	20992753591	those	those	DD2
304953	100736380	20992753592	with	with	IW
304953	100736380	20992753593	low	low	JJ
304953	100736380	20992753594	selenium	selenium	NN1
304953	100736380	20992753595	levels	level	NN2
304953	100736380	20992753596	.	.	.
304953	100736380	20992753597	<p>		NULL
304953	100736380	20992753598	Among	among	II
304953	100736380	20992753599	men	man	NN2
304953	100736380	20992753600	who	who	PNQS
304953	100736380	20992753601	did	do	VDD
304953	100736380	20992753602	n't 	n't	XX
304953	100736380	20992753603	take	take	VVI
304953	100736380	20992753604	either	either	RR
304953	100736380	20992753605	vitamin	vitamin	NN1
304953	100736380	20992753606	E	e	ZZ1
304953	100736380	20992753607	or	or	CC
304953	100736380	20992753608	selenium	selenium	NN1
304953	100736380	20992753609	,	,	,
304953	100736380	20992753610	those	those	DD2
304953	100736380	20992753611	@		II
304953	100736380	20992753612	@		II
304953	100736380	20992753613	@		II
304953	100736380	20992753614	@		II
304953	100736380	20992753615	@		II
304953	100736380	20992753616	@		II
304953	100736380	20992753617	@		II
304953	100736380	20992753618	@		II
304953	100736380	20992753619	@		II
304953	100736380	20992753620	@		II
304953	100736380	20992753621	more	more	RGR
304953	100736380	20992753622	likely	likely	JJ
304953	100736380	20992753623	to	to	TO
304953	100736380	20992753624	have	have	VHI
304953	100736380	20992753625	developed	develop	VVN_JJ
304953	100736380	20992753626	prostate	prostate	NN1
304953	100736380	20992753627	cancer	cancer	NN1
304953	100736380	20992753628	than	than	CSN
304953	100736380	20992753629	men	man	NN2
304953	100736380	20992753630	who	who	PNQS
304953	100736380	20992753631	started	start	VVD
304953	100736380	20992753632	it	it	PPH1
304953	100736380	20992753633	with	with	IW
304953	100736380	20992753634	low	low	JJ
304953	100736380	20992753635	selenium	selenium	NN1
304953	100736380	20992753636	levels	level	NN2
304953	100736380	20992753637	.	.	.
304953	100736380	20992753638	(	(	(
304953	100736380	20992753639	This	this	DD1
304953	100736380	20992753640	means	mean	VVZ
304953	100736380	20992753641	the	the	AT
304953	100736380	20992753642	culprit	culprit	NN1
304953	100736380	20992753643	is	be	VBZ
304953	100736380	20992753644	added	added	JJ_VVN
304953	100736380	20992753645	selenium	selenium	NN1
304953	100736380	20992753646	from	from	II
304953	100736380	20992753647	supplements	supplement	NN2
304953	100736380	20992753648	,	,	,
304953	100736380	20992753649	not	not	XX
304953	100736380	20992753650	selenium	selenium	NN1
304953	100736380	20992753651	from	from	II
304953	100736380	20992753652	food	food	NN1
304953	100736380	20992753653	.	.	.
304953	100736380	20992753654	)	)	)
304953	100736380	20992753655	<p>		NULL
304953	100736380	20992753656	"	"	"
304953	100736380	20992753657	The	the	AT
304953	100736380	20992753658	new	new	JJ
304953	100736380	20992753659	data	data	NN
304953	100736380	20992753660	are	be	VBR
304953	100736380	20992753661	very	very	RG
304953	100736380	20992753662	troubling	troubling	JJ
304953	100736380	20992753663	,	,	,
304953	100736380	20992753664	and	and	CC
304953	100736380	20992753665	emphasize	emphasize	VV0
304953	100736380	20992753666	that	that	CST
304953	100736380	20992753667	supplements	supplement	NN2
304953	100736380	20992753668	can	can	VM
304953	100736380	20992753669	cause	cause	VVI
304953	100736380	20992753670	real	real	JJ
304953	100736380	20992753671	and	and	CC
304953	100736380	20992753672	tangible	tangible	JJ
304953	100736380	20992753673	harm	harm	NN1
304953	100736380	20992753674	,	,	,
304953	100736380	20992753675	"	"	"
304953	100736380	20992753676	says	say	VVZ
304953	100736380	20992753677	Dr.		NNB
304953	100736380	20992753678	Garnick		NP1
304953	100736380	20992753679	.	.	.
304953	100736380	20992753680	"	"	"
304953	100736380	20992753681	Any	any	DD
304953	100736380	20992753682	claims	claim	NN2
304953	100736380	20992753683	of	of	IO
304953	100736380	20992753684	benefits	benefit	NN2
304953	100736380	20992753685	from	from	II
304953	100736380	20992753686	dietary	dietary	JJ
304953	100736380	20992753687	supplements	supplement	NN2
304953	100736380	20992753688	must	must	VM
304953	100736380	20992753689	be	be	VBI
304953	100736380	20992753690	ignored	ignore	VVN
304953	100736380	20992753691	unless	unless	CS
304953	100736380	20992753692	large	large	JJ
304953	100736380	20992753693	,	,	,
304953	100736380	20992753694	controlled	control	VVD_VVN
304953	100736380	20992753695	,	,	,
304953	100736380	20992753696	and	and	CC
304953	100736380	20992753697	well-conducted	well-conducted	JJ_NN1
304953	100736380	20992753698	investigations	investigation	NN2
304953	100736380	20992753699	confirm	confirm	VV0
304953	100736380	20992753700	such	such	DA
304953	100736380	20992753701	benefits	benefit	NN2
304953	100736380	20992753702	"	"	"
304953	100736380	20992753703	which	which	DDQ
304953	100736380	20992753704	I	i	PPIS1
304953	100736380	20992753705	believe	believe	VV0
304953	100736380	20992753706	will	will	VM
304953	100736380	20992753707	be	be	VBI
304953	100736380	20992753708	a	a	AT1
304953	100736380	20992753709	very	very	RG
304953	100736380	20992753710	rare	rare	JJ
304953	100736380	20992753711	occurrence	occurrence	NN1
304953	100736380	20992753712	.	.	.
304953	100736380	20992753713	"	"	"
304953	100736383	20992753733	@@##	----------	----------
304953	100736383	20992753734	@@100736383		FO
304953	100736383	20992753735	@4936383/		VV0_NN1
304953	100736383	20992753736	46989		MC
304953	100736383	20992753737	@qwx906989		FO
304953	100736383	20992753738	<p>		NULL
304953	100736383	20992753739	In	in	II
304953	100736383	20992753740	December	december	NPM1
304953	100736383	20992753741	2008	2008	MC
304953	100736383	20992753742	,	,	,
304953	100736383	20992753743	the	the	AT
304953	100736383	20992753744	FDA	fda	NP1_NN1
304953	100736383	20992753745	approved	approve	VVD_VVN
304953	100736383	20992753746	the	the	AT
304953	100736383	20992753747	injectable	injectable	JJ
304953	100736383	20992753748	drug	drug	NN1
304953	100736383	20992753749	degarelix		NN1
304953	100736383	20992753750	(	(	(
304953	100736383	20992753751	Firmagon		NP1
304953	100736383	20992753752	)	)	)
304953	100736383	20992753753	for	for	IF
304953	100736383	20992753754	the	the	AT
304953	100736383	20992753755	treatment	treatment	NN1
304953	100736383	20992753756	of	of	IO
304953	100736383	20992753757	advanced	advanced	JJ
304953	100736383	20992753758	prostate	prostate	NN1
304953	100736383	20992753759	cancer	cancer	NN1
304953	100736383	20992753760	.	.	.
304953	100736383	20992753761	Degarelix		NN1_NP1@
304953	100736383	20992753762	belongs	belong	VVZ
304953	100736383	20992753763	to	to	II
304953	100736383	20992753764	a	a	AT1
304953	100736383	20992753765	class	class	NN1
304953	100736383	20992753766	of	of	IO
304953	100736383	20992753767	agents	agent	NN2
304953	100736383	20992753768	called	call	VVN_VVD@
304953	100736383	20992753769	gonadotropin-releasing	gonadotropin-releasing	JJ_NN1
304953	100736383	20992753770	hormone	hormone	NN1
304953	100736383	20992753771	(	(	(
304953	100736383	20992753772	GnRH	gnrh	NP1
304953	100736383	20992753773	)	)	)
304953	100736383	20992753774	antagonists.		NNU
304953	100736383	20992753775	*	*	FU
304953	100736383	20992753776	GnRH	gnrh	NP1
304953	100736383	20992753777	antagonists	antagonist	NN2
304953	100736383	20992753778	and	and	CC
304953	100736383	20992753779	drugs	drug	NN2
304953	100736383	20992753780	called	call	VVN_VVD@
304953	100736383	20992753781	luteinizing	luteinizing	VVG_JJ@
304953	100736383	20992753782	hormone	hormone	NN1
304953	100736383	20992753783	"	"	"
304953	100736383	20992753784	releasing	release	VVG
304953	100736383	20992753785	hormone	hormone	NN1
304953	100736383	20992753786	(	(	(
304953	100736383	20992753787	LHRH	lhrh	NP1
304953	100736383	20992753788	)	)	)
304953	100736383	20992753789	agonists	agonist	NN2
304953	100736383	20992753790	are	be	VBR
304953	100736383	20992753791	prescribed	prescribe	VVN
304953	100736383	20992753792	to	to	II
304953	100736383	20992753793	men	man	NN2
304953	100736383	20992753794	as	as	CSA_II@
304953	100736383	20992753795	hormone	hormone	NN1
304953	100736383	20992753796	therapy	therapy	NN1
304953	100736383	20992753797	for	for	IF
304953	100736383	20992753798	prostate	prostate	NN1
304953	100736383	20992753799	cancer	cancer	NN1
304953	100736383	20992753800	.	.	.
304953	100736383	20992753801	The	the	AT
304953	100736383	20992753802	drugs	drug	NN2
304953	100736383	20992753803	slow	slow	JJ_VV0@
304953	100736383	20992753804	disease	disease	NN1
304953	100736383	20992753805	progression	progression	NN1
304953	100736383	20992753806	by	by	II
304953	100736383	20992753807	suppressing	suppress	VVG
304953	100736383	20992753808	testosterone	testosterone	NN1
304953	100736383	20992753809	,	,	,
304953	100736383	20992753810	which	which	DDQ
304953	100736383	20992753811	plays	play	VVZ
304953	100736383	20992753812	a	a	AT1
304953	100736383	20992753813	key	key	JJ
304953	100736383	20992753814	role	role	NN1
304953	100736383	20992753815	in	in	II
304953	100736383	20992753816	the	the	AT
304953	100736383	20992753817	growth	growth	NN1
304953	100736383	20992753818	of	of	IO
304953	100736383	20992753819	prostate	prostate	NN1
304953	100736383	20992753820	cancer	cancer	NN1
304953	100736383	20992753821	.	.	.
304953	100736383	20992753822	<p>		NULL
304953	100736383	20992753823	LHRH	lhrh	NP1
304953	100736383	20992753824	agonists	agonist	NN2
304953	100736383	20992753825	"	"	"
304953	100736383	20992753826	leuprolide		VV0_NN1
304953	100736383	20992753827	(	(	(
304953	100736383	20992753828	Lupron		NP1
304953	100736383	20992753829	)	)	)
304953	100736383	20992753830	is	be	VBZ
304953	100736383	20992753831	one	one	PN1
304953	100736383	20992753832	"	"	"
304953	100736383	20992753833	may	may	VM
304953	100736383	20992753834	cause	cause	VVI
304953	100736383	20992753835	an	a	AT1
304953	100736383	20992753836	initial	initial	JJ_NN1
304953	100736383	20992753837	surge	surge	NN1
304953	100736383	20992753838	in	in	II
304953	100736383	20992753839	testosterone	testosterone	NN1
304953	100736383	20992753840	production	production	NN1
304953	100736383	20992753841	before	before	II
304953	100736383	20992753842	lowering	lower	VVG
304953	100736383	20992753843	testosterone	testosterone	NN1
304953	100736383	20992753844	levels	level	NN2
304953	100736383	20992753845	.	.	.
304953	100736383	20992753846	To	to	TO
304953	100736383	20992753847	block	block	VVI
304953	100736383	20992753848	that	that	DD1_CST
304953	100736383	20992753849	surge	surge	NN1_VV0
304953	100736383	20992753850	and	and	CC
304953	100736383	20992753851	help	help	VVI
304953	100736383	20992753852	prevent	prevent	VV0
304953	100736383	20992753853	any	any	DD
304953	100736383	20992753854	tumor	tumor	NN1
304953	100736383	20992753855	growth	growth	NN1
304953	100736383	20992753856	,	,	,
304953	100736383	20992753857	doctors	doctor	NN2
304953	100736383	20992753858	often	often	RR
304953	100736383	20992753859	prescribe	prescribe	VV0
304953	100736383	20992753860	a	a	AT1
304953	100736383	20992753861	short	short	JJ
304953	100736383	20992753862	course	course	NN1
304953	100736383	20992753863	of	of	IO
304953	100736383	20992753864	anti-androgen	anti-androgen	JJ_NN1
304953	100736383	20992753865	therapy	therapy	NN1
304953	100736383	20992753866	,	,	,
304953	100736383	20992753867	which	which	DDQ
304953	100736383	20992753868	can	can	VM
304953	100736383	20992753869	worsen	worsen	VVI
304953	100736383	20992753870	or	or	CC
304953	100736383	20992753871	cause	cause	VVI
304953	100736383	20992753872	additional	additional	JJ
304953	100736383	20992753873	side	side	NN1
304953	100736383	20992753874	effects	effect	NN2
304953	100736383	20992753875	.	.	.
304953	100736383	20992753876	But	but	CCB
304953	100736383	20992753877	because	because	CS
304953	100736383	20992753878	it	it	PPH1
304953	100736383	20992753879	works	work	VVZ
304953	100736383	20992753880	differently	differently	RR
304953	100736383	20992753881	,	,	,
304953	100736383	20992753882	degarelix		NN1_VV0
304953	100736383	20992753883	does	do	VDZ
304953	100736383	20992753884	n't	n't	XX
304953	100736383	20992753885	raise	raise	VVI
304953	100736383	20992753886	testosterone	testosterone	NN1
304953	100736383	20992753887	levels	level	NN2
304953	100736383	20992753888	,	,	,
304953	100736383	20992753889	making	make	VVG
304953	100736383	20992753890	an	a	AT1
304953	100736383	20992753891	anti-androgen	anti-androgen	JJ
304953	100736383	20992753892	unnecessary	unnecessary	JJ
304953	100736383	20992753893	.	.	.
304953	100736383	20992753894	<p>		NULL
304953	100736383	20992753895	FDA	fda	NP1_NN1
304953	100736383	20992753896	approval	approval	NN1
304953	100736383	20992753897	of	of	IO
304953	100736383	20992753898	degarelix		NN1
304953	100736383	20992753899	was	be	VBDZ
304953	100736383	20992753900	based	base	VVN
304953	100736383	20992753901	on	on	II
304953	100736383	20992753902	a	a	AT1
304953	100736383	20992753903	year-long	year-long	JJ
304953	100736383	20992753904	phase	phase	NN1
304953	100736383	20992753905	III	iii	MC
304953	100736383	20992753906	randomized	randomize	VVD_JJ@
304953	100736383	20992753907	clinical	clinical	JJ
304953	100736383	20992753908	trial	trial	NN1
304953	100736383	20992753909	that	that	CST
304953	100736383	20992753910	compared	compare	VVD
304953	100736383	20992753911	it	it	PPH1
304953	100736383	20992753912	with	with	IW
304953	100736383	20992753913	leuprolide	leuprolide	NN1
304953	100736383	20992753914	.	.	.
304953	100736383	20992753915	Both	both	DB2
304953	100736383	20992753916	drugs	drug	NN2
304953	100736383	20992753917	were	be	VBDR
304953	100736383	20992753918	equally	equally	RR
304953	100736383	20992753919	effective	effective	JJ
304953	100736383	20992753920	at	at	II
304953	100736383	20992753921	suppressing	suppress	VVG
304953	100736383	20992753922	testosterone	testosterone	NN1
304953	100736383	20992753923	levels	level	NN2
304953	100736383	20992753924	,	,	,
304953	100736383	20992753925	@		II
304953	100736383	20992753926	@		II
304953	100736383	20992753927	@		II
304953	100736383	20992753928	@		II
304953	100736383	20992753929	@		II
304953	100736383	20992753930	@		II
304953	100736383	20992753931	@		II
304953	100736383	20992753932	@		II
304953	100736383	20992753933	@		II
304953	100736383	20992753934	@		II
304953	100736383	20992753935	common	common	JJ
304953	100736383	20992753936	side	side	NN1
304953	100736383	20992753937	effects	effect	NN2
304953	100736383	20992753938	were	be	VBDR
304953	100736383	20992753939	pain	pain	NN1
304953	100736383	20992753940	,	,	,
304953	100736383	20992753941	redness	redness	NN1
304953	100736383	20992753942	,	,	,
304953	100736383	20992753943	and	and	CC
304953	100736383	20992753944	swelling	swell	VVG_JJ
304953	100736383	20992753945	at	at	II
304953	100736383	20992753946	the	the	AT
304953	100736383	20992753947	injection	injection	NN1
304953	100736383	20992753948	site	site	NN1
304953	100736383	20992753949	;	;	;
304953	100736383	20992753950	hot	hot	JJ
304953	100736383	20992753951	flashes	flash	NN2
304953	100736383	20992753952	;	;	;
304953	100736383	20992753953	weight	weight	NN1
304953	100736383	20992753954	gain	gain	NN1_VV0
304953	100736383	20992753955	;	;	;
304953	100736383	20992753956	fatigue	fatigue	NN1
304953	100736383	20992753957	;	;	;
304953	100736383	20992753958	and	and	CC
304953	100736383	20992753959	increases	increase	VVZ_NN2
304953	100736383	20992753960	in	in	II_RP@
304953	100736383	20992753961	some	some	DD
304953	100736383	20992753962	liver	liver	NN1
304953	100736383	20992753963	enzymes	enzyme	NN2
304953	100736383	20992753964	.	.	.
304953	100736383	20992753965	<p>		NULL
304953	100736383	20992753966	*Note:Editor		FO
304953	100736383	20992753967	in	in	II
304953	100736383	20992753968	Chief	chief	NNB
304953	100736383	20992753969	Marc	marc	NP1
304953	100736383	20992753970	Garnick		NP1
304953	100736383	20992753971	,	,	,
304953	100736383	20992753972	M.D.	m.d	NNA
304953	100736383	20992753973	,	,	,
304953	100736383	20992753974	helped	help	VVN_VVD
304953	100736383	20992753975	develop	develop	VVI
304953	100736383	20992753976	the	the	AT
304953	100736383	20992753977	first	first	MD
304953	100736383	20992753978	GnRH	gnrh	NP1
304953	100736383	20992753979	antagonist	antagonist	NN1
304953	100736383	20992753980	,	,	,
304953	100736383	20992753981	abarelix		NN1_VV0
304953	100736383	20992753982	(	(	(
304953	100736383	20992753983	Plenaxis		NP1
304953	100736383	20992753984	)	)	)
304953	100736383	20992753985	.	.	.
304953	100736383	20992753986	He	he	PPHS1
304953	100736383	20992753987	serves	serve	VVZ
304953	100736383	20992753988	as	as	II
304953	100736383	20992753989	a	a	AT1
304953	100736383	20992753990	consultant	consultant	NN1
304953	100736383	20992753991	to	to	II
304953	100736383	20992753992	Specialty	specialty	NP1_NN1
304953	100736383	20992753993	European	european	JJ
304953	100736383	20992753994	Pharma	pharma	NP1_NN1@
304953	100736383	20992753995	,	,	,
304953	100736383	20992753996	which	which	DDQ
304953	100736383	20992753997	is	be	VBZ
304953	100736383	20992753998	marketing	market	VVG@_NN1
304953	100736383	20992753999	abarelix		NN1_VV0
304953	100736383	20992754000	in	in	II
304953	100736383	20992754001	Europe	europe	NP1
304953	100736383	20992754002	.	.	.
304953	100736383	20992754003	<p>		NULL
304953	100736383	20992754004	was	be	VBDZ
304953	100736383	20992754005	positive	positive	JJ
304953	100736383	20992754006	.	.	.
304953	100736383	20992754007	They	they	PPHS2
304953	100736383	20992754008	came	come	VVD
304953	100736383	20992754009	up	up	RP
304953	100736383	20992754010	with	with	IW
304953	100736383	20992754011	no	no	AT
304953	100736383	20992754012	canecr		NN1
304953	100736383	20992754013	present	present	NN1
304953	100736383	20992754014	.	.	.
304953	100736383	20992754015	So	so	RR
304953	100736383	20992754016	my	my	APPGE
304953	100736383	20992754017	doctor	doctor	NN1
304953	100736383	20992754018	was	be	VBDZ
304953	100736383	20992754019	very	very	RG
304953	100736383	20992754020	adamant	adamant	JJ
304953	100736383	20992754021	that	that	CST
304953	100736383	20992754022	he	he	PPHS1
304953	100736383	20992754023	was	be	VBDZ
304953	100736383	20992754024	not	not	XX
304953	100736383	20992754025	wrong	wrong	JJ_RR@
304953	100736383	20992754026	and	and	CC
304953	100736383	20992754027	so	so	RR_CS@
304953	100736383	20992754028	I	i	PPIS1
304953	100736383	20992754029	went	go	VVD
304953	100736383	20992754030	back	back	RP
304953	100736383	20992754031	to	to	II
304953	100736383	20992754032	the	the	AT
304953	100736383	20992754033	hospital	hospital	NN1
304953	100736383	20992754034	two	two	MC
304953	100736383	20992754035	months	month	NNT2
304953	100736383	20992754036	later	later	RRR
304953	100736383	20992754037	and	and	CC
304953	100736383	20992754038	they	they	PPHS2
304953	100736383	20992754039	did	do	VDD
304953	100736383	20992754040	their	their	APPGE
304953	100736383	20992754041	own	own	DA
304953	100736383	20992754042	biopsy	biopsy	NN1
304953	100736383	20992754043	which	which	DDQ
304953	100736383	20992754044	came	come	VVD
304953	100736383	20992754045	back	back	RP
304953	100736383	20992754046	negative	negative	JJ_NN1@
304953	100736383	20992754047	.	.	.
304953	100736383	20992754048	In	in	II
304953	100736383	20992754049	fact	fact	NN1
304953	100736383	20992754050	they	they	PPHS2
304953	100736383	20992754051	were	be	VBDR
304953	100736383	20992754052	surprised	surprised	JJ_VVN%
304953	100736383	20992754053	that	that	CST
304953	100736383	20992754054	my	my	APPGE
304953	100736383	20992754055	Urologist	urologist	NN1
304953	100736383	20992754056	even	even	RR
304953	100736383	20992754057	did	do	VDD
304953	100736383	20992754058	a	a	AT1
304953	100736383	20992754059	biopsy	biopsy	NN1
304953	100736383	20992754060	on	on	II
304953	100736383	20992754061	a	a	AT1
304953	100736383	20992754062	PSA	psa	NP1
304953	100736383	20992754063	that	that	DD1_CST
304953	100736383	20992754064	was	be	VBDZ
304953	100736383	20992754065	only	only	JJ
304953	100736383	20992754066	2.0		NN1
304953	100736383	20992754067	and	and	CC
304953	100736383	20992754068	that	that	CST_DD1
304953	100736383	20992754069	had	have	VHD
304953	100736383	20992754070	increased	increase	VVN
304953	100736383	20992754071	one	one	MC1
304953	100736383	20992754072	point	point	NN1
304953	100736383	20992754073	in	in	II
304953	100736383	20992754074	a	a	AT1
304953	100736383	20992754075	year	year	NNT1
304953	100736383	20992754076	based	base	VVN
304953	100736383	20992754077	on	on	II
304953	100736383	20992754078	my	my	APPGE
304953	100736383	20992754079	family	family	NN1
304953	100736383	20992754080	doctors	doctor	NN2
304953	100736383	20992754081	information	information	NN1
304953	100736383	20992754082	.	.	.
304953	100736383	20992754083	Here	here	RL
304953	100736383	20992754084	are	be	VBR
304953	100736383	20992754085	some	some	DD
304953	100736383	20992754086	original	original	JJ
304953	100736383	20992754087	mistakes	mistake	NN2
304953	100736383	20992754088	to	to	TO
304953	100736383	20992754089	watch	watch	VVI
304953	100736383	20992754090	out	out	RP
304953	100736383	20992754091	for	for	IF
304953	100736383	20992754092	all	all	DB
304953	100736383	20992754093	of	of	IO
304953	100736383	20992754094	you	you	PPY
304953	100736383	20992754095	who	who	PNQS
304953	100736383	20992754096	may	may	VM
304953	100736383	20992754097	experieince		VVI
304953	100736383	20992754098	this	this	DD1
304953	100736383	20992754099	:	:	:
304953	100736383	20992754100	my	my	APPGE
304953	100736383	20992754101	family	family	NN1
304953	100736383	20992754102	doctor	doctor	NN1
304953	100736383	20992754103	who	who	PNQS
304953	100736383	20992754104	said	say	VVD
304953	100736383	20992754105	my	my	APPGE
304953	100736383	20992754106	PSA	psa	NP1
304953	100736383	20992754107	went	go	VVD
304953	100736383	20992754108	up	up	RP
304953	100736383	20992754109	one	one	MC1
304953	100736383	20992754110	point	point	NN1
304953	100736383	20992754111	in	in	II
304953	100736383	20992754112	a	a	AT1
304953	100736383	20992754113	year	year	NNT1
304953	100736383	20992754114	had	have	VHD
304953	100736383	20992754115	both	both	DB2
304953	100736383	20992754116	readings	reading	NN2
304953	100736383	20992754117	done	do	VDN
304953	100736383	20992754118	by	by	II
304953	100736383	20992754119	different	different	JJ
304953	100736383	20992754120	labs	lab	NN2
304953	100736383	20992754121	,	,	,
304953	100736383	20992754122	not	not	XX
304953	100736383	20992754123	good	good	JJ_RR%
304953	100736383	20992754124	,	,	,
304953	100736383	20992754125	@		II
304953	100736383	20992754126	@		II
304953	100736383	20992754127	@		II
304953	100736383	20992754128	@		II
304953	100736383	20992754129	@		II
304953	100736383	20992754130	@		II
304953	100736383	20992754131	@		II
304953	100736383	20992754132	@		II
304953	100736383	20992754133	@		II
304953	100736383	20992754134	@		II
304953	100736383	20992754135	based	base	VVN
304953	100736383	20992754136	on	on	II
304953	100736383	20992754137	that	that	DD1
304953	100736383	20992754138	information	information	NN1
304953	100736383	20992754139	without	without	RR%_IW
304953	100736383	20992754140	doing	do	VDG
304953	100736383	20992754141	his	his	APPGE
304953	100736383	20992754142	own	own	DA
304953	100736383	20992754143	PSA	psa	NP1
304953	100736383	20992754144	test	test	VV0_NN1
304953	100736383	20992754145	to	to	TO
304953	100736383	20992754146	confirm	confirm	VVI
304953	100736383	20992754147	.	.	.
304953	100736383	20992754148	Clearly	clearly	RR
304953	100736383	20992754149	I	i	PPIS1
304953	100736383	20992754150	should	should	VM
304953	100736383	20992754151	have	have	VHI
304953	100736383	20992754152	been	be	VBN
304953	100736383	20992754153	smarter	smart	JJR
304953	100736383	20992754154	and	and	CC
304953	100736383	20992754155	seen	see	VVN
304953	100736383	20992754156	that	that	DD1
304953	100736383	20992754157	error	error	NN1
304953	100736383	20992754158	.	.	.
304953	100736383	20992754159	But	but	CCB
304953	100736383	20992754160	then	then	RT
304953	100736383	20992754161	there	there	EX
304953	100736383	20992754162	is	be	VBZ
304953	100736383	20992754163	so	so	RG
304953	100736383	20992754164	much	much	DA1
304953	100736383	20992754165	money	money	NN1
304953	100736383	20992754166	to	to	TO
304953	100736383	20992754167	be	be	VBI
304953	100736383	20992754168	made	make	VVN
304953	100736383	20992754169	from	from	II
304953	100736383	20992754170	biopsies	biopsy	NN2
304953	100736383	20992754171	and	and	CC
304953	100736383	20992754172	radical	radical	JJ_NN1
304953	100736383	20992754173	surgery	surgery	NN1
304953	100736383	20992754174	Urologists	urologist	NN2
304953	100736383	20992754175	will	will	VM
304953	100736383	20992754176	guide	guide	VVI
304953	100736383	20992754177	you	you	PPY
304953	100736383	20992754178	straight	straight	RR
304953	100736383	20992754179	down	down	II
304953	100736383	20992754180	that	that	DD1
304953	100736383	20992754181	road	road	NN1
304953	100736383	20992754182	.	.	.
304953	100736383	20992754183	This	this	DD1
304953	100736383	20992754184	was	be	VBDZ
304953	100736383	20992754185	all	all	DB_RR@
304953	100736383	20992754186	a	a	AT1
304953	100736383	20992754187	year	year	NNT1
304953	100736383	20992754188	and	and	CC
304953	100736383	20992754189	a	a	AT1
304953	100736383	20992754190	half	half	DB_NN1@_RR@
304953	100736383	20992754191	ago	ago	RA
304953	100736383	20992754192	and	and	CC
304953	100736383	20992754193	my	my	APPGE
304953	100736383	20992754194	PSA	psa	NP1
304953	100736383	20992754195	continues	continue	VVZ
304953	100736383	20992754196	to	to	TO
304953	100736383	20992754197	decline	decline	VVI
304953	100736383	20992754198	now	now	RT
304953	100736383	20992754199	to	to	II_TO
304953	100736383	20992754200	almost	almost	RR
304953	100736383	20992754201	1.0	1.0	MC
304953	100736383	20992754202	which	which	DDQ
304953	100736383	20992754203	I	i	PPIS1
304953	100736383	20992754204	check	check	VV0
304953	100736383	20992754205	every	every	AT1
304953	100736383	20992754206	thre	thre	NN1
304953	100736383	20992754207	months	month	NNT2
304953	100736383	20992754208	.	.	.
304953	100736383	20992754209	46996		MC
304953	100736383	20992754210	@qwx906996		FO
304953	100736385	20992754230	@@##	----------	----------
304953	100736385	20992754231	@@100736385		FO
304953	100736385	20992754232	@4936385/		VV0_NN1
304953	100736385	20992754233	46989		MC
304953	100736385	20992754234	@qwx906989		FO
304953	100736385	20992754235	<p>		NULL
304953	100736385	20992754236	Researchers	researcher	NN2
304953	100736385	20992754237	conducting	conduct	VVG
304953	100736385	20992754238	a	a	AT1
304953	100736385	20992754239	phase	phase	NN1
304953	100736385	20992754240	I/II	i/ii	FU
304953	100736385	20992754241	clinical	clinical	JJ
304953	100736385	20992754242	trial	trial	NN1
304953	100736385	20992754243	of	of	IO
304953	100736385	20992754244	proton	proton	NN1
304953	100736385	20992754245	radiation	radiation	NN1
304953	100736385	20992754246	for	for	IF
304953	100736385	20992754247	early	early	JJ
304953	100736385	20992754248	prostate	prostate	NN1
304953	100736385	20992754249	cancer	cancer	NN1
304953	100736385	20992754250	found	find	VVD_VVN
304953	100736385	20992754251	that	that	CST
304953	100736385	20992754252	the	the	AT
304953	100736385	20992754253	treatment	treatment	NN1
304953	100736385	20992754254	is	be	VBZ
304953	100736385	20992754255	safe	safe	JJ
304953	100736385	20992754256	and	and	CC
304953	100736385	20992754257	well-tolerated	well-tolerated	NN1_JJ
304953	100736385	20992754258	by	by	II
304953	100736385	20992754259	patients	patient	NN2
304953	100736385	20992754260	,	,	,
304953	100736385	20992754261	but	but	CCB
304953	100736385	20992754262	probably	probably	RR
304953	100736385	20992754263	no	no	AT
304953	100736385	20992754264	better	better	JJR_RRR
304953	100736385	20992754265	than	than	CSN
304953	100736385	20992754266	other	other	JJ
304953	100736385	20992754267	,	,	,
304953	100736385	20992754268	less	less	RGR
304953	100736385	20992754269	expensive	expensive	JJ
304953	100736385	20992754270	forms	form	NN2
304953	100736385	20992754271	of	of	IO
304953	100736385	20992754272	radiation	radiation	NN1
304953	100736385	20992754273	.	.	.
304953	100736385	20992754274	Their	their	APPGE
304953	100736385	20992754275	preliminary	preliminary	JJ
304953	100736385	20992754276	findings	finding	NN2
304953	100736385	20992754277	were	be	VBDR
304953	100736385	20992754278	presented	present	VVN
304953	100736385	20992754279	at	at	II
304953	100736385	20992754280	a	a	AT1
304953	100736385	20992754281	meeting	meeting	NN1
304953	100736385	20992754282	of	of	IO
304953	100736385	20992754283	the	the	AT
304953	100736385	20992754284	American	american	JJ
304953	100736385	20992754285	Society	society	NN1
304953	100736385	20992754286	for	for	IF
304953	100736385	20992754287	Therapeutic	therapeutic	JJ
304953	100736385	20992754288	Radiology	radiology	NN1
304953	100736385	20992754289	and	and	CC
304953	100736385	20992754290	Oncology	oncology	NN1_NP1
304953	100736385	20992754291	in	in	II
304953	100736385	20992754292	September	september	NPM1
304953	100736385	20992754293	2008	2008	MC
304953	100736385	20992754294	;	;	;
304953	100736385	20992754295	subsequent	subsequent	JJ
304953	100736385	20992754296	findings	finding	NN2
304953	100736385	20992754297	were	be	VBDR
304953	100736385	20992754298	published	publish	VVN
304953	100736385	20992754299	online	online	RR_JJ
304953	100736385	20992754300	in	in	II
304953	100736385	20992754301	2010	2010	MC
304953	100736385	20992754302	in	in	II
304953	100736385	20992754303	the	the	AT
304953	100736385	20992754304	International	international	JJ
304953	100736385	20992754305	Journal	journal	NN1
304953	100736385	20992754306	of	of	IO
304953	100736385	20992754307	Radiation	radiation	NN1
304953	100736385	20992754308	Oncology	oncology	NN1_NP1
304953	100736385	20992754309	,	,	,
304953	100736385	20992754310	Biology	biology	NN1
304953	100736385	20992754311	&amp;		CC
304953	100736385	20992754312	Physics	physics	NN1
304953	100736385	20992754313	.	.	.
304953	100736385	20992754314	<p>		NULL
304953	100736385	20992754315	The	the	AT
304953	100736385	20992754316	study	study	NN1
304953	100736385	20992754317	tested	test	VVD_VVN
304953	100736385	20992754318	a	a	AT1
304953	100736385	20992754319	total	total	JJ
304953	100736385	20992754320	radiation	radiation	NN1
304953	100736385	20992754321	dose	dose	NN1
304953	100736385	20992754322	of	of	IO
304953	100736385	20992754323	82	82	MC
304953	100736385	20992754324	Gray	gray	NP1
304953	100736385	20992754325	,	,	,
304953	100736385	20992754326	slightly	slightly	RR
304953	100736385	20992754327	higher	high	JJR
304953	100736385	20992754328	than	than	CSN
304953	100736385	20992754329	the	the	AT
304953	100736385	20992754330	traditional	traditional	JJ
304953	100736385	20992754331	dose	dose	NN1
304953	100736385	20992754332	of	of	IO
304953	100736385	20992754333	78	78	MC
304953	100736385	20992754334	Gray	gray	NP1
304953	100736385	20992754335	.	.	.
304953	100736385	20992754336	Of	of	IO
304953	100736385	20992754337	the	the	AT
304953	100736385	20992754338	84	84	MC
304953	100736385	20992754339	patients	patient	NN2
304953	100736385	20992754340	included	include	VVN_VVD
304953	100736385	20992754341	in	in	II
304953	100736385	20992754342	the	the	AT
304953	100736385	20992754343	study	study	NN1
304953	100736385	20992754344	,	,	,
304953	100736385	20992754345	about	about	II
304953	100736385	20992754346	two-thirds	two-thirds	MF
304953	100736385	20992754347	developed	developed	JJ
304953	100736385	20992754348	relatively	relatively	RR
304953	100736385	20992754349	minor	minor	JJ
304953	100736385	20992754350	genitourinary	genitourinary	NN1_JJ
304953	100736385	20992754351	or	or	CC
304953	100736385	20992754352	gastrointestinal	gastrointestinal	JJ
304953	100736385	20992754353	side	side	NN1
304953	100736385	20992754354	effects	effect	NN2
304953	100736385	20992754355	,	,	,
304953	100736385	20992754356	such	such	II21
304953	100736385	20992754357	as	as	II22
304953	100736385	20992754358	urinary	urinary	JJ_NN1
304953	100736385	20992754359	incontinence	incontinence	NN1
304953	100736385	20992754360	,	,	,
304953	100736385	20992754361	at	at	II
304953	100736385	20992754362	the	the	AT
304953	100736385	20992754363	time	time	NNT1
304953	100736385	20992754364	of	of	IO
304953	100736385	20992754365	the	the	AT
304953	100736385	20992754366	treatment	treatment	NN1
304953	100736385	20992754367	or	or	CC
304953	100736385	20992754368	shortly	shortly	RR
304953	100736385	20992754369	thereafter	thereafter	RT
304953	100736385	20992754370	.	.	.
304953	100736385	20992754371	Roughly	roughly	RR
304953	100736385	20992754372	the	the	AT
304953	100736385	20992754373	same	same	DA
304953	100736385	20992754374	number	number	NN1
304953	100736385	20992754375	of	of	IO
304953	100736385	20992754376	patients	patient	NN2
304953	100736385	20992754377	developed	developed	JJ_VVN_VVD
304953	100736385	20992754378	problems	problem	NN2
304953	100736385	20992754379	in	in	II
304953	100736385	20992754380	the	the	AT
304953	100736385	20992754381	months	month	NNT2
304953	100736385	20992754382	that	that	CST_DD1
304953	100736385	20992754383	followed	follow	VVD
304953	100736385	20992754384	,	,	,
304953	100736385	20992754385	notably	notably	RR
304953	100736385	20992754386	urinary	urinary	JJ
304953	100736385	20992754387	frequency/urgency		NN1
304953	100736385	20992754388	and	and	CC
304953	100736385	20992754389	rectal	rectal	JJ
304953	100736385	20992754390	bleeding	bleeding	JJ
304953	100736385	20992754391	.	.	.
304953	100736385	20992754392	Fewer	fewer	DAR
304953	100736385	20992754393	than	than	CSN
304953	100736385	20992754394	10%		NNU
304953	100736385	20992754395	of	of	IO
304953	100736385	20992754396	patients	patient	NN2
304953	100736385	20992754397	experienced	experience	VVD_VVN
304953	100736385	20992754398	more	more	RGR_DAR
304953	100736385	20992754399	serious	serious	JJ
304953	100736385	20992754400	side	side	NN1
304953	100736385	20992754401	effects	effect	NN2
304953	100736385	20992754402	.	.	.
304953	100736385	20992754403	Initially	initially	RR
304953	100736385	20992754404	,	,	,
304953	100736385	20992754405	the	the	AT
304953	100736385	20992754406	median	median	JJ_NN1
304953	100736385	20992754407	follow-up	follow-up	JJ_NN1
304953	100736385	20992754408	time	time	NNT1
304953	100736385	20992754409	was	be	VBDZ
304953	100736385	20992754410	23	23	MC
304953	100736385	20992754411	months	month	NNT2
304953	100736385	20992754412	,	,	,
304953	100736385	20992754413	but	but	CCB
304953	100736385	20992754414	that	that	DD1
304953	100736385	20992754415	time	time	NNT1
304953	100736385	20992754416	was	be	VBDZ
304953	100736385	20992754417	extended	extend	VVN
304953	100736385	20992754418	to	to	II
304953	100736385	20992754419	31.6	31.6	MC
304953	100736385	20992754420	months	month	NNT2
304953	100736385	20992754421	in	in	II
304953	100736385	20992754422	@		II
304953	100736385	20992754423	@		II
304953	100736385	20992754424	@		II
304953	100736385	20992754425	@		II
304953	100736385	20992754426	@		II
304953	100736385	20992754427	@		II
304953	100736385	20992754428	@		II
304953	100736385	20992754429	@		II
304953	100736385	20992754430	@		II
304953	100736385	20992754431	@		II
304953	100736385	20992754432	compare	compare	VVI
304953	100736385	20992754433	different	different	JJ
304953	100736385	20992754434	types	type	NN2
304953	100736385	20992754435	of	of	IO
304953	100736385	20992754436	radiation	radiation	NN1
304953	100736385	20992754437	therapy	therapy	NN1
304953	100736385	20992754438	.	.	.
304953	100736385	20992754439	Nor	nor	CC
304953	100736385	20992754440	did	do	VDD
304953	100736385	20992754441	it	it	PPH1
304953	100736385	20992754442	assess	assess	VVI
304953	100736385	20992754443	patient	patient	JJ_NN1
304953	100736385	20992754444	outcomes	outcome	NN2
304953	100736385	20992754445	,	,	,
304953	100736385	20992754446	such	such	II21
304953	100736385	20992754447	as	as	II22
304953	100736385	20992754448	biochemical	biochemical	JJ
304953	100736385	20992754449	recurrence	recurrence	NN1
304953	100736385	20992754450	of	of	IO
304953	100736385	20992754451	disease	disease	NN1
304953	100736385	20992754452	,	,	,
304953	100736385	20992754453	because	because	CS
304953	100736385	20992754454	the	the	AT
304953	100736385	20992754455	follow-up	follow-up	JJ_NN1
304953	100736385	20992754456	time	time	NNT1
304953	100736385	20992754457	was	be	VBDZ
304953	100736385	20992754458	too	too	RG
304953	100736385	20992754459	short	short	JJ_RR@
304953	100736385	20992754460	.	.	.
304953	100736385	20992754461	But	but	CCB
304953	100736385	20992754462	it	it	PPH1
304953	100736385	20992754463	does	do	VDZ
304953	100736385	20992754464	seem	seem	VVI
304953	100736385	20992754465	to	to	TO
304953	100736385	20992754466	indicate	indicate	VVI
304953	100736385	20992754467	that	that	CST
304953	100736385	20992754468	a	a	AT1
304953	100736385	20992754469	dose	dose	NN1
304953	100736385	20992754470	of	of	IO
304953	100736385	20992754471	proton	proton	NN1
304953	100736385	20992754472	radiation	radiation	NN1
304953	100736385	20992754473	up	up	RG21
304953	100736385	20992754474	to	to	RG22
304953	100736385	20992754475	82	82	MC
304953	100736385	20992754476	Gray	gray	NP1
304953	100736385	20992754477	is	be	VBZ
304953	100736385	20992754478	relatively	relatively	RR
304953	100736385	20992754479	safe	safe	JJ
304953	100736385	20992754480	and	and	CC
304953	100736385	20992754481	tolerable	tolerable	JJ
304953	100736385	20992754482	for	for	IF
304953	100736385	20992754483	patients	patient	NN2
304953	100736385	20992754484	.	.	.
304953	100736385	20992754485	<p>		NULL
304953	100736385	20992754486	I	i	PPIS1
304953	100736385	20992754487	specialize	specialize	VV0
304953	100736385	20992754488	in	in	II_RP@
304953	100736385	20992754489	the	the	AT
304953	100736385	20992754490	imnume		NN1
304953	100736385	20992754491	system	system	NN1
304953	100736385	20992754492	,	,	,
304953	100736385	20992754493	prostate	prostate	NN1
304953	100736385	20992754494	cancer	cancer	NN1
304953	100736385	20992754495	and	and	CC
304953	100736385	20992754496	other	other	JJ
304953	100736385	20992754497	cancers	cancer	NN2
304953	100736385	20992754498	but	but	CCB
304953	100736385	20992754499	can	can	VM
304953	100736385	20992754500	tell	tell	VVI
304953	100736385	20992754501	you	you	PPY
304953	100736385	20992754502	that	that	CST_DD1
304953	100736385	20992754503	AHCC	ahcc	NP1_NN1
304953	100736385	20992754504	(	(	(
304953	100736385	20992754505	ImmunoKinoko		NP1
304953	100736385	20992754506	)	)	)
304953	100736385	20992754507	sold	sell	VVD_VVN
304953	100736385	20992754508	on	on	II_RP@
304953	100736385	20992754509	our	our	APPGE
304953	100736385	20992754510	site	site	NN1
304953	100736385	20992754511	helps	help	VVZ
304953	100736385	20992754512	with	with	IW
304953	100736385	20992754513	the	the	AT
304953	100736385	20992754514	production	production	NN1
304953	100736385	20992754515	of	of	IO
304953	100736385	20992754516	insulin	insulin	NN1
304953	100736385	20992754517	and	and	CC
304953	100736385	20992754518	has	have	VHZ
304953	100736385	20992754519	been	be	VBN
304953	100736385	20992754520	useful	useful	JJ
304953	100736385	20992754521	to	to	II
304953	100736385	20992754522	Type	type	NN1
304953	100736385	20992754523	I	i	ZZ1%_MC1%
304953	100736385	20992754524	Diabetics	diabetic	NN2
304953	100736385	20992754525	.	.	.
304953	100736385	20992754526	Other	other	II21
304953	100736385	20992754527	than	than	II22
304953	100736385	20992754528	that	that	DD1
304953	100736385	20992754529	,	,	,
304953	100736385	20992754530	I	i	PPIS1
304953	100736385	20992754531	do	do	VD0
304953	100736385	20992754532	offer	offer	VVI
304953	100736385	20992754533	free	free	JJ
304953	100736385	20992754534	consults	consult	VVZ
304953	100736385	20992754535	regarding	regarding	II
304953	100736385	20992754536	eating	eat	VVG_NN1
304953	100736385	20992754537	properly	properly	RR
304953	100736385	20992754538	for	for	IF
304953	100736385	20992754539	prevent	prevent	VV0
304953	100736385	20992754540	the	the	AT
304953	100736385	20992754541	epidemic	epidemic	NN1
304953	100736385	20992754542	of	of	IO
304953	100736385	20992754543	Type	type	NN1
304953	100736385	20992754544	II	ii	MC
304953	100736385	20992754545	Diabetics	diabetic	NN2
304953	100736385	20992754546	striking	strike	VVG
304953	100736385	20992754547	younger	young	JJR
304953	100736385	20992754548	and	and	CC
304953	100736385	20992754549	younger	young	JJR
304953	100736385	20992754550	segments	segment	NN2
304953	100736385	20992754551	of	of	IO
304953	100736385	20992754552	the	the	AT
304953	100736385	20992754553	population	population	NN1
304953	100736385	20992754554	do	do	VD0
304953	100736385	20992754555	to	to	II
304953	100736385	20992754556	refined	refined	JJ
304953	100736385	20992754557	carbohydrates	carbohydrate	NN2
304953	100736385	20992754558	and	and	CC
304953	100736385	20992754559	fast	fast	RR_JJ
304953	100736385	20992754560	foods.I		NNU
304953	100736385	20992754561	do	do	VD0
304953	100736385	20992754562	focus	focus	VVI
304953	100736385	20992754563	,	,	,
304953	100736385	20992754564	though	though	CS_RR@
304953	100736385	20992754565	,	,	,
304953	100736385	20992754566	as	as	CSA
304953	100736385	20992754567	stated	state	VVN
304953	100736385	20992754568	,	,	,
304953	100736385	20992754569	on	on	II
304953	100736385	20992754570	first	first	MD
304953	100736385	20992754571	and	and	CC
304953	100736385	20992754572	foremost	foremost	JJT
304953	100736385	20992754573	prostate	prostate	NN1
304953	100736385	20992754574	cancer	cancer	NN1
304953	100736385	20992754575	,	,	,
304953	100736385	20992754576	other	other	JJ
304953	100736385	20992754577	cancers	cancer	NN2
304953	100736385	20992754578	and	and	CC
304953	100736385	20992754579	the	the	AT
304953	100736385	20992754580	imnume		NN1
304953	100736385	20992754581	sytem		NN1
304953	100736385	20992754582	and	and	CC
304953	100736385	20992754583	imnume		VV0_NN1
304953	100736385	20992754584	disorders	disorder	NN2
304953	100736385	20992754585	.	.	.
304953	100736385	20992754586	Fell	fell	NP1
304953	100736385	20992754587	free	free	JJ_VV0@
304953	100736385	20992754588	to	to	TO
304953	100736385	20992754589	write	write	VVI
304953	100736385	20992754590	if	if	CSW@_CS
304953	100736385	20992754591	you	you	PPY
304953	100736385	20992754592	have	have	VH0
304953	100736385	20992754593	a	a	AT1
304953	100736385	20992754594	specific	specific	JJ
304953	100736385	20992754595	questionPatricia		NN1
304953	100736385	20992754596	46996		MC
304953	100736385	20992754597	@qwx906996		FO
304953	100736386	20992754617	@@##	----------	----------
304953	100736386	20992754618	@@100736386		FO
304953	100736386	20992754619	@4936386/		VV0_NN1
304953	100736386	20992754620	46989		MC
304953	100736386	20992754621	@qwx906989		FO
304953	100736386	20992754622	<h>		NULL
304953	100736386	20992754623	Posts	post	NN2
304953	100736386	20992754624	Tagged	tag	VVD_VVN
304953	100736386	20992754625	news	news	NN1
304953	100736386	20992754626	<p>		NULL
304953	100736386	20992754627	A	a	ZZ1_AT1
304953	100736386	20992754628	womans	woman	NN2
304953	100736386	20992754629	use	use	NN1_VV0
304953	100736386	20992754630	of	of	IO
304953	100736386	20992754631	a	a	AT1
304953	100736386	20992754632	testosterone-based		JJ
304953	100736386	20992754633	vaginal	vaginal	JJ
304953	100736386	20992754634	cream	cream	NN1
304953	100736386	20992754635	may	may	VM
304953	100736386	20992754636	have	have	VHI
304953	100736386	20992754637	contributed	contribute	VVN
304953	100736386	20992754638	to	to	II
304953	100736386	20992754639	a	a	AT1
304953	100736386	20992754640	spike	spike	NN1
304953	100736386	20992754641	in	in	II
304953	100736386	20992754642	her	her	APPGE
304953	100736386	20992754643	husbands	husband	NN2
304953	100736386	20992754644	prostate-specific	prostate-specific	JJ
304953	100736386	20992754645	antigen	antigen	NN1
304953	100736386	20992754646	and	and	CC
304953	100736386	20992754647	testosterone	testosterone	NN1
304953	100736386	20992754648	levels	level	NN2
304953	100736386	20992754649	after	after	CS
304953	100736386	20992754650	he	he	PPHS1
304953	100736386	20992754651	had	have	VHD
304953	100736386	20992754652	his	his	APPGE
304953	100736386	20992754653	prostate	prostate	NN1
304953	100736386	20992754654	removed	remove	VVN
304953	100736386	20992754655	to	to	TO
304953	100736386	20992754656	fight	fight	VVI
304953	100736386	20992754657	advanced	advanced	JJ
304953	100736386	20992754658	prostate	prostate	NN1
304953	100736386	20992754659	cancer	cancer	NN1
304953	100736386	20992754660	.	.	.
304953	100736386	20992754661	<p>		NULL
304953	100736386	20992754662	Men	man	NN2
304953	100736386	20992754663	are	be	VBR
304953	100736386	20992754664	at	at	II
304953	100736386	20992754665	greater	great	JJR
304953	100736386	20992754666	risk	risk	NN1
304953	100736386	20992754667	for	for	IF
304953	100736386	20992754668	developing	developing	JJ_VVG
304953	100736386	20992754669	prostate	prostate	NN1
304953	100736386	20992754670	cancer	cancer	NN1
304953	100736386	20992754671	if	if	CS
304953	100736386	20992754672	their	their	APPGE
304953	100736386	20992754673	fathers	father	NN2
304953	100736386	20992754674	or	or	CC
304953	100736386	20992754675	brothers	brother	NN2
304953	100736386	20992754676	also	also	RR
304953	100736386	20992754677	developed	develop	VVN_VVD
304953	100736386	20992754678	the	the	AT
304953	100736386	20992754679	disease	disease	NN1
304953	100736386	20992754680	.	.	.
304953	100736386	20992754681	A	a	AT1_ZZ1
304953	100736386	20992754682	new	new	JJ
304953	100736386	20992754683	study	study	NN1
304953	100736386	20992754684	shows	show	VVZ
304953	100736386	20992754685	that	that	CST_DD1
304953	100736386	20992754686	having	have	VHG
304953	100736386	20992754687	second-	second--	JJ
304953	100736386	20992754688	or	or	CC
304953	100736386	20992754689	third-degree	third-degree	JJ_NN1
304953	100736386	20992754690	relatives	relative	NN2
304953	100736386	20992754691	with	with	IW
304953	100736386	20992754692	the	the	AT
304953	100736386	20992754693	disease	disease	NN1
304953	100736386	20992754694	also	also	RR
304953	100736386	20992754695	increases	increase	VVZ
304953	100736386	20992754696	a	a	AT1
304953	100736386	20992754697	mans	man	NN2
304953	100736386	20992754698	risk	risk	VV0_NN1
304953	100736386	20992754699	.	.	.
304953	100736386	20992754700	<p>		NULL
304953	100736386	20992754701	A	a	AT1_ZZ1
304953	100736386	20992754702	growing	growing	JJ
304953	100736386	20992754703	number	number	NN1
304953	100736386	20992754704	of	of	IO
304953	100736386	20992754705	aging	aging	JJ_VVG_NN1
304953	100736386	20992754706	men	man	NN2
304953	100736386	20992754707	are	be	VBR
304953	100736386	20992754708	trying	try	VVG
304953	100736386	20992754709	to	to	TO
304953	100736386	20992754710	hold	hold	VVI
304953	100736386	20992754711	on	on	RP_II21
304953	100736386	20992754712	to	to	II_II22
304953	100736386	20992754713	their	their	APPGE
304953	100736386	20992754714	youthful	youthful	JJ
304953	100736386	20992754715	vigor	vigor	NN1
304953	100736386	20992754716	by	by	II
304953	100736386	20992754717	taking	take	VVG
304953	100736386	20992754718	testosterone	testosterone	NN1
304953	100736386	20992754719	.	.	.
304953	100736386	20992754720	Unsettling	unsettle	VVG_JJ@_NP1@
304953	100736386	20992754721	study	study	NN1
304953	100736386	20992754722	results	result	NN2
304953	100736386	20992754723	suggest	suggest	VV0
304953	100736386	20992754724	that	that	CST
304953	100736386	20992754725	men	man	NN2
304953	100736386	20992754726	with	with	IW
304953	100736386	20992754727	low	low	JJ
304953	100736386	20992754728	but	but	CCB
304953	100736386	20992754729	"	"	"
304953	100736386	20992754730	normal	normal	JJ
304953	100736386	20992754731	"	"	"
304953	100736386	20992754732	testosterone	testosterone	NN1
304953	100736386	20992754733	levels	level	NN2
304953	100736386	20992754734	who	who	PNQS
304953	100736386	20992754735	take	take	VV0
304953	100736386	20992754736	a	a	AT1
304953	100736386	20992754737	testosterone	testosterone	NN1
304953	100736386	20992754738	supplement	supplement	NN1
304953	100736386	20992754739	may	may	VM
304953	100736386	20992754740	be	be	VBI
304953	100736386	20992754741	increasing	increase	VVG
304953	100736386	20992754742	their	their	APPGE
304953	100736386	20992754743	risk	risk	NN1
304953	100736386	20992754744	of	of	IO
304953	100736386	20992754745	having	have	VHG
304953	100736386	20992754746	a	a	AT1
304953	100736386	20992754747	heart	heart	NN1
304953	100736386	20992754748	attack	attack	NN1
304953	100736386	20992754749	,	,	,
304953	100736386	20992754750	stroke	stroke	VV0_NN1
304953	100736386	20992754751	,	,	,
304953	100736386	20992754752	or	or	CC
304953	100736386	20992754753	developing	developing	JJ_VVG
304953	100736386	20992754754	heart	heart	NN1
304953	100736386	20992754755	disease	disease	NN1
304953	100736386	20992754756	.	.	.
304953	100736386	20992754757	<p>		NULL
304953	100736386	20992754758	A	a	AT1
304953	100736386	20992754759	study	study	NN1
304953	100736386	20992754760	published	publish	VVN
304953	100736386	20992754761	in	in	II
304953	100736386	20992754762	the	the	AT
304953	100736386	20992754763	journal	journal	NN1
304953	100736386	20992754764	European	european	JJ
304953	100736386	20992754765	Urology	urology	NN1_NP1
304953	100736386	20992754766	suggests	suggest	VVZ
304953	100736386	20992754767	that	that	CST
304953	100736386	20992754768	men	man	NN2
304953	100736386	20992754769	who	who	PNQS
304953	100736386	20992754770	have	have	VH0
304953	100736386	20992754771	defects	defect	NN2
304953	100736386	20992754772	in	in	II
304953	100736386	20992754773	a	a	AT1
304953	100736386	20992754774	cancer-suppressing		JJ_NN1
304953	100736386	20992754775	gene	gene	NN1
304953	100736386	20992754776	known	know	VVN
304953	100736386	20992754777	as	as	II
304953	100736386	20992754778	BRCA	brca	NP1_NN1
304953	100736386	20992754779	are	be	VBR
304953	100736386	20992754780	at	at	II
304953	100736386	20992754781	high	high	JJ
304953	100736386	20992754782	risk	risk	NN1
304953	100736386	20992754783	for	for	IF
304953	100736386	20992754784	aggressive	aggressive	JJ
304953	100736386	20992754785	prostate	prostate	NN1
304953	100736386	20992754786	tumors	tumor	NN2
304953	100736386	20992754787	,	,	,
304953	100736386	20992754788	and	and	CC
304953	100736386	20992754789	so	so	RR
304953	100736386	20992754790	could	could	VM
304953	100736386	20992754791	benefit	benefit	VVI
304953	100736386	20992754792	from	from	II
304953	100736386	20992754793	PSA	psa	NP1
304953	100736386	20992754794	testing	testing	NN1_VVG
304953	100736386	20992754795	.	.	.
304953	100736386	20992754796	<p>		NULL
304953	100736386	20992754797	In	in	II
304953	100736386	20992754798	men	man	NN2
304953	100736386	20992754799	with	with	IW
304953	100736386	20992754800	cancer	cancer	NN1
304953	100736386	20992754801	that	that	CST_DD1
304953	100736386	20992754802	has	have	VHZ
304953	100736386	20992754803	spread	spread	VVN
304953	100736386	20992754804	beyond	beyond	II
304953	100736386	20992754805	the	the	AT
304953	100736386	20992754806	prostate	prostate	NN1
304953	100736386	20992754807	gland	gland	NN1
304953	100736386	20992754808	,	,	,
304953	100736386	20992754809	@		II
304953	100736386	20992754810	@		II
304953	100736386	20992754811	@		II
304953	100736386	20992754812	@		II
304953	100736386	20992754813	@		II
304953	100736386	20992754814	@		II
304953	100736386	20992754815	@		II
304953	100736386	20992754816	@		II
304953	100736386	20992754817	@		II
304953	100736386	20992754818	@		II
304953	100736386	20992754819	survival	survival	NN1
304953	100736386	20992754820	.	.	.
304953	100736386	20992754821	But	but	CCB
304953	100736386	20992754822	some	some	DD
304953	100736386	20992754823	doctors	doctor	NN2
304953	100736386	20992754824	give	give	VV0
304953	100736386	20992754825	hormone	hormone	NN1
304953	100736386	20992754826	therapy	therapy	NN1
304953	100736386	20992754827	by	by	II
304953	100736386	20992754828	itself	itself	PPX1
304953	100736386	20992754829	to	to	II
304953	100736386	20992754830	millions	million	NNO2
304953	100736386	20992754831	of	of	IO
304953	100736386	20992754832	men	man	NN2
304953	100736386	20992754833	with	with	IW
304953	100736386	20992754834	localized	localized	JJ
304953	100736386	20992754835	tumors	tumor	NN2
304953	100736386	20992754836	that	that	CST_DD1
304953	100736386	20992754837	have n't		VV0_NN1
304953	100736386	20992754838	spread	spread	NN1_VVN_VVD_VV0
304953	100736386	20992754839	beyond	beyond	II
304953	100736386	20992754840	the	the	AT
304953	100736386	20992754841	prostate	prostate	NN1
304953	100736386	20992754842	.	.	.
304953	100736386	20992754843	A	a	AT1_ZZ1
304953	100736386	20992754844	new	new	JJ
304953	100736386	20992754845	study	study	NN1
304953	100736386	20992754846	shows	show	VVZ
304953	100736386	20992754847	that	that	CST
304953	100736386	20992754848	this	this	DD1
304953	100736386	20992754849	approach	approach	NN1
304953	100736386	20992754850	does	do	VDZ
304953	100736386	20992754851	n't 	n't	XX
304953	100736386	20992754852	help	help	VVI
304953	100736386	20992754853	,	,	,
304953	100736386	20992754854	and	and	CC
304953	100736386	20992754855	may	may	VM
304953	100736386	20992754856	hurt	hurt	VVI
304953	100736386	20992754857	.	.	.
304953	100736386	20992754858	<p>		NULL
304953	100736386	20992754859	With	with	IW
304953	100736386	20992754860	their	their	APPGE
304953	100736386	20992754861	ability	ability	NN1
304953	100736386	20992754862	to	to	TO
304953	100736386	20992754863	smell	smell	VVI
304953	100736386	20992754864	tiny	tiny	JJ
304953	100736386	20992754865	amounts	amount	NN2
304953	100736386	20992754866	of	of	IO
304953	100736386	20992754867	chemicals	chemical	NN2
304953	100736386	20992754868	,	,	,
304953	100736386	20992754869	trained	trained	JJ@_VVN_VVD@
304953	100736386	20992754870	dogs	dog	NN2
304953	100736386	20992754871	can	can	VM
304953	100736386	20992754872	easily	easily	RR
304953	100736386	20992754873	find	find	VVI
304953	100736386	20992754874	explosives	explosives	NN2
304953	100736386	20992754875	or	or	CC
304953	100736386	20992754876	illegal	illegal	JJ
304953	100736386	20992754877	drugs	drug	NN2
304953	100736386	20992754878	hidden	hide	VVN
304953	100736386	20992754879	in	in	II
304953	100736386	20992754880	a	a	AT1
304953	100736386	20992754881	suitcase	suitcase	NN1
304953	100736386	20992754882	.	.	.
304953	100736386	20992754883	But	but	CCB
304953	100736386	20992754884	mounting	mount	VVG_JJ@
304953	100736386	20992754885	evidence	evidence	NN1
304953	100736386	20992754886	points	point	VVZ_NN2
304953	100736386	20992754887	to	to	II
304953	100736386	20992754888	another	another	DD1
304953	100736386	20992754889	helpful	helpful	JJ
304953	100736386	20992754890	job	job	NN1
304953	100736386	20992754891	for	for	IF
304953	100736386	20992754892	mans	man	NN2
304953	100736386	20992754893	best	best	VV0%_JJT
304953	100736386	20992754894	friend	friend	NN1
304953	100736386	20992754895	:	:	:
304953	100736386	20992754896	finding	find	VVG_JJ@_NN1
304953	100736386	20992754897	prostate	prostate	NN1
304953	100736386	20992754898	cancer	cancer	NN1
304953	100736386	20992754899	before	before	CS
304953	100736386	20992754900	it	it	PPH1
304953	100736386	20992754901	causes	cause	VVZ
304953	100736386	20992754902	any	any	DD
304953	100736386	20992754903	symptoms	symptom	NN2
304953	100736386	20992754904	.	.	.
304953	100736387	20992754924	@@##	----------	----------
304953	100736387	20992754925	@@100736387		FO
304953	100736387	20992754926	@4936387/		VV0_NN1
304953	100736387	20992754927	46989		MC
304953	100736387	20992754928	@qwx906989		FO
304953	100736387	20992754929	<p>		NULL
304953	100736387	20992754930	Transrectal	transrectal	JJ
304953	100736387	20992754931	ultrasonography	ultrasonography	NN1
304953	100736387	20992754932	(	(	(
304953	100736387	20992754933	TRUS		NP1
304953	100736387	20992754934	)	)	)
304953	100736387	20992754935	is	be	VBZ
304953	100736387	20992754936	a	a	AT1
304953	100736387	20992754937	way	way	NN1
304953	100736387	20992754938	of	of	IO
304953	100736387	20992754939	creating	create	VVG
304953	100736387	20992754940	an	a	AT1
304953	100736387	20992754941	image	image	NN1
304953	100736387	20992754942	of	of	IO
304953	100736387	20992754943	the	the	AT
304953	100736387	20992754944	prostate	prostate	NN1
304953	100736387	20992754945	gland	gland	NN1
304953	100736387	20992754946	using	use	VVG
304953	100736387	20992754947	sound	sound	NN1_JJ@
304953	100736387	20992754948	waves	wave	NN2
304953	100736387	20992754949	.	.	.
304953	100736387	20992754950	In	in	II
304953	100736387	20992754951	conventional	conventional	JJ
304953	100736387	20992754952	ultrasound	ultrasound	NN1
304953	100736387	20992754953	procedures	procedure	NN2
304953	100736387	20992754954	,	,	,
304953	100736387	20992754955	a	a	AT1
304953	100736387	20992754956	probe	probe	NN1
304953	100736387	20992754957	placed	place	VVN
304953	100736387	20992754958	against	against	II
304953	100736387	20992754959	the	the	AT
304953	100736387	20992754960	skin	skin	NN1
304953	100736387	20992754961	sends	send	VVZ
304953	100736387	20992754962	painless	painless	JJ
304953	100736387	20992754963	,	,	,
304953	100736387	20992754964	ultra-high-frequency		JJ_VV0
304953	100736387	20992754965	sound	sound	NN1_JJ@
304953	100736387	20992754966	waves	wave	NN2_VVZ@
304953	100736387	20992754967	into	into	II
304953	100736387	20992754968	the	the	AT
304953	100736387	20992754969	body	body	NN1
304953	100736387	20992754970	.	.	.
304953	100736387	20992754971	As	as	II_CSA
304953	100736387	20992754972	the	the	AT
304953	100736387	20992754973	waves	wave	NN2
304953	100736387	20992754974	strike	strike	VV0
304953	100736387	20992754975	internal	internal	JJ
304953	100736387	20992754976	organs	organ	NN2
304953	100736387	20992754977	,	,	,
304953	100736387	20992754978	they	they	PPHS2
304953	100736387	20992754979	produce	produce	VV0
304953	100736387	20992754980	echo	echo	NN1_VV0
304953	100736387	20992754981	patterns	pattern	NN2
304953	100736387	20992754982	that	that	CST
304953	100736387	20992754983	a	a	AT1
304953	100736387	20992754984	computer	computer	NN1
304953	100736387	20992754985	converts	convert	VVZ_NN2
304953	100736387	20992754986	into	into	II
304953	100736387	20992754987	images	image	NN2
304953	100736387	20992754988	(	(	(
304953	100736387	20992754989	sonograms	sonograms	VVZ_NN2
304953	100736387	20992754990	)	)	)
304953	100736387	20992754991	on	on	II
304953	100736387	20992754992	a	a	AT1
304953	100736387	20992754993	video	video	NN1
304953	100736387	20992754994	screen	screen	NN1
304953	100736387	20992754995	.	.	.
304953	100736387	20992754996	<p>		NULL
304953	100736387	20992754997	Ultrasound	ultrasound	VV0_NN1
304953	100736387	20992754998	tests	test	NN2
304953	100736387	20992754999	are	be	VBR
304953	100736387	20992755000	much	much	RR
304953	100736387	20992755001	more	more	RGR
304953	100736387	20992755002	sophisticated	sophisticated	JJ
304953	100736387	20992755003	than	than	CSN
304953	100736387	20992755004	they	they	PPHS2
304953	100736387	20992755005	used	use	VMK
304953	100736387	20992755006	to	to	TO
304953	100736387	20992755007	be	be	VBI
304953	100736387	20992755008	.	.	.
304953	100736387	20992755009	For	for	REX21
304953	100736387	20992755010	example	example	REX22
304953	100736387	20992755011	,	,	,
304953	100736387	20992755012	in	in	II
304953	100736387	20992755013	TRUS		NP1_NN1
304953	100736387	20992755014	,	,	,
304953	100736387	20992755015	the	the	AT
304953	100736387	20992755016	doctor	doctor	NN1
304953	100736387	20992755017	places	place	VVZ@_NN2
304953	100736387	20992755018	a	a	AT1
304953	100736387	20992755019	probe	probe	NN1
304953	100736387	20992755020	,	,	,
304953	100736387	20992755021	called	call	VVN_VVD@
304953	100736387	20992755022	the	the	AT
304953	100736387	20992755023	ultrasound	ultrasound	NN1
304953	100736387	20992755024	transducer	transducer	NN1
304953	100736387	20992755025	,	,	,
304953	100736387	20992755026	into	into	II
304953	100736387	20992755027	the	the	AT
304953	100736387	20992755028	rectum	rectum	NN1
304953	100736387	20992755029	.	.	.
304953	100736387	20992755030	Painless	painless	JJ
304953	100736387	20992755031	sound	sound	NN1_JJ@
304953	100736387	20992755032	waves	wave	NN2
304953	100736387	20992755033	scan	scan	VV0
304953	100736387	20992755034	the	the	AT
304953	100736387	20992755035	prostate	prostate	NN1
304953	100736387	20992755036	gland	gland	NN1
304953	100736387	20992755037	in	in	II
304953	100736387	20992755038	two	two	MC
304953	100736387	20992755039	planes	plane	NN2
304953	100736387	20992755040	.	.	.
304953	100736387	20992755041	The	the	AT
304953	100736387	20992755042	resulting	resulting	JJ
304953	100736387	20992755043	pictures	picture	NN2
304953	100736387	20992755044	(	(	(
304953	100736387	20992755045	see	see	VV0
304953	100736387	20992755046	Figure	figure	NN1
304953	100736387	20992755047	1	1	MC1
304953	100736387	20992755048	below	below	RL
304953	100736387	20992755049	)	)	)
304953	100736387	20992755050	often	often	RR
304953	100736387	20992755051	serve	serve	VV0
304953	100736387	20992755052	as	as	II_CSA
304953	100736387	20992755053	a	a	AT1
304953	100736387	20992755054	guide	guide	NN1
304953	100736387	20992755055	for	for	IF
304953	100736387	20992755056	a	a	AT1
304953	100736387	20992755057	biopsy	biopsy	NN1
304953	100736387	20992755058	of	of	IO
304953	100736387	20992755059	the	the	AT
304953	100736387	20992755060	prostate	prostate	NN1
304953	100736387	20992755061	,	,	,
304953	100736387	20992755062	helping	help	VVG
304953	100736387	20992755063	to	to	TO
304953	100736387	20992755064	pinpoint	pinpoint	VVI
304953	100736387	20992755065	suspicious	suspicious	JJ
304953	100736387	20992755066	areas	area	NN2
304953	100736387	20992755067	.	.	.
304953	100736387	20992755068	<p>		NULL
304953	100736387	20992755069	Doctors	doctor	NN2
304953	100736387	20992755070	may	may	VM
304953	100736387	20992755071	recommend	recommend	VVI
304953	100736387	20992755072	TRUS		NN1_NP1
304953	100736387	20992755073	when	when	CS_RRQ
304953	100736387	20992755074	they	they	PPHS2
304953	100736387	20992755075	suspect	suspect	VV0
304953	100736387	20992755076	prostate	prostate	NN1
304953	100736387	20992755077	cancer	cancer	NN1
304953	100736387	20992755078	based	base	VVN
304953	100736387	20992755079	on	on	II
304953	100736387	20992755080	an	a	AT1
304953	100736387	20992755081	abnormal	abnormal	JJ
304953	100736387	20992755082	DRE	dre	NN1
304953	100736387	20992755083	or	or	CC
304953	100736387	20992755084	an	a	AT1
304953	100736387	20992755085	elevated	elevated	JJ
304953	100736387	20992755086	PSA	psa	NP1
304953	100736387	20992755087	.	.	.
304953	100736387	20992755088	However	however	RR
304953	100736387	20992755089	,	,	,
304953	100736387	20992755090	TRUS		NP1_NN1
304953	100736387	20992755091	is	be	VBZ
304953	100736387	20992755092	costly	costly	JJ
304953	100736387	20992755093	,	,	,
304953	100736387	20992755094	and	and	CC
304953	100736387	20992755095	it	it	PPH1
304953	100736387	20992755096	rarely	rarely	RR
304953	100736387	20992755097	detects	detect	VVZ
304953	100736387	20992755098	prostate	prostate	NN1
304953	100736387	20992755099	cancers	cancer	NN2
304953	100736387	20992755100	that	that	CST
304953	100736387	20992755101	a	a	AT1
304953	100736387	20992755102	DRE	dre	NN1
304953	100736387	20992755103	or	or	CC
304953	100736387	20992755104	PSA	psa	NP1
304953	100736387	20992755105	can	can	VM
304953	100736387	20992755106	not	not	XX
304953	100736387	20992755107	find	find	VVI
304953	100736387	20992755108	.	.	.
304953	100736387	20992755109	As	as	II
304953	100736387	20992755110	a	a	AT1
304953	100736387	20992755111	result	result	NN1
304953	100736387	20992755112	,	,	,
304953	100736387	20992755113	although	although	CS
304953	100736387	20992755114	TRUS		NP1_NN1
304953	100736387	20992755115	is	be	VBZ
304953	100736387	20992755116	@		II
304953	100736387	20992755117	@		II
304953	100736387	20992755118	@		II
304953	100736387	20992755119	@		II
304953	100736387	20992755120	@		II
304953	100736387	20992755121	@		II
304953	100736387	20992755122	@		II
304953	100736387	20992755123	@		II
304953	100736387	20992755124	@		II
304953	100736387	20992755125	@		II
304953	100736387	20992755126	recommended	recommend	VVN
304953	100736387	20992755127	for	for	IF
304953	100736387	20992755128	routine	routine	NN1_JJ@
304953	100736387	20992755129	screening	screening	NN1_VVG
304953	100736387	20992755130	.	.	.
304953	100736387	20992755131	<h>		NULL
304953	100736387	20992755132	Figure	figure	VV0@_NN1
304953	100736387	20992755133	1	1	MC1
304953	100736387	20992755134	:	:	:
304953	100736387	20992755135	Transrectal		JJ_NP1
304953	100736387	20992755136	ultrasonography	ultrasonography	NN1
304953	100736387	20992755137	<p>		NULL
304953	100736387	20992755138	In	in	II
304953	100736387	20992755139	this	this	DD1
304953	100736387	20992755140	procedure	procedure	NN1
304953	100736387	20992755141	,	,	,
304953	100736387	20992755142	the	the	AT
304953	100736387	20992755143	patient	patient	JJ_NN1
304953	100736387	20992755144	lies	lie	NN2_VVZ
304953	100736387	20992755145	on	on	II
304953	100736387	20992755146	his	his	APPGE
304953	100736387	20992755147	side	side	NN1
304953	100736387	20992755148	and	and	CC
304953	100736387	20992755149	a	a	AT1
304953	100736387	20992755150	small	small	JJ
304953	100736387	20992755151	probe	probe	NN1
304953	100736387	20992755152	(	(	(
304953	100736387	20992755153	the	the	AT
304953	100736387	20992755154	ultrasound	ultrasound	NN1
304953	100736387	20992755155	transducer	transducer	NN1
304953	100736387	20992755156	)	)	)
304953	100736387	20992755157	is	be	VBZ
304953	100736387	20992755158	placed	place	VVN
304953	100736387	20992755159	in	in	II
304953	100736387	20992755160	the	the	AT
304953	100736387	20992755161	rectum	rectum	NN1
304953	100736387	20992755162	.	.	.
304953	100736387	20992755163	Sound	sound	NN1_JJ@_VV0@
304953	100736387	20992755164	waves	wave	NN2
304953	100736387	20992755165	are	be	VBR
304953	100736387	20992755166	beamed	beam	VVN
304953	100736387	20992755167	at	at	II
304953	100736387	20992755168	the	the	AT
304953	100736387	20992755169	prostate	prostate	NN1
304953	100736387	20992755170	,	,	,
304953	100736387	20992755171	and	and	CC
304953	100736387	20992755172	the	the	AT
304953	100736387	20992755173	waves	wave	NN2
304953	100736387	20992755174	that	that	CST
304953	100736387	20992755175	are	be	VBR
304953	100736387	20992755176	reflected	reflect	VVN
304953	100736387	20992755177	back	back	RP_NN1
304953	100736387	20992755178	are	be	VBR
304953	100736387	20992755179	transformed	transform	VVN
304953	100736387	20992755180	by	by	II
304953	100736387	20992755181	a	a	AT1
304953	100736387	20992755182	computer	computer	NN1
304953	100736387	20992755183	into	into	II
304953	100736387	20992755184	images	image	NN2
304953	100736387	20992755185	on	on	II
304953	100736387	20992755186	a	a	AT1
304953	100736387	20992755187	video	video	NN1
304953	100736387	20992755188	screen	screen	NN1
304953	100736387	20992755189	.	.	.
304953	100736387	20992755190	In	in	II
304953	100736387	20992755191	the	the	AT
304953	100736387	20992755192	sonograph		NN1
304953	100736387	20992755193	above	above	RL
304953	100736387	20992755194	,	,	,
304953	100736387	20992755195	the	the	AT
304953	100736387	20992755196	irregular	irregular	JJ
304953	100736387	20992755197	dark	dark	JJ_NN1
304953	100736387	20992755198	area	area	NN1
304953	100736387	20992755199	within	within	II
304953	100736387	20992755200	the	the	AT
304953	100736387	20992755201	prostate	prostate	NN1
304953	100736387	20992755202	is	be	VBZ
304953	100736387	20992755203	a	a	AT1
304953	100736387	20992755204	cancer	cancer	NN1
304953	100736387	20992755205	.	.	.
304953	100736387	20992755206	<p>		NULL
304953	100736387	20992755207	Hello	hello	UH
304953	100736387	20992755208	there	there	RL
304953	100736387	20992755209	,	,	,
304953	100736387	20992755210	1	1	MC1
304953	100736387	20992755211	:	:	:
304953	100736387	20992755212	I	i	PPIS1
304953	100736387	20992755213	have	have	VH0
304953	100736387	20992755214	a	a	AT1
304953	100736387	20992755215	problem	problem	NN1
304953	100736387	20992755216	with	with	IW
304953	100736387	20992755217	my	my	APPGE
304953	100736387	20992755218	prostate	prostate	NN1
304953	100736387	20992755219	..	...	...
304953	100736387	20992755220	The	the	AT
304953	100736387	20992755221	problem	problem	NN1
304953	100736387	20992755222	is	be	VBZ
304953	100736387	20992755223	I	i	MC1%
304953	100736387	20992755224	ca n't		NN1
304953	100736387	20992755225	able	able	JK
304953	100736387	20992755226	to	to	TO
304953	100736387	20992755227	sex	sex	NN1_VV0%
304953	100736387	20992755228	normally	normally	RR
304953	100736387	20992755229	,	,	,
304953	100736387	20992755230	my	my	APPGE
304953	100736387	20992755231	cock	cock	NN1
304953	100736387	20992755232	does	do	VDZ
304953	100736387	20992755233	n't 	n't	XX
304953	100736387	20992755234	work	work	VVI
304953	100736387	20992755235	properly	properly	RR
304953	100736387	20992755236	when	when	CS_RRQ
304953	100736387	20992755237	I	i	PPIS1
304953	100736387	20992755238	try	try	VV0
304953	100736387	20992755239	to	to	TO
304953	100736387	20992755240	sex	sex	NN1
304953	100736387	20992755241	2	2	MC
304953	100736387	20992755242	:	:	:
304953	100736387	20992755243	there	there	EX
304953	100736387	20992755244	is	be	VBZ
304953	100736387	20992755245	usually	usually	RR
304953	100736387	20992755246	something	something	PN1
304953	100736387	20992755247	make	make	VV0
304953	100736387	20992755248	my	my	APPGE
304953	100736387	20992755249	cock	cock	NN1
304953	100736387	20992755250	close	close	VVI
304953	100736387	20992755251	doing	do	VDG
304953	100736387	20992755252	piss	piss	NN1
304953	100736387	20992755253	,	,	,
304953	100736387	20992755254	I	i	PPIS1
304953	100736387	20992755255	feel	feel	VV0
304953	100736387	20992755256	like	like	II_JJ@
304953	100736387	20992755257	pain	pain	NN1
304953	100736387	20992755258	doing	do	VDG
304953	100736387	20992755259	piss	piss	NN1
304953	100736387	20992755260	..	...	...
304953	100736387	20992755261	3	3	MC
304953	100736387	20992755262	:	:	:
304953	100736387	20992755263	always	always	RR
304953	100736387	20992755264	fell	fall	VVD_JJ@
304953	100736387	20992755265	backache	backache	NN1
304953	100736387	20992755266	46996		MC
304953	100736387	20992755267	@qwx906996		FO
304953	100736389	20992755287	@@##	----------	----------
304953	100736389	20992755288	@@100736389		FO
304953	100736389	20992755289	@4936389/		VV0_NN1
304953	100736389	20992755290	46989		MC
304953	100736389	20992755291	@qwx906989		FO
304953	100736389	20992755292	<h>		NULL
304953	100736389	20992755293	Nutrition	nutrition	NN1
304953	100736389	20992755294	and	and	CC
304953	100736389	20992755295	vitamins	vitamin	NN2
304953	100736389	20992755296	<p>		NULL
304953	100736389	20992755297	Can	can	VV0%
304953	100736389	20992755298	a	a	AT1
304953	100736389	20992755299	healthy	healthy	JJ
304953	100736389	20992755300	diet	diet	NN1
304953	100736389	20992755301	help	help	NN1_VV0
304953	100736389	20992755302	men	man	NN2
304953	100736389	20992755303	with	with	IW
304953	100736389	20992755304	low-risk	low-risk	JJ
304953	100736389	20992755305	prostate	prostate	NN1
304953	100736389	20992755306	cancer	cancer	NN1
304953	100736389	20992755307	live	live	VV0_RR@
304953	100736389	20992755308	longer	long	JJR_RRR
304953	100736389	20992755309	?	?	?
304953	100736389	20992755310	The	the	AT
304953	100736389	20992755311	authors	author	NN2
304953	100736389	20992755312	of	of	IO
304953	100736389	20992755313	a	a	AT1
304953	100736389	20992755314	new	new	JJ
304953	100736389	20992755315	study	study	NN1
304953	100736389	20992755316	say	say	VV0
304953	100736389	20992755317	"	"	"
304953	100736389	20992755318	yes	yes	UH
304953	100736389	20992755319	.	.	.
304953	100736389	20992755320	"	"	"
304953	100736389	20992755321	A	a	AT1_ZZ1
304953	100736389	20992755322	long-running	long-running	JJ
304953	100736389	20992755323	Physicians	physician	NN2
304953	100736389	20992755324	Health	health	NN1
304953	100736389	20992755325	Study	study	NN1
304953	100736389	20992755326	,	,	,
304953	100736389	20992755327	suggests	suggest	VVZ
304953	100736389	20992755328	that	that	CST
304953	100736389	20992755329	a	a	AT1
304953	100736389	20992755330	diet	diet	NN1
304953	100736389	20992755331	that	that	CST_DD1
304953	100736389	20992755332	is	be	VBZ
304953	100736389	20992755333	good	good	JJ
304953	100736389	20992755334	for	for	IF
304953	100736389	20992755335	the	the	AT
304953	100736389	20992755336	heart	heart	NN1
304953	100736389	20992755337	,	,	,
304953	100736389	20992755338	brain	brain	NN1
304953	100736389	20992755339	,	,	,
304953	100736389	20992755340	and	and	CC
304953	100736389	20992755341	other	other	JJ
304953	100736389	20992755342	parts	part	NN2
304953	100736389	20992755343	of	of	IO
304953	100736389	20992755344	the	the	AT
304953	100736389	20992755345	body	body	NN1
304953	100736389	20992755346	may	may	VM
304953	100736389	20992755347	also	also	RR
304953	100736389	20992755348	help	help	VVI
304953	100736389	20992755349	keep	keep	VVI
304953	100736389	20992755350	low-risk	low-risk	JJ_NN1
304953	100736389	20992755351	prostate	prostate	NN1
304953	100736389	20992755352	cancer	cancer	NN1
304953	100736389	20992755353	at	at	II
304953	100736389	20992755354	bay	bay	NN1
304953	100736389	20992755355	.	.	.
304953	100736389	20992755356	On	on	II
304953	100736389	20992755357	the	the	AT
304953	100736389	20992755358	flip	flip	NN1
304953	100736389	20992755359	side	side	NN1
304953	100736389	20992755360	,	,	,
304953	100736389	20992755361	a	a	AT1
304953	100736389	20992755362	diet	diet	NN1
304953	100736389	20992755363	rich	rich	JJ
304953	100736389	20992755364	in	in	II
304953	100736389	20992755365	red	red	JJ
304953	100736389	20992755366	meat	meat	NN1
304953	100736389	20992755367	and	and	CC
304953	100736389	20992755368	high-fat	high-fat	JJ_NN1
304953	100736389	20992755369	dairy	dairy	NN1
304953	100736389	20992755370	foods	food	NN2
304953	100736389	20992755371	appears	appear	VVZ
304953	100736389	20992755372	to	to	TO
304953	100736389	20992755373	be	be	VBI
304953	100736389	20992755374	hazardous	hazardous	JJ
304953	100736389	20992755375	for	for	IF
304953	100736389	20992755376	men	man	NN2
304953	100736389	20992755377	with	with	IW
304953	100736389	20992755378	this	this	DD1
304953	100736389	20992755379	kind	kind	NN1
304953	100736389	20992755380	of	of	IO
304953	100736389	20992755381	cancer	cancer	NN1
304953	100736389	20992755382	.	.	.
304953	100736389	20992755383	It	it	PPH1
304953	100736389	20992755384	is n't		VV0_NN1
304953	100736389	20992755385	clear	clear	RR@_VV0@_JJ
304953	100736389	20992755386	why	why	RRQ
304953	100736389	20992755387	a	a	AT1
304953	100736389	20992755388	diet	diet	NN1
304953	100736389	20992755389	that	that	CST_DD1
304953	100736389	20992755390	protects	protect	VVZ
304953	100736389	20992755391	against	against	II
304953	100736389	20992755392	heart	heart	NN1
304953	100736389	20992755393	disease	disease	NN1
304953	100736389	20992755394	would	would	VM
304953	100736389	20992755395	also	also	RR
304953	100736389	20992755396	protect	protect	VVI
304953	100736389	20992755397	against	against	II
304953	100736389	20992755398	death	death	NN1
304953	100736389	20992755399	from	from	II
304953	100736389	20992755400	prostate	prostate	NN1
304953	100736389	20992755401	cancer	cancer	NN1
304953	100736389	20992755402	.	.	.
304953	100736389	20992755403	Dr.		NNB
304953	100736389	20992755404	Chavarro		NP1
304953	100736389	20992755405	speculates	speculate	VVZ
304953	100736389	20992755406	that	that	CST
304953	100736389	20992755407	its	its	APPGE
304953	100736389	20992755408	because	because	CS
304953	100736389	20992755409	high-fat	high-fat	JJ
304953	100736389	20992755410	foods	food	NN2
304953	100736389	20992755411	are	be	VBR
304953	100736389	20992755412	easily	easily	RR
304953	100736389	20992755413	broken	break	VVN
304953	100736389	20992755414	down	down	RP
304953	100736389	20992755415	and	and	CC
304953	100736389	20992755416	absorbed	absorb	VVN
304953	100736389	20992755417	by	by	II
304953	100736389	20992755418	the	the	AT
304953	100736389	20992755419	digestive	digestive	JJ
304953	100736389	20992755420	system	system	NN1
304953	100736389	20992755421	,	,	,
304953	100736389	20992755422	and	and	CC
304953	100736389	20992755423	so	so	CS@_RR
304953	100736389	20992755424	they	they	PPHS2
304953	100736389	20992755425	might	might	VM
304953	100736389	20992755426	provide	provide	VVI
304953	100736389	20992755427	quick	quick	JJ
304953	100736389	20992755428	energy	energy	NN1
304953	100736389	20992755429	sources	source	NN2
304953	100736389	20992755430	for	for	IF
304953	100736389	20992755431	growing	growing	JJ_VVG
304953	100736389	20992755432	tumors	tumor	NN2
304953	100736389	20992755433	.	.	.
304953	100736389	20992755434	Nevertheless	nevertheless	RR
304953	100736389	20992755435	,	,	,
304953	100736389	20992755436	the	the	AT
304953	100736389	20992755437	results	result	NN2
304953	100736389	20992755438	suggest	suggest	VV0
304953	100736389	20992755439	that	that	CST_DD1
304953	100736389	20992755440	by	by	II
304953	100736389	20992755441	eating	eat	VVG
304953	100736389	20992755442	healthily	healthily	RR
304953	100736389	20992755443	,	,	,
304953	100736389	20992755444	men	man	NN2
304953	100736389	20992755445	with	with	IW
304953	100736389	20992755446	prostate	prostate	NN1
304953	100736389	20992755447	cancer	cancer	NN1
304953	100736389	20992755448	can	can	VM
304953	100736389	20992755449	take	take	VVI
304953	100736389	20992755450	a	a	AT1
304953	100736389	20992755451	proactive	proactive	JJ
304953	100736389	20992755452	step	step	NN1
304953	100736389	20992755453	towards	towards	II
304953	100736389	20992755454	living	live	VVG
304953	100736389	20992755455	a	a	AT1
304953	100736389	20992755456	long	long	JJ
304953	100736389	20992755457	life	life	NN1
304953	100736389	20992755458	.	.	.
304953	100736389	20992755459	<p>		NULL
304953	100736389	20992755460	New	new	JJ
304953	100736389	20992755461	results	result	NN2
304953	100736389	20992755462	from	from	II
304953	100736389	20992755463	a	a	AT1
304953	100736389	20992755464	major	major	JJ
304953	100736389	20992755465	clinical	clinical	JJ
304953	100736389	20992755466	trial	trial	NN1
304953	100736389	20992755467	called	call	VVN_VVD@
304953	100736389	20992755468	SELECT	select	JJ
304953	100736389	20992755469	show	show	NN1_VV0
304953	100736389	20992755470	that	that	CST_DD1
304953	100736389	20992755471	taking	take	VVG_JJ%
304953	100736389	20992755472	selenium	selenium	NN1
304953	100736389	20992755473	or	or	CC
304953	100736389	20992755474	vitamin	vitamin	NN1
304953	100736389	20992755475	E	e	ZZ1
304953	100736389	20992755476	can	can	VM
304953	100736389	20992755477	increase	increase	VVI
304953	100736389	20992755478	the	the	AT
304953	100736389	20992755479	@		II
304953	100736389	20992755480	@		II
304953	100736389	20992755481	@		II
304953	100736389	20992755482	@		II
304953	100736389	20992755483	@		II
304953	100736389	20992755484	@		II
304953	100736389	20992755485	@		II
304953	100736389	20992755486	@		II
304953	100736389	20992755487	@		II
304953	100736389	20992755488	@		II
304953	100736389	20992755489	should n't		VV0
304953	100736389	20992755490	take	take	VV0
304953	100736389	20992755491	selenium	selenium	NN1
304953	100736389	20992755492	or	or	CC
304953	100736389	20992755493	vitamin	vitamin	NN1
304953	100736389	20992755494	E	e	ZZ1
304953	100736389	20992755495	as	as	II_CSA
304953	100736389	20992755496	a	a	AT1
304953	100736389	20992755497	way	way	NN1
304953	100736389	20992755498	to	to	TO
304953	100736389	20992755499	prevent	prevent	VVI
304953	100736389	20992755500	prostate	prostate	NN1
304953	100736389	20992755501	cancer	cancer	NN1
304953	100736389	20992755502	,	,	,
304953	100736389	20992755503	or	or	CC
304953	100736389	20992755504	anything	anything	PN1
304953	100736389	20992755505	else	else	RR
304953	100736389	20992755506	for	for	IF
304953	100736389	20992755507	that	that	DD1
304953	100736389	20992755508	matter	matter	NN1
304953	100736389	20992755509	.	.	.
304953	100736389	20992755510	<p>		NULL
304953	100736389	20992755511	The	the	AT
304953	100736389	20992755512	omega-3	omega-3	MC
304953	100736389	20992755513	fats	fat	NN2
304953	100736389	20992755514	in	in	II
304953	100736389	20992755515	fish	fish	NN
304953	100736389	20992755516	have	have	VH0
304953	100736389	20992755517	been	be	VBN
304953	100736389	20992755518	linked	link	VVN
304953	100736389	20992755519	to	to	II
304953	100736389	20992755520	all	all	DB
304953	100736389	20992755521	sorts	sort	NN2
304953	100736389	20992755522	of	of	IO
304953	100736389	20992755523	health	health	NN1
304953	100736389	20992755524	benefits	benefit	NN2
304953	100736389	20992755525	,	,	,
304953	100736389	20992755526	including	including	II_VVG@
304953	100736389	20992755527	protection	protection	NN1
304953	100736389	20992755528	against	against	II
304953	100736389	20992755529	prostate	prostate	NN1
304953	100736389	20992755530	cancer	cancer	NN1
304953	100736389	20992755531	.	.	.
304953	100736389	20992755532	But	but	II21_CCB
304953	100736389	20992755533	for	for	II22_IF
304953	100736389	20992755534	the	the	AT
304953	100736389	20992755535	second	second	MD
304953	100736389	20992755536	time	time	NNT1
304953	100736389	20992755537	in	in	II
304953	100736389	20992755538	two	two	MC
304953	100736389	20992755539	years	year	NNT2
304953	100736389	20992755540	,	,	,
304953	100736389	20992755541	researchers	researcher	NN2
304953	100736389	20992755542	have	have	VH0
304953	100736389	20992755543	found	find	VVN
304953	100736389	20992755544	a	a	AT1
304953	100736389	20992755545	link	link	NN1
304953	100736389	20992755546	between	between	II
304953	100736389	20992755547	high	high	JJ
304953	100736389	20992755548	levels	level	NN2
304953	100736389	20992755549	of	of	IO
304953	100736389	20992755550	omega-3	omega-3	MC
304953	100736389	20992755551	fats	fat	NN2
304953	100736389	20992755552	in	in	II
304953	100736389	20992755553	the	the	AT
304953	100736389	20992755554	blood	blood	NN1
304953	100736389	20992755555	and	and	CC
304953	100736389	20992755556	prostate	prostate	NN1
304953	100736389	20992755557	cancer	cancer	NN1
304953	100736389	20992755558	.	.	.
304953	100736389	20992755559	Researchers	researcher	NN2
304953	100736389	20992755560	at	at	II
304953	100736389	20992755561	the	the	AT
304953	100736389	20992755562	Fred	fred	NP1
304953	100736389	20992755563	Hutchinson	hutchinson	NP1
304953	100736389	20992755564	Cancer	cancer	NN1
304953	100736389	20992755565	Center	center	NN1
304953	100736389	20992755566	in	in	II
304953	100736389	20992755567	Seattle	seattle	NP1
304953	100736389	20992755568	men	man	NN2
304953	100736389	20992755569	with	with	IW
304953	100736389	20992755570	high	high	JJ
304953	100736389	20992755571	levels	level	NN2
304953	100736389	20992755572	of	of	IO
304953	100736389	20992755573	omega-3	omega-3	MC
304953	100736389	20992755574	fats	fat	NN2
304953	100736389	20992755575	were	be	VBDR
304953	100736389	20992755576	43%		NNU
304953	100736389	20992755577	more	more	DAR_RRR
304953	100736389	20992755578	likely	likely	JJ
304953	100736389	20992755579	to	to	TO
304953	100736389	20992755580	have	have	VHI
304953	100736389	20992755581	been	be	VBN
304953	100736389	20992755582	diagnosed	diagnose	VVN
304953	100736389	20992755583	with	with	IW
304953	100736389	20992755584	prostate	prostate	NN1
304953	100736389	20992755585	cancer	cancer	NN1
304953	100736389	20992755586	than	than	CSN
304953	100736389	20992755587	men	man	NN2
304953	100736389	20992755588	with	with	IW
304953	100736389	20992755589	low	low	JJ
304953	100736389	20992755590	levels	level	NN2
304953	100736389	20992755591	.	.	.
304953	100736389	20992755592	The	the	AT
304953	100736389	20992755593	finding	finding	NN1
304953	100736389	20992755594	were	be	VBDR
304953	100736389	20992755595	published	publish	VVN
304953	100736389	20992755596	online	online	RR_JJ
304953	100736389	20992755597	in	in	II
304953	100736389	20992755598	the	the	AT
304953	100736389	20992755599	Journal	journal	NN1
304953	100736389	20992755600	of	of	IO
304953	100736389	20992755601	the	the	AT
304953	100736389	20992755602	National	national	JJ
304953	100736389	20992755603	Cancer	cancer	NN1
304953	100736389	20992755604	Institute	institute	NN1
304953	100736389	20992755605	.	.	.
304953	100736389	20992755606	<p>		NULL
304953	100736389	20992755607	Nutritionist	nutritionist	NP1@
304953	100736389	20992755608	Sheila	sheila	NP1
304953	100736389	20992755609	Wolfson	wolfson	NP1
304953	100736389	20992755610	spoke	speak	VVD
304953	100736389	20992755611	about	about	II
304953	100736389	20992755612	healthful	healthful	JJ
304953	100736389	20992755613	eating	eating	NN1
304953	100736389	20992755614	for	for	IF
304953	100736389	20992755615	men	man	NN2
304953	100736389	20992755616	who	who	PNQS
304953	100736389	20992755617	have	have	VH0
304953	100736389	20992755618	been	be	VBN
304953	100736389	20992755619	diagnosed	diagnose	VVN
304953	100736389	20992755620	with	with	IW
304953	100736389	20992755621	prostate	prostate	NN1
304953	100736389	20992755622	cancer	cancer	NN1
304953	100736389	20992755623	at	at	II
304953	100736389	20992755624	the	the	AT
304953	100736389	20992755625	Massachusetts	massachusetts	NP1
304953	100736389	20992755626	Prostate	prostate	NN1
304953	100736389	20992755627	Cancer	cancer	NN1
304953	100736389	20992755628	Coalitions	coalition	NN2
304953	100736389	20992755629	14th	14th	MD
304953	100736389	20992755630	annual	annual	JJ
304953	100736389	20992755631	symposium	symposium	NN1
304953	100736389	20992755632	in	in	II
304953	100736389	20992755633	May	may	NPM1
304953	100736389	20992755634	2011	2011	MC
304953	100736389	20992755635	.	.	.
304953	100736389	20992755636	A	a	AT1_ZZ1
304953	100736389	20992755637	good	good	JJ
304953	100736389	20992755638	diet	diet	NN1
304953	100736389	20992755639	,	,	,
304953	100736389	20992755640	she	she	PPHS1
304953	100736389	20992755641	said	say	VVD
304953	100736389	20992755642	,	,	,
304953	100736389	20992755643	can	can	VM
304953	100736389	20992755644	boost	boost	VVI
304953	100736389	20992755645	energy	energy	NN1
304953	100736389	20992755646	and	and	CC
304953	100736389	20992755647	improve	improve	VVI
304953	100736389	20992755648	quality	quality	NN1
304953	100736389	20992755649	of	of	IO
304953	100736389	20992755650	life	life	NN1
304953	100736389	20992755651	.	.	.
304953	100736389	20992755652	<p>		NULL
304953	100736389	20992755653	Physicians	physician	NN2
304953	100736389	20992755654	and	and	CC
304953	100736389	20992755655	researchers	researcher	NN2
304953	100736389	20992755656	have	have	VH0
304953	100736389	20992755657	long	long	RR
304953	100736389	20992755658	believed	believe	VVN
304953	100736389	20992755659	that	that	CST_DD1
304953	100736389	20992755660	consuming	consume	VVG_JJ@
304953	100736389	20992755661	high	high	JJ
304953	100736389	20992755662	amounts	amount	NN2
304953	100736389	20992755663	of	of	IO
304953	100736389	20992755664	calcium	calcium	NN1
304953	100736389	20992755665	and	and	CC
304953	100736389	20992755666	dairy	dairy	NN1
304953	100736389	20992755667	products	product	NN2
304953	100736389	20992755668	increases	increase	VVZ
304953	100736389	20992755669	the	the	AT
304953	100736389	20992755670	risk	risk	NN1
304953	100736389	20992755671	of	of	IO
304953	100736389	20992755672	prostate	prostate	NN1
304953	100736389	20992755673	cancer	cancer	NN1
304953	100736389	20992755674	,	,	,
304953	100736389	20992755675	although	although	CS
304953	100736389	20992755676	study	study	NN1
304953	100736389	20992755677	results	result	NN2
304953	100736389	20992755678	have	have	VH0
304953	100736389	20992755679	@		II
304953	100736389	20992755680	@		II
304953	100736389	20992755681	@		II
304953	100736389	20992755682	@		II
304953	100736389	20992755683	@		II
304953	100736389	20992755684	@		II
304953	100736389	20992755685	@		II
304953	100736389	20992755686	@		II
304953	100736389	20992755687	@		II
304953	100736389	20992755688	@		II
304953	100736389	20992755689	jury	jury	NN1
304953	100736389	20992755690	is	be	VBZ
304953	100736389	20992755691	still	still	RR
304953	100736389	20992755692	out	out	RP
304953	100736389	20992755693	.	.	.
304953	100736390	20992755713	@@##	----------	----------
304953	100736390	20992755714	@@100736390		FO
304953	100736390	20992755715	@4936390/		VV0_NN1
304953	100736390	20992755716	46989		MC
304953	100736390	20992755717	@qwx906989		FO
304953	100736390	20992755718	<p>		NULL
304953	100736390	20992755719	A	a	AT1
304953	100736390	20992755720	study	study	NN1
304953	100736390	20992755721	by	by	II
304953	100736390	20992755722	Northwestern	northwestern	JJ
304953	100736390	20992755723	University	university	NN1
304953	100736390	20992755724	Medical	medical	JJ
304953	100736390	20992755725	School	school	NN1
304953	100736390	20992755726	researchers	researcher	NN2
304953	100736390	20992755727	,	,	,
304953	100736390	20992755728	reported	report	VVN_VVD
304953	100736390	20992755729	in	in	II
304953	100736390	20992755730	April	april	NPM1
304953	100736390	20992755731	2007	2007	MC
304953	100736390	20992755732	,	,	,
304953	100736390	20992755733	provides	provide	VVZ
304953	100736390	20992755734	further	far	JJR@_RRR
304953	100736390	20992755735	evidence	evidence	NN1
304953	100736390	20992755736	that	that	CST_DD1
304953	100736390	20992755737	erectile	erectile	JJ
304953	100736390	20992755738	dysfunction	dysfunction	NN1
304953	100736390	20992755739	drugs	drug	NN2
304953	100736390	20992755740	may	may	VM
304953	100736390	20992755741	also	also	RR
304953	100736390	20992755742	alleviate	alleviate	VVI
304953	100736390	20992755743	urinary	urinary	JJ_NN1
304953	100736390	20992755744	symptoms	symptom	NN2
304953	100736390	20992755745	in	in	II
304953	100736390	20992755746	benign	benign	JJ
304953	100736390	20992755747	prostatic	prostatic	JJ
304953	100736390	20992755748	hyperplasia	hyperplasia	NN1
304953	100736390	20992755749	(	(	(
304953	100736390	20992755750	BPH	bph	NP1
304953	100736390	20992755751	)	)	)
304953	100736390	20992755752	.	.	.
304953	100736390	20992755753	The	the	AT
304953	100736390	20992755754	study	study	NN1
304953	100736390	20992755755	involved	involve	VVD_VVN
304953	100736390	20992755756	281	281	MC
304953	100736390	20992755757	men	man	NN2
304953	100736390	20992755758	who	who	PNQS
304953	100736390	20992755759	were	be	VBDR
304953	100736390	20992755760	randomly	randomly	RR
304953	100736390	20992755761	assigned	assign	VVN
304953	100736390	20992755762	to	to	TO
304953	100736390	20992755763	take	take	VVI
304953	100736390	20992755764	low	low	JJ
304953	100736390	20992755765	doses	dose	NN2
304953	100736390	20992755766	of	of	IO
304953	100736390	20992755767	tadalafil		NN1
304953	100736390	20992755768	(	(	(
304953	100736390	20992755769	Cialis		NP1
304953	100736390	20992755770	)	)	)
304953	100736390	20992755771	or	or	CC
304953	100736390	20992755772	a	a	AT1
304953	100736390	20992755773	placebo	placebo	NN1
304953	100736390	20992755774	for	for	IF
304953	100736390	20992755775	12	12	MC
304953	100736390	20992755776	weeks	week	NNT2
304953	100736390	20992755777	.	.	.
304953	100736390	20992755778	The	the	AT
304953	100736390	20992755779	researchers	researcher	NN2
304953	100736390	20992755780	found	find	VVD_VVN
304953	100736390	20992755781	that	that	CST
304953	100736390	20992755782	the	the	AT
304953	100736390	20992755783	men	man	NN2
304953	100736390	20992755784	who	who	PNQS
304953	100736390	20992755785	took	take	VVD
304953	100736390	20992755786	tadalafil		NN1
304953	100736390	20992755787	,	,	,
304953	100736390	20992755788	starting	start	VVG
304953	100736390	20992755789	at	at	II
304953	100736390	20992755790	5	5	MC
304953	100736390	20992755791	mg	mg	NNU
304953	100736390	20992755792	daily	daily	JJ_RR_NN1@
304953	100736390	20992755793	for	for	IF
304953	100736390	20992755794	six	six	MC
304953	100736390	20992755795	weeks	week	NNT2
304953	100736390	20992755796	,	,	,
304953	100736390	20992755797	then	then	RT
304953	100736390	20992755798	increasing	increase	VVG
304953	100736390	20992755799	the	the	AT
304953	100736390	20992755800	dose	dose	NN1
304953	100736390	20992755801	to	to	II
304953	100736390	20992755802	20	20	MC
304953	100736390	20992755803	mg	mg	NNU
304953	100736390	20992755804	daily	daily	JJ_RR_NN1@
304953	100736390	20992755805	for	for	IF
304953	100736390	20992755806	another	another	DD1
304953	100736390	20992755807	six	six	MC
304953	100736390	20992755808	weeks	week	NNT2
304953	100736390	20992755809	,	,	,
304953	100736390	20992755810	experienced	experience	VVD_JJ_VVN
304953	100736390	20992755811	significant	significant	JJ
304953	100736390	20992755812	improvement	improvement	NN1
304953	100736390	20992755813	in	in	II
304953	100736390	20992755814	urinary	urinary	NN1_JJ
304953	100736390	20992755815	and	and	CC
304953	100736390	20992755816	other	other	JJ
304953	100736390	20992755817	symptoms	symptom	NN2
304953	100736390	20992755818	of	of	IO
304953	100736390	20992755819	BPH	bph	NP1
304953	100736390	20992755820	.	.	.
304953	100736390	20992755821	<p>		NULL
304953	100736390	20992755822	Although	although	CS
304953	100736390	20992755823	further	far	JJR@_RRR
304953	100736390	20992755824	research	research	NN1
304953	100736390	20992755825	is	be	VBZ
304953	100736390	20992755826	needed	need	VVN
304953	100736390	20992755827	,	,	,
304953	100736390	20992755828	studies	study	NN2
304953	100736390	20992755829	of	of	IO
304953	100736390	20992755830	other	other	JJ
304953	100736390	20992755831	erectile	erectile	JJ
304953	100736390	20992755832	dysfunction	dysfunction	NN1
304953	100736390	20992755833	drugs	drug	NN2
304953	100736390	20992755834	have	have	VH0
304953	100736390	20992755835	also	also	RR
304953	100736390	20992755836	had	have	VHN
304953	100736390	20992755837	promising	promising	JJ
304953	100736390	20992755838	results	result	NN2
304953	100736390	20992755839	.	.	.
304953	100736390	20992755840	If	if	CS
304953	100736390	20992755841	you	you	PPY
304953	100736390	20992755842	are	be	VBR
304953	100736390	20992755843	interested	interested	JJ
304953	100736390	20992755844	in	in	II
304953	100736390	20992755845	exploring	explore	VVG
304953	100736390	20992755846	this	this	DD1
304953	100736390	20992755847	option	option	NN1
304953	100736390	20992755848	for	for	IF
304953	100736390	20992755849	BPH	bph	NP1
304953	100736390	20992755850	treatment	treatment	NN1
304953	100736390	20992755851	,	,	,
304953	100736390	20992755852	talk	talk	VV0_NN1
304953	100736390	20992755853	with	with	IW
304953	100736390	20992755854	your	your	APPGE
304953	100736390	20992755855	doctor	doctor	NN1
304953	100736390	20992755856	.	.	.
304953	100736390	20992755857	<p>		NULL
304953	100736390	20992755858	I 'm		VV0_NN1
304953	100736390	20992755859	thinking	thinking	NN1_VVG
304953	100736390	20992755860	,	,	,
304953	100736390	20992755861	actually	actually	RR
304953	100736390	20992755862	planning	plan	VVG
304953	100736390	20992755863	to	to	TO
304953	100736390	20992755864	have	have	VHI
304953	100736390	20992755865	the	the	AT
304953	100736390	20992755866	green	green	JJ
304953	100736390	20992755867	light	light	JJ_NN1
304953	100736390	20992755868	therapy	therapy	NN1
304953	100736390	20992755869	procedure	procedure	NN1
304953	100736390	20992755870	done	do	VDN
304953	100736390	20992755871	.	.	.
304953	100736390	20992755872	My	my	APPGE
304953	100736390	20992755873	prostate	prostate	NN1
304953	100736390	20992755874	is	be	VBZ
304953	100736390	20992755875	30%		NNU
304953	100736390	20992755876	enlarged	enlarged	JJ_VVN
304953	100736390	20992755877	but	but	CCB
304953	100736390	20992755878	my	my	APPGE
304953	100736390	20992755879	situation	situation	NN1
304953	100736390	20992755880	seems	seem	VVZ
304953	100736390	20992755881	to	to	TO
304953	100736390	20992755882	be	be	VBI
304953	100736390	20992755883	unique	unique	JJ
304953	100736390	20992755884	in	in	II_CS21%
304953	100736390	20992755885	that	that	DD1_CS22@
304953	100736390	20992755886	i	i	ZZ1_MC1
304953	100736390	20992755887	retain	retain	VV0
304953	100736390	20992755888	urine	urine	NN1
304953	100736390	20992755889	.	.	.
304953	100736390	20992755890	My	my	APPGE
304953	100736390	20992755891	last	last	MD
304953	100736390	20992755892	ultra	ultra	RR
304953	100736390	20992755893	sound		RR%_NN1_VV0@_JJ@
304953	100736390	20992755894	revealed	reveal	VVN_JJ@_VVD
304953	100736390	20992755895	66o		FO
304953	100736390	20992755896	milliliters	milliliter	NN2
304953	100736390	20992755897	of	of	IO
304953	100736390	20992755898	urine	urine	NN1
304953	100736390	20992755899	.	.	.
304953	100736390	20992755900	There	there	EX
304953	100736390	20992755901	has	have	VHZ
304953	100736390	20992755902	been	be	VBN
304953	100736390	20992755903	no	no	AT
304953	100736390	20992755904	bacteria	bacteria	NN2
304953	100736390	20992755905	@		II
304953	100736390	20992755906	@		II
304953	100736390	20992755907	@		II
304953	100736390	20992755908	@		II
304953	100736390	20992755909	@		II
304953	100736390	20992755910	@		II
304953	100736390	20992755911	@		II
304953	100736390	20992755912	@		II
304953	100736390	20992755913	@		II
304953	100736390	20992755914	@		II
304953	100736390	20992755915	discomfort	discomfort	NN1
304953	100736390	20992755916	,	,	,
304953	100736390	20992755917	take	take	VV0
304953	100736390	20992755918	rapiflow		VV0_NN1
304953	100736390	20992755919	to	to	TO
304953	100736390	20992755920	help	help	VVI
304953	100736390	20992755921	with	with	IW
304953	100736390	20992755922	elimination	elimination	NN1
304953	100736390	20992755923	.	.	.
304953	100736390	20992755924	What	what	DDQ
304953	100736390	20992755925	else	else	RR
304953	100736390	20992755926	can	can	VM_VV0%
304953	100736390	20992755927	one	one	PN1
304953	100736390	20992755928	do	do	VDI
304953	100736390	20992755929	?	?	?
304953	100736390	20992755930	Does	do	VDZ
304953	100736390	20992755931	viagra	viagra	NN1
304953	100736390	20992755932	and	and	CC
304953	100736390	20992755933	cialis	cialis	NN1
304953	100736390	20992755934	work	work	NN1_VV0
304953	100736390	20992755935	?	?	?
304953	100736390	20992755936	I	i	PPIS1
304953	100736390	20992755937	have	have	VH0
304953	100736390	20992755938	tried	try	VVN
304953	100736390	20992755939	vitamins	vitamin	NN2
304953	100736390	20992755940	,	,	,
304953	100736390	20992755941	internet	internet	NN1
304953	100736390	20992755942	supplements	supplement	NN2
304953	100736390	20992755943	,	,	,
304953	100736390	20992755944	saw	see	VVD
304953	100736390	20992755945	palmetto	palmetto	NN1
304953	100736390	20992755946	and	and	CC
304953	100736390	20992755947	Dr.		NNB
304953	100736390	20992755948	Winstons		NP1
304953	100736390	20992755949	remedies	remedy	NN2_VVZ@
304953	100736390	20992755950	.	.	.
304953	100736390	20992755951	nothing	nothing	PN1
304953	100736390	20992755952	seems	seem	VVZ
304953	100736390	20992755953	to	to	TO@_II
304953	100736390	20992755954	work	work	VVI_NN1
304953	100736390	20992755955	or	or	CC
304953	100736390	20992755956	it	it	PPH1
304953	100736390	20992755957	is	be	VBZ
304953	100736390	20992755958	cost	cost	VVN%_NN1
304953	100736390	20992755959	prohibitive	prohibitive	JJ
304953	100736390	20992755960	.	.	.
304953	100736390	20992755961	What	what	DDQ
304953	100736390	20992755962	else	else	RR
304953	100736390	20992755963	.	.	.
304953	100736390	20992755964	<p>		NULL
304953	100736390	20992755965	I 'm		VV0_NN1
304953	100736390	20992755966	heading	head	VVG_NN1
304953	100736390	20992755967	to	to	II
304953	100736390	20992755968	Hackensack	hackensack	NP1_NN1
304953	100736390	20992755969	M.C.	mc	NN1
304953	100736390	20992755970	for	for	IF
304953	100736390	20992755971	P.A.E.		NP1
304953	100736390	20992755972	procedure	procedure	NN1
304953	100736390	20992755973	to	to	II
304953	100736390	20992755974	enlarged	enlarged	JJ
304953	100736390	20992755975	prostate	prostate	NN1
304953	100736390	20992755976	.	.	.
304953	100736390	20992755977	Finesteride		VV0_NN1_NP1@
304953	100736390	20992755978	and	and	CC
304953	100736390	20992755979	Tamsulosin		NP1_NN1
304953	100736390	20992755980	have	have	VH0
304953	100736390	20992755981	not	not	XX
304953	100736390	20992755982	helped	help	VVN
304953	100736390	20992755983	at	at	RR21_II
304953	100736390	20992755984	all	all	RR22_DB
304953	100736390	20992755985	and	and	CC
304953	100736390	20992755986	are	be	VBR
304953	100736390	20992755987	of	of	IO
304953	100736390	20992755988	no	no	AT
304953	100736390	20992755989	consequence	consequence	NN1
304953	100736390	20992755990	in	in	II
304953	100736390	20992755991	helping	help	VVG_NN1
304953	100736390	20992755992	with	with	IW
304953	100736390	20992755993	B.P.H.		NP1
304953	100736390	20992755994	;	;	;
304953	100736390	20992755995	and	and	CC
304953	100736390	20992755996	side	side	NN1
304953	100736390	20992755997	effects	effect	NN2
304953	100736390	20992755998	of	of	IO
304953	100736390	20992755999	both	both	DB2
304953	100736390	20992756000	drugs	drug	NN2
304953	100736390	20992756001	suck	suck	VV0
304953	100736390	20992756002	.	.	.
304953	100736390	20992756003	Sometime	sometime	RT
304953	100736390	20992756004	,	,	,
304953	100736390	20992756005	chelated		VVD
304953	100736390	20992756006	Zinc	zinc	NP1
304953	100736390	20992756007	,	,	,
304953	100736390	20992756008	taken	take	VVN
304953	100736390	20992756009	daily	daily	RR_JJ
304953	100736390	20992756010	,	,	,
304953	100736390	20992756011	can	can	VM
304953	100736390	20992756012	help	help	VVI
304953	100736390	20992756013	with	with	IW
304953	100736390	20992756014	evacuation	evacuation	NN1
304953	100736390	20992756015	of	of	IO
304953	100736390	20992756016	urine	urine	NN1
304953	100736390	20992756017	but	but	CCB
304953	100736390	20992756018	personally	personally	RR
304953	100736390	20992756019	,	,	,
304953	100736390	20992756020	I 'm		VV0_NP1
304953	100736390	20992756021	totally	totally	RR
304953	100736390	20992756022	beyond	beyond	II
304953	100736390	20992756023	the	the	AT
304953	100736390	20992756024	vitamin	vitamin	NN1
304953	100736390	20992756025	,	,	,
304953	100736390	20992756026	supplements	supplement	NN2
304953	100736390	20992756027	,	,	,
304953	100736390	20992756028	saw	see	VVD
304953	100736390	20992756029	palmetto	palmetto	NN1
304953	100736390	20992756030	,	,	,
304953	100736390	20992756031	etc.		RA
304953	100736390	20992756032	,	,	,
304953	100736390	20992756033	remidies		NN2
304953	100736390	20992756034	.	.	.
304953	100736390	20992756035	Its	its	APPGE
304953	100736390	20992756036	either	either	RR
304953	100736390	20992756037	P.A.E.		NP1
304953	100736390	20992756038	of	of	IO
304953	100736390	20992756039	invasive	invasive	JJ
304953	100736390	20992756040	surgery	surgery	NN1
304953	100736390	20992756041	.	.	.
304953	100736390	20992756042	46996		MC
304953	100736390	20992756043	@qwx906996		FO
304953	100736391	20992756063	@@##	----------	----------
304953	100736391	20992756064	@@100736391		FO
304953	100736391	20992756065	@4936391/		VV0_NN1
304953	100736391	20992756066	46989		MC
304953	100736391	20992756067	@qwx906989		FO
304953	100736391	20992756068	<p>		NULL
304953	100736391	20992756069	Ever	ever	RR
304953	100736391	20992756070	since	since	CS_II@
304953	100736391	20992756071	the	the	AT
304953	100736391	20992756072	FDA	fda	NP1_NN1
304953	100736391	20992756073	approved	approve	VVD_VVN
304953	100736391	20992756074	the	the	AT
304953	100736391	20992756075	first	first	MD
304953	100736391	20992756076	cholesterol-lowering	cholesterol-lowering	JJ_NN1
304953	100736391	20992756077	statin	statin	NN1
304953	100736391	20992756078	in	in	II
304953	100736391	20992756079	1987	1987	MC
304953	100736391	20992756080	,	,	,
304953	100736391	20992756081	use	use	NN1
304953	100736391	20992756082	of	of	IO
304953	100736391	20992756083	the	the	AT
304953	100736391	20992756084	drugs	drug	NN2
304953	100736391	20992756085	has	have	VHZ
304953	100736391	20992756086	steadily	steadily	RR
304953	100736391	20992756087	increased	increase	VVN
304953	100736391	20992756088	,	,	,
304953	100736391	20992756089	with	with	IW
304953	100736391	20992756090	an	a	AT1
304953	100736391	20992756091	estimated	estimated	JJ@
304953	100736391	20992756092	13	13	MC
304953	100736391	20992756093	million	million	NNO
304953	100736391	20992756094	Americans	american	NN2
304953	100736391	20992756095	taking	take	VVG
304953	100736391	20992756096	them	them	PPHO2
304953	100736391	20992756097	to	to	II
304953	100736391	20992756098	ward	ward	NN1
304953	100736391	20992756099	off	off	II
304953	100736391	20992756100	heart	heart	NN1
304953	100736391	20992756101	and	and	CC
304953	100736391	20992756102	vascular	vascular	JJ
304953	100736391	20992756103	disease	disease	NN1
304953	100736391	20992756104	.	.	.
304953	100736391	20992756105	Recently	recently	RR
304953	100736391	20992756106	,	,	,
304953	100736391	20992756107	statins	statin	NN2
304953	100736391	20992756108	have	have	VH0
304953	100736391	20992756109	gained	gain	VVN
304953	100736391	20992756110	additional	additional	JJ
304953	100736391	20992756111	attention	attention	NN1
304953	100736391	20992756112	,	,	,
304953	100736391	20992756113	thanks	thanks	NN2
304953	100736391	20992756114	to	to	II
304953	100736391	20992756115	studies	study	NN2
304953	100736391	20992756116	showing	show	VVG
304953	100736391	20992756117	the	the	AT
304953	100736391	20992756118	drugs	drug	NN2
304953	100736391	20992756119	might	might	VM
304953	100736391	20992756120	have	have	VHI
304953	100736391	20992756121	anticancer	anticancer	NN1
304953	100736391	20992756122	properties	property	NN2
304953	100736391	20992756123	.	.	.
304953	100736391	20992756124	<p>		NULL
304953	100736391	20992756125	But	but	CCB
304953	100736391	20992756126	researchers	researcher	NN2
304953	100736391	20992756127	have	have	VH0
304953	100736391	20992756128	inconsistent	inconsistent	JJ
304953	100736391	20992756129	answers	answer	NN2
304953	100736391	20992756130	to	to	II
304953	100736391	20992756131	the	the	AT
304953	100736391	20992756132	question	question	NN1
304953	100736391	20992756133	of	of	IO
304953	100736391	20992756134	whether	whether	CSW
304953	100736391	20992756135	statins	statin	NN2
304953	100736391	20992756136	might	might	VM
304953	100736391	20992756137	help	help	VVI
304953	100736391	20992756138	control	control	NN1_VV0
304953	100736391	20992756139	PSA	psa	NP1
304953	100736391	20992756140	following	follow	VVG_JJ@_II@_NN1@
304953	100736391	20992756141	radiation	radiation	NN1
304953	100736391	20992756142	therapy	therapy	NN1
304953	100736391	20992756143	:	:	:
304953	100736391	20992756144	one	one	MC1
304953	100736391	20992756145	trial	trial	NN1
304953	100736391	20992756146	noted	note	VVD_VVN
304953	100736391	20992756147	improved	improved	JJ
304953	100736391	20992756148	biochemical	biochemical	JJ
304953	100736391	20992756149	control	control	NN1
304953	100736391	20992756150	with	with	IW
304953	100736391	20992756151	statins	statin	NN2
304953	100736391	20992756152	,	,	,
304953	100736391	20992756153	while	while	CS
304953	100736391	20992756154	another	another	DD1
304953	100736391	20992756155	found	find	VVD
304953	100736391	20992756156	no	no	AT
304953	100736391	20992756157	impact	impact	NN1
304953	100736391	20992756158	.	.	.
304953	100736391	20992756159	Michigan	michigan	NP1
304953	100736391	20992756160	researchers	researcher	NN2
304953	100736391	20992756161	recently	recently	RR
304953	100736391	20992756162	completed	complete	VVD_VVN
304953	100736391	20992756163	their	their	APPGE
304953	100736391	20992756164	own	own	DA
304953	100736391	20992756165	study	study	NN1
304953	100736391	20992756166	,	,	,
304953	100736391	20992756167	looking	look	VVG
304953	100736391	20992756168	back	back	RP
304953	100736391	20992756169	at	at	II
304953	100736391	20992756170	968	968	MC
304953	100736391	20992756171	patients	patient	NN2
304953	100736391	20992756172	who	who	PNQS
304953	100736391	20992756173	were	be	VBDR
304953	100736391	20992756174	treated	treat	VVN
304953	100736391	20992756175	with	with	IW
304953	100736391	20992756176	radiation	radiation	NN1
304953	100736391	20992756177	therapy	therapy	NN1
304953	100736391	20992756178	,	,	,
304953	100736391	20992756179	23%		NNU
304953	100736391	20992756180	of	of	IO
304953	100736391	20992756181	whom	whom	PNQO
304953	100736391	20992756182	had	have	VHD
304953	100736391	20992756183	been	be	VBN
304953	100736391	20992756184	taking	take	VVG
304953	100736391	20992756185	statins	statin	NN2
304953	100736391	20992756186	.	.	.
304953	100736391	20992756187	<p>		NULL
304953	100736391	20992756188	After	after	II
304953	100736391	20992756189	adjusting	adjust	VVG
304953	100736391	20992756190	the	the	AT
304953	100736391	20992756191	analyses	analysis	NN2
304953	100736391	20992756192	for	for	IF
304953	100736391	20992756193	multiple	multiple	JJ_NN1
304953	100736391	20992756194	factors	factor	NN2
304953	100736391	20992756195	,	,	,
304953	100736391	20992756196	such	such	II21
304953	100736391	20992756197	as	as	II22
304953	100736391	20992756198	age	age	NN1
304953	100736391	20992756199	,	,	,
304953	100736391	20992756200	Gleason	gleason	NP1
304953	100736391	20992756201	score	score	NN1_VV0
304953	100736391	20992756202	,	,	,
304953	100736391	20992756203	and	and	CC
304953	100736391	20992756204	total	total	JJ
304953	100736391	20992756205	radiation	radiation	NN1
304953	100736391	20992756206	dose	dose	NN1
304953	100736391	20992756207	,	,	,
304953	100736391	20992756208	they	they	PPHS2
304953	100736391	20992756209	concluded	conclude	VVD
304953	100736391	20992756210	that	that	CST
304953	100736391	20992756211	statins	statin	NN2
304953	100736391	20992756212	had	have	VHD
304953	100736391	20992756213	no	no	AT
304953	100736391	20992756214	significant	significant	JJ
304953	100736391	20992756215	effect	effect	NN1
304953	100736391	20992756216	on	on	II
304953	100736391	20992756217	the	the	AT
304953	100736391	20992756218	likelihood	likelihood	NN1
304953	100736391	20992756219	that	that	CST
304953	100736391	20992756220	patients	patient	NN2
304953	100736391	20992756221	would	would	VM
304953	100736391	20992756222	experience	experience	VVI
304953	100736391	20992756223	biochemical	biochemical	JJ
304953	100736391	20992756224	failure	failure	NN1
304953	100736391	20992756225	,	,	,
304953	100736391	20992756226	which	which	DDQ
304953	100736391	20992756227	was	be	VBDZ
304953	100736391	20992756228	defined	define	VVN
304953	100736391	20992756229	as	as	CSA_RG@
304953	100736391	20992756230	either	either	RR_DD1
304953	100736391	20992756231	a	a	AT1
304953	100736391	20992756232	PSA	psa	NP1
304953	100736391	20992756233	test	test	NN1_VV0
304953	100736391	20992756234	result	result	NN1_VV0
304953	100736391	20992756235	2	2	MC
304953	100736391	20992756236	ng/ml	ng/ml	FU
304953	100736391	20992756237	above	above	II
304953	100736391	20992756238	the	the	AT
304953	100736391	20992756239	patient	patient	NN1
304953	100736391	20992756240	's	's	GE
304953	100736391	20992756241	lowest	low	JJT
304953	100736391	20992756242	PSA	psa	NP1
304953	100736391	20992756243	after	after	II_CS
304953	100736391	20992756244	radiation	radiation	NN1
304953	100736391	20992756245	,	,	,
304953	100736391	20992756246	or	or	CC
304953	100736391	20992756247	the	the	AT
304953	100736391	20992756248	start	start	NN1
304953	100736391	20992756249	of	of	IO
304953	100736391	20992756250	hormone	hormone	NN1
304953	100736391	20992756251	therapy	therapy	NN1
304953	100736391	20992756252	.	.	.
304953	100736391	20992756253	<p>		NULL
304953	100736391	20992756254	Tracking	tracking	JJ_NN1
304953	100736391	20992756255	@		II
304953	100736391	20992756256	@		II
304953	100736391	20992756257	@		II
304953	100736391	20992756258	@		II
304953	100736391	20992756259	@		II
304953	100736391	20992756260	@		II
304953	100736391	20992756261	@		II
304953	100736391	20992756262	@		II
304953	100736391	20992756263	@		II
304953	100736391	20992756264	@		II
304953	100736391	20992756265	a	a	AT1
304953	100736391	20992756266	difference	difference	NN1
304953	100736391	20992756267	between	between	II
304953	100736391	20992756268	the	the	AT
304953	100736391	20992756269	two	two	MC
304953	100736391	20992756270	groups	group	NN2
304953	100736391	20992756271	to	to	TO
304953	100736391	20992756272	emerge	emerge	VVI
304953	100736391	20992756273	.	.	.
304953	100736391	20992756274	The	the	AT
304953	100736391	20992756275	median	median	JJ_NN1
304953	100736391	20992756276	follow-up	follow-up	JJ_NN1
304953	100736391	20992756277	time	time	NNT1
304953	100736391	20992756278	in	in	II
304953	100736391	20992756279	the	the	AT
304953	100736391	20992756280	study	study	NN1
304953	100736391	20992756281	was	be	VBDZ
304953	100736391	20992756282	just	just	RR
304953	100736391	20992756283	47	47	MC
304953	100736391	20992756284	months	month	NNT2
304953	100736391	20992756285	.	.	.
304953	100736391	20992756286	<p>		NULL
304953	100736391	20992756287	True	true	JJ
304953	100736391	20992756288	..	...	...
304953	100736391	20992756289	when	when	CS_RRQ
304953	100736391	20992756290	ur	ur	FO
304953	100736391	20992756291	working	work	VVG
304953	100736391	20992756292	i	i	ZZ1_MC1
304953	100736391	20992756293	guess	guess	VV0
304953	100736391	20992756294	you	you	PPY
304953	100736391	20992756295	can	can	VM
304953	100736391	20992756296	get	get	VVI
304953	100736391	20992756297	btiefnes		NN2
304953	100736391	20992756298	but	but	CCB
304953	100736391	20992756299	yea	yea	UH
304953	100736391	20992756300	,	,	,
304953	100736391	20992756301	hopefully	hopefully	RR
304953	100736391	20992756302	Obama	obama	NP1
304953	100736391	20992756303	can	can	VM
304953	100736391	20992756304	do	do	VDI
304953	100736391	20992756305	something	something	PN1
304953	100736391	20992756306	so	-so	RR_CS@_RG
304953	100736391	20992756307	its	its	APPGE
304953	100736391	20992756308	affordable	affordable	JJ
304953	100736391	20992756309	or	or	CC
304953	100736391	20992756310	available	available	JJ
304953	100736391	20992756311	to	to	II
304953	100736391	20992756312	everyone	everyone	PN1
304953	100736391	20992756313	..	...	...
304953	100736391	20992756314	even	even	RR
304953	100736391	20992756315	part-time	part-time	JJ
304953	100736391	20992756316	workers	worker	NN2
304953	100736391	20992756317	or	or	CC
304953	100736391	20992756318	the	the	AT
304953	100736391	20992756319	unemployed	unemployed	JJ
304953	100736391	20992756320	..	...	...
304953	100736391	20992756321	all	all	DB
304953	100736391	20992756322	citizens	citizen	NN2
304953	100736391	20992756323	should	should	VM
304953	100736391	20992756324	have	have	VHI
304953	100736391	20992756325	health	health	NN1
304953	100736391	20992756326	care	care	NN1_VV0
304953	100736391	20992756327	in	in	II
304953	100736391	20992756328	the	the	AT
304953	100736391	20992756329	country	country	NN1
304953	100736391	20992756330	they	they	PPHS2
304953	100736391	20992756331	live	live	VV0
304953	100736391	20992756332	in	in	II_RP@
304953	100736391	20992756333	my	my	APPGE
304953	100736391	20992756334	uncle	uncle	NN1
304953	100736391	20992756335	died	die	VVD
304953	100736391	20992756336	last	last	MD
304953	100736391	20992756337	Sunday	sunday	NPD1
304953	100736391	20992756338	of	of	IO
304953	100736391	20992756339	prostate	prostate	NN1
304953	100736391	20992756340	cancer	cancer	NN1
304953	100736391	20992756341	..	...	...
304953	100736391	20992756342	<p>		NULL
304953	100736391	20992756343	I	i	PPIS1
304953	100736391	20992756344	desire	desire	VV0@
304953	100736391	20992756345	to	to	II
304953	100736391	20992756346	coveny		NN1_JJ
304953	100736391	20992756347	a	a	AT1
304953	100736391	20992756348	few	few	DA2
304953	100736391	20992756349	appreciation	appreciation	NN1
304953	100736391	20992756350	for	for	IF
304953	100736391	20992756351	you	you	PPY
304953	100736391	20992756352	for	for	IF
304953	100736391	20992756353	bailing	bail	VVG
304953	100736391	20992756354	me	me	PPIO1
304953	100736391	20992756355	from	from	II
304953	100736391	20992756356	this	this	DD1
304953	100736391	20992756357	type	type	NN1
304953	100736391	20992756358	of	of	IO
304953	100736391	20992756359	concern	concern	NN1
304953	100736391	20992756360	.	.	.
304953	100736391	20992756361	Soon	soon	RR
304953	100736391	20992756362	after	after	II
304953	100736391	20992756363	surfing	surf	VVG
304953	100736391	20992756364	through	through	II
304953	100736391	20992756365	the	the	AT
304953	100736391	20992756366	internet	internet	NN1
304953	100736391	20992756367	as	as	II31
304953	100736391	20992756368	well	well	II32
304953	100736391	20992756369	as	as	II33
304953	100736391	20992756370	obtaining	obtain	VVG
304953	100736391	20992756371	plans	plan	NN2
304953	100736391	20992756372	which	which	DDQ
304953	100736391	20992756373	were	be	VBDR
304953	100736391	20992756374	in	in	II
304953	100736391	20992756375	no	no	AT
304953	100736391	20992756376	way	way	NN1
304953	100736391	20992756377	effective	effective	JJ
304953	100736391	20992756378	,	,	,
304953	100736391	20992756379	I	i	PPIS1
304953	100736391	20992756380	believed	believe	VVD
304953	100736391	20992756381	my	my	APPGE
304953	100736391	20992756382	personal	personal	JJ
304953	100736391	20992756383	entire	entire	JJ
304953	100736391	20992756384	life	life	NN1
304953	100736391	20992756385	had	have	VHD
304953	100736391	20992756386	been	be	VBN
304953	100736391	20992756387	essentially	essentially	RR
304953	100736391	20992756388	done	do	VDN
304953	100736391	20992756389	.	.	.
304953	100736391	20992756390	Residing	reside	VVG
304953	100736391	20992756391	devoid	devoid	JJ
304953	100736391	20992756392	of	of	IO
304953	100736391	20992756393	the	the	AT
304953	100736391	20992756394	answers	answer	NN2
304953	100736391	20992756395	towards	towards	II
304953	100736391	20992756396	the	the	AT
304953	100736391	20992756397	difficulties	difficulty	NN2
304953	100736391	20992756398	you	you	PPY
304953	100736391	20992756399	have	have	VH0
304953	100736391	20992756400	fixed	fix	VVN
304953	100736391	20992756401	by	by	II31
304953	100736391	20992756402	way	way	II32
304953	100736391	20992756403	of	of	II33
304953	100736391	20992756404	your	your	APPGE
304953	100736391	20992756405	own	own	DA
304953	100736391	20992756406	evaluation	evaluation	NN1
304953	100736391	20992756407	can	can	VM
304953	100736391	20992756408	be	be	VBI
304953	100736391	20992756409	defined	define	VVN
304953	100736391	20992756410	as	as	CSA_RG@_II@
304953	100736391	20992756411	serious	serious	JJ
304953	100736391	20992756412	declare	declare	VV0
304953	100736391	20992756413	,	,	,
304953	100736391	20992756414	as	as	II31
304953	100736391	20992756415	well	well	II32
304953	100736391	20992756416	as	as	II33
304953	100736391	20992756417	ones	one	NN2
304953	100736391	20992756418	that	that	CST_DD1
304953	100736391	20992756419	could	could	VM
304953	100736391	20992756420	require	require	VVI
304953	100736391	20992756421	inside	inside	II_RL
304953	100736391	20992756422	a	a	AT1
304953	100736391	20992756423	wrong	wrong	JJ
304953	100736391	20992756424	way	way	NN1
304953	100736391	20992756425	impacted	impact	VVD
304953	100736391	20992756426	your	your	APPGE
304953	100736391	20992756427	job	job	NN1
304953	100736391	20992756428	substantially	substantially	RR
304953	100736391	20992756429	more	more	DAR_RRR
304953	100736391	20992756430	than	than	CSN
304953	100736391	20992756431	merely	merely	RR
304953	100736391	20992756432	had	have	VHD
304953	100736391	20992756433	not	not	XX
304953	100736391	20992756434	run	run	VVN
304953	100736391	20992756435	into	into	II
304953	100736391	20992756436	your	your	APPGE
304953	100736391	20992756437	website	website	NN1
304953	100736391	20992756438	.	.	.
304953	100736391	20992756439	Your	your	APPGE
304953	100736391	20992756440	personal	personal	JJ
304953	100736391	20992756441	skills	skill	NN2
304953	100736391	20992756442	as	as	II31
304953	100736391	20992756443	well	well	II32
304953	100736391	20992756444	as	as	II33
304953	100736391	20992756445	kindness	kindness	NN1
304953	100736391	20992756446	through	through	II
304953	100736391	20992756447	coping	cope	VVG
304953	100736391	20992756448	with	with	IW
304953	100736391	20992756449	almost	almost	RR
304953	100736391	20992756450	anything	anything	PN1
304953	100736391	20992756451	was	be	VBDZ
304953	100736391	20992756452	basically	basically	RR
304953	100736391	20992756453	helpful	helpful	JJ
304953	100736391	20992756454	.	.	.
304953	100736391	20992756455	@		II
304953	100736391	20992756456	@		II
304953	100736391	20992756457	@		II
304953	100736391	20992756458	@		II
304953	100736391	20992756459	@		II
304953	100736391	20992756460	@		II
304953	100736391	20992756461	@		II
304953	100736391	20992756462	@		II
304953	100736391	20992756463	@		II
304953	100736391	20992756464	@		II
304953	100736391	20992756465	more	more	DAR_RRR
304953	100736391	20992756466	than	than	CSN
304953	100736391	20992756467	merely	merely	RR
304953	100736391	20992756468	had	have	VHD
304953	100736391	20992756469	not	not	XX
304953	100736391	20992756470	run	run	VVN
304953	100736391	20992756471	into	into	II
304953	100736391	20992756472	this	this	DD1
304953	100736391	20992756473	task	task	NN1
304953	100736391	20992756474	of	of	IO
304953	100736391	20992756475	the	the	AT
304953	100736391	20992756476	character	character	NN1
304953	100736391	20992756477	.	.	.
304953	100736391	20992756478	I 'm		VV0
304953	100736391	20992756479	also	also	RR
304953	100736391	20992756480	able	able	JK
304953	100736391	20992756481	to	to	TO
304953	100736391	20992756482	now	now	RT
304953	100736391	20992756483	thrive	thrive	VVI
304953	100736391	20992756484	on	on	II_RP@
304953	100736391	20992756485	your	your	APPGE
304953	100736391	20992756486	own	own	DA
304953	100736391	20992756487	forthcoming	forthcoming	JJ
304953	100736391	20992756488	.	.	.
304953	100736391	20992756489	Thanks	thanks	NN2
304953	100736391	20992756490	a	a	RR21
304953	100736391	20992756491	lot	lot	RR22
304953	100736391	20992756492	for	for	IF
304953	100736391	20992756493	the	the	AT
304953	100736391	20992756494	top	top	JJ_NN1
304953	100736391	20992756495	quality	quality	NN1
304953	100736391	20992756496	as	as	II31
304953	100736391	20992756497	well	well	II32
304953	100736391	20992756498	as	as	II33
304953	100736391	20992756499	results-oriented	results-oriented	JJ
304953	100736391	20992756500	guide	guide	NN1
304953	100736391	20992756501	.	.	.
304953	100736391	20992756502	Ill		JJ_RR%_NP1@
304953	100736391	20992756503	not	not	XX
304953	100736391	20992756504	really	really	RR
304953	100736391	20992756505	think	think	VV0
304953	100736391	20992756506	twice	twice	RR
304953	100736391	20992756507	in	in	II
304953	100736391	20992756508	the	the	AT
304953	100736391	20992756509	direction	direction	NN1
304953	100736391	20992756510	of	of	IO
304953	100736391	20992756511	send	send	VV0
304953	100736391	20992756512	your	your	APPGE
304953	100736391	20992756513	own	own	DA
304953	100736391	20992756514	web	web	NN1
304953	100736391	20992756515	site	site	NN1
304953	100736391	20992756516	in	in	II
304953	100736391	20992756517	the	the	AT
304953	100736391	20992756518	direction	direction	NN1
304953	100736391	20992756519	of	of	IO
304953	100736391	20992756520	any	any	DD
304953	100736391	20992756521	individual	individual	NN1_JJ
304953	100736391	20992756522	what	what	DDQ
304953	100736391	20992756523	individuals	individual	NN2
304953	100736391	20992756524	ought	ought	VMK
304953	100736391	20992756525	to	to	TO
304953	100736391	20992756526	receive	receive	VVI
304953	100736391	20992756527	support	support	NN1_VV0
304953	100736391	20992756528	about	about	II
304953	100736391	20992756529	this	this	DD1
304953	100736391	20992756530	region	region	NN1
304953	100736391	20992756531	.	.	.
304953	100736391	20992756532	46996		MC
304953	100736391	20992756533	@qwx906996		FO
304953	100736392	20992756553	@@##	----------	----------
304953	100736392	20992756554	@@100736392		FO
304953	100736392	20992756555	@4936392/		NN1_VV0
304953	100736392	20992756556	<p>		NULL
304953	100736392	20992756557	While	while	CS
304953	100736392	20992756558	you	you	PPY
304953	100736392	20992756559	lie	lie	VV0
304953	100736392	20992756560	on	on	II_RP@
304953	100736392	20992756561	your	your	APPGE
304953	100736392	20992756562	side	side	NN1
304953	100736392	20992756563	,	,	,
304953	100736392	20992756564	the	the	AT
304953	100736392	20992756565	doctor	doctor	NN1
304953	100736392	20992756566	inserts	insert	VVZ
304953	100736392	20992756567	an	a	AT1
304953	100736392	20992756568	ultrasound	ultrasound	NN1
304953	100736392	20992756569	probe	probe	NN1_VV0
304953	100736392	20992756570	into	into	II
304953	100736392	20992756571	the	the	AT
304953	100736392	20992756572	rectum	rectum	NN1
304953	100736392	20992756573	and	and	CC
304953	100736392	20992756574	scans	scan	VVZ@_NN2
304953	100736392	20992756575	the	the	AT
304953	100736392	20992756576	prostate	prostate	NN1
304953	100736392	20992756577	.	.	.
304953	100736392	20992756578	A	a	AT1_ZZ1
304953	100736392	20992756579	spring-loaded	spring-loaded	JJ_NN1
304953	100736392	20992756580	device	device	NN1
304953	100736392	20992756581	rapidly	rapidly	RR
304953	100736392	20992756582	inserts	insert	VVZ
304953	100736392	20992756583	a	a	AT1
304953	100736392	20992756584	needle	needle	NN1
304953	100736392	20992756585	through	through	II
304953	100736392	20992756586	the	the	AT
304953	100736392	20992756587	rectal	rectal	JJ
304953	100736392	20992756588	wall	wall	NN1
304953	100736392	20992756589	into	into	II
304953	100736392	20992756590	the	the	AT
304953	100736392	20992756591	prostate	prostate	NN1
304953	100736392	20992756592	and	and	CC
304953	100736392	20992756593	retrieves	retrieve	VVZ
304953	100736392	20992756594	a	a	AT1
304953	100736392	20992756595	tiny	tiny	JJ
304953	100736392	20992756596	tissue	tissue	NN1
304953	100736392	20992756597	sample	sample	NN1
304953	100736392	20992756598	.	.	.
304953	100736392	20992756599	The	the	AT
304953	100736392	20992756600	doctor	doctor	NN1
304953	100736392	20992756601	uses	use	VVZ
304953	100736392	20992756602	the	the	AT
304953	100736392	20992756603	ultrasound	ultrasound	NN1
304953	100736392	20992756604	image	image	NN1
304953	100736392	20992756605	as	as	II_CSA
304953	100736392	20992756606	a	a	AT1
304953	100736392	20992756607	guide	guide	NN1
304953	100736392	20992756608	in	in	II
304953	100736392	20992756609	taking	take	VVG
304953	100736392	20992756610	biopsies	biopsy	NN2
304953	100736392	20992756611	from	from	II
304953	100736392	20992756612	specific	specific	JJ
304953	100736392	20992756613	areas	area	NN2
304953	100736392	20992756614	.	.	.
304953	100736392	20992756615	Usually	usually	RR
304953	100736392	20992756616	,	,	,
304953	100736392	20992756617	six	six	MC
304953	100736392	20992756618	to	to	II
304953	100736392	20992756619	12	12	MC
304953	100736392	20992756620	samples	sample	NN2
304953	100736392	20992756621	are	be	VBR
304953	100736392	20992756622	obtained	obtain	VVN
304953	100736392	20992756623	.	.	.
304953	100736392	20992756624	The	the	AT
304953	100736392	20992756625	doctor	doctor	NN1
304953	100736392	20992756626	may	may	VM
304953	100736392	20992756627	inject	inject	VVI
304953	100736392	20992756628	an	a	AT1
304953	100736392	20992756629	anesthetic	anesthetic	JJ_NN1@
304953	100736392	20992756630	into	into	II
304953	100736392	20992756631	the	the	AT
304953	100736392	20992756632	prostate	prostate	NN1
304953	100736392	20992756633	after	after	II_CS
304953	100736392	20992756634	the	the	AT
304953	100736392	20992756635	ultrasound	ultrasound	NN1
304953	100736392	20992756636	probe	probe	NN1
304953	100736392	20992756637	is	be	VBZ
304953	100736392	20992756638	introduced	introduce	VVN
304953	100736392	20992756639	and	and	CC
304953	100736392	20992756640	before	before	CS_II
304953	100736392	20992756641	the	the	AT
304953	100736392	20992756642	biopsies	biopsy	NN2
304953	100736392	20992756643	are	be	VBR
304953	100736392	20992756644	taken	take	VVN
304953	100736392	20992756645	,	,	,
304953	100736392	20992756646	again	again	RT
304953	100736392	20992756647	guided	guide	VVN
304953	100736392	20992756648	by	by	II
304953	100736392	20992756649	the	the	AT
304953	100736392	20992756650	ultrasound	ultrasound	NN1
304953	100736392	20992756651	image	image	NN1
304953	100736392	20992756652	.	.	.
304953	100736392	20992756653	Although	although	CS
304953	100736392	20992756654	you	you	PPY
304953	100736392	20992756655	may	may	VM
304953	100736392	20992756656	feel	feel	VVI
304953	100736392	20992756657	a	a	AT1
304953	100736392	20992756658	pinch	pinch	NN1
304953	100736392	20992756659	,	,	,
304953	100736392	20992756660	no	no	AT
304953	100736392	20992756661	additional	additional	JJ
304953	100736392	20992756662	anesthesia	anesthesia	NN1
304953	100736392	20992756663	is	be	VBZ
304953	100736392	20992756664	necessary	necessary	JJ
304953	100736392	20992756665	.	.	.
304953	100736392	20992756666	<p>		NULL
304953	100736392	20992756667	Taking	take	VVG
304953	100736392	20992756668	an	a	AT1
304953	100736392	20992756669	antibiotic	antibiotic	NN1
304953	100736392	20992756670	before	before	II_CS_RT@
304953	100736392	20992756671	and	and	CC
304953	100736392	20992756672	after	after	CS_II
304953	100736392	20992756673	the	the	AT
304953	100736392	20992756674	procedure	procedure	NN1
304953	100736392	20992756675	reduces	reduce	VVZ
304953	100736392	20992756676	the	the	AT
304953	100736392	20992756677	risk	risk	NN1
304953	100736392	20992756678	for	for	IF
304953	100736392	20992756679	infection	infection	NN1
304953	100736392	20992756680	.	.	.
304953	100736392	20992756681	Avoiding	avoid	VVG
304953	100736392	20992756682	aspirin	aspirin	NN
304953	100736392	20992756683	and	and	CC
304953	100736392	20992756684	similar	similar	JJ
304953	100736392	20992756685	drugs	drug	NN2
304953	100736392	20992756686	,	,	,
304953	100736392	20992756687	such	such	II21
304953	100736392	20992756688	as	as	II22
304953	100736392	20992756689	ibuprofen	ibuprofen	NN1_JJ
304953	100736392	20992756690	(	(	(
304953	100736392	20992756691	Advil	advil	NP1
304953	100736392	20992756692	,	,	,
304953	100736392	20992756693	Motrin	motrin	NP1
304953	100736392	20992756694	)	)	)
304953	100736392	20992756695	and	and	CC
304953	100736392	20992756696	naproxen	naproxen	NN1_JJ
304953	100736392	20992756697	(	(	(
304953	100736392	20992756698	Aleve	aleve	NP1
304953	100736392	20992756699	)	)	)
304953	100736392	20992756700	,	,	,
304953	100736392	20992756701	for	for	IF
304953	100736392	20992756702	a	a	AT1
304953	100736392	20992756703	week	week	NNT1
304953	100736392	20992756704	before	before	II_CS
304953	100736392	20992756705	the	the	AT
304953	100736392	20992756706	biopsy	biopsy	NN1
304953	100736392	20992756707	protects	protect	VVZ
304953	100736392	20992756708	against	against	II
304953	100736392	20992756709	excessive	excessive	JJ
304953	100736392	20992756710	bleeding	bleeding	JJ
304953	100736392	20992756711	,	,	,
304953	100736392	20992756712	which	which	DDQ
304953	100736392	20992756713	is	be	VBZ
304953	100736392	20992756714	a	a	AT1
304953	100736392	20992756715	possible	possible	JJ
304953	100736392	20992756716	complication	complication	NN1
304953	100736392	20992756717	.	.	.
304953	100736392	20992756718	<p>		NULL
304953	100736392	20992756719	A	a	AT1
304953	100736392	20992756720	prostate	prostate	NN1
304953	100736392	20992756721	cancer	cancer	NN1
304953	100736392	20992756722	diagnosis	diagnosis	NN1
304953	100736392	20992756723	may	may	VM
304953	100736392	20992756724	send	send	VVI
304953	100736392	20992756725	a	a	AT1
304953	100736392	20992756726	man	man	NN1
304953	100736392	20992756727	to	to	II
304953	100736392	20992756728	the	the	AT
304953	100736392	20992756729	operating	operating	NN1
304953	100736392	20992756730	room	room	NN1
304953	100736392	20992756731	or	or	CC
304953	100736392	20992756732	drive	drive	VV0
304953	100736392	20992756733	him	him	PPHO1
304953	100736392	20992756734	to	to	TO
304953	100736392	20992756735	get	get	VVI
304953	100736392	20992756736	radiation	radiation	NN1
304953	100736392	20992756737	therapy	therapy	NN1
304953	100736392	20992756738	"	"	"
304953	100736392	20992756739	even	even	CS21
304953	100736392	20992756740	when	when	CS22
304953	100736392	20992756741	the	the	AT
304953	100736392	20992756742	cancer	cancer	NN1
304953	100736392	20992756743	is	be	VBZ
304953	100736392	20992756744	unlikely	unlikely	JJ
304953	100736392	20992756745	@		II
304953	100736392	20992756746	@		II
304953	100736392	20992756747	@		II
304953	100736392	20992756748	@		II
304953	100736392	20992756749	@		II
304953	100736392	20992756750	@		II
304953	100736392	20992756751	@		II
304953	100736392	20992756752	@		II
304953	100736392	20992756753	@		II
304953	100736392	20992756754	@		II
304953	100736392	20992756755	wonder	wonder	VVI
304953	100736392	20992756756	when	when	RRQ
304953	100736392	20992756757	a	a	AT1
304953	100736392	20992756758	biopsy	biopsy	NN1
304953	100736392	20992756759	should	should	VM
304953	100736392	20992756760	really	really	RR
304953	100736392	20992756761	be	be	VBI
304953	100736392	20992756762	done	do	VDN
304953	100736392	20992756763	.	.	.
304953	100736392	20992756764	<p>		NULL
304953	100736392	20992756765	Elliot	elliot	NP1
304953	100736392	20992756766	and	and	CC
304953	100736392	20992756767	Elizabeth	elizabeth	NP1
304953	100736392	20992756768	Boyd	boyd	NP1
304953	100736392	20992756769	share	share	VV0
304953	100736392	20992756770	their	their	APPGE
304953	100736392	20992756771	experience	experience	NN1
304953	100736392	20992756772	with	with	IW
304953	100736392	20992756773	a	a	AT1
304953	100736392	20992756774	prostate	prostate	NN1
304953	100736392	20992756775	cancer	cancer	NN1
304953	100736392	20992756776	diagnosis	diagnosis	NN1
304953	100736392	20992756777	,	,	,
304953	100736392	20992756778	explain	explain	VV0
304953	100736392	20992756779	their	their	APPGE
304953	100736392	20992756780	next	next	MD
304953	100736392	20992756781	steps	step	NN2
304953	100736392	20992756782	in	in	II31
304953	100736392	20992756783	light	light	II32
304953	100736392	20992756784	of	of	II33
304953	100736392	20992756785	seemingly	seemingly	RR
304953	100736392	20992756786	contradictory	contradictory	JJ
304953	100736392	20992756787	test	test	NN1
304953	100736392	20992756788	results	result	NN2
304953	100736392	20992756789	,	,	,
304953	100736392	20992756790	and	and	CC
304953	100736392	20992756791	offer	offer	VV0_NN1
304953	100736392	20992756792	advice	advice	NN1
304953	100736392	20992756793	to	to	II
304953	100736392	20992756794	those	those	DD2
304953	100736392	20992756795	coping	cope	VVG
304953	100736392	20992756796	with	with	IW
304953	100736392	20992756797	their	their	APPGE
304953	100736392	20992756798	diagnosis	diagnosis	NN1
304953	100736392	20992756799	and	and	CC
304953	100736392	20992756800	weighing	weigh	VVG_NN1
304953	100736392	20992756801	treatment	treatment	NN1
304953	100736392	20992756802	options	option	NN2
304953	100736392	20992756803	.	.	.
304953	100736392	20992756804	<p>		NULL
304953	100736392	20992756805	Even	even	CS21
304953	100736392	20992756806	if	if	CS22
304953	100736392	20992756807	my	my	APPGE
304953	100736392	20992756808	father	father	NN1
304953	100736392	20992756809	takes	take	VVZ
304953	100736392	20992756810	antibiotics	antibiotic	NN2
304953	100736392	20992756811	beforehand	beforehand	RR
304953	100736392	20992756812	,	,	,
304953	100736392	20992756813	could	could	VM
304953	100736392	20992756814	he	he	PPHS1
304953	100736392	20992756815	develop	develop	VVI
304953	100736392	20992756816	a	a	AT1
304953	100736392	20992756817	serious	serious	JJ
304953	100736392	20992756818	infection	infection	NN1
304953	100736392	20992756819	when	when	CS_RRQ
304953	100736392	20992756820	he	he	PPHS1
304953	100736392	20992756821	has	have	VHZ
304953	100736392	20992756822	a	a	AT1
304953	100736392	20992756823	prostate	prostate	NN1
304953	100736392	20992756824	biopsy	biopsy	NN1
304953	100736392	20992756825	later	later	RRR
304953	100736392	20992756826	this	this	DD1
304953	100736392	20992756827	year	year	NNT1
304953	100736392	20992756828	?	?	?
304953	100736392	20992756829	Are	be	VBR
304953	100736392	20992756830	there	there	RL_EX
304953	100736392	20992756831	other	other	JJ
304953	100736392	20992756832	possible	possible	JJ
304953	100736392	20992756833	complications	complication	NN2
304953	100736392	20992756834	we	we	PPIS2
304953	100736392	20992756835	should	should	VM
304953	100736392	20992756836	be	be	VBI
304953	100736392	20992756837	on	on	II
304953	100736392	20992756838	the	the	AT
304953	100736392	20992756839	lookout	lookout	NN1
304953	100736392	20992756840	for	for	IF
304953	100736392	20992756841	?	?	?
304953	100736393	20992756861	@@##	----------	----------
304953	100736393	20992756862	@@100736393		FO
304953	100736393	20992756863	@4936393/		VV0_NN1
304953	100736393	20992756864	46989		MC
304953	100736393	20992756865	@qwx906989		FO
304953	100736393	20992756866	<h>		NULL
304953	100736393	20992756867	Understanding	understand	VVG_NN1
304953	100736393	20992756868	PSA	psa	NP1
304953	100736393	20992756869	<p>		NULL
304953	100736393	20992756870	Your	your	APPGE
304953	100736393	20992756871	PSA	psa	NP1
304953	100736393	20992756872	level	level	NN1
304953	100736393	20992756873	is	be	VBZ
304953	100736393	20992756874	moderately	moderately	RR
304953	100736393	20992756875	elevated	elevate	VVN_VVD_JJ
304953	100736393	20992756876	.	.	.
304953	100736393	20992756877	About	about	II
304953	100736393	20992756878	one	one	MC1
304953	100736393	20992756879	in	in	II
304953	100736393	20992756880	three	three	MC
304953	100736393	20992756881	men	man	NN2
304953	100736393	20992756882	with	with	IW
304953	100736393	20992756883	a	a	AT1
304953	100736393	20992756884	moderately	moderately	RR
304953	100736393	20992756885	elevated	elevate	VVD_VVN_JJ
304953	100736393	20992756886	PSA	psa	NP1
304953	100736393	20992756887	level	level	NN1
304953	100736393	20992756888	will	will	VM
304953	100736393	20992756889	be	be	VBI
304953	100736393	20992756890	found	find	VVN
304953	100736393	20992756891	to	to	TO
304953	100736393	20992756892	have	have	VHI
304953	100736393	20992756893	early	early	JJ
304953	100736393	20992756894	stage	stage	NN1
304953	100736393	20992756895	prostate	prostate	NN1
304953	100736393	20992756896	cancer	cancer	NN1
304953	100736393	20992756897	if	if	CS
304953	100736393	20992756898	a	a	AT1
304953	100736393	20992756899	biopsy	biopsy	NN1
304953	100736393	20992756900	is	be	VBZ
304953	100736393	20992756901	performed	perform	VVN
304953	100736393	20992756902	.	.	.
304953	100736393	20992756903	Early	early	JJ
304953	100736393	20992756904	stage	stage	NN1
304953	100736393	20992756905	prostate	prostate	NN1
304953	100736393	20992756906	cancer	cancer	NN1
304953	100736393	20992756907	rarely	rarely	RR
304953	100736393	20992756908	causes	cause	VVZ
304953	100736393	20992756909	symptoms	symptom	NN2
304953	100736393	20992756910	,	,	,
304953	100736393	20992756911	and	and	CC
304953	100736393	20992756912	your	your	APPGE
304953	100736393	20992756913	prostate	prostate	NN1
304953	100736393	20992756914	may	may	VM
304953	100736393	20992756915	feel	feel	VVI
304953	100736393	20992756916	totally	totally	RR
304953	100736393	20992756917	normal	normal	JJ
304953	100736393	20992756918	when	when	CS
304953	100736393	20992756919	examined	examine	VVN
304953	100736393	20992756920	by	by	II
304953	100736393	20992756921	your	your	APPGE
304953	100736393	20992756922	doctor	doctor	NN1
304953	100736393	20992756923	(	(	(
304953	100736393	20992756924	digital	digital	JJ
304953	100736393	20992756925	rectal	rectal	JJ
304953	100736393	20992756926	exam	exam	NN1
304953	100736393	20992756927	)	)	)
304953	100736393	20992756928	.	.	.
304953	100736393	20992756929	One	one	MC1
304953	100736393	20992756930	piece	piece	NN1
304953	100736393	20992756931	of	of	IO
304953	100736393	20992756932	good	good	JJ
304953	100736393	20992756933	news	news	NN1
304953	100736393	20992756934	is	be	VBZ
304953	100736393	20992756935	that	that	RG
304953	100736393	20992756936	early	early	RR
304953	100736393	20992756937	stage	stage	NN1_VV0%
304953	100736393	20992756938	prostate	prostate	NN1
304953	100736393	20992756939	cancer	cancer	NN1
304953	100736393	20992756940	can	can	VM
304953	100736393	20992756941	often	often	RR
304953	100736393	20992756942	be	be	VBI
304953	100736393	20992756943	cured	cure	VVN
304953	100736393	20992756944	.	.	.
304953	100736393	20992756945	<p>		NULL
304953	100736393	20992756946	The	the	AT
304953	100736393	20992756947	other	other	JJ
304953	100736393	20992756948	piece	piece	NN1
304953	100736393	20992756949	of	of	IO
304953	100736393	20992756950	good	good	JJ
304953	100736393	20992756951	news	news	NN1
304953	100736393	20992756952	is	be	VBZ
304953	100736393	20992756953	that	that	CST
304953	100736393	20992756954	most	most	DAT
304953	100736393	20992756955	men	man	NN2
304953	100736393	20992756956	with	with	IW
304953	100736393	20992756957	a	a	AT1
304953	100736393	20992756958	moderately	moderately	RR
304953	100736393	20992756959	elevated	elevate	VVD_VVN_JJ
304953	100736393	20992756960	PSA	psa	NP1
304953	100736393	20992756961	level	level	NN1
304953	100736393	20992756962	do	do	VD0
304953	100736393	20992756963	n't 	n't	XX
304953	100736393	20992756964	have	have	VHI
304953	100736393	20992756965	prostate	prostate	NN1
304953	100736393	20992756966	cancer	cancer	NN1
304953	100736393	20992756967	.	.	.
304953	100736393	20992756968	Instead	instead	RR
304953	100736393	20992756969	,	,	,
304953	100736393	20992756970	their	their	APPGE
304953	100736393	20992756971	PSA	psa	NP1
304953	100736393	20992756972	level	level	NN1
304953	100736393	20992756973	has	have	VHZ
304953	100736393	20992756974	risen	rise	VVN
304953	100736393	20992756975	for	for	IF
304953	100736393	20992756976	another	another	DD1
304953	100736393	20992756977	reason	reason	NN1
304953	100736393	20992756978	,	,	,
304953	100736393	20992756979	such	such	II21
304953	100736393	20992756980	as	as	II22
304953	100736393	20992756981	:	:	:
304953	100736393	20992756982	<p>		NULL
304953	100736393	20992756983	benign	benign	JJ
304953	100736393	20992756984	growth	growth	NN1
304953	100736393	20992756985	of	of	IO
304953	100736393	20992756986	the	the	AT
304953	100736393	20992756987	prostate	prostate	NN1
304953	100736393	20992756988	gland	gland	NN1
304953	100736393	20992756989	(	(	(
304953	100736393	20992756990	also	also	RR
304953	100736393	20992756991	known	know	VVN
304953	100736393	20992756992	as	as	II
304953	100736393	20992756993	BPH	bph	NP1
304953	100736393	20992756994	or	or	CC
304953	100736393	20992756995	benign	benign	JJ
304953	100736393	20992756996	prostatatic		JJ
304953	100736393	20992756997	hyperplasia	hyperplasia	NN1
304953	100736393	20992756998	)	)	)
304953	100736393	20992756999	<p>		NULL
304953	100736393	20992757000	a	a	AT1
304953	100736393	20992757001	prostate	prostate	NN1
304953	100736393	20992757002	infection	infection	NN1
304953	100736393	20992757003	or	or	CC
304953	100736393	20992757004	urinary	urinary	JJ_NN1
304953	100736393	20992757005	tract	tract	NN1
304953	100736393	20992757006	infection	infection	NN1
304953	100736393	20992757007	<p>		NULL
304953	100736393	20992757008	damage	damage	VV0_NN1
304953	100736393	20992757009	to	to	II
304953	100736393	20992757010	the	the	AT
304953	100736393	20992757011	prostate	prostate	NN1
304953	100736393	20992757012	caused	cause	VVN
304953	100736393	20992757013	by	by	II
304953	100736393	20992757014	a	a	AT1
304953	100736393	20992757015	surgery	surgery	NN1
304953	100736393	20992757016	or	or	CC
304953	100736393	20992757017	trauma	trauma	NN1
304953	100736393	20992757018	.	.	.
304953	100736393	20992757019	<p>		NULL
304953	100736393	20992757020	Therefore	therefore	RR
304953	100736393	20992757021	,	,	,
304953	100736393	20992757022	if	if	CS
304953	100736393	20992757023	your	your	APPGE
304953	100736393	20992757024	PSA	psa	NP1
304953	100736393	20992757025	level	level	NN1
304953	100736393	20992757026	is	be	VBZ
304953	100736393	20992757027	between	between	II
304953	100736393	20992757028	four	four	MC
304953	100736393	20992757029	and	and	CC
304953	100736393	20992757030	ten	ten	MC
304953	100736393	20992757031	,	,	,
304953	100736393	20992757032	the	the	AT
304953	100736393	20992757033	first	first	MD
304953	100736393	20992757034	thing	thing	NN1
304953	100736393	20992757035	to	to	TO
304953	100736393	20992757036	find	find	VVI
304953	100736393	20992757037	out	out	RP
304953	100736393	20992757038	is	be	VBZ
304953	100736393	20992757039	whether	whether	CSW
304953	100736393	20992757040	you	you	PPY
304953	100736393	20992757041	may	may	VM
304953	100736393	20992757042	have	have	VHI
304953	100736393	20992757043	had	have	VHN@
304953	100736393	20992757044	any	any	DD
304953	100736393	20992757045	of	of	IO
304953	100736393	20992757046	the	the	AT
304953	100736393	20992757047	following	following	JJ
304953	100736393	20992757048	within	within	II
304953	100736393	20992757049	the	the	AT
304953	100736393	20992757050	past	past	JJ
304953	100736393	20992757051	two	two	MC
304953	100736393	20992757052	months	month	NNT2
304953	100736393	20992757053	@		II
304953	100736393	20992757054	@		II
304953	100736393	20992757055	@		II
304953	100736393	20992757056	@		II
304953	100736393	20992757057	@		II
304953	100736393	20992757058	@		II
304953	100736393	20992757059	@		II
304953	100736393	20992757060	@		II
304953	100736393	20992757061	@		II
304953	100736393	20992757062	@		II
304953	100736393	20992757063	such	such	II21
304953	100736393	20992757064	as	as	II22
304953	100736393	20992757065	burning	burn	VVG_JJ
304953	100736393	20992757066	with	with	IW
304953	100736393	20992757067	urination	urination	NN1
304953	100736393	20992757068	,	,	,
304953	100736393	20992757069	dribbling	dribble	VVG
304953	100736393	20992757070	,	,	,
304953	100736393	20992757071	hesitancy	hesitancy	NN1
304953	100736393	20992757072	,	,	,
304953	100736393	20992757073	or	or	CC
304953	100736393	20992757074	pain	pain	NN1
304953	100736393	20992757075	in	in	II
304953	100736393	20992757076	the	the	AT
304953	100736393	20992757077	groin	groin	NN1
304953	100736393	20992757078	<p>		NULL
304953	100736393	20992757079	prostate	prostate	NN1
304953	100736393	20992757080	or	or	CC
304953	100736393	20992757081	bladder	bladder	NN1
304953	100736393	20992757082	surgery	surgery	NN1
304953	100736393	20992757083	<p>		NULL
304953	100736393	20992757084	a	a	AT1
304953	100736393	20992757085	bladder	bladder	NN1
304953	100736393	20992757086	catheter	catheter	NN1
304953	100736393	20992757087	used	use	VMK
304953	100736393	20992757088	to	to	TO
304953	100736393	20992757089	drain	drain	VVI
304953	100736393	20992757090	urine	urine	NN1
304953	100736393	20992757091	while	while	CS
304953	100736393	20992757092	you	you	PPY
304953	100736393	20992757093	are	be	VBR
304953	100736393	20992757094	in	in	II
304953	100736393	20992757095	the	the	AT
304953	100736393	20992757096	hospital	hospital	NN1
304953	100736393	20992757097	or	or	CC
304953	100736393	20992757098	during	during	II
304953	100736393	20992757099	minor	minor	JJ
304953	100736393	20992757100	surgery	surgery	NN1
304953	100736393	20992757101	<p>		NULL
304953	100736393	20992757102	Regards	regard	NN2_VVZ
304953	100736393	20992757103	for	for	IF
304953	100736393	20992757104	those	those	DD2
304953	100736393	20992757105	who	who	PNQS
304953	100736393	20992757106	suggestions	suggestion	NN2
304953	100736393	20992757107	about	about	II
304953	100736393	20992757108	crdiet		NN1
304953	100736393	20992757109	ratings	rating	NN2
304953	100736393	20992757110	.	.	.
304953	100736393	20992757111	remedy	remedy	VV0_NN1
304953	100736393	20992757112	on	on	II
304953	100736393	20992757113	the	the	AT
304953	100736393	20992757114	subject	subject	NN1
304953	100736393	20992757115	of	of	IO
304953	100736393	20992757116	this	this	DD1
304953	100736393	20992757117	dramatic	dramatic	JJ
304953	100736393	20992757118	weblog	weblog	NN1
304953	100736393	20992757119	.	.	.
304953	100736393	20992757120	Some	some	DD
304953	100736393	20992757121	tips	tip	NN2
304953	100736393	20992757122	i 'd		NN1
304953	100736393	20992757123	personally	personally	RR
304953	100736393	20992757124	advice	advice	NN1
304953	100736393	20992757125	plenty	plenty	PN
304953	100736393	20992757126	of	of	IO
304953	100736393	20992757127	people	people	NN
304953	100736393	20992757128	must	must	VM
304953	100736393	20992757129	be	be	VBI
304953	100736393	20992757130	to	to	TO
304953	100736393	20992757131	take	take	VVI
304953	100736393	20992757132	out	out	RP
304953	100736393	20992757133	any	any	DD
304953	100736393	20992757134	entertaining	entertaining	JJ_VVG@
304953	100736393	20992757135	the	the	AT
304953	100736393	20992757136	idea	idea	NN1
304953	100736393	20992757137	of	of	IO
304953	100736393	20992757138	process	process	NN1
304953	100736393	20992757139	that	that	CST
304953	100736393	20992757140	they	they	PPHS2
304953	100736393	20992757141	may	may	VM
304953	100736393	20992757142	might	might	VM
304953	100736393	20992757143	require	require	VVI
304953	100736393	20992757144	to	to	TO
304953	100736393	20992757145	purchase	purchase	VVI
304953	100736393	20992757146	currently	currently	RR
304953	100736393	20992757147	combined	combine	VVN
304953	100736393	20992757148	with	with	IW
304953	100736393	20992757149	pay	pay	NN1_VV0
304953	100736393	20992757150	back	back	RP_NN1
304953	100736393	20992757151	at	at	II
304953	100736393	20992757152	some	some	DD
304953	100736393	20992757153	point	point	NN1
304953	100736393	20992757154	.	.	.
304953	100736393	20992757155	Like	like	II_VV0@
304953	100736393	20992757156	whatever	whatever	DDQV
304953	100736393	20992757157	population	population	NN1
304953	100736393	20992757158	many	many	DA2
304953	100736393	20992757159	of	of	IO
304953	100736393	20992757160	us	us	PPIO2
304953	100736393	20992757161	may	may	VM
304953	100736393	20992757162	maintain	maintain	VVI
304953	100736393	20992757163	this	this	DD1
304953	100736393	20992757164	for	for	IF
304953	100736393	20992757165	a	a	AT1
304953	100736393	20992757166	few	few	DA2
304953	100736393	20992757167	things	thing	NN2
304953	100736393	20992757168	.	.	.
304953	100736393	20992757169	Restricted	restrict	VVN_JJ
304953	100736393	20992757170	for	for	IF
304953	100736393	20992757171	you	you	PPY
304953	100736393	20992757172	to	to	TO_II
304953	100736393	20992757173	,	,	,
304953	100736393	20992757174	vacation	vacation	NN1
304953	100736393	20992757175	journeys	journey	NN2
304953	100736393	20992757176	,	,	,
304953	100736393	20992757177	bed	bed	NN1
304953	100736393	20992757178	room	room	NN1
304953	100736393	20992757179	or	or	CC
304953	100736393	20992757180	space	space	NN1
304953	100736393	20992757181	components	component	NN2
304953	100736393	20992757182	,	,	,
304953	100736393	20992757183	along	along	RP_II
304953	100736393	20992757184	together	together	RL
304953	100736393	20992757185	using	use	VVG
304953	100736393	20992757186	elements	element	NN2
304953	100736393	20992757187	we	we	PPIS2
304953	100736393	20992757188	really	really	RR
304953	100736393	20992757189	should	should	VM
304953	100736393	20992757190	have	have	VHI
304953	100736393	20992757191	.	.	.
304953	100736393	20992757192	All	all	RR31
304953	100736393	20992757193	the	the	RR32
304953	100736393	20992757194	same	same	RR33
304953	100736393	20992757195	,	,	,
304953	100736393	20992757196	you	you	PPY
304953	100736393	20992757197	would	would	VM
304953	100736393	20992757198	plan	plan	VVI
304953	100736393	20992757199	to	to	TO
304953	100736393	20992757200	isolate	isolate	VVI
304953	100736393	20992757201	your	your	APPGE
304953	100736393	20992757202	overall	overall	NN1
304953	100736393	20992757203	expects	expect	VVZ
304953	100736393	20992757204	from	from	II
304953	100736393	20992757205	each	each	DD1
304953	100736393	20992757206	one	one	PN1
304953	100736393	20992757207	of	of	IO
304953	100736393	20992757208	the	the	AT
304953	100736393	20992757209	really	really	RR
304953	100736393	20992757210	expects	expect	VVZ
304953	100736393	20992757211	.	.	.
304953	100736393	20992757212	If	if	CS
304953	100736393	20992757213	you	you	PPY
304953	100736393	20992757214	might	might	VM
304953	100736393	20992757215	fitting	fitting	NN1_JJ
304953	100736393	20992757216	in	in	II
304953	100736393	20992757217	using	use	VVG
304953	100736393	20992757218	boost	boost	VV0_NN1
304953	100736393	20992757219	your	your	APPGE
304953	100736393	20992757220	overall	overall	JJ_NN1
304953	100736393	20992757221	crdiet		NN1
304953	100736393	20992757222	score	score	NN1_VV0
304953	100736393	20992757223	get	get	VV0
304953	100736393	20992757224	make	make	VV0
304953	100736393	20992757225	several	several	DA2
304953	100736393	20992757226	trade-offs	trade-off	NN2
304953	100736393	20992757227	.	.	.
304953	100736393	20992757228	As	as	II_CSA
304953	100736393	20992757229	a	a	AT1
304953	100736393	20992757230	superb	superb	JJ
304953	100736393	20992757231	illustration	illustration	NN1
304953	100736393	20992757232	it	it	PPH1
304953	100736393	20992757233	is	be	VBZ
304953	100736393	20992757234	easy	easy	JJ
304953	100736393	20992757235	to	to	TO
304953	100736393	20992757236	retailer		VVI
304953	100736393	20992757237	via	via	II
304953	100736393	20992757238	line	line	NN1
304953	100736393	20992757239	to	to	TO
304953	100736393	20992757240	use	use	VVI
304953	100736393	20992757241	less	less	RRR_DAR
304953	100736393	20992757242	combined	combine	VVN
304953	100736393	20992757243	with	with	IW
304953	100736393	20992757244	you	you	PPY
304953	100736393	20992757245	will	will	VM
304953	100736393	20992757246	probably	probably	RR
304953	100736393	20992757247	can	can	VM
304953	100736393	20992757248	analyze	analyze	VVI
304953	100736393	20992757249	pre-owned	pre-owned	JJ_NN1
304953	100736393	20992757250	merchants	merchant	NN2
304953	100736393	20992757251	beyond	beyond	II
304953	100736393	20992757252	high-priced	high-priced	JJ_NN1
304953	100736393	20992757253	chain	chain	NN1
304953	100736393	20992757254	stores	store	NN2
304953	100736393	20992757255	concerning	concerning	II_VVG
304953	100736393	20992757256	gear	gear	NN1
304953	100736393	20992757257	.	.	.
304953	100736393	20992757258	46996		MC
304953	100736393	20992757259	@qwx906996		FO
304953	100736396	20992757279	@@##	----------	----------
304953	100736396	20992757280	@@100736396		FO
304953	100736396	20992757281	@4936396/		VV0_NN1
304953	100736396	20992757282	46989		MC
304953	100736396	20992757283	@qwx906989		FO
304953	100736396	20992757284	<p>		NULL
304953	100736396	20992757285	Obesity	obesity	NN1_NP1@
304953	100736396	20992757286	has	have	VHZ
304953	100736396	20992757287	been	be	VBN
304953	100736396	20992757288	linked	link	VVN
304953	100736396	20992757289	to	to	II
304953	100736396	20992757290	death	death	NN1
304953	100736396	20992757291	from	from	II
304953	100736396	20992757292	a	a	AT1
304953	100736396	20992757293	variety	variety	NN1
304953	100736396	20992757294	of	of	IO
304953	100736396	20992757295	cancers	cancer	NN2
304953	100736396	20992757296	,	,	,
304953	100736396	20992757297	including	including	II_VVG@
304953	100736396	20992757298	colon	colon	NN1
304953	100736396	20992757299	and	and	CC
304953	100736396	20992757300	breast	breast	NN1
304953	100736396	20992757301	cancers	cancer	NN2
304953	100736396	20992757302	.	.	.
304953	100736396	20992757303	The	the	AT
304953	100736396	20992757304	biological	biological	JJ
304953	100736396	20992757305	impact	impact	NN1
304953	100736396	20992757306	of	of	IO
304953	100736396	20992757307	obesity	obesity	NN1
304953	100736396	20992757308	shoulders	shoulder	NN2_VVZ%
304953	100736396	20992757309	some	some	DD
304953	100736396	20992757310	of	of	IO
304953	100736396	20992757311	the	the	AT
304953	100736396	20992757312	blame	blame	NN1
304953	100736396	20992757313	,	,	,
304953	100736396	20992757314	but	but	CCB
304953	100736396	20992757315	excess	excess	JJ
304953	100736396	20992757316	body	body	NN1
304953	100736396	20992757317	fat	fat	NN1
304953	100736396	20992757318	can	can	VM
304953	100736396	20992757319	also	also	RR
304953	100736396	20992757320	interfere	interfere	VVI
304953	100736396	20992757321	with	with	IW
304953	100736396	20992757322	imaging	image	VVG_NN1_JJ@
304953	100736396	20992757323	tests	test	NN2
304953	100736396	20992757324	and	and	CC
304953	100736396	20992757325	hinder	hinder	VVI
304953	100736396	20992757326	physical	physical	JJ
304953	100736396	20992757327	examination	examination	NN1
304953	100736396	20992757328	.	.	.
304953	100736396	20992757329	Multiple	multiple	JJ_NN1
304953	100736396	20992757330	studies	study	NN2
304953	100736396	20992757331	have	have	VH0
304953	100736396	20992757332	also	also	RR
304953	100736396	20992757333	found	find	VVN
304953	100736396	20992757334	that	that	CST_DD1
304953	100736396	20992757335	obese	obese	JJ
304953	100736396	20992757336	men	man	NN2
304953	100736396	20992757337	have	have	VH0
304953	100736396	20992757338	lower	low	JJR_RRR@
304953	100736396	20992757339	PSA	psa	NP1
304953	100736396	20992757340	concentrations	concentration	NN2
304953	100736396	20992757341	than	than	CSN
304953	100736396	20992757342	those	those	DD2
304953	100736396	20992757343	with	with	IW
304953	100736396	20992757344	healthier	healthy	JJR
304953	100736396	20992757345	weights	weight	NN2
304953	100736396	20992757346	.	.	.
304953	100736396	20992757347	Why	why	RRQ
304953	100736396	20992757348	?	?	?
304953	100736396	20992757349	One	one	MC1
304953	100736396	20992757350	theory	theory	NN1
304953	100736396	20992757351	is	be	VBZ
304953	100736396	20992757352	that	that	DD1_CST_RG%
304953	100736396	20992757353	obese	obese	JJ
304953	100736396	20992757354	men	man	NN2
304953	100736396	20992757355	simply	simply	RR
304953	100736396	20992757356	have	have	VH0
304953	100736396	20992757357	less	less	RGR_DAR
304953	100736396	20992757358	hormonal	hormonal	JJ
304953	100736396	20992757359	activity	activity	NN1
304953	100736396	20992757360	.	.	.
304953	100736396	20992757361	Recently	recently	RR
304953	100736396	20992757362	,	,	,
304953	100736396	20992757363	a	a	AT1
304953	100736396	20992757364	team	team	NN1
304953	100736396	20992757365	of	of	IO
304953	100736396	20992757366	researchers	researcher	NN2
304953	100736396	20992757367	tested	test	VVD_VVN
304953	100736396	20992757368	another	another	DD1
304953	100736396	20992757369	hypothesis	hypothesis	NN1
304953	100736396	20992757370	:	:	:
304953	100736396	20992757371	obese	obese	JJ
304953	100736396	20992757372	men	man	NN2
304953	100736396	20992757373	have	have	VH0
304953	100736396	20992757374	a	a	AT1
304953	100736396	20992757375	higher	high	JJR
304953	100736396	20992757376	volume	volume	NN1
304953	100736396	20992757377	of	of	IO
304953	100736396	20992757378	plasma	plasma	NN1
304953	100736396	20992757379	in	in	II
304953	100736396	20992757380	their	their	APPGE
304953	100736396	20992757381	circulation	circulation	NN1
304953	100736396	20992757382	,	,	,
304953	100736396	20992757383	essentially	essentially	RR
304953	100736396	20992757384	diluting	dilute	VVG
304953	100736396	20992757385	the	the	AT
304953	100736396	20992757386	concentration	concentration	NN1
304953	100736396	20992757387	of	of	IO
304953	100736396	20992757388	PSA	psa	NP1
304953	100736396	20992757389	.	.	.
304953	100736396	20992757390	<p>		NULL
304953	100736396	20992757391	The	the	AT
304953	100736396	20992757392	researchers	researcher	NN2
304953	100736396	20992757393	tested	test	VVD_VVN
304953	100736396	20992757394	the	the	AT
304953	100736396	20992757395	idea	idea	NN1
304953	100736396	20992757396	in	in	II_RP@
304953	100736396	20992757397	nearly	nearly	RR
304953	100736396	20992757398	14,000	14,000	MC
304953	100736396	20992757399	men	man	NN2
304953	100736396	20992757400	,	,	,
304953	100736396	20992757401	drawn	draw	VVN
304953	100736396	20992757402	from	from	II
304953	100736396	20992757403	three	three	MC
304953	100736396	20992757404	different	different	JJ
304953	100736396	20992757405	patient	patient	JJ_NN1
304953	100736396	20992757406	databases	database	NN2
304953	100736396	20992757407	,	,	,
304953	100736396	20992757408	all	all	DB
304953	100736396	20992757409	of	of	IO
304953	100736396	20992757410	whom	whom	PNQO
304953	100736396	20992757411	had	have	VHD
304953	100736396	20992757412	had	have	VHN
304953	100736396	20992757413	a	a	AT1
304953	100736396	20992757414	radical	radical	JJ_NN1
304953	100736396	20992757415	prostatectomy	prostatectomy	NN1
304953	100736396	20992757416	.	.	.
304953	100736396	20992757417	They	they	PPHS2
304953	100736396	20992757418	found	find	VVD
304953	100736396	20992757419	that	that	CST_DD1
304953	100736396	20992757420	obese	obese	JJ
304953	100736396	20992757421	men	man	NN2
304953	100736396	20992757422	not	not	XX
304953	100736396	20992757423	only	only	JJ
304953	100736396	20992757424	had	had-	VHN
304953	100736396	20992757425	lower	low	JJR_RRR@_VV0@
304953	100736396	20992757426	PSA	psa	NP1
304953	100736396	20992757427	values	value	NN2_VVZ@
304953	100736396	20992757428	on	on	II
304953	100736396	20992757429	average	average	NN1_JJ
304953	100736396	20992757430	,	,	,
304953	100736396	20992757431	but	but	CCB
304953	100736396	20992757432	also	also	RR
304953	100736396	20992757433	a	a	AT1
304953	100736396	20992757434	greater	great	JJR
304953	100736396	20992757435	volume	volume	NN1
304953	100736396	20992757436	of	of	IO
304953	100736396	20992757437	plasma	plasma	NN1
304953	100736396	20992757438	.	.	.
304953	100736396	20992757439	The	the	AT
304953	100736396	20992757440	PSA	psa	NP1
304953	100736396	20992757441	mass		NN1_VV0%
304953	100736396	20992757442	"	"	"
304953	100736396	20992757443	the	the	AT
304953	100736396	20992757444	actual	actual	JJ
304953	100736396	20992757445	amount	amount	NN1
304953	100736396	20992757446	of	of	IO
304953	100736396	20992757447	PSA	psa	NP1
304953	100736396	20992757448	in	in	II
304953	100736396	20992757449	the	the	AT
304953	100736396	20992757450	blood	blood	NN1
304953	100736396	20992757451	"	"	"
304953	100736396	20992757452	was	be	VBDZ
304953	100736396	20992757453	similar	similar	JJ
304953	100736396	20992757454	to	to	II
304953	100736396	20992757455	that	that	DD1
304953	100736396	20992757456	in	in	II
304953	100736396	20992757457	non-obese	non-obese	JJ
304953	100736396	20992757458	men	man	NN2
304953	100736396	20992757459	.	.	.
304953	100736396	20992757460	Given	give	VVN
304953	100736396	20992757461	the	the	AT
304953	100736396	20992757462	greater	great	JJR
304953	100736396	20992757463	volume	volume	NN1
304953	100736396	20992757464	of	of	IO
304953	100736396	20992757465	fluid	fluid	NN1
304953	100736396	20992757466	in	in	II
304953	100736396	20992757467	the	the	AT
304953	100736396	20992757468	blood	blood	NN1
304953	100736396	20992757469	,	,	,
304953	100736396	20992757470	PSA	psa	NP1
304953	100736396	20992757471	@		II
304953	100736396	20992757472	@		II
304953	100736396	20992757473	@		II
304953	100736396	20992757474	@		II
304953	100736396	20992757475	@		II
304953	100736396	20992757476	@		II
304953	100736396	20992757477	@		II
304953	100736396	20992757478	@		II
304953	100736396	20992757479	@		II
304953	100736396	20992757480	@		II
304953	100736396	20992757481	<p>		NULL
304953	100736396	20992757482	With	with	IW
304953	100736396	20992757483	seemingly	seemingly	RR
304953	100736396	20992757484	low	low	JJ
304953	100736396	20992757485	PSAs	psas	NP2
304953	100736396	20992757486	,	,	,
304953	100736396	20992757487	fewer	fewer	DAR
304953	100736396	20992757488	obese	obese	JJ
304953	100736396	20992757489	men	man	NN2
304953	100736396	20992757490	have	have	VH0
304953	100736396	20992757491	prostate	prostate	NN1
304953	100736396	20992757492	biopsies	biopsy	NN2
304953	100736396	20992757493	,	,	,
304953	100736396	20992757494	leaving	leave	VVG
304953	100736396	20992757495	their	their	APPGE
304953	100736396	20992757496	cancers	cancer	NN2
304953	100736396	20992757497	undetected	undetected	JJ
304953	100736396	20992757498	until	until	CS
304953	100736396	20992757499	they	they	PPHS2
304953	100736396	20992757500	are	be	VBR
304953	100736396	20992757501	larger	large	JJR
304953	100736396	20992757502	,	,	,
304953	100736396	20992757503	and	and	CC
304953	100736396	20992757504	thus	thus	RR
304953	100736396	20992757505	more	more	RGR
304953	100736396	20992757506	difficult	difficult	JJ
304953	100736396	20992757507	to	to	TO
304953	100736396	20992757508	treat	treat	VVI
304953	100736396	20992757509	.	.	.
304953	100736396	20992757510	However	however	RR
304953	100736396	20992757511	,	,	,
304953	100736396	20992757512	the	the	AT
304953	100736396	20992757513	degree	degree	NN1
304953	100736396	20992757514	to	to	II
304953	100736396	20992757515	which	which	DDQ
304953	100736396	20992757516	that	that	DD1
304953	100736396	20992757517	contributes	contribute	VVZ
304953	100736396	20992757518	to	to	II
304953	100736396	20992757519	worsened	worsen	VVD_VVN
304953	100736396	20992757520	outcomes	outcome	NN2
304953	100736396	20992757521	,	,	,
304953	100736396	20992757522	the	the	AT
304953	100736396	20992757523	researchers	researcher	NN2
304953	100736396	20992757524	say	say	VV0
304953	100736396	20992757525	,	,	,
304953	100736396	20992757526	remains	remain	VVZ
304953	100736396	20992757527	to	to	TO
304953	100736396	20992757528	be	be	VBI
304953	100736396	20992757529	determined	determine	VVN
304953	100736396	20992757530	.	.	.
304953	100736396	20992757531	46996		MC
304953	100736396	20992757532	@qwx906996		FO
304953	100736399	20992757552	@@##	----------	----------
304953	100736399	20992757553	@@100736399		FO
304953	100736399	20992757554	@4936399/		VV0_NN1
304953	100736399	20992757555	46989		MC
304953	100736399	20992757556	@qwx906989		FO
304953	100736399	20992757557	<p>		NULL
304953	100736399	20992757558	Based	base	VVN
304953	100736399	20992757559	on	on	II
304953	100736399	20992757560	data	data	NN
304953	100736399	20992757561	from	from	II
304953	100736399	20992757562	the	the	AT
304953	100736399	20992757563	Geneva	geneva	NP1
304953	100736399	20992757564	Cancer	cancer	NN1
304953	100736399	20992757565	Registry	registry	NN1
304953	100736399	20992757566	,	,	,
304953	100736399	20992757567	men	man	NN2
304953	100736399	20992757568	who	who	PNQS
304953	100736399	20992757569	undergo	undergo	VV0
304953	100736399	20992757570	external	external	JJ
304953	100736399	20992757571	beam	beam	NN1
304953	100736399	20992757572	radiation	radiation	NN1
304953	100736399	20992757573	for	for	IF
304953	100736399	20992757574	prostate	prostate	NN1
304953	100736399	20992757575	cancer	cancer	NN1
304953	100736399	20992757576	may	may	VM
304953	100736399	20992757577	have	have	VHI
304953	100736399	20992757578	an	a	AT1
304953	100736399	20992757579	increased	increased	JJ
304953	100736399	20992757580	,	,	,
304953	100736399	20992757581	though	though	CS
304953	100736399	20992757582	still	still	RR
304953	100736399	20992757583	small	small	JJ
304953	100736399	20992757584	,	,	,
304953	100736399	20992757585	risk	risk	VV0_NN1
304953	100736399	20992757586	for	for	IF
304953	100736399	20992757587	colon	colon	NN1
304953	100736399	20992757588	cancer	cancer	NN1
304953	100736399	20992757589	compared	compare	VVN
304953	100736399	20992757590	with	with	IW
304953	100736399	20992757591	men	man	NN2
304953	100736399	20992757592	who	who	PNQS
304953	100736399	20992757593	do	do	VD0
304953	100736399	20992757594	not	not	XX
304953	100736399	20992757595	receive	receive	VVI
304953	100736399	20992757596	radiation	radiation	NN1
304953	100736399	20992757597	for	for	IF
304953	100736399	20992757598	their	their	APPGE
304953	100736399	20992757599	disease	disease	NN1
304953	100736399	20992757600	.	.	.
304953	100736399	20992757601	<p>		NULL
304953	100736399	20992757602	Swiss	swiss	JJ
304953	100736399	20992757603	researchers	researcher	NN2
304953	100736399	20992757604	analyzed	analyze	VVD
304953	100736399	20992757605	data	data	NN
304953	100736399	20992757606	on	on	II
304953	100736399	20992757607	1,134	1,134	MC
304953	100736399	20992757608	men	man	NN2
304953	100736399	20992757609	with	with	IW
304953	100736399	20992757610	prostate	prostate	NN1
304953	100736399	20992757611	cancer	cancer	NN1
304953	100736399	20992757612	between	between	II
304953	100736399	20992757613	1980	1980	MC
304953	100736399	20992757614	and	and	CC
304953	100736399	20992757615	1998	1998	MC
304953	100736399	20992757616	who	who	PNQS
304953	100736399	20992757617	survived	survive	VVD
304953	100736399	20992757618	at	at	RR21
304953	100736399	20992757619	least	least	RR22
304953	100736399	20992757620	five	five	MC
304953	100736399	20992757621	years	year	NNT2
304953	100736399	20992757622	following	following	RA@_VVG_II@
304953	100736399	20992757623	diagnosis	diagnosis	NN1
304953	100736399	20992757624	.	.	.
304953	100736399	20992757625	Of	of	IO
304953	100736399	20992757626	that	that	DD1
304953	100736399	20992757627	group	group	NN1
304953	100736399	20992757628	,	,	,
304953	100736399	20992757629	264	264	MC
304953	100736399	20992757630	were	be	VBDR
304953	100736399	20992757631	treated	treat	VVN
304953	100736399	20992757632	with	with	IW
304953	100736399	20992757633	external	external	JJ
304953	100736399	20992757634	beam	beam	NN1
304953	100736399	20992757635	radiation	radiation	NN1
304953	100736399	20992757636	.	.	.
304953	100736399	20992757637	By	by	II
304953	100736399	20992757638	the	the	AT
304953	100736399	20992757639	end	end	NN1
304953	100736399	20992757640	of	of	IO
304953	100736399	20992757641	2003	2003	MC
304953	100736399	20992757642	,	,	,
304953	100736399	20992757643	19	19	MC
304953	100736399	20992757644	of	of	IO
304953	100736399	20992757645	those	those	DD2
304953	100736399	20992757646	men	man	NN2
304953	100736399	20992757647	had	have	VHD
304953	100736399	20992757648	been	be	VBN
304953	100736399	20992757649	diagnosed	diagnose	VVN
304953	100736399	20992757650	with	with	IW
304953	100736399	20992757651	colorectal	colorectal	JJ
304953	100736399	20992757652	cancer	cancer	NN1
304953	100736399	20992757653	,	,	,
304953	100736399	20992757654	making	make	VVG
304953	100736399	20992757655	the	the	AT
304953	100736399	20992757656	risk	risk	NN1
304953	100736399	20992757657	of	of	IO
304953	100736399	20992757658	developing	develop	VVG
304953	100736399	20992757659	this	this	DD1
304953	100736399	20992757660	cancer	cancer	NN1
304953	100736399	20992757661	3.4	3.4	MC
304953	100736399	20992757662	times	time	NNT2
304953	100736399	20992757663	greater	great	JJR
304953	100736399	20992757664	among	among	II
304953	100736399	20992757665	patients	patient	NN2
304953	100736399	20992757666	who	who	PNQS
304953	100736399	20992757667	received	receive	VVD
304953	100736399	20992757668	radiation	radiation	NN1
304953	100736399	20992757669	than	than	CSN
304953	100736399	20992757670	among	among	II
304953	100736399	20992757671	those	those	DD2
304953	100736399	20992757672	prostate	prostate	NN1
304953	100736399	20992757673	cancer	cancer	NN1
304953	100736399	20992757674	patients	patient	NN2
304953	100736399	20992757675	who	who	PNQS
304953	100736399	20992757676	opted	opt	VVD
304953	100736399	20992757677	for	for	IF
304953	100736399	20992757678	a	a	AT1
304953	100736399	20992757679	different	different	JJ
304953	100736399	20992757680	form	form	NN1
304953	100736399	20992757681	of	of	IO
304953	100736399	20992757682	treatment	treatment	NN1
304953	100736399	20992757683	.	.	.
304953	100736399	20992757684	The	the	AT
304953	100736399	20992757685	risk	risk	NN1
304953	100736399	20992757686	was	be	VBDZ
304953	100736399	20992757687	significantly	significantly	RR
304953	100736399	20992757688	higher	high	JJR
304953	100736399	20992757689	for	for	IF
304953	100736399	20992757690	colon	colon	NN1
304953	100736399	20992757691	cancer	cancer	NN1
304953	100736399	20992757692	,	,	,
304953	100736399	20992757693	but	but	CCB
304953	100736399	20992757694	not	not	XX
304953	100736399	20992757695	for	for	IF
304953	100736399	20992757696	rectal	rectal	JJ
304953	100736399	20992757697	cancer	cancer	NN1
304953	100736399	20992757698	.	.	.
304953	100736399	20992757699	<p>		NULL
304953	100736399	20992757700	The	the	AT
304953	100736399	20992757701	findings	finding	NN2
304953	100736399	20992757702	may	may	VM
304953	100736399	20992757703	not	not	XX
304953	100736399	20992757704	apply	apply	VVI
304953	100736399	20992757705	to	to	II
304953	100736399	20992757706	patients	patient	NN2
304953	100736399	20992757707	who	who	PNQS
304953	100736399	20992757708	received	receive	VVD
304953	100736399	20992757709	radiation	radiation	NN1
304953	100736399	20992757710	more	more	RGR_RRR
304953	100736399	20992757711	recently	recently	RR
304953	100736399	20992757712	,	,	,
304953	100736399	20992757713	the	the	AT
304953	100736399	20992757714	researchers	researcher	NN2
304953	100736399	20992757715	note	note	VV0
304953	100736399	20992757716	,	,	,
304953	100736399	20992757717	because	because	CS
304953	100736399	20992757718	treatment	treatment	NN1
304953	100736399	20992757719	has	have	VHZ
304953	100736399	20992757720	become	become	VVN@
304953	100736399	20992757721	much	much	DA1_RR
304953	100736399	20992757722	more	more	DAR_RRR
304953	100736399	20992757723	targeted	target	VVN_VVD
304953	100736399	20992757724	.	.	.
304953	100736399	20992757725	Patients	patient	NN2
304953	100736399	20992757726	now	now	RT
304953	100736399	20992757727	receive	receive	VV0
304953	100736399	20992757728	radiation	radiation	NN1
304953	100736399	20992757729	that	that	CST_DD1
304953	100736399	20992757730	conforms	conform	VVZ
304953	100736399	20992757731	to	to	II
304953	100736399	20992757732	the	the	AT
304953	100736399	20992757733	shape	shape	NN1
304953	100736399	20992757734	of	of	IO
304953	100736399	20992757735	the	the	AT
304953	100736399	20992757736	prostate	prostate	NN1
304953	100736399	20992757737	,	,	,
304953	100736399	20992757738	sparing	spare	VVG
304953	100736399	20992757739	nearby	nearby	JJ_RL
304953	100736399	20992757740	structures	structure	NN2
304953	100736399	20992757741	like	like	II
304953	100736399	20992757742	the	the	AT
304953	100736399	20992757743	colon	colon	NN1
304953	100736399	20992757744	@		II
304953	100736399	20992757745	@		II
304953	100736399	20992757746	@		II
304953	100736399	20992757747	@		II
304953	100736399	20992757748	@		II
304953	100736399	20992757749	@		II
304953	100736399	20992757750	@		II
304953	100736399	20992757751	@		II
304953	100736399	20992757752	@		II
304953	100736399	20992757753	@		II
304953	100736399	20992757754	physicians	physician	NN2
304953	100736399	20992757755	should	should	VM
304953	100736399	20992757756	monitor	monitor	VVI
304953	100736399	20992757757	radiation	radiation	NN1
304953	100736399	20992757758	patients	patient	NN2
304953	100736399	20992757759	for	for	IF
304953	100736399	20992757760	colorectal	colorectal	JJ
304953	100736399	20992757761	cancer	cancer	NN1
304953	100736399	20992757762	,	,	,
304953	100736399	20992757763	especially	especially	RR
304953	100736399	20992757764	five	five	MC
304953	100736399	20992757765	to	to	II
304953	100736399	20992757766	nine	nine	MC
304953	100736399	20992757767	years	year	NNT2
304953	100736399	20992757768	after	after	II_CS
304953	100736399	20992757769	the	the	AT
304953	100736399	20992757770	initial	initial	JJ_NN1
304953	100736399	20992757771	treatment	treatment	NN1
304953	100736399	20992757772	;	;	;
304953	100736399	20992757773	that	that	DD1
304953	100736399	20992757774	's	be	VBZ
304953	100736399	20992757775	when	when	RRQ
304953	100736399	20992757776	the	the	AT
304953	100736399	20992757777	cancers	cancer	NN2
304953	100736399	20992757778	are	be	VBR
304953	100736399	20992757779	most	most	RGT
304953	100736399	20992757780	likely	likely	JJ
304953	100736399	20992757781	to	to	TO
304953	100736399	20992757782	emerge	emerge	VVI
304953	100736399	20992757783	.	.	.
304953	100736399	20992757784	46996		MC
304953	100736399	20992757785	@qwx906996		FO
304953	100736400	20992757805	@@##	----------	----------
304953	100736400	20992757806	@@100736400		FO
304953	100736400	20992757807	@4936400/		VV0_NN1
304953	100736400	20992757808	46989		MC
304953	100736400	20992757809	@qwx906989		FO
304953	100736400	20992757810	<p>		NULL
304953	100736400	20992757811	Welcome	welcome	VV0
304953	100736400	20992757812	!	!	!
304953	100736400	20992757813	This	this	DD1
304953	100736400	20992757814	Web	web	NN1
304953	100736400	20992757815	site	site	NN1
304953	100736400	20992757816	combines	combine	VVZ
304953	100736400	20992757817	prostate	prostate	NN1
304953	100736400	20992757818	cancer	cancer	NN1
304953	100736400	20992757819	news	news	NN1
304953	100736400	20992757820	,	,	,
304953	100736400	20992757821	expert	expert	NN1_JJ@
304953	100736400	20992757822	commentary	commentary	NN1
304953	100736400	20992757823	,	,	,
304953	100736400	20992757824	relevant	relevant	JJ
304953	100736400	20992757825	clinical	clinical	JJ
304953	100736400	20992757826	findings	finding	NN2
304953	100736400	20992757827	,	,	,
304953	100736400	20992757828	updates	update	VVZ_NN2
304953	100736400	20992757829	on	on	II
304953	100736400	20992757830	important	important	JJ
304953	100736400	20992757831	prostate	prostate	NN1
304953	100736400	20992757832	cancer	cancer	NN1
304953	100736400	20992757833	research	research	NN1
304953	100736400	20992757834	,	,	,
304953	100736400	20992757835	and	and	CC
304953	100736400	20992757836	personal	personal	JJ
304953	100736400	20992757837	case	case	NN1
304953	100736400	20992757838	histories	history	NN2
304953	100736400	20992757839	to	to	TO
304953	100736400	20992757840	help	help	VVI
304953	100736400	20992757841	you	you	PPY
304953	100736400	20992757842	fully	fully	RR
304953	100736400	20992757843	understand	understand	VV0
304953	100736400	20992757844	the	the	AT
304953	100736400	20992757845	important	important	JJ
304953	100736400	20992757846	considerations	consideration	NN2
304953	100736400	20992757847	in	in	II
304953	100736400	20992757848	the	the	AT
304953	100736400	20992757849	diagnosis	diagnosis	NN1
304953	100736400	20992757850	and	and	CC
304953	100736400	20992757851	treatment	treatment	NN1
304953	100736400	20992757852	of	of	IO
304953	100736400	20992757853	disorders	disorder	NN2
304953	100736400	20992757854	of	of	IO
304953	100736400	20992757855	the	the	AT
304953	100736400	20992757856	prostate	prostate	NN1
304953	100736400	20992757857	.	.	.
304953	100736400	20992757858	We	we	PPIS2
304953	100736400	20992757859	hope	hope	VV0
304953	100736400	20992757860	you	you	PPY
304953	100736400	20992757861	find	find	VV0
304953	100736400	20992757862	it	it	PPH1
304953	100736400	20992757863	useful	useful	JJ
304953	100736400	20992757864	.	.	.
304953	100736400	20992757865	<h>		NULL
304953	100736400	20992757866	PSA	psa	NP1
304953	100736400	20992757867	screening	screening	NN1_VVG
304953	100736400	20992757868	not	not	XX
304953	100736400	20992757869	recommended	recommend	VVN
304953	100736400	20992757870	for	for	IF
304953	100736400	20992757871	men	man	NN2
304953	100736400	20992757872	over	over	II
304953	100736400	20992757873	age	age	NN1
304953	100736400	20992757874	75	75	MC
304953	100736400	20992757875	<p>		NULL
304953	100736400	20992757876	Cancers	cancer	NN2
304953	100736400	20992757877	discovered	discover	VVD_VVN@
304953	100736400	20992757878	through	through	II
304953	100736400	20992757879	PSA	psa	NP1
304953	100736400	20992757880	testing	testing	NN1
304953	100736400	20992757881	can	can	VM
304953	100736400	20992757882	take	take	VVI
304953	100736400	20992757883	years	year	NNT2
304953	100736400	20992757884	to	to	TO
304953	100736400	20992757885	affect	affect	VVI
304953	100736400	20992757886	health	health	NN1
304953	100736400	20992757887	.	.	.
304953	100736400	20992757888	That 's		NN2_VVZ
304953	100736400	20992757889	why	why	RRQ
304953	100736400	20992757890	the	the	AT
304953	100736400	20992757891	U.S.	us	NP1
304953	100736400	20992757892	Preventive	preventive	JJ
304953	100736400	20992757893	Services	service	NN2
304953	100736400	20992757894	Task	task	NN1
304953	100736400	20992757895	Force	force	NN1
304953	100736400	20992757896	recommends	recommend	VVZ
304953	100736400	20992757897	that	that	CST
304953	100736400	20992757898	doctors	doctor	NN2
304953	100736400	20992757899	stop	stop	VV0
304953	100736400	20992757900	testing	test	VVG_NN1_JJ@
304953	100736400	20992757901	men	man	NN2
304953	100736400	20992757902	who	who	PNQS
304953	100736400	20992757903	are	be	VBR
304953	100736400	20992757904	75	75	MC
304953	100736400	20992757905	or	or	CC
304953	100736400	20992757906	older	old	JJR
304953	100736400	20992757907	.	.	.
304953	100736400	20992757908	Anthony	anthony	NP1
304953	100736400	20992757909	Komaroff	komaroff	NP1
304953	100736400	20992757910	,	,	,
304953	100736400	20992757911	M.D.	m.d	NNA
304953	100736400	20992757912	,	,	,
304953	100736400	20992757913	discusses	discuss	VVZ
304953	100736400	20992757914	the	the	AT
304953	100736400	20992757915	panels	panel	NN2
304953	100736400	20992757916	recommendation	recommendation	NN1
304953	100736400	20992757917	.	.	.
304953	100736400	20992757918	Watch	watch	VV0
304953	100736400	20992757919	the	the	AT
304953	100736400	20992757920	video	video	NN1
304953	100736400	20992757921	<h>		NULL
304953	100736400	20992757922	Are	be	VBR
304953	100736400	20992757923	PSA	psa	NP1
304953	100736400	20992757924	tests	test	VVZ@_NN2
304953	100736400	20992757925	beneficial	beneficial	JJ
304953	100736400	20992757926	?	?	?
304953	100736400	20992757927	<p>		NULL
304953	100736400	20992757928	Two	two	MC
304953	100736400	20992757929	large	large	JJ
304953	100736400	20992757930	randomized	randomized	JJ@
304953	100736400	20992757931	studies	study	NN2
304953	100736400	20992757932	,	,	,
304953	100736400	20992757933	one	one	PN1_MC1
304953	100736400	20992757934	in	in	II
304953	100736400	20992757935	the	the	AT
304953	100736400	20992757936	U.S.	us	NP1
304953	100736400	20992757937	and	and	CC
304953	100736400	20992757938	one	one	PN1_MC1
304953	100736400	20992757939	in	in	II
304953	100736400	20992757940	Europe	europe	NP1
304953	100736400	20992757941	,	,	,
304953	100736400	20992757942	come	come	VV0_VVN@
304953	100736400	20992757943	to	to	II
304953	100736400	20992757944	different	different	JJ
304953	100736400	20992757945	conclusions	conclusion	NN2
304953	100736400	20992757946	about	about	II
304953	100736400	20992757947	whether	whether	CSW
304953	100736400	20992757948	screening	screening	NN1_VVG
304953	100736400	20992757949	saves	save	VVZ_NN2
304953	100736400	20992757950	lives	life	NN2_VVZ
304953	100736400	20992757951	.	.	.
304953	100736400	20992757952	Harvey	harvey	NP1
304953	100736400	20992757953	Simon	simon	NP1
304953	100736400	20992757954	,	,	,
304953	100736400	20992757955	M.D.	m.d	NNA
304953	100736400	20992757956	,	,	,
304953	100736400	20992757957	summarizes	summarize	VVZ
304953	100736400	20992757958	the	the	AT
304953	100736400	20992757959	studies	study	NN2
304953	100736400	20992757960	findings	finding	NN2
304953	100736400	20992757961	and	and	CC
304953	100736400	20992757962	outlines	outline	NN2
304953	100736400	20992757963	the	the	AT
304953	100736400	20992757964	pros	pro	NN2
304953	100736400	20992757965	and	and	CC
304953	100736400	20992757966	cons	con	NN2
304953	100736400	20992757967	of	of	IO
304953	100736400	20992757968	screening.Read		NNU
304953	100736400	20992757969	the	the	AT
304953	100736400	20992757970	article	article	NN1
304953	100736400	20992757971	<h>		NULL
304953	100736400	20992757972	Interactive	interactive	JJ
304953	100736400	20992757973	guide	guide	NN1
304953	100736400	20992757974	to	to	II
304953	100736400	20992757975	PSA	psa	NP1
304953	100736400	20992757976	<p>		NULL
304953	100736400	20992757977	Prostate-specific	prostate-specific	JJ
304953	100736400	20992757978	antigen	antigen	NN1
304953	100736400	20992757979	,	,	,
304953	100736400	20992757980	or	or	CC
304953	100736400	20992757981	PSA	psa	NP1
304953	100736400	20992757982	,	,	,
304953	100736400	20992757983	is	be	VBZ
304953	100736400	20992757984	a	a	AT1
304953	100736400	20992757985	blood	blood	NN1
304953	100736400	20992757986	test	test	NN1
304953	100736400	20992757987	used	use	VVN
304953	100736400	20992757988	by	by	II
304953	100736400	20992757989	many	many	DA2
304953	100736400	20992757990	doctors	doctor	NN2
304953	100736400	20992757991	to	to	TO
304953	100736400	20992757992	screen	screen	VVI
304953	100736400	20992757993	for	for	IF
304953	100736400	20992757994	prostate	prostate	NN1
304953	100736400	20992757995	cancer	cancer	NN1
304953	100736400	20992757996	.	.	.
304953	100736400	20992757997	@		II
304953	100736400	20992757998	@		II
304953	100736400	20992757999	@		II
304953	100736400	20992758000	@		II
304953	100736400	20992758001	@		II
304953	100736400	20992758002	@		II
304953	100736400	20992758003	@		II
304953	100736400	20992758004	@		II
304953	100736400	20992758005	@		II
304953	100736400	20992758006	@		II
304953	100736400	20992758007	considered	consider	VVD_VVN
304953	100736400	20992758008	reassuring	reassuring	JJ_VVG
304953	100736400	20992758009	or	or	CC
304953	100736400	20992758010	worrisome	worrisome	JJ
304953	100736400	20992758011	for	for	IF
304953	100736400	20992758012	men	man	NN2
304953	100736400	20992758013	of	of	IO
304953	100736400	20992758014	different	different	JJ
304953	100736400	20992758015	ages.Go		NNU
304953	100736400	20992758016	to	to	II
304953	100736400	20992758017	"	"	"
304953	100736400	20992758018	Understanding	understand	VVG_NN1
304953	100736400	20992758019	PSA	psa	NP1
304953	100736400	20992758020	"	"	"
304953	100736400	20992758021	<h>		NULL
304953	100736400	20992758022	Flomax		NP1_NN1
304953	100736400	20992758023	and	and	CC
304953	100736400	20992758024	cataract	cataract	VV0_NN1
304953	100736400	20992758025	surgery	surgery	NN1
304953	100736400	20992758026	<p>		NULL
304953	100736400	20992758027	A	a	AT1
304953	100736400	20992758028	reader	reader	NN1
304953	100736400	20992758029	wonders	wonder	VVZ_NN2
304953	100736400	20992758030	if	if	CS_CSW@
304953	100736400	20992758031	he	he	PPHS1
304953	100736400	20992758032	can	can	VM
304953	100736400	20992758033	have	have	VHI
304953	100736400	20992758034	cataracts	cataract	NN2
304953	100736400	20992758035	removed	remove	VVN
304953	100736400	20992758036	safely	safely	RR
304953	100736400	20992758037	if	if	CS
304953	100736400	20992758038	he	he	PPHS1
304953	100736400	20992758039	takes	take	VVZ
304953	100736400	20992758040	Flomax		NP1_NN1
304953	100736400	20992758041	,	,	,
304953	100736400	20992758042	a	a	AT1
304953	100736400	20992758043	prescription	prescription	NN1
304953	100736400	20992758044	drug	drug	NN1
304953	100736400	20992758045	that	that	CST_DD1
304953	100736400	20992758046	can	can	VM
304953	100736400	20992758047	ease	ease	VVI
304953	100736400	20992758048	the	the	AT
304953	100736400	20992758049	urinary	urinary	JJ_NN1
304953	100736400	20992758050	symptoms	symptom	NN2
304953	100736400	20992758051	of	of	IO
304953	100736400	20992758052	BPH.A		NP1
304953	100736400	20992758053	doctor	doctor	NN1
304953	100736400	20992758054	responds	respond	VVZ
304953	100736400	20992758055	<h>		NULL
304953	100736400	20992758056	Eating	eat	VVG_NN1
304953	100736400	20992758057	for	for	IF
304953	100736400	20992758058	prostate	prostate	NN1
304953	100736400	20992758059	health	health	NN1
304953	100736400	20992758060	<p>		NULL
304953	100736400	20992758061	Two	two	MC
304953	100736400	20992758062	registered	registered	JJ
304953	100736400	20992758063	dietitians	dietitian	NN2
304953	100736400	20992758064	from	from	II
304953	100736400	20992758065	Harvard-affiliated	harvard-affiliated	JJ_NN1
304953	100736400	20992758066	hospitals	hospital	NN2
304953	100736400	20992758067	discuss	discuss	VV0
304953	100736400	20992758068	the	the	AT
304953	100736400	20992758069	benefits	benefit	NN2
304953	100736400	20992758070	of	of	IO
304953	100736400	20992758071	a	a	AT1
304953	100736400	20992758072	diet	diet	NN1
304953	100736400	20992758073	rich	rich	JJ
304953	100736400	20992758074	in	in	II
304953	100736400	20992758075	vegetables	vegetable	NN2
304953	100736400	20992758076	,	,	,
304953	100736400	20992758077	fruits	fruit	NN2
304953	100736400	20992758078	,	,	,
304953	100736400	20992758079	and	and	CC
304953	100736400	20992758080	whole	whole	JJ_NN1
304953	100736400	20992758081	grains.Follow		NNU
304953	100736400	20992758082	the	the	AT
304953	100736400	20992758083	discussion	discussion	NN1
304953	100736400	20992758084	<h>		NULL
304953	100736400	20992758085	Provenge	provenge	NN1_NP1
304953	100736400	20992758086	approved	approve	VVN
304953	100736400	20992758087	by	by	II
304953	100736400	20992758088	FDA	fda	NP1_NN1
304953	100736400	20992758089	<p>		NULL
304953	100736400	20992758090	The	the	AT
304953	100736400	20992758091	"	"	"
304953	100736400	20992758092	vaccine	vaccine	NN1
304953	100736400	20992758093	"	"	"
304953	100736400	20992758094	extends	extend	VVZ
304953	100736400	20992758095	life	life	NN1
304953	100736400	20992758096	by	by	II
304953	100736400	20992758097	a	a	AT1
304953	100736400	20992758098	patients	patient	NN2
304953	100736400	20992758099	own	own	VV0@_DA
304953	100736400	20992758100	immune	immune	JJ
304953	100736400	20992758101	system	system	NN1
304953	100736400	20992758102	to	to	TO
304953	100736400	20992758103	fight	fight	VVI
304953	100736400	20992758104	prostate	prostate	NN1
304953	100736400	20992758105	cancer	cancer	NN1
304953	100736400	20992758106	that	that	CST
304953	100736400	20992758107	no	no	RR21
304953	100736400	20992758108	longer	long	RR22
304953	100736400	20992758109	responds	respond	VVZ
304953	100736400	20992758110	to	to	II
304953	100736400	20992758111	other	other	JJ
304953	100736400	20992758112	treatments.Read		NNU
304953	100736400	20992758113	the	the	AT
304953	100736400	20992758114	story	story	NN1
304953	100736400	20992758115	<p>		NULL
304953	100736400	20992758116	The	the	AT
304953	100736400	20992758117	products	product	NN2
304953	100736400	20992758118	we	we	PPIS2
304953	100736400	20992758119	enxeriepce		VV0
304953	100736400	20992758120	seen	see	VVN
304953	100736400	20992758121	in	in	II
304953	100736400	20992758122	content	content	NN1_JJ
304953	100736400	20992758123	regarding	regarding	II_VVG
304953	100736400	20992758124	laptop	laptop	NN1
304953	100736400	20992758125	along	along	II21
304953	100736400	20992758126	with	with	II22
304953	100736400	20992758127	computer	computer	NN1
304953	100736400	20992758128	thoughts	thought	NN2
304953	100736400	20992758129	perhaps	perhaps	RR
304953	100736400	20992758130	there 's		NN2
304953	100736400	20992758131	is	be	VBZ
304953	100736400	20992758132	characteristics	characteristic	NN2
304953	100736400	20992758133	for	for	REX21
304953	100736400	20992758134	instance	instance	REX22
304953	100736400	20992758135	SDRAM	sdram	NP1_NN1_VV0
304953	100736400	20992758136	,	,	,
304953	100736400	20992758137	DDR	ddr	NP1
304953	100736400	20992758138	and	and	RR31
304953	100736400	20992758139	so	so	RR32
304953	100736400	20992758140	on	on	RR33
304953	100736400	20992758141	,	,	,
304953	100736400	20992758142	that	that	DD1_CST
304953	100736400	20992758143	must	must	VM
304953	100736400	20992758144	take	take	VVI
304953	100736400	20992758145	part	part	NN1
304953	100736400	20992758146	in	in	II
304953	100736400	20992758147	every	every	AT1
304953	100736400	20992758148	the	the	AT
304953	100736400	20992758149	actual	actual	JJ
304953	100736400	20992758150	features	feature	NN2
304953	100736400	20992758151	for	for	IF
304953	100736400	20992758152	that	that	DD1
304953	100736400	20992758153	mother	mother	NN1
304953	100736400	20992758154	desk	desk	NN1
304953	100736400	20992758155	.	.	.
304953	100736400	20992758156	If	if	CS
304953	100736400	20992758157	the	the	AT
304953	100736400	20992758158	specific	specific	JJ
304953	100736400	20992758159	computers	computer	NN2
304953	100736400	20992758160	motherboard	motherboard	NN1
304953	100736400	20992758161	is	be	VBZ
304953	100736400	20992758162	actually	actually	RR
304953	100736400	20992758163	pretty	pretty	RG_JJ
304953	100736400	20992758164	the	the	AT
304953	100736400	20992758165	current	current	JJ_NN1@
304953	100736400	20992758166	although	although	CS
304953	100736400	20992758167	you	you	PPY
304953	100736400	20992758168	will	will	VM
304953	100736400	20992758169	discover	discover	VVI
304953	100736400	20992758170	basically	basically	RR
304953	100736400	20992758171	simply	simply	RR
304953	100736400	20992758172	virtually	virtually	RR
304953	100736400	20992758173	no	no	AT
304953	100736400	20992758174	pc	pc	NNU
304953	100736400	20992758175	OPERATING-SYSTEM		JJ_NN1
304953	100736400	20992758176	problems	problem	NN2
304953	100736400	20992758177	,	,	,
304953	100736400	20992758178	modernizing	modernize	VVG
304953	100736400	20992758179	every	every	AT1
304953	100736400	20992758180	among	among	II
304953	100736400	20992758181	the	the	AT
304953	100736400	20992758182	memory	memory	NN1
304953	100736400	20992758183	region	region	NN1
304953	100736400	20992758184	almost	almost	RR
304953	100736400	20992758185	often	often	RR
304953	100736400	20992758186	takes	take	VVZ
304953	100736400	20992758187	using	use	VVG
304953	100736400	20992758188	1	1	MC1
304953	100736400	20992758189	hours	hour	NNT2
304953	100736400	20992758190	.	.	.
304953	100736400	20992758191	It	it	PPH1
304953	100736400	20992758192	will	will	VM
304953	100736400	20992758193	be	be	VBI
304953	100736400	20992758194	one	one	MC1
304953	100736400	20992758195	of	of	IO
304953	100736400	20992758196	numerous	numerous	JJ
304953	100736400	20992758197	@		II
304953	100736400	20992758198	@		II
304953	100736400	20992758199	@		II
304953	100736400	20992758200	@		II
304953	100736400	20992758201	@		II
304953	100736400	20992758202	@		II
304953	100736400	20992758203	@		II
304953	100736400	20992758204	@		II
304953	100736400	20992758205	@		II
304953	100736400	20992758206	@		II
304953	100736400	20992758207	consider	consider	VV0
304953	100736400	20992758208	.	.	.
304953	100736400	20992758209	Regards	regard	VVZ_NN2
304953	100736400	20992758210	only	only	JJ
304953	100736400	20992758211	regarding		NN1
304953	100736400	20992758212	expressing	express	VVG
304953	100736400	20992758213	the	the	AT
304953	100736400	20992758214	particular	particular	JJ
304953	100736400	20992758215	views	view	NN2
304953	100736400	20992758216	.	.	.
304953	100736400	20992758217	46996		MC
304953	100736400	20992758218	@qwx906996		FO
304953	100736401	20992758238	@@##	----------	----------
304953	100736401	20992758239	@@100736401		FO
304953	100736401	20992758240	@4936401/		VV0_NN1
304953	100736401	20992758241	46989		MC
304953	100736401	20992758242	@qwx906989		FO
304953	100736401	20992758243	<p>		NULL
304953	100736401	20992758244	Can	can	VV0%
304953	100736401	20992758245	a	a	AT1
304953	100736401	20992758246	healthy	healthy	JJ
304953	100736401	20992758247	diet	diet	NN1
304953	100736401	20992758248	help	help	NN1_VV0
304953	100736401	20992758249	men	man	NN2
304953	100736401	20992758250	with	with	IW
304953	100736401	20992758251	low-risk	low-risk	JJ
304953	100736401	20992758252	prostate	prostate	NN1
304953	100736401	20992758253	cancer	cancer	NN1
304953	100736401	20992758254	live	live	VV0_RR@
304953	100736401	20992758255	longer	long	JJR_RRR
304953	100736401	20992758256	?	?	?
304953	100736401	20992758257	The	the	AT
304953	100736401	20992758258	authors	author	NN2
304953	100736401	20992758259	of	of	IO
304953	100736401	20992758260	a	a	AT1
304953	100736401	20992758261	new	new	JJ
304953	100736401	20992758262	study	study	NN1
304953	100736401	20992758263	say	say	VV0
304953	100736401	20992758264	"	"	"
304953	100736401	20992758265	yes	yes	UH
304953	100736401	20992758266	.	.	.
304953	100736401	20992758267	"	"	"
304953	100736401	20992758268	<p>		NULL
304953	100736401	20992758269	This	this	DD1
304953	100736401	20992758270	new	new	JJ
304953	100736401	20992758271	work	work	NN1
304953	100736401	20992758272	,	,	,
304953	100736401	20992758273	part	part	NN1
304953	100736401	20992758274	of	of	IO
304953	100736401	20992758275	the	the	AT
304953	100736401	20992758276	long-running	long-running	JJ
304953	100736401	20992758277	Physicians	physician	NN2
304953	100736401	20992758278	Health	health	NN1
304953	100736401	20992758279	Study	study	NN1
304953	100736401	20992758280	,	,	,
304953	100736401	20992758281	suggests	suggest	VVZ
304953	100736401	20992758282	that	that	CST
304953	100736401	20992758283	a	a	AT1
304953	100736401	20992758284	diet	diet	NN1
304953	100736401	20992758285	that	that	CST_DD1
304953	100736401	20992758286	is	be	VBZ
304953	100736401	20992758287	good	good	JJ
304953	100736401	20992758288	for	for	IF
304953	100736401	20992758289	the	the	AT
304953	100736401	20992758290	heart	heart	NN1
304953	100736401	20992758291	,	,	,
304953	100736401	20992758292	brain	brain	NN1
304953	100736401	20992758293	,	,	,
304953	100736401	20992758294	and	and	CC
304953	100736401	20992758295	other	other	JJ
304953	100736401	20992758296	parts	part	NN2
304953	100736401	20992758297	of	of	IO
304953	100736401	20992758298	the	the	AT
304953	100736401	20992758299	body	body	NN1
304953	100736401	20992758300	may	may	VM
304953	100736401	20992758301	also	also	RR
304953	100736401	20992758302	help	help	VVI
304953	100736401	20992758303	keep	keep	VVI
304953	100736401	20992758304	low-risk	low-risk	JJ_NN1
304953	100736401	20992758305	prostate	prostate	NN1
304953	100736401	20992758306	cancer	cancer	NN1
304953	100736401	20992758307	at	at	II
304953	100736401	20992758308	bay	bay	NN1
304953	100736401	20992758309	.	.	.
304953	100736401	20992758310	On	on	II
304953	100736401	20992758311	the	the	AT
304953	100736401	20992758312	flip	flip	NN1
304953	100736401	20992758313	side	side	NN1
304953	100736401	20992758314	,	,	,
304953	100736401	20992758315	a	a	AT1
304953	100736401	20992758316	diet	diet	NN1
304953	100736401	20992758317	rich	rich	JJ
304953	100736401	20992758318	in	in	II
304953	100736401	20992758319	red	red	JJ
304953	100736401	20992758320	meat	meat	NN1
304953	100736401	20992758321	and	and	CC
304953	100736401	20992758322	high-fat	high-fat	JJ_NN1
304953	100736401	20992758323	dairy	dairy	NN1
304953	100736401	20992758324	foods	food	NN2
304953	100736401	20992758325	appears	appear	VVZ
304953	100736401	20992758326	to	to	TO
304953	100736401	20992758327	be	be	VBI
304953	100736401	20992758328	hazardous	hazardous	JJ
304953	100736401	20992758329	for	for	IF
304953	100736401	20992758330	men	man	NN2
304953	100736401	20992758331	with	with	IW
304953	100736401	20992758332	this	this	DD1
304953	100736401	20992758333	kind	kind	NN1
304953	100736401	20992758334	of	of	IO
304953	100736401	20992758335	cancer	cancer	NN1
304953	100736401	20992758336	.	.	.
304953	100736401	20992758337	<p>		NULL
304953	100736401	20992758338	The	the	AT
304953	100736401	20992758339	new	new	JJ
304953	100736401	20992758340	study	study	NN1
304953	100736401	20992758341	involved	involve	VVD_VVN
304953	100736401	20992758342	more	more	DAR
304953	100736401	20992758343	than	than	CSN
304953	100736401	20992758344	900	900	MC
304953	100736401	20992758345	Physicians	physician	NN2
304953	100736401	20992758346	Health	health	NN1
304953	100736401	20992758347	Study	study	NN1
304953	100736401	20992758348	participants	participant	NN2
304953	100736401	20992758349	.	.	.
304953	100736401	20992758350	Five	five	MC
304953	100736401	20992758351	years	year	NNT2
304953	100736401	20992758352	after	after	II
304953	100736401	20992758353	being	be	VBG
304953	100736401	20992758354	diagnosed	diagnose	VVN
304953	100736401	20992758355	with	with	IW
304953	100736401	20992758356	non-metastatic		JJ
304953	100736401	20992758357	prostate	prostate	NN1
304953	100736401	20992758358	cancer	cancer	NN1
304953	100736401	20992758359	,	,	,
304953	100736401	20992758360	they	they	PPHS2
304953	100736401	20992758361	completed	complete	VVD
304953	100736401	20992758362	lengthy	lengthy	JJ
304953	100736401	20992758363	questionnaires	questionnaire	NN2
304953	100736401	20992758364	about	about	II
304953	100736401	20992758365	what	what	DDQ
304953	100736401	20992758366	they	they	PPHS2
304953	100736401	20992758367	ate	eat	VVD
304953	100736401	20992758368	.	.	.
304953	100736401	20992758369	Researchers	researcher	NN2
304953	100736401	20992758370	then	then	RT
304953	100736401	20992758371	tracked	track	VVD
304953	100736401	20992758372	their	their	APPGE
304953	100736401	20992758373	health	health	NN1
304953	100736401	20992758374	for	for	IF
304953	100736401	20992758375	another	another	DD1
304953	100736401	20992758376	10	10	MC
304953	100736401	20992758377	years	year	NNT2
304953	100736401	20992758378	.	.	.
304953	100736401	20992758379	What	what	DDQ
304953	100736401	20992758380	the	the	AT
304953	100736401	20992758381	men	man	NN2
304953	100736401	20992758382	ate	eat	VVD
304953	100736401	20992758383	fell	fall	VVD_NN1@_JJ@
304953	100736401	20992758384	into	into	II
304953	100736401	20992758385	two	two	MC
304953	100736401	20992758386	distinct	distinct	JJ
304953	100736401	20992758387	patterns	pattern	NN2
304953	100736401	20992758388	:	:	:
304953	100736401	20992758389	a	a	AT1
304953	100736401	20992758390	"	"	"
304953	100736401	20992758391	Western	western	JJ
304953	100736401	20992758392	"	"	"
304953	100736401	20992758393	diet	diet	NN1
304953	100736401	20992758394	heavy	heavy	JJ_NN1%
304953	100736401	20992758395	in	in	II
304953	100736401	20992758396	processed	processed	JJ
304953	100736401	20992758397	and	and	CC
304953	100736401	20992758398	red	red	JJ
304953	100736401	20992758399	meats	meat	NN2
304953	100736401	20992758400	,	,	,
304953	100736401	20992758401	eggs	egg	NN2
304953	100736401	20992758402	,	,	,
304953	100736401	20992758403	potatoes	potato	NN2
304953	100736401	20992758404	,	,	,
304953	100736401	20992758405	high-fat	high-fat	JJ_NN1
304953	100736401	20992758406	dairy	dairy	NN1
304953	100736401	20992758407	products	product	NN2
304953	100736401	20992758408	,	,	,
304953	100736401	20992758409	refined	refined	JJ
304953	100736401	20992758410	grains	grain	NN2
304953	100736401	20992758411	,	,	,
304953	100736401	20992758412	and	and	CC
304953	100736401	20992758413	desserts	dessert	NN2
304953	100736401	20992758414	;	;	;
304953	100736401	20992758415	and	and	CC
304953	100736401	20992758416	a	a	AT1
304953	100736401	20992758417	"	"	"
304953	100736401	20992758418	prudent	prudent	JJ
304953	100736401	20992758419	"	"	"
304953	100736401	20992758420	diet	diet	NN1
304953	100736401	20992758421	weighted	weight	VVN_VVD
304953	100736401	20992758422	towards	towards	II
304953	100736401	20992758423	fish	fish	NN
304953	100736401	20992758424	,	,	,
304953	100736401	20992758425	poultry	poultry	NN
304953	100736401	20992758426	,	,	,
304953	100736401	20992758427	plant-based		JJ
304953	100736401	20992758428	protein	protein	NN1
304953	100736401	20992758429	,	,	,
304953	100736401	20992758430	@		II
304953	100736401	20992758431	@		II
304953	100736401	20992758432	@		II
304953	100736401	20992758433	@		II
304953	100736401	20992758434	@		II
304953	100736401	20992758435	@		II
304953	100736401	20992758436	@		II
304953	100736401	20992758437	@		II
304953	100736401	20992758438	@		II
304953	100736401	20992758439	@		II
304953	100736401	20992758440	<p>		NULL
304953	100736401	20992758441	Men	man	NN2
304953	100736401	20992758442	whose	whose	DDQGE
304953	100736401	20992758443	diets	diet	NN2
304953	100736401	20992758444	scored	score	VVD
304953	100736401	20992758445	highest	high	RRT@_JJT
304953	100736401	20992758446	in	in	II
304953	100736401	20992758447	resembling	resemble	VVG
304953	100736401	20992758448	the	the	AT
304953	100736401	20992758449	typical	typical	JJ
304953	100736401	20992758450	Western	western	JJ
304953	100736401	20992758451	pattern	pattern	NN1
304953	100736401	20992758452	had	have	VHD
304953	100736401	20992758453	a	a	AT1
304953	100736401	20992758454	2.5-fold	2.5-fold	JJ_NN1
304953	100736401	20992758455	higher	high	JJR
304953	100736401	20992758456	risk	risk	NN1
304953	100736401	20992758457	of	of	IO
304953	100736401	20992758458	dying	die	VVG_JJ
304953	100736401	20992758459	from	from	II
304953	100736401	20992758460	prostate	prostate	NN1
304953	100736401	20992758461	cancer	cancer	NN1
304953	100736401	20992758462	over	over	II
304953	100736401	20992758463	the	the	AT
304953	100736401	20992758464	study	study	NN1
304953	100736401	20992758465	period	period	NN1
304953	100736401	20992758466	than	than	CSN
304953	100736401	20992758467	men	man	NN2
304953	100736401	20992758468	with	with	IW
304953	100736401	20992758469	the	the	AT
304953	100736401	20992758470	lowest	low	JJT
304953	100736401	20992758471	Western	western	JJ
304953	100736401	20992758472	pattern	pattern	NN1
304953	100736401	20992758473	scores	score	NN2
304953	100736401	20992758474	.	.	.
304953	100736401	20992758475	They	they	PPHS2
304953	100736401	20992758476	were	be	VBDR
304953	100736401	20992758477	also	also	RR
304953	100736401	20992758478	less	less	RGR
304953	100736401	20992758479	likely	likely	JJ
304953	100736401	20992758480	to	to	TO
304953	100736401	20992758481	have	have	VHI
304953	100736401	20992758482	died	die	VVN@
304953	100736401	20992758483	of	of	IO
304953	100736401	20992758484	any	any	DD
304953	100736401	20992758485	cause	cause	NN1
304953	100736401	20992758486	.	.	.
304953	100736401	20992758487	Men	man	NN2
304953	100736401	20992758488	with	with	IW
304953	100736401	20992758489	the	the	AT
304953	100736401	20992758490	highest	high	JJT
304953	100736401	20992758491	prudent	prudent	JJ
304953	100736401	20992758492	pattern	pattern	NN1
304953	100736401	20992758493	scores	score	NN2
304953	100736401	20992758494	were	be	VBDR
304953	100736401	20992758495	less	less	RGR
304953	100736401	20992758496	likely	likely	JJ
304953	100736401	20992758497	to	to	TO
304953	100736401	20992758498	have	have	VHI
304953	100736401	20992758499	died	die	VVN@
304953	100736401	20992758500	from	from	II
304953	100736401	20992758501	prostate	prostate	NN1
304953	100736401	20992758502	cancer	cancer	NN1
304953	100736401	20992758503	or	or	CC
304953	100736401	20992758504	any	any	DD
304953	100736401	20992758505	cause	cause	NN1
304953	100736401	20992758506	.	.	.
304953	100736401	20992758507	<p>		NULL
304953	100736401	20992758508	In	in	II
304953	100736401	20992758509	the	the	AT
304953	100736401	20992758510	Western	western	JJ
304953	100736401	20992758511	pattern	pattern	NN1
304953	100736401	20992758512	,	,	,
304953	100736401	20992758513	processed	processed	JJ_VVD
304953	100736401	20992758514	meats	meat	NN2
304953	100736401	20992758515	such	such	II21
304953	100736401	20992758516	as	as	II22
304953	100736401	20992758517	salami	salami	NN1
304953	100736401	20992758518	,	,	,
304953	100736401	20992758519	hot	hot	JJ
304953	100736401	20992758520	dogs	dog	NN2
304953	100736401	20992758521	,	,	,
304953	100736401	20992758522	and	and	CC
304953	100736401	20992758523	bacon	bacon	NN1
304953	100736401	20992758524	accounted	account	VVN_VVD
304953	100736401	20992758525	for	for	IF
304953	100736401	20992758526	much	much	DA1
304953	100736401	20992758527	of	of	IO
304953	100736401	20992758528	the	the	AT
304953	100736401	20992758529	increase	increase	NN1
304953	100736401	20992758530	in	in	II
304953	100736401	20992758531	risk	risk	NN1
304953	100736401	20992758532	,	,	,
304953	100736401	20992758533	while	while	CS
304953	100736401	20992758534	in	in	II
304953	100736401	20992758535	the	the	AT
304953	100736401	20992758536	prudent	prudent	JJ
304953	100736401	20992758537	pattern	pattern	NN1
304953	100736401	20992758538	,	,	,
304953	100736401	20992758539	the	the	AT
304953	100736401	20992758540	intake	intake	NN1
304953	100736401	20992758541	of	of	IO
304953	100736401	20992758542	olive	olive	JJ_NN1
304953	100736401	20992758543	oil	oil	NN1
304953	100736401	20992758544	and	and	CC
304953	100736401	20992758545	vinegar	vinegar	NN1
304953	100736401	20992758546	salad	salad	NN1
304953	100736401	20992758547	dressing	dress	VVG_NN1@
304953	100736401	20992758548	contributed	contribute	VVN_VVD
304953	100736401	20992758549	to	to	II
304953	100736401	20992758550	the	the	AT
304953	100736401	20992758551	survival	survival	NN1
304953	100736401	20992758552	benefits	benefit	NN2
304953	100736401	20992758553	.	.	.
304953	100736401	20992758554	"	"	"
304953	100736401	20992758555	The	the	AT
304953	100736401	20992758556	bottom	bottom	JJ_NN1
304953	100736401	20992758557	line	line	NN1
304953	100736401	20992758558	is	be	VBZ
304953	100736401	20992758559	that	that	CST
304953	100736401	20992758560	men	man	NN2
304953	100736401	20992758561	with	with	IW
304953	100736401	20992758562	prostate	prostate	NN1
304953	100736401	20992758563	cancer	cancer	NN1
304953	100736401	20992758564	will	will	VM
304953	100736401	20992758565	benefit	benefit	VVI
304953	100736401	20992758566	from	from	II
304953	100736401	20992758567	the	the	AT
304953	100736401	20992758568	same	same	DA
304953	100736401	20992758569	diets	diet	NN2
304953	100736401	20992758570	recommended	recommend	VVN_VVD
304953	100736401	20992758571	for	for	IF
304953	100736401	20992758572	preventing	prevent	VVG
304953	100736401	20992758573	heart	heart	NN1
304953	100736401	20992758574	disease	disease	NN1
304953	100736401	20992758575	,	,	,
304953	100736401	20992758576	"	"	"
304953	100736401	20992758577	said	say	VVD
304953	100736401	20992758578	the	the	AT
304953	100736401	20992758579	studys		NN2
304953	100736401	20992758580	corresponding	correspond	VVG_JJ
304953	100736401	20992758581	author	author	NN1
304953	100736401	20992758582	,	,	,
304953	100736401	20992758583	Dr.		NNB
304953	100736401	20992758584	Jorge	jorge	NP1
304953	100736401	20992758585	E.		NP1
304953	100736401	20992758586	Chavarro		NP1
304953	100736401	20992758587	,	,	,
304953	100736401	20992758588	assistant	assistant	JJ_NN1
304953	100736401	20992758589	professor	professor	NN1
304953	100736401	20992758590	of	of	IO
304953	100736401	20992758591	nutrition	nutrition	NN1
304953	100736401	20992758592	and	and	CC
304953	100736401	20992758593	epidemiology	epidemiology	NN1
304953	100736401	20992758594	at	at	II
304953	100736401	20992758595	the	the	AT
304953	100736401	20992758596	Harvard	harvard	NP1
304953	100736401	20992758597	T.H.	th	NP1
304953	100736401	20992758598	Chan	chan	NP1
304953	100736401	20992758599	School	school	NN1
304953	100736401	20992758600	of	of	IO
304953	100736401	20992758601	Public	public	JJ_NN1
304953	100736401	20992758602	Health	health	NN1
304953	100736401	20992758603	.	.	.
304953	100736401	20992758604	<p>		NULL
304953	100736401	20992758605	The	the	AT
304953	100736401	20992758606	study	study	NN1
304953	100736401	20992758607	had	have	VHD
304953	100736401	20992758608	some	some	DD
304953	100736401	20992758609	limitations	limitation	NN2
304953	100736401	20992758610	.	.	.
304953	100736401	20992758611	Nearly	nearly	RR
304953	100736401	20992758612	all	all	DB
304953	100736401	20992758613	the	the	AT
304953	100736401	20992758614	participants	participant	NN2
304953	100736401	20992758615	were	be	VBDR
304953	100736401	20992758616	Caucasian	caucasian	JJ
304953	100736401	20992758617	doctors	doctor	NN2
304953	100736401	20992758618	,	,	,
304953	100736401	20992758619	so	so	CS@_RR
304953	100736401	20992758620	the	the	AT
304953	100736401	20992758621	findings	finding	NN2
304953	100736401	20992758622	may	may	VM
304953	100736401	20992758623	not	not	XX
304953	100736401	20992758624	apply	apply	VVI
304953	100736401	20992758625	to	to	II
304953	100736401	20992758626	men	man	NN2
304953	100736401	20992758627	of	of	IO
304953	100736401	20992758628	other	other	JJ
304953	100736401	20992758629	ethnicities	ethnicity	NN2
304953	100736401	20992758630	@		II
304953	100736401	20992758631	@		II
304953	100736401	20992758632	@		II
304953	100736401	20992758633	@		II
304953	100736401	20992758634	@		II
304953	100736401	20992758635	@		II
304953	100736401	20992758636	@		II
304953	100736401	20992758637	@		II
304953	100736401	20992758638	@		II
304953	100736401	20992758639	@		II
304953	100736401	20992758640	the	the	AT
304953	100736401	20992758641	study	study	NN1
304953	100736401	20992758642	did	do	VDD
304953	100736401	20992758643	n't 	n't	XX
304953	100736401	20992758644	account	account	VVI
304953	100736401	20992758645	for	for	IF
304953	100736401	20992758646	the	the	AT
304953	100736401	20992758647	role	role	NN1
304953	100736401	20992758648	of	of	IO
304953	100736401	20992758649	physical	physical	JJ
304953	100736401	20992758650	exercise	exercise	NN1
304953	100736401	20992758651	or	or	CC
304953	100736401	20992758652	each	each	DD1
304953	100736401	20992758653	participants	participant	NN2
304953	100736401	20992758654	personal	personal	JJ
304953	100736401	20992758655	history	history	NN1
304953	100736401	20992758656	of	of	IO
304953	100736401	20992758657	PSA	psa	NP1
304953	100736401	20992758658	screening	screening	NN1_VVG
304953	100736401	20992758659	.	.	.
304953	100736401	20992758660	<p>		NULL
304953	100736401	20992758661	It	it	PPH1
304953	100736401	20992758662	is n't		VV0_NN1
304953	100736401	20992758663	clear	clear	RR@_VV0@_JJ
304953	100736401	20992758664	why	why	RRQ
304953	100736401	20992758665	a	a	AT1
304953	100736401	20992758666	diet	diet	NN1
304953	100736401	20992758667	that	that	CST_DD1
304953	100736401	20992758668	protects	protect	VVZ
304953	100736401	20992758669	against	against	II
304953	100736401	20992758670	heart	heart	NN1
304953	100736401	20992758671	disease	disease	NN1
304953	100736401	20992758672	would	would	VM
304953	100736401	20992758673	also	also	RR
304953	100736401	20992758674	protect	protect	VVI
304953	100736401	20992758675	against	against	II
304953	100736401	20992758676	death	death	NN1
304953	100736401	20992758677	from	from	II
304953	100736401	20992758678	prostate	prostate	NN1
304953	100736401	20992758679	cancer	cancer	NN1
304953	100736401	20992758680	.	.	.
304953	100736401	20992758681	Dr.		NNB
304953	100736401	20992758682	Chavarro		NP1
304953	100736401	20992758683	speculates	speculate	VVZ
304953	100736401	20992758684	that	that	CST
304953	100736401	20992758685	its	its	APPGE
304953	100736401	20992758686	because	because	CS
304953	100736401	20992758687	high-fat	high-fat	JJ
304953	100736401	20992758688	foods	food	NN2
304953	100736401	20992758689	are	be	VBR
304953	100736401	20992758690	easily	easily	RR
304953	100736401	20992758691	broken	break	VVN
304953	100736401	20992758692	down	down	RP
304953	100736401	20992758693	and	and	CC
304953	100736401	20992758694	absorbed	absorb	VVN
304953	100736401	20992758695	by	by	II
304953	100736401	20992758696	the	the	AT
304953	100736401	20992758697	digestive	digestive	JJ
304953	100736401	20992758698	system	system	NN1
304953	100736401	20992758699	,	,	,
304953	100736401	20992758700	and	and	CC
304953	100736401	20992758701	so	so	CS@_RR
304953	100736401	20992758702	they	they	PPHS2
304953	100736401	20992758703	might	might	VM
304953	100736401	20992758704	provide	provide	VVI
304953	100736401	20992758705	quick	quick	JJ
304953	100736401	20992758706	energy	energy	NN1
304953	100736401	20992758707	sources	source	NN2
304953	100736401	20992758708	for	for	IF
304953	100736401	20992758709	growing	growing	JJ_VVG
304953	100736401	20992758710	tumors	tumor	NN2
304953	100736401	20992758711	.	.	.
304953	100736401	20992758712	Nevertheless	nevertheless	RR
304953	100736401	20992758713	,	,	,
304953	100736401	20992758714	the	the	AT
304953	100736401	20992758715	results	result	NN2
304953	100736401	20992758716	suggest	suggest	VV0
304953	100736401	20992758717	that	that	CST_DD1
304953	100736401	20992758718	by	by	II
304953	100736401	20992758719	eating	eat	VVG
304953	100736401	20992758720	healthily	healthily	RR
304953	100736401	20992758721	,	,	,
304953	100736401	20992758722	men	man	NN2
304953	100736401	20992758723	with	with	IW
304953	100736401	20992758724	prostate	prostate	NN1
304953	100736401	20992758725	cancer	cancer	NN1
304953	100736401	20992758726	can	can	VM
304953	100736401	20992758727	take	take	VVI
304953	100736401	20992758728	a	a	AT1
304953	100736401	20992758729	proactive	proactive	JJ
304953	100736401	20992758730	step	step	NN1
304953	100736401	20992758731	towards	towards	II
304953	100736401	20992758732	living	live	VVG
304953	100736401	20992758733	a	a	AT1
304953	100736401	20992758734	long	long	JJ
304953	100736401	20992758735	life	life	NN1
304953	100736401	20992758736	.	.	.
304953	100736401	20992758737	<p>		NULL
304953	100736401	20992758738	"	"	"
304953	100736401	20992758739	This	this	DD1
304953	100736401	20992758740	study	study	NN1
304953	100736401	20992758741	adds	add	VVZ
304953	100736401	20992758742	to	to	II
304953	100736401	20992758743	the	the	AT
304953	100736401	20992758744	expanding	expanding	JJ
304953	100736401	20992758745	knowledge	knowledge	NN1
304953	100736401	20992758746	base	base	NN1
304953	100736401	20992758747	that	that	CST
304953	100736401	20992758748	foods	food	NN2
304953	100736401	20992758749	and	and	CC
304953	100736401	20992758750	diets	diet	NN2_VVZ@
304953	100736401	20992758751	that	that	CST
304953	100736401	20992758752	are	be	VBR
304953	100736401	20992758753	heart-healthy	heart-healthy	JJ
304953	100736401	20992758754	may	may	VM
304953	100736401	20992758755	also	also	RR
304953	100736401	20992758756	be	be	VBI
304953	100736401	20992758757	prostate-healthy		JJ
304953	100736401	20992758758	,	,	,
304953	100736401	20992758759	"	"	"
304953	100736401	20992758760	said	say	VVD
304953	100736401	20992758761	Dr.		NNB
304953	100736401	20992758762	Marc	marc	NP1
304953	100736401	20992758763	Garnick		NP1
304953	100736401	20992758764	,	,	,
304953	100736401	20992758765	the	the	AT
304953	100736401	20992758766	Gorman	gorman	NN1_NP1
304953	100736401	20992758767	Brothers	brother	NN2
304953	100736401	20992758768	Professor	professor	NN1
304953	100736401	20992758769	of	of	IO
304953	100736401	20992758770	Medicine	medicine	NN1
304953	100736401	20992758771	at	at	II
304953	100736401	20992758772	Harvard	harvard	NP1
304953	100736401	20992758773	Medical	medical	JJ
304953	100736401	20992758774	School	school	NN1
304953	100736401	20992758775	and	and	CC
304953	100736401	20992758776	Beth	beth	NP1
304953	100736401	20992758777	Israel	israel	NP1
304953	100736401	20992758778	Deaconess	deaconess	NN1
304953	100736401	20992758779	Medical	medical	JJ
304953	100736401	20992758780	Center	center	NN1
304953	100736401	20992758781	,	,	,
304953	100736401	20992758782	and	and	CC
304953	100736401	20992758783	Editor	editor	NN1
304953	100736401	20992758784	in	in	II
304953	100736401	20992758785	Chief	chief	NN1
304953	100736401	20992758786	of	of	IO
304953	100736401	20992758787	**28;331;TOOLONG		NP1
304953	100736401	20992758788	.	.	.
304953	100736401	20992758789	"	"	"
304953	100736401	20992758790	The	the	AT
304953	100736401	20992758791	advice	advice	NN1
304953	100736401	20992758792	I	i	PPIS1
304953	100736401	20992758793	give	give	VV0
304953	100736401	20992758794	my	my	APPGE
304953	100736401	20992758795	prostate	prostate	NN1
304953	100736401	20992758796	cancer	cancer	NN1
304953	100736401	20992758797	patients	patient	NN2
304953	100736401	20992758798	is	be	VBZ
304953	100736401	20992758799	to	to	TO
304953	100736401	20992758800	avoid	avoid	VVI
304953	100736401	20992758801	red	red	JJ
304953	100736401	20992758802	meat	meat	NN1
304953	100736401	20992758803	,	,	,
304953	100736401	20992758804	lots	lots	PN
304953	100736401	20992758805	of	of	IO
304953	100736401	20992758806	dairy	dairy	NN1
304953	100736401	20992758807	products	product	NN2
304953	100736401	20992758808	,	,	,
304953	100736401	20992758809	and	and	CC
304953	100736401	20992758810	vitamin	vitamin	NN1
304953	100736401	20992758811	E	e	ZZ1
304953	100736401	20992758812	and	and	CC
304953	100736401	20992758813	selenium	selenium	NN1
304953	100736401	20992758814	supplements	supplement	NN2
304953	100736401	20992758815	.	.	.
304953	100736401	20992758816	That	that	DD1
304953	100736401	20992758817	has	have	VHZ
304953	100736401	20992758818	been	be	VBN
304953	100736401	20992758819	my	my	APPGE
304953	100736401	20992758820	advice	advice	NN1
304953	100736401	20992758821	for	for	IF
304953	100736401	20992758822	years	year	NNT2
304953	100736401	20992758823	and	and	CC
304953	100736401	20992758824	the	the	AT
304953	100736401	20992758825	current	current	JJ
304953	100736401	20992758826	findings	finding	NN2
304953	100736401	20992758827	support	support	VV0
304953	100736401	20992758828	this	this	DD1
304953	100736401	20992758829	approach	approach	NN1
304953	100736401	20992758830	.	.	.
304953	100736401	20992758831	"	"	"
304953	100736402	20992758851	@@##	----------	----------
304953	100736402	20992758852	@@100736402		FO
304953	100736402	20992758853	@4936402/		JJ_NN1_VV0
304953	100736402	20992758854	<h>		NULL
304953	100736402	20992758855	Prostate	prostate	NN1
304953	100736402	20992758856	Cancer	cancer	NN1
304953	100736402	20992758857	46988		MC
304953	100736402	20992758858	@qwx906988		FO
304953	100736402	20992758859	46994		MC
304953	100736402	20992758860	@qwx906994		FO
304953	100736402	20992758861	46995		MC
304953	100736402	20992758862	@qwx906995		FO
304953	100736402	20992758863	46992		MC
304953	100736402	20992758864	@qwx906992		FO
304953	100736402	20992758865	46991		MC
304953	100736402	20992758866	@qwx906991		FO
304953	100736402	20992758867	46990		MC
304953	100736402	20992758868	@qwx906990		FO
304953	100736402	20992758869	46989		MC
304953	100736402	20992758870	@qwx906989		FO
304953	100736402	20992758871	46993		MC
304953	100736402	20992758872	@qwx906993		FO
304953	100736402	20992758873	<h>		NULL
304953	100736402	20992758874	PSA	psa	NP1
304953	100736402	20992758875	<p>		NULL
304953	100736402	20992758876	The	the	AT
304953	100736402	20992758877	PSA	psa	NP1
304953	100736402	20992758878	test	test	NN1
304953	100736402	20992758879	is	be	VBZ
304953	100736402	20992758880	a	a	AT1
304953	100736402	20992758881	blood	blood	NN1
304953	100736402	20992758882	test	test	NN1
304953	100736402	20992758883	used	use	VMK
304953	100736402	20992758884	to	to	TO
304953	100736402	20992758885	detect	detect	VVI
304953	100736402	20992758886	prostate	prostate	NN1
304953	100736402	20992758887	cancer	cancer	NN1
304953	100736402	20992758888	.	.	.
304953	100736402	20992758889	Doctors	doctor	NN2
304953	100736402	20992758890	suspect	suspect	VV0
304953	100736402	20992758891	prostate	prostate	NN1
304953	100736402	20992758892	cancer	cancer	NN1
304953	100736402	20992758893	if	if	CS
304953	100736402	20992758894	the	the	AT
304953	100736402	20992758895	blood	blood	NN1
304953	100736402	20992758896	contains	contain	VVZ
304953	100736402	20992758897	high	high	JJ
304953	100736402	20992758898	levels	level	NN2
304953	100736402	20992758899	of	of	IO
304953	100736402	20992758900	a	a	AT1
304953	100736402	20992758901	protein	protein	NN1
304953	100736402	20992758902	called	call	VVN_VVD@
304953	100736402	20992758903	prostate-specific	prostate-specific	JJ
304953	100736402	20992758904	antigen	antigen	NN1
304953	100736402	20992758905	.	.	.
304953	100736402	20992758906	For	for	IF
304953	100736402	20992758907	men	man	NN2
304953	100736402	20992758908	who	who	PNQS
304953	100736402	20992758909	want	want	VV0
304953	100736402	20992758910	to	to	TO
304953	100736402	20992758911	be	be	VBI
304953	100736402	20992758912	screened	screen	VVN
304953	100736402	20992758913	for	for	IF
304953	100736402	20992758914	prostate	prostate	NN1
304953	100736402	20992758915	cancer	cancer	NN1
304953	100736402	20992758916	,	,	,
304953	100736402	20992758917	the	the	AT
304953	100736402	20992758918	test	test	NN1
304953	100736402	20992758919	is	be	VBZ
304953	100736402	20992758920	usually	usually	RR
304953	100736402	20992758921	done	do	VDN
304953	100736402	20992758922	every	every	AT1
304953	100736402	20992758923	year	year	NNT1
304953	100736402	20992758924	beginning	begin	VVG_NN1
304953	100736402	20992758925	between	between	II
304953	100736402	20992758926	ages	age	NN2
304953	100736402	20992758927	40	40	MC
304953	100736402	20992758928	and	and	CC
304953	100736402	20992758929	50	50	MC
304953	100736402	20992758930	,	,	,
304953	100736402	20992758931	depending	depending	II21
304953	100736402	20992758932	on	on	II22
304953	100736402	20992758933	individual	individual	JJ_NN1
304953	100736402	20992758934	risk	risk	NN1
304953	100736402	20992758935	factors	factor	NN2
304953	100736402	20992758936	.	.	.
304953	100736402	20992758937	<p>		NULL
304953	100736402	20992758938	PSA	psa	NP1
304953	100736402	20992758939	testing	test	VVG_NN1
304953	100736402	20992758940	to	to	TO
304953	100736402	20992758941	screen	screen	VVI
304953	100736402	20992758942	for	for	IF
304953	100736402	20992758943	prostate	prostate	NN1
304953	100736402	20992758944	cancer	cancer	NN1
304953	100736402	20992758945	might	might	VM
304953	100736402	20992758946	seem	seem	VVI
304953	100736402	20992758947	like	like	II
304953	100736402	20992758948	a	a	AT1
304953	100736402	20992758949	no-brainer	no-brainer	NN1_JJ
304953	100736402	20992758950	.	.	.
304953	100736402	20992758951	However	however	RR
304953	100736402	20992758952	,	,	,
304953	100736402	20992758953	the	the	AT
304953	100736402	20992758954	test	test	NN1
304953	100736402	20992758955	has	have	VHZ
304953	100736402	20992758956	become	become	VVN@
304953	100736402	20992758957	controversial	controversial	JJ
304953	100736402	20992758958	.	.	.
304953	100736402	20992758959	If	if	CS
304953	100736402	20992758960	a	a	AT1
304953	100736402	20992758961	man	man	NN1
304953	100736402	20992758962	's	's	GE_VBZ
304953	100736402	20992758963	PSA	psa	NP1
304953	100736402	20992758964	is	be	VBZ
304953	100736402	20992758965	elevated	elevate	VVN_JJ
304953	100736402	20992758966	,	,	,
304953	100736402	20992758967	he	he	PPHS1
304953	100736402	20992758968	'll	will	VM
304953	100736402	20992758969	likely	likely	RR@
304953	100736402	20992758970	undergo	undergo	VVI
304953	100736402	20992758971	a	a	AT1
304953	100736402	20992758972	biopsy	biopsy	NN1
304953	100736402	20992758973	and	and	CC
304953	100736402	20992758974	,	,	,
304953	100736402	20992758975	if	if	CS
304953	100736402	20992758976	cancer	cancer	NN1
304953	100736402	20992758977	is	be	VBZ
304953	100736402	20992758978	diagnosed	diagnose	VVN
304953	100736402	20992758979	,	,	,
304953	100736402	20992758980	invasive	invasive	JJ
304953	100736402	20992758981	treatment	treatment	NN1
304953	100736402	20992758982	.	.	.
304953	100736402	20992758983	But	but	CCB
304953	100736402	20992758984	because	because	CS
304953	100736402	20992758985	most	most	DAT
304953	100736402	20992758986	prostate	prostate	NN1
304953	100736402	20992758987	cancers	cancer	NN2
304953	100736402	20992758988	grow	grow	VV0
304953	100736402	20992758989	slowly	slowly	RR
304953	100736402	20992758990	,	,	,
304953	100736402	20992758991	they	they	PPHS2
304953	100736402	20992758992	are	be	VBR
304953	100736402	20992758993	n't	n't	XX
304953	100736402	20992758994	likely	likely	JJ_RR@
304953	100736402	20992758995	to	to	TO
304953	100736402	20992758996	affect	affect	VVI
304953	100736402	20992758997	the	the	AT
304953	100736402	20992758998	man	man	NN1
304953	100736402	20992758999	during	during	II
304953	100736402	20992759000	his	his	APPGE
304953	100736402	20992759001	lifetime	lifetime	NNT1
304953	100736402	20992759002	.	.	.
304953	100736402	20992759003	In	in	RR21
304953	100736402	20992759004	addition	addition	RR22
304953	100736402	20992759005	,	,	,
304953	100736402	20992759006	experts	expert	NN2
304953	100736402	20992759007	no	no	RR21
304953	100736402	20992759008	longer	long	RR22
304953	100736402	20992759009	recommend	recommend	VV0
304953	100736402	20992759010	routine	routine	NN1_JJ@
304953	100736402	20992759011	PSA	psa	NP1
304953	100736402	20992759012	screening	screening	NN1_VVG
304953	100736402	20992759013	for	for	IF
304953	100736402	20992759014	men	man	NN2
304953	100736402	20992759015	ages	age	VVZ@_NN2
304953	100736402	20992759016	75	75	MC
304953	100736402	20992759017	and	and	CC
304953	100736402	20992759018	older	old	JJR
304953	100736402	20992759019	because	because	CS
304953	100736402	20992759020	they	they	PPHS2
304953	100736402	20992759021	are	be	VBR
304953	100736402	20992759022	more	more	RGR
304953	100736402	20992759023	likely	likely	JJ
304953	100736402	20992759024	to	to	TO
304953	100736402	20992759025	die	die	VVI
304953	100736402	20992759026	from	from	II
304953	100736402	20992759027	another	another	DD1
304953	100736402	20992759028	condition	condition	NN1
304953	100736402	20992759029	than	than	CSN
304953	100736402	20992759030	from	from	II
304953	100736402	20992759031	undetected	undetected	JJ
304953	100736402	20992759032	prostate	prostate	NN1
304953	100736402	20992759033	cancer	cancer	NN1
304953	100736402	20992759034	.	.	.
304953	100736402	20992759035	<h>		NULL
304953	100736402	20992759036	Related	related	JJ
304953	100736402	20992759037	Articles	article	NN2
304953	100736402	20992759038	<p>		NULL
304953	100736402	20992759039	Men	man	NN2
304953	100736402	20992759040	who	who	PNQS
304953	100736402	20992759041	have	have	VH0
304953	100736402	20992759042	high	high	JJ
304953	100736402	20992759043	@		II
304953	100736402	20992759044	@		II
304953	100736402	20992759045	@		II
304953	100736402	20992759046	@		II
304953	100736402	20992759047	@		II
304953	100736402	20992759048	@		II
304953	100736402	20992759049	@		II
304953	100736402	20992759050	@		II
304953	100736402	20992759051	@		II
304953	100736402	20992759052	@		II
304953	100736402	20992759053	face	face	VV0_NN1
304953	100736402	20992759054	troubling	troubling	JJ_VVG
304953	100736402	20992759055	uncertainties	uncertainty	NN2
304953	100736402	20992759056	.	.	.
304953	100736402	20992759057	While	while	CS
304953	100736402	20992759058	it	it	PPH1
304953	100736402	20992759059	's	be	VBZ
304953	100736402	20992759060	true	true	JJ_RR%
304953	100736402	20992759061	that	that	CST_DD1
304953	100736402	20992759062	prostate	prostate	NN1
304953	100736402	20992759063	cancer	cancer	NN1
304953	100736402	20992759064	can	can	VM
304953	100736402	20992759065	elevate	elevate	VVI
304953	100736402	20992759066	PSA	psa	NP1
304953	100736402	20992759067	,	,	,
304953	100736402	20992759068	so	so	RR
304953	100736402	20992759069	can	can	VV0%_VM
304953	100736402	20992759070	other	other	JJ
304953	100736402	20992759071	conditions	condition	NN2
304953	100736402	20992759072	,	,	,
304953	100736402	20992759073	including	including	II_VVG@
304953	100736402	20992759074	the	the	AT
304953	100736402	20992759075	benign	benign	JJ
304953	100736402	20992759076	prostate	prostate	NN1
304953	100736402	20992759077	enlargement	enlargement	NN1
304953	100736402	20992759078	that	that	CST_DD1
304953	100736402	20992759079	afflicts	afflict	VVZ
304953	100736402	20992759080	many	many	DA2
304953	100736402	20992759081	men	man	NN2
304953	100736402	20992759082	as	as	CSA
304953	100736402	20992759083	they	they	PPHS2
304953	100736402	20992759084	get	get	VV0
304953	100736402	20992759085	older	old	JJR
304953	100736402	20992759086	.	.	.
304953	100736402	20992759087	PSA	psa	NP1
304953	100736402	20992759088	levels	level	NN2_VVZ%
304953	100736402	20992759089	also	also	RR
304953	100736402	20992759090	vary	vary	VV0
304953	100736402	20992759091	normally	normally	RR
304953	100736402	20992759092	from	from	II
304953	100736402	20992759093	one	one	MC1
304953	100736402	20992759094	man	man	NN1
304953	100736402	20992759095	to	to	II
304953	100736402	20992759096	the	the	AT
304953	100736402	20992759097	next	next	MD
304953	100736402	20992759098	,	,	,
304953	100736402	20992759099	and	and	CC
304953	100736402	20992759100	some	some	DD
304953	100736402	20992759101	men	man	NN2
304953	100736402	20992759102	<p>		NULL
304953	100736402	20992759103	Suspicious	suspicious	JJ
304953	100736402	20992759104	findings	finding	NN2
304953	100736402	20992759105	from	from	II
304953	100736402	20992759106	prostate	prostate	NN1
304953	100736402	20992759107	cancer	cancer	NN1
304953	100736402	20992759108	screening	screening	NN1_VVG
304953	100736402	20992759109	are	be	VBR
304953	100736402	20992759110	often	often	RR
304953	100736402	20992759111	followed	follow	VVN
304953	100736402	20992759112	by	by	II
304953	100736402	20992759113	a	a	AT1
304953	100736402	20992759114	procedure	procedure	NN1
304953	100736402	20992759115	most	most	DAT
304953	100736402	20992759116	men	man	NN2
304953	100736402	20992759117	would	would	VM
304953	100736402	20992759118	prefer	prefer	VVI
304953	100736402	20992759119	to	to	TO
304953	100736402	20992759120	avoid	avoid	VVI
304953	100736402	20992759121	:	:	:
304953	100736402	20992759122	a	a	AT1
304953	100736402	20992759123	prostate	prostate	NN1
304953	100736402	20992759124	biopsy	biopsy	NN1
304953	100736402	20992759125	.	.	.
304953	100736402	20992759126	But	but	CCB
304953	100736402	20992759127	what	what	DDQ
304953	100736402	20992759128	if	if	CS
304953	100736402	20992759129	biopsies	biopsy	NN2
304953	100736402	20992759130	actually	actually	RR
304953	100736402	20992759131	could	could	VM
304953	100736402	20992759132	be	be	VBI
304953	100736402	20992759133	avoided	avoid	VVN
304953	100736402	20992759134	on	on	II
304953	100736402	20992759135	the	the	AT
304953	100736402	20992759136	basis	basis	NN1
304953	100736402	20992759137	of	of	IO
304953	100736402	20992759138	non-invasive	noninvasive	JJ
304953	100736402	20992759139	test	test	NN1
304953	100736402	20992759140	results	result	NN2_VVZ@
304953	100736402	20992759141	?	?	?
304953	100736402	20992759142	Screening	screen	VVG_NN1
304953	100736402	20992759143	tests	test	NN2
304953	100736402	20992759144	are	be	VBR
304953	100736402	20992759145	moving	move	VVG
304953	100736402	20992759146	in	in	II
304953	100736402	20992759147	that	that	DD1
304953	100736402	20992759148	direction	direction	NN1
304953	100736402	20992759149	,	,	,
304953	100736402	20992759150	with	with	IW
304953	100736402	20992759151	some	some	DD
304953	100736402	20992759152	intriguing	intriguing	JJ
304953	100736402	20992759153	results	result	NN2
304953	100736402	20992759154	.	.	.
304953	100736402	20992759155	One	one	MC1
304953	100736402	20992759156	of	of	IO
304953	100736402	20992759157	them	them	PPHO2
304953	100736402	20992759158	,	,	,
304953	100736402	20992759159	the	the	AT
304953	100736402	20992759160	Prostate	prostate	NN1
304953	100736402	20992759161	Health	health	NN1
304953	100736402	20992759162	Index	index	NN1
304953	100736402	20992759163	blood	blood	NN1
304953	100736402	20992759164	test	test	NN1_VV0
304953	100736402	20992759165	,	,	,
304953	100736402	20992759166	combines	combine	VVZ
304953	100736402	20992759167	measures	measure	NN2
304953	100736402	20992759168	of	of	IO
304953	100736402	20992759169	three	three	MC
304953	100736402	20992759170	forms	form	NN2
304953	100736402	20992759171	of	of	IO
304953	100736402	20992759172	prostate-specific	prostate-specific	JJ
304953	100736402	20992759173	antigen	antigen	NN1
304953	100736402	20992759174	(	(	(
304953	100736402	20992759175	PSA	psa	NP1
304953	100736402	20992759176	)	)	)
304953	100736402	20992759177	into	into	II
304953	100736402	20992759178	a	a	AT1
304953	100736402	20992759179	score	score	NN1
304953	100736402	20992759180	that	that	CST_DD1
304953	100736402	20992759181	helps	help	VVZ
304953	100736402	20992759182	doctors	doctor	NN2
304953	100736402	20992759183	predict	predict	VVI
304953	100736402	20992759184	if	if	CSW@_CS
304953	100736402	20992759185	a	a	AT1
304953	100736402	20992759186	cancer	cancer	NN1
304953	100736402	20992759187	is	be	VBZ
304953	100736402	20992759188	likely	likely	JJ
304953	100736402	20992759189	to	to	TO
304953	100736402	20992759190	progress	progress	VVI
304953	100736402	20992759191	,	,	,
304953	100736402	20992759192	with	with	IW
304953	100736402	20992759193	an	a	AT1
304953	100736402	20992759194	aim	aim	NN1
304953	100736402	20992759195	to	to	TO
304953	100736402	20992759196	circumvent	circumvent	VVI
304953	100736402	20992759197	biopsies	biopsy	NN2
304953	100736402	20992759198	that	that	CST
304953	100736402	20992759199	are	be	VBR
304953	100736402	20992759200	n't	n't	XX
304953	100736402	20992759201	necessary	necessary	JJ
304953	100736402	20992759202	.	.	.
304953	100736402	20992759203	<p>		NULL
304953	100736402	20992759204	Fewer	fewer	DAR
304953	100736402	20992759205	men	man	NN2
304953	100736402	20992759206	are	be	VBR
304953	100736402	20992759207	being	be	VBG
304953	100736402	20992759208	given	give	VVN
304953	100736402	20992759209	PSA	psa	NP1
304953	100736402	20992759210	tests	test	VVZ@_NN2
304953	100736402	20992759211	to	to	TO
304953	100736402	20992759212	screen	screen	VVI
304953	100736402	20992759213	for	for	IF
304953	100736402	20992759214	prostate	prostate	NN1
304953	100736402	20992759215	cancer	cancer	NN1
304953	100736402	20992759216	.	.	.
304953	100736402	20992759217	As	as	CSA_II@
304953	100736402	20992759218	screening	screen	VVG_NN1
304953	100736402	20992759219	rates	rate	NN2
304953	100736402	20992759220	have	have	VH0
304953	100736402	20992759221	fallen	fall	VVN
304953	100736402	20992759222	,	,	,
304953	100736402	20992759223	so	so	RR
304953	100736402	20992759224	have	have	VH0
304953	100736402	20992759225	the	the	AT
304953	100736402	20992759226	number	number	NN1
304953	100736402	20992759227	of	of	IO
304953	100736402	20992759228	prostate	prostate	NN1
304953	100736402	20992759229	cancer	cancer	NN1
304953	100736402	20992759230	diagnoses	diagnosis	NN2_VVZ
304953	100736402	20992759231	.	.	.
304953	100736402	20992759232	This	this	DD1
304953	100736402	20992759233	probably	probably	RR
304953	100736402	20992759234	also	also	RR
304953	100736402	20992759235	means	mean	VVZ
304953	100736402	20992759236	that	that	CST
304953	100736402	20992759237	fewer	fewer	DAR
304953	100736402	20992759238	men	man	NN2
304953	100736402	20992759239	are	be	VBR
304953	100736402	20992759240	receiving	receive	VVG
304953	100736402	20992759241	potentially	potentially	RR
304953	100736402	20992759242	unnecessary	unnecessary	JJ
304953	100736402	20992759243	@		II
304953	100736402	20992759244	@		II
304953	100736402	20992759245	@		II
304953	100736402	20992759246	@		II
304953	100736402	20992759247	@		II
304953	100736402	20992759248	@		II
304953	100736402	20992759249	@		II
304953	100736402	20992759250	@		II
304953	100736402	20992759251	@		II
304953	100736402	20992759252	@		II
304953	100736402	20992759253	the	the	AT
304953	100736402	20992759254	same	same	DA
304953	100736402	20992759255	time	time	NNT1
304953	100736402	20992759256	,	,	,
304953	100736402	20992759257	it	it	PPH1
304953	100736402	20992759258	is	be	VBZ
304953	100736402	20992759259	n't	n't	XX
304953	100736402	20992759260	yet	yet	RR
304953	100736402	20992759261	clear	clear	JJ_VV0@
304953	100736402	20992759262	whether	whether	CSW
304953	100736402	20992759263	that	that	DD1
304953	100736402	20992759264	comes	come	VVZ
304953	100736402	20992759265	at	at	II
304953	100736402	20992759266	the	the	AT
304953	100736402	20992759267	cost	cost	NN1
304953	100736402	20992759268	of	of	IO
304953	100736402	20992759269	more	more	RGR
304953	100736402	20992759270	aggressive	aggressive	JJ
304953	100736402	20992759271	cancers	cancer	NN2
304953	100736402	20992759272	being	be	VBG
304953	100736402	20992759273	caught	catch	VVN
304953	100736402	20992759274	at	at	II
304953	100736402	20992759275	an	a	AT1
304953	100736402	20992759276	incurable	incurable	JJ
304953	100736402	20992759277	stage	stage	NN1
304953	100736402	20992759278	.	.	.
304953	100736402	20992759279	Better	better	JJR_RRR
304953	100736402	20992759280	screening	screening	NN1_VVG
304953	100736402	20992759281	tests	test	NN2
304953	100736402	20992759282	may	may	VM
304953	100736402	20992759283	make	make	VVI
304953	100736402	20992759284	the	the	AT
304953	100736402	20992759285	difference	difference	NN1
304953	100736402	20992759286	in	in	II
304953	100736402	20992759287	helping	help	VVG_NN1
304953	100736402	20992759288	strike	strike	VVI
304953	100736402	20992759289	the	the	AT
304953	100736402	20992759290	right	right	JJ_NN1
304953	100736402	20992759291	balance	balance	NN1
304953	100736402	20992759292	between	between	II
304953	100736402	20992759293	limiting	limiting	JJ_VVG
304953	100736402	20992759294	harm	harm	NN1
304953	100736402	20992759295	and	and	CC
304953	100736402	20992759296	preventing	prevent	VVG
304953	100736402	20992759297	prostate	prostate	NN1
304953	100736402	20992759298	cancer	cancer	NN1
304953	100736402	20992759299	deaths	death	NN2
304953	100736402	20992759300	.	.	.
304953	100736402	20992759301	<p>		NULL
304953	100736402	20992759302	A	a	ZZ1_AT1
304953	100736402	20992759303	womans	woman	NN2
304953	100736402	20992759304	use	use	NN1_VV0
304953	100736402	20992759305	of	of	IO
304953	100736402	20992759306	a	a	AT1
304953	100736402	20992759307	testosterone-based		JJ
304953	100736402	20992759308	vaginal	vaginal	JJ
304953	100736402	20992759309	cream	cream	NN1
304953	100736402	20992759310	may	may	VM
304953	100736402	20992759311	have	have	VHI
304953	100736402	20992759312	contributed	contribute	VVN
304953	100736402	20992759313	to	to	II
304953	100736402	20992759314	a	a	AT1
304953	100736402	20992759315	spike	spike	NN1
304953	100736402	20992759316	in	in	II
304953	100736402	20992759317	her	her	APPGE
304953	100736402	20992759318	husbands	husband	NN2
304953	100736402	20992759319	prostate-specific	prostate-specific	JJ
304953	100736402	20992759320	antigen	antigen	NN1
304953	100736402	20992759321	and	and	CC
304953	100736402	20992759322	testosterone	testosterone	NN1
304953	100736402	20992759323	levels	level	NN2
304953	100736402	20992759324	after	after	CS
304953	100736402	20992759325	he	he	PPHS1
304953	100736402	20992759326	had	have	VHD
304953	100736402	20992759327	his	his	APPGE
304953	100736402	20992759328	prostate	prostate	NN1
304953	100736402	20992759329	removed	remove	VVN
304953	100736402	20992759330	to	to	TO
304953	100736402	20992759331	fight	fight	VVI
304953	100736402	20992759332	advanced	advanced	JJ
304953	100736402	20992759333	prostate	prostate	NN1
304953	100736402	20992759334	cancer	cancer	NN1
304953	100736402	20992759335	.	.	.
304953	100736402	20992759336	<p>		NULL
304953	100736402	20992759337	A	a	AT1
304953	100736402	20992759338	study	study	NN1
304953	100736402	20992759339	published	publish	VVN
304953	100736402	20992759340	in	in	II
304953	100736402	20992759341	the	the	AT
304953	100736402	20992759342	journal	journal	NN1
304953	100736402	20992759343	European	european	JJ
304953	100736402	20992759344	Urology	urology	NN1_NP1
304953	100736402	20992759345	suggests	suggest	VVZ
304953	100736402	20992759346	that	that	CST
304953	100736402	20992759347	men	man	NN2
304953	100736402	20992759348	who	who	PNQS
304953	100736402	20992759349	have	have	VH0
304953	100736402	20992759350	defects	defect	NN2
304953	100736402	20992759351	in	in	II
304953	100736402	20992759352	a	a	AT1
304953	100736402	20992759353	cancer-suppressing		JJ_NN1
304953	100736402	20992759354	gene	gene	NN1
304953	100736402	20992759355	known	know	VVN
304953	100736402	20992759356	as	as	II
304953	100736402	20992759357	BRCA	brca	NP1_NN1
304953	100736402	20992759358	are	be	VBR
304953	100736402	20992759359	at	at	II
304953	100736402	20992759360	high	high	JJ
304953	100736402	20992759361	risk	risk	NN1
304953	100736402	20992759362	for	for	IF
304953	100736402	20992759363	aggressive	aggressive	JJ
304953	100736402	20992759364	prostate	prostate	NN1
304953	100736402	20992759365	tumors	tumor	NN2
304953	100736402	20992759366	,	,	,
304953	100736402	20992759367	and	and	CC
304953	100736402	20992759368	so	so	RR
304953	100736402	20992759369	could	could	VM
304953	100736402	20992759370	benefit	benefit	VVI
304953	100736402	20992759371	from	from	II
304953	100736402	20992759372	PSA	psa	NP1
304953	100736402	20992759373	testing	testing	NN1_VVG
304953	100736402	20992759374	.	.	.
304953	100736402	20992759375	<p>		NULL
304953	100736402	20992759376	Men	man	NN2
304953	100736402	20992759377	who	who	PNQS
304953	100736402	20992759378	experience	experience	VV0
304953	100736402	20992759379	a	a	AT1
304953	100736402	20992759380	spike	spike	NN1
304953	100736402	20992759381	in	in	II
304953	100736402	20992759382	PSA	psa	NP1
304953	100736402	20992759383	but	but	CCB
304953	100736402	20992759384	who	who	PNQS
304953	100736402	20992759385	have	have	VH0
304953	100736402	20992759386	no	no	AT
304953	100736402	20992759387	symptoms	symptom	NN2
304953	100736402	20992759388	after	after	II_CS
304953	100736402	20992759389	surgery	surgery	NN1
304953	100736402	20992759390	or	or	CC
304953	100736402	20992759391	radiation	radiation	NN1
304953	100736402	20992759392	therapy	therapy	NN1
304953	100736402	20992759393	for	for	IF
304953	100736402	20992759394	prostate	prostate	NN1
304953	100736402	20992759395	cancer	cancer	NN1
304953	100736402	20992759396	can	can	VM
304953	100736402	20992759397	wait	wait	VVI
304953	100736402	20992759398	for	for	IF
304953	100736402	20992759399	up	up	RG21
304953	100736402	20992759400	to	to	RG22
304953	100736402	20992759401	two	two	MC
304953	100736402	20992759402	years	year	NNT2
304953	100736402	20992759403	before	before	II
304953	100736402	20992759404	starting	start	VVG
304953	100736402	20992759405	hormone	hormone	NN1
304953	100736402	20992759406	therapy	therapy	NN1
304953	100736402	20992759407	,	,	,
304953	100736402	20992759408	according	according	II21
304953	100736402	20992759409	to	to	II22
304953	100736402	20992759410	a	a	AT1
304953	100736402	20992759411	new	new	JJ
304953	100736402	20992759412	study	study	NN1
304953	100736402	20992759413	.	.	.
304953	100736402	20992759414	<p>		NULL
304953	100736402	20992759415	Two	two	MC
304953	100736402	20992759416	international	international	JJ
304953	100736402	20992759417	and	and	CC
304953	100736402	20992759418	large	large	JJ
304953	100736402	20992759419	randomized	randomized	JJ@
304953	100736402	20992759420	studies	study	NN2
304953	100736402	20992759421	provide	provide	VV0
304953	100736402	20992759422	the	the	AT
304953	100736402	20992759423	most	most	RGT
304953	100736402	20992759424	convincing	convincing	JJ
304953	100736402	20992759425	evidence	evidence	NN1
304953	100736402	20992759426	thus	thus	RR
304953	100736402	20992759427	far	far	JJ_RR
304953	100736402	20992759428	that	that	CST
304953	100736402	20992759429	PSA	psa	NP1
304953	100736402	20992759430	based	base	VVD@_VVN
304953	100736402	20992759431	testing	testing	NN1
304953	100736402	20992759432	does	do	VDZ
304953	100736402	20992759433	nothing	nothing	PN1
304953	100736402	20992759434	or	or	CC
304953	100736402	20992759435	meaningfully	meaningfully	RR
304953	100736402	20992759436	little	little	DA1_JJ_RR
304953	100736402	20992759437	to	to	TO
304953	100736402	20992759438	reduce	reduce	VVI
304953	100736402	20992759439	the	the	AT
304953	100736402	20992759440	death	death	NN1
304953	100736402	20992759441	rate	rate	NN1
304953	100736402	20992759442	from	from	II
304953	100736402	20992759443	@		II
304953	100736402	20992759444	@		II
304953	100736402	20992759445	@		II
304953	100736402	20992759446	@		II
304953	100736402	20992759447	@		II
304953	100736402	20992759448	@		II
304953	100736402	20992759449	@		II
304953	100736402	20992759450	@		II
304953	100736402	20992759451	@		II
304953	100736402	20992759452	@		II
304953	100736402	20992759453	the	the	AT
304953	100736402	20992759454	same	same	DA
304953	100736402	20992759455	conclusions	conclusion	NN2
304953	100736402	20992759456	.	.	.
304953	100736402	20992759457	In	in	II
304953	100736402	20992759458	this	this	DD1
304953	100736402	20992759459	video	video	NN1
304953	100736402	20992759460	,	,	,
304953	100736402	20992759461	Marc	marc	NP1
304953	100736402	20992759462	Garnick		NP1
304953	100736402	20992759463	,	,	,
304953	100736402	20992759464	MD	md	NNA
304953	100736402	20992759465	,	,	,
304953	100736402	20992759466	discusses	discuss	VVZ
304953	100736402	20992759467	the	the	AT
304953	100736402	20992759468	implications	implication	NN2
304953	100736402	20992759469	.	.	.
304953	100736403	20992759489	@@##	----------	----------
304953	100736403	20992759490	@@100736403		FO
304953	100736403	20992759491	@4936403/		VV0_NN1
304953	100736403	20992759492	46989		MC
304953	100736403	20992759493	@qwx906989		FO
304953	100736403	20992759494	<p>		NULL
304953	100736403	20992759495	To	to	TO
304953	100736403	20992759496	determine	determine	VVI
304953	100736403	20992759497	any	any	DD
304953	100736403	20992759498	differences	difference	NN2
304953	100736403	20992759499	in	in	II
304953	100736403	20992759500	survival	survival	NN1
304953	100736403	20992759501	times	time	NNT2
304953	100736403	20992759502	,	,	,
304953	100736403	20992759503	the	the	AT
304953	100736403	20992759504	Scandinavian	scandinavian	JJ_NN1
304953	100736403	20992759505	Prostate	prostate	NN1
304953	100736403	20992759506	Cancer	cancer	NN1
304953	100736403	20992759507	Group	group	NN1
304953	100736403	20992759508	Study	study	NN1
304953	100736403	20992759509	Number	number	NN1
304953	100736403	20992759510	4	4	MC
304953	100736403	20992759511	randomly	randomly	RR
304953	100736403	20992759512	assigned	assign	VVN
304953	100736403	20992759513	695	695	MC
304953	100736403	20992759514	prostate	prostate	NN1
304953	100736403	20992759515	cancer	cancer	NN1
304953	100736403	20992759516	patients	patient	NN2
304953	100736403	20992759517	to	to	TO
304953	100736403	20992759518	pursue	pursue	VVI
304953	100736403	20992759519	watchful	watchful	JJ
304953	100736403	20992759520	waiting	waiting	NN1@_JJ@
304953	100736403	20992759521	or	or	CC
304953	100736403	20992759522	undergo	undergo	VV0
304953	100736403	20992759523	a	a	AT1
304953	100736403	20992759524	radical	radical	JJ_NN1
304953	100736403	20992759525	prostatectomy	prostatectomy	NN1
304953	100736403	20992759526	between	between	II
304953	100736403	20992759527	1989	1989	MC
304953	100736403	20992759528	and	and	CC
304953	100736403	20992759529	1999	1999	MC
304953	100736403	20992759530	.	.	.
304953	100736403	20992759531	The	the	AT
304953	100736403	20992759532	average	average	JJ_NN1
304953	100736403	20992759533	age	age	NN1
304953	100736403	20992759534	of	of	IO
304953	100736403	20992759535	participants	participant	NN2
304953	100736403	20992759536	was	be	VBDZ
304953	100736403	20992759537	65	65	MC
304953	100736403	20992759538	.	.	.
304953	100736403	20992759539	<p>		NULL
304953	100736403	20992759540	In	in	II
304953	100736403	20992759541	2002	2002	MC
304953	100736403	20992759542	,	,	,
304953	100736403	20992759543	when	when	RRQ
304953	100736403	20992759544	the	the	AT
304953	100736403	20992759545	initial	initial	JJ_NN1
304953	100736403	20992759546	results	result	NN2
304953	100736403	20992759547	were	be	VBDR
304953	100736403	20992759548	published	publish	VVN
304953	100736403	20992759549	after	after	II
304953	100736403	20992759550	a	a	AT1
304953	100736403	20992759551	median	median	JJ
304953	100736403	20992759552	follow-up	follow-up	JJ_NN1
304953	100736403	20992759553	time	time	NNT1
304953	100736403	20992759554	of	of	IO
304953	100736403	20992759555	about	about	RG
304953	100736403	20992759556	six	six	MC
304953	100736403	20992759557	years	year	NNT2
304953	100736403	20992759558	,	,	,
304953	100736403	20992759559	researchers	researcher	NN2
304953	100736403	20992759560	reported	report	VVD_VVN
304953	100736403	20992759561	that	that	DD1_CST
304953	100736403	20992759562	surgery	surgery	NN1
304953	100736403	20992759563	significantly	significantly	RR
304953	100736403	20992759564	reduced	reduce	VVD_VVN
304953	100736403	20992759565	the	the	AT
304953	100736403	20992759566	chances	chance	NN2
304953	100736403	20992759567	of	of	IO
304953	100736403	20992759568	dying	die	VVG_JJ
304953	100736403	20992759569	from	from	II
304953	100736403	20992759570	prostate	prostate	NN1
304953	100736403	20992759571	cancer	cancer	NN1
304953	100736403	20992759572	.	.	.
304953	100736403	20992759573	However	however	RR
304953	100736403	20992759574	,	,	,
304953	100736403	20992759575	there	there	EX
304953	100736403	20992759576	was	be	VBDZ
304953	100736403	20992759577	no	no	AT
304953	100736403	20992759578	difference	difference	NN1
304953	100736403	20992759579	in	in	II
304953	100736403	20992759580	overall	overall	JJ_NN1
304953	100736403	20992759581	survival	survival	NN1
304953	100736403	20992759582	between	between	II
304953	100736403	20992759583	the	the	AT
304953	100736403	20992759584	two	two	MC
304953	100736403	20992759585	groups	group	NN2
304953	100736403	20992759586	.	.	.
304953	100736403	20992759587	After	after	II
304953	100736403	20992759588	tracking	track	VVG
304953	100736403	20992759589	the	the	AT
304953	100736403	20992759590	men	man	NN2
304953	100736403	20992759591	for	for	IF
304953	100736403	20992759592	a	a	AT1
304953	100736403	20992759593	few	few	DA2
304953	100736403	20992759594	more	more	DAR
304953	100736403	20992759595	years	year	NNT2
304953	100736403	20992759596	,	,	,
304953	100736403	20992759597	researchers	researcher	NN2
304953	100736403	20992759598	reported	report	VVN_VVD
304953	100736403	20992759599	in	in	II
304953	100736403	20992759600	2005	2005	MC
304953	100736403	20992759601	that	that	CST
304953	100736403	20992759602	patients	patient	NN2
304953	100736403	20992759603	who	who	PNQS
304953	100736403	20992759604	had	have	VHD
304953	100736403	20992759605	had	have	VHN
304953	100736403	20992759606	surgery	surgery	NN1
304953	100736403	20992759607	were	be	VBDR
304953	100736403	20992759608	significantly	significantly	RR
304953	100736403	20992759609	less	less	RGR
304953	100736403	20992759610	likely	likely	JJ
304953	100736403	20992759611	to	to	TO
304953	100736403	20992759612	die	die	VVI
304953	100736403	20992759613	from	from	II
304953	100736403	20992759614	prostate	prostate	NN1
304953	100736403	20992759615	cancer	cancer	NN1
304953	100736403	20992759616	and	and	CC
304953	100736403	20992759617	from	from	II
304953	100736403	20992759618	all	all	DB
304953	100736403	20992759619	other	other	JJ
304953	100736403	20992759620	causes	cause	NN2
304953	100736403	20992759621	than	than	CSN
304953	100736403	20992759622	the	the	AT
304953	100736403	20992759623	watchful	watchful	JJ
304953	100736403	20992759624	waiting	waiting	NN1@_JJ@
304953	100736403	20992759625	group	group	NN1
304953	100736403	20992759626	.	.	.
304953	100736403	20992759627	<p>		NULL
304953	100736403	20992759628	In	in	II
304953	100736403	20992759629	August	august	NPM1
304953	100736403	20992759630	2008	2008	MC
304953	100736403	20992759631	,	,	,
304953	100736403	20992759632	researchers	researcher	NN2
304953	100736403	20992759633	reported	report	VVN_VVD
304953	100736403	20992759634	on	on	II
304953	100736403	20992759635	study	study	NN1
304953	100736403	20992759636	participants	participant	NN2
304953	100736403	20992759637	for	for	IF
304953	100736403	20992759638	the	the	AT
304953	100736403	20992759639	third	third	MD
304953	100736403	20992759640	time	time	NNT1
304953	100736403	20992759641	.	.	.
304953	100736403	20992759642	After	after	CS_II
304953	100736403	20992759643	more	more	DAR_RRR
304953	100736403	20992759644	than	than	CSN
304953	100736403	20992759645	a	a	AT1
304953	100736403	20992759646	decade	decade	NNT1
304953	100736403	20992759647	of	of	IO
304953	100736403	20992759648	follow-up	follow-up	NN1_JJ
304953	100736403	20992759649	,	,	,
304953	100736403	20992759650	13.5%	13.5%	FO
304953	100736403	20992759651	of	of	IO
304953	100736403	20992759652	the	the	AT
304953	100736403	20992759653	men	man	NN2
304953	100736403	20992759654	who	who	PNQS
304953	100736403	20992759655	'd	have	VHD
304953	100736403	20992759656	had	have	VHN
304953	100736403	20992759657	surgery	surgery	NN1
304953	100736403	20992759658	had	have	VHN
304953	100736403	20992759659	died	die	VVN
304953	100736403	20992759660	from	from	II
304953	100736403	20992759661	prostate	prostate	NN1
304953	100736403	20992759662	cancer	cancer	NN1
304953	100736403	20992759663	,	,	,
304953	100736403	20992759664	compared	compare	VVN
304953	100736403	20992759665	with	with	IW
304953	100736403	20992759666	19.5%	-19.5%	FO
304953	100736403	20992759667	in	in	II
304953	100736403	20992759668	the	the	AT
304953	100736403	20992759669	watchful	watchful	JJ
304953	100736403	20992759670	waiting	waiting	NN1@_JJ@
304953	100736403	20992759671	group	group	NN1
304953	100736403	20992759672	.	.	.
304953	100736403	20992759673	After	after	II_CS
304953	100736403	20992759674	12	12	MC
304953	100736403	20992759675	years	year	NNT2
304953	100736403	20992759676	,	,	,
304953	100736403	20992759677	researchers	researcher	NN2
304953	100736403	20992759678	estimated	estimate	VVD_VVN
304953	100736403	20992759679	,	,	,
304953	100736403	20992759680	any	any	DD
304953	100736403	20992759681	@		II
304953	100736403	20992759682	@		II
304953	100736403	20992759683	@		II
304953	100736403	20992759684	@		II
304953	100736403	20992759685	@		II
304953	100736403	20992759686	@		II
304953	100736403	20992759687	@		II
304953	100736403	20992759688	@		II
304953	100736403	20992759689	@		II
304953	100736403	20992759690	@		II
304953	100736403	20992759691	statistically	statistically	RR
304953	100736403	20992759692	significant	significant	JJ
304953	100736403	20992759693	.	.	.
304953	100736403	20992759694	<p>		NULL
304953	100736403	20992759695	One	one	MC1
304953	100736403	20992759696	caveat	caveat	NN1
304953	100736403	20992759697	:	:	:
304953	100736403	20992759698	only	only	JJ
304953	100736403	20992759699	12%		NN1
304953	100736403	20992759700	of	of	IO
304953	100736403	20992759701	study	study	NN1
304953	100736403	20992759702	participants	participant	NN2
304953	100736403	20992759703	had	have	VHD
304953	100736403	20992759704	their	their	APPGE
304953	100736403	20992759705	cancers	cancer	NN2
304953	100736403	20992759706	detected	detect	VVN
304953	100736403	20992759707	with	with	IW
304953	100736403	20992759708	prostate-specific	prostate-specific	JJ
304953	100736403	20992759709	antigen	antigen	NN1
304953	100736403	20992759710	(	(	(
304953	100736403	20992759711	PSA	psa	NP1
304953	100736403	20992759712	)	)	)
304953	100736403	20992759713	testing	testing	NN1_VVG
304953	100736403	20992759714	.	.	.
304953	100736403	20992759715	The	the	AT
304953	100736403	20992759716	rest	rest	NN1
304953	100736403	20992759717	had	have	VHD
304953	100736403	20992759718	cancers	cancer	NN2
304953	100736403	20992759719	that	that	CST_DD1
304953	100736403	20992759720	could	could	VM
304953	100736403	20992759721	be	be	VBI
304953	100736403	20992759722	felt	feel	VVN
304953	100736403	20992759723	during	during	II
304953	100736403	20992759724	a	a	AT1
304953	100736403	20992759725	digital	digital	JJ
304953	100736403	20992759726	rectal	rectal	JJ
304953	100736403	20992759727	exam	exam	NN1
304953	100736403	20992759728	,	,	,
304953	100736403	20992759729	meaning	mean	VVG
304953	100736403	20992759730	that	that	CST
304953	100736403	20992759731	they	they	PPHS2
304953	100736403	20992759732	had	have	VHD
304953	100736403	20992759733	relatively	relatively	RR
304953	100736403	20992759734	more	more	RRR
304953	100736403	20992759735	advanced	advance	VVN
304953	100736403	20992759736	tumors	tumor	NN2
304953	100736403	20992759737	.	.	.
304953	100736403	20992759738	Whether	whether	CSW
304953	100736403	20992759739	the	the	AT
304953	100736403	20992759740	findings	finding	NN2
304953	100736403	20992759741	would	would	VM
304953	100736403	20992759742	be	be	VBI
304953	100736403	20992759743	similar	similar	JJ
304953	100736403	20992759744	for	for	IF
304953	100736403	20992759745	asymptomatic	asymptomatic	JJ
304953	100736403	20992759746	men	man	NN2
304953	100736403	20992759747	with	with	IW
304953	100736403	20992759748	cancers	cancer	NN2
304953	100736403	20992759749	diagnosed	diagnose	VVN_VVD
304953	100736403	20992759750	through	through	II
304953	100736403	20992759751	PSA	psa	NP1
304953	100736403	20992759752	screening	screening	NN1
304953	100736403	20992759753	remains	remain	VVZ
304953	100736403	20992759754	unclear	unclear	JJ
304953	100736403	20992759755	.	.	.
304953	100736403	20992759756	<p>		NULL
304953	100736403	20992759757	You	you	PPY
304953	100736403	20992759758	would	would	VM
304953	100736403	20992759759	n't	n't	XX
304953	100736403	20992759760	ecxpet		VVI
304953	100736403	20992759761	to	to	TO
304953	100736403	20992759762	pay	pay	VVI
304953	100736403	20992759763	the	the	AT
304953	100736403	20992759764	same	same	DA
304953	100736403	20992759765	price	price	NN1
304953	100736403	20992759766	for	for	IF
304953	100736403	20992759767	a	a	AT1
304953	100736403	20992759768	house	house	NN1
304953	100736403	20992759769	in	in	II
304953	100736403	20992759770	Iowa	iowa	NP1
304953	100736403	20992759771	as	as	CSA
304953	100736403	20992759772	you	you	PPY
304953	100736403	20992759773	would	would	VM
304953	100736403	20992759774	in	in	II
304953	100736403	20992759775	Malibu	malibu	NP1_NN1
304953	100736403	20992759776	.	.	.
304953	100736403	20992759777	Medical	medical	JJ
304953	100736403	20992759778	treatment	treatment	NN1
304953	100736403	20992759779	is	be	VBZ
304953	100736403	20992759780	the	the	AT
304953	100736403	20992759781	same	same	DA
304953	100736403	20992759782	;	;	;
304953	100736403	20992759783	it	it	PPH1
304953	100736403	20992759784	depends	depend	VVZ
304953	100736403	20992759785	on	on	II
304953	100736403	20992759786	where	where	RRQ
304953	100736403	20992759787	you	you	PPY
304953	100736403	20992759788	live	live	VV0
304953	100736403	20992759789	.	.	.
304953	100736403	20992759790	Usually	usually	RR
304953	100736403	20992759791	teaching	teach	VVG
304953	100736403	20992759792	hospitals	hospital	NN2
304953	100736403	20992759793	are	be	VBR
304953	100736403	20992759794	more	more	RGR
304953	100736403	20992759795	expensive	expensive	JJ
304953	100736403	20992759796	than	than	CSN
304953	100736403	20992759797	non-teaching	non-teaching	JJ
304953	100736403	20992759798	hospitals	hospital	NN2
304953	100736403	20992759799	though	though	RR@
304953	100736403	20992759800	.	.	.
304953	100736403	20992759801	Calypso	calypso	NN1_NP1@
304953	100736403	20992759802	is	be	VBZ
304953	100736403	20992759803	a	a	AT1
304953	100736403	20992759804	recommended	recommended	JJ@
304953	100736403	20992759805	option	option	NN1
304953	100736403	20992759806	,	,	,
304953	100736403	20992759807	but	but	CCB
304953	100736403	20992759808	there	there	EX
304953	100736403	20992759809	are	be	VBR
304953	100736403	20992759810	so	so	RG
304953	100736403	20992759811	many	many	DA2
304953	100736403	20992759812	options	option	NN2
304953	100736403	20992759813	for	for	IF
304953	100736403	20992759814	prostate	prostate	NN1
304953	100736403	20992759815	cancer	cancer	NN1
304953	100736403	20992759816	and	and	CC
304953	100736403	20992759817	so	so	RG
304953	100736403	20992759818	many	many	DA2
304953	100736403	20992759819	variables	variable	NN2
304953	100736403	20992759820	to	to	TO
304953	100736403	20992759821	consider	consider	VVI
304953	100736403	20992759822	there	there	RL_EX
304953	100736403	20992759823	is	be	VBZ
304953	100736403	20992759824	n't	n't	XX
304953	100736403	20992759825	a	a	AT1
304953	100736403	20992759826	best	best	JJT
304953	100736403	20992759827	option	option	NN1
304953	100736403	20992759828	for	for	IF
304953	100736403	20992759829	all	all	DB
304953	100736403	20992759830	.	.	.
304953	100736403	20992759831	If	if	CS
304953	100736403	20992759832	you	you	PPY
304953	100736403	20992759833	are	be	VBR
304953	100736403	20992759834	not	not	XX
304953	100736403	20992759835	sure	sure	JJ_RR%
304953	100736403	20992759836	about	about	II
304953	100736403	20992759837	which	which	DDQ
304953	100736403	20992759838	option	option	NN1
304953	100736403	20992759839	to	to	TO
304953	100736403	20992759840	choose	choose	VVI
304953	100736403	20992759841	try	try	VV0_NN1@
304953	100736403	20992759842	getting	get	VVG
304953	100736403	20992759843	another	another	DD1
304953	100736403	20992759844	opinion	opinion	NN1
304953	100736403	20992759845	from	from	II
304953	100736403	20992759846	another	another	DD1
304953	100736403	20992759847	oncologist.		NNU
304953	100736403	20992759848	46996		MC
304953	100736403	20992759849	@qwx906996		FO
304953	100736407	20992759869	@@##	----------	----------
304953	100736407	20992759870	@@100736407		FO
304953	100736407	20992759871	@4936407/		JJ_NN1_VV0
304953	100736407	20992759872	<h>		NULL
304953	100736407	20992759873	Prostate	prostate	NN1
304953	100736407	20992759874	Cancer	cancer	NN1
304953	100736407	20992759875	46988		MC
304953	100736407	20992759876	@qwx906988		FO
304953	100736407	20992759877	46994		MC
304953	100736407	20992759878	@qwx906994		FO
304953	100736407	20992759879	46995		MC
304953	100736407	20992759880	@qwx906995		FO
304953	100736407	20992759881	46992		MC
304953	100736407	20992759882	@qwx906992		FO
304953	100736407	20992759883	46991		MC
304953	100736407	20992759884	@qwx906991		FO
304953	100736407	20992759885	46990		MC
304953	100736407	20992759886	@qwx906990		FO
304953	100736407	20992759887	46989		MC
304953	100736407	20992759888	@qwx906989		FO
304953	100736407	20992759889	46993		MC
304953	100736407	20992759890	@qwx906993		FO
304953	100736407	20992759891	<h>		NULL
304953	100736407	20992759892	Hormone	hormone	NN1
304953	100736407	20992759893	Therapy	therapy	NN1
304953	100736407	20992759894	<p>		NULL
304953	100736407	20992759895	One	one	MC1
304953	100736407	20992759896	treatment	treatment	NN1
304953	100736407	20992759897	for	for	IF
304953	100736407	20992759898	prostate	prostate	NN1
304953	100736407	20992759899	cancer	cancer	NN1
304953	100736407	20992759900	is	be	VBZ
304953	100736407	20992759901	androgen-deprivation		JJ
304953	100736407	20992759902	therapy	therapy	NN1
304953	100736407	20992759903	,	,	,
304953	100736407	20992759904	also	also	RR
304953	100736407	20992759905	called	call	VVN
304953	100736407	20992759906	hormone	hormone	NN1
304953	100736407	20992759907	therapy	therapy	NN1
304953	100736407	20992759908	.	.	.
304953	100736407	20992759909	Androgens		NN2_NP1@
304953	100736407	20992759910	,	,	,
304953	100736407	20992759911	the	the	AT
304953	100736407	20992759912	family	family	NN1
304953	100736407	20992759913	of	of	IO
304953	100736407	20992759914	male	male	JJ_NN1
304953	100736407	20992759915	sex	sex	NN1
304953	100736407	20992759916	hormones	hormone	NN2
304953	100736407	20992759917	that	that	CST_DD1
304953	100736407	20992759918	includes	include	VVZ
304953	100736407	20992759919	testosterone	testosterone	NN1
304953	100736407	20992759920	,	,	,
304953	100736407	20992759921	fuel	fuel	VV0%_NN1
304953	100736407	20992759922	the	the	AT
304953	100736407	20992759923	growth	growth	NN1
304953	100736407	20992759924	of	of	IO
304953	100736407	20992759925	prostate	prostate	NN1
304953	100736407	20992759926	cancer	cancer	NN1
304953	100736407	20992759927	.	.	.
304953	100736407	20992759928	Stopping	stop	VVG
304953	100736407	20992759929	the	the	AT
304953	100736407	20992759930	body	body	NN1
304953	100736407	20992759931	from	from	II
304953	100736407	20992759932	making	make	VVG
304953	100736407	20992759933	these	these	DD2
304953	100736407	20992759934	hormones	hormone	NN2
304953	100736407	20992759935	can	can	VM
304953	100736407	20992759936	,	,	,
304953	100736407	20992759937	for	for	IF
304953	100736407	20992759938	a	a	AT1
304953	100736407	20992759939	time	time	NNT1
304953	100736407	20992759940	,	,	,
304953	100736407	20992759941	stop	stop	VV0
304953	100736407	20992759942	the	the	AT
304953	100736407	20992759943	growth	growth	NN1
304953	100736407	20992759944	of	of	IO
304953	100736407	20992759945	prostate	prostate	NN1
304953	100736407	20992759946	cancer	cancer	NN1
304953	100736407	20992759947	.	.	.
304953	100736407	20992759948	But	but	CCB
304953	100736407	20992759949	hormone	hormone	NN1
304953	100736407	20992759950	therapy	therapy	NN1
304953	100736407	20992759951	is	be	VBZ
304953	100736407	20992759952	n't	n't	XX
304953	100736407	20992759953	for	for	IF
304953	100736407	20992759954	everyone	everyone	PN1
304953	100736407	20992759955	,	,	,
304953	100736407	20992759956	and	and	CC
304953	100736407	20992759957	it	it	PPH1
304953	100736407	20992759958	can	can	VM
304953	100736407	20992759959	cause	cause	VVI
304953	100736407	20992759960	some	some	DD
304953	100736407	20992759961	bothersome	bothersome	JJ
304953	100736407	20992759962	,	,	,
304953	100736407	20992759963	even	even	RR
304953	100736407	20992759964	serious	serious	JJ
304953	100736407	20992759965	,	,	,
304953	100736407	20992759966	side	side	NN1
304953	100736407	20992759967	effects	effect	NN2
304953	100736407	20992759968	such	such	II21
304953	100736407	20992759969	as	as	II22
304953	100736407	20992759970	hot	hot	JJ
304953	100736407	20992759971	flashes	flash	NN2
304953	100736407	20992759972	,	,	,
304953	100736407	20992759973	decreased	decrease	VVD_JJ@_VVN
304953	100736407	20992759974	libido	libido	NN1
304953	100736407	20992759975	,	,	,
304953	100736407	20992759976	erectile	erectile	JJ
304953	100736407	20992759977	dysfunction	dysfunction	NN1
304953	100736407	20992759978	,	,	,
304953	100736407	20992759979	osteoporosis	osteoporosis	NN1
304953	100736407	20992759980	(	(	(
304953	100736407	20992759981	thinning	thinning	NN1@_VVG
304953	100736407	20992759982	of	of	IO
304953	100736407	20992759983	bones	bone	NN2
304953	100736407	20992759984	)	)	)
304953	100736407	20992759985	,	,	,
304953	100736407	20992759986	fatigue	fatigue	NN1
304953	100736407	20992759987	,	,	,
304953	100736407	20992759988	weight	weight	NN1
304953	100736407	20992759989	gain	gain	NN1_VV0
304953	100736407	20992759990	,	,	,
304953	100736407	20992759991	loss	loss	NN1
304953	100736407	20992759992	of	of	IO
304953	100736407	20992759993	muscle	muscle	NN1
304953	100736407	20992759994	mass	mass	NN1
304953	100736407	20992759995	,	,	,
304953	100736407	20992759996	anemia	anemia	NN1
304953	100736407	20992759997	,	,	,
304953	100736407	20992759998	and	and	CC
304953	100736407	20992759999	changes	change	NN2_VVZ@
304953	100736407	20992760000	in	in	II
304953	100736407	20992760001	blood	blood	NN1
304953	100736407	20992760002	cholesterol	cholesterol	NN1
304953	100736407	20992760003	and	and	CC
304953	100736407	20992760004	glucose	glucose	NN1
304953	100736407	20992760005	levels	level	NN2
304953	100736407	20992760006	.	.	.
304953	100736407	20992760007	<p>		NULL
304953	100736407	20992760008	Hormone	hormone	NN1
304953	100736407	20992760009	therapy	therapy	NN1
304953	100736407	20992760010	is	be	VBZ
304953	100736407	20992760011	an	a	AT1
304953	100736407	20992760012	option	option	NN1
304953	100736407	20992760013	for	for	IF
304953	100736407	20992760014	men	man	NN2
304953	100736407	20992760015	with	with	IW
304953	100736407	20992760016	prostate	prostate	NN1
304953	100736407	20992760017	cancer	cancer	NN1
304953	100736407	20992760018	when	when	CS_RRQ
304953	100736407	20992760019	:	:	:
304953	100736407	20992760020	cancer	cancer	NN1
304953	100736407	20992760021	has	have	VHZ
304953	100736407	20992760022	spread	spread	VVN
304953	100736407	20992760023	beyond	beyond	II
304953	100736407	20992760024	the	the	AT
304953	100736407	20992760025	prostate	prostate	NN1
304953	100736407	20992760026	cancer	cancer	NN1
304953	100736407	20992760027	is	be	VBZ
304953	100736407	20992760028	confined	confine	VVN
304953	100736407	20992760029	to	to	II
304953	100736407	20992760030	the	the	AT
304953	100736407	20992760031	prostate	prostate	NN1
304953	100736407	20992760032	but	but	CCB
304953	100736407	20992760033	doctors	doctor	NN2
304953	100736407	20992760034	want	want	VV0
304953	100736407	20992760035	to	to	TO
304953	100736407	20992760036	boost	boost	VVI
304953	100736407	20992760037	the	the	AT
304953	100736407	20992760038	effectiveness	effectiveness	NN1
304953	100736407	20992760039	of	of	IO
304953	100736407	20992760040	radiation	radiation	NN1
304953	100736407	20992760041	therapy	therapy	NN1
304953	100736407	20992760042	or	or	CC
304953	100736407	20992760043	shrink	shrink	VV0
304953	100736407	20992760044	a	a	AT1
304953	100736407	20992760045	tumor	tumor	NN1
304953	100736407	20992760046	before	before	II_CS
304953	100736407	20992760047	brachytherapy	brachytherapy	NN1
304953	100736407	20992760048	(	(	(
304953	100736407	20992760049	seed	seed	NN1_VV0@
304953	100736407	20992760050	therapy	therapy	NN1
304953	100736407	20992760051	,	,	,
304953	100736407	20992760052	a	a	AT1
304953	100736407	20992760053	type	type	NN1
304953	100736407	20992760054	of	of	IO
304953	100736407	20992760055	radiation	radiation	NN1
304953	100736407	20992760056	)	)	)
304953	100736407	20992760057	PSA	psa	NP1
304953	100736407	20992760058	begins	begin	VVZ
304953	100736407	20992760059	to	to	TO
304953	100736407	20992760060	rise	rise	VVI
304953	100736407	20992760061	@		II
304953	100736407	20992760062	@		II
304953	100736407	20992760063	@		II
304953	100736407	20992760064	@		II
304953	100736407	20992760065	@		II
304953	100736407	20992760066	@		II
304953	100736407	20992760067	@		II
304953	100736407	20992760068	@		II
304953	100736407	20992760069	@		II
304953	100736407	20992760070	@		II
304953	100736407	20992760071	that	that	CST_DD1
304953	100736407	20992760072	cancer	cancer	NN1
304953	100736407	20992760073	may	may	VM
304953	100736407	20992760074	have	have	VHI
304953	100736407	20992760075	recurred		VVN@
304953	100736407	20992760076	.	.	.
304953	100736407	20992760077	<h>		NULL
304953	100736407	20992760078	Related	related	JJ
304953	100736407	20992760079	Articles	article	NN2
304953	100736407	20992760080	<p>		NULL
304953	100736407	20992760081	High-grade	high-grade	JJ_NN1
304953	100736407	20992760082	cancer	cancer	NN1
304953	100736407	20992760083	that	that	CST_DD1
304953	100736407	20992760084	's	be	VBZ
304953	100736407	20992760085	still	still	RR
304953	100736407	20992760086	confined	confine	VVN
304953	100736407	20992760087	to	to	II
304953	100736407	20992760088	the	the	AT
304953	100736407	20992760089	prostate	prostate	NN1
304953	100736407	20992760090	is	be	VBZ
304953	100736407	20992760091	generally	generally	RR
304953	100736407	20992760092	treated	treat	VVN
304953	100736407	20992760093	surgically	surgically	RR
304953	100736407	20992760094	.	.	.
304953	100736407	20992760095	But	but	CCB
304953	100736407	20992760096	a	a	AT1
304953	100736407	20992760097	third	third	MD
304953	100736407	20992760098	of	of	IO
304953	100736407	20992760099	the	the	AT
304953	100736407	20992760100	men	man	NN2
304953	100736407	20992760101	who	who	PNQS
304953	100736407	20992760102	have	have	VH0
304953	100736407	20992760103	their	their	APPGE
304953	100736407	20992760104	cancerous	cancerous	JJ
304953	100736407	20992760105	prostates	prostate	NN2
304953	100736407	20992760106	removed	remove	VVN
304953	100736407	20992760107	will	will	VM
304953	100736407	20992760108	experience	experience	VVI
304953	100736407	20992760109	a	a	AT1
304953	100736407	20992760110	rise	rise	NN1
304953	100736407	20992760111	in	in	II
304953	100736407	20992760112	blood	blood	NN1
304953	100736407	20992760113	levels	level	NN2
304953	100736407	20992760114	of	of	IO
304953	100736407	20992760115	prostate-specific	prostate-specific	JJ
304953	100736407	20992760116	antigen	antigen	NN1
304953	100736407	20992760117	(	(	(
304953	100736407	20992760118	PSA	psa	NP1
304953	100736407	20992760119	)	)	)
304953	100736407	20992760120	.	.	.
304953	100736407	20992760121	This	this	DD1
304953	100736407	20992760122	is	be	VBZ
304953	100736407	20992760123	called	call	VVN
304953	100736407	20992760124	PSA	psa	NP1
304953	100736407	20992760125	recurrence	recurrence	NN1
304953	100736407	20992760126	.	.	.
304953	100736407	20992760127	And	and	CC
304953	100736407	20992760128	since	since	CS_RR@
304953	100736407	20992760129	detectable	detectable	JJ
304953	100736407	20992760130	PSA	psa	NP1
304953	100736407	20992760131	could	could	VM
304953	100736407	20992760132	signal	signal	VVI
304953	100736407	20992760133	the	the	AT
304953	100736407	20992760134	cancer	cancer	NN1
304953	100736407	20992760135	's	's	GE
304953	100736407	20992760136	return	return	NN1
304953	100736407	20992760137	,	,	,
304953	100736407	20992760138	doctors	doctor	NN2
304953	100736407	20992760139	will	will	VM
304953	100736407	20992760140	often	often	RR
304953	100736407	20992760141	treat	treat	VVI
304953	100736407	20992760142	it	it	PPH1
304953	100736407	20992760143	by	by	II_RP%
304953	100736407	20992760144	<p>		NULL
304953	100736407	20992760145	Hormonal	hormonal	JJ
304953	100736407	20992760146	therapy	therapy	NN1
304953	100736407	20992760147	,	,	,
304953	100736407	20992760148	also	also	RR
304953	100736407	20992760149	known	know	VVN
304953	100736407	20992760150	as	as	II
304953	100736407	20992760151	androgen-deprivation		JJ
304953	100736407	20992760152	therapy	therapy	NN1
304953	100736407	20992760153	,	,	,
304953	100736407	20992760154	can	can	VM
304953	100736407	20992760155	be	be	VBI
304953	100736407	20992760156	a	a	AT1
304953	100736407	20992760157	powerful	powerful	JJ
304953	100736407	20992760158	weapon	weapon	NN1
304953	100736407	20992760159	in	in	II
304953	100736407	20992760160	the	the	AT
304953	100736407	20992760161	fight	fight	NN1
304953	100736407	20992760162	against	against	II
304953	100736407	20992760163	prostate	prostate	NN1
304953	100736407	20992760164	cancer	cancer	NN1
304953	100736407	20992760165	because	because	CS
304953	100736407	20992760166	it	it	PPH1
304953	100736407	20992760167	deprives	deprive	VVZ
304953	100736407	20992760168	malignant	malignant	JJ
304953	100736407	20992760169	cells	cell	NN2
304953	100736407	20992760170	of	of	IO
304953	100736407	20992760171	the	the	AT
304953	100736407	20992760172	fuel	fuel	NN1
304953	100736407	20992760173	they	they	PPHS2
304953	100736407	20992760174	need	need	VV0
304953	100736407	20992760175	to	to	TO
304953	100736407	20992760176	grow	grow	VVI
304953	100736407	20992760177	.	.	.
304953	100736407	20992760178	Androgens	androgen	NN2
304953	100736407	20992760179	"	"	"
304953	100736407	20992760180	meaning	mean	VVG
304953	100736407	20992760181	the	the	AT
304953	100736407	20992760182	family	family	NN1
304953	100736407	20992760183	of	of	IO
304953	100736407	20992760184	male	male	JJ_NN1
304953	100736407	20992760185	sex	sex	NN1
304953	100736407	20992760186	hormones	hormone	NN2
304953	100736407	20992760187	that	that	CST_DD1
304953	100736407	20992760188	includes	include	VVZ
304953	100736407	20992760189	testosterone	testosterone	NN1
304953	100736407	20992760190	"	"	"
304953	100736407	20992760191	contribute	contribute	VV0
304953	100736407	20992760192	to	to	II
304953	100736407	20992760193	physical	physical	JJ
304953	100736407	20992760194	characteristics	characteristic	NN2
304953	100736407	20992760195	such	such	II21
304953	100736407	20992760196	as	as	II22
304953	100736407	20992760197	a	a	AT1
304953	100736407	20992760198	deeper	deep	JJR
304953	100736407	20992760199	voice	voice	NN1
304953	100736407	20992760200	,	,	,
304953	100736407	20992760201	thick	thick	JJ_RR@
304953	100736407	20992760202	facial	facial	JJ
304953	100736407	20992760203	hair	hair	NN1
304953	100736407	20992760204	,	,	,
304953	100736407	20992760205	and	and	CC
304953	100736407	20992760206	increased	increased	JJ
304953	100736407	20992760207	muscle	muscle	NN1
304953	100736407	20992760208	strength	strength	NN1
304953	100736407	20992760209	and	and	CC
304953	100736407	20992760210	bone	bone	NN1
304953	100736407	20992760211	mass	mass	NN1
304953	100736407	20992760212	.	.	.
304953	100736407	20992760213	But	but	CCB
304953	100736407	20992760214	when	when	CS
304953	100736407	20992760215	prostate	prostate	NN1
304953	100736407	20992760216	cancer	cancer	NN1
304953	100736407	20992760217	develops	develop	VVZ
304953	100736407	20992760218	,	,	,
304953	100736407	20992760219	testosterone	testosterone	NN1
304953	100736407	20992760220	also	also	RR
304953	100736407	20992760221	contributes	contribute	VVZ
304953	100736407	20992760222	to	to	II
304953	100736407	20992760223	tumor	tumor	NN1
304953	100736407	20992760224	growth	growth	NN1
304953	100736407	20992760225	and	and	CC
304953	100736407	20992760226	progression	progression	NN1
304953	100736407	20992760227	.	.	.
304953	100736407	20992760228	Depending	depending	II21
304953	100736407	20992760229	on	on	II22
304953	100736407	20992760230	the	the	AT
304953	100736407	20992760231	specific	specific	JJ
304953	100736407	20992760232	treatment	treatment	NN1
304953	100736407	20992760233	used	use	VVD_VVN
304953	100736407	20992760234	,	,	,
304953	100736407	20992760235	hormonal	hormonal	JJ
304953	100736407	20992760236	therapy	therapy	NN1
304953	100736407	20992760237	can	can	VM
304953	100736407	20992760238	either	either	RR
304953	100736407	20992760239	stop	stop	VVI
304953	100736407	20992760240	the	the	AT
304953	100736407	20992760241	body	body	NN1
304953	100736407	20992760242	from	from	II
304953	100736407	20992760243	making	make	VVG
304953	100736407	20992760244	testosterone	testosterone	NN1
304953	100736407	20992760245	or	or	CC
304953	100736407	20992760246	prevent	prevent	VV0
304953	100736407	20992760247	it	it	PPH1
304953	100736407	20992760248	from	from	II
304953	100736407	20992760249	interacting	interact	VVG_JJ
304953	100736407	20992760250	with	with	IW
304953	100736407	20992760251	cancer	cancer	NN1
304953	100736407	20992760252	cells	cell	NN2
304953	100736407	20992760253	.	.	.
304953	100736407	20992760254	<p>		NULL
304953	100736407	20992760255	In	in	II
304953	100736407	20992760256	men	man	NN2
304953	100736407	20992760257	with	with	IW
304953	100736407	20992760258	cancer	cancer	NN1
304953	100736407	20992760259	that	that	CST_DD1
304953	100736407	20992760260	has	have	VHZ
304953	100736407	20992760261	@		II
304953	100736407	20992760262	@		II
304953	100736407	20992760263	@		II
304953	100736407	20992760264	@		II
304953	100736407	20992760265	@		II
304953	100736407	20992760266	@		II
304953	100736407	20992760267	@		II
304953	100736407	20992760268	@		II
304953	100736407	20992760269	@		II
304953	100736407	20992760270	@		II
304953	100736407	20992760271	therapy	therapy	NN1
304953	100736407	20992760272	can	can	VM
304953	100736407	20992760273	ease	ease	VVI
304953	100736407	20992760274	symptoms	symptom	NN2
304953	100736407	20992760275	and	and	CC
304953	100736407	20992760276	improve	improve	VVI
304953	100736407	20992760277	survival	survival	NN1
304953	100736407	20992760278	.	.	.
304953	100736407	20992760279	But	but	CCB
304953	100736407	20992760280	some	some	DD
304953	100736407	20992760281	doctors	doctor	NN2
304953	100736407	20992760282	give	give	VV0
304953	100736407	20992760283	hormone	hormone	NN1
304953	100736407	20992760284	therapy	therapy	NN1
304953	100736407	20992760285	by	by	II
304953	100736407	20992760286	itself	itself	PPX1
304953	100736407	20992760287	to	to	II
304953	100736407	20992760288	millions	million	NNO2
304953	100736407	20992760289	of	of	IO
304953	100736407	20992760290	men	man	NN2
304953	100736407	20992760291	with	with	IW
304953	100736407	20992760292	localized	localized	JJ
304953	100736407	20992760293	tumors	tumor	NN2
304953	100736407	20992760294	that	that	CST_DD1
304953	100736407	20992760295	have n't		VV0_NN1
304953	100736407	20992760296	spread	spread	NN1_VVN_VVD_VV0
304953	100736407	20992760297	beyond	beyond	II
304953	100736407	20992760298	the	the	AT
304953	100736407	20992760299	prostate	prostate	NN1
304953	100736407	20992760300	.	.	.
304953	100736407	20992760301	A	a	AT1_ZZ1
304953	100736407	20992760302	new	new	JJ
304953	100736407	20992760303	study	study	NN1
304953	100736407	20992760304	shows	show	VVZ
304953	100736407	20992760305	that	that	CST
304953	100736407	20992760306	this	this	DD1
304953	100736407	20992760307	approach	approach	NN1
304953	100736407	20992760308	does	do	VDZ
304953	100736407	20992760309	n't 	n't	XX
304953	100736407	20992760310	help	help	VVI
304953	100736407	20992760311	,	,	,
304953	100736407	20992760312	and	and	CC
304953	100736407	20992760313	may	may	VM
304953	100736407	20992760314	hurt	hurt	VVI
304953	100736407	20992760315	.	.	.
304953	100736407	20992760316	<p>		NULL
304953	100736407	20992760317	Prostate	prostate	NN1
304953	100736407	20992760318	cancer	cancer	NN1
304953	100736407	20992760319	drug	drug	NN1
304953	100736407	20992760320	treatments	treatment	NN2
304953	100736407	20992760321	that	that	CST
304953	100736407	20992760322	block	block	VV0@
304953	100736407	20992760323	the	the	AT
304953	100736407	20992760324	activity	activity	NN1
304953	100736407	20992760325	of	of	IO
304953	100736407	20992760326	hormones	hormone	NN2
304953	100736407	20992760327	have	have	VH0
304953	100736407	20992760328	been	be	VBN
304953	100736407	20992760329	associated	associate	VVN
304953	100736407	20992760330	with	with	IW
304953	100736407	20992760331	a	a	AT1
304953	100736407	20992760332	higher	high	JJR
304953	100736407	20992760333	risk	risk	NN1
304953	100736407	20992760334	of	of	IO
304953	100736407	20992760335	heart	heart	NN1
304953	100736407	20992760336	attack	attack	NN1
304953	100736407	20992760337	and	and	CC
304953	100736407	20992760338	heart	heart	NN1
304953	100736407	20992760339	disease	disease	NN1
304953	100736407	20992760340	.	.	.
304953	100736407	20992760341	But	but	CCB
304953	100736407	20992760342	a	a	AT1
304953	100736407	20992760343	2009	2009	MC
304953	100736407	20992760344	study	study	NN1
304953	100736407	20992760345	suggests	suggest	VVZ
304953	100736407	20992760346	that	that	CST
304953	100736407	20992760347	these	these	DD2
304953	100736407	20992760348	drugs	drug	NN2
304953	100736407	20992760349	may	may	VM
304953	100736407	20992760350	not	not	XX
304953	100736407	20992760351	cause	cause	VVI
304953	100736407	20992760352	cardiovascular	cardiovascular	JJ
304953	100736407	20992760353	problems	problem	NN2
304953	100736407	20992760354	after	after	II
304953	100736407	20992760355	all	all	DB
304953	100736407	20992760356	.	.	.
304953	100736407	20992760357	<p>		NULL
304953	100736407	20992760358	A	a	AT1_ZZ1
304953	100736407	20992760359	European	european	JJ
304953	100736407	20992760360	study	study	NN1
304953	100736407	20992760361	finds	find	VVZ
304953	100736407	20992760362	that	that	DD1_CST
304953	100736407	20992760363	mortality	mortality	NN1
304953	100736407	20992760364	is	be	VBZ
304953	100736407	20992760365	higher	high	JJR
304953	100736407	20992760366	among	among	II
304953	100736407	20992760367	men	man	NN2
304953	100736407	20992760368	who	who	PNQS
304953	100736407	20992760369	pursue	pursue	VV0
304953	100736407	20992760370	hormone	hormone	NN1
304953	100736407	20992760371	therapy	therapy	NN1
304953	100736407	20992760372	for	for	IF
304953	100736407	20992760373	just	just	RR
304953	100736407	20992760374	six	six	MC
304953	100736407	20992760375	months	month	NNT2
304953	100736407	20992760376	.	.	.
304953	100736407	20992760377	But	but	CCB
304953	100736407	20992760378	the	the	AT
304953	100736407	20992760379	study	study	NN1
304953	100736407	20992760380	was	be	VBDZ
304953	100736407	20992760381	conducted	conduct	VVN
304953	100736407	20992760382	in	in	II
304953	100736407	20992760383	men	man	NN2
304953	100736407	20992760384	with	with	IW
304953	100736407	20992760385	relatively	relatively	RR
304953	100736407	20992760386	large	large	JJ
304953	100736407	20992760387	tumors	tumor	NN2
304953	100736407	20992760388	,	,	,
304953	100736407	20992760389	not	not	XX
304953	100736407	20992760390	small	small	JJ_RR%
304953	100736407	20992760391	,	,	,
304953	100736407	20992760392	early-stage	early-stage	JJ_NN1
304953	100736407	20992760393	tumors	tumor	NN2
304953	100736407	20992760394	,	,	,
304953	100736407	20992760395	the	the	AT
304953	100736407	20992760396	kind	kind	NN1
304953	100736407	20992760397	found	find	VVD_VVN
304953	100736407	20992760398	most	most	RGT
304953	100736407	20992760399	often	often	RR
304953	100736407	20992760400	in	in	II
304953	100736407	20992760401	American	american	JJ
304953	100736407	20992760402	men	man	NN2
304953	100736407	20992760403	.	.	.
304953	100736408	20992760423	@@##	----------	----------
304953	100736408	20992760424	@@100736408		FO
304953	100736408	20992760425	@4936408/		VV0_NN1
304953	100736408	20992760426	46989		MC
304953	100736408	20992760427	@qwx906989		FO
304953	100736408	20992760428	<h>		NULL
304953	100736408	20992760429	Posts	post	NN2
304953	100736408	20992760430	Tagged	tag	VVD_VVN
304953	100736408	20992760431	news	news	NN1
304953	100736408	20992760432	<p>		NULL
304953	100736408	20992760433	Even	even	CS21
304953	100736408	20992760434	if	if	CS22
304953	100736408	20992760435	my	my	APPGE
304953	100736408	20992760436	father	father	NN1
304953	100736408	20992760437	takes	take	VVZ
304953	100736408	20992760438	antibiotics	antibiotic	NN2
304953	100736408	20992760439	beforehand	beforehand	RR
304953	100736408	20992760440	,	,	,
304953	100736408	20992760441	could	could	VM
304953	100736408	20992760442	he	he	PPHS1
304953	100736408	20992760443	develop	develop	VVI
304953	100736408	20992760444	a	a	AT1
304953	100736408	20992760445	serious	serious	JJ
304953	100736408	20992760446	infection	infection	NN1
304953	100736408	20992760447	when	when	CS_RRQ
304953	100736408	20992760448	he	he	PPHS1
304953	100736408	20992760449	has	have	VHZ
304953	100736408	20992760450	a	a	AT1
304953	100736408	20992760451	prostate	prostate	NN1
304953	100736408	20992760452	biopsy	biopsy	NN1
304953	100736408	20992760453	later	later	RRR
304953	100736408	20992760454	this	this	DD1
304953	100736408	20992760455	year	year	NNT1
304953	100736408	20992760456	?	?	?
304953	100736408	20992760457	Are	be	VBR
304953	100736408	20992760458	there	there	RL_EX
304953	100736408	20992760459	other	other	JJ
304953	100736408	20992760460	possible	possible	JJ
304953	100736408	20992760461	complications	complication	NN2
304953	100736408	20992760462	we	we	PPIS2
304953	100736408	20992760463	should	should	VM
304953	100736408	20992760464	be	be	VBI
304953	100736408	20992760465	on	on	II
304953	100736408	20992760466	the	the	AT
304953	100736408	20992760467	lookout	lookout	NN1
304953	100736408	20992760468	for	for	IF
304953	100736408	20992760469	?	?	?
304953	100736408	20992760470	<p>		NULL
304953	100736408	20992760471	Androgen		NN1_NP1@
304953	100736408	20992760472	deprivation	deprivation	NN1
304953	100736408	20992760473	,	,	,
304953	100736408	20992760474	whether	whether	CSW
304953	100736408	20992760475	through	through	II
304953	100736408	20992760476	surgical	surgical	JJ
304953	100736408	20992760477	removal	removal	NN1
304953	100736408	20992760478	of	of	IO
304953	100736408	20992760479	the	the	AT
304953	100736408	20992760480	testicles	testicle	NN2
304953	100736408	20992760481	or	or	CC
304953	100736408	20992760482	with	with	IW
304953	100736408	20992760483	medication	medication	NN1
304953	100736408	20992760484	,	,	,
304953	100736408	20992760485	is	be	VBZ
304953	100736408	20992760486	an	a	AT1
304953	100736408	20992760487	effective	effective	JJ
304953	100736408	20992760488	treatment	treatment	NN1
304953	100736408	20992760489	for	for	IF
304953	100736408	20992760490	recurring	recurring	JJ_VVG
304953	100736408	20992760491	prostate	prostate	NN1
304953	100736408	20992760492	cancer	cancer	NN1
304953	100736408	20992760493	"	"	"
304953	100736408	20992760494	at	at	RR21
304953	100736408	20992760495	least	least	RR22
304953	100736408	20992760496	for	for	IF
304953	100736408	20992760497	a	a	AT1
304953	100736408	20992760498	while	while	NNT1@
304953	100736408	20992760499	.	.	.
304953	100736408	20992760500	An	a	AT1
304953	100736408	20992760501	improved	improved	JJ
304953	100736408	20992760502	understanding	understanding	NN1
304953	100736408	20992760503	of	of	IO
304953	100736408	20992760504	the	the	AT
304953	100736408	20992760505	biology	biology	NN1
304953	100736408	20992760506	of	of	IO
304953	100736408	20992760507	prostate	prostate	NN1
304953	100736408	20992760508	cancer	cancer	NN1
304953	100736408	20992760509	has	have	VHZ
304953	100736408	20992760510	led	lead	VVN
304953	100736408	20992760511	to	to	II
304953	100736408	20992760512	the	the	AT
304953	100736408	20992760513	development	development	NN1
304953	100736408	20992760514	of	of	IO
304953	100736408	20992760515	two	two	MC
304953	100736408	20992760516	drugs	drug	NN2
304953	100736408	20992760517	that	that	CST_DD1
304953	100736408	20992760518	might	might	VM
304953	100736408	20992760519	slow	slow	VVI
304953	100736408	20992760520	disease	disease	NN1
304953	100736408	20992760521	progression	progression	NN1
304953	100736408	20992760522	in	in	II
304953	100736408	20992760523	prostate	prostate	NN1
304953	100736408	20992760524	cancer	cancer	NN1
304953	100736408	20992760525	patients	patient	NN2
304953	100736408	20992760526	whose	whose	DDQGE
304953	100736408	20992760527	disease	disease	NN1
304953	100736408	20992760528	no	no	RR21
304953	100736408	20992760529	longer	long	RR22
304953	100736408	20992760530	responds	respond	VVZ
304953	100736408	20992760531	to	to	II
304953	100736408	20992760532	androgen	androgen	NN1
304953	100736408	20992760533	deprivation	deprivation	NN1
304953	100736408	20992760534	.	.	.
304953	100736409	20992760554	@@##	----------	----------
304953	100736409	20992760555	@@100736409		FO
304953	100736409	20992760556	@4936409/		VV0_NN1
304953	100736409	20992760557	46989		MC
304953	100736409	20992760558	@qwx906989		FO
304953	100736409	20992760559	<p>		NULL
304953	100736409	20992760560	Combining	combine	VVG
304953	100736409	20992760561	two	two	MC
304953	100736409	20992760562	widely	widely	RR
304953	100736409	20992760563	prescribed	prescribed	JJ_VVN
304953	100736409	20992760564	medications	medication	NN2
304953	100736409	20992760565	"	"	"
304953	100736409	20992760566	the	the	AT
304953	100736409	20992760567	anti-inflammatory	anti-inflammatory	JJ
304953	100736409	20992760568	drug	drug	NN1
304953	100736409	20992760569	celecoxib	celecoxib	NN1
304953	100736409	20992760570	(	(	(
304953	100736409	20992760571	Celebrex	celebrex	NP1
304953	100736409	20992760572	)	)	)
304953	100736409	20992760573	and	and	CC
304953	100736409	20992760574	the	the	AT
304953	100736409	20992760575	cholesterol-lowering	cholesterol-lowering	JJ_NN1
304953	100736409	20992760576	statin	statin	NN1
304953	100736409	20992760577	drug	drug	NN1
304953	100736409	20992760578	atorvastatin	atorvastatin	NN1
304953	100736409	20992760579	(	(	(
304953	100736409	20992760580	Lipitor	lipitor	NP1
304953	100736409	20992760581	)	)	)
304953	100736409	20992760582	"	"	"
304953	100736409	20992760583	may	may	VM
304953	100736409	20992760584	help	help	VVI
304953	100736409	20992760585	stop	stop	VVI
304953	100736409	20992760586	the	the	AT
304953	100736409	20992760587	progression	progression	NN1
304953	100736409	20992760588	of	of	IO
304953	100736409	20992760589	prostate	prostate	NN1
304953	100736409	20992760590	cancer	cancer	NN1
304953	100736409	20992760591	,	,	,
304953	100736409	20992760592	according	according	II21
304953	100736409	20992760593	to	to	II22
304953	100736409	20992760594	a	a	AT1
304953	100736409	20992760595	study	study	NN1
304953	100736409	20992760596	presented	present	VVN_VVD
304953	100736409	20992760597	at	at	II
304953	100736409	20992760598	the	the	AT
304953	100736409	20992760599	American	american	JJ
304953	100736409	20992760600	Association	association	NN1
304953	100736409	20992760601	for	for	IF
304953	100736409	20992760602	Cancer	cancer	NN1
304953	100736409	20992760603	Research	research	NN1_VV0@
304953	100736409	20992760604	annual	annual	JJ_NN1@
304953	100736409	20992760605	meeting	meeting	NN1_VVG
304953	100736409	20992760606	in	in	II
304953	100736409	20992760607	April	april	NPM1
304953	100736409	20992760608	2008	2008	MC
304953	100736409	20992760609	.	.	.
304953	100736409	20992760610	But	but	CCB
304953	100736409	20992760611	do	do	VD0
304953	100736409	20992760612	n't	n't	XX
304953	100736409	20992760613	ask	ask	VVI
304953	100736409	20992760614	your	your	APPGE
304953	100736409	20992760615	doctor	doctor	NN1
304953	100736409	20992760616	for	for	IF
304953	100736409	20992760617	prescriptions	prescription	NN2
304953	100736409	20992760618	just	just	RR
304953	100736409	20992760619	yet	yet	RR
304953	100736409	20992760620	:	:	:
304953	100736409	20992760621	the	the	AT
304953	100736409	20992760622	research	research	NN1
304953	100736409	20992760623	was	be	VBDZ
304953	100736409	20992760624	conducted	conduct	VVN
304953	100736409	20992760625	in	in	II
304953	100736409	20992760626	mice	mouse	NN2
304953	100736409	20992760627	.	.	.
304953	100736409	20992760628	<p>		NULL
304953	100736409	20992760629	Researchers	researcher	NN2
304953	100736409	20992760630	aimed	aim	VVD_VVN
304953	100736409	20992760631	to	to	TO
304953	100736409	20992760632	delay	delay	VVI
304953	100736409	20992760633	the	the	AT
304953	100736409	20992760634	progression	progression	NN1
304953	100736409	20992760635	of	of	IO
304953	100736409	20992760636	androgen-dependent		JJ
304953	100736409	20992760637	tumors	tumor	NN2
304953	100736409	20992760638	,	,	,
304953	100736409	20992760639	which	which	DDQ
304953	100736409	20992760640	rely	rely	VV0
304953	100736409	20992760641	on	on	II_RP@
304953	100736409	20992760642	male	male	JJ_NN1
304953	100736409	20992760643	hormones	hormone	NN2
304953	100736409	20992760644	to	to	TO
304953	100736409	20992760645	grow	grow	VVI
304953	100736409	20992760646	,	,	,
304953	100736409	20992760647	to	to	II
304953	100736409	20992760648	androgen-independent		JJ
304953	100736409	20992760649	tumors	tumor	NN2
304953	100736409	20992760650	,	,	,
304953	100736409	20992760651	which	which	DDQ
304953	100736409	20992760652	no	no	RR21
304953	100736409	20992760653	longer	long	RR22
304953	100736409	20992760654	respond	respond	VV0
304953	100736409	20992760655	to	to	II
304953	100736409	20992760656	hormone	hormone	NN1
304953	100736409	20992760657	therapy	therapy	NN1
304953	100736409	20992760658	.	.	.
304953	100736409	20992760659	To	to	TO
304953	100736409	20992760660	do	do	VDI
304953	100736409	20992760661	so	so	RR
304953	100736409	20992760662	,	,	,
304953	100736409	20992760663	they	they	PPHS2
304953	100736409	20992760664	shrank	shrink	VVD
304953	100736409	20992760665	prostate	prostate	NN1
304953	100736409	20992760666	tumors	tumor	NN2
304953	100736409	20992760667	in	in	II
304953	100736409	20992760668	mice	mouse	NN2
304953	100736409	20992760669	by	by	II
304953	100736409	20992760670	depriving	deprive	VVG
304953	100736409	20992760671	the	the	AT
304953	100736409	20992760672	animals	animal	NN2
304953	100736409	20992760673	of	of	IO
304953	100736409	20992760674	androgens	androgen	NN2
304953	100736409	20992760675	.	.	.
304953	100736409	20992760676	The	the	AT
304953	100736409	20992760677	mice	mouse	NN2
304953	100736409	20992760678	were	be	VBDR
304953	100736409	20992760679	then	then	RT
304953	100736409	20992760680	divided	divide	VVN_VVD
304953	100736409	20992760681	into	into	II
304953	100736409	20992760682	four	four	MC
304953	100736409	20992760683	groups	group	NN2
304953	100736409	20992760684	:	:	:
304953	100736409	20992760685	one	one	MC1
304953	100736409	20992760686	group	group	NN1
304953	100736409	20992760687	received	receive	VVD_VVN
304953	100736409	20992760688	atorvastatin	atorvastatin	NN1
304953	100736409	20992760689	;	;	;
304953	100736409	20992760690	the	the	AT
304953	100736409	20992760691	second	second	NNT1_MD
304953	100736409	20992760692	,	,	,
304953	100736409	20992760693	celecoxib		VV0_NN1
304953	100736409	20992760694	;	;	;
304953	100736409	20992760695	the	the	AT
304953	100736409	20992760696	third	third	MD
304953	100736409	20992760697	,	,	,
304953	100736409	20992760698	both	both	DB2
304953	100736409	20992760699	drugs	drug	NN2
304953	100736409	20992760700	;	;	;
304953	100736409	20992760701	and	and	CC
304953	100736409	20992760702	the	the	AT
304953	100736409	20992760703	fourth	fourth	MD
304953	100736409	20992760704	,	,	,
304953	100736409	20992760705	no	no	AT
304953	100736409	20992760706	medications	medication	NN2
304953	100736409	20992760707	at	at	RR21
304953	100736409	20992760708	all	all	RR22
304953	100736409	20992760709	.	.	.
304953	100736409	20992760710	Tumors	tumor	NN2_NP1@
304953	100736409	20992760711	began	begin	VVD
304953	100736409	20992760712	to	to	TO
304953	100736409	20992760713	regrow	regrow	VVI
304953	100736409	20992760714	within	within	II
304953	100736409	20992760715	two	two	MC
304953	100736409	20992760716	weeks	week	NNT2
304953	100736409	20992760717	in	in	II
304953	100736409	20992760718	the	the	AT
304953	100736409	20992760719	mice	mouse	NN2
304953	100736409	20992760720	that	that	CST_DD1
304953	100736409	20992760721	did	do	VDD
304953	100736409	20992760722	n't	n't	XX
304953	100736409	20992760723	receive	receive	VVI
304953	100736409	20992760724	any	any	DD
304953	100736409	20992760725	drugs	drug	NN2
304953	100736409	20992760726	.	.	.
304953	100736409	20992760727	In	in	II
304953	100736409	20992760728	contrast	contrast	NN1
304953	100736409	20992760729	,	,	,
304953	100736409	20992760730	all	all	DB_RR@
304953	100736409	20992760731	three	three	MC
304953	100736409	20992760732	drug	drug	NN1
304953	100736409	20992760733	regimens	regimen	NN2
304953	100736409	20992760734	slowed	slow	VVD_VVN
304953	100736409	20992760735	tumor	tumor	NN1
304953	100736409	20992760736	growth	growth	NN1
304953	100736409	20992760737	,	,	,
304953	100736409	20992760738	with	with	IW
304953	100736409	20992760739	the	the	AT
304953	100736409	20992760740	combination	combination	NN1
304953	100736409	20992760741	packing	pack	VVG
304953	100736409	20992760742	the	the	AT
304953	100736409	20992760743	biggest	big	JJT
304953	100736409	20992760744	punch	punch	NN1
304953	100736409	20992760745	.	.	.
304953	100736409	20992760746	@		II
304953	100736409	20992760747	@		II
304953	100736409	20992760748	@		II
304953	100736409	20992760749	@		II
304953	100736409	20992760750	@		II
304953	100736409	20992760751	@		II
304953	100736409	20992760752	@		II
304953	100736409	20992760753	@		II
304953	100736409	20992760754	@		II
304953	100736409	20992760755	@		II
304953	100736409	20992760756	and	and	CC
304953	100736409	20992760757	Celebrex	celebrex	NP1_NN1
304953	100736409	20992760758	have	have	VH0
304953	100736409	20992760759	this	this	DD1
304953	100736409	20992760760	effect	effect	NN1
304953	100736409	20992760761	on	on	II
304953	100736409	20992760762	prostate	prostate	NN1
304953	100736409	20992760763	tumors	tumor	NN2
304953	100736409	20992760764	,	,	,
304953	100736409	20992760765	they	they	PPHS2
304953	100736409	20992760766	are	be	VBR
304953	100736409	20992760767	planning	plan	VVG
304953	100736409	20992760768	a	a	AT1
304953	100736409	20992760769	study	study	NN1
304953	100736409	20992760770	in	in	II
304953	100736409	20992760771	prostate	prostate	NN1
304953	100736409	20992760772	cancer	cancer	NN1
304953	100736409	20992760773	patients	patient	NN2
304953	100736409	20992760774	.	.	.
304953	100736409	20992760775	46996		MC
304953	100736409	20992760776	@qwx906996		FO
304953	100736413	20992760796	@@##	----------	----------
304953	100736413	20992760797	@@100736413		FO
304953	100736413	20992760798	@4936413/		VV0_NN1
304953	100736413	20992760799	46989		MC
304953	100736413	20992760800	@qwx906989		FO
304953	100736413	20992760801	<p>		NULL
304953	100736413	20992760802	Because	because	CS
304953	100736413	20992760803	stretching	stretch	VVG
304953	100736413	20992760804	cold	cold	JJ
304953	100736413	20992760805	muscles	muscle	NN2
304953	100736413	20992760806	can	can	VM
304953	100736413	20992760807	lead	lead	VVI
304953	100736413	20992760808	to	to	II
304953	100736413	20992760809	injury	injury	NN1
304953	100736413	20992760810	,	,	,
304953	100736413	20992760811	it	it	PPH1
304953	100736413	20992760812	's	be	VBZ
304953	100736413	20992760813	best	best	JJT
304953	100736413	20992760814	to	to	TO
304953	100736413	20992760815	stretch	stretch	VVI
304953	100736413	20992760816	after	after	II_CS
304953	100736413	20992760817	your	your	APPGE
304953	100736413	20992760818	muscles	muscle	NN2
304953	100736413	20992760819	have	have	VH0
304953	100736413	20992760820	been	be	VBN
304953	100736413	20992760821	adequately	adequately	RR
304953	100736413	20992760822	warmed	warm	VVN_VVD
304953	100736413	20992760823	up	up	RP
304953	100736413	20992760824	"	"	"
304953	100736413	20992760825	either	either	RR
304953	100736413	20992760826	at	at	II
304953	100736413	20992760827	the	the	AT
304953	100736413	20992760828	end	end	NN1
304953	100736413	20992760829	of	of	IO
304953	100736413	20992760830	your	your	APPGE
304953	100736413	20992760831	workout	workout	NN1
304953	100736413	20992760832	or	or	CC
304953	100736413	20992760833	after	after	CS
304953	100736413	20992760834	you	you	PPY
304953	100736413	20992760835	've	have	VH0
304953	100736413	20992760836	completed	complete	VVN
304953	100736413	20992760837	your	your	APPGE
304953	100736413	20992760838	warm-up	warm-up	NN1
304953	100736413	20992760839	.	.	.
304953	100736413	20992760840	Stretching	stretch	VVG
304953	100736413	20992760841	at	at	II
304953	100736413	20992760842	the	the	AT
304953	100736413	20992760843	end	end	NN1
304953	100736413	20992760844	of	of	IO
304953	100736413	20992760845	your	your	APPGE
304953	100736413	20992760846	workout	workout	NN1
304953	100736413	20992760847	can	can	VM
304953	100736413	20992760848	be	be	VBI
304953	100736413	20992760849	a	a	AT1
304953	100736413	20992760850	good	good	JJ
304953	100736413	20992760851	way	way	NN1
304953	100736413	20992760852	to	to	TO
304953	100736413	20992760853	cool	cool	VVI
304953	100736413	20992760854	down	down	RP
304953	100736413	20992760855	.	.	.
304953	100736413	20992760856	Stretch	stretch	VV0
304953	100736413	20992760857	several	several	DA2
304953	100736413	20992760858	times	time	NNT2
304953	100736413	20992760859	a	a	AT1
304953	100736413	20992760860	week	week	NNT1
304953	100736413	20992760861	for	for	IF
304953	100736413	20992760862	maximum	maximum	JJ_NN1
304953	100736413	20992760863	benefit	benefit	NN1
304953	100736413	20992760864	,	,	,
304953	100736413	20992760865	and	and	CC
304953	100736413	20992760866	include	include	VV0
304953	100736413	20992760867	stretches	stretch	NN2_VVZ
304953	100736413	20992760868	that	that	CST
304953	100736413	20992760869	work	work	VV0
304953	100736413	20992760870	all	all	DB
304953	100736413	20992760871	major	major	JJ
304953	100736413	20992760872	muscle	muscle	NN1
304953	100736413	20992760873	groups	group	NN2
304953	100736413	20992760874	.	.	.
304953	100736413	20992760875	As	as	CSA
304953	100736413	20992760876	you	you	PPY
304953	100736413	20992760877	stretch	stretch	VV0
304953	100736413	20992760878	,	,	,
304953	100736413	20992760879	keep	keep	VV0
304953	100736413	20992760880	these	these	DD2
304953	100736413	20992760881	guidelines	guideline	NN2
304953	100736413	20992760882	in	in	II
304953	100736413	20992760883	mind	mind	NN1
304953	100736413	20992760884	:	:	:
304953	100736413	20992760885	<p>		NULL
304953	100736413	20992760886	Hold	hold	VV0
304953	100736413	20992760887	each	each	DD1
304953	100736413	20992760888	stretch	stretch	NN1@_VV0
304953	100736413	20992760889	for	for	IF
304953	100736413	20992760890	30	30	MC
304953	100736413	20992760891	seconds	second	NNT2
304953	100736413	20992760892	.	.	.
304953	100736413	20992760893	<p>		NULL
304953	100736413	20992760894	Never	never	RR
304953	100736413	20992760895	bounce	bounce	VV0
304953	100736413	20992760896	as	as	CSA
304953	100736413	20992760897	you	you	PPY
304953	100736413	20992760898	stretch	stretch	VV0
304953	100736413	20992760899	.	.	.
304953	100736413	20992760900	<p>		NULL
304953	100736413	20992760901	Extend	extend	VV0
304953	100736413	20992760902	the	the	AT
304953	100736413	20992760903	muscle	muscle	NN1
304953	100736413	20992760904	to	to	II
304953	100736413	20992760905	the	the	AT
304953	100736413	20992760906	point	point	NN1
304953	100736413	20992760907	where	where	RRQ
304953	100736413	20992760908	you	you	PPY
304953	100736413	20992760909	feel	feel	VV0
304953	100736413	20992760910	mild	mild	JJ
304953	100736413	20992760911	tension	tension	NN1
304953	100736413	20992760912	and	and	CC
304953	100736413	20992760913	hold	hold	VV0
304953	100736413	20992760914	that	that	DD1
304953	100736413	20992760915	position	position	NN1
304953	100736413	20992760916	.	.	.
304953	100736413	20992760917	Do	do	VD0
304953	100736413	20992760918	n't	n't	XX
304953	100736413	20992760919	extend	extend	VVI
304953	100736413	20992760920	the	the	AT
304953	100736413	20992760921	muscle	muscle	NN1
304953	100736413	20992760922	to	to	II
304953	100736413	20992760923	the	the	AT
304953	100736413	20992760924	point	point	NN1
304953	100736413	20992760925	that	that	CST
304953	100736413	20992760926	you	you	PPY
304953	100736413	20992760927	feel	feel	VV0
304953	100736413	20992760928	pain	pain	NN1
304953	100736413	20992760929	.	.	.
304953	100736413	20992760930	<h>		NULL
304953	100736413	20992760931	Calf	calf	NN1
304953	100736413	20992760932	stretch	stretch	NN1@_VV0
304953	100736413	20992760933	<p>		NULL
304953	100736413	20992760934	Stretches	stretch	VVZ_NN2
304953	100736413	20992760935	the	the	AT
304953	100736413	20992760936	Achilles	achilles	NP1
304953	100736413	20992760937	tendon	tendon	NN1
304953	100736413	20992760938	and	and	CC
304953	100736413	20992760939	calf	calf	NN1
304953	100736413	20992760940	<p>		NULL
304953	100736413	20992760941	Stand	stand	VV0_NN1
304953	100736413	20992760942	in	in	II31
304953	100736413	20992760943	front	front	II32
304953	100736413	20992760944	of	of	II33
304953	100736413	20992760945	a	a	AT1
304953	100736413	20992760946	wall	wall	NN1
304953	100736413	20992760947	.	.	.
304953	100736413	20992760948	Put	put	VV0
304953	100736413	20992760949	your	your	APPGE
304953	100736413	20992760950	hands	hand	NN2
304953	100736413	20992760951	against	against	II
304953	100736413	20992760952	the	the	AT
304953	100736413	20992760953	wall	wall	NN1
304953	100736413	20992760954	with	with	IW
304953	100736413	20992760955	your	your	APPGE
304953	100736413	20992760956	elbows	elbow	NN2
304953	100736413	20992760957	almost	almost	RR
304953	100736413	20992760958	straight	straight	JJ_RR
304953	100736413	20992760959	.	.	.
304953	100736413	20992760960	Keeping	keep	VVG
304953	100736413	20992760961	your	your	APPGE
304953	100736413	20992760962	left	left	JJ
304953	100736413	20992760963	knee	knee	NN1
304953	100736413	20992760964	slightly	slightly	RR
304953	100736413	20992760965	bent	bend	VVN_VVD
304953	100736413	20992760966	,	,	,
304953	100736413	20992760967	step	step	VV0
304953	100736413	20992760968	back	back	RP
304953	100736413	20992760969	a	a	AT1
304953	100736413	20992760970	foot	foot	NN1
304953	100736413	20992760971	or	or	CC
304953	100736413	20992760972	two	two	MC
304953	100736413	20992760973	with	with	IW
304953	100736413	20992760974	your	your	APPGE
304953	100736413	20992760975	right	right	JJ_NN1
304953	100736413	20992760976	leg	leg	NN1
304953	100736413	20992760977	,	,	,
304953	100736413	20992760978	positioning	position	VVG
304953	100736413	20992760979	the	the	AT
304953	100736413	20992760980	heel	heel	NN1
304953	100736413	20992760981	and	and	CC
304953	100736413	20992760982	foot	foot	NN1
304953	100736413	20992760983	flat	flat	NN1
304953	100736413	20992760984	on	on	II
304953	100736413	20992760985	the	the	AT
304953	100736413	20992760986	floor	floor	NN1
304953	100736413	20992760987	.	.	.
304953	100736413	20992760988	@		II
304953	100736413	20992760989	@		II
304953	100736413	20992760990	@		II
304953	100736413	20992760991	@		II
304953	100736413	20992760992	@		II
304953	100736413	20992760993	@		II
304953	100736413	20992760994	@		II
304953	100736413	20992760995	@		II
304953	100736413	20992760996	@		II
304953	100736413	20992760997	@		II
304953	100736413	20992760998	tendon	tendon	NN1
304953	100736413	20992760999	.	.	.
304953	100736413	20992761000	If	if	CS
304953	100736413	20992761001	not	not	XX
304953	100736413	20992761002	,	,	,
304953	100736413	20992761003	move	move	VV0
304953	100736413	20992761004	your	your	APPGE
304953	100736413	20992761005	right	right	JJ_NN1
304953	100736413	20992761006	leg	leg	NN1
304953	100736413	20992761007	back	back	RP_NN1
304953	100736413	20992761008	a	a	RR21
304953	100736413	20992761009	bit	bit	RR22
304953	100736413	20992761010	farther	far	RRR_JJR
304953	100736413	20992761011	.	.	.
304953	100736413	20992761012	Hold	hold	VV0
304953	100736413	20992761013	for	for	IF
304953	100736413	20992761014	30	30	MC
304953	100736413	20992761015	seconds	second	NNT2
304953	100736413	20992761016	.	.	.
304953	100736413	20992761017	Switch	switch	VV0_NN1
304953	100736413	20992761018	legs	leg	NN2
304953	100736413	20992761019	and	and	CC
304953	100736413	20992761020	repeat	repeat	VV0
304953	100736413	20992761021	.	.	.
304953	100736413	20992761022	<h>		NULL
304953	100736413	20992761023	Starter	starter	NN1
304953	100736413	20992761024	's	's	GE
304953	100736413	20992761025	stretch	stretch	NN1@
304953	100736413	20992761026	<p>		NULL
304953	100736413	20992761027	For	for	IF
304953	100736413	20992761028	your	your	APPGE
304953	100736413	20992761029	thighs	thigh	NN2
304953	100736413	20992761030	<p>		NULL
304953	100736413	20992761031	Get	get	VV0
304953	100736413	20992761032	in	in	II_RP@
304953	100736413	20992761033	a	a	AT1
304953	100736413	20992761034	sprinter	sprinter	NN1
304953	100736413	20992761035	's	's	GE
304953	100736413	20992761036	starting	start	VVG_NN1
304953	100736413	20992761037	position	position	NN1
304953	100736413	20992761038	,	,	,
304953	100736413	20992761039	with	with	IW
304953	100736413	20992761040	your	your	APPGE
304953	100736413	20992761041	rear	rear	JJ_NN1
304953	100736413	20992761042	knee	knee	NN1
304953	100736413	20992761043	on	on	II
304953	100736413	20992761044	the	the	AT
304953	100736413	20992761045	floor	floor	NN1
304953	100736413	20992761046	and	and	CC
304953	100736413	20992761047	your	your	APPGE
304953	100736413	20992761048	front	front	JJ_NN1
304953	100736413	20992761049	foot	foot	NN1
304953	100736413	20992761050	flat	flat	NN1
304953	100736413	20992761051	on	on	II
304953	100736413	20992761052	the	the	AT
304953	100736413	20992761053	floor	floor	NN1
304953	100736413	20992761054	.	.	.
304953	100736413	20992761055	Place	place	VV0
304953	100736413	20992761056	your	your	APPGE
304953	100736413	20992761057	hands	hand	NN2
304953	100736413	20992761058	at	at	II
304953	100736413	20992761059	the	the	AT
304953	100736413	20992761060	sides	side	NN2
304953	100736413	20992761061	of	of	IO
304953	100736413	20992761062	your	your	APPGE
304953	100736413	20992761063	front	front	JJ_NN1
304953	100736413	20992761064	foot	foot	NN1
304953	100736413	20992761065	.	.	.
304953	100736413	20992761066	Gradually	gradually	RR
304953	100736413	20992761067	straighten	straighten	VV0
304953	100736413	20992761068	your	your	APPGE
304953	100736413	20992761069	back	back	NN1_JJ@
304953	100736413	20992761070	knee	knee	NN1
304953	100736413	20992761071	as	as	CSA
304953	100736413	20992761072	you	you	PPY
304953	100736413	20992761073	lift	lift	VV0
304953	100736413	20992761074	up	up	RP
304953	100736413	20992761075	on	on	II
304953	100736413	20992761076	your	your	APPGE
304953	100736413	20992761077	toes	toe	NN2
304953	100736413	20992761078	and	and	CC
304953	100736413	20992761079	bend	bend	VV0
304953	100736413	20992761080	forward	forward	RL
304953	100736413	20992761081	.	.	.
304953	100736413	20992761082	Hold	hold	VV0
304953	100736413	20992761083	for	for	IF
304953	100736413	20992761084	30	30	MC
304953	100736413	20992761085	seconds	second	NNT2
304953	100736413	20992761086	.	.	.
304953	100736413	20992761087	Switch	switch	VV0_NN1
304953	100736413	20992761088	to	to	II
304953	100736413	20992761089	the	the	AT
304953	100736413	20992761090	other	other	JJ
304953	100736413	20992761091	side	side	NN1
304953	100736413	20992761092	.	.	.
304953	100736413	20992761093	<h>		NULL
304953	100736413	20992761094	Thigh	thigh	NN1
304953	100736413	20992761095	stretch	stretch	NN1@_VV0
304953	100736413	20992761096	<p>		NULL
304953	100736413	20992761097	Stretches	stretch	VVZ_NN2
304953	100736413	20992761098	the	the	AT
304953	100736413	20992761099	front	front	NN1
304953	100736413	20992761100	of	of	IO
304953	100736413	20992761101	the	the	AT
304953	100736413	20992761102	thigh	thigh	NN1
304953	100736413	20992761103	<p>		NULL
304953	100736413	20992761104	Stand	stand	VV0_NN1
304953	100736413	20992761105	in	in	II31
304953	100736413	20992761106	front	front	II32
304953	100736413	20992761107	of	of	II33
304953	100736413	20992761108	a	a	AT1
304953	100736413	20992761109	wall	wall	NN1
304953	100736413	20992761110	so	so	CS@_RR
304953	100736413	20992761111	you	you	PPY
304953	100736413	20992761112	can	can	VM
304953	100736413	20992761113	touch	touch	VVI
304953	100736413	20992761114	it	it	PPH1
304953	100736413	20992761115	for	for	IF
304953	100736413	20992761116	balance	balance	NN1
304953	100736413	20992761117	if	if	CS
304953	100736413	20992761118	necessary	necessary	JJ
304953	100736413	20992761119	.	.	.
304953	100736413	20992761120	Keep	keep	VV0
304953	100736413	20992761121	one	one	MC1
304953	100736413	20992761122	leg	leg	NN1
304953	100736413	20992761123	straight	straight	RR
304953	100736413	20992761124	while	while	CS
304953	100736413	20992761125	you	you	PPY
304953	100736413	20992761126	bend	bend	VV0
304953	100736413	20992761127	your	your	APPGE
304953	100736413	20992761128	other	other	JJ
304953	100736413	20992761129	knee	knee	NN1
304953	100736413	20992761130	and	and	CC
304953	100736413	20992761131	grasp	grasp	VV0
304953	100736413	20992761132	your	your	APPGE
304953	100736413	20992761133	ankle	ankle	NN1
304953	100736413	20992761134	to	to	TO
304953	100736413	20992761135	pull	pull	VVI
304953	100736413	20992761136	your	your	APPGE
304953	100736413	20992761137	heel	heel	NN1
304953	100736413	20992761138	up	up	RP
304953	100736413	20992761139	toward	toward	II
304953	100736413	20992761140	your	your	APPGE
304953	100736413	20992761141	buttock	buttocks	NN1
304953	100736413	20992761142	.	.	.
304953	100736413	20992761143	Hold	hold	VV0
304953	100736413	20992761144	for	for	IF
304953	100736413	20992761145	30	30	MC
304953	100736413	20992761146	seconds	second	NNT2
304953	100736413	20992761147	.	.	.
304953	100736413	20992761148	Switch	switch	VV0_NN1
304953	100736413	20992761149	legs	leg	NN2
304953	100736413	20992761150	and	and	CC
304953	100736413	20992761151	repeat	repeat	VV0
304953	100736413	20992761152	.	.	.
304953	100736413	20992761153	<h>		NULL
304953	100736413	20992761154	William	william	NP1
304953	100736413	20992761155	's	's	GE
304953	100736413	20992761156	stretch	stretch	NN1@
304953	100736413	20992761157	<p>		NULL
304953	100736413	20992761158	Lie	lie	VV0
304953	100736413	20992761159	on	on	II_RP@
304953	100736413	20992761160	your	your	APPGE
304953	100736413	20992761161	back	back	NN1
304953	100736413	20992761162	with	with	IW
304953	100736413	20992761163	both	both	DB2
304953	100736413	20992761164	legs	leg	NN2
304953	100736413	20992761165	extended	extend	VVD_VVN
304953	100736413	20992761166	.	.	.
304953	100736413	20992761167	Bring	bring	VV0
304953	100736413	20992761168	one	one	MC1
304953	100736413	20992761169	knee	knee	NN1
304953	100736413	20992761170	up	up	II21
304953	100736413	20992761171	to	to	II22
304953	100736413	20992761172	your	your	APPGE
304953	100736413	20992761173	chest	chest	NN1
304953	100736413	20992761174	,	,	,
304953	100736413	20992761175	pulling	pull	VVG
304953	100736413	20992761176	it	it	PPH1
304953	100736413	20992761177	with	with	IW
304953	100736413	20992761178	your	your	APPGE
304953	100736413	20992761179	hands	hand	NN2
304953	100736413	20992761180	as	as	CSA
304953	100736413	20992761181	you	you	PPY
304953	100736413	20992761182	curl	curl	VV0@
304953	100736413	20992761183	your	your	APPGE
304953	100736413	20992761184	head	head	NN1
304953	100736413	20992761185	toward	toward	II
304953	100736413	20992761186	your	your	APPGE
304953	100736413	20992761187	knee	knee	NN1
304953	100736413	20992761188	@		II
304953	100736413	20992761189	@		II
304953	100736413	20992761190	@		II
304953	100736413	20992761191	@		II
304953	100736413	20992761192	@		II
304953	100736413	20992761193	@		II
304953	100736413	20992761194	@		II
304953	100736413	20992761195	@		II
304953	100736413	20992761196	@		II
304953	100736413	20992761197	@		II
304953	100736413	20992761198	side	side	NN1
304953	100736413	20992761199	.	.	.
304953	100736413	20992761200	<h>		NULL
304953	100736413	20992761201	Hamstring	hamstring	NN1
304953	100736413	20992761202	stretch	stretch	NN1@_VV0
304953	100736413	20992761203	<p>		NULL
304953	100736413	20992761204	Stretches	stretch	VVZ_NN2
304953	100736413	20992761205	the	the	AT
304953	100736413	20992761206	back	back	NN1
304953	100736413	20992761207	of	of	IO
304953	100736413	20992761208	the	the	AT
304953	100736413	20992761209	thigh	thigh	NN1
304953	100736413	20992761210	<p>		NULL
304953	100736413	20992761211	Stand	stand	VV0
304953	100736413	20992761212	far	far	RR
304953	100736413	20992761213	enough	enough	RR
304953	100736413	20992761214	behind	behind	II
304953	100736413	20992761215	a	a	AT1
304953	100736413	20992761216	chair	chair	NN1
304953	100736413	20992761217	so	so	CS21
304953	100736413	20992761218	that	that	CS22
304953	100736413	20992761219	you	you	PPY
304953	100736413	20992761220	can	can	VM
304953	100736413	20992761221	hold	hold	VVI
304953	100736413	20992761222	it	it	PPH1
304953	100736413	20992761223	while	while	CS
304953	100736413	20992761224	bending	bend	VVG
304953	100736413	20992761225	over	over	RP
304953	100736413	20992761226	at	at	II
304953	100736413	20992761227	the	the	AT
304953	100736413	20992761228	hips	hip	NN2
304953	100736413	20992761229	until	until	CS_II@
304953	100736413	20992761230	your	your	APPGE
304953	100736413	20992761231	torso	torso	NN1
304953	100736413	20992761232	is	be	VBZ
304953	100736413	20992761233	parallel	parallel	RR_JJ
304953	100736413	20992761234	to	to	II
304953	100736413	20992761235	the	the	AT
304953	100736413	20992761236	floor	floor	NN1
304953	100736413	20992761237	.	.	.
304953	100736413	20992761238	Try	try	VV0
304953	100736413	20992761239	to	to	TO
304953	100736413	20992761240	keep	keep	VVI
304953	100736413	20992761241	your	your	APPGE
304953	100736413	20992761242	back	back	NN1
304953	100736413	20992761243	and	and	CC
304953	100736413	20992761244	shoulders	shoulder	NN2
304953	100736413	20992761245	straight	straight	RR
304953	100736413	20992761246	so	so	CS21
304953	100736413	20992761247	that	that	CS22
304953	100736413	20992761248	you	you	PPY
304953	100736413	20992761249	feel	feel	VV0
304953	100736413	20992761250	the	the	AT
304953	100736413	20992761251	stretch	stretch	NN1@
304953	100736413	20992761252	in	in	II
304953	100736413	20992761253	the	the	AT
304953	100736413	20992761254	back	back	NN1
304953	100736413	20992761255	of	of	IO
304953	100736413	20992761256	your	your	APPGE
304953	100736413	20992761257	thighs	thigh	NN2
304953	100736413	20992761258	.	.	.
304953	100736413	20992761259	Hold	hold	VV0
304953	100736413	20992761260	for	for	IF
304953	100736413	20992761261	30	30	MC
304953	100736413	20992761262	seconds	second	NNT2
304953	100736413	20992761263	.	.	.
304953	100736413	20992761264	<h>		NULL
304953	100736413	20992761265	Cat	cat	NN1
304953	100736413	20992761266	stretch	stretch	NN1@_VV0
304953	100736413	20992761267	<p>		NULL
304953	100736413	20992761268	For	for	IF
304953	100736413	20992761269	your	your	APPGE
304953	100736413	20992761270	upper	upper	JJ
304953	100736413	20992761271	back	back	NN1
304953	100736413	20992761272	and	and	CC
304953	100736413	20992761273	shoulders	shoulder	NN2
304953	100736413	20992761274	<p>		NULL
304953	100736413	20992761275	Rest	rest	VV0_NN1
304953	100736413	20992761276	on	on	II_RP@
304953	100736413	20992761277	your	your	APPGE
304953	100736413	20992761278	knees	knee	NN2
304953	100736413	20992761279	,	,	,
304953	100736413	20992761280	then	then	RT
304953	100736413	20992761281	lower	lower	VV0@
304953	100736413	20992761282	your	your	APPGE
304953	100736413	20992761283	head	head	NN1
304953	100736413	20992761284	and	and	CC
304953	100736413	20992761285	reach	reach	VV0
304953	100736413	20992761286	forward	forward	RL
304953	100736413	20992761287	with	with	IW
304953	100736413	20992761288	one	one	MC1
304953	100736413	20992761289	arm	arm	NN1
304953	100736413	20992761290	and	and	CC
304953	100736413	20992761291	then	then	RT
304953	100736413	20992761292	the	the	AT
304953	100736413	20992761293	other	other	JJ_NN1@
304953	100736413	20992761294	.	.	.
304953	100736413	20992761295	Both	both	DB2
304953	100736413	20992761296	arms	arm	NN2
304953	100736413	20992761297	will	will	VM
304953	100736413	20992761298	be	be	VBI
304953	100736413	20992761299	stretched	stretch	VVN
304953	100736413	20992761300	out	out	RP
304953	100736413	20992761301	in	in	II31
304953	100736413	20992761302	front	front	II32
304953	100736413	20992761303	of	of	II33
304953	100736413	20992761304	you	you	PPY
304953	100736413	20992761305	.	.	.
304953	100736413	20992761306	Hold	hold	VV0
304953	100736413	20992761307	for	for	IF
304953	100736413	20992761308	30	30	MC
304953	100736413	20992761309	seconds	second	NNT2
304953	100736413	20992761310	.	.	.
304953	100736413	20992761311	<h>		NULL
304953	100736413	20992761312	Triceps	triceps	NN2
304953	100736413	20992761313	stretch	stretch	VV0
304953	100736413	20992761314	<p>		NULL
304953	100736413	20992761315	Stretches	stretch	VVZ_NN2
304953	100736413	20992761316	the	the	AT
304953	100736413	20992761317	triceps	triceps	NN2
304953	100736413	20992761318	and	and	CC
304953	100736413	20992761319	upper	upper	JJ
304953	100736413	20992761320	back	back	NN1
304953	100736413	20992761321	<p>		NULL
304953	100736413	20992761322	Bend	bend	VV0
304953	100736413	20992761323	your	your	APPGE
304953	100736413	20992761324	right	right	JJ_NN1
304953	100736413	20992761325	arm	arm	NN1
304953	100736413	20992761326	behind	behind	II
304953	100736413	20992761327	your	your	APPGE
304953	100736413	20992761328	neck	neck	NN1
304953	100736413	20992761329	,	,	,
304953	100736413	20992761330	pointing	point	VVG
304953	100736413	20992761331	your	your	APPGE
304953	100736413	20992761332	elbow	elbow	NN1
304953	100736413	20992761333	toward	toward	II
304953	100736413	20992761334	the	the	AT
304953	100736413	20992761335	ceiling	ceiling	NN1
304953	100736413	20992761336	.	.	.
304953	100736413	20992761337	Grasp	grasp	VV0
304953	100736413	20992761338	your	your	APPGE
304953	100736413	20992761339	elbow	elbow	NN1
304953	100736413	20992761340	with	with	IW
304953	100736413	20992761341	your	your	APPGE
304953	100736413	20992761342	left	left	JJ
304953	100736413	20992761343	hand	hand	NN1
304953	100736413	20992761344	.	.	.
304953	100736413	20992761345	Pull	pull	VV0
304953	100736413	20992761346	the	the	AT
304953	100736413	20992761347	raised	raised	JJ@
304953	100736413	20992761348	right	right	JJ_NN1
304953	100736413	20992761349	elbow	elbow	NN1
304953	100736413	20992761350	gently	gently	RR
304953	100736413	20992761351	toward	toward	II
304953	100736413	20992761352	the	the	AT
304953	100736413	20992761353	left	left	JJ_NN1@
304953	100736413	20992761354	until	until	CS
304953	100736413	20992761355	you	you	PPY
304953	100736413	20992761356	feel	feel	VV0
304953	100736413	20992761357	a	a	AT1
304953	100736413	20992761358	mild	mild	JJ_NN1@
304953	100736413	20992761359	stretch	stretch	VVI
304953	100736413	20992761360	at	at	II
304953	100736413	20992761361	the	the	AT
304953	100736413	20992761362	back	back	NN1
304953	100736413	20992761363	of	of	IO
304953	100736413	20992761364	your	your	APPGE
304953	100736413	20992761365	upper	upper	JJ
304953	100736413	20992761366	right	right	JJ_NN1
304953	100736413	20992761367	arm	arm	NN1
304953	100736413	20992761368	.	.	.
304953	100736413	20992761369	Hold	hold	VV0
304953	100736413	20992761370	for	for	IF
304953	100736413	20992761371	30	30	MC
304953	100736413	20992761372	seconds	second	NNT2
304953	100736413	20992761373	.	.	.
304953	100736413	20992761374	Repeat	repeat	VV0
304953	100736413	20992761375	with	with	IW
304953	100736413	20992761376	the	the	AT
304953	100736413	20992761377	left	left	JJ
304953	100736413	20992761378	arm	arm	NN1
304953	100736413	20992761379	.	.	.
304953	100736413	20992761380	46996		MC
304953	100736413	20992761381	@qwx906996		FO
304953	100736414	20992761401	@@##	----------	----------
304953	100736414	20992761402	@@100736414		FO
304953	100736414	20992761403	@4936414/		NN1_VV0
304953	100736414	20992761404	<p>		NULL
304953	100736414	20992761405	I	i	PPIS1
304953	100736414	20992761406	had	have	VHD
304953	100736414	20992761407	brachytherapy	brachytherapy	NN1
304953	100736414	20992761408	to	to	TO
304953	100736414	20992761409	treat	treat	VVI
304953	100736414	20992761410	my	my	APPGE
304953	100736414	20992761411	prostate	prostate	NN1
304953	100736414	20992761412	cancer	cancer	NN1
304953	100736414	20992761413	and	and	CC
304953	100736414	20992761414	my	my	APPGE
304953	100736414	20992761415	PSA	psa	NP1
304953	100736414	20992761416	had	have	VHD
304953	100736414	20992761417	dropped	drop	VVN
304953	100736414	20992761418	to	to	II
304953	100736414	20992761419	0.3	0.3	MC
304953	100736414	20992761420	ng/ml	ng/ml	FU
304953	100736414	20992761421	.	.	.
304953	100736414	20992761422	But	but	CCB
304953	100736414	20992761423	six	six	MC
304953	100736414	20992761424	months	month	NNT2
304953	100736414	20992761425	ago	ago	RA
304953	100736414	20992761426	,	,	,
304953	100736414	20992761427	my	my	APPGE
304953	100736414	20992761428	PSA	psa	NP1
304953	100736414	20992761429	had	have	VHD
304953	100736414	20992761430	gone	go	VVN
304953	100736414	20992761431	up	up	RG21
304953	100736414	20992761432	to	to	RG22
304953	100736414	20992761433	0.5	0.5	MC
304953	100736414	20992761434	,	,	,
304953	100736414	20992761435	and	and	CC
304953	100736414	20992761436	now	now	RT
304953	100736414	20992761437	it	it	PPH1
304953	100736414	20992761438	's	be	VBZ
304953	100736414	20992761439	up	up	RG21
304953	100736414	20992761440	to	to	RG22
304953	100736414	20992761441	0.8	0.8	MC
304953	100736414	20992761442	ng/ml	ng/ml	FU
304953	100736414	20992761443	.	.	.
304953	100736414	20992761444	Im		VV0_NP1@_NN1
304953	100736414	20992761445	worried	worried	JJ_VVD@
304953	100736414	20992761446	that	that	CST
304953	100736414	20992761447	the	the	AT
304953	100736414	20992761448	cancer	cancer	NN1
304953	100736414	20992761449	is	be	VBZ
304953	100736414	20992761450	back	back	RP_NN1_JJ@
304953	100736414	20992761451	;	;	;
304953	100736414	20992761452	my	my	APPGE
304953	100736414	20992761453	doctor	doctor	NN1
304953	100736414	20992761454	said	say	VVD
304953	100736414	20992761455	it	it	PPH1
304953	100736414	20992761456	could	could	VM
304953	100736414	20992761457	be	be	VBI
304953	100736414	20992761458	a	a	AT1
304953	100736414	20992761459	"	"	"
304953	100736414	20992761460	PSA	psa	NP1
304953	100736414	20992761461	bounce	bounce	NN1_VV0
304953	100736414	20992761462	.	.	.
304953	100736414	20992761463	"	"	"
304953	100736414	20992761464	What 's		NN2
304953	100736414	20992761465	that	that	DD1
304953	100736414	20992761466	?	?	?
304953	100736414	20992761467	<p>		NULL
304953	100736414	20992761468	Even	even	CS21
304953	100736414	20992761469	if	if	CS22
304953	100736414	20992761470	my	my	APPGE
304953	100736414	20992761471	father	father	NN1
304953	100736414	20992761472	takes	take	VVZ
304953	100736414	20992761473	antibiotics	antibiotic	NN2
304953	100736414	20992761474	beforehand	beforehand	RR
304953	100736414	20992761475	,	,	,
304953	100736414	20992761476	could	could	VM
304953	100736414	20992761477	he	he	PPHS1
304953	100736414	20992761478	develop	develop	VVI
304953	100736414	20992761479	a	a	AT1
304953	100736414	20992761480	serious	serious	JJ
304953	100736414	20992761481	infection	infection	NN1
304953	100736414	20992761482	when	when	CS_RRQ
304953	100736414	20992761483	he	he	PPHS1
304953	100736414	20992761484	has	have	VHZ
304953	100736414	20992761485	a	a	AT1
304953	100736414	20992761486	prostate	prostate	NN1
304953	100736414	20992761487	biopsy	biopsy	NN1
304953	100736414	20992761488	later	later	RRR
304953	100736414	20992761489	this	this	DD1
304953	100736414	20992761490	year	year	NNT1
304953	100736414	20992761491	?	?	?
304953	100736414	20992761492	Are	be	VBR
304953	100736414	20992761493	there	there	RL_EX
304953	100736414	20992761494	other	other	JJ
304953	100736414	20992761495	possible	possible	JJ
304953	100736414	20992761496	complications	complication	NN2
304953	100736414	20992761497	we	we	PPIS2
304953	100736414	20992761498	should	should	VM
304953	100736414	20992761499	be	be	VBI
304953	100736414	20992761500	on	on	II
304953	100736414	20992761501	the	the	AT
304953	100736414	20992761502	lookout	lookout	NN1
304953	100736414	20992761503	for	for	IF
304953	100736414	20992761504	?	?	?
304953	100736415	20992761524	@@##	----------	----------
304953	100736415	20992761525	@@100736415		FO
304953	100736415	20992761526	@4936415/		VV0_NN1
304953	100736415	20992761527	46989		MC
304953	100736415	20992761528	@qwx906989		FO
304953	100736415	20992761529	<p>		NULL
304953	100736415	20992761530	Physicians	physician	NN2
304953	100736415	20992761531	often	often	RR
304953	100736415	20992761532	prescribe	prescribe	VV0
304953	100736415	20992761533	hormone	hormone	NN1
304953	100736415	20992761534	therapy	therapy	NN1
304953	100736415	20992761535	to	to	TO
304953	100736415	20992761536	reduce	reduce	VVI
304953	100736415	20992761537	testosterone	testosterone	NN1
304953	100736415	20992761538	levels	level	NN2
304953	100736415	20992761539	in	in	II
304953	100736415	20992761540	men	man	NN2
304953	100736415	20992761541	with	with	IW
304953	100736415	20992761542	advanced	advanced	JJ
304953	100736415	20992761543	prostate	prostate	NN1
304953	100736415	20992761544	cancer	cancer	NN1
304953	100736415	20992761545	.	.	.
304953	100736415	20992761546	Without	without	IW
304953	100736415	20992761547	testosterone	testosterone	NN1
304953	100736415	20992761548	to	to	II
304953	100736415	20992761549	fuel	fuel	NN1
304953	100736415	20992761550	tumor	tumor	NN1
304953	100736415	20992761551	growth	growth	NN1
304953	100736415	20992761552	,	,	,
304953	100736415	20992761553	the	the	AT
304953	100736415	20992761554	cancer	cancer	NN1
304953	100736415	20992761555	recedes	recede	VVZ
304953	100736415	20992761556	.	.	.
304953	100736415	20992761557	However	however	RR
304953	100736415	20992761558	,	,	,
304953	100736415	20992761559	men	man	NN2
304953	100736415	20992761560	often	often	RR
304953	100736415	20992761561	complain	complain	VV0
304953	100736415	20992761562	that	that	CST
304953	100736415	20992761563	the	the	AT
304953	100736415	20992761564	drugs	drug	NN2
304953	100736415	20992761565	dampen	dampen	VV0
304953	100736415	20992761566	their	their	APPGE
304953	100736415	20992761567	libido	libido	NN1
304953	100736415	20992761568	,	,	,
304953	100736415	20992761569	lead	lead	VV0_NN1
304953	100736415	20992761570	to	to	II
304953	100736415	20992761571	weight	weight	NN1
304953	100736415	20992761572	gain	gain	NN1_VV0
304953	100736415	20992761573	,	,	,
304953	100736415	20992761574	and	and	CC
304953	100736415	20992761575	cause	cause	NN1_VV0
304953	100736415	20992761576	fatigue	fatigue	NN1
304953	100736415	20992761577	,	,	,
304953	100736415	20992761578	hot	hot	JJ
304953	100736415	20992761579	flashes	flash	NN2
304953	100736415	20992761580	,	,	,
304953	100736415	20992761581	and	and	CC
304953	100736415	20992761582	breast	breast	NN1
304953	100736415	20992761583	enlargement	enlargement	NN1
304953	100736415	20992761584	.	.	.
304953	100736415	20992761585	Some	some	DD
304953	100736415	20992761586	studies	study	NN2
304953	100736415	20992761587	have	have	VH0
304953	100736415	20992761588	shown	show	VVN
304953	100736415	20992761589	that	that	CST_DD1
304953	100736415	20992761590	taking	take	VVG_JJ%
304953	100736415	20992761591	hormone	hormone	NN1
304953	100736415	20992761592	therapy	therapy	NN1
304953	100736415	20992761593	intermittently	intermittently	RR
304953	100736415	20992761594	,	,	,
304953	100736415	20992761595	rather	rather	CS21@_II21
304953	100736415	20992761596	than	than	CS22@_II22
304953	100736415	20992761597	continuously	continuously	RR
304953	100736415	20992761598	,	,	,
304953	100736415	20992761599	can	can	VM
304953	100736415	20992761600	improve	improve	VVI
304953	100736415	20992761601	patients	patient	NN2
304953	100736415	20992761602	'	'	GE
304953	100736415	20992761603	quality	quality	NN1
304953	100736415	20992761604	of	of	IO
304953	100736415	20992761605	life	life	NN1
304953	100736415	20992761606	.	.	.
304953	100736415	20992761607	But	but	CCB
304953	100736415	20992761608	does	do	VDZ
304953	100736415	20992761609	going	going	NN1%_JJ%_VVG
304953	100736415	20992761610	off	off	II_RP
304953	100736415	20992761611	the	the	AT
304953	100736415	20992761612	medication	medication	NN1
304953	100736415	20992761613	from	from	RR41
304953	100736415	20992761614	time	time	RR42
304953	100736415	20992761615	to	to	RR43
304953	100736415	20992761616	time	time	RR44
304953	100736415	20992761617	hasten	hasten	VV0
304953	100736415	20992761618	death	death	NN1
304953	100736415	20992761619	?	?	?
304953	100736415	20992761620	<p>		NULL
304953	100736415	20992761621	According	according	II21
304953	100736415	20992761622	to	to	II22
304953	100736415	20992761623	a	a	AT1
304953	100736415	20992761624	recent	recent	JJ
304953	100736415	20992761625	study	study	NN1
304953	100736415	20992761626	conducted	conduct	VVN_VVD
304953	100736415	20992761627	at	at	II
304953	100736415	20992761628	32	32	MC
304953	100736415	20992761629	centers	center	NN2
304953	100736415	20992761630	across	across	II
304953	100736415	20992761631	Europe	europe	NP1
304953	100736415	20992761632	,	,	,
304953	100736415	20992761633	the	the	AT
304953	100736415	20992761634	answer	answer	NN1
304953	100736415	20992761635	is	be	VBZ
304953	100736415	20992761636	no	no	UH
304953	100736415	20992761637	.	.	.
304953	100736415	20992761638	Researchers	researcher	NN2
304953	100736415	20992761639	started	start	VVD
304953	100736415	20992761640	626	626	MC
304953	100736415	20992761641	patients	patient	NN2
304953	100736415	20992761642	on	on	II
304953	100736415	20992761643	hormone	hormone	NN1
304953	100736415	20992761644	therapy	therapy	NN1
304953	100736415	20992761645	for	for	IF
304953	100736415	20992761646	three	three	MC
304953	100736415	20992761647	months	month	NNT2
304953	100736415	20992761648	.	.	.
304953	100736415	20992761649	Patients	patient	NN2
304953	100736415	20992761650	were	be	VBDR
304953	100736415	20992761651	then	then	RT
304953	100736415	20992761652	randomly	randomly	RR
304953	100736415	20992761653	assigned	assign	VVN
304953	100736415	20992761654	to	to	II_TO
304953	100736415	20992761655	either	either	RR
304953	100736415	20992761656	intermittent	intermittent	JJ
304953	100736415	20992761657	or	or	CC
304953	100736415	20992761658	continuous	continuous	JJ
304953	100736415	20992761659	therapy	therapy	NN1
304953	100736415	20992761660	.	.	.
304953	100736415	20992761661	Those	those	DD2
304953	100736415	20992761662	on	on	II
304953	100736415	20992761663	IHT		NP1_NN1
304953	100736415	20992761664	stopped	stop	VVD
304953	100736415	20992761665	taking	take	VVG
304953	100736415	20992761666	the	the	AT
304953	100736415	20992761667	drugs	drug	NN2
304953	100736415	20992761668	until	until	CS_II@
304953	100736415	20992761669	their	their	APPGE
304953	100736415	20992761670	prostate-specific	prostate-specific	JJ
304953	100736415	20992761671	antigen	antigen	NN1
304953	100736415	20992761672	(	(	(
304953	100736415	20992761673	PSA	psa	NP1
304953	100736415	20992761674	)	)	)
304953	100736415	20992761675	level	level	JJ_NN1
304953	100736415	20992761676	rose	rose	NN1_VVD
304953	100736415	20992761677	to	to	II
304953	100736415	20992761678	10	10	MC
304953	100736415	20992761679	ng/ml	ng/ml	FU
304953	100736415	20992761680	or	or	CC
304953	100736415	20992761681	greater	great	JJR
304953	100736415	20992761682	or	or	CC
304953	100736415	20992761683	to	to	II
304953	100736415	20992761684	20	20	MC
304953	100736415	20992761685	ng/ml	ng/ml	FU
304953	100736415	20992761686	or	or	CC
304953	100736415	20992761687	greater	great	JJR
304953	100736415	20992761688	,	,	,
304953	100736415	20992761689	depending	depending	II21
304953	100736415	20992761690	on	on	II22
304953	100736415	20992761691	whether	whether	CSW31
304953	100736415	20992761692	or	or	CSW32
304953	100736415	20992761693	not	not	CSW33
304953	100736415	20992761694	they	they	PPHS2
304953	100736415	20992761695	had	have	VHD
304953	100736415	20992761696	symptoms	symptom	NN2
304953	100736415	20992761697	of	of	IO
304953	100736415	20992761698	disease	disease	NN1
304953	100736415	20992761699	progression	progression	NN1
304953	100736415	20992761700	.	.	.
304953	100736415	20992761701	(	(	(
304953	100736415	20992761702	Half	half	DB
304953	100736415	20992761703	were	be	VBDR
304953	100736415	20992761704	off	off	II_RP
304953	100736415	20992761705	therapy	therapy	NN1
304953	100736415	20992761706	for	for	IF
304953	100736415	20992761707	at	at	RR21
304953	100736415	20992761708	least	least	RR22
304953	100736415	20992761709	a	a	AT1
304953	100736415	20992761710	year	year	NNT1
304953	100736415	20992761711	.	.	.
304953	100736415	20992761712	)	)	)
304953	100736415	20992761713	After	after	CS_II
304953	100736415	20992761714	a	a	AT1
304953	100736415	20992761715	median	median	JJ
304953	100736415	20992761716	@		II
304953	100736415	20992761717	@		II
304953	100736415	20992761718	@		II
304953	100736415	20992761719	@		II
304953	100736415	20992761720	@		II
304953	100736415	20992761721	@		II
304953	100736415	20992761722	@		II
304953	100736415	20992761723	@		II
304953	100736415	20992761724	@		II
304953	100736415	20992761725	@		II
304953	100736415	20992761726	stopped	stop	VVN_VVD
304953	100736415	20992761727	taking	take	VVG
304953	100736415	20992761728	the	the	AT
304953	100736415	20992761729	drugs	drug	NN2
304953	100736415	20992761730	.	.	.
304953	100736415	20992761731	Those	those	DD2
304953	100736415	20992761732	on	on	II
304953	100736415	20992761733	continuous	continuous	JJ
304953	100736415	20992761734	therapy	therapy	NN1
304953	100736415	20992761735	never	never	RR
304953	100736415	20992761736	stopped	stop	VVN_JJ@_VVD
304953	100736415	20992761737	treatment	treatment	NN1
304953	100736415	20992761738	.	.	.
304953	100736415	20992761739	<p>		NULL
304953	100736415	20992761740	After	after	II
304953	100736415	20992761741	following	follow	VVG
304953	100736415	20992761742	patients	patient	NN2
304953	100736415	20992761743	for	for	IF
304953	100736415	20992761744	a	a	AT1
304953	100736415	20992761745	median	median	JJ
304953	100736415	20992761746	time	time	NNT1
304953	100736415	20992761747	of	of	IO
304953	100736415	20992761748	51	51	MC
304953	100736415	20992761749	months	month	NNT2
304953	100736415	20992761750	,	,	,
304953	100736415	20992761751	the	the	AT
304953	100736415	20992761752	researchers	researcher	NN2
304953	100736415	20992761753	found	find	VVD_VVN
304953	100736415	20992761754	that	that	CST
304953	100736415	20992761755	the	the	AT
304953	100736415	20992761756	cancer	cancer	NN1
304953	100736415	20992761757	progressed	progress	VVD_VVN
304953	100736415	20992761758	a	a	RR21
304953	100736415	20992761759	bit	bit	RR22
304953	100736415	20992761760	more	more	RGR
304953	100736415	20992761761	quickly	quickly	RR
304953	100736415	20992761762	in	in	II
304953	100736415	20992761763	men	man	NN2
304953	100736415	20992761764	on	on	II
304953	100736415	20992761765	IHT		NP1_NN1
304953	100736415	20992761766	,	,	,
304953	100736415	20992761767	but	but	CCB
304953	100736415	20992761768	there	there	EX
304953	100736415	20992761769	was	be	VBDZ
304953	100736415	20992761770	no	no	AT
304953	100736415	20992761771	difference	difference	NN1
304953	100736415	20992761772	in	in	II
304953	100736415	20992761773	overall	overall	JJ_NN1
304953	100736415	20992761774	survival	survival	NN1
304953	100736415	20992761775	between	between	II
304953	100736415	20992761776	the	the	AT
304953	100736415	20992761777	groups	group	NN2
304953	100736415	20992761778	.	.	.
304953	100736415	20992761779	Patients	patient	NN2
304953	100736415	20992761780	on	on	II
304953	100736415	20992761781	IHT		NP1_NN1
304953	100736415	20992761782	also	also	RR
304953	100736415	20992761783	experienced	experience	VVD_VVN
304953	100736415	20992761784	fewer	fewer	DAR
304953	100736415	20992761785	side	side	NN1
304953	100736415	20992761786	effects	effect	NN2
304953	100736415	20992761787	and	and	CC
304953	100736415	20992761788	had	have	VHD
304953	100736415	20992761789	more	more	DAR_RRR
304953	100736415	20992761790	sexual	sexual	JJ
304953	100736415	20992761791	activity	activity	NN1
304953	100736415	20992761792	.	.	.
304953	100736415	20992761793	Another	another	DD1
304953	100736415	20992761794	plus	plus	NN1@_II
304953	100736415	20992761795	:	:	:
304953	100736415	20992761796	intermittent	intermittent	JJ
304953	100736415	20992761797	therapy	therapy	NN1
304953	100736415	20992761798	could	could	VM
304953	100736415	20992761799	keep	keep	VVI
304953	100736415	20992761800	more	more	DAR
304953	100736415	20992761801	money	money	NN1
304953	100736415	20992761802	in	in	II
304953	100736415	20992761803	patients	patient	NN2
304953	100736415	20992761804	'	'	GE
304953	100736415	20992761805	pockets	pocket	NN2
304953	100736415	20992761806	.	.	.
304953	100736415	20992761807	<p>		NULL
304953	100736415	20992761808	Given	give	VVN
304953	100736415	20992761809	the	the	AT
304953	100736415	20992761810	beneficial	beneficial	JJ
304953	100736415	20992761811	effects	effect	NN2
304953	100736415	20992761812	and	and	CC
304953	100736415	20992761813	the	the	AT
304953	100736415	20992761814	lack	lack	NN1
304953	100736415	20992761815	of	of	IO
304953	100736415	20992761816	a	a	AT1
304953	100736415	20992761817	survival	survival	NN1
304953	100736415	20992761818	difference	difference	NN1
304953	100736415	20992761819	,	,	,
304953	100736415	20992761820	the	the	AT
304953	100736415	20992761821	researchers	researcher	NN2
304953	100736415	20992761822	conclude	conclude	VV0
304953	100736415	20992761823	that	that	CST
304953	100736415	20992761824	patients	patient	NN2
304953	100736415	20992761825	and	and	CC
304953	100736415	20992761826	doctors	doctor	NN2
304953	100736415	20992761827	should	should	VM
304953	100736415	20992761828	consider	consider	VVI
304953	100736415	20992761829	IHT.		NP1
304953	100736415	20992761830	46996		MC
304953	100736415	20992761831	@qwx906996		FO
304953	100736416	20992761851	@@##	----------	----------
304953	100736416	20992761852	@@100736416		FO
304953	100736416	20992761853	@4936416/		VV0_NN1
304953	100736416	20992761854	46988		MC
304953	100736416	20992761855	@qwx906988		FO
304953	100736416	20992761856	46994		MC
304953	100736416	20992761857	@qwx906994		FO
304953	100736416	20992761858	46995		MC
304953	100736416	20992761859	@qwx906995		FO
304953	100736416	20992761860	46992		MC
304953	100736416	20992761861	@qwx906992		FO
304953	100736416	20992761862	46991		MC
304953	100736416	20992761863	@qwx906991		FO
304953	100736416	20992761864	46990		MC
304953	100736416	20992761865	@qwx906990		FO
304953	100736416	20992761866	46989		MC
304953	100736416	20992761867	@qwx906989		FO
304953	100736416	20992761868	46993		MC
304953	100736416	20992761869	@qwx906993		FO
304953	100736416	20992761870	<h>		NULL
304953	100736416	20992761871	About	about	II
304953	100736416	20992761872	Us	us	NP1@_PPIO2
304953	100736416	20992761873	<h>		NULL
304953	100736416	20992761874	Harvard	harvard	NP1
304953	100736416	20992761875	Medical	medical	JJ
304953	100736416	20992761876	School	school	NN1
304953	100736416	20992761877	<p>		NULL
304953	100736416	20992761878	Harvard	harvard	NP1
304953	100736416	20992761879	Medical	medical	JJ
304953	100736416	20992761880	School	school	NN1
304953	100736416	20992761881	is	be	VBZ
304953	100736416	20992761882	part	part	NN1
304953	100736416	20992761883	of	of	IO
304953	100736416	20992761884	Harvard	harvard	NP1
304953	100736416	20992761885	University	university	NN1
304953	100736416	20992761886	.	.	.
304953	100736416	20992761887	The	the	AT
304953	100736416	20992761888	goal	goal	NN1
304953	100736416	20992761889	of	of	IO
304953	100736416	20992761890	all	all	DB
304953	100736416	20992761891	Harvard	harvard	NP1
304953	100736416	20992761892	Medical	medical	JJ
304953	100736416	20992761893	School	school	NN1
304953	100736416	20992761894	publications	publication	NN2
304953	100736416	20992761895	is	be	VBZ
304953	100736416	20992761896	to	to	TO
304953	100736416	20992761897	bring	bring	VVI
304953	100736416	20992761898	the	the	AT
304953	100736416	20992761899	public	public	NN1_JJ
304953	100736416	20992761900	,	,	,
304953	100736416	20992761901	around	around	II
304953	100736416	20992761902	the	the	AT
304953	100736416	20992761903	world	world	NN1
304953	100736416	20992761904	,	,	,
304953	100736416	20992761905	the	the	AT
304953	100736416	20992761906	most	most	RGT
304953	100736416	20992761907	current	current	JJ
304953	100736416	20992761908	practical	practical	JJ_NN1@
304953	100736416	20992761909	,	,	,
304953	100736416	20992761910	authoritative	authoritative	JJ
304953	100736416	20992761911	health	health	NN1
304953	100736416	20992761912	information	information	NN1
304953	100736416	20992761913	,	,	,
304953	100736416	20992761914	drawing	draw	VVG
304953	100736416	20992761915	on	on	II
304953	100736416	20992761916	the	the	AT
304953	100736416	20992761917	expertise	expertise	NN1
304953	100736416	20992761918	of	of	IO
304953	100736416	20992761919	the	the	AT
304953	100736416	20992761920	8,000	8,000	MC
304953	100736416	20992761921	faculty	faculty	NN1
304953	100736416	20992761922	physicians	physician	NN2
304953	100736416	20992761923	at	at	II
304953	100736416	20992761924	the	the	AT
304953	100736416	20992761925	Harvard	harvard	NP1
304953	100736416	20992761926	Medical	medical	JJ
304953	100736416	20992761927	School	school	NN1
304953	100736416	20992761928	and	and	CC
304953	100736416	20992761929	its	its	APPGE
304953	100736416	20992761930	world-famous	world-famous	JJ
304953	100736416	20992761931	affiliated	affiliated	JJ
304953	100736416	20992761932	hospitals	hospital	NN2
304953	100736416	20992761933	.	.	.
304953	100736416	20992761934	<h>		NULL
304953	100736416	20992761935	Prostate	prostate	NN1
304953	100736416	20992761936	Knowledge	knowledge	NN1
304953	100736416	20992761937	"	"	"
304953	100736416	20992761938	Advisory	advisory	JJ
304953	100736416	20992761939	Board	board	NN1
304953	100736416	20992761940	<p>		NULL
304953	100736416	20992761941	Marc	marc	NP1
304953	100736416	20992761942	B.		NP1
304953	100736416	20992761943	Garnick		NP1
304953	100736416	20992761944	,	,	,
304953	100736416	20992761945	M.D.	m.d	NNA
304953	100736416	20992761946	,	,	,
304953	100736416	20992761947	Chief	chief	JJ
304953	100736416	20992761948	Medical	medical	JJ
304953	100736416	20992761949	Advisor	advisor	NN1
304953	100736416	20992761950	Dr.		NNB
304953	100736416	20992761951	Garnick		NP1
304953	100736416	20992761952	is	be	VBZ
304953	100736416	20992761953	an	a	AT1
304953	100736416	20992761954	internationally	internationally	RR
304953	100736416	20992761955	renowned	renowned	JJ
304953	100736416	20992761956	expert	expert	NN1
304953	100736416	20992761957	in	in	II
304953	100736416	20992761958	medical	medical	JJ
304953	100736416	20992761959	oncology	oncology	NN1
304953	100736416	20992761960	and	and	CC
304953	100736416	20992761961	urologic	urologic	JJ
304953	100736416	20992761962	cancer	cancer	NN1
304953	100736416	20992761963	.	.	.
304953	100736416	20992761964	A	a	AT1_ZZ1
304953	100736416	20992761965	clinical	clinical	JJ
304953	100736416	20992761966	professor	professor	NN1
304953	100736416	20992761967	of	of	IO
304953	100736416	20992761968	medicine	medicine	NN1
304953	100736416	20992761969	at	at	II
304953	100736416	20992761970	Harvard	harvard	NP1
304953	100736416	20992761971	Medical	medical	JJ
304953	100736416	20992761972	School	school	NN1
304953	100736416	20992761973	,	,	,
304953	100736416	20992761974	he	he	PPHS1
304953	100736416	20992761975	also	also	RR
304953	100736416	20992761976	maintains	maintain	VVZ
304953	100736416	20992761977	an	a	AT1
304953	100736416	20992761978	active	active	JJ
304953	100736416	20992761979	clinical	clinical	JJ
304953	100736416	20992761980	practice	practice	NN1
304953	100736416	20992761981	at	at	II
304953	100736416	20992761982	Beth	beth	NP1
304953	100736416	20992761983	Israel	israel	NP1
304953	100736416	20992761984	Deaconess	deaconess	NN1
304953	100736416	20992761985	Medical	medical	JJ
304953	100736416	20992761986	Center	center	NN1
304953	100736416	20992761987	,	,	,
304953	100736416	20992761988	and	and	CC
304953	100736416	20992761989	has	have	VHZ
304953	100736416	20992761990	dedicated	dedicate	VVN
304953	100736416	20992761991	his	his	APPGE
304953	100736416	20992761992	career	career	NN1
304953	100736416	20992761993	to	to	II
304953	100736416	20992761994	the	the	AT
304953	100736416	20992761995	development	development	NN1
304953	100736416	20992761996	of	of	IO
304953	100736416	20992761997	new	new	JJ
304953	100736416	20992761998	therapies	therapy	NN2
304953	100736416	20992761999	for	for	IF
304953	100736416	20992762000	the	the	AT
304953	100736416	20992762001	treatment	treatment	NN1
304953	100736416	20992762002	of	of	IO
304953	100736416	20992762003	prostate	prostate	NN1
304953	100736416	20992762004	cancer	cancer	NN1
304953	100736416	20992762005	.	.	.
304953	100736416	20992762006	The	the	AT
304953	100736416	20992762007	Annual	annual	JJ
304953	100736416	20992762008	Report	report	NN1
304953	100736416	20992762009	on	on	II
304953	100736416	20992762010	Prostate	prostate	NN1
304953	100736416	20992762011	Diseases	disease	NN2
304953	100736416	20992762012	,	,	,
304953	100736416	20992762013	formerly	formerly	RR
304953	100736416	20992762014	Perspectives	perspective	NN2
304953	100736416	20992762015	on	on	II
304953	100736416	20992762016	Prostate	prostate	NN1
304953	100736416	20992762017	Disease	disease	NN1
304953	100736416	20992762018	,	,	,
304953	100736416	20992762019	emerged	emerge	VVD_VVN@
304953	100736416	20992762020	from	from	II
304953	100736416	20992762021	Dr.		NNB
304953	100736416	20992762022	Garnick		NP1
304953	100736416	20992762023	's	's	GE
304953	100736416	20992762024	keen	keen	JJ
304953	100736416	20992762025	interest	interest	NN1
304953	100736416	20992762026	in	in	II
304953	100736416	20992762027	explaining	explain	VVG
304953	100736416	20992762028	issues	issue	NN2
304953	100736416	20992762029	of	of	IO
304953	100736416	20992762030	medical	medical	JJ
304953	100736416	20992762031	importance	importance	NN1
304953	100736416	20992762032	to	to	II
304953	100736416	20992762033	patients	patient	NN2
304953	100736416	20992762034	and	and	CC
304953	100736416	20992762035	their	their	APPGE
304953	100736416	20992762036	families	family	NN2
304953	100736416	20992762037	to	to	TO
304953	100736416	20992762038	help	help	VVI
304953	100736416	20992762039	them	them	PPHO2
304953	100736416	20992762040	select	select	JJ_VV0
304953	100736416	20992762041	appropriate	appropriate	JJ
304953	100736416	20992762042	treatment	treatment	NN1
304953	100736416	20992762043	@		II
304953	100736416	20992762044	@		II
304953	100736416	20992762045	@		II
304953	100736416	20992762046	@		II
304953	100736416	20992762047	@		II
304953	100736416	20992762048	@		II
304953	100736416	20992762049	@		II
304953	100736416	20992762050	@		II
304953	100736416	20992762051	@		II
304953	100736416	20992762052	@		II
304953	100736416	20992762053	on	on	II
304953	100736416	20992762054	clinical	clinical	JJ
304953	100736416	20992762055	research	research	NN1
304953	100736416	20992762056	,	,	,
304953	100736416	20992762057	drug	drug	NN1
304953	100736416	20992762058	development	development	NN1
304953	100736416	20992762059	,	,	,
304953	100736416	20992762060	and	and	CC
304953	100736416	20992762061	cancer	cancer	NN1
304953	100736416	20992762062	biology	biology	NN1
304953	100736416	20992762063	and	and	CC
304953	100736416	20992762064	has	have	VHZ
304953	100736416	20992762065	written	write	VVN
304953	100736416	20992762066	or	or	CC
304953	100736416	20992762067	edited	edit	VVD_VVN
304953	100736416	20992762068	six	six	MC
304953	100736416	20992762069	books	book	NN2
304953	100736416	20992762070	,	,	,
304953	100736416	20992762071	including	including	II_VVG@
304953	100736416	20992762072	A	a	AT1@_ZZ1
304953	100736416	20992762073	Patient	patient	NN1
304953	100736416	20992762074	's	's	GE
304953	100736416	20992762075	Guide	guide	NN1
304953	100736416	20992762076	to	to	II
304953	100736416	20992762077	Prostate	prostate	NN1
304953	100736416	20992762078	Cancer	cancer	NN1
304953	100736416	20992762079	.	.	.
304953	100736416	20992762080	In	in	II31
304953	100736416	20992762081	addition	addition	II32
304953	100736416	20992762082	to	to	II33
304953	100736416	20992762083	his	his	APPGE
304953	100736416	20992762084	academic	academic	JJ
304953	100736416	20992762085	affiliations	affiliation	NN2
304953	100736416	20992762086	,	,	,
304953	100736416	20992762087	Dr.		NNB
304953	100736416	20992762088	Garnick		NP1
304953	100736416	20992762089	founded	found	VVD
304953	100736416	20992762090	the	the	AT
304953	100736416	20992762091	Hershey	hershey	NP1_NN1@_JJ%
304953	100736416	20992762092	Family	family	NN1
304953	100736416	20992762093	Foundation	foundation	NN1
304953	100736416	20992762094	for	for	IF
304953	100736416	20992762095	Prostate	prostate	NN1
304953	100736416	20992762096	Cancer	cancer	NN1
304953	100736416	20992762097	Research	research	NN1
304953	100736416	20992762098	at	at	II
304953	100736416	20992762099	Beth	beth	NP1
304953	100736416	20992762100	Israel	israel	NP1
304953	100736416	20992762101	Deaconess	deaconess	NN1
304953	100736416	20992762102	Medical	medical	JJ
304953	100736416	20992762103	Center	center	NN1
304953	100736416	20992762104	,	,	,
304953	100736416	20992762105	serves	serve	VVZ
304953	100736416	20992762106	as	as	RG@_CSA
304953	100736416	20992762107	medical	medical	JJ
304953	100736416	20992762108	advisor	advisor	NN1
304953	100736416	20992762109	to	to	II
304953	100736416	20992762110	World	world	NN1
304953	100736416	20992762111	Book	book	NN1
304953	100736416	20992762112	Encyclopedia	encyclopedia	NP1_NN1@
304953	100736416	20992762113	,	,	,
304953	100736416	20992762114	and	and	CC
304953	100736416	20992762115	serves	serve	VVZ
304953	100736416	20992762116	on	on	II
304953	100736416	20992762117	the	the	AT
304953	100736416	20992762118	boards	board	NN2
304953	100736416	20992762119	of	of	IO
304953	100736416	20992762120	trustees	trustee	NN2
304953	100736416	20992762121	of	of	IO
304953	100736416	20992762122	Bowdoin	bowdoin	NP1_NN1
304953	100736416	20992762123	College	college	NN1
304953	100736416	20992762124	and	and	CC
304953	100736416	20992762125	the	the	AT
304953	100736416	20992762126	University	university	NN1
304953	100736416	20992762127	of	of	IO
304953	100736416	20992762128	Pennsylvania	pennsylvania	NP1
304953	100736416	20992762129	School	school	NN1
304953	100736416	20992762130	of	of	IO
304953	100736416	20992762131	Medicine	medicine	NN1
304953	100736416	20992762132	.	.	.
304953	100736416	20992762133	<p>		NULL
304953	100736416	20992762134	Per-Anders		NP1
304953	100736416	20992762135	Abrahamsson	abrahamsson	NP1
304953	100736416	20992762136	,	,	,
304953	100736416	20992762137	M.D.	m.d	NNA
304953	100736416	20992762138	,	,	,
304953	100736416	20992762139	Ph.D	phd	NP1
304953	100736416	20992762140	.	.	.
304953	100736416	20992762141	Dr.		NNB
304953	100736416	20992762142	Abrahamsson	abrahamsson	NP1
304953	100736416	20992762143	is	be	VBZ
304953	100736416	20992762144	an	a	AT1
304953	100736416	20992762145	internationally	internationally	RR
304953	100736416	20992762146	respected	respected	JJ_VVN
304953	100736416	20992762147	leader	leader	NN1
304953	100736416	20992762148	in	in	II
304953	100736416	20992762149	urology	urology	NN1
304953	100736416	20992762150	who	who	PNQS
304953	100736416	20992762151	currently	currently	RR
304953	100736416	20992762152	serves	serve	VVZ
304953	100736416	20992762153	as	as	CSA_II@
304953	100736416	20992762154	Secretary	secretary	NN1
304953	100736416	20992762155	General	general	JJ
304953	100736416	20992762156	of	of	IO
304953	100736416	20992762157	the	the	AT
304953	100736416	20992762158	European	european	JJ
304953	100736416	20992762159	Association	association	NN1
304953	100736416	20992762160	of	of	IO
304953	100736416	20992762161	Urology	urology	NP1_NN1
304953	100736416	20992762162	,	,	,
304953	100736416	20992762163	the	the	AT
304953	100736416	20992762164	leading	leading	JJ
304953	100736416	20992762165	professional	professional	JJ
304953	100736416	20992762166	organization	organization	NN1
304953	100736416	20992762167	overseas.		NNU
304953	100736416	20992762168	-	-	-
304953	100736416	20992762169	He	he	PPHS1
304953	100736416	20992762170	is	be	VBZ
304953	100736416	20992762171	Chairman	chairman	NN1
304953	100736416	20992762172	of	of	IO
304953	100736416	20992762173	the	the	AT
304953	100736416	20992762174	Department	department	NN1
304953	100736416	20992762175	of	of	IO
304953	100736416	20992762176	Urology	urology	NN1_NP1
304953	100736416	20992762177	at	at	II
304953	100736416	20992762178	Sk+ne		FO
304953	100736416	20992762179	University	university	NN1
304953	100736416	20992762180	Hospital	hospital	NN1
304953	100736416	20992762181	,	,	,
304953	100736416	20992762182	Malm+		FO
304953	100736416	20992762183	,	,	,
304953	100736416	20992762184	Lund	lund	NP1
304953	100736416	20992762185	University	university	NN1
304953	100736416	20992762186	,	,	,
304953	100736416	20992762187	in	in	II
304953	100736416	20992762188	Sweden	sweden	NP1
304953	100736416	20992762189	,	,	,
304953	100736416	20992762190	and	and	CC
304953	100736416	20992762191	an	a	AT1
304953	100736416	20992762192	Adjunct	adjunct	NN1
304953	100736416	20992762193	Professor	professor	NN1
304953	100736416	20992762194	in	in	II
304953	100736416	20992762195	the	the	AT
304953	100736416	20992762196	Department	department	NN1
304953	100736416	20992762197	of	of	IO
304953	100736416	20992762198	Urology	urology	NP1_NN1
304953	100736416	20992762199	,	,	,
304953	100736416	20992762200	University	university	NN1
304953	100736416	20992762201	of	of	IO
304953	100736416	20992762202	Rochester	rochester	NP1
304953	100736416	20992762203	Medical	medical	JJ
304953	100736416	20992762204	Center	center	NN1
304953	100736416	20992762205	,	,	,
304953	100736416	20992762206	in	in	II
304953	100736416	20992762207	New	new	NP1
304953	100736416	20992762208	York	york	NP1
304953	100736416	20992762209	.	.	.
304953	100736416	20992762210	The	the	AT
304953	100736416	20992762211	author	author	NN1
304953	100736416	20992762212	of	of	IO
304953	100736416	20992762213	numerous	numerous	JJ
304953	100736416	20992762214	scientific	scientific	JJ
304953	100736416	20992762215	publications	publication	NN2
304953	100736416	20992762216	,	,	,
304953	100736416	20992762217	including	including	II_VVG@
304953	100736416	20992762218	book	book	NN1
304953	100736416	20992762219	chapters	chapter	NN2
304953	100736416	20992762220	and	and	CC
304953	100736416	20992762221	books	book	NN2
304953	100736416	20992762222	,	,	,
304953	100736416	20992762223	he	he	PPHS1
304953	100736416	20992762224	serves	serve	VVZ
304953	100736416	20992762225	on	on	II
304953	100736416	20992762226	the	the	AT
304953	100736416	20992762227	editorial	editorial	JJ_NN1
304953	100736416	20992762228	boards	board	NN2
304953	100736416	20992762229	of	of	IO
304953	100736416	20992762230	several	several	DA2
304953	100736416	20992762231	scientific	scientific	JJ
304953	100736416	20992762232	journals	journal	NN2
304953	100736416	20992762233	.	.	.
304953	100736416	20992762234	He	he	PPHS1
304953	100736416	20992762235	has	have	VHZ
304953	100736416	20992762236	received	receive	VVN
304953	100736416	20992762237	a	a	AT1
304953	100736416	20992762238	number	number	NN1
304953	100736416	20992762239	of	of	IO
304953	100736416	20992762240	national	national	JJ
304953	100736416	20992762241	and	and	CC
304953	100736416	20992762242	international	international	JJ
304953	100736416	20992762243	@		II
304953	100736416	20992762244	@		II
304953	100736416	20992762245	@		II
304953	100736416	20992762246	@		II
304953	100736416	20992762247	@		II
304953	100736416	20992762248	@		II
304953	100736416	20992762249	@		II
304953	100736416	20992762250	@		II
304953	100736416	20992762251	@		II
304953	100736416	20992762252	@		II
304953	100736416	20992762253	physicians	physician	NN2
304953	100736416	20992762254	together	together	RL
304953	100736416	20992762255	from	from	II
304953	100736416	20992762256	multiple	multiple	JJ_NN1
304953	100736416	20992762257	disciplines	discipline	NN2
304953	100736416	20992762258	.	.	.
304953	100736416	20992762259	<p>		NULL
304953	100736416	20992762260	William	william	NP1
304953	100736416	20992762261	C.		NP1
304953	100736416	20992762262	DeWolf	dewolf	NP1
304953	100736416	20992762263	,	,	,
304953	100736416	20992762264	M.D.	m.d	NNA
304953	100736416	20992762265	A	a	ZZ1_AT1@
304953	100736416	20992762266	Professor	professor	NN1
304953	100736416	20992762267	of	of	IO
304953	100736416	20992762268	Surgery	surgery	NN1
304953	100736416	20992762269	(	(	(
304953	100736416	20992762270	Urology		NP1
304953	100736416	20992762271	)	)	)
304953	100736416	20992762272	at	at	II
304953	100736416	20992762273	Harvard	harvard	NP1
304953	100736416	20992762274	Medical	medical	JJ
304953	100736416	20992762275	School	school	NN1
304953	100736416	20992762276	and	and	CC
304953	100736416	20992762277	Chief	chief	NN1
304953	100736416	20992762278	of	of	IO
304953	100736416	20992762279	the	the	AT
304953	100736416	20992762280	Division	division	NN1
304953	100736416	20992762281	of	of	IO
304953	100736416	20992762282	Urology	urology	NN1_NP1
304953	100736416	20992762283	at	at	II
304953	100736416	20992762284	Beth	beth	NP1
304953	100736416	20992762285	Israel	israel	NP1
304953	100736416	20992762286	Deaconess	deaconess	NN1
304953	100736416	20992762287	Medical	medical	JJ
304953	100736416	20992762288	Center	center	NN1
304953	100736416	20992762289	in	in	II
304953	100736416	20992762290	Boston	boston	NP1
304953	100736416	20992762291	,	,	,
304953	100736416	20992762292	Dr.		NNB
304953	100736416	20992762293	DeWolf	dewolf	NP1
304953	100736416	20992762294	is	be	VBZ
304953	100736416	20992762295	a	a	AT1
304953	100736416	20992762296	member	member	NN1
304953	100736416	20992762297	of	of	IO
304953	100736416	20992762298	many	many	DA2
304953	100736416	20992762299	professional	professional	JJ
304953	100736416	20992762300	societies	society	NN2
304953	100736416	20992762301	and	and	CC
304953	100736416	20992762302	the	the	AT
304953	100736416	20992762303	author	author	NN1
304953	100736416	20992762304	of	of	IO
304953	100736416	20992762305	numerous	numerous	JJ
304953	100736416	20992762306	original	original	JJ
304953	100736416	20992762307	reports	report	NN2
304953	100736416	20992762308	,	,	,
304953	100736416	20992762309	abstracts	abstract	NN2
304953	100736416	20992762310	,	,	,
304953	100736416	20992762311	and	and	CC
304953	100736416	20992762312	review	review	NN1_VV0
304953	100736416	20992762313	articles	article	NN2
304953	100736416	20992762314	published	publish	VVN
304953	100736416	20992762315	in	in	II
304953	100736416	20992762316	peer-reviewed	peer-reviewed	JJ_NN1
304953	100736416	20992762317	journals	journal	NN2
304953	100736416	20992762318	.	.	.
304953	100736416	20992762319	Also	also	RR
304953	100736416	20992762320	a	a	AT1
304953	100736416	20992762321	member	member	NN1
304953	100736416	20992762322	of	of	IO
304953	100736416	20992762323	the	the	AT
304953	100736416	20992762324	American	american	JJ
304953	100736416	20992762325	Urologic	urologic	JJ
304953	100736416	20992762326	Association	association	NN1
304953	100736416	20992762327	Program	program	NN1
304953	100736416	20992762328	Committee	committee	NN1
304953	100736416	20992762329	for	for	IF
304953	100736416	20992762330	Basic	basic	JJ
304953	100736416	20992762331	Research	research	NN1
304953	100736416	20992762332	in	in	II
304953	100736416	20992762333	Prostate	prostate	NN1
304953	100736416	20992762334	Cancer	cancer	NN1
304953	100736416	20992762335	,	,	,
304953	100736416	20992762336	Dr.		NNB
304953	100736416	20992762337	DeWolf	dewolf	NP1
304953	100736416	20992762338	's	's	GE
304953	100736416	20992762339	own	own	DA
304953	100736416	20992762340	research	research	NN1
304953	100736416	20992762341	interests	interest	NN2
304953	100736416	20992762342	include	include	VV0
304953	100736416	20992762343	the	the	AT
304953	100736416	20992762344	identification	identification	NN1
304953	100736416	20992762345	of	of	IO
304953	100736416	20992762346	urinary	urinary	JJ_NN1
304953	100736416	20992762347	biomarkers	biomarker	NN2
304953	100736416	20992762348	for	for	IF
304953	100736416	20992762349	prostate	prostate	NN1
304953	100736416	20992762350	cancer	cancer	NN1
304953	100736416	20992762351	and	and	CC
304953	100736416	20992762352	a	a	AT1
304953	100736416	20992762353	better	better	JJR
304953	100736416	20992762354	understanding	understanding	NN1
304953	100736416	20992762355	of	of	IO
304953	100736416	20992762356	the	the	AT
304953	100736416	20992762357	molecular	molecular	JJ
304953	100736416	20992762358	biology	biology	NN1
304953	100736416	20992762359	of	of	IO
304953	100736416	20992762360	prostate	prostate	NN1
304953	100736416	20992762361	cancer	cancer	NN1
304953	100736416	20992762362	.	.	.
304953	100736416	20992762363	<p>		NULL
304953	100736416	20992762364	Carolyn	carolyn	NP1
304953	100736416	20992762365	C.		NP1
304953	100736416	20992762366	Lamb	lamb	NP1
304953	100736416	20992762367	,	,	,
304953	100736416	20992762368	M.D.	m.d	NNA
304953	100736416	20992762369	Dr.		NNB
304953	100736416	20992762370	Lamb	lamb	NP1
304953	100736416	20992762371	is	be	VBZ
304953	100736416	20992762372	an	a	AT1
304953	100736416	20992762373	Instructor	instructor	NN1
304953	100736416	20992762374	in	in	II
304953	100736416	20992762375	Radiology	radiology	NP1_NN1
304953	100736416	20992762376	at	at	II
304953	100736416	20992762377	Harvard	harvard	NP1
304953	100736416	20992762378	Medical	medical	JJ
304953	100736416	20992762379	School	school	NN1
304953	100736416	20992762380	and	and	CC
304953	100736416	20992762381	a	a	AT1
304953	100736416	20992762382	radiation	radiation	NN1
304953	100736416	20992762383	oncologist	oncologist	NN1
304953	100736416	20992762384	at	at	II
304953	100736416	20992762385	Mt	mt	NP1
304953	100736416	20992762386	.	.	.
304953	100736416	20992762387	Auburn	auburn	JJ
304953	100736416	20992762388	Hospital	hospital	NN1
304953	100736416	20992762389	in	in	II
304953	100736416	20992762390	Cambridge	cambridge	NP1
304953	100736416	20992762391	.	.	.
304953	100736416	20992762392	She	she	PPHS1
304953	100736416	20992762393	is	be	VBZ
304953	100736416	20992762394	a	a	AT1
304953	100736416	20992762395	member	member	NN1
304953	100736416	20992762396	of	of	IO
304953	100736416	20992762397	several	several	DA2
304953	100736416	20992762398	professional	professional	JJ
304953	100736416	20992762399	societies	society	NN2
304953	100736416	20992762400	,	,	,
304953	100736416	20992762401	including	including	II_VVG@
304953	100736416	20992762402	the	the	AT
304953	100736416	20992762403	American	american	JJ
304953	100736416	20992762404	Society	society	NN1
304953	100736416	20992762405	for	for	IF
304953	100736416	20992762406	Therapeutic	therapeutic	JJ
304953	100736416	20992762407	Radiation	radiation	NN1
304953	100736416	20992762408	and	and	CC
304953	100736416	20992762409	Oncology	oncology	NP1_NN1
304953	100736416	20992762410	and	and	CC
304953	100736416	20992762411	the	the	AT
304953	100736416	20992762412	American	american	JJ
304953	100736416	20992762413	Medical	medical	JJ
304953	100736416	20992762414	Women	woman	NN2
304953	100736416	20992762415	's	's	GE
304953	100736416	20992762416	Association	association	NN1
304953	100736416	20992762417	.	.	.
304953	100736416	20992762418	She	she	PPHS1
304953	100736416	20992762419	has	have	VHZ
304953	100736416	20992762420	published	publish	VVN
304953	100736416	20992762421	a	a	AT1
304953	100736416	20992762422	number	number	NN1
304953	100736416	20992762423	of	of	IO
304953	100736416	20992762424	scientific	scientific	JJ
304953	100736416	20992762425	papers	paper	NN2
304953	100736416	20992762426	on	on	II
304953	100736416	20992762427	the	the	AT
304953	100736416	20992762428	treatment	treatment	NN1
304953	100736416	20992762429	of	of	IO
304953	100736416	20992762430	prostate	prostate	NN1
304953	100736416	20992762431	cancer	cancer	NN1
304953	100736416	20992762432	,	,	,
304953	100736416	20992762433	including	including	II_VVG@
304953	100736416	20992762434	the	the	AT
304953	100736416	20992762435	implantation	implantation	NN1
304953	100736416	20992762436	of	of	IO
304953	100736416	20992762437	radioactive	radioactive	JJ
304953	100736416	20992762438	seeds	seed	NN2
304953	100736416	20992762439	and	and	CC
304953	100736416	20992762440	treatment	treatment	NN1
304953	100736416	20992762441	of	of	IO
304953	100736416	20992762442	genitourinary	genitourinary	JJ_NN1
304953	100736416	20992762443	@		II
304953	100736416	20992762444	@		II
304953	100736416	20992762445	@		II
304953	100736416	20992762446	@		II
304953	100736416	20992762447	@		II
304953	100736416	20992762448	@		II
304953	100736416	20992762449	@		II
304953	100736416	20992762450	@		II
304953	100736416	20992762451	@		II
304953	100736416	20992762452	@		II
304953	100736416	20992762453	more	more	RGR
304953	100736416	20992762454	precise	precise	JJ
304953	100736416	20992762455	methods	method	NN2
304953	100736416	20992762456	of	of	IO
304953	100736416	20992762457	delivering	deliver	VVG
304953	100736416	20992762458	radiation	radiation	NN1
304953	100736416	20992762459	therapy	therapy	NN1
304953	100736416	20992762460	,	,	,
304953	100736416	20992762461	in	in	BCL21
304953	100736416	20992762462	order	order	BCL22
304953	100736416	20992762463	to	to	TO
304953	100736416	20992762464	target	target	VVI
304953	100736416	20992762465	tumors	tumor	NN2
304953	100736416	20992762466	while	while	CS
304953	100736416	20992762467	sparing	spare	VVG
304953	100736416	20992762468	healthy	healthy	JJ
304953	100736416	20992762469	tissue	tissue	NN1
304953	100736416	20992762470	.	.	.
304953	100736416	20992762471	<p>		NULL
304953	100736416	20992762472	Kevin	kevin	NP1
304953	100736416	20992762473	R.		NP1
304953	100736416	20992762474	Loughlin	loughlin	NP1
304953	100736416	20992762475	,	,	,
304953	100736416	20992762476	M.D.	m.d	NNA
304953	100736416	20992762477	,	,	,
304953	100736416	20992762478	M.B.A	m.b.a	NP1
304953	100736416	20992762479	.	.	.
304953	100736416	20992762480	A	a	AT1
304953	100736416	20992762481	Professor	professor	NN1
304953	100736416	20992762482	of	of	IO
304953	100736416	20992762483	Surgery	surgery	NN1
304953	100736416	20992762484	(	(	(
304953	100736416	20992762485	Urology		NP1
304953	100736416	20992762486	)	)	)
304953	100736416	20992762487	at	at	II
304953	100736416	20992762488	Harvard	harvard	NP1
304953	100736416	20992762489	Medical	medical	JJ
304953	100736416	20992762490	School	school	NN1
304953	100736416	20992762491	and	and	CC
304953	100736416	20992762492	Director	director	NN1
304953	100736416	20992762493	of	of	IO
304953	100736416	20992762494	Urologic	urologic	JJ
304953	100736416	20992762495	Research	research	NN1
304953	100736416	20992762496	at	at	II
304953	100736416	20992762497	Brigham	brigham	NP1
304953	100736416	20992762498	and	and	CC
304953	100736416	20992762499	Women	woman	NN2
304953	100736416	20992762500	's	's	GE
304953	100736416	20992762501	Hospital	hospital	NN1
304953	100736416	20992762502	,	,	,
304953	100736416	20992762503	Dr.		NNB
304953	100736416	20992762504	Loughlin	loughlin	NP1
304953	100736416	20992762505	is	be	VBZ
304953	100736416	20992762506	also	also	RR
304953	100736416	20992762507	staff	staff	NN_VV0@
304953	100736416	20992762508	urologist	urologist	NN1
304953	100736416	20992762509	at	at	II
304953	100736416	20992762510	the	the	AT
304953	100736416	20992762511	Harvard	harvard	NP1
304953	100736416	20992762512	University	university	NN1
304953	100736416	20992762513	Health	health	NN1
304953	100736416	20992762514	Service	service	NN1
304953	100736416	20992762515	,	,	,
304953	100736416	20992762516	a	a	AT1
304953	100736416	20992762517	large	large	JJ
304953	100736416	20992762518	university	university	NN1
304953	100736416	20992762519	health	health	NN1
304953	100736416	20992762520	program	program	NN1_VV0@
304953	100736416	20992762521	that	that	CST_DD1
304953	100736416	20992762522	serves	serve	VVZ
304953	100736416	20992762523	the	the	AT
304953	100736416	20992762524	needs	need	NN2
304953	100736416	20992762525	of	of	IO
304953	100736416	20992762526	Harvard	harvard	NP1
304953	100736416	20992762527	students	student	NN2
304953	100736416	20992762528	,	,	,
304953	100736416	20992762529	faculty	faculty	NN1
304953	100736416	20992762530	,	,	,
304953	100736416	20992762531	employees	employee	NN2
304953	100736416	20992762532	,	,	,
304953	100736416	20992762533	and	and	CC
304953	100736416	20992762534	their	their	APPGE
304953	100736416	20992762535	families	family	NN2
304953	100736416	20992762536	.	.	.
304953	100736416	20992762537	His	his	APPGE
304953	100736416	20992762538	clinical	clinical	JJ
304953	100736416	20992762539	interests	interest	NN2
304953	100736416	20992762540	include	include	VV0
304953	100736416	20992762541	urologic	urologic	JJ
304953	100736416	20992762542	oncology	oncology	NN1
304953	100736416	20992762543	and	and	CC
304953	100736416	20992762544	urologic	urologic	JJ
304953	100736416	20992762545	incontinence	incontinence	NN1
304953	100736416	20992762546	.	.	.
304953	100736416	20992762547	In	in	II31
304953	100736416	20992762548	addition	addition	II32
304953	100736416	20992762549	to	to	II33
304953	100736416	20992762550	publishing	publish	VVG
304953	100736416	20992762551	numerous	numerous	JJ
304953	100736416	20992762552	scientific	scientific	JJ
304953	100736416	20992762553	articles	article	NN2
304953	100736416	20992762554	on	on	II
304953	100736416	20992762555	prostate	prostate	NN1
304953	100736416	20992762556	disease	disease	NN1
304953	100736416	20992762557	,	,	,
304953	100736416	20992762558	he	he	PPHS1
304953	100736416	20992762559	is	be	VBZ
304953	100736416	20992762560	the	the	AT
304953	100736416	20992762561	author	author	NN1
304953	100736416	20992762562	of	of	IO
304953	100736416	20992762563	several	several	DA2
304953	100736416	20992762564	books	book	NN2
304953	100736416	20992762565	,	,	,
304953	100736416	20992762566	including	including	II
304953	100736416	20992762567	100	100	MC
304953	100736416	20992762568	Questions	question	NN2
304953	100736416	20992762569	and	and	CC
304953	100736416	20992762570	Answers	answer	VVZ_NN2
304953	100736416	20992762571	about	about	II
304953	100736416	20992762572	Benign	benign	JJ
304953	100736416	20992762573	Prostate	prostate	NN1
304953	100736416	20992762574	Disease	disease	NN1
304953	100736416	20992762575	and	and	CC
304953	100736416	20992762576	The	the	AT
304953	100736416	20992762577	Clinical	clinical	JJ
304953	100736416	20992762578	Guide	guide	NN1
304953	100736416	20992762579	to	to	II
304953	100736416	20992762580	Prostate	prostate	NN1
304953	100736416	20992762581	Specific	specific	JJ
304953	100736416	20992762582	Antigen	antigen	NN1
304953	100736416	20992762583	.	.	.
304953	100736416	20992762584	<p>		NULL
304953	100736416	20992762585	Abraham	abraham	NP1
304953	100736416	20992762586	Morgentaler		NP1
304953	100736416	20992762587	,	,	,
304953	100736416	20992762588	M.D.	m.d	NNA
304953	100736416	20992762589	Dr.		NNB
304953	100736416	20992762590	Morgentaler		NP1
304953	100736416	20992762591	is	be	VBZ
304953	100736416	20992762592	an	a	AT1
304953	100736416	20992762593	Associate	associate	JJ
304953	100736416	20992762594	Clinical	clinical	JJ
304953	100736416	20992762595	Professor	professor	NN1
304953	100736416	20992762596	of	of	IO
304953	100736416	20992762597	Surgery	surgery	NN1
304953	100736416	20992762598	(	(	(
304953	100736416	20992762599	Urology		NP1
304953	100736416	20992762600	)	)	)
304953	100736416	20992762601	at	at	II
304953	100736416	20992762602	Harvard	harvard	NP1
304953	100736416	20992762603	Medical	medical	JJ
304953	100736416	20992762604	School	school	NN1
304953	100736416	20992762605	and	and	CC
304953	100736416	20992762606	Director	director	NN1
304953	100736416	20992762607	of	of	IO
304953	100736416	20992762608	Men	man	NN2
304953	100736416	20992762609	's	's	GE
304953	100736416	20992762610	Health	health	NN1
304953	100736416	20992762611	Boston	boston	NP1
304953	100736416	20992762612	,	,	,
304953	100736416	20992762613	where	where	CS_RRQ
304953	100736416	20992762614	he	he	PPHS1
304953	100736416	20992762615	specializes	specialize	VVZ
304953	100736416	20992762616	in	in	II_RP@
304953	100736416	20992762617	treating	treat	VVG
304953	100736416	20992762618	a	a	AT1
304953	100736416	20992762619	range	range	NN1
304953	100736416	20992762620	of	of	IO
304953	100736416	20992762621	prostate	prostate	NN1
304953	100736416	20992762622	diseases	disease	NN2
304953	100736416	20992762623	and	and	CC
304953	100736416	20992762624	male	male	JJ
304953	100736416	20992762625	sexual	sexual	JJ
304953	100736416	20992762626	and	and	CC
304953	100736416	20992762627	reproductive	reproductive	JJ
304953	100736416	20992762628	difficulties	difficulty	NN2
304953	100736416	20992762629	.	.	.
304953	100736416	20992762630	He	he	PPHS1
304953	100736416	20992762631	has	have	VHZ
304953	100736416	20992762632	developed	develop	VVN
304953	100736416	20992762633	a	a	AT1
304953	100736416	20992762634	particular	particular	JJ
304953	100736416	20992762635	expertise	expertise	NN1
304953	100736416	20992762636	in	in	II
304953	100736416	20992762637	treating	treat	VVG
304953	100736416	20992762638	erectile	erectile	JJ
304953	100736416	20992762639	dysfunction	dysfunction	NN1
304953	100736416	20992762640	,	,	,
304953	100736416	20992762641	low	low	JJ
304953	100736416	20992762642	testosterone	testosterone	NN1
304953	100736416	20992762643	@		II
304953	100736416	20992762644	@		II
304953	100736416	20992762645	@		II
304953	100736416	20992762646	@		II
304953	100736416	20992762647	@		II
304953	100736416	20992762648	@		II
304953	100736416	20992762649	@		II
304953	100736416	20992762650	@		II
304953	100736416	20992762651	@		II
304953	100736416	20992762652	@		II
304953	100736416	20992762653	numerous	numerous	JJ
304953	100736416	20992762654	scientific	scientific	JJ
304953	100736416	20992762655	articles	article	NN2
304953	100736416	20992762656	,	,	,
304953	100736416	20992762657	especially	especially	RR
304953	100736416	20992762658	on	on	II
304953	100736416	20992762659	the	the	AT
304953	100736416	20992762660	issues	issue	NN2
304953	100736416	20992762661	of	of	IO
304953	100736416	20992762662	erectile	erectile	JJ
304953	100736416	20992762663	dysfunction	dysfunction	NN1
304953	100736416	20992762664	and	and	CC
304953	100736416	20992762665	testosterone-replacement		JJ_NN1
304953	100736416	20992762666	therapy	therapy	NN1
304953	100736416	20992762667	.	.	.
304953	100736416	20992762668	He	he	PPHS1
304953	100736416	20992762669	is	be	VBZ
304953	100736416	20992762670	also	also	RR
304953	100736416	20992762671	the	the	AT
304953	100736416	20992762672	author	author	NN1
304953	100736416	20992762673	of	of	IO
304953	100736416	20992762674	several	several	DA2
304953	100736416	20992762675	articles	article	NN2
304953	100736416	20992762676	and	and	CC
304953	100736416	20992762677	books	book	NN2
304953	100736416	20992762678	for	for	IF
304953	100736416	20992762679	the	the	AT
304953	100736416	20992762680	lay	lay	JJ@
304953	100736416	20992762681	public	public	NN1_JJ
304953	100736416	20992762682	,	,	,
304953	100736416	20992762683	including	including	II_VVG@
304953	100736416	20992762684	The	the	AT
304953	100736416	20992762685	Viagra	viagra	NP1_NN1@
304953	100736416	20992762686	Myth	myth	NN1
304953	100736416	20992762687	:	:	:
304953	100736416	20992762688	The	the	AT
304953	100736416	20992762689	Surprising	surprising	JJ
304953	100736416	20992762690	Impact	impact	NN1
304953	100736416	20992762691	on	on	II
304953	100736416	20992762692	Love	love	NN1
304953	100736416	20992762693	and	and	CC
304953	100736416	20992762694	Relationships	relationship	NN2
304953	100736416	20992762695	and	and	CC
304953	100736416	20992762696	Testosterone	testosterone	NN1
304953	100736416	20992762697	for	for	IF
304953	100736416	20992762698	Life	life	NN1
304953	100736416	20992762699	.	.	.
304953	100736416	20992762700	<p>		NULL
304953	100736416	20992762701	David	david	NP1
304953	100736416	20992762702	S.		NP1
304953	100736416	20992762703	Rosenthal	rosenthal	NP1
304953	100736416	20992762704	,	,	,
304953	100736416	20992762705	M.D.	m.d	NNA
304953	100736416	20992762706	A	a	ZZ1
304953	100736416	20992762707	past	past	JJ
304953	100736416	20992762708	President	president	NN1
304953	100736416	20992762709	of	of	IO
304953	100736416	20992762710	the	the	AT
304953	100736416	20992762711	American	american	JJ
304953	100736416	20992762712	Cancer	cancer	NN1
304953	100736416	20992762713	Society	society	NN1
304953	100736416	20992762714	,	,	,
304953	100736416	20992762715	Dr.		NNB
304953	100736416	20992762716	Rosenthal	rosenthal	NP1
304953	100736416	20992762717	is	be	VBZ
304953	100736416	20992762718	currently	currently	RR
304953	100736416	20992762719	a	a	AT1
304953	100736416	20992762720	Professor	professor	NN1
304953	100736416	20992762721	of	of	IO
304953	100736416	20992762722	Medicine	medicine	NN1
304953	100736416	20992762723	at	at	II
304953	100736416	20992762724	Harvard	harvard	NP1
304953	100736416	20992762725	Medical	medical	JJ
304953	100736416	20992762726	School	school	NN1
304953	100736416	20992762727	and	and	CC
304953	100736416	20992762728	Director	director	NN1
304953	100736416	20992762729	and	and	CC
304953	100736416	20992762730	Chief	chief	JJ_NN1
304953	100736416	20992762731	Executive	executive	NN1_JJ@
304953	100736416	20992762732	Officer	officer	NN1
304953	100736416	20992762733	of	of	IO
304953	100736416	20992762734	Harvard	harvard	NP1
304953	100736416	20992762735	University	university	NN1
304953	100736416	20992762736	Health	health	NN1
304953	100736416	20992762737	Service	service	NN1
304953	100736416	20992762738	,	,	,
304953	100736416	20992762739	coordinating	coordinate	VVG
304953	100736416	20992762740	the	the	AT
304953	100736416	20992762741	care	care	NN1
304953	100736416	20992762742	and	and	CC
304953	100736416	20992762743	management	management	NN1
304953	100736416	20992762744	of	of	IO
304953	100736416	20992762745	35,000	35,000	MC
304953	100736416	20992762746	members	member	NN2
304953	100736416	20992762747	of	of	IO
304953	100736416	20992762748	the	the	AT
304953	100736416	20992762749	Harvard	harvard	NP1
304953	100736416	20992762750	University	university	NN1
304953	100736416	20992762751	community	community	NN1
304953	100736416	20992762752	.	.	.
304953	100736416	20992762753	He	he	PPHS1
304953	100736416	20992762754	is	be	VBZ
304953	100736416	20992762755	also	also	RR
304953	100736416	20992762756	the	the	AT
304953	100736416	20992762757	Medical	medical	JJ
304953	100736416	20992762758	Director	director	NN1
304953	100736416	20992762759	of	of	IO
304953	100736416	20992762760	the	the	AT
304953	100736416	20992762761	Leonard	leonard	NP1
304953	100736416	20992762762	P.		NP1
304953	100736416	20992762763	Zakim		NP1_NN1
304953	100736416	20992762764	Center	center	NN1
304953	100736416	20992762765	for	for	IF
304953	100736416	20992762766	Integrative	integrative	JJ
304953	100736416	20992762767	Therapies	therapy	NN2
304953	100736416	20992762768	at	at	II
304953	100736416	20992762769	Dana-Farber	dana-farber	NP1
304953	100736416	20992762770	Cancer	cancer	NN1
304953	100736416	20992762771	Institute	institute	NN1
304953	100736416	20992762772	,	,	,
304953	100736416	20992762773	which	which	DDQ
304953	100736416	20992762774	seeks	seek	VVZ
304953	100736416	20992762775	to	to	TO
304953	100736416	20992762776	integrate	integrate	VVI
304953	100736416	20992762777	complementary	complementary	JJ
304953	100736416	20992762778	therapies	therapy	NN2
304953	100736416	20992762779	with	with	IW
304953	100736416	20992762780	conventional	conventional	JJ
304953	100736416	20992762781	cancer	cancer	NN1
304953	100736416	20992762782	treatments	treatment	NN2
304953	100736416	20992762783	.	.	.
304953	100736416	20992762784	He	he	PPHS1
304953	100736416	20992762785	is	be	VBZ
304953	100736416	20992762786	the	the	AT
304953	100736416	20992762787	author	author	NN1
304953	100736416	20992762788	of	of	IO
304953	100736416	20992762789	numerous	numerous	JJ
304953	100736416	20992762790	scientific	scientific	JJ
304953	100736416	20992762791	articles	article	NN2
304953	100736416	20992762792	as	as	II31
304953	100736416	20992762793	well	well	II32
304953	100736416	20992762794	as	as	II33
304953	100736416	20992762795	several	several	DA2
304953	100736416	20992762796	publications	publication	NN2
304953	100736416	20992762797	for	for	IF
304953	100736416	20992762798	laypeople	laypeople	NN1
304953	100736416	20992762799	,	,	,
304953	100736416	20992762800	including	including	II_VVG@
304953	100736416	20992762801	The	the	AT
304953	100736416	20992762802	American	american	JJ
304953	100736416	20992762803	Cancer	cancer	NN1
304953	100736416	20992762804	Society	society	NN1
304953	100736416	20992762805	's	's	GE
304953	100736416	20992762806	Guide	guide	NN1
304953	100736416	20992762807	to	to	II
304953	100736416	20992762808	Complementary	complementary	JJ
304953	100736416	20992762809	and	and	CC
304953	100736416	20992762810	Alternative	alternative	JJ_NN1
304953	100736416	20992762811	Cancer	cancer	NN1
304953	100736416	20992762812	Methods	method	NN2
304953	100736416	20992762813	.	.	.
304953	100736416	20992762814	<p>		NULL
304953	100736416	20992762815	Harvey	harvey	NP1
304953	100736416	20992762816	B.		NP1
304953	100736416	20992762817	Simon	simon	NP1
304953	100736416	20992762818	,	,	,
304953	100736416	20992762819	M.D.	m.d	NNA
304953	100736416	20992762820	Dr.		NNB
304953	100736416	20992762821	Simon	simon	NP1
304953	100736416	20992762822	is	be	VBZ
304953	100736416	20992762823	an	a	AT1
304953	100736416	20992762824	Associate	associate	JJ_NN1
304953	100736416	20992762825	Professor	professor	NN1
304953	100736416	20992762826	of	of	IO
304953	100736416	20992762827	Medicine	medicine	NN1
304953	100736416	20992762828	at	at	II
304953	100736416	20992762829	Harvard	harvard	NP1
304953	100736416	20992762830	Medical	medical	JJ
304953	100736416	20992762831	School	school	NN1
304953	100736416	20992762832	,	,	,
304953	100736416	20992762833	a	a	AT1
304953	100736416	20992762834	member	member	NN1
304953	100736416	20992762835	of	of	IO
304953	100736416	20992762836	the	the	AT
304953	100736416	20992762837	Health	health	NN1
304953	100736416	20992762838	Sciences	science	NN2
304953	100736416	20992762839	Technology	technology	NN1
304953	100736416	20992762840	Faculty	faculty	NN1
304953	100736416	20992762841	at	at	II
304953	100736416	20992762842	Massachusetts	massachusetts	NP1
304953	100736416	20992762843	@		II
304953	100736416	20992762844	@		II
304953	100736416	20992762845	@		II
304953	100736416	20992762846	@		II
304953	100736416	20992762847	@		II
304953	100736416	20992762848	@		II
304953	100736416	20992762849	@		II
304953	100736416	20992762850	@		II
304953	100736416	20992762851	@		II
304953	100736416	20992762852	@		II
304953	100736416	20992762853	Massachusetts	massachusetts	NP1
304953	100736416	20992762854	General	general	JJ_NN1
304953	100736416	20992762855	Hospital	hospital	NN1
304953	100736416	20992762856	in	in	II
304953	100736416	20992762857	Boston	boston	NP1
304953	100736416	20992762858	.	.	.
304953	100736416	20992762859	In	in	II31
304953	100736416	20992762860	addition	addition	II32
304953	100736416	20992762861	to	to	II33
304953	100736416	20992762862	authoring	author	VVG
304953	100736416	20992762863	numerous	numerous	JJ
304953	100736416	20992762864	scientific	scientific	JJ
304953	100736416	20992762865	articles	article	NN2
304953	100736416	20992762866	and	and	CC
304953	100736416	20992762867	textbook	textbook	NN1
304953	100736416	20992762868	chapters	chapter	NN2
304953	100736416	20992762869	,	,	,
304953	100736416	20992762870	he	he	PPHS1
304953	100736416	20992762871	is	be	VBZ
304953	100736416	20992762872	the	the	AT
304953	100736416	20992762873	founding	founding	JJ@_NN1@
304953	100736416	20992762874	editor	editor	NN1
304953	100736416	20992762875	of	of	IO
304953	100736416	20992762876	the	the	AT
304953	100736416	20992762877	monthly	monthly	JJ
304953	100736416	20992762878	newsletter	newsletter	NN1
304953	100736416	20992762879	Harvard	harvard	NP1
304953	100736416	20992762880	Men	man	NN2
304953	100736416	20992762881	's	's	GE
304953	100736416	20992762882	Health	health	NN1
304953	100736416	20992762883	Watch	watch	NN1_VV0
304953	100736416	20992762884	,	,	,
304953	100736416	20992762885	where	where	CS_RRQ
304953	100736416	20992762886	he	he	PPHS1
304953	100736416	20992762887	writes	write	VVZ
304953	100736416	20992762888	frequently	frequently	RR
304953	100736416	20992762889	about	about	II
304953	100736416	20992762890	prostate	prostate	NN1
304953	100736416	20992762891	disease	disease	NN1
304953	100736416	20992762892	and	and	CC
304953	100736416	20992762893	erectile	erectile	JJ
304953	100736416	20992762894	dysfunction	dysfunction	NN1
304953	100736416	20992762895	.	.	.
304953	100736416	20992762896	He	he	PPHS1
304953	100736416	20992762897	is	be	VBZ
304953	100736416	20992762898	also	also	RR
304953	100736416	20992762899	the	the	AT
304953	100736416	20992762900	author	author	NN1
304953	100736416	20992762901	of	of	IO
304953	100736416	20992762902	six	six	MC
304953	100736416	20992762903	consumer	consumer	NN1
304953	100736416	20992762904	health	health	NN1
304953	100736416	20992762905	books	book	NN2
304953	100736416	20992762906	,	,	,
304953	100736416	20992762907	including	including	II_VVG@
304953	100736416	20992762908	The	the	AT
304953	100736416	20992762909	Harvard	harvard	NP1
304953	100736416	20992762910	Medical	medical	JJ
304953	100736416	20992762911	School	school	NN1
304953	100736416	20992762912	Guide	guide	NN1_VV0
304953	100736416	20992762913	to	to	II
304953	100736416	20992762914	Men	man	NN2
304953	100736416	20992762915	's	's	GE
304953	100736416	20992762916	Health	health	NN1
304953	100736416	20992762917	and	and	CC
304953	100736416	20992762918	The	the	AT
304953	100736416	20992762919	No	no	AT
304953	100736416	20992762920	Sweat	sweat	NN1
304953	100736416	20992762921	Exercise	exercise	NN1_VV0
304953	100736416	20992762922	Plan	plan	NN1_VV0
304953	100736416	20992762923	:	:	:
304953	100736416	20992762924	Lose	lose	VV0
304953	100736416	20992762925	Weight	weight	NN1
304953	100736416	20992762926	,	,	,
304953	100736416	20992762927	Get	get	VV0
304953	100736416	20992762928	Healthy	healthy	JJ
304953	100736416	20992762929	,	,	,
304953	100736416	20992762930	and	and	CC
304953	100736416	20992762931	Live	live	VV0_RR@
304953	100736416	20992762932	Longer	long	RRR_JJR
304953	100736416	20992762933	.	.	.
304953	100736416	20992762934	<p>		NULL
304953	100736416	20992762935	Cora	cora	NP1
304953	100736416	20992762936	N.		NP1
304953	100736416	20992762937	Sternberg	sternberg	NP1
304953	100736416	20992762938	,	,	,
304953	100736416	20992762939	M.D.	m.d	NNA
304953	100736416	20992762940	,	,	,
304953	100736416	20992762941	F.A.C.P.		NP1
304953	100736416	20992762942	Dr.		NNB
304953	100736416	20992762943	Sternberg	sternberg	NP1
304953	100736416	20992762944	is	be	VBZ
304953	100736416	20992762945	an	a	AT1
304953	100736416	20992762946	internationally	internationally	RR
304953	100736416	20992762947	respected	respected	JJ_VVN
304953	100736416	20992762948	leader	leader	NN1
304953	100736416	20992762949	in	in	II
304953	100736416	20992762950	medical	medical	JJ
304953	100736416	20992762951	oncology	oncology	NN1
304953	100736416	20992762952	and	and	CC
304953	100736416	20992762953	urologic	urologic	JJ
304953	100736416	20992762954	cancer	cancer	NN1
304953	100736416	20992762955	.	.	.
304953	100736416	20992762956	She	she	PPHS1
304953	100736416	20992762957	is	be	VBZ
304953	100736416	20992762958	Chief	chief	JJ_NN1
304953	100736416	20992762959	of	of	IO
304953	100736416	20992762960	the	the	AT
304953	100736416	20992762961	Department	department	NN1
304953	100736416	20992762962	of	of	IO
304953	100736416	20992762963	Medical	medical	JJ
304953	100736416	20992762964	Oncology	oncology	NN1
304953	100736416	20992762965	at	at	II
304953	100736416	20992762966	the	the	AT
304953	100736416	20992762967	San	san	NP1
304953	100736416	20992762968	Camillo-Foranini		NP1
304953	100736416	20992762969	Hospital	hospital	NN1
304953	100736416	20992762970	and	and	CC
304953	100736416	20992762971	an	a	AT1
304953	100736416	20992762972	Adjunct	adjunct	NN1
304953	100736416	20992762973	Professor	professor	NN1
304953	100736416	20992762974	at	at	II
304953	100736416	20992762975	La	la	NP1
304953	100736416	20992762976	Sapienza	sapienza	NP1
304953	100736416	20992762977	University	university	NN1
304953	100736416	20992762978	,	,	,
304953	100736416	20992762979	both	both	RR_DB2
304953	100736416	20992762980	in	in	II
304953	100736416	20992762981	Rome	rome	NP1
304953	100736416	20992762982	.	.	.
304953	100736416	20992762983	The	the	AT
304953	100736416	20992762984	Scientific	scientific	JJ
304953	100736416	20992762985	Coordinator	coordinator	NN1
304953	100736416	20992762986	of	of	IO
304953	100736416	20992762987	many	many	DA2
304953	100736416	20992762988	international	international	JJ
304953	100736416	20992762989	conferences	conference	NN2
304953	100736416	20992762990	,	,	,
304953	100736416	20992762991	Dr.		NNB
304953	100736416	20992762992	Sternberg	sternberg	NP1
304953	100736416	20992762993	is	be	VBZ
304953	100736416	20992762994	an	a	AT1
304953	100736416	20992762995	elected	elected	JJ@
304953	100736416	20992762996	board	board	NN1
304953	100736416	20992762997	member	member	NN1
304953	100736416	20992762998	of	of	IO
304953	100736416	20992762999	the	the	AT
304953	100736416	20992763000	European	european	JJ
304953	100736416	20992763001	Organization	organization	NN1
304953	100736416	20992763002	for	for	IF
304953	100736416	20992763003	Research	research	NN1
304953	100736416	20992763004	and	and	CC
304953	100736416	20992763005	Treatment	treatment	NN1
304953	100736416	20992763006	of	of	IO
304953	100736416	20992763007	Cancer	cancer	NN1
304953	100736416	20992763008	and	and	CC
304953	100736416	20992763009	serves	serve	VVZ
304953	100736416	20992763010	as	as	CSA_II@
304953	100736416	20992763011	Coordinator	coordinator	NN1
304953	100736416	20992763012	for	for	IF
304953	100736416	20992763013	Genitourinary		JJ_NP1
304953	100736416	20992763014	Oncology	oncology	NN1_NP1
304953	100736416	20992763015	Education	education	NN1
304953	100736416	20992763016	for	for	IF
304953	100736416	20992763017	the	the	AT
304953	100736416	20992763018	European	european	JJ
304953	100736416	20992763019	Society	society	NN1
304953	100736416	20992763020	for	for	IF
304953	100736416	20992763021	Medical	medical	JJ
304953	100736416	20992763022	Oncology	oncology	NN1
304953	100736416	20992763023	.	.	.
304953	100736416	20992763024	She	she	PPHS1
304953	100736416	20992763025	has	have	VHZ
304953	100736416	20992763026	authored	author	VVN
304953	100736416	20992763027	numerous	numerous	JJ
304953	100736416	20992763028	scientific	scientific	JJ
304953	100736416	20992763029	articles	article	NN2
304953	100736416	20992763030	and	and	CC
304953	100736416	20992763031	co-edited	co-edit	VVN
304953	100736416	20992763032	three	three	MC
304953	100736416	20992763033	textbooks	textbook	NN2
304953	100736416	20992763034	and	and	CC
304953	100736416	20992763035	serves	serve	VVZ
304953	100736416	20992763036	on	on	II
304953	100736416	20992763037	the	the	AT
304953	100736416	20992763038	editorial	editorial	JJ_NN1
304953	100736416	20992763039	boards	board	NN2
304953	100736416	20992763040	of	of	IO
304953	100736416	20992763041	several	several	DA2
304953	100736416	20992763042	international	international	JJ
304953	100736416	20992763043	@		II
304953	100736416	20992763044	@		II
304953	100736416	20992763045	@		II
304953	100736416	20992763046	@		II
304953	100736416	20992763047	@		II
304953	100736416	20992763048	@		II
304953	100736416	20992763049	@		II
304953	100736416	20992763050	@		II
304953	100736416	20992763051	@		II
304953	100736416	20992763052	@		II
304953	100736416	20992763053	is	be	VBZ
304953	100736416	20992763054	a	a	AT1
304953	100736416	20992763055	Professor	professor	NN1
304953	100736416	20992763056	of	of	IO
304953	100736416	20992763057	Radiation	radiation	NN1
304953	100736416	20992763058	Oncology	oncology	NN1
304953	100736416	20992763059	at	at	II
304953	100736416	20992763060	Harvard	harvard	NP1
304953	100736416	20992763061	Medical	medical	JJ
304953	100736416	20992763062	School	school	NN1
304953	100736416	20992763063	and	and	CC
304953	100736416	20992763064	a	a	AT1
304953	100736416	20992763065	radiation	radiation	NN1
304953	100736416	20992763066	oncologist	oncologist	NN1
304953	100736416	20992763067	at	at	II
304953	100736416	20992763068	Massachusetts	massachusetts	NP1
304953	100736416	20992763069	General	general	JJ_NN1
304953	100736416	20992763070	Hospital	hospital	NN1
304953	100736416	20992763071	.	.	.
304953	100736416	20992763072	In	in	RR21
304953	100736416	20992763073	addition	addition	RR22
304953	100736416	20992763074	,	,	,
304953	100736416	20992763075	he	he	PPHS1
304953	100736416	20992763076	is	be	VBZ
304953	100736416	20992763077	President	president	NN1
304953	100736416	20992763078	of	of	IO
304953	100736416	20992763079	the	the	AT
304953	100736416	20992763080	American	american	JJ
304953	100736416	20992763081	Society	society	NN1
304953	100736416	20992763082	for	for	IF
304953	100736416	20992763083	Radiation	radiation	NN1
304953	100736416	20992763084	Oncology	oncology	NN1_NP1
304953	100736416	20992763085	,	,	,
304953	100736416	20992763086	serves	serve	VVZ
304953	100736416	20992763087	on	on	II
304953	100736416	20992763088	the	the	AT
304953	100736416	20992763089	genitourinary	genitourinary	JJ_NN1
304953	100736416	20992763090	committee	committee	NN1
304953	100736416	20992763091	of	of	IO
304953	100736416	20992763092	the	the	AT
304953	100736416	20992763093	Radiation	radiation	NN1
304953	100736416	20992763094	Therapy	therapy	NN1
304953	100736416	20992763095	Oncology	oncology	NN1_NP1
304953	100736416	20992763096	Group	group	NN1
304953	100736416	20992763097	,	,	,
304953	100736416	20992763098	and	and	CC
304953	100736416	20992763099	is	be	VBZ
304953	100736416	20992763100	a	a	AT1
304953	100736416	20992763101	Trustee	trustee	NN1
304953	100736416	20992763102	of	of	IO
304953	100736416	20992763103	the	the	AT
304953	100736416	20992763104	American	american	JJ
304953	100736416	20992763105	Board	board	NN1
304953	100736416	20992763106	of	of	IO
304953	100736416	20992763107	Radiology	radiology	NN1_NP1
304953	100736416	20992763108	.	.	.
304953	100736416	20992763109	Dr.		NNB
304953	100736416	20992763110	Zietman		NP1
304953	100736416	20992763111	's	's	GE
304953	100736416	20992763112	research	research	NN1
304953	100736416	20992763113	interests	interest	NN2
304953	100736416	20992763114	include	include	VV0
304953	100736416	20992763115	the	the	AT
304953	100736416	20992763116	role	role	NN1
304953	100736416	20992763117	of	of	IO
304953	100736416	20992763118	active	active	JJ
304953	100736416	20992763119	surveillance	surveillance	NN1
304953	100736416	20992763120	,	,	,
304953	100736416	20992763121	brachytherapy	brachytherapy	NN1
304953	100736416	20992763122	,	,	,
304953	100736416	20992763123	hormone	hormone	NN1
304953	100736416	20992763124	therapy	therapy	NN1
304953	100736416	20992763125	,	,	,
304953	100736416	20992763126	and	and	CC
304953	100736416	20992763127	proton	proton	NN1
304953	100736416	20992763128	beam	beam	NN1_VV0
304953	100736416	20992763129	therapy	therapy	NN1
304953	100736416	20992763130	in	in	II
304953	100736416	20992763131	the	the	AT
304953	100736416	20992763132	treatment	treatment	NN1
304953	100736416	20992763133	of	of	IO
304953	100736416	20992763134	prostate	prostate	NN1
304953	100736416	20992763135	cancer	cancer	NN1
304953	100736416	20992763136	.	.	.
304953	100736416	20992763137	He	he	PPHS1
304953	100736416	20992763138	has	have	VHZ
304953	100736416	20992763139	authored	author	VVN
304953	100736416	20992763140	more	more	DAR
304953	100736416	20992763141	than	than	CSN
304953	100736416	20992763142	100	100	MC
304953	100736416	20992763143	articles	article	NN2
304953	100736416	20992763144	and	and	CC
304953	100736416	20992763145	reviews	review	VVZ_NN2
304953	100736416	20992763146	on	on	II
304953	100736416	20992763147	many	many	DA2
304953	100736416	20992763148	aspects	aspect	NN2
304953	100736416	20992763149	of	of	IO
304953	100736416	20992763150	genitourinary	genitourinary	JJ_NN1
304953	100736416	20992763151	cancer	cancer	NN1
304953	100736416	20992763152	.	.	.
304953	100736417	20992763172	@@##	----------	----------
304953	100736417	20992763173	@@100736417		FO
304953	100736417	20992763174	@4936417/		NN1_VV0
304953	100736417	20992763175	<p>		NULL
304953	100736417	20992763176	If	if	CS
304953	100736417	20992763177	you	you	PPY
304953	100736417	20992763178	have	have	VH0
304953	100736417	20992763179	been	be	VBN
304953	100736417	20992763180	diagnosed	diagnose	VVN
304953	100736417	20992763181	with	with	IW
304953	100736417	20992763182	prostate	prostate	NN1
304953	100736417	20992763183	disease	disease	NN1
304953	100736417	20992763184	,	,	,
304953	100736417	20992763185	chances	chance	NN2
304953	100736417	20992763186	are	be	VBR
304953	100736417	20992763187	that	that	DD1_CST
304953	100736417	20992763188	you 've		NN1_VV0
304953	100736417	20992763189	thought	think	VVN_VVD_NN1
304953	100736417	20992763190	about	about	II
304953	100736417	20992763191	trying	try	VVG
304953	100736417	20992763192	some	some	DD
304953	100736417	20992763193	type	type	NN1
304953	100736417	20992763194	of	of	IO
304953	100736417	20992763195	complementary	complementary	JJ
304953	100736417	20992763196	therapy	therapy	NN1
304953	100736417	20992763197	in	in	II31
304953	100736417	20992763198	addition	addition	II32
304953	100736417	20992763199	to	to	II33
304953	100736417	20992763200	conventional	conventional	JJ
304953	100736417	20992763201	medical	medical	JJ
304953	100736417	20992763202	treatment	treatment	NN1
304953	100736417	20992763203	from	from	II
304953	100736417	20992763204	a	a	AT1
304953	100736417	20992763205	physician	physician	NN1
304953	100736417	20992763206	.	.	.
304953	100736417	20992763207	If	if	CS
304953	100736417	20992763208	you	you	PPY
304953	100736417	20992763209	have	have	VH0
304953	100736417	20992763210	,	,	,
304953	100736417	20992763211	you	you	PPY
304953	100736417	20992763212	are	be	VBR
304953	100736417	20992763213	not	not	XX
304953	100736417	20992763214	alone	alone	JJ
304953	100736417	20992763215	.	.	.
304953	100736417	20992763216	Various	various	JJ
304953	100736417	20992763217	studies	study	NN2
304953	100736417	20992763218	have	have	VH0
304953	100736417	20992763219	found	find	VVN
304953	100736417	20992763220	that	that	CST_DD1
304953	100736417	20992763221	anywhere	anywhere	RL
304953	100736417	20992763222	from	from	II
304953	100736417	20992763223	27%		NNU
304953	100736417	20992763224	to	to	II
304953	100736417	20992763225	43%		NNU
304953	100736417	20992763226	of	of	IO
304953	100736417	20992763227	American	american	JJ
304953	100736417	20992763228	men	man	NN2
304953	100736417	20992763229	with	with	IW
304953	100736417	20992763230	prostate	prostate	NN1
304953	100736417	20992763231	cancer	cancer	NN1
304953	100736417	20992763232	use	use	NN1_VV0
304953	100736417	20992763233	at	at	RR21
304953	100736417	20992763234	least	least	RR22
304953	100736417	20992763235	one	one	MC1
304953	100736417	20992763236	form	form	NN1
304953	100736417	20992763237	of	of	IO
304953	100736417	20992763238	complementary	complementary	JJ
304953	100736417	20992763239	therapy	therapy	NN1
304953	100736417	20992763240	.	.	.
304953	100736417	20992763241	Similar	similar	JJ
304953	100736417	20992763242	findings	finding	NN2
304953	100736417	20992763243	have	have	VH0
304953	100736417	20992763244	been	be	VBN
304953	100736417	20992763245	reported	report	VVN
304953	100736417	20992763246	in	in	II
304953	100736417	20992763247	Canada	canada	NP1
304953	100736417	20992763248	and	and	CC
304953	100736417	20992763249	Europe	europe	NP1
304953	100736417	20992763250	.	.	.
304953	100736417	20992763251	Although	although	CS
304953	100736417	20992763252	statistics	statistics	NN
304953	100736417	20992763253	are	be	VBR
304953	100736417	20992763254	harder	hard	JJR
304953	100736417	20992763255	to	to	TO
304953	100736417	20992763256	find	find	VVI
304953	100736417	20992763257	for	for	IF
304953	100736417	20992763258	how	how	RGQ@
304953	100736417	20992763259	many	many	DA2
304953	100736417	20992763260	men	man	NN2
304953	100736417	20992763261	use	use	VV0
304953	100736417	20992763262	complementary	complementary	JJ
304953	100736417	20992763263	therapies	therapy	NN2
304953	100736417	20992763264	for	for	IF
304953	100736417	20992763265	benign	benign	JJ
304953	100736417	20992763266	prostatic	prostatic	JJ
304953	100736417	20992763267	hyperplasia	hyperplasia	NN1
304953	100736417	20992763268	(	(	(
304953	100736417	20992763269	BPH	bph	NP1
304953	100736417	20992763270	)	)	)
304953	100736417	20992763271	,	,	,
304953	100736417	20992763272	erectile	erectile	JJ
304953	100736417	20992763273	dysfunction	dysfunction	NN1
304953	100736417	20992763274	,	,	,
304953	100736417	20992763275	or	or	CC
304953	100736417	20992763276	prostatitis	prostatitis	NN1
304953	100736417	20992763277	,	,	,
304953	100736417	20992763278	it	it	PPH1
304953	100736417	20992763279	is	be	VBZ
304953	100736417	20992763280	likely	likely	JJ
304953	100736417	20992763281	that	that	CST
304953	100736417	20992763282	the	the	AT
304953	100736417	20992763283	practice	practice	NN1
304953	100736417	20992763284	is	be	VBZ
304953	100736417	20992763285	common	common	JJ
304953	100736417	20992763286	.	.	.
304953	100736417	20992763287	<p>		NULL
304953	100736417	20992763288	Unfortunately	unfortunately	RR
304953	100736417	20992763289	,	,	,
304953	100736417	20992763290	the	the	AT
304953	100736417	20992763291	issue	issue	NN1
304953	100736417	20992763292	of	of	IO
304953	100736417	20992763293	complementary	complementary	JJ
304953	100736417	20992763294	therapies	therapy	NN2
304953	100736417	20992763295	does	do	VDZ
304953	100736417	20992763296	n't 	n't	XX
304953	100736417	20992763297	often	often	RR
304953	100736417	20992763298	come	come	VVI
304953	100736417	20992763299	up	up	RP
304953	100736417	20992763300	during	during	II
304953	100736417	20992763301	a	a	AT1
304953	100736417	20992763302	visit	visit	NN1
304953	100736417	20992763303	to	to	II
304953	100736417	20992763304	the	the	AT
304953	100736417	20992763305	physician	physician	NN1
304953	100736417	20992763306	.	.	.
304953	100736417	20992763307	Patients	patient	NN2
304953	100736417	20992763308	tend	tend	VV0
304953	100736417	20992763309	not	not	XX
304953	100736417	20992763310	to	to	TO
304953	100736417	20992763311	mention	mention	VVI
304953	100736417	20992763312	the	the	AT
304953	100736417	20992763313	complementary	complementary	JJ
304953	100736417	20992763314	therapies	therapy	NN2
304953	100736417	20992763315	they	they	PPHS2
304953	100736417	20992763316	are	be	VBR
304953	100736417	20992763317	using	use	VVG
304953	100736417	20992763318	,	,	,
304953	100736417	20992763319	while	while	CS
304953	100736417	20992763320	doctors	doctor	NN2
304953	100736417	20992763321	may	may	VM
304953	100736417	20992763322	not	not	XX
304953	100736417	20992763323	ask	ask	VVI
304953	100736417	20992763324	about	about	II
304953	100736417	20992763325	them	them	PPHO2
304953	100736417	20992763326	.	.	.
304953	100736417	20992763327	Often	often	RR
304953	100736417	20992763328	this	this	DD1
304953	100736417	20992763329	is	be	VBZ
304953	100736417	20992763330	a	a	AT1
304953	100736417	20992763331	function	function	NN1
304953	100736417	20992763332	of	of	IO
304953	100736417	20992763333	time	time	NNT1
304953	100736417	20992763334	:	:	:
304953	100736417	20992763335	A	a	AT1@_ZZ1
304953	100736417	20992763336	man	man	NN1
304953	100736417	20992763337	and	and	CC
304953	100736417	20992763338	his	his	APPGE
304953	100736417	20992763339	doctor	doctor	NN1
304953	100736417	20992763340	may	may	VM
304953	100736417	20992763341	have	have	VHI
304953	100736417	20992763342	only	only	JJ
304953	100736417	20992763343	10		NN1
304953	100736417	20992763344	or	or	CC
304953	100736417	20992763345	15	15	MC
304953	100736417	20992763346	minutes	minute	NNT2
304953	100736417	20992763347	together	together	RL
304953	100736417	20992763348	in	in	II
304953	100736417	20992763349	a	a	AT1
304953	100736417	20992763350	typical	typical	JJ
304953	100736417	20992763351	office	office	NN1
304953	100736417	20992763352	visit	visit	NN1
304953	100736417	20992763353	.	.	.
304953	100736417	20992763354	<p>		NULL
304953	100736417	20992763355	To	to	TO
304953	100736417	20992763356	learn	learn	VVI
304953	100736417	20992763357	more	more	RRR_DAR
304953	100736417	20992763358	about	about	II
304953	100736417	20992763359	what	what	DDQ
304953	100736417	20992763360	physicians	physician	NN2
304953	100736417	20992763361	think	think	VV0
304953	100736417	20992763362	about	about	II
304953	100736417	20992763363	various	various	JJ
304953	100736417	20992763364	@		II
304953	100736417	20992763365	@		II
304953	100736417	20992763366	@		II
304953	100736417	20992763367	@		II
304953	100736417	20992763368	@		II
304953	100736417	20992763369	@		II
304953	100736417	20992763370	@		II
304953	100736417	20992763371	@		II
304953	100736417	20992763372	@		II
304953	100736417	20992763373	@		II
304953	100736417	20992763374	invited	invite	VVD_VVN
304953	100736417	20992763375	three	three	MC
304953	100736417	20992763376	experts	expert	NN2
304953	100736417	20992763377	to	to	TO
304953	100736417	20992763378	participate	participate	VVI
304953	100736417	20992763379	in	in	II_RP@
304953	100736417	20992763380	a	a	AT1
304953	100736417	20992763381	roundtable	roundtable	JJ
304953	100736417	20992763382	discussion	discussion	NN1
304953	100736417	20992763383	on	on	II
304953	100736417	20992763384	this	this	DD1
304953	100736417	20992763385	important	important	JJ
304953	100736417	20992763386	topic	topic	NN1
304953	100736417	20992763387	.	.	.
304953	100736417	20992763388	The	the	AT
304953	100736417	20992763389	panel	panel	NN1
304953	100736417	20992763390	consisted	consist	VVN_VVD
304953	100736417	20992763391	of	of	IO
304953	100736417	20992763392	these	these	DD2
304953	100736417	20992763393	people	people	NN
304953	100736417	20992763394	:	:	:
304953	100736417	20992763395	<p>		NULL
304953	100736417	20992763396	Dr.		NNB
304953	100736417	20992763397	Edward	edward	NP1
304953	100736417	20992763398	Giovannucci	giovannucci	NP1
304953	100736417	20992763399	,	,	,
304953	100736417	20992763400	a	a	AT1
304953	100736417	20992763401	professor	professor	NN1
304953	100736417	20992763402	of	of	IO
304953	100736417	20992763403	nutrition	nutrition	NN1
304953	100736417	20992763404	and	and	CC
304953	100736417	20992763405	epidemiology	epidemiology	NN1
304953	100736417	20992763406	at	at	II
304953	100736417	20992763407	the	the	AT
304953	100736417	20992763408	Harvard	harvard	NP1
304953	100736417	20992763409	School	school	NN1
304953	100736417	20992763410	of	of	IO
304953	100736417	20992763411	Public	public	JJ_NN1
304953	100736417	20992763412	Health	health	NN1
304953	100736417	20992763413	whose	whose	DDQGE
304953	100736417	20992763414	research	research	NN1
304953	100736417	20992763415	has	have	VHZ
304953	100736417	20992763416	focused	focus	VVN
304953	100736417	20992763417	on	on	II
304953	100736417	20992763418	how	how	RRQ
304953	100736417	20992763419	lifestyle	lifestyle	NN1
304953	100736417	20992763420	factors	factor	NN2
304953	100736417	20992763421	such	such	II21
304953	100736417	20992763422	as	as	II22
304953	100736417	20992763423	diet	diet	NN1
304953	100736417	20992763424	and	and	CC
304953	100736417	20992763425	physical	physical	JJ
304953	100736417	20992763426	activity	activity	NN1
304953	100736417	20992763427	contribute	contribute	VV0
304953	100736417	20992763428	to	to	II
304953	100736417	20992763429	the	the	AT
304953	100736417	20992763430	development	development	NN1
304953	100736417	20992763431	of	of	IO
304953	100736417	20992763432	cancer	cancer	NN1
304953	100736417	20992763433	,	,	,
304953	100736417	20992763434	particularly	particularly	RR
304953	100736417	20992763435	colon	colon	NN1
304953	100736417	20992763436	cancer	cancer	NN1
304953	100736417	20992763437	and	and	CC
304953	100736417	20992763438	prostate	prostate	NN1
304953	100736417	20992763439	cancer	cancer	NN1
304953	100736417	20992763440	.	.	.
304953	100736417	20992763441	Dr.		NNB
304953	100736417	20992763442	Giovannucci	giovannucci	NP1
304953	100736417	20992763443	is	be	VBZ
304953	100736417	20992763444	considered	consider	VVN
304953	100736417	20992763445	one	one	MC1
304953	100736417	20992763446	of	of	IO
304953	100736417	20992763447	the	the	AT
304953	100736417	20992763448	nations	nation	NN2
304953	100736417	20992763449	pre-eminent	pre-eminent	JJ
304953	100736417	20992763450	experts	expert	NN2
304953	100736417	20992763451	on	on	II
304953	100736417	20992763452	nutrition	nutrition	NN1
304953	100736417	20992763453	and	and	CC
304953	100736417	20992763454	prostate	prostate	NN1
304953	100736417	20992763455	cancer	cancer	NN1
304953	100736417	20992763456	.	.	.
304953	100736417	20992763457	<p>		NULL
304953	100736417	20992763458	Dr.		NNB
304953	100736417	20992763459	David	david	NP1
304953	100736417	20992763460	S.		NP1
304953	100736417	20992763461	Rosenthal	rosenthal	NP1
304953	100736417	20992763462	,	,	,
304953	100736417	20992763463	a	a	AT1
304953	100736417	20992763464	professor	professor	NN1
304953	100736417	20992763465	of	of	IO
304953	100736417	20992763466	medicine	medicine	NN1
304953	100736417	20992763467	at	at	II
304953	100736417	20992763468	Harvard	harvard	NP1
304953	100736417	20992763469	Medical	medical	JJ
304953	100736417	20992763470	School	school	NN1
304953	100736417	20992763471	,	,	,
304953	100736417	20992763472	director	director	NN1
304953	100736417	20992763473	and	and	CC
304953	100736417	20992763474	chief	chief	JJ_NN1
304953	100736417	20992763475	executive	executive	NN1_JJ@
304953	100736417	20992763476	officer	officer	NN1
304953	100736417	20992763477	of	of	IO
304953	100736417	20992763478	Harvard	harvard	NP1
304953	100736417	20992763479	University	university	NN1
304953	100736417	20992763480	Health	health	NN1
304953	100736417	20992763481	Service	service	NN1
304953	100736417	20992763482	,	,	,
304953	100736417	20992763483	and	and	CC
304953	100736417	20992763484	medical	medical	JJ
304953	100736417	20992763485	director	director	NN1
304953	100736417	20992763486	of	of	IO
304953	100736417	20992763487	the	the	AT
304953	100736417	20992763488	Leonard	leonard	NP1
304953	100736417	20992763489	P.		NP1
304953	100736417	20992763490	Zakim		NP1_NN1
304953	100736417	20992763491	Center	center	NN1
304953	100736417	20992763492	for	for	IF
304953	100736417	20992763493	Integrative	integrative	JJ
304953	100736417	20992763494	Therapies	therapy	NN2
304953	100736417	20992763495	at	at	II
304953	100736417	20992763496	Dana-Farber	dana-farber	NP1
304953	100736417	20992763497	Cancer	cancer	NN1
304953	100736417	20992763498	Institute	institute	NN1
304953	100736417	20992763499	.	.	.
304953	100736417	20992763500	In	in	II31
304953	100736417	20992763501	addition	addition	II32
304953	100736417	20992763502	to	to	II33
304953	100736417	20992763503	serving	serve	VVG
304953	100736417	20992763504	on	on	II
304953	100736417	20992763505	the	the	AT
304953	100736417	20992763506	editorial	editorial	JJ_NN1
304953	100736417	20992763507	board	board	NN1
304953	100736417	20992763508	of	of	IO
304953	100736417	20992763509	Perspectives	perspective	NN2
304953	100736417	20992763510	,	,	,
304953	100736417	20992763511	he	he	PPHS1
304953	100736417	20992763512	is	be	VBZ
304953	100736417	20992763513	the	the	AT
304953	100736417	20992763514	author	author	NN1
304953	100736417	20992763515	of	of	IO
304953	100736417	20992763516	numerous	numerous	JJ
304953	100736417	20992763517	scientific	scientific	JJ
304953	100736417	20992763518	articles	article	NN2
304953	100736417	20992763519	and	and	CC
304953	100736417	20992763520	several	several	DA2
304953	100736417	20992763521	publications	publication	NN2
304953	100736417	20992763522	for	for	IF
304953	100736417	20992763523	laypeople	laypeople	NN1
304953	100736417	20992763524	.	.	.
304953	100736417	20992763525	<p>		NULL
304953	100736417	20992763526	Dr.		NNB
304953	100736417	20992763527	Harvey	harvey	NP1
304953	100736417	20992763528	B.		NP1
304953	100736417	20992763529	Simon	simon	NP1
304953	100736417	20992763530	,	,	,
304953	100736417	20992763531	an	a	AT1
304953	100736417	20992763532	associate	associate	JJ_NN1
304953	100736417	20992763533	professor	professor	NN1
304953	100736417	20992763534	of	of	IO
304953	100736417	20992763535	medicine	medicine	NN1
304953	100736417	20992763536	at	at	II
304953	100736417	20992763537	Harvard	harvard	NP1
304953	100736417	20992763538	Medical	medical	JJ
304953	100736417	20992763539	School	school	NN1
304953	100736417	20992763540	,	,	,
304953	100736417	20992763541	a	a	AT1
304953	100736417	20992763542	member	member	NN1
304953	100736417	20992763543	of	of	IO
304953	100736417	20992763544	the	the	AT
304953	100736417	20992763545	Health	health	NN1
304953	100736417	20992763546	Sciences	science	NN2
304953	100736417	20992763547	Technology	technology	NN1
304953	100736417	20992763548	Faculty	faculty	NN1
304953	100736417	20992763549	at	at	II
304953	100736417	20992763550	Massachusetts	massachusetts	NP1
304953	100736417	20992763551	Institute	institute	NN1
304953	100736417	20992763552	of	of	IO
304953	100736417	20992763553	Technology	technology	NN1
304953	100736417	20992763554	,	,	,
304953	100736417	20992763555	and	and	CC
304953	100736417	20992763556	a	a	AT1
304953	100736417	20992763557	primary	primary	JJ_NN1
304953	100736417	20992763558	care	care	NN1
304953	100736417	20992763559	physician	physician	NN1
304953	100736417	20992763560	at	at	II
304953	100736417	20992763561	Massachusetts	massachusetts	NP1
304953	100736417	20992763562	General	general	JJ_NN1
304953	100736417	20992763563	Hospital	hospital	NN1
304953	100736417	20992763564	@		II
304953	100736417	20992763565	@		II
304953	100736417	20992763566	@		II
304953	100736417	20992763567	@		II
304953	100736417	20992763568	@		II
304953	100736417	20992763569	@		II
304953	100736417	20992763570	@		II
304953	100736417	20992763571	@		II
304953	100736417	20992763572	@		II
304953	100736417	20992763573	@		II
304953	100736417	20992763574	Prostate	prostate	NN1
304953	100736417	20992763575	Disease	disease	NN1
304953	100736417	20992763576	,	,	,
304953	100736417	20992763577	he	he	PPHS1
304953	100736417	20992763578	has	have	VHZ
304953	100736417	20992763579	authored	author	VVN
304953	100736417	20992763580	numerous	numerous	JJ
304953	100736417	20992763581	scientific	scientific	JJ
304953	100736417	20992763582	articles	article	NN2
304953	100736417	20992763583	and	and	CC
304953	100736417	20992763584	textbook	textbook	NN1
304953	100736417	20992763585	chapters	chapter	NN2
304953	100736417	20992763586	and	and	CC
304953	100736417	20992763587	is	be	VBZ
304953	100736417	20992763588	the	the	AT
304953	100736417	20992763589	founding	founding	JJ@_NN1@
304953	100736417	20992763590	editor	editor	NN1
304953	100736417	20992763591	of	of	IO
304953	100736417	20992763592	the	the	AT
304953	100736417	20992763593	monthly	monthly	JJ
304953	100736417	20992763594	newsletter	newsletter	NN1
304953	100736417	20992763595	Harvard	harvard	NP1
304953	100736417	20992763596	Mens	mens	NP1
304953	100736417	20992763597	Health	health	NN1
304953	100736417	20992763598	Watch	watch	NN1
304953	100736417	20992763599	.	.	.
304953	100736417	20992763600	<p>		NULL
304953	100736417	20992763601	Here	here	RL
304953	100736417	20992763602	you	you	PPY
304953	100736417	20992763603	will	will	VM
304953	100736417	20992763604	learn	learn	VVI
304953	100736417	20992763605	what	what	DDQ
304953	100736417	20992763606	these	these	DD2
304953	100736417	20992763607	experts	expert	NN2
304953	100736417	20992763608	had	have	VHD
304953	100736417	20992763609	to	to	TO
304953	100736417	20992763610	say	say	VVI
304953	100736417	20992763611	about	about	II
304953	100736417	20992763612	the	the	AT
304953	100736417	20992763613	issue	issue	NN1
304953	100736417	20992763614	of	of	IO
304953	100736417	20992763615	complementary	complementary	JJ
304953	100736417	20992763616	therapies	therapy	NN2
304953	100736417	20992763617	in	in	RR21
304953	100736417	20992763618	general	general	RR22
304953	100736417	20992763619	,	,	,
304953	100736417	20992763620	as	as	II31
304953	100736417	20992763621	well	well	II32
304953	100736417	20992763622	as	as	II33
304953	100736417	20992763623	their	their	APPGE
304953	100736417	20992763624	interpretation	interpretation	NN1
304953	100736417	20992763625	of	of	IO
304953	100736417	20992763626	what	what	DDQ
304953	100736417	20992763627	the	the	AT
304953	100736417	20992763628	published	published	JJ@
304953	100736417	20992763629	evidence	evidence	NN1
304953	100736417	20992763630	shows	show	VVZ_NN2
304953	100736417	20992763631	about	about	II
304953	100736417	20992763632	the	the	AT
304953	100736417	20992763633	effectiveness	effectiveness	NN1
304953	100736417	20992763634	of	of	IO
304953	100736417	20992763635	specific	specific	JJ
304953	100736417	20992763636	foods	food	NN2
304953	100736417	20992763637	,	,	,
304953	100736417	20992763638	herbs	herb	NN2
304953	100736417	20992763639	,	,	,
304953	100736417	20992763640	and	and	CC
304953	100736417	20992763641	other	other	JJ
304953	100736417	20992763642	complementary	complementary	JJ
304953	100736417	20992763643	remedies	remedy	NN2
304953	100736417	20992763644	.	.	.
304953	100736417	20992763645	<p>		NULL
304953	100736417	20992763646	But	but	CCB
304953	100736417	20992763647	first	first	MD
304953	100736417	20992763648	,	,	,
304953	100736417	20992763649	a	a	AT1
304953	100736417	20992763650	brief	brief	JJ
304953	100736417	20992763651	explanation	explanation	NN1
304953	100736417	20992763652	of	of	IO
304953	100736417	20992763653	the	the	AT
304953	100736417	20992763654	terminology	terminology	NN1
304953	100736417	20992763655	that	that	CST_DD1
304953	100736417	20992763656	will	will	VM
304953	100736417	20992763657	be	be	VBI
304953	100736417	20992763658	used	use	VVN
304953	100736417	20992763659	.	.	.
304953	100736417	20992763660	The	the	AT
304953	100736417	20992763661	panel	panel	NN1
304953	100736417	20992763662	agreed	agree	VVD_VVN
304953	100736417	20992763663	to	to	TO
304953	100736417	20992763664	use	use	VVI
304953	100736417	20992763665	the	the	AT
304953	100736417	20992763666	language	language	NN1
304953	100736417	20992763667	as	as	CSA
304953	100736417	20992763668	defined	define	VVN
304953	100736417	20992763669	by	by	II
304953	100736417	20992763670	the	the	AT
304953	100736417	20992763671	National	national	JJ
304953	100736417	20992763672	Center	center	NN1
304953	100736417	20992763673	for	for	IF
304953	100736417	20992763674	Complementary	complementary	JJ
304953	100736417	20992763675	and	and	CC
304953	100736417	20992763676	Alternative	alternative	JJ_NN1
304953	100736417	20992763677	Medicine	medicine	NN1
304953	100736417	20992763678	(	(	(
304953	100736417	20992763679	NCCAM	nccam	NP1
304953	100736417	20992763680	)	)	)
304953	100736417	20992763681	,	,	,
304953	100736417	20992763682	a	a	AT1
304953	100736417	20992763683	division	division	NN1
304953	100736417	20992763684	of	of	IO
304953	100736417	20992763685	the	the	AT
304953	100736417	20992763686	National	national	JJ
304953	100736417	20992763687	Institutes	institute	NN2
304953	100736417	20992763688	of	of	IO
304953	100736417	20992763689	Health	health	NN1
304953	100736417	20992763690	.	.	.
304953	100736417	20992763691	NCCAM	nccam	NP1_NN1
304953	100736417	20992763692	defines	define	VVZ
304953	100736417	20992763693	alternative	alternative	JJ
304953	100736417	20992763694	medicine	medicine	NN1
304953	100736417	20992763695	as	as	CSA_II@
304953	100736417	20992763696	therapies	therapy	NN2
304953	100736417	20992763697	used	use	VVN_VVD
304953	100736417	20992763698	in	in	II31
304953	100736417	20992763699	place	place	II32
304953	100736417	20992763700	of	of	II33
304953	100736417	20992763701	conventional	conventional	JJ
304953	100736417	20992763702	medicine	medicine	NN1
304953	100736417	20992763703	,	,	,
304953	100736417	20992763704	while	while	CS
304953	100736417	20992763705	complementary	complementary	JJ
304953	100736417	20992763706	medicine	medicine	NN1
304953	100736417	20992763707	consists	consist	VVZ
304953	100736417	20992763708	of	of	IO
304953	100736417	20992763709	therapies	therapy	NN2
304953	100736417	20992763710	used	use	VVN_VVD
304953	100736417	20992763711	together	together	RL
304953	100736417	20992763712	with	with	IW
304953	100736417	20992763713	conventional	conventional	JJ
304953	100736417	20992763714	medicine	medicine	NN1
304953	100736417	20992763715	.	.	.
304953	100736417	20992763716	Although	although	CS
304953	100736417	20992763717	an	a	AT1
304953	100736417	20992763718	even	even	RR
304953	100736417	20992763719	newer	new	JJR
304953	100736417	20992763720	term	term	NN1
304953	100736417	20992763721	,	,	,
304953	100736417	20992763722	integrative	integrative	JJ
304953	100736417	20992763723	medicine	medicine	NN1
304953	100736417	20992763724	,	,	,
304953	100736417	20992763725	is	be	VBZ
304953	100736417	20992763726	becoming	become	VVG
304953	100736417	20992763727	popular	popular	JJ
304953	100736417	20992763728	with	with	IW
304953	100736417	20992763729	physicians	physician	NN2
304953	100736417	20992763730	and	and	CC
304953	100736417	20992763731	patients	patient	NN2
304953	100736417	20992763732	who	who	PNQS
304953	100736417	20992763733	want	want	VV0
304953	100736417	20992763734	to	to	TO
304953	100736417	20992763735	fully	fully	RR
304953	100736417	20992763736	integrate	integrate	VVI
304953	100736417	20992763737	both	both	RR
304953	100736417	20992763738	conventional	conventional	JJ
304953	100736417	20992763739	and	and	CC
304953	100736417	20992763740	complementary	complementary	JJ
304953	100736417	20992763741	practices	practice	NN2
304953	100736417	20992763742	,	,	,
304953	100736417	20992763743	for	for	IF
304953	100736417	20992763744	the	the	AT
304953	100736417	20992763745	sake	sake	NN1
304953	100736417	20992763746	of	of	IO
304953	100736417	20992763747	simplicity	simplicity	NN1
304953	100736417	20992763748	this	this	DD1
304953	100736417	20992763749	article	article	NN1
304953	100736417	20992763750	will	will	VM
304953	100736417	20992763751	use	use	VVI
304953	100736417	20992763752	"	"	"
304953	100736417	20992763753	complementary	complementary	JJ
304953	100736417	20992763754	"	"	"
304953	100736417	20992763755	to	to	TO
304953	100736417	20992763756	underscore	underscore	VVI
304953	100736417	20992763757	a	a	AT1
304953	100736417	20992763758	point	point	NN1
304953	100736417	20992763759	our	our	APPGE
304953	100736417	20992763760	experts	expert	NN2
304953	100736417	20992763761	all	all	RR@_DB
304953	100736417	20992763762	agreed	agree	VVN_VVD
304953	100736417	20992763763	on	on	II_RP@
304953	100736417	20992763764	@		II
304953	100736417	20992763765	@		II
304953	100736417	20992763766	@		II
304953	100736417	20992763767	@		II
304953	100736417	20992763768	@		II
304953	100736417	20992763769	@		II
304953	100736417	20992763770	@		II
304953	100736417	20992763771	@		II
304953	100736417	20992763772	@		II
304953	100736417	20992763773	@		II
304953	100736417	20992763774	with	with	II22
304953	100736417	20992763775	rather	rather	II21_CS21@
304953	100736417	20992763776	than	than	II22_CS22@
304953	100736417	20992763777	as	as	II_CSA
304953	100736417	20992763778	a	a	AT1
304953	100736417	20992763779	substitute	substitute	NN1_JJ
304953	100736417	20992763780	for	for	IF
304953	100736417	20992763781	conventional	conventional	JJ
304953	100736417	20992763782	medical	medical	JJ
304953	100736417	20992763783	therapy	therapy	NN1
304953	100736417	20992763784	.	.	.
304953	100736417	20992763785	<p>		NULL
304953	100736417	20992763786	How	how	RRQ
304953	100736417	20992763787	do	do	VD0
304953	100736417	20992763788	you	you	PPY
304953	100736417	20992763789	advise	advise	VVI
304953	100736417	20992763790	your	your	APPGE
304953	100736417	20992763791	patients	patient	NN2
304953	100736417	20992763792	when	when	CS_RRQ
304953	100736417	20992763793	they	they	PPHS2
304953	100736417	20992763794	ask	ask	VV0
304953	100736417	20992763795	about	about	II
304953	100736417	20992763796	complementary	complementary	JJ
304953	100736417	20992763797	therapies	therapy	NN2
304953	100736417	20992763798	?	?	?
304953	100736417	20992763799	<p>		NULL
304953	100736417	20992763800	ROSENTHAL	rosenthal	NP1
304953	100736417	20992763801	:	:	:
304953	100736417	20992763802	The	the	AT
304953	100736417	20992763803	major	major	JJ
304953	100736417	20992763804	role	role	NN1
304953	100736417	20992763805	of	of	IO
304953	100736417	20992763806	a	a	AT1
304953	100736417	20992763807	physician	physician	NN1
304953	100736417	20992763808	is	be	VBZ
304953	100736417	20992763809	to	to	TO
304953	100736417	20992763810	provide	provide	VVI
304953	100736417	20992763811	advice	advice	NN1
304953	100736417	20992763812	about	about	RG
304953	100736417	20992763813	two	two	MC
304953	100736417	20992763814	areas	area	NN2
304953	100736417	20992763815	,	,	,
304953	100736417	20992763816	efficacy	efficacy	NN1
304953	100736417	20992763817	and	and	CC
304953	100736417	20992763818	safety	safety	NN1
304953	100736417	20992763819	.	.	.
304953	100736417	20992763820	I	i	PPIS1
304953	100736417	20992763821	tend	tend	VV0
304953	100736417	20992763822	to	to	TO
304953	100736417	20992763823	divide	divide	VVI
304953	100736417	20992763824	these	these	DD2
304953	100736417	20992763825	therapies	therapy	NN2
304953	100736417	20992763826	into	into	II
304953	100736417	20992763827	three	three	MC
304953	100736417	20992763828	categories	category	NN2
304953	100736417	20992763829	based	base	VVN
304953	100736417	20992763830	on	on	II
304953	100736417	20992763831	safety	safety	NN1
304953	100736417	20992763832	and	and	CC
304953	100736417	20992763833	efficacy	efficacy	NN1
304953	100736417	20992763834	:	:	:
304953	100736417	20992763835	the	the	AT
304953	100736417	20992763836	first	first	MD
304953	100736417	20992763837	category	category	NN1
304953	100736417	20992763838	consists	consist	VVZ
304953	100736417	20992763839	of	of	IO
304953	100736417	20992763840	those	those	DD2
304953	100736417	20992763841	that	that	CST
304953	100736417	20992763842	are	be	VBR
304953	100736417	20992763843	both	both	RR_DB2
304953	100736417	20992763844	safe	safe	JJ
304953	100736417	20992763845	and	and	CC
304953	100736417	20992763846	have	have	VH0
304953	100736417	20992763847	evidence	evidence	NN1
304953	100736417	20992763848	of	of	IO
304953	100736417	20992763849	effectiveness	effectiveness	NN1
304953	100736417	20992763850	;	;	;
304953	100736417	20992763851	the	the	AT
304953	100736417	20992763852	second	second	MD_NNT1
304953	100736417	20992763853	includes	include	VVZ
304953	100736417	20992763854	those	those	DD2
304953	100736417	20992763855	that	that	CST
304953	100736417	20992763856	are	be	VBR
304953	100736417	20992763857	safe	safe	JJ
304953	100736417	20992763858	but	but	CCB
304953	100736417	20992763859	lack	lack	NN1_VV0@
304953	100736417	20992763860	evidence	evidence	NN1
304953	100736417	20992763861	of	of	IO
304953	100736417	20992763862	efficacy	efficacy	NN1
304953	100736417	20992763863	;	;	;
304953	100736417	20992763864	and	and	CC
304953	100736417	20992763865	the	the	AT
304953	100736417	20992763866	third	third	MD
304953	100736417	20992763867	consists	consist	VVZ
304953	100736417	20992763868	of	of	IO
304953	100736417	20992763869	those	those	DD2
304953	100736417	20992763870	that	that	CST
304953	100736417	20992763871	are	be	VBR
304953	100736417	20992763872	unsafe	unsafe	JJ
304953	100736417	20992763873	and	and	CC
304953	100736417	20992763874	have	have	VH0
304953	100736417	20992763875	been	be	VBN
304953	100736417	20992763876	proven	prove	VVN_JJ
304953	100736417	20992763877	ineffective	ineffective	JJ
304953	100736417	20992763878	.	.	.
304953	100736417	20992763879	The	the	AT
304953	100736417	20992763880	middle	middle	JJ_NN1
304953	100736417	20992763881	category	category	NN1
304953	100736417	20992763882	is	be	VBZ
304953	100736417	20992763883	by	by	RR21
304953	100736417	20992763884	far	far	RR22
304953	100736417	20992763885	the	the	AT
304953	100736417	20992763886	largest	large	JJT
304953	100736417	20992763887	.	.	.
304953	100736417	20992763888	It	it	PPH1
304953	100736417	20992763889	includes	include	VVZ
304953	100736417	20992763890	herbs	herb	NN2
304953	100736417	20992763891	such	such	II21
304953	100736417	20992763892	as	as	II22
304953	100736417	20992763893	saw	saw	NN1@
304953	100736417	20992763894	palmetto	palmetto	NN1
304953	100736417	20992763895	,	,	,
304953	100736417	20992763896	which	which	DDQ
304953	100736417	20992763897	some	some	DD
304953	100736417	20992763898	men	man	NN2
304953	100736417	20992763899	take	take	VV0
304953	100736417	20992763900	for	for	IF
304953	100736417	20992763901	BPH	bph	NP1
304953	100736417	20992763902	.	.	.
304953	100736417	20992763903	These	these	DD2
304953	100736417	20992763904	herbs	herb	NN2
304953	100736417	20992763905	and	and	CC
304953	100736417	20992763906	botanicals	botanical	NN2
304953	100736417	20992763907	are	be	VBR
304953	100736417	20992763908	probably	probably	RR
304953	100736417	20992763909	safe	safe	JJ
304953	100736417	20992763910	when	when	CS
304953	100736417	20992763911	used	use	VVN_JJ
304953	100736417	20992763912	alone	alone	RR_JJ
304953	100736417	20992763913	.	.	.
304953	100736417	20992763914	But	but	CCB
304953	100736417	20992763915	in	in	II
304953	100736417	20992763916	many	many	DA2
304953	100736417	20992763917	cases	case	NN2
304953	100736417	20992763918	there	there	EX_RL
304953	100736417	20992763919	is	be	VBZ
304953	100736417	20992763920	no	no	AT
304953	100736417	20992763921	evidence	evidence	NN1
304953	100736417	20992763922	that	that	CST
304953	100736417	20992763923	they	they	PPHS2
304953	100736417	20992763924	actually	actually	RR
304953	100736417	20992763925	have	have	VH0
304953	100736417	20992763926	any	any	DD
304953	100736417	20992763927	effect	effect	NN1
304953	100736417	20992763928	,	,	,
304953	100736417	20992763929	or	or	CC
304953	100736417	20992763930	the	the	AT
304953	100736417	20992763931	only	only	JJ
304953	100736417	20992763932	evidence	evidence	NN1
304953	100736417	20992763933	has	have	VHZ
304953	100736417	20992763934	come	come	VVN
304953	100736417	20992763935	from	from	II
304953	100736417	20992763936	small	small	JJ
304953	100736417	20992763937	pilot	pilot	NN1
304953	100736417	20992763938	studies	study	NN2
304953	100736417	20992763939	rather	rather	II21_CS21@
304953	100736417	20992763940	than	than	II22_CS22@
304953	100736417	20992763941	from	from	II
304953	100736417	20992763942	randomized	randomized	JJ@
304953	100736417	20992763943	clinical	clinical	JJ
304953	100736417	20992763944	trials	trial	NN2
304953	100736417	20992763945	.	.	.
304953	100736417	20992763946	So	so	RR
304953	100736417	20992763947	the	the	AT
304953	100736417	20992763948	evidence	evidence	NN1
304953	100736417	20992763949	is	be	VBZ
304953	100736417	20992763950	suggestive	suggestive	JJ
304953	100736417	20992763951	,	,	,
304953	100736417	20992763952	not	not	XX
304953	100736417	20992763953	conclusive	conclusive	JJ
304953	100736417	20992763954	.	.	.
304953	100736417	20992763955	<p>		NULL
304953	100736417	20992763956	SIMON	simon	NP1
304953	100736417	20992763957	:	:	:
304953	100736417	20992763958	I	i	PPIS1
304953	100736417	20992763959	think	think	VV0
304953	100736417	20992763960	its	its	APPGE
304953	100736417	20992763961	also	also	RR
304953	100736417	20992763962	important	important	JJ
304953	100736417	20992763963	that	that	CST
304953	100736417	20992763964	@		II
304953	100736417	20992763965	@		II
304953	100736417	20992763966	@		II
304953	100736417	20992763967	@		II
304953	100736417	20992763968	@		II
304953	100736417	20992763969	@		II
304953	100736417	20992763970	@		II
304953	100736417	20992763971	@		II
304953	100736417	20992763972	@		II
304953	100736417	20992763973	@		II
304953	100736417	20992763974	any	any	DD
304953	100736417	20992763975	complementary	complementary	JJ
304953	100736417	20992763976	therapies	therapy	NN2
304953	100736417	20992763977	the	the	AT
304953	100736417	20992763978	patient	patient	NN1
304953	100736417	20992763979	is	be	VBZ
304953	100736417	20992763980	taking	take	VVG
304953	100736417	20992763981	.	.	.
304953	100736417	20992763982	Of	of	RR21
304953	100736417	20992763983	course	course	RR22
304953	100736417	20992763984	,	,	,
304953	100736417	20992763985	how	how	RRQ
304953	100736417	20992763986	to	to	TO
304953	100736417	20992763987	do	do	VDI
304953	100736417	20992763988	all	all	DB
304953	100736417	20992763989	that	that	CST_DD1
304953	100736417	20992763990	in	in	II
304953	100736417	20992763991	the	the	AT
304953	100736417	20992763992	allotted	allotted	JJ@
304953	100736417	20992763993	10-minute	10-minute	JJ
304953	100736417	20992763994	office	office	NN1
304953	100736417	20992763995	visit	visit	NN1
304953	100736417	20992763996	is	be	VBZ
304953	100736417	20992763997	another	another	DD1
304953	100736417	20992763998	matter	matter	NN1
304953	100736417	20992763999	.	.	.
304953	100736417	20992764000	<p>		NULL
304953	100736417	20992764001	ROSENTHAL	rosenthal	NP1
304953	100736417	20992764002	:	:	:
304953	100736417	20992764003	(	(	(
304953	100736417	20992764004	Laughs	laugh	VVZ
304953	100736417	20992764005	.	.	.
304953	100736417	20992764006	)	)	)
304953	100736417	20992764007	That 's		NN2_VVZ_NP1@
304953	100736417	20992764008	exactly	exactly	RR
304953	100736417	20992764009	why	why	RRQ
304953	100736417	20992764010	I	i	PPIS1
304953	100736417	20992764011	started	start	VVD
304953	100736417	20992764012	doing	do	VDG
304953	100736417	20992764013	integrative	integrative	JJ
304953	100736417	20992764014	medicine	medicine	NN1
304953	100736417	20992764015	consultations	consultation	NN2
304953	100736417	20992764016	,	,	,
304953	100736417	20992764017	which	which	DDQ
304953	100736417	20992764018	take	take	VV0
304953	100736417	20992764019	up	up	RG21
304953	100736417	20992764020	to	to	RG22
304953	100736417	20992764021	45	45	MC
304953	100736417	20992764022	minutes	minute	NNT2
304953	100736417	20992764023	to	to	II
304953	100736417	20992764024	an	a	AT1
304953	100736417	20992764025	hour	hour	NNT1
304953	100736417	20992764026	.	.	.
304953	100736417	20992764027	<p>		NULL
304953	100736417	20992764028	SIMON	simon	NP1
304953	100736417	20992764029	:	:	:
304953	100736417	20992764030	Another	another	DD1
304953	100736417	20992764031	issue	issue	NN1
304953	100736417	20992764032	that	that	CST
304953	100736417	20992764033	both	both	RR
304953	100736417	20992764034	patients	patient	NN2
304953	100736417	20992764035	and	and	CC
304953	100736417	20992764036	physicians	physician	NN2
304953	100736417	20992764037	need	need	VV0
304953	100736417	20992764038	to	to	TO
304953	100736417	20992764039	be	be	VBI
304953	100736417	20992764040	aware	aware	JJ
304953	100736417	20992764041	of	of	IO
304953	100736417	20992764042	is	be	VBZ
304953	100736417	20992764043	that	that	CST
304953	100736417	20992764044	herbs	herb	NN2
304953	100736417	20992764045	can	can	VM
304953	100736417	20992764046	interact	interact	VVI
304953	100736417	20992764047	with	with	IW
304953	100736417	20992764048	other	other	JJ
304953	100736417	20992764049	herbs	herb	NN2
304953	100736417	20992764050	,	,	,
304953	100736417	20992764051	and	and	CC
304953	100736417	20992764052	with	with	IW
304953	100736417	20992764053	drugs	drug	NN2
304953	100736417	20992764054	that	that	CST
304953	100736417	20992764055	we	we	PPIS2
304953	100736417	20992764056	prescribe	prescribe	VV0
304953	100736417	20992764057	.	.	.
304953	100736417	20992764058	<p>		NULL
304953	100736417	20992764059	ROSENTHAL	rosenthal	NP1
304953	100736417	20992764060	:	:	:
304953	100736417	20992764061	One	one	MC1
304953	100736417	20992764062	of	of	IO
304953	100736417	20992764063	the	the	AT
304953	100736417	20992764064	most	most	RGT
304953	100736417	20992764065	common	common	JJ
304953	100736417	20992764066	interactions	interaction	NN2
304953	100736417	20992764067	involves	involve	VVZ
304953	100736417	20992764068	herbs	herb	NN2
304953	100736417	20992764069	and	and	CC
304953	100736417	20992764070	botanicals	botanical	NN2
304953	100736417	20992764071	that	that	CST
304953	100736417	20992764072	affect	affect	VV0
304953	100736417	20992764073	the	the	AT
304953	100736417	20992764074	liver	liver	NN1
304953	100736417	20992764075	,	,	,
304953	100736417	20992764076	by	by	II
304953	100736417	20992764077	acting	act	VVG
304953	100736417	20992764078	on	on	II
304953	100736417	20992764079	cytochrome	cytochrome	NN1_JJ
304953	100736417	20992764080	P450		FO
304953	100736417	20992764081	enzymes	enzyme	NN2
304953	100736417	20992764082	see	see	VV0
304953	100736417	20992764083	below	below	RL
304953	100736417	20992764084	.	.	.
304953	100736417	20992764085	Many	many	DA2
304953	100736417	20992764086	herbs	herb	NN2
304953	100736417	20992764087	,	,	,
304953	100736417	20992764088	such	such	II21
304953	100736417	20992764089	as	as	II22
304953	100736417	20992764090	St.		NNB_NP1
304953	100736417	20992764091	Johns	john	NP1
304953	100736417	20992764092	wort	wort	NN1
304953	100736417	20992764093	,	,	,
304953	100736417	20992764094	affect	affect	VV0
304953	100736417	20992764095	this	this	DD1
304953	100736417	20992764096	system	system	NN1
304953	100736417	20992764097	.	.	.
304953	100736417	20992764098	So	so	RR
304953	100736417	20992764099	its	its	APPGE
304953	100736417	20992764100	important	important	JJ
304953	100736417	20992764101	that	that	CST
304953	100736417	20992764102	patients	patient	NN2
304953	100736417	20992764103	understand	understand	VV0
304953	100736417	20992764104	that	that	CST
304953	100736417	20992764105	some	some	DD
304953	100736417	20992764106	herbs	herb	NN2
304953	100736417	20992764107	can	can	VM
304953	100736417	20992764108	enhance	enhance	VVI
304953	100736417	20992764109	the	the	AT
304953	100736417	20992764110	effects	effect	NN2
304953	100736417	20992764111	of	of	IO
304953	100736417	20992764112	medications	medication	NN2
304953	100736417	20992764113	,	,	,
304953	100736417	20992764114	or	or	CC
304953	100736417	20992764115	sometimes	sometimes	RT
304953	100736417	20992764116	negate	negate	VV0
304953	100736417	20992764117	any	any	DD
304953	100736417	20992764118	beneficial	beneficial	JJ
304953	100736417	20992764119	effect	effect	NN1
304953	100736417	20992764120	.	.	.
304953	100736417	20992764121	<p>		NULL
304953	100736417	20992764122	When	when	CS_RRQ
304953	100736417	20992764123	I	i	PPIS1
304953	100736417	20992764124	do	do	VD0
304953	100736417	20992764125	integrative	integrative	JJ
304953	100736417	20992764126	medicine	medicine	NN1
304953	100736417	20992764127	consultations	consultation	NN2
304953	100736417	20992764128	,	,	,
304953	100736417	20992764129	I	i	PPIS1
304953	100736417	20992764130	advise	advise	VV0
304953	100736417	20992764131	people	people	NN
304953	100736417	20992764132	not	not	XX
304953	100736417	20992764133	to	to	TO
304953	100736417	20992764134	try	try	VVI
304953	100736417	20992764135	too	too	RG
304953	100736417	20992764136	many	many	DA2
304953	100736417	20992764137	supplements	supplement	NN2
304953	100736417	20992764138	at	at	II
304953	100736417	20992764139	one	one	MC1
304953	100736417	20992764140	time	time	NNT1
304953	100736417	20992764141	.	.	.
304953	100736417	20992764142	Try	try	VV0
304953	100736417	20992764143	one	one	MC1
304953	100736417	20992764144	herb	herb	NN1
304953	100736417	20992764145	or	or	CC
304953	100736417	20992764146	botanical	botanical	JJ
304953	100736417	20992764147	first	first	MD
304953	100736417	20992764148	,	,	,
304953	100736417	20992764149	and	and	CC
304953	100736417	20992764150	see	see	VV0
304953	100736417	20992764151	if	if	CS_CSW@
304953	100736417	20992764152	you	you	PPY
304953	100736417	20992764153	tolerate	tolerate	VV0
304953	100736417	20992764154	it	it	PPH1
304953	100736417	20992764155	without	without	IW
304953	100736417	20992764156	any	any	DD
304953	100736417	20992764157	side	side	NN1
304953	100736417	20992764158	effects	effect	NN2
304953	100736417	20992764159	before	before	II
304953	100736417	20992764160	adding	add	VVG
304953	100736417	20992764161	anything	anything	PN1
304953	100736417	20992764162	else	else	RR
304953	100736417	20992764163	.	.	.
304953	100736417	20992764164	@		II
304953	100736417	20992764165	@		II
304953	100736417	20992764166	@		II
304953	100736417	20992764167	@		II
304953	100736417	20992764168	@		II
304953	100736417	20992764169	@		II
304953	100736417	20992764170	@		II
304953	100736417	20992764171	@		II
304953	100736417	20992764172	@		II
304953	100736417	20992764173	@		II
304953	100736417	20992764174	any	any	DD
304953	100736417	20992764175	medication	medication	NN1
304953	100736417	20992764176	.	.	.
304953	100736417	20992764177	<h>		NULL
304953	100736417	20992764178	Cytochrome		NN1_NP1@_JJ
304953	100736417	20992764179	P450		FO
304953	100736417	20992764180	enzymes	enzyme	NN2
304953	100736417	20992764181	<p>		NULL
304953	100736417	20992764182	Cytochrome		NN1_NP1@_JJ
304953	100736417	20992764183	P450		FO
304953	100736417	20992764184	enzymes	enzyme	NN2
304953	100736417	20992764185	,	,	,
304953	100736417	20992764186	most	most	RGT
304953	100736417	20992764187	often	often	RR
304953	100736417	20992764188	found	find	VVN_VVD
304953	100736417	20992764189	in	in	II
304953	100736417	20992764190	the	the	AT
304953	100736417	20992764191	liver	liver	NN1
304953	100736417	20992764192	,	,	,
304953	100736417	20992764193	help	help	VV0_NN1
304953	100736417	20992764194	people	people	NN
304953	100736417	20992764195	metabolize	metabolize	VVI
304953	100736417	20992764196	drugs	drug	NN2
304953	100736417	20992764197	and	and	CC
304953	100736417	20992764198	herbs	herb	NN2
304953	100736417	20992764199	.	.	.
304953	100736417	20992764200	But	but	CCB
304953	100736417	20992764201	health	health	NN1
304953	100736417	20992764202	problems	problem	NN2
304953	100736417	20992764203	may	may	VM
304953	100736417	20992764204	occur	occur	VVI
304953	100736417	20992764205	when	when	RRQ_CS
304953	100736417	20992764206	you	you	PPY
304953	100736417	20992764207	are	be	VBR
304953	100736417	20992764208	taking	take	VVG
304953	100736417	20992764209	a	a	AT1
304953	100736417	20992764210	drug	drug	NN1
304953	100736417	20992764211	metabolized		VVD_VVN@
304953	100736417	20992764212	by	by	II
304953	100736417	20992764213	cytochrome	cytochrome	NN1_JJ
304953	100736417	20992764214	P450		FO
304953	100736417	20992764215	and	and	CC
304953	100736417	20992764216	then	then	RT
304953	100736417	20992764217	take	take	VV0
304953	100736417	20992764218	another	another	DD1
304953	100736417	20992764219	drug	drug	NN1
304953	100736417	20992764220	or	or	CC
304953	100736417	20992764221	herb	herb	NN1
304953	100736417	20992764222	that	that	CST_DD1
304953	100736417	20992764223	interferes	interfere	VVZ
304953	100736417	20992764224	with	with	IW
304953	100736417	20992764225	this	this	DD1
304953	100736417	20992764226	process	process	NN1
304953	100736417	20992764227	.	.	.
304953	100736417	20992764228	Some	some	DD
304953	100736417	20992764229	drugs	drug	NN2
304953	100736417	20992764230	and	and	CC
304953	100736417	20992764231	herbs	herb	NN2
304953	100736417	20992764232	inhibit	inhibit	VV0
304953	100736417	20992764233	the	the	AT
304953	100736417	20992764234	function	function	NN1
304953	100736417	20992764235	of	of	IO
304953	100736417	20992764236	cytochrome	cytochrome	NN1_JJ
304953	100736417	20992764237	P450		FO
304953	100736417	20992764238	enzymes	enzyme	NN2
304953	100736417	20992764239	,	,	,
304953	100736417	20992764240	which	which	DDQ
304953	100736417	20992764241	can	can	VM
304953	100736417	20992764242	lead	lead	VVI
304953	100736417	20992764243	to	to	II
304953	100736417	20992764244	increased	increased	JJ
304953	100736417	20992764245	effect	effect	NN1
304953	100736417	20992764246	of	of	IO
304953	100736417	20992764247	a	a	AT1
304953	100736417	20992764248	drug	drug	NN1
304953	100736417	20992764249	and	and	CC
304953	100736417	20992764250	possibly	possibly	RR
304953	100736417	20992764251	toxic	toxic	JJ
304953	100736417	20992764252	side	side	NN1
304953	100736417	20992764253	effects	effect	NN2
304953	100736417	20992764254	.	.	.
304953	100736417	20992764255	Other	other	JJ
304953	100736417	20992764256	drugs	drug	NN2
304953	100736417	20992764257	and	and	CC
304953	100736417	20992764258	herbs	herb	NN2
304953	100736417	20992764259	stimulate	stimulate	VV0
304953	100736417	20992764260	cytochrome	cytochrome	NN1_JJ
304953	100736417	20992764261	P450		FO
304953	100736417	20992764262	,	,	,
304953	100736417	20992764263	so	so	CS21
304953	100736417	20992764264	that	that	CS22
304953	100736417	20992764265	any	any	DD
304953	100736417	20992764266	other	other	JJ
304953	100736417	20992764267	drugs	drug	NN2
304953	100736417	20992764268	you	you	PPY
304953	100736417	20992764269	are	be	VBR
304953	100736417	20992764270	taking	take	VVG
304953	100736417	20992764271	may	may	VM
304953	100736417	20992764272	be	be	VBI
304953	100736417	20992764273	metabolized	metabolize	VVN@
304953	100736417	20992764274	so	so	RG
304953	100736417	20992764275	quickly	quickly	RR
304953	100736417	20992764276	that	that	CST
304953	100736417	20992764277	they	they	PPHS2
304953	100736417	20992764278	have	have	VH0
304953	100736417	20992764279	little	little	DA1_RR_JJ
304953	100736417	20992764280	or	or	CC
304953	100736417	20992764281	no	no	AT
304953	100736417	20992764282	beneficial	beneficial	JJ
304953	100736417	20992764283	effect	effect	NN1
304953	100736417	20992764284	.	.	.
304953	100736417	20992764285	<p>		NULL
304953	100736417	20992764286	A	a	AT1_ZZ1
304953	100736417	20992764287	partial	partial	JJ
304953	100736417	20992764288	list	list	NN1
304953	100736417	20992764289	of	of	IO
304953	100736417	20992764290	drugs	drug	NN2
304953	100736417	20992764291	,	,	,
304953	100736417	20992764292	herbs	herb	NN2
304953	100736417	20992764293	,	,	,
304953	100736417	20992764294	and	and	CC
304953	100736417	20992764295	foods	food	NN2
304953	100736417	20992764296	that	that	CST_DD1
304953	100736417	20992764297	affect	affect	VV0_NN1
304953	100736417	20992764298	cytochrome	cytochrome	NN1_JJ
304953	100736417	20992764299	P450		FO
304953	100736417	20992764300	follows	follow	VVZ
304953	100736417	20992764301	,	,	,
304953	100736417	20992764302	but	but	CCB
304953	100736417	20992764303	you	you	PPY
304953	100736417	20992764304	should	should	VM
304953	100736417	20992764305	check	check	VVI
304953	100736417	20992764306	with	with	IW
304953	100736417	20992764307	your	your	APPGE
304953	100736417	20992764308	own	own	DA
304953	100736417	20992764309	doctor	doctor	NN1
304953	100736417	20992764310	to	to	TO
304953	100736417	20992764311	avoid	avoid	VVI
304953	100736417	20992764312	problems	problem	NN2
304953	100736417	20992764313	.	.	.
304953	100736417	20992764314	<p>		NULL
304953	100736417	20992764315	Antidepressants	anti-depressant	NN2_NP1@
304953	100736417	20992764316	<p>		NULL
304953	100736417	20992764317	Fluoxetine		NP1@_NN1_JJ
304953	100736417	20992764318	(	(	(
304953	100736417	20992764319	Prozac	prozac	NP1
304953	100736417	20992764320	)	)	)
304953	100736417	20992764321	Sertraline		NP1
304953	100736417	20992764322	(	(	(
304953	100736417	20992764323	Zoloft	zoloft	NP1
304953	100736417	20992764324	)	)	)
304953	100736417	20992764325	<p>		NULL
304953	100736417	20992764326	Antifungals		NP1
304953	100736417	20992764327	<p>		NULL
304953	100736417	20992764328	Ketoconazole		NP1@_NN1
304953	100736417	20992764329	(	(	(
304953	100736417	20992764330	Nizoral		NP1
304953	100736417	20992764331	)	)	)
304953	100736417	20992764332	Itraconazole		NP1_NN1
304953	100736417	20992764333	(	(	(
304953	100736417	20992764334	Sporanox		NP1
304953	100736417	20992764335	)	)	)
304953	100736417	20992764336	<p>		NULL
304953	100736417	20992764337	Other	other	JJ
304953	100736417	20992764338	medications	medication	NN2
304953	100736417	20992764339	<p>		NULL
304953	100736417	20992764340	Cimetidine		NP1@_VV0_NN1
304953	100736417	20992764341	(	(	(
304953	100736417	20992764342	Tagamet	tagamet	NP1
304953	100736417	20992764343	)	)	)
304953	100736417	20992764344	Omeprazole		NP1_NN1
304953	100736417	20992764345	(	(	(
304953	100736417	20992764346	Prilosec	prilosec	NP1
304953	100736417	20992764347	)	)	)
304953	100736417	20992764348	<p>		NULL
304953	100736417	20992764349	Foods	food	NN2
304953	100736417	20992764350	and	and	CC
304953	100736417	20992764351	herbs	herb	NN2
304953	100736417	20992764352	<p>		NULL
304953	100736417	20992764353	GarlicGinsengGrapefruit		NP1@_NN1
304953	100736417	20992764354	juiceCharcoal-broiled		JJ
304953	100736417	20992764355	meat	meat	NN1
304953	100736417	20992764356	<p>		NULL
304953	100736417	20992764357	When	when	CS_RRQ
304953	100736417	20992764358	it	it	PPH1
304953	100736417	20992764359	comes	come	VVZ
304953	100736417	20992764360	to	to	II
304953	100736417	20992764361	vitamins	vitamin	NN2
304953	100736417	20992764362	and	and	CC
304953	100736417	20992764363	antioxidants	antioxidant	NN2
304953	100736417	20992764364	@		II
304953	100736417	20992764365	@		II
304953	100736417	20992764366	@		II
304953	100736417	20992764367	@		II
304953	100736417	20992764368	@		II
304953	100736417	20992764369	@		II
304953	100736417	20992764370	@		II
304953	100736417	20992764371	@		II
304953	100736417	20992764372	@		II
304953	100736417	20992764373	@		II
304953	100736417	20992764374	food	food	NN1
304953	100736417	20992764375	or	or	CC
304953	100736417	20992764376	take	take	VV0
304953	100736417	20992764377	them	them	PPHO2
304953	100736417	20992764378	as	as	CSA_II@
304953	100736417	20992764379	supplements	supplement	NN2
304953	100736417	20992764380	?	?	?
304953	100736417	20992764381	<p>		NULL
304953	100736417	20992764382	SIMON	simon	NP1
304953	100736417	20992764383	:	:	:
304953	100736417	20992764384	In	in	II
304953	100736417	20992764385	studies	study	NN2
304953	100736417	20992764386	done	do	VDN
304953	100736417	20992764387	in	in	II
304953	100736417	20992764388	adults	adult	NN2
304953	100736417	20992764389	,	,	,
304953	100736417	20992764390	a	a	AT1
304953	100736417	20992764391	finding	finding	NN1
304953	100736417	20992764392	that	that	CST_DD1
304953	100736417	20992764393	high	high	JJ
304953	100736417	20992764394	blood	blood	NN1
304953	100736417	20992764395	levels	level	NN2
304953	100736417	20992764396	of	of	IO
304953	100736417	20992764397	antioxidants	antioxidant	NN2
304953	100736417	20992764398	correlate	correlate	VV0
304953	100736417	20992764399	with	with	IW
304953	100736417	20992764400	a	a	AT1
304953	100736417	20992764401	good	good	JJ
304953	100736417	20992764402	health	health	NN1
304953	100736417	20992764403	outcome	outcome	NN1
304953	100736417	20992764404	does	do	VDZ
304953	100736417	20992764405	n't 	n't	XX
304953	100736417	20992764406	mean	mean	VVI
304953	100736417	20992764407	at	at	RR21_II
304953	100736417	20992764408	all	all	RR22_DB
304953	100736417	20992764409	that	that	DD1_CST
304953	100736417	20992764410	people	people	NN
304953	100736417	20992764411	will	will	VM
304953	100736417	20992764412	get	get	VVI
304953	100736417	20992764413	the	the	AT
304953	100736417	20992764414	same	same	DA
304953	100736417	20992764415	good	good	JJ
304953	100736417	20992764416	effect	effect	NN1
304953	100736417	20992764417	by	by	II
304953	100736417	20992764418	taking	take	VVG
304953	100736417	20992764419	a	a	AT1
304953	100736417	20992764420	pill	pill	NN1
304953	100736417	20992764421	or	or	CC
304953	100736417	20992764422	a	a	AT1
304953	100736417	20992764423	vitamin	vitamin	NN1
304953	100736417	20992764424	.	.	.
304953	100736417	20992764425	<p>		NULL
304953	100736417	20992764426	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992764427	:	:	:
304953	100736417	20992764428	Thats		NP1_VVZ_NN2
304953	100736417	20992764429	generally	generally	RR
304953	100736417	20992764430	correct	correct	JJ_VV0@
304953	100736417	20992764431	.	.	.
304953	100736417	20992764432	Blood	blood	NN1
304953	100736417	20992764433	levels	level	NN2
304953	100736417	20992764434	of	of	IO
304953	100736417	20992764435	particular	particular	JJ
304953	100736417	20992764436	carotenoids	carotenoid	NN2
304953	100736417	20992764437	usually	usually	RR
304953	100736417	20992764438	reflect	reflect	VV0
304953	100736417	20992764439	a	a	AT1
304953	100736417	20992764440	diet	diet	NN1
304953	100736417	20992764441	consistently	consistently	RR
304953	100736417	20992764442	high	high	JJ_RR@
304953	100736417	20992764443	in	in	II
304953	100736417	20992764444	fruits	fruit	NN2
304953	100736417	20992764445	and	and	CC
304953	100736417	20992764446	vegetables	vegetable	NN2
304953	100736417	20992764447	,	,	,
304953	100736417	20992764448	rather	rather	II21_CS21@
304953	100736417	20992764449	than	than	II22_CS22@
304953	100736417	20992764450	any	any	DD
304953	100736417	20992764451	benefit	benefit	NN1_VV0
304953	100736417	20992764452	from	from	II
304953	100736417	20992764453	taking	take	VVG
304953	100736417	20992764454	a	a	AT1
304953	100736417	20992764455	supplement	supplement	NN1
304953	100736417	20992764456	.	.	.
304953	100736417	20992764457	<p>		NULL
304953	100736417	20992764458	ROSENTHAL	rosenthal	NP1
304953	100736417	20992764459	:	:	:
304953	100736417	20992764460	And	and	CC
304953	100736417	20992764461	I	i	PPIS1
304953	100736417	20992764462	always	always	RR
304953	100736417	20992764463	warn	warn	VV0
304953	100736417	20992764464	patients	patient	NN2
304953	100736417	20992764465	that	that	CST
304953	100736417	20992764466	nothing	nothing	PN1
304953	100736417	20992764467	is	be	VBZ
304953	100736417	20992764468	standardized	standardize	VVN
304953	100736417	20992764469	with	with	II31
304953	100736417	20992764470	respect	respect	II32
304953	100736417	20992764471	to	to	II33
304953	100736417	20992764472	over-the-counter	over-the-counter	JJ_NN1
304953	100736417	20992764473	substances	substance	NN2
304953	100736417	20992764474	.	.	.
304953	100736417	20992764475	The	the	AT
304953	100736417	20992764476	PC	pc	NN1
304953	100736417	20992764477	SPES	spe	NN2_NP2
304953	100736417	20992764478	story	story	NN1
304953	100736417	20992764479	is	be	VBZ
304953	100736417	20992764480	a	a	AT1
304953	100736417	20992764481	glaring	glaring	JJ
304953	100736417	20992764482	example	example	NN1
304953	100736417	20992764483	of	of	IO
304953	100736417	20992764484	what	what	DDQ
304953	100736417	20992764485	can	can	VM
304953	100736417	20992764486	happen	happen	VVI
304953	100736417	20992764487	because	because	CS
304953	100736417	20992764488	there	there	EX
304953	100736417	20992764489	is	be	VBZ
304953	100736417	20992764490	no	no	AT
304953	100736417	20992764491	standardization	standardization	NN1
304953	100736417	20992764492	see	see	VV0
304953	100736417	20992764493	"	"	"
304953	100736417	20992764494	PC	pc	NN1
304953	100736417	20992764495	SPES	spe	NN2
304953	100736417	20992764496	:	:	:
304953	100736417	20992764497	A	a	ZZ1_AT1@
304953	100736417	20992764498	cautionary	cautionary	JJ
304953	100736417	20992764499	tale	tale	NN1
304953	100736417	20992764500	"	"	"
304953	100736417	20992764501	.	.	.
304953	100736417	20992764502	Patients	patient	NN2
304953	100736417	20992764503	lost	lose	VVD_VVN
304953	100736417	20992764504	faith	faith	NN1
304953	100736417	20992764505	.	.	.
304953	100736417	20992764506	And	and	CC
304953	100736417	20992764507	clinical	clinical	JJ
304953	100736417	20992764508	researchers	researcher	NN2
304953	100736417	20992764509	lost	lose	VVD_VVN
304953	100736417	20992764510	a	a	AT1
304953	100736417	20992764511	great	great	JJ
304953	100736417	20992764512	deal	deal	NN1
304953	100736417	20992764513	of	of	IO
304953	100736417	20992764514	time	time	NNT1
304953	100736417	20992764515	and	and	CC
304953	100736417	20992764516	energy	energy	NN1
304953	100736417	20992764517	.	.	.
304953	100736417	20992764518	<p>		NULL
304953	100736417	20992764519	SIMON	simon	NP1
304953	100736417	20992764520	:	:	:
304953	100736417	20992764521	Exactly	exactly	RR
304953	100736417	20992764522	!	!	!
304953	100736417	20992764523	PC	pc	NN1
304953	100736417	20992764524	SPES	spe	NN2_NP2
304953	100736417	20992764525	was	be	VBDZ
304953	100736417	20992764526	heavily	heavily	RR
304953	100736417	20992764527	promoted	promote	VVN
304953	100736417	20992764528	as	as	II
304953	100736417	20992764529	a	a	AT1
304953	100736417	20992764530	treatment	treatment	NN1
304953	100736417	20992764531	for	for	IF
304953	100736417	20992764532	prostate	prostate	NN1
304953	100736417	20992764533	cancer	cancer	NN1
304953	100736417	20992764534	.	.	.
304953	100736417	20992764535	But	but	CCB
304953	100736417	20992764536	it	it	PPH1
304953	100736417	20992764537	turns	turn	VVZ
304953	100736417	20992764538	out	out	RP
304953	100736417	20992764539	that	that	CST
304953	100736417	20992764540	the	the	AT
304953	100736417	20992764541	product	product	NN1
304953	100736417	20992764542	contained	contain	VVD_VVN
304953	100736417	20992764543	not	not	XX
304953	100736417	20992764544	only	only	JJ
304953	100736417	20992764545	the	the-	AT
304953	100736417	20992764546	eight	eight	MC
304953	100736417	20992764547	Chinese	chinese	JJ
304953	100736417	20992764548	herbs	herb	NN2
304953	100736417	20992764549	listed	list	VVN_VVD
304953	100736417	20992764550	on	on	II
304953	100736417	20992764551	the	the	AT
304953	100736417	20992764552	bottle	bottle	NN1
304953	100736417	20992764553	,	,	,
304953	100736417	20992764554	but	but	CCB
304953	100736417	20992764555	also	also	RR
304953	100736417	20992764556	a	a	AT1
304953	100736417	20992764557	little	little	JJ
304953	100736417	20992764558	estrogen	estrogen	NN1
304953	100736417	20992764559	and	and	CC
304953	100736417	20992764560	some	some	DD
304953	100736417	20992764561	other	other	JJ
304953	100736417	20992764562	contaminants	contaminant	NN2
304953	100736417	20992764563	.	.	.
304953	100736417	20992764564	@		II
304953	100736417	20992764565	@		II
304953	100736417	20992764566	@		II
304953	100736417	20992764567	@		II
304953	100736417	20992764568	@		II
304953	100736417	20992764569	@		II
304953	100736417	20992764570	@		II
304953	100736417	20992764571	@		II
304953	100736417	20992764572	@		II
304953	100736417	20992764573	@		II
304953	100736417	20992764574	over	over	II
304953	100736417	20992764575	the	the	AT
304953	100736417	20992764576	quality	quality	NN1
304953	100736417	20992764577	of	of	IO
304953	100736417	20992764578	these	these	DD2
304953	100736417	20992764579	products	product	NN2
304953	100736417	20992764580	.	.	.
304953	100736417	20992764581	We	we	PPIS2
304953	100736417	20992764582	cant	cant	NN1_JJ
304953	100736417	20992764583	verify	verify	VV0
304953	100736417	20992764584	what	what	DDQ
304953	100736417	20992764585	ingredients	ingredient	NN2
304953	100736417	20992764586	are	be	VBR
304953	100736417	20992764587	in	in	II
304953	100736417	20992764588	a	a	AT1
304953	100736417	20992764589	particular	particular	JJ
304953	100736417	20992764590	bottle	bottle	NN1
304953	100736417	20992764591	.	.	.
304953	100736417	20992764592	So	so	RR
304953	100736417	20992764593	unless	unless	CS
304953	100736417	20992764594	there 's		NN2
304953	100736417	20992764595	a	a	AT1
304953	100736417	20992764596	pretty	pretty	RG_JJ
304953	100736417	20992764597	good	good	JJ
304953	100736417	20992764598	reason	reason	NN1
304953	100736417	20992764599	to	to	TO
304953	100736417	20992764600	think	think	VVI
304953	100736417	20992764601	that	that	CST_DD1
304953	100736417	20992764602	something	something	PN1
304953	100736417	20992764603	may	may	VM
304953	100736417	20992764604	be	be	VBI
304953	100736417	20992764605	useful	useful	JJ
304953	100736417	20992764606	,	,	,
304953	100736417	20992764607	I	i	PPIS1
304953	100736417	20992764608	tell	tell	VV0
304953	100736417	20992764609	my	my	APPGE
304953	100736417	20992764610	patients	patient	NN2
304953	100736417	20992764611	,	,	,
304953	100736417	20992764612	"	"	"
304953	100736417	20992764613	Caveat	caveat	UH21
304953	100736417	20992764614	emptor	emptor	UH22
304953	100736417	20992764615	:	:	:
304953	100736417	20992764616	Buyer	buyer	NN1
304953	100736417	20992764617	beware	beware	VV0
304953	100736417	20992764618	.	.	.
304953	100736417	20992764619	"	"	"
304953	100736417	20992764620	<p>		NULL
304953	100736417	20992764621	Let 's		VVZ
304953	100736417	20992764622	look	look	NN1
304953	100736417	20992764623	at	at	II
304953	100736417	20992764624	particular	particular	JJ
304953	100736417	20992764625	prostate	prostate	NN1
304953	100736417	20992764626	diseases	disease	NN2
304953	100736417	20992764627	.	.	.
304953	100736417	20992764628	What	what	DDQ
304953	100736417	20992764629	does	do	VDZ
304953	100736417	20992764630	the	the	AT
304953	100736417	20992764631	research	research	NN1
304953	100736417	20992764632	show	show	VVI
304953	100736417	20992764633	in	in	II31
304953	100736417	20992764634	terms	terms	II32
304953	100736417	20992764635	of	of	II33
304953	100736417	20992764636	what	what	DDQ
304953	100736417	20992764637	men	man	NN2
304953	100736417	20992764638	can	can	VM
304953	100736417	20992764639	do	do	VDI
304953	100736417	20992764640	to	to	TO
304953	100736417	20992764641	help	help	VVI
304953	100736417	20992764642	themselves	themselves	PPX2
304953	100736417	20992764643	?	?	?
304953	100736417	20992764644	<p>		NULL
304953	100736417	20992764645	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992764646	:	:	:
304953	100736417	20992764647	My	my	APPGE
304953	100736417	20992764648	research	research	NN1
304953	100736417	20992764649	focuses	focus	VVZ
304953	100736417	20992764650	on	on	II
304953	100736417	20992764651	lifestyle	lifestyle	NN1
304953	100736417	20992764652	factors	factor	NN2
304953	100736417	20992764653	,	,	,
304953	100736417	20992764654	which	which	DDQ
304953	100736417	20992764655	include	include	VV0
304953	100736417	20992764656	nutrition	nutrition	NN1
304953	100736417	20992764657	,	,	,
304953	100736417	20992764658	physical	physical	JJ
304953	100736417	20992764659	activity	activity	NN1
304953	100736417	20992764660	,	,	,
304953	100736417	20992764661	and	and	CC
304953	100736417	20992764662	body	body	NN1
304953	100736417	20992764663	weight	weight	NN1
304953	100736417	20992764664	.	.	.
304953	100736417	20992764665	The	the	AT
304953	100736417	20992764666	studies	study	NN2
304953	100736417	20992764667	show	show	VV0
304953	100736417	20992764668	that	that	CST
304953	100736417	20992764669	these	these	DD2
304953	100736417	20992764670	basic	basic	JJ
304953	100736417	20992764671	lifestyle	lifestyle	NN1
304953	100736417	20992764672	factors	factor	NN2
304953	100736417	20992764673	actually	actually	RR
304953	100736417	20992764674	have	have	VH0
304953	100736417	20992764675	a	a	AT1
304953	100736417	20992764676	lot	lot	NN1
304953	100736417	20992764677	of	of	IO
304953	100736417	20992764678	impact	impact	NN1
304953	100736417	20992764679	on	on	II
304953	100736417	20992764680	the	the	AT
304953	100736417	20992764681	risk	risk	NN1
304953	100736417	20992764682	of	of	IO
304953	100736417	20992764683	developing	developing	JJ_VVG
304953	100736417	20992764684	various	various	JJ
304953	100736417	20992764685	types	type	NN2
304953	100736417	20992764686	of	of	IO
304953	100736417	20992764687	prostate	prostate	NN1
304953	100736417	20992764688	disease	disease	NN1
304953	100736417	20992764689	.	.	.
304953	100736417	20992764690	For	for	REX21
304953	100736417	20992764691	example	example	REX22
304953	100736417	20992764692	,	,	,
304953	100736417	20992764693	there 's		NN2
304953	100736417	20992764694	more	more	RRR_RGR
304953	100736417	20992764695	and	and	CC
304953	100736417	20992764696	more	more	DAR
304953	100736417	20992764697	evidence	evidence	NN1
304953	100736417	20992764698	that	that	CST_DD1
304953	100736417	20992764699	cardiovascular	cardiovascular	JJ
304953	100736417	20992764700	disease	disease	NN1
304953	100736417	20992764701	contributes	contribute	VVZ
304953	100736417	20992764702	to	to	II
304953	100736417	20992764703	erectile	erectile	JJ
304953	100736417	20992764704	dysfunction	dysfunction	NN1
304953	100736417	20992764705	.	.	.
304953	100736417	20992764706	To	to	TO
304953	100736417	20992764707	lower	lower	VVI
304953	100736417	20992764708	risk	risk	NN1
304953	100736417	20992764709	for	for	IF
304953	100736417	20992764710	developing	develop	VVG_JJ
304953	100736417	20992764711	erectile	erectile	JJ
304953	100736417	20992764712	dysfunction	dysfunction	NN1
304953	100736417	20992764713	,	,	,
304953	100736417	20992764714	or	or	CC
304953	100736417	20992764715	even	even	RR
304953	100736417	20992764716	to	to	TO
304953	100736417	20992764717	alleviate	alleviate	VVI
304953	100736417	20992764718	it	it	PPH1
304953	100736417	20992764719	,	,	,
304953	100736417	20992764720	the	the	AT
304953	100736417	20992764721	best	best	JJT
304953	100736417	20992764722	advice	advice	NN1
304953	100736417	20992764723	is	be	VBZ
304953	100736417	20992764724	to	to	TO
304953	100736417	20992764725	start	start	VVI
304953	100736417	20992764726	exercising	exercise	VVG
304953	100736417	20992764727	more	more	RRR_DAR
304953	100736417	20992764728	,	,	,
304953	100736417	20992764729	maintain	maintain	VV0
304953	100736417	20992764730	a	a	AT1
304953	100736417	20992764731	normal	normal	JJ
304953	100736417	20992764732	body	body	NN1
304953	100736417	20992764733	weight	weight	NN1
304953	100736417	20992764734	,	,	,
304953	100736417	20992764735	and	and	CC
304953	100736417	20992764736	avoid	avoid	VV0
304953	100736417	20992764737	smoking	smoking	NN1_JJ_VVG
304953	100736417	20992764738	.	.	.
304953	100736417	20992764739	And	and	CC
304953	100736417	20992764740	some	some	DD
304953	100736417	20992764741	of	of	IO
304953	100736417	20992764742	this	this	DD1
304953	100736417	20992764743	advice	advice	NN1
304953	100736417	20992764744	is	be	VBZ
304953	100736417	20992764745	probably	probably	RR
304953	100736417	20992764746	also	also	RR
304953	100736417	20992764747	important	important	JJ
304953	100736417	20992764748	for	for	IF
304953	100736417	20992764749	prostate	prostate	NN1
304953	100736417	20992764750	cancer	cancer	NN1
304953	100736417	20992764751	and	and	CC
304953	100736417	20992764752	BPH	bph	NP1
304953	100736417	20992764753	.	.	.
304953	100736417	20992764754	<p>		NULL
304953	100736417	20992764755	SIMON	simon	NP1
304953	100736417	20992764756	:	:	:
304953	100736417	20992764757	We	we	PPIS2
304953	100736417	20992764758	also	also	RR
304953	100736417	20992764759	need	need	VV0
304953	100736417	20992764760	to	to	TO
304953	100736417	20992764761	educate	educate	VVI
304953	100736417	20992764762	physicians	physician	NN2
304953	100736417	20992764763	about	about	II
304953	100736417	20992764764	@		II
304953	100736417	20992764765	@		II
304953	100736417	20992764766	@		II
304953	100736417	20992764767	@		II
304953	100736417	20992764768	@		II
304953	100736417	20992764769	@		II
304953	100736417	20992764770	@		II
304953	100736417	20992764771	@		II
304953	100736417	20992764772	@		II
304953	100736417	20992764773	@		II
304953	100736417	20992764774	is	be	VBZ
304953	100736417	20992764775	the	the	AT
304953	100736417	20992764776	best	best	JJT
304953	100736417	20992764777	example	example	NN1
304953	100736417	20992764778	,	,	,
304953	100736417	20992764779	since	since	CS
304953	100736417	20992764780	its	its	APPGE
304953	100736417	20992764781	basically	basically	RR
304953	100736417	20992764782	a	a	AT1
304953	100736417	20992764783	manifestation	manifestation	NN1
304953	100736417	20992764784	of	of	IO
304953	100736417	20992764785	atherosclerosis	atherosclerosis	NN1
304953	100736417	20992764786	,	,	,
304953	100736417	20992764787	which	which	DDQ
304953	100736417	20992764788	is	be	VBZ
304953	100736417	20992764789	a	a	AT1
304953	100736417	20992764790	highly	highly	RR
304953	100736417	20992764791	preventable	preventable	JJ
304953	100736417	20992764792	disease	disease	NN1
304953	100736417	20992764793	.	.	.
304953	100736417	20992764794	<p>		NULL
304953	100736417	20992764795	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992764796	:	:	:
304953	100736417	20992764797	There	there	EX
304953	100736417	20992764798	is	be	VBZ
304953	100736417	20992764799	also	also	RR
304953	100736417	20992764800	some	some	DD
304953	100736417	20992764801	evidence	evidence	NN1
304953	100736417	20992764802	that	that	CST_DD1
304953	100736417	20992764803	metabolic	metabolic	JJ
304953	100736417	20992764804	syndrome	syndrome	NN1
304953	100736417	20992764805	might	might	VM
304953	100736417	20992764806	be	be	VBI
304953	100736417	20992764807	a	a	AT1
304953	100736417	20992764808	factor	factor	NN1
304953	100736417	20992764809	in	in	II
304953	100736417	20992764810	prostate	prostate	NN1
304953	100736417	20992764811	cancer	cancer	NN1
304953	100736417	20992764812	progression	progression	NN1
304953	100736417	20992764813	see	see	VV0
304953	100736417	20992764814	"	"	"
304953	100736417	20992764815	Metabolic	metabolic	JJ
304953	100736417	20992764816	syndrome	syndrome	NN1
304953	100736417	20992764817	"	"	"
304953	100736417	20992764818	.	.	.
304953	100736417	20992764819	And	and	CC
304953	100736417	20992764820	you	you	PPY
304953	100736417	20992764821	can	can	VM
304953	100736417	20992764822	prevent	prevent	VVI
304953	100736417	20992764823	or	or	CC
304953	100736417	20992764824	ameliorate	ameliorate	VVI
304953	100736417	20992764825	metabolic	metabolic	JJ
304953	100736417	20992764826	syndrome	syndrome	NN1
304953	100736417	20992764827	by	by	II
304953	100736417	20992764828	following	follow	VVG
304953	100736417	20992764829	the	the	AT
304953	100736417	20992764830	same	same	DA
304953	100736417	20992764831	basic	basic	JJ
304953	100736417	20992764832	advice	advice	NN1
304953	100736417	20992764833	:	:	:
304953	100736417	20992764834	more	more	DAR_RRR
304953	100736417	20992764835	exercise	exercise	NN1_VV0
304953	100736417	20992764836	,	,	,
304953	100736417	20992764837	a	a	AT1
304953	100736417	20992764838	better	better	JJR
304953	100736417	20992764839	diet	diet	NN1
304953	100736417	20992764840	.	.	.
304953	100736417	20992764841	I	i	PPIS1
304953	100736417	20992764842	know	know	VV0
304953	100736417	20992764843	that 's		NN2
304953	100736417	20992764844	going	go	VVGK
304953	100736417	20992764845	to	to	TO
304953	100736417	20992764846	sound	sound	VVI
304953	100736417	20992764847	like	like	II
304953	100736417	20992764848	the	the	AT
304953	100736417	20992764849	same	same	DA
304953	100736417	20992764850	old	old	JJ
304953	100736417	20992764851	boring	boring	JJ
304953	100736417	20992764852	message	message	NN1
304953	100736417	20992764853	,	,	,
304953	100736417	20992764854	but	but	CCB
304953	100736417	20992764855	following	follow	VVG_II@
304953	100736417	20992764856	this	this	DD1
304953	100736417	20992764857	advice	advice	NN1
304953	100736417	20992764858	can	can	VM
304953	100736417	20992764859	have	have	VHI
304953	100736417	20992764860	a	a	AT1
304953	100736417	20992764861	huge	huge	JJ
304953	100736417	20992764862	benefit	benefit	NN1
304953	100736417	20992764863	on	on	II
304953	100736417	20992764864	overall	overall	JJ_NN1
304953	100736417	20992764865	health	health	NN1
304953	100736417	20992764866	and	and	CC
304953	100736417	20992764867	on	on	II
304953	100736417	20992764868	prostate	prostate	NN1
304953	100736417	20992764869	diseases	disease	NN2
304953	100736417	20992764870	in	in	RR21
304953	100736417	20992764871	particular	particular	RR22
304953	100736417	20992764872	.	.	.
304953	100736417	20992764873	So	so	RR
304953	100736417	20992764874	patients	patient	NN2
304953	100736417	20992764875	do	do	VD0
304953	100736417	20992764876	n't 	n't	XX
304953	100736417	20992764877	have	have	VHI
304953	100736417	20992764878	to	to	TO
304953	100736417	20992764879	go	go	VVI
304953	100736417	20992764880	searching	search	VVG
304953	100736417	20992764881	for	for	IF
304953	100736417	20992764882	exotic	exotic	JJ
304953	100736417	20992764883	herbs	herb	NN2
304953	100736417	20992764884	,	,	,
304953	100736417	20992764885	especially	especially	RR
304953	100736417	20992764886	when	when	CS_RRQ
304953	100736417	20992764887	there	there	EX
304953	100736417	20992764888	is	be	VBZ
304953	100736417	20992764889	essentially	essentially	RR
304953	100736417	20992764890	no	no	AT
304953	100736417	20992764891	evidence	evidence	NN1
304953	100736417	20992764892	that	that	CST
304953	100736417	20992764893	they	they	PPHS2
304953	100736417	20992764894	are	be	VBR
304953	100736417	20992764895	beneficial	beneficial	JJ
304953	100736417	20992764896	.	.	.
304953	100736417	20992764897	<h>		NULL
304953	100736417	20992764898	Metabolic	metabolic	JJ
304953	100736417	20992764899	syndrome	syndrome	NN1
304953	100736417	20992764900	<p>		NULL
304953	100736417	20992764901	Anyone	anyone	PN1
304953	100736417	20992764902	with	with	IW
304953	100736417	20992764903	three	three	MC
304953	100736417	20992764904	or	or	CC
304953	100736417	20992764905	more	more	DAR
304953	100736417	20992764906	of	of	IO
304953	100736417	20992764907	the	the	AT
304953	100736417	20992764908	following	following	JJ
304953	100736417	20992764909	attributes	attribute	NN2
304953	100736417	20992764910	meets	meet	VVZ
304953	100736417	20992764911	the	the	AT
304953	100736417	20992764912	diagnostic	diagnostic	JJ
304953	100736417	20992764913	criteria	criteria	NN2
304953	100736417	20992764914	for	for	IF
304953	100736417	20992764915	metabolic	metabolic	JJ
304953	100736417	20992764916	syndrome	syndrome	NN1
304953	100736417	20992764917	,	,	,
304953	100736417	20992764918	which	which	DDQ
304953	100736417	20992764919	increases	increase	VVZ
304953	100736417	20992764920	the	the	AT
304953	100736417	20992764921	risk	risk	NN1
304953	100736417	20992764922	of	of	IO
304953	100736417	20992764923	diabetes	diabetes	NN1
304953	100736417	20992764924	or	or	CC
304953	100736417	20992764925	heart	heart	NN1
304953	100736417	20992764926	disease	disease	NN1
304953	100736417	20992764927	:	:	:
304953	100736417	20992764928	<p>		NULL
304953	100736417	20992764929	waist	waist	NN1
304953	100736417	20992764930	size	size	NN1
304953	100736417	20992764931	greater	great	JJR
304953	100736417	20992764932	than	than	CSN
304953	100736417	20992764933	40	40	MC
304953	100736417	20992764934	inches	inch	NNU2
304953	100736417	20992764935	in	in	II
304953	100736417	20992764936	men	man	NN2
304953	100736417	20992764937	,	,	,
304953	100736417	20992764938	or	or	CC
304953	100736417	20992764939	35	35	MC
304953	100736417	20992764940	inches	inch	NNU2
304953	100736417	20992764941	in	in	II
304953	100736417	20992764942	women	woman	NN2
304953	100736417	20992764943	<p>		NULL
304953	100736417	20992764944	blood	blood	NN1
304953	100736417	20992764945	pressure	pressure	NN1
304953	100736417	20992764946	of	of	IO
304953	100736417	20992764947	130/85	130/85	MF
304953	100736417	20992764948	mm	mm	NNU@
304953	100736417	20992764949	Hg	hg	FO
304953	100736417	20992764950	or	or	CC
304953	100736417	20992764951	more	more	RRR_DAR
304953	100736417	20992764952	<p>		NULL
304953	100736417	20992764953	HDL	hdl	NP1
304953	100736417	20992764954	cholesterol	cholesterol	NN1
304953	100736417	20992764955	less	less	DAR
304953	100736417	20992764956	than	than	CSN
304953	100736417	20992764957	40	40	MC
304953	100736417	20992764958	mg/dl	mg/dl	FU
304953	100736417	20992764959	in	in	II
304953	100736417	20992764960	men	man	NN2
304953	100736417	20992764961	and	and	CC
304953	100736417	20992764962	less	less	DAR
304953	100736417	20992764963	than	than	CSN
304953	100736417	20992764964	@		II
304953	100736417	20992764965	@		II
304953	100736417	20992764966	@		II
304953	100736417	20992764967	@		II
304953	100736417	20992764968	@		II
304953	100736417	20992764969	@		II
304953	100736417	20992764970	@		II
304953	100736417	20992764971	@		II
304953	100736417	20992764972	@		II
304953	100736417	20992764973	@		II
304953	100736417	20992764974	or	or	CC
304953	100736417	20992764975	more	more	RRR_DAR
304953	100736417	20992764976	<p>		NULL
304953	100736417	20992764977	fasting	fast	VVG_JJ@
304953	100736417	20992764978	blood	blood	NN1
304953	100736417	20992764979	glucose	glucose	NN1
304953	100736417	20992764980	level	level	NN1
304953	100736417	20992764981	of	of	IO
304953	100736417	20992764982	110	110	MC
304953	100736417	20992764983	mg/dl	mg/dl	FU
304953	100736417	20992764984	or	or	CC
304953	100736417	20992764985	more	more	RRR_DAR
304953	100736417	20992764986	<p>		NULL
304953	100736417	20992764987	What	what	DDQ
304953	100736417	20992764988	do	do	VD0
304953	100736417	20992764989	the	the	AT
304953	100736417	20992764990	studies	study	NN2
304953	100736417	20992764991	say	say	VVI
304953	100736417	20992764992	about	about	II
304953	100736417	20992764993	the	the	AT
304953	100736417	20992764994	impact	impact	NN1
304953	100736417	20992764995	of	of	IO
304953	100736417	20992764996	lifestyle	lifestyle	NN1
304953	100736417	20992764997	factors	factor	NN2
304953	100736417	20992764998	on	on	II
304953	100736417	20992764999	prostate	prostate	NN1
304953	100736417	20992765000	cancer	cancer	NN1
304953	100736417	20992765001	?	?	?
304953	100736417	20992765002	Is	be	VBZ
304953	100736417	20992765003	there	there	EX
304953	100736417	20992765004	any	any	DD
304953	100736417	20992765005	way	way	NN1
304953	100736417	20992765006	for	for	IF
304953	100736417	20992765007	a	a	AT1
304953	100736417	20992765008	man	man	NN1
304953	100736417	20992765009	to	to	TO
304953	100736417	20992765010	adjust	adjust	VVI
304953	100736417	20992765011	his	his	APPGE
304953	100736417	20992765012	diet	diet	NN1
304953	100736417	20992765013	to	to	TO
304953	100736417	20992765014	reduce	reduce	VVI
304953	100736417	20992765015	the	the	AT
304953	100736417	20992765016	risk	risk	NN1
304953	100736417	20992765017	of	of	IO
304953	100736417	20992765018	prostate	prostate	NN1
304953	100736417	20992765019	cancer	cancer	NN1
304953	100736417	20992765020	or	or	CC
304953	100736417	20992765021	slow	slow	VV0@
304953	100736417	20992765022	its	its	APPGE
304953	100736417	20992765023	progression	progression	NN1
304953	100736417	20992765024	?	?	?
304953	100736417	20992765025	<p>		NULL
304953	100736417	20992765026	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992765027	:	:	:
304953	100736417	20992765028	Unfortunately	unfortunately	RR
304953	100736417	20992765029	,	,	,
304953	100736417	20992765030	not	not	XX
304953	100736417	20992765031	all	all	DB
304953	100736417	20992765032	of	of	IO
304953	100736417	20992765033	the	the	AT
304953	100736417	20992765034	answers	answer	NN2
304953	100736417	20992765035	are	be	VBR
304953	100736417	20992765036	in	in	RP@
304953	100736417	20992765037	for	for	IF
304953	100736417	20992765038	preventing	prevent	VVG
304953	100736417	20992765039	prostate	prostate	NN1
304953	100736417	20992765040	cancer	cancer	NN1
304953	100736417	20992765041	,	,	,
304953	100736417	20992765042	and	and	CC
304953	100736417	20992765043	there 's		NN2
304953	100736417	20992765044	even	even	RR
304953	100736417	20992765045	less	less	DAR
304953	100736417	20992765046	evidence	evidence	NN1
304953	100736417	20992765047	about	about	II
304953	100736417	20992765048	how	how	RRQ
304953	100736417	20992765049	to	to	TO
304953	100736417	20992765050	stop	stop	VVI
304953	100736417	20992765051	its	its	APPGE
304953	100736417	20992765052	progression	progression	NN1
304953	100736417	20992765053	.	.	.
304953	100736417	20992765054	Again	again	RT
304953	100736417	20992765055	,	,	,
304953	100736417	20992765056	what	what	DDQ
304953	100736417	20992765057	seems	seem	VVZ
304953	100736417	20992765058	to	to	TO
304953	100736417	20992765059	be	be	VBI
304953	100736417	20992765060	most	most	RGT
304953	100736417	20992765061	important	important	JJ
304953	100736417	20992765062	is	be	VBZ
304953	100736417	20992765063	reducing	reduce	VVG_JJ@
304953	100736417	20992765064	body	body	NN1
304953	100736417	20992765065	weight	weight	NN1
304953	100736417	20992765066	or	or	CC
304953	100736417	20992765067	keeping	keep	VVG
304953	100736417	20992765068	body	body	NN1
304953	100736417	20992765069	weight	weight	NN1
304953	100736417	20992765070	normal	normal	JJ
304953	100736417	20992765071	.	.	.
304953	100736417	20992765072	There 's		NN2_NP1@
304953	100736417	20992765073	a	a	AT1
304953	100736417	20992765074	little	little	JJ
304953	100736417	20992765075	bit	bit	NN1
304953	100736417	20992765076	of	of	IO
304953	100736417	20992765077	evidence	evidence	NN1
304953	100736417	20992765078	that	that	CST_DD1
304953	100736417	20992765079	physical	physical	JJ
304953	100736417	20992765080	activity	activity	NN1
304953	100736417	20992765081	may	may	VM
304953	100736417	20992765082	be	be	VBI
304953	100736417	20992765083	helpful	helpful	JJ
304953	100736417	20992765084	,	,	,
304953	100736417	20992765085	but	but	CCB
304953	100736417	20992765086	probably	probably	RR
304953	100736417	20992765087	only	only	JJ
304953	100736417	20992765088	at	at-	II
304953	100736417	20992765089	a	a	AT1
304953	100736417	20992765090	fairly	fairly	RR
304953	100736417	20992765091	high	high	JJ
304953	100736417	20992765092	level	level	NN1_JJ
304953	100736417	20992765093	.	.	.
304953	100736417	20992765094	Walking	walking	NN1_VVG
304953	100736417	20992765095	is	be	VBZ
304953	100736417	20992765096	probably	probably	RR
304953	100736417	20992765097	not	not	XX
304953	100736417	20992765098	sufficient	sufficient	JJ
304953	100736417	20992765099	to	to	TO
304953	100736417	20992765100	reduce	reduce	VVI
304953	100736417	20992765101	risk	risk	NN1
304953	100736417	20992765102	.	.	.
304953	100736417	20992765103	<p>		NULL
304953	100736417	20992765104	In	in	II31
304953	100736417	20992765105	terms	terms	II32
304953	100736417	20992765106	of	of	II33
304953	100736417	20992765107	specific	specific	JJ
304953	100736417	20992765108	foods	food	NN2
304953	100736417	20992765109	,	,	,
304953	100736417	20992765110	there	there	EX
304953	100736417	20992765111	is	be	VBZ
304953	100736417	20992765112	reason	reason	NN1
304953	100736417	20992765113	to	to	TO
304953	100736417	20992765114	believe	believe	VVI
304953	100736417	20992765115	that	that	CST_DD1
304953	100736417	20992765116	fish	fish	NN
304953	100736417	20992765117	,	,	,
304953	100736417	20992765118	selenium	selenium	NN1
304953	100736417	20992765119	,	,	,
304953	100736417	20992765120	and	and	CC
304953	100736417	20992765121	tomatoes	tomato	NN2
304953	100736417	20992765122	might	might	VM
304953	100736417	20992765123	all	all	DB_RR@
304953	100736417	20992765124	be	be	VBI
304953	100736417	20992765125	important	important	JJ
304953	100736417	20992765126	in	in	II
304953	100736417	20992765127	reducing	reduce	VVG_JJ@
304953	100736417	20992765128	risk	risk	NN1
304953	100736417	20992765129	of	of	IO
304953	100736417	20992765130	developing	developing	JJ_VVG
304953	100736417	20992765131	prostate	prostate	NN1
304953	100736417	20992765132	cancer	cancer	NN1
304953	100736417	20992765133	see	see	VV0
304953	100736417	20992765134	Table	table	NN1
304953	100736417	20992765135	3	3	MC
304953	100736417	20992765136	.	.	.
304953	100736417	20992765137	But	but	CCB
304953	100736417	20992765138	there 's		NN2
304953	100736417	20992765139	almost	almost	RR
304953	100736417	20992765140	no	no	AT
304953	100736417	20992765141	evidence	evidence	NN1
304953	100736417	20992765142	that	that	CST
304953	100736417	20992765143	changing	change	VVG
304953	100736417	20992765144	your	your	APPGE
304953	100736417	20992765145	diet	diet	NN1
304953	100736417	20992765146	after	after	II_CS
304953	100736417	20992765147	diagnosis	diagnosis	NN1
304953	100736417	20992765148	will	will	VM
304953	100736417	20992765149	have	have	VHI
304953	100736417	20992765150	any	any	DD
304953	100736417	20992765151	impact	impact	NN1
304953	100736417	20992765152	on	on	II
304953	100736417	20992765153	prostate	prostate	NN1
304953	100736417	20992765154	cancer	cancer	NN1
304953	100736417	20992765155	progression	progression	NN1
304953	100736417	20992765156	.	.	.
304953	100736417	20992765157	Of	of	RR21
304953	100736417	20992765158	course	course	RR22
304953	100736417	20992765159	,	,	,
304953	100736417	20992765160	eating	eat	VVG
304953	100736417	20992765161	a	a	AT1
304953	100736417	20992765162	healthy	healthy	JJ
304953	100736417	20992765163	diet	diet	NN1
304953	100736417	20992765164	@		II
304953	100736417	20992765165	@		II
304953	100736417	20992765166	@		II
304953	100736417	20992765167	@		II
304953	100736417	20992765168	@		II
304953	100736417	20992765169	@		II
304953	100736417	20992765170	@		II
304953	100736417	20992765171	@		II
304953	100736417	20992765172	@		II
304953	100736417	20992765173	@		II
304953	100736417	20992765174	do	do	VD0
304953	100736417	20992765175	harm	harm	VVI
304953	100736417	20992765176	and	and	CC
304953	100736417	20992765177	would	would	VM
304953	100736417	20992765178	improve	improve	VVI
304953	100736417	20992765179	overall	overall	JJ_NN1
304953	100736417	20992765180	health	health	NN1
304953	100736417	20992765181	,	,	,
304953	100736417	20992765182	which	which	DDQ
304953	100736417	20992765183	would	would	VM
304953	100736417	20992765184	help	help	VVI
304953	100736417	20992765185	men	man	NN2
304953	100736417	20992765186	going	go	VVG
304953	100736417	20992765187	through	through	II
304953	100736417	20992765188	treatment	treatment	NN1
304953	100736417	20992765189	for	for	IF
304953	100736417	20992765190	prostate	prostate	NN1
304953	100736417	20992765191	cancer	cancer	NN1
304953	100736417	20992765192	.	.	.
304953	100736417	20992765193	<p>		NULL
304953	100736417	20992765194	SIMON	simon	NP1
304953	100736417	20992765195	:	:	:
304953	100736417	20992765196	The	the	AT
304953	100736417	20992765197	studies	study	NN2
304953	100736417	20992765198	done	do	VDN
304953	100736417	20992765199	to	to	II
304953	100736417	20992765200	date	date	NN1
304953	100736417	20992765201	on	on	II
304953	100736417	20992765202	this	this	DD1
304953	100736417	20992765203	issue	issue	NN1
304953	100736417	20992765204	are	be	VBR
304953	100736417	20992765205	preliminary	preliminary	JJ
304953	100736417	20992765206	,	,	,
304953	100736417	20992765207	and	and	CC
304953	100736417	20992765208	they	they	PPHS2
304953	100736417	20992765209	do	do	VD0
304953	100736417	20992765210	n't 	n't	XX
304953	100736417	20992765211	produce	produce	VVI
304953	100736417	20992765212	solid	solid	JJ
304953	100736417	20992765213	evidence	evidence	NN1
304953	100736417	20992765214	that	that	CST
304953	100736417	20992765215	something	something	PN1
304953	100736417	20992765216	really	really	RR
304953	100736417	20992765217	will	will	VM
304953	100736417	20992765218	slow	slow	VVI
304953	100736417	20992765219	the	the	AT
304953	100736417	20992765220	progression	progression	NN1
304953	100736417	20992765221	of	of	IO
304953	100736417	20992765222	prostate	prostate	NN1
304953	100736417	20992765223	cancer	cancer	NN1
304953	100736417	20992765224	.	.	.
304953	100736417	20992765225	But	but	CCB
304953	100736417	20992765226	I 'm		VV0
304953	100736417	20992765227	all	all	DB_RR@
304953	100736417	20992765228	for	for	IF
304953	100736417	20992765229	giving	give	VVG
304953	100736417	20992765230	patients	patient	NN2
304953	100736417	20992765231	a	a	AT1
304953	100736417	20992765232	ray	ray	NN1
304953	100736417	20992765233	of	of	IO
304953	100736417	20992765234	hope	hope	NN1
304953	100736417	20992765235	.	.	.
304953	100736417	20992765236	An	a	AT1
304953	100736417	20992765237	example	example	NN1
304953	100736417	20992765238	is	be	VBZ
304953	100736417	20992765239	that	that	CST
304953	100736417	20992765240	I	i	PPIS1
304953	100736417	20992765241	now	now	RT
304953	100736417	20992765242	advise	advise	VV0
304953	100736417	20992765243	my	my	APPGE
304953	100736417	20992765244	patients	patient	NN2
304953	100736417	20992765245	to	to	TO
304953	100736417	20992765246	consider	consider	VVI
304953	100736417	20992765247	selenium	selenium	NN1
304953	100736417	20992765248	and	and	CC
304953	100736417	20992765249	possibly	possibly	RR
304953	100736417	20992765250	pomegranate	pomegranate	NN1
304953	100736417	20992765251	juice	juice	NN1
304953	100736417	20992765252	.	.	.
304953	100736417	20992765253	They 're		NN1_NP1@
304953	100736417	20992765254	not	not	XX
304953	100736417	20992765255	going	go	VVGK
304953	100736417	20992765256	to	to	TO
304953	100736417	20992765257	hurt	hurt	VVI
304953	100736417	20992765258	you	you	PPY
304953	100736417	20992765259	,	,	,
304953	100736417	20992765260	and	and	CC
304953	100736417	20992765261	a	a	AT1
304953	100736417	20992765262	small	small	JJ
304953	100736417	20992765263	study	study	NN1
304953	100736417	20992765264	suggests	suggest	VVZ
304953	100736417	20992765265	pomegranate	pomegranate	NN1
304953	100736417	20992765266	juice	juice	NN1
304953	100736417	20992765267	might	might	VM
304953	100736417	20992765268	slow	slow	VVI
304953	100736417	20992765269	progression	progression	NN1
304953	100736417	20992765270	.	.	.
304953	100736417	20992765271	But	but	CCB
304953	100736417	20992765272	I	i	PPIS1
304953	100736417	20992765273	also	also	RR
304953	100736417	20992765274	advise	advise	VV0
304953	100736417	20992765275	them	them	PPHO2
304953	100736417	20992765276	not	not	XX
304953	100736417	20992765277	to	to	TO
304953	100736417	20992765278	expect	expect	VVI
304953	100736417	20992765279	too	too	RG
304953	100736417	20992765280	much	much	DA1_RR
304953	100736417	20992765281	from	from	II
304953	100736417	20992765282	it	it	PPH1
304953	100736417	20992765283	.	.	.
304953	100736417	20992765284	<h>		NULL
304953	100736417	20992765285	PC	pc	NN1
304953	100736417	20992765286	SPES	spe	NN2
304953	100736417	20992765287	:	:	:
304953	100736417	20992765288	A	a	ZZ1_AT1@
304953	100736417	20992765289	cautionary	cautionary	JJ
304953	100736417	20992765290	tale	tale	NN1
304953	100736417	20992765291	<p>		NULL
304953	100736417	20992765292	PC	pc	NN1
304953	100736417	20992765293	SPES	spe	NN2
304953	100736417	20992765294	is	be	VBZ
304953	100736417	20992765295	now	now	RT
304953	100736417	20992765296	off	off	II_RP
304953	100736417	20992765297	the	the	AT
304953	100736417	20992765298	market	market	NN1
304953	100736417	20992765299	,	,	,
304953	100736417	20992765300	but	but	CCB
304953	100736417	20992765301	in	in	II
304953	100736417	20992765302	the	the	AT
304953	100736417	20992765303	1990s	1990s	MC2
304953	100736417	20992765304	this	this	DD1
304953	100736417	20992765305	herbal	herbal	JJ_NN1
304953	100736417	20992765306	product	product	NN1
304953	100736417	20992765307	was	be	VBDZ
304953	100736417	20992765308	promoted	promote	VVN
304953	100736417	20992765309	as	as	CSA
304953	100736417	20992765310	being	be	VBG
304953	100736417	20992765311	good	good	JJ
304953	100736417	20992765312	for	for	IF
304953	100736417	20992765313	"	"	"
304953	100736417	20992765314	prostate	prostate	NN1
304953	100736417	20992765315	health	health	NN1
304953	100736417	20992765316	.	.	.
304953	100736417	20992765317	"	"	"
304953	100736417	20992765318	After	after	CS_II
304953	100736417	20992765319	anecdotal	anecdotal	JJ
304953	100736417	20992765320	reports	report	NN2
304953	100736417	20992765321	and	and	CC
304953	100736417	20992765322	preliminary	preliminary	JJ
304953	100736417	20992765323	laboratory	laboratory	NN1
304953	100736417	20992765324	studies	study	NN2
304953	100736417	20992765325	indicated	indicate	VVD_VVN
304953	100736417	20992765326	that	that	DD1_CST
304953	100736417	20992765327	PC	pc	NN1
304953	100736417	20992765328	SPES	spe	NN2
304953	100736417	20992765329	might	might	VM
304953	100736417	20992765330	help	help	VVI
304953	100736417	20992765331	men	man	NN2
304953	100736417	20992765332	with	with	IW
304953	100736417	20992765333	advanced	advanced	JJ
304953	100736417	20992765334	prostate	prostate	NN1
304953	100736417	20992765335	cancer	cancer	NN1
304953	100736417	20992765336	,	,	,
304953	100736417	20992765337	the	the	AT
304953	100736417	20992765338	National	national	JJ
304953	100736417	20992765339	Center	center	NN1
304953	100736417	20992765340	for	for	IF
304953	100736417	20992765341	Complementary	complementary	JJ
304953	100736417	20992765342	and	and	CC
304953	100736417	20992765343	Alternative	alternative	JJ_NN1
304953	100736417	20992765344	Medicine	medicine	NN1
304953	100736417	20992765345	(	(	(
304953	100736417	20992765346	NCCAM	nccam	NP1
304953	100736417	20992765347	)	)	)
304953	100736417	20992765348	funded	fund	VVD@_VVN_JJ
304953	100736417	20992765349	four	four	MC
304953	100736417	20992765350	research	research	NN1
304953	100736417	20992765351	studies	study	NN2
304953	100736417	20992765352	including	including	II
304953	100736417	20992765353	one	one	MC1
304953	100736417	20992765354	in	in	II
304953	100736417	20992765355	patients	patient	NN2
304953	100736417	20992765356	to	to	TO
304953	100736417	20992765357	determine	determine	VVI
304953	100736417	20992765358	its	its	APPGE
304953	100736417	20992765359	efficacy	efficacy	NN1
304953	100736417	20992765360	,	,	,
304953	100736417	20992765361	safety	safety	NN1
304953	100736417	20992765362	,	,	,
304953	100736417	20992765363	and	and	CC
304953	100736417	20992765364	@		II
304953	100736417	20992765365	@		II
304953	100736417	20992765366	@		II
304953	100736417	20992765367	@		II
304953	100736417	20992765368	@		II
304953	100736417	20992765369	@		II
304953	100736417	20992765370	@		II
304953	100736417	20992765371	@		II
304953	100736417	20992765372	@		II
304953	100736417	20992765373	@		II
304953	100736417	20992765374	2002	2002	MC
304953	100736417	20992765375	,	,	,
304953	100736417	20992765376	however	however	RR
304953	100736417	20992765377	,	,	,
304953	100736417	20992765378	when	when	CS_RRQ
304953	100736417	20992765379	the	the	AT
304953	100736417	20992765380	FDA	fda	NP1_NN1
304953	100736417	20992765381	issued	issue	VVD_VVN
304953	100736417	20992765382	a	a	AT1
304953	100736417	20992765383	warning	warning	NN1
304953	100736417	20992765384	about	about	II
304953	100736417	20992765385	PC	pc	NN1
304953	100736417	20992765386	SPES	spe	NN2
304953	100736417	20992765387	,	,	,
304953	100736417	20992765388	based	base	VVN
304953	100736417	20992765389	on	on	II
304953	100736417	20992765390	reports	report	NN2
304953	100736417	20992765391	that	that	CST
304953	100736417	20992765392	men	man	NN2
304953	100736417	20992765393	taking	take	VVG
304953	100736417	20992765394	the	the	AT
304953	100736417	20992765395	supplement	supplement	NN1
304953	100736417	20992765396	developed	developed	JJ_VVD_VVN
304953	100736417	20992765397	blood	blood	NN1
304953	100736417	20992765398	clots	clot	NN2_VVZ
304953	100736417	20992765399	;	;	;
304953	100736417	20992765400	some	some	DD
304953	100736417	20992765401	patients	patient	NN2
304953	100736417	20992765402	died	die	VVD
304953	100736417	20992765403	.	.	.
304953	100736417	20992765404	Shortly	shortly	RR
304953	100736417	20992765405	after	after	II_CS
304953	100736417	20992765406	the	the	AT
304953	100736417	20992765407	FDA	fda	NN1_NP1
304953	100736417	20992765408	warning	warning	NN1
304953	100736417	20992765409	,	,	,
304953	100736417	20992765410	NCCAM	nccam	NP1
304953	100736417	20992765411	halted	halt	VVD
304953	100736417	20992765412	all	all	DB_RR@
304953	100736417	20992765413	four	four	MC
304953	100736417	20992765414	studies	study	NN2
304953	100736417	20992765415	(	(	(
304953	100736417	20992765416	although	although	CS
304953	100736417	20992765417	it	it	PPH1
304953	100736417	20992765418	eventually	eventually	RR
304953	100736417	20992765419	restarted	restart	VVD_VVN
304953	100736417	20992765420	the	the	AT
304953	100736417	20992765421	laboratory	laboratory	NN1
304953	100736417	20992765422	trials	trial	NN2
304953	100736417	20992765423	)	)	)
304953	100736417	20992765424	.	.	.
304953	100736417	20992765425	The	the	AT
304953	100736417	20992765426	U.S.	us	NP1
304953	100736417	20992765427	distributor	distributor	NN1
304953	100736417	20992765428	issued	issue	VVD_VVN
304953	100736417	20992765429	a	a	AT1
304953	100736417	20992765430	voluntary	voluntary	JJ
304953	100736417	20992765431	recall	recall	NN1@
304953	100736417	20992765432	and	and	CC
304953	100736417	20992765433	eventually	eventually	RR
304953	100736417	20992765434	went	go	VVD
304953	100736417	20992765435	out	out	II21
304953	100736417	20992765436	of	of	II22
304953	100736417	20992765437	business	business	NN1
304953	100736417	20992765438	.	.	.
304953	100736417	20992765439	<p>		NULL
304953	100736417	20992765440	Researchers	researcher	NN2
304953	100736417	20992765441	analyzed	analyze	VVD_JJ@
304953	100736417	20992765442	samples	sample	NN2
304953	100736417	20992765443	of	of	IO
304953	100736417	20992765444	PC	pc	NN1
304953	100736417	20992765445	SPES	spe	NN2
304953	100736417	20992765446	to	to	TO
304953	100736417	20992765447	determine	determine	VVI
304953	100736417	20992765448	what	what	DDQ
304953	100736417	20992765449	went	go	VVD
304953	100736417	20992765450	wrong	wrong	RR
304953	100736417	20992765451	and	and	CC
304953	100736417	20992765452	discovered	discover	VVD
304953	100736417	20992765453	that	that	CST
304953	100736417	20992765454	some	some	DD
304953	100736417	20992765455	batches	batch	NN2
304953	100736417	20992765456	were	be	VBDR
304953	100736417	20992765457	contaminated	contaminate	VVN
304953	100736417	20992765458	with	with	IW
304953	100736417	20992765459	DES	des	NP1_FW
304953	100736417	20992765460	,	,	,
304953	100736417	20992765461	an	a	AT1
304953	100736417	20992765462	estrogen	estrogen	NN1
304953	100736417	20992765463	.	.	.
304953	100736417	20992765464	This	this	DD1
304953	100736417	20992765465	helped	help	VVN_VVD_JJ@
304953	100736417	20992765466	explain	explain	VVI
304953	100736417	20992765467	a	a	AT1
304953	100736417	20992765468	puzzling	puzzling	JJ
304953	100736417	20992765469	side	side	NN1
304953	100736417	20992765470	effect	effect	NN1_VV0@
304953	100736417	20992765471	many	many	DA2
304953	100736417	20992765472	patients	patient	NN2
304953	100736417	20992765473	had	have	VHD
304953	100736417	20992765474	experienced	experience	VVN
304953	100736417	20992765475	while	while	CS
304953	100736417	20992765476	taking	take	VVG
304953	100736417	20992765477	PC	pc	NN1
304953	100736417	20992765478	SPES	spe	NN2_NP2
304953	100736417	20992765479	breast	breast	NN1_VV0%
304953	100736417	20992765480	enlargement	enlargement	NN1
304953	100736417	20992765481	and	and	CC
304953	100736417	20992765482	soreness	soreness	NN1
304953	100736417	20992765483	that	that	CST_DD1
304953	100736417	20992765484	could	could	VM
304953	100736417	20992765485	result	result	VVI
304953	100736417	20992765486	from	from	II
304953	100736417	20992765487	taking	take	VVG
304953	100736417	20992765488	female	female	JJ_NN1
304953	100736417	20992765489	hormones	hormone	NN2
304953	100736417	20992765490	.	.	.
304953	100736417	20992765491	Scientists	scientist	NN2
304953	100736417	20992765492	discovered	discover	VVD
304953	100736417	20992765493	that	that	CST_DD1
304953	100736417	20992765494	other	other	JJ
304953	100736417	20992765495	batches	batch	NN2
304953	100736417	20992765496	of	of	IO
304953	100736417	20992765497	PC	pc	NN1
304953	100736417	20992765498	SPES	spe	NN2
304953	100736417	20992765499	contained	contain	VVD_VVN
304953	100736417	20992765500	indomethacin	indomethacin	NN1
304953	100736417	20992765501	,	,	,
304953	100736417	20992765502	a	a	AT1
304953	100736417	20992765503	pain	pain	NN1
304953	100736417	20992765504	reliever	reliever	VV0
304953	100736417	20992765505	,	,	,
304953	100736417	20992765506	and	and	CC
304953	100736417	20992765507	warfarin	warfarin	NN1
304953	100736417	20992765508	,	,	,
304953	100736417	20992765509	a	a	AT1
304953	100736417	20992765510	blood	blood	NN1
304953	100736417	20992765511	thinner	thin	JJR
304953	100736417	20992765512	.	.	.
304953	100736417	20992765513	<p>		NULL
304953	100736417	20992765514	Harvards	harvard	NP2
304953	100736417	20992765515	Osher	osher	NN1_NP1
304953	100736417	20992765516	Institute	institute	NN1
304953	100736417	20992765517	,	,	,
304953	100736417	20992765518	which	which	DDQ
304953	100736417	20992765519	conducts	conduct	VVZ
304953	100736417	20992765520	research	research	NN1
304953	100736417	20992765521	into	into	II
304953	100736417	20992765522	complementary	complementary	JJ
304953	100736417	20992765523	therapies	therapy	NN2
304953	100736417	20992765524	,	,	,
304953	100736417	20992765525	is	be	VBZ
304953	100736417	20992765526	currently	currently	RR
304953	100736417	20992765527	trying	try	VVG
304953	100736417	20992765528	to	to	TO
304953	100736417	20992765529	develop	develop	VVI
304953	100736417	20992765530	a	a	AT1
304953	100736417	20992765531	research	research	NN1
304953	100736417	20992765532	"	"	"
304953	100736417	20992765533	bank	bank	NN1
304953	100736417	20992765534	"	"	"
304953	100736417	20992765535	of	of	IO
304953	100736417	20992765536	purified	purified	JJ@
304953	100736417	20992765537	,	,	,
304953	100736417	20992765538	standardized	standardized	JJ_VVD
304953	100736417	20992765539	herbs	herb	NN2
304953	100736417	20992765540	so	so	CS21
304953	100736417	20992765541	that	that	CS22
304953	100736417	20992765542	future	future	JJ
304953	100736417	20992765543	studies	study	NN2
304953	100736417	20992765544	can	can	VM
304953	100736417	20992765545	avoid	avoid	VVI
304953	100736417	20992765546	these	these	DD2
304953	100736417	20992765547	problems	problem	NN2
304953	100736417	20992765548	.	.	.
304953	100736417	20992765549	<p>		NULL
304953	100736417	20992765550	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992765551	:	:	:
304953	100736417	20992765552	I	i	PPIS1
304953	100736417	20992765553	agree	agree	VV0
304953	100736417	20992765554	.	.	.
304953	100736417	20992765555	And	and	CC
304953	100736417	20992765556	just	just	RR
304953	100736417	20992765557	one	one	MC1
304953	100736417	20992765558	further	far	JJR@
304953	100736417	20992765559	point	point	NN1
304953	100736417	20992765560	is	be	VBZ
304953	100736417	20992765561	that	that	CST_DD1
304953	100736417	20992765562	for	for	IF
304953	100736417	20992765563	prostate	prostate	NN1
304953	100736417	20992765564	@		II
304953	100736417	20992765565	@		II
304953	100736417	20992765566	@		II
304953	100736417	20992765567	@		II
304953	100736417	20992765568	@		II
304953	100736417	20992765569	@		II
304953	100736417	20992765570	@		II
304953	100736417	20992765571	@		II
304953	100736417	20992765572	@		II
304953	100736417	20992765573	@		II
304953	100736417	20992765574	good	good	JJ
304953	100736417	20992765575	prognosis	prognosis	NN1
304953	100736417	20992765576	,	,	,
304953	100736417	20992765577	such	such	II21
304953	100736417	20992765578	as	as	II22
304953	100736417	20992765579	localized	localized	JJ
304953	100736417	20992765580	cancer	cancer	NN1
304953	100736417	20992765581	,	,	,
304953	100736417	20992765582	its	its	APPGE
304953	100736417	20992765583	much	much	RR
304953	100736417	20992765584	more	more	RGR
304953	100736417	20992765585	likely	likely	JJ
304953	100736417	20992765586	that	that	CST
304953	100736417	20992765587	a	a	AT1
304953	100736417	20992765588	man	man	NN1
304953	100736417	20992765589	will	will	VM
304953	100736417	20992765590	die	die	VVI
304953	100736417	20992765591	of	of	IO
304953	100736417	20992765592	something	something	PN1
304953	100736417	20992765593	else	else	RR
304953	100736417	20992765594	,	,	,
304953	100736417	20992765595	possibly	possibly	RR
304953	100736417	20992765596	heart	heart	NN1
304953	100736417	20992765597	disease	disease	NN1
304953	100736417	20992765598	,	,	,
304953	100736417	20992765599	before	before	CS
304953	100736417	20992765600	he	he	PPHS1
304953	100736417	20992765601	dies	die	VVZ
304953	100736417	20992765602	of	of	IO
304953	100736417	20992765603	prostate	prostate	NN1
304953	100736417	20992765604	cancer	cancer	NN1
304953	100736417	20992765605	.	.	.
304953	100736417	20992765606	So	so	RR
304953	100736417	20992765607	I	i	PPIS1
304953	100736417	20992765608	think	think	VV0
304953	100736417	20992765609	that	that	CST
304953	100736417	20992765610	its	its	APPGE
304953	100736417	20992765611	probably	probably	RR
304953	100736417	20992765612	worth	worth	II
304953	100736417	20992765613	putting	put	VVG
304953	100736417	20992765614	more	more	DAR
304953	100736417	20992765615	energy	energy	NN1
304953	100736417	20992765616	into	into	II
304953	100736417	20992765617	the	the	AT
304953	100736417	20992765618	basics	basics	NN2
304953	100736417	20992765619	,	,	,
304953	100736417	20992765620	such	such	II21
304953	100736417	20992765621	as	as	II22
304953	100736417	20992765622	diet	diet	NN1
304953	100736417	20992765623	and	and	CC
304953	100736417	20992765624	lifestyle	lifestyle	NN1
304953	100736417	20992765625	,	,	,
304953	100736417	20992765626	to	to	TO
304953	100736417	20992765627	prevent	prevent	VVI
304953	100736417	20992765628	conditions	condition	NN2
304953	100736417	20992765629	like	like	II
304953	100736417	20992765630	heart	heart	NN1
304953	100736417	20992765631	disease	disease	NN1
304953	100736417	20992765632	.	.	.
304953	100736417	20992765633	<p>		NULL
304953	100736417	20992765634	What	what	DDQ
304953	100736417	20992765635	is	be	VBZ
304953	100736417	20992765636	the	the	AT
304953	100736417	20992765637	current	current	JJ
304953	100736417	20992765638	thinking	thinking	NN1
304953	100736417	20992765639	about	about	II
304953	100736417	20992765640	lycopene	lycopene	NN1
304953	100736417	20992765641	,	,	,
304953	100736417	20992765642	which	which	DDQ
304953	100736417	20992765643	has	have	VHZ
304953	100736417	20992765644	certainly	certainly	RR
304953	100736417	20992765645	received	receive	VVN
304953	100736417	20992765646	a	a	AT1
304953	100736417	20992765647	lot	lot	NN1
304953	100736417	20992765648	of	of	IO
304953	100736417	20992765649	attention	attention	NN1
304953	100736417	20992765650	in	in	II
304953	100736417	20992765651	the	the	AT
304953	100736417	20992765652	press	press	NN1
304953	100736417	20992765653	?	?	?
304953	100736417	20992765654	<p>		NULL
304953	100736417	20992765655	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992765656	:	:	:
304953	100736417	20992765657	The	the	AT
304953	100736417	20992765658	evidence	evidence	NN1
304953	100736417	20992765659	is	be	VBZ
304953	100736417	20992765660	still	still	RR
304953	100736417	20992765661	mainly	mainly	RR
304953	100736417	20992765662	from	from	II
304953	100736417	20992765663	epidemiological	epidemiological	JJ
304953	100736417	20992765664	studies	study	NN2
304953	100736417	20992765665	,	,	,
304953	100736417	20992765666	so	so	CS@_RR
304953	100736417	20992765667	its	its	APPGE
304953	100736417	20992765668	suggestive	suggestive	JJ
304953	100736417	20992765669	,	,	,
304953	100736417	20992765670	not	not	XX
304953	100736417	20992765671	definitive	definitive	JJ
304953	100736417	20992765672	.	.	.
304953	100736417	20992765673	But	but	CCB
304953	100736417	20992765674	the	the	AT
304953	100736417	20992765675	important	important	JJ
304953	100736417	20992765676	point	point	NN1
304953	100736417	20992765677	is	be	VBZ
304953	100736417	20992765678	that	that	CST
304953	100736417	20992765679	even	even	CS21
304953	100736417	20992765680	if	if	CS22
304953	100736417	20992765681	you	you	PPY
304953	100736417	20992765682	go	go	VV0
304953	100736417	20992765683	by	by	II
304953	100736417	20992765684	the	the	AT
304953	100736417	20992765685	epidemiologic	epidemiologic	JJ
304953	100736417	20992765686	evidence	evidence	NN1
304953	100736417	20992765687	,	,	,
304953	100736417	20992765688	the	the	AT
304953	100736417	20992765689	benefits	benefit	NN2
304953	100736417	20992765690	are	be	VBR
304953	100736417	20992765691	really	really	RR
304953	100736417	20992765692	based	base	VVN
304953	100736417	20992765693	on	on	II
304953	100736417	20992765694	tomato	tomato	NN1
304953	100736417	20992765695	consumption	consumption	NN1
304953	100736417	20992765696	,	,	,
304953	100736417	20992765697	and	and	CC
304953	100736417	20992765698	tomatoes	tomato	NN2
304953	100736417	20992765699	contain	contain	VV0
304953	100736417	20992765700	many	many	DA2
304953	100736417	20992765701	nutrients	nutrient	NN2
304953	100736417	20992765702	besides	besides	II
304953	100736417	20992765703	lycopene	lycopene	NN1
304953	100736417	20992765704	.	.	.
304953	100736417	20992765705	So	so	RR
304953	100736417	20992765706	I	i	PPIS1
304953	100736417	20992765707	would	would	VM
304953	100736417	20992765708	probably	probably	RR
304953	100736417	20992765709	recommend	recommend	VVI
304953	100736417	20992765710	slightly	slightly	RR
304953	100736417	20992765711	or	or	CC
304953	100736417	20992765712	somewhat	somewhat	RR
304953	100736417	20992765713	increasing	increasing	JJ_VVG
304953	100736417	20992765714	consumption	consumption	NN1
304953	100736417	20992765715	of	of	IO
304953	100736417	20992765716	tomatoes	tomato	NN2
304953	100736417	20992765717	or	or	CC
304953	100736417	20992765718	tomato	tomato	NN1
304953	100736417	20992765719	products	product	NN2
304953	100736417	20992765720	,	,	,
304953	100736417	20992765721	such	such	II21
304953	100736417	20992765722	as	as	II22
304953	100736417	20992765723	tomato	tomato	NN1
304953	100736417	20992765724	sauce	sauce	NN1
304953	100736417	20992765725	.	.	.
304953	100736417	20992765726	<p>		NULL
304953	100736417	20992765727	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992765728	:	:	:
304953	100736417	20992765729	The	the	AT
304953	100736417	20992765730	epidemiologic	epidemiologic	JJ
304953	100736417	20992765731	data	data	NN
304953	100736417	20992765732	provide	provide	VV0
304953	100736417	20992765733	good	good	JJ
304953	100736417	20992765734	evidence	evidence	NN1
304953	100736417	20992765735	that	that	CST_DD1
304953	100736417	20992765736	cooked	cooked	JJ_VVD
304953	100736417	20992765737	tomatoes	tomato	NN2
304953	100736417	20992765738	enhance	enhance	VV0
304953	100736417	20992765739	absorption	absorption	NN1
304953	100736417	20992765740	of	of	IO
304953	100736417	20992765741	lycopene	lycopene	NN1
304953	100736417	20992765742	.	.	.
304953	100736417	20992765743	There 's		NN2_NP1@
304953	100736417	20992765744	also	also	RR
304953	100736417	20992765745	evidence	evidence	NN1
304953	100736417	20992765746	that	that	CST_DD1
304953	100736417	20992765747	oil	oil	NN1
304953	100736417	20992765748	enhances	enhance	VVZ
304953	100736417	20992765749	absorption	absorption	NN1
304953	100736417	20992765750	of	of	IO
304953	100736417	20992765751	lycopene	lycopene	NN1
304953	100736417	20992765752	but	but	CCB
304953	100736417	20992765753	that	that	DD1
304953	100736417	20992765754	does	do	VDZ
304953	100736417	20992765755	n't 	n't	XX
304953	100736417	20992765756	mean	mean	VVI
304953	100736417	20992765757	people	people	NN
304953	100736417	20992765758	should	should	VM
304953	100736417	20992765759	eat	eat	VVI
304953	100736417	20992765760	fatty	fatty	JJ_NN1
304953	100736417	20992765761	pizza	pizza	NN1
304953	100736417	20992765762	.	.	.
304953	100736417	20992765763	You	you	PPY
304953	100736417	20992765764	@		II
304953	100736417	20992765765	@		II
304953	100736417	20992765766	@		II
304953	100736417	20992765767	@		II
304953	100736417	20992765768	@		II
304953	100736417	20992765769	@		II
304953	100736417	20992765770	@		II
304953	100736417	20992765771	@		II
304953	100736417	20992765772	@		II
304953	100736417	20992765773	@		II
304953	100736417	20992765774	:	:	:
304953	100736417	20992765775	I 've		NP1
304953	100736417	20992765776	found	find	VVD
304953	100736417	20992765777	that	that	CST
304953	100736417	20992765778	when	when	CS
304953	100736417	20992765779	I	i	PPIS1
304953	100736417	20992765780	tell	tell	VV0
304953	100736417	20992765781	patients	patient	NN2
304953	100736417	20992765782	to	to	TO
304953	100736417	20992765783	eat	eat	VVI
304953	100736417	20992765784	more	more	DAR
304953	100736417	20992765785	tomatoes	tomato	NN2
304953	100736417	20992765786	,	,	,
304953	100736417	20992765787	they 're		NN1
304953	100736417	20992765788	not	not	XX
304953	100736417	20992765789	impressed	impress	VVN
304953	100736417	20992765790	.	.	.
304953	100736417	20992765791	But	but	CCB
304953	100736417	20992765792	if	if	CS
304953	100736417	20992765793	someone	someone	PN1
304953	100736417	20992765794	else	else	RR
304953	100736417	20992765795	tells	tell	VVZ
304953	100736417	20992765796	them	them	PPHO2
304953	100736417	20992765797	to	to	TO
304953	100736417	20992765798	go	go	VVI
304953	100736417	20992765799	to	to	II
304953	100736417	20992765800	the	the	AT
304953	100736417	20992765801	health	health	NN1
304953	100736417	20992765802	food	food	NN1
304953	100736417	20992765803	store	store	NN1
304953	100736417	20992765804	and	and	CC
304953	100736417	20992765805	buy	buy	VV0
304953	100736417	20992765806	some	some	DD
304953	100736417	20992765807	lycopene	lycopene	NN1
304953	100736417	20992765808	pills	pill	NN2
304953	100736417	20992765809	,	,	,
304953	100736417	20992765810	they	they	PPHS2
304953	100736417	20992765811	dash	dash	VV0
304953	100736417	20992765812	right	right	RR_NN1
304953	100736417	20992765813	over	over	RP
304953	100736417	20992765814	.	.	.
304953	100736417	20992765815	And	and	CC
304953	100736417	20992765816	the	the	AT
304953	100736417	20992765817	data	data	NN
304953	100736417	20992765818	suggest	suggest	VV0
304953	100736417	20992765819	that	that	DD1_CST
304953	100736417	20992765820	eating	eating	NN1_VVG
304953	100736417	20992765821	tomatoes	tomato	NN2
304953	100736417	20992765822	can	can	VM
304953	100736417	20992765823	help	help	VVI
304953	100736417	20992765824	reduce	reduce	VVI
304953	100736417	20992765825	risk	risk	NN1
304953	100736417	20992765826	of	of	IO
304953	100736417	20992765827	prostate	prostate	NN1
304953	100736417	20992765828	cancer	cancer	NN1
304953	100736417	20992765829	,	,	,
304953	100736417	20992765830	but	but	CCB
304953	100736417	20992765831	the	the	AT
304953	100736417	20992765832	evidence	evidence	NN1
304953	100736417	20992765833	is	be	VBZ
304953	100736417	20992765834	not	not	XX
304953	100736417	20992765835	there	there	RL
304953	100736417	20992765836	for	for	IF
304953	100736417	20992765837	lycopene	lycopene	NN1
304953	100736417	20992765838	supplements	supplement	NN2
304953	100736417	20992765839	.	.	.
304953	100736417	20992765840	<p>		NULL
304953	100736417	20992765841	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992765842	:	:	:
304953	100736417	20992765843	Another	another	DD1
304953	100736417	20992765844	problem	problem	NN1
304953	100736417	20992765845	is	be	VBZ
304953	100736417	20992765846	that	that	CST
304953	100736417	20992765847	we	we	PPIS2
304953	100736417	20992765848	have	have	VH0
304953	100736417	20992765849	no	no	AT
304953	100736417	20992765850	idea	idea	NN1
304953	100736417	20992765851	how	how	RGQ@_RRQ
304953	100736417	20992765852	much	much	DA1
304953	100736417	20992765853	of	of	IO
304953	100736417	20992765854	the	the	AT
304953	100736417	20992765855	lycopene	lycopene	NN1
304953	100736417	20992765856	contained	contain	VVN_VVD
304953	100736417	20992765857	in	in	II_RP@
304953	100736417	20992765858	a	a	AT1
304953	100736417	20992765859	supplement	supplement	NN1
304953	100736417	20992765860	is	be	VBZ
304953	100736417	20992765861	absorbed	absorb	VVN
304953	100736417	20992765862	by	by	II
304953	100736417	20992765863	the	the	AT
304953	100736417	20992765864	body	body	NN1
304953	100736417	20992765865	.	.	.
304953	100736417	20992765866	<p>		NULL
304953	100736417	20992765867	ROSENTHAL	rosenthal	NP1
304953	100736417	20992765868	:	:	:
304953	100736417	20992765869	We	we	PPIS2
304953	100736417	20992765870	advise	advise	VV0
304953	100736417	20992765871	patients	patient	NN2
304953	100736417	20992765872	that	that	CST_DD1
304953	100736417	20992765873	,	,	,
304953	100736417	20992765874	because	because	II21
304953	100736417	20992765875	of	of	II22
304953	100736417	20992765876	the	the	AT
304953	100736417	20992765877	unknown	unknown	JJ
304953	100736417	20992765878	nature	nature	NN1
304953	100736417	20992765879	of	of	IO
304953	100736417	20992765880	over-the-counter	over-the-counter	JJ_NN1
304953	100736417	20992765881	supplements	supplement	NN2
304953	100736417	20992765882	,	,	,
304953	100736417	20992765883	the	the	AT
304953	100736417	20992765884	best	best	JJT
304953	100736417	20992765885	way	way	NN1
304953	100736417	20992765886	to	to	TO
304953	100736417	20992765887	get	get	VVI
304953	100736417	20992765888	all	all	DB
304953	100736417	20992765889	of	of	IO
304953	100736417	20992765890	the	the	AT
304953	100736417	20992765891	vitamins	vitamin	NN2
304953	100736417	20992765892	and	and	CC
304953	100736417	20992765893	antioxidants	antioxidant	NN2
304953	100736417	20992765894	you	you	PPY
304953	100736417	20992765895	need	need	VV0
304953	100736417	20992765896	is	be	VBZ
304953	100736417	20992765897	to	to	TO
304953	100736417	20992765898	eat	eat	VVI
304953	100736417	20992765899	healthy	healthy	JJ
304953	100736417	20992765900	foods	food	NN2
304953	100736417	20992765901	.	.	.
304953	100736417	20992765902	<p>		NULL
304953	100736417	20992765903	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992765904	:	:	:
304953	100736417	20992765905	I	i	PPIS1
304953	100736417	20992765906	think	think	VV0
304953	100736417	20992765907	that	that	CST_DD1
304953	100736417	20992765908	definitely	definitely	RR
304953	100736417	20992765909	makes	make	VVZ
304953	100736417	20992765910	sense	sense	NN1
304953	100736417	20992765911	because	because	CS
304953	100736417	20992765912	lycopene	lycopene	NN1
304953	100736417	20992765913	is	be	VBZ
304953	100736417	20992765914	not	not	XX
304953	100736417	20992765915	the	the	AT
304953	100736417	20992765916	only	only	JJ
304953	100736417	20992765917	dietary		NN1
304953	100736417	20992765918	factor	factor	NN1
304953	100736417	20992765919	to	to	TO
304953	100736417	20992765920	think	think	VVI
304953	100736417	20992765921	about	about	II
304953	100736417	20992765922	.	.	.
304953	100736417	20992765923	Studies	study	NN2
304953	100736417	20992765924	show	show	VV0
304953	100736417	20992765925	that	that	CST
304953	100736417	20992765926	you	you	PPY
304953	100736417	20992765927	may	may	VM
304953	100736417	20992765928	also	also	RR
304953	100736417	20992765929	be	be	VBI
304953	100736417	20992765930	able	able	JK
304953	100736417	20992765931	to	to	TO
304953	100736417	20992765932	reduce	reduce	VVI
304953	100736417	20992765933	your	your	APPGE
304953	100736417	20992765934	risk	risk	NN1
304953	100736417	20992765935	of	of	IO
304953	100736417	20992765936	prostate	prostate	NN1
304953	100736417	20992765937	cancer	cancer	NN1
304953	100736417	20992765938	by	by	II
304953	100736417	20992765939	eating	eat	VVG
304953	100736417	20992765940	more	more	RGR_DAR
304953	100736417	20992765941	fatty	fatty	JJ
304953	100736417	20992765942	fish	fish	NN
304953	100736417	20992765943	,	,	,
304953	100736417	20992765944	which	which	DDQ
304953	100736417	20992765945	are	be	VBR
304953	100736417	20992765946	full	full	JJ
304953	100736417	20992765947	of	of	IO
304953	100736417	20992765948	omega-3	omega-3	MC
304953	100736417	20992765949	fatty	fatty	JJ
304953	100736417	20992765950	acids	acid	NN2
304953	100736417	20992765951	and	and	CC
304953	100736417	20992765952	also	also	RR
304953	100736417	20992765953	contain	contain	VV0
304953	100736417	20992765954	vitamin	vitamin	NN1
304953	100736417	20992765955	D.		NP1
304953	100736417	20992765956	Theres		NP1_NN2
304953	100736417	20992765957	also	also	RR
304953	100736417	20992765958	some	some	DD
304953	100736417	20992765959	evidence	evidence	NN1
304953	100736417	20992765960	that	that	CST_DD1
304953	100736417	20992765961	cruciferous	cruciferous	JJ
304953	100736417	20992765962	vegetables	vegetable	NN2
304953	100736417	20992765963	,	,	,
304953	100736417	20992765964	@		II
304953	100736417	20992765965	@		II
304953	100736417	20992765966	@		II
304953	100736417	20992765967	@		II
304953	100736417	20992765968	@		II
304953	100736417	20992765969	@		II
304953	100736417	20992765970	@		II
304953	100736417	20992765971	@		II
304953	100736417	20992765972	@		II
304953	100736417	20992765973	@		II
304953	100736417	20992765974	<p>		NULL
304953	100736417	20992765975	SIMON	simon	NP1
304953	100736417	20992765976	:	:	:
304953	100736417	20992765977	Whole	whole	JJ
304953	100736417	20992765978	grains	grain	NN2
304953	100736417	20992765979	have	have	VH0
304953	100736417	20992765980	also	also	RR
304953	100736417	20992765981	shown	show	VVN
304953	100736417	20992765982	some	some	DD
304953	100736417	20992765983	potential	potential	JJ_NN1
304953	100736417	20992765984	benefit	benefit	NN1
304953	100736417	20992765985	for	for	IF
304953	100736417	20992765986	preventing	prevent	VVG
304953	100736417	20992765987	prostate	prostate	NN1
304953	100736417	20992765988	cancer	cancer	NN1
304953	100736417	20992765989	,	,	,
304953	100736417	20992765990	perhaps	perhaps	RR
304953	100736417	20992765991	because	because	CS
304953	100736417	20992765992	they	they	PPHS2
304953	100736417	20992765993	contain	contain	VV0
304953	100736417	20992765994	selenium	selenium	NN1
304953	100736417	20992765995	.	.	.
304953	100736417	20992765996	But	but	CCB
304953	100736417	20992765997	we	we	PPIS2
304953	100736417	20992765998	do	do	VD0
304953	100736417	20992765999	n't 	n't	XX
304953	100736417	20992766000	know	know	VVI
304953	100736417	20992766001	for	for	RR21
304953	100736417	20992766002	sure	sure	RR22
304953	100736417	20992766003	.	.	.
304953	100736417	20992766004	<p>		NULL
304953	100736417	20992766005	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992766006	:	:	:
304953	100736417	20992766007	Right	right	RR_NN1_JJ
304953	100736417	20992766008	.	.	.
304953	100736417	20992766009	And	and	CC
304953	100736417	20992766010	if	if	CS_CSW@
304953	100736417	20992766011	patients	patient	NN2
304953	100736417	20992766012	want	want	VV0
304953	100736417	20992766013	to	to	TO
304953	100736417	20992766014	take	take	VVI
304953	100736417	20992766015	selenium	selenium	NN1
304953	100736417	20992766016	supplements	supplement	NN2
304953	100736417	20992766017	,	,	,
304953	100736417	20992766018	its	its	APPGE
304953	100736417	20992766019	important	important	JJ
304953	100736417	20992766020	not	not	XX
304953	100736417	20992766021	to	to	TO
304953	100736417	20992766022	overdo	overdo	VVI
304953	100736417	20992766023	it	it	PPH1
304953	100736417	20992766024	.	.	.
304953	100736417	20992766025	<p>		NULL
304953	100736417	20992766026	SIMON	simon	NP1
304953	100736417	20992766027	:	:	:
304953	100736417	20992766028	Taking	take	VVG
304953	100736417	20992766029	a	a	AT1
304953	100736417	20992766030	daily	daily	JJ
304953	100736417	20992766031	multivitamin	multivitamin	NN1
304953	100736417	20992766032	is	be	VBZ
304953	100736417	20992766033	probably	probably	RR
304953	100736417	20992766034	good	good	JJ
304953	100736417	20992766035	insurance	insurance	NN1
304953	100736417	20992766036	for	for	IF
304953	100736417	20992766037	all	all	DB
304953	100736417	20992766038	men	man	NN2
304953	100736417	20992766039	.	.	.
304953	100736417	20992766040	For	for	RR41
304953	100736417	20992766041	the	the	RR42
304953	100736417	20992766042	most	most	RR43
304953	100736417	20992766043	part	part	RR44
304953	100736417	20992766044	,	,	,
304953	100736417	20992766045	its	its	APPGE
304953	100736417	20992766046	a	a	AT1
304953	100736417	20992766047	way	way	NN1
304953	100736417	20992766048	to	to	TO
304953	100736417	20992766049	ensure	ensure	VVI
304953	100736417	20992766050	that	that	CST
304953	100736417	20992766051	you	you	PPY
304953	100736417	20992766052	get	get	VV0
304953	100736417	20992766053	adequate	adequate	JJ
304953	100736417	20992766054	daily	daily	JJ
304953	100736417	20992766055	requirements	requirement	NN2
304953	100736417	20992766056	of	of	IO
304953	100736417	20992766057	vitamins	vitamin	NN2
304953	100736417	20992766058	without	without	IW
304953	100736417	20992766059	overdoing	overdo	VVG
304953	100736417	20992766060	it	it	PPH1
304953	100736417	20992766061	.	.	.
304953	100736417	20992766062	But	but	CCB
304953	100736417	20992766063	there	there	EX
304953	100736417	20992766064	are	be	VBR
304953	100736417	20992766065	three	three	MC
304953	100736417	20992766066	possible	possible	JJ
304953	100736417	20992766067	exceptions	exception	NN2
304953	100736417	20992766068	to	to	TO
304953	100736417	20992766069	be	be	VBI
304953	100736417	20992766070	aware	aware	JJ
304953	100736417	20992766071	of	of	IO
304953	100736417	20992766072	.	.	.
304953	100736417	20992766073	The	the	AT
304953	100736417	20992766074	first	first	MD
304953	100736417	20992766075	is	be	VBZ
304953	100736417	20992766076	selenium	selenium	NN1
304953	100736417	20992766077	,	,	,
304953	100736417	20992766078	since	since	CS
304953	100736417	20992766079	most	most	DAT
304953	100736417	20992766080	multivitamins	multivitamin	NN2
304953	100736417	20992766081	contain	contain	VV0
304953	100736417	20992766082	less	less	DAR_RRR
304953	100736417	20992766083	than	than	CSN
304953	100736417	20992766084	the	the	AT
304953	100736417	20992766085	200	200	MC
304953	100736417	20992766086	mcg	mcg	NNU
304953	100736417	20992766087	that	that	DD1
304953	100736417	20992766088	appears	appear	VVZ
304953	100736417	20992766089	protective	protective	JJ
304953	100736417	20992766090	in	in	II
304953	100736417	20992766091	the	the	AT
304953	100736417	20992766092	Nutritional	nutritional	JJ
304953	100736417	20992766093	Prevention	prevention	NN1
304953	100736417	20992766094	of	of	IO
304953	100736417	20992766095	Cancer	cancer	NN1
304953	100736417	20992766096	Trial	trial	NN1
304953	100736417	20992766097	see	see	VV0
304953	100736417	20992766098	"	"	"
304953	100736417	20992766099	What	what	DDQ
304953	100736417	20992766100	may	may	VM
304953	100736417	20992766101	work	work	VVI
304953	100736417	20992766102	for	for	IF
304953	100736417	20992766103	prostate	prostate	NN1
304953	100736417	20992766104	cancer	cancer	NN1
304953	100736417	20992766105	"	"	"
304953	100736417	20992766106	.	.	.
304953	100736417	20992766107	Second	second	MD
304953	100736417	20992766108	,	,	,
304953	100736417	20992766109	most	most	DAT
304953	100736417	20992766110	multivitamins	multivitamin	NN2
304953	100736417	20992766111	contain	contain	VV0
304953	100736417	20992766112	400	400	MC
304953	100736417	20992766113	IU	iu	NP1
304953	100736417	20992766114	of	of	IO
304953	100736417	20992766115	vitamin	vitamin	NN1
304953	100736417	20992766116	D	d	ZZ1
304953	100736417	20992766117	,	,	,
304953	100736417	20992766118	but	but	CCB
304953	100736417	20992766119	many	many	DA2
304953	100736417	20992766120	experts	expert	NN2
304953	100736417	20992766121	now	now	RT
304953	100736417	20992766122	recommend	recommend	VV0
304953	100736417	20992766123	600800		MC
304953	100736417	20992766124	IU	iu	NP1
304953	100736417	20992766125	a	a	AT1
304953	100736417	20992766126	day	day	NNT1
304953	100736417	20992766127	.	.	.
304953	100736417	20992766128	Finally	finally	RR
304953	100736417	20992766129	,	,	,
304953	100736417	20992766130	multivitamins	multivitamin	NN2
304953	100736417	20992766131	do	do	VD0
304953	100736417	20992766132	n't 	n't	XX
304953	100736417	20992766133	contain	contain	VVI
304953	100736417	20992766134	any	any	DD
304953	100736417	20992766135	fish	fish	NN
304953	100736417	20992766136	oil	oil	NN1
304953	100736417	20992766137	,	,	,
304953	100736417	20992766138	but	but	CCB
304953	100736417	20992766139	men	man	NN2
304953	100736417	20992766140	with	with	IW
304953	100736417	20992766141	coronary	coronary	JJ
304953	100736417	20992766142	artery	artery	NN1
304953	100736417	20992766143	disease	disease	NN1
304953	100736417	20992766144	,	,	,
304953	100736417	20992766145	or	or	CC
304953	100736417	20992766146	with	with	IW
304953	100736417	20992766147	major	major	JJ
304953	100736417	20992766148	risk	risk	NN1
304953	100736417	20992766149	factors	factor	NN2
304953	100736417	20992766150	for	for	IF
304953	100736417	20992766151	heart	heart	NN1
304953	100736417	20992766152	disease	disease	NN1
304953	100736417	20992766153	,	,	,
304953	100736417	20992766154	may	may	VM
304953	100736417	20992766155	benefit	benefit	VVI
304953	100736417	20992766156	from	from	II
304953	100736417	20992766157	1,000	1,000	MC
304953	100736417	20992766158	mg	mg	NNU
304953	100736417	20992766159	of	of	IO
304953	100736417	20992766160	omega-3	omega-3	MC
304953	100736417	20992766161	fatty	fatty	JJ
304953	100736417	20992766162	acids	acid	NN2
304953	100736417	20992766163	a	a	AT1
304953	100736417	20992766164	@		II
304953	100736417	20992766165	@		II
304953	100736417	20992766166	@		II
304953	100736417	20992766167	@		II
304953	100736417	20992766168	@		II
304953	100736417	20992766169	@		II
304953	100736417	20992766170	@		II
304953	100736417	20992766171	@		II
304953	100736417	20992766172	@		II
304953	100736417	20992766173	@		II
304953	100736417	20992766174	if	if	CS
304953	100736417	20992766175	they	they	PPHS2
304953	100736417	20992766176	do	do	VD0
304953	100736417	20992766177	n't 	n't	XX
304953	100736417	20992766178	get	get	VVI
304953	100736417	20992766179	that	that	DD1
304953	100736417	20992766180	amount	amount	NN1
304953	100736417	20992766181	in	in	II
304953	100736417	20992766182	their	their	APPGE
304953	100736417	20992766183	diet	diet	NN1
304953	100736417	20992766184	.	.	.
304953	100736417	20992766185	<p>		NULL
304953	100736417	20992766186	ROSENTHAL	rosenthal	NP1
304953	100736417	20992766187	:	:	:
304953	100736417	20992766188	I	i	PPIS1
304953	100736417	20992766189	think	think	VV0
304953	100736417	20992766190	another	another	DD1
304953	100736417	20992766191	important	important	JJ
304953	100736417	20992766192	piece	piece	NN1
304953	100736417	20992766193	of	of	IO
304953	100736417	20992766194	advice	advice	NN1
304953	100736417	20992766195	for	for	IF
304953	100736417	20992766196	patients	patient	NN2
304953	100736417	20992766197	is	be	VBZ
304953	100736417	20992766198	that	that	CST
304953	100736417	20992766199	they	they	PPHS2
304953	100736417	20992766200	should	should	VM
304953	100736417	20992766201	not	not	XX
304953	100736417	20992766202	go	go	VVI
304953	100736417	20992766203	on	on	II_RP@
304953	100736417	20992766204	a	a	AT1
304953	100736417	20992766205	diet	diet	NN1
304953	100736417	20992766206	while	while	CS
304953	100736417	20992766207	undergoing	undergo	VVG
304953	100736417	20992766208	treatment	treatment	NN1
304953	100736417	20992766209	for	for	IF
304953	100736417	20992766210	cancer	cancer	NN1
304953	100736417	20992766211	.	.	.
304953	100736417	20992766212	Its	its	APPGE
304953	100736417	20992766213	not	not	XX
304953	100736417	20992766214	healthy	healthy	JJ
304953	100736417	20992766215	to	to	TO
304953	100736417	20992766216	lose	lose	VVI
304953	100736417	20992766217	significant	significant	JJ
304953	100736417	20992766218	amounts	amount	NN2
304953	100736417	20992766219	of	of	IO
304953	100736417	20992766220	weight	weight	NN1
304953	100736417	20992766221	,	,	,
304953	100736417	20992766222	which	which	DDQ
304953	100736417	20992766223	a	a	AT1
304953	100736417	20992766224	lot	lot	NN1
304953	100736417	20992766225	of	of	IO
304953	100736417	20992766226	fad	fad	NN1
304953	100736417	20992766227	diets	diet	NN2
304953	100736417	20992766228	will	will	VM
304953	100736417	20992766229	cause	cause	VVI
304953	100736417	20992766230	.	.	.
304953	100736417	20992766231	<p>		NULL
304953	100736417	20992766232	SIMON	simon	NP1
304953	100736417	20992766233	:	:	:
304953	100736417	20992766234	Although	although	CS
304953	100736417	20992766235	if	if	CS
304953	100736417	20992766236	someone	someone	PN1
304953	100736417	20992766237	is	be	VBZ
304953	100736417	20992766238	obese	obese	JJ
304953	100736417	20992766239	and	and	CC
304953	100736417	20992766240	has	have	VHZ
304953	100736417	20992766241	prostate	prostate	NN1
304953	100736417	20992766242	cancer	cancer	NN1
304953	100736417	20992766243	,	,	,
304953	100736417	20992766244	it	it	PPH1
304953	100736417	20992766245	might	might	VM
304953	100736417	20992766246	be	be	VBI
304953	100736417	20992766247	a	a	AT1
304953	100736417	20992766248	good	good	JJ
304953	100736417	20992766249	idea	idea	NN1
304953	100736417	20992766250	to	to	TO
304953	100736417	20992766251	she 'd		VVI
304953	100736417	20992766252	some	some	DD
304953	100736417	20992766253	body	body	NN1
304953	100736417	20992766254	weight	weight	NN1
304953	100736417	20992766255	.	.	.
304953	100736417	20992766256	<p>		NULL
304953	100736417	20992766257	ROSENTHAL	rosenthal	NP1
304953	100736417	20992766258	:	:	:
304953	100736417	20992766259	Thats		NP1_VVZ_NN2
304953	100736417	20992766260	true	true	JJ
304953	100736417	20992766261	,	,	,
304953	100736417	20992766262	but	but	CCB
304953	100736417	20992766263	once	once	RR_CS@
304953	100736417	20992766264	you 've		NN1_VV0
304953	100736417	20992766265	been	be	VBN
304953	100736417	20992766266	diagnosed	diagnose	VVN
304953	100736417	20992766267	with	with	IW
304953	100736417	20992766268	prostate	prostate	NN1
304953	100736417	20992766269	cancer	cancer	NN1
304953	100736417	20992766270	its	its	APPGE
304953	100736417	20992766271	important	important	JJ
304953	100736417	20992766272	not	not	XX
304953	100736417	20992766273	to	to	TO
304953	100736417	20992766274	go	go	VVI
304953	100736417	20992766275	on	on	II_RP@
304953	100736417	20992766276	a	a	AT1
304953	100736417	20992766277	crash	crash	NN1
304953	100736417	20992766278	diet	diet	NN1
304953	100736417	20992766279	,	,	,
304953	100736417	20992766280	but	but	CCB
304953	100736417	20992766281	instead	instead	RR
304953	100736417	20992766282	adopt	adopt	VV0
304953	100736417	20992766283	a	a	AT1
304953	100736417	20992766284	healthy	healthy	JJ
304953	100736417	20992766285	one	one	PN1
304953	100736417	20992766286	.	.	.
304953	100736417	20992766287	<p>		NULL
304953	100736417	20992766288	How	how	RRQ
304953	100736417	20992766289	should	should	VM
304953	100736417	20992766290	people	people	NN
304953	100736417	20992766291	react	react	VV0
304953	100736417	20992766292	when	when	RRQ_CS
304953	100736417	20992766293	they	they	PPHS2
304953	100736417	20992766294	read	read	VV0_VVD
304953	100736417	20992766295	about	about	II_RP@
304953	100736417	20992766296	something	something	PN1
304953	100736417	20992766297	new	new	JJ
304953	100736417	20992766298	in	in	II
304953	100736417	20992766299	the	the	AT
304953	100736417	20992766300	paper	paper	NN1
304953	100736417	20992766301	,	,	,
304953	100736417	20992766302	whether	whether	CSW
304953	100736417	20992766303	its	its	APPGE
304953	100736417	20992766304	about	about	II
304953	100736417	20992766305	pomegranate	pomegranate	NN1
304953	100736417	20992766306	juice	juice	NN1
304953	100736417	20992766307	or	or	CC
304953	100736417	20992766308	some	some	DD
304953	100736417	20992766309	new	new	JJ
304953	100736417	20992766310	herb	herb	NN1
304953	100736417	20992766311	or	or	CC
304953	100736417	20992766312	botanical	botanical	JJ
304953	100736417	20992766313	?	?	?
304953	100736417	20992766314	<p>		NULL
304953	100736417	20992766315	SIMON	simon	NP1
304953	100736417	20992766316	:	:	:
304953	100736417	20992766317	The	the	AT
304953	100736417	20992766318	answer	answer	NN1
304953	100736417	20992766319	is	be	VBZ
304953	100736417	20992766320	simple	simple	JJ
304953	100736417	20992766321	:	:	:
304953	100736417	20992766322	React	react	VV0
304953	100736417	20992766323	with	with	IW
304953	100736417	20992766324	caution	caution	NN1
304953	100736417	20992766325	.	.	.
304953	100736417	20992766326	As	as	CSA
304953	100736417	20992766327	physicians	physician	NN2
304953	100736417	20992766328	,	,	,
304953	100736417	20992766329	I	i	PPIS1
304953	100736417	20992766330	think	think	VV0
304953	100736417	20992766331	we	we	PPIS2
304953	100736417	20992766332	first	first	MD
304953	100736417	20992766333	have	have	VH0
304953	100736417	20992766334	to	to	TO
304953	100736417	20992766335	point	point	VVI
304953	100736417	20992766336	out	out	RP
304953	100736417	20992766337	that	that	DD1_CST
304953	100736417	20992766338	medicine	medicine	NN1
304953	100736417	20992766339	is	be	VBZ
304953	100736417	20992766340	science	science	NN1
304953	100736417	20992766341	,	,	,
304953	100736417	20992766342	that	that	CST
304953	100736417	20992766343	therapies	therapy	NN2
304953	100736417	20992766344	can	can	VM
304953	100736417	20992766345	be	be	VBI
304953	100736417	20992766346	evaluated	evaluate	VVN
304953	100736417	20992766347	,	,	,
304953	100736417	20992766348	and	and	CC
304953	100736417	20992766349	that	that	CST
304953	100736417	20992766350	there	there	EX
304953	100736417	20992766351	are	be	VBR
304953	100736417	20992766352	big	big	JJ
304953	100736417	20992766353	bucks	buck	NN2
304953	100736417	20992766354	involved	involved	JJ
304953	100736417	20992766355	in	in	II
304953	100736417	20992766356	the	the	AT
304953	100736417	20992766357	selling	selling	NN1
304953	100736417	20992766358	of	of	IO
304953	100736417	20992766359	herbs	herb	NN2
304953	100736417	20992766360	and	and	CC
304953	100736417	20992766361	other	other	JJ
304953	100736417	20992766362	unregulated	unregulated	JJ
304953	100736417	20992766363	remedies	remedy	NN2
304953	100736417	20992766364	@		II
304953	100736417	20992766365	@		II
304953	100736417	20992766366	@		II
304953	100736417	20992766367	@		II
304953	100736417	20992766368	@		II
304953	100736417	20992766369	@		II
304953	100736417	20992766370	@		II
304953	100736417	20992766371	@		II
304953	100736417	20992766372	@		II
304953	100736417	20992766373	@		II
304953	100736417	20992766374	sounds	sound	VVZ
304953	100736417	20992766375	too	too	RG
304953	100736417	20992766376	good	good	JJ
304953	100736417	20992766377	to	to	TO
304953	100736417	20992766378	be	be	VBI
304953	100736417	20992766379	true	true	JJ
304953	100736417	20992766380	,	,	,
304953	100736417	20992766381	it	it	PPH1
304953	100736417	20992766382	is	be	VBZ
304953	100736417	20992766383	.	.	.
304953	100736417	20992766384	<p>		NULL
304953	100736417	20992766385	ROSENTHAL	rosenthal	NP1
304953	100736417	20992766386	:	:	:
304953	100736417	20992766387	I	i	PPIS1
304953	100736417	20992766388	think	think	VV0
304953	100736417	20992766389	that	that	CST
304953	100736417	20992766390	we	we	PPIS2
304953	100736417	20992766391	should	should	VM
304953	100736417	20992766392	obviously	obviously	RR
304953	100736417	20992766393	also	also	RR
304953	100736417	20992766394	advise	advise	VVI
304953	100736417	20992766395	people	people	NN
304953	100736417	20992766396	to	to	TO
304953	100736417	20992766397	be	be	VBI
304953	100736417	20992766398	skeptical	skeptical	JJ
304953	100736417	20992766399	of	of	IO
304953	100736417	20992766400	anything	anything	PN1
304953	100736417	20992766401	touted	tout	VVD_VVN
304953	100736417	20992766402	as	as	II
304953	100736417	20992766403	a	a	AT1
304953	100736417	20992766404	cure	cure	NN1
304953	100736417	20992766405	for	for	IF
304953	100736417	20992766406	cancer	cancer	NN1
304953	100736417	20992766407	.	.	.
304953	100736417	20992766408	And	and	CC
304953	100736417	20992766409	yet	yet	RR
304953	100736417	20992766410	there	there	EX
304953	100736417	20992766411	are	be	VBR
304953	100736417	20992766412	still	still	RR
304953	100736417	20992766413	some	some	DD
304953	100736417	20992766414	people	people	NN
304953	100736417	20992766415	out	out	RP
304953	100736417	20992766416	there	there	RL
304953	100736417	20992766417	who	who	PNQS
304953	100736417	20992766418	are	be	VBR
304953	100736417	20992766419	going	go	VVGK
304953	100736417	20992766420	to	to	TO
304953	100736417	20992766421	prey	prey	VVI
304953	100736417	20992766422	on	on	II_RP@
304953	100736417	20992766423	patients	patient	NN2
304953	100736417	20992766424	hope	hope	VV0
304953	100736417	20992766425	that	that	CST_DD1
304953	100736417	20992766426	something	something	PN1
304953	100736417	20992766427	is	be	VBZ
304953	100736417	20992766428	going	go	VVG
304953	100736417	20992766429	to	to	II
304953	100736417	20992766430	work	work	NN1
304953	100736417	20992766431	,	,	,
304953	100736417	20992766432	and	and	CC
304953	100736417	20992766433	encourage	encourage	VV0
304953	100736417	20992766434	them	them	PPHO2
304953	100736417	20992766435	to	to	TO
304953	100736417	20992766436	use	use	VVI
304953	100736417	20992766437	an	a	AT1
304953	100736417	20992766438	alternative	alternative	JJ_NN1
304953	100736417	20992766439	therapy	therapy	NN1
304953	100736417	20992766440	instead	instead	II21
304953	100736417	20992766441	of	of	II22
304953	100736417	20992766442	proven	proven	JJ
304953	100736417	20992766443	medical	medical	JJ
304953	100736417	20992766444	therapy	therapy	NN1
304953	100736417	20992766445	.	.	.
304953	100736417	20992766446	<p>		NULL
304953	100736417	20992766447	GIOVANNUCCI	giovannucci	NP1
304953	100736417	20992766448	:	:	:
304953	100736417	20992766449	Maybe	maybe	RR
304953	100736417	20992766450	people	people	NN
304953	100736417	20992766451	get	get	VV0
304953	100736417	20992766452	tired	tired	JJ
304953	100736417	20992766453	of	of	IO
304953	100736417	20992766454	hearing	hear	VVG
304953	100736417	20992766455	the	the	AT
304953	100736417	20992766456	same	same	DA
304953	100736417	20992766457	old	old	JJ
304953	100736417	20992766458	message	message	NN1
304953	100736417	20992766459	,	,	,
304953	100736417	20992766460	but	but	CCB
304953	100736417	20992766461	the	the	AT
304953	100736417	20992766462	fact	fact	NN1
304953	100736417	20992766463	is	be	VBZ
304953	100736417	20992766464	,	,	,
304953	100736417	20992766465	we	we	PPIS2
304953	100736417	20992766466	do	do	VD0
304953	100736417	20992766467	know	know	VVI
304953	100736417	20992766468	a	a	AT1_RR21@
304953	100736417	20992766469	lot	lot	NN1_RR22
304953	100736417	20992766470	about	about	II
304953	100736417	20992766471	prevention	prevention	NN1
304953	100736417	20992766472	of	of	IO
304953	100736417	20992766473	various	various	JJ
304953	100736417	20992766474	diseases	disease	NN2
304953	100736417	20992766475	,	,	,
304953	100736417	20992766476	and	and	CC
304953	100736417	20992766477	I	i	PPIS1
304953	100736417	20992766478	think	think	VV0
304953	100736417	20992766479	people	people	NN
304953	100736417	20992766480	get	get	VV0
304953	100736417	20992766481	distracted	distract	VVN
304953	100736417	20992766482	.	.	.
304953	100736417	20992766483	They	they	PPHS2
304953	100736417	20992766484	are	be	VBR
304953	100736417	20992766485	confronted	confront	VVN
304953	100736417	20992766486	every	every	AT1
304953	100736417	20992766487	day	day	NNT1
304953	100736417	20992766488	with	with	IW
304953	100736417	20992766489	news	news	NN1
304953	100736417	20992766490	about	about	II
304953	100736417	20992766491	something	something	PN1
304953	100736417	20992766492	that 's		VVZ
304953	100736417	20992766493	different	different	JJ
304953	100736417	20992766494	,	,	,
304953	100736417	20992766495	and	and	CC
304953	100736417	20992766496	may	may	VM
304953	100736417	20992766497	,	,	,
304953	100736417	20992766498	in	in	II
304953	100736417	20992766499	fact	fact	NN1
304953	100736417	20992766500	,	,	,
304953	100736417	20992766501	have	have	VH0
304953	100736417	20992766502	promise	promise	NN1
304953	100736417	20992766503	down	down	II
304953	100736417	20992766504	the	the	AT
304953	100736417	20992766505	road	road	NN1
304953	100736417	20992766506	.	.	.
304953	100736417	20992766507	But	but	CCB
304953	100736417	20992766508	even	even	CS21
304953	100736417	20992766509	if	if	CS22
304953	100736417	20992766510	it	it	PPH1
304953	100736417	20992766511	does	do	VDZ
304953	100736417	20992766512	,	,	,
304953	100736417	20992766513	its	its	APPGE
304953	100736417	20992766514	effect	effect	NN1
304953	100736417	20992766515	may	may	VM
304953	100736417	20992766516	be	be	VBI
304953	100736417	20992766517	relatively	relatively	RR
304953	100736417	20992766518	modest	modest	JJ
304953	100736417	20992766519	compared	compare	VVN
304953	100736417	20992766520	to	to	II
304953	100736417	20992766521	what	what	DDQ
304953	100736417	20992766522	we	we	PPIS2
304953	100736417	20992766523	know	know	VV0
304953	100736417	20992766524	is	be	VBZ
304953	100736417	20992766525	effective	effective	JJ
304953	100736417	20992766526	diet	diet	NN1
304953	100736417	20992766527	and	and	CC
304953	100736417	20992766528	physical	physical	JJ
304953	100736417	20992766529	activity	activity	NN1
304953	100736417	20992766530	.	.	.
304953	100736417	20992766531	<h>		NULL
304953	100736417	20992766532	Reliable	reliable	JJ
304953	100736417	20992766533	online	online	JJ
304953	100736417	20992766534	resources	resource	NN2
304953	100736417	20992766535	<p>		NULL
304953	100736417	20992766536	More	more	RRR_DAR_RGR
304953	100736417	20992766537	and	and	CC
304953	100736417	20992766538	more	more	DAR
304953	100736417	20992766539	men	man	NN2
304953	100736417	20992766540	with	with	IW
304953	100736417	20992766541	prostate	prostate	NN1
304953	100736417	20992766542	disease	disease	NN1
304953	100736417	20992766543	are	be	VBR
304953	100736417	20992766544	going	go	VVG
304953	100736417	20992766545	online	online	RR_JJ
304953	100736417	20992766546	to	to	TO
304953	100736417	20992766547	find	find	VVI
304953	100736417	20992766548	information	information	NN1
304953	100736417	20992766549	about	about	II
304953	100736417	20992766550	health	health	NN1
304953	100736417	20992766551	topics	topic	NN2
304953	100736417	20992766552	,	,	,
304953	100736417	20992766553	including	including	II_VVG@
304953	100736417	20992766554	complementary	complementary	JJ
304953	100736417	20992766555	therapies	therapy	NN2
304953	100736417	20992766556	.	.	.
304953	100736417	20992766557	Our	our	APPGE
304953	100736417	20992766558	Harvard	harvard	NP1
304953	100736417	20992766559	experts	expert	NN2
304953	100736417	20992766560	recommend	recommend	VV0
304953	100736417	20992766561	the	the	AT
304953	100736417	20992766562	following	following	JJ
304953	100736417	20992766563	Web	web	NN1
304953	100736417	20992766564	@		II
304953	100736417	20992766565	@		II
304953	100736417	20992766566	@		II
304953	100736417	20992766567	@		II
304953	100736417	20992766568	@		II
304953	100736417	20992766569	@		II
304953	100736417	20992766570	@		II
304953	100736417	20992766571	@		II
304953	100736417	20992766572	@		II
304953	100736417	20992766573	@		II
304953	100736417	20992766574	Cancer	cancer	NN1
304953	100736417	20992766575	Complementary	complementary	JJ
304953	100736417	20992766576	and	and	CC
304953	100736417	20992766577	Alternative	alternative	JJ_NN1
304953	100736417	20992766578	**26;361;TOOLONG		FU
304953	100736417	20992766579	<p>		NULL
304953	100736417	20992766580	Offers	offer	NN2
304953	100736417	20992766581	information	information	NN1
304953	100736417	20992766582	about	about	II
304953	100736417	20992766583	particular	particular	JJ
304953	100736417	20992766584	types	type	NN2
304953	100736417	20992766585	of	of	IO
304953	100736417	20992766586	cancer	cancer	NN1
304953	100736417	20992766587	as	as	II31
304953	100736417	20992766588	well	well	II32
304953	100736417	20992766589	as	as	II33
304953	100736417	20992766590	clinical	clinical	JJ
304953	100736417	20992766591	trials	trial	NN2
304953	100736417	20992766592	and	and	CC
304953	100736417	20992766593	research	research	NN1_VV0@
304953	100736417	20992766594	evaluating	evaluate	VVG
304953	100736417	20992766595	complementary	complementary	JJ
304953	100736417	20992766596	therapies	therapy	NN2
304953	100736417	20992766597	.	.	.
304953	100736417	20992766598	Features	feature	NN2
304953	100736417	20992766599	information	information	NN1
304953	100736417	20992766600	from	from	II
304953	100736417	20992766601	the	the	AT
304953	100736417	20992766602	Best	best	JJT
304953	100736417	20992766603	Case	case	NN1
304953	100736417	20992766604	Series	series	NN
304953	100736417	20992766605	Program	program	NN1_VV0@
304953	100736417	20992766606	,	,	,
304953	100736417	20992766607	an	a	AT1
304953	100736417	20992766608	independent	independent	JJ
304953	100736417	20992766609	review	review	NN1
304953	100736417	20992766610	of	of	IO
304953	100736417	20992766611	medical	medical	JJ
304953	100736417	20992766612	records	record	NN2
304953	100736417	20992766613	of	of	IO
304953	100736417	20992766614	patients	patient	NN2
304953	100736417	20992766615	treated	treat	VVN
304953	100736417	20992766616	with	with	IW
304953	100736417	20992766617	complementary	complementary	JJ
304953	100736417	20992766618	therapies	therapy	NN2
304953	100736417	20992766619	for	for	IF
304953	100736417	20992766620	cancer	cancer	NN1
304953	100736417	20992766621	,	,	,
304953	100736417	20992766622	to	to	TO
304953	100736417	20992766623	determine	determine	VVI
304953	100736417	20992766624	which	which	DDQ
304953	100736417	20992766625	ones	one	NN2
304953	100736417	20992766626	hold	hold	VV0
304953	100736417	20992766627	promise	promise	NN1_VV0
304953	100736417	20992766628	.	.	.
304953	100736417	20992766629	<p>		NULL
304953	100736417	20992766630	National	national	JJ
304953	100736417	20992766631	Institutes	institute	NN2
304953	100736417	20992766632	of	of	IO
304953	100736417	20992766633	HealthNational		JJ_NP1
304953	100736417	20992766634	Center	center	NN1
304953	100736417	20992766635	for	for	IF
304953	100736417	20992766636	Complementary	complementary	JJ
304953	100736417	20992766637	and	and	CC
304953	100736417	20992766638	Alternative	alternative	JJ_NN1
304953	100736417	20992766639	**25;389;TOOLONG		NP1
304953	100736417	20992766640	<p>		NULL
304953	100736417	20992766641	Provides	provide	VVZ
304953	100736417	20992766642	general	general	JJ
304953	100736417	20992766643	information	information	NN1
304953	100736417	20992766644	about	about	II
304953	100736417	20992766645	complementary	complementary	JJ
304953	100736417	20992766646	therapies	therapy	NN2
304953	100736417	20992766647	,	,	,
304953	100736417	20992766648	as	as	II31
304953	100736417	20992766649	well	well	II32
304953	100736417	20992766650	as	as	II33
304953	100736417	20992766651	a	a	AT1
304953	100736417	20992766652	list	list	NN1
304953	100736417	20992766653	of	of	IO
304953	100736417	20992766654	clinical	clinical	JJ
304953	100736417	20992766655	studies	study	NN2
304953	100736417	20992766656	that	that	CST
304953	100736417	20992766657	are	be	VBR
304953	100736417	20992766658	recruiting	recruit	VVG
304953	100736417	20992766659	patients	patient	NN2
304953	100736417	20992766660	.	.	.
304953	100736417	20992766661	Posts	post	NN2
304953	100736417	20992766662	fact	fact	NN1
304953	100736417	20992766663	sheets	sheet	NN2
304953	100736417	20992766664	about	about	II
304953	100736417	20992766665	particular	particular	JJ
304953	100736417	20992766666	herbs	herb	NN2
304953	100736417	20992766667	and	and	CC
304953	100736417	20992766668	supplements	supplement	NN2
304953	100736417	20992766669	and	and	CC
304953	100736417	20992766670	diseases	disease	NN2
304953	100736417	20992766671	although	although	CS
304953	100736417	20992766672	not	not	XX
304953	100736417	20992766673	yet	yet	RR
304953	100736417	20992766674	on	on	II
304953	100736417	20992766675	prostate	prostate	NN1
304953	100736417	20992766676	disease	disease	NN1
304953	100736417	20992766677	or	or	CC
304953	100736417	20992766678	prostate	prostate	NN1
304953	100736417	20992766679	cancer	cancer	NN1
304953	100736417	20992766680	.	.	.
304953	100736417	20992766681	<p>		NULL
304953	100736417	20992766682	Posts	post	NN2
304953	100736417	20992766683	information	information	NN1
304953	100736417	20992766684	that	that	CST_DD1
304953	100736417	20992766685	is	be	VBZ
304953	100736417	20992766686	medically	medically	RR
304953	100736417	20992766687	reviewed	review	VVN_VVD
304953	100736417	20992766688	and	and	CC
304953	100736417	20992766689	contains	contain	VVZ
304953	100736417	20992766690	references	reference	NN2
304953	100736417	20992766691	to	to	II
304953	100736417	20992766692	particular	particular	JJ
304953	100736417	20992766693	studies	study	NN2
304953	100736417	20992766694	.	.	.
304953	100736417	20992766695	Search	search	NN1_VV0@
304953	100736417	20992766696	by	by	II
304953	100736417	20992766697	product	product	NN1
304953	100736417	20992766698	name	name	NN1
304953	100736417	20992766699	or	or	CC
304953	100736417	20992766700	medical	medical	JJ
304953	100736417	20992766701	condition	condition	NN1
304953	100736417	20992766702	and	and	CC
304953	100736417	20992766703	see	see	VV0
304953	100736417	20992766704	drug/herb		NN1
304953	100736417	20992766705	interactions	interaction	NN2
304953	100736417	20992766706	.	.	.
304953	100736417	20992766707	Web	web	NN1
304953	100736417	20992766708	access	access	NN1
304953	100736417	20992766709	costs	cost	VVZ
304953	100736417	20992766710	$9.97		NNU
304953	100736417	20992766711	per	per	II
304953	100736417	20992766712	month	month	NNT1
304953	100736417	20992766713	,	,	,
304953	100736417	20992766714	or	or	CC
304953	100736417	20992766715	$92		NNU
304953	100736417	20992766716	per	per	II
304953	100736417	20992766717	year	year	NNT1
304953	100736417	20992766718	.	.	.
304953	100736417	20992766719	<p>		NULL
304953	100736417	20992766720	What	what	DDQ
304953	100736417	20992766721	large	large	JJ
304953	100736417	20992766722	studies	study	NN2
304953	100736417	20992766723	on	on	II
304953	100736417	20992766724	complementary	complementary	JJ
304953	100736417	20992766725	therapies	therapy	NN2
304953	100736417	20992766726	for	for	IF
304953	100736417	20992766727	prostate	prostate	NN1
304953	100736417	20992766728	disease	disease	NN1
304953	100736417	20992766729	should	should	VM
304953	100736417	20992766730	men	man	NN2
304953	100736417	20992766731	be	be	VBI
304953	100736417	20992766732	aware	aware	JJ
304953	100736417	20992766733	of	of	IO
304953	100736417	20992766734	?	?	?
304953	100736417	20992766735	<p>		NULL
304953	100736417	20992766736	ROSENTHAL	rosenthal	NP1
304953	100736417	20992766737	:	:	:
304953	100736417	20992766738	The	the	AT
304953	100736417	20992766739	SELECT	select	JJ
304953	100736417	20992766740	study	study	NN1
304953	100736417	20992766741	is	be	VBZ
304953	100736417	20992766742	the	the	AT
304953	100736417	20992766743	big	big	JJ
304953	100736417	20992766744	one	one	PN1
304953	100736417	20992766745	,	,	,
304953	100736417	20992766746	which	which	DDQ
304953	100736417	20992766747	everyone	everyone	PN1
304953	100736417	20992766748	is	be	VBZ
304953	100736417	20992766749	waiting	wait	VVG
304953	100736417	20992766750	for	for	IF
304953	100736417	20992766751	,	,	,
304953	100736417	20992766752	because	because	CS
304953	100736417	20992766753	it	it	PPH1
304953	100736417	20992766754	will	will	VM
304953	100736417	20992766755	help	help	VVI
304953	100736417	20992766756	determine	determine	VVI
304953	100736417	20992766757	whether	whether	CSW
304953	100736417	20992766758	taking	take	VVG
304953	100736417	20992766759	selenium	selenium	NN1
304953	100736417	20992766760	and	and	CC
304953	100736417	20992766761	vitamin	vitamin	NN1
304953	100736417	20992766762	E	e	ZZ1
304953	100736417	20992766763	might	might	VM
304953	100736417	20992766764	@		II
304953	100736417	20992766765	@		II
304953	100736417	20992766766	@		II
304953	100736417	20992766767	@		II
304953	100736417	20992766768	@		II
304953	100736417	20992766769	@		II
304953	100736417	20992766770	@		II
304953	100736417	20992766771	@		II
304953	100736417	20992766772	@		II
304953	100736417	20992766773	@		II
304953	100736417	20992766774	"	"	"
304953	100736417	20992766775	.	.	.
304953	100736417	20992766776	But	but	CCB
304953	100736417	20992766777	the	the	AT
304953	100736417	20992766778	results	result	NN2
304953	100736417	20992766779	are	be	VB0
304953	100736417	20992766780	n't 	n't	XX
304953	100736417	20992766781	going	go	VVGK
304953	100736417	20992766782	to	to	TO
304953	100736417	20992766783	be	be	VBI
304953	100736417	20992766784	known	know	VVN
304953	100736417	20992766785	for	for	IF
304953	100736417	20992766786	years	year	NNT2
304953	100736417	20992766787	.	.	.
304953	100736417	20992766788	<h>		NULL
304953	100736417	20992766789	SELECT	select	JJ_VV0
304953	100736417	20992766790	study	study	NN1
304953	100736417	20992766791	<p>		NULL
304953	100736417	20992766792	SELECT	select	VV0_JJ
304953	100736417	20992766793	(	(	(
304953	100736417	20992766794	Selenium	selenium	NP1_NN1
304953	100736417	20992766795	and	and	CC
304953	100736417	20992766796	Vitamin	vitamin	NN1
304953	100736417	20992766797	E	e	ZZ1
304953	100736417	20992766798	Cancer	cancer	NN1
304953	100736417	20992766799	Prevention	prevention	NN1
304953	100736417	20992766800	Trial	trial	NN1
304953	100736417	20992766801	)	)	)
304953	100736417	20992766802	is	be	VBZ
304953	100736417	20992766803	the	the	AT
304953	100736417	20992766804	largest	large	JJT
304953	100736417	20992766805	prostate	prostate	NN1
304953	100736417	20992766806	cancer	cancer	NN1
304953	100736417	20992766807	prevention	prevention	NN1
304953	100736417	20992766808	study	study	NN1
304953	100736417	20992766809	ever	ever	RR
304953	100736417	20992766810	undertaken	undertake	VVN
304953	100736417	20992766811	,	,	,
304953	100736417	20992766812	with	with	IW
304953	100736417	20992766813	more	more	DAR
304953	100736417	20992766814	than	than	CSN
304953	100736417	20992766815	35,000	35,000	MC
304953	100736417	20992766816	men	man	NN2
304953	100736417	20992766817	participating	participate	VVG_JJ
304953	100736417	20992766818	.	.	.
304953	100736417	20992766819	Participants	participant	NN2
304953	100736417	20992766820	have	have	VH0
304953	100736417	20992766821	been	be	VBN
304953	100736417	20992766822	randomly	randomly	RR
304953	100736417	20992766823	assigned	assign	VVN
304953	100736417	20992766824	to	to	TO
304953	100736417	20992766825	take	take	VVI
304953	100736417	20992766826	200	200	MC
304953	100736417	20992766827	mcg	mcg	NNU
304953	100736417	20992766828	of	of	IO
304953	100736417	20992766829	selenium	selenium	NN1
304953	100736417	20992766830	or	or	CC
304953	100736417	20992766831	400	400	MC
304953	100736417	20992766832	IU	iu	NP1
304953	100736417	20992766833	of	of	IO
304953	100736417	20992766834	vitamin	vitamin	NN1
304953	100736417	20992766835	E	e	ZZ1
304953	100736417	20992766836	or	or	CC
304953	100736417	20992766837	the	the	AT
304953	100736417	20992766838	two	two	MC
304953	100736417	20992766839	in	in	II
304953	100736417	20992766840	combination	combination	NN1
304953	100736417	20992766841	,	,	,
304953	100736417	20992766842	or	or	CC
304953	100736417	20992766843	a	a	AT1
304953	100736417	20992766844	placebo	placebo	NN1
304953	100736417	20992766845	and	and	CC
304953	100736417	20992766846	will	will	VM
304953	100736417	20992766847	be	be	VBI
304953	100736417	20992766848	followed	follow	VVN
304953	100736417	20992766849	for	for	IF
304953	100736417	20992766850	a	a	AT1
304953	100736417	20992766851	minimum	minimum	NN1
304953	100736417	20992766852	of	of	IO
304953	100736417	20992766853	seven	seven	MC
304953	100736417	20992766854	years	year	NNT2
304953	100736417	20992766855	and	and	CC
304953	100736417	20992766856	a	a	AT1
304953	100736417	20992766857	maximum	maximum	NN1
304953	100736417	20992766858	of	of	IO
304953	100736417	20992766859	12	12	MC
304953	100736417	20992766860	years	year	NNT2
304953	100736417	20992766861	.	.	.
304953	100736417	20992766862	By	by	II
304953	100736417	20992766863	that	that	DD1
304953	100736417	20992766864	time	time	NNT1
304953	100736417	20992766865	it	it	PPH1
304953	100736417	20992766866	should	should	VM
304953	100736417	20992766867	become	become	VVI
304953	100736417	20992766868	clear	clear	JJ
304953	100736417	20992766869	whether	whether	CSW
304953	100736417	20992766870	taking	take	VVG
304953	100736417	20992766871	selenium	selenium	NN1
304953	100736417	20992766872	or	or	CC
304953	100736417	20992766873	vitamin	vitamin	NN1
304953	100736417	20992766874	E	e	ZZ1
304953	100736417	20992766875	,	,	,
304953	100736417	20992766876	or	or	CC
304953	100736417	20992766877	both	both	RR_DB2
304953	100736417	20992766878	together	together	RL
304953	100736417	20992766879	,	,	,
304953	100736417	20992766880	will	will	VM
304953	100736417	20992766881	reduce	reduce	VVI
304953	100736417	20992766882	the	the	AT
304953	100736417	20992766883	risk	risk	NN1
304953	100736417	20992766884	of	of	IO
304953	100736417	20992766885	prostate	prostate	NN1
304953	100736417	20992766886	cancer	cancer	NN1
304953	100736417	20992766887	.	.	.
304953	100736417	20992766888	<p>		NULL
304953	100736417	20992766889	To	to	TO
304953	100736417	20992766890	read	read	VVI
304953	100736417	20992766891	more	more	RRR_DAR
304953	100736417	20992766892	about	about	II
304953	100736417	20992766893	the	the	AT
304953	100736417	20992766894	studies	study	NN2
304953	100736417	20992766895	cited	cite	VVN_VVD
304953	100736417	20992766896	in	in	II
304953	100736417	20992766897	this	this	DD1
304953	100736417	20992766898	table	table	NN1
304953	100736417	20992766899	,	,	,
304953	100736417	20992766900	see	see	VV0
304953	100736417	20992766901	"	"	"
304953	100736417	20992766902	What	what	DDQ
304953	100736417	20992766903	may	may	VM
304953	100736417	20992766904	work	work	VVI
304953	100736417	20992766905	for	for	IF
304953	100736417	20992766906	BPH	bph	NP1
304953	100736417	20992766907	.	.	.
304953	100736417	20992766908	"	"	"
304953	100736417	20992766909	<p>		NULL
304953	100736417	20992766910	Substances	substance	NN2
304953	100736417	20992766911	that	that	CST_DD1
304953	100736417	20992766912	may	may	VM
304953	100736417	20992766913	work	work	VVI
304953	100736417	20992766914	<p>		NULL
304953	100736417	20992766915	Substance	substance	NN1
304953	100736417	20992766916	and	and	CC
304953	100736417	20992766917	possible	possible	JJ
304953	100736417	20992766918	mechanism	mechanism	NN1
304953	100736417	20992766919	of	of	IO
304953	100736417	20992766920	action	action	NN1
304953	100736417	20992766921	<p>		NULL
304953	100736417	20992766922	Assessment	assessment	NN1
304953	100736417	20992766923	<p>		NULL
304953	100736417	20992766924	Beta-sitosterol		NN1_JJ
304953	100736417	20992766925	<p>		NULL
304953	100736417	20992766926	Mixture	mixture	NN1
304953	100736417	20992766927	of	of	IO
304953	100736417	20992766928	several	several	DA2
304953	100736417	20992766929	extracts	extract	NN2
304953	100736417	20992766930	of	of	IO
304953	100736417	20992766931	plants	plant	NN2
304953	100736417	20992766932	containing	contain	VVG
304953	100736417	20992766933	substances	substance	NN2
304953	100736417	20992766934	that	that	CST_DD1
304953	100736417	20992766935	mimic	mimic	VV0_NN1
304953	100736417	20992766936	cholesterol	cholesterol	NN1
304953	100736417	20992766937	;	;	;
304953	100736417	20992766938	not	not	XX
304953	100736417	20992766939	clear	clear	JJ
304953	100736417	20992766940	how	how	RRQ
304953	100736417	20992766941	it	it	PPH1
304953	100736417	20992766942	alleviates	alleviate	VVZ
304953	100736417	20992766943	BPH	bph	NP1
304953	100736417	20992766944	symptoms	symptom	NN2
304953	100736417	20992766945	.	.	.
304953	100736417	20992766946	<p>		NULL
304953	100736417	20992766947	One	one	MC1
304953	100736417	20992766948	review	review	NN1
304953	100736417	20992766949	of	of	IO
304953	100736417	20992766950	four	four	MC
304953	100736417	20992766951	randomized	randomized	JJ@_VVD
304953	100736417	20992766952	trials	trial	NN2
304953	100736417	20992766953	involving	involve	VVG
304953	100736417	20992766954	a	a	AT1
304953	100736417	20992766955	total	total	NN1_JJ
304953	100736417	20992766956	of	of	IO
304953	100736417	20992766957	519	519	MC
304953	100736417	20992766958	men	man	NN2
304953	100736417	20992766959	,	,	,
304953	100736417	20992766960	published	publish	VVN
304953	100736417	20992766961	in	in	II
304953	100736417	20992766962	1999	1999	MC
304953	100736417	20992766963	in	in	II
304953	100736417	20992766964	@		II
304953	100736417	20992766965	@		II
304953	100736417	20992766966	@		II
304953	100736417	20992766967	@		II
304953	100736417	20992766968	@		II
304953	100736417	20992766969	@		II
304953	100736417	20992766970	@		II
304953	100736417	20992766971	@		II
304953	100736417	20992766972	@		II
304953	100736417	20992766973	@		II
304953	100736417	20992766974	but	but	CCB
304953	100736417	20992766975	cautioned	caution	VVD_VVN
304953	100736417	20992766976	that	that	CST_DD1
304953	100736417	20992766977	long-term	long-term	JJ
304953	100736417	20992766978	safety	safety	NN1
304953	100736417	20992766979	and	and	CC
304953	100736417	20992766980	effectiveness	effectiveness	NN1
304953	100736417	20992766981	were	be	VBDR
304953	100736417	20992766982	unknown	unknown	JJ
304953	100736417	20992766983	.	.	.
304953	100736417	20992766984	<p>		NULL
304953	100736417	20992766985	Pygeum		NN1_NP1@
304953	100736417	20992766986	<p>		NULL
304953	100736417	20992766987	Derived	derive	VVN
304953	100736417	20992766988	from	from	II
304953	100736417	20992766989	the	the	AT
304953	100736417	20992766990	bark	bark	NN1
304953	100736417	20992766991	of	of	IO
304953	100736417	20992766992	an	a	AT1
304953	100736417	20992766993	African	african	JJ
304953	100736417	20992766994	evergreen	evergreen	JJ_NN1
304953	100736417	20992766995	tree	tree	NN1
304953	100736417	20992766996	;	;	;
304953	100736417	20992766997	not	not	XX
304953	100736417	20992766998	clear	clear	JJ
304953	100736417	20992766999	how	how	RRQ
304953	100736417	20992767000	it	it	PPH1
304953	100736417	20992767001	works	work	VVZ
304953	100736417	20992767002	,	,	,
304953	100736417	20992767003	but	but	CCB
304953	100736417	20992767004	some	some	DD
304953	100736417	20992767005	researchers	researcher	NN2
304953	100736417	20992767006	have	have	VH0
304953	100736417	20992767007	proposed	propose	VVN
304953	100736417	20992767008	that	that	CST
304953	100736417	20992767009	it	it	PPH1
304953	100736417	20992767010	reduces	reduce	VVZ
304953	100736417	20992767011	inflammation	inflammation	NN1
304953	100736417	20992767012	or	or	CC
304953	100736417	20992767013	slows	slow	VVZ
304953	100736417	20992767014	prostate	prostate	NN1
304953	100736417	20992767015	growth	growth	NN1
304953	100736417	20992767016	.	.	.
304953	100736417	20992767017	<p>		NULL
304953	100736417	20992767018	One	one	MC1
304953	100736417	20992767019	study	study	NN1
304953	100736417	20992767020	,	,	,
304953	100736417	20992767021	involving	involve	VVG
304953	100736417	20992767022	263	263	MC
304953	100736417	20992767023	men	man	NN2
304953	100736417	20992767024	recruited	recruit	VVN
304953	100736417	20992767025	at	at	II
304953	100736417	20992767026	eight	eight	MC
304953	100736417	20992767027	sites	site	NN2
304953	100736417	20992767028	in	in	II
304953	100736417	20992767029	Europe	europe	NP1
304953	100736417	20992767030	,	,	,
304953	100736417	20992767031	found	find	VVD_VVN
304953	100736417	20992767032	that	that	CST
304953	100736417	20992767033	participants	participant	NN2
304953	100736417	20992767034	who	who	PNQS
304953	100736417	20992767035	took	take	VVD
304953	100736417	20992767036	pygeum	pygeum	NN1
304953	100736417	20992767037	experienced	experienced	JJ_VVD_VVN
304953	100736417	20992767038	improvement	improvement	NN1
304953	100736417	20992767039	in	in	II
304953	100736417	20992767040	urinary	urinary	JJ_NN1
304953	100736417	20992767041	symptoms	symptom	NN2
304953	100736417	20992767042	.	.	.
304953	100736417	20992767043	(	(	(
304953	100736417	20992767044	The	the	AT
304953	100736417	20992767045	study	study	NN1
304953	100736417	20992767046	is	be	VBZ
304953	100736417	20992767047	available	available	JJ
304953	100736417	20992767048	only	only	JJ
304953	100736417	20992767049	in	-in	II
304953	100736417	20992767050	German	german	NN1
304953	100736417	20992767051	,	,	,
304953	100736417	20992767052	so	-so	RR_CS@_RG
304953	100736417	20992767053	a	a	AT1
304953	100736417	20992767054	citation	citation	NN1
304953	100736417	20992767055	is	be	VBZ
304953	100736417	20992767056	not	not	XX
304953	100736417	20992767057	provided	provide	VVN
304953	100736417	20992767058	here	here	RL
304953	100736417	20992767059	.	.	.
304953	100736417	20992767060	)	)	)
304953	100736417	20992767061	<p>		NULL
304953	100736417	20992767062	Saw	saw	NN1@_VVD_VV0%
304953	100736417	20992767063	palmetto	palmetto	NN1
304953	100736417	20992767064	<p>		NULL
304953	100736417	20992767065	Derived	derive	VVN
304953	100736417	20992767066	from	from	II
304953	100736417	20992767067	the	the	AT
304953	100736417	20992767068	berry	berry	NN1
304953	100736417	20992767069	of	of	IO
304953	100736417	20992767070	the	the	AT
304953	100736417	20992767071	saw	saw	NN1@
304953	100736417	20992767072	palmetto	palmetto	NN1
304953	100736417	20992767073	tree	tree	NN1
304953	100736417	20992767074	;	;	;
304953	100736417	20992767075	not	not	XX
304953	100736417	20992767076	clear	clear	JJ
304953	100736417	20992767077	how	how	RRQ
304953	100736417	20992767078	it	it	PPH1
304953	100736417	20992767079	works	work	VVZ
304953	100736417	20992767080	,	,	,
304953	100736417	20992767081	although	although	CS
304953	100736417	20992767082	a	a	AT1
304953	100736417	20992767083	leading	leading	JJ
304953	100736417	20992767084	theory	theory	NN1
304953	100736417	20992767085	is	be	VBZ
304953	100736417	20992767086	that	that	CST
304953	100736417	20992767087	it	it	PPH1
304953	100736417	20992767088	affects	affect	VVZ
304953	100736417	20992767089	male	male	JJ
304953	100736417	20992767090	hormones	hormone	NN2
304953	100736417	20992767091	.	.	.
304953	100736417	20992767092	<p>		NULL
304953	100736417	20992767093	Safety	safety	NN1
304953	100736417	20992767094	considerations	consideration	NN2
304953	100736417	20992767095	:	:	:
304953	100736417	20992767096	May	may	VM@
304953	100736417	20992767097	increase	increase	VVI
304953	100736417	20992767098	the	the	AT
304953	100736417	20992767099	risk	risk	NN1
304953	100736417	20992767100	of	of	IO
304953	100736417	20992767101	bleeding	bleeding	JJ_VVG
304953	100736417	20992767102	when	when	CS_RRQ
304953	100736417	20992767103	taken	take	VVN
304953	100736417	20992767104	with	with	IW
304953	100736417	20992767105	herbs	herb	NN2
304953	100736417	20992767106	and	and	CC
304953	100736417	20992767107	drugs	drug	NN2
304953	100736417	20992767108	that	that	CST
304953	100736417	20992767109	also	also	RR
304953	100736417	20992767110	have	have	VH0
304953	100736417	20992767111	this	this	DD1
304953	100736417	20992767112	effect	effect	NN1
304953	100736417	20992767113	(	(	(
304953	100736417	20992767114	such	such	II21
304953	100736417	20992767115	as	as	II22
304953	100736417	20992767116	garlic	garlic	NN1
304953	100736417	20992767117	,	,	,
304953	100736417	20992767118	aspirin	aspirin	NN
304953	100736417	20992767119	,	,	,
304953	100736417	20992767120	anticoagulants	anticoagulant	NN2
304953	100736417	20992767121	,	,	,
304953	100736417	20992767122	antiplatelet	antiplatelet	NN1
304953	100736417	20992767123	medications	medication	NN2
304953	100736417	20992767124	,	,	,
304953	100736417	20992767125	NSAIDs	nsaid	NP2
304953	100736417	20992767126	)	)	)
304953	100736417	20992767127	;	;	;
304953	100736417	20992767128	should	should	VM
304953	100736417	20992767129	not	not	XX
304953	100736417	20992767130	be	be	VBI
304953	100736417	20992767131	taken	take	VVN
304953	100736417	20992767132	with	with	IW
304953	100736417	20992767133	drugs	drug	NN2
304953	100736417	20992767134	that	that	CST_DD1
304953	100736417	20992767135	affect	affect	VV0_NN1
304953	100736417	20992767136	levels	level	NN2
304953	100736417	20992767137	of	of	IO
304953	100736417	20992767138	male	male	JJ_NN1
304953	100736417	20992767139	hormones	hormone	NN2
304953	100736417	20992767140	.	.	.
304953	100736417	20992767141	<p>		NULL
304953	100736417	20992767142	Probably	probably	RR
304953	100736417	20992767143	the	the	AT
304953	100736417	20992767144	best	best	RRT_JJT
304953	100736417	20992767145	studied	study	VVN_JJ@
304953	100736417	20992767146	herb	herb	NN1
304953	100736417	20992767147	for	for	IF
304953	100736417	20992767148	BPH	bph	NP1
304953	100736417	20992767149	treatment	treatment	NN1
304953	100736417	20992767150	,	,	,
304953	100736417	20992767151	but	but	CCB
304953	100736417	20992767152	studies	study	NN2
304953	100736417	20992767153	are	be	VBR
304953	100736417	20992767154	conflicting	conflicting	JJ_VVG@
304953	100736417	20992767155	.	.	.
304953	100736417	20992767156	<p>		NULL
304953	100736417	20992767157	A	a	AT1
304953	100736417	20992767158	review	review	NN1
304953	100736417	20992767159	of	of	IO
304953	100736417	20992767160	18	18	MC
304953	100736417	20992767161	studies	study	NN2
304953	100736417	20992767162	involving	involve	VVG
304953	100736417	20992767163	2,939		MC
304953	100736417	20992767164	@		II
304953	100736417	20992767165	@		II
304953	100736417	20992767166	@		II
304953	100736417	20992767167	@		II
304953	100736417	20992767168	@		II
304953	100736417	20992767169	@		II
304953	100736417	20992767170	@		II
304953	100736417	20992767171	@		II
304953	100736417	20992767172	@		II
304953	100736417	20992767173	@		II
304953	100736417	20992767174	American	american	JJ
304953	100736417	20992767175	Medical	medical	JJ
304953	100736417	20992767176	Association	association	NN1
304953	100736417	20992767177	,	,	,
304953	100736417	20992767178	concluded	conclude	VVD_VVN
304953	100736417	20992767179	that	that	CST_DD1
304953	100736417	20992767180	saw	see	VVD_NN1@
304953	100736417	20992767181	palmetto	palmetto	NN1
304953	100736417	20992767182	supplements	supplement	NN2
304953	100736417	20992767183	improved	improve	VVD_VVN_JJ
304953	100736417	20992767184	urinary	urinary	JJ_NN1
304953	100736417	20992767185	symptoms	symptom	NN2
304953	100736417	20992767186	about	about	RG
304953	100736417	20992767187	as	as	RG
304953	100736417	20992767188	much	much	DA1
304953	100736417	20992767189	as	as	CSA
304953	100736417	20992767190	the	the	AT
304953	100736417	20992767191	medication	medication	NN1
304953	100736417	20992767192	finasteride	finasteride	NN1
304953	100736417	20992767193	(	(	(
304953	100736417	20992767194	Proscar	proscar	NP1
304953	100736417	20992767195	)	)	)
304953	100736417	20992767196	.	.	.
304953	100736417	20992767197	But	but	CCB
304953	100736417	20992767198	a	a	AT1
304953	100736417	20992767199	randomized	randomized	JJ@
304953	100736417	20992767200	trial	trial	NN1
304953	100736417	20992767201	involving	involve	VVG
304953	100736417	20992767202	225	225	MC
304953	100736417	20992767203	men	man	NN2
304953	100736417	20992767204	who	who	PNQS
304953	100736417	20992767205	took	take	VVD
304953	100736417	20992767206	saw	saw	NN1@_VVD
304953	100736417	20992767207	palmetto	palmetto	NN1
304953	100736417	20992767208	for	for	IF
304953	100736417	20992767209	a	a	AT1
304953	100736417	20992767210	year	year	NNT1
304953	100736417	20992767211	,	,	,
304953	100736417	20992767212	published	publish	VVN
304953	100736417	20992767213	in	in	II
304953	100736417	20992767214	2006	2006	MC
304953	100736417	20992767215	in	in	II
304953	100736417	20992767216	the	the	AT
304953	100736417	20992767217	New	new	NP1
304953	100736417	20992767218	England	england	NP1
304953	100736417	20992767219	Journal	journal	NN1
304953	100736417	20992767220	of	of	IO
304953	100736417	20992767221	Medicine	medicine	NN1
304953	100736417	20992767222	,	,	,
304953	100736417	20992767223	found	find	VVD_VVN
304953	100736417	20992767224	no	no	AT
304953	100736417	20992767225	evidence	evidence	NN1
304953	100736417	20992767226	that	that	CST
304953	100736417	20992767227	saw	see	VVD
304953	100736417	20992767228	palmetto	palmetto	NN1
304953	100736417	20992767229	was	be	VBDZ
304953	100736417	20992767230	any	any	DD_RR%
304953	100736417	20992767231	better	better	JJR_RRR
304953	100736417	20992767232	at	at	II
304953	100736417	20992767233	improving	improve	VVG_JJ
304953	100736417	20992767234	urinary	urinary	JJ_NN1
304953	100736417	20992767235	symptoms	symptom	NN2
304953	100736417	20992767236	than	than	CSN
304953	100736417	20992767237	placebo	placebo	NN1
304953	100736417	20992767238	.	.	.
304953	100736417	20992767239	<h>		NULL
304953	100736417	20992767240	Table	table	NN1
304953	100736417	20992767241	2	2	MC
304953	100736417	20992767242	:	:	:
304953	100736417	20992767243	Complementary	complementary	JJ
304953	100736417	20992767244	therapies	therapy	NN2
304953	100736417	20992767245	for	for	IF
304953	100736417	20992767246	erectile	erectile	JJ
304953	100736417	20992767247	dysfunction	dysfunction	NN1
304953	100736417	20992767248	<p>		NULL
304953	100736417	20992767249	To	to	TO
304953	100736417	20992767250	read	read	VVI
304953	100736417	20992767251	more	more	RRR_DAR
304953	100736417	20992767252	about	about	II
304953	100736417	20992767253	the	the	AT
304953	100736417	20992767254	substances	substance	NN2
304953	100736417	20992767255	discussed	discuss	VVN_VVD
304953	100736417	20992767256	in	in	II
304953	100736417	20992767257	this	this	DD1
304953	100736417	20992767258	table	table	NN1
304953	100736417	20992767259	,	,	,
304953	100736417	20992767260	see	see	VV0
304953	100736417	20992767261	"	"	"
304953	100736417	20992767262	Assessing	assess	VVG
304953	100736417	20992767263	the	the	AT
304953	100736417	20992767264	evidence	evidence	NN1
304953	100736417	20992767265	:	:	:
304953	100736417	20992767266	Erectile	erectile	JJ_NP1
304953	100736417	20992767267	dysfunction	dysfunction	NN1
304953	100736417	20992767268	.	.	.
304953	100736417	20992767269	"	"	"
304953	100736417	20992767270	<p>		NULL
304953	100736417	20992767271	Substances	substance	NN2
304953	100736417	20992767272	that	that	CST_DD1
304953	100736417	20992767273	may	may	VM
304953	100736417	20992767274	work	work	VVI
304953	100736417	20992767275	<p>		NULL
304953	100736417	20992767276	Substance	substance	NN1
304953	100736417	20992767277	and	and	CC
304953	100736417	20992767278	possible	possible	JJ
304953	100736417	20992767279	mechanism	mechanism	NN1
304953	100736417	20992767280	of	of	IO
304953	100736417	20992767281	action	action	NN1
304953	100736417	20992767282	<p>		NULL
304953	100736417	20992767283	Assessment	assessment	NN1
304953	100736417	20992767284	<p>		NULL
304953	100736417	20992767285	Korean	korean	JJ
304953	100736417	20992767286	red	red	JJ_NN1
304953	100736417	20992767287	ginseng	ginseng	NN1
304953	100736417	20992767288	<p>		NULL
304953	100736417	20992767289	Derived	derive	VVN
304953	100736417	20992767290	from	from	II
304953	100736417	20992767291	a	a	AT1
304953	100736417	20992767292	plant	plant	NN1
304953	100736417	20992767293	root	root	NN1
304953	100736417	20992767294	;	;	;
304953	100736417	20992767295	not	not	XX
304953	100736417	20992767296	clear	clear	JJ
304953	100736417	20992767297	how	how	RRQ
304953	100736417	20992767298	it	it	PPH1
304953	100736417	20992767299	may	may	VM
304953	100736417	20992767300	help	help	VVI
304953	100736417	20992767301	alleviate	alleviate	VVI
304953	100736417	20992767302	erectile	erectile	JJ
304953	100736417	20992767303	dysfunction	dysfunction	NN1
304953	100736417	20992767304	,	,	,
304953	100736417	20992767305	but	but	CCB
304953	100736417	20992767306	one	one	MC1
304953	100736417	20992767307	theory	theory	NN1
304953	100736417	20992767308	is	be	VBZ
304953	100736417	20992767309	that	that	CST
304953	100736417	20992767310	it	it	PPH1
304953	100736417	20992767311	increases	increase	VVZ
304953	100736417	20992767312	levels	level	NN2
304953	100736417	20992767313	of	of	IO
304953	100736417	20992767314	nitric	nitric	JJ
304953	100736417	20992767315	oxide	oxide	NN1
304953	100736417	20992767316	,	,	,
304953	100736417	20992767317	a	a	AT1
304953	100736417	20992767318	chemical	chemical	NN1_JJ
304953	100736417	20992767319	that	that	CST_DD1
304953	100736417	20992767320	occurs	occur	VVZ
304953	100736417	20992767321	naturally	naturally	RR
304953	100736417	20992767322	in	in	II
304953	100736417	20992767323	the	the	AT
304953	100736417	20992767324	body	body	NN1
304953	100736417	20992767325	and	and	CC
304953	100736417	20992767326	contributes	contribute	VVZ
304953	100736417	20992767327	to	to	II
304953	100736417	20992767328	erections	erection	NN2
304953	100736417	20992767329	.	.	.
304953	100736417	20992767330	<p>		NULL
304953	100736417	20992767331	Safety	safety	NN1
304953	100736417	20992767332	considerations	consideration	NN2
304953	100736417	20992767333	:	:	:
304953	100736417	20992767334	Some	some	DD
304953	100736417	20992767335	formulations	formulation	NN2
304953	100736417	20992767336	may	may	VM
304953	100736417	20992767337	lower	lower	VVI
304953	100736417	20992767338	blood	blood	NN1
304953	100736417	20992767339	sugar	sugar	NN1
304953	100736417	20992767340	levels	level	NN2
304953	100736417	20992767341	and	and	CC
304953	100736417	20992767342	alter	alter	VVI
304953	100736417	20992767343	the	the	AT
304953	100736417	20992767344	effects	effect	NN2
304953	100736417	20992767345	of	of	IO
304953	100736417	20992767346	blood	blood	NN1
304953	100736417	20992767347	pressure	pressure	NN1
304953	100736417	20992767348	or	or	CC
304953	100736417	20992767349	heart	heart	NN1
304953	100736417	20992767350	medications	medication	NN2
304953	100736417	20992767351	;	;	;
304953	100736417	20992767352	may	may	VM
304953	100736417	20992767353	affect	affect	VVI
304953	100736417	20992767354	the	the	AT
304953	100736417	20992767355	cytochrome	cytochrome	NN1_JJ
304953	100736417	20992767356	P450		FO
304953	100736417	20992767357	system	system	NN1
304953	100736417	20992767358	.	.	.
304953	100736417	20992767359	<p>		NULL
304953	100736417	20992767360	Three	three	MC
304953	100736417	20992767361	small	small	JJ
304953	100736417	20992767362	studies	study	NN2
304953	100736417	20992767363	suggest	suggest	VV0
304953	100736417	20992767364	@		II
304953	100736417	20992767365	@		II
304953	100736417	20992767366	@		II
304953	100736417	20992767367	@		II
304953	100736417	20992767368	@		II
304953	100736417	20992767369	@		II
304953	100736417	20992767370	@		II
304953	100736417	20992767371	@		II
304953	100736417	20992767372	@		II
304953	100736417	20992767373	@		II
304953	100736417	20992767374	,	,	,
304953	100736417	20992767375	but	but	CCB
304953	100736417	20992767376	further	far	RRR_JJR@
304953	100736417	20992767377	study	study	NN1
304953	100736417	20992767378	is	be	VBZ
304953	100736417	20992767379	necessary	necessary	JJ
304953	100736417	20992767380	.	.	.
304953	100736417	20992767381	<p>		NULL
304953	100736417	20992767382	L-arginine	l-arginine	NN1_JJ
304953	100736417	20992767383	<p>		NULL
304953	100736417	20992767384	A	a	AT1
304953	100736417	20992767385	precursor	precursor	NN1
304953	100736417	20992767386	to	to	II
304953	100736417	20992767387	nitric	nitric	JJ
304953	100736417	20992767388	oxide	oxide	NN1
304953	100736417	20992767389	;	;	;
304953	100736417	20992767390	may	may	VM
304953	100736417	20992767391	help	help	VVI
304953	100736417	20992767392	erectile	erectile	JJ
304953	100736417	20992767393	function	function	NN1
304953	100736417	20992767394	by	by	II
304953	100736417	20992767395	increasing	increasing	JJ_VVG
304953	100736417	20992767396	blood	blood	NN1
304953	100736417	20992767397	levels	level	NN2
304953	100736417	20992767398	of	of	IO
304953	100736417	20992767399	this	this	DD1
304953	100736417	20992767400	substance	substance	NN1
304953	100736417	20992767401	.	.	.
304953	100736417	20992767402	<p>		NULL
304953	100736417	20992767403	Safety	safety	NN1
304953	100736417	20992767404	considerations	consideration	NN2
304953	100736417	20992767405	:	:	:
304953	100736417	20992767406	May	may	VM@
304953	100736417	20992767407	increase	increase	VVI
304953	100736417	20992767408	risk	risk	NN1
304953	100736417	20992767409	of	of	IO
304953	100736417	20992767410	bleeding	bleeding	JJ_VVG
304953	100736417	20992767411	when	when	CS_RRQ
304953	100736417	20992767412	used	use	VVN_JJ
304953	100736417	20992767413	with	with	IW
304953	100736417	20992767414	anticoagulants	anticoagulant	NN2
304953	100736417	20992767415	or	or	CC
304953	100736417	20992767416	antiplatelet	antiplatelet	NN1
304953	100736417	20992767417	drugs	drug	NN2
304953	100736417	20992767418	,	,	,
304953	100736417	20992767419	or	or	CC
304953	100736417	20992767420	with	with	IW
304953	100736417	20992767421	herbs	herb	NN2
304953	100736417	20992767422	such	such	II21
304953	100736417	20992767423	as	as	II22
304953	100736417	20992767424	ginkgo	ginkgo	NN1
304953	100736417	20992767425	biloba	biloba	FW
304953	100736417	20992767426	,	,	,
304953	100736417	20992767427	garlic	garlic	NN1
304953	100736417	20992767428	,	,	,
304953	100736417	20992767429	or	or	CC
304953	100736417	20992767430	saw	see	VVD_NN1@
304953	100736417	20992767431	palmetto	palmetto	NN1
304953	100736417	20992767432	;	;	;
304953	100736417	20992767433	when	when	CS_RRQ
304953	100736417	20992767434	used	use	VVN_JJ
304953	100736417	20992767435	with	with	IW
304953	100736417	20992767436	nitroglycerin	nitroglycerin	NN1
304953	100736417	20992767437	or	or	CC
304953	100736417	20992767438	erectile	erectile	JJ
304953	100736417	20992767439	dysfunction	dysfunction	NN1
304953	100736417	20992767440	drugs	drug	NN2
304953	100736417	20992767441	,	,	,
304953	100736417	20992767442	may	may	VM
304953	100736417	20992767443	cause	cause	VVI
304953	100736417	20992767444	blood	blood	NN1
304953	100736417	20992767445	pressure	pressure	NN1
304953	100736417	20992767446	to	to	TO
304953	100736417	20992767447	drop	drop	VVI
304953	100736417	20992767448	;	;	;
304953	100736417	20992767449	may	may	VM
304953	100736417	20992767450	increase	increase	VVI
304953	100736417	20992767451	blood	blood	NN1
304953	100736417	20992767452	sugar	sugar	NN1
304953	100736417	20992767453	levels	level	NN2
304953	100736417	20992767454	.	.	.
304953	100736417	20992767455	<p>		NULL
304953	100736417	20992767456	Three	three	MC
304953	100736417	20992767457	small	small	JJ
304953	100736417	20992767458	preliminary	preliminary	JJ
304953	100736417	20992767459	studies	study	NN2
304953	100736417	20992767460	indicate	indicate	VV0
304953	100736417	20992767461	that	that	CST
304953	100736417	20992767462	this	this	DD1
304953	100736417	20992767463	substance	substance	NN1
304953	100736417	20992767464	may	may	VM
304953	100736417	20992767465	benefit	benefit	VVI
304953	100736417	20992767466	men	man	NN2
304953	100736417	20992767467	with	with	IW
304953	100736417	20992767468	low	low	JJ
304953	100736417	20992767469	levels	level	NN2
304953	100736417	20992767470	of	of	IO
304953	100736417	20992767471	nitric	nitric	JJ
304953	100736417	20992767472	oxide	oxide	NN1
304953	100736417	20992767473	,	,	,
304953	100736417	20992767474	but	but	CCB
304953	100736417	20992767475	larger	large	JJR
304953	100736417	20992767476	studies	study	NN2
304953	100736417	20992767477	are	be	VBR
304953	100736417	20992767478	needed	need	VVN
304953	100736417	20992767479	.	.	.
304953	100736417	20992767480	Men	man	NN2
304953	100736417	20992767481	at	at	II
304953	100736417	20992767482	risk	risk	NN1
304953	100736417	20992767483	for	for	IF
304953	100736417	20992767484	heart	heart	NN1
304953	100736417	20992767485	disease	disease	NN1
304953	100736417	20992767486	should	should	VM
304953	100736417	20992767487	avoid	avoid	VVI
304953	100736417	20992767488	taking	take	VVG
304953	100736417	20992767489	this	this	DD1
304953	100736417	20992767490	substance	substance	NN1
304953	100736417	20992767491	,	,	,
304953	100736417	20992767492	as	as	CSA_II
304953	100736417	20992767493	a	a	AT1
304953	100736417	20992767494	study	study	NN1
304953	100736417	20992767495	of	of	IO
304953	100736417	20992767496	possible	possible	JJ
304953	100736417	20992767497	benefits	benefit	NN2
304953	100736417	20992767498	of	of	IO
304953	100736417	20992767499	taking	take	VVG
304953	100736417	20992767500	L-arginine	l-arginine	JJ_NN1
304953	100736417	20992767501	to	to	TO
304953	100736417	20992767502	treat	treat	VVI
304953	100736417	20992767503	heart	heart	NN1
304953	100736417	20992767504	attack	attack	NN1
304953	100736417	20992767505	survivors	survivor	NN2
304953	100736417	20992767506	was	be	VBDZ
304953	100736417	20992767507	stopped	stop	VVN
304953	100736417	20992767508	early	early	RR
304953	100736417	20992767509	when	when	CS_RRQ
304953	100736417	20992767510	six	six	MC
304953	100736417	20992767511	volunteers	volunteer	NN2
304953	100736417	20992767512	taking	take	VVG
304953	100736417	20992767513	this	this	DD1
304953	100736417	20992767514	substance	substance	NN1
304953	100736417	20992767515	died	die	VVD
304953	100736417	20992767516	.	.	.
304953	100736417	20992767517	<p>		NULL
304953	100736417	20992767518	Vitamin	vitamin	NN1
304953	100736417	20992767519	supplements	supplement	NN2
304953	100736417	20992767520	<p>		NULL
304953	100736417	20992767521	May	may	VM
304953	100736417	20992767522	have	have	VHI
304953	100736417	20992767523	a	a	AT1
304953	100736417	20992767524	synergistic	synergistic	JJ
304953	100736417	20992767525	effect	effect	NN1
304953	100736417	20992767526	when	when	CS_RRQ
304953	100736417	20992767527	used	use	VVN_JJ
304953	100736417	20992767528	with	with	IW
304953	100736417	20992767529	erectile	erectile	JJ
304953	100736417	20992767530	dysfunction	dysfunction	NN1
304953	100736417	20992767531	medication	medication	NN1
304953	100736417	20992767532	.	.	.
304953	100736417	20992767533	<p>		NULL
304953	100736417	20992767534	A	a	AT1_ZZ1
304953	100736417	20992767535	small	small	JJ
304953	100736417	20992767536	study	study	NN1
304953	100736417	20992767537	of	of	IO
304953	100736417	20992767538	men	man	NN2
304953	100736417	20992767539	who	who	PNQS
304953	100736417	20992767540	did	do	VDD
304953	100736417	20992767541	not	not	XX
304953	100736417	20992767542	respond	respond	VVI
304953	100736417	20992767543	to	to	II
304953	100736417	20992767544	medication	medication	NN1
304953	100736417	20992767545	alone	alone	RR
304953	100736417	20992767546	found	find	VVN_VVD
304953	100736417	20992767547	that	that	CST_DD1
304953	100736417	20992767548	erectile	erectile	JJ
304953	100736417	20992767549	function	function	NN1
304953	100736417	20992767550	and	and	CC
304953	100736417	20992767551	patient	patient	JJ_NN1
304953	100736417	20992767552	satisfaction	satisfaction	NN1
304953	100736417	20992767553	improved	improve	VVN_VVD
304953	100736417	20992767554	in	in	II
304953	100736417	20992767555	many	many	DA2
304953	100736417	20992767556	who	who	PNQS
304953	100736417	20992767557	took	take	VVD
304953	100736417	20992767558	daily	daily	RR_JJ
304953	100736417	20992767559	folic	folic	JJ
304953	100736417	20992767560	acid	acid	NN1
304953	100736417	20992767561	and	and	CC
304953	100736417	20992767562	vitamin	vitamin	NN1
304953	100736417	20992767563	E	e	ZZ1
304953	100736417	20992767564	@		II
304953	100736417	20992767565	@		II
304953	100736417	20992767566	@		II
304953	100736417	20992767567	@		II
304953	100736417	20992767568	@		II
304953	100736417	20992767569	@		II
304953	100736417	20992767570	@		II
304953	100736417	20992767571	@		II
304953	100736417	20992767572	@		II
304953	100736417	20992767573	@		II
304953	100736417	20992767574	Table	table	NN1
304953	100736417	20992767575	3	3	MC
304953	100736417	20992767576	:	:	:
304953	100736417	20992767577	Complementary	complementary	JJ
304953	100736417	20992767578	therapies	therapy	NN2
304953	100736417	20992767579	for	for	IF
304953	100736417	20992767580	prostate	prostate	NN1
304953	100736417	20992767581	cancer	cancer	NN1
304953	100736417	20992767582	<p>		NULL
304953	100736417	20992767583	Many	many	DA2
304953	100736417	20992767584	complementary	complementary	JJ
304953	100736417	20992767585	therapies	therapy	NN2
304953	100736417	20992767586	used	use	VVN_VVD
304953	100736417	20992767587	for	for	IF
304953	100736417	20992767588	prostate	prostate	NN1
304953	100736417	20992767589	cancer	cancer	NN1
304953	100736417	20992767590	,	,	,
304953	100736417	20992767591	such	such	II21
304953	100736417	20992767592	as	as	II22
304953	100736417	20992767593	vitamins	vitamin	NN2
304953	100736417	20992767594	and	and	CC
304953	100736417	20992767595	particular	particular	JJ
304953	100736417	20992767596	nutrients	nutrient	NN2
304953	100736417	20992767597	,	,	,
304953	100736417	20992767598	are	be	VBR
304953	100736417	20992767599	found	find	VVN
304953	100736417	20992767600	naturally	naturally	RR
304953	100736417	20992767601	in	in	II
304953	100736417	20992767602	food	food	NN1
304953	100736417	20992767603	.	.	.
304953	100736417	20992767604	Our	our	APPGE
304953	100736417	20992767605	panel	panel	NN1
304953	100736417	20992767606	of	of	IO
304953	100736417	20992767607	Harvard	harvard	NP1
304953	100736417	20992767608	experts	expert	NN2
304953	100736417	20992767609	agreed	agree	VVD_VVN
304953	100736417	20992767610	that	that	CST
304953	100736417	20992767611	men	man	NN2
304953	100736417	20992767612	seeking	seek	VVG
304953	100736417	20992767613	to	to	TO
304953	100736417	20992767614	reduce	reduce	VVI
304953	100736417	20992767615	their	their	APPGE
304953	100736417	20992767616	risk	risk	NN1
304953	100736417	20992767617	of	of	IO
304953	100736417	20992767618	developing	developing	JJ_VVG
304953	100736417	20992767619	prostate	prostate	NN1
304953	100736417	20992767620	cancer	cancer	NN1
304953	100736417	20992767621	or	or	CC
304953	100736417	20992767622	of	of	IO
304953	100736417	20992767623	having	have	VHG
304953	100736417	20992767624	it	it	PPH1
304953	100736417	20992767625	progress	progress	NN1_VV0@
304953	100736417	20992767626	,	,	,
304953	100736417	20992767627	if	if	CS
304953	100736417	20992767628	its	its	APPGE
304953	100736417	20992767629	already	already	RR
304953	100736417	20992767630	been	be	VBN
304953	100736417	20992767631	diagnosed	diagnose	VVN
304953	100736417	20992767632	should	should	VM
304953	100736417	20992767633	eat	eat	VVI
304953	100736417	20992767634	a	a	AT1
304953	100736417	20992767635	healthy	healthy	JJ
304953	100736417	20992767636	diet	diet	NN1
304953	100736417	20992767637	and	and	CC
304953	100736417	20992767638	engage	engage	VVI
304953	100736417	20992767639	in	in	II_RP@
304953	100736417	20992767640	regular	regular	JJ
304953	100736417	20992767641	physical	physical	JJ
304953	100736417	20992767642	activity	activity	NN1
304953	100736417	20992767643	.	.	.
304953	100736417	20992767644	These	these	DD2
304953	100736417	20992767645	"	"	"
304953	100736417	20992767646	lifestyle	lifestyle	NN1
304953	100736417	20992767647	"	"	"
304953	100736417	20992767648	habits	habit	NN2
304953	100736417	20992767649	offer	offer	VV0
304953	100736417	20992767650	the	the	AT
304953	100736417	20992767651	best	best	JJT
304953	100736417	20992767652	all-around	all-around	RR@_DB
304953	100736417	20992767653	protection	protection	NN1
304953	100736417	20992767654	because	because	CS
304953	100736417	20992767655	they	they	PPHS2
304953	100736417	20992767656	reduce	reduce	VV0
304953	100736417	20992767657	the	the	AT
304953	100736417	20992767658	risk	risk	NN1
304953	100736417	20992767659	of	of	IO
304953	100736417	20992767660	the	the	AT
304953	100736417	20992767661	number	number	NN1
304953	100736417	20992767662	1	1	MC1
304953	100736417	20992767663	threat	threat	NN1
304953	100736417	20992767664	to	to	II
304953	100736417	20992767665	men	man	NN2
304953	100736417	20992767666	heart	heart	NN1
304953	100736417	20992767667	disease	disease	NN1
304953	100736417	20992767668	.	.	.
304953	100736417	20992767669	<p>		NULL
304953	100736417	20992767670	Nevertheless	nevertheless	RR
304953	100736417	20992767671	,	,	,
304953	100736417	20992767672	epidemiologic	epidemiologic	JJ
304953	100736417	20992767673	studies	study	NN2
304953	100736417	20992767674	(	(	(
304953	100736417	20992767675	which	which	DDQ
304953	100736417	20992767676	follow	follow	VV0
304953	100736417	20992767677	large	large	JJ
304953	100736417	20992767678	groups	group	NN2
304953	100736417	20992767679	over	over	II
304953	100736417	20992767680	time	time	NNT1
304953	100736417	20992767681	)	)	)
304953	100736417	20992767682	have	have	VH0
304953	100736417	20992767683	identified	identify	VVN
304953	100736417	20992767684	a	a	AT1
304953	100736417	20992767685	number	number	NN1
304953	100736417	20992767686	of	of	IO
304953	100736417	20992767687	specific	specific	JJ
304953	100736417	20992767688	dietary	dietary	JJ
304953	100736417	20992767689	factors	factor	NN2
304953	100736417	20992767690	that	that	CST
304953	100736417	20992767691	appear	appear	VV0
304953	100736417	20992767692	to	to	TO
304953	100736417	20992767693	affect	affect	VVI
304953	100736417	20992767694	risk	risk	NN1
304953	100736417	20992767695	of	of	IO
304953	100736417	20992767696	prostate	prostate	NN1
304953	100736417	20992767697	cancer	cancer	NN1
304953	100736417	20992767698	development	development	NN1
304953	100736417	20992767699	.	.	.
304953	100736417	20992767700	Data	data	NN
304953	100736417	20992767701	are	be	VBR
304953	100736417	20992767702	limited	limit	VVN_JJ
304953	100736417	20992767703	,	,	,
304953	100736417	20992767704	however	however	RR
304953	100736417	20992767705	,	,	,
304953	100736417	20992767706	about	about	II
304953	100736417	20992767707	whether	whether	CSW
304953	100736417	20992767708	dietary	dietary	JJ
304953	100736417	20992767709	changes	change	NN2
304953	100736417	20992767710	made	make	VVN_VVD
304953	100736417	20992767711	after	after	II
304953	100736417	20992767712	diagnosis	diagnosis	NN1
304953	100736417	20992767713	will	will	VM
304953	100736417	20992767714	have	have	VHI
304953	100736417	20992767715	any	any	DD
304953	100736417	20992767716	impact	impact	NN1
304953	100736417	20992767717	on	on	II
304953	100736417	20992767718	cancer	cancer	NN1
304953	100736417	20992767719	progression	progression	NN1
304953	100736417	20992767720	.	.	.
304953	100736417	20992767721	To	to	TO
304953	100736417	20992767722	learn	learn	VVI
304953	100736417	20992767723	more	more	RRR_DAR
304953	100736417	20992767724	about	about	II
304953	100736417	20992767725	the	the	AT
304953	100736417	20992767726	studies	study	NN2
304953	100736417	20992767727	cited	cite	VVN_VVD
304953	100736417	20992767728	in	in	II
304953	100736417	20992767729	this	this	DD1
304953	100736417	20992767730	table	table	NN1
304953	100736417	20992767731	,	,	,
304953	100736417	20992767732	see	see	VV0
304953	100736417	20992767733	"	"	"
304953	100736417	20992767734	What	what	DDQ
304953	100736417	20992767735	may	may	VM
304953	100736417	20992767736	work	work	VVI
304953	100736417	20992767737	for	for	IF
304953	100736417	20992767738	prostate	prostate	NN1
304953	100736417	20992767739	cancer	cancer	NN1
304953	100736417	20992767740	.	.	.
304953	100736417	20992767741	"	"	"
304953	100736417	20992767742	<p>		NULL
304953	100736417	20992767743	Substances	substance	NN2
304953	100736417	20992767744	that	that	CST_DD1
304953	100736417	20992767745	may	may	VM
304953	100736417	20992767746	reduce	reduce	VVI
304953	100736417	20992767747	risk	risk	NN1
304953	100736417	20992767748	<p>		NULL
304953	100736417	20992767749	Substance	substance	NN1
304953	100736417	20992767750	and	and	CC
304953	100736417	20992767751	possible	possible	JJ
304953	100736417	20992767752	mechanism	mechanism	NN1
304953	100736417	20992767753	of	of	IO
304953	100736417	20992767754	action	action	NN1
304953	100736417	20992767755	<p>		NULL
304953	100736417	20992767756	Impact	impact	NN1
304953	100736417	20992767757	on	on	II
304953	100736417	20992767758	prostate	prostate	NN1
304953	100736417	20992767759	cancer	cancer	NN1
304953	100736417	20992767760	risk	risk	NN1
304953	100736417	20992767761	<p>		NULL
304953	100736417	20992767762	Impact	impact	NN1
304953	100736417	20992767763	on	on	II
304953	100736417	20992767764	@		II
304953	100736417	20992767765	@		II
304953	100736417	20992767766	@		II
304953	100736417	20992767767	@		II
304953	100736417	20992767768	@		II
304953	100736417	20992767769	@		II
304953	100736417	20992767770	@		II
304953	100736417	20992767771	@		II
304953	100736417	20992767772	@		II
304953	100736417	20992767773	@		II
304953	100736417	20992767774	may	may	VM
304953	100736417	20992767775	be	be	VBI
304953	100736417	20992767776	protective	protective	JJ
304953	100736417	20992767777	;	;	;
304953	100736417	20992767778	one	one	MC1
304953	100736417	20992767779	theory	theory	NN1
304953	100736417	20992767780	is	be	VBZ
304953	100736417	20992767781	that	that	CST_RG%_DD1
304953	100736417	20992767782	omega-3	omega-3	MC
304953	100736417	20992767783	fatty	fatty	JJ
304953	100736417	20992767784	acids	acid	NN2
304953	100736417	20992767785	contained	contain	VVN_VVD
304953	100736417	20992767786	in	in	II
304953	100736417	20992767787	fatty	fatty	JJ_NN1
304953	100736417	20992767788	fish	fish	NN
304953	100736417	20992767789	may	may	VM
304953	100736417	20992767790	inhibit	inhibit	VVI
304953	100736417	20992767791	a	a	AT1
304953	100736417	20992767792	particular	particular	JJ
304953	100736417	20992767793	molecular	molecular	JJ
304953	100736417	20992767794	pathway	pathway	NN1
304953	100736417	20992767795	involved	involved	JJ
304953	100736417	20992767796	in	in	II
304953	100736417	20992767797	cancer	cancer	NN1
304953	100736417	20992767798	development	development	NN1
304953	100736417	20992767799	.	.	.
304953	100736417	20992767800	<p>		NULL
304953	100736417	20992767801	Fair	fair	JJ_RR@_NN1@
304953	100736417	20992767802	to	to	II
304953	100736417	20992767803	good	good	JJ
304953	100736417	20992767804	evidence	evidence	NN1
304953	100736417	20992767805	exists	exist	VVZ
304953	100736417	20992767806	that	that	CST_DD1
304953	100736417	20992767807	eating	eat	VVG_NN1
304953	100736417	20992767808	fish	fish	NN
304953	100736417	20992767809	may	may	VM
304953	100736417	20992767810	reduce	reduce	VVI
304953	100736417	20992767811	risk	risk	NN1
304953	100736417	20992767812	of	of	IO
304953	100736417	20992767813	prostate	prostate	NN1
304953	100736417	20992767814	cancer	cancer	NN1
304953	100736417	20992767815	.	.	.
304953	100736417	20992767816	Two	two	MC
304953	100736417	20992767817	large	large	JJ
304953	100736417	20992767818	prospective	prospective	JJ
304953	100736417	20992767819	studies	study	NN2
304953	100736417	20992767820	,	,	,
304953	100736417	20992767821	for	for	REX21
304953	100736417	20992767822	example	example	REX22
304953	100736417	20992767823	,	,	,
304953	100736417	20992767824	found	find	VVD_VVN
304953	100736417	20992767825	that	that	CST
304953	100736417	20992767826	men	man	NN2
304953	100736417	20992767827	who	who	PNQS
304953	100736417	20992767828	ate	eat	VVD
304953	100736417	20992767829	fish	fish	NN
304953	100736417	20992767830	were	be	VBDR
304953	100736417	20992767831	less	less	RGR
304953	100736417	20992767832	likely	likely	JJ
304953	100736417	20992767833	to	to	TO
304953	100736417	20992767834	develop	develop	VVI
304953	100736417	20992767835	prostate	prostate	NN1
304953	100736417	20992767836	cancer	cancer	NN1
304953	100736417	20992767837	or	or	CC
304953	100736417	20992767838	die	die	VV0
304953	100736417	20992767839	from	from	II
304953	100736417	20992767840	it	it	PPH1
304953	100736417	20992767841	.	.	.
304953	100736417	20992767842	<p>		NULL
304953	100736417	20992767843	May	may	VM
304953	100736417	20992767844	reduce	reduce	VVI
304953	100736417	20992767845	progression	progression	NN1
304953	100736417	20992767846	,	,	,
304953	100736417	20992767847	but	but	CCB
304953	100736417	20992767848	less	less	DAR
304953	100736417	20992767849	data	data	NN
304953	100736417	20992767850	are	be	VBR
304953	100736417	20992767851	available	available	JJ
304953	100736417	20992767852	.	.	.
304953	100736417	20992767853	A	a	ZZ1_AT1
304953	100736417	20992767854	2006	2006	MC
304953	100736417	20992767855	study	study	NN1
304953	100736417	20992767856	found	find	VVD_VVN
304953	100736417	20992767857	that	that	CST
304953	100736417	20992767858	men	man	NN2
304953	100736417	20992767859	with	with	IW
304953	100736417	20992767860	the	the	AT
304953	100736417	20992767861	highest	high	JJT
304953	100736417	20992767862	intake	intake	NN1
304953	100736417	20992767863	of	of	IO
304953	100736417	20992767864	fish	fish	NN
304953	100736417	20992767865	after	after	II
304953	100736417	20992767866	diagnosis	diagnosis	NN1
304953	100736417	20992767867	were	be	VBDR
304953	100736417	20992767868	27%		NNU
304953	100736417	20992767869	less	less	DAR_RRR
304953	100736417	20992767870	likely	likely	JJ
304953	100736417	20992767871	to	to	TO
304953	100736417	20992767872	have	have	VHI
304953	100736417	20992767873	their	their	APPGE
304953	100736417	20992767874	cancer	cancer	NN1
304953	100736417	20992767875	progress	progress	NN1
304953	100736417	20992767876	than	than	CSN
304953	100736417	20992767877	men	man	NN2
304953	100736417	20992767878	with	with	IW
304953	100736417	20992767879	the	the	AT
304953	100736417	20992767880	lowest	low	JJT
304953	100736417	20992767881	consumption	consumption	NN1
304953	100736417	20992767882	.	.	.
304953	100736417	20992767883	<p>		NULL
304953	100736417	20992767884	Selenium	selenium	NN1_NP1@
304953	100736417	20992767885	<p>		NULL
304953	100736417	20992767886	May	may	VM
304953	100736417	20992767887	inhibit	inhibit	VVI
304953	100736417	20992767888	several	several	DA2
304953	100736417	20992767889	biological	biological	JJ
304953	100736417	20992767890	pathways	pathway	NN2
304953	100736417	20992767891	that	that	CST
304953	100736417	20992767892	encourage	encourage	VV0
304953	100736417	20992767893	cancer	cancer	NN1
304953	100736417	20992767894	growth	growth	NN1
304953	100736417	20992767895	,	,	,
304953	100736417	20992767896	such	such	II21
304953	100736417	20992767897	as	as	II22
304953	100736417	20992767898	cell	cell	NN1
304953	100736417	20992767899	proliferation	proliferation	NN1
304953	100736417	20992767900	and	and	CC
304953	100736417	20992767901	angiogenesis	angiogenesis	NN1
304953	100736417	20992767902	.	.	.
304953	100736417	20992767903	<p>		NULL
304953	100736417	20992767904	Safety	safety	NN1
304953	100736417	20992767905	considerations	consideration	NN2
304953	100736417	20992767906	:	:	:
304953	100736417	20992767907	Taking	take	VVG
304953	100736417	20992767908	too	too	RG
304953	100736417	20992767909	much	much	DA1
304953	100736417	20992767910	can	can	VM
304953	100736417	20992767911	cause	cause	VVI
304953	100736417	20992767912	nausea	nausea	NN1
304953	100736417	20992767913	and	and	CC
304953	100736417	20992767914	vomiting	vomit	VVG_NN1@_JJ@
304953	100736417	20992767915	;	;	;
304953	100736417	20992767916	consult	consult	VVI
304953	100736417	20992767917	with	with	IW
304953	100736417	20992767918	your	your	APPGE
304953	100736417	20992767919	doctor	doctor	NN1
304953	100736417	20992767920	if	if	CS
304953	100736417	20992767921	you	you	PPY
304953	100736417	20992767922	are	be	VBR
304953	100736417	20992767923	undergoing	undergo	VVG
304953	100736417	20992767924	radiation	radiation	NN1
304953	100736417	20992767925	treatment	treatment	NN1
304953	100736417	20992767926	,	,	,
304953	100736417	20992767927	as	as	CSA
304953	100736417	20992767928	this	this	DD1
304953	100736417	20992767929	supplement	supplement	NN1
304953	100736417	20992767930	(	(	(
304953	100736417	20992767931	and	and	CC
304953	100736417	20992767932	any	any	DD
304953	100736417	20992767933	antioxidant	antioxidant	NN1_JJ
304953	100736417	20992767934	)	)	)
304953	100736417	20992767935	may	may	VM
304953	100736417	20992767936	interfere	interfere	VVI
304953	100736417	20992767937	with	with	IW
304953	100736417	20992767938	treatment	treatment	NN1
304953	100736417	20992767939	.	.	.
304953	100736417	20992767940	<p>		NULL
304953	100736417	20992767941	Strong	strong	JJ
304953	100736417	20992767942	evidence	evidence	NN1
304953	100736417	20992767943	exists	exist	VVZ
304953	100736417	20992767944	that	that	DD1_CST
304953	100736417	20992767945	selenium	selenium	NN1
304953	100736417	20992767946	reduces	reduce	VVZ
304953	100736417	20992767947	risk	risk	NN1
304953	100736417	20992767948	.	.	.
304953	100736417	20992767949	A	a	ZZ1_AT1
304953	100736417	20992767950	2003	2003	MC
304953	100736417	20992767951	randomized	randomize	VVD_JJ@
304953	100736417	20992767952	controlled	controlled	JJ@
304953	100736417	20992767953	study	study	NN1
304953	100736417	20992767954	found	find	VVD_VVN
304953	100736417	20992767955	that	that	CST
304953	100736417	20992767956	men	man	NN2
304953	100736417	20992767957	who	who	PNQS
304953	100736417	20992767958	took	take	VVD
304953	100736417	20992767959	selenium	selenium	NN1
304953	100736417	20992767960	supplements	supplement	NN2
304953	100736417	20992767961	were	be	VBDR
304953	100736417	20992767962	50%		NNU
304953	100736417	20992767963	less	less	DAR_RRR
304953	100736417	20992767964	@		II
304953	100736417	20992767965	@		II
304953	100736417	20992767966	@		II
304953	100736417	20992767967	@		II
304953	100736417	20992767968	@		II
304953	100736417	20992767969	@		II
304953	100736417	20992767970	@		II
304953	100736417	20992767971	@		II
304953	100736417	20992767972	@		II
304953	100736417	20992767973	@		II
304953	100736417	20992767974	pills	pill	NN2
304953	100736417	20992767975	.	.	.
304953	100736417	20992767976	Several	several	DA2
304953	100736417	20992767977	other	other	JJ
304953	100736417	20992767978	studies	study	NN2
304953	100736417	20992767979	reported	report	VVD_VVN
304953	100736417	20992767980	similar	similar	JJ
304953	100736417	20992767981	findings	finding	NN2
304953	100736417	20992767982	.	.	.
304953	100736417	20992767983	<p>		NULL
304953	100736417	20992767984	Insufficient	insufficient	JJ
304953	100736417	20992767985	evidence	evidence	NN1
304953	100736417	20992767986	exists	exist	VVZ
304953	100736417	20992767987	regarding	regarding	II_VVG
304953	100736417	20992767988	impact	impact	NN1
304953	100736417	20992767989	on	on	II
304953	100736417	20992767990	progression	progression	NN1
304953	100736417	20992767991	.	.	.
304953	100736417	20992767992	<p>		NULL
304953	100736417	20992767993	Tomatoes	tomato	NN2
304953	100736417	20992767994	<p>		NULL
304953	100736417	20992767995	Contain	contain	VV0
304953	100736417	20992767996	a	a	AT1
304953	100736417	20992767997	number	number	NN1
304953	100736417	20992767998	of	of	IO
304953	100736417	20992767999	nutrients	nutrient	NN2
304953	100736417	20992768000	;	;	;
304953	100736417	20992768001	it	it	PPH1
304953	100736417	20992768002	remains	remain	VVZ
304953	100736417	20992768003	unclear	unclear	JJ
304953	100736417	20992768004	whether	whether	CSW
304953	100736417	20992768005	the	the	AT
304953	100736417	20992768006	antioxidant	antioxidant	JJ_NN1
304953	100736417	20992768007	lycopene	lycopene	NN1
304953	100736417	20992768008	,	,	,
304953	100736417	20992768009	some	some	DD
304953	100736417	20992768010	other	other	JJ
304953	100736417	20992768011	nutrient	nutrient	NN1
304953	100736417	20992768012	,	,	,
304953	100736417	20992768013	or	or	CC
304953	100736417	20992768014	combinations	combination	NN2
304953	100736417	20992768015	of	of	IO
304953	100736417	20992768016	nutrients	nutrient	NN2
304953	100736417	20992768017	underlie	underlie	VV0
304953	100736417	20992768018	protective	protective	JJ
304953	100736417	20992768019	effect	effect	NN1
304953	100736417	20992768020	.	.	.
304953	100736417	20992768021	<p>		NULL
304953	100736417	20992768022	Good	good	JJ
304953	100736417	20992768023	evidence	evidence	NN1
304953	100736417	20992768024	that	that	CST_DD1
304953	100736417	20992768025	consumption	consumption	NN1
304953	100736417	20992768026	of	of	IO
304953	100736417	20992768027	cooked	cooked	JJ
304953	100736417	20992768028	tomatoes	tomato	NN2
304953	100736417	20992768029	may	may	VM
304953	100736417	20992768030	reduce	reduce	VVI
304953	100736417	20992768031	risk	risk	NN1
304953	100736417	20992768032	.	.	.
304953	100736417	20992768033	A	a	ZZ1_AT1
304953	100736417	20992768034	2002	2002	MC
304953	100736417	20992768035	study	study	NN1
304953	100736417	20992768036	found	find	VVD_VVN
304953	100736417	20992768037	that	that	CST
304953	100736417	20992768038	men	man	NN2
304953	100736417	20992768039	who	who	PNQS
304953	100736417	20992768040	regularly	regularly	RR
304953	100736417	20992768041	consumed	consume	VVD_VVN
304953	100736417	20992768042	two	two	MC
304953	100736417	20992768043	or	or	CC
304953	100736417	20992768044	more	more	DAR
304953	100736417	20992768045	servings	serving	NN2
304953	100736417	20992768046	of	of	IO
304953	100736417	20992768047	tomato	tomato	NN1
304953	100736417	20992768048	sauce	sauce	NN1
304953	100736417	20992768049	per	per	II
304953	100736417	20992768050	week	week	NNT1
304953	100736417	20992768051	could	could	VM
304953	100736417	20992768052	reduce	reduce	VVI
304953	100736417	20992768053	their	their	APPGE
304953	100736417	20992768054	risk	risk	NN1
304953	100736417	20992768055	of	of	IO
304953	100736417	20992768056	developing	developing	JJ_VVG
304953	100736417	20992768057	prostate	prostate	NN1
304953	100736417	20992768058	cancer	cancer	NN1
304953	100736417	20992768059	by	by	II
304953	100736417	20992768060	35%		NNU
304953	100736417	20992768061	compared	compare	VVN
304953	100736417	20992768062	with	with	IW
304953	100736417	20992768063	men	man	NN2
304953	100736417	20992768064	who	who	PNQS
304953	100736417	20992768065	ate	eat	VVD
304953	100736417	20992768066	tomato	tomato	NN1
304953	100736417	20992768067	sauce	sauce	NN1
304953	100736417	20992768068	less	less	RRR_DAR
304953	100736417	20992768069	than	than	CSN
304953	100736417	20992768070	once	once	RR
304953	100736417	20992768071	a	a	AT1
304953	100736417	20992768072	month	month	NNT1
304953	100736417	20992768073	.	.	.
304953	100736417	20992768074	A	a	AT1
304953	100736417	20992768075	review	review	NN1
304953	100736417	20992768076	of	of	IO
304953	100736417	20992768077	21	21	MC
304953	100736417	20992768078	studies	study	NN2
304953	100736417	20992768079	found	find	VVN_VVD
304953	100736417	20992768080	anywhere	anywhere	RL
304953	100736417	20992768081	from	from	II
304953	100736417	20992768082	a	a	AT1
304953	100736417	20992768083	10%		NNU
304953	100736417	20992768084	to	to	II
304953	100736417	20992768085	20%		NNU
304953	100736417	20992768086	reduction	reduction	NN1
304953	100736417	20992768087	in	in	II
304953	100736417	20992768088	risk	risk	NN1
304953	100736417	20992768089	among	among	II
304953	100736417	20992768090	men	man	NN2
304953	100736417	20992768091	with	with	IW
304953	100736417	20992768092	the	the	AT
304953	100736417	20992768093	highest	high	JJT
304953	100736417	20992768094	intake	intake	NN1
304953	100736417	20992768095	of	of	IO
304953	100736417	20992768096	tomatoes	tomato	NN2
304953	100736417	20992768097	,	,	,
304953	100736417	20992768098	with	with	IW
304953	100736417	20992768099	cooked	cooked	JJ
304953	100736417	20992768100	tomatoes	tomato	NN2
304953	100736417	20992768101	offering	offer	VVG
304953	100736417	20992768102	the	the	AT
304953	100736417	20992768103	most	most	DAT_RGT
304953	100736417	20992768104	protection	protection	NN1
304953	100736417	20992768105	.	.	.
304953	100736417	20992768106	<p>		NULL
304953	100736417	20992768107	Increasing	increasing	JJ_VVG
304953	100736417	20992768108	consumption	consumption	NN1
304953	100736417	20992768109	after	after	II_CS
304953	100736417	20992768110	diagnosis	diagnosis	NN1
304953	100736417	20992768111	may	may	VM
304953	100736417	20992768112	reduce	reduce	VVI
304953	100736417	20992768113	progression	progression	NN1
304953	100736417	20992768114	but	but	CCB
304953	100736417	20992768115	data	data	NN
304953	100736417	20992768116	are	be	VBR
304953	100736417	20992768117	more	more	RGR_RRR
304953	100736417	20992768118	limited	limited	JJ_VVN
304953	100736417	20992768119	.	.	.
304953	100736417	20992768120	A	a	ZZ1_AT1
304953	100736417	20992768121	2006	2006	MC
304953	100736417	20992768122	study	study	NN1
304953	100736417	20992768123	found	find	VVD_VVN
304953	100736417	20992768124	that	that	CST_DD1
304953	100736417	20992768125	increased	increased	JJ_VVD
304953	100736417	20992768126	intake	intake	NN1
304953	100736417	20992768127	of	of	IO
304953	100736417	20992768128	tomato	tomato	NN1
304953	100736417	20992768129	sauce	sauce	NN1
304953	100736417	20992768130	after	after	II_CS
304953	100736417	20992768131	diagnosis	diagnosis	NN1
304953	100736417	20992768132	might	might	VM
304953	100736417	20992768133	reduce	reduce	VVI
304953	100736417	20992768134	risk	risk	NN1
304953	100736417	20992768135	of	of	IO
304953	100736417	20992768136	prostate	prostate	NN1
304953	100736417	20992768137	cancer	cancer	NN1
304953	100736417	20992768138	progression	progression	NN1
304953	100736417	20992768139	by	by	II
304953	100736417	20992768140	30%		NNU
304953	100736417	20992768141	to	to	II
304953	100736417	20992768142	40%		NNU
304953	100736417	20992768143	.	.	.
304953	100736417	20992768144	Other	other	JJ
304953	100736417	20992768145	studies	study	NN2
304953	100736417	20992768146	reporting	report	VVG
304953	100736417	20992768147	a	a	AT1
304953	100736417	20992768148	protective	protective	JJ
304953	100736417	20992768149	effect	effect	NN1
304953	100736417	20992768150	from	from	II
304953	100736417	20992768151	increased	increased	JJ
304953	100736417	20992768152	tomato	tomato	NN1
304953	100736417	20992768153	consumption	consumption	NN1
304953	100736417	20992768154	after	after	II_CS
304953	100736417	20992768155	treatment	treatment	NN1
304953	100736417	20992768156	have	have	VH0
304953	100736417	20992768157	been	be	VBN
304953	100736417	20992768158	small	small	JJ
304953	100736417	20992768159	or	or	CC
304953	100736417	20992768160	poorly	poorly	RR
304953	100736417	20992768161	designed	design	VVN_VVD
304953	100736417	20992768162	.	.	.
304953	100736417	20992768163	<p>		NULL
304953	100736417	20992768164	@		II
304953	100736417	20992768165	@		II
304953	100736417	20992768166	@		II
304953	100736417	20992768167	@		II
304953	100736417	20992768168	@		II
304953	100736417	20992768169	@		II
304953	100736417	20992768170	@		II
304953	100736417	20992768171	@		II
304953	100736417	20992768172	@		II
304953	100736417	20992768173	@		II
304953	100736417	20992768174	;	;	;
304953	100736417	20992768175	supplements	supplement	NN2
304953	100736417	20992768176	contain	contain	VV0
304953	100736417	20992768177	alpha-tocopherol		NN1_JJ
304953	100736417	20992768178	,	,	,
304953	100736417	20992768179	a	a	AT1
304953	100736417	20992768180	form	form	NN1
304953	100736417	20992768181	of	of	IO
304953	100736417	20992768182	vitamin	vitamin	NN1
304953	100736417	20992768183	E.		NP1
304953	100736417	20992768184	<p>		NULL
304953	100736417	20992768185	Safety	safety	NN1
304953	100736417	20992768186	considerations	consideration	NN2
304953	100736417	20992768187	:	:	:
304953	100736417	20992768188	May	may	VM@
304953	100736417	20992768189	increase	increase	VVI
304953	100736417	20992768190	risk	risk	NN1
304953	100736417	20992768191	of	of	IO
304953	100736417	20992768192	bleeding	bleeding	JJ_VVG
304953	100736417	20992768193	if	if	CS_CSW@
304953	100736417	20992768194	you	you	PPY
304953	100736417	20992768195	are	be	VBR
304953	100736417	20992768196	taking	take	VVG
304953	100736417	20992768197	anticoagulants	anticoagulant	NN2
304953	100736417	20992768198	or	or	CC
304953	100736417	20992768199	antiplatelet	antiplatelet	NN1
304953	100736417	20992768200	medications	medication	NN2
304953	100736417	20992768201	;	;	;
304953	100736417	20992768202	may	may	VM
304953	100736417	20992768203	interfere	interfere	VVI
304953	100736417	20992768204	with	with	IW
304953	100736417	20992768205	treatment	treatment	NN1
304953	100736417	20992768206	if	if	CS
304953	100736417	20992768207	you	you	PPY
304953	100736417	20992768208	are	be	VBR
304953	100736417	20992768209	undergoing	undergo	VVG
304953	100736417	20992768210	radiation	radiation	NN1
304953	100736417	20992768211	therapy	therapy	NN1
304953	100736417	20992768212	(	(	(
304953	100736417	20992768213	ask	ask	VV0
304953	100736417	20992768214	your	your	APPGE
304953	100736417	20992768215	doctor	doctor	NN1
304953	100736417	20992768216	)	)	)
304953	100736417	20992768217	.	.	.
304953	100736417	20992768218	<p>		NULL
304953	100736417	20992768219	Good	good	JJ
304953	100736417	20992768220	evidence	evidence	NN1
304953	100736417	20992768221	that	that	CST
304953	100736417	20992768222	this	this	DD1
304953	100736417	20992768223	may	may	VM
304953	100736417	20992768224	reduce	reduce	VVI
304953	100736417	20992768225	risk	risk	NN1
304953	100736417	20992768226	,	,	,
304953	100736417	20992768227	but	but	CCB
304953	100736417	20992768228	the	the	AT
304953	100736417	20992768229	benefit	benefit	NN1
304953	100736417	20992768230	is	be	VBZ
304953	100736417	20992768231	seen	see	VVN
304953	100736417	20992768232	only	only	JJ
304953	100736417	20992768233	in	-in	II
304953	100736417	20992768234	men	man	NN2
304953	100736417	20992768235	who	who	PNQS
304953	100736417	20992768236	smoke	smoke	VV0
304953	100736417	20992768237	.	.	.
304953	100736417	20992768238	The	the	AT
304953	100736417	20992768239	Alpha-Tocopherol		NP1
304953	100736417	20992768240	Beta-Carotene		NP1
304953	100736417	20992768241	study	study	NN1
304953	100736417	20992768242	,	,	,
304953	100736417	20992768243	for	for	REX21
304953	100736417	20992768244	example	example	REX22
304953	100736417	20992768245	,	,	,
304953	100736417	20992768246	reported	report	VVD_VVN
304953	100736417	20992768247	that	that	CST
304953	100736417	20992768248	men	man	NN2
304953	100736417	20992768249	who	who	PNQS
304953	100736417	20992768250	smoked	smoke	VVD
304953	100736417	20992768251	and	and	CC
304953	100736417	20992768252	took	take	VVD
304953	100736417	20992768253	50-IU		JJ_NP1
304953	100736417	20992768254	vitamin	vitamin	NN1
304953	100736417	20992768255	E	e	ZZ1
304953	100736417	20992768256	supplements	supplement	NN2
304953	100736417	20992768257	a	a	AT1
304953	100736417	20992768258	day	day	NNT1
304953	100736417	20992768259	reduced	reduce	VVD_VVN_JJ@
304953	100736417	20992768260	risk	risk	NN1
304953	100736417	20992768261	of	of	IO
304953	100736417	20992768262	prostate	prostate	NN1
304953	100736417	20992768263	cancer	cancer	NN1
304953	100736417	20992768264	by	by	II
304953	100736417	20992768265	30%		NNU
304953	100736417	20992768266	to	to	II
304953	100736417	20992768267	40%		NNU
304953	100736417	20992768268	.	.	.
304953	100736417	20992768269	Other	other	JJ
304953	100736417	20992768270	studies	study	NN2
304953	100736417	20992768271	have	have	VH0
304953	100736417	20992768272	confirmed	confirm	VVN
304953	100736417	20992768273	a	a	AT1
304953	100736417	20992768274	protective	protective	JJ
304953	100736417	20992768275	effect	effect	NN1
304953	100736417	20992768276	for	for	IF
304953	100736417	20992768277	smokers	smoker	NN2
304953	100736417	20992768278	.	.	.
304953	100736417	20992768279	<p>		NULL
304953	100736417	20992768280	Limited	limited	JJ
304953	100736417	20992768281	data	data	NN
304953	100736417	20992768282	exist	exist	VV0
304953	100736417	20992768283	regarding	regarding	II_VVG
304953	100736417	20992768284	impact	impact	NN1
304953	100736417	20992768285	on	on	II
304953	100736417	20992768286	progression	progression	NN1
304953	100736417	20992768287	.	.	.
304953	100736417	20992768288	<p>		NULL
304953	100736417	20992768289	Substances	substance	NN2
304953	100736417	20992768290	that	that	CST_DD1
304953	100736417	20992768291	may	may	VM
304953	100736417	20992768292	be	be	VBI
304953	100736417	20992768293	protective	protective	JJ
304953	100736417	20992768294	,	,	,
304953	100736417	20992768295	but	but	CCB
304953	100736417	20992768296	evidence	evidence	NN1
304953	100736417	20992768297	is	be	VBZ
304953	100736417	20992768298	limited	limit	VVN_JJ
304953	100736417	20992768299	<p>		NULL
304953	100736417	20992768300	Substance	substance	NN1
304953	100736417	20992768301	and	and	CC
304953	100736417	20992768302	possible	possible	JJ
304953	100736417	20992768303	mechanism	mechanism	NN1
304953	100736417	20992768304	of	of	IO
304953	100736417	20992768305	action	action	NN1
304953	100736417	20992768306	<p>		NULL
304953	100736417	20992768307	Impact	impact	NN1
304953	100736417	20992768308	on	on	II
304953	100736417	20992768309	prostate	prostate	NN1
304953	100736417	20992768310	cancer	cancer	NN1
304953	100736417	20992768311	risk	risk	NN1
304953	100736417	20992768312	<p>		NULL
304953	100736417	20992768313	Impact	impact	NN1
304953	100736417	20992768314	on	on	II
304953	100736417	20992768315	prostate	prostate	NN1
304953	100736417	20992768316	cancer	cancer	NN1
304953	100736417	20992768317	progression	progression	NN1
304953	100736417	20992768318	<p>		NULL
304953	100736417	20992768319	Carotenoids	carotenoid	NN2_NP1@
304953	100736417	20992768320	<p>		NULL
304953	100736417	20992768321	(	(	(
304953	100736417	20992768322	Other	other	II21
304953	100736417	20992768323	than	than	II22
304953	100736417	20992768324	lycopene	lycopene	NN1
304953	100736417	20992768325	;	;	;
304953	100736417	20992768326	see	see	VV0
304953	100736417	20992768327	"	"	"
304953	100736417	20992768328	Tomatoes	tomato	NN2
304953	100736417	20992768329	,	,	,
304953	100736417	20992768330	"	"	"
304953	100736417	20992768331	above	above	RL
304953	100736417	20992768332	)	)	)
304953	100736417	20992768333	<p>		NULL
304953	100736417	20992768334	Occur	occur	VV0
304953	100736417	20992768335	naturally	naturally	RR
304953	100736417	20992768336	in	in	II
304953	100736417	20992768337	plants	plant	NN2
304953	100736417	20992768338	;	;	;
304953	100736417	20992768339	may	may	VM
304953	100736417	20992768340	have	have	VHI
304953	100736417	20992768341	antioxidant	antioxidant	JJ
304953	100736417	20992768342	properties	property	NN2
304953	100736417	20992768343	.	.	.
304953	100736417	20992768344	<p>		NULL
304953	100736417	20992768345	Some	some	DD
304953	100736417	20992768346	evidence	evidence	NN1
304953	100736417	20992768347	of	of	IO
304953	100736417	20992768348	reduced	reduced	JJ@
304953	100736417	20992768349	risk	risk	NN1
304953	100736417	20992768350	,	,	,
304953	100736417	20992768351	but	but	CCB
304953	100736417	20992768352	data	data	NN
304953	100736417	20992768353	are	be	VBR
304953	100736417	20992768354	limited	limit	VVN_JJ
304953	100736417	20992768355	and	and	CC
304953	100736417	20992768356	findings	finding	NN2
304953	100736417	20992768357	have	have	VH0
304953	100736417	20992768358	been	be	VBN
304953	100736417	20992768359	mixed	mix	VVN
304953	100736417	20992768360	.	.	.
304953	100736417	20992768361	One	one	MC1
304953	100736417	20992768362	study	study	NN1
304953	100736417	20992768363	reported	report	VVD_VVN
304953	100736417	20992768364	@		II
304953	100736417	20992768365	@		II
304953	100736417	20992768366	@		II
304953	100736417	20992768367	@		II
304953	100736417	20992768368	@		II
304953	100736417	20992768369	@		II
304953	100736417	20992768370	@		II
304953	100736417	20992768371	@		II
304953	100736417	20992768372	@		II
304953	100736417	20992768373	@		II
304953	100736417	20992768374	,	,	,
304953	100736417	20992768375	beta-cryptoxanthin		NN1_JJ
304953	100736417	20992768376	,	,	,
304953	100736417	20992768377	and	and	CC
304953	100736417	20992768378	zeaxanthin	zeaxanthin	NN1
304953	100736417	20992768379	had	have	VHD
304953	100736417	20992768380	a	a	AT1
304953	100736417	20992768381	70%		NNU
304953	100736417	20992768382	to	to	II
304953	100736417	20992768383	80%		NNU
304953	100736417	20992768384	reduced	reduced	JJ@_VVD_VVN
304953	100736417	20992768385	risk	risk	NN1
304953	100736417	20992768386	of	of	IO
304953	100736417	20992768387	prostate	prostate	NN1
304953	100736417	20992768388	cancer	cancer	NN1
304953	100736417	20992768389	.	.	.
304953	100736417	20992768390	But	but	CCB
304953	100736417	20992768391	a	a	AT1
304953	100736417	20992768392	randomized	randomized	JJ@
304953	100736417	20992768393	clinical	clinical	JJ
304953	100736417	20992768394	trial	trial	NN1
304953	100736417	20992768395	found	find	VVD_VVN
304953	100736417	20992768396	that	that	CST
304953	100736417	20992768397	men	man	NN2
304953	100736417	20992768398	who	who	PNQS
304953	100736417	20992768399	took	take	VVD
304953	100736417	20992768400	beta	beta	NN1
304953	100736417	20992768401	carotene	carotene	NN1
304953	100736417	20992768402	supplements	supplement	NN2
304953	100736417	20992768403	had	have	VHD
304953	100736417	20992768404	an	a	AT1
304953	100736417	20992768405	increased	increased	JJ
304953	100736417	20992768406	risk	risk	NN1
304953	100736417	20992768407	of	of	IO
304953	100736417	20992768408	prostate	prostate	NN1
304953	100736417	20992768409	cancer	cancer	NN1
304953	100736417	20992768410	if	if	CS
304953	100736417	20992768411	they	they	PPHS2
304953	100736417	20992768412	already	already	RR
304953	100736417	20992768413	had	have	VHN@_VHD
304953	100736417	20992768414	high	high	JJ
304953	100736417	20992768415	blood	blood	NN1
304953	100736417	20992768416	levels	level	NN2
304953	100736417	20992768417	of	of	IO
304953	100736417	20992768418	this	this	DD1
304953	100736417	20992768419	antioxidant	antioxidant	NN1_JJ
304953	100736417	20992768420	.	.	.
304953	100736417	20992768421	<p>		NULL
304953	100736417	20992768422	Limited	limited	JJ
304953	100736417	20992768423	data	data	NN
304953	100736417	20992768424	exist	exist	VV0
304953	100736417	20992768425	regarding	regarding	II_VVG
304953	100736417	20992768426	impact	impact	NN1
304953	100736417	20992768427	on	on	II
304953	100736417	20992768428	progression	progression	NN1
304953	100736417	20992768429	.	.	.
304953	100736417	20992768430	<p>		NULL
304953	100736417	20992768431	Melatonin	melatonin	NN1_NP1@
304953	100736417	20992768432	<p>		NULL
304953	100736417	20992768433	Inhibits		NP1@_NN2_VVZ
304953	100736417	20992768434	prostate	prostate	NN1
304953	100736417	20992768435	cancer	cancer	NN1
304953	100736417	20992768436	cell	cell	NN1
304953	100736417	20992768437	growth	growth	NN1
304953	100736417	20992768438	in	in	II
304953	100736417	20992768439	test	test	NN1
304953	100736417	20992768440	tubes	tube	NN2
304953	100736417	20992768441	.	.	.
304953	100736417	20992768442	<p>		NULL
304953	100736417	20992768443	Safety	safety	NN1
304953	100736417	20992768444	considerations	consideration	NN2
304953	100736417	20992768445	:	:	:
304953	100736417	20992768446	Avoid	avoid	VV0
304953	100736417	20992768447	if	if	CS_CSW@
304953	100736417	20992768448	you	you	PPY
304953	100736417	20992768449	are	be	VBR
304953	100736417	20992768450	taking	take	VVG
304953	100736417	20992768451	anticoagulants	anticoagulant	NN2
304953	100736417	20992768452	or	or	CC
304953	100736417	20992768453	antiplatelet	antiplatelet	NN1
304953	100736417	20992768454	medications	medication	NN2
304953	100736417	20992768455	;	;	;
304953	100736417	20992768456	may	may	VM
304953	100736417	20992768457	increase	increase	VVI
304953	100736417	20992768458	or	or	CC
304953	100736417	20992768459	decrease	decrease	VVI
304953	100736417	20992768460	blood	blood	NN1
304953	100736417	20992768461	pressure	pressure	NN1
304953	100736417	20992768462	,	,	,
304953	100736417	20992768463	and	and	CC
304953	100736417	20992768464	may	may	VM
304953	100736417	20992768465	increase	increase	VVI
304953	100736417	20992768466	blood	blood	NN1
304953	100736417	20992768467	sugar	sugar	NN1
304953	100736417	20992768468	levels	level	NN2
304953	100736417	20992768469	in	in	II
304953	100736417	20992768470	people	people	NN
304953	100736417	20992768471	with	with	IW
304953	100736417	20992768472	diabetes	diabetes	NN1
304953	100736417	20992768473	.	.	.
304953	100736417	20992768474	<p>		NULL
304953	100736417	20992768475	Insufficient	insufficient	JJ
304953	100736417	20992768476	evidence	evidence	NN1
304953	100736417	20992768477	,	,	,
304953	100736417	20992768478	although	although	CS
304953	100736417	20992768479	some	some	DD
304953	100736417	20992768480	studies	study	NN2
304953	100736417	20992768481	have	have	VH0
304953	100736417	20992768482	suggested	suggest	VVN
304953	100736417	20992768483	that	that	CST
304953	100736417	20992768484	men	man	NN2
304953	100736417	20992768485	with	with	IW
304953	100736417	20992768486	prostate	prostate	NN1
304953	100736417	20992768487	cancer	cancer	NN1
304953	100736417	20992768488	have	have	VH0
304953	100736417	20992768489	lower	low	JJR
304953	100736417	20992768490	levels	level	NN2
304953	100736417	20992768491	of	of	IO
304953	100736417	20992768492	melatonin	melatonin	NN1
304953	100736417	20992768493	than	than	CSN
304953	100736417	20992768494	other	other	JJ
304953	100736417	20992768495	men	man	NN2
304953	100736417	20992768496	.	.	.
304953	100736417	20992768497	<p>		NULL
304953	100736417	20992768498	A	a	AT1_ZZ1
304953	100736417	20992768499	small	small	JJ
304953	100736417	20992768500	study	study	NN1
304953	100736417	20992768501	involving	involve	VVG
304953	100736417	20992768502	14	14	MC
304953	100736417	20992768503	men	man	NN2
304953	100736417	20992768504	with	with	IW
304953	100736417	20992768505	advanced	advanced	JJ
304953	100736417	20992768506	prostate	prostate	NN1
304953	100736417	20992768507	cancer	cancer	NN1
304953	100736417	20992768508	who	who	PNQS
304953	100736417	20992768509	were	be	VBDR
304953	100736417	20992768510	not	not	XX
304953	100736417	20992768511	responding	respond	VVG
304953	100736417	20992768512	to	to	II
304953	100736417	20992768513	hormone	hormone	NN1
304953	100736417	20992768514	therapy	therapy	NN1
304953	100736417	20992768515	alone	alone	RR
304953	100736417	20992768516	found	find	VVN_VVD
304953	100736417	20992768517	that	that	CST_DD1
304953	100736417	20992768518	taking	take	VVG_JJ%
304953	100736417	20992768519	melatonin	melatonin	NN1
304953	100736417	20992768520	supplements	supplement	NN2
304953	100736417	20992768521	in	in	II31
304953	100736417	20992768522	addition	addition	II32
304953	100736417	20992768523	to	to	II33
304953	100736417	20992768524	hormone	hormone	NN1
304953	100736417	20992768525	therapy	therapy	NN1
304953	100736417	20992768526	improved	improved	JJ_VVD_VVN
304953	100736417	20992768527	response	response	NN1
304953	100736417	20992768528	.	.	.
304953	100736417	20992768529	PSA	psa	NP1
304953	100736417	20992768530	levels	level	NN2
304953	100736417	20992768531	decreased	decrease	VVN
304953	100736417	20992768532	by	by	II
304953	100736417	20992768533	more	more	DAR
304953	100736417	20992768534	than	than	CSN
304953	100736417	20992768535	half	half	DB
304953	100736417	20992768536	in	in	II
304953	100736417	20992768537	eight	eight	MC
304953	100736417	20992768538	men	man	NN2
304953	100736417	20992768539	,	,	,
304953	100736417	20992768540	and	and	CC
304953	100736417	20992768541	nine	nine	MC
304953	100736417	20992768542	lived	live	VVD_VVN
304953	100736417	20992768543	longer	long	RRR_JJR
304953	100736417	20992768544	than	than	CSN
304953	100736417	20992768545	one	one	MC1
304953	100736417	20992768546	year	year	NNT1
304953	100736417	20992768547	.	.	.
304953	100736417	20992768548	<p>		NULL
304953	100736417	20992768549	Pomegranate	pomegranate	NN1
304953	100736417	20992768550	juice	juice	NN1
304953	100736417	20992768551	<p>		NULL
304953	100736417	20992768552	Contains	contain	VVZ
304953	100736417	20992768553	a	a	AT1
304953	100736417	20992768554	variety	variety	NN1
304953	100736417	20992768555	of	of	IO
304953	100736417	20992768556	antioxidants	antioxidant	NN2
304953	100736417	20992768557	and	and	CC
304953	100736417	20992768558	flavonoids	flavonoid	NN2
304953	100736417	20992768559	,	,	,
304953	100736417	20992768560	which	which	DDQ
304953	100736417	20992768561	may	may	VM
304953	100736417	20992768562	inhibit	inhibit	VVI
304953	100736417	20992768563	cancer	cancer	NN1
304953	100736417	20992768564	@		II
304953	100736417	20992768565	@		II
304953	100736417	20992768566	@		II
304953	100736417	20992768567	@		II
304953	100736417	20992768568	@		II
304953	100736417	20992768569	@		II
304953	100736417	20992768570	@		II
304953	100736417	20992768571	@		II
304953	100736417	20992768572	@		II
304953	100736417	20992768573	@		II
304953	100736417	20992768574	cancer	cancer	NN1
304953	100736417	20992768575	.	.	.
304953	100736417	20992768576	<p>		NULL
304953	100736417	20992768577	A	a	AT1_ZZ1
304953	100736417	20992768578	small	small	JJ
304953	100736417	20992768579	2006	2006	MC
304953	100736417	20992768580	study	study	NN1
304953	100736417	20992768581	suggests	suggest	VVZ
304953	100736417	20992768582	that	that	CST
304953	100736417	20992768583	men	man	NN2
304953	100736417	20992768584	whose	whose	DDQGE
304953	100736417	20992768585	PSA	psa	NP1
304953	100736417	20992768586	is	be	VBZ
304953	100736417	20992768587	rising	rise	VVG
304953	100736417	20992768588	after	after	II
304953	100736417	20992768589	cancer	cancer	NN1
304953	100736417	20992768590	treatment	treatment	NN1
304953	100736417	20992768591	may	may	VM
304953	100736417	20992768592	be	be	VBI
304953	100736417	20992768593	able	able	JK
304953	100736417	20992768594	to	to	TO
304953	100736417	20992768595	slow	slow	VVI
304953	100736417	20992768596	the	the	AT
304953	100736417	20992768597	rate	rate	NN1
304953	100736417	20992768598	at	at	II
304953	100736417	20992768599	which	which	DDQ
304953	100736417	20992768600	PSA	psa	NP1
304953	100736417	20992768601	increases	increase	VVZ_NN2
304953	100736417	20992768602	by	by	II
304953	100736417	20992768603	drinking	drink	VVG_NN1
304953	100736417	20992768604	8	8	MC
304953	100736417	20992768605	ounces	ounce	NNU2
304953	100736417	20992768606	of	of	IO
304953	100736417	20992768607	pomegranate	pomegranate	NN1
304953	100736417	20992768608	juice	juice	NN1
304953	100736417	20992768609	every	every	AT1
304953	100736417	20992768610	day	day	NNT1
304953	100736417	20992768611	.	.	.
304953	100736417	20992768612	The	the	AT
304953	100736417	20992768613	study	study	NN1
304953	100736417	20992768614	involved	involve	VVD_VVN
304953	100736417	20992768615	50	50	MC
304953	100736417	20992768616	men	man	NN2
304953	100736417	20992768617	who	who	PNQS
304953	100736417	20992768618	were	be	VBDR
304953	100736417	20992768619	followed	follow	VVN
304953	100736417	20992768620	until	until	CS_II@
304953	100736417	20992768621	their	their	APPGE
304953	100736417	20992768622	PSA	psa	NP1
304953	100736417	20992768623	doubled	double	VVD
304953	100736417	20992768624	.	.	.
304953	100736417	20992768625	Investigators	investigator	NN2
304953	100736417	20992768626	found	find	VVD_VVN
304953	100736417	20992768627	that	that	CST_DD1
304953	100736417	20992768628	average	average	JJ_NN1_VV0@
304953	100736417	20992768629	PSA	psa	NP1
304953	100736417	20992768630	doubling	doubling	NN1_VVG
304953	100736417	20992768631	time	time	NNT1
304953	100736417	20992768632	slowed	slow	VVN_VVD
304953	100736417	20992768633	from	from	II
304953	100736417	20992768634	an	a	AT1
304953	100736417	20992768635	average	average	NN1
304953	100736417	20992768636	of	of	IO
304953	100736417	20992768637	15	15	MC
304953	100736417	20992768638	months	month	NNT2
304953	100736417	20992768639	before	before	II_CS
304953	100736417	20992768640	the	the	AT
304953	100736417	20992768641	study	study	NN1
304953	100736417	20992768642	began	begin	VVD
304953	100736417	20992768643	to	to	II
304953	100736417	20992768644	an	a	AT1
304953	100736417	20992768645	average	average	NN1
304953	100736417	20992768646	of	of	IO
304953	100736417	20992768647	54	54	MC
304953	100736417	20992768648	months	month	NNT2
304953	100736417	20992768649	afterward	afterward	RL
304953	100736417	20992768650	.	.	.
304953	100736417	20992768651	<p>		NULL
304953	100736417	20992768652	Soy	soy	JJ
304953	100736417	20992768653	<p>		NULL
304953	100736417	20992768654	Contains	contain	VVZ
304953	100736417	20992768655	isoflavones	isoflavone	NN2
304953	100736417	20992768656	,	,	,
304953	100736417	20992768657	nutrients	nutrient	NN2
304953	100736417	20992768658	that	that	CST_DD1
304953	100736417	20992768659	can	can	VM
304953	100736417	20992768660	inhibit	inhibit	VVI
304953	100736417	20992768661	cell	cell	NN1
304953	100736417	20992768662	growth	growth	NN1
304953	100736417	20992768663	and	and	CC
304953	100736417	20992768664	affect	affect	VVI
304953	100736417	20992768665	hormones	hormone	NN2
304953	100736417	20992768666	that	that	CST_DD1
304953	100736417	20992768667	may	may	VM
304953	100736417	20992768668	fuel	fuel	VVI
304953	100736417	20992768669	the	the	AT
304953	100736417	20992768670	growth	growth	NN1
304953	100736417	20992768671	of	of	IO
304953	100736417	20992768672	prostate	prostate	NN1
304953	100736417	20992768673	cancer	cancer	NN1
304953	100736417	20992768674	.	.	.
304953	100736417	20992768675	<p>		NULL
304953	100736417	20992768676	Safety	safety	NN1
304953	100736417	20992768677	considerations	consideration	NN2
304953	100736417	20992768678	:	:	:
304953	100736417	20992768679	May	may	VM@
304953	100736417	20992768680	interact	interact	VVI
304953	100736417	20992768681	with	with	IW
304953	100736417	20992768682	warfarin	warfarin	NN1
304953	100736417	20992768683	(	(	(
304953	100736417	20992768684	Coumadin	coumadin	NP1
304953	100736417	20992768685	)	)	)
304953	100736417	20992768686	;	;	;
304953	100736417	20992768687	check	check	VV0_NN1
304953	100736417	20992768688	with	with	IW
304953	100736417	20992768689	your	your	APPGE
304953	100736417	20992768690	doctor	doctor	NN1
304953	100736417	20992768691	for	for	IF
304953	100736417	20992768692	advice	advice	NN1
304953	100736417	20992768693	.	.	.
304953	100736417	20992768694	<p>		NULL
304953	100736417	20992768695	Good	good	JJ
304953	100736417	20992768696	evidence	evidence	NN1
304953	100736417	20992768697	that	that	CST
304953	100736417	20992768698	higher	high	JJR
304953	100736417	20992768699	intake	intake	NN1
304953	100736417	20992768700	increases	increase	VVZ_NN2
304953	100736417	20992768701	risk	risk	NN1_VV0
304953	100736417	20992768702	.	.	.
304953	100736417	20992768703	One	one	MC1
304953	100736417	20992768704	study	study	NN1
304953	100736417	20992768705	found	find	VVD_VVN
304953	100736417	20992768706	that	that	CST
304953	100736417	20992768707	men	man	NN2
304953	100736417	20992768708	who	who	PNQS
304953	100736417	20992768709	consumed	consume	VVD
304953	100736417	20992768710	more	more	DAR
304953	100736417	20992768711	than	than	CSN
304953	100736417	20992768712	2,000	2,000	MC
304953	100736417	20992768713	mg	mg	NNU
304953	100736417	20992768714	of	of	IO
304953	100736417	20992768715	calcium	calcium	NN1
304953	100736417	20992768716	daily	daily	RR_NN1@
304953	100736417	20992768717	were	be	VBDR
304953	100736417	20992768718	five	five	MC
304953	100736417	20992768719	times	time	NNT2
304953	100736417	20992768720	as	as	RG
304953	100736417	20992768721	likely	likely	JJ
304953	100736417	20992768722	to	to	TO
304953	100736417	20992768723	develop	develop	VVI
304953	100736417	20992768724	metastatic	metastatic	JJ
304953	100736417	20992768725	prostate	prostate	NN1
304953	100736417	20992768726	cancer	cancer	NN1
304953	100736417	20992768727	as	as	CSA
304953	100736417	20992768728	those	those	DD2
304953	100736417	20992768729	who	who	PNQS
304953	100736417	20992768730	consumed	consume	VVD
304953	100736417	20992768731	less	less	DAR
304953	100736417	20992768732	than	than	CSN
304953	100736417	20992768733	500	500	MC
304953	100736417	20992768734	mg	mg	NNU
304953	100736417	20992768735	of	of	IO
304953	100736417	20992768736	calcium	calcium	NN1
304953	100736417	20992768737	per	per	II
304953	100736417	20992768738	day	day	NNT1
304953	100736417	20992768739	.	.	.
304953	100736417	20992768740	A	a	AT1_ZZ1
304953	100736417	20992768741	large	large	JJ
304953	100736417	20992768742	epidemiologic	epidemiologic	JJ
304953	100736417	20992768743	study	study	NN1
304953	100736417	20992768744	found	find	VVD_VVN
304953	100736417	20992768745	that	that	DD1_CST
304953	100736417	20992768746	intake	intake	NN1
304953	100736417	20992768747	of	of	IO
304953	100736417	20992768748	more	more	DAR
304953	100736417	20992768749	than	than	CSN
304953	100736417	20992768750	1,500	1,500	MC
304953	100736417	20992768751	mg	mg	NNU
304953	100736417	20992768752	of	of	IO
304953	100736417	20992768753	calcium	calcium	NN1
304953	100736417	20992768754	per	per	II
304953	100736417	20992768755	day	day	NNT1
304953	100736417	20992768756	might	might	VM
304953	100736417	20992768757	increase	increase	VVI
304953	100736417	20992768758	the	the	AT
304953	100736417	20992768759	risk	risk	NN1
304953	100736417	20992768760	of	of	IO
304953	100736417	20992768761	aggressive	aggressive	JJ
304953	100736417	20992768762	and	and	CC
304953	100736417	20992768763	fatal	fatal	JJ
304953	100736417	20992768764	@		II
304953	100736417	20992768765	@		II
304953	100736417	20992768766	@		II
304953	100736417	20992768767	@		II
304953	100736417	20992768768	@		II
304953	100736417	20992768769	@		II
304953	100736417	20992768770	@		II
304953	100736417	20992768771	@		II
304953	100736417	20992768772	@		II
304953	100736417	20992768773	@		II
304953	100736417	20992768774	,	,	,
304953	100736417	20992768775	localized	localized	JJ_VVD
304953	100736417	20992768776	cancer	cancer	NN1
304953	100736417	20992768777	.	.	.
304953	100736417	20992768778	<p>		NULL
304953	100736417	20992768779	Studies	study	NN2
304953	100736417	20992768780	suggest	suggest	VV0
304953	100736417	20992768781	that	that	CST_DD1
304953	100736417	20992768782	high	high	JJ
304953	100736417	20992768783	calcium	calcium	NN1
304953	100736417	20992768784	intake	intake	NN1
304953	100736417	20992768785	may	may	VM
304953	100736417	20992768786	increase	increase	VVI
304953	100736417	20992768787	the	the	AT
304953	100736417	20992768788	likelihood	likelihood	NN1
304953	100736417	20992768789	of	of	IO
304953	100736417	20992768790	progression	progression	NN1
304953	100736417	20992768791	.	.	.
304953	100736417	20992768792	One	one	MC1
304953	100736417	20992768793	theory	theory	NN1
304953	100736417	20992768794	is	be	VBZ
304953	100736417	20992768795	that	that	DD1_CST
304953	100736417	20992768796	calcium	calcium	NN1
304953	100736417	20992768797	has	have	VHZ
304953	100736417	20992768798	different	different	JJ
304953	100736417	20992768799	effects	effect	NN2
304953	100736417	20992768800	,	,	,
304953	100736417	20992768801	depending	depending	II21
304953	100736417	20992768802	on	on	II22
304953	100736417	20992768803	the	the	AT
304953	100736417	20992768804	stage	stage	NN1
304953	100736417	20992768805	of	of	IO
304953	100736417	20992768806	cancer	cancer	NN1
304953	100736417	20992768807	development	development	NN1
304953	100736417	20992768808	or	or	CC
304953	100736417	20992768809	progression	progression	NN1
304953	100736417	20992768810	.	.	.
304953	100736417	20992768811	<p>		NULL
304953	100736417	20992768812	Meat	meat	NN1
304953	100736417	20992768813	consumption	consumption	NN1
304953	100736417	20992768814	<p>		NULL
304953	100736417	20992768815	A	a	AT1
304953	100736417	20992768816	number	number	NN1
304953	100736417	20992768817	of	of	IO
304953	100736417	20992768818	studies	study	NN2
304953	100736417	20992768819	have	have	VH0
304953	100736417	20992768820	found	find	VVN
304953	100736417	20992768821	that	that	CST_DD1
304953	100736417	20992768822	increased	increased	JJ_VVD
304953	100736417	20992768823	consumption	consumption	NN1
304953	100736417	20992768824	of	of	IO
304953	100736417	20992768825	meat	meat	NN1
304953	100736417	20992768826	,	,	,
304953	100736417	20992768827	especially	especially	RR
304953	100736417	20992768828	red	red	JJ
304953	100736417	20992768829	meat	meat	NN1
304953	100736417	20992768830	,	,	,
304953	100736417	20992768831	increases	increase	VVZ_NN2
304953	100736417	20992768832	risk	risk	NN1
304953	100736417	20992768833	of	of	IO
304953	100736417	20992768834	developing	developing	JJ_VVG
304953	100736417	20992768835	prostate	prostate	NN1
304953	100736417	20992768836	cancer	cancer	NN1
304953	100736417	20992768837	,	,	,
304953	100736417	20992768838	possibly	possibly	RR
304953	100736417	20992768839	because	because	II21
304953	100736417	20992768840	of	of	II22
304953	100736417	20992768841	high	high	JJ
304953	100736417	20992768842	fat	fat	JJ_NN1
304953	100736417	20992768843	content	content	NN1_JJ
304953	100736417	20992768844	or	or	CC
304953	100736417	20992768845	the	the	AT
304953	100736417	20992768846	way	way	NN1
304953	100736417	20992768847	the	the	AT
304953	100736417	20992768848	meat	meat	NN1
304953	100736417	20992768849	is	be	VBZ
304953	100736417	20992768850	cooked	cook	VVN_JJ
304953	100736417	20992768851	.	.	.
304953	100736417	20992768852	<p>		NULL
304953	100736417	20992768853	Insufficient	insufficient	JJ
304953	100736417	20992768854	evidence	evidence	NN1
304953	100736417	20992768855	regarding	regarding	II_VVG
304953	100736417	20992768856	impact	impact	NN1
304953	100736417	20992768857	on	on	II
304953	100736417	20992768858	progression	progression	NN1
304953	100736417	20992768859	.	.	.
304953	100736417	20992768860	<p>		NULL
304953	100736417	20992768861	Zinc	zinc	NN1_NP1@
304953	100736417	20992768862	<p>		NULL
304953	100736417	20992768863	Because	because	CS
304953	100736417	20992768864	zinc	zinc	NN1
304953	100736417	20992768865	contributes	contribute	VVZ
304953	100736417	20992768866	to	to	II
304953	100736417	20992768867	many	many	DA2
304953	100736417	20992768868	bodily	bodily	JJ
304953	100736417	20992768869	functions	function	NN2
304953	100736417	20992768870	,	,	,
304953	100736417	20992768871	including	including	II_VVG@
304953	100736417	20992768872	healthy	healthy	JJ
304953	100736417	20992768873	immune	immune	JJ
304953	100736417	20992768874	functioning	functioning	NN1@_JJ@
304953	100736417	20992768875	and	and	CC
304953	100736417	20992768876	wound	wound	NN1_VVD_VVN
304953	100736417	20992768877	healing	healing	NN1_JJ
304953	100736417	20992768878	,	,	,
304953	100736417	20992768879	zinc	zinc	NN1
304953	100736417	20992768880	supplements	supplement	NN2
304953	100736417	20992768881	have	have	VH0
304953	100736417	20992768882	sometimes	sometimes	RT
304953	100736417	20992768883	been	be	VBN
304953	100736417	20992768884	touted	tout	VVN
304953	100736417	20992768885	as	as	II
304953	100736417	20992768886	a	a	AT1
304953	100736417	20992768887	cure	cure	NN1
304953	100736417	20992768888	for	for	IF
304953	100736417	20992768889	various	various	JJ
304953	100736417	20992768890	prostate	prostate	NN1
304953	100736417	20992768891	diseases	disease	NN2
304953	100736417	20992768892	.	.	.
304953	100736417	20992768893	However	however	RR
304953	100736417	20992768894	,	,	,
304953	100736417	20992768895	there	there	EX
304953	100736417	20992768896	is	be	VBZ
304953	100736417	20992768897	no	no	AT
304953	100736417	20992768898	evidence	evidence	NN1
304953	100736417	20992768899	that	that	CST_DD1
304953	100736417	20992768900	zinc	zinc	NN1
304953	100736417	20992768901	supplements	supplement	NN2
304953	100736417	20992768902	help	help	VV0_NN1
304953	100736417	20992768903	and	and	CC
304953	100736417	20992768904	in	in	II
304953	100736417	20992768905	prostate	prostate	NN1
304953	100736417	20992768906	cancer	cancer	NN1
304953	100736417	20992768907	,	,	,
304953	100736417	20992768908	such	such	DA
304953	100736417	20992768909	supplements	supplement	NN2
304953	100736417	20992768910	may	may	VM
304953	100736417	20992768911	cause	cause	VVI
304953	100736417	20992768912	harm	harm	NN1
304953	100736417	20992768913	.	.	.
304953	100736417	20992768914	<p>		NULL
304953	100736417	20992768915	Limited	limited	JJ
304953	100736417	20992768916	evidence	evidence	NN1
304953	100736417	20992768917	that	that	CST_DD1
304953	100736417	20992768918	zinc	zinc	NN1
304953	100736417	20992768919	supplements	supplement	NN2
304953	100736417	20992768920	may	may	VM
304953	100736417	20992768921	increase	increase	VVI
304953	100736417	20992768922	risk	risk	NN1
304953	100736417	20992768923	.	.	.
304953	100736417	20992768924	One	one	MC1
304953	100736417	20992768925	study	study	NN1
304953	100736417	20992768926	found	find	VVD_VVN
304953	100736417	20992768927	that	that	CST
304953	100736417	20992768928	men	man	NN2
304953	100736417	20992768929	who	who	PNQS
304953	100736417	20992768930	took	take	VVD
304953	100736417	20992768931	100-mg		JJ_NNU
304953	100736417	20992768932	zinc	zinc	NN1
304953	100736417	20992768933	supplements	supplement	NN2
304953	100736417	20992768934	daily	daily	RR
304953	100736417	20992768935	were	be	VBDR
304953	100736417	20992768936	more	more	DAR
304953	100736417	20992768937	than	than	CSN
304953	100736417	20992768938	twice	twice	RR
304953	100736417	20992768939	as	as	CSA_RG@
304953	100736417	20992768940	likely	likely	JJ
304953	100736417	20992768941	to	to	TO
304953	100736417	20992768942	develop	develop	VVI
304953	100736417	20992768943	advanced	advanced	JJ
304953	100736417	20992768944	prostate	prostate	NN1
304953	100736417	20992768945	cancer	cancer	NN1
304953	100736417	20992768946	as	as	CSA_II@
304953	100736417	20992768947	men	man	NN2
304953	100736417	20992768948	who	who	PNQS
304953	100736417	20992768949	did	do	VDD
304953	100736417	20992768950	not	not	XX
304953	100736417	20992768951	take	take	VVI
304953	100736417	20992768952	the	the	AT
304953	100736417	20992768953	supplements	supplement	NN2
304953	100736417	20992768954	.	.	.
304953	100736417	20992768955	<p>		NULL
304953	100736417	20992768956	No	no	AT
304953	100736417	20992768957	data	data	NN
304953	100736417	20992768958	are	be	VBR
304953	100736417	20992768959	available	available	JJ
304953	100736417	20992768960	regarding	regarding	II
304953	100736417	20992768961	impact	impact	NN1
304953	100736417	20992768962	on	on	II
304953	100736417	20992768963	progression	progression	NN1
304953	100736417	20992768964	@		II
304953	100736417	20992768965	@		II
304953	100736417	20992768966	@		II
304953	100736417	20992768967	@		II
304953	100736417	20992768968	@		II
304953	100736417	20992768969	@		II
304953	100736417	20992768970	@		II
304953	100736417	20992768971	@		II
304953	100736417	20992768972	@		II
304953	100736417	20992768973	@		II
304953	100736417	20992768974	To	to	TO
304953	100736417	20992768975	learn	learn	VVI
304953	100736417	20992768976	more	more	RRR_DAR
304953	100736417	20992768977	about	about	II
304953	100736417	20992768978	complementary	complementary	JJ
304953	100736417	20992768979	therapies	therapy	NN2
304953	100736417	20992768980	for	for	IF
304953	100736417	20992768981	prostatitis	prostatitis	NN1
304953	100736417	20992768982	,	,	,
304953	100736417	20992768983	see	see	VV0
304953	100736417	20992768984	"	"	"
304953	100736417	20992768985	Assessing	assess	VVG
304953	100736417	20992768986	the	the	AT
304953	100736417	20992768987	evidence	evidence	NN1
304953	100736417	20992768988	:	:	:
304953	100736417	20992768989	Prostatitis		NP1_NN1
304953	100736417	20992768990	.	.	.
304953	100736417	20992768991	"	"	"
304953	100736417	20992768992	<p>		NULL
304953	100736417	20992768993	Substance	substance	NN1
304953	100736417	20992768994	that	that	CST_DD1
304953	100736417	20992768995	may	may	VM
304953	100736417	20992768996	work	work	VVI
304953	100736417	20992768997	<p>		NULL
304953	100736417	20992768998	Substance	substance	NN1
304953	100736417	20992768999	and	and	CC
304953	100736417	20992769000	possible	possible	JJ
304953	100736417	20992769001	mechanism	mechanism	NN1
304953	100736417	20992769002	of	of	IO
304953	100736417	20992769003	action	action	NN1
304953	100736417	20992769004	<p>		NULL
304953	100736417	20992769005	Assessment	assessment	NN1
304953	100736417	20992769006	<p>		NULL
304953	100736417	20992769007	Quercetin	quercetin	NN1_NP1@
304953	100736417	20992769008	<p>		NULL
304953	100736417	20992769009	A	a	AT1_ZZ1
304953	100736417	20992769010	bioflavonoid	bioflavonoid	NN1_JJ
304953	100736417	20992769011	,	,	,
304953	100736417	20992769012	a	a	AT1
304953	100736417	20992769013	chemical	chemical	NN1_JJ
304953	100736417	20992769014	that	that	CST_DD1
304953	100736417	20992769015	contributes	contribute	VVZ
304953	100736417	20992769016	to	to	TO
304953	100736417	20992769017	color	color	VVI
304953	100736417	20992769018	in	in	II_RP@
304953	100736417	20992769019	plants	plant	NN2
304953	100736417	20992769020	;	;	;
304953	100736417	20992769021	its	its	APPGE
304953	100736417	20992769022	antioxidant	antioxidant	NN1_JJ
304953	100736417	20992769023	and	and	CC
304953	100736417	20992769024	anti-inflammatory	anti-inflammatory	JJ
304953	100736417	20992769025	effects	effect	NN2
304953	100736417	20992769026	may	may	VM
304953	100736417	20992769027	explain	explain	VVI
304953	100736417	20992769028	how	how	RRQ
304953	100736417	20992769029	it	it	PPH1
304953	100736417	20992769030	works	work	VVZ
304953	100736417	20992769031	.	.	.
304953	100736417	20992769032	<p>		NULL
304953	100736417	20992769033	One	one	MC1_PN1
304953	100736417	20992769034	small	small	JJ_RR%
304953	100736417	20992769035	randomized	randomized	JJ@_VVD
304953	100736417	20992769036	controlled	controlled	JJ@
304953	100736417	20992769037	study	study	NN1
304953	100736417	20992769038	has	have	VHZ
304953	100736417	20992769039	evaluated	evaluate	VVN
304953	100736417	20992769040	quercetin	quercetin	NN1
304953	100736417	20992769041	for	for	IF
304953	100736417	20992769042	the	the	AT
304953	100736417	20992769043	treatment	treatment	NN1
304953	100736417	20992769044	of	of	IO
304953	100736417	20992769045	chronic	chronic	JJ
304953	100736417	20992769046	nonbacterial	nonbacterial	JJ
304953	100736417	20992769047	prostatitis	prostatitis	NN1
304953	100736417	20992769048	(	(	(
304953	100736417	20992769049	chronic	chronic	JJ
304953	100736417	20992769050	pelvic	pelvic	JJ
304953	100736417	20992769051	pain	pain	NN1
304953	100736417	20992769052	syndrome	syndrome	NN1
304953	100736417	20992769053	)	)	)
304953	100736417	20992769054	.	.	.
304953	100736417	20992769055	The	the	AT
304953	100736417	20992769056	study	study	NN1
304953	100736417	20992769057	involved	involve	VVD_VVN
304953	100736417	20992769058	30	30	MC
304953	100736417	20992769059	men	man	NN2
304953	100736417	20992769060	who	who	PNQS
304953	100736417	20992769061	took	take	VVD
304953	100736417	20992769062	quercetin	quercetin	NN1
304953	100736417	20992769063	for	for	IF
304953	100736417	20992769064	a	a	AT1
304953	100736417	20992769065	month	month	NNT1
304953	100736417	20992769066	.	.	.
304953	100736417	20992769067	Investigators	investigator	NN2
304953	100736417	20992769068	reported	report	VVN_VVD
304953	100736417	20992769069	in	in	II
304953	100736417	20992769070	1999	1999	MC
304953	100736417	20992769071	in	in	II
304953	100736417	20992769072	Urology	urology	NN1_NP1
304953	100736417	20992769073	that	that	CST_DD1
304953	100736417	20992769074	67%		NNU
304953	100736417	20992769075	of	of	IO
304953	100736417	20992769076	men	man	NN2
304953	100736417	20992769077	taking	take	VVG
304953	100736417	20992769078	quercetin	quercetin	NN1
304953	100736417	20992769079	reported	report	VVD_VVN_JJ@
304953	100736417	20992769080	improvement	improvement	NN1
304953	100736417	20992769081	of	of	IO
304953	100736417	20992769082	symptoms	symptom	NN2
304953	100736417	20992769083	,	,	,
304953	100736417	20992769084	compared	compare	VVN
304953	100736417	20992769085	with	with	IW
304953	100736417	20992769086	20%		NNU
304953	100736417	20992769087	of	of	IO
304953	100736417	20992769088	men	man	NN2
304953	100736417	20992769089	taking	take	VVG
304953	100736417	20992769090	placebo	placebo	NN1
304953	100736417	20992769091	.	.	.
304953	100736417	20992769092	<p>		NULL
304953	100736417	20992769093	My	my	APPGE
304953	100736417	20992769094	PSA	psa	NP1
304953	100736417	20992769095	went	go	VVD
304953	100736417	20992769096	from	from	II
304953	100736417	20992769097	a	a	AT1
304953	100736417	20992769098	consistent	consistent	JJ
304953	100736417	20992769099	(	(	(
304953	100736417	20992769100	4.5	-4.5	MC
304953	100736417	20992769101	+	+	FO
304953	100736417	20992769102	or	or	CC
304953	100736417	20992769103	0.2	0.2	MC
304953	100736417	20992769104	)	)	)
304953	100736417	20992769105	to	to	II
304953	100736417	20992769106	7.47	7.47	MC
304953	100736417	20992769107	in	in	II
304953	100736417	20992769108	17	17	MC
304953	100736417	20992769109	mos	mo	NN2
304953	100736417	20992769110	.	.	.
304953	100736417	20992769111	I	i	PPIS1
304953	100736417	20992769112	was	be	VBDZ
304953	100736417	20992769113	treated	treat	VVN
304953	100736417	20992769114	with	with	IW
304953	100736417	20992769115	several	several	DA2
304953	100736417	20992769116	antibiotics	antibiotic	NN2
304953	100736417	20992769117	thinking	think	VVG
304953	100736417	20992769118	it	it	PPH1
304953	100736417	20992769119	was	be	VBDZ
304953	100736417	20992769120	prostatitis	prostatitis	NN1
304953	100736417	20992769121	then	then	RT
304953	100736417	20992769122	it	it	PPH1
304953	100736417	20992769123	went	go	VVD
304953	100736417	20992769124	to	to	II
304953	100736417	20992769125	9.89	9.89	MC
304953	100736417	20992769126	in	in	II
304953	100736417	20992769127	two	two	MC
304953	100736417	20992769128	mos	mo	NN2
304953	100736417	20992769129	.	.	.
304953	100736417	20992769130	I	i	PPIS1
304953	100736417	20992769131	postponed	postpone	VVD
304953	100736417	20992769132	my	my	APPGE
304953	100736417	20992769133	next	next	MD
304953	100736417	20992769134	urologic	urologic	JJ
304953	100736417	20992769135	appointment	appointment	NN1
304953	100736417	20992769136	because	because	CS
304953	100736417	20992769137	I	i	PPIS1
304953	100736417	20992769138	was	be	VBDZ
304953	100736417	20992769139	scared	scared	JJ_VVN%
304953	100736417	20992769140	it	it	PPH1
304953	100736417	20992769141	is	be	VBZ
304953	100736417	20992769142	probably	probably	RR
304953	100736417	20992769143	prostate	prostate	NN1
304953	100736417	20992769144	cancer	cancer	NN1
304953	100736417	20992769145	.	.	.
304953	100736417	20992769146	That	that	DD1
304953	100736417	20992769147	is	be	VBZ
304953	100736417	20992769148	when	when	RRQ_CS
304953	100736417	20992769149	I	i	PPIS1
304953	100736417	20992769150	began	begin	VVD
304953	100736417	20992769151	my	my	APPGE
304953	100736417	20992769152	research	research	NN1
304953	100736417	20992769153	.	.	.
304953	100736417	20992769154	I	i	PPIS1
304953	100736417	20992769155	was	be	VBDZ
304953	100736417	20992769156	already	already	RR
304953	100736417	20992769157	eating	eat	VVG
304953	100736417	20992769158	healthful	healthful	JJ
304953	100736417	20992769159	(	(	(
304953	100736417	20992769160	I	i	MC1%_PPIS1_ZZ1%
304953	100736417	20992769161	thought	thought	NN1_VVD
304953	100736417	20992769162	)	)	)
304953	100736417	20992769163	and	and	CC
304953	100736417	20992769164	@		II
304953	100736417	20992769165	@		II
304953	100736417	20992769166	@		II
304953	100736417	20992769167	@		II
304953	100736417	20992769168	@		II
304953	100736417	20992769169	@		II
304953	100736417	20992769170	@		II
304953	100736417	20992769171	@		II
304953	100736417	20992769172	@		II
304953	100736417	20992769173	@		II
304953	100736417	20992769174	for	for	IF
304953	100736417	20992769175	a	a	AT1
304953	100736417	20992769176	prostate	prostate	NN1
304953	100736417	20992769177	biopsy	biopsy	NN1
304953	100736417	20992769178	.	.	.
304953	100736417	20992769179	I	i	PPIS1
304953	100736417	20992769180	began	begin	VVD
304953	100736417	20992769181	adding	add	VVG_JJ@
304953	100736417	20992769182	nutrients	nutrient	NN2
304953	100736417	20992769183	to	to	II
304953	100736417	20992769184	my	my	APPGE
304953	100736417	20992769185	program	program	NN1
304953	100736417	20992769186	and	and	CC
304953	100736417	20992769187	continued	continue	VVD_VVN_JJ
304953	100736417	20992769188	to	to	TO
304953	100736417	20992769189	discover	discover	VVI
304953	100736417	20992769190	more	more	RRR_DAR
304953	100736417	20992769191	to	to	TO
304953	100736417	20992769192	add	add	VVI
304953	100736417	20992769193	.	.	.
304953	100736417	20992769194	My	my	APPGE
304953	100736417	20992769195	PSA	psa	NP1
304953	100736417	20992769196	dropped	drop	VVD
304953	100736417	20992769197	to	to	II
304953	100736417	20992769198	6.3	-6.3	MC
304953	100736417	20992769199	in	in	II
304953	100736417	20992769200	two	two	MC
304953	100736417	20992769201	mos.		NNU
304953	100736417	20992769202	and	and	CC
304953	100736417	20992769203	to	to	II
304953	100736417	20992769204	4.2	4.2	MC
304953	100736417	20992769205	in	in	II
304953	100736417	20992769206	another	another	DD1
304953	100736417	20992769207	mo	mo	NN1
304953	100736417	20992769208	.	.	.
304953	100736417	20992769209	3.64	3.64	MC
304953	100736417	20992769210	in	in	II
304953	100736417	20992769211	two	two	MC
304953	100736417	20992769212	more	more	DAR
304953	100736417	20992769213	months	month	NNT2
304953	100736417	20992769214	.	.	.
304953	100736417	20992769215	This	this	DD1
304953	100736417	20992769216	was	be	VBDZ
304953	100736417	20992769217	lower	low	JJR_RRR@
304953	100736417	20992769218	than	than	CSN
304953	100736417	20992769219	it	it	PPH1
304953	100736417	20992769220	was	be	VBDZ
304953	100736417	20992769221	six	six	MC
304953	100736417	20992769222	years	year	NNT2
304953	100736417	20992769223	ago	ago	RA
304953	100736417	20992769224	.	.	.
304953	100736417	20992769225	I	i	PPIS1
304953	100736417	20992769226	cancelled	cancel	VVD
304953	100736417	20992769227	my	my	APPGE
304953	100736417	20992769228	biopsy	biopsy	NN1
304953	100736417	20992769229	.	.	.
304953	100736417	20992769230	Here	here	RL
304953	100736417	20992769231	is	be	VBZ
304953	100736417	20992769232	my	my	APPGE
304953	100736417	20992769233	program	program	NN1
304953	100736417	20992769234	:	:	:
304953	100736417	20992769235	NUTRIENTS	nutrient	NN2
304953	100736417	20992769236	FOR	for	IF
304953	100736417	20992769237	PROSTATE	prostate	NN1
304953	100736417	20992769238	CANCER	cancer	NN1
304953	100736417	20992769239	PREVENTION	prevention	NN1
304953	100736417	20992769240	AND	and	CC
304953	100736417	20992769241	ERADICATION		NP1_NN1
304953	100736417	20992769242	NATURAL	natural	JJ_RR@
304953	100736417	20992769243	NON-TOXIC	nontoxic	JJ
304953	100736417	20992769244	CHEMOTHERAPY	chemotherapy	NN1
304953	100736417	20992769245	FOR	for	IF
304953	100736417	20992769246	PROSTATE	prostate	NN1
304953	100736417	20992769247	CANCER	cancer	NN1
304953	100736417	20992769248	Available	available	JJ
304953	100736417	20992769249	at	at	II
304953	100736417	20992769250	Amazon.com	amazon.com	NP1
304953	100736417	20992769251	46996		MC
304953	100736417	20992769252	@qwx906996		FO
304953	100736418	20992769272	@@##	----------	----------
304953	100736418	20992769273	@@100736418		FO
304953	100736418	20992769274	@4936418/		VV0_NN1
304953	100736418	20992769275	46989		MC
304953	100736418	20992769276	@qwx906989		FO
304953	100736418	20992769277	<p>		NULL
304953	100736418	20992769278	The	the	AT
304953	100736418	20992769279	prostate-specific	prostate-specific	JJ
304953	100736418	20992769280	antigen	antigen	NN1
304953	100736418	20992769281	(	(	(
304953	100736418	20992769282	PSA	psa	NP1
304953	100736418	20992769283	)	)	)
304953	100736418	20992769284	test	test	NN1_VV0
304953	100736418	20992769285	can	can	VM
304953	100736418	20992769286	generate	generate	VVI
304953	100736418	20992769287	more	more	DAR
304953	100736418	20992769288	questions	question	NN2
304953	100736418	20992769289	than	than	CSN
304953	100736418	20992769290	answers	answer	NN2
304953	100736418	20992769291	.	.	.
304953	100736418	20992769292	If	if	CS
304953	100736418	20992769293	your	your	APPGE
304953	100736418	20992769294	level	level	NN1
304953	100736418	20992769295	is	be	VBZ
304953	100736418	20992769296	high	high	JJ_RR@
304953	100736418	20992769297	,	,	,
304953	100736418	20992769298	it	it	PPH1
304953	100736418	20992769299	could	could	VM
304953	100736418	20992769300	mean	mean	VVI
304953	100736418	20992769301	that	that	CST
304953	100736418	20992769302	your	your	APPGE
304953	100736418	20992769303	prostate	prostate	NN1
304953	100736418	20992769304	is	be	VBZ
304953	100736418	20992769305	enlarged	enlarge	VVN_JJ
304953	100736418	20992769306	or	or	CC
304953	100736418	20992769307	infected	infect	VVD_JJ_VVN
304953	100736418	20992769308	.	.	.
304953	100736418	20992769309	It	it	PPH1
304953	100736418	20992769310	could	could	VM
304953	100736418	20992769311	mean	mean	VVI
304953	100736418	20992769312	that	that	CST
304953	100736418	20992769313	you	you	PPY
304953	100736418	20992769314	have	have	VH0
304953	100736418	20992769315	prostate	prostate	NN1
304953	100736418	20992769316	cancer	cancer	NN1
304953	100736418	20992769317	.	.	.
304953	100736418	20992769318	It	it	PPH1
304953	100736418	20992769319	could	could	VM
304953	100736418	20992769320	also	also	RR
304953	100736418	20992769321	mean	mean	VVI
304953	100736418	20992769322	that	that	CST
304953	100736418	20992769323	your	your	APPGE
304953	100736418	20992769324	prostate	prostate	NN1
304953	100736418	20992769325	gland	gland	NN1
304953	100736418	20992769326	is	be	VBZ
304953	100736418	20992769327	healthy	healthy	JJ
304953	100736418	20992769328	,	,	,
304953	100736418	20992769329	since	since	CS
304953	100736418	20992769330	normal	normal	JJ
304953	100736418	20992769331	PSA	psa	NP1
304953	100736418	20992769332	levels	level	NN2
304953	100736418	20992769333	vary	vary	VV0
304953	100736418	20992769334	widely	widely	RR
304953	100736418	20992769335	from	from	II
304953	100736418	20992769336	one	one	MC1
304953	100736418	20992769337	man	man	NN1
304953	100736418	20992769338	to	to	II
304953	100736418	20992769339	another	another	DD1
304953	100736418	20992769340	.	.	.
304953	100736418	20992769341	Because	because	II21
304953	100736418	20992769342	of	of	II22
304953	100736418	20992769343	this	this	DD1
304953	100736418	20992769344	variability	variability	NN1
304953	100736418	20992769345	,	,	,
304953	100736418	20992769346	PSA	psa	NP1
304953	100736418	20992769347	tests	test	VVZ@_NN2
304953	100736418	20992769348	often	often	RR
304953	100736418	20992769349	lead	lead	VV0_VVN@
304953	100736418	20992769350	to	to	II
304953	100736418	20992769351	prostate	prostate	NN1
304953	100736418	20992769352	biopsies	biopsy	NN2
304953	100736418	20992769353	among	among	II
304953	100736418	20992769354	men	man	NN2
304953	100736418	20992769355	who	who	PNQS
304953	100736418	20992769356	do	do	VD0
304953	100736418	20992769357	n't 	n't	XX
304953	100736418	20992769358	have	have	VHI
304953	100736418	20992769359	cancer	cancer	NN1
304953	100736418	20992769360	.	.	.
304953	100736418	20992769361	That 's		NN2_VVZ
304953	100736418	20992769362	why	why	RRQ
304953	100736418	20992769363	doctors	doctor	NN2
304953	100736418	20992769364	would	would	VM
304953	100736418	20992769365	prefer	prefer	VVI
304953	100736418	20992769366	that	that	DD1_CST
304953	100736418	20992769367	only	only	JJ
304953	100736418	20992769368	men	men-	NN1
304953	100736418	20992769369	at	at	II
304953	100736418	20992769370	high	high	JJ
304953	100736418	20992769371	risk	risk	NN1
304953	100736418	20992769372	for	for	IF
304953	100736418	20992769373	prostate	prostate	NN1
304953	100736418	20992769374	cancer	cancer	NN1
304953	100736418	20992769375	have	have	VH0
304953	100736418	20992769376	PSA	psa	NP1
304953	100736418	20992769377	tests	test	NN2_VVZ@
304953	100736418	20992769378	.	.	.
304953	100736418	20992769379	A	a	AT1
304953	100736418	20992769380	study	study	NN1
304953	100736418	20992769381	published	publish	VVD_VVN
304953	100736418	20992769382	this	this	DD1
304953	100736418	20992769383	month	month	NNT1
304953	100736418	20992769384	in	in	II
304953	100736418	20992769385	the	the	AT
304953	100736418	20992769386	journal	journal	NN1
304953	100736418	20992769387	European	european	JJ
304953	100736418	20992769388	Urology	urology	NN1_NP1
304953	100736418	20992769389	suggests	suggest	VVZ
304953	100736418	20992769390	that	that	CST
304953	100736418	20992769391	men	man	NN2
304953	100736418	20992769392	who	who	PNQS
304953	100736418	20992769393	have	have	VH0
304953	100736418	20992769394	defects	defect	NN2
304953	100736418	20992769395	in	in	II
304953	100736418	20992769396	a	a	AT1
304953	100736418	20992769397	cancer-suppressing		JJ_NN1
304953	100736418	20992769398	gene	gene	NN1
304953	100736418	20992769399	known	know	VVN
304953	100736418	20992769400	as	as	II
304953	100736418	20992769401	BRCA	brca	NP1_NN1
304953	100736418	20992769402	are	be	VBR
304953	100736418	20992769403	at	at	II
304953	100736418	20992769404	high	high	JJ
304953	100736418	20992769405	risk	risk	NN1
304953	100736418	20992769406	for	for	IF
304953	100736418	20992769407	aggressive	aggressive	JJ
304953	100736418	20992769408	prostate	prostate	NN1
304953	100736418	20992769409	tumors	tumor	NN2
304953	100736418	20992769410	,	,	,
304953	100736418	20992769411	and	and	CC
304953	100736418	20992769412	so	so	RR
304953	100736418	20992769413	could	could	VM
304953	100736418	20992769414	benefit	benefit	VVI
304953	100736418	20992769415	from	from	II
304953	100736418	20992769416	PSA	psa	NP1
304953	100736418	20992769417	testing	testing	NN1_VVG
304953	100736418	20992769418	.	.	.
304953	100736418	20992769419	<p>		NULL
304953	100736418	20992769420	The	the	AT
304953	100736418	20992769421	BRCA	brca	NN1_NP1
304953	100736418	20992769422	gene	gene	NN1
304953	100736418	20992769423	comes	come	VVZ
304953	100736418	20992769424	in	in	II
304953	100736418	20992769425	two	two	MC
304953	100736418	20992769426	forms	form	NN2
304953	100736418	20992769427	,	,	,
304953	100736418	20992769428	BRCA1	brca1	FO
304953	100736418	20992769429	and	and	CC
304953	100736418	20992769430	BRCA2	brca2	FO
304953	100736418	20992769431	.	.	.
304953	100736418	20992769432	Both	both	DB2_RR
304953	100736418	20992769433	make	make	VV0
304953	100736418	20992769434	proteins	protein	NN2
304953	100736418	20992769435	that	that	CST
304953	100736418	20992769436	repair	repair	VV0
304953	100736418	20992769437	the	the	AT
304953	100736418	20992769438	genetic	genetic	JJ
304953	100736418	20992769439	damage	damage	NN1
304953	100736418	20992769440	that	that	CST
304953	100736418	20992769441	all	all	DB
304953	100736418	20992769442	cells	cell	NN2
304953	100736418	20992769443	experience	experience	VV0
304953	100736418	20992769444	thousands	thousand	NNO2
304953	100736418	20992769445	of	of	IO
304953	100736418	20992769446	times	time	NNT2
304953	100736418	20992769447	a	a	AT1
304953	100736418	20992769448	day	day	NNT1
304953	100736418	20992769449	.	.	.
304953	100736418	20992769450	When	when	CS
304953	100736418	20992769451	these	these	DD2
304953	100736418	20992769452	genes	gene	NN2
304953	100736418	20992769453	carry	carry	VV0
304953	100736418	20992769454	the	the	AT
304953	100736418	20992769455	wrong	wrong	JJ
304953	100736418	20992769456	code	code	NN1
304953	100736418	20992769457	,	,	,
304953	100736418	20992769458	they	they	PPHS2
304953	100736418	20992769459	do	do	VD0
304953	100736418	20992769460	n't 	n't	XX
304953	100736418	20992769461	work	work	VVI
304953	100736418	20992769462	as	as	CSA
304953	100736418	20992769463	intended	intend	VVN_JJ@
304953	100736418	20992769464	@		II
304953	100736418	20992769465	@		II
304953	100736418	20992769466	@		II
304953	100736418	20992769467	@		II
304953	100736418	20992769468	@		II
304953	100736418	20992769469	@		II
304953	100736418	20992769470	@		II
304953	100736418	20992769471	@		II
304953	100736418	20992769472	@		II
304953	100736418	20992769473	@		II
304953	100736418	20992769474	another	another	DD1
304953	100736418	20992769475	.	.	.
304953	100736418	20992769476	"	"	"
304953	100736418	20992769477	Bad	bad	JJ
304953	100736418	20992769478	"	"	"
304953	100736418	20992769479	BRCA	brca	NN1
304953	100736418	20992769480	genes	gene	NN2
304953	100736418	20992769481	(	(	(
304953	100736418	20992769482	BRCA-positive		JJ
304953	100736418	20992769483	)	)	)
304953	100736418	20992769484	lose	lose	VV0
304953	100736418	20992769485	their	their	APPGE
304953	100736418	20992769486	DNA-fixing		JJ_NN1
304953	100736418	20992769487	ability	ability	NN1
304953	100736418	20992769488	.	.	.
304953	100736418	20992769489	As	as	II
304953	100736418	20992769490	a	a	AT1
304953	100736418	20992769491	result	result	NN1
304953	100736418	20992769492	,	,	,
304953	100736418	20992769493	genetic	genetic	JJ
304953	100736418	20992769494	damage	damage	NN1
304953	100736418	20992769495	can	can	VM
304953	100736418	20992769496	accumulate	accumulate	VVI
304953	100736418	20992769497	to	to	II
304953	100736418	20992769498	the	the	AT
304953	100736418	20992769499	extent	extent	NN1
304953	100736418	20992769500	that	that	CST_DD1
304953	100736418	20992769501	healthy	healthy	JJ
304953	100736418	20992769502	cells	cell	NN2
304953	100736418	20992769503	turn	turn	VV0
304953	100736418	20992769504	cancerous	cancerous	JJ
304953	100736418	20992769505	.	.	.
304953	100736418	20992769506	<p>		NULL
304953	100736418	20992769507	In	in	II
304953	100736418	20992769508	women	woman	NN2
304953	100736418	20992769509	,	,	,
304953	100736418	20992769510	miscoded		VVD_JJ@
304953	100736418	20992769511	BRCA	brca	NP1_NN1
304953	100736418	20992769512	genes	gene	NN2
304953	100736418	20992769513	are	be	VBR
304953	100736418	20992769514	well-known	well-known	JJ
304953	100736418	20992769515	risk	risk	NN1
304953	100736418	20992769516	factors	factor	NN2
304953	100736418	20992769517	for	for	IF
304953	100736418	20992769518	breast	breast	NN1
304953	100736418	20992769519	and	and	CC
304953	100736418	20992769520	ovarian	ovarian	JJ_NN1
304953	100736418	20992769521	cancer	cancer	NN1
304953	100736418	20992769522	.	.	.
304953	100736418	20992769523	This	this	DD1
304953	100736418	20992769524	new	new	JJ
304953	100736418	20992769525	study	study	NN1
304953	100736418	20992769526	shows	show	VVZ
304953	100736418	20992769527	that	that	CST
304953	100736418	20992769528	they	they	PPHS2
304953	100736418	20992769529	can	can	VM
304953	100736418	20992769530	also	also	RR
304953	100736418	20992769531	pose	pose	VVI
304953	100736418	20992769532	problems	problem	NN2
304953	100736418	20992769533	for	for	IF
304953	100736418	20992769534	men	man	NN2
304953	100736418	20992769535	.	.	.
304953	100736418	20992769536	The	the	AT
304953	100736418	20992769537	authors	author	NN2
304953	100736418	20992769538	of	of	IO
304953	100736418	20992769539	the	the	AT
304953	100736418	20992769540	study	study	NN1
304953	100736418	20992769541	recommend	recommend	VV0
304953	100736418	20992769542	that	that	CST
304953	100736418	20992769543	men	man	NN2
304953	100736418	20992769544	with	with	IW
304953	100736418	20992769545	miscoded		JJ@
304953	100736418	20992769546	BRCA	brca	NN1
304953	100736418	20992769547	genes	gene	NN2
304953	100736418	20992769548	have	have	VH0
304953	100736418	20992769549	routine	routine	NN1_JJ@
304953	100736418	20992769550	PSA	psa	NP1
304953	100736418	20992769551	tests	test	NN2_VVZ@
304953	100736418	20992769552	.	.	.
304953	100736418	20992769553	<p>		NULL
304953	100736418	20992769554	"	"	"
304953	100736418	20992769555	PSA	psa	NP1
304953	100736418	20992769556	might	might	VM
304953	100736418	20992769557	detect	detect	VVI
304953	100736418	20992769558	early	early	JJ
304953	100736418	20992769559	stage	stage	NN1
304953	100736418	20992769560	cancers	cancer	NN2
304953	100736418	20992769561	in	in	II
304953	100736418	20992769562	these	these	DD2
304953	100736418	20992769563	men	man	NN2
304953	100736418	20992769564	while	while	CS
304953	100736418	20992769565	they 're		NN1
304953	100736418	20992769566	still	still	RR
304953	100736418	20992769567	curable	curable	JJ
304953	100736418	20992769568	,	,	,
304953	100736418	20992769569	"	"	"
304953	100736418	20992769570	says	say	VVZ
304953	100736418	20992769571	William	william	NP1
304953	100736418	20992769572	Isaacs	isaacs	NP1
304953	100736418	20992769573	,	,	,
304953	100736418	20992769574	Ph.D.		NNA
304953	100736418	20992769575	,	,	,
304953	100736418	20992769576	a	a	AT1
304953	100736418	20992769577	professor	professor	NN1
304953	100736418	20992769578	of	of	IO
304953	100736418	20992769579	urology	urology	NN1
304953	100736418	20992769580	at	at	II
304953	100736418	20992769581	Johns	john	NP1
304953	100736418	20992769582	Hopkins	hopkins	NP1
304953	100736418	20992769583	University	university	NN1
304953	100736418	20992769584	School	school	NN1
304953	100736418	20992769585	of	of	IO
304953	100736418	20992769586	Medicine	medicine	NN1
304953	100736418	20992769587	in	in	II
304953	100736418	20992769588	Baltimore	baltimore	NP1
304953	100736418	20992769589	,	,	,
304953	100736418	20992769590	who	who	PNQS
304953	100736418	20992769591	was	be	VBDZ
304953	100736418	20992769592	not	not	XX
304953	100736418	20992769593	involved	involved	JJ
304953	100736418	20992769594	in	in	II
304953	100736418	20992769595	the	the	AT
304953	100736418	20992769596	study	study	NN1
304953	100736418	20992769597	.	.	.
304953	100736418	20992769598	<p>		NULL
304953	100736418	20992769599	An	a	AT1
304953	100736418	20992769600	international	international	JJ
304953	100736418	20992769601	team	team	NN1
304953	100736418	20992769602	of	of	IO
304953	100736418	20992769603	researchers	researcher	NN2
304953	100736418	20992769604	has	have	VHZ
304953	100736418	20992769605	been	be	VBN
304953	100736418	20992769606	following	follow	VVG
304953	100736418	20992769607	nearly	nearly	RR
304953	100736418	20992769608	2,500	2,500	MC
304953	100736418	20992769609	men	man	NN2
304953	100736418	20992769610	as	as	II
304953	100736418	20992769611	part	part	NN1
304953	100736418	20992769612	of	of	IO
304953	100736418	20992769613	a	a	AT1
304953	100736418	20992769614	study	study	NN1
304953	100736418	20992769615	called	call	VVN_VVD@
304953	100736418	20992769616	IMPACT	impact	NN1
304953	100736418	20992769617	.	.	.
304953	100736418	20992769618	It	it	PPH1
304953	100736418	20992769619	includes	include	VVZ
304953	100736418	20992769620	some	some	DD
304953	100736418	20992769621	men	man	NN2
304953	100736418	20992769622	with	with	IW
304953	100736418	20992769623	miscoded		JJ@
304953	100736418	20992769624	BRCA	brca	NN1
304953	100736418	20992769625	genes	gene	NN2
304953	100736418	20992769626	and	and	CC
304953	100736418	20992769627	others	others	NN2
304953	100736418	20992769628	with	with	IW
304953	100736418	20992769629	normal	normal	JJ
304953	100736418	20992769630	BRCA	brca	NN1
304953	100736418	20992769631	genes	gene	NN2
304953	100736418	20992769632	.	.	.
304953	100736418	20992769633	Of	of	IO
304953	100736418	20992769634	these	these	DD2
304953	100736418	20992769635	,	,	,
304953	100736418	20992769636	199	199	MC
304953	100736418	20992769637	had	have	VHD
304953	100736418	20992769638	high	high	JJ_RR@
304953	100736418	20992769639	PSA	psa	NP1
304953	100736418	20992769640	levels	level	NN2
304953	100736418	20992769641	,	,	,
304953	100736418	20992769642	of	of	IO
304953	100736418	20992769643	whom	whom	PNQO
304953	100736418	20992769644	162	162	MC
304953	100736418	20992769645	had	have	VHD
304953	100736418	20992769646	prostate	prostate	NN1
304953	100736418	20992769647	biopsies	biopsy	NN2
304953	100736418	20992769648	to	to	TO
304953	100736418	20992769649	look	look	VVI
304953	100736418	20992769650	for	for	IF
304953	100736418	20992769651	prostate	prostate	NN1
304953	100736418	20992769652	cancer	cancer	NN1
304953	100736418	20992769653	.	.	.
304953	100736418	20992769654	Biopsies	biopsy	NN2
304953	100736418	20992769655	revealed	reveal	VVD_VVN
304953	100736418	20992769656	prostate	prostate	NN1
304953	100736418	20992769657	cancer	cancer	NN1
304953	100736418	20992769658	in	in	II
304953	100736418	20992769659	59	59	MC
304953	100736418	20992769660	men	man	NN2
304953	100736418	20992769661	.	.	.
304953	100736418	20992769662	The	the	AT
304953	100736418	20992769663	cancer	cancer	NN1
304953	100736418	20992769664	@		II
304953	100736418	20992769665	@		II
304953	100736418	20992769666	@		II
304953	100736418	20992769667	@		II
304953	100736418	20992769668	@		II
304953	100736418	20992769669	@		II
304953	100736418	20992769670	@		II
304953	100736418	20992769671	@		II
304953	100736418	20992769672	@		II
304953	100736418	20992769673	@		II
304953	100736418	20992769674	men	man	NN2
304953	100736418	20992769675	with	with	IW
304953	100736418	20992769676	normal	normal	JJ
304953	100736418	20992769677	BRCA	brca	NN1
304953	100736418	20992769678	genes	gene	NN2
304953	100736418	20992769679	.	.	.
304953	100736418	20992769680	Equally	equally	RR
304953	100736418	20992769681	important	important	JJ
304953	100736418	20992769682	,	,	,
304953	100736418	20992769683	men	man	NN2
304953	100736418	20992769684	in	in	II
304953	100736418	20992769685	the	the	AT
304953	100736418	20992769686	BRCA-positive		JJ
304953	100736418	20992769687	group	group	NN1
304953	100736418	20992769688	"	"	"
304953	100736418	20992769689	especially	especially	RR
304953	100736418	20992769690	those	those	DD2
304953	100736418	20992769691	with	with	IW
304953	100736418	20992769692	BRCA2	brca2	FO
304953	100736418	20992769693	mutations	mutation	NN2
304953	100736418	20992769694	"	"	"
304953	100736418	20992769695	tended	tend	VVD
304953	100736418	20992769696	to	to	TO
304953	100736418	20992769697	have	have	VHI
304953	100736418	20992769698	more	more	DAR
304953	100736418	20992769699	high-grade	high-grade	NN1_JJ
304953	100736418	20992769700	,	,	,
304953	100736418	20992769701	aggressive	aggressive	JJ
304953	100736418	20992769702	tumors	tumor	NN2
304953	100736418	20992769703	.	.	.
304953	100736418	20992769704	<p>		NULL
304953	100736418	20992769705	What	what	DDQ
304953	100736418	20992769706	remains	remain	VVZ
304953	100736418	20992769707	unclear	unclear	JJ
304953	100736418	20992769708	is	be	VBZ
304953	100736418	20992769709	which	which	DDQ
304953	100736418	20992769710	men	man	NN2
304953	100736418	20992769711	should	should	VM
304953	100736418	20992769712	have	have	VHI
304953	100736418	20992769713	their	their	APPGE
304953	100736418	20992769714	BRCA	brca	NN1
304953	100736418	20992769715	genes	gene	NN2
304953	100736418	20992769716	checked	check	VVD_VVN
304953	100736418	20992769717	.	.	.
304953	100736418	20992769718	Men	man	NN2
304953	100736418	20992769719	whose	whose	DDQGE
304953	100736418	20992769720	mothers	mother	NN2
304953	100736418	20992769721	or	or	CC
304953	100736418	20992769722	sisters	sister	NN2
304953	100736418	20992769723	have	have	VH0
304953	100736418	20992769724	or	or	CC
304953	100736418	20992769725	had	have	VHD_VHN@
304953	100736418	20992769726	breast	breast	NN1
304953	100736418	20992769727	or	or	CC
304953	100736418	20992769728	ovarian	ovarian	JJ_NN1
304953	100736418	20992769729	cancer	cancer	NN1
304953	100736418	20992769730	might	might	VM
304953	100736418	20992769731	consider	consider	VVI
304953	100736418	20992769732	BRCA	brca	NN1_NP1
304953	100736418	20992769733	testing	testing	NN1_VVG
304953	100736418	20992769734	.	.	.
304953	100736418	20992769735	But	but	CCB
304953	100736418	20992769736	widespread	widespread	JJ
304953	100736418	20992769737	use	use	NN1
304953	100736418	20992769738	of	of	IO
304953	100736418	20992769739	BRCA	brca	NP1_NN1
304953	100736418	20992769740	testing	testing	NN1
304953	100736418	20992769741	"	"	"
304953	100736418	20992769742	will	will	VM
304953	100736418	20992769743	require	require	VVI
304953	100736418	20992769744	significantly	significantly	RR
304953	100736418	20992769745	more	more	DAR
304953	100736418	20992769746	data	data	NN
304953	100736418	20992769747	,	,	,
304953	100736418	20992769748	"	"	"
304953	100736418	20992769749	says	say	VVZ
304953	100736418	20992769750	prostate	prostate	NN1
304953	100736418	20992769751	cancer	cancer	NN1
304953	100736418	20992769752	specialist	specialist	NN1
304953	100736418	20992769753	Dr.		NNB
304953	100736418	20992769754	Marc	marc	NP1
304953	100736418	20992769755	B.		NP1
304953	100736418	20992769756	Garnick		NP1
304953	100736418	20992769757	,	,	,
304953	100736418	20992769758	the	the	AT
304953	100736418	20992769759	Gorman	gorman	NN1_NP1
304953	100736418	20992769760	Brothers	brother	NN2
304953	100736418	20992769761	Professor	professor	NN1
304953	100736418	20992769762	of	of	IO
304953	100736418	20992769763	Medicine	medicine	NN1
304953	100736418	20992769764	at	at	II
304953	100736418	20992769765	Harvard	harvard	NP1
304953	100736418	20992769766	Medical	medical	JJ
304953	100736418	20992769767	School	school	NN1
304953	100736418	20992769768	and	and	CC
304953	100736418	20992769769	Beth	beth	NP1
304953	100736418	20992769770	Israel	israel	NP1
304953	100736418	20992769771	Deaconess	deaconess	NN1
304953	100736418	20992769772	Medical	medical	JJ
304953	100736418	20992769773	Center	center	NN1
304953	100736418	20992769774	,	,	,
304953	100736418	20992769775	and	and	CC
304953	100736418	20992769776	Editor	editor	NN1
304953	100736418	20992769777	in	in	II
304953	100736418	20992769778	Chief	chief	NN1
304953	100736418	20992769779	of	of	IO
304953	100736418	20992769780	Harvard	harvard	NP1
304953	100736418	20992769781	Medical	medical	JJ
304953	100736418	20992769782	Schools	school	NN2
304953	100736418	20992769783	2014	2014	MC
304953	100736418	20992769784	Annual	annual	JJ
304953	100736418	20992769785	Report	report	NN1
304953	100736418	20992769786	on	on	II
304953	100736418	20992769787	Prostate	prostate	NN1
304953	100736418	20992769788	Diseases	disease	NN2
304953	100736418	20992769789	.	.	.
304953	100736418	20992769790	"	"	"
304953	100736418	20992769791	Nevertheless	nevertheless	RR
304953	100736418	20992769792	,	,	,
304953	100736418	20992769793	BRCA	brca	NP1_NN1
304953	100736418	20992769794	information	information	NN1
304953	100736418	20992769795	could	could	VM
304953	100736418	20992769796	be	be	VBI
304953	100736418	20992769797	useful	useful	JJ
304953	100736418	20992769798	,	,	,
304953	100736418	20992769799	especially	especially	RR
304953	100736418	20992769800	if	if	CS
304953	100736418	20992769801	it	it	PPH1
304953	100736418	20992769802	provides	provide	VVZ
304953	100736418	20992769803	for	for	IF
304953	100736418	20992769804	other	other	JJ
304953	100736418	20992769805	treatment	treatment	NN1
304953	100736418	20992769806	options	option	NN2
304953	100736418	20992769807	for	for	IF
304953	100736418	20992769808	men	man	NN2
304953	100736418	20992769809	that	that	CST_DD1
304953	100736418	20992769810	might	might	VM
304953	100736418	20992769811	not	not	XX
304953	100736418	20992769812	be	be	VBI
304953	100736418	20992769813	considered	consider	VVN
304953	100736418	20992769814	in	in	II
304953	100736418	20992769815	its	its	APPGE
304953	100736418	20992769816	absence	absence	NN1
304953	100736418	20992769817	.	.	.
304953	100736418	20992769818	"	"	"
304953	100736419	20992769838	@@##	----------	----------
304953	100736419	20992769839	@@100736419		FO
304953	100736419	20992769840	@4936419/		VV0_NN1
304953	100736419	20992769841	46988		MC
304953	100736419	20992769842	@qwx906988		FO
304953	100736419	20992769843	46994		MC
304953	100736419	20992769844	@qwx906994		FO
304953	100736419	20992769845	46995		MC
304953	100736419	20992769846	@qwx906995		FO
304953	100736419	20992769847	46992		MC
304953	100736419	20992769848	@qwx906992		FO
304953	100736419	20992769849	46991		MC
304953	100736419	20992769850	@qwx906991		FO
304953	100736419	20992769851	46990		MC
304953	100736419	20992769852	@qwx906990		FO
304953	100736419	20992769853	46989		MC
304953	100736419	20992769854	@qwx906989		FO
304953	100736419	20992769855	46993		MC
304953	100736419	20992769856	@qwx906993		FO
304953	100736419	20992769857	<h>		NULL
304953	100736419	20992769858	Patient	patient	JJ_NN1
304953	100736419	20992769859	Perspectives	perspective	NN2
304953	100736419	20992769860	<p>		NULL
304953	100736419	20992769861	In	in	II
304953	100736419	20992769862	these	these	DD2
304953	100736419	20992769863	stories	story	NN2
304953	100736419	20992769864	,	,	,
304953	100736419	20992769865	real	real	JJ
304953	100736419	20992769866	patients	patient	NN2
304953	100736419	20992769867	share	share	VV0
304953	100736419	20992769868	their	their	APPGE
304953	100736419	20992769869	experiences	experience	NN2
304953	100736419	20992769870	.	.	.
304953	100736419	20992769871	Learn	learn	VV0
304953	100736419	20992769872	what	what	DDQ
304953	100736419	20992769873	men	man	NN2
304953	100736419	20992769874	going	go	VVG
304953	100736419	20992769875	through	through	II_RP@
304953	100736419	20992769876	situations	situation	NN2
304953	100736419	20992769877	like	like	II
304953	100736419	20992769878	yours	yours	PPGE
304953	100736419	20992769879	chose	choose	VVD
304953	100736419	20992769880	to	to	TO
304953	100736419	20992769881	do	do	VDI
304953	100736419	20992769882	,	,	,
304953	100736419	20992769883	what	what	DDQ
304953	100736419	20992769884	they	they	PPHS2
304953	100736419	20992769885	wish	wish	VV0
304953	100736419	20992769886	they	they	PPHS2
304953	100736419	20992769887	knew	know	VVD
304953	100736419	20992769888	beforehand	beforehand	RR
304953	100736419	20992769889	,	,	,
304953	100736419	20992769890	and	and	CC
304953	100736419	20992769891	what	what	DDQ
304953	100736419	20992769892	decisions	decision	NN2
304953	100736419	20992769893	they	they	PPHS2
304953	100736419	20992769894	're	be	VBR
304953	100736419	20992769895	happy	happy	JJ
304953	100736419	20992769896	they	they	PPHS2
304953	100736419	20992769897	made	make	VVD
304953	100736419	20992769898	.	.	.
304953	100736419	20992769899	<h>		NULL
304953	100736419	20992769900	Related	related	JJ
304953	100736419	20992769901	Articles	article	NN2
304953	100736419	20992769902	<p>		NULL
304953	100736419	20992769903	Elliot	elliot	NP1
304953	100736419	20992769904	and	and	CC
304953	100736419	20992769905	Elizabeth	elizabeth	NP1
304953	100736419	20992769906	Boyd	boyd	NP1
304953	100736419	20992769907	share	share	VV0
304953	100736419	20992769908	their	their	APPGE
304953	100736419	20992769909	experience	experience	NN1
304953	100736419	20992769910	with	with	IW
304953	100736419	20992769911	a	a	AT1
304953	100736419	20992769912	prostate	prostate	NN1
304953	100736419	20992769913	cancer	cancer	NN1
304953	100736419	20992769914	diagnosis	diagnosis	NN1
304953	100736419	20992769915	,	,	,
304953	100736419	20992769916	explain	explain	VV0
304953	100736419	20992769917	their	their	APPGE
304953	100736419	20992769918	next	next	MD
304953	100736419	20992769919	steps	step	NN2
304953	100736419	20992769920	in	in	II31
304953	100736419	20992769921	light	light	II32
304953	100736419	20992769922	of	of	II33
304953	100736419	20992769923	seemingly	seemingly	RR
304953	100736419	20992769924	contradictory	contradictory	JJ
304953	100736419	20992769925	test	test	NN1
304953	100736419	20992769926	results	result	NN2
304953	100736419	20992769927	,	,	,
304953	100736419	20992769928	and	and	CC
304953	100736419	20992769929	offer	offer	VV0_NN1
304953	100736419	20992769930	advice	advice	NN1
304953	100736419	20992769931	to	to	II
304953	100736419	20992769932	those	those	DD2
304953	100736419	20992769933	coping	cope	VVG
304953	100736419	20992769934	with	with	IW
304953	100736419	20992769935	their	their	APPGE
304953	100736419	20992769936	diagnosis	diagnosis	NN1
304953	100736419	20992769937	and	and	CC
304953	100736419	20992769938	weighing	weigh	VVG_NN1
304953	100736419	20992769939	treatment	treatment	NN1
304953	100736419	20992769940	options	option	NN2
304953	100736419	20992769941	.	.	.
304953	100736419	20992769942	<p>		NULL
304953	100736419	20992769943	After	after	II
304953	100736419	20992769944	talking	talk	VVG
304953	100736419	20992769945	with	with	IW
304953	100736419	20992769946	numerous	numerous	JJ
304953	100736419	20992769947	medical	medical	JJ
304953	100736419	20992769948	professionals	professional	NN2
304953	100736419	20992769949	and	and	CC
304953	100736419	20992769950	asking	ask	VVG
304953	100736419	20992769951	friends	friend	NN2
304953	100736419	20992769952	about	about	II
304953	100736419	20992769953	how	how	RRQ
304953	100736419	20992769954	they	they	PPHS2
304953	100736419	20992769955	treated	treat	VVD@
304953	100736419	20992769956	their	their	APPGE
304953	100736419	20992769957	prostate	prostate	NN1
304953	100736419	20992769958	cancers	cancer	NN2
304953	100736419	20992769959	,	,	,
304953	100736419	20992769960	financial	financial	JJ
304953	100736419	20992769961	services	service	NN2
304953	100736419	20992769962	executive	executive	NN1_JJ@
304953	100736419	20992769963	Steve	steve	NP1
304953	100736419	20992769964	Henley	henley	NP1
304953	100736419	20992769965	opted	opt	VVD
304953	100736419	20992769966	to	to	TO
304953	100736419	20992769967	have	have	VHI
304953	100736419	20992769968	a	a	AT1
304953	100736419	20992769969	robotic-assisted		JJ
304953	100736419	20992769970	laparoscopic	laparoscopic	JJ
304953	100736419	20992769971	prostatectomy	prostatectomy	NN1
304953	100736419	20992769972	.	.	.
304953	100736419	20992769973	In	in	II
304953	100736419	20992769974	this	this	DD1
304953	100736419	20992769975	interview	interview	NN1
304953	100736419	20992769976	,	,	,
304953	100736419	20992769977	he	he	PPHS1
304953	100736419	20992769978	explains	explain	VVZ
304953	100736419	20992769979	what	what	DDQ
304953	100736419	20992769980	factors	factor	NN2
304953	100736419	20992769981	went	go	VVD
304953	100736419	20992769982	into	into	II
304953	100736419	20992769983	that	that	DD1
304953	100736419	20992769984	decision	decision	NN1
304953	100736419	20992769985	.	.	.
304953	100736419	20992769986	<p>		NULL
304953	100736419	20992769987	The	the	AT
304953	100736419	20992769988	jury	jury	NN1
304953	100736419	20992769989	is	be	VBZ
304953	100736419	20992769990	still	still	RR
304953	100736419	20992769991	out	out	RP
304953	100736419	20992769992	on	on	II
304953	100736419	20992769993	whether	whether	CSW
304953	100736419	20992769994	intermittent	intermittent	JJ
304953	100736419	20992769995	hormone	hormone	NN1
304953	100736419	20992769996	therapy	therapy	NN1
304953	100736419	20992769997	,	,	,
304953	100736419	20992769998	which	which	DDQ
304953	100736419	20992769999	involves	involve	VVZ
304953	100736419	20992770000	repeated	repeated	JJ@
304953	100736419	20992770001	cycles	cycle	NN2
304953	100736419	20992770002	of	of	IO
304953	100736419	20992770003	hormone	hormone	NN1
304953	100736419	20992770004	therapy	therapy	NN1
304953	100736419	20992770005	followed	follow	VVN
304953	100736419	20992770006	by	by	II
304953	100736419	20992770007	breaks	break	NN2
304953	100736419	20992770008	in	in	II
304953	100736419	20992770009	treatment	treatment	NN1
304953	100736419	20992770010	,	,	,
304953	100736419	20992770011	might	might	VM
304953	100736419	20992770012	help	help	VVI
304953	100736419	20992770013	patients	patient	NN2
304953	100736419	20992770014	live	live	VVI
304953	100736419	20992770015	longer	long	RRR_JJR
304953	100736419	20992770016	than	than	CSN
304953	100736419	20992770017	continuous	continuous	JJ
304953	100736419	20992770018	hormone	hormone	NN1
304953	100736419	20992770019	therapy	therapy	NN1
304953	100736419	20992770020	.	.	.
304953	100736419	20992770021	But	but	CCB
304953	100736419	20992770022	Patrick	patrick	NP1
304953	100736419	20992770023	Kirbys	kirbys	NP2
304953	100736419	20992770024	story	story	NN1
304953	100736419	20992770025	might	might	VM
304953	100736419	20992770026	help	help	VVI
304953	100736419	20992770027	patients	patient	NN2
304953	100736419	20992770028	who	who	PNQS
304953	100736419	20992770029	are	be	VBR
304953	100736419	20992770030	@		II
304953	100736419	20992770031	@		II
304953	100736419	20992770032	@		II
304953	100736419	20992770033	@		II
304953	100736419	20992770034	@		II
304953	100736419	20992770035	@		II
304953	100736419	20992770036	@		II
304953	100736419	20992770037	@		II
304953	100736419	20992770038	@		II
304953	100736419	20992770039	@		II
304953	100736419	20992770040	,	,	,
304953	100736419	20992770041	a	a	AT1
304953	100736419	20992770042	successful	successful	JJ
304953	100736419	20992770043	business	business	NN1
304953	100736419	20992770044	owner	owner	NN1
304953	100736419	20992770045	in	in	II
304953	100736419	20992770046	his	his	APPGE
304953	100736419	20992770047	mid-60s	mid-60s	MC2
304953	100736419	20992770048	,	,	,
304953	100736419	20992770049	describes	describe	VVZ
304953	100736419	20992770050	how	how	RRQ
304953	100736419	20992770051	he	he	PPHS1
304953	100736419	20992770052	was	be	VBDZ
304953	100736419	20992770053	able	able	JK
304953	100736419	20992770054	to	to	TO
304953	100736419	20992770055	maintain	maintain	VVI
304953	100736419	20992770056	his	his	APPGE
304953	100736419	20992770057	sex	sex	NN1
304953	100736419	20992770058	life	life	NN1
304953	100736419	20992770059	and	and	CC
304953	100736419	20992770060	other	other	JJ
304953	100736419	20992770061	aspects	aspect	NN2
304953	100736419	20992770062	of	of	IO
304953	100736419	20992770063	his	his	APPGE
304953	100736419	20992770064	physical	physical	JJ
304953	100736419	20992770065	emotional	emotional	JJ
304953	100736419	20992770066	well-being	well-being	NN1
304953	100736419	20992770067	during	during	II
304953	100736419	20992770068	and	and	CC
304953	100736419	20992770069	after	after	II_CS
304953	100736419	20992770070	treatment	treatment	NN1
304953	100736419	20992770071	for	for	IF
304953	100736419	20992770072	prostate	prostate	NN1
304953	100736419	20992770073	cancer	cancer	NN1
304953	100736419	20992770074	.	.	.
304953	100736419	20992770075	<p>		NULL
304953	100736419	20992770076	How	how	RRQ
304953	100736419	20992770077	one	one	MC1
304953	100736419	20992770078	man	man	NN1
304953	100736419	20992770079	persisted	persist	VVN_VVD
304953	100736419	20992770080	for	for	IF
304953	100736419	20992770081	almost	almost	RR
304953	100736419	20992770082	two	two	MC
304953	100736419	20992770083	years	year	NNT2
304953	100736419	20992770084	in	in	II
304953	100736419	20992770085	an	a	AT1
304953	100736419	20992770086	effort	effort	NN1
304953	100736419	20992770087	to	to	TO
304953	100736419	20992770088	remedy	remedy	VVI
304953	100736419	20992770089	one	one	MC1
304953	100736419	20992770090	of	of	IO
304953	100736419	20992770091	the	the	AT
304953	100736419	20992770092	most	most	RGT
304953	100736419	20992770093	bothersome	bothersome	JJ
304953	100736419	20992770094	possible	possible	JJ
304953	100736419	20992770095	side	side	NN1
304953	100736419	20992770096	effects	effect	NN2
304953	100736419	20992770097	of	of	IO
304953	100736419	20992770098	prostate	prostate	NN1
304953	100736419	20992770099	cancer	cancer	NN1
304953	100736419	20992770100	treatment	treatment	NN1
304953	100736419	20992770101	,	,	,
304953	100736419	20992770102	and	and	CC
304953	100736419	20992770103	what	what	DDQ
304953	100736419	20992770104	men	man	NN2
304953	100736419	20992770105	facing	face	VVG
304953	100736419	20992770106	therapeutic	therapeutic	JJ
304953	100736419	20992770107	decisions	decision	NN2
304953	100736419	20992770108	can	can	VM
304953	100736419	20992770109	learn	learn	VVI
304953	100736419	20992770110	from	from	II
304953	100736419	20992770111	his	his	APPGE
304953	100736419	20992770112	experience	experience	NN1
304953	100736419	20992770113	.	.	.
304953	100736420	20992770133	@@##	----------	----------
304953	100736420	20992770134	@@100736420		FO
304953	100736420	20992770135	@4936420/		VV0_NN1
304953	100736420	20992770136	46989		MC
304953	100736420	20992770137	@qwx906989		FO
304953	100736420	20992770138	<h>		NULL
304953	100736420	20992770139	Posts	post	NN2
304953	100736420	20992770140	Tagged	tag	VVD_VVN
304953	100736420	20992770141	news	news	NN1
304953	100736420	20992770142	<p>		NULL
304953	100736420	20992770143	How	how	RRQ
304953	100736420	20992770144	one	one	MC1
304953	100736420	20992770145	man	man	NN1
304953	100736420	20992770146	persisted	persist	VVN_VVD
304953	100736420	20992770147	for	for	IF
304953	100736420	20992770148	almost	almost	RR
304953	100736420	20992770149	two	two	MC
304953	100736420	20992770150	years	year	NNT2
304953	100736420	20992770151	in	in	II
304953	100736420	20992770152	an	a	AT1
304953	100736420	20992770153	effort	effort	NN1
304953	100736420	20992770154	to	to	TO
304953	100736420	20992770155	remedy	remedy	VVI
304953	100736420	20992770156	one	one	MC1
304953	100736420	20992770157	of	of	IO
304953	100736420	20992770158	the	the	AT
304953	100736420	20992770159	most	most	RGT
304953	100736420	20992770160	bothersome	bothersome	JJ
304953	100736420	20992770161	possible	possible	JJ
304953	100736420	20992770162	side	side	NN1
304953	100736420	20992770163	effects	effect	NN2
304953	100736420	20992770164	of	of	IO
304953	100736420	20992770165	prostate	prostate	NN1
304953	100736420	20992770166	cancer	cancer	NN1
304953	100736420	20992770167	treatment	treatment	NN1
304953	100736420	20992770168	,	,	,
304953	100736420	20992770169	and	and	CC
304953	100736420	20992770170	what	what	DDQ
304953	100736420	20992770171	men	man	NN2
304953	100736420	20992770172	facing	face	VVG
304953	100736420	20992770173	therapeutic	therapeutic	JJ
304953	100736420	20992770174	decisions	decision	NN2
304953	100736420	20992770175	can	can	VM
304953	100736420	20992770176	learn	learn	VVI
304953	100736420	20992770177	from	from	II
304953	100736420	20992770178	his	his	APPGE
304953	100736420	20992770179	experience	experience	NN1
304953	100736420	20992770180	.	.	.
304953	100736420	20992770181	<p>		NULL
304953	100736420	20992770182	We	we	PPIS2
304953	100736420	20992770183	often	often	RR
304953	100736420	20992770184	hear	hear	VV0
304953	100736420	20992770185	the	the	AT
304953	100736420	20992770186	term	term	NN1
304953	100736420	20992770187	prostate	prostate	NN1
304953	100736420	20992770188	cancer	cancer	NN1
304953	100736420	20992770189	and	and	CC
304953	100736420	20992770190	assume	assume	VV0
304953	100736420	20992770191	it	it	PPH1
304953	100736420	20992770192	is	be	VBZ
304953	100736420	20992770193	one	one	MC1
304953	100736420	20992770194	disease	disease	NN1
304953	100736420	20992770195	.	.	.
304953	100736420	20992770196	Practically	practically	RR
304953	100736420	20992770197	speaking	speak	VVG_JJ@
304953	100736420	20992770198	,	,	,
304953	100736420	20992770199	it	it	PPH1
304953	100736420	20992770200	is	be	VBZ
304953	100736420	20992770201	.	.	.
304953	100736420	20992770202	On	on	II
304953	100736420	20992770203	a	a	AT1
304953	100736420	20992770204	molecular	molecular	JJ
304953	100736420	20992770205	level	level	NN1_JJ
304953	100736420	20992770206	,	,	,
304953	100736420	20992770207	however	however	RR
304953	100736420	20992770208	,	,	,
304953	100736420	20992770209	scientists	scientist	NN2
304953	100736420	20992770210	are	be	VBR
304953	100736420	20992770211	revealing	reveal	VVG
304953	100736420	20992770212	a	a	AT1
304953	100736420	20992770213	far	far	RG
304953	100736420	20992770214	more	more	RGR
304953	100736420	20992770215	complex	complex	JJ
304953	100736420	20992770216	picture	picture	NN1
304953	100736420	20992770217	.	.	.
304953	100736420	20992770218	Cancer	cancer	NN1
304953	100736420	20992770219	has	have	VHZ
304953	100736420	20992770220	an	a	AT1
304953	100736420	20992770221	innate	innate	JJ
304953	100736420	20992770222	ability	ability	NN1
304953	100736420	20992770223	to	to	TO
304953	100736420	20992770224	adapt	adapt	VVI
304953	100736420	20992770225	to	to	II
304953	100736420	20992770226	its	its	APPGE
304953	100736420	20992770227	surroundings	surroundings	NN2
304953	100736420	20992770228	.	.	.
304953	100736420	20992770229	As	as	CSA
304953	100736420	20992770230	it	it	PPH1
304953	100736420	20992770231	progresses	progress	VVZ
304953	100736420	20992770232	,	,	,
304953	100736420	20992770233	cancer	cancer	NN1
304953	100736420	20992770234	cells	cell	NN2
304953	100736420	20992770235	tend	tend	VV0
304953	100736420	20992770236	to	to	TO
304953	100736420	20992770237	change	change	VVI
304953	100736420	20992770238	,	,	,
304953	100736420	20992770239	morphing	morph	VVG
304953	100736420	20992770240	to	to	II
304953	100736420	20992770241	a	a	AT1
304953	100736420	20992770242	point	point	NN1
304953	100736420	20992770243	where	where	RRQ
304953	100736420	20992770244	the	the	AT
304953	100736420	20992770245	differences	difference	NN2
304953	100736420	20992770246	between	between	II
304953	100736420	20992770247	tumor	tumor	NN1
304953	100736420	20992770248	cells	cell	NN2
304953	100736420	20992770249	can	can	VM
304953	100736420	20992770250	be	be	VBI
304953	100736420	20992770251	dramatic	dramatic	JJ
304953	100736420	20992770252	.	.	.
304953	100736420	20992770253	That 's		NN2_VVZ
304953	100736420	20992770254	why	why	RRQ
304953	100736420	20992770255	some	some	DD
304953	100736420	20992770256	researchers	researcher	NN2
304953	100736420	20992770257	believe	believe	VV0
304953	100736420	20992770258	late-stage	late-stage	JJ_NN1
304953	100736420	20992770259	prostate	prostate	NN1
304953	100736420	20992770260	cancer	cancer	NN1
304953	100736420	20992770261	is	be	VBZ
304953	100736420	20992770262	more	more	RGR
304953	100736420	20992770263	accurately	accurately	RR
304953	100736420	20992770264	described	describe	VVN
304953	100736420	20992770265	as	as	II
304953	100736420	20992770266	a	a	AT1
304953	100736420	20992770267	mix	mix	NN1
304953	100736420	20992770268	of	of	IO
304953	100736420	20992770269	cancer	cancer	NN1
304953	100736420	20992770270	cell	cell	NN1
304953	100736420	20992770271	types	type	NN2
304953	100736420	20992770272	.	.	.
304953	100736420	20992770273	<p>		NULL
304953	100736420	20992770274	When	when	CS_RRQ
304953	100736420	20992770275	it	it	PPH1
304953	100736420	20992770276	comes	come	VVZ
304953	100736420	20992770277	to	to	II
304953	100736420	20992770278	early-stage	early-stage	JJ_NN1
304953	100736420	20992770279	prostate	prostate	NN1
304953	100736420	20992770280	cancer	cancer	NN1
304953	100736420	20992770281	,	,	,
304953	100736420	20992770282	there	there	EX
304953	100736420	20992770283	is	be	VBZ
304953	100736420	20992770284	no	no	AT
304953	100736420	20992770285	evidence	evidence	NN1
304953	100736420	20992770286	that	that	CST
304953	100736420	20992770287	one	one	MC1
304953	100736420	20992770288	treatment	treatment	NN1
304953	100736420	20992770289	is	be	VBZ
304953	100736420	20992770290	better	better	JJR_RRR
304953	100736420	20992770291	than	than	CSN
304953	100736420	20992770292	another	another	DD1
304953	100736420	20992770293	or	or	CC
304953	100736420	20992770294	that	that	CST
304953	100736420	20992770295	any	any	DD
304953	100736420	20992770296	treatment	treatment	NN1
304953	100736420	20992770297	at	at	RR21_II
304953	100736420	20992770298	all	all	RR22_DB
304953	100736420	20992770299	actually	actually	RR
304953	100736420	20992770300	prolongs	prolong	VVZ
304953	100736420	20992770301	life	life	NN1
304953	100736420	20992770302	.	.	.
304953	100736420	20992770303	If	if	CS
304953	100736420	20992770304	you	you	PPY
304953	100736420	20992770305	are	be	VBR
304953	100736420	20992770306	diagnosed	diagnose	VVN
304953	100736420	20992770307	with	with	IW
304953	100736420	20992770308	early-stage	early-stage	JJ
304953	100736420	20992770309	prostate	prostate	NN1
304953	100736420	20992770310	cancer	cancer	NN1
304953	100736420	20992770311	,	,	,
304953	100736420	20992770312	you 'll		VV0_NN1
304953	100736420	20992770313	want	want	VV0
304953	100736420	20992770314	to	to	TO
304953	100736420	20992770315	consider	consider	VVI
304953	100736420	20992770316	factors	factor	NN2
304953	100736420	20992770317	such	such	II21
304953	100736420	20992770318	as	as	II22
304953	100736420	20992770319	your	your	APPGE
304953	100736420	20992770320	values	value	NN2
304953	100736420	20992770321	,	,	,
304953	100736420	20992770322	your	your	APPGE
304953	100736420	20992770323	quality	quality	NN1
304953	100736420	20992770324	of	of	IO
304953	100736420	20992770325	@		II
304953	100736420	20992770326	@		II
304953	100736420	20992770327	@		II
304953	100736420	20992770328	@		II
304953	100736420	20992770329	@		II
304953	100736420	20992770330	@		II
304953	100736420	20992770331	@		II
304953	100736420	20992770332	@		II
304953	100736420	20992770333	@		II
304953	100736420	20992770334	@		II
304953	100736420	20992770335	before	before	II
304953	100736420	20992770336	making	make	VVG
304953	100736420	20992770337	a	a	AT1
304953	100736420	20992770338	decision	decision	NN1
304953	100736420	20992770339	.	.	.
304953	100736421	20992770359	@@##	----------	----------
304953	100736421	20992770360	@@100736421		FO
304953	100736421	20992770361	@4936421/		NN1_VV0
304953	100736421	20992770362	<p>		NULL
304953	100736421	20992770363	Over	over	II
304953	100736421	20992770364	the	the	AT
304953	100736421	20992770365	past	past	JJ
304953	100736421	20992770366	four	four	MC
304953	100736421	20992770367	years	year	NNT2
304953	100736421	20992770368	,	,	,
304953	100736421	20992770369	I 've		NP1
304953	100736421	20992770370	read	read	VVD_VV0
304953	100736421	20992770371	numerous	numerous	JJ
304953	100736421	20992770372	studies	study	NN2
304953	100736421	20992770373	and	and	CC
304953	100736421	20992770374	spoken	speak	VVN
304953	100736421	20992770375	with	with	IW
304953	100736421	20992770376	several	several	DA2
304953	100736421	20992770377	experts	expert	NN2
304953	100736421	20992770378	on	on	II
304953	100736421	20992770379	the	the	AT
304953	100736421	20992770380	connection	connection	NN1
304953	100736421	20992770381	between	between	II
304953	100736421	20992770382	nutrition	nutrition	NN1
304953	100736421	20992770383	and	and	CC
304953	100736421	20992770384	prostate	prostate	NN1
304953	100736421	20992770385	cancer	cancer	NN1
304953	100736421	20992770386	.	.	.
304953	100736421	20992770387	Although	although	CS
304953	100736421	20992770388	their	their	APPGE
304953	100736421	20992770389	recommendations	recommendation	NN2
304953	100736421	20992770390	for	for	IF
304953	100736421	20992770391	men	man	NN2
304953	100736421	20992770392	concerned	concerned	JJ
304953	100736421	20992770393	about	about	II
304953	100736421	20992770394	prostate	prostate	NN1
304953	100736421	20992770395	health	health	NN1
304953	100736421	20992770396	havent		NN1_VV0
304953	100736421	20992770397	always	always	RR
304953	100736421	20992770398	been	be	VBN
304953	100736421	20992770399	consistent	consistent	JJ
304953	100736421	20992770400	,	,	,
304953	100736421	20992770401	most	most	RRT@_DAT_RGT
304953	100736421	20992770402	agreed	agree	VVN_VVD
304953	100736421	20992770403	on	on	II
304953	100736421	20992770404	two	two	MC
304953	100736421	20992770405	things	thing	NN2
304953	100736421	20992770406	:	:	:
304953	100736421	20992770407	eat	eat	VV0
304953	100736421	20992770408	more	more	RGR_DAR
304953	100736421	20992770409	healthy	healthy	JJ
304953	100736421	20992770410	fat	fat	NN1_JJ
304953	100736421	20992770411	,	,	,
304953	100736421	20992770412	particularly	particularly	RR
304953	100736421	20992770413	the	the	AT
304953	100736421	20992770414	omega-3	omega-3	MC
304953	100736421	20992770415	fats	fat	NN2
304953	100736421	20992770416	found	find	VVN_VVD
304953	100736421	20992770417	in	in	II
304953	100736421	20992770418	fatty	fatty	JJ_NN1
304953	100736421	20992770419	fish	fish	NN
304953	100736421	20992770420	like	like	II_JJ@_VV0@
304953	100736421	20992770421	salmon	salmon	NN
304953	100736421	20992770422	,	,	,
304953	100736421	20992770423	and	and	CC
304953	100736421	20992770424	eat	eat	VV0
304953	100736421	20992770425	less	less	RGR_DAR
304953	100736421	20992770426	unhealthy	unhealthy	JJ
304953	100736421	20992770427	fat	fat	NN1_JJ
304953	100736421	20992770428	,	,	,
304953	100736421	20992770429	namely	namely	REX
304953	100736421	20992770430	trans	trans	NN2
304953	100736421	20992770431	and	and	CC
304953	100736421	20992770432	saturated	saturated	JJ
304953	100736421	20992770433	fats	fat	NN2
304953	100736421	20992770434	.	.	.
304953	100736421	20992770435	So	so	RR
304953	100736421	20992770436	I	i	PPIS1
304953	100736421	20992770437	did	do	VDD
304953	100736421	20992770438	a	a	AT1
304953	100736421	20992770439	double	double	NN1_RR@
304953	100736421	20992770440	take	take	VVI
304953	100736421	20992770441	when	when	RRQ_CS
304953	100736421	20992770442	I	i	PPIS1
304953	100736421	20992770443	came	come	VVD
304953	100736421	20992770444	across	across	II
304953	100736421	20992770445	a	a	AT1
304953	100736421	20992770446	study	study	NN1
304953	100736421	20992770447	in	in	II
304953	100736421	20992770448	the	the	AT
304953	100736421	20992770449	American	american	JJ
304953	100736421	20992770450	Journal	journal	NN1
304953	100736421	20992770451	of	of	IO
304953	100736421	20992770452	Epidemiology	epidemiology	NN1_NP1
304953	100736421	20992770453	that	that	CST
304953	100736421	20992770454	came	come	VVD
304953	100736421	20992770455	to	to	II
304953	100736421	20992770456	the	the	AT
304953	100736421	20992770457	opposite	opposite	JJ
304953	100736421	20992770458	conclusion	conclusion	NN1
304953	100736421	20992770459	.	.	.
304953	100736421	20992770460	<p>		NULL
304953	100736421	20992770461	Chronic	chronic	JJ
304953	100736421	20992770462	inflammation	inflammation	NN1
304953	100736421	20992770463	may	may	VM
304953	100736421	20992770464	play	play	VVI
304953	100736421	20992770465	a	a	AT1
304953	100736421	20992770466	role	role	NN1
304953	100736421	20992770467	in	in	II
304953	100736421	20992770468	the	the	AT
304953	100736421	20992770469	development	development	NN1
304953	100736421	20992770470	and	and	CC
304953	100736421	20992770471	progression	progression	NN1
304953	100736421	20992770472	of	of	IO
304953	100736421	20992770473	prostate	prostate	NN1
304953	100736421	20992770474	cancer	cancer	NN1
304953	100736421	20992770475	.	.	.
304953	100736421	20992770476	Omega-3	omega-3	MC
304953	100736421	20992770477	fats	fat	NN2
304953	100736421	20992770478	tend	tend	VV0
304953	100736421	20992770479	to	to	TO
304953	100736421	20992770480	be	be	VBI
304953	100736421	20992770481	calm	calm	JJ
304953	100736421	20992770482	inflammation	inflammation	NN1
304953	100736421	20992770483	,	,	,
304953	100736421	20992770484	while	while	CS
304953	100736421	20992770485	trans	trans	NN2
304953	100736421	20992770486	fats	fat	NN2
304953	100736421	20992770487	tend	tend	VV0
304953	100736421	20992770488	promote	promote	VV0
304953	100736421	20992770489	it	it	PPH1
304953	100736421	20992770490	.	.	.
304953	100736421	20992770491	So	so	RR
304953	100736421	20992770492	researchers	researcher	NN2
304953	100736421	20992770493	analyzed	analyze	VVD
304953	100736421	20992770494	data	data	NN
304953	100736421	20992770495	and	and	CC
304953	100736421	20992770496	blood	blood	NN1
304953	100736421	20992770497	samples	sample	NN2_VVZ@
304953	100736421	20992770498	from	from	II
304953	100736421	20992770499	3,461		MC
304953	100736421	20992770500	men	man	NN2
304953	100736421	20992770501	ages	age	VVZ@_NN2
304953	100736421	20992770502	55	55	MC
304953	100736421	20992770503	to	to	II
304953	100736421	20992770504	84	84	MC
304953	100736421	20992770505	in	in	II
304953	100736421	20992770506	the	the	AT
304953	100736421	20992770507	nationwide	nationwide	JJ
304953	100736421	20992770508	Prostate	prostate	NN1
304953	100736421	20992770509	Cancer	cancer	NN1
304953	100736421	20992770510	Prevention	prevention	NN1
304953	100736421	20992770511	Trial	trial	NN1
304953	100736421	20992770512	to	to	TO
304953	100736421	20992770513	examine	examine	VVI
304953	100736421	20992770514	the	the	AT
304953	100736421	20992770515	relationship	relationship	NN1
304953	100736421	20992770516	between	between	II
304953	100736421	20992770517	the	the	AT
304953	100736421	20992770518	levels	level	NN2
304953	100736421	20992770519	of	of	IO
304953	100736421	20992770520	these	these	DD2
304953	100736421	20992770521	and	and	CC
304953	100736421	20992770522	other	other	JJ
304953	100736421	20992770523	fats	fat	NN2
304953	100736421	20992770524	and	and	CC
304953	100736421	20992770525	prostate	prostate	NN1
304953	100736421	20992770526	cancer	cancer	NN1
304953	100736421	20992770527	risk	risk	NN1
304953	100736421	20992770528	.	.	.
304953	100736421	20992770529	<p>		NULL
304953	100736421	20992770530	Men	man	NN2
304953	100736421	20992770531	with	with	IW
304953	100736421	20992770532	the	the	AT
304953	100736421	20992770533	highest	high	JJT
304953	100736421	20992770534	levels	level	NN2
304953	100736421	20992770535	of	of	IO
304953	100736421	20992770536	DHA	dha	NP1_NN1
304953	100736421	20992770537	,	,	,
304953	100736421	20992770538	a	a	AT1
304953	100736421	20992770539	type	type	NN1
304953	100736421	20992770540	of	of	IO
304953	100736421	20992770541	omega-3	omega-3	MC
304953	100736421	20992770542	,	,	,
304953	100736421	20992770543	were	be	VBDR
304953	100736421	20992770544	2.5	2.5	MC
304953	100736421	20992770545	times	time	NNT2
304953	100736421	20992770546	more	more	RRR_RGR
304953	100736421	20992770547	likely	likely	JJ
304953	100736421	20992770548	to	to	TO
304953	100736421	20992770549	have	have	VHI
304953	100736421	20992770550	developed	develop	VVN
304953	100736421	20992770551	@		II
304953	100736421	20992770552	@		II
304953	100736421	20992770553	@		II
304953	100736421	20992770554	@		II
304953	100736421	20992770555	@		II
304953	100736421	20992770556	@		II
304953	100736421	20992770557	@		II
304953	100736421	20992770558	@		II
304953	100736421	20992770559	@		II
304953	100736421	20992770560	@		II
304953	100736421	20992770561	with	with	IW
304953	100736421	20992770562	men	man	NN2
304953	100736421	20992770563	who	who	PNQS
304953	100736421	20992770564	had	have	VHD
304953	100736421	20992770565	the	the	AT
304953	100736421	20992770566	lowest	low	JJT
304953	100736421	20992770567	levels	level	NN2
304953	100736421	20992770568	of	of	IO
304953	100736421	20992770569	DHA	dha	NP1_NN1
304953	100736421	20992770570	"	"	"
304953	100736421	20992770571	the	the	AT
304953	100736421	20992770572	exact	exact	JJ
304953	100736421	20992770573	opposite	opposite	NN1@_JJ
304953	100736421	20992770574	of	of	IO
304953	100736421	20992770575	what	what	DDQ
304953	100736421	20992770576	the	the	AT
304953	100736421	20992770577	researchers	researcher	NN2
304953	100736421	20992770578	had	have	VHD
304953	100736421	20992770579	hypothesized	hypothesize	VVN
304953	100736421	20992770580	.	.	.
304953	100736421	20992770581	Another	another	DD1
304953	100736421	20992770582	surprising	surprising	JJ
304953	100736421	20992770583	result	result	NN1
304953	100736421	20992770584	was	be	VBDZ
304953	100736421	20992770585	that	that	CST
304953	100736421	20992770586	men	man	NN2
304953	100736421	20992770587	with	with	IW
304953	100736421	20992770588	the	the	AT
304953	100736421	20992770589	highest	high	JJT
304953	100736421	20992770590	blood	blood	NN1
304953	100736421	20992770591	levels	level	NN2
304953	100736421	20992770592	of	of	IO
304953	100736421	20992770593	trans	trans	NN2
304953	100736421	20992770594	fats	fat	NN2
304953	100736421	20992770595	,	,	,
304953	100736421	20992770596	often	often	RR
304953	100736421	20992770597	found	find	VVN_VVD
304953	100736421	20992770598	in	in	II
304953	100736421	20992770599	processed	processed	JJ
304953	100736421	20992770600	foods	food	NN2
304953	100736421	20992770601	,	,	,
304953	100736421	20992770602	were	be	VBDR
304953	100736421	20992770603	50%		NNU
304953	100736421	20992770604	less	less	DAR_RRR
304953	100736421	20992770605	likely	likely	JJ
304953	100736421	20992770606	to	to	TO
304953	100736421	20992770607	have	have	VHI
304953	100736421	20992770608	developed	develop	VVN
304953	100736421	20992770609	aggressive	aggressive	JJ
304953	100736421	20992770610	,	,	,
304953	100736421	20992770611	high-grade	high-grade	JJ_NN1
304953	100736421	20992770612	prostate	prostate	NN1
304953	100736421	20992770613	cancer	cancer	NN1
304953	100736421	20992770614	compared	compare	VVN
304953	100736421	20992770615	with	with	IW
304953	100736421	20992770616	those	those	DD2
304953	100736421	20992770617	who	who	PNQS
304953	100736421	20992770618	had	have	VHD
304953	100736421	20992770619	the	the	AT
304953	100736421	20992770620	lowest	low	JJT
304953	100736421	20992770621	levels	level	NN2
304953	100736421	20992770622	.	.	.
304953	100736421	20992770623	<p>		NULL
304953	100736421	20992770624	Should	should	VM
304953	100736421	20992770625	these	these	DD2
304953	100736421	20992770626	results	result	NN2
304953	100736421	20992770627	prompt	prompt	VVI
304953	100736421	20992770628	men	man	NN2
304953	100736421	20992770629	to	to	TO
304953	100736421	20992770630	scale	scale	VVI
304953	100736421	20992770631	back	back	RP
304953	100736421	20992770632	on	on	II
304953	100736421	20992770633	fish	fish	NN
304953	100736421	20992770634	and	and	CC
304953	100736421	20992770635	eat	eat	VVI
304953	100736421	20992770636	more	more	RGR_DAR_RRR
304953	100736421	20992770637	processed	processed	JJ
304953	100736421	20992770638	food	food	NN1
304953	100736421	20992770639	?	?	?
304953	100736421	20992770640	I	i	PPIS1
304953	100736421	20992770641	put	put	VV0_VVD
304953	100736421	20992770642	that	that	DD1
304953	100736421	20992770643	question	question	NN1
304953	100736421	20992770644	to	to	II
304953	100736421	20992770645	Stacy	stacy	NP1
304953	100736421	20992770646	Kennedy	kennedy	NP1
304953	100736421	20992770647	,	,	,
304953	100736421	20992770648	senior	senior	JJ
304953	100736421	20992770649	clinical	clinical	JJ
304953	100736421	20992770650	nutritionist	nutritionist	NN1
304953	100736421	20992770651	at	at	II
304953	100736421	20992770652	Dana-Farber	dana-farber	NP1
304953	100736421	20992770653	Cancer	cancer	NN1
304953	100736421	20992770654	Institute	institute	NN1
304953	100736421	20992770655	,	,	,
304953	100736421	20992770656	and	and	CC
304953	100736421	20992770657	Dr.		NNB
304953	100736421	20992770658	David	david	NP1
304953	100736421	20992770659	Rosenthal	rosenthal	NP1
304953	100736421	20992770660	,	,	,
304953	100736421	20992770661	director	director	NN1
304953	100736421	20992770662	of	of	IO
304953	100736421	20992770663	Harvard	harvard	NP1
304953	100736421	20992770664	University	university	NN1
304953	100736421	20992770665	Health	health	NN1
304953	100736421	20992770666	Service	service	NN1
304953	100736421	20992770667	and	and	CC
304953	100736421	20992770668	medical	medical	JJ
304953	100736421	20992770669	director	director	NN1
304953	100736421	20992770670	of	of	IO
304953	100736421	20992770671	the	the	AT
304953	100736421	20992770672	Leonard	leonard	NP1
304953	100736421	20992770673	P.		NP1
304953	100736421	20992770674	Zakim		NP1_NN1
304953	100736421	20992770675	Center	center	NN1
304953	100736421	20992770676	for	for	IF
304953	100736421	20992770677	Integrative	integrative	JJ
304953	100736421	20992770678	Therapies	therapy	NN2
304953	100736421	20992770679	at	at	II
304953	100736421	20992770680	Dana-Farber	dana-farber	NP1
304953	100736421	20992770681	.	.	.
304953	100736421	20992770682	Both	both	DB2_RR
304953	100736421	20992770683	gave	give	VVD
304953	100736421	20992770684	me	me	PPIO1
304953	100736421	20992770685	an	a	AT1
304953	100736421	20992770686	emphatic	emphatic	JJ
304953	100736421	20992770687	"	"	"
304953	100736421	20992770688	no	no	UH
304953	100736421	20992770689	.	.	.
304953	100736421	20992770690	"	"	"
304953	100736421	20992770691	One	one	MC1
304953	100736421	20992770692	key	key	JJ_NN1
304953	100736421	20992770693	reason	reason	NN1
304953	100736421	20992770694	:	:	:
304953	100736421	20992770695	the	the	AT
304953	100736421	20992770696	risk	risk	NN1
304953	100736421	20992770697	of	of	IO
304953	100736421	20992770698	dying	die	VVG_JJ
304953	100736421	20992770699	from	from	II
304953	100736421	20992770700	heart	heart	NN1
304953	100736421	20992770701	disease	disease	NN1
304953	100736421	20992770702	is	be	VBZ
304953	100736421	20992770703	much	much	RR_DA1
304953	100736421	20992770704	higher	high	JJR
304953	100736421	20992770705	than	than	CSN
304953	100736421	20992770706	the	the	AT
304953	100736421	20992770707	risk	risk	NN1
304953	100736421	20992770708	of	of	IO
304953	100736421	20992770709	dying	die	VVG_JJ
304953	100736421	20992770710	from	from	II
304953	100736421	20992770711	prostate	prostate	NN1
304953	100736421	20992770712	cancer	cancer	NN1
304953	100736421	20992770713	.	.	.
304953	100736421	20992770714	<p>		NULL
304953	100736421	20992770715	Eating	eat	VVG
304953	100736421	20992770716	moderate	moderate	JJ
304953	100736421	20992770717	amounts	amount	NN2
304953	100736421	20992770718	of	of	IO
304953	100736421	20992770719	wild	wild	JJ
304953	100736421	20992770720	salmon	salmon	NN
304953	100736421	20992770721	,	,	,
304953	100736421	20992770722	walnuts	walnut	NN2
304953	100736421	20992770723	,	,	,
304953	100736421	20992770724	pumpkin	pumpkin	NN1
304953	100736421	20992770725	seeds	seed	NN2
304953	100736421	20992770726	,	,	,
304953	100736421	20992770727	and	and	CC
304953	100736421	20992770728	other	other	JJ
304953	100736421	20992770729	foods	food	NN2
304953	100736421	20992770730	rich	rich	JJ
304953	100736421	20992770731	in	in	II
304953	100736421	20992770732	omega-3s	omega-3s	MC2
304953	100736421	20992770733	is	be	VBZ
304953	100736421	20992770734	a	a	AT1
304953	100736421	20992770735	healthy	healthy	JJ
304953	100736421	20992770736	strategy	strategy	NN1
304953	100736421	20992770737	,	,	,
304953	100736421	20992770738	Kennedy	kennedy	NP1
304953	100736421	20992770739	told	tell	VVD
304953	100736421	20992770740	me	me	PPIO1
304953	100736421	20992770741	.	.	.
304953	100736421	20992770742	The	the	AT
304953	100736421	20992770743	best	best	JJT
304953	100736421	20992770744	"	"	"
304953	100736421	20992770745	medicine	medicine	NN1
304953	100736421	20992770746	"	"	"
304953	100736421	20992770747	for	for	IF
304953	100736421	20992770748	men	man	NN2
304953	100736421	20992770749	who	who	PNQS
304953	100736421	20992770750	are	be	VBR
304953	100736421	20992770751	@		II
304953	100736421	20992770752	@		II
304953	100736421	20992770753	@		II
304953	100736421	20992770754	@		II
304953	100736421	20992770755	@		II
304953	100736421	20992770756	@		II
304953	100736421	20992770757	@		II
304953	100736421	20992770758	@		II
304953	100736421	20992770759	@		II
304953	100736421	20992770760	@		II
304953	100736421	20992770761	a	a	AT1
304953	100736421	20992770762	healthy	healthy	JJ
304953	100736421	20992770763	weight	weight	NN1
304953	100736421	20992770764	,	,	,
304953	100736421	20992770765	eat	eat	VV0
304953	100736421	20992770766	plenty	plenty	PN
304953	100736421	20992770767	of	of	IO
304953	100736421	20992770768	fruits	fruit	NN2
304953	100736421	20992770769	and	and	CC
304953	100736421	20992770770	vegetables	vegetable	NN2
304953	100736421	20992770771	,	,	,
304953	100736421	20992770772	exercise	exercise	VV0
304953	100736421	20992770773	regularly	regularly	RR
304953	100736421	20992770774	,	,	,
304953	100736421	20992770775	and	and	CC
304953	100736421	20992770776	control	control	NN1_VV0
304953	100736421	20992770777	stress	stress	NN1
304953	100736421	20992770778	.	.	.
304953	100736421	20992770779	The	the	AT
304953	100736421	20992770780	good	good	JJ
304953	100736421	20992770781	news	news	NN1
304953	100736421	20992770782	is	be	VBZ
304953	100736421	20992770783	that	that	CST_DD1
304953	100736421	20992770784	taking	take	VVG
304953	100736421	20992770785	these	these	DD2
304953	100736421	20992770786	steps	step	NN2
304953	100736421	20992770787	will	will	VM
304953	100736421	20992770788	promote	promote	VVI
304953	100736421	20992770789	heart	heart	NN1
304953	100736421	20992770790	health	health	NN1
304953	100736421	20992770791	,	,	,
304953	100736421	20992770792	too	too	RR@
304953	100736421	20992770793	.	.	.
304953	100736421	20992770794	<p>		NULL
304953	100736421	20992770795	What	what	DDQ
304953	100736421	20992770796	would	would	VM
304953	100736421	20992770797	be	be	VBI
304953	100736421	20992770798	a	a	AT1
304953	100736421	20992770799	moderate	moderate	JJ
304953	100736421	20992770800	amount	amount	NN1
304953	100736421	20992770801	of	of	IO
304953	100736421	20992770802	salmon	salmon	NN
304953	100736421	20992770803	?	?	?
304953	100736421	20992770804	I	i	PPIS1
304953	100736421	20992770805	consume	consume	VV0
304953	100736421	20992770806	about	about	II_RP@
304953	100736421	20992770807	a	a	AT1
304953	100736421	20992770808	pound	pound	NN1
304953	100736421	20992770809	of	of	IO
304953	100736421	20992770810	wild	wild	JJ
304953	100736421	20992770811	salmon	salmon	NN
304953	100736421	20992770812	a	a	AT1
304953	100736421	20992770813	week	week	NNT1
304953	100736421	20992770814	.	.	.
304953	100736421	20992770815	<p>		NULL
304953	100736421	20992770816	Are	be	VBR
304953	100736421	20992770817	there	there	RL
304953	100736421	20992770818	still	still	RR
304953	100736421	20992770819	any	any	DD
304953	100736421	20992770820	cultures	culture	NN2
304953	100736421	20992770821	still	still	RR
304953	100736421	20992770822	known	know	VVN
304953	100736421	20992770823	for	for	IF
304953	100736421	20992770824	a	a	AT1
304953	100736421	20992770825	high	high	JJ
304953	100736421	20992770826	salmon	salmon	NN
304953	100736421	20992770827	or	or	CC
304953	100736421	20992770828	other	other	JJ
304953	100736421	20992770829	high	high	JJ
304953	100736421	20992770830	omega	omega	NN1
304953	100736421	20992770831	3	3	MC
304953	100736421	20992770832	fish	fish	NN
304953	100736421	20992770833	dietsay		VV0_NN1
304953	100736421	20992770834	in	in	II
304953	100736421	20992770835	the	the	AT
304953	100736421	20992770836	Pacific	pacific	NP1
304953	100736421	20992770837	coast	coast	NN1
304953	100736421	20992770838	areas	area	NN2
304953	100736421	20992770839	from	from	II
304953	100736421	20992770840	British	british	NP1
304953	100736421	20992770841	Columbia	columbia	NP1
304953	100736421	20992770842	to	to	II
304953	100736421	20992770843	Alaska	alaska	NP1
304953	100736421	20992770844	?	?	?
304953	100736421	20992770845	If	if	CS
304953	100736421	20992770846	so	so	RR
304953	100736421	20992770847	,	,	,
304953	100736421	20992770848	it	it	PPH1
304953	100736421	20992770849	would	would	VM
304953	100736421	20992770850	be	be	VBI
304953	100736421	20992770851	interesting	interesting	JJ
304953	100736421	20992770852	to	to	TO
304953	100736421	20992770853	know	know	VVI
304953	100736421	20992770854	of	of	IO
304953	100736421	20992770855	the	the	AT
304953	100736421	20992770856	prostate	prostate	NN1
304953	100736421	20992770857	cancer	cancer	NN1
304953	100736421	20992770858	incidence	incidence	NN1
304953	100736421	20992770859	rate	rate	NN1
304953	100736421	20992770860	in	in	II
304953	100736421	20992770861	those	those	DD2
304953	100736421	20992770862	populations	population	NN2
304953	100736421	20992770863	.	.	.
304953	100736421	20992770864	<p>		NULL
304953	100736421	20992770865	I	i	PPIS1
304953	100736421	20992770866	wish	wish	VV0
304953	100736421	20992770867	the	the	AT
304953	100736421	20992770868	absolute	absolute	JJ
304953	100736421	20992770869	risk	risk	NN1
304953	100736421	20992770870	increase	increase	NN1
304953	100736421	20992770871	had	have	VHD
304953	100736421	20992770872	been	be	VBN
304953	100736421	20992770873	given	give	VVN
304953	100736421	20992770874	.	.	.
304953	100736421	20992770875	This	this	DD1
304953	100736421	20992770876	report	report	NN1
304953	100736421	20992770877	does	do	VDZ
304953	100736421	20992770878	n't 	n't	XX
304953	100736421	20992770879	give	give	VVI
304953	100736421	20992770880	sufficient	sufficient	JJ
304953	100736421	20992770881	information	information	NN1
304953	100736421	20992770882	to	to	TO
304953	100736421	20992770883	make	make	VVI
304953	100736421	20992770884	an	a	AT1
304953	100736421	20992770885	informed	informed	JJ@
304953	100736421	20992770886	judgment	judgment	NN1
304953	100736421	20992770887	.	.	.
304953	100736421	20992770888	What	what	DDQ
304953	100736421	20992770889	is	be	VBZ
304953	100736421	20992770890	the	the	AT
304953	100736421	20992770891	value	value	NN1
304953	100736421	20992770892	that	that	CST_DD1
304953	100736421	20992770893	is	be	VBZ
304953	100736421	20992770894	increased	increase	VVN
304953	100736421	20992770895	by	by	II
304953	100736421	20992770896	a	a	AT1
304953	100736421	20992770897	factor	factor	NN1
304953	100736421	20992770898	of	of	IO
304953	100736421	20992770899	2.5	2.5	MC
304953	100736421	20992770900	?	?	?
304953	100736421	20992770901	If	if	CS
304953	100736421	20992770902	it	it	PPH1
304953	100736421	20992770903	is	be	VBZ
304953	100736421	20992770904	very	very	RG
304953	100736421	20992770905	low	low	JJ_RR@
304953	100736421	20992770906	then	then	RT
304953	100736421	20992770907	its	its	APPGE
304953	100736421	20992770908	not	not	XX
304953	100736421	20992770909	a	a	AT1
304953	100736421	20992770910	big	big	JJ
304953	100736421	20992770911	deal	deal	NN1
304953	100736421	20992770912	.	.	.
304953	100736421	20992770913	If	if	CS
304953	100736421	20992770914	it	it	PPH1
304953	100736421	20992770915	is	be	VBZ
304953	100736421	20992770916	not	not	XX
304953	100736421	20992770917	so	so	RG_RR
304953	100736421	20992770918	low	low	JJ_RR@
304953	100736421	20992770919	then	then	RT
304953	100736421	20992770920	there	there	EX
304953	100736421	20992770921	is	be	VBZ
304953	100736421	20992770922	reason	reason	NN1
304953	100736421	20992770923	for	for	IF
304953	100736421	20992770924	concern	concern	NN1
304953	100736421	20992770925	.	.	.
304953	100736421	20992770926	<p>		NULL
304953	100736421	20992770927	just	just	RR
304953	100736421	20992770928	basing	base	VVG_JJ@
304953	100736421	20992770929	research	research	NN1
304953	100736421	20992770930	on	on	II
304953	100736421	20992770931	diet	diet	NN1
304953	100736421	20992770932	and	and	CC
304953	100736421	20992770933	food	food	NN1
304953	100736421	20992770934	without	without	IW
304953	100736421	20992770935	looking	look	VVG
304953	100736421	20992770936	at	at	II
304953	100736421	20992770937	pesticide	pesticide	NN1
304953	100736421	20992770938	residues	residue	NN2
304953	100736421	20992770939	in	in	II
304953	100736421	20992770940	fat	fat	NN1_JJ
304953	100736421	20992770941	and	and	CC
304953	100736421	20992770942	lipid	lipid	JJ
304953	100736421	20992770943	production	production	NN1
304953	100736421	20992770944	and	and	CC
304953	100736421	20992770945	the	the	AT
304953	100736421	20992770946	resulting	resulting	JJ
304953	100736421	20992770947	endocrine	endocrine	JJ_NN1
304953	100736421	20992770948	disruption	disruption	NN1
304953	100736421	20992770949	and	and	CC
304953	100736421	20992770950	neurotoxicity	neurotoxicity	NN1
304953	100736421	20992770951	@		II
304953	100736421	20992770952	@		II
304953	100736421	20992770953	@		II
304953	100736421	20992770954	@		II
304953	100736421	20992770955	@		II
304953	100736421	20992770956	@		II
304953	100736421	20992770957	@		II
304953	100736421	20992770958	@		II
304953	100736421	20992770959	@		II
304953	100736421	20992770960	@		II
304953	100736421	20992770961	There	there	EX
304953	100736421	20992770962	is	be	VBZ
304953	100736421	20992770963	no	no	AT
304953	100736421	20992770964	greater	great	JJR
304953	100736421	20992770965	cause	cause	NN1
304953	100736421	20992770966	of	of	IO
304953	100736421	20992770967	oxidative	oxidative	JJ
304953	100736421	20992770968	stress	stress	NN1
304953	100736421	20992770969	in	in	II
304953	100736421	20992770970	my	my	APPGE
304953	100736421	20992770971	view	view	NN1
304953	100736421	20992770972	than	than	CSN
304953	100736421	20992770973	the	the	AT
304953	100736421	20992770974	continued	continued	JJ
304953	100736421	20992770975	use	use	NN1
304953	100736421	20992770976	of	of	IO
304953	100736421	20992770977	excess	excess	JJ_NN1
304953	100736421	20992770978	pesticides	pesticide	NN2
304953	100736421	20992770979	with	with	IW
304953	100736421	20992770980	associated	associated	JJ
304953	100736421	20992770981	penetrants		NN2
304953	100736421	20992770982	or	or	CC
304953	100736421	20992770983	surfucants		NN2
304953	100736421	20992770984	designed	design	VVN_VVD
304953	100736421	20992770985	to	to	TO
304953	100736421	20992770986	permeate	permeate	VVI
304953	100736421	20992770987	the	the	AT
304953	100736421	20992770988	plant	plant	NN1
304953	100736421	20992770989	waxes	wax	VVZ_NN2
304953	100736421	20992770990	possibly	possibly	RR
304953	100736421	20992770991	causing	cause	VVG
304953	100736421	20992770992	chaos	chaos	NN1
304953	100736421	20992770993	in	in	II
304953	100736421	20992770994	the	the	AT
304953	100736421	20992770995	human	human	JJ_NN1
304953	100736421	20992770996	fat	fat	NN1_JJ
304953	100736421	20992770997	and	and	CC
304953	100736421	20992770998	lipid	lipid	JJ
304953	100736421	20992770999	chain	chain	NN1
304953	100736421	20992771000	.	.	.
304953	100736421	20992771001	<p>		NULL
304953	100736421	20992771002	Once	once	RR21
304953	100736421	20992771003	again	again	RR22
304953	100736421	20992771004	the	the	AT
304953	100736421	20992771005	epidemiologists	epidemiologist	NN2
304953	100736421	20992771006	have	have	VH0
304953	100736421	20992771007	stirred	stir	VVN
304953	100736421	20992771008	up	up	RP_II@
304953	100736421	20992771009	some	some	DD
304953	100736421	20992771010	cloudy	cloudy	JJ
304953	100736421	20992771011	soup	soup	NN1
304953	100736421	20992771012	!	!	!
304953	100736421	20992771013	The	the	AT
304953	100736421	20992771014	contrairian		JJ_NN1
304953	100736421	20992771015	results	result	NN2
304953	100736421	20992771016	of	of	IO
304953	100736421	20992771017	this	this	DD1
304953	100736421	20992771018	study	study	NN1
304953	100736421	20992771019	are	be	VBR
304953	100736421	20992771020	so	so	RG_RR
304953	100736421	20992771021	outstanding	outstanding	JJ
304953	100736421	20992771022	that	that	CST
304953	100736421	20992771023	they	they	PPHS2
304953	100736421	20992771024	have	have	VH0
304953	100736421	20992771025	to	to	TO
304953	100736421	20992771026	be	be	VBI
304953	100736421	20992771027	approached	approach	VVN
304953	100736421	20992771028	with	with	IW
304953	100736421	20992771029	great	great	JJ
304953	100736421	20992771030	caution	caution	NN1
304953	100736421	20992771031	.	.	.
304953	100736421	20992771032	The	the	AT
304953	100736421	20992771033	statistical	statistical	JJ
304953	100736421	20992771034	analyses	analysis	NN2
304953	100736421	20992771035	shows	show	VVZ
304953	100736421	20992771036	confidence	confidence	NN1
304953	100736421	20992771037	limits	limit	VVZ_NN2
304953	100736421	20992771038	around	around	II_RP
304953	100736421	20992771039	the	the	AT
304953	100736421	20992771040	mean	mean	JJ
304953	100736421	20992771041	values	value	NN2
304953	100736421	20992771042	big	big	JJ_RR%
304953	100736421	20992771043	enoug		NN1_VV0
304953	100736421	20992771044	to	to	TO
304953	100736421	20992771045	drive	drive	VVI
304953	100736421	20992771046	a	a	AT1
304953	100736421	20992771047	truck	truck	NN1
304953	100736421	20992771048	through	through	RP@_II
304953	100736421	20992771049	.	.	.
304953	100736421	20992771050	<p>		NULL
304953	100736421	20992771051	So	so	RR
304953	100736421	20992771052	before	before	CS_II
304953	100736421	20992771053	anyone	anyone	PN1
304953	100736421	20992771054	dumps	dump	NN2
304953	100736421	20992771055	the	the	AT
304953	100736421	20992771056	accepted	accepted	JJ
304953	100736421	20992771057	wisdom	wisdom	NN1
304953	100736421	20992771058	regarding	regarding	II_VVG
304953	100736421	20992771059	omega	omega	NN1
304953	100736421	20992771060	3s	3s	MC2
304953	100736421	20992771061	and	and	CC
304953	100736421	20992771062	their	their	APPGE
304953	100736421	20992771063	ilk	ilk	NN1
304953	100736421	20992771064	,	,	,
304953	100736421	20992771065	let 's		VVZ
304953	100736421	20992771066	see	see	VVI
304953	100736421	20992771067	if	if	CSW@_CS
304953	100736421	20992771068	anyone	anyone	PN1
304953	100736421	20992771069	replicates	replicate	VVZ
304953	100736421	20992771070	the	the	AT
304953	100736421	20992771071	results	result	NN2
304953	100736421	20992771072	.	.	.
304953	100736421	20992771073	Keep	keep	VV0
304953	100736421	20992771074	the	the	AT
304953	100736421	20992771075	grill	grill	NN1
304953	100736421	20992771076	hot	hot	JJ
304953	100736421	20992771077	and	and	CC
304953	100736421	20992771078	the	the	AT
304953	100736421	20992771079	fresh	fresh	JJ
304953	100736421	20992771080	fish	fish	NN
304953	100736421	20992771081	broiling	broil	VVG
304953	100736421	20992771082	!	!	!
304953	100736421	20992771083	<p>		NULL
304953	100736421	20992771084	I	i	PPIS1
304953	100736421	20992771085	too	too	RR@
304953	100736421	20992771086	would	would	VM
304953	100736421	20992771087	be	be	VBI
304953	100736421	20992771088	interested	interested	JJ
304953	100736421	20992771089	in	in	II
304953	100736421	20992771090	knowing	know	VVG
304953	100736421	20992771091	the	the	AT
304953	100736421	20992771092	incidence	incidence	NN1
304953	100736421	20992771093	of	of	IO
304953	100736421	20992771094	prostate	prostate	NN1
304953	100736421	20992771095	cancer	cancer	NN1
304953	100736421	20992771096	in	in	II
304953	100736421	20992771097	Japan	japan	NP1
304953	100736421	20992771098	and	and	CC
304953	100736421	20992771099	surrounding	surrounding	JJ_VVG
304953	100736421	20992771100	areas	area	NN2
304953	100736421	20992771101	that	that	CST
304953	100736421	20992771102	consume	consume	VV0
304953	100736421	20992771103	large	large	JJ
304953	100736421	20992771104	amounts	amount	NN2
304953	100736421	20992771105	of	of	IO
304953	100736421	20992771106	Omega	omega	NN1
304953	100736421	20992771107	3	3	MC
304953	100736421	20992771108	.	.	.
304953	100736421	20992771109	<p>		NULL
304953	100736421	20992771110	I	i	PPIS1
304953	100736421	20992771111	am	be	VBM
304953	100736421	20992771112	a	a	AT1
304953	100736421	20992771113	nutritionist	nutritionist	NN1
304953	100736421	20992771114	and	and	CC
304953	100736421	20992771115	have	have	VH0
304953	100736421	20992771116	learned	learn	VVN
304953	100736421	20992771117	that	that	CST
304953	100736421	20992771118	men	man	NN2
304953	100736421	20992771119	that	that	CST
304953	100736421	20992771120	consume	consume	VV0
304953	100736421	20992771121	large	large	JJ
304953	100736421	20992771122	amounts	amount	NN2
304953	100736421	20992771123	of	of	IO
304953	100736421	20992771124	omega	omega	NN1
304953	100736421	20992771125	6	6	MC
304953	100736421	20992771126	increase	increase	VV0
304953	100736421	20992771127	their	their	APPGE
304953	100736421	20992771128	risk	risk	NN1
304953	100736421	20992771129	of	of	IO
304953	100736421	20992771130	prostate	prostate	NN1
304953	100736421	20992771131	cancer	cancer	NN1
304953	100736421	20992771132	?	?	?
304953	100736421	20992771133	<p>		NULL
304953	100736421	20992771134	My	my	APPGE
304953	100736421	20992771135	husband	husband	NN1
304953	100736421	20992771136	has	have	VHZ
304953	100736421	20992771137	had	have	VHN
304953	100736421	20992771138	prostitis		NN1
304953	100736421	20992771139	for	for	IF
304953	100736421	20992771140	6+	6+	FO
304953	100736421	20992771141	months	month	NNT2
304953	100736421	20992771142	.	.	.
304953	100736421	20992771143	He	he	PPHS1
304953	100736421	20992771144	has	have	VHZ
304953	100736421	20992771145	been	be	VBN
304953	100736421	20992771146	on	on	II
304953	100736421	20992771147	antibiotics	antibiotic	NN2
304953	100736421	20992771148	for	for	IF
304953	100736421	20992771149	all	all	DB
304953	100736421	20992771150	this	this	DD1
304953	100736421	20992771151	@		II
304953	100736421	20992771152	@		II
304953	100736421	20992771153	@		II
304953	100736421	20992771154	@		II
304953	100736421	20992771155	@		II
304953	100736421	20992771156	@		II
304953	100736421	20992771157	@		II
304953	100736421	20992771158	@		II
304953	100736421	20992771159	@		II
304953	100736421	20992771160	@		II
304953	100736421	20992771161	off	off	II_RP
304953	100736421	20992771162	omega	omega	NN1
304953	100736421	20992771163	3	3	MC
304953	100736421	20992771164	for	for	IF
304953	100736421	20992771165	now	now	RT
304953	100736421	20992771166	.	.	.
304953	100736421	20992771167	What	what	DDQ
304953	100736421	20992771168	is	be	VBZ
304953	100736421	20992771169	causing	cause	VVG
304953	100736421	20992771170	this	this	DD1
304953	100736421	20992771171	inflammation	inflammation	NN1
304953	100736421	20992771172	and	and	CC
304953	100736421	20992771173	why	why	RRQ
304953	100736421	20992771174	can	can	VM
304953	100736421	20992771175	no	no	RR
304953	100736421	20992771176	one	one	MC1
304953	100736421	20992771177	treat	treat	VV0_NN1
304953	100736421	20992771178	it	it	PPH1
304953	100736421	20992771179	.	.	.
304953	100736421	20992771180	My	my	APPGE
304953	100736421	20992771181	Osteopath		NN1_NP1
304953	100736421	20992771182	suggested	suggest	VVD
304953	100736421	20992771183	he	he	PPHS1
304953	100736421	20992771184	could	could	VM
304953	100736421	20992771185	release	release	VVI
304953	100736421	20992771186	some	some	DD
304953	100736421	20992771187	of	of	IO
304953	100736421	20992771188	the	the	AT
304953	100736421	20992771189	scar	scar	NN1
304953	100736421	20992771190	tissue	tissue	NN1
304953	100736421	20992771191	from	from	II
304953	100736421	20992771192	all	all	DB
304953	100736421	20992771193	the	the	AT
304953	100736421	20992771194	inflammation	inflammation	NN1
304953	100736421	20992771195	,	,	,
304953	100736421	20992771196	any	any	DD
304953	100736421	20992771197	thoughts	thought	NN2
304953	100736421	20992771198	or	or	CC
304953	100736421	20992771199	recommendations	recommendation	NN2
304953	100736421	20992771200	would	would	VM
304953	100736421	20992771201	be	be	VBI
304953	100736421	20992771202	greatly	greatly	RR
304953	100736421	20992771203	appreciated	appreciate	VVN_VVD
304953	100736421	20992771204	!	!	!
304953	100736421	20992771205	!	!	!
304953	100736421	20992771206	!	!	!
304953	100736421	20992771207	<p>		NULL
304953	100736421	20992771208	When	when	CS_RRQ
304953	100736421	20992771209	you	you	PPY
304953	100736421	20992771210	ask	ask	VV0
304953	100736421	20992771211	your	your	APPGE
304953	100736421	20992771212	doctor	doctor	NN1
304953	100736421	20992771213	or	or	CC
304953	100736421	20992771214	any	any	DD
304953	100736421	20992771215	doctor(specialist)about		NN1_VV0
304953	100736421	20992771216	prostate	prostate	NN1
304953	100736421	20992771217	cancer	cancer	NN1
304953	100736421	20992771218	,	,	,
304953	100736421	20992771219	cholesterol	cholesterol	NN1
304953	100736421	20992771220	,	,	,
304953	100736421	20992771221	cardio-vascular	cardiovascular	JJ
304953	100736421	20992771222	related	related	JJ
304953	100736421	20992771223	problems	problem	NN2
304953	100736421	20992771224	,	,	,
304953	100736421	20992771225	blood	blood	NN1
304953	100736421	20992771226	pressure	pressure	NN1
304953	100736421	20992771227	,	,	,
304953	100736421	20992771228	diabets1,2		FO
304953	100736421	20992771229	the	the	AT
304953	100736421	20992771230	answer	answer	NN1
304953	100736421	20992771231	will	will	VM
304953	100736421	20992771232	be	be	VBI
304953	100736421	20992771233	,	,	,
304953	100736421	20992771234	you	you	PPY
304953	100736421	20992771235	have	have	VH0
304953	100736421	20992771236	to	to	TO
304953	100736421	20992771237	avoid	avoid	VVI
304953	100736421	20992771238	saturated	saturated	JJ
304953	100736421	20992771239	fats	fat	NN2
304953	100736421	20992771240	,	,	,
304953	100736421	20992771241	trans	trans	NN2
304953	100736421	20992771242	fats	fat	NN2
304953	100736421	20992771243	,	,	,
304953	100736421	20992771244	etc.		RA
304953	100736421	20992771245	and	and	CC
304953	100736421	20992771246	gives	give	VVZ
304953	100736421	20992771247	you	you	PPY
304953	100736421	20992771248	advise	advise	VV0
304953	100736421	20992771249	to	to	TO
304953	100736421	20992771250	chenge		VVI
304953	100736421	20992771251	your	your	APPGE
304953	100736421	20992771252	diet	diet	NN1
304953	100736421	20992771253	(	(	(
304953	100736421	20992771254	eat	eat	VV0
304953	100736421	20992771255	vegetables	vegetable	NN2
304953	100736421	20992771256	fruits	fruit	NN2
304953	100736421	20992771257	Omega3	omega3	FO
304953	100736421	20992771258	rich	rich	JJ
304953	100736421	20992771259	foods	food	NN2
304953	100736421	20992771260	)	)	)
304953	100736421	20992771261	,	,	,
304953	100736421	20992771262	do	do	VD0
304953	100736421	20992771263	excercise		VVI
304953	100736421	20992771264	,	,	,
304953	100736421	20992771265	approach	approach	NN1_VV0@
304953	100736421	20992771266	to	to	II
304953	100736421	20992771267	proper	proper	JJ
304953	100736421	20992771268	weight	weight	NN1
304953	100736421	20992771269	,	,	,
304953	100736421	20992771270	etc.		RA
304953	100736421	20992771271	it	it	PPH1
304953	100736421	20992771272	seems	seem	VVZ
304953	100736421	20992771273	that	that	CST
304953	100736421	20992771274	all	all	DB
304953	100736421	20992771275	these	these	DD2
304953	100736421	20992771276	illeness		NN1
304953	100736421	20992771277	have	have	VH0
304953	100736421	20992771278	a	a	AT1
304953	100736421	20992771279	common	common	JJ
304953	100736421	20992771280	trigger	trigger	NN1
304953	100736421	20992771281	,	,	,
304953	100736421	20992771282	then	then	RT
304953	100736421	20992771283	what	what	DDQ
304953	100736421	20992771284	is	be	VBZ
304953	100736421	20992771285	taht	taht	NN1
304953	100736421	20992771286	common	common	JJ
304953	100736421	20992771287	trigger	trigger	NN1
304953	100736421	20992771288	?	?	?
304953	100736421	20992771289	i	i	ZZ1
304953	100736421	20992771290	think	think	VV0
304953	100736421	20992771291	this	this	DD1
304953	100736421	20992771292	need	need	NN1
304953	100736421	20992771293	deeper	deep	JJR_RRR
304953	100736421	20992771294	researchs		NN2_VVZ@
304953	100736421	20992771295	on	on	II
304953	100736421	20992771296	the	the	AT
304953	100736421	20992771297	matter	matter	NN1
304953	100736421	20992771298	.	.	.
304953	100736421	20992771299	<p>		NULL
304953	100736421	20992771300	What	what	DDQ
304953	100736421	20992771301	this	this	DD1
304953	100736421	20992771302	study	study	NN1
304953	100736421	20992771303	shows	show	VVZ_NN2
304953	100736421	20992771304	to	to	II
304953	100736421	20992771305	me	me	PPIO1
304953	100736421	20992771306	is	be	VBZ
304953	100736421	20992771307	that	that	CST
304953	100736421	20992771308	men	man	NN2
304953	100736421	20992771309	who	who	PNQS
304953	100736421	20992771310	develop	develop	VV0
304953	100736421	20992771311	aggressive	aggressive	JJ
304953	100736421	20992771312	prostate	prostate	NN1
304953	100736421	20992771313	cancer	cancer	NN1
304953	100736421	20992771314	tend	tend	VV0
304953	100736421	20992771315	to	to	TO
304953	100736421	20992771316	modify	modify	VVI
304953	100736421	20992771317	their	their	APPGE
304953	100736421	20992771318	diets	diet	NN2
304953	100736421	20992771319	to	to	TO
304953	100736421	20992771320	increase	increase	VVI
304953	100736421	20992771321	Omega	omega	NN1
304953	100736421	20992771322	3	3	MC
304953	100736421	20992771323	and	and	CC
304953	100736421	20992771324	reduce	reduce	VVI
304953	100736421	20992771325	transfats	transfats	NN2
304953	100736421	20992771326	,	,	,
304953	100736421	20992771327	thereby	thereby	RR
304953	100736421	20992771328	giving	give	VVG
304953	100736421	20992771329	the	the	AT
304953	100736421	20992771330	appearance	appearance	NN1
304953	100736421	20992771331	,	,	,
304953	100736421	20992771332	after	after	II
304953	100736421	20992771333	developing	develop	VVG
304953	100736421	20992771334	the	the	AT
304953	100736421	20992771335	disease	disease	NN1
304953	100736421	20992771336	,	,	,
304953	100736421	20992771337	that	that	CST_DD1
304953	100736421	20992771338	less	less	II%_DAR
304953	100736421	20992771339	O3	o3	FO
304953	100736421	20992771340	&amp;		CC
304953	100736421	20992771341	more	more	DAR_RRR
304953	100736421	20992771342	transfats		NN2_VVZ
304953	100736421	20992771343	in	in	II
304953	100736421	20992771344	blood	blood	NN1
304953	100736421	20992771345	is	be	VBZ
304953	100736421	20992771346	found	find	VVN
304953	100736421	20992771347	in	in	II
304953	100736421	20992771348	those	those	DD2
304953	100736421	20992771349	who	who	PNQS
304953	100736421	20992771350	do	do	VD0
304953	100736421	20992771351	@		II
304953	100736421	20992771352	@		II
304953	100736421	20992771353	@		II
304953	100736421	20992771354	@		II
304953	100736421	20992771355	@		II
304953	100736421	20992771356	@		II
304953	100736421	20992771357	@		II
304953	100736421	20992771358	@		II
304953	100736421	20992771359	@		II
304953	100736421	20992771360	@		II
304953	100736421	20992771361	O3	o3	FO
304953	100736421	20992771362	and	and	CC
304953	100736421	20992771363	less	less	DAR_RRR
304953	100736421	20992771364	transfat		NN1_VV0
304953	100736421	20992771365	in	in	II
304953	100736421	20992771366	blood	blood	NN1
304953	100736421	20992771367	is	be	VBZ
304953	100736421	20992771368	found	find	VVN
304953	100736421	20992771369	in	in	II
304953	100736421	20992771370	those	those	DD2
304953	100736421	20992771371	who	who	PNQS
304953	100736421	20992771372	do	do	VD0
304953	100736421	20992771373	.	.	.
304953	100736421	20992771374	This	this	DD1
304953	100736421	20992771375	is	be	VBZ
304953	100736421	20992771376	a	a	AT1
304953	100736421	20992771377	good	good	JJ
304953	100736421	20992771378	example	example	NN1
304953	100736421	20992771379	of	of	IO
304953	100736421	20992771380	how	how	RRQ
304953	100736421	20992771381	a	a	AT1
304953	100736421	20992771382	study	study	NN1
304953	100736421	20992771383	can	can	VM
304953	100736421	20992771384	be	be	VBI
304953	100736421	20992771385	interpreted	interpret	VVN
304953	100736421	20992771386	incorrectly	incorrectly	RR
304953	100736421	20992771387	.	.	.
304953	100736421	20992771388	46996		MC
304953	100736421	20992771389	@qwx906996		FO
304953	100736422	20992771409	@@##	----------	----------
304953	100736422	20992771410	@@100736422		FO
304953	100736422	20992771411	@4936422/		VV0_NN1
304953	100736422	20992771412	46989		MC
304953	100736422	20992771413	@qwx906989		FO
304953	100736422	20992771414	<h>		NULL
304953	100736422	20992771415	Treatment	treatment	NN1
304953	100736422	20992771416	<p>		NULL
304953	100736422	20992771417	Men	man	NN2
304953	100736422	20992771418	diagnosed	diagnose	VVN_VVD
304953	100736422	20992771419	with	with	IW
304953	100736422	20992771420	slow-growing	slow-growing	JJ
304953	100736422	20992771421	prostate	prostate	NN1
304953	100736422	20992771422	tumors	tumor	NN2
304953	100736422	20992771423	that	that	CST_DD1
304953	100736422	20992771424	likely	likely	JJ_RR@
304953	100736422	20992771425	wo	will	VM
304953	100736422	20992771426	n't	n't	XX
304953	100736422	20992771427	be	be	VBI
304953	100736422	20992771428	harmful	harmful	JJ
304953	100736422	20992771429	during	during	II
304953	100736422	20992771430	their	their	APPGE
304953	100736422	20992771431	lifetimes	lifetime	NNT2
304953	100736422	20992771432	can	can	VM
304953	100736422	20992771433	often	often	RR
304953	100736422	20992771434	avoid	avoid	VVI
304953	100736422	20992771435	immediate	immediate	JJ
304953	100736422	20992771436	treatment	treatment	NN1
304953	100736422	20992771437	.	.	.
304953	100736422	20992771438	Instead	instead	RR
304953	100736422	20992771439	,	,	,
304953	100736422	20992771440	they	they	PPHS2
304953	100736422	20992771441	can	can	VM
304953	100736422	20992771442	have	have	VHI
304953	100736422	20992771443	their	their	APPGE
304953	100736422	20992771444	tumor	tumor	NN1
304953	100736422	20992771445	monitored	monitor	VVN
304953	100736422	20992771446	using	use	VVG
304953	100736422	20992771447	a	a	AT1
304953	100736422	20992771448	strategy	strategy	NN1
304953	100736422	20992771449	called	call	VVN_VVD@
304953	100736422	20992771450	active	active	JJ
304953	100736422	20992771451	surveillance	surveillance	NN1
304953	100736422	20992771452	.	.	.
304953	100736422	20992771453	With	with	IW
304953	100736422	20992771454	this	this	DD1
304953	100736422	20992771455	approach	approach	NN1
304953	100736422	20992771456	,	,	,
304953	100736422	20992771457	doctors	doctor	NN2
304953	100736422	20992771458	perform	perform	VV0
304953	100736422	20992771459	periodic	periodic	JJ
304953	100736422	20992771460	checks	check	NN2
304953	100736422	20992771461	for	for	IF
304953	100736422	20992771462	tumor	tumor	NN1
304953	100736422	20992771463	progression	progression	NN1
304953	100736422	20992771464	and	and	CC
304953	100736422	20992771465	start	start	VV0_NN1
304953	100736422	20992771466	treatment	treatment	NN1
304953	100736422	20992771467	only	only	JJ
304953	100736422	20992771468	if	if-	CS
304953	100736422	20992771469	the	the	AT
304953	100736422	20992771470	cancer	cancer	NN1
304953	100736422	20992771471	begins	begin	VVZ
304953	100736422	20992771472	to	to	TO
304953	100736422	20992771473	metastasize	metastasize	VVI
304953	100736422	20992771474	,	,	,
304953	100736422	20992771475	or	or	CC
304953	100736422	20992771476	spread	spread	NN1_VVD_VV0_VVN
304953	100736422	20992771477	.	.	.
304953	100736422	20992771478	Active	active	JJ
304953	100736422	20992771479	<p>		NULL
304953	100736422	20992771480	It	it	PPH1
304953	100736422	20992771481	's	be	VBZ
304953	100736422	20992771482	well	well	RR
304953	100736422	20992771483	known	know	VVN
304953	100736422	20992771484	that	that	CST_DD1
304953	100736422	20992771485	defective	defective	JJ
304953	100736422	20992771486	BRCA	brca	NN1
304953	100736422	20992771487	genes	gene	NN2
304953	100736422	20992771488	can	can	VM
304953	100736422	20992771489	increase	increase	VVI
304953	100736422	20992771490	a	a	AT1
304953	100736422	20992771491	woman	woman	NN1
304953	100736422	20992771492	's	's	GE
304953	100736422	20992771493	chances	chance	NN2
304953	100736422	20992771494	of	of	IO
304953	100736422	20992771495	developing	developing	JJ_VVG
304953	100736422	20992771496	breast	breast	NN1
304953	100736422	20992771497	,	,	,
304953	100736422	20992771498	ovarian	ovarian	NN1_JJ
304953	100736422	20992771499	,	,	,
304953	100736422	20992771500	and	and	CC
304953	100736422	20992771501	other	other	JJ
304953	100736422	20992771502	cancers	cancer	NN2
304953	100736422	20992771503	.	.	.
304953	100736422	20992771504	But	but	CCB
304953	100736422	20992771505	these	these	DD2
304953	100736422	20992771506	same	same	DA
304953	100736422	20992771507	gene	gene	NN1
304953	100736422	20992771508	changes	change	NN2
304953	100736422	20992771509	can	can	VM
304953	100736422	20992771510	also	also	RR
304953	100736422	20992771511	increase	increase	VVI
304953	100736422	20992771512	a	a	AT1
304953	100736422	20992771513	man	man	NN1
304953	100736422	20992771514	's	's	GE
304953	100736422	20992771515	risk	risk	NN1
304953	100736422	20992771516	of	of	IO
304953	100736422	20992771517	dying	die	VVG_JJ
304953	100736422	20992771518	from	from	II
304953	100736422	20992771519	prostate	prostate	NN1
304953	100736422	20992771520	cancer	cancer	NN1
304953	100736422	20992771521	.	.	.
304953	100736422	20992771522	Now	now	RT
304953	100736422	20992771523	,	,	,
304953	100736422	20992771524	a	a	AT1
304953	100736422	20992771525	new	new	JJ
304953	100736422	20992771526	study	study	NN1
304953	100736422	20992771527	published	publish	VVN
304953	100736422	20992771528	in	in	II
304953	100736422	20992771529	The	the	AT
304953	100736422	20992771530	New	new	NP1
304953	100736422	20992771531	England	england	NP1
304953	100736422	20992771532	Journal	journal	NN1
304953	100736422	20992771533	of	of	IO
304953	100736422	20992771534	Medicine	medicine	NN1
304953	100736422	20992771535	has	have	VHZ
304953	100736422	20992771536	shown	show	VVN
304953	100736422	20992771537	that	that	CST
304953	100736422	20992771538	men	man	NN2
304953	100736422	20992771539	with	with	IW
304953	100736422	20992771540	prostate	prostate	NN1
304953	100736422	20992771541	cancer	cancer	NN1
304953	100736422	20992771542	who	who	PNQS
304953	100736422	20992771543	<p>		NULL
304953	100736422	20992771544	New	new	JJ
304953	100736422	20992771545	research	research	NN1
304953	100736422	20992771546	has	have	VHZ
304953	100736422	20992771547	has	have	VHZ
304953	100736422	20992771548	identified	identify	VVN
304953	100736422	20992771549	an	a	AT1
304953	100736422	20992771550	enzyme	enzyme	NN1
304953	100736422	20992771551	that	that	CST_DD1
304953	100736422	20992771552	may	may	VM
304953	100736422	20992771553	be	be	VBI
304953	100736422	20992771554	the	the	AT
304953	100736422	20992771555	escape	escape	NN1
304953	100736422	20992771556	hatch	hatch	VV0_NN1
304953	100736422	20992771557	that	that	CST_DD1
304953	100736422	20992771558	advanced	advanced	JJ_VVD
304953	100736422	20992771559	prostate	prostate	NN1
304953	100736422	20992771560	cancer	cancer	NN1
304953	100736422	20992771561	uses	use	VVZ
304953	100736422	20992771562	to	to	TO
304953	100736422	20992771563	evade	evade	VVI
304953	100736422	20992771564	hormone	hormone	NN1
304953	100736422	20992771565	therapy	therapy	NN1
304953	100736422	20992771566	.	.	.
304953	100736422	20992771567	If	if	CS
304953	100736422	20992771568	the	the	AT
304953	100736422	20992771569	findings	finding	NN2
304953	100736422	20992771570	hold	hold	VV0
304953	100736422	20992771571	up	up	RP
304953	100736422	20992771572	,	,	,
304953	100736422	20992771573	the	the	AT
304953	100736422	20992771574	enzyme	enzyme	NN1
304953	100736422	20992771575	might	might	VM
304953	100736422	20992771576	be	be	VBI
304953	100736422	20992771577	a	a	AT1
304953	100736422	20992771578	prime	prime	JJ
304953	100736422	20992771579	target	target	NN1
304953	100736422	20992771580	for	for	IF
304953	100736422	20992771581	a	a	AT1
304953	100736422	20992771582	drug	drug	NN1
304953	100736422	20992771583	that	that	CST_DD1
304953	100736422	20992771584	would	would	VM
304953	100736422	20992771585	treat	treat	VVI
304953	100736422	20992771586	castration-resistant		JJ
304953	100736422	20992771587	prostate	prostate	NN1
304953	100736422	20992771588	cancer	cancer	NN1
304953	100736422	20992771589	.	.	.
304953	100736422	20992771590	<p>		NULL
304953	100736422	20992771591	When	when	CS_RRQ
304953	100736422	20992771592	it	it	PPH1
304953	100736422	20992771593	comes	come	VVZ
304953	100736422	20992771594	to	to	II
304953	100736422	20992771595	prostate	prostate	NN1
304953	100736422	20992771596	cancer	cancer	NN1
304953	100736422	20992771597	and	and	CC
304953	100736422	20992771598	other	other	JJ
304953	100736422	20992771599	prostate	prostate	NN1
304953	100736422	20992771600	diseases	disease	NN2
304953	100736422	20992771601	@		II
304953	100736422	20992771602	@		II
304953	100736422	20992771603	@		II
304953	100736422	20992771604	@		II
304953	100736422	20992771605	@		II
304953	100736422	20992771606	@		II
304953	100736422	20992771607	@		II
304953	100736422	20992771608	@		II
304953	100736422	20992771609	@		II
304953	100736422	20992771610	@		II
304953	100736422	20992771611	patients	patient	NN2
304953	100736422	20992771612	rely	rely	VVI
304953	100736422	20992771613	on	on	II_RP@
304953	100736422	20992771614	reported	reported	JJ@
304953	100736422	20992771615	figures	figure	NN2
304953	100736422	20992771616	to	to	TO
304953	100736422	20992771617	determine	determine	VVI
304953	100736422	20992771618	their	their	APPGE
304953	100736422	20992771619	risk	risk	NN1
304953	100736422	20992771620	of	of	IO
304953	100736422	20992771621	suffering	suffering	JJ_VVG_NN1
304953	100736422	20992771622	complications	complication	NN2
304953	100736422	20992771623	such	such	II21
304953	100736422	20992771624	as	as	II22
304953	100736422	20992771625	incontinence	incontinence	NN1
304953	100736422	20992771626	and	and	CC
304953	100736422	20992771627	impotence	impotence	NN1
304953	100736422	20992771628	?	?	?
304953	100736422	20992771629	Why	why	RRQ
304953	100736422	20992771630	do	do	VD0
304953	100736422	20992771631	data	data	NN
304953	100736422	20992771632	vary	vary	VV0
304953	100736422	20992771633	from	from	II
304953	100736422	20992771634	one	one	MC1
304953	100736422	20992771635	organization	organization	NN1
304953	100736422	20992771636	to	to	II
304953	100736422	20992771637	another	another	DD1
304953	100736422	20992771638	?	?	?
304953	100736422	20992771639	Three	three	MC
304953	100736422	20992771640	experts	expert	NN2
304953	100736422	20992771641	discuss	discuss	VV0
304953	100736422	20992771642	these	these	DD2
304953	100736422	20992771643	questions	question	NN2
304953	100736422	20992771644	and	and	CC
304953	100736422	20992771645	the	the	AT
304953	100736422	20992771646	growing	growing	JJ
304953	100736422	20992771647	field	field	NN1
304953	100736422	20992771648	of	of	IO
304953	100736422	20992771649	outcomes	outcome	NN2
304953	100736422	20992771650	research	research	NN1_VV0@
304953	100736422	20992771651	.	.	.
304953	100736422	20992771652	<p>		NULL
304953	100736422	20992771653	When	when	CS_RRQ
304953	100736422	20992771654	it	it	PPH1
304953	100736422	20992771655	comes	come	VVZ
304953	100736422	20992771656	to	to	II
304953	100736422	20992771657	early-stage	early-stage	JJ_NN1
304953	100736422	20992771658	prostate	prostate	NN1
304953	100736422	20992771659	cancer	cancer	NN1
304953	100736422	20992771660	,	,	,
304953	100736422	20992771661	there	there	EX
304953	100736422	20992771662	is	be	VBZ
304953	100736422	20992771663	no	no	AT
304953	100736422	20992771664	evidence	evidence	NN1
304953	100736422	20992771665	that	that	CST
304953	100736422	20992771666	one	one	MC1
304953	100736422	20992771667	treatment	treatment	NN1
304953	100736422	20992771668	is	be	VBZ
304953	100736422	20992771669	better	better	JJR_RRR
304953	100736422	20992771670	than	than	CSN
304953	100736422	20992771671	another	another	DD1
304953	100736422	20992771672	or	or	CC
304953	100736422	20992771673	that	that	CST
304953	100736422	20992771674	any	any	DD
304953	100736422	20992771675	treatment	treatment	NN1
304953	100736422	20992771676	at	at	RR21_II
304953	100736422	20992771677	all	all	RR22_DB
304953	100736422	20992771678	actually	actually	RR
304953	100736422	20992771679	prolongs	prolong	VVZ
304953	100736422	20992771680	life	life	NN1
304953	100736422	20992771681	.	.	.
304953	100736422	20992771682	If	if	CS
304953	100736422	20992771683	you	you	PPY
304953	100736422	20992771684	are	be	VBR
304953	100736422	20992771685	diagnosed	diagnose	VVN
304953	100736422	20992771686	with	with	IW
304953	100736422	20992771687	early-stage	early-stage	JJ
304953	100736422	20992771688	prostate	prostate	NN1
304953	100736422	20992771689	cancer	cancer	NN1
304953	100736422	20992771690	,	,	,
304953	100736422	20992771691	you 'll		VV0_NN1
304953	100736422	20992771692	want	want	VV0
304953	100736422	20992771693	to	to	TO
304953	100736422	20992771694	consider	consider	VVI
304953	100736422	20992771695	factors	factor	NN2
304953	100736422	20992771696	such	such	II21
304953	100736422	20992771697	as	as	II22
304953	100736422	20992771698	your	your	APPGE
304953	100736422	20992771699	values	value	NN2
304953	100736422	20992771700	,	,	,
304953	100736422	20992771701	your	your	APPGE
304953	100736422	20992771702	quality	quality	NN1
304953	100736422	20992771703	of	of	IO
304953	100736422	20992771704	life	life	NN1
304953	100736422	20992771705	,	,	,
304953	100736422	20992771706	and	and	CC
304953	100736422	20992771707	the	the	AT
304953	100736422	20992771708	potential	potential	JJ_NN1
304953	100736422	20992771709	side	side	NN1
304953	100736422	20992771710	effects	effect	NN2
304953	100736422	20992771711	of	of	IO
304953	100736422	20992771712	various	various	JJ
304953	100736422	20992771713	treatments	treatment	NN2
304953	100736422	20992771714	before	before	II
304953	100736422	20992771715	making	make	VVG
304953	100736422	20992771716	a	a	AT1
304953	100736422	20992771717	decision	decision	NN1
304953	100736422	20992771718	.	.	.
304953	100736423	20992771738	@@##	----------	----------
304953	100736423	20992771739	@@100736423		FO
304953	100736423	20992771740	@4936423/		VV0_NN1
304953	100736423	20992771741	46989		MC
304953	100736423	20992771742	@qwx906989		FO
304953	100736423	20992771743	<p>		NULL
304953	100736423	20992771744	Men	man	NN2
304953	100736423	20992771745	with	with	IW
304953	100736423	20992771746	metastatic	metastatic	JJ
304953	100736423	20992771747	prostate	prostate	NN1
304953	100736423	20992771748	cancer	cancer	NN1
304953	100736423	20992771749	that	that	CST
304953	100736423	20992771750	no	no	RR21
304953	100736423	20992771751	longer	long	RR22
304953	100736423	20992771752	responds	respond	VVZ
304953	100736423	20992771753	to	to	II
304953	100736423	20992771754	hormone	hormone	NN1
304953	100736423	20992771755	therapy	therapy	NN1
304953	100736423	20992771756	now	now	RT
304953	100736423	20992771757	have	have	VH0
304953	100736423	20992771758	yet	yet	RR
304953	100736423	20992771759	another	another	DD1
304953	100736423	20992771760	treatment	treatment	NN1
304953	100736423	20992771761	option	option	NN1
304953	100736423	20992771762	:	:	:
304953	100736423	20992771763	abiraterone		VV0_NN1
304953	100736423	20992771764	(	(	(
304953	100736423	20992771765	Zytiga		NP1
304953	100736423	20992771766	)	)	)
304953	100736423	20992771767	.	.	.
304953	100736423	20992771768	The	the	AT
304953	100736423	20992771769	FDA	fda	NP1_NN1
304953	100736423	20992771770	approved	approve	VVD_VVN
304953	100736423	20992771771	the	the	AT
304953	100736423	20992771772	drug	drug	NN1
304953	100736423	20992771773	,	,	,
304953	100736423	20992771774	which	which	DDQ
304953	100736423	20992771775	is	be	VBZ
304953	100736423	20992771776	used	use	VVN
304953	100736423	20992771777	in	in	II
304953	100736423	20992771778	combination	combination	NN1
304953	100736423	20992771779	with	with	IW
304953	100736423	20992771780	a	a	AT1
304953	100736423	20992771781	low-dose	low-dose	JJ_NN1
304953	100736423	20992771782	steroid	steroids	NN1_JJ
304953	100736423	20992771783	,	,	,
304953	100736423	20992771784	at	at	II
304953	100736423	20992771785	the	the	AT
304953	100736423	20992771786	end	end	NN1
304953	100736423	20992771787	of	of	IO
304953	100736423	20992771788	April	april	NPM1
304953	100736423	20992771789	2011	2011	MC
304953	100736423	20992771790	.	.	.
304953	100736423	20992771791	<p>		NULL
304953	100736423	20992771792	Approval	approval	NN1
304953	100736423	20992771793	was	be	VBDZ
304953	100736423	20992771794	granted	grant	VVN
304953	100736423	20992771795	based	base	VVN
304953	100736423	20992771796	on	on	II
304953	100736423	20992771797	findings	finding	NN2
304953	100736423	20992771798	of	of	IO
304953	100736423	20992771799	a	a	AT1
304953	100736423	20992771800	large	large	JJ
304953	100736423	20992771801	,	,	,
304953	100736423	20992771802	multicenter	multicenter	JJR_VV0
304953	100736423	20992771803	phase	phase	NN1
304953	100736423	20992771804	III	iii	MC
304953	100736423	20992771805	clinical	clinical	JJ
304953	100736423	20992771806	trial	trial	NN1
304953	100736423	20992771807	that	that	CST
304953	100736423	20992771808	were	be	VBDR
304953	100736423	20992771809	announced	announce	VVN
304953	100736423	20992771810	last	last	MD
304953	100736423	20992771811	fall	fall	NN1
304953	100736423	20992771812	.	.	.
304953	100736423	20992771813	Participants	participant	NN2
304953	100736423	20992771814	who	who	PNQS
304953	100736423	20992771815	were	be	VBDR
304953	100736423	20992771816	treated	treat	VVN
304953	100736423	20992771817	with	with	IW
304953	100736423	20992771818	both	both	DB2_RR
304953	100736423	20992771819	abiraterone		VV0_NN1
304953	100736423	20992771820	and	and	CC
304953	100736423	20992771821	the	the	AT
304953	100736423	20992771822	steroid	steroid	JJ_NN1
304953	100736423	20992771823	prednisone	prednisone	NN1
304953	100736423	20992771824	lived	live	VVD_VVN
304953	100736423	20992771825	,	,	,
304953	100736423	20992771826	on	on	II
304953	100736423	20992771827	average	average	NN1_JJ
304953	100736423	20992771828	,	,	,
304953	100736423	20992771829	almost	almost	RR
304953	100736423	20992771830	four	four	MC
304953	100736423	20992771831	months	month	NNT2
304953	100736423	20992771832	longer	long	RRR
304953	100736423	20992771833	than	than	CSN
304953	100736423	20992771834	those	those	DD2
304953	100736423	20992771835	treated	treat	VVN
304953	100736423	20992771836	with	with	IW
304953	100736423	20992771837	the	the	AT
304953	100736423	20992771838	steroid	steroid	JJ_NN1
304953	100736423	20992771839	alone	alone	JJ_RR
304953	100736423	20992771840	(	(	(
304953	100736423	20992771841	14.8	14.8	MC
304953	100736423	20992771842	months	month	NNT2
304953	100736423	20992771843	compared	compare	VVN
304953	100736423	20992771844	with	with	IW
304953	100736423	20992771845	10.9	-10.9	MC
304953	100736423	20992771846	months	month	NNT2
304953	100736423	20992771847	)	)	)
304953	100736423	20992771848	.	.	.
304953	100736423	20992771849	The	the	AT
304953	100736423	20992771850	trial	trial	NN1
304953	100736423	20992771851	involved	involve	VVD_VVN
304953	100736423	20992771852	1,195	1,195	MC
304953	100736423	20992771853	men	man	NN2
304953	100736423	20992771854	from	from	II
304953	100736423	20992771855	13	13	MC
304953	100736423	20992771856	countries	country	NN2
304953	100736423	20992771857	with	with	IW
304953	100736423	20992771858	castration-resistant		JJ
304953	100736423	20992771859	prostate	prostate	NN1
304953	100736423	20992771860	cancer	cancer	NN1
304953	100736423	20992771861	,	,	,
304953	100736423	20992771862	which	which	DDQ
304953	100736423	20992771863	means	mean	VVZ
304953	100736423	20992771864	that	that	CST_DD1
304953	100736423	20992771865	traditional	traditional	JJ
304953	100736423	20992771866	hormone	hormone	NN1
304953	100736423	20992771867	therapy	therapy	NN1
304953	100736423	20992771868	is	be	VBZ
304953	100736423	20992771869	no	no	RR21
304953	100736423	20992771870	longer	long	RR22
304953	100736423	20992771871	keeping	keep	VVG
304953	100736423	20992771872	the	the	AT
304953	100736423	20992771873	disease	disease	NN1
304953	100736423	20992771874	in	in	II
304953	100736423	20992771875	check	check	NN1
304953	100736423	20992771876	.	.	.
304953	100736423	20992771877	Prior	prior	II21
304953	100736423	20992771878	to	to	II22
304953	100736423	20992771879	the	the	AT
304953	100736423	20992771880	trial	trial	NN1
304953	100736423	20992771881	,	,	,
304953	100736423	20992771882	patients	patient	NN2
304953	100736423	20992771883	had	have	VHD
304953	100736423	20992771884	also	also	RR
304953	100736423	20992771885	received	receive	VVN
304953	100736423	20992771886	docetaxel	docetaxel	NN1
304953	100736423	20992771887	(	(	(
304953	100736423	20992771888	Taxotere		NP1
304953	100736423	20992771889	)	)	)
304953	100736423	20992771890	,	,	,
304953	100736423	20992771891	a	a	AT1
304953	100736423	20992771892	type	type	NN1
304953	100736423	20992771893	of	of	IO
304953	100736423	20992771894	chemotherapy	chemotherapy	NN1
304953	100736423	20992771895	.	.	.
304953	100736423	20992771896	<p>		NULL
304953	100736423	20992771897	The	the	AT
304953	100736423	20992771898	most	most	RGT
304953	100736423	20992771899	commonly	commonly	RR
304953	100736423	20992771900	reported	report	VVN_JJ@_VVD
304953	100736423	20992771901	side	side	NN1
304953	100736423	20992771902	effects	effect	NN2
304953	100736423	20992771903	of	of	IO
304953	100736423	20992771904	abiraterone	abiraterone	NN1
304953	100736423	20992771905	included	include	VVD_VVN
304953	100736423	20992771906	joint	joint	JJ
304953	100736423	20992771907	swelling	swelling	JJ
304953	100736423	20992771908	or	or	CC
304953	100736423	20992771909	discomfort	discomfort	NN1
304953	100736423	20992771910	,	,	,
304953	100736423	20992771911	low	low	JJ
304953	100736423	20992771912	levels	level	NN2
304953	100736423	20992771913	of	of	IO
304953	100736423	20992771914	potassium	potassium	NN1
304953	100736423	20992771915	in	in	II
304953	100736423	20992771916	the	the	AT
304953	100736423	20992771917	blood	blood	NN1
304953	100736423	20992771918	,	,	,
304953	100736423	20992771919	fluid	fluid	NN1_JJ@
304953	100736423	20992771920	retention	retention	NN1
304953	100736423	20992771921	in	in	II
304953	100736423	20992771922	the	the	AT
304953	100736423	20992771923	legs	leg	NN2
304953	100736423	20992771924	and	and	CC
304953	100736423	20992771925	feet	foot	NN2
304953	100736423	20992771926	,	,	,
304953	100736423	20992771927	increases	increase	VVZ_NN2
304953	100736423	20992771928	in	in	II
304953	100736423	20992771929	blood	blood	NN1
304953	100736423	20992771930	@		II
304953	100736423	20992771931	@		II
304953	100736423	20992771932	@		II
304953	100736423	20992771933	@		II
304953	100736423	20992771934	@		II
304953	100736423	20992771935	@		II
304953	100736423	20992771936	@		II
304953	100736423	20992771937	@		II
304953	100736423	20992771938	@		II
304953	100736423	20992771939	@		II
304953	100736423	20992771940	and	and	CC
304953	100736423	20992771941	gastrointestinal	gastrointestinal	JJ
304953	100736423	20992771942	problems	problem	NN2
304953	100736423	20992771943	.	.	.
304953	100736423	20992771944	<p>		NULL
304953	100736423	20992771945	Abiraterone		NN1_VV0_NP1@
304953	100736423	20992771946	is	be	VBZ
304953	100736423	20992771947	the	the	AT
304953	100736423	20992771948	third	third	MD
304953	100736423	20992771949	drug	drug	NN1
304953	100736423	20992771950	to	to	TO
304953	100736423	20992771951	be	be	VBI
304953	100736423	20992771952	approved	approve	VVN
304953	100736423	20992771953	for	for	IF
304953	100736423	20992771954	men	man	NN2
304953	100736423	20992771955	with	with	IW
304953	100736423	20992771956	late-stage	late-stage	JJ
304953	100736423	20992771957	prostate	prostate	NN1
304953	100736423	20992771958	cancer	cancer	NN1
304953	100736423	20992771959	in	in	II
304953	100736423	20992771960	the	the	AT
304953	100736423	20992771961	last	last	MD
304953	100736423	20992771962	year	year	NNT1
304953	100736423	20992771963	.	.	.
304953	100736423	20992771964	In	in	II
304953	100736423	20992771965	April	april	NPM1
304953	100736423	20992771966	2010	2010	MC
304953	100736423	20992771967	,	,	,
304953	100736423	20992771968	the	the	AT
304953	100736423	20992771969	FDA	fda	NP1_NN1
304953	100736423	20992771970	approved	approve	VVD
304953	100736423	20992771971	sipuleucel-T		NP1
304953	100736423	20992771972	(	(	(
304953	100736423	20992771973	Provenge		NP1
304953	100736423	20992771974	)	)	)
304953	100736423	20992771975	,	,	,
304953	100736423	20992771976	a	a	AT1
304953	100736423	20992771977	vaccine	vaccine	NN1
304953	100736423	20992771978	that	that	CST_DD1
304953	100736423	20992771979	uses	use	VVZ
304953	100736423	20992771980	the	the	AT
304953	100736423	20992771981	immune	immune	JJ
304953	100736423	20992771982	system	system	NN1
304953	100736423	20992771983	to	to	TO
304953	100736423	20992771984	fight	fight	VVI
304953	100736423	20992771985	advanced-stage	advanced-stage	JJ_NN1
304953	100736423	20992771986	disease	disease	NN1
304953	100736423	20992771987	.	.	.
304953	100736423	20992771988	Two	two	MC
304953	100736423	20992771989	months	month	NNT2
304953	100736423	20992771990	later	later	RRR
304953	100736423	20992771991	,	,	,
304953	100736423	20992771992	the	the	AT
304953	100736423	20992771993	agency	agency	NN1
304953	100736423	20992771994	gave	give	VVD
304953	100736423	20992771995	the	the	AT
304953	100736423	20992771996	green	green	JJ_NN1
304953	100736423	20992771997	light	light	NN1
304953	100736423	20992771998	to	to	II
304953	100736423	20992771999	the	the	AT
304953	100736423	20992772000	chemotherapy	chemotherapy	NN1
304953	100736423	20992772001	drug	drug	NN1
304953	100736423	20992772002	cabazitaxel		NN1
304953	100736423	20992772003	(	(	(
304953	100736423	20992772004	Jevtana		NP1
304953	100736423	20992772005	)	)	)
304953	100736423	20992772006	.	.	.
304953	100736423	20992772007	Prior	prior	II21
304953	100736423	20992772008	to	to	II22
304953	100736423	20992772009	that	that	DD1
304953	100736423	20992772010	,	,	,
304953	100736423	20992772011	patients	patient	NN2
304953	100736423	20992772012	had	have	VHD
304953	100736423	20992772013	few	few	DA2
304953	100736423	20992772014	options	option	NN2
304953	100736423	20992772015	.	.	.
304953	100736423	20992772016	<p>		NULL
304953	100736423	20992772017	Bloomberg	bloomberg	NP1
304953	100736423	20992772018	business	business	NN1
304953	100736423	20992772019	news	news	NN1
304953	100736423	20992772020	reported	report	VVD_VVN
304953	100736423	20992772021	that	that	DD1_CST
304953	100736423	20992772022	abiraterone	abiraterone	NN1
304953	100736423	20992772023	's	's	GE
304953	100736423	20992772024	manufacturer	manufacturer	NN1
304953	100736423	20992772025	,	,	,
304953	100736423	20992772026	Johnson	johnson	NP1
304953	100736423	20992772027	&amp;		CC
304953	100736423	20992772028	Johnson	johnson	NP1
304953	100736423	20992772029	,	,	,
304953	100736423	20992772030	is	be	VBZ
304953	100736423	20992772031	likely	likely	JJ
304953	100736423	20992772032	to	to	TO
304953	100736423	20992772033	sell	sell	VVI
304953	100736423	20992772034	the	the	AT
304953	100736423	20992772035	drug	drug	NN1
304953	100736423	20992772036	for	for	IF
304953	100736423	20992772037	an	a	AT1
304953	100736423	20992772038	average	average	JJ
304953	100736423	20992772039	wholesale	wholesale	JJ
304953	100736423	20992772040	price	price	NN1
304953	100736423	20992772041	of	of	IO
304953	100736423	20992772042	$5,000		NNU
304953	100736423	20992772043	a	a	AT1
304953	100736423	20992772044	month	month	NNT1
304953	100736423	20992772045	,	,	,
304953	100736423	20992772046	with	with	IW
304953	100736423	20992772047	treatment	treatment	NN1
304953	100736423	20992772048	typically	typically	RR
304953	100736423	20992772049	lasting	last	VVG_JJ
304953	100736423	20992772050	about	about	RG
304953	100736423	20992772051	eight	eight	MC
304953	100736423	20992772052	months	month	NNT2
304953	100736423	20992772053	.	.	.
304953	100736423	20992772054	<p>		NULL
304953	100736423	20992772055	Delight	delight	VV0@_NN1
304953	100736423	20992772056	alright	alright	RR
304953	100736423	20992772057	be	be	VBI
304953	100736423	20992772058	aware	aware	JJ
304953	100736423	20992772059	of	of	IO
304953	100736423	20992772060	any	any	DD
304953	100736423	20992772061	time	time	NNT1
304953	100736423	20992772062	you	you	PPY
304953	100736423	20992772063	want	want	VV0
304953	100736423	20992772064	a	a	AT1
304953	100736423	20992772065	fuablous		JJ
304953	100736423	20992772066	article	article	NN1
304953	100736423	20992772067	writer	writer	NN1
304953	100736423	20992772068	for	for	IF
304953	100736423	20992772069	use	use	NN1
304953	100736423	20992772070	in	in	II
304953	100736423	20992772071	your	your	APPGE
304953	100736423	20992772072	site	site	NN1
304953	100736423	20992772073	.	.	.
304953	100736423	20992772074	Youve		NN1_VV0
304953	100736423	20992772075	gotten	get	VVN
304953	100736423	20992772076	lots	lots	PN
304953	100736423	20992772077	of	of	IO
304953	100736423	20992772078	very	very	RG
304953	100736423	20992772079	good	good	JJ
304953	100736423	20992772080	articles	article	NN2
304953	100736423	20992772081	and	and	CC
304953	100736423	20992772082	also	also	RR
304953	100736423	20992772083	Document	document	VV0@_NN1
304953	100736423	20992772084	think	think	VV0
304953	100736423	20992772085	Document	document	NN1
304953	100736423	20992772086	became	become	VVD
304953	100736423	20992772087	a	a	AT1
304953	100736423	20992772088	wonderful	wonderful	JJ
304953	100736423	20992772089	investment	investment	NN1
304953	100736423	20992772090	.	.	.
304953	100736423	20992772091	In	in	II
304953	100736423	20992772092	the	the	AT
304953	100736423	20992772093	event	event	NN1
304953	100736423	20992772094	that	that	CST
304953	100736423	20992772095	individuals	individual	NN2
304953	100736423	20992772096	just	just	RR
304953	100736423	20992772097	want	want	VV0
304953	100736423	20992772098	to	to	TO
304953	100736423	20992772099	get	get	VVI
304953	100736423	20992772100	a	a	AT1
304953	100736423	20992772101	portion	portion	NN1
304953	100736423	20992772102	of	of	IO
304953	100736423	20992772103	the	the	AT
304953	100736423	20992772104	load	load	NN1_VV0
304953	100736423	20992772105	up	up	RP
304953	100736423	20992772106	shut	shut	VVD_VV0
304953	100736423	20992772107	off	off	RP
304953	100736423	20992772108	,	,	,
304953	100736423	20992772109	I 'll		NP1_JJ
304953	100736423	20992772110	absolutely	absolutely	RR
304953	100736423	20992772111	love	love	VV0
304953	100736423	20992772112	for	for	IF
304953	100736423	20992772113	you	you	PPY
304953	100736423	20992772114	personally	personally	RR
304953	100736423	20992772115	to	to	II
304953	100736423	20992772116	a	a	AT1
304953	100736423	20992772117	lot	lot	NN1
304953	100736423	20992772118	of	of	IO
304953	100736423	20992772119	material	material	NN1
304953	100736423	20992772120	for	for	IF
304953	100736423	20992772121	make	make	NN1%_VV0
304953	100736423	20992772122	use	use	NN1
304953	100736423	20992772123	of	of	IO
304953	100736423	20992772124	on	on	II
304953	100736423	20992772125	your	your	APPGE
304953	100736423	20992772126	web	web	NN1
304953	100736423	20992772127	page	page	NN1
304953	100736423	20992772128	in	in	II
304953	100736423	20992772129	trade	trade	NN1
304953	100736423	20992772130	@		II
304953	100736423	20992772131	@		II
304953	100736423	20992772132	@		II
304953	100736423	20992772133	@		II
304953	100736423	20992772134	@		II
304953	100736423	20992772135	@		II
304953	100736423	20992772136	@		II
304953	100736423	20992772137	@		II
304953	100736423	20992772138	@		II
304953	100736423	20992772139	@		II
304953	100736423	20992772140	deliver	deliver	VV0
304953	100736423	20992772141	others	others	NN2
304953	100736423	20992772142	any	any	DD
304953	100736423	20992772143	kind	kind	NN1
304953	100736423	20992772144	of	of	IO
304953	100736423	20992772145	email	email	NN1
304953	100736423	20992772146	whenever	whenever	RRQV
304953	100736423	20992772147	planning	planning	NN1
304953	100736423	20992772148	to	to	TO
304953	100736423	20992772149	pursue	pursue	VVI
304953	100736423	20992772150	.	.	.
304953	100736423	20992772151	Thank	thank	VV0
304953	100736423	20992772152	you	you	PPY
304953	100736423	20992772153	!	!	!
304953	100736423	20992772154	inch	inch	VV0%
304953	100736423	20992772155	46996		MC
304953	100736423	20992772156	@qwx906996		FO
304953	100736424	20992772176	@@##	----------	----------
304953	100736424	20992772177	@@100736424		FO
304953	100736424	20992772178	@4936424/		JJ_NN1_VV0
304953	100736424	20992772179	<h>		NULL
304953	100736424	20992772180	Prostate	prostate	NN1
304953	100736424	20992772181	Knowledge	knowledge	NN1
304953	100736424	20992772182	Blog	blog	NN1_NP1_VV0
304953	100736424	20992772183	<h>		NULL
304953	100736424	20992772184	Join	join	VV0
304953	100736424	20992772185	in	in	II_RP@
304953	100736424	20992772186	the	the	AT
304953	100736424	20992772187	conversation	conversation	NN1
304953	100736424	20992772188	about	about	II
304953	100736424	20992772189	common	common	JJ
304953	100736424	20992772190	issues	issue	NN2
304953	100736424	20992772191	,	,	,
304953	100736424	20992772192	breaking	break	VVG
304953	100736424	20992772193	news	news	NN1
304953	100736424	20992772194	,	,	,
304953	100736424	20992772195	and	and	CC
304953	100736424	20992772196	research	research	NN1
304953	100736424	20992772197	related	relate	VVN_VVD
304953	100736424	20992772198	to	to	II
304953	100736424	20992772199	prostate	prostate	NN1
304953	100736424	20992772200	health	health	NN1
304953	100736424	20992772201	.	.	.
304953	100736424	20992772202	<p>		NULL
304953	100736424	20992772203	Penile	penile	JJ_NN1
304953	100736424	20992772204	rehabilitation	rehabilitation	NN1
304953	100736424	20992772205	,	,	,
304953	100736424	20992772206	which	which	DDQ
304953	100736424	20992772207	typically	typically	RR
304953	100736424	20992772208	consists	consist	VVZ
304953	100736424	20992772209	of	of	IO
304953	100736424	20992772210	oral	oral	NN1_JJ
304953	100736424	20992772211	or	or	CC
304953	100736424	20992772212	injected	inject	VVD_JJ@_VVN
304953	100736424	20992772213	medications	medication	NN2
304953	100736424	20992772214	,	,	,
304953	100736424	20992772215	alone	alone	JJ_RR
304953	100736424	20992772216	or	or	CC
304953	100736424	20992772217	with	with	IW
304953	100736424	20992772218	other	other	JJ
304953	100736424	20992772219	interventions	intervention	NN2
304953	100736424	20992772220	,	,	,
304953	100736424	20992772221	may	may	VM
304953	100736424	20992772222	help	help	VVI
304953	100736424	20992772223	restore	restore	VVI
304953	100736424	20992772224	erectile	erectile	JJ
304953	100736424	20992772225	function	function	NN1
304953	100736424	20992772226	after	after	II_CS
304953	100736424	20992772227	treatment	treatment	NN1
304953	100736424	20992772228	for	for	IF
304953	100736424	20992772229	prostate	prostate	NN1
304953	100736424	20992772230	cancer	cancer	NN1
304953	100736424	20992772231	.	.	.
304953	100736424	20992772232	However	however	RR
304953	100736424	20992772233	,	,	,
304953	100736424	20992772234	this	this	DD1
304953	100736424	20992772235	therapy	therapy	NN1
304953	100736424	20992772236	remains	remain	VVZ
304953	100736424	20992772237	controversial	controversial	JJ
304953	100736424	20992772238	.	.	.
304953	100736424	20992772239	<p>		NULL
304953	100736424	20992772240	Even	even	CS21
304953	100736424	20992772241	if	if	CS22
304953	100736424	20992772242	your	your	APPGE
304953	100736424	20992772243	doctor	doctor	NN1
304953	100736424	20992772244	has	have	VHZ
304953	100736424	20992772245	given	give	VVN
304953	100736424	20992772246	you	you	PPY
304953	100736424	20992772247	a	a	AT1
304953	100736424	20992772248	clean	clean	JJ
304953	100736424	20992772249	bill	bill	NN1
304953	100736424	20992772250	of	of	IO
304953	100736424	20992772251	health	health	NN1
304953	100736424	20992772252	,	,	,
304953	100736424	20992772253	beware	beware	VV0
304953	100736424	20992772254	:	:	:
304953	100736424	20992772255	problems	problem	NN2
304953	100736424	20992772256	getting	get	VVG
304953	100736424	20992772257	or	or	CC
304953	100736424	20992772258	keeping	keep	VVG
304953	100736424	20992772259	an	a	AT1
304953	100736424	20992772260	erection	erection	NN1
304953	100736424	20992772261	firm	firm	NN1
304953	100736424	20992772262	enough	enough	RR
304953	100736424	20992772263	for	for	IF
304953	100736424	20992772264	sexual	sexual	JJ
304953	100736424	20992772265	intercourse	intercourse	NN1
304953	100736424	20992772266	may	may	VM
304953	100736424	20992772267	signal	signal	VVI
304953	100736424	20992772268	trouble	trouble	NN1
304953	100736424	20992772269	,	,	,
304953	100736424	20992772270	especially	especially	RR
304953	100736424	20992772271	cardiovascular	cardiovascular	JJ
304953	100736424	20992772272	disease	disease	NN1
304953	100736424	20992772273	,	,	,
304953	100736424	20992772274	down	down	II
304953	100736424	20992772275	the	the	AT
304953	100736424	20992772276	road	road	NN1
304953	100736424	20992772277	.	.	.
304953	100736424	20992772278	<p>		NULL
304953	100736424	20992772279	If	if	CS
304953	100736424	20992772280	you	you	PPY
304953	100736424	20992772281	are	be	VBR
304953	100736424	20992772282	like	like	II
304953	100736424	20992772283	many	many	DA2
304953	100736424	20992772284	of	of	IO
304953	100736424	20992772285	the	the	AT
304953	100736424	20992772286	14	14	MC
304953	100736424	20992772287	million	million	NNO
304953	100736424	20992772288	men	man	NN2
304953	100736424	20992772289	in	in	II
304953	100736424	20992772290	the	the	AT
304953	100736424	20992772291	United	united	NP1
304953	100736424	20992772292	States	state	NP1
304953	100736424	20992772293	who	who	PNQS
304953	100736424	20992772294	have	have	VH0
304953	100736424	20992772295	been	be	VBN
304953	100736424	20992772296	diagnosed	diagnose	VVN
304953	100736424	20992772297	with	with	IW
304953	100736424	20992772298	benign	benign	JJ
304953	100736424	20992772299	prostatic	prostatic	JJ
304953	100736424	20992772300	hyperplasia	hyperplasia	NN1
304953	100736424	20992772301	(	(	(
304953	100736424	20992772302	BPH	bph	NP1
304953	100736424	20992772303	)	)	)
304953	100736424	20992772304	,	,	,
304953	100736424	20992772305	youve		VV0
304953	100736424	20992772306	probably	probably	RR
304953	100736424	20992772307	been	be	VBN
304953	100736424	20992772308	taking	take	VVG
304953	100736424	20992772309	the	the	AT
304953	100736424	20992772310	same	same	DA
304953	100736424	20992772311	medication	medication	NN1
304953	100736424	20992772312	,	,	,
304953	100736424	20992772313	at	at	II
304953	100736424	20992772314	the	the	AT
304953	100736424	20992772315	same	same	DA
304953	100736424	20992772316	dose	dose	NN1
304953	100736424	20992772317	,	,	,
304953	100736424	20992772318	for	for	IF
304953	100736424	20992772319	years	year	NNT2
304953	100736424	20992772320	.	.	.
304953	100736424	20992772321	If	if	CS
304953	100736424	20992772322	so	so	RR
304953	100736424	20992772323	,	,	,
304953	100736424	20992772324	consider	consider	VV0
304953	100736424	20992772325	the	the	AT
304953	100736424	20992772326	experiences	experience	NN2
304953	100736424	20992772327	of	of	IO
304953	100736424	20992772328	two	two	MC
304953	100736424	20992772329	patients	patient	NN2
304953	100736424	20992772330	,	,	,
304953	100736424	20992772331	both	both	DB2
304953	100736424	20992772332	of	of	IO
304953	100736424	20992772333	whom	whom	PNQO
304953	100736424	20992772334	were	be	VBDR
304953	100736424	20992772335	taking	take	VVG
304953	100736424	20992772336	some	some	DD
304953	100736424	20992772337	type	type	NN1
304953	100736424	20992772338	of	of	IO
304953	100736424	20992772339	medication	medication	NN1
304953	100736424	20992772340	for	for	IF
304953	100736424	20992772341	BPH	bph	NP1
304953	100736424	20992772342	.	.	.
304953	100736424	20992772343	Their	their	APPGE
304953	100736424	20992772344	names	name	NN2
304953	100736424	20992772345	have	have	VH0
304953	100736424	20992772346	been	be	VBN
304953	100736424	20992772347	changed	change	VVN
304953	100736424	20992772348	,	,	,
304953	100736424	20992772349	but	but	CCB
304953	100736424	20992772350	all	all	DB_RR@
304953	100736424	20992772351	other	other	JJ
304953	100736424	20992772352	details	detail	NN2
304953	100736424	20992772353	are	be	VBR
304953	100736424	20992772354	accurate	accurate	JJ
304953	100736424	20992772355	(	(	(
304953	100736424	20992772356	see	see	VV0
304953	100736424	20992772357	"	"	"
304953	100736424	20992772358	Jack	jack	NP1
304953	100736424	20992772359	Muriel	muriel	NP1
304953	100736424	20992772360	"	"	"
304953	100736424	20992772361	and	and	CC
304953	100736424	20992772362	"	"	"
304953	100736424	20992772363	Henry	henry	NP1
304953	100736424	20992772364	Banks	banks	NP1@_NN2
304953	100736424	20992772365	"	"	"
304953	100736424	20992772366	)	)	)
304953	100736424	20992772367	.	.	.
304953	100736424	20992772368	@		II
304953	100736424	20992772369	@		II
304953	100736424	20992772370	@		II
304953	100736424	20992772371	@		II
304953	100736424	20992772372	@		II
304953	100736424	20992772373	@		II
304953	100736424	20992772374	@		II
304953	100736424	20992772375	@		II
304953	100736424	20992772376	@		II
304953	100736424	20992772377	@		II
304953	100736424	20992772378	prostate	prostate	NN1
304953	100736424	20992772379	healthy	healthy	JJ
304953	100736424	20992772380	<p>		NULL
304953	100736424	20992772381	By	by	RT21
304953	100736424	20992772382	now	now	RT22
304953	100736424	20992772383	,	,	,
304953	100736424	20992772384	weve		VV0
304953	100736424	20992772385	all	all	DB_RR@
304953	100736424	20992772386	heard	hear	VVN_VVD
304953	100736424	20992772387	about	about	II
304953	100736424	20992772388	the	the	AT
304953	100736424	20992772389	value	value	NN1
304953	100736424	20992772390	of	of	IO
304953	100736424	20992772391	exercise	exercise	NN1
304953	100736424	20992772392	in	in	II
304953	100736424	20992772393	maintaining	maintain	VVG
304953	100736424	20992772394	good	good	JJ
304953	100736424	20992772395	health	health	NN1
304953	100736424	20992772396	.	.	.
304953	100736424	20992772397	Literally	literally	RR
304953	100736424	20992772398	hundreds	hundred	NNO2
304953	100736424	20992772399	of	of	IO
304953	100736424	20992772400	studies	study	NN2
304953	100736424	20992772401	conducted	conduct	VVD_VVN
304953	100736424	20992772402	over	over	RP_II
304953	100736424	20992772403	more	more	DAR
304953	100736424	20992772404	than	than	CSN
304953	100736424	20992772405	half	half	DB
304953	100736424	20992772406	a	a	AT1
304953	100736424	20992772407	century	century	NNT1
304953	100736424	20992772408	demonstrate	demonstrate	VV0
304953	100736424	20992772409	that	that	CST_DD1
304953	100736424	20992772410	regular	regular	JJ
304953	100736424	20992772411	exercise	exercise	NN1
304953	100736424	20992772412	pares	pare	VVZ
304953	100736424	20992772413	down	down	RP
304953	100736424	20992772414	your	your	APPGE
304953	100736424	20992772415	risk	risk	NN1
304953	100736424	20992772416	of	of	IO
304953	100736424	20992772417	developing	develop	VVG
304953	100736424	20992772418	some	some	DD
304953	100736424	20992772419	deadly	deadly	JJ
304953	100736424	20992772420	problems	problem	NN2
304953	100736424	20992772421	,	,	,
304953	100736424	20992772422	including	including	II_VVG@
304953	100736424	20992772423	heart	heart	NN1
304953	100736424	20992772424	disease	disease	NN1
304953	100736424	20992772425	,	,	,
304953	100736424	20992772426	stroke	stroke	VV0_NN1
304953	100736424	20992772427	,	,	,
304953	100736424	20992772428	and	and	CC
304953	100736424	20992772429	certain	certain	JJ
304953	100736424	20992772430	types	type	NN2
304953	100736424	20992772431	of	of	IO
304953	100736424	20992772432	cancer	cancer	NN1
304953	100736424	20992772433	(	(	(
304953	100736424	20992772434	colorectal	colorectal	JJ
304953	100736424	20992772435	cancer	cancer	NN1
304953	100736424	20992772436	,	,	,
304953	100736424	20992772437	for	for	REX21
304953	100736424	20992772438	example	example	REX22
304953	100736424	20992772439	)	)	)
304953	100736424	20992772440	.	.	.
304953	100736424	20992772441	It	it	PPH1
304953	100736424	20992772442	also	also	RR
304953	100736424	20992772443	eases	ease	VVZ
304953	100736424	20992772444	the	the	AT
304953	100736424	20992772445	toll	toll	NN1
304953	100736424	20992772446	of	of	IO
304953	100736424	20992772447	chronic	chronic	JJ
304953	100736424	20992772448	ailments	ailment	NN2
304953	100736424	20992772449	like	like	II
304953	100736424	20992772450	high	high	JJ
304953	100736424	20992772451	blood	blood	NN1
304953	100736424	20992772452	pressure	pressure	NN1
304953	100736424	20992772453	,	,	,
304953	100736424	20992772454	diabetes	diabetes	NN1
304953	100736424	20992772455	,	,	,
304953	100736424	20992772456	and	and	CC
304953	100736424	20992772457	arthritis	arthritis	NN1
304953	100736424	20992772458	.	.	.
304953	100736424	20992772459	<p>		NULL
304953	100736424	20992772460	"	"	"
304953	100736424	20992772461	What	what	DDQ
304953	100736424	20992772462	can	can	VM
304953	100736424	20992772463	I	i	PPIS1
304953	100736424	20992772464	eat	eat	VVI
304953	100736424	20992772465	to	to	TO
304953	100736424	20992772466	reduce	reduce	VVI
304953	100736424	20992772467	my	my	APPGE
304953	100736424	20992772468	risk	risk	NN1
304953	100736424	20992772469	of	of	IO
304953	100736424	20992772470	developing	developing	JJ_VVG
304953	100736424	20992772471	prostate	prostate	NN1
304953	100736424	20992772472	cancer	cancer	NN1
304953	100736424	20992772473	?	?	?
304953	100736424	20992772474	"	"	"
304953	100736424	20992772475	That 's		VVZ_NN2_NP1@
304953	100736424	20992772476	one	one	MC1
304953	100736424	20992772477	of	of	IO
304953	100736424	20992772478	the	the	AT
304953	100736424	20992772479	most	most	RGT
304953	100736424	20992772480	common	common	JJ
304953	100736424	20992772481	questions	question	NN2
304953	100736424	20992772482	physicians	physician	NN2
304953	100736424	20992772483	hear	hear	VV0
304953	100736424	20992772484	from	from	II
304953	100736424	20992772485	men	man	NN2
304953	100736424	20992772486	concerned	concerned	JJ
304953	100736424	20992772487	about	about	II
304953	100736424	20992772488	prostate	prostate	NN1
304953	100736424	20992772489	health	health	NN1
304953	100736424	20992772490	.	.	.
304953	100736424	20992772491	Undoubtedly	undoubtedly	RR
304953	100736424	20992772492	,	,	,
304953	100736424	20992772493	many	many	DA2
304953	100736424	20992772494	hope	hope	VV0_NN1
304953	100736424	20992772495	to	to	TO
304953	100736424	20992772496	hear	hear	VVI
304953	100736424	20992772497	their	their	APPGE
304953	100736424	20992772498	doctor	doctor	NN1
304953	100736424	20992772499	rattle	rattle	NN1_VV0
304953	100736424	20992772500	off	off	II_RP
304953	100736424	20992772501	a	a	AT1
304953	100736424	20992772502	few	few	DA2
304953	100736424	20992772503	foods	food	NN2
304953	100736424	20992772504	guaranteed	guarantee	VVD_VVN
304953	100736424	20992772505	to	to	TO
304953	100736424	20992772506	shield	shield	VVI
304953	100736424	20992772507	them	them	PPHO2
304953	100736424	20992772508	from	from	II
304953	100736424	20992772509	disease	disease	NN1
304953	100736424	20992772510	.	.	.
304953	100736424	20992772511	Although	although	CS
304953	100736424	20992772512	some	some	DD
304953	100736424	20992772513	foods	food	NN2
304953	100736424	20992772514	have	have	VH0
304953	100736424	20992772515	been	be	VBN
304953	100736424	20992772516	linked	link	VVN
304953	100736424	20992772517	with	with	IW
304953	100736424	20992772518	reduced	reduced	JJ@
304953	100736424	20992772519	risk	risk	NN1
304953	100736424	20992772520	of	of	IO
304953	100736424	20992772521	prostate	prostate	NN1
304953	100736424	20992772522	cancer	cancer	NN1
304953	100736424	20992772523	,	,	,
304953	100736424	20992772524	the	the	AT
304953	100736424	20992772525	proof	proof	NN1
304953	100736424	20992772526	is	be	VBZ
304953	100736424	20992772527	lacking	lack	VVG
304953	100736424	20992772528	,	,	,
304953	100736424	20992772529	at	at	RR21
304953	100736424	20992772530	least	least	RR22
304953	100736424	20992772531	for	for	IF
304953	100736424	20992772532	now	now	RT
304953	100736424	20992772533	.	.	.
304953	100736424	20992772534	<p>		NULL
304953	100736424	20992772535	When	when	CS_RRQ
304953	100736424	20992772536	it	it	PPH1
304953	100736424	20992772537	comes	come	VVZ
304953	100736424	20992772538	to	to	II
304953	100736424	20992772539	prostate	prostate	NN1
304953	100736424	20992772540	cancer	cancer	NN1
304953	100736424	20992772541	and	and	CC
304953	100736424	20992772542	other	other	JJ
304953	100736424	20992772543	prostate	prostate	NN1
304953	100736424	20992772544	diseases	disease	NN2
304953	100736424	20992772545	,	,	,
304953	100736424	20992772546	how	how	RRQ_RGQ@
304953	100736424	20992772547	accurate	accurate	JJ
304953	100736424	20992772548	are	be	VBR
304953	100736424	20992772549	the	the	AT
304953	100736424	20992772550	statistics	statistics	NN
304953	100736424	20992772551	we	we	PPIS2
304953	100736424	20992772552	hear	hear	VV0
304953	100736424	20992772553	?	?	?
304953	100736424	20992772554	Can	can	VV0%_NN1%_VM
304953	100736424	20992772555	patients	patient	NN2
304953	100736424	20992772556	rely	rely	VVI
304953	100736424	20992772557	on	on	II_RP@
304953	100736424	20992772558	reported	reported	JJ@
304953	100736424	20992772559	figures	figure	NN2
304953	100736424	20992772560	to	to	TO
304953	100736424	20992772561	determine	determine	VVI
304953	100736424	20992772562	their	their	APPGE
304953	100736424	20992772563	risk	risk	NN1
304953	100736424	20992772564	of	of	IO
304953	100736424	20992772565	suffering	suffering	JJ_VVG_NN1
304953	100736424	20992772566	complications	complication	NN2
304953	100736424	20992772567	such	such	II21
304953	100736424	20992772568	@		II
304953	100736424	20992772569	@		II
304953	100736424	20992772570	@		II
304953	100736424	20992772571	@		II
304953	100736424	20992772572	@		II
304953	100736424	20992772573	@		II
304953	100736424	20992772574	@		II
304953	100736424	20992772575	@		II
304953	100736424	20992772576	@		II
304953	100736424	20992772577	@		II
304953	100736424	20992772578	one	one	MC1
304953	100736424	20992772579	organization	organization	NN1
304953	100736424	20992772580	to	to	II
304953	100736424	20992772581	another	another	DD1
304953	100736424	20992772582	?	?	?
304953	100736424	20992772583	Three	three	MC
304953	100736424	20992772584	experts	expert	NN2
304953	100736424	20992772585	discuss	discuss	VV0
304953	100736424	20992772586	these	these	DD2
304953	100736424	20992772587	questions	question	NN2
304953	100736424	20992772588	and	and	CC
304953	100736424	20992772589	the	the	AT
304953	100736424	20992772590	growing	growing	JJ
304953	100736424	20992772591	field	field	NN1
304953	100736424	20992772592	of	of	IO
304953	100736424	20992772593	outcomes	outcome	NN2
304953	100736424	20992772594	research	research	NN1_VV0@
304953	100736424	20992772595	.	.	.
304953	100736424	20992772596	<p>		NULL
304953	100736424	20992772597	Mr.		NNB
304953	100736424	20992772598	Williams	williams	NP1
304953	100736424	20992772599	,	,	,
304953	100736424	20992772600	a	a	AT1
304953	100736424	20992772601	successful	successful	JJ
304953	100736424	20992772602	business	business	NN1
304953	100736424	20992772603	owner	owner	NN1
304953	100736424	20992772604	in	in	II
304953	100736424	20992772605	his	his	APPGE
304953	100736424	20992772606	mid-60s	mid-60s	MC2
304953	100736424	20992772607	,	,	,
304953	100736424	20992772608	describes	describe	VVZ
304953	100736424	20992772609	how	how	RRQ
304953	100736424	20992772610	he	he	PPHS1
304953	100736424	20992772611	was	be	VBDZ
304953	100736424	20992772612	able	able	JK
304953	100736424	20992772613	to	to	TO
304953	100736424	20992772614	maintain	maintain	VVI
304953	100736424	20992772615	his	his	APPGE
304953	100736424	20992772616	sex	sex	NN1
304953	100736424	20992772617	life	life	NN1
304953	100736424	20992772618	and	and	CC
304953	100736424	20992772619	other	other	JJ
304953	100736424	20992772620	aspects	aspect	NN2
304953	100736424	20992772621	of	of	IO
304953	100736424	20992772622	his	his	APPGE
304953	100736424	20992772623	physical	physical	JJ
304953	100736424	20992772624	emotional	emotional	JJ
304953	100736424	20992772625	well-being	well-being	NN1
304953	100736424	20992772626	during	during	II
304953	100736424	20992772627	and	and	CC
304953	100736424	20992772628	after	after	II_CS
304953	100736424	20992772629	treatment	treatment	NN1
304953	100736424	20992772630	for	for	IF
304953	100736424	20992772631	prostate	prostate	NN1
304953	100736424	20992772632	cancer	cancer	NN1
304953	100736424	20992772633	.	.	.
304953	100736426	20992772653	@@##	----------	----------
304953	100736426	20992772654	@@100736426		FO
304953	100736426	20992772655	@4936426/		VV0_NN1
304953	100736426	20992772656	46989		MC
304953	100736426	20992772657	@qwx906989		FO
304953	100736426	20992772658	<p>		NULL
304953	100736426	20992772659	When	when	CS_RRQ
304953	100736426	20992772660	it	it	PPH1
304953	100736426	20992772661	comes	come	VVZ
304953	100736426	20992772662	to	to	II
304953	100736426	20992772663	prolonging	prolong	VVG
304953	100736426	20992772664	survival	survival	NN1
304953	100736426	20992772665	,	,	,
304953	100736426	20992772666	external	external	JJ
304953	100736426	20992772667	beam	beam	NN1
304953	100736426	20992772668	radiation	radiation	NN1
304953	100736426	20992772669	therapy	therapy	NN1
304953	100736426	20992772670	combined	combine	VVN
304953	100736426	20992772671	with	with	IW
304953	100736426	20992772672	long-term	long-term	JJ
304953	100736426	20992772673	hormone	hormone	NN1
304953	100736426	20992772674	therapy	therapy	NN1
304953	100736426	20992772675	has	have	VHZ
304953	100736426	20992772676	been	be	VBN
304953	100736426	20992772677	shown	show	VVN
304953	100736426	20992772678	superior	superior	JJ_NN1@
304953	100736426	20992772679	to	to	II
304953	100736426	20992772680	radiation	radiation	NN1
304953	100736426	20992772681	therapy	therapy	NN1
304953	100736426	20992772682	and	and	CC
304953	100736426	20992772683	deferred	deferred	JJ
304953	100736426	20992772684	hormone	hormone	NN1
304953	100736426	20992772685	therapy	therapy	NN1
304953	100736426	20992772686	.	.	.
304953	100736426	20992772687	However	however	RR
304953	100736426	20992772688	,	,	,
304953	100736426	20992772689	long-term	long-term	JJ
304953	100736426	20992772690	hormone	hormone	NN1
304953	100736426	20992772691	therapy	therapy	NN1
304953	100736426	20992772692	can	can	VM
304953	100736426	20992772693	harm	harm	VVI
304953	100736426	20992772694	quality	quality	NN1
304953	100736426	20992772695	of	of	IO
304953	100736426	20992772696	life	life	NN1
304953	100736426	20992772697	and	and	CC
304953	100736426	20992772698	increase	increase	VVI
304953	100736426	20992772699	the	the	AT
304953	100736426	20992772700	risk	risk	NN1
304953	100736426	20992772701	of	of	IO
304953	100736426	20992772702	heart	heart	NN1
304953	100736426	20992772703	attacks	attack	NN2
304953	100736426	20992772704	,	,	,
304953	100736426	20992772705	fractures	fracture	NN2
304953	100736426	20992772706	,	,	,
304953	100736426	20992772707	and	and	CC
304953	100736426	20992772708	metabolic	metabolic	JJ
304953	100736426	20992772709	syndrome	syndrome	NN1
304953	100736426	20992772710	.	.	.
304953	100736426	20992772711	Could	could	VM
304953	100736426	20992772712	the	the	AT
304953	100736426	20992772713	risks	risk	NN2
304953	100736426	20992772714	be	be	VBI
304953	100736426	20992772715	minimized	minimize	VVN
304953	100736426	20992772716	by	by	II
304953	100736426	20992772717	replacing	replace	VVG
304953	100736426	20992772718	long-term	long-term	JJ
304953	100736426	20992772719	hormone	hormone	NN1
304953	100736426	20992772720	therapy	therapy	NN1
304953	100736426	20992772721	,	,	,
304953	100736426	20992772722	lasting		VVG
304953	100736426	20992772723	two	two	MC
304953	100736426	20992772724	years	year	NNT2
304953	100736426	20992772725	or	or	CC
304953	100736426	20992772726	longer	long	RRR_JJR
304953	100736426	20992772727	,	,	,
304953	100736426	20992772728	with	with	IW
304953	100736426	20992772729	short-term	short-term	JJ
304953	100736426	20992772730	therapy	therapy	NN1
304953	100736426	20992772731	lasting		VVG
304953	100736426	20992772732	just	just	RR
304953	100736426	20992772733	six	six	MC
304953	100736426	20992772734	months	month	NNT2
304953	100736426	20992772735	?	?	?
304953	100736426	20992772736	<p>		NULL
304953	100736426	20992772737	In	in	II
304953	100736426	20992772738	1997	1997	MC
304953	100736426	20992772739	,	,	,
304953	100736426	20992772740	the	the	AT
304953	100736426	20992772741	European	european	JJ
304953	100736426	20992772742	Organization	organization	NN1
304953	100736426	20992772743	for	for	IF
304953	100736426	20992772744	Research	research	NN1
304953	100736426	20992772745	and	and	CC
304953	100736426	20992772746	Treatment	treatment	NN1
304953	100736426	20992772747	of	of	IO
304953	100736426	20992772748	Cancer	cancer	NN1
304953	100736426	20992772749	(	(	(
304953	100736426	20992772750	EORTC		NP1
304953	100736426	20992772751	)	)	)
304953	100736426	20992772752	launched	launch	VVD
304953	100736426	20992772753	a	a	AT1
304953	100736426	20992772754	trial	trial	NN1
304953	100736426	20992772755	to	to	TO
304953	100736426	20992772756	find	find	VVI
304953	100736426	20992772757	out	out	RP
304953	100736426	20992772758	.	.	.
304953	100736426	20992772759	After	after	II_CS
304953	100736426	20992772760	six	six	MC
304953	100736426	20992772761	months	month	NNT2
304953	100736426	20992772762	of	of	IO
304953	100736426	20992772763	androgen	androgen	NN1
304953	100736426	20992772764	deprivation	deprivation	NN1
304953	100736426	20992772765	,	,	,
304953	100736426	20992772766	which	which	DDQ
304953	100736426	20992772767	started	start	VVD
304953	100736426	20992772768	at	at	II
304953	100736426	20992772769	the	the	AT
304953	100736426	20992772770	same	same	DA
304953	100736426	20992772771	time	time	NNT1
304953	100736426	20992772772	as	as	CSA
304953	100736426	20992772773	seven	seven	MC
304953	100736426	20992772774	weeks	week	NNT2
304953	100736426	20992772775	of	of	IO
304953	100736426	20992772776	radiation	radiation	NN1
304953	100736426	20992772777	therapy	therapy	NN1
304953	100736426	20992772778	,	,	,
304953	100736426	20992772779	970	970	MC
304953	100736426	20992772780	prostate	prostate	NN1
304953	100736426	20992772781	cancer	cancer	NN1
304953	100736426	20992772782	patients	patient	NN2
304953	100736426	20992772783	were	be	VBDR
304953	100736426	20992772784	randomly	randomly	RR
304953	100736426	20992772785	assigned	assign	VVN
304953	100736426	20992772786	to	to	II_TO
304953	100736426	20992772787	either	either	RR
304953	100736426	20992772788	long-term	long-term	JJ
304953	100736426	20992772789	or	or	CC
304953	100736426	20992772790	short-term	short-term	JJ
304953	100736426	20992772791	hormone	hormone	NN1
304953	100736426	20992772792	therapy	therapy	NN1
304953	100736426	20992772793	.	.	.
304953	100736426	20992772794	The	the	AT
304953	100736426	20992772795	short-term	short-term	JJ
304953	100736426	20992772796	group	group	NN1
304953	100736426	20992772797	immediately	immediately	RR
304953	100736426	20992772798	stopped	stop	VVN_VVD
304953	100736426	20992772799	taking	take	VVG
304953	100736426	20992772800	medications	medication	NN2
304953	100736426	20992772801	while	while	CS
304953	100736426	20992772802	the	the	AT
304953	100736426	20992772803	long-term	long-term	JJ
304953	100736426	20992772804	group	group	NN1
304953	100736426	20992772805	continued	continue	VVD_VVN
304953	100736426	20992772806	for	for	IF
304953	100736426	20992772807	another	another	DD1
304953	100736426	20992772808	two-and-a-half	two-and-a-half	MF
304953	100736426	20992772809	years	year	NNT2
304953	100736426	20992772810	.	.	.
304953	100736426	20992772811	In	in	II31
304953	100736426	20992772812	addition	addition	II32
304953	100736426	20992772813	to	to	II33
304953	100736426	20992772814	monitoring	monitor	VVG_NN1
304953	100736426	20992772815	disease	disease	NN1
304953	100736426	20992772816	progression	progression	NN1
304953	100736426	20992772817	,	,	,
304953	100736426	20992772818	the	the	AT
304953	100736426	20992772819	researchers	researcher	NN2
304953	100736426	20992772820	gathered	gather	VVD_JJ_VVN
304953	100736426	20992772821	data	data	NN
304953	100736426	20992772822	about	about	II
304953	100736426	20992772823	participants	participant	NN2
304953	100736426	20992772824	'	'	GE
304953	100736426	20992772825	quality	quality	NN1
304953	100736426	20992772826	of	of	IO
304953	100736426	20992772827	life	life	NN1
304953	100736426	20992772828	.	.	.
304953	100736426	20992772829	<p>		NULL
304953	100736426	20992772830	Five	five	MC
304953	100736426	20992772831	years	year	NNT2
304953	100736426	20992772832	later	later	RRR
304953	100736426	20992772833	,	,	,
304953	100736426	20992772834	the	the	AT
304953	100736426	20992772835	rate	rate	NN1
304953	100736426	20992772836	of	of	IO
304953	100736426	20992772837	death	death	NN1
304953	100736426	20992772838	from	from	II
304953	100736426	20992772839	prostate	prostate	NN1
304953	100736426	20992772840	cancer	cancer	NN1
304953	100736426	20992772841	and	and	CC
304953	100736426	20992772842	overall	overall	JJ_NN1
304953	100736426	20992772843	mortality	mortality	NN1
304953	100736426	20992772844	were	be	VBDR
304953	100736426	20992772845	@		II
304953	100736426	20992772846	@		II
304953	100736426	20992772847	@		II
304953	100736426	20992772848	@		II
304953	100736426	20992772849	@		II
304953	100736426	20992772850	@		II
304953	100736426	20992772851	@		II
304953	100736426	20992772852	@		II
304953	100736426	20992772853	@		II
304953	100736426	20992772854	@		II
304953	100736426	20992772855	the	the	AT
304953	100736426	20992772856	long-term	long-term	JJ
304953	100736426	20992772857	group	group	NN1
304953	100736426	20992772858	.	.	.
304953	100736426	20992772859	As	as	II
304953	100736426	20992772860	a	a	AT1
304953	100736426	20992772861	result	result	NN1
304953	100736426	20992772862	,	,	,
304953	100736426	20992772863	the	the	AT
304953	100736426	20992772864	researchers	researcher	NN2
304953	100736426	20992772865	suggest	suggest	VV0
304953	100736426	20992772866	radiotherapy	radiotherapy	NN1
304953	100736426	20992772867	and	and	CC
304953	100736426	20992772868	three	three	MC
304953	100736426	20992772869	years	year	NNT2
304953	100736426	20992772870	of	of	IO
304953	100736426	20992772871	hormone	hormone	NN1
304953	100736426	20992772872	therapy	therapy	NN1
304953	100736426	20992772873	for	for	IF
304953	100736426	20992772874	men	man	NN2
304953	100736426	20992772875	with	with	IW
304953	100736426	20992772876	locally	locally	RR
304953	100736426	20992772877	advanced	advanced	JJ_VVN
304953	100736426	20992772878	prostate	prostate	NN1
304953	100736426	20992772879	cancer	cancer	NN1
304953	100736426	20992772880	.	.	.
304953	100736426	20992772881	<p>		NULL
304953	100736426	20992772882	One	one	MC1
304953	100736426	20992772883	caveat	caveat	NN1
304953	100736426	20992772884	:	:	:
304953	100736426	20992772885	the	the	AT
304953	100736426	20992772886	study	study	NN1
304953	100736426	20992772887	was	be	VBDZ
304953	100736426	20992772888	conducted	conduct	VVN
304953	100736426	20992772889	in	in	II
304953	100736426	20992772890	men	man	NN2
304953	100736426	20992772891	with	with	IW
304953	100736426	20992772892	relatively	relatively	RR
304953	100736426	20992772893	large	large	JJ
304953	100736426	20992772894	tumors	tumor	NN2
304953	100736426	20992772895	.	.	.
304953	100736426	20992772896	The	the	AT
304953	100736426	20992772897	results	result	NN2
304953	100736426	20992772898	are	be	VBR
304953	100736426	20992772899	n't	n't	XX
304953	100736426	20992772900	likely	likely	JJ_RR@
304953	100736426	20992772901	to	to	TO
304953	100736426	20992772902	apply	apply	VVI
304953	100736426	20992772903	to	to	II
304953	100736426	20992772904	men	man	NN2
304953	100736426	20992772905	with	with	IW
304953	100736426	20992772906	small	small	JJ
304953	100736426	20992772907	,	,	,
304953	100736426	20992772908	early-stage	early-stage	JJ_NN1
304953	100736426	20992772909	tumors	tumor	NN2
304953	100736426	20992772910	,	,	,
304953	100736426	20992772911	the	the	AT
304953	100736426	20992772912	kind	kind	NN1
304953	100736426	20992772913	found	find	VVD_VVN
304953	100736426	20992772914	most	most	RGT
304953	100736426	20992772915	often	often	RR
304953	100736426	20992772916	in	in	II
304953	100736426	20992772917	American	american	JJ
304953	100736426	20992772918	men	man	NN2
304953	100736426	20992772919	.	.	.
304953	100736426	20992772920	46996		MC
304953	100736426	20992772921	@qwx906996		FO
304953	100736427	20992772941	@@##	----------	----------
304953	100736427	20992772942	@@100736427		FO
304953	100736427	20992772943	@4936427/		VV0_NN1
304953	100736427	20992772944	46989		MC
304953	100736427	20992772945	@qwx906989		FO
304953	100736427	20992772946	<p>		NULL
304953	100736427	20992772947	Doctors	doctor	NN2
304953	100736427	20992772948	commonly	commonly	RR
304953	100736427	20992772949	prescribe	prescribe	VV0
304953	100736427	20992772950	the	the	AT
304953	100736427	20992772951	drugs	drug	NN2
304953	100736427	20992772952	dutasteride		VV0_NN1
304953	100736427	20992772953	(	(	(
304953	100736427	20992772954	Avodart		NP1
304953	100736427	20992772955	)	)	)
304953	100736427	20992772956	and	and	CC
304953	100736427	20992772957	tamsulosin		NN1
304953	100736427	20992772958	(	(	(
304953	100736427	20992772959	Flomax		NP1
304953	100736427	20992772960	)	)	)
304953	100736427	20992772961	for	for	IF
304953	100736427	20992772962	the	the	AT
304953	100736427	20992772963	treatment	treatment	NN1
304953	100736427	20992772964	of	of	IO
304953	100736427	20992772965	an	a	AT1
304953	100736427	20992772966	enlarged	enlarged	JJ
304953	100736427	20992772967	prostate	prostate	NN1
304953	100736427	20992772968	and	and	CC
304953	100736427	20992772969	the	the	AT
304953	100736427	20992772970	moderate-to-severe	moderate-to-severe	JJ
304953	100736427	20992772971	urinary	urinary	JJ_NN1
304953	100736427	20992772972	symptoms	symptom	NN2
304953	100736427	20992772973	that	that	CST
304953	100736427	20992772974	accompany	accompany	VV0
304953	100736427	20992772975	BPH	bph	NP1
304953	100736427	20992772976	(	(	(
304953	100736427	20992772977	benign	benign	JJ
304953	100736427	20992772978	prostatic	prostatic	JJ
304953	100736427	20992772979	hyperplasia	hyperplasia	NN1
304953	100736427	20992772980	)	)	)
304953	100736427	20992772981	.	.	.
304953	100736427	20992772982	But	but	CCB
304953	100736427	20992772983	because	because	CS
304953	100736427	20992772984	the	the	AT
304953	100736427	20992772985	drugs	drug	NN2
304953	100736427	20992772986	work	work	VV0
304953	100736427	20992772987	differently	differently	RR
304953	100736427	20992772988	,	,	,
304953	100736427	20992772989	researchers	researcher	NN2
304953	100736427	20992772990	hypothesized	hypothesize	VVD
304953	100736427	20992772991	that	that	CST_DD1
304953	100736427	20992772992	taking	take	VVG
304953	100736427	20992772993	both	both	DB2_RR
304953	100736427	20992772994	might	might	VM
304953	100736427	20992772995	be	be	VBI
304953	100736427	20992772996	more	more	RGR
304953	100736427	20992772997	effective	effective	JJ
304953	100736427	20992772998	at	at	II
304953	100736427	20992772999	controlling	control	VVG_JJ@
304953	100736427	20992773000	symptoms	symptom	NN2
304953	100736427	20992773001	than	than	CSN
304953	100736427	20992773002	taking	take	VVG
304953	100736427	20992773003	just	just	RR
304953	100736427	20992773004	one	one	MC1_PN1
304953	100736427	20992773005	.	.	.
304953	100736427	20992773006	The	the	AT
304953	100736427	20992773007	CombAT	combat	NN1@
304953	100736427	20992773008	trial	trial	NN1
304953	100736427	20992773009	,	,	,
304953	100736427	20992773010	a	a	AT1
304953	100736427	20992773011	four-year	four-year	JJ
304953	100736427	20992773012	randomized	randomized	JJ@_VVD
304953	100736427	20992773013	,	,	,
304953	100736427	20992773014	double-blind	double-blind	JJ
304953	100736427	20992773015	study	study	NN1
304953	100736427	20992773016	of	of	IO
304953	100736427	20992773017	4,844		MC
304953	100736427	20992773018	men	man	NN2
304953	100736427	20992773019	diagnosed	diagnose	VVN_VVD
304953	100736427	20992773020	with	with	IW
304953	100736427	20992773021	BPH	bph	NP1
304953	100736427	20992773022	,	,	,
304953	100736427	20992773023	was	be	VBDZ
304953	100736427	20992773024	launched	launch	VVN
304953	100736427	20992773025	to	to	TO
304953	100736427	20992773026	test	test	VVI
304953	100736427	20992773027	that	that	DD1
304953	100736427	20992773028	hypothesis	hypothesis	NN1
304953	100736427	20992773029	.	.	.
304953	100736427	20992773030	Each	each	DD1
304953	100736427	20992773031	participant	participant	NN1
304953	100736427	20992773032	was	be	VBDZ
304953	100736427	20992773033	randomly	randomly	RR
304953	100736427	20992773034	assigned	assign	VVN
304953	100736427	20992773035	to	to	TO
304953	100736427	20992773036	receive	receive	VVI
304953	100736427	20992773037	a	a	AT1
304953	100736427	20992773038	daily	daily	JJ
304953	100736427	20992773039	combination	combination	NN1
304953	100736427	20992773040	of	of	IO
304953	100736427	20992773041	dutasteride		NN1
304953	100736427	20992773042	and	and	CC
304953	100736427	20992773043	tamsulosin		NN1
304953	100736427	20992773044	,	,	,
304953	100736427	20992773045	dutasteride		NN1_VV0
304953	100736427	20992773046	and	and	CC
304953	100736427	20992773047	a	a	AT1
304953	100736427	20992773048	placebo	placebo	NN1
304953	100736427	20992773049	,	,	,
304953	100736427	20992773050	or	or	CC
304953	100736427	20992773051	tamsulosin		NN1
304953	100736427	20992773052	and	and	CC
304953	100736427	20992773053	a	a	AT1
304953	100736427	20992773054	placebo	placebo	NN1
304953	100736427	20992773055	.	.	.
304953	100736427	20992773056	<p>		NULL
304953	100736427	20992773057	After	after	II
304953	100736427	20992773058	following	follow	VVG
304953	100736427	20992773059	the	the	AT
304953	100736427	20992773060	participants	participant	NN2
304953	100736427	20992773061	for	for	IF
304953	100736427	20992773062	two	two	MC
304953	100736427	20992773063	years	year	NNT2
304953	100736427	20992773064	,	,	,
304953	100736427	20992773065	the	the	AT
304953	100736427	20992773066	researchers	researcher	NN2
304953	100736427	20992773067	found	find	VVD_VVN
304953	100736427	20992773068	that	that	CST_DD1
304953	100736427	20992773069	taking	take	VVG
304953	100736427	20992773070	the	the	AT
304953	100736427	20992773071	drug	drug	NN1
304953	100736427	20992773072	combination	combination	NN1
304953	100736427	20992773073	resulted	result	VVN_VVD
304953	100736427	20992773074	in	in	II
304953	100736427	20992773075	significantly	significantly	RR
304953	100736427	20992773076	greater	great	JJR
304953	100736427	20992773077	improvements	improvement	NN2
304953	100736427	20992773078	in	in	II
304953	100736427	20992773079	symptoms	symptom	NN2
304953	100736427	20992773080	,	,	,
304953	100736427	20992773081	such	such	II21
304953	100736427	20992773082	as	as	II22
304953	100736427	20992773083	improved	improved	JJ
304953	100736427	20992773084	urinary	urinary	JJ_NN1
304953	100736427	20992773085	flow	flow	NN1
304953	100736427	20992773086	,	,	,
304953	100736427	20992773087	than	than	CSN
304953	100736427	20992773088	taking	take	VVG
304953	100736427	20992773089	either	either	DD1
304953	100736427	20992773090	drug	drug	NN1
304953	100736427	20992773091	alone	alone	RR_JJ
304953	100736427	20992773092	"	"	"
304953	100736427	20992773093	so-called	so-called	JJ
304953	100736427	20992773094	monotherapy	monotherapy	NN1
304953	100736427	20992773095	.	.	.
304953	100736427	20992773096	However	however	RR
304953	100736427	20992773097	,	,	,
304953	100736427	20992773098	men	man	NN2
304953	100736427	20992773099	who	who	PNQS
304953	100736427	20992773100	took	take	VVD
304953	100736427	20992773101	both	both	DB2
304953	100736427	20992773102	drugs	drug	NN2
304953	100736427	20992773103	experienced	experience	VVD_VVN
304953	100736427	20992773104	more	more	DAR
304953	100736427	20992773105	side	side	NN1
304953	100736427	20992773106	effects	effect	NN2
304953	100736427	20992773107	than	than	CSN
304953	100736427	20992773108	the	the	AT
304953	100736427	20992773109	men	man	NN2
304953	100736427	20992773110	taking	take	VVG
304953	100736427	20992773111	one	one	MC1
304953	100736427	20992773112	drug	drug	NN1
304953	100736427	20992773113	;	;	;
304953	100736427	20992773114	in	in	II
304953	100736427	20992773115	most	most	DAT
304953	100736427	20992773116	cases	case	NN2
304953	100736427	20992773117	,	,	,
304953	100736427	20992773118	the	the	AT
304953	100736427	20992773119	side	side	NN1
304953	100736427	20992773120	effects	effect	NN2
304953	100736427	20992773121	were	be	VBDR
304953	100736427	20992773122	minor	minor	JJ
304953	100736427	20992773123	and	and	CC
304953	100736427	20992773124	did	do	VDD
304953	100736427	20992773125	n't	n't	XX
304953	100736427	20992773126	cause	cause	VVI
304953	100736427	20992773127	the	the	AT
304953	100736427	20992773128	men	man	NN2
304953	100736427	20992773129	to	to	TO
304953	100736427	20992773130	stop	stop	VVI
304953	100736427	20992773131	the	the	AT
304953	100736427	20992773132	medication	medication	NN1
304953	100736427	20992773133	@		II
304953	100736427	20992773134	@		II
304953	100736427	20992773135	@		II
304953	100736427	20992773136	@		II
304953	100736427	20992773137	@		II
304953	100736427	20992773138	@		II
304953	100736427	20992773139	@		II
304953	100736427	20992773140	@		II
304953	100736427	20992773141	@		II
304953	100736427	20992773142	@		II
304953	100736427	20992773143	also	also	RR
304953	100736427	20992773144	resulted	result	VVN_VVD
304953	100736427	20992773145	in	in	II
304953	100736427	20992773146	significant	significant	JJ
304953	100736427	20992773147	improvements	improvement	NN2
304953	100736427	20992773148	in	in	II
304953	100736427	20992773149	quality	quality	NN1
304953	100736427	20992773150	of	of	IO
304953	100736427	20992773151	life	life	NN1
304953	100736427	20992773152	and	and	CC
304953	100736427	20992773153	satisfaction	satisfaction	NN1
304953	100736427	20992773154	with	with	IW
304953	100736427	20992773155	treatment	treatment	NN1
304953	100736427	20992773156	over	over	II
304953	100736427	20992773157	monotherapy	monotherapy	NN1
304953	100736427	20992773158	.	.	.
304953	100736427	20992773159	To	to	TO
304953	100736427	20992773160	assess	assess	VVI
304953	100736427	20992773161	quality	quality	NN1
304953	100736427	20992773162	of	of	IO
304953	100736427	20992773163	life	life	NN1
304953	100736427	20992773164	and	and	CC
304953	100736427	20992773165	treatment	treatment	NN1
304953	100736427	20992773166	satisfaction	satisfaction	NN1
304953	100736427	20992773167	,	,	,
304953	100736427	20992773168	participants	participant	NN2
304953	100736427	20992773169	responded	respond	VVN_VVD
304953	100736427	20992773170	to	to	II
304953	100736427	20992773171	questionnaires	questionnaire	NN2
304953	100736427	20992773172	every	every	AT1
304953	100736427	20992773173	three	three	MC
304953	100736427	20992773174	months	month	NNT2
304953	100736427	20992773175	that	that	CST_DD1
304953	100736427	20992773176	asked	ask	VVD
304953	100736427	20992773177	about	about	II
304953	100736427	20992773178	the	the	AT
304953	100736427	20992773179	strength	strength	NN1
304953	100736427	20992773180	of	of	IO
304953	100736427	20992773181	the	the	AT
304953	100736427	20992773182	urinary	urinary	JJ_NN1
304953	100736427	20992773183	stream	stream	NN1
304953	100736427	20992773184	,	,	,
304953	100736427	20992773185	pain	pain	NN1
304953	100736427	20992773186	upon	upon	II
304953	100736427	20992773187	urination	urination	NN1
304953	100736427	20992773188	,	,	,
304953	100736427	20992773189	physical	physical	JJ
304953	100736427	20992773190	discomfort	discomfort	NN1
304953	100736427	20992773191	,	,	,
304953	100736427	20992773192	worries	worry	NN2_VVZ@
304953	100736427	20992773193	about	about	II
304953	100736427	20992773194	health	health	NN1
304953	100736427	20992773195	,	,	,
304953	100736427	20992773196	and	and	CC
304953	100736427	20992773197	changes	change	NN2_VVZ@
304953	100736427	20992773198	in	in	II
304953	100736427	20992773199	daily	daily	JJ
304953	100736427	20992773200	activities	activity	NN2
304953	100736427	20992773201	.	.	.
304953	100736427	20992773202	<p>		NULL
304953	100736427	20992773203	The	the	AT
304953	100736427	20992773204	CombAT	combat	NN1@
304953	100736427	20992773205	trial	trial	NN1
304953	100736427	20992773206	mimics	mimic	VVZ
304953	100736427	20992773207	an	a	AT1
304953	100736427	20992773208	earlier	early	JJR
304953	100736427	20992773209	study	study	NN1
304953	100736427	20992773210	,	,	,
304953	100736427	20992773211	which	which	DDQ
304953	100736427	20992773212	showed	show	VVD
304953	100736427	20992773213	that	that	CST
304953	100736427	20992773214	the	the	AT
304953	100736427	20992773215	combination	combination	NN1
304953	100736427	20992773216	of	of	IO
304953	100736427	20992773217	finasteride	finasteride	NN1
304953	100736427	20992773218	(	(	(
304953	100736427	20992773219	Proscar	proscar	NP1
304953	100736427	20992773220	)	)	)
304953	100736427	20992773221	and	and	CC
304953	100736427	20992773222	doxazosin	doxazosin	NN1
304953	100736427	20992773223	(	(	(
304953	100736427	20992773224	Cardura	cardura	NP1
304953	100736427	20992773225	)	)	)
304953	100736427	20992773226	was	be	VBDZ
304953	100736427	20992773227	more	more	RGR
304953	100736427	20992773228	effective	effective	JJ
304953	100736427	20992773229	at	at	II
304953	100736427	20992773230	easing	ease	VVG
304953	100736427	20992773231	BPH	bph	NP1
304953	100736427	20992773232	than	than	CSN
304953	100736427	20992773233	either	either	DD1
304953	100736427	20992773234	drug	drug	NN1
304953	100736427	20992773235	alone	alone	RR_JJ
304953	100736427	20992773236	.	.	.
304953	100736427	20992773237	46996		MC
304953	100736427	20992773238	@qwx906996		FO
304953	100736428	20992773258	@@##	----------	----------
304953	100736428	20992773259	@@100736428		FO
304953	100736428	20992773260	@4936428/		VV0_JJ
304953	100736428	20992773261	<h>		NULL
304953	100736428	20992773262	Other	other	JJ
304953	100736428	20992773263	Conditions	condition	NN2
304953	100736428	20992773264	46988		MC
304953	100736428	20992773265	@qwx906988		FO
304953	100736428	20992773266	46994		MC
304953	100736428	20992773267	@qwx906994		FO
304953	100736428	20992773268	46995		MC
304953	100736428	20992773269	@qwx906995		FO
304953	100736428	20992773270	46992		MC
304953	100736428	20992773271	@qwx906992		FO
304953	100736428	20992773272	46991		MC
304953	100736428	20992773273	@qwx906991		FO
304953	100736428	20992773274	46990		MC
304953	100736428	20992773275	@qwx906990		FO
304953	100736428	20992773276	46989		MC
304953	100736428	20992773277	@qwx906989		FO
304953	100736428	20992773278	46993		MC
304953	100736428	20992773279	@qwx906993		FO
304953	100736428	20992773280	<h>		NULL
304953	100736428	20992773281	Prostatitis		NN1_NP1
304953	100736428	20992773282	<p>		NULL
304953	100736428	20992773283	Prostatitis	prostatitis	NN1_NP1@
304953	100736428	20992773284	is	be	VBZ
304953	100736428	20992773285	inflammation	inflammation	NN1
304953	100736428	20992773286	of	of	IO
304953	100736428	20992773287	the	the	AT
304953	100736428	20992773288	prostate	prostate	NN1
304953	100736428	20992773289	gland	gland	NN1
304953	100736428	20992773290	.	.	.
304953	100736428	20992773291	Acute	acute	JJ
304953	100736428	20992773292	prostatitis	prostatitis	NN1
304953	100736428	20992773293	is	be	VBZ
304953	100736428	20992773294	inflammation	inflammation	NN1
304953	100736428	20992773295	that	that	CST
304953	100736428	20992773296	suddenly	suddenly	RR
304953	100736428	20992773297	causes	cause	VVZ
304953	100736428	20992773298	symptoms	symptom	NN2
304953	100736428	20992773299	such	such	II21
304953	100736428	20992773300	as	as	II22
304953	100736428	20992773301	painful	painful	JJ
304953	100736428	20992773302	or	or	CC
304953	100736428	20992773303	difficult	difficult	JJ
304953	100736428	20992773304	urination	urination	NN1
304953	100736428	20992773305	.	.	.
304953	100736428	20992773306	When	when	RRQ_CS
304953	100736428	20992773307	symptoms	symptom	NN2
304953	100736428	20992773308	start	start	VV0
304953	100736428	20992773309	gradually	gradually	RR
304953	100736428	20992773310	and	and	CC
304953	100736428	20992773311	linger	linger	VV0
304953	100736428	20992773312	for	for	IF
304953	100736428	20992773313	more	more	DAR
304953	100736428	20992773314	than	than	CSN
304953	100736428	20992773315	a	a	AT1
304953	100736428	20992773316	couple	couple	NN1
304953	100736428	20992773317	of	of	IO
304953	100736428	20992773318	weeks	week	NNT2
304953	100736428	20992773319	,	,	,
304953	100736428	20992773320	the	the	AT
304953	100736428	20992773321	condition	condition	NN1
304953	100736428	20992773322	is	be	VBZ
304953	100736428	20992773323	called	call	VVN
304953	100736428	20992773324	chronic	chronic	JJ
304953	100736428	20992773325	prostatitis	prostatitis	NN1
304953	100736428	20992773326	.	.	.
304953	100736428	20992773327	Prostatitis	prostatitis	NN1_NP1@
304953	100736428	20992773328	can	can	VM
304953	100736428	20992773329	be	be	VBI
304953	100736428	20992773330	caused	cause	VVN
304953	100736428	20992773331	by	by	II
304953	100736428	20992773332	a	a	AT1
304953	100736428	20992773333	bacterial	bacterial	JJ
304953	100736428	20992773334	infection	infection	NN1
304953	100736428	20992773335	.	.	.
304953	100736428	20992773336	Some	some	DD
304953	100736428	20992773337	of	of	IO
304953	100736428	20992773338	these	these	DD2
304953	100736428	20992773339	bacteria	bacteria	NN2
304953	100736428	20992773340	are	be	VBR
304953	100736428	20992773341	the	the	AT
304953	100736428	20992773342	normal	normal	JJ
304953	100736428	20992773343	germs	germ	NN2
304953	100736428	20992773344	that	that	CST
304953	100736428	20992773345	live	live	VV0
304953	100736428	20992773346	on	on	RP@
304953	100736428	20992773347	and	and	CC
304953	100736428	20992773348	inside	inside	II
304953	100736428	20992773349	your	your	APPGE
304953	100736428	20992773350	body	body	NN1
304953	100736428	20992773351	.	.	.
304953	100736428	20992773352	Other	other	JJ
304953	100736428	20992773353	infections	infection	NN2
304953	100736428	20992773354	are	be	VBR
304953	100736428	20992773355	transmitted	transmit	VVN
304953	100736428	20992773356	through	through	II
304953	100736428	20992773357	sexual	sexual	JJ
304953	100736428	20992773358	contact	contact	NN1
304953	100736428	20992773359	.	.	.
304953	100736428	20992773360	<h>		NULL
304953	100736428	20992773361	Related	related	JJ
304953	100736428	20992773362	Articles	article	NN2
304953	100736428	20992773363	<p>		NULL
304953	100736428	20992773364	Prostatitis		NP1@_NN1
304953	100736428	20992773365	(	(	(
304953	100736428	20992773366	infection	infection	NN1
304953	100736428	20992773367	or	or	CC
304953	100736428	20992773368	inflammation	inflammation	NN1
304953	100736428	20992773369	of	of	IO
304953	100736428	20992773370	the	the	AT
304953	100736428	20992773371	prostate	prostate	NN1
304953	100736428	20992773372	gland	gland	NN1
304953	100736428	20992773373	)	)	)
304953	100736428	20992773374	flies	fly	VVZ_NN2
304953	100736428	20992773375	under	under	II
304953	100736428	20992773376	the	the	AT
304953	100736428	20992773377	radar	radar	NN1
304953	100736428	20992773378	even	even	CS21
304953	100736428	20992773379	though	though	CS22
304953	100736428	20992773380	it	it	PPH1
304953	100736428	20992773381	affects	affect	VVZ
304953	100736428	20992773382	up	up	RG21
304953	100736428	20992773383	to	to	RG22
304953	100736428	20992773384	one	one	MC1_PN1
304953	100736428	20992773385	in	in	II
304953	100736428	20992773386	six	six	MC
304953	100736428	20992773387	men	man	NN2
304953	100736428	20992773388	at	at	II
304953	100736428	20992773389	some	some	DD
304953	100736428	20992773390	point	point	NN1
304953	100736428	20992773391	in	in	II
304953	100736428	20992773392	their	their	APPGE
304953	100736428	20992773393	lifetimes	lifetime	NNT2
304953	100736428	20992773394	.	.	.
304953	100736428	20992773395	It	it	PPH1
304953	100736428	20992773396	triggers	trigger	VVZ
304953	100736428	20992773397	more	more	DAR
304953	100736428	20992773398	than	than	CSN
304953	100736428	20992773399	two	two	MC
304953	100736428	20992773400	million	million	NNO
304953	100736428	20992773401	visits	visit	NN2
304953	100736428	20992773402	to	to	II
304953	100736428	20992773403	doctors	doctor	NN2
304953	100736428	20992773404	and	and	CC
304953	100736428	20992773405	untold	untold	JJ
304953	100736428	20992773406	agony	agony	NN1
304953	100736428	20992773407	each	each	DD1
304953	100736428	20992773408	year	year	NNT1
304953	100736428	20992773409	.	.	.
304953	100736428	20992773410	<p>		NULL
304953	100736428	20992773411	Standard	standard	JJ_NN1
304953	100736428	20992773412	treatments	treatment	NN2
304953	100736428	20992773413	for	for	IF
304953	100736428	20992773414	prostatitis	prostatitis	NN1
304953	100736428	20992773415	,	,	,
304953	100736428	20992773416	including	including	II_VVG@
304953	100736428	20992773417	antibiotics	antibiotic	NN2
304953	100736428	20992773418	,	,	,
304953	100736428	20992773419	anti-inflammatory	anti-inflammatory	JJ
304953	100736428	20992773420	medications	medication	NN2
304953	100736428	20992773421	,	,	,
304953	100736428	20992773422	and	and	CC
304953	100736428	20992773423	alpha	alpha	NN1
304953	100736428	20992773424	blockers	blocker	NN2
304953	100736428	20992773425	,	,	,
304953	100736428	20992773426	are	be	VBR
304953	100736428	20992773427	often	often	RR
304953	100736428	20992773428	ineffective	ineffective	JJ
304953	100736428	20992773429	.	.	.
304953	100736428	20992773430	Patients	patient	NN2
304953	100736428	20992773431	might	might	VM
304953	100736428	20992773432	find	find	VVI
304953	100736428	20992773433	relief	relief	NN1
304953	100736428	20992773434	by	by	II
304953	100736428	20992773435	using	use	VVG
304953	100736428	20992773436	drugs	drug	NN2
304953	100736428	20992773437	currently	currently	RR
304953	100736428	20992773438	in	in	II
304953	100736428	20992773439	clinical	clinical	JJ
304953	100736428	20992773440	trials	trial	NN2
304953	100736428	20992773441	or	or	CC
304953	100736428	20992773442	nontraditional	nontraditional	JJ
304953	100736428	20992773443	therapies	therapy	NN2
304953	100736428	20992773444	such	such	II21
304953	100736428	20992773445	as	as	II22
304953	100736428	20992773446	biofeedback	biofeedback	NN1
304953	100736428	20992773447	and	and	CC
304953	100736428	20992773448	myofascial	myofascial	JJ
304953	100736428	20992773449	trigger	trigger	NN1
304953	100736428	20992773450	release	release	NN1_VV0
304953	100736428	20992773451	,	,	,
304953	100736428	20992773452	a	a	AT1
304953	100736428	20992773453	form	form	NN1
304953	100736428	20992773454	of	of	IO
304953	100736428	20992773455	massage	massage	NN1
304953	100736428	20992773456	.	.	.
304953	100736430	20992773476	@@##	----------	----------
304953	100736430	20992773477	@@100736430		FO
304953	100736430	20992773478	@4936430/		NN1_VV0
304953	100736430	20992773479	<p>		NULL
304953	100736430	20992773480	Researchers	researcher	NN2
304953	100736430	20992773481	have	have	VH0
304953	100736430	20992773482	answered	answer	VVN
304953	100736430	20992773483	these	these	DD2
304953	100736430	20992773484	questions	question	NN2
304953	100736430	20992773485	and	and	CC
304953	100736430	20992773486	countless	countless	JJ
304953	100736430	20992773487	others	others	NN2
304953	100736430	20992773488	through	through	II
304953	100736430	20992773489	clinical	clinical	JJ
304953	100736430	20992773490	trials	trial	NN2
304953	100736430	20992773491	,	,	,
304953	100736430	20992773492	scientific	scientific	JJ
304953	100736430	20992773493	studies	study	NN2
304953	100736430	20992773494	that	that	CST
304953	100736430	20992773495	compare	compare	VV0
304953	100736430	20992773496	novel	novel	JJ_NN1
304953	100736430	20992773497	drugs	drug	NN2
304953	100736430	20992773498	and	and	CC
304953	100736430	20992773499	treatments	treatment	NN2
304953	100736430	20992773500	with	with	IW
304953	100736430	20992773501	the	the	AT
304953	100736430	20992773502	current	current	JJ
304953	100736430	20992773503	standard	standard	NN1
304953	100736430	20992773504	of	of	IO
304953	100736430	20992773505	care	care	NN1
304953	100736430	20992773506	to	to	TO
304953	100736430	20992773507	determine	determine	VVI
304953	100736430	20992773508	what 's		NN2
304953	100736430	20992773509	best	best	RRT
304953	100736430	20992773510	for	for	IF
304953	100736430	20992773511	patients	patient	NN2
304953	100736430	20992773512	and	and	CC
304953	100736430	20992773513	improve	improve	VVI
304953	100736430	20992773514	medical	medical	JJ
304953	100736430	20992773515	practice	practice	NN1
304953	100736430	20992773516	.	.	.
304953	100736430	20992773517	<p>		NULL
304953	100736430	20992773518	But	but	CCB
304953	100736430	20992773519	launching	launch	VVG
304953	100736430	20992773520	a	a	AT1
304953	100736430	20992773521	clinical	clinical	JJ
304953	100736430	20992773522	trial	trial	NN1
304953	100736430	20992773523	is n't		VV0_NN1
304953	100736430	20992773524	easy	easy	JJ_RR@
304953	100736430	20992773525	,	,	,
304953	100736430	20992773526	and	and	CC
304953	100736430	20992773527	it	it	PPH1
304953	100736430	20992773528	requires	require	VVZ
304953	100736430	20992773529	more	more	DAR_RRR
304953	100736430	20992773530	than	than	CSN
304953	100736430	20992773531	simply	simply	RR
304953	100736430	20992773532	coming	come	VVG
304953	100736430	20992773533	up	up	RP
304953	100736430	20992773534	with	with	IW
304953	100736430	20992773535	a	a	AT1
304953	100736430	20992773536	testable	testable	JJ
304953	100736430	20992773537	hypothesis	hypothesis	NN1
304953	100736430	20992773538	.	.	.
304953	100736430	20992773539	Its	its	APPGE
304953	100736430	20992773540	costly	costly	JJ
304953	100736430	20992773541	,	,	,
304953	100736430	20992773542	too	too	RR@
304953	100736430	20992773543	.	.	.
304953	100736430	20992773544	Today	today	RT
304953	100736430	20992773545	,	,	,
304953	100736430	20992773546	a	a	AT1
304953	100736430	20992773547	pharmaceutical	pharmaceutical	JJ
304953	100736430	20992773548	company	company	NN1
304953	100736430	20992773549	seeking	seek	VVG
304953	100736430	20992773550	to	to	TO
304953	100736430	20992773551	test	test	VVI
304953	100736430	20992773552	a	a	AT1
304953	100736430	20992773553	drug	drug	NN1
304953	100736430	20992773554	may	may	VM
304953	100736430	20992773555	spend	spend	VVI
304953	100736430	20992773556	tens	tens	MC2
304953	100736430	20992773557	of	of	IO
304953	100736430	20992773558	millions	million	NNO2
304953	100736430	20992773559	of	of	IO
304953	100736430	20992773560	dollars	dollar	NNU2
304953	100736430	20992773561	to	to	TO
304953	100736430	20992773562	recruit	recruit	VVI
304953	100736430	20992773563	study	study	NN1
304953	100736430	20992773564	participants	participant	NN2
304953	100736430	20992773565	,	,	,
304953	100736430	20992773566	provide	provide	VV0
304953	100736430	20992773567	them	them	PPHO2
304953	100736430	20992773568	with	with	IW
304953	100736430	20992773569	the	the	AT
304953	100736430	20992773570	drug	drug	NN1
304953	100736430	20992773571	,	,	,
304953	100736430	20992773572	track	track	VV0@
304953	100736430	20992773573	their	their	APPGE
304953	100736430	20992773574	response	response	NN1
304953	100736430	20992773575	to	to	II
304953	100736430	20992773576	the	the	AT
304953	100736430	20992773577	drug	drug	NN1
304953	100736430	20992773578	over	over	II
304953	100736430	20992773579	time	time	NNT1
304953	100736430	20992773580	,	,	,
304953	100736430	20992773581	and	and	CC
304953	100736430	20992773582	analyze	analyze	VV0
304953	100736430	20992773583	mountains	mountain	NN2
304953	100736430	20992773584	of	of	IO
304953	100736430	20992773585	data	data	NN
304953	100736430	20992773586	.	.	.
304953	100736430	20992773587	<p>		NULL
304953	100736430	20992773588	Decades	decade	NNT2
304953	100736430	20992773589	ago	ago	RA
304953	100736430	20992773590	,	,	,
304953	100736430	20992773591	individual	individual	JJ
304953	100736430	20992773592	investigators	investigator	NN2
304953	100736430	20992773593	decided	decide	VVD_VVN
304953	100736430	20992773594	that	that	CST
304953	100736430	20992773595	they	they	PPHS2
304953	100736430	20992773596	might	might	VM
304953	100736430	20992773597	find	find	VVI
304953	100736430	20992773598	a	a	AT1
304953	100736430	20992773599	cure	cure	NN1
304953	100736430	20992773600	for	for	IF
304953	100736430	20992773601	cancer	cancer	NN1
304953	100736430	20992773602	more	more	RGR_RRR
304953	100736430	20992773603	quickly	quickly	RR
304953	100736430	20992773604	if	if	CS
304953	100736430	20992773605	they	they	PPHS2
304953	100736430	20992773606	collaborated	collaborate	VVD
304953	100736430	20992773607	on	on	II_RP@
304953	100736430	20992773608	clinical	clinical	JJ
304953	100736430	20992773609	trials	trial	NN2
304953	100736430	20992773610	.	.	.
304953	100736430	20992773611	They	they	PPHS2
304953	100736430	20992773612	started	start	VVD
304953	100736430	20992773613	cooperative	cooperative	JJ
304953	100736430	20992773614	groups	group	NN2
304953	100736430	20992773615	networks	network	NN2
304953	100736430	20992773616	of	of	IO
304953	100736430	20992773617	medical	medical	JJ
304953	100736430	20992773618	centers	center	NN2
304953	100736430	20992773619	,	,	,
304953	100736430	20992773620	universities	university	NN2
304953	100736430	20992773621	,	,	,
304953	100736430	20992773622	community	community	NN1
304953	100736430	20992773623	hospitals	hospital	NN2
304953	100736430	20992773624	,	,	,
304953	100736430	20992773625	oncologists	oncologist	NN2
304953	100736430	20992773626	,	,	,
304953	100736430	20992773627	laboratory	laboratory	NN1
304953	100736430	20992773628	scientists	scientist	NN2
304953	100736430	20992773629	,	,	,
304953	100736430	20992773630	statisticians	statistician	NN2
304953	100736430	20992773631	,	,	,
304953	100736430	20992773632	and	and	CC
304953	100736430	20992773633	administrators	administrator	NN2
304953	100736430	20992773634	to	to	TO
304953	100736430	20992773635	develop	develop	VVI
304953	100736430	20992773636	and	and	CC
304953	100736430	20992773637	sustain	sustain	VVI
304953	100736430	20992773638	trials	trial	NN2
304953	100736430	20992773639	.	.	.
304953	100736430	20992773640	The	the	AT
304953	100736430	20992773641	goal	goal	NN1
304953	100736430	20992773642	:	:	:
304953	100736430	20992773643	find	find	VV0
304953	100736430	20992773644	new	new	JJ
304953	100736430	20992773645	strategies	strategy	NN2
304953	100736430	20992773646	for	for	IF
304953	100736430	20992773647	the	the	AT
304953	100736430	20992773648	prevention	prevention	NN1
304953	100736430	20992773649	,	,	,
304953	100736430	20992773650	detection	detection	NN1
304953	100736430	20992773651	,	,	,
304953	100736430	20992773652	and	and	CC
304953	100736430	20992773653	treatment	treatment	NN1
304953	100736430	20992773654	of	of	IO
304953	100736430	20992773655	cancers	cancer	NN2
304953	100736430	20992773656	and	and	CC
304953	100736430	20992773657	improve	improve	VV0
304953	100736430	20992773658	understanding	understanding	NN1
304953	100736430	20992773659	of	of	IO
304953	100736430	20992773660	the	the	AT
304953	100736430	20992773661	biology	biology	NN1
304953	100736430	20992773662	of	of	IO
304953	100736430	20992773663	the	the	AT
304953	100736430	20992773664	disease	disease	NN1
304953	100736430	20992773665	.	.	.
304953	100736430	20992773666	Several	several	DA2
304953	100736430	20992773667	cooperative	cooperative	JJ
304953	100736430	20992773668	@		II
304953	100736430	20992773669	@		II
304953	100736430	20992773670	@		II
304953	100736430	20992773671	@		II
304953	100736430	20992773672	@		II
304953	100736430	20992773673	@		II
304953	100736430	20992773674	@		II
304953	100736430	20992773675	@		II
304953	100736430	20992773676	@		II
304953	100736430	20992773677	@		II
304953	100736430	20992773678	Europe	europe	NP1
304953	100736430	20992773679	,	,	,
304953	100736430	20992773680	including	including	II_VVG@
304953	100736430	20992773681	the	the	AT
304953	100736430	20992773682	Southwest	southwest	ND1
304953	100736430	20992773683	Oncology	oncology	NN1_NP1
304953	100736430	20992773684	Group	group	NN1
304953	100736430	20992773685	(	(	(
304953	100736430	20992773686	SWOG		NP1
304953	100736430	20992773687	)	)	)
304953	100736430	20992773688	,	,	,
304953	100736430	20992773689	Eastern	eastern	JJ
304953	100736430	20992773690	Cooperative	cooperative	JJ
304953	100736430	20992773691	Oncology	oncology	NN1
304953	100736430	20992773692	Group	group	NN1
304953	100736430	20992773693	(	(	(
304953	100736430	20992773694	ECOG	ecog	NP1
304953	100736430	20992773695	)	)	)
304953	100736430	20992773696	,	,	,
304953	100736430	20992773697	European	european	JJ
304953	100736430	20992773698	Organization	organization	NN1
304953	100736430	20992773699	for	for	IF
304953	100736430	20992773700	Research	research	NN1
304953	100736430	20992773701	and	and	CC
304953	100736430	20992773702	Treatment	treatment	NN1
304953	100736430	20992773703	of	of	IO
304953	100736430	20992773704	Cancer	cancer	NN1
304953	100736430	20992773705	(	(	(
304953	100736430	20992773706	EORTC		NP1
304953	100736430	20992773707	)	)	)
304953	100736430	20992773708	,	,	,
304953	100736430	20992773709	Cancer	cancer	NN1
304953	100736430	20992773710	and	and	CC
304953	100736430	20992773711	Leukemia	leukemia	NP1
304953	100736430	20992773712	Group	group	NN1
304953	100736430	20992773713	B	b	ZZ1
304953	100736430	20992773714	(	(	(
304953	100736430	20992773715	CALGB		NP1
304953	100736430	20992773716	)	)	)
304953	100736430	20992773717	,	,	,
304953	100736430	20992773718	and	and	CC
304953	100736430	20992773719	Radiation	radiation	NN1
304953	100736430	20992773720	Therapy	therapy	NN1
304953	100736430	20992773721	Oncology	oncology	NN1_NP1
304953	100736430	20992773722	Group	group	NN1
304953	100736430	20992773723	(	(	(
304953	100736430	20992773724	RTOG		NP1
304953	100736430	20992773725	)	)	)
304953	100736430	20992773726	.	.	.
304953	100736430	20992773727	<p>		NULL
304953	100736430	20992773728	At	at	II
304953	100736430	20992773729	the	the	AT
304953	100736430	20992773730	American	american	JJ
304953	100736430	20992773731	Urological	urological	JJ
304953	100736430	20992773732	Associations	association	NN2
304953	100736430	20992773733	annual	annual	JJ
304953	100736430	20992773734	meeting	meeting	NN1
304953	100736430	20992773735	in	in	II
304953	100736430	20992773736	May	may	NPM1
304953	100736430	20992773737	2008	2008	MC
304953	100736430	20992773738	,	,	,
304953	100736430	20992773739	Dr.		NNB
304953	100736430	20992773740	E.		NP1
304953	100736430	20992773741	David	david	NP1
304953	100736430	20992773742	Crawford	crawford	NP1
304953	100736430	20992773743	,	,	,
304953	100736430	20992773744	chairman	chairman	NN1
304953	100736430	20992773745	of	of	IO
304953	100736430	20992773746	SWOGs		NP2_NN2
304953	100736430	20992773747	Genitourinary	genitourinary	JJ_NN1
304953	100736430	20992773748	Committee	committee	NN1
304953	100736430	20992773749	since	since	II
304953	100736430	20992773750	1980	1980	MC
304953	100736430	20992773751	,	,	,
304953	100736430	20992773752	highlighted	highlight	VVD_VVN
304953	100736430	20992773753	some	some	DD
304953	100736430	20992773754	of	of	IO
304953	100736430	20992773755	the	the	AT
304953	100736430	20992773756	current	current	JJ
304953	100736430	20992773757	trials	trial	NN2
304953	100736430	20992773758	under	under	RR21
304953	100736430	20992773759	way	way	RR22
304953	100736430	20992773760	around	around	II_RP
304953	100736430	20992773761	the	the	AT
304953	100736430	20992773762	world	world	NN1
304953	100736430	20992773763	in	in	II
304953	100736430	20992773764	urologic	urologic	JJ
304953	100736430	20992773765	oncology	oncology	NN1
304953	100736430	20992773766	.	.	.
304953	100736430	20992773767	He	he	PPHS1
304953	100736430	20992773768	also	also	RR
304953	100736430	20992773769	spoke	speak	VVD
304953	100736430	20992773770	about	about	II
304953	100736430	20992773771	the	the	AT
304953	100736430	20992773772	need	need	NN1
304953	100736430	20992773773	to	to	TO
304953	100736430	20992773774	enroll	enroll	VVI
304953	100736430	20992773775	more	more	DAR
304953	100736430	20992773776	patients	patient	NN2
304953	100736430	20992773777	in	in	II
304953	100736430	20992773778	clinical	clinical	JJ
304953	100736430	20992773779	trials	trial	NN2
304953	100736430	20992773780	and	and	CC
304953	100736430	20992773781	the	the	AT
304953	100736430	20992773782	many	many	DA2
304953	100736430	20992773783	challenges	challenge	NN2
304953	100736430	20992773784	investigators	investigator	NN2
304953	100736430	20992773785	face	face	VV0
304953	100736430	20992773786	in	in	II_RP@
304953	100736430	20992773787	completing	complete	VVG
304953	100736430	20992773788	a	a	AT1
304953	100736430	20992773789	trial	trial	NN1
304953	100736430	20992773790	.	.	.
304953	100736430	20992773791	<p>		NULL
304953	100736430	20992773792	After	after	II
304953	100736430	20992773793	hearing	hear	VVG
304953	100736430	20992773794	his	his	APPGE
304953	100736430	20992773795	presentation	presentation	NN1
304953	100736430	20992773796	,	,	,
304953	100736430	20992773797	editors	editor	NN2
304953	100736430	20992773798	at	at	II
304953	100736430	20992773799	Harvard	harvard	NP1
304953	100736430	20992773800	Medical	medical	JJ
304953	100736430	20992773801	School	school	NN1
304953	100736430	20992773802	invited	invite	VVD
304953	100736430	20992773803	Dr.		NNB
304953	100736430	20992773804	Crawford	crawford	NP1
304953	100736430	20992773805	to	to	TO
304953	100736430	20992773806	share	share	VVI
304953	100736430	20992773807	his	his	APPGE
304953	100736430	20992773808	thoughts	thought	NN2
304953	100736430	20992773809	on	on	II
304953	100736430	20992773810	prostate	prostate	NN1
304953	100736430	20992773811	research	research	NN1
304953	100736430	20992773812	with	with	IW
304953	100736430	20992773813	readers	reader	NN2
304953	100736430	20992773814	.	.	.
304953	100736430	20992773815	In	in	II31
304953	100736430	20992773816	addition	addition	II32
304953	100736430	20992773817	to	to	II33
304953	100736430	20992773818	being	be	VBG
304953	100736430	20992773819	a	a	AT1
304953	100736430	20992773820	principal	principal	JJ_NN1
304953	100736430	20992773821	investigator	investigator	NN1
304953	100736430	20992773822	on	on	II
304953	100736430	20992773823	many	many	DA2
304953	100736430	20992773824	studies	study	NN2
304953	100736430	20992773825	that	that	CST
304953	100736430	20992773826	have	have	VH0
304953	100736430	20992773827	shaped	shape	VVN
304953	100736430	20992773828	our	our	APPGE
304953	100736430	20992773829	thinking	thinking	NN1
304953	100736430	20992773830	on	on	II
304953	100736430	20992773831	prostate	prostate	NN1
304953	100736430	20992773832	diseases	disease	NN2
304953	100736430	20992773833	,	,	,
304953	100736430	20992773834	Dr.		NNB
304953	100736430	20992773835	Crawford	crawford	NP1
304953	100736430	20992773836	is	be	VBZ
304953	100736430	20992773837	a	a	AT1
304953	100736430	20992773838	professor	professor	NN1
304953	100736430	20992773839	of	of	IO
304953	100736430	20992773840	surgery	surgery	NN1
304953	100736430	20992773841	,	,	,
304953	100736430	20992773842	urology	urology	NN1
304953	100736430	20992773843	,	,	,
304953	100736430	20992773844	and	and	CC
304953	100736430	20992773845	radiation	radiation	NN1
304953	100736430	20992773846	oncology	oncology	NN1
304953	100736430	20992773847	,	,	,
304953	100736430	20992773848	and	and	CC
304953	100736430	20992773849	senior	senior	JJ
304953	100736430	20992773850	associate	associate	JJ_NN1
304953	100736430	20992773851	director	director	NN1
304953	100736430	20992773852	of	of	IO
304953	100736430	20992773853	the	the	AT
304953	100736430	20992773854	Comprehensive	comprehensive	JJ
304953	100736430	20992773855	Cancer	cancer	NN1
304953	100736430	20992773856	Center	center	NN1
304953	100736430	20992773857	at	at	II
304953	100736430	20992773858	the	the	AT
304953	100736430	20992773859	University	university	NN1
304953	100736430	20992773860	of	of	IO
304953	100736430	20992773861	Colorado	colorado	NP1
304953	100736430	20992773862	Health	health	NN1
304953	100736430	20992773863	Sciences	science	NN2
304953	100736430	20992773864	Center	center	NN1
304953	100736430	20992773865	in	in	II
304953	100736430	20992773866	Denver	denver	NP1
304953	100736430	20992773867	.	.	.
304953	100736430	20992773868	@		II
304953	100736430	20992773869	@		II
304953	100736430	20992773870	@		II
304953	100736430	20992773871	@		II
304953	100736430	20992773872	@		II
304953	100736430	20992773873	@		II
304953	100736430	20992773874	@		II
304953	100736430	20992773875	@		II
304953	100736430	20992773876	@		II
304953	100736430	20992773877	@		II
304953	100736430	20992773878	an	a	AT1
304953	100736430	20992773879	interest	interest	NN1
304953	100736430	20992773880	in	in	II
304953	100736430	20992773881	SWOG		NP1_NN1
304953	100736430	20992773882	?	?	?
304953	100736430	20992773883	<p>		NULL
304953	100736430	20992773884	SWOG		NP1
304953	100736430	20992773885	began	begin	VVD
304953	100736430	20992773886	about	about	II
304953	100736430	20992773887	50	50	MC
304953	100736430	20992773888	years	year	NNT2
304953	100736430	20992773889	ago	ago	RA
304953	100736430	20992773890	as	as	II_CSA
304953	100736430	20992773891	a	a	AT1
304953	100736430	20992773892	leukemia	leukemia	NN1
304953	100736430	20992773893	study	study	NN1
304953	100736430	20992773894	group	group	NN1
304953	100736430	20992773895	.	.	.
304953	100736430	20992773896	It	it	PPH1
304953	100736430	20992773897	has	have	VHZ
304953	100736430	20992773898	evolved	evolve	VVN
304953	100736430	20992773899	into	into	II
304953	100736430	20992773900	a	a	AT1
304953	100736430	20992773901	multidisciplinary	multidisciplinary	JJ_NN1
304953	100736430	20992773902	group	group	NN1
304953	100736430	20992773903	that	that	CST
304953	100736430	20992773904	studies	study	NN2_VVZ%
304953	100736430	20992773905	melanoma	melanoma	NN1
304953	100736430	20992773906	,	,	,
304953	100736430	20992773907	leukemia	leukemia	NN1
304953	100736430	20992773908	,	,	,
304953	100736430	20992773909	and	and	CC
304953	100736430	20992773910	gastrointestinal	gastrointestinal	JJ
304953	100736430	20992773911	,	,	,
304953	100736430	20992773912	genitourinary	genitourinary	NN1_JJ
304953	100736430	20992773913	,	,	,
304953	100736430	20992773914	lung	lung	NN1
304953	100736430	20992773915	,	,	,
304953	100736430	20992773916	and	and	CC
304953	100736430	20992773917	breast	breast	NN1
304953	100736430	20992773918	cancers	cancer	NN2
304953	100736430	20992773919	.	.	.
304953	100736430	20992773920	We	we	PPIS2
304953	100736430	20992773921	also	also	RR
304953	100736430	20992773922	have	have	VH0
304953	100736430	20992773923	committees	committee	NN2
304953	100736430	20992773924	focused	focus	VVN
304953	100736430	20992773925	on	on	II
304953	100736430	20992773926	biology	biology	NN1
304953	100736430	20992773927	,	,	,
304953	100736430	20992773928	pathology	pathology	NN1
304953	100736430	20992773929	,	,	,
304953	100736430	20992773930	and	and	CC
304953	100736430	20992773931	translational	translational	JJ
304953	100736430	20992773932	medicine	medicine	NN1
304953	100736430	20992773933	,	,	,
304953	100736430	20992773934	which	which	DDQ
304953	100736430	20992773935	focuses	focus	VVZ
304953	100736430	20992773936	on	on	II_RP@
304953	100736430	20992773937	moving	move	VVG_JJ@
304953	100736430	20992773938	discoveries	discovery	NN2
304953	100736430	20992773939	from	from	II
304953	100736430	20992773940	the	the	AT
304953	100736430	20992773941	laboratory	laboratory	NN1
304953	100736430	20992773942	bench	bench	NN1
304953	100736430	20992773943	to	to	II
304953	100736430	20992773944	the	the	AT
304953	100736430	20992773945	bedside	bedside	NN1
304953	100736430	20992773946	and	and	CC
304953	100736430	20992773947	vice	vice	RR21
304953	100736430	20992773948	versa	versa	RR22
304953	100736430	20992773949	.	.	.
304953	100736430	20992773950	That 's		VVZ
304953	100736430	20992773951	an	a	AT1
304953	100736430	20992773952	area	area	NN1
304953	100736430	20992773953	of	of	IO
304953	100736430	20992773954	intense	intense	JJ
304953	100736430	20992773955	interest	interest	NN1
304953	100736430	20992773956	right	right	RR_NN1
304953	100736430	20992773957	now	now	RT
304953	100736430	20992773958	.	.	.
304953	100736430	20992773959	<p>		NULL
304953	100736430	20992773960	SWOGs		NP2_NN2_VVZ
304953	100736430	20992773961	mission	mission	NN1
304953	100736430	20992773962	is	be	VBZ
304953	100736430	20992773963	to	to	TO
304953	100736430	20992773964	ask	ask	VVI
304953	100736430	20992773965	and	and	CC
304953	100736430	20992773966	answer	answer	VVI
304953	100736430	20992773967	difficult	difficult	JJ
304953	100736430	20992773968	questions	question	NN2
304953	100736430	20992773969	through	through	II
304953	100736430	20992773970	clinical	clinical	JJ
304953	100736430	20992773971	trials	trial	NN2
304953	100736430	20992773972	to	to	TO
304953	100736430	20992773973	advance	advance	VVI
304953	100736430	20992773974	cancer	cancer	NN1
304953	100736430	20992773975	care	care	NN1
304953	100736430	20992773976	.	.	.
304953	100736430	20992773977	SWOG		NP1_NN1
304953	100736430	20992773978	has	have	VHZ
304953	100736430	20992773979	several	several	DA2
304953	100736430	20992773980	thousand	thousand	NNO
304953	100736430	20992773981	members	member	NN2
304953	100736430	20992773982	,	,	,
304953	100736430	20992773983	representing	represent	VVG
304953	100736430	20992773984	just	just	RR21
304953	100736430	20992773985	about	about	RR22
304953	100736430	20992773986	every	every	AT1
304953	100736430	20992773987	state	state	NN1
304953	100736430	20992773988	in	in	II
304953	100736430	20992773989	the	the	AT
304953	100736430	20992773990	United	united	NP1
304953	100736430	20992773991	States	state	NP1
304953	100736430	20992773992	and	and	CC
304953	100736430	20992773993	many	many	DA2
304953	100736430	20992773994	countries	country	NN2
304953	100736430	20992773995	around	around	II
304953	100736430	20992773996	the	the	AT
304953	100736430	20992773997	world	world	NN1
304953	100736430	20992773998	.	.	.
304953	100736430	20992773999	Members	member	NN2
304953	100736430	20992774000	include	include	VV0
304953	100736430	20992774001	physicians	physician	NN2
304953	100736430	20992774002	,	,	,
304953	100736430	20992774003	researchers	researcher	NN2
304953	100736430	20992774004	,	,	,
304953	100736430	20992774005	and	and	CC
304953	100736430	20992774006	clinical	clinical	JJ
304953	100736430	20992774007	investigators	investigator	NN2
304953	100736430	20992774008	who	who	PNQS
304953	100736430	20992774009	can	can	VM
304953	100736430	20992774010	enroll	enroll	VVI
304953	100736430	20992774011	patients	patient	NN2
304953	100736430	20992774012	in	in	II
304953	100736430	20992774013	studies	study	NN2
304953	100736430	20992774014	.	.	.
304953	100736430	20992774015	<p>		NULL
304953	100736430	20992774016	What	what	DDQ
304953	100736430	20992774017	are	be	VBR
304953	100736430	20992774018	some	some	DD
304953	100736430	20992774019	of	of	IO
304953	100736430	20992774020	the	the	AT
304953	100736430	20992774021	highlights	highlight	NN2
304953	100736430	20992774022	of	of	IO
304953	100736430	20992774023	SWOG		NN1_NP1
304953	100736430	20992774024	studies	study	NN2
304953	100736430	20992774025	in	in	RR21_II
304953	100736430	20992774026	general	general	RR22_JJ
304953	100736430	20992774027	and	and	CC
304953	100736430	20992774028	with	with	II31
304953	100736430	20992774029	respect	respect	II32
304953	100736430	20992774030	to	to	II33
304953	100736430	20992774031	prostate	prostate	NN1
304953	100736430	20992774032	cancer	cancer	NN1
304953	100736430	20992774033	?	?	?
304953	100736430	20992774034	How	how	RRQ
304953	100736430	20992774035	has	have	VHZ
304953	100736430	20992774036	SWOG		NN1_NP1
304953	100736430	20992774037	changed	change	VVN
304953	100736430	20992774038	urologic	urologic	JJ
304953	100736430	20992774039	practice	practice	NN1
304953	100736430	20992774040	?	?	?
304953	100736430	20992774041	<p>		NULL
304953	100736430	20992774042	Well	well	RR
304953	100736430	20992774043	,	,	,
304953	100736430	20992774044	I	i	PPIS1
304953	100736430	20992774045	think	think	VV0
304953	100736430	20992774046	the	the	AT
304953	100736430	20992774047	first	first	MD
304953	100736430	20992774048	highlight	highlight	NN1
304953	100736430	20992774049	has	have	VHZ
304953	100736430	20992774050	been	be	VBN
304953	100736430	20992774051	our	our	APPGE
304953	100736430	20992774052	ability	ability	NN1
304953	100736430	20992774053	to	to	TO
304953	100736430	20992774054	bring	bring	VVI
304953	100736430	20992774055	together	together	RL
304953	100736430	20992774056	a	a	AT1
304953	100736430	20992774057	strong	strong	JJ
304953	100736430	20992774058	multidisciplinary	multidisciplinary	JJ_NN1
304953	100736430	20992774059	team	team	NN1
304953	100736430	20992774060	,	,	,
304953	100736430	20992774061	including	including	II_VVG@
304953	100736430	20992774062	medical	medical	JJ
304953	100736430	20992774063	oncologists	oncologist	NN2
304953	100736430	20992774064	,	,	,
304953	100736430	20992774065	radiation	radiation	NN1
304953	100736430	20992774066	oncologists	oncologist	NN2
304953	100736430	20992774067	,	,	,
304953	100736430	20992774068	@		II
304953	100736430	20992774069	@		II
304953	100736430	20992774070	@		II
304953	100736430	20992774071	@		II
304953	100736430	20992774072	@		II
304953	100736430	20992774073	@		II
304953	100736430	20992774074	@		II
304953	100736430	20992774075	@		II
304953	100736430	20992774076	@		II
304953	100736430	20992774077	@		II
304953	100736430	20992774078	are	be	VBR
304953	100736430	20992774079	an	a	AT1
304953	100736430	20992774080	important	important	JJ
304953	100736430	20992774081	part	part	NN1
304953	100736430	20992774082	of	of	IO
304953	100736430	20992774083	the	the	AT
304953	100736430	20992774084	team	team	NN1
304953	100736430	20992774085	because	because	CS
304953	100736430	20992774086	they	they	PPHS2
304953	100736430	20992774087	often	often	RR
304953	100736430	20992774088	see	see	VV0
304953	100736430	20992774089	the	the	AT
304953	100736430	20992774090	patients	patient	NN2
304953	100736430	20992774091	first	first	MD
304953	100736430	20992774092	.	.	.
304953	100736430	20992774093	Theyve		NP1@_NN1
304953	100736430	20992774094	contributed	contribute	VVD
304953	100736430	20992774095	a	a	AT1_RR21@
304953	100736430	20992774096	lot	lot	NN1_RR22
304953	100736430	20992774097	to	to	II
304953	100736430	20992774098	prostate	prostate	NN1
304953	100736430	20992774099	research	research	NN1
304953	100736430	20992774100	over	over	II
304953	100736430	20992774101	the	the	AT
304953	100736430	20992774102	years	year	NNT2
304953	100736430	20992774103	.	.	.
304953	100736430	20992774104	Many	many	DA2
304953	100736430	20992774105	people	people	NN
304953	100736430	20992774106	in	in	II
304953	100736430	20992774107	the	the	AT
304953	100736430	20992774108	Southwest	southwest	ND1
304953	100736430	20992774109	Oncology	oncology	NN1_NP1
304953	100736430	20992774110	Group	group	NN1
304953	100736430	20992774111	have	have	VH0
304953	100736430	20992774112	made	make	VVN
304953	100736430	20992774113	significant	significant	JJ
304953	100736430	20992774114	contributions	contribution	NN2
304953	100736430	20992774115	to	to	II
304953	100736430	20992774116	our	our	APPGE
304953	100736430	20992774117	understanding	understanding	NN1
304953	100736430	20992774118	of	of	IO
304953	100736430	20992774119	prostate	prostate	NN1
304953	100736430	20992774120	cancer	cancer	NN1
304953	100736430	20992774121	and	and	CC
304953	100736430	20992774122	have	have	VH0
304953	100736430	20992774123	become	become	VVN@
304953	100736430	20992774124	internationally	internationally	RR
304953	100736430	20992774125	known	know	VVN
304953	100736430	20992774126	.	.	.
304953	100736430	20992774127	<p>		NULL
304953	100736430	20992774128	In	in	II
304953	100736430	20992774129	the	the	AT
304953	100736430	20992774130	area	area	NN1
304953	100736430	20992774131	of	of	IO
304953	100736430	20992774132	prostate	prostate	NN1
304953	100736430	20992774133	cancer	cancer	NN1
304953	100736430	20992774134	,	,	,
304953	100736430	20992774135	you 're		VV0
304953	100736430	20992774136	probably	probably	RR
304953	100736430	20992774137	very	very	RG
304953	100736430	20992774138	familiar	familiar	JJ
304953	100736430	20992774139	with	with	IW
304953	100736430	20992774140	the	the	AT
304953	100736430	20992774141	concept	concept	NN1
304953	100736430	20992774142	of	of	IO
304953	100736430	20992774143	combined	combined	JJ
304953	100736430	20992774144	androgen	androgen	NN1
304953	100736430	20992774145	blockade	blockade	NN1
304953	100736430	20992774146	.	.	.
304953	100736430	20992774147	Much	much	DA1
304953	100736430	20992774148	of	of	IO
304953	100736430	20992774149	what	what	DDQ
304953	100736430	20992774150	we	we	PPIS2
304953	100736430	20992774151	know	know	VV0
304953	100736430	20992774152	about	about	II
304953	100736430	20992774153	the	the	AT
304953	100736430	20992774154	combined	combined	JJ
304953	100736430	20992774155	androgen	androgen	NN1
304953	100736430	20992774156	blockade	blockade	NN1
304953	100736430	20992774157	comes	come	VVZ
304953	100736430	20992774158	from	from	II
304953	100736430	20992774159	a	a	AT1
304953	100736430	20992774160	study	study	NN1
304953	100736430	20992774161	we	we	PPIS2
304953	100736430	20992774162	did	do	VDD
304953	100736430	20992774163	that	that	DD1
304953	100736430	20992774164	was	be	VBDZ
304953	100736430	20992774165	published	publish	VVN
304953	100736430	20992774166	in	in	II
304953	100736430	20992774167	The	the	AT
304953	100736430	20992774168	New	new	NP1
304953	100736430	20992774169	England	england	NP1
304953	100736430	20992774170	Journal	journal	NN1
304953	100736430	20992774171	of	of	IO
304953	100736430	20992774172	Medicine.		NP1
304953	100736430	20992774173	*	*	FU
304953	100736430	20992774174	More	more	RRR
304953	100736430	20992774175	New	new	NP1
304953	100736430	20992774176	England	england	NP1
304953	100736430	20992774177	Journal	journal	NN1
304953	100736430	20992774178	of	of	IO
304953	100736430	20992774179	Medicine	medicine	NN1
304953	100736430	20992774180	studies	study	NN2
304953	100736430	20992774181	on	on	II
304953	100736430	20992774182	hormone	hormone	NN1
304953	100736430	20992774183	therapy	therapy	NN1
304953	100736430	20992774184	followed	follow	VVD_VVN
304953	100736430	20992774185	that	that	DD1_CST
304953	100736430	20992774186	first	first	MD
304953	100736430	20992774187	one	one	PN1
304953	100736430	20992774188	.	.	.
304953	100736430	20992774189	Our	our	APPGE
304953	100736430	20992774190	work	work	NN1
304953	100736430	20992774191	got	get	VVD_VVN
304953	100736430	20992774192	the	the	AT
304953	100736430	20992774193	anti-androgen	anti-androgen	JJ_NN1
304953	100736430	20992774194	flutamide		NN1
304953	100736430	20992774195	approved	approve	VVD_VVN
304953	100736430	20992774196	.	.	.
304953	100736430	20992774197	And	and	CC
304953	100736430	20992774198	we 've		VV0_NN1
304953	100736430	20992774199	also	also	RR
304953	100736430	20992774200	studied	study	VVD_VVN
304953	100736430	20992774201	the	the	AT
304953	100736430	20992774202	use	use	NN1
304953	100736430	20992774203	of	of	IO
304953	100736430	20992774204	chemotherapy	chemotherapy	NN1
304953	100736430	20992774205	prior	prior	II21
304953	100736430	20992774206	to	to	II22
304953	100736430	20992774207	surgery	surgery	NN1
304953	100736430	20992774208	.	.	.
304953	100736430	20992774209	<p>		NULL
304953	100736430	20992774210	Another	another	DD1
304953	100736430	20992774211	one	one	MC1
304953	100736430	20992774212	of	of	IO
304953	100736430	20992774213	the	the	AT
304953	100736430	20992774214	star	star	NN1_JJ@
304953	100736430	20992774215	trials	trial	NN2
304953	100736430	20992774216	that	that	CST
304953	100736430	20992774217	the	the	AT
304953	100736430	20992774218	Southwest	southwest	ND1
304953	100736430	20992774219	Oncology	oncology	NN1_NP1
304953	100736430	20992774220	Group	group	NN1
304953	100736430	20992774221	did	do	VDD
304953	100736430	20992774222	looked	look	VVN_VVD
304953	100736430	20992774223	at	at	II
304953	100736430	20992774224	the	the	AT
304953	100736430	20992774225	use	use	NN1
304953	100736430	20992774226	of	of	IO
304953	100736430	20992774227	finasteride	finasteride	NN1
304953	100736430	20992774228	in	in	II
304953	100736430	20992774229	preventing	prevent	VVG
304953	100736430	20992774230	prostate	prostate	NN1
304953	100736430	20992774231	cancer	cancer	NN1
304953	100736430	20992774232	.	.	.
304953	100736430	20992774233	In	in	II
304953	100736430	20992774234	the	the	AT
304953	100736430	20992774235	Prostate	prostate	NN1
304953	100736430	20992774236	Cancer	cancer	NN1
304953	100736430	20992774237	Prevention	prevention	NN1
304953	100736430	20992774238	Trial	trial	NN1
304953	100736430	20992774239	(	(	(
304953	100736430	20992774240	PCPT		NP1
304953	100736430	20992774241	)	)	)
304953	100736430	20992774242	,	,	,
304953	100736430	20992774243	we	we	PPIS2
304953	100736430	20992774244	showed	show	VVD
304953	100736430	20992774245	that	that	CST
304953	100736430	20992774246	the	the	AT
304953	100736430	20992774247	drug	drug	NN1
304953	100736430	20992774248	could	could	VM
304953	100736430	20992774249	reduce	reduce	VVI
304953	100736430	20992774250	the	the	AT
304953	100736430	20992774251	risk	risk	NN1
304953	100736430	20992774252	of	of	IO
304953	100736430	20992774253	cancer	cancer	NN1
304953	100736430	20992774254	by	by	II_RP%
304953	100736430	20992774255	about	about	RG
304953	100736430	20992774256	25%		NNU
304953	100736430	20992774257	.	.	.
304953	100736430	20992774258	But	but	CCB
304953	100736430	20992774259	because	because	CS
304953	100736430	20992774260	the	the	AT
304953	100736430	20992774261	initial	initial	JJ_NN1
304953	100736430	20992774262	analysis	analysis	NN1
304953	100736430	20992774263	of	of	IO
304953	100736430	20992774264	the	the	AT
304953	100736430	20992774265	data	data	NN
304953	100736430	20992774266	also	also	RR
304953	100736430	20992774267	indicated	indicate	VVD_VVN
304953	100736430	20992774268	@		II
304953	100736430	20992774269	@		II
304953	100736430	20992774270	@		II
304953	100736430	20992774271	@		II
304953	100736430	20992774272	@		II
304953	100736430	20992774273	@		II
304953	100736430	20992774274	@		II
304953	100736430	20992774275	@		II
304953	100736430	20992774276	@		II
304953	100736430	20992774277	@		II
304953	100736430	20992774278	a	a	AT1
304953	100736430	20992774279	subset	subset	NN1
304953	100736430	20992774280	of	of	IO
304953	100736430	20992774281	men	man	NN2
304953	100736430	20992774282	,	,	,
304953	100736430	20992774283	its	its	APPGE
304953	100736430	20992774284	use	use	NN1
304953	100736430	20992774285	for	for	IF
304953	100736430	20992774286	cancer	cancer	NN1
304953	100736430	20992774287	prevention	prevention	NN1
304953	100736430	20992774288	never	never	RR
304953	100736430	20992774289	caught	catch	VVN_VVD
304953	100736430	20992774290	on	on	RP@
304953	100736430	20992774291	.	.	.
304953	100736430	20992774292	<p>		NULL
304953	100736430	20992774293	As	as	CSA
304953	100736430	20992774294	you	you	PPY
304953	100736430	20992774295	know	know	VV0
304953	100736430	20992774296	,	,	,
304953	100736430	20992774297	we	we	PPIS2
304953	100736430	20992774298	went	go	VVD
304953	100736430	20992774299	back	back	RP
304953	100736430	20992774300	and	and	CC
304953	100736430	20992774301	did	do	VDD
304953	100736430	20992774302	a	a	AT1
304953	100736430	20992774303	new	new	JJ
304953	100736430	20992774304	analysis	analysis	NN1
304953	100736430	20992774305	of	of	IO
304953	100736430	20992774306	the	the	AT
304953	100736430	20992774307	data	data	NN
304953	100736430	20992774308	and	and	CC
304953	100736430	20992774309	prostate	prostate	NN1
304953	100736430	20992774310	tissue	tissue	NN1
304953	100736430	20992774311	samples	sample	NN2
304953	100736430	20992774312	.	.	.
304953	100736430	20992774313	In	in	II31
304953	100736430	20992774314	addition	addition	II32
304953	100736430	20992774315	to	to	II33
304953	100736430	20992774316	reducing	reduce	VVG
304953	100736430	20992774317	overall	overall	JJ_NN1
304953	100736430	20992774318	prostate	prostate	NN1
304953	100736430	20992774319	cancer	cancer	NN1
304953	100736430	20992774320	risk	risk	NN1_VV0
304953	100736430	20992774321	by	by	II
304953	100736430	20992774322	25%		NNU
304953	100736430	20992774323	to	to	II
304953	100736430	20992774324	30%		NNU
304953	100736430	20992774325	,	,	,
304953	100736430	20992774326	finasteride	finasteride	NN1
304953	100736430	20992774327	showed	show	VVD
304953	100736430	20992774328	no	no	AT
304953	100736430	20992774329	tendency	tendency	NN1
304953	100736430	20992774330	to	to	TO
304953	100736430	20992774331	increase	increase	VVI
304953	100736430	20992774332	the	the	AT
304953	100736430	20992774333	risk	risk	NN1
304953	100736430	20992774334	of	of	IO
304953	100736430	20992774335	high-grade	high-grade	JJ_NN1
304953	100736430	20992774336	tumors	tumor	NN2
304953	100736430	20992774337	.	.	.
304953	100736430	20992774338	In	in	II
304953	100736430	20992774339	fact	fact	NN1
304953	100736430	20992774340	,	,	,
304953	100736430	20992774341	it	it	PPH1
304953	100736430	20992774342	decreased	decrease	VVD
304953	100736430	20992774343	the	the	AT
304953	100736430	20992774344	rate	rate	NN1
304953	100736430	20992774345	of	of	IO
304953	100736430	20992774346	aggressive	aggressive	JJ
304953	100736430	20992774347	tumors	tumor	NN2
304953	100736430	20992774348	by	by	II
304953	100736430	20992774349	27%		NNU
304953	100736430	20992774350	.	.	.
304953	100736430	20992774351	There 's		NN2_NP1@
304953	100736430	20992774352	nothing	nothing	PN1
304953	100736430	20992774353	else	else	RR
304953	100736430	20992774354	out	out	RP
304953	100736430	20992774355	there	there	RL
304953	100736430	20992774356	that	that	CST_DD1
304953	100736430	20992774357	comes	come	VVZ
304953	100736430	20992774358	close	close	RR_JJ
304953	100736430	20992774359	to	to	II
304953	100736430	20992774360	that	that	DD1
304953	100736430	20992774361	.	.	.
304953	100736430	20992774362	<p>		NULL
304953	100736430	20992774363	What	what	DDQ
304953	100736430	20992774364	"	"	"
304953	100736430	20992774365	caused	cause	VVD
304953	100736430	20992774366	"	"	"
304953	100736430	20992774367	the	the	AT
304953	100736430	20992774368	aggressive	aggressive	JJ
304953	100736430	20992774369	tumors	tumor	NN2
304953	100736430	20992774370	in	in	II
304953	100736430	20992774371	the	the	AT
304953	100736430	20992774372	first	first	MD
304953	100736430	20992774373	analysis	analysis	NN1
304953	100736430	20992774374	of	of	IO
304953	100736430	20992774375	the	the	AT
304953	100736430	20992774376	PCPT		NP1
304953	100736430	20992774377	data	data	NN
304953	100736430	20992774378	?	?	?
304953	100736430	20992774379	Why	why	RRQ
304953	100736430	20992774380	the	the	AT
304953	100736430	20992774381	discrepancy	discrepancy	NN1
304953	100736430	20992774382	between	between	II
304953	100736430	20992774383	the	the	AT
304953	100736430	20992774384	initial	initial	JJ_NN1
304953	100736430	20992774385	findings	finding	NN2
304953	100736430	20992774386	and	and	CC
304953	100736430	20992774387	the	the	AT
304953	100736430	20992774388	recent	recent	JJ
304953	100736430	20992774389	results	result	NN2
304953	100736430	20992774390	?	?	?
304953	100736430	20992774391	<p>		NULL
304953	100736430	20992774392	If	if	CS
304953	100736430	20992774393	you	you	PPY
304953	100736430	20992774394	put	put	VV0_VVD
304953	100736430	20992774395	six	six	MC
304953	100736430	20992774396	needles	needle	NN2
304953	100736430	20992774397	in	in	II
304953	100736430	20992774398	a	a	AT1
304953	100736430	20992774399	prostate	prostate	NN1
304953	100736430	20992774400	for	for	IF
304953	100736430	20992774401	a	a	AT1
304953	100736430	20992774402	biopsy	biopsy	NN1
304953	100736430	20992774403	,	,	,
304953	100736430	20992774404	you 're		VV0
304953	100736430	20992774405	more	more	RGR_DAR
304953	100736430	20992774406	likely	likely	JJ
304953	100736430	20992774407	to	to	TO
304953	100736430	20992774408	find	find	VVI
304953	100736430	20992774409	cancer	cancer	NN1
304953	100736430	20992774410	in	in	II
304953	100736430	20992774411	a	a	AT1
304953	100736430	20992774412	smaller	small	JJR
304953	100736430	20992774413	prostate	prostate	NN1
304953	100736430	20992774414	than	than	CSN
304953	100736430	20992774415	in	in	II
304953	100736430	20992774416	a	a	AT1
304953	100736430	20992774417	larger	large	JJR
304953	100736430	20992774418	prostate	prostate	NN1
304953	100736430	20992774419	.	.	.
304953	100736430	20992774420	Because	because	CS
304953	100736430	20992774421	finasteride	finasteride	NN1
304953	100736430	20992774422	shrinks	shrink	VVZ
304953	100736430	20992774423	the	the	AT
304953	100736430	20992774424	prostate	prostate	NN1
304953	100736430	20992774425	,	,	,
304953	100736430	20992774426	you	you	PPY
304953	100736430	20992774427	have	have	VH0
304953	100736430	20992774428	a	a	AT1
304953	100736430	20992774429	higher	high	JJR
304953	100736430	20992774430	chance	chance	NN1
304953	100736430	20992774431	of	of	IO
304953	100736430	20992774432	detecting	detect	VVG
304953	100736430	20992774433	cancer	cancer	NN1
304953	100736430	20992774434	including	including	II
304953	100736430	20992774435	high-grade	high-grade	JJ_NN1
304953	100736430	20992774436	cancer	cancer	NN1
304953	100736430	20992774437	in	in	II
304953	100736430	20992774438	men	man	NN2
304953	100736430	20992774439	who	who	PNQS
304953	100736430	20992774440	take	take	VV0
304953	100736430	20992774441	it	it	PPH1
304953	100736430	20992774442	compared	compare	VVN_VVD@
304953	100736430	20992774443	with	with	IW
304953	100736430	20992774444	men	man	NN2
304953	100736430	20992774445	who	who	PNQS
304953	100736430	20992774446	have	have	VH0
304953	100736430	20992774447	larger	large	JJR
304953	100736430	20992774448	prostates	prostate	NN2
304953	100736430	20992774449	and	and	CC
304953	100736430	20992774450	do	do	VD0
304953	100736430	20992774451	n't 	n't	XX
304953	100736430	20992774452	take	take	VVI
304953	100736430	20992774453	the	the	AT
304953	100736430	20992774454	drug	drug	NN1
304953	100736430	20992774455	.	.	.
304953	100736430	20992774456	Its	its	APPGE
304953	100736430	20992774457	like	like	NN1%_JJ@_II
304953	100736430	20992774458	looking	look	VVG
304953	100736430	20992774459	for	for	IF
304953	100736430	20992774460	oil	oil	NN1
304953	100736430	20992774461	:	:	:
304953	100736430	20992774462	if	if	CS
304953	100736430	20992774463	you	you	PPY
304953	100736430	20992774464	can	can	VM_VV0%
304953	100736430	20992774465	narrow	narrow	VVI
304953	100736430	20992774466	your	your	APPGE
304953	100736430	20992774467	search	search	NN1
304953	100736430	20992774468	@		II
304953	100736430	20992774469	@		II
304953	100736430	20992774470	@		II
304953	100736430	20992774471	@		II
304953	100736430	20992774472	@		II
304953	100736430	20992774473	@		II
304953	100736430	20992774474	@		II
304953	100736430	20992774475	@		II
304953	100736430	20992774476	@		II
304953	100736430	20992774477	@		II
304953	100736430	20992774478	to	to	TO
304953	100736430	20992774479	find	find	VVI
304953	100736430	20992774480	it	it	PPH1
304953	100736430	20992774481	.	.	.
304953	100736430	20992774482	<p>		NULL
304953	100736430	20992774483	Also	also	RR
304953	100736430	20992774484	,	,	,
304953	100736430	20992774485	finasteride	finasteride	NN1
304953	100736430	20992774486	takes	take	VVZ
304953	100736430	20992774487	BPH	bph	NP1
304953	100736430	20992774488	out	out	II21
304953	100736430	20992774489	of	of	II22
304953	100736430	20992774490	the	the	AT
304953	100736430	20992774491	picture	picture	NN1
304953	100736430	20992774492	.	.	.
304953	100736430	20992774493	When	when	RRQ_CS
304953	100736430	20992774494	men	man	NN2
304953	100736430	20992774495	take	take	VV0
304953	100736430	20992774496	it	it	PPH1
304953	100736430	20992774497	,	,	,
304953	100736430	20992774498	their	their	APPGE
304953	100736430	20992774499	PSA	psa	NP1
304953	100736430	20992774500	should	should	VM
304953	100736430	20992774501	drop	drop	VVI
304953	100736430	20992774502	by	by	II
304953	100736430	20992774503	half	half	DB_NN1@
304953	100736430	20992774504	.	.	.
304953	100736430	20992774505	If	if	CS
304953	100736430	20992774506	it	it	PPH1
304953	100736430	20992774507	does	do	VDZ
304953	100736430	20992774508	n't 	n't	XX
304953	100736430	20992774509	,	,	,
304953	100736430	20992774510	you 're		VV0_NN1
304953	100736430	20992774511	going	go	VVG
304953	100736430	20992774512	to	to	TO
304953	100736430	20992774513	have	have	VHI
304953	100736430	20992774514	a	a	AT1
304953	100736430	20992774515	higher	high	JJR
304953	100736430	20992774516	chance	chance	NN1
304953	100736430	20992774517	of	of	IO
304953	100736430	20992774518	detecting	detect	VVG
304953	100736430	20992774519	cancer	cancer	NN1
304953	100736430	20992774520	.	.	.
304953	100736430	20992774521	In	in	II
304953	100736430	20992774522	my	my	APPGE
304953	100736430	20992774523	mind	mind	NN1
304953	100736430	20992774524	,	,	,
304953	100736430	20992774525	there 's		NN2
304953	100736430	20992774526	no	no	AT
304953	100736430	20992774527	discrepancy	discrepancy	NN1
304953	100736430	20992774528	,	,	,
304953	100736430	20992774529	but	but	CCB
304953	100736430	20992774530	not	not	XX
304953	100736430	20992774531	everybodys	everybody	NN2
304953	100736430	20992774532	convinced	convinced	JJ_VVN@_VVD@
304953	100736430	20992774533	of	of	IO
304953	100736430	20992774534	that	that	DD1
304953	100736430	20992774535	.	.	.
304953	100736430	20992774536	<p>		NULL
304953	100736430	20992774537	Do	do	VD0
304953	100736430	20992774538	you	you	PPY
304953	100736430	20992774539	prescribe	prescribe	VVI
304953	100736430	20992774540	finasteride	finasteride	NN1_VV0
304953	100736430	20992774541	for	for	IF
304953	100736430	20992774542	all	all	DB
304953	100736430	20992774543	of	of	IO
304953	100736430	20992774544	your	your	APPGE
304953	100736430	20992774545	patients	patient	NN2
304953	100736430	20992774546	?	?	?
304953	100736430	20992774547	<p>		NULL
304953	100736430	20992774548	No	no	UH
304953	100736430	20992774549	,	,	,
304953	100736430	20992774550	I	i	PPIS1
304953	100736430	20992774551	do	do	VD0
304953	100736430	20992774552	n't 	n't	XX
304953	100736430	20992774553	.	.	.
304953	100736430	20992774554	Nobody	nobody	PN1
304953	100736430	20992774555	does	do	VDZ
304953	100736430	20992774556	.	.	.
304953	100736430	20992774557	Finasteride		VV0_NN1_NP1@
304953	100736430	20992774558	and	and	CC
304953	100736430	20992774559	dutasteride		NN1_VV0
304953	100736430	20992774560	,	,	,
304953	100736430	20992774561	which	which	DDQ
304953	100736430	20992774562	belong	belong	VV0
304953	100736430	20992774563	to	to	II
304953	100736430	20992774564	a	a	AT1
304953	100736430	20992774565	class	class	NN1
304953	100736430	20992774566	of	of	IO
304953	100736430	20992774567	drugs	drug	NN2
304953	100736430	20992774568	called	call	VVN_VVD@
304953	100736430	20992774569	5-alpha-reductase		JJ_NN1
304953	100736430	20992774570	inhibitors	inhibitor	NN2
304953	100736430	20992774571	,	,	,
304953	100736430	20992774572	are	be	VBR
304953	100736430	20992774573	wonderful	wonderful	JJ
304953	100736430	20992774574	drugs	drug	NN2
304953	100736430	20992774575	.	.	.
304953	100736430	20992774576	They	they	PPHS2
304953	100736430	20992774577	can	can	VM
304953	100736430	20992774578	help	help	VVI
304953	100736430	20992774579	men	man	NN2
304953	100736430	20992774580	keep	keep	VVI
304953	100736430	20992774581	their	their	APPGE
304953	100736430	20992774582	hair	hair	NN1
304953	100736430	20992774583	,	,	,
304953	100736430	20992774584	*	*	FU
304953	100736430	20992774585	prevent	prevent	VV0
304953	100736430	20992774586	BPH	bph	NP1
304953	100736430	20992774587	from	from	II
304953	100736430	20992774588	progressing	progress	VVG
304953	100736430	20992774589	and	and	CC
304953	100736430	20992774590	ease	ease	VV0
304953	100736430	20992774591	its	its	APPGE
304953	100736430	20992774592	symptoms	symptom	NN2
304953	100736430	20992774593	,	,	,
304953	100736430	20992774594	and	and	CC
304953	100736430	20992774595	reduce	reduce	VV0
304953	100736430	20992774596	the	the	AT
304953	100736430	20992774597	risk	risk	NN1
304953	100736430	20992774598	of	of	IO
304953	100736430	20992774599	prostate	prostate	NN1
304953	100736430	20992774600	cancer	cancer	NN1
304953	100736430	20992774601	.	.	.
304953	100736430	20992774602	But	but	CCB
304953	100736430	20992774603	men	man	NN2
304953	100736430	20992774604	are	be	VB0
304953	100736430	20992774605	n't 	n't	XX
304953	100736430	20992774606	going	go	VVGK
304953	100736430	20992774607	to	to	TO
304953	100736430	20992774608	go	go	VVI
304953	100736430	20992774609	on	on	II
304953	100736430	20992774610	them	them	PPHO2
304953	100736430	20992774611	wholesale	wholesale	JJ_RR@
304953	100736430	20992774612	.	.	.
304953	100736430	20992774613	I	i	PPIS1
304953	100736430	20992774614	discuss	discuss	VV0
304953	100736430	20992774615	these	these	DD2
304953	100736430	20992774616	drugs	drug	NN2
304953	100736430	20992774617	with	with	IW
304953	100736430	20992774618	men	man	NN2
304953	100736430	20992774619	who	who	PNQS
304953	100736430	20992774620	are	be	VBR
304953	100736430	20992774621	over	over	RG
304953	100736430	20992774622	50	50	MC
304953	100736430	20992774623	,	,	,
304953	100736430	20992774624	have	have	VH0
304953	100736430	20992774625	a	a	AT1
304953	100736430	20992774626	family	family	NN1
304953	100736430	20992774627	history	history	NN1
304953	100736430	20992774628	of	of	IO
304953	100736430	20992774629	prostate	prostate	NN1
304953	100736430	20992774630	cancer	cancer	NN1
304953	100736430	20992774631	,	,	,
304953	100736430	20992774632	or	or	CC
304953	100736430	20992774633	have	have	VH0
304953	100736430	20992774634	urinary	urinary	JJ
304953	100736430	20992774635	symptoms	symptom	NN2
304953	100736430	20992774636	.	.	.
304953	100736430	20992774637	<p>		NULL
304953	100736430	20992774638	In	in	II
304953	100736430	20992774639	the	the	AT
304953	100736430	20992774640	PCPT		NP1
304953	100736430	20992774641	,	,	,
304953	100736430	20992774642	we	we	PPIS2
304953	100736430	20992774643	gathered	gather	VVD
304953	100736430	20992774644	a	a	AT1
304953	100736430	20992774645	wealth	wealth	NN1
304953	100736430	20992774646	of	of	IO
304953	100736430	20992774647	data	data	NN
304953	100736430	20992774648	,	,	,
304953	100736430	20992774649	including	include	VVG@_II
304953	100736430	20992774650	lots	lots	PN
304953	100736430	20992774651	of	of	IO
304953	100736430	20992774652	blood	blood	NN1
304953	100736430	20992774653	and	and	CC
304953	100736430	20992774654	tissue	tissue	NN1
304953	100736430	20992774655	samples	sample	NN2
304953	100736430	20992774656	.	.	.
304953	100736430	20992774657	Using	use	VVG
304953	100736430	20992774658	that	that	CST_DD1
304953	100736430	20992774659	data	data	NN
304953	100736430	20992774660	,	,	,
304953	100736430	20992774661	I	i	PPIS1
304953	100736430	20992774662	think	think	VV0
304953	100736430	20992774663	we	we	PPIS2
304953	100736430	20992774664	will	will	VM
304953	100736430	20992774665	be	be	VBI
304953	100736430	20992774666	able	able	JK
304953	100736430	20992774667	to	to	TO
304953	100736430	20992774668	@		II
304953	100736430	20992774669	@		II
304953	100736430	20992774670	@		II
304953	100736430	20992774671	@		II
304953	100736430	20992774672	@		II
304953	100736430	20992774673	@		II
304953	100736430	20992774674	@		II
304953	100736430	20992774675	@		II
304953	100736430	20992774676	@		II
304953	100736430	20992774677	@		II
304953	100736430	20992774678	will	will	VM
304953	100736430	20992774679	benefit	benefit	VVI
304953	100736430	20992774680	from	from	II
304953	100736430	20992774681	the	the	AT
304953	100736430	20992774682	drug	drug	NN1
304953	100736430	20992774683	.	.	.
304953	100736430	20992774684	<p>		NULL
304953	100736430	20992774685	*Note	*note	FO
304953	100736430	20992774686	:	:	:
304953	100736430	20992774687	The	the	AT
304953	100736430	20992774688	hair-loss	hair-loss	JJ_NN1
304953	100736430	20992774689	drug	drug	NN1
304953	100736430	20992774690	Propecia	propecia	NP1_NN1@
304953	100736430	20992774691	contains	contain	VVZ
304953	100736430	20992774692	a	a	AT1
304953	100736430	20992774693	low	low	JJ
304953	100736430	20992774694	dose	dose	NN1
304953	100736430	20992774695	of	of	IO
304953	100736430	20992774696	finasteride	finasteride	NN1
304953	100736430	20992774697	.	.	.
304953	100736430	20992774698	Physicians	physician	NN2
304953	100736430	20992774699	prescribe	prescribe	VV0
304953	100736430	20992774700	higher	high	JJR
304953	100736430	20992774701	doses	dose	NN2
304953	100736430	20992774702	of	of	IO
304953	100736430	20992774703	finasteride	finasteride	NN1
304953	100736430	20992774704	(	(	(
304953	100736430	20992774705	Proscar	proscar	NP1
304953	100736430	20992774706	)	)	)
304953	100736430	20992774707	for	for	IF
304953	100736430	20992774708	the	the	AT
304953	100736430	20992774709	treatment	treatment	NN1
304953	100736430	20992774710	of	of	IO
304953	100736430	20992774711	BPH	bph	NP1
304953	100736430	20992774712	,	,	,
304953	100736430	20992774713	also	also	RR
304953	100736430	20992774714	called	call	VVN
304953	100736430	20992774715	an	a	AT1
304953	100736430	20992774716	enlarged	enlarged	JJ
304953	100736430	20992774717	prostate	prostate	NN1
304953	100736430	20992774718	.	.	.
304953	100736430	20992774719	The	the	AT
304953	100736430	20992774720	PCPT		NP1
304953	100736430	20992774721	did	do	VDD
304953	100736430	20992774722	not	not	XX
304953	100736430	20992774723	specifically	specifically	RR
304953	100736430	20992774724	look	look	VVI
304953	100736430	20992774725	at	at	II
304953	100736430	20992774726	hair	hair	NN1
304953	100736430	20992774727	loss	loss	NN1
304953	100736430	20992774728	,	,	,
304953	100736430	20992774729	but	but	CCB
304953	100736430	20992774730	researchers	researcher	NN2
304953	100736430	20992774731	suspect	suspect	VV0
304953	100736430	20992774732	that	that	CST
304953	100736430	20992774733	the	the	AT
304953	100736430	20992774734	finasteride	finasteride	NN1
304953	100736430	20992774735	in	in	II
304953	100736430	20992774736	Proscar	proscar	NP1
304953	100736430	20992774737	regrows	regrow	VVZ
304953	100736430	20992774738	hair	hair	NN1
304953	100736430	20992774739	,	,	,
304953	100736430	20992774740	or	or	CC
304953	100736430	20992774741	prevents	prevent	VVZ
304953	100736430	20992774742	further	far	JJR@_RRR
304953	100736430	20992774743	hair	hair	NN1
304953	100736430	20992774744	loss	loss	NN1
304953	100736430	20992774745	,	,	,
304953	100736430	20992774746	like	like	II
304953	100736430	20992774747	Propecia	propecia	NP1
304953	100736430	20992774748	does	do	VDZ
304953	100736430	20992774749	.	.	.
304953	100736430	20992774750	<p>		NULL
304953	100736430	20992774751	How	how	RRQ
304953	100736430	20992774752	are	be	VBR
304953	100736430	20992774753	you	you	PPY
304953	100736430	20992774754	going	go	VVG
304953	100736430	20992774755	to	to	TO
304953	100736430	20992774756	do	do	VDI
304953	100736430	20992774757	that	that	DD1
304953	100736430	20992774758	?	?	?
304953	100736430	20992774759	<p>		NULL
304953	100736430	20992774760	There	there	EX
304953	100736430	20992774761	are	be	VBR
304953	100736430	20992774762	new	new	JJ
304953	100736430	20992774763	markers	marker	NN2
304953	100736430	20992774764	coming	come	VVG
304953	100736430	20992774765	out	out	RP
304953	100736430	20992774766	.	.	.
304953	100736430	20992774767	You	you	PPY
304953	100736430	20992774768	could	could	VM
304953	100736430	20992774769	have	have	VHI
304953	100736430	20992774770	a	a	AT1
304953	100736430	20992774771	molecular	molecular	JJ
304953	100736430	20992774772	chromosomal	chromosomal	JJ
304953	100736430	20992774773	profile	profile	NN1
304953	100736430	20992774774	to	to	TO
304953	100736430	20992774775	determine	determine	VVI
304953	100736430	20992774776	prostate	prostate	NN1
304953	100736430	20992774777	cancer	cancer	NN1
304953	100736430	20992774778	risk	risk	NN1
304953	100736430	20992774779	.	.	.
304953	100736430	20992774780	Some	some	DD
304953	100736430	20992774781	people	people	NN
304953	100736430	20992774782	are	be	VBR
304953	100736430	20992774783	doing	do	VDG
304953	100736430	20992774784	that	that	DD1
304953	100736430	20992774785	now	now	RT
304953	100736430	20992774786	,	,	,
304953	100736430	20992774787	but	but	CCB
304953	100736430	20992774788	I	i	PPIS1
304953	100736430	20992774789	do	do	VD0
304953	100736430	20992774790	n't 	n't	XX
304953	100736430	20992774791	know	know	VVI
304953	100736430	20992774792	how	how	RGQ@_RRQ
304953	100736430	20992774793	accurate	accurate	JJ
304953	100736430	20992774794	it	it	PPH1
304953	100736430	20992774795	is	be	VBZ
304953	100736430	20992774796	.	.	.
304953	100736430	20992774797	Well	well	RR
304953	100736430	20992774798	put	put	VVD_VV0_VVN
304953	100736430	20992774799	PSA	psa	NP1
304953	100736430	20992774800	,	,	,
304953	100736430	20992774801	family	family	NN1
304953	100736430	20992774802	history	history	NN1
304953	100736430	20992774803	,	,	,
304953	100736430	20992774804	molecular	molecular	JJ
304953	100736430	20992774805	information	information	NN1
304953	100736430	20992774806	,	,	,
304953	100736430	20992774807	and	and	CC
304953	100736430	20992774808	a	a	AT1
304953	100736430	20992774809	bunch	bunch	NN1
304953	100736430	20992774810	of	of	IO
304953	100736430	20992774811	other	other	JJ
304953	100736430	20992774812	factors	factor	NN2
304953	100736430	20992774813	into	into	II
304953	100736430	20992774814	a	a	AT1
304953	100736430	20992774815	risk	risk	NN1
304953	100736430	20992774816	calculator	calculator	NN1
304953	100736430	20992774817	.	.	.
304953	100736430	20992774818	Were	be	VBDR
304953	100736430	20992774819	not	not	XX
304953	100736430	20992774820	there	there	RL
304953	100736430	20992774821	yet	yet	RR
304953	100736430	20992774822	,	,	,
304953	100736430	20992774823	but	but	CCB
304953	100736430	20992774824	I	i	PPIS1
304953	100736430	20992774825	think	think	VV0
304953	100736430	20992774826	well	well	RR
304953	100736430	20992774827	be	be	VBI
304953	100736430	20992774828	able	able	JK
304953	100736430	20992774829	to	to	TO
304953	100736430	20992774830	tell	tell	VVI
304953	100736430	20992774831	a	a	AT1
304953	100736430	20992774832	patient	patient	NN1_JJ
304953	100736430	20992774833	,	,	,
304953	100736430	20992774834	"	"	"
304953	100736430	20992774835	Heres		NN2_NP1
304953	100736430	20992774836	what	what	DDQ
304953	100736430	20992774837	your	your	APPGE
304953	100736430	20992774838	risk	risk	NN1
304953	100736430	20992774839	is	be	VBZ
304953	100736430	20992774840	,	,	,
304953	100736430	20992774841	"	"	"
304953	100736430	20992774842	and	and	CC
304953	100736430	20992774843	determine	determine	VV0
304953	100736430	20992774844	when	when	RRQ_CS
304953	100736430	20992774845	it	it	PPH1
304953	100736430	20992774846	would	would	VM
304953	100736430	20992774847	be	be	VBI
304953	100736430	20992774848	appropriate	appropriate	JJ
304953	100736430	20992774849	for	for	IF
304953	100736430	20992774850	him	him	PPHO1
304953	100736430	20992774851	to	to	TO
304953	100736430	20992774852	go	go	VVI
304953	100736430	20992774853	on	on	II_RP@
304953	100736430	20992774854	a	a	AT1
304953	100736430	20992774855	5-alpha-reductase		JJ_NN1
304953	100736430	20992774856	inhibitor	inhibitor	NN1
304953	100736430	20992774857	like	like	II
304953	100736430	20992774858	finasteride	finasteride	NN1
304953	100736430	20992774859	or	or	CC
304953	100736430	20992774860	dutasteride		NN1_VV0
304953	100736430	20992774861	.	.	.
304953	100736430	20992774862	<p>		NULL
304953	100736430	20992774863	Do	do	VD0
304953	100736430	20992774864	you	you	PPY
304953	100736430	20992774865	receive	receive	VVI
304953	100736430	20992774866	requests	request	NN2
304953	100736430	20992774867	to	to	TO
304953	100736430	20992774868	@		II
304953	100736430	20992774869	@		II
304953	100736430	20992774870	@		II
304953	100736430	20992774871	@		II
304953	100736430	20992774872	@		II
304953	100736430	20992774873	@		II
304953	100736430	20992774874	@		II
304953	100736430	20992774875	@		II
304953	100736430	20992774876	@		II
304953	100736430	20992774877	@		II
304953	100736430	20992774878	<p>		NULL
304953	100736430	20992774879	We	we	PPIS2
304953	100736430	20992774880	do	do	VD0
304953	100736430	20992774881	receive	receive	VVI
304953	100736430	20992774882	requests	request	NN2
304953	100736430	20992774883	.	.	.
304953	100736430	20992774884	How	how	RRQ
304953	100736430	20992774885	do	do	VD0
304953	100736430	20992774886	we	we	PPIS2
304953	100736430	20992774887	sort	sort	VVI
304953	100736430	20992774888	them	them	PPHO2
304953	100736430	20992774889	out	out	RP
304953	100736430	20992774890	?	?	?
304953	100736430	20992774891	Its	its	APPGE
304953	100736430	20992774892	a	a	AT1
304953	100736430	20992774893	democratic	democratic	JJ
304953	100736430	20992774894	system	system	NN1
304953	100736430	20992774895	in	in	CS21%_II
304953	100736430	20992774896	that	that	CS22@_DD1
304953	100736430	20992774897	the	the	AT
304953	100736430	20992774898	information	information	NN1
304953	100736430	20992774899	is	be	VBZ
304953	100736430	20992774900	passed	pass	VVN
304953	100736430	20992774901	around	around	RP
304953	100736430	20992774902	and	and	CC
304953	100736430	20992774903	discussed	discuss	VVN
304953	100736430	20992774904	.	.	.
304953	100736430	20992774905	Things	thing	NN2
304953	100736430	20992774906	have	have	VH0
304953	100736430	20992774907	a	a	AT1
304953	100736430	20992774908	way	way	NN1
304953	100736430	20992774909	of	of	IO
304953	100736430	20992774910	either	either	RR
304953	100736430	20992774911	smelling	smell	VVG
304953	100736430	20992774912	good	good	JJ
304953	100736430	20992774913	or	or	CC
304953	100736430	20992774914	smelling	smell	VVG
304953	100736430	20992774915	bad	bad	JJ
304953	100736430	20992774916	.	.	.
304953	100736430	20992774917	Something	something	PN1
304953	100736430	20992774918	may	may	VM
304953	100736430	20992774919	sound	sound	VVI
304953	100736430	20992774920	like	like	II
304953	100736430	20992774921	a	a	AT1
304953	100736430	20992774922	great	great	JJ
304953	100736430	20992774923	idea	idea	NN1
304953	100736430	20992774924	at	at	RR21
304953	100736430	20992774925	first	first	RR22
304953	100736430	20992774926	,	,	,
304953	100736430	20992774927	but	but	CCB
304953	100736430	20992774928	once	once	CS@_RR
304953	100736430	20992774929	it	it	PPH1
304953	100736430	20992774930	gets	get	VVZ
304953	100736430	20992774931	circulated	circulate	VVN
304953	100736430	20992774932	and	and	CC
304953	100736430	20992774933	people	people	NN
304953	100736430	20992774934	talk	talk	VV0_NN1
304953	100736430	20992774935	about	about	II
304953	100736430	20992774936	what	what	DDQ
304953	100736430	20992774937	the	the	AT
304953	100736430	20992774938	challenges	challenge	NN2
304953	100736430	20992774939	will	will	VM
304953	100736430	20992774940	be	be	VBI
304953	100736430	20992774941	,	,	,
304953	100736430	20992774942	you	you	PPY
304953	100736430	20992774943	see	see	VV0
304953	100736430	20992774944	that	that	CST
304953	100736430	20992774945	it	it	PPH1
304953	100736430	20992774946	is	be	VBZ
304953	100736430	20992774947	just	just	RR
304953	100736430	20992774948	not	not	XX
304953	100736430	20992774949	going	go	VVGK
304953	100736430	20992774950	to	to	TO
304953	100736430	20992774951	make	make	VVI
304953	100736430	20992774952	it	it	PPH1
304953	100736430	20992774953	into	into	II
304953	100736430	20992774954	development	development	NN1
304953	100736430	20992774955	.	.	.
304953	100736430	20992774956	<p>		NULL
304953	100736430	20992774957	What	what	DDQ
304953	100736430	20992774958	resources	resource	NN2
304953	100736430	20992774959	do	do	VD0
304953	100736430	20992774960	you	you	PPY
304953	100736430	20992774961	need	need	VVI
304953	100736430	20992774962	to	to	TO
304953	100736430	20992774963	complete	complete	VVI
304953	100736430	20992774964	a	a	AT1
304953	100736430	20992774965	trial	trial	NN1
304953	100736430	20992774966	?	?	?
304953	100736430	20992774967	For	for	REX21
304953	100736430	20992774968	example	example	REX22
304953	100736430	20992774969	,	,	,
304953	100736430	20992774970	what	what	DDQ
304953	100736430	20992774971	did	do	VDD
304953	100736430	20992774972	it	it	PPH1
304953	100736430	20992774973	take	take	VVI
304953	100736430	20992774974	to	to	TO
304953	100736430	20992774975	complete	complete	VVI
304953	100736430	20992774976	the	the	AT
304953	100736430	20992774977	study	study	NN1
304953	100736430	20992774978	of	of	IO
304953	100736430	20992774979	leuprolide	leuprolide	NN1
304953	100736430	20992774980	plus	plus	II
304953	100736430	20992774981	placebo	placebo	NN1
304953	100736430	20992774982	versus	versus	II
304953	100736430	20992774983	leuprolide	leuprolide	NN1
304953	100736430	20992774984	plus	plus	II
304953	100736430	20992774985	flutamide		NN1
304953	100736430	20992774986	?	?	?
304953	100736430	20992774987	<p>		NULL
304953	100736430	20992774988	Well	well	RR
304953	100736430	20992774989	,	,	,
304953	100736430	20992774990	that 's		VVZ
304953	100736430	20992774991	an	a	AT1
304953	100736430	20992774992	older	old	JJR
304953	100736430	20992774993	study	study	NN1
304953	100736430	20992774994	,	,	,
304953	100736430	20992774995	and	and	CC
304953	100736430	20992774996	things	thing	NN2
304953	100736430	20992774997	have	have	VH0
304953	100736430	20992774998	changed	change	VVN
304953	100736430	20992774999	a	a	RR21@_AT1
304953	100736430	20992775000	lot	lot	RR22_NN1
304953	100736430	20992775001	since	since	II
304953	100736430	20992775002	then	then	RT
304953	100736430	20992775003	.	.	.
304953	100736430	20992775004	If	if	CS
304953	100736430	20992775005	you	you	PPY
304953	100736430	20992775006	turn	turn	VV0
304953	100736430	20992775007	back	back	RP
304953	100736430	20992775008	the	the	AT
304953	100736430	20992775009	calendar	calendar	NN1
304953	100736430	20992775010	to	to	II
304953	100736430	20992775011	the	the	AT
304953	100736430	20992775012	1980s	1980s	MC2
304953	100736430	20992775013	when	when	CS
304953	100736430	20992775014	that	that	DD1
304953	100736430	20992775015	study	study	NN1
304953	100736430	20992775016	was	be	VBDZ
304953	100736430	20992775017	designed	design	VVN
304953	100736430	20992775018	,	,	,
304953	100736430	20992775019	you	you	PPY
304953	100736430	20992775020	had	have	VHD
304953	100736430	20992775021	some	some	DD
304953	100736430	20992775022	physicians	physician	NN2
304953	100736430	20992775023	with	with	IW
304953	100736430	20992775024	enough	enough	DD
304953	100736430	20992775025	data	data	NN
304953	100736430	20992775026	from	from	II
304953	100736430	20992775027	patients	patient	NN2
304953	100736430	20992775028	to	to	TO
304953	100736430	20992775029	show	show	VVI
304953	100736430	20992775030	that	that	CST
304953	100736430	20992775031	a	a	AT1
304953	100736430	20992775032	certain	certain	JJ
304953	100736430	20992775033	dose	dose	NN1
304953	100736430	20992775034	of	of	IO
304953	100736430	20992775035	flutamide		NN1
304953	100736430	20992775036	was	be	VBDZ
304953	100736430	20992775037	safe	safe	JJ
304953	100736430	20992775038	and	and	CC
304953	100736430	20992775039	that	that	CST
304953	100736430	20992775040	it	it	PPH1
304953	100736430	20992775041	might	might	VM
304953	100736430	20992775042	be	be	VBI
304953	100736430	20992775043	effective	effective	JJ
304953	100736430	20992775044	when	when	CS
304953	100736430	20992775045	combined	combine	VVN
304953	100736430	20992775046	with	with	IW
304953	100736430	20992775047	leuprolide	leuprolide	NN1
304953	100736430	20992775048	.	.	.
304953	100736430	20992775049	What	what	DDQ
304953	100736430	20992775050	they	they	PPHS2
304953	100736430	20992775051	wanted	want	VVD
304953	100736430	20992775052	to	to	TO
304953	100736430	20992775053	do	do	VDI
304953	100736430	20992775054	was	be	VBDZ
304953	100736430	20992775055	challenge	challenge	NN1
304953	100736430	20992775056	the	the	AT
304953	100736430	20992775057	gold	gold	NN1_JJ@
304953	100736430	20992775058	standard	standard	NN1
304953	100736430	20992775059	of	of	IO
304953	100736430	20992775060	taking	take	VVG
304953	100736430	20992775061	leuprolide		NN1_VV0
304953	100736430	20992775062	alone	alone	RR_JJ
304953	100736430	20992775063	.	.	.
304953	100736430	20992775064	So	so	RR
304953	100736430	20992775065	they	they	PPHS2
304953	100736430	20992775066	did	do	VDD
304953	100736430	20992775067	this	this	DD1
304953	100736430	20992775068	@		II
304953	100736430	20992775069	@		II
304953	100736430	20992775070	@		II
304953	100736430	20992775071	@		II
304953	100736430	20992775072	@		II
304953	100736430	20992775073	@		II
304953	100736430	20992775074	@		II
304953	100736430	20992775075	@		II
304953	100736430	20992775076	@		II
304953	100736430	20992775077	@		II
304953	100736430	20992775078	.	.	.
304953	100736430	20992775079	It	it	PPH1
304953	100736430	20992775080	was	be	VBDZ
304953	100736430	20992775081	pretty	pretty	RG
304953	100736430	20992775082	straightforward	straightforward	JJ
304953	100736430	20992775083	.	.	.
304953	100736430	20992775084	The	the	AT
304953	100736430	20992775085	variable	variable	NN1
304953	100736430	20992775086	was	be	VBDZ
304953	100736430	20992775087	an	a	AT1
304953	100736430	20992775088	anti-androgen	anti-androgen	NN1_JJ
304953	100736430	20992775089	,	,	,
304953	100736430	20992775090	flutamide		VV0_NN1
304953	100736430	20992775091	.	.	.
304953	100736430	20992775092	And	and	CC
304953	100736430	20992775093	it	it	PPH1
304953	100736430	20992775094	was	be	VBDZ
304953	100736430	20992775095	relatively	relatively	RR
304953	100736430	20992775096	easy	easy	JJ
304953	100736430	20992775097	to	to	TO
304953	100736430	20992775098	enroll	enroll	VVI
304953	100736430	20992775099	patients	patient	NN2
304953	100736430	20992775100	because	because	CS
304953	100736430	20992775101	,	,	,
304953	100736430	20992775102	unless	unless	CS
304953	100736430	20992775103	they	they	PPHS2
304953	100736430	20992775104	wanted	want	VVD
304953	100736430	20992775105	to	to	TO
304953	100736430	20992775106	go	go	VVI
304953	100736430	20992775107	to	to	II
304953	100736430	20992775108	Canada	canada	NP1
304953	100736430	20992775109	,	,	,
304953	100736430	20992775110	they	they	PPHS2
304953	100736430	20992775111	could n't		VV0
304953	100736430	20992775112	get	get	VV0
304953	100736430	20992775113	flutamide		NN1_VV0
304953	100736430	20992775114	.	.	.
304953	100736430	20992775115	<p>		NULL
304953	100736430	20992775116	Now	now	RT
304953	100736430	20992775117	,	,	,
304953	100736430	20992775118	it	it	PPH1
304953	100736430	20992775119	takes	take	VVZ
304953	100736430	20992775120	a	a	RR21@
304953	100736430	20992775121	lot	lot	RR22
304953	100736430	20992775122	more	more	DAR
304953	100736430	20992775123	paperwork	paperwork	NN1
304953	100736430	20992775124	and	and	CC
304953	100736430	20992775125	effort	effort	NN1
304953	100736430	20992775126	to	to	TO
304953	100736430	20992775127	get	get	VVI
304953	100736430	20992775128	studies	study	NN2
304953	100736430	20992775129	approved	approve	VVN
304953	100736430	20992775130	by	by	II
304953	100736430	20992775131	institutional	institutional	JJ
304953	100736430	20992775132	review	review	NN1
304953	100736430	20992775133	boards	board	NN2
304953	100736430	20992775134	and	and	CC
304953	100736430	20992775135	activated	activate	VVD_VVN
304953	100736430	20992775136	.	.	.
304953	100736430	20992775137	On	on	II
304953	100736430	20992775138	the	the	AT
304953	100736430	20992775139	one	one	MC1
304953	100736430	20992775140	hand	hand	NN1
304953	100736430	20992775141	,	,	,
304953	100736430	20992775142	that	that	DD1_CST
304953	100736430	20992775143	protects	protect	VVZ
304953	100736430	20992775144	patients	patient	NN2
304953	100736430	20992775145	and	and	CC
304953	100736430	20992775146	ensures	ensure	VVZ
304953	100736430	20992775147	that	that	CST
304953	100736430	20992775148	the	the	AT
304953	100736430	20992775149	data	data	NN
304953	100736430	20992775150	you	you	PPY
304953	100736430	20992775151	collect	collect	VV0
304953	100736430	20992775152	are	be	VBR
304953	100736430	20992775153	uniform	uniform	JJ
304953	100736430	20992775154	and	and	CC
304953	100736430	20992775155	can	can	VM
304953	100736430	20992775156	be	be	VBI
304953	100736430	20992775157	submitted	submit	VVN
304953	100736430	20992775158	as	as	II
304953	100736430	20992775159	part	part	NN1
304953	100736430	20992775160	of	of	IO
304953	100736430	20992775161	the	the	AT
304953	100736430	20992775162	drug-approval	drug-approval	JJ_NN1
304953	100736430	20992775163	process	process	NN1
304953	100736430	20992775164	.	.	.
304953	100736430	20992775165	But	but	CCB
304953	100736430	20992775166	that	that	DD1
304953	100736430	20992775167	also	also	RR
304953	100736430	20992775168	means	mean	VVZ
304953	100736430	20992775169	that	that	CST
304953	100736430	20992775170	the	the	AT
304953	100736430	20992775171	whole	whole	JJ
304953	100736430	20992775172	process	process	NN1
304953	100736430	20992775173	has	have	VHZ
304953	100736430	20992775174	gotten	get	VVN
304953	100736430	20992775175	extremely	extremely	RR
304953	100736430	20992775176	complicated	complicated	JJ_VVN@
304953	100736430	20992775177	and	and	CC
304953	100736430	20992775178	expensive	expensive	JJ
304953	100736430	20992775179	.	.	.
304953	100736430	20992775180	The	the	AT
304953	100736430	20992775181	amount	amount	NN1
304953	100736430	20992775182	of	of	IO
304953	100736430	20992775183	paperwork	paperwork	NN1
304953	100736430	20992775184	is	be	VBZ
304953	100736430	20992775185	just	just	RR_JJ@
304953	100736430	20992775186	mind-boggling	mind-boggling	JJ_NN1
304953	100736430	20992775187	.	.	.
304953	100736430	20992775188	So	so	RR
304953	100736430	20992775189	we	we	PPIS2
304953	100736430	20992775190	have	have	VH0
304953	100736430	20992775191	to	to	TO
304953	100736430	20992775192	pick	pick	VVI
304953	100736430	20992775193	studies	study	NN2
304953	100736430	20992775194	very	very	RG
304953	100736430	20992775195	carefully	carefully	RR
304953	100736430	20992775196	.	.	.
304953	100736430	20992775197	We	we	PPIS2
304953	100736430	20992775198	do	do	VD0
304953	100736430	20992775199	n't 	n't	XX
304953	100736430	20992775200	have	have	VHI
304953	100736430	20992775201	unlimited	unlimited	JJ
304953	100736430	20992775202	resources	resource	NN2
304953	100736430	20992775203	.	.	.
304953	100736430	20992775204	<p>		NULL
304953	100736430	20992775205	How	how	RRQ
304953	100736430	20992775206	are	be	VBR
304953	100736430	20992775207	the	the	AT
304953	100736430	20992775208	SWOG		NN1_NP1
304953	100736430	20992775209	studies	study	NN2
304953	100736430	20992775210	funded	fund	VVN_JJ
304953	100736430	20992775211	?	?	?
304953	100736430	20992775212	How	how	RGQ@
304953	100736430	20992775213	much	much	DA1
304953	100736430	20992775214	does	do	VDZ
304953	100736430	20992775215	it	it	PPH1
304953	100736430	20992775216	cost	cost	VVI
304953	100736430	20992775217	to	to	TO
304953	100736430	20992775218	do	do	VDI
304953	100736430	20992775219	a	a	AT1
304953	100736430	20992775220	study	study	NN1
304953	100736430	20992775221	?	?	?
304953	100736430	20992775222	<p>		NULL
304953	100736430	20992775223	We	we	PPIS2
304953	100736430	20992775224	are	be	VBR
304953	100736430	20992775225	supported	support	VVN
304953	100736430	20992775226	almost	almost	RR
304953	100736430	20992775227	exclusively	exclusively	RR
304953	100736430	20992775228	by	by	II
304953	100736430	20992775229	the	the	AT
304953	100736430	20992775230	National	national	JJ
304953	100736430	20992775231	Cancer	cancer	NN1
304953	100736430	20992775232	Institute	institute	NN1
304953	100736430	20992775233	.	.	.
304953	100736430	20992775234	There 's		NN2_NP1@
304953	100736430	20992775235	a	a	AT1
304953	100736430	20992775236	competitive	competitive	JJ
304953	100736430	20992775237	renewal	renewal	NN1
304953	100736430	20992775238	of	of	IO
304953	100736430	20992775239	grants	grant	NN2
304953	100736430	20992775240	every	every	AT1
304953	100736430	20992775241	year	year	NNT1
304953	100736430	20992775242	.	.	.
304953	100736430	20992775243	Its	its	APPGE
304953	100736430	20992775244	hard	hard	JJ
304953	100736430	20992775245	to	to	TO
304953	100736430	20992775246	put	put	VVI
304953	100736430	20992775247	a	a	AT1
304953	100736430	20992775248	price	price	NN1
304953	100736430	20992775249	tag	tag	NN1_VV0
304953	100736430	20992775250	on	on	II
304953	100736430	20992775251	a	a	AT1
304953	100736430	20992775252	study	study	NN1
304953	100736430	20992775253	because	because	CS
304953	100736430	20992775254	its	its	APPGE
304953	100736430	20992775255	financed	finance	VVN_VVD
304953	100736430	20992775256	through	through	II
304953	100736430	20992775257	a	a	AT1
304953	100736430	20992775258	cooperative	cooperative	JJ
304953	100736430	20992775259	group	group	NN1
304953	100736430	20992775260	,	,	,
304953	100736430	20992775261	but	but	CCB
304953	100736430	20992775262	its	its	APPGE
304953	100736430	20992775263	expensive	expensive	JJ
304953	100736430	20992775264	.	.	.
304953	100736430	20992775265	Trials	trial	NN2
304953	100736430	20992775266	are	be	VBR
304953	100736430	20992775267	particularly	particularly	RR
304953	100736430	20992775268	@		II
304953	100736430	20992775269	@		II
304953	100736430	20992775270	@		II
304953	100736430	20992775271	@		II
304953	100736430	20992775272	@		II
304953	100736430	20992775273	@		II
304953	100736430	20992775274	@		II
304953	100736430	20992775275	@		II
304953	100736430	20992775276	@		II
304953	100736430	20992775277	@		II
304953	100736430	20992775278	sponsored	sponsor	VVN
304953	100736430	20992775279	by	by	II
304953	100736430	20992775280	a	a	AT1
304953	100736430	20992775281	pharmaceutical	pharmaceutical	JJ
304953	100736430	20992775282	company	company	NN1
304953	100736430	20992775283	that 's		NN2
304953	100736430	20992775284	been	be	VBN
304953	100736430	20992775285	ongoing	ongoing	JJ
304953	100736430	20992775286	in	in	II
304953	100736430	20992775287	prostate	prostate	NN1
304953	100736430	20992775288	cancer	cancer	NN1
304953	100736430	20992775289	has	have	VHZ
304953	100736430	20992775290	cost	cost	VVN
304953	100736430	20992775291	over	over	RG
304953	100736430	20992775292	$300		NNU
304953	100736430	20992775293	million	million	NNO
304953	100736430	20992775294	to	to	TO
304953	100736430	20992775295	do	do	VDI
304953	100736430	20992775296	.	.	.
304953	100736430	20992775297	I	i	PPIS1
304953	100736430	20992775298	think	think	VV0
304953	100736430	20992775299	trials	trial	NN2
304953	100736430	20992775300	are	be	VBR
304953	100736430	20992775301	less	less	RGR
304953	100736430	20992775302	expensive	expensive	JJ
304953	100736430	20992775303	when	when	CS_RRQ
304953	100736430	20992775304	they 're		NN1
304953	100736430	20992775305	done	do	VDN
304953	100736430	20992775306	through	through	II
304953	100736430	20992775307	a	a	AT1
304953	100736430	20992775308	cooperative	cooperative	JJ
304953	100736430	20992775309	group	group	NN1
304953	100736430	20992775310	like	like	II
304953	100736430	20992775311	SWOG		NP1_NN1
304953	100736430	20992775312	because	because	CS
304953	100736430	20992775313	the	the	AT
304953	100736430	20992775314	investigators	investigator	NN2
304953	100736430	20992775315	are	be	VBR
304953	100736430	20992775316	already	already	RR
304953	100736430	20992775317	in	in	II
304953	100736430	20992775318	place	place	NN1
304953	100736430	20992775319	and	and	CC
304953	100736430	20992775320	all	all	DB
304953	100736430	20992775321	of	of	IO
304953	100736430	20992775322	the	the	AT
304953	100736430	20992775323	mechanisms	mechanism	NN2
304953	100736430	20992775324	are	be	VBR
304953	100736430	20992775325	in	in	II
304953	100736430	20992775326	place	place	NN1
304953	100736430	20992775327	.	.	.
304953	100736430	20992775328	But	but	CCB
304953	100736430	20992775329	they 're		NN1
304953	100736430	20992775330	still	still	RR
304953	100736430	20992775331	expensive	expensive	JJ
304953	100736430	20992775332	and	and	CC
304953	100736430	20992775333	time-consuming	time-consuming	JJ
304953	100736430	20992775334	.	.	.
304953	100736430	20992775335	<p>		NULL
304953	100736430	20992775336	What 's		NN2
304953	100736430	20992775337	the	the	AT
304953	100736430	20992775338	largest	large	JJT
304953	100736430	20992775339	phase	phase	NN1
304953	100736430	20992775340	III	iii	MC
304953	100736430	20992775341	SWOG		NP1_NN1_VV0
304953	100736430	20992775342	prostate	prostate	NN1
304953	100736430	20992775343	cancer	cancer	NN1
304953	100736430	20992775344	study	study	NN1
304953	100736430	20992775345	under	under	RR21
304953	100736430	20992775346	way	way	RR22
304953	100736430	20992775347	now	now	RT
304953	100736430	20992775348	?	?	?
304953	100736430	20992775349	<p>		NULL
304953	100736430	20992775350	The	the	AT
304953	100736430	20992775351	one	one	PN1
304953	100736430	20992775352	that 's		VVZ
304953	100736430	20992775353	ongoing	ongoing	JJ
304953	100736430	20992775354	right	right	NN1_JJ_RR
304953	100736430	20992775355	now	now	RT
304953	100736430	20992775356	will	will	VM
304953	100736430	20992775357	be	be	VBI
304953	100736430	20992775358	another	another	DD1
304953	100736430	20992775359	blockbuster	blockbuster	NN1
304953	100736430	20992775360	trial	trial	NN1
304953	100736430	20992775361	.	.	.
304953	100736430	20992775362	It	it	PPH1
304953	100736430	20992775363	was	be	VBDZ
304953	100736430	20992775364	designed	design	VVN
304953	100736430	20992775365	to	to	TO
304953	100736430	20992775366	answer	answer	VVI
304953	100736430	20992775367	the	the	AT
304953	100736430	20992775368	question	question	NN1
304953	100736430	20992775369	of	of	IO
304953	100736430	20992775370	whether	whether	CSW
304953	100736430	20992775371	intermittent	intermittent	JJ
304953	100736430	20992775372	hormone	hormone	NN1
304953	100736430	20992775373	therapy	therapy	NN1
304953	100736430	20992775374	might	might	VM
304953	100736430	20992775375	be	be	VBI
304953	100736430	20992775376	better	better	JJR_RRR
304953	100736430	20992775377	than	than	CSN
304953	100736430	20992775378	continuous	continuous	JJ
304953	100736430	20992775379	hormone	hormone	NN1
304953	100736430	20992775380	therapy	therapy	NN1
304953	100736430	20992775381	for	for	IF
304953	100736430	20992775382	patients	patient	NN2
304953	100736430	20992775383	with	with	IW
304953	100736430	20992775384	advanced	advanced	JJ
304953	100736430	20992775385	disease.		NNU
304953	100736430	20992775386	*	*	FU
304953	100736430	20992775387	Were	be	VBDR
304953	100736430	20992775388	looking	look	VVG
304953	100736430	20992775389	to	to	TO
304953	100736430	20992775390	enroll	enroll	VVI
304953	100736430	20992775391	about	about	RG
304953	100736430	20992775392	2,300	2,300	MC
304953	100736430	20992775393	participants	participant	NN2
304953	100736430	20992775394	in	in	II
304953	100736430	20992775395	this	this	DD1
304953	100736430	20992775396	study	study	NN1
304953	100736430	20992775397	.	.	.
304953	100736430	20992775398	<p>		NULL
304953	100736430	20992775399	*Note	*note	FO
304953	100736430	20992775400	:	:	:
304953	100736430	20992775401	To	to	TO
304953	100736430	20992775402	learn	learn	VVI
304953	100736430	20992775403	more	more	RRR_DAR
304953	100736430	20992775404	about	about	II
304953	100736430	20992775405	this	this	DD1
304953	100736430	20992775406	study	study	NN1
304953	100736430	20992775407	,	,	,
304953	100736430	20992775408	log	log	NN1_VV0@
304953	100736430	20992775409	on	on	II21_RP
304953	100736430	20992775410	to	to	II22_II
304953	100736430	20992775411	www.clinicaltrials.gov	www.clinicaltrials.gov	NNU
304953	100736430	20992775412	and	and	CC
304953	100736430	20992775413	click	click	VV0_NN1
304953	100736430	20992775414	on	on	II
304953	100736430	20992775415	"	"	"
304953	100736430	20992775416	Search	search	NN1
304953	100736430	20992775417	for	for	IF
304953	100736430	20992775418	Clinical	clinical	JJ
304953	100736430	20992775419	Trials	trial	NN2
304953	100736430	20992775420	.	.	.
304953	100736430	20992775421	"	"	"
304953	100736430	20992775422	Then	then	RT
304953	100736430	20992775423	enter	enter	VV0
304953	100736430	20992775424	the	the	AT
304953	100736430	20992775425	protocol	protocol	NN1
304953	100736430	20992775426	identification	identification	NN1
304953	100736430	20992775427	number	number	NN1
304953	100736430	20992775428	SWOG-9346		MC
304953	100736430	20992775429	.	.	.
304953	100736430	20992775430	<p>		NULL
304953	100736430	20992775431	Weve		NN1
304953	100736430	20992775432	been	be	VBN
304953	100736430	20992775433	wondering	wonder	VVG
304953	100736430	20992775434	whether	whether	CSW
304953	100736430	20992775435	we	we	PPIS2
304953	100736430	20992775436	could	could	VM
304953	100736430	20992775437	cycle	cycle	NN1
304953	100736430	20992775438	patients	patient	NN2
304953	100736430	20992775439	on	on	II_RP@
304953	100736430	20992775440	and	and	CC
304953	100736430	20992775441	off	off	II_RP_JJ%
304953	100736430	20992775442	hormone	hormone	NN1
304953	100736430	20992775443	therapy	therapy	NN1
304953	100736430	20992775444	,	,	,
304953	100736430	20992775445	not	not	XX
304953	100736430	20992775446	only	only	RR
304953	100736430	20992775447	prolonging	prolong	VVG
304953	100736430	20992775448	survival	survival	NN1
304953	100736430	20992775449	,	,	,
304953	100736430	20992775450	but	but	CCB
304953	100736430	20992775451	reducing	reduce	VVG_JJ@
304953	100736430	20992775452	side	side	NN1
304953	100736430	20992775453	effects	effect	NN2
304953	100736430	20992775454	and	and	CC
304953	100736430	20992775455	costs	cost	VVZ_NN2
304953	100736430	20992775456	as	as	RR21_RG
304953	100736430	20992775457	well	well	RR22_RR
304953	100736430	20992775458	.	.	.
304953	100736430	20992775459	Its	its	APPGE
304953	100736430	20992775460	a	a	AT1
304953	100736430	20992775461	great	great	JJ
304953	100736430	20992775462	question	question	NN1
304953	100736430	20992775463	.	.	.
304953	100736430	20992775464	The	the	AT
304953	100736430	20992775465	idea	idea	NN1
304953	100736430	20992775466	was	be	VBDZ
304953	100736430	20992775467	put	put	VVN
304953	100736430	20992775468	@		II
304953	100736430	20992775469	@		II
304953	100736430	20992775470	@		II
304953	100736430	20992775471	@		II
304953	100736430	20992775472	@		II
304953	100736430	20992775473	@		II
304953	100736430	20992775474	@		II
304953	100736430	20992775475	@		II
304953	100736430	20992775476	@		II
304953	100736430	20992775477	@		II
304953	100736430	20992775478	it	it	PPH1
304953	100736430	20992775479	.	.	.
304953	100736430	20992775480	There	there	RL_EX
304953	100736430	20992775481	was n't		VV0
304953	100736430	20992775482	a	a	AT1
304953	100736430	20992775483	lot	lot	NN1
304953	100736430	20992775484	of	of	IO
304953	100736430	20992775485	argument	argument	NN1
304953	100736430	20992775486	about	about	II
304953	100736430	20992775487	it	it	PPH1
304953	100736430	20992775488	the	the	AT
304953	100736430	20992775489	idea	idea	NN1
304953	100736430	20992775490	was	be	VBDZ
304953	100736430	20992775491	very	very	RG
304953	100736430	20992775492	well	well	RR
304953	100736430	20992775493	received	receive	VVN_VVD
304953	100736430	20992775494	.	.	.
304953	100736430	20992775495	There	there	EX
304953	100736430	20992775496	was	be	VBDZ
304953	100736430	20992775497	discussion	discussion	NN1
304953	100736430	20992775498	,	,	,
304953	100736430	20992775499	though	though	CS_RR@
304953	100736430	20992775500	,	,	,
304953	100736430	20992775501	about	about	II
304953	100736430	20992775502	how	how	RGQ@_RRQ
304953	100736430	20992775503	long	long	JJ
304953	100736430	20992775504	people	people	NN
304953	100736430	20992775505	should	should	VM
304953	100736430	20992775506	be	be	VBI
304953	100736430	20992775507	treated	treat	VVN
304953	100736430	20992775508	,	,	,
304953	100736430	20992775509	how	how	RRQ_RGQ@
304953	100736430	20992775510	long	long	RR
304953	100736430	20992775511	they	they	PPHS2
304953	100736430	20992775512	should	should	VM
304953	100736430	20992775513	be	be	VBI
304953	100736430	20992775514	off	off	II_RP_JJ%
304953	100736430	20992775515	treatment	treatment	NN1
304953	100736430	20992775516	,	,	,
304953	100736430	20992775517	and	and	CC
304953	100736430	20992775518	what	what	DDQ
304953	100736430	20992775519	the	the	AT
304953	100736430	20992775520	PSA	psa	NP1
304953	100736430	20992775521	nadir	nadir	NN1
304953	100736430	20992775522	should	should	VM
304953	100736430	20992775523	be	be	VBI
304953	100736430	20992775524	before	before	II
304953	100736430	20992775525	temporarily	temporarily	RR
304953	100736430	20992775526	halting	halting	JJ_VVG
304953	100736430	20992775527	treatment	treatment	NN1
304953	100736430	20992775528	.	.	.
304953	100736430	20992775529	<p>		NULL
304953	100736430	20992775530	The	the	AT
304953	100736430	20992775531	trial	trial	NN1
304953	100736430	20992775532	has	have	VHZ
304953	100736430	20992775533	been	be	VBN
304953	100736430	20992775534	activated	activate	VVN
304953	100736430	20992775535	,	,	,
304953	100736430	20992775536	and	and	CC
304953	100736430	20992775537	its	its	APPGE
304953	100736430	20992775538	been	be	VBN
304953	100736430	20992775539	accruing	accrue	VVG
304953	100736430	20992775540	pretty	pretty	RG
304953	100736430	20992775541	steadily	steadily	RR
304953	100736430	20992775542	,	,	,
304953	100736430	20992775543	though	though	CS
304953	100736430	20992775544	not	not	XX
304953	100736430	20992775545	as	as	RG
304953	100736430	20992775546	rapidly	rapidly	RR
304953	100736430	20992775547	as	as	CSA
304953	100736430	20992775548	wed		VVN
304953	100736430	20992775549	like	like	II_JJ@_VV0@
304953	100736430	20992775550	to	to	TO
304953	100736430	20992775551	see	see	VVI
304953	100736430	20992775552	.	.	.
304953	100736430	20992775553	One	one	MC1
304953	100736430	20992775554	reason	reason	NN1
304953	100736430	20992775555	is	be	VBZ
304953	100736430	20992775556	that	that	CST
304953	100736430	20992775557	if	if	CS
304953	100736430	20992775558	people	people	NN
304953	100736430	20992775559	think	think	VV0
304953	100736430	20992775560	they	they	PPHS2
304953	100736430	20992775561	know	know	VV0
304953	100736430	20992775562	the	the	AT
304953	100736430	20992775563	answer	answer	NN1
304953	100736430	20992775564	to	to	II
304953	100736430	20992775565	the	the	AT
304953	100736430	20992775566	question	question	NN1
304953	100736430	20992775567	about	about	II
304953	100736430	20992775568	which	which	DDQ
304953	100736430	20992775569	treatment	treatment	NN1
304953	100736430	20992775570	regimen	regimen	NN1
304953	100736430	20992775571	is	be	VBZ
304953	100736430	20992775572	better	better	JJR
304953	100736430	20992775573	,	,	,
304953	100736430	20992775574	they	they	PPHS2
304953	100736430	20992775575	are	be	VBR
304953	100736430	20992775576	going	go	VVGK
304953	100736430	20992775577	to	to	TO
304953	100736430	20992775578	pursue	pursue	VVI
304953	100736430	20992775579	that	that	DD1_CST
304953	100736430	20992775580	regimen	regimen	NN1
304953	100736430	20992775581	on	on	II
304953	100736430	20992775582	their	their	APPGE
304953	100736430	20992775583	own	own	DA
304953	100736430	20992775584	.	.	.
304953	100736430	20992775585	Given	give	VVN
304953	100736430	20992775586	a	a	AT1
304953	100736430	20992775587	choice	choice	NN1
304953	100736430	20992775588	,	,	,
304953	100736430	20992775589	patients	patient	NN2
304953	100736430	20992775590	will	will	VM
304953	100736430	20992775591	say	say	VVI
304953	100736430	20992775592	,	,	,
304953	100736430	20992775593	"	"	"
304953	100736430	20992775594	I	i	PPIS1
304953	100736430	20992775595	know	know	VV0
304953	100736430	20992775596	I	i	PPIS1
304953	100736430	20992775597	want	want	VV0
304953	100736430	20992775598	this	this	DD1
304953	100736430	20992775599	,	,	,
304953	100736430	20992775600	not	not	XX
304953	100736430	20992775601	that	that	DD1_CST
304953	100736430	20992775602	,	,	,
304953	100736430	20992775603	so	so	RR
304953	100736430	20992775604	I 'm		VV0
304953	100736430	20992775605	not	not	XX
304953	100736430	20992775606	going	go	VVGK
304953	100736430	20992775607	to	to	TO
304953	100736430	20992775608	enter	enter	VVI
304953	100736430	20992775609	the	the	AT
304953	100736430	20992775610	trial	trial	NN1
304953	100736430	20992775611	.	.	.
304953	100736430	20992775612	"	"	"
304953	100736430	20992775613	The	the	AT
304953	100736430	20992775614	second	second	MD
304953	100736430	20992775615	reason	reason	NN1
304953	100736430	20992775616	is	be	VBZ
304953	100736430	20992775617	that	that	CST
304953	100736430	20992775618	the	the	AT
304953	100736430	20992775619	pool	pool	NN1
304953	100736430	20992775620	of	of	IO
304953	100736430	20992775621	patients	patient	NN2
304953	100736430	20992775622	with	with	IW
304953	100736430	20992775623	advanced	advanced	JJ
304953	100736430	20992775624	prostate	prostate	NN1
304953	100736430	20992775625	cancer	cancer	NN1
304953	100736430	20992775626	has	have	VHZ
304953	100736430	20992775627	shrunk	shrink	VVN
304953	100736430	20992775628	substantially	substantially	RR
304953	100736430	20992775629	.	.	.
304953	100736430	20992775630	We	we	PPIS2
304953	100736430	20992775631	just	just	RR
304953	100736430	20992775632	do	do	VD0
304953	100736430	20992775633	n't 	n't	XX
304953	100736430	20992775634	have	have	VHI
304953	100736430	20992775635	as	as	RG
304953	100736430	20992775636	many	many	DA2
304953	100736430	20992775637	as	as	CSA
304953	100736430	20992775638	we	we	PPIS2
304953	100736430	20992775639	used	use	VVD
304953	100736430	20992775640	to	to	II_TO
304953	100736430	20992775641	.	.	.
304953	100736430	20992775642	And	and	CC
304953	100736430	20992775643	even	even	CS21
304953	100736430	20992775644	though	though	CS22
304953	100736430	20992775645	they 've		NN1
304953	100736430	20992775646	been	be	VBN
304953	100736430	20992775647	diagnosed	diagnose	VVN
304953	100736430	20992775648	with	with	IW
304953	100736430	20992775649	advanced	advanced	JJ
304953	100736430	20992775650	prostate	prostate	NN1
304953	100736430	20992775651	cancer	cancer	NN1
304953	100736430	20992775652	,	,	,
304953	100736430	20992775653	a	a	AT1
304953	100736430	20992775654	lot	lot	NN1
304953	100736430	20992775655	of	of	IO
304953	100736430	20992775656	them	them	PPHO2
304953	100736430	20992775657	do	do	VD0
304953	100736430	20992775658	n't 	n't	XX
304953	100736430	20992775659	have	have	VHI
304953	100736430	20992775660	any	any	DD
304953	100736430	20992775661	symptoms	symptom	NN2
304953	100736430	20992775662	.	.	.
304953	100736430	20992775663	But	but	CCB
304953	100736430	20992775664	I	i	PPIS1
304953	100736430	20992775665	think	think	VV0
304953	100736430	20992775666	were	be	VBDR
304953	100736430	20992775667	just	just	RR21
304953	100736430	20992775668	@		II
304953	100736430	20992775669	@		II
304953	100736430	20992775670	@		II
304953	100736430	20992775671	@		II
304953	100736430	20992775672	@		II
304953	100736430	20992775673	@		II
304953	100736430	20992775674	@		II
304953	100736430	20992775675	@		II
304953	100736430	20992775676	@		II
304953	100736430	20992775677	@		II
304953	100736430	20992775678	Data	data	NN
304953	100736430	20992775679	Safety	safety	NN1
304953	100736430	20992775680	and	and	CC
304953	100736430	20992775681	Monitoring	monitoring	NN1_JJ@
304953	100736430	20992775682	Committee	committee	NN1
304953	100736430	20992775683	to	to	TO
304953	100736430	20992775684	say	say	VVI
304953	100736430	20992775685	that	that	CST
304953	100736430	20992775686	they	they	PPHS2
304953	100736430	20992775687	have	have	VH0
304953	100736430	20992775688	some	some	DD
304953	100736430	20992775689	preliminary	preliminary	JJ
304953	100736430	20992775690	results	result	NN2
304953	100736430	20992775691	.	.	.
304953	100736430	20992775692	<p>		NULL
304953	100736430	20992775693	What	what	DDQ
304953	100736430	20992775694	hormonal	hormonal	JJ
304953	100736430	20992775695	therapies	therapy	NN2
304953	100736430	20992775696	were	be	VBDR
304953	100736430	20992775697	chosen	choose	VVN
304953	100736430	20992775698	for	for	IF
304953	100736430	20992775699	the	the	AT
304953	100736430	20992775700	trial	trial	NN1
304953	100736430	20992775701	?	?	?
304953	100736430	20992775702	<p>		NULL
304953	100736430	20992775703	Its	its	APPGE
304953	100736430	20992775704	a	a	AT1
304953	100736430	20992775705	combined	combined	JJ
304953	100736430	20992775706	androgen	androgen	NN1
304953	100736430	20992775707	blockade	blockade	NN1_VV0
304953	100736430	20992775708	for	for	IF
304953	100736430	20992775709	nine	nine	MC
304953	100736430	20992775710	months	month	NNT2
304953	100736430	20992775711	.	.	.
304953	100736430	20992775712	After	after	II
304953	100736430	20992775713	that	that	DD1
304953	100736430	20992775714	,	,	,
304953	100736430	20992775715	those	those	DD2
304953	100736430	20992775716	with	with	IW
304953	100736430	20992775717	a	a	AT1
304953	100736430	20992775718	PSA	psa	NP1
304953	100736430	20992775719	less	less	DAR
304953	100736430	20992775720	than	than	CSN
304953	100736430	20992775721	4	4	MC
304953	100736430	20992775722	ng/ml	ng/ml	FU
304953	100736430	20992775723	randomly	randomly	RR
304953	100736430	20992775724	receive	receive	VV0
304953	100736430	20992775725	either	either	RR
304953	100736430	20992775726	continuous	continuous	JJ
304953	100736430	20992775727	or	or	CC
304953	100736430	20992775728	intermittent	intermittent	JJ
304953	100736430	20992775729	hormone	hormone	NN1
304953	100736430	20992775730	therapy	therapy	NN1
304953	100736430	20992775731	,	,	,
304953	100736430	20992775732	with	with	IW
304953	100736430	20992775733	a	a	AT1
304953	100736430	20992775734	combined	combined	JJ
304953	100736430	20992775735	androgen	androgen	NN1
304953	100736430	20992775736	blockage	blockage	NN1
304953	100736430	20992775737	throughout	throughout	RL@_II
304953	100736430	20992775738	.	.	.
304953	100736430	20992775739	<p>		NULL
304953	100736430	20992775740	There	there	EX
304953	100736430	20992775741	are	be	VBR
304953	100736430	20992775742	parallel	parallel	JJ_RR
304953	100736430	20992775743	studies	study	NN2
304953	100736430	20992775744	ongoing	ongoing	JJ
304953	100736430	20992775745	in	in	II
304953	100736430	20992775746	another	another	DD1
304953	100736430	20992775747	cooperative	cooperative	JJ
304953	100736430	20992775748	group	group	NN1
304953	100736430	20992775749	in	in	II
304953	100736430	20992775750	Canada	canada	NP1
304953	100736430	20992775751	.	.	.
304953	100736430	20992775752	They	they	PPHS2
304953	100736430	20992775753	are	be	VBR
304953	100736430	20992775754	looking	look	VVG
304953	100736430	20992775755	at	at	II
304953	100736430	20992775756	intermittent	intermittent	JJ
304953	100736430	20992775757	versus	versus	II
304953	100736430	20992775758	continuous	continuous	JJ
304953	100736430	20992775759	hormone	hormone	NN1
304953	100736430	20992775760	therapy	therapy	NN1
304953	100736430	20992775761	for	for	IF
304953	100736430	20992775762	biochemical	biochemical	JJ
304953	100736430	20992775763	failure	failure	NN1
304953	100736430	20992775764	after	after	II_CS
304953	100736430	20992775765	radiation	radiation	NN1
304953	100736430	20992775766	,	,	,
304953	100736430	20992775767	so	so	CS@_RR
304953	100736430	20992775768	we	we	PPIS2
304953	100736430	20992775769	should	should	VM
304953	100736430	20992775770	get	get	VVI
304953	100736430	20992775771	some	some	DD
304953	100736430	20992775772	answers	answer	NN2
304953	100736430	20992775773	there	there	RL
304953	100736430	20992775774	,	,	,
304953	100736430	20992775775	too	too	RR@
304953	100736430	20992775776	.	.	.
304953	100736430	20992775777	<p>		NULL
304953	100736430	20992775778	Can	can	VM_VV0%
304953	100736430	20992775779	you	you	PPY
304953	100736430	20992775780	ask	ask	VVI
304953	100736430	20992775781	multiple	multiple	JJ_NN1
304953	100736430	20992775782	questions	question	NN2
304953	100736430	20992775783	or	or	CC
304953	100736430	20992775784	test	test	VV0_NN1
304953	100736430	20992775785	multiple	multiple	JJ_NN1
304953	100736430	20992775786	hypotheses	hypothesis	NN2
304953	100736430	20992775787	in	in	II
304953	100736430	20992775788	one	one	MC1
304953	100736430	20992775789	trial	trial	NN1
304953	100736430	20992775790	?	?	?
304953	100736430	20992775791	<p>		NULL
304953	100736430	20992775792	Well	well	RR
304953	100736430	20992775793	,	,	,
304953	100736430	20992775794	we	we	PPIS2
304953	100736430	20992775795	do	do	VD0
304953	100736430	20992775796	collect	collect	VVI
304953	100736430	20992775797	a	a	AT1
304953	100736430	20992775798	lot	lot	NN1
304953	100736430	20992775799	of	of	IO
304953	100736430	20992775800	data	data	NN
304953	100736430	20992775801	that	that	CST
304953	100736430	20992775802	we	we	PPIS2
304953	100736430	20992775803	mine	mine	VV0%
304953	100736430	20992775804	for	for	IF
304953	100736430	20992775805	other	other	JJ
304953	100736430	20992775806	information	information	NN1
304953	100736430	20992775807	.	.	.
304953	100736430	20992775808	For	for	REX21
304953	100736430	20992775809	example	example	REX22
304953	100736430	20992775810	,	,	,
304953	100736430	20992775811	one	one	MC1
304953	100736430	20992775812	of	of	IO
304953	100736430	20992775813	the	the	AT
304953	100736430	20992775814	things	thing	NN2
304953	100736430	20992775815	that	that	CST
304953	100736430	20992775816	came	come	VVD
304953	100736430	20992775817	out	out	II21
304953	100736430	20992775818	of	of	II22
304953	100736430	20992775819	a	a	AT1
304953	100736430	20992775820	recent	recent	JJ
304953	100736430	20992775821	trial	trial	NN1
304953	100736430	20992775822	that	that	CST_DD1
304953	100736430	20992775823	was	be	VBDZ
304953	100736430	20992775824	presented	present	VVN
304953	100736430	20992775825	at	at	II
304953	100736430	20992775826	a	a	AT1
304953	100736430	20992775827	meeting	meeting	NN1
304953	100736430	20992775828	of	of	IO
304953	100736430	20992775829	the	the	AT
304953	100736430	20992775830	American	american	JJ
304953	100736430	20992775831	Society	society	NN1
304953	100736430	20992775832	of	of	IO
304953	100736430	20992775833	Clinical	clinical	JJ
304953	100736430	20992775834	Oncology	oncology	NN1
304953	100736430	20992775835	is	be	VBZ
304953	100736430	20992775836	that	that	CST
304953	100736430	20992775837	people	people	NN
304953	100736430	20992775838	with	with	IW
304953	100736430	20992775839	metastatic	metastatic	JJ
304953	100736430	20992775840	disease	disease	NN1
304953	100736430	20992775841	who	who	PNQS
304953	100736430	20992775842	lowered	lower	VVD
304953	100736430	20992775843	their	their	APPGE
304953	100736430	20992775844	PSA	psa	NP1
304953	100736430	20992775845	to	to	II
304953	100736430	20992775846	undetectable	undetectable	JJ
304953	100736430	20992775847	levels	level	NN2
304953	100736430	20992775848	lived	live	VVD_VVN
304953	100736430	20992775849	longer	long	RRR_JJR
304953	100736430	20992775850	than	than	CSN
304953	100736430	20992775851	people	people	NN
304953	100736430	20992775852	who	who	PNQS
304953	100736430	20992775853	did	do	VDD
304953	100736430	20992775854	n't 	n't	XX
304953	100736430	20992775855	get	get	VVI
304953	100736430	20992775856	their	their	APPGE
304953	100736430	20992775857	PSA	psa	NP1
304953	100736430	20992775858	to	to	II
304953	100736430	20992775859	less	less	DAR
304953	100736430	20992775860	than	than	CSN
304953	100736430	20992775861	4	4	MC
304953	100736430	20992775862	ng/ml.		FU
304953	100736430	20992775863	*	*	FU
304953	100736430	20992775864	So	so	RR
304953	100736430	20992775865	we	we	PPIS2
304953	100736430	20992775866	defined	define	VVD
304953	100736430	20992775867	a	a	AT1
304953	100736430	20992775868	@		II
304953	100736430	20992775869	@		II
304953	100736430	20992775870	@		II
304953	100736430	20992775871	@		II
304953	100736430	20992775872	@		II
304953	100736430	20992775873	@		II
304953	100736430	20992775874	@		II
304953	100736430	20992775875	@		II
304953	100736430	20992775876	@		II
304953	100736430	20992775877	@		II
304953	100736430	20992775878	.	.	.
304953	100736430	20992775879	Researchers	researcher	NN2
304953	100736430	20992775880	are	be	VBR
304953	100736430	20992775881	now	now	RT
304953	100736430	20992775882	interested	interested	JJ
304953	100736430	20992775883	in	in	II
304953	100736430	20992775884	doing	do	VDG
304953	100736430	20992775885	clinical	clinical	JJ
304953	100736430	20992775886	trials	trial	NN2
304953	100736430	20992775887	to	to	TO
304953	100736430	20992775888	evaluate	evaluate	VVI
304953	100736430	20992775889	drugs	drug	NN2
304953	100736430	20992775890	in	in	II
304953	100736430	20992775891	these	these	DD2
304953	100736430	20992775892	patients	patient	NN2
304953	100736430	20992775893	.	.	.
304953	100736430	20992775894	<p>		NULL
304953	100736430	20992775895	We	we	PPIS2
304953	100736430	20992775896	do	do	VD0
304953	100736430	20992775897	n't 	n't	XX
304953	100736430	20992775898	have	have	VHI
304953	100736430	20992775899	all	all	DB
304953	100736430	20992775900	that	that	DD1_CST
304953	100736430	20992775901	data	data	NN
304953	100736430	20992775902	yet	yet	RR
304953	100736430	20992775903	,	,	,
304953	100736430	20992775904	but	but	CCB
304953	100736430	20992775905	yes	yes	UH
304953	100736430	20992775906	,	,	,
304953	100736430	20992775907	it	it	PPH1
304953	100736430	20992775908	does	do	VDZ
304953	100736430	20992775909	.	.	.
304953	100736430	20992775910	The	the	AT
304953	100736430	20992775911	faster	faster	JJR_RRR
304953	100736430	20992775912	you	you	PPY
304953	100736430	20992775913	reach	reach	VV0
304953	100736430	20992775914	your	your	APPGE
304953	100736430	20992775915	nadir	nadir	NN1
304953	100736430	20992775916	,	,	,
304953	100736430	20992775917	the	the	AT
304953	100736430	20992775918	better	better	RRR
304953	100736430	20992775919	your	your	APPGE
304953	100736430	20992775920	outcome	outcome	NN1
304953	100736430	20992775921	as	as	CS31
304953	100736430	20992775922	long	long	CS32
304953	100736430	20992775923	as	as	CS33
304953	100736430	20992775924	the	the	AT
304953	100736430	20992775925	PSA	psa	NP1
304953	100736430	20992775926	nadir	nadir	NN1
304953	100736430	20992775927	is	be	VBZ
304953	100736430	20992775928	undetectable	undetectable	JJ
304953	100736430	20992775929	.	.	.
304953	100736430	20992775930	<p>		NULL
304953	100736430	20992775931	Do	do	VD0
304953	100736430	20992775932	you	you	PPY
304953	100736430	20992775933	always	always	RR
304953	100736430	20992775934	get	get	VVI
304953	100736430	20992775935	enough	enough	DD
304953	100736430	20992775936	patients	patient	NN2
304953	100736430	20992775937	to	to	TO
304953	100736430	20992775938	enroll	enroll	VVI
304953	100736430	20992775939	to	to	TO
304953	100736430	20992775940	have	have	VHI
304953	100736430	20992775941	statistically	statistically	RR
304953	100736430	20992775942	significant	significant	JJ
304953	100736430	20992775943	results	result	NN2
304953	100736430	20992775944	?	?	?
304953	100736430	20992775945	<p>		NULL
304953	100736430	20992775946	Occasionally	occasionally	RR
304953	100736430	20992775947	and	and	CC
304953	100736430	20992775948	more	more	RGR
304953	100736430	20992775949	often	often	RR
304953	100736430	20992775950	than	than	CSN
304953	100736430	20992775951	I	i	PPIS1
304953	100736430	20992775952	like	like	VV0
304953	100736430	20992775953	to	to	TO
304953	100736430	20992775954	see	see	VVI
304953	100736430	20992775955	we	we	PPIS2
304953	100736430	20992775956	have	have	VHI
304953	100736430	20992775957	great	great	JJ
304953	100736430	20992775958	ideas	idea	NN2
304953	100736430	20992775959	and	and	CC
304953	100736430	20992775960	activate	activate	VV0
304953	100736430	20992775961	studies	study	NN2
304953	100736430	20992775962	,	,	,
304953	100736430	20992775963	but	but	CCB
304953	100736430	20992775964	we	we	PPIS2
304953	100736430	20992775965	do	do	VD0
304953	100736430	20992775966	n't 	n't	XX
304953	100736430	20992775967	get	get	VVI
304953	100736430	20992775968	patients	patient	NN2
304953	100736430	20992775969	enrolling	enroll	VVG
304953	100736430	20992775970	.	.	.
304953	100736430	20992775971	One	one	MC1
304953	100736430	20992775972	example	example	NN1
304953	100736430	20992775973	is	be	VBZ
304953	100736430	20992775974	the	the	AT
304953	100736430	20992775975	START	start	NN1
304953	100736430	20992775976	study	study	NN1
304953	100736430	20992775977	.	.	.
304953	100736430	20992775978	This	this	DD1
304953	100736430	20992775979	is	be	VBZ
304953	100736430	20992775980	a	a	AT1
304953	100736430	20992775981	phase	phase	NN1
304953	100736430	20992775982	III	iii	MC
304953	100736430	20992775983	randomized	randomized	JJ@_VVD
304953	100736430	20992775984	trial	trial	NN1
304953	100736430	20992775985	comparing	compare	VVG
304953	100736430	20992775986	active	active	JJ
304953	100736430	20992775987	surveillance	surveillance	NN1
304953	100736430	20992775988	with	with	IW
304953	100736430	20992775989	radical	radical	JJ
304953	100736430	20992775990	treatment	treatment	NN1
304953	100736430	20992775991	either	either	RR
304953	100736430	20992775992	surgery	surgery	NN1
304953	100736430	20992775993	or	or	CC
304953	100736430	20992775994	radiation	radiation	NN1
304953	100736430	20992775995	therapy	therapy	NN1
304953	100736430	20992775996	.	.	.
304953	100736430	20992775997	Its	its	APPGE
304953	100736430	20992775998	an	a	AT1
304953	100736430	20992775999	excellent	excellent	JJ
304953	100736430	20992776000	,	,	,
304953	100736430	20992776001	state-of-the-art	state-of-the-art	JJ_NN1
304953	100736430	20992776002	study	study	NN1
304953	100736430	20992776003	attempting	attempt	VVG
304953	100736430	20992776004	to	to	TO
304953	100736430	20992776005	answer	answer	VVI
304953	100736430	20992776006	critical	critical	JJ
304953	100736430	20992776007	questions	question	NN2
304953	100736430	20992776008	,	,	,
304953	100736430	20992776009	but	but	CCB
304953	100736430	20992776010	since	since	CS
304953	100736430	20992776011	it	it	PPH1
304953	100736430	20992776012	started	start	VVD
304953	100736430	20992776013	about	about	RG
304953	100736430	20992776014	a	a	AT1
304953	100736430	20992776015	year	year	NNT1
304953	100736430	20992776016	ago	ago	RA
304953	100736430	20992776017	,	,	,
304953	100736430	20992776018	I	i	PPIS1
304953	100736430	20992776019	think	think	VV0
304953	100736430	20992776020	only	only	JJ
304953	100736430	20992776021	a	a-i	AT1
304953	100736430	20992776022	few	few	DA2
304953	100736430	20992776023	dozen	dozen	NNO
304953	100736430	20992776024	men	man	NN2
304953	100736430	20992776025	have	have	VH0
304953	100736430	20992776026	enrolled	enroll	VVN
304953	100736430	20992776027	.	.	.
304953	100736430	20992776028	<p>		NULL
304953	100736430	20992776029	Another	another	DD1
304953	100736430	20992776030	example	example	NN1
304953	100736430	20992776031	is	be	VBZ
304953	100736430	20992776032	a	a	AT1
304953	100736430	20992776033	CALGB		NN1
304953	100736430	20992776034	study	study	NN1
304953	100736430	20992776035	called	call	VVN_VVD@
304953	100736430	20992776036	the	the	AT
304953	100736430	20992776037	PUNCH	punch	NN1_NP1
304953	100736430	20992776038	trial	trial	NN1
304953	100736430	20992776039	.	.	.
304953	100736430	20992776040	Its	its	APPGE
304953	100736430	20992776041	comparing	compare	VVG
304953	100736430	20992776042	the	the	AT
304953	100736430	20992776043	rate	rate	NN1
304953	100736430	20992776044	of	of	IO
304953	100736430	20992776045	biochemical	biochemical	JJ
304953	100736430	20992776046	progressionfree		JJ
304953	100736430	20992776047	survival	survival	NN1
304953	100736430	20992776048	in	in	II
304953	100736430	20992776049	high-risk	high-risk	JJ
304953	100736430	20992776050	patients	patient	NN2
304953	100736430	20992776051	with	with	IW
304953	100736430	20992776052	localized	localized	JJ
304953	100736430	20992776053	prostate	prostate	NN1
304953	100736430	20992776054	cancer	cancer	NN1
304953	100736430	20992776055	who	who	PNQS
304953	100736430	20992776056	have	have	VH0
304953	100736430	20992776057	a	a	AT1
304953	100736430	20992776058	radical	radical	JJ_NN1
304953	100736430	20992776059	prostatectomy	prostatectomy	NN1
304953	100736430	20992776060	with	with	IW
304953	100736430	20992776061	or	or	CC
304953	100736430	20992776062	with	with	IW
304953	100736430	20992776063	out	out	II%
304953	100736430	20992776064	chemotherapy	chemotherapy	NN1
304953	100736430	20992776065	and	and	CC
304953	100736430	20992776066	hormones	hormone	NN2
304953	100736430	20992776067	beforehand	beforehand	RR
304953	100736430	20992776068	@		II
304953	100736430	20992776069	@		II
304953	100736430	20992776070	@		II
304953	100736430	20992776071	@		II
304953	100736430	20992776072	@		II
304953	100736430	20992776073	@		II
304953	100736430	20992776074	@		II
304953	100736430	20992776075	@		II
304953	100736430	20992776076	@		II
304953	100736430	20992776077	@		II
304953	100736430	20992776078	before	before	II_CS
304953	100736430	20992776079	surgery	surgery	NN1
304953	100736430	20992776080	slows	slow	VVZ
304953	100736430	20992776081	the	the	AT
304953	100736430	20992776082	cancers	cancer	NN2
304953	100736430	20992776083	possible	possible	JJ
304953	100736430	20992776084	return	return	NN1
304953	100736430	20992776085	;	;	;
304953	100736430	20992776086	its	its	APPGE
304953	100736430	20992776087	a	a	AT1
304953	100736430	20992776088	critical	critical	JJ
304953	100736430	20992776089	question	question	NN1
304953	100736430	20992776090	.	.	.
304953	100736430	20992776091	But	but	CCB
304953	100736430	20992776092	this	this	DD1
304953	100736430	20992776093	study	study	NN1
304953	100736430	20992776094	is	be	VBZ
304953	100736430	20992776095	not	not	XX
304953	100736430	20992776096	accruing	accrue	VVG
304953	100736430	20992776097	well	well	RR
304953	100736430	20992776098	either	either	RR_DD1
304953	100736430	20992776099	.	.	.
304953	100736430	20992776100	<p>		NULL
304953	100736430	20992776101	I	i	PPIS1
304953	100736430	20992776102	think	think	VV0
304953	100736430	20992776103	its	its	APPGE
304953	100736430	20992776104	sad	sad	JJ
304953	100736430	20992776105	that	that	CST
304953	100736430	20992776106	these	these	DD2
304953	100736430	20992776107	studies	study	NN2
304953	100736430	20992776108	exist	exist	VV0
304953	100736430	20992776109	but	but	CCB
304953	100736430	20992776110	patients	patient	NN2
304953	100736430	20992776111	are	be	VB0
304953	100736430	20992776112	n't 	n't	XX
304953	100736430	20992776113	enrolling	enroll	VVG
304953	100736430	20992776114	.	.	.
304953	100736430	20992776115	These	these	DD2
304953	100736430	20992776116	important	important	JJ
304953	100736430	20992776117	trials	trial	NN2
304953	100736430	20992776118	are	be	VBR
304953	100736430	20992776119	just	just	RR
304953	100736430	20992776120	languishing	languish	VVG_JJ@
304953	100736430	20992776121	and	and	CC
304953	100736430	20992776122	dying	die	VVG_JJ
304953	100736430	20992776123	on	on	II
304953	100736430	20992776124	the	the	AT
304953	100736430	20992776125	vine	vine	NN1
304953	100736430	20992776126	because	because	II21
304953	100736430	20992776127	of	of	II22
304953	100736430	20992776128	a	a	AT1
304953	100736430	20992776129	lack	lack	NN1
304953	100736430	20992776130	of	of	IO
304953	100736430	20992776131	accrual	accrual	NN1
304953	100736430	20992776132	and	and	CC
304953	100736430	20992776133	support.		NNU
304953	100736430	20992776134	*	*	FU
304953	100736430	20992776135	<p>		NULL
304953	100736430	20992776136	*Note	*note	FO
304953	100736430	20992776137	:	:	:
304953	100736430	20992776138	To	to	TO
304953	100736430	20992776139	learn	learn	VVI
304953	100736430	20992776140	more	more	RRR_DAR
304953	100736430	20992776141	about	about	II
304953	100736430	20992776142	these	these	DD2
304953	100736430	20992776143	two	two	MC
304953	100736430	20992776144	studies	study	NN2
304953	100736430	20992776145	,	,	,
304953	100736430	20992776146	log	log	NN1_VV0@
304953	100736430	20992776147	on	on	II21_RP
304953	100736430	20992776148	to	to	II22_II
304953	100736430	20992776149	www.clinicaltrials.gov	www.clinicaltrials.gov	NNU
304953	100736430	20992776150	and	and	CC
304953	100736430	20992776151	click	click	VV0_NN1
304953	100736430	20992776152	on	on	II
304953	100736430	20992776153	"	"	"
304953	100736430	20992776154	Search	search	NN1
304953	100736430	20992776155	for	for	IF
304953	100736430	20992776156	Clinical	clinical	JJ
304953	100736430	20992776157	Trials	trial	NN2
304953	100736430	20992776158	.	.	.
304953	100736430	20992776159	"	"	"
304953	100736430	20992776160	For	for	IF
304953	100736430	20992776161	details	detail	NN2
304953	100736430	20992776162	on	on	II
304953	100736430	20992776163	the	the	AT
304953	100736430	20992776164	START	start	NN1
304953	100736430	20992776165	study	study	NN1
304953	100736430	20992776166	,	,	,
304953	100736430	20992776167	enter	enter	VV0
304953	100736430	20992776168	the	the	AT
304953	100736430	20992776169	protocol	protocol	NN1
304953	100736430	20992776170	identification	identification	NN1
304953	100736430	20992776171	number	number	NN1
304953	100736430	20992776172	NCT00499174		FO
304953	100736430	20992776173	.	.	.
304953	100736430	20992776174	For	for	IF
304953	100736430	20992776175	details	detail	NN2
304953	100736430	20992776176	on	on	II
304953	100736430	20992776177	the	the	AT
304953	100736430	20992776178	PUNCH	punch	NN1_NP1
304953	100736430	20992776179	trial	trial	NN1
304953	100736430	20992776180	,	,	,
304953	100736430	20992776181	enter	enter	VV0
304953	100736430	20992776182	the	the	AT
304953	100736430	20992776183	protocol	protocol	NN1
304953	100736430	20992776184	identification	identification	NN1
304953	100736430	20992776185	number	number	NN1
304953	100736430	20992776186	CALGB-90203		MC
304953	100736430	20992776187	.	.	.
304953	100736430	20992776188	<p>		NULL
304953	100736430	20992776189	Part	part	NN1
304953	100736430	20992776190	of	of	IO
304953	100736430	20992776191	the	the	AT
304953	100736430	20992776192	problem	problem	NN1
304953	100736430	20992776193	is	be	VBZ
304953	100736430	20992776194	also	also	RR
304953	100736430	20992776195	that	that	CST_DD1
304953	100736430	20992776196	even	even	CS21
304953	100736430	20992776197	though	though	CS22
304953	100736430	20992776198	we	we	PPIS2
304953	100736430	20992776199	have	have	VH0
304953	100736430	20992776200	well-designed	well-designed	JJ
304953	100736430	20992776201	studies	study	NN2
304953	100736430	20992776202	,	,	,
304953	100736430	20992776203	we	we	PPIS2
304953	100736430	20992776204	do	do	VD0
304953	100736430	20992776205	n't 	n't	XX
304953	100736430	20992776206	market	market	VVI
304953	100736430	20992776207	them	them	PPHO2
304953	100736430	20992776208	.	.	.
304953	100736430	20992776209	By	by	RP%_II
304953	100736430	20992776210	"	"	"
304953	100736430	20992776211	we	we	PPIS2
304953	100736430	20992776212	,	,	,
304953	100736430	20992776213	"	"	"
304953	100736430	20992776214	I	i	PPIS1
304953	100736430	20992776215	mean	mean	VV0
304953	100736430	20992776216	cooperative	cooperative	JJ
304953	100736430	20992776217	groups	group	NN2
304953	100736430	20992776218	,	,	,
304953	100736430	20992776219	individual	individual	JJ
304953	100736430	20992776220	researchers	researcher	NN2
304953	100736430	20992776221	,	,	,
304953	100736430	20992776222	and	and	CC
304953	100736430	20992776223	,	,	,
304953	100736430	20992776224	to	to	II
304953	100736430	20992776225	some	some	DD
304953	100736430	20992776226	degree	degree	NN1
304953	100736430	20992776227	,	,	,
304953	100736430	20992776228	pharmaceutical	pharmaceutical	JJ
304953	100736430	20992776229	companies	company	NN2
304953	100736430	20992776230	.	.	.
304953	100736430	20992776231	This	this	DD1
304953	100736430	20992776232	is	be	VBZ
304953	100736430	20992776233	where	where	RRQ_CS
304953	100736430	20992776234	we	we	PPIS2
304953	100736430	20992776235	fall	fall	VV0
304953	100736430	20992776236	behind	behind	RL@
304953	100736430	20992776237	.	.	.
304953	100736430	20992776238	We	we	PPIS2
304953	100736430	20992776239	do	do	VD0
304953	100736430	20992776240	n't 	n't	XX
304953	100736430	20992776241	have	have	VHI
304953	100736430	20992776242	CDs	cd	NN2
304953	100736430	20992776243	,	,	,
304953	100736430	20992776244	pamphlets	pamphlet	NN2
304953	100736430	20992776245	,	,	,
304953	100736430	20992776246	or	or	CC
304953	100736430	20992776247	reminders	reminder	NN2
304953	100736430	20992776248	.	.	.
304953	100736430	20992776249	If	if	CS
304953	100736430	20992776250	you	you	PPY
304953	100736430	20992776251	have	have	VH0
304953	100736430	20992776252	materials	material	NN2
304953	100736430	20992776253	that	that	CST
304953	100736430	20992776254	you	you	PPY
304953	100736430	20992776255	can	can	VM
304953	100736430	20992776256	pass	pass	VVI
304953	100736430	20992776257	out	out	RP
304953	100736430	20992776258	to	to	II
304953	100736430	20992776259	investigators	investigator	NN2
304953	100736430	20992776260	and	and	CC
304953	100736430	20992776261	to	to	II
304953	100736430	20992776262	physicians	physician	NN2
304953	100736430	20992776263	in	in	II
304953	100736430	20992776264	busy	busy	JJ
304953	100736430	20992776265	clinics	clinic	NN2
304953	100736430	20992776266	,	,	,
304953	100736430	20992776267	patients	patient	NN2
304953	100736430	20992776268	@		II
304953	100736430	20992776269	@		II
304953	100736430	20992776270	@		II
304953	100736430	20992776271	@		II
304953	100736430	20992776272	@		II
304953	100736430	20992776273	@		II
304953	100736430	20992776274	@		II
304953	100736430	20992776275	@		II
304953	100736430	20992776276	@		II
304953	100736430	20992776277	@		II
304953	100736430	20992776278	aids	aids	NN2
304953	100736430	20992776279	.	.	.
304953	100736430	20992776280	If	if	CS
304953	100736430	20992776281	Procter	procter	NP1_NN1
304953	100736430	20992776282	&amp;		CC
304953	100736430	20992776283	Gamble	gamble	NN1
304953	100736430	20992776284	comes	come	VVZ
304953	100736430	20992776285	out	out	RP
304953	100736430	20992776286	with	with	IW
304953	100736430	20992776287	a	a	AT1
304953	100736430	20992776288	new	new	JJ
304953	100736430	20992776289	soap	soap	NN1
304953	100736430	20992776290	and	and	CC
304953	100736430	20992776291	does	do	VDZ
304953	100736430	20992776292	n't 	n't	XX
304953	100736430	20992776293	market	market	VVI
304953	100736430	20992776294	it	it	PPH1
304953	100736430	20992776295	,	,	,
304953	100736430	20992776296	the	the	AT
304953	100736430	20992776297	soap	soap	NN1
304953	100736430	20992776298	does	do	VDZ
304953	100736430	20992776299	n't 	n't	XX
304953	100736430	20992776300	sell	sell	VVI
304953	100736430	20992776301	.	.	.
304953	100736430	20992776302	Unfortunately	unfortunately	RR
304953	100736430	20992776303	,	,	,
304953	100736430	20992776304	that 's		NN2_VVZ
304953	100736430	20992776305	what	what	DDQ
304953	100736430	20992776306	we	we	PPIS2
304953	100736430	20992776307	do	do	VD0
304953	100736430	20992776308	.	.	.
304953	100736430	20992776309	We	we	PPIS2
304953	100736430	20992776310	think	think	VV0
304953	100736430	20992776311	that	that	CST
304953	100736430	20992776312	investigators	investigator	NN2
304953	100736430	20992776313	will	will	VM
304953	100736430	20992776314	remember	remember	VVI
304953	100736430	20992776315	all	all	DB
304953	100736430	20992776316	of	of	IO
304953	100736430	20992776317	the	the	AT
304953	100736430	20992776318	studies	study	NN2
304953	100736430	20992776319	and	and	CC
304953	100736430	20992776320	enroll	enroll	VVI
304953	100736430	20992776321	patients	patient	NN2
304953	100736430	20992776322	.	.	.
304953	100736430	20992776323	But	but	CCB
304953	100736430	20992776324	we	we	PPIS2
304953	100736430	20992776325	know	know	VV0
304953	100736430	20992776326	from	from	II
304953	100736430	20992776327	experience	experience	NN1
304953	100736430	20992776328	that	that	CST
304953	100736430	20992776329	that	that	DD1
304953	100736430	20992776330	does	do	VDZ
304953	100736430	20992776331	n't 	n't	XX
304953	100736430	20992776332	happen	happen	VVI
304953	100736430	20992776333	.	.	.
304953	100736430	20992776334	<p>		NULL
304953	100736430	20992776335	Do	do	VD0
304953	100736430	20992776336	studies	study	NN2
304953	100736430	20992776337	ever	ever	RR
304953	100736430	20992776338	get	get	VVI
304953	100736430	20992776339	cancelled	cancel	VVN
304953	100736430	20992776340	due	due	JJ
304953	100736430	20992776341	to	to	TO
304953	100736430	20992776342	lack	lack	VVI
304953	100736430	20992776343	of	of	IO
304953	100736430	20992776344	enrollment	enrollment	NN1
304953	100736430	20992776345	?	?	?
304953	100736430	20992776346	<p>		NULL
304953	100736430	20992776347	Unfortunately	unfortunately	RR
304953	100736430	20992776348	,	,	,
304953	100736430	20992776349	yes	yes	UH
304953	100736430	20992776350	.	.	.
304953	100736430	20992776351	Its	its	APPGE
304953	100736430	20992776352	not	not	XX
304953	100736430	20992776353	that	that	CST
304953	100736430	20992776354	they	they	PPHS2
304953	100736430	20992776355	close	close	VV0
304953	100736430	20992776356	because	because	CS
304953	100736430	20992776357	we	we	PPIS2
304953	100736430	20992776358	are	be	VB0
304953	100736430	20992776359	n't 	n't	XX
304953	100736430	20992776360	asking	ask	VVG
304953	100736430	20992776361	great	great	JJ
304953	100736430	20992776362	questions	question	NN2
304953	100736430	20992776363	.	.	.
304953	100736430	20992776364	We	we	PPIS2
304953	100736430	20992776365	are	be	VBR
304953	100736430	20992776366	.	.	.
304953	100736430	20992776367	Its	its	APPGE
304953	100736430	20992776368	that	that	DD1_CST
304953	100736430	20992776369	patients	patient	NN2
304953	100736430	20992776370	do	do	VD0
304953	100736430	20992776371	n't 	n't	XX
304953	100736430	20992776372	know	know	VVI
304953	100736430	20992776373	about	about	II
304953	100736430	20992776374	the	the	AT
304953	100736430	20992776375	trials	trial	NN2
304953	100736430	20992776376	or	or	CC
304953	100736430	20992776377	that	that	CST
304953	100736430	20992776378	they	they	PPHS2
304953	100736430	20992776379	are	be	VB0
304953	100736430	20992776380	n't 	n't	XX
304953	100736430	20992776381	willing	willing	JJ
304953	100736430	20992776382	to	to	TO
304953	100736430	20992776383	enroll	enroll	VVI
304953	100736430	20992776384	.	.	.
304953	100736430	20992776385	One	one	MC1
304953	100736430	20992776386	trial	trial	NN1
304953	100736430	20992776387	that	that	CST
304953	100736430	20992776388	closed	close	VVD_JJ
304953	100736430	20992776389	was	be	VBDZ
304953	100736430	20992776390	SWOG		NP1_NN1
304953	100736430	20992776391	8890		MC
304953	100736430	20992776392	,	,	,
304953	100736430	20992776393	which	which	DDQ
304953	100736430	20992776394	looked	look	VVD
304953	100736430	20992776395	at	at	II
304953	100736430	20992776396	radiation	radiation	NN1
304953	100736430	20992776397	versus	versus	II
304953	100736430	20992776398	surgery	surgery	NN1
304953	100736430	20992776399	,	,	,
304953	100736430	20992776400	an	a	AT1
304953	100736430	20992776401	age-old	age-old	JJ
304953	100736430	20992776402	question	question	NN1
304953	100736430	20992776403	.	.	.
304953	100736430	20992776404	But	but	CCB
304953	100736430	20992776405	investigators	investigator	NN2
304953	100736430	20992776406	did	do	VDD
304953	100736430	20992776407	n't 	n't	XX
304953	100736430	20992776408	put	put	VVI
304953	100736430	20992776409	patients	patient	NN2
304953	100736430	20992776410	on	on	II
304953	100736430	20992776411	it	it	PPH1
304953	100736430	20992776412	.	.	.
304953	100736430	20992776413	Another	another	DD1
304953	100736430	20992776414	such	such	DA
304953	100736430	20992776415	trial	trial	NN1
304953	100736430	20992776416	was	be	VBDZ
304953	100736430	20992776417	to	to	TO
304953	100736430	20992776418	compare	compare	VVI
304953	100736430	20992776419	brachytherapy	brachytherapy	NN1
304953	100736430	20992776420	with	with	IW
304953	100736430	20992776421	surgery	surgery	NN1
304953	100736430	20992776422	.	.	.
304953	100736430	20992776423	That	that	DD1
304953	100736430	20992776424	one	one	PN1
304953	100736430	20992776425	did	do	VDD
304953	100736430	20992776426	n't 	n't	XX
304953	100736430	20992776427	accrue	accrue	VVI
304953	100736430	20992776428	enough	enough	DD
304953	100736430	20992776429	patients	patient	NN2
304953	100736430	20992776430	.	.	.
304953	100736430	20992776431	Another	another	DD1
304953	100736430	20992776432	one	one	PN1
304953	100736430	20992776433	was	be	VBDZ
304953	100736430	20992776434	looking	look	VVG
304953	100736430	20992776435	at	at	II
304953	100736430	20992776436	hormone	hormone	NN1
304953	100736430	20992776437	therapy	therapy	NN1
304953	100736430	20992776438	prior	prior	II21
304953	100736430	20992776439	to	to	II22
304953	100736430	20992776440	radical	radical	JJ_NN1
304953	100736430	20992776441	prostatectomy	prostatectomy	NN1
304953	100736430	20992776442	.	.	.
304953	100736430	20992776443	That	that	DD1
304953	100736430	20992776444	one	one	PN1
304953	100736430	20992776445	did	do	VDD
304953	100736430	20992776446	n't 	n't	XX
304953	100736430	20992776447	accrue	accrue	VVI
304953	100736430	20992776448	enough	enough	DD
304953	100736430	20992776449	patients	patient	NN2
304953	100736430	20992776450	.	.	.
304953	100736430	20992776451	<p>		NULL
304953	100736430	20992776452	For	for	IF
304953	100736430	20992776453	SWOG		NP1_NN1
304953	100736430	20992776454	,	,	,
304953	100736430	20992776455	it	it	PPH1
304953	100736430	20992776456	used	use	VMK
304953	100736430	20992776457	to	to	TO
304953	100736430	20992776458	be	be	VBI
304953	100736430	20992776459	that	that	CST
304953	100736430	20992776460	I	i	PPIS1
304953	100736430	20992776461	would	would	VM
304953	100736430	20992776462	decide	decide	VVI
304953	100736430	20992776463	that	that	CST_DD1
304953	100736430	20992776464	pursuing	pursue	VVG
304953	100736430	20992776465	the	the	AT
304953	100736430	20992776466	trial	trial	NN1
304953	100736430	20992776467	was	be	VBDZ
304953	100736430	20992776468	@		II
304953	100736430	20992776469	@		II
304953	100736430	20992776470	@		II
304953	100736430	20992776471	@		II
304953	100736430	20992776472	@		II
304953	100736430	20992776473	@		II
304953	100736430	20992776474	@		II
304953	100736430	20992776475	@		II
304953	100736430	20992776476	@		II
304953	100736430	20992776477	@		II
304953	100736430	20992776478	the	the	AT
304953	100736430	20992776479	Data	data	NN
304953	100736430	20992776480	Safety	safety	NN1
304953	100736430	20992776481	and	and	CC
304953	100736430	20992776482	Monitoring	monitoring	NN1_JJ@
304953	100736430	20992776483	Committee	committee	NN1
304953	100736430	20992776484	tracks	track	NN2_VVZ@
304953	100736430	20992776485	accrual	accrual	NN1
304953	100736430	20992776486	.	.	.
304953	100736430	20992776487	If	if	CS
304953	100736430	20992776488	it	it	PPH1
304953	100736430	20992776489	looks	look	VVZ
304953	100736430	20992776490	like	like	II
304953	100736430	20992776491	were	be	VBDR
304953	100736430	20992776492	not	not	XX
304953	100736430	20992776493	going	go	VVG
304953	100736430	20992776494	to	to	TO
304953	100736430	20992776495	have	have	VHI
304953	100736430	20992776496	enough	enough	DD
304953	100736430	20992776497	people	people	NN
304953	100736430	20992776498	,	,	,
304953	100736430	20992776499	they	they	PPHS2
304953	100736430	20992776500	say	say	VV0
304953	100736430	20992776501	its	its	APPGE
304953	100736430	20992776502	futile	futile	JJ
304953	100736430	20992776503	and	and	CC
304953	100736430	20992776504	the	the	AT
304953	100736430	20992776505	trial	trial	NN1
304953	100736430	20992776506	closes	close	VVZ
304953	100736430	20992776507	.	.	.
304953	100736430	20992776508	<p>		NULL
304953	100736430	20992776509	One	one	MC1
304953	100736430	20992776510	of	of	IO
304953	100736430	20992776511	the	the	AT
304953	100736430	20992776512	more	more	RGR
304953	100736430	20992776513	recent	recent	JJ
304953	100736430	20992776514	trials	trial	NN2
304953	100736430	20992776515	to	to	TO
304953	100736430	20992776516	close	close	VVI
304953	100736430	20992776517	was	be	VBDZ
304953	100736430	20992776518	sponsored	sponsor	VVN
304953	100736430	20992776519	by	by	II
304953	100736430	20992776520	a	a	AT1
304953	100736430	20992776521	pharmaceutical	pharmaceutical	JJ
304953	100736430	20992776522	company	company	NN1
304953	100736430	20992776523	.	.	.
304953	100736430	20992776524	They	they	PPHS2
304953	100736430	20992776525	were	be	VBDR
304953	100736430	20992776526	studying	study	VVG
304953	100736430	20992776527	Taxotere		NP1_NN1_JJ
304953	100736430	20992776528	(	(	(
304953	100736430	20992776529	docetaxel		NN1_VV0
304953	100736430	20992776530	)	)	)
304953	100736430	20992776531	,	,	,
304953	100736430	20992776532	a	a	AT1
304953	100736430	20992776533	type	type	NN1
304953	100736430	20992776534	of	of	IO
304953	100736430	20992776535	chemotherapy	chemotherapy	NN1
304953	100736430	20992776536	,	,	,
304953	100736430	20992776537	in	in	II
304953	100736430	20992776538	high-risk	high-risk	JJ
304953	100736430	20992776539	patients	patient	NN2
304953	100736430	20992776540	after	after	II_CS
304953	100736430	20992776541	radical	radical	JJ_NN1
304953	100736430	20992776542	prostatectomy	prostatectomy	NN1
304953	100736430	20992776543	.	.	.
304953	100736430	20992776544	The	the	AT
304953	100736430	20992776545	trial	trial	NN1
304953	100736430	20992776546	was	be	VBDZ
304953	100736430	20992776547	supposed	supposed	JJ
304953	100736430	20992776548	to	to	TO
304953	100736430	20992776549	accrue	accrue	VVI
304953	100736430	20992776550	several	several	DA2
304953	100736430	20992776551	thousand	thousand	NNO
304953	100736430	20992776552	patients	patient	NN2
304953	100736430	20992776553	,	,	,
304953	100736430	20992776554	but	but	CCB
304953	100736430	20992776555	only	only	JJ
304953	100736430	20992776556	about	about	RG
304953	100736430	20992776557	1,700	1,700	MC
304953	100736430	20992776558	enrolled	enroll	VVD_VVN
304953	100736430	20992776559	in	in	II_RP@
304953	100736430	20992776560	a	a	AT1
304953	100736430	20992776561	few	few	DA2
304953	100736430	20992776562	years	year	NNT2
304953	100736430	20992776563	,	,	,
304953	100736430	20992776564	so	so	CS@_RR
304953	100736430	20992776565	the	the	AT
304953	100736430	20992776566	company	company	NN1
304953	100736430	20992776567	closed	close	VVD
304953	100736430	20992776568	it	it	PPH1
304953	100736430	20992776569	.	.	.
304953	100736430	20992776570	As	as	II21
304953	100736430	20992776571	for	for	II22
304953	100736430	20992776572	when	when	RRQ
304953	100736430	20992776573	to	to	TO
304953	100736430	20992776574	close	close	VVI
304953	100736430	20992776575	a	a	AT1
304953	100736430	20992776576	trial	trial	NN1
304953	100736430	20992776577	,	,	,
304953	100736430	20992776578	that	that	DD1_CST
304953	100736430	20992776579	varies	vary	VVZ
304953	100736430	20992776580	,	,	,
304953	100736430	20992776581	but	but	CCB
304953	100736430	20992776582	you	you	PPY
304953	100736430	20992776583	get	get	VV0
304953	100736430	20992776584	to	to	II
304953	100736430	20992776585	a	a	AT1
304953	100736430	20992776586	point	point	NN1
304953	100736430	20992776587	where	where	RRQ
304953	100736430	20992776588	you	you	PPY
304953	100736430	20992776589	realize	realize	VV0
304953	100736430	20992776590	that	that	CST
304953	100736430	20992776591	you 're		VV0
304953	100736430	20992776592	not	not	XX
304953	100736430	20992776593	going	go	VVG
304953	100736430	20992776594	to	to	TO
304953	100736430	20992776595	have	have	VHI
304953	100736430	20992776596	enough	enough	DD
304953	100736430	20992776597	patients	patient	NN2
304953	100736430	20992776598	to	to	TO
304953	100736430	20992776599	get	get	VVI
304953	100736430	20992776600	a	a	AT1
304953	100736430	20992776601	statistically	statistically	RR
304953	100736430	20992776602	significant	significant	JJ
304953	100736430	20992776603	answer	answer	NN1
304953	100736430	20992776604	.	.	.
304953	100736430	20992776605	Continuing	continue	VVG
304953	100736430	20992776606	the	the	AT
304953	100736430	20992776607	trial	trial	NN1
304953	100736430	20992776608	at	at	II
304953	100736430	20992776609	that	that	DD1
304953	100736430	20992776610	point	point	NN1
304953	100736430	20992776611	is	be	VBZ
304953	100736430	20992776612	a	a	AT1
304953	100736430	20992776613	waste	waste	NN1
304953	100736430	20992776614	of	of	IO
304953	100736430	20992776615	resources	resource	NN2
304953	100736430	20992776616	and	and	CC
304953	100736430	20992776617	not	not	XX
304953	100736430	20992776618	the	the	AT
304953	100736430	20992776619	right	right	JJ_NN1
304953	100736430	20992776620	thing	thing	NN1
304953	100736430	20992776621	to	to	TO
304953	100736430	20992776622	do	do	VDI
304953	100736430	20992776623	for	for	IF
304953	100736430	20992776624	patients	patient	NN2
304953	100736430	20992776625	.	.	.
304953	100736430	20992776626	<p>		NULL
304953	100736430	20992776627	So	so	RR
304953	100736430	20992776628	patients	patient	NN2
304953	100736430	20992776629	should	should	VM
304953	100736430	20992776630	ask	ask	VVI
304953	100736430	20992776631	their	their	APPGE
304953	100736430	20992776632	primary	primary	JJ_NN1
304953	100736430	20992776633	care	care	NN1
304953	100736430	20992776634	physicians	physician	NN2
304953	100736430	20992776635	and	and	CC
304953	100736430	20992776636	specialists	specialist	NN2
304953	100736430	20992776637	about	about	II
304953	100736430	20992776638	participating	participate	VVG
304953	100736430	20992776639	in	in	II_RP@
304953	100736430	20992776640	studies	study	NN2
304953	100736430	20992776641	?	?	?
304953	100736430	20992776642	<p>		NULL
304953	100736430	20992776643	Prostate	prostate	NN1
304953	100736430	20992776644	research	research	NN1
304953	100736430	20992776645	is	be	VBZ
304953	100736430	20992776646	about	about	RG
304953	100736430	20992776647	10	10	MC
304953	100736430	20992776648	to	to	II
304953	100736430	20992776649	15	15	MC
304953	100736430	20992776650	years	year	NNT2
304953	100736430	20992776651	behind	behind	II
304953	100736430	20992776652	research	research	NN1
304953	100736430	20992776653	into	into	II
304953	100736430	20992776654	breast	breast	NN1
304953	100736430	20992776655	and	and	CC
304953	100736430	20992776656	colorectal	colorectal	JJ
304953	100736430	20992776657	cancers	cancer	NN2
304953	100736430	20992776658	because	because	CS
304953	100736430	20992776659	,	,	,
304953	100736430	20992776660	in	in	RR21
304953	100736430	20992776661	general	general	RR22
304953	100736430	20992776662	,	,	,
304953	100736430	20992776663	men	man	NN2
304953	100736430	20992776664	are	be	VBR
304953	100736430	20992776665	more	more	RGR
304953	100736430	20992776666	reluctant	reluctant	JJ
304953	100736430	20992776667	than	than	CSN
304953	100736430	20992776668	@		II
304953	100736430	20992776669	@		II
304953	100736430	20992776670	@		II
304953	100736430	20992776671	@		II
304953	100736430	20992776672	@		II
304953	100736430	20992776673	@		II
304953	100736430	20992776674	@		II
304953	100736430	20992776675	@		II
304953	100736430	20992776676	@		II
304953	100736430	20992776677	@		II
304953	100736430	20992776678	at	at	II
304953	100736430	20992776679	the	the	AT
304953	100736430	20992776680	number	number	NN1
304953	100736430	20992776681	of	of	IO
304953	100736430	20992776682	women	woman	NN2
304953	100736430	20992776683	who	who	PNQS
304953	100736430	20992776684	go	go	VV0
304953	100736430	20992776685	on	on	II_RP@
304953	100736430	20992776686	breast	breast	NN1
304953	100736430	20992776687	cancer	cancer	NN1
304953	100736430	20992776688	trials	trial	NN2
304953	100736430	20992776689	versus	versus	II
304953	100736430	20992776690	men	man	NN2
304953	100736430	20992776691	on	on	II
304953	100736430	20992776692	prostate	prostate	NN1
304953	100736430	20992776693	cancer	cancer	NN1
304953	100736430	20992776694	trials	trial	NN2
304953	100736430	20992776695	,	,	,
304953	100736430	20992776696	you	you	PPY
304953	100736430	20992776697	are	be	VBR
304953	100736430	20992776698	looking	look	VVG
304953	100736430	20992776699	at	at	II
304953	100736430	20992776700	about	about	RG
304953	100736430	20992776701	30,000	30,000	MC
304953	100736430	20992776702	versus	versus	II
304953	100736430	20992776703	9,000	9,000	MC
304953	100736430	20992776704	a	a	AT1
304953	100736430	20992776705	year	year	NNT1
304953	100736430	20992776706	.	.	.
304953	100736430	20992776707	That 's		NN2_VVZ
304953	100736430	20992776708	why	why	RRQ
304953	100736430	20992776709	we 've		NN1
304953	100736430	20992776710	learned	learn	VVD_VVN
304953	100736430	20992776711	so	so	RG
304953	100736430	20992776712	much	much	DA1_RR
304953	100736430	20992776713	about	about	II
304953	100736430	20992776714	breast	breast	NN1
304953	100736430	20992776715	cancer	cancer	NN1
304953	100736430	20992776716	in	in	II
304953	100736430	20992776717	recent	recent	JJ
304953	100736430	20992776718	years	year	NNT2
304953	100736430	20992776719	.	.	.
304953	100736430	20992776720	Hopefully	hopefully	RR
304953	100736430	20992776721	,	,	,
304953	100736430	20992776722	we	we	PPIS2
304953	100736430	20992776723	can	can	VM
304953	100736430	20992776724	encourage	encourage	VVI
304953	100736430	20992776725	more	more	DAR
304953	100736430	20992776726	men	man	NN2
304953	100736430	20992776727	to	to	TO
304953	100736430	20992776728	consider	consider	VVI
304953	100736430	20992776729	participating	participate	VVG_JJ
304953	100736430	20992776730	in	in	II_RP@
304953	100736430	20992776731	a	a	AT1
304953	100736430	20992776732	clinical	clinical	JJ
304953	100736430	20992776733	trial	trial	NN1
304953	100736430	20992776734	.	.	.
304953	100736430	20992776735	<p>		NULL
304953	100736430	20992776736	What	what	DDQ
304953	100736430	20992776737	exciting	exciting	JJ
304953	100736430	20992776738	developments	development	NN2
304953	100736430	20992776739	can	can	VM_VV0%
304953	100736430	20992776740	prostate	prostate	NN1
304953	100736430	20992776741	cancer	cancer	NN1
304953	100736430	20992776742	patients	patient	NN2
304953	100736430	20992776743	expect	expect	VV0
304953	100736430	20992776744	in	in	II_RP@
304953	100736430	20992776745	the	the	AT
304953	100736430	20992776746	next	next	MD
304953	100736430	20992776747	five	five	MC
304953	100736430	20992776748	years	year	NNT2
304953	100736430	20992776749	?	?	?
304953	100736430	20992776750	What	what	DDQ
304953	100736430	20992776751	does	do	VDZ
304953	100736430	20992776752	the	the	AT
304953	100736430	20992776753	future	future	NN1
304953	100736430	20992776754	look	look	VVI
304953	100736430	20992776755	like	like	CS_II
304953	100736430	20992776756	in	in	II31
304953	100736430	20992776757	terms	terms	II32
304953	100736430	20992776758	of	of	II33
304953	100736430	20992776759	prostate	prostate	NN1
304953	100736430	20992776760	cancer	cancer	NN1
304953	100736430	20992776761	treatment	treatment	NN1
304953	100736430	20992776762	?	?	?
304953	100736430	20992776763	<p>		NULL
304953	100736430	20992776764	I	i	PPIS1
304953	100736430	20992776765	think	think	VV0
304953	100736430	20992776766	were	be	VBDR
304953	100736430	20992776767	going	go	VVGK
304953	100736430	20992776768	to	to	TO
304953	100736430	20992776769	continue	continue	VVI
304953	100736430	20992776770	finding	find	VVG_NN1_JJ@
304953	100736430	20992776771	prostate	prostate	NN1
304953	100736430	20992776772	cancers	cancer	NN2
304953	100736430	20992776773	early	early	RR
304953	100736430	20992776774	on	on	RP@_II
304953	100736430	20992776775	,	,	,
304953	100736430	20992776776	but	but	CCB
304953	100736430	20992776777	well	well	RR
304953	100736430	20992776778	use	use	VV0
304953	100736430	20992776779	less	less	RGR_DAR
304953	100736430	20992776780	aggressive	aggressive	JJ
304953	100736430	20992776781	treatments	treatment	NN2
304953	100736430	20992776782	than	than	CSN
304953	100736430	20992776783	we	we	PPIS2
304953	100736430	20992776784	have	have	VH0
304953	100736430	20992776785	right	right	RR
304953	100736430	20992776786	now	now	RT
304953	100736430	20992776787	.	.	.
304953	100736430	20992776788	All	all	DB
304953	100736430	20992776789	of	of	IO
304953	100736430	20992776790	the	the	AT
304953	100736430	20992776791	talk	talk	NN1
304953	100736430	20992776792	has	have	VHZ
304953	100736430	20992776793	been	be	VBN
304953	100736430	20992776794	about	about	II_RG%
304953	100736430	20992776795	surgical	surgical	JJ
304953	100736430	20992776796	robots	robot	NN2
304953	100736430	20992776797	and	and	CC
304953	100736430	20992776798	how	how	RGQ@
304953	100736430	20992776799	much	much	DA1
304953	100736430	20992776800	radiation	radiation	NN1
304953	100736430	20992776801	we	we	PPIS2
304953	100736430	20992776802	can	can	VM
304953	100736430	20992776803	use	use	VVI
304953	100736430	20992776804	without	without	IW
304953	100736430	20992776805	destroying	destroy	VVG
304953	100736430	20992776806	surrounding	surrounding	JJ
304953	100736430	20992776807	tissues	tissue	NN2
304953	100736430	20992776808	.	.	.
304953	100736430	20992776809	But	but	CCB
304953	100736430	20992776810	robots	robot	NN2
304953	100736430	20992776811	in	in	RR21
304953	100736430	20992776812	particular	particular	RR22
304953	100736430	20992776813	have	have	VH0
304953	100736430	20992776814	been	be	VBN
304953	100736430	20992776815	a	a	AT1
304953	100736430	20992776816	lateral	lateral	JJ
304953	100736430	20992776817	step	step	NN1
304953	100736430	20992776818	,	,	,
304953	100736430	20992776819	not	not	XX
304953	100736430	20992776820	a	a	AT1
304953	100736430	20992776821	step	step	NN1
304953	100736430	20992776822	forward	forward	RL
304953	100736430	20992776823	,	,	,
304953	100736430	20992776824	in	in	II
304953	100736430	20992776825	the	the	AT
304953	100736430	20992776826	treatment	treatment	NN1
304953	100736430	20992776827	of	of	IO
304953	100736430	20992776828	prostate	prostate	NN1
304953	100736430	20992776829	cancer	cancer	NN1
304953	100736430	20992776830	.	.	.
304953	100736430	20992776831	There 's		NN2_NP1@
304953	100736430	20992776832	no	no	AT
304953	100736430	20992776833	question	question	NN1
304953	100736430	20992776834	that	that	CST
304953	100736430	20992776835	in	in	II
304953	100736430	20992776836	some	some	DD
304953	100736430	20992776837	peoples	people	NN2
304953	100736430	20992776838	hands	hand	NN2
304953	100736430	20992776839	,	,	,
304953	100736430	20992776840	robotic	robotic	JJ
304953	100736430	20992776841	surgery	surgery	NN1
304953	100736430	20992776842	may	may	VM
304953	100736430	20992776843	be	be	VBI
304953	100736430	20992776844	a	a	RR31
304953	100736430	20992776845	little	little	RR32
304953	100736430	20992776846	bit	bit	RR33
304953	100736430	20992776847	better	better	RRR_JJR
304953	100736430	20992776848	than	than	CSN
304953	100736430	20992776849	a	a	AT1
304953	100736430	20992776850	traditional	traditional	JJ
304953	100736430	20992776851	approach	approach	NN1
304953	100736430	20992776852	.	.	.
304953	100736430	20992776853	But	but	CCB
304953	100736430	20992776854	its	its	APPGE
304953	100736430	20992776855	the	the	AT
304953	100736430	20992776856	person	person	NN1
304953	100736430	20992776857	who	who	PNQS
304953	100736430	20992776858	performs	perform	VVZ
304953	100736430	20992776859	the	the	AT
304953	100736430	20992776860	robotic	robotic	JJ
304953	100736430	20992776861	procedure	procedure	NN1
304953	100736430	20992776862	that	that	CST
304953	100736430	20992776863	matters	matter	NN2_VVZ@
304953	100736430	20992776864	,	,	,
304953	100736430	20992776865	not	not	XX
304953	100736430	20992776866	the	the	AT
304953	100736430	20992776867	robot	robot	NN1
304953	100736430	20992776868	@		II
304953	100736430	20992776869	@		II
304953	100736430	20992776870	@		II
304953	100736430	20992776871	@		II
304953	100736430	20992776872	@		II
304953	100736430	20992776873	@		II
304953	100736430	20992776874	@		II
304953	100736430	20992776875	@		II
304953	100736430	20992776876	@		II
304953	100736430	20992776877	@		II
304953	100736430	20992776878	have	have	VHI
304953	100736430	20992776879	made	make	VVN
304953	100736430	20992776880	more	more	DAR_RRR
304953	100736430	20992776881	progress	progress	NN1
304953	100736430	20992776882	by	by	II
304953	100736430	20992776883	focusing	focus	VVG
304953	100736430	20992776884	on	on	II_RP@
304953	100736430	20992776885	other	other	JJ
304953	100736430	20992776886	areas	area	NN2
304953	100736430	20992776887	,	,	,
304953	100736430	20992776888	such	such	II21
304953	100736430	20992776889	as	as	II22
304953	100736430	20992776890	less	less	RGR
304953	100736430	20992776891	aggressive	aggressive	JJ
304953	100736430	20992776892	treatments	treatment	NN2
304953	100736430	20992776893	with	with	IW
304953	100736430	20992776894	targeted	targeted	JJ%
304953	100736430	20992776895	,	,	,
304953	100736430	20992776896	or	or	CC
304953	100736430	20992776897	focal	focal	JJ
304953	100736430	20992776898	,	,	,
304953	100736430	20992776899	therapies	therapy	NN2
304953	100736430	20992776900	.	.	.
304953	100736430	20992776901	I	i	PPIS1
304953	100736430	20992776902	think	think	VV0
304953	100736430	20992776903	we	we	PPIS2
304953	100736430	20992776904	really	really	RR
304953	100736430	20992776905	need	need	VV0
304953	100736430	20992776906	to	to	TO
304953	100736430	20992776907	look	look	VVI
304953	100736430	20992776908	at	at	II
304953	100736430	20992776909	whether	whether	CSW
304953	100736430	20992776910	we	we	PPIS2
304953	100736430	20992776911	can	can	VM
304953	100736430	20992776912	treat	treat	VVI
304953	100736430	20992776913	just	just	JJ@_RR
304953	100736430	20992776914	part	part	NN1
304953	100736430	20992776915	of	of	IO
304953	100736430	20992776916	the	the	AT
304953	100736430	20992776917	prostate	prostate	NN1
304953	100736430	20992776918	something	something	PN1
304953	100736430	20992776919	equivalent	equivalent	JJ
304953	100736430	20992776920	to	to	II
304953	100736430	20992776921	a	a	AT1
304953	100736430	20992776922	lumpectomy	lumpectomy	NN1
304953	100736430	20992776923	,	,	,
304953	100736430	20992776924	instead	instead	II21_CS21%
304953	100736430	20992776925	of	of	II22_CS22
304953	100736430	20992776926	a	a	AT1
304953	100736430	20992776927	mastectomy	mastectomy	NN1
304953	100736430	20992776928	,	,	,
304953	100736430	20992776929	in	in	II
304953	100736430	20992776930	women	woman	NN2
304953	100736430	20992776931	with	with	IW
304953	100736430	20992776932	breast	breast	NN1
304953	100736430	20992776933	cancer	cancer	NN1
304953	100736430	20992776934	.	.	.
304953	100736430	20992776935	<p>		NULL
304953	100736430	20992776936	Youve		NP1@_NN1_VV0
304953	100736430	20992776937	talked	talk	VVD
304953	100736430	20992776938	about	about	II
304953	100736430	20992776939	the	the	AT
304953	100736430	20992776940	male	male	JJ_NN1
304953	100736430	20992776941	lumpectomy	lumpectomy	NN1
304953	100736430	20992776942	in	in	II
304953	100736430	20992776943	the	the	AT
304953	100736430	20992776944	past	past	NN1_JJ
304953	100736430	20992776945	and	and	CC
304953	100736430	20992776946	now	now	RT
304953	100736430	20992776947	it	it	PPH1
304953	100736430	20992776948	seems	seem	VVZ
304953	100736430	20992776949	to	to	TO
304953	100736430	20992776950	be	be	VBI
304953	100736430	20992776951	coming	come	VVG
304953	100736430	20992776952	to	to	II
304953	100736430	20992776953	fruition	fruition	NN1
304953	100736430	20992776954	.	.	.
304953	100736430	20992776955	<p>		NULL
304953	100736430	20992776956	Yes	yes	UH
304953	100736430	20992776957	,	,	,
304953	100736430	20992776958	the	the	AT
304953	100736430	20992776959	train	train	NN1
304953	100736430	20992776960	has	have	VHZ
304953	100736430	20992776961	left	leave	VVN
304953	100736430	20992776962	the	the	AT
304953	100736430	20992776963	station	station	NN1
304953	100736430	20992776964	,	,	,
304953	100736430	20992776965	so	so	RR
304953	100736430	20992776966	to	to	TO
304953	100736430	20992776967	speak	speak	VVI
304953	100736430	20992776968	.	.	.
304953	100736430	20992776969	The	the	AT
304953	100736430	20992776970	problem	problem	NN1
304953	100736430	20992776971	is	be	VBZ
304953	100736430	20992776972	that	that	CST
304953	100736430	20992776973	people	people	NN
304953	100736430	20992776974	are	be	VBR
304953	100736430	20992776975	doing	do	VDG
304953	100736430	20992776976	it	it	PPH1
304953	100736430	20992776977	,	,	,
304953	100736430	20992776978	but	but	CCB
304953	100736430	20992776979	I	i	PPIS1
304953	100736430	20992776980	do	do	VD0
304953	100736430	20992776981	n't 	n't	XX
304953	100736430	20992776982	think	think	VVI
304953	100736430	20992776983	some	some	DD
304953	100736430	20992776984	of	of	IO
304953	100736430	20992776985	them	them	PPHO2
304953	100736430	20992776986	are	be	VBR
304953	100736430	20992776987	doing	do	VDG
304953	100736430	20992776988	it	it	PPH1
304953	100736430	20992776989	right	right	RR_JJ
304953	100736430	20992776990	.	.	.
304953	100736430	20992776991	Some	some	DD
304953	100736430	20992776992	people	people	NN
304953	100736430	20992776993	are	be	VBR
304953	100736430	20992776994	looking	look	VVG
304953	100736430	20992776995	at	at	II
304953	100736430	20992776996	eight	eight	MC
304953	100736430	20992776997	biopsies	biopsy	NN2
304953	100736430	20992776998	,	,	,
304953	100736430	20992776999	or	or	CC
304953	100736430	20992777000	cores	core	NN2
304953	100736430	20992777001	,	,	,
304953	100736430	20992777002	in	in	II
304953	100736430	20992777003	a	a	AT1
304953	100736430	20992777004	patient	patient	NN1_JJ
304953	100736430	20992777005	with	with	IW
304953	100736430	20992777006	prostate	prostate	NN1
304953	100736430	20992777007	cancer	cancer	NN1
304953	100736430	20992777008	;	;	;
304953	100736430	20992777009	most	most	DAT
304953	100736430	20992777010	of	of	IO
304953	100736430	20992777011	those	those	DD2
304953	100736430	20992777012	biopsy	biopsy	NN1
304953	100736430	20992777013	samples	sample	NN2
304953	100736430	20992777014	were	be	VBDR
304953	100736430	20992777015	probably	probably	RR
304953	100736430	20992777016	taken	take	VVN
304953	100736430	20992777017	from	from	II
304953	100736430	20992777018	one	one	MC1
304953	100736430	20992777019	side	side	NN1
304953	100736430	20992777020	of	of	IO
304953	100736430	20992777021	the	the	AT
304953	100736430	20992777022	prostate	prostate	NN1
304953	100736430	20992777023	or	or	CC
304953	100736430	20992777024	were	be	VBDR
304953	100736430	20992777025	only	only	JJ
304953	100736430	20992777026	positive		NN1
304953	100736430	20992777027	on	on	II
304953	100736430	20992777028	one	one	MC1
304953	100736430	20992777029	side	side	NN1
304953	100736430	20992777030	of	of	IO
304953	100736430	20992777031	the	the	AT
304953	100736430	20992777032	prostate	prostate	NN1
304953	100736430	20992777033	,	,	,
304953	100736430	20992777034	so	so	CS@_RR
304953	100736430	20992777035	they	they	PPHS2
304953	100736430	20992777036	only	only	JJ
304953	100736430	20992777037	treat	treat	NN1
304953	100736430	20992777038	half	half	NN1@_DB
304953	100736430	20992777039	of	of	IO
304953	100736430	20992777040	the	the	AT
304953	100736430	20992777041	prostate	prostate	NN1
304953	100736430	20992777042	.	.	.
304953	100736430	20992777043	Weve		NN1_VV0
304953	100736430	20992777044	shown	show	VVN
304953	100736430	20992777045	that	that	CST
304953	100736430	20992777046	that	that	DD1
304953	100736430	20992777047	is n't		NN1
304953	100736430	20992777048	going	go	VVG
304953	100736430	20992777049	to	to	II
304953	100736430	20992777050	work	work	NN1
304953	100736430	20992777051	because	because	CS
304953	100736430	20992777052	small	small	JJ
304953	100736430	20992777053	but	but	CCB
304953	100736430	20992777054	significant	significant	JJ
304953	100736430	20992777055	cancers	cancer	NN2
304953	100736430	20992777056	can	can	VM
304953	100736430	20992777057	be	be	VBI
304953	100736430	20992777058	missed	miss	VVN
304953	100736430	20992777059	.	.	.
304953	100736430	20992777060	You	you	PPY
304953	100736430	20992777061	simply	simply	RR
304953	100736430	20992777062	cant	cant	JJ_NN1
304953	100736430	20992777063	rely	rely	VV0
304953	100736430	20992777064	on	on	II_RP@
304953	100736430	20992777065	a	a	AT1
304953	100736430	20992777066	few	few	DA2
304953	100736430	20992777067	biopsy	biopsy	NN1
304953	100736430	20992777068	@		II
304953	100736430	20992777069	@		II
304953	100736430	20992777070	@		II
304953	100736430	20992777071	@		II
304953	100736430	20992777072	@		II
304953	100736430	20992777073	@		II
304953	100736430	20992777074	@		II
304953	100736430	20992777075	@		II
304953	100736430	20992777076	@		II
304953	100736430	20992777077	@		II
304953	100736430	20992777078	to	to	TO
304953	100736430	20992777079	do	do	VDI
304953	100736430	20992777080	biopsies	biopsy	NN2
304953	100736430	20992777081	at	at	II
304953	100736430	20992777082	5-millimeter		JJ_NN1
304953	100736430	20992777083	intervals	interval	NN2
304953	100736430	20992777084	aided	aid	VVN
304953	100736430	20992777085	by	by	II
304953	100736430	20992777086	a	a	AT1
304953	100736430	20992777087	grid	grid	NN1
304953	100736430	20992777088	like	like	II
304953	100736430	20992777089	those	those	DD2
304953	100736430	20992777090	used	use	VVN_JJ
304953	100736430	20992777091	for	for	IF
304953	100736430	20992777092	placing	place	VVG
304953	100736430	20992777093	radioactive	radioactive	JJ
304953	100736430	20992777094	seeds	seed	NN2
304953	100736430	20992777095	during	during	II
304953	100736430	20992777096	brachytherapy.		NNU
304953	100736430	20992777097	*	*	FU
304953	100736430	20992777098	If	if	CSW@_CS
304953	100736430	20992777099	you	you	PPY
304953	100736430	20992777100	biopsy	biopsy	NN1
304953	100736430	20992777101	every	every	AT1
304953	100736430	20992777102	one	one	MC1
304953	100736430	20992777103	of	of	IO
304953	100736430	20992777104	those	those	DD2
304953	100736430	20992777105	5-millimeter		JJ
304953	100736430	20992777106	holes	hole	NN2
304953	100736430	20992777107	where	where	RRQ_CS
304953	100736430	20992777108	the	the	AT
304953	100736430	20992777109	seeds	seed	NN2
304953	100736430	20992777110	would	would	VM
304953	100736430	20992777111	go	go	VVI
304953	100736430	20992777112	,	,	,
304953	100736430	20992777113	you	you	PPY
304953	100736430	20992777114	will	will	VM
304953	100736430	20992777115	not	not	XX
304953	100736430	20992777116	miss	miss	VVI
304953	100736430	20992777117	the	the	AT
304953	100736430	20992777118	cancer	cancer	NN1
304953	100736430	20992777119	.	.	.
304953	100736430	20992777120	We	we	PPIS2
304953	100736430	20992777121	found	find	VVD
304953	100736430	20992777122	this	this	DD1
304953	100736430	20992777123	out	out	RP
304953	100736430	20992777124	through	through	II
304953	100736430	20992777125	autopsies	autopsy	NN2
304953	100736430	20992777126	of	of	IO
304953	100736430	20992777127	men	man	NN2
304953	100736430	20992777128	who	who	PNQS
304953	100736430	20992777129	werent		JJ
304953	100736430	20992777130	known	know	VVN_JJ@
304953	100736430	20992777131	to	to	TO
304953	100736430	20992777132	have	have	VHI
304953	100736430	20992777133	prostate	prostate	NN1
304953	100736430	20992777134	cancer	cancer	NN1
304953	100736430	20992777135	and	and	CC
304953	100736430	20992777136	from	from	II
304953	100736430	20992777137	men	man	NN2
304953	100736430	20992777138	who	who	PNQS
304953	100736430	20992777139	had	have	VHD
304953	100736430	20992777140	a	a	AT1
304953	100736430	20992777141	radical	radical	JJ_NN1
304953	100736430	20992777142	prostatectomy	prostatectomy	NN1
304953	100736430	20992777143	.	.	.
304953	100736430	20992777144	That	that	DD1
304953	100736430	20992777145	was	be	VBDZ
304953	100736430	20992777146	the	the	AT
304953	100736430	20992777147	first	first	MD
304953	100736430	20992777148	thing	thing	NN1
304953	100736430	20992777149	I	i	PPIS1
304953	100736430	20992777150	did	do	VDD
304953	100736430	20992777151	before	before	CS
304953	100736430	20992777152	we	we	PPIS2
304953	100736430	20992777153	embarked	embark	VVD
304953	100736430	20992777154	on	on	II_RP@
304953	100736430	20992777155	focal	focal	JJ
304953	100736430	20992777156	therapy	therapy	NN1
304953	100736430	20992777157	:	:	:
304953	100736430	20992777158	prove	prove	VV0
304953	100736430	20992777159	that	that	CST
304953	100736430	20992777160	we	we	PPIS2
304953	100736430	20992777161	werent		NN1_JJ
304953	100736430	20992777162	going	go	VVGK
304953	100736430	20992777163	to	to	TO
304953	100736430	20992777164	miss	miss	VVI
304953	100736430	20992777165	the	the	AT
304953	100736430	20992777166	cancer	cancer	NN1
304953	100736430	20992777167	.	.	.
304953	100736430	20992777168	<p>		NULL
304953	100736430	20992777169	So	so	RR_CS@
304953	100736430	20992777170	that	that	DD1_CST
304953	100736430	20992777171	means	mean	VVZ_NN
304953	100736430	20992777172	we	we	PPIS2
304953	100736430	20992777173	might	might	VM
304953	100736430	20992777174	do	do	VDI
304953	100736430	20992777175	60	60	MC
304953	100736430	20992777176	to	to	II
304953	100736430	20992777177	90	90	MC
304953	100736430	20992777178	biopsies	biopsy	NN2
304953	100736430	20992777179	,	,	,
304953	100736430	20992777180	or	or	CC
304953	100736430	20992777181	more	more	RGR
304953	100736430	20992777182	specifically	specifically	RR
304953	100736430	20992777183	,	,	,
304953	100736430	20992777184	mapping	map	VVG_NN1
304953	100736430	20992777185	biopsies	biopsy	NN2
304953	100736430	20992777186	.	.	.
304953	100736430	20992777187	We	we	PPIS2
304953	100736430	20992777188	map	map	VV0@
304953	100736430	20992777189	very	very	RG
304953	100736430	20992777190	precisely	precisely	RR
304953	100736430	20992777191	where	where	CS_RRQ
304953	100736430	20992777192	the	the	AT
304953	100736430	20992777193	cancer	cancer	NN1
304953	100736430	20992777194	is	be	VBZ
304953	100736430	20992777195	in	in	II
304953	100736430	20992777196	three	three	MC
304953	100736430	20992777197	dimensions	dimension	NN2
304953	100736430	20992777198	and	and	CC
304953	100736430	20992777199	then	then	RT
304953	100736430	20992777200	treat	treat	VV0
304953	100736430	20992777201	just	just	RR
304953	100736430	20992777202	the	the	AT
304953	100736430	20992777203	cancer	cancer	NN1
304953	100736430	20992777204	,	,	,
304953	100736430	20992777205	not	not	XX
304953	100736430	20992777206	the	the	AT
304953	100736430	20992777207	whole	whole	JJ
304953	100736430	20992777208	prostate	prostate	NN1
304953	100736430	20992777209	.	.	.
304953	100736430	20992777210	<p>		NULL
304953	100736430	20992777211	Right	right	RR
304953	100736430	20992777212	now	now	RT
304953	100736430	20992777213	,	,	,
304953	100736430	20992777214	were	be	VBDR
304953	100736430	20992777215	using	use	VVG
304953	100736430	20992777216	cryotherapy	cryotherapy	NN1
304953	100736430	20992777217	to	to	TO
304953	100736430	20992777218	freeze	freeze	VVI
304953	100736430	20992777219	cancerous	cancerous	JJ
304953	100736430	20992777220	tissue	tissue	NN1
304953	100736430	20992777221	.	.	.
304953	100736430	20992777222	We	we	PPIS2
304953	100736430	20992777223	will	will	VM
304953	100736430	20992777224	be	be	VBI
304953	100736430	20992777225	using	use	VVG
304953	100736430	20992777226	HIFU		NP1_NN1
304953	100736430	20992777227	,	,	,
304953	100736430	20992777228	which	which	DDQ
304953	100736430	20992777229	stands	stand	VVZ
304953	100736430	20992777230	for	for	IF
304953	100736430	20992777231	high-intensity	high-intensity	JJ_NN1
304953	100736430	20992777232	focused	focused	JJ@_VVD_VVN
304953	100736430	20992777233	ultrasound	ultrasound	NN1
304953	100736430	20992777234	,	,	,
304953	100736430	20992777235	to	to	TO
304953	100736430	20992777236	heat	heat	VVI
304953	100736430	20992777237	tissue	tissue	NN1
304953	100736430	20992777238	.	.	.
304953	100736430	20992777239	We	we	PPIS2
304953	100736430	20992777240	will	will	VM
304953	100736430	20992777241	also	also	RR
304953	100736430	20992777242	be	be	VBI
304953	100736430	20992777243	using	use	VVG
304953	100736430	20992777244	a	a	AT1
304953	100736430	20992777245	technique	technique	NN1
304953	100736430	20992777246	called	call	VVN_VVD@
304953	100736430	20992777247	irreversible	irreversible	JJ
304953	100736430	20992777248	electroporation	electroporation	NN1
304953	100736430	20992777249	,	,	,
304953	100736430	20992777250	which	which	DDQ
304953	100736430	20992777251	uses	use	VVZ
304953	100736430	20992777252	two	two	MC
304953	100736430	20992777253	electrodes	electrode	NN2
304953	100736430	20992777254	and	and	CC
304953	100736430	20992777255	an	a	AT1
304953	100736430	20992777256	electrical	electrical	JJ
304953	100736430	20992777257	current	current	JJ_NN1@
304953	100736430	20992777258	to	to	TO
304953	100736430	20992777259	"	"	"
304953	100736430	20992777260	drill	drill	VVI
304953	100736430	20992777261	"	"	"
304953	100736430	20992777262	microscopic	microscopic	JJ
304953	100736430	20992777263	holes	hole	NN2
304953	100736430	20992777264	in	in	II
304953	100736430	20992777265	tumor	tumor	NN1
304953	100736430	20992777266	cell	cell	NN1
304953	100736430	20992777267	membranes	membrane	NN2
304953	100736430	20992777268	@		II
304953	100736430	20992777269	@		II
304953	100736430	20992777270	@		II
304953	100736430	20992777271	@		II
304953	100736430	20992777272	@		II
304953	100736430	20992777273	@		II
304953	100736430	20992777274	@		II
304953	100736430	20992777275	@		II
304953	100736430	20992777276	@		II
304953	100736430	20992777277	@		II
304953	100736430	20992777278	membrane	membrane	NN1
304953	100736430	20992777279	.	.	.
304953	100736430	20992777280	If	if	CS
304953	100736430	20992777281	we	we	PPIS2
304953	100736430	20992777282	can	can	VM
304953	100736430	20992777283	kill	kill	VVI
304953	100736430	20992777284	all	all	DB
304953	100736430	20992777285	the	the	AT
304953	100736430	20992777286	cancer	cancer	NN1
304953	100736430	20992777287	cells	cell	NN2
304953	100736430	20992777288	with	with	IW
304953	100736430	20992777289	electrical	electrical	JJ
304953	100736430	20992777290	pulses	pulse	NN2
304953	100736430	20992777291	,	,	,
304953	100736430	20992777292	we	we	PPIS2
304953	100736430	20992777293	would n't		VV0
304953	100736430	20992777294	need	need	VV0_NN1
304953	100736430	20992777295	to	to	TO
304953	100736430	20992777296	use	use	VVI
304953	100736430	20992777297	toxic	toxic	JJ
304953	100736430	20992777298	chemotherapy	chemotherapy	NN1
304953	100736430	20992777299	drugs	drug	NN2
304953	100736430	20992777300	.	.	.
304953	100736430	20992777301	That 's		NN2_VVZ
304953	100736430	20992777302	why	why	RRQ
304953	100736430	20992777303	this	this	DD1
304953	100736430	20992777304	is	be	VBZ
304953	100736430	20992777305	such	such	DA
304953	100736430	20992777306	exciting	exciting	JJ
304953	100736430	20992777307	technology	technology	NN1
304953	100736430	20992777308	.	.	.
304953	100736430	20992777309	<p>		NULL
304953	100736430	20992777310	Who	who	PNQS
304953	100736430	20992777311	is	be	VBZ
304953	100736430	20992777312	a	a	AT1
304953	100736430	20992777313	candidate	candidate	NN1
304953	100736430	20992777314	for	for	IF
304953	100736430	20992777315	targeted	target	VVN_JJ%
304953	100736430	20992777316	focal	focal	JJ
304953	100736430	20992777317	therapy	therapy	NN1
304953	100736430	20992777318	?	?	?
304953	100736430	20992777319	<p>		NULL
304953	100736430	20992777320	The	the	AT
304953	100736430	20992777321	average	average	JJ_NN1
304953	100736430	20992777322	patient	patient	NN1_JJ
304953	100736430	20992777323	I	i	PPIS1
304953	100736430	20992777324	see	see	VV0
304953	100736430	20992777325	right	right	RR_NN1
304953	100736430	20992777326	now	now	RT
304953	100736430	20992777327	is	be	VBZ
304953	100736430	20992777328	a	a	AT1
304953	100736430	20992777329	58-year-old	58-year-old	JJ
304953	100736430	20992777330	man	man	NN1
304953	100736430	20992777331	with	with	IW
304953	100736430	20992777332	a	a	AT1
304953	100736430	20992777333	PSA	psa	NP1
304953	100736430	20992777334	of	of	IO
304953	100736430	20992777335	5	5	MC
304953	100736430	20992777336	ng/ml	ng/ml	FU
304953	100736430	20992777337	and	and	CC
304953	100736430	20992777338	one	one	MC1
304953	100736430	20992777339	positive	positive	JJ
304953	100736430	20992777340	biopsy	biopsy	NN1
304953	100736430	20992777341	with	with	IW
304953	100736430	20992777342	a	a	AT1
304953	100736430	20992777343	Gleason	gleason	NN1@_NP1
304953	100736430	20992777344	6	6	MC
304953	100736430	20992777345	cancer	cancer	NN1
304953	100736430	20992777346	.	.	.
304953	100736430	20992777347	This	this	DD1
304953	100736430	20992777348	patient	patient	NN1
304953	100736430	20992777349	will	will	VM
304953	100736430	20992777350	generally	generally	RR
304953	100736430	20992777351	have	have	VHI
304953	100736430	20992777352	a	a	AT1
304953	100736430	20992777353	radical	radical	JJ_NN1
304953	100736430	20992777354	prostatectomy	prostatectomy	NN1
304953	100736430	20992777355	or	or	CC
304953	100736430	20992777356	radiation	radiation	NN1
304953	100736430	20992777357	therapy	therapy	NN1
304953	100736430	20992777358	and	and	CC
304953	100736430	20992777359	be	be	VBI
304953	100736430	20992777360	cured	cure	VVN
304953	100736430	20992777361	.	.	.
304953	100736430	20992777362	But	but	CCB
304953	100736430	20992777363	then	then	RT
304953	100736430	20992777364	I	i	PPIS1
304953	100736430	20992777365	start	start	VV0
304953	100736430	20992777366	wondering	wonder	VVG
304953	100736430	20992777367	whether	whether	CSW
304953	100736430	20992777368	I 've		NP1
304953	100736430	20992777369	overtreated		VVD
304953	100736430	20992777370	the	the	AT
304953	100736430	20992777371	patient	patient	NN1_JJ
304953	100736430	20992777372	.	.	.
304953	100736430	20992777373	So	so	RR
304953	100736430	20992777374	what	what	DDQ
304953	100736430	20992777375	I	i	PPIS1
304953	100736430	20992777376	do	do	VD0
304953	100736430	20992777377	is	be	VBZ
304953	100736430	20992777378	take	take	NN1%
304953	100736430	20992777379	patients	patient	NN2
304953	100736430	20992777380	who	who	PNQS
304953	100736430	20992777381	probably	probably	RR
304953	100736430	20992777382	have	have	VH0
304953	100736430	20992777383	low-risk	low-risk	JJ
304953	100736430	20992777384	cancers	cancer	NN2
304953	100736430	20992777385	and	and	CC
304953	100736430	20992777386	do	do	VD0
304953	100736430	20992777387	the	the	AT
304953	100736430	20992777388	mapping	mapping	NN1
304953	100736430	20992777389	biopsies	biopsy	NN2
304953	100736430	20992777390	.	.	.
304953	100736430	20992777391	We	we	PPIS2
304953	100736430	20992777392	find	find	VV0
304953	100736430	20992777393	that	that	CST_DD1
304953	100736430	20992777394	about	about	RG
304953	100736430	20992777395	60%		NNU
304953	100736430	20992777396	of	of	IO
304953	100736430	20992777397	them	them	PPHO2
304953	100736430	20992777398	have	have	VH0
304953	100736430	20992777399	bilateral	bilateral	JJ
304953	100736430	20992777400	disease	disease	NN1
304953	100736430	20992777401	cancer	cancer	NN1
304953	100736430	20992777402	that 's		VVZ_NN2
304953	100736430	20992777403	on	on	II
304953	100736430	20992777404	both	both	DB2
304953	100736430	20992777405	sides	side	NN2
304953	100736430	20992777406	of	of	IO
304953	100736430	20992777407	the	the	AT
304953	100736430	20992777408	prostate	prostate	NN1
304953	100736430	20992777409	that 's		VVZ
304953	100736430	20992777410	more	more	RGR
304953	100736430	20992777411	extensive	extensive	JJ
304953	100736430	20992777412	or	or	CC
304953	100736430	20992777413	of	of	IO
304953	100736430	20992777414	a	a	AT1
304953	100736430	20992777415	higher	high	JJR
304953	100736430	20992777416	grade	grade	NN1
304953	100736430	20992777417	than	than	CSN
304953	100736430	20992777418	we	we	PPIS2
304953	100736430	20992777419	originally	originally	RR
304953	100736430	20992777420	thought	think	VVN_VVD
304953	100736430	20992777421	.	.	.
304953	100736430	20992777422	I	i	PPIS1
304953	100736430	20992777423	do	do	VD0
304953	100736430	20992777424	n't 	n't	XX
304953	100736430	20992777425	think	think	VVI
304953	100736430	20992777426	we	we	PPIS2
304953	100736430	20992777427	can	can	VM
304953	100736430	20992777428	accurately	accurately	RR
304953	100736430	20992777429	treat	treat	VVI
304953	100736430	20992777430	them	them	PPHO2
304953	100736430	20992777431	with	with	IW
304953	100736430	20992777432	targeted	targeted	JJ%
304953	100736430	20992777433	focal	focal	JJ
304953	100736430	20992777434	therapy	therapy	NN1
304953	100736430	20992777435	.	.	.
304953	100736430	20992777436	But	but	CCB
304953	100736430	20992777437	about	about	RG
304953	100736430	20992777438	40%		NNU
304953	100736430	20992777439	of	of	IO
304953	100736430	20992777440	patients	patient	NN2
304953	100736430	20992777441	who	who	PNQS
304953	100736430	20992777442	have	have	VH0
304953	100736430	20992777443	mapping	mapping	NN1
304953	100736430	20992777444	biopsies	biopsy	NN2
304953	100736430	20992777445	have	have	VH0
304953	100736430	20992777446	low-risk	low-risk	JJ
304953	100736430	20992777447	cancers	cancer	NN2
304953	100736430	20992777448	that	that	CST_DD1
304953	100736430	20992777449	can	can	VM
304953	100736430	20992777450	be	be	VBI
304953	100736430	20992777451	treated	treat	VVN
304953	100736430	20992777452	this	this	DD1
304953	100736430	20992777453	way	way	NN1
304953	100736430	20992777454	.	.	.
304953	100736430	20992777455	<h>		NULL
304953	100736430	20992777456	Figure	figure	VV0@_NN1
304953	100736430	20992777457	1	1	MC1
304953	100736430	20992777458	:	:	:
304953	100736430	20992777459	Mapping	map	VVG_NN1
304953	100736430	20992777460	biopsy	biopsy	NN1
304953	100736430	20992777461	<p>		NULL
304953	100736430	20992777462	Doctors	doctor	NN2
304953	100736430	20992777463	use	use	VV0
304953	100736430	20992777464	a	a	AT1
304953	100736430	20992777465	grid	grid	NN1
304953	100736430	20992777466	like	like	II
304953	100736430	20992777467	this	this	DD1
304953	100736430	20992777468	@		II
304953	100736430	20992777469	@		II
304953	100736430	20992777470	@		II
304953	100736430	20992777471	@		II
304953	100736430	20992777472	@		II
304953	100736430	20992777473	@		II
304953	100736430	20992777474	@		II
304953	100736430	20992777475	@		II
304953	100736430	20992777476	@		II
304953	100736430	20992777477	@		II
304953	100736430	20992777478	therapy	therapy	NN1
304953	100736430	20992777479	called	call	VVN_VVD@
304953	100736430	20992777480	brachytherapy	brachytherapy	NN1
304953	100736430	20992777481	.	.	.
304953	100736430	20992777482	The	the	AT
304953	100736430	20992777483	grid	grid	NN1
304953	100736430	20992777484	can	can	VM
304953	100736430	20992777485	also	also	RR
304953	100736430	20992777486	aid	aid	VVI
304953	100736430	20992777487	doctors	doctor	NN2
304953	100736430	20992777488	performing	perform	VVG
304953	100736430	20992777489	a	a	AT1
304953	100736430	20992777490	mapping	mapping	NN1
304953	100736430	20992777491	biopsy	biopsy	NN1
304953	100736430	20992777492	.	.	.
304953	100736430	20992777493	Tissue	tissue	NN1
304953	100736430	20992777494	samples	sample	NN2
304953	100736430	20992777495	are	be	VBR
304953	100736430	20992777496	taken	take	VVN
304953	100736430	20992777497	every	every	AT1
304953	100736430	20992777498	5	5	MC
304953	100736430	20992777499	millimeters	millimeter	NN2
304953	100736430	20992777500	,	,	,
304953	100736430	20992777501	front	front	NN1_JJ_VV0@
304953	100736430	20992777502	to	to	II
304953	100736430	20992777503	back	back	NN1
304953	100736430	20992777504	and	and	CC
304953	100736430	20992777505	side	side	NN1
304953	100736430	20992777506	to	to	II
304953	100736430	20992777507	side	side	NN1
304953	100736430	20992777508	.	.	.
304953	100736430	20992777509	(	(	(
304953	100736430	20992777510	Each	each	DD1
304953	100736430	20992777511	dot	dot	NN1
304953	100736430	20992777512	on	on	II
304953	100736430	20992777513	the	the	AT
304953	100736430	20992777514	grid	grid	NN1
304953	100736430	20992777515	represents	represent	VVZ
304953	100736430	20992777516	a	a	AT1
304953	100736430	20992777517	hole	hole	NN1
304953	100736430	20992777518	through	through	II
304953	100736430	20992777519	which	which	DDQ
304953	100736430	20992777520	a	a	AT1
304953	100736430	20992777521	needle	needle	NN1
304953	100736430	20992777522	can	can	VM
304953	100736430	20992777523	be	be	VBI
304953	100736430	20992777524	inserted	insert	VVN
304953	100736430	20992777525	.	.	.
304953	100736430	20992777526	)	)	)
304953	100736430	20992777527	This	this	DD1
304953	100736430	20992777528	allows	allow	VVZ
304953	100736430	20992777529	doctors	doctor	NN2
304953	100736430	20992777530	to	to	TO
304953	100736430	20992777531	map	map	VVI
304953	100736430	20992777532	the	the	AT
304953	100736430	20992777533	location	location	NN1
304953	100736430	20992777534	of	of	IO
304953	100736430	20992777535	tumors	tumor	NN2
304953	100736430	20992777536	in	in	II
304953	100736430	20992777537	three	three	MC
304953	100736430	20992777538	dimensions	dimension	NN2
304953	100736430	20992777539	and	and	CC
304953	100736430	20992777540	determine	determine	VV0
304953	100736430	20992777541	if	if	CSW@_CS
304953	100736430	20992777542	a	a	AT1
304953	100736430	20992777543	patient	patient	NN1
304953	100736430	20992777544	might	might	VM
304953	100736430	20992777545	be	be	VBI
304953	100736430	20992777546	a	a	AT1
304953	100736430	20992777547	candidate	candidate	NN1
304953	100736430	20992777548	for	for	IF
304953	100736430	20992777549	focal	focal	JJ
304953	100736430	20992777550	therapy	therapy	NN1
304953	100736430	20992777551	.	.	.
304953	100736430	20992777552	<p>		NULL
304953	100736430	20992777553	Are	be	VB0
304953	100736430	20992777554	n't 	n't	XX
304953	100736430	20992777555	those	those	DD2
304953	100736430	20992777556	patients	patient	NN2
304953	100736430	20992777557	also	also	RR
304953	100736430	20992777558	candidates	candidate	NN2
304953	100736430	20992777559	for	for	IF
304953	100736430	20992777560	active	active	JJ
304953	100736430	20992777561	surveillance	surveillance	NN1
304953	100736430	20992777562	?	?	?
304953	100736430	20992777563	<p>		NULL
304953	100736430	20992777564	Yes	yes	UH
304953	100736430	20992777565	,	,	,
304953	100736430	20992777566	they	they	PPHS2
304953	100736430	20992777567	could	could	VM
304953	100736430	20992777568	pursue	pursue	VVI
304953	100736430	20992777569	active	active	JJ
304953	100736430	20992777570	surveillance	surveillance	NN1
304953	100736430	20992777571	.	.	.
304953	100736430	20992777572	But	but	CCB
304953	100736430	20992777573	most	most	DAT
304953	100736430	20992777574	men	man	NN2
304953	100736430	20992777575	,	,	,
304953	100736430	20992777576	given	give	VVN
304953	100736430	20992777577	the	the	AT
304953	100736430	20992777578	choice	choice	NN1
304953	100736430	20992777579	between	between	II
304953	100736430	20992777580	active	active	JJ
304953	100736430	20992777581	surveillance	surveillance	NN1
304953	100736430	20992777582	and	and	CC
304953	100736430	20992777583	focal	focal	JJ
304953	100736430	20992777584	therapy	therapy	NN1
304953	100736430	20992777585	,	,	,
304953	100736430	20992777586	will	will	VM
304953	100736430	20992777587	choose	choose	VVI
304953	100736430	20992777588	focal	focal	JJ
304953	100736430	20992777589	therapy	therapy	NN1
304953	100736430	20992777590	because	because	CS
304953	100736430	20992777591	they	they	PPHS2
304953	100736430	20992777592	want	want	VV0
304953	100736430	20992777593	to	to	TO
304953	100736430	20992777594	do	do	VDI
304953	100736430	20992777595	something	something	PN1
304953	100736430	20992777596	.	.	.
304953	100736430	20992777597	That 's		NN2
304953	100736430	20992777598	what	what	DDQ
304953	100736430	20992777599	makes	make	VVZ
304953	100736430	20992777600	focal	focal	JJ
304953	100736430	20992777601	therapy	therapy	NN1
304953	100736430	20992777602	so	so	RG_RR
304953	100736430	20992777603	appealing	appealing	JJ_VVG
304953	100736430	20992777604	.	.	.
304953	100736430	20992777605	<p>		NULL
304953	100736430	20992777606	What 's		NN2
304953	100736430	20992777607	on	on	II
304953	100736430	20992777608	the	the	AT
304953	100736430	20992777609	horizon	horizon	NN1
304953	100736430	20992777610	in	in	II31
304953	100736430	20992777611	terms	terms	II32
304953	100736430	20992777612	of	of	II33
304953	100736430	20992777613	advanced	advanced	JJ
304953	100736430	20992777614	disease	disease	NN1
304953	100736430	20992777615	?	?	?
304953	100736430	20992777616	What	what	DDQ
304953	100736430	20992777617	about	about	II
304953	100736430	20992777618	hormone	hormone	NN1
304953	100736430	20992777619	therapy	therapy	NN1
304953	100736430	20992777620	and	and	CC
304953	100736430	20992777621	chemotherapy	chemotherapy	NN1
304953	100736430	20992777622	?	?	?
304953	100736430	20992777623	<p>		NULL
304953	100736430	20992777624	In	in	II31
304953	100736430	20992777625	terms	terms	II32
304953	100736430	20992777626	of	of	II33
304953	100736430	20992777627	advanced	advanced	JJ
304953	100736430	20992777628	disease	disease	NN1
304953	100736430	20992777629	,	,	,
304953	100736430	20992777630	I	i	PPIS1
304953	100736430	20992777631	think	think	VV0
304953	100736430	20992777632	we 've		NN1_VV0
304953	100736430	20992777633	come	come	VV0_VVN@
304953	100736430	20992777634	as	as	RG
304953	100736430	20992777635	far	far	RR
304953	100736430	20992777636	as	as	CSA
304953	100736430	20992777637	were	be	VBDR
304953	100736430	20992777638	going	go	VVGK
304953	100736430	20992777639	to	to	TO
304953	100736430	20992777640	go	go	VVI
304953	100736430	20992777641	with	with	IW
304953	100736430	20992777642	chemotherapy	chemotherapy	NN1
304953	100736430	20992777643	.	.	.
304953	100736430	20992777644	Its	its	APPGE
304953	100736430	20992777645	just	just	RR
304953	100736430	20992777646	going	go	VVG
304953	100736430	20992777647	to	to	TO
304953	100736430	20992777648	be	be	VBI
304953	100736430	20992777649	a	a	AT1
304953	100736430	20992777650	matter	matter	NN1
304953	100736430	20992777651	of	of	IO
304953	100736430	20992777652	reducing	reduce	VVG_JJ@
304953	100736430	20992777653	toxicity	toxicity	NN1
304953	100736430	20992777654	.	.	.
304953	100736430	20992777655	In	in	II
304953	100736430	20992777656	the	the	AT
304953	100736430	20992777657	future	future	NN1_JJ
304953	100736430	20992777658	,	,	,
304953	100736430	20992777659	well	well	RR
304953	100736430	20992777660	be	be	VBI
304953	100736430	20992777661	looking	look	VVG
304953	100736430	20992777662	more	more	RRR_DAR
304953	100736430	20992777663	at	at	II
304953	100736430	20992777664	combining	combine	VVG_JJ@
304953	100736430	20992777665	chemotherapy	chemotherapy	NN1
304953	100736430	20992777666	with	with	IW
304953	100736430	20992777667	other	other	JJ_NN1@
304953	100736430	20992777668	@		II
304953	100736430	20992777669	@		II
304953	100736430	20992777670	@		II
304953	100736430	20992777671	@		II
304953	100736430	20992777672	@		II
304953	100736430	20992777673	@		II
304953	100736430	20992777674	@		II
304953	100736430	20992777675	@		II
304953	100736430	20992777676	@		II
304953	100736430	20992777677	@		II
304953	100736430	20992777678	vessels	vessel	NN2
304953	100736430	20992777679	feeding	feed	VVG
304953	100736430	20992777680	the	the	AT
304953	100736430	20992777681	tumors	tumor	NN2
304953	100736430	20992777682	or	or	CC
304953	100736430	20992777683	the	the	AT
304953	100736430	20992777684	spread	spread	NN1
304953	100736430	20992777685	of	of	IO
304953	100736430	20992777686	cancer	cancer	NN1
304953	100736430	20992777687	into	into	II
304953	100736430	20992777688	bone	bone	NN1
304953	100736430	20992777689	.	.	.
304953	100736430	20992777690	I	i	PPIS1
304953	100736430	20992777691	think	think	VV0
304953	100736430	20992777692	well	well	RR
304953	100736430	20992777693	also	also	RR
304953	100736430	20992777694	see	see	VV0
304953	100736430	20992777695	chemotherapy	chemotherapy	NN1
304953	100736430	20992777696	used	use	VVD_VVN
304953	100736430	20992777697	earlier	early	RRR
304953	100736430	20992777698	on	on	RP@
304953	100736430	20992777699	in	in	II
304953	100736430	20992777700	high-risk	high-risk	JJ
304953	100736430	20992777701	patients	patient	NN2
304953	100736430	20992777702	and	and	CC
304953	100736430	20992777703	not	not	XX
304953	100736430	20992777704	just	just	RR
304953	100736430	20992777705	in	in	II
304953	100736430	20992777706	patients	patient	NN2
304953	100736430	20992777707	who	who	PNQS
304953	100736430	20992777708	have	have	VH0
304953	100736430	20992777709	exhausted	exhaust	VVN
304953	100736430	20992777710	other	other	JJ
304953	100736430	20992777711	treatment	treatment	NN1
304953	100736430	20992777712	possibilities	possibility	NN2
304953	100736430	20992777713	.	.	.
304953	100736430	20992777714	<p>		NULL
304953	100736430	20992777715	There	there	EX
304953	100736430	20992777716	is	be	VBZ
304953	100736430	20992777717	renewed	renewed	JJ
304953	100736430	20992777718	interest	interest	NN1
304953	100736430	20992777719	in	in	II
304953	100736430	20992777720	androgens	androgen	NN2
304953	100736430	20992777721	and	and	CC
304953	100736430	20992777722	androgen	androgen	NN1
304953	100736430	20992777723	receptors	receptor	NN2
304953	100736430	20992777724	.	.	.
304953	100736430	20992777725	Its	its	APPGE
304953	100736430	20992777726	almost	almost	RR
304953	100736430	20992777727	as	as	CS21
304953	100736430	20992777728	if	if	CS22
304953	100736430	20992777729	we 've		NN1
304953	100736430	20992777730	rediscovered	rediscover	VVD
304953	100736430	20992777731	that	that	CST
304953	100736430	20992777732	the	the	AT
304953	100736430	20992777733	lower	low	RRR@_VV0@
304953	100736430	20992777734	a	a	AT1
304953	100736430	20992777735	man	man	NN1
304953	100736430	20992777736	can	can	VM
304953	100736430	20992777737	get	get	VVI
304953	100736430	20992777738	his	his	APPGE
304953	100736430	20992777739	testosterone	testosterone	NN1
304953	100736430	20992777740	and	and	CC
304953	100736430	20992777741	the	the	AT
304953	100736430	20992777742	longer	long	RRR
304953	100736430	20992777743	he	he	PPHS1
304953	100736430	20992777744	can	can	VM
304953	100736430	20992777745	keep	keep	VVI
304953	100736430	20992777746	it	it	PPH1
304953	100736430	20992777747	down	down	RP
304953	100736430	20992777748	or	or	CC
304953	100736430	20992777749	block	block	VV0@_NN1
304953	100736430	20992777750	it	it	PPH1
304953	100736430	20992777751	,	,	,
304953	100736430	20992777752	the	the	AT
304953	100736430	20992777753	better	better	RRR_JJR
304953	100736430	20992777754	off	off	RP
304953	100736430	20992777755	he	he	PPHS1
304953	100736430	20992777756	is	be	VBZ
304953	100736430	20992777757	.	.	.
304953	100736430	20992777758	And	and	CC
304953	100736430	20992777759	people	people	NN
304953	100736430	20992777760	whose	whose	DDQGE
304953	100736430	20992777761	cancers	cancer	NN2
304953	100736430	20992777762	would	would	VM
304953	100736430	20992777763	have	have	VHI
304953	100736430	20992777764	been	be	VBN
304953	100736430	20992777765	considered	consider	VVN
304953	100736430	20992777766	hormone-refractory		JJ
304953	100736430	20992777767	in	in	II
304953	100736430	20992777768	the	the	AT
304953	100736430	20992777769	past	past	NN1_JJ
304953	100736430	20992777770	really	really	RR
304953	100736430	20992777771	are	be	VB0
304953	100736430	20992777772	n't 	n't	XX
304953	100736430	20992777773	termed	term	VVN
304953	100736430	20992777774	that	that	CST_DD1
304953	100736430	20992777775	anymore	anymore	RR
304953	100736430	20992777776	.	.	.
304953	100736430	20992777777	They	they	PPHS2
304953	100736430	20992777778	are	be	VBR
304953	100736430	20992777779	now	now	RT
304953	100736430	20992777780	hormone-insensitive		JJ
304953	100736430	20992777781	cancers	cancer	NN2
304953	100736430	20992777782	.	.	.
304953	100736430	20992777783	We	we	PPIS2
304953	100736430	20992777784	can	can	VM
304953	100736430	20992777785	try	try	VVI
304953	100736430	20992777786	different	different	JJ
304953	100736430	20992777787	hormones	hormone	NN2
304953	100736430	20992777788	for	for	IF
304953	100736430	20992777789	them	them	PPHO2
304953	100736430	20992777790	.	.	.
304953	100736430	20992777791	Were	be	VBDR
304953	100736430	20992777792	also	also	RR
304953	100736430	20992777793	developing	develop	VVG_JJ
304953	100736430	20992777794	new	new	JJ
304953	100736430	20992777795	agents	agent	NN2
304953	100736430	20992777796	to	to	TO
304953	100736430	20992777797	attack	attack	VVI
304953	100736430	20992777798	testosterone	testosterone	NN1
304953	100736430	20992777799	development	development	NN1
304953	100736430	20992777800	early	early	RR
304953	100736430	20992777801	on	on	RP@_II
304953	100736430	20992777802	.	.	.
304953	100736430	20992777803	<p>		NULL
304953	100736430	20992777804	Can	can	VM_VV0%
304953	100736430	20992777805	you	you	PPY
304953	100736430	20992777806	make	make	VVI
304953	100736430	20992777807	some	some	DD
304953	100736430	20992777808	comments	comment	NN2
304953	100736430	20992777809	about	about	II
304953	100736430	20992777810	your	your	APPGE
304953	100736430	20992777811	work	work	NN1
304953	100736430	20992777812	on	on	II
304953	100736430	20992777813	BPH	bph	NP1
304953	100736430	20992777814	and	and	CC
304953	100736430	20992777815	what	what	DDQ
304953	100736430	20992777816	you	you	PPY
304953	100736430	20992777817	see	see	VV0
304953	100736430	20992777818	on	on	II_RP@
304953	100736430	20992777819	the	the	AT
304953	100736430	20992777820	horizon	horizon	NN1
304953	100736430	20992777821	there	there	RL
304953	100736430	20992777822	?	?	?
304953	100736430	20992777823	<p>		NULL
304953	100736430	20992777824	I	i	PPIS1
304953	100736430	20992777825	think	think	VV0
304953	100736430	20992777826	that	that	CST
304953	100736430	20992777827	we	we	PPIS2
304953	100736430	20992777828	have	have	VH0
304953	100736430	20992777829	made	make	VVN
304953	100736430	20992777830	a	a	AT1
304953	100736430	20992777831	great	great	JJ
304953	100736430	20992777832	deal	deal	NN1
304953	100736430	20992777833	of	of	IO
304953	100736430	20992777834	progress	progress	NN1
304953	100736430	20992777835	in	in	II
304953	100736430	20992777836	the	the	AT
304953	100736430	20992777837	understanding	understanding	NN1
304953	100736430	20992777838	of	of	IO
304953	100736430	20992777839	BPH	bph	NP1
304953	100736430	20992777840	over	over	II
304953	100736430	20992777841	the	the	AT
304953	100736430	20992777842	years	year	NNT2
304953	100736430	20992777843	,	,	,
304953	100736430	20992777844	and	and	CC
304953	100736430	20992777845	we	we	PPIS2
304953	100736430	20992777846	understand	understand	VV0
304953	100736430	20992777847	a	a	RR21@_AT1
304953	100736430	20992777848	lot	lot	RR22_NN1
304953	100736430	20992777849	more	more	RRR_DAR
304953	100736430	20992777850	about	about	II
304953	100736430	20992777851	the	the	AT
304953	100736430	20992777852	role	role	NN1
304953	100736430	20992777853	of	of	IO
304953	100736430	20992777854	medical	medical	JJ
304953	100736430	20992777855	therapy	therapy	NN1
304953	100736430	20992777856	in	in	II
304953	100736430	20992777857	treating	treat	VVG
304953	100736430	20992777858	BPH	bph	NP1
304953	100736430	20992777859	.	.	.
304953	100736430	20992777860	Patients	patient	NN2
304953	100736430	20992777861	do	do	VD0
304953	100736430	20992777862	n't 	n't	XX
304953	100736430	20992777863	need	need	VVI
304953	100736430	20992777864	to	to	TO
304953	100736430	20992777865	wait	wait	VVI
304953	100736430	20992777866	until	until	CS_II@
304953	100736430	20992777867	their	their	APPGE
304953	100736430	20992777868	@		II
304953	100736430	20992777869	@		II
304953	100736430	20992777870	@		II
304953	100736430	20992777871	@		II
304953	100736430	20992777872	@		II
304953	100736430	20992777873	@		II
304953	100736430	20992777874	@		II
304953	100736430	20992777875	@		II
304953	100736430	20992777876	@		II
304953	100736430	20992777877	@		II
304953	100736430	20992777878	can	can	VM
304953	100736430	20992777879	help	help	VVI
304953	100736430	20992777880	with	with	IW
304953	100736430	20992777881	symptoms	symptom	NN2
304953	100736430	20992777882	like	like	II
304953	100736430	20992777883	urinary	urinary	JJ_NN1
304953	100736430	20992777884	retention	retention	NN1
304953	100736430	20992777885	.	.	.
304953	100736430	20992777886	<p>		NULL
304953	100736430	20992777887	One	one	MC1
304953	100736430	20992777888	thing	thing	NN1
304953	100736430	20992777889	that	that	CST_DD1
304953	100736430	20992777890	we 've		NN1
304953	100736430	20992777891	been	be	VBN
304953	100736430	20992777892	able	able	JK
304953	100736430	20992777893	to	to	TO
304953	100736430	20992777894	do	do	VDI
304953	100736430	20992777895	is	be	VBZ
304953	100736430	20992777896	identify	identify	VVI
304953	100736430	20992777897	men	man	NN2
304953	100736430	20992777898	who	who	PNQS
304953	100736430	20992777899	are	be	VBR
304953	100736430	20992777900	at	at	II
304953	100736430	20992777901	risk	risk	NN1
304953	100736430	20992777902	of	of	IO
304953	100736430	20992777903	progression	progression	NN1
304953	100736430	20992777904	men	man	NN2
304953	100736430	20992777905	with	with	IW
304953	100736430	20992777906	BPH	bph	NP1
304953	100736430	20992777907	who	who	PNQS
304953	100736430	20992777908	have	have	VH0
304953	100736430	20992777909	a	a	AT1
304953	100736430	20992777910	PSA	psa	NP1
304953	100736430	20992777911	of	of	IO
304953	100736430	20992777912	1.6	1.6	MC
304953	100736430	20992777913	ng/ml	ng/ml	FU
304953	100736430	20992777914	or	or	CC
304953	100736430	20992777915	greater	great	JJR
304953	100736430	20992777916	and	and	CC
304953	100736430	20992777917	a	a	AT1
304953	100736430	20992777918	prostate	prostate	NN1
304953	100736430	20992777919	that	that	CST_DD1
304953	100736430	20992777920	weighs	weigh	VVZ
304953	100736430	20992777921	31	31	MC
304953	100736430	20992777922	grams	gram	NNU2
304953	100736430	20992777923	or	or	CC
304953	100736430	20992777924	more.		NNU
304953	100736430	20992777925	*	*	FU
304953	100736430	20992777926	They	they	PPHS2
304953	100736430	20992777927	are	be	VBR
304953	100736430	20992777928	on	on	II
304953	100736430	20992777929	the	the	AT
304953	100736430	20992777930	slippery	slippery	JJ
304953	100736430	20992777931	slope	slope	NN1
304953	100736430	20992777932	,	,	,
304953	100736430	20992777933	meaning	mean	VVG
304953	100736430	20992777934	that	that	CST
304953	100736430	20992777935	they	they	PPHS2
304953	100736430	20992777936	are	be	VBR
304953	100736430	20992777937	more	more	RGR
304953	100736430	20992777938	likely	likely	JJ
304953	100736430	20992777939	to	to	TO
304953	100736430	20992777940	have	have	VHI
304953	100736430	20992777941	continued	continue	VVN_JJ
304953	100736430	20992777942	prostate	prostate	NN1
304953	100736430	20992777943	growth	growth	NN1
304953	100736430	20992777944	and	and	CC
304953	100736430	20992777945	urinary	urinary	JJ_NN1
304953	100736430	20992777946	retention	retention	NN1
304953	100736430	20992777947	and	and	CC
304953	100736430	20992777948	need	need	VV0
304953	100736430	20992777949	surgery	surgery	NN1
304953	100736430	20992777950	.	.	.
304953	100736430	20992777951	So	so	RR
304953	100736430	20992777952	its	its	APPGE
304953	100736430	20992777953	important	important	JJ
304953	100736430	20992777954	to	to	TO
304953	100736430	20992777955	identify	identify	VVI
304953	100736430	20992777956	men	man	NN2
304953	100736430	20992777957	in	in	II
304953	100736430	20992777958	that	that	DD1
304953	100736430	20992777959	group	group	NN1
304953	100736430	20992777960	and	and	CC
304953	100736430	20992777961	institute	institute	NN1_VV0%
304953	100736430	20992777962	medical	medical	JJ
304953	100736430	20992777963	therapy	therapy	NN1
304953	100736430	20992777964	.	.	.
304953	100736430	20992777965	<p>		NULL
304953	100736430	20992777966	*Note	*note	FO
304953	100736430	20992777967	:	:	:
304953	100736430	20992777968	See	see	VV0
304953	100736430	20992777969	"	"	"
304953	100736430	20992777970	BPH	bph	NP1
304953	100736430	20992777971	progression	progression	NN1
304953	100736430	20992777972	.	.	.
304953	100736430	20992777973	"	"	"
304953	100736430	20992777974	<p>		NULL
304953	100736430	20992777975	The	the	AT
304953	100736430	20992777976	two	two	MC
304953	100736430	20992777977	most	most	RGT
304953	100736430	20992777978	common	common	JJ
304953	100736430	20992777979	therapies	therapy	NN2
304953	100736430	20992777980	are	be	VBR
304953	100736430	20992777981	alpha-1	alpha-1	MC1
304953	100736430	20992777982	blockers	blocker	NN2
304953	100736430	20992777983	the	the	AT
304953	100736430	20992777984	most	most	RGT
304953	100736430	20992777985	common	common	JJ
304953	100736430	20992777986	of	of	IO
304953	100736430	20992777987	which	which	DDQ
304953	100736430	20992777988	is	be	VBZ
304953	100736430	20992777989	tamsulosin		NN1
304953	100736430	20992777990	(	(	(
304953	100736430	20992777991	Flomax		NP1
304953	100736430	20992777992	)	)	)
304953	100736430	20992777993	and	and	CC
304953	100736430	20992777994	5-alpha-reductase		JJ_NN1
304953	100736430	20992777995	inhibitors	inhibitor	NN2
304953	100736430	20992777996	the	the	AT
304953	100736430	20992777997	most	most	RGT
304953	100736430	20992777998	common	common	JJ
304953	100736430	20992777999	of	of	IO
304953	100736430	20992778000	which	which	DDQ
304953	100736430	20992778001	is	be	VBZ
304953	100736430	20992778002	dutasteride		NN1
304953	100736430	20992778003	(	(	(
304953	100736430	20992778004	Avodart		NP1
304953	100736430	20992778005	)	)	)
304953	100736430	20992778006	.	.	.
304953	100736430	20992778007	These	these	DD2
304953	100736430	20992778008	drugs	drug	NN2
304953	100736430	20992778009	are	be	VBR
304953	100736430	20992778010	capable	capable	JJ
304953	100736430	20992778011	of	of	IO
304953	100736430	20992778012	arresting	arrest	VVG
304953	100736430	20992778013	the	the	AT
304953	100736430	20992778014	disease	disease	NN1
304953	100736430	20992778015	and	and	CC
304953	100736430	20992778016	providing	provide	VVG
304953	100736430	20992778017	almost	almost	RR
304953	100736430	20992778018	instant	instant	JJ
304953	100736430	20992778019	gratification	gratification	NN1
304953	100736430	20992778020	in	in	II31
304953	100736430	20992778021	terms	terms	II32
304953	100736430	20992778022	of	of	II33
304953	100736430	20992778023	symptom	symptom	NN1
304953	100736430	20992778024	relief	relief	NN1
304953	100736430	20992778025	.	.	.
304953	100736430	20992778026	<p>		NULL
304953	100736430	20992778027	We	we	PPIS2
304953	100736430	20992778028	need	need	VV0
304953	100736430	20992778029	to	to	TO
304953	100736430	20992778030	get	get	VVI
304953	100736430	20992778031	the	the	AT
304953	100736430	20992778032	word	word	NN1
304953	100736430	20992778033	out	out	RP
304953	100736430	20992778034	to	to	II
304953	100736430	20992778035	family	family	NN1
304953	100736430	20992778036	practitioners	practitioner	NN2
304953	100736430	20992778037	that	that	CST
304953	100736430	20992778038	an	a	AT1
304953	100736430	20992778039	elevated	elevated	JJ
304953	100736430	20992778040	PSA	psa	NP1
304953	100736430	20992778041	is	be	VBZ
304953	100736430	20992778042	a	a	AT1
304953	100736430	20992778043	surrogate	surrogate	NN1
304953	100736430	20992778044	for	for	IF
304953	100736430	20992778045	an	a	AT1
304953	100736430	20992778046	enlarged	enlarged	JJ
304953	100736430	20992778047	prostate	prostate	NN1
304953	100736430	20992778048	.	.	.
304953	100736430	20992778049	Even	even	CS21
304953	100736430	20992778050	if	if	CS22
304953	100736430	20992778051	you	you	PPY
304953	100736430	20992778052	do	do	VD0
304953	100736430	20992778053	n't 	n't	XX
304953	100736430	20992778054	have	have	VHI
304953	100736430	20992778055	symptoms	symptom	NN2
304953	100736430	20992778056	,	,	,
304953	100736430	20992778057	if	if	CS
304953	100736430	20992778058	you	you	PPY
304953	100736430	20992778059	have	have	VH0
304953	100736430	20992778060	an	a	AT1
304953	100736430	20992778061	enlarged	enlarged	JJ
304953	100736430	20992778062	prostate	prostate	NN1
304953	100736430	20992778063	,	,	,
304953	100736430	20992778064	then	then	RT
304953	100736430	20992778065	you 're		VV0
304953	100736430	20992778066	at	at	II
304953	100736430	20992778067	risk	risk	NN1
304953	100736430	20992778068	@		II
304953	100736430	20992778069	@		II
304953	100736430	20992778070	@		II
304953	100736430	20992778071	@		II
304953	100736430	20992778072	@		II
304953	100736430	20992778073	@		II
304953	100736430	20992778074	@		II
304953	100736430	20992778075	@		II
304953	100736430	20992778076	@		II
304953	100736430	20992778077	@		II
304953	100736430	20992778078	We 've		NP1@_NN1
304953	100736430	20992778079	made	make	VVD
304953	100736430	20992778080	a	a	AT1
304953	100736430	20992778081	lot	lot	NN1
304953	100736430	20992778082	of	of	IO
304953	100736430	20992778083	progress	progress	NN1
304953	100736430	20992778084	against	against	II
304953	100736430	20992778085	prostate	prostate	NN1
304953	100736430	20992778086	cancer	cancer	NN1
304953	100736430	20992778087	in	in	II
304953	100736430	20992778088	the	the	AT
304953	100736430	20992778089	last	last	MD
304953	100736430	20992778090	two	two	MC
304953	100736430	20992778091	decades	decade	NNT2
304953	100736430	20992778092	.	.	.
304953	100736430	20992778093	Screening	screening	NN1
304953	100736430	20992778094	has	have	VHZ
304953	100736430	20992778095	resulted	result	VVN
304953	100736430	20992778096	in	in	II
304953	100736430	20992778097	the	the	AT
304953	100736430	20992778098	discovery	discovery	NN1
304953	100736430	20992778099	of	of	IO
304953	100736430	20992778100	early-stage	early-stage	JJ_NN1
304953	100736430	20992778101	disease	disease	NN1
304953	100736430	20992778102	.	.	.
304953	100736430	20992778103	And	and	CC
304953	100736430	20992778104	we 've		NN1_VV0
304953	100736430	20992778105	made	make	VVD_VVN
304953	100736430	20992778106	strides	stride	NN2_VVZ
304953	100736430	20992778107	in	in	II
304953	100736430	20992778108	hormone	hormone	NN1
304953	100736430	20992778109	therapy	therapy	NN1
304953	100736430	20992778110	and	and	CC
304953	100736430	20992778111	established	establish	VVD
304953	100736430	20992778112	the	the	AT
304953	100736430	20992778113	value	value	NN1
304953	100736430	20992778114	of	of	IO
304953	100736430	20992778115	chemotherapy	chemotherapy	NN1
304953	100736430	20992778116	in	in	II
304953	100736430	20992778117	men	man	NN2
304953	100736430	20992778118	with	with	IW
304953	100736430	20992778119	advanced	advanced	JJ
304953	100736430	20992778120	prostate	prostate	NN1
304953	100736430	20992778121	cancer	cancer	NN1
304953	100736430	20992778122	.	.	.
304953	100736430	20992778123	With	with	IW
304953	100736430	20992778124	new	new	JJ
304953	100736430	20992778125	biomarkers	biomarker	NN2
304953	100736430	20992778126	and	and	CC
304953	100736430	20992778127	targeted	target	VVD_VVN
304953	100736430	20992778128	therapies	therapy	NN2
304953	100736430	20992778129	on	on	II
304953	100736430	20992778130	the	the	AT
304953	100736430	20992778131	horizon	horizon	NN1
304953	100736430	20992778132	,	,	,
304953	100736430	20992778133	the	the	AT
304953	100736430	20992778134	future	future	NN1
304953	100736430	20992778135	looks	look	VVZ
304953	100736430	20992778136	even	even	RR
304953	100736430	20992778137	brighter	bright	JJR_RRR@
304953	100736430	20992778138	.	.	.
304953	100736430	20992778139	<p>		NULL
304953	100736430	20992778140	Thank	thank	VV0
304953	100736430	20992778141	you	you	PPY
304953	100736430	20992778142	for	for	IF
304953	100736430	20992778143	your	your	APPGE
304953	100736430	20992778144	kind	kind	NN1_JJ@
304953	100736430	20992778145	words	word	NN2
304953	100736430	20992778146	.	.	.
304953	100736430	20992778147	I	i	PPIS1
304953	100736430	20992778148	work	work	VV0
304953	100736430	20992778149	with	with	IW
304953	100736430	20992778150	many	many	DA2
304953	100736430	20992778151	prestigious	prestigious	JJ
304953	100736430	20992778152	drs		NNU
304953	100736430	20992778153	and	and	CC
304953	100736430	20992778154	some	some	DD
304953	100736430	20992778155	of	of	IO
304953	100736430	20992778156	the	the	AT
304953	100736430	20992778157	itnrnvoes		NN2
304953	100736430	20992778158	of	of	IO
304953	100736430	20992778159	AHCC	ahcc	NP1_NN1
304953	100736430	20992778160	and	and	CC
304953	100736430	20992778161	GCP	gcp	NP1
304953	100736430	20992778162	and	and	CC
304953	100736430	20992778163	have	have	VH0
304953	100736430	20992778164	spoken	speak	VVN
304953	100736430	20992778165	at	at	II
304953	100736430	20992778166	teaching	teach	VVG_NN1
304953	100736430	20992778167	hospitals	hospital	NN2
304953	100736430	20992778168	on	on	II
304953	100736430	20992778169	AHCC	ahcc	NP1_NN1
304953	100736430	20992778170	.	.	.
304953	100736430	20992778171	Our	our	APPGE
304953	100736430	20992778172	web	web	NN1
304953	100736430	20992778173	does	do	VDZ
304953	100736430	20992778174	accept	accept	VVI
304953	100736430	20992778175	MasterCard	mastercard	NP1_NN1@
304953	100736430	20992778176	from	from	II
304953	100736430	20992778177	South	south	NP1
304953	100736430	20992778178	Africa	africa	NP1
304953	100736430	20992778179	and	and	CC
304953	100736430	20992778180	also	also	RR
304953	100736430	20992778181	most	most	RGT
304953	100736430	20992778182	all	all	RR@
304953	100736430	20992778183	of	of	IO
304953	100736430	20992778184	Europe	europe	NP1
304953	100736430	20992778185	and	and	CC
304953	100736430	20992778186	Asia	asia	NP1
304953	100736430	20992778187	.	.	.
304953	100736430	20992778188	Email	email	NN1_VV0@
304953	100736430	20992778189	if	if	CS_CSW@
304953	100736430	20992778190	you	you	PPY
304953	100736430	20992778191	would	would	VM
304953	100736430	20992778192	like	like	VVI
304953	100736430	20992778193	to	to	TO
304953	100736430	20992778194	discuss	discuss	VVI
304953	100736430	20992778195	your	your	APPGE
304953	100736430	20992778196	personal	personal	JJ
304953	100736430	20992778197	needs	need	NN2
304953	100736430	20992778198	regarding	regarding	II_VVG
304953	100736430	20992778199	prostate	prostate	NN1
304953	100736430	20992778200	health	health	NN1
304953	100736430	20992778201	.	.	.
304953	100736430	20992778202	I	i	PPIS1
304953	100736430	20992778203	will	will	VM
304953	100736430	20992778204	do	do	VDI
304953	100736430	20992778205	what	what	DDQ
304953	100736430	20992778206	I	i	PPIS1
304953	100736430	20992778207	can	can	VV0%_VM
304953	100736430	20992778208	to	to	TO
304953	100736430	20992778209	assist	assist	VVI
304953	100736430	20992778210	you	you	PPY
304953	100736430	20992778211	.	.	.
304953	100736430	20992778212	Regards	regard	NN2
304953	100736430	20992778213	,	,	,
304953	100736430	20992778214	Patricia	patricia	NP1
304953	100736430	20992778215	46996		MC
304953	100736430	20992778216	@qwx906996		FO
304953	100736431	20992778236	@@##	----------	----------
304953	100736431	20992778237	@@100736431		FO
304953	100736431	20992778238	@4936431/		VV0_NN1
304953	100736431	20992778239	46988		MC
304953	100736431	20992778240	@qwx906988		FO
304953	100736431	20992778241	46994		MC
304953	100736431	20992778242	@qwx906994		FO
304953	100736431	20992778243	46995		MC
304953	100736431	20992778244	@qwx906995		FO
304953	100736431	20992778245	46992		MC
304953	100736431	20992778246	@qwx906992		FO
304953	100736431	20992778247	46991		MC
304953	100736431	20992778248	@qwx906991		FO
304953	100736431	20992778249	46990		MC
304953	100736431	20992778250	@qwx906990		FO
304953	100736431	20992778251	46989		MC
304953	100736431	20992778252	@qwx906989		FO
304953	100736431	20992778253	46993		MC
304953	100736431	20992778254	@qwx906993		FO
304953	100736431	20992778255	<h>		NULL
304953	100736431	20992778256	Prostate	prostate	NN1
304953	100736431	20992778257	Basics	basics	NN2
304953	100736431	20992778258	<p>		NULL
304953	100736431	20992778259	The	the	AT
304953	100736431	20992778260	walnut-sized	walnut-sized	JJ
304953	100736431	20992778261	prostate	prostate	NN1
304953	100736431	20992778262	gland	gland	NN1
304953	100736431	20992778263	produces	produce	VVZ
304953	100736431	20992778264	a	a	AT1
304953	100736431	20992778265	thick	thick	JJ
304953	100736431	20992778266	,	,	,
304953	100736431	20992778267	milky-white	milky-white	JJ
304953	100736431	20992778268	fluid	fluid	NN1
304953	100736431	20992778269	that	that	CST_DD1
304953	100736431	20992778270	becomes	become	VVZ
304953	100736431	20992778271	part	part	NN1
304953	100736431	20992778272	of	of	IO
304953	100736431	20992778273	the	the	AT
304953	100736431	20992778274	semen	semen	NN1
304953	100736431	20992778275	,	,	,
304953	100736431	20992778276	the	the	AT
304953	100736431	20992778277	liquid	liquid	NN1
304953	100736431	20992778278	ejaculated	ejaculate	VVD_VVN@
304953	100736431	20992778279	during	during	II
304953	100736431	20992778280	sexual	sexual	JJ
304953	100736431	20992778281	activity	activity	NN1
304953	100736431	20992778282	.	.	.
304953	100736431	20992778283	It	it	PPH1
304953	100736431	20992778284	is	be	VBZ
304953	100736431	20992778285	located	locate	VVN
304953	100736431	20992778286	in	in	II31
304953	100736431	20992778287	front	front	II32
304953	100736431	20992778288	of	of	II33
304953	100736431	20992778289	the	the	AT
304953	100736431	20992778290	rectum	rectum	NN1
304953	100736431	20992778291	and	and	CC
304953	100736431	20992778292	just	just	RR
304953	100736431	20992778293	below	below	II
304953	100736431	20992778294	the	the	AT
304953	100736431	20992778295	bladder	bladder	NN1
304953	100736431	20992778296	(	(	(
304953	100736431	20992778297	see	see	VV0
304953	100736431	20992778298	illustration	illustration	NN1
304953	100736431	20992778299	below	below	RL
304953	100736431	20992778300	)	)	)
304953	100736431	20992778301	.	.	.
304953	100736431	20992778302	It	it	PPH1
304953	100736431	20992778303	also	also	RR
304953	100736431	20992778304	wraps	wrap	VVZ
304953	100736431	20992778305	around	around	II_RP
304953	100736431	20992778306	the	the	AT
304953	100736431	20992778307	upper	upper	JJ
304953	100736431	20992778308	part	part	NN1
304953	100736431	20992778309	of	of	IO
304953	100736431	20992778310	the	the	AT
304953	100736431	20992778311	urethra	urethra	NN1
304953	100736431	20992778312	,	,	,
304953	100736431	20992778313	the	the	AT
304953	100736431	20992778314	tube	tube	NN1
304953	100736431	20992778315	that	that	CST_DD1
304953	100736431	20992778316	carries	carry	VVZ
304953	100736431	20992778317	urine	urine	NN1
304953	100736431	20992778318	from	from	II
304953	100736431	20992778319	the	the	AT
304953	100736431	20992778320	bladder	bladder	NN1
304953	100736431	20992778321	out	out	II21
304953	100736431	20992778322	of	of	II22
304953	100736431	20992778323	the	the	AT
304953	100736431	20992778324	body	body	NN1
304953	100736431	20992778325	.	.	.
304953	100736431	20992778326	Counterintuitively	counterintuitively	RR_NP1@
304953	100736431	20992778327	,	,	,
304953	100736431	20992778328	the	the	AT
304953	100736431	20992778329	top	top	NN1
304953	100736431	20992778330	of	of	IO
304953	100736431	20992778331	the	the	AT
304953	100736431	20992778332	prostate	prostate	NN1
304953	100736431	20992778333	is	be	VBZ
304953	100736431	20992778334	called	call	VVN
304953	100736431	20992778335	the	the	AT
304953	100736431	20992778336	base	base	NN1
304953	100736431	20992778337	and	and	CC
304953	100736431	20992778338	the	the	AT
304953	100736431	20992778339	bottom	bottom	NN1
304953	100736431	20992778340	is	be	VBZ
304953	100736431	20992778341	called	call	VVN
304953	100736431	20992778342	the	the	AT
304953	100736431	20992778343	apex	apex	NN1
304953	100736431	20992778344	.	.	.
304953	100736431	20992778345	<h>		NULL
304953	100736431	20992778346	Location	location	NN1
304953	100736431	20992778347	of	of	IO
304953	100736431	20992778348	the	the	AT
304953	100736431	20992778349	prostate	prostate	NN1
304953	100736431	20992778350	gland	gland	NN1
304953	100736431	20992778351	<p>		NULL
304953	100736431	20992778352	In	in	RR21
304953	100736431	20992778353	general	general	RR22
304953	100736431	20992778354	,	,	,
304953	100736431	20992778355	doctors	doctor	NN2
304953	100736431	20992778356	divide	divide	VV0
304953	100736431	20992778357	the	the	AT
304953	100736431	20992778358	prostate	prostate	NN1
304953	100736431	20992778359	into	into	II
304953	100736431	20992778360	three	three	MC
304953	100736431	20992778361	zones	zone	NN2
304953	100736431	20992778362	(	(	(
304953	100736431	20992778363	see	see	VV0
304953	100736431	20992778364	image	image	NN1
304953	100736431	20992778365	below	below	RL
304953	100736431	20992778366	)	)	)
304953	100736431	20992778367	:	:	:
304953	100736431	20992778368	the	the	AT
304953	100736431	20992778369	peripheral	peripheral	JJ
304953	100736431	20992778370	(	(	(
304953	100736431	20992778371	1	1	MC1
304953	100736431	20992778372	)	)	)
304953	100736431	20992778373	,	,	,
304953	100736431	20992778374	central	central	JJ
304953	100736431	20992778375	(	(	(
304953	100736431	20992778376	2	2	MC
304953	100736431	20992778377	)	)	)
304953	100736431	20992778378	,	,	,
304953	100736431	20992778379	and	and	CC
304953	100736431	20992778380	transition	transition	NN1
304953	100736431	20992778381	(	(	(
304953	100736431	20992778382	3	3	MC
304953	100736431	20992778383	)	)	)
304953	100736431	20992778384	zones	zone	NN2
304953	100736431	20992778385	.	.	.
304953	100736431	20992778386	Most	most	DAT
304953	100736431	20992778387	prostate	prostate	NN1
304953	100736431	20992778388	cancers	cancer	NN2
304953	100736431	20992778389	arise	arise	VV0
304953	100736431	20992778390	in	in	II_RP@
304953	100736431	20992778391	the	the	AT
304953	100736431	20992778392	peripheral	peripheral	JJ
304953	100736431	20992778393	zone	zone	NN1
304953	100736431	20992778394	,	,	,
304953	100736431	20992778395	the	the	AT
304953	100736431	20992778396	outer	outer	JJ
304953	100736431	20992778397	area	area	NN1
304953	100736431	20992778398	of	of	IO
304953	100736431	20992778399	the	the	AT
304953	100736431	20992778400	prostate	prostate	NN1
304953	100736431	20992778401	,	,	,
304953	100736431	20992778402	which	which	DDQ
304953	100736431	20992778403	is	be	VBZ
304953	100736431	20992778404	next	next	II21
304953	100736431	20992778405	to	to	II22
304953	100736431	20992778406	the	the	AT
304953	100736431	20992778407	rectum	rectum	NN1
304953	100736431	20992778408	.	.	.
304953	100736431	20992778409	Doctors	doctor	NN2
304953	100736431	20992778410	can	can	VM
304953	100736431	20992778411	sometimes	sometimes	RT
304953	100736431	20992778412	feel	feel	VVI
304953	100736431	20992778413	a	a	AT1
304953	100736431	20992778414	prostate	prostate	NN1
304953	100736431	20992778415	tumor	tumor	NN1
304953	100736431	20992778416	through	through	II
304953	100736431	20992778417	the	the	AT
304953	100736431	20992778418	rectal	rectal	JJ
304953	100736431	20992778419	wall	wall	NN1
304953	100736431	20992778420	during	during	II
304953	100736431	20992778421	a	a	AT1
304953	100736431	20992778422	digital	digital	JJ
304953	100736431	20992778423	rectal	rectal	JJ
304953	100736431	20992778424	examination	examination	NN1
304953	100736431	20992778425	.	.	.
304953	100736431	20992778426	Semen	semen	NN1
304953	100736431	20992778427	stored	store	VVN_VVD
304953	100736431	20992778428	@		II
304953	100736431	20992778429	@		II
304953	100736431	20992778430	@		II
304953	100736431	20992778431	@		II
304953	100736431	20992778432	@		II
304953	100736431	20992778433	@		II
304953	100736431	20992778434	@		II
304953	100736431	20992778435	@		II
304953	100736431	20992778436	@		II
304953	100736431	20992778437	@		II
304953	100736431	20992778438	into	into	II
304953	100736431	20992778439	the	the	AT
304953	100736431	20992778440	urethra	urethra	NN1
304953	100736431	20992778441	for	for	IF
304953	100736431	20992778442	ejaculation	ejaculation	NN1
304953	100736431	20992778443	.	.	.
304953	100736431	20992778444	The	the	AT
304953	100736431	20992778445	transition	transition	NN1
304953	100736431	20992778446	zone	zone	NN1
304953	100736431	20992778447	is	be	VBZ
304953	100736431	20992778448	the	the	AT
304953	100736431	20992778449	innermost	innermost	JJ
304953	100736431	20992778450	section	section	NN1
304953	100736431	20992778451	of	of	IO
304953	100736431	20992778452	the	the	AT
304953	100736431	20992778453	prostate	prostate	NN1
304953	100736431	20992778454	.	.	.
304953	100736431	20992778455	Prostate	prostate	NN1
304953	100736431	20992778456	tissue	tissue	NN1
304953	100736431	20992778457	in	in	II
304953	100736431	20992778458	this	this	DD1
304953	100736431	20992778459	area	area	NN1
304953	100736431	20992778460	wraps	wrap	VVZ_NN2
304953	100736431	20992778461	around	around	II_RP
304953	100736431	20992778462	the	the	AT
304953	100736431	20992778463	urethra	urethra	NN1
304953	100736431	20992778464	.	.	.
304953	100736431	20992778465	<h>		NULL
304953	100736431	20992778466	Zones	zone	NN2
304953	100736431	20992778467	of	of	IO
304953	100736431	20992778468	the	the	AT
304953	100736431	20992778469	prostate	prostate	NN1
304953	100736431	20992778470	<p>		NULL
304953	100736431	20992778471	Because	because	CS
304953	100736431	20992778472	the	the	AT
304953	100736431	20992778473	prostate	prostate	NN1
304953	100736431	20992778474	is	be	VBZ
304953	100736431	20992778475	located	locate	VVN
304953	100736431	20992778476	so	so	RG_RR
304953	100736431	20992778477	close	close	RR_JJ
304953	100736431	20992778478	to	to	II
304953	100736431	20992778479	urinary	urinary	NN1_JJ
304953	100736431	20992778480	and	and	CC
304953	100736431	20992778481	sexual	sexual	JJ
304953	100736431	20992778482	organs	organ	NN2
304953	100736431	20992778483	,	,	,
304953	100736431	20992778484	prostate	prostate	NN1
304953	100736431	20992778485	problems	problem	NN2
304953	100736431	20992778486	can	can	VM
304953	100736431	20992778487	affect	affect	VVI
304953	100736431	20992778488	urination	urination	NN1
304953	100736431	20992778489	and	and	CC
304953	100736431	20992778490	sexual	sexual	JJ
304953	100736431	20992778491	function	function	NN1
304953	100736431	20992778492	.	.	.
304953	100736431	20992778493	For	for	REX21
304953	100736431	20992778494	example	example	REX22
304953	100736431	20992778495	,	,	,
304953	100736431	20992778496	when	when	CS_RRQ
304953	100736431	20992778497	men	man	NN2
304953	100736431	20992778498	reach	reach	VV0
304953	100736431	20992778499	their	their	APPGE
304953	100736431	20992778500	40s	40s	MC2
304953	100736431	20992778501	,	,	,
304953	100736431	20992778502	the	the	AT
304953	100736431	20992778503	prostate	prostate	NN1
304953	100736431	20992778504	often	often	RR
304953	100736431	20992778505	begins	begin	VVZ
304953	100736431	20992778506	to	to	TO
304953	100736431	20992778507	enlarge	enlarge	VVI
304953	100736431	20992778508	.	.	.
304953	100736431	20992778509	Over	over	II
304953	100736431	20992778510	time	time	NNT1
304953	100736431	20992778511	,	,	,
304953	100736431	20992778512	it	it	PPH1
304953	100736431	20992778513	can	can	VM
304953	100736431	20992778514	press	press	VVI
304953	100736431	20992778515	on	on	II
304953	100736431	20992778516	the	the	AT
304953	100736431	20992778517	urethra	urethra	NN1
304953	100736431	20992778518	and	and	CC
304953	100736431	20992778519	slow	slow	JJ
304953	100736431	20992778520	or	or	CC
304953	100736431	20992778521	even	even	RR
304953	100736431	20992778522	prevent	prevent	VV0
304953	100736431	20992778523	the	the	AT
304953	100736431	20992778524	flow	flow	NN1
304953	100736431	20992778525	of	of	IO
304953	100736431	20992778526	urine	urine	NN1
304953	100736431	20992778527	,	,	,
304953	100736431	20992778528	in	in	II_RP@
304953	100736431	20992778529	much	much	RR
304953	100736431	20992778530	the	the	AT
304953	100736431	20992778531	same	same	DA
304953	100736431	20992778532	way	way	NN1
304953	100736431	20992778533	that	that	CST
304953	100736431	20992778534	bending	bend	VVG
304953	100736431	20992778535	a	a	AT1
304953	100736431	20992778536	running	running	JJ_NN1
304953	100736431	20992778537	garden	garden	NN1
304953	100736431	20992778538	hose	hose	NN1
304953	100736431	20992778539	halts	halt	VVZ
304953	100736431	20992778540	the	the	AT
304953	100736431	20992778541	flow	flow	NN1
304953	100736431	20992778542	of	of	IO
304953	100736431	20992778543	water	water	NN1
304953	100736431	20992778544	.	.	.
304953	100736431	20992778545	This	this	DD1
304953	100736431	20992778546	condition	condition	NN1
304953	100736431	20992778547	is	be	VBZ
304953	100736431	20992778548	called	call	VVN
304953	100736431	20992778549	benign	benign	JJ
304953	100736431	20992778550	prostatic	prostatic	JJ
304953	100736431	20992778551	hyperplasia	hyperplasia	NN1
304953	100736431	20992778552	,	,	,
304953	100736431	20992778553	or	or	CC
304953	100736431	20992778554	BPH	bph	NP1
304953	100736431	20992778555	(	(	(
304953	100736431	20992778556	see	see	VV0
304953	100736431	20992778557	image	image	NN1
304953	100736431	20992778558	below	below	RL
304953	100736431	20992778559	)	)	)
304953	100736431	20992778560	.	.	.
304953	100736431	20992778561	<p>		NULL
304953	100736431	20992778562	To	to	TO
304953	100736431	20992778563	function	function	VVI
304953	100736431	20992778564	properly	properly	RR
304953	100736431	20992778565	,	,	,
304953	100736431	20992778566	the	the	AT
304953	100736431	20992778567	prostate	prostate	NN1
304953	100736431	20992778568	requires	require	VVZ
304953	100736431	20992778569	adequate	adequate	JJ
304953	100736431	20992778570	amounts	amount	NN2
304953	100736431	20992778571	of	of	IO
304953	100736431	20992778572	certain	certain	JJ
304953	100736431	20992778573	hormones	hormone	NN2
304953	100736431	20992778574	,	,	,
304953	100736431	20992778575	including	including	II_VVG@
304953	100736431	20992778576	testosterone	testosterone	NN1
304953	100736431	20992778577	,	,	,
304953	100736431	20992778578	produced	produce	VVN
304953	100736431	20992778579	by	by	II
304953	100736431	20992778580	the	the	AT
304953	100736431	20992778581	testicles	testicle	NN2
304953	100736431	20992778582	,	,	,
304953	100736431	20992778583	as	as	II31
304953	100736431	20992778584	well	well	II32
304953	100736431	20992778585	as	as	II33
304953	100736431	20992778586	others	others	NN2
304953	100736431	20992778587	produced	produce	VVN
304953	100736431	20992778588	by	by	II
304953	100736431	20992778589	the	the	AT
304953	100736431	20992778590	pituitary	pituitary	NN1_JJ
304953	100736431	20992778591	and	and	CC
304953	100736431	20992778592	adrenal	adrenal	JJ
304953	100736431	20992778593	glands	gland	NN2
304953	100736431	20992778594	.	.	.
304953	100736432	20992778614	@@##	----------	----------
304953	100736432	20992778615	@@100736432		FO
304953	100736432	20992778616	@4936432/		JJ_NN1_VV0
304953	100736432	20992778617	<h>		NULL
304953	100736432	20992778618	Prostate	prostate	NN1
304953	100736432	20992778619	Cancer	cancer	NN1
304953	100736432	20992778620	46988		MC
304953	100736432	20992778621	@qwx906988		FO
304953	100736432	20992778622	46994		MC
304953	100736432	20992778623	@qwx906994		FO
304953	100736432	20992778624	46995		MC
304953	100736432	20992778625	@qwx906995		FO
304953	100736432	20992778626	46992		MC
304953	100736432	20992778627	@qwx906992		FO
304953	100736432	20992778628	46991		MC
304953	100736432	20992778629	@qwx906991		FO
304953	100736432	20992778630	46990		MC
304953	100736432	20992778631	@qwx906990		FO
304953	100736432	20992778632	46989		MC
304953	100736432	20992778633	@qwx906989		FO
304953	100736432	20992778634	46993		MC
304953	100736432	20992778635	@qwx906993		FO
304953	100736432	20992778636	<h>		NULL
304953	100736432	20992778637	Radiation	radiation	NN1
304953	100736432	20992778638	Therapy	therapy	NN1
304953	100736432	20992778639	<p>		NULL
304953	100736432	20992778640	Radiation	radiation	NN1
304953	100736432	20992778641	therapy	therapy	NN1
304953	100736432	20992778642	,	,	,
304953	100736432	20992778643	which	which	DDQ
304953	100736432	20992778644	may	may	VM
304953	100736432	20992778645	be	be	VBI
304953	100736432	20992778646	used	use	VVN
304953	100736432	20992778647	instead	instead	II21
304953	100736432	20992778648	of	of	II22
304953	100736432	20992778649	or	or	CC
304953	100736432	20992778650	after	after	II_CS
304953	100736432	20992778651	surgery	surgery	NN1
304953	100736432	20992778652	,	,	,
304953	100736432	20992778653	damages	damage	VVZ@_NN2
304953	100736432	20992778654	the	the	AT
304953	100736432	20992778655	DNA	dna	NN1
304953	100736432	20992778656	in	in	II
304953	100736432	20992778657	cancer	cancer	NN1
304953	100736432	20992778658	cells	cell	NN2
304953	100736432	20992778659	,	,	,
304953	100736432	20992778660	preventing	prevent	VVG
304953	100736432	20992778661	the	the	AT
304953	100736432	20992778662	cells	cell	NN2
304953	100736432	20992778663	from	from	II
304953	100736432	20992778664	replicating	replicate	VVG
304953	100736432	20992778665	and	and	CC
304953	100736432	20992778666	causing	cause	VVG
304953	100736432	20992778667	the	the	AT
304953	100736432	20992778668	tumor	tumor	NN1
304953	100736432	20992778669	to	to	TO
304953	100736432	20992778670	shrink	shrink	VVI
304953	100736432	20992778671	.	.	.
304953	100736432	20992778672	There	there	EX
304953	100736432	20992778673	are	be	VBR
304953	100736432	20992778674	two	two	MC
304953	100736432	20992778675	ways	way	NN2
304953	100736432	20992778676	to	to	TO
304953	100736432	20992778677	deliver	deliver	VVI
304953	100736432	20992778678	radiation	radiation	NN1
304953	100736432	20992778679	:	:	:
304953	100736432	20992778680	by	by	II
304953	100736432	20992778681	aiming	aim	VVG
304953	100736432	20992778682	an	a	AT1
304953	100736432	20992778683	external	external	JJ
304953	100736432	20992778684	beam	beam	NN1
304953	100736432	20992778685	of	of	IO
304953	100736432	20992778686	radiation	radiation	NN1
304953	100736432	20992778687	at	at	II
304953	100736432	20992778688	the	the	AT
304953	100736432	20992778689	tumor	tumor	NN1
304953	100736432	20992778690	,	,	,
304953	100736432	20992778691	or	or	CC
304953	100736432	20992778692	by	by	II
304953	100736432	20992778693	surgically	surgically	RR
304953	100736432	20992778694	implanting	implant	VVG
304953	100736432	20992778695	small	small	JJ
304953	100736432	20992778696	radioactive	radioactive	JJ
304953	100736432	20992778697	pellets	pellet	NN2
304953	100736432	20992778698	into	into	II
304953	100736432	20992778699	the	the	AT
304953	100736432	20992778700	prostate	prostate	NN1
304953	100736432	20992778701	gland	gland	NN1
304953	100736432	20992778702	,	,	,
304953	100736432	20992778703	an	a	AT1
304953	100736432	20992778704	approach	approach	NN1
304953	100736432	20992778705	called	call	VVN_VVD@
304953	100736432	20992778706	brachytherapy	brachytherapy	NN1
304953	100736432	20992778707	.	.	.
304953	100736432	20992778708	<p>		NULL
304953	100736432	20992778709	Several	several	DA2
304953	100736432	20992778710	types	type	NN2
304953	100736432	20992778711	of	of	IO
304953	100736432	20992778712	external	external	JJ
304953	100736432	20992778713	beam	beam	NN1
304953	100736432	20992778714	radiation	radiation	NN1
304953	100736432	20992778715	exist	exist	VV0
304953	100736432	20992778716	.	.	.
304953	100736432	20992778717	These	these	DD2
304953	100736432	20992778718	include	include	VV0
304953	100736432	20992778719	three-dimensional	three-dimensional	JJ
304953	100736432	20992778720	conformal	conformal	JJ
304953	100736432	20992778721	radiation	radiation	NN1
304953	100736432	20992778722	therapy	therapy	NN1
304953	100736432	20992778723	(	(	(
304953	100736432	20992778724	3D-CRT		NP1
304953	100736432	20992778725	)	)	)
304953	100736432	20992778726	,	,	,
304953	100736432	20992778727	intensity-modulated	intensity-modulated	JJ_NN1
304953	100736432	20992778728	radiation	radiation	NN1
304953	100736432	20992778729	therapy	therapy	NN1
304953	100736432	20992778730	(	(	(
304953	100736432	20992778731	IMRT		NP1
304953	100736432	20992778732	)	)	)
304953	100736432	20992778733	,	,	,
304953	100736432	20992778734	proton	proton	NN1
304953	100736432	20992778735	beam	beam	NN1_VV0
304953	100736432	20992778736	therapy	therapy	NN1
304953	100736432	20992778737	,	,	,
304953	100736432	20992778738	CyberKnife		NP1
304953	100736432	20992778739	,	,	,
304953	100736432	20992778740	and	and	CC
304953	100736432	20992778741	TomoTherapy		NP1_NN1
304953	100736432	20992778742	.	.	.
304953	100736432	20992778743	Depending	depending	II21
304953	100736432	20992778744	on	on	II22
304953	100736432	20992778745	how	how	RRQ
304953	100736432	20992778746	the	the	AT
304953	100736432	20992778747	treatment	treatment	NN1
304953	100736432	20992778748	is	be	VBZ
304953	100736432	20992778749	delivered	deliver	VVN
304953	100736432	20992778750	,	,	,
304953	100736432	20992778751	treatment	treatment	NN1
304953	100736432	20992778752	sessions	session	NNT2
304953	100736432	20992778753	can	can	VM
304953	100736432	20992778754	last	last	VVI
304953	100736432	20992778755	from	from	II
304953	100736432	20992778756	about	about	RG
304953	100736432	20992778757	15	15	MC
304953	100736432	20992778758	minutes	minute	NNT2
304953	100736432	20992778759	to	to	II
304953	100736432	20992778760	an	a	AT1
304953	100736432	20992778761	hour	hour	NNT1
304953	100736432	20992778762	or	or	CC
304953	100736432	20992778763	longer	long	RRR_JJR
304953	100736432	20992778764	.	.	.
304953	100736432	20992778765	Because	because	CS
304953	100736432	20992778766	the	the	AT
304953	100736432	20992778767	dose	dose	NN1
304953	100736432	20992778768	of	of	IO
304953	100736432	20992778769	radiation	radiation	NN1
304953	100736432	20992778770	must	must	VM
304953	100736432	20992778771	be	be	VBI
304953	100736432	20992778772	spread	spread	VVN
304953	100736432	20992778773	out	out	RP
304953	100736432	20992778774	over	over	II
304953	100736432	20992778775	time	time	NNT1
304953	100736432	20992778776	,	,	,
304953	100736432	20992778777	treatments	treatment	NN2
304953	100736432	20992778778	are	be	VBR
304953	100736432	20992778779	generally	generally	RR
304953	100736432	20992778780	repeated	repeat	VVN
304953	100736432	20992778781	five	five	MC
304953	100736432	20992778782	times	time	NNT2
304953	100736432	20992778783	a	a	AT1
304953	100736432	20992778784	week	week	NNT1
304953	100736432	20992778785	for	for	IF
304953	100736432	20992778786	about	about	RG
304953	100736432	20992778787	eight	eight	MC
304953	100736432	20992778788	weeks	week	NNT2
304953	100736432	20992778789	.	.	.
304953	100736432	20992778790	<p>		NULL
304953	100736432	20992778791	With	with	IW
304953	100736432	20992778792	brachytherapy	brachytherapy	NN1
304953	100736432	20992778793	,	,	,
304953	100736432	20992778794	a	a	AT1
304953	100736432	20992778795	doctor	doctor	NN1
304953	100736432	20992778796	inserts	insert	VVZ
304953	100736432	20992778797	the	the	AT
304953	100736432	20992778798	radioactive	radioactive	JJ
304953	100736432	20992778799	seeds	seed	NN2
304953	100736432	20992778800	into	into	II
304953	100736432	20992778801	the	the	AT
304953	100736432	20992778802	prostate	prostate	NN1
304953	100736432	20992778803	,	,	,
304953	100736432	20992778804	and	and	CC
304953	100736432	20992778805	the	the	AT
304953	100736432	20992778806	@		II
304953	100736432	20992778807	@		II
304953	100736432	20992778808	@		II
304953	100736432	20992778809	@		II
304953	100736432	20992778810	@		II
304953	100736432	20992778811	@		II
304953	100736432	20992778812	@		II
304953	100736432	20992778813	@		II
304953	100736432	20992778814	@		II
304953	100736432	20992778815	@		II
304953	100736432	20992778816	the	the	AT
304953	100736432	20992778817	seeds	seed	NN2
304953	100736432	20992778818	give	give	VV0
304953	100736432	20992778819	off	off	RP
304953	100736432	20992778820	less	less	RRR_DAR
304953	100736432	20992778821	and	and	CC
304953	100736432	20992778822	less	less	DAR
304953	100736432	20992778823	radiation	radiation	NN1
304953	100736432	20992778824	until	until	CS
304953	100736432	20992778825	they	they	PPHS2
304953	100736432	20992778826	become	become	VV0
304953	100736432	20992778827	inert	inert	JJ
304953	100736432	20992778828	.	.	.
304953	100736432	20992778829	<h>		NULL
304953	100736432	20992778830	Related	related	JJ
304953	100736432	20992778831	Articles	article	NN2
304953	100736432	20992778832	<p>		NULL
304953	100736432	20992778833	Following	follow	VVG_JJ@_II@
304953	100736432	20992778834	surgery	surgery	NN1
304953	100736432	20992778835	to	to	TO
304953	100736432	20992778836	remove	remove	VVI
304953	100736432	20992778837	a	a	AT1
304953	100736432	20992778838	cancerous	cancerous	JJ
304953	100736432	20992778839	prostate	prostate	NN1
304953	100736432	20992778840	gland	gland	NN1
304953	100736432	20992778841	,	,	,
304953	100736432	20992778842	some	some	DD
304953	100736432	20992778843	men	man	NN2
304953	100736432	20992778844	experience	experience	VV0
304953	100736432	20992778845	a	a	AT1
304953	100736432	20992778846	biochemical	biochemical	JJ
304953	100736432	20992778847	recurrence	recurrence	NN1
304953	100736432	20992778848	,	,	,
304953	100736432	20992778849	meaning	mean	VVG
304953	100736432	20992778850	that	that	DD1_CST
304953	100736432	20992778851	prostate-specific	prostate-specific	JJ
304953	100736432	20992778852	antigen	antigen	NN1
304953	100736432	20992778853	(	(	(
304953	100736432	20992778854	PSA	psa	NP1
304953	100736432	20992778855	)	)	)
304953	100736432	20992778856	has	have	VHZ
304953	100736432	20992778857	become	become	VVN@
304953	100736432	20992778858	detectable	detectable	JJ
304953	100736432	20992778859	in	in	II
304953	100736432	20992778860	their	their	APPGE
304953	100736432	20992778861	blood	blood	NN1
304953	100736432	20992778862	.	.	.
304953	100736432	20992778863	Since	since	CS_RR@
304953	100736432	20992778864	only	only	JJ
304953	100736432	20992778865	the	the-	AT
304953	100736432	20992778866	prostate	prostate	NN1
304953	100736432	20992778867	releases	release	VVZ
304953	100736432	20992778868	PSA	psa	NP1
304953	100736432	20992778869	,	,	,
304953	100736432	20992778870	removing	remove	VVG
304953	100736432	20992778871	the	the	AT
304953	100736432	20992778872	gland	gland	NN1
304953	100736432	20992778873	should	should	VM
304953	100736432	20992778874	drop	drop	VVI
304953	100736432	20992778875	this	this	DD1
304953	100736432	20992778876	protein	protein	NN1
304953	100736432	20992778877	to	to	II
304953	100736432	20992778878	undetectable	undetectable	JJ
304953	100736432	20992778879	levels	level	NN2
304953	100736432	20992778880	in	in	II
304953	100736432	20992778881	the	the	AT
304953	100736432	20992778882	body	body	NN1
304953	100736432	20992778883	.	.	.
304953	100736432	20992778884	Detecting	detect	VVG
304953	100736432	20992778885	PSA	psa	NP1
304953	100736432	20992778886	could	could	VM
304953	100736432	20992778887	signify	signify	VVI
304953	100736432	20992778888	that	that	DD1_CST
304953	100736432	20992778889	prostate	prostate	NN1
304953	100736432	20992778890	cancer	cancer	NN1
304953	100736432	20992778891	cells	cell	NN2
304953	100736432	20992778892	are	be	VBR
304953	100736432	20992778893	lingering	lingering	JJ
304953	100736432	20992778894	,	,	,
304953	100736432	20992778895	and	and	CC
304953	100736432	20992778896	<p>		NULL
304953	100736432	20992778897	Here	here	RL
304953	100736432	20992778898	is	be	VBZ
304953	100736432	20992778899	a	a	AT1
304953	100736432	20992778900	table	table	NN1
304953	100736432	20992778901	that	that	CST_DD1
304953	100736432	20992778902	contains	contain	VVZ
304953	100736432	20992778903	the	the	AT
304953	100736432	20992778904	many	many	DA2
304953	100736432	20992778905	different	different	JJ
304953	100736432	20992778906	radiation	radiation	NN1
304953	100736432	20992778907	therapy	therapy	NN1
304953	100736432	20992778908	options	option	NN2
304953	100736432	20992778909	for	for	IF
304953	100736432	20992778910	prostate	prostate	NN1
304953	100736432	20992778911	cancer	cancer	NN1
304953	100736432	20992778912	.	.	.
304953	100736432	20992778913	It	it	PPH1
304953	100736432	20992778914	includes	include	VVZ
304953	100736432	20992778915	who	who	PNQS
304953	100736432	20992778916	the	the	AT
304953	100736432	20992778917	ideal	ideal	JJ
304953	100736432	20992778918	candidates	candidate	NN2
304953	100736432	20992778919	are	be	VBR
304953	100736432	20992778920	,	,	,
304953	100736432	20992778921	recovery	recovery	NN1
304953	100736432	20992778922	time	time	NNT1
304953	100736432	20992778923	,	,	,
304953	100736432	20992778924	possible	possible	JJ
304953	100736432	20992778925	side	side	NN1
304953	100736432	20992778926	effects	effect	NN2
304953	100736432	20992778927	,	,	,
304953	100736432	20992778928	and	and	CC
304953	100736432	20992778929	the	the	AT
304953	100736432	20992778930	advantages/disadvantages	advantages/disadvantages	NN2
304953	100736432	20992778931	for	for	IF
304953	100736432	20992778932	each	each	DD1
304953	100736432	20992778933	.	.	.
304953	100736432	20992778934	<p>		NULL
304953	100736432	20992778935	The	the	AT
304953	100736432	20992778936	radioactive	radioactive	JJ
304953	100736432	20992778937	element	element	NN1
304953	100736432	20992778938	radium	radium	NN1
304953	100736432	20992778939	has	have	VHZ
304953	100736432	20992778940	been	be	VBN
304953	100736432	20992778941	used	use	VVN
304953	100736432	20992778942	to	to	TO
304953	100736432	20992778943	treat	treat	VVI
304953	100736432	20992778944	cancer	cancer	NN1
304953	100736432	20992778945	since	since	CS
304953	100736432	20992778946	soon	soon	RR
304953	100736432	20992778947	after	after	II_CS
304953	100736432	20992778948	its	its	APPGE
304953	100736432	20992778949	discovery	discovery	NN1
304953	100736432	20992778950	in	in	II
304953	100736432	20992778951	1898	1898	MC
304953	100736432	20992778952	by	by	II
304953	100736432	20992778953	Marie	marie	NP1
304953	100736432	20992778954	Curie	curie	NP1
304953	100736432	20992778955	and	and	CC
304953	100736432	20992778956	her	her	APPGE
304953	100736432	20992778957	husband	husband	NN1
304953	100736432	20992778958	,	,	,
304953	100736432	20992778959	Pierre	pierre	NP1
304953	100736432	20992778960	.	.	.
304953	100736432	20992778961	And	and	CC
304953	100736432	20992778962	its	its	APPGE
304953	100736432	20992778963	still	still	JJ
304953	100736432	20992778964	finding	finding	NN1_JJ@_VVG
304953	100736432	20992778965	new	new	JJ
304953	100736432	20992778966	uses	use	NN2_VVZ
304953	100736432	20992778967	"	"	"
304953	100736432	20992778968	a	a	AT1
304953	100736432	20992778969	recently	recently	RR
304953	100736432	20992778970	approved	approved	JJ_VVN
304953	100736432	20992778971	form	form	NN1
304953	100736432	20992778972	of	of	IO
304953	100736432	20992778973	radium	radium	NN1
304953	100736432	20992778974	,	,	,
304953	100736432	20992778975	radium-223		MC
304953	100736432	20992778976	(	(	(
304953	100736432	20992778977	Xofigo		NP1
304953	100736432	20992778978	)	)	)
304953	100736432	20992778979	,	,	,
304953	100736432	20992778980	is	be	VBZ
304953	100736432	20992778981	now	now	RT
304953	100736432	20992778982	being	be	VBG
304953	100736432	20992778983	used	use	VVN
304953	100736432	20992778984	to	to	TO
304953	100736432	20992778985	treat	treat	VVI
304953	100736432	20992778986	prostate	prostate	NN1
304953	100736432	20992778987	cancer	cancer	NN1
304953	100736432	20992778988	that	that	CST_DD1
304953	100736432	20992778989	has	have	VHZ
304953	100736432	20992778990	spread	spread	VVN
304953	100736432	20992778991	to	to	II
304953	100736432	20992778992	the	the	AT
304953	100736432	20992778993	bones	bone	NN2
304953	100736432	20992778994	.	.	.
304953	100736432	20992778995	Researchers	researcher	NN2
304953	100736432	20992778996	say	say	VV0
304953	100736432	20992778997	that	that	CST_DD1
304953	100736432	20992778998	Xofigo		NP1_NN1
304953	100736432	20992778999	addresses	address	VVZ
304953	100736432	20992779000	"	"	"
304953	100736432	20992779001	an	a	AT1
304953	100736432	20992779002	unmet	unmet	JJ
304953	100736432	20992779003	need	need	NN1
304953	100736432	20992779004	"	"	"
304953	100736432	20992779005	in	in	II
304953	100736432	20992779006	@		II
304953	100736432	20992779007	@		II
304953	100736432	20992779008	@		II
304953	100736432	20992779009	@		II
304953	100736432	20992779010	@		II
304953	100736432	20992779011	@		II
304953	100736432	20992779012	@		II
304953	100736432	20992779013	@		II
304953	100736432	20992779014	@		II
304953	100736432	20992779015	@		II
304953	100736432	20992779016	therapies	therapy	NN2
304953	100736432	20992779017	do	do	VD0
304953	100736432	20992779018	n't 	n't	XX
304953	100736432	20992779019	work	work	VVI
304953	100736432	20992779020	very	very	RG
304953	100736432	20992779021	well	well	RR
304953	100736432	20992779022	against	against	II
304953	100736432	20992779023	it	it	PPH1
304953	100736432	20992779024	.	.	.
304953	100736433	20992779044	@@##	----------	----------
304953	100736433	20992779045	@@100736433		FO
304953	100736433	20992779046	@4936433/		VV0_NN1
304953	100736433	20992779047	46989		MC
304953	100736433	20992779048	@qwx906989		FO
304953	100736433	20992779049	<p>		NULL
304953	100736433	20992779050	Just	just	RR
304953	100736433	20992779051	being	be	VBG
304953	100736433	20992779052	diagnosed	diagnose	VVN
304953	100736433	20992779053	with	with	IW
304953	100736433	20992779054	prostate	prostate	NN1
304953	100736433	20992779055	cancer	cancer	NN1
304953	100736433	20992779056	may	may	VM
304953	100736433	20992779057	be	be	VBI
304953	100736433	20992779058	hazardous	hazardous	JJ
304953	100736433	20992779059	to	to	II
304953	100736433	20992779060	a	a	AT1
304953	100736433	20992779061	man	man	NN1
304953	100736433	20992779062	's	's	GE
304953	100736433	20992779063	health	health	NN1
304953	100736433	20992779064	.	.	.
304953	100736433	20992779065	According	according	II21
304953	100736433	20992779066	to	to	II22
304953	100736433	20992779067	a	a	AT1
304953	100736433	20992779068	study	study	NN1
304953	100736433	20992779069	from	from	II
304953	100736433	20992779070	the	the	AT
304953	100736433	20992779071	Harvard	harvard	NP1
304953	100736433	20992779072	School	school	NN1
304953	100736433	20992779073	of	of	IO
304953	100736433	20992779074	Public	public	JJ_NN1
304953	100736433	20992779075	Health	health	NN1
304953	100736433	20992779076	,	,	,
304953	100736433	20992779077	a	a	AT1
304953	100736433	20992779078	prostate	prostate	NN1
304953	100736433	20992779079	cancer	cancer	NN1
304953	100736433	20992779080	diagnosis	diagnosis	NN1
304953	100736433	20992779081	may	may	VM
304953	100736433	20992779082	raise	raise	VVI
304953	100736433	20992779083	the	the	AT
304953	100736433	20992779084	risk	risk	NN1
304953	100736433	20992779085	of	of	IO
304953	100736433	20992779086	suicide	suicide	NN1
304953	100736433	20992779087	.	.	.
304953	100736433	20992779088	<p>		NULL
304953	100736433	20992779089	Published	publish	VVN
304953	100736433	20992779090	in	in	II
304953	100736433	20992779091	the	the	AT
304953	100736433	20992779092	March	march	NPM1
304953	100736433	20992779093	3	3	MC
304953	100736433	20992779094	,	,	,
304953	100736433	20992779095	2010	2010	MC
304953	100736433	20992779096	,	,	,
304953	100736433	20992779097	issue	issue	NN1
304953	100736433	20992779098	of	of	IO
304953	100736433	20992779099	the	the	AT
304953	100736433	20992779100	Journal	journal	NN1
304953	100736433	20992779101	of	of	IO
304953	100736433	20992779102	the	the	AT
304953	100736433	20992779103	National	national	JJ
304953	100736433	20992779104	Cancer	cancer	NN1
304953	100736433	20992779105	Institute	institute	NN1
304953	100736433	20992779106	,	,	,
304953	100736433	20992779107	the	the	AT
304953	100736433	20992779108	study	study	NN1
304953	100736433	20992779109	followed	follow	VVD_VVN
304953	100736433	20992779110	more	more	DAR
304953	100736433	20992779111	than	than	CSN
304953	100736433	20992779112	342,000	342,000	MC
304953	100736433	20992779113	American	american	JJ
304953	100736433	20992779114	men	man	NN2
304953	100736433	20992779115	with	with	IW
304953	100736433	20992779116	prostate	prostate	NN1
304953	100736433	20992779117	cancer	cancer	NN1
304953	100736433	20992779118	between	between	II
304953	100736433	20992779119	1979	1979	MC
304953	100736433	20992779120	and	and	CC
304953	100736433	20992779121	2004	2004	MC
304953	100736433	20992779122	.	.	.
304953	100736433	20992779123	One	one	MC1
304953	100736433	20992779124	hundred	hundred	NNO
304953	100736433	20992779125	forty-eight	forty-eight	MC
304953	100736433	20992779126	of	of	IO
304953	100736433	20992779127	them	them	PPHO2
304953	100736433	20992779128	committed	committed	JJ
304953	100736433	20992779129	suicide	suicide	NN1
304953	100736433	20992779130	over	over	II
304953	100736433	20992779131	the	the	AT
304953	100736433	20992779132	course	course	NN1
304953	100736433	20992779133	of	of	IO
304953	100736433	20992779134	the	the	AT
304953	100736433	20992779135	study	study	NN1
304953	100736433	20992779136	.	.	.
304953	100736433	20992779137	Though	though	CS_RR@
304953	100736433	20992779138	small	small	JJ
304953	100736433	20992779139	,	,	,
304953	100736433	20992779140	this	this	DD1
304953	100736433	20992779141	number	number	NN1
304953	100736433	20992779142	represents	represent	VVZ
304953	100736433	20992779143	a	a	AT1
304953	100736433	20992779144	higher	high	JJR
304953	100736433	20992779145	rate	rate	NN1
304953	100736433	20992779146	of	of	IO
304953	100736433	20992779147	suicide	suicide	NN1
304953	100736433	20992779148	compared	compare	VVN
304953	100736433	20992779149	with	with	IW
304953	100736433	20992779150	the	the	AT
304953	100736433	20992779151	general	general	JJ_NN1
304953	100736433	20992779152	population	population	NN1
304953	100736433	20992779153	.	.	.
304953	100736433	20992779154	The	the	AT
304953	100736433	20992779155	risk	risk	NN1
304953	100736433	20992779156	of	of	IO
304953	100736433	20992779157	suicide	suicide	NN1
304953	100736433	20992779158	was	be	VBDZ
304953	100736433	20992779159	greatest	greatest	JJT
304953	100736433	20992779160	within	within	II
304953	100736433	20992779161	the	the	AT
304953	100736433	20992779162	first	first	MD
304953	100736433	20992779163	three	three	MC
304953	100736433	20992779164	months	month	NNT2
304953	100736433	20992779165	of	of	IO
304953	100736433	20992779166	diagnosis	diagnosis	NN1
304953	100736433	20992779167	and	and	CC
304953	100736433	20992779168	remained	remain	VVD_VVN
304953	100736433	20992779169	elevated	elevated	JJ_VVN
304953	100736433	20992779170	for	for	IF
304953	100736433	20992779171	a	a	AT1
304953	100736433	20992779172	full	full	JJ
304953	100736433	20992779173	year	year	NNT1
304953	100736433	20992779174	.	.	.
304953	100736433	20992779175	The	the	AT
304953	100736433	20992779176	risk	risk	NN1
304953	100736433	20992779177	was	be	VBDZ
304953	100736433	20992779178	even	even	RR
304953	100736433	20992779179	higher	high	JJR
304953	100736433	20992779180	among	among	II
304953	100736433	20992779181	patients	patient	NN2
304953	100736433	20992779182	with	with	IW
304953	100736433	20992779183	metastatic	metastatic	JJ
304953	100736433	20992779184	cancer	cancer	NN1
304953	100736433	20992779185	.	.	.
304953	100736433	20992779186	<p>		NULL
304953	100736433	20992779187	The	the	AT
304953	100736433	20992779188	researchers	researcher	NN2
304953	100736433	20992779189	observed	observe	VVD_VVN
304953	100736433	20992779190	that	that	CST
304953	100736433	20992779191	the	the	AT
304953	100736433	20992779192	risk	risk	NN1
304953	100736433	20992779193	of	of	IO
304953	100736433	20992779194	suicide	suicide	NN1
304953	100736433	20992779195	was	be	VBDZ
304953	100736433	20992779196	highest	high	JJT
304953	100736433	20992779197	before	before	II_CS
304953	100736433	20992779198	prostate-specific	prostate-specific	JJ
304953	100736433	20992779199	antigen	antigen	NN1
304953	100736433	20992779200	(	(	(
304953	100736433	20992779201	PSA	psa	NP1
304953	100736433	20992779202	)	)	)
304953	100736433	20992779203	screening	screening	NN1
304953	100736433	20992779204	became	become	VVD
304953	100736433	20992779205	widespread	widespread	JJ
304953	100736433	20992779206	;	;	;
304953	100736433	20992779207	the	the	AT
304953	100736433	20992779208	risk	risk	NN1
304953	100736433	20992779209	decreased	decrease	VVN_VVD
304953	100736433	20992779210	after	after	II
304953	100736433	20992779211	1993	1993	MC
304953	100736433	20992779212	when	when	RRQ_CS
304953	100736433	20992779213	PSA	psa	NP1
304953	100736433	20992779214	testing	testing	NN1
304953	100736433	20992779215	became	become	VVD
304953	100736433	20992779216	the	the	AT
304953	100736433	20992779217	standard	standard	NN1
304953	100736433	20992779218	of	of	IO
304953	100736433	20992779219	care	care	NN1
304953	100736433	20992779220	.	.	.
304953	100736433	20992779221	The	the	AT
304953	100736433	20992779222	drop	drop	NN1
304953	100736433	20992779223	may	may	VM
304953	100736433	20992779224	be	be	VBI
304953	100736433	20992779225	explained	explain	VVN
304953	100736433	20992779226	by	by	II
304953	100736433	20992779227	the	the	AT
304953	100736433	20992779228	test	test	NN1
304953	100736433	20992779229	's	's	GE
304953	100736433	20992779230	ability	ability	NN1
304953	100736433	20992779231	to	to	TO
304953	100736433	20992779232	hint	hint	VVI
304953	100736433	20992779233	at	at	II
304953	100736433	20992779234	prostate	prostate	NN1
304953	100736433	20992779235	cancer	cancer	NN1
304953	100736433	20992779236	@		II
304953	100736433	20992779237	@		II
304953	100736433	20992779238	@		II
304953	100736433	20992779239	@		II
304953	100736433	20992779240	@		II
304953	100736433	20992779241	@		II
304953	100736433	20992779242	@		II
304953	100736433	20992779243	@		II
304953	100736433	20992779244	@		II
304953	100736433	20992779245	@		II
304953	100736433	20992779246	the	the	AT
304953	100736433	20992779247	diagnosis	diagnosis	NN1
304953	100736433	20992779248	somewhat	somewhat	RR
304953	100736433	20992779249	less	less	RGR
304953	100736433	20992779250	devastating	devastating	JJ
304953	100736433	20992779251	.	.	.
304953	100736433	20992779252	<p>		NULL
304953	100736433	20992779253	Of	of	IO
304953	100736433	20992779254	note	note	NN1
304953	100736433	20992779255	,	,	,
304953	100736433	20992779256	the	the	AT
304953	100736433	20992779257	researchers	researcher	NN2
304953	100736433	20992779258	did	do	VDD
304953	100736433	20992779259	not	not	XX
304953	100736433	20992779260	assess	assess	VVI
304953	100736433	20992779261	the	the	AT
304953	100736433	20992779262	overall	overall	JJ_NN1
304953	100736433	20992779263	physical	physical	JJ
304953	100736433	20992779264	or	or	CC
304953	100736433	20992779265	mental	mental	JJ
304953	100736433	20992779266	health	health	NN1
304953	100736433	20992779267	of	of	IO
304953	100736433	20992779268	the	the	AT
304953	100736433	20992779269	men	man	NN2
304953	100736433	20992779270	in	in	II
304953	100736433	20992779271	the	the	AT
304953	100736433	20992779272	study	study	NN1
304953	100736433	20992779273	.	.	.
304953	100736433	20992779274	Nor	nor	CC
304953	100736433	20992779275	did	do	VDD
304953	100736433	20992779276	they	they	PPHS2
304953	100736433	20992779277	have	have	VHI
304953	100736433	20992779278	a	a	AT1
304953	100736433	20992779279	cancer-free	cancer-free	JJ
304953	100736433	20992779280	reference	reference	NN1
304953	100736433	20992779281	group	group	NN1
304953	100736433	20992779282	available	available	JJ
304953	100736433	20992779283	for	for	IF
304953	100736433	20992779284	comparison	comparison	NN1
304953	100736433	20992779285	.	.	.
304953	100736433	20992779286	The	the	AT
304953	100736433	20992779287	researchers	researcher	NN2
304953	100736433	20992779288	suggested	suggest	VVD_VVN
304953	100736433	20992779289	that	that	CST_DD1
304953	100736433	20992779290	further	far	JJR@
304953	100736433	20992779291	research	research	NN1
304953	100736433	20992779292	could	could	VM
304953	100736433	20992779293	evaluate	evaluate	VVI
304953	100736433	20992779294	the	the	AT
304953	100736433	20992779295	impact	impact	NN1
304953	100736433	20992779296	of	of	IO
304953	100736433	20992779297	a	a	AT1
304953	100736433	20992779298	prostate	prostate	NN1
304953	100736433	20992779299	cancer	cancer	NN1
304953	100736433	20992779300	diagnosis	diagnosis	NN1
304953	100736433	20992779301	on	on	II
304953	100736433	20992779302	mental	mental	JJ
304953	100736433	20992779303	health	health	NN1
304953	100736433	20992779304	.	.	.
304953	100736433	20992779305	46996		MC
304953	100736433	20992779306	@qwx906996		FO
304953	100736434	20992779326	@@##	----------	----------
304953	100736434	20992779327	@@100736434		FO
304953	100736434	20992779328	@4936434/		VV0_NN1
304953	100736434	20992779329	46989		MC
304953	100736434	20992779330	@qwx906989		FO
304953	100736434	20992779331	<p>		NULL
304953	100736434	20992779332	Men	man	NN2
304953	100736434	20992779333	who	who	PNQS
304953	100736434	20992779334	have	have	VH0
304953	100736434	20992779335	been	be	VBN
304953	100736434	20992779336	adding	add	VVG_JJ@
304953	100736434	20992779337	lycopene	lycopene	NN1
304953	100736434	20992779338	,	,	,
304953	100736434	20992779339	a	a	AT1
304953	100736434	20992779340	nutrient	nutrient	NN1
304953	100736434	20992779341	found	find	VVN_VVD
304953	100736434	20992779342	in	in	II
304953	100736434	20992779343	tomatoes	tomato	NN2
304953	100736434	20992779344	,	,	,
304953	100736434	20992779345	and	and	CC
304953	100736434	20992779346	other	other	JJ
304953	100736434	20992779347	carotenoids	carotenoid	NN2
304953	100736434	20992779348	to	to	II
304953	100736434	20992779349	their	their	APPGE
304953	100736434	20992779350	diet	diet	NN1
304953	100736434	20992779351	in	in	II
304953	100736434	20992779352	the	the	AT
304953	100736434	20992779353	hopes	hope	NN2
304953	100736434	20992779354	of	of	IO
304953	100736434	20992779355	staving	stave	VVG
304953	100736434	20992779356	off	off	II_RP
304953	100736434	20992779357	prostate	prostate	NN1
304953	100736434	20992779358	cancer	cancer	NN1
304953	100736434	20992779359	might	might	VM
304953	100736434	20992779360	want	want	VVI
304953	100736434	20992779361	to	to	TO
304953	100736434	20992779362	reconsider	reconsider	VVI
304953	100736434	20992779363	.	.	.
304953	100736434	20992779364	According	according	II21
304953	100736434	20992779365	to	to	II22
304953	100736434	20992779366	a	a	AT1
304953	100736434	20992779367	study	study	NN1
304953	100736434	20992779368	published	publish	VVN
304953	100736434	20992779369	in	in	II
304953	100736434	20992779370	September	september	NPM1
304953	100736434	20992779371	2007	2007	MC
304953	100736434	20992779372	,	,	,
304953	100736434	20992779373	which	which	DDQ
304953	100736434	20992779374	included	include	VVD
304953	100736434	20992779375	almost	almost	RR
304953	100736434	20992779376	2,000	2,000	MC
304953	100736434	20992779377	men	man	NN2
304953	100736434	20992779378	in	in	II
304953	100736434	20992779379	eight	eight	MC
304953	100736434	20992779380	countries	country	NN2
304953	100736434	20992779381	,	,	,
304953	100736434	20992779382	carotenoids	carotenoid	NN2
304953	100736434	20992779383	such	such	II21
304953	100736434	20992779384	as	as	II22
304953	100736434	20992779385	lycopene	lycopene	NN1
304953	100736434	20992779386	do	do	VD0
304953	100736434	20992779387	not	not	XX
304953	100736434	20992779388	cut	cut	VVI
304953	100736434	20992779389	the	the	AT
304953	100736434	20992779390	odds	odds	NN2
304953	100736434	20992779391	of	of	IO
304953	100736434	20992779392	prostate	prostate	NN1
304953	100736434	20992779393	malignancy	malignancy	NN1
304953	100736434	20992779394	.	.	.
304953	100736434	20992779395	While	while	CS
304953	100736434	20992779396	researchers	researcher	NN2
304953	100736434	20992779397	found	find	VVD_VVN
304953	100736434	20992779398	that	that	CST_DD1
304953	100736434	20992779399	high	high	JJ
304953	100736434	20992779400	levels	level	NN2
304953	100736434	20992779401	of	of	IO
304953	100736434	20992779402	carotenoids	carotenoid	NN2
304953	100736434	20992779403	could	could	VM
304953	100736434	20992779404	reduce	reduce	VVI
304953	100736434	20992779405	by	by	II
304953	100736434	20992779406	60%		NNU
304953	100736434	20992779407	the	the	AT
304953	100736434	20992779408	risk	risk	NN1
304953	100736434	20992779409	of	of	IO
304953	100736434	20992779410	an	a	AT1
304953	100736434	20992779411	existing	existing	JJ
304953	100736434	20992779412	tumor	tumor	NN1
304953	100736434	20992779413	progressing	progress	VVG
304953	100736434	20992779414	to	to	II
304953	100736434	20992779415	advanced-stage	advanced-stage	JJ_NN1
304953	100736434	20992779416	prostate	prostate	NN1
304953	100736434	20992779417	cancer	cancer	NN1
304953	100736434	20992779418	,	,	,
304953	100736434	20992779419	they	they	PPHS2
304953	100736434	20992779420	noted	note	VVD
304953	100736434	20992779421	that	that	CST
304953	100736434	20992779422	carotenoids	carotenoid	NN2
304953	100736434	20992779423	had	have	VHD
304953	100736434	20992779424	no	no	AT
304953	100736434	20992779425	effect	effect	NN1
304953	100736434	20992779426	on	on	II
304953	100736434	20992779427	the	the	AT
304953	100736434	20992779428	rate	rate	NN1
304953	100736434	20992779429	of	of	IO
304953	100736434	20992779430	localized	localized	JJ
304953	100736434	20992779431	,	,	,
304953	100736434	20992779432	early-stage	early-stage	JJ_NN1
304953	100736434	20992779433	disease	disease	NN1
304953	100736434	20992779434	.	.	.
304953	100736434	20992779435	<p>		NULL
304953	100736434	20992779436	The	the	AT
304953	100736434	20992779437	finding	finding	NN1
304953	100736434	20992779438	on	on	II
304953	100736434	20992779439	advanced-stage	advanced-stage	JJ_NN1
304953	100736434	20992779440	cancer	cancer	NN1
304953	100736434	20992779441	contradicts	contradict	VVZ
304953	100736434	20992779442	two	two	MC
304953	100736434	20992779443	other	other	JJ
304953	100736434	20992779444	recent	recent	JJ
304953	100736434	20992779445	reports	report	NN2
304953	100736434	20992779446	.	.	.
304953	100736434	20992779447	A	a	AT1
304953	100736434	20992779448	study	study	NN1
304953	100736434	20992779449	reported	report	VVN_VVD
304953	100736434	20992779450	in	in	II
304953	100736434	20992779451	May	may	NPM1
304953	100736434	20992779452	2007	2007	MC
304953	100736434	20992779453	yielded	yield	VVD
304953	100736434	20992779454	no	no	AT
304953	100736434	20992779455	proof	proof	NN1
304953	100736434	20992779456	that	that	CST_DD1
304953	100736434	20992779457	lycopene	lycopene	NN1
304953	100736434	20992779458	affects	affect	VVZ
304953	100736434	20992779459	the	the	AT
304953	100736434	20992779460	risk	risk	NN1
304953	100736434	20992779461	of	of	IO
304953	100736434	20992779462	developing	developing	JJ_VVG
304953	100736434	20992779463	prostate	prostate	NN1
304953	100736434	20992779464	cancer	cancer	NN1
304953	100736434	20992779465	,	,	,
304953	100736434	20992779466	including	including	II_VVG@
304953	100736434	20992779467	advanced-stage	advanced-stage	JJ_NN1
304953	100736434	20992779468	disease	disease	NN1
304953	100736434	20992779469	.	.	.
304953	100736434	20992779470	FDA	fda	NP1_NN1
304953	100736434	20992779471	researchers	researcher	NN2
304953	100736434	20992779472	examined	examine	VVD_VVN
304953	100736434	20992779473	81	81	MC
304953	100736434	20992779474	studies	study	NN2
304953	100736434	20992779475	on	on	II
304953	100736434	20992779476	lycopene	lycopene	NN1
304953	100736434	20992779477	and	and	CC
304953	100736434	20992779478	concluded	conclude	VVN_VVD
304953	100736434	20992779479	in	in	II_RP@
304953	100736434	20992779480	a	a	AT1
304953	100736434	20992779481	July	july	NPM1
304953	100736434	20992779482	2007	2007	MC
304953	100736434	20992779483	report	report	NN1_VV0@
304953	100736434	20992779484	that	that	CST
304953	100736434	20992779485	none	none	PN
304953	100736434	20992779486	offered	offer	VVD
304953	100736434	20992779487	any	any	DD
304953	100736434	20992779488	credible	credible	JJ
304953	100736434	20992779489	evidence	evidence	NN1
304953	100736434	20992779490	to	to	TO
304953	100736434	20992779491	support	support	VVI
304953	100736434	20992779492	a	a	AT1
304953	100736434	20992779493	relationship	relationship	NN1
304953	100736434	20992779494	between	between	II
304953	100736434	20992779495	consumption	consumption	NN1
304953	100736434	20992779496	and	and	CC
304953	100736434	20992779497	the	the	AT
304953	100736434	20992779498	risk	risk	NN1
304953	100736434	20992779499	of	of	IO
304953	100736434	20992779500	prostate	prostate	NN1
304953	100736434	20992779501	cancer	cancer	NN1
304953	100736434	20992779502	.	.	.
304953	100736434	20992779503	They	they	PPHS2
304953	100736434	20992779504	also	also	RR
304953	100736434	20992779505	reviewed	review	VVD
304953	100736434	20992779506	39	39	MC
304953	100736434	20992779507	studies	study	NN2
304953	100736434	20992779508	on	on	II
304953	100736434	20992779509	tomato	tomato	NN1
304953	100736434	20992779510	consumption	consumption	NN1
304953	100736434	20992779511	and	and	CC
304953	100736434	20992779512	found	find	VVD_VVN
304953	100736434	20992779513	limited	limited	JJ
304953	100736434	20992779514	evidence	evidence	NN1
304953	100736434	20992779515	to	to	TO
304953	100736434	20992779516	support	support	VVI
304953	100736434	20992779517	the	the	AT
304953	100736434	20992779518	@		II
304953	100736434	20992779519	@		II
304953	100736434	20992779520	@		II
304953	100736434	20992779521	@		II
304953	100736434	20992779522	@		II
304953	100736434	20992779523	@		II
304953	100736434	20992779524	@		II
304953	100736434	20992779525	@		II
304953	100736434	20992779526	@		II
304953	100736434	20992779527	@		II
304953	100736434	20992779528	46996		MC
304953	100736434	20992779529	@qwx906996		FO
304953	100736439	20992779549	@@##	----------	----------
304953	100736439	20992779550	@@100736439		FO
304953	100736439	20992779551	@4936439/		JJ_NN1_VV0
304953	100736439	20992779552	<h>		NULL
304953	100736439	20992779553	Prostate	prostate	NN1
304953	100736439	20992779554	Knowledge	knowledge	NN1
304953	100736439	20992779555	Blog	blog	NN1_NP1_VV0
304953	100736439	20992779556	<h>		NULL
304953	100736439	20992779557	Join	join	VV0
304953	100736439	20992779558	in	in	II_RP@
304953	100736439	20992779559	the	the	AT
304953	100736439	20992779560	conversation	conversation	NN1
304953	100736439	20992779561	about	about	II
304953	100736439	20992779562	common	common	JJ
304953	100736439	20992779563	issues	issue	NN2
304953	100736439	20992779564	,	,	,
304953	100736439	20992779565	breaking	break	VVG
304953	100736439	20992779566	news	news	NN1
304953	100736439	20992779567	,	,	,
304953	100736439	20992779568	and	and	CC
304953	100736439	20992779569	research	research	NN1
304953	100736439	20992779570	related	relate	VVN_VVD
304953	100736439	20992779571	to	to	II
304953	100736439	20992779572	prostate	prostate	NN1
304953	100736439	20992779573	health	health	NN1
304953	100736439	20992779574	.	.	.
304953	100736439	20992779575	<h>		NULL
304953	100736439	20992779576	Searching	search	VVG
304953	100736439	20992779577	PubMed	pubmed	JJ
304953	100736439	20992779578	in	in	II
304953	100736439	20992779579	five	five	MC
304953	100736439	20992779580	easy	easy	JJ
304953	100736439	20992779581	steps	step	NN2
304953	100736439	20992779582	<p>		NULL
304953	100736439	20992779583	You	you	PPY
304953	100736439	20992779584	can	can	VM
304953	100736439	20992779585	find	find	VVI
304953	100736439	20992779586	and	and	CC
304953	100736439	20992779587	read	read	VVI
304953	100736439	20992779588	the	the	AT
304953	100736439	20992779589	studies	study	NN2
304953	100736439	20992779590	that	that	CST
304953	100736439	20992779591	are	be	VBR
304953	100736439	20992779592	referenced	reference	VVN@
304953	100736439	20992779593	on	on	II
304953	100736439	20992779594	this	this	DD1
304953	100736439	20992779595	Web	web	NN1
304953	100736439	20992779596	site	site	NN1
304953	100736439	20992779597	by	by	II
304953	100736439	20992779598	searching	search	VVG
304953	100736439	20992779599	PubMed	pubmed	JJ
304953	100736439	20992779600	,	,	,
304953	100736439	20992779601	a	a	AT1
304953	100736439	20992779602	resource	resource	NN1
304953	100736439	20992779603	of	of	IO
304953	100736439	20992779604	the	the	AT
304953	100736439	20992779605	National	national	JJ
304953	100736439	20992779606	Library	library	NN1
304953	100736439	20992779607	of	of	IO
304953	100736439	20992779608	Medicine	medicine	NN1
304953	100736439	20992779609	.	.	.
304953	100736439	20992779610	The	the	AT
304953	100736439	20992779611	abstracts	abstract	NN2
304953	100736439	20992779612	(	(	(
304953	100736439	20992779613	short	short	JJ
304953	100736439	20992779614	summaries	summary	NN2
304953	100736439	20992779615	)	)	)
304953	100736439	20992779616	of	of	IO
304953	100736439	20992779617	the	the	AT
304953	100736439	20992779618	studies	study	NN2
304953	100736439	20992779619	are	be	VBR
304953	100736439	20992779620	available	available	JJ
304953	100736439	20992779621	for	for	IF
304953	100736439	20992779622	free	free	JJ
304953	100736439	20992779623	,	,	,
304953	100736439	20992779624	but	but	CCB
304953	100736439	20992779625	in	in	II
304953	100736439	20992779626	most	most	DAT
304953	100736439	20992779627	cases	case	NN2
304953	100736439	20992779628	you	you	PPY
304953	100736439	20992779629	will	will	VM
304953	100736439	20992779630	have	have	VHI
304953	100736439	20992779631	to	to	TO
304953	100736439	20992779632	pay	pay	VVI
304953	100736439	20992779633	to	to	TO
304953	100736439	20992779634	obtain	obtain	VVI
304953	100736439	20992779635	the	the	AT
304953	100736439	20992779636	full	full	JJ
304953	100736439	20992779637	report	report	NN1
304953	100736439	20992779638	.	.	.
304953	100736439	20992779639	<p>		NULL
304953	100736439	20992779640	here 's		NN2_NP1@
304953	100736439	20992779641	how	how	RRQ
304953	100736439	20992779642	to	to	TO
304953	100736439	20992779643	access	access	VVI
304953	100736439	20992779644	an	a	AT1
304953	100736439	20992779645	abstract	abstract	JJ_NN1@
304953	100736439	20992779646	:	:	:
304953	100736439	20992779647	<p>		NULL
304953	100736439	20992779648	Open	open	VV0
304953	100736439	20992779649	up	up	RP
304953	100736439	20992779650	your	your	APPGE
304953	100736439	20992779651	browsers	browser	NN2
304953	100736439	20992779652	window	window	NN1_VV0%
304953	100736439	20992779653	while	while	CS
304953	100736439	20992779654	connected	connect	VVN
304953	100736439	20992779655	to	to	II
304953	100736439	20992779656	the	the	AT
304953	100736439	20992779657	Internet	internet	NN1_NP1
304953	100736439	20992779658	.	.	.
304953	100736439	20992779659	Type	type	NN1_VV0%
304953	100736439	20992779660	www.pubmed.gov		NNU
304953	100736439	20992779661	and	and	CC
304953	100736439	20992779662	hit	hit	VVD_VVN_VV0@
304953	100736439	20992779663	return	return	NN1
304953	100736439	20992779664	.	.	.
304953	100736439	20992779665	<p>		NULL
304953	100736439	20992779666	Erectile	erectile	JJ
304953	100736439	20992779667	dysfunction	dysfunction	NN1
304953	100736439	20992779668	can	can	VM
304953	100736439	20992779669	have	have	VHI
304953	100736439	20992779670	many	many	DA2
304953	100736439	20992779671	causes	cause	NN2
304953	100736439	20992779672	,	,	,
304953	100736439	20992779673	including	including	II_VVG@
304953	100736439	20992779674	some	some	DD
304953	100736439	20992779675	forms	form	NN2
304953	100736439	20992779676	of	of	IO
304953	100736439	20992779677	prostate	prostate	NN1
304953	100736439	20992779678	disease	disease	NN1
304953	100736439	20992779679	and	and	CC
304953	100736439	20992779680	prostate	prostate	NN1
304953	100736439	20992779681	cancer	cancer	NN1
304953	100736439	20992779682	surgery	surgery	NN1
304953	100736439	20992779683	.	.	.
304953	100736439	20992779684	The	the	AT
304953	100736439	20992779685	problem	problem	NN1
304953	100736439	20992779686	can	can	VM
304953	100736439	20992779687	often	often	RR
304953	100736439	20992779688	be	be	VBI
304953	100736439	20992779689	effectively	effectively	RR
304953	100736439	20992779690	addressed	address	VVN_VVD
304953	100736439	20992779691	.	.	.
304953	100736439	20992779692	Some	some	DD
304953	100736439	20992779693	men	man	NN2
304953	100736439	20992779694	find	find	VV0
304953	100736439	20992779695	relief	relief	NN1
304953	100736439	20992779696	by	by	II
304953	100736439	20992779697	taking	take	VVG
304953	100736439	20992779698	medications	medication	NN2
304953	100736439	20992779699	.	.	.
304953	100736439	20992779700	If	if	CS
304953	100736439	20992779701	these	these	DD2
304953	100736439	20992779702	are	be	VBR
304953	100736439	20992779703	n't	n't	XX
304953	100736439	20992779704	effective	effective	JJ
304953	100736439	20992779705	for	for	IF
304953	100736439	20992779706	you	you	PPY
304953	100736439	20992779707	,	,	,
304953	100736439	20992779708	a	a	AT1
304953	100736439	20992779709	number	number	NN1
304953	100736439	20992779710	of	of	IO
304953	100736439	20992779711	other	other	JJ
304953	100736439	20992779712	options	option	NN2
304953	100736439	20992779713	,	,	,
304953	100736439	20992779714	including	including	II_VVG@
304953	100736439	20992779715	injections	injection	NN2
304953	100736439	20992779716	and	and	CC
304953	100736439	20992779717	vacuum	vacuum	NN1_VV0@
304953	100736439	20992779718	devices	device	NN2
304953	100736439	20992779719	,	,	,
304953	100736439	20992779720	are	be	VBR
304953	100736439	20992779721	available	available	JJ
304953	100736439	20992779722	.	.	.
304953	100736439	20992779723	<p>		NULL
304953	100736439	20992779724	In	in	II
304953	100736439	20992779725	a	a	AT1
304953	100736439	20992779726	business	business	NN1
304953	100736439	20992779727	,	,	,
304953	100736439	20992779728	due	due	JJ
304953	100736439	20992779729	diligence	diligence	NN1
304953	100736439	20992779730	means	mean	VVZ_NN
304953	100736439	20992779731	doing	do	VDG
304953	100736439	20992779732	your	your	APPGE
304953	100736439	20992779733	homework	homework	NN1
304953	100736439	20992779734	,	,	,
304953	100736439	20992779735	exploring	explore	VVG
304953	100736439	20992779736	all	all	DB
304953	100736439	20992779737	the	the	AT
304953	100736439	20992779738	options	option	NN2
304953	100736439	20992779739	,	,	,
304953	100736439	20992779740	and	and	CC
304953	100736439	20992779741	@		II
304953	100736439	20992779742	@		II
304953	100736439	20992779743	@		II
304953	100736439	20992779744	@		II
304953	100736439	20992779745	@		II
304953	100736439	20992779746	@		II
304953	100736439	20992779747	@		II
304953	100736439	20992779748	@		II
304953	100736439	20992779749	@		II
304953	100736439	20992779750	@		II
304953	100736439	20992779751	make	make	VVI
304953	100736439	20992779752	a	a	AT1
304953	100736439	20992779753	decision	decision	NN1
304953	100736439	20992779754	about	about	II
304953	100736439	20992779755	how	how	RRQ
304953	100736439	20992779756	to	to	TO
304953	100736439	20992779757	treat	treat	VVI
304953	100736439	20992779758	early-stage	early-stage	JJ_NN1
304953	100736439	20992779759	prostate	prostate	NN1
304953	100736439	20992779760	cancer	cancer	NN1
304953	100736439	20992779761	,	,	,
304953	100736439	20992779762	taking	take	VVG
304953	100736439	20992779763	time	time	NNT1
304953	100736439	20992779764	to	to	TO
304953	100736439	20992779765	conduct	conduct	VVI
304953	100736439	20992779766	due	due	JJ
304953	100736439	20992779767	diligence	diligence	NN1
304953	100736439	20992779768	is	be	VBZ
304953	100736439	20992779769	absolutely	absolutely	RR
304953	100736439	20992779770	vital	vital	JJ
304953	100736439	20992779771	for	for	IF
304953	100736439	20992779772	three	three	MC
304953	100736439	20992779773	reasons	reason	NN2
304953	100736439	20992779774	:	:	:
304953	100736439	20992779775	<p>		NULL
304953	100736439	20992779776	No	no	AT
304953	100736439	20992779777	expert	expert	NN1_JJ@
304953	100736439	20992779778	consensus	consensus	NN1
304953	100736439	20992779779	exists	exist	VVZ
304953	100736439	20992779780	about	about	II
304953	100736439	20992779781	which	which	DDQ
304953	100736439	20992779782	treatment	treatment	NN1
304953	100736439	20992779783	for	for	IF
304953	100736439	20992779784	early-stage	early-stage	JJ_NN1
304953	100736439	20992779785	prostate	prostate	NN1
304953	100736439	20992779786	cancer	cancer	NN1
304953	100736439	20992779787	is	be	VBZ
304953	100736439	20992779788	best	best	JJT
304953	100736439	20992779789	(	(	(
304953	100736439	20992779790	or	or	CC
304953	100736439	20992779791	when	when	RRQ_CS
304953	100736439	20992779792	treatment	treatment	NN1
304953	100736439	20992779793	is	be	VBZ
304953	100736439	20992779794	best	best	RRT
304953	100736439	20992779795	postponed	postpone	VVN
304953	100736439	20992779796	)	)	)
304953	100736439	20992779797	.	.	.
304953	100736439	20992779798	<h>		NULL
304953	100736439	20992779799	Understanding	understand	VVG_NN1
304953	100736439	20992779800	PSA	psa	NP1
304953	100736439	20992779801	<p>		NULL
304953	100736439	20992779802	Your	your	APPGE
304953	100736439	20992779803	PSA	psa	NP1
304953	100736439	20992779804	level	level	NN1
304953	100736439	20992779805	is	be	VBZ
304953	100736439	20992779806	moderately	moderately	RR
304953	100736439	20992779807	elevated	elevate	VVN_JJ_VVD
304953	100736439	20992779808	and	and	CC
304953	100736439	20992779809	increasing	increase	VVG_JJ
304953	100736439	20992779810	at	at	II
304953	100736439	20992779811	a	a	AT1
304953	100736439	20992779812	worrisome	worrisome	JJ
304953	100736439	20992779813	rate	rate	NN1
304953	100736439	20992779814	.	.	.
304953	100736439	20992779815	Follow-up	follow-up	NN1
304953	100736439	20992779816	is	be	VBZ
304953	100736439	20992779817	needed	need	VVN
304953	100736439	20992779818	.	.	.
304953	100736439	20992779819	However	however	RR
304953	100736439	20992779820	,	,	,
304953	100736439	20992779821	keep	keep	VV0
304953	100736439	20992779822	in	in	II_RP@
304953	100736439	20992779823	mind	mind	NN1
304953	100736439	20992779824	that	that	CST
304953	100736439	20992779825	your	your	APPGE
304953	100736439	20992779826	risk	risk	NN1
304953	100736439	20992779827	of	of	IO
304953	100736439	20992779828	prostate	prostate	NN1
304953	100736439	20992779829	cancer	cancer	NN1
304953	100736439	20992779830	still	still	RR
304953	100736439	20992779831	less	less	DAR
304953	100736439	20992779832	than	than	CSN
304953	100736439	20992779833	40	40	MC
304953	100736439	20992779834	percent	percent	NNU
304953	100736439	20992779835	.	.	.
304953	100736439	20992779836	<p>		NULL
304953	100736439	20992779837	Your	your	APPGE
304953	100736439	20992779838	options	option	NN2
304953	100736439	20992779839	include	include	VV0
304953	100736439	20992779840	<p>		NULL
304953	100736439	20992779841	referral	referral	NN1
304953	100736439	20992779842	to	to	II
304953	100736439	20992779843	a	a	AT1
304953	100736439	20992779844	urologist	urologist	NN1
304953	100736439	20992779845	(	(	(
304953	100736439	20992779846	prostate	prostate	NN1
304953	100736439	20992779847	specialist	specialist	NN1
304953	100736439	20992779848	)	)	)
304953	100736439	20992779849	<p>		NULL
304953	100736439	20992779850	repeat	repeat	VV0
304953	100736439	20992779851	PSA	psa	NP1
304953	100736439	20992779852	testing	testing	NN1_VVG
304953	100736439	20992779853	in	in	II
304953	100736439	20992779854	several	several	DA2
304953	100736439	20992779855	months	month	NNT2
304953	100736439	20992779856	<p>		NULL
304953	100736439	20992779857	measuring	measure	VVG
304953	100736439	20992779858	your	your	APPGE
304953	100736439	20992779859	"	"	"
304953	100736439	20992779860	free	free	JJ
304953	100736439	20992779861	"	"	"
304953	100736439	20992779862	PSA	psa	NP1
304953	100736439	20992779863	level	level	VV0@_NN1
304953	100736439	20992779864	This	this	DD1
304953	100736439	20992779865	special	special	JJ
304953	100736439	20992779866	way	way	NN1
304953	100736439	20992779867	of	of	IO
304953	100736439	20992779868	testing	test	VVG
304953	100736439	20992779869	your	your	APPGE
304953	100736439	20992779870	PSA	psa	NP1
304953	100736439	20992779871	level	level	NN1
304953	100736439	20992779872	may	may	VM
304953	100736439	20992779873	help	help	VVI
304953	100736439	20992779874	to	to	TO
304953	100736439	20992779875	decide	decide	VVI
304953	100736439	20992779876	if	if	CSW@_CS
304953	100736439	20992779877	a	a	AT1
304953	100736439	20992779878	biopsy	biopsy	NN1
304953	100736439	20992779879	is	be	VBZ
304953	100736439	20992779880	needed	need	VVN
304953	100736439	20992779881	.	.	.
304953	100736439	20992779882	High	high	JJ
304953	100736439	20992779883	levels	level	NN2
304953	100736439	20992779884	of	of	IO
304953	100736439	20992779885	free	free	JJ
304953	100736439	20992779886	PSA	psa	NP1
304953	100736439	20992779887	are	be	VBR
304953	100736439	20992779888	reassuring	reassure	VVG_JJ
304953	100736439	20992779889	,	,	,
304953	100736439	20992779890	while	while	CS
304953	100736439	20992779891	low	low	JJ
304953	100736439	20992779892	levels	level	NN2
304953	100736439	20992779893	are	be	VBR
304953	100736439	20992779894	worrisome	worrisome	JJ
304953	100736439	20992779895	for	for	IF
304953	100736439	20992779896	cancer	cancer	NN1
304953	100736439	20992779897	.	.	.
304953	100736440	20992779917	@@##	----------	----------
304953	100736440	20992779918	@@100736440		FO
304953	100736440	20992779919	@4936440/		JJ_NN1_VV0
304953	100736440	20992779920	<h>		NULL
304953	100736440	20992779921	Prostate	prostate	NN1
304953	100736440	20992779922	Cancer	cancer	NN1
304953	100736440	20992779923	46988		MC
304953	100736440	20992779924	@qwx906988		FO
304953	100736440	20992779925	46994		MC
304953	100736440	20992779926	@qwx906994		FO
304953	100736440	20992779927	46995		MC
304953	100736440	20992779928	@qwx906995		FO
304953	100736440	20992779929	46992		MC
304953	100736440	20992779930	@qwx906992		FO
304953	100736440	20992779931	46991		MC
304953	100736440	20992779932	@qwx906991		FO
304953	100736440	20992779933	46990		MC
304953	100736440	20992779934	@qwx906990		FO
304953	100736440	20992779935	46989		MC
304953	100736440	20992779936	@qwx906989		FO
304953	100736440	20992779937	46993		MC
304953	100736440	20992779938	@qwx906993		FO
304953	100736440	20992779939	<h>		NULL
304953	100736440	20992779940	Imaging	imaging	NN1_VVG_JJ@
304953	100736440	20992779941	Tests	test	NN2
304953	100736440	20992779942	<p>		NULL
304953	100736440	20992779943	Imaging	image	VVG_NN1_JJ@
304953	100736440	20992779944	tests	test	NN2
304953	100736440	20992779945	may	may	VM
304953	100736440	20992779946	be	be	VBI
304953	100736440	20992779947	helpful	helpful	JJ
304953	100736440	20992779948	in	in	II
304953	100736440	20992779949	diagnosing	diagnose	VVG_JJ@
304953	100736440	20992779950	prostate	prostate	NN1
304953	100736440	20992779951	cancer	cancer	NN1
304953	100736440	20992779952	,	,	,
304953	100736440	20992779953	pinpointing	pinpoint	VVG
304953	100736440	20992779954	its	its	APPGE
304953	100736440	20992779955	location	location	NN1
304953	100736440	20992779956	,	,	,
304953	100736440	20992779957	and	and	CC
304953	100736440	20992779958	determining	determine	VVG
304953	100736440	20992779959	how	how	RRQ_RGQ@
304953	100736440	20992779960	advanced	advance	VVD_JJ_VVN
304953	100736440	20992779961	it	it	PPH1
304953	100736440	20992779962	is	be	VBZ
304953	100736440	20992779963	(	(	(
304953	100736440	20992779964	its	its	APPGE
304953	100736440	20992779965	stage	stage	NN1
304953	100736440	20992779966	)	)	)
304953	100736440	20992779967	.	.	.
304953	100736440	20992779968	Magnetic	magnetic	JJ
304953	100736440	20992779969	resonance	resonance	NN1
304953	100736440	20992779970	imaging	imaging	NN1_VVG
304953	100736440	20992779971	(	(	(
304953	100736440	20992779972	MRI	mri	NP1
304953	100736440	20992779973	)	)	)
304953	100736440	20992779974	,	,	,
304953	100736440	20992779975	for	for	REX21
304953	100736440	20992779976	example	example	REX22
304953	100736440	20992779977	,	,	,
304953	100736440	20992779978	can	can	VM
304953	100736440	20992779979	be	be	VBI
304953	100736440	20992779980	helpful	helpful	JJ
304953	100736440	20992779981	in	in	II
304953	100736440	20992779982	staging	staging	NN1_VVG
304953	100736440	20992779983	.	.	.
304953	100736440	20992779984	This	this	DD1
304953	100736440	20992779985	test	test	NN1
304953	100736440	20992779986	uses	use	VVZ
304953	100736440	20992779987	a	a	AT1
304953	100736440	20992779988	magnetic	magnetic	JJ
304953	100736440	20992779989	field	field	NN1
304953	100736440	20992779990	to	to	TO
304953	100736440	20992779991	produce	produce	VVI
304953	100736440	20992779992	pictures	picture	NN2
304953	100736440	20992779993	of	of	IO
304953	100736440	20992779994	structures	structure	NN2
304953	100736440	20992779995	inside	inside	II
304953	100736440	20992779996	the	the	AT
304953	100736440	20992779997	body	body	NN1
304953	100736440	20992779998	.	.	.
304953	100736440	20992779999	Another	another	DD1
304953	100736440	20992780000	imaging	imaging	NN1_JJ@
304953	100736440	20992780001	test	test	NN1
304953	100736440	20992780002	,	,	,
304953	100736440	20992780003	transrectal	transrectal	JJ
304953	100736440	20992780004	ultrasonography	ultrasonography	NN1
304953	100736440	20992780005	(	(	(
304953	100736440	20992780006	TRUS		NP1
304953	100736440	20992780007	)	)	)
304953	100736440	20992780008	uses	use	VVZ
304953	100736440	20992780009	sound	sound	NN1_JJ@
304953	100736440	20992780010	waves	wave	NN2_VVZ@
304953	100736440	20992780011	to	to	TO
304953	100736440	20992780012	create	create	VVI
304953	100736440	20992780013	pictures	picture	NN2
304953	100736440	20992780014	.	.	.
304953	100736440	20992780015	However	however	RR
304953	100736440	20992780016	,	,	,
304953	100736440	20992780017	doctors	doctor	NN2
304953	100736440	20992780018	generally	generally	RR
304953	100736440	20992780019	use	use	VV0
304953	100736440	20992780020	it	it	PPH1
304953	100736440	20992780021	to	to	TO
304953	100736440	20992780022	guide	guide	VVI
304953	100736440	20992780023	a	a	AT1
304953	100736440	20992780024	biopsy	biopsy	NN1
304953	100736440	20992780025	,	,	,
304953	100736440	20992780026	not	not	XX
304953	100736440	20992780027	for	for	IF
304953	100736440	20992780028	screening	screen	VVG_NN1
304953	100736440	20992780029	or	or	CC
304953	100736440	20992780030	diagnosis	diagnosis	NN1
304953	100736440	20992780031	.	.	.
304953	100736441	20992780051	@@##	----------	----------
304953	100736441	20992780052	@@100736441		FO
304953	100736441	20992780053	@4936441/		VV0_NN1
304953	100736441	20992780054	46989		MC
304953	100736441	20992780055	@qwx906989		FO
304953	100736441	20992780056	<p>		NULL
304953	100736441	20992780057	Data	data	NN
304953	100736441	20992780058	on	on	II
304953	100736441	20992780059	the	the	AT
304953	100736441	20992780060	impact	impact	NN1
304953	100736441	20992780061	of	of	IO
304953	100736441	20992780062	diet	diet	NN1
304953	100736441	20992780063	on	on	II
304953	100736441	20992780064	benign	benign	JJ
304953	100736441	20992780065	prostatic	prostatic	JJ
304953	100736441	20992780066	hyperplasia	hyperplasia	NN1
304953	100736441	20992780067	(	(	(
304953	100736441	20992780068	BPH	bph	NP1
304953	100736441	20992780069	)	)	)
304953	100736441	20992780070	are	be	VBR
304953	100736441	20992780071	scant	scant	JJ
304953	100736441	20992780072	,	,	,
304953	100736441	20992780073	though	though	CS
304953	100736441	20992780074	studies	study	NN2
304953	100736441	20992780075	have	have	VH0
304953	100736441	20992780076	shown	show	VVN
304953	100736441	20992780077	that	that	CST
304953	100736441	20992780078	vegetables	vegetable	NN2
304953	100736441	20992780079	and	and	CC
304953	100736441	20992780080	fruits	fruit	NN2
304953	100736441	20992780081	may	may	VM
304953	100736441	20992780082	have	have	VHI
304953	100736441	20992780083	a	a	AT1
304953	100736441	20992780084	favorable	favorable	JJ
304953	100736441	20992780085	effect	effect	NN1
304953	100736441	20992780086	on	on	II
304953	100736441	20992780087	the	the	AT
304953	100736441	20992780088	condition	condition	NN1
304953	100736441	20992780089	.	.	.
304953	100736441	20992780090	An	a	AT1
304953	100736441	20992780091	Italian	italian	NN1_JJ
304953	100736441	20992780092	multicenter	multicenter	VV0_JJR
304953	100736441	20992780093	,	,	,
304953	100736441	20992780094	case-control	case-control	JJ_NN1
304953	100736441	20992780095	study	study	NN1
304953	100736441	20992780096	examined	examine	VVD_VVN
304953	100736441	20992780097	the	the	AT
304953	100736441	20992780098	potential	potential	JJ_NN1
304953	100736441	20992780099	role	role	NN1
304953	100736441	20992780100	of	of	IO
304953	100736441	20992780101	allium	allium	NN1
304953	100736441	20992780102	vegetables	vegetable	NN2
304953	100736441	20992780103	,	,	,
304953	100736441	20992780104	namely	namely	REX
304953	100736441	20992780105	onions	onion	NN2
304953	100736441	20992780106	and	and	CC
304953	100736441	20992780107	garlic	garlic	NN1
304953	100736441	20992780108	,	,	,
304953	100736441	20992780109	on	on	II
304953	100736441	20992780110	BPH	bph	NP1
304953	100736441	20992780111	.	.	.
304953	100736441	20992780112	Using	use	VVG
304953	100736441	20992780113	dietary	dietary	JJ
304953	100736441	20992780114	questionnaires	questionnaire	NN2
304953	100736441	20992780115	,	,	,
304953	100736441	20992780116	researchers	researcher	NN2
304953	100736441	20992780117	found	find	VVD_VVN
304953	100736441	20992780118	that	that	CST
304953	100736441	20992780119	men	man	NN2
304953	100736441	20992780120	with	with	IW
304953	100736441	20992780121	BPH	bph	NP1
304953	100736441	20992780122	typically	typically	RR
304953	100736441	20992780123	ate	eat	VVD
304953	100736441	20992780124	less	less	DAR
304953	100736441	20992780125	garlic	garlic	NN1
304953	100736441	20992780126	and	and	CC
304953	100736441	20992780127	fewer	fewer	DAR
304953	100736441	20992780128	servings	serving	NN2
304953	100736441	20992780129	of	of	IO
304953	100736441	20992780130	onions	onion	NN2
304953	100736441	20992780131	per	per	II
304953	100736441	20992780132	week	week	NNT1
304953	100736441	20992780133	than	than	CSN
304953	100736441	20992780134	those	those	DD2
304953	100736441	20992780135	without	without	IW
304953	100736441	20992780136	BPH	bph	NP1
304953	100736441	20992780137	.	.	.
304953	100736441	20992780138	<p>		NULL
304953	100736441	20992780139	Researchers	researcher	NN2
304953	100736441	20992780140	did	do	VDD
304953	100736441	20992780141	point	point	VVI
304953	100736441	20992780142	out	out	RP
304953	100736441	20992780143	a	a	AT1
304953	100736441	20992780144	few	few	DA2
304953	100736441	20992780145	weaknesses	weakness	NN2
304953	100736441	20992780146	in	in	II
304953	100736441	20992780147	their	their	APPGE
304953	100736441	20992780148	study	study	NN1
304953	100736441	20992780149	,	,	,
304953	100736441	20992780150	such	such	II21
304953	100736441	20992780151	as	as	II22
304953	100736441	20992780152	the	the	AT
304953	100736441	20992780153	fact	fact	NN1
304953	100736441	20992780154	that	that	CST
304953	100736441	20992780155	they	they	PPHS2
304953	100736441	20992780156	did	do	VDD
304953	100736441	20992780157	n't	n't	XX
304953	100736441	20992780158	collect	collect	VVI
304953	100736441	20992780159	information	information	NN1
304953	100736441	20992780160	on	on	II
304953	100736441	20992780161	the	the	AT
304953	100736441	20992780162	types	type	NN2
304953	100736441	20992780163	of	of	IO
304953	100736441	20992780164	onions	onion	NN2
304953	100736441	20992780165	and	and	CC
304953	100736441	20992780166	garlic	garlic	NN1
304953	100736441	20992780167	that	that	CST
304953	100736441	20992780168	participants	participant	NN2
304953	100736441	20992780169	ate	eat	VVD
304953	100736441	20992780170	,	,	,
304953	100736441	20992780171	how	how	RRQ
304953	100736441	20992780172	the	the	AT
304953	100736441	20992780173	vegetables	vegetable	NN2
304953	100736441	20992780174	were	be	VBDR
304953	100736441	20992780175	prepared	prepare	VVN
304953	100736441	20992780176	,	,	,
304953	100736441	20992780177	or	or	CC
304953	100736441	20992780178	the	the	AT
304953	100736441	20992780179	consumption	consumption	NN1
304953	100736441	20992780180	of	of	IO
304953	100736441	20992780181	other	other	JJ
304953	100736441	20992780182	allium	allium	NN1
304953	100736441	20992780183	vegetables	vegetable	NN2
304953	100736441	20992780184	,	,	,
304953	100736441	20992780185	such	such	II21
304953	100736441	20992780186	as	as	II22
304953	100736441	20992780187	scallions	scallions	NN2
304953	100736441	20992780188	.	.	.
304953	100736441	20992780189	Nor	nor	CC
304953	100736441	20992780190	did	do	VDD
304953	100736441	20992780191	the	the	AT
304953	100736441	20992780192	study	study	NN1
304953	100736441	20992780193	account	account	VVI
304953	100736441	20992780194	for	for	IF
304953	100736441	20992780195	changes	change	NN2
304953	100736441	20992780196	in	in	II
304953	100736441	20992780197	diet	diet	NN1
304953	100736441	20992780198	over	over	II
304953	100736441	20992780199	time	time	NNT1
304953	100736441	20992780200	.	.	.
304953	100736441	20992780201	Even	even	RR21
304953	100736441	20992780202	so	so	RR22
304953	100736441	20992780203	,	,	,
304953	100736441	20992780204	the	the	AT
304953	100736441	20992780205	findings	finding	NN2
304953	100736441	20992780206	suggest	suggest	VV0
304953	100736441	20992780207	that	that	CST
304953	100736441	20992780208	a	a	AT1
304953	100736441	20992780209	diet	diet	NN1
304953	100736441	20992780210	rich	rich	JJ
304953	100736441	20992780211	in	in	II
304953	100736441	20992780212	onions	onion	NN2
304953	100736441	20992780213	and	and	CC
304953	100736441	20992780214	garlic	garlic	NN1
304953	100736441	20992780215	may	may	VM
304953	100736441	20992780216	cut	cut	VVI
304953	100736441	20992780217	the	the	AT
304953	100736441	20992780218	odds	odds	NN2
304953	100736441	20992780219	of	of	IO
304953	100736441	20992780220	developing	develop	VVG_JJ
304953	100736441	20992780221	BPH.		NP1
304953	100736441	20992780222	46996		MC
304953	100736441	20992780223	@qwx906996		FO
304953	100736442	20992780243	@@##	----------	----------
304953	100736442	20992780244	@@100736442		FO
304953	100736442	20992780245	@4936442/		VV0_JJ_NN1
304953	100736442	20992780246	<h>		NULL
304953	100736442	20992780247	PSA	psa	NP1
304953	100736442	20992780248	Quiz	quiz	NN1
304953	100736442	20992780249	<p>		NULL
304953	100736442	20992780250	True	true	JJ
304953	100736442	20992780251	or	or	CC
304953	100736442	20992780252	False	false	JJ_RR@
304953	100736442	20992780253	:	:	:
304953	100736442	20992780254	<p>		NULL
304953	100736442	20992780255	A	a	ZZ1_AT1
304953	100736442	20992780256	PSA	psa	NP1
304953	100736442	20992780257	level	level	NN1_JJ
304953	100736442	20992780258	above	above	II
304953	100736442	20992780259	the	the	AT
304953	100736442	20992780260	normal	normal	JJ
304953	100736442	20992780261	of	of	IO
304953	100736442	20992780262	4	4	MC
304953	100736442	20992780263	nanograms	nanogram	NN2_VVZ
304953	100736442	20992780264	per	per	II
304953	100736442	20992780265	milliliter	milliliter	NN1
304953	100736442	20992780266	means	mean	VVZ
304953	100736442	20992780267	that	that	CST
304953	100736442	20992780268	you	you	PPY
304953	100736442	20992780269	have	have	VH0
304953	100736442	20992780270	prostate	prostate	NN1
304953	100736442	20992780271	cancer	cancer	NN1
304953	100736442	20992780272	.	.	.
304953	100736442	20992780273	<p>		NULL
304953	100736442	20992780274	PSA	psa	NP1
304953	100736442	20992780275	Quiz	quiz	NN1
304953	100736442	20992780276	<p>		NULL
304953	100736442	20992780277	Score	score	VV0
304953	100736442	20992780278	so	so	RG
304953	100736442	20992780279	far	far	RR
304953	100736442	20992780280	:	:	:
304953	100736442	20992780281	<p>		NULL
304953	100736442	20992780282	INCORRECT	incorrect	JJ
304953	100736442	20992780283	<p>		NULL
304953	100736442	20992780284	Question	question	VV0@_NN1
304953	100736442	20992780285	1	1	MC1
304953	100736442	20992780286	of	of	IO
304953	100736442	20992780287	10	10	MC
304953	100736442	20992780288	<p>		NULL
304953	100736442	20992780289	NEXT-+		FO
304953	100736442	20992780290	<p>		NULL
304953	100736442	20992780291	points	point	NN2_VVZ
304953	100736442	20992780292	out	out	II21
304953	100736442	20992780293	of	of	II22
304953	100736442	20992780294	10	10	MC
304953	100736442	20992780295	<p>		NULL
304953	100736442	20992780296	Most	most	DAT
304953	100736442	20992780297	men	man	NN2
304953	100736442	20992780298	with	with	IW
304953	100736442	20992780299	PSA	psa	NP1
304953	100736442	20992780300	levels	level	NN2_VVZ%
304953	100736442	20992780301	greater	great	JJR
304953	100736442	20992780302	than	than	CSN
304953	100736442	20992780303	4	4	MC
304953	100736442	20992780304	do	do	VD0
304953	100736442	20992780305	not	not	XX
304953	100736442	20992780306	have	have	VHI
304953	100736442	20992780307	prostate	prostate	NN1
304953	100736442	20992780308	cancer	cancer	NN1
304953	100736442	20992780309	.	.	.
304953	100736442	20992780310	If	if	CS
304953	100736442	20992780311	your	your	APPGE
304953	100736442	20992780312	doctor	doctor	NN1
304953	100736442	20992780313	does	do	VDZ
304953	100736442	20992780314	not	not	XX
304953	100736442	20992780315	feel	feel	VVI
304953	100736442	20992780316	any	any	DD
304953	100736442	20992780317	prostate	prostate	NN1
304953	100736442	20992780318	irregularities	irregularity	NN2
304953	100736442	20992780319	on	on	II
304953	100736442	20992780320	rectal	rectal	JJ
304953	100736442	20992780321	examination	examination	NN1
304953	100736442	20992780322	,	,	,
304953	100736442	20992780323	the	the	AT
304953	100736442	20992780324	risk	risk	NN1
304953	100736442	20992780325	of	of	IO
304953	100736442	20992780326	prostate	prostate	NN1
304953	100736442	20992780327	cancer	cancer	NN1
304953	100736442	20992780328	is	be	VBZ
304953	100736442	20992780329	less	less	DAR
304953	100736442	20992780330	than	than	CSN
304953	100736442	20992780331	one	one	MC1
304953	100736442	20992780332	in	in	II
304953	100736442	20992780333	three	three	MC
304953	100736442	20992780334	.	.	.
304953	100736442	20992780335	Reasons	reason	NN2
304953	100736442	20992780336	for	for	IF
304953	100736442	20992780337	an	a	AT1
304953	100736442	20992780338	elevated	elevated	JJ
304953	100736442	20992780339	PSA	psa	NP1
304953	100736442	20992780340	other	other	II21
304953	100736442	20992780341	than	than	II22
304953	100736442	20992780342	cancer	cancer	NN1
304953	100736442	20992780343	include	include	VV0
304953	100736442	20992780344	benign	benign	JJ
304953	100736442	20992780345	prostatic	prostatic	JJ
304953	100736442	20992780346	hyperplasia	hyperplasia	NN1
304953	100736442	20992780347	(	(	(
304953	100736442	20992780348	an	a	AT1
304953	100736442	20992780349	enlarged	enlarged	JJ
304953	100736442	20992780350	prostate	prostate	NN1
304953	100736442	20992780351	gland	gland	NN1
304953	100736442	20992780352	)	)	)
304953	100736442	20992780353	,	,	,
304953	100736442	20992780354	sexual	sexual	JJ
304953	100736442	20992780355	intercourse	intercourse	NN1
304953	100736442	20992780356	or	or	CC
304953	100736442	20992780357	ejaculation	ejaculation	NN1
304953	100736442	20992780358	in	in	II
304953	100736442	20992780359	the	the	AT
304953	100736442	20992780360	48	48	MC
304953	100736442	20992780361	hours	hour	NNT2
304953	100736442	20992780362	before	before	II_CS
304953	100736442	20992780363	the	the	AT
304953	100736442	20992780364	blood	blood	NN1
304953	100736442	20992780365	test	test	NN1
304953	100736442	20992780366	was	be	VBDZ
304953	100736442	20992780367	drawn	draw	VVN
304953	100736442	20992780368	,	,	,
304953	100736442	20992780369	a	a	AT1
304953	100736442	20992780370	prostate	prostate	NN1
304953	100736442	20992780371	or	or	CC
304953	100736442	20992780372	bladder	bladder	NN1
304953	100736442	20992780373	infection	infection	NN1
304953	100736442	20992780374	,	,	,
304953	100736442	20992780375	a	a	AT1
304953	100736442	20992780376	long	long	JJ
304953	100736442	20992780377	bike	bike	NN1
304953	100736442	20992780378	ride	ride	NN1_VV0
304953	100736442	20992780379	,	,	,
304953	100736442	20992780380	and	and	CC
304953	100736442	20992780381	placement	placement	NN1
304953	100736442	20992780382	of	of	IO
304953	100736442	20992780383	a	a	AT1
304953	100736442	20992780384	urinary	urinary	JJ_NN1
304953	100736442	20992780385	catheter	catheter	NN1
304953	100736442	20992780386	.	.	.
304953	100736442	20992780387	<p>		NULL
304953	100736442	20992780388	Question	question	NN1
304953	100736442	20992780389	2	2	MC
304953	100736442	20992780390	of	of	IO
304953	100736442	20992780391	10	10	MC
304953	100736442	20992780392	<p>		NULL
304953	100736442	20992780393	FALSE	false	JJ_RR@
304953	100736442	20992780394	<p>		NULL
304953	100736442	20992780395	A	a	ZZ1_AT1
304953	100736442	20992780396	PSA	psa	NP1
304953	100736442	20992780397	level	level	NN1_JJ
304953	100736442	20992780398	under	under	RG
304953	100736442	20992780399	4	4	MC
304953	100736442	20992780400	nanograms	nanogram	NN2_VVZ
304953	100736442	20992780401	per	per	II
304953	100736442	20992780402	milliliter	milliliter	NN1
304953	100736442	20992780403	means	mean	VVZ
304953	100736442	20992780404	that	that	CST
304953	100736442	20992780405	you	you	PPY
304953	100736442	20992780406	have	have	VH0
304953	100736442	20992780407	do	do	VD0
304953	100736442	20992780408	not	not	XX
304953	100736442	20992780409	have	have	VHI
304953	100736442	20992780410	prostate	prostate	NN1
304953	100736442	20992780411	cancer	cancer	NN1
304953	100736442	20992780412	.	.	.
304953	100736442	20992780413	<p>		NULL
304953	100736442	20992780414	TRUE	true	JJ
304953	100736442	20992780415	<p>		NULL
304953	100736442	20992780416	A	a	AT1
304953	100736442	20992780417	study	study	NN1
304953	100736442	20992780418	published	publish	VVN
304953	100736442	20992780419	in	in	II
304953	100736442	20992780420	the	the	AT
304953	100736442	20992780421	May	may	NPM1
304953	100736442	20992780422	27	27	MC
304953	100736442	20992780423	,	,	,
304953	100736442	20992780424	2004	2004	MC
304953	100736442	20992780425	issue	issue	NN1
304953	100736442	20992780426	of	of	IO
304953	100736442	20992780427	the	the	AT
304953	100736442	20992780428	New	new	NP1
304953	100736442	20992780429	England	england	NP1
304953	100736442	20992780430	Journal	journal	NN1
304953	100736442	20992780431	of	of	IO
304953	100736442	20992780432	Medicine	medicine	NN1
304953	100736442	20992780433	found	find	VVD_VVN
304953	100736442	20992780434	that	that	CST_DD1
304953	100736442	20992780435	@		II
304953	100736442	20992780436	@		II
304953	100736442	20992780437	@		II
304953	100736442	20992780438	@		II
304953	100736442	20992780439	@		II
304953	100736442	20992780440	@		II
304953	100736442	20992780441	@		II
304953	100736442	20992780442	@		II
304953	100736442	20992780443	@		II
304953	100736442	20992780444	@		II
304953	100736442	20992780445	values	value	NN2
304953	100736442	20992780446	of	of	IO
304953	100736442	20992780447	less	less	DAR
304953	100736442	20992780448	than	than	CSN
304953	100736442	20992780449	4	4	MC
304953	100736442	20992780450	had	have	VHD
304953	100736442	20992780451	biopsy-proven	biopsy-proven	JJ
304953	100736442	20992780452	prostate	prostate	NN1
304953	100736442	20992780453	cancer	cancer	NN1
304953	100736442	20992780454	,	,	,
304953	100736442	20992780455	and	and	CC
304953	100736442	20992780456	some	some	DD
304953	100736442	20992780457	had	have	VHN@_VHD
304953	100736442	20992780458	very	very	RG
304953	100736442	20992780459	low	low	JJ
304953	100736442	20992780460	PSA	psa	NP1
304953	100736442	20992780461	levels	level	NN2
304953	100736442	20992780462	.	.	.
304953	100736442	20992780463	<p>		NULL
304953	100736442	20992780464	NEXT	next	MD
304953	100736442	20992780465	QUESTION-+		FO
304953	100736442	20992780466	<p>		NULL
304953	100736442	20992780467	CORRECT	correct	JJ_VV0@
304953	100736442	20992780468	<p>		NULL
304953	100736442	20992780469	African-American	african-american	JJ
304953	100736442	20992780470	men	man	NN2
304953	100736442	20992780471	have	have	VH0
304953	100736442	20992780472	a	a	AT1
304953	100736442	20992780473	greater	great	JJR
304953	100736442	20992780474	risk	risk	NN1
304953	100736442	20992780475	of	of	IO
304953	100736442	20992780476	dying	die	VVG_JJ
304953	100736442	20992780477	from	from	II
304953	100736442	20992780478	prostate	prostate	NN1
304953	100736442	20992780479	cancer	cancer	NN1
304953	100736442	20992780480	than	than	CSN
304953	100736442	20992780481	most	most	DAT
304953	100736442	20992780482	other	other	JJ
304953	100736442	20992780483	racial	racial	JJ
304953	100736442	20992780484	groups	group	NN2
304953	100736442	20992780485	.	.	.
304953	100736442	20992780486	<p>		NULL
304953	100736442	20992780487	Question	question	NN1
304953	100736442	20992780488	3	3	MC
304953	100736442	20992780489	of	of	IO
304953	100736442	20992780490	10	10	MC
304953	100736442	20992780491	<p>		NULL
304953	100736442	20992780492	NEXT	next	MD
304953	100736442	20992780493	QUESTION-+		FO
304953	100736442	20992780494	<p>		NULL
304953	100736442	20992780495	Compared	compare	VVN
304953	100736442	20992780496	to	to	II
304953	100736442	20992780497	white	white	JJ
304953	100736442	20992780498	men	man	NN2
304953	100736442	20992780499	,	,	,
304953	100736442	20992780500	African-American	african-american	JJ
304953	100736442	20992780501	men	man	NN2
304953	100736442	20992780502	are	be	VBR
304953	100736442	20992780503	one	one	MC1_PN1
304953	100736442	20992780504	and	and	CC
304953	100736442	20992780505	one-half	one-half	MF
304953	100736442	20992780506	times	time	NNT2
304953	100736442	20992780507	more	more	RRR_RGR
304953	100736442	20992780508	likely	likely	JJ
304953	100736442	20992780509	to	to	TO
304953	100736442	20992780510	develop	develop	VVI
304953	100736442	20992780511	prostate	prostate	NN1
304953	100736442	20992780512	cancer	cancer	NN1
304953	100736442	20992780513	and	and	CC
304953	100736442	20992780514	are	be	VBR
304953	100736442	20992780515	two	two	MC
304953	100736442	20992780516	to	to	II
304953	100736442	20992780517	three	three	MC
304953	100736442	20992780518	times	time	NNT2
304953	100736442	20992780519	more	more	RRR_RGR
304953	100736442	20992780520	likely	likely	JJ
304953	100736442	20992780521	to	to	TO
304953	100736442	20992780522	die	die	VVI
304953	100736442	20992780523	from	from	II
304953	100736442	20992780524	the	the	AT
304953	100736442	20992780525	cancer	cancer	NN1
304953	100736442	20992780526	.	.	.
304953	100736442	20992780527	Many	many	DA2
304953	100736442	20992780528	experts	expert	NN2
304953	100736442	20992780529	suggest	suggest	VV0
304953	100736442	20992780530	that	that	CST_DD1
304953	100736442	20992780531	African-American	african-american	JJ
304953	100736442	20992780532	men	man	NN2
304953	100736442	20992780533	begin	begin	VV0
304953	100736442	20992780534	screening	screen	VVG
304953	100736442	20992780535	for	for	IF
304953	100736442	20992780536	prostrate	prostrate	JJ
304953	100736442	20992780537	cancer	cancer	NN1
304953	100736442	20992780538	at	at	II
304953	100736442	20992780539	age	age	NN1
304953	100736442	20992780540	40	40	MC
304953	100736442	20992780541	to	to	II
304953	100736442	20992780542	45	45	MC
304953	100736442	20992780543	with	with	IW
304953	100736442	20992780544	yearly	yearly	JJ_RR
304953	100736442	20992780545	digital	digital	JJ
304953	100736442	20992780546	rectal	rectal	JJ
304953	100736442	20992780547	examination	examination	NN1
304953	100736442	20992780548	and	and	CC
304953	100736442	20992780549	a	a	AT1
304953	100736442	20992780550	PSA	psa	NP1
304953	100736442	20992780551	blood	blood	NN1
304953	100736442	20992780552	test	test	NN1
304953	100736442	20992780553	.	.	.
304953	100736442	20992780554	<p>		NULL
304953	100736442	20992780555	Younger	young	JJR
304953	100736442	20992780556	men	man	NN2
304953	100736442	20992780557	generally	generally	RR
304953	100736442	20992780558	have	have	VH0
304953	100736442	20992780559	higher	high	JJR_RRR@
304953	100736442	20992780560	PSA	psa	NP1
304953	100736442	20992780561	levels	level	NN2
304953	100736442	20992780562	than	than	CSN
304953	100736442	20992780563	older	old	JJR
304953	100736442	20992780564	men	man	NN2
304953	100736442	20992780565	.	.	.
304953	100736442	20992780566	<p>		NULL
304953	100736442	20992780567	Question	question	NN1
304953	100736442	20992780568	4	4	MC
304953	100736442	20992780569	of	of	IO
304953	100736442	20992780570	10	10	MC
304953	100736442	20992780571	<p>		NULL
304953	100736442	20992780572	Older	old	JJR
304953	100736442	20992780573	men	man	NN2
304953	100736442	20992780574	have	have	VH0
304953	100736442	20992780575	higher	high	JJR_RRR@
304953	100736442	20992780576	PSA	psa	NP1
304953	100736442	20992780577	levels	level	NN2
304953	100736442	20992780578	than	than	CSN
304953	100736442	20992780579	younger	young	JJR
304953	100736442	20992780580	men	man	NN2
304953	100736442	20992780581	.	.	.
304953	100736442	20992780582	In	in	II
304953	100736442	20992780583	the	the	AT
304953	100736442	20992780584	absence	absence	NN1
304953	100736442	20992780585	of	of	IO
304953	100736442	20992780586	prostate	prostate	NN1
304953	100736442	20992780587	cancer	cancer	NN1
304953	100736442	20992780588	,	,	,
304953	100736442	20992780589	infection	infection	NN1
304953	100736442	20992780590	or	or	CC
304953	100736442	20992780591	other	other	JJ
304953	100736442	20992780592	irritation	irritation	NN1
304953	100736442	20992780593	of	of	IO
304953	100736442	20992780594	the	the	AT
304953	100736442	20992780595	gland	gland	NN1
304953	100736442	20992780596	,	,	,
304953	100736442	20992780597	PSA	psa	NP1
304953	100736442	20992780598	levels	level	NN2
304953	100736442	20992780599	increase	increase	VV0
304953	100736442	20992780600	by	by	RP%_II
304953	100736442	20992780601	about	about	RG
304953	100736442	20992780602	0.5	0.5	MC
304953	100736442	20992780603	nanograms	nanogram	NN2_VVZ
304953	100736442	20992780604	per	per	II
304953	100736442	20992780605	milliliter	milliliter	NN1
304953	100736442	20992780606	every	every	AT1
304953	100736442	20992780607	10	10	MC
304953	100736442	20992780608	years	year	NNT2
304953	100736442	20992780609	.	.	.
304953	100736442	20992780610	The	the	AT
304953	100736442	20992780611	rise	rise	NN1
304953	100736442	20992780612	is	be	VBZ
304953	100736442	20992780613	very	very	RG
304953	100736442	20992780614	gradual	gradual	JJ
304953	100736442	20992780615	.	.	.
304953	100736442	20992780616	A	a	AT1
304953	100736442	20992780617	more	more	RGR
304953	100736442	20992780618	sudden	sudden	JJ
304953	100736442	20992780619	increase	increase	NN1
304953	100736442	20992780620	in	in	II
304953	100736442	20992780621	PSA	psa	NP1
304953	100736442	20992780622	level	level	NN1_JJ
304953	100736442	20992780623	from	from	II
304953	100736442	20992780624	one	one	MC1
304953	100736442	20992780625	year	year	NNT1
304953	100736442	20992780626	to	to	II
304953	100736442	20992780627	the	the	AT
304953	100736442	20992780628	next	next	MD
304953	100736442	20992780629	may	may	VM
304953	100736442	20992780630	indicate	indicate	VVI
304953	100736442	20992780631	a	a	AT1
304953	100736442	20992780632	problem	problem	NN1
304953	100736442	20992780633	.	.	.
304953	100736442	20992780634	<p>		NULL
304953	100736442	20992780635	@		II
304953	100736442	20992780636	@		II
304953	100736442	20992780637	@		II
304953	100736442	20992780638	@		II
304953	100736442	20992780639	@		II
304953	100736442	20992780640	@		II
304953	100736442	20992780641	@		II
304953	100736442	20992780642	@		II
304953	100736442	20992780643	@		II
304953	100736442	20992780644	@		II
304953	100736442	20992780645	cancer	cancer	NN1
304953	100736442	20992780646	if	if	CS
304953	100736442	20992780647	they	they	PPHS2
304953	100736442	20992780648	live	live	VV0
304953	100736442	20992780649	to	to	TO
304953	100736442	20992780650	age	age	VVI
304953	100736442	20992780651	100	100	MC
304953	100736442	20992780652	.	.	.
304953	100736442	20992780653	<p>		NULL
304953	100736442	20992780654	Actually	actually	RR
304953	100736442	20992780655	almost	almost	RR
304953	100736442	20992780656	every	every	AT1
304953	100736442	20992780657	man	man	NN1
304953	100736442	20992780658	who	who	PNQS
304953	100736442	20992780659	lives	live	VVZ
304953	100736442	20992780660	to	to	TO
304953	100736442	20992780661	age	age	VVI
304953	100736442	20992780662	100	100	MC
304953	100736442	20992780663	has	have	VHZ
304953	100736442	20992780664	prostate	prostate	NN1
304953	100736442	20992780665	cancer	cancer	NN1
304953	100736442	20992780666	,	,	,
304953	100736442	20992780667	but	but	CCB
304953	100736442	20992780668	the	the	AT
304953	100736442	20992780669	chance	chance	NN1
304953	100736442	20992780670	that	that	CST
304953	100736442	20992780671	a	a	AT1
304953	100736442	20992780672	very	very	RG
304953	100736442	20992780673	old	old	JJ
304953	100736442	20992780674	man	man	NN1
304953	100736442	20992780675	will	will	VM
304953	100736442	20992780676	die	die	VVI
304953	100736442	20992780677	of	of	IO
304953	100736442	20992780678	the	the	AT
304953	100736442	20992780679	disease	disease	NN1
304953	100736442	20992780680	is	be	VBZ
304953	100736442	20992780681	very	very	RG
304953	100736442	20992780682	slim	slim	JJ
304953	100736442	20992780683	.	.	.
304953	100736442	20992780684	Autopsy	autopsy	NN1
304953	100736442	20992780685	studies	study	NN2
304953	100736442	20992780686	show	show	VV0
304953	100736442	20992780687	that	that	CST_DD1
304953	100736442	20992780688	approximately	approximately	RR
304953	100736442	20992780689	40	40	MC
304953	100736442	20992780690	percent	percent	NNU
304953	100736442	20992780691	of	of	IO
304953	100736442	20992780692	men	man	NN2
304953	100736442	20992780693	over	over	II
304953	100736442	20992780694	age	age	NN1
304953	100736442	20992780695	70	70	MC
304953	100736442	20992780696	,	,	,
304953	100736442	20992780697	70	70	MC
304953	100736442	20992780698	percent	percent	NNU
304953	100736442	20992780699	of	of	IO
304953	100736442	20992780700	men	man	NN2
304953	100736442	20992780701	over	over	II
304953	100736442	20992780702	the	the	AT
304953	100736442	20992780703	age	age	NN1
304953	100736442	20992780704	of	of	IO
304953	100736442	20992780705	80	80	MC
304953	100736442	20992780706	,	,	,
304953	100736442	20992780707	and	and	CC
304953	100736442	20992780708	over	over	RG
304953	100736442	20992780709	95	95	MC
304953	100736442	20992780710	percent	percent	NNU
304953	100736442	20992780711	of	of	IO
304953	100736442	20992780712	men	man	NN2
304953	100736442	20992780713	over	over	II
304953	100736442	20992780714	age	age	NN1
304953	100736442	20992780715	90	90	MC
304953	100736442	20992780716	have	have	VH0
304953	100736442	20992780717	cancer	cancer	NN1
304953	100736442	20992780718	cells	cell	NN2
304953	100736442	20992780719	in	in	II
304953	100736442	20992780720	their	their	APPGE
304953	100736442	20992780721	prostates	prostate	NN2
304953	100736442	20992780722	.	.	.
304953	100736442	20992780723	<p>		NULL
304953	100736442	20992780724	Question	question	NN1
304953	100736442	20992780725	6	6	MC
304953	100736442	20992780726	of	of	IO
304953	100736442	20992780727	10	10	MC
304953	100736442	20992780728	<p>		NULL
304953	100736442	20992780729	The	the	AT
304953	100736442	20992780730	PSA	psa	NP1
304953	100736442	20992780731	level	level	NN1_JJ_VV0@
304953	100736442	20992780732	reliably	reliably	RR
304953	100736442	20992780733	predicts	predict	VVZ
304953	100736442	20992780734	who	who	PNQS
304953	100736442	20992780735	can	can	VM
304953	100736442	20992780736	be	be	VBI
304953	100736442	20992780737	cured	cure	VVN
304953	100736442	20992780738	with	with	IW
304953	100736442	20992780739	prostate	prostate	NN1
304953	100736442	20992780740	surgery	surgery	NN1
304953	100736442	20992780741	(	(	(
304953	100736442	20992780742	called	call	VVN
304953	100736442	20992780743	radical	radical	JJ_NN1
304953	100736442	20992780744	prostatectomy	prostatectomy	NN1
304953	100736442	20992780745	)	)	)
304953	100736442	20992780746	<p>		NULL
304953	100736442	20992780747	Although	although	CS
304953	100736442	20992780748	the	the	AT
304953	100736442	20992780749	higher	high	JJR
304953	100736442	20992780750	the	the	AT
304953	100736442	20992780751	PSA	psa	NP1
304953	100736442	20992780752	level	level	NN1_JJ
304953	100736442	20992780753	,	,	,
304953	100736442	20992780754	the	the	AT
304953	100736442	20992780755	greater	great	JJR
304953	100736442	20992780756	the	the	AT
304953	100736442	20992780757	chance	chance	NN1
304953	100736442	20992780758	that	that	CST
304953	100736442	20992780759	the	the	AT
304953	100736442	20992780760	prostate	prostate	NN1
304953	100736442	20992780761	cancer	cancer	NN1
304953	100736442	20992780762	has	have	VHZ
304953	100736442	20992780763	spread	spread	VVN
304953	100736442	20992780764	outside	outside	II
304953	100736442	20992780765	the	the	AT
304953	100736442	20992780766	gland	gland	NN1
304953	100736442	20992780767	,	,	,
304953	100736442	20992780768	the	the	AT
304953	100736442	20992780769	PSA	psa	NP1
304953	100736442	20992780770	level	level	NN1
304953	100736442	20992780771	can	can	VM
304953	100736442	20992780772	not	not	XX
304953	100736442	20992780773	predict	predict	VVI
304953	100736442	20992780774	which	which	DDQ
304953	100736442	20992780775	individuals	individual	NN2
304953	100736442	20992780776	should	should	VM
304953	100736442	20992780777	be	be	VBI
304953	100736442	20992780778	treated	treat	VVN
304953	100736442	20992780779	and	and	CC
304953	100736442	20992780780	what	what	DDQ
304953	100736442	20992780781	will	will	VM
304953	100736442	20992780782	be	be	VBI
304953	100736442	20992780783	the	the	AT
304953	100736442	20992780784	optimal	optimal	JJ
304953	100736442	20992780785	treatment	treatment	NN1
304953	100736442	20992780786	.	.	.
304953	100736442	20992780787	In	in	II
304953	100736442	20992780788	fact	fact	NN1
304953	100736442	20992780789	,	,	,
304953	100736442	20992780790	some	some	DD
304953	100736442	20992780791	very	very	RG
304953	100736442	20992780792	aggressive	aggressive	JJ
304953	100736442	20992780793	prostate	prostate	NN1
304953	100736442	20992780794	cancers	cancer	NN2
304953	100736442	20992780795	that	that	CST
304953	100736442	20992780796	have	have	VH0
304953	100736442	20992780797	a	a	AT1
304953	100736442	20992780798	poor	poor	JJ
304953	100736442	20992780799	prognosis	prognosis	NN1
304953	100736442	20992780800	produce	produce	VV0
304953	100736442	20992780801	little	little	JJ_RR
304953	100736442	20992780802	PSA	psa	NP1
304953	100736442	20992780803	.	.	.
304953	100736442	20992780804	Prostate	prostate	NN1
304953	100736442	20992780805	cancer	cancer	NN1
304953	100736442	20992780806	treatment	treatment	NN1
304953	100736442	20992780807	is	be	VBZ
304953	100736442	20992780808	based	base	VVN
304953	100736442	20992780809	on	on	II
304953	100736442	20992780810	the	the	AT
304953	100736442	20992780811	symptoms	symptom	NN2
304953	100736442	20992780812	,	,	,
304953	100736442	20992780813	the	the	AT
304953	100736442	20992780814	analysis	analysis	NN1
304953	100736442	20992780815	of	of	IO
304953	100736442	20992780816	the	the	AT
304953	100736442	20992780817	prostrate	prostrate	JJ
304953	100736442	20992780818	biopsy	biopsy	NN1
304953	100736442	20992780819	and	and	CC
304953	100736442	20992780820	staging	staging	NN1_VVG
304953	100736442	20992780821	(	(	(
304953	100736442	20992780822	to	to	TO
304953	100736442	20992780823	determine	determine	VVI
304953	100736442	20992780824	the	the	AT
304953	100736442	20992780825	extent	extent	NN1
304953	100736442	20992780826	of	of	IO
304953	100736442	20992780827	the	the	AT
304953	100736442	20992780828	cancer	cancer	NN1
304953	100736442	20992780829	)	)	)
304953	100736442	20992780830	.	.	.
304953	100736442	20992780831	<p>		NULL
304953	100736442	20992780832	Question	question	NN1
304953	100736442	20992780833	7	7	MC
304953	100736442	20992780834	of	of	IO
304953	100736442	20992780835	@		II
304953	100736442	20992780836	@		II
304953	100736442	20992780837	@		II
304953	100736442	20992780838	@		II
304953	100736442	20992780839	@		II
304953	100736442	20992780840	@		II
304953	100736442	20992780841	@		II
304953	100736442	20992780842	@		II
304953	100736442	20992780843	@		II
304953	100736442	20992780844	@		II
304953	100736442	20992780845	risk	risk	NN1
304953	100736442	20992780846	of	of	IO
304953	100736442	20992780847	side	side	NN1
304953	100736442	20992780848	effects	effect	NN2
304953	100736442	20992780849	<p>		NULL
304953	100736442	20992780850	Radiation	radiation	NN1
304953	100736442	20992780851	therapy	therapy	NN1
304953	100736442	20992780852	,	,	,
304953	100736442	20992780853	either	either	RR
304953	100736442	20992780854	by	by	II
304953	100736442	20992780855	external	external	JJ
304953	100736442	20992780856	beam	beam	NN1
304953	100736442	20992780857	or	or	CC
304953	100736442	20992780858	with	with	IW
304953	100736442	20992780859	implanted	implanted	JJ@
304953	100736442	20992780860	radioactive	radioactive	JJ
304953	100736442	20992780861	seeds	seed	NN2
304953	100736442	20992780862	(	(	(
304953	100736442	20992780863	called	call	VVN_JJ%
304953	100736442	20992780864	brachytherapy	brachytherapy	NN1
304953	100736442	20992780865	)	)	)
304953	100736442	20992780866	,	,	,
304953	100736442	20992780867	is	be	VBZ
304953	100736442	20992780868	used	use	VVN_JJ
304953	100736442	20992780869	most	most	RGT
304953	100736442	20992780870	often	often	RR
304953	100736442	20992780871	when	when	CS_RRQ
304953	100736442	20992780872	the	the	AT
304953	100736442	20992780873	cancer	cancer	NN1
304953	100736442	20992780874	remains	remain	VVZ
304953	100736442	20992780875	confined	confine	VVN
304953	100736442	20992780876	within	within	II
304953	100736442	20992780877	the	the	AT
304953	100736442	20992780878	gland	gland	NN1
304953	100736442	20992780879	.	.	.
304953	100736442	20992780880	Incontinence	incontinence	NN1
304953	100736442	20992780881	and	and	CC
304953	100736442	20992780882	erectile	erectile	JJ
304953	100736442	20992780883	dysfunction	dysfunction	NN1
304953	100736442	20992780884	can	can	VM
304953	100736442	20992780885	occur	occur	VVI
304953	100736442	20992780886	after	after	II_CS
304953	100736442	20992780887	radiation	radiation	NN1
304953	100736442	20992780888	therapy	therapy	NN1
304953	100736442	20992780889	,	,	,
304953	100736442	20992780890	but	but	CCB
304953	100736442	20992780891	perhaps	perhaps	RR
304953	100736442	20992780892	less	less	RGR
304953	100736442	20992780893	often	often	RR
304953	100736442	20992780894	compared	compare	VVN
304953	100736442	20992780895	to	to	II
304953	100736442	20992780896	radical	radical	JJ_NN1
304953	100736442	20992780897	prostatectomy	prostatectomy	NN1
304953	100736442	20992780898	.	.	.
304953	100736442	20992780899	Prostate	prostate	NN1
304953	100736442	20992780900	radiation	radiation	NN1
304953	100736442	20992780901	can	can	VM
304953	100736442	20992780902	sometimes	sometimes	RT
304953	100736442	20992780903	cause	cause	VVI
304953	100736442	20992780904	irritation	irritation	NN1
304953	100736442	20992780905	of	of	IO
304953	100736442	20992780906	the	the	AT
304953	100736442	20992780907	bladder	bladder	NN1
304953	100736442	20992780908	or	or	CC
304953	100736442	20992780909	rectum	rectum	NN1
304953	100736442	20992780910	.	.	.
304953	100736442	20992780911	This	this	DD1
304953	100736442	20992780912	may	may	VM
304953	100736442	20992780913	result	result	VVI
304953	100736442	20992780914	in	in	II
304953	100736442	20992780915	frequent	frequent	JJ
304953	100736442	20992780916	urination	urination	NN1
304953	100736442	20992780917	or	or	CC
304953	100736442	20992780918	diarrhea	diarrhea	NN1
304953	100736442	20992780919	and	and	CC
304953	100736442	20992780920	bleeding	bleeding	JJ_VVG
304953	100736442	20992780921	.	.	.
304953	100736442	20992780922	<p>		NULL
304953	100736442	20992780923	A	a	AT1_ZZ1
304953	100736442	20992780924	rising	rising	JJ@_VVG_NN1@
304953	100736442	20992780925	PSA	psa	NP1
304953	100736442	20992780926	year	year	NNT1
304953	100736442	20992780927	over	over	II
304953	100736442	20992780928	year	year	NNT1
304953	100736442	20992780929	may	may	VM
304953	100736442	20992780930	be	be	VBI
304953	100736442	20992780931	a	a	AT1
304953	100736442	20992780932	better	better	JJR
304953	100736442	20992780933	marker	marker	NN1
304953	100736442	20992780934	for	for	IF
304953	100736442	20992780935	prostate	prostate	NN1
304953	100736442	20992780936	cancer	cancer	NN1
304953	100736442	20992780937	than	than	CSN
304953	100736442	20992780938	a	a	AT1
304953	100736442	20992780939	number	number	NN1
304953	100736442	20992780940	over	over	RG
304953	100736442	20992780941	4	4	MC
304953	100736442	20992780942	that	that	DD1_CST
304953	100736442	20992780943	is	be	VBZ
304953	100736442	20992780944	not	not	XX
304953	100736442	20992780945	rising	rise	VVG
304953	100736442	20992780946	.	.	.
304953	100736442	20992780947	<p>		NULL
304953	100736442	20992780948	Question	question	NN1
304953	100736442	20992780949	8	8	MC
304953	100736442	20992780950	of	of	IO
304953	100736442	20992780951	10	10	MC
304953	100736442	20992780952	<p>		NULL
304953	100736442	20992780953	This	this	DD1
304953	100736442	20992780954	is	be	VBZ
304953	100736442	20992780955	called	call	VVN
304953	100736442	20992780956	the	the	AT
304953	100736442	20992780957	PSA	psa	NP1
304953	100736442	20992780958	velocity	velocity	NN1
304953	100736442	20992780959	and	and	CC
304953	100736442	20992780960	is	be	VBZ
304953	100736442	20992780961	a	a	AT1
304953	100736442	20992780962	measure	measure	NN1
304953	100736442	20992780963	of	of	IO
304953	100736442	20992780964	how	how	RGQ@_RRQ
304953	100736442	20992780965	rapidly	rapidly	RR
304953	100736442	20992780966	PSA	psa	NP1
304953	100736442	20992780967	levels	level	NN2
304953	100736442	20992780968	are	be	VBR
304953	100736442	20992780969	rising	rise	VVG
304953	100736442	20992780970	over	over	II
304953	100736442	20992780971	time	time	NNT1
304953	100736442	20992780972	.	.	.
304953	100736442	20992780973	Men	man	NN2
304953	100736442	20992780974	with	with	IW
304953	100736442	20992780975	benign	benign	JJ
304953	100736442	20992780976	enlarged	enlarged	JJ
304953	100736442	20992780977	prostrates		NN2
304953	100736442	20992780978	(	(	(
304953	100736442	20992780979	benign	benign	JJ
304953	100736442	20992780980	prostatic	prostatic	JJ
304953	100736442	20992780981	hyperplasia	hyperplasia	NN1
304953	100736442	20992780982	,	,	,
304953	100736442	20992780983	or	or	CC
304953	100736442	20992780984	BPH	bph	NP1
304953	100736442	20992780985	)	)	)
304953	100736442	20992780986	,	,	,
304953	100736442	20992780987	show	show	VV0
304953	100736442	20992780988	very	very	RG
304953	100736442	20992780989	minimal	minimal	JJ
304953	100736442	20992780990	increases	increase	NN2
304953	100736442	20992780991	in	in	II
304953	100736442	20992780992	PSA	psa	NP1
304953	100736442	20992780993	levels	level	NN2
304953	100736442	20992780994	from	from	II
304953	100736442	20992780995	one	one	MC1
304953	100736442	20992780996	year	year	NNT1
304953	100736442	20992780997	to	to	II
304953	100736442	20992780998	the	the	AT
304953	100736442	20992780999	next	next	MD
304953	100736442	20992781000	.	.	.
304953	100736442	20992781001	A	a	ZZ1_AT1
304953	100736442	20992781002	PSA	psa	NP1
304953	100736442	20992781003	level	level	NN1_VV0@_JJ
304953	100736442	20992781004	that	that	CST_DD1
304953	100736442	20992781005	increases	increase	VVZ
304953	100736442	20992781006	quickly	quickly	RR
304953	100736442	20992781007	from	from	II
304953	100736442	20992781008	one	one	MC1
304953	100736442	20992781009	test	test	NN1
304953	100736442	20992781010	to	to	II
304953	100736442	20992781011	the	the	AT
304953	100736442	20992781012	next	next	MD
304953	100736442	20992781013	suggests	suggest	VVZ
304953	100736442	20992781014	either	either	RR
304953	100736442	20992781015	irritation	irritation	NN1
304953	100736442	20992781016	of	of	IO
304953	100736442	20992781017	the	the	AT
304953	100736442	20992781018	prostrate	prostrate	JJ
304953	100736442	20992781019	or	or	CC
304953	100736442	20992781020	prostate	prostate	NN1
304953	100736442	20992781021	cancer	cancer	NN1
304953	100736442	20992781022	.	.	.
304953	100736442	20992781023	<p>		NULL
304953	100736442	20992781024	Question	question	NN1
304953	100736442	20992781025	9	9	MC
304953	100736442	20992781026	of	of	IO
304953	100736442	20992781027	10	10	MC
304953	100736442	20992781028	<p>		NULL
304953	100736442	20992781029	If	if	CS
304953	100736442	20992781030	your	your	APPGE
304953	100736442	20992781031	brother	brother	NN1
304953	100736442	20992781032	has	have	VHZ
304953	100736442	20992781033	prostate	prostate	NN1
304953	100736442	20992781034	cancer	cancer	NN1
304953	100736442	20992781035	@		II
304953	100736442	20992781036	@		II
304953	100736442	20992781037	@		II
304953	100736442	20992781038	@		II
304953	100736442	20992781039	@		II
304953	100736442	20992781040	@		II
304953	100736442	20992781041	@		II
304953	100736442	20992781042	@		II
304953	100736442	20992781043	@		II
304953	100736442	20992781044	@		II
304953	100736442	20992781045	than	than	CSN
304953	100736442	20992781046	the	the	AT
304953	100736442	20992781047	average	average	NN1_JJ
304953	100736442	20992781048	.	.	.
304953	100736442	20992781049	<p>		NULL
304953	100736442	20992781050	Family	family	NN1
304953	100736442	20992781051	history	history	NN1
304953	100736442	20992781052	of	of	IO
304953	100736442	20992781053	prostate	prostate	NN1
304953	100736442	20992781054	cancer	cancer	NN1
304953	100736442	20992781055	,	,	,
304953	100736442	20992781056	especially	especially	RR
304953	100736442	20992781057	prostate	prostate	NN1
304953	100736442	20992781058	cancer	cancer	NN1
304953	100736442	20992781059	in	in	II
304953	100736442	20992781060	a	a	AT1
304953	100736442	20992781061	first-degree	first-degree	JJ_NN1
304953	100736442	20992781062	relative	relative	NN1_JJ
304953	100736442	20992781063	,	,	,
304953	100736442	20992781064	increases	increase	VVZ
304953	100736442	20992781065	your	your	APPGE
304953	100736442	20992781066	personal	personal	JJ
304953	100736442	20992781067	risk	risk	NN1
304953	100736442	20992781068	of	of	IO
304953	100736442	20992781069	developing	develop	VVG
304953	100736442	20992781070	the	the	AT
304953	100736442	20992781071	disease	disease	NN1
304953	100736442	20992781072	.	.	.
304953	100736442	20992781073	Of	of	IO
304953	100736442	20992781074	all	all	DB
304953	100736442	20992781075	your	your	APPGE
304953	100736442	20992781076	relatives	relative	NN2
304953	100736442	20992781077	,	,	,
304953	100736442	20992781078	a	a	AT1
304953	100736442	20992781079	brother	brother	NN1
304953	100736442	20992781080	with	with	IW
304953	100736442	20992781081	prostate	prostate	NN1
304953	100736442	20992781082	cancer	cancer	NN1
304953	100736442	20992781083	increases	increase	VVZ
304953	100736442	20992781084	your	your	APPGE
304953	100736442	20992781085	risk	risk	NN1
304953	100736442	20992781086	the	the	AT
304953	100736442	20992781087	most	most	RRT@_DAT
304953	100736442	20992781088	.	.	.
304953	100736442	20992781089	If	if	CS
304953	100736442	20992781090	you	you	PPY
304953	100736442	20992781091	have	have	VH0
304953	100736442	20992781092	brother	brother	NN1
304953	100736442	20992781093	with	with	IW
304953	100736442	20992781094	prostate	prostate	NN1
304953	100736442	20992781095	cancer	cancer	NN1
304953	100736442	20992781096	,	,	,
304953	100736442	20992781097	you	you	PPY
304953	100736442	20992781098	should	should	VM
304953	100736442	20992781099	discuss	discuss	VVI
304953	100736442	20992781100	when	when	RRQ
304953	100736442	20992781101	to	to	TO
304953	100736442	20992781102	start	start	VVI
304953	100736442	20992781103	screening	screen	VVG_NN1
304953	100736442	20992781104	for	for	IF
304953	100736442	20992781105	prostate	prostate	NN1
304953	100736442	20992781106	cancer	cancer	NN1
304953	100736442	20992781107	with	with	IW
304953	100736442	20992781108	your	your	APPGE
304953	100736442	20992781109	doctor	doctor	NN1
304953	100736442	20992781110	.	.	.
304953	100736442	20992781111	<p>		NULL
304953	100736442	20992781112	Men	man	NN2
304953	100736442	20992781113	fear	fear	VV0
304953	100736442	20992781114	colon	colon	NN1
304953	100736442	20992781115	cancer	cancer	NN1
304953	100736442	20992781116	more	more	RRR_DAR
304953	100736442	20992781117	than	than	CSN
304953	100736442	20992781118	prostate	prostate	NN1
304953	100736442	20992781119	cancer	cancer	NN1
304953	100736442	20992781120	.	.	.
304953	100736442	20992781121	<p>		NULL
304953	100736442	20992781122	Question	question	NN1
304953	100736442	20992781123	10	10	MC
304953	100736442	20992781124	of	of	IO
304953	100736442	20992781125	10	10	MC
304953	100736442	20992781126	<p>		NULL
304953	100736442	20992781127	A	a	AT1
304953	100736442	20992781128	survey	survey	NN1
304953	100736442	20992781129	from	from	II
304953	100736442	20992781130	the	the	AT
304953	100736442	20992781131	Harvard	harvard	NP1
304953	100736442	20992781132	Risk	risk	NN1_VV0
304953	100736442	20992781133	Management	management	NN1
304953	100736442	20992781134	Foundation	foundation	NN1
304953	100736442	20992781135	found	find	VVD_VVN
304953	100736442	20992781136	that	that	CST_DD1
304953	100736442	20992781137	,	,	,
304953	100736442	20992781138	on	on	II
304953	100736442	20992781139	a	a	AT1
304953	100736442	20992781140	scale	scale	NN1
304953	100736442	20992781141	of	of	IO
304953	100736442	20992781142	men	man	NN2
304953	100736442	20992781143	's	's	GE
304953	100736442	20992781144	cancer	cancer	NN1
304953	100736442	20992781145	fears	fear	NN2_VVZ
304953	100736442	20992781146	,	,	,
304953	100736442	20992781147	prostate	prostate	NN1
304953	100736442	20992781148	cancer	cancer	NN1
304953	100736442	20992781149	ranked	rank	VVN_JJ@_VVD@
304953	100736442	20992781150	number	number	NN1
304953	100736442	20992781151	one	one	MC1
304953	100736442	20992781152	.	.	.
304953	100736442	20992781153	Colon	colon	NN1
304953	100736442	20992781154	cancer	cancer	NN1
304953	100736442	20992781155	ranked	rank	VVN_JJ@_VVD@
304953	100736442	20992781156	number	number	NN1
304953	100736442	20992781157	seven	seven	MC
304953	100736442	20992781158	,	,	,
304953	100736442	20992781159	behind	behind	II
304953	100736442	20992781160	a	a	AT1
304953	100736442	20992781161	variety	variety	NN1
304953	100736442	20992781162	of	of	IO
304953	100736442	20992781163	less	less	RGR
304953	100736442	20992781164	common	common	JJ
304953	100736442	20992781165	diseases	disease	NN2
304953	100736442	20992781166	.	.	.
304953	100736442	20992781167	Both	both	DB2
304953	100736442	20992781168	cancers	cancer	NN2
304953	100736442	20992781169	kill	kill	VV0
304953	100736442	20992781170	almost	almost	RR
304953	100736442	20992781171	30,000	30,000	MC
304953	100736442	20992781172	men	man	NN2
304953	100736442	20992781173	a	a	AT1
304953	100736442	20992781174	year	year	NNT1
304953	100736442	20992781175	.	.	.
304953	100736442	20992781176	While	while	CS
304953	100736442	20992781177	colon	colon	NN1
304953	100736442	20992781178	cancer	cancer	NN1
304953	100736442	20992781179	screening	screen	VVG_NN1
304953	100736442	20992781180	clearly	clearly	RR
304953	100736442	20992781181	decreases	decrease	VVZ
304953	100736442	20992781182	the	the	AT
304953	100736442	20992781183	cancer	cancer	NN1
304953	100736442	20992781184	death	death	NN1
304953	100736442	20992781185	rate	rate	NN1
304953	100736442	20992781186	,	,	,
304953	100736442	20992781187	it	it	PPH1
304953	100736442	20992781188	is	be	VBZ
304953	100736442	20992781189	controversial	controversial	JJ
304953	100736442	20992781190	as	as	II21
304953	100736442	20992781191	to	to	II22
304953	100736442	20992781192	whether	whether	CSW
304953	100736442	20992781193	PSA	psa	NP1
304953	100736442	20992781194	testing	testing	NN1
304953	100736442	20992781195	reduces	reduce	VVZ
304953	100736442	20992781196	prostate	prostate	NN1
304953	100736442	20992781197	cancer	cancer	NN1
304953	100736442	20992781198	death	death	NN1
304953	100736442	20992781199	rate	rate	NN1
304953	100736442	20992781200	.	.	.
304953	100736442	20992781201	<p>		NULL
304953	100736442	20992781202	RETAKE-+		FO
304953	100736442	20992781203	<p>		NULL
304953	100736442	20992781204	correct	correct	VV0@_JJ
304953	100736442	20992781205	out	out	II21
304953	100736442	20992781206	of	of	II22
304953	100736442	20992781207	10	10	MC
304953	100736442	20992781208	<p>		NULL
304953	100736442	20992781209	Thanks	thanks	NN2
304953	100736442	20992781210	for	for	IF
304953	100736442	20992781211	taking	take	VVG
304953	100736442	20992781212	the	the	AT
304953	100736442	20992781213	quiz	quiz	NN1
304953	100736442	20992781214	!	!	!
304953	100736442	20992781215	<p>		NULL
304953	100736442	20992781216	Your	your	APPGE
304953	100736442	20992781217	Score	score	NN1
304953	100736442	20992781218	<p>		NULL
304953	100736442	20992781219	0	0	MC
304953	100736442	20992781220	<p>		NULL
304953	100736442	20992781221	Male	male	JJ_NN1
304953	100736442	20992781222	celebrities	celebrity	NN2
304953	100736442	20992781223	are	be	VBR
304953	100736442	20992781224	encouraging	encourage	VVG@_JJ
304953	100736442	20992781225	all	all	DB
304953	100736442	20992781226	men	man	NN2
304953	100736442	20992781227	over	over	RG
304953	100736442	20992781228	fifty	fifty	MC
304953	100736442	20992781229	to	to	TO
304953	100736442	20992781230	get	get	VVI
304953	100736442	20992781231	a	a	AT1
304953	100736442	20992781232	PSA	psa	NP1
304953	100736442	20992781233	blood	blood	NN1
304953	100736442	20992781234	test	test	NN1_VV0
304953	100736442	20992781235	@		II
304953	100736442	20992781236	@		II
304953	100736442	20992781237	@		II
304953	100736442	20992781238	@		II
304953	100736442	20992781239	@		II
304953	100736442	20992781240	@		II
304953	100736442	20992781241	@		II
304953	100736442	20992781242	@		II
304953	100736442	20992781243	@		II
304953	100736442	20992781244	@		II
304953	100736442	20992781245	believe	believe	VV0
304953	100736442	20992781246	that	that	CST
304953	100736442	20992781247	this	this	DD1
304953	100736442	20992781248	message	message	NN1
304953	100736442	20992781249	is	be	VBZ
304953	100736442	20992781250	not	not	XX
304953	100736442	20992781251	supported	support	VVN
304953	100736442	20992781252	by	by	II
304953	100736442	20992781253	medical	medical	JJ
304953	100736442	20992781254	evidence	evidence	NN1
304953	100736442	20992781255	.	.	.
304953	100736442	20992781256	Take	take	VV0
304953	100736442	20992781257	our	our	APPGE
304953	100736442	20992781258	quiz	quiz	NN1
304953	100736442	20992781259	to	to	TO
304953	100736442	20992781260	help	help	VVI
304953	100736442	20992781261	you	you	PPY
304953	100736442	20992781262	decide	decide	VVI
304953	100736442	20992781263	if	if	CS_CSW@
304953	100736442	20992781264	PSA	psa	NP1
304953	100736442	20992781265	screening	screening	NN1
304953	100736442	20992781266	is	be	VBZ
304953	100736442	20992781267	right	right	JJ
304953	100736442	20992781268	for	for	IF
304953	100736442	20992781269	you	you	PPY
304953	100736442	20992781270	.	.	.
304953	100736442	20992781271	<p>		NULL
304953	100736442	20992781272	Older	old	JJR
304953	100736442	20992781273	men	man	NN2
304953	100736442	20992781274	have	have	VH0
304953	100736442	20992781275	higher	high	JJR_RRR@
304953	100736442	20992781276	PSA	psa	NP1
304953	100736442	20992781277	levels	level	NN2
304953	100736442	20992781278	than	than	CSN
304953	100736442	20992781279	younger	young	JJR
304953	100736442	20992781280	men	man	NN2
304953	100736442	20992781281	.	.	.
304953	100736442	20992781282	In	in	II
304953	100736442	20992781283	the	the	AT
304953	100736442	20992781284	absence	absence	NN1
304953	100736442	20992781285	of	of	IO
304953	100736442	20992781286	prostate	prostate	NN1
304953	100736442	20992781287	cancer	cancer	NN1
304953	100736442	20992781288	,	,	,
304953	100736442	20992781289	infection	infection	NN1
304953	100736442	20992781290	or	or	CC
304953	100736442	20992781291	other	other	JJ
304953	100736442	20992781292	irritation	irritation	NN1
304953	100736442	20992781293	of	of	IO
304953	100736442	20992781294	the	the	AT
304953	100736442	20992781295	gland	gland	NN1
304953	100736442	20992781296	,	,	,
304953	100736442	20992781297	PSA	psa	NP1
304953	100736442	20992781298	levels	level	NN2
304953	100736442	20992781299	increase	increase	VV0
304953	100736442	20992781300	by	by	RP%_II
304953	100736442	20992781301	about	about	RG
304953	100736442	20992781302	0.5	0.5	MC
304953	100736442	20992781303	nanograms	nanogram	NN2_VVZ
304953	100736442	20992781304	per	per	II
304953	100736442	20992781305	milliliter	milliliter	NN1
304953	100736442	20992781306	every	every	AT1
304953	100736442	20992781307	10	10	MC
304953	100736442	20992781308	years	year	NNT2
304953	100736442	20992781309	.	.	.
304953	100736442	20992781310	The	the	AT
304953	100736442	20992781311	rise	rise	NN1
304953	100736442	20992781312	is	be	VBZ
304953	100736442	20992781313	very	very	RG
304953	100736442	20992781314	gradual	gradual	JJ
304953	100736442	20992781315	.	.	.
304953	100736442	20992781316	A	a	AT1
304953	100736442	20992781317	more	more	RGR
304953	100736442	20992781318	sudden	sudden	JJ
304953	100736442	20992781319	increase	increase	NN1
304953	100736442	20992781320	in	in	II
304953	100736442	20992781321	PSA	psa	NP1
304953	100736442	20992781322	level	level	NN1_JJ
304953	100736442	20992781323	from	from	II
304953	100736442	20992781324	one	one	MC1
304953	100736442	20992781325	year	year	NNT1
304953	100736442	20992781326	to	to	II
304953	100736442	20992781327	the	the	AT
304953	100736442	20992781328	next	next	MD
304953	100736442	20992781329	may	may	VM
304953	100736442	20992781330	indicate	indicate	VVI
304953	100736442	20992781331	a	a	AT1
304953	100736442	20992781332	problem	problem	NN1
304953	100736442	20992781333	.	.	.
304953	100736442	20992781334	<p>		NULL
304953	100736442	20992781335	A	a	AT1_ZZ1
304953	100736442	20992781336	rising	rising	JJ@_VVG_NN1@
304953	100736442	20992781337	PSA	psa	NP1
304953	100736442	20992781338	year	year	NNT1
304953	100736442	20992781339	over	over	II
304953	100736442	20992781340	year	year	NNT1
304953	100736442	20992781341	may	may	VM
304953	100736442	20992781342	be	be	VBI
304953	100736442	20992781343	a	a	AT1
304953	100736442	20992781344	better	better	JJR
304953	100736442	20992781345	marker	marker	NN1
304953	100736442	20992781346	for	for	IF
304953	100736442	20992781347	prostate	prostate	NN1
304953	100736442	20992781348	cancer	cancer	NN1
304953	100736442	20992781349	than	than	CSN
304953	100736442	20992781350	a	a	AT1
304953	100736442	20992781351	number	number	NN1
304953	100736442	20992781352	over	over	RG
304953	100736442	20992781353	4	4	MC
304953	100736442	20992781354	that	that	DD1_CST
304953	100736442	20992781355	is	be	VBZ
304953	100736442	20992781356	not	not	XX
304953	100736442	20992781357	rising	rise	VVG
304953	100736442	20992781358	.	.	.
304953	100736442	20992781359	<p>		NULL
304953	100736442	20992781360	NEXTQUESTION-+		FO
304953	100736442	20992781361	<p>		NULL
304953	100736442	20992781362	A	a	AT1
304953	100736442	20992781363	survey	survey	NN1
304953	100736442	20992781364	from	from	II
304953	100736442	20992781365	the	the	AT
304953	100736442	20992781366	Harvard	harvard	NP1
304953	100736442	20992781367	Risk	risk	NN1_VV0
304953	100736442	20992781368	Management	management	NN1
304953	100736442	20992781369	Foundation	foundation	NN1
304953	100736442	20992781370	found	find	VVD_VVN
304953	100736442	20992781371	that	that	CST_DD1
304953	100736442	20992781372	,	,	,
304953	100736442	20992781373	on	on	II
304953	100736442	20992781374	a	a	AT1
304953	100736442	20992781375	scale	scale	NN1
304953	100736442	20992781376	of	of	IO
304953	100736442	20992781377	men	man	NN2
304953	100736442	20992781378	's	's	GE
304953	100736442	20992781379	cancer	cancer	NN1
304953	100736442	20992781380	fears	fear	NN2_VVZ
304953	100736442	20992781381	,	,	,
304953	100736442	20992781382	prostate	prostate	NN1
304953	100736442	20992781383	cancer	cancer	NN1
304953	100736442	20992781384	ranked	rank	VVN_JJ@_VVD@
304953	100736442	20992781385	number	number	NN1
304953	100736442	20992781386	one	one	MC1
304953	100736442	20992781387	.	.	.
304953	100736442	20992781388	Colon	colon	NN1
304953	100736442	20992781389	cancer	cancer	NN1
304953	100736442	20992781390	ranked	rank	VVN_JJ@_VVD@
304953	100736442	20992781391	number	number	NN1
304953	100736442	20992781392	seven	seven	MC
304953	100736442	20992781393	,	,	,
304953	100736442	20992781394	behind	behind	II
304953	100736442	20992781395	a	a	AT1
304953	100736442	20992781396	variety	variety	NN1
304953	100736442	20992781397	of	of	IO
304953	100736442	20992781398	less	less	RGR
304953	100736442	20992781399	common	common	JJ
304953	100736442	20992781400	diseases	disease	NN2
304953	100736442	20992781401	.	.	.
304953	100736442	20992781402	Both	both	DB2
304953	100736442	20992781403	cancers	cancer	NN2
304953	100736442	20992781404	kill	kill	VV0
304953	100736442	20992781405	almost	almost	RR
304953	100736442	20992781406	30,000	30,000	MC
304953	100736442	20992781407	men	man	NN2
304953	100736442	20992781408	a	a	AT1
304953	100736442	20992781409	year	year	NNT1
304953	100736442	20992781410	.	.	.
304953	100736442	20992781411	While	while	CS
304953	100736442	20992781412	colon	colon	NN1
304953	100736442	20992781413	cancer	cancer	NN1
304953	100736442	20992781414	screening	screen	VVG_NN1
304953	100736442	20992781415	clearly	clearly	RR
304953	100736442	20992781416	decreases	decrease	VVZ
304953	100736442	20992781417	the	the	AT
304953	100736442	20992781418	cancer	cancer	NN1
304953	100736442	20992781419	death	death	NN1
304953	100736442	20992781420	rate	rate	NN1
304953	100736442	20992781421	,	,	,
304953	100736442	20992781422	it	it	PPH1
304953	100736442	20992781423	is	be	VBZ
304953	100736442	20992781424	controversial	controversial	JJ
304953	100736442	20992781425	as	as	II21
304953	100736442	20992781426	to	to	II22
304953	100736442	20992781427	whether	whether	CSW
304953	100736442	20992781428	PSA	psa	NP1
304953	100736442	20992781429	testing	testing	NN1
304953	100736442	20992781430	reduces	reduce	VVZ
304953	100736442	20992781431	prostate	prostate	NN1
304953	100736442	20992781432	cancer	cancer	NN1
304953	100736442	20992781433	death	death	NN1
304953	100736442	20992781434	rate	rate	NN1
304953	100736442	20992781435	.	.	.
304953	100736446	20992781479	@@##	----------	----------
304953	100736446	20992781480	@@100736446		FO
304953	100736446	20992781481	@4936446/		VV0_JJ
304953	100736446	20992781482	<h>		NULL
304953	100736446	20992781483	Other	other	JJ
304953	100736446	20992781484	Conditions	condition	NN2
304953	100736446	20992781485	46988		MC
304953	100736446	20992781486	@qwx906988		FO
304953	100736446	20992781487	46994		MC
304953	100736446	20992781488	@qwx906994		FO
304953	100736446	20992781489	46995		MC
304953	100736446	20992781490	@qwx906995		FO
304953	100736446	20992781491	46992		MC
304953	100736446	20992781492	@qwx906992		FO
304953	100736446	20992781493	46991		MC
304953	100736446	20992781494	@qwx906991		FO
304953	100736446	20992781495	46990		MC
304953	100736446	20992781496	@qwx906990		FO
304953	100736446	20992781497	46989		MC
304953	100736446	20992781498	@qwx906989		FO
304953	100736446	20992781499	46993		MC
304953	100736446	20992781500	@qwx906993		FO
304953	100736446	20992781501	<h>		NULL
304953	100736446	20992781502	Hypogonadism	hypogonadism	NN1
304953	100736446	20992781503	<p>		NULL
304953	100736446	20992781504	In	in	II
304953	100736446	20992781505	some	some	DD
304953	100736446	20992781506	men	man	NN2
304953	100736446	20992781507	,	,	,
304953	100736446	20992781508	particularly	particularly	RR
304953	100736446	20992781509	older	old	JJR
304953	100736446	20992781510	men	man	NN2
304953	100736446	20992781511	,	,	,
304953	100736446	20992781512	the	the	AT
304953	100736446	20992781513	testes	teste	NN2
304953	100736446	20992781514	may	may	VM
304953	100736446	20992781515	not	not	XX
304953	100736446	20992781516	produce	produce	VVI
304953	100736446	20992781517	enough	enough	DD
304953	100736446	20992781518	testosterone	testosterone	NN1
304953	100736446	20992781519	.	.	.
304953	100736446	20992781520	Some	some	DD
304953	100736446	20992781521	signs	sign	NN2
304953	100736446	20992781522	and	and	CC
304953	100736446	20992781523	symptoms	symptom	NN2
304953	100736446	20992781524	of	of	IO
304953	100736446	20992781525	low	low	JJ
304953	100736446	20992781526	testosterone	testosterone	NN1
304953	100736446	20992781527	,	,	,
304953	100736446	20992781528	also	also	RR
304953	100736446	20992781529	called	call	VVN
304953	100736446	20992781530	hypogonadism	hypogonadism	NN1
304953	100736446	20992781531	,	,	,
304953	100736446	20992781532	include	include	VV0
304953	100736446	20992781533	reduced	reduced	JJ@
304953	100736446	20992781534	sex	sex	NN1
304953	100736446	20992781535	drive	drive	NN1
304953	100736446	20992781536	and	and	CC
304953	100736446	20992781537	sense	sense	NN1
304953	100736446	20992781538	of	of	IO
304953	100736446	20992781539	vitality	vitality	NN1
304953	100736446	20992781540	,	,	,
304953	100736446	20992781541	erectile	erectile	JJ
304953	100736446	20992781542	dysfunction	dysfunction	NN1
304953	100736446	20992781543	,	,	,
304953	100736446	20992781544	decreased	decrease	VVD_JJ@_VVN
304953	100736446	20992781545	energy	energy	NN1
304953	100736446	20992781546	,	,	,
304953	100736446	20992781547	lower	low	JJR
304953	100736446	20992781548	muscle	muscle	NN1
304953	100736446	20992781549	mass	mass	NN1
304953	100736446	20992781550	and	and	CC
304953	100736446	20992781551	bone	bone	NN1
304953	100736446	20992781552	density	density	NN1
304953	100736446	20992781553	,	,	,
304953	100736446	20992781554	and	and	CC
304953	100736446	20992781555	anemia	anemia	NN1
304953	100736446	20992781556	.	.	.
304953	100736446	20992781557	Supplementing	supplement	VVG
304953	100736446	20992781558	testosterone	testosterone	NN1
304953	100736446	20992781559	is	be	VBZ
304953	100736446	20992781560	an	a	AT1
304953	100736446	20992781561	effective	effective	JJ
304953	100736446	20992781562	treatment	treatment	NN1
304953	100736446	20992781563	for	for	IF
304953	100736446	20992781564	hypogonadism	hypogonadism	NN1
304953	100736446	20992781565	,	,	,
304953	100736446	20992781566	but	but	CCB
304953	100736446	20992781567	testosterone	testosterone	NN1
304953	100736446	20992781568	supplementation	supplementation	NN1
304953	100736446	20992781569	carries	carry	VVZ
304953	100736446	20992781570	certain	certain	JJ
304953	100736446	20992781571	risks	risk	NN2
304953	100736446	20992781572	.	.	.
304953	100736446	20992781573	For	for	REX21
304953	100736446	20992781574	example	example	REX22
304953	100736446	20992781575	,	,	,
304953	100736446	20992781576	it	it	PPH1
304953	100736446	20992781577	may	may	VM
304953	100736446	20992781578	promote	promote	VVI
304953	100736446	20992781579	prostate	prostate	NN1
304953	100736446	20992781580	cancer	cancer	NN1
304953	100736446	20992781581	,	,	,
304953	100736446	20992781582	cardiovascular	cardiovascular	JJ
304953	100736446	20992781583	disease	disease	NN1
304953	100736446	20992781584	,	,	,
304953	100736446	20992781585	and	and	CC
304953	100736446	20992781586	sleep	sleep	VV0_NN1
304953	100736446	20992781587	problems	problem	NN2
304953	100736446	20992781588	.	.	.
304953	100736446	20992781589	<p>		NULL
304953	100736446	20992781590	As	as	CSA
304953	100736446	20992781591	men	man	NN2
304953	100736446	20992781592	age	age	NN1_VV0@
304953	100736446	20992781593	,	,	,
304953	100736446	20992781594	their	their	APPGE
304953	100736446	20992781595	testosterone	testosterone	NN1
304953	100736446	20992781596	production	production	NN1
304953	100736446	20992781597	begins	begin	VVZ
304953	100736446	20992781598	to	to	TO
304953	100736446	20992781599	slow	slow	VVI
304953	100736446	20992781600	.	.	.
304953	100736446	20992781601	As	as	CSA
304953	100736446	20992781602	men	man	NN2
304953	100736446	20992781603	get	get	VV0
304953	100736446	20992781604	into	into	II
304953	100736446	20992781605	their	their	APPGE
304953	100736446	20992781606	50s	50s	MC2
304953	100736446	20992781607	,	,	,
304953	100736446	20992781608	60s	60s	MC2
304953	100736446	20992781609	,	,	,
304953	100736446	20992781610	and	and	CC
304953	100736446	20992781611	beyond	beyond	RL@
304953	100736446	20992781612	,	,	,
304953	100736446	20992781613	they	they	PPHS2
304953	100736446	20992781614	may	may	VM
304953	100736446	20992781615	start	start	VVI
304953	100736446	20992781616	to	to	TO
304953	100736446	20992781617	have	have	VHI
304953	100736446	20992781618	signs	sign	NN2
304953	100736446	20992781619	and	and	CC
304953	100736446	20992781620	symptoms	symptom	NN2
304953	100736446	20992781621	of	of	IO
304953	100736446	20992781622	low	low	JJ
304953	100736446	20992781623	testosterone	testosterone	NN1
304953	100736446	20992781624	including	including	II
304953	100736446	20992781625	reduced	reduced	JJ@
304953	100736446	20992781626	sex	sex	NN1
304953	100736446	20992781627	drive	drive	NN1
304953	100736446	20992781628	and	and	CC
304953	100736446	20992781629	sense	sense	NN1
304953	100736446	20992781630	of	of	IO
304953	100736446	20992781631	vitality	vitality	NN1
304953	100736446	20992781632	,	,	,
304953	100736446	20992781633	erectile	erectile	JJ
304953	100736446	20992781634	dysfunction	dysfunction	NN1
304953	100736446	20992781635	,	,	,
304953	100736446	20992781636	decreased	decrease	VVD_JJ@_VVN
304953	100736446	20992781637	energy	energy	NN1
304953	100736446	20992781638	,	,	,
304953	100736446	20992781639	lower	low	JJR
304953	100736446	20992781640	muscle	muscle	NN1
304953	100736446	20992781641	mass	mass	NN1
304953	100736446	20992781642	and	and	CC
304953	100736446	20992781643	bone	bone	NN1
304953	100736446	20992781644	density	density	NN1
304953	100736446	20992781645	,	,	,
304953	100736446	20992781646	and	and	CC
304953	100736446	20992781647	anemia	anemia	NN1
304953	100736446	20992781648	.	.	.
304953	100736446	20992781649	In	in	II
304953	100736446	20992781650	some	some	DD
304953	100736446	20992781651	cases	case	NN2
304953	100736446	20992781652	,	,	,
304953	100736446	20992781653	supplemental	supplemental	JJ
304953	100736446	20992781654	testosterone	testosterone	NN1
304953	100736446	20992781655	may	may	VM
304953	100736446	20992781656	help	help	VVI
304953	100736446	20992781657	.	.	.
304953	100736446	20992781658	However	however	RR
304953	100736446	20992781659	,	,	,
304953	100736446	20992781660	doctors	doctor	NN2
304953	100736446	20992781661	disagree	disagree	VV0
304953	100736446	20992781662	over	over	RP_II
304953	100736446	20992781663	the	the	AT
304953	100736446	20992781664	wisdom	wisdom	NN1
304953	100736446	20992781665	of	of	IO
304953	100736446	20992781666	prescribing	prescribe	VVG
304953	100736446	20992781667	testosterone	testosterone	NN1
304953	100736446	20992781668	to	to	II
304953	100736446	20992781669	prostate	prostate	NN1
304953	100736446	20992781670	cancer	cancer	NN1
304953	100736446	20992781671	@		II
304953	100736446	20992781672	@		II
304953	100736446	20992781673	@		II
304953	100736446	20992781674	@		II
304953	100736446	20992781675	@		II
304953	100736446	20992781676	@		II
304953	100736446	20992781677	@		II
304953	100736446	20992781678	@		II
304953	100736446	20992781679	@		II
304953	100736446	20992781680	@		II
304953	100736446	20992781681	of	of	IO
304953	100736446	20992781682	surgery	surgery	NN1
304953	100736446	20992781683	at	at	II
304953	100736446	20992781684	Harvard	harvard	NP1
304953	100736446	20992781685	Medical	medical	JJ
304953	100736446	20992781686	School	school	NN1
304953	100736446	20992781687	and	and	CC
304953	100736446	20992781688	the	the	AT
304953	100736446	20992781689	director	director	NN1
304953	100736446	20992781690	of	of	IO
304953	100736446	20992781691	Men	man	NN2
304953	100736446	20992781692	's	's	GE
304953	100736446	20992781693	Health	health	NN1
304953	100736446	20992781694	Boston	boston	NP1
304953	100736446	20992781695	,	,	,
304953	100736446	20992781696	shares	share	VVZ@
304953	100736446	20992781697	his	his	APPGE
304953	100736446	20992781698	views	view	NN2
304953	100736446	20992781699	on	on	II
304953	100736446	20992781700	current	current	JJ
304953	100736446	20992781701	controversies	controversy	NN2
304953	100736446	20992781702	regarding	regarding	II_VVG
304953	100736446	20992781703	testosterone-replacement		JJ_NN1
304953	100736446	20992781704	therapy	therapy	NN1
304953	100736446	20992781705	.	.	.
304953	100736447	20992781725	@@##	----------	----------
304953	100736447	20992781726	@@100736447		FO
304953	100736447	20992781727	@4936447/		VV0_NN1
304953	100736447	20992781728	46989		MC
304953	100736447	20992781729	@qwx906989		FO
304953	100736447	20992781730	<p>		NULL
304953	100736447	20992781731	Research	research	NN1
304953	100736447	20992781732	confirms	confirm	VVZ
304953	100736447	20992781733	what	what	DDQ
304953	100736447	20992781734	many	many	DA2
304953	100736447	20992781735	prostate	prostate	NN1
304953	100736447	20992781736	cancer	cancer	NN1
304953	100736447	20992781737	patients	patient	NN2
304953	100736447	20992781738	pursuing	pursue	VVG
304953	100736447	20992781739	active	active	JJ
304953	100736447	20992781740	surveillance	surveillance	NN1
304953	100736447	20992781741	know	know	VV0
304953	100736447	20992781742	intuitively	intuitively	RR
304953	100736447	20992781743	:	:	:
304953	100736447	20992781744	Anxiety	anxiety	NN1
304953	100736447	20992781745	,	,	,
304953	100736447	20992781746	not	not	XX
304953	100736447	20992781747	clinical	clinical	JJ
304953	100736447	20992781748	symptoms	symptom	NN2
304953	100736447	20992781749	and	and	CC
304953	100736447	20992781750	disease	disease	NN1
304953	100736447	20992781751	progression	progression	NN1
304953	100736447	20992781752	,	,	,
304953	100736447	20992781753	may	may	VM
304953	100736447	20992781754	sway	sway	VVI
304953	100736447	20992781755	patients	patient	NN2
304953	100736447	20992781756	toward	toward	II
304953	100736447	20992781757	treatment	treatment	NN1
304953	100736447	20992781758	.	.	.
304953	100736447	20992781759	Among	among	II
304953	100736447	20992781760	105	105	MC
304953	100736447	20992781761	men	man	NN2
304953	100736447	20992781762	pursuing	pursue	VVG
304953	100736447	20992781763	active	active	JJ
304953	100736447	20992781764	surveillance	surveillance	NN1
304953	100736447	20992781765	as	as	II
304953	100736447	20992781766	part	part	NN1
304953	100736447	20992781767	of	of	IO
304953	100736447	20992781768	the	the	AT
304953	100736447	20992781769	nationwide	nationwide	JJ
304953	100736447	20992781770	observational	observational	JJ
304953	100736447	20992781771	CaPSURE		NN1
304953	100736447	20992781772	trial	trial	NN1
304953	100736447	20992781773	,	,	,
304953	100736447	20992781774	researchers	researcher	NN2
304953	100736447	20992781775	found	find	VVD_VVN
304953	100736447	20992781776	that	that	CST_DD1
304953	100736447	20992781777	regular	regular	JJ
304953	100736447	20992781778	screening	screening	NN1
304953	100736447	20992781779	visits	visit	NN2
304953	100736447	20992781780	and	and	CC
304953	100736447	20992781781	follow-up	follow-up	JJ_NN1
304953	100736447	20992781782	PSA	psa	NP1
304953	100736447	20992781783	measurements	measurement	NN2
304953	100736447	20992781784	often	often	RR
304953	100736447	20992781785	evoke	evoke	VV0
304953	100736447	20992781786	considerable	considerable	JJ
304953	100736447	20992781787	anxiety	anxiety	NN1
304953	100736447	20992781788	.	.	.
304953	100736447	20992781789	Wanting	want	VVG_JJ
304953	100736447	20992781790	off	off	II_RP
304953	100736447	20992781791	the	the	AT
304953	100736447	20992781792	emotional	emotional	JJ
304953	100736447	20992781793	roller	roller	NN1
304953	100736447	20992781794	coaster	coaster	NN1
304953	100736447	20992781795	,	,	,
304953	100736447	20992781796	41%		NNU
304953	100736447	20992781797	of	of	IO
304953	100736447	20992781798	men	man	NN2
304953	100736447	20992781799	deemed	deem	VVN
304953	100736447	20992781800	at	at	II
304953	100736447	20992781801	low	low	JJ
304953	100736447	20992781802	risk	risk	NN1
304953	100736447	20992781803	for	for	IF
304953	100736447	20992781804	cancer	cancer	NN1
304953	100736447	20992781805	progression	progression	NN1
304953	100736447	20992781806	opted	opt	VVN_VVD
304953	100736447	20992781807	for	for	IF
304953	100736447	20992781808	treatment	treatment	NN1
304953	100736447	20992781809	"	"	"
304953	100736447	20992781810	and	and	CC
304953	100736447	20992781811	the	the	AT
304953	100736447	20992781812	reduced	reduced	JJ@
304953	100736447	20992781813	quality	quality	NN1
304953	100736447	20992781814	of	of	IO
304953	100736447	20992781815	life	life	NN1
304953	100736447	20992781816	that	that	CST
304953	100736447	20992781817	often	often	RR
304953	100736447	20992781818	follows	follow	VVZ
304953	100736447	20992781819	"	"	"
304953	100736447	20992781820	within	within	II
304953	100736447	20992781821	three	three	MC
304953	100736447	20992781822	years	year	NNT2
304953	100736447	20992781823	of	of	IO
304953	100736447	20992781824	diagnosis	diagnosis	NN1
304953	100736447	20992781825	.	.	.
304953	100736447	20992781826	Type	type	NN1
304953	100736447	20992781827	of	of	IO
304953	100736447	20992781828	insurance	insurance	NN1
304953	100736447	20992781829	or	or	CC
304953	100736447	20992781830	more	more	RGR
304953	100736447	20992781831	favorable	favorable	JJ
304953	100736447	20992781832	coverage	coverage	NN1
304953	100736447	20992781833	had	have	VHD
304953	100736447	20992781834	little	little	DA1
304953	100736447	20992781835	impact	impact	NN1
304953	100736447	20992781836	on	on	II
304953	100736447	20992781837	treatment	treatment	NN1
304953	100736447	20992781838	decisions	decision	NN2
304953	100736447	20992781839	.	.	.
304953	100736447	20992781840	Additional	additional	JJ
304953	100736447	20992781841	patient	patient	JJ_NN1
304953	100736447	20992781842	education	education	NN1
304953	100736447	20992781843	and	and	CC
304953	100736447	20992781844	anxiety	anxiety	NN1
304953	100736447	20992781845	management	management	NN1
304953	100736447	20992781846	,	,	,
304953	100736447	20992781847	the	the	AT
304953	100736447	20992781848	researchers	researcher	NN2
304953	100736447	20992781849	suggest	suggest	VV0
304953	100736447	20992781850	,	,	,
304953	100736447	20992781851	might	might	VM
304953	100736447	20992781852	help	help	VVI
304953	100736447	20992781853	patients	patient	NN2
304953	100736447	20992781854	with	with	IW
304953	100736447	20992781855	no	no	AT
304953	100736447	20992781856	signs	sign	NN2
304953	100736447	20992781857	or	or	CC
304953	100736447	20992781858	symptoms	symptom	NN2
304953	100736447	20992781859	of	of	IO
304953	100736447	20992781860	worsening	worsening	JJ
304953	100736447	20992781861	disease	disease	NN1
304953	100736447	20992781862	to	to	II
304953	100736447	20992781863	further	far	JJR@_RRR
304953	100736447	20992781864	delay	delay	NN1_VV0
304953	100736447	20992781865	treatment	treatment	NN1
304953	100736447	20992781866	.	.	.
304953	100736447	20992781867	<p>		NULL
304953	100736447	20992781868	If	if	CS
304953	100736447	20992781869	it	it	PPH1
304953	100736447	20992781870	is	be	VBZ
304953	100736447	20992781871	on	on	II
304953	100736447	20992781872	initial	initial	JJ_NN1
304953	100736447	20992781873	stage	stage	NN1
304953	100736447	20992781874	Best	best	JJT
304953	100736447	20992781875	way	way	NN1
304953	100736447	20992781876	to	to	TO
304953	100736447	20992781877	get	get	VVI
304953	100736447	20992781878	it	it	PPH1
304953	100736447	20992781879	opareted		VVN
304953	100736447	20992781880	I	i	MC1%_ZZ1%
304953	100736447	20992781881	f	f	ZZ1_RA@
304953	100736447	20992781882	it	it	PPH1
304953	100736447	20992781883	is	be	VBZ
304953	100736447	20992781884	on	on	II
304953	100736447	20992781885	next	next	MD
304953	100736447	20992781886	even	even	NNT1%_RR
304953	100736447	20992781887	after	after	II_CS
304953	100736447	20992781888	operation	operation	NN1
304953	100736447	20992781889	u	u	ZZ1
304953	100736447	20992781890	may	may	VM
304953	100736447	20992781891	have	have	VHI
304953	100736447	20992781892	to	to	TO
304953	100736447	20992781893	go	go	VVI
304953	100736447	20992781894	for	for	IF
304953	100736447	20992781895	chemo	chemo	NN1
304953	100736447	20992781896	.	.	.
304953	100736447	20992781897	now	now	RT
304953	100736447	20992781898	there	there	EX
304953	100736447	20992781899	are	be	VBR
304953	100736447	20992781900	certain	certain	JJ
304953	100736447	20992781901	injection	injection	NN1
304953	100736447	20992781902	in	in	II
304953	100736447	20992781903	market	market	NN1
304953	100736447	20992781904	that	that	CST_DD1
304953	100736447	20992781905	will	will	VM
304953	100736447	20992781906	hold	hold	VVI
304953	100736447	20992781907	good	good	JJ
304953	100736447	20992781908	for	for	IF
304953	100736447	20992781909	chemo	chemo	NN1
304953	100736447	20992781910	Though	though	CS
304953	100736447	20992781911	the	the	AT
304953	100736447	20992781912	injection	injection	NN1
304953	100736447	20992781913	is	be	VBZ
304953	100736447	20992781914	costly	costly	JJ
304953	100736447	20992781915	but	but	CCB
304953	100736447	20992781916	will	will	VM
304953	100736447	20992781917	@		II
304953	100736447	20992781918	@		II
304953	100736447	20992781919	@		II
304953	100736447	20992781920	@		II
304953	100736447	20992781921	@		II
304953	100736447	20992781922	@		II
304953	100736447	20992781923	@		II
304953	100736447	20992781924	@		II
304953	100736447	20992781925	@		II
304953	100736447	20992781926	@		II
304953	100736447	20992781927	effect	effect	NN1
304953	100736447	20992781928	like	like	II
304953	100736447	20992781929	loosing	loose	VVG_JJ@
304953	100736447	20992781930	hair	hair	NN1
304953	100736447	20992781931	,	,	,
304953	100736447	20992781932	vomiting	vomit	VVG
304953	100736447	20992781933	etc.Injection		NNU
304953	100736447	20992781934	will	will	VM
304953	100736447	20992781935	have	have	VHI
304953	100736447	20992781936	to	to	TO
304953	100736447	20992781937	take	take	VVI
304953	100736447	20992781938	every	every	AT1
304953	100736447	20992781939	2	2	MC
304953	100736447	20992781940	months	month	NNT2
304953	100736447	20992781941	consult	consult	VV0
304953	100736447	20992781942	your	your	APPGE
304953	100736447	20992781943	surgeon	surgeon	NN1
304953	100736447	20992781944	wish	wish	NN1_VV0
304953	100736447	20992781945	u	u	ZZ1
304953	100736447	20992781946	peaceful	peaceful	JJ
304953	100736447	20992781947	speeedy		JJ
304953	100736447	20992781948	recovery	recovery	NN1
304953	100736447	20992781949	to	to	II
304953	100736447	20992781950	your	your	APPGE
304953	100736447	20992781951	dadAMEN		NN2
304953	100736447	20992781952	46996		MC
304953	100736447	20992781953	@qwx906996		FO
304953	100736448	20992781973	@@##	----------	----------
304953	100736448	20992781974	@@100736448		FO
304953	100736448	20992781975	@4936448/		JJ_NN1_VV0
304953	100736448	20992781976	<h>		NULL
304953	100736448	20992781977	Prostate	prostate	NN1
304953	100736448	20992781978	Cancer	cancer	NN1
304953	100736448	20992781979	46988		MC
304953	100736448	20992781980	@qwx906988		FO
304953	100736448	20992781981	46994		MC
304953	100736448	20992781982	@qwx906994		FO
304953	100736448	20992781983	46995		MC
304953	100736448	20992781984	@qwx906995		FO
304953	100736448	20992781985	46992		MC
304953	100736448	20992781986	@qwx906992		FO
304953	100736448	20992781987	46991		MC
304953	100736448	20992781988	@qwx906991		FO
304953	100736448	20992781989	46990		MC
304953	100736448	20992781990	@qwx906990		FO
304953	100736448	20992781991	46989		MC
304953	100736448	20992781992	@qwx906989		FO
304953	100736448	20992781993	46993		MC
304953	100736448	20992781994	@qwx906993		FO
304953	100736448	20992781995	<h>		NULL
304953	100736448	20992781996	PSA	psa	NP1
304953	100736448	20992781997	<p>		NULL
304953	100736448	20992781998	The	the	AT
304953	100736448	20992781999	PSA	psa	NP1
304953	100736448	20992782000	test	test	NN1
304953	100736448	20992782001	is	be	VBZ
304953	100736448	20992782002	a	a	AT1
304953	100736448	20992782003	blood	blood	NN1
304953	100736448	20992782004	test	test	NN1
304953	100736448	20992782005	used	use	VMK
304953	100736448	20992782006	to	to	TO
304953	100736448	20992782007	detect	detect	VVI
304953	100736448	20992782008	prostate	prostate	NN1
304953	100736448	20992782009	cancer	cancer	NN1
304953	100736448	20992782010	.	.	.
304953	100736448	20992782011	Doctors	doctor	NN2
304953	100736448	20992782012	suspect	suspect	VV0
304953	100736448	20992782013	prostate	prostate	NN1
304953	100736448	20992782014	cancer	cancer	NN1
304953	100736448	20992782015	if	if	CS
304953	100736448	20992782016	the	the	AT
304953	100736448	20992782017	blood	blood	NN1
304953	100736448	20992782018	contains	contain	VVZ
304953	100736448	20992782019	high	high	JJ
304953	100736448	20992782020	levels	level	NN2
304953	100736448	20992782021	of	of	IO
304953	100736448	20992782022	a	a	AT1
304953	100736448	20992782023	protein	protein	NN1
304953	100736448	20992782024	called	call	VVN_VVD@
304953	100736448	20992782025	prostate-specific	prostate-specific	JJ
304953	100736448	20992782026	antigen	antigen	NN1
304953	100736448	20992782027	.	.	.
304953	100736448	20992782028	For	for	IF
304953	100736448	20992782029	men	man	NN2
304953	100736448	20992782030	who	who	PNQS
304953	100736448	20992782031	want	want	VV0
304953	100736448	20992782032	to	to	TO
304953	100736448	20992782033	be	be	VBI
304953	100736448	20992782034	screened	screen	VVN
304953	100736448	20992782035	for	for	IF
304953	100736448	20992782036	prostate	prostate	NN1
304953	100736448	20992782037	cancer	cancer	NN1
304953	100736448	20992782038	,	,	,
304953	100736448	20992782039	the	the	AT
304953	100736448	20992782040	test	test	NN1
304953	100736448	20992782041	is	be	VBZ
304953	100736448	20992782042	usually	usually	RR
304953	100736448	20992782043	done	do	VDN
304953	100736448	20992782044	every	every	AT1
304953	100736448	20992782045	year	year	NNT1
304953	100736448	20992782046	beginning	begin	VVG_NN1
304953	100736448	20992782047	between	between	II
304953	100736448	20992782048	ages	age	NN2
304953	100736448	20992782049	40	40	MC
304953	100736448	20992782050	and	and	CC
304953	100736448	20992782051	50	50	MC
304953	100736448	20992782052	,	,	,
304953	100736448	20992782053	depending	depending	II21
304953	100736448	20992782054	on	on	II22
304953	100736448	20992782055	individual	individual	JJ_NN1
304953	100736448	20992782056	risk	risk	NN1
304953	100736448	20992782057	factors	factor	NN2
304953	100736448	20992782058	.	.	.
304953	100736448	20992782059	<p>		NULL
304953	100736448	20992782060	PSA	psa	NP1
304953	100736448	20992782061	testing	test	VVG_NN1
304953	100736448	20992782062	to	to	TO
304953	100736448	20992782063	screen	screen	VVI
304953	100736448	20992782064	for	for	IF
304953	100736448	20992782065	prostate	prostate	NN1
304953	100736448	20992782066	cancer	cancer	NN1
304953	100736448	20992782067	might	might	VM
304953	100736448	20992782068	seem	seem	VVI
304953	100736448	20992782069	like	like	II
304953	100736448	20992782070	a	a	AT1
304953	100736448	20992782071	no-brainer	no-brainer	NN1_JJ
304953	100736448	20992782072	.	.	.
304953	100736448	20992782073	However	however	RR
304953	100736448	20992782074	,	,	,
304953	100736448	20992782075	the	the	AT
304953	100736448	20992782076	test	test	NN1
304953	100736448	20992782077	has	have	VHZ
304953	100736448	20992782078	become	become	VVN@
304953	100736448	20992782079	controversial	controversial	JJ
304953	100736448	20992782080	.	.	.
304953	100736448	20992782081	If	if	CS
304953	100736448	20992782082	a	a	AT1
304953	100736448	20992782083	man	man	NN1
304953	100736448	20992782084	's	's	GE_VBZ
304953	100736448	20992782085	PSA	psa	NP1
304953	100736448	20992782086	is	be	VBZ
304953	100736448	20992782087	elevated	elevate	VVN_JJ
304953	100736448	20992782088	,	,	,
304953	100736448	20992782089	he	he	PPHS1
304953	100736448	20992782090	'll	will	VM
304953	100736448	20992782091	likely	likely	RR@
304953	100736448	20992782092	undergo	undergo	VVI
304953	100736448	20992782093	a	a	AT1
304953	100736448	20992782094	biopsy	biopsy	NN1
304953	100736448	20992782095	and	and	CC
304953	100736448	20992782096	,	,	,
304953	100736448	20992782097	if	if	CS
304953	100736448	20992782098	cancer	cancer	NN1
304953	100736448	20992782099	is	be	VBZ
304953	100736448	20992782100	diagnosed	diagnose	VVN
304953	100736448	20992782101	,	,	,
304953	100736448	20992782102	invasive	invasive	JJ
304953	100736448	20992782103	treatment	treatment	NN1
304953	100736448	20992782104	.	.	.
304953	100736448	20992782105	But	but	CCB
304953	100736448	20992782106	because	because	CS
304953	100736448	20992782107	most	most	DAT
304953	100736448	20992782108	prostate	prostate	NN1
304953	100736448	20992782109	cancers	cancer	NN2
304953	100736448	20992782110	grow	grow	VV0
304953	100736448	20992782111	slowly	slowly	RR
304953	100736448	20992782112	,	,	,
304953	100736448	20992782113	they	they	PPHS2
304953	100736448	20992782114	are	be	VBR
304953	100736448	20992782115	n't	n't	XX
304953	100736448	20992782116	likely	likely	JJ_RR@
304953	100736448	20992782117	to	to	TO
304953	100736448	20992782118	affect	affect	VVI
304953	100736448	20992782119	the	the	AT
304953	100736448	20992782120	man	man	NN1
304953	100736448	20992782121	during	during	II
304953	100736448	20992782122	his	his	APPGE
304953	100736448	20992782123	lifetime	lifetime	NNT1
304953	100736448	20992782124	.	.	.
304953	100736448	20992782125	In	in	RR21
304953	100736448	20992782126	addition	addition	RR22
304953	100736448	20992782127	,	,	,
304953	100736448	20992782128	experts	expert	NN2
304953	100736448	20992782129	no	no	RR21
304953	100736448	20992782130	longer	long	RR22
304953	100736448	20992782131	recommend	recommend	VV0
304953	100736448	20992782132	routine	routine	NN1_JJ@
304953	100736448	20992782133	PSA	psa	NP1
304953	100736448	20992782134	screening	screening	NN1_VVG
304953	100736448	20992782135	for	for	IF
304953	100736448	20992782136	men	man	NN2
304953	100736448	20992782137	ages	age	VVZ@_NN2
304953	100736448	20992782138	75	75	MC
304953	100736448	20992782139	and	and	CC
304953	100736448	20992782140	older	old	JJR
304953	100736448	20992782141	because	because	CS
304953	100736448	20992782142	they	they	PPHS2
304953	100736448	20992782143	are	be	VBR
304953	100736448	20992782144	more	more	RGR
304953	100736448	20992782145	likely	likely	JJ
304953	100736448	20992782146	to	to	TO
304953	100736448	20992782147	die	die	VVI
304953	100736448	20992782148	from	from	II
304953	100736448	20992782149	another	another	DD1
304953	100736448	20992782150	condition	condition	NN1
304953	100736448	20992782151	than	than	CSN
304953	100736448	20992782152	from	from	II
304953	100736448	20992782153	undetected	undetected	JJ
304953	100736448	20992782154	prostate	prostate	NN1
304953	100736448	20992782155	cancer	cancer	NN1
304953	100736448	20992782156	.	.	.
304953	100736448	20992782157	<p>		NULL
304953	100736448	20992782158	I	i	PPIS1
304953	100736448	20992782159	had	have	VHD
304953	100736448	20992782160	brachytherapy	brachytherapy	NN1
304953	100736448	20992782161	to	to	TO
304953	100736448	20992782162	treat	treat	VVI
304953	100736448	20992782163	my	my	APPGE
304953	100736448	20992782164	prostate	prostate	NN1
304953	100736448	20992782165	@		II
304953	100736448	20992782166	@		II
304953	100736448	20992782167	@		II
304953	100736448	20992782168	@		II
304953	100736448	20992782169	@		II
304953	100736448	20992782170	@		II
304953	100736448	20992782171	@		II
304953	100736448	20992782172	@		II
304953	100736448	20992782173	@		II
304953	100736448	20992782174	@		II
304953	100736448	20992782175	But	but	CCB
304953	100736448	20992782176	six	six	MC
304953	100736448	20992782177	months	month	NNT2
304953	100736448	20992782178	ago	ago	RA
304953	100736448	20992782179	,	,	,
304953	100736448	20992782180	my	my	APPGE
304953	100736448	20992782181	PSA	psa	NP1
304953	100736448	20992782182	had	have	VHD
304953	100736448	20992782183	gone	go	VVN
304953	100736448	20992782184	up	up	RG21
304953	100736448	20992782185	to	to	RG22
304953	100736448	20992782186	0.5	0.5	MC
304953	100736448	20992782187	,	,	,
304953	100736448	20992782188	and	and	CC
304953	100736448	20992782189	now	now	RT
304953	100736448	20992782190	it	it	PPH1
304953	100736448	20992782191	's	be	VBZ
304953	100736448	20992782192	up	up	RG21
304953	100736448	20992782193	to	to	RG22
304953	100736448	20992782194	0.8	0.8	MC
304953	100736448	20992782195	ng/ml	ng/ml	FU
304953	100736448	20992782196	.	.	.
304953	100736448	20992782197	Im		VV0_NP1@_NN1
304953	100736448	20992782198	worried	worried	JJ_VVD@
304953	100736448	20992782199	that	that	CST
304953	100736448	20992782200	the	the	AT
304953	100736448	20992782201	cancer	cancer	NN1
304953	100736448	20992782202	is	be	VBZ
304953	100736448	20992782203	back	back	RP_NN1_JJ@
304953	100736448	20992782204	;	;	;
304953	100736448	20992782205	my	my	APPGE
304953	100736448	20992782206	doctor	doctor	NN1
304953	100736448	20992782207	said	say	VVD
304953	100736448	20992782208	it	it	PPH1
304953	100736448	20992782209	could	could	VM
304953	100736448	20992782210	be	be	VBI
304953	100736448	20992782211	a	a	AT1
304953	100736448	20992782212	"	"	"
304953	100736448	20992782213	PSA	psa	NP1
304953	100736448	20992782214	bounce	bounce	NN1_VV0
304953	100736448	20992782215	.	.	.
304953	100736448	20992782216	"	"	"
304953	100736448	20992782217	What 's		NN2
304953	100736448	20992782218	that	that	DD1
304953	100736448	20992782219	?	?	?
304953	100736449	20992782239	@@##	----------	----------
304953	100736449	20992782240	@@100736449		FO
304953	100736449	20992782241	@4936449/		VV0_NN1
304953	100736449	20992782242	46989		MC
304953	100736449	20992782243	@qwx906989		FO
304953	100736449	20992782244	<p>		NULL
304953	100736449	20992782245	By	by	II
304953	100736449	20992782246	examining	examine	VVG
304953	100736449	20992782247	DNA	dna	NN1
304953	100736449	20992782248	from	from	II
304953	100736449	20992782249	2,893		MC
304953	100736449	20992782250	men	man	NN2
304953	100736449	20992782251	with	with	IW
304953	100736449	20992782252	prostate	prostate	NN1
304953	100736449	20992782253	cancer	cancer	NN1
304953	100736449	20992782254	and	and	CC
304953	100736449	20992782255	1,781	1,781	MC
304953	100736449	20992782256	healthy	healthy	JJ
304953	100736449	20992782257	control	control	NN1
304953	100736449	20992782258	subjects	subject	NN2
304953	100736449	20992782259	,	,	,
304953	100736449	20992782260	all	all	DB_RR@
304953	100736449	20992782261	from	from	II
304953	100736449	20992782262	Sweden	sweden	NP1
304953	100736449	20992782263	,	,	,
304953	100736449	20992782264	scientists	scientist	NN2
304953	100736449	20992782265	have	have	VH0
304953	100736449	20992782266	found	find	VVN
304953	100736449	20992782267	five	five	MC
304953	100736449	20992782268	genetic	genetic	JJ
304953	100736449	20992782269	variations	variation	NN2
304953	100736449	20992782270	that	that	CST
304953	100736449	20992782271	dramatically	dramatically	RR
304953	100736449	20992782272	raise	raise	VV0
304953	100736449	20992782273	the	the	AT
304953	100736449	20992782274	risk	risk	NN1
304953	100736449	20992782275	of	of	IO
304953	100736449	20992782276	the	the	AT
304953	100736449	20992782277	disease	disease	NN1
304953	100736449	20992782278	.	.	.
304953	100736449	20992782279	When	when	CS
304953	100736449	20992782280	combined	combine	VVN
304953	100736449	20992782281	with	with	IW
304953	100736449	20992782282	family	family	NN1
304953	100736449	20992782283	history	history	NN1
304953	100736449	20992782284	,	,	,
304953	100736449	20992782285	they	they	PPHS2
304953	100736449	20992782286	accounted	account	VVD
304953	100736449	20992782287	for	for	IF
304953	100736449	20992782288	almost	almost	RR
304953	100736449	20992782289	half	half	DB
304953	100736449	20992782290	of	of	IO
304953	100736449	20992782291	all	all	DB
304953	100736449	20992782292	cases	case	NN2
304953	100736449	20992782293	of	of	IO
304953	100736449	20992782294	prostate	prostate	NN1
304953	100736449	20992782295	cancer	cancer	NN1
304953	100736449	20992782296	in	in	II
304953	100736449	20992782297	Swedish	swedish	JJ
304953	100736449	20992782298	men	man	NN2
304953	100736449	20992782299	.	.	.
304953	100736449	20992782300	<p>		NULL
304953	100736449	20992782301	On	on	II
304953	100736449	20992782302	their	their	APPGE
304953	100736449	20992782303	own	own	DA
304953	100736449	20992782304	,	,	,
304953	100736449	20992782305	none	none	PN
304953	100736449	20992782306	of	of	IO
304953	100736449	20992782307	the	the	AT
304953	100736449	20992782308	five	five	MC
304953	100736449	20992782309	did	do	VDD
304953	100736449	20992782310	much	much	DA1
304953	100736449	20992782311	to	to	TO
304953	100736449	20992782312	raise	raise	VVI
304953	100736449	20992782313	prostate	prostate	NN1
304953	100736449	20992782314	cancer	cancer	NN1
304953	100736449	20992782315	risk	risk	NN1
304953	100736449	20992782316	.	.	.
304953	100736449	20992782317	However	however	RR
304953	100736449	20992782318	,	,	,
304953	100736449	20992782319	combinations	combination	NN2
304953	100736449	20992782320	of	of	IO
304953	100736449	20992782321	them	them	PPHO2
304953	100736449	20992782322	did	do	VDD
304953	100736449	20992782323	.	.	.
304953	100736449	20992782324	Men	man	NN2
304953	100736449	20992782325	with	with	IW
304953	100736449	20992782326	four	four	MC
304953	100736449	20992782327	of	of	IO
304953	100736449	20992782328	the	the	AT
304953	100736449	20992782329	five	five	MC
304953	100736449	20992782330	genetic	genetic	JJ
304953	100736449	20992782331	variants	variant	NN2
304953	100736449	20992782332	were	be	VBDR
304953	100736449	20992782333	more	more	DAR
304953	100736449	20992782334	than	than	CSN
304953	100736449	20992782335	four	four	MC
304953	100736449	20992782336	times	time	NNT2
304953	100736449	20992782337	as	as	RG
304953	100736449	20992782338	likely	likely	JJ
304953	100736449	20992782339	to	to	TO
304953	100736449	20992782340	develop	develop	VVI
304953	100736449	20992782341	prostate	prostate	NN1
304953	100736449	20992782342	cancer	cancer	NN1
304953	100736449	20992782343	than	than	CSN
304953	100736449	20992782344	those	those	DD2
304953	100736449	20992782345	with	with	IW
304953	100736449	20992782346	none	none	PN
304953	100736449	20992782347	of	of	IO
304953	100736449	20992782348	the	the	AT
304953	100736449	20992782349	markers	marker	NN2
304953	100736449	20992782350	.	.	.
304953	100736449	20992782351	Men	man	NN2
304953	100736449	20992782352	with	with	IW
304953	100736449	20992782353	at	at	RR21
304953	100736449	20992782354	least	least	RR22
304953	100736449	20992782355	four	four	MC
304953	100736449	20992782356	of	of	IO
304953	100736449	20992782357	the	the	AT
304953	100736449	20992782358	five	five	MC
304953	100736449	20992782359	markers	marker	NN2
304953	100736449	20992782360	and	and	CC
304953	100736449	20992782361	a	a	AT1
304953	100736449	20992782362	family	family	NN1
304953	100736449	20992782363	history	history	NN1
304953	100736449	20992782364	of	of	IO
304953	100736449	20992782365	the	the	AT
304953	100736449	20992782366	disease	disease	NN1
304953	100736449	20992782367	were	be	VBDR
304953	100736449	20992782368	more	more	DAR
304953	100736449	20992782369	than	than	CSN
304953	100736449	20992782370	nine	nine	MC
304953	100736449	20992782371	times	time	NNT2
304953	100736449	20992782372	as	as	RG
304953	100736449	20992782373	likely	likely	JJ
304953	100736449	20992782374	to	to	TO
304953	100736449	20992782375	develop	develop	VVI
304953	100736449	20992782376	the	the	AT
304953	100736449	20992782377	disease	disease	NN1
304953	100736449	20992782378	.	.	.
304953	100736449	20992782379	<p>		NULL
304953	100736449	20992782380	Interestingly	interestingly	RR
304953	100736449	20992782381	,	,	,
304953	100736449	20992782382	the	the	AT
304953	100736449	20992782383	combination	combination	NN1
304953	100736449	20992782384	of	of	IO
304953	100736449	20992782385	genetic	genetic	JJ
304953	100736449	20992782386	variants	variant	NN2
304953	100736449	20992782387	did	do	VDD
304953	100736449	20992782388	not	not	XX
304953	100736449	20992782389	correlate	correlate	VVI
304953	100736449	20992782390	with	with	IW
304953	100736449	20992782391	levels	level	NN2
304953	100736449	20992782392	of	of	IO
304953	100736449	20992782393	prostate-specific	prostate-specific	JJ
304953	100736449	20992782394	antigen	antigen	NN1
304953	100736449	20992782395	(	(	(
304953	100736449	20992782396	PSA	psa	NP1
304953	100736449	20992782397	)	)	)
304953	100736449	20992782398	,	,	,
304953	100736449	20992782399	the	the	AT
304953	100736449	20992782400	substance	substance	NN1
304953	100736449	20992782401	measured	measure	VVN_VVD
304953	100736449	20992782402	during	during	II
304953	100736449	20992782403	current	current	JJ
304953	100736449	20992782404	screening	screening	NN1
304953	100736449	20992782405	tests	test	NN2_VVZ@
304953	100736449	20992782406	for	for	IF
304953	100736449	20992782407	prostate	prostate	NN1
304953	100736449	20992782408	cancer	cancer	NN1
304953	100736449	20992782409	.	.	.
304953	100736449	20992782410	Nor	nor	CC
304953	100736449	20992782411	did	do	VDD
304953	100736449	20992782412	they	they	PPHS2
304953	100736449	20992782413	have	have	VHI
304953	100736449	20992782414	anything	anything	PN1
304953	100736449	20992782415	to	to	TO
304953	100736449	20992782416	do	do	VDI
304953	100736449	20992782417	with	with	IW
304953	100736449	20992782418	the	the	AT
304953	100736449	20992782419	aggressiveness	aggressiveness	NN1
304953	100736449	20992782420	of	of	IO
304953	100736449	20992782421	the	the	AT
304953	100736449	20992782422	cancer	cancer	NN1
304953	100736449	20992782423	.	.	.
304953	100736449	20992782424	But	but	CCB
304953	100736449	20992782425	if	if	CS
304953	100736449	20992782426	the	the	AT
304953	100736449	20992782427	findings	finding	NN2
304953	100736449	20992782428	can	can	VM
304953	100736449	20992782429	be	be	VBI
304953	100736449	20992782430	replicated	replicate	VVN
304953	100736449	20992782431	@		II
304953	100736449	20992782432	@		II
304953	100736449	20992782433	@		II
304953	100736449	20992782434	@		II
304953	100736449	20992782435	@		II
304953	100736449	20992782436	@		II
304953	100736449	20992782437	@		II
304953	100736449	20992782438	@		II
304953	100736449	20992782439	@		II
304953	100736449	20992782440	@		II
304953	100736449	20992782441	blood	blood	NN1
304953	100736449	20992782442	test	test	NN1_VV0
304953	100736449	20992782443	to	to	TO
304953	100736449	20992782444	predict	predict	VVI
304953	100736449	20992782445	who	who	PNQS
304953	100736449	20992782446	might	might	VM
304953	100736449	20992782447	develop	develop	VVI
304953	100736449	20992782448	the	the	AT
304953	100736449	20992782449	disease	disease	NN1
304953	100736449	20992782450	.	.	.
304953	100736449	20992782451	46996		MC
304953	100736449	20992782452	@qwx906996		FO
304953	100736450	20992782472	@@##	----------	----------
304953	100736450	20992782473	@@100736450		FO
304953	100736450	20992782474	@4936450/		VV0_NN1
304953	100736450	20992782475	46989		MC
304953	100736450	20992782476	@qwx906989		FO
304953	100736450	20992782477	<h>		NULL
304953	100736450	20992782478	Understanding	understand	VVG_NN1
304953	100736450	20992782479	PSA	psa	NP1
304953	100736450	20992782480	<p>		NULL
304953	100736450	20992782481	Knowing	know	VVG
304953	100736450	20992782482	your	your	APPGE
304953	100736450	20992782483	previous	previous	JJ
304953	100736450	20992782484	PSA	psa	NP1
304953	100736450	20992782485	levels	level	NN2
304953	100736450	20992782486	is	be	VBZ
304953	100736450	20992782487	helpful	helpful	JJ
304953	100736450	20992782488	,	,	,
304953	100736450	20992782489	but	but	CCB
304953	100736450	20992782490	not	not	XX
304953	100736450	20992782491	necessary	necessary	JJ
304953	100736450	20992782492	.	.	.
304953	100736450	20992782493	Nonetheless	nonetheless	RR
304953	100736450	20992782494	,	,	,
304953	100736450	20992782495	your	your	APPGE
304953	100736450	20992782496	PSA	psa	NP1
304953	100736450	20992782497	level	level	NN1
304953	100736450	20992782498	is	be	VBZ
304953	100736450	20992782499	mildly	mildly	RR
304953	100736450	20992782500	elevated	elevate	VVN_VVD_JJ
304953	100736450	20992782501	.	.	.
304953	100736450	20992782502	Follow-up	follow-up	NN1
304953	100736450	20992782503	is	be	VBZ
304953	100736450	20992782504	needed	need	VVN
304953	100736450	20992782505	.	.	.
304953	100736450	20992782506	Keep	keep	VV0
304953	100736450	20992782507	in	in	II_RP@
304953	100736450	20992782508	mind	mind	NN1
304953	100736450	20992782509	that	that	CST
304953	100736450	20992782510	your	your	APPGE
304953	100736450	20992782511	risk	risk	NN1
304953	100736450	20992782512	of	of	IO
304953	100736450	20992782513	prostate	prostate	NN1
304953	100736450	20992782514	cancer	cancer	NN1
304953	100736450	20992782515	is	be	VBZ
304953	100736450	20992782516	still	still	RR
304953	100736450	20992782517	less	less	DAR
304953	100736450	20992782518	than	than	CSN
304953	100736450	20992782519	40	40	MC
304953	100736450	20992782520	percent	percent	NNU
304953	100736450	20992782521	.	.	.
304953	100736450	20992782522	<p>		NULL
304953	100736450	20992782523	Your	your	APPGE
304953	100736450	20992782524	options	option	NN2
304953	100736450	20992782525	include	include	VV0
304953	100736450	20992782526	<p>		NULL
304953	100736450	20992782527	referral	referral	NN1
304953	100736450	20992782528	to	to	II
304953	100736450	20992782529	a	a	AT1
304953	100736450	20992782530	urologist	urologist	NN1
304953	100736450	20992782531	(	(	(
304953	100736450	20992782532	prostate	prostate	NN1
304953	100736450	20992782533	specialist	specialist	NN1
304953	100736450	20992782534	)	)	)
304953	100736450	20992782535	<p>		NULL
304953	100736450	20992782536	repeat	repeat	VV0
304953	100736450	20992782537	PSA	psa	NP1
304953	100736450	20992782538	testing	testing	NN1_VVG
304953	100736450	20992782539	in	in	II
304953	100736450	20992782540	several	several	DA2
304953	100736450	20992782541	months	month	NNT2
304953	100736450	20992782542	<p>		NULL
304953	100736450	20992782543	measuring	measure	VVG
304953	100736450	20992782544	your	your	APPGE
304953	100736450	20992782545	"	"	"
304953	100736450	20992782546	free	free	JJ
304953	100736450	20992782547	"	"	"
304953	100736450	20992782548	PSA	psa	NP1
304953	100736450	20992782549	level	level	VV0@_NN1
304953	100736450	20992782550	This	this	DD1
304953	100736450	20992782551	special	special	JJ
304953	100736450	20992782552	way	way	NN1
304953	100736450	20992782553	of	of	IO
304953	100736450	20992782554	testing	test	VVG
304953	100736450	20992782555	your	your	APPGE
304953	100736450	20992782556	PSA	psa	NP1
304953	100736450	20992782557	level	level	NN1
304953	100736450	20992782558	may	may	VM
304953	100736450	20992782559	help	help	VVI
304953	100736450	20992782560	to	to	TO
304953	100736450	20992782561	decide	decide	VVI
304953	100736450	20992782562	if	if	CSW@_CS
304953	100736450	20992782563	a	a	AT1
304953	100736450	20992782564	biopsy	biopsy	NN1
304953	100736450	20992782565	is	be	VBZ
304953	100736450	20992782566	needed	need	VVN
304953	100736450	20992782567	.	.	.
304953	100736450	20992782568	High	high	JJ
304953	100736450	20992782569	levels	level	NN2
304953	100736450	20992782570	of	of	IO
304953	100736450	20992782571	free	free	JJ
304953	100736450	20992782572	PSA	psa	NP1
304953	100736450	20992782573	are	be	VBR
304953	100736450	20992782574	reassuring	reassure	VVG_JJ
304953	100736450	20992782575	,	,	,
304953	100736450	20992782576	while	while	CS
304953	100736450	20992782577	low	low	JJ
304953	100736450	20992782578	levels	level	NN2
304953	100736450	20992782579	are	be	VBR
304953	100736450	20992782580	worrisome	worrisome	JJ
304953	100736450	20992782581	for	for	IF
304953	100736450	20992782582	cancer	cancer	NN1
304953	100736450	20992782583	.	.	.
304953	100736450	20992782584	46996		MC
304953	100736450	20992782585	@qwx906996		FO
304953	100736451	20992782605	@@##	----------	----------
304953	100736451	20992782606	@@100736451		FO
304953	100736451	20992782607	@4936451/		NN1_VV0
304953	100736451	20992782608	<p>		NULL
304953	100736451	20992782609	An	a	AT1
304953	100736451	20992782610	experimental	experimental	JJ
304953	100736451	20992782611	drug	drug	NN1
304953	100736451	20992782612	may	may	VM
304953	100736451	20992782613	halt	halt	VVI
304953	100736451	20992782614	the	the	AT
304953	100736451	20992782615	production	production	NN1
304953	100736451	20992782616	of	of	IO
304953	100736451	20992782617	male	male	JJ_NN1
304953	100736451	20992782618	hormones	hormone	NN2
304953	100736451	20992782619	in	in	II
304953	100736451	20992782620	the	the	AT
304953	100736451	20992782621	body	body	NN1
304953	100736451	20992782622	,	,	,
304953	100736451	20992782623	making	make	VVG
304953	100736451	20992782624	it	it	PPH1
304953	100736451	20992782625	a	a	AT1
304953	100736451	20992782626	promising	promising	JJ
304953	100736451	20992782627	treatment	treatment	NN1
304953	100736451	20992782628	for	for	IF
304953	100736451	20992782629	prostate	prostate	NN1
304953	100736451	20992782630	cancer	cancer	NN1
304953	100736451	20992782631	patients	patient	NN2
304953	100736451	20992782632	whose	whose	DDQGE
304953	100736451	20992782633	tumors	tumor	NN2
304953	100736451	20992782634	have	have	VH0
304953	100736451	20992782635	not	not	XX
304953	100736451	20992782636	responded	respond	VVN
304953	100736451	20992782637	to	to	II
304953	100736451	20992782638	other	other	JJ
304953	100736451	20992782639	therapies	therapy	NN2
304953	100736451	20992782640	.	.	.
304953	100736451	20992782641	Preliminary	preliminary	JJ
304953	100736451	20992782642	studies	study	NN2
304953	100736451	20992782643	showed	show	VVD
304953	100736451	20992782644	shrinking	shrinking	JJ_VVG
304953	100736451	20992782645	tumors	tumor	NN2
304953	100736451	20992782646	and	and	CC
304953	100736451	20992782647	drops	drop	VVZ_NN2
304953	100736451	20992782648	in	in	II
304953	100736451	20992782649	PSA	psa	NP1
304953	100736451	20992782650	levels	level	NN2
304953	100736451	20992782651	.	.	.
304953	100736451	20992782652	<p>		NULL
304953	100736451	20992782653	A	a	AT1_ZZ1
304953	100736451	20992782654	new	new	JJ
304953	100736451	20992782655	prostate	prostate	NN1
304953	100736451	20992782656	cancer	cancer	NN1
304953	100736451	20992782657	vaccine	vaccine	NN1
304953	100736451	20992782658	may	may	VM
304953	100736451	20992782659	give	give	VVI
304953	100736451	20992782660	hope	hope	NN1_VV0
304953	100736451	20992782661	to	to	II
304953	100736451	20992782662	men	man	NN2
304953	100736451	20992782663	with	with	IW
304953	100736451	20992782664	metastatic	metastatic	JJ
304953	100736451	20992782665	prostate	prostate	NN1
304953	100736451	20992782666	cancer	cancer	NN1
304953	100736451	20992782667	by	by	II
304953	100736451	20992782668	spurring	spur	VVG
304953	100736451	20992782669	their	their	APPGE
304953	100736451	20992782670	immune	immune	JJ
304953	100736451	20992782671	systems	system	NN2
304953	100736451	20992782672	to	to	TO
304953	100736451	20992782673	fight	fight	VVI
304953	100736451	20992782674	the	the	AT
304953	100736451	20992782675	disease	disease	NN1
304953	100736451	20992782676	,	,	,
304953	100736451	20992782677	according	according	II21
304953	100736451	20992782678	to	to	II22
304953	100736451	20992782679	a	a	AT1
304953	100736451	20992782680	presentation	presentation	NN1
304953	100736451	20992782681	by	by	II
304953	100736451	20992782682	Iowa	iowa	NP1
304953	100736451	20992782683	researchers	researcher	NN2
304953	100736451	20992782684	at	at	II
304953	100736451	20992782685	the	the	AT
304953	100736451	20992782686	American	american	JJ
304953	100736451	20992782687	Urological	urological	JJ
304953	100736451	20992782688	Associations	association	NN2
304953	100736451	20992782689	annual	annual	JJ
304953	100736451	20992782690	meeting	meeting	NN1
304953	100736451	20992782691	in	in	II
304953	100736451	20992782692	May	may	NPM1
304953	100736451	20992782693	2008	2008	MC
304953	100736451	20992782694	.	.	.
304953	100736451	20992782695	Enabling	enable	VVG
304953	100736451	20992782696	a	a	AT1
304953	100736451	20992782697	patients	patient	NN2
304953	100736451	20992782698	immune	immune	JJ
304953	100736451	20992782699	system	system	NN1
304953	100736451	20992782700	to	to	TO
304953	100736451	20992782701	attack	attack	VVI
304953	100736451	20992782702	cancer	cancer	NN1
304953	100736451	20992782703	cells	cell	NN2
304953	100736451	20992782704	can	can	VM
304953	100736451	20992782705	improve	improve	VVI
304953	100736451	20992782706	quality	quality	NN1
304953	100736451	20992782707	of	of	IO
304953	100736451	20992782708	life	life	NN1
304953	100736451	20992782709	and	and	CC
304953	100736451	20992782710	extend	extend	VVI
304953	100736451	20992782711	survival	survival	NN1
304953	100736451	20992782712	.	.	.
304953	100736451	20992782713	<p>		NULL
304953	100736451	20992782714	Research	research	NN1
304953	100736451	20992782715	shows	show	VVZ_NN2
304953	100736451	20992782716	that	that	CST
304953	100736451	20992782717	combining	combine	VVG
304953	100736451	20992782718	the	the	AT
304953	100736451	20992782719	anti-inflammatory	anti-inflammatory	JJ
304953	100736451	20992782720	drug	drug	NN1
304953	100736451	20992782721	celecoxib	celecoxib	NN1
304953	100736451	20992782722	(	(	(
304953	100736451	20992782723	Celebrex	celebrex	NP1
304953	100736451	20992782724	)	)	)
304953	100736451	20992782725	and	and	CC
304953	100736451	20992782726	the	the	AT
304953	100736451	20992782727	cholesterol-lowering	cholesterol-lowering	JJ_NN1
304953	100736451	20992782728	statin	statin	NN1
304953	100736451	20992782729	drug	drug	NN1
304953	100736451	20992782730	atorvastatin	atorvastatin	NN1
304953	100736451	20992782731	(	(	(
304953	100736451	20992782732	Lipitor	lipitor	NP1
304953	100736451	20992782733	)	)	)
304953	100736451	20992782734	halted	halt	VVD
304953	100736451	20992782735	the	the	AT
304953	100736451	20992782736	progression	progression	NN1
304953	100736451	20992782737	of	of	IO
304953	100736451	20992782738	prostate	prostate	NN1
304953	100736451	20992782739	tumors	tumor	NN2
304953	100736451	20992782740	in	in	II
304953	100736451	20992782741	mice	mouse	NN2
304953	100736451	20992782742	.	.	.
304953	100736451	20992782743	Investigators	investigator	NN2
304953	100736451	20992782744	are	be	VBR
304953	100736451	20992782745	now	now	RT
304953	100736451	20992782746	planning	plan	VVG
304953	100736451	20992782747	to	to	TO
304953	100736451	20992782748	test	test	VVI
304953	100736451	20992782749	the	the	AT
304953	100736451	20992782750	combo	combo	NN1
304953	100736451	20992782751	in	in	II
304953	100736451	20992782752	prostate	prostate	NN1
304953	100736451	20992782753	cancer	cancer	NN1
304953	100736451	20992782754	patients	patient	NN2
304953	100736451	20992782755	.	.	.
304953	100736452	20992782775	@@##	----------	----------
304953	100736452	20992782776	@@100736452		FO
304953	100736452	20992782777	@4936452/		VV0_NN1
304953	100736452	20992782778	46989		MC
304953	100736452	20992782779	@qwx906989		FO
304953	100736452	20992782780	<h>		NULL
304953	100736452	20992782781	Posts	post	NN2
304953	100736452	20992782782	Tagged	tag	VVD_VVN
304953	100736452	20992782783	news	news	NN1
304953	100736452	20992782784	<p>		NULL
304953	100736452	20992782785	Sixty-five-year-old	sixty-five-year-old	JJ
304953	100736452	20992782786	George	george	NP1
304953	100736452	20992782787	Lincoln*		FO
304953	100736452	20992782788	never	never	RR
304953	100736452	20992782789	suspected	suspect	VVN_VVD
304953	100736452	20992782790	that	that	CST_DD1
304953	100736452	20992782791	anything	anything	PN1
304953	100736452	20992782792	was	be	VBDZ
304953	100736452	20992782793	wrong	wrong	JJ_RR@
304953	100736452	20992782794	.	.	.
304953	100736452	20992782795	Aside	aside	II21
304953	100736452	20992782796	from	from	II22
304953	100736452	20992782797	some	some	DD
304953	100736452	20992782798	of	of	IO
304953	100736452	20992782799	the	the	AT
304953	100736452	20992782800	typical	typical	JJ
304953	100736452	20992782801	side	side	NN1
304953	100736452	20992782802	effects	effect	NN2
304953	100736452	20992782803	of	of	IO
304953	100736452	20992782804	hormone	hormone	NN1
304953	100736452	20992782805	therapy	therapy	NN1
304953	100736452	20992782806	for	for	IF
304953	100736452	20992782807	his	his	APPGE
304953	100736452	20992782808	prostate	prostate	NN1
304953	100736452	20992782809	cancer	cancer	NN1
304953	100736452	20992782810	,	,	,
304953	100736452	20992782811	such	such	II21
304953	100736452	20992782812	as	as	II22
304953	100736452	20992782813	fatigue	fatigue	NN1
304953	100736452	20992782814	,	,	,
304953	100736452	20992782815	occasional	occasional	JJ
304953	100736452	20992782816	hot	hot	JJ
304953	100736452	20992782817	flashes	flash	NN2
304953	100736452	20992782818	,	,	,
304953	100736452	20992782819	mild	mild	JJ
304953	100736452	20992782820	weight	weight	NN1
304953	100736452	20992782821	gain	gain	NN1_VV0
304953	100736452	20992782822	,	,	,
304953	100736452	20992782823	and	and	CC
304953	100736452	20992782824	a	a	AT1
304953	100736452	20992782825	loss	loss	NN1
304953	100736452	20992782826	of	of	IO
304953	100736452	20992782827	libido	libido	NN1
304953	100736452	20992782828	,	,	,
304953	100736452	20992782829	he	he	PPHS1
304953	100736452	20992782830	felt	feel	VVD
304953	100736452	20992782831	okay	okay	JJ
304953	100736452	20992782832	.	.	.
304953	100736452	20992782833	He	he	PPHS1
304953	100736452	20992782834	did	do	VDD
304953	100736452	20992782835	n't 	n't	XX
304953	100736452	20992782836	have	have	VHI
304953	100736452	20992782837	abdominal	abdominal	JJ
304953	100736452	20992782838	pain	pain	NN1
304953	100736452	20992782839	,	,	,
304953	100736452	20992782840	nausea	nausea	NN1
304953	100736452	20992782841	,	,	,
304953	100736452	20992782842	jaundice	jaundice	NN1
304953	100736452	20992782843	,	,	,
304953	100736452	20992782844	or	or	CC
304953	100736452	20992782845	any	any	DD
304953	100736452	20992782846	other	other	JJ
304953	100736452	20992782847	symptoms	symptom	NN2
304953	100736452	20992782848	that	that	CST_DD1
304953	100736452	20992782849	might	might	VM
304953	100736452	20992782850	indicate	indicate	VVI
304953	100736452	20992782851	a	a	AT1
304953	100736452	20992782852	potentially	potentially	RR
304953	100736452	20992782853	life-threatening	life-threatening	JJ
304953	100736452	20992782854	problem	problem	NN1
304953	100736452	20992782855	.	.	.
304953	100736452	20992782856	<p>		NULL
304953	100736452	20992782857	As	as	CSA
304953	100736452	20992782858	men	man	NN2
304953	100736452	20992782859	age	age	NN1_VV0@
304953	100736452	20992782860	,	,	,
304953	100736452	20992782861	their	their	APPGE
304953	100736452	20992782862	testosterone	testosterone	NN1
304953	100736452	20992782863	production	production	NN1
304953	100736452	20992782864	begins	begin	VVZ
304953	100736452	20992782865	to	to	TO
304953	100736452	20992782866	slow	slow	VVI
304953	100736452	20992782867	.	.	.
304953	100736452	20992782868	As	as	CSA
304953	100736452	20992782869	men	man	NN2
304953	100736452	20992782870	get	get	VV0
304953	100736452	20992782871	into	into	II
304953	100736452	20992782872	their	their	APPGE
304953	100736452	20992782873	50s	50s	MC2
304953	100736452	20992782874	,	,	,
304953	100736452	20992782875	60s	60s	MC2
304953	100736452	20992782876	,	,	,
304953	100736452	20992782877	and	and	CC
304953	100736452	20992782878	beyond	beyond	RL@
304953	100736452	20992782879	,	,	,
304953	100736452	20992782880	they	they	PPHS2
304953	100736452	20992782881	may	may	VM
304953	100736452	20992782882	start	start	VVI
304953	100736452	20992782883	to	to	TO
304953	100736452	20992782884	have	have	VHI
304953	100736452	20992782885	signs	sign	NN2
304953	100736452	20992782886	and	and	CC
304953	100736452	20992782887	symptoms	symptom	NN2
304953	100736452	20992782888	of	of	IO
304953	100736452	20992782889	low	low	JJ
304953	100736452	20992782890	testosterone	testosterone	NN1
304953	100736452	20992782891	including	including	II
304953	100736452	20992782892	reduced	reduced	JJ@
304953	100736452	20992782893	sex	sex	NN1
304953	100736452	20992782894	drive	drive	NN1
304953	100736452	20992782895	and	and	CC
304953	100736452	20992782896	sense	sense	NN1
304953	100736452	20992782897	of	of	IO
304953	100736452	20992782898	vitality	vitality	NN1
304953	100736452	20992782899	,	,	,
304953	100736452	20992782900	erectile	erectile	JJ
304953	100736452	20992782901	dysfunction	dysfunction	NN1
304953	100736452	20992782902	,	,	,
304953	100736452	20992782903	decreased	decrease	VVD_JJ@_VVN
304953	100736452	20992782904	energy	energy	NN1
304953	100736452	20992782905	,	,	,
304953	100736452	20992782906	lower	low	JJR
304953	100736452	20992782907	muscle	muscle	NN1
304953	100736452	20992782908	mass	mass	NN1
304953	100736452	20992782909	and	and	CC
304953	100736452	20992782910	bone	bone	NN1
304953	100736452	20992782911	density	density	NN1
304953	100736452	20992782912	,	,	,
304953	100736452	20992782913	and	and	CC
304953	100736452	20992782914	anemia	anemia	NN1
304953	100736452	20992782915	.	.	.
304953	100736452	20992782916	In	in	II
304953	100736452	20992782917	some	some	DD
304953	100736452	20992782918	cases	case	NN2
304953	100736452	20992782919	,	,	,
304953	100736452	20992782920	supplemental	supplemental	JJ
304953	100736452	20992782921	testosterone	testosterone	NN1
304953	100736452	20992782922	may	may	VM
304953	100736452	20992782923	help	help	VVI
304953	100736452	20992782924	.	.	.
304953	100736452	20992782925	However	however	RR
304953	100736452	20992782926	,	,	,
304953	100736452	20992782927	doctors	doctor	NN2
304953	100736452	20992782928	disagree	disagree	VV0
304953	100736452	20992782929	over	over	RP_II
304953	100736452	20992782930	the	the	AT
304953	100736452	20992782931	wisdom	wisdom	NN1
304953	100736452	20992782932	of	of	IO
304953	100736452	20992782933	prescribing	prescribe	VVG
304953	100736452	20992782934	testosterone	testosterone	NN1
304953	100736452	20992782935	to	to	II
304953	100736452	20992782936	prostate	prostate	NN1
304953	100736452	20992782937	cancer	cancer	NN1
304953	100736452	20992782938	survivors	survivor	NN2
304953	100736452	20992782939	.	.	.
304953	100736452	20992782940	<p>		NULL
304953	100736452	20992782941	Today	today	RT
304953	100736452	20992782942	,	,	,
304953	100736452	20992782943	about	about	RG
304953	100736452	20992782944	10%		NNU
304953	100736452	20992782945	to	to	II
304953	100736452	20992782946	20%		NNU
304953	100736452	20992782947	of	of	IO
304953	100736452	20992782948	patients	patient	NN2
304953	100736452	20992782949	who	who	PNQS
304953	100736452	20992782950	have	have	VH0
304953	100736452	20992782951	their	their	APPGE
304953	100736452	20992782952	prostate	prostate	NN1
304953	100736452	20992782953	surgically	surgically	RR
304953	100736452	20992782954	removed	remove	VVN
304953	100736452	20992782955	are	be	VBR
304953	100736452	20992782956	told	tell	VVN
304953	100736452	20992782957	that	that	CST
304953	100736452	20992782958	they	they	PPHS2
304953	100736452	20992782959	have	have	VH0
304953	100736452	20992782960	positive	positive	JJ
304953	100736452	20992782961	surgical	surgical	JJ
304953	100736452	20992782962	margins	margin	NN2
304953	100736452	20992782963	,	,	,
304953	100736452	20992782964	meaning	mean	VVG
304953	100736452	20992782965	some	some	DD
304953	100736452	20992782966	cancer	cancer	NN1
304953	100736452	20992782967	@		II
304953	100736452	20992782968	@		II
304953	100736452	20992782969	@		II
304953	100736452	20992782970	@		II
304953	100736452	20992782971	@		II
304953	100736452	20992782972	@		II
304953	100736452	20992782973	@		II
304953	100736452	20992782974	@		II
304953	100736452	20992782975	@		II
304953	100736452	20992782976	@		II
304953	100736452	20992782977	discussion	discussion	NN1
304953	100736452	20992782978	,	,	,
304953	100736452	20992782979	three	three	MC
304953	100736452	20992782980	Harvard	harvard	NP1
304953	100736452	20992782981	physicians	physician	NN2
304953	100736452	20992782982	discuss	discuss	VV0
304953	100736452	20992782983	positive	positive	JJ
304953	100736452	20992782984	surgical	surgical	JJ
304953	100736452	20992782985	margins	margin	NN2
304953	100736452	20992782986	what	what	DDQ
304953	100736452	20992782987	patients	patient	NN2
304953	100736452	20992782988	with	with	IW
304953	100736452	20992782989	positive	positive	JJ
304953	100736452	20992782990	margins	margin	NN2
304953	100736452	20992782991	should	should	VM
304953	100736452	20992782992	consider	consider	VVI
304953	100736452	20992782993	next	next	MD
304953	100736452	20992782994	.	.	.
304953	100736452	20992782995	<p>		NULL
304953	100736452	20992782996	Knowing	know	VVG
304953	100736452	20992782997	the	the	AT
304953	100736452	20992782998	basics	basics	NN2
304953	100736452	20992782999	of	of	IO
304953	100736452	20992783000	scientific	scientific	JJ
304953	100736452	20992783001	research	research	NN1
304953	100736452	20992783002	and	and	CC
304953	100736452	20992783003	statistics	statistics	NN
304953	100736452	20992783004	can	can	VM
304953	100736452	20992783005	help	help	VVI
304953	100736452	20992783006	you	you	PPY
304953	100736452	20992783007	understand	understand	VVI
304953	100736452	20992783008	what	what	DDQ
304953	100736452	20992783009	medical	medical	JJ
304953	100736452	20992783010	studies	study	NN2
304953	100736452	20992783011	really	really	RR
304953	100736452	20992783012	say	say	VV0
304953	100736452	20992783013	<p>		NULL
304953	100736452	20992783014	In	in	II
304953	100736452	20992783015	the	the	AT
304953	100736452	20992783016	late	late	JJ
304953	100736452	20992783017	1990s	1990s	MC2
304953	100736452	20992783018	,	,	,
304953	100736452	20992783019	word	word	NN1_VV0%
304953	100736452	20992783020	that	that	CST_DD1
304953	100736452	20992783021	selenium	selenium	NN1
304953	100736452	20992783022	and	and	CC
304953	100736452	20992783023	vitamin	vitamin	NN1
304953	100736452	20992783024	E	e	ZZ1
304953	100736452	20992783025	might	might	VM
304953	100736452	20992783026	lower	lower	VVI
304953	100736452	20992783027	the	the	AT
304953	100736452	20992783028	risk	risk	NN1
304953	100736452	20992783029	of	of	IO
304953	100736452	20992783030	prostate	prostate	NN1
304953	100736452	20992783031	cancer	cancer	NN1
304953	100736452	20992783032	was	be	VBDZ
304953	100736452	20992783033	reported	report	VVN
304953	100736452	20992783034	by	by	II
304953	100736452	20992783035	newspapers	newspaper	NN2
304953	100736452	20992783036	and	and	CC
304953	100736452	20992783037	magazines	magazine	NN2
304953	100736452	20992783038	,	,	,
304953	100736452	20992783039	broadcast	broadcast	VVN_VV0
304953	100736452	20992783040	on	on	II
304953	100736452	20992783041	television	television	NN1
304953	100736452	20992783042	and	and	CC
304953	100736452	20992783043	radio	radio	NN1
304953	100736452	20992783044	,	,	,
304953	100736452	20992783045	and	and	CC
304953	100736452	20992783046	announced	announce	VVN_VVD
304953	100736452	20992783047	on	on	II
304953	100736452	20992783048	Web	web	NN1
304953	100736452	20992783049	sites	site	NN2
304953	100736452	20992783050	.	.	.
304953	100736452	20992783051	Eager	eager	JJ
304953	100736452	20992783052	to	to	TO
304953	100736452	20992783053	prevent	prevent	VVI
304953	100736452	20992783054	the	the	AT
304953	100736452	20992783055	disease	disease	NN1
304953	100736452	20992783056	and	and	CC
304953	100736452	20992783057	convinced	convinced	JJ_VVD@
304953	100736452	20992783058	that	that	CST
304953	100736452	20992783059	vitamins	vitamin	NN2
304953	100736452	20992783060	and	and	CC
304953	100736452	20992783061	minerals	mineral	NN2
304953	100736452	20992783062	couldnt		NN1
304953	100736452	20992783063	be	be	VBI
304953	100736452	20992783064	harmful	harmful	JJ
304953	100736452	20992783065	men	man	NN2
304953	100736452	20992783066	around	around	II
304953	100736452	20992783067	the	the	AT
304953	100736452	20992783068	world	world	NN1
304953	100736452	20992783069	began	begin	VVD
304953	100736452	20992783070	taking	take	VVG
304953	100736452	20992783071	the	the	AT
304953	100736452	20992783072	supplements	supplement	NN2
304953	100736452	20992783073	.	.	.
304953	100736452	20992783074	<p>		NULL
304953	100736452	20992783075	Dr.		NNB
304953	100736452	20992783076	Ian	ian	NP1
304953	100736452	20992783077	Thompson	thompson	NP1
304953	100736452	20992783078	,	,	,
304953	100736452	20992783079	chairman	chairman	NN1
304953	100736452	20992783080	of	of	IO
304953	100736452	20992783081	the	the	AT
304953	100736452	20992783082	Department	department	NN1
304953	100736452	20992783083	of	of	IO
304953	100736452	20992783084	Urology	urology	NN1_NP1
304953	100736452	20992783085	at	at	II
304953	100736452	20992783086	the	the	AT
304953	100736452	20992783087	University	university	NN1
304953	100736452	20992783088	of	of	IO
304953	100736452	20992783089	Texas	texas	NP1
304953	100736452	20992783090	Health	health	NN1
304953	100736452	20992783091	Science	science	NN1
304953	100736452	20992783092	Center	center	NN1
304953	100736452	20992783093	at	at	II
304953	100736452	20992783094	San	san	NP1
304953	100736452	20992783095	Antonio	antonio	NP1
304953	100736452	20992783096	and	and	CC
304953	100736452	20992783097	the	the	AT
304953	100736452	20992783098	principal	principal	JJ_NN1
304953	100736452	20992783099	investigator	investigator	NN1
304953	100736452	20992783100	for	for	IF
304953	100736452	20992783101	the	the	AT
304953	100736452	20992783102	Prostate	prostate	NN1
304953	100736452	20992783103	Cancer	cancer	NN1
304953	100736452	20992783104	Prevention	prevention	NN1
304953	100736452	20992783105	Trial	trial	NN1
304953	100736452	20992783106	,	,	,
304953	100736452	20992783107	discusses	discuss	VVZ
304953	100736452	20992783108	the	the	AT
304953	100736452	20992783109	trials	trial	NN2
304953	100736452	20992783110	findings	finding	NN2
304953	100736452	20992783111	and	and	CC
304953	100736452	20992783112	outlines	outline	NN2
304953	100736452	20992783113	finasteride	finasteride	NN1
304953	100736452	20992783114	's	's	GE
304953	100736452	20992783115	risks	risk	NN2
304953	100736452	20992783116	and	and	CC
304953	100736452	20992783117	benefits	benefit	NN2
304953	100736452	20992783118	.	.	.
304953	100736452	20992783119	<p>		NULL
304953	100736452	20992783120	Welcome	welcome	VV0
304953	100736452	20992783121	!	!	!
304953	100736452	20992783122	This	this	DD1
304953	100736452	20992783123	Web	web	NN1
304953	100736452	20992783124	site	site	NN1
304953	100736452	20992783125	combines	combine	VVZ
304953	100736452	20992783126	prostate	prostate	NN1
304953	100736452	20992783127	cancer	cancer	NN1
304953	100736452	20992783128	news	news	NN1
304953	100736452	20992783129	,	,	,
304953	100736452	20992783130	expert	expert	NN1_JJ@
304953	100736452	20992783131	commentary	commentary	NN1
304953	100736452	20992783132	,	,	,
304953	100736452	20992783133	relevant	relevant	JJ
304953	100736452	20992783134	clinical	clinical	JJ
304953	100736452	20992783135	findings	finding	NN2
304953	100736452	20992783136	,	,	,
304953	100736452	20992783137	updates	update	VVZ_NN2
304953	100736452	20992783138	on	on	II
304953	100736452	20992783139	important	important	JJ
304953	100736452	20992783140	prostate	prostate	NN1
304953	100736452	20992783141	cancer	cancer	NN1
304953	100736452	20992783142	research	research	NN1
304953	100736452	20992783143	,	,	,
304953	100736452	20992783144	and	and	CC
304953	100736452	20992783145	personal	personal	JJ
304953	100736452	20992783146	case	case	NN1
304953	100736452	20992783147	histories	history	NN2
304953	100736452	20992783148	to	to	TO
304953	100736452	20992783149	help	help	VVI
304953	100736452	20992783150	you	you	PPY
304953	100736452	20992783151	fully	fully	RR
304953	100736452	20992783152	understand	understand	VV0
304953	100736452	20992783153	the	the	AT
304953	100736452	20992783154	important	important	JJ
304953	100736452	20992783155	considerations	consideration	NN2
304953	100736452	20992783156	in	in	II
304953	100736452	20992783157	the	the	AT
304953	100736452	20992783158	diagnosis	diagnosis	NN1
304953	100736452	20992783159	and	and	CC
304953	100736452	20992783160	treatment	treatment	NN1
304953	100736452	20992783161	of	of	IO
304953	100736452	20992783162	disorders	disorder	NN2
304953	100736452	20992783163	of	of	IO
304953	100736452	20992783164	the	the	AT
304953	100736452	20992783165	prostate	prostate	NN1
304953	100736452	20992783166	.	.	.
304953	100736452	20992783167	@		II
304953	100736452	20992783168	@		II
304953	100736452	20992783169	@		II
304953	100736452	20992783170	@		II
304953	100736452	20992783171	@		II
304953	100736452	20992783172	@		II
304953	100736452	20992783173	@		II
304953	100736452	20992783174	@		II
304953	100736452	20992783175	@		II
304953	100736452	20992783176	@		II
304953	100736452	20992783177	possible	possible	JJ
304953	100736452	20992783178	side	side	NN1
304953	100736452	20992783179	effects	effect	NN2
304953	100736452	20992783180	of	of	IO
304953	100736452	20992783181	hormone	hormone	NN1
304953	100736452	20992783182	therapy	therapy	NN1
304953	100736452	20992783183	,	,	,
304953	100736452	20992783184	such	such	II21
304953	100736452	20992783185	as	as	II22
304953	100736452	20992783186	bone	bone	NN1
304953	100736452	20992783187	loss	loss	NN1
304953	100736452	20992783188	,	,	,
304953	100736452	20992783189	fractures	fracture	NN2
304953	100736452	20992783190	,	,	,
304953	100736452	20992783191	diabetes	diabetes	NN1
304953	100736452	20992783192	,	,	,
304953	100736452	20992783193	and	and	CC
304953	100736452	20992783194	heart	heart	NN1
304953	100736452	20992783195	trouble	trouble	NN1
304953	100736452	20992783196	,	,	,
304953	100736452	20992783197	clinicians	clinician	NN2
304953	100736452	20992783198	might	might	VM
304953	100736452	20992783199	want	want	VVI
304953	100736452	20992783200	to	to	TO
304953	100736452	20992783201	think	think	VVI
304953	100736452	20992783202	twice	twice	RR
304953	100736452	20992783203	before	before	II
304953	100736452	20992783204	prescribing	prescribe	VVG
304953	100736452	20992783205	hormone	hormone	NN1
304953	100736452	20992783206	therapy	therapy	NN1
304953	100736452	20992783207	as	as	II_CSA
304953	100736452	20992783208	the	the	AT
304953	100736452	20992783209	primary	primary	JJ_NN1
304953	100736452	20992783210	cancer	cancer	NN1
304953	100736452	20992783211	treatment	treatment	NN1
304953	100736452	20992783212	for	for	IF
304953	100736452	20992783213	older	old	JJR
304953	100736452	20992783214	men	man	NN2
304953	100736452	20992783215	with	with	IW
304953	100736452	20992783216	early-stage	early-stage	JJ
304953	100736452	20992783217	disease	disease	NN1
304953	100736452	20992783218	.	.	.
304953	100736454	20992783238	@@##	----------	----------
304953	100736454	20992783239	@@100736454		FO
304953	100736454	20992783240	@4936454/		JJ_NN1_VV0
304953	100736454	20992783241	<h>		NULL
304953	100736454	20992783242	Prostate	prostate	NN1
304953	100736454	20992783243	Cancer	cancer	NN1
304953	100736454	20992783244	46988		MC
304953	100736454	20992783245	@qwx906988		FO
304953	100736454	20992783246	46994		MC
304953	100736454	20992783247	@qwx906994		FO
304953	100736454	20992783248	46995		MC
304953	100736454	20992783249	@qwx906995		FO
304953	100736454	20992783250	46992		MC
304953	100736454	20992783251	@qwx906992		FO
304953	100736454	20992783252	46991		MC
304953	100736454	20992783253	@qwx906991		FO
304953	100736454	20992783254	46990		MC
304953	100736454	20992783255	@qwx906990		FO
304953	100736454	20992783256	46989		MC
304953	100736454	20992783257	@qwx906989		FO
304953	100736454	20992783258	46993		MC
304953	100736454	20992783259	@qwx906993		FO
304953	100736454	20992783260	<h>		NULL
304953	100736454	20992783261	Risks	risk	NN2_VVZ@
304953	100736454	20992783262	and	and	CC
304953	100736454	20992783263	Prevention	prevention	NN1
304953	100736454	20992783264	<p>		NULL
304953	100736454	20992783265	The	the	AT
304953	100736454	20992783266	cause	cause	NN1
304953	100736454	20992783267	of	of	IO
304953	100736454	20992783268	prostate	prostate	NN1
304953	100736454	20992783269	cancer	cancer	NN1
304953	100736454	20992783270	is	be	VBZ
304953	100736454	20992783271	unknown	unknown	JJ
304953	100736454	20992783272	,	,	,
304953	100736454	20992783273	which	which	DDQ
304953	100736454	20992783274	means	mean	VVZ
304953	100736454	20992783275	it	it	PPH1
304953	100736454	20992783276	's	be	VBZ
304953	100736454	20992783277	hard	hard	JJ
304953	100736454	20992783278	to	to	TO
304953	100736454	20992783279	suggest	suggest	VVI
304953	100736454	20992783280	ways	way	NN2
304953	100736454	20992783281	to	to	TO
304953	100736454	20992783282	prevent	prevent	VVI
304953	100736454	20992783283	it	it	PPH1
304953	100736454	20992783284	.	.	.
304953	100736454	20992783285	Although	although	CS
304953	100736454	20992783286	some	some	DD
304953	100736454	20992783287	studies	study	NN2
304953	100736454	20992783288	suggest	suggest	VV0
304953	100736454	20992783289	that	that	CST_DD1
304953	100736454	20992783290	eating	eat	VVG_NN1
304953	100736454	20992783291	specific	specific	JJ
304953	100736454	20992783292	foods	food	NN2
304953	100736454	20992783293	and	and	CC
304953	100736454	20992783294	taking	take	VVG
304953	100736454	20992783295	certain	certain	JJ
304953	100736454	20992783296	medications	medication	NN2
304953	100736454	20992783297	(	(	(
304953	100736454	20992783298	called	call	VVN_JJ%
304953	100736454	20992783299	chemoprevention	chemoprevention	NN1
304953	100736454	20992783300	)	)	)
304953	100736454	20992783301	may	may	VM
304953	100736454	20992783302	help	help	VVI
304953	100736454	20992783303	reduce	reduce	VVI
304953	100736454	20992783304	the	the	AT
304953	100736454	20992783305	risk	risk	NN1
304953	100736454	20992783306	of	of	IO
304953	100736454	20992783307	prostate	prostate	NN1
304953	100736454	20992783308	cancer	cancer	NN1
304953	100736454	20992783309	or	or	CC
304953	100736454	20992783310	even	even	RR
304953	100736454	20992783311	prevent	prevent	VV0
304953	100736454	20992783312	its	its	APPGE
304953	100736454	20992783313	return	return	NN1
304953	100736454	20992783314	after	after	II_CS
304953	100736454	20992783315	treatment	treatment	NN1
304953	100736454	20992783316	,	,	,
304953	100736454	20992783317	there	there	EX
304953	100736454	20992783318	is	be	VBZ
304953	100736454	20992783319	no	no	AT
304953	100736454	20992783320	proof	proof	NN1
304953	100736454	20992783321	that	that	CST
304953	100736454	20992783322	taking	take	VVG
304953	100736454	20992783323	these	these	DD2
304953	100736454	20992783324	steps	step	NN2
304953	100736454	20992783325	will	will	VM
304953	100736454	20992783326	work	work	VVI
304953	100736454	20992783327	for	for	IF
304953	100736454	20992783328	particular	particular	JJ
304953	100736454	20992783329	individuals	individual	NN2
304953	100736454	20992783330	.	.	.
304953	100736454	20992783331	However	however	RR
304953	100736454	20992783332	,	,	,
304953	100736454	20992783333	certain	certain	JJ
304953	100736454	20992783334	characteristics	characteristic	NN2
304953	100736454	20992783335	,	,	,
304953	100736454	20992783336	or	or	CC
304953	100736454	20992783337	risk	risk	NN1_VV0
304953	100736454	20992783338	factors	factor	NN2
304953	100736454	20992783339	,	,	,
304953	100736454	20992783340	increase	increase	VV0
304953	100736454	20992783341	a	a	AT1
304953	100736454	20992783342	man	man	NN1
304953	100736454	20992783343	's	's	GE
304953	100736454	20992783344	chances	chance	NN2
304953	100736454	20992783345	of	of	IO
304953	100736454	20992783346	getting	get	VVG
304953	100736454	20992783347	prostate	prostate	NN1
304953	100736454	20992783348	cancer	cancer	NN1
304953	100736454	20992783349	.	.	.
304953	100736454	20992783350	These	these	DD2
304953	100736454	20992783351	articles	article	NN2
304953	100736454	20992783352	discuss	discuss	VV0
304953	100736454	20992783353	specific	specific	JJ
304953	100736454	20992783354	factors	factor	NN2
304953	100736454	20992783355	that	that	CST_DD1
304953	100736454	20992783356	may	may	VM
304953	100736454	20992783357	raise	raise	VVI
304953	100736454	20992783358	or	or	CC
304953	100736454	20992783359	lower	lower	VVI
304953	100736454	20992783360	your	your	APPGE
304953	100736454	20992783361	risk	risk	NN1
304953	100736454	20992783362	of	of	IO
304953	100736454	20992783363	developing	develop	VVG
304953	100736454	20992783364	the	the	AT
304953	100736454	20992783365	disease	disease	NN1
304953	100736454	20992783366	.	.	.
304953	100736456	20992783386	@@##	----------	----------
304953	100736456	20992783387	@@100736456		FO
304953	100736456	20992783388	@4936456/		VV0_NN1
304953	100736456	20992783389	46989		MC
304953	100736456	20992783390	@qwx906989		FO
304953	100736456	20992783391	<h>		NULL
304953	100736456	20992783392	Understanding	understand	VVG_NN1
304953	100736456	20992783393	PSA	psa	NP1
304953	100736456	20992783394	<p>		NULL
304953	100736456	20992783395	Your	your	APPGE
304953	100736456	20992783396	PSA	psa	NP1
304953	100736456	20992783397	level	level	NN1
304953	100736456	20992783398	is	be	VBZ
304953	100736456	20992783399	above	above	II
304953	100736456	20992783400	four	four	MC
304953	100736456	20992783401	ng/ml	ng/ml	FU
304953	100736456	20992783402	.	.	.
304953	100736456	20992783403	In	in	II
304953	100736456	20992783404	younger	young	JJR
304953	100736456	20992783405	men	man	NN2
304953	100736456	20992783406	,	,	,
304953	100736456	20992783407	this	this	DD1
304953	100736456	20992783408	is	be	VBZ
304953	100736456	20992783409	usually	usually	RR
304953	100736456	20992783410	considered	consider	VVN_VVD
304953	100736456	20992783411	to	to	TO
304953	100736456	20992783412	be	be	VBI
304953	100736456	20992783413	a	a	AT1
304953	100736456	20992783414	worrisome	worrisome	JJ
304953	100736456	20992783415	level	level	NN1
304953	100736456	20992783416	.	.	.
304953	100736456	20992783417	However	however	RR
304953	100736456	20992783418	,	,	,
304953	100736456	20992783419	your	your	APPGE
304953	100736456	20992783420	PSA	psa	NP1
304953	100736456	20992783421	level	level	NN1
304953	100736456	20992783422	may	may	VM
304953	100736456	20992783423	be	be	VBI
304953	100736456	20992783424	normal	normal	JJ
304953	100736456	20992783425	for	for	IF
304953	100736456	20992783426	someone	someone	PN1
304953	100736456	20992783427	in	in	II
304953	100736456	20992783428	your	your	APPGE
304953	100736456	20992783429	age	age	NN1
304953	100736456	20992783430	group	group	NN1
304953	100736456	20992783431	.	.	.
304953	100736456	20992783432	<p>		NULL
304953	100736456	20992783433	Speak	speak	VV0
304953	100736456	20992783434	with	with	IW
304953	100736456	20992783435	your	your	APPGE
304953	100736456	20992783436	doctor	doctor	NN1
304953	100736456	20992783437	about	about	II
304953	100736456	20992783438	options	option	NN2
304953	100736456	20992783439	for	for	IF
304953	100736456	20992783440	follow-up	follow-up	NN1_JJ
304953	100736456	20992783441	,	,	,
304953	100736456	20992783442	including	include	VVG@_II
304953	100736456	20992783443	<p>		NULL
304953	100736456	20992783444	referral	referral	NN1
304953	100736456	20992783445	to	to	II
304953	100736456	20992783446	a	a	AT1
304953	100736456	20992783447	urologist	urologist	NN1
304953	100736456	20992783448	(	(	(
304953	100736456	20992783449	prostate	prostate	NN1
304953	100736456	20992783450	specialist	specialist	NN1
304953	100736456	20992783451	)	)	)
304953	100736456	20992783452	<p>		NULL
304953	100736456	20992783453	repeat	repeat	VV0
304953	100736456	20992783454	testing	test	VVG_NN1
304953	100736456	20992783455	in	in	II
304953	100736456	20992783456	3-6	3-6	MCMC
304953	100736456	20992783457	months	month	NNT2
304953	100736456	20992783458	to	to	TO
304953	100736456	20992783459	make	make	VVI
304953	100736456	20992783460	sure	sure	JJ
304953	100736456	20992783461	that	that	CST
304953	100736456	20992783462	your	your	APPGE
304953	100736456	20992783463	PSA	psa	NP1
304953	100736456	20992783464	level	level	NN1
304953	100736456	20992783465	is	be	VBZ
304953	100736456	20992783466	not	not	XX
304953	100736456	20992783467	rising	rise	VVG
304953	100736456	20992783468	by	by	II
304953	100736456	20992783469	measuring	measure	VVG
304953	100736456	20992783470	your	your	APPGE
304953	100736456	20992783471	"	"	"
304953	100736456	20992783472	free	free	JJ
304953	100736456	20992783473	"	"	"
304953	100736456	20992783474	PSA	psa	NP1
304953	100736456	20992783475	level	level	VV0@_NN1
304953	100736456	20992783476	This	this	DD1
304953	100736456	20992783477	special	special	JJ
304953	100736456	20992783478	way	way	NN1
304953	100736456	20992783479	of	of	IO
304953	100736456	20992783480	testing	test	VVG
304953	100736456	20992783481	your	your	APPGE
304953	100736456	20992783482	PSA	psa	NP1
304953	100736456	20992783483	level	level	NN1
304953	100736456	20992783484	may	may	VM
304953	100736456	20992783485	help	help	VVI
304953	100736456	20992783486	to	to	TO
304953	100736456	20992783487	decide	decide	VVI
304953	100736456	20992783488	if	if	CSW@_CS
304953	100736456	20992783489	a	a	AT1
304953	100736456	20992783490	prostate	prostate	NN1
304953	100736456	20992783491	biopsy	biopsy	NN1
304953	100736456	20992783492	is	be	VBZ
304953	100736456	20992783493	needed	need	VVN
304953	100736456	20992783494	.	.	.
304953	100736456	20992783495	High	high	JJ
304953	100736456	20992783496	levels	level	NN2
304953	100736456	20992783497	of	of	IO
304953	100736456	20992783498	free	free	JJ
304953	100736456	20992783499	PSA	psa	NP1
304953	100736456	20992783500	are	be	VBR
304953	100736456	20992783501	reassuring	reassure	VVG_JJ
304953	100736456	20992783502	,	,	,
304953	100736456	20992783503	while	while	CS
304953	100736456	20992783504	low	low	JJ
304953	100736456	20992783505	levels	level	NN2
304953	100736456	20992783506	are	be	VBR
304953	100736456	20992783507	worrisome	worrisome	JJ
304953	100736456	20992783508	for	for	IF
304953	100736456	20992783509	cancer	cancer	NN1
304953	100736456	20992783510	.	.	.
304953	100736456	20992783511	46996		MC
304953	100736456	20992783512	@qwx906996		FO
304953	100736457	20992783532	@@##	----------	----------
304953	100736457	20992783533	@@100736457		FO
304953	100736457	20992783534	@4936457/		VV0_NN1
304953	100736457	20992783535	46989		MC
304953	100736457	20992783536	@qwx906989		FO
304953	100736457	20992783537	<p>		NULL
304953	100736457	20992783538	Short	short	NP1_JJ_RR@
304953	100736457	20992783539	for	for	IF
304953	100736457	20992783540	prostatic	prostatic	JJ
304953	100736457	20992783541	intraepithelial	intraepithelial	JJ
304953	100736457	20992783542	neoplasia	neoplasia	NN1
304953	100736457	20992783543	,	,	,
304953	100736457	20992783544	PIN	pin	NN1
304953	100736457	20992783545	is	be	VBZ
304953	100736457	20992783546	a	a	AT1
304953	100736457	20992783547	condition	condition	NN1
304953	100736457	20992783548	in	in	II
304953	100736457	20992783549	which	which	DDQ
304953	100736457	20992783550	some	some	DD
304953	100736457	20992783551	prostate	prostate	NN1
304953	100736457	20992783552	cells	cell	NN2
304953	100736457	20992783553	have	have	VH0
304953	100736457	20992783554	begun	begin	VVN
304953	100736457	20992783555	to	to	TO
304953	100736457	20992783556	look	look	VVI
304953	100736457	20992783557	and	and	CC
304953	100736457	20992783558	behave	behave	VVI
304953	100736457	20992783559	abnormally	abnormally	RR
304953	100736457	20992783560	.	.	.
304953	100736457	20992783561	In	in	II
304953	100736457	20992783562	some	some	DD
304953	100736457	20992783563	cases	case	NN2
304953	100736457	20992783564	,	,	,
304953	100736457	20992783565	PIN	pin	NN1
304953	100736457	20992783566	can	can	VM
304953	100736457	20992783567	progress	progress	VVI
304953	100736457	20992783568	to	to	II
304953	100736457	20992783569	cancer	cancer	NN1
304953	100736457	20992783570	.	.	.
304953	100736457	20992783571	The	the	AT
304953	100736457	20992783572	condition	condition	NN1
304953	100736457	20992783573	is	be	VBZ
304953	100736457	20992783574	usually	usually	RR
304953	100736457	20992783575	diagnosed	diagnose	VVN_VVD
304953	100736457	20992783576	following	following	II@_VVG
304953	100736457	20992783577	a	a	AT1
304953	100736457	20992783578	prostate	prostate	NN1
304953	100736457	20992783579	biopsy	biopsy	NN1
304953	100736457	20992783580	or	or	CC
304953	100736457	20992783581	surgery	surgery	NN1
304953	100736457	20992783582	for	for	IF
304953	100736457	20992783583	benign	benign	JJ
304953	100736457	20992783584	prostatic	prostatic	JJ
304953	100736457	20992783585	hyperplasia	hyperplasia	NN1
304953	100736457	20992783586	(	(	(
304953	100736457	20992783587	BPH	bph	NP1
304953	100736457	20992783588	)	)	)
304953	100736457	20992783589	.	.	.
304953	100736457	20992783590	But	but	CCB
304953	100736457	20992783591	the	the	AT
304953	100736457	20992783592	diagnosis	diagnosis	NN1
304953	100736457	20992783593	,	,	,
304953	100736457	20992783594	which	which	DDQ
304953	100736457	20992783595	is	be	VBZ
304953	100736457	20992783596	based	base	VVN
304953	100736457	20992783597	on	on	II
304953	100736457	20992783598	a	a	AT1
304953	100736457	20992783599	pathologist	pathologist	NN1
304953	100736457	20992783600	's	's	GE
304953	100736457	20992783601	reading	reading	NN1
304953	100736457	20992783602	of	of	IO
304953	100736457	20992783603	the	the	AT
304953	100736457	20992783604	tissue	tissue	NN1
304953	100736457	20992783605	sample	sample	NN1
304953	100736457	20992783606	,	,	,
304953	100736457	20992783607	is	be	VBZ
304953	100736457	20992783608	rather	rather	RG
304953	100736457	20992783609	subjective	subjective	JJ
304953	100736457	20992783610	,	,	,
304953	100736457	20992783611	resulting	result	VVG
304953	100736457	20992783612	in	in	II
304953	100736457	20992783613	large	large	JJ
304953	100736457	20992783614	differences	difference	NN2
304953	100736457	20992783615	in	in	II
304953	100736457	20992783616	the	the	AT
304953	100736457	20992783617	reported	reported	JJ@
304953	100736457	20992783618	incidence	incidence	NN1
304953	100736457	20992783619	of	of	IO
304953	100736457	20992783620	PIN	pin	NN1
304953	100736457	20992783621	.	.	.
304953	100736457	20992783622	<p>		NULL
304953	100736457	20992783623	To	to	TO
304953	100736457	20992783624	study	study	VVI
304953	100736457	20992783625	the	the	AT
304953	100736457	20992783626	magnitude	magnitude	NN1
304953	100736457	20992783627	of	of	IO
304953	100736457	20992783628	overdiagnosis	overdiagnosis	NN1
304953	100736457	20992783629	,	,	,
304953	100736457	20992783630	researchers	researcher	NN2
304953	100736457	20992783631	in	in	II
304953	100736457	20992783632	Virginia	virginia	NP1
304953	100736457	20992783633	reviewed	review	VVD
304953	100736457	20992783634	251	251	MC
304953	100736457	20992783635	patients	patient	NN2
304953	100736457	20992783636	who	who	PNQS
304953	100736457	20992783637	had	have	VHD
304953	100736457	20992783638	been	be	VBN
304953	100736457	20992783639	diagnosed	diagnose	VVN
304953	100736457	20992783640	initially	initially	RR
304953	100736457	20992783641	with	with	IW
304953	100736457	20992783642	PIN	pin	NN1
304953	100736457	20992783643	.	.	.
304953	100736457	20992783644	The	the	AT
304953	100736457	20992783645	diagnosis	diagnosis	NN1
304953	100736457	20992783646	was	be	VBDZ
304953	100736457	20992783647	confirmed	confirm	VVN
304953	100736457	20992783648	in	in	II
304953	100736457	20992783649	191	191	MC
304953	100736457	20992783650	cases	case	NN2
304953	100736457	20992783651	,	,	,
304953	100736457	20992783652	meaning	mean	VVG
304953	100736457	20992783653	that	that	CST_DD1_RG%
304953	100736457	20992783654	60	60	MC
304953	100736457	20992783655	patients	patient	NN2
304953	100736457	20992783656	who	who	PNQS
304953	100736457	20992783657	were	be	VBDR
304953	100736457	20992783658	told	tell	VVN
304953	100736457	20992783659	they	they	PPHS2
304953	100736457	20992783660	had	have	VHD
304953	100736457	20992783661	PIN	pin	NN1
304953	100736457	20992783662	did	do	VDD
304953	100736457	20992783663	n't	n't	XX
304953	100736457	20992783664	have	have	VHI
304953	100736457	20992783665	it	it	PPH1
304953	100736457	20992783666	.	.	.
304953	100736457	20992783667	A	a	AT1
304953	100736457	20992783668	variety	variety	NN1
304953	100736457	20992783669	of	of	IO
304953	100736457	20992783670	benign	benign	JJ
304953	100736457	20992783671	conditions	condition	NN2
304953	100736457	20992783672	were	be	VBDR
304953	100736457	20992783673	misinterpreted	misinterpret	VVN
304953	100736457	20992783674	as	as	CSA_II@
304953	100736457	20992783675	PIN	pin	NN1
304953	100736457	20992783676	.	.	.
304953	100736457	20992783677	Although	although	CS
304953	100736457	20992783678	no	no	AT
304953	100736457	20992783679	cancers	cancer	NN2
304953	100736457	20992783680	were	be	VBDR
304953	100736457	20992783681	mistaken	mistake	VVN
304953	100736457	20992783682	for	for	IF
304953	100736457	20992783683	PIN	pin	NN1
304953	100736457	20992783684	,	,	,
304953	100736457	20992783685	the	the	AT
304953	100736457	20992783686	overdiagnosis	overdiagnosis	NN1
304953	100736457	20992783687	of	of	IO
304953	100736457	20992783688	PIN	pin	NN1
304953	100736457	20992783689	causes	cause	VVZ_NN2
304953	100736457	20992783690	concern	concern	NN1_VV0@
304953	100736457	20992783691	among	among	II
304953	100736457	20992783692	both	both	RR
304953	100736457	20992783693	patients	patient	NN2
304953	100736457	20992783694	and	and	CC
304953	100736457	20992783695	physicians	physician	NN2
304953	100736457	20992783696	about	about	II
304953	100736457	20992783697	the	the	AT
304953	100736457	20992783698	possibility	possibility	NN1
304953	100736457	20992783699	of	of	IO
304953	100736457	20992783700	subsequent	subsequent	JJ
304953	100736457	20992783701	cancers	cancer	NN2
304953	100736457	20992783702	and	and	CC
304953	100736457	20992783703	may	may	VM
304953	100736457	20992783704	lead	lead	VVI
304953	100736457	20992783705	to	to	II
304953	100736457	20992783706	unnecessary	unnecessary	JJ
304953	100736457	20992783707	repeat	repeat	NN1%_VV0
304953	100736457	20992783708	biopsies	biopsy	NN2
304953	100736457	20992783709	.	.	.
304953	100736457	20992783710	The	the	AT
304953	100736457	20992783711	rate	rate	NN1
304953	100736457	20992783712	of	of	IO
304953	100736457	20992783713	overdiagnosis	overdiagnosis	NN1
304953	100736457	20992783714	might	might	VM
304953	100736457	20992783715	also	also	RR
304953	100736457	20992783716	account	account	VVI
304953	100736457	20992783717	for	for	IF
304953	100736457	20992783718	the	the	AT
304953	100736457	20992783719	variation	variation	NN1
304953	100736457	20992783720	in	in	II
304953	100736457	20992783721	the	the	AT
304953	100736457	20992783722	incidence	incidence	NN1
304953	100736457	20992783723	of	of	IO
304953	100736457	20992783724	PIN	pin	NN1
304953	100736457	20992783725	reported	report	VVN_VVD
304953	100736457	20992783726	in	in	II
304953	100736457	20992783727	different	different	JJ
304953	100736457	20992783728	publications	publication	NN2
304953	100736457	20992783729	.	.	.
304953	100736457	20992783730	46996		MC
304953	100736457	20992783731	@qwx906996		FO
304953	100736459	20992783817	@@##	----------	----------
304953	100736459	20992783818	@@100736459		FO
304953	100736459	20992783819	@4936459/		NN1_VV0
304953	100736459	20992783820	<p>		NULL
304953	100736459	20992783821	Two	two	MC
304953	100736459	20992783822	teams	team	NN2
304953	100736459	20992783823	of	of	IO
304953	100736459	20992783824	researchers	researcher	NN2
304953	100736459	20992783825	suggest	suggest	VV0
304953	100736459	20992783826	that	that	CST_DD1
304953	100736459	20992783827	focal	focal	JJ
304953	100736459	20992783828	therapy	therapy	NN1
304953	100736459	20992783829	may	may	VM
304953	100736459	20992783830	be	be	VBI
304953	100736459	20992783831	a	a	AT1
304953	100736459	20992783832	promising	promising	JJ
304953	100736459	20992783833	treatment	treatment	NN1
304953	100736459	20992783834	option	option	NN1
304953	100736459	20992783835	for	for	IF
304953	100736459	20992783836	men	man	NN2
304953	100736459	20992783837	with	with	IW
304953	100736459	20992783838	cancer	cancer	NN1
304953	100736459	20992783839	confined	confine	VVN
304953	100736459	20992783840	to	to	II
304953	100736459	20992783841	the	the	AT
304953	100736459	20992783842	prostate	prostate	NN1
304953	100736459	20992783843	.	.	.
304953	100736459	20992783844	However	however	RR
304953	100736459	20992783845	,	,	,
304953	100736459	20992783846	more	more	DAR
304953	100736459	20992783847	research	research	NN1
304953	100736459	20992783848	is	be	VBZ
304953	100736459	20992783849	needed	need	VVN
304953	100736459	20992783850	to	to	TO
304953	100736459	20992783851	determine	determine	VVI
304953	100736459	20992783852	its	its	APPGE
304953	100736459	20992783853	long-term	long-term	JJ
304953	100736459	20992783854	effectiveness	effectiveness	NN1
304953	100736459	20992783855	.	.	.
304953	100736459	20992783856	<p>		NULL
304953	100736459	20992783857	Physicians	physician	NN2
304953	100736459	20992783858	and	and	CC
304953	100736459	20992783859	researchers	researcher	NN2
304953	100736459	20992783860	have	have	VH0
304953	100736459	20992783861	long	long	RR
304953	100736459	20992783862	believed	believe	VVN
304953	100736459	20992783863	that	that	CST_DD1
304953	100736459	20992783864	consuming	consume	VVG_JJ@
304953	100736459	20992783865	high	high	JJ
304953	100736459	20992783866	amounts	amount	NN2
304953	100736459	20992783867	of	of	IO
304953	100736459	20992783868	calcium	calcium	NN1
304953	100736459	20992783869	and	and	CC
304953	100736459	20992783870	dairy	dairy	NN1
304953	100736459	20992783871	products	product	NN2
304953	100736459	20992783872	increases	increase	VVZ
304953	100736459	20992783873	the	the	AT
304953	100736459	20992783874	risk	risk	NN1
304953	100736459	20992783875	of	of	IO
304953	100736459	20992783876	prostate	prostate	NN1
304953	100736459	20992783877	cancer	cancer	NN1
304953	100736459	20992783878	,	,	,
304953	100736459	20992783879	although	although	CS
304953	100736459	20992783880	study	study	NN1
304953	100736459	20992783881	results	result	NN2
304953	100736459	20992783882	have	have	VH0
304953	100736459	20992783883	been	be	VBN
304953	100736459	20992783884	inconsistent	inconsistent	JJ
304953	100736459	20992783885	.	.	.
304953	100736459	20992783886	Two	two	MC
304953	100736459	20992783887	recent	recent	JJ
304953	100736459	20992783888	studies	study	NN2
304953	100736459	20992783889	make	make	VV0
304953	100736459	20992783890	clear	clear	JJ
304953	100736459	20992783891	that	that	CST
304953	100736459	20992783892	the	the	AT
304953	100736459	20992783893	jury	jury	NN1
304953	100736459	20992783894	is	be	VBZ
304953	100736459	20992783895	still	still	RR
304953	100736459	20992783896	out	out	RP
304953	100736459	20992783897	.	.	.
304953	100736461	20992783917	@@##	----------	----------
304953	100736461	20992783918	@@100736461		FO
304953	100736461	20992783919	@4936461/		VV0_NN1
304953	100736461	20992783920	46989		MC
304953	100736461	20992783921	@qwx906989		FO
304953	100736461	20992783922	<p>		NULL
304953	100736461	20992783923	In	in	II
304953	100736461	20992783924	October	october	NPM1
304953	100736461	20992783925	2008	2008	MC
304953	100736461	20992783926	,	,	,
304953	100736461	20992783927	the	the	AT
304953	100736461	20992783928	National	national	JJ
304953	100736461	20992783929	Cancer	cancer	NN1
304953	100736461	20992783930	Institute	institute	NN1
304953	100736461	20992783931	halted	halt	VVD_VVN
304953	100736461	20992783932	a	a	AT1
304953	100736461	20992783933	study	study	NN1
304953	100736461	20992783934	designed	design	VVN_VVD
304953	100736461	20992783935	to	to	TO
304953	100736461	20992783936	test	test	VVI
304953	100736461	20992783937	whether	whether	CSW
304953	100736461	20992783938	vitamin	vitamin	NN1
304953	100736461	20992783939	E	e	ZZ1
304953	100736461	20992783940	and	and	CC
304953	100736461	20992783941	selenium	selenium	NN1
304953	100736461	20992783942	,	,	,
304953	100736461	20992783943	taken	take	VVN
304953	100736461	20992783944	alone	alone	RR_JJ
304953	100736461	20992783945	or	or	CC
304953	100736461	20992783946	in	in	II
304953	100736461	20992783947	combination	combination	NN1
304953	100736461	20992783948	,	,	,
304953	100736461	20992783949	could	could	VM
304953	100736461	20992783950	prevent	prevent	VVI
304953	100736461	20992783951	prostate	prostate	NN1
304953	100736461	20992783952	cancer	cancer	NN1
304953	100736461	20992783953	after	after	II_CS
304953	100736461	20992783954	data	data	NN
304953	100736461	20992783955	showed	show	VVD
304953	100736461	20992783956	the	the	AT
304953	100736461	20992783957	supplements	supplement	NN2
304953	100736461	20992783958	might	might	VM
304953	100736461	20992783959	be	be	VBI
304953	100736461	20992783960	doing	do	VDG
304953	100736461	20992783961	more	more	DAR
304953	100736461	20992783962	harm	harm	NN1
304953	100736461	20992783963	than	than	CSN
304953	100736461	20992783964	good	good	JJ
304953	100736461	20992783965	.	.	.
304953	100736461	20992783966	The	the	AT
304953	100736461	20992783967	news	news	NN1
304953	100736461	20992783968	did	do	VDD
304953	100736461	20992783969	n't	n't	XX
304953	100736461	20992783970	get	get	VVI
304953	100736461	20992783971	any	any	DD
304953	100736461	20992783972	better	better	JJR
304953	100736461	20992783973	at	at	II
304953	100736461	20992783974	the	the	AT
304953	100736461	20992783975	annual	annual	JJ
304953	100736461	20992783976	meeting	meeting	NN1
304953	100736461	20992783977	of	of	IO
304953	100736461	20992783978	the	the	AT
304953	100736461	20992783979	American	american	JJ
304953	100736461	20992783980	Urological	urological	JJ
304953	100736461	20992783981	Association	association	NN1
304953	100736461	20992783982	in	in	II
304953	100736461	20992783983	April	april	NPM1
304953	100736461	20992783984	2009	2009	MC
304953	100736461	20992783985	.	.	.
304953	100736461	20992783986	<p>		NULL
304953	100736461	20992783987	Canadian	canadian	JJ_NN1
304953	100736461	20992783988	researchers	researcher	NN2
304953	100736461	20992783989	hypothesized	hypothesize	VVD
304953	100736461	20992783990	that	that	DD1_CST
304953	100736461	20992783991	vitamin	vitamin	NN1
304953	100736461	20992783992	E	e	ZZ1
304953	100736461	20992783993	and	and	CC
304953	100736461	20992783994	selenium	selenium	NN1
304953	100736461	20992783995	,	,	,
304953	100736461	20992783996	taken	take	VVN
304953	100736461	20992783997	with	with	IW
304953	100736461	20992783998	soy	soy	JJ
304953	100736461	20992783999	protein	protein	NN1
304953	100736461	20992784000	,	,	,
304953	100736461	20992784001	might	might	VM
304953	100736461	20992784002	prevent	prevent	VVI
304953	100736461	20992784003	the	the	AT
304953	100736461	20992784004	development	development	NN1
304953	100736461	20992784005	of	of	IO
304953	100736461	20992784006	prostate	prostate	NN1
304953	100736461	20992784007	cancer	cancer	NN1
304953	100736461	20992784008	in	in	II
304953	100736461	20992784009	men	man	NN2
304953	100736461	20992784010	who	who	PNQS
304953	100736461	20992784011	had	have	VHD
304953	100736461	20992784012	already	already	RR
304953	100736461	20992784013	been	be	VBN
304953	100736461	20992784014	diagnosed	diagnose	VVN
304953	100736461	20992784015	with	with	IW
304953	100736461	20992784016	high-grade	high-grade	JJ
304953	100736461	20992784017	prostatic	prostatic	JJ
304953	100736461	20992784018	intraepithelial	intraepithelial	JJ
304953	100736461	20992784019	neoplasia	neoplasia	NN1
304953	100736461	20992784020	(	(	(
304953	100736461	20992784021	HGPIN		NP1
304953	100736461	20992784022	)	)	)
304953	100736461	20992784023	,	,	,
304953	100736461	20992784024	a	a	AT1
304953	100736461	20992784025	condition	condition	NN1
304953	100736461	20992784026	thought	think	VVD_VVN_NN1
304953	100736461	20992784027	to	to	TO
304953	100736461	20992784028	be	be	VBI
304953	100736461	20992784029	a	a	AT1
304953	100736461	20992784030	cancer	cancer	NN1
304953	100736461	20992784031	precursor	precursor	NN1
304953	100736461	20992784032	.	.	.
304953	100736461	20992784033	They	they	PPHS2
304953	100736461	20992784034	tested	test	VVD
304953	100736461	20992784035	their	their	APPGE
304953	100736461	20992784036	theory	theory	NN1
304953	100736461	20992784037	in	in	II
304953	100736461	20992784038	303	303	MC
304953	100736461	20992784039	men	man	NN2
304953	100736461	20992784040	,	,	,
304953	100736461	20992784041	with	with	IW
304953	100736461	20992784042	half	half	DB
304953	100736461	20992784043	taking	take	VVG
304953	100736461	20992784044	the	the	AT
304953	100736461	20992784045	supplements	supplement	NN2
304953	100736461	20992784046	and	and	CC
304953	100736461	20992784047	the	the	AT
304953	100736461	20992784048	other	other	JJ
304953	100736461	20992784049	half	half	NN1@_DB_RR@
304953	100736461	20992784050	taking	take	VVG
304953	100736461	20992784051	a	a	AT1
304953	100736461	20992784052	placebo	placebo	NN1
304953	100736461	20992784053	daily	daily	RR_NN1@_JJ
304953	100736461	20992784054	for	for	IF
304953	100736461	20992784055	three	three	MC
304953	100736461	20992784056	years	year	NNT2
304953	100736461	20992784057	.	.	.
304953	100736461	20992784058	The	the	AT
304953	100736461	20992784059	men	man	NN2
304953	100736461	20992784060	had	have	VHD
304953	100736461	20992784061	prostate	prostate	NN1
304953	100736461	20992784062	biopsies	biopsy	NN2
304953	100736461	20992784063	after	after	II
304953	100736461	20992784064	six	six	MC
304953	100736461	20992784065	,	,	,
304953	100736461	20992784066	12	12	MC
304953	100736461	20992784067	,	,	,
304953	100736461	20992784068	24	24	MC
304953	100736461	20992784069	,	,	,
304953	100736461	20992784070	and	and	CC
304953	100736461	20992784071	36	36	MC
304953	100736461	20992784072	months	month	NNT2
304953	100736461	20992784073	to	to	TO
304953	100736461	20992784074	see	see	VVI
304953	100736461	20992784075	if	if	CSW@_CS
304953	100736461	20992784076	they	they	PPHS2
304953	100736461	20992784077	developed	develop	VVD
304953	100736461	20992784078	prostate	prostate	NN1
304953	100736461	20992784079	cancer	cancer	NN1
304953	100736461	20992784080	.	.	.
304953	100736461	20992784081	<p>		NULL
304953	100736461	20992784082	Over	over	II
304953	100736461	20992784083	all	all	DB
304953	100736461	20992784084	,	,	,
304953	100736461	20992784085	26.4%	26.4%	FO
304953	100736461	20992784086	of	of	IO
304953	100736461	20992784087	the	the	AT
304953	100736461	20992784088	study	study	NN1
304953	100736461	20992784089	's	's	GE
304953	100736461	20992784090	participants	participant	NN2
304953	100736461	20992784091	developed	develop	VVD_VVN
304953	100736461	20992784092	invasive	invasive	JJ
304953	100736461	20992784093	prostate	prostate	NN1
304953	100736461	20992784094	cancer	cancer	NN1
304953	100736461	20992784095	,	,	,
304953	100736461	20992784096	with	with	IW
304953	100736461	20992784097	no	no	AT
304953	100736461	20992784098	meaningful	meaningful	JJ
304953	100736461	20992784099	difference	difference	NN1
304953	100736461	20992784100	in	in	II
304953	100736461	20992784101	the	the	AT
304953	100736461	20992784102	number	number	NN1
304953	100736461	20992784103	of	of	IO
304953	100736461	20992784104	cancer	cancer	NN1
304953	100736461	20992784105	cases	case	NN2
304953	100736461	20992784106	between	between	II
304953	100736461	20992784107	the	the	AT
304953	100736461	20992784108	two	two	MC
304953	100736461	20992784109	@		II
304953	100736461	20992784110	@		II
304953	100736461	20992784111	@		II
304953	100736461	20992784112	@		II
304953	100736461	20992784113	@		II
304953	100736461	20992784114	@		II
304953	100736461	20992784115	@		II
304953	100736461	20992784116	@		II
304953	100736461	20992784117	@		II
304953	100736461	20992784118	@		II
304953	100736461	20992784119	trials	trial	NN2
304953	100736461	20992784120	of	of	IO
304953	100736461	20992784121	dietary	dietary	JJ
304953	100736461	20992784122	supplements	supplement	NN2
304953	100736461	20992784123	,	,	,
304953	100736461	20992784124	many	many	DA2
304953	100736461	20992784125	of	of	IO
304953	100736461	20992784126	which	which	DDQ
304953	100736461	20992784127	are	be	VBR
304953	100736461	20992784128	falsely	falsely	RR
304953	100736461	20992784129	promoted	promote	VVN
304953	100736461	20992784130	as	as	CSA_II@
304953	100736461	20992784131	cancer	cancer	NN1
304953	100736461	20992784132	fighters	fighter	NN2
304953	100736461	20992784133	.	.	.
304953	100736461	20992784134	<p>		NULL
304953	100736461	20992784135	I	i	PPIS1
304953	100736461	20992784136	believe	believe	VV0
304953	100736461	20992784137	this	this	DD1
304953	100736461	20992784138	is	be	VBZ
304953	100736461	20992784139	among	among	II
304953	100736461	20992784140	the	the	AT
304953	100736461	20992784141	so	so	RG
304953	100736461	20992784142	much	much	DA1_RR
304953	100736461	20992784143	important	important	JJ
304953	100736461	20992784144	information	information	NN1
304953	100736461	20992784145	forr	forr	NN1
304953	100736461	20992784146	me	me	PPIO1
304953	100736461	20992784147	.	.	.
304953	100736461	20992784148	And	and	CC
304953	100736461	20992784149	i 'm		VV0
304953	100736461	20992784150	happy	happy	JJ
304953	100736461	20992784151	studying	study	VVG
304953	100736461	20992784152	your	your	APPGE
304953	100736461	20992784153	article	article	NN1
304953	100736461	20992784154	.	.	.
304953	100736461	20992784155	However	however	RR
304953	100736461	20992784156	should	should	VM
304953	100736461	20992784157	observation	observation	NN1
304953	100736461	20992784158	on	on	II
304953	100736461	20992784159	some	some	DD
304953	100736461	20992784160	normal	normal	JJ
304953	100736461	20992784161	issues	issue	NN2
304953	100736461	20992784162	,	,	,
304953	100736461	20992784163	The	the	AT
304953	100736461	20992784164	web	web	NN1
304953	100736461	20992784165	site	site	NN1
304953	100736461	20992784166	style	style	NN1
304953	100736461	20992784167	is	be	VBZ
304953	100736461	20992784168	wonderful	wonderful	JJ
304953	100736461	20992784169	,	,	,
304953	100736461	20992784170	the	the	AT
304953	100736461	20992784171	articles	article	NN2
304953	100736461	20992784172	is	be	VBZ
304953	100736461	20992784173	reallly		RR
304953	100736461	20992784174	excellent	excellent	JJ
304953	100736461	20992784175	:	:	:
304953	100736461	20992784176	D.		NP1
304953	100736461	20992784177	46996		MC
304953	100736461	20992784178	@qwx906996		FO
304953	100736464	20992784198	@@##	----------	----------
304953	100736464	20992784199	@@100736464		FO
304953	100736464	20992784200	@4936464/		JJ_NN1_VV0
304953	100736464	20992784201	<h>		NULL
304953	100736464	20992784202	Prostate	prostate	NN1
304953	100736464	20992784203	Cancer	cancer	NN1
304953	100736464	20992784204	46988		MC
304953	100736464	20992784205	@qwx906988		FO
304953	100736464	20992784206	46994		MC
304953	100736464	20992784207	@qwx906994		FO
304953	100736464	20992784208	46995		MC
304953	100736464	20992784209	@qwx906995		FO
304953	100736464	20992784210	46992		MC
304953	100736464	20992784211	@qwx906992		FO
304953	100736464	20992784212	46991		MC
304953	100736464	20992784213	@qwx906991		FO
304953	100736464	20992784214	46990		MC
304953	100736464	20992784215	@qwx906990		FO
304953	100736464	20992784216	46989		MC
304953	100736464	20992784217	@qwx906989		FO
304953	100736464	20992784218	46993		MC
304953	100736464	20992784219	@qwx906993		FO
304953	100736464	20992784220	<h>		NULL
304953	100736464	20992784221	Screening	screening	NN1_VVG
304953	100736464	20992784222	<p>		NULL
304953	100736464	20992784223	Whether	whether	CSW
304953	100736464	20992784224	a	a	AT1
304953	100736464	20992784225	man	man	NN1
304953	100736464	20992784226	without	without	IW
304953	100736464	20992784227	symptoms	symptom	NN2
304953	100736464	20992784228	of	of	IO
304953	100736464	20992784229	prostate	prostate	NN1
304953	100736464	20992784230	cancer	cancer	NN1
304953	100736464	20992784231	should	should	VM
304953	100736464	20992784232	be	be	VBI
304953	100736464	20992784233	screened	screen	VVN
304953	100736464	20992784234	with	with	IW
304953	100736464	20992784235	a	a	AT1
304953	100736464	20992784236	prostate-specific	prostate-specific	JJ
304953	100736464	20992784237	antigen	antigen	NN1
304953	100736464	20992784238	(	(	(
304953	100736464	20992784239	PSA	psa	NP1
304953	100736464	20992784240	)	)	)
304953	100736464	20992784241	test	test	NN1_VV0
304953	100736464	20992784242	is	be	VBZ
304953	100736464	20992784243	a	a	AT1
304953	100736464	20992784244	controversial	controversial	JJ
304953	100736464	20992784245	question	question	NN1
304953	100736464	20992784246	.	.	.
304953	100736464	20992784247	Prostate	prostate	NN1
304953	100736464	20992784248	cancer	cancer	NN1
304953	100736464	20992784249	is	be	VBZ
304953	100736464	20992784250	usually	usually	RR
304953	100736464	20992784251	a	a	AT1
304953	100736464	20992784252	very	very	RG
304953	100736464	20992784253	slow	slow	JJ_RR@
304953	100736464	20992784254	growing	growing	JJ
304953	100736464	20992784255	cancer	cancer	NN1
304953	100736464	20992784256	,	,	,
304953	100736464	20992784257	and	and	CC
304953	100736464	20992784258	many	many	DA2
304953	100736464	20992784259	men	man	NN2
304953	100736464	20992784260	die	die	VV0
304953	100736464	20992784261	with	with	IW
304953	100736464	20992784262	prostate	prostate	NN1
304953	100736464	20992784263	cancer	cancer	NN1
304953	100736464	20992784264	,	,	,
304953	100736464	20992784265	not	not	XX
304953	100736464	20992784266	from	from	II
304953	100736464	20992784267	it	it	PPH1
304953	100736464	20992784268	.	.	.
304953	100736464	20992784269	Learning	learn	VVG_NN1
304953	100736464	20992784270	that	that	CST
304953	100736464	20992784271	you	you	PPY
304953	100736464	20992784272	have	have	VH0
304953	100736464	20992784273	a	a	AT1
304953	100736464	20992784274	slow-growing	slow-growing	JJ
304953	100736464	20992784275	cancer	cancer	NN1
304953	100736464	20992784276	may	may	VM
304953	100736464	20992784277	just	just	RR
304953	100736464	20992784278	worry	worry	VVI
304953	100736464	20992784279	you	you	PPY
304953	100736464	20992784280	and	and	CC
304953	100736464	20992784281	may	may	VM
304953	100736464	20992784282	lead	lead	VVI
304953	100736464	20992784283	you	you	PPY
304953	100736464	20992784284	to	to	TO
304953	100736464	20992784285	have	have	VHI
304953	100736464	20992784286	unnecessary	unnecessary	JJ
304953	100736464	20992784287	,	,	,
304953	100736464	20992784288	sometimes	sometimes	RT
304953	100736464	20992784289	invasive	invasive	JJ
304953	100736464	20992784290	tests	test	NN2
304953	100736464	20992784291	or	or	CC
304953	100736464	20992784292	undergo	undergo	VV0
304953	100736464	20992784293	treatment	treatment	NN1
304953	100736464	20992784294	.	.	.
304953	100736464	20992784295	On	on	II
304953	100736464	20992784296	the	the	AT
304953	100736464	20992784297	other	other	JJ
304953	100736464	20992784298	hand	hand	NN1
304953	100736464	20992784299	,	,	,
304953	100736464	20992784300	some	some	DD
304953	100736464	20992784301	doctors	doctor	NN2
304953	100736464	20992784302	argue	argue	VV0
304953	100736464	20992784303	that	that	CST_DD1
304953	100736464	20992784304	knowing	know	VVG
304953	100736464	20992784305	a	a	AT1
304953	100736464	20992784306	man	man	NN1
304953	100736464	20992784307	's	's	GE_VBZ
304953	100736464	20992784308	PSA	psa	NP1
304953	100736464	20992784309	level	level	NN1_JJ
304953	100736464	20992784310	and	and	CC
304953	100736464	20992784311	watching	watch	VVG
304953	100736464	20992784312	how	how	RRQ
304953	100736464	20992784313	it	it	PPH1
304953	100736464	20992784314	changes	change	VVZ@
304953	100736464	20992784315	over	over	II
304953	100736464	20992784316	time	time	NNT1
304953	100736464	20992784317	is	be	VBZ
304953	100736464	20992784318	valuable	valuable	JJ
304953	100736464	20992784319	information	information	NN1
304953	100736464	20992784320	.	.	.
304953	100736465	20992784340	@@##	----------	----------
304953	100736465	20992784341	@@100736465		FO
304953	100736465	20992784342	@4936465/		JJ_NN1_VV0
304953	100736465	20992784343	<h>		NULL
304953	100736465	20992784344	Prostate	prostate	NN1
304953	100736465	20992784345	Cancer	cancer	NN1
304953	100736465	20992784346	46988		MC
304953	100736465	20992784347	@qwx906988		FO
304953	100736465	20992784348	46994		MC
304953	100736465	20992784349	@qwx906994		FO
304953	100736465	20992784350	46995		MC
304953	100736465	20992784351	@qwx906995		FO
304953	100736465	20992784352	46992		MC
304953	100736465	20992784353	@qwx906992		FO
304953	100736465	20992784354	46991		MC
304953	100736465	20992784355	@qwx906991		FO
304953	100736465	20992784356	46990		MC
304953	100736465	20992784357	@qwx906990		FO
304953	100736465	20992784358	46989		MC
304953	100736465	20992784359	@qwx906989		FO
304953	100736465	20992784360	46993		MC
304953	100736465	20992784361	@qwx906993		FO
304953	100736465	20992784362	<h>		NULL
304953	100736465	20992784363	Diagnosis	diagnosis	NN1
304953	100736465	20992784364	<p>		NULL
304953	100736465	20992784365	If	if	CS
304953	100736465	20992784366	your	your	APPGE
304953	100736465	20992784367	doctor	doctor	NN1
304953	100736465	20992784368	feels	feel	VVZ
304953	100736465	20992784369	anything	anything	PN1
304953	100736465	20992784370	abnormal	abnormal	JJ
304953	100736465	20992784371	during	during	II
304953	100736465	20992784372	a	a	AT1
304953	100736465	20992784373	digital	digital	JJ
304953	100736465	20992784374	rectal	rectal	JJ
304953	100736465	20992784375	exam	exam	NN1
304953	100736465	20992784376	(	(	(
304953	100736465	20992784377	DRE	dre	NP1
304953	100736465	20992784378	)	)	)
304953	100736465	20992784379	or	or	CC
304953	100736465	20992784380	your	your	APPGE
304953	100736465	20992784381	prostate-specific	prostate-specific	JJ
304953	100736465	20992784382	antigen	antigen	NN1
304953	100736465	20992784383	(	(	(
304953	100736465	20992784384	PSA	psa	NP1
304953	100736465	20992784385	)	)	)
304953	100736465	20992784386	level	level	NN1
304953	100736465	20992784387	is	be	VBZ
304953	100736465	20992784388	elevated	elevate	VVN_JJ
304953	100736465	20992784389	,	,	,
304953	100736465	20992784390	your	your	APPGE
304953	100736465	20992784391	doctor	doctor	NN1
304953	100736465	20992784392	may	may	VM
304953	100736465	20992784393	recommend	recommend	VVI
304953	100736465	20992784394	a	a	AT1
304953	100736465	20992784395	prostate	prostate	NN1
304953	100736465	20992784396	biopsy	biopsy	NN1
304953	100736465	20992784397	.	.	.
304953	100736465	20992784398	During	during	II
304953	100736465	20992784399	this	this	DD1
304953	100736465	20992784400	test	test	NN1
304953	100736465	20992784401	,	,	,
304953	100736465	20992784402	several	several	DA2
304953	100736465	20992784403	small	small	JJ
304953	100736465	20992784404	bits	bit	NN2
304953	100736465	20992784405	of	of	IO
304953	100736465	20992784406	tissue	tissue	NN1
304953	100736465	20992784407	are	be	VBR
304953	100736465	20992784408	removed	remove	VVN
304953	100736465	20992784409	from	from	II
304953	100736465	20992784410	your	your	APPGE
304953	100736465	20992784411	prostate	prostate	NN1
304953	100736465	20992784412	.	.	.
304953	100736465	20992784413	A	a	AT1
304953	100736465	20992784414	pathologist	pathologist	NN1
304953	100736465	20992784415	then	then	RT
304953	100736465	20992784416	studies	study	VVZ%
304953	100736465	20992784417	the	the	AT
304953	100736465	20992784418	tissue	tissue	NN1
304953	100736465	20992784419	under	under	II
304953	100736465	20992784420	a	a	AT1
304953	100736465	20992784421	microscope	microscope	NN1
304953	100736465	20992784422	to	to	TO
304953	100736465	20992784423	see	see	VVI
304953	100736465	20992784424	if	if	CSW@_CS
304953	100736465	20992784425	cancer	cancer	NN1
304953	100736465	20992784426	is	be	VBZ
304953	100736465	20992784427	present	present	JJ_NN1
304953	100736465	20992784428	;	;	;
304953	100736465	20992784429	a	a	AT1
304953	100736465	20992784430	pathology	pathology	NN1
304953	100736465	20992784431	report	report	NN1
304953	100736465	20992784432	conveys	convey	VVZ
304953	100736465	20992784433	the	the	AT
304953	100736465	20992784434	biopsy	biopsy	NN1
304953	100736465	20992784435	findings	finding	NN2
304953	100736465	20992784436	.	.	.
304953	100736465	20992784437	Pathology	pathology	NN1
304953	100736465	20992784438	reports	report	NN2
304953	100736465	20992784439	should	should	VM
304953	100736465	20992784440	contain	contain	VVI
304953	100736465	20992784441	lots	lots	PN
304953	100736465	20992784442	of	of	IO
304953	100736465	20992784443	details	detail	NN2
304953	100736465	20992784444	,	,	,
304953	100736465	20992784445	especially	especially	RR
304953	100736465	20992784446	if	if	CS
304953	100736465	20992784447	cancer	cancer	NN1
304953	100736465	20992784448	is	be	VBZ
304953	100736465	20992784449	diagnosed	diagnose	VVN
304953	100736465	20992784450	,	,	,
304953	100736465	20992784451	and	and	CC
304953	100736465	20992784452	it	it	PPH1
304953	100736465	20992784453	is	be	VBZ
304953	100736465	20992784454	important	important	JJ
304953	100736465	20992784455	that	that	CST
304953	100736465	20992784456	you	you	PPY
304953	100736465	20992784457	understand	understand	VV0
304953	100736465	20992784458	your	your	APPGE
304953	100736465	20992784459	report	report	NN1
304953	100736465	20992784460	.	.	.
304953	100736465	20992784461	In	in	II
304953	100736465	20992784462	some	some	DD
304953	100736465	20992784463	cases	case	NN2
304953	100736465	20992784464	,	,	,
304953	100736465	20992784465	imaging	image	VVG_NN1
304953	100736465	20992784466	tests	test	NN2
304953	100736465	20992784467	may	may	VM
304953	100736465	20992784468	be	be	VBI
304953	100736465	20992784469	helpful	helpful	JJ
304953	100736465	20992784470	in	in	II
304953	100736465	20992784471	diagnosing	diagnose	VVG_JJ@
304953	100736465	20992784472	prostate	prostate	NN1
304953	100736465	20992784473	cancer	cancer	NN1
304953	100736465	20992784474	,	,	,
304953	100736465	20992784475	pinpointing	pinpoint	VVG
304953	100736465	20992784476	its	its	APPGE
304953	100736465	20992784477	location	location	NN1
304953	100736465	20992784478	,	,	,
304953	100736465	20992784479	or	or	CC
304953	100736465	20992784480	determining	determine	VVG
304953	100736465	20992784481	its	its	APPGE
304953	100736465	20992784482	stage	stage	NN1
304953	100736465	20992784483	(	(	(
304953	100736465	20992784484	how	how	RRQ_RGQ@
304953	100736465	20992784485	advanced	advance	VVD_JJ_VVN
304953	100736465	20992784486	it	it	PPH1
304953	100736465	20992784487	is	be	VBZ
304953	100736465	20992784488	)	)	)
304953	100736465	20992784489	.	.	.
304953	100736466	20992784509	@@##	----------	----------
304953	100736466	20992784510	@@100736466		FO
304953	100736466	20992784511	@4936466/		VV0_JJ
304953	100736466	20992784512	<h>		NULL
304953	100736466	20992784513	Other	other	JJ
304953	100736466	20992784514	Conditions	condition	NN2
304953	100736466	20992784515	46988		MC
304953	100736466	20992784516	@qwx906988		FO
304953	100736466	20992784517	46994		MC
304953	100736466	20992784518	@qwx906994		FO
304953	100736466	20992784519	46995		MC
304953	100736466	20992784520	@qwx906995		FO
304953	100736466	20992784521	46992		MC
304953	100736466	20992784522	@qwx906992		FO
304953	100736466	20992784523	46991		MC
304953	100736466	20992784524	@qwx906991		FO
304953	100736466	20992784525	46990		MC
304953	100736466	20992784526	@qwx906990		FO
304953	100736466	20992784527	46989		MC
304953	100736466	20992784528	@qwx906989		FO
304953	100736466	20992784529	46993		MC
304953	100736466	20992784530	@qwx906993		FO
304953	100736466	20992784531	<h>		NULL
304953	100736466	20992784532	Hematospermia		NP1
304953	100736466	20992784533	<p>		NULL
304953	100736466	20992784534	Hematospermia		NN1_NP1@
304953	100736466	20992784535	is	be	VBZ
304953	100736466	20992784536	a	a	AT1
304953	100736466	20992784537	condition	condition	NN1
304953	100736466	20992784538	that	that	CST_DD1
304953	100736466	20992784539	causes	cause	VVZ
304953	100736466	20992784540	blood	blood	NN1
304953	100736466	20992784541	in	in	II
304953	100736466	20992784542	a	a	AT1
304953	100736466	20992784543	man	man	NN1
304953	100736466	20992784544	's	's	GE
304953	100736466	20992784545	ejaculate	ejaculate	NN1
304953	100736466	20992784546	.	.	.
304953	100736466	20992784547	Although	although	CS
304953	100736466	20992784548	bloody	bloody	JJ_RR
304953	100736466	20992784549	ejaculate	ejaculate	NN1_VV0
304953	100736466	20992784550	can	can	VM
304953	100736466	20992784551	be	be	VBI
304953	100736466	20992784552	a	a	AT1
304953	100736466	20992784553	symptom	symptom	NN1
304953	100736466	20992784554	of	of	IO
304953	100736466	20992784555	prostate	prostate	NN1
304953	100736466	20992784556	cancer	cancer	NN1
304953	100736466	20992784557	and	and	CC
304953	100736466	20992784558	sexually	sexually	RR
304953	100736466	20992784559	transmitted	transmitted	JJ_VVN
304953	100736466	20992784560	diseases	disease	NN2
304953	100736466	20992784561	,	,	,
304953	100736466	20992784562	it	it	PPH1
304953	100736466	20992784563	can	can	VM
304953	100736466	20992784564	occur	occur	VVI
304953	100736466	20992784565	as	as	II
304953	100736466	20992784566	a	a	AT1
304953	100736466	20992784567	side	side	NN1
304953	100736466	20992784568	effect	effect	NN1
304953	100736466	20992784569	of	of	IO
304953	100736466	20992784570	a	a	AT1
304953	100736466	20992784571	recent	recent	JJ
304953	100736466	20992784572	medical	medical	JJ
304953	100736466	20992784573	procedure	procedure	NN1
304953	100736466	20992784574	or	or	CC
304953	100736466	20992784575	for	for	IF
304953	100736466	20992784576	no	no	AT
304953	100736466	20992784577	apparent	apparent	JJ
304953	100736466	20992784578	reason	reason	NN1
304953	100736466	20992784579	.	.	.
304953	100736466	20992784580	It	it	PPH1
304953	100736466	20992784581	often	often	RR
304953	100736466	20992784582	requires	require	VVZ
304953	100736466	20992784583	some	some	DD
304953	100736466	20992784584	detective	detective	NN1
304953	100736466	20992784585	work	work	NN1_VV0
304953	100736466	20992784586	to	to	TO
304953	100736466	20992784587	sort	sort	VVI
304953	100736466	20992784588	out	out	RP
304953	100736466	20992784589	.	.	.
304953	100736467	20992784609	@@##	----------	----------
304953	100736467	20992784610	@@100736467		FO
304953	100736467	20992784611	@4936467/		JJ_NN1_VV0
304953	100736467	20992784612	<h>		NULL
304953	100736467	20992784613	Prostate	prostate	NN1
304953	100736467	20992784614	Cancer	cancer	NN1
304953	100736467	20992784615	46988		MC
304953	100736467	20992784616	@qwx906988		FO
304953	100736467	20992784617	46994		MC
304953	100736467	20992784618	@qwx906994		FO
304953	100736467	20992784619	46995		MC
304953	100736467	20992784620	@qwx906995		FO
304953	100736467	20992784621	46992		MC
304953	100736467	20992784622	@qwx906992		FO
304953	100736467	20992784623	46991		MC
304953	100736467	20992784624	@qwx906991		FO
304953	100736467	20992784625	46990		MC
304953	100736467	20992784626	@qwx906990		FO
304953	100736467	20992784627	46989		MC
304953	100736467	20992784628	@qwx906989		FO
304953	100736467	20992784629	46993		MC
304953	100736467	20992784630	@qwx906993		FO
304953	100736467	20992784631	<h>		NULL
304953	100736467	20992784632	Living	live	VVG_NN1
304953	100736467	20992784633	With	with	IW
304953	100736467	20992784634	Prostate	prostate	NN1
304953	100736467	20992784635	Cancer	cancer	NN1
304953	100736467	20992784636	<p>		NULL
304953	100736467	20992784637	Living	live	VVG_NN1_JJ
304953	100736467	20992784638	with	with	IW
304953	100736467	20992784639	prostate	prostate	NN1
304953	100736467	20992784640	cancer	cancer	NN1
304953	100736467	20992784641	means	mean	VVZ_NN
304953	100736467	20992784642	different	different	JJ
304953	100736467	20992784643	things	thing	NN2
304953	100736467	20992784644	for	for	IF
304953	100736467	20992784645	different	different	JJ
304953	100736467	20992784646	patients	patient	NN2
304953	100736467	20992784647	.	.	.
304953	100736467	20992784648	For	for	IF
304953	100736467	20992784649	those	those	DD2
304953	100736467	20992784650	who	who	PNQS
304953	100736467	20992784651	chose	choose	VVD
304953	100736467	20992784652	active	active	JJ
304953	100736467	20992784653	surveillance	surveillance	NN1
304953	100736467	20992784654	,	,	,
304953	100736467	20992784655	it	it	PPH1
304953	100736467	20992784656	means	mean	VVZ
304953	100736467	20992784657	living	live	VVG_NN1_JJ
304953	100736467	20992784658	with	with	IW
304953	100736467	20992784659	frequent	frequent	JJ
304953	100736467	20992784660	monitoring	monitoring	NN1
304953	100736467	20992784661	tests	test	NN2_VVZ@
304953	100736467	20992784662	to	to	TO
304953	100736467	20992784663	keep	keep	VVI
304953	100736467	20992784664	an	a	AT1
304953	100736467	20992784665	eye	eye	NN1
304953	100736467	20992784666	on	on	II
304953	100736467	20992784667	the	the	AT
304953	100736467	20992784668	cancer	cancer	NN1
304953	100736467	20992784669	.	.	.
304953	100736467	20992784670	For	for	IF
304953	100736467	20992784671	those	those	DD2
304953	100736467	20992784672	who	who	PNQS
304953	100736467	20992784673	chose	choose	VVD
304953	100736467	20992784674	surgery	surgery	NN1
304953	100736467	20992784675	or	or	CC
304953	100736467	20992784676	another	another	DD1
304953	100736467	20992784677	treatment	treatment	NN1
304953	100736467	20992784678	,	,	,
304953	100736467	20992784679	it	it	PPH1
304953	100736467	20992784680	may	may	VM
304953	100736467	20992784681	mean	mean	VVI
304953	100736467	20992784682	coping	cope	VVG
304953	100736467	20992784683	with	with	IW
304953	100736467	20992784684	the	the	AT
304953	100736467	20992784685	side	side	NN1
304953	100736467	20992784686	effects	effect	NN2
304953	100736467	20992784687	,	,	,
304953	100736467	20992784688	including	including	II_VVG@
304953	100736467	20992784689	incontinence	incontinence	NN1
304953	100736467	20992784690	and	and	CC
304953	100736467	20992784691	erectile	erectile	JJ
304953	100736467	20992784692	dysfunction	dysfunction	NN1
304953	100736467	20992784693	.	.	.
304953	100736467	20992784694	For	for	IF
304953	100736467	20992784695	men	man	NN2
304953	100736467	20992784696	whose	whose	DDQGE
304953	100736467	20992784697	cancer	cancer	NN1
304953	100736467	20992784698	has	have	VHZ
304953	100736467	20992784699	been	be	VBN
304953	100736467	20992784700	treated	treat	VVN
304953	100736467	20992784701	,	,	,
304953	100736467	20992784702	it	it	PPH1
304953	100736467	20992784703	also	also	RR
304953	100736467	20992784704	means	mean	VVZ_NN
304953	100736467	20992784705	being	be	VBG
304953	100736467	20992784706	alert	alert	JJ
304953	100736467	20992784707	for	for	IF
304953	100736467	20992784708	the	the	AT
304953	100736467	20992784709	disease	disease	NN1
304953	100736467	20992784710	's	's	GE_VBZ
304953	100736467	20992784711	possible	possible	JJ
304953	100736467	20992784712	recurrence.		NNU
304953	100736468	20992784732	@@##	----------	----------
304953	100736468	20992784733	@@100736468		FO
304953	100736468	20992784734	@4936468/		JJ_NN1_VV0
304953	100736468	20992784735	<h>		NULL
304953	100736468	20992784736	Prostate	prostate	NN1
304953	100736468	20992784737	Cancer	cancer	NN1
304953	100736468	20992784738	46988		MC
304953	100736468	20992784739	@qwx906988		FO
304953	100736468	20992784740	46994		MC
304953	100736468	20992784741	@qwx906994		FO
304953	100736468	20992784742	46995		MC
304953	100736468	20992784743	@qwx906995		FO
304953	100736468	20992784744	46992		MC
304953	100736468	20992784745	@qwx906992		FO
304953	100736468	20992784746	46991		MC
304953	100736468	20992784747	@qwx906991		FO
304953	100736468	20992784748	46990		MC
304953	100736468	20992784749	@qwx906990		FO
304953	100736468	20992784750	46989		MC
304953	100736468	20992784751	@qwx906989		FO
304953	100736468	20992784752	46993		MC
304953	100736468	20992784753	@qwx906993		FO
304953	100736468	20992784754	<h>		NULL
304953	100736468	20992784755	Pathology	pathology	NN1
304953	100736468	20992784756	Report	report	NN1
304953	100736468	20992784757	<p>		NULL
304953	100736468	20992784758	If	if	CS
304953	100736468	20992784759	you	you	PPY
304953	100736468	20992784760	have	have	VH0
304953	100736468	20992784761	been	be	VBN
304953	100736468	20992784762	diagnosed	diagnose	VVN
304953	100736468	20992784763	with	with	IW
304953	100736468	20992784764	prostate	prostate	NN1
304953	100736468	20992784765	cancer	cancer	NN1
304953	100736468	20992784766	,	,	,
304953	100736468	20992784767	your	your	APPGE
304953	100736468	20992784768	pathology	pathology	NN1
304953	100736468	20992784769	report	report	NN1
304953	100736468	20992784770	contains	contain	VVZ
304953	100736468	20992784771	critical	critical	JJ
304953	100736468	20992784772	information	information	NN1
304953	100736468	20992784773	.	.	.
304953	100736468	20992784774	For	for	REX21
304953	100736468	20992784775	example	example	REX22
304953	100736468	20992784776	,	,	,
304953	100736468	20992784777	it	it	PPH1
304953	100736468	20992784778	can	can	VM
304953	100736468	20992784779	tell	tell	VVI
304953	100736468	20992784780	you	you	PPY
304953	100736468	20992784781	the	the	AT
304953	100736468	20992784782	location	location	NN1
304953	100736468	20992784783	and	and	CC
304953	100736468	20992784784	extent	extent	NN1
304953	100736468	20992784785	of	of	IO
304953	100736468	20992784786	the	the	AT
304953	100736468	20992784787	cancer	cancer	NN1
304953	100736468	20992784788	.	.	.
304953	100736468	20992784789	This	this	DD1
304953	100736468	20992784790	information	information	NN1
304953	100736468	20992784791	can	can	VM
304953	100736468	20992784792	help	help	VVI
304953	100736468	20992784793	you	you	PPY
304953	100736468	20992784794	and	and	CC
304953	100736468	20992784795	your	your	APPGE
304953	100736468	20992784796	doctor	doctor	NN1
304953	100736468	20992784797	decide	decide	VV0
304953	100736468	20992784798	what	what	DDQ
304953	100736468	20992784799	treatment	treatment	NN1
304953	100736468	20992784800	,	,	,
304953	100736468	20992784801	if	if	CS
304953	100736468	20992784802	any	any	DD
304953	100736468	20992784803	,	,	,
304953	100736468	20992784804	is	be	VBZ
304953	100736468	20992784805	best	best	JJT
304953	100736468	20992784806	.	.	.
304953	100736468	20992784807	<p>		NULL
304953	100736468	20992784808	It	it	PPH1
304953	100736468	20992784809	should	should	VM
304953	100736468	20992784810	be	be	VBI
304953	100736468	20992784811	clear	clear	JJ
304953	100736468	20992784812	by	by	II
304953	100736468	20992784813	now	now	CS21_RT@
304953	100736468	20992784814	that	that	CS22_DD1
304953	100736468	20992784815	pathology	pathology	NN1
304953	100736468	20992784816	reports	report	NN2
304953	100736468	20992784817	vary	vary	VV0
304953	100736468	20992784818	in	in	II_RP@
304953	100736468	20992784819	large	large	JJ
304953	100736468	20992784820	part	part	NN1
304953	100736468	20992784821	because	because	CS
304953	100736468	20992784822	the	the	AT
304953	100736468	20992784823	clinical	clinical	JJ
304953	100736468	20992784824	features	feature	NN2
304953	100736468	20992784825	they	they	PPHS2
304953	100736468	20992784826	analyze	analyze	VV0
304953	100736468	20992784827	often	often	RR
304953	100736468	20992784828	require	require	VV0
304953	100736468	20992784829	some	some	DD
304953	100736468	20992784830	subjective	subjective	JJ
304953	100736468	20992784831	interpretation	interpretation	NN1
304953	100736468	20992784832	.	.	.
304953	100736468	20992784833	This	this	DD1
304953	100736468	20992784834	means	mean	VVZ
304953	100736468	20992784835	it	it	PPH1
304953	100736468	20992784836	's	be	VBZ
304953	100736468	20992784837	important	important	JJ
304953	100736468	20992784838	to	to	TO
304953	100736468	20992784839	question	question	VVI
304953	100736468	20992784840	the	the	AT
304953	100736468	20992784841	findings	finding	NN2
304953	100736468	20992784842	and	and	CC
304953	100736468	20992784843	make	make	VVI
304953	100736468	20992784844	sure	sure	JJ
304953	100736468	20992784845	you	you	PPY
304953	100736468	20992784846	understand	understand	VV0
304953	100736468	20992784847	them	them	PPHO2
304953	100736468	20992784848	before	before	CS
304953	100736468	20992784849	you	you	PPY
304953	100736468	20992784850	make	make	VV0
304953	100736468	20992784851	any	any	DD
304953	100736468	20992784852	decisions	decision	NN2
304953	100736468	20992784853	about	about	II
304953	100736468	20992784854	treatment	treatment	NN1
304953	100736468	20992784855	.	.	.
304953	100736468	20992784856	Start	start	VV0_NN1
304953	100736468	20992784857	by	by	II
304953	100736468	20992784858	studying	study	VVG
304953	100736468	20992784859	your	your	APPGE
304953	100736468	20992784860	pathology	pathology	NN1
304953	100736468	20992784861	report	report	NN1
304953	100736468	20992784862	closely	closely	RR
304953	100736468	20992784863	.	.	.
304953	100736468	20992784864	Circle	circle	VV0@
304953	100736468	20992784865	anything	anything	PN1
304953	100736468	20992784866	that	that	CST
304953	100736468	20992784867	<p>		NULL
304953	100736468	20992784868	Not	not	XX
304953	100736468	20992784869	all	all	DB
304953	100736468	20992784870	pathology	pathology	NN1
304953	100736468	20992784871	reports	report	NN2
304953	100736468	20992784872	are	be	VBR
304953	100736468	20992784873	created	create	VVN
304953	100736468	20992784874	equal	equal	JJ
304953	100736468	20992784875	.	.	.
304953	100736468	20992784876	In	in	II
304953	100736468	20992784877	fact	fact	NN1
304953	100736468	20992784878	,	,	,
304953	100736468	20992784879	they	they	PPHS2
304953	100736468	20992784880	can	can	VM
304953	100736468	20992784881	vary	vary	VVI
304953	100736468	20992784882	widely	widely	RR
304953	100736468	20992784883	even	even	RR
304953	100736468	20992784884	within	within	II
304953	100736468	20992784885	a	a	AT1
304953	100736468	20992784886	single	single	JJ
304953	100736468	20992784887	institution	institution	NN1
304953	100736468	20992784888	.	.	.
304953	100736468	20992784889	Learn	learn	VV0
304953	100736468	20992784890	what	what	DDQ
304953	100736468	20992784891	your	your	APPGE
304953	100736468	20992784892	report	report	NN1
304953	100736468	20992784893	should	should	VM
304953	100736468	20992784894	contain	contain	VVI
304953	100736468	20992784895	,	,	,
304953	100736468	20992784896	what	what	DDQ
304953	100736468	20992784897	it	it	PPH1
304953	100736468	20992784898	means	mean	VVZ
304953	100736468	20992784899	,	,	,
304953	100736468	20992784900	and	and	CC
304953	100736468	20992784901	why	why	RRQ
304953	100736468	20992784902	asking	asking	NN1@
304953	100736468	20992784903	questions	question	NN2
304953	100736468	20992784904	about	about	II
304953	100736468	20992784905	it	it	PPH1
304953	100736468	20992784906	can	can	VM
304953	100736468	20992784907	lead	lead	VVI
304953	100736468	20992784908	to	to	II
304953	100736468	20992784909	better	better	JJR
304953	100736468	20992784910	care	care	NN1
304953	100736468	20992784911	.	.	.
304953	100736469	20992784931	@@##	----------	----------
304953	100736469	20992784932	@@100736469		FO
304953	100736469	20992784933	@4936469/		JJ_NN1_VV0
304953	100736469	20992784934	<h>		NULL
304953	100736469	20992784935	Prostate	prostate	NN1
304953	100736469	20992784936	Cancer	cancer	NN1
304953	100736469	20992784937	46988		MC
304953	100736469	20992784938	@qwx906988		FO
304953	100736469	20992784939	46994		MC
304953	100736469	20992784940	@qwx906994		FO
304953	100736469	20992784941	46995		MC
304953	100736469	20992784942	@qwx906995		FO
304953	100736469	20992784943	46992		MC
304953	100736469	20992784944	@qwx906992		FO
304953	100736469	20992784945	46991		MC
304953	100736469	20992784946	@qwx906991		FO
304953	100736469	20992784947	46990		MC
304953	100736469	20992784948	@qwx906990		FO
304953	100736469	20992784949	46989		MC
304953	100736469	20992784950	@qwx906989		FO
304953	100736469	20992784951	46993		MC
304953	100736469	20992784952	@qwx906993		FO
304953	100736469	20992784953	<h>		NULL
304953	100736469	20992784954	Erectile	erectile	JJ_NP1
304953	100736469	20992784955	Dysfunction	dysfunction	NN1_NP1@
304953	100736469	20992784956	(	(	(
304953	100736469	20992784957	ED	ed	NP1
304953	100736469	20992784958	)	)	)
304953	100736469	20992784959	<p>		NULL
304953	100736469	20992784960	Erectile	erectile	JJ
304953	100736469	20992784961	dysfunction	dysfunction	NN1
304953	100736469	20992784962	(	(	(
304953	100736469	20992784963	ED	ed	NP1
304953	100736469	20992784964	)	)	)
304953	100736469	20992784965	is	be	VBZ
304953	100736469	20992784966	a	a	AT1
304953	100736469	20992784967	common	common	JJ
304953	100736469	20992784968	side	side	NN1
304953	100736469	20992784969	effect	effect	NN1
304953	100736469	20992784970	of	of	IO
304953	100736469	20992784971	many	many	DA2
304953	100736469	20992784972	prostate	prostate	NN1
304953	100736469	20992784973	cancer	cancer	NN1
304953	100736469	20992784974	treatments	treatment	NN2
304953	100736469	20992784975	.	.	.
304953	100736469	20992784976	Coping	cope	VVG
304953	100736469	20992784977	with	with	IW
304953	100736469	20992784978	ED	ed	NP1_NN1@
304953	100736469	20992784979	can	can	VM
304953	100736469	20992784980	be	be	VBI
304953	100736469	20992784981	frustrating	frustrating	JJ
304953	100736469	20992784982	,	,	,
304953	100736469	20992784983	but	but	CCB
304953	100736469	20992784984	it	it	PPH1
304953	100736469	20992784985	can	can	VM
304953	100736469	20992784986	be	be	VBI
304953	100736469	20992784987	treated	treat	VVN
304953	100736469	20992784988	and	and	CC
304953	100736469	20992784989	managed	manage	VVN
304953	100736469	20992784990	,	,	,
304953	100736469	20992784991	allowing	allow	VVG
304953	100736469	20992784992	a	a	AT1
304953	100736469	20992784993	man	man	NN1
304953	100736469	20992784994	and	and	CC
304953	100736469	20992784995	his	his	APPGE
304953	100736469	20992784996	partner	partner	NN1
304953	100736469	20992784997	to	to	TO
304953	100736469	20992784998	have	have	VHI
304953	100736469	20992784999	a	a	AT1
304953	100736469	20992785000	satisfying	satisfying	JJ
304953	100736469	20992785001	sexual	sexual	JJ
304953	100736469	20992785002	relationship	relationship	NN1
304953	100736469	20992785003	.	.	.
304953	100736469	20992785004	<h>		NULL
304953	100736469	20992785005	Related	related	JJ
304953	100736469	20992785006	Articles	article	NN2
304953	100736469	20992785007	<p>		NULL
304953	100736469	20992785008	Some	some	DD
304953	100736469	20992785009	men	man	NN2
304953	100736469	20992785010	have	have	VH0
304953	100736469	20992785011	a	a	AT1
304953	100736469	20992785012	slightly	slightly	RR
304953	100736469	20992785013	shorter	short	JJR
304953	100736469	20992785014	penis	penis	NN1
304953	100736469	20992785015	after	after	II
304953	100736469	20992785016	undergoing	undergo	VVG
304953	100736469	20992785017	surgery	surgery	NN1
304953	100736469	20992785018	to	to	TO
304953	100736469	20992785019	remove	remove	VVI
304953	100736469	20992785020	a	a	AT1
304953	100736469	20992785021	cancerous	cancerous	JJ
304953	100736469	20992785022	prostate	prostate	NN1
304953	100736469	20992785023	gland	gland	NN1
304953	100736469	20992785024	.	.	.
304953	100736469	20992785025	A	a	AT1_ZZ1
304953	100736469	20992785026	new	new	JJ
304953	100736469	20992785027	study	study	NN1
304953	100736469	20992785028	shows	show	VVZ
304953	100736469	20992785029	that	that	CST
304953	100736469	20992785030	taking	take	VVG
304953	100736469	20992785031	an	a	AT1
304953	100736469	20992785032	erectile	erectile	JJ
304953	100736469	20992785033	dysfunction	dysfunction	NN1
304953	100736469	20992785034	drug	drug	NN1
304953	100736469	20992785035	like	like	II
304953	100736469	20992785036	Viagra	viagra	NP1
304953	100736469	20992785037	or	or	CC
304953	100736469	20992785038	Cialis	cialis	NN1_NP1
304953	100736469	20992785039	after	after	II_CS
304953	100736469	20992785040	surgery	surgery	NN1
304953	100736469	20992785041	can	can	VM
304953	100736469	20992785042	prevent	prevent	VVI
304953	100736469	20992785043	that	that	CST_DD1
304953	100736469	20992785044	from	from	II
304953	100736469	20992785045	happening	happening	NN1_VVG
304953	100736469	20992785046	.	.	.
304953	100736469	20992785047	<p>		NULL
304953	100736469	20992785048	Radical	radical	JJ_NN1
304953	100736469	20992785049	prostatectomy	prostatectomy	NN1
304953	100736469	20992785050	changes	change	VVZ@_NN2
304953	100736469	20992785051	the	the	AT
304953	100736469	20992785052	experience	experience	NN1
304953	100736469	20992785053	of	of	IO
304953	100736469	20992785054	orgasm	orgasm	NN1
304953	100736469	20992785055	.	.	.
304953	100736469	20992785056	But	but	CCB
304953	100736469	20992785057	it	it	PPH1
304953	100736469	20992785058	does	do	VDZ
304953	100736469	20992785059	n't 	n't	XX
304953	100736469	20992785060	need	need	VVI
304953	100736469	20992785061	to	to	TO
304953	100736469	20992785062	be	be	VBI
304953	100736469	20992785063	any	any	DD
304953	100736469	20992785064	less	less	DAR_RGR
304953	100736469	20992785065	pleasurable	pleasurable	JJ
304953	100736469	20992785066	or	or	CC
304953	100736469	20992785067	satisfying	satisfying	JJ
304953	100736469	20992785068	,	,	,
304953	100736469	20992785069	says	say	VVZ
304953	100736469	20992785070	Dr.		NNB
304953	100736469	20992785071	Ravi	ravi	NP1
304953	100736469	20992785072	Kacker		NP1
304953	100736469	20992785073	,	,	,
304953	100736469	20992785074	a	a	AT1
304953	100736469	20992785075	urologist	urologist	NN1
304953	100736469	20992785076	and	and	CC
304953	100736469	20992785077	fellow	fellow	NN1_JJ
304953	100736469	20992785078	in	in	II
304953	100736469	20992785079	male	male	JJ
304953	100736469	20992785080	sexual	sexual	JJ
304953	100736469	20992785081	medicine	medicine	NN1
304953	100736469	20992785082	at	at	II
304953	100736469	20992785083	Harvard-affiliated	harvard-affiliated	JJ_NN1
304953	100736469	20992785084	Beth	beth	NP1
304953	100736469	20992785085	Israel	israel	NP1
304953	100736469	20992785086	Deaconess	deaconess	NN1
304953	100736469	20992785087	Medical	medical	JJ
304953	100736469	20992785088	Center	center	NN1
304953	100736469	20992785089	.	.	.
304953	100736469	20992785090	<p>		NULL
304953	100736469	20992785091	Emerging	emerging	JJ_VVG
304953	100736469	20992785092	scientific	scientific	JJ
304953	100736469	20992785093	evidence	evidence	NN1
304953	100736469	20992785094	suggests	suggest	VVZ
304953	100736469	20992785095	that	that	CST_DD1
304953	100736469	20992785096	engaging	engage	VVG_JJ
304953	100736469	20992785097	in	in	II_RP@
304953	100736469	20992785098	a	a	AT1
304953	100736469	20992785099	few	few	DA2
304953	100736469	20992785100	hours	hour	NNT2
304953	100736469	20992785101	of	of	IO
304953	100736469	20992785102	exercise	exercise	NN1_VV0
304953	100736469	20992785103	a	a	AT1
304953	100736469	20992785104	week	week	NNT1
304953	100736469	20992785105	"	"	"
304953	100736469	20992785106	including	including	II
304953	100736469	20992785107	strength	strength	NN1
304953	100736469	20992785108	training	training	NN1
304953	100736469	20992785109	,	,	,
304953	100736469	20992785110	stretching	stretch	VVG
304953	100736469	20992785111	,	,	,
304953	100736469	20992785112	and	and	CC
304953	100736469	20992785113	balance	balance	NN1_VV0@
304953	100736469	20992785114	exercises	exercise	NN2_VVZ
304953	100736469	20992785115	"	"	"
304953	100736469	20992785116	may	may	VM
304953	100736469	20992785117	reduce	reduce	VVI
304953	100736469	20992785118	the	the	AT
304953	100736469	20992785119	risk	risk	NN1
304953	100736469	20992785120	of	of	IO
304953	100736469	20992785121	erectile	erectile	JJ
304953	100736469	20992785122	dysfunction	dysfunction	NN1
304953	100736469	20992785123	@		II
304953	100736469	20992785124	@		II
304953	100736469	20992785125	@		II
304953	100736469	20992785126	@		II
304953	100736469	20992785127	@		II
304953	100736469	20992785128	@		II
304953	100736469	20992785129	@		II
304953	100736469	20992785130	@		II
304953	100736469	20992785131	@		II
304953	100736469	20992785132	@		II
304953	100736469	20992785133	men	man	NN2
304953	100736469	20992785134	who	who	PNQS
304953	100736469	20992785135	have	have	VH0
304953	100736469	20992785136	their	their	APPGE
304953	100736469	20992785137	neurovascular		JJ
304953	100736469	20992785138	bundles	bundle	NN2
304953	100736469	20992785139	removed	remove	VVN_VVD
304953	100736469	20992785140	during	during	II
304953	100736469	20992785141	a	a	AT1
304953	100736469	20992785142	radical	radical	JJ_NN1
304953	100736469	20992785143	prostatectomy	prostatectomy	NN1
304953	100736469	20992785144	may	may	VM
304953	100736469	20992785145	regain	regain	VVI
304953	100736469	20992785146	erectile	erectile	JJ
304953	100736469	20992785147	function	function	NN1
304953	100736469	20992785148	with	with	IW
304953	100736469	20992785149	nerve	nerve	NN1
304953	100736469	20992785150	grafts	graft	NN2_VVZ
304953	100736469	20992785151	.	.	.
304953	100736469	20992785152	But	but	CCB
304953	100736469	20992785153	a	a	AT1
304953	100736469	20992785154	patients	patient	NN2
304953	100736469	20992785155	best	best	RRT
304953	100736469	20992785156	bet	bet	VV0
304953	100736469	20992785157	for	for	IF
304953	100736469	20992785158	preserving	preserve	VVG_JJ
304953	100736469	20992785159	erectile	erectile	JJ
304953	100736469	20992785160	function	function	NN1
304953	100736469	20992785161	is	be	VBZ
304953	100736469	20992785162	to	to	TO
304953	100736469	20992785163	find	find	VVI
304953	100736469	20992785164	an	a	AT1
304953	100736469	20992785165	experienced	experienced	JJ
304953	100736469	20992785166	surgeon	surgeon	NN1
304953	100736469	20992785167	.	.	.
304953	100736469	20992785168	<p>		NULL
304953	100736469	20992785169	Erectile	erectile	JJ
304953	100736469	20992785170	dysfunction	dysfunction	NN1
304953	100736469	20992785171	can	can	VM
304953	100736469	20992785172	have	have	VHI
304953	100736469	20992785173	many	many	DA2
304953	100736469	20992785174	causes	cause	NN2
304953	100736469	20992785175	,	,	,
304953	100736469	20992785176	including	including	II_VVG@
304953	100736469	20992785177	some	some	DD
304953	100736469	20992785178	forms	form	NN2
304953	100736469	20992785179	of	of	IO
304953	100736469	20992785180	prostate	prostate	NN1
304953	100736469	20992785181	disease	disease	NN1
304953	100736469	20992785182	and	and	CC
304953	100736469	20992785183	prostate	prostate	NN1
304953	100736469	20992785184	cancer	cancer	NN1
304953	100736469	20992785185	surgery	surgery	NN1
304953	100736469	20992785186	.	.	.
304953	100736469	20992785187	The	the	AT
304953	100736469	20992785188	problem	problem	NN1
304953	100736469	20992785189	can	can	VM
304953	100736469	20992785190	often	often	RR
304953	100736469	20992785191	be	be	VBI
304953	100736469	20992785192	effectively	effectively	RR
304953	100736469	20992785193	addressed	address	VVN_VVD
304953	100736469	20992785194	.	.	.
304953	100736469	20992785195	Some	some	DD
304953	100736469	20992785196	men	man	NN2
304953	100736469	20992785197	find	find	VV0
304953	100736469	20992785198	relief	relief	NN1
304953	100736469	20992785199	by	by	II
304953	100736469	20992785200	taking	take	VVG
304953	100736469	20992785201	medications	medication	NN2
304953	100736469	20992785202	.	.	.
304953	100736469	20992785203	If	if	CS
304953	100736469	20992785204	these	these	DD2
304953	100736469	20992785205	are	be	VBR
304953	100736469	20992785206	n't	n't	XX
304953	100736469	20992785207	effective	effective	JJ
304953	100736469	20992785208	for	for	IF
304953	100736469	20992785209	you	you	PPY
304953	100736469	20992785210	,	,	,
304953	100736469	20992785211	a	a	AT1
304953	100736469	20992785212	number	number	NN1
304953	100736469	20992785213	of	of	IO
304953	100736469	20992785214	other	other	JJ
304953	100736469	20992785215	options	option	NN2
304953	100736469	20992785216	,	,	,
304953	100736469	20992785217	including	including	II_VVG@
304953	100736469	20992785218	injections	injection	NN2
304953	100736469	20992785219	and	and	CC
304953	100736469	20992785220	vacuum	vacuum	NN1_VV0@
304953	100736469	20992785221	devices	device	NN2
304953	100736469	20992785222	,	,	,
304953	100736469	20992785223	are	be	VBR
304953	100736469	20992785224	available	available	JJ
304953	100736469	20992785225	.	.	.
304953	100736469	20992785226	<p>		NULL
304953	100736469	20992785227	Penile	penile	JJ_NN1
304953	100736469	20992785228	rehabilitation	rehabilitation	NN1
304953	100736469	20992785229	,	,	,
304953	100736469	20992785230	which	which	DDQ
304953	100736469	20992785231	typically	typically	RR
304953	100736469	20992785232	consists	consist	VVZ
304953	100736469	20992785233	of	of	IO
304953	100736469	20992785234	oral	oral	NN1_JJ
304953	100736469	20992785235	or	or	CC
304953	100736469	20992785236	injected	inject	VVD_JJ@_VVN
304953	100736469	20992785237	medications	medication	NN2
304953	100736469	20992785238	,	,	,
304953	100736469	20992785239	alone	alone	JJ_RR
304953	100736469	20992785240	or	or	CC
304953	100736469	20992785241	with	with	IW
304953	100736469	20992785242	other	other	JJ
304953	100736469	20992785243	interventions	intervention	NN2
304953	100736469	20992785244	,	,	,
304953	100736469	20992785245	may	may	VM
304953	100736469	20992785246	help	help	VVI
304953	100736469	20992785247	restore	restore	VVI
304953	100736469	20992785248	erectile	erectile	JJ
304953	100736469	20992785249	function	function	NN1
304953	100736469	20992785250	after	after	II_CS
304953	100736469	20992785251	treatment	treatment	NN1
304953	100736469	20992785252	for	for	IF
304953	100736469	20992785253	prostate	prostate	NN1
304953	100736469	20992785254	cancer	cancer	NN1
304953	100736469	20992785255	.	.	.
304953	100736469	20992785256	However	however	RR
304953	100736469	20992785257	,	,	,
304953	100736469	20992785258	this	this	DD1
304953	100736469	20992785259	therapy	therapy	NN1
304953	100736469	20992785260	remains	remain	VVZ
304953	100736469	20992785261	controversial	controversial	JJ
304953	100736469	20992785262	.	.	.
304953	100736469	20992785263	<p>		NULL
304953	100736469	20992785264	Even	even	CS21
304953	100736469	20992785265	if	if	CS22
304953	100736469	20992785266	your	your	APPGE
304953	100736469	20992785267	doctor	doctor	NN1
304953	100736469	20992785268	has	have	VHZ
304953	100736469	20992785269	given	give	VVN
304953	100736469	20992785270	you	you	PPY
304953	100736469	20992785271	a	a	AT1
304953	100736469	20992785272	clean	clean	JJ
304953	100736469	20992785273	bill	bill	NN1
304953	100736469	20992785274	of	of	IO
304953	100736469	20992785275	health	health	NN1
304953	100736469	20992785276	,	,	,
304953	100736469	20992785277	beware	beware	VV0
304953	100736469	20992785278	:	:	:
304953	100736469	20992785279	problems	problem	NN2
304953	100736469	20992785280	getting	get	VVG
304953	100736469	20992785281	or	or	CC
304953	100736469	20992785282	keeping	keep	VVG
304953	100736469	20992785283	an	a	AT1
304953	100736469	20992785284	erection	erection	NN1
304953	100736469	20992785285	firm	firm	NN1
304953	100736469	20992785286	enough	enough	RR
304953	100736469	20992785287	for	for	IF
304953	100736469	20992785288	sexual	sexual	JJ
304953	100736469	20992785289	intercourse	intercourse	NN1
304953	100736469	20992785290	may	may	VM
304953	100736469	20992785291	signal	signal	VVI
304953	100736469	20992785292	trouble	trouble	NN1
304953	100736469	20992785293	,	,	,
304953	100736469	20992785294	especially	especially	RR
304953	100736469	20992785295	cardiovascular	cardiovascular	JJ
304953	100736469	20992785296	disease	disease	NN1
304953	100736469	20992785297	,	,	,
304953	100736469	20992785298	down	down	II
304953	100736469	20992785299	the	the	AT
304953	100736469	20992785300	road	road	NN1
304953	100736469	20992785301	.	.	.
304953	100736471	20992785321	@@##	----------	----------
304953	100736471	20992785322	@@100736471		FO
304953	100736471	20992785323	@4936471/		NN1_VV0
304953	100736471	20992785324	<p>		NULL
304953	100736471	20992785325	Researchers	researcher	NN2
304953	100736471	20992785326	are	be	VBR
304953	100736471	20992785327	developing	develop	VVG
304953	100736471	20992785328	more	more	DAR_RRR
304953	100736471	20992785329	screening	screening	NN1_VVG
304953	100736471	20992785330	tests	test	NN2
304953	100736471	20992785331	for	for	IF
304953	100736471	20992785332	prostate	prostate	NN1
304953	100736471	20992785333	cancer	cancer	NN1
304953	100736471	20992785334	.	.	.
304953	100736471	20992785335	Like	like	II
304953	100736471	20992785336	the	the	AT
304953	100736471	20992785337	PSA	psa	NP1
304953	100736471	20992785338	test	test	NN1_VV0
304953	100736471	20992785339	,	,	,
304953	100736471	20992785340	they	they	PPHS2
304953	100736471	20992785341	rely	rely	VV0
304953	100736471	20992785342	on	on	II_RP@
304953	100736471	20992785343	biomarkers	biomarker	NN2
304953	100736471	20992785344	,	,	,
304953	100736471	20992785345	such	such	II21
304953	100736471	20992785346	as	as	II22
304953	100736471	20992785347	antigens	antigen	NN2
304953	100736471	20992785348	or	or	CC
304953	100736471	20992785349	proteins	protein	NN2
304953	100736471	20992785350	,	,	,
304953	100736471	20992785351	which	which	DDQ
304953	100736471	20992785352	are	be	VBR
304953	100736471	20992785353	elevated	elevate	VVN_JJ
304953	100736471	20992785354	or	or	CC
304953	100736471	20992785355	may	may	VM
304953	100736471	20992785356	only	only	JJ
304953	100736471	20992785357	be	be-	VBI
304953	100736471	20992785358	present	present	NN1
304953	100736471	20992785359	in	in	II
304953	100736471	20992785360	men	man	NN2
304953	100736471	20992785361	who	who	PNQS
304953	100736471	20992785362	have	have	VH0
304953	100736471	20992785363	prostate	prostate	NN1
304953	100736471	20992785364	cancer	cancer	NN1
304953	100736471	20992785365	.	.	.
304953	100736471	20992785366	The	the	AT
304953	100736471	20992785367	hope	hope	NN1
304953	100736471	20992785368	is	be	VBZ
304953	100736471	20992785369	that	that	CST
304953	100736471	20992785370	these	these	DD2
304953	100736471	20992785371	newer	new	JJR
304953	100736471	20992785372	tests	test	NN2
304953	100736471	20992785373	will	will	VM
304953	100736471	20992785374	better	better	RRR
304953	100736471	20992785375	detect	detect	VVI
304953	100736471	20992785376	existing	existing	JJ
304953	100736471	20992785377	cancers	cancer	NN2
304953	100736471	20992785378	(	(	(
304953	100736471	20992785379	better	better	JJR_RRR
304953	100736471	20992785380	sensitivity	sensitivity	NN1
304953	100736471	20992785381	)	)	)
304953	100736471	20992785382	,	,	,
304953	100736471	20992785383	and	and	CC
304953	100736471	20992785384	will	will	VM
304953	100736471	20992785385	not	not	XX
304953	100736471	20992785386	raise	raise	VVI
304953	100736471	20992785387	the	the	AT
304953	100736471	20992785388	alarm	alarm	NN1
304953	100736471	20992785389	for	for	IF
304953	100736471	20992785390	cancer	cancer	NN1
304953	100736471	20992785391	when	when	CS_RRQ
304953	100736471	20992785392	it	it	PPH1
304953	100736471	20992785393	is	be	VBZ
304953	100736471	20992785394	not	not	XX
304953	100736471	20992785395	present	present	JJ_NN1
304953	100736471	20992785396	(	(	(
304953	100736471	20992785397	better	better	JJR_RRR
304953	100736471	20992785398	specificity	specificity	NN1
304953	100736471	20992785399	)	)	)
304953	100736471	20992785400	.	.	.
304953	100736471	20992785401	<p>		NULL
304953	100736471	20992785402	In	in	II
304953	100736471	20992785403	this	this	DD1
304953	100736471	20992785404	test	test	NN1
304953	100736471	20992785405	,	,	,
304953	100736471	20992785406	the	the	AT
304953	100736471	20992785407	doctor	doctor	NN1
304953	100736471	20992785408	inserts	insert	VVZ
304953	100736471	20992785409	a	a	AT1
304953	100736471	20992785410	lubricated	lubricated	JJ
304953	100736471	20992785411	,	,	,
304953	100736471	20992785412	gloved	gloved	JJ
304953	100736471	20992785413	finger	finger	NN1
304953	100736471	20992785414	into	into	II
304953	100736471	20992785415	the	the	AT
304953	100736471	20992785416	rectum	rectum	NN1
304953	100736471	20992785417	and	and	CC
304953	100736471	20992785418	feels	feel	VVZ
304953	100736471	20992785419	the	the	AT
304953	100736471	20992785420	surface	surface	NN1
304953	100736471	20992785421	of	of	IO
304953	100736471	20992785422	the	the	AT
304953	100736471	20992785423	prostate	prostate	NN1
304953	100736471	20992785424	to	to	TO
304953	100736471	20992785425	determine	determine	VVI
304953	100736471	20992785426	whether	whether	CSW
304953	100736471	20992785427	it	it	PPH1
304953	100736471	20992785428	is	be	VBZ
304953	100736471	20992785429	swollen	swell	VVN_JJ
304953	100736471	20992785430	or	or	CC
304953	100736471	20992785431	has	have	VHZ
304953	100736471	20992785432	any	any	DD
304953	100736471	20992785433	lumps	lump	NN2
304953	100736471	20992785434	or	or	CC
304953	100736471	20992785435	abnormally	abnormally	RR
304953	100736471	20992785436	textured	textured	JJ
304953	100736471	20992785437	areas	area	NN2
304953	100736471	20992785438	(	(	(
304953	100736471	20992785439	see	see	VV0
304953	100736471	20992785440	Figure	figure	NN1
304953	100736471	20992785441	1	1	MC1
304953	100736471	20992785442	)	)	)
304953	100736471	20992785443	.	.	.
304953	100736471	20992785444	This	this	DD1
304953	100736471	20992785445	exam	exam	NN1
304953	100736471	20992785446	also	also	RR
304953	100736471	20992785447	helps	help	VVZ
304953	100736471	20992785448	doctors	doctor	NN2
304953	100736471	20992785449	screen	screen	VVI
304953	100736471	20992785450	for	for	IF
304953	100736471	20992785451	diseases	disease	NN2
304953	100736471	20992785452	of	of	IO
304953	100736471	20992785453	the	the	AT
304953	100736471	20992785454	rectum	rectum	NN1
304953	100736471	20992785455	,	,	,
304953	100736471	20992785456	such	such	II21
304953	100736471	20992785457	as	as	II22
304953	100736471	20992785458	rectal	rectal	JJ
304953	100736471	20992785459	cancer	cancer	NN1
304953	100736471	20992785460	.	.	.
304953	100736471	20992785461	<p>		NULL
304953	100736471	20992785462	The	the	AT
304953	100736471	20992785463	jury	jury	NN1
304953	100736471	20992785464	is	be	VBZ
304953	100736471	20992785465	still	still	RR
304953	100736471	20992785466	out	out	RP
304953	100736471	20992785467	on	on	II
304953	100736471	20992785468	whether	whether	CSW
304953	100736471	20992785469	intermittent	intermittent	JJ
304953	100736471	20992785470	hormone	hormone	NN1
304953	100736471	20992785471	therapy	therapy	NN1
304953	100736471	20992785472	,	,	,
304953	100736471	20992785473	which	which	DDQ
304953	100736471	20992785474	involves	involve	VVZ
304953	100736471	20992785475	repeated	repeated	JJ@
304953	100736471	20992785476	cycles	cycle	NN2
304953	100736471	20992785477	of	of	IO
304953	100736471	20992785478	hormone	hormone	NN1
304953	100736471	20992785479	therapy	therapy	NN1
304953	100736471	20992785480	followed	follow	VVN
304953	100736471	20992785481	by	by	II
304953	100736471	20992785482	breaks	break	NN2
304953	100736471	20992785483	in	in	II
304953	100736471	20992785484	treatment	treatment	NN1
304953	100736471	20992785485	,	,	,
304953	100736471	20992785486	might	might	VM
304953	100736471	20992785487	help	help	VVI
304953	100736471	20992785488	patients	patient	NN2
304953	100736471	20992785489	live	live	VVI
304953	100736471	20992785490	longer	long	RRR_JJR
304953	100736471	20992785491	than	than	CSN
304953	100736471	20992785492	continuous	continuous	JJ
304953	100736471	20992785493	hormone	hormone	NN1
304953	100736471	20992785494	therapy	therapy	NN1
304953	100736471	20992785495	.	.	.
304953	100736471	20992785496	But	but	CCB
304953	100736471	20992785497	Patrick	patrick	NP1
304953	100736471	20992785498	Kirbys	kirbys	NP2
304953	100736471	20992785499	story	story	NN1
304953	100736471	20992785500	might	might	VM
304953	100736471	20992785501	help	help	VVI
304953	100736471	20992785502	patients	patient	NN2
304953	100736471	20992785503	who	who	PNQS
304953	100736471	20992785504	are	be	VBR
304953	100736471	20992785505	debating	debate	VVG
304953	100736471	20992785506	various	various	JJ
304953	100736471	20992785507	options	option	NN2
304953	100736471	20992785508	in	in	II
304953	100736471	20992785509	hormone	hormone	NN1
304953	100736471	20992785510	therapy	therapy	NN1
304953	100736471	20992785511	.	.	.
304953	100736471	20992785512	<p>		NULL
304953	100736471	20992785513	@		II
304953	100736471	20992785514	@		II
304953	100736471	20992785515	@		II
304953	100736471	20992785516	@		II
304953	100736471	20992785517	@		II
304953	100736471	20992785518	@		II
304953	100736471	20992785519	@		II
304953	100736471	20992785520	@		II
304953	100736471	20992785521	@		II
304953	100736471	20992785522	@		II
304953	100736471	20992785523	Harvard	harvard	NP1
304953	100736471	20992785524	Medical	medical	JJ
304953	100736471	20992785525	School	school	NN1
304953	100736471	20992785526	and	and	CC
304953	100736471	20992785527	the	the	AT
304953	100736471	20992785528	director	director	NN1
304953	100736471	20992785529	of	of	IO
304953	100736471	20992785530	Men	man	NN2
304953	100736471	20992785531	's	's	GE
304953	100736471	20992785532	Health	health	NN1
304953	100736471	20992785533	Boston	boston	NP1
304953	100736471	20992785534	,	,	,
304953	100736471	20992785535	shares	share	VVZ@
304953	100736471	20992785536	his	his	APPGE
304953	100736471	20992785537	views	view	NN2
304953	100736471	20992785538	on	on	II
304953	100736471	20992785539	current	current	JJ
304953	100736471	20992785540	controversies	controversy	NN2
304953	100736471	20992785541	regarding	regarding	II_VVG
304953	100736471	20992785542	testosterone-replacement		JJ_NN1
304953	100736471	20992785543	therapy	therapy	NN1
304953	100736471	20992785544	.	.	.
304953	100736473	20992785564	@@##	----------	----------
304953	100736473	20992785565	@@100736473		FO
304953	100736473	20992785566	@4936473/		VV0_NN1
304953	100736473	20992785567	46989		MC
304953	100736473	20992785568	@qwx906989		FO
304953	100736473	20992785569	<p>		NULL
304953	100736473	20992785570	Men	man	NN2
304953	100736473	20992785571	diagnosed	diagnose	VVN_VVD
304953	100736473	20992785572	with	with	IW
304953	100736473	20992785573	prostate	prostate	NN1
304953	100736473	20992785574	cancer	cancer	NN1
304953	100736473	20992785575	often	often	RR
304953	100736473	20992785576	face	face	VV0
304953	100736473	20992785577	a	a	AT1
304953	100736473	20992785578	dilemma	dilemma	NN1
304953	100736473	20992785579	when	when	CS_RRQ
304953	100736473	20992785580	it	it	PPH1
304953	100736473	20992785581	comes	come	VVZ
304953	100736473	20992785582	to	to	II
304953	100736473	20992785583	choosing	choose	VVG
304953	100736473	20992785584	a	a	AT1
304953	100736473	20992785585	treatment	treatment	NN1
304953	100736473	20992785586	.	.	.
304953	100736473	20992785587	Radiation	radiation	NN1
304953	100736473	20992785588	and	and	CC
304953	100736473	20992785589	surgery	surgery	NN1
304953	100736473	20992785590	are	be	VBR
304953	100736473	20992785591	effective	effective	JJ
304953	100736473	20992785592	in	in	II
304953	100736473	20992785593	controlling	control	VVG_JJ@
304953	100736473	20992785594	cancer	cancer	NN1
304953	100736473	20992785595	,	,	,
304953	100736473	20992785596	but	but	CCB
304953	100736473	20992785597	most	most	DAT
304953	100736473	20992785598	patients	patient	NN2
304953	100736473	20992785599	subsequently	subsequently	RR
304953	100736473	20992785600	experience	experience	VV0
304953	100736473	20992785601	sexual	sexual	JJ
304953	100736473	20992785602	difficulties	difficulty	NN2
304953	100736473	20992785603	,	,	,
304953	100736473	20992785604	urological	urological	JJ
304953	100736473	20992785605	side	side	NN1
304953	100736473	20992785606	effects	effect	NN2
304953	100736473	20992785607	,	,	,
304953	100736473	20992785608	or	or	CC
304953	100736473	20992785609	both	both	DB2
304953	100736473	20992785610	.	.	.
304953	100736473	20992785611	Active	active	JJ
304953	100736473	20992785612	surveillance	surveillance	NN1
304953	100736473	20992785613	preserves	preserve	VVZ
304953	100736473	20992785614	genitourinary		JJ
304953	100736473	20992785615	function	function	NN1
304953	100736473	20992785616	,	,	,
304953	100736473	20992785617	but	but	CCB
304953	100736473	20992785618	it	it	PPH1
304953	100736473	20992785619	can	can	VM
304953	100736473	20992785620	cause	cause	VVI
304953	100736473	20992785621	anxiety	anxiety	NN1
304953	100736473	20992785622	.	.	.
304953	100736473	20992785623	Regular	regular	JJ
304953	100736473	20992785624	monitoring	monitoring	NN1
304953	100736473	20992785625	can	can	VM
304953	100736473	20992785626	also	also	RR
304953	100736473	20992785627	prove	prove	VVI
304953	100736473	20992785628	burdensome	burdensome	JJ
304953	100736473	20992785629	.	.	.
304953	100736473	20992785630	<p>		NULL
304953	100736473	20992785631	Two	two	MC
304953	100736473	20992785632	teams	team	NN2
304953	100736473	20992785633	of	of	IO
304953	100736473	20992785634	researchers	researcher	NN2
304953	100736473	20992785635	suggest	suggest	VV0
304953	100736473	20992785636	some	some	DD
304953	100736473	20992785637	middle	middle	JJ_NN1
304953	100736473	20992785638	ground	ground	NN1
304953	100736473	20992785639	,	,	,
304953	100736473	20992785640	a	a	AT1
304953	100736473	20992785641	treatment	treatment	NN1
304953	100736473	20992785642	that	that	CST_DD1
304953	100736473	20992785643	can	can	VM
304953	100736473	20992785644	effectively	effectively	RR
304953	100736473	20992785645	kill	kill	VVI
304953	100736473	20992785646	cancer	cancer	NN1
304953	100736473	20992785647	and	and	CC
304953	100736473	20992785648	preserve	preserve	VVI
304953	100736473	20992785649	function	function	NN1
304953	100736473	20992785650	.	.	.
304953	100736473	20992785651	They	they	PPHS2
304953	100736473	20992785652	argue	argue	VV0
304953	100736473	20992785653	in	in	II31
304953	100736473	20992785654	favor	favor	II32
304953	100736473	20992785655	of	of	II33
304953	100736473	20992785656	testing	test	VVG
304953	100736473	20992785657	focal	focal	JJ
304953	100736473	20992785658	therapy	therapy	NN1
304953	100736473	20992785659	,	,	,
304953	100736473	20992785660	which	which	DDQ
304953	100736473	20992785661	only	only	JJ
304953	100736473	20992785662	treats		NN1
304953	100736473	20992785663	the	the	AT
304953	100736473	20992785664	tumor	tumor	NN1
304953	100736473	20992785665	and	and	CC
304953	100736473	20992785666	a	a	AT1
304953	100736473	20992785667	small	small	JJ
304953	100736473	20992785668	margin	margin	NN1
304953	100736473	20992785669	of	of	IO
304953	100736473	20992785670	normal	normal	JJ
304953	100736473	20992785671	tissue	tissue	NN1
304953	100736473	20992785672	around	around	II
304953	100736473	20992785673	it	it	PPH1
304953	100736473	20992785674	.	.	.
304953	100736473	20992785675	In	in	II
304953	100736473	20992785676	contrast	contrast	NN1
304953	100736473	20992785677	,	,	,
304953	100736473	20992785678	radical	radical	JJ_NN1
304953	100736473	20992785679	therapies	therapy	NN2
304953	100736473	20992785680	target	target	VV0@
304953	100736473	20992785681	the	the	AT
304953	100736473	20992785682	entire	entire	JJ
304953	100736473	20992785683	prostate	prostate	NN1
304953	100736473	20992785684	,	,	,
304953	100736473	20992785685	often	often	RR
304953	100736473	20992785686	damaging	damage	VVG_JJ
304953	100736473	20992785687	surrounding	surrounding	JJ
304953	100736473	20992785688	structures	structure	NN2
304953	100736473	20992785689	.	.	.
304953	100736473	20992785690	<p>		NULL
304953	100736473	20992785691	Candidates	candidate	NN2
304953	100736473	20992785692	for	for	IF
304953	100736473	20992785693	focal	focal	JJ
304953	100736473	20992785694	therapy	therapy	NN1
304953	100736473	20992785695	might	might	VM
304953	100736473	20992785696	include	include	VVI
304953	100736473	20992785697	patients	patient	NN2
304953	100736473	20992785698	with	with	IW
304953	100736473	20992785699	cancer	cancer	NN1
304953	100736473	20992785700	that	that	CST_DD1
304953	100736473	20992785701	's	be	VBZ_VHZ@
304953	100736473	20992785702	confined	confine	VVN
304953	100736473	20992785703	to	to	II
304953	100736473	20992785704	the	the	AT
304953	100736473	20992785705	prostate	prostate	NN1
304953	100736473	20992785706	and	and	CC
304953	100736473	20992785707	limited	limit	VVN_JJ
304953	100736473	20992785708	in	in	II
304953	100736473	20992785709	scope	scope	NN1
304953	100736473	20992785710	(	(	(
304953	100736473	20992785711	one	one	MC1
304953	100736473	20992785712	or	or	CC
304953	100736473	20992785713	two	two	MC
304953	100736473	20992785714	cancerous	cancerous	JJ
304953	100736473	20992785715	areas	area	NN2
304953	100736473	20992785716	)	)	)
304953	100736473	20992785717	.	.	.
304953	100736473	20992785718	Few	few	DA2
304953	100736473	20992785719	studies	study	NN2
304953	100736473	20992785720	of	of	IO
304953	100736473	20992785721	focal	focal	JJ
304953	100736473	20992785722	therapy	therapy	NN1
304953	100736473	20992785723	have	have	VH0
304953	100736473	20992785724	been	be	VBN
304953	100736473	20992785725	completed	complete	VVN
304953	100736473	20992785726	,	,	,
304953	100736473	20992785727	and	and	CC
304953	100736473	20992785728	those	those	DD2
304953	100736473	20992785729	included	include	VVN_VVD
304953	100736473	20992785730	few	few	DA2
304953	100736473	20992785731	patients	patient	NN2
304953	100736473	20992785732	,	,	,
304953	100736473	20992785733	used	use	VVD_JJ_VVN
304953	100736473	20992785734	varying	varying	JJ_VVG
304953	100736473	20992785735	techniques	technique	NN2
304953	100736473	20992785736	,	,	,
304953	100736473	20992785737	and	and	CC
304953	100736473	20992785738	lacked	lack	VVD
304953	100736473	20992785739	solid	solid	JJ
304953	100736473	20992785740	data	data	NN
304953	100736473	20992785741	on	on	II
304953	100736473	20992785742	adverse	adverse	JJ
304953	100736473	20992785743	effects	effect	NN2
304953	100736473	20992785744	.	.	.
304953	100736473	20992785745	But	but	CCB
304953	100736473	20992785746	with	with	IW
304953	100736473	20992785747	dramatic	dramatic	JJ
304953	100736473	20992785748	improvements	improvement	NN2
304953	100736473	20992785749	in	in	II
304953	100736473	20992785750	technologies	technology	NN2
304953	100736473	20992785751	like	like	II
304953	100736473	20992785752	magnetic	magnetic	JJ
304953	100736473	20992785753	resonance	resonance	NN1
304953	100736473	20992785754	imaging	imaging	NN1_VVG
304953	100736473	20992785755	,	,	,
304953	100736473	20992785756	@		II
304953	100736473	20992785757	@		II
304953	100736473	20992785758	@		II
304953	100736473	20992785759	@		II
304953	100736473	20992785760	@		II
304953	100736473	20992785761	@		II
304953	100736473	20992785762	@		II
304953	100736473	20992785763	@		II
304953	100736473	20992785764	@		II
304953	100736473	20992785765	@		II
304953	100736473	20992785766	<p>		NULL
304953	100736473	20992785767	Given	give	VVN
304953	100736473	20992785768	the	the	AT
304953	100736473	20992785769	availability	availability	NN1
304953	100736473	20992785770	of	of	IO
304953	100736473	20992785771	the	the	AT
304953	100736473	20992785772	technology	technology	NN1
304953	100736473	20992785773	needed	need	VVD_VVN
304953	100736473	20992785774	to	to	TO
304953	100736473	20992785775	locate	locate	VVI
304953	100736473	20992785776	and	and	CC
304953	100736473	20992785777	treat	treat	VVI
304953	100736473	20992785778	cancerous	cancerous	JJ
304953	100736473	20992785779	lesions	lesion	NN2
304953	100736473	20992785780	,	,	,
304953	100736473	20992785781	the	the	AT
304953	100736473	20992785782	researchers	researcher	NN2
304953	100736473	20992785783	conclude	conclude	VV0
304953	100736473	20992785784	that	that	CST
304953	100736473	20992785785	the	the	AT
304953	100736473	20992785786	concept	concept	NN1
304953	100736473	20992785787	of	of	IO
304953	100736473	20992785788	focal	focal	JJ
304953	100736473	20992785789	therapy	therapy	NN1
304953	100736473	20992785790	should	should	VM
304953	100736473	20992785791	be	be	VBI
304953	100736473	20992785792	investigated	investigate	VVN
304953	100736473	20992785793	.	.	.
304953	100736473	20992785794	46996		MC
304953	100736473	20992785795	@qwx906996		FO
304953	100736474	20992785815	@@##	----------	----------
304953	100736474	20992785816	@@100736474		FO
304953	100736474	20992785817	@4936474/		VV0_NN1
304953	100736474	20992785818	46989		MC
304953	100736474	20992785819	@qwx906989		FO
304953	100736474	20992785820	<p>		NULL
304953	100736474	20992785821	When	when	CS_RRQ
304953	100736474	20992785822	it	it	PPH1
304953	100736474	20992785823	comes	come	VVZ
304953	100736474	20992785824	to	to	II
304953	100736474	20992785825	having	have	VHG
304953	100736474	20992785826	a	a	AT1
304953	100736474	20992785827	radical	radical	JJ_NN1
304953	100736474	20992785828	prostatectomy	prostatectomy	NN1
304953	100736474	20992785829	,	,	,
304953	100736474	20992785830	do	do	VD0
304953	100736474	20992785831	patients	patient	NN2
304953	100736474	20992785832	fare	fare	VVI
304953	100736474	20992785833	better	better	RRR_JJR
304953	100736474	20992785834	in	in	II
304953	100736474	20992785835	a	a	AT1
304953	100736474	20992785836	hospital	hospital	NN1
304953	100736474	20992785837	that	that	CST_DD1
304953	100736474	20992785838	handles	handle	VVZ
304953	100736474	20992785839	a	a	AT1
304953	100736474	20992785840	large	large	JJ
304953	100736474	20992785841	number	number	NN1
304953	100736474	20992785842	of	of	IO
304953	100736474	20992785843	surgeries	surgery	NN2
304953	100736474	20992785844	versus	versus	II
304953	100736474	20992785845	one	one	PN1
304953	100736474	20992785846	that	that	CST
304953	100736474	20992785847	handles	handle	VVZ
304953	100736474	20992785848	relatively	relatively	RR
304953	100736474	20992785849	few	few	DA2
304953	100736474	20992785850	?	?	?
304953	100736474	20992785851	Is	be	VBZ
304953	100736474	20992785852	the	the	AT
304953	100736474	20992785853	number	number	NN1
304953	100736474	20992785854	of	of	IO
304953	100736474	20992785855	operations	operation	NN2
304953	100736474	20992785856	performed	perform	VVN
304953	100736474	20992785857	by	by	II
304953	100736474	20992785858	a	a	AT1
304953	100736474	20992785859	particular	particular	JJ
304953	100736474	20992785860	surgeon	surgeon	NN1
304953	100736474	20992785861	a	a	AT1
304953	100736474	20992785862	better	better	JJR
304953	100736474	20992785863	gauge	gauge	NN1
304953	100736474	20992785864	of	of	IO
304953	100736474	20992785865	patient	patient	JJ_NN1
304953	100736474	20992785866	outcomes	outcome	NN2
304953	100736474	20992785867	than	than	CSN
304953	100736474	20992785868	hospital	hospital	NN1
304953	100736474	20992785869	volume	volume	NN1
304953	100736474	20992785870	?	?	?
304953	100736474	20992785871	<p>		NULL
304953	100736474	20992785872	Although	although	CS
304953	100736474	20992785873	similar	similar	JJ
304953	100736474	20992785874	questions	question	NN2
304953	100736474	20992785875	have	have	VH0
304953	100736474	20992785876	been	be	VBN
304953	100736474	20992785877	answered	answer	VVN
304953	100736474	20992785878	for	for	IF
304953	100736474	20992785879	other	other	JJ
304953	100736474	20992785880	surgical	surgical	JJ
304953	100736474	20992785881	procedures	procedure	NN2
304953	100736474	20992785882	,	,	,
304953	100736474	20992785883	the	the	AT
304953	100736474	20992785884	relationship	relationship	NN1
304953	100736474	20992785885	between	between	II
304953	100736474	20992785886	numbers	number	NN2
304953	100736474	20992785887	of	of	IO
304953	100736474	20992785888	prostate	prostate	NN1
304953	100736474	20992785889	surgeries	surgery	NN2
304953	100736474	20992785890	and	and	CC
304953	100736474	20992785891	how	how	RGQ@_RRQ
304953	100736474	20992785892	well	well	JJ@_RR
304953	100736474	20992785893	patients	patient	NN2
304953	100736474	20992785894	do	do	VD0
304953	100736474	20992785895	has	have	VHZ
304953	100736474	20992785896	not	not	XX
304953	100736474	20992785897	been	be	VBN
304953	100736474	20992785898	evaluated	evaluate	VVN
304953	100736474	20992785899	on	on	II
304953	100736474	20992785900	a	a	AT1
304953	100736474	20992785901	large	large	JJ
304953	100736474	20992785902	scale	scale	NN1
304953	100736474	20992785903	until	until	II
304953	100736474	20992785904	now	now	RT
304953	100736474	20992785905	.	.	.
304953	100736474	20992785906	To	to	TO
304953	100736474	20992785907	find	find	VVI
304953	100736474	20992785908	out	out	RP
304953	100736474	20992785909	,	,	,
304953	100736474	20992785910	Minnesota	minnesota	NP1
304953	100736474	20992785911	researchers	researcher	NN2
304953	100736474	20992785912	reviewed	review	VVD_VVN
304953	100736474	20992785913	17	17	MC
304953	100736474	20992785914	previously	previously	RR
304953	100736474	20992785915	published	publish	VVN_VVD_JJ@
304953	100736474	20992785916	studies	study	NN2
304953	100736474	20992785917	that	that	CST
304953	100736474	20992785918	reported	report	VVD
304953	100736474	20992785919	the	the	AT
304953	100736474	20992785920	results	result	NN2
304953	100736474	20992785921	of	of	IO
304953	100736474	20992785922	235,763		MC
304953	100736474	20992785923	radical	radical	JJ
304953	100736474	20992785924	prostatectomies	prostatectomy	NN2
304953	100736474	20992785925	.	.	.
304953	100736474	20992785926	<p>		NULL
304953	100736474	20992785927	They	they	PPHS2
304953	100736474	20992785928	determined	determine	VVD
304953	100736474	20992785929	that	that	CST
304953	100736474	20992785930	hospitals	hospital	NN2
304953	100736474	20992785931	where	where	CS_RRQ
304953	100736474	20992785932	more	more	DAR
304953	100736474	20992785933	than	than	CSN
304953	100736474	20992785934	43	43	MC
304953	100736474	20992785935	prostatectomies	prostatectomy	NN2
304953	100736474	20992785936	were	be	VBDR
304953	100736474	20992785937	performed	perform	VVN
304953	100736474	20992785938	per	per	II
304953	100736474	20992785939	year	year	NNT1
304953	100736474	20992785940	had	have	VHD
304953	100736474	20992785941	lower	low	JJR
304953	100736474	20992785942	mortality	mortality	NN1
304953	100736474	20992785943	rates	rate	NN2
304953	100736474	20992785944	than	than	CSN
304953	100736474	20992785945	smaller-volume		JJ
304953	100736474	20992785946	hospitals	hospital	NN2
304953	100736474	20992785947	.	.	.
304953	100736474	20992785948	Patients	patient	NN2
304953	100736474	20992785949	at	at	II
304953	100736474	20992785950	these	these	DD2
304953	100736474	20992785951	high-volume	high-volume	JJ
304953	100736474	20992785952	hospitals	hospital	NN2
304953	100736474	20992785953	were	be	VBDR
304953	100736474	20992785954	also	also	RR
304953	100736474	20992785955	9.7%	9.7%	FO
304953	100736474	20992785956	less	less	RRR
304953	100736474	20992785957	likely	likely	JJ
304953	100736474	20992785958	to	to	TO
304953	100736474	20992785959	experience	experience	VVI
304953	100736474	20992785960	complications	complication	NN2
304953	100736474	20992785961	.	.	.
304953	100736474	20992785962	Teaching	teach	VVG_NN1
304953	100736474	20992785963	hospitals	hospital	NN2
304953	100736474	20992785964	had	have	VHD
304953	100736474	20992785965	an	a	AT1
304953	100736474	20992785966	18%		NNU
304953	100736474	20992785967	lower	low	JJR
304953	100736474	20992785968	rate	rate	NN1
304953	100736474	20992785969	of	of	IO
304953	100736474	20992785970	complications	complication	NN2
304953	100736474	20992785971	.	.	.
304953	100736474	20992785972	<p>		NULL
304953	100736474	20992785973	Interestingly	interestingly	RR
304953	100736474	20992785974	,	,	,
304953	100736474	20992785975	the	the	AT
304953	100736474	20992785976	number	number	NN1
304953	100736474	20992785977	of	of	IO
304953	100736474	20992785978	operations	operation	NN2
304953	100736474	20992785979	a	a	AT1
304953	100736474	20992785980	surgeon	surgeon	NN1
304953	100736474	20992785981	performed	perform	VVD_VVN
304953	100736474	20992785982	did	do	VDD
304953	100736474	20992785983	not	not	XX
304953	100736474	20992785984	significantly	significantly	RR
304953	100736474	20992785985	affect	affect	VVI
304953	100736474	20992785986	mortality	mortality	NN1
304953	100736474	20992785987	rates	rate	NN2
304953	100736474	20992785988	or	or	CC
304953	100736474	20992785989	the	the	AT
304953	100736474	20992785990	chances	chance	NN2
304953	100736474	20992785991	of	of	IO
304953	100736474	20992785992	having	have	VHG
304953	100736474	20992785993	left	leave	VVN
304953	100736474	20992785994	some	some	DD
304953	100736474	20992785995	of	of	IO
304953	100736474	20992785996	the	the	AT
304953	100736474	20992785997	cancer	cancer	NN1
304953	100736474	20992785998	behind	behind	RL@_II
304953	100736474	20992785999	.	.	.
304953	100736474	20992786000	But	but	CCB
304953	100736474	20992786001	the	the	AT
304953	100736474	20992786002	number	number	NN1
304953	100736474	20992786003	of	of	IO
304953	100736474	20992786004	operations	operation	NN2
304953	100736474	20992786005	a	a	AT1
304953	100736474	20992786006	surgeon	surgeon	NN1
304953	100736474	20992786007	@		II
304953	100736474	20992786008	@		II
304953	100736474	20992786009	@		II
304953	100736474	20992786010	@		II
304953	100736474	20992786011	@		II
304953	100736474	20992786012	@		II
304953	100736474	20992786013	@		II
304953	100736474	20992786014	@		II
304953	100736474	20992786015	@		II
304953	100736474	20992786016	@		II
304953	100736474	20992786017	complications	complication	NN2
304953	100736474	20992786018	"	"	"
304953	100736474	20992786019	for	for	IF
304953	100736474	20992786020	every	every	AT1
304953	100736474	20992786021	10	10	MC
304953	100736474	20992786022	additional	additional	JJ
304953	100736474	20992786023	radical	radical	JJ_NN1
304953	100736474	20992786024	prostatectomies	prostatectomy	NN2
304953	100736474	20992786025	the	the	AT
304953	100736474	20992786026	surgeon	surgeon	NN1
304953	100736474	20992786027	performed	perform	VVD_VVN
304953	100736474	20992786028	,	,	,
304953	100736474	20992786029	the	the	AT
304953	100736474	20992786030	urinary	urinary	JJ_NN1
304953	100736474	20992786031	complication	complication	NN1
304953	100736474	20992786032	rate	rate	NN1
304953	100736474	20992786033	dropped	drop	VVN
304953	100736474	20992786034	by	by	II
304953	100736474	20992786035	2.4%	2.4%	FO
304953	100736474	20992786036	.	.	.
304953	100736474	20992786037	<p>		NULL
304953	100736474	20992786038	Although	although	CS
304953	100736474	20992786039	many	many	DA2
304953	100736474	20992786040	patients	patient	NN2
304953	100736474	20992786041	may	may	VM
304953	100736474	20992786042	be	be	VBI
304953	100736474	20992786043	restricted	restrict	VVN
304953	100736474	20992786044	in	in	II
304953	100736474	20992786045	their	their	APPGE
304953	100736474	20992786046	choice	choice	NN1
304953	100736474	20992786047	of	of	IO
304953	100736474	20992786048	hospital	hospital	NN1
304953	100736474	20992786049	based	base	VVN
304953	100736474	20992786050	on	on	II
304953	100736474	20992786051	where	where	RRQ
304953	100736474	20992786052	they	they	PPHS2
304953	100736474	20992786053	live	live	VV0
304953	100736474	20992786054	or	or	CC
304953	100736474	20992786055	their	their	APPGE
304953	100736474	20992786056	insurance	insurance	NN1
304953	100736474	20992786057	plan	plan	NN1
304953	100736474	20992786058	,	,	,
304953	100736474	20992786059	the	the	AT
304953	100736474	20992786060	findings	finding	NN2
304953	100736474	20992786061	suggest	suggest	VV0
304953	100736474	20992786062	that	that	DD1_CST
304953	100736474	20992786063	prostate	prostate	NN1
304953	100736474	20992786064	patients	patient	NN2
304953	100736474	20992786065	do	do	VD0
304953	100736474	20992786066	better	better	RRR_JJR_NN1%
304953	100736474	20992786067	when	when	CS
304953	100736474	20992786068	surgery	surgery	NN1
304953	100736474	20992786069	is	be	VBZ
304953	100736474	20992786070	done	do	VDN
304953	100736474	20992786071	at	at	II
304953	100736474	20992786072	a	a	AT1
304953	100736474	20992786073	high-volume	high-volume	JJ_NN1
304953	100736474	20992786074	hospital	hospital	NN1
304953	100736474	20992786075	by	by	II
304953	100736474	20992786076	a	a	AT1
304953	100736474	20992786077	doctor	doctor	NN1
304953	100736474	20992786078	who	who	PNQS
304953	100736474	20992786079	performs	perform	VVZ
304953	100736474	20992786080	the	the	AT
304953	100736474	20992786081	operation	operation	NN1
304953	100736474	20992786082	regularly	regularly	RR
304953	100736474	20992786083	.	.	.
304953	100736474	20992786084	46996		MC
304953	100736474	20992786085	@qwx906996		FO
304953	100736486	20992786367	@@##	----------	----------
304953	100736486	20992786368	@@100736486		FO
304953	100736486	20992786369	@4936486/		VV0_NN1
304953	100736486	20992786370	46989		MC
304953	100736486	20992786371	@qwx906989		FO
304953	100736486	20992786372	<p>		NULL
304953	100736486	20992786373	Two	two	MC
304953	100736486	20992786374	international	international	JJ
304953	100736486	20992786375	and	and	CC
304953	100736486	20992786376	large	large	JJ
304953	100736486	20992786377	randomized	randomized	JJ@
304953	100736486	20992786378	studies	study	NN2
304953	100736486	20992786379	provide	provide	VV0
304953	100736486	20992786380	the	the	AT
304953	100736486	20992786381	most	most	RGT
304953	100736486	20992786382	convincing	convincing	JJ
304953	100736486	20992786383	evidence	evidence	NN1
304953	100736486	20992786384	thus	thus	RR
304953	100736486	20992786385	far	far	JJ_RR
304953	100736486	20992786386	that	that	CST
304953	100736486	20992786387	PSA	psa	NP1
304953	100736486	20992786388	based	base	VVD@_VVN
304953	100736486	20992786389	testing	testing	NN1
304953	100736486	20992786390	does	do	VDZ
304953	100736486	20992786391	nothing	nothing	PN1
304953	100736486	20992786392	or	or	CC
304953	100736486	20992786393	meaningfully	meaningfully	RR
304953	100736486	20992786394	little	little	DA1_JJ_RR
304953	100736486	20992786395	to	to	TO
304953	100736486	20992786396	reduce	reduce	VVI
304953	100736486	20992786397	the	the	AT
304953	100736486	20992786398	death	death	NN1
304953	100736486	20992786399	rate	rate	NN1
304953	100736486	20992786400	from	from	II
304953	100736486	20992786401	prostate	prostate	NN1
304953	100736486	20992786402	cancer	cancer	NN1
304953	100736486	20992786403	and	and	CC
304953	100736486	20992786404	confirm	confirm	VV0
304953	100736486	20992786405	many	many	DA2
304953	100736486	20992786406	earlier	early	JJR
304953	100736486	20992786407	studies	study	NN2
304953	100736486	20992786408	that	that	CST
304953	100736486	20992786409	came	come	VVD
304953	100736486	20992786410	to	to	II
304953	100736486	20992786411	the	the	AT
304953	100736486	20992786412	same	same	DA
304953	100736486	20992786413	conclusions	conclusion	NN2
304953	100736486	20992786414	.	.	.
304953	100736486	20992786415	In	in	II
304953	100736486	20992786416	this	this	DD1
304953	100736486	20992786417	video	video	NN1
304953	100736486	20992786418	,	,	,
304953	100736486	20992786419	Marc	marc	NP1
304953	100736486	20992786420	Garnick		NP1
304953	100736486	20992786421	,	,	,
304953	100736486	20992786422	MD	md	NNA
304953	100736486	20992786423	,	,	,
304953	100736486	20992786424	discusses	discuss	VVZ
304953	100736486	20992786425	the	the	AT
304953	100736486	20992786426	implications	implication	NN2
304953	100736486	20992786427	.	.	.
304953	100736486	20992786428	46996		MC
304953	100736486	20992786429	@qwx906996		FO
304953	100736489	20992786529	@@##	----------	----------
304953	100736489	20992786530	@@100736489		FO
304953	100736489	20992786531	@4936489/		NN1_VV0
304953	100736489	20992786532	<p>		NULL
304953	100736489	20992786533	Dr.		NNB
304953	100736489	20992786534	Ian	ian	NP1
304953	100736489	20992786535	Thompson	thompson	NP1
304953	100736489	20992786536	,	,	,
304953	100736489	20992786537	chairman	chairman	NN1
304953	100736489	20992786538	of	of	IO
304953	100736489	20992786539	the	the	AT
304953	100736489	20992786540	Department	department	NN1
304953	100736489	20992786541	of	of	IO
304953	100736489	20992786542	Urology	urology	NN1_NP1
304953	100736489	20992786543	at	at	II
304953	100736489	20992786544	the	the	AT
304953	100736489	20992786545	University	university	NN1
304953	100736489	20992786546	of	of	IO
304953	100736489	20992786547	Texas	texas	NP1
304953	100736489	20992786548	Health	health	NN1
304953	100736489	20992786549	Science	science	NN1
304953	100736489	20992786550	Center	center	NN1
304953	100736489	20992786551	at	at	II
304953	100736489	20992786552	San	san	NP1
304953	100736489	20992786553	Antonio	antonio	NP1
304953	100736489	20992786554	and	and	CC
304953	100736489	20992786555	the	the	AT
304953	100736489	20992786556	principal	principal	JJ_NN1
304953	100736489	20992786557	investigator	investigator	NN1
304953	100736489	20992786558	for	for	IF
304953	100736489	20992786559	the	the	AT
304953	100736489	20992786560	Prostate	prostate	NN1
304953	100736489	20992786561	Cancer	cancer	NN1
304953	100736489	20992786562	Prevention	prevention	NN1
304953	100736489	20992786563	Trial	trial	NN1
304953	100736489	20992786564	,	,	,
304953	100736489	20992786565	discusses	discuss	VVZ
304953	100736489	20992786566	the	the	AT
304953	100736489	20992786567	trials	trial	NN2
304953	100736489	20992786568	findings	finding	NN2
304953	100736489	20992786569	and	and	CC
304953	100736489	20992786570	outlines	outline	NN2
304953	100736489	20992786571	finasteride	finasteride	NN1
304953	100736489	20992786572	's	's	GE
304953	100736489	20992786573	risks	risk	NN2
304953	100736489	20992786574	and	and	CC
304953	100736489	20992786575	benefits	benefit	NN2
304953	100736489	20992786576	.	.	.
304953	100736489	20992786577	<p>		NULL
304953	100736489	20992786578	Study	study	NN1
304953	100736489	20992786579	finds	find	VVZ
304953	100736489	20992786580	that	that	DD1_CST
304953	100736489	20992786581	finasteride	finasteride	NN1_VV0
304953	100736489	20992786582	may	may	VM
304953	100736489	20992786583	actually	actually	RR
304953	100736489	20992786584	lower	lower	VVI
304953	100736489	20992786585	the	the	AT
304953	100736489	20992786586	overall	overall	JJ_NN1
304953	100736489	20992786587	risk	risk	NN1
304953	100736489	20992786588	of	of	IO
304953	100736489	20992786589	prostate	prostate	NN1
304953	100736489	20992786590	cancer	cancer	NN1
304953	100736489	20992786591	and	and	CC
304953	100736489	20992786592	aid	aid	NN1_VV0@
304953	100736489	20992786593	in	in	II
304953	100736489	20992786594	the	the	AT
304953	100736489	20992786595	detection	detection	NN1
304953	100736489	20992786596	of	of	IO
304953	100736489	20992786597	aggressive	aggressive	JJ
304953	100736489	20992786598	tumors	tumor	NN2
304953	100736489	20992786599	.	.	.
304953	100736489	20992786600	An	a	AT1
304953	100736489	20992786601	earlier	early	JJR
304953	100736489	20992786602	study	study	NN1
304953	100736489	20992786603	had	have	VHD
304953	100736489	20992786604	implicated	implicate	VVN
304953	100736489	20992786605	finasteride	finasteride	NN1_VV0
304953	100736489	20992786606	in	in	II
304953	100736489	20992786607	the	the	AT
304953	100736489	20992786608	development	development	NN1
304953	100736489	20992786609	of	of	IO
304953	100736489	20992786610	these	these	DD2
304953	100736489	20992786611	deadlier	deadly	JJR
304953	100736489	20992786612	tumors.		NNU
